words,sentence_id,labels
Binding,0,O
of,0,O
dimemorfan,0,B-CHEMICAL
to,0,O
sigma-1,0,B-GENE-Y
receptor,0,I-GENE-Y
and,0,O
its,0,O
anticonvulsant,0,O
and,0,O
locomotor,0,O
effects,0,O
in,0,O
mice,0,O
",",0,O
compared,0,O
with,0,O
dextromethorphan,0,B-CHEMICAL
and,0,O
dextrorphan,0,B-CHEMICAL
.,0,O
Dextromethorphan,1,B-CHEMICAL
(,1,O
(,1,B-CHEMICAL
+,1,I-CHEMICAL
),1,I-CHEMICAL
-3-methoxy-N-methylmorphinan,1,I-CHEMICAL
",",1,O
DM,1,B-CHEMICAL
),1,O
has,1,O
been,1,O
shown,1,O
to,1,O
have,1,O
both,1,O
anticonvulsant,1,O
and,1,O
neuroprotective,1,O
effects,1,O
.,1,O
The,2,O
mechanisms,2,O
of,2,O
these,2,O
CNS,2,O
effects,2,O
of,2,O
DM,2,B-CHEMICAL
have,2,O
been,2,O
suggested,2,O
to,2,O
be,2,O
associated,2,O
with,2,O
the,2,O
low-affinity,2,O
",",2,O
noncompetitive,2,O
",",2,O
N-methyl-d-aspartate,2,B-CHEMICAL
(,2,O
NMDA,2,B-CHEMICAL
),2,O
antagonism,2,O
of,2,O
DM,2,B-CHEMICAL
and/or,2,O
the,2,O
high-affinity,2,O
DM/sigma,2,B-CHEMICAL
receptors,2,O
.,2,O
DM,3,B-CHEMICAL
is,3,O
largely,3,O
O-demethylated,3,B-CHEMICAL
into,3,O
the,3,O
phencyclidine,3,B-CHEMICAL
(,3,O
PCP,3,B-CHEMICAL
),3,O
-like,3,O
compound,3,O
dextrorphan,3,B-CHEMICAL
(,3,O
DR,3,B-CHEMICAL
),3,O
",",3,O
which,3,O
may,3,O
limit,3,O
its,3,O
therapeutic,3,O
use,3,O
by,3,O
producing,3,O
PCP-like,3,B-CHEMICAL
adverse,3,O
effects,3,O
",",3,O
such,3,O
as,3,O
hyperlocomotion,3,O
.,3,O
Dimemorfan,4,B-CHEMICAL
(,4,O
(,4,B-CHEMICAL
+,4,I-CHEMICAL
),4,I-CHEMICAL
-3-methyl-N-methylmorphinan,4,I-CHEMICAL
",",4,O
DF,4,B-CHEMICAL
),4,O
",",4,O
an,4,O
analog,4,O
of,4,O
DM,4,B-CHEMICAL
",",4,O
which,4,O
has,4,O
been,4,O
safely,4,O
used,4,O
as,4,O
an,4,O
antitussive,4,O
for,4,O
more,4,O
than,4,O
20,4,O
years,4,O
",",4,O
is,4,O
also,4,O
known,4,O
not,4,O
to,4,O
form,4,O
DR,4,B-CHEMICAL
.,4,O
This,5,O
study,5,O
therefore,5,O
characterized,5,O
the,5,O
binding,5,O
of,5,O
DF,5,B-CHEMICAL
to,5,O
the,5,O
sigma,5,B-GENE-N
receptors,5,I-GENE-N
and,5,O
NMDA-linked,5,B-CHEMICAL
PCP,5,B-CHEMICAL
sites,5,O
and,5,O
examined,5,O
the,5,O
anticonvulsant,5,O
as,5,O
well,5,O
as,5,O
locomotor,5,O
effects,5,O
of,5,O
DF,5,B-CHEMICAL
in,5,O
mice,5,O
in,5,O
comparison,5,O
with,5,O
those,5,O
of,5,O
DM,5,B-CHEMICAL
and,5,O
DR.,5,B-CHEMICAL
We,5,O
found,5,O
that,5,O
DF,5,B-CHEMICAL
",",5,O
DM,5,B-CHEMICAL
",",5,O
and,5,O
DR,5,B-CHEMICAL
were,5,O
relative,5,O
high-affinity,5,O
ligands,5,O
at,5,O
sigma-1,5,B-GENE-Y
receptors,5,I-GENE-Y
(,5,O
Ki=151,5,O
",",5,O
205,5,O
",",5,O
144,5,O
nM,5,O
",",5,O
respectively,5,O
),5,O
while,5,O
all,5,O
of,5,O
them,5,O
were,5,O
with,5,O
low,5,O
affinity,5,O
at,5,O
sigma-2,5,B-GENE-N
receptors,5,I-GENE-N
(,5,O
Ki=4-11,5,O
microM,5,O
),5,O
.,5,O
Only,6,O
DR,6,B-CHEMICAL
exhibited,6,O
moderate,6,O
affinity,6,O
for,6,O
PCP,6,B-CHEMICAL
sites,6,O
(,6,O
Ki=0.9,6,O
microM,6,O
),6,O
",",6,O
whereas,6,O
DF,6,B-CHEMICAL
(,6,O
Ki=17,6,O
microM,6,O
),6,O
and,6,O
DM,6,B-CHEMICAL
(,6,O
Ki=7,6,O
microM,6,O
),6,O
were,6,O
much,6,O
less,6,O
active,6,O
.,6,O
DF,7,O
",",7,O
DM,7,B-CHEMICAL
and,7,O
DR,7,B-CHEMICAL
produced,7,O
prominent,7,O
anticonvulsant,7,O
effects,7,O
in,7,O
mice,7,O
as,7,O
measured,7,O
by,7,O
the,7,O
supramaximal,7,O
electroshock,7,O
test,7,O
with,7,O
comparable,7,O
potency,7,O
(,7,O
ED50,7,O
approximately,7,O
70,7,O
micromol/kg,7,O
",",7,O
i.p,7,O
.,7,O
),7,O
.,7,O
At,8,O
the,8,O
tested,8,O
doses,8,O
(,8,O
20-260,8,O
micromol/kg,8,O
",",8,O
i.p,8,O
.,8,O
),9,O
",",9,O
DM,9,O
and,9,O
DR,9,O
exhibited,9,O
biphasic,9,O
effects,9,O
on,9,O
the,9,O
locomotor,9,O
activity,9,O
whereas,9,O
DF,9,O
produced,9,O
a,9,O
consistent,9,O
dose-dependent,9,O
decrease,9,O
.,9,O
These,10,O
results,10,O
revealed,10,O
that,10,O
",",10,O
unlike,10,O
DM,10,O
and,10,O
DR,10,O
",",10,O
DF,10,O
did,10,O
not,10,O
cause,10,O
a,10,O
PCP-like,10,O
hyperlocomotion,10,O
adverse,10,O
effect,10,O
that,10,O
is,10,O
parallel,10,O
with,10,O
the,10,O
PCP,10,O
sites,10,O
binding,10,O
data,10,O
.,10,O
Furthermore,11,O
",",11,O
since,11,O
they,11,O
have,11,O
equipotent,11,O
anticonvulsant,11,O
effects,11,O
and,11,O
similar,11,O
binding,11,O
affinities,11,O
to,11,O
sigma-1,11,I-GENE-Y
receptors,11,O
",",11,O
the,11,O
very,11,O
low,11,O
affinity,11,O
of,11,O
DF,11,O
at,11,O
PCP,11,O
sites,11,O
may,11,O
suggest,11,O
that,11,O
acting,11,O
on,11,O
the,11,O
PCP,11,O
sites,11,O
may,11,O
not,11,O
be,11,O
the,11,O
requisite,11,O
for,11,O
mediating,11,O
the,11,O
anticonvulsant,11,O
activity,11,O
of,11,O
these,11,O
DM,11,O
analogs,11,O
.,11,O
With,12,O
the,12,O
history,12,O
of,12,O
safety,12,O
and,12,O
relative,12,O
less,12,O
adverse,12,O
effects,12,O
",",12,O
DF,12,O
appears,12,O
to,12,O
be,12,O
worth,12,O
further,12,O
studying,12,O
on,12,O
its,12,O
CNS,12,O
effects,12,O
other,12,O
than,12,O
the,12,O
antitussive,12,O
effect,12,O
.,12,O
Angiotensin,13,B-GENE-N
II,13,I-GENE-N
receptor,13,I-GENE-N
blockade,13,O
in,13,O
normotensive,13,O
subjects,13,O
:,13,O
A,13,O
direct,13,O
comparison,13,O
of,13,O
three,13,O
AT1,13,B-GENE-Y
receptor,13,I-GENE-Y
antagonists,13,O
.,13,O
Use,14,O
of,14,O
angiotensin,14,B-GENE-Y
(,14,I-GENE-Y
Ang,14,B-CHEMICAL
),14,I-GENE-Y
II,14,I-GENE-Y
AT1,14,I-GENE-Y
receptor,14,I-GENE-Y
antagonists,14,O
for,14,O
treatment,14,O
of,14,O
hypertension,14,O
is,14,O
rapidly,14,O
increasing,14,O
",",14,O
yet,14,O
direct,14,O
comparisons,14,O
of,14,O
the,14,O
relative,14,O
efficacy,14,O
of,14,O
antagonists,14,O
to,14,O
block,14,O
the,14,O
renin-angiotensin,14,O
system,14,O
in,14,O
humans,14,O
are,14,O
lacking,14,O
.,14,O
In,15,O
this,15,O
study,15,O
",",15,O
the,15,O
Ang,15,B-CHEMICAL
II,15,I-CHEMICAL
receptor,15,I-GENE-N
blockade,15,O
induced,15,O
by,15,O
the,15,O
recommended,15,O
starting,15,O
dose,15,O
of,15,O
3,15,O
antagonists,15,O
was,15,O
evaluated,15,O
in,15,O
normotensive,15,O
subjects,15,O
in,15,O
a,15,O
double-blind,15,O
",",15,O
placebo-controlled,15,O
",",15,O
randomized,15,O
",",15,O
4-way,15,O
crossover,15,O
study,15,O
.,15,O
At,16,O
1-week,16,O
intervals,16,O
",",16,O
12,16,O
subjects,16,O
received,16,O
a,16,O
single,16,O
dose,16,O
of,16,O
losartan,16,B-CHEMICAL
(,16,O
50,16,O
mg,16,O
),16,O
",",16,O
valsartan,16,B-CHEMICAL
(,16,O
80,16,O
mg,16,O
),16,O
",",16,O
irbesartan,16,B-CHEMICAL
(,16,O
150,16,O
mg,16,O
),16,O
",",16,O
or,16,O
placebo,16,O
.,16,O
Blockade,17,O
of,17,O
the,17,O
renin-angiotensin,17,B-GENE-Y
system,17,O
was,17,O
assessed,17,O
before,17,O
and,17,O
4,17,O
",",17,O
24,17,O
",",17,O
and,17,O
30,17,O
hours,17,O
after,17,O
drug,17,O
intake,17,O
by,17,O
3,17,O
independent,17,O
methods,17,O
:,17,O
inhibition,17,O
of,17,O
the,17,O
blood,17,O
pressure,17,O
response,17,O
to,17,O
exogenous,17,O
Ang,17,B-GENE-Y
II,17,I-GENE-Y
",",17,O
in,17,O
vitro,17,O
Ang,17,B-GENE-N
II,17,I-GENE-N
receptor,17,I-GENE-N
assay,17,O
",",17,O
and,17,O
reactive,17,O
changes,17,O
in,17,O
plasma,17,O
Ang,17,B-GENE-Y
II,17,I-GENE-Y
levels,17,O
.,17,O
At,18,O
4,18,O
hours,18,O
",",18,O
losartan,18,O
blocked,18,O
43,18,O
%,18,O
of,18,O
the,18,O
Ang,18,B-GENE-Y
II-induced,18,O
systolic,18,O
blood,18,O
pressure,18,O
increase,18,O
;,18,O
valsartan,18,B-CHEMICAL
",",18,O
51,18,O
%,18,O
;,18,O
and,18,O
irbesartan,18,B-CHEMICAL
",",18,O
88,18,O
%,18,O
(,18,O
P,18,O
<,18,O
0.01,18,O
between,18,O
drugs,18,O
),18,O
.,18,O
The,19,O
effect,19,O
of,19,O
each,19,O
drug,19,O
declined,19,O
with,19,O
time,19,O
.,19,O
At,20,O
24,20,O
hours,20,O
",",20,O
a,20,O
residual,20,O
effect,20,O
was,20,O
found,20,O
with,20,O
all,20,O
3,20,O
drugs,20,O
",",20,O
but,20,O
at,20,O
30,20,O
hours,20,O
",",20,O
only,20,O
irbesartan,20,B-CHEMICAL
induced,20,O
a,20,O
marked,20,O
",",20,O
significant,20,O
blockade,20,O
versus,20,O
placebo,20,O
.,20,O
Similar,21,O
results,21,O
were,21,O
obtained,21,O
when,21,O
Ang,21,B-CHEMICAL
II,21,I-CHEMICAL
receptor,21,I-GENE-N
blockade,21,O
was,21,O
assessed,21,O
with,21,O
an,21,O
in,21,O
vitro,21,O
receptor,21,O
assay,21,O
and,21,O
by,21,O
the,21,O
reactive,21,O
rise,21,O
in,21,O
plasma,21,O
Ang,21,B-CHEMICAL
II,21,I-CHEMICAL
levels,21,O
.,21,O
This,22,O
study,22,O
thus,22,O
demonstrates,22,O
that,22,O
the,22,O
first,22,O
administration,22,O
of,22,O
the,22,O
recommended,22,O
starting,22,O
dose,22,O
of,22,O
irbesartan,22,B-CHEMICAL
induces,22,O
a,22,O
greater,22,O
and,22,O
longer,22,O
lasting,22,O
Ang,22,B-CHEMICAL
II,22,I-CHEMICAL
receptor,22,I-GENE-N
blockade,22,O
than,22,O
that,22,O
of,22,O
valsartan,22,B-CHEMICAL
and,22,O
losartan,22,B-CHEMICAL
in,22,O
normotensive,22,O
subjects,22,O
.,22,O
Characterisation,23,O
of,23,O
the,23,O
5-HT,23,B-GENE-N
receptor,23,I-GENE-N
binding,23,O
profile,23,O
of,23,O
eletriptan,23,B-CHEMICAL
and,23,O
kinetics,23,O
of,23,O
[,23,B-CHEMICAL
3H,23,I-CHEMICAL
],23,I-CHEMICAL
eletriptan,23,I-CHEMICAL
binding,23,O
at,23,O
human,23,B-GENE-Y
5-HT1B,23,I-GENE-Y
and,23,O
5-HT1D,23,B-GENE-Y
receptors,23,O
.,23,O
The,24,O
affinity,24,O
of,24,O
eletriptan,24,B-CHEMICAL
(,24,O
(,24,B-CHEMICAL
R,24,I-CHEMICAL
),24,I-CHEMICAL
-3-,24,I-CHEMICAL
(,24,I-CHEMICAL
1-methyl-2-pyrrolidinylmethyl,24,I-CHEMICAL
),24,I-CHEMICAL
-5-,24,I-CHEMICAL
[,24,I-CHEMICAL
2-,24,I-CHEMICAL
(,24,I-CHEMICAL
phenylsulphonyl,24,I-CHEMICAL
),24,I-CHEMICAL
ethyl,24,I-CHEMICAL
],24,I-CHEMICAL
-1H-indole,24,I-CHEMICAL
),24,O
for,24,O
a,24,O
range,24,O
of,24,O
5-HT,24,B-CHEMICAL
receptors,24,I-GENE-N
was,24,O
compared,24,O
to,24,O
values,24,O
obtained,24,O
for,24,O
other,24,O
5-HT1B/1D,24,B-GENE-N
receptor,24,O
agonists,24,O
known,24,O
to,24,O
be,24,O
effective,24,O
in,24,O
the,24,O
treatment,24,O
of,24,O
migraine,24,O
.,24,O
Eletriptan,25,B-CHEMICAL
",",25,O
like,25,O
sumatriptan,25,B-CHEMICAL
",",25,O
zolmitriptan,25,B-CHEMICAL
",",25,O
naratriptan,25,B-CHEMICAL
and,25,O
rizatriptan,25,B-CHEMICAL
had,25,O
highest,25,O
affinity,25,O
for,25,O
the,25,O
human,25,B-GENE-Y
5-HT1B,25,I-GENE-Y
",",25,O
5-HT1D,25,B-GENE-Y
and,25,O
putative,25,O
5-ht1f,25,B-GENE-Y
receptor,25,O
.,25,O
Kinetic,26,O
studies,26,O
comparing,26,O
the,26,O
binding,26,O
of,26,O
[,26,B-CHEMICAL
3H,26,I-CHEMICAL
],26,I-CHEMICAL
eletriptan,26,I-CHEMICAL
and,26,O
[,26,B-CHEMICAL
3H,26,I-CHEMICAL
],26,I-CHEMICAL
sumatriptan,26,I-CHEMICAL
to,26,O
the,26,O
human,26,B-GENE-Y
recombinant,26,I-GENE-Y
5-HT1B,26,I-GENE-Y
and,26,O
5-HT1D,26,B-GENE-Y
receptors,26,O
expressed,26,O
in,26,O
HeLa,26,O
cells,26,O
revealed,26,O
that,26,O
both,26,O
radioligands,26,O
bound,26,O
with,26,O
high,26,O
specificity,26,O
(,26,O
>,26,O
90,26,O
%,26,O
),26,O
and,26,O
reached,26,O
equilibrium,26,O
within,26,O
10-15,26,O
min,26,O
.,26,O
However,27,O
",",27,O
[,27,B-CHEMICAL
3H,27,I-CHEMICAL
],27,I-CHEMICAL
eletriptan,27,I-CHEMICAL
had,27,O
over,27,O
6-fold,27,O
higher,27,O
affinity,27,O
than,27,O
[,27,B-CHEMICAL
3H,27,I-CHEMICAL
],27,I-CHEMICAL
sumatriptan,27,I-CHEMICAL
at,27,O
the,27,O
5-HT1D,27,B-GENE-Y
receptor,27,O
(,27,O
K,27,O
(,27,O
D,27,O
),27,O
),27,O
:,27,O
0.92,27,O
and,27,O
6.58,27,O
nM,27,O
",",27,O
respectively,27,O
),27,O
and,27,O
over,27,O
3-fold,27,O
higher,27,O
affinity,27,O
than,27,O
[,27,B-CHEMICAL
3H,27,I-CHEMICAL
],27,I-CHEMICAL
sumatriptan,27,I-CHEMICAL
at,27,O
the,27,O
5-HT1B,27,B-GENE-Y
receptor,27,O
(,27,O
K,27,O
(,27,O
D,27,O
),27,O
:,27,O
3.14,27,O
and,27,O
11.07,27,O
nM,27,O
",",27,O
respectively,27,O
),27,O
.,27,O
Association,28,O
and,28,O
dissociation,28,O
rates,28,O
for,28,O
both,28,O
radioligands,28,O
could,28,O
only,28,O
be,28,O
accurately,28,O
determined,28,O
at,28,O
the,28,O
5-HT1D,28,B-GENE-Y
receptor,28,O
and,28,O
then,28,O
only,28,O
at,28,O
4,28,O
degrees,28,O
C.,28,O
At,28,O
this,28,O
temperature,28,O
",",28,O
[,28,B-CHEMICAL
3H,28,I-CHEMICAL
],28,I-CHEMICAL
eletriptan,28,I-CHEMICAL
had,28,O
a,28,O
significantly,28,O
(,28,O
P,28,O
<,28,O
0.05,28,O
),28,O
faster,28,O
association,28,O
rate,28,O
(,28,O
K,28,O
(,28,O
on,28,O
),28,O
0.249,28,O
min,28,O
(,28,O
-1,28,O
),28,O
nM,28,O
(,28,O
-1,28,O
),28,O
),28,O
than,28,O
[,28,B-CHEMICAL
3H,28,I-CHEMICAL
],28,I-CHEMICAL
sumatriptan,28,I-CHEMICAL
(,28,O
K,28,O
(,28,O
on,28,O
),28,O
0.024,28,O
min,28,O
(,28,O
-1,28,O
),28,O
nM,28,O
(,28,O
-1,28,O
),28,O
),28,O
and,28,O
a,28,O
significantly,28,O
(,28,O
P,28,O
<,28,O
0.05,28,O
),28,O
slower,28,O
off-rate,28,O
(,28,O
K,28,O
(,28,O
off,28,O
),28,O
0.027,28,O
min,28,O
(,28,O
-1,28,O
),28,O
compared,28,O
to,28,O
0.037,28,O
min,28,O
(,28,O
-1,28,O
),28,O
for,28,O
[,28,B-CHEMICAL
3H,28,I-CHEMICAL
],28,I-CHEMICAL
sumatriptan,28,I-CHEMICAL
),28,O
.,28,O
These,29,O
data,29,O
indicate,29,O
that,29,O
eletriptan,29,O
is,29,O
a,29,O
potent,29,O
ligand,29,O
at,29,O
the,29,O
human,29,B-GENE-Y
5-HT1B,29,I-GENE-Y
",",29,O
5-HT1D,29,B-GENE-Y
",",29,O
and,29,O
5-ht1f,29,B-GENE-Y
receptors,29,O
and,29,O
are,29,O
consistent,29,O
with,29,O
its,29,O
potent,29,O
vasoconstrictor,29,O
activity,29,O
and,29,O
use,29,O
as,29,O
a,29,O
drug,29,O
for,29,O
the,29,O
acute,29,O
treatment,29,O
of,29,O
migraine,29,O
headache,29,O
.,29,O
Pharmacological,30,O
profile,30,O
of,30,O
neuroleptics,30,B-CHEMICAL
at,30,O
human,30,B-GENE-N
monoamine,30,I-GENE-N
transporters,30,I-GENE-N
.,30,O
Using,31,O
radioligand,31,O
binding,31,O
techniques,31,O
",",31,O
we,31,O
determined,31,O
the,31,O
equilibrium,31,O
dissociation,31,O
constants,31,O
(,31,O
K,31,O
(,31,O
D,31,O
),31,O
),31,O
for,31,O
37,31,O
neuroleptics,31,B-CHEMICAL
and,31,O
one,31,O
metabolite,31,O
of,31,O
a,31,O
neuroleptic,31,O
(,31,O
haloperidol,31,B-CHEMICAL
metabolite,31,O
),31,O
for,31,O
the,31,O
human,31,B-GENE-N
serotonin,31,B-CHEMICAL
",",31,I-GENE-N
norepinephrine,31,B-CHEMICAL
",",31,I-GENE-N
and,31,I-GENE-N
dopamine,31,B-CHEMICAL
transporters,31,I-GENE-N
with,31,O
[,31,B-CHEMICAL
3H,31,I-CHEMICAL
],31,I-CHEMICAL
imipramine,31,I-CHEMICAL
",",31,O
[,31,B-CHEMICAL
3H,31,I-CHEMICAL
],31,I-CHEMICAL
nisoxetine,31,I-CHEMICAL
",",31,O
and,31,O
[,31,B-CHEMICAL
3H,31,I-CHEMICAL
],31,I-CHEMICAL
WIN35428,31,I-CHEMICAL
",",31,O
respectively,31,O
.,31,O
Among,32,O
neuroleptics,32,B-CHEMICAL
",",32,O
the,32,O
four,32,O
most,32,O
potent,32,O
compounds,32,O
at,32,O
the,32,O
human,32,B-GENE-Y
serotonin,32,I-GENE-Y
transporter,32,I-GENE-Y
were,32,O
triflupromazine,32,B-CHEMICAL
",",32,O
fluperlapine,32,B-CHEMICAL
",",32,O
chlorpromazine,32,B-CHEMICAL
",",32,O
and,32,O
ziprasidone,32,B-CHEMICAL
(,32,O
K,32,O
(,32,O
D,32,O
),32,O
24-39,32,O
nM,32,O
),32,O
;,32,O
and,32,O
at,32,O
the,32,O
norepinephrine,32,B-GENE-Y
transporter,32,I-GENE-Y
",",32,O
chlorpromazine,32,B-CHEMICAL
",",32,O
zotepine,32,B-CHEMICAL
",",32,O
chlorprothixene,32,B-CHEMICAL
",",32,O
and,32,O
promazine,32,B-CHEMICAL
(,32,O
K,32,O
(,32,O
D,32,O
),32,O
19-25,32,O
nM,32,O
),32,O
.,32,O
At,33,O
the,33,O
human,33,B-GENE-Y
dopamine,33,I-GENE-Y
transporter,33,I-GENE-Y
",",33,O
only,33,O
pimozide,33,B-CHEMICAL
(,33,O
K,33,O
(,33,O
D,33,O
),33,O
=,33,O
69+/-3,33,O
),33,O
ziprasidone,33,B-CHEMICAL
(,33,O
K,33,O
(,33,O
D,33,O
),33,O
=,33,O
76+/-5,33,O
),33,O
had,33,O
notable,33,O
potency,33,O
.,33,O
These,34,O
data,34,O
may,34,O
be,34,O
useful,34,O
in,34,O
predicting,34,O
therapeutic,34,O
and,34,O
adverse,34,O
effects,34,O
",",34,O
including,34,O
drug,34,O
interactions,34,O
of,34,O
neuroleptics,34,B-CHEMICAL
.,34,O
Disodium,35,B-CHEMICAL
cromoglycate,35,I-CHEMICAL
does,35,O
not,35,O
prevent,35,O
terbutaline-induced,35,B-CHEMICAL
desensitization,35,O
of,35,O
beta,35,B-GENE-Y
2-adrenoceptor-mediated,35,O
cardiovascular,35,O
in,35,O
vivo,35,O
functions,35,O
in,35,O
human,35,O
volunteers,35,O
.,35,O
In,36,O
humans,36,O
",",36,O
prolonged,36,O
administration,36,O
of,36,O
the,36,O
beta,36,B-GENE-Y
2-adrenoceptor,36,I-GENE-Y
agonist,36,O
terbutaline,36,B-CHEMICAL
leads,36,O
to,36,O
a,36,O
desensitization,36,O
of,36,O
beta,36,B-GENE-Y
2-adrenoceptor-mediated,36,O
cardiovascular,36,O
responses,36,O
",",36,O
which,36,O
can,36,O
be,36,O
blunted,36,O
by,36,O
concomitant,36,O
administration,36,O
of,36,O
the,36,O
antianaphylactic,36,O
drug,36,O
ketotifen,36,B-CHEMICAL
.,36,O
This,37,O
study,37,O
investigated,37,O
the,37,O
effect,37,O
of,37,O
disodium,37,B-CHEMICAL
cromoglycate,37,I-CHEMICAL
",",37,O
another,37,O
antiallergic,37,O
drug,37,O
",",37,O
on,37,O
terbutaline-induced,37,B-CHEMICAL
desensitization,37,O
of,37,O
beta-adrenoceptor-mediated,37,B-GENE-N
cardiovascular,37,O
and,37,O
noncardiovascular,37,O
responses,37,O
.,37,O
In,38,O
a,38,O
double-blind,38,O
",",38,O
placebo-controlled,38,O
",",38,O
randomized,38,O
design,38,O
",",38,O
nine,38,O
healthy,38,O
male,38,O
volunteers,38,O
received,38,O
disodium,38,B-CHEMICAL
cromoglycate,38,I-CHEMICAL
(,38,O
4,38,O
x,38,O
200,38,O
mg/day,38,O
",",38,O
p.o,38,O
.,38,O
),38,O
or,39,O
placebo,39,O
for,39,O
3,39,O
weeks,39,O
with,39,O
terbutaline,39,B-CHEMICAL
(,39,O
3,39,O
x,39,O
5,39,O
mg/day,39,O
",",39,O
p.o,39,O
.,39,O
),39,O
administered,40,O
concomitantly,40,O
during,40,O
the,40,O
last,40,O
2,40,O
weeks,40,O
.,40,O
beta,41,B-GENE-Y
2-Adrenoceptor,41,I-GENE-Y
cardiovascular,41,O
function,41,O
was,41,O
assessed,41,O
by,41,O
the,41,O
increase,41,O
in,41,O
heart,41,O
rate,41,O
and,41,O
reduction,41,O
of,41,O
diastolic,41,O
blood,41,O
pressure,41,O
induced,41,O
by,41,O
an,41,O
incremental,41,O
intravenous,41,O
infusion,41,O
of,41,O
the,41,O
unselective,41,O
beta-adrenoceptor,41,B-GENE-N
agonist,41,O
isoprenaline,41,B-CHEMICAL
;,41,O
beta,41,B-GENE-Y
1-adrenoceptor,41,I-GENE-Y
cardiovascular,41,O
function,41,O
was,41,O
assessed,41,O
by,41,O
exercise-induced,41,O
tachycardia,41,O
.,41,O
Tremulousness,42,O
was,42,O
monitored,42,O
as,42,O
a,42,O
beta,42,B-GENE-Y
2-adrenoceptor-mediated,42,O
noncardiovascular,42,O
effect,42,O
.,42,O
After,43,O
2,43,O
weeks,43,O
',43,O
administration,43,O
of,43,O
terbutaline,43,B-CHEMICAL
",",43,O
there,43,O
was,43,O
a,43,O
marked,43,O
and,43,O
significant,43,O
(,43,O
p,43,O
<,43,O
0.001,43,O
),43,O
attenuation,43,O
of,43,O
isoprenaline-induced,43,B-CHEMICAL
tachycardia,43,O
(,43,O
mean,43,O
percentage,43,O
attenuation,43,O
",",43,O
53.3,43,O
%,43,O
),43,O
and,43,O
of,43,O
the,43,O
isoprenaline-induced,43,B-CHEMICAL
decrease,43,O
in,43,O
diastolic,43,O
blood,43,O
pressure,43,O
(,43,O
mean,43,O
percentage,43,O
attenuation,43,O
",",43,O
55.6,43,O
%,43,O
),43,O
.,43,O
Exercise-induced,44,O
tachycardia,44,O
also,44,O
was,44,O
significantly,44,O
(,44,O
p,44,O
<,44,O
0.001,44,O
),44,O
blunted,44,O
",",44,O
but,44,O
the,44,O
magnitude,44,O
of,44,O
this,44,O
attenuation,44,O
was,44,O
only,44,O
very,44,O
small,44,O
(,44,O
mean,44,O
attenuation,44,O
",",44,O
5.6,44,O
%,44,O
),44,O
.,44,O
Disodium,45,B-CHEMICAL
cromoglycate,45,I-CHEMICAL
affected,45,O
neither,45,O
the,45,O
rightward,45,O
shift,45,O
of,45,O
beta,45,B-GENE-Y
2-adrenoceptor-mediated,45,O
responses,45,O
nor,45,O
the,45,O
small,45,O
rightward,45,O
shift,45,O
in,45,O
beta,45,B-GENE-Y
1-adrenoceptor-mediated,45,O
exercise,45,O
tachycardia,45,O
after,45,O
2,45,O
weeks,45,O
',45,O
administration,45,O
of,45,O
terbutaline,45,B-CHEMICAL
.,45,O
Tremulousness,46,O
observed,46,O
during,46,O
the,46,O
first,46,O
few,46,O
days,46,O
of,46,O
terbutaline,46,B-CHEMICAL
administration,46,O
disappeared,46,O
after,46,O
4,46,O
to,46,O
8,46,O
days,46,O
",",46,O
indicating,46,O
development,46,O
of,46,O
desensitization,46,O
of,46,O
beta,46,B-GENE-Y
2-adrenoceptor-mediated,46,O
noncardiovascular,46,O
responses,46,O
.,46,O
This,47,O
was,47,O
not,47,O
prevented,47,O
by,47,O
disodium,47,B-CHEMICAL
cromoglycate,47,I-CHEMICAL
.,47,O
These,48,O
results,48,O
confirm,48,O
that,48,O
long-term,48,O
beta,48,B-GENE-Y
2-adrenoceptor,48,I-GENE-Y
agonist,48,O
therapy,48,O
leads,48,O
to,48,O
a,48,O
desensitization,48,O
of,48,O
beta,48,B-GENE-Y
2-adrenoceptor-mediated,48,O
cardiovascular,48,O
and,48,O
noncardiovascular,48,O
effects,48,O
in,48,O
humans,48,O
in,48,O
vivo,48,O
.,48,O
However,49,O
",",49,O
unlike,49,O
ketotifen,49,B-CHEMICAL
",",49,O
cromolyn,49,B-CHEMICAL
sodium,49,I-CHEMICAL
is,49,O
not,49,O
able,49,O
to,49,O
attenuate,49,O
this,49,O
desensitization,49,O
.,49,O
A,50,O
multicenter,50,O
",",50,O
randomized,50,O
study,50,O
of,50,O
argatroban,50,B-CHEMICAL
versus,50,O
heparin,50,O
as,50,O
adjunct,50,O
to,50,O
tissue,50,B-GENE-Y
plasminogen,50,I-GENE-Y
activator,50,I-GENE-Y
(,50,O
TPA,50,B-GENE-Y
),50,O
in,50,O
acute,50,O
myocardial,50,O
infarction,50,O
:,50,O
myocardial,50,O
infarction,50,O
with,50,O
novastan,50,B-CHEMICAL
and,50,O
TPA,50,B-GENE-Y
(,50,O
MINT,50,O
),50,O
study,50,O
.,50,O
OBJECTIVES,51,O
:,51,O
This,51,O
study,51,O
examined,51,O
the,51,O
effect,51,O
of,51,O
a,51,O
small-molecule,51,O
",",51,O
direct,51,O
thrombin,51,B-GENE-Y
inhibitor,51,O
",",51,O
argatroban,51,B-CHEMICAL
",",51,O
on,51,O
reperfusion,51,O
induced,51,O
by,51,O
tissue,51,B-GENE-Y
plasminogen,51,I-GENE-Y
activator,51,I-GENE-Y
(,51,O
TPA,51,B-GENE-Y
),51,O
in,51,O
patients,51,O
with,51,O
acute,51,O
myocardial,51,O
infarction,51,O
(,51,O
AMI,51,O
),51,O
.,51,O
BACKGROUND,52,O
:,52,O
Thrombin,52,B-GENE-Y
plays,52,O
a,52,O
crucial,52,O
role,52,O
in,52,O
thrombosis,52,O
and,52,O
thrombolysis,52,O
.,52,O
In,53,O
vitro,53,O
and,53,O
in,53,O
vivo,53,O
studies,53,O
have,53,O
shown,53,O
that,53,O
argatroban,53,B-CHEMICAL
has,53,O
advantages,53,O
over,53,O
heparin,53,O
for,53,O
the,53,O
inhibition,53,O
of,53,O
clot-bound,53,O
thrombin,53,B-GENE-Y
and,53,O
for,53,O
the,53,O
enhancement,53,O
of,53,O
thrombolysis,53,O
with,53,O
TPA,53,B-GENE-Y
.,53,O
METHODS,54,O
:,54,O
One,54,O
hundred,54,O
and,54,O
twenty-five,54,O
patients,54,O
with,54,O
AMI,54,O
within,54,O
6,54,O
h,54,O
were,54,O
randomized,54,O
to,54,O
heparin,54,O
",",54,O
low-dose,54,O
argatroban,54,B-CHEMICAL
or,54,O
high-dose,54,O
argatroban,54,B-CHEMICAL
in,54,O
addition,54,O
to,54,O
TPA,54,B-GENE-Y
.,54,O
The,55,O
primary,55,O
end,55,O
point,55,O
was,55,O
the,55,O
rate,55,O
of,55,O
thrombolysis,55,O
in,55,O
myocardial,55,O
infarction,55,O
(,55,O
TIMI,55,O
),55,O
grade,55,O
3,55,O
flow,55,O
at,55,O
90,55,O
min,55,O
.,55,O
RESULTS,56,O
:,56,O
TIMI,56,O
grade,56,O
3,56,O
flow,56,O
was,56,O
achieved,56,O
in,56,O
42.1,56,O
%,56,O
of,56,O
heparin,56,O
",",56,O
56.8,56,O
%,56,O
of,56,O
low-dose,56,O
argatroban,56,B-CHEMICAL
(,56,O
p,56,O
=,56,O
0.20,56,O
vs.,56,O
heparin,56,O
),56,O
and,56,O
58.7,56,O
%,56,O
of,56,O
high-dose,56,O
argatroban,56,B-CHEMICAL
patients,56,O
(,56,O
p,56,O
=,56,O
0.13,56,O
vs.,56,O
heparin,56,O
),56,O
.,56,O
In,57,O
patients,57,O
presenting,57,O
after,57,O
3,57,O
h,57,O
",",57,O
TIMI,57,O
grade,57,O
3,57,O
flow,57,O
was,57,O
significantly,57,O
more,57,O
frequent,57,O
in,57,O
high-dose,57,O
argatroban,57,B-CHEMICAL
versus,57,O
heparin,57,O
patients,57,O
:,57,O
57.1,57,O
%,57,O
versus,57,O
20.0,57,O
%,57,O
(,57,O
p,57,O
=,57,O
0.03,57,O
vs.,57,O
heparin,57,O
),57,O
.,57,O
Major,58,O
bleeding,58,O
was,58,O
observed,58,O
in,58,O
10.0,58,O
%,58,O
of,58,O
heparin,58,O
",",58,O
and,58,O
in,58,O
2.6,58,O
%,58,O
and,58,O
4.3,58,O
%,58,O
of,58,O
low-dose,58,O
and,58,O
high-dose,58,O
argatroban,58,B-CHEMICAL
patients,58,O
",",58,O
respectively,58,O
.,58,O
The,59,O
composite,59,O
of,59,O
death,59,O
",",59,O
recurrent,59,O
myocardial,59,O
infarction,59,O
",",59,O
cardiogenic,59,O
shock,59,O
or,59,O
congestive,59,O
heart,59,O
failure,59,O
",",59,O
revascularization,59,O
and,59,O
recurrent,59,O
ischemia,59,O
at,59,O
30,59,O
days,59,O
occurred,59,O
in,59,O
37.5,59,O
%,59,O
of,59,O
heparin,59,O
",",59,O
32.0,59,O
%,59,O
of,59,O
low-dose,59,O
argatroban,59,B-CHEMICAL
and,59,O
25.5,59,O
%,59,O
of,59,O
high-dose,59,O
argatroban,59,B-CHEMICAL
patients,59,O
(,59,O
p,59,O
=,59,O
0.23,59,O
),59,O
.,59,O
CONCLUSIONS,60,O
:,60,O
Argatroban,60,B-CHEMICAL
",",60,O
as,60,O
compared,60,O
with,60,O
heparin,60,O
",",60,O
appears,60,O
to,60,O
enhance,60,O
reperfusion,60,O
with,60,O
TPA,60,B-GENE-Y
in,60,O
patients,60,O
with,60,O
AMI,60,O
",",60,O
particularly,60,O
in,60,O
those,60,O
patients,60,O
with,60,O
delayed,60,O
presentation,60,O
.,60,O
The,61,O
incidences,61,O
of,61,O
major,61,O
bleeding,61,O
and,61,O
adverse,61,O
clinical,61,O
outcome,61,O
were,61,O
lower,61,O
in,61,O
the,61,O
patients,61,O
receiving,61,O
argatroban,61,B-CHEMICAL
.,61,O
Mechanistic,62,O
differences,62,O
of,62,O
various,62,O
AT1-receptor,62,B-GENE-Y
blockers,62,O
in,62,O
isolated,62,O
vessels,62,O
of,62,O
different,62,O
origin,62,O
.,62,O
The,63,O
functional,63,O
inhibitory,63,O
characteristics,63,O
of,63,O
the,63,O
angiotensin,63,B-GENE-N
II,63,I-GENE-N
type,63,I-GENE-N
1,63,I-GENE-N
receptor,63,I-GENE-N
blockers,63,O
(,63,O
ARB,63,O
),63,O
candesartan,63,B-CHEMICAL
;,63,O
irbesartan,63,B-CHEMICAL
;,63,O
and,63,O
losartan,63,B-CHEMICAL
and,63,O
its,63,O
active,63,O
metabolite,63,O
EXP,63,B-CHEMICAL
3174,63,I-CHEMICAL
(,63,O
EXP,63,B-CHEMICAL
),63,O
were,63,O
studied,63,O
in,63,O
rabbit,63,O
aortic,63,O
strips,63,O
and,63,O
rat,63,O
portal,63,O
vein,63,O
preparations,63,O
in,63,O
vitro,63,O
.,63,O
Moreover,64,O
",",64,O
plasma-protein,64,O
binding,64,O
was,64,O
determined,64,O
",",64,O
and,64,O
the,64,O
binding,64,O
was,64,O
high,64,O
(,64,O
>,64,O
98,64,O
.,64,O
5,65,O
%,65,O
),65,O
for,65,O
all,65,O
ARBs,65,O
.,65,O
These,66,O
values,66,O
were,66,O
needed,66,O
to,66,O
relate,66,O
the,66,O
concentrations,66,O
of,66,O
the,66,O
ARBs,66,O
used,66,O
in,66,O
vitro,66,O
to,66,O
the,66,O
nonprotein,66,O
bound,66,O
concentrations,66,O
in,66,O
clinical,66,O
use,66,O
.,66,O
In,67,O
both,67,O
vascular,67,O
preparations,67,O
",",67,O
candesartan,67,B-CHEMICAL
caused,67,O
a,67,O
marked,67,O
decrease,67,O
in,67,O
the,67,O
maximal,67,O
contractile,67,O
response,67,O
of,67,O
the,67,O
angiotensin,67,B-GENE-N
II,67,I-GENE-N
(,67,O
Ang,67,B-GENE-N
II,67,I-GENE-N
),67,O
concentration-response,67,O
curve,67,O
.,67,O
Losartan,68,B-CHEMICAL
",",68,O
EXP,68,B-CHEMICAL
",",68,O
and,68,O
irbesartan,68,B-CHEMICAL
caused,68,O
a,68,O
rightward,68,O
parallel,68,O
shift,68,O
without,68,O
any,68,O
major,68,O
effects,68,O
on,68,O
the,68,O
maximal,68,O
response,68,O
to,68,O
Ang,68,B-GENE-N
II,68,I-GENE-N
.,68,O
The,69,O
inhibitory,69,O
effect,69,O
of,69,O
candesartan,69,B-CHEMICAL
developed,69,O
slowly,69,O
(,69,O
maximal,69,O
effect,69,O
after,69,O
>,69,O
30,69,O
minutes,69,O
),69,O
and,69,O
lasted,69,O
>,69,O
2,69,O
hours,69,O
despite,69,O
repeated,69,O
washing,69,O
of,69,O
the,69,O
vessels,69,O
.,69,O
The,70,O
effect,70,O
of,70,O
losartan,70,B-CHEMICAL
",",70,O
irbesartan,70,B-CHEMICAL
",",70,O
and,70,O
EXP,70,B-CHEMICAL
had,70,O
a,70,O
faster,70,O
onset,70,O
",",70,O
and,70,O
most,70,O
of,70,O
the,70,O
inhibitory,70,O
effect,70,O
disappeared,70,O
after,70,O
washing,70,O
.,70,O
The,71,O
duration,71,O
of,71,O
the,71,O
inhibitory,71,O
effects,71,O
of,71,O
the,71,O
ARBs,71,O
were,71,O
not,71,O
related,71,O
to,71,O
lipophilicity,71,O
of,71,O
the,71,O
compounds,71,O
.,71,O
Cooling,72,O
of,72,O
the,72,O
rat,72,O
portal,72,O
vein,72,O
preparations,72,O
to,72,O
4,72,O
degrees,72,O
C,72,O
before,72,O
administration,72,O
of,72,O
candesartan,72,B-CHEMICAL
prevented,72,O
the,72,O
persistent,72,O
inhibition,72,O
of,72,O
Ang,72,B-CHEMICAL
II,72,I-CHEMICAL
response,72,O
seen,72,O
at,72,O
37,72,O
degrees,72,O
C.,72,O
For,72,O
the,72,O
other,72,O
ARBs,72,O
studied,72,O
",",72,O
the,72,O
magnitude,72,O
of,72,O
inhibition,72,O
and,72,O
the,72,O
speed,72,O
of,72,O
recovery,72,O
of,72,O
the,72,O
Ang,72,B-CHEMICAL
II,72,I-CHEMICAL
response,72,O
were,72,O
independent,72,O
of,72,O
the,72,O
incubation,72,O
temperature,72,O
before,72,O
washing,72,O
.,72,O
In,73,O
addition,73,O
",",73,O
when,73,O
candesartan,73,B-CHEMICAL
was,73,O
given,73,O
to,73,O
conscious,73,O
rats,73,O
",",73,O
the,73,O
inhibitory,73,O
effect,73,O
on,73,O
Ang,73,B-CHEMICAL
II-induced,73,O
blood,73,O
pressure,73,O
responses,73,O
persisted,73,O
during,73,O
the,73,O
24-hour,73,O
period,73,O
despite,73,O
nondetectable,73,O
plasma,73,O
concentrations,73,O
of,73,O
candesartan,73,B-CHEMICAL
at,73,O
24,73,O
hours,73,O
.,73,O
It,74,O
is,74,O
concluded,74,O
that,74,O
functional,74,O
inhibitory,74,O
characteristics,74,O
of,74,O
candesartan,74,B-CHEMICAL
differ,74,O
from,74,O
those,74,O
of,74,O
the,74,O
other,74,O
ARBs,74,O
tested,74,O
.,74,O
At,75,O
clinically,75,O
relevant,75,O
concentrations,75,O
",",75,O
candesartan,75,B-CHEMICAL
is,75,O
an,75,O
insurmountable,75,O
and,75,O
long-lasting,75,O
antagonist,75,O
of,75,O
the,75,O
vascular,75,O
contractile,75,O
responses,75,O
to,75,O
Ang,75,B-GENE-N
II,75,I-GENE-N
.,75,O
Dose-dependent,76,O
inhibition,76,O
of,76,O
platelet,76,O
cyclooxygenase-1,76,B-GENE-Y
and,76,O
monocyte,76,O
cyclooxygenase-2,76,B-GENE-Y
by,76,O
meloxicam,76,B-CHEMICAL
in,76,O
healthy,76,O
subjects,76,O
.,76,O
We,77,O
evaluated,77,O
whether,77,O
therapeutic,77,O
blood,77,O
levels,77,O
of,77,O
meloxicam,77,B-CHEMICAL
are,77,O
associated,77,O
with,77,O
selective,77,O
inhibition,77,O
of,77,O
monocyte,77,O
cyclooxygenase,77,B-GENE-Y
(,77,I-GENE-Y
COX,77,I-GENE-Y
),77,I-GENE-Y
-2,77,I-GENE-Y
in,77,O
vitro,77,O
and,77,O
ex,77,O
vivo,77,O
.,77,O
Concentration-response,78,O
curves,78,O
for,78,O
the,78,O
inhibition,78,O
of,78,O
monocyte,78,O
COX-2,78,B-GENE-Y
and,78,O
platelet,78,O
COX-1,78,B-GENE-Y
were,78,O
obtained,78,O
in,78,O
vitro,78,O
after,78,O
the,78,O
incubation,78,O
of,78,O
meloxicam,78,B-CHEMICAL
with,78,O
whole,78,O
blood,78,O
samples,78,O
.,78,O
Moreover,79,O
",",79,O
11,79,O
healthy,79,O
volunteers,79,O
received,79,O
placebo,79,O
or,79,O
7.5,79,O
or,79,O
15,79,O
mg/day,79,O
meloxicam,79,B-CHEMICAL
",",79,O
each,79,O
treatment,79,O
for,79,O
7,79,O
consecutive,79,O
days,79,O
",",79,O
according,79,O
to,79,O
a,79,O
randomized,79,O
",",79,O
double-blind,79,O
",",79,O
crossover,79,O
design,79,O
.,79,O
Before,80,O
dosing,80,O
and,80,O
24,80,O
h,80,O
after,80,O
the,80,O
seventh,80,O
dose,80,O
of,80,O
each,80,O
regimen,80,O
",",80,O
heparinized,80,O
whole,80,O
blood,80,O
samples,80,O
were,80,O
incubated,80,O
with,80,O
lipopolysaccharide,80,O
(,80,O
10,80,O
microgram/ml,80,O
),80,O
for,80,O
24,80,O
h,80,O
at,80,O
37,80,O
degrees,80,O
C,80,O
",",80,O
and,80,O
prostaglandin,80,B-CHEMICAL
E2,80,I-CHEMICAL
was,80,O
measured,80,O
in,80,O
plasma,80,O
as,80,O
an,80,O
index,80,O
of,80,O
monocyte,80,O
COX-2,80,B-GENE-Y
activity,80,O
.,80,O
The,81,O
production,81,O
of,81,O
thromboxane,81,B-CHEMICAL
B2,81,I-CHEMICAL
in,81,O
whole,81,O
blood,81,O
allowed,81,O
to,81,O
clot,81,O
at,81,O
37,81,O
degrees,81,O
C,81,O
for,81,O
60,81,O
min,81,O
was,81,O
assessed,81,O
as,81,O
an,81,O
index,81,O
of,81,O
platelet,81,O
COX-1,81,B-GENE-Y
activity,81,O
.,81,O
The,82,O
administration,82,O
of,82,O
placebo,82,O
did,82,O
not,82,O
significantly,82,O
affect,82,O
plasma,82,O
prostaglandin,82,B-CHEMICAL
E2,82,I-CHEMICAL
(,82,O
21,82,O
.,82,O
3,83,O
+/-,83,O
7.5,83,O
versus,83,O
19.1,83,O
+/-,83,O
4,83,O
ng/ml,83,O
",",83,O
mean,83,O
+/-,83,O
S.D.,83,O
",",83,O
n,83,O
=,83,O
11,83,O
),83,O
or,83,O
serum,83,O
thromboxane,83,B-CHEMICAL
B2,83,I-CHEMICAL
(,83,O
426,83,O
+/-,83,O
167,83,O
versus,83,O
425,83,O
+/-,83,O
150,83,O
ng/ml,83,O
),83,O
levels,83,O
.,83,O
In,84,O
contrast,84,O
",",84,O
the,84,O
administration,84,O
of,84,O
7.5,84,O
and,84,O
15,84,O
mg,84,O
of,84,O
meloxicam,84,B-CHEMICAL
caused,84,O
dose-dependent,84,O
reductions,84,O
in,84,O
monocyte,84,O
COX-2,84,B-GENE-Y
activity,84,O
by,84,O
51,84,O
%,84,O
and,84,O
70,84,O
%,84,O
",",84,O
respectively,84,O
",",84,O
and,84,O
in,84,O
platelet,84,O
COX-1,84,B-GENE-Y
activity,84,O
by,84,O
25,84,O
%,84,O
and,84,O
35,84,O
%,84,O
",",84,O
respectively,84,O
.,84,O
Although,85,O
the,85,O
IC50,85,O
value,85,O
of,85,O
meloxicam,85,B-CHEMICAL
for,85,O
inhibition,85,O
of,85,O
COX-1,85,B-GENE-Y
was,85,O
10-fold,85,O
higher,85,O
than,85,O
the,85,O
IC50,85,O
value,85,O
of,85,O
COX-2,85,B-GENE-Y
in,85,O
vitro,85,O
",",85,O
this,85,O
biochemical,85,O
selectivity,85,O
was,85,O
inadequate,85,O
to,85,O
clearly,85,O
separate,85,O
the,85,O
effects,85,O
of,85,O
meloxicam,85,B-CHEMICAL
on,85,O
the,85,O
two,85,O
isozymes,85,O
after,85,O
oral,85,O
dosing,85,O
as,85,O
a,85,O
function,85,O
of,85,O
the,85,O
daily,85,O
dose,85,O
and,85,O
interindividual,85,O
variation,85,O
in,85,O
steady-state,85,O
plasma,85,O
levels,85,O
.,85,O
Modulation,86,O
of,86,O
dialysate,86,O
levels,86,O
of,86,O
dopamine,86,B-CHEMICAL
",",86,O
noradrenaline,86,B-CHEMICAL
",",86,O
and,86,O
serotonin,86,B-CHEMICAL
(,86,O
5-HT,86,B-CHEMICAL
),86,O
in,86,O
the,86,O
frontal,86,O
cortex,86,O
of,86,O
freely-moving,86,O
rats,86,O
by,86,O
(,86,B-CHEMICAL
-,86,I-CHEMICAL
),86,I-CHEMICAL
-pindolol,86,I-CHEMICAL
alone,86,O
and,86,O
in,86,O
association,86,O
with,86,O
5-HT,86,B-CHEMICAL
reuptake,86,O
inhibitors,86,O
:,86,O
comparative,86,O
roles,86,O
of,86,O
beta-adrenergic,86,O
",",86,O
5-HT1A,86,B-GENE-Y
",",86,I-GENE-Y
and,86,O
5-HT1B,86,B-GENE-Y
receptors,86,O
.,86,O
(,87,B-CHEMICAL
-,87,I-CHEMICAL
),87,I-CHEMICAL
-Pindolol,87,I-CHEMICAL
",",87,O
which,87,O
possesses,87,O
significant,87,O
affinity,87,O
for,87,O
5-HT1A,87,B-GENE-Y
",",87,O
5-HT1B,87,B-GENE-Y
",",87,O
and,87,O
beta,87,B-GENE-N
1/2-adrenergic,87,I-GENE-N
receptors,87,I-GENE-N
(,87,B-GENE-N
AR,87,I-GENE-N
),87,I-GENE-N
s,87,I-GENE-N
",",87,O
dose-dependently,87,O
increased,87,O
extracellular,87,O
levels,87,O
of,87,O
dopamine,87,B-CHEMICAL
(,87,O
DA,87,B-CHEMICAL
),87,O
and,87,O
noradrenaline,87,B-CHEMICAL
(,87,O
NAD,87,B-CHEMICAL
),87,O
versus,87,O
5-HT,87,B-CHEMICAL
",",87,O
in,87,O
dialysates,87,O
of,87,O
the,87,O
frontal,87,O
cortex,87,O
(,87,O
FCX,87,O
),87,O
",",87,O
but,87,O
not,87,O
accumbens,87,O
and,87,O
striatum,87,O
",",87,O
of,87,O
freely-moving,87,O
rats,87,O
.,87,O
In,88,O
distinction,88,O
",",88,O
the,88,O
preferential,88,O
beta,88,B-GENE-Y
1-AR,88,I-GENE-Y
antagonist,88,O
",",88,O
betaxolol,88,B-CHEMICAL
",",88,O
and,88,O
the,88,O
preferential,88,O
beta,88,B-GENE-Y
2-AR,88,I-GENE-Y
antagonist,88,O
",",88,O
"ICI118,551",88,B-CHEMICAL
",",88,O
did,88,O
not,88,O
increase,88,O
basal,88,O
levels,88,O
of,88,O
DA,88,B-CHEMICAL
",",88,O
NAD,88,B-CHEMICAL
",",88,O
or,88,O
5-HT,88,B-CHEMICAL
.,88,O
Further,89,O
",",89,O
they,89,O
both,89,O
dose-dependently,89,O
and,89,O
markedly,89,O
blunted,89,O
the,89,O
influence,89,O
of,89,O
(,89,B-CHEMICAL
-,89,I-CHEMICAL
),89,I-CHEMICAL
-pindolol,89,I-CHEMICAL
upon,89,O
DA,89,B-CHEMICAL
and,89,O
NAD,89,B-CHEMICAL
levels,89,O
.,89,O
The,90,O
selective,90,O
5-HT1A,90,B-GENE-Y
receptor,90,O
antagonist,90,O
",",90,O
"WAY100,635",90,B-CHEMICAL
",",90,O
slightly,90,O
attenuated,90,O
the,90,O
(,90,B-CHEMICAL
-,90,I-CHEMICAL
),90,I-CHEMICAL
-pindolol-induced,90,O
increase,90,O
in,90,O
DA,90,B-CHEMICAL
and,90,O
NAD,90,B-CHEMICAL
levels,90,O
",",90,O
while,90,O
the,90,O
selective,90,O
5-HT1B,90,B-GENE-Y
antagonist,90,O
",",90,O
"SB224,289",90,B-CHEMICAL
",",90,O
was,90,O
ineffective,90,O
.,90,O
These,91,O
data,91,O
suggest,91,O
that,91,O
(,91,B-CHEMICAL
-,91,I-CHEMICAL
),91,I-CHEMICAL
-pindolol,91,I-CHEMICAL
facilitates,91,O
frontocortical,91,O
dopaminergic,91,O
(,91,O
and,91,O
adrenergic,91,O
),91,O
transmission,91,O
primarily,91,O
by,91,O
activation,91,O
of,91,O
beta,91,B-GENE-N
1/2-ARs,91,I-GENE-N
and,91,O
",",91,O
to,91,O
a,91,O
lesser,91,O
degree,91,O
",",91,O
by,91,O
stimulation,91,O
of,91,O
5-HT1A,91,B-GENE-Y
receptors,91,O
",",91,O
whereas,91,O
5-HT1B,91,B-GENE-Y
receptors,91,O
are,91,O
not,91,O
involved,91,O
.,91,O
(,92,B-CHEMICAL
-,92,I-CHEMICAL
),92,I-CHEMICAL
-Pindolol,92,I-CHEMICAL
potentiated,92,O
the,92,O
increase,92,O
in,92,O
FCX,92,O
levels,92,O
of,92,O
5-HT,92,B-CHEMICAL
elicited,92,O
by,92,O
the,92,O
5-HT,92,B-CHEMICAL
reuptake,92,O
inhibitors,92,O
",",92,O
fluoxetine,92,B-CHEMICAL
and,92,O
duloxetine,92,B-CHEMICAL
",",92,O
and,92,O
also,92,O
enhanced,92,O
their,92,O
ability,92,O
to,92,O
elevate,92,O
FCX,92,O
levels,92,O
of,92,O
DA,92,B-CHEMICAL
--,92,O
though,92,O
not,92,O
of,92,O
NAD,92,B-CHEMICAL
.,92,O
In,93,O
contrast,93,O
to,93,O
(,93,B-CHEMICAL
-,93,I-CHEMICAL
),93,I-CHEMICAL
-pindolol,93,I-CHEMICAL
",",93,O
betaxolol,93,B-CHEMICAL
and,93,O
"ICI118,551",93,B-CHEMICAL
did,93,O
not,93,O
affect,93,O
the,93,O
actions,93,O
of,93,O
fluoxetine,93,B-CHEMICAL
",",93,O
whereas,93,O
both,93,O
"WAY100,635",93,B-CHEMICAL
and,93,O
"SB224,289",93,B-CHEMICAL
potentiated,93,O
the,93,O
increase,93,O
in,93,O
levels,93,O
of,93,O
5-HT,93,B-CHEMICAL
--,93,O
but,93,O
not,93,O
DA,93,B-CHEMICAL
or,93,O
NAD,93,B-CHEMICAL
levels,93,O
--,93,O
elicited,93,O
by,93,O
fluoxetine,93,B-CHEMICAL
.,93,O
In,94,O
conclusion,94,O
",",94,O
(,94,B-CHEMICAL
-,94,I-CHEMICAL
),94,I-CHEMICAL
-pindolol,94,I-CHEMICAL
modulates,94,O
",",94,O
both,94,O
alone,94,O
and,94,O
together,94,O
with,94,O
5-HT,94,B-CHEMICAL
reuptake,94,O
inhibitors,94,O
",",94,O
dopaminergic,94,O
",",94,O
adrenergic,94,O
",",94,O
and,94,O
serotonergic,94,O
transmission,94,O
in,94,O
the,94,O
FCX,94,O
via,94,O
a,94,O
complex,94,O
pattern,94,O
of,94,O
actions,94,O
at,94,O
beta,94,B-GENE-N
1/2-ARs,94,I-GENE-N
",",94,O
5-HT1A,94,B-GENE-Y
",",94,O
and,94,O
5-HT1B,94,B-GENE-Y
receptors,94,O
.,94,O
These,95,O
findings,95,O
have,95,O
important,95,O
implications,95,O
for,95,O
clinical,95,O
studies,95,O
of,95,O
the,95,O
influence,95,O
of,95,O
(,95,B-CHEMICAL
-,95,I-CHEMICAL
),95,I-CHEMICAL
-pindolol,95,I-CHEMICAL
upon,95,O
the,95,O
actions,95,O
of,95,O
antidepressant,95,O
agents,95,O
.,95,O
Entacapone,96,B-CHEMICAL
.,96,O
A,97,O
review,97,O
of,97,O
its,97,O
use,97,O
in,97,O
Parkinson,97,O
's,97,O
disease,97,O
.,97,O
UNLABELLED,98,O
:,98,O
Entacapone,98,B-CHEMICAL
is,98,O
a,98,O
potent,98,O
and,98,O
specific,98,O
peripheral,98,O
catechol-O-methyltransferase,98,B-GENE-Y
(,98,O
COMT,98,B-GENE-Y
),98,O
inhibitor,98,O
.,98,O
It,99,O
has,99,O
been,99,O
shown,99,O
to,99,O
improve,99,O
the,99,O
clinical,99,O
benefits,99,O
of,99,O
levodopa,99,B-CHEMICAL
plus,99,O
an,99,O
aromatic,99,B-CHEMICAL
L-amino,99,I-CHEMICAL
acid,99,I-CHEMICAL
decarboxylase,99,I-GENE-Y
inhibitor,99,O
(,99,O
AADC,99,B-GENE-Y
),99,O
when,99,O
given,99,O
to,99,O
patients,99,O
with,99,O
Parkinson,99,O
's,99,O
disease,99,O
and,99,O
end-of-dose,99,O
deterioration,99,O
in,99,O
the,99,O
response,99,O
to,99,O
levodopa,99,B-CHEMICAL
(,99,O
the,99,O
'wearing,99,O
off,99,O
',99,O
phenomenon,99,O
),99,O
.,99,O
The,100,O
efficacy,100,O
of,100,O
entacapone,100,B-CHEMICAL
is,100,O
currently,100,O
being,100,O
assessed,100,O
in,100,O
patients,100,O
with,100,O
stable,100,O
Parkinson,100,O
's,100,O
disease,100,O
.,100,O
In,101,O
2,101,O
well,101,O
conducted,101,O
trials,101,O
of,101,O
6,101,O
months,101,O
',101,O
duration,101,O
and,101,O
smaller,101,O
short,101,O
term,101,O
studies,101,O
",",101,O
treatment,101,O
with,101,O
entacapone,101,B-CHEMICAL
(,101,O
200,101,O
mg,101,O
with,101,O
each,101,O
dose,101,O
of,101,O
levodopa/AADC,101,B-CHEMICAL
inhibitor,101,O
),101,O
was,101,O
associated,101,O
with,101,O
significant,101,O
increases,101,O
in,101,O
daily,101,O
'on,101,O
',101,O
time,101,O
and,101,O
decreases,101,O
in,101,O
'off,101,O
',101,O
time,101,O
.,101,O
Changes,102,O
in,102,O
Unified,102,O
Parkinson,102,O
's,102,O
Disease,102,O
Rating,102,O
Scale,102,O
(,102,O
UPDRS,102,O
),102,O
scores,102,O
concurred,102,O
with,102,O
changes,102,O
in,102,O
'on,102,O
',102,O
and,102,O
'off,102,O
',102,O
times,102,O
:,102,O
entacapone,102,B-CHEMICAL
improved,102,O
total,102,O
",",102,O
activities,102,O
of,102,O
daily,102,O
living,102,O
and,102,O
motor,102,O
function,102,O
scores,102,O
",",102,O
but,102,O
it,102,O
had,102,O
no,102,O
effect,102,O
on,102,O
mentation,102,O
scores,102,O
.,102,O
Entacapone,103,B-CHEMICAL
also,103,O
provided,103,O
benefits,103,O
when,103,O
given,103,O
with,103,O
controlled,103,O
release,103,O
levodopa/,103,B-CHEMICAL
AADC,103,B-GENE-Y
inhibitor,103,O
or,103,O
with,103,O
standard,103,O
levodopa/AADC,103,B-CHEMICAL
inhibitor,103,O
and,103,O
selegiline,103,B-CHEMICAL
in,103,O
small,103,O
trials,103,O
.,103,O
Dopaminergic,104,O
events,104,O
",",104,O
including,104,O
dyskinesia,104,O
and,104,O
nausea,104,O
",",104,O
are,104,O
among,104,O
the,104,O
most,104,O
common,104,O
events,104,O
with,104,O
entacapone,104,B-CHEMICAL
",",104,O
and,104,O
are,104,O
related,104,O
to,104,O
the,104,O
drug,104,O
's,104,O
ability,104,O
to,104,O
potentiate,104,O
the,104,O
effects,104,O
of,104,O
levodopa,104,B-CHEMICAL
.,104,O
Diarrhoea,105,O
",",105,O
abdominal,105,O
pain,105,O
",",105,O
constipation,105,O
and,105,O
urine,105,O
discolouration,105,O
are,105,O
the,105,O
most,105,O
common,105,O
nondopaminergic,105,O
events,105,O
",",105,O
although,105,O
the,105,O
latter,105,O
event,105,O
is,105,O
the,105,O
only,105,O
one,105,O
to,105,O
occur,105,O
consistently,105,O
more,105,O
frequently,105,O
with,105,O
entacapone,105,O
than,105,O
with,105,O
placebo,105,O
.,105,O
However,106,O
",",106,O
adverse,106,O
events,106,O
of,106,O
any,106,O
type,106,O
infrequently,106,O
led,106,O
to,106,O
study,106,O
discontinuation,106,O
.,106,O
CONCLUSIONS,107,O
:,107,O
The,107,O
efficacy,107,O
and,107,O
tolerability,107,O
of,107,O
entacapone,107,O
administered,107,O
with,107,O
levodopa/AADC,107,B-CHEMICAL
inhibitor,107,O
have,107,O
not,107,O
yet,107,O
been,107,O
compared,107,O
with,107,O
those,107,O
of,107,O
other,107,O
strategies,107,O
for,107,O
the,107,O
treatment,107,O
of,107,O
Parkinson,107,O
's,107,O
disease,107,O
.,107,O
However,108,O
",",108,O
once,108,O
the,108,O
decision,108,O
to,108,O
initiate,108,O
levodopa,108,B-CHEMICAL
therapy,108,O
has,108,O
been,108,O
made,108,O
",",108,O
studies,108,O
generally,108,O
support,108,O
the,108,O
use,108,O
of,108,O
entacapone,108,O
as,108,O
an,108,O
adjunct,108,O
to,108,O
levodopa,108,B-CHEMICAL
in,108,O
patients,108,O
with,108,O
Parkinson,108,O
's,108,O
disease,108,O
and,108,O
the,108,O
'wearing,108,O
off,108,O
',108,O
phenomenon,108,O
.,108,O
5-hydroxytryptamine,109,B-CHEMICAL
evokes,109,O
endothelial,109,B-GENE-Y
nitric,109,I-GENE-Y
oxide,109,I-GENE-Y
synthase,109,I-GENE-Y
activation,109,O
in,109,O
bovine,109,O
aortic,109,O
endothelial,109,O
cell,109,O
cultures,109,O
.,109,O
Activation,110,O
of,110,O
endothelial,110,B-GENE-Y
nitric,110,B-CHEMICAL
oxide,110,I-CHEMICAL
synthase,110,I-GENE-Y
(,110,O
eNOS,110,B-GENE-Y
),110,O
results,110,O
in,110,O
the,110,O
production,110,O
of,110,O
nitric,110,B-CHEMICAL
oxide,110,I-CHEMICAL
(,110,O
NO,110,B-CHEMICAL
),110,O
that,110,O
mediates,110,O
the,110,O
vasorelaxing,110,O
properties,110,O
of,110,O
endothelial,110,O
cells,110,O
.,110,O
The,111,O
goal,111,O
of,111,O
this,111,O
project,111,O
was,111,O
to,111,O
address,111,O
the,111,O
possibility,111,O
that,111,O
5-hydroxytryptamine,111,B-CHEMICAL
(,111,O
5-HT,111,B-CHEMICAL
),111,O
stimulates,111,O
eNOS,111,B-GENE-Y
activity,111,O
in,111,O
bovine,111,O
aortic,111,O
endothelial,111,O
cell,111,O
(,111,O
BAEC,111,O
),111,O
cultures,111,O
.,111,O
Here,112,O
",",112,O
we,112,O
tested,112,O
the,112,O
hypothesis,112,O
that,112,O
5-HT,112,B-GENE-N
receptors,112,I-GENE-N
mediate,112,O
eNOS,112,B-GENE-Y
activation,112,O
by,112,O
measuring,112,O
agonist-stimulated,112,O
[,112,B-CHEMICAL
3H,112,I-CHEMICAL
],112,I-CHEMICAL
L-citrulline,112,I-CHEMICAL
(,112,O
[,112,B-CHEMICAL
3H,112,I-CHEMICAL
],112,I-CHEMICAL
L-Cit,112,I-CHEMICAL
),112,O
formation,112,O
in,112,O
BAEC,112,O
cultures,112,O
.,112,O
We,113,O
found,113,O
that,113,O
5-HT,113,B-CHEMICAL
stimulated,113,O
the,113,O
conversion,113,O
of,113,O
[,113,B-CHEMICAL
3H,113,I-CHEMICAL
],113,I-CHEMICAL
L-arginine,113,I-CHEMICAL
(,113,O
[,113,B-CHEMICAL
3H,113,I-CHEMICAL
],113,I-CHEMICAL
L-Arg,113,I-CHEMICAL
),113,O
to,113,O
[,113,B-CHEMICAL
3H,113,I-CHEMICAL
],113,I-CHEMICAL
L-Cit,113,I-CHEMICAL
",",113,O
indicating,113,O
eNOS,113,B-GENE-Y
activation,113,O
.,113,O
The,114,O
high,114,O
affinity,114,O
5-HT1B,114,B-GENE-Y
receptor,114,O
agonist,114,O
",",114,O
5-nonyloxytryptamine,114,B-CHEMICAL
(,114,O
5-NOT,114,O
),114,O
-stimulated,114,O
[,114,B-CHEMICAL
3H,114,I-CHEMICAL
],114,I-CHEMICAL
L-Cit,114,I-CHEMICAL
turnover,114,O
responses,114,O
were,114,O
concentration-,114,O
(,114,O
0.01,114,O
nM,114,O
to,114,O
100,114,O
microM,114,O
),114,O
and,114,O
time-dependent,114,O
.,114,O
Maximal,115,O
responses,115,O
were,115,O
observed,115,O
within,115,O
10,115,O
min,115,O
following,115,O
agonist,115,O
exposures,115,O
.,115,O
These,116,O
responses,116,O
were,116,O
effectively,116,O
blocked,116,O
by,116,O
the,116,O
5-HT1B,116,B-GENE-Y
receptor,116,O
antagonist,116,O
",",116,O
isamoltane,116,O
",",116,O
the,116,O
5-HT1B/5-HT2,116,B-GENE-Y
receptor,116,I-GENE-N
antagonist,116,O
",",116,O
methiothepin,116,B-CHEMICAL
",",116,O
and,116,O
the,116,O
eNOS,116,B-GENE-Y
selective,116,O
antagonists,116,O
(,116,O
0.01-10,116,O
microM,116,O
),116,O
:,116,O
L-Nomega,116,B-CHEMICAL
-monomethyl-L-arginine,116,I-CHEMICAL
(,116,O
L-NMMA,116,B-CHEMICAL
),116,O
and,116,O
L-N,116,B-CHEMICAL
omega-iminoethyl-L-ornithine,116,I-CHEMICAL
(,116,O
L-NIO,116,B-CHEMICAL
),116,O
.,116,O
Pretreatment,117,O
of,117,O
BAEC,117,O
cultures,117,O
with,117,O
pertussis,117,B-GENE-N
toxin,117,I-GENE-N
(,117,O
PTX,117,B-GENE-N
;,117,O
1-100,117,O
ng/ml,117,O
),117,O
for,117,O
16,117,O
hr,117,O
resulted,117,O
in,117,O
significant,117,O
inhibition,117,O
of,117,O
the,117,O
agonist-stimulated,117,O
eNOS,117,B-GENE-Y
activity,117,O
",",117,O
indicating,117,O
the,117,O
involvement,117,O
of,117,O
Gi,117,B-GENE-N
proteins,117,I-GENE-N
.,117,O
These,118,O
findings,118,O
lend,118,O
evidence,118,O
of,118,O
a,118,O
5-HT1B,118,B-GENE-Y
receptor/eNOS,118,O
pathway,118,O
",",118,O
accounting,118,O
in,118,O
part,118,O
for,118,O
the,118,O
activation,118,O
of,118,O
eNOS,118,B-GENE-Y
by,118,O
5-HT,118,B-CHEMICAL
.,118,O
Further,119,O
investigation,119,O
is,119,O
needed,119,O
to,119,O
determine,119,O
the,119,O
role,119,O
of,119,O
other,119,O
vascular,119,O
5-HT,119,B-CHEMICAL
receptors,119,I-GENE-N
in,119,O
the,119,O
stimulation,119,O
of,119,O
eNOS,119,B-GENE-Y
activity,119,O
.,119,O
Caffeine,120,B-CHEMICAL
inhibits,120,O
the,120,O
checkpoint,120,O
kinase,120,B-GENE-N
ATM,120,B-GENE-Y
.,120,O
The,121,O
basis,121,O
of,121,O
many,121,O
anti-cancer,121,O
therapies,121,O
is,121,O
the,121,O
use,121,O
of,121,O
genotoxic,121,O
agents,121,O
that,121,O
damage,121,O
DNA,121,O
and,121,O
thus,121,O
kill,121,O
dividing,121,O
cells,121,O
.,121,O
Agents,122,O
that,122,O
cause,122,O
cells,122,O
to,122,O
override,122,O
the,122,O
DNA-damage,122,O
checkpoint,122,O
are,122,O
predicted,122,O
to,122,O
sensitize,122,O
cells,122,O
to,122,O
killing,122,O
by,122,O
genotoxic,122,O
agents,122,O
.,122,O
They,123,O
have,123,O
therefore,123,O
been,123,O
sought,123,O
as,123,O
adjuncts,123,O
in,123,O
radiation,123,O
therapy,123,O
and,123,O
chemotherapy,123,O
.,123,O
One,124,O
such,124,O
compound,124,O
",",124,O
caffeine,124,B-CHEMICAL
",",124,O
uncouples,124,O
cell-cycle,124,O
progression,124,O
from,124,O
the,124,O
replication,124,O
and,124,O
repair,124,O
of,124,O
DNA,124,O
[,124,O
1,124,O
],124,O
[,124,O
2,124,O
],124,O
.,124,O
Caffeine,125,B-CHEMICAL
therefore,125,O
servers,125,O
as,125,O
a,125,O
model,125,O
compound,125,O
in,125,O
establishing,125,O
the,125,O
principle,125,O
that,125,O
agents,125,O
that,125,O
override,125,O
DNA-damage,125,O
checkpoints,125,O
can,125,O
be,125,O
used,125,O
to,125,O
sensitize,125,O
cells,125,O
to,125,O
the,125,O
killing,125,O
effects,125,O
of,125,O
genotoxic,125,O
drugs,125,O
[,125,O
3,125,O
],125,O
.,125,O
But,126,O
despite,126,O
more,126,O
than,126,O
20,126,O
years,126,O
of,126,O
use,126,O
",",126,O
the,126,O
molecular,126,O
mechanisms,126,O
by,126,O
which,126,O
caffeine,126,O
affects,126,O
the,126,O
cell,126,O
cycle,126,O
and,126,O
checkpoint,126,O
responses,126,O
have,126,O
not,126,O
been,126,O
identified,126,O
.,126,O
We,127,O
investigated,127,O
the,127,O
effects,127,O
of,127,O
caffeine,127,O
on,127,O
the,127,O
G2/M,127,O
DNA-damage,127,O
checkpoint,127,O
in,127,O
human,127,O
cells,127,O
.,127,O
We,128,O
report,128,O
that,128,O
the,128,O
radiation-induced,128,O
activation,128,O
of,128,O
the,128,O
kinase,128,B-GENE-N
Cds1,128,B-GENE-Y
[,128,O
4,128,O
],128,O
(,128,O
also,128,O
known,128,O
as,128,O
Chk2,128,B-GENE-Y
[,128,O
5,128,O
],128,O
),128,O
is,128,O
inhibited,128,O
by,128,O
caffeine,128,B-CHEMICAL
in,128,O
vivo,128,O
and,128,O
that,128,O
ATM,128,B-GENE-Y
kinase,128,B-GENE-N
activity,128,O
is,128,O
directly,128,O
inhibited,128,O
by,128,O
caffeine,128,B-CHEMICAL
in,128,O
vitro,128,O
.,128,O
Inhibition,129,O
of,129,O
ATM,129,B-GENE-Y
provides,129,O
a,129,O
molecular,129,O
explanation,129,O
of,129,O
the,129,O
attenuation,129,O
of,129,O
DNA-damage,129,O
checkpoint,129,O
responses,129,O
and,129,O
for,129,O
the,129,O
increased,129,O
radiosensitivity,129,O
of,129,O
caffeine-treated,129,B-CHEMICAL
cells,129,O
[,129,O
6,129,O
],129,O
[,129,O
7,129,O
],129,O
[,129,O
8,129,O
],129,O
.,129,O
Serotonin,130,B-CHEMICAL
transporter,130,I-GENE-Y
production,130,O
and,130,O
degradation,130,O
rates,130,O
:,130,O
studies,130,O
with,130,O
RTI-76,130,B-CHEMICAL
.,130,O
The,131,O
objective,131,O
of,131,O
this,131,O
study,131,O
was,131,O
to,131,O
examine,131,O
the,131,O
turnover,131,O
of,131,O
the,131,O
serotonin,131,B-CHEMICAL
transporter,131,I-GENE-Y
(,131,O
SERT,131,B-GENE-Y
),131,O
by,131,O
determining,131,O
its,131,O
production,131,O
rate,131,O
(,131,O
r,131,O
),131,O
",",131,O
degradation,131,O
rate,131,O
constant,131,O
(,131,O
k,131,O
),131,O
and,131,O
half-life,131,O
of,131,O
recovery,131,O
(,131,O
t1/2,131,O
),131,O
.,131,O
The,132,O
turnover,132,O
of,132,O
SERT,132,B-GENE-Y
was,132,O
determined,132,O
from,132,O
the,132,O
rate,132,O
of,132,O
recovery,132,O
of,132,O
binding,132,O
after,132,O
administration,132,O
of,132,O
RTI-76,132,B-CHEMICAL
",",132,O
an,132,O
irreversible,132,O
inhibitor,132,O
of,132,O
ligand,132,O
binding,132,O
.,132,O
In,133,O
preliminary,133,O
studies,133,O
",",133,O
in,133,O
vitro,133,O
incubation,133,O
of,133,O
rat,133,O
cerebral,133,O
cortex,133,O
with,133,O
RTI-76,133,B-CHEMICAL
produced,133,O
a,133,O
wash,133,O
and,133,O
temperature,133,O
resistant,133,O
inhibition,133,O
of,133,O
SERT,133,B-GENE-Y
binding,133,O
densities,133,O
(,133,O
Bmax,133,O
),133,O
.,133,O
Citalopram,134,B-CHEMICAL
protected,134,O
against,134,O
the,134,O
RTI-76-induced,134,B-CHEMICAL
inhibition,134,O
of,134,O
SERT,134,B-GENE-Y
binding,134,O
.,134,O
Following,135,O
6,135,O
h,135,O
of,135,O
in,135,O
vivo,135,O
intracerebroventricular,135,O
injections,135,O
of,135,O
100,135,O
nmol,135,O
of,135,O
RTI-76,135,B-CHEMICAL
",",135,O
there,135,O
was,135,O
a,135,O
dose-,135,O
and,135,O
time-dependent,135,O
reduction,135,O
(,135,O
-,135,O
60,135,O
%,135,O
),135,O
of,135,O
SERT,135,B-GENE-Y
binding,135,O
in,135,O
hippocampus,135,O
and,135,O
striatum,135,O
",",135,O
without,135,O
a,135,O
change,135,O
in,135,O
the,135,O
Kd,135,O
.,135,O
SERT,136,B-GENE-Y
binding,136,O
densities,136,O
recovered,136,O
over,136,O
several,136,O
days,136,O
",",136,O
reaching,136,O
control,136,O
levels,136,O
by,136,O
day,136,O
14,136,O
.,136,O
The,137,O
recovery,137,O
curve,137,O
fit,137,O
the,137,O
standard,137,O
model,137,O
of,137,O
protein,137,O
synthesis,137,O
and,137,O
degradation,137,O
.,137,O
The,138,O
turnover,138,O
parameters,138,O
of,138,O
SERT,138,B-GENE-Y
were,138,O
determined,138,O
in,138,O
hippocampus,138,O
and,138,O
striatum,138,O
",",138,O
regions,138,O
that,138,O
receive,138,O
serotonergic,138,O
innervation,138,O
from,138,O
the,138,O
dorsal,138,O
and,138,O
median,138,O
midbrain,138,O
raphe,138,O
nuclei,138,O
",",138,O
respectively,138,O
.,138,O
In,139,O
the,139,O
hippocampus,139,O
",",139,O
the,139,O
production,139,O
rate,139,O
constant,139,O
was,139,O
2.36,139,O
fmol,139,O
mg,139,O
protein,139,O
(,139,O
-1,139,O
),139,O
h,139,O
(,139,O
-1,139,O
),139,O
;,139,O
the,139,O
degradation,139,O
rate,139,O
constant,139,O
was,139,O
0.0077,139,O
h,139,O
(,139,O
-1,139,O
),139,O
;,139,O
and,139,O
the,139,O
half-life,139,O
of,139,O
the,139,O
SERT,139,B-GENE-Y
recovery,139,O
was,139,O
3.4,139,O
days,139,O
.,139,O
The,140,O
values,140,O
in,140,O
the,140,O
striatum,140,O
were,140,O
similar,140,O
.,140,O
The,141,O
decrease,141,O
and,141,O
recovery,141,O
of,141,O
[,141,B-CHEMICAL
3H,141,I-CHEMICAL
],141,I-CHEMICAL
-5-HT,141,I-CHEMICAL
uptake,141,O
correlated,141,O
highly,141,O
(,141,O
r,141,O
=,141,O
0.93,141,O
),141,O
with,141,O
the,141,O
recovery,141,O
of,141,O
SERT,141,B-GENE-Y
binding,141,O
.,141,O
Cannabis,142,O
and,142,O
cannabinoids,142,O
:,142,O
pharmacology,142,O
and,142,O
rationale,142,O
for,142,O
clinical,142,O
use,142,O
.,142,O
It,143,O
is,143,O
now,143,O
known,143,O
that,143,O
there,143,O
are,143,O
at,143,O
least,143,O
two,143,O
types,143,O
of,143,O
cannabinoid,143,B-GENE-N
receptors,143,I-GENE-N
.,143,O
These,144,O
are,144,O
CB1,144,B-GENE-Y
receptors,144,O
",",144,O
present,144,O
mainly,144,O
on,144,O
central,144,O
and,144,O
peripheral,144,O
neurones,144,O
",",144,O
and,144,O
CB2,144,B-GENE-Y
receptors,144,O
",",144,O
present,144,O
mainly,144,O
on,144,O
immune,144,O
cells,144,O
.,144,O
Endogenous,145,O
cannabinoid,145,B-GENE-N
receptor,145,I-GENE-N
agonists,145,O
(,145,O
'endocannabinoids,145,O
',145,O
),145,O
have,145,O
also,145,O
been,145,O
identified,145,O
.,145,O
The,146,O
discovery,146,O
of,146,O
this,146,O
'endogenous,146,O
cannabinoid,146,O
system,146,O
',146,O
has,146,O
led,146,O
to,146,O
the,146,O
development,146,O
of,146,O
selective,146,O
CB1,146,B-GENE-Y
and,146,O
CB2,146,B-GENE-Y
receptor,146,O
ligands,146,O
and,146,O
fueled,146,O
renewed,146,O
interest,146,O
in,146,O
the,146,O
clinical,146,O
potential,146,O
of,146,O
cannabinoids,146,O
.,146,O
Two,147,O
cannabinoid,147,O
CB1,147,B-GENE-Y
receptor,147,O
agonists,147,O
are,147,O
already,147,O
used,147,O
clinically,147,O
",",147,O
as,147,O
antiemetics,147,O
or,147,O
as,147,O
appetite,147,O
stimulants,147,O
.,147,O
These,148,O
are,148,O
D,148,B-CHEMICAL
9,148,I-CHEMICAL
-,148,I-CHEMICAL
tetrahydrocannabinol,148,I-CHEMICAL
(,148,O
THC,148,B-CHEMICAL
),148,O
and,148,O
nabilone,148,B-CHEMICAL
.,148,O
Other,149,O
possible,149,O
uses,149,O
for,149,O
CB1,149,B-GENE-Y
receptor,149,O
agonists,149,O
include,149,O
the,149,O
suppression,149,O
of,149,O
muscle,149,O
spasm/spasticity,149,O
associated,149,O
with,149,O
multiple,149,O
sclerosis,149,O
or,149,O
spinal,149,O
cord,149,O
injury,149,O
",",149,O
the,149,O
relief,149,O
of,149,O
chronic,149,O
pain,149,O
and,149,O
the,149,O
management,149,O
of,149,O
glaucoma,149,O
and,149,O
bronchial,149,O
asthma,149,O
.,149,O
CB1,150,B-GENE-Y
receptor,150,O
antagonists,150,O
may,150,O
also,150,O
have,150,O
clinical,150,O
applications,150,O
",",150,O
e.,150,O
g.,150,O
as,150,O
appetite,150,O
suppressants,150,O
and,150,O
in,150,O
the,150,O
management,150,O
of,150,O
schizophrenia,150,O
or,150,O
disorders,150,O
of,150,O
cognition,150,O
and,150,O
memory,150,O
.,150,O
So,151,O
too,151,O
may,151,O
CB2,151,B-GENE-Y
receptor,151,O
ligands,151,O
and,151,O
drugs,151,O
that,151,O
activate,151,O
cannabinoid,151,B-GENE-N
receptors,151,I-GENE-N
indirectly,151,O
by,151,O
augmenting,151,O
endocannabinoid,151,O
levels,151,O
at,151,O
cannabinoid,151,B-GENE-N
receptors,151,I-GENE-N
.,151,O
When,152,O
taken,152,O
orally,152,O
",",152,O
THC,152,B-CHEMICAL
seems,152,O
to,152,O
undergo,152,O
variable,152,O
absorption,152,O
and,152,O
to,152,O
have,152,O
a,152,O
narrow,152,O
'therapeutic,152,O
window,152,O
',152,O
(,152,O
dose,152,O
range,152,O
in,152,O
which,152,O
it,152,O
is,152,O
effective,152,O
without,152,O
producing,152,O
significant,152,O
unwanted,152,O
effects,152,O
),152,O
.,152,O
This,153,O
makes,153,O
it,153,O
difficult,153,O
to,153,O
predict,153,O
an,153,O
oral,153,O
dose,153,O
that,153,O
will,153,O
be,153,O
both,153,O
effective,153,O
and,153,O
tolerable,153,O
to,153,O
a,153,O
patient,153,O
and,153,O
indicates,153,O
a,153,O
need,153,O
for,153,O
better,153,O
cannabinoid,153,O
formulations,153,O
and,153,O
modes,153,O
of,153,O
administration,153,O
.,153,O
For,154,O
the,154,O
therapeutic,154,O
potential,154,O
of,154,O
cannabis,154,O
or,154,O
CB1,154,B-GENE-Y
receptor,154,O
agonists,154,O
to,154,O
be,154,O
fully,154,O
exploited,154,O
",",154,O
it,154,O
will,154,O
be,154,O
important,154,O
to,154,O
establish,154,O
objectively,154,O
and,154,O
conclusively,154,O
(,154,O
a,154,O
),154,O
whether,154,O
these,154,O
agents,154,O
have,154,O
efficacy,154,O
against,154,O
selected,154,O
symptoms,154,O
that,154,O
is,154,O
of,154,O
clinical,154,O
significance,154,O
and,154,O
",",154,O
if,154,O
so,154,O
",",154,O
whether,154,O
the,154,O
benefits,154,O
outweigh,154,O
the,154,O
risks,154,O
",",154,O
(,154,O
b,154,O
),154,O
whether,154,O
cannabis,154,O
has,154,O
therapeutic,154,O
advantages,154,O
over,154,O
individual,154,O
cannabinoids,154,O
",",154,O
(,154,O
c,154,O
),154,O
whether,154,O
there,154,O
is,154,O
a,154,O
need,154,O
for,154,O
additional,154,O
drug,154,O
treatments,154,O
to,154,O
manage,154,O
any,154,O
of,154,O
the,154,O
disorders,154,O
against,154,O
which,154,O
cannabinoids,154,O
are,154,O
effective,154,O
",",154,O
and,154,O
(,154,O
d,154,O
),154,O
whether,154,O
it,154,O
will,154,O
be,154,O
possible,154,O
to,154,O
develop,154,O
drugs,154,O
that,154,O
have,154,O
reduced,154,O
psychotropic,154,O
activity,154,O
and,154,O
yet,154,O
retain,154,O
the,154,O
ability,154,O
to,154,O
act,154,O
through,154,O
CB1,154,B-GENE-Y
receptors,154,O
to,154,O
produce,154,O
their,154,O
sought-after,154,O
effects,154,O
.,154,O
Pharmacological,155,O
properties,155,O
of,155,O
angiotensin,155,B-GENE-N
II,155,I-GENE-N
receptor,155,I-GENE-N
antagonists,155,O
.,155,O
The,156,O
availability,156,O
of,156,O
selective,156,O
",",156,O
potent,156,O
",",156,O
orally,156,O
active,156,O
and,156,O
long,156,O
acting,156,O
nonpeptide,156,O
angiotensin,156,B-GENE-Y
II,156,I-GENE-Y
type,156,I-GENE-Y
1,156,I-GENE-Y
(,156,I-GENE-Y
AT1,156,I-GENE-Y
),156,I-GENE-Y
receptor,156,I-GENE-Y
antagonists,156,O
has,156,O
provided,156,O
the,156,O
opportunity,156,O
to,156,O
obtain,156,O
the,156,O
benefits,156,O
of,156,O
selectively,156,O
blocking,156,O
the,156,O
renin-angiotensin-aldosterone,156,B-GENE-Y
system,156,O
at,156,O
the,156,O
level,156,O
of,156,O
the,156,O
AT1,156,B-GENE-Y
receptor,156,O
that,156,O
mediates,156,O
most,156,O
",",156,O
if,156,O
not,156,O
all,156,O
",",156,O
of,156,O
the,156,O
important,156,O
actions,156,O
of,156,O
angiotensin,156,B-GENE-Y
II,156,I-GENE-Y
",",156,O
and,156,O
avoid,156,O
the,156,O
nonspecificity,156,O
of,156,O
the,156,O
angiotensin,156,B-GENE-Y
I,156,I-GENE-Y
converting,156,I-GENE-Y
enzyme,156,I-GENE-Y
inhibitors,156,O
.,156,O
Losartan,157,B-CHEMICAL
was,157,O
the,157,O
first,157,O
",",157,O
but,157,O
by,157,O
no,157,O
means,157,O
remained,157,O
the,157,O
only,157,O
",",157,O
AT1,157,B-GENE-Y
receptor,157,O
antagonist,157,O
.,157,O
Numerous,158,O
other,158,O
'sartans,158,O
',158,O
have,158,O
emerged,158,O
in,158,O
the,158,O
past,158,O
several,158,O
years,158,O
and,158,O
successfully,158,O
completed,158,O
clinical,158,O
development,158,O
.,158,O
With,159,O
the,159,O
exception,159,O
of,159,O
eprosartan,159,B-CHEMICAL
",",159,O
all,159,O
others,159,O
",",159,O
ie,159,O
",",159,O
candesartan,159,B-CHEMICAL
",",159,O
irbesartan,159,B-CHEMICAL
",",159,O
saprisartan,159,B-CHEMICAL
",",159,O
tasosartan,159,B-CHEMICAL
",",159,O
telmisartan,159,B-CHEMICAL
",",159,O
valsartan,159,B-CHEMICAL
and,159,O
zolasartan,159,B-CHEMICAL
",",159,O
are,159,O
based,159,O
on,159,O
medications,159,O
of,159,O
losartan,159,O
's,159,O
prototypical,159,O
chemical,159,O
structure,159,O
.,159,O
Among,160,O
the,160,O
current,160,O
AT1,160,B-GENE-Y
receptor,160,O
antagonists,160,O
",",160,O
the,160,O
rank,160,O
order,160,O
of,160,O
the,160,O
relative,160,O
binding,160,O
affinities,160,O
(,160,O
highest,160,O
affinity,160,O
=,160,O
1,160,O
),160,O
is,160,O
:,160,O
candesartan,160,B-CHEMICAL
1,160,O
",",160,O
telmisartan,160,B-CHEMICAL
10,160,O
",",160,O
E3174,160,B-CHEMICAL
(,160,O
the,160,O
active,160,O
metabolite,160,O
of,160,O
losartan,160,B-CHEMICAL
),160,O
10,160,O
",",160,O
tasosartan,160,B-CHEMICAL
20,160,O
",",160,O
losartan,160,B-CHEMICAL
50,160,O
",",160,O
eprosartan,160,B-CHEMICAL
100,160,O
and,160,O
the,160,O
prodrug,160,O
candesartan,160,B-CHEMICAL
cilexetil,160,I-CHEMICAL
280,160,O
.,160,O
The,161,O
mode,161,O
of,161,O
(,161,O
functional,161,O
),161,O
AT1,161,B-GENE-Y
receptor,161,O
antagonism,161,O
has,161,O
been,161,O
characterized,161,O
as,161,O
surmountable/noncompetitive,161,O
(,161,O
losartan,161,B-CHEMICAL
",",161,O
tasosartan,161,B-CHEMICAL
",",161,O
eprosartan,161,B-CHEMICAL
),161,O
or,161,O
insurmountable/noncompetitive,161,O
(,161,O
candesartan,161,B-CHEMICAL
",",161,O
saprisartan,161,B-CHEMICAL
",",161,O
zolasartan,161,B-CHEMICAL
",",161,O
irbesartan,161,B-CHEMICAL
",",161,O
valsartan,161,B-CHEMICAL
",",161,O
telmisartan,161,B-CHEMICAL
",",161,O
E3174,161,B-CHEMICAL
),161,O
.,161,O
It,162,O
is,162,O
very,162,O
likely,162,O
that,162,O
slow,162,O
dissociation,162,O
kinetics,162,O
from,162,O
the,162,O
AT1,162,B-GENE-Y
receptor,162,O
underlie,162,O
insurmountable,162,O
antagonism,162,O
.,162,O
However,163,O
",",163,O
competitive,163,O
or,163,O
noncompetitive,163,O
antagonism,163,O
does,163,O
not,163,O
determine,163,O
the,163,O
antihypertensive,163,O
efficacy,163,O
",",163,O
but,163,O
the,163,O
slow,163,O
off-rate,163,O
may,163,O
extend,163,O
the,163,O
occupancy,163,O
of,163,O
the,163,O
AT1,163,B-GENE-Y
receptor,163,O
and,163,O
thereby,163,O
lengthen,163,O
the,163,O
duration,163,O
of,163,O
the,163,O
antihypertensive,163,O
effect,163,O
.,163,O
Comparison,164,O
of,164,O
chemotherapy,164,O
with,164,O
chemohormonal,164,O
therapy,164,O
as,164,O
first-line,164,O
therapy,164,O
for,164,O
metastatic,164,O
",",164,O
hormone-sensitive,164,O
breast,164,O
cancer,164,O
:,164,O
An,164,O
Eastern,164,O
Cooperative,164,O
Oncology,164,O
Group,164,O
study,164,O
.,164,O
PURPOSE,165,O
:,165,O
Although,165,O
hormonal,165,O
therapy,165,O
represents,165,O
standard,165,O
therapy,165,O
for,165,O
metastatic,165,O
hormone-sensitive,165,O
disease,165,O
",",165,O
many,165,O
patients,165,O
receive,165,O
initial,165,O
chemotherapy,165,O
because,165,O
of,165,O
the,165,O
location,165,O
",",165,O
bulk,165,O
",",165,O
or,165,O
aggressiveness,165,O
of,165,O
their,165,O
disease,165,O
.,165,O
It,166,O
is,166,O
uncertain,166,O
whether,166,O
simultaneous,166,O
hormonal,166,O
therapy,166,O
provides,166,O
additional,166,O
benefit,166,O
compared,166,O
with,166,O
chemotherapy,166,O
alone,166,O
.,166,O
Eastern,167,O
Cooperative,167,O
Oncology,167,O
Group,167,O
trial,167,O
E3186,167,O
was,167,O
initiated,167,O
to,167,O
explore,167,O
this,167,O
question,167,O
.,167,O
PATIENTS,168,O
AND,168,O
METHODS,168,O
:,168,O
Between,168,O
January,168,O
1988,168,O
and,168,O
December,168,O
1992,168,O
",",168,O
231,168,O
patients,168,O
with,168,O
estrogen,168,B-CHEMICAL
receptor,168,I-GENE-Y
(,168,O
ER,168,B-GENE-Y
),168,O
-positive,168,O
or,168,O
ER-unknown,168,B-GENE-Y
metastatic,168,O
breast,168,O
cancer,168,O
were,168,O
randomized,168,O
to,168,O
receive,168,O
either,168,O
chemotherapy,168,O
(,168,O
cyclophosphamide,168,B-CHEMICAL
",",168,O
doxorubicin,168,B-CHEMICAL
",",168,O
and,168,O
fluorouracil,168,B-CHEMICAL
inverted,168,O
question,168,O
markCAF,168,O
),168,O
or,168,O
chemohormonal,168,O
therapy,168,O
(,168,O
CAF,168,O
plus,168,O
tamoxifen,168,B-CHEMICAL
and,168,O
Halotestin,168,B-CHEMICAL
inverted,168,O
question,168,O
markfluoxymesterone,168,O
;,168,O
Pharmacia-Upjohn,168,O
",",168,O
Kalamazoo,168,O
",",168,O
MI,168,O
inverted,168,O
question,168,O
markCAFTH,168,O
),168,O
as,168,O
front-line,168,O
therapy,168,O
for,168,O
metastatic,168,O
breast,168,O
cancer,168,O
.,168,O
Patients,169,O
who,169,O
experienced,169,O
a,169,O
complete,169,O
response,169,O
to,169,O
induction,169,O
therapy,169,O
either,169,O
received,169,O
or,169,O
did,169,O
not,169,O
receive,169,O
maintenance,169,O
cyclophosphamide,169,B-CHEMICAL
",",169,O
methotrexate,169,B-CHEMICAL
",",169,O
fluorouracil,169,B-CHEMICAL
",",169,O
prednisone,169,B-CHEMICAL
",",169,O
and,169,O
TH,169,O
as,169,O
a,169,O
secondary,169,O
randomization,169,O
.,169,O
RESULTS,170,O
:,170,O
The,170,O
response,170,O
rates,170,O
(,170,O
complete,170,O
response,170,O
and,170,O
partial,170,O
response,170,O
),170,O
of,170,O
patients,170,O
who,170,O
received,170,O
CAF,170,O
and,170,O
CAFTH,170,O
were,170,O
similar,170,O
(,170,O
69.2,170,O
%,170,O
v,170,O
68.9,170,O
%,170,O
",",170,O
respectively,170,O
;,170,O
P,170,O
=.99,170,O
),170,O
.,170,O
Time,171,O
to,171,O
treatment,171,O
failure,171,O
(,171,O
TTF,171,O
),171,O
was,171,O
slightly,171,O
longer,171,O
for,171,O
patients,171,O
who,171,O
received,171,O
chemohormonal,171,O
therapy,171,O
compared,171,O
with,171,O
chemotherapy,171,O
alone,171,O
patients,171,O
(,171,O
13.4,171,O
months,171,O
v,171,O
10.3,171,O
months,171,O
",",171,O
respectively,171,O
;,171,O
P,171,O
=.087,171,O
),171,O
",",171,O
and,171,O
TTF,171,O
was,171,O
significantly,171,O
longer,171,O
in,171,O
ER-positive,171,B-GENE-Y
compared,171,O
with,171,O
ER-negative,171,B-GENE-Y
patients,171,O
(,171,O
17.4,171,O
months,171,O
v,171,O
10.3,171,O
months,171,O
",",171,O
respectively,171,O
;,171,O
P,171,O
=.048,171,O
),171,O
.,171,O
However,172,O
",",172,O
ER,172,B-GENE-Y
status,172,O
had,172,O
no,172,O
effect,172,O
on,172,O
overall,172,O
survival,172,O
(,172,O
30.0,172,O
months,172,O
for,172,O
CAF,172,O
v,172,O
29.3,172,O
months,172,O
for,172,O
CAFTH,172,O
),172,O
.,172,O
CONCLUSION,173,O
:,173,O
In,173,O
patients,173,O
with,173,O
potentially,173,O
hormone-sensitive,173,O
metastatic,173,O
breast,173,O
cancer,173,O
",",173,O
chemohormonal,173,O
therapy,173,O
prolongs,173,O
TTF,173,O
for,173,O
ER-positive,173,B-GENE-Y
patients,173,O
without,173,O
improving,173,O
overall,173,O
survival,173,O
.,173,O
Characterization,174,O
and,174,O
partial,174,O
purification,174,O
of,174,O
microsomal,174,O
NAD,174,B-GENE-N
(,174,I-GENE-N
P,174,I-GENE-N
),174,I-GENE-N
H,174,I-GENE-N
:,174,I-GENE-N
quinone,174,I-GENE-N
oxidoreductases,174,I-GENE-N
.,174,O
Quinone,175,B-CHEMICAL
oxidoreductases,175,I-GENE-N
are,175,O
flavoproteins,175,O
that,175,O
catalyze,175,O
two-electron,175,O
reduction,175,O
and,175,O
detoxification,175,O
of,175,O
quinones,175,B-CHEMICAL
.,175,O
This,176,O
leads,176,O
to,176,O
the,176,O
protection,176,O
of,176,O
cells,176,O
against,176,O
toxicity,176,O
",",176,O
mutagenicity,176,O
",",176,O
and,176,O
cancer,176,O
due,176,O
to,176,O
exposure,176,O
to,176,O
environmental,176,O
and,176,O
synthetic,176,O
quinones,176,B-CHEMICAL
and,176,O
its,176,O
precursors,176,O
.,176,O
Two,177,O
cytosolic,177,O
forms,177,O
of,177,O
quinone,177,B-CHEMICAL
oxidoreductases,177,I-GENE-N
[,177,B-GENE-Y
NAD,177,B-CHEMICAL
(,177,I-CHEMICAL
P,177,I-CHEMICAL
),177,I-CHEMICAL
H,177,I-CHEMICAL
:,177,I-GENE-Y
quinone,177,B-CHEMICAL
oxidoreductase,177,I-GENE-Y
1,177,I-GENE-Y
(,177,O
NQO1,177,B-GENE-Y
),177,O
and,177,O
NRH,177,B-GENE-Y
:,177,I-GENE-Y
quinone,177,I-GENE-Y
oxidoreductase,177,I-GENE-Y
2,177,I-GENE-Y
(,177,O
NQO2,177,B-GENE-Y
),177,O
],177,O
were,177,O
previously,177,O
identified,177,O
",",177,O
purified,177,O
",",177,O
and,177,O
cloned,177,O
.,177,O
A,178,O
role,178,O
of,178,O
cytosolic,178,O
NQO1,178,B-GENE-Y
in,178,O
protection,178,O
of,178,O
cells,178,O
from,178,O
oxidative,178,O
stress,178,O
",",178,O
cytotoxicity,178,O
",",178,O
and,178,O
mutagenicity,178,O
of,178,O
quinones,178,B-CHEMICAL
was,178,O
established,178,O
.,178,O
Currently,179,O
",",179,O
we,179,O
have,179,O
characterized,179,O
and,179,O
partially,179,O
purified,179,O
the,179,O
NQO,179,B-GENE-N
activity,179,O
from,179,O
rat,179,O
liver,179,O
microsomes,179,O
.,179,O
This,180,O
activity,180,O
was,180,O
designated,180,O
as,180,O
microsomal,180,O
NQO,180,B-GENE-N
(,180,O
mNQO,180,B-GENE-N
),180,O
.,180,O
The,181,O
mNQO,181,B-GENE-N
activity,181,O
showed,181,O
significantly,181,O
higher,181,O
affinity,181,O
for,181,O
NADH,181,B-CHEMICAL
than,181,O
NADPH,181,B-CHEMICAL
as,181,O
electron,181,O
donors,181,O
and,181,O
catalyzed,181,O
reduction,181,O
of,181,O
"2,6-dichlorophenolindophenol",181,B-CHEMICAL
and,181,O
menadione,181,B-CHEMICAL
.,181,O
The,182,O
mNQO,182,B-GENE-N
activity,182,O
was,182,O
insensitive,182,O
to,182,O
dicoumarol,182,B-CHEMICAL
",",182,O
a,182,O
potent,182,O
inhibitor,182,O
of,182,O
cytosolic,182,O
NQO1,182,B-GENE-Y
.,182,O
Western,183,O
analysis,183,O
of,183,O
microsomal,183,O
proteins,183,O
revealed,183,O
29-,183,O
and,183,O
18-kDa,183,O
bands,183,O
that,183,O
cross-reacted,183,O
with,183,O
polyclonal,183,O
antibodies,183,O
raised,183,O
against,183,O
cytosolic,183,O
NQO1,183,B-GENE-Y
.,183,O
The,184,O
mNQO,184,B-GENE-N
activity,184,O
was,184,O
partially,184,O
purified,184,O
by,184,O
solubilization,184,O
of,184,O
microsomes,184,O
with,184,O
detergent,184,O
Chaps,184,O
",",184,O
ammonium,184,B-CHEMICAL
sulfate,184,I-CHEMICAL
fractionation,184,O
",",184,O
and,184,O
DEAE-Sephacel,184,B-CHEMICAL
column,184,O
chromatography,184,O
.,184,O
The,185,O
microsomal,185,O
mNQO,185,B-GENE-N
proteins,185,O
are,185,O
expected,185,O
to,185,O
provide,185,O
additional,185,O
protection,185,O
after,185,O
cytosolic,185,O
NQOs,185,B-GENE-N
against,185,O
quinone,185,B-CHEMICAL
toxicity,185,O
and,185,O
mutagenicity,185,O
.,185,O
Opioid,186,O
activity,186,O
profiles,186,O
indicate,186,O
similarities,186,O
between,186,O
the,186,O
nociceptin/orphanin,186,B-GENE-Y
FQ,186,I-GENE-Y
and,186,O
opioid,186,B-GENE-N
receptors,186,I-GENE-N
.,186,O
Nociceptin,187,B-GENE-Y
(,187,O
orphanin,187,B-GENE-Y
FQ,187,I-GENE-Y
),187,O
is,187,O
the,187,O
recently,187,O
discovered,187,O
peptide,187,O
agonist,187,O
for,187,O
the,187,O
orphan,187,B-GENE-N
receptor,187,I-GENE-N
opioid,187,B-GENE-Y
receptor-like,187,I-GENE-Y
1,187,I-GENE-Y
(,187,O
ORL1,187,B-GENE-Y
),187,O
.,187,O
Despite,188,O
the,188,O
high,188,O
sequence,188,O
homology,188,O
between,188,O
ORL1,188,B-GENE-Y
and,188,O
the,188,O
opioid,188,B-GENE-N
receptors,188,I-GENE-N
",",188,O
most,188,O
opioids,188,O
lack,188,O
affinity,188,O
for,188,O
the,188,O
nociceptin,188,B-GENE-Y
receptor,188,I-GENE-Y
.,188,O
The,189,O
affinity,189,O
and,189,O
functional,189,O
profile,189,O
of,189,O
opioids,189,O
possessing,189,O
activity,189,O
at,189,O
the,189,O
nociceptin,189,B-GENE-Y
receptor,189,I-GENE-Y
was,189,O
determined,189,O
using,189,O
[,189,O
3H,189,O
],189,O
nociceptin,189,O
and,189,O
nociceptin-stimulated,189,O
[,189,B-CHEMICAL
35S,189,I-CHEMICAL
],189,I-CHEMICAL
GTPgammaS,189,I-CHEMICAL
binding,189,O
.,189,O
The,190,O
mu-opioid,190,B-GENE-Y
receptor-selective,190,O
agonist,190,O
lofentanil,190,B-CHEMICAL
potently,190,O
and,190,O
competitively,190,O
displaced,190,O
[,190,O
3H,190,O
],190,O
nociceptin,190,O
at,190,O
rat,190,O
brain,190,O
receptors,190,O
(,190,O
IC,190,O
(,190,O
50,190,O
),190,O
62,190,O
nM,190,O
),190,O
.,190,O
Lofentanil,191,B-CHEMICAL
exhibited,191,O
full,191,O
agonism,191,O
for,191,O
enhancement,191,O
of,191,O
[,191,B-CHEMICAL
35S,191,I-CHEMICAL
],191,I-CHEMICAL
GTPgammaS,191,I-CHEMICAL
binding,191,O
to,191,O
human,191,O
recombinant,191,O
ORL1,191,B-GENE-Y
receptors,191,O
(,191,O
EC,191,O
(,191,O
50,191,O
),191,O
50,191,O
nM,191,O
),191,O
.,191,O
The,192,O
related,192,O
piperidines,192,B-CHEMICAL
ohmefentanyl,192,B-CHEMICAL
and,192,O
sufentanil,192,B-CHEMICAL
and,192,O
the,192,O
nonselective,192,O
opioid,192,B-GENE-N
receptor,192,I-GENE-N
agonist,192,O
etorphine,192,B-CHEMICAL
were,192,O
less,192,O
potent,192,O
nociceptin,192,B-GENE-Y
receptor,192,I-GENE-Y
agonists,192,O
.,192,O
The,193,O
kappa,193,O
(,193,O
1,193,O
),193,O
+kappa,193,O
(,193,O
3,193,O
),193,O
-opioid,193,O
receptor,193,O
agonist/mu-opioid,193,O
receptor,193,I-GENE-Y
antagonist,193,O
naloxone,193,B-CHEMICAL
benzoylhydrazone,193,I-CHEMICAL
was,193,O
a,193,O
pure,193,O
antagonist,193,O
at,193,O
both,193,O
rat,193,O
brain,193,O
and,193,O
human,193,O
ORL1,193,B-GENE-N
receptors,193,O
.,193,O
The,194,O
nonselective,194,O
opioid,194,B-GENE-N
receptor,194,I-GENE-N
partial,194,O
agonist,194,O
buprenorphine,194,B-CHEMICAL
and,194,O
the,194,O
nonselective,194,O
opioid,194,B-GENE-N
receptor,194,I-GENE-N
antagonist,194,O
(,194,B-CHEMICAL
-,194,I-CHEMICAL
),194,I-CHEMICAL
-quadazocine,194,I-CHEMICAL
exhibited,194,O
pure,194,O
antagonism,194,O
at,194,O
rat,194,O
brain,194,O
receptors,194,O
",",194,O
but,194,O
displayed,194,O
partial,194,O
agonism,194,O
at,194,O
human,194,B-GENE-Y
ORL1,194,I-GENE-Y
receptors,194,O
.,194,O
Thus,195,O
",",195,O
opioids,195,O
displaying,195,O
full,195,O
agonism,195,O
at,195,O
the,195,O
nociceptin,195,B-GENE-Y
receptor,195,I-GENE-Y
are,195,O
also,195,O
opioid,195,B-GENE-N
receptor,195,I-GENE-N
agonists,195,O
",",195,O
whereas,195,O
opioids,195,O
that,195,O
are,195,O
antagonists,195,O
or,195,O
partial,195,O
agonists,195,O
at,195,O
the,195,O
nociceptin,195,B-GENE-Y
receptor,195,I-GENE-Y
show,195,O
antagonism,195,O
or,195,O
partial,195,O
agonism,195,O
at,195,O
opioid,195,B-GENE-N
receptors,195,I-GENE-N
.,195,O
In,196,O
addition,196,O
",",196,O
the,196,O
stereospecificity,196,O
required,196,O
at,196,O
opioid,196,B-GENE-N
receptors,196,I-GENE-N
appears,196,O
to,196,O
be,196,O
retained,196,O
at,196,O
the,196,O
nociceptin,196,B-GENE-Y
receptor,196,I-GENE-Y
",",196,O
since,196,O
(,196,B-CHEMICAL
+,196,I-CHEMICAL
),196,I-CHEMICAL
-quadazocine,196,I-CHEMICAL
is,196,O
inactive,196,O
at,196,O
both,196,O
receptors,196,O
.,196,O
These,197,O
findings,197,O
illustrate,197,O
the,197,O
structural,197,O
and,197,O
functional,197,O
homology,197,O
of,197,O
the,197,O
opioid,197,O
recognition,197,O
site,197,O
on,197,O
these,197,O
two,197,O
receptor,197,O
classes,197,O
and,197,O
suggest,197,O
that,197,O
opioids,197,O
may,197,O
provide,197,O
leads,197,O
for,197,O
the,197,O
design,197,O
of,197,O
nonpeptide,197,O
nociceptin,197,B-GENE-Y
receptor,197,I-GENE-Y
agonists,197,O
and,197,O
antagonists,197,O
lacking,197,O
affinity,197,O
for,197,O
the,197,O
classical,197,O
opioid,197,B-GENE-N
receptors,197,I-GENE-N
.,197,O
Effects,198,O
of,198,O
long-term,198,O
administration,198,O
of,198,O
UFT,198,O
plus,198,O
leucovorin,198,B-CHEMICAL
on,198,O
colorectal,198,O
tumors,198,O
induced,198,O
with,198,O
"1,2-dimethylhydrazine",198,B-CHEMICAL
in,198,O
rats,198,O
.,198,O
Thymidylate,199,B-GENE-Y
synthase,199,I-GENE-Y
and,199,O
thymidine,199,B-CHEMICAL
kinase,199,I-GENE-Y
are,199,O
key,199,O
enzymes,199,O
involved,199,O
in,199,O
the,199,O
de,199,O
novo,199,O
and,199,O
salvage,199,O
pathways,199,O
for,199,O
pyrimidine,199,B-CHEMICAL
nucleotide,199,I-CHEMICAL
synthesis,199,O
",",199,O
respectively,199,O
.,199,O
Thymidylate,200,B-CHEMICAL
synthase,200,I-GENE-Y
is,200,O
inhibited,200,O
by,200,O
5-fluorodeoxyuridine,200,B-CHEMICAL
monophosphate,200,I-CHEMICAL
",",200,O
forming,200,O
an,200,O
inactive,200,O
ternary,200,O
complex,200,O
with,200,O
intracellular,200,O
folate,200,B-CHEMICAL
.,200,O
We,201,O
investigated,201,O
the,201,O
effects,201,O
of,201,O
1-,201,B-CHEMICAL
(,201,I-CHEMICAL
2-tetrahydrofuryl,201,I-CHEMICAL
),201,I-CHEMICAL
-5-FU,201,I-CHEMICAL
plus,201,O
uracil,201,B-CHEMICAL
(,201,O
UFT,201,B-CHEMICAL
),201,O
with,201,O
or,201,O
without,201,O
leucovorin,201,B-CHEMICAL
on,201,O
"1,2-dimethylhydrazine-induced",201,B-CHEMICAL
rat,201,O
colorectal,201,O
carcinomas,201,O
.,201,O
Thirty-week,202,O
administration,202,O
of,202,O
UFT,202,B-CHEMICAL
with,202,O
or,202,O
without,202,O
leucovorin,202,B-CHEMICAL
markedly,202,O
suppressed,202,O
both,202,O
colorectal,202,O
carcinogenesis,202,O
and,202,O
tumor,202,O
growth,202,O
",",202,O
resulted,202,O
in,202,O
the,202,O
increase,202,O
of,202,O
thymidylate,202,B-GENE-Y
synthase,202,I-GENE-Y
inhibition,202,O
and,202,O
the,202,O
decrease,202,O
of,202,O
thymidine,202,B-GENE-Y
kinase,202,I-GENE-Y
activity,202,O
in,202,O
the,202,O
tumor,202,O
cells,202,O
.,202,O
These,203,O
results,203,O
indicate,203,O
that,203,O
the,203,O
combination,203,O
of,203,O
UFT,203,B-CHEMICAL
with,203,O
leucovorin,203,B-CHEMICAL
could,203,O
be,203,O
useful,203,O
in,203,O
the,203,O
development,203,O
of,203,O
pre-,203,O
and,203,O
post-operative,203,O
adjuvant,203,O
chemotherapy,203,O
programs,203,O
.,203,O
Antizyme,204,B-GENE-N
inhibitor,204,I-GENE-N
is,204,O
rapidly,204,O
induced,204,O
in,204,O
growth-stimulated,204,O
mouse,204,O
fibroblasts,204,O
and,204,O
releases,204,O
ornithine,204,B-CHEMICAL
decarboxylase,204,I-GENE-Y
from,204,O
antizyme,204,B-GENE-N
suppression,204,O
.,204,O
Ornithine,205,B-GENE-Y
decarboxylase,205,I-GENE-Y
(,205,O
ODC,205,B-GENE-Y
),205,O
catalyses,205,O
the,205,O
first,205,O
step,205,O
in,205,O
the,205,O
synthesis,205,O
of,205,O
the,205,O
polyamines,205,O
putrescine,205,B-CHEMICAL
",",205,O
spermidine,205,B-CHEMICAL
and,205,O
spermine,205,B-CHEMICAL
.,205,O
The,206,O
polyamines,206,O
are,206,O
essential,206,O
for,206,O
cell,206,O
growth,206,O
",",206,O
but,206,O
at,206,O
elevated,206,O
levels,206,O
they,206,O
may,206,O
be,206,O
tumorigenic,206,O
",",206,O
toxic,206,O
",",206,O
or,206,O
may,206,O
induce,206,O
apoptosis,206,O
.,206,O
Therefore,207,O
",",207,O
ODC,207,B-GENE-Y
activity,207,O
is,207,O
highly,207,O
regulated,207,O
.,207,O
It,208,O
is,208,O
induced,208,O
when,208,O
cells,208,O
are,208,O
stimulated,208,O
to,208,O
grow,208,O
",",208,O
and,208,O
it,208,O
is,208,O
subjected,208,O
to,208,O
feedback,208,O
inhibition,208,O
by,208,O
the,208,O
polyamines,208,O
.,208,O
By,209,O
causing,209,O
ribosomal,209,O
frameshifting,209,O
",",209,O
polyamines,209,O
induce,209,O
the,209,O
synthesis,209,O
of,209,O
antizyme,209,B-GENE-N
",",209,O
a,209,O
23-kDa,209,O
protein,209,O
",",209,O
which,209,O
binds,209,O
to,209,O
ODC,209,B-GENE-Y
",",209,O
inhibits,209,O
its,209,O
activity,209,O
and,209,O
promotes,209,O
its,209,O
degradation,209,O
by,209,O
the,209,O
26,209,B-GENE-N
S,209,I-GENE-N
proteasome,209,I-GENE-N
.,209,O
Antizyme,210,B-GENE-N
",",210,O
in,210,O
turn,210,O
",",210,O
is,210,O
inhibited,210,O
by,210,O
antizyme,210,B-GENE-N
inhibitor,210,I-GENE-N
(,210,O
AZI,210,B-GENE-N
),210,O
.,210,O
We,211,O
describe,211,O
the,211,O
cloning,211,O
of,211,O
a,211,O
mouse,211,B-GENE-N
AZI,211,I-GENE-N
cDNA,211,O
",",211,O
encoding,211,O
a,211,O
protein,211,O
with,211,O
high,211,O
homology,211,O
to,211,O
mouse,211,B-GENE-Y
ODC,211,I-GENE-Y
.,211,O
Using,212,O
purified,212,O
recombinant,212,O
proteins,212,O
",",212,O
we,212,O
show,212,O
that,212,O
AZI,212,B-GENE-N
(,212,O
which,212,O
has,212,O
no,212,O
ODC,212,B-GENE-Y
activity,212,O
),212,O
can,212,O
release,212,O
enzymically,212,O
active,212,O
ODC,212,B-GENE-Y
from,212,O
antizyme,212,B-GENE-N
suppression,212,O
in,212,O
vitro,212,O
.,212,O
We,213,O
also,213,O
show,213,O
that,213,O
ODC,213,B-GENE-Y
reactivation,213,O
takes,213,O
place,213,O
in,213,O
mouse,213,O
fibroblasts,213,O
upon,213,O
transient,213,O
transfection,213,O
with,213,O
an,213,O
AZI-expressing,213,B-GENE-N
plasmid,213,O
construct,213,O
.,213,O
Finally,214,O
we,214,O
demonstrate,214,O
that,214,O
the,214,O
AZI,214,B-GENE-N
mRNA,214,O
content,214,O
of,214,O
mouse,214,O
fibroblasts,214,O
increases,214,O
significantly,214,O
within,214,O
an,214,O
hour,214,O
of,214,O
growth,214,O
stimulation,214,O
",",214,O
i.e,214,O
.,214,O
much,215,O
earlier,215,O
than,215,O
ODC,215,B-GENE-Y
transcripts,215,O
.,215,O
Our,216,O
results,216,O
indicate,216,O
that,216,O
induction,216,O
of,216,O
AZI,216,B-GENE-N
synthesis,216,O
may,216,O
represent,216,O
a,216,O
means,216,O
of,216,O
rescuing,216,O
ODC,216,B-GENE-Y
molecules,216,O
that,216,O
have,216,O
been,216,O
inactivated,216,O
and,216,O
tagged,216,O
for,216,O
degradation,216,O
by,216,O
antizyme,216,B-GENE-N
",",216,O
when,216,O
culture,216,O
conditions,216,O
improve,216,O
and,216,O
polyamine,216,O
production,216,O
is,216,O
needed,216,O
for,216,O
cell,216,O
growth,216,O
and,216,O
proliferation,216,O
.,216,O
Characterization,217,O
of,217,O
human,217,O
recombinant,217,O
alpha,217,B-GENE-Y
(,217,I-GENE-Y
2A,217,I-GENE-Y
),217,I-GENE-Y
-adrenoceptors,217,I-GENE-Y
expressed,217,O
in,217,O
Chinese,217,O
hamster,217,O
lung,217,O
cells,217,O
using,217,O
extracellular,217,O
acidification,217,O
rate,217,O
changes,217,O
.,217,O
1,218,O
.,218,O
Human,219,B-GENE-Y
alpha,219,I-GENE-Y
(,219,I-GENE-Y
2A,219,I-GENE-Y
),219,I-GENE-Y
-adrenoceptors,219,I-GENE-Y
heterologously,219,O
expressed,219,O
in,219,O
Chinese,219,O
hamster,219,O
lung,219,O
(,219,O
CHL,219,O
),219,O
fibroblasts,219,O
have,219,O
been,219,O
characterized,219,O
pharmacologically,219,O
using,219,O
a,219,O
cytosensor,219,O
microphysiometer,219,O
to,219,O
measure,219,O
ligand-induced,219,O
extracellular,219,O
acidification,219,O
rate,219,O
changes,219,O
.,219,O
2,220,O
.,220,O
In,221,O
untransfected,221,O
CHL,221,O
cells,221,O
",",221,O
noradrenaline,221,B-CHEMICAL
had,221,O
no,221,O
effect,221,O
at,221,O
concentrations,221,O
up,221,O
to,221,O
100,221,O
microM,221,O
.,221,O
In,222,O
alpha,222,B-GENE-Y
(,222,I-GENE-Y
2A,222,I-GENE-Y
),222,I-GENE-Y
-adrenoceptor,222,I-GENE-Y
transfected,222,O
cells,222,O
the,222,O
rank,222,O
order,222,O
of,222,O
agonist,222,O
potency,222,O
was,222,O
A-54741,222,B-CHEMICAL
(,222,O
mean,222,O
pEC,222,O
(,222,O
50,222,O
),222,O
=8.96,222,O
),222,O
>,222,O
dexmedetomidine,222,B-CHEMICAL
(,222,O
8.88,222,O
),222,O
>,222,O
UK-14304,222,B-CHEMICAL
(,222,O
8.42,222,O
),222,O
>,222,O
B-HT,222,B-CHEMICAL
920,222,I-CHEMICAL
(,222,O
7.05,222,O
),222,O
>,222,O
noradrenaline,222,B-CHEMICAL
(,222,O
6.92,222,O
),222,O
.,222,O
A-54741,223,B-CHEMICAL
",",223,O
UK-14304,223,B-CHEMICAL
and,223,O
noradrenaline,223,B-CHEMICAL
had,223,O
the,223,O
same,223,O
maximum,223,O
response,223,O
while,223,O
dexmedetomidine,223,B-CHEMICAL
and,223,O
B-HT,223,B-CHEMICAL
920,223,I-CHEMICAL
behaved,223,O
as,223,O
partial,223,O
agonists,223,O
.,223,O
3,224,O
.,224,O
The,225,O
selective,225,O
alpha,225,B-GENE-N
(,225,I-GENE-N
2,225,I-GENE-N
),225,I-GENE-N
-adrenoceptor,225,I-GENE-N
ligand,225,O
rauwolscine,225,B-CHEMICAL
antagonized,225,O
acidification,225,O
rate,225,O
changes,225,O
with,225,O
an,225,O
affinity,225,O
independent,225,O
of,225,O
the,225,O
agonist,225,O
used,225,O
;,225,O
the,225,O
affinity,225,O
(,225,O
mean,225,O
pK,225,O
(,225,O
B,225,O
),225,O
),225,O
against,225,O
noradrenaline,225,B-CHEMICAL
was,225,O
8.43,225,O
.,225,O
4,226,O
.,226,O
The,227,O
selective,227,O
alpha,227,B-GENE-N
(,227,I-GENE-N
1,227,I-GENE-N
),227,I-GENE-N
-adrenoceptor,227,I-GENE-N
ligands,227,O
prazosin,227,B-CHEMICAL
and,227,O
doxazosin,227,B-CHEMICAL
(,227,O
each,227,O
3,227,O
microM,227,O
),227,O
had,227,O
no,227,O
effect,227,O
on,227,O
noradrenaline,227,B-CHEMICAL
responses,227,O
.,227,O
5,228,O
.,228,O
Acidification,229,O
rate,229,O
changes,229,O
induced,229,O
by,229,O
each,229,O
agonist,229,O
were,229,O
abolished,229,O
by,229,O
pre-treatment,229,O
of,229,O
cells,229,O
with,229,O
pertussis,229,B-GENE-N
toxin,229,I-GENE-N
.,229,O
6,230,O
.,230,O
These,231,O
data,231,O
suggest,231,O
that,231,O
agonist-induced,231,O
acidification,231,O
rate,231,O
responses,231,O
in,231,O
CHL,231,O
cells,231,O
transfected,231,O
with,231,O
the,231,O
human,231,B-GENE-Y
alpha,231,I-GENE-Y
(,231,I-GENE-Y
2A,231,I-GENE-Y
),231,I-GENE-Y
-adrenoceptor,231,I-GENE-Y
are,231,O
mediated,231,O
exclusively,231,O
by,231,O
the,231,O
recombinant,231,O
protein,231,O
",",231,O
via,231,O
pertussis,231,B-GENE-N
toxin,231,I-GENE-N
sensitive,231,O
G,231,B-GENE-N
(,231,I-GENE-N
i/o,231,I-GENE-N
),231,I-GENE-N
proteins,231,I-GENE-N
.,231,O
Pharmacological,232,O
characterization,232,O
of,232,O
glucocorticoid,232,B-GENE-N
receptors,232,I-GENE-N
in,232,O
primary,232,O
human,232,O
bronchial,232,O
epithelial,232,O
cells,232,O
.,232,O
Bronchial,233,O
epithelial,233,O
cells,233,O
play,233,O
an,233,O
important,233,O
role,233,O
in,233,O
amplifying,233,O
and,233,O
perpetuating,233,O
airway,233,O
inflammation,233,O
and,233,O
may,233,O
be,233,O
a,233,O
target,233,O
for,233,O
inhaled,233,O
steroids,233,B-CHEMICAL
.,233,O
We,234,O
have,234,O
characterized,234,O
glucocorticoid,234,B-GENE-Y
receptors,234,I-GENE-Y
in,234,O
primary,234,O
human,234,O
bronchial,234,O
epithelial,234,O
cells,234,O
.,234,O
Northern,235,O
and,235,O
western,235,O
blot,235,O
analyses,235,O
demonstrated,235,O
the,235,O
expression,235,O
of,235,O
glucocorticoid,235,B-GENE-N
receptor,235,I-GENE-N
mRNA,235,O
and,235,O
protein,235,O
",",235,O
respectively,235,O
",",235,O
in,235,O
primary,235,O
bronchial,235,O
epithelial,235,O
cells,235,O
.,235,O
The,236,O
activity,236,O
of,236,O
these,236,O
receptors,236,O
was,236,O
shown,236,O
using,236,O
a,236,O
radioligand,236,O
binding,236,O
assay,236,O
.,236,O
High-affinity,237,O
binding,237,O
with,237,O
pharmacological,237,O
specificity,237,O
was,237,O
demonstrated,237,O
for,237,O
[,237,B-CHEMICAL
3H,237,I-CHEMICAL
],237,I-CHEMICAL
dexamethasone,237,I-CHEMICAL
.,237,O
The,238,O
equilibrium,238,O
dissociation,238,O
constant,238,O
(,238,O
Kd,238,O
),238,O
and,238,O
density,238,O
of,238,O
binding,238,O
sites,238,O
(,238,O
Bmax,238,O
),238,O
for,238,O
[,238,B-CHEMICAL
3H,238,I-CHEMICAL
],238,I-CHEMICAL
dexamethasone,238,I-CHEMICAL
determined,238,O
from,238,O
saturation,238,O
isotherms,238,O
were,238,O
4.4,238,O
nM,238,O
x/divided,238,O
by,238,O
0.95,238,O
(,238,O
SEM,238,O
),238,O
and,238,O
30.1,238,O
fmol/mg,238,O
protein,238,O
+/-6.4,238,O
(,238,O
SEM,238,O
),238,O
.,238,O
Glucocorticoid,239,B-GENE-Y
receptors,239,I-GENE-Y
were,239,O
activated,239,O
by,239,O
dexamethasone,239,B-CHEMICAL
as,239,O
assessed,239,O
using,239,O
a,239,O
glucocorticoid-responsive,239,O
reporter,239,O
plasmid,239,O
",",239,O
pTAT3-CAT,239,O
.,239,O
Transfection,240,O
of,240,O
primary,240,O
human,240,O
bronchial,240,O
epithelial,240,O
cells,240,O
with,240,O
this,240,O
reporter,240,O
plasmid,240,O
resulted,240,O
in,240,O
35-fold,240,O
activation,240,O
of,240,O
transcription,240,O
following,240,O
dexamethasone,240,B-CHEMICAL
stimulation,240,O
(,240,O
10,240,O
(,240,O
-6,240,O
),240,O
M,240,O
),240,O
.,240,O
The,241,O
glucocorticoid,241,B-GENE-Y
receptor,241,I-GENE-Y
antagonist,241,O
RU-486,241,B-CHEMICAL
(,241,O
mifepristone,241,B-CHEMICAL
),241,O
significantly,241,O
counteracted,241,O
the,241,O
effect,241,O
of,241,O
dexamethasone,241,B-CHEMICAL
on,241,O
glucocorticoid,241,B-GENE-Y
receptor,241,I-GENE-Y
activation,241,O
",",241,O
indicating,241,O
that,241,O
the,241,O
dexamethasone,241,B-CHEMICAL
effect,241,O
is,241,O
specific,241,O
and,241,O
is,241,O
mediated,241,O
through,241,O
the,241,O
glucocorticoid,241,B-GENE-Y
receptor,241,I-GENE-Y
.,241,O
In,242,O
summary,242,O
",",242,O
our,242,O
study,242,O
demonstrated,242,O
that,242,O
primary,242,O
cultures,242,O
of,242,O
human,242,O
bronchial,242,O
epithelial,242,O
cells,242,O
possess,242,O
glucocorticoid,242,B-GENE-Y
receptors,242,I-GENE-Y
that,242,O
function,242,O
as,242,O
a,242,O
ligand-activated,242,O
transcriptional,242,O
regulator,242,O
.,242,O
The,243,O
presence,243,O
of,243,O
glucocorticoid,243,B-GENE-Y
receptors,243,I-GENE-Y
confers,243,O
their,243,O
responsiveness,243,O
to,243,O
glucocorticoids,243,O
and,243,O
indicates,243,O
that,243,O
the,243,O
airway,243,O
epithelium,243,O
may,243,O
be,243,O
a,243,O
target,243,O
for,243,O
the,243,O
anti-inflammatory,243,O
effects,243,O
of,243,O
inhaled,243,O
steroids,243,B-CHEMICAL
.,243,O
Molecular,244,O
characterization,244,O
of,244,O
the,244,O
surface,244,O
of,244,O
apoptotic,244,O
neutrophils,244,O
:,244,O
implications,244,O
for,244,O
functional,244,O
downregulation,244,O
and,244,O
recognition,244,O
by,244,O
phagocytes,244,O
.,244,O
We,245,O
have,245,O
used,245,O
a,245,O
panel,245,O
of,245,O
monoclonal,245,O
antibodies,245,O
and,245,O
lectins,245,B-GENE-N
to,245,O
examine,245,O
the,245,O
profile,245,O
of,245,O
surface,245,O
molecule,245,O
expression,245,O
on,245,O
human,245,O
neutrophils,245,O
that,245,O
have,245,O
undergone,245,O
spontaneous,245,O
apoptosis,245,O
during,245,O
in,245,O
vitro,245,O
culture,245,O
.,245,O
Neutrophil,246,O
apoptosis,246,O
was,246,O
found,246,O
to,246,O
be,246,O
accompanied,246,O
by,246,O
down-regulation,246,O
of,246,O
the,246,O
immunoglobulin,246,B-GENE-N
superfamily,246,O
members,246,O
PECAM-1,246,B-GENE-Y
(,246,O
CD31,246,B-GENE-Y
),246,O
",",246,O
ICAM-3,246,B-GENE-Y
(,246,O
CD50,246,B-GENE-Y
),246,O
",",246,O
CD66acde,246,B-GENE-N
",",246,O
and,246,O
CD66b,246,B-GENE-Y
and,246,O
the,246,O
integrin-associated,246,B-GENE-N
proteins,246,O
CD63,246,B-GENE-Y
and,246,O
urokinase,246,B-GENE-Y
plasminogen,246,I-GENE-Y
activator,246,I-GENE-Y
receptor,246,I-GENE-Y
(,246,O
CD87,246,B-GENE-Y
),246,O
that,246,O
may,246,O
alter,246,O
the,246,O
potential,246,O
for,246,O
adhesive,246,O
interactions,246,O
.,246,O
Cellular,247,O
interactions,247,O
may,247,O
be,247,O
further,247,O
influenced,247,O
by,247,O
the,247,O
reduction,247,O
of,247,O
the,247,O
expression,247,O
of,247,O
surface,247,O
carbohydrate,247,B-CHEMICAL
moieties,247,O
",",247,O
including,247,O
sialic,247,B-CHEMICAL
acid,247,I-CHEMICAL
.,247,O
Reduced,248,O
expression,248,O
of,248,O
FcgammaRII,248,B-GENE-N
(,248,O
CD32,248,B-GENE-Y
),248,O
",",248,O
complement,248,B-GENE-Y
receptor,248,I-GENE-Y
type,248,I-GENE-Y
1,248,I-GENE-Y
(,248,O
CD35,248,B-GENE-Y
),248,O
and,248,O
receptors,248,O
for,248,O
pro-inflammatory,248,O
mediators,248,O
C5a,248,B-GENE-Y
(,248,O
CD88,248,B-GENE-Y
),248,O
and,248,O
TNFalpha,248,B-GENE-Y
(,248,O
CD120b,248,B-GENE-Y
),248,O
associated,248,O
with,248,O
apoptosis,248,O
might,248,O
limit,248,O
neutrophil,248,O
responsiveness,248,O
to,248,O
stimuli,248,O
that,248,O
trigger,248,O
degranulation,248,O
responses,248,O
.,248,O
Although,249,O
many,249,O
of,249,O
the,249,O
receptors,249,O
we,249,O
have,249,O
examined,249,O
are,249,O
expressed,249,O
at,249,O
reduced,249,O
levels,249,O
on,249,O
apoptotic,249,O
neutrophils,249,O
",",249,O
we,249,O
found,249,O
that,249,O
there,249,O
was,249,O
differential,249,O
loss,249,O
of,249,O
certain,249,O
receptors,249,O
(,249,O
e.g,249,O
.,249,O
CD16,250,B-GENE-Y
",",250,O
CD15,250,B-GENE-Y
and,250,O
CD120b,250,B-GENE-Y
),250,O
and,250,O
increased,250,O
expression,250,O
of,250,O
aminopeptidase-N,250,B-GENE-Y
(,250,O
CD13,250,B-GENE-Y
),250,O
.,250,O
Together,251,O
with,251,O
our,251,O
previous,251,O
data,251,O
showing,251,O
that,251,O
expression,251,O
of,251,O
certain,251,O
molecules,251,O
e.g,251,O
.,251,O
LFA-3,252,B-GENE-Y
(,252,O
CD58,252,B-GENE-Y
),252,O
is,252,O
not,252,O
altered,252,O
during,252,O
neutrophil,252,O
apoptosis,252,O
",",252,O
these,252,O
data,252,O
are,252,O
suggestive,252,O
of,252,O
specific,252,O
changes,252,O
in,252,O
receptor,252,O
mobilisation,252,O
and,252,O
shedding,252,O
associated,252,O
with,252,O
apoptosis,252,O
.,252,O
Although,253,O
reduced,253,O
expression,253,O
of,253,O
CD63,253,B-GENE-Y
(,253,O
azurophilic,253,O
granules,253,O
),253,O
and,253,O
CR1,253,B-GENE-Y
(,253,O
specific,253,O
granules,253,O
),253,O
indicates,253,O
that,253,O
granule,253,O
mobilisation,253,O
does,253,O
not,253,O
accompany,253,O
apoptosis,253,O
",",253,O
a,253,O
monoclonal,253,O
antibody,253,O
(,253,O
BOB78,253,O
),253,O
",",253,O
that,253,O
recognises,253,O
a,253,O
90,253,O
kDa,253,O
antigen,253,O
localised,253,O
in,253,O
intracellular,253,O
granules,253,O
",",253,O
defines,253,O
a,253,O
subpopulation,253,O
of,253,O
apoptotic,253,O
neutrophils,253,O
that,253,O
exhibit,253,O
nuclear,253,O
degradation,253,O
yet,253,O
retain,253,O
intact,253,O
plasma,253,O
membranes,253,O
.,253,O
BOB78,254,O
positive,254,O
neutrophils,254,O
were,254,O
found,254,O
to,254,O
bind,254,O
biotinylated,254,O
thrombospondin,254,B-GENE-Y
",",254,O
suggesting,254,O
that,254,O
this,254,O
mAb,254,O
defines,254,O
surface,254,O
molecular,254,O
changes,254,O
associated,254,O
with,254,O
exposure,254,O
of,254,O
thrombospondin,254,B-GENE-Y
binding,254,O
moieties,254,O
.,254,O
A,255,O
positron,255,O
emission,255,O
tomography,255,O
study,255,O
of,255,O
quetiapine,255,B-CHEMICAL
in,255,O
schizophrenia,255,O
:,255,O
a,255,O
preliminary,255,O
finding,255,O
of,255,O
an,255,O
antipsychotic,255,O
effect,255,O
with,255,O
only,255,O
transiently,255,O
high,255,O
dopamine,255,B-CHEMICAL
D2,255,I-GENE-Y
receptor,255,I-GENE-Y
occupancy,255,O
.,255,O
BACKGROUND,256,O
:,256,O
Quetiapine,256,B-CHEMICAL
is,256,O
a,256,O
new,256,O
atypical,256,O
antipsychotic,256,O
medication,256,O
.,256,O
As,257,O
such,257,O
",",257,O
relatively,257,O
little,257,O
has,257,O
been,257,O
published,257,O
regarding,257,O
its,257,O
in,257,O
vivo,257,O
effects,257,O
at,257,O
the,257,O
dopamine,257,B-CHEMICAL
type,257,I-GENE-Y
2,257,I-GENE-Y
(,257,O
D2,257,B-GENE-Y
),257,O
and,257,O
serotonin,257,B-CHEMICAL
type,257,I-GENE-Y
2a,257,I-GENE-Y
(,257,I-GENE-Y
5-HT2a,257,I-GENE-Y
),257,I-GENE-Y
receptor,257,I-GENE-Y
systems,257,O
.,257,O
The,258,O
following,258,O
study,258,O
was,258,O
undertaken,258,O
to,258,O
explore,258,O
these,258,O
effects,258,O
across,258,O
the,258,O
clinical,258,O
dose,258,O
range,258,O
and,258,O
relate,258,O
this,258,O
information,258,O
to,258,O
its,258,O
clinical,258,O
profile,258,O
.,258,O
METHODS,259,O
:,259,O
Twelve,259,O
patients,259,O
with,259,O
schizophrenia,259,O
were,259,O
randomly,259,O
assigned,259,O
to,259,O
doses,259,O
of,259,O
150,259,O
to,259,O
600,259,O
mg/d,259,O
(,259,O
n=3,259,O
",",259,O
at,259,O
150,259,O
",",259,O
300,259,O
",",259,O
450,259,O
",",259,O
and,259,O
600,259,O
mg/d,259,O
),259,O
of,259,O
quetiapine,259,B-CHEMICAL
.,259,O
After,260,O
3,260,O
weeks,260,O
of,260,O
treatment,260,O
",",260,O
D2,260,B-GENE-Y
and,260,O
5-HT2a,260,B-GENE-Y
occupancy,260,O
were,260,O
measured,260,O
using,260,O
positron,260,O
emission,260,O
tomography,260,O
(,260,O
PET,260,O
),260,O
imaging,260,O
",",260,O
12,260,O
to,260,O
14,260,O
hours,260,O
after,260,O
the,260,O
last,260,O
dose,260,O
.,260,O
Clinical,261,O
efficacy,261,O
and,261,O
adverse,261,O
effect,261,O
ratings,261,O
were,261,O
obtained,261,O
at,261,O
baseline,261,O
",",261,O
at,261,O
the,261,O
time,261,O
of,261,O
PET,261,O
scanning,261,O
",",261,O
and,261,O
at,261,O
12,261,O
weeks,261,O
.,261,O
Two,262,O
additional,262,O
patients,262,O
were,262,O
included,262,O
to,262,O
examine,262,O
the,262,O
effects,262,O
of,262,O
the,262,O
drug,262,O
2,262,O
to,262,O
3,262,O
hours,262,O
after,262,O
last,262,O
dose,262,O
.,262,O
RESULTS,263,O
:,263,O
Quetiapine,263,B-CHEMICAL
was,263,O
an,263,O
effective,263,O
antipsychotic,263,O
and,263,O
improved,263,O
the,263,O
extrapyramidal,263,O
symptoms,263,O
and,263,O
prolactin,263,B-GENE-Y
level,263,O
elevation,263,O
noted,263,O
at,263,O
baseline,263,O
.,263,O
It,264,O
achieved,264,O
these,264,O
results,264,O
with,264,O
minimal,264,O
(,264,O
0,264,O
%,264,O
-27,264,O
%,264,O
),264,O
D2,264,B-GENE-Y
occupancy,264,O
12,264,O
hours,264,O
after,264,O
the,264,O
last,264,O
dose,264,O
.,264,O
Study,265,O
of,265,O
the,265,O
additional,265,O
subjects,265,O
revealed,265,O
that,265,O
quetiapine,265,B-CHEMICAL
does,265,O
give,265,O
rise,265,O
to,265,O
transiently,265,O
high,265,O
(,265,O
58,265,O
%,265,O
-64,265,O
%,265,O
),265,O
D2,265,B-GENE-Y
occupancy,265,O
2,265,O
to,265,O
3,265,O
hours,265,O
after,265,O
a,265,O
single,265,O
dose,265,O
that,265,O
then,265,O
decreases,265,O
to,265,O
minimal,265,O
levels,265,O
in,265,O
12,265,O
hours,265,O
.,265,O
CONCLUSIONS,266,O
:,266,O
Quetiapine,266,B-CHEMICAL
shows,266,O
a,266,O
transiently,266,O
high,266,O
D2,266,B-GENE-Y
occupancy,266,O
",",266,O
which,266,O
decreases,266,O
to,266,O
very,266,O
low,266,O
levels,266,O
by,266,O
the,266,O
end,266,O
of,266,O
the,266,O
dosing,266,O
interval,266,O
.,266,O
Quetiapine,267,O
's,267,O
low,267,O
D2,267,B-GENE-Y
occupancy,267,O
can,267,O
explain,267,O
its,267,O
freedom,267,O
from,267,O
extrapyramidal,267,O
symptoms,267,O
and,267,O
prolactin,267,O
level,267,O
elevation,267,O
.,267,O
The,268,O
data,268,O
suggest,268,O
that,268,O
transient,268,O
D2,268,B-GENE-Y
occupancy,268,O
may,268,O
be,268,O
sufficient,268,O
for,268,O
its,268,O
antipsychotic,268,O
effect,268,O
.,268,O
Future,269,O
studies,269,O
controlling,269,O
for,269,O
nonpharmacological,269,O
effects,269,O
as,269,O
well,269,O
as,269,O
activities,269,O
on,269,O
other,269,O
receptors,269,O
will,269,O
be,269,O
necessary,269,O
to,269,O
confirm,269,O
this,269,O
suggestion,269,O
.,269,O
Correlations,270,O
of,270,O
receptor,270,O
binding,270,O
and,270,O
metabolic,270,O
and,270,O
mitogenic,270,O
potencies,270,O
of,270,O
insulin,270,B-GENE-Y
analogs,270,O
designed,270,O
for,270,O
clinical,270,O
use,270,O
.,270,O
In,271,O
recent,271,O
years,271,O
",",271,O
analogs,271,O
of,271,O
human,271,B-GENE-Y
insulin,271,I-GENE-Y
have,271,O
been,271,O
engineered,271,O
with,271,O
the,271,O
aim,271,O
of,271,O
improving,271,O
therapy,271,O
for,271,O
people,271,O
with,271,O
diabetes,271,O
.,271,O
To,272,O
ensure,272,O
that,272,O
the,272,O
safety,272,O
profile,272,O
of,272,O
the,272,O
human,272,O
hormone,272,O
is,272,O
not,272,O
compromised,272,O
by,272,O
the,272,O
molecular,272,O
modifications,272,O
",",272,O
the,272,O
toxico-pharmacological,272,O
properties,272,O
of,272,O
insulin,272,B-GENE-Y
analogs,272,O
should,272,O
be,272,O
carefully,272,O
monitored,272,O
.,272,O
In,273,O
this,273,O
study,273,O
",",273,O
we,273,O
compared,273,O
the,273,O
insulin,273,B-GENE-Y
and,273,O
IGF-I,273,B-GENE-Y
receptor,273,I-GENE-Y
binding,273,O
properties,273,O
and,273,O
metabolic,273,O
and,273,O
mitogenic,273,O
potencies,273,O
of,273,O
insulin,273,B-GENE-Y
aspart,273,O
(,273,O
B28Asp,273,O
human,273,B-GENE-Y
insulin,273,I-GENE-Y
),273,O
",",273,O
insulin,273,B-GENE-Y
lispro,273,O
(,273,O
B28Lys,273,O
",",273,O
B29Pro,273,O
human,273,B-GENE-Y
insulin,273,I-GENE-Y
),273,O
",",273,O
insulin,273,B-GENE-Y
glargine,273,O
(,273,O
A21Gly,273,O
",",273,O
B31Arg,273,O
",",273,O
B32Arg,273,O
human,273,B-GENE-Y
insulin,273,I-GENE-Y
),273,O
",",273,O
insulin,273,B-GENE-Y
detemir,273,O
(,273,O
NN304,273,O
),273,O
[,273,O
B29Lys,273,O
(,273,O
epsilon-tetradecanoyl,273,B-CHEMICAL
),273,O
",",273,O
desB30,273,O
human,273,O
insulin,273,B-GENE-Y
],273,O
",",273,O
and,273,O
reference,273,O
insulin,273,B-GENE-Y
analogs,273,O
.,273,O
Receptor,274,O
affinities,274,O
were,274,O
measured,274,O
using,274,O
purified,274,O
human,274,O
receptors,274,O
",",274,O
insulin,274,B-GENE-Y
receptor,274,I-GENE-Y
dissociation,274,O
rates,274,O
were,274,O
determined,274,O
using,274,O
Chinese,274,O
hamster,274,O
ovary,274,O
cells,274,O
overexpressing,274,O
the,274,O
human,274,B-GENE-Y
insulin,274,I-GENE-Y
receptor,274,I-GENE-Y
",",274,O
metabolic,274,O
potencies,274,O
were,274,O
evaluated,274,O
using,274,O
primary,274,O
mouse,274,O
adipocytes,274,O
",",274,O
and,274,O
mitogenic,274,O
potencies,274,O
were,274,O
determined,274,O
in,274,O
human,274,O
osteosarcoma,274,O
cells,274,O
.,274,O
Metabolic,275,O
potencies,275,O
correlated,275,O
well,275,O
with,275,O
insulin,275,B-GENE-Y
receptor,275,I-GENE-Y
affinities,275,O
.,275,O
Mitogenic,276,O
potencies,276,O
in,276,O
general,276,O
correlated,276,O
better,276,O
with,276,O
IGF-I,276,B-GENE-Y
receptor,276,I-GENE-Y
affinities,276,O
than,276,O
with,276,O
insulin,276,B-GENE-Y
receptor,276,I-GENE-Y
off-rates,276,O
.,276,O
The,277,O
2,277,O
rapid-acting,277,O
insulin,277,B-GENE-Y
analogs,277,O
aspart,277,O
and,277,O
lispro,277,O
resembled,277,O
human,277,B-GENE-Y
insulin,277,I-GENE-Y
on,277,O
all,277,O
parameters,277,O
",",277,O
except,277,O
for,277,O
a,277,O
slightly,277,O
elevated,277,O
IGF-I,277,B-GENE-Y
receptor,277,I-GENE-Y
affinity,277,O
of,277,O
lispro,277,O
.,277,O
In,278,O
contrast,278,O
",",278,O
the,278,O
2,278,O
long-acting,278,O
insulin,278,B-GENE-Y
analogs,278,O
",",278,O
glargine,278,O
and,278,O
detemir,278,O
",",278,O
differed,278,O
significantly,278,O
from,278,O
human,278,B-GENE-Y
insulin,278,I-GENE-Y
.,278,O
The,279,O
combination,279,O
of,279,O
the,279,O
B31B32diArg,279,O
and,279,O
A21Gly,279,O
substitutions,279,O
provided,279,O
insulin,279,B-GENE-Y
glargine,279,O
with,279,O
a,279,O
6-,279,O
to,279,O
8-fold,279,O
increased,279,O
IGF-I,279,B-GENE-Y
receptor,279,I-GENE-Y
affinity,279,O
and,279,O
mitogenic,279,O
potency,279,O
compared,279,O
with,279,O
human,279,B-GENE-Y
insulin,279,I-GENE-Y
.,279,O
The,280,O
attachment,280,O
of,280,O
a,280,O
fatty,280,B-CHEMICAL
acid,280,I-CHEMICAL
chain,280,O
to,280,O
LysB29,280,O
provided,280,O
insulin,280,B-GENE-Y
detemir,280,O
with,280,O
reduced,280,O
receptor,280,O
affinities,280,O
and,280,O
metabolic,280,O
and,280,O
mitogenic,280,O
potencies,280,O
but,280,O
did,280,O
not,280,O
change,280,O
the,280,O
balance,280,O
between,280,O
mitogenic,280,O
and,280,O
metabolic,280,O
potencies,280,O
.,280,O
The,281,O
safety,281,O
implications,281,O
of,281,O
the,281,O
increased,281,O
growth-stimulating,281,O
potential,281,O
of,281,O
insulin,281,B-GENE-Y
glargine,281,O
are,281,O
unclear,281,O
.,281,O
The,282,O
reduced,282,O
in,282,O
vitro,282,O
potency,282,O
of,282,O
insulin,282,B-GENE-Y
detemir,282,O
might,282,O
explain,282,O
why,282,O
this,282,O
analog,282,O
is,282,O
not,282,O
as,282,O
effective,282,O
on,282,O
a,282,O
molar,282,O
basis,282,O
as,282,O
human,282,B-GENE-Y
insulin,282,I-GENE-Y
in,282,O
humans,282,O
.,282,O
TWIK-2,283,B-GENE-Y
",",283,O
an,283,O
inactivating,283,O
2P,283,B-GENE-Y
domain,283,I-GENE-Y
K+,283,I-GENE-Y
channel,283,I-GENE-Y
.,283,O
We,284,O
cloned,284,O
human,284,O
and,284,O
rat,284,O
TWIK-2,284,B-GENE-N
and,284,O
expressed,284,O
this,284,O
novel,284,O
2P,284,B-GENE-N
domain,284,I-GENE-N
K,284,B-CHEMICAL
(,284,I-CHEMICAL
+,284,I-CHEMICAL
),284,I-CHEMICAL
channel,284,I-GENE-N
in,284,O
transiently,284,O
transfected,284,O
COS,284,O
cells,284,O
.,284,O
TWIK-2,285,B-GENE-Y
is,285,O
highly,285,O
expressed,285,O
in,285,O
the,285,O
gastrointestinal,285,O
tract,285,O
",",285,O
the,285,O
vasculature,285,O
",",285,O
and,285,O
the,285,O
immune,285,O
system,285,O
.,285,O
Rat,286,B-GENE-Y
TWIK-2,286,I-GENE-Y
currents,286,O
are,286,O
about,286,O
15,286,O
times,286,O
larger,286,O
than,286,O
human,286,B-GENE-Y
TWIK-2,286,I-GENE-Y
currents,286,O
",",286,O
but,286,O
both,286,O
exhibit,286,O
outward,286,O
rectification,286,O
in,286,O
a,286,O
physiological,286,O
K,286,B-CHEMICAL
(,286,I-CHEMICAL
+,286,I-CHEMICAL
),286,I-CHEMICAL
gradient,286,O
and,286,O
mild,286,O
inward,286,O
rectification,286,O
in,286,O
symmetrical,286,O
K,286,B-CHEMICAL
(,286,I-CHEMICAL
+,286,I-CHEMICAL
),286,I-CHEMICAL
conditions,286,O
.,286,O
TWIK-2,287,B-GENE-Y
currents,287,O
are,287,O
inactivating,287,O
at,287,O
depolarized,287,O
potentials,287,O
",",287,O
and,287,O
the,287,O
kinetic,287,O
of,287,O
inactivation,287,O
is,287,O
highly,287,O
temperature-sensitive,287,O
.,287,O
TWIK-2,288,B-GENE-Y
shows,288,O
an,288,O
extremely,288,O
low,288,O
conductance,288,O
",",288,O
which,288,O
prevents,288,O
the,288,O
visualization,288,O
of,288,O
discrete,288,O
single,288,O
channel,288,O
events,288,O
.,288,O
The,289,O
inactivation,289,O
and,289,O
rectification,289,O
are,289,O
intrinsic,289,O
properties,289,O
of,289,O
TWIK-2,289,B-GENE-Y
channels,289,O
.,289,O
In,290,O
a,290,O
physiological,290,O
K,290,B-CHEMICAL
(,290,I-CHEMICAL
+,290,I-CHEMICAL
),290,I-CHEMICAL
gradient,290,O
",",290,O
TWIK-2,290,B-GENE-Y
is,290,O
half,290,O
inhibited,290,O
by,290,O
0.1,290,O
mm,290,O
Ba,290,B-CHEMICAL
(,290,I-CHEMICAL
2+,290,I-CHEMICAL
),290,I-CHEMICAL
",",290,O
quinine,290,B-CHEMICAL
",",290,O
and,290,O
quinidine,290,B-CHEMICAL
.,290,O
Finally,291,O
",",291,O
cysteine,291,B-CHEMICAL
53,291,O
in,291,O
the,291,O
M1P1,291,B-GENE-N
external,291,I-GENE-N
loop,291,I-GENE-N
is,291,O
required,291,O
for,291,O
functional,291,O
expression,291,O
of,291,O
TWIK-2,291,B-GENE-Y
but,291,O
is,291,O
not,291,O
critical,291,O
for,291,O
subunit,291,O
self-assembly,291,O
.,291,O
TWIK-2,292,B-GENE-Y
is,292,O
the,292,O
first,292,O
reported,292,O
2P,292,B-GENE-Y
domain,292,I-GENE-Y
K,292,B-CHEMICAL
(,292,I-CHEMICAL
+,292,I-CHEMICAL
),292,I-CHEMICAL
channel,292,I-GENE-Y
that,292,O
inactivates,292,O
.,292,O
The,293,O
base-line,293,O
",",293,O
transient,293,O
",",293,O
and,293,O
delayed,293,O
activities,293,O
of,293,O
TWIK-2,293,B-GENE-Y
suggest,293,O
that,293,O
this,293,O
novel,293,O
2P,293,B-GENE-Y
domain,293,I-GENE-Y
K,293,B-CHEMICAL
(,293,I-CHEMICAL
+,293,I-CHEMICAL
),293,I-CHEMICAL
channel,293,I-GENE-Y
may,293,O
play,293,O
an,293,O
important,293,O
functional,293,O
role,293,O
in,293,O
cell,293,O
electrogenesis,293,O
.,293,O
Addition,294,O
of,294,O
eicosapentaenoic,294,B-CHEMICAL
acid,294,I-CHEMICAL
to,294,O
gamma-linolenic,294,B-CHEMICAL
acid-supplemented,294,O
diets,294,O
prevents,294,O
serum,294,O
arachidonic,294,B-CHEMICAL
acid,294,I-CHEMICAL
accumulation,294,O
in,294,O
humans,294,O
.,294,O
Previous,295,O
studies,295,O
reveal,295,O
that,295,O
supplementation,295,O
of,295,O
human,295,O
diets,295,O
with,295,O
gamma-linolenic,295,B-CHEMICAL
acid,295,I-CHEMICAL
(,295,O
GLA,295,B-CHEMICAL
),295,O
reduces,295,O
the,295,O
generation,295,O
of,295,O
lipid,295,O
mediators,295,O
of,295,O
inflammation,295,O
and,295,O
attenuates,295,O
clinical,295,O
symptoms,295,O
of,295,O
chronic,295,O
inflammatory,295,O
disorders,295,O
such,295,O
as,295,O
rheumatoid,295,O
arthritis,295,O
.,295,O
However,296,O
",",296,O
we,296,O
have,296,O
shown,296,O
that,296,O
supplementation,296,O
with,296,O
this,296,O
same,296,O
fatty,296,B-CHEMICAL
acid,296,I-CHEMICAL
also,296,O
causes,296,O
a,296,O
marked,296,O
increase,296,O
in,296,O
serum,296,O
arachidonate,296,B-CHEMICAL
(,296,O
AA,296,B-CHEMICAL
),296,O
levels,296,O
",",296,O
a,296,O
potentially,296,O
harmful,296,O
side,296,O
effect,296,O
.,296,O
The,297,O
objective,297,O
of,297,O
this,297,O
study,297,O
was,297,O
to,297,O
design,297,O
a,297,O
supplementation,297,O
strategy,297,O
that,297,O
maintained,297,O
the,297,O
capacity,297,O
of,297,O
GLA,297,B-CHEMICAL
to,297,O
reduce,297,O
lipid,297,O
mediators,297,O
without,297,O
causing,297,O
elevations,297,O
in,297,O
serum,297,O
AA,297,B-CHEMICAL
levels,297,O
.,297,O
Initial,298,O
in,298,O
vitro,298,O
studies,298,O
utilizing,298,O
HEP-G2,298,O
liver,298,O
cells,298,O
revealed,298,O
that,298,O
addition,298,O
of,298,O
eicosapentaenoic,298,B-CHEMICAL
acid,298,I-CHEMICAL
(,298,O
EPA,298,B-CHEMICAL
),298,O
blocked,298,O
Delta-5-desaturase,298,B-GENE-Y
activity,298,O
",",298,O
the,298,O
terminal,298,O
enzymatic,298,O
step,298,O
in,298,O
AA,298,B-CHEMICAL
synthesis,298,O
.,298,O
To,299,O
test,299,O
the,299,O
in,299,O
vivo,299,O
effects,299,O
of,299,O
a,299,O
GLA,299,B-CHEMICAL
and,299,O
EPA,299,B-CHEMICAL
combination,299,O
in,299,O
humans,299,O
",",299,O
adult,299,O
volunteers,299,O
consuming,299,O
controlled,299,O
diets,299,O
supplemented,299,O
these,299,O
diets,299,O
with,299,O
3.0,299,O
g/d,299,O
of,299,O
GLA,299,B-CHEMICAL
and,299,O
EPA,299,B-CHEMICAL
.,299,O
This,300,O
supplementation,300,O
strategy,300,O
significantly,300,O
increased,300,O
serum,300,O
levels,300,O
of,300,O
EPA,300,B-CHEMICAL
",",300,O
but,300,O
did,300,O
not,300,O
increase,300,O
AA,300,B-CHEMICAL
levels,300,O
.,300,O
EPA,301,B-CHEMICAL
and,301,O
the,301,O
elongation,301,O
product,301,O
of,301,O
GLA,301,B-CHEMICAL
",",301,O
dihomo-gamma-linolenic,301,B-CHEMICAL
acid,301,I-CHEMICAL
(,301,O
DGLA,301,B-CHEMICAL
),301,O
levels,301,O
in,301,O
neutrophil,301,O
glycerolipids,301,O
increased,301,O
significantly,301,O
during,301,O
the,301,O
3-wk,301,O
supplementation,301,O
period,301,O
.,301,O
Neutrophils,302,O
isolated,302,O
from,302,O
volunteers,302,O
fed,302,O
diets,302,O
supplemented,302,O
with,302,O
GLA,302,B-CHEMICAL
and,302,O
EPA,302,B-CHEMICAL
released,302,O
similar,302,O
quantities,302,O
of,302,O
AA,302,B-CHEMICAL
",",302,O
but,302,O
synthesized,302,O
significantly,302,O
lower,302,O
quantities,302,O
of,302,O
leukotrienes,302,B-CHEMICAL
compared,302,O
with,302,O
their,302,O
neutrophils,302,O
before,302,O
supplementation,302,O
.,302,O
This,303,O
study,303,O
revealed,303,O
that,303,O
a,303,O
GLA,303,B-CHEMICAL
and,303,O
EPA,303,B-CHEMICAL
supplement,303,O
combination,303,O
may,303,O
be,303,O
utilized,303,O
to,303,O
reduce,303,O
the,303,O
synthesis,303,O
of,303,O
proinflammatory,303,O
AA,303,B-CHEMICAL
metabolites,303,O
",",303,O
and,303,O
importantly,303,O
",",303,O
not,303,O
induce,303,O
potentially,303,O
harmful,303,O
increases,303,O
in,303,O
serum,303,O
AA,303,B-CHEMICAL
levels,303,O
.,303,O
Effects,304,O
of,304,O
a,304,O
K,304,B-GENE-N
(,304,I-GENE-N
+,304,I-GENE-N
),304,I-GENE-N
channel,304,I-GENE-N
opener,304,O
to,304,O
reduce,304,O
transmural,304,O
dispersion,304,O
of,304,O
repolarization,304,O
and,304,O
prevent,304,O
torsade,304,O
de,304,O
pointes,304,O
in,304,O
LQT1,304,O
",",304,O
LQT2,304,O
",",304,O
and,304,O
LQT3,304,O
models,304,O
of,304,O
the,304,O
long-QT,304,O
syndrome,304,O
.,304,O
BACKGROUND,305,O
:,305,O
This,305,O
study,305,O
examines,305,O
the,305,O
effects,305,O
of,305,O
nicorandil,305,B-CHEMICAL
",",305,O
a,305,O
K,305,B-CHEMICAL
(,305,I-CHEMICAL
+,305,I-CHEMICAL
),305,I-CHEMICAL
channel,305,I-GENE-N
opener,305,O
",",305,O
on,305,O
transmural,305,O
dispersion,305,O
of,305,O
repolarization,305,O
(,305,O
TDR,305,O
),305,O
and,305,O
induction,305,O
of,305,O
torsade,305,O
de,305,O
pointes,305,O
(,305,O
TdP,305,O
),305,O
under,305,O
conditions,305,O
mimicking,305,O
the,305,O
LQT1,305,O
",",305,O
LQT2,305,O
",",305,O
and,305,O
LQT3,305,O
forms,305,O
of,305,O
the,305,O
congenital,305,O
long-QT,305,O
syndrome,305,O
(,305,O
LQTS,305,O
),305,O
.,305,O
METHODS,306,O
AND,306,O
RESULTS,306,O
:,306,O
Transmembrane,306,O
action,306,O
potentials,306,O
of,306,O
epicardial,306,O
",",306,O
M,306,O
",",306,O
and,306,O
endocardial,306,O
cells,306,O
were,306,O
recorded,306,O
simultaneously,306,O
from,306,O
an,306,O
arterially,306,O
perfused,306,O
wedge,306,O
of,306,O
canine,306,O
left,306,O
ventricle,306,O
together,306,O
with,306,O
a,306,O
transmural,306,O
ECG,306,O
.,306,O
Chromanol,307,O
293B,307,O
(,307,O
30,307,O
micromol/L,307,O
),307,O
was,307,O
used,307,O
to,307,O
block,307,O
I,307,B-GENE-N
(,307,I-GENE-N
Ks,307,I-GENE-N
),307,I-GENE-N
(,307,O
LQT1,307,O
model,307,O
),307,O
.,307,O
Isoproterenol,308,B-CHEMICAL
(,308,O
50,308,O
to,308,O
100,308,O
nmol/L,308,O
),308,O
was,308,O
used,308,O
to,308,O
mimic,308,O
an,308,O
increase,308,O
in,308,O
beta-adrenergic,308,O
tone,308,O
",",308,O
d-sotalol,308,B-CHEMICAL
(,308,O
100,308,O
micromol/L,308,O
),308,O
to,308,O
block,308,O
I,308,B-GENE-N
(,308,I-GENE-N
Kr,308,I-GENE-N
),308,I-GENE-N
(,308,O
LQT2,308,O
model,308,O
),308,O
",",308,O
and,308,O
ATX-II,308,B-GENE-Y
(,308,O
20,308,O
nmol/L,308,O
),308,O
to,308,O
augment,308,O
late,308,O
I,308,O
(,308,O
Na,308,B-CHEMICAL
),308,O
(,308,O
LQT3,308,O
model,308,O
),308,O
.,308,O
Isoproterenol+chromanol,309,B-CHEMICAL
293B,309,I-CHEMICAL
",",309,O
d-sotalol,309,B-CHEMICAL
",",309,O
and,309,O
ATX-II,309,B-GENE-Y
produced,309,O
preferential,309,O
prolongation,309,O
of,309,O
the,309,O
action,309,O
potential,309,O
duration,309,O
at,309,O
90,309,O
%,309,O
repolarization,309,O
(,309,O
APD,309,O
(,309,O
90,309,O
),309,O
),309,O
of,309,O
the,309,O
M,309,O
cell,309,O
",",309,O
an,309,O
increase,309,O
of,309,O
TDR,309,O
",",309,O
and,309,O
spontaneous,309,O
as,309,O
well,309,O
as,309,O
stimulation-induced,309,O
TdP,309,O
(,309,O
LQT1,309,O
",",309,O
3/6,309,O
;,309,O
LQT2,309,O
",",309,O
3/6,309,O
;,309,O
LQT3,309,O
",",309,O
5/6,309,O
),309,O
.,309,O
Nicorandil,310,B-CHEMICAL
(,310,O
2,310,O
to,310,O
20,310,O
micromol/L,310,O
),310,O
abbreviated,310,O
the,310,O
QT,310,O
interval,310,O
and,310,O
APD,310,O
(,310,O
90,310,O
),310,O
of,310,O
the,310,O
3,310,O
cell,310,O
types,310,O
in,310,O
the,310,O
3,310,O
models,310,O
.,310,O
High,311,O
concentrations,311,O
(,311,O
10,311,O
to,311,O
20,311,O
micromol/L,311,O
),311,O
completely,311,O
reversed,311,O
the,311,O
effects,311,O
of,311,O
293B+/-isoproterenol,311,O
and,311,O
those,311,O
of,311,O
d-sotalol,311,B-CHEMICAL
to,311,O
increase,311,O
APD,311,O
(,311,O
90,311,O
),311,O
and,311,O
TDR,311,O
and,311,O
to,311,O
induce,311,O
TdP,311,O
in,311,O
LQT1,311,O
and,311,O
LQT2,311,O
models,311,O
.,311,O
Nicorandil,312,B-CHEMICAL
20,312,O
micromol/L,312,O
reversed,312,O
only,312,O
50,312,O
%,312,O
of,312,O
the,312,O
effect,312,O
of,312,O
ATX-II,312,B-GENE-Y
and,312,O
failed,312,O
to,312,O
completely,312,O
suppress,312,O
TdP,312,O
in,312,O
the,312,O
LQT3,312,O
model,312,O
(,312,O
5/6,312,O
to,312,O
3/6,312,O
),312,O
.,312,O
CONCLUSIONS,313,O
:,313,O
Our,313,O
data,313,O
suggest,313,O
that,313,O
K,313,B-CHEMICAL
(,313,I-CHEMICAL
+,313,I-CHEMICAL
),313,I-CHEMICAL
channel,313,I-GENE-N
openers,313,O
may,313,O
be,313,O
capable,313,O
of,313,O
abbreviating,313,O
the,313,O
long,313,O
QT,313,O
interval,313,O
",",313,O
reducing,313,O
TDR,313,O
",",313,O
and,313,O
preventing,313,O
spontaneous,313,O
and,313,O
stimulation-induced,313,O
TdP,313,O
when,313,O
congenital,313,O
or,313,O
acquired,313,O
LQTS,313,O
is,313,O
secondary,313,O
to,313,O
reduced,313,O
I,313,B-GENE-N
(,313,I-GENE-N
Kr,313,I-GENE-N
),313,I-GENE-N
or,313,O
I,313,B-GENE-N
(,313,I-GENE-N
Ks,313,I-GENE-N
),313,I-GENE-N
but,313,O
less,313,O
so,313,O
when,313,O
it,313,O
is,313,O
due,313,O
to,313,O
augmented,313,O
late,313,O
I,313,O
(,313,O
Na,313,B-CHEMICAL
),313,O
.,313,O
Peroxisome,314,B-GENE-Y
proliferator-activated,314,I-GENE-Y
receptor,314,I-GENE-Y
alpha,314,I-GENE-Y
(,314,O
PPARalpha,314,B-GENE-Y
),314,O
activators,314,O
",",314,O
bezafibrate,314,B-CHEMICAL
and,314,O
"Wy-14,643",314,B-CHEMICAL
",",314,O
increase,314,O
uncoupling,314,B-GENE-Y
protein-3,314,I-GENE-Y
mRNA,314,O
levels,314,O
without,314,O
modifying,314,O
the,314,O
mitochondrial,314,O
membrane,314,O
potential,314,O
in,314,O
primary,314,O
culture,314,O
of,314,O
rat,314,O
preadipocytes,314,O
.,314,O
Uncoupling,315,B-GENE-N
proteins,315,I-GENE-N
(,315,O
UCPs,315,B-GENE-N
),315,O
are,315,O
inner,315,O
mitochondrial,315,O
membrane,315,O
transporters,315,O
which,315,O
act,315,O
as,315,O
pores,315,O
for,315,O
H,315,B-CHEMICAL
(,315,I-CHEMICAL
+,315,I-CHEMICAL
),315,I-CHEMICAL
ions,315,O
",",315,O
dissipating,315,O
the,315,O
electrochemical,315,O
gradient,315,O
that,315,O
develops,315,O
during,315,O
mitochondrial,315,O
respiration,315,O
at,315,O
the,315,O
expense,315,O
of,315,O
ATP,315,O
synthesis,315,O
.,315,O
We,316,O
have,316,O
studied,316,O
the,316,O
effects,316,O
of,316,O
two,316,O
fibrates,316,O
",",316,O
bezafibrate,316,B-CHEMICAL
and,316,O
"Wy-14,643",316,B-CHEMICAL
",",316,O
on,316,O
UCP-3,316,B-GENE-Y
and,316,O
UCP-2,316,B-GENE-Y
mRNA,316,O
levels,316,O
in,316,O
primary,316,O
monolayer,316,O
cultures,316,O
of,316,O
rat,316,O
adipocytes,316,O
and,316,O
undifferentiated,316,O
preadipocytes,316,O
.,316,O
Treatment,317,O
with,317,O
both,317,O
PPARalpha,317,B-GENE-Y
activators,317,O
for,317,O
24,317,O
h,317,O
up-regulated,317,O
UCP-3,317,B-GENE-Y
mRNA,317,O
levels,317,O
.,317,O
Thus,318,O
",",318,O
bezafibrate,318,B-CHEMICAL
treatment,318,O
resulted,318,O
in,318,O
an,318,O
8-fold,318,O
induction,318,O
in,318,O
UCP-3,318,B-GENE-Y
mRNA,318,O
levels,318,O
in,318,O
preadipocytes,318,O
compared,318,O
with,318,O
the,318,O
3.5-fold,318,O
induction,318,O
observed,318,O
in,318,O
adipocytes,318,O
.,318,O
Differences,319,O
in,319,O
the,319,O
induction,319,O
of,319,O
UCP-3,319,B-GENE-Y
between,319,O
these,319,O
cells,319,O
correlated,319,O
well,319,O
with,319,O
the,319,O
higher,319,O
expression,319,O
of,319,O
PPARalpha,319,B-GENE-Y
and,319,O
RXRalpha,319,B-GENE-Y
mRNA,319,O
values,319,O
in,319,O
preadipocytes,319,O
compared,319,O
to,319,O
adipocytes,319,O
.,319,O
"Wy-14,643",320,O
caused,320,O
similar,320,O
effects,320,O
on,320,O
UCP-3,320,B-GENE-Y
mRNA,320,O
expression,320,O
.,320,O
In,321,O
contrast,321,O
to,321,O
UCP-3,321,B-GENE-Y
",",321,O
UCP-2,321,B-GENE-Y
mRNA,321,O
levels,321,O
were,321,O
only,321,O
slightly,321,O
modified,321,O
by,321,O
bezafibrate,321,B-CHEMICAL
in,321,O
adipocytes,321,O
.,321,O
The,322,O
induction,322,O
in,322,O
UCP-3,322,B-GENE-Y
expression,322,O
was,322,O
not,322,O
accompanied,322,O
by,322,O
changes,322,O
in,322,O
the,322,O
mitochondrial,322,O
membrane,322,O
potential,322,O
of,322,O
rat,322,O
primary,322,O
preadipocytes,322,O
after,322,O
bezafibrate,322,B-CHEMICAL
or,322,O
"Wy-14,643",322,B-CHEMICAL
treatment,322,O
.,322,O
Since,323,O
it,323,O
has,323,O
been,323,O
proposed,323,O
that,323,O
UCP-3,323,B-GENE-Y
could,323,O
be,323,O
involved,323,O
in,323,O
the,323,O
regulation,323,O
of,323,O
the,323,O
use,323,O
of,323,O
fatty,323,O
acids,323,O
as,323,O
fuel,323,O
substrates,323,O
",",323,O
the,323,O
UCP-3,323,B-GENE-Y
induction,323,O
achieved,323,O
after,323,O
bezafibrate,323,B-CHEMICAL
and,323,O
Wy-14,323,B-CHEMICAL
",",323,I-CHEMICAL
643,323,I-CHEMICAL
treatment,323,O
may,323,O
indicate,323,O
a,323,O
higher,323,O
oxidation,323,O
of,323,O
fatty,323,B-CHEMICAL
acids,323,I-CHEMICAL
",",323,O
limiting,323,O
their,323,O
availability,323,O
to,323,O
be,323,O
stored,323,O
as,323,O
triglycerides,323,B-CHEMICAL
.,323,O
This,324,O
change,324,O
may,324,O
result,324,O
in,324,O
a,324,O
reduced,324,O
rate,324,O
of,324,O
conversion,324,O
of,324,O
preadipocytes,324,O
to,324,O
adipocytes,324,O
",",324,O
which,324,O
directly,324,O
affects,324,O
fat,324,O
depots,324,O
.,324,O
Schisandrin,325,B-CHEMICAL
B,325,I-CHEMICAL
protects,325,O
against,325,O
menadione-induced,325,B-CHEMICAL
hepatotoxicity,325,O
by,325,O
enhancing,325,O
DT-diaphorase,325,B-GENE-Y
activity,325,O
.,325,O
Pretreating,326,O
mice,326,O
with,326,O
schisandrin,326,B-CHEMICAL
B,326,I-CHEMICAL
(,326,O
Sch,326,B-CHEMICAL
B,326,I-CHEMICAL
),326,O
",",326,O
a,326,O
dibenzocyclooctadiene,326,O
derivative,326,O
isolated,326,O
from,326,O
the,326,O
fruit,326,O
of,326,O
Schisandra,326,O
chinensis,326,O
",",326,O
at,326,O
a,326,O
daily,326,O
dose,326,O
of,326,O
1,326,O
mmol/kg,326,O
for,326,O
3,326,O
days,326,O
protected,326,O
against,326,O
menadione-induced,326,B-CHEMICAL
hepatic,326,O
oxidative,326,O
damage,326,O
in,326,O
mice,326,O
",",326,O
as,326,O
evidenced,326,O
by,326,O
decreases,326,O
in,326,O
plasma,326,O
alanine,326,B-GENE-N
aminotransferase,326,I-GENE-N
activity,326,O
(,326,O
78,326,O
%,326,O
),326,O
and,326,O
hepatic,326,O
malondialdehyde,326,B-CHEMICAL
level,326,O
(,326,O
70,326,O
%,326,O
),326,O
",",326,O
when,326,O
compared,326,O
with,326,O
the,326,O
menadione,326,B-CHEMICAL
intoxicated,326,O
control,326,O
.,326,O
In,327,O
order,327,O
to,327,O
define,327,O
the,327,O
biochemical,327,O
mechanism,327,O
involved,327,O
in,327,O
the,327,O
hepatoprotection,327,O
afforded,327,O
by,327,O
Sch,327,B-CHEMICAL
B,327,I-CHEMICAL
pretreatment,327,O
",",327,O
we,327,O
examined,327,O
the,327,O
activity,327,O
of,327,O
DT-diaphorase,327,B-GENE-Y
(,327,O
DTD,327,B-GENE-Y
),327,O
in,327,O
hepatocytes,327,O
isolated,327,O
from,327,O
Sch,327,B-CHEMICAL
B,327,I-CHEMICAL
pretreated,327,O
rats,327,O
.,327,O
Hepatocytes,328,O
isolated,328,O
from,328,O
Sch,328,B-CHEMICAL
B,328,I-CHEMICAL
pretreated,328,O
(,328,O
a,328,O
daily,328,O
dose,328,O
of,328,O
1,328,O
mmol/kg,328,O
for,328,O
3,328,O
days,328,O
),328,O
rats,328,O
showed,328,O
a,328,O
significant,328,O
increase,328,O
(,328,O
25,328,O
%,328,O
),328,O
in,328,O
DTD,328,B-GENE-Y
activity,328,O
.,328,O
The,329,O
increase,329,O
in,329,O
DTD,329,B-GENE-Y
activity,329,O
was,329,O
associated,329,O
with,329,O
the,329,O
enhanced,329,O
rate,329,O
of,329,O
menadione,329,B-CHEMICAL
elimination,329,O
in,329,O
the,329,O
hepatocyte,329,O
culture,329,O
.,329,O
The,330,O
ensemble,330,O
of,330,O
results,330,O
suggests,330,O
that,330,O
the,330,O
ability,330,O
of,330,O
Sch,330,B-CHEMICAL
B,330,I-CHEMICAL
pretreatment,330,O
to,330,O
enhance,330,O
hepatocellular,330,O
DTD,330,B-GENE-Y
activity,330,O
may,330,O
at,330,O
least,330,O
in,330,O
part,330,O
be,330,O
attributed,330,O
to,330,O
the,330,O
protection,330,O
against,330,O
menadione,330,B-CHEMICAL
hepatotoxicity,330,O
.,330,O
Interactive,331,O
and,331,O
delayed,331,O
effects,331,O
of,331,O
pyridostigmine,331,B-CHEMICAL
and,331,O
physical,331,O
stress,331,O
on,331,O
biochemical,331,O
and,331,O
histological,331,O
changes,331,O
in,331,O
peripheral,331,O
tissues,331,O
of,331,O
mice,331,O
.,331,O
Gulf,332,O
War,332,O
veterans,332,O
were,332,O
taking,332,O
pyridostigmine,332,B-CHEMICAL
orally,332,O
against,332,O
possible,332,O
exposure,332,O
to,332,O
nerve,332,O
agents,332,O
as,332,O
well,332,O
as,332,O
being,332,O
under,332,O
physical,332,O
stress,332,O
.,332,O
This,333,O
study,333,O
was,333,O
designed,333,O
to,333,O
investigate,333,O
the,333,O
delayed,333,O
effects,333,O
of,333,O
pyridostigmine,333,B-CHEMICAL
and,333,O
treadmill,333,O
exercise,333,O
on,333,O
cholinesterase,333,B-GENE-Y
activity,333,O
",",333,O
lipid,333,O
peroxidation,333,O
and,333,O
histology,333,O
of,333,O
peripheral,333,O
tissues,333,O
of,333,O
mice,333,O
.,333,O
Male,334,O
NIH,334,O
Swiss,334,O
mice,334,O
were,334,O
divided,334,O
into,334,O
four,334,O
groups,334,O
of,334,O
15,334,O
animals,334,O
each,334,O
and,334,O
treated,334,O
as,334,O
follows,334,O
:,334,O
sedentary,334,O
control,334,O
;,334,O
exercise,334,O
training,334,O
for,334,O
10,334,O
weeks,334,O
;,334,O
pyridostigmine,334,B-CHEMICAL
(,334,O
1.2,334,O
mg,334,O
kg,334,O
(,334,O
-1,334,O
),334,O
",",334,O
p.o,334,O
.,334,O
),334,O
for,335,O
2,335,O
weeks,335,O
during,335,O
weeks,335,O
5,335,O
and,335,O
6,335,O
;,335,O
and,335,O
pyridostigmine,335,B-CHEMICAL
plus,335,O
exercise,335,O
training,335,O
.,335,O
The,336,O
mice,336,O
were,336,O
sacrificed,336,O
24,336,O
h,336,O
after,336,O
the,336,O
last,336,O
exercise,336,O
",",336,O
and,336,O
blood,336,O
",",336,O
triceps,336,O
muscle,336,O
and,336,O
sciatic,336,O
nerve,336,O
were,336,O
isolated,336,O
and,336,O
analyzed,336,O
.,336,O
The,337,O
group,337,O
treated,337,O
with,337,O
pyridostigmine,337,B-CHEMICAL
alone,337,O
showed,337,O
decreased,337,O
plasma,337,O
butyrylcholinesterase,337,B-GENE-Y
(,337,O
BChE,337,B-GENE-Y
),337,O
activity,337,O
(,337,O
87,337,O
%,337,O
of,337,O
control,337,O
),337,O
",",337,O
whereas,337,O
pyridostigmine,337,B-CHEMICAL
plus,337,O
exercise,337,O
significantly,337,O
decreased,337,O
the,337,O
BChE,337,B-GENE-Y
activity,337,O
(,337,O
79,337,O
%,337,O
of,337,O
control,337,O
),337,O
",",337,O
indicating,337,O
an,337,O
interactive,337,O
effect,337,O
of,337,O
the,337,O
combination,337,O
.,337,O
Acetylcholinesterase,338,B-GENE-Y
(,338,O
AChE,338,B-GENE-Y
),338,O
activity,338,O
did,338,O
not,338,O
alter,338,O
significantly,338,O
in,338,O
red,338,O
blood,338,O
cells,338,O
",",338,O
platelets,338,O
or,338,O
sciatic,338,O
nerve,338,O
with,338,O
either,338,O
of,338,O
the,338,O
treatments,338,O
.,338,O
However,339,O
",",339,O
AChE,339,B-GENE-Y
activity,339,O
in,339,O
triceps,339,O
muscle,339,O
decreased,339,O
significantly,339,O
(,339,O
78,339,O
%,339,O
of,339,O
control,339,O
),339,O
in,339,O
the,339,O
group,339,O
treated,339,O
with,339,O
pyridostigmine,339,B-CHEMICAL
plus,339,O
exercise,339,O
.,339,O
Creatine,340,B-CHEMICAL
phosphokinase,340,I-GENE-N
activity,340,O
in,340,O
plasma,340,O
increased,340,O
slightly,340,O
(,340,O
compared,340,O
to,340,O
control,340,O
",",340,O
pyridostigmine,340,B-CHEMICAL
or,340,O
exercise,340,O
group,340,O
),340,O
in,340,O
mice,340,O
treated,340,O
with,340,O
pyridostigmine,340,B-CHEMICAL
plus,340,O
exercise,340,O
",",340,O
which,340,O
may,340,O
be,340,O
indicative,340,O
of,340,O
perturbation,340,O
in,340,O
the,340,O
integrity,340,O
of,340,O
the,340,O
skeletal,340,O
muscle,340,O
due,340,O
to,340,O
combination,340,O
.,340,O
However,341,O
",",341,O
there,341,O
were,341,O
no,341,O
obvious,341,O
histological,341,O
abnormalities,341,O
in,341,O
the,341,O
triceps,341,O
muscle,341,O
detected,341,O
between,341,O
experimental,341,O
and,341,O
control,341,O
groups,341,O
.,341,O
Interaction,342,O
of,342,O
pyridostigmine,342,B-CHEMICAL
and,342,O
exercise,342,O
significantly,342,O
increased,342,O
the,342,O
concentration,342,O
of,342,O
the,342,O
end,342,O
product,342,O
of,342,O
lipid,342,O
peroxidation,342,O
(,342,O
malondialdehyde,342,B-CHEMICAL
),342,O
(,342,O
124,342,O
%,342,O
of,342,O
control,342,O
),342,O
in,342,O
triceps,342,O
muscle,342,O
",",342,O
indicating,342,O
an,342,O
oxidative,342,O
stress,342,O
response,342,O
of,342,O
the,342,O
combination,342,O
.,342,O
These,343,O
results,343,O
indicate,343,O
that,343,O
physical,343,O
stress,343,O
enhanced,343,O
the,343,O
delayed,343,O
toxic,343,O
effects,343,O
of,343,O
a,343,O
subchronic,343,O
oral,343,O
dose,343,O
of,343,O
pyridostigmine,343,B-CHEMICAL
primarily,343,O
in,343,O
the,343,O
skeletal,343,O
muscle,343,O
of,343,O
mice,343,O
.,343,O
Effect,344,O
of,344,O
hormonal,344,O
agents,344,O
on,344,O
monocyte,344,B-GENE-Y
chemotactic,344,I-GENE-Y
protein-1,344,I-GENE-Y
expression,344,O
by,344,O
endometrial,344,O
epithelial,344,O
cells,344,O
of,344,O
women,344,O
with,344,O
endometriosis,344,O
.,344,O
OBJECTIVE,345,O
:,345,O
To,345,O
assess,345,O
whether,345,O
hormonal,345,O
agents,345,O
used,345,O
in,345,O
the,345,O
medical,345,O
treatment,345,O
of,345,O
endometriosis,345,O
",",345,O
such,345,O
as,345,O
danazol,345,B-CHEMICAL
and,345,O
GnRH,345,B-GENE-Y
agonist,345,O
",",345,O
exert,345,O
direct,345,O
regulatory,345,O
action,345,O
on,345,O
monocyte,345,B-GENE-Y
chemotactic,345,I-GENE-Y
protein-1,345,I-GENE-Y
(,345,O
MCP-1,345,B-GENE-Y
),345,O
expression,345,O
by,345,O
endometrial,345,O
epithelial,345,O
cells,345,O
.,345,O
DESIGN,346,O
:,346,O
Primary,346,O
cultures,346,O
of,346,O
epithelial,346,O
cells,346,O
isolated,346,O
from,346,O
human,346,O
endometrium,346,O
were,346,O
exposed,346,O
to,346,O
different,346,O
concentrations,346,O
of,346,O
cytokines,346,B-GENE-N
and,346,O
steroid,346,B-CHEMICAL
hormone,346,O
analogs,346,O
.,346,O
Expression,347,O
of,347,O
MCP-1,347,B-GENE-Y
was,347,O
analyzed,347,O
at,347,O
the,347,O
levels,347,O
of,347,O
protein,347,O
and,347,O
messenger,347,O
RNA,347,O
.,347,O
SETTING,348,O
:,348,O
Gynecology,348,O
clinic,348,O
and,348,O
laboratory,348,O
of,348,O
endocrinology,348,O
of,348,O
reproduction,348,O
.,348,O
PATIENT,349,O
(,349,O
S,349,O
),349,O
:,349,O
Women,349,O
presenting,349,O
for,349,O
infertility,349,O
or,349,O
pelvic,349,O
pain,349,O
in,349,O
whom,349,O
endometriosis,349,O
was,349,O
diagnosed,349,O
by,349,O
using,349,O
laparoscopy,349,O
.,349,O
INTERVENTION,350,O
(,350,O
S,350,O
),350,O
:,350,O
Endometrial,350,O
tissue,350,O
biopsy,350,O
performed,350,O
at,350,O
laparoscopy,350,O
.,350,O
MAIN,351,O
OUTCOME,351,O
MEASURE,351,O
(,351,O
S,351,O
),351,O
:,351,O
Secretion,351,O
of,351,O
MCP-1,351,B-GENE-Y
protein,351,O
was,351,O
measured,351,O
by,351,O
using,351,O
enzyme-linked,351,O
immunosorbent,351,O
assay,351,O
",",351,O
and,351,O
mRNA,351,O
steady-state,351,O
levels,351,O
were,351,O
measured,351,O
by,351,O
performing,351,O
Northern,351,O
blot,351,O
analysis,351,O
.,351,O
RESULT,352,O
(,352,O
S,352,O
),352,O
:,352,O
Buserelin,352,B-CHEMICAL
acetate,352,I-CHEMICAL
",",352,O
a,352,O
GnRH,352,B-GENE-Y
agonist,352,O
(,352,O
0.1-10,352,O
ng/mL,352,O
),352,O
",",352,O
had,352,O
no,352,O
significant,352,O
effect,352,O
on,352,O
MCP-1,352,B-GENE-Y
expression,352,O
",",352,O
whereas,352,O
danazol,352,B-CHEMICAL
(,352,O
10,352,O
(,352,O
-7,352,O
),352,O
-10,352,O
(,352,O
-5,352,O
),352,O
M,352,O
),352,O
",",352,O
a,352,O
testosterone,352,B-CHEMICAL
analog,352,O
",",352,O
and,352,O
dexamethasone,352,B-CHEMICAL
",",352,O
an,352,O
anti-inflammatory,352,O
glucocorticoid,352,O
hormone,352,O
(,352,O
10,352,O
(,352,O
-12,352,O
),352,O
-10,352,O
(,352,O
-6,352,O
),352,O
M,352,O
),352,O
",",352,O
showed,352,O
a,352,O
direct,352,O
and,352,O
a,352,O
dose-dependent,352,O
inhibitory,352,O
effect,352,O
on,352,O
MCP-1,352,B-GENE-Y
expression,352,O
.,352,O
This,353,O
effect,353,O
occurred,353,O
at,353,O
the,353,O
level,353,O
of,353,O
protein,353,O
and,353,O
mRNA,353,O
.,353,O
CONCLUSION,354,O
(,354,O
S,354,O
),354,O
:,354,O
The,354,O
findings,354,O
of,354,O
the,354,O
study,354,O
may,354,O
affect,354,O
understanding,354,O
of,354,O
the,354,O
mechanisms,354,O
by,354,O
which,354,O
hormonal,354,O
treatments,354,O
act,354,O
on,354,O
endometriosis,354,O
and,354,O
influence,354,O
its,354,O
clinical,354,O
manifestations,354,O
.,354,O
Pharmacological,355,O
modulation,355,O
of,355,O
nerve,355,B-GENE-Y
growth,355,I-GENE-Y
factor,355,I-GENE-Y
synthesis,355,O
:,355,O
a,355,O
mechanistic,355,O
comparison,355,O
of,355,O
vitamin,355,B-GENE-Y
D,355,I-GENE-Y
receptor,355,I-GENE-Y
and,355,O
beta,355,B-GENE-Y
(,355,I-GENE-Y
2,355,I-GENE-Y
),355,I-GENE-Y
-adrenoceptor,355,I-GENE-Y
agonists,355,O
.,355,O
Increasing,356,O
nerve,356,B-GENE-Y
growth,356,I-GENE-Y
factor,356,I-GENE-Y
(,356,O
NGF,356,B-GENE-Y
),356,O
in,356,O
the,356,O
PNS,356,O
is,356,O
a,356,O
rational,356,O
strategy,356,O
for,356,O
treating,356,O
certain,356,O
neurodegenerative,356,O
disorders,356,O
.,356,O
The,357,O
present,357,O
studies,357,O
were,357,O
undertaken,357,O
to,357,O
compare,357,O
two,357,O
compounds,357,O
",",357,O
a,357,O
vitamin,357,B-CHEMICAL
D,357,I-CHEMICAL
(,357,I-CHEMICAL
3,357,I-CHEMICAL
),357,I-CHEMICAL
analogue,357,O
(,357,O
CB1093,357,B-CHEMICAL
),357,O
with,357,O
minimal,357,O
calcaemic,357,O
effects,357,O
",",357,O
and,357,O
clenbuterol,357,B-CHEMICAL
",",357,O
a,357,O
long-acting,357,O
beta,357,B-GENE-Y
(,357,I-GENE-Y
2,357,I-GENE-Y
),357,I-GENE-Y
-adrenoceptor,357,I-GENE-Y
agonist,357,O
",",357,O
both,357,O
of,357,O
which,357,O
induce,357,O
NGF,357,B-GENE-Y
synthesis,357,O
in,357,O
vivo,357,O
.,357,O
Clenbuterol,358,B-CHEMICAL
caused,358,O
significant,358,O
increases,358,O
in,358,O
both,358,O
NGF,358,B-GENE-Y
mRNA,358,O
and,358,O
protein,358,O
in,358,O
3T3,358,O
cells,358,O
;,358,O
with,358,O
maxima,358,O
at,358,O
10,358,O
nM,358,O
and,358,O
at,358,O
8-12,358,O
h,358,O
exposure,358,O
.,358,O
Effects,359,O
of,359,O
clenbuterol,359,B-CHEMICAL
on,359,O
NGF,359,B-GENE-Y
mRNA,359,O
were,359,O
antagonized,359,O
by,359,O
propranolol,359,B-CHEMICAL
.,359,O
Mobility,360,O
shift,360,O
assays,360,O
on,360,O
whole,360,O
cell,360,O
extracts,360,O
showed,360,O
that,360,O
clenbuterol,360,B-CHEMICAL
increased,360,O
AP1,360,B-GENE-Y
binding,360,O
in,360,O
3T3,360,O
cells,360,O
prior,360,O
to,360,O
increasing,360,O
NGF,360,B-GENE-Y
synthesis,360,O
.,360,O
Clenbuterol,361,B-CHEMICAL
was,361,O
without,361,O
effect,361,O
on,361,O
NGF,361,B-GENE-Y
mRNA,361,O
levels,361,O
in,361,O
L929,361,O
cells,361,O
",",361,O
whereas,361,O
CB1093,361,B-CHEMICAL
caused,361,O
significant,361,O
increases,361,O
in,361,O
both,361,O
NGF,361,B-GENE-Y
mRNA,361,O
and,361,O
protein,361,O
levels,361,O
in,361,O
both,361,O
3T3,361,O
and,361,O
L929,361,O
cells,361,O
.,361,O
Stimulation,362,O
was,362,O
almost,362,O
maximal,362,O
at,362,O
24,362,O
h,362,O
exposure,362,O
and,362,O
was,362,O
sustained,362,O
for,362,O
at,362,O
least,362,O
72,362,O
h.,362,O
The,362,O
magnitude,362,O
of,362,O
the,362,O
increase,362,O
was,362,O
much,362,O
greater,362,O
in,362,O
L929,362,O
(,362,O
700,362,O
%,362,O
increase,362,O
),362,O
than,362,O
in,362,O
3T3,362,O
cells,362,O
(,362,O
80,362,O
%,362,O
),362,O
.,362,O
Binding,363,O
to,363,O
the,363,O
vitamin,363,B-CHEMICAL
D,363,I-CHEMICAL
nuclear,363,I-GENE-Y
receptor,363,I-GENE-Y
(,363,O
VDR,363,B-GENE-Y
),363,O
",",363,O
which,363,O
acts,363,O
as,363,O
a,363,O
transcription,363,O
factor,363,O
itself,363,O
",",363,O
was,363,O
increased,363,O
as,363,O
early,363,O
as,363,O
30,363,O
min,363,O
after,363,O
exposure,363,O
to,363,O
of,363,O
CB1093,363,B-CHEMICAL
and,363,O
maintained,363,O
up,363,O
to,363,O
24,363,O
h.,363,O
Increased,363,O
VDR,363,B-GENE-Y
binding,363,O
preceded,363,O
increased,363,O
NGF,363,B-GENE-Y
mRNA,363,O
.,363,O
A,364,O
150,364,O
%,364,O
increase,364,O
in,364,O
AP-1,364,B-GENE-Y
binding,364,O
was,364,O
also,364,O
evident,364,O
.,364,O
This,365,O
study,365,O
demonstrates,365,O
that,365,O
CB1093,365,B-CHEMICAL
and,365,O
clenbuterol,365,B-CHEMICAL
stimulate,365,O
NGF,365,B-GENE-Y
levels,365,O
in,365,O
vitro,365,O
and,365,O
that,365,O
AP-1,365,B-GENE-Y
binding,365,O
could,365,O
be,365,O
a,365,O
commonality,365,O
between,365,O
the,365,O
mechanism,365,O
of,365,O
NGF,365,B-GENE-Y
induction,365,O
of,365,O
these,365,O
two,365,O
compounds,365,O
.,365,O
Protective,366,O
effect,366,O
of,366,O
halothane,366,B-CHEMICAL
anesthesia,366,O
on,366,O
retinal,366,O
light,366,O
damage,366,O
:,366,O
inhibition,366,O
of,366,O
metabolic,366,O
rhodopsin,366,B-GENE-N
regeneration,366,O
.,366,O
PURPOSE,367,O
:,367,O
To,367,O
determine,367,O
whether,367,O
the,367,O
volatile,367,O
anesthetic,367,O
halothane,367,B-CHEMICAL
protects,367,O
against,367,O
light-induced,367,O
photoreceptor,367,B-GENE-N
degeneration,367,O
in,367,O
the,367,O
rodent,367,O
retina,367,O
.,367,O
METHODS,368,O
:,368,O
Albino,368,O
mice,368,O
and,368,O
rats,368,O
were,368,O
anesthetized,368,O
with,368,O
halothane,368,B-CHEMICAL
and,368,O
exposed,368,O
to,368,O
high,368,O
levels,368,O
of,368,O
white,368,O
or,368,O
blue,368,O
light,368,O
.,368,O
Nonanesthetized,369,O
animals,369,O
served,369,O
as,369,O
controls,369,O
.,369,O
Retinal,370,O
morphology,370,O
was,370,O
assessed,370,O
by,370,O
light,370,O
microscopy,370,O
",",370,O
and,370,O
apoptosis,370,O
of,370,O
photoreceptor,370,B-GENE-N
cells,370,O
was,370,O
verified,370,O
by,370,O
detection,370,O
of,370,O
fragmented,370,O
genomic,370,O
DNA,370,O
and,370,O
in,370,O
situ,370,O
staining,370,O
of,370,O
apoptotic,370,O
nuclei,370,O
(,370,O
TUNEL,370,O
assay,370,O
),370,O
.,370,O
Rhodopsin,371,B-GENE-N
regeneration,371,O
after,371,O
bleaching,371,O
was,371,O
determined,371,O
by,371,O
measuring,371,O
rhodopsin,371,B-GENE-N
levels,371,O
in,371,O
retinas,371,O
of,371,O
mice,371,O
or,371,O
rats,371,O
at,371,O
different,371,O
time,371,O
points,371,O
in,371,O
darkness,371,O
.,371,O
RESULTS,372,O
:,372,O
Halothane,372,B-CHEMICAL
anesthesia,372,O
reversibly,372,O
inhibited,372,O
metabolic,372,O
rhodopsin,372,B-GENE-N
regeneration,372,O
and,372,O
thus,372,O
prevented,372,O
rhodopsin,372,B-GENE-N
from,372,O
absorbing,372,O
high,372,O
numbers,372,O
of,372,O
photons,372,O
during,372,O
light,372,O
exposure,372,O
.,372,O
Consequently,373,O
",",373,O
photoreceptors,373,B-GENE-N
of,373,O
mice,373,O
and,373,O
rats,373,O
anesthetized,373,O
with,373,O
halothane,373,B-CHEMICAL
were,373,O
completely,373,O
protected,373,O
against,373,O
degeneration,373,O
induced,373,O
by,373,O
white,373,O
light,373,O
.,373,O
In,374,O
remarkable,374,O
contrast,374,O
",",374,O
however,374,O
",",374,O
halothane,374,B-CHEMICAL
anesthesia,374,O
did,374,O
not,374,O
protect,374,O
against,374,O
blue-light-induced,374,O
photoreceptor,374,O
cell,374,O
death,374,O
.,374,O
CONCLUSIONS,375,O
:,375,O
After,375,O
the,375,O
initial,375,O
bleach,375,O
",",375,O
halothane,375,B-CHEMICAL
impeded,375,O
photon,375,O
absorption,375,O
by,375,O
rhodopsin,375,B-GENE-N
by,375,O
inhibiting,375,O
metabolic,375,O
rhodopsin,375,B-GENE-N
regeneration,375,O
.,375,O
Apparently,376,O
",",376,O
the,376,O
rhodopsin-mediated,376,B-GENE-N
uptake,376,O
of,376,O
the,376,O
critical,376,O
number,376,O
of,376,O
photons,376,O
to,376,O
initiate,376,O
white,376,O
light-induced,376,O
retinal,376,O
degeneration,376,O
was,376,O
prevented,376,O
.,376,O
In,377,O
contrast,377,O
",",377,O
halothane,377,B-CHEMICAL
did,377,O
not,377,O
protect,377,O
the,377,O
retina,377,O
against,377,O
blue,377,O
light,377,O
.,377,O
Blue,378,O
light,378,O
can,378,O
efficiently,378,O
restore,378,O
functional,378,O
rhodopsin,378,B-GENE-N
from,378,O
bleaching,378,O
intermediates,378,O
through,378,O
a,378,O
process,378,O
termed,378,O
photoreversal,378,O
of,378,O
bleaching,378,O
.,378,O
This,379,O
process,379,O
does,379,O
not,379,O
depend,379,O
on,379,O
the,379,O
visual,379,O
cycle,379,O
via,379,O
the,379,O
pigment,379,O
epithelium,379,O
but,379,O
nevertheless,379,O
enables,379,O
rhodopsin,379,B-GENE-N
molecules,379,O
to,379,O
absorb,379,O
the,379,O
critical,379,O
number,379,O
of,379,O
photons,379,O
required,379,O
to,379,O
induce,379,O
retinal,379,O
degeneration,379,O
.,379,O
Comparison,380,O
of,380,O
antidepressant,380,O
activity,380,O
in,380,O
4-,380,O
and,380,O
40-week-old,380,O
male,380,O
mice,380,O
in,380,O
the,380,O
forced,380,O
swimming,380,O
test,380,O
:,380,O
involvement,380,O
of,380,O
5-HT1A,380,B-GENE-Y
and,380,O
5-HT1B,380,B-GENE-Y
receptors,380,O
in,380,O
old,380,O
mice,380,O
.,380,O
RATIONALE,381,O
:,381,O
A,381,O
recent,381,O
study,381,O
suggested,381,O
that,381,O
selective,381,O
serotonin,381,B-CHEMICAL
reuptake,381,O
inhibitors,381,O
were,381,O
inactive,381,O
in,381,O
40-week-old,381,O
male,381,O
mice,381,O
in,381,O
the,381,O
mouse,381,O
forced,381,O
swimming,381,O
test,381,O
",",381,O
possibly,381,O
because,381,O
of,381,O
alteration,381,O
of,381,O
5-HT1,381,B-GENE-N
receptors,381,O
.,381,O
OBJECTIVES,382,O
:,382,O
The,382,O
present,382,O
study,382,O
was,382,O
aimed,382,O
at,382,O
investigating,382,O
the,382,O
action,382,O
of,382,O
various,382,O
antidepressant,382,O
drugs,382,O
in,382,O
4-,382,O
and,382,O
40-week-old,382,O
male,382,O
mice,382,O
using,382,O
the,382,O
mouse,382,O
forced,382,O
swimming,382,O
test,382,O
and,382,O
determining,382,O
the,382,O
involvement,382,O
of,382,O
5-HT1A,382,B-GENE-Y
and,382,O
5-HT1B,382,B-GENE-Y
receptors,382,O
mediating,382,O
the,382,O
effects,382,O
.,382,O
METHODS,383,O
:,383,O
Different,383,O
classes,383,O
of,383,O
antidepressants,383,O
[,383,O
imipramine,383,B-CHEMICAL
(,383,O
tricyclic,383,B-CHEMICAL
),383,O
",",383,O
maprotiline,383,B-CHEMICAL
(,383,O
noradrenline,383,B-CHEMICAL
reuptake,383,O
inhibitor,383,O
),383,O
",",383,O
venlafaxine,383,B-CHEMICAL
(,383,O
mixed,383,O
serotonin,383,B-CHEMICAL
and,383,O
noradrenaline,383,B-CHEMICAL
reuptake,383,O
inhibitors,383,O
),383,O
",",383,O
fluvoxamine,383,B-CHEMICAL
and,383,O
sertraline,383,B-CHEMICAL
(,383,O
selective,383,O
serotonin,383,B-CHEMICAL
reuptake,383,O
inhibitor,383,O
),383,O
],383,O
were,383,O
tested,383,O
in,383,O
the,383,O
same,383,O
randomised,383,O
experimental,383,O
session,383,O
",",383,O
alone,383,O
and,383,O
in,383,O
combination,383,O
with,383,O
5-HT1A,383,B-GENE-Y
and,383,O
5-HT1B,383,B-GENE-Y
receptor,383,O
agonists,383,O
[,383,O
buspirone,383,B-CHEMICAL
(,383,O
partial,383,O
5-HT1A,383,B-GENE-Y
agonist,383,O
),383,O
",",383,O
anpirtoline,383,B-CHEMICAL
(,383,O
5-HT1B,383,B-GENE-Y
agonist,383,O
),383,O
],383,O
in,383,O
the,383,O
mouse,383,O
forced,383,O
swimming,383,O
test,383,O
.,383,O
RESULTS,384,O
:,384,O
All,384,O
antidepressants,384,O
were,384,O
found,384,O
to,384,O
be,384,O
active,384,O
in,384,O
the,384,O
mouse,384,O
forced,384,O
swimming,384,O
test,384,O
in,384,O
4-week-old,384,O
mice,384,O
and,384,O
40-week-old,384,O
mice,384,O
",",384,O
with,384,O
the,384,O
exception,384,O
of,384,O
fluvoxamine,384,B-CHEMICAL
in,384,O
the,384,O
40-week-old,384,O
mice,384,O
.,384,O
The,385,O
anti-immobility,385,O
effect,385,O
after,385,O
antidepressant,385,O
administration,385,O
was,385,O
higher,385,O
in,385,O
4-week-old,385,O
male,385,O
mice,385,O
than,385,O
in,385,O
40-week-old,385,O
male,385,O
mice,385,O
.,385,O
Venlafaxine,386,B-CHEMICAL
is,386,O
the,386,O
most,386,O
active,386,O
antidepressant,386,O
drug,386,O
in,386,O
40-week-old,386,O
mice,386,O
.,386,O
Prior,387,O
administration,387,O
of,387,O
buspirone,387,B-CHEMICAL
(,387,O
0.06,387,O
mg/kg,387,O
",",387,O
i.p,387,O
.,387,O
),387,O
or,388,O
anpirtoline,388,B-CHEMICAL
(,388,O
1,388,O
mg/kg,388,O
",",388,O
i.p,388,O
.,388,O
),388,O
enhanced,389,O
the,389,O
antidepressant-like,389,O
effects,389,O
in,389,O
4-week-old,389,O
mice,389,O
(,389,O
except,389,O
in,389,O
the,389,O
case,389,O
of,389,O
sertraline,389,B-CHEMICAL
",",389,O
8,389,O
mg/kg,389,O
),389,O
.,389,O
In,390,O
elderly,390,O
mice,390,O
",",390,O
only,390,O
prior,390,O
administration,390,O
of,390,O
buspirone,390,B-CHEMICAL
enhanced,390,O
the,390,O
antidepressant-like,390,O
effects,390,O
of,390,O
fluvoxamine,390,B-CHEMICAL
.,390,O
A,391,O
neurochemical,391,O
study,391,O
showed,391,O
that,391,O
significantly,391,O
higher,391,O
serotonin,391,B-CHEMICAL
and,391,O
dopamine,391,B-CHEMICAL
concentrations,391,O
were,391,O
found,391,O
in,391,O
40-week-old,391,O
control,391,O
mice,391,O
brains,391,O
than,391,O
4-week-old,391,O
control,391,O
mice,391,O
brains,391,O
but,391,O
that,391,O
the,391,O
noradrenaline,391,B-CHEMICAL
concentration,391,O
is,391,O
higher,391,O
in,391,O
4-week-old,391,O
mice,391,O
.,391,O
CONCLUSION,392,O
:,392,O
Tricyclic,392,B-CHEMICAL
",",392,O
noradrenaline,392,B-CHEMICAL
reuptake,392,O
inhibitors,392,O
and,392,O
serotonin,392,B-CHEMICAL
reuptake,392,O
inhibitors,392,O
are,392,O
more,392,O
active,392,O
in,392,O
4-week-old,392,O
mice,392,O
than,392,O
40-week-old,392,O
mice,392,O
.,392,O
Our,393,O
results,393,O
suggested,393,O
that,393,O
5-HT1B,393,B-GENE-Y
receptors,393,O
may,393,O
be,393,O
more,393,O
altered,393,O
than,393,O
5-HT1A,393,B-GENE-Y
receptors,393,O
in,393,O
40-week-old,393,O
mice,393,O
.,393,O
Cytochrome,394,B-GENE-N
P450,394,I-GENE-N
4A,394,I-GENE-N
",",394,O
peroxisomal,394,O
enzymes,394,O
and,394,O
nicotinamide,394,B-CHEMICAL
cofactors,394,O
in,394,O
koala,394,O
liver,394,O
.,394,O
We,395,O
have,395,O
examined,395,O
hepatic,395,O
levels,395,O
of,395,O
microsomal,395,O
lauric,395,B-CHEMICAL
acid,395,I-CHEMICAL
hydroxylase,395,I-GENE-N
activity,395,O
and,395,O
cyanide-insensitive,395,O
palmitoyl,395,O
coenzyme,395,O
A,395,O
oxidative,395,O
activity,395,O
in,395,O
koala,395,O
(,395,O
Phascolarctos,395,O
cinereus,395,O
),395,O
and,395,O
tammar,395,O
wallaby,395,O
(,395,O
Macropus,395,O
eugenii,395,O
),395,O
and,395,O
compared,395,O
our,395,O
results,395,O
to,395,O
those,395,O
determined,395,O
in,395,O
rat,395,O
.,395,O
Microsomal,396,O
lauric,396,B-CHEMICAL
acid,396,I-CHEMICAL
hydroxylation,396,O
was,396,O
significantly,396,O
higher,396,O
in,396,O
koala,396,O
than,396,O
in,396,O
tammar,396,O
wallaby,396,O
or,396,O
rat,396,O
.,396,O
However,397,O
",",397,O
cyanide-insensitive,397,O
palmitoyl-CoA,397,O
oxidation,397,O
was,397,O
absent,397,O
in,397,O
the,397,O
koala,397,O
.,397,O
We,398,O
have,398,O
also,398,O
determined,398,O
the,398,O
hepatic,398,O
nicotinamide,398,B-CHEMICAL
cofactors,398,O
in,398,O
these,398,O
species,398,O
.,398,O
Hepatic,399,O
nicotinamide-adenine,399,B-CHEMICAL
dinucleotide,399,I-CHEMICAL
(,399,O
NAD,399,B-CHEMICAL
),399,O
and,399,O
the,399,O
ratio,399,O
of,399,O
NAD/nicotinamide-adenine,399,B-CHEMICAL
dinucleotide,399,I-CHEMICAL
phosphate,399,I-CHEMICAL
(,399,O
NADP,399,B-CHEMICAL
),399,O
were,399,O
higher,399,O
in,399,O
koala,399,O
than,399,O
in,399,O
tammar,399,O
wallaby,399,O
and,399,O
rat,399,O
liver,399,O
.,399,O
Reverse,400,O
transcription,400,O
of,400,O
koala,400,O
liver,400,O
mRNA,400,O
",",400,O
followed,400,O
by,400,O
polymerase,400,O
chain,400,O
reaction,400,O
using,400,O
primers,400,O
based,400,O
on,400,O
highly,400,O
conserved,400,O
areas,400,O
in,400,O
the,400,O
CYP4A,400,B-GENE-N
family,400,O
led,400,O
to,400,O
the,400,O
cloning,400,O
of,400,O
a,400,O
partial,400,O
",",400,O
near,400,O
full,400,O
length,400,O
",",400,O
cDNA,400,O
clone,400,O
with,400,O
approximately,400,O
70,400,O
%,400,O
nucleotide,400,B-CHEMICAL
and,400,O
deduced,400,O
amino,400,B-CHEMICAL
acid,400,I-CHEMICAL
sequence,400,O
identity,400,O
to,400,O
human,400,B-GENE-Y
CYP4A11,400,I-GENE-Y
.,400,O
The,401,O
CYP,401,B-GENE-N
has,401,O
been,401,O
named,401,O
CYP4A15,401,B-GENE-Y
.,401,O
Gemcitabine,402,B-CHEMICAL
and,402,O
Pemetrexed,402,B-CHEMICAL
disodium,402,I-CHEMICAL
in,402,O
treating,402,O
breast,402,O
cancer,402,O
.,402,O
Pemetrexed,403,B-CHEMICAL
disodium,403,I-CHEMICAL
(,403,O
Alimta,403,B-CHEMICAL
",",403,O
LY231514,403,B-CHEMICAL
),403,O
is,403,O
a,403,O
novel,403,O
",",403,O
multitargeted,403,O
antifolate,403,O
that,403,O
inhibits,403,O
thymidylate,403,B-CHEMICAL
synthase,403,I-GENE-Y
",",403,O
dihydrofolate,403,B-CHEMICAL
reductase,403,I-GENE-Y
",",403,O
and,403,O
glycinamide,403,B-CHEMICAL
ribonucleotide,403,I-CHEMICAL
formyl,403,I-CHEMICAL
transferase,403,I-GENE-Y
.,403,O
This,404,O
agent,404,O
is,404,O
broadly,404,O
active,404,O
in,404,O
a,404,O
wide,404,O
variety,404,O
of,404,O
solid,404,O
tumors,404,O
",",404,O
including,404,O
breast,404,O
cancer,404,O
.,404,O
Pemetrexed,405,B-CHEMICAL
disodium,405,I-CHEMICAL
has,405,O
also,405,O
shown,405,O
clinically,405,O
relevant,405,O
activity,405,O
in,405,O
combination,405,O
with,405,O
gemcitabine,405,B-CHEMICAL
(,405,O
Gemzar,405,B-CHEMICAL
),405,O
.,405,O
This,406,O
combination,406,O
is,406,O
being,406,O
evaluated,406,O
for,406,O
the,406,O
treatment,406,O
of,406,O
metastatic,406,O
breast,406,O
cancer,406,O
.,406,O
Distal,407,O
bowel,407,O
selectivity,407,O
in,407,O
the,407,O
chemoprevention,407,O
of,407,O
experimental,407,O
colon,407,O
carcinogenesis,407,O
by,407,O
the,407,O
non-steroidal,407,O
anti-inflammatory,407,O
drug,407,O
nabumetone,407,B-CHEMICAL
.,407,O
Use,408,O
of,408,O
non-steroidal,408,O
anti-inflammatory,408,O
drugs,408,O
(,408,O
NSAIDs,408,O
),408,O
for,408,O
chemoprevention,408,O
of,408,O
colon,408,O
cancer,408,O
has,408,O
been,408,O
hindered,408,O
by,408,O
their,408,O
potential,408,O
gastro-intestinal,408,O
toxicity,408,O
.,408,O
Nabumetone,409,B-CHEMICAL
",",409,O
which,409,O
is,409,O
approximately,409,O
10,409,O
to,409,O
36,409,O
times,409,O
safer,409,O
than,409,O
conventional,409,O
NSAIDs,409,O
",",409,O
was,409,O
evaluated,409,O
in,409,O
2,409,O
models,409,O
of,409,O
experimental,409,O
colon,409,O
carcinogenesis,409,O
.,409,O
In,410,O
azoxymethane,410,B-CHEMICAL
(,410,O
AOM,410,B-CHEMICAL
),410,O
-treated,410,O
Fisher,410,O
344,410,O
rats,410,O
",",410,O
nabumetone,410,B-CHEMICAL
caused,410,O
dose-dependent,410,O
inhibition,410,O
of,410,O
aberrant,410,O
crypt,410,O
foci,410,O
(,410,O
ACF,410,O
),410,O
",",410,O
with,410,O
750,410,O
and,410,O
"1,500",410,O
ppm,410,O
resulting,410,O
in,410,O
15,410,O
%,410,O
and,410,O
37,410,O
%,410,O
reductions,410,O
",",410,O
respectively,410,O
(,410,O
p,410,O
<,410,O
0.05,410,O
),410,O
.,410,O
Moreover,411,O
",",411,O
complex,411,O
ACF,411,O
were,411,O
reduced,411,O
by,411,O
48,411,O
%,411,O
in,411,O
the,411,O
latter,411,O
group,411,O
.,411,O
MIN,412,O
mice,412,O
studies,412,O
confirmed,412,O
the,412,O
chemopreventive,412,O
efficacy,412,O
of,412,O
nabumetone,412,B-CHEMICAL
",",412,O
with,412,O
900,412,O
ppm,412,O
suppressing,412,O
approximately,412,O
half,412,O
of,412,O
the,412,O
intestinal,412,O
tumors,412,O
.,412,O
Interestingly,413,O
",",413,O
inhibition,413,O
of,413,O
intermediate,413,O
biomarkers,413,O
in,413,O
both,413,O
models,413,O
was,413,O
markedly,413,O
greater,413,O
in,413,O
the,413,O
distal,413,O
than,413,O
the,413,O
proximal,413,O
bowel,413,O
.,413,O
To,414,O
mechanistically,414,O
evaluate,414,O
this,414,O
regional,414,O
selectivity,414,O
",",414,O
we,414,O
assessed,414,O
cyclo-oxygenase-2,414,B-GENE-N
(,414,O
COX-2,414,B-GENE-N
),414,O
expression,414,O
in,414,O
the,414,O
uninvolved,414,O
mucosa,414,O
and,414,O
demonstrated,414,O
a,414,O
3-,414,O
to,414,O
4-fold,414,O
excess,414,O
in,414,O
the,414,O
distal,414,O
relative,414,O
to,414,O
the,414,O
proximal,414,O
bowel,414,O
in,414,O
both,414,O
MIN,414,O
mice,414,O
and,414,O
AOM-treated,414,B-CHEMICAL
rats,414,O
.,414,O
We,415,O
then,415,O
investigated,415,O
another,415,O
putative,415,O
NSAID,415,O
target,415,O
",",415,O
peroxisome,415,B-GENE-N
proliferator-activated,415,I-GENE-N
receptor-delta,415,I-GENE-N
(,415,O
PPAR-delta,415,B-GENE-N
),415,O
and,415,O
demonstrated,415,O
up-regulation,415,O
during,415,O
AOM-induced,415,O
colonic,415,O
tumorigenesis,415,O
.,415,O
Furthermore,416,O
",",416,O
in,416,O
pre-neoplastic,416,O
mucosa,416,O
",",416,O
there,416,O
was,416,O
a,416,O
3-fold,416,O
excess,416,O
of,416,O
PPAR-delta,416,B-GENE-N
in,416,O
the,416,O
distal,416,O
colon,416,O
.,416,O
We,417,O
demonstrate,417,O
that,417,O
nabumetone,417,B-CHEMICAL
is,417,O
an,417,O
effective,417,O
protective,417,O
agent,417,O
in,417,O
both,417,O
experimental,417,O
models,417,O
of,417,O
colon,417,O
carcinogenesis,417,O
.,417,O
The,418,O
striking,418,O
distal,418,O
predilection,418,O
of,418,O
nabumetone,418,B-CHEMICAL
may,418,O
be,418,O
",",418,O
at,418,O
least,418,O
partially,418,O
",",418,O
explained,418,O
by,418,O
distal,418,O
bowel,418,O
over-expression,418,O
of,418,O
COX-2,418,B-GENE-N
and,418,O
PPAR-delta,418,B-GENE-N
.,418,O
Nuclear,419,O
diacylglycerol,419,B-CHEMICAL
kinase-theta,419,I-GENE-Y
is,419,O
activated,419,O
in,419,O
response,419,O
to,419,O
alpha-thrombin,419,B-GENE-Y
.,419,O
Currently,420,O
",",420,O
there,420,O
is,420,O
substantial,420,O
evidence,420,O
that,420,O
nuclear,420,O
lipid,420,O
metabolism,420,O
plays,420,O
a,420,O
critical,420,O
role,420,O
in,420,O
a,420,O
number,420,O
of,420,O
signal,420,O
transduction,420,O
cascades,420,O
.,420,O
Previous,421,O
work,421,O
from,421,O
our,421,O
laboratory,421,O
showed,421,O
that,421,O
stimulation,421,O
of,421,O
quiescent,421,O
fibroblasts,421,O
with,421,O
alpha-thrombin,421,B-GENE-Y
leads,421,O
to,421,O
the,421,O
production,421,O
of,421,O
two,421,O
lipid,421,O
second,421,O
messengers,421,O
in,421,O
the,421,O
nucleus,421,O
:,421,O
an,421,O
increase,421,O
in,421,O
nuclear,421,O
diacylglycerol,421,B-CHEMICAL
mass,421,O
and,421,O
an,421,O
activation,421,O
of,421,O
phospholipase,421,O
D,421,O
",",421,O
which,421,O
catalyzes,421,O
the,421,O
hydrolysis,421,O
of,421,O
phosphatidylcholine,421,B-CHEMICAL
to,421,O
generate,421,O
phosphatidic,421,B-CHEMICAL
acid,421,I-CHEMICAL
.,421,O
Diacylglycerol,422,B-CHEMICAL
kinase,422,I-GENE-N
(,422,O
DGK,422,B-GENE-N
),422,O
catalyzes,422,O
the,422,O
conversion,422,O
of,422,O
diacylglycerol,422,B-CHEMICAL
to,422,O
phosphatidic,422,B-CHEMICAL
acid,422,I-CHEMICAL
",",422,O
making,422,O
it,422,O
an,422,O
attractive,422,O
candidate,422,O
for,422,O
a,422,O
signal,422,O
transduction,422,O
component,422,O
.,422,O
There,423,O
is,423,O
substantial,423,O
evidence,423,O
that,423,O
this,423,O
activity,423,O
is,423,O
indeed,423,O
regulated,423,O
in,423,O
a,423,O
number,423,O
of,423,O
signaling,423,O
cascades,423,O
(,423,O
reviewed,423,O
by,423,O
van,423,O
Blitterswijk,423,O
",",423,O
W.,423,O
J.,423,O
",",423,O
and,423,O
Houssa,423,O
",",423,O
B,423,O
.,423,O
(,424,O
1999,424,O
),424,O
Chem,424,O
.,424,O
Phys,425,O
.,425,O
Lipids,426,O
98,426,O
",",426,O
95-108,426,O
),426,O
.,426,O
In,427,O
this,427,O
report,427,O
",",427,O
we,427,O
show,427,O
that,427,O
the,427,O
addition,427,O
of,427,O
alpha-thrombin,427,B-GENE-Y
to,427,O
quiescent,427,O
IIC9,427,O
fibroblasts,427,O
results,427,O
in,427,O
an,427,O
increase,427,O
in,427,O
nuclear,427,O
DGK,427,B-GENE-N
activity,427,O
.,427,O
The,428,O
examination,428,O
of,428,O
nuclei,428,O
isolated,428,O
from,428,O
quiescent,428,O
IIC9,428,O
cells,428,O
indicates,428,O
that,428,O
DGK-theta,428,B-GENE-Y
and,428,O
DGK-delta,428,B-GENE-Y
are,428,O
both,428,O
present,428,O
.,428,O
We,429,O
took,429,O
advantage,429,O
of,429,O
the,429,O
previous,429,O
observations,429,O
that,429,O
phosphatidylserine,429,B-CHEMICAL
inhibits,429,O
DGK-delta,429,B-GENE-Y
(,429,O
reviewed,429,O
by,429,O
Sakane,429,O
",",429,O
F.,429,O
",",429,O
Imai,429,O
",",429,O
S.,429,O
",",429,O
Kai,429,O
",",429,O
M.,429,O
",",429,O
Wada,429,O
",",429,O
I.,429,O
",",429,O
and,429,O
Kanoh,429,O
",",429,O
H.,429,O
(,429,O
1996,429,O
),429,O
J.,429,O
Biol,429,O
.,429,O
Chem,430,O
.,430,O
271,431,O
",",431,O
8394-8401,431,O
),431,O
",",431,O
and,431,O
constitutively,431,O
active,431,O
RhoA,431,B-GENE-Y
inhibits,431,O
DGK-theta,431,B-GENE-Y
(,431,O
reviewed,431,O
by,431,O
Houssa,431,O
",",431,O
B.,431,O
",",431,O
de,431,O
Widt,431,O
",",431,O
J.,431,O
",",431,O
Kranenburg,431,O
",",431,O
O.,431,O
",",431,O
Moolenaar,431,O
",",431,O
W.,431,O
H.,431,O
",",431,O
and,431,O
van,431,O
Blitterswijk,431,O
",",431,O
W.,431,O
J,431,O
.,431,O
(,432,O
1999,432,O
),432,O
J.,432,O
Biol,432,O
.,432,O
Chem,433,O
.,433,O
274,434,O
",",434,O
6820-6822,434,O
),434,O
to,434,O
identify,434,O
the,434,O
activity,434,O
induced,434,O
by,434,O
alpha-thrombin,434,B-GENE-Y
.,434,O
Constitutively,435,O
active,435,O
RhoA,435,B-GENE-Y
inhibited,435,O
the,435,O
nuclear,435,O
stimulated,435,O
activity,435,O
",",435,O
whereas,435,O
phosphatidylserine,435,B-CHEMICAL
did,435,O
not,435,O
have,435,O
an,435,O
inhibitory,435,O
effect,435,O
.,435,O
In,436,O
addition,436,O
",",436,O
a,436,O
monoclonal,436,O
anti-DGK-theta,436,O
antibody,436,O
inhibited,436,O
the,436,O
alpha-thrombin-stimulated,436,B-GENE-Y
nuclear,436,O
activity,436,O
in,436,O
vitro,436,O
.,436,O
These,437,O
results,437,O
demonstrate,437,O
that,437,O
DGK-theta,437,B-GENE-Y
is,437,O
the,437,O
isoform,437,O
responsive,437,O
to,437,O
alpha-thrombin,437,B-GENE-Y
stimulation,437,O
.,437,O
Western,438,O
blot,438,O
and,438,O
immunofluorescence,438,O
microscopy,438,O
analyses,438,O
showed,438,O
that,438,O
alpha-thrombin,438,B-GENE-Y
induced,438,O
the,438,O
translocation,438,O
of,438,O
DGK-theta,438,B-GENE-Y
to,438,O
the,438,O
nucleus,438,O
",",438,O
implicating,438,O
that,438,O
this,438,O
translocation,438,O
is,438,O
at,438,O
least,438,O
partly,438,O
responsible,438,O
for,438,O
the,438,O
increased,438,O
nuclear,438,O
activity,438,O
.,438,O
Taken,439,O
together,439,O
",",439,O
these,439,O
data,439,O
are,439,O
the,439,O
first,439,O
to,439,O
demonstrate,439,O
an,439,O
agonist-induced,439,O
activity,439,O
of,439,O
nuclear,439,O
DGK-theta,439,B-GENE-Y
activity,439,O
and,439,O
a,439,O
nuclear,439,O
localization,439,O
of,439,O
DGK-delta,439,B-GENE-Y
.,439,O
Pharmacokinetic,440,O
analysis,440,O
by,440,O
high-performance,440,O
liquid,440,O
chromatography,440,O
of,440,O
intravenous,440,O
nordihydroguaiaretic,440,B-CHEMICAL
acid,440,I-CHEMICAL
in,440,O
the,440,O
mouse,440,O
.,440,O
Nordihydroguaiaretic,441,B-CHEMICAL
acid,441,I-CHEMICAL
(,441,O
NDGA,441,B-CHEMICAL
),441,O
has,441,O
been,441,O
shown,441,O
to,441,O
inhibit,441,O
both,441,O
5-lipoxygenase,441,B-GENE-Y
and,441,O
ornithine,441,B-CHEMICAL
decarboxylase,441,I-GENE-Y
and,441,O
is,441,O
active,441,O
against,441,O
several,441,O
cancer,441,O
cell,441,O
lines,441,O
and,441,O
at,441,O
least,441,O
one,441,O
mouse,441,O
tumor,441,O
model,441,O
.,441,O
Despite,442,O
these,442,O
findings,442,O
",",442,O
there,442,O
have,442,O
been,442,O
no,442,O
reports,442,O
on,442,O
the,442,O
pharmacokinetics,442,O
of,442,O
NDGA,442,B-CHEMICAL
.,442,O
A,443,O
reverse-phase,443,O
high-performance,443,O
liquid,443,O
chromatography,443,O
(,443,O
HPLC,443,O
),443,O
method,443,O
was,443,O
developed,443,O
to,443,O
detect,443,O
NDGA,443,B-CHEMICAL
in,443,O
mouse,443,O
plasma,443,O
.,443,O
The,444,O
limit,444,O
of,444,O
detection,444,O
of,444,O
this,444,O
method,444,O
was,444,O
0.5,444,O
microg/ml,444,O
.,444,O
Administration,445,O
of,445,O
NDGA,445,B-CHEMICAL
(,445,O
50,445,O
mg/kg,445,O
",",445,O
i.v,445,O
.,445,O
),445,O
to,446,O
mice,446,O
resulted,446,O
in,446,O
a,446,O
peak,446,O
plasma,446,O
concentration,446,O
of,446,O
14.7,446,O
microg/ml,446,O
.,446,O
The,447,O
terminal,447,O
half-life,447,O
of,447,O
NDGA,447,B-CHEMICAL
was,447,O
135.0,447,O
min,447,O
with,447,O
a,447,O
clearance,447,O
of,447,O
201.9,447,O
ml/min,447,O
x,447,O
kg,447,O
.,447,O
Vasoconstrictive,448,O
drugs,448,O
increase,448,O
carbonic,448,B-GENE-Y
anhydrase,448,I-GENE-Y
I,448,I-GENE-Y
in,448,O
vascular,448,O
smooth,448,O
muscle,448,O
while,448,O
vasodilating,448,O
drugs,448,O
reduce,448,O
the,448,O
activity,448,O
of,448,O
this,448,O
isozyme,448,O
by,448,O
a,448,O
direct,448,O
mechanism,448,O
of,448,O
action,448,O
.,448,O
Carbonic,449,B-GENE-N
anhydrase,449,I-GENE-N
(,449,O
CA,449,B-GENE-N
),449,O
is,449,O
a,449,O
zinc,449,B-CHEMICAL
enzyme,449,O
that,449,O
catalyses,449,O
the,449,O
reversible,449,O
hydration,449,O
reaction,449,O
of,449,O
CO2,449,B-CHEMICAL
and,449,O
plays,449,O
a,449,O
major,449,O
role,449,O
in,449,O
the,449,O
acid-base,449,O
balance,449,O
.,449,O
We,450,O
have,450,O
previously,450,O
shown,450,O
that,450,O
certain,450,O
vasoconstrictive,450,O
therapeutic,450,O
agents,450,O
increase,450,O
CA,450,B-GENE-Y
I,450,I-GENE-Y
activity,450,O
whereas,450,O
vasodilating,450,O
drugs,450,O
reduce,450,O
the,450,O
activity,450,O
of,450,O
this,450,O
isozyme,450,O
by,450,O
a,450,O
direct,450,O
mechanism,450,O
of,450,O
action,450,O
.,450,O
In,451,O
this,451,O
paper,451,O
we,451,O
studied,451,O
the,451,O
effect,451,O
of,451,O
other,451,O
vasoconstrictive,451,O
and,451,O
vasodilating,451,O
agents,451,O
on,451,O
CA,451,B-GENE-Y
I,451,I-GENE-Y
activity,451,O
in,451,O
order,451,O
to,451,O
elucidate,451,O
the,451,O
involvement,451,O
of,451,O
vascular,451,O
smooth,451,O
muscle,451,O
CA,451,B-GENE-Y
I,451,I-GENE-Y
in,451,O
vasoconstrictive,451,O
and,451,O
vasodilating,451,O
processes,451,O
.,451,O
We,452,O
studied,452,O
the,452,O
in,452,O
vitro,452,O
effects,452,O
of,452,O
noradrenaline,452,B-CHEMICAL
",",452,O
prostaglandin,452,B-CHEMICAL
F2,452,I-CHEMICAL
alpha,452,I-CHEMICAL
",",452,O
thromboxane,452,B-CHEMICAL
A2,452,I-CHEMICAL
",",452,O
leukotriene,452,B-CHEMICAL
B4,452,I-CHEMICAL
",",452,O
angiotensin,452,B-GENE-Y
II,452,I-GENE-Y
",",452,O
vasopressin,452,B-GENE-Y
",",452,O
indomethacin,452,B-CHEMICAL
",",452,O
prazosin,452,B-CHEMICAL
",",452,O
hydralazine,452,B-CHEMICAL
",",452,O
clonidine,452,B-CHEMICAL
",",452,O
reserpine,452,B-CHEMICAL
",",452,O
prostaglandin,452,B-CHEMICAL
I2,452,I-CHEMICAL
",",452,O
indapamide,452,B-CHEMICAL
",",452,O
furosemide,452,B-CHEMICAL
",",452,O
amlodipine,452,B-CHEMICAL
",",452,O
verapamil,452,B-CHEMICAL
and,452,O
irbesartan,452,B-CHEMICAL
on,452,O
purified,452,O
human,452,B-GENE-Y
red,452,I-GENE-Y
blood,452,I-GENE-Y
cell,452,I-GENE-Y
CA,452,I-GENE-Y
I,452,I-GENE-Y
and,452,O
vascular,452,O
smooth,452,O
muscle,452,O
CA,452,B-GENE-Y
I,452,I-GENE-Y
isolated,452,O
from,452,O
rabbits,452,O
.,452,O
In,453,O
vivo,453,O
",",453,O
we,453,O
selected,453,O
six,453,O
groups,453,O
of,453,O
five,453,O
rabbits,453,O
each,453,O
",",453,O
which,453,O
were,453,O
administered,453,O
the,453,O
following,453,O
substances,453,O
in,453,O
acute,453,O
experiments,453,O
:,453,O
orciprenaline,453,B-CHEMICAL
(,453,O
group,453,O
1,453,O
),453,O
",",453,O
desmopressin,453,B-CHEMICAL
(,453,O
group,453,O
2,453,O
),453,O
",",453,O
verapamil,453,B-CHEMICAL
(,453,O
group,453,O
3,453,O
),453,O
",",453,O
irbesartan,453,B-CHEMICAL
(,453,O
group,453,O
4,453,O
),453,O
",",453,O
acetazolamide,453,B-CHEMICAL
(,453,O
group,453,O
5,453,O
),453,O
and,453,O
placebo,453,O
(,453,O
control,453,O
group,453,O
),453,O
.,453,O
Vascular,454,O
smooth,454,O
muscle,454,O
CA,454,B-GENE-Y
I,454,I-GENE-Y
activity,454,O
and,454,O
systolic,454,O
blood,454,O
pressure,454,O
were,454,O
determined,454,O
and,454,O
compared,454,O
with,454,O
those,454,O
of,454,O
the,454,O
control,454,O
group,454,O
.,454,O
In,455,O
vitro,455,O
results,455,O
showed,455,O
that,455,O
all,455,O
the,455,O
vasoconstrictive,455,O
agents,455,O
studied,455,O
increased,455,O
purified,455,O
and,455,O
human,455,B-GENE-Y
erythrocyte,455,I-GENE-Y
CA,455,I-GENE-Y
I,455,I-GENE-Y
activity,455,O
as,455,O
well,455,O
as,455,O
vascular,455,O
smooth,455,O
muscle,455,O
CA,455,B-GENE-Y
I,455,I-GENE-Y
",",455,O
while,455,O
vasodilating,455,O
substances,455,O
reduced,455,O
the,455,O
activity,455,O
of,455,O
isozyme,455,O
by,455,O
a,455,O
direct,455,O
mechanism,455,O
of,455,O
action,455,O
.,455,O
The,456,O
same,456,O
results,456,O
obtained,456,O
in,456,O
vivo,456,O
showed,456,O
that,456,O
activation,456,O
of,456,O
vascular,456,O
smooth,456,O
muscle,456,O
CA,456,B-GENE-Y
I,456,I-GENE-Y
increased,456,O
blood,456,O
pressure,456,O
while,456,O
its,456,O
inhibition,456,O
reduced,456,O
blood,456,O
pressure,456,O
.,456,O
The,457,O
results,457,O
of,457,O
this,457,O
study,457,O
suggest,457,O
that,457,O
pHi,457,O
changes,457,O
",",457,O
induced,457,O
by,457,O
activating,457,O
or,457,O
inhibiting,457,O
CA,457,B-GENE-Y
I,457,I-GENE-Y
in,457,O
vascular,457,O
smooth,457,O
muscle,457,O
",",457,O
might,457,O
be,457,O
responsible,457,O
for,457,O
changes,457,O
in,457,O
vascular,457,O
tonus,457,O
.,457,O
Neuroparalysis,458,O
and,458,O
oxime,458,B-CHEMICAL
efficacy,458,O
in,458,O
organophosphate,458,B-CHEMICAL
poisoning,458,O
:,458,O
a,458,O
study,458,O
of,458,O
butyrylcholinesterase,458,B-GENE-Y
.,458,O
The,459,O
temporal,459,O
profile,459,O
of,459,O
butyrylcholinesterase,459,B-GENE-Y
(,459,O
BuChE,459,B-GENE-Y
),459,O
and,459,O
in,459,O
vitro,459,O
pralidoxime-reactivated,459,B-CHEMICAL
BuChE,459,B-GENE-Y
was,459,O
studied,459,O
in,459,O
a,459,O
cohort,459,O
of,459,O
25,459,O
organophosphate-poisoned,459,B-CHEMICAL
patients,459,O
to,459,O
examine,459,O
their,459,O
relationship,459,O
to,459,O
the,459,O
development,459,O
of,459,O
intermediate,459,O
syndrome,459,O
and,459,O
to,459,O
understand,459,O
reasons,459,O
for,459,O
lack,459,O
of,459,O
efficacy,459,O
of,459,O
oxime,459,B-CHEMICAL
treatment,459,O
.,459,O
The,460,O
clinical,460,O
severity,460,O
of,460,O
poisoning,460,O
(,460,O
assessed,460,O
by,460,O
the,460,O
Namba,460,O
Scale,460,O
),460,O
correlated,460,O
significantly,460,O
with,460,O
the,460,O
severity,460,O
of,460,O
intermediate,460,O
syndrome,460,O
.,460,O
BuChE,461,B-GENE-Y
activity,461,O
increased,461,O
significantly,461,O
over,461,O
time,461,O
and,461,O
showed,461,O
significant,461,O
relationship,461,O
to,461,O
muscle,461,O
power,461,O
.,461,O
The,462,O
temporal,462,O
profile,462,O
of,462,O
the,462,O
enzyme,462,O
was,462,O
correlated,462,O
to,462,O
the,462,O
clinical,462,O
severity,462,O
of,462,O
poisoning,462,O
.,462,O
Reactivation,463,O
potentials,463,O
of,463,O
BuChE,463,B-GENE-Y
(,463,O
the,463,O
difference,463,O
between,463,O
oxime-reactivated,463,B-CHEMICAL
and,463,O
-unreactivated,463,O
enzyme,463,O
activity,463,O
),463,O
declined,463,O
significantly,463,O
with,463,O
time,463,O
after,463,O
organophosphate,463,B-CHEMICAL
ingestion,463,O
.,463,O
The,464,O
reactivation,464,O
potential,464,O
of,464,O
the,464,O
enzyme,464,O
at,464,O
admission,464,O
decreased,464,O
significantly,464,O
with,464,O
increasing,464,O
severity,464,O
of,464,O
poisoning,464,O
and,464,O
was,464,O
lower,464,O
in,464,O
patients,464,O
who,464,O
developed,464,O
intermediate,464,O
syndrome,464,O
.,464,O
Patients,465,O
who,465,O
received,465,O
oxime,465,B-CHEMICAL
prior,465,O
to,465,O
hospitalization,465,O
had,465,O
a,465,O
higher,465,O
rate,465,O
of,465,O
intermediate,465,O
syndrome,465,O
and,465,O
lower,465,O
levels,465,O
of,465,O
BuChE,465,B-GENE-Y
at,465,O
admission,465,O
than,465,O
those,465,O
who,465,O
had,465,O
not,465,O
.,465,O
The,466,O
study,466,O
suggests,466,O
that,466,O
(,466,O
i,466,O
),466,O
BuChE,466,B-GENE-Y
reflects,466,O
the,466,O
clinical,466,O
course,466,O
of,466,O
poisoning,466,O
",",466,O
confirming,466,O
earlier,466,O
studies,466,O
;,466,O
(,466,O
ii,466,O
),466,O
intermediate,466,O
syndrome,466,O
may,466,O
be,466,O
associated,466,O
with,466,O
a,466,O
persistent,466,O
inhibition,466,O
of,466,O
BuChE,466,B-GENE-Y
;,466,O
and,466,O
(,466,O
iii,466,O
),466,O
the,466,O
lack,466,O
of,466,O
oxime,466,B-CHEMICAL
efficacy,466,O
in,466,O
our,466,O
patients,466,O
maybe,466,O
due,466,O
to,466,O
their,466,O
severity,466,O
of,466,O
poisoning,466,O
and,466,O
the,466,O
timing,466,O
of,466,O
oxime,466,B-CHEMICAL
treatment,466,O
.,466,O
Potent,467,O
alpha,467,B-GENE-Y
(,467,I-GENE-Y
2A,467,I-GENE-Y
),467,I-GENE-Y
-adrenoceptor-mediated,467,O
vasoconstriction,467,O
by,467,O
brimonidine,467,B-CHEMICAL
in,467,O
porcine,467,O
ciliary,467,O
arteries,467,O
.,467,O
PURPOSE,468,O
:,468,O
An,468,O
investigation,468,O
into,468,O
whether,468,O
alpha,468,B-GENE-N
(,468,I-GENE-N
2,468,I-GENE-N
),468,I-GENE-N
-adrenoceptor,468,I-GENE-N
agonists,468,O
induce,468,O
contractions,468,O
in,468,O
the,468,O
porcine,468,O
ciliary,468,O
arteries,468,O
and,468,O
to,468,O
characterize,468,O
the,468,O
functional,468,O
receptor,468,O
subtype,468,O
mediating,468,O
these,468,O
responses,468,O
.,468,O
METHODS,469,O
:,469,O
Isolated,469,O
arteries,469,O
from,469,O
the,469,O
intraocular,469,O
part,469,O
of,469,O
the,469,O
porcine,469,O
ciliary,469,O
artery,469,O
were,469,O
suspended,469,O
in,469,O
microvascular,469,O
myographs,469,O
for,469,O
isometric,469,O
tension,469,O
recording,469,O
.,469,O
The,470,O
segments,470,O
were,470,O
contracted,470,O
with,470,O
the,470,O
alpha,470,B-GENE-N
(,470,I-GENE-N
2,470,I-GENE-N
),470,I-GENE-N
-adrenoceptor,470,I-GENE-N
agonists,470,O
brimonidine,470,B-CHEMICAL
",",470,O
apraclonidine,470,B-CHEMICAL
",",470,O
and,470,O
oxymetazoline,470,B-CHEMICAL
.,470,O
To,471,O
determine,471,O
which,471,O
subtypes,471,O
of,471,O
the,471,O
alpha,471,B-GENE-N
(,471,I-GENE-N
2,471,I-GENE-N
),471,I-GENE-N
-adrenoceptor,471,I-GENE-N
mediate,471,O
this,471,O
contraction,471,O
",",471,O
antagonists,471,O
subselective,471,O
for,471,O
the,471,O
different,471,O
alpha,471,B-GENE-N
(,471,I-GENE-N
2,471,I-GENE-N
),471,I-GENE-N
-adrenoceptors,471,I-GENE-N
were,471,O
added,471,O
to,471,O
the,471,O
vessel,471,O
bath,471,O
before,471,O
concentration-response,471,O
curves,471,O
for,471,O
brimonidine,471,B-CHEMICAL
were,471,O
obtained,471,O
.,471,O
The,472,O
following,472,O
alpha,472,B-GENE-N
(,472,I-GENE-N
2,472,I-GENE-N
),472,I-GENE-N
-adrenoceptor,472,I-GENE-N
antagonists,472,O
were,472,O
applied,472,O
:,472,O
BRL44408,472,B-CHEMICAL
(,472,O
alpha,472,B-GENE-Y
(,472,I-GENE-Y
2A,472,I-GENE-Y
),472,I-GENE-Y
-selective,472,O
),472,O
",",472,O
ARC239,472,B-CHEMICAL
(,472,O
alpha,472,B-GENE-Y
(,472,I-GENE-Y
2B,472,I-GENE-Y
),472,I-GENE-Y
-,472,O
and,472,O
alpha,472,B-GENE-Y
(,472,I-GENE-Y
2C,472,I-GENE-Y
),472,I-GENE-Y
-selective,472,O
),472,O
",",472,O
and,472,O
prazosin,472,B-CHEMICAL
(,472,O
alpha,472,B-GENE-Y
(,472,I-GENE-Y
2B,472,I-GENE-Y
),472,I-GENE-Y
-,472,O
and,472,O
alpha,472,B-GENE-Y
(,472,I-GENE-Y
2C,472,I-GENE-Y
),472,I-GENE-Y
-selective,472,O
),472,O
.,472,O
RESULTS,473,O
:,473,O
The,473,O
alpha,473,B-GENE-N
(,473,I-GENE-N
2,473,I-GENE-N
),473,I-GENE-N
-adrenoceptor,473,I-GENE-N
agonists,473,O
induced,473,O
vasoconstriction,473,O
in,473,O
the,473,O
porcine,473,O
ciliary,473,O
artery,473,O
with,473,O
the,473,O
following,473,O
potency,473,O
order,473,O
(,473,O
EC,473,O
(,473,O
50,473,O
),473,O
),473,O
expressed,473,O
in,473,O
nanomolar,473,O
:,473,O
brimonidine,473,B-CHEMICAL
2.11,473,O
",",473,O
oxymetazoline,473,B-CHEMICAL
5.26,473,O
",",473,O
and,473,O
apraclonidine,473,B-CHEMICAL
13.0,473,O
.,473,O
As,474,O
a,474,O
reference,474,O
",",474,O
noradrenaline,474,B-CHEMICAL
was,474,O
tested,474,O
",",474,O
and,474,O
its,474,O
EC,474,O
(,474,O
50,474,O
),474,O
was,474,O
determined,474,O
to,474,O
be,474,O
247,474,O
nM,474,O
in,474,O
the,474,O
ciliary,474,O
artery,474,O
.,474,O
In,475,O
the,475,O
porcine,475,O
ciliary,475,O
arteries,475,O
BRL44408,475,B-CHEMICAL
",",475,O
ARC239,475,B-CHEMICAL
",",475,O
and,475,O
prazosin,475,B-CHEMICAL
caused,475,O
concentration-dependent,475,O
and,475,O
parallel,475,O
rightward,475,O
shifts,475,O
of,475,O
the,475,O
concentration-response,475,O
curves,475,O
for,475,O
brimonidine,475,B-CHEMICAL
.,475,O
Schild,476,O
analyses,476,O
for,476,O
the,476,O
antagonists,476,O
against,476,O
brimonidine,476,B-CHEMICAL
yielded,476,O
regression,476,O
lines,476,O
with,476,O
slopes,476,O
of,476,O
unity,476,O
and,476,O
functional,476,O
antagonist,476,O
potencies,476,O
(,476,O
pK,476,O
(,476,O
B,476,O
),476,O
),476,O
for,476,O
BRL44408,476,B-CHEMICAL
(,476,O
7.8,476,O
),476,O
",",476,O
ARC,476,B-CHEMICAL
239,476,I-CHEMICAL
(,476,O
5.8,476,O
),476,O
and,476,O
for,476,O
prazosin,476,B-CHEMICAL
(,476,O
6.0,476,O
),476,O
suggesting,476,O
the,476,O
presence,476,O
of,476,O
functional,476,O
alpha,476,B-GENE-Y
(,476,I-GENE-Y
2A,476,I-GENE-Y
),476,I-GENE-Y
-adrenoceptors,476,I-GENE-Y
.,476,O
Moreover,477,O
",",477,O
there,477,O
was,477,O
a,477,O
good,477,O
correlation,477,O
of,477,O
pK,477,O
(,477,O
B,477,O
),477,O
with,477,O
ligand-binding,477,O
affinity,477,O
(,477,O
pK,477,O
(,477,O
i,477,O
),477,O
),477,O
of,477,O
the,477,O
alpha,477,B-GENE-Y
(,477,I-GENE-Y
2A,477,I-GENE-Y
),477,I-GENE-Y
-adrenoceptor,477,I-GENE-Y
in,477,O
the,477,O
porcine,477,O
eye,477,O
tissue,477,O
.,477,O
CONCLUSIONS,478,O
:,478,O
The,478,O
alpha,478,B-GENE-N
(,478,I-GENE-N
2,478,I-GENE-N
),478,I-GENE-N
-adrenoceptor,478,I-GENE-N
agonists,478,O
brimonidine,478,B-CHEMICAL
",",478,O
apraclonidine,478,B-CHEMICAL
",",478,O
and,478,O
oxymetazoline,478,B-CHEMICAL
are,478,O
potent,478,O
vasoconstrictors,478,O
in,478,O
the,478,O
porcine,478,O
ciliary,478,O
artery,478,O
.,478,O
In,479,O
the,479,O
present,479,O
work,479,O
",",479,O
it,479,O
was,479,O
shown,479,O
for,479,O
the,479,O
first,479,O
time,479,O
that,479,O
the,479,O
alpha,479,B-GENE-Y
(,479,I-GENE-Y
2A,479,I-GENE-Y
),479,I-GENE-Y
-adrenoceptor,479,I-GENE-Y
subtype,479,O
mediates,479,O
this,479,O
contraction,479,O
.,479,O
Gemcitabine,480,B-CHEMICAL
and,480,O
pemetrexed,480,B-CHEMICAL
disodium,480,I-CHEMICAL
combinations,480,O
in,480,O
vitro,480,O
and,480,O
in,480,O
vivo,480,O
.,480,O
Pemetrexed,481,B-CHEMICAL
disodium,481,I-CHEMICAL
(,481,O
ALIMTA,481,B-CHEMICAL
),481,O
is,481,O
a,481,O
novel,481,O
antimetabolite,481,O
that,481,O
inhibits,481,O
at,481,O
least,481,O
three,481,O
folate-dependent,481,B-CHEMICAL
enzymes,481,O
",",481,O
thymidylate,481,B-CHEMICAL
synthase,481,I-GENE-Y
",",481,O
dihydrofolate,481,B-CHEMICAL
reductase,481,I-GENE-Y
",",481,O
and,481,O
glycinamide,481,B-CHEMICAL
ribonucleotide,481,I-CHEMICAL
formyltransferase,481,I-GENE-Y
.,481,O
Pemetrexed,482,B-CHEMICAL
disodium,482,I-CHEMICAL
is,482,O
broadly,482,O
active,482,O
in,482,O
a,482,O
wide,482,O
variety,482,O
of,482,O
solid,482,O
tumours,482,O
",",482,O
including,482,O
non-small,482,O
cell,482,O
lung,482,O
",",482,O
breast,482,O
",",482,O
bladder,482,O
",",482,O
head,482,O
and,482,O
neck,482,O
and,482,O
ovarian,482,O
cancers,482,O
.,482,O
Gemcitabine,483,B-CHEMICAL
is,483,O
a,483,O
broadly,483,O
active,483,O
pyrimidine,483,B-CHEMICAL
nucleoside,483,I-CHEMICAL
antimetabolite,483,O
",",483,O
which,483,O
is,483,O
approved,483,O
for,483,O
the,483,O
treatment,483,O
of,483,O
pancreatic,483,O
and,483,O
non-small,483,O
cell,483,O
lung,483,O
cancers,483,O
.,483,O
Three,484,O
preclinical,484,O
studies,484,O
have,484,O
been,484,O
reported,484,O
that,484,O
show,484,O
cytotoxic,484,O
synergy,484,O
between,484,O
gemcitabine,484,B-CHEMICAL
and,484,O
pemetrexed,484,B-CHEMICAL
.,484,O
Clinical,485,O
activity,485,O
with,485,O
this,485,O
combination,485,O
has,485,O
been,485,O
observed,485,O
in,485,O
a,485,O
phase,485,O
I,485,O
study,485,O
",",485,O
with,485,O
partial,485,O
responses,485,O
in,485,O
three,485,O
of,485,O
five,485,O
patients,485,O
previously,485,O
treated,485,O
for,485,O
non-small,485,O
cell,485,O
lung,485,O
cancer,485,O
.,485,O
An,486,O
international,486,O
phase,486,O
II,486,O
study,486,O
of,486,O
this,486,O
combination,486,O
in,486,O
non-small,486,O
cell,486,O
lung,486,O
cancer,486,O
is,486,O
ongoing,486,O
.,486,O
Tetrahydrofolate,487,B-CHEMICAL
biosynthesis,487,O
in,487,O
plants,487,O
:,487,O
molecular,487,O
and,487,O
functional,487,O
characterization,487,O
of,487,O
dihydrofolate,487,B-GENE-Y
synthetase,487,I-GENE-Y
and,487,O
three,487,O
isoforms,487,O
of,487,O
folylpolyglutamate,487,B-GENE-N
synthetase,487,I-GENE-N
in,487,O
Arabidopsis,487,O
thaliana,487,O
.,487,O
Tetrahydrofolate,488,B-CHEMICAL
coenzymes,488,O
involved,488,O
in,488,O
one-carbon,488,O
(,488,O
C1,488,B-CHEMICAL
),488,O
metabolism,488,O
are,488,O
polyglutamylated,488,O
.,488,O
In,489,O
organisms,489,O
that,489,O
synthesize,489,O
tetrahydrofolate,489,B-CHEMICAL
de,489,O
novo,489,O
",",489,O
dihydrofolate,489,B-CHEMICAL
synthetase,489,I-GENE-Y
(,489,O
DHFS,489,B-GENE-Y
),489,O
and,489,O
folylpolyglutamate,489,B-GENE-N
synthetase,489,I-GENE-N
(,489,O
FPGS,489,B-GENE-N
),489,O
catalyze,489,O
the,489,O
attachment,489,O
of,489,O
glutamate,489,B-CHEMICAL
residues,489,O
to,489,O
the,489,O
folate,489,B-CHEMICAL
molecule,489,O
.,489,O
In,490,O
this,490,O
study,490,O
we,490,O
isolated,490,O
cDNAs,490,O
coding,490,O
a,490,O
DHFS,490,B-GENE-Y
and,490,O
three,490,O
isoforms,490,O
of,490,O
FPGS,490,B-GENE-N
from,490,O
Arabidopsis,490,O
thaliana,490,O
.,490,O
The,491,O
function,491,O
of,491,O
each,491,O
enzyme,491,O
was,491,O
demonstrated,491,O
by,491,O
complementation,491,O
of,491,O
yeast,491,O
mutants,491,O
deficient,491,O
in,491,O
DHFS,491,B-GENE-Y
or,491,O
FPGS,491,B-GENE-Y
activity,491,O
",",491,O
and,491,O
by,491,O
measuring,491,O
in,491,O
vitro,491,O
glutamate,491,B-CHEMICAL
incorporation,491,O
into,491,O
dihydrofolate,491,B-CHEMICAL
or,491,O
tetrahydrofolate,491,B-CHEMICAL
.,491,O
DHFS,492,B-GENE-Y
is,492,O
present,492,O
exclusively,492,O
in,492,O
the,492,O
mitochondria,492,O
",",492,O
making,492,O
this,492,O
compartment,492,O
the,492,O
sole,492,O
site,492,O
of,492,O
synthesis,492,O
of,492,O
dihydrofolate,492,B-CHEMICAL
in,492,O
the,492,O
plant,492,O
cell,492,O
.,492,O
In,493,O
contrast,493,O
",",493,O
FPGS,493,B-GENE-N
is,493,O
present,493,O
as,493,O
distinct,493,O
isoforms,493,O
in,493,O
the,493,O
mitochondria,493,O
",",493,O
the,493,O
cytosol,493,O
",",493,O
and,493,O
the,493,O
chloroplast,493,O
.,493,O
Each,494,O
isoform,494,O
is,494,O
encoded,494,O
by,494,O
a,494,O
separate,494,O
gene,494,O
",",494,O
a,494,O
situation,494,O
that,494,O
is,494,O
unique,494,O
among,494,O
eukaryotes,494,O
.,494,O
The,495,O
compartmentation,495,O
of,495,O
FPGS,495,B-GENE-N
isoforms,495,O
is,495,O
in,495,O
agreement,495,O
with,495,O
the,495,O
predominance,495,O
of,495,O
gamma-glutamyl-conjugated,495,B-CHEMICAL
tetrahydrofolate,495,I-CHEMICAL
derivatives,495,O
and,495,O
the,495,O
presence,495,O
of,495,O
serine,495,B-CHEMICAL
hydroxymethyltransferase,495,I-GENE-N
and,495,O
C1-tetrahydrofolate,495,B-CHEMICAL
interconverting,495,I-GENE-N
enzymes,495,I-GENE-N
in,495,O
the,495,O
cytosol,495,O
",",495,O
the,495,O
mitochondria,495,O
",",495,O
and,495,O
the,495,O
plastids,495,O
.,495,O
Thus,496,O
",",496,O
the,496,O
combination,496,O
of,496,O
FPGS,496,B-GENE-N
with,496,O
these,496,O
folate-mediated,496,B-CHEMICAL
reactions,496,O
can,496,O
supply,496,O
each,496,O
compartment,496,O
with,496,O
the,496,O
polyglutamylated,496,O
folate,496,B-CHEMICAL
coenzymes,496,O
required,496,O
for,496,O
the,496,O
reactions,496,O
of,496,O
C1,496,B-CHEMICAL
metabolism,496,O
.,496,O
Also,497,O
",",497,O
the,497,O
multicompartmentation,497,O
of,497,O
FPGS,497,B-GENE-N
in,497,O
the,497,O
plant,497,O
cell,497,O
suggests,497,O
that,497,O
the,497,O
transported,497,O
forms,497,O
of,497,O
folate,497,B-CHEMICAL
are,497,O
unconjugated,497,O
.,497,O
Rabeprazole,498,B-CHEMICAL
:,498,O
an,498,O
update,498,O
of,498,O
its,498,O
use,498,O
in,498,O
acid-related,498,O
disorders,498,O
.,498,O
UNLABELLED,499,O
:,499,O
Rabeprazole,499,B-CHEMICAL
is,499,O
an,499,O
inhibitor,499,O
of,499,O
the,499,O
gastric,499,B-GENE-N
proton,499,I-GENE-N
pump,499,I-GENE-N
.,499,O
It,500,O
causes,500,O
dose-dependent,500,O
inhibition,500,O
of,500,O
acid,500,O
secretion,500,O
.,500,O
In,501,O
8-week,501,O
studies,501,O
",",501,O
among,501,O
patients,501,O
with,501,O
gastro-oesophageal,501,O
reflux,501,O
disease,501,O
(,501,O
GORD,501,O
),501,O
",",501,O
rabeprazole,501,B-CHEMICAL
20,501,O
mg/day,501,O
or,501,O
10mg,501,O
twice,501,O
daily,501,O
was,501,O
as,501,O
effective,501,O
as,501,O
omeprazole,501,B-CHEMICAL
and,501,O
superior,501,O
to,501,O
ranitidine,501,B-CHEMICAL
in,501,O
the,501,O
healing,501,O
of,501,O
GORD,501,O
.,501,O
Symptom,502,O
relief,502,O
with,502,O
rabeprazole,502,B-CHEMICAL
was,502,O
superior,502,O
to,502,O
that,502,O
provided,502,O
by,502,O
placebo,502,O
and,502,O
ranitidine,502,B-CHEMICAL
and,502,O
similar,502,O
to,502,O
omeprazole,502,B-CHEMICAL
.,502,O
In,503,O
long-term,503,O
trials,503,O
rabeprazole,503,B-CHEMICAL
10,503,O
mg/day,503,O
was,503,O
similar,503,O
to,503,O
omeprazole,503,B-CHEMICAL
20,503,O
mg/day,503,O
in,503,O
a,503,O
2-year,503,O
study,503,O
and,503,O
superior,503,O
to,503,O
placebo,503,O
in,503,O
1-year,503,O
studies,503,O
",",503,O
in,503,O
both,503,O
the,503,O
maintenance,503,O
of,503,O
healing,503,O
and,503,O
prevention,503,O
of,503,O
symptoms,503,O
in,503,O
patients,503,O
with,503,O
healed,503,O
GORD,503,O
.,503,O
In,504,O
nonerosive,504,O
GORD,504,O
",",504,O
4-week,504,O
studies,504,O
have,504,O
shown,504,O
rabeprazole,504,B-CHEMICAL
to,504,O
be,504,O
more,504,O
effective,504,O
than,504,O
placebo,504,O
in,504,O
relieving,504,O
heartburn,504,O
and,504,O
various,504,O
other,504,O
gastrointestinal,504,O
symptoms,504,O
.,504,O
Data,505,O
among,505,O
patients,505,O
with,505,O
Barrett,505,O
's,505,O
oesophagus,505,O
suggest,505,O
rabeprazole,505,B-CHEMICAL
20,505,O
mg/day,505,O
may,505,O
be,505,O
more,505,O
effective,505,O
than,505,O
placebo,505,O
in,505,O
maintaining,505,O
healing,505,O
of,505,O
associated,505,O
oesophagitis,505,O
after,505,O
1,505,O
year,505,O
of,505,O
treatment,505,O
.,505,O
One-week,506,O
triple,506,O
Helicobacter,506,O
pylori,506,O
eradication,506,O
therapy,506,O
with,506,O
rabeprazole,506,B-CHEMICAL
plus,506,O
clarithromycin,506,B-CHEMICAL
and,506,O
amoxicillin,506,B-CHEMICAL
achieved,506,O
eradication,506,O
rates,506,O
of,506,O
>,506,O
or,506,O
=85,506,O
%,506,O
.,506,O
Rabeprazole,507,B-CHEMICAL
is,507,O
as,507,O
effective,507,O
as,507,O
omeprazole,507,B-CHEMICAL
and,507,O
lansoprazole,507,B-CHEMICAL
when,507,O
included,507,O
as,507,O
part,507,O
of,507,O
a,507,O
triple-therapy,507,O
regimen,507,O
for,507,O
the,507,O
eradication,507,O
of,507,O
H.,507,O
pylori,507,O
.,507,O
Eradication,508,O
rates,508,O
of,508,O
>,508,O
90,508,O
%,508,O
were,508,O
achieved,508,O
when,508,O
rabeprazole,508,B-CHEMICAL
20,508,O
to,508,O
40,508,O
mg/day,508,O
was,508,O
included,508,O
as,508,O
part,508,O
of,508,O
a,508,O
quadruple,508,O
eradication,508,O
regimen,508,O
.,508,O
As,509,O
monotherapy,509,O
for,509,O
peptic,509,O
ulcer,509,O
healing,509,O
and,509,O
symptom,509,O
relief,509,O
",",509,O
4-,509,O
to,509,O
8-week,509,O
studies,509,O
have,509,O
shown,509,O
rabeprazole,509,B-CHEMICAL
10,509,O
to,509,O
40,509,O
mg/day,509,O
to,509,O
be,509,O
superior,509,O
to,509,O
placebo,509,O
and,509,O
ranitidine,509,B-CHEMICAL
and,509,O
have,509,O
similar,509,O
efficacy,509,O
to,509,O
omeprazole,509,B-CHEMICAL
.,509,O
Preliminary,510,O
1-year,510,O
data,510,O
among,510,O
16,510,O
patients,510,O
with,510,O
Zollinger-Ellison,510,O
syndrome,510,O
suggest,510,O
rabeprazole,510,B-CHEMICAL
60,510,O
to,510,O
120,510,O
mg/day,510,O
can,510,O
resolve,510,O
and,510,O
prevent,510,O
the,510,O
recurrence,510,O
of,510,O
symptoms,510,O
and,510,O
endoscopic,510,O
lesions,510,O
associated,510,O
with,510,O
this,510,O
condition,510,O
.,510,O
In,511,O
clinical,511,O
trials,511,O
of,511,O
up,511,O
to,511,O
2,511,O
years,511,O
',511,O
duration,511,O
the,511,O
tolerability,511,O
of,511,O
rabeprazole,511,B-CHEMICAL
is,511,O
similar,511,O
to,511,O
that,511,O
of,511,O
placebo,511,O
",",511,O
ranitidine,511,B-CHEMICAL
and,511,O
omeprazole,511,B-CHEMICAL
.,511,O
Common,512,O
adverse,512,O
events,512,O
assigned,512,O
to,512,O
rabeprazole,512,B-CHEMICAL
have,512,O
been,512,O
diarrhoea,512,O
",",512,O
headache,512,O
",",512,O
rhinitis,512,O
",",512,O
nausea,512,O
",",512,O
pharyngitis,512,O
and,512,O
abdominal,512,O
pain,512,O
.,512,O
Histological,513,O
changes,513,O
and,513,O
increases,513,O
in,513,O
serum,513,O
gastrin,513,B-GENE-Y
levels,513,O
were,513,O
unremarkable,513,O
and,513,O
typical,513,O
of,513,O
proton,513,B-GENE-N
pump,513,I-GENE-N
inhibitors,513,O
.,513,O
No,514,O
dosage,514,O
adjustment,514,O
is,514,O
necessary,514,O
in,514,O
renal,514,O
and,514,O
mild,514,O
to,514,O
moderate,514,O
hepatic,514,O
impairment,514,O
.,514,O
CONCLUSION,515,O
:,515,O
Rabeprazole,515,B-CHEMICAL
is,515,O
a,515,O
well,515,O
tolerated,515,O
proton,515,B-GENE-N
pump,515,I-GENE-N
inhibitor,515,O
.,515,O
It,516,O
has,516,O
proven,516,O
efficacy,516,O
in,516,O
healing,516,O
",",516,O
symptom,516,O
relief,516,O
and,516,O
prevention,516,O
of,516,O
relapse,516,O
of,516,O
peptic,516,O
ulcers,516,O
and,516,O
GORD,516,O
and,516,O
can,516,O
form,516,O
part,516,O
of,516,O
effective,516,O
H.,516,O
pylori,516,O
eradication,516,O
regimens,516,O
.,516,O
It,517,O
is,517,O
an,517,O
important,517,O
alternative,517,O
to,517,O
H,517,O
(,517,O
2,517,O
),517,O
antagonists,517,O
and,517,O
an,517,O
additional,517,O
treatment,517,O
option,517,O
to,517,O
other,517,O
proton,517,B-GENE-N
pump,517,I-GENE-N
inhibitors,517,O
in,517,O
the,517,O
management,517,O
of,517,O
acid-related,517,O
disorders,517,O
.,517,O
Angiotensin,518,B-GENE-Y
II,518,I-GENE-Y
suppression,518,O
in,518,O
humans,518,O
by,518,O
the,518,O
orally,518,O
active,518,O
renin,518,B-GENE-Y
inhibitor,518,O
Aliskiren,518,B-CHEMICAL
(,518,O
SPP100,518,B-CHEMICAL
),518,O
:,518,O
comparison,518,O
with,518,O
enalapril,518,B-CHEMICAL
.,518,O
Renin,519,B-GENE-Y
is,519,O
the,519,O
main,519,O
determinant,519,O
of,519,O
angiotensin,519,B-GENE-Y
(,519,I-GENE-Y
Ang,519,I-GENE-Y
),519,I-GENE-Y
II,519,I-GENE-Y
levels,519,O
.,519,O
It,520,O
",",520,O
therefore,520,O
",",520,O
always,520,O
appeared,520,O
desirable,520,O
to,520,O
reduce,520,O
Ang,520,B-GENE-Y
II,520,I-GENE-Y
levels,520,O
by,520,O
direct,520,O
inhibition,520,O
of,520,O
renin,520,B-GENE-Y
.,520,O
So,521,O
far,521,O
",",521,O
specific,521,O
renin,521,B-GENE-Y
inhibitors,521,O
lacked,521,O
potency,521,O
and/or,521,O
oral,521,O
availability,521,O
.,521,O
We,522,O
tested,522,O
the,522,O
new,522,O
orally,522,O
active,522,O
nonpeptidic,522,O
renin,522,B-GENE-Y
inhibitor,522,O
SPP100,522,B-CHEMICAL
(,522,O
Aliskiren,522,B-CHEMICAL
",",522,O
an,522,O
octanamide,522,B-CHEMICAL
with,522,O
a,522,O
50,522,O
%,522,O
inhibitory,522,O
concentration,522,O
[,522,O
IC50,522,O
],522,O
in,522,O
the,522,O
low,522,O
nanomolar,522,O
range,522,O
),522,O
in,522,O
18,522,O
healthy,522,O
volunteers,522,O
on,522,O
a,522,O
constant,522,O
100,522,O
mmol/d,522,O
sodium,522,B-CHEMICAL
diet,522,O
using,522,O
a,522,O
double-blind,522,O
",",522,O
3-way,522,O
crossover,522,O
protocol,522,O
.,522,O
In,523,O
3,523,O
periods,523,O
of,523,O
8,523,O
days,523,O
",",523,O
separated,523,O
by,523,O
wash-outs,523,O
of,523,O
6,523,O
days,523,O
",",523,O
each,523,O
volunteer,523,O
received,523,O
2,523,O
dosage,523,O
levels,523,O
of,523,O
Aliskiren,523,B-CHEMICAL
(,523,O
low,523,O
before,523,O
high,523,O
;,523,O
40,523,O
and,523,O
80,523,O
or,523,O
160,523,O
and,523,O
640,523,O
mg/d,523,O
),523,O
and,523,O
randomized,523,O
placebo,523,O
or,523,O
20,523,O
mg,523,O
enalapril,523,B-CHEMICAL
.,523,O
Aliskiren,524,B-CHEMICAL
was,524,O
well,524,O
tolerated,524,O
.,524,O
Not,525,O
surprisingly,525,O
",",525,O
blood,525,O
pressure,525,O
and,525,O
heart,525,O
rate,525,O
remained,525,O
unchanged,525,O
in,525,O
these,525,O
normotensive,525,O
subjects,525,O
.,525,O
There,526,O
was,526,O
a,526,O
dose-dependent,526,O
decrease,526,O
in,526,O
plasma,526,O
renin,526,B-GENE-Y
activity,526,O
",",526,O
Ang,526,B-GENE-Y
I,526,I-GENE-Y
",",526,O
and,526,O
Ang,526,B-GENE-Y
II,526,I-GENE-Y
following,526,O
single,526,O
doses,526,O
of,526,O
Aliskiren,526,B-CHEMICAL
starting,526,O
with,526,O
40,526,O
mg.,526,O
Inhibition,526,O
was,526,O
still,526,O
marked,526,O
and,526,O
significant,526,O
after,526,O
repeated,526,O
dosing,526,O
with,526,O
maximal,526,O
decreases,526,O
in,526,O
Ang,526,B-GENE-Y
II,526,I-GENE-Y
levels,526,O
by,526,O
89,526,O
%,526,O
and,526,O
75,526,O
%,526,O
on,526,O
Days,526,O
1,526,O
and,526,O
8,526,O
",",526,O
respectively,526,O
",",526,O
when,526,O
the,526,O
highest,526,O
dose,526,O
of,526,O
Aliskiren,526,B-CHEMICAL
was,526,O
compared,526,O
with,526,O
placebo,526,O
.,526,O
At,527,O
the,527,O
same,527,O
time,527,O
",",527,O
mean,527,O
plasma,527,O
active,527,O
renin,527,B-GENE-Y
was,527,O
increased,527,O
16-,527,O
and,527,O
34-fold,527,O
at,527,O
the,527,O
highest,527,O
dose,527,O
of,527,O
Aliskiren,527,B-CHEMICAL
.,527,O
Plasma,528,O
drug,528,O
levels,528,O
of,528,O
Aliskiren,528,B-CHEMICAL
were,528,O
dose-dependent,528,O
with,528,O
maximal,528,O
concentrations,528,O
reached,528,O
between,528,O
3,528,O
to,528,O
6,528,O
hours,528,O
after,528,O
administration,528,O
;,528,O
steady,528,O
state,528,O
was,528,O
reached,528,O
between,528,O
5,528,O
and,528,O
8,528,O
days,528,O
after,528,O
multiple,528,O
dosing,528,O
.,528,O
Less,529,O
than,529,O
1,529,O
%,529,O
of,529,O
dose,529,O
was,529,O
excreted,529,O
in,529,O
the,529,O
urine,529,O
.,529,O
Plasma,530,O
and,530,O
urinary,530,O
aldosterone,530,B-CHEMICAL
levels,530,O
were,530,O
decreased,530,O
after,530,O
doses,530,O
of,530,O
Aliskiren,530,B-CHEMICAL
>,530,O
or,530,O
=80,530,O
mg,530,O
and,530,O
after,530,O
enalapril,530,B-CHEMICAL
.,530,O
Aliskiren,531,B-CHEMICAL
at,531,O
160,531,O
and,531,O
640,531,O
mg,531,O
enhanced,531,O
natriuresis,531,O
on,531,O
Day,531,O
1,531,O
by,531,O
+45,531,O
%,531,O
and,531,O
+62,531,O
%,531,O
",",531,O
respectively,531,O
",",531,O
compared,531,O
with,531,O
placebo,531,O
(,531,O
100,531,O
%,531,O
",",531,O
ie,531,O
",",531,O
87+/-11,531,O
mmol/24h,531,O
),531,O
and,531,O
enalapril,531,B-CHEMICAL
(,531,O
+54,531,O
%,531,O
),531,O
;,531,O
kaliuresis,531,O
remained,531,O
unchanged,531,O
.,531,O
In,532,O
conclusion,532,O
",",532,O
the,532,O
renin,532,B-GENE-Y
inhibitor,532,O
Aliskiren,532,B-CHEMICAL
dose-dependently,532,O
decreases,532,O
Ang,532,B-GENE-Y
II,532,I-GENE-Y
levels,532,O
in,532,O
humans,532,O
following,532,O
oral,532,O
administration,532,O
.,532,O
The,533,O
effect,533,O
is,533,O
long-lasting,533,O
and,533,O
",",533,O
at,533,O
a,533,O
dose,533,O
of,533,O
160,533,O
mg,533,O
",",533,O
is,533,O
equivalent,533,O
to,533,O
that,533,O
of,533,O
20,533,O
mg,533,O
enalapril,533,B-CHEMICAL
.,533,O
Aliskiren,534,B-CHEMICAL
has,534,O
the,534,O
potential,534,O
to,534,O
become,534,O
the,534,O
first,534,O
orally,534,O
active,534,O
renin,534,B-GENE-Y
inhibitor,534,O
that,534,O
provides,534,O
a,534,O
true,534,O
alternative,534,O
to,534,O
ACE-inhibitors,534,B-GENE-Y
and,534,O
Ang,534,B-GENE-N
II,534,I-GENE-N
receptor,534,I-GENE-N
antagonists,534,O
in,534,O
therapy,534,O
for,534,O
hypertension,534,O
and,534,O
other,534,O
cardiovascular,534,O
and,534,O
renal,534,O
diseases,534,O
.,534,O
Heterogeneity,535,O
of,535,O
persistent,535,O
hyperinsulinaemic,535,O
hypoglycaemia,535,O
.,535,O
A,536,O
series,536,O
of,536,O
175,536,O
cases,536,O
.,536,O
UNLABELLED,537,O
:,537,O
Hyperinsulinism,537,O
is,537,O
a,537,O
heterogeneous,537,O
disorder,537,O
characterised,537,O
by,537,O
severe,537,O
hypoglycaemia,537,O
due,537,O
to,537,O
an,537,O
inappropriate,537,O
oversecretion,537,O
of,537,O
insulin,537,B-GENE-Y
.,537,O
In,538,O
a,538,O
personal,538,O
series,538,O
of,538,O
175,538,O
patients,538,O
investigated,538,O
for,538,O
hyperinsulinaemic,538,O
hypoglycaemia,538,O
over,538,O
the,538,O
last,538,O
20,538,O
years,538,O
",",538,O
we,538,O
review,538,O
clinical,538,O
presentations,538,O
",",538,O
molecular,538,O
studies,538,O
and,538,O
therapeutic,538,O
management,538,O
of,538,O
hyperinsulinism,538,O
.,538,O
There,539,O
were,539,O
98,539,O
neonatal-onset,539,O
patients,539,O
",",539,O
including,539,O
86,539,O
permanent,539,O
hyperinsulinism,539,O
and,539,O
12,539,O
transient,539,O
forms,539,O
",",539,O
68,539,O
with,539,O
infancy-onset,539,O
and,539,O
nine,539,O
with,539,O
childhood-onset,539,O
.,539,O
Hyperammonaemia,540,O
was,540,O
found,540,O
in,540,O
12,540,O
out,540,O
of,540,O
69,540,O
patients,540,O
tested,540,O
",",540,O
4,540,O
neonates,540,O
and,540,O
8,540,O
infants,540,O
.,540,O
Neonates,541,O
were,541,O
clinically,541,O
more,541,O
severely,541,O
affected,541,O
than,541,O
infants,541,O
.,541,O
Diagnosis,542,O
of,542,O
infancy-onset,542,O
hyperinsulinism,542,O
was,542,O
often,542,O
delayed,542,O
because,542,O
of,542,O
less,542,O
profound,542,O
hypoglycaemia,542,O
and,542,O
better,542,O
tolerance,542,O
to,542,O
hypoglycaemia,542,O
.,542,O
Neonates,543,O
required,543,O
higher,543,O
rates,543,O
of,543,O
i.v,543,O
.,543,O
glucose,544,B-CHEMICAL
than,544,O
infants,544,O
to,544,O
maintain,544,O
normal,544,O
plasma,544,O
glucose,544,B-CHEMICAL
levels,544,O
(,544,O
16,544,O
mg/kg,544,O
per,544,O
min,544,O
versus,544,O
12,544,O
mg/kg,544,O
per,544,O
min,544,O
),544,O
.,544,O
Only,545,O
16,545,O
%,545,O
of,545,O
neonates,545,O
were,545,O
diazoxide-sensitive,545,B-CHEMICAL
compared,545,O
to,545,O
66,545,O
%,545,O
of,545,O
the,545,O
infants,545,O
.,545,O
Neonates,546,O
with,546,O
hyperammonaemia,546,O
or,546,O
transient,546,O
hyperinsulinism,546,O
were,546,O
diazoxide-sensitive,546,B-CHEMICAL
.,546,O
Most,547,O
neonates,547,O
were,547,O
pancreatectomised,547,O
whereas,547,O
65,547,O
%,547,O
of,547,O
the,547,O
infants,547,O
were,547,O
treated,547,O
medically,547,O
.,547,O
Among,548,O
surgically-treated,548,O
patients,548,O
",",548,O
47,548,O
%,548,O
had,548,O
a,548,O
focal,548,O
adenomatous,548,O
hyperplasia,548,O
(,548,O
31,548,O
neonates,548,O
and,548,O
13,548,O
infants,548,O
),548,O
and,548,O
53,548,O
%,548,O
a,548,O
diffuse,548,O
form,548,O
of,548,O
hyperinsulinism,548,O
(,548,O
39,548,O
neonates,548,O
and,548,O
11,548,O
infants,548,O
),548,O
.,548,O
Diazoxide-responsiveness,549,B-CHEMICAL
in,549,O
the,549,O
focal,549,O
and,549,O
diffuse,549,O
forms,549,O
did,549,O
not,549,O
differ,549,O
in,549,O
both,549,O
neonates,549,O
and,549,O
infants,549,O
;,549,O
it,549,O
depended,549,O
only,549,O
upon,549,O
the,549,O
age,549,O
of,549,O
onset,549,O
of,549,O
hypoglycaemia,549,O
.,549,O
One,550,O
or,550,O
two,550,O
mutations,550,O
",",550,O
SUR1,550,B-GENE-Y
or,550,O
KIR6.2,550,B-GENE-Y
",",550,O
were,550,O
found,550,O
in,550,O
41,550,O
of,550,O
73,550,O
neonates,550,O
who,550,O
were,550,O
investigated,550,O
and,550,O
in,550,O
13/38,550,O
infants,550,O
using,550,O
polymerase,550,O
chain,550,O
reaction-single,550,O
strand,550,O
conformational,550,O
polymorphism,550,O
analysis,550,O
of,550,O
both,550,O
genes,550,O
.,550,O
Almost,551,O
all,551,O
patients,551,O
with,551,O
SUR1,551,B-GENE-Y
(,551,O
38/41,551,O
),551,O
or,551,O
KIR6.2,551,B-GENE-Y
(,551,O
5/7,551,O
),551,O
mutations,551,O
were,551,O
resistant,551,O
to,551,O
diazoxide,551,B-CHEMICAL
.,551,O
Ten,552,O
patients,552,O
with,552,O
hyperinsulinism-hyperammonaemia,552,O
syndrome,552,O
had,552,O
a,552,O
mutation,552,O
in,552,O
the,552,O
glutamate,552,B-CHEMICAL
dehydrogenase,552,I-GENE-N
gene,552,O
(,552,O
three,552,O
neonates,552,O
and,552,O
seven,552,O
infants,552,O
),552,O
after,552,O
reverse,552,O
transcriptase-polymerase,552,O
chain,552,O
reaction,552,O
and,552,O
sequence,552,O
analysis,552,O
of,552,O
cDNA,552,O
.,552,O
No,553,O
mutation,553,O
was,553,O
found,553,O
by,553,O
polymerase,553,O
chain,553,O
reaction-single,553,O
strand,553,O
conformational,553,O
polymorphism,553,O
in,553,O
the,553,O
glucokinase,553,B-GENE-Y
gene,553,O
.,553,O
Eight,554,O
of,554,O
nine,554,O
patients,554,O
with,554,O
childhood,554,O
onset,554,O
hyperinsulinism,554,O
were,554,O
treated,554,O
surgically,554,O
and,554,O
histological,554,O
examination,554,O
confirmed,554,O
an,554,O
adenoma,554,O
in,554,O
each,554,O
case,554,O
.,554,O
CONCLUSION,555,O
:,555,O
the,555,O
clinical,555,O
severity,555,O
of,555,O
hyperinsulinism,555,O
varies,555,O
mainly,555,O
with,555,O
age,555,O
at,555,O
onset,555,O
of,555,O
hypoglycaemia,555,O
.,555,O
The,556,O
heterogeneity,556,O
of,556,O
hyperinsulinism,556,O
has,556,O
major,556,O
consequences,556,O
in,556,O
terms,556,O
of,556,O
therapeutic,556,O
outcome,556,O
and,556,O
genetic,556,O
counselling,556,O
.,556,O
Donepezil,557,B-CHEMICAL
hydrochloride,557,I-CHEMICAL
:,557,O
a,557,O
treatment,557,O
drug,557,O
for,557,O
Alzheimer,557,O
's,557,O
disease,557,O
.,557,O
The,558,O
role,558,O
of,558,O
the,558,O
cholinergic,558,O
system,558,O
with,558,O
respect,558,O
to,558,O
cognitive,558,O
deficits,558,O
characteristic,558,O
of,558,O
Alzheimer,558,O
's,558,O
disease,558,O
(,558,O
AD,558,O
),558,O
has,558,O
led,558,O
to,558,O
a,558,O
number,558,O
of,558,O
studies,558,O
focusing,558,O
on,558,O
the,558,O
development,558,O
of,558,O
acetylcholinesterase,558,B-GENE-Y
(,558,O
AChE,558,B-GENE-Y
),558,O
inhibitors,558,O
as,558,O
a,558,O
drug,558,O
for,558,O
treating,558,O
this,558,O
disease,558,O
.,558,O
The,559,O
earliest,559,O
known,559,O
AChE,559,B-GENE-Y
inhibitors,559,O
",",559,O
namely,559,O
",",559,O
physostigmine,559,B-CHEMICAL
and,559,O
tacrine,559,B-CHEMICAL
",",559,O
performed,559,O
poorly,559,O
in,559,O
clinical,559,O
trials,559,O
(,559,O
e.g.,559,O
",",559,O
poor,559,O
oral,559,O
activity,559,O
",",559,O
brain,559,O
penetration,559,O
",",559,O
and,559,O
hepatotoxic,559,O
liability,559,O
),559,O
.,559,O
Studies,560,O
were,560,O
then,560,O
focused,560,O
on,560,O
finding,560,O
a,560,O
new,560,O
type,560,O
of,560,O
acetylcholinesterase,560,O
inhibitor,560,O
that,560,O
would,560,O
overcome,560,O
the,560,O
disadvantages,560,O
of,560,O
these,560,O
two,560,O
compounds,560,O
.,560,O
Donepezil,561,B-CHEMICAL
hydrochloride,561,I-CHEMICAL
inaugurates,561,O
a,561,O
new,561,O
class,561,O
of,561,O
AChE,561,B-GENE-Y
inhibitors,561,O
with,561,O
longer,561,O
and,561,O
more,561,O
selective,561,O
action,561,O
and,561,O
with,561,O
manageable,561,O
adverse,561,O
effects,561,O
.,561,O
Alefacept,562,B-GENE-Y
",",562,O
an,562,O
immunomodulatory,562,O
recombinant,562,O
LFA-3/IgG1,562,B-GENE-Y
fusion,562,O
protein,562,O
",",562,O
induces,562,O
CD16,562,B-GENE-N
signaling,562,O
and,562,O
CD2/CD16-dependent,562,B-GENE-Y
apoptosis,562,O
of,562,O
CD2,562,O
(,562,O
+,562,O
),562,O
cells,562,O
.,562,O
Alefacept,563,B-GENE-Y
",",563,O
an,563,O
immunomodulatory,563,O
recombinant,563,O
fusion,563,O
protein,563,O
composed,563,O
of,563,O
the,563,O
first,563,O
extracellular,563,O
domain,563,O
of,563,O
LFA-3,563,B-GENE-Y
fused,563,O
to,563,O
the,563,O
human,563,B-GENE-N
IgG1,563,I-GENE-N
hinge,563,I-GENE-N
",",563,I-GENE-N
C,563,I-GENE-N
(,563,I-GENE-N
H,563,I-GENE-N
),563,I-GENE-N
2,563,I-GENE-N
",",563,I-GENE-N
and,563,I-GENE-N
C,563,I-GENE-N
(,563,I-GENE-N
H,563,I-GENE-N
),563,I-GENE-N
3,563,I-GENE-N
domains,563,I-GENE-N
",",563,O
has,563,O
recently,563,O
been,563,O
shown,563,O
in,563,O
phase,563,O
II,563,O
and,563,O
III,563,O
clinical,563,O
trials,563,O
to,563,O
safely,563,O
reduce,563,O
disease,563,O
expression,563,O
in,563,O
patients,563,O
with,563,O
chronic,563,O
plaque,563,O
psoriasis,563,O
.,563,O
Alefacept,564,B-GENE-Y
modulates,564,O
the,564,O
function,564,O
of,564,O
and,564,O
selectively,564,O
induces,564,O
apoptosis,564,O
of,564,O
CD2,564,O
(,564,O
+,564,O
),564,O
human,564,O
memory-effector,564,O
T,564,O
cells,564,O
in,564,O
vivo,564,O
.,564,O
We,565,O
have,565,O
sought,565,O
to,565,O
gain,565,O
further,565,O
understanding,565,O
of,565,O
the,565,O
mechanisms,565,O
of,565,O
action,565,O
that,565,O
influence,565,O
the,565,O
biological,565,O
activity,565,O
of,565,O
alefacept,565,B-GENE-Y
and,565,O
may,565,O
contribute,565,O
to,565,O
its,565,O
efficacy,565,O
and,565,O
patient,565,O
responsiveness,565,O
.,565,O
Specifically,566,O
evaluated,566,O
is,566,O
the,566,O
ability,566,O
of,566,O
alefacept,566,B-GENE-Y
to,566,O
activate,566,O
intracellular,566,O
signals,566,O
mediated,566,O
via,566,O
CD2,566,B-GENE-Y
and/or,566,O
Fc,566,B-GENE-N
gamma,566,I-GENE-N
RIII,566,I-GENE-N
(,566,O
CD16,566,B-GENE-N
),566,O
.,566,O
Experimentation,567,O
using,567,O
isoforms,567,O
of,567,O
alefacept,567,B-GENE-Y
engineered,567,O
to,567,O
have,567,O
amino,567,B-CHEMICAL
acid,567,I-CHEMICAL
substitutions,567,O
in,567,O
the,567,O
IgG1,567,B-GENE-N
C,567,I-GENE-N
(,567,I-GENE-N
H,567,I-GENE-N
),567,I-GENE-N
2,567,I-GENE-N
domain,567,I-GENE-N
that,567,O
impact,567,O
Fc,567,B-GENE-N
gamma,567,I-GENE-N
R,567,I-GENE-N
binding,567,O
indicate,567,O
that,567,O
alefacept,567,B-GENE-Y
mediates,567,O
cognate,567,O
interactions,567,O
between,567,O
cells,567,O
expressing,567,O
human,567,B-GENE-Y
CD2,567,I-GENE-Y
and,567,O
CD16,567,B-GENE-N
to,567,O
activate,567,O
cells,567,O
",",567,O
e.g.,567,O
",",567,O
increase,567,O
extracellular,567,B-GENE-N
signal-regulated,567,I-GENE-N
kinase,567,I-GENE-N
phosphorylation,567,O
",",567,O
up-regulate,567,O
cell,567,O
surface,567,O
expression,567,O
of,567,O
the,567,O
activation,567,O
marker,567,O
CD25,567,B-GENE-Y
",",567,O
and,567,O
induce,567,O
release,567,O
of,567,O
granzyme,567,B-GENE-Y
B,567,I-GENE-Y
.,567,O
In,568,O
the,568,O
systems,568,O
used,568,O
",",568,O
this,568,O
signaling,568,O
is,568,O
shown,568,O
to,568,O
require,568,O
binding,568,O
to,568,O
CD2,568,B-GENE-Y
and,568,O
CD16,568,B-GENE-N
and,568,O
be,568,O
mediated,568,O
through,568,O
CD16,568,B-GENE-N
",",568,O
but,568,O
not,568,O
CD2,568,B-GENE-Y
.,568,O
Experimentation,569,O
using,569,O
human,569,B-GENE-Y
CD2-transgenic,569,O
mice,569,O
and,569,O
isoforms,569,O
of,569,O
alefacept,569,B-GENE-Y
confirmed,569,O
the,569,O
requirement,569,O
for,569,O
Fc,569,B-GENE-N
gamma,569,I-GENE-N
R,569,I-GENE-N
binding,569,O
for,569,O
detection,569,O
of,569,O
the,569,O
pharmacological,569,O
effects,569,O
of,569,O
alefacept,569,O
in,569,O
vivo,569,O
.,569,O
Thus,570,O
alefacept,570,B-GENE-Y
acts,570,O
as,570,O
an,570,O
effector,570,O
molecule,570,O
",",570,O
mediating,570,O
cognate,570,O
interactions,570,O
to,570,O
activate,570,O
Fc,570,O
gamma,570,O
R,570,O
(,570,O
+,570,O
),570,O
cells,570,O
(,570,O
e.g.,570,O
",",570,O
NK,570,O
cells,570,O
),570,O
to,570,O
induce,570,O
apoptosis,570,O
of,570,O
sensitive,570,O
CD2,570,O
(,570,O
+,570,O
),570,O
target,570,O
cells,570,O
.,570,O
Thalidomide,571,B-CHEMICAL
in,571,O
multiple,571,O
myeloma,571,O
.,571,O
Thalidomide,572,B-CHEMICAL
--,572,O
removed,572,O
from,572,O
widespread,572,O
clinical,572,O
use,572,O
by,572,O
1962,572,O
because,572,O
of,572,O
severe,572,O
teratogenicity,572,O
--,572,O
has,572,O
anti-angiogenic,572,O
and,572,O
immunomodulatory,572,O
effects,572,O
",",572,O
including,572,O
the,572,O
inhibition,572,O
of,572,O
TNF,572,B-GENE-Y
alpha,572,I-GENE-Y
.,572,O
It,573,O
has,573,O
returned,573,O
to,573,O
practice,573,O
as,573,O
an,573,O
effective,573,O
oral,573,O
agent,573,O
in,573,O
the,573,O
management,573,O
of,573,O
various,573,O
disease,573,O
states,573,O
including,573,O
erythema,573,O
nodosum,573,O
leprosum,573,O
",",573,O
for,573,O
which,573,O
it,573,O
was,573,O
FDA-approved,573,O
in,573,O
1998,573,O
",",573,O
and,573,O
more,573,O
recently,573,O
certain,573,O
malignancies,573,O
",",573,O
including,573,O
multiple,573,O
myeloma,573,O
.,573,O
Whilst,574,O
the,574,O
mechanism,574,O
of,574,O
action,574,O
of,574,O
thalidomide,574,B-CHEMICAL
remains,574,O
incompletely,574,O
understood,574,O
",",574,O
considerable,574,O
insight,574,O
has,574,O
been,574,O
generated,574,O
by,574,O
extensive,574,O
preclinical,574,O
studies,574,O
in,574,O
multiple,574,O
myeloma,574,O
.,574,O
Moreover,575,O
",",575,O
clinical,575,O
trials,575,O
both,575,O
as,575,O
a,575,O
single,575,O
agent,575,O
and,575,O
in,575,O
combination,575,O
have,575,O
confirmed,575,O
benefit,575,O
in,575,O
relapsed,575,O
and,575,O
refractory,575,O
disease,575,O
.,575,O
Thalidomide,576,O
's,576,O
role,576,O
in,576,O
treating,576,O
newly,576,O
diagnosed,576,O
patients,576,O
is,576,O
currently,576,O
under,576,O
study,576,O
and,576,O
it,576,O
is,576,O
now,576,O
established,576,O
as,576,O
an,576,O
important,576,O
therapeutic,576,O
option,576,O
in,576,O
the,576,O
treatment,576,O
of,576,O
multiple,576,O
myeloma,576,O
.,576,O
[,577,O
Leflunomide,577,B-CHEMICAL
--,577,O
a,577,O
new,577,O
drug,577,O
for,577,O
pharmacological,577,O
immunomodulation,577,O
],577,O
.,577,O
The,578,O
novel,578,O
immunomodulatory,578,O
agent,578,O
leflunomide,578,B-CHEMICAL
exhibits,578,O
a,578,O
strong,578,O
anti-inflammatory,578,O
action,578,O
.,578,O
This,579,O
isoxazole,579,B-CHEMICAL
derivative,579,O
is,579,O
chemically,579,O
unrelated,579,O
to,579,O
any,579,O
hitherto,579,O
applied,579,O
immunosuppressants,579,O
.,579,O
As,580,O
a,580,O
prodrug,580,O
leflunomide,580,B-CHEMICAL
is,580,O
completely,580,O
converted,580,O
to,580,O
its,580,O
active,580,O
metabolite,580,O
A,580,B-CHEMICAL
77,580,I-CHEMICAL
1726,580,I-CHEMICAL
(,580,O
M1,580,O
),580,O
which,580,O
blocks,580,O
the,580,O
dihydroorotate,580,B-CHEMICAL
dehydrogenase,580,I-GENE-Y
",",580,O
a,580,O
key,580,O
enzyme,580,O
of,580,O
the,580,O
pyrimidine,580,B-CHEMICAL
de,580,O
novo,580,O
synthesis,580,O
.,580,O
Drug-related,581,O
adverse,581,O
effects,581,O
are,581,O
mild,581,O
",",581,O
dose-related,581,O
and,581,O
reversible,581,O
",",581,O
characterising,581,O
leflunomide,581,B-CHEMICAL
as,581,O
a,581,O
safe,581,O
immunosuppressant,581,O
.,581,O
While,582,O
up,582,O
to,582,O
now,582,O
leflunomide,582,B-CHEMICAL
has,582,O
just,582,O
been,582,O
approved,582,O
for,582,O
therapy,582,O
of,582,O
rheumatoid,582,O
arthritis,582,O
",",582,O
its,582,O
mechanism,582,O
of,582,O
action,582,O
affects,582,O
multiple,582,O
inflammatory,582,O
pathways,582,O
",",582,O
thereby,582,O
suggesting,582,O
it,582,O
to,582,O
be,582,O
a,582,O
potent,582,O
therapeutic,582,O
agent,582,O
in,582,O
autoimmune,582,O
diseases,582,O
",",582,O
graft,582,O
rejection,582,O
",",582,O
and,582,O
tumour,582,O
therapy,582,O
.,582,O
First,583,O
dermatological,583,O
experience,583,O
has,583,O
been,583,O
gained,583,O
in,583,O
psoriasis,583,O
and,583,O
bullous,583,O
pemphigoid,583,O
.,583,O
The,584,O
role,584,O
of,584,O
leflunomide,584,B-CHEMICAL
in,584,O
the,584,O
dermatologist,584,O
's,584,O
therapeutic,584,O
armamentarium,584,O
will,584,O
evolve,584,O
during,584,O
the,584,O
next,584,O
years,584,O
.,584,O
Existing,585,O
and,585,O
emerging,585,O
endocrine,585,O
therapies,585,O
for,585,O
breast,585,O
cancer,585,O
.,585,O
Endocrine,586,O
therapy,586,O
is,586,O
first-line,586,O
therapy,586,O
for,586,O
patients,586,O
with,586,O
estrogen,586,B-GENE-Y
receptor-positive,586,O
or,586,O
progesterone,586,B-GENE-Y
receptor-positive,586,O
metastatic,586,O
breast,586,O
cancer,586,O
.,586,O
Commonly,587,O
used,587,O
endocrine,587,O
therapies,587,O
are,587,O
tamoxifen,587,B-CHEMICAL
",",587,O
megestrol,587,B-CHEMICAL
acetate,587,I-CHEMICAL
",",587,O
and,587,O
aromatase,587,B-GENE-Y
inhibitors,587,O
.,587,O
Although,588,O
tamoxifen,588,B-CHEMICAL
and,588,O
megestrol,588,B-CHEMICAL
acetate,588,I-CHEMICAL
have,588,O
a,588,O
favorable,588,O
therapeutic,588,O
profile,588,O
",",588,O
there,588,O
are,588,O
risks,588,O
associated,588,O
with,588,O
these,588,O
agents,588,O
.,588,O
With,589,O
tamoxifen,589,B-CHEMICAL
",",589,O
the,589,O
partial,589,O
agonist,589,O
property,589,O
can,589,O
lead,589,O
to,589,O
thromboembolic,589,O
events,589,O
.,589,O
An,590,O
important,590,O
adverse,590,O
event,590,O
of,590,O
megestrol,590,B-CHEMICAL
acetate,590,I-CHEMICAL
is,590,O
weight,590,O
gain,590,O
and,590,O
fluid,590,O
retention,590,O
in,590,O
some,590,O
patients,590,O
.,590,O
The,591,O
aromatase,591,B-GENE-Y
inhibitors,591,O
are,591,O
currently,591,O
used,591,O
as,591,O
second-line,591,O
therapy,591,O
after,591,O
tamoxifen,591,B-CHEMICAL
failure,591,O
.,591,O
A,592,O
recent,592,O
study,592,O
showed,592,O
that,592,O
anastrozole,592,B-CHEMICAL
",",592,O
an,592,O
aromatase,592,B-GENE-Y
inhibitor,592,O
",",592,O
is,592,O
as,592,O
effective,592,O
or,592,O
even,592,O
superior,592,O
to,592,O
tamoxifen,592,B-CHEMICAL
when,592,O
used,592,O
as,592,O
a,592,O
first-line,592,O
therapy,592,O
.,592,O
However,593,O
",",593,O
not,593,O
all,593,O
patients,593,O
will,593,O
respond,593,O
to,593,O
currently,593,O
available,593,O
therapies,593,O
.,593,O
A,594,O
new,594,O
class,594,O
of,594,O
drug,594,O
",",594,O
the,594,O
estrogen,594,B-GENE-Y
receptor,594,I-GENE-Y
downregulators,594,O
",",594,O
has,594,O
been,594,O
developed,594,O
.,594,O
Fulvestrant,595,B-CHEMICAL
",",595,O
the,595,O
first,595,O
agent,595,O
in,595,O
this,595,O
new,595,O
class,595,O
",",595,O
not,595,O
only,595,O
induces,595,O
the,595,O
degradation,595,O
of,595,O
the,595,O
estrogen,595,B-CHEMICAL
receptor,595,I-GENE-Y
but,595,O
also,595,O
is,595,O
an,595,O
estrogen,595,B-CHEMICAL
antagonist,595,O
;,595,O
further,595,O
",",595,O
its,595,O
lack,595,O
of,595,O
agonist,595,O
activity,595,O
provides,595,O
a,595,O
better,595,O
safety,595,O
profile,595,O
.,595,O
Two,596,O
phase,596,O
III,596,O
trials,596,O
have,596,O
proven,596,O
that,596,O
fulvestrant,596,B-CHEMICAL
is,596,O
at,596,O
least,596,O
as,596,O
effective,596,O
as,596,O
anastrozole,596,B-CHEMICAL
in,596,O
postmenopausal,596,O
women,596,O
with,596,O
advanced,596,O
breast,596,O
cancer,596,O
.,596,O
Fulvestrant,597,B-CHEMICAL
is,597,O
an,597,O
effective,597,O
and,597,O
safe,597,O
endocrine,597,O
therapy,597,O
for,597,O
postmenopausal,597,O
women,597,O
who,597,O
have,597,O
failed,597,O
prior,597,O
endocrine,597,O
therapy,597,O
.,597,O
Microarray,598,O
and,598,O
biochemical,598,O
analysis,598,O
of,598,O
lovastatin-induced,598,B-CHEMICAL
apoptosis,598,O
of,598,O
squamous,598,O
cell,598,O
carcinomas,598,O
.,598,O
We,599,O
recently,599,O
identified,599,O
3-hydroxy-3-methylglutaryl,599,B-GENE-Y
coenzyme,599,I-GENE-Y
A,599,I-GENE-Y
(,599,I-GENE-Y
HMG-CoA,599,I-GENE-Y
),599,I-GENE-Y
reductase,599,I-GENE-Y
",",599,O
the,599,O
rate-limiting,599,O
enzyme,599,O
of,599,O
the,599,O
mevalonate,599,O
pathway,599,O
",",599,O
as,599,O
a,599,O
potential,599,O
therapeutic,599,O
target,599,O
of,599,O
the,599,O
head,599,O
and,599,O
neck,599,O
squamous,599,O
cell,599,O
carcinomas,599,O
(,599,O
HNSCC,599,O
),599,O
and,599,O
cervical,599,O
carcinomas,599,O
(,599,O
CC,599,O
),599,O
.,599,O
The,600,O
products,600,O
of,600,O
this,600,O
complex,600,O
biochemical,600,O
pathway,600,O
",",600,O
including,600,O
de,600,O
novo,600,O
cholesterol,600,B-CHEMICAL
",",600,O
are,600,O
vital,600,O
for,600,O
a,600,O
variety,600,O
of,600,O
key,600,O
cellular,600,O
functions,600,O
affecting,600,O
membrane,600,O
integrity,600,O
",",600,O
cell,600,O
signaling,600,O
",",600,O
protein,600,O
synthesis,600,O
",",600,O
and,600,O
cell,600,O
cycle,600,O
progression,600,O
.,600,O
Lovastatin,601,B-CHEMICAL
",",601,O
a,601,O
specific,601,O
inhibitor,601,O
of,601,O
HMG-CoA,601,B-GENE-Y
reductase,601,I-GENE-Y
",",601,O
induces,601,O
a,601,O
pronounced,601,O
apoptotic,601,O
response,601,O
in,601,O
a,601,O
specific,601,O
subset,601,O
of,601,O
tumor,601,O
types,601,O
",",601,O
including,601,O
HNSCC,601,O
and,601,O
CC,601,O
.,601,O
The,602,O
mediators,602,O
of,602,O
this,602,O
response,602,O
are,602,O
not,602,O
well,602,O
established,602,O
.,602,O
Identification,603,O
of,603,O
differentially,603,O
expressed,603,O
genes,603,O
represents,603,O
a,603,O
feasible,603,O
approach,603,O
to,603,O
delineate,603,O
these,603,O
mediators,603,O
as,603,O
lovastatin,603,B-CHEMICAL
has,603,O
the,603,O
potential,603,O
to,603,O
modulate,603,O
transcription,603,O
indirectly,603,O
by,603,O
perturbing,603,O
levels,603,O
of,603,O
sterols,603,O
and,603,O
other,603,O
mevalonate,603,B-CHEMICAL
metabolites,603,O
.,603,O
Expression,604,O
analysis,604,O
following,604,O
treatment,604,O
of,604,O
the,604,O
HNSCC,604,O
cell,604,O
lines,604,O
SCC9,604,O
or,604,O
SCC25,604,O
with,604,O
10,604,O
microM,604,O
lovastatin,604,B-CHEMICAL
for,604,O
1,604,O
day,604,O
showed,604,O
that,604,O
less,604,O
than,604,O
2,604,O
%,604,O
(,604,O
9,604,O
cDNAs,604,O
),604,O
of,604,O
the,604,O
588,604,O
cDNAs,604,O
on,604,O
this,604,O
microarray,604,O
were,604,O
affected,604,O
in,604,O
both,604,O
cell,604,O
lines,604,O
.,604,O
These,605,O
included,605,O
diazepam-binding,605,B-CHEMICAL
inhibitor/acyl-CoA-binding,605,O
protein,605,I-GENE-Y
",",605,I-GENE-Y
the,605,O
activated,605,B-GENE-Y
transcription,605,I-GENE-Y
factor,605,I-GENE-Y
4,605,I-GENE-Y
and,605,O
rhoA,605,B-GENE-Y
.,605,O
Because,606,O
the,606,O
biosynthesis,606,O
of,606,O
mevalonate,606,B-CHEMICAL
leads,606,O
to,606,O
its,606,O
incorporation,606,O
into,606,O
more,606,O
than,606,O
a,606,O
dozen,606,O
classes,606,O
of,606,O
end,606,O
products,606,O
",",606,O
their,606,O
role,606,O
in,606,O
lovastatin-induced,606,B-CHEMICAL
apoptosis,606,O
was,606,O
also,606,O
evaluated,606,O
.,606,O
Addition,607,O
of,607,O
the,607,O
metabolites,607,O
of,607,O
all,607,O
the,607,O
major,607,O
branches,607,O
of,607,O
the,607,O
mevalonate,607,B-CHEMICAL
pathway,607,O
indicated,607,O
that,607,O
only,607,O
the,607,O
nonsterol,607,O
moiety,607,O
",",607,O
geranylgeranyl,607,B-CHEMICAL
pyrophosphate,607,I-CHEMICAL
(,607,O
GGPP,607,B-CHEMICAL
),607,O
",",607,O
significantly,607,O
inhibited,607,O
the,607,O
apoptotic,607,O
effects,607,O
of,607,O
lovastatin,607,B-CHEMICAL
in,607,O
HNSCC,607,O
and,607,O
CC,607,O
cells,607,O
.,607,O
Because,608,O
rhoA,608,B-GENE-Y
requires,608,O
GGPP,608,B-CHEMICAL
for,608,O
its,608,O
function,608,O
",",608,O
this,608,O
links,608,O
the,608,O
microarray,608,O
and,608,O
biochemical,608,O
data,608,O
and,608,O
identifies,608,O
rhoA,608,B-GENE-Y
as,608,O
a,608,O
potential,608,O
mediator,608,O
of,608,O
the,608,O
anticancer,608,O
properties,608,O
of,608,O
lovastatin,608,B-CHEMICAL
.,608,O
Our,609,O
data,609,O
suggest,609,O
that,609,O
the,609,O
depletion,609,O
of,609,O
nonsterol,609,O
mevalonate,609,O
metabolites,609,O
",",609,O
particularly,609,O
GGPP,609,B-CHEMICAL
",",609,O
can,609,O
be,609,O
potential,609,O
mediators,609,O
of,609,O
lovastatin-induced,609,B-CHEMICAL
apoptosis,609,O
of,609,O
HNSCC,609,O
and,609,O
CC,609,O
cells,609,O
.,609,O
Regulation,610,O
of,610,O
norepinephrine,610,B-GENE-Y
transporter,610,I-GENE-Y
abundance,610,O
by,610,O
catecholamines,610,B-CHEMICAL
and,610,O
desipramine,610,B-CHEMICAL
in,610,O
vivo,610,O
.,610,O
The,611,O
norepinephrine,611,B-CHEMICAL
transporter,611,I-GENE-Y
(,611,O
NET,611,B-GENE-Y
),611,O
regulates,611,O
adrenoreceptor,611,B-GENE-N
signaling,611,O
by,611,O
controlling,611,O
the,611,O
availability,611,O
of,611,O
synaptic,611,O
norepinephrine,611,B-CHEMICAL
(,611,O
NE,611,B-CHEMICAL
),611,O
",",611,O
and,611,O
it,611,O
is,611,O
a,611,O
direct,611,O
target,611,O
for,611,O
some,611,O
classes,611,O
of,611,O
antidepressant,611,O
drugs,611,O
.,611,O
NET,612,B-GENE-Y
levels,612,O
are,612,O
normal,612,O
in,612,O
dopamine,612,B-GENE-Y
beta-hydroxylase,612,I-GENE-Y
knockout,612,O
(,612,O
Dbh,612,B-GENE-Y
-/-,612,O
),612,O
mice,612,O
that,612,O
lack,612,O
NE,612,B-CHEMICAL
",",612,O
demonstrating,612,O
that,612,O
the,612,O
NET,612,B-GENE-Y
does,612,O
not,612,O
require,612,O
endogenous,612,O
NE,612,B-CHEMICAL
for,612,O
appropriate,612,O
regulation,612,O
under,612,O
physiological,612,O
conditions,612,O
.,612,O
In,613,O
contrast,613,O
",",613,O
tyrosine,613,B-GENE-Y
hydroxylase,613,I-GENE-Y
knockout,613,O
(,613,O
Th,613,B-GENE-Y
-/-,613,O
),613,O
mice,613,O
that,613,O
lack,613,O
both,613,O
NE,613,B-CHEMICAL
and,613,O
dopamine,613,B-CHEMICAL
(,613,O
DA,613,B-CHEMICAL
),613,O
have,613,O
reduced,613,O
levels,613,O
of,613,O
NET,613,B-GENE-Y
",",613,O
suggesting,613,O
that,613,O
it,613,O
is,613,O
down-regulated,613,O
by,613,O
a,613,O
complete,613,O
absence,613,O
of,613,O
catecholamines,613,B-CHEMICAL
and,613,O
not,613,O
NE,613,B-CHEMICAL
per,613,O
se,613,O
.,613,O
Chronic,614,O
treatment,614,O
with,614,O
the,614,O
NET,614,B-GENE-Y
inhibitor,614,O
",",614,O
desipramine,614,B-CHEMICAL
(,614,O
DMI,614,O
),614,O
",",614,O
reduced,614,O
NET,614,B-GENE-Y
levels,614,O
in,614,O
both,614,O
control,614,O
and,614,O
Dbh,614,B-GENE-Y
-/-,614,O
mice,614,O
",",614,O
demonstrating,614,O
that,614,O
NE,614,B-CHEMICAL
is,614,O
not,614,O
required,614,O
for,614,O
the,614,O
regulation,614,O
of,614,O
NET,614,B-GENE-Y
by,614,O
antidepressant,614,O
drugs,614,O
.,614,O
There,615,O
are,615,O
some,615,O
qualitative,615,O
and,615,O
quantitative,615,O
differences,615,O
in,615,O
the,615,O
down-regulation,615,O
of,615,O
the,615,O
NET,615,B-GENE-Y
by,615,O
catecholamine,615,O
depletion,615,O
and,615,O
DMI,615,O
treatment,615,O
",",615,O
suggesting,615,O
that,615,O
different,615,O
mechanisms,615,O
may,615,O
be,615,O
involved,615,O
.,615,O
Nicotinic,616,B-GENE-N
acetylcholine,616,I-GENE-N
receptor,616,I-GENE-N
regulation,616,O
of,616,O
spinal,616,O
norepinephrine,616,B-CHEMICAL
release,616,O
.,616,O
BACKGROUND,617,O
:,617,O
Neuronal,617,B-GENE-N
nicotinic,617,I-GENE-N
acetylcholine,617,I-GENE-N
receptor,617,I-GENE-N
(,617,O
nAChR,617,B-GENE-N
),617,O
agonists,617,O
produce,617,O
antinociception,617,O
in,617,O
animals,617,O
.,617,O
nAChRs,618,B-GENE-N
exist,618,O
almost,618,O
exclusively,618,O
on,618,O
presynaptic,618,O
terminals,618,O
in,618,O
the,618,O
central,618,O
nervous,618,O
system,618,O
and,618,O
stimulate,618,O
neurotransmitter,618,O
release,618,O
.,618,O
This,619,O
study,619,O
tested,619,O
whether,619,O
nAChR,619,B-GENE-N
agonists,619,O
stimulate,619,O
spinal,619,O
release,619,O
of,619,O
the,619,O
neurotransmitter,619,O
norepinephrine,619,B-CHEMICAL
either,619,O
by,619,O
direct,619,O
actions,619,O
on,619,O
noradrenergic,619,O
terminals,619,O
or,619,O
indirectly,619,O
by,619,O
stimulating,619,O
release,619,O
of,619,O
other,619,O
neurotransmitters,619,O
to,619,O
induce,619,O
norepinephrine,619,B-CHEMICAL
release,619,O
.,619,O
METHODS,620,O
:,620,O
Adult,620,O
male,620,O
rats,620,O
were,620,O
anesthetized,620,O
and,620,O
microdialysis,620,O
probes,620,O
inserted,620,O
in,620,O
the,620,O
L2-L4,620,O
dermatomes,620,O
of,620,O
the,620,O
spinal,620,O
cord,620,O
.,620,O
Probes,621,O
were,621,O
perfused,621,O
with,621,O
artificial,621,O
cerebrospinal,621,O
fluid,621,O
containing,621,O
nicotine,621,O
",",621,O
the,621,O
specific,621,O
alpha,621,B-GENE-Y
(,621,I-GENE-Y
4,621,I-GENE-Y
),621,I-GENE-Y
beta,621,I-GENE-Y
(,621,I-GENE-Y
2,621,I-GENE-Y
*,621,I-GENE-Y
),621,I-GENE-Y
nAChR,621,I-GENE-Y
agonist,621,O
metanicotine,621,B-CHEMICAL
",",621,O
or,621,O
nicotine,621,B-CHEMICAL
plus,621,O
nAChR,621,B-GENE-N
antagonists,621,O
and,621,O
norepinephrine,621,B-CHEMICAL
measured,621,O
in,621,O
the,621,O
microdialysates,621,O
.,621,O
The,622,O
effects,622,O
of,622,O
specific,622,O
glutamate,622,B-GENE-N
receptor,622,I-GENE-N
antagonists,622,O
and,622,O
nitric,622,B-GENE-N
oxide,622,I-GENE-N
synthase,622,I-GENE-N
inhibitors,622,O
were,622,O
also,622,O
examined,622,O
.,622,O
To,623,O
determine,623,O
direct,623,O
effects,623,O
on,623,O
noradrenergic,623,O
terminals,623,O
",",623,O
synaptosomes,623,O
were,623,O
prepared,623,O
from,623,O
spinal,623,O
cord,623,O
and,623,O
incubated,623,O
with,623,O
nAChR,623,B-GENE-N
agonists,623,O
and,623,O
antagonists,623,O
.,623,O
RESULTS,624,O
:,624,O
Both,624,O
nicotine,624,B-CHEMICAL
and,624,O
metanicotine,624,B-CHEMICAL
induced,624,O
norepinephrine,624,B-CHEMICAL
release,624,O
in,624,O
spinal,624,O
microdialsyates,624,O
",",624,O
an,624,O
effect,624,O
reduced,624,O
by,624,O
nicotinic,624,O
antagonists,624,O
but,624,O
not,624,O
glutamate,624,B-CHEMICAL
antagonists,624,O
or,624,O
nitric,624,B-CHEMICAL
oxide,624,I-CHEMICAL
synthase,624,I-GENE-N
inhibitors,624,O
.,624,O
Both,625,O
of,625,O
the,625,O
nicotinic,625,O
agonists,625,O
stimulated,625,O
norepinephrine,625,B-CHEMICAL
release,625,O
in,625,O
synaptosomes,625,O
",",625,O
and,625,O
the,625,O
effect,625,O
of,625,O
metanicotine,625,B-CHEMICAL
was,625,O
blocked,625,O
at,625,O
lower,625,O
concentrations,625,O
of,625,O
alpha,625,B-GENE-Y
(,625,I-GENE-Y
4,625,I-GENE-Y
),625,I-GENE-Y
beta,625,I-GENE-Y
(,625,I-GENE-Y
2,625,I-GENE-Y
*,625,I-GENE-Y
),625,I-GENE-Y
-,625,O
than,625,O
alpha,625,B-GENE-Y
(,625,I-GENE-Y
7,625,I-GENE-Y
*,625,I-GENE-Y
),625,I-GENE-Y
-preferring,625,O
nAChR,625,B-GENE-N
antagonists,625,O
.,625,O
CONCLUSION,626,O
:,626,O
These,626,O
results,626,O
suggest,626,O
that,626,O
one,626,O
mechanism,626,O
by,626,O
which,626,O
nAChR,626,B-GENE-N
agonists,626,O
act,626,O
for,626,O
analgesia,626,O
is,626,O
to,626,O
stimulate,626,O
spinal,626,O
norepinephrine,626,B-CHEMICAL
release,626,O
.,626,O
They,627,O
do,627,O
so,627,O
by,627,O
actions,627,O
on,627,O
alpha,627,B-GENE-Y
(,627,I-GENE-Y
4,627,I-GENE-Y
),627,I-GENE-Y
beta,627,I-GENE-Y
(,627,I-GENE-Y
2,627,I-GENE-Y
*,627,I-GENE-Y
),627,I-GENE-Y
nAChRs,627,I-GENE-Y
",",627,O
and,627,O
perhaps,627,O
other,627,O
subtypes,627,O
",",627,O
most,627,O
likely,627,O
located,627,O
on,627,O
noradrenergic,627,O
terminals,627,O
",",627,O
rather,627,O
than,627,O
by,627,O
indirectly,627,O
stimulating,627,O
norepinephrine,627,B-CHEMICAL
release,627,O
through,627,O
glutamate,627,B-CHEMICAL
release,627,O
or,627,O
nitric,627,B-CHEMICAL
oxide,627,I-CHEMICAL
synthesis,627,O
.,627,O
The,628,O
pharmacology,628,O
of,628,O
cilostazol,628,B-CHEMICAL
.,628,O
Cilostazol,629,B-CHEMICAL
(,629,B-CHEMICAL
6-,629,I-CHEMICAL
[,629,I-CHEMICAL
4-,629,I-CHEMICAL
(,629,I-CHEMICAL
1-cyclohexyl-1H-tetrazol-5-yl,629,I-CHEMICAL
),629,I-CHEMICAL
butoxy,629,I-CHEMICAL
],629,I-CHEMICAL
"-3,4-dihydro-2",629,I-CHEMICAL
(,629,I-CHEMICAL
1H,629,I-CHEMICAL
),629,I-CHEMICAL
-quinolinone,629,I-CHEMICAL
;,629,O
OPC-13013,629,B-CHEMICAL
),629,O
is,629,O
a,629,O
2-oxo-quinoline,629,B-CHEMICAL
derivative,629,O
with,629,O
antithrombotic,629,O
",",629,O
vasodilator,629,O
",",629,O
antimitogenic,629,O
and,629,O
cardiotonic,629,O
properties,629,O
.,629,O
The,630,O
compound,630,O
is,630,O
a,630,O
potent,630,O
inhibitor,630,O
of,630,O
phosphodiesterase,630,B-GENE-Y
(,630,I-GENE-Y
PDE,630,I-GENE-Y
),630,I-GENE-Y
3A,630,I-GENE-Y
",",630,O
the,630,O
isoform,630,O
of,630,O
PDE,630,B-GENE-N
3,630,I-GENE-N
in,630,O
the,630,O
cardiovascular,630,O
system,630,O
(,630,O
IC50,630,O
:,630,O
0.2,630,O
microM,630,O
),630,O
.,630,O
In,631,O
addition,631,O
",",631,O
there,631,O
is,631,O
inhibition,631,O
of,631,O
adenosine,631,B-CHEMICAL
uptake,631,O
",",631,O
eventually,631,O
resulting,631,O
in,631,O
changes,631,O
in,631,O
cAMP,631,B-CHEMICAL
levels,631,O
",",631,O
dependent,631,O
on,631,O
the,631,O
type,631,O
of,631,O
adenosine,631,B-CHEMICAL
receptors,631,I-GENE-N
(,631,I-GENE-N
A1,631,I-GENE-N
or,631,I-GENE-N
A2,631,I-GENE-N
),631,I-GENE-N
.,631,O
Cilostazol,632,B-CHEMICAL
inhibits,632,O
platelet,632,O
aggregation,632,O
and,632,O
has,632,O
considerable,632,O
antithrombotic,632,O
effects,632,O
in,632,O
vivo,632,O
.,632,O
The,633,O
compound,633,O
relaxes,633,O
vascular,633,O
smooth,633,O
muscle,633,O
and,633,O
inhibits,633,O
mitogenesis,633,O
and,633,O
migration,633,O
of,633,O
vascular,633,O
smooth,633,O
muscle,633,O
cells,633,O
.,633,O
In,634,O
the,634,O
heart,634,O
",",634,O
cilostazol,634,B-CHEMICAL
causes,634,O
positive,634,O
inotropic,634,O
and,634,O
chronotropic,634,O
effects,634,O
.,634,O
Most,635,O
",",635,O
if,635,O
not,635,O
all,635,O
",",635,O
of,635,O
these,635,O
actions,635,O
are,635,O
cAMP-mediated,635,B-CHEMICAL
",",635,O
including,635,O
the,635,O
modification,635,O
of,635,O
cAMP-controlled,635,B-CHEMICAL
gene,635,O
expression,635,O
.,635,O
Cilostazol,636,B-CHEMICAL
decreases,636,O
levels,636,O
of,636,O
serum,636,O
triglycerides,636,O
and,636,O
causes,636,O
some,636,O
increase,636,O
in,636,O
HDL-cholesterol,636,B-GENE-N
levels,636,O
.,636,O
The,637,O
compound,637,O
has,637,O
a,637,O
number,637,O
of,637,O
additional,637,O
effects,637,O
which,637,O
might,637,O
contribute,637,O
to,637,O
its,637,O
overall,637,O
clinical,637,O
efficacy,637,O
.,637,O
Cilostazol,638,B-CHEMICAL
undergoes,638,O
intensive,638,O
and,638,O
finally,638,O
complete,638,O
hepatic,638,O
metabolism,638,O
via,638,O
the,638,O
cytochrome,638,B-GENE-N
P450,638,I-GENE-N
systems,638,O
.,638,O
This,639,O
might,639,O
result,639,O
in,639,O
some,639,O
drug,639,O
interaction,639,O
",",639,O
i.e,639,O
.,639,O
with,640,O
erythromycin,640,B-CHEMICAL
and,640,O
omeprazole,640,B-CHEMICAL
.,640,O
The,641,O
half-life,641,O
is,641,O
approximately,641,O
10,641,O
h,641,O
",",641,O
resulting,641,O
in,641,O
about,641,O
2-fold,641,O
accumulation,641,O
of,641,O
the,641,O
drug,641,O
during,641,O
repeated,641,O
administration,641,O
.,641,O
Identification,642,O
of,642,O
interaction,642,O
sites,642,O
of,642,O
cyclic,642,O
nucleotide,642,B-CHEMICAL
phosphodiesterase,642,B-GENE-Y
type,642,I-GENE-Y
3A,642,I-GENE-Y
with,642,O
milrinone,642,B-CHEMICAL
and,642,O
cilostazol,642,B-CHEMICAL
using,642,O
molecular,642,O
modeling,642,O
and,642,O
site-directed,642,O
mutagenesis,642,O
.,642,O
To,643,O
identify,643,O
amino,643,B-CHEMICAL
acid,643,I-CHEMICAL
residues,643,O
involved,643,O
in,643,O
PDE3-selective,643,B-GENE-Y
inhibitor,643,O
binding,643,O
",",643,O
we,643,O
selected,643,O
eight,643,O
presumed,643,O
interacting,643,O
residues,643,O
in,643,O
the,643,O
substrate-binding,643,O
pocket,643,O
of,643,O
PDE3A,643,B-GENE-Y
using,643,O
a,643,O
model,643,O
created,643,O
on,643,O
basis,643,O
of,643,O
homology,643,O
to,643,O
the,643,O
PDE4B,643,B-GENE-Y
crystal,643,O
structure,643,O
.,643,O
We,644,O
changed,644,O
the,644,O
residues,644,O
to,644,O
alanine,644,B-CHEMICAL
using,644,O
site-directed,644,O
mutagenesis,644,O
technique,644,O
",",644,O
expressed,644,O
the,644,O
mutants,644,O
in,644,O
a,644,O
baculovirus/Sf9,644,O
cell,644,O
system,644,O
",",644,O
and,644,O
analyzed,644,O
the,644,O
kinetic,644,O
characteristics,644,O
of,644,O
inhibition,644,O
of,644,O
the,644,O
mutant,644,O
enzymes,644,O
by,644,O
milrinone,644,B-CHEMICAL
and,644,O
cilostazol,644,B-CHEMICAL
",",644,O
specific,644,O
inhibitors,644,O
of,644,O
PDE3,644,B-GENE-Y
.,644,O
The,645,O
mutants,645,O
displayed,645,O
differential,645,O
sensitivity,645,O
to,645,O
the,645,O
inhibitors,645,O
.,645,O
Mutants,646,O
Y751A,646,B-GENE-N
",",646,O
D950A,646,B-GENE-N
",",646,O
and,646,O
F1004A,646,B-GENE-N
had,646,O
reduced,646,O
sensitivity,646,O
to,646,O
milrinone,646,B-CHEMICAL
(,646,O
K,646,O
(,646,O
i,646,O
),646,O
changed,646,O
from,646,O
0.66,646,O
microM,646,O
for,646,O
the,646,O
recombinant,646,O
PDE3A,646,B-GENE-Y
to,646,O
7.5,646,O
to,646,O
156,646,O
microM,646,O
for,646,O
the,646,O
mutants,646,O
),646,O
",",646,O
and,646,O
diminished,646,O
sensitivity,646,O
to,646,O
cilostazol,646,B-CHEMICAL
(,646,O
K,646,O
(,646,O
i,646,O
),646,O
of,646,O
the,646,O
mutants,646,O
were,646,O
18-,646,O
to,646,O
371-fold,646,O
higher,646,O
than,646,O
that,646,O
of,646,O
the,646,O
recombinant,646,O
PDE3A,646,B-GENE-Y
),646,O
.,646,O
In,647,O
contrast,647,O
",",647,O
the,647,O
mutants,647,O
T844A,647,B-GENE-N
",",647,O
F972A,647,B-GENE-N
and,647,O
Q975A,647,B-GENE-N
showed,647,O
increased,647,O
K,647,O
(,647,O
i,647,O
),647,O
for,647,O
cilostazol,647,B-CHEMICAL
but,647,O
no,647,O
difference,647,O
for,647,O
milrinone,647,B-CHEMICAL
from,647,O
the,647,O
recombinant,647,O
PDE3A,647,B-GENE-Y
.,647,O
Molecular,648,O
models,648,O
show,648,O
that,648,O
the,648,O
PDE3,648,B-GENE-Y
inhibitors,648,O
cilostazol,648,B-CHEMICAL
and,648,O
milrinone,648,B-CHEMICAL
share,648,O
some,648,O
of,648,O
common,648,O
residues,648,O
but,648,O
interact,648,O
with,648,O
distinct,648,O
residues,648,O
at,648,O
the,648,O
active,648,O
site,648,O
",",648,O
suggesting,648,O
that,648,O
selective,648,O
inhibitors,648,O
can,648,O
be,648,O
designed,648,O
with,648,O
flexible,648,O
size,648,O
against,648,O
PDE3,648,B-GENE-Y
active,648,O
site,648,O
.,648,O
Our,649,O
study,649,O
implies,649,O
that,649,O
highly,649,O
conserved,649,O
residuals,649,O
Y751,649,O
",",649,O
D950,649,O
and,649,O
F1004,649,O
in,649,O
the,649,O
PDE,649,B-GENE-Y
families,649,O
are,649,O
key,649,O
residues,649,O
for,649,O
binding,649,O
of,649,O
both,649,O
substrate,649,O
and,649,O
inhibitors,649,O
",",649,O
and,649,O
nonconserved,649,O
T844,649,O
may,649,O
be,649,O
responsible,649,O
for,649,O
the,649,O
cilostazol,649,B-CHEMICAL
selectivity,649,O
of,649,O
PDE3A,649,B-GENE-Y
.,649,O
Detailed,650,O
knowledge,650,O
of,650,O
the,650,O
structure,650,O
of,650,O
inhibitory,650,O
sites,650,O
should,650,O
contribute,650,O
to,650,O
development,650,O
of,650,O
more,650,O
potent,650,O
and,650,O
specific,650,O
inhibitory,650,O
drugs,650,O
.,650,O
Enzymatic,651,O
catalysis,651,O
in,651,O
crystals,651,O
of,651,O
Escherichia,651,B-GENE-Y
coli,651,I-GENE-Y
maltodextrin,651,I-GENE-Y
phosphorylase,651,I-GENE-Y
.,651,O
The,652,O
bacterial,652,O
enzyme,652,O
maltodextrin,652,B-GENE-N
phosphorylase,652,I-GENE-N
(,652,O
MalP,652,B-GENE-N
),652,O
catalyses,652,O
the,652,O
phosphorolysis,652,O
of,652,O
an,652,O
"alpha-1,4-glycosidic",652,O
bond,652,O
in,652,O
maltodextrins,652,O
",",652,O
removing,652,O
the,652,O
non-reducing,652,O
glucosyl,652,B-CHEMICAL
residues,652,O
of,652,O
linear,652,O
oligosaccharides,652,O
as,652,O
glucose-1-phosphate,652,B-CHEMICAL
(,652,O
Glc1P,652,B-CHEMICAL
),652,O
.,652,O
In,653,O
contrast,653,O
to,653,O
the,653,O
well-studied,653,O
muscle,653,O
glycogen,653,B-GENE-Y
phosphorylase,653,I-GENE-Y
(,653,O
GP,653,B-GENE-Y
),653,O
",",653,O
MalP,653,B-GENE-Y
exhibits,653,O
no,653,O
allosteric,653,O
properties,653,O
and,653,O
has,653,O
a,653,O
higher,653,O
affinity,653,O
for,653,O
linear,653,O
oligosaccharides,653,O
than,653,O
GP,653,B-GENE-Y
.,653,O
We,654,O
have,654,O
used,654,O
MalP,654,B-GENE-Y
as,654,O
a,654,O
model,654,O
system,654,O
to,654,O
study,654,O
catalysis,654,O
in,654,O
the,654,O
crystal,654,O
in,654,O
the,654,O
direction,654,O
of,654,O
maltodextrin,654,O
synthesis,654,O
.,654,O
The,655,O
2.0A,655,O
crystal,655,O
structure,655,O
of,655,O
the,655,O
MalP/Glc1P,655,B-GENE-Y
binary,655,O
complex,655,O
shows,655,O
that,655,O
the,655,O
Glc1P,655,B-CHEMICAL
substrate,655,O
adopts,655,O
a,655,O
conformation,655,O
seen,655,O
previously,655,O
with,655,O
both,655,O
inactive,655,O
and,655,O
active,655,O
forms,655,O
of,655,O
mammalian,655,B-GENE-N
GP,655,I-GENE-N
",",655,O
with,655,O
the,655,O
phosphate,655,B-CHEMICAL
group,655,O
not,655,O
in,655,O
close,655,O
contact,655,O
with,655,O
the,655,O
5'-phosphate,655,B-CHEMICAL
group,655,O
of,655,O
the,655,O
essential,655,O
pyridoxal,655,B-CHEMICAL
phosphate,655,I-CHEMICAL
(,655,O
PLP,655,B-CHEMICAL
),655,O
cofactor,655,O
.,655,O
In,656,O
the,656,O
active,656,O
MalP,656,B-GENE-Y
enzyme,656,O
",",656,O
the,656,O
residue,656,O
Arg569,656,O
stabilizes,656,O
the,656,O
negative-charged,656,O
Glc1P,656,B-CHEMICAL
",",656,O
whereas,656,O
in,656,O
the,656,O
inactive,656,O
form,656,O
of,656,O
GP,656,B-GENE-Y
this,656,O
key,656,O
residue,656,O
is,656,O
held,656,O
away,656,O
from,656,O
the,656,O
catalytic,656,O
site,656,O
by,656,O
loop,656,O
280s,656,O
and,656,O
an,656,O
allosteric,656,O
transition,656,O
of,656,O
the,656,O
mammalian,656,O
enzyme,656,O
is,656,O
required,656,O
for,656,O
activation,656,O
.,656,O
The,657,O
comparison,657,O
between,657,O
MalP,657,B-GENE-Y
structures,657,O
shows,657,O
that,657,O
His377,657,O
",",657,O
through,657,O
a,657,O
hydrogen,657,O
bond,657,O
with,657,O
the,657,O
6-hydroxyl,657,B-CHEMICAL
group,657,O
of,657,O
Glc1P,657,B-CHEMICAL
substrate,657,O
",",657,O
triggers,657,O
a,657,O
conformational,657,O
change,657,O
of,657,O
the,657,O
380s,657,O
loop,657,O
.,657,O
This,658,O
mobile,658,O
region,658,O
folds,658,O
over,658,O
the,658,O
catalytic,658,O
site,658,O
and,658,O
contributes,658,O
to,658,O
the,658,O
specific,658,O
recognition,658,O
of,658,O
the,658,O
oligosaccharide,658,O
and,658,O
to,658,O
the,658,O
synergism,658,O
between,658,O
substrates,658,O
in,658,O
promoting,658,O
the,658,O
formation,658,O
of,658,O
the,658,O
MalP,658,B-GENE-Y
ternary,658,O
complex,658,O
.,658,O
The,659,O
structures,659,O
solved,659,O
after,659,O
the,659,O
diffusion,659,O
of,659,O
oligosaccharides,659,O
(,659,O
either,659,O
maltotetraose,659,B-CHEMICAL
",",659,O
G4,659,O
or,659,O
maltopentaose,659,B-CHEMICAL
",",659,O
G5,659,O
),659,O
into,659,O
MalP/Glc1P,659,B-GENE-Y
crystals,659,O
show,659,O
the,659,O
formation,659,O
of,659,O
phosphate,659,B-CHEMICAL
and,659,O
elongation,659,O
of,659,O
the,659,O
oligosaccharide,659,O
chain,659,O
.,659,O
These,660,O
structures,660,O
",",660,O
refined,660,O
at,660,O
1.8A,660,O
and,660,O
at,660,O
2.2A,660,O
",",660,O
confirm,660,O
that,660,O
only,660,O
when,660,O
an,660,O
oligosaccharide,660,O
is,660,O
bound,660,O
to,660,O
the,660,O
catalytic,660,O
site,660,O
will,660,O
Glc1P,660,B-CHEMICAL
bend,660,O
its,660,O
phosphate,660,B-CHEMICAL
group,660,O
down,660,O
so,660,O
it,660,O
can,660,O
contact,660,O
the,660,O
PLP,660,B-CHEMICAL
5,660,B-CHEMICAL
',660,I-CHEMICAL
phosphate,660,I-CHEMICAL
group,660,O
and,660,O
promote,660,O
catalysis,660,O
.,660,O
The,661,O
relatively,661,O
large,661,O
oligosaccharide,661,O
substrates,661,O
can,661,O
diffuse,661,O
quickly,661,O
into,661,O
the,661,O
MalP/Glc1P,661,B-GENE-Y
crystals,661,O
and,661,O
the,661,O
enzymatic,661,O
reaction,661,O
can,661,O
occur,661,O
without,661,O
significant,661,O
crystal,661,O
damage,661,O
.,661,O
These,662,O
structures,662,O
obtained,662,O
before,662,O
and,662,O
after,662,O
catalysis,662,O
have,662,O
been,662,O
used,662,O
as,662,O
frames,662,O
of,662,O
a,662,O
molecular,662,O
movie,662,O
.,662,O
This,663,O
movie,663,O
reveals,663,O
the,663,O
relative,663,O
positions,663,O
of,663,O
substrates,663,O
in,663,O
the,663,O
catalytic,663,O
channel,663,O
and,663,O
shows,663,O
a,663,O
minimal,663,O
movement,663,O
of,663,O
the,663,O
protein,663,O
",",663,O
involving,663,O
mainly,663,O
Arg569,663,O
",",663,O
which,663,O
tracks,663,O
the,663,O
substrate,663,O
phosphate,663,B-CHEMICAL
group,663,O
.,663,O
The,664,O
pharmacokinetics,664,O
of,664,O
fondaparinux,664,B-CHEMICAL
sodium,664,I-CHEMICAL
in,664,O
healthy,664,O
volunteers,664,O
.,664,O
OBJECTIVE,665,O
:,665,O
Fondaparinux,665,B-CHEMICAL
sodium,665,I-CHEMICAL
is,665,O
the,665,O
first,665,O
in,665,O
a,665,O
new,665,O
class,665,O
of,665,O
synthetic,665,O
factor,665,B-GENE-Y
Xa,665,I-GENE-Y
inhibitors,665,O
that,665,O
binds,665,O
reversibly,665,O
with,665,O
high,665,O
affinity,665,O
to,665,O
antithrombin,665,B-GENE-Y
III,665,I-GENE-Y
.,665,O
It,666,O
has,666,O
been,666,O
investigated,666,O
for,666,O
the,666,O
prevention,666,O
and,666,O
treatment,666,O
of,666,O
arterial,666,O
and,666,O
venous,666,O
thrombotic,666,O
disorders,666,O
and,666,O
approved,666,O
for,666,O
use,666,O
at,666,O
a,666,O
dose,666,O
of,666,O
2.5mg,666,O
once,666,O
daily,666,O
in,666,O
the,666,O
prevention,666,O
of,666,O
venous,666,O
thromboembolism,666,O
in,666,O
major,666,O
orthopaedic,666,O
surgery,666,O
.,666,O
The,667,O
pharmacokinetics,667,O
of,667,O
fondaparinux,667,B-CHEMICAL
sodium,667,I-CHEMICAL
were,667,O
determined,667,O
in,667,O
eight,667,O
studies,667,O
in,667,O
young,667,O
and,667,O
elderly,667,O
healthy,667,O
volunteers,667,O
.,667,O
RESULTS,668,O
:,668,O
After,668,O
a,668,O
2.5mg,668,O
subcutaneous,668,O
dose,668,O
to,668,O
young,668,O
volunteers,668,O
",",668,O
absolute,668,O
bioavailability,668,O
was,668,O
100,668,O
%,668,O
and,668,O
absorption,668,O
was,668,O
rapid,668,O
and,668,O
complete,668,O
[,668,O
peak,668,O
plasma,668,O
concentration,668,O
(,668,O
C,668,O
(,668,O
max,668,O
),668,O
),668,O
0.34,668,O
mg/L,668,O
occurred,668,O
at,668,O
approximately,668,O
2,668,O
hours,668,O
],668,O
.,668,O
Within-,669,O
and,669,O
total-subject,669,O
variability,669,O
estimates,669,O
were,669,O
small,669,O
:,669,O
5.5,669,O
and,669,O
11.6,669,O
%,669,O
",",669,O
respectively,669,O
",",669,O
for,669,O
C,669,O
(,669,O
max,669,O
),669,O
and,669,O
4.4,669,O
and,669,O
17.5,669,O
%,669,O
for,669,O
area,669,O
under,669,O
the,669,O
concentration-time,669,O
curve,669,O
(,669,O
AUC,669,O
),669,O
.,669,O
Steady,670,O
state,670,O
was,670,O
obtained,670,O
after,670,O
the,670,O
third,670,O
or,670,O
fourth,670,O
once-daily,670,O
dose,670,O
",",670,O
with,670,O
a,670,O
1.3-fold,670,O
increase,670,O
in,670,O
C,670,O
(,670,O
max,670,O
),670,O
and,670,O
AUC,670,O
.,670,O
Distribution,671,O
volume,671,O
(,671,O
7,671,O
to,671,O
11L,671,O
),671,O
was,671,O
limited,671,O
to,671,O
blood,671,O
volume,671,O
.,671,O
There,672,O
was,672,O
no,672,O
evidence,672,O
of,672,O
metabolism,672,O
.,672,O
Fondaparinux,673,B-CHEMICAL
sodium,673,I-CHEMICAL
was,673,O
almost,673,O
completely,673,O
excreted,673,O
in,673,O
urine,673,O
as,673,O
unchanged,673,O
compound,673,O
(,673,O
64,673,O
to,673,O
77,673,O
%,673,O
of,673,O
the,673,O
dose,673,O
was,673,O
recovered,673,O
at,673,O
72,673,O
hours,673,O
after,673,O
administration,673,O
),673,O
.,673,O
Plasma,674,O
clearance,674,O
was,674,O
5.1,674,O
to,674,O
7.9,674,O
ml/min,674,O
",",674,O
renal,674,O
clearance,674,O
4.0,674,O
to,674,O
7.9,674,O
ml/min,674,O
",",674,O
and,674,O
the,674,O
terminal,674,O
half-life,674,O
was,674,O
17,674,O
hours,674,O
in,674,O
young,674,O
volunteers,674,O
and,674,O
21,674,O
hours,674,O
in,674,O
elderly,674,O
volunteers,674,O
.,674,O
Pharmacokinetics,675,O
of,675,O
fondaparinux,675,B-CHEMICAL
sodium,675,I-CHEMICAL
were,675,O
linear,675,O
in,675,O
the,675,O
range,675,O
2,675,O
to,675,O
8mg,675,O
subcutaneously,675,O
and,675,O
2,675,O
to,675,O
20mg,675,O
intravenously,675,O
.,675,O
Pharmacokinetics,676,O
observed,676,O
in,676,O
healthy,676,O
elderly,676,O
volunteers,676,O
were,676,O
consistent,676,O
with,676,O
findings,676,O
in,676,O
young,676,O
male,676,O
volunteers,676,O
.,676,O
CONCLUSION,677,O
:,677,O
The,677,O
favourable,677,O
pharmacokinetic,677,O
profile,677,O
of,677,O
fondaparinux,677,B-CHEMICAL
sodium,677,I-CHEMICAL
is,677,O
likely,677,O
to,677,O
play,677,O
an,677,O
important,677,O
role,677,O
in,677,O
the,677,O
major,677,O
advance,677,O
that,677,O
the,677,O
drug,677,O
represents,677,O
in,677,O
the,677,O
prevention,677,O
and,677,O
treatment,677,O
of,677,O
thrombotic,677,O
disorders,677,O
.,677,O
Molecular,678,O
analysis,678,O
of,678,O
PCCB,678,B-GENE-Y
gene,678,O
in,678,O
Korean,678,O
patients,678,O
with,678,O
propionic,678,B-CHEMICAL
acidemia,678,O
.,678,O
Propionic,679,O
acidemia,679,O
(,679,O
PA,679,O
),679,O
is,679,O
an,679,O
autosomal,679,O
recessive,679,O
inborn,679,O
error,679,O
in,679,O
the,679,O
catabolism,679,O
of,679,O
methionine,679,B-CHEMICAL
",",679,O
isoleucine,679,B-CHEMICAL
",",679,O
threonine,679,B-CHEMICAL
",",679,O
and,679,O
valine,679,B-CHEMICAL
",",679,O
odd-numbered,679,B-CHEMICAL
chain,679,I-CHEMICAL
length,679,I-CHEMICAL
fatty,679,I-CHEMICAL
acids,679,I-CHEMICAL
and,679,O
cholesterol,679,B-CHEMICAL
.,679,O
Clinical,680,O
symptoms,680,O
are,680,O
very,680,O
heterogeneous,680,O
and,680,O
present,680,O
as,680,O
a,680,O
severe,680,O
neonatal-onset,680,O
or,680,O
a,680,O
late-onset,680,O
form,680,O
.,680,O
It,681,O
is,681,O
caused,681,O
by,681,O
a,681,O
deficiency,681,O
of,681,O
propionyl-CoA,681,B-CHEMICAL
carboxylase,681,I-GENE-N
(,681,O
PCC,681,B-GENE-N
",",681,O
EC,681,B-GENE-Y
6.4.1.3,681,I-GENE-Y
),681,O
",",681,O
a,681,O
biotin-dependent,681,B-CHEMICAL
enzyme,681,O
that,681,O
catalyzes,681,O
the,681,O
carboxylation,681,O
of,681,O
propionyl-CoA,681,B-CHEMICAL
to,681,O
D-methylmalonyl-CoA,681,B-CHEMICAL
.,681,O
PCC,682,B-GENE-N
is,682,O
a,682,O
heteropolymeric,682,O
enzyme,682,O
composed,682,O
of,682,O
alpha-,682,O
and,682,O
beta-subunits,682,O
.,682,O
A,683,O
greater,683,O
heterogeneity,683,O
is,683,O
observed,683,O
in,683,O
the,683,O
PCCA,683,B-GENE-Y
gene,683,O
",",683,O
while,683,O
for,683,O
the,683,O
PCCB,683,B-GENE-Y
gene,683,O
",",683,O
a,683,O
limited,683,O
number,683,O
of,683,O
mutations,683,O
is,683,O
responsible,683,O
for,683,O
the,683,O
majority,683,O
of,683,O
the,683,O
alleles,683,O
characterized,683,O
in,683,O
both,683,O
Caucasian,683,O
and,683,O
Oriental,683,O
populations,683,O
.,683,O
We,684,O
identified,684,O
eight,684,O
Korean,684,O
patients,684,O
with,684,O
PA,684,O
by,684,O
organic,684,O
acid,684,O
analysis,684,O
confirmed,684,O
in,684,O
five,684,O
patients,684,O
by,684,O
the,684,O
PCC,684,B-GENE-N
enzyme,684,O
assay,684,O
in,684,O
the,684,O
lymphoblasts,684,O
.,684,O
Two,685,O
neonatal-onset,685,O
patients,685,O
showed,685,O
undetectable,685,O
PCC,685,B-GENE-N
activities,685,O
while,685,O
three,685,O
cases,685,O
with,685,O
residual,685,O
enzyme,685,O
activities,685,O
had,685,O
relatively,685,O
late,685,O
manifestations,685,O
.,685,O
In,686,O
the,686,O
molecular,686,O
analysis,686,O
",",686,O
we,686,O
identified,686,O
five,686,O
novel,686,O
mutations,686,O
",",686,O
Y439C,686,B-GENE-N
",",686,O
1527del3,686,O
",",686,O
1357insT,686,O
",",686,O
IVS12-8T,686,B-GENE-N
--,686,I-GENE-N
>,686,I-GENE-N
A,686,I-GENE-N
",",686,O
and,686,O
31del10,686,O
",",686,O
and,686,O
one,686,O
known,686,O
mutation,686,O
",",686,O
T428I,686,B-GENE-N
in,686,O
PCCB,686,B-GENE-Y
gene,686,O
.,686,O
Alleleic,687,O
frequency,687,O
of,687,O
T428I,687,B-GENE-N
in,687,O
Korean,687,O
patients,687,O
with,687,O
PA,687,O
was,687,O
56.3,687,O
%,687,O
in,687,O
this,687,O
study,687,O
.,687,O
Two,688,O
neonatal-onset,688,O
patients,688,O
with,688,O
null,688,O
enzyme,688,O
activities,688,O
were,688,O
homozygotes,688,O
with,688,O
1527del3,688,O
and,688,O
T428I,688,B-GENE-N
",",688,O
respectively,688,O
.,688,O
This,689,O
finding,689,O
implies,689,O
that,689,O
T428I,689,B-GENE-N
and,689,O
1527del3,689,O
mutation,689,O
could,689,O
be,689,O
responsible,689,O
for,689,O
their,689,O
severe,689,O
clinical,689,O
courses,689,O
and,689,O
null,689,O
enzyme,689,O
activities,689,O
.,689,O
The,690,O
mRNA,690,O
of,690,O
PCCB,690,B-GENE-Y
gene,690,O
in,690,O
T428I,690,B-GENE-N
and,690,O
1527del3,690,O
homozygotes,690,O
were,690,O
normal,690,O
but,690,O
in,690,O
Western,690,O
blot,690,O
analysis,690,O
",",690,O
the,690,O
betaPCC-subunit,690,B-GENE-Y
was,690,O
only,690,O
absent,690,O
in,690,O
1527del3,690,O
homozygote,690,O
patient,690,O
suggesting,690,O
different,690,O
molecular,690,O
pathology,690,O
.,690,O
Atypical,691,O
antipsychotic,691,O
drugs,691,O
",",691,O
quetiapine,691,B-CHEMICAL
",",691,O
iloperidone,691,B-CHEMICAL
",",691,O
and,691,O
melperone,691,B-CHEMICAL
",",691,O
preferentially,691,O
increase,691,O
dopamine,691,B-CHEMICAL
and,691,O
acetylcholine,691,B-CHEMICAL
release,691,O
in,691,O
rat,691,O
medial,691,O
prefrontal,691,O
cortex,691,O
:,691,O
role,691,O
of,691,O
5-HT1A,691,B-GENE-Y
receptor,691,O
agonism,691,O
.,691,O
Preferential,692,O
increases,692,O
in,692,O
both,692,O
cortical,692,O
dopamine,692,B-CHEMICAL
(,692,O
DA,692,B-CHEMICAL
),692,O
and,692,O
acetylcholine,692,B-CHEMICAL
(,692,O
ACh,692,B-CHEMICAL
),692,O
release,692,O
have,692,O
been,692,O
proposed,692,O
to,692,O
distinguish,692,O
the,692,O
atypical,692,O
antipsychotic,692,O
drugs,692,O
(,692,O
APDs,692,O
),692,O
clozapine,692,B-CHEMICAL
",",692,O
olanzapine,692,B-CHEMICAL
",",692,O
risperidone,692,B-CHEMICAL
and,692,O
ziprasidone,692,B-CHEMICAL
from,692,O
typical,692,O
APDs,692,O
such,692,O
as,692,O
haloperidol,692,B-CHEMICAL
.,692,O
Although,693,O
only,693,O
clozapine,693,B-CHEMICAL
and,693,O
ziprasidone,693,B-CHEMICAL
are,693,O
directly,693,O
acting,693,O
5-HT,693,B-GENE-Y
(,693,I-GENE-Y
1A,693,I-GENE-Y
),693,I-GENE-Y
agonists,693,O
",",693,O
WAY100635,693,B-CHEMICAL
",",693,O
a,693,O
selective,693,O
5-HT,693,B-GENE-Y
(,693,I-GENE-Y
1A,693,I-GENE-Y
),693,I-GENE-Y
antagonist,693,O
",",693,O
partially,693,O
attenuates,693,O
these,693,O
atypical,693,O
APD-induced,693,O
increases,693,O
in,693,O
cortical,693,O
DA,693,B-CHEMICAL
release,693,O
that,693,O
may,693,O
be,693,O
due,693,O
to,693,O
combined,693,O
5-HT,693,B-GENE-Y
(,693,I-GENE-Y
2A,693,I-GENE-Y
),693,I-GENE-Y
and,693,O
D,693,B-GENE-Y
(,693,I-GENE-Y
2,693,I-GENE-Y
),693,I-GENE-Y
blockade,693,O
.,693,O
However,694,O
",",694,O
WAY100635,694,B-CHEMICAL
does,694,O
not,694,O
attenuate,694,O
clozapine-induced,694,B-CHEMICAL
cortical,694,O
ACh,694,B-CHEMICAL
release,694,O
.,694,O
The,695,O
present,695,O
study,695,O
determined,695,O
whether,695,O
quetiapine,695,B-CHEMICAL
",",695,O
iloperidone,695,B-CHEMICAL
and,695,O
melperone,695,B-CHEMICAL
",",695,O
5-HT,695,B-GENE-Y
(,695,I-GENE-Y
2A,695,I-GENE-Y
),695,I-GENE-Y
/D,695,O
(,695,I-GENE-Y
2,695,I-GENE-Y
),695,I-GENE-Y
antagonist,695,O
atypical,695,O
APDs,695,O
",",695,O
also,695,O
increase,695,O
cortical,695,O
DA,695,B-CHEMICAL
and,695,O
ACh,695,B-CHEMICAL
release,695,O
",",695,O
and,695,O
whether,695,O
these,695,O
effects,695,O
are,695,O
related,695,O
to,695,O
5-HT,695,B-GENE-Y
(,695,I-GENE-Y
1A,695,I-GENE-Y
),695,I-GENE-Y
agonism,695,O
.,695,O
Quetiapine,696,B-CHEMICAL
(,696,O
30,696,O
mg/kg,696,O
),696,O
",",696,O
iloperidone,696,B-CHEMICAL
(,696,O
1-10,696,O
mg/kg,696,O
),696,O
",",696,O
and,696,O
melperone,696,B-CHEMICAL
(,696,O
3-10,696,O
mg/kg,696,O
),696,O
increased,696,O
DA,696,B-CHEMICAL
and,696,O
ACh,696,B-CHEMICAL
release,696,O
in,696,O
the,696,O
medial,696,O
prefrontal,696,O
cortex,696,O
(,696,O
mPFC,696,O
),696,O
.,696,O
Iloperidone,697,B-CHEMICAL
(,697,O
10,697,O
mg/kg,697,O
),697,O
and,697,O
melperone,697,B-CHEMICAL
(,697,O
10,697,O
mg/kg,697,O
),697,O
",",697,O
but,697,O
not,697,O
quetiapine,697,B-CHEMICAL
(,697,O
30,697,O
mg/kg,697,O
),697,O
",",697,O
produced,697,O
an,697,O
equivalent,697,O
or,697,O
a,697,O
smaller,697,O
increase,697,O
in,697,O
DA,697,B-CHEMICAL
release,697,O
in,697,O
the,697,O
nucleus,697,O
accumbens,697,O
(,697,O
NAC,697,O
),697,O
",",697,O
respectively,697,O
",",697,O
compared,697,O
to,697,O
the,697,O
mPFC,697,O
",",697,O
whereas,697,O
none,697,O
of,697,O
them,697,O
increased,697,O
ACh,697,B-CHEMICAL
release,697,O
in,697,O
the,697,O
NAC,697,O
.,697,O
WAY100635,698,B-CHEMICAL
(,698,O
0.2,698,O
mg/kg,698,O
),698,O
",",698,O
which,698,O
alone,698,O
did,698,O
not,698,O
affect,698,O
DA,698,B-CHEMICAL
or,698,O
ACh,698,B-CHEMICAL
release,698,O
",",698,O
partially,698,O
attenuated,698,O
quetiapine,698,B-CHEMICAL
(,698,O
30,698,O
mg/kg,698,O
),698,O
-,698,O
",",698,O
iloperidone,698,B-CHEMICAL
(,698,O
10,698,O
mg/kg,698,O
),698,O
-,698,O
and,698,O
melperone,698,B-CHEMICAL
(,698,O
10,698,O
mg/kg,698,O
),698,O
-induced,698,O
DA,698,B-CHEMICAL
release,698,O
in,698,O
the,698,O
mPFC,698,O
.,698,O
WAY100635,699,B-CHEMICAL
also,699,O
partially,699,O
attenuated,699,O
quetiapine,699,B-CHEMICAL
(,699,O
30,699,O
mg/kg,699,O
),699,O
-induced,699,O
ACh,699,B-CHEMICAL
release,699,O
in,699,O
the,699,O
mPFC,699,O
",",699,O
but,699,O
not,699,O
that,699,O
induced,699,O
by,699,O
iloperidone,699,B-CHEMICAL
(,699,O
10,699,O
mg/kg,699,O
),699,O
or,699,O
melperone,699,B-CHEMICAL
(,699,O
10,699,O
mg/kg,699,O
),699,O
.,699,O
These,700,O
results,700,O
indicate,700,O
that,700,O
quetiapine,700,B-CHEMICAL
",",700,O
iloperidone,700,B-CHEMICAL
and,700,O
melperone,700,B-CHEMICAL
preferentially,700,O
increase,700,O
DA,700,B-CHEMICAL
release,700,O
in,700,O
the,700,O
mPFC,700,O
",",700,O
compared,700,O
to,700,O
the,700,O
NAC,700,O
via,700,O
a,700,O
5-HT,700,B-GENE-Y
(,700,I-GENE-Y
1A,700,I-GENE-Y
),700,I-GENE-Y
-related,700,O
mechanism,700,O
.,700,O
However,701,O
",",701,O
5-HT,701,B-GENE-Y
(,701,I-GENE-Y
1A,701,I-GENE-Y
),701,I-GENE-Y
agonism,701,O
may,701,O
be,701,O
important,701,O
only,701,O
for,701,O
quetiapine-induced,701,B-CHEMICAL
ACh,701,B-CHEMICAL
release,701,O
.,701,O
Effects,702,O
of,702,O
age,702,O
and,702,O
sex,702,O
on,702,O
the,702,O
disposition,702,O
of,702,O
retigabine,702,B-CHEMICAL
.,702,O
BACKGROUND,703,O
:,703,O
The,703,O
novel,703,O
antiepileptic,703,O
drug,703,O
retigabine,703,B-CHEMICAL
is,703,O
the,703,O
first,703,O
selective,703,O
M-current,703,B-GENE-N
potassium,703,I-GENE-N
channel,703,I-GENE-N
opener,703,O
for,703,O
KCNQ2/3,703,B-GENE-N
and,703,O
KCNQ3/5,703,B-GENE-N
channels,703,O
.,703,O
Retigabine,704,B-CHEMICAL
undergoes,704,O
phase,704,O
II,704,O
metabolism,704,O
(,704,O
N-glucuronidation,704,B-CHEMICAL
",",704,O
acetylation,704,O
),704,O
exclusively,704,O
and,704,O
renal,704,O
excretion,704,O
.,704,O
OBJECTIVE,705,O
:,705,O
Our,705,O
objective,705,O
was,705,O
to,705,O
evaluate,705,O
the,705,O
effects,705,O
of,705,O
age,705,O
and,705,O
sex,705,O
on,705,O
the,705,O
pharmacokinetics,705,O
of,705,O
retigabine,705,B-CHEMICAL
.,705,O
METHODS,706,O
:,706,O
Healthy,706,O
young,706,O
(,706,O
age,706,O
range,706,O
",",706,O
18-40,706,O
years,706,O
),706,O
and,706,O
elderly,706,O
(,706,O
age,706,O
range,706,O
",",706,O
66-81,706,O
years,706,O
),706,O
white,706,O
subjects,706,O
(,706,O
12,706,O
men,706,O
and,706,O
12,706,O
women,706,O
in,706,O
each,706,O
group,706,O
),706,O
received,706,O
a,706,O
single,706,O
200-mg,706,O
oral,706,O
dose,706,O
of,706,O
retigabine,706,B-CHEMICAL
.,706,O
After,707,O
dosing,707,O
",",707,O
blood,707,O
was,707,O
collected,707,O
over,707,O
a,707,O
72-hour,707,O
period,707,O
to,707,O
determine,707,O
plasma,707,O
concentrations,707,O
of,707,O
retigabine,707,B-CHEMICAL
and,707,O
its,707,O
acetylated,707,O
metabolite,707,O
",",707,O
AWD21-360,707,B-CHEMICAL
.,707,O
Pharmacokinetics,708,O
was,708,O
compared,708,O
for,708,O
age,708,O
group,708,O
and,708,O
sex,708,O
by,708,O
ANOVA,708,O
.,708,O
RESULTS,709,O
:,709,O
In,709,O
young,709,O
men,709,O
",",709,O
retigabine,709,B-CHEMICAL
was,709,O
rapidly,709,O
absorbed,709,O
",",709,O
with,709,O
the,709,O
maximum,709,O
concentration,709,O
occurring,709,O
within,709,O
2,709,O
hours,709,O
",",709,O
and,709,O
was,709,O
eliminated,709,O
with,709,O
an,709,O
apparent,709,O
clearance,709,O
of,709,O
0.67,709,O
L,709,O
x,709,O
h,709,O
(,709,O
-1,709,O
),709,O
x,709,O
kg,709,O
(,709,O
-1,709,O
),709,O
and,709,O
a,709,O
mean,709,O
terminal,709,O
half-life,709,O
of,709,O
8.5,709,O
hours,709,O
.,709,O
Subjects,710,O
were,710,O
similarly,710,O
exposed,710,O
to,710,O
AWD21-360,710,B-CHEMICAL
.,710,O
Compared,711,O
with,711,O
young,711,O
men,711,O
",",711,O
young,711,O
women,711,O
had,711,O
higher,711,O
retigabine,711,B-CHEMICAL
maximum,711,O
concentration,711,O
(,711,O
56,711,O
%,711,O
),711,O
and,711,O
exposure,711,O
(,711,O
20,711,O
%,711,O
),711,O
but,711,O
similar,711,O
clearance,711,O
(,711,O
0.68,711,O
L,711,O
x,711,O
h,711,O
(,711,O
-1,711,O
),711,O
x,711,O
kg,711,O
(,711,O
-1,711,O
),711,O
),711,O
;,711,O
these,711,O
differences,711,O
were,711,O
related,711,O
to,711,O
differences,711,O
in,711,O
body,711,O
weight,711,O
.,711,O
Although,712,O
maximum,712,O
concentration,712,O
was,712,O
similar,712,O
in,712,O
elderly,712,O
subjects,712,O
",",712,O
retigabine,712,B-CHEMICAL
elimination,712,O
was,712,O
slower,712,O
(,712,O
30,712,O
%,712,O
lower,712,O
apparent,712,O
clearance,712,O
normalized,712,O
for,712,O
weight,712,O
),712,O
",",712,O
resulting,712,O
in,712,O
higher,712,O
exposure,712,O
(,712,O
42,712,O
%,712,O
),712,O
and,712,O
a,712,O
longer,712,O
half-life,712,O
(,712,O
30,712,O
%,712,O
),712,O
.,712,O
Because,713,O
phase,713,O
II,713,O
metabolism,713,O
is,713,O
scarcely,713,O
affected,713,O
by,713,O
age,713,O
",",713,O
these,713,O
differences,713,O
may,713,O
be,713,O
related,713,O
to,713,O
the,713,O
known,713,O
decline,713,O
of,713,O
renal,713,O
function,713,O
with,713,O
age,713,O
.,713,O
CONCLUSIONS,714,O
:,714,O
Although,714,O
there,714,O
are,714,O
no,714,O
substantial,714,O
sex-related,714,O
differences,714,O
in,714,O
the,714,O
disposition,714,O
of,714,O
retigabine,714,B-CHEMICAL
",",714,O
a,714,O
relevant,714,O
decrease,714,O
in,714,O
clearance,714,O
resulting,714,O
in,714,O
higher,714,O
exposure,714,O
occurs,714,O
in,714,O
elderly,714,O
patients,714,O
.,714,O
The,715,O
results,715,O
suggest,715,O
that,715,O
decline,715,O
of,715,O
renal,715,O
function,715,O
with,715,O
age,715,O
may,715,O
account,715,O
for,715,O
some,715,O
of,715,O
the,715,O
observed,715,O
changes,715,O
.,715,O
Selective,716,O
cyclooxygenase-2,716,B-GENE-Y
inhibition,716,O
does,716,O
not,716,O
affect,716,O
the,716,O
healing,716,O
of,716,O
cutaneous,716,O
full-thickness,716,O
incisional,716,O
wounds,716,O
in,716,O
SKH-1,716,O
mice,716,O
.,716,O
BACKGROUND,717,O
:,717,O
The,717,O
inducible,717,O
cyclooxygenase-2,717,B-GENE-Y
(,717,O
COX-2,717,B-GENE-Y
),717,O
enzyme,717,O
is,717,O
upregulated,717,O
in,717,O
inflammatory,717,O
diseases,717,O
",",717,O
as,717,O
well,717,O
as,717,O
in,717,O
epithelial,717,O
cancers,717,O
",",717,O
and,717,O
has,717,O
an,717,O
established,717,O
role,717,O
in,717,O
angiogenesis,717,O
and,717,O
tissue,717,O
repair,717,O
.,717,O
OBJECTIVE,718,O
:,718,O
Because,718,O
of,718,O
these,718,O
physiological,718,O
effects,718,O
and,718,O
the,718,O
widespread,718,O
use,718,O
of,718,O
the,718,O
selective,718,O
COX-2,718,B-GENE-Y
inhibitor,718,O
",",718,O
celecoxib,718,B-CHEMICAL
",",718,O
we,718,O
wanted,718,O
to,718,O
determine,718,O
if,718,O
inhibition,718,O
of,718,O
COX-2,718,B-GENE-Y
would,718,O
affect,718,O
incisional,718,O
skin,718,O
wound,718,O
healing,718,O
.,718,O
METHODS,719,O
:,719,O
Using,719,O
a,719,O
cutaneous,719,O
full-thickness,719,O
",",719,O
sutured,719,O
",",719,O
incisional,719,O
wound,719,O
model,719,O
in,719,O
hairless,719,O
SKH-1,719,O
mice,719,O
",",719,O
we,719,O
evaluated,719,O
the,719,O
role,719,O
of,719,O
COX-2,719,B-GENE-Y
in,719,O
the,719,O
wound,719,O
healing,719,O
process,719,O
by,719,O
comparing,719,O
the,719,O
effects,719,O
of,719,O
a,719,O
nonselective,719,O
COX,719,B-GENE-N
inhibitor,719,O
",",719,O
diclofenac,719,B-CHEMICAL
",",719,O
with,719,O
a,719,O
selective,719,O
COX-2,719,B-GENE-Y
inhibitor,719,O
",",719,O
SC-791,719,O
.,719,O
Healing,720,O
was,720,O
monitored,720,O
for,720,O
up,720,O
to,720,O
28,720,O
days,720,O
postincision,720,O
histologically,720,O
and,720,O
for,720,O
recovery,720,O
of,720,O
wound,720,O
strength,720,O
.,720,O
RESULTS,721,O
:,721,O
COX-2,721,B-GENE-Y
expression,721,O
was,721,O
observed,721,O
over,721,O
the,721,O
first,721,O
week,721,O
of,721,O
healing,721,O
",",721,O
peaking,721,O
at,721,O
day,721,O
3,721,O
and,721,O
was,721,O
not,721,O
affected,721,O
by,721,O
treatment,721,O
with,721,O
the,721,O
selective,721,O
COX-2,721,B-GENE-Y
or,721,O
nonselective,721,O
COX,721,B-GENE-N
inhibitors,721,O
.,721,O
Infiltrating,722,O
macrophages,722,O
",",722,O
as,722,O
well,722,O
as,722,O
keratinocytes,722,O
and,722,O
dermal,722,O
fibroblasts,722,O
at,722,O
the,722,O
wound,722,O
site,722,O
",",722,O
expressed,722,O
COX-2,722,B-GENE-Y
.,722,O
Neither,723,O
selective,723,O
COX-2,723,B-GENE-Y
",",723,O
nor,723,O
nonselective,723,O
COX,723,B-GENE-N
inhibition,723,O
had,723,O
a,723,O
significant,723,O
effect,723,O
on,723,O
the,723,O
macroscopic,723,O
or,723,O
microscopic,723,O
morphology,723,O
of,723,O
the,723,O
wounds,723,O
",",723,O
whereas,723,O
dexamethasone,723,B-CHEMICAL
treatment,723,O
resulted,723,O
in,723,O
epidermal,723,O
and,723,O
granulation,723,O
tissue,723,O
atrophy,723,O
.,723,O
In,724,O
addition,724,O
",",724,O
neither,724,O
selective,724,O
COX-2,724,B-GENE-Y
",",724,O
nor,724,O
nonselective,724,O
COX,724,B-GENE-N
inhibition,724,O
altered,724,O
keratinocyte,724,O
proliferation,724,O
and,724,O
differentiation,724,O
",",724,O
dermal,724,O
angiogenesis,724,O
or,724,O
the,724,O
recovery,724,O
of,724,O
wound,724,O
tensile,724,O
strength,724,O
",",724,O
whereas,724,O
dexamethasone,724,B-CHEMICAL
reduced,724,O
the,724,O
tensile,724,O
strength,724,O
of,724,O
the,724,O
wounds,724,O
by,724,O
30-38,724,O
%,724,O
throughout,724,O
the,724,O
healing,724,O
period,724,O
.,724,O
CONCLUSIONS,725,O
:,725,O
These,725,O
data,725,O
indicate,725,O
that,725,O
selective,725,O
COX-2,725,B-GENE-Y
inhibition,725,O
does,725,O
not,725,O
affect,725,O
the,725,O
healing,725,O
of,725,O
surgical,725,O
skin,725,O
wounds,725,O
.,725,O
Synthesis,726,O
and,726,O
in,726,O
vivo,726,O
evaluation,726,O
of,726,O
novel,726,O
radiotracers,726,O
for,726,O
the,726,O
in,726,O
vivo,726,O
imaging,726,O
of,726,O
the,726,O
norepinephrine,726,B-GENE-Y
transporter,726,I-GENE-Y
.,726,O
The,727,O
(,727,B-CHEMICAL
R,727,I-CHEMICAL
",",727,I-CHEMICAL
R,727,I-CHEMICAL
),727,I-CHEMICAL
and,727,I-CHEMICAL
(,727,I-CHEMICAL
S,727,I-CHEMICAL
",",727,I-CHEMICAL
S,727,I-CHEMICAL
),727,I-CHEMICAL
enantiomers,727,I-CHEMICAL
of,727,I-CHEMICAL
2-,727,I-CHEMICAL
[,727,I-CHEMICAL
(,727,I-CHEMICAL
2-methoxyphenoxy,727,I-CHEMICAL
),727,I-CHEMICAL
phenylmethyl,727,I-CHEMICAL
],727,I-CHEMICAL
morpholine,727,I-CHEMICAL
(,727,O
MeNER,727,B-CHEMICAL
),727,O
have,727,O
been,727,O
radiolabelled,727,O
with,727,O
carbon-11,727,B-CHEMICAL
in,727,O
good,727,O
yield,727,O
and,727,O
at,727,O
high,727,O
specific,727,O
activity,727,O
.,727,O
These,728,O
radiotracers,728,O
are,728,O
close,728,O
analogues,728,O
of,728,O
reboxetine,728,B-CHEMICAL
",",728,O
a,728,O
potent,728,O
and,728,O
selective,728,O
ligand,728,O
for,728,O
the,728,O
norepinephrine,728,B-GENE-Y
transporter,728,I-GENE-Y
(,728,O
NET,728,B-GENE-Y
),728,O
.,728,O
They,729,O
were,729,O
examined,729,O
as,729,O
potential,729,O
ligands,729,O
for,729,O
imaging,729,O
NET,729,B-GENE-Y
in,729,O
vivo,729,O
by,729,O
positron,729,O
emission,729,O
tomography,729,O
(,729,O
PET,729,O
),729,O
.,729,O
The,730,O
in,730,O
vivo,730,O
brain,730,O
distribution,730,O
of,730,O
both,730,O
[,730,O
(,730,B-CHEMICAL
11,730,I-CHEMICAL
),730,I-CHEMICAL
C,730,I-CHEMICAL
],730,O
-labeled,730,O
enantiomers,730,O
were,730,O
evaluated,730,O
in,730,O
rats,730,O
.,730,O
Following,731,O
tail-vein,731,O
injection,731,O
of,731,O
the,731,O
(,731,O
R,731,O
",",731,O
R,731,O
),731,O
-enantiomer,731,O
regional,731,O
brain,731,O
uptake,731,O
and,731,O
washout,731,O
of,731,O
radioactivity,731,O
was,731,O
homogeneous,731,O
at,731,O
all,731,O
time,731,O
points,731,O
examined,731,O
(,731,O
5-60,731,O
min,731,O
),731,O
.,731,O
In,732,O
contrast,732,O
",",732,O
administration,732,O
of,732,O
the,732,O
(,732,O
S,732,O
",",732,O
S,732,O
),732,O
-enantiomer,732,O
produced,732,O
a,732,O
heterogeneous,732,O
distribution,732,O
of,732,O
radioactivity,732,O
in,732,O
brain,732,O
with,732,O
highest,732,O
uptake,732,O
in,732,O
the,732,O
hypothalamus,732,O
",",732,O
a,732,O
NET,732,B-GENE-Y
rich,732,O
region,732,O
",",732,O
and,732,O
lowest,732,O
uptake,732,O
in,732,O
the,732,O
striatum,732,O
",",732,O
a,732,O
brain,732,O
region,732,O
devoid,732,O
of,732,O
NET,732,B-GENE-Y
.,732,O
Hypothalamus,733,O
to,733,O
striatum,733,O
ratios,733,O
of,733,O
2.5,733,O
to,733,O
one,733,O
were,733,O
achieved,733,O
at,733,O
60,733,O
min,733,O
post,733,O
injection,733,O
of,733,O
(,733,B-CHEMICAL
S,733,I-CHEMICAL
",",733,I-CHEMICAL
S,733,I-CHEMICAL
),733,I-CHEMICAL
-,733,I-CHEMICAL
[,733,I-CHEMICAL
(,733,I-CHEMICAL
11,733,I-CHEMICAL
),733,I-CHEMICAL
C,733,I-CHEMICAL
],733,I-CHEMICAL
-MeNER,733,I-CHEMICAL
.,733,O
Pre-injection,734,O
of,734,O
the,734,O
norepinephrine,734,B-CHEMICAL
reuptake,734,O
inhibitors,734,O
",",734,O
reboxetine,734,B-CHEMICAL
or,734,O
desipramine,734,B-CHEMICAL
",",734,O
reduced,734,O
hypothalamus,734,O
to,734,O
striatum,734,O
ratios,734,O
to,734,O
near,734,O
unity,734,O
while,734,O
reuptake,734,O
inhibitors,734,O
of,734,O
dopamine,734,B-CHEMICAL
and,734,O
serotonin,734,B-CHEMICAL
had,734,O
no,734,O
significant,734,O
effect,734,O
on,734,O
binding,734,O
.,734,O
In,735,O
vitro,735,O
autoradiography,735,O
studies,735,O
(,735,O
rat,735,O
brain,735,O
slices,735,O
),735,O
with,735,O
(,735,B-CHEMICAL
S,735,I-CHEMICAL
",",735,I-CHEMICAL
S,735,I-CHEMICAL
),735,I-CHEMICAL
-,735,I-CHEMICAL
[,735,I-CHEMICAL
(,735,I-CHEMICAL
11,735,I-CHEMICAL
),735,I-CHEMICAL
C,735,I-CHEMICAL
],735,I-CHEMICAL
-MeNER,735,I-CHEMICAL
produced,735,O
a,735,O
regional,735,O
distribution,735,O
pattern,735,O
that,735,O
was,735,O
consistent,735,O
with,735,O
the,735,O
reported,735,O
distribution,735,O
of,735,O
NET,735,B-GENE-Y
.,735,O
(,736,B-CHEMICAL
S,736,I-CHEMICAL
",",736,I-CHEMICAL
S,736,I-CHEMICAL
),736,I-CHEMICAL
-,736,I-CHEMICAL
[,736,I-CHEMICAL
(,736,I-CHEMICAL
11,736,I-CHEMICAL
),736,I-CHEMICAL
C,736,I-CHEMICAL
],736,I-CHEMICAL
-MeNER,736,I-CHEMICAL
has,736,O
the,736,O
potential,736,O
to,736,O
be,736,O
the,736,O
first,736,O
successful,736,O
PET,736,O
ligand,736,O
to,736,O
image,736,O
NET,736,B-GENE-Y
.,736,O
Histamine,737,B-GENE-Y
H1-receptor,737,I-GENE-Y
antagonists,737,O
",",737,O
promethazine,737,B-CHEMICAL
and,737,O
homochlorcyclizine,737,B-CHEMICAL
",",737,O
increase,737,O
the,737,O
steady-state,737,O
plasma,737,O
concentrations,737,O
of,737,O
haloperidol,737,B-CHEMICAL
and,737,O
reduced,737,O
haloperidol,737,B-CHEMICAL
.,737,O
The,738,O
effects,738,O
of,738,O
histamine,738,B-CHEMICAL
H1-receptor,738,I-GENE-Y
antagonists,738,O
",",738,O
promethazine,738,B-CHEMICAL
and,738,O
homochlorcyclizine,738,B-CHEMICAL
",",738,O
both,738,O
of,738,O
which,738,O
are,738,O
inhibitors,738,O
of,738,O
CYP2D6,738,B-GENE-Y
",",738,O
on,738,O
the,738,O
steady-state,738,O
plasma,738,O
concentrations,738,O
(,738,O
Css,738,O
),738,O
of,738,O
haloperidol,738,B-CHEMICAL
and,738,O
reduced,738,O
haloperidol,738,B-CHEMICAL
were,738,O
studied,738,O
in,738,O
23,738,O
schizophrenic,738,O
inpatients,738,O
receiving,738,O
haloperidol,738,B-CHEMICAL
",",738,O
12,738,O
to,738,O
36,738,O
mg/d,738,O
",",738,O
for,738,O
2,738,O
to,738,O
29,738,O
weeks,738,O
.,738,O
Promethazine,739,B-CHEMICAL
",",739,O
150,739,O
mg/d,739,O
",",739,O
in,739,O
11,739,O
patients,739,O
and,739,O
homochlorcyclizine,739,B-CHEMICAL
",",739,O
60,739,O
mg/d,739,O
",",739,O
in,739,O
the,739,O
others,739,O
were,739,O
coadministered,739,O
for,739,O
at,739,O
least,739,O
1,739,O
week,739,O
.,739,O
Blood,740,O
sampling,740,O
was,740,O
performed,740,O
before,740,O
and,740,O
during,740,O
coadministration,740,O
of,740,O
promethazine,740,B-CHEMICAL
or,740,O
homochlorcyclizine,740,B-CHEMICAL
and,740,O
1,740,O
week,740,O
after,740,O
the,740,O
discontinuation,740,O
",",740,O
together,740,O
with,740,O
clinical,740,O
assessments,740,O
by,740,O
Brief,740,O
Psychiatric,740,O
Rating,740,O
Scale,740,O
(,740,O
BPRS,740,O
),740,O
and,740,O
Udvalg,740,O
for,740,O
kliniske,740,O
undersogelser,740,O
(,740,O
UKU,740,O
),740,O
side,740,O
effect,740,O
rating,740,O
scale,740,O
.,740,O
The,741,O
Css,741,O
(,741,O
mean,741,O
+/-,741,O
SD,741,O
),741,O
of,741,O
haloperidol,741,B-CHEMICAL
and,741,O
reduced,741,O
haloperidol,741,B-CHEMICAL
during,741,O
promethazine,741,B-CHEMICAL
coadministration,741,O
(,741,O
27.6,741,O
+/-,741,O
24.9,741,O
and,741,O
8.6,741,O
+/-,741,O
13.2,741,O
ng/mL,741,O
),741,O
were,741,O
significantly,741,O
higher,741,O
than,741,O
those,741,O
before,741,O
the,741,O
coadministration,741,O
(,741,O
12.7,741,O
+/-,741,O
10.8,741,O
and,741,O
5.0,741,O
+/-,741,O
6.0,741,O
ng/mL,741,O
;,741,O
P,741,O
<,741,O
0.01,741,O
),741,O
or,741,O
1,741,O
week,741,O
after,741,O
the,741,O
discontinuation,741,O
(,741,O
15.6,741,O
+/-,741,O
14.8,741,O
and,741,O
5.8,741,O
+/-,741,O
7.9,741,O
ng/mL,741,O
;,741,O
P,741,O
<,741,O
0.05,741,O
),741,O
.,741,O
The,742,O
Css,742,O
of,742,O
haloperidol,742,B-CHEMICAL
and,742,O
reduced,742,O
haloperidol,742,B-CHEMICAL
during,742,O
homochlorcyclizine,742,B-CHEMICAL
coadministration,742,O
(,742,O
14.9,742,O
+/-,742,O
8.1,742,O
and,742,O
6.4,742,O
+/-,742,O
5.4,742,O
ng/mL,742,O
),742,O
were,742,O
also,742,O
significantly,742,O
higher,742,O
than,742,O
those,742,O
before,742,O
the,742,O
coadministration,742,O
(,742,O
10.9,742,O
+/-,742,O
7.2,742,O
and,742,O
3.8,742,O
+/-,742,O
3.6,742,O
ng/mL,742,O
;,742,O
P,742,O
<,742,O
0.01,742,O
),742,O
or,742,O
1,742,O
week,742,O
after,742,O
the,742,O
discontinuation,742,O
(,742,O
12.9,742,O
+/-,742,O
7.4,742,O
and,742,O
4.8,742,O
+/-,742,O
4.1,742,O
ng/mL,742,O
;,742,O
P,742,O
<,742,O
0.05,742,O
),742,O
.,742,O
No,743,O
change,743,O
in,743,O
BPRS,743,O
or,743,O
UKU,743,O
score,743,O
was,743,O
found,743,O
throughout,743,O
the,743,O
study,743,O
.,743,O
Thus,744,O
",",744,O
the,744,O
current,744,O
study,744,O
suggests,744,O
that,744,O
coadministration,744,O
of,744,O
clinical,744,O
doses,744,O
of,744,O
promethazine,744,B-CHEMICAL
and,744,O
homochlorcyclizine,744,B-CHEMICAL
increases,744,O
the,744,O
Css,744,O
of,744,O
haloperidol,744,B-CHEMICAL
and,744,O
reduced,744,O
haloperidol,744,B-CHEMICAL
via,744,O
the,744,O
inhibitory,744,O
effects,744,O
on,744,O
the,744,O
CYP2D6-catalyzed,744,B-GENE-Y
metabolism,744,O
of,744,O
haloperidol,744,B-CHEMICAL
and,744,O
reduced,744,O
haloperidol,744,B-CHEMICAL
.,744,O
Yeast,745,B-GENE-Y
epiarginase,745,I-GENE-Y
regulation,745,O
",",745,O
an,745,O
enzyme-enzyme,745,O
activity,745,O
control,745,O
:,745,O
identification,745,O
of,745,O
residues,745,O
of,745,O
ornithine,745,B-GENE-Y
carbamoyltransferase,745,I-GENE-Y
and,745,O
arginase,745,B-GENE-Y
responsible,745,O
for,745,O
enzyme,745,O
catalytic,745,O
and,745,O
regulatory,745,O
activities,745,O
.,745,O
In,746,O
the,746,O
presence,746,O
of,746,O
ornithine,746,B-CHEMICAL
and,746,O
arginine,746,B-CHEMICAL
",",746,O
ornithine,746,B-CHEMICAL
carbamoyltransferase,746,I-GENE-Y
(,746,O
OTCase,746,B-GENE-Y
),746,O
and,746,O
arginase,746,B-GENE-Y
form,746,O
a,746,O
one-to-one,746,O
enzyme,746,O
complex,746,O
in,746,O
which,746,O
the,746,O
activity,746,O
of,746,O
OTCase,746,B-GENE-Y
is,746,O
inhibited,746,O
whereas,746,O
arginase,746,B-GENE-Y
remains,746,O
catalytically,746,O
active,746,O
.,746,O
The,747,O
mechanism,747,O
by,747,O
which,747,O
these,747,O
nonallosteric,747,O
enzymes,747,O
form,747,O
a,747,O
stable,747,O
complex,747,O
triggered,747,O
by,747,O
the,747,O
binding,747,O
of,747,O
their,747,O
respective,747,O
substrates,747,O
raises,747,O
the,747,O
question,747,O
of,747,O
how,747,O
such,747,O
a,747,O
cooperative,747,O
association,747,O
is,747,O
induced,747,O
.,747,O
Analyses,748,O
of,748,O
mutations,748,O
in,748,O
both,748,O
enzymes,748,O
identify,748,O
residues,748,O
that,748,O
are,748,O
required,748,O
for,748,O
their,748,O
association,748,O
",",748,O
some,748,O
of,748,O
them,748,O
being,748,O
important,748,O
for,748,O
catalysis,748,O
.,748,O
In,749,O
arginase,749,B-GENE-Y
",",749,O
two,749,O
cysteines,749,B-CHEMICAL
at,749,O
the,749,O
C,749,B-CHEMICAL
terminus,749,O
of,749,O
the,749,O
protein,749,O
are,749,O
crucial,749,O
for,749,O
its,749,O
epiarginase,749,B-GENE-Y
function,749,O
but,749,O
not,749,O
for,749,O
its,749,O
catalytic,749,O
activity,749,O
and,749,O
trimeric,749,O
structure,749,O
.,749,O
In,750,O
OTCase,750,B-GENE-Y
",",750,O
mutations,750,O
of,750,O
putative,750,O
ornithine,750,B-CHEMICAL
binding,750,O
residues,750,O
",",750,O
Asp-182,750,B-CHEMICAL
",",750,O
Asn-184,750,B-CHEMICAL
",",750,O
Asn-185,750,B-CHEMICAL
",",750,O
Cys-289,750,B-CHEMICAL
",",750,O
and,750,O
Glu-256,750,B-CHEMICAL
greatly,750,O
reduced,750,O
the,750,O
affinity,750,O
for,750,O
ornithine,750,B-CHEMICAL
and,750,O
impaired,750,O
the,750,O
interaction,750,O
with,750,O
arginase,750,B-GENE-Y
.,750,O
The,751,O
four,751,O
lysine,751,B-CHEMICAL
residues,751,O
located,751,O
in,751,O
the,751,O
SMG,751,O
loop,751,O
",",751,O
Lys-260,751,B-CHEMICAL
",",751,O
Lys-263,751,B-CHEMICAL
",",751,O
Lys-265,751,B-CHEMICAL
",",751,O
and,751,O
Lys-268,751,B-CHEMICAL
",",751,O
also,751,O
play,751,O
an,751,O
important,751,O
role,751,O
in,751,O
mediating,751,O
the,751,O
sensitivity,751,O
of,751,O
OTCase,751,B-GENE-Y
to,751,O
ornithine,751,B-CHEMICAL
and,751,O
to,751,O
arginase,751,B-GENE-Y
and,751,O
appear,751,O
to,751,O
be,751,O
involved,751,O
in,751,O
transducing,751,O
and,751,O
enhancing,751,O
the,751,O
signal,751,O
given,751,O
by,751,O
ornithine,751,B-CHEMICAL
for,751,O
the,751,O
closure,751,O
of,751,O
the,751,O
catalytic,751,O
domain,751,O
.,751,O
[,752,O
Study,752,O
on,752,O
the,752,O
effect,752,O
of,752,O
cysteinyl,752,B-CHEMICAL
leukotriene,752,I-CHEMICAL
antagonist,752,O
",",752,O
pranlukast,752,B-CHEMICAL
hydrate,752,I-CHEMICAL
",",752,O
on,752,O
adhesive,752,O
interaction,752,O
between,752,O
eosinophils,752,O
and,752,O
pulmonary,752,O
endothelial,752,O
cells,752,O
],752,O
.,752,O
It,753,O
has,753,O
been,753,O
reported,753,O
that,753,O
cysteinyl,753,B-CHEMICAL
leukotriene,753,I-CHEMICAL
(,753,O
CysLT,753,B-CHEMICAL
),753,O
antagonists,753,O
reduce,753,O
the,753,O
accumulation,753,O
of,753,O
eosinophils,753,O
in,753,O
the,753,O
asthmatic,753,O
airway,753,O
.,753,O
However,754,O
",",754,O
the,754,O
exact,754,O
mechanism,754,O
of,754,O
this,754,O
action,754,O
remains,754,O
to,754,O
be,754,O
established,754,O
.,754,O
In,755,O
the,755,O
present,755,O
study,755,O
",",755,O
we,755,O
examined,755,O
whether,755,O
a,755,O
CysLT,755,B-CHEMICAL
antagonist,755,O
modifies,755,O
the,755,O
adhesive,755,O
interaction,755,O
between,755,O
blood,755,O
eosinophils,755,O
and,755,O
endothelial,755,O
cells,755,O
.,755,O
Pranlukast,756,B-CHEMICAL
hydrate,756,I-CHEMICAL
",",756,O
a,756,O
CysLT,756,B-CHEMICAL
antagonist,756,O
",",756,O
blocked,756,O
the,756,O
chemotactic,756,O
response,756,O
and,756,O
adhesion,756,O
of,756,O
eosinophils,756,O
induced,756,O
by,756,O
LTD4,756,B-CHEMICAL
.,756,O
On,757,O
the,757,O
other,757,O
hand,757,O
",",757,O
pranlukast,757,B-CHEMICAL
did,757,O
not,757,O
modify,757,O
the,757,O
eosinophil,757,O
spontaneous,757,O
adhesion,757,O
to,757,O
the,757,O
resting,757,O
or,757,O
IL-4,757,B-GENE-Y
plus,757,O
TNF-alpha-stimulated,757,B-GENE-Y
pulmonary,757,O
endothelial,757,O
cells,757,O
.,757,O
Similarly,758,O
",",758,O
pranlukast,758,B-CHEMICAL
did,758,O
not,758,O
modulate,758,O
IL-5-,758,B-GENE-Y
or,758,O
FMLP-activated,758,O
eosinophil,758,O
adhesion,758,O
to,758,O
the,758,O
resting,758,O
endothelial,758,O
cells,758,O
.,758,O
Finally,759,O
",",759,O
pranlukast,759,B-CHEMICAL
did,759,O
not,759,O
modify,759,O
the,759,O
expression,759,O
of,759,O
adhesion,759,O
molecules,759,O
on,759,O
endothelial,759,O
cells,759,O
stimulated,759,O
with,759,O
endothelial,759,O
activating,759,O
cytokines,759,O
.,759,O
These,760,O
results,760,O
suggest,760,O
that,760,O
the,760,O
inhibitory,760,O
action,760,O
of,760,O
CysLT,760,B-CHEMICAL
antagonist,760,O
on,760,O
eosinophil,760,O
accumulation,760,O
in,760,O
the,760,O
asthmatic,760,O
airways,760,O
involves,760,O
mechanisms,760,O
other,760,O
than,760,O
the,760,O
adhesive,760,O
interaction,760,O
between,760,O
eosinophils,760,O
and,760,O
endothelial,760,O
cells,760,O
.,760,O
Comparison,761,O
of,761,O
in,761,O
vitro,761,O
P-glycoprotein,761,B-GENE-N
screening,761,O
assays,761,O
:,761,O
recommendations,761,O
for,761,O
their,761,O
use,761,O
in,761,O
drug,761,O
discovery,761,O
.,761,O
The,762,O
ATP-dependent,762,B-CHEMICAL
drug,762,I-GENE-N
efflux,762,I-GENE-N
pump,762,I-GENE-N
P-glycoprotein,762,B-GENE-N
(,762,O
P-gp,762,B-GENE-N
),762,O
affects,762,O
the,762,O
absorption,762,O
and,762,O
disposition,762,O
of,762,O
many,762,O
compounds,762,O
.,762,O
P-gp,763,B-GENE-N
may,763,O
also,763,O
play,763,O
role,763,O
in,763,O
clinically,763,O
significant,763,O
drug-drug,763,O
interactions,763,O
.,763,O
Therefore,764,O
",",764,O
it,764,O
is,764,O
important,764,O
to,764,O
find,764,O
potential,764,O
substrates,764,O
or,764,O
inhibitors,764,O
of,764,O
P-gp,764,B-GENE-N
early,764,O
in,764,O
the,764,O
drug,764,O
discovery,764,O
process,764,O
.,764,O
To,765,O
identify,765,O
compounds,765,O
that,765,O
interact,765,O
with,765,O
this,765,O
transporter,765,O
",",765,O
several,765,O
P-gp,765,B-GENE-N
assays,765,O
were,765,O
validated,765,O
and,765,O
compared,765,O
by,765,O
testing,765,O
a,765,O
set,765,O
of,765,O
28,765,O
reference,765,O
compounds,765,O
",",765,O
including,765,O
inhibitors,765,O
of,765,O
cytochrome,765,B-GENE-Y
P450,765,I-GENE-Y
3A4,765,I-GENE-Y
(,765,O
CYP3A4,765,B-GENE-Y
),765,O
.,765,O
The,766,O
assays,766,O
included,766,O
in,766,O
silico,766,B-CHEMICAL
predictions,766,O
",",766,O
inhibition,766,O
assays,766,O
(,766,O
based,766,O
on,766,O
cellular,766,O
uptake,766,O
of,766,O
rhodamine-123,766,B-CHEMICAL
or,766,O
calcein,766,B-CHEMICAL
AM,766,I-CHEMICAL
),766,O
",",766,O
and,766,O
functional,766,O
assays,766,O
(,766,O
ATPase,766,B-GENE-N
activity,766,O
assay,766,O
and,766,O
transcellular,766,O
transport,766,O
assay,766,O
",",766,O
the,766,O
latter,766,O
for,766,O
a,766,O
subset,766,O
of,766,O
compounds,766,O
),766,O
.,766,O
In,767,O
addition,767,O
",",767,O
species,767,O
differences,767,O
were,767,O
studied,767,O
in,767,O
an,767,O
indirect,767,O
fluorescence,767,O
indicator,767,O
screening,767,O
assay,767,O
and,767,O
test,767,O
systems,767,O
expressing,767,O
porcine,767,O
",",767,O
mouse,767,O
",",767,O
or,767,O
human,767,O
P-gp,767,B-GENE-N
.,767,O
Our,768,O
results,768,O
suggest,768,O
that,768,O
several,768,O
P-gp,768,B-GENE-N
assays,768,O
should,768,O
be,768,O
used,768,O
in,768,O
combination,768,O
to,768,O
classify,768,O
compounds,768,O
as,768,O
substrates,768,O
or,768,O
inhibitors,768,O
of,768,O
P-gp,768,B-GENE-N
.,768,O
Recommendations,769,O
are,769,O
given,769,O
on,769,O
screening,769,O
strategies,769,O
which,769,O
can,769,O
be,769,O
applied,769,O
to,769,O
different,769,O
phases,769,O
of,769,O
the,769,O
drug,769,O
discovery,769,O
and,769,O
development,769,O
process,769,O
.,769,O
Incorporation,770,O
of,770,O
trifluoroisoleucine,770,B-CHEMICAL
into,770,O
proteins,770,O
in,770,O
vivo,770,O
.,770,O
Two,771,O
fluorinated,771,O
derivatives,771,O
of,771,O
isoleucine,771,B-CHEMICAL
:,771,O
d,771,B-CHEMICAL
",",771,I-CHEMICAL
l-2-amino-3-trifluoromethyl,771,I-CHEMICAL
pentanoic,771,I-CHEMICAL
acid,771,I-CHEMICAL
(,771,O
3TFI,771,B-CHEMICAL
",",771,O
2,771,O
),771,O
and,771,O
d,771,B-CHEMICAL
",",771,I-CHEMICAL
"l-2-amino-5,5,5-trifluoro-3-methyl",771,I-CHEMICAL
pentanoic,771,I-CHEMICAL
acid,771,I-CHEMICAL
(,771,O
5TFI,771,B-CHEMICAL
",",771,O
3,771,O
),771,O
were,771,O
prepared,771,O
.,771,O
5TFI,772,B-CHEMICAL
was,772,O
incorporated,772,O
into,772,O
a,772,O
model,772,O
target,772,O
protein,772,O
",",772,O
murine,772,B-GENE-Y
dihydrofolate,772,B-CHEMICAL
reductase,772,I-GENE-Y
(,772,O
mDHFR,772,B-GENE-Y
),772,O
",",772,O
in,772,O
an,772,O
isoleucine,772,B-CHEMICAL
auxotrophic,772,O
Escherichia,772,O
coli,772,O
host,772,O
strain,772,O
suspended,772,O
in,772,O
5TFI-supplemented,772,B-CHEMICAL
minimal,772,O
medium,772,O
depleted,772,O
of,772,O
isoleucine,772,B-CHEMICAL
.,772,O
Incorporation,773,O
of,773,O
5TFI,773,B-CHEMICAL
was,773,O
confirmed,773,O
by,773,O
tryptic,773,O
peptide,773,O
analysis,773,O
and,773,O
matrix-assisted,773,O
laser,773,O
desorption,773,O
ionization,773,O
mass,773,O
spectrometry,773,O
(,773,O
MALDI-MS,773,O
),773,O
of,773,O
the,773,O
protein,773,O
product,773,O
.,773,O
Amino,774,B-CHEMICAL
acid,774,I-CHEMICAL
analysis,774,O
showed,774,O
that,774,O
more,774,O
than,774,O
93,774,O
%,774,O
of,774,O
the,774,O
encoded,774,O
isoleucine,774,B-CHEMICAL
residues,774,O
were,774,O
replaced,774,O
by,774,O
5TFI,774,B-CHEMICAL
.,774,O
Measurement,775,O
of,775,O
the,775,O
rate,775,O
of,775,O
activation,775,O
of,775,O
5TFI,775,B-CHEMICAL
by,775,O
the,775,O
E.,775,B-GENE-Y
coli,775,I-GENE-Y
isoleucyl-tRNA,775,I-GENE-Y
synthetase,775,I-GENE-Y
(,775,O
IleRS,775,B-GENE-Y
),775,O
yielded,775,O
a,775,O
specificity,775,O
constant,775,O
(,775,O
k,775,O
(,775,O
cat,775,O
),775,O
/K,775,O
(,775,O
m,775,O
),775,O
),775,O
134-fold,775,O
lower,775,O
than,775,O
that,775,O
for,775,O
isoleucine,775,B-CHEMICAL
.,775,O
5TFI,776,B-CHEMICAL
was,776,O
successfully,776,O
introduced,776,O
into,776,O
the,776,O
cytokine,776,B-GENE-N
murine,776,B-GENE-Y
interleukin-2,776,I-GENE-Y
(,776,O
mIL-2,776,B-GENE-Y
),776,O
at,776,O
the,776,O
encoded,776,O
isoleucine,776,B-CHEMICAL
positions,776,O
.,776,O
The,777,O
concentration,777,O
of,777,O
fluorinated,777,O
protein,777,O
that,777,O
elicits,777,O
50,777,O
%,777,O
of,777,O
the,777,O
maximal,777,O
proliferative,777,O
response,777,O
is,777,O
3.87,777,O
ng/mL,777,O
",",777,O
about,777,O
30,777,O
%,777,O
higher,777,O
than,777,O
that,777,O
of,777,O
wild-type,777,O
mIL-2,777,B-GENE-Y
(,777,O
EC,777,O
(,777,O
50,777,O
),777,O
=,777,O
2.70,777,O
ng/mL,777,O
),777,O
.,777,O
The,778,O
maximal,778,O
responses,778,O
are,778,O
equivalent,778,O
for,778,O
the,778,O
fluorinated,778,O
and,778,O
wild-type,778,O
cytokines,778,B-GENE-N
",",778,O
indicating,778,O
that,778,O
fluorinated,778,O
proteins,778,O
can,778,O
fold,778,O
into,778,O
stable,778,O
and,778,O
functional,778,O
structures,778,O
.,778,O
3TFI,779,B-CHEMICAL
yielded,779,O
no,779,O
evidence,779,O
for,779,O
in,779,O
vivo,779,O
incorporation,779,O
into,779,O
recombinant,779,O
proteins,779,O
",",779,O
and,779,O
no,779,O
evidence,779,O
for,779,O
activation,779,O
by,779,O
IleRS,779,B-GENE-Y
in,779,O
vitro,779,O
.,779,O
Analysis,780,O
of,780,O
plasmin,780,B-GENE-Y
binding,780,O
and,780,O
urokinase,780,B-GENE-Y
activation,780,O
of,780,O
plasminogen,780,B-GENE-Y
bound,780,O
to,780,O
the,780,O
Heymann,780,B-GENE-Y
nephritis,780,I-GENE-Y
autoantigen,780,I-GENE-Y
",",780,O
gp330,780,B-GENE-Y
.,780,O
Previously,781,O
",",781,O
we,781,O
demonstrated,781,O
that,781,O
the,781,O
Heymann,781,B-GENE-Y
nephritis,781,I-GENE-Y
autoantigen,781,I-GENE-Y
",",781,O
gp330,781,B-GENE-Y
",",781,O
can,781,O
serve,781,O
as,781,O
a,781,O
receptor,781,O
site,781,O
for,781,O
plasminogen,781,B-GENE-Y
.,781,O
This,782,O
binding,782,O
was,782,O
not,782,O
significantly,782,O
inhibited,782,O
by,782,O
the,782,O
lysine,782,B-CHEMICAL
analogue,782,O
epsilon-amino,782,B-CHEMICAL
caproic,782,I-CHEMICAL
acid,782,I-CHEMICAL
(,782,O
EACA,782,B-CHEMICAL
),782,O
",",782,O
indicating,782,O
that,782,O
plasminogen,782,B-GENE-Y
binding,782,O
was,782,O
not,782,O
just,782,O
through,782,O
lysine,782,B-CHEMICAL
binding,782,O
sites,782,O
as,782,O
suggested,782,O
for,782,O
other,782,O
plasminogen,782,B-GENE-Y
binding,782,O
sites,782,O
.,782,O
We,783,O
now,783,O
report,783,O
that,783,O
once,783,O
plasminogen,783,B-GENE-Y
is,783,O
bound,783,O
to,783,O
gp330,783,B-GENE-Y
",",783,O
it,783,O
can,783,O
be,783,O
converted,783,O
to,783,O
its,783,O
active,783,O
form,783,O
of,783,O
plasmin,783,B-GENE-Y
by,783,O
urokinase,783,B-GENE-Y
.,783,O
This,784,O
conversion,784,O
of,784,O
plasminogen,784,B-GENE-Y
to,784,O
plasmin,784,B-GENE-Y
proceeds,784,O
at,784,O
a,784,O
faster,784,O
rate,784,O
when,784,O
plasminogen,784,B-GENE-Y
is,784,O
first,784,O
prebound,784,O
to,784,O
gp330,784,B-GENE-Y
.,784,O
Although,785,O
there,785,O
is,785,O
a,785,O
proportional,785,O
increase,785,O
in,785,O
the,785,O
Vmax,785,O
of,785,O
the,785,O
urokinase-catalyzed,785,B-GENE-Y
reaction,785,O
with,785,O
increasing,785,O
gp330,785,B-GENE-Y
concentrations,785,O
",",785,O
no,785,O
change,785,O
in,785,O
Km,785,O
was,785,O
observed,785,O
.,785,O
Once,786,O
activated,786,O
",",786,O
plasmin,786,B-GENE-Y
remains,786,O
bound,786,O
to,786,O
gp330,786,B-GENE-Y
in,786,O
an,786,O
active,786,O
state,786,O
capable,786,O
of,786,O
cleaving,786,O
the,786,O
chromogenic,786,O
tripeptide,786,O
",",786,O
S-2251,786,O
.,786,O
The,787,O
binding,787,O
of,787,O
plasmin,787,B-GENE-Y
to,787,O
gp330,787,B-GENE-Y
did,787,O
not,787,O
significantly,787,O
change,787,O
its,787,O
enzymatic,787,O
activity,787,O
;,787,O
however,787,O
",",787,O
gp330,787,B-GENE-Y
did,787,O
have,787,O
a,787,O
stabilizing,787,O
effect,787,O
on,787,O
plasmin,787,B-GENE-Y
activity,787,O
at,787,O
37,787,O
degrees,787,O
C.,787,O
While,787,O
bound,787,O
to,787,O
gp330,787,B-GENE-Y
",",787,O
plasmin,787,B-GENE-Y
is,787,O
protected,787,O
from,787,O
inactivation,787,O
by,787,O
its,787,O
natural,787,O
inhibitor,787,O
alpha,787,B-GENE-Y
2-antiplasmin,787,I-GENE-Y
.,787,O
The,788,O
binding,788,O
of,788,O
plasmin,788,B-GENE-Y
to,788,O
gp330,788,B-GENE-Y
as,788,O
analyzed,788,O
by,788,O
ELISA,788,O
was,788,O
shown,788,O
to,788,O
be,788,O
time,788,O
dependent,788,O
",",788,O
reversible,788,O
",",788,O
saturable,788,O
",",788,O
and,788,O
specific,788,O
for,788,O
gp330,788,B-GENE-Y
.,788,O
Inhibition,789,O
of,789,O
binding,789,O
of,789,O
both,789,O
plasminogen,789,B-GENE-Y
and,789,O
plasmin,789,B-GENE-Y
to,789,O
gp330,789,B-GENE-Y
by,789,O
benzamidine,789,B-CHEMICAL
was,789,O
similar,789,O
",",789,O
although,789,O
EACA,789,B-CHEMICAL
inhibited,789,O
the,789,O
binding,789,O
of,789,O
plasmin,789,B-GENE-Y
to,789,O
gp330,789,B-GENE-Y
slightly,789,O
more,789,O
than,789,O
the,789,O
binding,789,O
of,789,O
plasminogen,789,B-GENE-Y
to,789,O
gp330,789,B-GENE-Y
.,789,O
These,790,O
results,790,O
indicate,790,O
that,790,O
the,790,O
binding,790,O
of,790,O
plasminogen,790,B-GENE-Y
to,790,O
gp330,790,B-GENE-Y
serves,790,O
as,790,O
an,790,O
effective,790,O
means,790,O
of,790,O
increasing,790,O
the,790,O
rate,790,O
of,790,O
plasmin,790,B-GENE-Y
production,790,O
on,790,O
the,790,O
glomerular,790,O
and,790,O
tubular,790,O
epithelial,790,O
cell,790,O
surface,790,O
while,790,O
protecting,790,O
the,790,O
active,790,O
plasmin,790,B-GENE-Y
from,790,O
natural,790,O
inhibitors,790,O
.,790,O
Functional,791,O
characterization,791,O
of,791,O
alpha-adrenoceptors,791,B-GENE-N
mediating,791,O
pupillary,791,O
dilation,791,O
in,791,O
rats,791,O
.,791,O
Previously,792,O
",",792,O
we,792,O
reported,792,O
that,792,O
the,792,O
alpha,792,B-GENE-Y
(,792,I-GENE-Y
1A,792,I-GENE-Y
),792,I-GENE-Y
-adrenoceptor,792,I-GENE-Y
",",792,O
but,792,O
not,792,O
the,792,O
alpha,792,B-GENE-Y
(,792,I-GENE-Y
1D,792,I-GENE-Y
),792,I-GENE-Y
-adrenoceptor,792,I-GENE-Y
",",792,O
mediates,792,O
pupillary,792,O
dilation,792,O
elicited,792,O
by,792,O
sympathetic,792,O
nerve,792,O
stimulation,792,O
in,792,O
rats,792,O
.,792,O
This,793,O
study,793,O
was,793,O
undertaken,793,O
to,793,O
further,793,O
characterize,793,O
the,793,O
alpha-adrenoceptor,793,B-GENE-N
subtypes,793,O
mediating,793,O
pupillary,793,O
dilation,793,O
in,793,O
response,793,O
to,793,O
both,793,O
neural,793,O
and,793,O
agonist,793,O
activation,793,O
.,793,O
Pupillary,794,O
dilator,794,O
response,794,O
curves,794,O
were,794,O
generated,794,O
by,794,O
intravenous,794,O
injection,794,O
of,794,O
norepinephrine,794,B-CHEMICAL
in,794,O
pentobarbital-anesthetized,794,B-CHEMICAL
rats,794,O
.,794,O
Involvement,795,O
of,795,O
alpha,795,B-GENE-N
(,795,I-GENE-N
1,795,I-GENE-N
),795,I-GENE-N
-adrenoceptors,795,I-GENE-N
was,795,O
established,795,O
as,795,O
mydriatic,795,O
responses,795,O
were,795,O
inhibited,795,O
by,795,O
systemic,795,O
administration,795,O
of,795,O
nonselective,795,O
alpha-adrenoceptor,795,B-GENE-N
antagonists,795,O
",",795,O
phentolamine,795,B-CHEMICAL
(,795,O
0.3-3,795,O
mg/kg,795,O
),795,O
and,795,O
phenoxybenzamine,795,B-CHEMICAL
(,795,O
0.03-0.3,795,O
mg/kg,795,O
),795,O
",",795,O
as,795,O
well,795,O
as,795,O
by,795,O
the,795,O
selective,795,O
alpha,795,B-GENE-N
(,795,I-GENE-N
1,795,I-GENE-N
),795,I-GENE-N
-adrenoceptor,795,I-GENE-N
antagonist,795,O
",",795,O
prazosin,795,B-CHEMICAL
(,795,O
0.3,795,O
mg/kg,795,O
),795,O
.,795,O
The,796,O
alpha,796,B-GENE-N
(,796,I-GENE-N
2,796,I-GENE-N
),796,I-GENE-N
-adrenoceptor,796,I-GENE-N
antagonist,796,O
",",796,O
rauwolscine,796,B-CHEMICAL
(,796,O
0.5,796,O
mg/kg,796,O
),796,O
",",796,O
was,796,O
without,796,O
antagonistic,796,O
effects,796,O
.,796,O
alpha,797,B-GENE-Y
(,797,I-GENE-Y
1A,797,I-GENE-Y
),797,I-GENE-Y
-Adrenoceptor,797,I-GENE-Y
selective,797,O
antagonists,797,O
",",797,O
2-,797,B-CHEMICAL
(,797,I-CHEMICAL
[,797,I-CHEMICAL
"2,6-dimethoxyphenoxyethyl",797,I-CHEMICAL
],797,I-CHEMICAL
aminomethyl,797,I-CHEMICAL
),797,I-CHEMICAL
"-1,4-benzodioxane",797,I-CHEMICAL
(,797,O
WB-4101,797,B-CHEMICAL
;,797,O
0.1-1,797,O
mg/kg,797,O
),797,O
and,797,O
5-methylurapidil,797,B-CHEMICAL
(,797,O
0.1-1,797,O
mg/kg,797,O
),797,O
",",797,O
the,797,O
alpha,797,B-GENE-Y
(,797,I-GENE-Y
1B,797,I-GENE-Y
),797,I-GENE-Y
-adrenoceptor,797,I-GENE-Y
selective,797,O
antagonist,797,O
",",797,O
4-amino-2-,797,B-CHEMICAL
[,797,I-CHEMICAL
4-,797,I-CHEMICAL
[,797,I-CHEMICAL
1-,797,I-CHEMICAL
(,797,I-CHEMICAL
benzyloxycarbonyl,797,I-CHEMICAL
),797,I-CHEMICAL
-2,797,I-CHEMICAL
(,797,I-CHEMICAL
S,797,I-CHEMICAL
),797,I-CHEMICAL
-,797,I-CHEMICAL
[,797,I-CHEMICAL
[,797,I-CHEMICAL
(,797,I-CHEMICAL
"1,1-dimethylethyl",797,I-CHEMICAL
),797,I-CHEMICAL
amino,797,I-CHEMICAL
],797,I-CHEMICAL
carbonyl,797,I-CHEMICAL
],797,I-CHEMICAL
-piperazinyl,797,I-CHEMICAL
],797,I-CHEMICAL
"-6,7-dimethoxyquinazoline",797,I-CHEMICAL
(,797,O
L-765314,797,B-CHEMICAL
;,797,O
0.3-1,797,O
mg/kg,797,O
),797,O
",",797,O
as,797,O
well,797,O
as,797,O
the,797,O
alpha,797,B-GENE-Y
(,797,I-GENE-Y
1D,797,I-GENE-Y
),797,I-GENE-Y
-adrenoceptor,797,I-GENE-Y
selective,797,O
antagonist,797,O
",",797,O
8-,797,B-CHEMICAL
[,797,I-CHEMICAL
2-,797,I-CHEMICAL
[,797,I-CHEMICAL
4-,797,I-CHEMICAL
(,797,I-CHEMICAL
2-methoxyphenyl,797,I-CHEMICAL
),797,I-CHEMICAL
-1-piperazinyl,797,I-CHEMICAL
],797,I-CHEMICAL
ethyl,797,I-CHEMICAL
],797,I-CHEMICAL
-8-azaspiro,797,I-CHEMICAL
[,797,I-CHEMICAL
4.5,797,I-CHEMICAL
],797,I-CHEMICAL
"decane-7,9-dione",797,I-CHEMICAL
(,797,O
BMY-7378,797,B-CHEMICAL
;,797,O
1,797,O
mg/kg,797,O
),797,O
",",797,O
were,797,O
used,797,O
to,797,O
delineate,797,O
the,797,O
adrenoceptor,797,B-GENE-N
subtypes,797,O
involved,797,O
.,797,O
Mydriatic,798,O
responses,798,O
to,798,O
norepinephrine,798,B-CHEMICAL
were,798,O
significantly,798,O
antagonized,798,O
by,798,O
intravenous,798,O
administration,798,O
of,798,O
both,798,O
WB-4101,798,B-CHEMICAL
and,798,O
5-methylurapidil,798,B-CHEMICAL
",",798,O
but,798,O
neither,798,O
by,798,O
L-765314,798,B-CHEMICAL
nor,798,O
by,798,O
BMY-7378,798,B-CHEMICAL
.,798,O
L-765314,799,B-CHEMICAL
(,799,O
0.3-3,799,O
mg/kg,799,O
",",799,O
i.v,799,O
.,799,O
),799,O
was,800,O
also,800,O
ineffective,800,O
in,800,O
inhibiting,800,O
the,800,O
mydriasis,800,O
evoked,800,O
by,800,O
cervical,800,O
sympathetic,800,O
nerve,800,O
stimulation,800,O
.,800,O
These,801,O
results,801,O
suggest,801,O
that,801,O
alpha,801,B-GENE-Y
(,801,I-GENE-Y
1B,801,I-GENE-Y
),801,I-GENE-Y
-adrenoceptors,801,I-GENE-Y
do,801,O
not,801,O
mediate,801,O
sympathetic,801,O
mydriasis,801,O
in,801,O
rats,801,O
",",801,O
and,801,O
that,801,O
the,801,O
alpha,801,B-GENE-Y
(,801,I-GENE-Y
1A,801,I-GENE-Y
),801,I-GENE-Y
-adrenoceptor,801,I-GENE-Y
is,801,O
the,801,O
exclusive,801,O
subtype,801,O
mediating,801,O
mydriatic,801,O
responses,801,O
in,801,O
this,801,O
species,801,O
.,801,O
Colon,802,O
cancer,802,O
cells,802,O
with,802,O
high,802,O
invasive,802,O
potential,802,O
are,802,O
susceptible,802,O
to,802,O
induction,802,O
of,802,O
apoptosis,802,O
by,802,O
a,802,O
selective,802,O
COX-2,802,B-GENE-Y
inhibitor,802,O
.,802,O
Cyclooxygenase-2,803,B-GENE-Y
(,803,O
COX-2,803,B-GENE-Y
),803,O
expression,803,O
has,803,O
been,803,O
shown,803,O
to,803,O
correlate,803,O
with,803,O
the,803,O
invasiveness,803,O
of,803,O
colon,803,O
cancer,803,O
cells,803,O
.,803,O
To,804,O
further,804,O
investigate,804,O
this,804,O
positive,804,O
correlation,804,O
and,804,O
its,804,O
possible,804,O
therapeutic,804,O
implications,804,O
",",804,O
a,804,O
selective,804,O
COX-2,804,B-GENE-Y
inhibitor,804,O
",",804,O
etodolac,804,B-CHEMICAL
",",804,O
was,804,O
tested,804,O
on,804,O
three,804,O
variants,804,O
of,804,O
HT-29,804,O
colon,804,O
cancer,804,O
cell,804,O
lines,804,O
",",804,O
HT-29/Inv1,804,O
",",804,O
HT-29/Inv2,804,O
and,804,O
HT-29/Inv3,804,O
",",804,O
with,804,O
graded,804,O
increases,804,O
of,804,O
in,804,O
vitro,804,O
Matrigel,804,O
invasive,804,O
potential,804,O
and,804,O
COX-2,804,B-GENE-Y
expression,804,O
levels,804,O
.,804,O
HT-29,805,O
variants,805,O
with,805,O
higher,805,O
invasive,805,O
potential,805,O
were,805,O
found,805,O
to,805,O
be,805,O
more,805,O
sensitive,805,O
to,805,O
etodolac,805,B-CHEMICAL
by,805,O
in,805,O
vitro,805,O
growth,805,O
inhibition,805,O
assays,805,O
",",805,O
the,805,O
estimated,805,O
LD,805,O
(,805,O
50,805,O
),805,O
being,805,O
0.5,805,O
mM,805,O
for,805,O
highly,805,O
invasive,805,O
HT-29/Inv2,805,O
and,805,O
HT-29/Inv3,805,O
cells,805,O
",",805,O
0.6,805,O
mM,805,O
for,805,O
slightly,805,O
less,805,O
invasive,805,O
HT-29/Inv1,805,O
",",805,O
and,805,O
1.8,805,O
mM,805,O
for,805,O
the,805,O
parental,805,O
HT-29,805,O
.,805,O
Treatment,806,O
of,806,O
the,806,O
highly,806,O
invasive,806,O
HT-29/Inv2,806,O
and,806,O
Inv3,806,O
variants,806,O
with,806,O
as,806,O
little,806,O
as,806,O
0.1,806,O
mM,806,O
etodolac,806,B-CHEMICAL
in,806,O
the,806,O
growth,806,O
medium,806,O
produced,806,O
signs,806,O
of,806,O
apoptosis,806,O
",",806,O
as,806,O
detected,806,O
by,806,O
DNA,806,O
fragmentation,806,O
and,806,O
TUNEL,806,O
(,806,O
terminal,806,O
deoxynucleotidyl,806,O
transferase,806,O
dUTP-biotin,806,B-CHEMICAL
nick,806,O
end,806,O
labeling,806,O
),806,O
assay,806,O
.,806,O
In,807,O
vivo,807,O
experiments,807,O
in,807,O
SCID,807,O
mice,807,O
showed,807,O
that,807,O
etolodac,807,B-CHEMICAL
inhibited,807,O
the,807,O
growth,807,O
of,807,O
subcutaneous,807,O
tumors,807,O
induced,807,O
by,807,O
HT-29/Inv3,807,O
cells,807,O
significantly,807,O
more,807,O
than,807,O
those,807,O
by,807,O
the,807,O
parental,807,O
HT-29,807,O
cells,807,O
.,807,O
These,808,O
results,808,O
suggest,808,O
that,808,O
COX-2,808,B-GENE-Y
inhibitors,808,O
have,808,O
a,808,O
potential,808,O
role,808,O
in,808,O
prevention,808,O
of,808,O
tumor,808,O
invasion,808,O
in,808,O
colon,808,O
cancer,808,O
patients,808,O
.,808,O
Pharmacological,809,O
characterization,809,O
of,809,O
unique,809,O
prazosin-binding,809,B-CHEMICAL
sites,809,O
in,809,O
human,809,O
kidney,809,O
.,809,O
In,810,O
human,810,O
kidney,810,O
",",810,O
we,810,O
found,810,O
unique,810,O
prazosin-binding,810,B-CHEMICAL
sites,810,O
that,810,O
were,810,O
insensitive,810,O
to,810,O
phentolamine,810,B-CHEMICAL
and,810,O
were,810,O
thus,810,O
unlikely,810,O
to,810,O
be,810,O
alpha,810,B-GENE-N
(,810,I-GENE-N
1,810,I-GENE-N
),810,I-GENE-N
-adrenoceptors,810,I-GENE-N
.,810,O
As,811,O
the,811,O
binding,811,O
of,811,O
[,811,B-CHEMICAL
(,811,I-CHEMICAL
3,811,I-CHEMICAL
),811,I-CHEMICAL
H,811,I-CHEMICAL
],811,I-CHEMICAL
prazosin,811,I-CHEMICAL
to,811,O
phentolamine-insensitive,811,B-CHEMICAL
sites,811,O
was,811,O
prevented,811,O
by,811,O
100,811,O
microM,811,O
guanabenz,811,B-CHEMICAL
",",811,O
the,811,O
insensitive,811,O
sites,811,O
were,811,O
evaluated,811,O
by,811,O
subtracting,811,O
[,811,B-CHEMICAL
(,811,I-CHEMICAL
3,811,I-CHEMICAL
),811,I-CHEMICAL
H,811,I-CHEMICAL
],811,I-CHEMICAL
prazosin,811,I-CHEMICAL
binding,811,O
in,811,O
the,811,O
presence,811,O
of,811,O
100,811,O
microM,811,O
guanabenz,811,B-CHEMICAL
from,811,O
that,811,O
in,811,O
the,811,O
presence,811,O
of,811,O
10,811,O
microM,811,O
phentolamine,811,B-CHEMICAL
.,811,O
[,812,B-CHEMICAL
(,812,I-CHEMICAL
3,812,I-CHEMICAL
),812,I-CHEMICAL
H,812,I-CHEMICAL
],812,I-CHEMICAL
Prazosin,812,I-CHEMICAL
bound,812,O
to,812,O
the,812,O
phentolamine-insensitive,812,B-CHEMICAL
sites,812,O
monophasically,812,O
with,812,O
a,812,O
high,812,O
affinity,812,O
(,812,O
pK,812,O
(,812,O
d,812,O
),812,O
;,812,O
9.1+/-0.08,812,O
",",812,O
n=8,812,O
),812,O
",",812,O
and,812,O
the,812,O
B,812,O
(,812,O
max,812,O
),812,O
value,812,O
(,812,O
814+/-204,812,O
fmol,812,O
mg,812,O
(,812,O
-1,812,O
),812,O
protein,812,O
",",812,O
n=8,812,O
),812,O
was,812,O
more,812,O
than,812,O
ten,812,O
times,812,O
that,812,O
of,812,O
the,812,O
phentolamine-sensitive,812,B-CHEMICAL
alpha,812,B-GENE-N
(,812,I-GENE-N
1,812,I-GENE-N
),812,I-GENE-N
-adrenoceptor,812,I-GENE-N
(,812,O
pK,812,O
(,812,O
d,812,O
),812,O
=9.9+/-0.13,812,O
",",812,O
B,812,O
(,812,O
max,812,O
),812,O
=66+/-23,812,O
fmol,812,O
mg,812,O
(,812,O
-1,812,O
),812,O
protein,812,O
",",812,O
n=7,812,O
),812,O
.,812,O
The,813,O
phentolamine-insensitive,813,B-CHEMICAL
sites,813,O
in,813,O
human,813,O
kidney,813,O
were,813,O
highly,813,O
sensitive,813,O
to,813,O
other,813,O
quinazoline,813,B-CHEMICAL
derivatives,813,O
such,813,O
as,813,O
terazosin,813,B-CHEMICAL
and,813,O
doxazosin,813,B-CHEMICAL
.,813,O
However,814,O
",",814,O
other,814,O
alpha,814,B-GENE-N
(,814,I-GENE-N
1,814,I-GENE-N
),814,I-GENE-N
-adrenoceptor,814,I-GENE-N
antagonists,814,O
(,814,O
tamsulosin,814,B-CHEMICAL
",",814,O
WB4101,814,B-CHEMICAL
and,814,O
corynanthine,814,B-CHEMICAL
),814,O
did,814,O
not,814,O
inhibit,814,O
the,814,O
binding,814,O
at,814,O
a,814,O
range,814,O
of,814,O
concentrations,814,O
that,814,O
generally,814,O
exhibit,814,O
alpha,814,B-GENE-N
(,814,I-GENE-N
1,814,I-GENE-N
),814,I-GENE-N
-adrenoceptor,814,I-GENE-N
antagonism,814,O
",",814,O
and,814,O
noradrenaline,814,B-CHEMICAL
",",814,O
rauwolscine,814,B-CHEMICAL
and,814,O
propranolol,814,B-CHEMICAL
were,814,O
without,814,O
effect,814,O
on,814,O
the,814,O
[,814,B-CHEMICAL
(,814,I-CHEMICAL
3,814,I-CHEMICAL
),814,I-CHEMICAL
H,814,I-CHEMICAL
],814,I-CHEMICAL
prazosin,814,I-CHEMICAL
binding,814,O
.,814,O
On,815,O
the,815,O
other,815,O
hand,815,O
",",815,O
ligands,815,O
for,815,O
the,815,O
renal,815,O
Na,815,B-CHEMICAL
(,815,I-CHEMICAL
+,815,I-CHEMICAL
),815,I-CHEMICAL
-transporter,815,I-GENE-N
(,815,O
amiloride,815,B-CHEMICAL
and,815,O
triamterene,815,B-CHEMICAL
),815,O
and,815,O
for,815,O
imidazoline,815,B-CHEMICAL
recognition,815,O
sites,815,O
(,815,O
guanabenz,815,B-CHEMICAL
",",815,O
guanfacine,815,B-CHEMICAL
and,815,O
agmatine,815,B-CHEMICAL
),815,O
displaced,815,O
the,815,O
binding,815,O
of,815,O
[,815,B-CHEMICAL
(,815,I-CHEMICAL
3,815,I-CHEMICAL
),815,I-CHEMICAL
H,815,I-CHEMICAL
],815,I-CHEMICAL
prazosin,815,I-CHEMICAL
to,815,O
phentolamine-insensitive,815,B-CHEMICAL
sites,815,O
at,815,O
micromolar,815,O
concentrations,815,O
.,815,O
Photoaffinity,816,O
labeling,816,O
with,816,O
[,816,B-CHEMICAL
(,816,I-CHEMICAL
125,816,I-CHEMICAL
),816,I-CHEMICAL
I,816,I-CHEMICAL
],816,I-CHEMICAL
iodoarylazidoprazosin,816,I-CHEMICAL
showed,816,O
phentolamine-insensitive,816,B-CHEMICAL
labeling,816,O
at,816,O
around,816,O
100,816,O
kDa,816,O
",",816,O
a,816,O
molecular,816,O
size,816,O
larger,816,O
than,816,O
that,816,O
of,816,O
human,816,B-GENE-N
alpha,816,I-GENE-N
(,816,I-GENE-N
1a,816,I-GENE-N
),816,I-GENE-N
-,816,I-GENE-N
and,816,I-GENE-N
alpha,816,I-GENE-N
(,816,I-GENE-N
1b,816,I-GENE-N
),816,I-GENE-N
-adrenoceptors,816,I-GENE-N
expressed,816,O
in,816,O
293,816,O
cells,816,O
(,816,O
50-60,816,O
and,816,O
70-80,816,O
kDa,816,O
",",816,O
respectively,816,O
),816,O
on,816,O
electrophoresis,816,O
.,816,O
In,817,O
contrast,817,O
",",817,O
there,817,O
was,817,O
no,817,O
detectable,817,O
phentolamine-insensitive,817,B-CHEMICAL
binding,817,O
site,817,O
but,817,O
were,817,O
phentolamine-sensitive,817,B-CHEMICAL
alpha,817,B-GENE-N
(,817,I-GENE-N
1,817,I-GENE-N
),817,I-GENE-N
-adrenoceptors,817,I-GENE-N
in,817,O
human,817,O
liver,817,O
(,817,O
pK,817,O
(,817,O
d,817,O
),817,O
=10.0+/-0.06,817,O
",",817,O
B,817,O
(,817,O
max,817,O
),817,O
=44+/-6,817,O
fmol,817,O
mg,817,O
(,817,O
-1,817,O
),817,O
protein,817,O
",",817,O
n=3,817,O
),817,O
.,817,O
Phentolamine-insensitive,818,B-CHEMICAL
prazosin,818,B-CHEMICAL
binding,818,O
sites,818,O
were,818,O
also,818,O
detected,818,O
in,818,O
rabbit,818,O
kidney,818,O
(,818,O
approximately,818,O
50,818,O
%,818,O
of,818,O
specific,818,O
binding,818,O
sites,818,O
),818,O
but,818,O
were,818,O
minor,818,O
in,818,O
rat,818,O
kidney,818,O
(,818,O
less,818,O
than,818,O
20,818,O
%,818,O
),818,O
.,818,O
In,819,O
conclusion,819,O
",",819,O
there,819,O
are,819,O
unique,819,O
prazosin-binding,819,B-CHEMICAL
sites,819,O
in,819,O
human,819,O
kidney,819,O
",",819,O
the,819,O
pharmacological,819,O
profiles,819,O
of,819,O
which,819,O
were,819,O
distinct,819,O
from,819,O
those,819,O
of,819,O
known,819,O
adrenoceptors,819,O
.,819,O
chi-Conopeptide,820,O
MrIA,820,O
partially,820,O
overlaps,820,O
desipramine,820,B-GENE-N
and,820,I-GENE-N
cocaine,820,I-GENE-N
binding,820,I-GENE-N
sites,820,I-GENE-N
on,820,O
the,820,O
human,820,B-GENE-Y
norepinephrine,820,I-GENE-Y
transporter,820,I-GENE-Y
.,820,O
The,821,O
interactions,821,O
of,821,O
chi-conopeptide,821,O
MrIA,821,O
with,821,O
the,821,O
human,821,B-GENE-Y
norepinephrine,821,I-GENE-Y
transporter,821,I-GENE-Y
(,821,O
hNET,821,B-GENE-Y
),821,O
were,821,O
investigated,821,O
by,821,O
determining,821,O
the,821,O
effects,821,O
of,821,O
hNET,821,B-GENE-Y
point,821,O
mutations,821,O
on,821,O
the,821,O
inhibitory,821,O
potency,821,O
of,821,O
MrIA,821,O
.,821,O
The,822,O
mutants,822,O
were,822,O
produced,822,O
by,822,O
site-directed,822,O
mutagenesis,822,O
and,822,O
expressed,822,O
in,822,O
COS-7,822,O
cells,822,O
.,822,O
The,823,O
potency,823,O
of,823,O
MrIA,823,O
was,823,O
greater,823,O
for,823,O
inhibition,823,O
of,823,O
uptake,823,O
by,823,O
hNET,823,B-GENE-Y
of,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
norepinephrine,823,I-CHEMICAL
(,823,O
Ki,823,O
1.89,823,O
microM,823,O
),823,O
than,823,O
[,823,B-CHEMICAL
3H,823,I-CHEMICAL
],823,I-CHEMICAL
dopamine,823,I-CHEMICAL
(,823,O
Ki,823,O
4.33,823,O
microM,823,O
),823,O
",",823,O
and,823,O
the,823,O
human,823,B-GENE-Y
dopamine,823,B-CHEMICAL
transporter,823,I-GENE-Y
and,823,O
serotonin,823,B-CHEMICAL
transporter,823,I-GENE-Y
were,823,O
not,823,O
inhibited,823,O
by,823,O
MrIA,823,O
(,823,O
to,823,O
7,823,O
microM,823,O
),823,O
.,823,O
Of,824,O
18,824,O
mutations,824,O
where,824,O
hNET,824,B-GENE-Y
amino,824,B-CHEMICAL
acid,824,I-CHEMICAL
residues,824,O
were,824,O
exchanged,824,O
with,824,O
those,824,O
of,824,O
the,824,O
human,824,B-GENE-Y
dopamine,824,I-GENE-Y
transporter,824,I-GENE-Y
",",824,O
MrIA,824,O
had,824,O
increased,824,O
potency,824,O
for,824,O
inhibition,824,O
of,824,O
[,824,B-CHEMICAL
3H,824,I-CHEMICAL
],824,I-CHEMICAL
norepinephrine,824,I-CHEMICAL
uptake,824,O
for,824,O
three,824,O
mutations,824,O
(,824,O
in,824,O
predicted,824,O
extracellular,824,O
loops,824,O
3,824,O
and,824,O
4,824,O
and,824,O
transmembrane,824,O
domain,824,O
(,824,O
TMD,824,O
),824,O
8,824,O
),824,O
and,824,O
decreased,824,O
potency,824,O
for,824,O
one,824,O
mutation,824,O
(,824,O
in,824,O
TMD6,824,O
and,824,O
intracellular,824,O
loop,824,O
(,824,O
IL,824,O
),824,O
3,824,O
),824,O
.,824,O
Of,825,O
the,825,O
12,825,O
additional,825,O
mutations,825,O
in,825,O
TMDs,825,O
2,825,O
",",825,O
4,825,O
",",825,O
5,825,O
",",825,O
and,825,O
11,825,O
and,825,O
IL1,825,O
",",825,O
three,825,O
mutations,825,O
(,825,O
in,825,O
TMD2,825,O
and,825,O
IL1,825,O
),825,O
had,825,O
reduced,825,O
MrIA,825,O
inhibitory,825,O
potency,825,O
.,825,O
All,826,O
of,826,O
the,826,O
other,826,O
mutations,826,O
tested,826,O
had,826,O
no,826,O
influence,826,O
on,826,O
MrIA,826,O
potency,826,O
.,826,O
A,827,O
comparison,827,O
of,827,O
the,827,O
results,827,O
with,827,O
previous,827,O
data,827,O
for,827,O
desipramine,827,B-CHEMICAL
and,827,O
cocaine,827,O
inhibition,827,O
of,827,O
norepinephrine,827,B-CHEMICAL
uptake,827,O
by,827,O
the,827,O
mutant,827,O
hNETs,827,B-GENE-Y
reveals,827,O
that,827,O
MrIA,827,O
binding,827,O
to,827,O
hNET,827,B-GENE-Y
occurs,827,O
at,827,O
a,827,O
site,827,O
that,827,O
is,827,O
distinct,827,O
from,827,O
but,827,O
overlaps,827,O
with,827,O
the,827,O
binding,827,O
sites,827,O
for,827,O
tricyclic,827,B-CHEMICAL
antidepressants,827,O
and,827,O
cocaine,827,B-CHEMICAL
.,827,O
The,828,O
primary,828,O
structure,828,O
of,828,O
porcine,828,B-GENE-Y
aminoacylase,828,I-GENE-Y
1,828,I-GENE-Y
deduced,828,O
from,828,O
cDNA,828,O
sequence,828,O
.,828,O
A,829,O
cDNA,829,O
encoding,829,O
the,829,O
complete,829,O
amino,829,B-CHEMICAL
acid,829,I-CHEMICAL
sequence,829,O
of,829,O
aminoacylase,829,B-GENE-Y
1,829,I-GENE-Y
(,829,O
N-acylamino,829,B-GENE-Y
acid,829,I-GENE-Y
aminohydrolase,829,I-GENE-Y
",",829,O
ACY-1,829,B-GENE-Y
),829,O
[,829,O
EC,829,B-GENE-Y
3.5.1.14,829,I-GENE-Y
],829,O
",",829,O
a,829,O
dimeric,829,O
metalloprotein,829,B-GENE-N
having,829,O
two,829,O
Zn2+,829,B-CHEMICAL
in,829,O
the,829,O
molecule,829,O
",",829,O
which,829,O
catalyzes,829,O
the,829,O
deacylation,829,O
of,829,O
N-acylated,829,B-CHEMICAL
L-amino,829,I-CHEMICAL
acids,829,I-CHEMICAL
except,829,O
L-aspartic,829,B-CHEMICAL
acid,829,I-CHEMICAL
",",829,O
has,829,O
been,829,O
isolated,829,O
from,829,O
porcine,829,O
kidney,829,O
lambda,829,O
gt10,829,O
cDNA,829,O
library,829,O
and,829,O
sequenced,829,O
.,829,O
From,830,O
sequence,830,O
analysis,830,O
of,830,O
the,830,O
cDNA,830,O
and,830,O
the,830,O
N-,830,B-CHEMICAL
and,830,O
C-terminal,830,B-CHEMICAL
amino,830,B-CHEMICAL
acid,830,I-CHEMICAL
analyses,830,O
of,830,O
the,830,O
purified,830,O
protein,830,O
",",830,O
it,830,O
is,830,O
deduced,830,O
that,830,O
porcine,830,B-GENE-Y
kidney,830,I-GENE-Y
ACY-1,830,I-GENE-Y
consists,830,O
of,830,O
two,830,O
identical,830,O
subunits,830,O
(,830,O
M,830,O
(,830,O
r,830,O
),830,O
"45,260",830,O
),830,O
",",830,O
each,830,O
of,830,O
which,830,O
consists,830,O
of,830,O
a,830,O
single,830,O
chain,830,O
of,830,O
406,830,O
amino,830,B-CHEMICAL
acids,830,I-CHEMICAL
with,830,O
acetylalanine,830,B-CHEMICAL
at,830,O
the,830,O
N-terminus,830,B-CHEMICAL
.,830,O
A,831,O
cDNA,831,O
encoding,831,O
porcine,831,B-GENE-Y
liver,831,I-GENE-Y
ACY-1,831,I-GENE-Y
was,831,O
also,831,O
cloned,831,O
.,831,O
The,832,O
amino,832,B-CHEMICAL
acid,832,I-CHEMICAL
sequence,832,O
deduced,832,O
from,832,O
the,832,O
nucleotide,832,B-CHEMICAL
sequence,832,O
of,832,O
the,832,O
cDNA,832,O
from,832,O
porcine,832,O
liver,832,O
was,832,O
identical,832,O
to,832,O
that,832,O
deduced,832,O
for,832,O
porcine,832,B-GENE-Y
kidney,832,I-GENE-Y
ACY-1,832,I-GENE-Y
.,832,O
Northern,833,O
blot,833,O
analysis,833,O
suggested,833,O
that,833,O
ACY-1,833,B-GENE-Y
is,833,O
more,833,O
highly,833,O
expressed,833,O
in,833,O
kidney,833,O
than,833,O
in,833,O
liver,833,O
.,833,O
Comparison,834,O
of,834,O
the,834,O
amino,834,B-CHEMICAL
acid,834,I-CHEMICAL
sequence,834,O
of,834,O
porcine,834,B-GENE-Y
ACY-1,834,I-GENE-Y
with,834,O
those,834,O
of,834,O
other,834,O
Zn2+-binding,834,B-CHEMICAL
metalloenzymes,834,I-GENE-N
showed,834,O
no,834,O
significant,834,O
homologies,834,O
in,834,O
either,834,O
the,834,O
overall,834,O
sequence,834,O
or,834,O
the,834,O
consensus,834,O
sequences,834,O
for,834,O
the,834,O
metal,834,O
binding,834,O
sites,834,O
.,834,O
This,835,O
indicates,835,O
that,835,O
ACY-1,835,B-GENE-Y
is,835,O
a,835,O
new,835,O
type,835,O
of,835,O
metalloprotein,835,B-GENE-N
.,835,O
Beta,836,B-GENE-Y
1-adrenergic,836,I-GENE-Y
receptor,836,I-GENE-Y
polymorphisms,836,O
and,836,O
antihypertensive,836,O
response,836,O
to,836,O
metoprolol,836,B-CHEMICAL
.,836,O
OBJECTIVES,837,O
:,837,O
Marked,837,O
interpatient,837,O
variability,837,O
exists,837,O
in,837,O
blood,837,O
pressure,837,O
response,837,O
to,837,O
beta-blocker,837,O
monotherapy,837,O
.,837,O
We,838,O
tested,838,O
the,838,O
hypothesis,838,O
that,838,O
2,838,O
common,838,O
polymorphisms,838,O
in,838,O
the,838,O
gene,838,O
for,838,O
beta,838,B-GENE-Y
(,838,I-GENE-Y
1,838,I-GENE-Y
),838,I-GENE-Y
-adrenergic,838,I-GENE-Y
receptor,838,I-GENE-Y
are,838,O
associated,838,O
with,838,O
antihypertensive,838,O
response,838,O
to,838,O
metoprolol,838,B-CHEMICAL
in,838,O
patients,838,O
with,838,O
uncomplicated,838,O
hypertension,838,O
.,838,O
METHODS,839,O
:,839,O
Forty,839,O
hypertensive,839,O
men,839,O
and,839,O
women,839,O
aged,839,O
35,839,O
to,839,O
65,839,O
years,839,O
were,839,O
studied,839,O
.,839,O
Baseline,840,O
studies,840,O
included,840,O
24-hour,840,O
ambulatory,840,O
blood,840,O
pressure,840,O
monitoring,840,O
.,840,O
Patients,841,O
took,841,O
50,841,O
mg,841,O
metoprolol,841,B-CHEMICAL
twice,841,O
daily,841,O
with,841,O
weekly,841,O
titration,841,O
to,841,O
response,841,O
or,841,O
200,841,O
mg,841,O
twice,841,O
daily,841,O
.,841,O
After,842,O
a,842,O
minimum,842,O
of,842,O
4,842,O
weeks,842,O
at,842,O
stable,842,O
dose,842,O
",",842,O
treatment,842,O
phase,842,O
24-hour,842,O
ambulatory,842,O
blood,842,O
pressure,842,O
monitoring,842,O
was,842,O
repeated,842,O
.,842,O
The,843,O
codon,843,O
49,843,O
and,843,O
389,843,O
genotypes,843,O
for,843,O
beta,843,B-GENE-Y
(,843,I-GENE-Y
1,843,I-GENE-Y
),843,I-GENE-Y
-adrenergic,843,I-GENE-Y
receptor,843,I-GENE-Y
were,843,O
determined,843,O
by,843,O
polymerase,843,O
chain,843,O
reaction,843,O
with,843,O
restriction,843,O
fragment,843,O
length,843,O
polymorphism,843,O
.,843,O
Multilinear,844,O
regression,844,O
was,844,O
performed,844,O
to,844,O
determine,844,O
the,844,O
impact,844,O
of,844,O
genotype,844,O
and,844,O
other,844,O
variables,844,O
on,844,O
blood,844,O
pressure,844,O
response,844,O
to,844,O
metoprolol,844,B-CHEMICAL
.,844,O
RESULTS,845,O
:,845,O
Patients,845,O
homozygous,845,O
for,845,O
Arg,845,B-CHEMICAL
at,845,O
codon,845,O
389,845,O
had,845,O
a,845,O
nearly,845,O
3-fold,845,O
greater,845,O
reduction,845,O
in,845,O
daytime,845,O
diastolic,845,O
blood,845,O
pressure,845,O
(,845,O
-13.3,845,O
%,845,O
+/-,845,O
8.4,845,O
%,845,O
versus,845,O
-4.5,845,O
%,845,O
+/-,845,O
8.2,845,O
%,845,O
",",845,O
P,845,O
=.0018,845,O
),845,O
compared,845,O
with,845,O
those,845,O
who,845,O
carried,845,O
the,845,O
variant,845,O
allele,845,O
.,845,O
The,846,O
haplotype,846,O
pair,846,O
(,846,O
diplotype,846,O
),846,O
for,846,O
beta,846,B-GENE-Y
(,846,I-GENE-Y
1,846,I-GENE-Y
),846,I-GENE-Y
-adrenergic,846,I-GENE-Y
receptor,846,I-GENE-Y
was,846,O
also,846,O
a,846,O
significant,846,O
predictor,846,O
of,846,O
response,846,O
",",846,O
with,846,O
patients,846,O
having,846,O
the,846,O
Ser49Arg389/Ser49Arg389,846,B-GENE-N
diplotype,846,O
demonstrating,846,O
a,846,O
decline,846,O
in,846,O
blood,846,O
pressure,846,O
of,846,O
14.7,846,O
mm,846,O
Hg,846,O
versus,846,O
0.5,846,O
mm,846,O
Hg,846,O
in,846,O
patients,846,O
with,846,O
the,846,O
Gly49Arg389/Ser49Gly389,846,B-GENE-N
diplotype,846,O
.,846,O
In,847,O
multiregression,847,O
analysis,847,O
",",847,O
baseline,847,O
daytime,847,O
diastolic,847,O
blood,847,O
pressure,847,O
",",847,O
codon,847,O
389,847,O
genotype,847,O
",",847,O
and,847,O
codon,847,O
49,847,O
genotype,847,O
were,847,O
significant,847,O
predictors,847,O
of,847,O
blood,847,O
pressure,847,O
after,847,O
treatment,847,O
.,847,O
CONCLUSIONS,848,O
:,848,O
Our,848,O
data,848,O
suggest,848,O
that,848,O
beta,848,B-GENE-Y
(,848,I-GENE-Y
1,848,I-GENE-Y
),848,I-GENE-Y
-adrenergic,848,I-GENE-Y
receptor,848,I-GENE-Y
polymorphisms,848,O
are,848,O
important,848,O
determinants,848,O
of,848,O
antihypertensive,848,O
response,848,O
to,848,O
metoprolol,848,B-CHEMICAL
.,848,O
In,849,O
the,849,O
future,849,O
",",849,O
codon,849,O
49,849,O
and,849,O
389,849,O
genotypes,849,O
or,849,O
beta,849,B-GENE-Y
(,849,I-GENE-Y
1,849,I-GENE-Y
),849,I-GENE-Y
-adrenergic,849,I-GENE-Y
receptor,849,I-GENE-Y
haplotypes,849,O
might,849,O
be,849,O
used,849,O
to,849,O
predict,849,O
the,849,O
diastolic,849,O
blood,849,O
pressure,849,O
response,849,O
to,849,O
metoprolol,849,B-CHEMICAL
in,849,O
patients,849,O
with,849,O
hypertension,849,O
.,849,O
Interaction,850,O
of,850,O
rofecoxib,850,B-CHEMICAL
and,850,O
celecoxib,850,B-CHEMICAL
with,850,O
warfarin,850,B-CHEMICAL
.,850,O
The,851,O
interaction,851,O
of,851,O
celecoxib,851,B-CHEMICAL
and,851,O
rofecoxib,851,B-CHEMICAL
with,851,O
warfarin,851,B-CHEMICAL
was,851,O
studied,851,O
.,851,O
Patients,852,O
stable,852,O
on,852,O
warfarin,852,B-CHEMICAL
therapy,852,O
and,852,O
concurrently,852,O
taking,852,O
a,852,O
cyclooxygenase-2,852,B-GENE-Y
(,852,O
COX-2,852,B-GENE-Y
),852,O
inhibitor,852,O
comparator,852,O
(,852,O
traditional,852,O
nonsteroidal,852,O
antiinflammatory,852,O
medications,852,O
",",852,O
salsalate,852,B-CHEMICAL
",",852,O
or,852,O
acetaminophen,852,B-CHEMICAL
),852,O
randomly,852,O
received,852,O
celecoxib,852,B-CHEMICAL
200,852,O
mg/day,852,O
or,852,O
rofecoxib,852,B-CHEMICAL
25,852,O
mg/day,852,O
for,852,O
three,852,O
weeks,852,O
.,852,O
After,853,O
a,853,O
one-week,853,O
washout,853,O
period,853,O
",",853,O
the,853,O
patients,853,O
were,853,O
crossed,853,O
over,853,O
to,853,O
treatment,853,O
with,853,O
the,853,O
opposite,853,O
COX-2,853,B-GENE-Y
inhibitor,853,O
for,853,O
three,853,O
more,853,O
weeks,853,O
.,853,O
The,854,O
International,854,O
Normalized,854,O
Ratio,854,O
(,854,O
INR,854,O
),854,O
was,854,O
measured,854,O
at,854,O
baseline,854,O
and,854,O
at,854,O
weeks,854,O
1,854,O
",",854,O
2,854,O
",",854,O
and,854,O
3,854,O
of,854,O
therapy,854,O
with,854,O
each,854,O
COX-2,854,B-GENE-Y
inhibitor,854,O
by,854,O
testing,854,O
blood,854,O
samples,854,O
obtained,854,O
by,854,O
finger,854,O
stick,854,O
.,854,O
Data,855,O
for,855,O
16,855,O
patients,855,O
were,855,O
analyzed,855,O
.,855,O
The,856,O
INR,856,O
increased,856,O
by,856,O
13,856,O
%,856,O
",",856,O
6,856,O
%,856,O
",",856,O
and,856,O
5,856,O
%,856,O
on,856,O
average,856,O
in,856,O
patients,856,O
taking,856,O
celecoxib,856,B-CHEMICAL
at,856,O
weeks,856,O
1,856,O
",",856,O
2,856,O
",",856,O
and,856,O
3,856,O
",",856,O
respectively,856,O
",",856,O
and,856,O
by,856,O
5,856,O
%,856,O
",",856,O
9,856,O
%,856,O
",",856,O
and,856,O
5,856,O
%,856,O
in,856,O
patients,856,O
taking,856,O
rofecoxib,856,B-CHEMICAL
.,856,O
Changes,857,O
in,857,O
the,857,O
INR,857,O
were,857,O
statistically,857,O
significant,857,O
at,857,O
week,857,O
1,857,O
for,857,O
celecoxib,857,B-CHEMICAL
and,857,O
at,857,O
week,857,O
2,857,O
for,857,O
rofecoxib,857,B-CHEMICAL
.,857,O
Of,858,O
the,858,O
12,858,O
subjects,858,O
who,858,O
had,858,O
a,858,O
clinically,858,O
significant,858,O
>,858,O
or,858,O
=,858,O
15,858,O
%,858,O
change,858,O
in,858,O
the,858,O
INR,858,O
while,858,O
receiving,858,O
either,858,O
COX-2,858,B-GENE-Y
inhibitor,858,O
",",858,O
4,858,O
showed,858,O
this,858,O
change,858,O
for,858,O
both,858,O
agents,858,O
.,858,O
Adverse,859,O
drug,859,O
reactions,859,O
were,859,O
similar,859,O
for,859,O
each,859,O
COX-2,859,B-GENE-Y
inhibitor,859,O
",",859,O
but,859,O
the,859,O
rate,859,O
of,859,O
edema,859,O
requiring,859,O
medical,859,O
intervention,859,O
was,859,O
higher,859,O
in,859,O
the,859,O
rofecoxib,859,B-CHEMICAL
group,859,O
.,859,O
Significant,860,O
increases,860,O
in,860,O
the,860,O
INR,860,O
were,860,O
observed,860,O
in,860,O
patients,860,O
who,860,O
were,860,O
stable,860,O
on,860,O
warfarin,860,B-CHEMICAL
therapy,860,O
after,860,O
the,860,O
addition,860,O
of,860,O
therapy,860,O
with,860,O
rofecoxib,860,B-CHEMICAL
or,860,O
celecoxib,860,B-CHEMICAL
.,860,O
AT1,861,B-GENE-Y
antagonism,861,O
by,861,O
eprosartan,861,B-CHEMICAL
lowers,861,O
heart,861,O
rate,861,O
variability,861,O
and,861,O
baroreflex,861,O
gain,861,O
.,861,O
INTRODUCTION,862,O
:,862,O
Blockade,862,O
of,862,O
the,862,O
renin-angiotensin,862,B-GENE-Y
system,862,O
(,862,O
RAS,862,O
),862,O
by,862,O
ACE,862,B-GENE-Y
inhibitors,862,O
has,862,O
been,862,O
demonstrated,862,O
to,862,O
reduce,862,O
total,862,O
mortality,862,O
in,862,O
cardiovascular,862,O
diseases,862,O
.,862,O
This,863,O
advantage,863,O
was,863,O
attributed,863,O
in,863,O
part,863,O
to,863,O
changes,863,O
of,863,O
autonomic,863,O
cardiovascular,863,O
control,863,O
",",863,O
exemplified,863,O
by,863,O
an,863,O
increase,863,O
of,863,O
heart,863,O
rate,863,O
variability,863,O
(,863,O
HRV,863,O
),863,O
and,863,O
baroreflex,863,O
gain,863,O
(,863,O
BRG,863,O
),863,O
.,863,O
We,864,O
sought,864,O
to,864,O
assess,864,O
the,864,O
effects,864,O
of,864,O
the,864,O
angiotensin,864,B-CHEMICAL
type,864,I-GENE-Y
1,864,I-GENE-Y
(,864,I-GENE-Y
AT1,864,I-GENE-Y
),864,I-GENE-Y
receptor,864,I-GENE-Y
blocker,864,O
eprosartan,864,B-CHEMICAL
on,864,O
HRV,864,O
and,864,O
BRG,864,O
.,864,O
MATERIALS,865,O
AND,865,O
METHODS,865,O
:,865,O
In,865,O
a,865,O
double-blind,865,O
randomized,865,O
cross-over,865,O
design,865,O
25,865,O
young,865,O
males,865,O
took,865,O
eprosartan,865,B-CHEMICAL
(,865,O
600,865,O
mg/day,865,O
),865,O
and,865,O
placebo,865,O
each,865,O
for,865,O
a,865,O
period,865,O
of,865,O
7,865,O
days,865,O
with,865,O
a,865,O
wash-out,865,O
period,865,O
of,865,O
at,865,O
least,865,O
4,865,O
weeks,865,O
in,865,O
between,865,O
.,865,O
At,866,O
the,866,O
end,866,O
of,866,O
the,866,O
intake,866,O
phases,866,O
simultaneous,866,O
recordings,866,O
of,866,O
arterial,866,O
blood,866,O
pressure,866,O
(,866,O
AP,866,O
;,866,O
Finapres,866,O
),866,O
and,866,O
electrocardiogram,866,O
(,866,O
ECG,866,O
),866,O
were,866,O
taken,866,O
.,866,O
Power,867,O
spectra,867,O
of,867,O
HRV,867,O
and,867,O
arterial,867,O
blood,867,O
pressure,867,O
variability,867,O
(,867,O
APV,867,O
),867,O
were,867,O
calculated,867,O
by,867,O
fast,867,O
Fourier,867,O
transform,867,O
(,867,O
FFT,867,O
),867,O
and,867,O
served,867,O
to,867,O
calculate,867,O
BRG,867,O
.,867,O
Ang-II,868,B-GENE-Y
levels,868,O
were,868,O
measured,868,O
by,868,O
radioimmunoassay,868,O
.,868,O
RESULTS,869,O
:,869,O
Eprosartan,869,B-CHEMICAL
tended,869,O
to,869,O
lower,869,O
mean,869,O
AP,869,O
",",869,O
it,869,O
slightly,869,O
increased,869,O
heart,869,O
rate,869,O
(,869,O
HR,869,O
),869,O
(,869,O
p,869,O
<,869,O
0.05,869,O
),869,O
",",869,O
and,869,O
markedly,869,O
increased,869,O
circulating,869,O
Ang-II,869,B-CHEMICAL
levels,869,O
(,869,O
p,869,O
<,869,O
0.01,869,O
),869,O
.,869,O
Eprosartan,870,B-CHEMICAL
diminished,870,O
the,870,O
total,870,O
power,870,O
of,870,O
HRV,870,O
(,870,O
p,870,O
<,870,O
0.05,870,O
),870,O
and,870,O
the,870,O
BRG,870,O
(,870,O
p,870,O
<,870,O
0.01,870,O
),870,O
.,870,O
The,871,O
low/high,871,O
frequency,871,O
(,871,O
LF/HF,871,O
),871,O
ratio,871,O
of,871,O
HRV,871,O
and,871,O
the,871,O
APV,871,O
were,871,O
not,871,O
altered,871,O
.,871,O
CONCLUSIONS,872,O
:,872,O
AT1,872,B-GENE-Y
antagonism,872,O
by,872,O
eprosartan,872,B-CHEMICAL
lowers,872,O
heart,872,O
rate,872,O
variability,872,O
and,872,O
baroreflex,872,O
gain,872,O
.,872,O
We,873,O
speculate,873,O
that,873,O
these,873,O
findings,873,O
are,873,O
due,873,O
to,873,O
the,873,O
marked,873,O
increase,873,O
in,873,O
circulating,873,O
angiotensin,873,B-CHEMICAL
II,873,I-CHEMICAL
(,873,O
Ang,873,B-CHEMICAL
II,873,I-CHEMICAL
),873,O
.,873,O
Further,874,O
studies,874,O
are,874,O
needed,874,O
to,874,O
clarify,874,O
whether,874,O
angiotensin,874,B-CHEMICAL
type,874,I-GENE-Y
1,874,I-GENE-Y
(,874,O
AT1,874,B-GENE-Y
),874,O
blockers,874,O
with,874,O
potential,874,O
actions,874,O
inside,874,O
the,874,O
blood-brain,874,O
barrier,874,O
(,874,O
BBB,874,O
),874,O
may,874,O
have,874,O
different,874,O
effects,874,O
on,874,O
HRV,874,O
and,874,O
BRG,874,O
.,874,O
Further,875,O
characterization,875,O
of,875,O
alpha,875,O
N-acetyl,875,B-CHEMICAL
beta-endorphin-,875,O
(,875,O
1-31,875,O
),875,O
regulatory,875,O
activity,875,O
",",875,O
I,875,O
:,875,O
Effect,875,O
on,875,O
opioid-,875,O
and,875,O
alpha,875,O
2-mediated,875,O
supraspinal,875,O
antinociception,875,O
in,875,O
mice,875,O
.,875,O
Picomol,876,O
doses,876,O
of,876,O
the,876,O
acetylated,876,O
derivative,876,O
of,876,O
beta-endorphin-,876,O
(,876,O
1-31,876,O
),876,O
",",876,O
injected,876,O
intracerebroventricularly,876,O
(,876,O
icv,876,O
),876,O
in,876,O
mice,876,O
",",876,O
reduced,876,O
the,876,O
analgesic,876,O
activity,876,O
of,876,O
morphine,876,B-CHEMICAL
",",876,O
etorphine,876,B-CHEMICAL
and,876,O
beta-endorphin-,876,O
(,876,O
1-31,876,O
),876,O
",",876,O
while,876,O
the,876,O
efficiency,876,O
of,876,O
DAGO,876,B-CHEMICAL
and,876,O
DADLE,876,B-CHEMICAL
in,876,O
producing,876,O
analgesia,876,O
was,876,O
enhanced,876,O
.,876,O
The,877,O
effects,877,O
of,877,O
the,877,O
delta,877,O
agonists,877,O
DPDPE,877,B-CHEMICAL
and,877,O
[,877,B-CHEMICAL
D-Ala2,877,I-CHEMICAL
],877,I-CHEMICAL
-Deltorphin,877,I-CHEMICAL
II,877,I-CHEMICAL
were,877,O
not,877,O
altered,877,O
by,877,O
this,877,O
treatment,877,O
.,877,O
After,878,O
alpha,878,O
N-acetyl,878,B-CHEMICAL
beta-endorphin-,878,O
(,878,O
1-31,878,O
),878,O
injection,878,O
",",878,O
morphine,878,B-CHEMICAL
antagonized,878,O
the,878,O
analgesia,878,O
of,878,O
DAGO,878,B-CHEMICAL
.,878,O
The,879,O
regulatory,879,O
effect,879,O
of,879,O
alpha,879,O
N-acetyl,879,B-CHEMICAL
beta-endorphin-,879,O
(,879,O
1-31,879,O
),879,O
was,879,O
exhibited,879,O
when,879,O
giving,879,O
the,879,O
peptide,879,O
both,879,O
before,879,O
(,879,O
up,879,O
to,879,O
24,879,O
h,879,O
),879,O
and,879,O
after,879,O
the,879,O
opioids,879,O
.,879,O
Naloxone,880,B-CHEMICAL
did,880,O
not,880,O
prevent,880,O
or,880,O
reverse,880,O
that,880,O
modulatory,880,O
activity,880,O
;,880,O
moreover,880,O
",",880,O
pretreatment,880,O
with,880,O
the,880,O
acetylated,880,O
peptide,880,O
did,880,O
not,880,O
change,880,O
the,880,O
pA2,880,O
value,880,O
displayed,880,O
by,880,O
the,880,O
antagonist,880,O
at,880,O
the,880,O
mu,880,B-GENE-Y
receptor,880,I-GENE-Y
.,880,O
The,881,O
antinociceptive,881,O
activity,881,O
of,881,O
the,881,O
alpha,881,B-GENE-N
2-adrenoceptor,881,I-GENE-N
agonist,881,O
clonidine,881,B-CHEMICAL
was,881,O
also,881,O
increased,881,O
in,881,O
mice,881,O
treated,881,O
with,881,O
alpha,881,O
N-acetyl,881,B-CHEMICAL
beta-endorphin-,881,O
(,881,O
1-31,881,O
),881,O
.,881,O
The,882,O
reducing,882,O
activity,882,O
of,882,O
alpha,882,O
N-acetyl,882,B-CHEMICAL
beta-endorphin-,882,O
(,882,O
1-31,882,O
),882,O
upon,882,O
morphine-,882,B-CHEMICAL
and,882,O
beta-endorphin-induced,882,O
analgesia,882,O
was,882,O
not,882,O
exhibited,882,O
in,882,O
mice,882,O
undergoing,882,O
treatment,882,O
with,882,O
pertussis,882,O
toxin,882,O
or,882,O
N-ethylmaleimide,882,B-CHEMICAL
",",882,O
agents,882,O
known,882,O
to,882,O
impair,882,O
the,882,O
function,882,O
of,882,O
Gi/Go,882,B-GENE-N
transducer,882,O
proteins,882,O
.,882,O
However,883,O
",",883,O
the,883,O
enhancing,883,O
activity,883,O
displayed,883,O
by,883,O
this,883,O
peptide,883,O
upon,883,O
DAGO-,883,B-CHEMICAL
DADLE,883,B-CHEMICAL
and,883,O
clonidine-evoked,883,B-CHEMICAL
antinociception,883,O
was,883,O
still,883,O
manifested,883,O
.,883,O
These,884,O
results,884,O
confirm,884,O
and,884,O
strengthen,884,O
the,884,O
idea,884,O
of,884,O
alpha,884,O
N-acetyl,884,B-CHEMICAL
beta-endorphin-,884,O
(,884,O
1-31,884,O
),884,O
acting,884,O
as,884,O
a,884,O
non-competitive,884,O
regulator,884,O
of,884,O
mu,884,B-GENE-Y
opioid-,884,O
and,884,O
alpha,884,B-GENE-N
2-adrenoceptor-mediated,884,O
supraspinal,884,O
antinociception,884,O
.,884,O
A,885,O
neural,885,O
substrate,885,O
acted,885,O
on,885,O
by,885,O
both,885,O
receptors,885,O
(,885,O
likely,885,O
Gi/Go,885,B-GENE-N
transducer,885,O
proteins,885,O
),885,O
appears,885,O
to,885,O
be,885,O
involved,885,O
in,885,O
the,885,O
effects,885,O
of,885,O
that,885,O
neuropeptide,885,O
.,885,O
Effects,886,O
of,886,O
loperamide,886,B-CHEMICAL
on,886,O
the,886,O
human,886,O
hypothalamo-pituitary-adrenal,886,O
axis,886,O
in,886,O
vivo,886,O
and,886,O
in,886,O
vitro,886,O
.,886,O
Loperamide,887,B-CHEMICAL
",",887,O
an,887,O
opiate,887,O
agonist,887,O
of,887,O
high,887,O
specificity,887,O
for,887,O
mu-receptors,887,O
",",887,O
was,887,O
recently,887,O
reported,887,O
to,887,O
suppress,887,O
ACTH,887,B-GENE-Y
and,887,O
cortisol,887,B-CHEMICAL
levels,887,O
in,887,O
normal,887,O
subjects,887,O
",",887,O
but,887,O
not,887,O
in,887,O
patients,887,O
with,887,O
proven,887,O
ACTH-dependent,887,B-GENE-Y
Cushing,887,O
's,887,O
disease,887,O
.,887,O
However,888,O
",",888,O
there,888,O
is,888,O
little,888,O
information,888,O
on,888,O
the,888,O
site,888,O
of,888,O
action,888,O
of,888,O
loperamide,888,B-CHEMICAL
in,888,O
the,888,O
hypothalamo-pituitary-adrenal,888,O
axis,888,O
of,888,O
man,888,O
.,888,O
We,889,O
investigated,889,O
the,889,O
effect,889,O
of,889,O
loperamide,889,B-CHEMICAL
on,889,O
pituitary,889,O
hormone,889,O
secretion,889,O
in,889,O
vivo,889,O
and,889,O
in,889,O
vitro,889,O
.,889,O
In,890,O
seven,890,O
normal,890,O
subjects,890,O
",",890,O
basal,890,O
ACTH,890,B-GENE-Y
plasma,890,O
levels,890,O
were,890,O
significantly,890,O
suppressed,890,O
3,890,O
h,890,O
after,890,O
loperamide,890,B-CHEMICAL
administration,890,O
(,890,O
16,890,O
mg,890,O
",",890,O
orally,890,O
),890,O
from,890,O
5,890,O
+/-,890,O
1,890,O
to,890,O
2,890,O
+/-,890,O
0,890,O
pmol/L,890,O
(,890,O
P,890,O
less,890,O
than,890,O
0.0001,890,O
),890,O
.,890,O
After,891,O
the,891,O
combined,891,O
pituitary,891,O
stimulation,891,O
test,891,O
(,891,O
100,891,O
micrograms,891,O
human,891,B-GENE-Y
CRH,891,I-GENE-Y
",",891,O
100,891,O
micrograms,891,O
GnRH,891,B-GENE-Y
",",891,O
100,891,O
micrograms,891,O
GH-releasing,891,B-GENE-Y
hormone,891,I-GENE-Y
",",891,O
and,891,O
200,891,O
micrograms,891,O
TRH,891,B-GENE-N
),891,O
",",891,O
the,891,O
ACTH,891,B-GENE-Y
peak,891,O
(,891,O
maximum,891,O
increase,891,O
at,891,O
30,891,O
min,891,O
),891,O
was,891,O
significantly,891,O
blunted,891,O
by,891,O
loperamide,891,B-CHEMICAL
from,891,O
9,891,O
+/-,891,O
1,891,O
to,891,O
4,891,O
+/-,891,O
1,891,O
pmol/L,891,O
(,891,O
P,891,O
less,891,O
than,891,O
0.001,891,O
),891,O
and,891,O
the,891,O
area,891,O
under,891,O
the,891,O
curve,891,O
of,891,O
ACTH,891,B-GENE-Y
from,891,O
0-120,891,O
min,891,O
was,891,O
reduced,891,O
from,891,O
35,891,O
+/-,891,O
5,891,O
to,891,O
23,891,O
+/-,891,O
4,891,O
pmol/L.2,891,O
h,891,O
(,891,O
P,891,O
less,891,O
than,891,O
0.05,891,O
),891,O
.,891,O
In,892,O
the,892,O
insulin-hypoglycemia,892,B-GENE-Y
test,892,O
(,892,O
0.15,892,O
IU/kg,892,O
BW,892,O
),892,O
",",892,O
neither,892,O
the,892,O
ACTH,892,B-GENE-Y
peak,892,O
nor,892,O
the,892,O
area,892,O
under,892,O
the,892,O
curve,892,O
of,892,O
ACTH,892,B-GENE-Y
was,892,O
affected,892,O
by,892,O
loperamide,892,B-CHEMICAL
.,892,O
In,893,O
six,893,O
patients,893,O
with,893,O
Cushing,893,O
's,893,O
disease,893,O
and,893,O
one,893,O
patient,893,O
with,893,O
secondary,893,O
adrenal,893,O
insufficiency,893,O
due,893,O
to,893,O
hypothalamic,893,O
failure,893,O
",",893,O
neither,893,O
basal,893,O
ACTH,893,B-GENE-Y
and,893,O
cortisol,893,B-CHEMICAL
levels,893,O
nor,893,O
CRH-stimulated,893,B-GENE-Y
levels,893,O
were,893,O
influenced,893,O
by,893,O
loperamide,893,B-CHEMICAL
.,893,O
In,894,O
four,894,O
cultured,894,O
human,894,O
corticotropic,894,O
adenomas,894,O
",",894,O
loperamide,894,B-CHEMICAL
was,894,O
not,894,O
able,894,O
to,894,O
reduce,894,O
basal,894,O
and,894,O
CRH-induced,894,B-GENE-Y
ACTH,894,B-GENE-Y
secretion,894,O
.,894,O
In,895,O
summary,895,O
",",895,O
loperamide,895,B-CHEMICAL
is,895,O
able,895,O
to,895,O
reduce,895,O
basal,895,O
and,895,O
CRH-induced,895,B-GENE-Y
ACTH,895,B-GENE-Y
and,895,O
cortisol,895,B-CHEMICAL
levels,895,O
in,895,O
normal,895,O
subjects,895,O
",",895,O
but,895,O
not,895,O
in,895,O
patients,895,O
with,895,O
Cushing,895,O
's,895,O
disease,895,O
or,895,O
secondary,895,O
adrenal,895,O
failure,895,O
of,895,O
hypothalamic,895,O
origin,895,O
.,895,O
Loperamide,896,B-CHEMICAL
has,896,O
no,896,O
significant,896,O
effect,896,O
on,896,O
insulin-hypoglycemia-induced,896,B-GENE-Y
ACTH,896,B-GENE-Y
and,896,O
cortisol,896,B-CHEMICAL
levels,896,O
and,896,O
",",896,O
therefore,896,O
",",896,O
no,896,O
effect,896,O
on,896,O
stress-induced,896,O
elevation,896,O
of,896,O
cortisol,896,O
levels,896,O
.,896,O
Loperamide,897,B-CHEMICAL
might,897,O
act,897,O
at,897,O
a,897,O
suprapituitary,897,O
site,897,O
in,897,O
man,897,O
in,897,O
vivo,897,O
",",897,O
but,897,O
",",897,O
nevertheless,897,O
",",897,O
a,897,O
pituitary,897,O
site,897,O
can,897,O
not,897,O
be,897,O
excluded,897,O
.,897,O
Effects,898,O
of,898,O
nedocromil,898,B-CHEMICAL
sodium,898,I-CHEMICAL
on,898,O
the,898,O
binding,898,O
of,898,O
N-formyl-methionyl-leucyl-phenylalanine,898,B-CHEMICAL
in,898,O
human,898,O
neutrophils,898,O
.,898,O
In,899,O
the,899,O
present,899,O
study,899,O
the,899,O
inhibition,899,O
by,899,O
nedocromil,899,B-CHEMICAL
sodium,899,I-CHEMICAL
of,899,O
the,899,O
specific,899,O
receptor,899,O
binding,899,O
of,899,O
FMLP,899,O
was,899,O
evaluated,899,O
in,899,O
human,899,O
neutrophils,899,O
(,899,O
PMNs,899,O
),899,O
using,899,O
a,899,O
FMLP-,899,O
(,899,O
3H,899,O
),899,O
binding,899,O
assay,899,O
.,899,O
The,900,O
time,900,O
course,900,O
of,900,O
the,900,O
binding,900,O
was,900,O
markedly,900,O
influenced,900,O
by,900,O
nedocromil,900,B-CHEMICAL
sodium,900,I-CHEMICAL
used,900,O
at,900,O
a,900,O
concentration,900,O
of,900,O
300,900,O
microM,900,O
.,900,O
No,901,O
significant,901,O
inhibition,901,O
was,901,O
obtained,901,O
when,901,O
the,901,O
cells,901,O
were,901,O
treated,901,O
with,901,O
nedocromil,901,B-CHEMICAL
sodium,901,I-CHEMICAL
3,901,O
microM,901,O
or,901,O
with,901,O
sodium,901,B-CHEMICAL
cromoglycate,901,O
300,901,O
microM,901,O
.,901,O
FMLP,902,O
binding,902,O
is,902,O
essentially,902,O
eliminated,902,O
by,902,O
the,902,O
highest,902,O
dose,902,O
of,902,O
nedocromil,902,B-CHEMICAL
sodium,902,I-CHEMICAL
.,902,O
The,903,O
biologic,903,O
meaning,903,O
of,903,O
this,903,O
effect,903,O
in,903,O
asthmatic,903,O
patients,903,O
should,903,O
be,903,O
further,903,O
evaluated,903,O
.,903,O
Effects,904,O
of,904,O
nedocromil,904,B-CHEMICAL
sodium,904,I-CHEMICAL
and,904,O
WEB,904,B-CHEMICAL
2086,904,I-CHEMICAL
on,904,O
chemoattractant-stimulated,904,O
neutrophil,904,O
migration,904,O
through,904,O
cellular,904,O
and,904,O
noncellular,904,O
barriers,904,O
.,904,O
Nedocromil,905,B-CHEMICAL
sodium,905,I-CHEMICAL
(,905,O
Tilade,905,B-CHEMICAL
),905,O
is,905,O
an,905,O
effective,905,O
therapeutic,905,O
agent,905,O
against,905,O
asthma,905,O
and,905,O
has,905,O
been,905,O
shown,905,O
to,905,O
exhibit,905,O
antiinflammatory,905,O
activity,905,O
in,905,O
vitro,905,O
;,905,O
however,905,O
",",905,O
its,905,O
mode,905,O
of,905,O
action,905,O
is,905,O
yet,905,O
to,905,O
be,905,O
described,905,O
fully,905,O
.,905,O
Using,906,O
an,906,O
in,906,O
vitro,906,O
assay,906,O
designed,906,O
to,906,O
mimic,906,O
the,906,O
extravasation,906,O
of,906,O
neutrophils,906,O
from,906,O
the,906,O
peripheral,906,O
circulation,906,O
through,906,O
cellular,906,O
barriers,906,O
to,906,O
sites,906,O
of,906,O
inflammation,906,O
",",906,O
the,906,O
effect,906,O
of,906,O
nedocromil,906,B-CHEMICAL
sodium,906,I-CHEMICAL
on,906,O
chemoattractant-stimulated,906,O
neutrophil,906,O
migration,906,O
was,906,O
examined,906,O
.,906,O
We,907,O
also,907,O
examined,907,O
the,907,O
effects,907,O
of,907,O
WEB,907,B-CHEMICAL
2086,907,I-CHEMICAL
",",907,O
a,907,O
platelet-activating,907,B-GENE-Y
factor,907,I-GENE-Y
(,907,I-GENE-Y
PAF,907,I-GENE-Y
),907,I-GENE-Y
receptor,907,I-GENE-Y
antagonist,907,O
",",907,O
in,907,O
parallel,907,O
.,907,O
Neutrophils,908,O
and,908,O
the,908,O
cellular,908,O
barrier,908,O
were,908,O
pretreated,908,O
and/or,908,O
co-incubated,908,O
with,908,O
nedocromil,908,O
or,908,O
WEB,908,B-CHEMICAL
2086,908,I-CHEMICAL
and,908,O
the,908,O
effects,908,O
on,908,O
neutrophil,908,O
chemotaxis,908,O
measured,908,O
.,908,O
In,909,O
all,909,O
treatments,909,O
",",909,O
nedocromil,909,B-CHEMICAL
did,909,O
not,909,O
significantly,909,O
affect,909,O
chemotaxis,909,O
through,909,O
cellular,909,O
or,909,O
noncellular,909,O
barriers,909,O
to,909,O
N-formyl-methionyl-leucyl-phenylalanine,909,B-CHEMICAL
(,909,O
FMLP,909,B-CHEMICAL
),909,O
",",909,O
leukotriene,909,B-CHEMICAL
B4,909,I-CHEMICAL
(,909,O
LTB4,909,B-CHEMICAL
),909,O
",",909,O
or,909,O
PAF,909,B-CHEMICAL
.,909,O
In,910,O
contrast,910,O
",",910,O
WEB,910,B-CHEMICAL
2086,910,I-CHEMICAL
inhibited,910,O
PAF-induced,910,B-CHEMICAL
neutrophil,910,O
migration,910,O
through,910,O
both,910,O
naked,910,O
filters,910,O
and,910,O
endothelial,910,O
and,910,O
epithelial,910,O
monolayers,910,O
cultured,910,O
on,910,O
these,910,O
filters,910,O
.,910,O
We,911,O
conclude,911,O
that,911,O
while,911,O
nedocromil,911,B-CHEMICAL
has,911,O
been,911,O
shown,911,O
to,911,O
have,911,O
inhibitory,911,O
effects,911,O
on,911,O
neutrophils,911,O
and,911,O
is,911,O
an,911,O
effective,911,O
therapeutic,911,O
agent,911,O
for,911,O
asthma,911,O
and,911,O
inflammatory,911,O
conditions,911,O
",",911,O
its,911,O
activity,911,O
is,911,O
not,911,O
primarily,911,O
mediated,911,O
by,911,O
inhibition,911,O
of,911,O
neutrophil,911,O
chemotaxis,911,O
.,911,O
Platelet-activating,912,B-GENE-Y
factor,912,I-GENE-Y
antagonists,912,O
may,912,O
partially,912,O
be,912,O
effective,912,O
in,912,O
asthma,912,O
through,912,O
inhibitory,912,O
effects,912,O
on,912,O
neutrophil,912,O
chemotaxis,912,O
.,912,O
Ocular,913,O
beta-blockers,913,O
in,913,O
glaucoma,913,O
management,913,O
.,913,O
Clinical,914,O
pharmacological,914,O
aspects,914,O
.,914,O
Topical,915,O
beta-blockers,915,O
reduce,915,O
the,915,O
intraocular,915,O
pressure,915,O
(,915,O
IOP,915,O
),915,O
by,915,O
blockade,915,O
of,915,O
sympathetic,915,O
nerve,915,O
endings,915,O
in,915,O
the,915,O
ciliary,915,O
epithelium,915,O
causing,915,O
a,915,O
fall,915,O
in,915,O
aqueous,915,O
humour,915,O
production,915,O
.,915,O
Two,916,O
types,916,O
of,916,O
topical,916,O
beta-blockers,916,O
are,916,O
available,916,O
for,916,O
use,916,O
in,916,O
glaucoma,916,O
:,916,O
nonselective,916,O
",",916,O
which,916,O
block,916,O
both,916,O
beta,916,B-GENE-N
1-,916,I-GENE-N
and,916,I-GENE-N
beta,916,I-GENE-N
2-adrenoceptors,916,I-GENE-N
;,916,O
and,916,O
cardioselective,916,O
",",916,O
which,916,O
block,916,O
only,916,O
beta,916,B-GENE-Y
1-receptors,916,I-GENE-Y
.,916,O
Of,917,O
the,917,O
beta-Blockers,917,O
commercially,917,O
available,917,O
",",917,O
timolol,917,B-CHEMICAL
",",917,O
levobunolol,917,B-CHEMICAL
",",917,O
metipranolol,917,B-CHEMICAL
and,917,O
carteolol,917,B-CHEMICAL
are,917,O
nonselective,917,O
",",917,O
and,917,O
betaxolol,917,B-CHEMICAL
is,917,O
cardioselective,917,O
.,917,O
Twice-daily,918,O
timolol,918,B-CHEMICAL
is,918,O
probably,918,O
the,918,O
most,918,O
effective,918,O
agent,918,O
in,918,O
lowering,918,O
IOP,918,O
",",918,O
although,918,O
levobunolol,918,B-CHEMICAL
is,918,O
equally,918,O
effective,918,O
and,918,O
can,918,O
be,918,O
used,918,O
once,918,O
daily,918,O
with,918,O
little,918,O
difference,918,O
in,918,O
effect,918,O
.,918,O
Carteolol,919,B-CHEMICAL
is,919,O
used,919,O
twice,919,O
daily,919,O
and,919,O
any,919,O
theoretical,919,O
advantage,919,O
in,919,O
diminished,919,O
side,919,O
effects,919,O
conferred,919,O
by,919,O
its,919,O
partial,919,O
beta-agonist,919,O
activity,919,O
compared,919,O
with,919,O
timolol,919,B-CHEMICAL
has,919,O
not,919,O
been,919,O
fully,919,O
substantiated,919,O
.,919,O
Metipranolol,920,B-CHEMICAL
is,920,O
effective,920,O
twice,920,O
daily,920,O
and,920,O
does,920,O
not,920,O
have,920,O
partial,920,O
beta-agonist,920,O
activity,920,O
.,920,O
Betaxolol,921,B-CHEMICAL
has,921,O
an,921,O
effect,921,O
comparable,921,O
to,921,O
timolol,921,B-CHEMICAL
in,921,O
lowering,921,O
IOP,921,O
",",921,O
but,921,O
is,921,O
less,921,O
effective,921,O
in,921,O
some,921,O
patients,921,O
.,921,O
beta-Blockers,922,O
can,922,O
be,922,O
used,922,O
with,922,O
other,922,O
antiglaucoma,922,O
medications,922,O
",",922,O
but,922,O
their,922,O
combined,922,O
action,922,O
with,922,O
epinephrine,922,B-CHEMICAL
(,922,O
adrenaline,922,B-CHEMICAL
),922,O
is,922,O
suspect,922,O
",",922,O
particularly,922,O
in,922,O
the,922,O
case,922,O
of,922,O
the,922,O
nonselective,922,O
beta-blockers,922,O
",",922,O
and,922,O
the,922,O
effect,922,O
should,922,O
be,922,O
assessed,922,O
in,922,O
patients,922,O
on,922,O
an,922,O
individual,922,O
basis,922,O
.,922,O
Local,923,O
stinging,923,O
can,923,O
be,923,O
a,923,O
problem,923,O
in,923,O
some,923,O
patients,923,O
with,923,O
betaxolol,923,B-CHEMICAL
.,923,O
The,924,O
most,924,O
serious,924,O
side,924,O
effects,924,O
of,924,O
beta-blockers,924,O
are,924,O
the,924,O
exacerbation,924,O
of,924,O
chronic,924,O
obstructive,924,O
airways,924,O
disease,924,O
with,924,O
nonselective,924,O
agents,924,O
and,924,O
the,924,O
precipitation,924,O
of,924,O
bronchospasm,924,O
in,924,O
some,924,O
patients,924,O
.,924,O
Betaxolol,925,B-CHEMICAL
seems,925,O
relatively,925,O
free,925,O
of,925,O
adverse,925,O
respiratory,925,O
effects,925,O
",",925,O
although,925,O
this,925,O
may,925,O
be,925,O
dose-related,925,O
and,925,O
extreme,925,O
caution,925,O
should,925,O
still,925,O
be,925,O
exercised,925,O
in,925,O
patients,925,O
with,925,O
any,925,O
history,925,O
of,925,O
respiratory,925,O
illness,925,O
.,925,O
Because,926,O
of,926,O
the,926,O
lower,926,O
risk,926,O
of,926,O
precipitating,926,O
side,926,O
effects,926,O
",",926,O
betaxolol,926,B-CHEMICAL
is,926,O
probably,926,O
the,926,O
beta-blocker,926,O
of,926,O
first,926,O
choice,926,O
for,926,O
use,926,O
in,926,O
glaucoma,926,O
;,926,O
timolol,926,B-CHEMICAL
or,926,O
levobunolol,926,B-CHEMICAL
are,926,O
reserved,926,O
for,926,O
patients,926,O
who,926,O
do,926,O
not,926,O
respond,926,O
satisfactorily,926,O
to,926,O
betaxolol,926,B-CHEMICAL
and,926,O
are,926,O
quite,926,O
free,926,O
of,926,O
respiratory,926,O
disease,926,O
.,926,O
5-Lipoxygenase,927,B-GENE-Y
inhibitors,927,O
for,927,O
the,927,O
treatment,927,O
of,927,O
inflammatory,927,O
bowel,927,O
disease,927,O
.,927,O
The,928,O
unique,928,O
role,928,O
of,928,O
the,928,O
enzyme,928,O
5-lipoxygenase,928,B-GENE-Y
(,928,O
5-LO,928,B-GENE-Y
),928,O
in,928,O
the,928,O
production,928,O
of,928,O
leukotrienes,928,B-CHEMICAL
(,928,O
LTs,928,B-CHEMICAL
),928,O
makes,928,O
it,928,O
a,928,O
likely,928,O
target,928,O
for,928,O
biochemical,928,O
manipulation,928,O
.,928,O
The,929,O
rationale,929,O
for,929,O
using,929,O
5-LO,929,B-GENE-Y
inhibitors,929,O
for,929,O
the,929,O
treatment,929,O
of,929,O
inflammatory,929,O
bowel,929,O
disease,929,O
(,929,O
IBD,929,O
),929,O
is,929,O
based,929,O
on,929,O
the,929,O
increased,929,O
generation,929,O
of,929,O
LTs,929,B-CHEMICAL
in,929,O
the,929,O
inflamed,929,O
mucosa,929,O
",",929,O
LTB4,929,B-CHEMICAL
being,929,O
the,929,O
most,929,O
potent,929,O
chemotactic,929,O
and,929,O
chemokinetic,929,O
metabolite,929,O
of,929,O
arachidonic,929,B-CHEMICAL
acid,929,I-CHEMICAL
.,929,O
Furthermore,930,O
",",930,O
conventional,930,O
drugs,930,O
",",930,O
such,930,O
as,930,O
corticosteroids,930,O
",",930,O
sulphasalazine,930,B-CHEMICAL
",",930,O
and,930,O
5-aminosalicylic,930,B-CHEMICAL
acid,930,I-CHEMICAL
",",930,O
inhibit,930,O
LT,930,B-CHEMICAL
production,930,O
and,930,O
specific,930,O
5-LO,930,B-GENE-Y
inhibition,930,O
accelerates,930,O
healing,930,O
in,930,O
animal,930,O
models,930,O
of,930,O
acute,930,O
colitis,930,O
.,930,O
The,931,O
compounds,931,O
identified,931,O
as,931,O
5-LO,931,B-GENE-Y
inhibitors,931,O
can,931,O
be,931,O
divided,931,O
into,931,O
antioxidants,931,O
",",931,O
substrate-analogous,931,O
",",931,O
and,931,O
a,931,O
large,931,O
miscellaneous,931,O
group,931,O
of,931,O
inhibitors,931,O
",",931,O
where,931,O
hydroxamic,931,B-CHEMICAL
acids,931,I-CHEMICAL
are,931,O
potent,931,O
and,931,O
more,931,O
selective,931,O
inhibitors,931,O
of,931,O
5-LO,931,B-GENE-Y
.,931,O
The,932,O
benzothiophene,932,B-CHEMICAL
hydroxyurea,932,I-CHEMICAL
",",932,O
zileuton,932,B-CHEMICAL
",",932,O
is,932,O
the,932,O
first,932,O
selective,932,O
5-LO,932,B-GENE-Y
inhibitor,932,O
evaluated,932,O
for,932,O
the,932,O
treatment,932,O
of,932,O
patients,932,O
with,932,O
IBD,932,O
.,932,O
An,933,O
800-mg,933,O
oral,933,O
dose,933,O
of,933,O
zileuton,933,B-CHEMICAL
was,933,O
shown,933,O
to,933,O
reduce,933,O
LTB4,933,B-CHEMICAL
",",933,O
but,933,O
not,933,O
prostaglandin,933,B-CHEMICAL
E2,933,I-CHEMICAL
",",933,O
concentrations,933,O
by,933,O
75-85,933,O
%,933,O
in,933,O
rectal,933,O
dialysates,933,O
from,933,O
patients,933,O
with,933,O
active,933,O
ulcerative,933,O
colitis,933,O
.,933,O
The,934,O
clinical,934,O
efficacy,934,O
of,934,O
zileuton,934,B-CHEMICAL
800,934,O
mg,934,O
b.i.d,934,O
.,934,O
has,935,O
also,935,O
been,935,O
tested,935,O
in,935,O
a,935,O
randomized,935,O
",",935,O
double-blind,935,O
",",935,O
placebo-controlled,935,O
trial,935,O
in,935,O
similar,935,O
patients,935,O
.,935,O
Zileuton,936,B-CHEMICAL
significantly,936,O
improved,936,O
the,936,O
symptom,936,O
scores,936,O
and,936,O
the,936,O
histology,936,O
score,936,O
",",936,O
but,936,O
not,936,O
the,936,O
sigmoidoscopy,936,O
score,936,O
",",936,O
compared,936,O
to,936,O
pretreatment,936,O
conditions,936,O
and,936,O
with,936,O
response,936,O
to,936,O
placebo,936,O
",",936,O
the,936,O
beneficial,936,O
effects,936,O
being,936,O
most,936,O
pronounced,936,O
in,936,O
patients,936,O
not,936,O
receiving,936,O
concomitant,936,O
sulphasalazine,936,B-CHEMICAL
treatment,936,O
.,936,O
The,937,O
mean,937,O
inhibition,937,O
of,937,O
LTB4,937,B-CHEMICAL
in,937,O
the,937,O
target,937,O
tissue,937,O
of,937,O
inflammation,937,O
was,937,O
70,937,O
%,937,O
.,937,O
The,938,O
proof,938,O
that,938,O
any,938,O
putative,938,O
5-LO,938,B-GENE-Y
inhibitor,938,O
is,938,O
blocking,938,O
LT,938,B-CHEMICAL
production,938,O
is,938,O
an,938,O
important,938,O
stage,938,O
in,938,O
assessing,938,O
any,938,O
such,938,O
drug,938,O
.,938,O
The,939,O
main,939,O
disadvantage,939,O
of,939,O
existing,939,O
new,939,O
LT,939,B-CHEMICAL
inhibitors,939,O
relates,939,O
to,939,O
the,939,O
high,939,O
potency,939,O
of,939,O
LTs,939,B-CHEMICAL
",",939,O
and,939,O
unless,939,O
a,939,O
higher,939,O
level,939,O
of,939,O
inhibition,939,O
can,939,O
be,939,O
achieved,939,O
",",939,O
endogenous,939,O
LTs,939,B-CHEMICAL
may,939,O
still,939,O
be,939,O
present,939,O
in,939,O
sufficient,939,O
amounts,939,O
to,939,O
produce,939,O
their,939,O
effects,939,O
.,939,O
Platelet-derived,940,B-GENE-Y
growth,940,I-GENE-Y
factor,940,I-GENE-Y
(,940,I-GENE-Y
PDGF,940,I-GENE-Y
),940,I-GENE-Y
receptor-alpha-activated,940,O
c-Jun,940,B-GENE-Y
NH2-terminal,940,I-GENE-Y
kinase-1,940,I-GENE-Y
is,940,O
critical,940,O
for,940,O
PDGF-induced,940,B-GENE-N
p21WAF1/CIP1,940,B-GENE-N
promoter,940,I-GENE-N
activity,940,O
independent,940,O
of,940,O
p53,940,B-GENE-Y
.,940,O
Platelet-derived,941,B-GENE-N
growth,941,I-GENE-N
factor,941,I-GENE-N
(,941,O
PDGF,941,B-GENE-N
),941,O
is,941,O
a,941,O
potent,941,O
mitogen,941,O
for,941,O
mesenchymal,941,O
cells,941,O
.,941,O
PDGF,942,B-GENE-Y
AA,942,I-GENE-Y
functions,942,O
as,942,O
a,942,O
``,942,O
competent,942,O
factor,942,O
'',942,O
that,942,O
stimulates,942,O
cell,942,O
cycle,942,O
entry,942,O
but,942,O
requires,942,O
additional,942,O
(,942,O
progression,942,O
),942,O
factors,942,O
in,942,O
serum,942,O
to,942,O
transit,942,O
the,942,O
cell,942,O
cycle,942,O
beyond,942,O
the,942,O
G1/S,942,O
checkpoint,942,O
.,942,O
Unlike,943,O
PDGF,943,B-GENE-Y
AA,943,I-GENE-Y
",",943,O
PDGF,943,B-GENE-Y
B-chain,943,O
(,943,O
c-sis,943,O
),943,O
homodimer,943,O
(,943,O
PDGF,943,B-GENE-Y
BB,943,I-GENE-Y
),943,O
and,943,O
its,943,O
viral,943,O
counterpart,943,O
v-sis,943,O
can,943,O
serve,943,O
as,943,O
both,943,O
competent,943,O
and,943,O
progression,943,O
factors,943,O
.,943,O
PDGF,944,B-GENE-Y
BB,944,I-GENE-Y
activates,944,O
alpha-,944,O
and,944,O
beta-receptor,944,O
subunits,944,O
(,944,O
alpha-PDGFR,944,B-GENE-Y
and,944,O
beta-PDGFR,944,B-GENE-Y
),944,O
and,944,O
induces,944,O
phenotypic,944,O
transformation,944,O
in,944,O
NIH,944,O
3T3,944,O
cells,944,O
",",944,O
whereas,944,O
PDGF,944,B-GENE-Y
AA,944,I-GENE-Y
activates,944,O
alpha-PDGFR,944,B-GENE-Y
only,944,O
and,944,O
fails,944,O
to,944,O
induce,944,O
transformation,944,O
.,944,O
We,945,O
showed,945,O
previously,945,O
that,945,O
alpha-PDGFR,945,B-GENE-Y
antagonizes,945,O
beta-PDGFR-mediated,945,B-GENE-Y
transformation,945,O
through,945,O
activation,945,O
of,945,O
stress-activated,945,B-GENE-Y
protein,945,I-GENE-Y
kinase-1/c-Jun,945,O
NH2-terminal,945,I-GENE-Y
kinase-1,945,I-GENE-Y
",",945,O
whereas,945,O
both,945,O
alpha-PDGFR,945,B-GENE-Y
and,945,O
beta-PDGFR,945,B-GENE-Y
induce,945,O
mitogenic,945,O
signals,945,O
.,945,O
These,946,O
studies,946,O
revealed,946,O
a,946,O
striking,946,O
feature,946,O
of,946,O
PDGF,946,B-GENE-N
signaling,946,O
;,946,O
the,946,O
specificity,946,O
and,946,O
the,946,O
strength,946,O
of,946,O
the,946,O
PDGF,946,B-GENE-N
growth,946,O
signal,946,O
is,946,O
modulated,946,O
by,946,O
alpha-PDGFR-mediated,946,B-GENE-Y
simultaneous,946,O
activation,946,O
of,946,O
growth,946,O
stimulatory,946,O
and,946,O
inhibitory,946,O
signals,946,O
",",946,O
whereas,946,O
beta-PDGFR,946,B-GENE-Y
mainly,946,O
induces,946,O
a,946,O
growth-promoting,946,O
signal,946,O
.,946,O
Here,947,O
we,947,O
demonstrate,947,O
that,947,O
PDGF,947,B-GENE-Y
BB,947,I-GENE-Y
activation,947,O
of,947,O
beta-PDGFR,947,B-GENE-Y
alone,947,O
results,947,O
in,947,O
more,947,O
efficient,947,O
cell,947,O
cycle,947,O
transition,947,O
from,947,O
G1,947,O
to,947,O
S,947,O
phase,947,O
than,947,O
PDGF,947,B-GENE-Y
BB,947,I-GENE-Y
activation,947,O
of,947,O
both,947,O
alpha-PDGFR,947,B-GENE-Y
and,947,O
beta-PDGFR,947,B-GENE-Y
.,947,O
PDGF,948,B-GENE-Y
AA,948,I-GENE-Y
activation,948,O
of,948,O
alpha-PDGFR,948,B-GENE-Y
or,948,O
PDGF,948,B-GENE-Y
BB,948,I-GENE-Y
activation,948,O
of,948,O
both,948,O
alpha-,948,B-GENE-N
and,948,I-GENE-N
beta-PDGFRs,948,I-GENE-N
up-regulates,948,O
expression,948,O
of,948,O
p21WAF1/CIP1,948,B-GENE-Y
",",948,O
an,948,O
inhibitor,948,O
of,948,O
cell,948,O
cycle-dependent,948,O
kinases,948,B-GENE-N
and,948,O
a,948,O
downstream,948,O
mediator,948,O
of,948,O
the,948,O
tumor,948,O
suppressor,948,O
gene,948,O
product,948,O
p53,948,B-GENE-Y
.,948,O
However,949,O
",",949,O
beta-PDGFR,949,B-GENE-Y
activation,949,O
alone,949,O
fails,949,O
to,949,O
induce,949,O
p21WAF1/CIP1,949,B-GENE-Y
expression,949,O
.,949,O
We,950,O
also,950,O
demonstrate,950,O
that,950,O
alpha-PDGFR-activated,950,B-GENE-Y
JNK-1,950,B-GENE-Y
is,950,O
a,950,O
critical,950,O
signaling,950,O
component,950,O
for,950,O
PDGF,950,B-GENE-N
induction,950,O
of,950,O
p21WAF1/CIP1,950,B-GENE-N
promoter,950,O
activity,950,O
.,950,O
The,951,O
ability,951,O
of,951,O
PDGF/JNK-1,951,B-GENE-N
to,951,O
induce,951,O
p21WAF1/CIP1,951,B-GENE-N
promoter,951,I-GENE-N
activity,951,O
is,951,O
independent,951,O
of,951,O
p53,951,B-GENE-Y
",",951,O
although,951,O
the,951,O
overall,951,O
p21WAF1/CIP1,951,B-GENE-N
promoter,951,I-GENE-N
activities,951,O
are,951,O
greatly,951,O
reduced,951,O
in,951,O
the,951,O
absence,951,O
of,951,O
p53,951,B-GENE-Y
.,951,O
These,952,O
results,952,O
provide,952,O
a,952,O
molecular,952,O
basis,952,O
for,952,O
differential,952,O
regulation,952,O
of,952,O
the,952,O
cell,952,O
cycle,952,O
and,952,O
transformation,952,O
by,952,O
alpha-,952,B-GENE-N
and,952,I-GENE-N
beta-PDGFRs,952,I-GENE-N
.,952,O
Searching,953,O
for,953,O
preventive,953,O
measures,953,O
of,953,O
cardiovascular,953,O
events,953,O
in,953,O
aged,953,O
Japanese,953,O
taxi,953,O
drivers,953,O
--,953,O
the,953,O
daily,953,O
rhythm,953,O
of,953,O
cardiovascular,953,O
risk,953,O
factors,953,O
during,953,O
a,953,O
night,953,O
duty,953,O
day,953,O
.,953,O
Previous,954,O
studies,954,O
have,954,O
shown,954,O
that,954,O
Japanese,954,O
taxi,954,O
drivers,954,O
are,954,O
exposed,954,O
to,954,O
more,954,O
risk,954,O
factors,954,O
and,954,O
have,954,O
a,954,O
higher,954,O
mortality,954,O
rate,954,O
due,954,O
to,954,O
cardiovascular,954,O
disease,954,O
than,954,O
other,954,O
occupational,954,O
groups,954,O
.,954,O
We,955,O
investigated,955,O
the,955,O
effect,955,O
of,955,O
night,955,O
taxi,955,O
driving,955,O
with,955,O
a,955,O
view,955,O
to,955,O
preventing,955,O
acute,955,O
events,955,O
of,955,O
cardiovascular,955,O
disease,955,O
among,955,O
aged,955,O
taxi,955,O
drivers,955,O
.,955,O
Twenty-nine,956,O
taxi,956,O
drivers,956,O
(,956,O
41-67,956,O
years,956,O
old,956,O
),956,O
were,956,O
examined,956,O
for,956,O
urine,956,O
normetanephrine/creatinine,956,B-CHEMICAL
",",956,O
von,956,B-GENE-Y
Willebrand,956,I-GENE-Y
factor,956,I-GENE-Y
",",956,O
anti-thrombin,956,B-GENE-Y
III,956,I-GENE-Y
",",956,O
t-plasminogen,956,B-GENE-Y
activator-plasminogen,956,O
activator,956,I-GENE-Y
inhibitor,956,I-GENE-Y
1-complex,956,O
",",956,O
hematocrit,956,O
",",956,O
blood,956,O
glucose,956,B-CHEMICAL
and,956,O
blood,956,O
pressure,956,O
in,956,O
the,956,O
morning,956,O
and,956,O
at,956,O
midnight,956,O
during,956,O
a,956,O
duty,956,O
day,956,O
and,956,O
in,956,O
the,956,O
following,956,O
morning,956,O
.,956,O
At,957,O
the,957,O
same,957,O
time,957,O
",",957,O
the,957,O
blood,957,O
pressure,957,O
and,957,O
blood,957,O
glucose,957,B-CHEMICAL
of,957,O
46,957,O
taxi,957,O
drivers,957,O
(,957,O
43-67,957,O
years,957,O
old,957,O
),957,O
in,957,O
the,957,O
morning,957,O
after,957,O
a,957,O
night,957,O
duty,957,O
with,957,O
little,957,O
sleep,957,O
and,957,O
in,957,O
the,957,O
morning,957,O
after,957,O
daytime,957,O
work,957,O
and,957,O
subsequent,957,O
night,957,O
sleep,957,O
were,957,O
compared,957,O
.,957,O
The,958,O
results,958,O
obtained,958,O
indicate,958,O
that,958,O
the,958,O
aggravation,958,O
of,958,O
sympathetic,958,O
nervous,958,O
system,958,O
functions,958,O
with,958,O
disturbed,958,O
circadian,958,O
rhythms,958,O
",",958,O
increased,958,O
blood,958,O
coagulation,958,O
and,958,O
blood,958,O
concentration,958,O
",",958,O
endothelial,958,O
injury,958,O
and,958,O
the,958,O
elevation,958,O
of,958,O
blood,958,O
glucose,958,O
at,958,O
midnight,958,O
or,958,O
the,958,O
next,958,O
morning,958,O
were,958,O
induced,958,O
by,958,O
their,958,O
night,958,O
work,958,O
.,958,O
These,959,O
conditions,959,O
are,959,O
supposed,959,O
to,959,O
favour,959,O
acute,959,O
vascular,959,O
events,959,O
in,959,O
aged,959,O
taxi,959,O
drivers,959,O
.,959,O
Preventive,960,O
measures,960,O
considered,960,O
include,960,O
social,960,O
support,960,O
for,960,O
anticoagulant,960,O
food,960,O
and,960,O
water,960,O
intake,960,O
",",960,O
short,960,O
exercise,960,O
and,960,O
walking,960,O
as,960,O
well,960,O
as,960,O
taking,960,O
a,960,O
rest,960,O
and,960,O
a,960,O
nap,960,O
during,960,O
night,960,O
work,960,O
.,960,O
The,961,O
human,961,B-GENE-Y
ribonucleotide,961,B-CHEMICAL
reductase,961,I-GENE-Y
subunit,961,I-GENE-Y
hRRM2,961,I-GENE-Y
complements,961,O
p53R2,961,B-GENE-Y
in,961,O
response,961,O
to,961,O
UV-induced,961,O
DNA,961,O
repair,961,O
in,961,O
cells,961,O
with,961,O
mutant,961,O
p53,961,B-GENE-Y
.,961,O
Ribonucleotide,962,B-GENE-N
reductase,962,I-GENE-N
(,962,O
RR,962,B-GENE-N
),962,O
is,962,O
responsible,962,O
for,962,O
the,962,O
de,962,O
novo,962,O
conversion,962,O
of,962,O
the,962,O
ribonucleoside,962,B-CHEMICAL
diphosphates,962,I-CHEMICAL
to,962,O
deoxyribonucleoside,962,B-CHEMICAL
diphosphates,962,I-CHEMICAL
",",962,O
which,962,O
are,962,O
essential,962,O
for,962,O
DNA,962,O
synthesis,962,O
and,962,O
repair,962,O
.,962,O
RR,963,B-GENE-N
consists,963,O
of,963,O
two,963,O
subunits,963,O
",",963,O
hRRM1,963,B-GENE-Y
and,963,O
hRRM2,963,B-GENE-Y
.,963,O
p53R2,964,B-GENE-Y
is,964,O
a,964,O
new,964,O
RR,964,B-GENE-N
family,964,O
member,964,O
.,964,O
Because,965,O
the,965,O
majority,965,O
of,965,O
human,965,O
tumors,965,O
possess,965,O
mutant,965,O
p53,965,B-GENE-Y
",",965,O
it,965,O
is,965,O
important,965,O
to,965,O
know,965,O
the,965,O
molecular,965,O
mechanism,965,O
by,965,O
which,965,O
mutant,965,O
p53,965,B-GENE-Y
regulates,965,O
RR,965,B-GENE-N
and,965,O
to,965,O
what,965,O
extent,965,O
.,965,O
In,966,O
this,966,O
study,966,O
",",966,O
we,966,O
investigated,966,O
the,966,O
expression,966,O
and,966,O
function,966,O
of,966,O
p53R2,966,B-GENE-Y
and,966,O
hRRM2,966,B-GENE-Y
after,966,O
UV,966,O
treatment,966,O
in,966,O
human,966,O
prostate,966,O
cancer,966,O
PC3,966,O
cells,966,O
",",966,O
which,966,O
possess,966,O
mutant,966,O
p53,966,B-GENE-Y
with,966,O
a,966,O
truncated,966,O
COOH-terminal,966,B-CHEMICAL
",",966,O
and,966,O
in,966,O
human,966,O
oropharyngeal,966,O
cancer,966,O
KB,966,O
cells,966,O
",",966,O
which,966,O
possess,966,O
wild-type,966,O
p53,966,B-GENE-Y
.,966,O
p53R2,967,B-GENE-Y
(,967,O
analyzed,967,O
by,967,O
Western,967,O
blot,967,O
and,967,O
standardized,967,O
relative,967,O
to,967,O
Coomassie,967,O
Blue-stained,967,O
band,967,O
),967,O
was,967,O
down-regulated,967,O
in,967,O
PC3,967,O
cells,967,O
and,967,O
up-regulated,967,O
in,967,O
KB,967,O
cells,967,O
after,967,O
UV,967,O
exposure,967,O
.,967,O
In,968,O
contrast,968,O
",",968,O
hRRM2,968,B-GENE-Y
was,968,O
up-regulated,968,O
by,968,O
UV,968,O
in,968,O
both,968,O
PC3,968,O
cells,968,O
and,968,O
KB,968,O
cells,968,O
.,968,O
hRRM2,969,B-GENE-Y
and,969,O
p53R2,969,B-GENE-Y
mRNA,969,O
levels,969,O
were,969,O
assessed,969,O
by,969,O
Northern,969,O
blot,969,O
",",969,O
and,969,O
the,969,O
results,969,O
paralleled,969,O
that,969,O
of,969,O
the,969,O
Western,969,O
blot,969,O
.,969,O
Coimmunoprecipitation,970,O
assays,970,O
using,970,O
agarose-conjugated,970,O
goat,970,O
antihuman,970,O
RRM1,970,B-GENE-Y
antibody,970,O
confirmed,970,O
that,970,O
the,970,O
p53R2,970,B-GENE-Y
binding,970,O
to,970,O
hRRM1,970,B-GENE-Y
decreased,970,O
in,970,O
PC3,970,O
cells,970,O
but,970,O
increased,970,O
in,970,O
KB,970,O
cells,970,O
after,970,O
UV,970,O
treatment,970,O
.,970,O
hRRM2,971,B-GENE-Y
binding,971,O
to,971,O
hRRM1,971,B-GENE-N
increased,971,O
in,971,O
both,971,O
cell,971,O
lines,971,O
under,971,O
the,971,O
same,971,O
conditions,971,O
.,971,O
These,972,O
results,972,O
suggest,972,O
that,972,O
PC3,972,O
cells,972,O
are,972,O
deficient,972,O
in,972,O
both,972,O
transcription,972,O
of,972,O
p53R2,972,B-GENE-Y
and,972,O
binding,972,O
to,972,O
hRRM1,972,B-GENE-Y
in,972,O
response,972,O
to,972,O
UV,972,O
irradiation,972,O
.,972,O
Confocal,973,O
microscopy,973,O
further,973,O
confirmed,973,O
that,973,O
these,973,O
findings,973,O
were,973,O
not,973,O
due,973,O
to,973,O
translocation,973,O
of,973,O
hRRM2,973,B-GENE-Y
and,973,O
p53R2,973,B-GENE-Y
from,973,O
the,973,O
cytoplasm,973,O
to,973,O
the,973,O
nucleus,973,O
.,973,O
RR,974,B-GENE-N
activity,974,O
was,974,O
measured,974,O
following,974,O
UV,974,O
treatment,974,O
and,974,O
shown,974,O
to,974,O
increase,974,O
in,974,O
PC3,974,O
cells,974,O
.,974,O
It,975,O
was,975,O
unchanged,975,O
in,975,O
proportional,975,O
of,975,O
KB,975,O
cells,975,O
.,975,O
The,976,O
RR,976,B-GENE-N
activity,976,O
is,976,O
consistent,976,O
with,976,O
the,976,O
expression,976,O
of,976,O
hRRM2,976,B-GENE-N
seen,976,O
in,976,O
the,976,O
Western,976,O
blots,976,O
.,976,O
Thus,977,O
",",977,O
we,977,O
hypothesize,977,O
that,977,O
hRRM2,977,B-GENE-Y
complements,977,O
p53R2,977,B-GENE-Y
to,977,O
form,977,O
RR,977,B-GENE-N
holoenzyme,977,O
and,977,O
maintain,977,O
RR,977,B-GENE-N
activity,977,O
in,977,O
PC3,977,O
cells,977,O
after,977,O
UV,977,O
treatment,977,O
.,977,O
To,978,O
further,978,O
confirm,978,O
this,978,O
hypothesis,978,O
",",978,O
we,978,O
examined,978,O
the,978,O
effect,978,O
of,978,O
RRM2,978,B-GENE-Y
inhibitors,978,O
on,978,O
cells,978,O
exposed,978,O
to,978,O
UV,978,O
.,978,O
In,979,O
PC3,979,O
cells,979,O
",",979,O
hydroxyurea,979,B-CHEMICAL
inhibited,979,O
hRRM2,979,B-GENE-Y
and,979,O
resulted,979,O
in,979,O
increased,979,O
sensitivity,979,O
to,979,O
UV,979,O
irradiation,979,O
.,979,O
We,980,O
also,980,O
examined,980,O
the,980,O
effect,980,O
of,980,O
UV,980,O
treatment,980,O
on,980,O
the,980,O
colony-forming,980,O
ability,980,O
of,980,O
cells,980,O
transfected,980,O
with,980,O
hRRM2,980,B-GENE-Y
as,980,O
well,980,O
as,980,O
p53R2,980,B-GENE-Y
sense,980,O
or,980,O
antisense,980,O
expression,980,O
vectors,980,O
.,980,O
Expression,981,O
of,981,O
antisense,981,O
hRRM2,981,B-GENE-Y
in,981,O
PC3,981,O
cells,981,O
led,981,O
to,981,O
decreased,981,O
hRRM2,981,B-GENE-Y
expression,981,O
and,981,O
resulted,981,O
in,981,O
greater,981,O
sensitivity,981,O
to,981,O
UV,981,O
than,981,O
observed,981,O
in,981,O
wild-type,981,O
PC3,981,O
cells,981,O
.,981,O
Taken,982,O
together,982,O
",",982,O
we,982,O
conclude,982,O
that,982,O
UV-induced,982,O
activation,982,O
of,982,O
p53R2,982,B-GENE-Y
transcription,982,O
and,982,O
binding,982,O
of,982,O
p53R2,982,B-GENE-N
to,982,O
hRRM1,982,B-GENE-Y
to,982,O
form,982,O
RR,982,B-GENE-N
holoenzyme,982,O
are,982,O
impaired,982,O
in,982,O
the,982,O
p53-mutant,982,B-GENE-Y
cell,982,O
line,982,O
PC3,982,O
.,982,O
Minocycline,983,B-CHEMICAL
reduces,983,O
cell,983,O
death,983,O
and,983,O
improves,983,O
functional,983,O
recovery,983,O
after,983,O
traumatic,983,O
spinal,983,O
cord,983,O
injury,983,O
in,983,O
the,983,O
rat,983,O
.,983,O
We,984,O
examined,984,O
the,984,O
effects,984,O
of,984,O
minocycline,984,B-CHEMICAL
",",984,O
an,984,O
anti-inflammatory,984,O
drug,984,O
",",984,O
on,984,O
functional,984,O
recovery,984,O
following,984,O
spinal,984,O
cord,984,O
injury,984,O
(,984,O
SCI,984,O
),984,O
.,984,O
Rats,985,O
received,985,O
a,985,O
mild,985,O
",",985,O
weight-drop,985,O
contusion,985,O
injury,985,O
to,985,O
the,985,O
spinal,985,O
cord,985,O
and,985,O
were,985,O
treated,985,O
with,985,O
the,985,O
vehicle,985,O
or,985,O
minocycline,985,B-CHEMICAL
at,985,O
a,985,O
dose,985,O
of,985,O
90,985,O
mg/kg,985,O
immediately,985,O
after,985,O
SCI,985,O
and,985,O
then,985,O
twice,985,O
at,985,O
a,985,O
dose,985,O
of,985,O
45,985,O
mg/kg,985,O
every,985,O
12,985,O
h.,985,O
Injecting,985,O
minocycline,985,B-CHEMICAL
after,985,O
SCI,985,O
improved,985,O
hind,985,O
limb,985,O
motor,985,O
function,985,O
as,985,O
determined,985,O
by,985,O
the,985,O
Basso-Beattie-Bresnahan,985,O
(,985,O
BBB,985,O
),985,O
locomotor,985,O
open,985,O
field,985,O
behavioral,985,O
rating,985,O
test,985,O
.,985,O
Twenty,986,O
four,986,O
to,986,O
38,986,O
days,986,O
after,986,O
SCI,986,O
",",986,O
BBB,986,O
scores,986,O
were,986,O
significantly,986,O
higher,986,O
in,986,O
minocycline-treated,986,B-CHEMICAL
rats,986,O
as,986,O
compared,986,O
with,986,O
those,986,O
in,986,O
vehicle-treated,986,O
rats,986,O
.,986,O
Morphological,987,O
analysis,987,O
showed,987,O
that,987,O
lesion,987,O
size,987,O
increased,987,O
progressively,987,O
in,987,O
both,987,O
vehicle-treated,987,O
and,987,O
minocycline-treated,987,B-CHEMICAL
spinal,987,O
cords,987,O
.,987,O
However,988,O
",",988,O
in,988,O
response,988,O
to,988,O
treatment,988,O
with,988,O
minocycline,988,B-CHEMICAL
",",988,O
the,988,O
lesion,988,O
size,988,O
was,988,O
significantly,988,O
reduced,988,O
at,988,O
21-38,988,O
days,988,O
after,988,O
SCI,988,O
when,988,O
compared,988,O
to,988,O
the,988,O
vehicle,988,O
control,988,O
.,988,O
Minocycline,989,B-CHEMICAL
treatment,989,O
significantly,989,O
reduced,989,O
the,989,O
number,989,O
of,989,O
terminal,989,O
deoxynucleotidyl,989,O
transferase,989,O
(,989,O
TdT,989,O
),989,O
-mediated,989,O
deoxyuridine,989,B-CHEMICAL
triphosphate-biotin,989,I-CHEMICAL
nick,989,O
end,989,O
labeling,989,O
(,989,O
TUNEL,989,O
),989,O
-positive,989,O
cells,989,O
24,989,O
h,989,O
after,989,O
SCI,989,O
as,989,O
compared,989,O
to,989,O
that,989,O
of,989,O
the,989,O
vehicle,989,O
control,989,O
.,989,O
DNA,990,O
gel,990,O
electrophoresis,990,O
also,990,O
revealed,990,O
a,990,O
marked,990,O
decrease,990,O
in,990,O
DNA,990,O
laddering,990,O
in,990,O
response,990,O
to,990,O
treatment,990,O
with,990,O
minocycline,990,B-CHEMICAL
.,990,O
In,991,O
addition,991,O
",",991,O
minocycline,991,B-CHEMICAL
treatment,991,O
significantly,991,O
reduced,991,O
the,991,O
specific,991,O
caspase-3,991,B-GENE-Y
activity,991,O
after,991,O
SCI,991,O
as,991,O
compared,991,O
to,991,O
that,991,O
of,991,O
vehicle,991,O
control,991,O
.,991,O
Furthermore,992,O
",",992,O
RT-PCR,992,O
analyses,992,O
revealed,992,O
that,992,O
minocycline,992,B-CHEMICAL
treatment,992,O
increased,992,O
expression,992,O
of,992,O
interleukin-10,992,B-GENE-Y
mRNA,992,O
but,992,O
decreased,992,O
tumor,992,B-GENE-Y
necrosis,992,I-GENE-Y
factor-alpha,992,I-GENE-Y
expression,992,O
.,992,O
These,993,O
data,993,O
suggest,993,O
that,993,O
",",993,O
after,993,O
SCI,993,O
",",993,O
minocycline,993,B-CHEMICAL
treatment,993,O
modulated,993,O
expression,993,O
of,993,O
cytokines,993,B-GENE-N
",",993,O
attenuated,993,O
cell,993,O
death,993,O
and,993,O
the,993,O
size,993,O
of,993,O
lesions,993,O
",",993,O
and,993,O
improved,993,O
functional,993,O
recovery,993,O
in,993,O
the,993,O
injured,993,O
rat,993,O
.,993,O
This,994,O
approach,994,O
may,994,O
provide,994,O
a,994,O
therapeutic,994,O
intervention,994,O
enabling,994,O
us,994,O
to,994,O
reduce,994,O
cell,994,O
death,994,O
and,994,O
improve,994,O
functional,994,O
recovery,994,O
after,994,O
SCI,994,O
.,994,O
Innovative,995,O
approach,995,O
for,995,O
improvement,995,O
of,995,O
an,995,O
antibiotic-overproducing,995,O
industrial,995,O
strain,995,O
of,995,O
Streptomyces,995,O
albus,995,O
.,995,O
Working,996,O
with,996,O
a,996,O
Streptomyces,996,O
albus,996,O
strain,996,O
that,996,O
had,996,O
previously,996,O
been,996,O
bred,996,O
to,996,O
produce,996,O
industrial,996,O
amounts,996,O
(,996,O
10,996,O
mg/ml,996,O
),996,O
of,996,O
salinomycin,996,B-CHEMICAL
",",996,O
we,996,O
demonstrated,996,O
the,996,O
efficacy,996,O
of,996,O
introducing,996,O
drug,996,O
resistance-producing,996,O
mutations,996,O
for,996,O
further,996,O
strain,996,O
improvement,996,O
.,996,O
Mutants,997,O
with,997,O
enhanced,997,O
salinomycin,997,B-CHEMICAL
production,997,O
were,997,O
detected,997,O
at,997,O
a,997,O
high,997,O
incidence,997,O
(,997,O
7,997,O
to,997,O
12,997,O
%,997,O
),997,O
among,997,O
spontaneous,997,O
isolates,997,O
resistant,997,O
to,997,O
streptomycin,997,B-CHEMICAL
(,997,O
Str,997,O
(,997,O
r,997,O
),997,O
),997,O
",",997,O
gentamicin,997,B-CHEMICAL
",",997,O
or,997,O
rifampin,997,B-CHEMICAL
(,997,O
Rif,997,O
(,997,O
r,997,O
),997,O
),997,O
.,997,O
Finally,998,O
",",998,O
we,998,O
successfully,998,O
demonstrated,998,O
improvement,998,O
of,998,O
the,998,O
salinomycin,998,B-CHEMICAL
productivity,998,O
of,998,O
the,998,O
industrial,998,O
strain,998,O
by,998,O
2.3-fold,998,O
by,998,O
introducing,998,O
a,998,O
triple,998,O
mutation,998,O
.,998,O
The,999,O
Str,999,O
(,999,O
r,999,O
),999,O
mutant,999,O
was,999,O
shown,999,O
to,999,O
have,999,O
a,999,O
point,999,O
mutation,999,O
within,999,O
the,999,O
rpsL,999,B-GENE-Y
gene,999,O
(,999,O
encoding,999,O
ribosomal,999,B-GENE-Y
protein,999,I-GENE-Y
S12,999,I-GENE-Y
),999,O
.,999,O
Likewise,1000,O
",",1000,O
the,1000,O
Rif,1000,O
(,1000,O
r,1000,O
),1000,O
mutant,1000,O
possessed,1000,O
a,1000,O
mutation,1000,O
in,1000,O
the,1000,O
rpoB,1000,B-GENE-Y
gene,1000,O
(,1000,O
encoding,1000,O
the,1000,O
RNA,1000,B-GENE-N
polymerase,1000,I-GENE-N
beta,1000,I-GENE-N
subunit,1000,O
),1000,O
.,1000,O
Increased,1001,O
productivity,1001,O
of,1001,O
salinomycin,1001,B-CHEMICAL
in,1001,O
the,1001,O
Str,1001,O
(,1001,O
r,1001,O
),1001,O
mutant,1001,O
(,1001,O
containing,1001,O
the,1001,O
K88R,1001,B-GENE-N
mutation,1001,O
in,1001,O
the,1001,O
S12,1001,B-GENE-Y
protein,1001,O
),1001,O
may,1001,O
be,1001,O
a,1001,O
result,1001,O
of,1001,O
an,1001,O
aberrant,1001,O
protein,1001,O
synthesis,1001,O
mechanism,1001,O
.,1001,O
This,1002,O
aberration,1002,O
may,1002,O
manifest,1002,O
itself,1002,O
as,1002,O
enhanced,1002,O
translation,1002,O
activity,1002,O
in,1002,O
stationary-phase,1002,O
cells,1002,O
",",1002,O
as,1002,O
we,1002,O
have,1002,O
observed,1002,O
with,1002,O
the,1002,O
poly,1002,O
(,1002,O
U,1002,O
),1002,O
-directed,1002,O
cell-free,1002,O
translation,1002,O
system,1002,O
.,1002,O
The,1003,O
K88R,1003,B-GENE-N
mutant,1003,O
ribosome,1003,O
was,1003,O
characterized,1003,O
by,1003,O
increased,1003,O
70S,1003,B-GENE-N
complex,1003,I-GENE-N
stability,1003,O
in,1003,O
low,1003,O
Mg,1003,B-CHEMICAL
(,1003,I-CHEMICAL
2+,1003,I-CHEMICAL
),1003,I-CHEMICAL
concentrations,1003,O
.,1003,O
We,1004,O
conclude,1004,O
that,1004,O
this,1004,O
aberrant,1004,O
protein,1004,O
synthesis,1004,O
ability,1004,O
in,1004,O
the,1004,O
Str,1004,O
(,1004,O
r,1004,O
),1004,O
mutant,1004,O
",",1004,O
which,1004,O
is,1004,O
a,1004,O
result,1004,O
of,1004,O
increased,1004,O
stability,1004,O
of,1004,O
the,1004,O
70S,1004,B-GENE-N
complex,1004,I-GENE-N
",",1004,O
is,1004,O
responsible,1004,O
for,1004,O
the,1004,O
remarkable,1004,O
salinomycin,1004,B-CHEMICAL
production,1004,O
enhancement,1004,O
obtained,1004,O
.,1004,O
[,1005,O
The,1005,O
effects,1005,O
of,1005,O
nandrolone,1005,B-CHEMICAL
phenylpropionate,1005,I-CHEMICAL
on,1005,O
androgen,1005,B-GENE-Y
receptor,1005,I-GENE-Y
of,1005,O
liver,1005,O
and,1005,O
sexual,1005,O
glands,1005,O
in,1005,O
burned,1005,O
rats,1005,O
],1005,O
.,1005,O
OBJECTIVE,1006,O
:,1006,O
To,1006,O
assess,1006,O
the,1006,O
effects,1006,O
of,1006,O
nandrolone,1006,B-CHEMICAL
phenylpropionate,1006,I-CHEMICAL
(,1006,O
NP,1006,B-CHEMICAL
),1006,O
on,1006,O
androgen,1006,B-GENE-Y
receptor,1006,I-GENE-Y
(,1006,O
AR,1006,B-GENE-Y
),1006,O
of,1006,O
liver,1006,O
and,1006,O
sexual,1006,O
glands,1006,O
in,1006,O
burned,1006,O
rats,1006,O
for,1006,O
supporting,1006,O
the,1006,O
clinical,1006,O
application,1006,O
of,1006,O
anabolic,1006,O
steroids,1006,O
.,1006,O
METHODS,1007,O
:,1007,O
Thirty-two,1007,O
Wistar,1007,O
rats,1007,O
with,1007,O
a,1007,O
deep,1007,O
second-degree,1007,O
cutaneous,1007,O
burn,1007,O
of,1007,O
20,1007,O
%,1007,O
total,1007,O
body,1007,O
surface,1007,O
area,1007,O
were,1007,O
randomly,1007,O
divided,1007,O
into,1007,O
two,1007,O
groups,1007,O
to,1007,O
receive,1007,O
either,1007,O
5,1007,O
mg/kg,1007,O
NP,1007,B-CHEMICAL
(,1007,O
NP,1007,B-CHEMICAL
group,1007,O
),1007,O
or,1007,O
normal,1007,O
saline,1007,O
as,1007,O
placebo,1007,O
(,1007,O
control,1007,O
group,1007,O
),1007,O
every,1007,O
other,1007,O
day,1007,O
.,1007,O
The,1008,O
mean,1008,O
integrated,1008,O
optical,1008,O
density,1008,O
(,1008,O
mIOD,1008,O
),1008,O
of,1008,O
androgen,1008,B-GENE-Y
receptor,1008,I-GENE-Y
(,1008,O
AR,1008,B-GENE-Y
),1008,O
in,1008,O
liver,1008,O
",",1008,O
testis,1008,O
",",1008,O
ovary,1008,O
tissues,1008,O
were,1008,O
measured,1008,O
by,1008,O
immunohistochemistry,1008,O
ENVISION,1008,O
and,1008,O
LSAB,1008,O
respectively,1008,O
on,1008,O
the,1008,O
4th,1008,O
",",1008,O
7th,1008,O
",",1008,O
14th,1008,O
and,1008,O
21st,1008,O
days,1008,O
after,1008,O
scalding,1008,O
.,1008,O
RESULTS,1009,O
:,1009,O
The,1009,O
density,1009,O
of,1009,O
AR,1009,B-GENE-Y
in,1009,O
liver,1009,O
tissue,1009,O
in,1009,O
NP,1009,B-CHEMICAL
group,1009,O
was,1009,O
higher,1009,O
than,1009,O
that,1009,O
in,1009,O
control,1009,O
group,1009,O
(,1009,O
P,1009,O
<,1009,O
0.05,1009,O
),1009,O
.,1009,O
The,1010,O
density,1010,O
of,1010,O
AR,1010,B-GENE-Y
in,1010,O
testis,1010,O
and,1010,O
ovary,1010,O
tissues,1010,O
showed,1010,O
no,1010,O
significant,1010,O
difference,1010,O
between,1010,O
NP,1010,B-CHEMICAL
group,1010,O
and,1010,O
control,1010,O
group,1010,O
at,1010,O
every,1010,O
time-point,1010,O
(,1010,O
P,1010,O
>,1010,O
0.05,1010,O
),1010,O
.,1010,O
The,1011,O
side-effect,1011,O
of,1011,O
NP,1011,B-CHEMICAL
at,1011,O
this,1011,O
dose,1011,O
level,1011,O
on,1011,O
sexual,1011,O
glands,1011,O
seemed,1011,O
limited,1011,O
.,1011,O
CONCLUSION,1012,O
:,1012,O
Nandrolone,1012,B-CHEMICAL
phenylpropionate,1012,I-CHEMICAL
up-regulated,1012,O
the,1012,O
density,1012,O
of,1012,O
AR,1012,B-GENE-Y
in,1012,O
liver,1012,O
tissue,1012,O
",",1012,O
whereas,1012,O
it,1012,O
had,1012,O
no,1012,O
significant,1012,O
effects,1012,O
on,1012,O
the,1012,O
density,1012,O
of,1012,O
AR,1012,B-GENE-Y
in,1012,O
testis,1012,O
and,1012,O
ovary,1012,O
tissues,1012,O
.,1012,O
NP,1013,B-CHEMICAL
was,1013,O
used,1013,O
with,1013,O
safety,1013,O
at,1013,O
this,1013,O
dose,1013,O
level,1013,O
in,1013,O
rats,1013,O
.,1013,O
Serotonin,1014,B-CHEMICAL
5-HT,1014,I-GENE-Y
(,1014,I-GENE-Y
2B,1014,I-GENE-Y
),1014,I-GENE-Y
receptor,1014,I-GENE-Y
loss,1014,O
of,1014,O
function,1014,O
mutation,1014,O
in,1014,O
a,1014,O
patient,1014,O
with,1014,O
fenfluramine-associated,1014,B-CHEMICAL
primary,1014,O
pulmonary,1014,O
hypertension,1014,O
.,1014,O
OBJECTIVE,1015,O
:,1015,O
Appetite-suppressant,1015,O
drug,1015,O
fenfluramine,1015,O
is,1015,O
implicated,1015,O
in,1015,O
primary,1015,O
pulmonary,1015,O
hypertension,1015,O
(,1015,O
PPH,1015,O
),1015,O
but,1015,O
the,1015,O
molecular,1015,O
pathways,1015,O
that,1015,O
mediate,1015,O
this,1015,O
effect,1015,O
are,1015,O
unknown,1015,O
.,1015,O
A,1016,O
mouse,1016,O
model,1016,O
incriminates,1016,O
the,1016,O
serotonin,1016,B-CHEMICAL
5-HT,1016,I-GENE-Y
(,1016,I-GENE-Y
2B,1016,I-GENE-Y
),1016,I-GENE-Y
receptor,1016,I-GENE-Y
but,1016,O
contrasts,1016,O
with,1016,O
other,1016,O
models,1016,O
where,1016,O
this,1016,O
receptor,1016,O
has,1016,O
been,1016,O
shown,1016,O
to,1016,O
mediate,1016,O
pulmonary,1016,O
arterial,1016,O
relaxation,1016,O
via,1016,O
nitric,1016,B-CHEMICAL
oxide,1016,I-CHEMICAL
production,1016,O
.,1016,O
METHODS,1017,O
:,1017,O
We,1017,O
analyzed,1017,O
the,1017,O
human,1017,B-GENE-Y
5-HT,1017,I-GENE-Y
(,1017,I-GENE-Y
2B,1017,I-GENE-Y
),1017,I-GENE-Y
gene,1017,O
in,1017,O
10,1017,O
patients,1017,O
with,1017,O
appetite-suppressant,1017,O
drug-associated,1017,O
PPH,1017,O
.,1017,O
RESULTS,1018,O
:,1018,O
A,1018,O
mutation,1018,O
causing,1018,O
premature,1018,O
truncation,1018,O
of,1018,O
the,1018,O
protein,1018,O
product,1018,O
was,1018,O
found,1018,O
in,1018,O
one,1018,O
patient,1018,O
.,1018,O
The,1019,O
mutation,1019,O
was,1019,O
not,1019,O
found,1019,O
in,1019,O
80,1019,O
control,1019,O
subjects,1019,O
and,1019,O
no,1019,O
5-HT,1019,B-GENE-Y
(,1019,I-GENE-Y
2B,1019,I-GENE-Y
),1019,I-GENE-Y
mutation,1019,O
was,1019,O
found,1019,O
in,1019,O
18,1019,O
PPH,1019,O
patients,1019,O
not,1019,O
associated,1019,O
with,1019,O
appetite-suppressants,1019,O
.,1019,O
Functional,1020,O
analysis,1020,O
of,1020,O
the,1020,O
transfected,1020,O
receptor,1020,O
expressed,1020,O
either,1020,O
transiently,1020,O
in,1020,O
COS,1020,O
cells,1020,O
or,1020,O
stably,1020,O
in,1020,O
CHO,1020,B-CHEMICAL
cells,1020,O
demonstrated,1020,O
that,1020,O
the,1020,O
mutated,1020,O
receptor,1020,O
fails,1020,O
to,1020,O
activate,1020,O
the,1020,O
second,1020,O
messenger,1020,O
inositol-phosphates,1020,B-CHEMICAL
cascade,1020,O
and,1020,O
subsequent,1020,O
intracellular,1020,O
calcium,1020,B-CHEMICAL
release,1020,O
",",1020,O
in,1020,O
spite,1020,O
of,1020,O
normal,1020,O
expression,1020,O
at,1020,O
the,1020,O
cell,1020,O
membrane,1020,O
.,1020,O
The,1021,O
mutated,1021,O
receptor,1021,O
had,1021,O
no,1021,O
constitutive,1021,O
activity,1021,O
",",1021,O
and,1021,O
produced,1021,O
no,1021,O
dominant,1021,O
negative,1021,O
effect,1021,O
on,1021,O
the,1021,O
wild-type,1021,O
receptor,1021,O
.,1021,O
CONCLUSION,1022,O
:,1022,O
Loss,1022,O
of,1022,O
serotonin,1022,B-CHEMICAL
5-HT,1022,B-GENE-Y
(,1022,I-GENE-Y
2B,1022,I-GENE-Y
),1022,I-GENE-Y
receptor,1022,I-GENE-Y
function,1022,O
may,1022,O
predispose,1022,O
to,1022,O
fenfluramine-associated,1022,B-CHEMICAL
PPH,1022,O
in,1022,O
man,1022,O
.,1022,O
The,1023,O
antileukemia,1023,O
drug,1023,O
2-chloro-2'-deoxyadenosine,1023,B-CHEMICAL
:,1023,O
an,1023,O
intrinsic,1023,O
transcriptional,1023,O
antagonist,1023,O
.,1023,O
The,1024,O
nucleoside,1024,O
analog,1024,O
2-chloro-2'-deoxyadenosine,1024,B-CHEMICAL
(,1024,O
CldAdo,1024,B-CHEMICAL
;,1024,O
cladribine,1024,B-CHEMICAL
),1024,O
is,1024,O
effective,1024,O
in,1024,O
the,1024,O
treatment,1024,O
of,1024,O
hairy,1024,O
cell,1024,O
leukemia,1024,O
and,1024,O
chronic,1024,O
lymphocytic,1024,O
leukemia,1024,O
.,1024,O
CldAdo,1025,B-CHEMICAL
is,1025,O
phosphorylated,1025,O
and,1025,O
incorporated,1025,O
into,1025,O
cellular,1025,O
DNA,1025,O
but,1025,O
is,1025,O
not,1025,O
an,1025,O
absolute,1025,O
chain,1025,O
terminator,1025,O
.,1025,O
We,1026,O
demonstrated,1026,O
by,1026,O
in,1026,O
vitro,1026,O
gel-shift,1026,O
assays,1026,O
that,1026,O
binding,1026,O
interactions,1026,O
of,1026,O
the,1026,O
human,1026,B-GENE-Y
TATA,1026,I-GENE-Y
box-binding,1026,I-GENE-Y
protein,1026,I-GENE-Y
(,1026,O
TBP,1026,B-GENE-Y
),1026,O
were,1026,O
disrupted,1026,O
on,1026,O
2-chlorodeoxyadenosine,1026,B-CHEMICAL
monophosphate,1026,I-CHEMICAL
(,1026,O
CldAMP,1026,B-CHEMICAL
),1026,O
-substituted,1026,O
TATA,1026,B-GENE-N
box,1026,I-GENE-N
consensus,1026,I-GENE-N
sequences,1026,I-GENE-N
.,1026,O
We,1027,O
hypothesized,1027,O
that,1027,O
human,1027,B-GENE-N
RNA,1027,I-GENE-N
polymerase,1027,I-GENE-N
II,1027,I-GENE-N
(,1027,O
pol,1027,B-GENE-N
II,1027,I-GENE-N
),1027,O
transcriptional,1027,O
processes,1027,O
would,1027,O
therefore,1027,O
be,1027,O
affected,1027,O
by,1027,O
2-chlorodeoxyadenosine,1027,B-CHEMICAL
triphosphate,1027,I-CHEMICAL
(,1027,O
CldATP,1027,B-CHEMICAL
),1027,O
incorporation,1027,O
into,1027,O
a,1027,O
promoter,1027,O
TATA,1027,B-GENE-N
element,1027,I-GENE-N
.,1027,O
Double-stranded,1028,O
DNA,1028,O
templates,1028,O
containing,1028,O
the,1028,O
adenovirus,1028,O
major,1028,O
late,1028,O
promoter,1028,O
and,1028,O
coding,1028,O
sequences,1028,O
were,1028,O
enzymatically,1028,O
synthesized,1028,O
as,1028,O
control,1028,O
or,1028,O
with,1028,O
site-specific,1028,O
CldAMP,1028,B-CHEMICAL
residues,1028,O
",",1028,O
incubated,1028,O
with,1028,O
HeLa,1028,O
extract,1028,O
",",1028,O
and,1028,O
the,1028,O
synthesis,1028,O
of,1028,O
radiolabeled,1028,O
44-base,1028,O
transcripts,1028,O
was,1028,O
assessed,1028,O
.,1028,O
With,1029,O
increasing,1029,O
amounts,1029,O
of,1029,O
HeLa,1029,O
extract,1029,O
",",1029,O
CldAMP,1029,B-CHEMICAL
substitution,1029,O
for,1029,O
dAMP,1029,B-CHEMICAL
within,1029,O
the,1029,O
TATA,1029,B-GENE-N
box,1029,I-GENE-N
decreased,1029,O
in,1029,O
vitro,1029,O
pol,1029,B-GENE-N
II,1029,I-GENE-N
transcription,1029,O
by,1029,O
approximately,1029,O
35,1029,O
%,1029,O
compared,1029,O
with,1029,O
control,1029,O
substrates,1029,O
.,1029,O
Time-course,1030,O
studies,1030,O
showed,1030,O
that,1030,O
transcript,1030,O
production,1030,O
increased,1030,O
in,1030,O
a,1030,O
linear,1030,O
fashion,1030,O
on,1030,O
control,1030,O
substrates,1030,O
.,1030,O
In,1031,O
contrast,1031,O
",",1031,O
transcription,1031,O
on,1031,O
CldAMP-substituted,1031,B-CHEMICAL
TATA,1031,B-GENE-N
sequences,1031,I-GENE-N
reached,1031,O
a,1031,O
plateau,1031,O
after,1031,O
20,1031,O
min,1031,O
.,1031,O
Furthermore,1032,O
",",1032,O
CldAMP-substituted,1032,B-CHEMICAL
promoter,1032,O
sequences,1032,O
trapped,1032,O
or,1032,O
sequestered,1032,O
TBP,1032,O
",",1032,O
preventing,1032,O
its,1032,O
dissociation,1032,O
from,1032,O
DNA,1032,O
and,1032,O
subsequent,1032,O
binding,1032,O
to,1032,O
additional,1032,O
TATA,1032,B-GENE-N
elements,1032,I-GENE-N
to,1032,O
reinitiate,1032,O
transcription,1032,O
.,1032,O
CldAdo,1033,B-CHEMICAL
thus,1033,O
represents,1033,O
the,1033,O
first,1033,O
example,1033,O
of,1033,O
a,1033,O
nucleoside,1033,O
analog,1033,O
that,1033,O
acts,1033,O
as,1033,O
a,1033,O
transcriptional,1033,O
antagonist,1033,O
.,1033,O
CldATP,1034,B-CHEMICAL
incorporation,1034,O
into,1034,O
gene,1034,O
regulatory,1034,O
sequences,1034,O
may,1034,O
provide,1034,O
a,1034,O
novel,1034,O
strategy,1034,O
to,1034,O
modulate,1034,O
specific,1034,O
protein/DNA,1034,O
interactions,1034,O
.,1034,O
Blockade,1035,O
of,1035,O
beta,1035,B-GENE-Y
1-,1035,O
and,1035,O
desensitization,1035,O
of,1035,O
beta,1035,B-GENE-Y
2-adrenoceptors,1035,I-GENE-Y
reduce,1035,O
isoprenaline-induced,1035,B-CHEMICAL
cardiac,1035,O
fibrosis,1035,O
.,1035,O
The,1036,O
aim,1036,O
of,1036,O
the,1036,O
present,1036,O
study,1036,O
was,1036,O
to,1036,O
analyse,1036,O
the,1036,O
role,1036,O
of,1036,O
beta,1036,B-GENE-N
(,1036,I-GENE-N
1,1036,I-GENE-N
),1036,I-GENE-N
-,1036,I-GENE-N
and,1036,I-GENE-N
beta,1036,I-GENE-N
(,1036,I-GENE-N
2,1036,I-GENE-N
),1036,I-GENE-N
-adrenoceptors,1036,I-GENE-N
in,1036,O
the,1036,O
catecholamine-induced,1036,B-CHEMICAL
myocardial,1036,O
remodeling,1036,O
",",1036,O
especially,1036,O
the,1036,O
interstitial,1036,O
fibrosis,1036,O
.,1036,O
Wistar,1037,O
rats,1037,O
were,1037,O
subjected,1037,O
to,1037,O
a,1037,O
2-week,1037,O
chronic,1037,O
isoprenaline,1037,B-CHEMICAL
administration,1037,O
(,1037,O
30,1037,O
microg/kg/h,1037,O
),1037,O
.,1037,O
Rats,1038,O
received,1038,O
a,1038,O
concomitant,1038,O
treatment,1038,O
with,1038,O
the,1038,O
selective,1038,O
beta,1038,B-GENE-Y
(,1038,I-GENE-Y
1,1038,I-GENE-Y
),1038,I-GENE-Y
-adrenoceptor,1038,I-GENE-Y
antagonist,1038,O
",",1038,O
bisoprolol,1038,B-CHEMICAL
(,1038,O
50,1038,O
mg/kg/day,1038,O
p.o,1038,O
.,1038,O
),1038,O
or,1039,O
were,1039,O
chronically,1039,O
pretreated,1039,O
with,1039,O
the,1039,O
selective,1039,O
beta,1039,B-GENE-Y
(,1039,I-GENE-Y
2,1039,I-GENE-Y
),1039,I-GENE-Y
-adrenoceptor,1039,I-GENE-Y
agonist,1039,O
salbutamol,1039,B-CHEMICAL
(,1039,O
40,1039,O
microg/kg/h,1039,O
),1039,O
for,1039,O
1,1039,O
week,1039,O
to,1039,O
induce,1039,O
beta,1039,B-GENE-Y
(,1039,I-GENE-Y
2,1039,I-GENE-Y
),1039,I-GENE-Y
-adrenoceptor,1039,I-GENE-Y
desensitization,1039,O
.,1039,O
The,1040,O
pretreatment,1040,O
with,1040,O
salbutamol,1040,B-CHEMICAL
induced,1040,O
a,1040,O
59,1040,O
%,1040,O
down-regulation,1040,O
of,1040,O
left,1040,O
ventricular,1040,O
beta,1040,B-GENE-Y
(,1040,I-GENE-Y
2,1040,I-GENE-Y
),1040,I-GENE-Y
-adrenoceptors,1040,I-GENE-Y
compared,1040,O
to,1040,O
control,1040,O
.,1040,O
The,1041,O
extent,1041,O
of,1041,O
the,1041,O
isoprenaline-induced,1041,B-CHEMICAL
left,1041,O
ventricular,1041,O
fibrosis,1041,O
was,1041,O
significantly,1041,O
reduced,1041,O
in,1041,O
both,1041,O
the,1041,O
bisoprolol,1041,B-CHEMICAL
and,1041,O
salbutamol,1041,B-CHEMICAL
groups,1041,O
compared,1041,O
with,1041,O
the,1041,O
control,1041,O
isoprenaline-treated,1041,B-CHEMICAL
group,1041,O
especially,1041,O
in,1041,O
the,1041,O
apical,1041,O
region,1041,O
(,1041,O
1.7+/-0.6,1041,O
%,1041,O
and,1041,O
1.4+/-0.3,1041,O
%,1041,O
versus,1041,O
6.0+/-1.3,1041,O
%,1041,O
",",1041,O
respectively,1041,O
",",1041,O
P,1041,O
<,1041,O
0.005,1041,O
),1041,O
.,1041,O
beta,1042,B-GENE-Y
(,1042,I-GENE-Y
1,1042,I-GENE-Y
),1042,I-GENE-Y
-adrenoceptor,1042,I-GENE-Y
blockade,1042,O
and,1042,O
beta,1042,B-GENE-Y
(,1042,I-GENE-Y
2,1042,I-GENE-Y
),1042,I-GENE-Y
-adrenoceptors,1042,I-GENE-Y
down-regulation,1042,O
provided,1042,O
similar,1042,O
protection,1042,O
against,1042,O
isoprenaline-induced,1042,B-CHEMICAL
cardiac,1042,O
interstitial,1042,O
fibrosis,1042,O
suggesting,1042,O
that,1042,O
both,1042,O
beta-adrenoceptors,1042,B-GENE-N
are,1042,O
involved,1042,O
in,1042,O
such,1042,O
cardiac,1042,O
remodeling,1042,O
process,1042,O
.,1042,O
Characterization,1043,O
of,1043,O
the,1043,O
mouse,1043,B-GENE-N
cold-menthol,1043,I-GENE-N
receptor,1043,I-GENE-N
TRPM8,1043,B-GENE-Y
and,1043,O
vanilloid,1043,B-GENE-Y
receptor,1043,I-GENE-Y
type-1,1043,I-GENE-Y
VR1,1043,B-GENE-Y
using,1043,O
a,1043,O
fluorometric,1043,O
imaging,1043,O
plate,1043,O
reader,1043,O
(,1043,O
FLIPR,1043,O
),1043,O
assay,1043,O
.,1043,O
1,1044,O
.,1044,O
TRPM8,1045,B-GENE-Y
(,1045,O
CMR1,1045,B-GENE-Y
),1045,O
is,1045,O
a,1045,O
Ca,1045,B-GENE-N
(,1045,I-GENE-N
2+,1045,I-GENE-N
),1045,I-GENE-N
-permeable,1045,I-GENE-N
channel,1045,I-GENE-N
",",1045,O
which,1045,O
can,1045,O
be,1045,O
activated,1045,O
by,1045,O
low,1045,O
temperatures,1045,O
",",1045,O
menthol,1045,B-CHEMICAL
",",1045,O
eucalyptol,1045,B-CHEMICAL
and,1045,O
icilin,1045,B-CHEMICAL
.,1045,O
It,1046,O
belongs,1046,O
to,1046,O
the,1046,O
transient,1046,B-GENE-N
receptor,1046,I-GENE-N
potential,1046,I-GENE-N
(,1046,I-GENE-N
TRP,1046,I-GENE-N
),1046,I-GENE-N
family,1046,I-GENE-N
",",1046,O
and,1046,O
therefore,1046,O
is,1046,O
related,1046,O
to,1046,O
vanilloid,1046,B-GENE-Y
receptor,1046,I-GENE-Y
type-1,1046,I-GENE-Y
(,1046,O
VR1,1046,B-GENE-Y
",",1046,O
TRPV1,1046,B-GENE-Y
),1046,O
.,1046,O
We,1047,O
tested,1047,O
whether,1047,O
substances,1047,O
which,1047,O
are,1047,O
structurally,1047,O
related,1047,O
to,1047,O
menthol,1047,B-CHEMICAL
",",1047,O
or,1047,O
which,1047,O
produce,1047,O
a,1047,O
cooling,1047,O
sensation,1047,O
",",1047,O
could,1047,O
activate,1047,O
TRPM8,1047,B-GENE-Y
",",1047,O
and,1047,O
compared,1047,O
the,1047,O
responses,1047,O
of,1047,O
TRPM8,1047,B-GENE-Y
and,1047,O
VR1,1047,B-GENE-Y
to,1047,O
these,1047,O
ligands,1047,O
.,1047,O
2,1048,O
.,1048,O
The,1049,O
effects,1049,O
of,1049,O
70,1049,O
odorants,1049,O
and,1049,O
menthol-related,1049,B-CHEMICAL
substances,1049,O
on,1049,O
recombinant,1049,O
mouse,1049,B-GENE-Y
TRPM8,1049,I-GENE-Y
(,1049,O
mTRPM8,1049,B-GENE-Y
),1049,O
",",1049,O
expressed,1049,O
in,1049,O
HEK293,1049,O
cells,1049,O
",",1049,O
were,1049,O
examined,1049,O
using,1049,O
a,1049,O
FLIPR,1049,O
assay,1049,O
.,1049,O
In,1050,O
all,1050,O
",",1050,O
10,1050,O
substances,1050,O
(,1050,O
linalool,1050,B-CHEMICAL
",",1050,O
geraniol,1050,B-CHEMICAL
",",1050,O
hydroxycitronellal,1050,B-CHEMICAL
",",1050,O
WS-3,1050,B-CHEMICAL
",",1050,O
WS-23,1050,B-CHEMICAL
",",1050,O
FrescolatMGA,1050,B-CHEMICAL
",",1050,O
FrescolatML,1050,B-CHEMICAL
",",1050,O
PMD38,1050,B-CHEMICAL
",",1050,O
CoolactP,1050,B-CHEMICAL
and,1050,O
Cooling,1050,B-CHEMICAL
Agent,1050,I-CHEMICAL
10,1050,I-CHEMICAL
),1050,O
were,1050,O
found,1050,O
to,1050,O
be,1050,O
agonists,1050,O
.,1050,O
3,1051,O
.,1051,O
The,1052,O
EC,1052,O
(,1052,O
50,1052,O
),1052,O
values,1052,O
of,1052,O
the,1052,O
agonists,1052,O
defined,1052,O
their,1052,O
relative,1052,O
potencies,1052,O
:,1052,O
icilin,1052,B-CHEMICAL
(,1052,O
0.2+/-0.1,1052,O
microM,1052,O
),1052,O
>,1052,O
FrescolatML,1052,B-CHEMICAL
(,1052,O
3.3+/-1.5,1052,O
microM,1052,O
),1052,O
>,1052,O
WS-3,1052,B-CHEMICAL
(,1052,O
3.7+/-1.7,1052,O
microM,1052,O
),1052,O
>,1052,O
(,1052,B-CHEMICAL
-,1052,I-CHEMICAL
),1052,I-CHEMICAL
menthol,1052,I-CHEMICAL
(,1052,O
4.1+/-1.3,1052,O
microM,1052,O
),1052,O
>,1052,O
frescolatMAG,1052,B-CHEMICAL
(,1052,O
4.8+/-1.1,1052,O
microM,1052,O
),1052,O
>,1052,O
cooling,1052,B-CHEMICAL
agent,1052,I-CHEMICAL
10,1052,I-CHEMICAL
(,1052,O
6+/-2.2,1052,O
microM,1052,O
),1052,O
>,1052,O
(,1052,B-CHEMICAL
+,1052,I-CHEMICAL
),1052,I-CHEMICAL
menthol,1052,I-CHEMICAL
(,1052,O
14.4+/-1.3,1052,O
microM,1052,O
),1052,O
>,1052,O
PMD38,1052,B-CHEMICAL
(,1052,O
31+/-1.1,1052,O
microM,1052,O
),1052,O
>,1052,O
WS-23,1052,B-CHEMICAL
(,1052,O
44+/-7.3,1052,O
microM,1052,O
),1052,O
>,1052,O
Coolact,1052,B-CHEMICAL
P,1052,I-CHEMICAL
(,1052,O
66+/-20,1052,O
microM,1052,O
),1052,O
>,1052,O
geraniol,1052,B-CHEMICAL
(,1052,O
5.9+/-1.6,1052,O
mM,1052,O
),1052,O
>,1052,O
linalool,1052,B-CHEMICAL
(,1052,O
6.7+/-2.0,1052,O
mM,1052,O
),1052,O
>,1052,O
eucalyptol,1052,B-CHEMICAL
(,1052,O
7.7+/-2.0,1052,O
mM,1052,O
),1052,O
>,1052,O
hydroxycitronellal,1052,B-CHEMICAL
(,1052,O
19.6+/-2.2,1052,O
mM,1052,O
),1052,O
.,1052,O
4,1053,O
.,1053,O
Known,1054,O
VR1,1054,B-GENE-Y
antagonists,1054,O
(,1054,O
BCTC,1054,B-CHEMICAL
",",1054,O
thio-BCTC,1054,B-CHEMICAL
and,1054,O
capsazepine,1054,B-CHEMICAL
),1054,O
were,1054,O
also,1054,O
able,1054,O
to,1054,O
block,1054,O
the,1054,O
response,1054,O
of,1054,O
TRPM8,1054,B-GENE-Y
to,1054,O
menthol,1054,B-CHEMICAL
(,1054,O
IC,1054,O
(,1054,O
50,1054,O
),1054,O
:,1054,O
0.8+/-1.0,1054,O
",",1054,O
3.5+/-1.1,1054,O
and,1054,O
18+/-1.1,1054,O
microM,1054,O
",",1054,O
respectively,1054,O
),1054,O
.,1054,O
5,1055,O
.,1055,O
The,1056,O
Ca,1056,B-CHEMICAL
(,1056,I-CHEMICAL
2+,1056,I-CHEMICAL
),1056,I-CHEMICAL
response,1056,O
of,1056,O
hVR1-transfected,1056,B-GENE-Y
HEK293,1056,O
cells,1056,O
to,1056,O
the,1056,O
endogenous,1056,O
VR1,1056,B-GENE-Y
agonist,1056,O
N-arachidonoyl-dopamine,1056,B-CHEMICAL
was,1056,O
potentiated,1056,O
by,1056,O
low,1056,O
pH,1056,O
.,1056,O
In,1057,O
contrast,1057,O
",",1057,O
menthol-,1057,B-CHEMICAL
and,1057,O
icilin-activated,1057,B-CHEMICAL
TRPM8,1057,B-GENE-Y
currents,1057,O
were,1057,O
suppressed,1057,O
by,1057,O
low,1057,O
pH,1057,O
.,1057,O
6,1058,O
.,1058,O
In,1059,O
conclusion,1059,O
",",1059,O
in,1059,O
the,1059,O
present,1059,O
study,1059,O
",",1059,O
we,1059,O
identified,1059,O
10,1059,O
new,1059,O
agonists,1059,O
and,1059,O
three,1059,O
antagonists,1059,O
of,1059,O
TRPM8,1059,B-GENE-Y
.,1059,O
We,1060,O
found,1060,O
that,1060,O
",",1060,O
in,1060,O
contrast,1060,O
to,1060,O
VR1,1060,B-GENE-Y
",",1060,O
TRPM8,1060,B-GENE-Y
is,1060,O
inhibited,1060,O
rather,1060,O
than,1060,O
potentiated,1060,O
by,1060,O
protons,1060,O
.,1060,O
Inhibitory,1061,O
effects,1061,O
of,1061,O
the,1061,O
monoamine,1061,B-CHEMICAL
oxidase,1061,I-GENE-N
inhibitor,1061,O
tranylcypromine,1061,B-CHEMICAL
on,1061,O
the,1061,O
cytochrome,1061,B-GENE-N
P450,1061,I-GENE-N
enzymes,1061,O
CYP2C19,1061,B-GENE-Y
",",1061,O
CYP2C9,1061,B-GENE-Y
",",1061,O
and,1061,O
CYP2D6,1061,B-GENE-Y
.,1061,O
1,1062,O
.,1062,O
The,1063,O
inhibitory,1063,O
effects,1063,O
of,1063,O
tranylcypromine,1063,B-CHEMICAL
",",1063,O
a,1063,O
nonselective,1063,O
irreversible,1063,O
inhibitor,1063,O
of,1063,O
monoamine,1063,B-CHEMICAL
oxidase,1063,I-GENE-N
(,1063,O
MAO,1063,B-GENE-N
),1063,O
",",1063,O
on,1063,O
three,1063,O
cytochrome,1063,B-GENE-N
P450,1063,I-GENE-N
(,1063,O
CYP,1063,B-GENE-N
),1063,O
enzymes,1063,O
",",1063,O
namely,1063,O
CYP2C9,1063,B-GENE-Y
",",1063,O
CYP2C19,1063,B-GENE-Y
",",1063,O
and,1063,O
CYP2D6,1063,B-GENE-Y
",",1063,O
have,1063,O
been,1063,O
evaluated,1063,O
in,1063,O
vitro,1063,O
.,1063,O
2,1064,O
.,1064,O
The,1065,O
studies,1065,O
were,1065,O
conducted,1065,O
using,1065,O
cDNA-expressed,1065,O
human,1065,B-GENE-N
CYP,1065,I-GENE-N
enzymes,1065,O
and,1065,O
probe,1065,O
substrates,1065,O
.,1065,O
3,1066,O
.,1066,O
A,1067,O
range,1067,O
of,1067,O
substrate,1067,O
concentrations,1067,O
was,1067,O
coincubated,1067,O
with,1067,O
a,1067,O
range,1067,O
of,1067,O
tranylcypromine,1067,B-CHEMICAL
concentrations,1067,O
in,1067,O
the,1067,O
presence,1067,O
of,1067,O
each,1067,O
of,1067,O
the,1067,O
CYP,1067,B-GENE-N
enzymes,1067,O
at,1067,O
37,1067,O
degrees,1067,O
C,1067,O
for,1067,O
a,1067,O
predetermined,1067,O
period,1067,O
of,1067,O
time,1067,O
.,1067,O
Product,1068,O
concentrations,1068,O
were,1068,O
quantified,1068,O
by,1068,O
HPLC,1068,O
with,1068,O
UV,1068,O
detection,1068,O
.,1068,O
4,1069,O
.,1069,O
The,1070,O
results,1070,O
demonstrated,1070,O
that,1070,O
tranylcypromine,1070,B-CHEMICAL
is,1070,O
a,1070,O
competitive,1070,O
inhibitor,1070,O
of,1070,O
CYP2C19,1070,B-GENE-Y
(,1070,O
Ki,1070,O
=,1070,O
32,1070,O
microM,1070,O
),1070,O
and,1070,O
CYP2D6,1070,B-GENE-Y
(,1070,O
Ki,1070,O
=,1070,O
367,1070,O
microM,1070,O
),1070,O
and,1070,O
a,1070,O
noncompetitive,1070,O
inhibitor,1070,O
of,1070,O
CYP2C9,1070,B-GENE-Y
(,1070,O
Ki,1070,O
=,1070,O
56,1070,O
microM,1070,O
),1070,O
.,1070,O
5,1071,O
.,1071,O
None,1072,O
of,1072,O
these,1072,O
inhibitory,1072,O
effects,1072,O
are,1072,O
considered,1072,O
clinically,1072,O
significant,1072,O
at,1072,O
usual,1072,O
therapeutic,1072,O
doses,1072,O
.,1072,O
However,1073,O
",",1073,O
in,1073,O
certain,1073,O
situations,1073,O
such,1073,O
as,1073,O
high,1073,O
dose,1073,O
tranylcypromine,1073,B-CHEMICAL
therapy,1073,O
",",1073,O
or,1073,O
in,1073,O
poor,1073,O
metabolizers,1073,O
of,1073,O
CYP2C19,1073,B-GENE-Y
substrates,1073,O
",",1073,O
clinically,1073,O
significant,1073,O
interactions,1073,O
might,1073,O
occur,1073,O
",",1073,O
particularly,1073,O
when,1073,O
tranylcypromine,1073,B-CHEMICAL
is,1073,O
coadministered,1073,O
with,1073,O
drugs,1073,O
with,1073,O
a,1073,O
narrow,1073,O
therapeutic,1073,O
index,1073,O
.,1073,O
Organization,1074,O
and,1074,O
expression,1074,O
of,1074,O
the,1074,O
SLC36,1074,B-GENE-N
cluster,1074,I-GENE-N
of,1074,I-GENE-N
amino,1074,B-CHEMICAL
acid,1074,I-CHEMICAL
transporter,1074,I-GENE-N
genes,1074,O
.,1074,O
Three,1075,O
closely,1075,O
related,1075,O
genes,1075,O
encoding,1075,O
amino,1075,B-CHEMICAL
acid,1075,I-CHEMICAL
transport,1075,O
proteins,1075,O
are,1075,O
clustered,1075,O
on,1075,O
5q32,1075,O
in,1075,O
humans,1075,O
",",1075,O
and,1075,O
Chromosome,1075,O
(,1075,O
Chr,1075,O
),1075,O
11,1075,O
in,1075,O
mice,1075,O
.,1075,O
The,1076,O
human,1076,B-GENE-Y
SLC36A1,1076,I-GENE-Y
gene,1076,O
",",1076,O
which,1076,O
encodes,1076,O
the,1076,O
lysosomal,1076,B-GENE-Y
amino,1076,I-GENE-Y
acid,1076,I-GENE-Y
transporter,1076,I-GENE-Y
LYAAT1/PAT1,1076,O
",",1076,O
generates,1076,O
multiple,1076,O
alternative,1076,O
mRNAs,1076,O
",",1076,O
some,1076,O
of,1076,O
which,1076,O
encode,1076,O
truncated,1076,O
proteins,1076,O
.,1076,O
SLC36A1,1077,B-GENE-Y
is,1077,O
expressed,1077,O
in,1077,O
numerous,1077,O
tissues,1077,O
",",1077,O
whereas,1077,O
expression,1077,O
of,1077,O
SLC36A2,1077,B-GENE-Y
",",1077,O
which,1077,O
encodes,1077,O
the,1077,O
glycine,1077,B-CHEMICAL
transporter,1077,I-GENE-N
tramdorinl/PAT2,1077,B-GENE-Y
",",1077,O
is,1077,O
most,1077,O
abundant,1077,O
in,1077,O
kidney,1077,O
and,1077,O
muscle,1077,O
.,1077,O
Expression,1078,O
of,1078,O
a,1078,O
third,1078,O
gene,1078,O
",",1078,O
SLC36A3,1078,B-GENE-Y
",",1078,O
is,1078,O
restricted,1078,O
to,1078,O
testis,1078,O
.,1078,O
Mouse,1079,B-GENE-Y
Slc36a2,1079,I-GENE-Y
also,1079,O
is,1079,O
expressed,1079,O
in,1079,O
bone,1079,O
and,1079,O
fat,1079,O
tissue,1079,O
.,1079,O
Polymorphisms,1080,O
in,1080,O
human,1080,B-GENE-Y
SLC36A2,1080,I-GENE-Y
exclude,1080,O
it,1080,O
as,1080,O
a,1080,O
candidate,1080,O
locus,1080,O
for,1080,O
a,1080,O
peripheral,1080,O
neuropathy,1080,O
that,1080,O
has,1080,O
been,1080,O
mapped,1080,O
to,1080,O
5q31-33,1080,O
.,1080,O
SLC36A2,1081,B-GENE-Y
is,1081,O
a,1081,O
candidate,1081,O
gene,1081,O
for,1081,O
5q-myelodysplastic,1081,O
syndrome,1081,O
",",1081,O
on,1081,O
the,1081,O
basis,1081,O
of,1081,O
its,1081,O
chromosomal,1081,O
location,1081,O
and,1081,O
its,1081,O
expression,1081,O
in,1081,O
bone,1081,O
.,1081,O
ATR,1082,B-GENE-Y
regulates,1082,O
a,1082,O
G2-phase,1082,O
cell-cycle,1082,O
checkpoint,1082,O
in,1082,O
Arabidopsis,1082,O
thaliana,1082,O
.,1082,O
Ataxia,1083,B-GENE-Y
telangiectasia-mutated,1083,I-GENE-Y
and,1083,I-GENE-Y
Rad3-related,1083,I-GENE-Y
(,1083,O
ATR,1083,B-GENE-Y
),1083,O
plays,1083,O
a,1083,O
central,1083,O
role,1083,O
in,1083,O
cell-cycle,1083,O
regulation,1083,O
",",1083,O
transmitting,1083,O
DNA,1083,O
damage,1083,O
signals,1083,O
to,1083,O
downstream,1083,O
effectors,1083,O
of,1083,O
cell-cycle,1083,O
progression,1083,O
.,1083,O
In,1084,O
animals,1084,O
",",1084,O
ATR,1084,B-GENE-Y
is,1084,O
an,1084,O
essential,1084,O
gene,1084,O
.,1084,O
Here,1085,O
",",1085,O
we,1085,O
find,1085,O
that,1085,O
Arabidopsis,1085,O
(,1085,O
Arabidopsis,1085,O
thaliana,1085,O
),1085,O
atr-/-,1085,B-GENE-Y
mutants,1085,O
were,1085,O
viable,1085,O
",",1085,O
fertile,1085,O
",",1085,O
and,1085,O
phenotypically,1085,O
wild-type,1085,O
in,1085,O
the,1085,O
absence,1085,O
of,1085,O
exogenous,1085,O
DNA,1085,O
damaging,1085,O
agents,1085,O
but,1085,O
exhibit,1085,O
altered,1085,O
expression,1085,O
of,1085,O
AtRNR1,1085,B-GENE-Y
(,1085,O
ribonucleotide,1085,B-GENE-Y
reductase,1085,I-GENE-Y
large,1085,I-GENE-Y
subunit,1085,I-GENE-Y
),1085,O
and,1085,O
alteration,1085,O
of,1085,O
some,1085,O
damage-induced,1085,O
cell-cycle,1085,O
checkpoints,1085,O
.,1085,O
atr,1086,B-GENE-Y
mutants,1086,O
were,1086,O
hypersensitive,1086,O
to,1086,O
hydroxyurea,1086,B-CHEMICAL
(,1086,O
HU,1086,B-CHEMICAL
),1086,O
",",1086,O
aphidicolin,1086,B-CHEMICAL
",",1086,O
and,1086,O
UV-B,1086,O
light,1086,O
but,1086,O
only,1086,O
mildly,1086,O
sensitive,1086,O
to,1086,O
gamma-radiation,1086,O
.,1086,O
G2,1087,O
arrest,1087,O
was,1087,O
observed,1087,O
in,1087,O
response,1087,O
to,1087,O
gamma-irradiation,1087,O
in,1087,O
both,1087,O
wild-type,1087,O
and,1087,O
atr,1087,B-GENE-Y
plants,1087,O
",",1087,O
albeit,1087,O
with,1087,O
slightly,1087,O
different,1087,O
kinetics,1087,O
",",1087,O
suggesting,1087,O
that,1087,O
ATR,1087,B-GENE-Y
plays,1087,O
a,1087,O
secondary,1087,O
role,1087,O
in,1087,O
response,1087,O
to,1087,O
double-strand,1087,O
breaks,1087,O
.,1087,O
G2,1088,O
arrest,1088,O
also,1088,O
was,1088,O
observed,1088,O
in,1088,O
wild-type,1088,O
plants,1088,O
in,1088,O
response,1088,O
to,1088,O
aphidicolin,1088,B-CHEMICAL
but,1088,O
was,1088,O
defective,1088,O
in,1088,O
atr,1088,B-GENE-Y
mutants,1088,O
",",1088,O
resulting,1088,O
in,1088,O
compaction,1088,O
of,1088,O
nuclei,1088,O
and,1088,O
subsequent,1088,O
cell,1088,O
death,1088,O
.,1088,O
By,1089,O
contrast,1089,O
",",1089,O
HU-treated,1089,O
wild-type,1089,O
and,1089,O
atr,1089,B-GENE-Y
plants,1089,O
arrested,1089,O
in,1089,O
G1,1089,O
and,1089,O
showed,1089,O
no,1089,O
obvious,1089,O
signs,1089,O
of,1089,O
cell,1089,O
death,1089,O
.,1089,O
We,1090,O
propose,1090,O
that,1090,O
",",1090,O
in,1090,O
plants,1090,O
",",1090,O
HU,1090,O
invokes,1090,O
a,1090,O
novel,1090,O
checkpoint,1090,O
responsive,1090,O
to,1090,O
low,1090,O
levels,1090,O
of,1090,O
deoxynucleotide,1090,B-CHEMICAL
triphosphates,1090,I-CHEMICAL
.,1090,O
These,1091,O
results,1091,O
demonstrate,1091,O
the,1091,O
important,1091,O
role,1091,O
of,1091,O
cell-cycle,1091,O
checkpoints,1091,O
in,1091,O
the,1091,O
ability,1091,O
of,1091,O
plant,1091,O
cells,1091,O
to,1091,O
sense,1091,O
and,1091,O
cope,1091,O
with,1091,O
problems,1091,O
associated,1091,O
with,1091,O
DNA,1091,O
replication,1091,O
.,1091,O
Selective,1092,O
activation,1092,O
of,1092,O
thyroid,1092,B-CHEMICAL
hormone,1092,I-CHEMICAL
signaling,1092,O
pathways,1092,O
by,1092,O
GC-1,1092,O
:,1092,O
a,1092,O
new,1092,O
approach,1092,O
to,1092,O
controlling,1092,O
cholesterol,1092,B-CHEMICAL
and,1092,O
body,1092,O
weight,1092,O
.,1092,O
The,1093,O
current,1093,O
report,1093,O
describes,1093,O
progress,1093,O
in,1093,O
development,1093,O
of,1093,O
a,1093,O
selective,1093,O
thyroid,1093,B-CHEMICAL
hormone,1093,I-CHEMICAL
receptor,1093,I-GENE-N
modulator,1093,O
",",1093,O
GC-1,1093,O
.,1093,O
This,1094,O
compound,1094,O
binds,1094,O
selectively,1094,O
to,1094,O
the,1094,O
beta-isoform,1094,B-GENE-Y
of,1094,I-GENE-Y
the,1094,I-GENE-Y
thyroid,1094,I-GENE-Y
hormone,1094,I-GENE-Y
receptor,1094,I-GENE-Y
",",1094,O
and,1094,O
its,1094,O
uptake,1094,O
into,1094,O
the,1094,O
heart,1094,O
is,1094,O
relatively,1094,O
low,1094,O
.,1094,O
Studies,1095,O
in,1095,O
rats,1095,O
",",1095,O
mice,1095,O
and,1095,O
monkeys,1095,O
show,1095,O
that,1095,O
GC-1,1095,O
lowers,1095,O
cholesterol,1095,B-CHEMICAL
with,1095,O
600-,1095,O
to,1095,O
1400-fold,1095,O
more,1095,O
potency,1095,O
and,1095,O
approximately,1095,O
two-,1095,O
to,1095,O
threefold,1095,O
more,1095,O
efficacy,1095,O
than,1095,O
atorvastatin,1095,B-CHEMICAL
",",1095,O
a,1095,O
compound,1095,O
that,1095,O
blocks,1095,O
HMG-CoA,1095,B-CHEMICAL
reductase,1095,I-GENE-Y
.,1095,O
GC-1,1096,O
also,1096,O
decreases,1096,O
plasma,1096,O
levels,1096,O
of,1096,O
triglyceride,1096,B-CHEMICAL
and,1096,O
lipoprotein,1096,B-GENE-N
(,1096,I-GENE-N
a,1096,I-GENE-N
),1096,I-GENE-N
",",1096,O
and,1096,O
induces,1096,O
loss,1096,O
of,1096,O
fat,1096,O
.,1096,O
These,1097,O
effects,1097,O
can,1097,O
be,1097,O
observed,1097,O
under,1097,O
conditions,1097,O
where,1097,O
there,1097,O
is,1097,O
either,1097,O
no,1097,O
or,1097,O
minimal,1097,O
effect,1097,O
on,1097,O
heart,1097,O
rate,1097,O
",",1097,O
and,1097,O
no,1097,O
detectable,1097,O
loss,1097,O
of,1097,O
muscle,1097,O
.,1097,O
Although,1098,O
more,1098,O
study,1098,O
is,1098,O
required,1098,O
",",1098,O
compounds,1098,O
of,1098,O
this,1098,O
class,1098,O
deserve,1098,O
further,1098,O
investigation,1098,O
for,1098,O
treating,1098,O
lipid,1098,O
disorders,1098,O
and,1098,O
obesity,1098,O
.,1098,O
Flt3,1099,B-GENE-Y
receptor,1099,I-GENE-Y
tyrosine,1099,I-GENE-Y
kinase,1099,I-GENE-Y
as,1099,O
a,1099,O
drug,1099,O
target,1099,O
in,1099,O
leukemia,1099,O
.,1099,O
The,1100,O
hematopoietic,1100,B-GENE-N
class,1100,I-GENE-N
III,1100,I-GENE-N
receptor,1100,I-GENE-N
tyrosine,1100,I-GENE-N
kinase,1100,I-GENE-N
(,1100,I-GENE-N
RTK,1100,I-GENE-N
),1100,I-GENE-N
Flt3,1100,I-GENE-N
(,1100,O
Flk2,1100,B-GENE-Y
",",1100,O
STK1,1100,B-GENE-Y
),1100,O
has,1100,O
recently,1100,O
received,1100,O
much,1100,O
attention,1100,O
as,1100,O
a,1100,O
potential,1100,O
drug,1100,O
target,1100,O
.,1100,O
Activation,1101,O
of,1101,O
Flt3,1101,B-GENE-Y
by,1101,O
different,1101,O
types,1101,O
of,1101,O
mutations,1101,O
plays,1101,O
an,1101,O
important,1101,O
role,1101,O
for,1101,O
proliferation,1101,O
",",1101,O
resistance,1101,O
to,1101,O
apoptosis,1101,O
",",1101,O
and,1101,O
prevention,1101,O
of,1101,O
differentiation,1101,O
of,1101,O
leukemic,1101,O
blasts,1101,O
in,1101,O
acute,1101,O
myeloid,1101,O
leukemia,1101,O
(,1101,O
AML,1101,O
),1101,O
.,1101,O
At,1102,O
least,1102,O
one,1102,O
type,1102,O
of,1102,O
such,1102,O
mutations,1102,O
-,1102,O
an,1102,O
internal,1102,O
tandem,1102,O
duplication,1102,O
in,1102,O
the,1102,O
Flt3,1102,B-GENE-N
juxtamembrane,1102,I-GENE-N
domain,1102,I-GENE-N
(,1102,O
Flt3-ITD,1102,B-GENE-N
),1102,O
-,1102,O
has,1102,O
been,1102,O
associated,1102,O
with,1102,O
an,1102,O
unfavorable,1102,O
prognosis,1102,O
.,1102,O
Signal,1103,O
transduction,1103,O
of,1103,O
Flt3,1103,B-GENE-Y
involves,1103,O
activation,1103,O
of,1103,O
several,1103,O
conserved,1103,O
pathways,1103,O
",",1103,O
including,1103,O
the,1103,O
RAS/MAP-Kinase,1103,B-GENE-N
and,1103,O
the,1103,O
phosphoinositide-3-kinase/Akt,1103,B-GENE-N
signaling,1103,O
cascades,1103,O
.,1103,O
Transforming,1104,O
versions,1104,O
of,1104,O
Flt3,1104,B-GENE-Y
exhibit,1104,O
altered,1104,O
signaling,1104,O
",",1104,O
for,1104,O
example,1104,O
a,1104,O
very,1104,O
pronounced,1104,O
activation,1104,O
of,1104,O
STAT5,1104,B-GENE-Y
",",1104,O
ultimately,1104,O
resulting,1104,O
in,1104,O
alternate,1104,O
profiles,1104,O
of,1104,O
gene,1104,O
expression,1104,O
and,1104,O
cell,1104,O
transformation,1104,O
.,1104,O
Selective,1105,O
inhibitors,1105,O
of,1105,O
Flt3,1105,B-GENE-Y
tyrosine,1105,B-GENE-N
kinase,1105,I-GENE-N
activity,1105,O
have,1105,O
the,1105,O
potential,1105,O
to,1105,O
suppress,1105,O
aberrant,1105,O
Flt3,1105,B-GENE-Y
signaling,1105,O
.,1105,O
Although,1106,O
highly,1106,O
homologous,1106,O
to,1106,O
other,1106,O
class,1106,B-GENE-N
III,1106,I-GENE-N
RTKs,1106,I-GENE-N
",",1106,O
Flt3,1106,B-GENE-Y
is,1106,O
resistant,1106,O
to,1106,O
the,1106,O
phenylaminopyrimidine,1106,B-CHEMICAL
STI571,1106,B-CHEMICAL
(,1106,O
Gleevec,1106,B-CHEMICAL
",",1106,O
Imatinib,1106,B-CHEMICAL
),1106,O
",",1106,O
a,1106,O
potent,1106,O
inhibitor,1106,O
of,1106,O
other,1106,O
RTKs,1106,B-GENE-N
in,1106,O
the,1106,O
family,1106,O
",",1106,O
such,1106,O
as,1106,O
the,1106,O
PDGFbeta-receptor,1106,B-GENE-Y
or,1106,O
c-Kit,1106,B-GENE-Y
.,1106,O
STI571,1107,B-CHEMICAL
binding,1107,O
to,1107,O
Flt3,1107,B-GENE-Y
is,1107,O
prevented,1107,O
by,1107,O
the,1107,O
phenylalanine,1107,B-CHEMICAL
691,1107,O
side-chain,1107,O
in,1107,O
the,1107,O
ATP,1107,B-CHEMICAL
binding,1107,O
center,1107,O
and,1107,O
mutating,1107,O
this,1107,O
site,1107,O
to,1107,O
threonine,1107,B-CHEMICAL
renders,1107,O
the,1107,O
corresponding,1107,O
Flt3,1107,B-GENE-Y
mutant,1107,O
sensitive,1107,O
to,1107,O
STI571,1107,B-CHEMICAL
.,1107,O
Compounds,1108,O
of,1108,O
several,1108,O
other,1108,O
structural,1108,O
families,1108,O
",",1108,O
including,1108,O
the,1108,O
quinoxaline,1108,B-CHEMICAL
AG1296,1108,B-CHEMICAL
",",1108,O
the,1108,O
bis,1108,B-CHEMICAL
(,1108,I-CHEMICAL
1H-2-indolyl,1108,I-CHEMICAL
),1108,I-CHEMICAL
-1-methanone,1108,I-CHEMICAL
D-65476,1108,B-CHEMICAL
",",1108,O
the,1108,O
indolinones,1108,B-CHEMICAL
SU5416,1108,B-CHEMICAL
and,1108,O
SU11248,1108,B-CHEMICAL
",",1108,O
the,1108,O
indolocarbazoles,1108,B-CHEMICAL
PKC412,1108,B-CHEMICAL
and,1108,O
CEP-701,1108,B-CHEMICAL
",",1108,O
and,1108,O
the,1108,O
piperazonyl,1108,B-CHEMICAL
quinazoline,1108,I-CHEMICAL
CT53518,1108,B-CHEMICAL
",",1108,O
are,1108,O
potent,1108,O
inhibitors,1108,O
of,1108,O
Flt3,1108,B-GENE-Y
kinase,1108,B-GENE-N
.,1108,O
They,1109,O
exhibit,1109,O
different,1109,O
selectivity,1109,O
profiles,1109,O
",",1109,O
both,1109,O
with,1109,O
respect,1109,O
to,1109,O
other,1109,O
kinases,1109,O
and,1109,O
among,1109,O
wildtype,1109,O
Flt3,1109,B-GENE-Y
and,1109,O
its,1109,O
activated,1109,O
versions,1109,O
.,1109,O
These,1110,O
compounds,1110,O
hold,1110,O
promise,1110,O
as,1110,O
novel,1110,O
drugs,1110,O
against,1110,O
AML,1110,O
and,1110,O
as,1110,O
probes,1110,O
for,1110,O
understanding,1110,O
activation,1110,O
mechanisms,1110,O
and,1110,O
signaling,1110,O
pathways,1110,O
in,1110,O
the,1110,O
class,1110,B-GENE-N
III,1110,I-GENE-N
RTK,1110,I-GENE-N
family,1110,O
.,1110,O
Novel,1111,O
mechanism,1111,O
of,1111,O
action,1111,O
for,1111,O
hydralazine,1111,B-CHEMICAL
:,1111,O
induction,1111,O
of,1111,O
hypoxia-inducible,1111,B-GENE-Y
factor-1alpha,1111,I-GENE-Y
",",1111,O
vascular,1111,B-GENE-Y
endothelial,1111,I-GENE-Y
growth,1111,I-GENE-Y
factor,1111,I-GENE-Y
",",1111,O
and,1111,O
angiogenesis,1111,O
by,1111,O
inhibition,1111,O
of,1111,O
prolyl,1111,B-GENE-N
hydroxylases,1111,I-GENE-N
.,1111,O
The,1112,O
vasodilator,1112,O
hydralazine,1112,B-CHEMICAL
",",1112,O
used,1112,O
clinically,1112,O
in,1112,O
cardiovascular,1112,O
therapy,1112,O
",",1112,O
relaxes,1112,O
arterial,1112,O
smooth,1112,O
muscle,1112,O
by,1112,O
inhibiting,1112,O
accumulation,1112,O
of,1112,O
intracellular,1112,O
free,1112,O
Ca2+,1112,B-CHEMICAL
via,1112,O
an,1112,O
unidentified,1112,O
primary,1112,O
target,1112,O
.,1112,O
Collagen,1113,B-GENE-N
prolyl,1113,B-CHEMICAL
hydroxylase,1113,I-GENE-N
is,1113,O
a,1113,O
known,1113,O
target,1113,O
of,1113,O
hydralazine,1113,B-CHEMICAL
.,1113,O
We,1114,O
therefore,1114,O
investigated,1114,O
whether,1114,O
inhibition,1114,O
of,1114,O
other,1114,O
members,1114,O
of,1114,O
this,1114,O
enzyme,1114,O
family,1114,O
",",1114,O
namely,1114,O
the,1114,O
hypoxia-inducible,1114,B-GENE-N
factor,1114,I-GENE-N
(,1114,O
HIF,1114,B-GENE-N
),1114,O
-regulating,1114,O
O2-dependent,1114,B-CHEMICAL
prolyl,1114,B-CHEMICAL
hydroxylase,1114,I-GENE-N
domain,1114,I-GENE-N
(,1114,O
PHD,1114,B-GENE-N
),1114,O
enzymes,1114,O
",",1114,O
could,1114,O
represent,1114,O
a,1114,O
novel,1114,O
mechanism,1114,O
of,1114,O
action,1114,O
.,1114,O
Hydralazine,1115,B-CHEMICAL
induced,1115,O
rapid,1115,O
and,1115,O
transient,1115,O
expression,1115,O
of,1115,O
HIF-1alpha,1115,B-GENE-Y
and,1115,O
downstream,1115,O
targets,1115,O
of,1115,O
HIF,1115,B-GENE-N
(,1115,O
endothelin-1,1115,B-GENE-Y
",",1115,O
adrenomedullin,1115,B-GENE-Y
",",1115,O
haem,1115,B-GENE-Y
oxygenase,1115,I-GENE-Y
1,1115,I-GENE-Y
",",1115,O
and,1115,O
vascular,1115,B-GENE-Y
endothelial,1115,I-GENE-Y
growth,1115,I-GENE-Y
factor,1115,I-GENE-Y
[,1115,O
VEGF,1115,B-GENE-Y
],1115,O
),1115,O
in,1115,O
endothelial,1115,O
and,1115,O
smooth,1115,O
muscle,1115,O
cells,1115,O
and,1115,O
induced,1115,O
endothelial,1115,O
cell-specific,1115,O
proliferation,1115,O
.,1115,O
Hydralazine,1116,B-CHEMICAL
dose-dependently,1116,O
inhibited,1116,O
PHD,1116,B-GENE-N
activity,1116,O
and,1116,O
induced,1116,O
nonhydroxylated,1116,O
HIF-1alpha,1116,B-GENE-Y
",",1116,O
evidence,1116,O
for,1116,O
HIF,1116,B-GENE-N
stabilization,1116,O
specifically,1116,O
by,1116,O
inhibition,1116,O
of,1116,O
PHD,1116,B-GENE-N
enzyme,1116,O
activity,1116,O
.,1116,O
In,1117,O
vivo,1117,O
",",1117,O
hydralazine,1117,B-CHEMICAL
induced,1117,O
HIF-1alpha,1117,B-GENE-Y
and,1117,O
VEGF,1117,B-GENE-Y
protein,1117,O
in,1117,O
tissue,1117,O
extracts,1117,O
and,1117,O
elevated,1117,O
plasma,1117,O
VEGF,1117,B-GENE-Y
levels,1117,O
.,1117,O
In,1118,O
sponge,1118,O
angiogenesis,1118,O
assays,1118,O
",",1118,O
hydralazine,1118,B-CHEMICAL
increased,1118,O
stromal,1118,O
cell,1118,O
infiltration,1118,O
and,1118,O
blood,1118,O
vessel,1118,O
density,1118,O
versus,1118,O
control,1118,O
animals,1118,O
.,1118,O
Thus,1119,O
",",1119,O
hydralazine,1119,B-CHEMICAL
activates,1119,O
the,1119,O
HIF,1119,B-GENE-N
pathway,1119,O
through,1119,O
inhibition,1119,O
of,1119,O
PHD,1119,B-GENE-N
activity,1119,O
and,1119,O
initiates,1119,O
a,1119,O
pro-angiogenic,1119,O
phenotype,1119,O
.,1119,O
This,1120,O
represents,1120,O
a,1120,O
novel,1120,O
mechanism,1120,O
of,1120,O
action,1120,O
for,1120,O
hydralazine,1120,B-CHEMICAL
and,1120,O
presents,1120,O
HIF,1120,B-GENE-N
as,1120,O
a,1120,O
potential,1120,O
target,1120,O
for,1120,O
treatment,1120,O
of,1120,O
ischemic,1120,O
disease,1120,O
.,1120,O
Determination,1121,O
of,1121,O
expression,1121,O
of,1121,O
cyclooxygenase-1,1121,B-GENE-N
and,1121,I-GENE-N
-2,1121,I-GENE-N
isozymes,1121,O
in,1121,O
canine,1121,O
tissues,1121,O
and,1121,O
their,1121,O
differential,1121,O
sensitivity,1121,O
to,1121,O
nonsteroidal,1121,O
anti-inflammatory,1121,O
drugs,1121,O
.,1121,O
OBJECTIVE,1122,O
:,1122,O
To,1122,O
evaluate,1122,O
cyclooxygenase,1122,B-GENE-N
isozyme,1122,O
distribution,1122,O
in,1122,O
tissues,1122,O
from,1122,O
dogs,1122,O
and,1122,O
determine,1122,O
the,1122,O
differential,1122,O
sensitivity,1122,O
of,1122,O
canine,1122,B-GENE-N
cyclooxygenase,1122,I-GENE-N
(,1122,I-GENE-N
COX,1122,I-GENE-N
),1122,I-GENE-N
-1,1122,I-GENE-N
and,1122,I-GENE-N
-2,1122,I-GENE-N
isozymes,1122,O
to,1122,O
nonsteroidal,1122,O
anti-inflammatory,1122,O
drugs,1122,O
(,1122,O
NSAIDs,1122,O
),1122,O
.,1122,O
SAMPLE,1123,O
POPULATION,1123,O
:,1123,O
Canine,1123,O
tissue,1123,O
samples,1123,O
(,1123,O
stomach,1123,O
",",1123,O
duodenum,1123,O
",",1123,O
ileum,1123,O
",",1123,O
jejunum,1123,O
",",1123,O
colon,1123,O
",",1123,O
spleen,1123,O
",",1123,O
cerebral,1123,O
cortex,1123,O
",",1123,O
lung,1123,O
",",1123,O
ovary,1123,O
",",1123,O
kidney,1123,O
",",1123,O
and,1123,O
liver,1123,O
),1123,O
were,1123,O
obtained,1123,O
from,1123,O
2,1123,O
dogs,1123,O
for,1123,O
northern,1123,O
and,1123,O
western,1123,O
blot,1123,O
analyses,1123,O
",",1123,O
and,1123,O
blood,1123,O
for,1123,O
whole,1123,O
blood,1123,O
COX,1123,B-GENE-N
assays,1123,O
was,1123,O
obtained,1123,O
from,1123,O
15,1123,O
dogs,1123,O
.,1123,O
PROCEDURE,1124,O
:,1124,O
11,1124,O
NSAIDs,1124,O
were,1124,O
evaluated,1124,O
to,1124,O
determine,1124,O
their,1124,O
COX-2,1124,B-GENE-Y
selectivity,1124,O
in,1124,O
whole,1124,O
blood,1124,O
assays,1124,O
.,1124,O
The,1125,O
concentrations,1125,O
of,1125,O
the,1125,O
drug,1125,O
needed,1125,O
to,1125,O
inhibit,1125,O
50,1125,O
%,1125,O
of,1125,O
enzyme,1125,O
activity,1125,O
(,1125,O
IC50,1125,O
),1125,O
were,1125,O
then,1125,O
calculated,1125,O
for,1125,O
comparison,1125,O
.,1125,O
Expression,1126,O
and,1126,O
tissue,1126,O
distribution,1126,O
of,1126,O
COX,1126,B-GENE-N
isozymes,1126,O
were,1126,O
determined,1126,O
by,1126,O
northern,1126,O
and,1126,O
western,1126,O
blot,1126,O
analysis,1126,O
.,1126,O
RESULTS,1127,O
:,1127,O
Aspirin,1127,B-CHEMICAL
",",1127,O
diclofenac,1127,B-CHEMICAL
",",1127,O
indomethacin,1127,B-CHEMICAL
",",1127,O
ketoprofen,1127,B-CHEMICAL
",",1127,O
meclofenamic,1127,B-CHEMICAL
acid,1127,I-CHEMICAL
",",1127,O
and,1127,O
piroxicam,1127,B-CHEMICAL
had,1127,O
little,1127,O
selectivity,1127,O
toward,1127,O
COX,1127,B-GENE-N
isozymes,1127,O
",",1127,O
whereas,1127,O
NS398,1127,B-CHEMICAL
",",1127,O
carprofen,1127,B-CHEMICAL
",",1127,O
tolfenamic,1127,B-CHEMICAL
acid,1127,I-CHEMICAL
",",1127,O
nimesulide,1127,B-CHEMICAL
",",1127,O
and,1127,O
etodolac,1127,B-CHEMICAL
had,1127,O
more,1127,O
than,1127,O
5,1127,O
times,1127,O
greater,1127,O
preference,1127,O
for,1127,O
inhibiting,1127,O
COX-2,1127,B-GENE-Y
than,1127,O
COX-1,1127,B-GENE-Y
.,1127,O
All,1128,O
canine,1128,O
tissues,1128,O
examined,1128,O
",",1128,O
including,1128,O
those,1128,O
from,1128,O
the,1128,O
gastrointestinal,1128,O
tract,1128,O
",",1128,O
coexpressed,1128,O
COX-1,1128,B-GENE-N
and,1128,I-GENE-N
-2,1128,I-GENE-N
mRNA,1128,O
",",1128,O
although,1128,O
protein,1128,O
expression,1128,O
was,1128,O
observed,1128,O
only,1128,O
for,1128,O
COX-1,1128,B-GENE-Y
.,1128,O
CONCLUSIONS,1129,O
AND,1129,O
CLINICAL,1129,O
RELEVANCE,1129,O
:,1129,O
Canine,1129,B-GENE-Y
COX-2,1129,I-GENE-Y
was,1129,O
selectively,1129,O
inhibited,1129,O
by,1129,O
etodolac,1129,B-CHEMICAL
",",1129,O
nimesulide,1129,B-CHEMICAL
",",1129,O
and,1129,O
NS398,1129,B-CHEMICAL
;,1129,O
tolfenamic,1129,B-CHEMICAL
acid,1129,I-CHEMICAL
and,1129,O
carprofen,1129,B-CHEMICAL
also,1129,O
appeared,1129,O
to,1129,O
be,1129,O
preferential,1129,O
COX-2,1129,B-GENE-Y
inhibitors,1129,O
in,1129,O
dogs,1129,O
.,1129,O
The,1130,O
roles,1130,O
of,1130,O
COX-1,1130,B-GENE-Y
as,1130,O
a,1130,O
constitutive,1130,O
housekeeping,1130,O
enzyme,1130,O
and,1130,O
COX-2,1130,B-GENE-Y
as,1130,O
a,1130,O
proinflammatory,1130,O
inducible,1130,O
enzyme,1130,O
(,1130,O
as,1130,O
determined,1130,O
in,1130,O
humans,1130,O
),1130,O
appear,1130,O
to,1130,O
apply,1130,O
to,1130,O
dogs,1130,O
;,1130,O
therefore,1130,O
",",1130,O
COX-2-selective,1130,B-GENE-Y
inhibitors,1130,O
should,1130,O
prove,1130,O
useful,1130,O
in,1130,O
reducing,1130,O
the,1130,O
adverse,1130,O
effects,1130,O
associated,1130,O
with,1130,O
nonselective,1130,O
NSAIDs,1130,O
.,1130,O
Ketoconazole,1131,B-CHEMICAL
binds,1131,O
to,1131,O
the,1131,O
human,1131,B-GENE-Y
androgen,1131,I-GENE-Y
receptor,1131,I-GENE-Y
.,1131,O
Ketoconazole,1132,B-CHEMICAL
",",1132,O
an,1132,O
imidazole,1132,B-CHEMICAL
anti-fungal,1132,O
agent,1132,O
",",1132,O
has,1132,O
often,1132,O
produced,1132,O
features,1132,O
of,1132,O
androgen,1132,B-CHEMICAL
deficiency,1132,O
including,1132,O
decreased,1132,O
libido,1132,O
",",1132,O
gynecomastia,1132,O
",",1132,O
impotence,1132,O
",",1132,O
oligospermia,1132,O
",",1132,O
and,1132,O
decreased,1132,O
testosterone,1132,B-CHEMICAL
levels,1132,O
",",1132,O
in,1132,O
men,1132,O
being,1132,O
treated,1132,O
for,1132,O
chronic,1132,O
mycotic,1132,O
infections,1132,O
.,1132,O
Based,1133,O
on,1133,O
these,1133,O
potent,1133,O
effects,1133,O
on,1133,O
gonadal,1133,O
function,1133,O
in,1133,O
vivo,1133,O
as,1133,O
well,1133,O
as,1133,O
previous,1133,O
work,1133,O
in,1133,O
vitro,1133,O
demonstrating,1133,O
affinity,1133,O
of,1133,O
ketoconazole,1133,B-CHEMICAL
for,1133,O
receptor,1133,O
proteins,1133,O
for,1133,O
glucocorticoids,1133,O
and,1133,O
"1,25",1133,B-CHEMICAL
(,1133,I-CHEMICAL
OH,1133,I-CHEMICAL
),1133,I-CHEMICAL
2,1133,I-CHEMICAL
vitamin,1133,I-CHEMICAL
D3,1133,I-CHEMICAL
and,1133,O
for,1133,O
sex,1133,B-GENE-Y
steroid,1133,I-GENE-Y
binding,1133,I-GENE-Y
globulin,1133,I-GENE-Y
(,1133,O
SSBG,1133,B-GENE-Y
),1133,O
",",1133,O
the,1133,O
binding,1133,O
of,1133,O
ketoconazole,1133,B-CHEMICAL
to,1133,O
human,1133,B-GENE-Y
androgen,1133,I-GENE-Y
receptors,1133,I-GENE-Y
(,1133,O
AR,1133,B-GENE-Y
),1133,O
in,1133,O
vitro,1133,O
was,1133,O
also,1133,O
examined,1133,O
.,1133,O
Ketoconazole,1134,B-CHEMICAL
competition,1134,O
with,1134,O
[,1134,B-CHEMICAL
3H,1134,I-CHEMICAL
],1134,I-CHEMICAL
methyltrienolone,1134,I-CHEMICAL
(,1134,O
R1881,1134,B-CHEMICAL
),1134,O
for,1134,O
androgen,1134,B-CHEMICAL
binding,1134,O
sites,1134,O
in,1134,O
dispersed,1134,O
",",1134,O
intact,1134,O
cultured,1134,O
human,1134,O
skin,1134,O
fibroblasts,1134,O
was,1134,O
determined,1134,O
at,1134,O
22,1134,O
degrees,1134,O
C.,1134,O
Fifty,1134,O
percent,1134,O
displacement,1134,O
of,1134,O
[,1134,B-CHEMICAL
3H,1134,I-CHEMICAL
],1134,I-CHEMICAL
R1881,1134,I-CHEMICAL
binding,1134,O
to,1134,O
AR,1134,B-GENE-Y
was,1134,O
achieved,1134,O
by,1134,O
6.4,1134,O
+/-,1134,O
1.8,1134,O
(,1134,O
SE,1134,O
),1134,O
x,1134,O
10,1134,O
(,1134,O
-5,1134,O
),1134,O
M,1134,O
ketoconazole,1134,B-CHEMICAL
.,1134,O
Additional,1135,O
binding,1135,O
studies,1135,O
performed,1135,O
with,1135,O
ketoconazole,1135,B-CHEMICAL
in,1135,O
the,1135,O
presence,1135,O
of,1135,O
increasing,1135,O
amounts,1135,O
of,1135,O
[,1135,B-CHEMICAL
3H,1135,I-CHEMICAL
],1135,I-CHEMICAL
R1881,1135,I-CHEMICAL
showed,1135,O
that,1135,O
the,1135,O
interaction,1135,O
of,1135,O
ketoconazole,1135,B-CHEMICAL
with,1135,O
AR,1135,B-GENE-Y
was,1135,O
competitive,1135,O
when,1135,O
the,1135,O
data,1135,O
were,1135,O
analyzed,1135,O
by,1135,O
the,1135,O
Scatchard,1135,O
method,1135,O
.,1135,O
It,1136,O
should,1136,O
be,1136,O
noted,1136,O
",",1136,O
however,1136,O
",",1136,O
that,1136,O
the,1136,O
dose,1136,O
of,1136,O
ketoconazole,1136,B-CHEMICAL
required,1136,O
for,1136,O
50,1136,O
%,1136,O
occupancy,1136,O
of,1136,O
the,1136,O
androgen,1136,B-CHEMICAL
receptor,1136,I-GENE-Y
is,1136,O
not,1136,O
likely,1136,O
to,1136,O
be,1136,O
achieved,1136,O
in,1136,O
vivo,1136,O
",",1136,O
at,1136,O
least,1136,O
in,1136,O
plasma,1136,O
.,1136,O
Finally,1137,O
",",1137,O
androgen,1137,B-CHEMICAL
binding,1137,O
studies,1137,O
performed,1137,O
with,1137,O
other,1137,O
imidazoles,1137,B-CHEMICAL
",",1137,O
such,1137,O
as,1137,O
clotrimazole,1137,B-CHEMICAL
",",1137,O
miconazole,1137,B-CHEMICAL
",",1137,O
and,1137,O
fluconozole,1137,B-CHEMICAL
",",1137,O
revealed,1137,O
that,1137,O
in,1137,O
this,1137,O
class,1137,O
of,1137,O
compounds,1137,O
only,1137,O
ketoconazole,1137,B-CHEMICAL
appears,1137,O
to,1137,O
interact,1137,O
with,1137,O
the,1137,O
androgen,1137,B-GENE-Y
receptor,1137,I-GENE-Y
.,1137,O
Ketoconazole,1138,B-CHEMICAL
appears,1138,O
to,1138,O
be,1138,O
the,1138,O
first,1138,O
example,1138,O
of,1138,O
a,1138,O
non-steroidal,1138,O
compound,1138,O
which,1138,O
binds,1138,O
competitively,1138,O
to,1138,O
both,1138,O
SSBG,1138,B-GENE-Y
and,1138,O
multiple,1138,O
steroid,1138,B-GENE-N
hormone,1138,I-GENE-N
receptors,1138,I-GENE-N
",",1138,O
suggesting,1138,O
that,1138,O
the,1138,O
ligand,1138,O
binding,1138,O
sites,1138,O
of,1138,O
these,1138,O
proteins,1138,O
share,1138,O
some,1138,O
features,1138,O
in,1138,O
common,1138,O
.,1138,O
P2,1139,B-GENE-N
receptor,1139,I-GENE-N
mRNA,1139,O
expression,1139,O
profiles,1139,O
in,1139,O
human,1139,O
lymphocytes,1139,O
",",1139,O
monocytes,1139,O
and,1139,O
CD34+,1139,O
stem,1139,O
and,1139,O
progenitor,1139,O
cells,1139,O
.,1139,O
BACKGROUND,1140,O
:,1140,O
Extracellular,1140,O
nucleotides,1140,B-CHEMICAL
(,1140,O
ATP,1140,B-CHEMICAL
",",1140,O
ADP,1140,B-CHEMICAL
",",1140,O
UTP,1140,B-CHEMICAL
and,1140,O
UDP,1140,B-CHEMICAL
),1140,O
exert,1140,O
a,1140,O
wide,1140,O
range,1140,O
of,1140,O
biological,1140,O
effects,1140,O
in,1140,O
blood,1140,O
cells,1140,O
mediated,1140,O
by,1140,O
multiple,1140,O
ionotropic,1140,O
P2X,1140,B-GENE-N
receptors,1140,O
and,1140,O
G,1140,B-GENE-N
protein-coupled,1140,I-GENE-N
P2Y,1140,I-GENE-N
receptors,1140,I-GENE-N
.,1140,O
Although,1141,O
pharmacological,1141,O
experiments,1141,O
have,1141,O
suggested,1141,O
the,1141,O
presence,1141,O
of,1141,O
several,1141,O
P2,1141,B-GENE-N
receptor,1141,I-GENE-N
subtypes,1141,O
on,1141,O
monocytes,1141,O
and,1141,O
lymphocytes,1141,O
",",1141,O
some,1141,O
results,1141,O
are,1141,O
contradictory,1141,O
.,1141,O
Few,1142,O
physiological,1142,O
functions,1142,O
have,1142,O
been,1142,O
firmly,1142,O
established,1142,O
to,1142,O
a,1142,O
specific,1142,O
receptor,1142,O
subtype,1142,O
",",1142,O
partly,1142,O
because,1142,O
of,1142,O
a,1142,O
lack,1142,O
of,1142,O
truly,1142,O
selective,1142,O
agonists,1142,O
and,1142,O
antagonists,1142,O
.,1142,O
This,1143,O
stimulated,1143,O
us,1143,O
to,1143,O
investigate,1143,O
the,1143,O
expression,1143,O
of,1143,O
P2X,1143,B-GENE-N
and,1143,O
P2Y,1143,B-GENE-N
receptors,1143,O
in,1143,O
human,1143,O
lymphocytes,1143,O
and,1143,O
monocytes,1143,O
with,1143,O
a,1143,O
newly,1143,O
established,1143,O
quantitative,1143,O
mRNA,1143,O
assay,1143,O
for,1143,O
P2,1143,B-GENE-N
receptors,1143,I-GENE-N
.,1143,O
In,1144,O
addition,1144,O
",",1144,O
we,1144,O
describe,1144,O
for,1144,O
the,1144,O
first,1144,O
time,1144,O
the,1144,O
expression,1144,O
of,1144,O
P2,1144,B-GENE-N
receptors,1144,I-GENE-N
in,1144,O
CD34+,1144,O
stem,1144,O
and,1144,O
progenitor,1144,O
cells,1144,O
implicating,1144,O
a,1144,O
potential,1144,O
role,1144,O
of,1144,O
P2,1144,B-GENE-N
receptors,1144,I-GENE-N
in,1144,O
hematopoietic,1144,O
lineage,1144,O
and,1144,O
progenitor/stem,1144,O
cell,1144,O
function,1144,O
.,1144,O
RESULTS,1145,O
:,1145,O
Using,1145,O
a,1145,O
quantitative,1145,O
mRNA,1145,O
assay,1145,O
",",1145,O
we,1145,O
assessed,1145,O
the,1145,O
hypothesis,1145,O
that,1145,O
there,1145,O
are,1145,O
specific,1145,O
P2,1145,B-GENE-N
receptor,1145,I-GENE-N
profiles,1145,O
in,1145,O
inflammatory,1145,O
cells,1145,O
.,1145,O
The,1146,O
P2X4,1146,B-GENE-Y
receptor,1146,O
had,1146,O
the,1146,O
highest,1146,O
expression,1146,O
in,1146,O
lymphocytes,1146,O
and,1146,O
monocytes,1146,O
.,1146,O
Among,1147,O
the,1147,O
P2Y,1147,B-GENE-N
receptors,1147,O
",",1147,O
P2Y12,1147,B-GENE-Y
and,1147,O
P2Y2,1147,B-GENE-Y
had,1147,O
highest,1147,O
expression,1147,O
in,1147,O
lymphocytes,1147,O
",",1147,O
while,1147,O
the,1147,O
P2Y2,1147,B-GENE-Y
and,1147,O
P2Y13,1147,B-GENE-Y
had,1147,O
highest,1147,O
expression,1147,O
in,1147,O
monocytes,1147,O
.,1147,O
Several,1148,O
P2,1148,B-GENE-N
receptors,1148,I-GENE-N
were,1148,O
expressed,1148,O
(,1148,O
P2Y2,1148,B-GENE-Y
",",1148,O
P2Y1,1148,B-GENE-Y
",",1148,O
P2Y12,1148,B-GENE-Y
",",1148,O
P2Y13,1148,B-GENE-Y
",",1148,O
P2Y11,1148,B-GENE-Y
",",1148,O
P2X1,1148,B-GENE-Y
",",1148,O
P2X4,1148,B-GENE-Y
),1148,O
in,1148,O
CD34+,1148,O
stem,1148,O
and,1148,O
progenitor,1148,O
cells,1148,O
.,1148,O
CONCLUSIONS,1149,O
:,1149,O
The,1149,O
most,1149,O
interesting,1149,O
findings,1149,O
were,1149,O
the,1149,O
high,1149,O
mRNA,1149,O
expression,1149,O
of,1149,O
P2Y12,1149,B-GENE-Y
receptors,1149,O
in,1149,O
lymphocytes,1149,O
potentially,1149,O
explaining,1149,O
the,1149,O
anti-inflammatory,1149,O
effects,1149,O
of,1149,O
clopidogrel,1149,B-CHEMICAL
",",1149,O
P2Y13,1149,B-GENE-Y
receptors,1149,O
in,1149,O
monocytes,1149,O
and,1149,O
a,1149,O
previously,1149,O
unrecognised,1149,O
expression,1149,O
of,1149,O
P2X4,1149,B-GENE-Y
in,1149,O
lymphocytes,1149,O
and,1149,O
monocytes,1149,O
.,1149,O
In,1150,O
addition,1150,O
",",1150,O
for,1150,O
the,1150,O
first,1150,O
time,1150,O
P2,1150,B-GENE-N
receptor,1150,I-GENE-N
mRNA,1150,O
expression,1150,O
patterns,1150,O
was,1150,O
studied,1150,O
in,1150,O
CD34+,1150,O
stem,1150,O
and,1150,O
progenitor,1150,O
cells,1150,O
.,1150,O
Several,1151,O
P2,1151,B-GENE-N
receptors,1151,I-GENE-N
were,1151,O
expressed,1151,O
(,1151,O
P2Y2,1151,B-GENE-Y
",",1151,O
P2Y1,1151,B-GENE-Y
",",1151,O
P2Y12,1151,B-GENE-Y
",",1151,O
P2Y13,1151,B-GENE-Y
",",1151,O
P2Y11,1151,B-GENE-Y
",",1151,O
P2X1,1151,B-GENE-Y
",",1151,O
P2X4,1151,B-GENE-Y
),1151,O
",",1151,O
indicating,1151,O
a,1151,O
role,1151,O
in,1151,O
differentiation,1151,O
and,1151,O
proliferation,1151,O
.,1151,O
Thus,1152,O
",",1152,O
it,1152,O
is,1152,O
possible,1152,O
that,1152,O
specific,1152,O
antibodies,1152,O
to,1152,O
P2,1152,B-GENE-N
receptors,1152,I-GENE-N
could,1152,O
be,1152,O
used,1152,O
to,1152,O
identify,1152,O
progenitors,1152,O
for,1152,O
monocytes,1152,O
",",1152,O
lymphocytes,1152,O
and,1152,O
megakaryocytes,1152,O
.,1152,O
Direct,1153,O
multiplex,1153,O
assay,1153,O
of,1153,O
lysosomal,1153,O
enzymes,1153,O
in,1153,O
dried,1153,O
blood,1153,O
spots,1153,O
for,1153,O
newborn,1153,O
screening,1153,O
.,1153,O
BACKGROUND,1154,O
:,1154,O
Newborn,1154,O
screening,1154,O
for,1154,O
deficiency,1154,O
in,1154,O
the,1154,O
lysosomal,1154,O
enzymes,1154,O
that,1154,O
cause,1154,O
Fabry,1154,O
",",1154,O
Gaucher,1154,O
",",1154,O
Krabbe,1154,O
",",1154,O
Niemann-Pick,1154,O
A/B,1154,O
",",1154,O
and,1154,O
Pompe,1154,O
diseases,1154,O
is,1154,O
warranted,1154,O
because,1154,O
treatment,1154,O
for,1154,O
these,1154,O
syndromes,1154,O
is,1154,O
now,1154,O
available,1154,O
or,1154,O
anticipated,1154,O
in,1154,O
the,1154,O
near,1154,O
feature,1154,O
.,1154,O
We,1155,O
describe,1155,O
a,1155,O
multiplex,1155,O
screening,1155,O
method,1155,O
for,1155,O
all,1155,O
five,1155,O
lysosomal,1155,O
enzymes,1155,O
that,1155,O
uses,1155,O
newborn-screening,1155,O
cards,1155,O
containing,1155,O
dried,1155,O
blood,1155,O
spots,1155,O
as,1155,O
the,1155,O
enzyme,1155,O
source,1155,O
.,1155,O
METHODS,1156,O
:,1156,O
We,1156,O
used,1156,O
a,1156,O
cassette,1156,O
of,1156,O
substrates,1156,O
and,1156,O
internal,1156,O
standards,1156,O
to,1156,O
directly,1156,O
quantify,1156,O
the,1156,O
enzymatic,1156,O
activities,1156,O
",",1156,O
and,1156,O
tandem,1156,O
mass,1156,O
spectrometry,1156,O
for,1156,O
enzymatic,1156,O
product,1156,O
detection,1156,O
.,1156,O
Rehydrated,1157,O
dried,1157,O
blood,1157,O
spots,1157,O
were,1157,O
incubated,1157,O
with,1157,O
the,1157,O
enzyme,1157,O
substrates,1157,O
.,1157,O
We,1158,O
used,1158,O
liquid-liquid,1158,O
extraction,1158,O
followed,1158,O
by,1158,O
solid-phase,1158,O
extraction,1158,O
with,1158,O
silica,1158,O
gel,1158,O
to,1158,O
remove,1158,O
buffer,1158,O
components,1158,O
.,1158,O
Acarbose,1159,B-CHEMICAL
served,1159,O
as,1159,O
inhibitor,1159,O
of,1159,O
an,1159,O
interfering,1159,O
acid,1159,B-GENE-Y
alpha-glucosidase,1159,I-GENE-Y
present,1159,O
in,1159,O
neutrophils,1159,O
",",1159,O
which,1159,O
allowed,1159,O
the,1159,O
lysosomal,1159,O
enzyme,1159,O
implicated,1159,O
in,1159,O
Pompe,1159,O
disease,1159,O
to,1159,O
be,1159,O
selectively,1159,O
analyzed,1159,O
.,1159,O
RESULTS,1160,O
:,1160,O
We,1160,O
analyzed,1160,O
dried,1160,O
blood,1160,O
spots,1160,O
from,1160,O
5,1160,O
patients,1160,O
with,1160,O
Gaucher,1160,O
",",1160,O
5,1160,O
with,1160,O
Niemann-Pick,1160,O
A/B,1160,O
",",1160,O
11,1160,O
with,1160,O
Pompe,1160,O
",",1160,O
5,1160,O
with,1160,O
Fabry,1160,O
",",1160,O
and,1160,O
12,1160,O
with,1160,O
Krabbe,1160,O
disease,1160,O
",",1160,O
and,1160,O
in,1160,O
all,1160,O
cases,1160,O
the,1160,O
enzyme,1160,O
activities,1160,O
were,1160,O
below,1160,O
the,1160,O
minimum,1160,O
activities,1160,O
measured,1160,O
in,1160,O
a,1160,O
collection,1160,O
of,1160,O
heterozygous,1160,O
carriers,1160,O
and,1160,O
healthy,1160,O
noncarrier,1160,O
individuals,1160,O
.,1160,O
The,1161,O
enzyme,1161,O
activities,1161,O
measured,1161,O
in,1161,O
5-9,1161,O
heterozygous,1161,O
carriers,1161,O
were,1161,O
approximately,1161,O
one-half,1161,O
those,1161,O
measured,1161,O
with,1161,O
15-32,1161,O
healthy,1161,O
individuals,1161,O
",",1161,O
but,1161,O
there,1161,O
was,1161,O
partial,1161,O
overlap,1161,O
of,1161,O
each,1161,O
condition,1161,O
between,1161,O
the,1161,O
data,1161,O
sets,1161,O
for,1161,O
carriers,1161,O
and,1161,O
healthy,1161,O
individuals,1161,O
.,1161,O
CONCLUSION,1162,O
:,1162,O
For,1162,O
all,1162,O
five,1162,O
diseases,1162,O
",",1162,O
the,1162,O
affected,1162,O
individuals,1162,O
were,1162,O
detected,1162,O
.,1162,O
The,1163,O
assay,1163,O
can,1163,O
be,1163,O
readily,1163,O
automated,1163,O
",",1163,O
and,1163,O
the,1163,O
anticipated,1163,O
reagent,1163,O
and,1163,O
supply,1163,O
costs,1163,O
are,1163,O
well,1163,O
within,1163,O
the,1163,O
budget,1163,O
limits,1163,O
of,1163,O
newborn-screening,1163,O
centers,1163,O
.,1163,O
A,1164,O
disorder,1164,O
to,1164,O
order,1164,O
transition,1164,O
accompanies,1164,O
catalysis,1164,O
in,1164,O
retinaldehyde,1164,B-CHEMICAL
dehydrogenase,1164,I-GENE-Y
type,1164,I-GENE-Y
II,1164,I-GENE-Y
.,1164,O
Retinaldehyde,1165,B-GENE-Y
dehydrogenase,1165,I-GENE-Y
II,1165,I-GENE-Y
(,1165,O
RalDH2,1165,B-GENE-Y
),1165,O
converts,1165,O
retinal,1165,O
to,1165,O
the,1165,O
transcriptional,1165,O
regulator,1165,O
retinoic,1165,O
acid,1165,O
in,1165,O
the,1165,O
developing,1165,O
embryo,1165,O
.,1165,O
The,1166,O
x-ray,1166,O
structure,1166,O
of,1166,O
the,1166,O
enzyme,1166,O
revealed,1166,O
an,1166,O
important,1166,O
structural,1166,O
difference,1166,O
between,1166,O
this,1166,O
protein,1166,O
and,1166,O
other,1166,O
aldehyde,1166,B-GENE-N
dehydrogenases,1166,I-GENE-N
of,1166,O
the,1166,O
same,1166,O
enzyme,1166,O
superfamily,1166,O
;,1166,O
a,1166,O
20-amino,1166,O
acid,1166,I-CHEMICAL
span,1166,O
in,1166,O
the,1166,O
substrate,1166,O
access,1166,O
channel,1166,O
in,1166,O
retinaldehyde,1166,B-CHEMICAL
dehydrogenase,1166,I-GENE-Y
II,1166,I-GENE-Y
is,1166,O
disordered,1166,O
",",1166,O
whereas,1166,O
in,1166,O
other,1166,O
aldehyde,1166,B-CHEMICAL
dehydrogenases,1166,I-GENE-N
this,1166,O
region,1166,O
forms,1166,O
a,1166,O
well,1166,O
defined,1166,O
wall,1166,O
of,1166,O
the,1166,O
substrate,1166,O
access,1166,O
channel,1166,O
.,1166,O
We,1167,O
asked,1167,O
whether,1167,O
this,1167,O
disordered,1167,O
loop,1167,O
might,1167,O
order,1167,O
during,1167,O
the,1167,O
course,1167,O
of,1167,O
catalysis,1167,O
and,1167,O
provide,1167,O
a,1167,O
means,1167,O
for,1167,O
an,1167,O
enzyme,1167,O
that,1167,O
requires,1167,O
a,1167,O
large,1167,O
substrate,1167,O
access,1167,O
channel,1167,O
to,1167,O
restrict,1167,O
access,1167,O
to,1167,O
the,1167,O
catalytic,1167,O
machinery,1167,O
by,1167,O
smaller,1167,O
compounds,1167,O
that,1167,O
might,1167,O
potentially,1167,O
enter,1167,O
the,1167,O
active,1167,O
site,1167,O
and,1167,O
be,1167,O
metabolized,1167,O
.,1167,O
Our,1168,O
experiments,1168,O
",",1168,O
a,1168,O
combination,1168,O
of,1168,O
kinetic,1168,O
",",1168,O
spectroscopic,1168,O
",",1168,O
and,1168,O
crystallographic,1168,O
techniques,1168,O
",",1168,O
suggest,1168,O
that,1168,O
a,1168,O
disorder,1168,O
to,1168,O
order,1168,O
transition,1168,O
is,1168,O
linked,1168,O
to,1168,O
catalytic,1168,O
activity,1168,O
.,1168,O
Effects,1169,O
of,1169,O
carvedilol,1169,B-CHEMICAL
on,1169,O
plasma,1169,B-GENE-Y
B-type,1169,I-GENE-Y
natriuretic,1169,I-GENE-Y
peptide,1169,I-GENE-Y
concentration,1169,O
and,1169,O
symptoms,1169,O
in,1169,O
patients,1169,O
with,1169,O
heart,1169,O
failure,1169,O
and,1169,O
preserved,1169,O
ejection,1169,O
fraction,1169,O
.,1169,O
Although,1170,O
the,1170,O
benefits,1170,O
of,1170,O
carvedilol,1170,B-CHEMICAL
in,1170,O
patients,1170,O
with,1170,O
heart,1170,O
failure,1170,O
and,1170,O
depressed,1170,O
ejection,1170,O
fraction,1170,O
(,1170,O
EF,1170,O
),1170,O
have,1170,O
been,1170,O
elucidated,1170,O
",",1170,O
those,1170,O
in,1170,O
patients,1170,O
with,1170,O
preserved,1170,O
EF,1170,O
are,1170,O
not,1170,O
understood,1170,O
.,1170,O
We,1171,O
enrolled,1171,O
40,1171,O
patients,1171,O
with,1171,O
mild,1171,O
or,1171,O
moderate,1171,O
heart,1171,O
failure,1171,O
and,1171,O
EF,1171,O
>,1171,O
/=45,1171,O
%,1171,O
.,1171,O
They,1172,O
were,1172,O
randomly,1172,O
assigned,1172,O
to,1172,O
carvedilol,1172,B-CHEMICAL
(,1172,O
n,1172,O
=,1172,O
19,1172,O
),1172,O
or,1172,O
conventional,1172,O
therapy,1172,O
(,1172,O
n,1172,O
=,1172,O
21,1172,O
),1172,O
.,1172,O
After,1173,O
12,1173,O
months,1173,O
of,1173,O
treatment,1173,O
",",1173,O
carvedilol,1173,B-CHEMICAL
significantly,1173,O
improved,1173,O
all,1173,O
end,1173,O
points,1173,O
(,1173,O
plasma,1173,O
concentration,1173,O
of,1173,O
B-type,1173,B-GENE-Y
natriuretic,1173,I-GENE-Y
peptide,1173,I-GENE-Y
[,1173,O
BNP,1173,B-GENE-Y
],1173,O
from,1173,O
175,1173,O
(,1173,O
35,1173,O
to,1173,O
209,1173,O
),1173,O
to,1173,O
106,1173,O
(,1173,O
52,1173,O
to,1173,O
160,1173,O
),1173,O
pg/ml,1173,O
",",1173,O
mean,1173,O
(,1173,O
95,1173,O
%,1173,O
confidence,1173,O
interval,1173,O
),1173,O
p,1173,O
<,1173,O
0.01,1173,O
;,1173,O
New,1173,O
York,1173,O
Heart,1173,O
Association,1173,O
functional,1173,O
class,1173,O
from,1173,O
2.37,1173,O
(,1173,O
2.13,1173,O
to,1173,O
2.61,1173,O
),1173,O
to,1173,O
1.56,1173,O
(,1173,O
1.21,1173,O
to,1173,O
1.91,1173,O
),1173,O
",",1173,O
p,1173,O
<,1173,O
0.01,1173,O
;,1173,O
exercise,1173,O
capacity,1173,O
estimated,1173,O
with,1173,O
the,1173,O
Specific,1173,O
Activity,1173,O
Scale,1173,O
from,1173,O
4.75,1173,O
(,1173,O
4.50,1173,O
to,1173,O
5.00,1173,O
),1173,O
to,1173,O
5.68,1173,O
(,1173,O
5.22,1173,O
to,1173,O
6.14,1173,O
),1173,O
METs,1173,O
",",1173,O
p,1173,O
<,1173,O
0.02,1173,O
),1173,O
",",1173,O
whereas,1173,O
conventional,1173,O
therapy,1173,O
did,1173,O
not,1173,O
(,1173,O
plasma,1173,B-GENE-Y
BNP,1173,I-GENE-Y
concentration,1173,O
from,1173,O
150,1173,O
(,1173,O
114,1173,O
to,1173,O
186,1173,O
),1173,O
to,1173,O
174,1173,O
(,1173,O
100,1173,O
to,1173,O
248,1173,O
),1173,O
pg/ml,1173,O
;,1173,O
New,1173,O
York,1173,O
Heart,1173,O
Association,1173,O
functional,1173,O
class,1173,O
from,1173,O
2.29,1173,O
(,1173,O
2.08,1173,O
to,1173,O
2.50,1173,O
),1173,O
to,1173,O
2.11,1173,O
(,1173,O
1.73,1173,O
to,1173,O
2.49,1173,O
),1173,O
;,1173,O
exercise,1173,O
capacity,1173,O
from,1173,O
4.57,1173,O
(,1173,O
4.34,1173,O
to,1173,O
4.80,1173,O
),1173,O
to,1173,O
4.72,1173,O
(,1173,O
4.41,1173,O
to,1173,O
5.03,1173,O
),1173,O
METs,1173,O
),1173,O
.,1173,O
Univariate,1174,O
regression,1174,O
analyses,1174,O
showed,1174,O
that,1174,O
only,1174,O
the,1174,O
use,1174,O
of,1174,O
carvedilol,1174,B-CHEMICAL
was,1174,O
correlated,1174,O
with,1174,O
the,1174,O
decrease,1174,O
in,1174,O
plasma,1174,B-GENE-Y
BNP,1174,I-GENE-Y
concentration,1174,O
(,1174,O
p,1174,O
<,1174,O
0.03,1174,O
),1174,O
.,1174,O
Multivariate,1175,O
analyses,1175,O
demonstrated,1175,O
that,1175,O
an,1175,O
ischemic,1175,O
cause,1175,O
of,1175,O
heart,1175,O
failure,1175,O
(,1175,O
p,1175,O
<,1175,O
0.02,1175,O
),1175,O
",",1175,O
high,1175,O
plasma,1175,O
concentration,1175,O
of,1175,O
BNP,1175,B-GENE-Y
(,1175,O
p,1175,O
<,1175,O
0.02,1175,O
),1175,O
",",1175,O
left,1175,O
ventricular,1175,O
dilation,1175,O
(,1175,O
p,1175,O
<,1175,O
0.03,1175,O
),1175,O
",",1175,O
and,1175,O
use,1175,O
of,1175,O
carvedilol,1175,B-CHEMICAL
(,1175,O
p,1175,O
<,1175,O
0.04,1175,O
),1175,O
at,1175,O
baseline,1175,O
were,1175,O
predictive,1175,O
of,1175,O
a,1175,O
decrease,1175,O
in,1175,O
plasma,1175,O
concentration,1175,O
of,1175,O
BNP,1175,B-GENE-Y
.,1175,O
In,1176,O
conclusion,1176,O
",",1176,O
carvedilol,1176,B-CHEMICAL
potentially,1176,O
decreased,1176,O
neurohumoral,1176,O
activation,1176,O
",",1176,O
decreased,1176,O
symptoms,1176,O
",",1176,O
and,1176,O
increased,1176,O
exercise,1176,O
capacity,1176,O
in,1176,O
patients,1176,O
with,1176,O
heart,1176,O
failure,1176,O
and,1176,O
preserved,1176,O
EF,1176,O
.,1176,O
Psychopharmacology,1177,O
of,1177,O
anticonvulsants,1177,O
:,1177,O
levetiracetam,1177,B-CHEMICAL
as,1177,O
a,1177,O
synaptic,1177,B-GENE-N
vesicle,1177,I-GENE-N
protein,1177,I-GENE-N
modulator,1177,O
.,1177,O
ISSUE,1178,O
:,1178,O
A,1178,O
novel,1178,O
mechanism,1178,O
of,1178,O
action,1178,O
has,1178,O
recently,1178,O
been,1178,O
described,1178,O
for,1178,O
levetiracetam,1178,B-CHEMICAL
",",1178,O
a,1178,O
member,1178,O
of,1178,O
a,1178,O
new,1178,O
class,1178,O
of,1178,O
anticonvulsants,1178,O
.,1178,O
Levetiracetam,1179,B-CHEMICAL
binds,1179,O
selectively,1179,O
and,1179,O
with,1179,O
high,1179,O
affinity,1179,O
to,1179,O
a,1179,O
synaptic,1179,B-GENE-N
vesicle,1179,I-GENE-N
protein,1179,I-GENE-N
known,1179,O
as,1179,O
SV2A,1179,B-GENE-Y
",",1179,O
thought,1179,O
to,1179,O
be,1179,O
involved,1179,O
with,1179,O
synaptic,1179,O
vesicle,1179,O
exocytosis,1179,O
and,1179,O
presynaptic,1179,O
neurotransmitter,1179,O
release,1179,O
.,1179,O
Terbinafine,1180,B-CHEMICAL
:,1180,O
mode,1180,O
of,1180,O
action,1180,O
and,1180,O
properties,1180,O
of,1180,O
the,1180,O
squalene,1180,B-GENE-Y
epoxidase,1180,I-GENE-Y
inhibition,1180,O
.,1180,O
Terbinafine,1181,B-CHEMICAL
(,1181,O
Lamisil,1181,B-CHEMICAL
),1181,O
has,1181,O
primarily,1181,O
fungicidal,1181,O
action,1181,O
against,1181,O
many,1181,O
fungi,1181,O
as,1181,O
a,1181,O
result,1181,O
of,1181,O
its,1181,O
specific,1181,O
mechanism,1181,O
of,1181,O
squalene,1181,B-CHEMICAL
epoxidase,1181,I-GENE-Y
inhibition,1181,O
.,1181,O
Treated,1182,O
fungi,1182,O
accumulate,1182,O
squalene,1182,B-CHEMICAL
while,1182,O
becoming,1182,O
deficient,1182,O
in,1182,O
ergosterol,1182,B-CHEMICAL
",",1182,O
an,1182,O
essential,1182,O
component,1182,O
of,1182,O
fungal,1182,O
cell,1182,O
membranes,1182,O
.,1182,O
The,1183,O
cidal,1183,O
action,1183,O
is,1183,O
closely,1183,O
associated,1183,O
with,1183,O
the,1183,O
development,1183,O
of,1183,O
high,1183,O
intracellular,1183,O
squalene,1183,B-CHEMICAL
concentrations,1183,O
",",1183,O
which,1183,O
are,1183,O
believed,1183,O
to,1183,O
interfere,1183,O
with,1183,O
fungal,1183,O
membrane,1183,O
function,1183,O
and,1183,O
cell,1183,O
wall,1183,O
synthesis,1183,O
.,1183,O
In,1184,O
the,1184,O
case,1184,O
of,1184,O
Candida,1184,O
albicans,1184,O
",",1184,O
growth,1184,O
inhibition,1184,O
with,1184,O
terbinafine,1184,B-CHEMICAL
appears,1184,O
to,1184,O
result,1184,O
from,1184,O
the,1184,O
ergosterol,1184,B-CHEMICAL
deficiency,1184,O
.,1184,O
The,1185,O
filamentous,1185,O
form,1185,O
of,1185,O
this,1185,O
fungus,1185,O
is,1185,O
more,1185,O
susceptible,1185,O
than,1185,O
the,1185,O
yeast,1185,O
form,1185,O
.,1185,O
Measurement,1186,O
of,1186,O
ergosterol,1186,B-CHEMICAL
biosynthesis,1186,O
by,1186,O
incorporation,1186,O
of,1186,O
radiolabelled,1186,O
precursors,1186,O
indicates,1186,O
a,1186,O
correlation,1186,O
between,1186,O
inhibition,1186,O
of,1186,O
growth,1186,O
and,1186,O
ergosterol,1186,B-CHEMICAL
biosynthesis,1186,O
in,1186,O
a,1186,O
range,1186,O
of,1186,O
pathogenic,1186,O
fungi,1186,O
.,1186,O
Terbinafine,1187,B-CHEMICAL
is,1187,O
a,1187,O
potent,1187,O
non-competitive,1187,O
inhibitor,1187,O
of,1187,O
squalene,1187,B-GENE-Y
epoxidase,1187,I-GENE-Y
from,1187,O
Candida,1187,O
(,1187,O
Ki,1187,O
=,1187,O
30,1187,O
nM,1187,O
),1187,O
.,1187,O
In,1188,O
contrast,1188,O
",",1188,O
inhibition,1188,O
of,1188,O
rat,1188,B-GENE-Y
liver,1188,I-GENE-Y
squalene,1188,I-GENE-Y
epoxidase,1188,I-GENE-Y
only,1188,O
occurs,1188,O
at,1188,O
higher,1188,O
drug,1188,O
concentrations,1188,O
(,1188,O
Ki,1188,O
=,1188,O
77,1188,O
microM,1188,O
),1188,O
",",1188,O
and,1188,O
is,1188,O
competitive,1188,O
with,1188,O
squalene,1188,B-CHEMICAL
.,1188,O
Thus,1189,O
",",1189,O
terbinafine,1189,B-CHEMICAL
has,1189,O
no,1189,O
effect,1189,O
on,1189,O
cholesterol,1189,B-CHEMICAL
biosynthesis,1189,O
in,1189,O
vivo,1189,O
.,1189,O
Squalene,1190,B-CHEMICAL
epoxidase,1190,I-GENE-Y
is,1190,O
not,1190,O
an,1190,O
enzyme,1190,O
of,1190,O
the,1190,O
cytochrome,1190,B-GENE-N
P-450,1190,I-GENE-N
type,1190,O
",",1190,O
thereby,1190,O
avoiding,1190,O
potential,1190,O
inhibition,1190,O
of,1190,O
this,1190,O
class,1190,O
of,1190,O
enzymes,1190,O
.,1190,O
[,1191,O
A,1191,O
case,1191,O
report,1191,O
of,1191,O
metastatic,1191,O
pancreatic,1191,O
cancer,1191,O
that,1191,O
responded,1191,O
remarkably,1191,O
to,1191,O
the,1191,O
combination,1191,O
of,1191,O
thalidomide,1191,B-CHEMICAL
",",1191,O
celecoxib,1191,B-CHEMICAL
and,1191,O
irinotecan,1191,B-CHEMICAL
],1191,O
.,1191,O
The,1192,O
prognosis,1192,O
of,1192,O
pancreatic,1192,O
cancer,1192,O
with,1192,O
metastases,1192,O
or,1192,O
recurrence,1192,O
is,1192,O
quite,1192,O
poor,1192,O
.,1192,O
Chemotherapy,1193,O
has,1193,O
not,1193,O
resulted,1193,O
in,1193,O
a,1193,O
significant,1193,O
survival,1193,O
benefit,1193,O
;,1193,O
median,1193,O
survival,1193,O
is,1193,O
3-6,1193,O
months,1193,O
.,1193,O
Various,1194,O
chemotherapeutic,1194,O
agents,1194,O
have,1194,O
been,1194,O
evaluated,1194,O
and,1194,O
the,1194,O
standard,1194,O
chemotherapy,1194,O
of,1194,O
pancreatic,1194,O
cancer,1194,O
is,1194,O
gemcitabine,1194,B-CHEMICAL
.,1194,O
The,1195,O
response,1195,O
rate,1195,O
",",1195,O
however,1195,O
",",1195,O
is,1195,O
low,1195,O
at,1195,O
13,1195,O
%,1195,O
.,1195,O
Thalidomide,1196,B-CHEMICAL
and,1196,O
celecoxib,1196,B-CHEMICAL
have,1196,O
different,1196,O
mechanisms,1196,O
of,1196,O
action,1196,O
and,1196,O
activity,1196,O
in,1196,O
various,1196,O
malignant,1196,O
tumors,1196,O
.,1196,O
Both,1197,O
have,1197,O
been,1197,O
evaluated,1197,O
and,1197,O
shown,1197,O
to,1197,O
demonstrate,1197,O
activity,1197,O
against,1197,O
solid,1197,O
tumors,1197,O
.,1197,O
Thalidomide,1198,B-CHEMICAL
decreased,1198,O
the,1198,O
stability,1198,O
of,1198,O
TNF-mRNA,1198,B-GENE-Y
and,1198,O
COX-2,1198,B-GENE-Y
mRNA,1198,O
.,1198,O
COX-2,1199,B-GENE-Y
is,1199,O
a,1199,O
bifunctional,1199,O
enzyme,1199,O
possessing,1199,O
both,1199,O
cyclooxygenase,1199,B-GENE-N
and,1199,O
peroxidase,1199,B-GENE-N
activities,1199,O
.,1199,O
Although,1200,O
celecoxib,1200,B-CHEMICAL
inhibits,1200,O
PG,1200,O
biosynthesis,1200,O
",",1200,O
most,1200,O
do,1200,O
not,1200,O
affect,1200,O
the,1200,O
peroxidase,1200,B-GENE-N
activity,1200,O
of,1200,O
COX,1200,B-GENE-N
",",1200,O
which,1200,O
can,1200,O
generate,1200,O
proximate,1200,O
carcinogens,1200,O
.,1200,O
Because,1201,O
thalidomide,1201,B-CHEMICAL
does,1201,O
not,1201,O
completely,1201,O
inhibit,1201,O
COX-2,1201,B-GENE-Y
expression,1201,O
or,1201,O
PG,1201,O
biosynthesis,1201,O
",",1201,O
a,1201,O
therapeutic,1201,O
strategy,1201,O
combining,1201,O
celecoxib,1201,B-CHEMICAL
with,1201,O
thalidomide,1201,B-CHEMICAL
might,1201,O
be,1201,O
more,1201,O
effective,1201,O
than,1201,O
using,1201,O
either,1201,O
agent,1201,O
alone,1201,O
.,1201,O
Differences,1202,O
in,1202,O
the,1202,O
mechanism,1202,O
of,1202,O
action,1202,O
of,1202,O
gemcitabine,1202,B-CHEMICAL
and,1202,O
irinotecan,1202,B-CHEMICAL
suggest,1202,O
that,1202,O
a,1202,O
change,1202,O
of,1202,O
gemcitabine,1202,B-CHEMICAL
to,1202,O
irinotecan,1202,B-CHEMICAL
could,1202,O
provide,1202,O
clinically,1202,O
efficacious,1202,O
outcomes,1202,O
.,1202,O
In,1203,O
order,1203,O
to,1203,O
accomplish,1203,O
new,1203,O
treatment,1203,O
strategies,1203,O
",",1203,O
we,1203,O
have,1203,O
been,1203,O
using,1203,O
thalidomide,1203,B-CHEMICAL
",",1203,O
celecoxib,1203,B-CHEMICAL
and,1203,O
irinotecan,1203,B-CHEMICAL
in,1203,O
low-doses,1203,O
.,1203,O
We,1204,O
believe,1204,O
this,1204,O
combination,1204,O
represents,1204,O
a,1204,O
viable,1204,O
treatment,1204,O
for,1204,O
patients,1204,O
of,1204,O
pancreatic,1204,O
cancer,1204,O
with,1204,O
recurrence,1204,O
or,1204,O
metastases,1204,O
.,1204,O
Effect,1205,O
of,1205,O
pitavastatin,1205,B-CHEMICAL
on,1205,O
apolipoprotein,1205,B-GENE-Y
A-I,1205,I-GENE-Y
production,1205,O
in,1205,O
HepG2,1205,O
cell,1205,O
.,1205,O
There,1206,O
are,1206,O
few,1206,O
reports,1206,O
describing,1206,O
the,1206,O
mechanism,1206,O
of,1206,O
HDL-elevating,1206,B-GENE-N
action,1206,O
of,1206,O
HMG-CoA,1206,B-GENE-Y
reductase,1206,I-GENE-Y
inhibitors,1206,O
(,1206,O
statins,1206,O
),1206,O
.,1206,O
As,1207,O
it,1207,O
is,1207,O
considered,1207,O
that,1207,O
the,1207,O
key,1207,O
step,1207,O
of,1207,O
HDL,1207,B-GENE-N
production,1207,O
is,1207,O
the,1207,O
secretion,1207,O
of,1207,O
apolipoprotein,1207,B-GENE-Y
A-I,1207,I-GENE-Y
(,1207,O
apoA-I,1207,B-GENE-Y
),1207,O
",",1207,O
we,1207,O
investigated,1207,O
the,1207,O
effect,1207,O
of,1207,O
statins,1207,O
on,1207,O
apoA-I,1207,B-GENE-Y
synthesis,1207,O
and,1207,O
secretion,1207,O
by,1207,O
HepG2,1207,O
cell,1207,O
to,1207,O
elucidate,1207,O
the,1207,O
mechanism,1207,O
of,1207,O
the,1207,O
action,1207,O
.,1207,O
Each,1208,O
statin,1208,O
induced,1208,O
apoA-I,1208,B-GENE-Y
expression,1208,O
(,1208,O
mRNA,1208,O
and,1208,O
protein,1208,O
),1208,O
dose-dependently,1208,O
:,1208,O
the,1208,O
rank,1208,O
order,1208,O
of,1208,O
the,1208,O
apoA-I,1208,B-GENE-Y
induction,1208,O
pitavastatin,1208,B-CHEMICAL
(,1208,O
3,1208,O
microM,1208,O
),1208,O
>,1208,O
simvastatin,1208,B-CHEMICAL
(,1208,O
10,1208,O
microM,1208,O
),1208,O
>,1208,O
atorvastatin,1208,B-CHEMICAL
(,1208,O
30,1208,O
microM,1208,O
),1208,O
.,1208,O
The,1209,O
induction,1209,O
of,1209,O
apoA-I,1209,B-GENE-Y
by,1209,O
statins,1209,O
disappeared,1209,O
with,1209,O
addition,1209,O
of,1209,O
mevalonate,1209,B-CHEMICAL
",",1209,O
which,1209,O
indicates,1209,O
that,1209,O
the,1209,O
effect,1209,O
is,1209,O
HMG-CoA,1209,B-CHEMICAL
reductase,1209,I-GENE-Y
inhibition-dependent,1209,O
.,1209,O
Based,1210,O
on,1210,O
HMG-CoA,1210,B-CHEMICAL
reductase,1210,I-GENE-Y
inhibition,1210,O
",",1210,O
pitavastatin-induced,1210,B-CHEMICAL
apoA-I,1210,B-GENE-Y
more,1210,O
efficiently,1210,O
than,1210,O
simvastatin,1210,B-CHEMICAL
and,1210,O
atorvastatin,1210,B-CHEMICAL
.,1210,O
Further,1211,O
study,1211,O
revealed,1211,O
that,1211,O
pitavastatin,1211,B-CHEMICAL
increased,1211,O
ABCA1,1211,B-GENE-Y
mRNA,1211,O
in,1211,O
HMG-CoA,1211,B-GENE-Y
reductase-dependent,1211,O
manner,1211,O
and,1211,O
that,1211,O
Rho,1211,B-GENE-N
and,1211,O
Rho,1211,B-GENE-N
kinase,1211,I-GENE-N
inhibitor,1211,O
(,1211,O
C3T,1211,O
and,1211,O
Y27632,1211,B-CHEMICAL
),1211,O
increased,1211,O
apoA-I,1211,B-GENE-Y
production,1211,O
in,1211,O
the,1211,O
HepG2,1211,O
cells,1211,O
.,1211,O
These,1212,O
results,1212,O
suggest,1212,O
that,1212,O
pitavastatin,1212,B-CHEMICAL
efficiently,1212,O
increases,1212,O
apoA-I,1212,B-GENE-Y
in,1212,O
the,1212,O
culture,1212,O
medium,1212,O
of,1212,O
HepG2,1212,O
cells,1212,O
by,1212,O
promoting,1212,O
apoA-I,1212,B-GENE-Y
production,1212,O
through,1212,O
inhibition,1212,O
of,1212,O
HMG-CoA,1212,B-CHEMICAL
reductase,1212,I-GENE-Y
and,1212,O
suppression,1212,O
of,1212,O
Rho,1212,B-GENE-N
activity,1212,O
and,1212,O
by,1212,O
protecting,1212,O
apoA-I,1212,B-GENE-Y
from,1212,O
catabolism,1212,O
through,1212,O
ABCA1,1212,B-GENE-Y
induction,1212,O
and,1212,O
lipidation,1212,O
of,1212,O
apoA-I,1212,B-GENE-Y
.,1212,O
A,1213,O
multitargeted,1213,O
",",1213,O
metronomic,1213,O
",",1213,O
and,1213,O
maximum-tolerated,1213,O
dose,1213,O
``,1213,O
chemo-switch,1213,O
'',1213,O
regimen,1213,O
is,1213,O
antiangiogenic,1213,O
",",1213,O
producing,1213,O
objective,1213,O
responses,1213,O
and,1213,O
survival,1213,O
benefit,1213,O
in,1213,O
a,1213,O
mouse,1213,O
model,1213,O
of,1213,O
cancer,1213,O
.,1213,O
PURPOSE,1214,O
:,1214,O
A,1214,O
transgenic,1214,O
mouse,1214,O
model,1214,O
has,1214,O
revealed,1214,O
parameters,1214,O
of,1214,O
the,1214,O
angiogenic,1214,O
switch,1214,O
during,1214,O
multistep,1214,O
tumorigenesis,1214,O
of,1214,O
pancreatic,1214,O
islets,1214,O
",",1214,O
and,1214,O
demonstrated,1214,O
efficacy,1214,O
of,1214,O
antiangiogenic,1214,O
therapies,1214,O
.,1214,O
Pericytes,1215,O
have,1215,O
been,1215,O
revealed,1215,O
as,1215,O
functionally,1215,O
important,1215,O
for,1215,O
tumor,1215,O
neovasculature,1215,O
",",1215,O
using,1215,O
kinase,1215,O
inhibitors,1215,O
targeting,1215,O
their,1215,O
platelet-derived,1215,B-GENE-Y
growth,1215,I-GENE-Y
factor,1215,I-GENE-Y
receptors,1215,I-GENE-Y
(,1215,O
PDGFRs,1215,B-GENE-Y
),1215,O
.,1215,O
Additionally,1216,O
",",1216,O
vascular,1216,B-GENE-N
endothelial,1216,I-GENE-N
growth,1216,I-GENE-N
factor,1216,I-GENE-N
receptor,1216,I-GENE-N
(,1216,O
VEGFR,1216,B-GENE-N
),1216,O
inhibitors,1216,O
and,1216,O
metronomic,1216,O
chemotherapy,1216,O
show,1216,O
modest,1216,O
benefit,1216,O
against,1216,O
early-,1216,O
but,1216,O
not,1216,O
late-stage,1216,O
disease,1216,O
.,1216,O
MATERIALS,1217,O
AND,1217,O
METHODS,1217,O
:,1217,O
Seeking,1217,O
to,1217,O
improve,1217,O
efficacy,1217,O
against,1217,O
otherwise,1217,O
intractable,1217,O
end-stage,1217,O
pancreatic,1217,O
islet,1217,O
tumors,1217,O
",",1217,O
two,1217,O
receptor,1217,B-GENE-N
tyrosine,1217,B-CHEMICAL
kinase,1217,I-GENE-N
inhibitors,1217,O
",",1217,O
imatinib,1217,B-CHEMICAL
and,1217,O
SU11248,1217,B-CHEMICAL
",",1217,O
were,1217,O
used,1217,O
to,1217,O
disrupt,1217,O
PDGFR-mediated,1217,B-GENE-Y
pericyte,1217,O
support,1217,O
of,1217,O
tumor,1217,O
endothelial,1217,O
cells,1217,O
in,1217,O
concert,1217,O
with,1217,O
maximum-tolerated,1217,O
dose,1217,O
(,1217,O
MTD,1217,O
),1217,O
or,1217,O
metronomic,1217,O
chemotherapy,1217,O
and/or,1217,O
VEGFR,1217,B-GENE-N
inhibition,1217,O
.,1217,O
RESULTS,1218,O
:,1218,O
Imatinib,1218,B-CHEMICAL
",",1218,O
despite,1218,O
equivocal,1218,O
efficacy,1218,O
as,1218,O
monotherapy,1218,O
",",1218,O
reduced,1218,O
pericyte,1218,O
coverage,1218,O
of,1218,O
tumor,1218,O
vessels,1218,O
and,1218,O
enhanced,1218,O
efficacy,1218,O
in,1218,O
combination,1218,O
with,1218,O
metronomic,1218,O
chemotherapy,1218,O
or,1218,O
VEGFR,1218,B-GENE-N
inhibition,1218,O
.,1218,O
A,1219,O
regimen,1219,O
involving,1219,O
all,1219,O
three,1219,O
was,1219,O
even,1219,O
better,1219,O
.,1219,O
MTD,1220,O
using,1220,O
cyclophosphamide,1220,B-CHEMICAL
caused,1220,O
transitory,1220,O
regression,1220,O
",",1220,O
but,1220,O
then,1220,O
rapid,1220,O
regrowth,1220,O
",",1220,O
in,1220,O
contrast,1220,O
to,1220,O
metronomic,1220,O
cyclophosphamide,1220,B-CHEMICAL
plus,1220,O
imatinib,1220,B-CHEMICAL
",",1220,O
which,1220,O
produced,1220,O
stable,1220,O
disease,1220,O
.,1220,O
The,1221,O
MTD,1221,O
regimen,1221,O
elicited,1221,O
apoptosis,1221,O
of,1221,O
tumor,1221,O
cells,1221,O
but,1221,O
not,1221,O
endothelial,1221,O
cells,1221,O
",",1221,O
whereas,1221,O
the,1221,O
other,1221,O
regimens,1221,O
increased,1221,O
endothelial,1221,O
cell,1221,O
apoptosis,1221,O
concordant,1221,O
with,1221,O
efficacy,1221,O
.,1221,O
A,1222,O
``,1222,O
chemo-switch,1222,O
'',1222,O
protocol,1222,O
",",1222,O
involving,1222,O
sequential,1222,O
MTD,1222,O
and,1222,O
then,1222,O
metronomic,1222,O
chemotherapy,1222,O
",",1222,O
overlaid,1222,O
with,1222,O
multitargeted,1222,O
inhibition,1222,O
of,1222,O
PDGFR,1222,B-GENE-Y
and,1222,O
VEGFR,1222,B-GENE-N
",",1222,O
gave,1222,O
complete,1222,O
responses,1222,O
and,1222,O
unprecedented,1222,O
survival,1222,O
advantage,1222,O
in,1222,O
this,1222,O
model,1222,O
.,1222,O
CONCLUSION,1223,O
:,1223,O
This,1223,O
study,1223,O
demonstrates,1223,O
a,1223,O
potentially,1223,O
tractable,1223,O
clinical,1223,O
strategy,1223,O
in,1223,O
a,1223,O
stringent,1223,O
preclinical,1223,O
model,1223,O
",",1223,O
wherein,1223,O
standard-of-care,1223,O
chemotherapy,1223,O
is,1223,O
followed,1223,O
by,1223,O
a,1223,O
novel,1223,O
maintenance,1223,O
regimen,1223,O
:,1223,O
PDFGR,1223,B-GENE-Y
is,1223,O
targeted,1223,O
to,1223,O
disrupt,1223,O
pericyte,1223,O
support,1223,O
",",1223,O
while,1223,O
metronomic,1223,O
chemotherapy,1223,O
and/or,1223,O
VEGFR,1223,B-GENE-N
inhibitors,1223,O
target,1223,O
consequently,1223,O
sensitized,1223,O
endothelial,1223,O
cells,1223,O
",",1223,O
collectively,1223,O
destabilizing,1223,O
pre-existing,1223,O
tumor,1223,O
vasculature,1223,O
and,1223,O
inhibiting,1223,O
ongoing,1223,O
angiogenesis,1223,O
.,1223,O
Preferential,1224,O
and,1224,O
non-selective,1224,O
cyclooxygenase,1224,B-GENE-N
inhibitors,1224,O
reduce,1224,O
inflammation,1224,O
during,1224,O
lipopolysaccharide-induced,1224,O
synovitis,1224,O
.,1224,O
Synovitis,1225,O
in,1225,O
horses,1225,O
is,1225,O
frequently,1225,O
treated,1225,O
by,1225,O
administration,1225,O
of,1225,O
non-steroidal,1225,O
anti-inflammatory,1225,O
drugs,1225,O
(,1225,O
NSAIDs,1225,O
),1225,O
",",1225,O
which,1225,O
inhibit,1225,O
cyclooxygenase,1225,B-GENE-N
isoforms,1225,O
(,1225,O
COX-1,1225,B-GENE-Y
and,1225,O
COX-2,1225,B-GENE-Y
),1225,O
.,1225,O
Constitutively,1226,O
expressed,1226,O
COX-1,1226,B-GENE-Y
is,1226,O
involved,1226,O
in,1226,O
physiologic,1226,O
functions,1226,O
such,1226,O
as,1226,O
maintenance,1226,O
of,1226,O
gastric,1226,O
mucosal,1226,O
integrity,1226,O
",",1226,O
whereas,1226,O
COX-2,1226,B-GENE-Y
is,1226,O
up-regulated,1226,O
at,1226,O
sites,1226,O
of,1226,O
inflammation,1226,O
.,1226,O
Thus,1227,O
",",1227,O
COX-2,1227,B-GENE-Y
inhibitors,1227,O
reduce,1227,O
inflammation,1227,O
with,1227,O
reduced,1227,O
gastrointestinal,1227,O
side,1227,O
effects,1227,O
as,1227,O
compared,1227,O
to,1227,O
non-selective,1227,O
COX,1227,B-GENE-Y
inhibitors,1227,O
.,1227,O
The,1228,O
objective,1228,O
of,1228,O
the,1228,O
present,1228,O
study,1228,O
was,1228,O
to,1228,O
compare,1228,O
the,1228,O
anti-inflammatory,1228,O
effects,1228,O
of,1228,O
the,1228,O
preferential,1228,O
COX-2,1228,B-GENE-Y
inhibitor,1228,O
etodolac,1228,O
with,1228,O
the,1228,O
non-selective,1228,O
COX,1228,B-GENE-N
inhibitor,1228,O
phenylbutazone,1228,B-CHEMICAL
in,1228,O
horses,1228,O
with,1228,O
lipopolysaccharide,1228,O
(,1228,O
LPS,1228,O
),1228,O
-induced,1228,O
synovitis,1228,O
.,1228,O
Three,1229,O
groups,1229,O
of,1229,O
horses,1229,O
(,1229,O
n=6,1229,O
),1229,O
received,1229,O
no,1229,O
treatment,1229,O
",",1229,O
phenylbutazone,1229,B-CHEMICAL
(,1229,O
4.4,1229,O
mg/kg,1229,O
",",1229,O
IV,1229,O
",",1229,O
q12h,1229,O
),1229,O
",",1229,O
or,1229,O
etodolac,1229,B-CHEMICAL
(,1229,O
23,1229,O
mg/kg,1229,O
",",1229,O
IV,1229,O
",",1229,O
q12h,1229,O
),1229,O
",",1229,O
respectively,1229,O
",",1229,O
2-h,1229,O
following,1229,O
injection,1229,O
of,1229,O
LPS,1229,O
into,1229,O
one,1229,O
middle,1229,O
carpal,1229,O
joint,1229,O
.,1229,O
Synovial,1230,O
fluid,1230,O
was,1230,O
analyzed,1230,O
for,1230,O
white,1230,O
blood,1230,O
cell,1230,O
(,1230,O
WBC,1230,O
),1230,O
count,1230,O
",",1230,O
and,1230,O
TXB2,1230,B-CHEMICAL
and,1230,O
PGE2,1230,B-CHEMICAL
levels,1230,O
.,1230,O
Phenylbutazone,1231,B-CHEMICAL
and,1231,O
etodolac,1231,B-CHEMICAL
significantly,1231,O
reduced,1231,O
WBC,1231,O
count,1231,O
6,1231,O
and,1231,O
24-h,1231,O
following,1231,O
injection,1231,O
of,1231,O
LPS,1231,O
compared,1231,O
to,1231,O
untreated,1231,O
horses,1231,O
.,1231,O
In,1232,O
addition,1232,O
",",1232,O
both,1232,O
drugs,1232,O
significantly,1232,O
reduced,1232,O
PGE2,1232,B-CHEMICAL
levels,1232,O
(,1232,O
P,1232,O
<,1232,O
0.05,1232,O
),1232,O
6-h,1232,O
following,1232,O
LPS,1232,O
injection,1232,O
",",1232,O
whereas,1232,O
the,1232,O
probable,1232,O
COX-1,1232,B-GENE-Y
prostanoid,1232,B-CHEMICAL
TXB2,1232,B-CHEMICAL
was,1232,O
significantly,1232,O
reduced,1232,O
by,1232,O
phenylbutazone,1232,B-CHEMICAL
(,1232,O
P,1232,O
<,1232,O
0.05,1232,O
),1232,O
",",1232,O
but,1232,O
not,1232,O
etodolac,1232,B-CHEMICAL
.,1232,O
Etodolac,1233,B-CHEMICAL
may,1233,O
serve,1233,O
as,1233,O
a,1233,O
more,1233,O
selective,1233,O
anti-inflammatory,1233,O
agent,1233,O
than,1233,O
phenylbutazone,1233,B-CHEMICAL
for,1233,O
treatment,1233,O
of,1233,O
equine,1233,O
synovitis,1233,O
.,1233,O
Genetic,1234,O
polymorphisms,1234,O
predisposing,1234,O
to,1234,O
hyperhomocysteinemia,1234,O
in,1234,O
cardiac,1234,O
transplant,1234,O
patients,1234,O
.,1234,O
Genetic,1235,O
determinants,1235,O
for,1235,O
high,1235,O
homocysteine,1235,B-CHEMICAL
(,1235,O
Hcy,1235,B-CHEMICAL
),1235,O
levels,1235,O
are,1235,O
now,1235,O
well,1235,O
known,1235,O
.,1235,O
We,1236,O
studied,1236,O
several,1236,O
single,1236,O
nucleotide,1236,O
polymorphisms,1236,O
(,1236,O
SNP,1236,O
),1236,O
in,1236,O
Hcy-regulating,1236,B-CHEMICAL
genes,1236,O
[,1236,O
methylenetetrahydrofolate,1236,B-CHEMICAL
reductase,1236,I-GENE-Y
(,1236,O
MTHFR,1236,B-GENE-Y
),1236,O
C677T,1236,B-GENE-N
and,1236,O
A1298C,1236,B-GENE-N
;,1236,O
methionine,1236,B-CHEMICAL
synthase,1236,I-GENE-Y
(,1236,O
MS,1236,B-GENE-Y
),1236,O
A2756G,1236,B-GENE-N
;,1236,O
methionine,1236,B-CHEMICAL
synthase,1236,I-GENE-Y
reductase,1236,I-GENE-Y
(,1236,O
MTRR,1236,B-GENE-Y
),1236,O
A66G,1236,B-GENE-N
],1236,O
in,1236,O
relation,1236,O
to,1236,O
total,1236,O
plasma,1236,O
Hcy,1236,B-CHEMICAL
levels,1236,O
",",1236,O
transplant,1236,O
coronary,1236,O
artery,1236,O
disease,1236,O
and,1236,O
thromboembolic,1236,O
episodes,1236,O
in,1236,O
84,1236,O
heart,1236,O
transplant,1236,O
patients,1236,O
",",1236,O
and,1236,O
we,1236,O
compared,1236,O
the,1236,O
incidence,1236,O
of,1236,O
these,1236,O
polymorphisms,1236,O
with,1236,O
those,1236,O
in,1236,O
a,1236,O
healthy,1236,O
adult,1236,O
controls,1236,O
.,1236,O
At,1237,O
least,1237,O
one,1237,O
copy,1237,O
of,1237,O
the,1237,O
G,1237,O
allele,1237,O
of,1237,O
the,1237,O
MTRR,1237,B-GENE-Y
A66G,1237,B-GENE-N
SNP,1237,O
was,1237,O
found,1237,O
in,1237,O
a,1237,O
significantly,1237,O
greater,1237,O
proportion,1237,O
of,1237,O
cardiac,1237,O
transplant,1237,O
(,1237,O
CTX,1237,O
),1237,O
recipients,1237,O
compared,1237,O
with,1237,O
controls,1237,O
(,1237,O
94.0,1237,O
%,1237,O
vs.,1237,O
79.9,1237,O
%,1237,O
respectively,1237,O
),1237,O
.,1237,O
None,1238,O
of,1238,O
the,1238,O
SNP,1238,O
analyzed,1238,O
were,1238,O
correlated,1238,O
with,1238,O
total,1238,O
Hcy,1238,B-CHEMICAL
plasma,1238,O
levels,1238,O
or,1238,O
the,1238,O
presence,1238,O
of,1238,O
transplant,1238,O
coronary,1238,O
artery,1238,O
disease,1238,O
.,1238,O
However,1239,O
",",1239,O
MS,1239,B-GENE-Y
A2756G,1239,B-GENE-N
was,1239,O
significantly,1239,O
associated,1239,O
with,1239,O
cobalamin,1239,B-CHEMICAL
levels,1239,O
(,1239,O
AA,1239,O
genotype,1239,O
:,1239,O
290,1239,O
+/-,1239,O
122,1239,O
pmol/l,1239,O
;,1239,O
AG,1239,O
:,1239,O
381,1239,O
+/-,1239,O
151,1239,O
pmol/l,1239,O
and,1239,O
GG,1239,O
:,1239,O
415,1239,O
+/-,1239,O
100,1239,O
pmol/l,1239,O
),1239,O
",",1239,O
as,1239,O
was,1239,O
MTRR,1239,B-GENE-Y
A66G,1239,B-GENE-N
(,1239,O
AA,1239,O
:,1239,O
478,1239,O
+/-,1239,O
219,1239,O
pmol/l,1239,O
",",1239,O
AG,1239,O
:,1239,O
306,1239,O
+/-,1239,O
124,1239,O
pmol/l,1239,O
and,1239,O
GG,1239,O
:,1239,O
306,1239,O
+/-,1239,O
123,1239,O
pmol/l,1239,O
),1239,O
.,1239,O
MTRR,1240,B-GENE-Y
A66G,1240,B-GENE-N
was,1240,O
also,1240,O
correlated,1240,O
with,1240,O
serum,1240,O
folate,1240,O
.,1240,O
No,1241,O
association,1241,O
was,1241,O
found,1241,O
with,1241,O
thromboembolic,1241,O
events,1241,O
.,1241,O
In,1242,O
conclusion,1242,O
",",1242,O
there,1242,O
was,1242,O
a,1242,O
significant,1242,O
difference,1242,O
in,1242,O
the,1242,O
frequency,1242,O
of,1242,O
the,1242,O
G,1242,O
allele,1242,O
genotype,1242,O
of,1242,O
the,1242,O
MTRR,1242,B-GENE-Y
A66G,1242,B-GENE-N
in,1242,O
CTX,1242,O
patients,1242,O
versus,1242,O
controls,1242,O
.,1242,O
Differences,1243,O
in,1243,O
cobalamin,1243,B-CHEMICAL
and,1243,O
folate,1243,O
levels,1243,O
with,1243,O
the,1243,O
MTRR,1243,B-GENE-Y
A66G,1243,B-GENE-N
and,1243,O
MS,1243,B-GENE-Y
A2756G,1243,B-GENE-N
polymorphisms,1243,O
were,1243,O
noted,1243,O
.,1243,O
Thus,1244,O
",",1244,O
SNP,1244,O
in,1244,O
Hcy-regulating,1244,B-CHEMICAL
genes,1244,O
may,1244,O
be,1244,O
important,1244,O
determinants,1244,O
of,1244,O
vitamin,1244,O
metabolism,1244,O
in,1244,O
CTX,1244,O
",",1244,O
raising,1244,O
the,1244,O
question,1244,O
of,1244,O
increased,1244,O
vitamin,1244,O
requirements,1244,O
to,1244,O
minimize,1244,O
increased,1244,O
plasma,1244,O
Hcy,1244,B-CHEMICAL
in,1244,O
this,1244,O
high-risk,1244,O
group,1244,O
.,1244,O
Effect,1245,O
of,1245,O
bosentan,1245,B-CHEMICAL
(,1245,O
ETA/ETB,1245,B-GENE-Y
receptor,1245,O
antagonist,1245,O
),1245,O
on,1245,O
metabolic,1245,O
changes,1245,O
during,1245,O
stress,1245,O
and,1245,O
diabetes,1245,O
.,1245,O
Elevated,1246,O
plasma,1246,O
ET-1,1246,B-GENE-Y
levels,1246,O
have,1246,O
been,1246,O
reported,1246,O
in,1246,O
several,1246,O
conditions,1246,O
such,1246,O
as,1246,O
stress,1246,O
and,1246,O
diabetes,1246,O
.,1246,O
ET-1,1247,B-GENE-Y
is,1247,O
found,1247,O
to,1247,O
cause,1247,O
insulin,1247,B-GENE-Y
resistance,1247,O
and,1247,O
to,1247,O
stimulate,1247,O
liver,1247,O
glycogenolysis,1247,O
.,1247,O
The,1248,O
question,1248,O
arises,1248,O
whether,1248,O
ET-1,1248,B-GENE-Y
has,1248,O
a,1248,O
role,1248,O
in,1248,O
the,1248,O
metabolic,1248,O
changes,1248,O
occurring,1248,O
in,1248,O
such,1248,O
conditions,1248,O
.,1248,O
To,1249,O
test,1249,O
this,1249,O
",",1249,O
we,1249,O
studied,1249,O
the,1249,O
possible,1249,O
effect,1249,O
of,1249,O
the,1249,O
endothelin,1249,B-GENE-N
receptor,1249,I-GENE-N
antagonist,1249,O
",",1249,O
bosentan,1249,B-CHEMICAL
(,1249,O
50,1249,O
and,1249,O
100,1249,O
mg,1249,O
kg,1249,O
(,1249,O
-1,1249,O
),1249,O
),1249,O
on,1249,O
serum,1249,O
glucose,1249,B-CHEMICAL
and,1249,O
insulin,1249,B-GENE-N
levels,1249,O
as,1249,O
well,1249,O
as,1249,O
on,1249,O
liver,1249,O
glycogen,1249,O
contents,1249,O
in,1249,O
normoglycemic,1249,O
stressed,1249,O
animals,1249,O
.,1249,O
In,1250,O
addition,1250,O
",",1250,O
the,1250,O
effect,1250,O
of,1250,O
bosentan,1250,B-CHEMICAL
on,1250,O
serum,1250,O
glucose,1250,B-CHEMICAL
and,1250,O
insulin,1250,B-GENE-N
levels,1250,O
in,1250,O
both,1250,O
mild,1250,O
and,1250,O
severely,1250,O
diabetic,1250,O
rats,1250,O
and,1250,O
its,1250,O
effect,1250,O
on,1250,O
insulin-induced,1250,B-GENE-N
hypoglycemia,1250,O
were,1250,O
also,1250,O
determined,1250,O
.,1250,O
Restraining,1251,O
water,1251,O
immersion,1251,O
stress,1251,O
was,1251,O
used,1251,O
as,1251,O
a,1251,O
model,1251,O
for,1251,O
severe,1251,O
stress,1251,O
reported,1251,O
to,1251,O
elevate,1251,O
plasma,1251,O
ET-1,1251,B-GENE-Y
level,1251,O
.,1251,O
Mild,1252,O
diabetes,1252,O
was,1252,O
induced,1252,O
in,1252,O
rats,1252,O
by,1252,O
intraperitoneal,1252,O
injection,1252,O
of,1252,O
a,1252,O
low,1252,O
dose,1252,O
of,1252,O
streptozotocin,1252,B-CHEMICAL
(,1252,O
38,1252,O
mg,1252,O
kg,1252,O
(,1252,O
-1,1252,O
),1252,O
),1252,O
while,1252,O
severe,1252,O
diabetes,1252,O
was,1252,O
induced,1252,O
by,1252,O
intraperitoneal,1252,O
injection,1252,O
of,1252,O
a,1252,O
higher,1252,O
dose,1252,O
of,1252,O
streptozotocin,1252,B-CHEMICAL
(,1252,O
45,1252,O
mg,1252,O
kg,1252,O
(,1252,O
-1,1252,O
),1252,O
),1252,O
.,1252,O
Bosentan,1253,B-CHEMICAL
partially,1253,O
prevented,1253,O
stress-induced,1253,O
both,1253,O
hyperglycemia,1253,O
and,1253,O
decrease,1253,O
in,1253,O
glycogen,1253,O
content,1253,O
while,1253,O
it,1253,O
completely,1253,O
blocked,1253,O
the,1253,O
stress-induced,1253,O
decrease,1253,O
in,1253,O
insulin,1253,B-GENE-N
level,1253,O
in,1253,O
normoglycemic,1253,O
stressed,1253,O
rats,1253,O
.,1253,O
Bosentan,1254,B-CHEMICAL
also,1254,O
decreased,1254,O
serum,1254,O
glucose,1254,B-CHEMICAL
level,1254,O
without,1254,O
any,1254,O
effect,1254,O
on,1254,O
insulin,1254,B-GENE-N
secretion,1254,O
in,1254,O
mild,1254,O
diabetic,1254,O
rats,1254,O
and,1254,O
potentiated,1254,O
the,1254,O
hypoglycemic,1254,O
action,1254,O
of,1254,O
insulin,1254,B-GENE-N
.,1254,O
Modification,1255,O
of,1255,O
radiation,1255,O
damage,1255,O
to,1255,O
mitochondrial,1255,O
system,1255,O
in,1255,O
vivo,1255,O
by,1255,O
Podophyllum,1255,O
hexandrum,1255,O
:,1255,O
mechanistic,1255,O
aspects,1255,O
.,1255,O
The,1256,O
present,1256,O
study,1256,O
was,1256,O
undertaken,1256,O
to,1256,O
investigate,1256,O
whether,1256,O
RP-1,1256,O
treatment,1256,O
protected,1256,O
mitochondrial,1256,O
system,1256,O
against,1256,O
radiation,1256,O
damage,1256,O
and,1256,O
also,1256,O
to,1256,O
unravel,1256,O
the,1256,O
mechanism,1256,O
associated,1256,O
with,1256,O
this,1256,O
process,1256,O
.,1256,O
Radioprotection,1257,O
of,1257,O
mitochondrial,1257,O
system,1257,O
by,1257,O
Podophyllum,1257,O
hexandrum,1257,O
(,1257,O
RP-1,1257,O
),1257,O
was,1257,O
investigated,1257,O
to,1257,O
understand,1257,O
its,1257,O
mechanism,1257,O
of,1257,O
action,1257,O
.,1257,O
Levels,1258,O
of,1258,O
superoxide,1258,B-CHEMICAL
anion,1258,O
(,1258,O
O2-,1258,B-CHEMICAL
),1258,O
",",1258,O
reduced,1258,O
or,1258,O
oxidized,1258,O
glutathione,1258,B-CHEMICAL
(,1258,O
GSH,1258,B-CHEMICAL
or,1258,O
GSSG,1258,B-CHEMICAL
),1258,O
",",1258,O
thiobarbituric,1258,B-CHEMICAL
acid,1258,I-CHEMICAL
reactive,1258,O
substance,1258,O
(,1258,O
TBARS,1258,O
),1258,O
",",1258,O
protein,1258,O
carbonyl,1258,O
(,1258,O
PC,1258,O
),1258,O
",",1258,O
ATP,1258,B-CHEMICAL
",",1258,O
NADH-ubiquinone,1258,B-GENE-N
oxidoreductase,1258,I-GENE-N
(,1258,O
complex-I,1258,B-GENE-N
),1258,O
",",1258,O
NADH-cytochrome,1258,B-GENE-N
c,1258,I-GENE-N
oxidoreductase,1258,I-GENE-N
(,1258,O
complex,1258,B-GENE-N
I/II,1258,I-GENE-N
),1258,O
",",1258,O
succinate-cytochrome,1258,B-GENE-N
c,1258,I-GENE-N
oxidoreductase,1258,I-GENE-N
(,1258,O
complex,1258,B-GENE-N
II/III,1258,I-GENE-N
),1258,O
and,1258,O
mitochondrial,1258,O
membrane,1258,O
potential,1258,O
(,1258,O
MMP,1258,O
),1258,O
were,1258,O
studied,1258,O
in,1258,O
mitochondria,1258,O
isolated,1258,O
from,1258,O
liver,1258,O
of,1258,O
mice,1258,O
belonging,1258,O
to,1258,O
various,1258,O
treatment,1258,O
groups,1258,O
.,1258,O
Whole,1259,O
body,1259,O
y-irradiation,1259,O
(,1259,O
10,1259,O
Gy,1259,O
),1259,O
significantly,1259,O
(,1259,O
p,1259,O
<,1259,O
0.01,1259,O
),1259,O
increased,1259,O
the,1259,O
formation,1259,O
of,1259,O
O2-,1259,B-CHEMICAL
",",1259,O
PC,1259,O
",",1259,O
and,1259,O
TBARS,1259,O
",",1259,O
upto,1259,O
24,1259,O
h,1259,O
as,1259,O
compared,1259,O
to,1259,O
untreated,1259,O
control,1259,O
.,1259,O
RP-1,1260,O
treatment,1260,O
(,1260,O
200,1260,O
mg/kg,1260,O
b.w,1260,O
.,1260,O
),1260,O
to,1261,O
mice,1261,O
2,1261,O
h,1261,O
before,1261,O
irradiation,1261,O
reduced,1261,O
the,1261,O
radiation-induced,1261,O
O2-,1261,B-CHEMICAL
generation,1261,O
within,1261,O
4,1261,O
h,1261,O
and,1261,O
formation,1261,O
of,1261,O
TBARS,1261,O
and,1261,O
PC,1261,O
upto,1261,O
24,1261,O
h,1261,O
significantly,1261,O
(,1261,O
p,1261,O
<,1261,O
0.01,1261,O
),1261,O
.,1261,O
Singularly,1262,O
irradiation,1262,O
or,1262,O
RP-1,1262,O
treatment,1262,O
significantly,1262,O
(,1262,O
p,1262,O
<,1262,O
0.01,1262,O
),1262,O
increased,1262,O
the,1262,O
levels,1262,O
of,1262,O
glutathione,1262,B-CHEMICAL
within,1262,O
an,1262,O
hour,1262,O
",",1262,O
as,1262,O
compared,1262,O
to,1262,O
untreated,1262,O
control,1262,O
.,1262,O
Pre-irradiation,1263,O
administration,1263,O
of,1263,O
RP-1,1263,O
enhanced,1263,O
levels,1263,O
of,1263,O
GSH,1263,B-CHEMICAL
induced,1263,O
increase,1263,O
in,1263,O
complex,1263,B-GENE-N
I,1263,I-GENE-N
(,1263,O
upto,1263,O
16,1263,O
h,1263,O
),1263,O
",",1263,O
complex,1263,B-GENE-N
I/III,1263,I-GENE-N
(,1263,O
4,1263,O
h,1263,O
),1263,O
complex,1263,B-GENE-N
II/III,1263,I-GENE-N
activity,1263,O
(,1263,O
upto,1263,O
24,1263,O
h,1263,O
;,1263,O
p,1263,O
<,1263,O
0.01,1263,O
),1263,O
and,1263,O
inhibited,1263,O
the,1263,O
radiation-induced,1263,O
decrease,1263,O
in,1263,O
MMP,1263,O
significantly,1263,O
(,1263,O
24,1263,O
h,1263,O
;,1263,O
p,1263,O
<,1263,O
0.01,1263,O
),1263,O
.,1263,O
The,1264,O
present,1264,O
study,1264,O
indicates,1264,O
that,1264,O
RP-1,1264,O
itself,1264,O
modulates,1264,O
several,1264,O
mitichondrial,1264,O
perameters,1264,O
due,1264,O
to,1264,O
its,1264,O
influence,1264,O
on,1264,O
the,1264,O
biochemical,1264,O
milieu,1264,O
within,1264,O
and,1264,O
outside,1264,O
the,1264,O
cells,1264,O
.,1264,O
However,1265,O
",",1265,O
RP-1,1265,O
treatment,1265,O
before,1265,O
irradiation,1265,O
modulates,1265,O
radiation,1265,O
induced,1265,O
perturbations,1265,O
such,1265,O
as,1265,O
the,1265,O
increase,1265,O
in,1265,O
electron,1265,O
transport,1265,O
chain,1265,O
enzyme,1265,O
activity,1265,O
",",1265,O
formation,1265,O
of,1265,O
O2-,1265,B-CHEMICAL
",",1265,O
TBARS,1265,O
and,1265,O
PC,1265,O
to,1265,O
offer,1265,O
radioprotection,1265,O
.,1265,O
Effects,1266,O
of,1266,O
minocycline,1266,B-CHEMICAL
on,1266,O
Fas-mediated,1266,B-GENE-Y
fulminant,1266,O
hepatitis,1266,O
in,1266,O
mice,1266,O
.,1266,O
1,1267,O
.,1267,O
Minocycline,1268,B-CHEMICAL
has,1268,O
anti-inflammatory,1268,O
and,1268,O
antiapoptotic,1268,O
effects,1268,O
on,1268,O
cartilage,1268,O
",",1268,O
neurons,1268,O
and,1268,O
periodontal,1268,O
tissues,1268,O
",",1268,O
and,1268,O
both,1268,O
properties,1268,O
are,1268,O
central,1268,O
to,1268,O
the,1268,O
pharmaceutical,1268,O
treatment,1268,O
of,1268,O
liver,1268,O
diseases,1268,O
.,1268,O
We,1269,O
investigated,1269,O
the,1269,O
effects,1269,O
of,1269,O
minocycline,1269,B-CHEMICAL
on,1269,O
fulminant,1269,O
hepatitis,1269,O
in,1269,O
C57BL/6J,1269,O
mice,1269,O
induced,1269,O
by,1269,O
lethal,1269,O
challenge,1269,O
of,1269,O
the,1269,O
activating,1269,O
anti-Fas,1269,O
antibody,1269,O
",",1269,O
Jo2,1269,O
.,1269,O
2,1270,O
.,1270,O
Intraperitoneal,1271,O
injection,1271,O
of,1271,O
Jo2,1271,O
(,1271,O
0.6,1271,O
microg,1271,O
g,1271,O
(,1271,O
-1,1271,O
),1271,O
),1271,O
to,1271,O
mice,1271,O
resulted,1271,O
in,1271,O
fulminant,1271,O
hepatitis,1271,O
",",1271,O
as,1271,O
evidenced,1271,O
by,1271,O
increase,1271,O
of,1271,O
serum,1271,B-GENE-N
alanine/aspartate,1271,B-CHEMICAL
transaminase,1271,I-GENE-N
activities,1271,O
and,1271,O
histopathological,1271,O
alterations,1271,O
in,1271,O
liver,1271,O
sections,1271,O
",",1271,O
as,1271,O
well,1271,O
as,1271,O
animal,1271,O
death,1271,O
.,1271,O
Nevertheless,1272,O
",",1272,O
mice,1272,O
pretreated,1272,O
with,1272,O
three,1272,O
doses,1272,O
of,1272,O
minocycline,1272,B-CHEMICAL
(,1272,O
5,1272,O
mg,1272,O
kg,1272,O
(,1272,O
-1,1272,O
),1272,O
),1272,O
resisted,1272,O
this,1272,O
lethal,1272,O
effect,1272,O
significantly,1272,O
.,1272,O
Minocycline,1273,B-CHEMICAL
treatment,1273,O
improved,1273,O
the,1273,O
survival,1273,O
kinetics,1273,O
",",1273,O
although,1273,O
to,1273,O
a,1273,O
lesser,1273,O
extent,1273,O
",",1273,O
when,1273,O
mice,1273,O
were,1273,O
challenged,1273,O
simultaneously,1273,O
with,1273,O
Jo2,1273,O
or,1273,O
even,1273,O
treated,1273,O
30,1273,O
min,1273,O
after,1273,O
the,1273,O
lethal,1273,O
challenge,1273,O
.,1273,O
3,1274,O
.,1274,O
Jo2-induced,1275,O
activation,1275,O
of,1275,O
caspase-3,1275,B-GENE-N
or,1275,I-GENE-N
-9,1275,I-GENE-N
in,1275,O
liver,1275,O
tissues,1275,O
was,1275,O
inhibited,1275,O
by,1275,O
minocycline,1275,B-CHEMICAL
pretreatment,1275,O
",",1275,O
and,1275,O
yet,1275,O
the,1275,O
direct,1275,O
addition,1275,O
of,1275,O
minocycline,1275,B-CHEMICAL
to,1275,O
liver,1275,O
extracts,1275,O
from,1275,O
Jo2-challenged,1275,O
mice,1275,O
failed,1275,O
to,1275,O
block,1275,O
caspase,1275,B-GENE-N
activation,1275,O
in,1275,O
vitro,1275,O
.,1275,O
Moreover,1276,O
",",1276,O
minocycline,1276,B-CHEMICAL
efficiently,1276,O
suppressed,1276,O
the,1276,O
release,1276,O
of,1276,O
cytochrome,1276,B-GENE-Y
c,1276,I-GENE-Y
from,1276,O
mitochondria,1276,O
of,1276,O
the,1276,O
liver,1276,O
tissues,1276,O
from,1276,O
Jo2-challenged,1276,O
mice,1276,O
.,1276,O
In,1277,O
contrast,1277,O
",",1277,O
caspase-8,1277,B-GENE-Y
activation,1277,O
and,1277,O
Bid,1277,B-GENE-Y
truncation,1277,O
triggered,1277,O
by,1277,O
Jo2,1277,O
were,1277,O
not,1277,O
diminished,1277,O
by,1277,O
minocycline,1277,B-CHEMICAL
pretreatment,1277,O
in,1277,O
mouse,1277,O
livers,1277,O
.,1277,O
4,1278,O
.,1278,O
Our,1279,O
results,1279,O
suggest,1279,O
that,1279,O
easing,1279,O
of,1279,O
Fas-triggered,1279,B-GENE-Y
fulminant,1279,O
hepatitis,1279,O
by,1279,O
minocycline,1279,B-CHEMICAL
may,1279,O
involve,1279,O
a,1279,O
mitochondrial,1279,O
apoptotic,1279,O
pathway,1279,O
",",1279,O
probably,1279,O
through,1279,O
preventing,1279,O
cytochrome,1279,B-GENE-Y
c,1279,I-GENE-Y
release,1279,O
and,1279,O
thereby,1279,O
blocking,1279,O
downstream,1279,O
caspase,1279,B-GENE-N
activation,1279,O
.,1279,O
Role,1280,O
of,1280,O
hydrogen,1280,B-CHEMICAL
sulfide,1280,I-CHEMICAL
in,1280,O
acute,1280,O
pancreatitis,1280,O
and,1280,O
associated,1280,O
lung,1280,O
injury,1280,O
.,1280,O
Hydrogen,1281,B-CHEMICAL
sulfide,1281,I-CHEMICAL
(,1281,O
H2S,1281,B-CHEMICAL
),1281,O
is,1281,O
a,1281,O
naturally,1281,O
occurring,1281,O
gas,1281,O
with,1281,O
potent,1281,O
vasodilator,1281,O
activity,1281,O
.,1281,O
Cystathionine-gamma-lyase,1282,B-GENE-Y
(,1282,O
CSE,1282,B-GENE-Y
),1282,O
and,1282,O
cystathionine-beta-synthase,1282,B-CHEMICAL
(,1282,O
CBS,1282,B-GENE-Y
),1282,O
utilize,1282,O
L-cysteine,1282,B-CHEMICAL
as,1282,O
substrate,1282,O
to,1282,O
form,1282,O
H2S,1282,B-CHEMICAL
.,1282,O
Of,1283,O
these,1283,O
two,1283,O
enzymes,1283,O
",",1283,O
cystathionine-gamma-lyase,1283,B-GENE-Y
(,1283,O
CSE,1283,B-GENE-Y
),1283,O
is,1283,O
believed,1283,O
to,1283,O
be,1283,O
the,1283,O
key,1283,O
enzyme,1283,O
that,1283,O
forms,1283,O
H2S,1283,B-CHEMICAL
in,1283,O
the,1283,O
cardiovascular,1283,O
system,1283,O
.,1283,O
Whilst,1284,O
H2S,1284,B-CHEMICAL
has,1284,O
been,1284,O
reported,1284,O
to,1284,O
relax,1284,O
precontracted,1284,O
rat,1284,O
arteries,1284,O
in,1284,O
vitro,1284,O
and,1284,O
to,1284,O
lower,1284,O
blood,1284,O
pressure,1284,O
in,1284,O
the,1284,O
rat,1284,O
",",1284,O
its,1284,O
effect,1284,O
in,1284,O
an,1284,O
inflammatory,1284,O
condition,1284,O
such,1284,O
as,1284,O
acute,1284,O
pancreatitis,1284,O
has,1284,O
not,1284,O
previously,1284,O
been,1284,O
reported,1284,O
.,1284,O
In,1285,O
this,1285,O
paper,1285,O
",",1285,O
we,1285,O
report,1285,O
the,1285,O
presence,1285,O
of,1285,O
H2S,1285,B-CHEMICAL
synthesizing,1285,O
enzyme,1285,O
activity,1285,O
and,1285,O
CSE,1285,B-GENE-Y
(,1285,O
as,1285,O
determined,1285,O
by,1285,O
mRNA,1285,O
signal,1285,O
),1285,O
in,1285,O
the,1285,O
pancreas,1285,O
.,1285,O
Also,1286,O
",",1286,O
prophylactic,1286,O
",",1286,O
as,1286,O
well,1286,O
as,1286,O
therapeutic,1286,O
",",1286,O
treatment,1286,O
with,1286,O
the,1286,O
CSE,1286,B-GENE-Y
inhibitor,1286,O
",",1286,O
DL-propargylglycine,1286,B-CHEMICAL
(,1286,O
PAG,1286,B-CHEMICAL
),1286,O
",",1286,O
significantly,1286,O
reduced,1286,O
the,1286,O
severity,1286,O
of,1286,O
caerulein-induced,1286,B-CHEMICAL
pancreatitis,1286,O
and,1286,O
associated,1286,O
lung,1286,O
injury,1286,O
",",1286,O
as,1286,O
determined,1286,O
by,1286,O
1,1286,O
),1286,O
hyperamylasemia,1286,O
[,1286,O
plasma,1286,O
amylase,1286,B-GENE-N
(,1286,O
U/L,1286,O
),1286,O
(,1286,O
control,1286,O
",",1286,O
1204+/-59,1286,O
),1286,O
;,1286,O
prophylactic,1286,O
treatment,1286,O
:,1286,O
placebo,1286,O
",",1286,O
10635+/-305,1286,O
;,1286,O
PAG,1286,B-CHEMICAL
",",1286,O
7904+/-495,1286,O
;,1286,O
therapeutic,1286,O
treatment,1286,O
:,1286,O
placebo,1286,O
",",1286,O
10427+/-470,1286,O
;,1286,O
PAG,1286,B-CHEMICAL
",",1286,O
7811+/-428,1286,O
;,1286,O
P,1286,O
<,1286,O
0.05,1286,O
PAG,1286,B-CHEMICAL
c.f,1286,O
.,1286,O
placebo,1287,O
;,1287,O
n=24,1287,O
animals,1287,O
in,1287,O
each,1287,O
group,1287,O
],1287,O
;,1287,O
2,1287,O
),1287,O
neutrophil,1287,O
sequestration,1287,O
in,1287,O
the,1287,O
pancreas,1287,O
[,1287,O
pancreatic,1287,O
myeloperoxidase,1287,B-GENE-Y
oxidase,1287,I-GENE-Y
(,1287,O
MPO,1287,B-GENE-Y
),1287,O
activity,1287,O
(,1287,O
fold,1287,O
increase,1287,O
over,1287,O
control,1287,O
),1287,O
(,1287,O
prophylactic,1287,O
treatment,1287,O
:,1287,O
placebo,1287,O
",",1287,O
5.78+/-0.63,1287,O
;,1287,O
PAG,1287,B-CHEMICAL
",",1287,O
2.97+/-0.39,1287,O
;,1287,O
therapeutic,1287,O
treatment,1287,O
:,1287,O
placebo,1287,O
",",1287,O
5.48+/-0.52,1287,O
;,1287,O
PAG,1287,B-CHEMICAL
",",1287,O
3.03+/-0.47,1287,O
;,1287,O
P,1287,O
<,1287,O
0.05,1287,O
PAG,1287,B-CHEMICAL
c.f,1287,O
.,1287,O
placebo,1288,O
;,1288,O
n=24,1288,O
animals,1288,O
in,1288,O
each,1288,O
group,1288,O
),1288,O
],1288,O
;,1288,O
3,1288,O
),1288,O
pancreatic,1288,O
acinar,1288,O
cell,1288,O
injury/necrosis,1288,O
;,1288,O
4,1288,O
),1288,O
lung,1288,O
MPO,1288,O
activity,1288,O
(,1288,O
fold,1288,O
increase,1288,O
over,1288,O
control,1288,O
),1288,O
[,1288,O
prophylactic,1288,O
treatment,1288,O
:,1288,O
placebo,1288,O
",",1288,O
1.99+/-0.16,1288,O
;,1288,O
PAG,1288,B-CHEMICAL
",",1288,O
1.34+/-0.14,1288,O
;,1288,O
therapeutic,1288,O
treatment,1288,O
:,1288,O
placebo,1288,O
",",1288,O
2.03+/-0.12,1288,O
;,1288,O
PAG,1288,B-CHEMICAL
",",1288,O
1.41+/-0.97,1288,O
;,1288,O
P,1288,O
<,1288,O
0.05,1288,O
PAG,1288,B-CHEMICAL
c.f,1288,O
.,1288,O
placebo,1289,O
;,1289,O
n=24,1289,O
animals,1289,O
in,1289,O
each,1289,O
group,1289,O
],1289,O
;,1289,O
and,1289,O
5,1289,O
),1289,O
histological,1289,O
evidence,1289,O
of,1289,O
lung,1289,O
injury,1289,O
.,1289,O
These,1290,O
effects,1290,O
of,1290,O
CSE,1290,B-GENE-Y
blockade,1290,O
suggest,1290,O
an,1290,O
important,1290,O
proinflammatory,1290,O
role,1290,O
of,1290,O
H2S,1290,B-CHEMICAL
in,1290,O
regulating,1290,O
the,1290,O
severity,1290,O
of,1290,O
pancreatitis,1290,O
and,1290,O
associated,1290,O
lung,1290,O
injury,1290,O
and,1290,O
raise,1290,O
the,1290,O
possibility,1290,O
that,1290,O
H2S,1290,B-CHEMICAL
may,1290,O
exert,1290,O
similar,1290,O
activity,1290,O
in,1290,O
other,1290,O
forms,1290,O
of,1290,O
inflammation,1290,O
.,1290,O
Atypical,1291,O
and,1291,O
typical,1291,O
antipsychotic,1291,O
drug,1291,O
interactions,1291,O
with,1291,O
the,1291,O
dopamine,1291,B-GENE-Y
D2,1291,I-GENE-Y
receptor,1291,I-GENE-Y
.,1291,O
A,1292,O
model,1292,O
of,1292,O
the,1292,O
dopamine,1292,B-CHEMICAL
D2,1292,I-GENE-Y
receptor,1292,I-GENE-Y
was,1292,O
used,1292,O
to,1292,O
study,1292,O
the,1292,O
receptor,1292,O
interactions,1292,O
of,1292,O
dopamine,1292,B-CHEMICAL
",",1292,O
the,1292,O
typical,1292,O
antipsychotics,1292,O
haloperidol,1292,B-CHEMICAL
and,1292,O
loxapine,1292,B-CHEMICAL
",",1292,O
and,1292,O
the,1292,O
atypical,1292,O
antipsychotics,1292,O
clozapine,1292,B-CHEMICAL
and,1292,O
melperone,1292,B-CHEMICAL
.,1292,O
The,1293,O
atypical,1293,O
antipsychotics,1293,O
interacted,1293,O
with,1293,O
the,1293,O
halogen,1293,B-CHEMICAL
atom,1293,O
of,1293,O
the,1293,O
ring,1293,O
system,1293,O
in,1293,O
the,1293,O
direction,1293,O
of,1293,O
the,1293,O
transmembrane,1293,O
helices,1293,O
(,1293,O
TMHs,1293,O
),1293,O
2,1293,O
",",1293,O
3,1293,O
and,1293,O
7,1293,O
",",1293,O
while,1293,O
the,1293,O
typical,1293,O
had,1293,O
the,1293,O
corresponding,1293,O
halogen,1293,B-CHEMICAL
atom,1293,O
in,1293,O
the,1293,O
direction,1293,O
of,1293,O
TMH5,1293,O
.,1293,O
Molecular,1294,O
dynamics,1294,O
simulations,1294,O
indicated,1294,O
that,1294,O
the,1294,O
average,1294,O
helical,1294,O
displacement,1294,O
upon,1294,O
binding,1294,O
increased,1294,O
in,1294,O
the,1294,O
order,1294,O
:,1294,O
typical,1294,O
<,1294,O
atypical,1294,O
<,1294,O
dopamine,1294,B-CHEMICAL
.,1294,O
Upon,1295,O
binding,1295,O
",",1295,O
the,1295,O
atypical,1295,O
induced,1295,O
larger,1295,O
displacements,1295,O
into,1295,O
TMH5,1295,O
than,1295,O
did,1295,O
the,1295,O
typical,1295,O
.,1295,O
The,1296,O
typical,1296,O
had,1296,O
stronger,1296,O
non-bonded,1296,O
interactions,1296,O
with,1296,O
the,1296,O
receptor,1296,O
than,1296,O
had,1296,O
the,1296,O
atypical,1296,O
",",1296,O
which,1296,O
is,1296,O
in,1296,O
agreement,1296,O
with,1296,O
the,1296,O
experimental,1296,O
observation,1296,O
that,1296,O
the,1296,O
atypical,1296,O
antipsychotic,1296,O
drugs,1296,O
dissociate,1296,O
faster,1296,O
from,1296,O
the,1296,O
receptor,1296,O
than,1296,O
the,1296,O
typical,1296,O
antipsychotic,1296,O
drugs,1296,O
.,1296,O
Pharmacokinetics,1297,O
",",1297,O
pharmacodynamics,1297,O
",",1297,O
and,1297,O
safety,1297,O
of,1297,O
exenatide,1297,O
in,1297,O
patients,1297,O
with,1297,O
type,1297,O
2,1297,O
diabetes,1297,O
mellitus,1297,O
.,1297,O
PURPOSE,1298,O
:,1298,O
The,1298,O
pharmacology,1298,O
and,1298,O
tolerability,1298,O
of,1298,O
exenatide,1298,O
in,1298,O
patients,1298,O
with,1298,O
type,1298,O
2,1298,O
diabetes,1298,O
mellitus,1298,O
were,1298,O
studied,1298,O
.,1298,O
METHODS,1299,O
:,1299,O
Two,1299,O
randomized,1299,O
",",1299,O
single-blind,1299,O
",",1299,O
placebo-controlled,1299,O
studies,1299,O
were,1299,O
conducted,1299,O
.,1299,O
Treatment,1300,O
with,1300,O
oral,1300,O
antidiabetic,1300,O
agents,1300,O
was,1300,O
stopped,1300,O
14,1300,O
days,1300,O
before,1300,O
study,1300,O
initiation,1300,O
.,1300,O
In,1301,O
the,1301,O
first,1301,O
study,1301,O
(,1301,O
study,1301,O
A,1301,O
),1301,O
",",1301,O
eight,1301,O
subjects,1301,O
received,1301,O
placebo,1301,O
",",1301,O
0.1-,1301,O
",",1301,O
0.2-,1301,O
",",1301,O
0.3-,1301,O
",",1301,O
and,1301,O
either,1301,O
0.4-microg/kg,1301,O
exenatide,1301,O
or,1301,O
placebo,1301,O
five,1301,O
minutes,1301,O
before,1301,O
a,1301,O
meal,1301,O
combined,1301,O
with,1301,O
liquid,1301,O
acetaminophen,1301,B-CHEMICAL
(,1301,O
to,1301,O
assess,1301,O
the,1301,O
rate,1301,O
of,1301,O
gastric,1301,O
emptying,1301,O
),1301,O
on,1301,O
days,1301,O
1,1301,O
",",1301,O
3,1301,O
",",1301,O
5,1301,O
",",1301,O
7,1301,O
",",1301,O
and,1301,O
9,1301,O
.,1301,O
In,1302,O
the,1302,O
second,1302,O
study,1302,O
(,1302,O
study,1302,O
B,1302,O
),1302,O
",",1302,O
subjects,1302,O
received,1302,O
a,1302,O
single,1302,O
s.c.,1302,O
dose,1302,O
of,1302,O
exenatide,1302,O
or,1302,O
placebo,1302,O
on,1302,O
consecutive,1302,O
days,1302,O
.,1302,O
Part,1303,O
1,1303,O
of,1303,O
study,1303,O
B,1303,O
used,1303,O
exenatide,1303,O
doses,1303,O
of,1303,O
0.01,1303,O
and,1303,O
0.1,1303,O
microg/,1303,O
kg,1303,O
;,1303,O
0.02-,1303,O
",",1303,O
0.05-,1303,O
",",1303,O
and,1303,O
0.1-microg/kg,1303,O
doses,1303,O
were,1303,O
given,1303,O
in,1303,O
part,1303,O
2,1303,O
.,1303,O
After,1304,O
an,1304,O
overnight,1304,O
fast,1304,O
",",1304,O
the,1304,O
study,1304,O
drug,1304,O
was,1304,O
injected,1304,O
15,1304,O
minutes,1304,O
before,1304,O
a,1304,O
meal,1304,O
(,1304,O
part,1304,O
1,1304,O
),1304,O
and,1304,O
before,1304,O
a,1304,O
meal,1304,O
and,1304,O
acetaminophen,1304,B-CHEMICAL
(,1304,O
part,1304,O
2,1304,O
),1304,O
.,1304,O
Parts,1305,O
1,1305,O
and,1305,O
2,1305,O
of,1305,O
study,1305,O
B,1305,O
enrolled,1305,O
six,1305,O
and,1305,O
eight,1305,O
patients,1305,O
",",1305,O
respectively,1305,O
.,1305,O
RESULTS,1306,O
:,1306,O
In,1306,O
both,1306,O
studies,1306,O
",",1306,O
plasma,1306,O
exenatide,1306,O
pharmacokinetic,1306,O
profiles,1306,O
appeared,1306,O
dose,1306,O
proportional,1306,O
.,1306,O
Exenatide,1307,O
doses,1307,O
of,1307,O
0.02-0.2,1307,O
microg/kg,1307,O
dose-dependently,1307,O
lowered,1307,O
postprandial,1307,O
glucose,1307,B-CHEMICAL
excursions,1307,O
.,1307,O
Exenatide,1308,O
suppressed,1308,O
postprandial,1308,O
plasma,1308,O
glucagon,1308,B-GENE-Y
and,1308,O
slowed,1308,O
gastric,1308,O
emptying,1308,O
.,1308,O
There,1309,O
were,1309,O
no,1309,O
serious,1309,O
adverse,1309,O
events,1309,O
and,1309,O
no,1309,O
patient,1309,O
withdrawals,1309,O
related,1309,O
to,1309,O
treatment,1309,O
.,1309,O
Nausea,1310,O
and,1310,O
vomiting,1310,O
were,1310,O
the,1310,O
most,1310,O
common,1310,O
adverse,1310,O
events,1310,O
and,1310,O
were,1310,O
mild,1310,O
to,1310,O
moderate,1310,O
in,1310,O
severity,1310,O
at,1310,O
doses,1310,O
ranging,1310,O
from,1310,O
0.02,1310,O
to,1310,O
0.2,1310,O
microg/kg,1310,O
.,1310,O
CONCLUSION,1311,O
:,1311,O
Administration,1311,O
of,1311,O
preprandial,1311,O
exenatide,1311,O
by,1311,O
s.c.,1311,O
injection,1311,O
resulted,1311,O
in,1311,O
dose-proportional,1311,O
exenatide,1311,O
pharmacokinetics,1311,O
and,1311,O
antidiabetic,1311,O
pharmacodynamic,1311,O
activity,1311,O
.,1311,O
At,1312,O
doses,1312,O
ranging,1312,O
from,1312,O
0.02,1312,O
to,1312,O
0.2,1312,O
microg/kg,1312,O
",",1312,O
exenatide,1312,O
dose-dependently,1312,O
reduced,1312,O
postprandial,1312,O
plasma,1312,O
glucose,1312,B-CHEMICAL
excursion,1312,O
by,1312,O
insulinotropism,1312,O
",",1312,O
suppression,1312,O
of,1312,O
plasma,1312,O
glucagon,1312,B-GENE-Y
",",1312,O
and,1312,O
slowing,1312,O
of,1312,O
gastric,1312,O
emptying,1312,O
.,1312,O
Sterol,1313,B-GENE-N
transporters,1313,I-GENE-N
:,1313,O
targets,1313,O
of,1313,O
natural,1313,O
sterols,1313,B-CHEMICAL
and,1313,O
new,1313,O
lipid,1313,O
lowering,1313,O
drugs,1313,O
.,1313,O
Recent,1314,O
insights,1314,O
in,1314,O
the,1314,O
role,1314,O
of,1314,O
ATP-binding,1314,B-GENE-N
cassette,1314,I-GENE-N
(,1314,I-GENE-N
ABC,1314,I-GENE-N
),1314,I-GENE-N
transporters,1314,I-GENE-N
ABCG5,1314,B-GENE-Y
and,1314,O
ABCG8,1314,B-GENE-Y
",",1314,O
the,1314,O
discovery,1314,O
of,1314,O
ezetimibe,1314,B-CHEMICAL
",",1314,O
the,1314,O
first,1314,O
approved,1314,O
direct,1314,O
cholesterol,1314,B-CHEMICAL
absorption,1314,O
inhibitor,1314,O
",",1314,O
as,1314,O
well,1314,O
as,1314,O
the,1314,O
identification,1314,O
of,1314,O
Niemann-Pick,1314,B-GENE-Y
C1,1314,I-GENE-Y
Like,1314,I-GENE-Y
1,1314,I-GENE-Y
(,1314,O
NPC1L1,1314,B-GENE-Y
),1314,O
protein,1314,O
as,1314,O
sterol,1314,B-CHEMICAL
transporter,1314,O
in,1314,O
the,1314,O
gut,1314,O
",",1314,O
focused,1314,O
attention,1314,O
on,1314,O
sterol,1314,B-CHEMICAL
transport,1314,O
processes,1314,O
in,1314,O
the,1314,O
small,1314,O
intestine,1314,O
and,1314,O
the,1314,O
liver,1314,O
.,1314,O
The,1315,O
identification,1315,O
of,1315,O
defective,1315,O
structures,1315,O
in,1315,O
the,1315,O
ABCG5,1315,B-GENE-Y
or,1315,O
ABCG8,1315,B-GENE-Y
transporters,1315,O
in,1315,O
patients,1315,O
with,1315,O
the,1315,O
rare,1315,O
disease,1315,O
of,1315,O
sitosterolemia,1315,O
elucidated,1315,O
their,1315,O
role,1315,O
as,1315,O
sterol,1315,B-GENE-N
efflux,1315,I-GENE-N
pumps,1315,I-GENE-N
regulating,1315,O
at,1315,O
least,1315,O
in,1315,O
parts,1315,O
the,1315,O
intestinal,1315,O
sterol,1315,B-CHEMICAL
absorption,1315,O
and,1315,O
the,1315,O
hepatic,1315,O
sterol,1315,B-CHEMICAL
output,1315,O
.,1315,O
ABCG5,1316,B-GENE-Y
and,1316,O
ABCG8,1316,B-GENE-Y
themselves,1316,O
are,1316,O
regulated,1316,O
by,1316,O
cholesterol,1316,B-CHEMICAL
via,1316,O
liver,1316,B-GENE-N
X,1316,I-GENE-N
receptors,1316,I-GENE-N
(,1316,O
LXRs,1316,B-GENE-N
),1316,O
",",1316,O
which,1316,O
are,1316,O
also,1316,O
activated,1316,O
by,1316,O
oxysterols,1316,O
and,1316,O
some,1316,O
derivatives,1316,O
of,1316,O
plant,1316,O
sterols,1316,B-CHEMICAL
.,1316,O
NPC1L1,1317,B-GENE-Y
could,1317,O
recently,1317,O
be,1317,O
identified,1317,O
as,1317,O
a,1317,O
major,1317,O
sterol,1317,B-GENE-N
transporter,1317,I-GENE-N
for,1317,O
the,1317,O
intestinal,1317,O
uptake,1317,O
of,1317,O
cholesterol,1317,B-CHEMICAL
as,1317,O
well,1317,O
as,1317,O
plant,1317,O
sterols,1317,B-CHEMICAL
.,1317,O
Studies,1318,O
in,1318,O
NPC1L1,1318,B-GENE-Y
knockout,1318,O
mice,1318,O
indicate,1318,O
that,1318,O
this,1318,O
transporter,1318,O
is,1318,O
essential,1318,O
for,1318,O
the,1318,O
intestinal,1318,O
uptake,1318,O
of,1318,O
sterols,1318,B-CHEMICAL
and,1318,O
that,1318,O
NPC1L1,1318,B-GENE-Y
might,1318,O
also,1318,O
be,1318,O
involved,1318,O
in,1318,O
the,1318,O
mechanism,1318,O
of,1318,O
action,1318,O
of,1318,O
ezetimibe,1318,B-CHEMICAL
.,1318,O
However,1319,O
",",1319,O
studies,1319,O
with,1319,O
photoreactive,1319,O
cholesterol,1319,B-CHEMICAL
as,1319,O
well,1319,O
as,1319,O
with,1319,O
photoreactive,1319,O
ezetimibe,1319,B-CHEMICAL
analogues,1319,O
suggest,1319,O
that,1319,O
other,1319,O
processes,1319,O
might,1319,O
also,1319,O
be,1319,O
involved,1319,O
in,1319,O
the,1319,O
mechanism,1319,O
of,1319,O
action,1319,O
of,1319,O
ezetimibe,1319,B-CHEMICAL
.,1319,O
[,1320,O
Change,1320,O
of,1320,O
dopamine,1320,B-CHEMICAL
transporter,1320,I-GENE-Y
activity,1320,O
(,1320,O
DAT,1320,B-GENE-Y
),1320,O
during,1320,O
the,1320,O
action,1320,O
of,1320,O
bupropion,1320,B-CHEMICAL
(,1320,O
in,1320,O
depression,1320,O
),1320,O
],1320,O
.,1320,O
Bupropion,1321,B-CHEMICAL
has,1321,O
an,1321,O
antidepressant,1321,O
effect,1321,O
through,1321,O
blocking,1321,O
the,1321,O
dopamine,1321,B-CHEMICAL
transporter,1321,I-GENE-Y
.,1321,O
By,1322,O
99mTc-TRODAT-SPECT,1322,O
",",1322,O
we,1322,O
measured,1322,O
the,1322,O
baseline,1322,O
DAT,1322,B-GENE-Y
activity,1322,O
of,1322,O
depressed,1322,O
patients,1322,O
.,1322,O
After,1323,O
3,1323,O
weeks,1323,O
',1323,O
bupropion,1323,B-CHEMICAL
treatment,1323,O
we,1323,O
studied,1323,O
the,1323,O
change,1323,O
in,1323,O
DAT,1323,B-GENE-Y
activity,1323,O
",",1323,O
which,1323,O
corresponds,1323,O
to,1323,O
the,1323,O
occupancy,1323,O
of,1323,O
bupropion,1323,B-CHEMICAL
.,1323,O
The,1324,O
average,1324,O
occupancy,1324,O
of,1324,O
bupropion,1324,B-CHEMICAL
on,1324,O
DAT,1324,B-GENE-Y
was,1324,O
similar,1324,O
to,1324,O
the,1324,O
international,1324,O
findings,1324,O
at,1324,O
20.84,1324,O
%,1324,O
in,1324,O
9,1324,O
depressed,1324,O
patients,1324,O
.,1324,O
A,1325,O
phase-1,1325,O
trial,1325,O
of,1325,O
bexarotene,1325,B-CHEMICAL
and,1325,O
denileukin,1325,O
diftitox,1325,O
in,1325,O
patients,1325,O
with,1325,O
relapsed,1325,O
or,1325,O
refractory,1325,O
cutaneous,1325,O
T-cell,1325,O
lymphoma,1325,O
.,1325,O
Denileukin,1326,O
diftitox,1326,O
",",1326,O
a,1326,O
genetically,1326,O
engineered,1326,O
fusion,1326,O
protein,1326,O
combining,1326,O
the,1326,O
enzymatically,1326,O
active,1326,O
domains,1326,O
of,1326,O
diphtheria,1326,O
toxin,1326,O
and,1326,O
the,1326,O
full-length,1326,O
sequence,1326,O
for,1326,O
interleukin-2,1326,B-GENE-Y
(,1326,O
IL-2,1326,B-GENE-Y
),1326,O
",",1326,O
efficiently,1326,O
targets,1326,O
lymphoma,1326,O
cells,1326,O
expressing,1326,O
the,1326,O
high-affinity,1326,O
IL-2,1326,B-GENE-N
receptor,1326,I-GENE-N
(,1326,O
IL-2R,1326,B-GENE-N
),1326,O
consisting,1326,O
of,1326,O
the,1326,O
alpha/p55/CD25,1326,O
",",1326,O
beta/p75/CD122,1326,O
",",1326,O
and,1326,O
gamma/p64/CD132,1326,O
chains,1326,O
.,1326,O
In,1327,O
vitro,1327,O
studies,1327,O
demonstrated,1327,O
that,1327,O
the,1327,O
retinoid,1327,B-GENE-N
X,1327,I-GENE-N
receptor,1327,I-GENE-N
(,1327,O
RXR,1327,B-GENE-N
),1327,O
retinoid,1327,O
",",1327,O
bexarotene,1327,B-CHEMICAL
",",1327,O
at,1327,O
biologically,1327,O
relevant,1327,O
concentrations,1327,O
of,1327,O
10,1327,O
(,1327,O
-6,1327,O
),1327,O
M,1327,O
to,1327,O
10,1327,O
(,1327,O
-8,1327,O
),1327,O
M,1327,O
",",1327,O
upregulated,1327,O
both,1327,O
the,1327,O
p55,1327,B-GENE-Y
and,1327,O
p75,1327,B-GENE-Y
subunits,1327,O
of,1327,O
the,1327,O
IL-2R,1327,B-GENE-N
and,1327,O
enhanced,1327,O
5-,1327,O
to,1327,O
10-fold,1327,O
the,1327,O
susceptibility,1327,O
of,1327,O
T-cell,1327,O
leukemia,1327,O
cells,1327,O
to,1327,O
denileukin,1327,O
diftitox,1327,O
.,1327,O
To,1328,O
determine,1328,O
whether,1328,O
this,1328,O
biomodulatory,1328,O
effect,1328,O
could,1328,O
be,1328,O
recapitulated,1328,O
in,1328,O
vivo,1328,O
",",1328,O
we,1328,O
treated,1328,O
14,1328,O
patients,1328,O
with,1328,O
relapsed,1328,O
or,1328,O
refractory,1328,O
cutaneous,1328,O
T-cell,1328,O
lymphoma,1328,O
with,1328,O
escalating,1328,O
doses,1328,O
of,1328,O
bexarotene,1328,B-CHEMICAL
(,1328,O
75,1328,O
mg/day-300,1328,O
mg/day,1328,O
),1328,O
and,1328,O
denileukin,1328,O
diftitox,1328,O
(,1328,O
18,1328,O
mcg/kg,1328,O
per,1328,O
day,1328,O
x,1328,O
3,1328,O
days,1328,O
every,1328,O
21,1328,O
days,1328,O
),1328,O
in,1328,O
a,1328,O
phase,1328,O
1,1328,O
trial,1328,O
.,1328,O
Overall,1329,O
response,1329,O
was,1329,O
67,1329,O
%,1329,O
(,1329,O
4,1329,O
complete,1329,O
responses,1329,O
",",1329,O
4,1329,O
partial,1329,O
responses,1329,O
),1329,O
.,1329,O
Modulation,1330,O
of,1330,O
IL-2R,1330,B-GENE-N
expression,1330,O
was,1330,O
observed,1330,O
at,1330,O
or,1330,O
above,1330,O
a,1330,O
bexarotene,1330,B-CHEMICAL
dose,1330,O
of,1330,O
150,1330,O
mg/day,1330,O
.,1330,O
Four,1331,O
patients,1331,O
experienced,1331,O
grade,1331,O
2,1331,O
or,1331,O
3,1331,O
leukopenia,1331,O
",",1331,O
and,1331,O
2,1331,O
had,1331,O
grade,1331,O
4,1331,O
lymphopenia,1331,O
.,1331,O
Our,1332,O
results,1332,O
demonstrate,1332,O
that,1332,O
the,1332,O
combination,1332,O
of,1332,O
denileukin,1332,O
diftitox,1332,O
and,1332,O
bexarotene,1332,B-CHEMICAL
is,1332,O
well,1332,O
tolerated,1332,O
and,1332,O
that,1332,O
even,1332,O
low,1332,O
doses,1332,O
(,1332,O
150,1332,O
mg/day,1332,O
),1332,O
of,1332,O
bexarotene,1332,B-CHEMICAL
are,1332,O
capable,1332,O
of,1332,O
in,1332,O
vivo,1332,O
upregulation,1332,O
of,1332,O
CD25,1332,B-GENE-Y
expression,1332,O
on,1332,O
circulating,1332,O
leukemia,1332,O
cells,1332,O
.,1332,O
Crystal,1333,O
structure,1333,O
of,1333,O
prostate-specific,1333,B-GENE-Y
membrane,1333,I-GENE-Y
antigen,1333,I-GENE-Y
",",1333,O
a,1333,O
tumor,1333,O
marker,1333,O
and,1333,O
peptidase,1333,B-GENE-N
.,1333,O
Prostate-specific,1334,B-GENE-Y
membrane,1334,I-GENE-Y
antigen,1334,I-GENE-Y
(,1334,O
PSMA,1334,B-GENE-Y
),1334,O
is,1334,O
highly,1334,O
expressed,1334,O
in,1334,O
prostate,1334,O
cancer,1334,O
cells,1334,O
and,1334,O
nonprostatic,1334,O
solid,1334,O
tumor,1334,O
neovasculature,1334,O
and,1334,O
is,1334,O
a,1334,O
target,1334,O
for,1334,O
anticancer,1334,O
imaging,1334,O
and,1334,O
therapeutic,1334,O
agents,1334,O
.,1334,O
PSMA,1335,B-GENE-Y
acts,1335,O
as,1335,O
a,1335,O
glutamate,1335,B-CHEMICAL
carboxypeptidase,1335,I-GENE-N
(,1335,O
GCPII,1335,B-GENE-Y
),1335,O
on,1335,O
small,1335,O
molecule,1335,O
substrates,1335,O
",",1335,O
including,1335,O
folate,1335,B-CHEMICAL
",",1335,O
the,1335,O
anticancer,1335,O
drug,1335,O
methotrexate,1335,B-CHEMICAL
",",1335,O
and,1335,O
the,1335,O
neuropeptide,1335,O
N-acetyl-l-aspartyl-l-glutamate,1335,B-CHEMICAL
.,1335,O
Here,1336,O
we,1336,O
present,1336,O
the,1336,O
3.5-A,1336,O
crystal,1336,O
structure,1336,O
of,1336,O
the,1336,O
PSMA,1336,B-GENE-N
ectodomain,1336,I-GENE-N
",",1336,O
which,1336,O
reveals,1336,O
a,1336,O
homodimer,1336,O
with,1336,O
structural,1336,O
similarity,1336,O
to,1336,O
transferrin,1336,B-GENE-N
receptor,1336,I-GENE-N
",",1336,O
a,1336,O
receptor,1336,O
for,1336,O
iron-loaded,1336,B-CHEMICAL
transferrin,1336,B-GENE-Y
that,1336,O
lacks,1336,O
protease,1336,B-GENE-N
activity,1336,O
.,1336,O
Unlike,1337,O
transferrin,1337,B-GENE-N
receptor,1337,I-GENE-N
",",1337,O
the,1337,O
protease,1337,B-GENE-N
domain,1337,I-GENE-N
of,1337,O
PSMA,1337,B-GENE-Y
contains,1337,O
a,1337,O
binuclear,1337,O
zinc,1337,B-CHEMICAL
site,1337,O
",",1337,O
catalytic,1337,O
residues,1337,O
",",1337,O
and,1337,O
a,1337,O
proposed,1337,O
substrate-binding,1337,O
arginine,1337,B-CHEMICAL
patch,1337,O
.,1337,O
Elucidation,1338,O
of,1338,O
the,1338,O
PSMA,1338,B-GENE-Y
structure,1338,O
combined,1338,O
with,1338,O
docking,1338,O
studies,1338,O
and,1338,O
a,1338,O
proposed,1338,O
catalytic,1338,O
mechanism,1338,O
provides,1338,O
insight,1338,O
into,1338,O
the,1338,O
recognition,1338,O
of,1338,O
inhibitors,1338,O
and,1338,O
the,1338,O
natural,1338,O
substrate,1338,O
N-acetyl-l-aspartyl-l-glutamate,1338,B-CHEMICAL
.,1338,O
The,1339,O
PSMA,1339,B-GENE-Y
structure,1339,O
will,1339,O
facilitate,1339,O
development,1339,O
of,1339,O
chemotherapeutics,1339,O
",",1339,O
cancer-imaging,1339,O
agents,1339,O
",",1339,O
and,1339,O
agents,1339,O
for,1339,O
treatment,1339,O
of,1339,O
neurological,1339,O
disorders,1339,O
.,1339,O
Conversion,1340,O
of,1340,O
5-aminolevulinate,1340,B-GENE-N
synthase,1340,I-GENE-N
into,1340,O
a,1340,O
more,1340,O
active,1340,O
enzyme,1340,O
by,1340,O
linking,1340,O
the,1340,O
two,1340,O
subunits,1340,O
:,1340,O
spectroscopic,1340,O
and,1340,O
kinetic,1340,O
properties,1340,O
.,1340,O
The,1341,O
two,1341,O
active,1341,O
sites,1341,O
of,1341,O
dimeric,1341,O
5-aminolevulinate,1341,B-CHEMICAL
synthase,1341,I-GENE-N
(,1341,O
ALAS,1341,B-GENE-N
),1341,O
",",1341,O
a,1341,O
pyridoxal,1341,B-CHEMICAL
5'-phosphate,1341,I-CHEMICAL
(,1341,O
PLP,1341,B-CHEMICAL
),1341,O
-dependent,1341,O
enzyme,1341,O
",",1341,O
are,1341,O
located,1341,O
on,1341,O
the,1341,O
subunit,1341,O
interface,1341,O
with,1341,O
contribution,1341,O
of,1341,O
essential,1341,O
amino,1341,B-CHEMICAL
acids,1341,I-CHEMICAL
from,1341,O
each,1341,O
subunit,1341,O
.,1341,O
Linking,1342,O
the,1342,O
two,1342,O
subunits,1342,O
into,1342,O
a,1342,O
single,1342,O
polypeptide,1342,O
chain,1342,O
dimer,1342,O
(,1342,O
2XALAS,1342,B-GENE-N
),1342,O
yielded,1342,O
an,1342,O
enzyme,1342,O
with,1342,O
an,1342,O
approximate,1342,O
sevenfold,1342,O
greater,1342,O
turnover,1342,O
number,1342,O
than,1342,O
that,1342,O
of,1342,O
wild-type,1342,O
ALAS,1342,B-GENE-N
.,1342,O
Spectroscopic,1343,O
and,1343,O
kinetic,1343,O
properties,1343,O
of,1343,O
2XALAS,1343,B-GENE-N
were,1343,O
investigated,1343,O
to,1343,O
explore,1343,O
the,1343,O
differences,1343,O
in,1343,O
the,1343,O
coenzyme,1343,O
structure,1343,O
and,1343,O
kinetic,1343,O
mechanism,1343,O
relative,1343,O
to,1343,O
those,1343,O
of,1343,O
wild-type,1343,O
ALAS,1343,B-GENE-N
that,1343,O
confer,1343,O
a,1343,O
more,1343,O
active,1343,O
enzyme,1343,O
.,1343,O
The,1344,O
absorption,1344,O
spectra,1344,O
of,1344,O
both,1344,O
ALAS,1344,B-GENE-N
and,1344,O
2XALAS,1344,B-GENE-N
had,1344,O
maxima,1344,O
at,1344,O
410,1344,O
and,1344,O
330,1344,O
nm,1344,O
",",1344,O
with,1344,O
a,1344,O
greater,1344,O
A,1344,O
(,1344,O
410,1344,O
),1344,O
/A,1344,O
(,1344,O
330,1344,O
),1344,O
ratio,1344,O
at,1344,O
pH,1344,O
approximately,1344,O
7.5,1344,O
for,1344,O
2XALAS,1344,B-GENE-N
.,1344,O
The,1345,O
330,1345,O
nm,1345,O
absorption,1345,O
band,1345,O
showed,1345,O
an,1345,O
intense,1345,O
fluorescence,1345,O
at,1345,O
385,1345,O
nm,1345,O
but,1345,O
not,1345,O
at,1345,O
510,1345,O
nm,1345,O
",",1345,O
indicating,1345,O
that,1345,O
the,1345,O
330,1345,O
nm,1345,O
absorption,1345,O
species,1345,O
is,1345,O
the,1345,O
substituted,1345,O
aldamine,1345,B-CHEMICAL
rather,1345,O
than,1345,O
the,1345,O
enolimine,1345,B-CHEMICAL
form,1345,O
of,1345,O
the,1345,O
Schiff,1345,B-CHEMICAL
base,1345,I-CHEMICAL
.,1345,O
The,1346,O
385,1346,O
nm,1346,O
emission,1346,O
intensity,1346,O
increased,1346,O
with,1346,O
increasing,1346,O
pH,1346,O
with,1346,O
a,1346,O
single,1346,O
pK,1346,O
of,1346,O
approximately,1346,O
8.5,1346,O
for,1346,O
both,1346,O
enzymes,1346,O
",",1346,O
and,1346,O
thus,1346,O
the,1346,O
410,1346,O
and,1346,O
330,1346,O
nm,1346,O
absorption,1346,O
species,1346,O
were,1346,O
attributed,1346,O
to,1346,O
the,1346,O
ketoenamine,1346,B-CHEMICAL
and,1346,O
substituted,1346,O
aldamine,1346,B-CHEMICAL
",",1346,O
respectively,1346,O
.,1346,O
Transient,1347,O
kinetic,1347,O
analysis,1347,O
of,1347,O
the,1347,O
formation,1347,O
and,1347,O
decay,1347,O
of,1347,O
the,1347,O
quinonoid,1347,B-CHEMICAL
intermediate,1347,O
EQ,1347,O
(,1347,O
2,1347,O
),1347,O
indicated,1347,O
that,1347,O
",",1347,O
although,1347,O
their,1347,O
rates,1347,O
were,1347,O
similar,1347,O
in,1347,O
ALAS,1347,B-GENE-N
and,1347,O
2XALAS,1347,B-GENE-N
",",1347,O
accumulation,1347,O
of,1347,O
this,1347,O
intermediate,1347,O
was,1347,O
greater,1347,O
in,1347,O
the,1347,O
2XALAS-catalyzed,1347,B-GENE-N
reaction,1347,O
.,1347,O
Collectively,1348,O
",",1348,O
these,1348,O
results,1348,O
suggest,1348,O
that,1348,O
ketoenamine,1348,B-CHEMICAL
is,1348,O
the,1348,O
active,1348,O
form,1348,O
of,1348,O
the,1348,O
coenzyme,1348,O
and,1348,O
forms,1348,O
a,1348,O
more,1348,O
prominent,1348,O
coenzyme,1348,O
structure,1348,O
in,1348,O
2XALAS,1348,B-GENE-N
than,1348,O
in,1348,O
ALAS,1348,B-GENE-N
at,1348,O
pH,1348,O
approximately,1348,O
7.5,1348,O
.,1348,O
Regulation,1349,O
of,1349,O
the,1349,O
expression,1349,O
of,1349,O
peptidylarginine,1349,B-GENE-Y
deiminase,1349,I-GENE-Y
type,1349,I-GENE-Y
II,1349,I-GENE-Y
gene,1349,O
(,1349,O
PADI2,1349,B-GENE-Y
),1349,O
in,1349,O
human,1349,O
keratinocytes,1349,O
involves,1349,O
Sp1,1349,B-GENE-Y
and,1349,O
Sp3,1349,B-GENE-Y
transcription,1349,O
factors,1349,O
.,1349,O
Peptidylarginine,1350,B-GENE-N
deiminases,1350,I-GENE-N
(,1350,O
PAD,1350,B-GENE-N
),1350,O
convert,1350,O
protein-bound,1350,O
arginine,1350,B-CHEMICAL
residues,1350,O
into,1350,O
citrulline,1350,B-CHEMICAL
residues,1350,O
in,1350,O
a,1350,O
Ca,1350,B-CHEMICAL
(,1350,I-CHEMICAL
2+,1350,I-CHEMICAL
),1350,I-CHEMICAL
ion-dependent,1350,O
manner,1350,O
.,1350,O
Among,1351,O
the,1351,O
five,1351,O
isoforms,1351,O
(,1351,O
PAD1,1351,B-GENE-N
",",1351,I-GENE-N
2,1351,I-GENE-N
",",1351,I-GENE-N
3,1351,I-GENE-N
",",1351,I-GENE-N
4,1351,I-GENE-N
",",1351,I-GENE-N
and,1351,I-GENE-N
6,1351,I-GENE-N
),1351,O
existing,1351,O
in,1351,O
rodents,1351,O
and,1351,O
humans,1351,O
",",1351,O
PAD2,1351,B-GENE-Y
is,1351,O
the,1351,O
most,1351,O
widely,1351,O
expressed,1351,O
in,1351,O
both,1351,O
species,1351,O
",",1351,O
tissues,1351,O
",",1351,O
and,1351,O
organs,1351,O
.,1351,O
In,1352,O
order,1352,O
to,1352,O
study,1352,O
the,1352,O
mechanisms,1352,O
regulating,1352,O
the,1352,O
expression,1352,O
of,1352,O
the,1352,O
human,1352,B-GENE-Y
PAD2,1352,I-GENE-Y
gene,1352,O
",",1352,O
PADI2,1352,B-GENE-Y
",",1352,O
we,1352,O
characterized,1352,O
its,1352,O
promoter,1352,O
region,1352,O
using,1352,O
transfected,1352,O
human,1352,O
keratinocytes,1352,O
.,1352,O
A,1353,O
series,1353,O
of,1353,O
reporter,1353,O
gene,1353,O
constructions,1353,O
derived,1353,O
from,1353,O
the,1353,O
2,1353,O
kb,1353,O
region,1353,O
upstream,1353,O
of,1353,O
the,1353,O
transcription,1353,B-GENE-N
initiation,1353,I-GENE-N
site,1353,I-GENE-N
defined,1353,O
a,1353,O
minimal,1353,O
promoter,1353,O
sequence,1353,O
from,1353,O
nucleotides,1353,O
-132,1353,O
to,1353,O
-41,1353,O
.,1353,O
This,1354,O
PADI2,1354,B-GENE-Y
region,1354,O
is,1354,O
GC-rich,1354,O
and,1354,O
lacks,1354,O
canonical,1354,O
TATA,1354,B-GENE-N
and,1354,O
CAAT,1354,B-GENE-N
boxes,1354,I-GENE-N
.,1354,O
Investigation,1355,O
of,1355,O
cis-acting,1355,B-GENE-N
elements,1355,I-GENE-N
in,1355,O
the,1355,O
region,1355,O
",",1355,O
further,1355,O
deletion,1355,O
analyses,1355,O
and,1355,O
electrophoretic,1355,O
mobility,1355,O
shift,1355,O
assays,1355,O
using,1355,O
specific,1355,O
antibodies,1355,O
revealed,1355,O
four,1355,O
Sp1-binding,1355,B-GENE-N
sites,1355,I-GENE-N
and,1355,O
identified,1355,O
Sp1,1355,B-GENE-Y
and,1355,O
Sp3,1355,B-GENE-Y
as,1355,O
binding,1355,O
factors,1355,O
important,1355,O
for,1355,O
the,1355,O
promoter,1355,O
activity,1355,O
.,1355,O
These,1356,O
results,1356,O
suggest,1356,O
that,1356,O
Sp1/Sp3,1356,B-GENE-Y
cooperation,1356,O
may,1356,O
provide,1356,O
a,1356,O
mechanism,1356,O
to,1356,O
control,1356,O
the,1356,O
transcription,1356,O
of,1356,O
PADI2,1356,B-GENE-Y
.,1356,O
Activator,1357,B-GENE-Y
of,1357,I-GENE-Y
G,1357,I-GENE-Y
protein,1357,I-GENE-Y
signaling,1357,I-GENE-Y
3,1357,I-GENE-Y
regulates,1357,O
opiate,1357,O
activation,1357,O
of,1357,O
protein,1357,B-GENE-N
kinase,1357,I-GENE-N
A,1357,I-GENE-N
signaling,1357,O
and,1357,O
relapse,1357,O
of,1357,O
heroin-seeking,1357,B-CHEMICAL
behavior,1357,O
.,1357,O
The,1358,O
nucleus,1358,O
accumbens,1358,O
(,1358,O
NAc,1358,O
),1358,O
is,1358,O
central,1358,O
to,1358,O
heroin,1358,B-CHEMICAL
addiction,1358,O
.,1358,O
Activation,1359,O
of,1359,O
opiate,1359,B-GENE-N
receptors,1359,I-GENE-N
in,1359,O
the,1359,O
NAc,1359,O
dissociates,1359,O
G,1359,B-GENE-N
(,1359,I-GENE-N
i/o,1359,I-GENE-N
),1359,I-GENE-N
into,1359,I-GENE-N
alpha,1359,I-GENE-N
and,1359,I-GENE-N
betagamma,1359,I-GENE-N
subunits,1359,O
.,1359,O
Galpha,1360,B-GENE-N
(,1360,I-GENE-N
i,1360,I-GENE-N
),1360,I-GENE-N
inhibits,1360,O
cAMP,1360,B-CHEMICAL
production,1360,O
",",1360,O
but,1360,O
betagamma,1360,O
regulates,1360,O
several,1360,O
molecular,1360,O
pathways,1360,O
",",1360,O
including,1360,O
protein,1360,B-GENE-N
kinase,1360,I-GENE-N
A,1360,I-GENE-N
(,1360,O
PKA,1360,B-GENE-N
),1360,O
.,1360,O
We,1361,O
show,1361,O
in,1361,O
NAc/striatal,1361,O
neurons,1361,O
that,1361,O
opiates,1361,O
paradoxically,1361,O
activate,1361,O
PKA,1361,B-GENE-N
signaling,1361,O
by,1361,O
means,1361,O
of,1361,O
betagamma,1361,O
dimers,1361,O
.,1361,O
Activation,1362,O
requires,1362,O
Galpha,1362,B-GENE-Y
(,1362,I-GENE-Y
i3,1362,I-GENE-Y
),1362,I-GENE-Y
and,1362,O
an,1362,O
activator,1362,B-GENE-Y
of,1362,I-GENE-Y
G,1362,I-GENE-Y
protein,1362,I-GENE-Y
signaling,1362,I-GENE-Y
3,1362,I-GENE-Y
(,1362,O
AGS3,1362,B-GENE-Y
),1362,O
.,1362,O
AGS3,1363,B-GENE-Y
competes,1363,O
with,1363,O
betagamma,1363,O
for,1363,O
binding,1363,O
to,1363,O
Galpha,1363,B-GENE-Y
(,1363,I-GENE-Y
i3,1363,I-GENE-Y
),1363,I-GENE-Y
-GDP,1363,O
and,1363,O
enhances,1363,O
the,1363,O
action,1363,O
of,1363,O
unbound,1363,O
betagamma,1363,O
.,1363,O
AGS3,1364,B-GENE-Y
and,1364,O
Galpha,1364,B-GENE-Y
(,1364,I-GENE-Y
i3,1364,I-GENE-Y
),1364,I-GENE-Y
knockdown,1364,O
prevents,1364,O
opiate,1364,O
activation,1364,O
of,1364,O
PKA,1364,B-GENE-N
signaling,1364,O
.,1364,O
In,1365,O
rats,1365,O
self-administering,1365,O
heroin,1365,B-CHEMICAL
",",1365,O
AGS3,1365,B-GENE-Y
antisense,1365,O
in,1365,O
the,1365,O
NAc,1365,O
core,1365,O
",",1365,O
but,1365,O
not,1365,O
shell,1365,O
",",1365,O
eliminates,1365,O
reinstatement,1365,O
of,1365,O
heroin-seeking,1365,B-CHEMICAL
behavior,1365,O
",",1365,O
a,1365,O
model,1365,O
of,1365,O
human,1365,O
relapse,1365,O
.,1365,O
Thus,1366,O
",",1366,O
Galpha,1366,B-GENE-N
(,1366,I-GENE-N
i3,1366,I-GENE-N
),1366,I-GENE-N
/betagamma/AGS3,1366,O
appears,1366,O
to,1366,O
mediate,1366,O
mu,1366,B-GENE-Y
opiate,1366,I-GENE-Y
receptor,1366,I-GENE-Y
activation,1366,O
of,1366,O
PKA,1366,B-GENE-N
signaling,1366,O
as,1366,O
well,1366,O
as,1366,O
heroin-seeking,1366,B-CHEMICAL
behavior,1366,O
.,1366,O
2-,1367,B-CHEMICAL
[,1367,I-CHEMICAL
4-,1367,I-CHEMICAL
(,1367,I-CHEMICAL
"3,4-Dimethylphenyl",1367,I-CHEMICAL
),1367,I-CHEMICAL
piperazin-1-ylmethyl,1367,I-CHEMICAL
],1367,I-CHEMICAL
-1H,1367,I-CHEMICAL
benzoimidazole,1367,I-CHEMICAL
(,1367,O
A-381393,1367,B-CHEMICAL
),1367,O
",",1367,O
a,1367,O
selective,1367,O
dopamine,1367,B-GENE-Y
D4,1367,I-GENE-Y
receptor,1367,I-GENE-Y
antagonist,1367,O
.,1367,O
2-,1368,B-CHEMICAL
[,1368,I-CHEMICAL
4-,1368,I-CHEMICAL
(,1368,I-CHEMICAL
"3,4-Dimethylphenlyl",1368,I-CHEMICAL
),1368,I-CHEMICAL
piperazin-1-ylmethyl,1368,I-CHEMICAL
],1368,I-CHEMICAL
-1H,1368,I-CHEMICAL
benzoimidazole,1368,I-CHEMICAL
(,1368,O
A-381393,1368,B-CHEMICAL
),1368,O
was,1368,O
identified,1368,O
as,1368,O
a,1368,O
potent,1368,O
dopamine,1368,B-CHEMICAL
D4,1368,I-GENE-Y
receptor,1368,I-GENE-Y
antagonist,1368,O
with,1368,O
excellent,1368,O
receptor,1368,O
selectivity,1368,O
.,1368,O
[,1369,B-CHEMICAL
3H,1369,I-CHEMICAL
],1369,I-CHEMICAL
-spiperone,1369,I-CHEMICAL
competition,1369,O
binding,1369,O
assays,1369,O
showed,1369,O
that,1369,O
A-381393,1369,B-CHEMICAL
potently,1369,O
bound,1369,O
to,1369,O
membrane,1369,O
from,1369,O
cells,1369,O
expressing,1369,O
recombinant,1369,O
human,1369,B-GENE-N
dopamine,1369,I-GENE-N
D4.4,1369,I-GENE-N
receptor,1369,I-GENE-N
(,1369,O
Ki=1.5,1369,O
nM,1369,O
),1369,O
",",1369,O
which,1369,O
was,1369,O
20-fold,1369,O
higher,1369,O
than,1369,O
that,1369,O
of,1369,O
clozapine,1369,B-CHEMICAL
(,1369,O
Ki=30.4,1369,O
nM,1369,O
),1369,O
.,1369,O
A-381393,1370,B-CHEMICAL
exhibited,1370,O
highly,1370,O
selective,1370,O
binding,1370,O
for,1370,O
the,1370,O
dopamine,1370,B-GENE-N
D4.4,1370,I-GENE-N
receptor,1370,I-GENE-N
(,1370,O
>,1370,O
2700-fold,1370,O
),1370,O
when,1370,O
compared,1370,O
to,1370,O
D1,1370,B-GENE-N
",",1370,I-GENE-N
D2,1370,I-GENE-N
",",1370,I-GENE-N
D3,1370,I-GENE-N
and,1370,I-GENE-N
D5,1370,I-GENE-N
dopamine,1370,I-GENE-N
receptors,1370,I-GENE-N
.,1370,O
Furthermore,1371,O
",",1371,O
in,1371,O
comparison,1371,O
to,1371,O
clozapine,1371,B-CHEMICAL
and,1371,O
L-745870,1371,B-CHEMICAL
",",1371,O
A-381393,1371,B-CHEMICAL
exhibits,1371,O
better,1371,O
receptor,1371,O
selectivity,1371,O
",",1371,O
showing,1371,O
no,1371,O
affinity,1371,O
up,1371,O
to,1371,O
10,1371,O
microM,1371,O
for,1371,O
a,1371,O
panel,1371,O
of,1371,O
more,1371,O
than,1371,O
70,1371,O
receptors,1371,O
and,1371,O
channels,1371,O
",",1371,O
with,1371,O
the,1371,O
exception,1371,O
of,1371,O
moderate,1371,O
affinity,1371,O
for,1371,O
5-HT2A,1371,B-GENE-Y
(,1371,O
Ki=370,1371,O
nM,1371,O
),1371,O
.,1371,O
A-381393,1372,B-CHEMICAL
potently,1372,O
inhibited,1372,O
the,1372,O
functional,1372,O
activity,1372,O
of,1372,O
agonist-induced,1372,O
GTP-gamma-S,1372,B-CHEMICAL
binding,1372,O
assay,1372,O
and,1372,O
1,1372,O
microM,1372,O
dopamine,1372,B-CHEMICAL
induced-Ca2+,1372,O
flux,1372,O
in,1372,O
human,1372,B-GENE-N
dopamine,1372,I-GENE-N
D4.4,1372,I-GENE-N
receptor,1372,I-GENE-N
expressing,1372,O
cells,1372,O
",",1372,O
but,1372,O
not,1372,O
in,1372,O
human,1372,B-GENE-N
dopamine,1372,I-GENE-N
D2L,1372,I-GENE-N
or,1372,I-GENE-N
D3,1372,I-GENE-N
receptor,1372,I-GENE-N
cells,1372,O
.,1372,O
In,1373,O
contrast,1373,O
to,1373,O
L-745870,1373,B-CHEMICAL
",",1373,O
A-381393,1373,B-CHEMICAL
did,1373,O
not,1373,O
exhibit,1373,O
any,1373,O
significant,1373,O
intrinsic,1373,O
activity,1373,O
in,1373,O
a,1373,O
D4.4,1373,B-GENE-N
receptor,1373,I-GENE-N
.,1373,O
In,1374,O
vivo,1374,O
",",1374,O
A-381393,1374,B-CHEMICAL
has,1374,O
good,1374,O
brain,1374,O
penetration,1374,O
after,1374,O
subcutaneous,1374,O
administration,1374,O
.,1374,O
A-381393,1375,B-CHEMICAL
inhibited,1375,O
penile,1375,O
erection,1375,O
induced,1375,O
by,1375,O
the,1375,O
selective,1375,O
D4,1375,O
agonist,1375,O
PD168077,1375,B-CHEMICAL
in,1375,O
conscious,1375,O
rats,1375,O
.,1375,O
Thus,1376,O
",",1376,O
A-381393,1376,B-CHEMICAL
is,1376,O
a,1376,O
novel,1376,O
selective,1376,O
D4,1376,O
antagonist,1376,O
that,1376,O
will,1376,O
enhance,1376,O
the,1376,O
ability,1376,O
to,1376,O
study,1376,O
dopamine,1376,B-GENE-N
D4,1376,I-GENE-N
receptors,1376,I-GENE-N
both,1376,O
in,1376,O
vitro,1376,O
and,1376,O
in,1376,O
vivo,1376,O
.,1376,O
Review,1377,O
article,1377,O
:,1377,O
5-hydroxytryptamine,1377,B-CHEMICAL
agonists,1377,O
and,1377,O
antagonists,1377,O
in,1377,O
the,1377,O
modulation,1377,O
of,1377,O
gastrointestinal,1377,O
motility,1377,O
and,1377,O
sensation,1377,O
:,1377,O
clinical,1377,O
implications,1377,O
.,1377,O
Serotonin,1378,B-CHEMICAL
(,1378,O
5-hydroxytryptamine,1378,B-CHEMICAL
;,1378,O
5-HT,1378,B-CHEMICAL
),1378,O
is,1378,O
found,1378,O
in,1378,O
the,1378,O
enteric,1378,O
nervous,1378,O
system,1378,O
where,1378,O
it,1378,O
has,1378,O
been,1378,O
implicated,1378,O
in,1378,O
controlling,1378,O
gastrointestinal,1378,O
motor,1378,O
function,1378,O
.,1378,O
A,1379,O
number,1379,O
of,1379,O
receptor,1379,O
or,1379,O
recognition,1379,O
sites,1379,O
have,1379,O
been,1379,O
identified,1379,O
in,1379,O
the,1379,O
gut,1379,O
",",1379,O
but,1379,O
recently,1379,O
most,1379,O
attention,1379,O
has,1379,O
focused,1379,O
on,1379,O
the,1379,O
5-HT3,1379,B-GENE-Y
and,1379,O
5-HT4,1379,B-GENE-Y
receptors,1379,O
.,1379,O
The,1380,O
functional,1380,O
role,1380,O
of,1380,O
the,1380,O
5-HT3,1380,B-GENE-Y
receptor,1380,O
remains,1380,O
incompletely,1380,O
understood,1380,O
",",1380,O
but,1380,O
it,1380,O
is,1380,O
probably,1380,O
involved,1380,O
in,1380,O
the,1380,O
modulation,1380,O
of,1380,O
colonic,1380,O
motility,1380,O
and,1380,O
visceral,1380,O
pain,1380,O
in,1380,O
the,1380,O
gut,1380,O
.,1380,O
A,1381,O
number,1381,O
of,1381,O
selective,1381,O
5-HT3,1381,B-GENE-Y
antagonists,1381,O
have,1381,O
been,1381,O
developed,1381,O
including,1381,O
ondansetron,1381,B-CHEMICAL
",",1381,O
granisetron,1381,B-CHEMICAL
",",1381,O
tropisetron,1381,B-CHEMICAL
renzapride,1381,B-CHEMICAL
and,1381,O
zacopride,1381,B-CHEMICAL
.,1381,O
While,1382,O
the,1382,O
substituted,1382,O
benzamide,1382,B-CHEMICAL
prokinetics,1382,O
(,1382,O
for,1382,O
example,1382,O
",",1382,O
metoclopramide,1382,B-CHEMICAL
",",1382,O
cisapride,1382,B-CHEMICAL
),1382,O
also,1382,O
block,1382,O
5-HT3,1382,B-GENE-Y
receptors,1382,O
in,1382,O
high,1382,O
concentrations,1382,O
",",1382,O
their,1382,O
prokinetic,1382,O
action,1382,O
is,1382,O
believed,1382,O
to,1382,O
be,1382,O
on,1382,O
the,1382,O
basis,1382,O
of,1382,O
their,1382,O
agonist,1382,O
effects,1382,O
on,1382,O
the,1382,O
putative,1382,O
5-HT4,1382,B-GENE-Y
receptor,1382,O
.,1382,O
Some,1383,O
5-HT3,1383,B-GENE-Y
antagonists,1383,O
have,1383,O
5-HT4,1383,B-GENE-Y
agonist,1383,O
activity,1383,O
(,1383,O
for,1383,O
example,1383,O
",",1383,O
renzapride,1383,B-CHEMICAL
",",1383,O
zacopride,1383,B-CHEMICAL
),1383,O
and,1383,O
others,1383,O
do,1383,O
not,1383,O
(,1383,O
for,1383,O
example,1383,O
",",1383,O
ondansetron,1383,B-CHEMICAL
",",1383,O
granisetron,1383,B-CHEMICAL
),1383,O
",",1383,O
while,1383,O
tropisetron,1383,B-CHEMICAL
in,1383,O
high,1383,O
concentrations,1383,O
is,1383,O
a,1383,O
5-HT4,1383,B-GENE-Y
antagonist,1383,O
.,1383,O
Based,1384,O
on,1384,O
the,1384,O
pharmacological,1384,O
data,1384,O
",",1384,O
it,1384,O
has,1384,O
been,1384,O
suggested,1384,O
that,1384,O
specific,1384,O
5-HT,1384,B-CHEMICAL
antagonists,1384,O
and,1384,O
agonists,1384,O
may,1384,O
prove,1384,O
to,1384,O
be,1384,O
beneficial,1384,O
in,1384,O
a,1384,O
number,1384,O
of,1384,O
gastrointestinal,1384,O
disorders,1384,O
including,1384,O
the,1384,O
irritable,1384,O
bowel,1384,O
syndrome,1384,O
",",1384,O
functional,1384,O
dyspepsia,1384,O
",",1384,O
non-cardiac,1384,O
chest,1384,O
pain,1384,O
",",1384,O
gastrooesophageal,1384,O
reflux,1384,O
and,1384,O
refractory,1384,O
nausea,1384,O
.,1384,O
In,1385,O
this,1385,O
review,1385,O
",",1385,O
the,1385,O
rationale,1385,O
for,1385,O
the,1385,O
use,1385,O
of,1385,O
these,1385,O
compounds,1385,O
is,1385,O
discussed,1385,O
",",1385,O
and,1385,O
the,1385,O
available,1385,O
experimental,1385,O
evidence,1385,O
is,1385,O
summarized,1385,O
.,1385,O
Niacin,1386,B-CHEMICAL
mediates,1386,O
lipolysis,1386,O
in,1386,O
adipose,1386,O
tissue,1386,O
through,1386,O
its,1386,O
G-protein,1386,B-GENE-Y
coupled,1386,I-GENE-Y
receptor,1386,I-GENE-Y
HM74A,1386,I-GENE-Y
.,1386,O
A,1387,O
G-protein,1387,B-GENE-N
coupled,1387,I-GENE-N
receptor,1387,I-GENE-N
to,1387,O
niacin,1387,B-CHEMICAL
(,1387,O
nicotinic,1387,B-CHEMICAL
acid,1387,I-CHEMICAL
),1387,O
was,1387,O
identified,1387,O
recently,1387,O
but,1387,O
the,1387,O
physiological/pharmacological,1387,O
role,1387,O
of,1387,O
the,1387,O
receptor,1387,O
remains,1387,O
poorly,1387,O
defined,1387,O
.,1387,O
We,1388,O
present,1388,O
our,1388,O
studies,1388,O
to,1388,O
demonstrate,1388,O
that,1388,O
HM74A,1388,B-GENE-N
",",1388,O
but,1388,O
not,1388,O
HM74,1388,B-GENE-N
",",1388,O
binds,1388,O
niacin,1388,B-CHEMICAL
at,1388,O
high,1388,O
affinities,1388,O
and,1388,O
effectively,1388,O
mediates,1388,O
Gi,1388,B-GENE-N
signaling,1388,O
events,1388,O
in,1388,O
human,1388,O
embryonic,1388,O
kidney,1388,O
HEK293,1388,O
cells,1388,O
as,1388,O
well,1388,O
as,1388,O
in,1388,O
3T3L1,1388,O
adipocytes,1388,O
expressing,1388,O
HM74A,1388,B-GENE-N
.,1388,O
Furthermore,1389,O
",",1389,O
HM74A,1389,B-GENE-Y
",",1389,O
but,1389,O
not,1389,O
HM74,1389,B-GENE-Y
",",1389,O
expressed,1389,O
in,1389,O
differentiated,1389,O
3T3L1,1389,O
adipocytes,1389,O
effectively,1389,O
mediated,1389,O
inhibition,1389,O
of,1389,O
lipolysis,1389,O
by,1389,O
niacin,1389,B-CHEMICAL
.,1389,O
Our,1390,O
results,1390,O
provided,1390,O
direct,1390,O
evidence,1390,O
indicating,1390,O
that,1390,O
HM74A,1390,B-GENE-Y
",",1390,O
but,1390,O
not,1390,O
HM74,1390,B-GENE-Y
",",1390,O
was,1390,O
sufficient,1390,O
to,1390,O
mediate,1390,O
anti-lipolytic,1390,O
effect,1390,O
of,1390,O
niacin,1390,B-CHEMICAL
in,1390,O
adipose,1390,O
tissue,1390,O
.,1390,O
Islet,1391,O
cell,1391,O
antibodies,1391,O
in,1391,O
normal,1391,O
French,1391,O
schoolchildren,1391,O
.,1391,O
Islet-cell,1392,O
antibodies,1392,O
have,1392,O
been,1392,O
reported,1392,O
to,1392,O
be,1392,O
of,1392,O
predictive,1392,O
value,1392,O
for,1392,O
the,1392,O
future,1392,O
development,1392,O
of,1392,O
Type,1392,O
1,1392,O
(,1392,O
insulin-dependent,1392,B-GENE-Y
),1392,O
diabetes,1392,O
in,1392,O
first,1392,O
degree,1392,O
relatives,1392,O
of,1392,O
diabetic,1392,O
patients,1392,O
with,1392,O
the,1392,O
risk,1392,O
increasing,1392,O
in,1392,O
these,1392,O
subjects,1392,O
with,1392,O
the,1392,O
islet-cell,1392,O
antibodies,1392,O
titre,1392,O
.,1392,O
However,1393,O
",",1393,O
very,1393,O
little,1393,O
is,1393,O
known,1393,O
about,1393,O
islet-cell,1393,O
antibodies,1393,O
in,1393,O
background,1393,O
populations,1393,O
.,1393,O
Sera,1394,O
(,1394,O
n,1394,O
=,1394,O
8363,1394,O
),1394,O
from,1394,O
schoolchildren,1394,O
(,1394,O
6-17,1394,O
years,1394,O
),1394,O
in,1394,O
the,1394,O
French,1394,O
background,1394,O
population,1394,O
were,1394,O
screened,1394,O
for,1394,O
the,1394,O
presence,1394,O
of,1394,O
islet-cell,1394,O
antibodies,1394,O
by,1394,O
the,1394,O
indirect,1394,O
immunofluorescence,1394,O
technique,1394,O
.,1394,O
Islet-cell,1395,O
antibodies,1395,O
greater,1395,O
than,1395,O
4.5,1395,O
Juvenile,1395,O
Diabetes,1395,O
Foundation,1395,O
units,1395,O
were,1395,O
found,1395,O
in,1395,O
150,1395,O
sera,1395,O
(,1395,O
prevalence,1395,O
rate,1395,O
1.8,1395,O
%,1395,O
;,1395,O
95,1395,O
%,1395,O
confidence,1395,O
interval,1395,O
1.5-2.1,1395,O
%,1395,O
),1395,O
.,1395,O
Only,1396,O
17,1396,O
sera,1396,O
demonstrated,1396,O
islet-cell,1396,O
antibody,1396,O
titre,1396,O
greater,1396,O
than,1396,O
or,1396,O
equal,1396,O
to,1396,O
24,1396,O
JDF,1396,O
units,1396,O
.,1396,O
No,1397,O
particular,1397,O
feature,1397,O
was,1397,O
found,1397,O
to,1397,O
be,1397,O
significantly,1397,O
different,1397,O
between,1397,O
islet-cell,1397,O
antibody-positive,1397,O
and,1397,O
islet-cell,1397,O
antibody-negative,1397,O
children,1397,O
(,1397,O
age,1397,O
",",1397,O
family,1397,O
history,1397,O
of,1397,O
diabetes,1397,O
",",1397,O
fasting,1397,O
plasma,1397,O
glucose,1397,B-CHEMICAL
",",1397,O
insulin,1397,O
autoantibodies,1397,O
),1397,O
.,1397,O
A,1398,O
second,1398,O
blood,1398,O
sample,1398,O
was,1398,O
obtained,1398,O
from,1398,O
80,1398,O
of,1398,O
150,1398,O
islet-cell,1398,O
antibody,1398,O
positive,1398,O
children,1398,O
after,1398,O
a,1398,O
mean,1398,O
interval,1398,O
of,1398,O
8,1398,O
months,1398,O
.,1398,O
Only,1399,O
11,1399,O
sera,1399,O
became,1399,O
less,1399,O
than,1399,O
4.5,1399,O
JDF,1399,O
units,1399,O
with,1399,O
islet-cell,1399,O
antibody,1399,O
titres,1399,O
being,1399,O
stable,1399,O
in,1399,O
the,1399,O
remaining,1399,O
sera,1399,O
",",1399,O
including,1399,O
the,1399,O
high-titre,1399,O
positive,1399,O
sera,1399,O
(,1399,O
greater,1399,O
than,1399,O
or,1399,O
equal,1399,O
to,1399,O
24,1399,O
JDF,1399,O
units,1399,O
),1399,O
.,1399,O
HLA-DQB,1400,B-GENE-Y
typing,1400,O
was,1400,O
performed,1400,O
by,1400,O
restriction,1400,O
mapping,1400,O
techniques,1400,O
in,1400,O
80,1400,O
islet-cell,1400,O
antibody-positive,1400,O
",",1400,O
in,1400,O
93,1400,O
islet-cell,1400,O
antibody-negative,1400,O
and,1400,O
in,1400,O
213,1400,O
Type,1400,O
1,1400,O
diabetic,1400,O
children,1400,O
.,1400,O
The,1401,O
distribution,1401,O
of,1401,O
the,1401,O
susceptibility,1401,O
alleles,1401,O
(,1401,O
DQB1-Asp57-negative,1401,B-GENE-Y
),1401,O
was,1401,O
not,1401,O
significantly,1401,O
different,1401,O
between,1401,O
islet-cell,1401,O
antibody-positive,1401,O
and,1401,O
islet-cell,1401,O
antibody-negative,1401,O
children,1401,O
.,1401,O
(,1402,O
ABSTRACT,1402,O
TRUNCATED,1402,O
AT,1402,O
250,1402,O
WORDS,1402,O
),1402,O
Effect,1403,O
of,1403,O
gene,1403,O
disruptions,1403,O
of,1403,O
the,1403,O
TCA,1403,B-CHEMICAL
cycle,1403,O
on,1403,O
production,1403,O
of,1403,O
succinic,1403,B-CHEMICAL
acid,1403,I-CHEMICAL
in,1403,O
Saccharomyces,1403,O
cerevisiae,1403,O
.,1403,O
Succinate,1404,B-CHEMICAL
is,1404,O
the,1404,O
main,1404,O
taste,1404,O
component,1404,O
produced,1404,O
by,1404,O
yeasts,1404,O
during,1404,O
sake,1404,O
(,1404,O
Japanese,1404,O
rice,1404,O
wine,1404,O
),1404,O
fermentation,1404,O
.,1404,O
The,1405,O
pathway,1405,O
leading,1405,O
to,1405,O
accumulation,1405,O
of,1405,O
succinate,1405,B-CHEMICAL
was,1405,O
examined,1405,O
in,1405,O
liquid,1405,O
culture,1405,O
in,1405,O
the,1405,O
presence,1405,O
of,1405,O
a,1405,O
high,1405,O
concentration,1405,O
(,1405,O
15,1405,O
%,1405,O
),1405,O
of,1405,O
glucose,1405,B-CHEMICAL
under,1405,O
aerobic,1405,O
and,1405,O
anaerobic,1405,O
conditions,1405,O
using,1405,O
a,1405,O
series,1405,O
of,1405,O
Saccharomyces,1405,O
cerevisiae,1405,O
strains,1405,O
in,1405,O
which,1405,O
various,1405,O
genes,1405,O
that,1405,O
encode,1405,O
the,1405,O
expression,1405,O
of,1405,O
enzymes,1405,O
required,1405,O
in,1405,O
TCA,1405,B-CHEMICAL
cycle,1405,O
were,1405,O
disrupted,1405,O
.,1405,O
When,1406,O
cultured,1406,O
in,1406,O
YPD,1406,O
medium,1406,O
containing,1406,O
15,1406,O
%,1406,O
glucose,1406,B-CHEMICAL
under,1406,O
aerobic,1406,O
conditions,1406,O
",",1406,O
the,1406,O
KGD1,1406,B-GENE-Y
(,1406,O
alpha-ketoglutarate,1406,B-GENE-Y
dehydrogenase,1406,I-GENE-Y
),1406,O
gene,1406,O
disrupted,1406,O
mutant,1406,O
produced,1406,O
a,1406,O
lower,1406,O
level,1406,O
of,1406,O
succinate,1406,B-CHEMICAL
than,1406,O
the,1406,O
wild-type,1406,O
strain,1406,O
",",1406,O
while,1406,O
the,1406,O
SDH1,1406,B-GENE-Y
(,1406,O
succinate,1406,B-GENE-Y
dehydrogenase,1406,I-GENE-Y
),1406,O
gene-disrupted,1406,O
mutant,1406,O
produced,1406,O
an,1406,O
increased,1406,O
level,1406,O
of,1406,O
succinate,1406,B-CHEMICAL
.,1406,O
On,1407,O
the,1407,O
other,1407,O
hand,1407,O
",",1407,O
the,1407,O
FUM1,1407,B-GENE-Y
(,1407,O
fumarase,1407,B-GENE-Y
),1407,O
gene,1407,O
disrupted,1407,O
mutant,1407,O
produced,1407,O
significantly,1407,O
higher,1407,O
levels,1407,O
of,1407,O
fumarate,1407,B-CHEMICAL
but,1407,O
did,1407,O
not,1407,O
form,1407,O
malate,1407,B-CHEMICAL
at,1407,O
all,1407,O
.,1407,O
These,1408,O
results,1408,O
indicate,1408,O
that,1408,O
succinate,1408,B-CHEMICAL
",",1408,O
fumarate,1408,B-CHEMICAL
and,1408,O
malate,1408,B-CHEMICAL
are,1408,O
mainly,1408,O
synthesized,1408,O
through,1408,O
the,1408,O
TCA,1408,B-CHEMICAL
cycle,1408,O
(,1408,O
oxidative,1408,O
direction,1408,O
),1408,O
even,1408,O
in,1408,O
the,1408,O
presence,1408,O
of,1408,O
glucose,1408,B-CHEMICAL
at,1408,O
a,1408,O
concentration,1408,O
as,1408,O
high,1408,O
as,1408,O
15,1408,O
%,1408,O
.,1408,O
When,1409,O
the,1409,O
growth,1409,O
condition,1409,O
was,1409,O
shifted,1409,O
from,1409,O
aerobic,1409,O
to,1409,O
anaerobic,1409,O
",",1409,O
the,1409,O
increased,1409,O
level,1409,O
of,1409,O
succinate,1409,B-CHEMICAL
in,1409,O
SDH1,1409,B-GENE-Y
disruptants,1409,O
was,1409,O
no,1409,O
longer,1409,O
observed,1409,O
",",1409,O
whereas,1409,O
the,1409,O
decreased,1409,O
level,1409,O
of,1409,O
succinate,1409,B-CHEMICAL
in,1409,O
the,1409,O
KGD1,1409,B-GENE-Y
diruptant,1409,O
was,1409,O
still,1409,O
observed,1409,O
.,1409,O
A,1410,O
double,1410,O
mutant,1410,O
of,1410,O
the,1410,O
two,1410,O
fumarate,1410,B-CHEMICAL
reductase,1410,I-GENE-N
isozyme,1410,O
genes,1410,O
(,1410,O
OSM1,1410,B-GENE-Y
and,1410,O
FRDS,1410,B-GENE-Y
),1410,O
showed,1410,O
a,1410,O
succinate,1410,B-CHEMICAL
productivity,1410,O
of,1410,O
50,1410,O
%,1410,O
as,1410,O
compared,1410,O
to,1410,O
the,1410,O
parent,1410,O
when,1410,O
cells,1410,O
were,1410,O
incubated,1410,O
in,1410,O
glucose-buffered,1410,B-CHEMICAL
solution,1410,O
.,1410,O
These,1411,O
results,1411,O
indicate,1411,O
that,1411,O
succinate,1411,B-CHEMICAL
could,1411,O
be,1411,O
synthesized,1411,O
through,1411,O
two,1411,O
pathways,1411,O
",",1411,O
namely,1411,O
",",1411,O
alpha-ketoglutarate,1411,B-CHEMICAL
oxidation,1411,O
via,1411,O
the,1411,O
TCA,1411,B-CHEMICAL
cycle,1411,O
and,1411,O
fumarate,1411,B-CHEMICAL
reduction,1411,O
under,1411,O
anaerobic,1411,O
conditions,1411,O
.,1411,O
The,1412,O
unexpected,1412,O
side,1412,O
effects,1412,O
of,1412,O
new,1412,O
nonsteroidal,1412,O
anti-inflammatory,1412,O
drugs,1412,O
.,1412,O
Conventional,1413,O
nonselective,1413,O
NSAIDs,1413,O
are,1413,O
classically,1413,O
associated,1413,O
with,1413,O
a,1413,O
risk,1413,O
of,1413,O
gastrointestinal,1413,O
disorders,1413,O
.,1413,O
These,1414,O
drugs,1414,O
have,1414,O
a,1414,O
broad,1414,O
range,1414,O
of,1414,O
relative,1414,O
selectivity,1414,O
towards,1414,O
the,1414,O
COX,1414,B-GENE-N
family,1414,O
",",1414,O
mainly,1414,O
towards,1414,O
two,1414,O
isoforms,1414,O
of,1414,O
these,1414,O
enzymes,1414,O
:,1414,O
COX-1,1414,B-GENE-N
and,1414,I-GENE-N
-2,1414,I-GENE-N
.,1414,O
As,1415,O
examples,1415,O
",",1415,O
ketorolac,1415,B-CHEMICAL
",",1415,O
flurbiprofen,1415,B-CHEMICAL
",",1415,O
ketoprofen,1415,B-CHEMICAL
and,1415,O
indomethacin,1415,B-CHEMICAL
have,1415,O
increased,1415,O
COX-1,1415,B-GENE-Y
selectivity,1415,O
when,1415,O
compared,1415,O
with,1415,O
naproxen,1415,B-CHEMICAL
and,1415,O
ibuprofen,1415,B-CHEMICAL
.,1415,O
Association,1416,O
of,1416,O
MTRRA66G,1416,B-GENE-Y
polymorphism,1416,O
(,1416,O
but,1416,O
not,1416,O
of,1416,O
MTHFR,1416,B-GENE-Y
C677T,1416,B-GENE-N
and,1416,O
A1298C,1416,B-GENE-N
",",1416,O
MTRA2756G,1416,B-GENE-Y
",",1416,O
TCN,1416,B-GENE-N
C776G,1416,B-GENE-N
),1416,O
with,1416,O
homocysteine,1416,B-CHEMICAL
and,1416,O
coronary,1416,O
artery,1416,O
disease,1416,O
in,1416,O
the,1416,O
French,1416,O
population,1416,O
.,1416,O
Methylenetetrahydrofolate,1417,B-CHEMICAL
reductase,1417,I-GENE-Y
polymorphism,1417,O
(,1417,O
MTHFR,1417,B-GENE-Y
C677T,1417,B-GENE-N
),1417,O
is,1417,O
an,1417,O
established,1417,O
determinant,1417,O
of,1417,O
homocysteine,1417,B-CHEMICAL
plasma,1417,O
level,1417,O
(,1417,O
t-Hcys,1417,O
),1417,O
while,1417,O
its,1417,O
association,1417,O
with,1417,O
coronary,1417,O
artery,1417,O
disease,1417,O
(,1417,O
CAD,1417,O
),1417,O
seems,1417,O
to,1417,O
be,1417,O
more,1417,O
limited,1417,O
.,1417,O
In,1418,O
contrast,1418,O
",",1418,O
the,1418,O
association,1418,O
of,1418,O
the,1418,O
substitutions,1418,O
A2756G,1418,B-GENE-N
of,1418,O
methionine,1418,B-CHEMICAL
synthase,1418,I-GENE-Y
(,1418,O
MTR,1418,B-GENE-Y
),1418,O
",",1418,O
A66G,1418,B-GENE-N
of,1418,O
methionine,1418,B-CHEMICAL
synthase,1418,I-GENE-Y
reductase,1418,I-GENE-Y
(,1418,O
MTRR,1418,B-GENE-Y
),1418,O
and,1418,O
C776G,1418,B-GENE-N
of,1418,O
transcobalamin,1418,B-GENE-N
(,1418,O
TCN,1418,B-GENE-N
),1418,O
to,1418,O
both,1418,O
t-Hcys,1418,O
and,1418,O
CAD,1418,O
needs,1418,O
to,1418,O
be,1418,O
evaluated,1418,O
further,1418,O
.,1418,O
The,1419,O
objective,1419,O
was,1419,O
to,1419,O
evaluate,1419,O
the,1419,O
association,1419,O
of,1419,O
these,1419,O
polymorphisms,1419,O
with,1419,O
t-Hcys,1419,O
and,1419,O
CAD,1419,O
in,1419,O
a,1419,O
French,1419,O
population,1419,O
.,1419,O
We,1420,O
investigated,1420,O
the,1420,O
individual,1420,O
and,1420,O
combined,1420,O
effects,1420,O
of,1420,O
these,1420,O
polymorphisms,1420,O
and,1420,O
of,1420,O
vitamin,1420,B-CHEMICAL
B12,1420,I-CHEMICAL
and,1420,O
folates,1420,B-CHEMICAL
with,1420,O
t-Hcys,1420,O
in,1420,O
530,1420,O
CAD,1420,O
patients,1420,O
and,1420,O
248,1420,O
matched,1420,O
healthy,1420,O
controls,1420,O
.,1420,O
t-Hcys,1421,O
was,1421,O
higher,1421,O
in,1421,O
the,1421,O
CAD,1421,O
group,1421,O
than,1421,O
in,1421,O
controls,1421,O
(,1421,O
11.8,1421,O
vs,1421,O
10.4,1421,O
microM,1421,O
",",1421,O
P,1421,O
<,1421,O
0.0001,1421,O
),1421,O
and,1421,O
in,1421,O
carriers,1421,O
of,1421,O
MTRRAA,1421,B-GENE-Y
and,1421,O
MTHFR,1421,B-GENE-Y
677TT,1421,O
than,1421,O
in,1421,O
those,1421,O
carrying,1421,O
the,1421,O
most,1421,O
frequent,1421,O
allele,1421,O
of,1421,O
both,1421,O
polymorphisms,1421,O
(,1421,O
13.8,1421,O
vs,1421,O
11.4,1421,O
microM,1421,O
",",1421,O
P,1421,O
=,1421,O
0.0102,1421,O
and,1421,O
12.5,1421,O
vs,1421,O
11.0,1421,O
mM,1421,O
",",1421,O
P,1421,O
=,1421,O
0.0065,1421,O
respectively,1421,O
),1421,O
.,1421,O
The,1422,O
frequency,1422,O
of,1422,O
MTRR,1422,B-GENE-Y
A,1422,O
allele,1422,O
was,1422,O
higher,1422,O
in,1422,O
CAD,1422,O
patients,1422,O
than,1422,O
in,1422,O
controls,1422,O
(,1422,O
0.48,1422,O
[,1422,O
95,1422,O
%,1422,O
CI,1422,O
:,1422,O
0.44-0.52,1422,O
],1422,O
vs,1422,O
0.38,1422,O
[,1422,O
95,1422,O
%,1422,O
CI,1422,O
:,1422,O
0.32-0.44,1422,O
],1422,O
",",1422,O
P,1422,O
=,1422,O
0.0081,1422,O
),1422,O
while,1422,O
no,1422,O
difference,1422,O
was,1422,O
observed,1422,O
for,1422,O
MTHFR,1422,B-GENE-Y
677T,1422,O
frequency,1422,O
.,1422,O
In,1423,O
multivariate,1423,O
analysis,1423,O
",",1423,O
t-Hcys,1423,O
>,1423,O
median,1423,O
and,1423,O
MTRRAA,1423,B-GENE-Y
genotype,1423,O
were,1423,O
two,1423,O
significant,1423,O
independent,1423,O
predictors,1423,O
of,1423,O
CAD,1423,O
with,1423,O
respective,1423,O
odds,1423,O
ratios,1423,O
of,1423,O
3.1,1423,O
(,1423,O
95,1423,O
%,1423,O
CI,1423,O
:,1423,O
1.8-5.1,1423,O
",",1423,O
P,1423,O
<,1423,O
0.0001,1423,O
),1423,O
and,1423,O
4.5,1423,O
(,1423,O
95,1423,O
%,1423,O
CI,1423,O
:,1423,O
1.5-13.1,1423,O
",",1423,O
P,1423,O
=,1423,O
0.0051,1423,O
),1423,O
.,1423,O
In,1424,O
conclusion,1424,O
",",1424,O
in,1424,O
contrast,1424,O
to,1424,O
North,1424,O
Europe,1424,O
studies,1424,O
",",1424,O
MTRRAA,1424,B-GENE-Y
genotype,1424,O
is,1424,O
a,1424,O
genetic,1424,O
determinant,1424,O
of,1424,O
moderate,1424,O
hyperhomocysteinemia,1424,O
associated,1424,O
with,1424,O
CAD,1424,O
in,1424,O
a,1424,O
French,1424,O
population,1424,O
without,1424,O
vitamin,1424,O
fortification,1424,O
.,1424,O
Vitamin,1425,B-CHEMICAL
E,1425,I-CHEMICAL
supplementation,1425,O
alters,1425,O
HDL-cholesterol,1425,B-GENE-N
concentration,1425,O
and,1425,O
paraoxonase,1425,B-GENE-Y
activity,1425,O
in,1425,O
rabbits,1425,O
fed,1425,O
high-cholesterol,1425,O
diet,1425,O
:,1425,O
comparison,1425,O
with,1425,O
probucol,1425,B-CHEMICAL
.,1425,O
Vitamin,1426,B-CHEMICAL
E,1426,I-CHEMICAL
and,1426,O
probucol,1426,B-CHEMICAL
are,1426,O
well-known,1426,O
antioxidants,1426,O
that,1426,O
prevent,1426,O
cells,1426,O
from,1426,O
the,1426,O
oxidative,1426,O
stress,1426,O
",",1426,O
which,1426,O
is,1426,O
a,1426,O
risk,1426,O
factor,1426,O
of,1426,O
atherosclerosis,1426,O
.,1426,O
Male,1427,O
rabbits,1427,O
were,1427,O
fed,1427,O
either,1427,O
0.03,1427,O
%,1427,O
vitamin,1427,B-CHEMICAL
E,1427,I-CHEMICAL
or,1427,O
0.05,1427,O
%,1427,O
probucol,1427,B-CHEMICAL
in,1427,O
a,1427,O
0.5,1427,O
%,1427,O
high-cholesterol,1427,O
(,1427,O
HC,1427,O
),1427,O
diet,1427,O
for,1427,O
8,1427,O
weeks,1427,O
.,1427,O
Vitamin,1428,B-CHEMICAL
E,1428,I-CHEMICAL
and,1428,O
probucol,1428,B-CHEMICAL
significantly,1428,O
suppressed,1428,O
an,1428,O
increase,1428,O
in,1428,O
plasma,1428,O
total-cholesterol,1428,O
(,1428,O
total-C,1428,O
),1428,O
and,1428,O
low-density,1428,B-GENE-N
lipoprotein,1428,I-GENE-N
cholesterol,1428,B-CHEMICAL
compared,1428,O
to,1428,O
HC-control,1428,O
group,1428,O
.,1428,O
However,1429,O
",",1429,O
plasma,1429,O
high-density,1429,B-GENE-N
lipoprotein-cholesterol,1429,O
(,1429,O
HDL-C,1429,B-GENE-N
),1429,O
and,1429,O
HDL-C/total-C,1429,B-GENE-N
ratio,1429,O
levels,1429,O
and,1429,O
plasma,1429,O
paraoxonase,1429,B-GENE-Y
activity,1429,O
were,1429,O
only,1429,O
significantly,1429,O
higher,1429,O
in,1429,O
vitamin,1429,B-CHEMICAL
E,1429,I-CHEMICAL
group,1429,O
after,1429,O
8,1429,O
weeks,1429,O
.,1429,O
Hepatic,1430,O
ACAT,1430,B-GENE-Y
activity,1430,O
was,1430,O
significantly,1430,O
lower,1430,O
in,1430,O
both,1430,O
vitamin,1430,B-CHEMICAL
E,1430,I-CHEMICAL
and,1430,O
probucol,1430,B-CHEMICAL
groups,1430,O
than,1430,O
in,1430,O
HC-control,1430,O
group,1430,O
",",1430,O
while,1430,O
HMG-CoA,1430,B-GENE-Y
reductase,1430,I-GENE-Y
activity,1430,O
was,1430,O
the,1430,O
highest,1430,O
only,1430,O
in,1430,O
the,1430,O
probucol,1430,B-CHEMICAL
group,1430,O
.,1430,O
Total,1431,O
fecal,1431,O
sterol,1431,B-CHEMICAL
content,1431,O
was,1431,O
significantly,1431,O
higher,1431,O
in,1431,O
probucol,1431,B-CHEMICAL
and,1431,O
vitamin,1431,B-CHEMICAL
E,1431,I-CHEMICAL
groups,1431,O
than,1431,O
in,1431,O
the,1431,O
two,1431,O
control,1431,O
groups,1431,O
.,1431,O
Some,1432,O
atherogenic,1432,O
signs,1432,O
were,1432,O
discovered,1432,O
in,1432,O
the,1432,O
aortic,1432,O
fatty,1432,O
streak,1432,O
of,1432,O
HC-control,1432,O
group,1432,O
",",1432,O
yet,1432,O
not,1432,O
in,1432,O
other,1432,O
groups,1432,O
.,1432,O
Hepatic,1433,O
mRNA,1433,O
expressions,1433,O
of,1433,O
apo,1433,B-GENE-Y
B-100,1433,I-GENE-Y
and,1433,O
apo,1433,B-GENE-Y
C-III,1433,I-GENE-Y
were,1433,O
significantly,1433,O
lower,1433,O
in,1433,O
probucol,1433,B-CHEMICAL
group,1433,O
than,1433,O
in,1433,O
other,1433,O
groups,1433,O
.,1433,O
Vitamin,1434,B-CHEMICAL
E,1434,I-CHEMICAL
supplementation,1434,O
was,1434,O
found,1434,O
to,1434,O
alter,1434,O
the,1434,O
plasma,1434,O
HDL-C-related,1434,B-GENE-N
factors,1434,O
;,1434,O
meanwhile,1434,O
",",1434,O
probucol,1434,B-CHEMICAL
supplementation,1434,O
was,1434,O
very,1434,O
effective,1434,O
in,1434,O
enhancing,1434,O
cholesterol,1434,B-CHEMICAL
metabolism,1434,O
",",1434,O
except,1434,O
for,1434,O
a,1434,O
negative,1434,O
effect,1434,O
that,1434,O
reduced,1434,O
plasma,1434,O
HDL-C,1434,B-GENE-N
concentration,1434,O
.,1434,O
Molecular,1435,O
cloning,1435,O
and,1435,O
radioligand,1435,O
binding,1435,O
characterization,1435,O
of,1435,O
the,1435,O
chemokine,1435,B-GENE-N
receptor,1435,I-GENE-N
CCR5,1435,I-GENE-N
from,1435,O
rhesus,1435,O
macaque,1435,O
and,1435,O
human,1435,O
.,1435,O
The,1436,O
aim,1436,O
of,1436,O
this,1436,O
study,1436,O
was,1436,O
to,1436,O
determine,1436,O
if,1436,O
macaque,1436,O
represents,1436,O
a,1436,O
suitable,1436,O
species,1436,O
for,1436,O
the,1436,O
pre-clinical,1436,O
evaluation,1436,O
of,1436,O
novel,1436,O
CCR5,1436,B-GENE-Y
antagonists,1436,O
",",1436,O
such,1436,O
as,1436,O
maraviroc,1436,B-CHEMICAL
(,1436,O
"UK-427,857",1436,B-CHEMICAL
),1436,O
.,1436,O
To,1437,O
do,1437,O
this,1437,O
we,1437,O
cloned,1437,O
and,1437,O
expressed,1437,O
CCR5,1437,B-GENE-Y
from,1437,O
rhesus,1437,O
macaque,1437,O
and,1437,O
compared,1437,O
the,1437,O
binding,1437,O
properties,1437,O
of,1437,O
[,1437,O
125I,1437,B-CHEMICAL
],1437,O
-MIP-1beta,1437,O
and,1437,O
[,1437,B-CHEMICAL
3H,1437,I-CHEMICAL
],1437,I-CHEMICAL
-maraviroc,1437,I-CHEMICAL
with,1437,O
human,1437,B-GENE-Y
recombinant,1437,I-GENE-Y
CCR5,1437,I-GENE-Y
.,1437,O
[,1438,O
125I,1438,B-CHEMICAL
],1438,O
-MIP-1beta,1438,O
bound,1438,O
with,1438,O
similar,1438,O
high,1438,O
affinity,1438,O
to,1438,O
CCR5,1438,B-GENE-N
from,1438,O
macaque,1438,O
(,1438,O
K,1438,O
(,1438,O
d,1438,O
),1438,O
=,1438,O
0.24,1438,O
+/-,1438,O
0.05,1438,O
nM,1438,O
),1438,O
and,1438,O
human,1438,O
(,1438,O
K,1438,O
(,1438,O
d,1438,O
),1438,O
=,1438,O
0.23,1438,O
+/-,1438,O
0.05,1438,O
nM,1438,O
),1438,O
and,1438,O
with,1438,O
similar,1438,O
kinetic,1438,O
properties,1438,O
.,1438,O
In,1439,O
competition,1439,O
binding,1439,O
studies,1439,O
the,1439,O
affinity,1439,O
of,1439,O
a,1439,O
range,1439,O
of,1439,O
human,1439,O
chemokines,1439,O
for,1439,O
macaque,1439,B-GENE-Y
CCR5,1439,I-GENE-Y
was,1439,O
also,1439,O
similar,1439,O
to,1439,O
human,1439,B-GENE-Y
CCR5,1439,I-GENE-Y
.,1439,O
Maraviroc,1440,B-CHEMICAL
inhibited,1440,O
binding,1440,O
of,1440,O
[,1440,O
125I,1440,B-CHEMICAL
],1440,O
-MIP-1beta,1440,O
to,1440,O
CCR5,1440,B-GENE-N
from,1440,O
macaque,1440,O
and,1440,O
human,1440,O
with,1440,O
similar,1440,O
potency,1440,O
(,1440,O
IC50,1440,O
=,1440,O
17.50,1440,O
+/-,1440,O
1.24,1440,O
nM,1440,O
and,1440,O
7.18,1440,O
+/-,1440,O
0.93,1440,O
nM,1440,O
",",1440,O
respectively,1440,O
),1440,O
and,1440,O
antagonised,1440,O
MIP-1beta,1440,O
induced,1440,O
intracellular,1440,O
calcium,1440,B-CHEMICAL
release,1440,O
mediated,1440,O
through,1440,O
CCR5,1440,B-GENE-N
from,1440,O
macaque,1440,O
and,1440,O
human,1440,O
with,1440,O
similar,1440,O
potency,1440,O
(,1440,O
IC50,1440,O
=,1440,O
17.50,1440,O
+/-,1440,O
3.30,1440,O
nM,1440,O
and,1440,O
12.07,1440,O
+/-,1440,O
1.89,1440,O
",",1440,O
respectively,1440,O
),1440,O
.,1440,O
[,1441,B-CHEMICAL
3H,1441,I-CHEMICAL
],1441,I-CHEMICAL
-maraviroc,1441,I-CHEMICAL
bound,1441,O
with,1441,O
high,1441,O
affinity,1441,O
to,1441,O
CCR5,1441,B-GENE-N
from,1441,O
macaque,1441,O
(,1441,O
K,1441,O
(,1441,O
d,1441,O
),1441,O
=,1441,O
1.36+/-0.07,1441,O
nM,1441,O
),1441,O
and,1441,O
human,1441,O
(,1441,O
K,1441,O
(,1441,O
d,1441,O
),1441,O
=,1441,O
0.86,1441,O
+/-,1441,O
0.08,1441,O
nM,1441,O
),1441,O
",",1441,O
but,1441,O
was,1441,O
found,1441,O
to,1441,O
dissociate,1441,O
approximately,1441,O
10-fold,1441,O
more,1441,O
quickly,1441,O
from,1441,O
macaque,1441,B-GENE-Y
CCR5,1441,I-GENE-Y
.,1441,O
However,1442,O
",",1442,O
as,1442,O
with,1442,O
the,1442,O
human,1442,O
receptor,1442,O
",",1442,O
maraviroc,1442,B-CHEMICAL
was,1442,O
shown,1442,O
to,1442,O
be,1442,O
a,1442,O
high,1442,O
affinity,1442,O
",",1442,O
potent,1442,O
functional,1442,O
antagonist,1442,O
of,1442,O
macaque,1442,B-GENE-Y
CCR5,1442,I-GENE-Y
thereby,1442,O
indicating,1442,O
that,1442,O
the,1442,O
macaque,1442,O
should,1442,O
be,1442,O
a,1442,O
suitable,1442,O
species,1442,O
in,1442,O
which,1442,O
to,1442,O
evaluate,1442,O
the,1442,O
pharmacology,1442,O
",",1442,O
safety,1442,O
and,1442,O
potential,1442,O
mechanism-related,1442,O
toxicology,1442,O
of,1442,O
novel,1442,O
CCR5,1442,B-GENE-Y
antagonists,1442,O
.,1442,O
A,1443,O
novel,1443,O
function,1443,O
of,1443,O
differentiation,1443,O
revealed,1443,O
by,1443,O
cDNA,1443,O
microarray,1443,O
profiling,1443,O
of,1443,O
p75NTR-regulated,1443,B-GENE-Y
gene,1443,O
expression,1443,O
.,1443,O
The,1444,O
expression,1444,O
of,1444,O
the,1444,O
p75,1444,B-GENE-Y
neurotrophin,1444,I-GENE-Y
receptor,1444,I-GENE-Y
(,1444,O
p75NTR,1444,B-GENE-Y
),1444,O
is,1444,O
diminished,1444,O
in,1444,O
epithelial,1444,O
cells,1444,O
during,1444,O
progression,1444,O
of,1444,O
prostate,1444,O
cancer,1444,O
in,1444,O
vivo,1444,O
and,1444,O
in,1444,O
vitro,1444,O
.,1444,O
Previous,1445,O
studies,1445,O
have,1445,O
demonstrated,1445,O
a,1445,O
role,1445,O
for,1445,O
p75NTR,1445,B-GENE-Y
as,1445,O
a,1445,O
tumor,1445,O
suppressor,1445,O
in,1445,O
prostate,1445,O
growth,1445,O
.,1445,O
To,1446,O
better,1446,O
understand,1446,O
the,1446,O
molecular,1446,O
mechanism,1446,O
of,1446,O
p75,1446,B-GENE-Y
(,1446,I-GENE-Y
NTR,1446,I-GENE-Y
),1446,I-GENE-Y
on,1446,O
tumor,1446,O
suppression,1446,O
",",1446,O
we,1446,O
utilized,1446,O
a,1446,O
complementary,1446,O
deoxyribonucleic,1446,B-CHEMICAL
acid,1446,I-CHEMICAL
microarray,1446,O
composed,1446,O
of,1446,O
approximately,1446,O
"6,000",1446,O
human,1446,O
cancer-related,1446,O
genes,1446,O
to,1446,O
determine,1446,O
the,1446,O
gene,1446,O
expression,1446,O
pattern,1446,O
altered,1446,O
by,1446,O
re-introduction,1446,O
of,1446,O
p75NTR,1446,B-GENE-Y
into,1446,O
PC-3,1446,O
prostate,1446,O
tumor,1446,O
cells,1446,O
.,1446,O
Comparison,1447,O
of,1447,O
the,1447,O
transcripts,1447,O
in,1447,O
the,1447,O
neo,1447,O
and,1447,O
p75NTR-transfected,1447,B-GENE-Y
cells,1447,O
revealed,1447,O
52,1447,O
differentially,1447,O
expressed,1447,O
genes,1447,O
",",1447,O
of,1447,O
which,1447,O
21,1447,O
were,1447,O
up-regulated,1447,O
and,1447,O
31,1447,O
were,1447,O
down-regulated,1447,O
in,1447,O
the,1447,O
presence,1447,O
of,1447,O
p75NTR,1447,B-GENE-Y
.,1447,O
Based,1448,O
on,1448,O
the,1448,O
known,1448,O
biological,1448,O
functions,1448,O
of,1448,O
the,1448,O
p75NTR-regulated,1448,B-GENE-Y
genes,1448,O
",",1448,O
we,1448,O
observed,1448,O
that,1448,O
p75NTR,1448,B-GENE-Y
modulated,1448,O
the,1448,O
expression,1448,O
of,1448,O
genes,1448,O
that,1448,O
are,1448,O
critically,1448,O
involved,1448,O
in,1448,O
the,1448,O
regulation,1448,O
of,1448,O
differentiation,1448,O
as,1448,O
well,1448,O
as,1448,O
cell,1448,O
adhesion,1448,O
",",1448,O
signal,1448,O
transduction,1448,O
",",1448,O
apoptosis,1448,O
",",1448,O
tumor,1448,O
cell,1448,O
invasion,1448,O
",",1448,O
and,1448,O
metastasis,1448,O
.,1448,O
Several,1449,O
differentially,1449,O
expressed,1449,O
genes,1449,O
identified,1449,O
by,1449,O
microarray,1449,O
were,1449,O
selected,1449,O
for,1449,O
confirmation,1449,O
using,1449,O
quantitative,1449,O
real-time,1449,O
polymerase,1449,O
chain,1449,O
reaction,1449,O
.,1449,O
Immunoblot,1450,O
analysis,1450,O
further,1450,O
confirmed,1450,O
increased,1450,O
cellular,1450,B-GENE-Y
retinoic,1450,I-GENE-Y
acid-binding,1450,I-GENE-Y
protein,1450,I-GENE-Y
I,1450,I-GENE-Y
(,1450,O
CRABPI,1450,B-GENE-Y
),1450,O
and,1450,O
IGFBP5,1450,B-GENE-Y
protein,1450,O
levels,1450,O
and,1450,O
decreased,1450,O
level,1450,O
of,1450,O
PLAUR,1450,B-GENE-Y
protein,1450,O
with,1450,O
increasing,1450,O
p75NTR,1450,B-GENE-Y
protein,1450,O
expression,1450,O
.,1450,O
As,1451,O
CRABPI,1451,B-GENE-Y
was,1451,O
elevated,1451,O
far,1451,O
more,1451,O
than,1451,O
any,1451,O
other,1451,O
genes,1451,O
",",1451,O
we,1451,O
observed,1451,O
that,1451,O
the,1451,O
retinoids,1451,B-CHEMICAL
",",1451,O
all-trans,1451,B-CHEMICAL
retinoic,1451,I-CHEMICAL
acid,1451,I-CHEMICAL
and,1451,O
9-cis,1451,B-CHEMICAL
retinoic,1451,I-CHEMICAL
acid,1451,I-CHEMICAL
",",1451,O
that,1451,O
bind,1451,O
CRABPI,1451,B-GENE-Y
",",1451,O
promoted,1451,O
nitroblue,1451,B-CHEMICAL
tetrazolium-associated,1451,O
functional,1451,O
cell,1451,O
differentiation,1451,O
in,1451,O
p75NTR,1451,B-GENE-Y
PC-3,1451,O
cells,1451,O
",",1451,O
but,1451,O
not,1451,O
in,1451,O
neo,1451,O
control,1451,O
PC-3,1451,O
cells,1451,O
.,1451,O
Subsequent,1452,O
examination,1452,O
of,1452,O
the,1452,O
retinoic,1452,B-CHEMICAL
acid,1452,I-CHEMICAL
receptors,1452,I-GENE-N
(,1452,B-GENE-N
RARs,1452,I-GENE-N
),1452,O
expression,1452,O
levels,1452,O
demonstrated,1452,O
an,1452,O
absence,1452,O
of,1452,O
RAR-beta,1452,B-GENE-Y
in,1452,O
the,1452,O
neo,1452,O
control,1452,O
cells,1452,O
and,1452,O
re-expression,1452,O
in,1452,O
the,1452,O
p75NTR,1452,B-GENE-Y
expressing,1452,O
cells,1452,O
",",1452,O
consistent,1452,O
with,1452,O
previous,1452,O
findings,1452,O
where,1452,O
RAR-beta,1452,B-GENE-Y
is,1452,O
believed,1452,O
to,1452,O
play,1452,O
a,1452,O
critical,1452,O
role,1452,O
as,1452,O
a,1452,O
tumor,1452,O
suppressor,1452,O
gene,1452,O
that,1452,O
is,1452,O
lost,1452,O
during,1452,O
de-differentiation,1452,O
of,1452,O
prostate,1452,O
epithelial,1452,O
cells,1452,O
.,1452,O
Whereas,1453,O
the,1453,O
RAR-alpha,1453,B-GENE-N
and,1453,I-GENE-N
-gamma,1453,I-GENE-N
protein,1453,O
levels,1453,O
remained,1453,O
unchanged,1453,O
",",1453,O
retinoid,1453,B-GENE-N
X,1453,I-GENE-N
receptor,1453,I-GENE-N
(,1453,I-GENE-N
RXR,1453,I-GENE-N
),1453,I-GENE-N
-alpha,1453,I-GENE-N
and,1453,I-GENE-N
-beta,1453,I-GENE-N
also,1453,O
exhibited,1453,O
increasing,1453,O
protein,1453,O
levels,1453,O
with,1453,O
re-expression,1453,O
of,1453,O
the,1453,O
p75NTR,1453,B-GENE-Y
protein,1453,O
.,1453,O
Moreover,1454,O
",",1454,O
the,1454,O
ability,1454,O
of,1454,O
p75NTR,1454,B-GENE-Y
siRNA,1454,O
to,1454,O
knockdown,1454,O
levels,1454,O
of,1454,O
RAR-beta,1454,B-GENE-Y
",",1454,O
RXR-alpha,1454,B-GENE-Y
",",1454,O
and,1454,O
RXR-beta,1454,B-GENE-Y
supports,1454,O
the,1454,O
specificity,1454,O
of,1454,O
the,1454,O
functional,1454,O
involvement,1454,O
of,1454,O
p75NTR,1454,B-GENE-Y
in,1454,O
differentiation,1454,O
.,1454,O
Hence,1455,O
",",1455,O
re-expression,1455,O
of,1455,O
the,1455,O
p75NTR,1455,B-GENE-Y
appears,1455,O
to,1455,O
partially,1455,O
reverse,1455,O
de-differentiation,1455,O
of,1455,O
prostate,1455,O
cancer,1455,O
cells,1455,O
by,1455,O
up-regulating,1455,O
the,1455,O
expression,1455,O
of,1455,O
CRABPI,1455,B-GENE-Y
for,1455,O
localized,1455,O
sequestration,1455,O
of,1455,O
retinoids,1455,B-CHEMICAL
that,1455,O
are,1455,O
available,1455,O
to,1455,O
newly,1455,O
up-regulated,1455,O
RAR-beta,1455,B-GENE-Y
",",1455,O
RXR-alpha,1455,B-GENE-Y
",",1455,O
and,1455,O
RXR-beta,1455,B-GENE-Y
.,1455,O
GPR109A,1456,B-GENE-Y
(,1456,O
PUMA-G/HM74A,1456,B-GENE-Y
),1456,O
mediates,1456,O
nicotinic,1456,B-CHEMICAL
acid-induced,1456,O
flushing,1456,O
.,1456,O
Nicotinic,1457,B-CHEMICAL
acid,1457,I-CHEMICAL
(,1457,O
niacin,1457,B-CHEMICAL
),1457,O
has,1457,O
long,1457,O
been,1457,O
used,1457,O
as,1457,O
an,1457,O
antidyslipidemic,1457,O
drug,1457,O
.,1457,O
Its,1458,O
special,1458,O
profile,1458,O
of,1458,O
actions,1458,O
",",1458,O
especially,1458,O
the,1458,O
rise,1458,O
in,1458,O
HDL-cholesterol,1458,B-GENE-N
levels,1458,O
induced,1458,O
by,1458,O
nicotinic,1458,B-CHEMICAL
acid,1458,I-CHEMICAL
",",1458,O
is,1458,O
unique,1458,O
among,1458,O
the,1458,O
currently,1458,O
available,1458,O
pharmacological,1458,O
tools,1458,O
to,1458,O
treat,1458,O
lipid,1458,O
disorders,1458,O
.,1458,O
Recently,1459,O
",",1459,O
a,1459,O
G-protein-coupled,1459,B-GENE-N
receptor,1459,I-GENE-N
",",1459,O
termed,1459,O
GPR109A,1459,B-GENE-Y
(,1459,O
HM74A,1459,B-GENE-Y
in,1459,O
humans,1459,O
",",1459,O
PUMA-G,1459,B-GENE-Y
in,1459,O
mice,1459,O
),1459,O
",",1459,O
was,1459,O
described,1459,O
and,1459,O
shown,1459,O
to,1459,O
mediate,1459,O
the,1459,O
nicotinic,1459,B-CHEMICAL
acid-induced,1459,O
antilipolytic,1459,O
effects,1459,O
in,1459,O
adipocytes,1459,O
.,1459,O
One,1460,O
of,1460,O
the,1460,O
major,1460,O
problems,1460,O
of,1460,O
the,1460,O
pharmacotherapeutical,1460,O
use,1460,O
of,1460,O
nicotinic,1460,B-CHEMICAL
acid,1460,I-CHEMICAL
is,1460,O
a,1460,O
strong,1460,O
flushing,1460,O
response,1460,O
.,1460,O
This,1461,O
side,1461,O
effect,1461,O
",",1461,O
although,1461,O
harmless,1461,O
",",1461,O
strongly,1461,O
affects,1461,O
patient,1461,O
compliance,1461,O
.,1461,O
In,1462,O
the,1462,O
present,1462,O
study,1462,O
",",1462,O
we,1462,O
show,1462,O
that,1462,O
mice,1462,O
lacking,1462,O
PUMA-G,1462,B-GENE-Y
did,1462,O
not,1462,O
show,1462,O
nicotinic,1462,B-CHEMICAL
acid-induced,1462,O
flushing,1462,O
.,1462,O
In,1463,O
addition,1463,O
",",1463,O
flushing,1463,O
in,1463,O
response,1463,O
to,1463,O
nicotinic,1463,B-CHEMICAL
acid,1463,I-CHEMICAL
was,1463,O
also,1463,O
abrogated,1463,O
in,1463,O
the,1463,O
absence,1463,O
of,1463,O
cyclooxygenase,1463,B-GENE-Y
type,1463,I-GENE-Y
1,1463,I-GENE-Y
",",1463,O
and,1463,O
mice,1463,O
lacking,1463,O
prostaglandin,1463,B-GENE-N
D,1463,I-GENE-N
(,1463,I-GENE-N
2,1463,I-GENE-N
),1463,I-GENE-N
(,1463,I-GENE-N
PGD,1463,I-GENE-N
(,1463,I-GENE-N
2,1463,I-GENE-N
),1463,I-GENE-N
),1463,I-GENE-N
and,1463,I-GENE-N
prostaglandin,1463,I-GENE-N
E,1463,I-GENE-N
(,1463,I-GENE-N
2,1463,I-GENE-N
),1463,I-GENE-N
(,1463,I-GENE-N
PGE,1463,I-GENE-N
(,1463,I-GENE-N
2,1463,I-GENE-N
),1463,I-GENE-N
),1463,I-GENE-N
receptors,1463,I-GENE-N
had,1463,O
reduced,1463,O
flushing,1463,O
responses,1463,O
.,1463,O
The,1464,O
mouse,1464,O
orthologue,1464,O
of,1464,O
GPR109A,1464,B-GENE-Y
",",1464,O
PUMA-G,1464,B-GENE-Y
",",1464,O
is,1464,O
highly,1464,O
expressed,1464,O
in,1464,O
macrophages,1464,O
and,1464,O
other,1464,O
immune,1464,O
cells,1464,O
",",1464,O
and,1464,O
transplantation,1464,O
of,1464,O
wild-type,1464,O
bone,1464,O
marrow,1464,O
into,1464,O
irradiated,1464,O
PUMA-G-deficient,1464,B-GENE-Y
mice,1464,O
restored,1464,O
the,1464,O
nicotinic,1464,B-CHEMICAL
acid-induced,1464,O
flushing,1464,O
response,1464,O
.,1464,O
Our,1465,O
data,1465,O
clearly,1465,O
indicate,1465,O
that,1465,O
GPR109A,1465,B-GENE-Y
mediates,1465,O
nicotinic,1465,B-CHEMICAL
acid-induced,1465,O
flushing,1465,O
and,1465,O
that,1465,O
this,1465,O
effect,1465,O
involves,1465,O
release,1465,O
of,1465,O
PGE,1465,B-CHEMICAL
(,1465,I-CHEMICAL
2,1465,I-CHEMICAL
),1465,I-CHEMICAL
and,1465,O
PGD,1465,B-CHEMICAL
(,1465,I-CHEMICAL
2,1465,I-CHEMICAL
),1465,I-CHEMICAL
",",1465,O
most,1465,O
likely,1465,O
from,1465,O
immune,1465,O
cells,1465,O
of,1465,O
the,1465,O
skin,1465,O
.,1465,O
The,1466,O
Arg389Gly,1466,B-GENE-N
beta1-adrenoceptor,1466,B-GENE-Y
polymorphism,1466,O
and,1466,O
catecholamine,1466,B-CHEMICAL
effects,1466,O
on,1466,O
plasma-renin,1466,O
activity,1466,O
.,1466,O
OBJECTIVES,1467,O
:,1467,O
The,1467,O
purpose,1467,O
of,1467,O
this,1467,O
research,1467,O
was,1467,O
to,1467,O
find,1467,O
out,1467,O
whether,1467,O
",",1467,O
in,1467,O
humans,1467,O
",",1467,O
dobutamine-induced,1467,B-CHEMICAL
hemodynamic,1467,O
effects,1467,O
and,1467,O
increase,1467,O
in,1467,O
plasma-renin,1467,O
activity,1467,O
(,1467,O
PRA,1467,O
),1467,O
might,1467,O
be,1467,O
beta1-adrenoceptor,1467,B-GENE-Y
(,1467,O
beta1AR,1467,B-GENE-Y
),1467,O
genotype-dependent,1467,O
.,1467,O
BACKGROUND,1468,O
:,1468,O
In,1468,O
vitro,1468,O
Arg389Gly-beta1AR,1468,B-GENE-N
polymorphism,1468,O
exhibits,1468,O
decreased,1468,O
receptor,1468,O
signaling,1468,O
.,1468,O
METHODS,1469,O
:,1469,O
We,1469,O
studied,1469,O
10,1469,O
male,1469,O
homozygous,1469,O
Arg389-beta1AR,1469,O
subjects,1469,O
and,1469,O
8,1469,O
male,1469,O
homozygous,1469,O
Gly389beta1AR,1469,O
subjects,1469,O
;,1469,O
to,1469,O
avoid,1469,O
influences,1469,O
of,1469,O
codon,1469,O
49,1469,O
polymorphism,1469,O
",",1469,O
all,1469,O
were,1469,O
homozygous,1469,O
Ser49-beta1AR,1469,O
.,1469,O
Subjects,1470,O
were,1470,O
infused,1470,O
with,1470,O
dobutamine,1470,B-CHEMICAL
(,1470,O
1,1470,O
to,1470,O
6,1470,O
microg/kg/min,1470,O
),1470,O
with,1470,O
or,1470,O
without,1470,O
bisoprolol,1470,B-CHEMICAL
(,1470,O
10,1470,O
mg,1470,O
orally,1470,O
),1470,O
pretreatment,1470,O
",",1470,O
and,1470,O
PRA,1470,O
",",1470,O
heart,1470,O
rate,1470,O
",",1470,O
contractility,1470,O
",",1470,O
and,1470,O
blood,1470,O
pressure,1470,O
were,1470,O
assessed,1470,O
.,1470,O
RESULTS,1471,O
:,1471,O
With,1471,O
regard,1471,O
to,1471,O
PRA,1471,O
",",1471,O
dobutamine,1471,B-CHEMICAL
increased,1471,O
PRA,1471,O
more,1471,O
potently,1471,O
in,1471,O
Arg389-beta1AR,1471,O
versus,1471,O
Gly389-beta1AR,1471,O
subjects,1471,O
.,1471,O
Bisoprolol,1472,B-CHEMICAL
markedly,1472,O
suppressed,1472,O
the,1472,O
dobutamine-induced,1472,B-CHEMICAL
PRA,1472,O
increase,1472,O
in,1472,O
Arg389-,1472,O
but,1472,O
only,1472,O
marginally,1472,O
in,1472,O
Gly389-beta1AR,1472,O
subjects,1472,O
.,1472,O
With,1473,O
regard,1473,O
to,1473,O
hemodynamics,1473,O
",",1473,O
dobutamine,1473,B-CHEMICAL
caused,1473,O
larger,1473,O
heart,1473,O
rate,1473,O
and,1473,O
contractility,1473,O
increases,1473,O
and,1473,O
diastolic,1473,O
blood,1473,O
pressure,1473,O
decreases,1473,O
in,1473,O
Arg389-,1473,O
versus,1473,O
Gly389-beta1AR,1473,O
subjects,1473,O
.,1473,O
Bisoprolol,1474,B-CHEMICAL
reduced,1474,O
dobutamine-induced,1474,B-CHEMICAL
heart,1474,O
rate,1474,O
and,1474,O
contractility,1474,O
increases,1474,O
and,1474,O
diastolic,1474,O
blood,1474,O
pressure,1474,O
decreases,1474,O
more,1474,O
potently,1474,O
in,1474,O
Arg389-,1474,O
versus,1474,O
Gly389-beta1AR,1474,O
subjects,1474,O
.,1474,O
CONCLUSIONS,1475,O
:,1475,O
Codon,1475,O
389,1475,O
beta1AR,1475,B-GENE-Y
polymorphism,1475,O
is,1475,O
a,1475,O
determinant,1475,O
not,1475,O
only,1475,O
of,1475,O
hemodynamic,1475,O
effects,1475,O
but,1475,O
also,1475,O
of,1475,O
PRA,1475,O
.,1475,O
Thus,1476,O
",",1476,O
beta1AR,1476,B-GENE-Y
polymorphisms,1476,O
may,1476,O
be,1476,O
useful,1476,O
for,1476,O
predicting,1476,O
therapeutic,1476,O
responses,1476,O
to,1476,O
betaAR-blocker,1476,B-GENE-N
treatment,1476,O
.,1476,O
Valproic,1477,B-CHEMICAL
acid,1477,I-CHEMICAL
selectively,1477,O
inhibits,1477,O
conversion,1477,O
of,1477,O
arachidonic,1477,B-CHEMICAL
acid,1477,I-CHEMICAL
to,1477,O
arachidonoyl-CoA,1477,B-CHEMICAL
by,1477,O
brain,1477,B-GENE-N
microsomal,1477,I-GENE-N
long-chain,1477,I-GENE-N
fatty,1477,I-GENE-N
acyl-CoA,1477,I-GENE-N
synthetases,1477,I-GENE-N
:,1477,O
relevance,1477,O
to,1477,O
bipolar,1477,O
disorder,1477,O
.,1477,O
RATIONALE,1478,O
:,1478,O
Several,1478,O
drugs,1478,O
used,1478,O
to,1478,O
treat,1478,O
bipolar,1478,O
disorder,1478,O
(,1478,O
lithium,1478,B-CHEMICAL
and,1478,O
carbamazepine,1478,B-CHEMICAL
),1478,O
",",1478,O
when,1478,O
administered,1478,O
chronically,1478,O
to,1478,O
rats,1478,O
",",1478,O
reduce,1478,O
the,1478,O
turnover,1478,O
of,1478,O
arachidonic,1478,B-CHEMICAL
acid,1478,I-CHEMICAL
",",1478,O
but,1478,O
not,1478,O
docosahexaenoic,1478,B-CHEMICAL
acid,1478,I-CHEMICAL
",",1478,O
in,1478,O
brain,1478,O
phospholipids,1478,O
by,1478,O
decreasing,1478,O
the,1478,O
activity,1478,O
of,1478,O
an,1478,O
arachidonic,1478,B-CHEMICAL
acid-selective,1478,O
phospholipase,1478,B-GENE-N
A,1478,I-GENE-N
(,1478,I-GENE-N
2,1478,I-GENE-N
),1478,I-GENE-N
.,1478,O
Although,1479,O
chronic,1479,O
valproic,1479,B-CHEMICAL
acid,1479,I-CHEMICAL
produces,1479,O
similar,1479,O
effects,1479,O
on,1479,O
brain,1479,O
arachidonic,1479,B-CHEMICAL
acid,1479,I-CHEMICAL
and,1479,O
docosahexaenoic,1479,B-CHEMICAL
acid,1479,I-CHEMICAL
turnover,1479,O
",",1479,O
it,1479,O
does,1479,O
not,1479,O
alter,1479,O
phospholipase,1479,B-GENE-N
A,1479,I-GENE-N
(,1479,I-GENE-N
2,1479,I-GENE-N
),1479,I-GENE-N
activity,1479,O
",",1479,O
suggesting,1479,O
that,1479,O
it,1479,O
targets,1479,O
a,1479,O
different,1479,O
enzyme,1479,O
in,1479,O
the,1479,O
turnover,1479,O
pathway,1479,O
.,1479,O
MATERIALS,1480,O
AND,1480,O
METHODS/RESULTS,1480,O
:,1480,O
By,1480,O
isolating,1480,O
rat,1480,B-GENE-N
brain,1480,I-GENE-N
microsomal,1480,I-GENE-N
long-chain,1480,I-GENE-N
fatty,1480,I-GENE-N
acyl-CoA,1480,I-GENE-N
synthetases,1480,I-GENE-N
(,1480,O
Acsl,1480,B-GENE-N
),1480,O
",",1480,O
we,1480,O
show,1480,O
in,1480,O
vitro,1480,O
that,1480,O
valproic,1480,B-CHEMICAL
acid,1480,I-CHEMICAL
is,1480,O
a,1480,O
non-competitive,1480,O
inhibitor,1480,O
of,1480,O
Acsl,1480,B-GENE-N
",",1480,O
as,1480,O
it,1480,O
reduces,1480,O
the,1480,O
maximal,1480,O
velocity,1480,O
of,1480,O
the,1480,O
reaction,1480,O
without,1480,O
changing,1480,O
the,1480,O
affinity,1480,O
of,1480,O
the,1480,O
substrate,1480,O
for,1480,O
the,1480,O
enzyme,1480,O
.,1480,O
While,1481,O
valproic,1481,B-CHEMICAL
acid,1481,I-CHEMICAL
inhibited,1481,O
the,1481,O
synthesis,1481,O
of,1481,O
arachidonoyl-CoA,1481,B-CHEMICAL
",",1481,O
palmitoyl-CoA,1481,B-CHEMICAL
",",1481,O
and,1481,O
docosahexaenoyl-CoA,1481,B-CHEMICAL
",",1481,O
the,1481,O
K,1481,O
(,1481,O
i,1481,O
),1481,O
for,1481,O
inhibition,1481,O
of,1481,O
arachidonoyl-CoA,1481,B-CHEMICAL
synthesis,1481,O
(,1481,O
14.1,1481,O
mM,1481,O
),1481,O
was,1481,O
approximately,1481,O
one,1481,O
fifth,1481,O
the,1481,O
K,1481,O
(,1481,O
i,1481,O
),1481,O
for,1481,O
inhibiting,1481,O
palmitoyl-CoA,1481,B-CHEMICAL
(,1481,O
85.4,1481,O
mM,1481,O
),1481,O
and,1481,O
docosahexaenoyl-CoA,1481,B-CHEMICAL
(,1481,O
78.2,1481,O
mM,1481,O
),1481,O
synthesis,1481,O
.,1481,O
As,1482,O
chronic,1482,O
administration,1482,O
of,1482,O
valproic,1482,B-CHEMICAL
acid,1482,I-CHEMICAL
in,1482,O
bipolar,1482,O
disorder,1482,O
achieves,1482,O
whole-brain,1482,O
levels,1482,O
of,1482,O
1.0,1482,O
to,1482,O
1.5,1482,O
mM,1482,O
",",1482,O
inhibition,1482,O
of,1482,O
arachidonoyl-CoA,1482,B-CHEMICAL
formation,1482,O
can,1482,O
occur,1482,O
at,1482,O
brain,1482,O
concentrations,1482,O
that,1482,O
are,1482,O
therapeutically,1482,O
relevant,1482,O
to,1482,O
this,1482,O
disease,1482,O
.,1482,O
Furthermore,1483,O
",",1483,O
brain,1483,B-GENE-N
microsomal,1483,I-GENE-N
Acsl,1483,I-GENE-N
did,1483,O
not,1483,O
produce,1483,O
valproyl-CoA,1483,B-CHEMICAL
.,1483,O
CONCLUSIONS,1484,O
:,1484,O
This,1484,O
study,1484,O
shows,1484,O
that,1484,O
valproic,1484,B-CHEMICAL
acid,1484,I-CHEMICAL
acts,1484,O
as,1484,O
a,1484,O
non-competitive,1484,O
inhibitor,1484,O
of,1484,O
brain,1484,B-GENE-N
microsomal,1484,I-GENE-N
Acsl,1484,I-GENE-N
",",1484,O
and,1484,O
that,1484,O
inhibition,1484,O
is,1484,O
substrate-selective,1484,O
.,1484,O
The,1485,O
study,1485,O
supports,1485,O
the,1485,O
hypothesis,1485,O
that,1485,O
valproic,1485,B-CHEMICAL
acid,1485,I-CHEMICAL
acts,1485,O
in,1485,O
bipolar,1485,O
disorder,1485,O
by,1485,O
reducing,1485,O
the,1485,O
brain,1485,O
arachidonic,1485,B-CHEMICAL
acid,1485,I-CHEMICAL
cascade,1485,O
",",1485,O
by,1485,O
inhibiting,1485,O
arachidonoyl-CoA,1485,B-CHEMICAL
formation,1485,O
.,1485,O
From,1486,O
an,1486,O
inborn,1486,O
error,1486,O
patient,1486,O
to,1486,O
a,1486,O
search,1486,O
for,1486,O
regulatory,1486,O
meaning,1486,O
:,1486,O
a,1486,O
biotin,1486,B-CHEMICAL
conducted,1486,O
voyage,1486,O
.,1486,O
This,1487,O
article,1487,O
summarizes,1487,O
some,1487,O
findings,1487,O
of,1487,O
a,1487,O
research,1487,O
that,1487,O
I,1487,O
have,1487,O
pursued,1487,O
for,1487,O
the,1487,O
past,1487,O
25,1487,O
years,1487,O
",",1487,O
whose,1487,O
roots,1487,O
are,1487,O
immersed,1487,O
in,1487,O
the,1487,O
field,1487,O
of,1487,O
inherited,1487,O
metabolic,1487,O
disorders,1487,O
",",1487,O
and,1487,O
deal,1487,O
with,1487,O
different,1487,O
aspects,1487,O
of,1487,O
the,1487,O
vitamin,1487,O
biotin,1487,B-CHEMICAL
",",1487,O
starting,1487,O
with,1487,O
a,1487,O
patient,1487,O
with,1487,O
multiple,1487,O
carboxylase,1487,B-GENE-N
deficiency,1487,O
(,1487,O
MCD,1487,O
),1487,O
.,1487,O
Several,1488,O
of,1488,O
MCD,1488,O
clinical,1488,O
manifestations,1488,O
resemble,1488,O
those,1488,O
of,1488,O
infant,1488,O
malnutrition,1488,O
;,1488,O
we,1488,O
demonstrated,1488,O
that,1488,O
about,1488,O
one-third,1488,O
of,1488,O
infants,1488,O
with,1488,O
this,1488,O
common,1488,O
nutritional,1488,O
disorder,1488,O
were,1488,O
indeed,1488,O
biotin-deficient,1488,B-CHEMICAL
",",1488,O
and,1488,O
that,1488,O
this,1488,O
deficiency,1488,O
is,1488,O
metabolically,1488,O
significant,1488,O
",",1488,O
by,1488,O
studying,1488,O
urine,1488,O
instead,1488,O
of,1488,O
blood,1488,O
",",1488,O
studying,1488,O
urinary,1488,O
organic,1488,O
acids,1488,O
by,1488,O
gas,1488,O
chromatography-mass,1488,O
spectrometry,1488,O
.,1488,O
Remarkably,1489,O
",",1489,O
the,1489,O
metabolic,1489,O
abnormalities,1489,O
became,1489,O
apparent,1489,O
only,1489,O
after,1489,O
protein,1489,O
feeding,1489,O
was,1489,O
started,1489,O
",",1489,O
suggesting,1489,O
that,1489,O
this,1489,O
phenomenon,1489,O
may,1489,O
contribute,1489,O
to,1489,O
the,1489,O
worsening,1489,O
of,1489,O
malnourished,1489,O
individuals,1489,O
when,1489,O
they,1489,O
are,1489,O
abruptly,1489,O
fed,1489,O
.,1489,O
Afterwards,1490,O
",",1490,O
we,1490,O
studied,1490,O
biotin,1490,B-CHEMICAL
deficiency,1490,O
at,1490,O
the,1490,O
tissue,1490,O
level,1490,O
.,1490,O
Carboxylase,1491,B-GENE-N
activities,1491,O
and,1491,O
masses,1491,O
were,1491,O
significantly,1491,O
reduced,1491,O
in,1491,O
liver,1491,O
",",1491,O
kidney,1491,O
",",1491,O
muscle,1491,O
",",1491,O
adipose,1491,O
tissue,1491,O
",",1491,O
intestine,1491,O
",",1491,O
and,1491,O
spleen,1491,O
",",1491,O
but,1491,O
brain,1491,O
and,1491,O
heart,1491,O
were,1491,O
spared,1491,O
;,1491,O
their,1491,O
mRNAs,1491,O
remained,1491,O
unchanged,1491,O
.,1491,O
On,1492,O
the,1492,O
other,1492,O
hand,1492,O
",",1492,O
holocarboxylase,1492,B-GENE-Y
synthetase,1492,I-GENE-Y
(,1492,O
HCS,1492,B-GENE-Y
),1492,O
mRNA,1492,O
levels,1492,O
were,1492,O
markedly,1492,O
low,1492,O
in,1492,O
the,1492,O
deficient,1492,O
animals,1492,O
",",1492,O
and,1492,O
increased,1492,O
upon,1492,O
biotin,1492,B-CHEMICAL
injection,1492,O
.,1492,O
Over,1493,O
2000,1493,O
human,1493,O
genes,1493,O
have,1493,O
been,1493,O
identified,1493,O
that,1493,O
depend,1493,O
on,1493,O
biotin,1493,B-CHEMICAL
for,1493,O
expression,1493,O
.,1493,O
To,1494,O
probe,1494,O
into,1494,O
the,1494,O
``,1494,O
logic,1494,O
'',1494,O
of,1494,O
this,1494,O
enigma,1494,O
",",1494,O
we,1494,O
have,1494,O
started,1494,O
comparative,1494,O
studies,1494,O
among,1494,O
evolutionarily,1494,O
distant,1494,O
organisms,1494,O
",",1494,O
such,1494,O
as,1494,O
mouse,1494,O
and,1494,O
Saccharomyces,1494,O
cerevisiae,1494,O
",",1494,O
and,1494,O
we,1494,O
are,1494,O
now,1494,O
looking,1494,O
for,1494,O
biotin,1494,B-CHEMICAL
effects,1494,O
on,1494,O
specific,1494,O
genes,1494,O
and,1494,O
proteins,1494,O
",",1494,O
such,1494,O
as,1494,O
HCS,1494,B-CHEMICAL
and,1494,O
hexokinases,1494,B-GENE-N
",",1494,O
and,1494,O
on,1494,O
their,1494,O
proteomes,1494,O
.,1494,O
Involvement,1495,O
of,1495,O
COX-1,1495,B-GENE-Y
and,1495,O
up-regulated,1495,O
prostaglandin,1495,B-GENE-Y
E,1495,I-GENE-Y
synthases,1495,I-GENE-Y
in,1495,O
phosphatidylserine,1495,B-CHEMICAL
liposome-induced,1495,O
prostaglandin,1495,B-CHEMICAL
E2,1495,I-CHEMICAL
production,1495,O
by,1495,O
microglia,1495,O
.,1495,O
After,1496,O
engulfment,1496,O
of,1496,O
apoptotic,1496,O
cells,1496,O
through,1496,O
phosphatidylserine,1496,B-CHEMICAL
(,1496,O
PS,1496,O
),1496,O
-mediated,1496,O
recognition,1496,O
",",1496,O
microglia,1496,O
secrete,1496,O
prostaglandin,1496,B-CHEMICAL
E2,1496,I-CHEMICAL
(,1496,O
PGE2,1496,B-CHEMICAL
),1496,O
",",1496,O
a,1496,O
potent,1496,O
anti-inflammatory,1496,O
molecule,1496,O
in,1496,O
the,1496,O
central,1496,O
nervous,1496,O
system,1496,O
.,1496,O
Despite,1497,O
the,1497,O
clinical,1497,O
significance,1497,O
",",1497,O
the,1497,O
mechanism,1497,O
underlying,1497,O
PGE2,1497,B-CHEMICAL
production,1497,O
by,1497,O
phagocytosis,1497,O
of,1497,O
apoptotic,1497,O
cells,1497,O
is,1497,O
poorly,1497,O
understood,1497,O
.,1497,O
In,1498,O
the,1498,O
present,1498,O
study,1498,O
",",1498,O
we,1498,O
used,1498,O
PS,1498,O
liposomes,1498,O
to,1498,O
elucidate,1498,O
the,1498,O
phagocytic,1498,O
pathway,1498,O
for,1498,O
PGE2,1498,B-CHEMICAL
production,1498,O
in,1498,O
microglia,1498,O
",",1498,O
because,1498,O
PS,1498,O
liposomes,1498,O
mimic,1498,O
the,1498,O
effects,1498,O
of,1498,O
apoptotic,1498,O
cells,1498,O
on,1498,O
microglia/macrophages,1498,O
.,1498,O
The,1499,O
level,1499,O
of,1499,O
PGE2,1499,B-CHEMICAL
in,1499,O
the,1499,O
culture,1499,O
medium,1499,O
of,1499,O
primary,1499,O
cultured,1499,O
rat,1499,O
microglia,1499,O
was,1499,O
significantly,1499,O
increased,1499,O
by,1499,O
PS,1499,O
liposomes,1499,O
treatment,1499,O
but,1499,O
not,1499,O
by,1499,O
phosphatidylcholine,1499,B-CHEMICAL
liposomes,1499,O
treatment,1499,O
.,1499,O
The,1500,O
specific,1500,O
ligand,1500,O
for,1500,O
class,1500,B-GENE-N
B,1500,I-GENE-N
scavenger,1500,I-GENE-N
receptor,1500,I-GENE-N
(,1500,O
SR-B,1500,B-GENE-N
),1500,O
",",1500,O
high,1500,B-GENE-N
density,1500,I-GENE-N
lipoprotein,1500,I-GENE-N
",",1500,O
significantly,1500,O
suppressed,1500,O
PS,1500,O
liposome-induced,1500,O
PGE2,1500,B-CHEMICAL
production,1500,O
.,1500,O
PS,1501,O
liposomes,1501,O
were,1501,O
immediately,1501,O
phagocytosed,1501,O
by,1501,O
microglia,1501,O
and,1501,O
sorted,1501,O
to,1501,O
endosomes/lysosomes,1501,O
.,1501,O
Cyclooxygenase,1502,B-GENE-N
(,1502,B-GENE-Y
COX,1502,I-GENE-Y
),1502,I-GENE-Y
-2,1502,I-GENE-Y
and,1502,O
membrane-bound,1502,O
prostaglandin,1502,B-GENE-Y
E,1502,I-GENE-Y
synthase-1,1502,I-GENE-Y
(,1502,O
mPGES-1,1502,B-GENE-Y
),1502,O
were,1502,O
induced,1502,O
by,1502,O
treatment,1502,O
with,1502,O
lipopolysaccharide,1502,O
(,1502,O
LPS,1502,O
),1502,O
but,1502,O
not,1502,O
with,1502,O
PS,1502,O
liposomes,1502,O
.,1502,O
On,1503,O
the,1503,O
other,1503,O
hand,1503,O
",",1503,O
mPGES-2,1503,B-GENE-Y
and,1503,O
cytosolic,1503,B-GENE-Y
PGES,1503,I-GENE-Y
(,1503,O
cPGES,1503,B-GENE-Y
),1503,O
that,1503,O
are,1503,O
functionally,1503,O
coupled,1503,O
with,1503,O
COX-1,1503,B-GENE-Y
were,1503,O
upregulated,1503,O
after,1503,O
treatment,1503,O
with,1503,O
PS,1503,O
liposomes,1503,O
or,1503,O
LPS,1503,O
.,1503,O
Furthermore,1504,O
",",1504,O
PS,1504,O
liposome-induced,1504,O
PGE2,1504,B-CHEMICAL
production,1504,O
was,1504,O
significantly,1504,O
suppressed,1504,O
by,1504,O
indomethacin,1504,B-CHEMICAL
",",1504,O
a,1504,O
preferential,1504,O
COX-1,1504,B-GENE-Y
inhibitor,1504,O
",",1504,O
but,1504,O
not,1504,O
by,1504,O
NS-398,1504,B-CHEMICAL
",",1504,O
a,1504,O
selective,1504,O
COX-2,1504,B-GENE-Y
inhibitor,1504,O
.,1504,O
PS,1505,O
liposomes,1505,O
induced,1505,O
activation,1505,O
of,1505,O
p44/p42,1505,B-GENE-Y
extracellular,1505,B-GENE-N
signal-regulated,1505,I-GENE-N
kinase,1505,I-GENE-N
(,1505,O
ERK,1505,B-GENE-N
),1505,O
but,1505,O
not,1505,O
p38,1505,B-GENE-N
mitogen-activated,1505,B-GENE-N
protein,1505,I-GENE-N
kinase,1505,I-GENE-N
in,1505,O
SR-BI,1505,B-GENE-Y
independent,1505,O
manner,1505,O
.,1505,O
These,1506,O
observations,1506,O
strongly,1506,O
suggest,1506,O
that,1506,O
the,1506,O
up-regulation,1506,O
of,1506,O
terminal,1506,O
PGESs,1506,B-GENE-Y
that,1506,O
are,1506,O
preferentially,1506,O
coupled,1506,O
with,1506,O
COX-1,1506,B-GENE-Y
",",1506,O
especially,1506,O
mPGES-2,1506,B-GENE-Y
",",1506,O
plays,1506,O
the,1506,O
pivotal,1506,O
role,1506,O
in,1506,O
PS,1506,O
liposome-induced,1506,O
PGE2,1506,B-CHEMICAL
production,1506,O
by,1506,O
microglia,1506,O
.,1506,O
Although,1507,O
SR-BI,1507,B-GENE-Y
plays,1507,O
an,1507,O
essential,1507,O
role,1507,O
in,1507,O
PS,1507,O
liposome-induced,1507,O
PGE2,1507,B-CHEMICAL
production,1507,O
",",1507,O
other,1507,O
PS-recognizing,1507,B-GENE-N
receptors,1507,I-GENE-N
",",1507,O
possibly,1507,O
PS-specific,1507,B-GENE-N
receptor,1507,I-GENE-N
",",1507,O
could,1507,O
also,1507,O
promote,1507,O
PGE2,1507,B-CHEMICAL
production,1507,O
by,1507,O
transducing,1507,O
intracellular,1507,O
signals,1507,O
including,1507,O
p44/p42,1507,B-GENE-Y
ERK,1507,B-GENE-N
after,1507,O
PS,1507,O
liposomes,1507,O
treatment,1507,O
.,1507,O
Sorafenib,1508,B-CHEMICAL
:,1508,O
scientific,1508,O
rationales,1508,O
for,1508,O
single-agent,1508,O
and,1508,O
combination,1508,O
therapy,1508,O
in,1508,O
clear-cell,1508,O
renal,1508,O
cell,1508,O
carcinoma,1508,O
.,1508,O
Clear-cell,1509,O
renal,1509,O
cell,1509,O
carcinoma,1509,O
(,1509,O
RCC,1509,O
),1509,O
is,1509,O
characterized,1509,O
by,1509,O
the,1509,O
loss,1509,O
of,1509,O
von,1509,B-GENE-Y
Hippel-Lindau,1509,I-GENE-Y
disease,1509,I-GENE-Y
protein,1509,I-GENE-Y
and,1509,O
the,1509,O
resultant,1509,O
dysregulation,1509,O
of,1509,O
the,1509,O
vascular,1509,B-GENE-Y
endothelial,1509,I-GENE-Y
growth,1509,I-GENE-Y
factor,1509,I-GENE-Y
(,1509,O
VEGF,1509,B-GENE-Y
),1509,O
/VEGF,1509,O
receptor,1509,I-GENE-N
(,1509,O
VEGFR,1509,B-GENE-N
),1509,O
",",1509,O
platelet-derived,1509,B-GENE-Y
growth,1509,I-GENE-Y
factor-beta,1509,I-GENE-Y
(,1509,O
PDGF-beta,1509,B-GENE-Y
),1509,O
/PDGF,1509,O
receptor-beta,1509,I-GENE-Y
(,1509,O
PDGFR-beta,1509,B-GENE-Y
),1509,O
",",1509,O
and,1509,O
transforming,1509,B-GENE-Y
growth,1509,I-GENE-Y
factor-alpha,1509,I-GENE-Y
(,1509,O
TGF-alpha,1509,B-GENE-Y
),1509,O
/epidermal,1509,O
growth,1509,I-GENE-Y
factor,1509,I-GENE-Y
receptor,1509,I-GENE-Y
(,1509,O
EGFR,1509,B-GENE-Y
),1509,O
/Raf,1509,O
pathways,1509,O
",",1509,O
which,1509,O
contribute,1509,O
to,1509,O
angiogenesis,1509,O
",",1509,O
lymphangiogenesis,1509,O
",",1509,O
and,1509,O
tumor,1509,O
cell,1509,O
growth,1509,O
and,1509,O
survival,1509,O
.,1509,O
Significant,1510,O
advances,1510,O
in,1510,O
the,1510,O
treatment,1510,O
of,1510,O
clear-cell,1510,O
RCC,1510,O
have,1510,O
been,1510,O
derived,1510,O
from,1510,O
agents,1510,O
that,1510,O
target,1510,O
these,1510,O
pathways,1510,O
",",1510,O
including,1510,O
the,1510,O
multiple-kinase,1510,O
inhibitors,1510,O
(,1510,O
MKIs,1510,O
),1510,O
sorafenib,1510,B-CHEMICAL
",",1510,O
sunitinib,1510,B-CHEMICAL
",",1510,O
and,1510,O
AG013736,1510,B-CHEMICAL
",",1510,O
which,1510,O
target,1510,O
multiple,1510,O
VEGFRs,1510,B-GENE-N
as,1510,O
well,1510,O
as,1510,O
PDGFR-beta,1510,B-GENE-Y
.,1510,O
Sorafenib,1511,B-CHEMICAL
has,1511,O
the,1511,O
added,1511,O
advantage,1511,O
of,1511,O
inhibiting,1511,O
multiple,1511,O
different,1511,O
Raf,1511,B-GENE-Y
isoforms,1511,O
",",1511,O
which,1511,O
enables,1511,O
it,1511,O
to,1511,O
target,1511,O
TGF-alpha/EGFR,1511,B-GENE-Y
signaling,1511,O
and,1511,O
may,1511,O
also,1511,O
enhance,1511,O
its,1511,O
inhibition,1511,O
of,1511,O
VEGFR,1511,B-GENE-N
and,1511,O
PDGFR-beta,1511,B-GENE-Y
.,1511,O
This,1512,O
review,1512,O
will,1512,O
examine,1512,O
the,1512,O
recent,1512,O
advances,1512,O
in,1512,O
our,1512,O
understanding,1512,O
of,1512,O
the,1512,O
biology,1512,O
of,1512,O
clear-cell,1512,O
RCC,1512,O
and,1512,O
show,1512,O
how,1512,O
those,1512,O
advances,1512,O
have,1512,O
helped,1512,O
delineate,1512,O
new,1512,O
targets,1512,O
of,1512,O
opportunity,1512,O
for,1512,O
treatment,1512,O
.,1512,O
It,1513,O
will,1513,O
also,1513,O
present,1513,O
the,1513,O
early,1513,O
clinical,1513,O
results,1513,O
of,1513,O
agents,1513,O
that,1513,O
target,1513,O
the,1513,O
pathways,1513,O
dysregulated,1513,O
in,1513,O
clear-cell,1513,O
RCC,1513,O
",",1513,O
with,1513,O
special,1513,O
emphasis,1513,O
on,1513,O
sorafenib,1513,B-CHEMICAL
and,1513,O
the,1513,O
other,1513,O
active,1513,O
MKIs,1513,O
",",1513,O
and,1513,O
will,1513,O
describe,1513,O
the,1513,O
scientific,1513,O
rationales,1513,O
for,1513,O
ongoing,1513,O
and,1513,O
future,1513,O
sorafenib-based,1513,B-CHEMICAL
combination,1513,O
therapy,1513,O
trials,1513,O
in,1513,O
RCC,1513,O
.,1513,O
A,1514,O
case,1514,O
of,1514,O
adult-onset,1514,O
type,1514,O
II,1514,O
citrullinemia,1514,O
--,1514,O
deterioration,1514,O
of,1514,O
clinical,1514,O
course,1514,O
after,1514,O
infusion,1514,O
of,1514,O
hyperosmotic,1514,O
and,1514,O
high,1514,O
sugar,1514,O
solutions,1514,O
.,1514,O
BACKGROUND,1515,O
:,1515,O
Adult-onset,1515,O
type,1515,O
II,1515,O
citrullinemia,1515,O
(,1515,O
CTLN2,1515,O
),1515,O
is,1515,O
an,1515,O
autosomal,1515,O
recessive,1515,O
disorder,1515,O
caused,1515,O
by,1515,O
mutations,1515,O
of,1515,O
SLC25A13,1515,B-GENE-Y
gene,1515,O
encoding,1515,O
citrin,1515,B-GENE-Y
and,1515,O
is,1515,O
characterized,1515,O
by,1515,O
recurrent,1515,O
encephalopathy,1515,O
with,1515,O
hyperammonemia,1515,O
.,1515,O
Factors,1516,O
affecting,1516,O
disease,1516,O
progression,1516,O
remain,1516,O
unknown,1516,O
.,1516,O
We,1517,O
report,1517,O
a,1517,O
case,1517,O
with,1517,O
CTLN2,1517,O
",",1517,O
whose,1517,O
clinical,1517,O
course,1517,O
was,1517,O
rapidly,1517,O
worsened,1517,O
by,1517,O
the,1517,O
administration,1517,O
of,1517,O
Glyceol,1517,O
",",1517,O
a,1517,O
hyperosmotic,1517,O
diuretic,1517,O
solution,1517,O
consisting,1517,O
of,1517,O
10,1517,O
%,1517,O
glycerol,1517,B-CHEMICAL
and,1517,O
5,1517,O
%,1517,O
fructose,1517,B-CHEMICAL
in,1517,O
saline,1517,O
.,1517,O
CASE,1518,O
REPORT,1518,O
:,1518,O
A,1518,O
34-year-old,1518,O
man,1518,O
was,1518,O
admitted,1518,O
in,1518,O
coma,1518,O
after,1518,O
repeated,1518,O
episodes,1518,O
of,1518,O
altered,1518,O
consciousness,1518,O
.,1518,O
His,1519,O
plasma,1519,O
ammonia,1519,B-CHEMICAL
level,1519,O
was,1519,O
markedly,1519,O
elevated,1519,O
without,1519,O
any,1519,O
evidence,1519,O
of,1519,O
liver,1519,O
diseases,1519,O
.,1519,O
Brain,1520,O
MRI,1520,O
revealed,1520,O
high,1520,O
signal,1520,O
intensities,1520,O
at,1520,O
the,1520,O
bilateral,1520,O
cingulate,1520,O
gyri,1520,O
and,1520,O
insular,1520,O
cortices,1520,O
",",1520,O
suggesting,1520,O
hepatic,1520,O
encephalopathy,1520,O
.,1520,O
We,1521,O
administered,1521,O
Glyceol,1521,O
.,1521,O
intravenously,1522,O
to,1522,O
alleviate,1522,O
brain,1522,O
edema,1522,O
",",1522,O
however,1522,O
",",1522,O
he,1522,O
developed,1522,O
intractable,1522,O
seizures,1522,O
along,1522,O
with,1522,O
steep,1522,O
increase,1522,O
in,1522,O
plasma,1522,O
ammonia,1522,B-CHEMICAL
levels,1522,O
(,1522,O
from,1522,O
808,1522,O
to,1522,O
2210,1522,O
microg/dL,1522,O
),1522,O
and,1522,O
died,1522,O
.,1522,O
The,1523,O
diagnosis,1523,O
of,1523,O
CTLN2,1523,O
was,1523,O
confirmed,1523,O
by,1523,O
elevations,1523,O
of,1523,O
plasma,1523,O
citrulline,1523,B-CHEMICAL
level,1523,O
(,1523,O
384.3,1523,O
nmol/mL,1523,O
;,1523,O
normal,1523,O
17-43,1523,O
nmol/mL,1523,O
),1523,O
and,1523,O
serum,1523,O
pancreatic,1523,B-GENE-Y
secretory,1523,I-GENE-Y
trypsin,1523,I-GENE-Y
inhibitor,1523,I-GENE-Y
(,1523,O
PSTI,1523,B-GENE-Y
),1523,O
(,1523,O
110,1523,O
ng/mL,1523,O
;,1523,O
normal,1523,O
4.6-12.2,1523,O
ng/mL,1523,O
),1523,O
",",1523,O
decrease,1523,O
in,1523,O
hepatic,1523,O
argininosuccinate,1523,B-CHEMICAL
synthetase,1523,I-GENE-Y
activity,1523,O
(,1523,O
5.5,1523,O
%,1523,O
of,1523,O
control,1523,O
),1523,O
",",1523,O
lack,1523,O
of,1523,O
hepatic,1523,O
citrin,1523,B-GENE-Y
protein,1523,O
expression,1523,O
and,1523,O
mutations,1523,O
in,1523,O
SLC25A13,1523,B-GENE-Y
gene,1523,O
(,1523,O
compound,1523,O
heterozygote,1523,O
with,1523,O
S225X,1523,B-GENE-N
and,1523,O
Ex1-1G,1523,B-GENE-N
>,1523,I-GENE-N
A,1523,I-GENE-N
),1523,O
.,1523,O
CONCLUSIONS,1524,O
:,1524,O
Physicians,1524,O
should,1524,O
take,1524,O
CTLN2,1524,O
into,1524,O
consideration,1524,O
as,1524,O
a,1524,O
differential,1524,O
diagnosis,1524,O
in,1524,O
Asian,1524,O
patients,1524,O
with,1524,O
a,1524,O
history,1524,O
of,1524,O
repeated,1524,O
unconsciousness,1524,O
with,1524,O
hyperammonemia,1524,O
and,1524,O
use,1524,O
D-mannitol,1524,B-CHEMICAL
but,1524,O
not,1524,O
glycerol,1524,B-CHEMICAL
to,1524,O
treat,1524,O
brain,1524,O
edema,1524,O
in,1524,O
patients,1524,O
with,1524,O
CTLN2,1524,O
.,1524,O
Inhibition,1525,O
of,1525,O
gentamicin,1525,B-CHEMICAL
binding,1525,O
to,1525,O
rat,1525,O
renal,1525,O
brush-border,1525,O
membrane,1525,O
by,1525,O
megalin,1525,B-GENE-Y
ligands,1525,O
and,1525,O
basic,1525,O
peptides,1525,O
.,1525,O
Our,1526,O
previous,1526,O
studies,1526,O
showed,1526,O
that,1526,O
coadministration,1526,O
of,1526,O
cytochrome,1526,B-GENE-Y
c,1526,I-GENE-Y
and,1526,O
a,1526,O
20-residue,1526,O
basic,1526,O
peptide,1526,O
",",1526,O
N-WASP181-200,1526,O
(,1526,O
NISHTKEKKKGKAKKKRLTK,1526,B-GENE-N
",",1526,O
pI=10.87,1526,O
),1526,O
inhibits,1526,O
renal,1526,O
accumulation,1526,O
of,1526,O
gentamicin,1526,B-CHEMICAL
.,1526,O
In,1527,O
this,1527,O
study,1527,O
",",1527,O
we,1527,O
examined,1527,O
effects,1527,O
of,1527,O
ligands,1527,O
of,1527,O
megalin,1527,B-GENE-Y
",",1527,O
an,1527,O
endocytic,1527,O
receptor,1527,O
involved,1527,O
in,1527,O
renal,1527,O
uptake,1527,O
of,1527,O
gentamicin,1527,B-CHEMICAL
",",1527,O
and,1527,O
basic,1527,O
peptides,1527,O
including,1527,O
N-WASP180-200,1527,O
and,1527,O
its,1527,O
mutant,1527,O
peptides,1527,O
on,1527,O
gentamicin,1527,B-CHEMICAL
binding,1527,O
to,1527,O
isolated,1527,O
rat,1527,O
renal,1527,O
brush-border,1527,O
membrane,1527,O
(,1527,O
BBM,1527,O
),1527,O
.,1527,O
Gentamicin,1528,B-CHEMICAL
binding,1528,O
to,1528,O
BBM,1528,O
was,1528,O
inhibited,1528,O
by,1528,O
megalin,1528,B-GENE-Y
ligands,1528,O
",",1528,O
basic,1528,O
peptide,1528,O
fragments,1528,O
of,1528,O
cytochrome,1528,B-GENE-Y
c,1528,I-GENE-Y
",",1528,O
and,1528,O
N-WASP181-200,1528,O
in,1528,O
a,1528,O
concentration-dependent,1528,O
manner,1528,O
.,1528,O
Klotz,1529,O
plot,1529,O
analysis,1529,O
showed,1529,O
that,1529,O
N-WASP181-200,1529,O
inhibited,1529,O
the,1529,O
binding,1529,O
of,1529,O
gentamicin,1529,B-CHEMICAL
in,1529,O
a,1529,O
competitive,1529,O
manner,1529,O
.,1529,O
By,1530,O
substituting,1530,O
glycines,1530,B-CHEMICAL
for,1530,O
lysines,1530,B-CHEMICAL
in,1530,O
N-WASP181-200,1530,O
at,1530,O
positions,1530,O
9,1530,O
and,1530,O
15,1530,O
",",1530,O
the,1530,O
inhibitory,1530,O
effect,1530,O
on,1530,O
gentamicin,1530,B-CHEMICAL
binding,1530,O
to,1530,O
BBM,1530,O
was,1530,O
reduced,1530,O
",",1530,O
which,1530,O
may,1530,O
be,1530,O
related,1530,O
to,1530,O
a,1530,O
decrease,1530,O
in,1530,O
the,1530,O
alpha-helix,1530,B-GENE-N
content,1530,O
in,1530,O
the,1530,O
peptide,1530,O
.,1530,O
Gentamicin,1531,B-CHEMICAL
binding,1531,O
to,1531,O
BBM,1531,O
treated,1531,O
with,1531,O
trypsin,1531,B-GENE-N
",",1531,O
in,1531,O
which,1531,O
megalin,1531,B-GENE-Y
completely,1531,O
disappeared,1531,O
",",1531,O
was,1531,O
significantly,1531,O
but,1531,O
not,1531,O
completely,1531,O
decreased,1531,O
compared,1531,O
with,1531,O
the,1531,O
native,1531,O
BBM,1531,O
.,1531,O
In,1532,O
addition,1532,O
",",1532,O
treatment,1532,O
of,1532,O
BBM,1532,O
with,1532,O
trypsin,1532,B-GENE-N
led,1532,O
to,1532,O
a,1532,O
decrease,1532,O
in,1532,O
the,1532,O
inhibitory,1532,O
effect,1532,O
of,1532,O
N-WASP181-200,1532,O
on,1532,O
gentamicin,1532,B-CHEMICAL
binding,1532,O
.,1532,O
These,1533,O
observations,1533,O
support,1533,O
that,1533,O
megalin,1533,B-GENE-Y
ligands,1533,O
and,1533,O
basic,1533,O
peptides,1533,O
including,1533,O
N-WASP181-200,1533,O
decrease,1533,O
renal,1533,O
accumulation,1533,O
of,1533,O
gentamicin,1533,B-CHEMICAL
by,1533,O
inhibiting,1533,O
its,1533,O
binding,1533,O
to,1533,O
BBM,1533,O
of,1533,O
proximal,1533,O
tubule,1533,O
cells,1533,O
",",1533,O
partly,1533,O
interacting,1533,O
with,1533,O
megalin,1533,B-GENE-Y
.,1533,O
In,1534,O
addition,1534,O
",",1534,O
the,1534,O
alpha-helix,1534,B-GENE-N
conformation,1534,O
may,1534,O
play,1534,O
an,1534,O
important,1534,O
role,1534,O
in,1534,O
the,1534,O
inhibitory,1534,O
effect,1534,O
of,1534,O
N-WASP181-200,1534,O
on,1534,O
the,1534,O
binding,1534,O
of,1534,O
gentamicin,1534,B-CHEMICAL
to,1534,O
BBM,1534,O
.,1534,O
Thymidylate,1535,B-CHEMICAL
synthase,1535,I-GENE-Y
expression,1535,O
pattern,1535,O
",",1535,O
expression,1535,O
level,1535,O
and,1535,O
single,1535,O
nucleotide,1535,B-CHEMICAL
polymorphism,1535,O
are,1535,O
predictors,1535,O
for,1535,O
disease-free,1535,O
survival,1535,O
in,1535,O
patients,1535,O
of,1535,O
colorectal,1535,O
cancer,1535,O
treated,1535,O
with,1535,O
5-fluorouracil,1535,B-CHEMICAL
.,1535,O
Several,1536,O
variables,1536,O
associated,1536,O
to,1536,O
thymidylate,1536,B-CHEMICAL
synthase,1536,I-GENE-Y
(,1536,O
TS,1536,B-GENE-Y
),1536,O
",",1536,O
the,1536,O
biological,1536,O
target,1536,O
of,1536,O
5-fluorouracil,1536,B-CHEMICAL
(,1536,O
5FU,1536,B-CHEMICAL
),1536,O
have,1536,O
been,1536,O
studied,1536,O
for,1536,O
their,1536,O
possible,1536,O
role,1536,O
as,1536,O
predictors,1536,O
of,1536,O
the,1536,O
clinical,1536,O
outcome,1536,O
and,1536,O
response,1536,O
to,1536,O
chemotherapy,1536,O
in,1536,O
colorectal,1536,O
cancer,1536,O
(,1536,O
CRC,1536,O
),1536,O
patients,1536,O
.,1536,O
The,1537,O
level,1537,O
of,1537,O
protein,1537,O
expression,1537,O
and,1537,O
the,1537,O
number,1537,O
of,1537,O
variable,1537,O
tandem-repeats,1537,O
of,1537,O
a,1537,O
28-bp,1537,O
sequence,1537,O
within,1537,O
the,1537,O
gene,1537,O
promoter,1537,O
have,1537,O
been,1537,O
proposed,1537,O
as,1537,O
predictive,1537,O
and/or,1537,O
prognostic,1537,O
factors,1537,O
with,1537,O
variable,1537,O
agreement,1537,O
",",1537,O
while,1537,O
consensus,1537,O
seems,1537,O
to,1537,O
be,1537,O
achieved,1537,O
with,1537,O
respect,1537,O
to,1537,O
the,1537,O
value,1537,O
of,1537,O
a,1537,O
single,1537,O
nucleotide,1537,B-CHEMICAL
polymorphism,1537,O
(,1537,O
SNP,1537,O
),1537,O
described,1537,O
within,1537,O
this,1537,O
same,1537,O
region,1537,O
.,1537,O
More,1538,O
recently,1538,O
",",1538,O
an,1538,O
association,1538,O
between,1538,O
TS,1538,O
expression,1538,O
pattern,1538,O
and,1538,O
survival,1538,O
has,1538,O
been,1538,O
disclosed,1538,O
.,1538,O
Paraffin-embedded,1539,O
sections,1539,O
from,1539,O
140,1539,O
CRC,1539,O
patients,1539,O
were,1539,O
analyzed,1539,O
by,1539,O
immuno-histochemistry,1539,O
(,1539,O
Mab,1539,O
TS106,1539,O
),1539,O
for,1539,O
TS,1539,B-GENE-Y
levels,1539,O
and,1539,O
expression,1539,O
pattern,1539,O
.,1539,O
Also,1540,O
",",1540,O
VNTR,1540,O
and,1540,O
SNP,1540,O
were,1540,O
determined,1540,O
by,1540,O
polymerase-chain,1540,O
reaction,1540,O
(,1540,O
PCR,1540,O
),1540,O
and,1540,O
restriction-length-fragment,1540,O
polymorphism,1540,O
(,1540,O
RFLP,1540,O
),1540,O
in,1540,O
123,1540,O
and,1540,O
112,1540,O
patients,1540,O
",",1540,O
respectively,1540,O
.,1540,O
Cytoplasmic,1541,O
expression,1541,O
pattern,1541,O
tended,1541,O
to,1541,O
be,1541,O
associated,1541,O
to,1541,O
C,1541,O
SNP,1541,O
(,1541,O
p=0.06,1541,O
),1541,O
.,1541,O
Low,1542,O
TS,1542,B-GENE-Y
expression,1542,O
levels,1542,O
",",1542,O
cytoplasmic,1542,O
expression,1542,O
pattern,1542,O
and,1542,O
C,1542,O
SNP,1542,O
arose,1542,O
as,1542,O
variables,1542,O
associated,1542,O
to,1542,O
longer,1542,O
progression-free,1542,O
survival,1542,O
(,1542,O
PFS,1542,O
),1542,O
in,1542,O
patients,1542,O
treated,1542,O
with,1542,O
5FU,1542,B-CHEMICAL
.,1542,O
Accordingly,1543,O
",",1543,O
patients,1543,O
having,1543,O
at,1543,O
least,1543,O
two,1543,O
favourable,1543,O
or,1543,O
unfavourable,1543,O
variables,1543,O
were,1543,O
classified,1543,O
respectively,1543,O
as,1543,O
'low,1543,O
risk,1543,O
',1543,O
and,1543,O
'high,1543,O
risk,1543,O
',1543,O
",",1543,O
the,1543,O
former,1543,O
showing,1543,O
significantly,1543,O
longer,1543,O
PFS,1543,O
(,1543,O
p=0.0299,1543,O
),1543,O
.,1543,O
The,1544,O
possibility,1544,O
for,1544,O
designing,1544,O
a,1544,O
selection,1544,O
method,1544,O
for,1544,O
subsequent,1544,O
therapies,1544,O
is,1544,O
suggested,1544,O
on,1544,O
the,1544,O
basis,1544,O
of,1544,O
a,1544,O
probable,1544,O
combined,1544,O
effect,1544,O
of,1544,O
the,1544,O
above,1544,O
mentioned,1544,O
parameters,1544,O
but,1544,O
further,1544,O
studies,1544,O
in,1544,O
larger,1544,O
populations,1544,O
are,1544,O
needed,1544,O
to,1544,O
confirm,1544,O
these,1544,O
results,1544,O
.,1544,O
Leishmania,1545,O
donovani,1545,O
singly,1545,O
deficient,1545,O
in,1545,O
HGPRT,1545,B-GENE-Y
",",1545,O
APRT,1545,B-GENE-Y
or,1545,O
XPRT,1545,B-GENE-Y
are,1545,O
viable,1545,O
in,1545,O
vitro,1545,O
and,1545,O
within,1545,O
mammalian,1545,O
macrophages,1545,O
.,1545,O
Leishmania,1546,O
species,1546,O
express,1546,O
three,1546,O
phosphoribosyltransferase,1546,B-GENE-N
enzymes,1546,O
",",1546,O
hypoxanthine-guanine,1546,B-CHEMICAL
phosphoribosyltransferase,1546,I-GENE-Y
(,1546,O
HGPRT,1546,B-GENE-Y
),1546,O
",",1546,O
adenine,1546,B-CHEMICAL
phosphoribosyltransferase,1546,I-GENE-Y
(,1546,O
APRT,1546,B-GENE-Y
),1546,O
",",1546,O
and,1546,O
xanthine,1546,B-CHEMICAL
phosphoribosyltransferase,1546,I-GENE-Y
(,1546,O
XPRT,1546,B-GENE-Y
),1546,O
",",1546,O
which,1546,O
enable,1546,O
this,1546,O
genus,1546,O
to,1546,O
acquire,1546,O
purine,1546,B-CHEMICAL
nutrients,1546,O
from,1546,O
their,1546,O
hosts,1546,O
.,1546,O
To,1547,O
test,1547,O
whether,1547,O
any,1547,O
of,1547,O
these,1547,O
enzymes,1547,O
is,1547,O
essential,1547,O
for,1547,O
viability,1547,O
",",1547,O
transformation,1547,O
into,1547,O
amastigotes,1547,O
",",1547,O
and,1547,O
infectivity,1547,O
and,1547,O
proliferation,1547,O
within,1547,O
mammalian,1547,O
macrophages,1547,O
",",1547,O
Deltahgprt,1547,O
",",1547,O
Deltaaprt,1547,O
",",1547,O
and,1547,O
Deltaxprt,1547,O
null,1547,O
mutants,1547,O
were,1547,O
created,1547,O
by,1547,O
targeted,1547,O
gene,1547,O
replacement,1547,O
within,1547,O
a,1547,O
virulent,1547,O
background,1547,O
of,1547,O
Leishmania,1547,O
donovani,1547,O
.,1547,O
Each,1548,O
of,1548,O
the,1548,O
three,1548,O
knockout,1548,O
strains,1548,O
was,1548,O
viable,1548,O
as,1548,O
promastigotes,1548,O
and,1548,O
axenic,1548,O
amastigotes,1548,O
and,1548,O
capable,1548,O
of,1548,O
maintaining,1548,O
an,1548,O
infection,1548,O
in,1548,O
bone,1548,O
marrow-derived,1548,O
murine,1548,O
macrophages,1548,O
.,1548,O
These,1549,O
data,1549,O
support,1549,O
the,1549,O
hypothesis,1549,O
that,1549,O
none,1549,O
of,1549,O
the,1549,O
three,1549,O
phosphoribosyltransferases,1549,B-GENE-N
is,1549,O
essential,1549,O
for,1549,O
purine,1549,B-CHEMICAL
salvage,1549,O
or,1549,O
viability,1549,O
by,1549,O
itself,1549,O
and,1549,O
that,1549,O
purine,1549,B-CHEMICAL
salvage,1549,O
occurs,1549,O
through,1549,O
multiple,1549,O
anabolic,1549,O
routes,1549,O
in,1549,O
both,1549,O
parasite,1549,O
life,1549,O
cycle,1549,O
stages,1549,O
.,1549,O
In,1550,O
addition,1550,O
these,1550,O
studies,1550,O
revealed,1550,O
the,1550,O
presence,1550,O
of,1550,O
an,1550,O
adenine,1550,B-GENE-Y
aminohydrolase,1550,I-GENE-Y
enzyme,1550,O
in,1550,O
L.,1550,O
donovani,1550,O
axenic,1550,O
amastigotes,1550,O
",",1550,O
an,1550,O
activity,1550,O
previously,1550,O
thought,1550,O
to,1550,O
be,1550,O
restricted,1550,O
to,1550,O
promastigotes,1550,O
.,1550,O
Loss,1551,O
of,1551,O
a,1551,O
primordial,1551,O
identity,1551,O
element,1551,O
for,1551,O
a,1551,O
mammalian,1551,O
mitochondrial,1551,O
aminoacylation,1551,O
system,1551,O
.,1551,O
In,1552,O
mammalian,1552,O
mitochondria,1552,O
the,1552,O
translational,1552,O
machinery,1552,O
is,1552,O
of,1552,O
dual,1552,O
origin,1552,O
with,1552,O
tRNAs,1552,O
encoded,1552,O
by,1552,O
a,1552,O
simplified,1552,O
and,1552,O
rapidly,1552,O
evolving,1552,O
mitochondrial,1552,O
(,1552,O
mt,1552,O
),1552,O
genome,1552,O
and,1552,O
aminoacyl-tRNA,1552,B-CHEMICAL
synthetases,1552,I-GENE-N
(,1552,O
aaRS,1552,B-GENE-N
),1552,O
coded,1552,O
by,1552,O
the,1552,O
nuclear,1552,O
genome,1552,O
",",1552,O
and,1552,O
imported,1552,O
.,1552,O
Mt-tRNAs,1553,O
are,1553,O
atypical,1553,O
with,1553,O
biased,1553,O
sequences,1553,O
",",1553,O
size,1553,O
variations,1553,O
in,1553,O
loops,1553,O
and,1553,O
stems,1553,O
",",1553,O
and,1553,O
absence,1553,O
of,1553,O
residues,1553,O
forming,1553,O
classical,1553,O
tertiary,1553,O
interactions,1553,O
",",1553,O
whereas,1553,O
synthetases,1553,B-GENE-N
appear,1553,O
typical,1553,O
.,1553,O
This,1554,O
raises,1554,O
questions,1554,O
about,1554,O
identity,1554,O
elements,1554,O
in,1554,O
mt-tRNAs,1554,O
and,1554,O
adaptation,1554,O
of,1554,O
their,1554,O
cognate,1554,O
mt-aaRSs,1554,B-GENE-N
.,1554,O
We,1555,O
have,1555,O
explored,1555,O
here,1555,O
the,1555,O
human,1555,O
mt-aspartate,1555,O
system,1555,O
in,1555,O
which,1555,O
a,1555,O
prokaryotic-type,1555,B-GENE-N
AspRS,1555,I-GENE-N
",",1555,O
highly,1555,O
similar,1555,O
to,1555,O
the,1555,O
Escherichia,1555,O
coli,1555,O
enzyme,1555,O
",",1555,O
recognizes,1555,O
a,1555,O
bizarre,1555,O
tRNA,1555,O
(,1555,O
Asp,1555,O
),1555,O
.,1555,O
Analysis,1556,O
of,1556,O
human,1556,B-GENE-N
mt-tRNA,1556,I-GENE-N
(,1556,I-GENE-N
Asp,1556,I-GENE-N
),1556,I-GENE-N
transcripts,1556,I-GENE-N
confirms,1556,O
the,1556,O
identity,1556,O
role,1556,O
of,1556,O
the,1556,O
GUC,1556,O
anticodon,1556,O
as,1556,O
in,1556,O
other,1556,O
aspartylation,1556,O
systems,1556,O
but,1556,O
reveals,1556,O
the,1556,O
non-involvement,1556,O
of,1556,O
position,1556,O
73,1556,O
.,1556,O
This,1557,O
position,1557,O
is,1557,O
otherwise,1557,O
known,1557,O
as,1557,O
the,1557,O
site,1557,O
of,1557,O
a,1557,O
universally,1557,O
conserved,1557,O
major,1557,O
aspartate,1557,B-CHEMICAL
identity,1557,O
element,1557,O
",",1557,O
G73,1557,B-GENE-N
",",1557,O
also,1557,O
known,1557,O
as,1557,O
a,1557,O
primordial,1557,O
identity,1557,O
signal,1557,O
.,1557,O
In,1558,O
mt-tRNA,1558,O
(,1558,O
Asp,1558,O
),1558,O
",",1558,O
position,1558,O
73,1558,O
can,1558,O
be,1558,O
occupied,1558,O
by,1558,O
any,1558,O
of,1558,O
the,1558,O
four,1558,O
nucleotides,1558,B-CHEMICAL
without,1558,O
affecting,1558,O
aspartylation,1558,O
.,1558,O
Sequence,1559,O
alignments,1559,O
of,1559,O
various,1559,O
AspRSs,1559,B-GENE-N
allowed,1559,O
placing,1559,O
Gly-269,1559,B-CHEMICAL
at,1559,O
a,1559,O
position,1559,O
occupied,1559,O
by,1559,O
Asp-220,1559,B-CHEMICAL
",",1559,O
the,1559,O
residue,1559,O
contacting,1559,O
G73,1559,B-GENE-N
in,1559,O
the,1559,O
crystallographic,1559,O
structure,1559,O
of,1559,O
E.,1559,B-GENE-Y
coli,1559,I-GENE-Y
AspRS-tRNA,1559,O
(,1559,O
Asp,1559,O
),1559,O
complex,1559,O
.,1559,O
Replacing,1560,O
this,1560,O
glycine,1560,B-CHEMICAL
by,1560,O
an,1560,O
aspartate,1560,B-CHEMICAL
renders,1560,O
human,1560,B-GENE-Y
mt-AspRS,1560,I-GENE-Y
more,1560,O
discriminative,1560,O
to,1560,O
G73,1560,B-GENE-N
.,1560,O
Restriction,1561,O
in,1561,O
the,1561,O
aspartylation,1561,O
identity,1561,O
set,1561,O
",",1561,O
driven,1561,O
by,1561,O
a,1561,O
rapid,1561,O
mutagenic,1561,O
rate,1561,O
of,1561,O
the,1561,O
mt-genome,1561,O
",",1561,O
suggests,1561,O
a,1561,O
reverse,1561,O
evolution,1561,O
of,1561,O
the,1561,O
mt-tRNA,1561,O
(,1561,O
Asp,1561,O
),1561,O
identity,1561,O
elements,1561,O
in,1561,O
regard,1561,O
to,1561,O
its,1561,O
bacterial,1561,O
ancestor,1561,O
.,1561,O
Metabolic,1562,O
syndrome,1562,O
:,1562,O
adenosine,1562,B-CHEMICAL
monophosphate-activated,1562,I-GENE-N
protein,1562,I-GENE-N
kinase,1562,I-GENE-N
and,1562,O
malonyl,1562,B-CHEMICAL
coenzyme,1562,I-CHEMICAL
A,1562,I-CHEMICAL
.,1562,O
The,1563,O
metabolic,1563,O
syndrome,1563,O
can,1563,O
be,1563,O
defined,1563,O
as,1563,O
a,1563,O
state,1563,O
of,1563,O
metabolic,1563,O
dysregulation,1563,O
characterized,1563,O
by,1563,O
insulin,1563,B-GENE-Y
resistance,1563,O
",",1563,O
central,1563,O
obesity,1563,O
",",1563,O
and,1563,O
a,1563,O
predisposition,1563,O
to,1563,O
type,1563,O
2,1563,O
diabetes,1563,O
",",1563,O
dyslipidemia,1563,O
",",1563,O
premature,1563,O
atherosclerosis,1563,O
",",1563,O
and,1563,O
other,1563,O
diseases,1563,O
.,1563,O
An,1564,O
increasing,1564,O
body,1564,O
of,1564,O
evidence,1564,O
has,1564,O
linked,1564,O
the,1564,O
metabolic,1564,O
syndrome,1564,O
to,1564,O
abnormalities,1564,O
in,1564,O
lipid,1564,O
metabolism,1564,O
that,1564,O
ultimately,1564,O
lead,1564,O
to,1564,O
cellular,1564,O
dysfunction,1564,O
.,1564,O
We,1565,O
review,1565,O
here,1565,O
the,1565,O
hypothesis,1565,O
that,1565,O
",",1565,O
in,1565,O
many,1565,O
instances,1565,O
",",1565,O
the,1565,O
cause,1565,O
of,1565,O
these,1565,O
lipid,1565,O
abnormalities,1565,O
could,1565,O
be,1565,O
a,1565,O
dysregulation,1565,O
of,1565,O
the,1565,O
adenosine,1565,B-GENE-N
monophosphate-activated,1565,I-GENE-N
protein,1565,I-GENE-N
kinase,1565,I-GENE-N
(,1565,O
AMPK,1565,B-GENE-N
),1565,O
/malonyl,1565,O
coenzyme,1565,I-CHEMICAL
A,1565,I-CHEMICAL
(,1565,O
CoA,1565,O
),1565,O
fuel-sensing,1565,O
and,1565,O
signaling,1565,O
mechanism,1565,O
.,1565,O
Such,1566,O
dysregulation,1566,O
could,1566,O
be,1566,O
reflected,1566,O
by,1566,O
isolated,1566,O
increases,1566,O
in,1566,O
malonyl,1566,B-CHEMICAL
CoA,1566,I-CHEMICAL
or,1566,O
by,1566,O
concurrent,1566,O
changes,1566,O
in,1566,O
malonyl,1566,B-CHEMICAL
CoA,1566,I-CHEMICAL
and,1566,O
AMPK,1566,B-GENE-N
",",1566,O
both,1566,O
of,1566,O
which,1566,O
would,1566,O
alter,1566,O
intracellular,1566,O
fatty,1566,O
acid,1566,O
partitioning,1566,O
.,1566,O
The,1567,O
possibility,1567,O
is,1567,O
also,1567,O
raised,1567,O
that,1567,O
pharmacological,1567,O
agents,1567,O
and,1567,O
other,1567,O
factors,1567,O
that,1567,O
activate,1567,O
AMPK,1567,B-GENE-N
and/or,1567,O
decrease,1567,O
malonyl,1567,B-CHEMICAL
CoA,1567,I-CHEMICAL
could,1567,O
be,1567,O
therapeutic,1567,O
targets,1567,O
.,1567,O
Chronic,1568,O
effect,1568,O
of,1568,O
[,1568,B-CHEMICAL
D-Pen2,1568,I-CHEMICAL
",",1568,I-CHEMICAL
D-Pen5,1568,I-CHEMICAL
],1568,I-CHEMICAL
enkephalin,1568,I-CHEMICAL
on,1568,O
rat,1568,B-GENE-N
brain,1568,I-GENE-N
opioid,1568,I-GENE-N
receptors,1568,I-GENE-N
.,1568,O
In,1569,O
previous,1569,O
studies,1569,O
",",1569,O
we,1569,O
have,1569,O
demonstrated,1569,O
that,1569,O
chronic,1569,O
etorphine,1569,B-CHEMICAL
or,1569,O
[,1569,B-CHEMICAL
D-Ala2,1569,I-CHEMICAL
",",1569,I-CHEMICAL
D-Leu5,1569,I-CHEMICAL
],1569,I-CHEMICAL
enkephalin,1569,I-CHEMICAL
(,1569,O
DADLE,1569,B-CHEMICAL
),1569,O
treatment,1569,O
of,1569,O
rats,1569,O
results,1569,O
in,1569,O
the,1569,O
reduction,1569,O
of,1569,O
mu-,1569,B-GENE-N
and,1569,I-GENE-N
delta-opioid,1569,I-GENE-N
receptor,1569,I-GENE-N
binding,1569,O
activities,1569,O
as,1569,O
tolerance,1569,O
develops,1569,O
.,1569,O
As,1570,O
both,1570,O
etorphine,1570,B-CHEMICAL
and,1570,O
DADLE,1570,B-CHEMICAL
are,1570,O
relatively,1570,O
non-specific,1570,O
opioid,1570,O
ligands,1570,O
",",1570,O
interacting,1570,O
with,1570,O
both,1570,O
mu-,1570,B-GENE-N
and,1570,I-GENE-N
delta-receptors,1570,I-GENE-N
",",1570,O
these,1570,O
studies,1570,O
could,1570,O
not,1570,O
determine,1570,O
whether,1570,O
down-regulation,1570,O
of,1570,O
a,1570,O
specific,1570,O
receptor,1570,O
type,1570,O
occurs,1570,O
.,1570,O
Therefore,1571,O
",",1571,O
in,1571,O
the,1571,O
present,1571,O
studies,1571,O
",",1571,O
animals,1571,O
were,1571,O
rendered,1571,O
tolerant,1571,O
to,1571,O
the,1571,O
delta-opioid,1571,B-GENE-Y
receptor-selective,1571,O
agonist,1571,O
[,1571,B-CHEMICAL
D-Pen2,1571,I-CHEMICAL
",",1571,I-CHEMICAL
D-Pen5,1571,I-CHEMICAL
],1571,I-CHEMICAL
enkephalin,1571,I-CHEMICAL
(,1571,O
DPDPE,1571,B-CHEMICAL
),1571,O
",",1571,O
and,1571,O
receptor,1571,O
binding,1571,O
activities,1571,O
were,1571,O
measured,1571,O
.,1571,O
Treating,1572,O
Sprague-Dawley,1572,O
rats,1572,O
with,1572,O
increasing,1572,O
doses,1572,O
of,1572,O
DPDPE,1572,B-CHEMICAL
(,1572,O
80-160-240-320,1572,O
micrograms/kg,1572,O
),1572,O
i.c.v,1572,O
.,1572,O
for,1573,O
1,1573,O
to,1573,O
4,1573,O
days,1573,O
resulted,1573,O
in,1573,O
a,1573,O
time-dependent,1573,O
increase,1573,O
in,1573,O
the,1573,O
AD50,1573,O
of,1573,O
DPDPE,1573,B-CHEMICAL
to,1573,O
elicit,1573,O
an,1573,O
antinociceptive,1573,O
response,1573,O
.,1573,O
When,1574,O
delta-receptor,1574,B-GENE-Y
binding,1574,O
was,1574,O
determined,1574,O
by,1574,O
using,1574,O
[,1574,B-CHEMICAL
3H,1574,I-CHEMICAL
],1574,I-CHEMICAL
DPDPE,1574,I-CHEMICAL
",",1574,O
a,1574,O
40-50,1574,O
%,1574,O
decrease,1574,O
in,1574,O
binding,1574,O
in,1574,O
the,1574,O
midbrain,1574,O
and,1574,O
cortex,1574,O
",",1574,O
and,1574,O
25-35,1574,O
%,1574,O
decrease,1574,O
in,1574,O
binding,1574,O
in,1574,O
the,1574,O
striatum,1574,O
were,1574,O
observed,1574,O
after,1574,O
3,1574,O
or,1574,O
4,1574,O
days,1574,O
of,1574,O
DPDPE,1574,B-CHEMICAL
treatment,1574,O
.,1574,O
Scatchard,1575,O
analysis,1575,O
of,1575,O
the,1575,O
[,1575,B-CHEMICAL
3H,1575,I-CHEMICAL
],1575,I-CHEMICAL
DPDPE,1575,I-CHEMICAL
saturation,1575,O
binding,1575,O
data,1575,O
revealed,1575,O
a,1575,O
decrease,1575,O
in,1575,O
Bmax,1575,O
values,1575,O
and,1575,O
no,1575,O
significant,1575,O
change,1575,O
in,1575,O
Kd,1575,O
values,1575,O
.,1575,O
To,1576,O
our,1576,O
surprise,1576,O
",",1576,O
when,1576,O
mu-receptor,1576,B-GENE-Y
binding,1576,O
was,1576,O
determined,1576,O
by,1576,O
using,1576,O
[,1576,B-CHEMICAL
3H,1576,I-CHEMICAL
],1576,I-CHEMICAL
Tyr-D-Ala-Gly-MePhe-Gly-ol,1576,I-CHEMICAL
(,1576,O
DAMGO,1576,B-CHEMICAL
),1576,O
",",1576,O
a,1576,O
10-15,1576,O
%,1576,O
decrease,1576,O
in,1576,O
binding,1576,O
was,1576,O
also,1576,O
observed,1576,O
in,1576,O
the,1576,O
midbrain,1576,O
and,1576,O
cortex,1576,O
after,1576,O
4,1576,O
days,1576,O
of,1576,O
DPDPE,1576,B-CHEMICAL
treatment,1576,O
.,1576,O
Our,1577,O
conclusion,1577,O
is,1577,O
that,1577,O
chronic,1577,O
DPDPE,1577,B-CHEMICAL
treatment,1577,O
preferentially,1577,O
reduces,1577,O
delta-opioid,1577,B-GENE-Y
receptor,1577,I-GENE-Y
binding,1577,O
activity,1577,O
.,1577,O
Its,1578,O
minor,1578,O
effect,1578,O
on,1578,O
the,1578,O
mu-opioid,1578,B-GENE-Y
receptor,1578,I-GENE-Y
maybe,1578,O
due,1578,O
to,1578,O
an,1578,O
interaction,1578,O
between,1578,O
delta,1578,B-GENE-Y
cx,1578,I-GENE-Y
and,1578,O
mu,1578,B-GENE-Y
cx,1578,I-GENE-Y
binding,1578,O
sites,1578,O
.,1578,O
[,1579,O
Preclinical,1579,O
pharmacology,1579,O
of,1579,O
amoxapine,1579,B-CHEMICAL
and,1579,O
amitriptyline,1579,B-CHEMICAL
.,1579,O
Implications,1580,O
of,1580,O
serotoninergic,1580,O
and,1580,O
opiodergic,1580,O
systems,1580,O
in,1580,O
their,1580,O
central,1580,O
effect,1580,O
in,1580,O
rats,1580,O
],1580,O
.,1580,O
The,1581,O
effects,1581,O
of,1581,O
two,1581,O
antidepressant,1581,O
drugs,1581,O
",",1581,O
amoxapine,1581,B-CHEMICAL
and,1581,O
amitriptyline,1581,B-CHEMICAL
",",1581,O
that,1581,O
belong,1581,O
to,1581,O
distinct,1581,O
chemical,1581,O
classes,1581,O
",",1581,O
have,1581,O
been,1581,O
examined,1581,O
on,1581,O
various,1581,O
biochemical,1581,O
parameters,1581,O
related,1581,O
to,1581,O
serotoninergic,1581,O
and,1581,O
opioidergic,1581,O
neurotransmission,1581,O
in,1581,O
the,1581,O
rat,1581,O
brain,1581,O
and,1581,O
spinal,1581,O
cord,1581,O
.,1581,O
In,1582,O
vitro,1582,O
binding,1582,O
studies,1582,O
showed,1582,O
that,1582,O
both,1582,O
amoxapine,1582,B-CHEMICAL
and,1582,O
amitriptyline,1582,B-CHEMICAL
interact,1582,O
in,1582,O
the,1582,O
nanomolar,1582,O
range,1582,O
with,1582,O
5-HT2,1582,B-GENE-N
receptors,1582,O
labelled,1582,O
by,1582,O
[,1582,B-CHEMICAL
3H,1582,I-CHEMICAL
],1582,I-CHEMICAL
ketanserin,1582,I-CHEMICAL
in,1582,O
cortical,1582,O
membranes,1582,O
.,1582,O
By,1583,O
contrast,1583,O
",",1583,O
neither,1583,O
amoxapine,1583,B-CHEMICAL
nor,1583,O
amitriptyline,1583,B-CHEMICAL
can,1583,O
be,1583,O
considered,1583,O
as,1583,O
possible,1583,O
ligands,1583,O
of,1583,O
5-HT1A,1583,B-GENE-Y
and,1583,O
5-HT1B,1583,B-GENE-Y
receptors,1583,O
because,1583,O
their,1583,O
affinities,1583,O
for,1583,O
these,1583,O
sites,1583,O
are,1583,O
in,1583,O
the,1583,O
micromolar,1583,O
range,1583,O
(,1583,O
or,1583,O
even,1583,O
worse,1583,O
),1583,O
.,1583,O
Interestingly,1584,O
",",1584,O
amoxapine,1584,B-CHEMICAL
binds,1584,O
with,1584,O
a,1584,O
good,1584,O
affinity,1584,O
(,1584,O
IC50,1584,O
=,1584,O
0.30,1584,O
microM,1584,O
),1584,O
to,1584,O
5-HT3,1584,B-GENE-N
receptors,1584,O
labelled,1584,O
by,1584,O
[,1584,B-CHEMICAL
3H,1584,I-CHEMICAL
],1584,I-CHEMICAL
zacopride,1584,I-CHEMICAL
in,1584,O
cortical,1584,O
membranes,1584,O
.,1584,O
Complementary,1585,O
experiments,1585,O
using,1585,O
the,1585,O
5-HT3-dependent,1585,B-GENE-N
Bezold-Jarisch,1585,O
reflex,1585,O
confirmed,1585,O
that,1585,O
amoxapine,1585,B-CHEMICAL
really,1585,O
acts,1585,O
in,1585,O
vivo,1585,O
as,1585,O
a,1585,O
5-HT3,1585,B-GENE-N
antagonist,1585,O
(,1585,O
IC50,1585,O
=,1585,O
50,1585,O
micrograms/kg,1585,O
i.v,1585,O
.,1585,O
),1586,O
",",1586,O
whereas,1586,O
amitriptyline,1586,O
is,1586,O
essentially,1586,O
inactive,1586,O
on,1586,O
5-HT3,1586,O
receptors,1586,O
.,1586,O
The,1587,O
second,1587,O
part,1587,O
of,1587,O
this,1587,O
study,1587,O
consisted,1587,O
of,1587,O
looking,1587,O
for,1587,O
possible,1587,O
changes,1587,O
in,1587,O
central,1587,O
5-HT,1587,I-GENE-N
receptors,1587,O
24,1587,O
h,1587,O
after,1587,O
either,1587,O
a,1587,O
single,1587,O
or,1587,O
a,1587,O
repeated,1587,O
(,1587,O
for,1587,O
14,1587,O
days,1587,O
),1587,O
treatment,1587,O
with,1587,O
amoxapine,1587,O
(,1587,O
10,1587,O
mg/kg,1587,O
i.p,1587,O
.,1587,O
each,1588,O
day,1588,O
),1588,O
or,1588,O
amitriptyline,1588,O
(,1588,O
10,1588,O
mg/kg,1588,O
i.p,1588,O
.,1588,O
),1588,O
.,1588,O
A,1589,O
marked,1589,O
decrease,1589,O
in,1589,O
the,1589,O
density,1589,O
of,1589,O
5-HT2,1589,O
receptors,1589,O
was,1589,O
found,1589,O
in,1589,O
the,1589,O
cerebral,1589,O
cortex,1589,O
in,1589,O
both,1589,O
treatment,1589,O
groups,1589,O
.,1589,O
By,1590,O
contrast,1590,O
",",1590,O
neither,1590,O
5-HT1A,1590,O
nor,1590,O
5-HT1B,1590,O
receptors,1590,O
were,1590,O
significantly,1590,O
affected,1590,O
in,1590,O
any,1590,O
brain,1590,O
region,1590,O
studied,1590,O
.,1590,O
Finally,1591,O
we,1591,O
explored,1591,O
whether,1591,O
acute,1591,O
and/or,1591,O
chronic,1591,O
administration,1591,O
of,1591,O
amoxapine,1591,O
or,1591,O
amitriptyline,1591,O
affected,1591,O
the,1591,O
levels,1591,O
of,1591,O
opioid,1591,O
peptides,1591,O
and,1591,O
the,1591,O
mu,1591,I-GENE-N
and,1591,I-GENE-N
delta,1591,I-GENE-N
classes,1591,I-GENE-N
of,1591,I-GENE-N
opioid,1591,I-GENE-N
receptors,1591,O
in,1591,O
various,1591,O
regions,1591,O
of,1591,O
the,1591,O
brain,1591,O
and,1591,O
the,1591,O
spinal,1591,O
cord,1591,O
.,1591,O
(,1592,O
ABSTRACT,1592,O
TRUNCATED,1592,O
AT,1592,O
250,1592,O
WORDS,1592,O
),1592,O
Desvenlafaxine,1593,B-CHEMICAL
succinate,1593,I-CHEMICAL
:,1593,O
A,1593,O
new,1593,O
serotonin,1593,B-CHEMICAL
and,1593,O
norepinephrine,1593,B-CHEMICAL
reuptake,1593,O
inhibitor,1593,O
.,1593,O
The,1594,O
purpose,1594,O
of,1594,O
this,1594,O
study,1594,O
was,1594,O
to,1594,O
characterize,1594,O
a,1594,O
new,1594,O
chemical,1594,O
entity,1594,O
",",1594,O
desvenlafaxine,1594,B-CHEMICAL
succinate,1594,I-CHEMICAL
(,1594,O
DVS,1594,B-CHEMICAL
),1594,O
.,1594,O
DVS,1595,B-CHEMICAL
is,1595,O
a,1595,O
novel,1595,O
salt,1595,O
form,1595,O
of,1595,O
the,1595,O
isolated,1595,O
major,1595,O
active,1595,O
metabolite,1595,O
of,1595,O
venlafaxine,1595,B-CHEMICAL
.,1595,O
Competitive,1596,O
radioligand,1596,O
binding,1596,O
assays,1596,O
were,1596,O
performed,1596,O
using,1596,O
cells,1596,O
expressing,1596,O
either,1596,O
the,1596,O
human,1596,B-GENE-Y
serotonin,1596,I-GENE-Y
(,1596,I-GENE-Y
5-HT,1596,I-GENE-Y
),1596,I-GENE-Y
transporter,1596,I-GENE-Y
(,1596,O
hSERT,1596,B-GENE-Y
),1596,O
or,1596,O
norepinephrine,1596,B-GENE-Y
(,1596,I-GENE-Y
NE,1596,I-GENE-Y
),1596,I-GENE-Y
transporter,1596,I-GENE-Y
(,1596,O
hNET,1596,B-GENE-Y
),1596,O
with,1596,O
K,1596,O
(,1596,O
i,1596,O
),1596,O
values,1596,O
for,1596,O
DVS,1596,B-CHEMICAL
of,1596,O
40.2,1596,O
+/-,1596,O
1.6,1596,O
and,1596,O
558.4,1596,O
+/-,1596,O
121.6,1596,O
nM,1596,O
",",1596,O
respectively,1596,O
.,1596,O
DVS,1597,B-CHEMICAL
showed,1597,O
weak,1597,O
binding,1597,O
affinity,1597,O
(,1597,O
62,1597,O
%,1597,O
inhibition,1597,O
at,1597,O
100,1597,O
microM,1597,O
),1597,O
at,1597,O
the,1597,O
human,1597,B-GENE-Y
dopamine,1597,I-GENE-Y
(,1597,I-GENE-Y
DA,1597,I-GENE-Y
),1597,I-GENE-Y
transporter,1597,I-GENE-Y
.,1597,O
Inhibition,1598,O
of,1598,O
[,1598,B-CHEMICAL
3H,1598,I-CHEMICAL
],1598,I-CHEMICAL
5-HT,1598,I-CHEMICAL
or,1598,O
[,1598,B-CHEMICAL
3H,1598,I-CHEMICAL
],1598,I-CHEMICAL
NE,1598,I-CHEMICAL
uptake,1598,O
by,1598,O
DVS,1598,B-CHEMICAL
for,1598,O
the,1598,O
hSERT,1598,B-GENE-Y
or,1598,O
hNET,1598,B-GENE-Y
produced,1598,O
IC50,1598,O
values,1598,O
of,1598,O
47.3,1598,O
+/-,1598,O
19.4,1598,O
and,1598,O
531.3,1598,O
+/-,1598,O
113.0,1598,O
nM,1598,O
",",1598,O
respectively,1598,O
.,1598,O
DVS,1599,B-CHEMICAL
(,1599,O
10,1599,O
microM,1599,O
),1599,O
",",1599,O
examined,1599,O
at,1599,O
a,1599,O
large,1599,O
number,1599,O
of,1599,O
nontransporter,1599,O
targets,1599,O
",",1599,O
showed,1599,O
no,1599,O
significant,1599,O
activity,1599,O
.,1599,O
DVS,1600,B-CHEMICAL
(,1600,O
30,1600,O
mg/kg,1600,O
orally,1600,O
),1600,O
rapidly,1600,O
penetrated,1600,O
the,1600,O
male,1600,O
rat,1600,O
brain,1600,O
and,1600,O
hypothalamus,1600,O
.,1600,O
DVS,1601,B-CHEMICAL
(,1601,O
30,1601,O
mg/kg,1601,O
orally,1601,O
),1601,O
significantly,1601,O
increased,1601,O
extracellular,1601,O
NE,1601,B-CHEMICAL
levels,1601,O
compared,1601,O
with,1601,O
baseline,1601,O
in,1601,O
the,1601,O
male,1601,O
rat,1601,O
hypothalamus,1601,O
but,1601,O
had,1601,O
no,1601,O
effect,1601,O
on,1601,O
DA,1601,B-CHEMICAL
levels,1601,O
using,1601,O
microdialysis,1601,O
.,1601,O
To,1602,O
mimic,1602,O
chronic,1602,O
selective,1602,O
serotonin,1602,B-CHEMICAL
reuptake,1602,O
inhibitor,1602,O
treatment,1602,O
and,1602,O
to,1602,O
block,1602,O
the,1602,O
inhibitory,1602,O
5-HT,1602,B-GENE-Y
(,1602,I-GENE-Y
1A,1602,I-GENE-Y
),1602,I-GENE-Y
autoreceptors,1602,O
",",1602,O
a,1602,O
5-HT,1602,B-GENE-Y
(,1602,I-GENE-Y
1A,1602,I-GENE-Y
),1602,I-GENE-Y
antagonist,1602,O
",",1602,O
N-,1602,B-CHEMICAL
[,1602,I-CHEMICAL
2-,1602,I-CHEMICAL
[,1602,I-CHEMICAL
4-,1602,I-CHEMICAL
(,1602,I-CHEMICAL
2-methoxyphenyl,1602,I-CHEMICAL
),1602,I-CHEMICAL
-1-piperazinyl,1602,I-CHEMICAL
],1602,I-CHEMICAL
ethyl,1602,I-CHEMICAL
],1602,I-CHEMICAL
-N-2-pyridinylcyclo,1602,I-CHEMICAL
hexanecarboxamide,1602,I-CHEMICAL
maleate,1602,I-CHEMICAL
salt,1602,I-CHEMICAL
(,1602,O
WAY-100635,1602,B-CHEMICAL
),1602,O
(,1602,O
0.3,1602,O
mg/kg,1602,O
s.c.,1602,O
),1602,O
",",1602,O
was,1602,O
administered,1602,O
with,1602,O
DVS,1602,B-CHEMICAL
(,1602,O
30,1602,O
mg/kg,1602,O
orally,1602,O
),1602,O
.,1602,O
5-HT,1603,B-CHEMICAL
increased,1603,O
78,1603,O
%,1603,O
compared,1603,O
with,1603,O
baseline,1603,O
with,1603,O
no,1603,O
additional,1603,O
increase,1603,O
in,1603,O
NE,1603,B-CHEMICAL
or,1603,O
DA,1603,B-CHEMICAL
levels,1603,O
.,1603,O
In,1604,O
conclusion,1604,O
",",1604,O
DVS,1604,B-CHEMICAL
is,1604,O
a,1604,O
new,1604,O
5-HT,1604,B-CHEMICAL
and,1604,O
NE,1604,B-CHEMICAL
reuptake,1604,O
inhibitor,1604,O
in,1604,O
vitro,1604,O
and,1604,O
in,1604,O
vivo,1604,O
that,1604,O
demonstrates,1604,O
good,1604,O
brain-to-plasma,1604,O
ratios,1604,O
",",1604,O
suggesting,1604,O
utility,1604,O
in,1604,O
a,1604,O
variety,1604,O
of,1604,O
central,1604,O
nervous,1604,O
system-related,1604,O
disorders,1604,O
.,1604,O
How,1605,O
may,1605,O
anticancer,1605,O
chemotherapy,1605,O
with,1605,O
fluorouracil,1605,B-CHEMICAL
be,1605,O
individualised,1605,O
?,1605,O
Fluorouracil,1606,B-CHEMICAL
is,1606,O
used,1606,O
clinically,1606,O
against,1606,O
various,1606,O
solid,1606,O
tumours,1606,O
.,1606,O
Both,1607,O
fluorouracil,1607,B-CHEMICAL
toxicity,1607,O
and,1607,O
pharmacokinetics,1607,O
vary,1607,O
highly,1607,O
within,1607,O
and,1607,O
between,1607,O
individuals,1607,O
.,1607,O
The,1608,O
reasons,1608,O
why,1608,O
doses,1608,O
are,1608,O
not,1608,O
individualised,1608,O
routinely,1608,O
are,1608,O
difficulties,1608,O
in,1608,O
defining,1608,O
",",1608,O
predicting,1608,O
and,1608,O
achieving,1608,O
an,1608,O
optimal,1608,O
fluorouracil,1608,B-CHEMICAL
exposure,1608,O
or,1608,O
dose,1608,O
because,1608,O
of,1608,O
a,1608,O
narrow,1608,O
therapeutic,1608,O
index,1608,O
",",1608,O
nonlinear,1608,O
pharmacokinetics,1608,O
",",1608,O
variabilities,1608,O
in,1608,O
administration,1608,O
rates,1608,O
and,1608,O
metabolism,1608,O
",",1608,O
and,1608,O
in,1608,O
targets,1608,O
like,1608,O
thymidylate,1608,B-GENE-Y
synthase,1608,I-GENE-Y
.,1608,O
To,1609,O
individualise,1609,O
fluorouracil,1609,B-CHEMICAL
administration,1609,O
before,1609,O
the,1609,O
first,1609,O
dose,1609,O
",",1609,O
assessment,1609,O
of,1609,O
the,1609,O
individual,1609,O
dihydropyrimidine,1609,B-GENE-Y
dehydrogenase,1609,I-GENE-Y
(,1609,O
DPD,1609,B-GENE-Y
),1609,O
activity,1609,O
may,1609,O
be,1609,O
useful,1609,O
",",1609,O
because,1609,O
this,1609,O
genetically,1609,O
highly,1609,O
polymorphic,1609,O
enzyme,1609,O
controls,1609,O
approximately,1609,O
80,1609,O
%,1609,O
of,1609,O
fluorouracil,1609,B-CHEMICAL
elimination,1609,O
.,1609,O
A,1610,O
complete,1610,O
or,1610,O
partial,1610,O
loss,1610,O
of,1610,O
DPD,1610,B-GENE-Y
activity,1610,O
in,1610,O
0.1,1610,O
and,1610,O
3-5,1610,O
%,1610,O
of,1610,O
Caucasians,1610,O
",",1610,O
respectively,1610,O
",",1610,O
leads,1610,O
to,1610,O
increased,1610,O
fluorouracil,1610,B-CHEMICAL
exposure,1610,O
and,1610,O
toxicity,1610,O
.,1610,O
Several,1611,O
methods,1611,O
to,1611,O
assess,1611,O
DPD,1611,B-GENE-Y
activity,1611,O
in,1611,O
patients,1611,O
have,1611,O
been,1611,O
proposed,1611,O
(,1611,O
genotyping,1611,O
",",1611,O
various,1611,O
phenotyping,1611,O
methods,1611,O
),1611,O
",",1611,O
but,1611,O
each,1611,O
of,1611,O
them,1611,O
has,1611,O
limitations,1611,O
",",1611,O
as,1611,O
has,1611,O
the,1611,O
fluorouracil,1611,B-CHEMICAL
test,1611,O
dose,1611,O
approach,1611,O
.,1611,O
To,1612,O
adapt,1612,O
exposure,1612,O
towards,1612,O
fluorouracil,1612,B-CHEMICAL
a,1612,O
priori,1612,O
",",1612,O
a,1612,O
combination,1612,O
of,1612,O
genotyping,1612,O
and,1612,O
phenotyping,1612,O
may,1612,O
yield,1612,O
better,1612,O
prediction,1612,O
of,1612,O
toxicity,1612,O
than,1612,O
one,1612,O
method,1612,O
alone,1612,O
.,1612,O
A,1613,O
prerequisite,1613,O
for,1613,O
dose,1613,O
adaptation,1613,O
is,1613,O
the,1613,O
definition,1613,O
of,1613,O
fluorouracil,1613,B-CHEMICAL
exposure,1613,O
ranges,1613,O
with,1613,O
sufficient,1613,O
therapeutic,1613,O
activity,1613,O
",",1613,O
but,1613,O
without,1613,O
serious,1613,O
toxicity,1613,O
.,1613,O
While,1614,O
an,1614,O
increased,1614,O
risk,1614,O
of,1614,O
leukopenia,1614,O
",",1614,O
diarrhoea,1614,O
",",1614,O
stomatitis,1614,O
",",1614,O
and,1614,O
hand-foot,1614,O
syndrome,1614,O
during,1614,O
continuous,1614,O
5-day,1614,O
infusions,1614,O
was,1614,O
related,1614,O
to,1614,O
fluorouracil,1614,B-CHEMICAL
exposures,1614,O
above,1614,O
an,1614,O
area,1614,O
under,1614,O
the,1614,O
plasma,1614,O
concentration-time,1614,O
curve,1614,O
(,1614,O
AUC,1614,O
),1614,O
threshold,1614,O
of,1614,O
25-30,1614,O
mg.h/L,1614,O
",",1614,O
tumour,1614,O
response,1614,O
was,1614,O
higher,1614,O
when,1614,O
an,1614,O
AUC,1614,O
of,1614,O
approximately,1614,O
30,1614,O
mg.h/L,1614,O
was,1614,O
achieved,1614,O
",",1614,O
illustrating,1614,O
the,1614,O
extremely,1614,O
narrow,1614,O
therapeutic,1614,O
window,1614,O
of,1614,O
fluorouracil,1614,B-CHEMICAL
.,1614,O
Pharmacokinetic,1615,O
target,1615,O
values,1615,O
are,1615,O
less,1615,O
clear,1615,O
for,1615,O
other,1615,O
regimens,1615,O
",",1615,O
including,1615,O
chronomodulated,1615,O
regimens,1615,O
",",1615,O
which,1615,O
yielded,1615,O
a,1615,O
superior,1615,O
clinically,1615,O
efficacy,1615,O
and,1615,O
tolerability,1615,O
in,1615,O
several,1615,O
trials,1615,O
.,1615,O
However,1616,O
",",1616,O
the,1616,O
monitoring,1616,O
of,1616,O
fluorouracil,1616,B-CHEMICAL
plasma,1616,O
concentrations,1616,O
seems,1616,O
principally,1616,O
useful,1616,O
for,1616,O
individual,1616,O
a,1616,O
posteriori,1616,O
dose,1616,O
adjustment,1616,O
.,1616,O
Whether,1617,O
an,1617,O
adaptation,1617,O
of,1617,O
the,1617,O
fluorouracil,1617,B-CHEMICAL
starting,1617,O
dose,1617,O
to,1617,O
the,1617,O
results,1617,O
of,1617,O
two,1617,O
DPD,1617,B-GENE-Y
activity,1617,O
tests,1617,O
before,1617,O
fluorouracil,1617,B-CHEMICAL
administration,1617,O
a,1617,O
priori,1617,O
",",1617,O
and,1617,O
the,1617,O
adaptation,1617,O
of,1617,O
doses,1617,O
to,1617,O
fluorouracil,1617,B-CHEMICAL
exposure,1617,O
a,1617,O
posteriori,1617,O
is,1617,O
a,1617,O
reasonable,1617,O
approach,1617,O
to,1617,O
better,1617,O
prevent,1617,O
toxicity,1617,O
and,1617,O
increase,1617,O
efficacy,1617,O
",",1617,O
remains,1617,O
to,1617,O
be,1617,O
evaluated,1617,O
in,1617,O
randomised,1617,O
clinical,1617,O
studies,1617,O
comparing,1617,O
these,1617,O
strategies,1617,O
to,1617,O
routine,1617,O
clinical,1617,O
safety,1617,O
monitoring,1617,O
.,1617,O
Expression,1618,O
of,1618,O
basic,1618,B-GENE-Y
fibroblast,1618,I-GENE-Y
growth,1618,I-GENE-Y
factor,1618,I-GENE-Y
correlates,1618,O
with,1618,O
resistance,1618,O
to,1618,O
paclitaxel,1618,B-CHEMICAL
in,1618,O
human,1618,O
patient,1618,O
tumors,1618,O
.,1618,O
BACKGROUND,1619,O
:,1619,O
Preclinical,1619,O
results,1619,O
indicate,1619,O
acidic,1619,B-GENE-Y
fibroblast,1619,I-GENE-Y
growth,1619,I-GENE-Y
factor,1619,I-GENE-Y
(,1619,O
aFGF,1619,B-GENE-Y
),1619,O
and,1619,O
basic,1619,B-GENE-Y
FGF,1619,I-GENE-Y
(,1619,O
bFGF,1619,B-GENE-Y
),1619,O
present,1619,O
in,1619,O
solid,1619,O
tumors,1619,O
as,1619,O
a,1619,O
cause,1619,O
of,1619,O
broad-spectrum,1619,O
chemoresistance,1619,O
",",1619,O
whereas,1619,O
earlier,1619,O
clinical,1619,O
studies,1619,O
suggest,1619,O
that,1619,O
bFGF,1619,B-GENE-Y
expression,1619,O
is,1619,O
associated,1619,O
with,1619,O
opposing,1619,O
outcomes,1619,O
in,1619,O
patients,1619,O
.,1619,O
We,1620,O
investigated,1620,O
the,1620,O
relationship,1620,O
between,1620,O
FGF,1620,B-GENE-N
expression,1620,O
and,1620,O
paclitaxel,1620,B-CHEMICAL
activity,1620,O
in,1620,O
tumors,1620,O
from,1620,O
bladder,1620,O
",",1620,O
breast,1620,O
",",1620,O
head,1620,O
and,1620,O
neck,1620,O
",",1620,O
ovarian,1620,O
",",1620,O
and,1620,O
prostate,1620,O
cancer,1620,O
patients,1620,O
.,1620,O
MATERIALS,1621,O
AND,1621,O
METHODS,1621,O
:,1621,O
Tumors,1621,O
(,1621,O
n,1621,O
=,1621,O
96,1621,O
),1621,O
were,1621,O
maintained,1621,O
in,1621,O
three-dimensional,1621,O
histocultures,1621,O
",",1621,O
retaining,1621,O
tumor-stromal,1621,O
interaction,1621,O
.,1621,O
Bladder,1622,O
tumors,1622,O
were,1622,O
treated,1622,O
with,1622,O
paclitaxel,1622,B-CHEMICAL
for,1622,O
2,1622,O
h,1622,O
",",1622,O
and,1622,O
the,1622,O
other,1622,O
tumors,1622,O
for,1622,O
24,1622,O
h.,1622,O
Antiproliferative,1622,O
and,1622,O
proapoptotic,1622,O
effects,1622,O
of,1622,O
paclitaxel,1622,B-CHEMICAL
were,1622,O
quantified,1622,O
and,1622,O
correlated,1622,O
with,1622,O
expression,1622,O
of,1622,O
aFGF,1622,B-GENE-Y
",",1622,O
bFGF,1622,B-GENE-Y
",",1622,O
P-glycoprotein,1622,B-GENE-N
(,1622,O
Pgp,1622,B-GENE-N
),1622,O
",",1622,O
p53,1622,B-GENE-Y
",",1622,O
and,1622,O
bcl-2,1622,B-GENE-Y
.,1622,O
RESULTS,1623,O
:,1623,O
Fifty-one,1623,O
percent,1623,O
(,1623,O
49/96,1623,O
),1623,O
and,1623,O
63,1623,O
%,1623,O
(,1623,O
61/96,1623,O
),1623,O
of,1623,O
tumors,1623,O
showed,1623,O
aFGF,1623,B-GENE-Y
and,1623,O
bFGF,1623,B-GENE-Y
staining,1623,O
",",1623,O
respectively,1623,O
.,1623,O
aFGF,1624,B-GENE-Y
expression,1624,O
was,1624,O
positively,1624,O
correlated,1624,O
with,1624,O
tumor,1624,O
stage,1624,O
(,1624,O
p,1624,O
<,1624,O
0.01,1624,O
),1624,O
",",1624,O
and,1624,O
bFGF,1624,B-GENE-Y
expression,1624,O
with,1624,O
tumor,1624,O
grade,1624,O
and,1624,O
Pgp,1624,B-GENE-N
expression,1624,O
(,1624,O
p,1624,O
<,1624,O
0.05,1624,O
),1624,O
.,1624,O
Paclitaxel,1625,B-CHEMICAL
inhibited,1625,O
antiproliferation,1625,O
in,1625,O
86,1625,O
%,1625,O
of,1625,O
tumors,1625,O
(,1625,O
83/96,1625,O
),1625,O
",",1625,O
with,1625,O
an,1625,O
average,1625,O
inhibition,1625,O
of,1625,O
46,1625,O
+/-,1625,O
19,1625,O
%,1625,O
(,1625,O
mean,1625,O
+/-,1625,O
SD,1625,O
),1625,O
in,1625,O
the,1625,O
responding,1625,O
tumors,1625,O
.,1625,O
Paclitaxel,1626,B-CHEMICAL
also,1626,O
induced,1626,O
apoptosis,1626,O
in,1626,O
96,1626,O
%,1626,O
of,1626,O
tumors,1626,O
(,1626,O
92/96,1626,O
),1626,O
",",1626,O
with,1626,O
an,1626,O
average,1626,O
apoptotic,1626,O
index,1626,O
of,1626,O
12,1626,O
+/-,1626,O
7,1626,O
%,1626,O
in,1626,O
the,1626,O
responding,1626,O
tumors,1626,O
.,1626,O
aFGF,1627,B-GENE-Y
expression,1627,O
did,1627,O
not,1627,O
correlate,1627,O
with,1627,O
tumor,1627,O
sensitivity,1627,O
to,1627,O
paclitaxel,1627,B-CHEMICAL
",",1627,O
whereas,1627,O
bFGF,1627,B-GENE-Y
expression,1627,O
showed,1627,O
an,1627,O
inverse,1627,O
correlation,1627,O
(,1627,O
p,1627,O
<,1627,O
0.01,1627,O
),1627,O
.,1627,O
bFGF,1628,B-GENE-Y
expression,1628,O
was,1628,O
a,1628,O
stronger,1628,O
predictor,1628,O
of,1628,O
paclitaxel,1628,B-CHEMICAL
resistance,1628,O
compared,1628,O
to,1628,O
Pgp,1628,B-GENE-N
",",1628,O
p53,1628,B-GENE-Y
",",1628,O
or,1628,O
Bcl-2,1628,B-GENE-Y
.,1628,O
CONCLUSION,1629,O
:,1629,O
These,1629,O
results,1629,O
support,1629,O
a,1629,O
role,1629,O
of,1629,O
bFGF,1629,B-GENE-Y
in,1629,O
paclitaxel,1629,B-CHEMICAL
resistance,1629,O
in,1629,O
human,1629,O
patient,1629,O
tumors,1629,O
.,1629,O
Thyroid,1630,B-GENE-N
hormone,1630,I-GENE-N
receptor,1630,I-GENE-N
expression,1630,O
in,1630,O
the,1630,O
obligatory,1630,O
paedomorphic,1630,O
salamander,1630,O
Necturus,1630,O
maculosus,1630,O
.,1630,O
Amphibian,1631,O
metamorphosis,1631,O
is,1631,O
under,1631,O
the,1631,O
strict,1631,O
control,1631,O
of,1631,O
thyroid,1631,B-CHEMICAL
hormones,1631,I-CHEMICAL
(,1631,O
TH,1631,B-CHEMICAL
),1631,O
.,1631,O
These,1632,O
hormones,1632,O
induce,1632,O
metamorphosis,1632,O
by,1632,O
controlling,1632,O
gene,1632,O
expression,1632,O
through,1632,O
binding,1632,O
to,1632,O
thyroid,1632,B-CHEMICAL
hormone,1632,I-CHEMICAL
receptors,1632,I-GENE-N
(,1632,O
TRs,1632,B-GENE-N
),1632,O
.,1632,O
Necturus,1633,O
maculosus,1633,O
is,1633,O
considered,1633,O
to,1633,O
be,1633,O
an,1633,O
obligatory,1633,O
paedomorphic,1633,O
Amphibian,1633,O
since,1633,O
metamorphosis,1633,O
never,1633,O
occurs,1633,O
spontaneously,1633,O
and,1633,O
can,1633,O
not,1633,O
be,1633,O
induced,1633,O
by,1633,O
pharmacological,1633,O
means,1633,O
.,1633,O
Since,1634,O
metamorphosis,1634,O
depends,1634,O
on,1634,O
the,1634,O
acquisition,1634,O
of,1634,O
response,1634,O
of,1634,O
tadpole,1634,O
tissues,1634,O
to,1634,O
thyroid,1634,B-CHEMICAL
hormone,1634,I-CHEMICAL
",",1634,O
we,1634,O
aimed,1634,O
to,1634,O
determine,1634,O
TR,1634,B-GENE-N
gene,1634,O
expression,1634,O
patterns,1634,O
in,1634,O
Necturus,1634,O
maculosus,1634,O
as,1634,O
well,1634,O
as,1634,O
the,1634,O
expression,1634,O
of,1634,O
two,1634,O
TH-related,1634,B-CHEMICAL
genes,1634,O
:,1634,O
Cytosolic,1634,B-GENE-N
Thyroid,1634,B-CHEMICAL
Hormone-Binding,1634,I-GENE-N
Protein,1634,I-GENE-N
(,1634,O
CTHBP,1634,B-GENE-N
),1634,O
-M2-pyruvate,1634,O
kinase,1634,I-GENE-N
",",1634,O
a,1634,O
gene,1634,O
encoding,1634,O
a,1634,O
cytosolic,1634,B-GENE-N
TH,1634,B-CHEMICAL
binding,1634,I-GENE-N
protein,1634,I-GENE-N
and,1634,O
stromelysin,1634,B-GENE-Y
3,1634,I-GENE-Y
",",1634,O
a,1634,O
direct,1634,O
TH,1634,O
target,1634,O
gene,1634,O
in,1634,O
Xenopus,1634,O
laevis,1634,O
.,1634,O
Tissue,1635,O
samples,1635,O
were,1635,O
obtained,1635,O
from,1635,O
specimens,1635,O
of,1635,O
Necturus,1635,O
maculosus,1635,O
.,1635,O
We,1636,O
performed,1636,O
in,1636,O
situ,1636,O
hybridization,1636,O
using,1636,O
non-cross-hybridizing,1636,O
RNA,1636,O
probes,1636,O
obtained,1636,O
from,1636,O
the,1636,O
cloned,1636,O
Necturus,1636,B-GENE-Y
TRalpha,1636,I-GENE-Y
and,1636,O
TRbeta,1636,B-GENE-Y
genes,1636,O
.,1636,O
We,1637,O
found,1637,O
clear,1637,O
expression,1637,O
of,1637,O
Necturus,1637,B-GENE-Y
TRalpha,1637,I-GENE-Y
gene,1637,O
in,1637,O
several,1637,O
tissues,1637,O
including,1637,O
the,1637,O
central,1637,O
nervous,1637,O
system,1637,O
",",1637,O
epithelial,1637,O
cells,1637,O
of,1637,O
digestive,1637,O
and,1637,O
urinary,1637,O
organs,1637,O
",",1637,O
as,1637,O
well,1637,O
as,1637,O
myocardium,1637,O
and,1637,O
skeletal,1637,O
muscle,1637,O
.,1637,O
TRbeta,1638,B-GENE-Y
was,1638,O
also,1638,O
expressed,1638,O
in,1638,O
the,1638,O
brain,1638,O
.,1638,O
In,1639,O
other,1639,O
tissues,1639,O
",",1639,O
hybridization,1639,O
signals,1639,O
were,1639,O
too,1639,O
low,1639,O
to,1639,O
draw,1639,O
reliable,1639,O
conclusions,1639,O
about,1639,O
their,1639,O
precise,1639,O
distribution,1639,O
.,1639,O
In,1640,O
addition,1640,O
",",1640,O
we,1640,O
observed,1640,O
that,1640,O
the,1640,O
expression,1640,O
of,1640,O
CTHBP,1640,B-GENE-N
and,1640,O
ST3,1640,B-GENE-Y
is,1640,O
largely,1640,O
distinct,1640,O
from,1640,O
that,1640,O
of,1640,O
TRs,1640,O
.,1640,O
The,1641,O
fact,1641,O
that,1641,O
we,1641,O
observed,1641,O
a,1641,O
clear,1641,O
expression,1641,O
of,1641,O
TRalpha,1641,B-GENE-Y
and,1641,O
TRbeta,1641,B-GENE-Y
which,1641,O
are,1641,O
evolutionary,1641,O
conserved,1641,O
",",1641,O
suggests,1641,O
that,1641,O
Necturus,1641,O
tissues,1641,O
express,1641,O
TRs,1641,B-GENE-N
.,1641,O
Our,1642,O
results,1642,O
thus,1642,O
indicate,1642,O
that,1642,O
",",1642,O
in,1642,O
contrast,1642,O
to,1642,O
previously,1642,O
held,1642,O
hypotheses,1642,O
",",1642,O
Necturus,1642,O
tissues,1642,O
are,1642,O
TH,1642,B-CHEMICAL
responsive,1642,O
.,1642,O
Regulation,1643,O
of,1643,O
retinal,1643,O
dehydrogenases,1643,O
and,1643,O
retinoic,1643,B-CHEMICAL
acid,1643,I-CHEMICAL
synthesis,1643,O
by,1643,O
cholesterol,1643,B-CHEMICAL
metabolites,1643,O
.,1643,O
Retinoic,1644,B-CHEMICAL
acid,1644,I-CHEMICAL
(,1644,O
RA,1644,B-CHEMICAL
),1644,O
constitutes,1644,O
the,1644,O
major,1644,O
active,1644,O
ingredient,1644,O
of,1644,O
vitamin,1644,B-CHEMICAL
A,1644,I-CHEMICAL
and,1644,O
is,1644,O
required,1644,O
for,1644,O
various,1644,O
biological,1644,O
processes,1644,O
.,1644,O
The,1645,O
tissue,1645,O
RA,1645,B-CHEMICAL
level,1645,O
is,1645,O
maintained,1645,O
through,1645,O
a,1645,O
cascade,1645,O
of,1645,O
metabolic,1645,O
reactions,1645,O
where,1645,O
retinal,1645,B-CHEMICAL
dehydrogenases,1645,I-GENE-N
(,1645,O
RALDHs,1645,B-GENE-N
),1645,O
catalyze,1645,O
the,1645,O
terminal,1645,O
reaction,1645,O
of,1645,O
RA,1645,B-CHEMICAL
biosynthesis,1645,O
from,1645,O
retinal,1645,B-CHEMICAL
",",1645,O
a,1645,O
rate-limiting,1645,O
step,1645,O
.,1645,O
We,1646,O
showed,1646,O
that,1646,O
dietary,1646,O
supplement,1646,O
of,1646,O
cholesterol,1646,B-CHEMICAL
enhanced,1646,O
the,1646,O
expression,1646,O
of,1646,O
RALDH1,1646,B-GENE-N
and,1646,I-GENE-N
2,1646,I-GENE-N
genes,1646,O
and,1646,O
the,1646,O
cellular,1646,O
RA,1646,B-CHEMICAL
content,1646,O
in,1646,O
vital,1646,O
organs,1646,O
such,1646,O
as,1646,O
brain,1646,O
",",1646,O
kidney,1646,O
",",1646,O
liver,1646,O
and,1646,O
heart,1646,O
.,1646,O
Consistently,1647,O
",",1647,O
the,1647,O
cholesterol-lowering,1647,B-CHEMICAL
agent,1647,O
(,1647,O
pravastatin,1647,B-CHEMICAL
sodium,1647,I-CHEMICAL
),1647,O
downregulated,1647,O
the,1647,O
expression,1647,O
of,1647,O
RALDH1,1647,B-GENE-N
and,1647,I-GENE-N
2,1647,I-GENE-N
genes,1647,O
in,1647,O
several,1647,O
organs,1647,O
especially,1647,O
the,1647,O
liver,1647,O
and,1647,O
in,1647,O
cultured,1647,O
liver,1647,O
cells,1647,O
.,1647,O
Further,1648,O
",",1648,O
cholesterol,1648,B-CHEMICAL
metabolites,1648,O
",",1648,O
predominantly,1648,O
the,1648,O
oxysterols,1648,B-CHEMICAL
",",1648,O
the,1648,O
natural,1648,O
ligands,1648,O
for,1648,O
liver,1648,B-GENE-N
X,1648,I-GENE-N
receptor,1648,I-GENE-N
(,1648,O
LXR,1648,B-GENE-N
),1648,O
",",1648,O
induced,1648,O
these,1648,O
genes,1648,O
via,1648,O
upregulation,1648,O
of,1648,O
sterol,1648,B-GENE-Y
regulatory,1648,I-GENE-Y
element,1648,I-GENE-Y
binding,1648,I-GENE-Y
protein-1c,1648,I-GENE-Y
(,1648,O
SREBP-1c,1648,B-GENE-Y
),1648,O
that,1648,O
bound,1648,O
to,1648,O
the,1648,O
regulatory,1648,O
regions,1648,O
of,1648,O
these,1648,O
genes,1648,O
.,1648,O
Knockdown,1649,O
of,1649,O
LXRalpha/beta,1649,B-GENE-N
or,1649,O
SREBP-1c,1649,B-GENE-Y
downregulated,1649,O
the,1649,O
expression,1649,O
of,1649,O
RALDH,1649,B-GENE-N
genes,1649,O
",",1649,O
which,1649,O
could,1649,O
be,1649,O
rescued,1649,O
by,1649,O
re-expressing,1649,O
SREBP-1c,1649,B-GENE-Y
",",1649,O
suggesting,1649,O
SREBP-1c,1649,B-GENE-Y
as,1649,O
a,1649,O
direct,1649,O
positive,1649,O
regulator,1649,O
for,1649,O
these,1649,O
genes,1649,O
.,1649,O
This,1650,O
study,1650,O
uncovered,1650,O
a,1650,O
novel,1650,O
crosstalk,1650,O
between,1650,O
cholesterol,1650,B-CHEMICAL
and,1650,O
RA,1650,B-CHEMICAL
biosynthesis,1650,O
.,1650,O
Reelin,1651,B-GENE-Y
down-regulation,1651,O
in,1651,O
mice,1651,O
and,1651,O
psychosis,1651,O
endophenotypes,1651,O
.,1651,O
Reelin,1652,B-GENE-Y
",",1652,O
a,1652,O
large,1652,O
glycoprotein,1652,O
secreted,1652,O
by,1652,O
telencephalic,1652,O
GABAergic,1652,O
neurons,1652,O
",",1652,O
plays,1652,O
an,1652,O
important,1652,O
role,1652,O
in,1652,O
neuronal,1652,O
guidance,1652,O
embryonically,1652,O
and,1652,O
in,1652,O
synaptic,1652,O
plasticity,1652,O
postnatally,1652,O
.,1652,O
The,1653,O
reeler,1653,O
heterozygous,1653,O
mouse,1653,O
(,1653,O
+/rl,1653,O
),1653,O
appears,1653,O
superficially,1653,O
normal,1653,O
but,1653,O
has,1653,O
been,1653,O
of,1653,O
interest,1653,O
as,1653,O
an,1653,O
animal,1653,O
model,1653,O
for,1653,O
psychosis,1653,O
since,1653,O
the,1653,O
discovery,1653,O
that,1653,O
reelin,1653,B-GENE-Y
is,1653,O
50,1653,O
%,1653,O
down-regulated,1653,O
in,1653,O
postmortem,1653,O
psychotic,1653,O
brain,1653,O
.,1653,O
Brain,1654,O
abnormalities,1654,O
in,1654,O
+/rl,1654,O
are,1654,O
similar,1654,O
to,1654,O
psychotic,1654,O
brain,1654,O
and,1654,O
include,1654,O
a,1654,O
reduction,1654,O
in,1654,O
glutamic,1654,B-GENE-Y
acid,1654,I-GENE-Y
de,1654,I-GENE-Y
carboxylase,1654,I-GENE-Y
67,1654,I-GENE-Y
(,1654,O
GAD67,1654,B-GENE-Y
),1654,O
",",1654,O
dendritic,1654,O
arbors,1654,O
and,1654,O
spine,1654,O
density,1654,O
in,1654,O
cortex,1654,O
and,1654,O
hippocampus,1654,O
",",1654,O
and,1654,O
abnormalities,1654,O
in,1654,O
synaptic,1654,O
function,1654,O
including,1654,O
long-term,1654,O
potentiation,1654,O
(,1654,O
LTP,1654,O
),1654,O
.,1654,O
In,1655,O
spite,1655,O
of,1655,O
these,1655,O
abnormalities,1655,O
",",1655,O
behavioral,1655,O
abnormalities,1655,O
in,1655,O
+/rl,1655,O
are,1655,O
subtle,1655,O
and,1655,O
controversial,1655,O
.,1655,O
Recent,1656,O
findings,1656,O
indicate,1656,O
that,1656,O
the,1656,O
reelin,1656,B-GENE-N
(,1656,I-GENE-N
RELN,1656,I-GENE-N
),1656,I-GENE-N
and,1656,I-GENE-N
GAD67,1656,I-GENE-N
promoters,1656,I-GENE-N
are,1656,O
hypermethylated,1656,O
in,1656,O
GABAergic,1656,O
neurons,1656,O
of,1656,O
psychotic,1656,O
postmortem,1656,O
brain,1656,O
and,1656,O
that,1656,O
DNA,1656,B-GENE-Y
methyltransferase,1656,I-GENE-Y
1,1656,I-GENE-Y
(,1656,O
DNMT1,1656,B-GENE-Y
),1656,O
is,1656,O
up-regulated,1656,O
.,1656,O
Hypermethlyation,1657,O
of,1657,O
RELN,1657,B-GENE-N
and,1657,I-GENE-N
GAD67,1657,I-GENE-N
promoters,1657,I-GENE-N
can,1657,O
be,1657,O
induced,1657,O
by,1657,O
treating,1657,O
mice,1657,O
with,1657,O
methionine,1657,B-CHEMICAL
",",1657,O
and,1657,O
these,1657,O
mice,1657,O
display,1657,O
brain,1657,O
and,1657,O
behavioral,1657,O
abnormalities,1657,O
similar,1657,O
to,1657,O
+/rl,1657,O
.,1657,O
Thus,1658,O
",",1658,O
an,1658,O
animal,1658,O
model,1658,O
that,1658,O
combines,1658,O
genetic,1658,O
heterozygocity,1658,O
with,1658,O
epigenesis,1658,O
holds,1658,O
promise,1658,O
for,1658,O
understanding,1658,O
the,1658,O
role,1658,O
of,1658,O
Reelin,1658,B-GENE-Y
down-regulation,1658,O
in,1658,O
psychosis,1658,O
.,1658,O
Functional,1659,O
and,1659,O
bioenergetic,1659,O
consequences,1659,O
of,1659,O
AT1,1659,B-GENE-Y
antagonist,1659,O
olmesartan,1659,B-CHEMICAL
medoxomil,1659,I-CHEMICAL
in,1659,O
hearts,1659,O
with,1659,O
postinfarction,1659,O
LV,1659,O
remodeling,1659,O
.,1659,O
The,1660,O
structural,1660,O
left,1660,O
ventricular,1660,O
(,1660,O
LV,1660,O
),1660,O
remodeling,1660,O
and,1660,O
contractile,1660,O
dysfunction,1660,O
of,1660,O
hearts,1660,O
with,1660,O
postinfarction,1660,O
LV,1660,O
remodeling,1660,O
are,1660,O
benefited,1660,O
by,1660,O
angiotensin,1660,B-GENE-Y
II,1660,I-GENE-Y
type,1660,I-GENE-Y
1,1660,I-GENE-Y
receptor,1660,I-GENE-Y
(,1660,O
AT1,1660,B-GENE-Y
),1660,O
blocker,1660,O
.,1660,O
However,1661,O
",",1661,O
the,1661,O
myocardial,1661,O
bioenergetic,1661,O
consequences,1661,O
of,1661,O
AT1,1661,B-GENE-Y
blocker,1661,O
in,1661,O
these,1661,O
hearts,1661,O
are,1661,O
not,1661,O
known,1661,O
.,1661,O
To,1662,O
investigate,1662,O
",",1662,O
we,1662,O
used,1662,O
a,1662,O
porcine,1662,O
model,1662,O
of,1662,O
postinfarction,1662,O
LV,1662,O
remodeling,1662,O
produced,1662,O
by,1662,O
ligation,1662,O
of,1662,O
the,1662,O
left,1662,O
circumflex,1662,O
coronary,1662,O
artery,1662,O
.,1662,O
After,1663,O
infarction,1663,O
",",1663,O
7,1663,O
pigs,1663,O
received,1663,O
olmesartan,1663,B-CHEMICAL
medoxomil,1663,I-CHEMICAL
(,1663,O
2,1663,O
mg/kg,1663,O
),1663,O
for,1663,O
comparison,1663,O
against,1663,O
9,1663,O
untreated,1663,O
and,1663,O
10,1663,O
normal,1663,O
pigs,1663,O
.,1663,O
Measurements,1664,O
of,1664,O
hemodynamics,1664,O
",",1664,O
myocardial,1664,O
perfusion,1664,O
",",1664,O
and,1664,O
myocardial,1664,O
bioenergetics,1664,O
were,1664,O
taken,1664,O
7,1664,O
weeks,1664,O
postinfarction,1664,O
.,1664,O
The,1665,O
treated,1665,O
group,1665,O
had,1665,O
an,1665,O
LV-to-body,1665,O
weight,1665,O
ratio,1665,O
significantly,1665,O
lower,1665,O
than,1665,O
the,1665,O
untreated,1665,O
group,1665,O
(,1665,O
2.69,1665,O
+/-,1665,O
0.70,1665,O
",",1665,O
2.96,1665,O
+/-,1665,O
0.51,1665,O
",",1665,O
3.66,1665,O
+/-,1665,O
0.60,1665,O
g/kg,1665,O
for,1665,O
control,1665,O
",",1665,O
treated,1665,O
",",1665,O
and,1665,O
untreated,1665,O
groups,1665,O
",",1665,O
respectively,1665,O
),1665,O
.,1665,O
The,1666,O
untreated,1666,O
group,1666,O
had,1666,O
a,1666,O
mean,1666,O
aortic,1666,O
pressure,1666,O
significantly,1666,O
higher,1666,O
than,1666,O
the,1666,O
control,1666,O
(,1666,O
73,1666,O
+/-,1666,O
16,1666,O
",",1666,O
86,1666,O
+/-,1666,O
14,1666,O
",",1666,O
and,1666,O
94,1666,O
+/-,1666,O
20,1666,O
mm,1666,O
Hg,1666,O
",",1666,O
respectively,1666,O
),1666,O
.,1666,O
The,1667,O
subendocardial,1667,O
phosphocreatine-to-ATP,1667,B-CHEMICAL
ratios,1667,O
of,1667,O
the,1667,O
treated,1667,O
group,1667,O
were,1667,O
significantly,1667,O
higher,1667,O
than,1667,O
that,1667,O
of,1667,O
the,1667,O
untreated,1667,O
group,1667,O
.,1667,O
The,1668,O
untreated,1668,O
group,1668,O
",",1668,O
but,1668,O
not,1668,O
the,1668,O
treated,1668,O
group,1668,O
",",1668,O
had,1668,O
significant,1668,O
reductions,1668,O
in,1668,O
mitochondrial,1668,O
F0F1-ATPase,1668,B-GENE-N
subunits,1668,O
compared,1668,O
with,1668,O
controls,1668,O
.,1668,O
Congestive,1669,O
heart,1669,O
failure,1669,O
as,1669,O
evidenced,1669,O
by,1669,O
significant,1669,O
ascites,1669,O
(,1669,O
100,1669,O
to,1669,O
2000,1669,O
mL,1669,O
),1669,O
developed,1669,O
in,1669,O
4,1669,O
of,1669,O
the,1669,O
9,1669,O
untreated,1669,O
animals,1669,O
",",1669,O
but,1669,O
was,1669,O
absent,1669,O
in,1669,O
the,1669,O
treated,1669,O
group,1669,O
.,1669,O
Animals,1670,O
with,1670,O
heart,1670,O
failure,1670,O
demonstrated,1670,O
reductions,1670,O
in,1670,O
both,1670,O
mitochondrial,1670,O
F0F1-ATPase,1670,B-GENE-N
expression,1670,O
and,1670,O
myocardial,1670,O
high-energy,1670,O
phosphate,1670,B-CHEMICAL
levels,1670,O
.,1670,O
Thus,1671,O
",",1671,O
severe,1671,O
LV,1671,O
dysfunction,1671,O
and,1671,O
accompanying,1671,O
abnormal,1671,O
myocardial,1671,O
bioenergetic,1671,O
phenotype,1671,O
were,1671,O
prevented,1671,O
by,1671,O
the,1671,O
AT1,1671,B-GENE-Y
antagonist,1671,O
olmesartan,1671,B-CHEMICAL
medoxomil,1671,I-CHEMICAL
.,1671,O
Regulation,1672,O
of,1672,O
retinoic,1672,B-GENE-N
acid,1672,I-GENE-N
receptors,1672,I-GENE-N
alpha,1672,I-GENE-N
",",1672,I-GENE-N
beta,1672,I-GENE-N
and,1672,O
retinoid,1672,B-GENE-Y
X,1672,I-GENE-Y
receptor,1672,I-GENE-Y
alpha,1672,I-GENE-Y
after,1672,O
sciatic,1672,O
nerve,1672,O
injury,1672,O
.,1672,O
Cell,1673,O
culture,1673,O
experiments,1673,O
indicated,1673,O
that,1673,O
activation,1673,O
of,1673,O
the,1673,O
retinoic,1673,B-CHEMICAL
acid,1673,I-CHEMICAL
signaling,1673,O
system,1673,O
is,1673,O
involved,1673,O
in,1673,O
axonal,1673,O
regeneration,1673,O
.,1673,O
This,1674,O
hypothesis,1674,O
was,1674,O
tested,1674,O
with,1674,O
sciatic,1674,O
nerve,1674,O
injury,1674,O
in,1674,O
the,1674,O
rat,1674,O
.,1674,O
Since,1675,O
the,1675,O
effect,1675,O
of,1675,O
retinoic,1675,B-CHEMICAL
acid,1675,I-CHEMICAL
is,1675,O
mediated,1675,O
via,1675,O
retinoic,1675,B-CHEMICAL
acid,1675,I-CHEMICAL
receptors,1675,I-GENE-N
and,1675,O
retinoid,1675,B-CHEMICAL
X,1675,I-GENE-N
receptors,1675,I-GENE-N
",",1675,O
we,1675,O
investigated,1675,O
mRNA,1675,O
and,1675,O
protein,1675,O
expression,1675,O
of,1675,O
these,1675,O
receptors,1675,O
during,1675,O
injury-induced,1675,O
degeneration,1675,O
and,1675,O
regeneration,1675,O
.,1675,O
Seven,1676,O
days,1676,O
after,1676,O
crush,1676,O
injury,1676,O
",",1676,O
transcript,1676,O
concentrations,1676,O
of,1676,O
all,1676,O
retinoic,1676,B-CHEMICAL
acid,1676,I-CHEMICAL
receptors,1676,I-GENE-N
and,1676,O
of,1676,O
retinoid,1676,B-GENE-Y
X,1676,I-GENE-Y
receptor,1676,I-GENE-Y
alpha,1676,I-GENE-Y
were,1676,O
significantly,1676,O
higher,1676,O
than,1676,O
in,1676,O
non-lesioned,1676,O
nerves,1676,O
.,1676,O
Protein,1677,O
levels,1677,O
of,1677,O
retinoic,1677,B-GENE-Y
acid,1677,I-GENE-Y
receptor,1677,I-GENE-Y
alpha,1677,I-GENE-Y
",",1677,O
retinoic,1677,B-GENE-Y
acid,1677,I-GENE-Y
receptor,1677,I-GENE-Y
beta,1677,I-GENE-Y
and,1677,O
retinoid,1677,B-GENE-Y
X,1677,I-GENE-Y
receptor,1677,I-GENE-Y
alpha,1677,I-GENE-Y
were,1677,O
upregulated,1677,O
4,1677,O
",",1677,O
7,1677,O
and,1677,O
14,1677,O
days,1677,O
after,1677,O
injury,1677,O
.,1677,O
In,1678,O
degenerating,1678,O
nerves,1678,O
a,1678,O
significant,1678,O
increase,1678,O
of,1678,O
retinoic,1678,B-GENE-Y
acid,1678,I-GENE-Y
receptor,1678,I-GENE-Y
alpha,1678,I-GENE-Y
was,1678,O
detected,1678,O
7,1678,O
and,1678,O
14,1678,O
days,1678,O
",",1678,O
and,1678,O
of,1678,O
retinoic,1678,B-GENE-Y
acid,1678,I-GENE-Y
receptor,1678,I-GENE-Y
beta,1678,I-GENE-Y
14,1678,O
and,1678,O
21,1678,O
days,1678,O
after,1678,O
complete,1678,O
transection,1678,O
.,1678,O
Immunohistochemical,1679,O
staining,1679,O
of,1679,O
retinoid,1679,B-GENE-N
receptors,1679,I-GENE-N
revealed,1679,O
their,1679,O
expression,1679,O
in,1679,O
Schwann,1679,O
cells,1679,O
and,1679,O
macrophages,1679,O
.,1679,O
In,1680,O
addition,1680,O
",",1680,O
we,1680,O
observed,1680,O
that,1680,O
retinoic,1680,B-GENE-Y
acid,1680,I-GENE-Y
receptor,1680,I-GENE-Y
alpha,1680,I-GENE-Y
and,1680,O
retinoid,1680,B-CHEMICAL
X,1680,I-GENE-Y
receptor,1680,I-GENE-Y
alpha,1680,I-GENE-Y
appeared,1680,O
in,1680,O
the,1680,O
cell,1680,O
nuclei,1680,O
of,1680,O
macrophages,1680,O
during,1680,O
the,1680,O
lesion-induced,1680,O
inflammatory,1680,O
reaction,1680,O
",",1680,O
and,1680,O
that,1680,O
retinoid,1680,B-CHEMICAL
X,1680,I-GENE-Y
receptor,1680,I-GENE-Y
alpha-staining,1680,O
co-localized,1680,O
with,1680,O
some,1680,O
regenerating,1680,O
axons,1680,O
.,1680,O
Experiments,1681,O
with,1681,O
Schwann,1681,O
cell,1681,O
primary,1681,O
cultures,1681,O
revealed,1681,O
an,1681,O
effect,1681,O
of,1681,O
retinoic,1681,B-CHEMICAL
acid,1681,I-CHEMICAL
on,1681,O
the,1681,O
expression,1681,O
of,1681,O
the,1681,O
neuregulin,1681,B-GENE-N
receptor,1681,I-GENE-N
ErbB3,1681,B-GENE-Y
",",1681,O
suggesting,1681,O
that,1681,O
one,1681,O
function,1681,O
of,1681,O
retinoic,1681,B-CHEMICAL
acid,1681,I-CHEMICAL
consists,1681,O
in,1681,O
the,1681,O
regulation,1681,O
of,1681,O
neuroglial,1681,O
interactions,1681,O
after,1681,O
peripheral,1681,O
nerve,1681,O
injury,1681,O
.,1681,O
Cellular,1682,O
effects,1682,O
of,1682,O
imatinib,1682,B-CHEMICAL
on,1682,O
medullary,1682,O
thyroid,1682,O
cancer,1682,O
cells,1682,O
harboring,1682,O
multiple,1682,O
endocrine,1682,O
neoplasia,1682,O
Type,1682,O
2A,1682,O
and,1682,O
2B,1682,O
associated,1682,O
RET,1682,B-GENE-Y
mutations,1682,O
.,1682,O
BACKGROUND,1683,O
:,1683,O
Activating,1683,O
mutations,1683,O
in,1683,O
the,1683,O
RET,1683,B-GENE-Y
gene,1683,O
",",1683,O
which,1683,O
encodes,1683,O
a,1683,O
tyrosine,1683,B-CHEMICAL
kinase,1683,I-GENE-N
receptor,1683,I-GENE-N
",",1683,O
often,1683,O
cause,1683,O
medullary,1683,O
thyroid,1683,O
carcinoma,1683,O
(,1683,O
MTC,1683,O
),1683,O
.,1683,O
Surgical,1684,O
resection,1684,O
is,1684,O
the,1684,O
only,1684,O
curative,1684,O
treatment,1684,O
;,1684,O
no,1684,O
effective,1684,O
systemic,1684,O
treatment,1684,O
is,1684,O
available,1684,O
.,1684,O
We,1685,O
evaluated,1685,O
imatinib,1685,B-CHEMICAL
",",1685,O
a,1685,O
tyrosine,1685,B-CHEMICAL
kinase,1685,I-GENE-N
inhibitor,1685,O
currently,1685,O
used,1685,O
to,1685,O
treat,1685,O
chronic,1685,O
myelogenous,1685,O
leukemia,1685,O
and,1685,O
gastrointestinal,1685,O
stromal,1685,O
tumors,1685,O
",",1685,O
as,1685,O
a,1685,O
potential,1685,O
drug,1685,O
for,1685,O
systemic,1685,O
treatment,1685,O
of,1685,O
MTC,1685,O
",",1685,O
in,1685,O
2,1685,O
MTC-derived,1685,O
cell,1685,O
lines,1685,O
expressing,1685,O
multiple,1685,O
endocrine,1685,O
neoplasia-associated,1685,O
mutant,1685,O
RET,1685,B-GENE-N
receptors,1685,I-GENE-N
.,1685,O
METHODS,1686,O
:,1686,O
We,1686,O
determined,1686,O
RET,1686,B-GENE-Y
expression,1686,O
and,1686,O
Y1062,1686,B-GENE-N
phosphorylation,1686,O
using,1686,O
Western,1686,O
blot,1686,O
analysis,1686,O
and,1686,O
quantitative,1686,O
polymerase,1686,O
chain,1686,O
reaction,1686,O
.,1686,O
We,1687,O
determined,1687,O
the,1687,O
effects,1687,O
on,1687,O
cell,1687,O
proliferation,1687,O
by,1687,O
a,1687,O
3-,1687,B-CHEMICAL
[,1687,I-CHEMICAL
"4,5-dimethylthiazol-2-yl",1687,I-CHEMICAL
],1687,I-CHEMICAL
"-2,5-diphenyltetrazolium",1687,I-CHEMICAL
bromide,1687,I-CHEMICAL
assay,1687,O
",",1687,O
and,1687,O
we,1687,O
used,1687,O
fluorescence-activated,1687,O
cell,1687,O
sorter,1687,O
analysis,1687,O
with,1687,O
annexin,1687,O
V/propidium,1687,O
iodide,1687,I-CHEMICAL
staining,1687,O
to,1687,O
study,1687,O
imatinib-induced,1687,B-CHEMICAL
cell-cycle,1687,O
arrest,1687,O
",",1687,O
apoptosis,1687,O
",",1687,O
and,1687,O
cell,1687,O
death,1687,O
.,1687,O
RESULTS,1688,O
:,1688,O
Imatinib,1688,B-CHEMICAL
inhibited,1688,O
RET,1688,B-GENE-Y
Y1062,1688,B-GENE-N
phosphorylation,1688,O
in,1688,O
a,1688,O
dose-dependent,1688,O
manner,1688,O
after,1688,O
1.5,1688,O
hours,1688,O
of,1688,O
exposure,1688,O
.,1688,O
After,1689,O
16,1689,O
hours,1689,O
both,1689,O
RET,1689,B-GENE-Y
Y1062,1689,B-GENE-N
phosphorylation,1689,O
and,1689,O
protein,1689,O
expression,1689,O
levels,1689,O
were,1689,O
affected,1689,O
.,1689,O
Dose-dependent,1690,O
decreases,1690,O
in,1690,O
cell,1690,O
proliferation,1690,O
of,1690,O
both,1690,O
cell,1690,O
lines,1690,O
after,1690,O
exposure,1690,O
to,1690,O
imatinib,1690,B-CHEMICAL
with,1690,O
inhibitory,1690,O
concentration,1690,O
of,1690,O
50,1690,O
%,1690,O
levels,1690,O
of,1690,O
23,1690,O
+/-,1690,O
2,1690,O
micromol/L,1690,O
and,1690,O
25,1690,O
+/-,1690,O
4,1690,O
micromol/L,1690,O
were,1690,O
seen,1690,O
.,1690,O
These,1691,O
values,1691,O
are,1691,O
high,1691,O
",",1691,O
compared,1691,O
with,1691,O
those,1691,O
for,1691,O
chronic,1691,O
myelogenous,1691,O
leukemia,1691,O
and,1691,O
gastrointestinal,1691,O
stromal,1691,O
tumors,1691,O
.,1691,O
We,1692,O
further,1692,O
could,1692,O
show,1692,O
that,1692,O
imatinib,1692,B-CHEMICAL
induced,1692,O
cell-cycle,1692,O
arrest,1692,O
",",1692,O
and,1692,O
apoptotic,1692,O
and,1692,O
nonapoptotic,1692,O
cell,1692,O
death,1692,O
.,1692,O
CONCLUSIONS,1693,O
:,1693,O
Imatinib,1693,B-CHEMICAL
inhibits,1693,O
RET-mediated,1693,B-GENE-Y
MTC,1693,O
cell,1693,O
growth,1693,O
affecting,1693,O
RET,1693,B-GENE-Y
protein,1693,O
levels,1693,O
in,1693,O
vitro,1693,O
in,1693,O
a,1693,O
dose-dependent,1693,O
manner,1693,O
.,1693,O
The,1694,O
concentration,1694,O
of,1694,O
imatinib,1694,B-CHEMICAL
necessary,1694,O
to,1694,O
inhibit,1694,O
RET,1694,B-GENE-Y
in,1694,O
vitro,1694,O
",",1694,O
however,1694,O
",",1694,O
makes,1694,O
it,1694,O
impossible,1694,O
to,1694,O
conclude,1694,O
that,1694,O
imatinib,1694,B-CHEMICAL
monotherapy,1694,O
will,1694,O
be,1694,O
a,1694,O
good,1694,O
option,1694,O
for,1694,O
systemic,1694,O
therapy,1694,O
of,1694,O
MTC,1694,O
.,1694,O
Cell,1695,O
biology,1695,O
of,1695,O
molybdenum,1695,B-CHEMICAL
.,1695,O
The,1696,O
transition,1696,O
element,1696,O
molybdenum,1696,B-CHEMICAL
(,1696,O
Mo,1696,B-CHEMICAL
),1696,O
is,1696,O
of,1696,O
essential,1696,O
importance,1696,O
for,1696,O
(,1696,O
nearly,1696,O
),1696,O
all,1696,O
biological,1696,O
systems,1696,O
as,1696,O
it,1696,O
is,1696,O
required,1696,O
by,1696,O
enzymes,1696,O
catalyzing,1696,O
diverse,1696,O
key,1696,O
reactions,1696,O
in,1696,O
the,1696,O
global,1696,O
carbon,1696,B-CHEMICAL
",",1696,O
sulfur,1696,B-CHEMICAL
and,1696,O
nitrogen,1696,B-CHEMICAL
metabolism,1696,O
.,1696,O
The,1697,O
metal,1697,O
itself,1697,O
is,1697,O
biologically,1697,O
inactive,1697,O
unless,1697,O
it,1697,O
is,1697,O
complexed,1697,O
by,1697,O
a,1697,O
special,1697,O
cofactor,1697,O
.,1697,O
With,1698,O
the,1698,O
exception,1698,O
of,1698,O
bacterial,1698,B-GENE-N
nitrogenase,1698,I-GENE-N
",",1698,O
where,1698,O
Mo,1698,B-CHEMICAL
is,1698,O
a,1698,O
constituent,1698,O
of,1698,O
the,1698,O
FeMo-cofactor,1698,B-CHEMICAL
",",1698,O
Mo,1698,B-CHEMICAL
is,1698,O
bound,1698,O
to,1698,O
a,1698,O
pterin,1698,B-CHEMICAL
",",1698,O
thus,1698,O
forming,1698,O
the,1698,O
molybdenum,1698,B-CHEMICAL
cofactor,1698,O
(,1698,O
Moco,1698,O
),1698,O
which,1698,O
is,1698,O
the,1698,O
active,1698,O
compound,1698,O
at,1698,O
the,1698,O
catalytic,1698,O
site,1698,O
of,1698,O
all,1698,O
other,1698,O
Mo-enzymes,1698,B-CHEMICAL
.,1698,O
In,1699,O
eukaryotes,1699,O
",",1699,O
the,1699,O
most,1699,O
prominent,1699,O
Mo-enzymes,1699,B-CHEMICAL
are,1699,O
(,1699,O
1,1699,O
),1699,O
sulfite,1699,B-GENE-Y
oxidase,1699,I-GENE-Y
",",1699,O
which,1699,O
catalyzes,1699,O
the,1699,O
final,1699,O
step,1699,O
in,1699,O
the,1699,O
degradation,1699,O
of,1699,O
sulfur-containing,1699,B-CHEMICAL
amino,1699,B-CHEMICAL
acids,1699,I-CHEMICAL
and,1699,O
is,1699,O
involved,1699,O
in,1699,O
detoxifying,1699,O
excess,1699,O
sulfite,1699,B-CHEMICAL
",",1699,O
(,1699,O
2,1699,O
),1699,O
xanthine,1699,B-GENE-Y
dehydrogenase,1699,I-GENE-Y
",",1699,O
which,1699,O
is,1699,O
involved,1699,O
in,1699,O
purine,1699,B-CHEMICAL
catabolism,1699,O
and,1699,O
reactive,1699,O
oxygen,1699,B-CHEMICAL
production,1699,O
",",1699,O
(,1699,O
3,1699,O
),1699,O
aldehyde,1699,B-GENE-Y
oxidase,1699,I-GENE-Y
",",1699,O
which,1699,O
oxidizes,1699,O
a,1699,O
variety,1699,O
of,1699,O
aldehydes,1699,B-CHEMICAL
and,1699,O
is,1699,O
essential,1699,O
for,1699,O
the,1699,O
biosynthesis,1699,O
of,1699,O
the,1699,O
phytohormone,1699,O
abscisic,1699,B-CHEMICAL
acid,1699,I-CHEMICAL
",",1699,O
and,1699,O
in,1699,O
autotrophic,1699,O
organisms,1699,O
also,1699,O
(,1699,O
4,1699,O
),1699,O
nitrate,1699,B-GENE-N
reductase,1699,I-GENE-N
",",1699,O
which,1699,O
catalyzes,1699,O
the,1699,O
key,1699,O
step,1699,O
in,1699,O
inorganic,1699,O
nitrogen,1699,B-CHEMICAL
assimilation,1699,O
.,1699,O
All,1700,O
Mo-enzymes,1700,B-CHEMICAL
",",1700,O
except,1700,O
plant,1700,B-GENE-N
sulfite,1700,B-CHEMICAL
oxidase,1700,I-GENE-N
",",1700,O
need,1700,O
at,1700,O
least,1700,O
one,1700,O
more,1700,O
redox,1700,O
active,1700,O
center,1700,O
",",1700,O
many,1700,O
of,1700,O
them,1700,O
involving,1700,O
iron,1700,B-CHEMICAL
in,1700,O
electron,1700,O
transfer,1700,O
.,1700,O
The,1701,O
biosynthesis,1701,O
of,1701,O
Moco,1701,O
involves,1701,O
the,1701,O
complex,1701,O
interaction,1701,O
of,1701,O
six,1701,O
proteins,1701,O
and,1701,O
is,1701,O
a,1701,O
process,1701,O
of,1701,O
four,1701,O
steps,1701,O
",",1701,O
which,1701,O
also,1701,O
includes,1701,O
iron,1701,O
as,1701,O
well,1701,O
as,1701,O
copper,1701,B-CHEMICAL
in,1701,O
an,1701,O
indispensable,1701,O
way,1701,O
.,1701,O
Moco,1702,O
as,1702,O
released,1702,O
after,1702,O
synthesis,1702,O
is,1702,O
likely,1702,O
to,1702,O
be,1702,O
distributed,1702,O
to,1702,O
the,1702,O
apoproteins,1702,O
of,1702,O
Mo-enzymes,1702,B-CHEMICAL
by,1702,O
putative,1702,O
Moco-carrier,1702,O
proteins,1702,O
.,1702,O
Xanthine,1703,B-CHEMICAL
dehydrogenase,1703,I-GENE-Y
and,1703,O
aldehyde,1703,B-CHEMICAL
oxidase,1703,I-GENE-Y
",",1703,O
but,1703,O
not,1703,O
sulfite,1703,B-GENE-Y
oxidase,1703,I-GENE-Y
and,1703,O
nitrate,1703,B-GENE-N
reductase,1703,I-GENE-N
",",1703,O
require,1703,O
the,1703,O
post-translational,1703,O
sulfuration,1703,O
of,1703,O
their,1703,O
Mo-site,1703,B-CHEMICAL
for,1703,O
becoming,1703,O
active,1703,O
.,1703,O
This,1704,O
final,1704,O
maturation,1704,O
step,1704,O
is,1704,O
catalyzed,1704,O
by,1704,O
a,1704,O
Moco-sulfurase,1704,B-GENE-Y
enzyme,1704,O
",",1704,O
which,1704,O
mobilizes,1704,O
sulfur,1704,B-CHEMICAL
from,1704,O
l-cysteine,1704,B-CHEMICAL
in,1704,O
a,1704,O
pyridoxal,1704,B-CHEMICAL
phosphate-dependent,1704,O
manner,1704,O
as,1704,O
typical,1704,O
for,1704,O
cysteine,1704,B-GENE-N
desulfurases,1704,I-GENE-N
.,1704,O
[,1705,O
Retinoid,1705,B-CHEMICAL
therapy,1705,O
for,1705,O
autoimmune,1705,O
diseases,1705,O
],1705,O
.,1705,O
Retinoid,1706,B-CHEMICAL
is,1706,O
a,1706,O
collective,1706,O
term,1706,O
for,1706,O
compounds,1706,O
which,1706,O
bind,1706,O
to,1706,O
and,1706,O
activate,1706,O
retinoic,1706,B-GENE-N
acid,1706,I-GENE-N
receptors,1706,I-GENE-N
(,1706,O
RARalpha,1706,B-GENE-N
",",1706,I-GENE-N
beta,1706,I-GENE-N
",",1706,I-GENE-N
gamma,1706,I-GENE-N
and,1706,O
RXRalpha,1706,B-GENE-N
",",1706,I-GENE-N
beta,1706,I-GENE-N
",",1706,I-GENE-N
gamma,1706,I-GENE-N
),1706,O
",",1706,O
members,1706,O
of,1706,O
nuclear,1706,B-GENE-N
hormone,1706,I-GENE-N
receptor,1706,I-GENE-N
superfamily,1706,O
.,1706,O
The,1707,O
most,1707,O
important,1707,O
endogeneous,1707,O
retinoid,1707,B-CHEMICAL
is,1707,O
all-trans-retinoic,1707,B-CHEMICAL
acid,1707,I-CHEMICAL
(,1707,O
ATRA,1707,B-CHEMICAL
),1707,O
which,1707,O
is,1707,O
an,1707,O
RARalpha,1707,B-GENE-N
",",1707,I-GENE-N
beta,1707,I-GENE-N
and,1707,I-GENE-N
gamma,1707,I-GENE-N
ligand,1707,O
.,1707,O
ATRA,1708,B-CHEMICAL
and,1708,O
its,1708,O
mimics,1708,O
have,1708,O
been,1708,O
in,1708,O
clinical,1708,O
use,1708,O
for,1708,O
treatment,1708,O
of,1708,O
acute,1708,O
promyelocytic,1708,O
leukemia,1708,O
(,1708,O
APL,1708,O
),1708,O
and,1708,O
some,1708,O
skin,1708,O
diseases,1708,O
.,1708,O
Many,1709,O
synthetic,1709,O
retinoids,1709,O
have,1709,O
been,1709,O
developed,1709,O
and,1709,O
attempts,1709,O
to,1709,O
improve,1709,O
their,1709,O
medicinal,1709,O
properties,1709,O
have,1709,O
been,1709,O
made,1709,O
.,1709,O
Among,1710,O
them,1710,O
",",1710,O
tamibarotene,1710,B-CHEMICAL
(,1710,O
Am80,1710,B-CHEMICAL
),1710,O
is,1710,O
an,1710,O
RARalpha-,1710,B-GENE-Y
and,1710,O
RARbeta-specific,1710,B-GENE-Y
(,1710,O
but,1710,O
RARgamma-,1710,B-GENE-Y
and,1710,O
RXRs-nonbinding,1710,B-GENE-N
),1710,O
synthetic,1710,O
retinoid,1710,B-CHEMICAL
that,1710,O
is,1710,O
effective,1710,O
in,1710,O
the,1710,O
treatment,1710,O
of,1710,O
psoriasis,1710,O
patients,1710,O
and,1710,O
relapsed,1710,O
APL,1710,O
.,1710,O
Experimentally,1711,O
",",1711,O
this,1711,O
compound,1711,O
is,1711,O
also,1711,O
active,1711,O
in,1711,O
animal,1711,O
models,1711,O
of,1711,O
rheumatoid,1711,O
arthritis,1711,O
and,1711,O
experimental,1711,O
autoimmune,1711,O
encephalomyelitis,1711,O
.,1711,O
On,1712,O
this,1712,O
background,1712,O
",",1712,O
possible,1712,O
application,1712,O
of,1712,O
retinoids,1712,B-CHEMICAL
for,1712,O
the,1712,O
treatment,1712,O
of,1712,O
autoimmune,1712,O
diseases,1712,O
was,1712,O
discussed,1712,O
.,1712,O
In,1713,O
particular,1713,O
",",1713,O
Th1,1713,O
dominant,1713,O
autoimmune,1713,O
diseases,1713,O
may,1713,O
be,1713,O
the,1713,O
targets,1713,O
of,1713,O
the,1713,O
retinoids,1713,B-CHEMICAL
.,1713,O
Simvastatin,1714,B-CHEMICAL
regulates,1714,O
non-neuronal,1714,O
cholinergic,1714,O
activity,1714,O
in,1714,O
T,1714,O
lymphocytes,1714,O
via,1714,O
CD11a-mediated,1714,B-GENE-Y
pathways,1714,O
.,1714,O
Lymphocyte,1715,B-GENE-Y
function,1715,I-GENE-Y
associated,1715,I-GENE-Y
antigen-1,1715,I-GENE-Y
(,1715,O
LFA-1,1715,B-GENE-Y
;,1715,O
CD11a/CD18,1715,B-GENE-Y
),1715,O
is,1715,O
an,1715,O
important,1715,O
mediator,1715,O
of,1715,O
leukocyte,1715,O
migration,1715,O
and,1715,O
T,1715,O
cell,1715,O
activation,1715,O
.,1715,O
We,1716,O
previously,1716,O
showed,1716,O
that,1716,O
antithymocyte,1716,B-GENE-N
globulin,1716,I-GENE-N
stimulates,1716,O
an,1716,O
independent,1716,O
",",1716,O
non-neuronal,1716,O
cholinergic,1716,O
system,1716,O
in,1716,O
T,1716,O
cells,1716,O
via,1716,O
LFA-1-mediated,1716,B-GENE-Y
pathways,1716,O
",",1716,O
as,1716,O
evidenced,1716,O
by,1716,O
increases,1716,O
in,1716,O
acetylcholine,1716,B-CHEMICAL
(,1716,O
ACh,1716,B-CHEMICAL
),1716,O
synthesis,1716,O
and,1716,O
choline,1716,B-GENE-Y
acetyltransferase,1716,I-GENE-Y
(,1716,O
ChAT,1716,B-GENE-Y
),1716,O
mRNA,1716,O
expression,1716,O
.,1716,O
The,1717,O
cholesterol-lowering,1717,B-CHEMICAL
drug,1717,O
simvastatin,1717,B-CHEMICAL
inhibits,1717,O
LFA-1,1717,B-GENE-Y
signaling,1717,O
by,1717,O
binding,1717,O
to,1717,O
an,1717,O
allosteric,1717,O
site,1717,O
on,1717,O
CD11a,1717,B-GENE-Y
(,1717,O
LFA-1,1717,B-GENE-Y
alpha,1717,I-GENE-Y
chain,1717,I-GENE-Y
),1717,O
",",1717,O
which,1717,O
leads,1717,O
to,1717,O
immunomodulation,1717,O
.,1717,O
In,1718,O
the,1718,O
present,1718,O
study,1718,O
",",1718,O
we,1718,O
investigated,1718,O
whether,1718,O
simvastatin,1718,B-CHEMICAL
modulates,1718,O
lymphocytic,1718,O
cholinergic,1718,O
activity,1718,O
in,1718,O
T,1718,O
cells,1718,O
.,1718,O
We,1719,O
found,1719,O
that,1719,O
anti-CD11a,1719,O
monoclonal,1719,O
antibody,1719,O
(,1719,O
mAb,1719,O
),1719,O
increased,1719,O
ChAT,1719,B-GENE-N
activity,1719,O
",",1719,O
ACh,1719,B-CHEMICAL
synthesis,1719,O
and,1719,O
release,1719,O
",",1719,O
and,1719,O
expression,1719,O
of,1719,O
ChAT,1719,B-GENE-Y
and,1719,O
M5,1719,B-GENE-Y
muscarinic,1719,I-GENE-Y
ACh,1719,B-CHEMICAL
receptor,1719,I-GENE-Y
mRNA,1719,O
in,1719,O
MOLT-3,1719,O
cells,1719,O
",",1719,O
a,1719,O
human,1719,O
leukemic,1719,O
T,1719,O
cell,1719,O
line,1719,O
.,1719,O
Simvastatin,1720,B-CHEMICAL
abolished,1720,O
these,1720,O
anti-CD11a,1720,O
mAb-induced,1720,O
increases,1720,O
in,1720,O
lymphocytic,1720,O
cholinergic,1720,O
activity,1720,O
in,1720,O
a,1720,O
manner,1720,O
independent,1720,O
of,1720,O
its,1720,O
cholesterol-lowering,1720,B-CHEMICAL
activity,1720,O
.,1720,O
These,1721,O
results,1721,O
indicate,1721,O
that,1721,O
LFA-1,1721,B-GENE-Y
contributes,1721,O
to,1721,O
the,1721,O
regulation,1721,O
of,1721,O
lymphocytic,1721,O
cholinergic,1721,O
activity,1721,O
via,1721,O
CD11a-mediated,1721,B-GENE-Y
pathways,1721,O
",",1721,O
and,1721,O
suggest,1721,O
that,1721,O
simvastatin,1721,B-CHEMICAL
exerts,1721,O
its,1721,O
immunosuppressive,1721,O
effects,1721,O
in,1721,O
part,1721,O
via,1721,O
modification,1721,O
of,1721,O
lymphocytic,1721,O
cholinergic,1721,O
activity,1721,O
.,1721,O
More,1722,O
than,1722,O
cool,1722,O
:,1722,O
promiscuous,1722,O
relationships,1722,O
of,1722,O
menthol,1722,B-CHEMICAL
and,1722,O
other,1722,O
sensory,1722,O
compounds,1722,O
.,1722,O
Several,1723,O
temperature-activated,1723,B-GENE-N
transient,1723,I-GENE-N
receptor,1723,I-GENE-N
potential,1723,I-GENE-N
(,1723,I-GENE-N
thermoTRP,1723,I-GENE-N
),1723,I-GENE-N
ion,1723,I-GENE-N
channels,1723,I-GENE-N
are,1723,O
the,1723,O
molecular,1723,O
receptors,1723,O
of,1723,O
natural,1723,O
compounds,1723,O
that,1723,O
evoke,1723,O
thermal,1723,O
and,1723,O
pain,1723,O
sensations,1723,O
.,1723,O
Menthol,1724,B-CHEMICAL
",",1724,O
popularly,1724,O
known,1724,O
for,1724,O
its,1724,O
cooling,1724,O
effect,1724,O
",",1724,O
activates,1724,O
TRPM8,1724,B-GENE-Y
--,1724,O
a,1724,O
cold-activated,1724,O
thermoTRP,1724,B-GENE-N
ion,1724,I-GENE-N
channel,1724,I-GENE-N
.,1724,O
However,1725,O
",",1725,O
human,1725,O
physiological,1725,O
studies,1725,O
demonstrate,1725,O
a,1725,O
paradoxical,1725,O
role,1725,O
of,1725,O
menthol,1725,B-CHEMICAL
in,1725,O
modulation,1725,O
of,1725,O
warm,1725,O
sensation,1725,O
",",1725,O
and,1725,O
here,1725,O
",",1725,O
we,1725,O
show,1725,O
that,1725,O
menthol,1725,B-CHEMICAL
also,1725,O
activates,1725,O
heat-activated,1725,O
TRPV3,1725,B-GENE-Y
.,1725,O
We,1726,O
further,1726,O
show,1726,O
that,1726,O
menthol,1726,B-CHEMICAL
inhibits,1726,O
TRPA1,1726,B-GENE-Y
",",1726,O
potentially,1726,O
explaining,1726,O
the,1726,O
use,1726,O
of,1726,O
menthol,1726,B-CHEMICAL
as,1726,O
an,1726,O
analgesic,1726,O
.,1726,O
Similar,1727,O
to,1727,O
menthol,1727,B-CHEMICAL
",",1727,O
both,1727,O
camphor,1727,B-CHEMICAL
and,1727,O
cinnamaldehyde,1727,B-CHEMICAL
(,1727,O
initially,1727,O
reported,1727,O
to,1727,O
be,1727,O
specific,1727,O
activators,1727,O
of,1727,O
TRPV3,1727,B-GENE-Y
and,1727,O
TRPA1,1727,B-GENE-Y
",",1727,O
respectively,1727,O
),1727,O
also,1727,O
modulate,1727,O
other,1727,O
thermoTRPs,1727,B-GENE-N
.,1727,O
Therefore,1728,O
",",1728,O
we,1728,O
find,1728,O
that,1728,O
many,1728,O
``,1728,O
sensory,1728,O
compounds,1728,O
'',1728,O
presumed,1728,O
to,1728,O
be,1728,O
specific,1728,O
have,1728,O
a,1728,O
promiscuous,1728,O
relationship,1728,O
with,1728,O
thermoTRPs,1728,B-GENE-N
.,1728,O
Effect,1729,O
of,1729,O
keratinocyte,1729,B-GENE-Y
growth,1729,I-GENE-Y
factor,1729,I-GENE-Y
on,1729,O
cell,1729,O
viability,1729,O
in,1729,O
primary,1729,O
cultured,1729,O
human,1729,O
prostate,1729,O
cancer,1729,O
stromal,1729,O
cells,1729,O
.,1729,O
In,1730,O
normal,1730,O
prostate,1730,O
",",1730,O
keratinocyte,1730,B-GENE-Y
growth,1730,I-GENE-Y
factor,1730,I-GENE-Y
(,1730,O
KGF,1730,B-GENE-Y
),1730,O
",",1730,O
also,1730,O
known,1730,O
as,1730,O
fibroblast,1730,B-GENE-Y
growth,1730,I-GENE-Y
factor-7,1730,I-GENE-Y
(,1730,O
FGF-7,1730,B-GENE-Y
),1730,O
serves,1730,O
as,1730,O
a,1730,O
paracrine,1730,O
growth,1730,O
factor,1730,O
synthesized,1730,O
in,1730,O
stromal,1730,O
cells,1730,O
that,1730,O
acts,1730,O
on,1730,O
epithelial,1730,O
cells,1730,O
through,1730,O
its,1730,O
receptor,1730,O
",",1730,O
KGFR,1730,B-GENE-Y
.,1730,O
KGF,1731,B-GENE-Y
and,1731,O
KGFR,1731,B-GENE-Y
were,1731,O
found,1731,O
in,1731,O
human,1731,O
cancer,1731,O
epithelial,1731,O
cells,1731,O
as,1731,O
well,1731,O
as,1731,O
stromal,1731,O
cells,1731,O
.,1731,O
Since,1732,O
KGF,1732,B-GENE-Y
expressed,1732,O
in,1732,O
epithelial,1732,O
cells,1732,O
of,1732,O
benign,1732,O
prostatic,1732,O
hyperplasia,1732,O
(,1732,O
BPH,1732,O
),1732,O
and,1732,O
in,1732,O
prostate,1732,O
cancer,1732,O
",",1732,O
it,1732,O
has,1732,O
been,1732,O
suggested,1732,O
that,1732,O
KGF,1732,B-GENE-Y
might,1732,O
act,1732,O
as,1732,O
an,1732,O
autocrine,1732,O
factor,1732,O
in,1732,O
BPH,1732,O
and,1732,O
prostate,1732,O
cancer,1732,O
.,1732,O
To,1733,O
investigate,1733,O
the,1733,O
roles,1733,O
of,1733,O
KGF,1733,B-GENE-Y
in,1733,O
cancerous,1733,O
stroma,1733,O
",",1733,O
primary,1733,O
cultured,1733,O
human,1733,O
prostate,1733,O
cancer,1733,O
stromal,1733,O
cells,1733,O
(,1733,O
PCSCs,1733,O
),1733,O
were,1733,O
isolated,1733,O
and,1733,O
evaluated,1733,O
.,1733,O
These,1734,O
PCSCs,1734,O
possessed,1734,O
estrogen,1734,B-CHEMICAL
receptors,1734,I-GENE-Y
and,1734,O
KGFR,1734,B-GENE-Y
",",1734,O
but,1734,O
not,1734,O
androgen,1734,B-CHEMICAL
receptor,1734,I-GENE-Y
as,1734,O
determined,1734,O
by,1734,O
RT-PCR,1734,O
and,1734,O
Western,1734,O
blot,1734,O
",",1734,O
respectively,1734,O
.,1734,O
KGF,1735,B-GENE-Y
exhibited,1735,O
mitogenic,1735,O
and,1735,O
anti-apoptotic,1735,O
effects,1735,O
that,1735,O
correlated,1735,O
with,1735,O
induction,1735,O
of,1735,O
cyclin-D1,1735,B-GENE-Y
",",1735,O
Bcl-2,1735,B-GENE-Y
",",1735,O
Bcl-xL,1735,B-GENE-Y
and,1735,O
phospho-Akt,1735,B-GENE-N
expression,1735,O
in,1735,O
PCSCs,1735,O
",",1735,O
where,1735,O
treatment,1735,O
with,1735,O
KGF,1735,B-GENE-Y
antiserum,1735,O
abolished,1735,O
cell,1735,O
proliferation,1735,O
and,1735,O
anti-apoptotic,1735,O
protein,1735,O
expression,1735,O
.,1735,O
PCSCs,1736,O
exposed,1736,O
to,1736,O
KGF,1736,B-GENE-Y
for,1736,O
various,1736,O
time,1736,O
periods,1736,O
resulted,1736,O
in,1736,O
phosphorylation,1736,O
of,1736,O
Akt,1736,B-GENE-N
and,1736,O
subsequent,1736,O
up-regulation,1736,O
of,1736,O
Bcl-2,1736,B-GENE-Y
.,1736,O
KGF,1737,B-GENE-Y
modulated,1737,O
dynamic,1737,O
protein,1737,O
expression,1737,O
indicated,1737,O
that,1737,O
KGF,1737,B-GENE-Y
triggered,1737,O
cell,1737,O
cycle,1737,O
machinery,1737,O
and,1737,O
then,1737,O
activated,1737,O
anti-apoptotic,1737,O
actions,1737,O
in,1737,O
PCSCs,1737,O
.,1737,O
Cell,1738,O
proliferation,1738,O
analysis,1738,O
indicated,1738,O
that,1738,O
tamoxifen,1738,B-CHEMICAL
or,1738,O
ICI,1738,B-CHEMICAL
"182,780",1738,I-CHEMICAL
reduced,1738,O
cell,1738,O
viability,1738,O
in,1738,O
a,1738,O
dose-dependent,1738,O
manner,1738,O
;,1738,O
however,1738,O
",",1738,O
KGF,1738,B-GENE-Y
prevented,1738,O
this,1738,O
inhibition,1738,O
",",1738,O
which,1738,O
further,1738,O
demonstrated,1738,O
KGF,1738,B-GENE-Y
triggered,1738,O
anti-apoptotic,1738,O
machinery,1738,O
through,1738,O
activating,1738,O
Bcl-2,1738,B-GENE-Y
and,1738,O
phospho-Akt,1738,B-GENE-N
expression,1738,O
.,1738,O
In,1739,O
summary,1739,O
",",1739,O
KGF,1739,B-GENE-Y
has,1739,O
an,1739,O
autocrine,1739,O
effect,1739,O
and,1739,O
serves,1739,O
as,1739,O
a,1739,O
survival,1739,O
factor,1739,O
in,1739,O
primary,1739,O
cultured,1739,O
human,1739,O
prostate,1739,O
cancer,1739,O
stromal,1739,O
cells,1739,O
.,1739,O
The,1740,O
glutamate-aspartate,1740,B-GENE-N
transporter,1740,I-GENE-N
GLAST,1740,B-GENE-N
mediates,1740,O
glutamate,1740,B-CHEMICAL
uptake,1740,O
at,1740,O
inner,1740,O
hair,1740,O
cell,1740,O
afferent,1740,O
synapses,1740,O
in,1740,O
the,1740,O
mammalian,1740,O
cochlea,1740,O
.,1740,O
Ribbon,1741,O
synapses,1741,O
formed,1741,O
between,1741,O
inner,1741,O
hair,1741,O
cells,1741,O
(,1741,O
IHCs,1741,O
),1741,O
and,1741,O
afferent,1741,O
dendrites,1741,O
in,1741,O
the,1741,O
mammalian,1741,O
cochlea,1741,O
can,1741,O
sustain,1741,O
high,1741,O
rates,1741,O
of,1741,O
release,1741,O
",",1741,O
placing,1741,O
strong,1741,O
demands,1741,O
on,1741,O
glutamate,1741,B-CHEMICAL
clearance,1741,O
mechanisms,1741,O
.,1741,O
To,1742,O
investigate,1742,O
the,1742,O
role,1742,O
of,1742,O
transporters,1742,O
in,1742,O
glutamate,1742,B-CHEMICAL
removal,1742,O
at,1742,O
these,1742,O
synapses,1742,O
",",1742,O
we,1742,O
made,1742,O
whole-cell,1742,O
recordings,1742,O
from,1742,O
IHCs,1742,O
",",1742,O
afferent,1742,O
dendrites,1742,O
",",1742,O
and,1742,O
glial,1742,O
cells,1742,O
adjacent,1742,O
to,1742,O
IHCs,1742,O
[,1742,O
inner,1742,O
phalangeal,1742,O
cells,1742,O
(,1742,O
IPCs,1742,O
),1742,O
],1742,O
in,1742,O
whole-mount,1742,O
preparations,1742,O
of,1742,O
rat,1742,O
organ,1742,O
of,1742,O
Corti,1742,O
.,1742,O
Focal,1743,O
application,1743,O
of,1743,O
the,1743,O
transporter,1743,O
substrate,1743,O
D-aspartate,1743,B-CHEMICAL
elicited,1743,O
inward,1743,O
currents,1743,O
in,1743,O
IPCs,1743,O
",",1743,O
which,1743,O
were,1743,O
larger,1743,O
in,1743,O
the,1743,O
presence,1743,O
of,1743,O
anions,1743,O
that,1743,O
permeate,1743,O
the,1743,O
transporter-associated,1743,O
anion,1743,B-GENE-N
channel,1743,I-GENE-N
and,1743,O
blocked,1743,O
by,1743,O
the,1743,O
transporter,1743,O
antagonist,1743,O
D,1743,B-CHEMICAL
",",1743,I-CHEMICAL
L-threo-beta-benzyloxyaspartate,1743,I-CHEMICAL
.,1743,O
These,1744,O
currents,1744,O
were,1744,O
produced,1744,O
by,1744,O
glutamate-aspartate,1744,B-GENE-Y
transporters,1744,I-GENE-Y
(,1744,O
GLAST,1744,B-GENE-Y
),1744,O
(,1744,O
excitatory,1744,B-GENE-Y
amino,1744,I-GENE-Y
acid,1744,I-GENE-Y
transporter,1744,I-GENE-Y
1,1744,I-GENE-Y
),1744,O
because,1744,O
they,1744,O
were,1744,O
weakly,1744,O
inhibited,1744,O
by,1744,O
dihydrokainate,1744,B-CHEMICAL
",",1744,O
an,1744,O
antagonist,1744,O
of,1744,O
glutamate,1744,B-GENE-Y
transporter-1,1744,I-GENE-Y
(,1744,O
excitatory,1744,B-GENE-Y
amino,1744,I-GENE-Y
acid,1744,I-GENE-Y
transporter,1744,I-GENE-Y
2,1744,I-GENE-Y
),1744,O
and,1744,O
were,1744,O
absent,1744,O
from,1744,O
IPCs,1744,O
in,1744,O
GLAST-/-,1744,B-GENE-Y
cochleas,1744,O
.,1744,O
Furthermore,1745,O
",",1745,O
D-aspartate-induced,1745,B-CHEMICAL
currents,1745,O
in,1745,O
outside-out,1745,O
patches,1745,O
from,1745,O
IPCs,1745,O
exhibited,1745,O
larger,1745,O
steady-state,1745,O
currents,1745,O
than,1745,O
responses,1745,O
elicited,1745,O
by,1745,O
L-glutamate,1745,B-CHEMICAL
",",1745,O
a,1745,O
prominent,1745,O
feature,1745,O
of,1745,O
GLAST,1745,B-GENE-Y
",",1745,O
and,1745,O
examination,1745,O
of,1745,O
cochlea,1745,O
from,1745,O
GLAST-Discosoma,1745,B-GENE-Y
red,1745,O
(,1745,O
DsRed,1745,O
),1745,O
promoter,1745,O
reporter,1745,O
mice,1745,O
revealed,1745,O
that,1745,O
DsRed,1745,O
expression,1745,O
was,1745,O
restricted,1745,O
to,1745,O
IPCs,1745,O
and,1745,O
other,1745,O
supporting,1745,O
cells,1745,O
surrounding,1745,O
IHCs,1745,O
.,1745,O
Saturation,1746,O
of,1746,O
transporters,1746,O
by,1746,O
photolysis,1746,O
of,1746,O
caged,1746,O
D-aspartate,1746,B-CHEMICAL
failed,1746,O
to,1746,O
elicit,1746,O
transporter,1746,O
currents,1746,O
in,1746,O
IHCs,1746,O
",",1746,O
as,1746,O
did,1746,O
local,1746,O
application,1746,O
of,1746,O
D-aspartate,1746,B-CHEMICAL
to,1746,O
afferent,1746,O
terminals,1746,O
",",1746,O
indicating,1746,O
that,1746,O
neither,1746,O
presynaptic,1746,O
nor,1746,O
postsynaptic,1746,O
membranes,1746,O
are,1746,O
major,1746,O
sites,1746,O
for,1746,O
glutamate,1746,B-CHEMICAL
removal,1746,O
.,1746,O
These,1747,O
data,1747,O
indicate,1747,O
that,1747,O
GLAST,1747,B-GENE-Y
in,1747,O
supporting,1747,O
cells,1747,O
is,1747,O
responsible,1747,O
for,1747,O
transmitter,1747,O
uptake,1747,O
at,1747,O
IHC,1747,O
afferent,1747,O
synapses,1747,O
.,1747,O
The,1748,O
alpha-,1748,B-GENE-N
and,1748,I-GENE-N
beta-adrenoceptor,1748,I-GENE-N
blocking,1748,O
activities,1748,O
of,1748,O
labetalol,1748,B-CHEMICAL
and,1748,O
its,1748,O
RR-SR,1748,O
(,1748,O
50:50,1748,O
),1748,O
stereoisomers,1748,O
.,1748,O
1,1749,O
.,1749,O
We,1750,O
compared,1750,O
the,1750,O
alpha,1750,B-GENE-N
1-,1750,I-GENE-N
",",1750,I-GENE-N
alpha,1750,I-GENE-N
2-,1750,I-GENE-N
and,1750,I-GENE-N
beta,1750,I-GENE-N
1-adrenoceptor,1750,I-GENE-N
blocking,1750,O
potencies,1750,O
of,1750,O
labetalol,1750,B-CHEMICAL
with,1750,O
those,1750,O
of,1750,O
its,1750,O
two,1750,O
stereoisomers,1750,O
(,1750,O
RR,1750,O
and,1750,O
SR,1750,O
),1750,O
in,1750,O
pithed,1750,O
rats,1750,O
and,1750,O
in,1750,O
homogenized,1750,O
rat,1750,O
cerebral,1750,O
cortex,1750,O
and,1750,O
heart,1750,O
.,1750,O
2,1751,O
.,1751,O
In,1752,O
pithed,1752,O
rats,1752,O
",",1752,O
labetalol,1752,B-CHEMICAL
and,1752,O
the,1752,O
RR-SR,1752,O
combination,1752,O
were,1752,O
given,1752,O
orally,1752,O
either,1752,O
at,1752,O
doses,1752,O
of,1752,O
25,1752,O
and,1752,O
50,1752,O
mg,1752,O
kg-1,1752,O
body,1752,O
wt,1752,O
.,1752,O
or,1753,O
intravenously,1753,O
at,1753,O
doses,1753,O
of,1753,O
1,1753,O
and,1753,O
5,1753,O
mg,1753,O
kg-1,1753,O
body,1753,O
wt,1753,O
.,1753,O
Prazosin,1754,B-CHEMICAL
4,1754,O
and,1754,O
20,1754,O
micrograms,1754,O
kg-1,1754,O
body,1754,O
wt,1754,O
.,1754,O
and,1755,O
propranolol,1755,B-CHEMICAL
1,1755,O
and,1755,O
5,1755,O
mg,1755,O
kg-1,1755,O
body,1755,O
wt.,1755,O
",",1755,O
were,1755,O
given,1755,O
intravenously,1755,O
for,1755,O
comparison,1755,O
studies,1755,O
of,1755,O
potency,1755,O
at,1755,O
alpha,1755,B-GENE-N
1-,1755,I-GENE-N
and,1755,I-GENE-N
beta,1755,I-GENE-N
1-adrenoceptors,1755,I-GENE-N
",",1755,O
respectively,1755,O
.,1755,O
Effects,1756,O
were,1756,O
studied,1756,O
before,1756,O
and,1756,O
after,1756,O
i.v,1756,O
.,1756,O
administration,1757,O
of,1757,O
either,1757,O
phenylephrine,1757,B-CHEMICAL
(,1757,O
at,1757,O
doses,1757,O
which,1757,O
increased,1757,O
the,1757,O
mean,1757,O
arterial,1757,O
pressure,1757,O
by,1757,O
approximately,1757,O
80,1757,O
mmHg,1757,O
),1757,O
or,1757,O
isoprenaline,1757,B-CHEMICAL
(,1757,O
at,1757,O
doses,1757,O
that,1757,O
increased,1757,O
heart,1757,O
rate,1757,O
by,1757,O
approximately,1757,O
100,1757,O
beats,1757,O
min-1,1757,O
),1757,O
.,1757,O
3,1758,O
.,1758,O
In,1759,O
pithed,1759,O
rats,1759,O
",",1759,O
labetalol,1759,B-CHEMICAL
and,1759,O
the,1759,O
RR-SR,1759,O
combination,1759,O
antagonized,1759,O
",",1759,O
in,1759,O
a,1759,O
dose-dependent,1759,O
manner,1759,O
",",1759,O
the,1759,O
pressor,1759,O
effect,1759,O
of,1759,O
phenylephrine,1759,B-CHEMICAL
(,1759,O
P,1759,O
less,1759,O
than,1759,O
0.05,1759,O
),1759,O
and,1759,O
the,1759,O
chronotropic,1759,O
effect,1759,O
of,1759,O
isoprenaline,1759,B-CHEMICAL
(,1759,O
P,1759,O
less,1759,O
than,1759,O
0.05,1759,O
),1759,O
.,1759,O
Following,1760,O
both,1760,O
oral,1760,O
and,1760,O
intravenous,1760,O
dosing,1760,O
",",1760,O
the,1760,O
RR-SR,1760,O
combination,1760,O
was,1760,O
twice,1760,O
potent,1760,O
as,1760,O
labetalol,1760,B-CHEMICAL
in,1760,O
terms,1760,O
of,1760,O
alpha,1760,B-GENE-N
1-,1760,I-GENE-N
and,1760,I-GENE-N
beta,1760,I-GENE-N
1-adrenoceptor,1760,I-GENE-N
antagonism,1760,O
at,1760,O
equivalent,1760,O
doses,1760,O
.,1760,O
4,1761,O
.,1761,O
Labetalol,1762,B-CHEMICAL
and,1762,O
the,1762,O
enantiomers,1762,O
lacked,1762,O
affinity,1762,O
at,1762,O
alpha,1762,B-GENE-N
2-adrenoceptors,1762,I-GENE-N
while,1762,O
at,1762,O
alpha,1762,B-GENE-N
1-adrenoceptors,1762,I-GENE-N
the,1762,O
order,1762,O
of,1762,O
potency,1762,O
was,1762,O
prazosin,1762,B-CHEMICAL
much,1762,O
greater,1762,O
than,1762,O
RR-SR,1762,O
greater,1762,O
than,1762,O
labetalol,1762,B-CHEMICAL
.,1762,O
At,1763,O
beta,1763,B-GENE-Y
1-adrenoceptors,1763,I-GENE-Y
",",1763,O
the,1763,O
affinity,1763,O
of,1763,O
the,1763,O
compound,1763,O
RR-SR,1763,O
was,1763,O
about,1763,O
3,1763,O
times,1763,O
that,1763,O
of,1763,O
labetalol.5,1763,B-CHEMICAL
.,1763,O
As,1764,O
labetalol,1764,B-CHEMICAL
is,1764,O
a,1764,O
mixture,1764,O
of,1764,O
active,1764,O
(,1764,O
RR,1764,O
and,1764,O
SR,1764,O
),1764,O
and,1764,O
inactive,1764,O
(,1764,O
SS,1764,O
and,1764,O
SR,1764,O
),1764,O
enantiomers,1764,O
(,1764,O
in,1764,O
terms,1764,O
of,1764,O
alpha,1764,B-GENE-N
and,1764,I-GENE-N
beta,1764,I-GENE-N
receptor,1764,I-GENE-N
actions,1764,O
),1764,O
",",1764,O
the,1764,O
combination,1764,O
of,1764,O
RR,1764,O
and,1764,O
SR,1764,O
may,1764,O
be,1764,O
a,1764,O
valuable,1764,O
substitute,1764,O
for,1764,O
labetalol,1764,B-CHEMICAL
in,1764,O
the,1764,O
treatment,1764,O
of,1764,O
systemic,1764,O
hypertension,1764,O
.,1764,O
Although,1765,O
the,1765,O
potential,1765,O
for,1765,O
non-specific,1765,O
side,1765,O
effects,1765,O
(,1765,O
common,1765,O
to,1765,O
all,1765,O
four,1765,O
enantiomers,1765,O
),1765,O
could,1765,O
be,1765,O
expected,1765,O
to,1765,O
be,1765,O
diminished,1765,O
",",1765,O
recent,1765,O
reports,1765,O
by,1765,O
postmarketing,1765,O
surveillance,1765,O
indicate,1765,O
that,1765,O
the,1765,O
RR,1765,O
isomer,1765,O
(,1765,O
dilevalol,1765,B-CHEMICAL
),1765,O
can,1765,O
induce,1765,O
liver,1765,O
toxicity,1765,O
.,1765,O
Interestingly,1766,O
",",1766,O
labetalol,1766,B-CHEMICAL
is,1766,O
devoid,1766,O
of,1766,O
this,1766,O
effect,1766,O
;,1766,O
whether,1766,O
the,1766,O
combination,1766,O
of,1766,O
RR,1766,O
and,1766,O
SR,1766,O
enantiomers,1766,O
could,1766,O
be,1766,O
of,1766,O
clinical,1766,O
importance,1766,O
warrants,1766,O
further,1766,O
investigation,1766,O
.,1766,O
Overexpression,1767,O
of,1767,O
proline,1767,B-GENE-Y
oxidase,1767,I-GENE-Y
induces,1767,O
proline-dependent,1767,B-CHEMICAL
and,1767,O
mitochondria-mediated,1767,O
apoptosis,1767,O
.,1767,O
Proline,1768,B-CHEMICAL
oxidase,1768,I-GENE-Y
(,1768,O
POX,1768,B-GENE-Y
),1768,O
",",1768,O
a,1768,O
mitochondrial,1768,O
inner-membrane,1768,O
protein,1768,O
",",1768,O
catalyzes,1768,O
the,1768,O
rate-limiting,1768,O
oxidation,1768,O
of,1768,O
proline,1768,B-CHEMICAL
to,1768,O
pyrroline-,1768,B-CHEMICAL
5-carboxylate,1768,I-CHEMICAL
(,1768,O
P5C,1768,B-CHEMICAL
),1768,O
.,1768,O
Previously,1769,O
we,1769,O
showed,1769,O
that,1769,O
overexpression,1769,O
of,1769,O
POX,1769,B-GENE-Y
is,1769,O
associated,1769,O
with,1769,O
generation,1769,O
of,1769,O
reactive,1769,O
oxygen,1769,B-CHEMICAL
species,1769,O
(,1769,O
ROS,1769,O
),1769,O
and,1769,O
apoptosis,1769,O
in,1769,O
POX-inducible,1769,B-GENE-Y
colorectal,1769,O
cancer,1769,O
cells,1769,O
",",1769,O
DLD-1.POX,1769,O
.,1769,O
We,1770,O
also,1770,O
showed,1770,O
expression,1770,O
of,1770,O
mitochondrial,1770,O
MnSOD,1770,B-GENE-Y
partially,1770,O
blunts,1770,O
POX-induced,1770,B-GENE-Y
ROS,1770,O
generation,1770,O
and,1770,O
apoptosis,1770,O
.,1770,O
To,1771,O
further,1771,O
investigate,1771,O
the,1771,O
molecular,1771,O
basis,1771,O
of,1771,O
POX-induced,1771,B-GENE-Y
apoptosis,1771,O
",",1771,O
we,1771,O
utilized,1771,O
the,1771,O
DLD-1.POX,1771,O
cells,1771,O
to,1771,O
show,1771,O
that,1771,O
cells,1771,O
overproducing,1771,O
POX,1771,B-GENE-Y
exhibit,1771,O
an,1771,O
L-proline-dependent,1771,B-CHEMICAL
apoptotic,1771,O
response,1771,O
.,1771,O
The,1772,O
apoptotic,1772,O
effect,1772,O
is,1772,O
specific,1772,O
for,1772,O
L-proline,1772,B-CHEMICAL
",",1772,O
detectable,1772,O
at,1772,O
0.2,1772,O
mM,1772,O
",",1772,O
maximal,1772,O
at,1772,O
1,1772,O
mM,1772,O
",",1772,O
and,1772,O
occurs,1772,O
during,1772,O
48-72,1772,O
h,1772,O
following,1772,O
the,1772,O
addition,1772,O
of,1772,O
L-proline,1772,B-CHEMICAL
to,1772,O
cells,1772,O
with,1772,O
maximally,1772,O
induced,1772,O
POX,1772,B-GENE-Y
.,1772,O
The,1773,O
apoptotic,1773,O
response,1773,O
is,1773,O
mitochondria-mediated,1773,O
with,1773,O
release,1773,O
of,1773,O
cytochrome,1773,B-GENE-Y
c,1773,I-GENE-Y
",",1773,O
activation,1773,O
of,1773,O
caspase-9,1773,B-GENE-Y
",",1773,O
chromatin,1773,O
condensation/DNA,1773,O
fragmentation,1773,O
",",1773,O
and,1773,O
cell,1773,O
shrinkage,1773,O
.,1773,O
We,1774,O
conclude,1774,O
that,1774,O
in,1774,O
the,1774,O
presence,1774,O
of,1774,O
proline,1774,B-CHEMICAL
",",1774,O
high,1774,O
POX,1774,B-GENE-Y
activity,1774,O
is,1774,O
sufficient,1774,O
to,1774,O
induce,1774,O
mitochondria-mediated,1774,O
apoptosis,1774,O
.,1774,O
The,1775,O
effects,1775,O
of,1775,O
norepinephrine,1775,B-GENE-Y
transporter,1775,I-GENE-Y
inactivation,1775,O
on,1775,O
locomotor,1775,O
activity,1775,O
in,1775,O
mice,1775,O
.,1775,O
BACKGROUND,1776,O
:,1776,O
Acute,1776,O
administration,1776,O
of,1776,O
different,1776,O
classes,1776,O
of,1776,O
antidepressants,1776,O
can,1776,O
enhance,1776,O
or,1776,O
reduce,1776,O
spontaneous,1776,O
locomotor,1776,O
activity,1776,O
in,1776,O
a,1776,O
novel,1776,O
environment,1776,O
",",1776,O
but,1776,O
the,1776,O
effects,1776,O
of,1776,O
chronic,1776,O
antidepressant,1776,O
treatment,1776,O
on,1776,O
spontaneous,1776,O
locomotor,1776,O
activity,1776,O
in,1776,O
novel,1776,O
and,1776,O
familiar,1776,O
environments,1776,O
are,1776,O
less,1776,O
well,1776,O
characterized,1776,O
.,1776,O
Because,1777,O
norepinephrine,1777,B-CHEMICAL
is,1777,O
an,1777,O
important,1777,O
regulator,1777,O
of,1777,O
spontaneous,1777,O
locomotor,1777,O
activity,1777,O
",",1777,O
we,1777,O
speculated,1777,O
that,1777,O
norepinephrine,1777,B-GENE-Y
transporter,1777,I-GENE-Y
blockade,1777,O
contributes,1777,O
to,1777,O
the,1777,O
effects,1777,O
of,1777,O
some,1777,O
antidepressants,1777,O
on,1777,O
spontaneous,1777,O
locomotor,1777,O
activity,1777,O
.,1777,O
METHODS,1778,O
:,1778,O
Antidepressant,1778,O
drugs,1778,O
(,1778,O
reboxetine,1778,B-CHEMICAL
",",1778,O
desipramine,1778,B-CHEMICAL
",",1778,O
imipramine,1778,B-CHEMICAL
",",1778,O
venlafaxine,1778,B-CHEMICAL
",",1778,O
bupropion,1778,B-CHEMICAL
),1778,O
were,1778,O
administered,1778,O
acutely,1778,O
(,1778,O
intraperitoneal,1778,O
),1778,O
or,1778,O
chronically,1778,O
(,1778,O
via,1778,O
osmotic,1778,O
minipump,1778,O
),1778,O
to,1778,O
control,1778,O
and,1778,O
norepinephrine,1778,B-GENE-Y
transporter,1778,I-GENE-Y
knockout,1778,O
mice,1778,O
",",1778,O
and,1778,O
spontaneous,1778,O
locomotor,1778,O
activity,1778,O
in,1778,O
novel,1778,O
or,1778,O
familiar,1778,O
environments,1778,O
was,1778,O
recorded,1778,O
.,1778,O
RESULTS,1779,O
:,1779,O
Acute,1779,O
treatment,1779,O
with,1779,O
most,1779,O
norepinephrine,1779,B-GENE-Y
transporter-blocking,1779,O
antidepressants,1779,O
decreased,1779,O
spontaneous,1779,O
locomotor,1779,O
activity,1779,O
in,1779,O
a,1779,O
novel,1779,O
environment,1779,O
",",1779,O
whereas,1779,O
chronic,1779,O
treatment,1779,O
decreased,1779,O
spontaneous,1779,O
locomotor,1779,O
activity,1779,O
in,1779,O
both,1779,O
novel,1779,O
and,1779,O
familiar,1779,O
environments,1779,O
.,1779,O
The,1780,O
exception,1780,O
was,1780,O
bupropion,1780,B-CHEMICAL
",",1780,O
a,1780,O
dual,1780,O
norepinephrine,1780,B-CHEMICAL
transporter/dopamine,1780,O
transporter,1780,I-GENE-Y
blocker,1780,O
",",1780,O
which,1780,O
tended,1780,O
to,1780,O
increase,1780,O
spontaneous,1780,O
locomotor,1780,O
activity,1780,O
.,1780,O
Coadministration,1781,O
of,1781,O
reboxetine,1781,B-CHEMICAL
and,1781,O
the,1781,O
dopamine,1781,B-CHEMICAL
transporter,1781,I-GENE-Y
blocker,1781,O
GBR,1781,B-CHEMICAL
12909,1781,I-CHEMICAL
also,1781,O
increased,1781,O
spontaneous,1781,O
locomotor,1781,O
activity,1781,O
.,1781,O
Norepinephrine,1782,B-CHEMICAL
transporter,1782,I-GENE-Y
knockout,1782,O
mice,1782,O
had,1782,O
low,1782,O
basal,1782,O
spontaneous,1782,O
locomotor,1782,O
activity,1782,O
",",1782,O
which,1782,O
was,1782,O
increased,1782,O
by,1782,O
bupropion,1782,B-CHEMICAL
",",1782,O
whereas,1782,O
reboxetine,1782,B-CHEMICAL
had,1782,O
no,1782,O
effect,1782,O
in,1782,O
norepinephrine,1782,B-GENE-Y
transporter,1782,I-GENE-Y
knockout,1782,O
mice,1782,O
.,1782,O
CONCLUSIONS,1783,O
:,1783,O
Acute,1783,O
or,1783,O
chronic,1783,O
inactivation,1783,O
of,1783,O
the,1783,O
norepinephrine,1783,B-GENE-Y
transporter,1783,I-GENE-Y
decreases,1783,O
spontaneous,1783,O
locomotor,1783,O
activity,1783,O
in,1783,O
novel,1783,O
and,1783,O
familiar,1783,O
environments,1783,O
unless,1783,O
coupled,1783,O
with,1783,O
dopamine,1783,B-GENE-Y
transporter,1783,I-GENE-Y
blockade,1783,O
.,1783,O
Treatment,1784,O
of,1784,O
Postmenopausal,1784,O
Breast,1784,O
Cancer,1784,O
with,1784,O
Selective,1784,O
Estrogen,1784,B-GENE-Y
Receptor,1784,I-GENE-Y
Modulators,1784,O
(,1784,O
SERMs,1784,O
),1784,O
.,1784,O
Endocrine,1785,O
therapy,1785,O
that,1785,O
targets,1785,O
the,1785,O
estrogen,1785,B-GENE-Y
receptor,1785,I-GENE-Y
(,1785,O
ER,1785,B-GENE-Y
),1785,O
is,1785,O
a,1785,O
standard,1785,O
of,1785,O
care,1785,O
for,1785,O
the,1785,O
treatment,1785,O
of,1785,O
postmenopausal,1785,O
women,1785,O
with,1785,O
ER-positive,1785,B-GENE-Y
breast,1785,O
cancer,1785,O
.,1785,O
The,1786,O
selective,1786,O
ER,1786,B-GENE-Y
modulator,1786,O
(,1786,O
SERM,1786,O
),1786,O
tamoxifen,1786,B-CHEMICAL
has,1786,O
been,1786,O
in,1786,O
use,1786,O
for,1786,O
the,1786,O
treatment,1786,O
of,1786,O
advanced,1786,O
breast,1786,O
cancer,1786,O
for,1786,O
more,1786,O
than,1786,O
30,1786,O
years,1786,O
and,1786,O
is,1786,O
currently,1786,O
a,1786,O
treatment,1786,O
option,1786,O
for,1786,O
all,1786,O
stages,1786,O
of,1786,O
ER-positive,1786,B-GENE-Y
disease,1786,O
.,1786,O
Tamoxifen,1787,B-CHEMICAL
blocks,1787,O
the,1787,O
action,1787,O
of,1787,O
estrogen,1787,B-CHEMICAL
by,1787,O
binding,1787,O
to,1787,O
the,1787,O
ER,1787,B-GENE-Y
",",1787,O
and,1787,O
possesses,1787,O
both,1787,O
ER-agonist,1787,B-GENE-Y
and,1787,O
antagonist,1787,O
properties,1787,O
.,1787,O
Unfortunately,1788,O
",",1788,O
long-term,1788,O
use,1788,O
of,1788,O
tamoxifen,1788,B-CHEMICAL
is,1788,O
associated,1788,O
with,1788,O
several,1788,O
important,1788,O
concerns,1788,O
including,1788,O
an,1788,O
increased,1788,O
risk,1788,O
of,1788,O
endometrial,1788,O
cancer,1788,O
and,1788,O
thromboembolic,1788,O
complications,1788,O
.,1788,O
In,1789,O
addition,1789,O
",",1789,O
many,1789,O
patients,1789,O
who,1789,O
initially,1789,O
respond,1789,O
to,1789,O
tamoxifen,1789,B-CHEMICAL
eventually,1789,O
relapse,1789,O
with,1789,O
resistant,1789,O
disease,1789,O
.,1789,O
New,1790,O
treatment,1790,O
approaches,1790,O
are,1790,O
therefore,1790,O
required,1790,O
.,1790,O
A,1791,O
number,1791,O
of,1791,O
alternative,1791,O
SERMs,1791,O
have,1791,O
been,1791,O
tested,1791,O
as,1791,O
substitutes,1791,O
for,1791,O
tamoxifen,1791,B-CHEMICAL
.,1791,O
These,1792,O
include,1792,O
;,1792,O
toremifene,1792,B-CHEMICAL
",",1792,O
droloxifene,1792,B-CHEMICAL
",",1792,O
idoxifene,1792,B-CHEMICAL
",",1792,O
and,1792,O
keoxifene,1792,B-CHEMICAL
.,1792,O
Unfortunately,1793,O
",",1793,O
the,1793,O
SERMs,1793,O
have,1793,O
not,1793,O
proved,1793,O
to,1793,O
be,1793,O
more,1793,O
effective,1793,O
than,1793,O
tamoxifen,1793,B-CHEMICAL
for,1793,O
the,1793,O
treatment,1793,O
of,1793,O
advanced,1793,O
breast,1793,O
cancer,1793,O
and,1793,O
have,1793,O
shown,1793,O
a,1793,O
high,1793,O
level,1793,O
of,1793,O
cross-resistance,1793,O
with,1793,O
tamoxifen,1793,B-CHEMICAL
.,1793,O
The,1794,O
subsequent,1794,O
development,1794,O
of,1794,O
the,1794,O
aromatase,1794,B-GENE-Y
inhibitors,1794,O
(,1794,O
AIs,1794,O
),1794,O
is,1794,O
an,1794,O
important,1794,O
therapeutic,1794,O
advance,1794,O
by,1794,O
creating,1794,O
a,1794,O
``,1794,O
no,1794,O
estrogen,1794,B-CHEMICAL
'',1794,O
environment,1794,O
.,1794,O
Another,1795,O
approach,1795,O
is,1795,O
the,1795,O
development,1795,O
of,1795,O
pure,1795,O
antiestrogens,1795,O
.,1795,O
Fulvestrant,1796,B-CHEMICAL
is,1796,O
a,1796,O
novel,1796,O
ER,1796,B-GENE-Y
antagonist,1796,O
that,1796,O
destroys,1796,O
the,1796,O
ER,1796,B-GENE-Y
and,1796,O
its,1796,O
signaling,1796,O
pathway,1796,O
and,1796,O
is,1796,O
not,1796,O
associated,1796,O
with,1796,O
tamoxifen-like,1796,B-CHEMICAL
agonist,1796,O
effects,1796,O
.,1796,O
It,1797,O
produces,1797,O
high,1797,O
response,1797,O
rates,1797,O
compared,1797,O
with,1797,O
other,1797,O
SERMs,1797,O
and,1797,O
is,1797,O
not,1797,O
cross-resistant,1797,O
to,1797,O
tamoxifen,1797,B-CHEMICAL
or,1797,O
aromatase,1797,B-GENE-Y
inhibitors,1797,O
and,1797,O
is,1797,O
equally,1797,O
as,1797,O
effective,1797,O
as,1797,O
the,1797,O
AI,1797,O
anastrozole,1797,B-CHEMICAL
in,1797,O
the,1797,O
treatment,1797,O
of,1797,O
postmenopausal,1797,O
women,1797,O
with,1797,O
advanced,1797,O
breast,1797,O
cancer,1797,O
who,1797,O
have,1797,O
progressed,1797,O
on,1797,O
prior,1797,O
adjuvant,1797,O
tamoxifen,1797,B-CHEMICAL
therapy,1797,O
.,1797,O
This,1798,O
review,1798,O
article,1798,O
discusses,1798,O
the,1798,O
significant,1798,O
and,1798,O
continuing,1798,O
value,1798,O
of,1798,O
SERMs,1798,O
for,1798,O
the,1798,O
treatment,1798,O
of,1798,O
postmenopausal,1798,O
ER-positive,1798,B-GENE-Y
breast,1798,O
cancer,1798,O
.,1798,O
A,1799,O
46-amino,1799,O
acid,1799,I-CHEMICAL
segment,1799,O
in,1799,O
phosphodiesterase-5,1799,B-GENE-Y
GAF-B,1799,B-GENE-N
domain,1799,I-GENE-N
provides,1799,O
for,1799,O
high,1799,O
vardenafil,1799,B-CHEMICAL
potency,1799,O
over,1799,O
sildenafil,1799,B-CHEMICAL
and,1799,O
tadalafil,1799,B-CHEMICAL
and,1799,O
is,1799,O
involved,1799,O
in,1799,O
phosphodiesterase-5,1799,B-GENE-Y
dimerization,1799,O
.,1799,O
Phosphodiesterase-5,1800,B-GENE-Y
(,1800,O
PDE5,1800,B-GENE-Y
),1800,O
contains,1800,O
a,1800,O
catalytic,1800,O
domain,1800,O
(,1800,O
C,1800,O
domain,1800,O
),1800,O
that,1800,O
hydrolyzes,1800,O
cGMP,1800,B-CHEMICAL
and,1800,O
a,1800,O
regulatory,1800,O
domain,1800,O
(,1800,O
R,1800,O
domain,1800,O
),1800,O
that,1800,O
contains,1800,O
two,1800,O
mammalian,1800,B-GENE-N
cGMP-binding,1800,B-CHEMICAL
phosphodiesterase,1800,I-GENE-N
",",1800,O
Anabaena,1800,B-GENE-Y
adenylyl,1800,I-GENE-Y
cyclases,1800,I-GENE-Y
",",1800,O
Escherichia,1800,B-GENE-Y
coli,1800,I-GENE-Y
FhlAs,1800,I-GENE-Y
(,1800,B-GENE-N
GAFs,1800,I-GENE-N
),1800,I-GENE-N
(,1800,I-GENE-N
A,1800,I-GENE-N
and,1800,I-GENE-N
B,1800,I-GENE-N
),1800,I-GENE-N
and,1800,O
a,1800,O
phosphorylation,1800,O
site,1800,O
for,1800,O
cyclic,1800,B-GENE-N
nucleotide-dependent,1800,I-GENE-N
protein,1800,I-GENE-N
kinases,1800,I-GENE-N
(,1800,O
cNPKs,1800,B-GENE-N
),1800,O
.,1800,O
Binding,1801,O
of,1801,O
cGMP,1801,B-CHEMICAL
to,1801,O
GAF-A,1801,B-GENE-N
increases,1801,O
cNPK,1801,B-GENE-N
phosphorylation,1801,O
of,1801,O
PDE5,1801,B-GENE-Y
and,1801,O
improves,1801,O
catalytic,1801,O
site,1801,O
affinity,1801,O
for,1801,O
cGMP,1801,B-CHEMICAL
or,1801,O
inhibitors,1801,O
.,1801,O
GAF-B,1802,B-GENE-N
contributes,1802,O
to,1802,O
dimerization,1802,O
of,1802,O
PDE5,1802,B-GENE-Y
",",1802,O
inhibition,1802,O
of,1802,O
cGMP,1802,B-CHEMICAL
binding,1802,O
to,1802,O
GAF-A,1802,B-GENE-N
",",1802,O
and,1802,O
sequestration,1802,O
of,1802,O
the,1802,O
phosphorylation,1802,O
site,1802,O
.,1802,O
To,1803,O
probe,1803,O
potential,1803,O
PDE5,1803,B-GENE-N
R,1803,I-GENE-N
domain,1803,I-GENE-N
effects,1803,O
on,1803,O
catalytic,1803,O
site,1803,O
affinity,1803,O
for,1803,O
certain,1803,O
inhibitors,1803,O
",",1803,O
four,1803,O
N-terminal,1803,B-CHEMICAL
truncation,1803,O
mutants,1803,O
were,1803,O
generated,1803,O
:,1803,O
PDE5Delta1-321,1803,B-GENE-Y
contained,1803,O
GAF-B,1803,B-GENE-N
domain,1803,I-GENE-N
",",1803,O
C,1803,O
domain,1803,O
",",1803,O
and,1803,O
the,1803,O
sequence,1803,O
between,1803,O
GAF-A,1803,B-GENE-N
and,1803,I-GENE-N
-B,1803,I-GENE-N
;,1803,O
PDE5Delta1-419,1803,B-GENE-Y
contained,1803,O
GAF-B,1803,B-GENE-N
and,1803,I-GENE-N
C,1803,I-GENE-N
domain,1803,I-GENE-N
;,1803,O
PDE5Delta1-465,1803,B-GENE-Y
contained,1803,O
the,1803,O
C,1803,O
domain,1803,O
and,1803,O
the,1803,O
C-terminal,1803,B-CHEMICAL
portion,1803,O
of,1803,O
GAF-B,1803,B-GENE-N
;,1803,O
and,1803,O
PDE5Delta1-534,1803,B-GENE-Y
contained,1803,O
only,1803,O
C,1803,O
domain,1803,O
.,1803,O
Truncated,1804,O
proteins,1804,O
with,1804,O
a,1804,O
complete,1804,O
GAF-B,1804,B-GENE-N
were,1804,O
dimers,1804,O
",",1804,O
but,1804,O
those,1804,O
lacking,1804,O
the,1804,O
N-terminal,1804,B-CHEMICAL
46,1804,O
amino,1804,B-CHEMICAL
acids,1804,I-CHEMICAL
of,1804,O
GAF-B,1804,B-GENE-N
were,1804,O
monomers,1804,O
",",1804,O
indicating,1804,O
that,1804,O
these,1804,O
residues,1804,O
are,1804,O
vital,1804,O
for,1804,O
GAF-B-mediated,1804,B-GENE-N
PDE5,1804,B-GENE-Y
dimerization,1804,O
.,1804,O
K,1805,O
(,1805,O
m,1805,O
),1805,O
values,1805,O
of,1805,O
the,1805,O
mutants,1805,O
for,1805,O
cGMP,1805,B-CHEMICAL
were,1805,O
similar,1805,O
to,1805,O
that,1805,O
of,1805,O
full-length,1805,O
PDE5,1805,B-GENE-Y
.,1805,O
All,1806,O
PDE5,1806,B-GENE-Y
constructs,1806,O
had,1806,O
similar,1806,O
affinities,1806,O
for,1806,O
3-isobutyl-1-methylxanthine,1806,B-CHEMICAL
",",1806,O
sildenafil,1806,B-CHEMICAL
",",1806,O
tadalafil,1806,B-CHEMICAL
",",1806,O
and,1806,O
UK-122764,1806,B-CHEMICAL
",",1806,O
but,1806,O
mutants,1806,O
containing,1806,O
a,1806,O
complete,1806,O
GAF-B,1806,B-GENE-N
had,1806,O
7-,1806,O
to,1806,O
18-fold,1806,O
higher,1806,O
affinity,1806,O
for,1806,O
vardenafil-based,1806,B-CHEMICAL
compounds,1806,O
compared,1806,O
with,1806,O
those,1806,O
lacking,1806,O
a,1806,O
complete,1806,O
GAF-B,1806,B-GENE-N
.,1806,O
This,1807,O
indicated,1807,O
that,1807,O
the,1807,O
N-terminal,1807,B-CHEMICAL
46,1807,O
amino,1807,B-CHEMICAL
acids,1807,I-CHEMICAL
in,1807,O
GAF-B,1807,B-GENE-N
are,1807,O
required,1807,O
for,1807,O
high,1807,O
vardenafil,1807,B-CHEMICAL
potency,1807,O
.,1807,O
This,1808,O
is,1808,O
the,1808,O
first,1808,O
evidence,1808,O
that,1808,O
PDE5,1808,B-GENE-N
R,1808,I-GENE-N
domain,1808,I-GENE-N
",",1808,O
and,1808,O
GAF-B,1808,B-GENE-N
in,1808,O
particular,1808,O
",",1808,O
influences,1808,O
affinity,1808,O
and,1808,O
selectivity,1808,O
of,1808,O
the,1808,O
catalytic,1808,O
site,1808,O
for,1808,O
certain,1808,O
classes,1808,O
of,1808,O
inhibitors,1808,O
.,1808,O
Telmisartan,1809,B-CHEMICAL
downregulates,1809,O
angiotensin,1809,B-GENE-Y
II,1809,I-GENE-Y
type,1809,I-GENE-Y
1,1809,I-GENE-Y
receptor,1809,I-GENE-Y
through,1809,O
activation,1809,O
of,1809,O
peroxisome,1809,B-GENE-Y
proliferator-activated,1809,I-GENE-Y
receptor,1809,I-GENE-Y
gamma,1809,I-GENE-Y
.,1809,O
OBJECTIVE,1810,O
:,1810,O
Telmisartan,1810,B-CHEMICAL
",",1810,O
an,1810,O
angiotensin,1810,B-GENE-Y
II,1810,I-GENE-Y
type,1810,I-GENE-Y
1,1810,I-GENE-Y
receptor,1810,I-GENE-Y
(,1810,O
AT1R,1810,B-GENE-Y
),1810,O
antagonist,1810,O
",",1810,O
was,1810,O
found,1810,O
to,1810,O
have,1810,O
a,1810,O
unique,1810,O
property,1810,O
:,1810,O
it,1810,O
is,1810,O
a,1810,O
partial,1810,O
agonist,1810,O
of,1810,O
peroxisome,1810,B-GENE-Y
proliferator-activated,1810,I-GENE-Y
receptor,1810,I-GENE-Y
gamma,1810,I-GENE-Y
(,1810,O
PPARgamma,1810,B-GENE-Y
),1810,O
.,1810,O
Since,1811,O
previous,1811,O
studies,1811,O
have,1811,O
demonstrated,1811,O
that,1811,O
PPARgamma,1811,B-GENE-Y
activators,1811,O
suppressed,1811,O
AT1R,1811,B-GENE-Y
expression,1811,O
",",1811,O
we,1811,O
examined,1811,O
whether,1811,O
telmisartan,1811,B-CHEMICAL
affects,1811,O
AT1R,1811,B-GENE-Y
expression,1811,O
in,1811,O
vascular,1811,O
smooth,1811,O
muscle,1811,O
cells,1811,O
.,1811,O
METHODS,1812,O
:,1812,O
Vascular,1812,O
smooth,1812,O
muscle,1812,O
cells,1812,O
were,1812,O
derived,1812,O
from,1812,O
the,1812,O
thoracic,1812,O
aorta,1812,O
of,1812,O
Wistar-Kyoto,1812,O
rat,1812,O
.,1812,O
Northern,1813,O
and,1813,O
Western,1813,O
blotting,1813,O
analysis,1813,O
were,1813,O
used,1813,O
to,1813,O
examine,1813,O
AT1R,1813,B-GENE-Y
mRNA,1813,O
and,1813,O
protein,1813,O
expression,1813,O
",",1813,O
respectively,1813,O
.,1813,O
The,1814,O
DEAE-dextran,1814,O
method,1814,O
was,1814,O
used,1814,O
for,1814,O
transfection,1814,O
",",1814,O
and,1814,O
the,1814,O
promoter,1814,O
activity,1814,O
of,1814,O
AT1R,1814,B-GENE-Y
was,1814,O
examined,1814,O
by,1814,O
luciferase,1814,O
assay,1814,O
.,1814,O
RESULTS,1815,O
:,1815,O
Telmisartan,1815,B-CHEMICAL
decreased,1815,O
the,1815,O
expression,1815,O
of,1815,O
AT1R,1815,B-GENE-Y
at,1815,O
the,1815,O
mRNA,1815,O
and,1815,O
protein,1815,O
levels,1815,O
in,1815,O
a,1815,O
dose-,1815,O
and,1815,O
time-dependent,1815,O
manner,1815,O
.,1815,O
Decreased,1816,O
AT1R,1816,B-GENE-N
promoter,1816,I-GENE-N
activity,1816,O
with,1816,O
unchanged,1816,O
mRNA,1816,O
stability,1816,O
suggested,1816,O
that,1816,O
telmisartan,1816,B-CHEMICAL
suppressed,1816,O
AT1R,1816,B-GENE-Y
gene,1816,O
expression,1816,O
at,1816,O
the,1816,O
transcriptional,1816,O
level,1816,O
.,1816,O
However,1817,O
",",1817,O
the,1817,O
expression,1817,O
of,1817,O
AT1R,1817,B-GENE-Y
was,1817,O
not,1817,O
suppressed,1817,O
by,1817,O
other,1817,O
AT1R,1817,B-GENE-Y
antagonists,1817,O
such,1817,O
as,1817,O
candesartan,1817,B-CHEMICAL
or,1817,O
olmesartan,1817,B-CHEMICAL
.,1817,O
Since,1818,O
the,1818,O
suppression,1818,O
of,1818,O
AT1R,1818,B-GENE-Y
expression,1818,O
was,1818,O
prevented,1818,O
by,1818,O
pretreatment,1818,O
with,1818,O
GW9662,1818,B-CHEMICAL
",",1818,O
a,1818,O
PPARgamma,1818,B-GENE-Y
antagonist,1818,O
",",1818,O
PPARgamma,1818,B-GENE-Y
should,1818,O
have,1818,O
participated,1818,O
in,1818,O
the,1818,O
process,1818,O
.,1818,O
The,1819,O
deletion,1819,O
and,1819,O
mutation,1819,O
analysis,1819,O
of,1819,O
the,1819,O
AT1R,1819,B-GENE-Y
gene,1819,O
promoter,1819,O
indicated,1819,O
that,1819,O
a,1819,O
GC,1819,B-GENE-N
box,1819,I-GENE-N
located,1819,O
in,1819,O
the,1819,O
proximal,1819,O
promoter,1819,O
region,1819,O
is,1819,O
responsible,1819,O
for,1819,O
the,1819,O
telmisartan-induced,1819,B-CHEMICAL
downregulation,1819,O
.,1819,O
CONCLUSION,1820,O
:,1820,O
Our,1820,O
data,1820,O
provides,1820,O
a,1820,O
novel,1820,O
insight,1820,O
into,1820,O
an,1820,O
effect,1820,O
of,1820,O
telmisartan,1820,B-CHEMICAL
:,1820,O
telmisartan,1820,B-CHEMICAL
inhibits,1820,O
AT1R,1820,B-GENE-Y
gene,1820,O
expression,1820,O
through,1820,O
PPARgamma,1820,B-GENE-Y
activation,1820,O
.,1820,O
The,1821,O
dual,1821,O
inhibition,1821,O
of,1821,O
angiotensin,1821,B-GENE-Y
II,1821,I-GENE-Y
function,1821,O
by,1821,O
telmisartan,1821,O
-,1821,O
AT1R,1821,B-GENE-Y
blockade,1821,O
and,1821,O
downregulation,1821,O
-,1821,O
would,1821,O
contribute,1821,O
to,1821,O
more,1821,O
complete,1821,O
inhibition,1821,O
of,1821,O
the,1821,O
renin-angiotensin,1821,B-GENE-Y
system,1821,O
.,1821,O
Secretion,1822,O
of,1822,O
L-glutamate,1822,B-CHEMICAL
from,1822,O
osteoclasts,1822,O
through,1822,O
transcytosis,1822,O
.,1822,O
Osteoclasts,1823,O
are,1823,O
involved,1823,O
in,1823,O
the,1823,O
catabolism,1823,O
of,1823,O
the,1823,O
bone,1823,O
matrix,1823,O
and,1823,O
eliminate,1823,O
the,1823,O
resulting,1823,O
degradation,1823,O
products,1823,O
through,1823,O
transcytosis,1823,O
",",1823,O
but,1823,O
the,1823,O
molecular,1823,O
mechanism,1823,O
and,1823,O
regulation,1823,O
of,1823,O
transcytosis,1823,O
remain,1823,O
poorly,1823,O
understood,1823,O
.,1823,O
Upon,1824,O
differentiation,1824,O
",",1824,O
osteoclasts,1824,O
express,1824,O
vesicular,1824,B-GENE-Y
glutamate,1824,B-CHEMICAL
transporter,1824,I-GENE-Y
1,1824,I-GENE-Y
(,1824,O
VGLUT1,1824,B-GENE-Y
),1824,O
",",1824,O
which,1824,O
is,1824,O
essential,1824,O
for,1824,O
vesicular,1824,O
storage,1824,O
and,1824,O
subsequent,1824,O
exocytosis,1824,O
of,1824,O
glutamate,1824,B-CHEMICAL
in,1824,O
neurons,1824,O
.,1824,O
VGLUT1,1825,B-GENE-Y
is,1825,O
localized,1825,O
in,1825,O
transcytotic,1825,O
vesicles,1825,O
and,1825,O
accumulates,1825,O
L-glutamate,1825,B-CHEMICAL
.,1825,O
Osteoclasts,1826,O
secrete,1826,O
L-glutamate,1826,B-CHEMICAL
and,1826,O
the,1826,O
bone,1826,O
degradation,1826,O
products,1826,O
upon,1826,O
stimulation,1826,O
with,1826,O
KCl,1826,B-CHEMICAL
or,1826,O
ATP,1826,B-CHEMICAL
in,1826,O
a,1826,O
Ca2+-dependent,1826,B-CHEMICAL
manner,1826,O
.,1826,O
KCl-,1827,B-CHEMICAL
and,1827,O
ATP-dependent,1827,B-CHEMICAL
secretion,1827,O
of,1827,O
L-glutamate,1827,B-CHEMICAL
was,1827,O
absent,1827,O
in,1827,O
osteoclasts,1827,O
prepared,1827,O
from,1827,O
VGLUT1-/-,1827,B-GENE-Y
knockout,1827,O
mice,1827,O
.,1827,O
Osteoclasts,1828,O
express,1828,O
mGluR8,1828,B-GENE-Y
",",1828,O
a,1828,O
class,1828,B-GENE-N
III,1828,I-GENE-N
metabotropic,1828,I-GENE-N
glutamate,1828,I-GENE-N
receptor,1828,I-GENE-N
.,1828,O
Its,1829,O
stimulation,1829,O
by,1829,O
a,1829,O
specific,1829,O
agonist,1829,O
inhibits,1829,O
secretion,1829,O
of,1829,O
L-glutamate,1829,B-CHEMICAL
and,1829,O
bone,1829,O
degradation,1829,O
products,1829,O
",",1829,O
whereas,1829,O
its,1829,O
suppression,1829,O
by,1829,O
a,1829,O
specific,1829,O
antagonist,1829,O
stimulates,1829,O
bone,1829,O
resorption,1829,O
.,1829,O
Finally,1830,O
",",1830,O
it,1830,O
was,1830,O
found,1830,O
that,1830,O
VGLUT1-/-,1830,B-GENE-Y
mice,1830,O
develop,1830,O
osteoporosis,1830,O
.,1830,O
Thus,1831,O
",",1831,O
in,1831,O
bone-resorbing,1831,O
osteoclasts,1831,O
",",1831,O
L-glutamate,1831,B-CHEMICAL
and,1831,O
bone,1831,O
degradation,1831,O
products,1831,O
are,1831,O
secreted,1831,O
through,1831,O
transcytosis,1831,O
and,1831,O
the,1831,O
released,1831,O
L-glutamate,1831,B-CHEMICAL
is,1831,O
involved,1831,O
in,1831,O
autoregulation,1831,O
of,1831,O
transcytosis,1831,O
.,1831,O
Glutamate,1832,B-CHEMICAL
signaling,1832,O
may,1832,O
play,1832,O
an,1832,O
important,1832,O
role,1832,O
in,1832,O
the,1832,O
bone,1832,O
homeostasis,1832,O
.,1832,O
Synthesis,1833,O
",",1833,O
dihydrofolate,1833,B-CHEMICAL
reductase,1833,I-GENE-Y
inhibition,1833,O
",",1833,O
antitumor,1833,O
testing,1833,O
",",1833,O
and,1833,O
molecular,1833,O
modeling,1833,O
study,1833,O
of,1833,O
some,1833,O
new,1833,O
4,1833,B-CHEMICAL
(,1833,I-CHEMICAL
3H,1833,I-CHEMICAL
),1833,I-CHEMICAL
-quinazolinone,1833,I-CHEMICAL
analogs,1833,O
.,1833,O
In,1834,O
order,1834,O
to,1834,O
produce,1834,O
potent,1834,O
new,1834,O
leads,1834,O
for,1834,O
anticancer,1834,O
drugs,1834,O
",",1834,O
a,1834,O
new,1834,O
series,1834,O
of,1834,O
quinazoline,1834,B-CHEMICAL
analogs,1834,O
was,1834,O
designed,1834,O
to,1834,O
resemble,1834,O
methotrexate,1834,B-CHEMICAL
(,1834,O
MTX,1834,B-CHEMICAL
",",1834,O
1,1834,O
),1834,O
structure,1834,O
features,1834,O
and,1834,O
fitted,1834,O
with,1834,O
functional,1834,O
groups,1834,O
believed,1834,O
to,1834,O
enhance,1834,O
inhibition,1834,O
of,1834,O
mammalian,1834,B-GENE-N
DHFR,1834,I-GENE-N
activity,1834,O
.,1834,O
Molecular,1835,O
modeling,1835,O
studies,1835,O
were,1835,O
used,1835,O
to,1835,O
assess,1835,O
the,1835,O
fit,1835,O
of,1835,O
these,1835,O
compounds,1835,O
within,1835,O
the,1835,O
active,1835,O
site,1835,O
of,1835,O
human,1835,B-GENE-Y
DHFR,1835,I-GENE-Y
.,1835,O
The,1836,O
synthesized,1836,O
compounds,1836,O
were,1836,O
evaluated,1836,O
for,1836,O
their,1836,O
ability,1836,O
to,1836,O
inhibit,1836,O
mammalian,1836,B-GENE-N
DHFR,1836,I-GENE-N
in,1836,O
vitro,1836,O
and,1836,O
for,1836,O
their,1836,O
antitumor,1836,O
activity,1836,O
in,1836,O
a,1836,O
standard,1836,O
in,1836,O
vitro,1836,O
tissue,1836,O
culture,1836,O
assay,1836,O
panel,1836,O
.,1836,O
Compounds,1837,O
28,1837,O
",",1837,O
30,1837,O
",",1837,O
and,1837,O
31,1837,O
were,1837,O
the,1837,O
most,1837,O
active,1837,O
DHFR,1837,B-GENE-Y
inhibitors,1837,O
with,1837,O
IC,1837,O
(,1837,O
50,1837,O
),1837,O
values,1837,O
of,1837,O
0.5,1837,O
",",1837,O
0.4,1837,O
",",1837,O
and,1837,O
0.4microM,1837,O
",",1837,O
respectively,1837,O
.,1837,O
The,1838,O
most,1838,O
active,1838,O
antitumor,1838,O
agents,1838,O
in,1838,O
this,1838,O
study,1838,O
were,1838,O
compounds,1838,O
19,1838,O
",",1838,O
31,1838,O
",",1838,O
41,1838,O
",",1838,O
and,1838,O
47,1838,O
with,1838,O
median,1838,O
growth,1838,O
inhibitory,1838,O
concentrations,1838,O
(,1838,O
GI,1838,O
(,1838,O
50,1838,O
),1838,O
),1838,O
of,1838,O
20.1,1838,O
",",1838,O
23.5,1838,O
",",1838,O
26.7,1838,O
",",1838,O
and,1838,O
9.1microM,1838,O
",",1838,O
respectively,1838,O
.,1838,O
Of,1839,O
this,1839,O
series,1839,O
of,1839,O
compounds,1839,O
",",1839,O
only,1839,O
compound,1839,O
31,1839,O
combined,1839,O
antitumor,1839,O
potency,1839,O
with,1839,O
potent,1839,O
DHFR,1839,B-GENE-Y
inhibition,1839,O
;,1839,O
the,1839,O
other,1839,O
active,1839,O
antitumor,1839,O
compounds,1839,O
(,1839,O
19,1839,O
",",1839,O
41,1839,O
",",1839,O
and,1839,O
47,1839,O
),1839,O
all,1839,O
had,1839,O
DHFR,1839,B-GENE-Y
IC,1839,O
(,1839,O
50,1839,O
),1839,O
values,1839,O
above,1839,O
15microM,1839,O
",",1839,O
suggesting,1839,O
that,1839,O
they,1839,O
might,1839,O
exert,1839,O
their,1839,O
antitumor,1839,O
potency,1839,O
through,1839,O
some,1839,O
other,1839,O
mode,1839,O
of,1839,O
action,1839,O
.,1839,O
Alternatively,1840,O
",",1840,O
the,1840,O
compounds,1840,O
could,1840,O
differ,1840,O
significantly,1840,O
in,1840,O
uptake,1840,O
or,1840,O
concentration,1840,O
within,1840,O
mammalian,1840,O
cells,1840,O
.,1840,O
Hyperphagia,1841,O
alters,1841,O
expression,1841,O
of,1841,O
hypothalamic,1841,O
5-HT2C,1841,B-GENE-Y
and,1841,O
5-HT1B,1841,B-GENE-Y
receptor,1841,O
genes,1841,O
and,1841,O
plasma,1841,O
des-acyl,1841,B-GENE-Y
ghrelin,1841,I-GENE-Y
levels,1841,O
in,1841,O
Ay,1841,O
mice,1841,O
.,1841,O
The,1842,O
central,1842,O
melanocortin,1842,B-GENE-Y
(,1842,O
MC,1842,B-GENE-Y
),1842,O
pathway,1842,O
is,1842,O
suggested,1842,O
to,1842,O
mediate,1842,O
satiety,1842,O
signaling,1842,O
downstream,1842,O
of,1842,O
serotonin,1842,B-GENE-Y
(,1842,I-GENE-Y
5-HT,1842,I-GENE-Y
),1842,I-GENE-Y
2C,1842,I-GENE-Y
receptors,1842,I-GENE-Y
.,1842,O
5-HT2C,1843,B-GENE-Y
receptor,1843,O
mutant,1843,O
mice,1843,O
consume,1843,O
more,1843,O
food,1843,O
",",1843,O
which,1843,O
leads,1843,O
to,1843,O
late-onset,1843,O
obesity,1843,O
and,1843,O
impaired,1843,O
glucose,1843,B-CHEMICAL
tolerance,1843,O
.,1843,O
Ay,1844,O
mice,1844,O
with,1844,O
ectopic,1844,O
expression,1844,O
of,1844,O
the,1844,O
agouti,1844,B-GENE-Y
peptide,1844,I-GENE-Y
",",1844,O
which,1844,O
leads,1844,O
to,1844,O
a,1844,O
perturbation,1844,O
of,1844,O
the,1844,O
central,1844,O
MC,1844,B-GENE-Y
pathway,1844,O
",",1844,O
develop,1844,O
obesity,1844,O
and,1844,O
diabetes,1844,O
",",1844,O
associated,1844,O
with,1844,O
low,1844,O
levels,1844,O
of,1844,O
plasma,1844,O
total,1844,O
ghrelin,1844,B-GENE-Y
.,1844,O
Here,1845,O
",",1845,O
we,1845,O
report,1845,O
that,1845,O
5-wk-old,1845,O
Ay,1845,O
mice,1845,O
consumed,1845,O
more,1845,O
food,1845,O
in,1845,O
association,1845,O
with,1845,O
decreases,1845,O
in,1845,O
levels,1845,O
of,1845,O
plasma,1845,O
des-acyl,1845,B-GENE-Y
ghrelin,1845,I-GENE-Y
",",1845,O
but,1845,O
not,1845,O
active,1845,O
ghrelin,1845,B-GENE-Y
",",1845,O
and,1845,O
increases,1845,O
in,1845,O
hypothalamic,1845,O
5-HT2C,1845,B-GENE-Y
and,1845,O
5-HT1B,1845,B-GENE-Y
receptor,1845,O
gene,1845,O
expression,1845,O
compared,1845,O
with,1845,O
wild-type,1845,O
mice,1845,O
matched,1845,O
for,1845,O
age,1845,O
and,1845,O
body,1845,O
weight,1845,O
.,1845,O
These,1846,O
alterations,1846,O
were,1846,O
also,1846,O
observed,1846,O
in,1846,O
8-wk-old,1846,O
obese,1846,O
Ay,1846,O
mice,1846,O
.,1846,O
Restricted,1847,O
feeding,1847,O
significantly,1847,O
decreased,1847,O
hypothalamic,1847,O
5-HT2C,1847,B-GENE-Y
and,1847,O
5-HT1B,1847,B-GENE-Y
receptor,1847,O
gene,1847,O
expression,1847,O
in,1847,O
association,1847,O
with,1847,O
a,1847,O
reversal,1847,O
of,1847,O
the,1847,O
decreases,1847,O
in,1847,O
plasma,1847,O
des-acyl,1847,B-GENE-Y
ghrelin,1847,I-GENE-Y
levels,1847,O
in,1847,O
5-wk-old,1847,O
Ay,1847,O
mice,1847,O
.,1847,O
Moreover,1848,O
",",1848,O
restricted,1848,O
feeding,1848,O
reduced,1848,O
body,1848,O
weight,1848,O
",",1848,O
hyperinsulinemia,1848,O
",",1848,O
and,1848,O
hyperglycemia,1848,O
in,1848,O
association,1848,O
with,1848,O
increases,1848,O
in,1848,O
plasma,1848,O
des-acyl,1848,B-GENE-Y
ghrelin,1848,I-GENE-Y
levels,1848,O
in,1848,O
8-wk-old,1848,O
obese,1848,O
Ay,1848,O
mice,1848,O
.,1848,O
Administration,1849,O
of,1849,O
m-chlorophenylpiperazine,1849,B-CHEMICAL
and,1849,O
fenfluramine,1849,B-CHEMICAL
",",1849,O
both,1849,O
of,1849,O
which,1849,O
induce,1849,O
anorexic,1849,O
effects,1849,O
via,1849,O
5-HT2C,1849,B-GENE-Y
receptors,1849,O
and/or,1849,O
5-HT1B,1849,B-GENE-Y
receptors,1849,O
",",1849,O
suppressed,1849,O
food,1849,O
intake,1849,O
in,1849,O
5-,1849,O
and,1849,O
8-wk-old,1849,O
Ay,1849,O
mice,1849,O
",",1849,O
whereas,1849,O
the,1849,O
anorexic,1849,O
effects,1849,O
were,1849,O
attenuated,1849,O
in,1849,O
food-restricted,1849,O
Ay,1849,O
mice,1849,O
.,1849,O
These,1850,O
findings,1850,O
suggest,1850,O
that,1850,O
the,1850,O
agouti,1850,B-GENE-Y
peptide,1850,I-GENE-Y
down-regulates,1850,O
hypothalamic,1850,O
5-HT2C,1850,B-GENE-Y
and,1850,O
5-HT1B,1850,B-GENE-Y
receptor,1850,O
gene,1850,O
expression,1850,O
under,1850,O
restricted,1850,O
feeding,1850,O
conditions,1850,O
",",1850,O
whereas,1850,O
chronic,1850,O
hyperphagia,1850,O
increases,1850,O
the,1850,O
expression,1850,O
of,1850,O
these,1850,O
genes,1850,O
and,1850,O
decreases,1850,O
plasma,1850,O
des-acyl,1850,B-GENE-Y
ghrelin,1850,I-GENE-Y
levels,1850,O
in,1850,O
Ay,1850,O
mice,1850,O
.,1850,O
Gonadotropin-releasing,1851,B-GENE-Y
hormone,1851,I-GENE-Y
antagonist,1851,O
in,1851,O
the,1851,O
management,1851,O
of,1851,O
prostate,1851,O
cancer,1851,O
.,1851,O
Luteinizing,1852,B-GENE-Y
hormone-releasing,1852,I-GENE-Y
hormone,1852,I-GENE-Y
(,1852,O
LHRH,1852,B-GENE-Y
),1852,O
agonist,1852,O
therapy,1852,O
to,1852,O
induce,1852,O
medical,1852,O
castration,1852,O
has,1852,O
become,1852,O
the,1852,O
most,1852,O
common,1852,O
form,1852,O
of,1852,O
hormonal,1852,O
therapy,1852,O
for,1852,O
advanced,1852,O
and,1852,O
metastatic,1852,O
prostate,1852,O
cancer,1852,O
.,1852,O
When,1853,O
treatment,1853,O
is,1853,O
started,1853,O
",",1853,O
LHRH,1853,B-GENE-Y
agonists,1853,O
initially,1853,O
stimulate,1853,O
the,1853,O
release,1853,O
of,1853,O
LH,1853,B-GENE-N
",",1853,O
causing,1853,O
a,1853,O
surge,1853,O
in,1853,O
serum,1853,O
testosterone,1853,B-CHEMICAL
that,1853,O
can,1853,O
precipitate,1853,O
a,1853,O
``,1853,O
flare,1853,O
'',1853,O
phenomenon,1853,O
or,1853,O
worsening,1853,O
of,1853,O
disease,1853,O
",",1853,O
particularly,1853,O
in,1853,O
patients,1853,O
with,1853,O
bone,1853,O
metastatic,1853,O
disease,1853,O
.,1853,O
Gonadotropin-releasing,1854,B-GENE-Y
hormone,1854,I-GENE-Y
(,1854,I-GENE-Y
GnRH,1854,I-GENE-Y
),1854,I-GENE-Y
receptor,1854,I-GENE-Y
antagonism,1854,O
represents,1854,O
a,1854,O
newer,1854,O
approach,1854,O
to,1854,O
medical,1854,O
castration,1854,O
.,1854,O
Abarelix,1855,O
is,1855,O
a,1855,O
pure,1855,O
GnRH,1855,B-GENE-Y
receptor,1855,I-GENE-Y
antagonist,1855,O
that,1855,O
is,1855,O
devoid,1855,O
of,1855,O
any,1855,O
LHRH,1855,B-GENE-Y
agonist,1855,O
activity,1855,O
.,1855,O
Results,1856,O
from,1856,O
1,1856,O
phase,1856,O
II,1856,O
and,1856,O
3,1856,O
phase,1856,O
III,1856,O
clinical,1856,O
trials,1856,O
demonstrate,1856,O
that,1856,O
abarelix,1856,O
produces,1856,O
medical,1856,O
castration,1856,O
more,1856,O
quickly,1856,O
and,1856,O
without,1856,O
causing,1856,O
testosterone,1856,B-CHEMICAL
surge,1856,O
",",1856,O
as,1856,O
compared,1856,O
with,1856,O
LHRH,1856,B-GENE-Y
agonists,1856,O
with,1856,O
or,1856,O
without,1856,O
a,1856,O
nonsteroidal,1856,O
antagonist,1856,O
.,1856,O
The,1857,O
safety,1857,O
profile,1857,O
in,1857,O
terms,1857,O
of,1857,O
adverse,1857,O
events,1857,O
is,1857,O
comparable,1857,O
between,1857,O
the,1857,O
2,1857,O
types,1857,O
of,1857,O
treatment,1857,O
",",1857,O
but,1857,O
the,1857,O
lack,1857,O
of,1857,O
testosterone,1857,B-CHEMICAL
surge,1857,O
with,1857,O
abarelix,1857,O
might,1857,O
confer,1857,O
a,1857,O
safety,1857,O
advantage,1857,O
by,1857,O
abolishing,1857,O
the,1857,O
risk,1857,O
of,1857,O
a,1857,O
disease,1857,O
flare,1857,O
.,1857,O
Diet,1858,O
and,1858,O
gene,1858,O
expression,1858,O
:,1858,O
delta-5,1858,B-GENE-N
and,1858,I-GENE-N
delta-6,1858,I-GENE-N
desaturases,1858,I-GENE-N
in,1858,O
healthy,1858,O
Chinese,1858,O
and,1858,O
European,1858,O
subjects,1858,O
.,1858,O
AIM,1859,O
:,1859,O
To,1859,O
compare,1859,O
the,1859,O
composition,1859,O
of,1859,O
fatty,1859,B-CHEMICAL
acids,1859,I-CHEMICAL
(,1859,O
FAs,1859,B-CHEMICAL
),1859,O
in,1859,O
diet,1859,O
",",1859,O
and,1859,O
the,1859,O
expression,1859,O
of,1859,O
delta-6,1859,B-GENE-Y
desaturase,1859,I-GENE-Y
(,1859,O
D6D,1859,B-GENE-Y
),1859,O
and,1859,O
delta-5,1859,B-GENE-Y
desaturase,1859,I-GENE-Y
(,1859,O
D5D,1859,B-GENE-Y
),1859,O
genes,1859,O
in,1859,O
peripheral,1859,O
blood,1859,O
mononuclear,1859,O
cells,1859,O
(,1859,O
PBMCs,1859,O
),1859,O
between,1859,O
Chinese,1859,O
and,1859,O
Europeans,1859,O
.,1859,O
METHODS,1860,O
:,1860,O
Three-day,1860,O
dietary,1860,O
records,1860,O
from,1860,O
20,1860,O
subjects,1860,O
from,1860,O
Beijing,1860,O
",",1860,O
China,1860,O
(,1860,O
n,1860,O
=,1860,O
10,1860,O
),1860,O
and,1860,O
Kent,1860,O
",",1860,O
UK,1860,O
(,1860,O
n,1860,O
=,1860,O
10,1860,O
),1860,O
were,1860,O
analysed,1860,O
.,1860,O
Expression,1861,O
of,1861,O
PBMC,1861,O
D6D,1861,B-GENE-Y
and,1861,O
D5D,1861,B-GENE-Y
genes,1861,O
of,1861,O
the,1861,O
subjects,1861,O
was,1861,O
determined,1861,O
using,1861,O
RT-PCR,1861,O
.,1861,O
RESULTS,1862,O
:,1862,O
The,1862,O
dietary,1862,O
intake,1862,O
of,1862,O
Chinese,1862,O
subjects,1862,O
contained,1862,O
less,1862,O
saturated,1862,B-CHEMICAL
fatty,1862,I-CHEMICAL
acids,1862,I-CHEMICAL
(,1862,O
SFAs,1862,B-CHEMICAL
),1862,O
and,1862,O
monounsaturated,1862,B-CHEMICAL
fatty,1862,I-CHEMICAL
acids,1862,I-CHEMICAL
(,1862,O
MUFAs,1862,B-CHEMICAL
),1862,O
",",1862,O
but,1862,O
more,1862,O
essential,1862,B-CHEMICAL
fatty,1862,I-CHEMICAL
acids,1862,I-CHEMICAL
(,1862,O
EFAs,1862,B-CHEMICAL
),1862,O
than,1862,O
that,1862,O
of,1862,O
Europeans,1862,O
.,1862,O
Levels,1863,O
of,1863,O
expression,1863,O
of,1863,O
PBMC,1863,O
D6D,1863,B-GENE-Y
and,1863,O
D5D,1863,B-GENE-Y
genes,1863,O
of,1863,O
Chinese,1863,O
subjects,1863,O
were,1863,O
significantly,1863,O
lower,1863,O
than,1863,O
those,1863,O
of,1863,O
Europeans,1863,O
.,1863,O
A,1864,O
significant,1864,O
positive,1864,O
correlation,1864,O
was,1864,O
found,1864,O
between,1864,O
dietary,1864,O
intake,1864,O
of,1864,O
total,1864,O
SFAs,1864,O
and,1864,O
total,1864,O
MUFAs,1864,O
and,1864,O
expression,1864,O
of,1864,O
PBMC,1864,O
D6D,1864,B-GENE-Y
and,1864,O
D5D,1864,B-GENE-Y
genes,1864,O
",",1864,O
but,1864,O
a,1864,O
significant,1864,O
negative,1864,O
correlation,1864,O
between,1864,O
dietary,1864,O
intake,1864,O
of,1864,O
linoleic,1864,B-CHEMICAL
acid,1864,I-CHEMICAL
(,1864,O
LA,1864,B-CHEMICAL
),1864,O
and,1864,O
alpha-linolenic,1864,B-CHEMICAL
acid,1864,I-CHEMICAL
(,1864,O
LNA,1864,B-CHEMICAL
),1864,O
and,1864,O
the,1864,O
expression,1864,O
of,1864,O
PBMC,1864,O
D6D,1864,B-GENE-Y
and,1864,O
D5D,1864,B-GENE-Y
genes,1864,O
.,1864,O
CONCLUSION,1865,O
:,1865,O
Intake,1865,O
of,1865,O
high,1865,O
SFAs,1865,B-CHEMICAL
and,1865,O
MUFAs,1865,B-CHEMICAL
appears,1865,O
to,1865,O
increase,1865,O
expression,1865,O
of,1865,O
PBMC,1865,O
D6D,1865,B-GENE-Y
and,1865,O
D5D,1865,B-GENE-Y
genes,1865,O
",",1865,O
whilst,1865,O
high,1865,O
EFAs,1865,B-CHEMICAL
intake,1865,O
appears,1865,O
to,1865,O
decrease,1865,O
expression,1865,O
of,1865,O
PBMC,1865,O
D6D,1865,B-GENE-Y
and,1865,O
D5D,1865,B-GENE-Y
genes,1865,O
.,1865,O
A,1866,O
follow-up,1866,O
study,1866,O
of,1866,O
the,1866,O
expression,1866,O
of,1866,O
D6D,1866,B-GENE-Y
and,1866,O
D5D,1866,B-GENE-Y
genes,1866,O
in,1866,O
Chinese,1866,O
who,1866,O
live,1866,O
in,1866,O
European,1866,O
countries,1866,O
with,1866,O
high,1866,O
SFA,1866,B-CHEMICAL
and,1866,O
MUFA,1866,B-CHEMICAL
diets,1866,O
would,1866,O
be,1866,O
of,1866,O
interest,1866,O
.,1866,O
The,1867,O
evolution,1867,O
of,1867,O
progesterone,1867,B-CHEMICAL
receptor,1867,I-GENE-Y
ligands,1867,O
.,1867,O
Progesterone,1868,B-CHEMICAL
is,1868,O
one,1868,O
of,1868,O
the,1868,O
first,1868,O
nuclear,1868,B-GENE-N
receptor,1868,I-GENE-N
hormones,1868,O
to,1868,O
be,1868,O
described,1868,O
functionally,1868,O
and,1868,O
subsequently,1868,O
approached,1868,O
as,1868,O
a,1868,O
drug,1868,O
target,1868,O
.,1868,O
Because,1869,O
progesterone,1869,B-CHEMICAL
(,1869,O
1,1869,O
),1869,O
affects,1869,O
both,1869,O
menstruation,1869,O
and,1869,O
gestation,1869,O
via,1869,O
the,1869,O
progesterone,1869,B-CHEMICAL
receptor,1869,I-GENE-Y
(,1869,O
PR,1869,B-GENE-Y
),1869,O
",",1869,O
research,1869,O
aimed,1869,O
at,1869,O
modulating,1869,O
its,1869,O
activity,1869,O
is,1869,O
usually,1869,O
surrounded,1869,O
by,1869,O
controversy,1869,O
.,1869,O
However,1870,O
",",1870,O
ligands,1870,O
for,1870,O
PR,1870,B-GENE-Y
were,1870,O
developed,1870,O
into,1870,O
drugs,1870,O
",",1870,O
and,1870,O
their,1870,O
evolution,1870,O
can,1870,O
be,1870,O
crudely,1870,O
divided,1870,O
into,1870,O
three,1870,O
periods,1870,O
:,1870,O
(,1870,O
1,1870,O
),1870,O
drug-like,1870,O
steroids,1870,B-CHEMICAL
that,1870,O
mimic,1870,O
the,1870,O
gestational,1870,O
properties,1870,O
of,1870,O
progesterone,1870,B-CHEMICAL
;,1870,O
(,1870,O
2,1870,O
),1870,O
drug-like,1870,O
steroids,1870,B-CHEMICAL
with,1870,O
different,1870,O
properties,1870,O
from,1870,O
progesterone,1870,B-CHEMICAL
and,1870,O
expanded,1870,O
therapeutic,1870,O
applications,1870,O
;,1870,O
and,1870,O
(,1870,O
3,1870,O
),1870,O
non-steroidal,1870,O
PR,1870,B-GENE-Y
ligands,1870,O
with,1870,O
improved,1870,O
selectivity,1870,O
and,1870,O
modulator,1870,O
properties,1870,O
and,1870,O
further,1870,O
expanded,1870,O
therapeutic,1870,O
applications,1870,O
.,1870,O
Although,1871,O
the,1871,O
latter,1871,O
have,1871,O
yet,1871,O
to,1871,O
see,1871,O
widespread,1871,O
clinical,1871,O
applications,1871,O
",",1871,O
their,1871,O
development,1871,O
is,1871,O
founded,1871,O
on,1871,O
a,1871,O
half,1871,O
century,1871,O
of,1871,O
research,1871,O
",",1871,O
and,1871,O
they,1871,O
represent,1871,O
the,1871,O
future,1871,O
for,1871,O
this,1871,O
drug,1871,O
target,1871,O
.,1871,O
Decitabine,1872,B-CHEMICAL
--,1872,O
bedside,1872,O
to,1872,O
bench,1872,O
.,1872,O
PURPOSE,1873,O
OF,1873,O
THE,1873,O
REVIEW,1873,O
:,1873,O
Epigenetic,1873,O
changes,1873,O
marked,1873,O
by,1873,O
DNA,1873,O
methylation,1873,O
are,1873,O
known,1873,O
to,1873,O
contribute,1873,O
to,1873,O
the,1873,O
malignant,1873,O
transformation,1873,O
of,1873,O
cells,1873,O
by,1873,O
silencing,1873,O
critical,1873,O
genes,1873,O
.,1873,O
Decitabine,1874,B-CHEMICAL
inhibits,1874,O
DNA,1874,B-GENE-N
methyltransferase,1874,I-GENE-N
and,1874,O
has,1874,O
shown,1874,O
therapeutic,1874,O
effects,1874,O
in,1874,O
patients,1874,O
with,1874,O
hematologic,1874,O
malignancies,1874,O
.,1874,O
However,1875,O
",",1875,O
the,1875,O
connection,1875,O
between,1875,O
the,1875,O
clinical,1875,O
activity,1875,O
of,1875,O
decitabine,1875,B-CHEMICAL
and,1875,O
its,1875,O
demethylating,1875,O
activity,1875,O
is,1875,O
not,1875,O
clear,1875,O
.,1875,O
Herein,1876,O
",",1876,O
we,1876,O
summarize,1876,O
the,1876,O
results,1876,O
of,1876,O
recent,1876,O
clinical,1876,O
trials,1876,O
of,1876,O
decitabine,1876,B-CHEMICAL
in,1876,O
hematologic,1876,O
malignancies,1876,O
",",1876,O
and,1876,O
review,1876,O
the,1876,O
translational,1876,O
research,1876,O
into,1876,O
decitabine,1876,O
's,1876,O
mechanism,1876,O
of,1876,O
clinical,1876,O
activity,1876,O
.,1876,O
RECENT,1877,O
FINDINGS,1877,O
:,1877,O
Low-dose,1877,O
decitabine,1877,B-CHEMICAL
has,1877,O
been,1877,O
studied,1877,O
recently,1877,O
in,1877,O
multiple,1877,O
clinical,1877,O
trials,1877,O
and,1877,O
has,1877,O
been,1877,O
shown,1877,O
to,1877,O
be,1877,O
effective,1877,O
for,1877,O
treatment,1877,O
of,1877,O
myelodysplastic,1877,O
syndromes,1877,O
.,1877,O
Correlative,1878,O
laboratory,1878,O
studies,1878,O
of,1878,O
clinical,1878,O
trials,1878,O
have,1878,O
shown,1878,O
that,1878,O
decitabine,1878,B-CHEMICAL
induces,1878,O
global,1878,O
hypomethylation,1878,O
as,1878,O
well,1878,O
as,1878,O
hypomethylation,1878,O
of,1878,O
gene-specific,1878,O
promoters,1878,O
and,1878,O
activation,1878,O
of,1878,O
gene,1878,O
expression,1878,O
.,1878,O
Past,1879,O
a,1879,O
given,1879,O
threshold,1879,O
",",1879,O
induction,1879,O
of,1879,O
higher,1879,O
degrees,1879,O
of,1879,O
hypomethylation,1879,O
is,1879,O
not,1879,O
directly,1879,O
associated,1879,O
with,1879,O
a,1879,O
better,1879,O
clinical,1879,O
outcome,1879,O
.,1879,O
Moreover,1880,O
",",1880,O
studies,1880,O
have,1880,O
suggested,1880,O
that,1880,O
patients,1880,O
with,1880,O
promoter,1880,O
hypermethylation,1880,O
of,1880,O
p15,1880,B-GENE-Y
(,1880,I-GENE-Y
INK4B,1880,I-GENE-Y
),1880,I-GENE-Y
at,1880,O
baseline,1880,O
have,1880,O
paradoxically,1880,O
a,1880,O
lower,1880,O
chance,1880,O
of,1880,O
achieving,1880,O
response,1880,O
than,1880,O
those,1880,O
without,1880,O
hypermethylation,1880,O
.,1880,O
Furthermore,1881,O
",",1881,O
several,1881,O
other,1881,O
genes,1881,O
activated,1881,O
by,1881,O
decitabine,1881,B-CHEMICAL
were,1881,O
independent,1881,O
of,1881,O
hypomethylation,1881,O
in,1881,O
the,1881,O
promoter,1881,O
regions,1881,O
.,1881,O
CONCLUSION,1882,O
:,1882,O
While,1882,O
at,1882,O
least,1882,O
part,1882,O
of,1882,O
decitabine,1882,O
's,1882,O
activity,1882,O
is,1882,O
through,1882,O
induction,1882,O
of,1882,O
hypomethylation,1882,O
and,1882,O
reactivation,1882,O
of,1882,O
critical,1882,O
genes,1882,O
",",1882,O
mechanisms,1882,O
independent,1882,O
from,1882,O
hypomethylation,1882,O
are,1882,O
also,1882,O
important,1882,O
for,1882,O
decitabine,1882,O
's,1882,O
antitumor,1882,O
activity,1882,O
.,1882,O
[,1883,O
Efalizumab,1883,O
],1883,O
.,1883,O
Efalizumab,1884,O
(,1884,O
Raptiva,1884,O
",",1884,O
Serono,1884,O
),1884,O
is,1884,O
a,1884,O
humanised,1884,O
monoclonal,1884,O
antibody,1884,O
(,1884,O
IgG1,1884,B-GENE-Y
),1884,O
produced,1884,O
by,1884,O
biotechnology,1884,O
.,1884,O
This,1885,O
antibody,1885,O
has,1885,O
a,1885,O
novel,1885,O
place,1885,O
among,1885,O
biotherapies,1885,O
for,1885,O
psoriasis,1885,O
.,1885,O
It,1886,O
is,1886,O
bound,1886,O
to,1886,O
the,1886,O
CD11a,1886,B-GENE-Y
subunit,1886,O
of,1886,O
a,1886,O
surface,1886,O
molecule,1886,O
of,1886,O
the,1886,O
T,1886,O
lymphocyte,1886,O
LFA-1,1886,B-GENE-N
(,1886,O
Leucocyte,1886,B-GENE-N
Function-associated,1886,I-GENE-N
Antigen-1,1886,I-GENE-N
),1886,O
.,1886,O
This,1887,O
molecule,1887,O
is,1887,O
essential,1887,O
for,1887,O
binding,1887,O
of,1887,O
T,1887,O
lymphocytes,1887,O
to,1887,O
the,1887,O
ICAM-1,1887,B-GENE-Y
molecule,1887,O
(,1887,O
Intercellular,1887,B-GENE-Y
Adhesion,1887,I-GENE-Y
Molecule-1,1887,I-GENE-Y
),1887,O
found,1887,O
on,1887,O
antigen-presenting,1887,O
cells,1887,O
",",1887,O
endothelial,1887,O
cells,1887,O
and,1887,O
keratinocytes,1887,O
.,1887,O
Binding,1888,O
of,1888,O
efalizumab,1888,O
to,1888,O
CD11a,1888,B-GENE-Y
prevents,1888,O
binding,1888,O
of,1888,O
LFA-1,1888,B-GENE-N
to,1888,O
ICAM-1,1888,B-GENE-Y
",",1888,O
thus,1888,O
inhibiting,1888,O
several,1888,O
steps,1888,O
in,1888,O
the,1888,O
immunological,1888,O
process,1888,O
responsible,1888,O
for,1888,O
formation,1888,O
of,1888,O
psoriatic,1888,O
plaque,1888,O
(,1888,O
activation,1888,O
of,1888,O
naive,1888,O
T,1888,O
lymphocytes,1888,O
to,1888,O
memory,1888,O
T,1888,O
lymphocytes,1888,O
",",1888,O
lymphocyte,1888,O
migration,1888,O
and,1888,O
reactivation,1888,O
of,1888,O
T,1888,O
lymphocytes,1888,O
in,1888,O
skin,1888,O
),1888,O
.,1888,O
Efalizumab,1889,O
was,1889,O
approved,1889,O
in,1889,O
the,1889,O
United,1889,O
States,1889,O
by,1889,O
the,1889,O
FDA,1889,O
(,1889,O
Food,1889,O
and,1889,O
Drug,1889,O
Administration,1889,O
),1889,O
in,1889,O
2003,1889,O
for,1889,O
the,1889,O
treatment,1889,O
of,1889,O
moderate-to-severe,1889,O
psoriasis,1889,O
requiring,1889,O
systemic,1889,O
therapy,1889,O
.,1889,O
It,1890,O
may,1890,O
be,1890,O
used,1890,O
as,1890,O
first-line,1890,O
therapy,1890,O
in,1890,O
the,1890,O
United,1890,O
States,1890,O
in,1890,O
this,1890,O
indication,1890,O
.,1890,O
In,1891,O
France,1891,O
",",1891,O
marketing,1891,O
authorisation,1891,O
(,1891,O
MA,1891,O
),1891,O
was,1891,O
granted,1891,O
more,1891,O
recently,1891,O
in,1891,O
September,1891,O
2005,1891,O
.,1891,O
The,1892,O
indications,1892,O
are,1892,O
moderate-to-severe,1892,O
cutaneous,1892,O
plaque,1892,O
psoriasis,1892,O
in,1892,O
adults,1892,O
in,1892,O
cases,1892,O
of,1892,O
failure,1892,O
",",1892,O
intolerance,1892,O
or,1892,O
contraindication,1892,O
of,1892,O
at,1892,O
least,1892,O
two,1892,O
systemic,1892,O
treatments,1892,O
including,1892,O
phototherapy,1892,O
",",1892,O
methotrexate,1892,B-CHEMICAL
and,1892,O
cyclosporine,1892,B-CHEMICAL
.,1892,O
Current,1893,O
clinical,1893,O
trial,1893,O
data,1893,O
is,1893,O
available,1893,O
for,1893,O
3500,1893,O
patients,1893,O
with,1893,O
plaque,1893,O
psoriasis,1893,O
.,1893,O
A,1894,O
75,1894,O
%,1894,O
improvement,1894,O
in,1894,O
PASI,1894,O
score,1894,O
was,1894,O
seen,1894,O
in,1894,O
between,1894,O
22,1894,O
and,1894,O
39,1894,O
%,1894,O
of,1894,O
patients,1894,O
treated,1894,O
with,1894,O
efalizumab,1894,O
(,1894,O
vs.,1894,O
2,1894,O
to,1894,O
5,1894,O
%,1894,O
for,1894,O
patients,1894,O
on,1894,O
placebo,1894,O
),1894,O
in,1894,O
a,1894,O
single,1894,O
weekly,1894,O
subcutaneous,1894,O
injection,1894,O
(,1894,O
1,1894,O
mg/kg,1894,O
),1894,O
.,1894,O
A,1895,O
study,1895,O
in,1895,O
good,1895,O
responders,1895,O
confirms,1895,O
the,1895,O
continuing,1895,O
long-term,1895,O
efficacy,1895,O
of,1895,O
prescription,1895,O
of,1895,O
the,1895,O
drug,1895,O
up,1895,O
to,1895,O
36,1895,O
months,1895,O
(,1895,O
with,1895,O
at,1895,O
least,1895,O
a,1895,O
75,1895,O
%,1895,O
improvement,1895,O
in,1895,O
PASI,1895,O
score,1895,O
in,1895,O
53,1895,O
%,1895,O
of,1895,O
patients,1895,O
),1895,O
.,1895,O
However,1896,O
",",1896,O
it,1896,O
is,1896,O
not,1896,O
effective,1896,O
against,1896,O
joint,1896,O
involvement,1896,O
in,1896,O
psoriasis,1896,O
.,1896,O
The,1897,O
most,1897,O
common,1897,O
side-effects,1897,O
(,1897,O
incidence,1897,O
>,1897,O
1/100,1897,O
),1897,O
are,1897,O
influenza-like,1897,O
syndrome,1897,O
",",1897,O
risk,1897,O
of,1897,O
outbreak,1897,O
of,1897,O
cutaneous,1897,O
psoriasis,1897,O
during,1897,O
or,1897,O
after,1897,O
discontinuation,1897,O
of,1897,O
treatment,1897,O
",",1897,O
worsening,1897,O
of,1897,O
arthralgia,1897,O
",",1897,O
minor,1897,O
hypersensitivity,1897,O
reactions,1897,O
",",1897,O
reversible,1897,O
changes,1897,O
in,1897,O
laboratory,1897,O
values,1897,O
(,1897,O
hyperlymphocytosis,1897,O
",",1897,O
elevated,1897,O
alkaline,1897,B-GENE-N
phosphatases,1897,I-GENE-N
and,1897,O
transaminases,1897,B-GENE-N
),1897,O
.,1897,O
Because,1898,O
of,1898,O
rare,1898,O
cases,1898,O
of,1898,O
thrombocytopenia,1898,O
(,1898,O
incidence,1898,O
<,1898,O
1/100,1898,O
),1898,O
",",1898,O
reversible,1898,O
on,1898,O
discontinuation,1898,O
of,1898,O
treatment,1898,O
",",1898,O
monthly,1898,O
monitoring,1898,O
of,1898,O
platelet,1898,O
counts,1898,O
is,1898,O
required,1898,O
over,1898,O
the,1898,O
first,1898,O
3,1898,O
months,1898,O
of,1898,O
therapy,1898,O
.,1898,O
There,1899,O
are,1899,O
currently,1899,O
no,1899,O
randomised,1899,O
studies,1899,O
comparing,1899,O
the,1899,O
various,1899,O
systemic,1899,O
treatments,1899,O
(,1899,O
standard,1899,O
therapy,1899,O
and,1899,O
biotherapy,1899,O
),1899,O
for,1899,O
psoriasis,1899,O
.,1899,O
However,1900,O
",",1900,O
on,1900,O
extrapolation,1900,O
of,1900,O
the,1900,O
available,1900,O
results,1900,O
concerning,1900,O
efficacy,1900,O
(,1900,O
PASI-75,1900,O
after,1900,O
12,1900,O
weeks,1900,O
of,1900,O
treatment,1900,O
),1900,O
",",1900,O
efalizumab,1900,O
appears,1900,O
to,1900,O
be,1900,O
less,1900,O
efficacious,1900,O
than,1900,O
anti-TNF,1900,O
alpha,1900,I-GENE-Y
agents,1900,O
.,1900,O
This,1901,O
drug,1901,O
constitutes,1901,O
an,1901,O
additional,1901,O
treatment,1901,O
option,1901,O
and,1901,O
its,1901,O
position,1901,O
in,1901,O
the,1901,O
therapeutic,1901,O
arsenal,1901,B-CHEMICAL
will,1901,O
depend,1901,O
upon,1901,O
its,1901,O
long-term,1901,O
benefit/risk,1901,O
ratio,1901,O
in,1901,O
relation,1901,O
to,1901,O
other,1901,O
biotherapies,1901,O
.,1901,O
Multiple,1902,O
pathways,1902,O
for,1902,O
cationic,1902,O
amino,1902,B-CHEMICAL
acid,1902,I-CHEMICAL
transport,1902,O
in,1902,O
rat,1902,O
seminiferous,1902,O
tubule,1902,O
cells,1902,O
.,1902,O
Arginine,1903,B-CHEMICAL
and,1903,O
ornithine,1903,B-CHEMICAL
are,1903,O
known,1903,O
to,1903,O
be,1903,O
important,1903,O
for,1903,O
various,1903,O
biological,1903,O
processes,1903,O
in,1903,O
the,1903,O
testis,1903,O
",",1903,O
but,1903,O
the,1903,O
delivery,1903,O
of,1903,O
extracellular,1903,O
cationic,1903,O
amino,1903,B-CHEMICAL
acids,1903,I-CHEMICAL
to,1903,O
the,1903,O
seminiferous,1903,O
tubule,1903,O
cells,1903,O
remains,1903,O
poorly,1903,O
understood,1903,O
.,1903,O
We,1904,O
investigated,1904,O
the,1904,O
activity,1904,O
and,1904,O
expression,1904,O
of,1904,O
cationic,1904,B-GENE-N
amino,1904,I-GENE-N
acid,1904,I-GENE-N
transporters,1904,I-GENE-N
in,1904,O
isolated,1904,O
rat,1904,O
Sertoli,1904,O
cells,1904,O
",",1904,O
peritubular,1904,O
cells,1904,O
",",1904,O
pachytene,1904,O
spermatocytes,1904,O
",",1904,O
and,1904,O
early,1904,O
spermatids,1904,O
.,1904,O
We,1905,O
assessed,1905,O
the,1905,O
l-arginine,1905,B-CHEMICAL
uptake,1905,O
kinetics,1905,O
",",1905,O
Na,1905,B-CHEMICAL
(,1905,I-CHEMICAL
+,1905,I-CHEMICAL
),1905,I-CHEMICAL
dependence,1905,O
of,1905,O
transport,1905,O
",",1905,O
profiles,1905,O
of,1905,O
cis,1905,O
inhibition,1905,O
of,1905,O
uptake,1905,O
by,1905,O
cationic,1905,O
and,1905,O
neutral,1905,O
amino,1905,B-CHEMICAL
acids,1905,I-CHEMICAL
",",1905,O
and,1905,O
sensitivity,1905,O
to,1905,O
trans,1905,O
stimulation,1905,O
of,1905,O
cationic,1905,B-GENE-N
amino,1905,I-GENE-N
acid,1905,I-GENE-N
transporters,1905,I-GENE-N
",",1905,O
and,1905,O
studied,1905,O
the,1905,O
expression,1905,O
of,1905,O
the,1905,O
genes,1905,O
encoding,1905,O
them,1905,O
by,1905,O
RT-PCR,1905,O
.,1905,O
Our,1906,O
data,1906,O
suggest,1906,O
that,1906,O
l-arginine,1906,B-CHEMICAL
is,1906,O
taken,1906,O
up,1906,O
by,1906,O
Sertoli,1906,O
cells,1906,O
and,1906,O
peritubular,1906,O
cells,1906,O
",",1906,O
principally,1906,O
via,1906,O
system,1906,O
y,1906,O
(,1906,O
+,1906,O
),1906,O
L,1906,O
(,1906,O
SLC3A2/SLC7A6,1906,B-GENE-Y
),1906,O
and,1906,O
system,1906,O
y,1906,O
(,1906,O
+,1906,O
),1906,O
(,1906,O
SLC7A1,1906,B-GENE-Y
and,1906,O
SLC7A2,1906,B-GENE-Y
),1906,O
",",1906,O
with,1906,O
system,1906,O
B,1906,O
(,1906,O
0+,1906,O
),1906,O
making,1906,O
a,1906,O
minor,1906,O
contribution,1906,O
.,1906,O
By,1907,O
contrast,1907,O
",",1907,O
system,1907,O
B,1907,O
(,1907,O
0+,1907,O
),1907,O
",",1907,O
associated,1907,O
with,1907,O
system,1907,O
y,1907,O
(,1907,O
+,1907,O
),1907,O
L,1907,O
(,1907,O
SLC3A2/SLC7A7,1907,B-GENE-Y
and,1907,O
SLC7A6,1907,B-GENE-Y
),1907,O
",",1907,O
made,1907,O
a,1907,O
major,1907,O
contribution,1907,O
to,1907,O
the,1907,O
transport,1907,O
of,1907,O
cationic,1907,O
amino,1907,B-CHEMICAL
acids,1907,I-CHEMICAL
in,1907,O
pachytene,1907,O
spermatocytes,1907,O
and,1907,O
early,1907,O
spermatids,1907,O
.,1907,O
Sertoli,1908,O
cells,1908,O
had,1908,O
higher,1908,O
rates,1908,O
of,1908,O
l-arginine,1908,B-CHEMICAL
transport,1908,O
than,1908,O
the,1908,O
other,1908,O
seminiferous,1908,O
tubule,1908,O
cells,1908,O
.,1908,O
This,1909,O
high,1909,O
efficiency,1909,O
of,1909,O
arginine,1909,B-CHEMICAL
transport,1909,O
in,1909,O
Sertoli,1909,O
cells,1909,O
and,1909,O
the,1909,O
properties,1909,O
of,1909,O
the,1909,O
y,1909,O
(,1909,O
+,1909,O
),1909,O
L,1909,O
system,1909,O
predominating,1909,O
in,1909,O
these,1909,O
cells,1909,O
strongly,1909,O
suggest,1909,O
that,1909,O
Sertoli,1909,O
cells,1909,O
play,1909,O
a,1909,O
key,1909,O
role,1909,O
in,1909,O
supplying,1909,O
germ,1909,O
cells,1909,O
with,1909,O
l-arginine,1909,B-CHEMICAL
and,1909,O
other,1909,O
cationic,1909,O
amino,1909,B-CHEMICAL
acids,1909,I-CHEMICAL
.,1909,O
Furthermore,1910,O
",",1910,O
whereas,1910,O
cytokines,1910,B-GENE-N
induce,1910,O
nitric,1910,B-CHEMICAL
oxide,1910,I-CHEMICAL
(,1910,O
NO,1910,B-CHEMICAL
),1910,O
production,1910,O
in,1910,O
peritubular,1910,O
and,1910,O
Sertoli,1910,O
cells,1910,O
",",1910,O
little,1910,O
or,1910,O
no,1910,O
upregulation,1910,O
of,1910,O
arginine,1910,B-CHEMICAL
transport,1910,O
by,1910,O
cytokines,1910,B-GENE-N
was,1910,O
observed,1910,O
in,1910,O
these,1910,O
cells,1910,O
.,1910,O
Thus,1911,O
",",1911,O
NO,1911,B-CHEMICAL
synthesis,1911,O
does,1911,O
not,1911,O
depend,1911,O
on,1911,O
the,1911,O
stimulation,1911,O
of,1911,O
arginine,1911,B-CHEMICAL
transport,1911,O
in,1911,O
these,1911,O
somatic,1911,O
tubular,1911,O
cells,1911,O
.,1911,O
Transition-state,1912,O
structure,1912,O
of,1912,O
human,1912,B-GENE-Y
5'-methylthioadenosine,1912,I-GENE-Y
phosphorylase,1912,I-GENE-Y
.,1912,O
Kinetic,1913,O
isotope,1913,O
effects,1913,O
(,1913,O
KIEs,1913,O
),1913,O
and,1913,O
computer,1913,O
modeling,1913,O
using,1913,O
density,1913,O
functional,1913,O
theory,1913,O
were,1913,O
used,1913,O
to,1913,O
approximate,1913,O
the,1913,O
transition,1913,O
state,1913,O
of,1913,O
human,1913,B-GENE-Y
5'-methylthioadenosine,1913,B-CHEMICAL
phosphorylase,1913,I-GENE-Y
(,1913,O
MTAP,1913,B-GENE-Y
),1913,O
.,1913,O
KIEs,1914,O
were,1914,O
measured,1914,O
on,1914,O
the,1914,O
arsenolysis,1914,O
of,1914,O
5'-methylthioadenosine,1914,B-CHEMICAL
(,1914,O
MTA,1914,B-CHEMICAL
),1914,O
catalyzed,1914,O
by,1914,O
MTAP,1914,B-GENE-Y
and,1914,O
were,1914,O
corrected,1914,O
for,1914,O
the,1914,O
forward,1914,O
commitment,1914,O
to,1914,O
catalysis,1914,O
.,1914,O
Intrinsic,1915,O
KIEs,1915,O
were,1915,O
obtained,1915,O
for,1915,O
[,1915,B-CHEMICAL
1'-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
H,1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
[,1915,I-CHEMICAL
1'-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
14,1915,I-CHEMICAL
),1915,I-CHEMICAL
C,1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
[,1915,I-CHEMICAL
2'-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
H,1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
[,1915,I-CHEMICAL
4'-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
H,1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
[,1915,I-CHEMICAL
5'-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
H,1915,I-CHEMICAL
(,1915,I-CHEMICAL
2,1915,I-CHEMICAL
),1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
[,1915,I-CHEMICAL
9-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
15,1915,I-CHEMICAL
),1915,I-CHEMICAL
N,1915,I-CHEMICAL
],1915,I-CHEMICAL
",",1915,I-CHEMICAL
and,1915,I-CHEMICAL
[,1915,I-CHEMICAL
Me-,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
H,1915,I-CHEMICAL
(,1915,I-CHEMICAL
3,1915,I-CHEMICAL
),1915,I-CHEMICAL
],1915,I-CHEMICAL
MTAs,1915,I-CHEMICAL
.,1915,O
The,1916,O
primary,1916,O
intrinsic,1916,O
KIEs,1916,O
(,1916,O
1'-,1916,B-CHEMICAL
(,1916,I-CHEMICAL
14,1916,I-CHEMICAL
),1916,I-CHEMICAL
C,1916,I-CHEMICAL
and,1916,O
9-,1916,B-CHEMICAL
(,1916,I-CHEMICAL
15,1916,I-CHEMICAL
),1916,I-CHEMICAL
N,1916,I-CHEMICAL
),1916,O
suggest,1916,O
that,1916,O
MTAP,1916,B-GENE-Y
has,1916,O
a,1916,O
dissociative,1916,O
S,1916,O
(,1916,O
N,1916,O
),1916,O
1,1916,O
transition,1916,O
state,1916,O
with,1916,O
its,1916,O
cationic,1916,O
center,1916,O
at,1916,O
the,1916,O
anomeric,1916,O
carbon,1916,B-CHEMICAL
and,1916,O
insignificant,1916,O
bond,1916,O
order,1916,O
to,1916,O
the,1916,O
leaving,1916,O
group,1916,O
.,1916,O
The,1917,O
9-,1917,B-CHEMICAL
(,1917,I-CHEMICAL
15,1917,I-CHEMICAL
),1917,I-CHEMICAL
N,1917,I-CHEMICAL
intrinsic,1917,O
KIE,1917,O
of,1917,O
1.039,1917,O
also,1917,O
establishes,1917,O
an,1917,O
anionic,1917,O
character,1917,O
for,1917,O
the,1917,O
adenine,1917,B-CHEMICAL
leaving,1917,O
group,1917,O
",",1917,O
whereas,1917,O
the,1917,O
alpha-primary,1917,O
1'-,1917,B-CHEMICAL
(,1917,I-CHEMICAL
14,1917,I-CHEMICAL
),1917,I-CHEMICAL
C,1917,I-CHEMICAL
KIE,1917,O
of,1917,O
1.031,1917,O
indicates,1917,O
significant,1917,O
nucleophilic,1917,O
participation,1917,O
at,1917,O
the,1917,O
transition,1917,O
state,1917,O
.,1917,O
Computational,1918,O
matching,1918,O
of,1918,O
the,1918,O
calculated,1918,O
EIEs,1918,O
to,1918,O
the,1918,O
intrinsic,1918,O
isotope,1918,O
effects,1918,O
places,1918,O
the,1918,O
oxygen,1918,B-CHEMICAL
nucleophile,1918,O
2.0,1918,O
Angstrom,1918,O
from,1918,O
the,1918,O
anomeric,1918,O
carbon,1918,B-CHEMICAL
.,1918,O
The,1919,O
4'-,1919,B-CHEMICAL
(,1919,I-CHEMICAL
3,1919,I-CHEMICAL
),1919,I-CHEMICAL
H,1919,I-CHEMICAL
KIE,1919,O
is,1919,O
sensitive,1919,O
to,1919,O
the,1919,O
polarization,1919,O
of,1919,O
the,1919,O
3'-OH,1919,B-CHEMICAL
group,1919,O
.,1919,O
Calculations,1920,O
suggest,1920,O
that,1920,O
a,1920,O
4'-,1920,B-CHEMICAL
(,1920,I-CHEMICAL
3,1920,I-CHEMICAL
),1920,I-CHEMICAL
H,1920,I-CHEMICAL
KIE,1920,O
of,1920,O
1.047,1920,O
is,1920,O
consistent,1920,O
with,1920,O
ionization,1920,O
of,1920,O
the,1920,O
3'-OH,1920,B-CHEMICAL
group,1920,O
",",1920,O
indicating,1920,O
formation,1920,O
of,1920,O
a,1920,O
zwitterion,1920,O
at,1920,O
the,1920,O
transition,1920,O
state,1920,O
.,1920,O
The,1921,O
transition,1921,O
state,1921,O
has,1921,O
cationic,1921,O
character,1921,O
at,1921,O
the,1921,O
anomeric,1921,O
carbon,1921,B-CHEMICAL
and,1921,O
is,1921,O
anionic,1921,O
at,1921,O
the,1921,O
3'-OH,1921,B-CHEMICAL
oxygen,1921,B-CHEMICAL
",",1921,O
with,1921,O
an,1921,O
anionic,1921,O
leaving,1921,O
group,1921,O
.,1921,O
The,1922,O
isotope,1922,O
effects,1922,O
predicted,1922,O
a,1922,O
3'-endo,1922,O
conformation,1922,O
for,1922,O
the,1922,O
ribosyl,1922,B-CHEMICAL
zwitterion,1922,I-CHEMICAL
",",1922,O
corresponding,1922,O
to,1922,O
a,1922,O
H1'-C1'-C2'-H2,1922,B-CHEMICAL
',1922,I-CHEMICAL
torsional,1922,O
angle,1922,O
of,1922,O
33,1922,O
degrees,1922,O
.,1922,O
The,1923,O
[,1923,O
Me-,1923,B-CHEMICAL
(,1923,I-CHEMICAL
3,1923,I-CHEMICAL
),1923,I-CHEMICAL
H,1923,I-CHEMICAL
(,1923,I-CHEMICAL
3,1923,I-CHEMICAL
),1923,I-CHEMICAL
],1923,O
and,1923,O
[,1923,O
5'-,1923,B-CHEMICAL
(,1923,I-CHEMICAL
3,1923,I-CHEMICAL
),1923,I-CHEMICAL
H,1923,I-CHEMICAL
(,1923,I-CHEMICAL
2,1923,I-CHEMICAL
),1923,I-CHEMICAL
],1923,O
KIEs,1923,O
arise,1923,O
predominantly,1923,O
from,1923,O
the,1923,O
negative,1923,O
hyperconjugation,1923,O
of,1923,O
the,1923,O
lone,1923,O
pairs,1923,O
of,1923,O
sulfur,1923,B-CHEMICAL
with,1923,O
the,1923,O
sigma,1923,O
(,1923,O
C-H,1923,B-CHEMICAL
),1923,O
antibonding,1923,O
orbitals,1923,O
.,1923,O
Human,1924,B-GENE-Y
MTAP,1924,I-GENE-Y
is,1924,O
characterized,1924,O
by,1924,O
a,1924,O
late,1924,O
S,1924,O
(,1924,O
N,1924,O
),1924,O
1,1924,O
transition,1924,O
state,1924,O
with,1924,O
significant,1924,O
participation,1924,O
of,1924,O
the,1924,O
phosphate,1924,B-CHEMICAL
nucleophile,1924,O
.,1924,O
Sequestration,1925,O
of,1925,O
retinyl,1925,B-CHEMICAL
esters,1925,I-CHEMICAL
is,1925,O
essential,1925,O
for,1925,O
retinoid,1925,O
signaling,1925,O
in,1925,O
the,1925,O
zebrafish,1925,O
embryo,1925,O
.,1925,O
For,1926,O
vertebrate,1926,O
development,1926,O
",",1926,O
vitamin,1926,B-CHEMICAL
A,1926,I-CHEMICAL
(,1926,O
all-trans,1926,B-CHEMICAL
retinol,1926,I-CHEMICAL
),1926,O
is,1926,O
required,1926,O
in,1926,O
quantitative,1926,O
different,1926,O
amounts,1926,O
and,1926,O
spatiotemporal,1926,O
distribution,1926,O
for,1926,O
the,1926,O
production,1926,O
of,1926,O
retinoic,1926,B-CHEMICAL
acid,1926,I-CHEMICAL
",",1926,O
a,1926,O
nuclear,1926,O
hormone,1926,O
receptor,1926,O
ligand,1926,O
",",1926,O
and,1926,O
11-cis,1926,B-CHEMICAL
retinal,1926,I-CHEMICAL
",",1926,O
the,1926,O
chromophore,1926,O
of,1926,O
visual,1926,O
pigments,1926,O
.,1926,O
We,1927,O
show,1927,O
here,1927,O
for,1927,O
zebrafish,1927,O
that,1927,O
embryonic,1927,O
retinoid,1927,O
homeostasis,1927,O
essentially,1927,O
depends,1927,O
on,1927,O
the,1927,O
activity,1927,O
of,1927,O
a,1927,O
leci-thin,1927,B-CHEMICAL
:,1927,I-GENE-Y
retinol,1927,B-CHEMICAL
acyltransferase,1927,I-GENE-Y
(,1927,O
Lratb,1927,B-GENE-Y
),1927,O
.,1927,O
During,1928,O
embryogenesis,1928,O
",",1928,O
lratb,1928,B-GENE-Y
is,1928,O
expressed,1928,O
in,1928,O
mostly,1928,O
non-overlapping,1928,O
domains,1928,O
opposite,1928,O
to,1928,O
retinal,1928,B-CHEMICAL
dehydrogenase,1928,I-GENE-Y
2,1928,I-GENE-Y
(,1928,O
raldh2,1928,B-GENE-Y
),1928,O
",",1928,O
the,1928,O
key,1928,O
enzyme,1928,O
for,1928,O
retinoic,1928,B-CHEMICAL
acid,1928,I-CHEMICAL
synthesis,1928,O
.,1928,O
Blocking,1929,O
retinyl,1929,B-CHEMICAL
ester,1929,I-CHEMICAL
formation,1929,O
by,1929,O
a,1929,O
targeted,1929,O
knock,1929,O
down,1929,O
of,1929,O
Lratb,1929,B-GENE-Y
results,1929,O
in,1929,O
significantly,1929,O
increased,1929,O
retinoic,1929,B-CHEMICAL
acid,1929,I-CHEMICAL
levels,1929,O
",",1929,O
which,1929,O
lead,1929,O
to,1929,O
severe,1929,O
embryonic,1929,O
patterning,1929,O
defects,1929,O
.,1929,O
Thus,1930,O
",",1930,O
we,1930,O
provide,1930,O
evidence,1930,O
that,1930,O
a,1930,O
balanced,1930,O
competition,1930,O
between,1930,O
Lratb,1930,B-GENE-Y
and,1930,O
Raldh2,1930,B-GENE-Y
for,1930,O
yolk,1930,O
vitamin,1930,B-CHEMICAL
A,1930,I-CHEMICAL
defines,1930,O
embryonic,1930,O
compartments,1930,O
either,1930,O
for,1930,O
retinyl,1930,B-CHEMICAL
ester,1930,I-CHEMICAL
or,1930,O
retinoic,1930,B-CHEMICAL
acid,1930,I-CHEMICAL
synthesis,1930,O
.,1930,O
This,1931,O
homeostatic,1931,O
mechanism,1931,O
dynamically,1931,O
adjusts,1931,O
embryonic,1931,O
retinoic,1931,B-CHEMICAL
acid,1931,I-CHEMICAL
levels,1931,O
for,1931,O
gene,1931,O
regulation,1931,O
",",1931,O
concomitantly,1931,O
sequestering,1931,O
excess,1931,O
yolk,1931,O
vitamin,1931,B-CHEMICAL
A,1931,I-CHEMICAL
in,1931,O
the,1931,O
form,1931,O
of,1931,O
retinyl,1931,O
esters,1931,O
for,1931,O
the,1931,O
establishment,1931,O
of,1931,O
larval,1931,O
vision,1931,O
later,1931,O
during,1931,O
development,1931,O
.,1931,O
A,1932,O
case,1932,O
of,1932,O
Ehlers,1932,O
Danlos,1932,O
syndrome,1932,O
type,1932,O
VI,1932,O
.,1932,O
Ehlers,1933,O
Danlos,1933,O
type,1933,O
VI,1933,O
is,1933,O
a,1933,O
rare,1933,O
autosomal,1933,O
recessive,1933,O
connective,1933,O
tissue,1933,O
disease,1933,O
involving,1933,O
primarily,1933,O
the,1933,O
skin,1933,O
and,1933,O
joints,1933,O
.,1933,O
The,1934,O
main,1934,O
feature,1934,O
of,1934,O
the,1934,O
condition,1934,O
is,1934,O
neonatal,1934,O
hypotonia,1934,O
and,1934,O
rare,1934,O
complications,1934,O
are,1934,O
ruptures,1934,O
of,1934,O
arteries,1934,O
and,1934,O
the,1934,O
eye,1934,O
globe,1934,O
.,1934,O
A,1935,O
4,1935,O
year,1935,O
old,1935,O
girl,1935,O
with,1935,O
a,1935,O
typical,1935,O
clinical,1935,O
presentation,1935,O
and,1935,O
molecular,1935,O
diagnosis,1935,O
of,1935,O
EDS,1935,O
VI,1935,O
is,1935,O
presented,1935,O
.,1935,O
Sequencing,1936,O
of,1936,O
PLOD1,1936,B-GENE-Y
gene,1936,O
revealed,1936,O
a,1936,O
homozygous,1936,O
deletion,1936,O
in,1936,O
exon,1936,O
13,1936,O
(,1936,O
c.1362delC,1936,O
),1936,O
",",1936,O
leading,1936,O
to,1936,O
a,1936,O
frameshift,1936,O
and,1936,O
truncation,1936,O
of,1936,O
the,1936,O
lysyl,1936,B-GENE-N
hydroxylase,1936,I-GENE-N
",",1936,O
an,1936,O
enzyme,1936,O
necessary,1936,O
for,1936,O
collagen,1936,B-GENE-N
biosynthesis,1936,O
.,1936,O
Early,1937,O
diagnosis,1937,O
allowed,1937,O
treatment,1937,O
with,1937,O
high,1937,O
doses,1937,O
of,1937,O
ascorbic,1937,B-CHEMICAL
acid,1937,I-CHEMICAL
in,1937,O
order,1937,O
to,1937,O
prevent,1937,O
complications,1937,O
",",1937,O
genetic,1937,O
counseling,1937,O
of,1937,O
the,1937,O
family,1937,O
and,1937,O
prenatal,1937,O
diagnosis,1937,O
of,1937,O
an,1937,O
unaffected,1937,O
embryo,1937,O
.,1937,O
Molecular,1938,O
modeling,1938,O
of,1938,O
purinergic,1938,B-GENE-N
receptor,1938,I-GENE-N
P2Y12,1938,B-GENE-Y
and,1938,O
interaction,1938,O
with,1938,O
its,1938,O
antagonists,1938,O
.,1938,O
Purinergic,1939,B-GENE-N
receptors,1939,I-GENE-N
are,1939,O
a,1939,O
class,1939,O
of,1939,O
cell,1939,O
surface,1939,O
receptors,1939,O
for,1939,O
purines,1939,B-CHEMICAL
that,1939,O
prefer,1939,O
ATP,1939,B-CHEMICAL
or,1939,O
ADP,1939,B-CHEMICAL
over,1939,O
adenosine,1939,B-CHEMICAL
.,1939,O
The,1940,O
surface,1940,O
receptors,1940,O
for,1940,O
extracellular,1940,O
nucleotides,1940,B-CHEMICAL
are,1940,O
called,1940,O
P2,1940,B-GENE-N
receptors,1940,I-GENE-N
.,1940,O
They,1941,O
are,1941,O
activated,1941,O
by,1941,O
both,1941,O
pyrimidine,1941,B-CHEMICAL
and,1941,I-CHEMICAL
purine,1941,I-CHEMICAL
nucleotides,1941,I-CHEMICAL
.,1941,O
ADP,1942,B-CHEMICAL
initiates,1942,O
platelet,1942,O
aggregation,1942,O
by,1942,O
'simultaneous,1942,O
activation,1942,O
of,1942,O
two,1942,O
G,1942,B-GENE-N
protein-coupled,1942,I-GENE-N
receptors,1942,I-GENE-N
",",1942,O
P2Y1,1942,B-GENE-Y
and,1942,O
P2Y12,1942,B-GENE-Y
.,1942,O
P2Y12,1943,B-GENE-Y
has,1943,O
been,1943,O
shown,1943,O
to,1943,O
be,1943,O
the,1943,O
target,1943,O
of,1943,O
the,1943,O
thienopyridine,1943,B-CHEMICAL
drugs,1943,O
",",1943,O
ticlopidine,1943,B-CHEMICAL
and,1943,O
clopidogrel,1943,B-CHEMICAL
.,1943,O
Here,1944,O
",",1944,O
the,1944,O
active,1944,O
sites,1944,O
of,1944,O
P2Y12,1944,B-GENE-Y
for,1944,O
ATP,1944,B-CHEMICAL
as,1944,O
well,1944,O
as,1944,O
ADP,1944,B-CHEMICAL
are,1944,O
predicted,1944,O
by,1944,O
bioinformatics,1944,O
and,1944,O
molecular,1944,O
modeling,1944,O
.,1944,O
First,1945,O
",",1945,O
the,1945,O
three-dimensional,1945,O
(,1945,O
3D,1945,O
),1945,O
structure,1945,O
of,1945,O
P2Y12,1945,B-GENE-Y
was,1945,O
constructed,1945,O
by,1945,O
InsightII/Homology,1945,O
module,1945,O
using,1945,O
the,1945,O
corresponding,1945,O
bovine,1945,B-GENE-Y
rhodopsin,1945,I-GENE-Y
(,1945,O
PDB,1945,B-GENE-Y
code,1945,I-GENE-Y
:,1945,I-GENE-Y
1HZX,1945,I-GENE-Y
),1945,O
as,1945,O
the,1945,O
template,1945,O
.,1945,O
Then,1946,O
the,1946,O
primary,1946,O
structures,1946,O
were,1946,O
optimized,1946,O
by,1946,O
energy,1946,O
minimization,1946,O
that,1946,O
has,1946,O
been,1946,O
successfully,1946,O
accepted,1946,O
by,1946,O
the,1946,O
Protein,1946,O
Data,1946,O
Bank,1946,O
(,1946,O
PDB,1946,B-GENE-Y
code,1946,I-GENE-Y
:,1946,I-GENE-Y
1VZ1,1946,I-GENE-Y
),1946,O
.,1946,O
Second,1947,O
",",1947,O
a,1947,O
simple,1947,O
scoring,1947,O
matrix,1947,O
was,1947,O
built,1947,O
up,1947,O
based,1947,O
on,1947,O
the,1947,O
analysis,1947,O
of,1947,O
13,1947,O
known,1947,O
ATP-binding,1947,B-CHEMICAL
proteins,1947,O
.,1947,O
And,1948,O
the,1948,O
most,1948,O
probable,1948,O
active,1948,O
sites,1948,O
of,1948,O
P2Y12,1948,B-GENE-Y
were,1948,O
predicted,1948,O
using,1948,O
the,1948,O
scoring,1948,O
matrix,1948,O
",",1948,O
which,1948,O
include,1948,O
three,1948,O
distant,1948,O
areas,1948,O
:,1948,O
``,1948,O
head,1948,O
area,1948,O
'',1948,O
(,1948,O
LGTGPLRTFV,1948,B-GENE-N
",",1948,O
87-96,1948,O
),1948,O
",",1948,O
``,1948,O
middle,1948,O
area,1948,O
'',1948,O
(,1948,O
VGLITNGLAM,1948,B-CHEMICAL
",",1948,O
38-47,1948,O
",",1948,O
and,1948,O
LGAKILSVVI,1948,B-CHEMICAL
",",1948,O
139-148,1948,O
),1948,O
",",1948,O
and,1948,O
``,1948,O
bottom,1948,O
area,1948,O
'',1948,O
(,1948,O
RTRGVGKVPR,1948,B-CHEMICAL
",",1948,O
222-231,1948,O
),1948,O
.,1948,O
Subsequently,1949,O
the,1949,O
structural,1949,O
model,1949,O
of,1949,O
P2Y12,1949,B-GENE-Y
was,1949,O
docked,1949,O
with,1949,O
ATP/ADP,1949,B-CHEMICAL
in,1949,O
comparison,1949,O
with,1949,O
P2Y1,1949,B-GENE-Y
(,1949,O
PDB,1949,B-GENE-Y
code,1949,I-GENE-Y
1ddd,1949,I-GENE-Y
),1949,O
.,1949,O
As,1950,O
a,1950,O
comparison,1950,O
",",1950,O
we,1950,O
docked,1950,O
its,1950,O
antagonists,1950,O
",",1950,O
such,1950,O
as,1950,O
ticlopidine,1950,B-CHEMICAL
and,1950,O
clopidogrel,1950,B-CHEMICAL
",",1950,O
to,1950,O
the,1950,O
most,1950,O
probable,1950,O
sites,1950,O
and,1950,O
calculated,1950,O
their,1950,O
intermolecular,1950,O
energy,1950,O
.,1950,O
Our,1951,O
results,1951,O
imply,1951,O
that,1951,O
P2Y12,1951,B-GENE-Y
has,1951,O
the,1951,O
potential,1951,O
to,1951,O
be,1951,O
inhibited,1951,O
by,1951,O
ADP/ATP,1951,B-CHEMICAL
analogs,1951,O
",",1951,O
and,1951,O
it,1951,O
suggests,1951,O
that,1951,O
P2Y12,1951,B-GENE-Y
acts,1951,O
as,1951,O
a,1951,O
target,1951,O
of,1951,O
new,1951,O
drugs,1951,O
that,1951,O
inhibit,1951,O
platelet,1951,O
aggregation,1951,O
.,1951,O
Cadmium,1952,B-CHEMICAL
induces,1952,O
mitogenic,1952,O
signaling,1952,O
in,1952,O
breast,1952,O
cancer,1952,O
cell,1952,O
by,1952,O
an,1952,O
ERalpha-dependent,1952,B-GENE-Y
mechanism,1952,O
.,1952,O
Breast,1953,O
cancer,1953,O
(,1953,O
BC,1953,O
),1953,O
is,1953,O
linked,1953,O
to,1953,O
estrogen,1953,O
exposure,1953,O
.,1953,O
Estradiol,1954,B-CHEMICAL
(,1954,O
E2,1954,B-CHEMICAL
),1954,O
stimulates,1954,O
BC,1954,O
cells,1954,O
proliferation,1954,O
by,1954,O
binding,1954,O
the,1954,O
estrogen,1954,B-GENE-Y
receptor,1954,I-GENE-Y
(,1954,O
ER,1954,B-GENE-Y
),1954,O
.,1954,O
Hormone-related,1955,O
cancers,1955,O
have,1955,O
been,1955,O
linked,1955,O
to,1955,O
estrogenic,1955,O
environmental,1955,O
contaminants,1955,O
.,1955,O
Cadmium,1956,B-CHEMICAL
(,1956,O
Cd,1956,B-CHEMICAL
),1956,O
a,1956,O
toxic,1956,O
pollutant,1956,O
",",1956,O
acts,1956,O
as,1956,O
estrogens,1956,O
in,1956,O
BC,1956,O
cells,1956,O
.,1956,O
Purpose,1957,O
of,1957,O
our,1957,O
study,1957,O
was,1957,O
to,1957,O
evaluate,1957,O
whether,1957,O
Cd,1957,B-CHEMICAL
regulates,1957,O
MCF-7,1957,O
cell,1957,O
proliferation,1957,O
by,1957,O
activating,1957,O
ERK1/2,1957,B-GENE-N
",",1957,O
Akt,1957,B-GENE-N
and,1957,O
PDGFRalpha,1957,B-GENE-Y
kinases,1957,B-GENE-N
.,1957,O
Cd,1958,B-CHEMICAL
increased,1958,O
cell,1958,O
proliferation,1958,O
and,1958,O
the,1958,O
ER-antagonist,1958,B-GENE-Y
ICI,1958,O
"182,780",1958,O
blunted,1958,O
it,1958,O
.,1958,O
To,1959,O
characterize,1959,O
an,1959,O
ER-dependent,1959,B-GENE-Y
mechanism,1959,O
",",1959,O
ERalpha/beta,1959,B-GENE-N
expression,1959,O
was,1959,O
evaluated,1959,O
.,1959,O
Cd,1960,B-CHEMICAL
decreased,1960,O
ERalpha,1960,B-GENE-Y
expression,1960,O
",",1960,O
but,1960,O
not,1960,O
ERbeta,1960,B-GENE-Y
.,1960,O
Cd,1961,B-CHEMICAL
also,1961,O
increased,1961,O
ERK1/2,1961,B-GENE-N
",",1961,O
Akt,1961,B-GENE-N
and,1961,O
PDGFRalpha,1961,B-GENE-Y
phosphorylation,1961,O
while,1961,O
ICI,1961,O
blocked,1961,O
it,1961,O
.,1961,O
Since,1962,O
stimulation,1962,O
of,1962,O
phosphorylation,1962,O
was,1962,O
slower,1962,O
than,1962,O
expected,1962,O
",",1962,O
c-fos,1962,B-GENE-Y
and,1962,O
c-jun,1962,B-GENE-Y
proto-oncogenes,1962,O
",",1962,O
and,1962,O
PDGFA,1962,B-GENE-Y
were,1962,O
analyzed,1962,O
.,1962,O
Cd,1963,B-CHEMICAL
rapidly,1963,O
increased,1963,O
c-jun,1963,B-GENE-N
",",1963,O
c-fos,1963,B-GENE-N
and,1963,O
PDGFA,1963,B-GENE-Y
expression,1963,O
.,1963,O
Cells,1964,O
were,1964,O
also,1964,O
co-incubated,1964,O
with,1964,O
the,1964,O
Cd,1964,B-CHEMICAL
and,1964,O
specific,1964,O
kinases,1964,B-GENE-N
inhibitors,1964,O
",",1964,O
which,1964,O
blocked,1964,O
the,1964,O
Cd-stimulated,1964,B-CHEMICAL
proliferation,1964,O
.,1964,O
In,1965,O
conclusion,1965,O
",",1965,O
our,1965,O
results,1965,O
indicate,1965,O
that,1965,O
Cd,1965,B-CHEMICAL
increases,1965,O
BC,1965,O
cell,1965,O
proliferation,1965,O
in,1965,O
vitro,1965,O
by,1965,O
stimulating,1965,O
Akt,1965,B-GENE-N
",",1965,O
ERK1/2,1965,B-GENE-N
and,1965,O
PDGFRalpha,1965,B-GENE-Y
kinases,1965,B-GENE-N
activity,1965,O
likely,1965,O
by,1965,O
activating,1965,O
c-fos,1965,B-GENE-Y
",",1965,O
c-jun,1965,B-GENE-Y
and,1965,O
PDGFA,1965,B-GENE-Y
by,1965,O
an,1965,O
ERalpha-dependent,1965,B-GENE-Y
mechanism,1965,O
.,1965,O
Gonadotropin-releasing,1966,B-GENE-Y
hormone,1966,I-GENE-Y
functionally,1966,O
antagonizes,1966,O
testosterone,1966,B-CHEMICAL
activation,1966,O
of,1966,O
the,1966,O
human,1966,B-GENE-Y
androgen,1966,I-GENE-Y
receptor,1966,I-GENE-Y
in,1966,O
prostate,1966,O
cells,1966,O
through,1966,O
focal,1966,O
adhesion,1966,O
complexes,1966,O
involving,1966,O
Hic-5,1966,B-GENE-Y
.,1966,O
Gonadotropin-releasing,1967,B-GENE-Y
hormone,1967,I-GENE-Y
(,1967,O
GnRH,1967,B-GENE-Y
),1967,O
analogs,1967,O
constitute,1967,O
the,1967,O
most,1967,O
widely,1967,O
employed,1967,O
medical,1967,O
treatment,1967,O
for,1967,O
prostatic,1967,O
cancer,1967,O
.,1967,O
The,1968,O
predominant,1968,O
mechanism,1968,O
of,1968,O
action,1968,O
is,1968,O
presumed,1968,O
to,1968,O
be,1968,O
via,1968,O
the,1968,O
inhibition,1968,O
of,1968,O
gonadotropins,1968,O
and,1968,O
resultant,1968,O
decrease,1968,O
in,1968,O
androgen,1968,O
.,1968,O
However,1969,O
",",1969,O
GnRH,1969,B-GENE-Y
analogs,1969,O
have,1969,O
also,1969,O
been,1969,O
shown,1969,O
to,1969,O
directly,1969,O
inhibit,1969,O
prostate,1969,O
cancer,1969,O
cells,1969,O
both,1969,O
in,1969,O
vitro,1969,O
and,1969,O
in,1969,O
vivo,1969,O
through,1969,O
antiproliferative,1969,O
cell,1969,O
cycle,1969,O
arrest,1969,O
and,1969,O
stimulation,1969,O
of,1969,O
apoptosis,1969,O
.,1969,O
Since,1970,O
the,1970,O
GnRH,1970,B-GENE-Y
receptor,1970,I-GENE-Y
has,1970,O
been,1970,O
shown,1970,O
to,1970,O
affect,1970,O
sex,1970,B-GENE-N
steroid,1970,I-GENE-N
hormone,1970,I-GENE-N
receptor,1970,I-GENE-N
function,1970,O
",",1970,O
we,1970,O
considered,1970,O
that,1970,O
part,1970,O
of,1970,O
GnRH,1970,B-GENE-Y
analog,1970,O
actions,1970,O
on,1970,O
prostate,1970,O
cells,1970,O
may,1970,O
be,1970,O
mediated,1970,O
through,1970,O
modulation,1970,O
of,1970,O
the,1970,O
human,1970,B-GENE-Y
androgen,1970,I-GENE-Y
receptor,1970,I-GENE-Y
.,1970,O
Using,1971,O
a,1971,O
model,1971,O
HEK293,1971,O
cell,1971,O
line,1971,O
expressing,1971,O
the,1971,O
GnRH,1971,B-GENE-Y
receptor,1971,I-GENE-Y
",",1971,O
we,1971,O
demonstrated,1971,O
a,1971,O
novel,1971,O
signalling,1971,O
pathway,1971,O
of,1971,O
the,1971,O
GnRH,1971,B-GENE-Y
receptor,1971,I-GENE-Y
that,1971,O
induces,1971,O
nuclear,1971,O
translocation,1971,O
of,1971,O
the,1971,O
androgen,1971,B-GENE-Y
receptor,1971,I-GENE-Y
that,1971,O
renders,1971,O
it,1971,O
transcriptionally,1971,O
inactive,1971,O
.,1971,O
This,1972,O
mechanism,1972,O
involves,1972,O
the,1972,O
calcium-dependent,1972,B-CHEMICAL
tyrosine,1972,B-GENE-N
kinase,1972,I-GENE-N
Pyk2,1972,B-GENE-Y
",",1972,O
the,1972,O
non-receptor,1972,B-GENE-N
tyrosine,1972,I-GENE-N
kinase,1972,I-GENE-N
c-Src,1972,B-GENE-Y
and,1972,O
the,1972,O
focal,1972,B-GENE-N
adhesion,1972,I-GENE-N
protein/steroid,1972,O
receptor,1972,I-GENE-N
co-factor,1972,I-GENE-N
",",1972,O
Hic-5,1972,B-GENE-Y
.,1972,O
In,1973,O
this,1973,O
setting,1973,O
there,1973,O
is,1973,O
a,1973,O
GnRH-induced,1973,B-GENE-Y
association,1973,O
and,1973,O
nuclear,1973,O
translocation,1973,O
of,1973,O
the,1973,O
androgen,1973,B-GENE-Y
receptor,1973,I-GENE-Y
with,1973,O
Hic-5,1973,B-GENE-Y
.,1973,O
GnRH-induced,1974,B-CHEMICAL
Pyk2,1974,B-GENE-Y
activation,1974,O
opposed,1974,O
the,1974,O
association,1974,O
of,1974,O
Hic-5,1974,B-GENE-Y
with,1974,O
androgen,1974,B-GENE-Y
receptor,1974,I-GENE-Y
as,1974,O
overexpression,1974,O
of,1974,O
a,1974,O
dominant,1974,O
negative,1974,O
Pyk2,1974,B-GENE-Y
enhanced,1974,O
the,1974,O
GnRH-induced,1974,B-CHEMICAL
nuclear,1974,O
translocation,1974,O
of,1974,O
a,1974,O
green,1974,O
fluorescent,1974,O
protein-tagged,1974,O
human,1974,B-GENE-Y
androgen,1974,I-GENE-Y
receptor,1974,I-GENE-Y
.,1974,O
GnRH-induced,1975,B-CHEMICAL
c-Src,1975,B-GENE-Y
activation,1975,O
resulted,1975,O
in,1975,O
the,1975,O
phosphorylation,1975,O
of,1975,O
expressed,1975,O
Hic-5,1975,B-GENE-Y
and,1975,O
promoted,1975,O
its,1975,O
association,1975,O
with,1975,O
the,1975,O
human,1975,B-GENE-Y
androgen,1975,I-GENE-Y
receptor,1975,I-GENE-Y
.,1975,O
In,1976,O
contrast,1976,O
to,1976,O
testosterone,1976,B-CHEMICAL
",",1976,O
GnRH-induced,1976,B-CHEMICAL
nuclear,1976,O
translocation,1976,O
did,1976,O
not,1976,O
transcriptionally,1976,O
activate,1976,O
the,1976,O
androgen,1976,B-GENE-Y
receptor,1976,I-GENE-Y
.,1976,O
We,1977,O
then,1977,O
demonstrated,1977,O
that,1977,O
GnRH,1977,B-CHEMICAL
can,1977,O
also,1977,O
stimulate,1977,O
androgen,1977,B-GENE-Y
receptor,1977,I-GENE-Y
mobilization,1977,O
in,1977,O
human,1977,O
prostate,1977,O
PC3,1977,O
",",1977,O
BPH-1,1977,O
and,1977,O
LNCaP,1977,O
cells,1977,O
",",1977,O
and,1977,O
in,1977,O
cultured,1977,O
rat,1977,O
ventral,1977,O
prostate,1977,O
cells,1977,O
through,1977,O
the,1977,O
same,1977,O
mechanism,1977,O
.,1977,O
To,1978,O
determine,1978,O
if,1978,O
GnRH,1978,B-CHEMICAL
could,1978,O
antagonize,1978,O
androgen,1978,O
effects,1978,O
in,1978,O
normal,1978,O
tissue,1978,O
",",1978,O
we,1978,O
examined,1978,O
the,1978,O
effect,1978,O
of,1978,O
GnRH,1978,B-GENE-Y
on,1978,O
rat,1978,O
ventral,1978,O
prostate,1978,O
organ,1978,O
cultures,1978,O
and,1978,O
demonstrated,1978,O
that,1978,O
GnRH,1978,B-GENE-Y
can,1978,O
functionally,1978,O
antagonize,1978,O
the,1978,O
actions,1978,O
of,1978,O
testosterone,1978,B-CHEMICAL
on,1978,O
prostate,1978,O
cell,1978,O
proliferation,1978,O
and,1978,O
tissue,1978,O
growth,1978,O
.,1978,O
This,1979,O
antagonism,1979,O
of,1979,O
testosterone,1979,B-CHEMICAL
action,1979,O
by,1979,O
GnRH,1979,B-GENE-Y
may,1979,O
underlie,1979,O
in,1979,O
part,1979,O
the,1979,O
capacity,1979,O
of,1979,O
GnRH,1979,B-GENE-Y
receptor,1979,I-GENE-Y
activation,1979,O
to,1979,O
inhibit,1979,O
prostate,1979,O
tumor,1979,O
growth,1979,O
.,1979,O
Trace,1980,B-GENE-Y
amine-associated,1980,I-GENE-Y
receptor,1980,I-GENE-Y
1,1980,I-GENE-Y
displays,1980,O
species-dependent,1980,O
stereoselectivity,1980,O
for,1980,O
isomers,1980,O
of,1980,O
methamphetamine,1980,B-CHEMICAL
",",1980,O
amphetamine,1980,B-CHEMICAL
",",1980,O
and,1980,O
para-hydroxyamphetamine,1980,B-CHEMICAL
.,1980,O
The,1981,O
synthetic,1981,O
amines,1981,B-CHEMICAL
methamphetamine,1981,B-CHEMICAL
(,1981,O
METH,1981,B-CHEMICAL
),1981,O
",",1981,O
amphetamine,1981,B-CHEMICAL
(,1981,O
AMPH,1981,B-CHEMICAL
),1981,O
",",1981,O
and,1981,O
their,1981,O
metabolite,1981,O
para-hydroxyamphetamine,1981,B-CHEMICAL
(,1981,O
POHA,1981,B-CHEMICAL
),1981,O
are,1981,O
chemically,1981,O
and,1981,O
structurally,1981,O
related,1981,O
to,1981,O
the,1981,O
catecholamine,1981,B-CHEMICAL
neurotransmitters,1981,O
and,1981,O
a,1981,O
small,1981,O
group,1981,O
of,1981,O
endogenous,1981,O
biogenic,1981,O
amines,1981,B-CHEMICAL
collectively,1981,O
referred,1981,O
to,1981,O
as,1981,O
the,1981,O
trace,1981,O
amines,1981,B-CHEMICAL
(,1981,O
TAs,1981,O
),1981,O
.,1981,O
Recently,1982,O
",",1982,O
it,1982,O
was,1982,O
reported,1982,O
that,1982,O
METH,1982,B-CHEMICAL
",",1982,O
AMPH,1982,B-CHEMICAL
",",1982,O
POHA,1982,B-CHEMICAL
",",1982,O
and,1982,O
the,1982,O
TAs,1982,O
para-tyramine,1982,B-CHEMICAL
(,1982,O
TYR,1982,B-CHEMICAL
),1982,O
and,1982,O
beta-phenylethylamine,1982,B-CHEMICAL
(,1982,O
PEA,1982,B-CHEMICAL
),1982,O
stimulate,1982,O
cAMP,1982,B-CHEMICAL
production,1982,O
in,1982,O
human,1982,O
embryonic,1982,O
kidney,1982,O
(,1982,O
HEK,1982,O
),1982,O
-293,1982,O
cells,1982,O
expressing,1982,O
rat,1982,B-GENE-Y
trace,1982,I-GENE-Y
amine-associated,1982,I-GENE-Y
receptor,1982,I-GENE-Y
1,1982,I-GENE-Y
(,1982,O
rTAAR1,1982,B-GENE-Y
),1982,O
.,1982,O
The,1983,O
discovery,1983,O
that,1983,O
METH,1983,B-CHEMICAL
and,1983,O
AMPH,1983,B-CHEMICAL
activate,1983,O
the,1983,O
rTAAR1,1983,B-GENE-Y
motivated,1983,O
us,1983,O
to,1983,O
study,1983,O
the,1983,O
effect,1983,O
of,1983,O
these,1983,O
drugs,1983,O
on,1983,O
the,1983,O
mouse,1983,B-GENE-Y
TAAR1,1983,I-GENE-Y
(,1983,O
mTAAR1,1983,B-GENE-Y
),1983,O
and,1983,O
a,1983,O
human-rat,1983,O
chimera,1983,O
(,1983,O
hrChTAAR1,1983,B-GENE-Y
),1983,O
.,1983,O
Furthermore,1984,O
",",1984,O
because,1984,O
S-,1984,O
(,1984,O
+,1984,O
),1984,O
-isomers,1984,O
of,1984,O
METH,1984,B-CHEMICAL
and,1984,O
AMPH,1984,B-CHEMICAL
are,1984,O
reported,1984,O
to,1984,O
be,1984,O
more,1984,O
potent,1984,O
and,1984,O
efficacious,1984,O
in,1984,O
vivo,1984,O
than,1984,O
R-,1984,O
(,1984,O
-,1984,O
),1984,O
",",1984,O
we,1984,O
determined,1984,O
the,1984,O
enantiomeric,1984,O
selectivity,1984,O
of,1984,O
all,1984,O
three,1984,O
species,1984,O
of,1984,O
TAAR1,1984,B-GENE-Y
.,1984,O
In,1985,O
response,1985,O
to,1985,O
METH,1985,B-CHEMICAL
",",1985,O
AMPH,1985,B-CHEMICAL
",",1985,O
or,1985,O
POHA,1985,B-CHEMICAL
exposure,1985,O
",",1985,O
the,1985,O
accumulation,1985,O
of,1985,O
cAMP,1985,B-CHEMICAL
by,1985,O
HEK-293,1985,O
cells,1985,O
stably,1985,O
expressing,1985,O
different,1985,O
species,1985,O
of,1985,O
TAAR1,1985,B-GENE-Y
was,1985,O
concentration-,1985,O
and,1985,O
isomer-dependent,1985,O
.,1985,O
EC50,1986,O
values,1986,O
for,1986,O
S-,1986,B-CHEMICAL
(,1986,I-CHEMICAL
+,1986,I-CHEMICAL
),1986,I-CHEMICAL
-METH,1986,I-CHEMICAL
were,1986,O
0.89,1986,O
",",1986,O
0.92,1986,O
",",1986,O
and,1986,O
4.44,1986,O
microM,1986,O
for,1986,O
rTAAR1,1986,B-GENE-Y
",",1986,O
mTAAR1,1986,B-GENE-Y
",",1986,O
and,1986,O
h-rChTAAR1,1986,B-GENE-Y
",",1986,O
respectively,1986,O
.,1986,O
PEA,1987,B-CHEMICAL
was,1987,O
a,1987,O
potent,1987,O
and,1987,O
full,1987,O
agonist,1987,O
at,1987,O
each,1987,O
species,1987,O
of,1987,O
TAAR1,1987,B-GENE-Y
",",1987,O
whereas,1987,O
TYR,1987,B-CHEMICAL
was,1987,O
a,1987,O
full,1987,O
agonist,1987,O
for,1987,O
the,1987,O
rodent,1987,B-GENE-Y
TAAR1s,1987,I-GENE-Y
but,1987,O
was,1987,O
a,1987,O
partial,1987,O
agonist,1987,O
at,1987,O
h-rChTAAR1,1987,B-GENE-Y
.,1987,O
Interestingly,1988,O
",",1988,O
both,1988,O
isomers,1988,O
of,1988,O
METH,1988,B-CHEMICAL
were,1988,O
full,1988,O
agonists,1988,O
at,1988,O
mTAAR1,1988,B-GENE-Y
and,1988,O
h-rChTAAR1,1988,B-GENE-Y
",",1988,O
whereas,1988,O
both,1988,O
were,1988,O
partial,1988,O
agonists,1988,O
at,1988,O
rTAAR1,1988,B-GENE-Y
.,1988,O
Taken,1989,O
together,1989,O
",",1989,O
these,1989,O
in,1989,O
vitro,1989,O
results,1989,O
suggest,1989,O
that,1989,O
",",1989,O
in,1989,O
vivo,1989,O
",",1989,O
TAAR1,1989,B-GENE-Y
could,1989,O
be,1989,O
a,1989,O
novel,1989,O
mediator,1989,O
of,1989,O
the,1989,O
effects,1989,O
of,1989,O
these,1989,O
drugs,1989,O
.,1989,O
Regulation,1990,O
of,1990,O
pancreatic,1990,O
endocrine,1990,O
cell,1990,O
differentiation,1990,O
by,1990,O
sulphated,1990,O
proteoglycans,1990,O
.,1990,O
AIMS/HYPOTHESIS,1991,O
:,1991,O
Epithelium-mesenchyme,1991,O
interactions,1991,O
play,1991,O
a,1991,O
major,1991,O
role,1991,O
in,1991,O
pancreas,1991,O
development,1991,O
.,1991,O
Recently,1992,O
",",1992,O
we,1992,O
demonstrated,1992,O
that,1992,O
embryonic,1992,O
pancreatic,1992,O
mesenchyme,1992,O
enhanced,1992,O
progenitor,1992,O
cell,1992,O
proliferation,1992,O
but,1992,O
inhibited,1992,O
endocrine,1992,O
cell,1992,O
differentiation,1992,O
.,1992,O
Here,1993,O
",",1993,O
we,1993,O
investigated,1993,O
the,1993,O
role,1993,O
played,1993,O
by,1993,O
sulphated,1993,O
proteoglycans,1993,O
",",1993,O
which,1993,O
are,1993,O
known,1993,O
to,1993,O
be,1993,O
essential,1993,O
to,1993,O
embryonic,1993,O
development,1993,O
",",1993,O
in,1993,O
this,1993,O
inhibitory,1993,O
effect,1993,O
.,1993,O
MATERIALS,1994,O
AND,1994,O
METHODS,1994,O
:,1994,O
We,1994,O
first,1994,O
determined,1994,O
the,1994,O
expression,1994,O
of,1994,O
the,1994,O
genes,1994,O
encoding,1994,O
glypicans,1994,B-GENE-N
",",1994,O
syndecans,1994,B-GENE-N
and,1994,O
the,1994,O
main,1994,O
glycosaminoglycan,1994,O
chain-modifying,1994,O
enzymes,1994,O
in,1994,O
immature,1994,O
embryonic,1994,O
day,1994,O
(,1994,O
E,1994,O
),1994,O
13.5,1994,O
and,1994,O
more,1994,O
differentiated,1994,O
E17.5,1994,O
rat,1994,O
pancreases,1994,O
.,1994,O
Next,1995,O
",",1995,O
using,1995,O
an,1995,O
in,1995,O
vitro,1995,O
model,1995,O
of,1995,O
pancreas,1995,O
development,1995,O
",",1995,O
we,1995,O
blocked,1995,O
the,1995,O
action,1995,O
of,1995,O
endogenous,1995,O
sulphated,1995,O
proteoglycans,1995,O
by,1995,O
treating,1995,O
embryonic,1995,O
pancreases,1995,O
in,1995,O
culture,1995,O
with,1995,O
chlorate,1995,B-CHEMICAL
",",1995,O
an,1995,O
inhibitor,1995,O
of,1995,O
proteoglycan,1995,O
sulphation,1995,O
",",1995,O
and,1995,O
examined,1995,O
the,1995,O
effects,1995,O
on,1995,O
pancreatic,1995,O
endocrine,1995,O
cell,1995,O
differentiation,1995,O
.,1995,O
RESULTS,1996,O
:,1996,O
We,1996,O
first,1996,O
showed,1996,O
that,1996,O
expression,1996,O
of,1996,O
the,1996,O
genes,1996,O
encoding,1996,O
glypicans,1996,B-GENE-N
1,1996,I-GENE-N
",",1996,I-GENE-N
2,1996,I-GENE-N
",",1996,I-GENE-N
3,1996,I-GENE-N
and,1996,I-GENE-N
5,1996,I-GENE-N
and,1996,O
heparan,1996,B-GENE-Y
sulphate,1996,B-CHEMICAL
2-sulfotransferase,1996,I-GENE-Y
decreased,1996,O
between,1996,O
E13.5,1996,O
and,1996,O
E17.5,1996,O
.,1996,O
We,1997,O
next,1997,O
found,1997,O
that,1997,O
alteration,1997,O
of,1997,O
proteoglycan,1997,O
action,1997,O
by,1997,O
chlorate,1997,B-CHEMICAL
blocked,1997,O
the,1997,O
inhibitory,1997,O
effect,1997,O
of,1997,O
the,1997,O
mesenchyme,1997,O
on,1997,O
endocrine,1997,O
differentiation,1997,O
.,1997,O
Chlorate-treated,1998,B-CHEMICAL
pancreases,1998,O
exhibited,1998,O
a,1998,O
dramatic,1998,O
increase,1998,O
in,1998,O
beta,1998,O
cell,1998,O
number,1998,O
in,1998,O
a,1998,O
dose-dependent,1998,O
manner,1998,O
(,1998,O
169-and,1998,O
375-fold,1998,O
increase,1998,O
with,1998,O
30,1998,O
mmol/l,1998,O
and,1998,O
40,1998,O
mmol/l,1998,O
chlorate,1998,B-CHEMICAL
",",1998,O
respectively,1998,O
),1998,O
and,1998,O
in,1998,O
alpha,1998,O
cell,1998,O
development,1998,O
.,1998,O
Insulin-positive,1999,B-GENE-N
cells,1999,O
that,1999,O
developed,1999,O
in,1999,O
the,1999,O
presence,1999,O
of,1999,O
chlorate,1999,B-CHEMICAL
exhibited,1999,O
a,1999,O
phenotype,1999,O
of,1999,O
mature,1999,O
cells,1999,O
with,1999,O
regard,1999,O
to,1999,O
the,1999,O
expression,1999,O
of,1999,O
the,1999,O
following,1999,O
genes,1999,O
:,1999,O
pancreatic,1999,B-GENE-Y
and,1999,I-GENE-Y
duodenal,1999,I-GENE-Y
homeobox,1999,I-GENE-Y
gene,1999,I-GENE-Y
1,1999,I-GENE-Y
(,1999,O
Pdx1,1999,B-GENE-Y
),1999,O
",",1999,O
proprotein,1999,B-GENE-Y
convertase,1999,I-GENE-Y
subtilisin/kexin,1999,I-GENE-Y
type,1999,I-GENE-Y
1,1999,I-GENE-Y
(,1999,O
Pcsk1,1999,B-GENE-Y
;,1999,O
previously,1999,O
known,1999,O
as,1999,O
pro-hormone,1999,B-GENE-Y
convertase,1999,I-GENE-Y
1/3,1999,I-GENE-Y
),1999,O
",",1999,O
proprotein,1999,B-GENE-Y
convertase,1999,I-GENE-Y
subtilisin/kexin,1999,I-GENE-Y
type,1999,I-GENE-Y
2,1999,I-GENE-Y
(,1999,O
Pcsk2,1999,B-GENE-Y
;,1999,O
previously,1999,O
known,1999,O
as,1999,O
pro-hormone,1999,B-GENE-Y
convertase,1999,I-GENE-Y
2,1999,I-GENE-Y
),1999,O
and,1999,O
solute,1999,B-GENE-Y
carrier,1999,I-GENE-Y
family,1999,I-GENE-Y
2,1999,I-GENE-Y
(,1999,I-GENE-Y
facilitated,1999,I-GENE-Y
glucose,1999,B-CHEMICAL
transporter,1999,I-GENE-Y
),1999,I-GENE-Y
",",1999,I-GENE-Y
member,1999,I-GENE-Y
2,1999,I-GENE-Y
(,1999,O
Slc2a1,1999,B-GENE-Y
;,1999,O
previously,1999,O
known,1999,O
as,1999,O
glucose,1999,B-CHEMICAL
transporter,1999,I-GENE-Y
2,1999,I-GENE-Y
),1999,O
.,1999,O
Finally,2000,O
",",2000,O
we,2000,O
showed,2000,O
that,2000,O
chlorate,2000,B-CHEMICAL
activated,2000,O
endocrine,2000,O
cell,2000,O
development,2000,O
by,2000,O
inducing,2000,O
neurogenin,2000,B-GENE-Y
3,2000,I-GENE-Y
(,2000,O
Neurog3,2000,B-GENE-Y
),2000,O
expression,2000,O
in,2000,O
early,2000,O
endocrine,2000,O
progenitor,2000,O
cells,2000,O
.,2000,O
CONCLUSIONS/INTERPRETATION,2001,O
:,2001,O
We,2001,O
demonstrated,2001,O
that,2001,O
sulphated,2001,O
proteoglycans,2001,O
control,2001,O
pancreatic,2001,O
endocrine,2001,O
cell,2001,O
differentiation,2001,O
.,2001,O
Understanding,2002,O
the,2002,O
mechanism,2002,O
by,2002,O
which,2002,O
sulphated,2002,O
proteoglycans,2002,O
affect,2002,O
beta,2002,O
cell,2002,O
development,2002,O
could,2002,O
be,2002,O
useful,2002,O
in,2002,O
the,2002,O
generation,2002,O
of,2002,O
beta,2002,O
cells,2002,O
from,2002,O
embryonic,2002,O
stem,2002,O
cells,2002,O
.,2002,O
Carbonic,2003,B-GENE-N
anhydrase,2003,I-GENE-N
inhibitors,2003,O
.,2003,O
DNA,2004,O
cloning,2004,O
",",2004,O
characterization,2004,O
",",2004,O
and,2004,O
inhibition,2004,O
studies,2004,O
of,2004,O
the,2004,O
human,2004,B-GENE-Y
secretory,2004,I-GENE-Y
isoform,2004,I-GENE-Y
VI,2004,I-GENE-Y
",",2004,O
a,2004,O
new,2004,O
target,2004,O
for,2004,O
sulfonamide,2004,B-CHEMICAL
and,2004,O
sulfamate,2004,B-CHEMICAL
inhibitors,2004,O
.,2004,O
The,2005,O
secretory,2005,O
isozyme,2005,O
of,2005,O
human,2005,B-GENE-N
carbonic,2005,I-GENE-N
anhydrase,2005,I-GENE-N
(,2005,O
hCA,2005,B-GENE-N
",",2005,O
EC,2005,B-GENE-N
4.2.1.1,2005,I-GENE-N
),2005,O
",",2005,O
hCA,2005,B-GENE-Y
VI,2005,I-GENE-Y
",",2005,O
has,2005,O
been,2005,O
cloned,2005,O
",",2005,O
expressed,2005,O
",",2005,O
and,2005,O
purified,2005,O
in,2005,O
a,2005,O
bacterial,2005,O
expression,2005,O
system,2005,O
.,2005,O
The,2006,O
kinetic,2006,O
parameters,2006,O
for,2006,O
the,2006,O
CO2,2006,B-CHEMICAL
hydration,2006,O
reaction,2006,O
proved,2006,O
hCA,2006,B-GENE-Y
VI,2006,I-GENE-Y
to,2006,O
possess,2006,O
a,2006,O
kcat,2006,O
of,2006,O
3.4,2006,O
x,2006,O
10,2006,O
(,2006,O
5,2006,O
),2006,O
s-1,2006,O
and,2006,O
kcat/KM,2006,O
of,2006,O
4.9,2006,O
x,2006,O
10,2006,O
(,2006,O
7,2006,O
),2006,O
M-1,2006,O
s-1,2006,O
(,2006,O
at,2006,O
pH,2006,O
7.5,2006,O
and,2006,O
20,2006,O
degrees,2006,O
C,2006,O
),2006,O
.,2006,O
hCA,2007,B-GENE-Y
VI,2007,I-GENE-Y
has,2007,O
a,2007,O
significant,2007,O
catalytic,2007,O
activity,2007,O
for,2007,O
the,2007,O
physiological,2007,O
reaction,2007,O
on,2007,O
the,2007,O
same,2007,O
order,2007,O
of,2007,O
magnitude,2007,O
as,2007,O
the,2007,O
ubiquitous,2007,O
isoform,2007,O
CA,2007,B-GENE-N
I,2007,I-GENE-N
or,2007,O
the,2007,O
transmembrane,2007,O
",",2007,O
tumor-associated,2007,O
isozyme,2007,O
CA,2007,B-GENE-N
IX,2007,I-GENE-N
.,2007,O
A,2008,O
series,2008,O
of,2008,O
sulfonamides,2008,B-CHEMICAL
and,2008,O
one,2008,O
sulfamate,2008,B-CHEMICAL
have,2008,O
been,2008,O
tested,2008,O
for,2008,O
their,2008,O
interaction,2008,O
with,2008,O
this,2008,O
isozyme,2008,O
.,2008,O
Simple,2009,O
benzenesulfonamides,2009,B-CHEMICAL
were,2009,O
rather,2009,O
ineffective,2009,O
hCA,2009,B-GENE-Y
VI,2009,I-GENE-Y
inhibitors,2009,O
",",2009,O
with,2009,O
inhibition,2009,O
constants,2009,O
in,2009,O
the,2009,O
range,2009,O
of,2009,O
1090-6680,2009,O
nM,2009,O
.,2009,O
Better,2010,O
inhibitors,2010,O
were,2010,O
detected,2010,O
among,2010,O
such,2010,O
derivatives,2010,O
bearing,2010,O
2-,2010,B-CHEMICAL
or,2010,I-CHEMICAL
4-amino-,2010,O
",",2010,O
4-aminomethyl-,2010,B-CHEMICAL
",",2010,O
or,2010,O
4-hydroxymethyl,2010,B-CHEMICAL
moieties,2010,O
or,2010,O
among,2010,O
halogenated,2010,O
sulfanilamides,2010,B-CHEMICAL
(,2010,O
KI,2010,O
values,2010,O
of,2010,O
608-955,2010,O
nM,2010,O
),2010,O
.,2010,O
Some,2011,O
clinically,2011,O
used,2011,O
compounds,2011,O
",",2011,O
such,2011,O
as,2011,O
acetazolamide,2011,B-CHEMICAL
",",2011,O
methazolamide,2011,B-CHEMICAL
",",2011,O
ethoxzolamide,2011,B-CHEMICAL
",",2011,O
dichlorophenamide,2011,B-CHEMICAL
",",2011,O
dorzolamide,2011,B-CHEMICAL
",",2011,O
brinzolamide,2011,B-CHEMICAL
",",2011,O
topiramate,2011,B-CHEMICAL
",",2011,O
sulpiride,2011,B-CHEMICAL
",",2011,O
and,2011,O
indisulam,2011,B-CHEMICAL
",",2011,O
or,2011,O
the,2011,O
orphan,2011,O
drug,2011,O
benzolamide,2011,B-CHEMICAL
",",2011,O
showed,2011,O
effective,2011,O
hCA,2011,B-GENE-Y
VI,2011,I-GENE-Y
inhibitory,2011,O
activity,2011,O
",",2011,O
with,2011,O
inhibition,2011,O
constants,2011,O
of,2011,O
0.8-79,2011,O
nM,2011,O
.,2011,O
The,2012,O
best,2012,O
inhibitors,2012,O
were,2012,O
brinzolamide,2012,B-CHEMICAL
and,2012,O
sulpiride,2012,B-CHEMICAL
(,2012,O
KI,2012,O
values,2012,O
of,2012,O
0.8-0.9,2012,O
nM,2012,O
),2012,O
",",2012,O
the,2012,O
latter,2012,O
compound,2012,O
being,2012,O
also,2012,O
a,2012,O
CA,2012,B-GENE-Y
VI-selective,2012,O
inhibitor,2012,O
.,2012,O
The,2013,O
metallic,2013,O
taste,2013,O
reported,2013,O
as,2013,O
a,2013,O
side,2013,O
effect,2013,O
after,2013,O
the,2013,O
treatment,2013,O
with,2013,O
systemic,2013,O
sulfonamides,2013,B-CHEMICAL
may,2013,O
be,2013,O
due,2013,O
to,2013,O
the,2013,O
inhibition,2013,O
of,2013,O
the,2013,O
salivary,2013,B-GENE-Y
CA,2013,I-GENE-Y
VI,2013,I-GENE-Y
.,2013,O
Some,2014,O
of,2014,O
the,2014,O
compounds,2014,O
investigated,2014,O
in,2014,O
this,2014,O
study,2014,O
might,2014,O
be,2014,O
used,2014,O
as,2014,O
additives,2014,O
in,2014,O
toothpastes,2014,O
for,2014,O
reducing,2014,O
the,2014,O
acidification,2014,O
produced,2014,O
by,2014,O
the,2014,O
relevant,2014,O
CO2,2014,B-CHEMICAL
hydrase,2014,O
activity,2014,O
of,2014,O
enamel,2014,O
CA,2014,B-GENE-Y
VI,2014,I-GENE-Y
",",2014,O
which,2014,O
leads,2014,O
to,2014,O
the,2014,O
formation,2014,O
of,2014,O
protons,2014,O
and,2014,O
bicarbonate,2014,B-CHEMICAL
and,2014,O
may,2014,O
have,2014,O
a,2014,O
role,2014,O
in,2014,O
cariogenesis,2014,O
.,2014,O
Role,2015,O
of,2015,O
the,2015,O
calcium,2015,B-GENE-N
modulated,2015,I-GENE-N
cyclases,2015,I-GENE-N
in,2015,O
the,2015,O
development,2015,O
of,2015,O
the,2015,O
retinal,2015,B-CHEMICAL
projections,2015,O
.,2015,O
Transmembrane,2016,O
isoforms,2016,O
of,2016,O
adenylate,2016,B-CHEMICAL
cyclases,2016,I-GENE-N
(,2016,O
AC,2016,B-GENE-N
),2016,O
integrate,2016,O
a,2016,O
wide,2016,O
variety,2016,O
of,2016,O
extracellular,2016,O
signals,2016,O
from,2016,O
neurotransmitters,2016,O
to,2016,O
morphogens,2016,O
and,2016,O
can,2016,O
also,2016,O
regulate,2016,O
cAMP,2016,B-CHEMICAL
production,2016,O
in,2016,O
response,2016,O
to,2016,O
calcium,2016,B-CHEMICAL
entry,2016,O
.,2016,O
Based,2017,O
on,2017,O
observations,2017,O
in,2017,O
the,2017,O
barrelless,2017,O
mouse,2017,O
strain,2017,O
",",2017,O
the,2017,O
Adcy1,2017,B-GENE-Y
gene,2017,O
(,2017,O
AC1,2017,B-GENE-Y
),2017,O
was,2017,O
involved,2017,O
in,2017,O
the,2017,O
segregation,2017,O
of,2017,O
binocular,2017,O
retinal,2017,B-CHEMICAL
inputs,2017,O
.,2017,O
To,2018,O
determine,2018,O
the,2018,O
potential,2018,O
role,2018,O
of,2018,O
other,2018,O
AC,2018,B-GENE-N
isoforms,2018,O
we,2018,O
localized,2018,O
the,2018,O
Adcy,2018,B-GENE-N
genes,2018,O
in,2018,O
the,2018,O
visual,2018,O
centres,2018,O
during,2018,O
development,2018,O
",",2018,O
using,2018,O
in,2018,O
situ,2018,O
hybridization,2018,O
.,2018,O
Six,2019,O
different,2019,O
AC,2019,B-GENE-N
subtypes,2019,O
were,2019,O
found,2019,O
in,2019,O
the,2019,O
developing,2019,O
retinal,2019,O
ganglion,2019,O
cell,2019,O
layer,2019,O
(,2019,O
RGC,2019,O
;,2019,O
AC1,2019,B-GENE-Y
",",2019,O
AC2,2019,B-GENE-Y
",",2019,O
AC3,2019,B-GENE-Y
",",2019,O
AC5,2019,B-GENE-Y
",",2019,O
AC8,2019,B-GENE-Y
",",2019,O
and,2019,O
AC9,2019,B-GENE-Y
),2019,O
",",2019,O
and,2019,O
three,2019,O
AC,2019,B-GENE-N
subtypes,2019,O
were,2019,O
expressed,2019,O
in,2019,O
the,2019,O
central,2019,O
brain,2019,O
targets,2019,O
",",2019,O
the,2019,O
dorsal,2019,O
lateral,2019,O
geniculate,2019,O
nucleus,2019,O
(,2019,O
AC1,2019,B-GENE-Y
and,2019,O
AC8,2019,B-GENE-Y
),2019,O
",",2019,O
the,2019,O
ventral,2019,O
lateral,2019,O
geniculate,2019,O
nucleus,2019,O
(,2019,O
AC2,2019,B-GENE-Y
and,2019,O
AC8,2019,B-GENE-Y
),2019,O
and,2019,O
the,2019,O
superior,2019,O
colliculus,2019,O
(,2019,O
AC1,2019,B-GENE-Y
",",2019,O
AC2,2019,B-GENE-Y
",",2019,O
AC8,2019,B-GENE-Y
),2019,O
.,2019,O
Using,2020,O
a,2020,O
genetic,2020,O
approach,2020,O
we,2020,O
tested,2020,O
the,2020,O
role,2020,O
of,2020,O
the,2020,O
calcium,2020,B-CHEMICAL
modulated,2020,I-GENE-N
cyclases,2020,I-GENE-N
AC1,2020,B-GENE-Y
",",2020,O
AC5,2020,B-GENE-Y
and,2020,O
AC8,2020,B-GENE-Y
for,2020,O
the,2020,O
segregation,2020,O
retinal,2020,B-CHEMICAL
fibres,2020,O
.,2020,O
Ipsilateral,2021,O
retinal,2021,B-CHEMICAL
axons,2021,O
remained,2021,O
exuberant,2021,O
in,2021,O
the,2021,O
AC1,2021,B-GENE-Y
(,2021,O
-/-,2021,O
),2021,O
mice,2021,O
",",2021,O
with,2021,O
overlapping,2021,O
retinal,2021,B-CHEMICAL
projections,2021,O
from,2021,O
both,2021,O
eyes,2021,O
in,2021,O
the,2021,O
superior,2021,O
colliculus,2021,O
and,2021,O
the,2021,O
visual,2021,O
thalamus,2021,O
.,2021,O
These,2022,O
abnormalities,2022,O
were,2022,O
similar,2022,O
to,2022,O
those,2022,O
of,2022,O
barrelless,2022,O
mouse,2022,O
mutants,2022,O
.,2022,O
No,2023,O
abnormalities,2023,O
were,2023,O
detectable,2023,O
in,2023,O
the,2023,O
AC5,2023,B-GENE-Y
(,2023,O
-/-,2023,O
),2023,O
or,2023,O
the,2023,O
AC8,2023,B-GENE-Y
(,2023,O
-/-,2023,O
),2023,O
mice,2023,O
.,2023,O
Similar,2024,O
abnormalities,2024,O
were,2024,O
noted,2024,O
in,2024,O
the,2024,O
single,2024,O
AC1,2024,B-GENE-Y
(,2024,O
-/-,2024,O
),2024,O
and,2024,O
the,2024,O
AC1/AC8,2024,B-GENE-Y
double-knockout,2024,O
mice,2024,O
(,2024,O
DKO,2024,O
),2024,O
.,2024,O
Thus,2025,O
",",2025,O
only,2025,O
AC1,2025,B-GENE-Y
is,2025,O
required,2025,O
for,2025,O
the,2025,O
maturation,2025,O
of,2025,O
the,2025,O
retinal,2025,B-CHEMICAL
axon,2025,O
terminals,2025,O
whereas,2025,O
AC5,2025,B-GENE-Y
and,2025,O
AC8,2025,B-GENE-Y
are,2025,O
not,2025,O
needed,2025,O
.,2025,O
The,2026,O
specificity,2026,O
of,2026,O
AC1,2026,B-GENE-Y
's,2026,I-GENE-Y
action,2026,O
is,2026,O
linked,2026,O
to,2026,O
its,2026,O
cellular,2026,O
localization,2026,O
in,2026,O
the,2026,O
RGCs,2026,O
and,2026,O
to,2026,O
its,2026,O
distinctive,2026,O
functional,2026,O
profile,2026,O
",",2026,O
compared,2026,O
with,2026,O
the,2026,O
other,2026,O
cyclases,2026,B-GENE-N
expressed,2026,O
in,2026,O
the,2026,O
same,2026,O
cells,2026,O
.,2026,O
Pirfenidone,2027,B-CHEMICAL
inhibits,2027,O
TGF-beta,2027,B-GENE-Y
expression,2027,O
in,2027,O
malignant,2027,O
glioma,2027,O
cells,2027,O
.,2027,O
Due,2028,O
to,2028,O
its,2028,O
immunosuppressive,2028,O
properties,2028,O
",",2028,O
the,2028,O
cytokine,2028,B-GENE-N
transforming,2028,B-GENE-Y
growth,2028,I-GENE-Y
factor,2028,I-GENE-Y
(,2028,I-GENE-Y
TGF,2028,I-GENE-Y
),2028,I-GENE-Y
-beta,2028,I-GENE-Y
has,2028,O
become,2028,O
a,2028,O
promising,2028,O
target,2028,O
in,2028,O
the,2028,O
experimental,2028,O
treatment,2028,O
of,2028,O
human,2028,O
malignant,2028,O
gliomas,2028,O
.,2028,O
Here,2029,O
",",2029,O
we,2029,O
report,2029,O
that,2029,O
the,2029,O
antifibrotic,2029,O
drug,2029,O
5-methyl-1-phenyl-2-,2029,B-CHEMICAL
(,2029,I-CHEMICAL
1H,2029,I-CHEMICAL
),2029,I-CHEMICAL
-pyridone,2029,I-CHEMICAL
(,2029,O
pirfenidone,2029,B-CHEMICAL
",",2029,O
PFD,2029,B-CHEMICAL
),2029,O
elicits,2029,O
growth-inhibitory,2029,O
effects,2029,O
and,2029,O
reduces,2029,O
TGF-beta2,2029,B-GENE-Y
protein,2029,O
levels,2029,O
in,2029,O
human,2029,O
glioma,2029,O
cell,2029,O
lines,2029,O
.,2029,O
This,2030,O
reduction,2030,O
in,2030,O
TGF-beta2,2030,B-GENE-Y
is,2030,O
biologically,2030,O
relevant,2030,O
since,2030,O
PFD,2030,B-CHEMICAL
treatment,2030,O
reduces,2030,O
the,2030,O
growth,2030,O
inhibition,2030,O
of,2030,O
TGF-beta-sensitive,2030,B-GENE-Y
CCL-64,2030,O
cells,2030,O
mediated,2030,O
by,2030,O
conditioned,2030,O
media,2030,O
of,2030,O
glioma,2030,O
cells,2030,O
.,2030,O
The,2031,O
downregulation,2031,O
of,2031,O
TGF-beta,2031,B-GENE-Y
is,2031,O
mediated,2031,O
at,2031,O
multiple,2031,O
levels,2031,O
.,2031,O
PFD,2032,B-CHEMICAL
leads,2032,O
to,2032,O
a,2032,O
reduction,2032,O
of,2032,O
TGF-beta2,2032,B-GENE-Y
mRNA,2032,O
levels,2032,O
and,2032,O
of,2032,O
the,2032,O
mature,2032,O
TGF-beta2,2032,B-GENE-Y
protein,2032,O
due,2032,O
to,2032,O
decreased,2032,O
expression,2032,O
and,2032,O
direct,2032,O
inhibition,2032,O
of,2032,O
the,2032,O
TGF-beta,2032,B-GENE-Y
pro-protein,2032,B-GENE-N
convertase,2032,I-GENE-N
furin,2032,B-GENE-Y
.,2032,O
In,2033,O
addition,2033,O
",",2033,O
PFD,2033,B-CHEMICAL
reduces,2033,O
the,2033,O
protein,2033,O
levels,2033,O
of,2033,O
the,2033,O
matrix,2033,B-GENE-Y
metalloproteinase,2033,I-GENE-Y
(,2033,I-GENE-Y
MMP,2033,I-GENE-Y
),2033,I-GENE-Y
-11,2033,I-GENE-Y
",",2033,O
a,2033,O
TGF-beta,2033,B-GENE-Y
target,2033,O
gene,2033,O
and,2033,O
furin,2033,B-GENE-Y
substrate,2033,O
involved,2033,O
in,2033,O
carcinogenesis,2033,O
.,2033,O
These,2034,O
data,2034,O
define,2034,O
PFD,2034,B-CHEMICAL
or,2034,O
PFD-related,2034,B-CHEMICAL
agents,2034,O
as,2034,O
promising,2034,O
agents,2034,O
for,2034,O
human,2034,O
cancers,2034,O
associated,2034,O
with,2034,O
enhanced,2034,O
TGF-beta,2034,B-GENE-Y
activity,2034,O
.,2034,O
Human,2035,O
and,2035,O
rat,2035,O
bile,2035,B-GENE-N
acid-CoA,2035,I-GENE-N
:,2035,I-GENE-N
amino,2035,I-GENE-N
acid,2035,I-GENE-N
N-acyltransferase,2035,I-GENE-N
are,2035,O
liver-specific,2035,O
peroxisomal,2035,O
enzymes,2035,O
:,2035,O
implications,2035,O
for,2035,O
intracellular,2035,O
bile,2035,B-CHEMICAL
salt,2035,I-CHEMICAL
transport,2035,O
.,2035,O
UNLABELLED,2036,O
:,2036,O
Bile,2036,B-GENE-Y
acid-coenzyme,2036,I-GENE-Y
A,2036,I-CHEMICAL
:,2036,I-GENE-Y
amino,2036,B-CHEMICAL
acid,2036,I-CHEMICAL
N-acyltransferase,2036,B-CHEMICAL
(,2036,O
BAAT,2036,B-GENE-Y
),2036,O
is,2036,O
the,2036,O
sole,2036,O
enzyme,2036,O
responsible,2036,O
for,2036,O
conjugation,2036,O
of,2036,O
primary,2036,O
and,2036,O
secondary,2036,O
bile,2036,B-CHEMICAL
acids,2036,I-CHEMICAL
to,2036,O
taurine,2036,B-CHEMICAL
and,2036,O
glycine,2036,B-CHEMICAL
.,2036,O
Previous,2037,O
studies,2037,O
indicate,2037,O
a,2037,O
peroxisomal,2037,O
location,2037,O
of,2037,O
BAAT,2037,B-GENE-Y
in,2037,O
peroxisomes,2037,O
with,2037,O
variable,2037,O
amounts,2037,O
up,2037,O
to,2037,O
95,2037,O
%,2037,O
detected,2037,O
in,2037,O
cytosolic,2037,O
fractions,2037,O
.,2037,O
The,2038,O
absence,2038,O
or,2038,O
presence,2038,O
of,2038,O
a,2038,O
cytosolic,2038,O
pool,2038,O
of,2038,O
BAAT,2038,B-GENE-Y
has,2038,O
important,2038,O
implications,2038,O
for,2038,O
the,2038,O
intracellular,2038,O
transport,2038,O
of,2038,O
unconjugated/deconjugated,2038,O
bile,2038,B-CHEMICAL
salts,2038,I-CHEMICAL
.,2038,O
We,2039,O
used,2039,O
immunofluorescence,2039,O
microscopy,2039,O
and,2039,O
digitonin,2039,B-CHEMICAL
permeabilization,2039,O
assays,2039,O
to,2039,O
determine,2039,O
the,2039,O
subcellular,2039,O
location,2039,O
of,2039,O
endogenous,2039,O
BAAT,2039,B-GENE-N
in,2039,O
primary,2039,O
human,2039,O
and,2039,O
rat,2039,O
hepatocytes,2039,O
.,2039,O
In,2040,O
addition,2040,O
",",2040,O
green,2040,O
fluorescent,2040,O
protein,2040,O
(,2040,O
GFP,2040,O
),2040,O
-tagged,2040,O
rat,2040,B-GENE-Y
Baat,2040,I-GENE-Y
(,2040,O
rBaat,2040,B-GENE-Y
),2040,O
and,2040,O
human,2040,B-GENE-Y
BAAT,2040,I-GENE-Y
(,2040,O
hBAAT,2040,B-GENE-Y
),2040,O
were,2040,O
transiently,2040,O
expressed,2040,O
in,2040,O
primary,2040,O
rat,2040,O
hepatocytes,2040,O
and,2040,O
human,2040,O
fibroblasts,2040,O
.,2040,O
Catalase,2041,B-GENE-Y
and,2041,O
recombinant,2041,O
GFP-SKL,2041,O
and,2041,O
DsRed-SKL,2041,O
were,2041,O
used,2041,O
as,2041,O
peroxisomal,2041,O
markers,2041,O
.,2041,O
Endogenous,2042,O
hBAAT,2042,B-GENE-Y
and,2042,O
rBaat,2042,B-GENE-Y
were,2042,O
found,2042,O
to,2042,O
specifically,2042,O
localize,2042,O
to,2042,O
peroxisomes,2042,O
in,2042,O
human,2042,O
and,2042,O
rat,2042,O
hepatocytes,2042,O
",",2042,O
respectively,2042,O
.,2042,O
No,2043,O
significant,2043,O
cytosolic,2043,O
fraction,2043,O
was,2043,O
detected,2043,O
for,2043,O
either,2043,O
protein,2043,O
.,2043,O
GFP-tagged,2044,O
hBAAT,2044,B-GENE-Y
and,2044,O
rBaat,2044,B-GENE-Y
were,2044,O
efficiently,2044,O
sorted,2044,O
to,2044,O
peroxisomes,2044,O
of,2044,O
primary,2044,O
rat,2044,O
hepatocytes,2044,O
.,2044,O
Significant,2045,O
amounts,2045,O
of,2045,O
GFP-tagged,2045,B-GENE-N
hBAAT,2045,B-GENE-Y
or,2045,O
rBaat,2045,B-GENE-Y
were,2045,O
detected,2045,O
in,2045,O
the,2045,O
cytosol,2045,O
only,2045,O
when,2045,O
coexpressed,2045,O
with,2045,O
DsRed-SKL,2045,O
",",2045,O
suggesting,2045,O
that,2045,O
hBAAT/rBaat,2045,B-GENE-Y
and,2045,O
DsRed-SKL,2045,O
compete,2045,O
for,2045,O
the,2045,O
same,2045,O
peroxisomal,2045,O
import,2045,O
machinery,2045,O
.,2045,O
When,2046,O
expressed,2046,O
in,2046,O
fibroblasts,2046,O
",",2046,O
GFP-tagged,2046,O
hBAAT,2046,B-GENE-Y
localized,2046,O
to,2046,O
the,2046,O
cytosol,2046,O
",",2046,O
confirming,2046,O
earlier,2046,O
observations,2046,O
.,2046,O
CONCLUSION,2047,O
:,2047,O
hBAAT,2047,B-GENE-Y
and,2047,O
rBaat,2047,B-GENE-Y
are,2047,O
peroxisomal,2047,O
enzymes,2047,O
present,2047,O
in,2047,O
undetectable,2047,O
amounts,2047,O
in,2047,O
the,2047,O
cytosol,2047,O
.,2047,O
Unconjugated,2048,O
or,2048,O
deconjugated,2048,O
bile,2048,B-CHEMICAL
salts,2048,I-CHEMICAL
returning,2048,O
to,2048,O
the,2048,O
liver,2048,O
need,2048,O
to,2048,O
shuttle,2048,O
through,2048,O
the,2048,O
peroxisome,2048,O
before,2048,O
reentering,2048,O
the,2048,O
enterohepatic,2048,O
circulation,2048,O
.,2048,O
[,2049,O
Construction,2049,O
of,2049,O
the,2049,O
flavinogenic,2049,O
yeast,2049,O
Candida,2049,O
famata,2049,O
strains,2049,O
with,2049,O
high,2049,O
riboflavin,2049,B-CHEMICAL
kinase,2049,I-GENE-N
activity,2049,O
using,2049,O
gene,2049,O
engineering,2049,O
],2049,O
.,2049,O
The,2050,O
recombinant,2050,O
strains,2050,O
of,2050,O
the,2050,O
flavinogenic,2050,O
yeast,2050,O
Candida,2050,O
famata,2050,O
",",2050,O
which,2050,O
contain,2050,O
the,2050,O
DNA,2050,O
fragment,2050,O
consisting,2050,O
of,2050,O
the,2050,O
FMN1,2050,B-GENE-N
gene,2050,O
(,2050,O
encoding,2050,O
the,2050,O
riboflavin,2050,B-GENE-N
kinase,2050,I-GENE-N
",",2050,O
enzyme,2050,O
that,2050,O
converts,2050,O
riboflavin,2050,B-CHEMICAL
to,2050,O
flavinmononucleotide,2050,B-CHEMICAL
),2050,O
driven,2050,O
by,2050,O
the,2050,O
strong,2050,O
promoters,2050,O
(,2050,O
the,2050,O
regulated,2050,O
RIB1,2050,B-GENE-N
or,2050,O
constitutive,2050,O
TEF1,2050,B-GENE-N
promoter,2050,I-GENE-N
),2050,O
were,2050,O
isolated,2050,O
.,2050,O
Riboflavin,2051,B-CHEMICAL
kinase,2051,I-GENE-N
activity,2051,O
in,2051,O
the,2051,O
isolated,2051,O
transformants,2051,O
was,2051,O
tested,2051,O
.,2051,O
The,2052,O
6-8-fold,2052,O
increase,2052,O
of,2052,O
the,2052,O
riboflavin,2052,B-CHEMICAL
kinase,2052,I-GENE-N
activity,2052,O
was,2052,O
shown,2052,O
in,2052,O
the,2052,O
recombinant,2052,O
strains,2052,O
containing,2052,O
the,2052,O
integrated,2052,O
Debaryomyces,2052,B-GENE-N
hansenii,2052,I-GENE-N
FMN1,2052,I-GENE-N
gene,2052,O
under,2052,O
the,2052,O
strong,2052,O
constitutive,2052,O
TEF1,2052,B-GENE-N
promoter,2052,I-GENE-N
.,2052,O
The,2053,O
recombinant,2053,O
strains,2053,O
can,2053,O
be,2053,O
used,2053,O
for,2053,O
the,2053,O
following,2053,O
construction,2053,O
of,2053,O
flavinmononucleotide,2053,B-CHEMICAL
overproducers,2053,O
.,2053,O
The,2054,O
impact,2054,O
of,2054,O
thyroid,2054,O
activity,2054,O
variations,2054,O
on,2054,O
some,2054,O
oxidizing-stress,2054,O
parameters,2054,O
in,2054,O
rats,2054,O
.,2054,O
The,2055,O
effect,2055,O
of,2055,O
the,2055,O
thyroid,2055,O
activity,2055,O
on,2055,O
the,2055,O
formation,2055,O
of,2055,O
lipid,2055,O
peroxidation,2055,O
and,2055,O
on,2055,O
liver,2055,O
and,2055,O
heart,2055,O
antioxidant,2055,O
enzyme,2055,O
activities,2055,O
was,2055,O
investigated,2055,O
in,2055,O
Wistar,2055,O
rats,2055,O
.,2055,O
Hypothyroidism,2056,O
and,2056,O
hyperthyroidism,2056,O
conditions,2056,O
were,2056,O
induced,2056,O
for,2056,O
five,2056,O
weeks,2056,O
by,2056,O
the,2056,O
administration,2056,O
of,2056,O
0.05,2056,O
%,2056,O
benzythiouracile,2056,B-CHEMICAL
(,2056,O
BTU,2056,B-CHEMICAL
),2056,O
and,2056,O
L-thyroxine,2056,B-CHEMICAL
sodium,2056,I-CHEMICAL
salt,2056,I-CHEMICAL
(,2056,O
0.0012,2056,O
%,2056,O
),2056,O
",",2056,O
in,2056,O
drinking,2056,O
water,2056,O
",",2056,O
respectively,2056,O
.,2056,O
No,2057,O
significant,2057,O
effect,2057,O
was,2057,O
observed,2057,O
on,2057,O
the,2057,O
rates,2057,O
of,2057,O
both,2057,O
lipid,2057,O
peroxidation,2057,O
and,2057,O
the,2057,O
vitamin,2057,B-CHEMICAL
E,2057,I-CHEMICAL
in,2057,O
hepatic,2057,O
and,2057,O
cardiac,2057,O
tissues,2057,O
of,2057,O
hypothyroidism,2057,O
rats,2057,O
compared,2057,O
to,2057,O
the,2057,O
controls,2057,O
",",2057,O
contrary,2057,O
to,2057,O
the,2057,O
hyperthyroidism,2057,O
rats,2057,O
",",2057,O
which,2057,O
expressed,2057,O
a,2057,O
pronounced,2057,O
increase,2057,O
.,2057,O
The,2058,O
increased,2058,O
glutathione,2058,B-GENE-N
peroxidase,2058,I-GENE-N
activity,2058,O
in,2058,O
rats,2058,O
suffering,2058,O
from,2058,O
hyperthyroidism,2058,O
was,2058,O
associated,2058,O
with,2058,O
a,2058,O
fall,2058,O
of,2058,O
the,2058,O
reduced,2058,O
glutathione,2058,B-CHEMICAL
in,2058,O
the,2058,O
homogenate,2058,O
and,2058,O
a,2058,O
marked,2058,O
increase,2058,O
in,2058,O
the,2058,O
glutathione,2058,B-CHEMICAL
reductase,2058,I-GENE-Y
activity,2058,O
.,2058,O
An,2059,O
increase,2059,O
in,2059,O
superoxide,2059,B-CHEMICAL
dismutase,2059,O
and,2059,O
catalase,2059,O
activities,2059,O
was,2059,O
also,2059,O
recorded,2059,O
in,2059,O
hyperthyroidism,2059,O
.,2059,O
Our,2060,O
results,2060,O
explain,2060,O
the,2060,O
thyroid,2060,O
activity,2060,O
variation,2060,O
in,2060,O
relation,2060,O
to,2060,O
the,2060,O
lipid,2060,O
peroxidation,2060,O
and,2060,O
the,2060,O
tissular,2060,O
contents,2060,O
of,2060,O
the,2060,O
enzymatic,2060,O
and,2060,O
the,2060,O
non-enzymatic,2060,O
antioxidants,2060,O
.,2060,O
To,2061,O
conclude,2061,O
",",2061,O
our,2061,O
results,2061,O
show,2061,O
the,2061,O
occurrence,2061,O
of,2061,O
a,2061,O
state,2061,O
of,2061,O
oxidizing,2061,O
stress,2061,O
in,2061,O
relation,2061,O
to,2061,O
hyperthyroidism,2061,O
.,2061,O
Mechanism,2062,O
of,2062,O
the,2062,O
irreversible,2062,O
inactivation,2062,O
of,2062,O
mouse,2062,B-GENE-Y
ornithine,2062,I-GENE-Y
decarboxylase,2062,I-GENE-Y
by,2062,O
alpha-difluoromethylornithine,2062,B-CHEMICAL
.,2062,O
Characterization,2063,O
of,2063,O
sequences,2063,O
at,2063,O
the,2063,O
inhibitor,2063,O
and,2063,O
coenzyme,2063,O
binding,2063,O
sites,2063,O
.,2063,O
Mouse,2064,B-GENE-Y
ornithine,2064,I-GENE-Y
decarboxylase,2064,I-GENE-Y
(,2064,O
ODC,2064,B-GENE-Y
),2064,O
was,2064,O
expressed,2064,O
in,2064,O
Escherichia,2064,O
coli,2064,O
and,2064,O
the,2064,O
purified,2064,O
recombinant,2064,O
enzyme,2064,O
used,2064,O
for,2064,O
determination,2064,O
of,2064,O
the,2064,O
binding,2064,O
site,2064,O
for,2064,O
pyridoxal,2064,B-CHEMICAL
5'-phosphate,2064,I-CHEMICAL
and,2064,O
of,2064,O
the,2064,O
residues,2064,O
modified,2064,O
in,2064,O
the,2064,O
inactivation,2064,O
of,2064,O
the,2064,O
enzyme,2064,O
by,2064,O
the,2064,O
enzyme-activated,2064,O
irreversible,2064,O
inhibitor,2064,O
",",2064,O
alpha-difluoromethylornithine,2064,B-CHEMICAL
(,2064,O
DFMO,2064,B-CHEMICAL
),2064,O
.,2064,O
The,2065,O
pyridoxal,2065,B-CHEMICAL
5'-phosphate,2065,I-CHEMICAL
binding,2065,O
lysine,2065,B-CHEMICAL
in,2065,O
mouse,2065,B-GENE-Y
ODC,2065,I-GENE-Y
was,2065,O
identified,2065,O
as,2065,O
lysine,2065,B-CHEMICAL
69,2065,O
of,2065,O
the,2065,O
mouse,2065,O
sequence,2065,O
by,2065,O
reduction,2065,O
of,2065,O
the,2065,O
purified,2065,O
holoenzyme,2065,O
form,2065,O
with,2065,O
NaB,2065,B-CHEMICAL
[,2065,I-CHEMICAL
3H,2065,I-CHEMICAL
],2065,I-CHEMICAL
4,2065,I-CHEMICAL
followed,2065,O
by,2065,O
digestion,2065,O
of,2065,O
the,2065,O
carboxymethylated,2065,O
protein,2065,O
with,2065,O
endoproteinase,2065,B-GENE-Y
Lys-C,2065,I-GENE-Y
",",2065,O
radioactive,2065,O
peptide,2065,O
mapping,2065,O
using,2065,O
reversed-phase,2065,O
high,2065,O
pressure,2065,O
liquid,2065,O
chromatography,2065,O
and,2065,O
gas-phase,2065,O
peptide,2065,O
sequencing,2065,O
.,2065,O
This,2066,O
lysine,2066,B-CHEMICAL
is,2066,O
contained,2066,O
in,2066,O
the,2066,O
sequence,2066,O
PFYAVKC,2066,B-GENE-N
",",2066,O
which,2066,O
is,2066,O
found,2066,O
in,2066,O
all,2066,O
known,2066,O
ODCs,2066,B-GENE-N
from,2066,O
eukaryotes,2066,O
.,2066,O
The,2067,O
preceding,2067,O
amino,2067,B-CHEMICAL
acids,2067,I-CHEMICAL
do,2067,O
not,2067,O
conform,2067,O
to,2067,O
the,2067,O
consensus,2067,O
sequence,2067,O
of,2067,O
SXHK,2067,B-GENE-N
",",2067,O
which,2067,O
contains,2067,O
the,2067,O
pyridoxal,2067,B-CHEMICAL
5'-phosphate,2067,I-CHEMICAL
binding,2067,O
lysine,2067,B-CHEMICAL
in,2067,O
a,2067,O
number,2067,O
of,2067,O
other,2067,O
decarboxylases,2067,B-GENE-N
including,2067,O
ODCs,2067,B-GENE-N
from,2067,O
E.,2067,O
coli,2067,O
.,2067,O
Using,2068,O
a,2068,O
similar,2068,O
procedure,2068,O
to,2068,O
analyze,2068,O
ODC,2068,B-GENE-Y
labeled,2068,O
by,2068,O
reaction,2068,O
with,2068,O
[,2068,B-CHEMICAL
5-14C,2068,I-CHEMICAL
],2068,I-CHEMICAL
DFMO,2068,I-CHEMICAL
",",2068,O
it,2068,O
was,2068,O
found,2068,O
that,2068,O
lysine,2068,B-CHEMICAL
69,2068,O
and,2068,O
cysteine,2068,B-CHEMICAL
360,2068,O
formed,2068,O
covalent,2068,O
adducts,2068,O
with,2068,O
the,2068,O
inhibitor,2068,O
.,2068,O
Cysteine,2069,B-CHEMICAL
360,2069,O
",",2069,O
which,2069,O
was,2069,O
the,2069,O
major,2069,O
adduct,2069,O
accounting,2069,O
for,2069,O
about,2069,O
90,2069,O
%,2069,O
of,2069,O
the,2069,O
total,2069,O
labeling,2069,O
",",2069,O
is,2069,O
contained,2069,O
within,2069,O
the,2069,O
sequence,2069,O
-WGPTCDGL,2069,O
(,2069,I-CHEMICAL
I,2069,I-CHEMICAL
),2069,I-CHEMICAL
D-,2069,O
",",2069,O
which,2069,O
is,2069,O
present,2069,O
in,2069,O
all,2069,O
known,2069,O
eukaryote,2069,B-GENE-N
ODCs,2069,I-GENE-N
.,2069,O
These,2070,O
results,2070,O
provide,2070,O
strong,2070,O
evidence,2070,O
that,2070,O
these,2070,O
two,2070,O
peptides,2070,O
form,2070,O
essential,2070,O
parts,2070,O
of,2070,O
the,2070,O
catalytic,2070,O
site,2070,O
of,2070,O
ODC,2070,B-GENE-Y
.,2070,O
Analysis,2071,O
by,2071,O
fast,2071,O
atom,2071,O
bombardment-mass,2071,O
spectrometry,2071,O
of,2071,O
tryptic,2071,O
peptides,2071,O
containing,2071,O
the,2071,O
DFMO-cysteine,2071,B-CHEMICAL
adduct,2071,O
indicated,2071,O
that,2071,O
the,2071,O
adduct,2071,O
formed,2071,O
in,2071,O
the,2071,O
enzyme,2071,O
was,2071,O
probably,2071,O
the,2071,O
cyclic,2071,B-CHEMICAL
imine,2071,I-CHEMICAL
S-,2071,B-CHEMICAL
(,2071,I-CHEMICAL
2-,2071,I-CHEMICAL
(,2071,I-CHEMICAL
1-pyrroline,2071,I-CHEMICAL
),2071,I-CHEMICAL
methyl,2071,I-CHEMICAL
),2071,I-CHEMICAL
cysteine,2071,I-CHEMICAL
.,2071,O
This,2072,O
is,2072,O
readily,2072,O
oxidized,2072,O
to,2072,O
S-,2072,B-CHEMICAL
(,2072,I-CHEMICAL
(,2072,I-CHEMICAL
2-pyrrole,2072,I-CHEMICAL
),2072,I-CHEMICAL
methyl,2072,I-CHEMICAL
),2072,I-CHEMICAL
cysteine,2072,I-CHEMICAL
or,2072,O
converted,2072,O
to,2072,O
S-,2072,B-CHEMICAL
(,2072,I-CHEMICAL
(,2072,I-CHEMICAL
2-pyrrolidine,2072,I-CHEMICAL
),2072,I-CHEMICAL
methyl,2072,I-CHEMICAL
),2072,I-CHEMICAL
cysteine,2072,I-CHEMICAL
by,2072,O
NaBH4,2072,B-CHEMICAL
reduction,2072,O
.,2072,O
This,2073,O
adduct,2073,O
is,2073,O
consistent,2073,O
with,2073,O
spectral,2073,O
evidence,2073,O
showing,2073,O
that,2073,O
inactivation,2073,O
of,2073,O
the,2073,O
enzyme,2073,O
with,2073,O
DFMO,2073,B-CHEMICAL
does,2073,O
not,2073,O
entail,2073,O
the,2073,O
formation,2073,O
of,2073,O
a,2073,O
stable,2073,O
adduct,2073,O
between,2073,O
the,2073,O
pyridoxal,2073,B-CHEMICAL
5'-phosphate,2073,I-CHEMICAL
",",2073,O
the,2073,O
enzyme,2073,O
",",2073,O
and,2073,O
the,2073,O
inhibitor,2073,O
.,2073,O
Pre-steady-state,2074,O
currents,2074,O
in,2074,O
neutral,2074,B-GENE-N
amino,2074,I-GENE-N
acid,2074,I-GENE-N
transporters,2074,I-GENE-N
induced,2074,O
by,2074,O
photolysis,2074,O
of,2074,O
a,2074,O
new,2074,O
caged,2074,O
alanine,2074,B-CHEMICAL
derivative,2074,O
.,2074,O
Na+-Dependent,2075,B-CHEMICAL
transmembrane,2075,O
transport,2075,O
of,2075,O
small,2075,O
neutral,2075,O
amino,2075,B-CHEMICAL
acids,2075,I-CHEMICAL
",",2075,O
such,2075,O
as,2075,O
glutamine,2075,B-CHEMICAL
and,2075,O
alanine,2075,B-CHEMICAL
",",2075,O
is,2075,O
mediated,2075,O
",",2075,O
among,2075,O
others,2075,O
",",2075,O
by,2075,O
the,2075,O
neutral,2075,B-GENE-N
amino,2075,B-CHEMICAL
acid,2075,I-CHEMICAL
transporters,2075,I-GENE-N
of,2075,O
the,2075,O
solute,2075,B-GENE-N
carrier,2075,I-GENE-N
1,2075,I-GENE-N
[,2075,O
SLC1,2075,B-GENE-N
",",2075,O
alanine,2075,B-CHEMICAL
serine,2075,I-GENE-Y
cysteine,2075,I-GENE-Y
transporter,2075,I-GENE-Y
1,2075,I-GENE-Y
(,2075,O
ASCT1,2075,B-GENE-Y
),2075,O
",",2075,O
and,2075,O
ASCT2,2075,B-GENE-Y
],2075,O
and,2075,O
SLC38,2075,B-GENE-N
families,2075,O
[,2075,O
sodium-coupled,2075,B-GENE-Y
neutral,2075,I-GENE-Y
amino,2075,I-GENE-Y
acid,2075,I-GENE-Y
transporter,2075,I-GENE-Y
1,2075,I-GENE-Y
(,2075,O
SNAT1,2075,B-GENE-Y
),2075,O
",",2075,O
SNAT2,2075,B-GENE-Y
",",2075,O
and,2075,O
SNAT4,2075,B-GENE-Y
],2075,O
.,2075,O
Many,2076,O
mechanistic,2076,O
aspects,2076,O
of,2076,O
amino,2076,B-CHEMICAL
acid,2076,I-CHEMICAL
transport,2076,O
by,2076,O
these,2076,O
systems,2076,O
are,2076,O
not,2076,O
well-understood,2076,O
.,2076,O
Here,2077,O
",",2077,O
we,2077,O
describe,2077,O
a,2077,O
new,2077,O
photolabile,2077,O
alanine,2077,B-CHEMICAL
derivative,2077,O
based,2077,O
on,2077,O
protection,2077,O
of,2077,O
alanine,2077,B-CHEMICAL
with,2077,O
the,2077,O
4-methoxy-7-nitroindolinyl,2077,B-CHEMICAL
(,2077,O
MNI,2077,B-CHEMICAL
),2077,O
caging,2077,O
group,2077,O
",",2077,O
which,2077,O
we,2077,O
use,2077,O
for,2077,O
pre-steady-state,2077,O
kinetic,2077,O
analysis,2077,O
of,2077,O
alanine,2077,O
transport,2077,O
by,2077,O
ASCT2,2077,B-GENE-Y
",",2077,O
SNAT1,2077,B-GENE-Y
",",2077,O
and,2077,O
SNAT2,2077,B-GENE-Y
.,2077,O
MNI-alanine,2078,O
has,2078,O
favorable,2078,O
photochemical,2078,O
properties,2078,O
and,2078,O
is,2078,O
stable,2078,O
in,2078,O
aqueous,2078,O
solution,2078,O
.,2078,O
It,2079,O
is,2079,O
also,2079,O
inert,2079,O
with,2079,O
respect,2079,O
to,2079,O
the,2079,O
transport,2079,O
systems,2079,O
studied,2079,O
.,2079,O
Photolytic,2080,O
release,2080,O
of,2080,O
free,2080,O
alanine,2080,B-CHEMICAL
results,2080,O
in,2080,O
the,2080,O
generation,2080,O
of,2080,O
significant,2080,O
transient,2080,O
current,2080,O
components,2080,O
in,2080,O
HEK293,2080,O
cells,2080,O
expressing,2080,O
the,2080,O
ASCT2,2080,B-GENE-Y
",",2080,O
SNAT1,2080,B-GENE-Y
",",2080,O
and,2080,O
SNAT2,2080,B-GENE-Y
proteins,2080,O
.,2080,O
In,2081,O
ASCT2,2081,B-GENE-Y
",",2081,O
these,2081,O
currents,2081,O
show,2081,O
biphasic,2081,O
decay,2081,O
with,2081,O
time,2081,O
constants,2081,O
",",2081,O
tau,2081,O
",",2081,O
in,2081,O
the,2081,O
1-30,2081,O
ms,2081,O
time,2081,O
range,2081,O
.,2081,O
They,2082,O
are,2082,O
fully,2082,O
inhibited,2082,O
in,2082,O
the,2082,O
absence,2082,O
of,2082,O
extracellular,2082,O
Na+,2082,B-CHEMICAL
",",2082,O
demonstrating,2082,O
that,2082,O
Na+,2082,B-CHEMICAL
binding,2082,O
to,2082,O
the,2082,O
transporter,2082,O
is,2082,O
necessary,2082,O
for,2082,O
induction,2082,O
of,2082,O
the,2082,O
alanine-mediated,2082,B-CHEMICAL
current,2082,O
.,2082,O
For,2083,O
SNAT1,2083,B-GENE-Y
",",2083,O
these,2083,O
transient,2083,O
currents,2083,O
differ,2083,O
in,2083,O
their,2083,O
time,2083,O
course,2083,O
(,2083,O
tau,2083,O
=,2083,O
1.6,2083,O
ms,2083,O
),2083,O
from,2083,O
previously,2083,O
described,2083,O
pre-steady-state,2083,O
currents,2083,O
generated,2083,O
by,2083,O
applying,2083,O
steps,2083,O
in,2083,O
the,2083,O
membrane,2083,O
potential,2083,O
(,2083,O
tau,2083,O
approximately,2083,O
4-5,2083,O
ms,2083,O
),2083,O
",",2083,O
indicating,2083,O
that,2083,O
they,2083,O
are,2083,O
associated,2083,O
with,2083,O
a,2083,O
fast,2083,O
",",2083,O
previously,2083,O
undetected,2083,O
",",2083,O
electrogenic,2083,O
partial,2083,O
reaction,2083,O
in,2083,O
the,2083,O
SNAT1,2083,B-GENE-Y
transport,2083,O
cycle,2083,O
.,2083,O
The,2084,O
implications,2084,O
of,2084,O
these,2084,O
results,2084,O
for,2084,O
the,2084,O
mechanisms,2084,O
of,2084,O
transmembrane,2084,O
transport,2084,O
of,2084,O
alanine,2084,B-CHEMICAL
are,2084,O
discussed,2084,O
.,2084,O
The,2085,O
new,2085,O
caged,2085,O
alanine,2085,B-CHEMICAL
derivative,2085,O
will,2085,O
provide,2085,O
a,2085,O
useful,2085,O
tool,2085,O
for,2085,O
future,2085,O
",",2085,O
more,2085,O
detailed,2085,O
studies,2085,O
of,2085,O
neutral,2085,O
amino,2085,B-CHEMICAL
acid,2085,I-CHEMICAL
transport,2085,O
.,2085,O
Histochemical,2086,O
staining,2086,O
and,2086,O
quantification,2086,O
of,2086,O
dihydrolipoamide,2086,B-GENE-Y
dehydrogenase,2086,I-GENE-Y
diaphorase,2086,B-GENE-N
activity,2086,O
using,2086,O
blue,2086,O
native,2086,O
PAGE,2086,O
.,2086,O
Mammalian,2087,B-GENE-Y
mitochondrial,2087,I-GENE-Y
dihydrolipoamide,2087,I-GENE-Y
dehydrogenase,2087,I-GENE-Y
(,2087,O
DLDH,2087,B-GENE-Y
",",2087,O
EC,2087,B-GENE-Y
1.8.1.4,2087,I-GENE-Y
),2087,O
catalyzes,2087,O
NAD,2087,B-CHEMICAL
(,2087,I-CHEMICAL
+,2087,I-CHEMICAL
),2087,I-CHEMICAL
-dependent,2087,O
oxidation,2087,O
of,2087,O
dihydrolipoamide,2087,B-CHEMICAL
in,2087,O
vivo,2087,O
and,2087,O
can,2087,O
also,2087,O
act,2087,O
as,2087,O
a,2087,O
diaphorase,2087,B-GENE-N
catalyzing,2087,O
in,2087,O
vitro,2087,O
nicotinamide,2087,B-CHEMICAL
adenine,2087,I-CHEMICAL
dinucleotide,2087,I-CHEMICAL
(,2087,I-CHEMICAL
reduced,2087,I-CHEMICAL
form,2087,I-CHEMICAL
),2087,I-CHEMICAL
(,2087,O
NADH,2087,B-CHEMICAL
),2087,O
-dependent,2087,O
reduction,2087,O
of,2087,O
electron-accepting,2087,O
molecules,2087,O
such,2087,O
as,2087,O
ubiquinone,2087,O
and,2087,O
nitroblue,2087,B-CHEMICAL
tetrazolium,2087,I-CHEMICAL
(,2087,O
NBT,2087,B-CHEMICAL
),2087,O
.,2087,O
In,2088,O
this,2088,O
paper,2088,O
",",2088,O
we,2088,O
report,2088,O
a,2088,O
gel-based,2088,O
method,2088,O
for,2088,O
histochemical,2088,O
staining,2088,O
and,2088,O
quantification,2088,O
of,2088,O
DLDH,2088,B-GENE-Y
diaphorase,2088,B-GENE-N
activity,2088,O
using,2088,O
blue,2088,O
native,2088,O
PAGE,2088,O
(,2088,O
BN-PAGE,2088,O
),2088,O
.,2088,O
Rat,2089,O
brain,2089,O
mitochondrial,2089,O
extracts,2089,O
",",2089,O
used,2089,O
as,2089,O
the,2089,O
source,2089,O
of,2089,O
DLDH,2089,B-GENE-Y
",",2089,O
were,2089,O
resolved,2089,O
by,2089,O
nongradient,2089,O
BN-PAGE,2089,O
(,2089,O
9,2089,O
%,2089,O
),2089,O
",",2089,O
which,2089,O
was,2089,O
followed,2089,O
by,2089,O
diaphorase,2089,B-GENE-N
activity,2089,O
staining,2089,O
using,2089,O
NADH,2089,B-CHEMICAL
as,2089,O
the,2089,O
electron,2089,O
donor,2089,O
and,2089,O
NBT,2089,B-CHEMICAL
as,2089,O
the,2089,O
electron,2089,O
acceptor,2089,O
.,2089,O
It,2090,O
was,2090,O
shown,2090,O
that,2090,O
activity,2090,O
staining,2090,O
of,2090,O
DLDH,2090,B-GENE-Y
diaphorase,2090,B-GENE-N
was,2090,O
both,2090,O
protein,2090,O
amount-,2090,O
and,2090,O
time-dependent,2090,O
.,2090,O
Moreover,2091,O
",",2091,O
this,2091,O
in-gel,2091,O
activity-staining,2091,O
method,2091,O
was,2091,O
demonstrated,2091,O
to,2091,O
be,2091,O
in,2091,O
good,2091,O
agreement,2091,O
with,2091,O
the,2091,O
conventional,2091,O
spectrophotometric,2091,O
method,2091,O
that,2091,O
measures,2091,O
DLDH,2091,B-GENE-Y
dehydrogenase,2091,B-GENE-N
activity,2091,O
using,2091,O
dihydrolipoamide,2091,B-CHEMICAL
as,2091,O
the,2091,O
substrate,2091,O
.,2091,O
The,2092,O
method,2092,O
was,2092,O
applied,2092,O
to,2092,O
determine,2092,O
levels,2092,O
of,2092,O
DLDH,2092,B-GENE-Y
diaphorase,2092,B-GENE-N
activity,2092,O
in,2092,O
several,2092,O
rat,2092,O
tissues,2092,O
other,2092,O
than,2092,O
the,2092,O
brain,2092,O
",",2092,O
and,2092,O
the,2092,O
results,2092,O
indicated,2092,O
a,2092,O
similar,2092,O
level,2092,O
of,2092,O
DLDH,2092,B-GENE-Y
diaphorase,2092,B-GENE-N
activity,2092,O
for,2092,O
all,2092,O
the,2092,O
tissues,2092,O
examined,2092,O
.,2092,O
Finally,2093,O
",",2093,O
the,2093,O
effects,2093,O
of,2093,O
thiol-reactive,2093,B-CHEMICAL
reagents,2093,O
such,2093,O
as,2093,O
N-ethylmaleimide,2093,B-CHEMICAL
(,2093,O
NEM,2093,B-CHEMICAL
),2093,O
and,2093,O
nitric,2093,B-CHEMICAL
oxide,2093,I-CHEMICAL
donors,2093,O
on,2093,O
DLDH,2093,B-GENE-Y
diaphorase,2093,B-GENE-N
activity,2093,O
were,2093,O
evaluated,2093,O
",",2093,O
demonstrating,2093,O
that,2093,O
",",2093,O
with,2093,O
this,2093,O
method,2093,O
",",2093,O
DLDH,2093,B-GENE-Y
diaphorase,2093,B-GENE-N
activity,2093,O
can,2093,O
be,2093,O
determined,2093,O
without,2093,O
having,2093,O
to,2093,O
remove,2093,O
these,2093,O
thiol-reactive,2093,B-CHEMICAL
reagents,2093,O
that,2093,O
may,2093,O
otherwise,2093,O
interfere,2093,O
with,2093,O
spectrophotometric,2093,O
measurement,2093,O
of,2093,O
DLDH,2093,B-GENE-Y
dehydrogenase,2093,B-GENE-N
activity,2093,O
.,2093,O
The,2094,O
gel-based,2094,O
method,2094,O
can,2094,O
also,2094,O
be,2094,O
used,2094,O
as,2094,O
a,2094,O
means,2094,O
to,2094,O
isolate,2094,O
mitochondrial,2094,O
DLDH,2094,B-GENE-Y
that,2094,O
is,2094,O
to,2094,O
be,2094,O
analyzed,2094,O
by,2094,O
mass,2094,O
spectral,2094,O
techniques,2094,O
in,2094,O
studying,2094,O
DLDH,2094,B-GENE-Y
post-translational,2094,O
modifications,2094,O
.,2094,O
Reticulated,2095,O
platelets,2095,O
and,2095,O
uninhibited,2095,O
COX-1,2095,B-GENE-Y
and,2095,O
COX-2,2095,B-GENE-Y
decrease,2095,O
the,2095,O
antiplatelet,2095,O
effects,2095,O
of,2095,O
aspirin,2095,B-CHEMICAL
.,2095,O
BACKGROUND,2096,O
:,2096,O
The,2096,O
mechanisms,2096,O
for,2096,O
the,2096,O
variability,2096,O
in,2096,O
antiplatelet,2096,O
effects,2096,O
of,2096,O
aspirin,2096,B-CHEMICAL
are,2096,O
unclear,2096,O
.,2096,O
Immature,2097,O
(,2097,O
reticulated,2097,O
),2097,O
platelets,2097,O
may,2097,O
modulate,2097,O
the,2097,O
antiplatelet,2097,O
effects,2097,O
of,2097,O
aspirin,2097,B-CHEMICAL
through,2097,O
uninhibited,2097,O
cyclooxygenase,2097,B-GENE-N
(,2097,B-GENE-Y
COX,2097,I-GENE-Y
),2097,I-GENE-Y
-1,2097,I-GENE-Y
and,2097,O
COX-2,2097,B-GENE-Y
.,2097,O
OBJECTIVES,2098,O
:,2098,O
To,2098,O
evaluate,2098,O
the,2098,O
role,2098,O
of,2098,O
reticulated,2098,O
platelets,2098,O
in,2098,O
the,2098,O
antiplatelet,2098,O
effects,2098,O
of,2098,O
aspirin,2098,B-CHEMICAL
.,2098,O
METHODS,2099,O
:,2099,O
Sixty,2099,O
healthy,2099,O
volunteers,2099,O
had,2099,O
platelet,2099,O
studies,2099,O
performed,2099,O
before,2099,O
and,2099,O
24,2099,O
h,2099,O
after,2099,O
a,2099,O
single,2099,O
325-mg,2099,O
dose,2099,O
of,2099,O
aspirin,2099,B-CHEMICAL
.,2099,O
Platelet,2100,O
studies,2100,O
included,2100,O
light,2100,O
transmission,2100,O
aggregometry,2100,O
;,2100,O
P-selectin,2100,B-GENE-Y
and,2100,O
integrin,2100,B-GENE-N
alpha,2100,I-GENE-N
(,2100,I-GENE-N
IIb,2100,I-GENE-N
),2100,I-GENE-N
beta,2100,I-GENE-N
(,2100,I-GENE-N
3,2100,I-GENE-N
),2100,I-GENE-N
expression,2100,O
",",2100,O
and,2100,O
serum,2100,O
thromboxane,2100,B-CHEMICAL
B,2100,I-CHEMICAL
(,2100,I-CHEMICAL
2,2100,I-CHEMICAL
),2100,I-CHEMICAL
(,2100,O
TxB,2100,B-CHEMICAL
(,2100,I-CHEMICAL
2,2100,I-CHEMICAL
),2100,I-CHEMICAL
),2100,O
levels,2100,O
.,2100,O
Reticulated,2101,O
platelets,2101,O
and,2101,O
platelet,2101,O
COX-2,2101,B-GENE-Y
expression,2101,O
were,2101,O
measured,2101,O
using,2101,O
flow,2101,O
cytometry,2101,O
.,2101,O
RESULTS,2102,O
:,2102,O
Subjects,2102,O
were,2102,O
divided,2102,O
into,2102,O
tertiles,2102,O
based,2102,O
on,2102,O
the,2102,O
percentage,2102,O
of,2102,O
reticulated,2102,O
platelets,2102,O
in,2102,O
whole,2102,O
blood,2102,O
.,2102,O
Baseline,2103,O
platelet,2103,O
aggregation,2103,O
to,2103,O
1,2103,O
microg,2103,O
mL,2103,O
(,2103,O
-1,2103,O
),2103,O
collagen,2103,B-GENE-N
",",2103,O
and,2103,O
postaspirin,2103,O
aggregations,2103,O
to,2103,O
5,2103,O
microm,2103,O
and,2103,O
20,2103,O
microm,2103,O
ADP,2103,B-CHEMICAL
and,2103,O
collagen,2103,B-GENE-N
",",2103,O
were,2103,O
greater,2103,O
in,2103,O
the,2103,O
upper,2103,O
than,2103,O
in,2103,O
the,2103,O
lower,2103,O
tertile,2103,O
of,2103,O
reticulated,2103,O
platelets,2103,O
.,2103,O
Stimulated,2104,O
P-selectin,2104,B-GENE-Y
and,2104,O
integrin,2104,B-GENE-N
alpha,2104,I-GENE-N
(,2104,I-GENE-N
IIb,2104,I-GENE-N
),2104,I-GENE-N
beta,2104,I-GENE-N
(,2104,I-GENE-N
3,2104,I-GENE-N
),2104,I-GENE-N
expression,2104,O
were,2104,O
also,2104,O
higher,2104,O
in,2104,O
the,2104,O
upper,2104,O
tertile,2104,O
both,2104,O
before,2104,O
and,2104,O
after,2104,O
aspirin,2104,B-CHEMICAL
.,2104,O
Platelet,2105,O
COX-2,2105,B-GENE-Y
expression,2105,O
was,2105,O
detected,2105,O
in,2105,O
12,2105,O
+/-,2105,O
7,2105,O
%,2105,O
(,2105,O
n,2105,O
=,2105,O
10,2105,O
),2105,O
of,2105,O
platelets,2105,O
in,2105,O
the,2105,O
upper,2105,O
tertile,2105,O
",",2105,O
and,2105,O
in,2105,O
7,2105,O
+/-,2105,O
3,2105,O
%,2105,O
(,2105,O
n,2105,O
=,2105,O
12,2105,O
),2105,O
of,2105,O
platelets,2105,O
in,2105,O
the,2105,O
lower,2105,O
two,2105,O
tertiles,2105,O
(,2105,O
P,2105,O
=,2105,O
0.03,2105,O
),2105,O
.,2105,O
Postaspirin,2106,O
serum,2106,O
TxB,2106,O
(,2106,O
2,2106,O
),2106,O
levels,2106,O
were,2106,O
higher,2106,O
in,2106,O
the,2106,O
upper,2106,O
(,2106,O
5.5,2106,O
+/-,2106,O
4,2106,O
ng,2106,O
mL,2106,O
(,2106,O
-1,2106,O
),2106,O
),2106,O
than,2106,O
in,2106,O
the,2106,O
lower,2106,O
tertile,2106,O
(,2106,O
3.2,2106,O
+/-,2106,O
2.5,2106,O
ng,2106,O
mL,2106,O
(,2106,O
-1,2106,O
),2106,O
",",2106,O
P,2106,O
=,2106,O
0.03,2106,O
),2106,O
",",2106,O
and,2106,O
decreased,2106,O
even,2106,O
further,2106,O
with,2106,O
ex,2106,O
vivo,2106,O
additional,2106,O
COX-1,2106,B-GENE-Y
and,2106,O
COX-2,2106,B-GENE-Y
inhibition,2106,O
.,2106,O
The,2107,O
incidence,2107,O
of,2107,O
aspirin,2107,O
resistance,2107,O
(,2107,O
>,2107,O
or=,2107,O
70,2107,O
%,2107,O
platelet,2107,O
aggregation,2107,O
to,2107,O
5,2107,O
microm,2107,O
ADP,2107,O
),2107,O
was,2107,O
significantly,2107,O
higher,2107,O
in,2107,O
the,2107,O
upper,2107,O
tertile,2107,O
(,2107,O
45,2107,O
%,2107,O
),2107,O
than,2107,O
in,2107,O
the,2107,O
lower,2107,O
tertile,2107,O
(,2107,O
5,2107,O
%,2107,O
",",2107,O
P,2107,O
<,2107,O
0.0001,2107,O
),2107,O
.,2107,O
CONCLUSIONS,2108,O
:,2108,O
Reticulated,2108,O
platelets,2108,O
are,2108,O
associated,2108,O
with,2108,O
diminished,2108,O
antiplatelet,2108,O
effects,2108,O
of,2108,O
aspirin,2108,B-CHEMICAL
and,2108,O
increased,2108,O
aspirin,2108,B-CHEMICAL
resistance,2108,O
",",2108,O
possibly,2108,O
because,2108,O
of,2108,O
increased,2108,O
reactivity,2108,O
",",2108,O
and,2108,O
uninhibited,2108,O
COX-1,2108,B-GENE-Y
and,2108,O
COX-2,2108,B-GENE-Y
activity,2108,O
.,2108,O
Neuroprotection,2109,O
by,2109,O
estrogen,2109,B-CHEMICAL
against,2109,O
MPP+-induced,2109,B-CHEMICAL
dopamine,2109,B-CHEMICAL
neuron,2109,O
death,2109,O
is,2109,O
mediated,2109,O
by,2109,O
ERalpha,2109,B-GENE-Y
in,2109,O
primary,2109,O
cultures,2109,O
of,2109,O
mouse,2109,O
mesencephalon,2109,O
.,2109,O
Estrogen,2110,B-CHEMICAL
involvement,2110,O
in,2110,O
neuroprotection,2110,O
is,2110,O
now,2110,O
widely,2110,O
accepted,2110,O
",",2110,O
although,2110,O
the,2110,O
specific,2110,O
molecular,2110,O
and,2110,O
cellular,2110,O
mechanisms,2110,O
of,2110,O
estrogen,2110,B-CHEMICAL
action,2110,O
in,2110,O
neuroprotection,2110,O
remain,2110,O
unclear,2110,O
.,2110,O
This,2111,O
study,2111,O
examines,2111,O
estrogenic,2111,O
effects,2111,O
in,2111,O
a,2111,O
mixed,2111,O
population,2111,O
of,2111,O
cells,2111,O
in,2111,O
attempts,2111,O
to,2111,O
identify,2111,O
the,2111,O
contributing,2111,O
cells,2111,O
that,2111,O
result,2111,O
in,2111,O
estrogen-mediated,2111,B-CHEMICAL
neuroprotection,2111,O
.,2111,O
Utilizing,2112,O
primary,2112,O
mesencephalic,2112,O
neurons,2112,O
",",2112,O
we,2112,O
found,2112,O
expression,2112,O
of,2112,O
both,2112,O
estrogen,2112,B-GENE-Y
receptor,2112,I-GENE-Y
alpha,2112,I-GENE-Y
(,2112,O
ERalpha,2112,B-GENE-Y
),2112,O
and,2112,O
estrogen,2112,B-GENE-Y
receptor,2112,I-GENE-Y
beta,2112,I-GENE-Y
(,2112,O
ERbeta,2112,B-GENE-Y
),2112,O
with,2112,O
a,2112,O
predominance,2112,O
of,2112,O
ERalpha,2112,B-GENE-Y
on,2112,O
both,2112,O
dopamine,2112,B-CHEMICAL
neurons,2112,O
and,2112,O
astrocytes,2112,O
.,2112,O
We,2113,O
also,2113,O
found,2113,O
that,2113,O
17beta-estradiol,2113,B-CHEMICAL
protects,2113,O
dopamine,2113,B-CHEMICAL
neurons,2113,O
from,2113,O
injury,2113,O
induced,2113,O
by,2113,O
the,2113,O
complex,2113,O
I,2113,O
inhibitor,2113,O
",",2113,O
1-methyl-4-phenyl,2113,B-CHEMICAL
pyridinium,2113,I-CHEMICAL
(,2113,O
MPP,2113,B-CHEMICAL
(,2113,I-CHEMICAL
+,2113,I-CHEMICAL
),2113,I-CHEMICAL
),2113,O
in,2113,O
a,2113,O
time-,2113,O
and,2113,O
ER-dependent,2113,B-GENE-Y
manner,2113,O
.,2113,O
At,2114,O
least,2114,O
4,2114,O
h,2114,O
of,2114,O
estrogen,2114,B-CHEMICAL
pre-treatment,2114,O
was,2114,O
required,2114,O
to,2114,O
elicit,2114,O
protection,2114,O
",",2114,O
an,2114,O
effect,2114,O
that,2114,O
was,2114,O
blocked,2114,O
by,2114,O
the,2114,O
ER,2114,B-GENE-Y
antagonist,2114,O
",",2114,O
ICI,2114,B-CHEMICAL
"182,780",2114,I-CHEMICAL
.,2114,O
Moreover,2115,O
",",2115,O
ERalpha,2115,B-GENE-Y
mediated,2115,O
the,2115,O
protection,2115,O
afforded,2115,O
by,2115,O
estrogen,2115,B-CHEMICAL
since,2115,O
only,2115,O
the,2115,O
ERalpha,2115,B-GENE-Y
agonist,2115,O
",",2115,O
HPTE,2115,O
",",2115,O
but,2115,O
not,2115,O
the,2115,O
ERbeta,2115,B-GENE-Y
agonist,2115,O
",",2115,O
DPN,2115,B-CHEMICAL
",",2115,O
protected,2115,O
against,2115,O
dopamine,2115,B-CHEMICAL
cell,2115,O
loss,2115,O
.,2115,O
Since,2116,O
glial,2116,O
cells,2116,O
were,2116,O
shown,2116,O
to,2116,O
express,2116,O
significant,2116,O
levels,2116,O
of,2116,O
ERalpha,2116,B-GENE-Y
",",2116,O
we,2116,O
investigated,2116,O
a,2116,O
possible,2116,O
indirect,2116,O
mechanism,2116,O
of,2116,O
estrogen-mediated,2116,B-CHEMICAL
neuroprotection,2116,O
through,2116,O
glial,2116,O
cell,2116,O
interaction,2116,O
.,2116,O
Removal,2117,O
of,2117,O
glial,2117,O
cells,2117,O
from,2117,O
the,2117,O
cultures,2117,O
by,2117,O
application,2117,O
of,2117,O
the,2117,O
mitotic,2117,O
inhibitor,2117,O
",",2117,O
5-fluoro-2'-deoxyuridine,2117,B-CHEMICAL
",",2117,O
significantly,2117,O
reduced,2117,O
the,2117,O
neuroprotective,2117,O
effects,2117,O
of,2117,O
estrogen,2117,B-CHEMICAL
.,2117,O
These,2118,O
data,2118,O
indicate,2118,O
that,2118,O
neuroprotection,2118,O
provided,2118,O
by,2118,O
estrogen,2118,B-CHEMICAL
against,2118,O
MPP,2118,B-CHEMICAL
(,2118,I-CHEMICAL
+,2118,I-CHEMICAL
),2118,I-CHEMICAL
toxicity,2118,O
is,2118,O
mediated,2118,O
by,2118,O
ERalpha,2118,B-GENE-Y
and,2118,O
involves,2118,O
an,2118,O
interplay,2118,O
among,2118,O
at,2118,O
least,2118,O
two,2118,O
cell,2118,O
types,2118,O
.,2118,O
Differential,2119,O
activation,2119,O
of,2119,O
cAMP,2119,B-GENE-N
response,2119,I-GENE-N
element,2119,I-GENE-N
binding,2119,I-GENE-N
protein,2119,I-GENE-N
in,2119,O
discrete,2119,O
nucleus,2119,O
accumbens,2119,O
subregions,2119,O
during,2119,O
early,2119,O
and,2119,O
late,2119,O
cocaine,2119,B-CHEMICAL
sensitization,2119,O
.,2119,O
The,2120,O
present,2120,O
study,2120,O
examined,2120,O
the,2120,O
differential,2120,O
cocaine-induced,2120,B-CHEMICAL
activation,2120,O
of,2120,O
the,2120,O
cyclic,2120,B-CHEMICAL
adenosine,2120,I-CHEMICAL
monophosphate,2120,I-CHEMICAL
(,2120,I-GENE-N
cAMP,2120,B-CHEMICAL
),2120,I-GENE-N
response,2120,I-GENE-N
element,2120,I-GENE-N
binding,2120,I-GENE-N
protein,2120,I-GENE-N
(,2120,O
CREB,2120,B-GENE-N
),2120,O
throughout,2120,O
discrete,2120,O
zones,2120,O
of,2120,O
analysis,2120,O
of,2120,O
the,2120,O
nucleus,2120,O
accumbens,2120,O
(,2120,O
NAc,2120,O
),2120,O
in,2120,O
rats,2120,O
.,2120,O
CREB-dependent,2121,B-GENE-N
gene,2121,O
transcription,2121,O
",",2121,O
which,2121,O
may,2121,O
underlie,2121,O
long-lasting,2121,O
drug-induced,2121,O
changes,2121,O
in,2121,O
behavior,2121,O
and,2121,O
the,2121,O
subjective,2121,O
effects,2121,O
of,2121,O
cocaine,2121,B-CHEMICAL
",",2121,O
varies,2121,O
depending,2121,O
on,2121,O
the,2121,O
stage,2121,O
of,2121,O
drug,2121,O
exposure,2121,O
or,2121,O
withdrawal,2121,O
and,2121,O
the,2121,O
cell,2121,O
population,2121,O
involved,2121,O
.,2121,O
Using,2122,O
immunohistochemistry,2122,O
",",2122,O
the,2122,O
authors,2122,O
analyzed,2122,O
changes,2122,O
in,2122,O
CREB,2122,B-GENE-N
phosphorylation,2122,O
in,2122,O
the,2122,O
NAc,2122,O
after,2122,O
5,2122,O
days,2122,O
of,2122,O
cocaine,2122,B-CHEMICAL
",",2122,O
a,2122,O
short,2122,O
or,2122,O
long,2122,O
drug-free,2122,O
period,2122,O
",",2122,O
and,2122,O
a,2122,O
subsequent,2122,O
challenge,2122,O
injection,2122,O
.,2122,O
The,2123,O
NAc,2123,O
shell,2123,O
was,2123,O
separated,2123,O
into,2123,O
5,2123,O
zones,2123,O
of,2123,O
analysis,2123,O
previously,2123,O
defined,2123,O
by,2123,O
neurochemistry,2123,O
and,2123,O
connectivity,2123,O
.,2123,O
Repeated,2124,O
cocaine,2124,B-CHEMICAL
resulted,2124,O
in,2124,O
CREB,2124,B-GENE-N
phosphorylation,2124,O
in,2124,O
all,2124,O
analyzed,2124,O
subregions,2124,O
of,2124,O
the,2124,O
NAc,2124,O
excluding,2124,O
the,2124,O
most,2124,O
ventrolateral,2124,O
region,2124,O
of,2124,O
the,2124,O
shell,2124,O
2,2124,O
weeks,2124,O
after,2124,O
cessation,2124,O
of,2124,O
repeated,2124,O
cocaine,2124,B-CHEMICAL
",",2124,O
but,2124,O
rats,2124,O
challenged,2124,O
after,2124,O
2,2124,O
drug-free,2124,O
days,2124,O
yielded,2124,O
a,2124,O
more,2124,O
localized,2124,O
activation,2124,O
of,2124,O
CREB,2124,B-GENE-N
in,2124,O
the,2124,O
3,2124,O
most,2124,O
dorsomedial,2124,O
zones,2124,O
of,2124,O
the,2124,O
shell,2124,O
.,2124,O
The,2125,O
temporal,2125,O
and,2125,O
anatomical,2125,O
determinants,2125,O
of,2125,O
cocaine-induced,2125,B-CHEMICAL
CREB,2125,B-GENE-N
activity,2125,O
may,2125,O
indicate,2125,O
functional,2125,O
differences,2125,O
among,2125,O
NAc,2125,O
shell,2125,O
subregions,2125,O
and,2125,O
suggest,2125,O
the,2125,O
involvement,2125,O
of,2125,O
CREB,2125,B-GENE-N
in,2125,O
early,2125,O
and,2125,O
late,2125,O
cocaine,2125,B-CHEMICAL
effects,2125,O
.,2125,O
Fatal,2126,O
hemorrhage,2126,O
in,2126,O
mice,2126,O
lacking,2126,O
gamma-glutamyl,2126,B-CHEMICAL
carboxylase,2126,I-GENE-Y
.,2126,O
The,2127,O
carboxylation,2127,O
of,2127,O
glutamic,2127,B-CHEMICAL
acid,2127,I-CHEMICAL
residues,2127,O
to,2127,O
gamma-carboxyglutamic,2127,B-CHEMICAL
acid,2127,I-CHEMICAL
(,2127,O
Gla,2127,B-CHEMICAL
),2127,O
by,2127,O
the,2127,O
vitamin,2127,B-CHEMICAL
K-dependent,2127,I-GENE-Y
gamma-glutamyl,2127,B-CHEMICAL
carboxylase,2127,I-GENE-Y
(,2127,O
gamma-carboxylase,2127,B-GENE-Y
),2127,O
is,2127,O
an,2127,O
essential,2127,O
posttranslational,2127,O
modification,2127,O
required,2127,O
for,2127,O
the,2127,O
biological,2127,O
activity,2127,O
of,2127,O
a,2127,O
number,2127,O
of,2127,O
proteins,2127,O
",",2127,O
including,2127,O
proteins,2127,O
involved,2127,O
in,2127,O
blood,2127,O
coagulation,2127,O
and,2127,O
its,2127,O
regulation,2127,O
.,2127,O
Heterozygous,2128,O
mice,2128,O
carrying,2128,O
a,2128,O
null,2128,O
mutation,2128,O
at,2128,O
the,2128,O
gamma-carboxylase,2128,B-GENE-Y
(,2128,O
Ggcx,2128,B-GENE-Y
),2128,O
gene,2128,O
exhibit,2128,O
normal,2128,O
development,2128,O
and,2128,O
survival,2128,O
with,2128,O
no,2128,O
evidence,2128,O
of,2128,O
hemorrhage,2128,O
and,2128,O
normal,2128,O
functional,2128,O
activity,2128,O
of,2128,O
the,2128,O
vitamin,2128,B-CHEMICAL
K-dependent,2128,I-GENE-N
clotting,2128,I-GENE-N
factors,2128,I-GENE-N
IX,2128,I-GENE-N
",",2128,I-GENE-N
X,2128,I-GENE-N
",",2128,O
and,2128,O
prothrombin,2128,B-GENE-Y
.,2128,O
Analysis,2129,O
of,2129,O
a,2129,O
Ggcx,2129,B-GENE-Y
(,2129,O
+/-,2129,O
),2129,O
intercross,2129,O
revealed,2129,O
a,2129,O
partial,2129,O
developmental,2129,O
block,2129,O
with,2129,O
only,2129,O
50,2129,O
%,2129,O
of,2129,O
expected,2129,O
Ggcx,2129,B-GENE-Y
(,2129,O
-/-,2129,O
),2129,O
offspring,2129,O
surviving,2129,O
to,2129,O
term,2129,O
",",2129,O
with,2129,O
the,2129,O
latter,2129,O
animals,2129,O
dying,2129,O
uniformly,2129,O
at,2129,O
birth,2129,O
of,2129,O
massive,2129,O
intra-abdominal,2129,O
hemorrhage,2129,O
.,2129,O
This,2130,O
phenotype,2130,O
closely,2130,O
resembles,2130,O
the,2130,O
partial,2130,O
midembryonic,2130,O
loss,2130,O
and,2130,O
postnatal,2130,O
hemorrhage,2130,O
previously,2130,O
reported,2130,O
for,2130,O
both,2130,O
prothrombin-,2130,B-GENE-Y
and,2130,O
factor,2130,B-GENE-Y
V,2130,I-GENE-Y
(,2130,O
F5,2130,B-GENE-Y
),2130,O
-deficient,2130,O
mice,2130,O
.,2130,O
These,2131,O
data,2131,O
exclude,2131,O
the,2131,O
existence,2131,O
of,2131,O
a,2131,O
redundant,2131,O
carboxylase,2131,B-GENE-N
pathway,2131,O
and,2131,O
suggest,2131,O
that,2131,O
functionally,2131,O
critical,2131,O
substrates,2131,O
for,2131,O
gamma-carboxylation,2131,O
",",2131,O
at,2131,O
least,2131,O
in,2131,O
the,2131,O
developing,2131,O
embryo,2131,O
and,2131,O
neonate,2131,O
",",2131,O
are,2131,O
primarily,2131,O
restricted,2131,O
to,2131,O
components,2131,O
of,2131,O
the,2131,O
blood,2131,O
coagulation,2131,O
cascade,2131,O
.,2131,O
Levels,2132,O
of,2132,O
2-thiothiazolidine-4-carboxylic,2132,B-CHEMICAL
acid,2132,I-CHEMICAL
(,2132,O
TTCA,2132,B-CHEMICAL
),2132,O
and,2132,O
effect,2132,O
modification,2132,O
of,2132,O
polymorphisms,2132,O
of,2132,O
glutathione-related,2132,B-CHEMICAL
genes,2132,O
in,2132,O
vulcanization,2132,O
workers,2132,O
in,2132,O
the,2132,O
southern,2132,O
Sweden,2132,O
rubber,2132,O
industries,2132,O
.,2132,O
OBJECTIVES,2133,O
:,2133,O
Workers,2133,O
in,2133,O
the,2133,O
rubber,2133,O
industry,2133,O
are,2133,O
exposed,2133,O
to,2133,O
a,2133,O
complex,2133,O
mixture,2133,O
of,2133,O
hazardous,2133,O
substances,2133,O
and,2133,O
have,2133,O
increased,2133,O
risk,2133,O
of,2133,O
developing,2133,O
several,2133,O
diseases,2133,O
.,2133,O
However,2134,O
",",2134,O
there,2134,O
is,2134,O
no,2134,O
up,2134,O
to,2134,O
date,2134,O
survey,2134,O
examining,2134,O
the,2134,O
exposure,2134,O
in,2134,O
the,2134,O
Swedish,2134,O
rubber,2134,O
industry,2134,O
.,2134,O
One,2135,O
of,2135,O
the,2135,O
toxic,2135,O
compounds,2135,O
in,2135,O
the,2135,O
industry,2135,O
is,2135,O
carbon,2135,O
disulfide,2135,O
(,2135,O
CS,2135,O
(,2135,O
2,2135,O
),2135,O
),2135,O
",",2135,O
which,2135,O
is,2135,O
biotransformed,2135,O
to,2135,O
2-thiothiazolidine-4-carboxylic,2135,B-CHEMICAL
acid,2135,I-CHEMICAL
(,2135,O
TTCA,2135,B-CHEMICAL
),2135,O
.,2135,O
TTCA,2136,B-CHEMICAL
is,2136,O
used,2136,O
as,2136,O
a,2136,O
biomarker,2136,O
of,2136,O
CS,2136,O
(,2136,O
2,2136,O
),2136,O
exposure,2136,O
",",2136,O
but,2136,O
there,2136,O
seem,2136,O
to,2136,O
exist,2136,O
inter-,2136,O
and,2136,O
intraindividual,2136,O
variability,2136,O
;,2136,O
which,2136,O
could,2136,O
partly,2136,O
be,2136,O
due,2136,O
to,2136,O
genetic,2136,O
variation,2136,O
.,2136,O
The,2137,O
aim,2137,O
of,2137,O
the,2137,O
study,2137,O
was,2137,O
to,2137,O
determine,2137,O
TTCA,2137,B-CHEMICAL
levels,2137,O
and,2137,O
the,2137,O
modifying,2137,O
effects,2137,O
of,2137,O
glutathione-related,2137,B-CHEMICAL
genes,2137,O
in,2137,O
a,2137,O
group,2137,O
of,2137,O
Swedish,2137,O
rubber,2137,O
workers,2137,O
.,2137,O
METHODS,2138,O
:,2138,O
Urine,2138,O
was,2138,O
collected,2138,O
from,2138,O
both,2138,O
exposed,2138,O
workers,2138,O
and,2138,O
controls,2138,O
during,2138,O
the,2138,O
last,2138,O
4,2138,O
h,2138,O
of,2138,O
the,2138,O
work,2138,O
shift,2138,O
.,2138,O
The,2139,O
level,2139,O
of,2139,O
TTCA,2139,B-CHEMICAL
in,2139,O
urine,2139,O
was,2139,O
analyzed,2139,O
by,2139,O
liquid,2139,O
chromatograpy,2139,O
tandem,2139,O
mass,2139,O
spectrometry,2139,O
.,2139,O
Genotyping,2140,O
of,2140,O
the,2140,O
single,2140,O
nucleotide,2140,B-CHEMICAL
polymorphisms,2140,O
GCLC-129,2140,B-GENE-Y
",",2140,O
GCLM-588,2140,B-GENE-Y
",",2140,O
GSTA1-52,2140,B-GENE-Y
",",2140,O
GSTP1-105,2140,B-GENE-Y
and,2140,O
GSTP1-114,2140,B-GENE-Y
and,2140,O
deletions,2140,O
of,2140,O
GSTM1,2140,B-GENE-Y
and,2140,O
GSTT1,2140,B-GENE-Y
were,2140,O
performed,2140,O
with,2140,O
real-time,2140,O
PCR,2140,O
or,2140,O
ordinary,2140,O
PCR,2140,O
and,2140,O
subsequent,2140,O
agarose,2140,O
electrophoresis,2140,O
.,2140,O
RESULTS,2141,O
:,2141,O
The,2141,O
highest,2141,O
levels,2141,O
of,2141,O
TTCA,2141,B-CHEMICAL
were,2141,O
found,2141,O
among,2141,O
workers,2141,O
curing,2141,O
with,2141,O
salt,2141,O
bath,2141,O
",",2141,O
hot,2141,O
air,2141,O
",",2141,O
microwaves,2141,O
or,2141,O
fluid-bed,2141,O
",",2141,O
and,2141,O
lower,2141,O
levels,2141,O
were,2141,O
found,2141,O
among,2141,O
workers,2141,O
curing,2141,O
with,2141,O
injection,2141,O
and,2141,O
compression,2141,O
molding,2141,O
.,2141,O
Furthermore,2142,O
",",2142,O
with,2142,O
respect,2142,O
to,2142,O
GSTM1,2142,B-GENE-Y
and,2142,O
GSTT1,2142,B-GENE-Y
there,2142,O
were,2142,O
statistically,2142,O
significant,2142,O
differences,2142,O
in,2142,O
TTCA-levels,2142,B-CHEMICAL
between,2142,O
genotypes,2142,O
among,2142,O
exposed,2142,O
workers,2142,O
but,2142,O
not,2142,O
among,2142,O
controls,2142,O
.,2142,O
The,2143,O
other,2143,O
five,2143,O
polymorphisms,2143,O
had,2143,O
no,2143,O
impact,2143,O
on,2143,O
the,2143,O
TTCA,2143,B-CHEMICAL
levels,2143,O
.,2143,O
CONCLUSIONS,2144,O
:,2144,O
The,2144,O
present,2144,O
study,2144,O
demonstrates,2144,O
relatively,2144,O
high,2144,O
levels,2144,O
of,2144,O
TTCA,2144,B-CHEMICAL
in,2144,O
urine,2144,O
from,2144,O
Swedish,2144,O
rubber,2144,O
workers,2144,O
.,2144,O
Polymorphisms,2145,O
in,2145,O
GSTM1,2145,B-GENE-Y
and,2145,O
GSTT1,2145,B-GENE-Y
modify,2145,O
the,2145,O
levels,2145,O
.,2145,O
H3,2146,B-GENE-Y
histamine,2146,I-GENE-Y
receptor,2146,I-GENE-Y
agonist,2146,O
inhibits,2146,O
biliary,2146,O
growth,2146,O
of,2146,O
BDL,2146,O
rats,2146,O
by,2146,O
downregulation,2146,O
of,2146,O
the,2146,O
cAMP-dependent,2146,B-GENE-N
PKA/ERK1/2/ELK-1,2146,O
pathway,2146,O
.,2146,O
Histamine,2147,B-CHEMICAL
regulates,2147,O
many,2147,O
functions,2147,O
by,2147,O
binding,2147,O
to,2147,O
four,2147,O
histamine,2147,B-GENE-N
G-coupled,2147,I-GENE-N
receptor,2147,I-GENE-N
proteins,2147,I-GENE-N
(,2147,O
H1R,2147,B-GENE-Y
",",2147,O
H2R,2147,B-GENE-Y
",",2147,O
H3R,2147,B-GENE-Y
and,2147,O
H4R,2147,B-GENE-Y
),2147,O
.,2147,O
As,2148,O
H3R,2148,B-GENE-N
exerts,2148,O
their,2148,O
effects,2148,O
by,2148,O
coupling,2148,O
to,2148,O
Galpha,2148,B-GENE-N
(,2148,I-GENE-N
i/o,2148,I-GENE-N
),2148,I-GENE-N
proteins,2148,O
reducing,2148,O
adenosine,2148,B-CHEMICAL
3,2148,I-CHEMICAL
',2148,I-CHEMICAL
",",2148,I-CHEMICAL
5'-monophosphate,2148,I-CHEMICAL
(,2148,O
cAMP,2148,B-CHEMICAL
),2148,O
levels,2148,O
(,2148,O
a,2148,O
key,2148,O
player,2148,O
in,2148,O
the,2148,O
modulation,2148,O
of,2148,O
cholangiocyte,2148,O
hyperplasia/damage,2148,O
),2148,O
",",2148,O
we,2148,O
evaluated,2148,O
the,2148,O
role,2148,O
of,2148,O
H3R,2148,B-GENE-Y
in,2148,O
the,2148,O
regulation,2148,O
of,2148,O
biliary,2148,O
growth,2148,O
.,2148,O
We,2149,O
posed,2149,O
the,2149,O
following,2149,O
questions,2149,O
:,2149,O
(,2149,O
1,2149,O
),2149,O
Do,2149,O
cholangiocytes,2149,O
express,2149,O
H3R,2149,B-GENE-N
?,2149,O
(,2150,O
2,2150,O
),2150,O
Does,2150,O
in,2150,O
vivo,2150,O
administration,2150,O
of,2150,O
(,2150,B-CHEMICAL
R,2150,I-CHEMICAL
),2150,I-CHEMICAL
-,2150,I-CHEMICAL
(,2150,I-CHEMICAL
alpha,2150,I-CHEMICAL
),2150,I-CHEMICAL
-,2150,I-CHEMICAL
(,2150,I-CHEMICAL
-,2150,I-CHEMICAL
),2150,I-CHEMICAL
-methylhistamine,2150,I-CHEMICAL
dihydrobromide,2150,I-CHEMICAL
(,2150,O
RAMH,2150,B-CHEMICAL
),2150,O
(,2150,O
H3R,2150,B-GENE-Y
agonist,2150,O
),2150,O
",",2150,O
thioperamide,2150,B-CHEMICAL
maleate,2150,I-CHEMICAL
(,2150,O
H3R,2150,B-GENE-Y
antagonist,2150,O
),2150,O
or,2150,O
histamine,2150,B-CHEMICAL
",",2150,O
in,2150,O
the,2150,O
absence/presence,2150,O
of,2150,O
thioperamide,2150,B-CHEMICAL
maleate,2150,I-CHEMICAL
",",2150,O
to,2150,O
bile,2150,O
duct,2150,O
ligated,2150,O
(,2150,O
BDL,2150,O
),2150,O
rats,2150,O
regulate,2150,O
cholangiocyte,2150,O
proliferation,2150,O
?,2150,O
and,2151,O
(,2151,O
3,2151,O
),2151,O
Does,2151,O
RAMH,2151,B-CHEMICAL
inhibit,2151,O
cholangiocyte,2151,O
proliferation,2151,O
by,2151,O
downregulation,2151,O
of,2151,O
cAMP-dependent,2151,B-CHEMICAL
phosphorylation,2151,O
of,2151,O
protein,2151,B-GENE-N
kinase,2151,I-GENE-N
A,2151,I-GENE-N
(,2151,O
PKA,2151,B-GENE-N
),2151,O
/extracellular,2151,O
signal-regulated,2151,I-GENE-N
kinase,2151,I-GENE-N
1/2,2151,I-GENE-N
(,2151,O
ERK1/2,2151,B-GENE-N
),2151,O
/ets-like,2151,O
gene-1,2151,I-GENE-Y
(,2151,O
Elk-1,2151,B-GENE-Y
),2151,O
?,2151,O
The,2152,O
expression,2152,O
of,2152,O
H3R,2152,B-GENE-Y
was,2152,O
evaluated,2152,O
in,2152,O
liver,2152,O
sections,2152,O
by,2152,O
immunohistochemistry,2152,O
and,2152,O
immunofluorescence,2152,O
",",2152,O
and,2152,O
by,2152,O
real-time,2152,O
PCR,2152,O
in,2152,O
cholangiocyte,2152,O
RNA,2152,O
from,2152,O
normal,2152,O
and,2152,O
BDL,2152,O
rats,2152,O
.,2152,O
BDL,2153,O
rats,2153,O
(,2153,O
immediately,2153,O
after,2153,O
BDL,2153,O
),2153,O
were,2153,O
treated,2153,O
daily,2153,O
with,2153,O
RAMH,2153,B-CHEMICAL
",",2153,O
thioperamide,2153,B-CHEMICAL
maleate,2153,I-CHEMICAL
or,2153,O
histamine,2153,B-CHEMICAL
in,2153,O
the,2153,O
absence/presence,2153,O
of,2153,O
thioperamide,2153,B-CHEMICAL
maleate,2153,I-CHEMICAL
for,2153,O
1,2153,O
week,2153,O
.,2153,O
Following,2154,O
in,2154,O
vivo,2154,O
treatment,2154,O
of,2154,O
BDL,2154,O
rats,2154,O
with,2154,O
RAMH,2154,B-CHEMICAL
for,2154,O
1,2154,O
week,2154,O
",",2154,O
and,2154,O
in,2154,O
vitro,2154,O
stimulation,2154,O
of,2154,O
BDL,2154,O
cholangiocytes,2154,O
with,2154,O
RAMH,2154,B-CHEMICAL
",",2154,O
we,2154,O
evaluated,2154,O
cholangiocyte,2154,O
proliferation,2154,O
",",2154,O
cAMP,2154,B-CHEMICAL
levels,2154,O
and,2154,O
PKA,2154,B-GENE-N
",",2154,O
ERK1/2,2154,B-GENE-N
and,2154,O
Elk-1,2154,B-GENE-Y
phosphorylation,2154,O
.,2154,O
Cholangiocytes,2155,O
from,2155,O
normal,2155,O
and,2155,O
BDL,2155,O
rats,2155,O
express,2155,O
H3R,2155,B-GENE-Y
.,2155,O
The,2156,O
expression,2156,O
of,2156,O
H3R,2156,B-GENE-Y
mRNA,2156,O
increased,2156,O
in,2156,O
BDL,2156,O
compared,2156,O
to,2156,O
normal,2156,O
cholangiocytes,2156,O
.,2156,O
Histamine,2157,B-CHEMICAL
decreased,2157,O
cholangiocyte,2157,O
growth,2157,O
of,2157,O
BDL,2157,O
rats,2157,O
to,2157,O
a,2157,O
lower,2157,O
extent,2157,O
than,2157,O
that,2157,O
observed,2157,O
in,2157,O
BDL,2157,O
RAMH-treated,2157,B-CHEMICAL
rats,2157,O
;,2157,O
histamine-induced,2157,B-CHEMICAL
inhibition,2157,O
of,2157,O
cholangiocyte,2157,O
growth,2157,O
was,2157,O
partly,2157,O
blocked,2157,O
by,2157,O
thioperamide,2157,B-CHEMICAL
maleate,2157,I-CHEMICAL
.,2157,O
In,2158,O
BDL,2158,O
rats,2158,O
treated,2158,O
with,2158,O
thioperamide,2158,B-CHEMICAL
maleate,2158,I-CHEMICAL
",",2158,O
cholangiocyte,2158,O
hyperplasia,2158,O
was,2158,O
slightly,2158,O
higher,2158,O
than,2158,O
that,2158,O
of,2158,O
BDL,2158,O
rats,2158,O
.,2158,O
In,2159,O
vitro,2159,O
",",2159,O
RAMH,2159,B-CHEMICAL
inhibited,2159,O
the,2159,O
proliferation,2159,O
of,2159,O
BDL,2159,O
cholangiocytes,2159,O
.,2159,O
RAMH,2160,B-CHEMICAL
inhibition,2160,O
of,2160,O
cholangiocyte,2160,O
growth,2160,O
was,2160,O
associated,2160,O
with,2160,O
decreased,2160,O
cAMP,2160,B-CHEMICAL
levels,2160,O
and,2160,O
PKA/ERK1/2/Elk-1,2160,B-GENE-N
phosphorylation,2160,O
.,2160,O
Downregulation,2161,O
of,2161,O
cAMP-dependent,2161,B-CHEMICAL
PKA/ERK1/2/Elk-1,2161,B-GENE-N
phosphorylation,2161,O
(,2161,O
by,2161,O
activation,2161,O
of,2161,O
H3R,2161,B-GENE-Y
),2161,O
is,2161,O
important,2161,O
in,2161,O
the,2161,O
inhibition,2161,O
of,2161,O
cholangiocyte,2161,O
growth,2161,O
in,2161,O
liver,2161,O
diseases,2161,O
.,2161,O
Structure,2162,O
and,2162,O
kinetics,2162,O
of,2162,O
monofunctional,2162,O
proline,2162,B-GENE-Y
dehydrogenase,2162,I-GENE-Y
from,2162,O
Thermus,2162,O
thermophilus,2162,O
.,2162,O
Proline,2163,B-CHEMICAL
dehydrogenase,2163,I-GENE-Y
(,2163,O
PRODH,2163,B-GENE-Y
),2163,O
and,2163,O
Delta,2163,B-CHEMICAL
(,2163,I-CHEMICAL
1,2163,I-CHEMICAL
),2163,I-CHEMICAL
-pyrroline-5-carboxylate,2163,I-CHEMICAL
dehydrogenase,2163,I-GENE-Y
(,2163,O
P5CDH,2163,B-GENE-Y
),2163,O
catalyze,2163,O
the,2163,O
two-step,2163,O
oxidation,2163,O
of,2163,O
proline,2163,B-CHEMICAL
to,2163,O
glutamate,2163,B-CHEMICAL
.,2163,O
They,2164,O
are,2164,O
distinct,2164,O
monofunctional,2164,O
enzymes,2164,O
in,2164,O
all,2164,O
eukaryotes,2164,O
and,2164,O
some,2164,O
bacteria,2164,O
but,2164,O
are,2164,O
fused,2164,O
into,2164,O
bifunctional,2164,O
enzymes,2164,O
known,2164,O
as,2164,O
proline,2164,B-GENE-N
utilization,2164,I-GENE-N
A,2164,I-GENE-N
(,2164,O
PutA,2164,B-GENE-N
),2164,O
in,2164,O
other,2164,O
bacteria,2164,O
.,2164,O
Here,2165,O
we,2165,O
report,2165,O
the,2165,O
first,2165,O
structure,2165,O
and,2165,O
biochemical,2165,O
data,2165,O
for,2165,O
a,2165,O
monofunctional,2165,O
PRODH,2165,B-GENE-Y
.,2165,O
The,2166,O
2.0-A,2166,O
resolution,2166,O
structure,2166,O
of,2166,O
Thermus,2166,B-GENE-Y
thermophilus,2166,I-GENE-Y
PRODH,2166,I-GENE-Y
reveals,2166,O
a,2166,O
distorted,2166,O
(,2166,B-GENE-N
betaalpha,2166,I-GENE-N
),2166,I-GENE-N
(,2166,I-GENE-N
8,2166,I-GENE-N
),2166,I-GENE-N
barrel,2166,I-GENE-N
catalytic,2166,I-GENE-N
core,2166,I-GENE-N
domain,2166,I-GENE-N
and,2166,O
a,2166,O
hydrophobic,2166,B-GENE-N
alpha-helical,2166,I-GENE-N
domain,2166,I-GENE-N
located,2166,O
above,2166,O
the,2166,O
carboxyl-terminal,2166,B-CHEMICAL
ends,2166,O
of,2166,O
the,2166,O
strands,2166,O
of,2166,O
the,2166,O
barrel,2166,O
.,2166,O
Although,2167,O
the,2167,O
catalytic,2167,O
core,2167,O
is,2167,O
similar,2167,O
to,2167,O
that,2167,O
of,2167,O
the,2167,O
PutA,2167,B-GENE-N
PRODH,2167,I-GENE-N
domain,2167,I-GENE-N
",",2167,O
the,2167,O
FAD,2167,O
conformation,2167,O
of,2167,O
T.,2167,B-GENE-Y
thermophilus,2167,I-GENE-Y
PRODH,2167,I-GENE-Y
is,2167,O
remarkably,2167,O
different,2167,O
and,2167,O
likely,2167,O
reflects,2167,O
unique,2167,O
requirements,2167,O
for,2167,O
membrane,2167,O
association,2167,O
and,2167,O
communication,2167,O
with,2167,O
P5CDH,2167,B-GENE-Y
.,2167,O
Also,2168,O
",",2168,O
the,2168,O
FAD,2168,O
of,2168,O
T.,2168,B-GENE-Y
thermophilus,2168,I-GENE-Y
PRODH,2168,I-GENE-Y
is,2168,O
highly,2168,O
solvent-exposed,2168,O
compared,2168,O
with,2168,O
PutA,2168,B-GENE-N
due,2168,O
to,2168,O
a,2168,O
4-A,2168,O
shift,2168,O
of,2168,O
helix,2168,O
8,2168,O
.,2168,O
Structure-based,2169,O
sequence,2169,O
analysis,2169,O
of,2169,O
the,2169,O
PutA/PRODH,2169,B-GENE-N
family,2169,O
led,2169,O
us,2169,O
to,2169,O
identify,2169,O
nine,2169,O
conserved,2169,O
motifs,2169,O
involved,2169,O
in,2169,O
cofactor,2169,O
and,2169,O
substrate,2169,O
recognition,2169,O
.,2169,O
Biochemical,2170,O
studies,2170,O
show,2170,O
that,2170,O
the,2170,O
midpoint,2170,O
potential,2170,O
of,2170,O
the,2170,O
FAD,2170,O
is,2170,O
-75,2170,O
mV,2170,O
and,2170,O
the,2170,O
kinetic,2170,O
parameters,2170,O
for,2170,O
proline,2170,O
are,2170,O
K,2170,O
(,2170,O
m,2170,O
),2170,O
=,2170,O
27,2170,O
mm,2170,O
and,2170,O
k,2170,O
(,2170,O
cat,2170,O
),2170,O
=,2170,O
13,2170,O
s,2170,O
(,2170,O
-1,2170,O
),2170,O
.,2170,O
"3,4-Dehydro-l-proline",2171,B-CHEMICAL
was,2171,O
found,2171,O
to,2171,O
be,2171,O
an,2171,O
efficient,2171,O
substrate,2171,O
",",2171,O
and,2171,O
l-tetrahydro-2-furoic,2171,B-CHEMICAL
acid,2171,I-CHEMICAL
is,2171,O
a,2171,O
competitive,2171,O
inhibitor,2171,O
(,2171,O
K,2171,O
(,2171,O
I,2171,O
),2171,O
=,2171,O
1.0,2171,O
mm,2171,O
),2171,O
.,2171,O
Finally,2172,O
",",2172,O
we,2172,O
demonstrate,2172,O
that,2172,O
T.,2172,B-GENE-Y
thermophilus,2172,I-GENE-Y
PRODH,2172,I-GENE-Y
reacts,2172,O
with,2172,O
O,2172,B-CHEMICAL
(,2172,I-CHEMICAL
2,2172,I-CHEMICAL
),2172,I-CHEMICAL
producing,2172,O
superoxide,2172,B-CHEMICAL
.,2172,O
This,2173,O
is,2173,O
significant,2173,O
because,2173,O
superoxide,2173,B-CHEMICAL
production,2173,O
underlies,2173,O
the,2173,O
role,2173,O
of,2173,O
human,2173,B-GENE-Y
PRODH,2173,I-GENE-Y
in,2173,O
p53-mediated,2173,B-GENE-Y
apoptosis,2173,O
",",2173,O
implying,2173,O
commonalities,2173,O
between,2173,O
eukaryotic,2173,B-GENE-N
and,2173,I-GENE-N
bacterial,2173,I-GENE-N
monofunctional,2173,I-GENE-N
PRODHs,2173,I-GENE-N
.,2173,O
Creatine,2174,B-CHEMICAL
uptake,2174,O
in,2174,O
brain,2174,O
and,2174,O
skeletal,2174,O
muscle,2174,O
of,2174,O
mice,2174,O
lacking,2174,O
guanidinoacetate,2174,B-GENE-Y
methyltransferase,2174,I-GENE-Y
assessed,2174,O
by,2174,O
magnetic,2174,O
resonance,2174,O
spectroscopy,2174,O
.,2174,O
Creatine,2175,B-CHEMICAL
(,2175,O
Cr,2175,B-CHEMICAL
),2175,O
levels,2175,O
in,2175,O
skeletal,2175,O
muscle,2175,O
and,2175,O
brain,2175,O
of,2175,O
a,2175,O
mouse,2175,O
model,2175,O
of,2175,O
Cr,2175,B-CHEMICAL
deficiency,2175,O
caused,2175,O
by,2175,O
guanidinoacetate,2175,B-GENE-Y
methyltransferase,2175,I-GENE-Y
absence,2175,O
(,2175,O
GAMT-/-,2175,B-GENE-Y
),2175,O
were,2175,O
studied,2175,O
after,2175,O
Cr,2175,B-CHEMICAL
supplementation,2175,O
with,2175,O
2,2175,O
g.kg,2175,O
body,2175,O
wt-1.day-1,2175,O
Cr,2175,B-CHEMICAL
for,2175,O
35,2175,O
days,2175,O
.,2175,O
Localized,2176,O
1H,2176,B-CHEMICAL
magnetic,2176,O
resonance,2176,O
spectroscopy,2176,O
(,2176,O
MRS,2176,O
),2176,O
was,2176,O
performed,2176,O
in,2176,O
brain,2176,O
(,2176,O
cerebellum,2176,O
and,2176,O
thalamus/hippocampus,2176,O
),2176,O
and,2176,O
in,2176,O
hind,2176,O
leg,2176,O
muscle,2176,O
of,2176,O
GAMT-/-,2176,B-GENE-Y
mice,2176,O
before,2176,O
and,2176,O
after,2176,O
Cr,2176,B-CHEMICAL
supplementation,2176,O
and,2176,O
in,2176,O
control,2176,O
(,2176,O
Con,2176,O
),2176,O
mice,2176,O
.,2176,O
As,2177,O
expected,2177,O
",",2177,O
a,2177,O
signal,2177,O
for,2177,O
Cr,2177,B-CHEMICAL
was,2177,O
hardly,2177,O
detectable,2177,O
in,2177,O
MR,2177,O
spectra,2177,O
of,2177,O
GAMT-/-,2177,B-GENE-Y
mice,2177,O
before,2177,O
Cr,2177,B-CHEMICAL
supplementation,2177,O
.,2177,O
In,2178,O
the,2178,O
thalamus/hippocampus,2178,O
region,2178,O
of,2178,O
these,2178,O
mice,2178,O
",",2178,O
an,2178,O
increase,2178,O
in,2178,O
N-acetylasparate,2178,B-CHEMICAL
(,2178,O
NAA,2178,B-CHEMICAL
),2178,O
was,2178,O
observed,2178,O
.,2178,O
During,2179,O
Cr,2179,B-CHEMICAL
administration,2179,O
",",2179,O
Cr,2179,B-CHEMICAL
levels,2179,O
increased,2179,O
faster,2179,O
in,2179,O
skeletal,2179,O
muscle,2179,O
compared,2179,O
with,2179,O
brain,2179,O
",",2179,O
but,2179,O
this,2179,O
occurred,2179,O
only,2179,O
during,2179,O
the,2179,O
first,2179,O
day,2179,O
of,2179,O
supplementation,2179,O
.,2179,O
Thereafter,2180,O
",",2180,O
Cr,2180,B-CHEMICAL
levels,2180,O
increased,2180,O
by,2180,O
0.8,2180,O
mM/day,2180,O
in,2180,O
all,2180,O
studied,2180,O
locations,2180,O
.,2180,O
After,2181,O
35,2181,O
days,2181,O
of,2181,O
Cr,2181,B-CHEMICAL
supplementation,2181,O
",",2181,O
Cr,2181,B-CHEMICAL
levels,2181,O
in,2181,O
all,2181,O
locations,2181,O
were,2181,O
higher,2181,O
compared,2181,O
with,2181,O
Con,2181,O
mice,2181,O
on,2181,O
a,2181,O
Cr-free,2181,B-CHEMICAL
diet,2181,O
and,2181,O
NAA,2181,B-CHEMICAL
levels,2181,O
normalized,2181,O
.,2181,O
Only,2182,O
because,2182,O
of,2182,O
the,2182,O
repeated,2182,O
MRS,2182,O
measurements,2182,O
performed,2182,O
in,2182,O
this,2182,O
longitudinal,2182,O
Cr,2182,B-CHEMICAL
supplementation,2182,O
study,2182,O
on,2182,O
GAMT-/-,2182,B-GENE-Y
mice,2182,O
were,2182,O
we,2182,O
able,2182,O
to,2182,O
discover,2182,O
the,2182,O
initial,2182,O
faster,2182,O
uptake,2182,O
of,2182,O
Cr,2182,B-CHEMICAL
in,2182,O
skeletal,2182,O
muscle,2182,O
compared,2182,O
with,2182,O
brain,2182,O
",",2182,O
which,2182,O
may,2182,O
represent,2182,O
muscular,2182,O
Cr,2182,B-CHEMICAL
uptake,2182,O
independent,2182,O
of,2182,O
Cr,2182,B-CHEMICAL
transporter,2182,O
expression,2182,O
.,2182,O
Our,2183,O
results,2183,O
can,2183,O
provide,2183,O
the,2183,O
basis,2183,O
for,2183,O
additional,2183,O
experiments,2183,O
to,2183,O
optimize,2183,O
Cr,2183,B-CHEMICAL
supplementation,2183,O
in,2183,O
GAMT,2183,B-GENE-Y
deficiency,2183,O
",",2183,O
as,2183,O
increases,2183,O
in,2183,O
brain,2183,O
Cr,2183,B-CHEMICAL
are,2183,O
slow,2183,O
in,2183,O
patients,2183,O
after,2183,O
Cr,2183,B-CHEMICAL
supplementation,2183,O
.,2183,O
Highly,2184,O
selective,2184,O
phosphodiesterase,2184,B-GENE-N
4,2184,I-GENE-N
inhibitors,2184,O
for,2184,O
the,2184,O
treatment,2184,O
of,2184,O
allergic,2184,O
skin,2184,O
diseases,2184,O
and,2184,O
psoriasis,2184,O
.,2184,O
The,2185,O
phosphodiesterase,2185,B-GENE-N
(,2185,I-GENE-N
PDE,2185,I-GENE-N
),2185,I-GENE-N
4,2185,I-GENE-N
is,2185,O
the,2185,O
predominant,2185,O
cyclic,2185,B-CHEMICAL
AMP,2185,I-CHEMICAL
degrading,2185,O
enzyme,2185,O
in,2185,O
a,2185,O
variety,2185,O
of,2185,O
inflammatory,2185,O
cells,2185,O
including,2185,O
eosinophils,2185,O
",",2185,O
neutrophils,2185,O
",",2185,O
macrophages,2185,O
",",2185,O
T,2185,O
cells,2185,O
and,2185,O
monocytes,2185,O
.,2185,O
In,2186,O
addition,2186,O
",",2186,O
this,2186,O
enzyme,2186,O
is,2186,O
expressed,2186,O
in,2186,O
non-immune,2186,O
cells,2186,O
such,2186,O
as,2186,O
keratinocytes,2186,O
and,2186,O
fibroblasts,2186,O
.,2186,O
Highly,2187,O
selective,2187,O
PDE4,2187,B-GENE-N
inhibitors,2187,O
are,2187,O
currently,2187,O
under,2187,O
evaluation,2187,O
for,2187,O
the,2187,O
treatment,2187,O
of,2187,O
asthma,2187,O
and/or,2187,O
chronic,2187,O
obstructive,2187,O
pulmonary,2187,O
disease,2187,O
.,2187,O
Due,2188,O
to,2188,O
the,2188,O
broad,2188,O
anti-inflammatory/immuno-modulatory,2188,O
action,2188,O
of,2188,O
PDE4,2188,B-GENE-N
inhibitors,2188,O
",",2188,O
it,2188,O
has,2188,O
been,2188,O
proposed,2188,O
that,2188,O
PDE4,2188,B-GENE-N
inhibitors,2188,O
might,2188,O
also,2188,O
be,2188,O
efficacious,2188,O
for,2188,O
skin,2188,O
disorders,2188,O
such,2188,O
as,2188,O
atopic,2188,O
dermatitis,2188,O
.,2188,O
Consequently,2189,O
",",2189,O
PDE4,2189,B-GENE-N
inhibitors,2189,O
including,2189,O
cilomilast,2189,B-CHEMICAL
and,2189,O
AWD,2189,B-CHEMICAL
12-281,2189,I-CHEMICAL
have,2189,O
been,2189,O
tested,2189,O
in,2189,O
several,2189,O
models,2189,O
of,2189,O
allergic,2189,O
and,2189,O
irritant,2189,O
skin,2189,O
inflammation,2189,O
.,2189,O
These,2190,O
PDE4,2190,B-GENE-N
inhibitors,2190,O
displayed,2190,O
strong,2190,O
anti-inflammatory,2190,O
action,2190,O
in,2190,O
models,2190,O
of,2190,O
allergic,2190,O
contact,2190,O
dermatitis,2190,O
in,2190,O
mice,2190,O
",",2190,O
in,2190,O
the,2190,O
arachidonic,2190,B-CHEMICAL
acid,2190,I-CHEMICAL
induced,2190,O
skin,2190,O
inflammation,2190,O
in,2190,O
mice,2190,O
and,2190,O
in,2190,O
ovalbumin,2190,B-GENE-Y
sensitised,2190,O
guinea,2190,O
pigs,2190,O
.,2190,O
The,2191,O
determination,2191,O
of,2191,O
cytokines,2191,B-GENE-N
in,2191,O
skin,2191,O
homogenates,2191,O
revealed,2191,O
that,2191,O
both,2191,O
Th1,2191,O
as,2191,O
well,2191,O
as,2191,O
Th2,2191,O
cytokines,2191,B-GENE-N
are,2191,O
suppressed,2191,O
by,2191,O
PDE4,2191,B-GENE-N
inhibitors,2191,O
",",2191,O
indicating,2191,O
an,2191,O
anti-inflammatory,2191,O
activity,2191,O
in,2191,O
both,2191,O
the,2191,O
Th2,2191,O
dominated,2191,O
acute,2191,O
phase,2191,O
as,2191,O
well,2191,O
as,2191,O
the,2191,O
Th1,2191,O
dominated,2191,O
chronic,2191,O
phase,2191,O
of,2191,O
atopic,2191,O
dermatitis,2191,O
.,2191,O
Due,2192,O
to,2192,O
the,2192,O
suppression,2192,O
of,2192,O
Th1,2192,O
cytokines,2192,B-GENE-N
",",2192,O
activity,2192,O
can,2192,O
also,2192,O
be,2192,O
expected,2192,O
in,2192,O
psoriasis,2192,O
.,2192,O
Results,2193,O
of,2193,O
early,2193,O
clinical,2193,O
trials,2193,O
with,2193,O
both,2193,O
topically,2193,O
(,2193,O
cipamfylline,2193,B-CHEMICAL
",",2193,O
"CP80,633",2193,B-CHEMICAL
),2193,O
and,2193,O
systemically,2193,O
(,2193,O
CC-10004,2193,O
),2193,O
active,2193,O
PDE4,2193,B-GENE-N
inhibitors,2193,O
demonstrated,2193,O
efficacy,2193,O
in,2193,O
atopic,2193,O
dermatitis,2193,O
and,2193,O
in,2193,O
the,2193,O
case,2193,O
of,2193,O
CC-10004,2193,O
",",2193,O
also,2193,O
in,2193,O
psoriasis,2193,O
.,2193,O
AWD,2194,B-CHEMICAL
12-281,2194,I-CHEMICAL
(,2194,O
GW,2194,B-CHEMICAL
842470,2194,I-CHEMICAL
),2194,O
is,2194,O
currently,2194,O
under,2194,O
clinical,2194,O
evaluation,2194,O
for,2194,O
the,2194,O
topical,2194,O
treatment,2194,O
of,2194,O
atopic,2194,O
dermatitis,2194,O
.,2194,O
Results,2195,O
concerning,2195,O
clinical,2195,O
efficacy,2195,O
of,2195,O
this,2195,O
potent,2195,O
and,2195,O
selective,2195,O
PDE4,2195,B-GENE-N
inhibitor,2195,O
are,2195,O
anxiously,2195,O
awaited,2195,O
.,2195,O
Aberrant,2196,O
regulation,2196,O
of,2196,O
argininosuccinate,2196,B-CHEMICAL
synthetase,2196,I-GENE-Y
by,2196,O
TNF-alpha,2196,B-GENE-Y
in,2196,O
human,2196,O
epithelial,2196,O
ovarian,2196,O
cancer,2196,O
.,2196,O
The,2197,O
pro-inflammatory,2197,O
cytokine,2197,B-GENE-N
",",2197,O
tumour,2197,B-GENE-Y
necrosis,2197,I-GENE-Y
factor-alpha,2197,I-GENE-Y
",",2197,O
TNF-alpha,2197,B-GENE-Y
",",2197,O
is,2197,O
dysregulated,2197,O
in,2197,O
malignant,2197,O
compared,2197,O
with,2197,O
normal,2197,O
ovarian,2197,O
surface,2197,O
epithelium,2197,O
(,2197,O
OSE,2197,O
),2197,O
.,2197,O
Several,2198,O
epidemiological,2198,O
studies,2198,O
have,2198,O
associated,2198,O
inflammation,2198,O
with,2198,O
ovarian,2198,O
tumorigenesis,2198,O
",",2198,O
with,2198,O
TNF-alpha,2198,B-GENE-Y
playing,2198,O
a,2198,O
key,2198,O
role,2198,O
in,2198,O
modulating,2198,O
invasion,2198,O
",",2198,O
angiogenesis,2198,O
and,2198,O
metastasis,2198,O
.,2198,O
Here,2199,O
",",2199,O
we,2199,O
show,2199,O
that,2199,O
TNF-alpha,2199,B-GENE-Y
also,2199,O
induces,2199,O
expression,2199,O
of,2199,O
arate-limiting,2199,O
enzyme,2199,O
in,2199,O
arginine,2199,B-CHEMICAL
synthesis,2199,O
",",2199,O
argininosuccinate,2199,B-CHEMICAL
synthetase,2199,I-GENE-Y
(,2199,O
AS,2199,B-GENE-Y
),2199,O
",",2199,O
thereby,2199,O
linking,2199,O
inflammation,2199,O
with,2199,O
several,2199,O
arginine-dependent,2199,B-CHEMICAL
metabolic,2199,O
pathways,2199,O
",",2199,O
implicated,2199,O
in,2199,O
accelerated,2199,O
carcinogenesis,2199,O
and,2199,O
tumour,2199,O
progression,2199,O
.,2199,O
Having,2200,O
identified,2200,O
AS,2200,B-GENE-Y
mRNA,2200,O
induction,2200,O
in,2200,O
TNF-alpha-treated,2200,B-GENE-Y
IGROV-1,2200,O
ovarian,2200,O
cancer,2200,O
cells,2200,O
",",2200,O
using,2200,O
RNA-arbitrarily,2200,O
primed-PCR,2200,O
",",2200,O
we,2200,O
then,2200,O
observed,2200,O
differential,2200,O
regulation,2200,O
of,2200,O
AS,2200,B-GENE-Y
mRNA,2200,O
and,2200,O
protein,2200,O
in,2200,O
malignant,2200,O
",",2200,O
compared,2200,O
with,2200,O
normal,2200,O
",",2200,O
OSE,2200,O
cells,2200,O
.,2200,O
A,2201,O
cDNA,2201,O
cancer,2201,O
profiling,2201,O
array,2201,O
with,2201,O
matched,2201,O
normal,2201,O
ovarian,2201,O
and,2201,O
ovarian,2201,O
tumour,2201,O
samples,2201,O
revealed,2201,O
increased,2201,O
expression,2201,O
of,2201,O
AS,2201,B-GENE-Y
mRNA,2201,O
in,2201,O
the,2201,O
latter,2201,O
.,2201,O
Moreover,2202,O
",",2202,O
AS,2202,B-GENE-Y
protein,2202,O
co-localised,2202,O
with,2202,O
TNF-alpha,2202,B-GENE-Y
in,2202,O
ovarian,2202,O
cancer,2202,O
cells,2202,O
",",2202,O
with,2202,O
significantly,2202,O
higher,2202,O
levels,2202,O
of,2202,O
AS,2202,B-GENE-Y
in,2202,O
malignant,2202,O
compared,2202,O
with,2202,O
normal,2202,O
ovarian,2202,O
tissue,2202,O
.,2202,O
Increased,2203,O
co-expression,2203,O
of,2203,O
AS,2203,B-GENE-Y
and,2203,O
TNF-alpha,2203,B-GENE-Y
mRNA,2203,O
was,2203,O
also,2203,O
observed,2203,O
in,2203,O
2,2203,O
other,2203,O
epithelial,2203,O
tumours,2203,O
",",2203,O
non-small,2203,O
cell,2203,O
lung,2203,O
and,2203,O
stomach,2203,O
cancer,2203,O
",",2203,O
compared,2203,O
with,2203,O
normal,2203,O
corresponding,2203,O
tissues,2203,O
.,2203,O
In,2204,O
summary,2204,O
",",2204,O
high,2204,O
levels,2204,O
of,2204,O
AS,2204,B-GENE-Y
expression,2204,O
",",2204,O
which,2204,O
may,2204,O
be,2204,O
required,2204,O
for,2204,O
several,2204,O
arginine-dependent,2204,B-CHEMICAL
processes,2204,O
in,2204,O
cancer,2204,O
",",2204,O
including,2204,O
the,2204,O
production,2204,O
of,2204,O
nitric,2204,B-CHEMICAL
oxide,2204,I-CHEMICAL
",",2204,O
proline,2204,B-CHEMICAL
",",2204,O
pyrimidines,2204,B-CHEMICAL
and,2204,O
polyamines,2204,B-CHEMICAL
",",2204,O
is,2204,O
regulated,2204,O
by,2204,O
TNF-alpha,2204,B-GENE-Y
and,2204,O
may,2204,O
provide,2204,O
an,2204,O
important,2204,O
molecular,2204,O
pathway,2204,O
linking,2204,O
inflammation,2204,O
and,2204,O
metabolism,2204,O
to,2204,O
ovarian,2204,O
tumorigenesis,2204,O
.,2204,O
Mechanism,2205,O
of,2205,O
specific,2205,O
membrane,2205,O
targeting,2205,O
by,2205,O
C2,2205,B-GENE-N
domains,2205,I-GENE-N
:,2205,O
localized,2205,O
pools,2205,O
of,2205,O
target,2205,O
lipids,2205,O
enhance,2205,O
Ca2+,2205,B-CHEMICAL
affinity,2205,O
.,2205,O
The,2206,O
C2,2206,B-GENE-N
domain,2206,I-GENE-N
is,2206,O
a,2206,O
ubiquitous,2206,O
",",2206,O
conserved,2206,O
protein,2206,B-GENE-N
signaling,2206,I-GENE-N
motif,2206,I-GENE-N
widely,2206,O
found,2206,O
in,2206,O
eukaryotic,2206,O
signaling,2206,O
proteins,2206,O
.,2206,O
Although,2207,O
considerable,2207,O
functional,2207,O
diversity,2207,O
exists,2207,O
",",2207,O
most,2207,O
C2,2207,B-GENE-N
domains,2207,I-GENE-N
are,2207,O
activated,2207,O
by,2207,O
Ca2+,2207,B-CHEMICAL
binding,2207,O
and,2207,O
then,2207,O
dock,2207,O
to,2207,O
a,2207,O
specific,2207,O
cellular,2207,O
membrane,2207,O
.,2207,O
The,2208,O
C2,2208,B-GENE-N
domains,2208,I-GENE-N
of,2208,O
protein,2208,B-GENE-Y
kinase,2208,I-GENE-Y
Calpha,2208,I-GENE-Y
(,2208,O
PKCalpha,2208,B-GENE-Y
),2208,O
and,2208,O
cytosolic,2208,B-GENE-Y
phospholipase,2208,I-GENE-Y
A2alpha,2208,I-GENE-Y
(,2208,O
cPLA2alpha,2208,B-GENE-Y
),2208,O
",",2208,O
for,2208,O
example,2208,O
",",2208,O
are,2208,O
known,2208,O
to,2208,O
dock,2208,O
to,2208,O
different,2208,O
membrane,2208,O
surfaces,2208,O
during,2208,O
an,2208,O
intracellular,2208,O
Ca2+,2208,B-CHEMICAL
signal,2208,O
.,2208,O
Ca2+,2209,B-CHEMICAL
activation,2209,O
targets,2209,O
the,2209,O
PKCalpha,2209,B-GENE-N
C2,2209,I-GENE-N
domain,2209,I-GENE-N
to,2209,O
the,2209,O
plasma,2209,O
membrane,2209,O
and,2209,O
the,2209,O
cPLA2alpha,2209,B-GENE-N
C2,2209,I-GENE-N
domain,2209,I-GENE-N
to,2209,O
the,2209,O
internal,2209,O
membranes,2209,O
",",2209,O
with,2209,O
no,2209,O
detectable,2209,O
spatial,2209,O
overlap,2209,O
.,2209,O
It,2210,O
is,2210,O
crucial,2210,O
to,2210,O
determine,2210,O
how,2210,O
such,2210,O
targeting,2210,O
specificity,2210,O
is,2210,O
achieved,2210,O
at,2210,O
physiological,2210,O
bulk,2210,O
Ca2+,2210,B-CHEMICAL
concentrations,2210,O
that,2210,O
during,2210,O
a,2210,O
typical,2210,O
signaling,2210,O
event,2210,O
rarely,2210,O
exceed,2210,O
1,2210,O
muM,2210,O
.,2210,O
For,2211,O
the,2211,O
isolated,2211,O
PKCalpha,2211,B-GENE-N
C2,2211,I-GENE-N
domain,2211,I-GENE-N
in,2211,O
the,2211,O
presence,2211,O
of,2211,O
physiological,2211,O
Ca2+,2211,B-CHEMICAL
levels,2211,O
",",2211,O
the,2211,O
target,2211,O
lipids,2211,O
phosphatidylserine,2211,B-CHEMICAL
(,2211,O
PS,2211,B-CHEMICAL
),2211,O
and,2211,O
"phosphatidylinositol-4,5-bisphosphate",2211,B-CHEMICAL
(,2211,O
PIP2,2211,B-CHEMICAL
),2211,O
are,2211,O
together,2211,O
sufficient,2211,O
to,2211,O
recruit,2211,O
the,2211,O
PKCalpha,2211,B-GENE-N
C2,2211,I-GENE-N
domain,2211,O
to,2211,O
a,2211,O
lipid,2211,O
mixture,2211,O
mimicking,2211,O
the,2211,O
plasma,2211,O
membrane,2211,O
inner,2211,O
leaflet,2211,O
.,2211,O
For,2212,O
the,2212,O
cPLA2alpha,2212,B-GENE-N
C2,2212,I-GENE-N
domain,2212,I-GENE-N
",",2212,O
the,2212,O
target,2212,O
lipid,2212,O
phosphatidylcholine,2212,B-CHEMICAL
(,2212,O
PC,2212,B-CHEMICAL
),2212,O
appears,2212,O
to,2212,O
be,2212,O
sufficient,2212,O
to,2212,O
drive,2212,O
membrane,2212,O
targeting,2212,O
to,2212,O
an,2212,O
internal,2212,O
membrane,2212,O
mimic,2212,O
at,2212,O
physiological,2212,O
Ca2+,2212,B-CHEMICAL
levels,2212,O
",",2212,O
although,2212,O
the,2212,O
results,2212,O
do,2212,O
not,2212,O
rule,2212,O
out,2212,O
a,2212,O
second,2212,O
",",2212,O
unknown,2212,O
target,2212,O
molecule,2212,O
.,2212,O
Stopped-flow,2213,O
kinetic,2213,O
studies,2213,O
provide,2213,O
additional,2213,O
information,2213,O
about,2213,O
the,2213,O
fundamental,2213,O
molecular,2213,O
events,2213,O
that,2213,O
occur,2213,O
during,2213,O
Ca2+-activated,2213,B-CHEMICAL
membrane,2213,O
docking,2213,O
.,2213,O
In,2214,O
principle,2214,O
",",2214,O
C2,2214,B-GENE-N
domain-directed,2214,O
intracellular,2214,O
targeting,2214,O
",",2214,O
which,2214,O
requires,2214,O
coincidence,2214,O
detection,2214,O
of,2214,O
multiple,2214,O
signals,2214,O
(,2214,O
Ca2+,2214,B-CHEMICAL
and,2214,O
one,2214,O
or,2214,O
more,2214,O
target,2214,O
lipids,2214,O
),2214,O
",",2214,O
can,2214,O
exhibit,2214,O
two,2214,O
different,2214,O
mechanisms,2214,O
:,2214,O
messenger-activated,2214,O
target,2214,O
affinity,2214,O
(,2214,O
MATA,2214,O
),2214,O
and,2214,O
target-activated,2214,O
messenger,2214,O
affinity,2214,O
(,2214,O
TAMA,2214,O
),2214,O
.,2214,O
The,2215,O
C2,2215,B-GENE-N
domains,2215,I-GENE-N
studied,2215,O
here,2215,O
both,2215,O
utilize,2215,O
the,2215,O
TAMA,2215,O
mechanism,2215,O
",",2215,O
in,2215,O
which,2215,O
the,2215,O
C2,2215,B-GENE-N
domain,2215,I-GENE-N
Ca2+,2215,B-CHEMICAL
affinity,2215,O
is,2215,O
too,2215,O
low,2215,O
to,2215,O
be,2215,O
activated,2215,O
by,2215,O
physiological,2215,O
Ca2+,2215,B-CHEMICAL
signals,2215,O
in,2215,O
most,2215,O
regions,2215,O
of,2215,O
the,2215,O
cell,2215,O
.,2215,O
Only,2216,O
when,2216,O
the,2216,O
C2,2216,B-GENE-N
domain,2216,I-GENE-N
nears,2216,O
its,2216,O
target,2216,O
membrane,2216,O
",",2216,O
which,2216,O
provides,2216,O
a,2216,O
high,2216,O
local,2216,O
concentration,2216,O
of,2216,O
target,2216,O
lipid,2216,O
",",2216,O
is,2216,O
the,2216,O
effective,2216,O
Ca2+,2216,B-CHEMICAL
affinity,2216,O
increased,2216,O
by,2216,O
the,2216,O
coupled,2216,O
binding,2216,O
equilibrium,2216,O
to,2216,O
a,2216,O
level,2216,O
that,2216,O
enables,2216,O
substantial,2216,O
Ca2+,2216,B-CHEMICAL
activation,2216,O
and,2216,O
target,2216,O
docking,2216,O
.,2216,O
Overall,2217,O
",",2217,O
the,2217,O
findings,2217,O
emphasize,2217,O
the,2217,O
importance,2217,O
of,2217,O
using,2217,O
physiological,2217,O
ligand,2217,O
concentrations,2217,O
in,2217,O
targeting,2217,O
studies,2217,O
because,2217,O
super-physiological,2217,O
concentrations,2217,O
can,2217,O
drive,2217,O
docking,2217,O
interactions,2217,O
even,2217,O
when,2217,O
an,2217,O
important,2217,O
targeting,2217,O
molecule,2217,O
is,2217,O
missing,2217,O
.,2217,O
Quantification,2218,O
and,2218,O
regulation,2218,O
of,2218,O
the,2218,O
subcellular,2218,O
distribution,2218,O
of,2218,O
bile,2218,B-GENE-Y
acid,2218,I-GENE-Y
coenzyme,2218,I-GENE-Y
A,2218,I-GENE-Y
:,2218,I-GENE-Y
amino,2218,I-GENE-Y
acid,2218,I-GENE-Y
N-acyltransferase,2218,I-GENE-Y
activity,2218,O
in,2218,O
rat,2218,O
liver,2218,O
.,2218,O
Bile,2219,B-CHEMICAL
acid,2219,I-CHEMICAL
coenzyme,2219,B-CHEMICAL
A,2219,I-CHEMICAL
:,2219,I-GENE-Y
amino,2219,B-CHEMICAL
acid,2219,I-CHEMICAL
N-acyltransferase,2219,I-GENE-Y
(,2219,O
BAT,2219,B-GENE-Y
),2219,O
is,2219,O
responsible,2219,O
for,2219,O
the,2219,O
amidation,2219,O
of,2219,O
bile,2219,B-CHEMICAL
acids,2219,I-CHEMICAL
with,2219,O
the,2219,O
amino,2219,B-CHEMICAL
acids,2219,I-CHEMICAL
glycine,2219,B-CHEMICAL
and,2219,O
taurine,2219,B-CHEMICAL
.,2219,O
To,2220,O
quantify,2220,O
total,2220,O
BAT,2220,B-GENE-Y
activity,2220,O
in,2220,O
liver,2220,O
subcellular,2220,O
organelles,2220,O
",",2220,O
livers,2220,O
from,2220,O
young,2220,O
adult,2220,O
male,2220,O
and,2220,O
female,2220,O
Sprague-Dawley,2220,O
rats,2220,O
were,2220,O
fractionated,2220,O
into,2220,O
multiple,2220,O
subcellular,2220,O
compartments,2220,O
.,2220,O
In,2221,O
male,2221,O
and,2221,O
female,2221,O
rats,2221,O
",",2221,O
65-75,2221,O
%,2221,O
of,2221,O
total,2221,O
liver,2221,O
BAT,2221,B-GENE-Y
activity,2221,O
was,2221,O
found,2221,O
in,2221,O
the,2221,O
cytosol,2221,O
",",2221,O
15-17,2221,O
%,2221,O
was,2221,O
found,2221,O
in,2221,O
the,2221,O
peroxisomes,2221,O
",",2221,O
and,2221,O
5-10,2221,O
%,2221,O
was,2221,O
found,2221,O
in,2221,O
the,2221,O
heavy,2221,O
mitochondrial,2221,O
fraction,2221,O
.,2221,O
After,2222,O
clofibrate,2222,O
treatment,2222,O
",",2222,O
male,2222,O
rats,2222,O
displayed,2222,O
an,2222,O
increase,2222,O
in,2222,O
peroxisomal,2222,O
BAT,2222,B-GENE-Y
specific,2222,O
activity,2222,O
and,2222,O
a,2222,O
decrease,2222,O
in,2222,O
cytosolic,2222,O
BAT,2222,B-GENE-Y
specific,2222,O
activity,2222,O
",",2222,O
whereas,2222,O
females,2222,O
showed,2222,O
an,2222,O
opposite,2222,O
response,2222,O
.,2222,O
However,2223,O
",",2223,O
there,2223,O
was,2223,O
no,2223,O
overall,2223,O
change,2223,O
in,2223,O
BAT,2223,B-GENE-Y
specific,2223,O
activity,2223,O
in,2223,O
whole,2223,O
liver,2223,O
homogenate,2223,O
.,2223,O
Treatment,2224,O
with,2224,O
rosiglitazone,2224,B-CHEMICAL
or,2224,O
cholestyramine,2224,B-CHEMICAL
had,2224,O
no,2224,O
effect,2224,O
on,2224,O
BAT,2224,B-GENE-Y
activity,2224,O
in,2224,O
any,2224,O
subcellular,2224,O
compartment,2224,O
.,2224,O
These,2225,O
experiments,2225,O
indicate,2225,O
that,2225,O
the,2225,O
majority,2225,O
of,2225,O
BAT,2225,B-GENE-Y
activity,2225,O
in,2225,O
the,2225,O
rat,2225,O
liver,2225,O
resides,2225,O
in,2225,O
the,2225,O
cytosol,2225,O
.,2225,O
Approximately,2226,O
15,2226,O
%,2226,O
of,2226,O
BAT,2226,B-GENE-Y
activity,2226,O
is,2226,O
present,2226,O
in,2226,O
the,2226,O
peroxisomal,2226,O
matrix,2226,O
.,2226,O
These,2227,O
data,2227,O
support,2227,O
the,2227,O
novel,2227,O
finding,2227,O
that,2227,O
clofibrate,2227,B-CHEMICAL
treatment,2227,O
does,2227,O
not,2227,O
directly,2227,O
regulate,2227,O
BAT,2227,B-GENE-Y
activity,2227,O
but,2227,O
does,2227,O
alter,2227,O
the,2227,O
subcellular,2227,O
localization,2227,O
of,2227,O
BAT,2227,B-GENE-Y
.,2227,O
Mesenchymal,2228,O
cells,2228,O
regulate,2228,O
the,2228,O
response,2228,O
of,2228,O
acute,2228,O
lymphoblastic,2228,O
leukemia,2228,O
cells,2228,O
to,2228,O
asparaginase,2228,B-GENE-N
.,2228,O
Because,2229,O
of,2229,O
their,2229,O
low,2229,O
asparagine,2229,B-GENE-Y
synthetase,2229,I-GENE-Y
(,2229,O
ASNS,2229,B-GENE-Y
),2229,O
expression,2229,O
and,2229,O
asparagine,2229,B-CHEMICAL
biosynthesis,2229,O
",",2229,O
acute,2229,O
lymphoblastic,2229,O
leukemia,2229,O
(,2229,O
ALL,2229,O
),2229,O
cells,2229,O
are,2229,O
exquisitely,2229,O
sensitive,2229,O
to,2229,O
asparagine,2229,B-CHEMICAL
depletion,2229,O
.,2229,O
Consequently,2230,O
",",2230,O
asparaginase,2230,B-GENE-N
is,2230,O
a,2230,O
major,2230,O
component,2230,O
of,2230,O
ALL,2230,O
therapy,2230,O
",",2230,O
but,2230,O
the,2230,O
mechanisms,2230,O
regulating,2230,O
the,2230,O
susceptibility,2230,O
of,2230,O
leukemic,2230,O
cells,2230,O
to,2230,O
this,2230,O
agent,2230,O
are,2230,O
unclear,2230,O
.,2230,O
In,2231,O
288,2231,O
children,2231,O
with,2231,O
ALL,2231,O
",",2231,O
cellular,2231,O
ASNS,2231,B-GENE-Y
expression,2231,O
was,2231,O
more,2231,O
likely,2231,O
to,2231,O
be,2231,O
high,2231,O
in,2231,O
T-lineage,2231,O
ALL,2231,O
and,2231,O
low,2231,O
in,2231,O
B-lineage,2231,O
ALL,2231,O
with,2231,O
TEL-AML1,2231,B-GENE-Y
or,2231,O
hyperdiploidy,2231,O
.,2231,O
However,2232,O
",",2232,O
ASNS,2232,B-GENE-Y
expression,2232,O
levels,2232,O
in,2232,O
bone,2232,O
marrow-derived,2232,O
mesenchymal,2232,O
cells,2232,O
(,2232,O
MSCs,2232,O
),2232,O
",",2232,O
which,2232,O
form,2232,O
the,2232,O
microenvironment,2232,O
where,2232,O
leukemic,2232,O
cells,2232,O
grow,2232,O
",",2232,O
were,2232,O
on,2232,O
average,2232,O
20,2232,O
times,2232,O
higher,2232,O
than,2232,O
those,2232,O
in,2232,O
ALL,2232,O
cells,2232,O
.,2232,O
MSCs,2233,O
protected,2233,O
ALL,2233,O
cells,2233,O
from,2233,O
asparaginase,2233,B-GENE-N
cytotoxicity,2233,O
in,2233,O
coculture,2233,O
experiments,2233,O
.,2233,O
This,2234,O
protective,2234,O
effect,2234,O
correlated,2234,O
with,2234,O
levels,2234,O
of,2234,O
ASNS,2234,B-GENE-Y
expression,2234,O
:,2234,O
downregulation,2234,O
by,2234,O
RNA,2234,O
interference,2234,O
decreased,2234,O
the,2234,O
capacity,2234,O
of,2234,O
MSCs,2234,O
to,2234,O
protect,2234,O
ALL,2234,O
cells,2234,O
from,2234,O
asparaginase,2234,B-GENE-N
",",2234,O
whereas,2234,O
enforced,2234,O
ASNS,2234,B-GENE-Y
expression,2234,O
conferred,2234,O
enhanced,2234,O
protection,2234,O
.,2234,O
Asparagine,2235,B-CHEMICAL
secretion,2235,O
by,2235,O
MSCs,2235,O
was,2235,O
directly,2235,O
related,2235,O
to,2235,O
their,2235,O
ASNS,2235,B-GENE-Y
expression,2235,O
levels,2235,O
",",2235,O
suggesting,2235,O
a,2235,O
mechanism,2235,O
-,2235,O
increased,2235,O
concentrations,2235,O
of,2235,O
asparagine,2235,B-CHEMICAL
in,2235,O
the,2235,O
leukemic,2235,O
cell,2235,O
microenvironment,2235,O
-,2235,O
for,2235,O
the,2235,O
protective,2235,O
effects,2235,O
we,2235,O
observed,2235,O
.,2235,O
These,2236,O
results,2236,O
provide,2236,O
what,2236,O
we,2236,O
believe,2236,O
to,2236,O
be,2236,O
a,2236,O
new,2236,O
basis,2236,O
for,2236,O
understanding,2236,O
asparaginase,2236,B-GENE-N
resistance,2236,O
in,2236,O
ALL,2236,O
and,2236,O
indicate,2236,O
that,2236,O
MSC,2236,O
niches,2236,O
in,2236,O
the,2236,O
bone,2236,O
marrow,2236,O
can,2236,O
form,2236,O
a,2236,O
safe,2236,O
haven,2236,O
for,2236,O
leukemic,2236,O
cells,2236,O
.,2236,O
Toxicity,2237,O
of,2237,O
beta-amyloid,2237,B-GENE-Y
in,2237,O
HEK293,2237,O
cells,2237,O
expressing,2237,O
NR1/NR2A,2237,B-GENE-Y
or,2237,O
NR1/NR2B,2237,B-GENE-Y
N-methyl-D-aspartate,2237,B-GENE-N
receptor,2237,I-GENE-N
subunits,2237,O
.,2237,O
Neurotoxicity,2238,O
induced,2238,O
by,2238,O
beta-amyloid,2238,B-GENE-Y
peptide,2238,I-GENE-Y
(,2238,O
Abeta,2238,B-GENE-Y
),2238,O
involves,2238,O
glutamate,2238,B-CHEMICAL
toxicity,2238,O
",",2238,O
resulting,2238,O
from,2238,O
overactivation,2238,O
of,2238,O
N-methyl-D-aspartate,2238,B-GENE-N
(,2238,I-GENE-N
NMDA,2238,B-CHEMICAL
),2238,I-GENE-N
receptors,2238,I-GENE-N
and,2238,O
elevation,2238,O
of,2238,O
intracellular,2238,O
calcium,2238,B-CHEMICAL
.,2238,O
However,2239,O
",",2239,O
the,2239,O
heterogeneity,2239,O
of,2239,O
the,2239,O
NMDA,2239,B-GENE-N
receptors,2239,I-GENE-N
",",2239,O
frequently,2239,O
composed,2239,O
of,2239,O
NR1,2239,B-GENE-Y
and,2239,O
NR2A-D,2239,B-GENE-N
subunits,2239,O
",",2239,O
has,2239,O
been,2239,O
less,2239,O
studied,2239,O
.,2239,O
Thus,2240,O
",",2240,O
we,2240,O
determined,2240,O
the,2240,O
contribution,2240,O
of,2240,O
NMDA,2240,B-GENE-N
receptor,2240,I-GENE-N
subtypes,2240,O
on,2240,O
Abeta,2240,B-GENE-Y
(,2240,I-GENE-Y
1-40,2240,I-GENE-Y
),2240,I-GENE-Y
toxicity,2240,O
in,2240,O
HEK293,2240,O
cells,2240,O
transiently,2240,O
expressing,2240,O
NR1/NR2A,2240,B-GENE-Y
or,2240,O
NR1/NR2B,2240,B-GENE-Y
subunits,2240,O
.,2240,O
Analysis,2241,O
of,2241,O
lactate,2241,B-GENE-N
dehydrogenase,2241,I-GENE-N
(,2241,O
LDH,2241,B-GENE-N
),2241,O
release,2241,O
and,2241,O
trypan,2241,B-CHEMICAL
blue,2241,I-CHEMICAL
exclusion,2241,O
revealed,2241,O
an,2241,O
increase,2241,O
in,2241,O
Abeta,2241,B-GENE-Y
(,2241,I-GENE-Y
1-40,2241,I-GENE-Y
),2241,I-GENE-Y
toxicity,2241,O
upon,2241,O
NR1/NR2A,2241,B-GENE-Y
expression,2241,O
",",2241,O
compared,2241,O
to,2241,O
NR1/NR2B,2241,B-GENE-Y
",",2241,O
indicating,2241,O
loss,2241,O
of,2241,O
plasma,2241,O
membrane,2241,O
integrity,2241,O
.,2241,O
Furthermore,2242,O
",",2242,O
Abeta,2242,B-GENE-Y
(,2242,I-GENE-Y
1-40,2242,I-GENE-Y
),2242,I-GENE-Y
decreased,2242,O
intracellular,2242,O
ATP,2242,B-CHEMICAL
in,2242,O
cells,2242,O
expressing,2242,O
NR1/NR2A,2242,B-GENE-Y
.,2242,O
MK-801,2243,B-CHEMICAL
(,2243,O
(,2243,B-CHEMICAL
+,2243,I-CHEMICAL
),2243,I-CHEMICAL
"-5-methyl-10,11-dihydro-5H-dibenzo",2243,I-CHEMICAL
[,2243,I-CHEMICAL
a,2243,I-CHEMICAL
",",2243,I-CHEMICAL
d,2243,I-CHEMICAL
],2243,I-CHEMICAL
"cyclohepten-5,10-imine",2243,I-CHEMICAL
maleate,2243,I-CHEMICAL
),2243,O
",",2243,O
a,2243,O
noncompetitive,2243,O
NMDA,2243,B-GENE-N
receptor,2243,I-GENE-N
antagonist,2243,O
",",2243,O
partially,2243,O
prevented,2243,O
the,2243,O
decrease,2243,O
in,2243,O
cell,2243,O
viability,2243,O
and,2243,O
the,2243,O
energy,2243,O
impairment,2243,O
.,2243,O
These,2244,O
differences,2244,O
were,2244,O
not,2244,O
accounted,2244,O
for,2244,O
by,2244,O
the,2244,O
activation,2244,O
of,2244,O
caspases,2244,B-GENE-N
2,2244,I-GENE-N
",",2244,I-GENE-N
3,2244,I-GENE-N
",",2244,I-GENE-N
8,2244,I-GENE-N
and,2244,I-GENE-N
9,2244,I-GENE-N
or,2244,O
calpains,2244,O
or,2244,O
by,2244,O
DNA,2244,O
fragmentation,2244,O
",",2244,O
excluding,2244,O
the,2244,O
hypothesis,2244,O
of,2244,O
apoptosis,2244,O
.,2244,O
Functional,2245,O
NR1/NR2A,2245,B-GENE-Y
and,2245,O
NR1/NR2B,2245,B-GENE-Y
receptor,2245,O
subtypes,2245,O
were,2245,O
further,2245,O
evidenced,2245,O
by,2245,O
single-cell,2245,O
calcium,2245,B-CHEMICAL
imaging,2245,O
.,2245,O
Stimulation,2246,O
of,2246,O
NR1/NR2A,2246,B-GENE-Y
receptors,2246,O
with,2246,O
NMDA/glycine,2246,B-CHEMICAL
revealed,2246,O
an,2246,O
increase,2246,O
in,2246,O
intracellular,2246,O
calcium,2246,B-CHEMICAL
in,2246,O
cells,2246,O
pre-exposed,2246,O
to,2246,O
Abeta,2246,B-GENE-Y
(,2246,I-GENE-Y
1-40,2246,I-GENE-Y
),2246,I-GENE-Y
.,2246,O
Opposite,2247,O
effects,2247,O
were,2247,O
observed,2247,O
upon,2247,O
activation,2247,O
of,2247,O
NR1/NR2B,2247,B-GENE-Y
receptors,2247,O
.,2247,O
These,2248,O
results,2248,O
suggest,2248,O
that,2248,O
NR1/NR2A-composed,2248,B-GENE-Y
NMDA,2248,B-CHEMICAL
receptors,2248,I-GENE-N
mediate,2248,O
necrotic,2248,O
cell,2248,O
death,2248,O
in,2248,O
HEK293,2248,O
cells,2248,O
exposed,2248,O
to,2248,O
Abeta,2248,B-GENE-Y
(,2248,I-GENE-Y
1-40,2248,I-GENE-Y
),2248,I-GENE-Y
through,2248,O
changes,2248,O
in,2248,O
calcium,2248,B-CHEMICAL
homeostasis,2248,O
.,2248,O
Competition,2249,O
between,2249,O
24:5n-3,2249,O
and,2249,O
ALA,2249,O
for,2249,O
Delta,2249,B-GENE-Y
6,2249,I-GENE-Y
desaturase,2249,I-GENE-Y
may,2249,O
limit,2249,O
the,2249,O
accumulation,2249,O
of,2249,O
DHA,2249,O
in,2249,O
HepG2,2249,O
cell,2249,O
membranes,2249,O
.,2249,O
The,2250,O
use,2250,O
of,2250,O
Delta,2250,B-GENE-Y
6,2250,I-GENE-Y
desaturase,2250,I-GENE-Y
(,2250,O
D6D,2250,B-GENE-Y
),2250,O
twice,2250,O
in,2250,O
the,2250,O
conversion,2250,O
of,2250,O
alpha-linolenic,2250,B-CHEMICAL
acid,2250,I-CHEMICAL
(,2250,O
ALA,2250,B-CHEMICAL
;,2250,O
18:3n-3,2250,O
),2250,O
to,2250,O
docosahexaenoic,2250,B-CHEMICAL
acid,2250,I-CHEMICAL
(,2250,O
DHA,2250,B-CHEMICAL
;,2250,O
22:6n-3,2250,O
),2250,O
suggests,2250,O
that,2250,O
this,2250,O
enzyme,2250,O
may,2250,O
play,2250,O
a,2250,O
key,2250,O
regulatory,2250,O
role,2250,O
in,2250,O
the,2250,O
synthesis,2250,O
and,2250,O
accumulation,2250,O
of,2250,O
DHA,2250,B-CHEMICAL
from,2250,O
ALA.,2250,B-CHEMICAL
We,2250,O
examined,2250,O
this,2250,O
using,2250,O
an,2250,O
in,2250,O
vitro,2250,O
model,2250,O
of,2250,O
fatty,2250,B-CHEMICAL
acid,2250,I-CHEMICAL
metabolism,2250,O
to,2250,O
measure,2250,O
the,2250,O
accumulation,2250,O
of,2250,O
the,2250,O
long-chain,2250,O
metabolites,2250,O
of,2250,O
ALA,2250,B-CHEMICAL
in,2250,O
HepG2,2250,O
cell,2250,O
phospholipids,2250,O
.,2250,O
The,2251,O
accumulation,2251,O
of,2251,O
ALA,2251,B-CHEMICAL
",",2251,O
eicosapentaenoic,2251,B-CHEMICAL
acid,2251,I-CHEMICAL
(,2251,O
20:5n-3,2251,O
),2251,O
",",2251,O
docosapentaenoic,2251,B-CHEMICAL
acid,2251,I-CHEMICAL
(,2251,O
22:5n-3,2251,O
),2251,O
",",2251,O
and,2251,O
24:5n-3,2251,O
in,2251,O
cell,2251,O
phospholipids,2251,O
was,2251,O
linearly,2251,O
related,2251,O
to,2251,O
the,2251,O
concentration,2251,O
of,2251,O
supplemented,2251,O
ALA,2251,B-CHEMICAL
over,2251,O
the,2251,O
range,2251,O
tested,2251,O
(,2251,O
1.8-72,2251,O
microM,2251,O
),2251,O
.,2251,O
The,2252,O
accumulation,2252,O
of,2252,O
the,2252,O
post-D6D,2252,O
products,2252,O
of,2252,O
22:5n-3,2252,O
",",2252,O
24:6n-3,2252,O
and,2252,O
DHA,2252,B-CHEMICAL
",",2252,O
in,2252,O
cell,2252,O
phospholipids,2252,O
was,2252,O
saturated,2252,O
at,2252,O
concentrations,2252,O
of,2252,O
>,2252,O
18,2252,O
microM,2252,O
ALA.,2252,B-CHEMICAL
Supplementation,2252,O
of,2252,O
HepG2,2252,O
cells,2252,O
with,2252,O
preformed,2252,O
DHA,2252,B-CHEMICAL
revealed,2252,O
that,2252,O
",",2252,O
although,2252,O
the,2252,O
accumulation,2252,O
of,2252,O
DHA,2252,B-CHEMICAL
in,2252,O
cell,2252,O
phospholipids,2252,O
approached,2252,O
saturation,2252,O
",",2252,O
the,2252,O
level,2252,O
of,2252,O
DHA,2252,B-CHEMICAL
in,2252,O
cell,2252,O
phospholipids,2252,O
was,2252,O
significantly,2252,O
greater,2252,O
compared,2252,O
with,2252,O
the,2252,O
accumulation,2252,O
of,2252,O
DHA,2252,B-CHEMICAL
from,2252,O
ALA,2252,B-CHEMICAL
",",2252,O
indicating,2252,O
that,2252,O
the,2252,O
accumulation,2252,O
of,2252,O
DHA,2252,B-CHEMICAL
from,2252,O
ALA,2252,B-CHEMICAL
was,2252,O
not,2252,O
limited,2252,O
by,2252,O
incorporation,2252,O
.,2252,O
The,2253,O
parallel,2253,O
pattern,2253,O
of,2253,O
accumulation,2253,O
of,2253,O
24:6n-3,2253,O
and,2253,O
DHA,2253,B-CHEMICAL
in,2253,O
response,2253,O
to,2253,O
increasing,2253,O
concentrations,2253,O
of,2253,O
ALA,2253,B-CHEMICAL
suggests,2253,O
that,2253,O
the,2253,O
competition,2253,O
between,2253,O
24:5n-3,2253,O
and,2253,O
ALA,2253,B-CHEMICAL
for,2253,O
D6D,2253,B-GENE-Y
may,2253,O
contribute,2253,O
to,2253,O
the,2253,O
limited,2253,O
accumulation,2253,O
of,2253,O
DHA,2253,B-CHEMICAL
in,2253,O
cell,2253,O
membranes,2253,O
.,2253,O
Plasma,2254,O
S/R,2254,O
ratio,2254,O
of,2254,O
warfarin,2254,B-CHEMICAL
co-varies,2254,O
with,2254,O
VKORC1,2254,B-GENE-Y
haplotype,2254,O
.,2254,O
We,2255,O
recently,2255,O
reported,2255,O
that,2255,O
the,2255,O
low-dose,2255,O
VKORC1,2255,B-GENE-Y
*,2255,O
2,2255,O
haplotype,2255,O
is,2255,O
an,2255,O
important,2255,O
genetic,2255,O
determinant,2255,O
for,2255,O
warfarin,2255,B-CHEMICAL
dose,2255,O
requirement,2255,O
and,2255,O
is,2255,O
associated,2255,O
with,2255,O
difficulties,2255,O
to,2255,O
attain,2255,O
stable,2255,O
therapeutic,2255,O
prothrombin,2255,B-GENE-Y
time,2255,O
--,2255,O
International,2255,O
Normalized,2255,O
Ratio,2255,O
in,2255,O
patients,2255,O
undergoing,2255,O
anticoagulation,2255,O
therapy,2255,O
.,2255,O
The,2256,O
aim,2256,O
of,2256,O
this,2256,O
study,2256,O
was,2256,O
to,2256,O
investigate,2256,O
whether,2256,O
patients,2256,O
with,2256,O
VKORC1,2256,B-GENE-Y
*,2256,O
2,2256,O
compared,2256,O
with,2256,O
patients,2256,O
carrying,2256,O
high-dose,2256,O
haplotypes,2256,O
VKORC1,2256,B-GENE-Y
*,2256,O
3,2256,O
or,2256,O
VKORC1,2256,B-GENE-Y
*,2256,O
4,2256,O
had,2256,O
different,2256,O
warfarin,2256,B-CHEMICAL
S/R,2256,I-CHEMICAL
ratios,2256,O
in,2256,O
their,2256,O
plasma,2256,O
",",2256,O
and,2256,O
whether,2256,O
that,2256,O
was,2256,O
related,2256,O
to,2256,O
CYP2C9,2256,B-GENE-Y
variants,2256,O
CYP2C9,2256,B-GENE-Y
*,2256,O
2,2256,O
and,2256,O
CYP2C9,2256,B-GENE-Y
*,2256,O
3,2256,O
or,2256,O
other,2256,O
factors,2256,O
.,2256,O
Samples,2257,O
from,2257,O
patients,2257,O
previously,2257,O
haplotyped,2257,O
for,2257,O
VKORC1,2257,B-GENE-Y
and,2257,O
measured,2257,O
for,2257,O
plasma,2257,O
warfarin,2257,B-CHEMICAL
concentration,2257,O
were,2257,O
genotyped,2257,O
for,2257,O
the,2257,O
CYP2C9,2257,B-GENE-Y
variants,2257,O
CYP2C9,2257,B-GENE-Y
*,2257,O
2,2257,O
and,2257,O
CYP2C9,2257,B-GENE-Y
*,2257,O
3,2257,O
.,2257,O
Nonparametric,2258,O
statistical,2258,O
analysis,2258,O
was,2258,O
performed,2258,O
to,2258,O
elucidate,2258,O
whether,2258,O
there,2258,O
was,2258,O
any,2258,O
significant,2258,O
difference,2258,O
in,2258,O
the,2258,O
warfarin,2258,B-CHEMICAL
S/R,2258,I-CHEMICAL
ratio,2258,O
between,2258,O
the,2258,O
two,2258,O
patient,2258,O
groups,2258,O
.,2258,O
Our,2259,O
result,2259,O
shows,2259,O
that,2259,O
there,2259,O
is,2259,O
a,2259,O
significant,2259,O
difference,2259,O
(,2259,O
P,2259,O
<,2259,O
0.01,2259,O
),2259,O
in,2259,O
warfarin,2259,B-CHEMICAL
S/R,2259,I-CHEMICAL
ratios,2259,O
between,2259,O
VKORC1,2259,B-GENE-Y
*,2259,O
2,2259,O
and,2259,O
VKORC1,2259,B-GENE-Y
*,2259,O
3,2259,O
or,2259,O
VKORC1,2259,B-GENE-Y
*,2259,O
4,2259,O
patients,2259,O
.,2259,O
This,2260,O
difference,2260,O
did,2260,O
not,2260,O
originate,2260,O
from,2260,O
CYP2C9,2260,B-GENE-Y
variants,2260,O
CYP2C9,2260,B-GENE-Y
*,2260,O
2,2260,O
and,2260,O
CYP2C9,2260,B-GENE-Y
*,2260,O
3,2260,O
.,2260,O
We,2261,O
speculate,2261,O
that,2261,O
VKORC1,2261,B-GENE-Y
haplotypes,2261,O
possibly,2261,O
are,2261,O
linked,2261,O
to,2261,O
some,2261,O
unidentified,2261,O
factors,2261,O
involved,2261,O
in,2261,O
the,2261,O
metabolic,2261,O
clearance,2261,O
of,2261,O
warfarin,2261,B-CHEMICAL
enantiomers,2261,O
.,2261,O
Dose-dependent,2262,O
variations,2262,O
in,2262,O
(,2262,B-CHEMICAL
S,2262,I-CHEMICAL
),2262,I-CHEMICAL
-warfarin,2262,I-CHEMICAL
and,2262,O
(,2262,B-CHEMICAL
R,2262,I-CHEMICAL
),2262,I-CHEMICAL
-warfarin,2262,I-CHEMICAL
clearance,2262,O
in,2262,O
these,2262,O
patients,2262,O
can,2262,O
also,2262,O
be,2262,O
a,2262,O
probable,2262,O
explanation,2262,O
for,2262,O
the,2262,O
difference,2262,O
in,2262,O
warfarin,2262,B-CHEMICAL
S/R,2262,I-CHEMICAL
ratios,2262,O
.,2262,O
Dopamine,2263,B-GENE-Y
D1,2263,I-GENE-Y
receptor,2263,I-GENE-Y
agonist,2263,O
and,2263,O
D2,2263,B-GENE-Y
receptor,2263,I-GENE-Y
antagonist,2263,O
effects,2263,O
of,2263,O
the,2263,O
natural,2263,O
product,2263,O
(,2263,B-CHEMICAL
-,2263,I-CHEMICAL
),2263,I-CHEMICAL
-stepholidine,2263,I-CHEMICAL
:,2263,O
molecular,2263,O
modeling,2263,O
and,2263,O
dynamics,2263,O
simulations,2263,O
.,2263,O
(,2264,B-CHEMICAL
-,2264,I-CHEMICAL
),2264,I-CHEMICAL
-Stepholidine,2264,I-CHEMICAL
(,2264,O
SPD,2264,B-CHEMICAL
),2264,O
",",2264,O
an,2264,O
active,2264,O
ingredient,2264,O
of,2264,O
the,2264,O
Chinese,2264,O
herb,2264,O
Stephania,2264,O
",",2264,O
is,2264,O
the,2264,O
first,2264,O
compound,2264,O
found,2264,O
to,2264,O
have,2264,O
dual,2264,O
function,2264,O
as,2264,O
a,2264,O
dopamine,2264,B-CHEMICAL
receptor,2264,I-GENE-Y
D1,2264,I-GENE-Y
agonist,2264,O
and,2264,O
D2,2264,B-GENE-Y
antagonist,2264,O
.,2264,O
Insights,2265,O
into,2265,O
dynamical,2265,O
behaviors,2265,O
of,2265,O
D1,2265,B-GENE-N
and,2265,I-GENE-N
D2,2265,I-GENE-N
receptors,2265,I-GENE-N
and,2265,O
their,2265,O
interaction,2265,O
modes,2265,O
with,2265,O
SPD,2265,B-CHEMICAL
are,2265,O
crucial,2265,O
in,2265,O
understanding,2265,O
the,2265,O
structural,2265,O
and,2265,O
functional,2265,O
characteristics,2265,O
of,2265,O
dopamine,2265,B-GENE-N
receptors,2265,I-GENE-N
.,2265,O
In,2266,O
this,2266,O
study,2266,O
a,2266,O
computational,2266,O
approach,2266,O
",",2266,O
integrating,2266,O
protein,2266,O
structure,2266,O
prediction,2266,O
",",2266,O
automated,2266,O
molecular,2266,O
docking,2266,O
",",2266,O
and,2266,O
molecular,2266,O
dynamics,2266,O
simulations,2266,O
were,2266,O
employed,2266,O
to,2266,O
investigate,2266,O
the,2266,O
dual,2266,O
action,2266,O
mechanism,2266,O
of,2266,O
SPD,2266,B-CHEMICAL
on,2266,O
the,2266,O
D1,2266,B-GENE-N
and,2266,I-GENE-N
D2,2266,I-GENE-N
receptors,2266,I-GENE-N
",",2266,O
with,2266,O
the,2266,O
eventual,2266,O
aim,2266,O
to,2266,O
develop,2266,O
new,2266,O
drugs,2266,O
for,2266,O
treating,2266,O
diseases,2266,O
affecting,2266,O
the,2266,O
central,2266,O
nervous,2266,O
system,2266,O
such,2266,O
as,2266,O
schizophrenia,2266,O
.,2266,O
The,2267,O
dynamics,2267,O
simulations,2267,O
revealed,2267,O
the,2267,O
surface,2267,O
features,2267,O
of,2267,O
the,2267,O
electrostatic,2267,O
potentials,2267,O
and,2267,O
the,2267,O
conformational,2267,O
``,2267,O
open-closed,2267,O
'',2267,O
process,2267,O
of,2267,O
the,2267,O
binding,2267,O
entrances,2267,O
of,2267,O
two,2267,O
dopamine,2267,B-GENE-N
receptors,2267,I-GENE-N
.,2267,O
Potential,2268,O
binding,2268,O
conformations,2268,O
of,2268,O
D1,2268,B-GENE-N
and,2268,I-GENE-N
D2,2268,I-GENE-N
receptors,2268,I-GENE-N
were,2268,O
obtained,2268,O
",",2268,O
and,2268,O
the,2268,O
D1-SPD,2268,B-GENE-Y
and,2268,O
D2-SPD,2268,B-GENE-Y
complexes,2268,O
were,2268,O
generated,2268,O
",",2268,O
which,2268,O
are,2268,O
in,2268,O
good,2268,O
agreement,2268,O
with,2268,O
most,2268,O
of,2268,O
experimental,2268,O
data,2268,O
.,2268,O
The,2269,O
D1-SPD,2269,B-GENE-Y
structure,2269,O
shows,2269,O
that,2269,O
the,2269,O
K-167_EL-2-E-302_EL-3,2269,O
(,2269,O
EL-2,2269,O
:,2269,O
extracellular,2269,O
loop,2269,O
2,2269,O
;,2269,O
EL-3,2269,O
:,2269,O
extracellular,2269,O
loop,2269,O
3,2269,O
),2269,O
salt,2269,O
bridge,2269,O
plays,2269,O
an,2269,O
important,2269,O
role,2269,O
for,2269,O
both,2269,O
the,2269,O
conformational,2269,O
change,2269,O
of,2269,O
the,2269,O
extracellular,2269,O
domain,2269,O
and,2269,O
the,2269,O
binding,2269,O
of,2269,O
SPD,2269,B-CHEMICAL
.,2269,O
Based,2270,O
on,2270,O
our,2270,O
modeling,2270,O
and,2270,O
simulations,2270,O
",",2270,O
we,2270,O
proposed,2270,O
a,2270,O
mechanism,2270,O
of,2270,O
the,2270,O
dual,2270,O
action,2270,O
of,2270,O
SPD,2270,B-CHEMICAL
and,2270,O
a,2270,O
subsequent,2270,O
signal,2270,O
transduction,2270,O
model,2270,O
.,2270,O
Further,2271,O
mutagenesis,2271,O
and,2271,O
biophysical,2271,O
experiments,2271,O
are,2271,O
needed,2271,O
to,2271,O
test,2271,O
and,2271,O
improve,2271,O
our,2271,O
proposed,2271,O
dual,2271,O
action,2271,O
mechanism,2271,O
of,2271,O
SPD,2271,B-CHEMICAL
and,2271,O
signal,2271,O
transduction,2271,O
model,2271,O
.,2271,O
GLP-1,2272,B-GENE-Y
receptor,2272,I-GENE-Y
expression,2272,O
in,2272,O
human,2272,O
tumors,2272,O
and,2272,O
human,2272,O
normal,2272,O
tissues,2272,O
:,2272,O
potential,2272,O
for,2272,O
in,2272,O
vivo,2272,O
targeting,2272,O
.,2272,O
UNLABELLED,2273,O
:,2273,O
Peptide,2273,B-GENE-N
hormone,2273,I-GENE-N
receptors,2273,I-GENE-N
overexpressed,2273,O
in,2273,O
human,2273,O
tumors,2273,O
",",2273,O
such,2273,O
as,2273,O
somatostatin,2273,B-CHEMICAL
receptors,2273,I-GENE-N
",",2273,O
can,2273,O
be,2273,O
used,2273,O
for,2273,O
in,2273,O
vivo,2273,O
targeting,2273,O
for,2273,O
diagnostic,2273,O
and,2273,O
therapeutic,2273,O
purposes,2273,O
.,2273,O
A,2274,O
novel,2274,O
promising,2274,O
candidate,2274,O
in,2274,O
this,2274,O
field,2274,O
is,2274,O
the,2274,O
GLP-1,2274,B-GENE-Y
receptor,2274,I-GENE-Y
",",2274,O
which,2274,O
was,2274,O
recently,2274,O
shown,2274,O
to,2274,O
be,2274,O
massively,2274,O
overexpressed,2274,O
in,2274,O
gut,2274,O
and,2274,O
lung,2274,O
neuroendocrine,2274,O
tumors,2274,O
--,2274,O
in,2274,O
particular,2274,O
",",2274,O
in,2274,O
insulinomas,2274,O
.,2274,O
Anticipating,2275,O
a,2275,O
major,2275,O
development,2275,O
of,2275,O
GLP-1,2275,B-GENE-Y
receptor,2275,I-GENE-Y
targeting,2275,O
in,2275,O
nuclear,2275,O
medicine,2275,O
",",2275,O
our,2275,O
aim,2275,O
was,2275,O
to,2275,O
evaluate,2275,O
in,2275,O
vitro,2275,O
the,2275,O
GLP-1,2275,B-GENE-Y
receptor,2275,I-GENE-Y
expression,2275,O
in,2275,O
a,2275,O
large,2275,O
variety,2275,O
of,2275,O
other,2275,O
tumors,2275,O
and,2275,O
to,2275,O
compare,2275,O
it,2275,O
with,2275,O
that,2275,O
in,2275,O
nonneoplastic,2275,O
tissues,2275,O
.,2275,O
METHODS,2276,O
:,2276,O
The,2276,O
GLP-1,2276,B-GENE-Y
receptor,2276,I-GENE-Y
protein,2276,O
expression,2276,O
was,2276,O
qualitatively,2276,O
and,2276,O
quantitatively,2276,O
investigated,2276,O
in,2276,O
a,2276,O
broad,2276,O
spectrum,2276,O
of,2276,O
human,2276,O
tumors,2276,O
(,2276,O
n=419,2276,O
),2276,O
and,2276,O
nonneoplastic,2276,O
human,2276,O
tissues,2276,O
(,2276,O
n=209,2276,O
),2276,O
with,2276,O
receptor,2276,O
autoradiography,2276,O
using,2276,O
(,2276,O
125,2276,O
),2276,O
I-GLP-1,2276,O
(,2276,I-GENE-Y
7-36,2276,I-GENE-Y
),2276,I-GENE-Y
amide,2276,O
.,2276,O
Pharmacologic,2277,O
competition,2277,O
experiments,2277,O
were,2277,O
performed,2277,O
to,2277,O
provide,2277,O
proof,2277,O
of,2277,O
specificity,2277,O
of,2277,O
the,2277,O
procedure,2277,O
.,2277,O
RESULTS,2278,O
:,2278,O
GLP-1,2278,B-GENE-Y
receptors,2278,I-GENE-Y
were,2278,O
expressed,2278,O
in,2278,O
various,2278,O
endocrine,2278,O
tumors,2278,O
",",2278,O
with,2278,O
particularly,2278,O
high,2278,O
amounts,2278,O
in,2278,O
pheochromocytomas,2278,O
",",2278,O
as,2278,O
well,2278,O
as,2278,O
in,2278,O
brain,2278,O
tumors,2278,O
and,2278,O
embryonic,2278,O
tumors,2278,O
but,2278,O
not,2278,O
in,2278,O
carcinomas,2278,O
or,2278,O
lymphomas,2278,O
.,2278,O
In,2279,O
nonneoplastic,2279,O
tissues,2279,O
",",2279,O
GLP-1,2279,B-GENE-Y
receptors,2279,I-GENE-Y
were,2279,O
present,2279,O
in,2279,O
generally,2279,O
low,2279,O
amounts,2279,O
in,2279,O
specific,2279,O
tissue,2279,O
compartments,2279,O
of,2279,O
several,2279,O
organs,2279,O
--,2279,O
namely,2279,O
",",2279,O
pancreas,2279,O
",",2279,O
intestine,2279,O
",",2279,O
lung,2279,O
",",2279,O
kidney,2279,O
",",2279,O
breast,2279,O
",",2279,O
and,2279,O
brain,2279,O
;,2279,O
no,2279,O
receptors,2279,O
were,2279,O
identified,2279,O
in,2279,O
lymph,2279,O
nodes,2279,O
",",2279,O
spleen,2279,O
",",2279,O
liver,2279,O
",",2279,O
or,2279,O
the,2279,O
adrenal,2279,O
gland,2279,O
.,2279,O
The,2280,O
rank,2280,O
order,2280,O
of,2280,O
potencies,2280,O
for,2280,O
receptor,2280,O
binding,2280,O
--,2280,O
namely,2280,O
",",2280,O
GLP-1,2280,B-GENE-Y
(,2280,I-GENE-Y
7-36,2280,I-GENE-Y
),2280,I-GENE-Y
amide,2280,O
=,2280,O
exendin-4,2280,B-GENE-Y
>,2280,O
>,2280,O
GLP-2,2280,B-GENE-Y
=,2280,O
glucagon,2280,B-GENE-Y
(,2280,I-GENE-Y
1-29,2280,I-GENE-Y
),2280,I-GENE-Y
--,2280,O
provided,2280,O
proof,2280,O
of,2280,O
specific,2280,O
GLP-1,2280,B-GENE-Y
receptor,2280,I-GENE-Y
identification,2280,O
.,2280,O
CONCLUSION,2281,O
:,2281,O
The,2281,O
GLP-1,2281,B-GENE-Y
receptors,2281,I-GENE-Y
may,2281,O
represent,2281,O
a,2281,O
novel,2281,O
molecular,2281,O
target,2281,O
for,2281,O
in,2281,O
vivo,2281,O
scintigraphy,2281,O
and,2281,O
targeted,2281,O
radiotherapy,2281,O
for,2281,O
a,2281,O
variety,2281,O
of,2281,O
GLP-1,2281,B-GENE-Y
receptor-expressing,2281,O
tumors,2281,O
.,2281,O
For,2282,O
GLP-1,2282,B-GENE-Y
receptor,2282,I-GENE-Y
scintigraphy,2282,O
",",2282,O
a,2282,O
low-background,2282,O
signal,2282,O
can,2282,O
be,2282,O
expected,2282,O
",",2282,O
on,2282,O
the,2282,O
basis,2282,O
of,2282,O
the,2282,O
low,2282,O
receptor,2282,O
expression,2282,O
in,2282,O
the,2282,O
normal,2282,O
tissues,2282,O
surrounding,2282,O
tumors,2282,O
.,2282,O
A,2283,O
novel,2283,O
variant,2283,O
L263F,2283,B-GENE-N
in,2283,O
human,2283,B-GENE-Y
inosine,2283,I-GENE-Y
5'-monophosphate,2283,I-GENE-Y
dehydrogenase,2283,I-GENE-Y
2,2283,I-GENE-Y
is,2283,O
associated,2283,O
with,2283,O
diminished,2283,O
enzyme,2283,O
activity,2283,O
.,2283,O
BACKGROUND,2284,O
AND,2284,O
OBJECTIVE,2284,O
:,2284,O
Inosine,2284,B-CHEMICAL
5'-monophosphate,2284,I-CHEMICAL
dehydrogenase,2284,I-GENE-Y
2,2284,I-GENE-Y
is,2284,O
required,2284,O
for,2284,O
purine,2284,O
synthesis,2284,O
in,2284,O
activated,2284,O
lymphocytes,2284,O
.,2284,O
Variants,2285,O
in,2285,O
the,2285,O
IMPDH2,2285,B-GENE-Y
gene,2285,O
may,2285,O
account,2285,O
for,2285,O
the,2285,O
large,2285,O
inter-individual,2285,O
variability,2285,O
in,2285,O
baseline,2285,O
enzyme,2285,O
activity,2285,O
",",2285,O
immunosuppressive,2285,O
efficacy,2285,O
and,2285,O
side,2285,O
effects,2285,O
in,2285,O
transplant,2285,O
recipients,2285,O
receiving,2285,O
mycophenolic,2285,B-CHEMICAL
acid,2285,I-CHEMICAL
.,2285,O
Therefore,2286,O
",",2286,O
the,2286,O
objective,2286,O
of,2286,O
this,2286,O
study,2286,O
was,2286,O
to,2286,O
identify,2286,O
and,2286,O
functionally,2286,O
characterize,2286,O
IMPDH2,2286,B-GENE-Y
variants,2286,O
.,2286,O
METHODS,2287,O
:,2287,O
DNA,2287,O
samples,2287,O
from,2287,O
152,2287,O
solid,2287,O
organ,2287,O
transplant,2287,O
patients,2287,O
were,2287,O
screened,2287,O
at,2287,O
exons,2287,O
and,2287,O
exon/intron,2287,O
junctions,2287,O
of,2287,O
the,2287,O
IMPDH2,2287,B-GENE-Y
genes,2287,O
by,2287,O
PCR,2287,O
amplification,2287,O
followed,2287,O
by,2287,O
bidirectional,2287,O
direct,2287,O
DNA,2287,O
sequencing,2287,O
.,2287,O
Genetic,2288,O
variant,2288,O
was,2288,O
constructed,2288,O
by,2288,O
site-directed,2288,O
mutagenesis,2288,O
and,2288,O
transformed,2288,O
to,2288,O
an,2288,O
inosine,2288,B-CHEMICAL
5'-monophosphate,2288,I-CHEMICAL
dehydrogenase-deficient,2288,O
strain,2288,O
of,2288,O
Escherichia,2288,O
coli,2288,O
h712,2288,O
.,2288,O
Proteins,2289,O
were,2289,O
purified,2289,O
to,2289,O
homogeneity,2289,O
and,2289,O
the,2289,O
enzymatic,2289,O
activity,2289,O
was,2289,O
measured,2289,O
by,2289,O
reduced,2289,O
nicotinamide,2289,B-CHEMICAL
adenine,2289,I-CHEMICAL
dinucleotide,2289,I-CHEMICAL
production,2289,O
.,2289,O
RESULTS,2290,O
:,2290,O
Nine,2290,O
genetic,2290,O
variants,2290,O
were,2290,O
identified,2290,O
in,2290,O
the,2290,O
IMPDH2,2290,B-GENE-Y
gene,2290,O
",",2290,O
with,2290,O
frequencies,2290,O
of,2290,O
the,2290,O
rarer,2290,O
alleles,2290,O
ranging,2290,O
from,2290,O
0.5,2290,O
to,2290,O
10.2,2290,O
%,2290,O
.,2290,O
A,2291,O
novel,2291,O
nonsynonymous,2291,O
variant,2291,O
L263F,2291,B-GENE-N
was,2291,O
identified,2291,O
",",2291,O
and,2291,O
the,2291,O
kinetic,2291,O
assay,2291,O
demonstrated,2291,O
that,2291,O
the,2291,O
inosine,2291,B-CHEMICAL
5'-monophosphate,2291,I-CHEMICAL
dehydrogenase,2291,I-GENE-N
activity,2291,O
of,2291,O
L263F,2291,B-GENE-N
variant,2291,O
was,2291,O
decreased,2291,O
to,2291,O
10,2291,O
%,2291,O
of,2291,O
the,2291,O
wild-type,2291,O
.,2291,O
The,2292,O
Ki,2292,O
for,2292,O
mycophenolic,2292,B-CHEMICAL
acid,2292,I-CHEMICAL
inhibition,2292,O
of,2292,O
the,2292,O
L263F,2292,B-GENE-N
variant,2292,O
was,2292,O
comparable,2292,O
with,2292,O
the,2292,O
wild-type,2292,O
",",2292,O
and,2292,O
the,2292,O
variant,2292,O
Km,2292,O
for,2292,O
inosine,2292,B-CHEMICAL
5'-monophosphate,2292,I-CHEMICAL
and,2292,O
nicotinamide,2292,B-CHEMICAL
adenine,2292,I-CHEMICAL
dinucleotide,2292,I-CHEMICAL
did,2292,O
not,2292,O
change,2292,O
significantly,2292,O
.,2292,O
CONCLUSIONS,2293,O
:,2293,O
IMPDH2,2293,B-GENE-Y
has,2293,O
low,2293,O
genetic,2293,O
diversity,2293,O
",",2293,O
but,2293,O
the,2293,O
nonsynonymous,2293,O
variant,2293,O
L263F,2293,B-GENE-N
has,2293,O
a,2293,O
significant,2293,O
impact,2293,O
on,2293,O
inosine,2293,B-CHEMICAL
5'-monophosphate,2293,I-CHEMICAL
dehydrogenase,2293,I-GENE-N
activity,2293,O
.,2293,O
This,2294,O
novel,2294,O
functional,2294,O
variant,2294,O
may,2294,O
be,2294,O
one,2294,O
of,2294,O
the,2294,O
factors,2294,O
contributing,2294,O
to,2294,O
the,2294,O
inter-individual,2294,O
difference,2294,O
of,2294,O
baseline,2294,O
inosine,2294,B-CHEMICAL
5'-monophosphate,2294,I-CHEMICAL
dehydrogenase,2294,I-GENE-N
activity,2294,O
as,2294,O
well,2294,O
as,2294,O
drug,2294,O
efficacy,2294,O
and,2294,O
adverse,2294,O
events,2294,O
in,2294,O
transplant,2294,O
patients,2294,O
.,2294,O
[,2295,O
Effects,2295,O
of,2295,O
Panax,2295,O
notoginseng,2295,O
saponins,2295,B-CHEMICAL
on,2295,O
mRNA,2295,O
expressions,2295,O
of,2295,O
interleukin-1,2295,B-GENE-Y
beta,2295,I-GENE-Y
",",2295,O
its,2295,O
correlative,2295,O
factors,2295,O
and,2295,O
cysteinyl-aspartate,2295,B-GENE-N
specific,2295,I-GENE-N
protease,2295,I-GENE-N
after,2295,O
cerebral,2295,O
ischemia-reperfusion,2295,O
in,2295,O
rats,2295,O
],2295,O
.,2295,O
OBJECTIVE,2296,O
:,2296,O
To,2296,O
investigate,2296,O
the,2296,O
effects,2296,O
of,2296,O
Panax,2296,O
notoginseng,2296,O
saponins,2296,B-CHEMICAL
(,2296,O
PNS,2296,O
),2296,O
on,2296,O
mRNA,2296,O
expressions,2296,O
of,2296,O
interleukin-1,2296,B-GENE-Y
beta,2296,I-GENE-Y
(,2296,O
IL-1,2296,B-GENE-Y
beta,2296,I-GENE-Y
),2296,O
",",2296,O
interleukin-1,2296,B-GENE-Y
receptor,2296,I-GENE-Y
type,2296,I-GENE-Y
I,2296,I-GENE-Y
(,2296,O
IL-1RI,2296,B-GENE-Y
),2296,O
",",2296,O
interleukin-1,2296,B-GENE-Y
receptor,2296,I-GENE-Y
antagonist,2296,I-GENE-Y
(,2296,O
IL-1ra,2296,B-GENE-Y
),2296,O
",",2296,O
intercellular,2296,B-GENE-Y
adhesion,2296,I-GENE-Y
molecule-1,2296,I-GENE-Y
(,2296,O
ICAM-1,2296,B-GENE-Y
),2296,O
",",2296,O
cysteinyl-aspartate,2296,B-GENE-Y
specific,2296,I-GENE-Y
protease-1,2296,I-GENE-Y
(,2296,O
caspase-1,2296,B-GENE-Y
),2296,O
",",2296,O
caspase-3,2296,B-GENE-Y
and,2296,O
caspase-8,2296,B-GENE-Y
after,2296,O
cerebral,2296,O
ischemia-reperfusion,2296,O
in,2296,O
rats,2296,O
.,2296,O
METHODS,2297,O
:,2297,O
Focal,2297,O
cerebral,2297,O
ischemia,2297,O
reperfusion,2297,O
in,2297,O
rats,2297,O
was,2297,O
induced,2297,O
by,2297,O
the,2297,O
method,2297,O
of,2297,O
nylon,2297,O
monofilament,2297,O
via,2297,O
the,2297,O
internal,2297,O
carotid,2297,O
artery,2297,O
.,2297,O
PNS,2298,O
was,2298,O
administered,2298,O
intraperitoneally,2298,O
respectively,2298,O
five,2298,O
minutes,2298,O
before,2298,O
cerebral,2298,O
ischemia,2298,O
and,2298,O
twelve,2298,O
hours,2298,O
after,2298,O
cerebral,2298,O
ischemia,2298,O
.,2298,O
After,2299,O
cerebral,2299,O
ischemia,2299,O
for,2299,O
two,2299,O
hours,2299,O
followed,2299,O
by,2299,O
reperfusion,2299,O
for,2299,O
twenty,2299,O
two,2299,O
hours,2299,O
",",2299,O
the,2299,O
mRNA,2299,O
expressions,2299,O
of,2299,O
IL-1,2299,B-GENE-Y
beta,2299,I-GENE-Y
",",2299,O
IL-1RI,2299,B-GENE-Y
",",2299,O
IL-1ra,2299,B-GENE-Y
",",2299,O
ICAM-1,2299,B-GENE-Y
",",2299,O
caspase-1,2299,B-GENE-Y
",",2299,O
caspase-3,2299,B-GENE-Y
and,2299,O
caspase-8,2299,B-GENE-Y
in,2299,O
brain,2299,O
tissue,2299,O
were,2299,O
determined,2299,O
by,2299,O
reverse,2299,O
transcription,2299,O
polymerase,2299,O
chain,2299,O
reaction,2299,O
assay,2299,O
.,2299,O
RESULTS,2300,O
:,2300,O
After,2300,O
cerebral,2300,O
ischemia,2300,O
for,2300,O
two,2300,O
hours,2300,O
followed,2300,O
by,2300,O
reperfusion,2300,O
for,2300,O
twenty,2300,O
two,2300,O
hours,2300,O
",",2300,O
the,2300,O
mRNA,2300,O
expression,2300,O
levels,2300,O
of,2300,O
IL-1,2300,B-GENE-Y
beta,2300,I-GENE-Y
",",2300,O
IL-1RI,2300,B-GENE-Y
",",2300,O
IL-1ra,2300,B-GENE-Y
",",2300,O
ICAM-1,2300,B-GENE-Y
",",2300,O
caspase-1,2300,B-GENE-Y
",",2300,O
caspase-3,2300,B-GENE-Y
and,2300,O
caspase-8,2300,B-GENE-Y
in,2300,O
brain,2300,O
tissue,2300,O
in,2300,O
the,2300,O
untreated,2300,O
group,2300,O
were,2300,O
obviously,2300,O
elevated,2300,O
as,2300,O
compared,2300,O
to,2300,O
those,2300,O
in,2300,O
the,2300,O
sham-operation,2300,O
group,2300,O
(,2300,O
P,2300,O
<,2300,O
0.05,2300,O
or,2300,O
P,2300,O
<,2300,O
0.01,2300,O
),2300,O
.,2300,O
The,2301,O
mRNA,2301,O
expression,2301,O
levels,2301,O
of,2301,O
IL-1,2301,B-GENE-Y
beta,2301,I-GENE-Y
",",2301,O
IL-1RI,2301,B-GENE-Y
",",2301,O
IL-1ra,2301,B-GENE-Y
in,2301,O
brain,2301,O
tissue,2301,O
in,2301,O
the,2301,O
PNS,2301,O
group,2301,O
were,2301,O
lower,2301,O
than,2301,O
those,2301,O
in,2301,O
the,2301,O
untreated,2301,O
group,2301,O
",",2301,O
but,2301,O
higher,2301,O
than,2301,O
those,2301,O
in,2301,O
the,2301,O
sham-operation,2301,O
group,2301,O
",",2301,O
and,2301,O
without,2301,O
statistical,2301,O
differences,2301,O
as,2301,O
compared,2301,O
to,2301,O
those,2301,O
in,2301,O
the,2301,O
sham-operation,2301,O
group,2301,O
and,2301,O
in,2301,O
the,2301,O
untreated,2301,O
group,2301,O
(,2301,O
P,2301,O
>,2301,O
0.05,2301,O
),2301,O
.,2301,O
The,2302,O
mRNA,2302,O
expression,2302,O
level,2302,O
of,2302,O
caspase-3,2302,B-GENE-Y
in,2302,O
brain,2302,O
tissue,2302,O
in,2302,O
the,2302,O
PNS,2302,O
group,2302,O
was,2302,O
significantly,2302,O
lower,2302,O
than,2302,O
that,2302,O
in,2302,O
the,2302,O
untreated,2302,O
group,2302,O
(,2302,O
P,2302,O
<,2302,O
0.05,2302,O
),2302,O
",",2302,O
but,2302,O
PNS,2302,O
had,2302,O
no,2302,O
effect,2302,O
on,2302,O
the,2302,O
mRNA,2302,O
expression,2302,O
levels,2302,O
of,2302,O
ICAM-1,2302,B-GENE-Y
",",2302,O
caspase-1,2302,B-GENE-Y
and,2302,O
caspase-8,2302,B-GENE-Y
in,2302,O
brain,2302,O
tissue,2302,O
.,2302,O
CONCLUSION,2303,O
:,2303,O
PNS,2303,O
can,2303,O
inhibit,2303,O
the,2303,O
mRNA,2303,O
expression,2303,O
of,2303,O
caspase-3,2303,B-GENE-Y
",",2303,O
slightly,2303,O
inhibit,2303,O
the,2303,O
mRNA,2303,O
expressions,2303,O
of,2303,O
IL-1,2303,B-GENE-Y
beta,2303,I-GENE-Y
and,2303,O
its,2303,O
correlative,2303,O
inflammatory,2303,O
factors,2303,O
in,2303,O
brain,2303,O
tissue,2303,O
.,2303,O
The,2304,O
protective,2304,O
effects,2304,O
of,2304,O
PNS,2304,O
on,2304,O
cerebral,2304,O
injury,2304,O
induced,2304,O
by,2304,O
ischemia-reperfusion,2304,O
may,2304,O
be,2304,O
related,2304,O
to,2304,O
inhibiting,2304,O
the,2304,O
mRNA,2304,O
expressions,2304,O
of,2304,O
caspase-3,2304,B-GENE-Y
",",2304,O
IL-1,2304,B-GENE-Y
beta,2304,I-GENE-Y
and,2304,O
its,2304,O
correlative,2304,O
inflammatory,2304,O
factors,2304,O
in,2304,O
brain,2304,O
tissue,2304,O
.,2304,O
Downregulation,2305,O
of,2305,O
glutaredoxin,2305,B-GENE-N
but,2305,O
not,2305,O
glutathione,2305,B-CHEMICAL
loss,2305,O
leads,2305,O
to,2305,O
mitochondrial,2305,O
dysfunction,2305,O
in,2305,O
female,2305,O
mice,2305,O
CNS,2305,O
:,2305,O
implications,2305,O
in,2305,O
excitotoxicity,2305,O
.,2305,O
Oxidative,2306,O
stress,2306,O
",",2306,O
excitotoxicity,2306,O
and,2306,O
mitochondrial,2306,O
dysfunction,2306,O
play,2306,O
synergistic,2306,O
roles,2306,O
in,2306,O
neurodegeneration,2306,O
.,2306,O
Maintenance,2307,O
of,2307,O
thiol,2307,B-CHEMICAL
homeostasis,2307,O
is,2307,O
important,2307,O
for,2307,O
normal,2307,O
mitochondrial,2307,O
function,2307,O
and,2307,O
dysregulation,2307,O
of,2307,O
protein,2307,O
thiol,2307,B-CHEMICAL
homeostasis,2307,O
by,2307,O
oxidative,2307,O
stress,2307,O
leads,2307,O
to,2307,O
mitochondrial,2307,O
dysfunction,2307,O
and,2307,O
neurodegeneration,2307,O
.,2307,O
We,2308,O
examined,2308,O
the,2308,O
critical,2308,O
roles,2308,O
played,2308,O
by,2308,O
the,2308,O
antioxidant,2308,O
",",2308,O
non-protein,2308,O
thiol,2308,B-CHEMICAL
",",2308,O
glutathione,2308,B-CHEMICAL
and,2308,O
related,2308,O
enzyme,2308,O
",",2308,O
glutaredoxin,2308,B-GENE-N
in,2308,O
maintaining,2308,O
mitochondrial,2308,O
function,2308,O
during,2308,O
excitotoxicity,2308,O
caused,2308,O
by,2308,O
beta-N-oxalyl,2308,B-CHEMICAL
amino-L-alanine,2308,I-CHEMICAL
(,2308,O
L-BOAA,2308,B-CHEMICAL
),2308,O
",",2308,O
the,2308,O
causative,2308,O
factor,2308,O
of,2308,O
neurolathyrism,2308,O
",",2308,O
a,2308,O
motor,2308,O
neuron,2308,O
disease,2308,O
involving,2308,O
the,2308,O
pyramidal,2308,O
system,2308,O
.,2308,O
L-BOAA,2309,B-CHEMICAL
causes,2309,O
loss,2309,O
of,2309,O
GSH,2309,B-CHEMICAL
and,2309,O
inhibition,2309,O
of,2309,O
mitochondrial,2309,B-GENE-N
complex,2309,I-GENE-N
I,2309,I-GENE-N
in,2309,O
lumbosacral,2309,O
cord,2309,O
of,2309,O
male,2309,O
mice,2309,O
through,2309,O
oxidation,2309,O
of,2309,O
thiol,2309,B-CHEMICAL
groups,2309,O
",",2309,O
while,2309,O
female,2309,O
mice,2309,O
are,2309,O
resistant,2309,O
.,2309,O
Reducing,2310,O
GSH,2310,B-CHEMICAL
levels,2310,O
in,2310,O
female,2310,O
mice,2310,O
CNS,2310,O
by,2310,O
pretreatment,2310,O
with,2310,O
diethyl,2310,B-CHEMICAL
maleate,2310,I-CHEMICAL
or,2310,O
L-propargyl,2310,B-CHEMICAL
glycine,2310,I-CHEMICAL
did,2310,O
not,2310,O
result,2310,O
in,2310,O
inhibition,2310,O
of,2310,O
complex,2310,B-GENE-N
I,2310,I-GENE-N
activity,2310,O
",",2310,O
unlike,2310,O
male,2310,O
mice,2310,O
.,2310,O
Further,2311,O
",",2311,O
treatment,2311,O
of,2311,O
female,2311,O
mice,2311,O
depleted,2311,O
of,2311,O
GSH,2311,B-CHEMICAL
with,2311,O
L-BOAA,2311,B-CHEMICAL
did,2311,O
not,2311,O
induce,2311,O
inhibition,2311,O
of,2311,O
complex,2311,B-GENE-N
I,2311,I-GENE-N
indicating,2311,O
that,2311,O
GSH,2311,B-CHEMICAL
levels,2311,O
were,2311,O
not,2311,O
critical,2311,O
for,2311,O
maintaining,2311,O
complex,2311,B-GENE-N
I,2311,I-GENE-N
activity,2311,O
in,2311,O
female,2311,O
mice,2311,O
unlike,2311,O
their,2311,O
male,2311,O
counterpart,2311,O
.,2311,O
Glutaredoxin,2312,B-GENE-N
",",2312,O
a,2312,O
thiol,2312,B-GENE-N
disulfide,2312,B-CHEMICAL
oxidoreductase,2312,I-GENE-N
helps,2312,O
maintain,2312,O
redox,2312,O
status,2312,O
of,2312,O
proteins,2312,O
and,2312,O
downregulation,2312,O
of,2312,O
glutaredoxin,2312,B-GENE-N
results,2312,O
in,2312,O
loss,2312,O
of,2312,O
mitochondrial,2312,B-GENE-N
complex,2312,I-GENE-N
I,2312,I-GENE-N
activity,2312,O
.,2312,O
Female,2313,O
mice,2313,O
express,2313,O
higher,2313,O
levels,2313,O
of,2313,O
glutaredoxin,2313,B-GENE-N
in,2313,O
certain,2313,O
CNS,2313,O
regions,2313,O
and,2313,O
downregulation,2313,O
of,2313,O
glutaredoxin,2313,B-GENE-N
using,2313,O
antisense,2313,O
oligonucleotides,2313,O
sensitizes,2313,O
them,2313,O
to,2313,O
L-BOAA,2313,B-CHEMICAL
toxicity,2313,O
seen,2313,O
as,2313,O
mitochondrial,2313,B-GENE-N
complex,2313,I-GENE-N
I,2313,I-GENE-N
loss,2313,O
.,2313,O
Ovariectomy,2314,O
downregulates,2314,O
glutaredoxin,2314,B-GENE-N
and,2314,O
renders,2314,O
female,2314,O
mice,2314,O
vulnerable,2314,O
to,2314,O
L-BOAA,2314,B-CHEMICAL
toxicity,2314,O
as,2314,O
evidenced,2314,O
by,2314,O
activation,2314,O
of,2314,O
AP1,2314,B-GENE-Y
",",2314,O
loss,2314,O
of,2314,O
GSH,2314,B-CHEMICAL
and,2314,O
complex,2314,B-GENE-N
I,2314,I-GENE-N
activity,2314,O
indicating,2314,O
the,2314,O
important,2314,O
role,2314,O
of,2314,O
glutaredoxin,2314,B-GENE-N
in,2314,O
neuroprotection,2314,O
.,2314,O
Estrogen,2315,B-CHEMICAL
protects,2315,O
against,2315,O
mitochondrial,2315,O
dysfunction,2315,O
caused,2315,O
by,2315,O
excitotoxicity,2315,O
by,2315,O
maintaining,2315,O
cellular,2315,O
redox,2315,O
status,2315,O
through,2315,O
higher,2315,O
constitutive,2315,O
expression,2315,O
of,2315,O
glutaredoxin,2315,B-GENE-N
in,2315,O
the,2315,O
CNS,2315,O
.,2315,O
Therapeutic,2316,O
interventions,2316,O
designed,2316,O
to,2316,O
upregulate,2316,O
glutaredoxin,2316,B-GENE-N
may,2316,O
offer,2316,O
neuroprotection,2316,O
against,2316,O
excitotoxicity,2316,O
in,2316,O
motor,2316,O
neurons,2316,O
.,2316,O
The,2317,O
calponin,2317,B-GENE-N
homology,2317,I-GENE-N
domain,2317,I-GENE-N
of,2317,O
Vav1,2317,B-GENE-Y
associates,2317,O
with,2317,O
calmodulin,2317,B-GENE-Y
and,2317,O
is,2317,O
prerequisite,2317,O
to,2317,O
T,2317,B-GENE-N
cell,2317,I-GENE-N
antigen,2317,I-GENE-N
receptor-induced,2317,O
calcium,2317,B-CHEMICAL
release,2317,O
in,2317,O
Jurkat,2317,O
T,2317,O
lymphocytes,2317,O
.,2317,O
Vav1,2318,B-GENE-Y
is,2318,O
a,2318,O
guanine,2318,B-CHEMICAL
nucleotide,2318,I-CHEMICAL
exchange,2318,I-GENE-N
factor,2318,I-GENE-N
that,2318,O
is,2318,O
expressed,2318,O
specifically,2318,O
in,2318,O
hematopoietic,2318,O
cells,2318,O
and,2318,O
plays,2318,O
important,2318,O
roles,2318,O
in,2318,O
T,2318,O
cell,2318,O
development,2318,O
and,2318,O
activation,2318,O
.,2318,O
Vav1,2319,B-GENE-Y
consists,2319,O
of,2319,O
multiple,2319,O
structural,2319,O
domains,2319,O
so,2319,O
as,2319,O
to,2319,O
facilitate,2319,O
both,2319,O
its,2319,O
guanine,2319,B-CHEMICAL
nucleotide,2319,I-CHEMICAL
exchange,2319,O
activity,2319,O
and,2319,O
scaffold,2319,O
function,2319,O
following,2319,O
T,2319,B-GENE-N
cell,2319,I-GENE-N
antigen,2319,I-GENE-N
receptor,2319,I-GENE-N
(,2319,O
TCR,2319,B-GENE-N
),2319,O
engagement,2319,O
.,2319,O
Previous,2320,O
studies,2320,O
demonstrated,2320,O
that,2320,O
the,2320,O
calponin,2320,B-GENE-N
homology,2320,I-GENE-N
(,2320,I-GENE-N
CH,2320,I-GENE-N
),2320,I-GENE-N
domain,2320,I-GENE-N
of,2320,O
Vav1,2320,B-GENE-Y
is,2320,O
required,2320,O
for,2320,O
TCR-stimulated,2320,B-GENE-Y
calcium,2320,B-CHEMICAL
mobilization,2320,O
and,2320,O
thus,2320,O
downstream,2320,O
activation,2320,O
of,2320,O
nuclear,2320,B-GENE-N
factor,2320,I-GENE-N
of,2320,I-GENE-N
activated,2320,I-GENE-N
T,2320,I-GENE-N
cells,2320,I-GENE-N
.,2320,O
However,2321,O
",",2321,O
it,2321,O
remained,2321,O
obscure,2321,O
how,2321,O
Vav1,2321,B-GENE-Y
functions,2321,O
in,2321,O
regulating,2321,O
calcium,2321,B-CHEMICAL
flux,2321,O
.,2321,O
In,2322,O
an,2322,O
effort,2322,O
to,2322,O
explore,2322,O
molecules,2322,O
interacting,2322,O
with,2322,O
Vav1,2322,B-GENE-Y
",",2322,O
we,2322,O
found,2322,O
that,2322,O
calmodulin,2322,B-GENE-Y
bound,2322,O
to,2322,O
Vav1,2322,B-GENE-Y
in,2322,O
a,2322,O
calcium-dependent,2322,B-CHEMICAL
and,2322,O
TCR,2322,B-GENE-N
activation-independent,2322,O
manner,2322,O
.,2322,O
The,2323,O
binding,2323,O
site,2323,O
was,2323,O
mapped,2323,O
to,2323,O
the,2323,O
CH,2323,B-GENE-N
domain,2323,I-GENE-N
of,2323,O
Vav1,2323,B-GENE-Y
.,2323,O
Reconstitution,2324,O
of,2324,O
vav1-null,2324,B-GENE-Y
Jurkat,2324,O
T,2324,O
cells,2324,O
(,2324,O
J.Vav1,2324,O
),2324,O
with,2324,O
CH-deleted,2324,B-GENE-N
Vav1,2324,B-GENE-Y
exhibited,2324,O
a,2324,O
severe,2324,O
deficiency,2324,O
in,2324,O
calcium,2324,B-CHEMICAL
release,2324,O
to,2324,O
the,2324,O
same,2324,O
extent,2324,O
as,2324,O
that,2324,O
of,2324,O
Jurkat,2324,O
cells,2324,O
treated,2324,O
with,2324,O
the,2324,O
calmodulin,2324,B-GENE-Y
inhibitor,2324,O
or,2324,O
J.Vav1,2324,O
cells,2324,O
.,2324,O
The,2325,O
defect,2325,O
persisted,2325,O
even,2325,O
when,2325,O
phospholipase-Cgamma1,2325,B-GENE-Y
was,2325,O
fully,2325,O
activated,2325,O
",",2325,O
indicating,2325,O
a,2325,O
prerequisite,2325,O
role,2325,O
of,2325,O
Vav1,2325,B-GENE-N
CH,2325,I-GENE-N
domain,2325,I-GENE-N
in,2325,O
calcium,2325,B-CHEMICAL
signaling,2325,O
.,2325,O
The,2326,O
results,2326,O
suggest,2326,O
that,2326,O
Vav1,2326,B-GENE-Y
and,2326,O
calmodulin,2326,B-GENE-Y
function,2326,O
cooperatively,2326,O
to,2326,O
potentiate,2326,O
TCR-induced,2326,B-GENE-N
calcium,2326,B-CHEMICAL
release,2326,O
.,2326,O
This,2327,O
study,2327,O
unveiled,2327,O
a,2327,O
mechanism,2327,O
by,2327,O
which,2327,O
the,2327,O
Vav1,2327,B-GENE-N
CH,2327,I-GENE-N
domain,2327,I-GENE-N
is,2327,O
involved,2327,O
in,2327,O
calcium,2327,B-CHEMICAL
signaling,2327,O
and,2327,O
provides,2327,O
insight,2327,O
into,2327,O
our,2327,O
understanding,2327,O
of,2327,O
the,2327,O
role,2327,O
of,2327,O
Vav1,2327,B-GENE-Y
in,2327,O
T,2327,O
cell,2327,O
activation,2327,O
.,2327,O
The,2328,O
transporters,2328,O
GlyT2,2328,B-GENE-Y
and,2328,O
VIAAT,2328,B-GENE-Y
cooperate,2328,O
to,2328,O
determine,2328,O
the,2328,O
vesicular,2328,O
glycinergic,2328,O
phenotype,2328,O
.,2328,O
The,2329,O
mechanisms,2329,O
that,2329,O
specify,2329,O
the,2329,O
vesicular,2329,O
phenotype,2329,O
of,2329,O
inhibitory,2329,O
interneurons,2329,O
in,2329,O
vertebrates,2329,O
are,2329,O
poorly,2329,O
understood,2329,O
because,2329,O
the,2329,O
two,2329,O
main,2329,O
inhibitory,2329,O
transmitters,2329,O
",",2329,O
glycine,2329,B-CHEMICAL
and,2329,O
GABA,2329,B-CHEMICAL
",",2329,O
share,2329,O
the,2329,O
same,2329,O
vesicular,2329,B-GENE-Y
inhibitory,2329,I-GENE-Y
amino,2329,B-CHEMICAL
acid,2329,I-CHEMICAL
transporter,2329,I-GENE-Y
(,2329,O
VIAAT,2329,B-GENE-Y
),2329,O
and,2329,O
are,2329,O
both,2329,O
present,2329,O
in,2329,O
neurons,2329,O
during,2329,O
postnatal,2329,O
development,2329,O
.,2329,O
We,2330,O
have,2330,O
expressed,2330,O
VIAAT,2330,B-GENE-Y
and,2330,O
the,2330,O
plasmalemmal,2330,B-GENE-N
transporters,2330,I-GENE-N
for,2330,O
glycine,2330,B-CHEMICAL
and,2330,O
GABA,2330,B-CHEMICAL
in,2330,O
a,2330,O
neuroendocrine,2330,O
cell,2330,O
line,2330,O
and,2330,O
measured,2330,O
the,2330,O
quantal,2330,O
release,2330,O
of,2330,O
glycine,2330,B-CHEMICAL
and,2330,O
GABA,2330,B-CHEMICAL
using,2330,O
a,2330,O
novel,2330,O
double-sniffer,2330,O
patch-clamp,2330,O
technique,2330,O
.,2330,O
We,2331,O
found,2331,O
that,2331,O
glycine,2331,B-CHEMICAL
is,2331,O
released,2331,O
from,2331,O
vesicles,2331,O
when,2331,O
VIAAT,2331,B-GENE-Y
is,2331,O
coexpressed,2331,O
with,2331,O
either,2331,O
the,2331,O
neuronal,2331,B-GENE-N
transporter,2331,I-GENE-N
GlyT2,2331,B-GENE-Y
or,2331,O
the,2331,O
glial,2331,B-GENE-N
transporter,2331,I-GENE-N
GlyT1,2331,B-GENE-Y
.,2331,O
However,2332,O
",",2332,O
GlyT2,2332,B-GENE-Y
was,2332,O
more,2332,O
effective,2332,O
than,2332,O
GlyT1,2332,B-GENE-Y
",",2332,O
probably,2332,O
because,2332,O
GlyT2,2332,B-GENE-Y
is,2332,O
unable,2332,O
to,2332,O
operate,2332,O
in,2332,O
the,2332,O
reverse,2332,O
mode,2332,O
",",2332,O
which,2332,O
gives,2332,O
it,2332,O
an,2332,O
advantage,2332,O
in,2332,O
maintaining,2332,O
the,2332,O
high,2332,O
cytosolic,2332,O
glycine,2332,B-CHEMICAL
concentration,2332,O
required,2332,O
for,2332,O
efficient,2332,O
vesicular,2332,O
loading,2332,O
by,2332,O
VIAAT,2332,B-GENE-Y
.,2332,O
The,2333,O
vesicular,2333,O
inhibitory,2333,O
phenotype,2333,O
was,2333,O
gradually,2333,O
altered,2333,O
from,2333,O
glycinergic,2333,O
to,2333,O
GABAergic,2333,O
through,2333,O
mixed,2333,O
events,2333,O
when,2333,O
GABA,2333,B-CHEMICAL
is,2333,O
introduced,2333,O
into,2333,O
the,2333,O
secretory,2333,O
cell,2333,O
and,2333,O
competes,2333,O
for,2333,O
uptake,2333,O
by,2333,O
VIAAT,2333,B-GENE-Y
.,2333,O
Interestingly,2334,O
",",2334,O
the,2334,O
VIAAT,2334,B-GENE-N
ortholog,2334,O
from,2334,O
Caenorhabditis,2334,O
elegans,2334,O
(,2334,O
UNC-47,2334,O
),2334,O
",",2334,O
a,2334,O
species,2334,O
lacking,2334,O
glycine,2334,B-CHEMICAL
transmission,2334,O
",",2334,O
also,2334,O
supports,2334,O
glycine,2334,B-CHEMICAL
exocytosis,2334,O
in,2334,O
the,2334,O
presence,2334,O
of,2334,O
GlyT2,2334,B-GENE-N
",",2334,O
and,2334,O
a,2334,O
point,2334,O
mutation,2334,O
of,2334,O
UNC-47,2334,O
that,2334,O
abolishes,2334,O
GABA,2334,B-CHEMICAL
transmission,2334,O
in,2334,O
the,2334,O
worm,2334,O
confers,2334,O
glycine,2334,O
specificity,2334,O
.,2334,O
Together,2335,O
",",2335,O
these,2335,O
results,2335,O
suggest,2335,O
that,2335,O
an,2335,O
increased,2335,O
cytosolic,2335,O
availability,2335,O
of,2335,O
glycine,2335,B-CHEMICAL
in,2335,O
VIAAT-containing,2335,B-GENE-Y
terminals,2335,O
was,2335,O
crucial,2335,O
for,2335,O
the,2335,O
emergence,2335,O
of,2335,O
glycinergic,2335,O
transmission,2335,O
in,2335,O
vertebrates,2335,O
.,2335,O
Biochemical,2336,O
assessments,2336,O
of,2336,O
total,2336,O
antioxidant,2336,O
status,2336,O
in,2336,O
active,2336,O
and,2336,O
nonactive,2336,O
female,2336,O
adults,2336,O
with,2336,O
intellectual,2336,O
disability,2336,O
.,2336,O
Long-term,2337,O
physical,2337,O
activity,2337,O
is,2337,O
known,2337,O
to,2337,O
increase,2337,O
the,2337,O
antioxidant,2337,O
defense,2337,O
(,2337,O
AOD,2337,O
),2337,O
system,2337,O
",",2337,O
whereas,2337,O
sedentary,2337,O
lifestyle,2337,O
is,2337,O
associated,2337,O
with,2337,O
oxidative,2337,O
stress,2337,O
(,2337,O
OS,2337,O
),2337,O
.,2337,O
The,2338,O
underlying,2338,O
molecular,2338,O
mechanisms,2338,O
are,2338,O
incompletely,2338,O
understood,2338,O
.,2338,O
The,2339,O
aim,2339,O
of,2339,O
this,2339,O
prospective,2339,O
",",2339,O
nonrandomized,2339,O
study,2339,O
was,2339,O
to,2339,O
evaluate,2339,O
and,2339,O
compare,2339,O
the,2339,O
relationship,2339,O
between,2339,O
long-term,2339,O
physical,2339,O
activity,2339,O
and,2339,O
inactivity,2339,O
and,2339,O
plasma,2339,O
antioxidant,2339,O
status,2339,O
in,2339,O
female,2339,O
adults,2339,O
with,2339,O
intellectual,2339,O
disability,2339,O
(,2339,O
ID,2339,O
),2339,O
that,2339,O
were,2339,O
diagnosed,2339,O
after,2339,O
birth,2339,O
.,2339,O
A,2340,O
total,2340,O
of,2340,O
21,2340,O
adults,2340,O
with,2340,O
ID,2340,O
were,2340,O
examined,2340,O
.,2340,O
The,2341,O
following,2341,O
AOD,2341,O
was,2341,O
examined,2341,O
:,2341,O
superoxide,2341,B-GENE-N
dismutase,2341,I-GENE-N
(,2341,O
SOD,2341,B-GENE-N
),2341,O
",",2341,O
catalase,2341,B-GENE-Y
(,2341,O
CAT,2341,B-GENE-Y
),2341,O
",",2341,O
glutathione,2341,B-CHEMICAL
peroxidase,2341,I-GENE-N
(,2341,O
GPX,2341,B-GENE-N
),2341,O
",",2341,O
vitamin,2341,B-CHEMICAL
E,2341,I-CHEMICAL
",",2341,O
and,2341,O
vitamin,2341,B-CHEMICAL
A.,2341,O
Inactive,2341,O
persons,2341,O
with,2341,O
ID,2341,O
had,2341,O
significantly,2341,O
lower,2341,O
SOD,2341,B-GENE-N
(,2341,O
p,2341,O
<,2341,O
0.05,2341,O
),2341,O
",",2341,O
CAT,2341,B-GENE-Y
(,2341,O
p,2341,O
<,2341,O
0.05,2341,O
),2341,O
",",2341,O
and,2341,O
GPX,2341,B-GENE-N
(,2341,O
p,2341,O
<,2341,O
0.05,2341,O
),2341,O
.,2341,O
All,2342,O
plasma,2342,O
vitamin,2342,O
levels,2342,O
were,2342,O
significantly,2342,O
higher,2342,O
in,2342,O
physically,2342,O
active,2342,O
subjects,2342,O
(,2342,O
vitamin,2342,B-CHEMICAL
A,2342,I-CHEMICAL
:,2342,O
1.42,2342,O
+/-,2342,O
0.05,2342,O
mmol/l,2342,O
",",2342,O
vitamin,2342,B-CHEMICAL
E,2342,I-CHEMICAL
:,2342,O
31.32,2342,O
+/-,2342,O
2.62,2342,O
mmol/l,2342,O
),2342,O
than,2342,O
in,2342,O
sedentary,2342,O
control,2342,O
subjects,2342,O
(,2342,O
vitamin,2342,B-CHEMICAL
A,2342,I-CHEMICAL
:,2342,O
1.02,2342,O
+/-,2342,O
0.03,2342,O
mmol/l,2342,O
",",2342,O
vitamin,2342,B-CHEMICAL
E,2342,I-CHEMICAL
:,2342,O
18.88,2342,O
+/-,2342,O
2.23,2342,O
mmol/l,2342,O
),2342,O
p,2342,O
<,2342,O
0.01,2342,O
.,2342,O
These,2343,O
results,2343,O
suggest,2343,O
that,2343,O
regular,2343,O
physical,2343,O
activity,2343,O
is,2343,O
associated,2343,O
with,2343,O
preserved,2343,O
AODs,2343,O
in,2343,O
adults,2343,O
with,2343,O
ID,2343,O
.,2343,O
As,2344,O
opposed,2344,O
to,2344,O
a,2344,O
physically,2344,O
active,2344,O
lifestyle,2344,O
",",2344,O
an,2344,O
inactive,2344,O
results,2344,O
in,2344,O
low,2344,O
levels,2344,O
of,2344,O
antioxidants,2344,O
.,2344,O
Na+/Cl-,2345,B-CHEMICAL
dipole,2345,O
couples,2345,O
agonist,2345,O
binding,2345,O
to,2345,O
kainate,2345,B-GENE-N
receptor,2345,I-GENE-N
activation,2345,O
.,2345,O
Kainate-selective,2346,B-CHEMICAL
ionotropic,2346,I-GENE-N
glutamate,2346,B-CHEMICAL
receptors,2346,I-GENE-N
(,2346,O
GluRs,2346,B-GENE-N
),2346,O
require,2346,O
external,2346,O
Na+,2346,B-CHEMICAL
and,2346,O
Cl-,2346,B-CHEMICAL
as,2346,O
well,2346,O
as,2346,O
the,2346,O
neurotransmitter,2346,O
L-glutamate,2346,B-CHEMICAL
for,2346,O
activation,2346,O
.,2346,O
Although,2347,O
",",2347,O
external,2347,O
anions,2347,O
and,2347,O
cations,2347,O
apparently,2347,O
coactivate,2347,O
kainate,2347,B-CHEMICAL
receptors,2347,I-GENE-N
(,2347,O
KARs,2347,B-GENE-N
),2347,O
in,2347,O
an,2347,O
identical,2347,O
manner,2347,O
",",2347,O
it,2347,O
has,2347,O
yet,2347,O
to,2347,O
be,2347,O
established,2347,O
how,2347,O
ions,2347,O
of,2347,O
opposite,2347,O
charge,2347,O
achieve,2347,O
this,2347,O
.,2347,O
An,2348,O
additional,2348,O
complication,2348,O
is,2348,O
that,2348,O
KARs,2348,B-GENE-N
are,2348,O
subject,2348,O
to,2348,O
other,2348,O
forms,2348,O
of,2348,O
cation,2348,O
modulation,2348,O
via,2348,O
extracellular,2348,O
acidification,2348,O
(,2348,O
i.e.,2348,O
",",2348,O
protons,2348,O
),2348,O
and,2348,O
divalent,2348,O
ions,2348,O
.,2348,O
Consequently,2349,O
",",2349,O
other,2349,O
cation,2349,O
species,2349,O
may,2349,O
compete,2349,O
with,2349,O
Na+,2349,B-CHEMICAL
to,2349,O
regulate,2349,O
the,2349,O
time,2349,O
KARs,2349,B-GENE-N
remain,2349,O
in,2349,O
the,2349,O
open,2349,O
state,2349,O
.,2349,O
Here,2350,O
we,2350,O
designed,2350,O
experiments,2350,O
to,2350,O
unravel,2350,O
how,2350,O
external,2350,O
ions,2350,O
regulate,2350,O
GluR6,2350,B-GENE-N
KARs,2350,B-GENE-N
.,2350,O
We,2351,O
show,2351,O
that,2351,O
GluR6,2351,B-GENE-Y
kinetics,2351,O
are,2351,O
unaffected,2351,O
by,2351,O
alterations,2351,O
in,2351,O
physiological,2351,O
pH,2351,O
but,2351,O
that,2351,O
divalent,2351,O
and,2351,O
alkali,2351,O
metal,2351,O
ions,2351,O
compete,2351,O
to,2351,O
determine,2351,O
the,2351,O
time,2351,O
course,2351,O
of,2351,O
KAR,2351,B-GENE-N
channel,2351,I-GENE-N
activity,2351,O
.,2351,O
Additionally,2352,O
",",2352,O
Na+,2352,B-CHEMICAL
and,2352,O
Cl-,2352,B-CHEMICAL
ions,2352,O
coactivate,2352,O
GluR6,2352,B-GENE-Y
receptors,2352,O
by,2352,O
establishing,2352,O
a,2352,O
dipole,2352,O
",",2352,O
accounting,2352,O
for,2352,O
their,2352,O
common,2352,O
effect,2352,O
on,2352,O
KARs,2352,B-GENE-N
.,2352,O
Using,2353,O
charged,2353,O
amino,2353,B-CHEMICAL
acids,2353,I-CHEMICAL
as,2353,O
tethered,2353,O
ions,2353,O
",",2353,O
we,2353,O
further,2353,O
demonstrate,2353,O
that,2353,O
the,2353,O
docking,2353,O
order,2353,O
is,2353,O
fixed,2353,O
with,2353,O
cations,2353,O
binding,2353,O
first,2353,O
",",2353,O
followed,2353,O
by,2353,O
anions,2353,O
.,2353,O
Together,2354,O
",",2354,O
our,2354,O
findings,2354,O
identify,2354,O
the,2354,O
dipole,2354,O
as,2354,O
a,2354,O
novel,2354,O
gating,2354,O
feature,2354,O
that,2354,O
couples,2354,O
neurotransmitter,2354,O
binding,2354,O
to,2354,O
KAR,2354,B-GENE-N
activation,2354,O
.,2354,O
Nicotine,2355,B-CHEMICAL
receptor,2355,O
gene,2355,O
CHRNA4,2355,B-GENE-Y
modulates,2355,O
early,2355,O
event-related,2355,O
potentials,2355,O
in,2355,O
auditory,2355,O
and,2355,O
visual,2355,O
oddball,2355,O
target,2355,O
detection,2355,O
tasks,2355,O
.,2355,O
The,2356,O
present,2356,O
study,2356,O
seeks,2356,O
to,2356,O
identify,2356,O
effects,2356,O
of,2356,O
a,2356,O
common,2356,O
genetic,2356,O
polymorphism,2356,O
in,2356,O
the,2356,O
human,2356,B-GENE-N
nicotinic,2356,I-GENE-N
alpha4beta2,2356,I-GENE-N
receptor,2356,I-GENE-N
on,2356,O
components,2356,O
of,2356,O
the,2356,O
cognitive,2356,O
event-related,2356,O
potentials,2356,O
in,2356,O
auditory,2356,O
and,2356,O
visual,2356,O
modalities,2356,O
.,2356,O
The,2357,O
same,2357,O
sense,2357,O
thymine-to-cytosine,2357,B-CHEMICAL
polymorphism,2357,O
(,2357,O
c.1629T-C,2357,O
;,2357,O
Ser543Ser,2357,B-GENE-N
),2357,O
was,2357,O
shown,2357,O
to,2357,O
preferentially,2357,O
modulate,2357,O
early,2357,O
components,2357,O
in,2357,O
both,2357,O
modalities,2357,O
.,2357,O
Specifically,2358,O
",",2358,O
the,2358,O
auditory,2358,O
N1,2358,O
component,2358,O
amplitude,2358,O
was,2358,O
higher,2358,O
for,2358,O
T,2358,O
allele,2358,O
homozygotes,2358,O
than,2358,O
for,2358,O
C,2358,O
allele,2358,O
carriers,2358,O
.,2358,O
The,2359,O
visual,2359,O
P1,2359,O
component,2359,O
revealed,2359,O
the,2359,O
same,2359,O
pattern,2359,O
of,2359,O
significant,2359,O
polymorphic,2359,O
modulation,2359,O
",",2359,O
but,2359,O
the,2359,O
later,2359,O
N1,2359,O
amplitude,2359,O
differences,2359,O
were,2359,O
only,2359,O
marginally,2359,O
significant,2359,O
.,2359,O
There,2360,O
was,2360,O
no,2360,O
reliable,2360,O
indication,2360,O
of,2360,O
interactions,2360,O
between,2360,O
genotype,2360,O
and,2360,O
task,2360,O
factors,2360,O
.,2360,O
Parallel,2361,O
modulation,2361,O
of,2361,O
early,2361,O
latency,2361,O
modality-specific,2361,O
event-related,2361,O
potential,2361,O
(,2361,O
ERP,2361,O
),2361,O
components,2361,O
in,2361,O
vision,2361,O
and,2361,O
audition,2361,O
may,2361,O
indicate,2361,O
that,2361,O
the,2361,O
CHRNA4,2361,B-GENE-Y
polymorphism,2361,O
affects,2361,O
factors,2361,O
that,2361,O
are,2361,O
common,2361,O
to,2361,O
top-down,2361,O
modulation,2361,O
of,2361,O
sensory,2361,O
processing,2361,O
across,2361,O
modalities,2361,O
.,2361,O
Phenserine,2362,B-CHEMICAL
.,2362,O
Phenserine,2363,B-CHEMICAL
",",2363,O
a,2363,O
derivative,2363,O
of,2363,O
physostigmine,2363,B-CHEMICAL
",",2363,O
was,2363,O
first,2363,O
described,2363,O
as,2363,O
an,2363,O
inhibitor,2363,O
of,2363,O
acetylcholinesterase,2363,B-GENE-N
(,2363,O
AChE,2363,B-GENE-N
),2363,O
and,2363,O
was,2363,O
shown,2363,O
to,2363,O
improve,2363,O
cognition,2363,O
in,2363,O
various,2363,O
experimental,2363,O
paradigms,2363,O
in,2363,O
rodents,2363,O
and,2363,O
dogs,2363,O
.,2363,O
It,2364,O
was,2364,O
clinically,2364,O
tested,2364,O
for,2364,O
Alzheimer,2364,O
's,2364,O
disease,2364,O
",",2364,O
with,2364,O
moderate,2364,O
success,2364,O
in,2364,O
initial,2364,O
Phase,2364,O
II,2364,O
studies,2364,O
.,2364,O
Phenserine,2365,B-CHEMICAL
deserves,2365,O
attention,2365,O
for,2365,O
an,2365,O
additional,2365,O
quality,2365,O
of,2365,O
action,2365,O
:,2365,O
in,2365,O
addition,2365,O
to,2365,O
inhibiting,2365,O
AChE,2365,B-GENE-Y
",",2365,O
it,2365,O
modulates,2365,O
the,2365,O
amount,2365,O
of,2365,O
beta-amyloid,2365,B-GENE-Y
precursor,2365,I-GENE-Y
protein,2365,I-GENE-Y
(,2365,O
APP,2365,B-GENE-Y
),2365,O
in,2365,O
neuronal,2365,O
cell,2365,O
culture,2365,O
by,2365,O
reducing,2365,O
APP,2365,B-GENE-Y
translation,2365,O
.,2365,O
This,2366,O
effect,2366,O
probably,2366,O
involves,2366,O
interaction,2366,O
of,2366,O
phenserine,2366,B-CHEMICAL
with,2366,O
a,2366,O
regulatory,2366,O
element,2366,O
in,2366,O
the,2366,O
5'-untranslated,2366,O
region,2366,O
of,2366,O
the,2366,O
APP,2366,B-GENE-Y
gene,2366,O
that,2366,O
controls,2366,O
APP,2366,B-GENE-Y
expression,2366,O
.,2366,O
Phenserine,2367,B-CHEMICAL
apparently,2367,O
reduces,2367,O
translational,2367,O
efficiency,2367,O
of,2367,O
APP,2367,B-GENE-Y
mRNA,2367,O
into,2367,O
protein,2367,O
",",2367,O
a,2367,O
process,2367,O
that,2367,O
may,2367,O
involve,2367,O
an,2367,O
interaction,2367,O
with,2367,O
iron,2367,B-CHEMICAL
and/or,2367,O
an,2367,O
iron-responsive,2367,B-CHEMICAL
element,2367,O
.,2367,O
As,2368,O
a,2368,O
consequence,2368,O
",",2368,O
phenserine,2368,B-CHEMICAL
reduces,2368,O
beta-amyloid,2368,B-GENE-Y
peptide,2368,O
(,2368,O
Abeta,2368,B-GENE-Y
),2368,O
formation,2368,O
in,2368,O
vitro,2368,O
and,2368,O
in,2368,O
vivo,2368,O
.,2368,O
Phenserine,2369,B-CHEMICAL
is,2369,O
also,2369,O
unique,2369,O
because,2369,O
of,2369,O
differing,2369,O
actions,2369,O
of,2369,O
its,2369,O
enantiomers,2369,O
:,2369,O
(,2369,B-CHEMICAL
-,2369,I-CHEMICAL
),2369,I-CHEMICAL
-phenserine,2369,I-CHEMICAL
is,2369,O
the,2369,O
active,2369,O
enantiomer,2369,O
for,2369,O
inhibition,2369,O
of,2369,O
AChE,2369,B-GENE-Y
",",2369,O
whereas,2369,O
(,2369,B-CHEMICAL
+,2369,I-CHEMICAL
),2369,I-CHEMICAL
-phenserine,2369,I-CHEMICAL
(,2369,O
'posiphen,2369,O
',2369,O
),2369,O
has,2369,O
weak,2369,O
activity,2369,O
as,2369,O
an,2369,O
AChE,2369,B-GENE-Y
inhibitor,2369,O
and,2369,O
can,2369,O
be,2369,O
dosed,2369,O
much,2369,O
higher,2369,O
.,2369,O
Both,2370,O
enantiomers,2370,O
are,2370,O
equipotent,2370,O
in,2370,O
downregulating,2370,O
APP,2370,B-GENE-Y
expression,2370,O
.,2370,O
(,2371,B-CHEMICAL
+,2371,I-CHEMICAL
),2371,I-CHEMICAL
-Posiphen,2371,I-CHEMICAL
may,2371,O
be,2371,O
a,2371,O
promising,2371,O
drug,2371,O
",",2371,O
either,2371,O
alone,2371,O
or,2371,O
in,2371,O
combination,2371,O
with,2371,O
(,2371,B-CHEMICAL
-,2371,I-CHEMICAL
),2371,I-CHEMICAL
-phenserine,2371,I-CHEMICAL
",",2371,O
to,2371,O
attenuate,2371,O
the,2371,O
progression,2371,O
of,2371,O
Alzheimer,2371,O
's,2371,O
disease,2371,O
.,2371,O
Alpha1-adrenoceptors,2372,B-GENE-N
are,2372,O
required,2372,O
for,2372,O
normal,2372,O
male,2372,O
sexual,2372,O
function,2372,O
.,2372,O
BACKGROUND,2373,O
AND,2373,O
PURPOSE,2373,O
:,2373,O
Alpha,2373,B-GENE-N
(,2373,I-GENE-N
1,2373,I-GENE-N
),2373,I-GENE-N
-adrenoceptor,2373,I-GENE-N
antagonists,2373,O
are,2373,O
extensively,2373,O
used,2373,O
in,2373,O
the,2373,O
treatment,2373,O
of,2373,O
hypertension,2373,O
and,2373,O
lower,2373,O
urinary,2373,O
tract,2373,O
symptoms,2373,O
associated,2373,O
with,2373,O
benign,2373,O
prostatic,2373,O
hyperplasia,2373,O
.,2373,O
Among,2374,O
the,2374,O
side,2374,O
effects,2374,O
",",2374,O
ejaculatory,2374,O
dysfunction,2374,O
occurs,2374,O
more,2374,O
frequently,2374,O
with,2374,O
drugs,2374,O
that,2374,O
are,2374,O
relatively,2374,O
selective,2374,O
for,2374,O
alpha,2374,B-GENE-Y
(,2374,I-GENE-Y
1A,2374,I-GENE-Y
),2374,I-GENE-Y
-adrenoceptors,2374,I-GENE-Y
compared,2374,O
with,2374,O
other,2374,O
drugs,2374,O
of,2374,O
this,2374,O
class,2374,O
.,2374,O
This,2375,O
suggests,2375,O
that,2375,O
alpha,2375,B-GENE-Y
(,2375,I-GENE-Y
1A,2375,I-GENE-Y
),2375,I-GENE-Y
-adrenoceptors,2375,I-GENE-Y
may,2375,O
contribute,2375,O
to,2375,O
ejaculation,2375,O
.,2375,O
However,2376,O
",",2376,O
this,2376,O
has,2376,O
not,2376,O
been,2376,O
studied,2376,O
at,2376,O
the,2376,O
molecular,2376,O
level,2376,O
.,2376,O
EXPERIMENTAL,2377,O
APPROACH,2377,O
:,2377,O
The,2377,O
physiological,2377,O
contribution,2377,O
of,2377,O
each,2377,O
alpha,2377,B-GENE-N
(,2377,I-GENE-N
1,2377,I-GENE-N
),2377,I-GENE-N
-adrenoceptor,2377,I-GENE-N
subtype,2377,O
was,2377,O
characterized,2377,O
using,2377,O
alpha,2377,B-GENE-N
(,2377,I-GENE-N
1,2377,I-GENE-N
),2377,I-GENE-N
-adrenoceptor,2377,I-GENE-N
subtype-selective,2377,O
knockout,2377,O
(,2377,O
KO,2377,O
),2377,O
mice,2377,O
(,2377,O
alpha,2377,B-GENE-N
(,2377,I-GENE-N
1A,2377,I-GENE-N
),2377,I-GENE-N
-,2377,I-GENE-N
",",2377,I-GENE-N
alpha,2377,I-GENE-N
(,2377,I-GENE-N
1B,2377,I-GENE-N
),2377,I-GENE-N
-,2377,I-GENE-N
and,2377,I-GENE-N
alpha,2377,I-GENE-N
(,2377,I-GENE-N
1D,2377,I-GENE-N
),2377,I-GENE-N
-AR,2377,I-GENE-N
KO,2377,O
mice,2377,O
),2377,O
since,2377,O
the,2377,O
subtype-specific,2377,O
drugs,2377,O
available,2377,O
are,2377,O
only,2377,O
moderately,2377,O
selective,2377,O
.,2377,O
We,2378,O
analysed,2378,O
the,2378,O
role,2378,O
of,2378,O
alpha,2378,B-GENE-N
(,2378,I-GENE-N
1,2378,I-GENE-N
),2378,I-GENE-N
-adrenoceptors,2378,I-GENE-N
in,2378,O
the,2378,O
blood,2378,O
pressure,2378,O
and,2378,O
vascular,2378,O
response,2378,O
as,2378,O
well,2378,O
as,2378,O
ejaculation,2378,O
by,2378,O
determining,2378,O
these,2378,O
variables,2378,O
in,2378,O
alpha,2378,B-GENE-N
(,2378,I-GENE-N
1,2378,I-GENE-N
),2378,I-GENE-N
-adrenoceptor,2378,I-GENE-N
subtype-selective,2378,O
KO,2378,O
mice,2378,O
and,2378,O
in,2378,O
mice,2378,O
with,2378,O
all,2378,O
their,2378,O
alpha,2378,B-GENE-N
(,2378,I-GENE-N
1,2378,I-GENE-N
),2378,I-GENE-N
-adrenoceptor,2378,I-GENE-N
subtypes,2378,O
deleted,2378,O
(,2378,O
alpha,2378,B-GENE-N
(,2378,I-GENE-N
1,2378,I-GENE-N
),2378,I-GENE-N
-AR,2378,I-GENE-N
triple-KO,2378,O
mice,2378,O
),2378,O
.,2378,O
KEY,2379,O
RESULTS,2379,O
:,2379,O
The,2379,O
pregnancy,2379,O
rate,2379,O
was,2379,O
reduced,2379,O
by,2379,O
50,2379,O
%,2379,O
in,2379,O
alpha,2379,B-GENE-Y
(,2379,I-GENE-Y
1A,2379,I-GENE-Y
),2379,I-GENE-Y
-adrenoceptor,2379,I-GENE-Y
KO,2379,O
mice,2379,O
",",2379,O
and,2379,O
this,2379,O
reduction,2379,O
was,2379,O
dramatically,2379,O
enhanced,2379,O
in,2379,O
alpha,2379,B-GENE-N
(,2379,I-GENE-N
1,2379,I-GENE-N
),2379,I-GENE-N
-adrenoceptor,2379,I-GENE-N
triple-KO,2379,O
mice,2379,O
.,2379,O
Contractile,2380,O
tension,2380,O
of,2380,O
the,2380,O
vas,2380,O
deferens,2380,O
in,2380,O
response,2380,O
to,2380,O
noradrenaline,2380,B-CHEMICAL
was,2380,O
markedly,2380,O
decreased,2380,O
in,2380,O
alpha,2380,B-GENE-Y
(,2380,I-GENE-Y
1A,2380,I-GENE-Y
),2380,I-GENE-Y
-adrenoceptor,2380,I-GENE-Y
KO,2380,O
mice,2380,O
",",2380,O
and,2380,O
this,2380,O
contraction,2380,O
was,2380,O
completely,2380,O
abolished,2380,O
in,2380,O
alpha,2380,B-GENE-N
(,2380,I-GENE-N
1,2380,I-GENE-N
),2380,I-GENE-N
-adrenoceptor,2380,I-GENE-N
triple-KO,2380,O
mice,2380,O
.,2380,O
This,2381,O
attenuation,2381,O
of,2381,O
contractility,2381,O
was,2381,O
also,2381,O
observed,2381,O
in,2381,O
the,2381,O
electrically,2381,O
stimulated,2381,O
vas,2381,O
deferens,2381,O
.,2381,O
CONCLUSIONS,2382,O
AND,2382,O
IMPLICATIONS,2382,O
:,2382,O
These,2382,O
results,2382,O
demonstrate,2382,O
that,2382,O
alpha,2382,B-GENE-N
(,2382,I-GENE-N
1,2382,I-GENE-N
),2382,I-GENE-N
-adrenoceptors,2382,I-GENE-N
",",2382,O
particularly,2382,O
alpha,2382,B-GENE-Y
(,2382,I-GENE-Y
1A,2382,I-GENE-Y
),2382,I-GENE-Y
-adrenoceptors,2382,I-GENE-Y
",",2382,O
are,2382,O
required,2382,O
for,2382,O
normal,2382,O
contractility,2382,O
of,2382,O
the,2382,O
vas,2382,O
deferens,2382,O
and,2382,O
consequent,2382,O
sperm,2382,O
ejaculation,2382,O
as,2382,O
well,2382,O
as,2382,O
having,2382,O
a,2382,O
function,2382,O
in,2382,O
fertility,2382,O
.,2382,O
Pharmacological,2383,O
activators,2383,O
of,2383,O
AMP-activated,2383,B-GENE-Y
protein,2383,I-GENE-Y
kinase,2383,I-GENE-Y
have,2383,O
different,2383,O
effects,2383,O
on,2383,O
Na+,2383,B-CHEMICAL
transport,2383,O
processes,2383,O
across,2383,O
human,2383,O
lung,2383,O
epithelial,2383,O
cells,2383,O
.,2383,O
BACKGROUND,2384,O
AND,2384,O
PURPOSE,2384,O
:,2384,O
AMP-activated,2384,B-GENE-Y
protein,2384,I-GENE-Y
kinase,2384,I-GENE-Y
(,2384,O
AMPK,2384,B-GENE-Y
),2384,O
is,2384,O
activated,2384,O
by,2384,O
metformin,2384,B-CHEMICAL
",",2384,O
phenformin,2384,B-CHEMICAL
",",2384,O
and,2384,O
the,2384,O
AMP,2384,B-CHEMICAL
mimetic,2384,O
",",2384,O
5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside,2384,B-CHEMICAL
(,2384,O
AICAR,2384,B-CHEMICAL
),2384,O
.,2384,O
We,2385,O
have,2385,O
completed,2385,O
an,2385,O
extensive,2385,O
study,2385,O
of,2385,O
the,2385,O
pharmacological,2385,O
effects,2385,O
of,2385,O
these,2385,O
drugs,2385,O
on,2385,O
AMPK,2385,B-GENE-Y
activation,2385,O
",",2385,O
adenine,2385,B-CHEMICAL
nucleotide,2385,I-CHEMICAL
concentration,2385,O
",",2385,O
transepithelial,2385,O
amiloride-sensitive,2385,B-CHEMICAL
(,2385,O
I,2385,O
(,2385,O
amiloride,2385,B-CHEMICAL
),2385,O
),2385,O
and,2385,O
ouabain-sensitive,2385,B-CHEMICAL
basolateral,2385,O
(,2385,O
I,2385,O
(,2385,O
ouabain,2385,B-CHEMICAL
),2385,O
),2385,O
short,2385,O
circuit,2385,O
current,2385,O
in,2385,O
H441,2385,O
lung,2385,O
epithelial,2385,O
cells,2385,O
.,2385,O
EXPERIMENTAL,2386,O
APPROACH,2386,O
:,2386,O
H441,2386,O
cells,2386,O
were,2386,O
grown,2386,O
on,2386,O
permeable,2386,O
filters,2386,O
at,2386,O
air,2386,O
interface,2386,O
.,2386,O
I,2387,O
(,2387,O
amiloride,2387,B-CHEMICAL
),2387,O
",",2387,O
I,2387,O
(,2387,O
ouabain,2387,B-CHEMICAL
),2387,O
and,2387,O
transepithelial,2387,O
resistance,2387,O
were,2387,O
measured,2387,O
in,2387,O
Ussing,2387,O
chambers,2387,O
.,2387,O
AMPK,2388,B-GENE-Y
activity,2388,O
was,2388,O
measured,2388,O
as,2388,O
the,2388,O
amount,2388,O
of,2388,O
radiolabelled,2388,O
phosphate,2388,B-CHEMICAL
transferred,2388,O
to,2388,O
the,2388,O
SAMS,2388,O
peptide,2388,O
.,2388,O
Adenine,2389,B-CHEMICAL
nucleotide,2389,I-CHEMICAL
concentration,2389,O
was,2389,O
analysed,2389,O
by,2389,O
reverse,2389,O
phase,2389,O
HPLC,2389,O
and,2389,O
NAD,2389,B-CHEMICAL
(,2389,I-CHEMICAL
P,2389,I-CHEMICAL
),2389,I-CHEMICAL
H,2389,I-CHEMICAL
autofluorescence,2389,O
was,2389,O
measured,2389,O
using,2389,O
confocal,2389,O
microscopy,2389,O
.,2389,O
KEY,2390,O
RESULTS,2390,O
:,2390,O
Phenformin,2390,B-CHEMICAL
",",2390,O
AICAR,2390,B-CHEMICAL
and,2390,O
metformin,2390,B-CHEMICAL
increased,2390,O
AMPK,2390,B-GENE-Y
(,2390,I-GENE-Y
alpha1,2390,I-GENE-Y
),2390,I-GENE-Y
activity,2390,O
and,2390,O
decreased,2390,O
I,2390,O
(,2390,O
amiloride,2390,B-CHEMICAL
),2390,O
.,2390,O
The,2391,O
AMPK,2391,B-GENE-Y
inhibitor,2391,O
Compound,2391,O
C,2391,O
prevented,2391,O
the,2391,O
action,2391,O
of,2391,O
metformin,2391,B-CHEMICAL
and,2391,O
AICAR,2391,B-CHEMICAL
but,2391,O
not,2391,O
phenformin,2391,B-CHEMICAL
.,2391,O
Phenformin,2392,B-CHEMICAL
and,2392,O
AICAR,2392,B-CHEMICAL
decreased,2392,O
I,2392,O
(,2392,O
ouabain,2392,B-CHEMICAL
),2392,O
across,2392,O
H441,2392,O
monolayers,2392,O
and,2392,O
decreased,2392,O
monolayer,2392,O
resistance,2392,O
.,2392,O
The,2393,O
decrease,2393,O
in,2393,O
I,2393,O
(,2393,O
amiloride,2393,B-CHEMICAL
),2393,O
was,2393,O
closely,2393,O
related,2393,O
to,2393,O
I,2393,O
(,2393,O
ouabain,2393,B-CHEMICAL
),2393,O
with,2393,O
phenformin,2393,B-CHEMICAL
",",2393,O
but,2393,O
not,2393,O
in,2393,O
AICAR,2393,B-CHEMICAL
treated,2393,O
monolayers,2393,O
.,2393,O
Metformin,2394,B-CHEMICAL
and,2394,O
phenformin,2394,B-CHEMICAL
increased,2394,O
the,2394,O
cellular,2394,O
AMP,2394,B-CHEMICAL
:,2394,O
ATP,2394,B-CHEMICAL
ratio,2394,O
but,2394,O
only,2394,O
phenformin,2394,B-CHEMICAL
and,2394,O
AICAR,2394,B-CHEMICAL
decreased,2394,O
cellular,2394,O
ATP,2394,B-CHEMICAL
.,2394,O
CONCLUSIONS,2395,O
AND,2395,O
IMPLICATIONS,2395,O
:,2395,O
Activation,2395,O
of,2395,O
alpha1-AMPK,2395,B-GENE-Y
is,2395,O
associated,2395,O
with,2395,O
inhibition,2395,O
of,2395,O
apical,2395,O
amiloride-sensitive,2395,B-GENE-N
Na,2395,I-GENE-N
(,2395,I-GENE-N
+,2395,I-GENE-N
),2395,I-GENE-N
channels,2395,I-GENE-N
(,2395,O
ENaC,2395,B-GENE-N
),2395,O
",",2395,O
which,2395,O
has,2395,O
important,2395,O
implications,2395,O
for,2395,O
the,2395,O
clinical,2395,O
use,2395,O
of,2395,O
metformin,2395,B-CHEMICAL
.,2395,O
Additional,2396,O
pharmacological,2396,O
effects,2396,O
evoked,2396,O
by,2396,O
AICAR,2396,B-CHEMICAL
and,2396,O
phenformin,2396,B-CHEMICAL
on,2396,O
I,2396,O
(,2396,O
ouabain,2396,B-CHEMICAL
),2396,O
",",2396,O
with,2396,O
potential,2396,O
secondary,2396,O
effects,2396,O
on,2396,O
apical,2396,O
Na+,2396,B-CHEMICAL
conductance,2396,O
",",2396,O
ENaC,2396,B-GENE-N
activity,2396,O
and,2396,O
monolayer,2396,O
resistance,2396,O
",",2396,O
have,2396,O
important,2396,O
consequences,2396,O
for,2396,O
their,2396,O
use,2396,O
as,2396,O
pharmacological,2396,O
activators,2396,O
of,2396,O
AMPK,2396,B-GENE-Y
in,2396,O
cell,2396,O
systems,2396,O
where,2396,O
Na+K+ATPase,2396,B-GENE-N
is,2396,O
an,2396,O
important,2396,O
component,2396,O
.,2396,O
Neuroprotective,2397,O
effect,2397,O
of,2397,O
nimesulide,2397,B-CHEMICAL
",",2397,O
a,2397,O
preferential,2397,O
COX-2,2397,B-GENE-Y
inhibitor,2397,O
",",2397,O
against,2397,O
pentylenetetrazol,2397,B-CHEMICAL
(,2397,O
PTZ,2397,B-CHEMICAL
),2397,O
-induced,2397,O
chemical,2397,O
kindling,2397,O
and,2397,O
associated,2397,O
biochemical,2397,O
parameters,2397,O
in,2397,O
mice,2397,O
.,2397,O
Brain,2398,O
cyclooxygenases,2398,B-GENE-N
(,2398,O
COX,2398,B-GENE-N
),2398,O
",",2398,O
the,2398,O
rate-limiting,2398,O
enzyme,2398,O
in,2398,O
prostaglandin,2398,B-CHEMICAL
synthesis,2398,O
",",2398,O
is,2398,O
rapidly,2398,O
and,2398,O
transiently,2398,O
induced,2398,O
by,2398,O
convulsions,2398,O
in,2398,O
hippocampal,2398,O
and,2398,O
cortical,2398,O
neurons,2398,O
.,2398,O
Previous,2399,O
studies,2399,O
have,2399,O
explored,2399,O
the,2399,O
protective,2399,O
effect,2399,O
of,2399,O
naproxen,2399,B-CHEMICAL
(,2399,O
non-selective,2399,O
COX-inhibitor,2399,B-GENE-N
),2399,O
or,2399,O
rofecoxib,2399,B-CHEMICAL
(,2399,O
selective,2399,O
COX-2,2399,B-GENE-Y
inhibitor,2399,O
),2399,O
against,2399,O
chemical,2399,O
kindling,2399,O
in,2399,O
mice,2399,O
.,2399,O
With,2400,O
this,2400,O
background,2400,O
",",2400,O
the,2400,O
present,2400,O
study,2400,O
was,2400,O
designed,2400,O
to,2400,O
explore,2400,O
the,2400,O
possible,2400,O
effect,2400,O
of,2400,O
nimesulide,2400,B-CHEMICAL
(,2400,O
a,2400,O
preferential,2400,O
COX-2,2400,B-GENE-Y
inhibitor,2400,O
),2400,O
against,2400,O
pentylenetetrazol,2400,B-CHEMICAL
(,2400,O
PTZ,2400,B-CHEMICAL
),2400,O
-induced,2400,O
kindling,2400,O
epilepsy,2400,O
in,2400,O
mice,2400,O
.,2400,O
To,2401,O
induce,2401,O
kindling,2401,O
",",2401,O
PTZ,2401,B-CHEMICAL
was,2401,O
injected,2401,O
in,2401,O
a,2401,O
subconvulsive,2401,O
dose,2401,O
(,2401,O
40,2401,O
mg/kg,2401,O
",",2401,O
i.p,2401,O
.,2401,O
),2401,O
every,2402,O
other,2402,O
day,2402,O
for,2402,O
15,2402,O
days,2402,O
.,2402,O
Nimesulide,2403,B-CHEMICAL
(,2403,O
2.5,2403,O
or,2403,O
5,2403,O
mg/kg,2403,O
",",2403,O
p.o,2403,O
.,2403,O
),2403,O
was,2404,O
administered,2404,O
each,2404,O
day,2404,O
45,2404,O
min,2404,O
before,2404,O
either,2404,O
PTZ,2404,B-CHEMICAL
or,2404,O
vehicle,2404,O
challenge,2404,O
.,2404,O
The,2405,O
intensity,2405,O
of,2405,O
kindling,2405,O
was,2405,O
assessed,2405,O
immediately,2405,O
after,2405,O
PTZ,2405,B-CHEMICAL
administration,2405,O
according,2405,O
to,2405,O
a,2405,O
prevalidated,2405,O
scoring,2405,O
scale,2405,O
.,2405,O
On,2406,O
16th,2406,O
day,2406,O
i.e,2406,O
.,2406,O
24,2407,O
h,2407,O
after,2407,O
the,2407,O
last,2407,O
dose,2407,O
of,2407,O
PTZ,2407,B-CHEMICAL
",",2407,O
animals,2407,O
were,2407,O
sacrificed,2407,O
and,2407,O
various,2407,O
biochemical,2407,O
parameters,2407,O
were,2407,O
assessed,2407,O
in,2407,O
the,2407,O
whole,2407,O
brain,2407,O
.,2407,O
Compared,2408,O
with,2408,O
normal,2408,O
control,2408,O
group,2408,O
",",2408,O
PTZ-kindled,2408,B-CHEMICAL
mice,2408,O
had,2408,O
significantly,2408,O
higher,2408,O
levels,2408,O
of,2408,O
malondialdehyde,2408,B-CHEMICAL
",",2408,O
nitrite,2408,B-CHEMICAL
",",2408,O
myeloperoxidase,2408,B-GENE-Y
but,2408,O
had,2408,O
lower,2408,O
levels,2408,O
of,2408,O
reduced,2408,O
glutathione,2408,B-CHEMICAL
in,2408,O
the,2408,O
whole,2408,O
brain,2408,O
homogenate,2408,O
.,2408,O
Chronic,2409,O
treatment,2409,O
with,2409,O
nimesulide,2409,B-CHEMICAL
(,2409,O
2.5,2409,O
or,2409,O
5,2409,O
mg/kg,2409,O
",",2409,O
p.o,2409,O
.,2409,O
),2409,O
for,2410,O
15,2410,O
days,2410,O
showed,2410,O
significant,2410,O
decrease,2410,O
in,2410,O
kindling,2410,O
score,2410,O
and,2410,O
could,2410,O
play,2410,O
a,2410,O
role,2410,O
in,2410,O
controlling,2410,O
the,2410,O
accompanying,2410,O
biochemical,2410,O
alterations,2410,O
due,2410,O
to,2410,O
PTZ,2410,B-CHEMICAL
.,2410,O
These,2411,O
results,2411,O
suggested,2411,O
that,2411,O
nimesulide,2411,B-CHEMICAL
",",2411,O
a,2411,O
preferential,2411,O
COX-2,2411,B-GENE-Y
inhibitor,2411,O
offered,2411,O
neuroprotection,2411,O
against,2411,O
PTZ-induced,2411,B-CHEMICAL
kindling,2411,O
in,2411,O
mice,2411,O
.,2411,O
Glutathione,2412,B-CHEMICAL
S-transferase,2412,B-CHEMICAL
polymorphisms,2412,O
",",2412,O
cruciferous,2412,O
vegetable,2412,O
intake,2412,O
and,2412,O
cancer,2412,O
risk,2412,O
in,2412,O
the,2412,O
Central,2412,O
and,2412,O
Eastern,2412,O
European,2412,O
Kidney,2412,O
Cancer,2412,O
Study,2412,O
.,2412,O
High,2413,O
consumption,2413,O
of,2413,O
cruciferous,2413,O
vegetables,2413,O
has,2413,O
been,2413,O
associated,2413,O
with,2413,O
reduced,2413,O
kidney,2413,O
cancer,2413,O
risk,2413,O
in,2413,O
many,2413,O
studies,2413,O
.,2413,O
Isothiocyanates,2414,B-CHEMICAL
",",2414,O
thought,2414,O
to,2414,O
be,2414,O
responsible,2414,O
for,2414,O
the,2414,O
chemopreventive,2414,O
properties,2414,O
of,2414,O
this,2414,O
food,2414,O
group,2414,O
",",2414,O
are,2414,O
conjugated,2414,O
to,2414,O
glutathione,2414,B-CHEMICAL
by,2414,O
glutathione,2414,B-CHEMICAL
S-transferases,2414,B-CHEMICAL
(,2414,O
GSTs,2414,B-GENE-N
),2414,O
before,2414,O
urinary,2414,O
excretion,2414,O
.,2414,O
Modification,2415,O
of,2415,O
this,2415,O
relationship,2415,O
by,2415,O
host,2415,O
genetic,2415,O
factors,2415,O
is,2415,O
unknown,2415,O
.,2415,O
We,2416,O
investigated,2416,O
cruciferous,2416,O
vegetable,2416,O
intake,2416,O
in,2416,O
1097,2416,O
cases,2416,O
and,2416,O
1555,2416,O
controls,2416,O
enrolled,2416,O
in,2416,O
a,2416,O
multicentric,2416,O
case-control,2416,O
study,2416,O
from,2416,O
the,2416,O
Czech,2416,O
Republic,2416,O
",",2416,O
Poland,2416,O
",",2416,O
Romania,2416,O
and,2416,O
Russia,2416,O
.,2416,O
To,2417,O
assess,2417,O
possible,2417,O
gene-diet,2417,O
interactions,2417,O
",",2417,O
genotyped,2417,O
cases,2417,O
(,2417,O
N,2417,O
=,2417,O
925,2417,O
),2417,O
and,2417,O
controls,2417,O
(,2417,O
N,2417,O
=,2417,O
1247,2417,O
),2417,O
for,2417,O
selected,2417,O
functional,2417,O
or,2417,O
non-synonymous,2417,O
polymorphisms,2417,O
including,2417,O
the,2417,O
GSTM1,2417,B-GENE-Y
deletion,2417,O
",",2417,O
GSTM3,2417,B-GENE-Y
3,2417,O
bp,2417,O
deletion,2417,O
(,2417,O
IVS6,2417,O
+,2417,O
22-AGG,2417,O
),2417,O
and,2417,O
V224I,2417,B-GENE-N
G,2417,B-GENE-N
>,2417,I-GENE-N
A,2417,I-GENE-N
substitution,2417,O
",",2417,O
GSTT1,2417,B-GENE-Y
deletion,2417,O
and,2417,O
the,2417,O
GSTP1,2417,B-GENE-Y
I105V,2417,B-GENE-N
A,2417,B-GENE-N
>,2417,I-GENE-N
G,2417,I-GENE-N
substitution,2417,O
.,2417,O
The,2418,O
odds,2418,O
ratio,2418,O
(,2418,O
OR,2418,O
),2418,O
for,2418,O
low,2418,O
(,2418,O
less,2418,O
than,2418,O
once,2418,O
per,2418,O
month,2418,O
),2418,O
versus,2418,O
high,2418,O
(,2418,O
at,2418,O
least,2418,O
once,2418,O
per,2418,O
week,2418,O
),2418,O
intake,2418,O
of,2418,O
cruciferous,2418,O
vegetables,2418,O
was,2418,O
1.29,2418,O
[,2418,O
95,2418,O
%,2418,O
confidence,2418,O
interval,2418,O
(,2418,O
CI,2418,O
),2418,O
:,2418,O
1.02-1.62,2418,O
;,2418,O
P-trend,2418,O
=,2418,O
0.03,2418,O
],2418,O
.,2418,O
When,2419,O
low,2419,O
intake,2419,O
of,2419,O
cruciferous,2419,O
vegetables,2419,O
(,2419,O
less,2419,O
than,2419,O
once,2419,O
per,2419,O
month,2419,O
),2419,O
was,2419,O
stratified,2419,O
by,2419,O
GST,2419,B-GENE-N
genotype,2419,O
",",2419,O
higher,2419,O
kidney,2419,O
cancer,2419,O
risks,2419,O
were,2419,O
observed,2419,O
among,2419,O
individuals,2419,O
with,2419,O
the,2419,O
GSTT1,2419,B-GENE-Y
null,2419,O
(,2419,O
OR,2419,O
=,2419,O
1.86,2419,O
;,2419,O
95,2419,O
%,2419,O
CI,2419,O
:,2419,O
1.07-3.23,2419,O
;,2419,O
P-interaction,2419,O
=,2419,O
0.05,2419,O
),2419,O
or,2419,O
with,2419,O
both,2419,O
GSTM1/T1,2419,B-GENE-N
null,2419,O
genotypes,2419,O
(,2419,O
OR,2419,O
=,2419,O
2.49,2419,O
;,2419,O
95,2419,O
%,2419,O
CI,2419,O
:,2419,O
1.08-5.77,2419,O
;,2419,O
P-interaction,2419,O
=,2419,O
0.05,2419,O
),2419,O
.,2419,O
These,2420,O
data,2420,O
provide,2420,O
additional,2420,O
evidence,2420,O
for,2420,O
the,2420,O
role,2420,O
of,2420,O
cruciferous,2420,O
vegetables,2420,O
in,2420,O
cancer,2420,O
prevention,2420,O
among,2420,O
individuals,2420,O
with,2420,O
common,2420,O
",",2420,O
functional,2420,O
genetic,2420,O
polymorphisms,2420,O
.,2420,O
Regulated,2421,O
function,2421,O
of,2421,O
the,2421,O
prolyl-4-hydroxylase,2421,B-GENE-N
domain,2421,I-GENE-N
(,2421,I-GENE-N
PHD,2421,I-GENE-N
),2421,I-GENE-N
oxygen,2421,I-GENE-N
sensor,2421,I-GENE-N
proteins,2421,I-GENE-N
.,2421,O
Cellular,2422,O
oxygen,2422,B-CHEMICAL
is,2422,O
sensed,2422,O
by,2422,O
prolyl-4-hydroxylase,2422,B-GENE-N
domain,2422,I-GENE-N
(,2422,I-GENE-N
PHD,2422,I-GENE-N
),2422,I-GENE-N
proteins,2422,I-GENE-N
that,2422,O
hydroxylate,2422,B-CHEMICAL
hypoxia-inducible,2422,B-GENE-N
factor,2422,I-GENE-N
(,2422,I-GENE-N
HIF,2422,I-GENE-N
),2422,I-GENE-N
alpha,2422,I-GENE-N
subunits,2422,O
.,2422,O
Under,2423,O
normoxic,2423,O
conditions,2423,O
",",2423,O
hydroxylated,2423,O
HIFalpha,2423,B-GENE-N
is,2423,O
bound,2423,O
by,2423,O
the,2423,O
von,2423,O
Hippel-Lindau,2423,O
(,2423,O
pVHL,2423,O
),2423,O
tumor,2423,O
suppressor,2423,O
",",2423,O
leading,2423,O
to,2423,O
ubiquitinylation,2423,O
and,2423,O
proteasomal,2423,O
degradation,2423,O
.,2423,O
Under,2424,O
hypoxic,2424,O
conditions,2424,O
",",2424,O
hydroxylation,2424,O
becomes,2424,O
reduced,2424,O
",",2424,O
leading,2424,O
to,2424,O
HIFalpha,2424,B-GENE-N
stabilization,2424,O
.,2424,O
The,2425,O
authors,2425,O
recently,2425,O
showed,2425,O
that,2425,O
changes,2425,O
in,2425,O
PHD,2425,B-GENE-N
abundance,2425,O
and,2425,O
activity,2425,O
can,2425,O
regulate,2425,O
HIFalpha,2425,B-GENE-N
stability,2425,O
under,2425,O
normoxic,2425,O
as,2425,O
well,2425,O
as,2425,O
under,2425,O
hypoxic,2425,O
conditions,2425,O
.,2425,O
Thus,2426,O
",",2426,O
the,2426,O
PHD,2426,B-GENE-N
oxygen,2426,B-CHEMICAL
sensors,2426,O
themselves,2426,O
represent,2426,O
effectors,2426,O
of,2426,O
cellular,2426,O
signalling,2426,O
pathways,2426,O
as,2426,O
well,2426,O
as,2426,O
potential,2426,O
drug,2426,O
targets,2426,O
.,2426,O
Here,2427,O
",",2427,O
a,2427,O
cell-free,2427,O
in,2427,O
vitro,2427,O
microtiter,2427,O
plate-based,2427,O
peptide,2427,O
hydroxylation,2427,O
assay,2427,O
was,2427,O
used,2427,O
to,2427,O
investigate,2427,O
the,2427,O
influence,2427,O
of,2427,O
ferrous,2427,B-CHEMICAL
iron,2427,I-CHEMICAL
",",2427,O
Krebs,2427,O
cycle,2427,O
intermediates,2427,O
",",2427,O
transition,2427,O
metals,2427,O
",",2427,O
and,2427,O
vitamin,2427,B-CHEMICAL
C,2427,I-CHEMICAL
and,2427,O
other,2427,O
antioxidants,2427,O
on,2427,O
the,2427,O
activity,2427,O
of,2427,O
purified,2427,O
PHD1,2427,B-GENE-N
to,2427,I-GENE-N
3,2427,I-GENE-N
.,2427,O
PHD,2428,B-GENE-N
activity,2428,O
depends,2428,O
not,2428,O
only,2428,O
on,2428,O
oxygen,2428,B-CHEMICAL
availability,2428,O
but,2428,O
is,2428,O
also,2428,O
regulated,2428,O
by,2428,O
iron,2428,B-CHEMICAL
",",2428,O
vitamin,2428,B-CHEMICAL
C,2428,I-CHEMICAL
",",2428,O
and,2428,O
Krebs,2428,O
cycle,2428,O
intermediates,2428,O
",",2428,O
suggesting,2428,O
a,2428,O
physiological,2428,O
relevance,2428,O
of,2428,O
their,2428,O
cellular,2428,O
concentrations,2428,O
.,2428,O
Copper,2429,B-CHEMICAL
but,2429,O
not,2429,O
iron,2429,B-CHEMICAL
",",2429,O
cobalt,2429,B-CHEMICAL
",",2429,O
or,2429,O
nickel,2429,B-CHEMICAL
salts,2429,O
catalyzed,2429,O
vitamin,2429,B-CHEMICAL
C,2429,I-CHEMICAL
oxidation,2429,O
.,2429,O
While,2430,O
vitamin,2430,B-CHEMICAL
C,2430,I-CHEMICAL
is,2430,O
essential,2430,O
for,2430,O
PHD,2430,B-GENE-N
activity,2430,O
in,2430,O
vitro,2430,O
",",2430,O
N-acetyl-L-cysteine,2430,B-CHEMICAL
had,2430,O
no,2430,O
effect,2430,O
",",2430,O
and,2430,O
gallic,2430,B-CHEMICAL
acid,2430,I-CHEMICAL
or,2430,O
n-propyl,2430,B-CHEMICAL
gallate,2430,I-CHEMICAL
efficiently,2430,O
inhibited,2430,O
the,2430,O
activity,2430,O
of,2430,O
all,2430,O
three,2430,O
PHDs,2430,B-GENE-N
",",2430,O
demonstrating,2430,O
different,2430,O
functions,2430,O
of,2430,O
these,2430,O
antioxidants,2430,O
.,2430,O
Crystal,2431,O
structure,2431,O
of,2431,O
a,2431,O
human,2431,O
membrane,2431,O
protein,2431,O
involved,2431,O
in,2431,O
cysteinyl,2431,B-CHEMICAL
leukotriene,2431,I-CHEMICAL
biosynthesis,2431,O
.,2431,O
The,2432,O
cysteinyl,2432,B-CHEMICAL
leukotrienes,2432,I-CHEMICAL
",",2432,O
namely,2432,O
leukotriene,2432,B-CHEMICAL
(,2432,I-CHEMICAL
LT,2432,I-CHEMICAL
),2432,I-CHEMICAL
C4,2432,I-CHEMICAL
and,2432,O
its,2432,O
metabolites,2432,O
LTD4,2432,B-CHEMICAL
and,2432,O
LTE4,2432,B-CHEMICAL
",",2432,O
the,2432,O
components,2432,O
of,2432,O
slow-reacting,2432,O
substance,2432,O
of,2432,O
anaphylaxis,2432,O
",",2432,O
are,2432,O
lipid,2432,O
mediators,2432,O
of,2432,O
smooth,2432,O
muscle,2432,O
constriction,2432,O
and,2432,O
inflammation,2432,O
",",2432,O
particularly,2432,O
implicated,2432,O
in,2432,O
bronchial,2432,O
asthma,2432,O
.,2432,O
LTC4,2433,B-GENE-Y
synthase,2433,I-GENE-Y
(,2433,O
LTC4S,2433,B-GENE-Y
),2433,O
",",2433,O
the,2433,O
pivotal,2433,O
enzyme,2433,O
for,2433,O
the,2433,O
biosynthesis,2433,O
of,2433,O
LTC4,2433,B-CHEMICAL
(,2433,O
ref,2433,O
.,2433,O
10,2434,O
),2434,O
",",2434,O
is,2434,O
an,2434,O
18-kDa,2434,O
integral,2434,O
nuclear,2434,O
membrane,2434,O
protein,2434,O
that,2434,O
belongs,2434,O
to,2434,O
a,2434,O
superfamily,2434,O
of,2434,O
membrane-associated,2434,O
proteins,2434,O
in,2434,O
eicosanoid,2434,B-CHEMICAL
and,2434,O
glutathione,2434,B-CHEMICAL
metabolism,2434,O
that,2434,O
includes,2434,O
5-lipoxygenase-activating,2434,B-GENE-Y
protein,2434,I-GENE-Y
",",2434,O
microsomal,2434,B-GENE-N
glutathione,2434,I-GENE-N
S-transferases,2434,I-GENE-N
(,2434,O
MGSTs,2434,B-GENE-N
),2434,O
",",2434,O
and,2434,O
microsomal,2434,B-GENE-Y
prostaglandin,2434,I-GENE-Y
E,2434,I-GENE-Y
synthase,2434,I-GENE-Y
1,2434,I-GENE-Y
(,2434,O
ref,2434,O
.,2434,O
13,2435,O
),2435,O
.,2435,O
LTC4S,2436,B-GENE-Y
conjugates,2436,O
glutathione,2436,B-CHEMICAL
to,2436,O
LTA4,2436,B-CHEMICAL
",",2436,O
the,2436,O
endogenous,2436,O
substrate,2436,O
derived,2436,O
from,2436,O
arachidonic,2436,B-CHEMICAL
acid,2436,I-CHEMICAL
through,2436,O
the,2436,O
5-lipoxygenase,2436,B-GENE-Y
pathway,2436,O
.,2436,O
In,2437,O
contrast,2437,O
with,2437,O
MGST2,2437,B-GENE-Y
and,2437,O
MGST3,2437,B-GENE-Y
(,2437,O
refs,2437,O
15,2437,O
",",2437,O
16,2437,O
),2437,O
",",2437,O
LTC4S,2437,B-GENE-Y
does,2437,O
not,2437,O
conjugate,2437,O
glutathione,2437,B-CHEMICAL
to,2437,O
xenobiotics,2437,O
.,2437,O
Here,2438,O
we,2438,O
show,2438,O
the,2438,O
atomic,2438,O
structure,2438,O
of,2438,O
human,2438,B-GENE-Y
LTC4S,2438,I-GENE-Y
in,2438,O
a,2438,O
complex,2438,O
with,2438,O
glutathione,2438,B-CHEMICAL
at,2438,O
3.3,2438,O
A,2438,O
resolution,2438,O
by,2438,O
X-ray,2438,O
crystallography,2438,O
and,2438,O
provide,2438,O
insights,2438,O
into,2438,O
the,2438,O
high,2438,O
substrate,2438,O
specificity,2438,O
for,2438,O
glutathione,2438,B-CHEMICAL
and,2438,O
LTA4,2438,B-CHEMICAL
that,2438,O
distinguishes,2438,O
LTC4S,2438,B-GENE-Y
from,2438,O
other,2438,O
MGSTs,2438,B-GENE-N
.,2438,O
The,2439,O
LTC4S,2439,B-GENE-Y
monomer,2439,O
has,2439,O
four,2439,O
transmembrane,2439,O
alpha-helices,2439,O
and,2439,O
forms,2439,O
a,2439,O
threefold,2439,O
symmetric,2439,O
trimer,2439,O
as,2439,O
a,2439,O
unit,2439,O
with,2439,O
functional,2439,O
domains,2439,O
across,2439,O
each,2439,O
interface,2439,O
.,2439,O
Glutathione,2440,B-CHEMICAL
resides,2440,O
in,2440,O
a,2440,O
U-shaped,2440,O
conformation,2440,O
within,2440,O
an,2440,O
interface,2440,O
between,2440,O
adjacent,2440,O
monomers,2440,O
",",2440,O
and,2440,O
this,2440,O
binding,2440,O
is,2440,O
stabilized,2440,O
by,2440,O
a,2440,O
loop,2440,O
structure,2440,O
at,2440,O
the,2440,O
top,2440,O
of,2440,O
the,2440,O
interface,2440,O
.,2440,O
LTA4,2441,B-CHEMICAL
would,2441,O
fit,2441,O
into,2441,O
the,2441,O
interface,2441,O
so,2441,O
that,2441,O
Arg,2441,B-CHEMICAL
104,2441,O
of,2441,O
one,2441,O
monomer,2441,O
activates,2441,O
glutathione,2441,B-CHEMICAL
to,2441,O
provide,2441,O
the,2441,O
thiolate,2441,B-CHEMICAL
anion,2441,O
that,2441,O
attacks,2441,O
C6,2441,B-CHEMICAL
of,2441,O
LTA4,2441,B-CHEMICAL
to,2441,O
form,2441,O
a,2441,O
thioether,2441,B-CHEMICAL
bond,2441,O
",",2441,O
and,2441,O
Arg,2441,B-CHEMICAL
31,2441,O
in,2441,O
the,2441,O
neighbouring,2441,O
monomer,2441,O
donates,2441,O
a,2441,O
proton,2441,O
to,2441,O
form,2441,O
a,2441,O
hydroxyl,2441,B-CHEMICAL
group,2441,O
at,2441,O
C5,2441,O
",",2441,O
resulting,2441,O
in,2441,O
5,2441,B-CHEMICAL
(,2441,I-CHEMICAL
S,2441,I-CHEMICAL
),2441,I-CHEMICAL
-hydroxy-6,2441,I-CHEMICAL
(,2441,I-CHEMICAL
R,2441,I-CHEMICAL
),2441,I-CHEMICAL
"-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic",2441,I-CHEMICAL
acid,2441,I-CHEMICAL
(,2441,O
LTC4,2441,B-CHEMICAL
),2441,O
.,2441,O
These,2442,O
findings,2442,O
provide,2442,O
a,2442,O
structural,2442,O
basis,2442,O
for,2442,O
the,2442,O
development,2442,O
of,2442,O
LTC4S,2442,B-GENE-Y
inhibitors,2442,O
for,2442,O
a,2442,O
proinflammatory,2442,O
pathway,2442,O
mediated,2442,O
by,2442,O
three,2442,O
cysteinyl,2442,B-CHEMICAL
leukotriene,2442,I-CHEMICAL
ligands,2442,O
whose,2442,O
stability,2442,O
and,2442,O
potency,2442,O
are,2442,O
different,2442,O
and,2442,O
by,2442,O
multiple,2442,O
cysteinyl,2442,B-GENE-N
leukotriene,2442,I-GENE-N
receptors,2442,I-GENE-N
whose,2442,O
functions,2442,O
may,2442,O
be,2442,O
non-redundant,2442,O
.,2442,O
FCGR2A,2443,B-GENE-Y
and,2443,O
FCGR3A,2443,B-GENE-Y
polymorphisms,2443,O
associated,2443,O
with,2443,O
clinical,2443,O
outcome,2443,O
of,2443,O
epidermal,2443,B-GENE-Y
growth,2443,I-GENE-Y
factor,2443,I-GENE-Y
receptor,2443,I-GENE-Y
expressing,2443,O
metastatic,2443,O
colorectal,2443,O
cancer,2443,O
patients,2443,O
treated,2443,O
with,2443,O
single-agent,2443,O
cetuximab,2443,O
.,2443,O
PURPOSE,2444,O
:,2444,O
Cetuximab,2444,O
",",2444,O
a,2444,O
chimeric,2444,O
immunoglobulin,2444,B-GENE-Y
G,2444,I-GENE-Y
1,2444,I-GENE-Y
(,2444,O
IgG1,2444,B-GENE-Y
),2444,O
anti-epidermal,2444,O
growth,2444,I-GENE-Y
factor,2444,I-GENE-Y
receptor,2444,I-GENE-Y
(,2444,O
EGFR,2444,B-GENE-Y
),2444,O
monoclonal,2444,O
antibody,2444,O
(,2444,O
mAb,2444,O
),2444,O
",",2444,O
has,2444,O
shown,2444,O
efficacy,2444,O
in,2444,O
10,2444,O
%,2444,O
of,2444,O
patients,2444,O
with,2444,O
metastatic,2444,O
colorectal,2444,O
cancer,2444,O
(,2444,O
CRC,2444,O
),2444,O
.,2444,O
Recent,2445,O
studies,2445,O
demonstrate,2445,O
antibody-dependent,2445,O
cell-mediated,2445,O
cytotoxicity,2445,O
(,2445,O
ADCC,2445,O
),2445,O
is,2445,O
one,2445,O
of,2445,O
the,2445,O
modes,2445,O
of,2445,O
action,2445,O
for,2445,O
rituximab,2445,O
and,2445,O
trastuzumab,2445,O
.,2445,O
Fragment,2446,O
c,2446,O
(,2446,O
Fc,2446,O
),2446,O
portion,2446,O
of,2446,O
IgG1,2446,B-GENE-Y
mAb,2446,O
has,2446,O
shown,2446,O
to,2446,O
induce,2446,O
ADCC,2446,O
.,2446,O
Fragment,2447,B-GENE-N
c,2447,I-GENE-N
gamma,2447,I-GENE-N
receptors,2447,I-GENE-N
(,2447,O
FcgammaR,2447,B-GENE-N
),2447,O
play,2447,O
an,2447,O
important,2447,O
role,2447,O
in,2447,O
initiating,2447,O
ADCC,2447,O
.,2447,O
Studies,2448,O
have,2448,O
shown,2448,O
that,2448,O
two,2448,O
IgG,2448,B-GENE-N
FcgammaR,2448,B-GENE-N
polymorphisms,2448,O
(,2448,O
FCGR2A-H131R,2448,B-GENE-Y
and,2448,O
FCGR3A-V158F,2448,B-GENE-Y
),2448,O
independently,2448,O
predict,2448,O
response,2448,O
to,2448,O
rituximab,2448,O
in,2448,O
patients,2448,O
with,2448,O
follicular,2448,O
lymphoma,2448,O
.,2448,O
We,2449,O
tested,2449,O
the,2449,O
hypothesis,2449,O
of,2449,O
whether,2449,O
these,2449,O
two,2449,O
polymorphisms,2449,O
are,2449,O
associated,2449,O
with,2449,O
clinical,2449,O
outcome,2449,O
in,2449,O
metastatic,2449,O
CRC,2449,O
patients,2449,O
treated,2449,O
with,2449,O
single-agent,2449,O
cetuximab,2449,O
.,2449,O
PATIENTS,2450,O
AND,2450,O
METHODS,2450,O
:,2450,O
Thirty-nine,2450,O
metastatic,2450,O
CRC,2450,O
patients,2450,O
were,2450,O
enrolled,2450,O
onto,2450,O
the,2450,O
ImClone0144,2450,O
trial,2450,O
.,2450,O
Using,2451,O
an,2451,O
allele-specific,2451,O
polymerase,2451,O
chain,2451,O
reaction,2451,O
(,2451,O
PCR,2451,O
),2451,O
-based,2451,O
method,2451,O
",",2451,O
gene,2451,O
polymorphisms,2451,O
of,2451,O
FCGA2A-H131R,2451,B-GENE-Y
and,2451,O
FCGA3A-V158F,2451,B-GENE-Y
were,2451,O
assessed,2451,O
from,2451,O
genomic,2451,O
DNA,2451,O
extracted,2451,O
from,2451,O
peripheral,2451,O
blood,2451,O
samples,2451,O
.,2451,O
RESULTS,2452,O
:,2452,O
FCGR2A-H131R,2452,B-GENE-Y
and,2452,O
FCGR3A-V158F,2452,B-GENE-Y
polymorphisms,2452,O
were,2452,O
independently,2452,O
associated,2452,O
with,2452,O
progression-free,2452,O
survival,2452,O
(,2452,O
PFS,2452,O
;,2452,O
P,2452,O
=,2452,O
.037,2452,O
and,2452,O
.055,2452,O
",",2452,O
respectively,2452,O
;,2452,O
log-rank,2452,O
test,2452,O
),2452,O
.,2452,O
Combined,2453,O
analysis,2453,O
of,2453,O
these,2453,O
two,2453,O
polymorphisms,2453,O
showed,2453,O
that,2453,O
patients,2453,O
with,2453,O
the,2453,O
favorable,2453,O
genotypes,2453,O
(,2453,O
FCGR2A,2453,B-GENE-Y
",",2453,O
any,2453,O
histidine,2453,B-CHEMICAL
allele,2453,O
",",2453,O
and,2453,O
FCGR3A,2453,B-GENE-Y
",",2453,O
any,2453,O
phenylalanine,2453,B-CHEMICAL
allele,2453,O
),2453,O
showed,2453,O
a,2453,O
median,2453,O
PFS,2453,O
of,2453,O
3.7,2453,O
months,2453,O
(,2453,O
95,2453,O
%,2453,O
CI,2453,O
",",2453,O
2.4,2453,O
to,2453,O
4.4,2453,O
months,2453,O
),2453,O
",",2453,O
whereas,2453,O
patients,2453,O
with,2453,O
any,2453,O
two,2453,O
unfavorable,2453,O
genotypes,2453,O
(,2453,O
FCGR2A,2453,B-GENE-Y
arginine/arginine,2453,B-CHEMICAL
or,2453,O
valine/valine,2453,B-CHEMICAL
),2453,O
had,2453,O
a,2453,O
PFS,2453,O
of,2453,O
1.1,2453,O
months,2453,O
(,2453,O
95,2453,O
%,2453,O
CI,2453,O
",",2453,O
1.0,2453,O
to,2453,O
1.4,2453,O
months,2453,O
;,2453,O
P,2453,O
=,2453,O
.004,2453,O
;,2453,O
log-rank,2453,O
test,2453,O
),2453,O
.,2453,O
CONCLUSION,2454,O
:,2454,O
Our,2454,O
preliminary,2454,O
data,2454,O
suggest,2454,O
that,2454,O
these,2454,O
two,2454,O
polymorphisms,2454,O
may,2454,O
be,2454,O
useful,2454,O
molecular,2454,O
markers,2454,O
to,2454,O
predict,2454,O
clinical,2454,O
outcome,2454,O
in,2454,O
metastatic,2454,O
CRC,2454,O
patients,2454,O
treated,2454,O
with,2454,O
cetuximab,2454,O
and,2454,O
that,2454,O
they,2454,O
may,2454,O
indicate,2454,O
a,2454,O
role,2454,O
of,2454,O
ADCC,2454,O
of,2454,O
cetuximab,2454,O
.,2454,O
Phenelzine,2455,B-CHEMICAL
causes,2455,O
an,2455,O
increase,2455,O
in,2455,O
brain,2455,O
ornithine,2455,O
that,2455,O
is,2455,O
prevented,2455,O
by,2455,O
prior,2455,O
monoamine,2455,B-GENE-N
oxidase,2455,I-GENE-N
inhibition,2455,O
.,2455,O
Phenelzine,2456,B-CHEMICAL
(,2456,O
PLZ,2456,B-CHEMICAL
),2456,O
",",2456,O
a,2456,O
nonselective,2456,O
irreversible,2456,O
inhibitor,2456,O
of,2456,O
monoamine,2456,B-GENE-N
oxidase,2456,I-GENE-N
(,2456,O
MAO,2456,B-GENE-N
),2456,O
",",2456,O
also,2456,O
inhibits,2456,O
GABA-transaminase,2456,B-GENE-Y
(,2456,O
GABA-T,2456,B-CHEMICAL
),2456,O
",",2456,O
markedly,2456,O
increasing,2456,O
brain,2456,O
GABA,2456,B-CHEMICAL
levels,2456,O
.,2456,O
PLZ,2457,B-CHEMICAL
is,2457,O
also,2457,O
a,2457,O
substrate,2457,O
for,2457,O
MAO,2457,B-GENE-N
",",2457,O
and,2457,O
studies,2457,O
suggest,2457,O
that,2457,O
a,2457,O
metabolite,2457,O
formed,2457,O
by,2457,O
the,2457,O
action,2457,O
of,2457,O
this,2457,O
enzyme,2457,O
on,2457,O
PLZ,2457,B-CHEMICAL
may,2457,O
be,2457,O
responsible,2457,O
for,2457,O
the,2457,O
increase,2457,O
in,2457,O
GABA,2457,B-CHEMICAL
observed,2457,O
.,2457,O
We,2458,O
have,2458,O
recently,2458,O
found,2458,O
that,2458,O
PLZ,2458,B-CHEMICAL
also,2458,O
elevates,2458,O
brain,2458,O
ornithine,2458,B-CHEMICAL
(,2458,O
ORN,2458,B-CHEMICAL
),2458,O
",",2458,O
an,2458,O
amino,2458,B-CHEMICAL
acid,2458,I-CHEMICAL
precursor,2458,O
to,2458,O
both,2458,O
glutamate,2458,B-CHEMICAL
(,2458,O
and,2458,O
GABA,2458,B-CHEMICAL
),2458,O
and,2458,O
the,2458,O
polyamines,2458,B-CHEMICAL
",",2458,O
and,2458,O
have,2458,O
conducted,2458,O
dose-,2458,O
and,2458,O
time-response,2458,O
studies,2458,O
on,2458,O
this,2458,O
effect,2458,O
.,2458,O
Rats,2459,O
were,2459,O
treated,2459,O
with,2459,O
vehicle,2459,O
or,2459,O
PLZ,2459,B-CHEMICAL
doses,2459,O
(,2459,O
7.5,2459,O
",",2459,O
15,2459,O
or,2459,O
30,2459,O
mg/kg,2459,O
i.p,2459,O
.,2459,O
),2460,O
",",2460,O
and,2460,O
brains,2460,O
were,2460,O
collected,2460,O
3,2460,O
h,2460,O
later,2460,O
.,2460,O
In,2461,O
the,2461,O
time-response,2461,O
study,2461,O
",",2461,O
animals,2461,O
were,2461,O
treated,2461,O
with,2461,O
vehicle,2461,O
or,2461,O
PLZ,2461,O
(,2461,O
15,2461,O
mg/kg,2461,O
i.p,2461,O
.,2461,O
),2461,O
and,2462,O
brains,2462,O
were,2462,O
collected,2462,O
1-24,2462,O
h,2462,O
later,2462,O
.,2462,O
To,2463,O
determine,2463,O
whether,2463,O
a,2463,O
metabolite,2463,O
formed,2463,O
by,2463,O
the,2463,O
action,2463,O
of,2463,O
MAO,2463,O
on,2463,O
PLZ,2463,O
may,2463,O
be,2463,O
responsible,2463,O
for,2463,O
the,2463,O
elevation,2463,O
in,2463,O
brain,2463,O
ORN,2463,O
observed,2463,O
",",2463,O
animals,2463,O
were,2463,O
pretreated,2463,O
with,2463,O
vehicle,2463,O
or,2463,O
the,2463,O
MAO,2463,O
inhibitor,2463,O
tranylcypromine,2463,O
(,2463,B-CHEMICAL
TCP,2463,O
),2463,O
before,2463,O
vehicle,2463,O
or,2463,O
PLZ,2463,O
(,2463,O
15,2463,O
mg/kg,2463,O
),2463,O
",",2463,O
and,2463,O
brains,2463,O
collected,2463,O
3,2463,O
h,2463,O
later,2463,O
.,2463,O
ORN,2464,O
levels,2464,O
(,2464,O
measured,2464,O
by,2464,O
an,2464,O
HPLC,2464,O
procedure,2464,O
),2464,O
were,2464,O
dose-,2464,O
and,2464,O
time-dependently,2464,O
increased,2464,O
in,2464,O
PLZ-treated,2464,O
animals,2464,O
",",2464,O
with,2464,O
levels,2464,O
reaching,2464,O
approximately,2464,O
650,2464,O
%,2464,O
of,2464,O
control,2464,O
at,2464,O
6,2464,O
and,2464,O
12,2464,O
h.,2464,O
Pretreatment,2464,O
with,2464,O
TCP,2464,O
completely,2464,O
abolished,2464,O
the,2464,O
PLZ-induced,2464,O
increase,2464,O
in,2464,O
brain,2464,O
ORN,2464,O
",",2464,O
suggesting,2464,O
",",2464,O
as,2464,O
with,2464,O
GABA,2464,O
",",2464,O
that,2464,O
a,2464,O
metabolite,2464,O
of,2464,O
PLZ,2464,O
formed,2464,O
by,2464,O
the,2464,O
action,2464,O
of,2464,O
MAO,2464,O
is,2464,O
responsible,2464,O
for,2464,O
the,2464,O
elevation,2464,O
of,2464,O
brain,2464,O
ORN,2464,O
observed,2464,O
.,2464,O
The,2465,O
possible,2465,O
contribution,2465,O
of,2465,O
increased,2465,O
ORN,2465,O
to,2465,O
therapeutic,2465,O
and/or,2465,O
neuroprotective,2465,O
properties,2465,O
of,2465,O
PLZ,2465,O
is,2465,O
discussed,2465,O
.,2465,O
Endothelial,2466,O
nitric,2466,B-CHEMICAL
oxide,2466,I-CHEMICAL
production,2466,O
is,2466,O
tightly,2466,O
coupled,2466,O
to,2466,O
the,2466,O
citrulline-NO,2466,B-CHEMICAL
cycle,2466,O
.,2466,O
Nitric,2467,B-CHEMICAL
oxide,2467,I-CHEMICAL
(,2467,O
NO,2467,B-CHEMICAL
),2467,O
is,2467,O
an,2467,O
important,2467,O
vasorelaxant,2467,O
produced,2467,O
along,2467,O
with,2467,O
L-citrulline,2467,B-CHEMICAL
from,2467,O
L-arginine,2467,B-CHEMICAL
in,2467,O
a,2467,O
reaction,2467,O
catalyzed,2467,O
by,2467,O
endothelial,2467,B-GENE-Y
nitric,2467,I-GENE-Y
oxide,2467,I-GENE-Y
synthase,2467,I-GENE-Y
(,2467,O
eNOS,2467,B-GENE-Y
),2467,O
.,2467,O
Previous,2468,O
studies,2468,O
suggested,2468,O
that,2468,O
the,2468,O
recycling,2468,O
of,2468,O
L-citrulline,2468,B-CHEMICAL
to,2468,O
L-arginine,2468,B-CHEMICAL
is,2468,O
essential,2468,O
for,2468,O
NO,2468,B-CHEMICAL
production,2468,O
in,2468,O
endothelial,2468,O
cells,2468,O
.,2468,O
However,2469,O
",",2469,O
there,2469,O
is,2469,O
no,2469,O
direct,2469,O
evidence,2469,O
demonstrating,2469,O
the,2469,O
degree,2469,O
to,2469,O
which,2469,O
the,2469,O
recycling,2469,O
of,2469,O
L-citrulline,2469,B-CHEMICAL
to,2469,O
L-arginine,2469,B-CHEMICAL
is,2469,O
coupled,2469,O
to,2469,O
NO,2469,B-CHEMICAL
production,2469,O
.,2469,O
We,2470,O
hypothesized,2470,O
that,2470,O
the,2470,O
amount,2470,O
of,2470,O
NO,2470,B-CHEMICAL
formed,2470,O
would,2470,O
be,2470,O
significantly,2470,O
higher,2470,O
than,2470,O
the,2470,O
amount,2470,O
of,2470,O
L-citrulline,2470,B-CHEMICAL
formed,2470,O
due,2470,O
to,2470,O
the,2470,O
efficiency,2470,O
of,2470,O
L-citrulline,2470,B-CHEMICAL
recycling,2470,O
via,2470,O
the,2470,O
citrulline-NO,2470,B-CHEMICAL
cycle,2470,O
.,2470,O
To,2471,O
test,2471,O
this,2471,O
hypothesis,2471,O
",",2471,O
endothelial,2471,O
cells,2471,O
were,2471,O
incubated,2471,O
with,2471,O
[,2471,B-CHEMICAL
14C,2471,I-CHEMICAL
],2471,I-CHEMICAL
-L-arginine,2471,I-CHEMICAL
and,2471,O
stimulated,2471,O
by,2471,O
various,2471,O
agents,2471,O
to,2471,O
produce,2471,O
NO,2471,B-CHEMICAL
.,2471,O
The,2472,O
extent,2472,O
of,2472,O
NO,2472,B-CHEMICAL
and,2472,O
[,2472,B-CHEMICAL
14C,2472,I-CHEMICAL
],2472,I-CHEMICAL
-L-citrulline,2472,I-CHEMICAL
formation,2472,O
were,2472,O
simultaneously,2472,O
determined,2472,O
.,2472,O
NO,2473,B-CHEMICAL
production,2473,O
exceeded,2473,O
apparent,2473,O
L-citrulline,2473,B-CHEMICAL
formation,2473,O
of,2473,O
the,2473,O
order,2473,O
of,2473,O
8,2473,O
to,2473,O
1,2473,O
",",2473,O
under,2473,O
both,2473,O
basal,2473,O
and,2473,O
stimulated,2473,O
conditions,2473,O
.,2473,O
As,2474,O
further,2474,O
support,2474,O
",",2474,O
alpha-methyl-DL-aspartate,2474,B-CHEMICAL
",",2474,O
an,2474,O
inhibitor,2474,O
of,2474,O
argininosuccinate,2474,B-GENE-Y
synthase,2474,I-GENE-Y
(,2474,O
AS,2474,B-GENE-Y
),2474,O
",",2474,O
a,2474,O
component,2474,O
of,2474,O
the,2474,O
citrulline-NO,2474,B-CHEMICAL
cycle,2474,O
",",2474,O
inhibited,2474,O
NO,2474,B-CHEMICAL
production,2474,O
in,2474,O
a,2474,O
dose-dependent,2474,O
manner,2474,O
.,2474,O
The,2475,O
results,2475,O
of,2475,O
this,2475,O
study,2475,O
provide,2475,O
evidence,2475,O
for,2475,O
the,2475,O
essential,2475,O
and,2475,O
efficient,2475,O
coupling,2475,O
of,2475,O
L-citrulline,2475,B-CHEMICAL
recycling,2475,O
",",2475,O
via,2475,O
the,2475,O
citrulline-NO,2475,B-CHEMICAL
cycle,2475,O
",",2475,O
to,2475,O
endothelial,2475,O
NO,2475,B-CHEMICAL
production,2475,O
.,2475,O
The,2476,O
use,2476,O
of,2476,O
escitalopram,2476,B-CHEMICAL
beyond,2476,O
major,2476,O
depression,2476,O
:,2476,O
pharmacological,2476,O
aspects,2476,O
",",2476,O
efficacy,2476,O
and,2476,O
tolerability,2476,O
in,2476,O
anxiety,2476,O
disorders,2476,O
.,2476,O
Escitalopram,2477,B-CHEMICAL
",",2477,O
the,2477,O
active,2477,O
(,2477,B-CHEMICAL
S,2477,I-CHEMICAL
),2477,I-CHEMICAL
-enantiomer,2477,I-CHEMICAL
of,2477,I-CHEMICAL
citalopram,2477,I-CHEMICAL
",",2477,O
has,2477,O
been,2477,O
approved,2477,O
in,2477,O
many,2477,O
countries,2477,O
throughout,2477,O
the,2477,O
world,2477,O
for,2477,O
the,2477,O
treatment,2477,O
of,2477,O
depression,2477,O
and,2477,O
anxiety,2477,O
disorders,2477,O
.,2477,O
It,2478,O
is,2478,O
more,2478,O
potent,2478,O
and,2478,O
selective,2478,O
than,2478,O
citalopram,2478,B-CHEMICAL
in,2478,O
inhibiting,2478,O
serotonin,2478,B-CHEMICAL
re-uptake,2478,O
in,2478,O
the,2478,O
CNS,2478,O
",",2478,O
and,2478,O
less,2478,O
potent,2478,O
than,2478,O
various,2478,O
other,2478,O
selective,2478,O
serotonin,2478,B-CHEMICAL
re-uptake,2478,O
inhibitors,2478,O
in,2478,O
relation,2478,O
to,2478,O
other,2478,O
transporter,2478,O
proteins,2478,O
and,2478,O
receptors,2478,O
:,2478,O
in,2478,O
particular,2478,O
",",2478,O
it,2478,O
is,2478,O
six,2478,O
times,2478,O
less,2478,O
potent,2478,O
than,2478,O
citalopram,2478,B-CHEMICAL
in,2478,O
binding,2478,O
to,2478,O
the,2478,O
histamine,2478,B-CHEMICAL
H1,2478,I-GENE-Y
and,2478,O
muscarinic,2478,B-GENE-N
receptors,2478,I-GENE-N
.,2478,O
Escitalopram,2479,B-CHEMICAL
has,2479,O
favourable,2479,O
pharmacokinetics,2479,O
:,2479,O
it,2479,O
is,2479,O
rapidly,2479,O
absorbed,2479,O
",",2479,O
has,2479,O
a,2479,O
bioavailability,2479,O
of,2479,O
80,2479,O
%,2479,O
and,2479,O
is,2479,O
not,2479,O
affected,2479,O
by,2479,O
food,2479,O
intake,2479,O
.,2479,O
It,2480,O
has,2480,O
little,2480,O
potential,2480,O
for,2480,O
drug,2480,O
interactions,2480,O
:,2480,O
it,2480,O
has,2480,O
low,2480,O
protein,2480,O
binding,2480,O
and,2480,O
",",2480,O
as,2480,O
it,2480,O
is,2480,O
metabolised,2480,O
by,2480,O
three,2480,O
CYP,2480,B-GENE-N
isozymes,2480,O
",",2480,O
any,2480,O
impairment,2480,O
in,2480,O
the,2480,O
activity,2480,O
of,2480,O
one,2480,O
is,2480,O
unlikely,2480,O
to,2480,O
have,2480,O
a,2480,O
significant,2480,O
effect,2480,O
on,2480,O
metabolic,2480,O
clearance,2480,O
.,2480,O
Caution,2481,O
is,2481,O
necessary,2481,O
only,2481,O
when,2481,O
it,2481,O
is,2481,O
coadministered,2481,O
with,2481,O
drugs,2481,O
metabolised,2481,O
by,2481,O
CYP2D6,2481,B-GENE-Y
",",2481,O
such,2481,O
as,2481,O
metoprolol,2481,B-CHEMICAL
",",2481,O
or,2481,O
administered,2481,O
to,2481,O
the,2481,O
elderly,2481,O
or,2481,O
patients,2481,O
with,2481,O
severe,2481,O
hepatic,2481,O
or,2481,O
renal,2481,O
impairment,2481,O
.,2481,O
The,2482,O
multiple-dose,2482,O
pharmacokinetics,2482,O
of,2482,O
oral,2482,O
escitalopram,2482,B-CHEMICAL
are,2482,O
proportional,2482,O
at,2482,O
a,2482,O
range,2482,O
of,2482,O
doses,2482,O
including,2482,O
its,2482,O
therapeutic,2482,O
doses,2482,O
.,2482,O
Escitalopram,2483,B-CHEMICAL
is,2483,O
approved,2483,O
for,2483,O
the,2483,O
treatment,2483,O
of,2483,O
a,2483,O
number,2483,O
of,2483,O
anxiety,2483,O
disorders,2483,O
.,2483,O
It,2484,O
seems,2484,O
to,2484,O
be,2484,O
well,2484,O
tolerated,2484,O
and,2484,O
induces,2484,O
few,2484,O
or,2484,O
no,2484,O
discontinuation,2484,O
symptoms,2484,O
",",2484,O
and,2484,O
may,2484,O
be,2484,O
considered,2484,O
a,2484,O
first-line,2484,O
agent,2484,O
for,2484,O
the,2484,O
pharmacotherapy,2484,O
of,2484,O
obsessive-compulsive,2484,O
disorder,2484,O
",",2484,O
generalised,2484,O
anxiety,2484,O
disorder,2484,O
",",2484,O
panic,2484,O
disorder,2484,O
and,2484,O
social,2484,O
phobia,2484,O
.,2484,O
Further,2485,O
studies,2485,O
are,2485,O
needed,2485,O
to,2485,O
define,2485,O
its,2485,O
activity,2485,O
in,2485,O
impulse,2485,O
control,2485,O
disorders,2485,O
.,2485,O
Inhibition,2486,O
of,2486,O
platelet,2486,O
aggregation,2486,O
by,2486,O
AZD6140,2486,B-CHEMICAL
",",2486,O
a,2486,O
reversible,2486,O
oral,2486,O
P2Y12,2486,B-GENE-Y
receptor,2486,O
antagonist,2486,O
",",2486,O
compared,2486,O
with,2486,O
clopidogrel,2486,B-CHEMICAL
in,2486,O
patients,2486,O
with,2486,O
acute,2486,O
coronary,2486,O
syndromes,2486,O
.,2486,O
OBJECTIVES,2487,O
:,2487,O
In,2487,O
a,2487,O
substudy,2487,O
of,2487,O
DISPERSE,2487,O
(,2487,O
Dose,2487,O
confIrmation,2487,O
Study,2487,O
assessing,2487,O
anti-Platelet,2487,O
Effects,2487,O
of,2487,O
AZD6140,2487,B-CHEMICAL
vs.,2487,O
clopidogRel,2487,O
in,2487,O
non-ST-segment,2487,O
Elevation,2487,O
myocardial,2487,O
infarction,2487,O
),2487,O
-2,2487,O
",",2487,O
we,2487,O
compared,2487,O
the,2487,O
antiplatelet,2487,O
effects,2487,O
of,2487,O
AZD6140,2487,B-CHEMICAL
and,2487,O
clopidogrel,2487,B-CHEMICAL
and,2487,O
assessed,2487,O
the,2487,O
effects,2487,O
of,2487,O
AZD6140,2487,B-CHEMICAL
in,2487,O
clopidogrel-pretreated,2487,B-CHEMICAL
patients,2487,O
.,2487,O
BACKGROUND,2488,O
:,2488,O
Clopidogrel,2488,B-CHEMICAL
",",2488,O
in,2488,O
combination,2488,O
with,2488,O
aspirin,2488,O
",",2488,O
reduces,2488,O
cardiovascular,2488,O
events,2488,O
in,2488,O
patients,2488,O
with,2488,O
acute,2488,O
coronary,2488,O
syndromes,2488,O
(,2488,O
ACS,2488,O
),2488,O
.,2488,O
However,2489,O
",",2489,O
patients,2489,O
with,2489,O
poor,2489,O
inhibition,2489,O
of,2489,O
platelet,2489,O
aggregation,2489,O
with,2489,O
clopidogrel,2489,B-CHEMICAL
may,2489,O
be,2489,O
less,2489,O
well,2489,O
protected,2489,O
.,2489,O
AZD6140,2490,B-CHEMICAL
is,2490,O
a,2490,O
reversible,2490,O
oral,2490,O
P2Y,2490,B-GENE-Y
(,2490,I-GENE-Y
12,2490,I-GENE-Y
),2490,I-GENE-Y
receptor,2490,O
antagonist,2490,O
that,2490,O
has,2490,O
been,2490,O
studied,2490,O
in,2490,O
ACS,2490,O
patients,2490,O
in,2490,O
comparison,2490,O
with,2490,O
clopidogrel,2490,B-CHEMICAL
(,2490,O
DISPERSE-2,2490,O
study,2490,O
),2490,O
.,2490,O
METHODS,2491,O
:,2491,O
Patients,2491,O
were,2491,O
randomized,2491,O
to,2491,O
receive,2491,O
either,2491,O
AZD6140,2491,B-CHEMICAL
90,2491,O
mg,2491,O
twice,2491,O
a,2491,O
day,2491,O
",",2491,O
AZD6140,2491,B-CHEMICAL
180,2491,O
mg,2491,O
twice,2491,O
a,2491,O
day,2491,O
",",2491,O
or,2491,O
clopidogrel,2491,B-CHEMICAL
75,2491,O
mg,2491,O
once,2491,O
a,2491,O
day,2491,O
for,2491,O
up,2491,O
to,2491,O
12,2491,O
weeks,2491,O
in,2491,O
a,2491,O
double-blind,2491,O
",",2491,O
double-dummy,2491,O
design,2491,O
.,2491,O
One-half,2492,O
the,2492,O
patients,2492,O
allocated,2492,O
AZD6140,2492,B-CHEMICAL
received,2492,O
a,2492,O
270-mg,2492,O
loading,2492,O
dose,2492,O
.,2492,O
Patients,2493,O
randomized,2493,O
to,2493,O
receive,2493,O
clopidogrel,2493,B-CHEMICAL
were,2493,O
given,2493,O
a,2493,O
300-mg,2493,O
loading,2493,O
dose,2493,O
unless,2493,O
they,2493,O
had,2493,O
already,2493,O
been,2493,O
treated,2493,O
with,2493,O
clopidogrel,2493,B-CHEMICAL
.,2493,O
Adenosine,2494,B-CHEMICAL
diphosphate-induced,2494,O
platelet,2494,O
aggregation,2494,O
was,2494,O
assessed,2494,O
by,2494,O
optical,2494,O
aggregometry,2494,O
on,2494,O
day,2494,O
1,2494,O
and,2494,O
at,2494,O
4-week,2494,O
intervals,2494,O
.,2494,O
RESULTS,2495,O
:,2495,O
AZD6140,2495,B-CHEMICAL
inhibited,2495,O
platelet,2495,O
aggregation,2495,O
in,2495,O
a,2495,O
dose-dependent,2495,O
fashion,2495,O
and,2495,O
both,2495,O
doses,2495,O
achieved,2495,O
greater,2495,O
levels,2495,O
of,2495,O
inhibition,2495,O
than,2495,O
clopidogrel,2495,B-CHEMICAL
(,2495,O
e.g.,2495,O
",",2495,O
4,2495,O
weeks,2495,O
",",2495,O
4-h,2495,O
postdose,2495,O
[,2495,O
mean,2495,O
(,2495,O
+/-SD,2495,O
),2495,O
],2495,O
:,2495,O
clopidogrel,2495,B-CHEMICAL
64,2495,O
%,2495,O
[,2495,O
+/-22,2495,O
%,2495,O
],2495,O
",",2495,O
AZD6140,2495,B-CHEMICAL
90,2495,O
mg,2495,O
79,2495,O
%,2495,O
[,2495,O
+/-22,2495,O
%,2495,O
],2495,O
",",2495,O
AZD6140,2495,B-CHEMICAL
180,2495,O
mg,2495,O
95,2495,O
%,2495,O
[,2495,O
+/-8,2495,O
%,2495,O
],2495,O
.,2495,O
AZD6140,2496,B-CHEMICAL
also,2496,O
produced,2496,O
further,2496,O
suppression,2496,O
of,2496,O
platelet,2496,O
aggregation,2496,O
in,2496,O
patients,2496,O
previously,2496,O
treated,2496,O
with,2496,O
clopidogrel,2496,B-CHEMICAL
.,2496,O
CONCLUSIONS,2497,O
:,2497,O
AZD6140,2497,B-CHEMICAL
exhibited,2497,O
greater,2497,O
mean,2497,O
inhibition,2497,O
of,2497,O
platelet,2497,O
aggregation,2497,O
than,2497,O
a,2497,O
standard,2497,O
regimen,2497,O
of,2497,O
clopidogrel,2497,B-CHEMICAL
in,2497,O
ACS,2497,O
patients,2497,O
.,2497,O
In,2498,O
addition,2498,O
",",2498,O
AZD6140,2498,B-CHEMICAL
further,2498,O
suppressed,2498,O
platelet,2498,O
aggregation,2498,O
in,2498,O
clopidogrel,2498,O
pretreated,2498,O
patients,2498,O
.,2498,O
The,2499,O
preparation,2499,O
and,2499,O
human,2499,B-GENE-N
muscarinic,2499,I-GENE-N
receptor,2499,I-GENE-N
profiling,2499,O
of,2499,O
oxybutynin,2499,B-CHEMICAL
and,2499,O
N-desethyloxybutynin,2499,B-CHEMICAL
enantiomers,2499,O
.,2499,O
Oxybutynin,2500,B-CHEMICAL
(,2500,O
1,2500,O
),2500,O
is,2500,O
a,2500,O
non-selective,2500,O
muscarinic,2500,B-GENE-N
receptor,2500,I-GENE-N
antagonist,2500,O
that,2500,O
is,2500,O
used,2500,O
clinically,2500,O
for,2500,O
the,2500,O
treatment,2500,O
of,2500,O
urinary,2500,O
incontinence,2500,O
.,2500,O
The,2501,O
major,2501,O
metabolite,2501,O
of,2501,O
oxybutynin,2501,B-CHEMICAL
in,2501,O
humans,2501,O
is,2501,O
desethyloxybutynin,2501,B-CHEMICAL
(,2501,O
2,2501,O
),2501,O
.,2501,O
We,2502,O
have,2502,O
prepared,2502,O
the,2502,O
enantiomers,2502,O
of,2502,O
1,2502,O
and,2502,O
2,2502,O
and,2502,O
evaluated,2502,O
their,2502,O
ability,2502,O
to,2502,O
displace,2502,O
N-CT,2502,B-CHEMICAL
(,2502,I-CHEMICAL
3,2502,I-CHEMICAL
),2502,I-CHEMICAL
-scopolamine,2502,I-CHEMICAL
chloride,2502,I-CHEMICAL
(,2502,O
(,2502,B-CHEMICAL
3,2502,I-CHEMICAL
),2502,I-CHEMICAL
H-NMS,2502,I-CHEMICAL
),2502,O
binding,2502,O
on,2502,O
human,2502,B-GENE-N
cloned,2502,I-GENE-N
muscarinic,2502,I-GENE-N
m1-5,2502,I-GENE-N
receptors,2502,I-GENE-N
.,2502,O
Compounds,2503,O
1,2503,O
and,2503,O
2,2503,O
potently,2503,O
displaced,2503,O
(,2503,B-CHEMICAL
3,2503,I-CHEMICAL
),2503,I-CHEMICAL
H-NMS,2503,I-CHEMICAL
binding,2503,O
at,2503,O
m1,2503,B-GENE-N
",",2503,I-GENE-N
m3,2503,I-GENE-N
and,2503,I-GENE-N
m4,2503,I-GENE-N
receptors,2503,I-GENE-N
",",2503,O
but,2503,O
were,2503,O
less,2503,O
potent,2503,O
at,2503,O
the,2503,O
m2,2503,B-GENE-Y
and,2503,O
m5,2503,B-GENE-Y
subtypes,2503,O
.,2503,O
However,2504,O
",",2504,O
metabolite,2504,O
2,2504,O
was,2504,O
more,2504,O
potent,2504,O
than,2504,O
the,2504,O
parent,2504,O
compound,2504,O
1,2504,O
in,2504,O
the,2504,O
binding,2504,O
assay,2504,O
.,2504,O
In,2505,O
general,2505,O
the,2505,O
R,2505,O
enantiomers,2505,O
were,2505,O
more,2505,O
potent,2505,O
than,2505,O
their,2505,O
respective,2505,O
S,2505,O
enantiomers,2505,O
.,2505,O
Therefore,2506,O
",",2506,O
we,2506,O
suggest,2506,O
that,2506,O
the,2506,O
cholinergic,2506,O
side,2506,O
effects,2506,O
associated,2506,O
with,2506,O
2,2506,O
may,2506,O
be,2506,O
due,2506,O
to,2506,O
its,2506,O
greater,2506,O
apparent,2506,O
potency,2506,O
with,2506,O
m1,2506,B-GENE-N
and,2506,I-GENE-N
m3,2506,I-GENE-N
receptors,2506,I-GENE-N
",",2506,O
especially,2506,O
of,2506,O
its,2506,O
R-enantiomer,2506,O
",",2506,O
when,2506,O
compared,2506,O
with,2506,O
parent,2506,O
drug,2506,O
1,2506,O
.,2506,O
Degradation,2507,O
of,2507,O
submandibular,2507,O
gland,2507,O
AQP5,2507,B-GENE-Y
by,2507,O
parasympathetic,2507,O
denervation,2507,O
of,2507,O
chorda,2507,O
tympani,2507,O
and,2507,O
its,2507,O
recovery,2507,O
by,2507,O
cevimeline,2507,B-CHEMICAL
",",2507,O
an,2507,O
M3,2507,B-GENE-Y
muscarinic,2507,I-GENE-Y
receptor,2507,I-GENE-Y
agonist,2507,O
.,2507,O
By,2508,O
chorda,2508,O
tympani,2508,O
denervation,2508,O
(,2508,O
CTD,2508,O
",",2508,O
parasympathectomy,2508,O
),2508,O
",",2508,O
the,2508,O
aquaporin,2508,B-GENE-Y
5,2508,I-GENE-Y
(,2508,O
AQP5,2508,B-GENE-Y
),2508,O
",",2508,O
but,2508,O
not,2508,O
AQP1,2508,B-GENE-Y
",",2508,O
protein,2508,O
level,2508,O
in,2508,O
the,2508,O
rat,2508,O
submandibular,2508,O
gland,2508,O
(,2508,O
SMG,2508,O
),2508,O
was,2508,O
significantly,2508,O
decreased,2508,O
",",2508,O
dropping,2508,O
to,2508,O
37,2508,O
%,2508,O
of,2508,O
that,2508,O
of,2508,O
the,2508,O
contralateral,2508,O
gland,2508,O
at,2508,O
4,2508,O
wk,2508,O
.,2508,O
The,2509,O
protein,2509,O
levels,2509,O
of,2509,O
AQP5,2509,B-GENE-Y
and,2509,O
AQP1,2509,B-GENE-Y
were,2509,O
not,2509,O
significantly,2509,O
affected,2509,O
by,2509,O
denervation,2509,O
of,2509,O
the,2509,O
cervical,2509,O
sympathetic,2509,O
trunk,2509,O
(,2509,O
sympathectomy,2509,O
),2509,O
.,2509,O
Administration,2510,O
of,2510,O
cevimeline,2510,B-CHEMICAL
hydrochloride,2510,I-CHEMICAL
",",2510,O
an,2510,O
M3,2510,B-GENE-Y
muscarinic,2510,I-GENE-Y
receptor,2510,I-GENE-Y
agonist,2510,O
(,2510,O
10,2510,O
mg/kg,2510,O
for,2510,O
7,2510,O
days,2510,O
po,2510,O
),2510,O
",",2510,O
but,2510,O
not,2510,O
pilocarpine,2510,B-CHEMICAL
(,2510,O
0.3,2510,O
mg/kg,2510,O
for,2510,O
7,2510,O
days,2510,O
po,2510,O
),2510,O
",",2510,O
recovered,2510,O
the,2510,O
AQP5,2510,B-GENE-Y
protein,2510,O
level,2510,O
reduced,2510,O
by,2510,O
CTD,2510,O
and,2510,O
increased,2510,O
the,2510,O
AQP1,2510,B-GENE-Y
protein,2510,O
level,2510,O
above,2510,O
the,2510,O
control,2510,O
one,2510,O
.,2510,O
The,2511,O
mRNA,2511,O
level,2511,O
of,2511,O
AQP5,2511,B-GENE-Y
was,2511,O
scarcely,2511,O
affected,2511,O
by,2511,O
CTD,2511,O
and,2511,O
cevimeline,2511,B-CHEMICAL
hydrochloride,2511,I-CHEMICAL
administration,2511,O
.,2511,O
Administration,2512,O
of,2512,O
chloroquine,2512,B-CHEMICAL
(,2512,O
50,2512,O
mg/kg,2512,O
for,2512,O
7,2512,O
days,2512,O
po,2512,O
),2512,O
",",2512,O
a,2512,O
denaturant,2512,O
of,2512,O
lysosomes,2512,O
",",2512,O
increased,2512,O
the,2512,O
AQP5,2512,B-GENE-Y
protein,2512,O
level,2512,O
reduced,2512,O
by,2512,O
CTD,2512,O
.,2512,O
An,2513,O
extract,2513,O
obtained,2513,O
from,2513,O
the,2513,O
submandibular,2513,O
lysosomal,2513,O
fraction,2513,O
degraded,2513,O
the,2513,O
AQP5,2513,B-GENE-Y
protein,2513,O
in,2513,O
the,2513,O
total,2513,O
membrane,2513,O
fraction,2513,O
in,2513,O
vitro,2513,O
.,2513,O
These,2514,O
results,2514,O
suggest,2514,O
the,2514,O
possible,2514,O
regulation,2514,O
of,2514,O
the,2514,O
AQP5,2514,B-GENE-Y
protein,2514,O
level,2514,O
in,2514,O
the,2514,O
SMG,2514,O
by,2514,O
the,2514,O
parasympathetic,2514,O
nerves/M3,2514,O
muscarinic,2514,I-GENE-Y
receptor,2514,I-GENE-Y
agonist,2514,O
and,2514,O
imply,2514,O
the,2514,O
involvement,2514,O
of,2514,O
lysosomal,2514,O
enzymes,2514,O
",",2514,O
but,2514,O
not,2514,O
a,2514,O
transcriptional,2514,O
mechanism,2514,O
",",2514,O
in,2514,O
this,2514,O
regulation,2514,O
.,2514,O
Multicenter,2515,O
trial,2515,O
of,2515,O
everolimus,2515,B-CHEMICAL
in,2515,O
pediatric,2515,O
renal,2515,O
transplant,2515,O
recipients,2515,O
:,2515,O
results,2515,O
at,2515,O
three,2515,O
year,2515,O
.,2515,O
There,2516,O
are,2516,O
few,2516,O
prospective,2516,O
clinical,2516,O
trials,2516,O
of,2516,O
mTOR,2516,B-GENE-Y
inhibitors,2516,O
(,2516,O
or,2516,O
proliferation,2516,O
signal,2516,O
inhibitors,2516,O
),2516,O
combined,2516,O
with,2516,O
CNI,2516,O
inhibitors,2516,O
in,2516,O
de,2516,O
novo,2516,O
pediatric,2516,O
renal,2516,O
transplantation,2516,O
.,2516,O
Results,2517,O
reported,2517,O
here,2517,O
are,2517,O
from,2517,O
a,2517,O
multicenter,2517,O
",",2517,O
open-label,2517,O
study,2517,O
in,2517,O
de,2517,O
novo,2517,O
pediatric,2517,O
renal,2517,O
transplant,2517,O
patients,2517,O
(,2517,O
<,2517,O
or=16,2517,O
yr,2517,O
),2517,O
",",2517,O
in,2517,O
which,2517,O
patients,2517,O
received,2517,O
everolimus,2517,O
with,2517,O
cyclosporine,2517,O
and,2517,O
corticosteroids,2517,O
for,2517,O
one,2517,O
yr,2517,O
",",2517,O
then,2517,O
entered,2517,O
an,2517,O
extension,2517,O
study,2517,O
for,2517,O
a,2517,O
further,2517,O
two,2517,O
yr.,2517,O
Nineteen,2517,O
patients,2517,O
completed,2517,O
the,2517,O
one-yr,2517,O
study,2517,O
",",2517,O
of,2517,O
whom,2517,O
three,2517,O
discontinued,2517,O
study,2517,O
medication,2517,O
.,2517,O
Fifteen,2518,O
of,2518,O
the,2518,O
remaining,2518,O
16,2518,O
patients,2518,O
entered,2518,O
the,2518,O
extension,2518,O
study,2518,O
",",2518,O
eight,2518,O
of,2518,O
whom,2518,O
were,2518,O
aged,2518,O
<,2518,O
10,2518,O
yr,2518,O
(,2518,O
Group,2518,O
1,2518,O
),2518,O
and,2518,O
seven,2518,O
were,2518,O
aged,2518,O
10-16,2518,O
yr,2518,O
(,2518,O
Group,2518,O
2,2518,O
),2518,O
.,2518,O
Mean,2519,O
daily,2519,O
dose,2519,O
of,2519,O
everolimus,2519,O
during,2519,O
the,2519,O
first,2519,O
36,2519,O
months,2519,O
was,2519,O
1.53,2519,O
mg/m,2519,O
(,2519,O
2,2519,O
),2519,O
BSA,2519,O
.,2519,O
Biopsy-proven,2520,O
acute,2520,O
rejection,2520,O
occurred,2520,O
in,2520,O
three,2520,O
patients,2520,O
in,2520,O
Group,2520,O
2,2520,O
and,2520,O
in,2520,O
one,2520,O
patient,2520,O
in,2520,O
Group,2520,O
1,2520,O
.,2520,O
Biopsy-proven,2521,O
chronic,2521,O
allograft,2521,O
rejection,2521,O
was,2521,O
reported,2521,O
in,2521,O
four,2521,O
patients,2521,O
(,2521,O
two,2521,O
in,2521,O
each,2521,O
age,2521,O
group,2521,O
),2521,O
.,2521,O
Graft,2522,O
survival,2522,O
at,2522,O
one,2522,O
yr,2522,O
was,2522,O
100,2522,O
%,2522,O
;,2522,O
one,2522,O
patient,2522,O
in,2522,O
Group,2522,O
2,2522,O
lost,2522,O
their,2522,O
graft,2522,O
subsequently,2522,O
during,2522,O
the,2522,O
extension,2522,O
.,2522,O
For,2523,O
patients,2523,O
entering,2523,O
the,2523,O
extension,2523,O
",",2523,O
patient,2523,O
survival,2523,O
at,2523,O
three,2523,O
yr,2523,O
was,2523,O
100,2523,O
%,2523,O
.,2523,O
There,2524,O
were,2524,O
three,2524,O
cases,2524,O
of,2524,O
viral,2524,O
infection,2524,O
",",2524,O
including,2524,O
one,2524,O
case,2524,O
of,2524,O
cytomegalovirus,2524,O
infection,2524,O
.,2524,O
At,2525,O
three,2525,O
yr,2525,O
",",2525,O
mean,2525,O
total,2525,O
cholesterol,2525,O
was,2525,O
5.5,2525,O
+/-,2525,O
0.8,2525,O
mm/L,2525,O
(,2525,O
213,2525,O
+/-,2525,O
31,2525,O
mg/dL,2525,O
),2525,O
and,2525,O
four,2525,O
patients,2525,O
received,2525,O
statin,2525,O
therapy,2525,O
.,2525,O
Mean,2526,O
serum,2526,O
creatinine,2526,O
at,2526,O
36,2526,O
months,2526,O
was,2526,O
96,2526,O
+/-,2526,O
36,2526,O
microm/L,2526,O
(,2526,O
1.1,2526,O
+/-,2526,O
0.4,2526,O
mg/dL,2526,O
),2526,O
.,2526,O
This,2527,O
is,2527,O
the,2527,O
first,2527,O
long-term,2527,O
prospective,2527,O
study,2527,O
to,2527,O
demonstrate,2527,O
that,2527,O
a,2527,O
regimen,2527,O
of,2527,O
everolimus,2527,O
",",2527,O
cyclosporine,2527,O
",",2527,O
and,2527,O
corticosteroids,2527,O
provides,2527,O
good,2527,O
efficacy,2527,O
",",2527,O
tolerability,2527,O
",",2527,O
and,2527,O
safety,2527,O
in,2527,O
de,2527,O
novo,2527,O
pediatric,2527,O
renal,2527,O
transplant,2527,O
patients,2527,O
.,2527,O
Differential,2528,O
pharmacokinetics,2528,O
and,2528,O
pharmacodynamics,2528,O
of,2528,O
methylphenidate,2528,B-CHEMICAL
enantiomers,2528,O
:,2528,O
does,2528,O
chirality,2528,O
matter,2528,O
?,2528,O
d,2529,B-CHEMICAL
",",2529,I-CHEMICAL
l-threo-methylphenidate,2529,I-CHEMICAL
(,2529,O
MPH,2529,B-CHEMICAL
),2529,O
is,2529,O
an,2529,O
effective,2529,O
first-line,2529,O
treatment,2529,O
for,2529,O
the,2529,O
symptoms,2529,O
associated,2529,O
with,2529,O
attention-deficit/hyperactivity,2529,O
disorder,2529,O
.,2529,O
threo-methylphenidate,2530,B-CHEMICAL
inhibits,2530,O
the,2530,O
dopamine,2530,B-GENE-Y
transporter,2530,I-GENE-Y
and,2530,O
the,2530,O
norepinephrine,2530,B-GENE-Y
transporter,2530,I-GENE-Y
",",2530,O
resulting,2530,O
in,2530,O
elevations,2530,O
of,2530,O
these,2530,O
monoamines,2530,B-CHEMICAL
after,2530,O
impulse,2530,O
release,2530,O
.,2530,O
Although,2531,O
MPH,2531,B-CHEMICAL
has,2531,O
long,2531,O
been,2531,O
administered,2531,O
as,2531,O
a,2531,O
racemic,2531,O
mixture,2531,O
of,2531,O
the,2531,O
2,2531,O
enantiomers,2531,O
",",2531,O
d-MPH,2531,B-CHEMICAL
and,2531,O
l-MPH,2531,B-CHEMICAL
",",2531,O
converging,2531,O
lines,2531,O
of,2531,O
evidence,2531,O
drawn,2531,O
from,2531,O
investigations,2531,O
using,2531,O
in,2531,O
vitro,2531,O
systems,2531,O
",",2531,O
animal,2531,O
models,2531,O
",",2531,O
and,2531,O
humans,2531,O
indicate,2531,O
that,2531,O
it,2531,O
is,2531,O
predominantly,2531,O
",",2531,O
if,2531,O
not,2531,O
exclusively,2531,O
",",2531,O
d-MPH,2531,B-CHEMICAL
that,2531,O
mediates,2531,O
the,2531,O
pharmacological/therapeutic,2531,O
actions,2531,O
of,2531,O
MPH,2531,B-CHEMICAL
.,2531,O
In,2532,O
both,2532,O
rodent,2532,O
and,2532,O
primate,2532,O
animal,2532,O
models,2532,O
",",2532,O
the,2532,O
binding,2532,O
of,2532,O
radiolabeled,2532,O
d-MPH,2532,B-CHEMICAL
to,2532,O
dopamine,2532,B-GENE-N
transporter,2532,I-GENE-N
was,2532,O
found,2532,O
to,2532,O
be,2532,O
selective,2532,O
",",2532,O
saturable,2532,O
",",2532,O
and,2532,O
reversible,2532,O
",",2532,O
whereas,2532,O
binding,2532,O
of,2532,O
l-MPH,2532,B-CHEMICAL
was,2532,O
diffuse,2532,O
and,2532,O
nonspecific,2532,O
.,2532,O
The,2533,O
behavioral,2533,O
effects,2533,O
of,2533,O
the,2533,O
enantiomers,2533,O
of,2533,O
MPH,2533,B-CHEMICAL
have,2533,O
been,2533,O
tested,2533,O
in,2533,O
several,2533,O
animal,2533,O
models,2533,O
",",2533,O
and,2533,O
results,2533,O
indicate,2533,O
these,2533,O
observed,2533,O
behavioral,2533,O
changes,2533,O
are,2533,O
likewise,2533,O
mediated,2533,O
by,2533,O
d-MPH,2533,B-CHEMICAL
",",2533,O
whereas,2533,O
l-MPH,2533,B-CHEMICAL
has,2533,O
little,2533,O
or,2533,O
no,2533,O
effect.The,2533,O
contribution,2533,O
of,2533,O
the,2533,O
l-isomer,2533,O
to,2533,O
the,2533,O
overall,2533,O
pharmacological,2533,O
profile,2533,O
of,2533,O
the,2533,O
racemate,2533,O
remains,2533,O
unclear,2533,O
",",2533,O
owing,2533,O
to,2533,O
several,2533,O
studies,2533,O
suggesting,2533,O
that,2533,O
l-MPH,2533,B-CHEMICAL
may,2533,O
not,2533,O
be,2533,O
merely,2533,O
an,2533,O
inert,2533,O
isomeric,2533,O
ballast,2533,O
.,2533,O
For,2534,O
example,2534,O
",",2534,O
behavioral,2534,O
studies,2534,O
conducted,2534,O
in,2534,O
rats,2534,O
demonstrate,2534,O
an,2534,O
attenuation,2534,O
of,2534,O
the,2534,O
effect,2534,O
of,2534,O
d-MPH,2534,B-CHEMICAL
in,2534,O
animals,2534,O
pretreated,2534,O
with,2534,O
l-MPH,2534,B-CHEMICAL
",",2534,O
suggesting,2534,O
that,2534,O
l-MPH,2534,B-CHEMICAL
may,2534,O
interfere,2534,O
with,2534,O
the,2534,O
action,2534,O
of,2534,O
the,2534,O
active,2534,O
enantiomer,2534,O
.,2534,O
The,2535,O
importance,2535,O
of,2535,O
MPH,2535,B-CHEMICAL
chirality,2535,O
to,2535,O
central,2535,O
nervous,2535,O
system,2535,O
MPH,2535,B-GENE-N
receptor,2535,I-GENE-N
targeting,2535,O
has,2535,O
culminated,2535,O
in,2535,O
human,2535,O
imaging,2535,O
studies,2535,O
revealing,2535,O
that,2535,O
d-MPH,2535,B-CHEMICAL
binds,2535,O
specifically,2535,O
to,2535,O
striatal,2535,O
structures,2535,O
",",2535,O
whereas,2535,O
l-MPH,2535,B-CHEMICAL
binding,2535,O
is,2535,O
nonspecific,2535,O
.,2535,O
Taken,2536,O
together,2536,O
",",2536,O
data,2536,O
from,2536,O
in,2536,O
vitro,2536,O
",",2536,O
animal,2536,O
",",2536,O
and,2536,O
human,2536,O
studies,2536,O
support,2536,O
the,2536,O
premise,2536,O
that,2536,O
the,2536,O
d-enantiomer,2536,B-CHEMICAL
of,2536,I-CHEMICAL
MPH,2536,I-CHEMICAL
mediates,2536,O
the,2536,O
neurophysiological,2536,O
actions,2536,O
of,2536,O
MPH,2536,B-CHEMICAL
and,2536,O
therefore,2536,O
likely,2536,O
mediates,2536,O
its,2536,O
clinical,2536,O
efficacy,2536,O
.,2536,O
Identification,2537,O
of,2537,O
N-terminal,2537,B-CHEMICAL
receptor,2537,O
activity-modifying,2537,O
protein,2537,O
residues,2537,O
important,2537,O
for,2537,O
calcitonin,2537,B-GENE-N
gene-related,2537,I-GENE-N
peptide,2537,I-GENE-N
",",2537,O
adrenomedullin,2537,B-GENE-Y
",",2537,O
and,2537,O
amylin,2537,B-GENE-N
receptor,2537,I-GENE-N
function,2537,O
.,2537,O
Calcitonin-family,2538,B-GENE-N
receptors,2538,I-GENE-N
comprise,2538,O
calcitonin,2538,B-GENE-Y
receptor-like,2538,I-GENE-Y
receptor,2538,I-GENE-Y
(,2538,O
CL,2538,B-GENE-Y
),2538,O
or,2538,O
calcitonin,2538,B-GENE-Y
receptor,2538,I-GENE-Y
and,2538,O
receptor,2538,B-GENE-N
activity-modifying,2538,I-GENE-N
protein,2538,I-GENE-N
(,2538,O
RAMP,2538,B-GENE-N
),2538,O
pairings,2538,O
.,2538,O
Calcitonin,2539,B-GENE-Y
gene-related,2539,I-GENE-Y
peptide,2539,I-GENE-Y
(,2539,I-GENE-Y
CGRP,2539,I-GENE-Y
),2539,I-GENE-Y
receptors,2539,I-GENE-Y
are,2539,O
CL/RAMP1,2539,B-GENE-Y
",",2539,O
whereas,2539,O
adrenomedullin,2539,B-GENE-N
(,2539,I-GENE-N
AM,2539,I-GENE-N
),2539,I-GENE-N
receptors,2539,I-GENE-N
are,2539,O
CL/RAMP2,2539,B-GENE-Y
(,2539,O
AM1,2539,B-GENE-Y
receptor,2539,I-GENE-Y
),2539,O
or,2539,O
CL/RAMP3,2539,B-GENE-Y
(,2539,O
AM2,2539,B-GENE-Y
receptor,2539,I-GENE-Y
),2539,O
.,2539,O
Amylin,2540,B-GENE-N
(,2540,I-GENE-N
Amy,2540,I-GENE-N
),2540,I-GENE-N
receptors,2540,I-GENE-N
are,2540,O
RAMP,2540,B-GENE-N
hetero-oligomers,2540,O
with,2540,O
the,2540,O
calcitonin,2540,B-GENE-Y
receptor,2540,I-GENE-Y
(,2540,O
AMY1,2540,B-GENE-Y
",",2540,O
AMY2,2540,B-GENE-Y
",",2540,O
and,2540,O
AMY3,2540,B-GENE-Y
",",2540,O
respectively,2540,O
),2540,O
.,2540,O
How,2541,O
RAMPs,2541,B-GENE-N
change,2541,O
G,2541,B-GENE-N
protein-coupled,2541,I-GENE-N
receptor,2541,I-GENE-N
pharmacology,2541,O
is,2541,O
not,2541,O
fully,2541,O
understood,2541,O
.,2541,O
We,2542,O
exploited,2542,O
sequence,2542,O
differences,2542,O
between,2542,O
RAMP1,2542,B-GENE-Y
and,2542,O
RAMP3,2542,B-GENE-Y
to,2542,O
identify,2542,O
individual,2542,O
residues,2542,O
capable,2542,O
of,2542,O
altering,2542,O
receptor,2542,O
pharmacology,2542,O
.,2542,O
Alignment,2543,O
of,2543,O
human,2543,B-GENE-N
RAMPs,2543,I-GENE-N
revealed,2543,O
eight,2543,O
residues,2543,O
that,2543,O
are,2543,O
conserved,2543,O
in,2543,O
RAMP2,2543,B-GENE-Y
and,2543,O
RAMP3,2543,B-GENE-Y
but,2543,O
are,2543,O
different,2543,O
in,2543,O
RAMP1,2543,B-GENE-Y
.,2543,O
We,2544,O
hypothesized,2544,O
that,2544,O
residues,2544,O
in,2544,O
RAMP2,2544,B-GENE-Y
and,2544,O
RAMP3,2544,B-GENE-Y
",",2544,O
but,2544,O
not,2544,O
RAMP1,2544,B-GENE-Y
",",2544,O
are,2544,O
responsible,2544,O
for,2544,O
making,2544,O
CL/RAMP2,2544,B-GENE-Y
and,2544,O
CL/RAMP3,2544,B-GENE-Y
AM,2544,B-GENE-N
receptors,2544,I-GENE-N
.,2544,O
Using,2545,O
site-directed,2545,O
mutagenesis,2545,O
",",2545,O
we,2545,O
introduced,2545,O
individual,2545,O
RAMP3,2545,B-GENE-Y
residues,2545,O
into,2545,O
RAMP1,2545,B-GENE-Y
and,2545,O
vice,2545,O
versa,2545,O
in,2545,O
these,2545,O
eight,2545,O
positions,2545,O
.,2545,O
Mutant,2546,O
or,2546,O
wild-type,2546,O
RAMPs,2546,B-GENE-N
were,2546,O
transfected,2546,O
into,2546,O
Cos7,2546,O
cells,2546,O
with,2546,O
CL,2546,B-GENE-Y
or,2546,O
the,2546,O
insert-negative,2546,O
form,2546,O
of,2546,O
the,2546,O
calcitonin,2546,B-GENE-Y
receptor,2546,I-GENE-Y
[,2546,O
CT,2546,B-GENE-Y
(,2546,I-GENE-Y
a,2546,I-GENE-Y
),2546,I-GENE-Y
],2546,O
.,2546,O
Agonist-stimulated,2547,O
cAMP,2547,O
production,2547,O
and,2547,O
cell-surface,2547,O
expression,2547,O
of,2547,O
constructs,2547,O
were,2547,O
measured,2547,O
.,2547,O
Position,2548,O
74,2548,O
in,2548,O
RAMP1,2548,B-GENE-Y
and,2548,O
RAMP3,2548,B-GENE-Y
was,2548,O
critical,2548,O
for,2548,O
determining,2548,O
AM,2548,B-GENE-Y
potency,2548,O
and,2548,O
affinity,2548,O
",",2548,O
and,2548,O
Phe93,2548,O
in,2548,O
RAMP1,2548,B-GENE-Y
was,2548,O
an,2548,O
important,2548,O
contributor,2548,O
to,2548,O
alphaCGRP,2548,B-GENE-Y
potency,2548,O
at,2548,O
CGRP,2548,B-GENE-Y
receptors,2548,I-GENE-Y
.,2548,O
Mutant,2549,O
RAMP/CT,2549,B-GENE-N
(,2549,I-GENE-Y
a,2549,I-GENE-Y
),2549,I-GENE-Y
receptor,2549,I-GENE-Y
complexes,2549,O
displayed,2549,O
different,2549,O
phenotypes,2549,O
.,2549,O
It,2550,O
is,2550,O
noteworthy,2550,O
that,2550,O
RAMP1,2550,B-GENE-Y
S103N,2550,B-GENE-N
and,2550,O
W74E,2550,B-GENE-N
mutations,2550,O
led,2550,O
to,2550,O
enhanced,2550,O
rAmy,2550,B-GENE-Y
potency,2550,O
",",2550,O
probably,2550,O
related,2550,O
to,2550,O
increased,2550,O
cell-surface,2550,O
expression,2550,O
of,2550,O
these,2550,O
complexes,2550,O
.,2550,O
This,2551,O
differs,2551,O
from,2551,O
the,2551,O
effect,2551,O
on,2551,O
CL-based,2551,B-GENE-Y
receptors,2551,O
where,2551,O
expression,2551,O
was,2551,O
unchanged,2551,O
.,2551,O
Targeted,2552,O
substitution,2552,O
has,2552,O
emphasized,2552,O
the,2552,O
importance,2552,O
of,2552,O
position,2552,O
74,2552,O
in,2552,O
RAMP1/RAMP3,2552,B-GENE-Y
as,2552,O
a,2552,O
key,2552,O
determinant,2552,O
of,2552,O
AM,2552,B-GENE-Y
pharmacology,2552,O
.,2552,O
Nitrosoureas,2553,O
inhibit,2553,O
the,2553,O
stathmin-mediated,2553,B-GENE-Y
migration,2553,O
and,2553,O
invasion,2553,O
of,2553,O
malignant,2553,O
glioma,2553,O
cells,2553,O
.,2553,O
Malignant,2554,O
gliomas,2554,O
are,2554,O
the,2554,O
most,2554,O
common,2554,O
primary,2554,O
intrinsic,2554,O
brain,2554,O
tumors,2554,O
and,2554,O
are,2554,O
highly,2554,O
lethal,2554,O
.,2554,O
The,2555,O
widespread,2555,O
migration,2555,O
and,2555,O
invasion,2555,O
of,2555,O
neoplastic,2555,O
cells,2555,O
from,2555,O
the,2555,O
initial,2555,O
site,2555,O
of,2555,O
tumor,2555,O
formation,2555,O
into,2555,O
the,2555,O
surrounding,2555,O
brain,2555,O
render,2555,O
these,2555,O
lesions,2555,O
refractory,2555,O
to,2555,O
definitive,2555,O
surgical,2555,O
treatment,2555,O
.,2555,O
Stathmin,2556,B-GENE-Y
",",2556,O
a,2556,O
microtubule-destabilizing,2556,B-GENE-N
protein,2556,O
that,2556,O
mediates,2556,O
cell,2556,O
cycle,2556,O
progression,2556,O
",",2556,O
can,2556,O
also,2556,O
regulate,2556,O
directed,2556,O
cell,2556,O
movement,2556,O
.,2556,O
Nitrosoureas,2557,O
",",2557,O
traditionally,2557,O
viewed,2557,O
as,2557,O
DNA,2557,O
alkylating,2557,O
agents,2557,O
",",2557,O
can,2557,O
also,2557,O
covalently,2557,O
modify,2557,O
proteins,2557,O
such,2557,O
as,2557,O
stathmin,2557,B-GENE-Y
.,2557,O
We,2558,O
therefore,2558,O
sought,2558,O
to,2558,O
establish,2558,O
a,2558,O
role,2558,O
for,2558,O
stathmin,2558,B-GENE-Y
in,2558,O
malignant,2558,O
glioma,2558,O
cell,2558,O
motility,2558,O
",",2558,O
migration,2558,O
",",2558,O
and,2558,O
invasion,2558,O
and,2558,O
determine,2558,O
the,2558,O
effects,2558,O
of,2558,O
nitrosoureas,2558,B-CHEMICAL
on,2558,O
these,2558,O
cell,2558,O
movement-related,2558,O
processes,2558,O
.,2558,O
Scratch,2559,O
wound-healing,2559,O
recovery,2559,O
",",2559,O
Boyden,2559,O
chamber,2559,O
migration,2559,O
",",2559,O
Matrigel,2559,O
invasion,2559,O
",",2559,O
and,2559,O
organotypic,2559,O
slice,2559,O
invasion,2559,O
assays,2559,O
were,2559,O
performed,2559,O
before,2559,O
and,2559,O
after,2559,O
the,2559,O
down-regulation,2559,O
of,2559,O
cellular,2559,O
stathmin,2559,B-GENE-Y
levels,2559,O
and,2559,O
in,2559,O
the,2559,O
absence,2559,O
and,2559,O
presence,2559,O
of,2559,O
sublethal,2559,O
nitrosourea,2559,B-CHEMICAL
(,2559,O
[,2559,B-CHEMICAL
1-,2559,I-CHEMICAL
(,2559,I-CHEMICAL
2-chloroethyl,2559,I-CHEMICAL
),2559,I-CHEMICAL
-3-cyclohexyl-l-nitrosourea,2559,I-CHEMICAL
],2559,I-CHEMICAL
;,2559,O
CCNU,2559,B-CHEMICAL
),2559,O
concentrations,2559,O
.,2559,O
We,2560,O
show,2560,O
that,2560,O
decreases,2560,O
in,2560,O
stathmin,2560,B-GENE-Y
expression,2560,O
lead,2560,O
to,2560,O
significant,2560,O
decreases,2560,O
in,2560,O
malignant,2560,O
glioma,2560,O
cell,2560,O
motility,2560,O
",",2560,O
migration,2560,O
",",2560,O
and,2560,O
invasion,2560,O
.,2560,O
CCNU,2561,B-CHEMICAL
",",2561,O
at,2561,O
a,2561,O
concentration,2561,O
of,2561,O
10,2561,O
micromol/L,2561,O
",",2561,O
causes,2561,O
similar,2561,O
significant,2561,O
decreases,2561,O
",",2561,O
even,2561,O
in,2561,O
the,2561,O
absence,2561,O
of,2561,O
any,2561,O
effects,2561,O
on,2561,O
cell,2561,O
viability,2561,O
.,2561,O
The,2562,O
direct,2562,O
inhibition,2562,O
of,2562,O
stathmin,2562,B-GENE-Y
by,2562,O
CCNU,2562,B-CHEMICAL
is,2562,O
likely,2562,O
a,2562,O
contributing,2562,O
factor,2562,O
.,2562,O
These,2563,O
findings,2563,O
suggest,2563,O
that,2563,O
the,2563,O
inhibition,2563,O
of,2563,O
stathmin,2563,O
expression,2563,O
and,2563,O
function,2563,O
may,2563,O
be,2563,O
useful,2563,O
in,2563,O
limiting,2563,O
the,2563,O
spread,2563,O
of,2563,O
malignant,2563,O
gliomas,2563,O
within,2563,O
the,2563,O
brain,2563,O
",",2563,O
and,2563,O
that,2563,O
nitrosoureas,2563,B-CHEMICAL
may,2563,O
have,2563,O
therapeutic,2563,O
benefits,2563,O
in,2563,O
addition,2563,O
to,2563,O
their,2563,O
antiproliferative,2563,O
effects,2563,O
.,2563,O
Interaction,2564,O
with,2564,O
the,2564,O
hERG,2564,B-GENE-Y
channel,2564,O
and,2564,O
cytotoxicity,2564,O
of,2564,O
amiodarone,2564,B-CHEMICAL
and,2564,O
amiodarone,2564,B-CHEMICAL
analogues,2564,O
.,2564,O
BACKGROUND,2565,O
AND,2565,O
PURPOSE,2565,O
:,2565,O
Amiodarone,2565,B-CHEMICAL
(,2565,O
2-n-butyl-3-,2565,B-CHEMICAL
[,2565,I-CHEMICAL
"3,5",2565,I-CHEMICAL
diiodo-4-diethylaminoethoxybenzoyl,2565,I-CHEMICAL
],2565,I-CHEMICAL
-benzofuran,2565,I-CHEMICAL
",",2565,O
B2-O-CH,2565,B-CHEMICAL
(,2565,I-CHEMICAL
2,2565,I-CHEMICAL
),2565,I-CHEMICAL
CH,2565,I-CHEMICAL
(,2565,I-CHEMICAL
2,2565,I-CHEMICAL
),2565,I-CHEMICAL
-N-diethyl,2565,I-CHEMICAL
),2565,O
is,2565,O
an,2565,O
effective,2565,O
class,2565,O
III,2565,O
antiarrhythmic,2565,O
drug,2565,O
demonstrating,2565,O
potentially,2565,O
life-threatening,2565,O
organ,2565,O
toxicity,2565,O
.,2565,O
The,2566,O
principal,2566,O
aim,2566,O
of,2566,O
the,2566,O
study,2566,O
was,2566,O
to,2566,O
find,2566,O
amiodarone,2566,B-CHEMICAL
analogues,2566,O
that,2566,O
retained,2566,O
human,2566,B-GENE-Y
ether-a-go-go-related,2566,I-GENE-Y
protein,2566,I-GENE-Y
(,2566,I-GENE-Y
hERG,2566,I-GENE-Y
),2566,I-GENE-Y
channel,2566,I-GENE-Y
inhibition,2566,O
but,2566,O
with,2566,O
reduced,2566,O
cytotoxicity,2566,O
.,2566,O
EXPERIMENTAL,2567,O
APPROACH,2567,O
:,2567,O
We,2567,O
synthesized,2567,O
amiodarone,2567,B-CHEMICAL
analogues,2567,O
with,2567,O
or,2567,O
without,2567,O
a,2567,O
positively,2567,O
ionizable,2567,O
nitrogen,2567,B-CHEMICAL
in,2567,O
the,2567,O
phenolic,2567,B-CHEMICAL
side,2567,O
chain,2567,O
.,2567,O
The,2568,O
cytotoxic,2568,O
properties,2568,O
of,2568,O
the,2568,O
compounds,2568,O
were,2568,O
evaluated,2568,O
using,2568,O
HepG2,2568,O
(,2568,O
a,2568,O
hepatocyte,2568,O
cell,2568,O
line,2568,O
),2568,O
and,2568,O
A549,2568,O
cells,2568,O
(,2568,O
a,2568,O
pneumocyte,2568,O
line,2568,O
),2568,O
.,2568,O
Interactions,2569,O
of,2569,O
all,2569,O
compounds,2569,O
with,2569,O
the,2569,O
hERG,2569,B-GENE-Y
channel,2569,O
were,2569,O
measured,2569,O
using,2569,O
pharmacological,2569,O
and,2569,O
in,2569,O
silico,2569,O
methods,2569,O
.,2569,O
KEY,2570,O
RESULTS,2570,O
:,2570,O
Compared,2570,O
with,2570,O
amiodarone,2570,B-CHEMICAL
",",2570,O
which,2570,O
displayed,2570,O
only,2570,O
a,2570,O
weak,2570,O
cytotoxicity,2570,O
",",2570,O
the,2570,O
mono-,2570,O
and,2570,O
bis-desethylated,2570,O
metabolites,2570,O
",",2570,O
the,2570,O
further,2570,O
degraded,2570,O
alcohol,2570,B-CHEMICAL
(,2570,O
B2-O-CH,2570,B-CHEMICAL
(,2570,I-CHEMICAL
2,2570,I-CHEMICAL
),2570,I-CHEMICAL
-CH,2570,I-CHEMICAL
(,2570,I-CHEMICAL
2,2570,I-CHEMICAL
),2570,I-CHEMICAL
-OH,2570,I-CHEMICAL
),2570,O
",",2570,O
the,2570,O
corresponding,2570,O
acid,2570,O
(,2570,O
B2-O-CH,2570,B-CHEMICAL
(,2570,I-CHEMICAL
2,2570,I-CHEMICAL
),2570,I-CHEMICAL
-COOH,2570,I-CHEMICAL
),2570,O
and,2570,O
",",2570,O
finally,2570,O
",",2570,O
the,2570,O
newly,2570,O
synthesized,2570,O
B2-O-CH,2570,B-CHEMICAL
(,2570,I-CHEMICAL
2,2570,I-CHEMICAL
),2570,I-CHEMICAL
-CH,2570,I-CHEMICAL
(,2570,I-CHEMICAL
2,2570,I-CHEMICAL
),2570,I-CHEMICAL
-N-pyrrolidine,2570,I-CHEMICAL
were,2570,O
equally,2570,O
or,2570,O
more,2570,O
toxic,2570,O
.,2570,O
Conversely,2571,O
",",2571,O
structural,2571,O
analogues,2571,O
such,2571,O
as,2571,O
the,2571,O
B2-O-CH,2571,B-CHEMICAL
(,2571,I-CHEMICAL
2,2571,I-CHEMICAL
),2571,I-CHEMICAL
-CH,2571,I-CHEMICAL
(,2571,I-CHEMICAL
2,2571,I-CHEMICAL
),2571,I-CHEMICAL
-N-diisopropyl,2571,I-CHEMICAL
and,2571,O
the,2571,O
B2-O-CH,2571,B-CHEMICAL
(,2571,I-CHEMICAL
2,2571,I-CHEMICAL
),2571,I-CHEMICAL
-CH,2571,I-CHEMICAL
(,2571,I-CHEMICAL
2,2571,I-CHEMICAL
),2571,I-CHEMICAL
-N-piperidine,2571,I-CHEMICAL
were,2571,O
significantly,2571,O
less,2571,O
toxic,2571,O
than,2571,O
amiodarone,2571,B-CHEMICAL
.,2571,O
Cytotoxicity,2572,O
was,2572,O
associated,2572,O
with,2572,O
a,2572,O
drop,2572,O
in,2572,O
the,2572,O
mitochondrial,2572,O
membrane,2572,O
potential,2572,O
",",2572,O
suggesting,2572,O
mitochondrial,2572,O
involvement,2572,O
.,2572,O
Pharmacological,2573,O
and,2573,O
in,2573,O
silico,2573,O
investigations,2573,O
concerning,2573,O
the,2573,O
interactions,2573,O
of,2573,O
these,2573,O
compounds,2573,O
with,2573,O
the,2573,O
hERG,2573,B-GENE-Y
channel,2573,O
revealed,2573,O
that,2573,O
compounds,2573,O
carrying,2573,O
a,2573,O
basic,2573,O
nitrogen,2573,B-CHEMICAL
in,2573,O
the,2573,O
side,2573,O
chain,2573,O
display,2573,O
a,2573,O
much,2573,O
higher,2573,O
affinity,2573,O
than,2573,O
those,2573,O
lacking,2573,O
such,2573,O
a,2573,O
group,2573,O
.,2573,O
Specifically,2574,O
",",2574,O
B2-O-CH,2574,B-CHEMICAL
(,2574,I-CHEMICAL
2,2574,I-CHEMICAL
),2574,I-CHEMICAL
-CH,2574,I-CHEMICAL
(,2574,I-CHEMICAL
2,2574,I-CHEMICAL
),2574,I-CHEMICAL
-N-piperidine,2574,I-CHEMICAL
and,2574,O
B2-O-CH,2574,B-CHEMICAL
(,2574,I-CHEMICAL
2,2574,I-CHEMICAL
),2574,I-CHEMICAL
-CH,2574,I-CHEMICAL
(,2574,I-CHEMICAL
2,2574,I-CHEMICAL
),2574,I-CHEMICAL
-N-pyrrolidine,2574,I-CHEMICAL
revealed,2574,O
a,2574,O
higher,2574,O
affinity,2574,O
towards,2574,O
hERG,2574,B-GENE-Y
channels,2574,O
than,2574,O
amiodarone,2574,B-CHEMICAL
.,2574,O
CONCLUSIONS,2575,O
AND,2575,O
IMPLICATIONS,2575,O
:,2575,O
Amiodarone,2575,B-CHEMICAL
analogues,2575,O
with,2575,O
better,2575,O
hERG,2575,B-GENE-Y
channel,2575,O
inhibition,2575,O
and,2575,O
cytotoxicity,2575,O
profiles,2575,O
than,2575,O
the,2575,O
parent,2575,O
compound,2575,O
have,2575,O
been,2575,O
identified,2575,O
",",2575,O
demonstrating,2575,O
that,2575,O
cytotoxicity,2575,O
and,2575,O
hERG,2575,B-GENE-Y
channel,2575,O
interaction,2575,O
are,2575,O
mechanistically,2575,O
distinct,2575,O
and,2575,O
separable,2575,O
properties,2575,O
of,2575,O
the,2575,O
compounds,2575,O
.,2575,O
Interaction,2576,O
of,2576,O
human,2576,B-GENE-Y
alpha-lactalbumin,2576,I-GENE-Y
with,2576,O
fatty,2576,B-CHEMICAL
acids,2576,I-CHEMICAL
:,2576,O
determination,2576,O
of,2576,O
binding,2576,O
parameters,2576,O
.,2576,O
The,2577,O
interaction,2577,O
of,2577,O
holo-,2577,O
and,2577,O
apo-forms,2577,O
of,2577,O
human,2577,B-GENE-Y
alpha-lactalbumin,2577,I-GENE-Y
with,2577,O
fatty,2577,B-CHEMICAL
acids,2577,I-CHEMICAL
was,2577,O
studied,2577,O
by,2577,O
a,2577,O
partition,2577,O
equilibrium,2577,O
method,2577,O
.,2577,O
Apo-alpha-lactalbumin,2578,B-GENE-Y
",",2578,O
obtained,2578,O
by,2578,O
treatment,2578,O
with,2578,O
EDTA,2578,B-CHEMICAL
",",2578,O
displays,2578,O
one,2578,O
binding,2578,O
site,2578,O
for,2578,O
fatty,2578,B-CHEMICAL
acids,2578,I-CHEMICAL
",",2578,O
the,2578,O
association,2578,O
constants,2578,O
for,2578,O
oleic,2578,B-CHEMICAL
and,2578,I-CHEMICAL
palmitic,2578,I-CHEMICAL
acids,2578,I-CHEMICAL
being,2578,O
1.9.10,2578,O
(,2578,O
6,2578,O
),2578,O
and,2578,O
4.2.10,2578,O
(,2578,O
5,2578,O
),2578,O
M,2578,O
(,2578,O
-1,2578,O
),2578,O
",",2578,O
respectively,2578,O
.,2578,O
However,2579,O
",",2579,O
holo-alpha-lactalbumin,2579,B-GENE-Y
was,2579,O
unable,2579,O
to,2579,O
bind,2579,O
fatty,2579,B-CHEMICAL
acids,2579,I-CHEMICAL
as,2579,O
measured,2579,O
by,2579,O
this,2579,O
technique,2579,O
.,2579,O
Likewise,2580,O
",",2580,O
no,2580,O
fatty,2580,B-CHEMICAL
acids,2580,I-CHEMICAL
bound,2580,O
to,2580,O
holo-alpha-lactalbumin,2580,B-GENE-Y
",",2580,O
isolated,2580,O
using,2580,O
nondenaturing,2580,O
conditions,2580,O
",",2580,O
were,2580,O
detected,2580,O
by,2580,O
gas,2580,O
chromatography,2580,O
.,2580,O
These,2581,O
results,2581,O
demonstrate,2581,O
that,2581,O
the,2581,O
conformational,2581,O
change,2581,O
induced,2581,O
in,2581,O
alpha-lactalbumin,2581,B-GENE-Y
by,2581,O
the,2581,O
removal,2581,O
of,2581,O
calcium,2581,B-CHEMICAL
enables,2581,O
the,2581,O
protein,2581,O
to,2581,O
interact,2581,O
with,2581,O
fatty,2581,O
acids,2581,O
.,2581,O
Peptide,2582,O
and,2582,O
non-peptide,2582,O
agonists,2582,O
and,2582,O
antagonists,2582,O
for,2582,O
the,2582,O
vasopressin,2582,B-GENE-Y
and,2582,O
oxytocin,2582,B-GENE-Y
V1a,2582,B-GENE-Y
",",2582,O
V1b,2582,B-GENE-Y
",",2582,O
V2,2582,B-GENE-Y
and,2582,O
OT,2582,B-GENE-Y
receptors,2582,I-GENE-Y
:,2582,O
research,2582,O
tools,2582,O
and,2582,O
potential,2582,O
therapeutic,2582,O
agents,2582,O
.,2582,O
Oxytocin,2583,B-GENE-Y
(,2583,O
OT,2583,B-GENE-Y
),2583,O
and,2583,O
vasopressin,2583,B-GENE-Y
(,2583,O
AVP,2583,B-GENE-Y
),2583,O
mediate,2583,O
their,2583,O
biological,2583,O
actions,2583,O
by,2583,O
acting,2583,O
on,2583,O
four,2583,O
known,2583,O
receptors,2583,O
:,2583,O
The,2583,O
OT,2583,B-CHEMICAL
(,2583,O
uterine,2583,O
),2583,O
and,2583,O
the,2583,O
AVP,2583,B-CHEMICAL
V,2583,B-GENE-Y
(,2583,I-GENE-Y
1a,2583,I-GENE-Y
),2583,I-GENE-Y
(,2583,O
vasopressor,2583,O
),2583,O
",",2583,O
V,2583,B-GENE-Y
(,2583,I-GENE-Y
1b,2583,I-GENE-Y
),2583,I-GENE-Y
(,2583,O
pituitary,2583,O
),2583,O
",",2583,O
V,2583,B-GENE-Y
(,2583,I-GENE-Y
2,2583,I-GENE-Y
),2583,I-GENE-Y
(,2583,O
renal,2583,O
),2583,O
receptors,2583,O
and,2583,O
a,2583,O
fifth,2583,O
putative,2583,O
AVP,2583,B-GENE-Y
V,2583,B-GENE-N
(,2583,I-GENE-N
1c,2583,I-GENE-N
),2583,I-GENE-N
?,2583,O
(,2584,O
vasodilating,2584,O
),2584,O
receptor,2584,O
.,2584,O
This,2585,O
presentation,2585,O
will,2585,O
summarize,2585,O
some,2585,O
highlights,2585,O
of,2585,O
the,2585,O
recent,2585,O
progress,2585,O
",",2585,O
in,2585,O
the,2585,O
design,2585,O
and,2585,O
synthesis,2585,O
of,2585,O
selective,2585,O
peptide,2585,O
agonists,2585,O
",",2585,O
antagonists,2585,O
",",2585,O
radioiodinated,2585,O
ligands,2585,O
",",2585,O
fluorescent,2585,O
ligands,2585,O
and,2585,O
bivalent,2585,O
ligands,2585,O
for,2585,O
these,2585,O
receptors,2585,O
.,2585,O
Here,2586,O
we,2586,O
present,2586,O
published,2586,O
and,2586,O
unpublished,2586,O
pharmacological,2586,O
data,2586,O
on,2586,O
the,2586,O
most,2586,O
widely,2586,O
used,2586,O
agonists,2586,O
",",2586,O
antagonists,2586,O
and,2586,O
labelled,2586,O
ligands,2586,O
.,2586,O
The,2587,O
pharmacological,2587,O
properties,2587,O
of,2587,O
promising,2587,O
new,2587,O
selective,2587,O
OT,2587,B-GENE-Y
antagonists,2587,O
and,2587,O
V,2587,B-GENE-Y
(,2587,I-GENE-Y
1b,2587,I-GENE-Y
),2587,I-GENE-Y
agonists,2587,O
are,2587,O
also,2587,O
presented,2587,O
.,2587,O
This,2588,O
review,2588,O
should,2588,O
serve,2588,O
as,2588,O
a,2588,O
useful,2588,O
guide,2588,O
for,2588,O
the,2588,O
selection,2588,O
of,2588,O
the,2588,O
most,2588,O
appropriate,2588,O
ligand,2588,O
for,2588,O
a,2588,O
given,2588,O
study,2588,O
.,2588,O
The,2589,O
current,2589,O
status,2589,O
of,2589,O
non-peptide,2589,O
OT,2589,B-GENE-Y
and,2589,O
AVP,2589,B-GENE-Y
antagonists,2589,O
and,2589,O
agonists,2589,O
is,2589,O
also,2589,O
summarized,2589,O
.,2589,O
The,2590,O
relative,2590,O
merits,2590,O
of,2590,O
peptide,2590,O
and,2590,O
non-peptide,2590,O
AVP,2590,B-GENE-Y
and,2590,O
OT,2590,B-GENE-Y
agonists,2590,O
and,2590,O
antagonists,2590,O
as,2590,O
:,2590,O
(,2590,O
1,2590,O
),2590,O
research,2590,O
tools,2590,O
and,2590,O
(,2590,O
2,2590,O
),2590,O
therapeutic,2590,O
agents,2590,O
will,2590,O
be,2590,O
evaluated,2590,O
.,2590,O
Many,2591,O
of,2591,O
the,2591,O
receptor,2591,O
selective,2591,O
peptide,2591,O
agonists,2591,O
and,2591,O
antagonists,2591,O
from,2591,O
this,2591,O
and,2591,O
other,2591,O
laboratories,2591,O
are,2591,O
far,2591,O
more,2591,O
widely,2591,O
used,2591,O
as,2591,O
pharmacological,2591,O
tools,2591,O
for,2591,O
studies,2591,O
on,2591,O
the,2591,O
peripheral,2591,O
and,2591,O
central,2591,O
effects,2591,O
of,2591,O
OT,2591,B-CHEMICAL
and,2591,O
AVP,2591,B-CHEMICAL
than,2591,O
their,2591,O
non-peptide,2591,O
counterparts,2591,O
.,2591,O
In,2592,O
addition,2592,O
to,2592,O
OT,2592,B-CHEMICAL
and,2592,O
to,2592,O
a,2592,O
lesser,2592,O
extent,2592,O
AVP,2592,B-CHEMICAL
(,2592,O
pitressin,2592,O
),2592,O
",",2592,O
a,2592,O
number,2592,O
of,2592,O
OT,2592,B-CHEMICAL
and,2592,O
AVP,2592,B-GENE-Y
analogues,2592,O
;,2592,O
such,2592,O
as,2592,O
carbetocin,2592,B-CHEMICAL
(,2592,O
OT,2592,B-GENE-Y
agonist,2592,O
),2592,O
dDAVP,2592,O
(,2592,O
desmopressin,2592,B-CHEMICAL
",",2592,O
V,2592,B-GENE-Y
(,2592,I-GENE-Y
2,2592,I-GENE-Y
),2592,I-GENE-Y
agonist,2592,O
),2592,O
",",2592,O
terlipressin,2592,B-CHEMICAL
(,2592,O
V,2592,B-GENE-Y
(,2592,I-GENE-Y
1a,2592,I-GENE-Y
),2592,I-GENE-Y
agonist,2592,O
),2592,O
",",2592,O
felypressin,2592,B-CHEMICAL
(,2592,O
V,2592,B-GENE-Y
(,2592,I-GENE-Y
1a,2592,I-GENE-Y
),2592,I-GENE-Y
agonist,2592,O
),2592,O
and,2592,O
atosiban,2592,B-CHEMICAL
(,2592,O
Tractocile,2592,B-CHEMICAL
OT,2592,B-GENE-Y
antagonist,2592,O
),2592,O
are,2592,O
also,2592,O
in,2592,O
clinical,2592,O
use,2592,O
.,2592,O
Despite,2593,O
much,2593,O
early,2593,O
promise,2593,O
",",2593,O
no,2593,O
non-peptide,2593,O
V,2593,B-GENE-Y
(,2593,I-GENE-Y
1a,2593,I-GENE-Y
),2593,I-GENE-Y
or,2593,O
OT,2593,B-GENE-Y
antagonists,2593,O
are,2593,O
currently,2593,O
in,2593,O
clinical,2593,O
trials,2593,O
.,2593,O
While,2594,O
a,2594,O
number,2594,O
of,2594,O
orally,2594,O
active,2594,O
non-peptide,2594,O
V,2594,B-GENE-Y
(,2594,I-GENE-Y
2,2594,I-GENE-Y
),2594,I-GENE-Y
antagonists,2594,O
(,2594,O
Vaptans,2594,O
),2594,O
;,2594,O
notably,2594,O
",",2594,O
Tolvaptan,2594,B-CHEMICAL
",",2594,O
Lixivaptan,2594,B-CHEMICAL
and,2594,O
Satavaptan,2594,B-CHEMICAL
",",2594,O
are,2594,O
currently,2594,O
in,2594,O
Phase,2594,O
III,2594,O
clinical,2594,O
trials,2594,O
;,2594,O
to,2594,O
date,2594,O
",",2594,O
only,2594,O
the,2594,O
mixed,2594,O
V,2594,B-GENE-Y
(,2594,I-GENE-Y
2,2594,I-GENE-Y
),2594,I-GENE-Y
/V,2594,O
(,2594,I-GENE-Y
1a,2594,I-GENE-Y
),2594,I-GENE-Y
",",2594,O
antagonist,2594,O
Conivaptan,2594,B-CHEMICAL
(,2594,O
Vaprisol,2594,B-CHEMICAL
),2594,O
",",2594,O
has,2594,O
been,2594,O
approved,2594,O
by,2594,O
the,2594,O
US,2594,O
FDA,2594,O
for,2594,O
clinical,2594,O
use,2594,O
(,2594,O
by,2594,O
i.v,2594,O
.,2594,O
administration,2595,O
),2595,O
",",2595,O
for,2595,O
the,2595,O
treatment,2595,O
of,2595,O
euvolemic,2595,O
and,2595,O
hypervolemic,2595,O
hyponatremia,2595,O
in,2595,O
hospitalized,2595,O
patients,2595,O
.,2595,O
Promising,2596,O
new,2596,O
non-peptide,2596,O
V,2596,B-GENE-Y
(,2596,I-GENE-Y
1b,2596,I-GENE-Y
),2596,I-GENE-Y
and,2596,O
OT,2596,B-GENE-Y
antagonists,2596,O
",",2596,O
as,2596,O
well,2596,O
as,2596,O
non-peptide,2596,O
V,2596,B-GENE-Y
(,2596,I-GENE-Y
2,2596,I-GENE-Y
),2596,I-GENE-Y
and,2596,O
OT,2596,B-GENE-Y
agonists,2596,O
are,2596,O
now,2596,O
in,2596,O
pre-clinical,2596,O
development,2596,O
.,2596,O
Mechanisms,2597,O
of,2597,O
lipid-lowering,2597,O
agents,2597,O
.,2597,O
Lipid-lowering,2598,O
agents,2598,O
are,2598,O
used,2598,O
with,2598,O
the,2598,O
purpose,2598,O
of,2598,O
ameliorating,2598,O
hyperlipoproteinemias,2598,O
",",2598,O
in,2598,O
order,2598,O
to,2598,O
prevent,2598,O
arterial,2598,O
disease,2598,O
.,2598,O
Lipid-lowering,2599,O
drugs,2599,O
can,2599,O
be,2599,O
classified,2599,O
into,2599,O
absorbable,2599,O
agents,2599,O
and,2599,O
into,2599,O
nonabsorbable,2599,O
compounds,2599,O
",",2599,O
acting,2599,O
within,2599,O
the,2599,O
gastrointestinal,2599,O
lumen,2599,O
.,2599,O
Absorbable,2600,O
drugs,2600,O
(,2600,O
fibric,2600,B-CHEMICAL
acids,2600,I-CHEMICAL
",",2600,O
nicotinic,2600,B-CHEMICAL
acid,2600,I-CHEMICAL
",",2600,O
probucol,2600,B-CHEMICAL
",",2600,O
HMG-CoA,2600,B-CHEMICAL
reductase,2600,I-GENE-Y
inhibitors,2600,O
),2600,O
reduce,2600,O
plasma,2600,B-GENE-N
very-low-density,2600,I-GENE-N
lipoproteins,2600,I-GENE-N
(,2600,O
VLDL,2600,B-GENE-N
),2600,O
and/or,2600,O
low-density,2600,B-GENE-N
lipoproteins,2600,I-GENE-N
(,2600,O
LDL,2600,B-GENE-N
),2600,O
by,2600,O
a,2600,O
variety,2600,O
of,2600,O
mechanisms,2600,O
.,2600,O
Fibric,2601,B-CHEMICAL
acids,2601,I-CHEMICAL
",",2601,O
in,2601,O
particular,2601,O
",",2601,O
act,2601,O
by,2601,O
stimulating,2601,O
the,2601,O
catabolism,2601,O
of,2601,O
VLDL,2601,B-GENE-N
and,2601,O
also,2601,O
",",2601,O
as,2601,O
a,2601,O
consequence,2601,O
",",2601,O
improving,2601,O
LDL,2601,B-GENE-N
delipidation,2601,O
",",2601,O
thus,2601,O
favoring,2601,O
receptor,2601,O
uptake,2601,O
.,2601,O
Nicotinic,2602,B-CHEMICAL
acid,2602,I-CHEMICAL
and,2602,O
acipimox,2602,O
interfere,2602,O
with,2602,O
the,2602,O
biosynthesis,2602,O
of,2602,O
LDL,2602,B-GENE-N
and,2602,O
can,2602,O
also,2602,O
improve,2602,O
the,2602,O
clearance,2602,O
of,2602,O
VLDL/LDL,2602,B-GENE-N
.,2602,O
Probucol,2603,B-CHEMICAL
acts,2603,O
by,2603,O
a,2603,O
newly,2603,O
described,2603,O
mechanism,2603,O
",",2603,O
i.e,2603,O
.,2603,O
accelerating,2604,O
reverse,2604,O
transport,2604,O
of,2604,O
cholesteryl,2604,B-CHEMICAL
esters,2604,I-CHEMICAL
from,2604,O
high-density,2604,B-GENE-N
lipoproteins,2604,I-GENE-N
to,2604,O
lower-density,2604,B-GENE-N
lipoproteins,2604,I-GENE-N
.,2604,O
Finally,2605,O
",",2605,O
HMG-CoA,2605,B-GENE-Y
reductase,2605,I-GENE-Y
inhibitors,2605,O
",",2605,O
interfering,2605,O
with,2605,O
the,2605,O
biosynthesis,2605,O
of,2605,O
cholesterol,2605,B-CHEMICAL
",",2605,O
can,2605,O
induce,2605,O
an,2605,O
increased,2605,O
expression,2605,O
of,2605,O
liver,2605,O
high-affinity,2605,O
lipoprotein,2605,B-GENE-N
receptors,2605,I-GENE-N
.,2605,O
Nonabsorbable,2606,O
agents,2606,O
(,2606,O
anion-exchange,2606,O
resins,2606,O
",",2606,O
neomycin,2606,B-CHEMICAL
",",2606,O
beta-sitosterol,2606,B-CHEMICAL
),2606,O
interrupt,2606,O
the,2606,O
recirculation,2606,O
of,2606,O
bile,2606,B-CHEMICAL
acids,2606,I-CHEMICAL
and/or,2606,O
reduce,2606,O
the,2606,O
absorption,2606,O
of,2606,O
cholesterol,2606,B-CHEMICAL
with,2606,O
the,2606,O
gut,2606,O
.,2606,O
They,2607,O
display,2607,O
a,2607,O
selective,2607,O
activity,2607,O
on,2607,O
hypercholesterolemia,2607,O
",",2607,O
again,2607,O
by,2607,O
increasing,2607,O
LDL,2607,B-GENE-N
receptor,2607,I-GENE-N
expression,2607,O
.,2607,O
The,2608,O
choice,2608,O
of,2608,O
one,2608,O
or,2608,O
more,2608,O
lipid-lowering,2608,O
agents,2608,O
will,2608,O
depend,2608,O
upon,2608,O
the,2608,O
patient,2608,O
's,2608,O
phenotype,2608,O
",",2608,O
determining,2608,O
responsiveness,2608,O
to,2608,O
the,2608,O
pharmacological,2608,O
treatment,2608,O
.,2608,O
Lapatinib,2609,B-CHEMICAL
:,2609,O
a,2609,O
dual,2609,O
inhibitor,2609,O
of,2609,O
human,2609,B-GENE-Y
epidermal,2609,I-GENE-Y
growth,2609,I-GENE-Y
factor,2609,I-GENE-Y
receptor,2609,I-GENE-Y
tyrosine,2609,B-GENE-N
kinases,2609,I-GENE-N
.,2609,O
BACKGROUND,2610,O
:,2610,O
Lapatinib,2610,B-CHEMICAL
",",2610,O
the,2610,O
first,2610,O
dual,2610,O
inhibitor,2610,O
of,2610,O
epidermal,2610,B-GENE-Y
growth,2610,I-GENE-Y
factor,2610,I-GENE-Y
receptor,2610,I-GENE-Y
(,2610,O
EGFR,2610,B-GENE-Y
),2610,O
and,2610,O
human,2610,B-GENE-Y
epidermal,2610,I-GENE-Y
growth,2610,I-GENE-Y
factor,2610,I-GENE-Y
receptor,2610,I-GENE-Y
2,2610,I-GENE-Y
(,2610,O
HER2,2610,B-GENE-Y
),2610,O
tyrosine,2610,B-CHEMICAL
kinases,2610,I-GENE-N
",",2610,O
was,2610,O
approved,2610,O
by,2610,O
the,2610,O
US,2610,O
Food,2610,O
and,2610,O
Drug,2610,O
Administration,2610,O
(,2610,O
FDA,2610,O
),2610,O
in,2610,O
2007,2610,O
.,2610,O
It,2611,O
is,2611,O
indicated,2611,O
for,2611,O
use,2611,O
in,2611,O
combination,2611,O
with,2611,O
capecitabine,2611,B-CHEMICAL
for,2611,O
the,2611,O
treatment,2611,O
of,2611,O
patients,2611,O
with,2611,O
advanced,2611,O
breast,2611,O
cancer,2611,O
or,2611,O
metastatic,2611,O
breast,2611,O
cancer,2611,O
(,2611,O
MBC,2611,O
),2611,O
whose,2611,O
tumors,2611,O
overexpress,2611,O
HER2,2611,B-GENE-Y
(,2611,O
ErbB2,2611,B-GENE-Y
),2611,O
and,2611,O
who,2611,O
have,2611,O
received,2611,O
previous,2611,O
treatment,2611,O
that,2611,O
included,2611,O
an,2611,O
anthracycline,2611,B-CHEMICAL
",",2611,O
a,2611,O
taxane,2611,B-CHEMICAL
",",2611,O
and,2611,O
trastuzumab,2611,O
.,2611,O
OBJECTIVE,2612,O
:,2612,O
This,2612,O
review,2612,O
summarizes,2612,O
the,2612,O
pharmacology,2612,O
",",2612,O
pharmacokinetics,2612,O
",",2612,O
clinical,2612,O
efficacy,2612,O
",",2612,O
and,2612,O
safety,2612,O
profile,2612,O
of,2612,O
lapatinib,2612,B-CHEMICAL
",",2612,O
and,2612,O
its,2612,O
current,2612,O
and,2612,O
potential,2612,O
role,2612,O
in,2612,O
the,2612,O
treatment,2612,O
of,2612,O
breast,2612,O
cancer,2612,O
and,2612,O
other,2612,O
malignancies,2612,O
.,2612,O
METHODS,2613,O
:,2613,O
Relevant,2613,O
English-language,2613,O
publications,2613,O
were,2613,O
identified,2613,O
through,2613,O
searches,2613,O
of,2613,O
MEDLINE,2613,O
(,2613,O
1966-May,2613,O
2008,2613,O
),2613,O
",",2613,O
the,2613,O
American,2613,O
Society,2613,O
of,2613,O
Clinical,2613,O
Oncology,2613,O
abstracts,2613,O
database,2613,O
(,2613,O
2000-2007,2613,O
),2613,O
",",2613,O
abstracts,2613,O
from,2613,O
the,2613,O
San,2613,O
Antonio,2613,O
Breast,2613,O
Cancer,2613,O
Symposium,2613,O
(,2613,O
2005-2007,2613,O
),2613,O
",",2613,O
and,2613,O
the,2613,O
FDA,2613,O
Web,2613,O
site,2613,O
(,2613,O
January,2613,O
2008,2613,O
),2613,O
.,2613,O
Search,2614,O
terms,2614,O
included,2614,O
lapatinib,2614,B-CHEMICAL
",",2614,O
GW572016,2614,B-CHEMICAL
",",2614,O
HER2,2614,B-GENE-Y
",",2614,O
EGFR,2614,B-GENE-Y
",",2614,O
receptor,2614,B-GENE-N
tyrosine,2614,B-CHEMICAL
kinase,2614,I-GENE-N
",",2614,O
dual-receptor,2614,O
blockade,2614,O
",",2614,O
adverse,2614,O
events,2614,O
",",2614,O
and,2614,O
clinical,2614,O
trials,2614,O
.,2614,O
RESULTS,2615,O
:,2615,O
The,2615,O
T,2615,O
(,2615,O
max,2615,O
),2615,O
of,2615,O
lapatinib,2615,B-CHEMICAL
after,2615,O
oral,2615,O
administration,2615,O
is,2615,O
3,2615,O
to,2615,O
4,2615,O
hours,2615,O
.,2615,O
Dividing,2616,O
the,2616,O
dose,2616,O
or,2616,O
administering,2616,O
it,2616,O
with,2616,O
food,2616,O
",",2616,O
particularly,2616,O
a,2616,O
high-fat,2616,O
meal,2616,O
",",2616,O
increases,2616,O
the,2616,O
AUC,2616,O
>,2616,O
2-fold,2616,O
.,2616,O
Lapatinib,2617,B-CHEMICAL
is,2617,O
metabolized,2617,O
primarily,2617,O
by,2617,O
the,2617,O
cytochrome,2617,B-GENE-Y
P450,2617,I-GENE-Y
3A4,2617,I-GENE-Y
isozyme,2617,O
",",2617,O
with,2617,O
1,2617,O
metabolite,2617,O
remaining,2617,O
active,2617,O
against,2617,O
EGFR,2617,B-GENE-Y
but,2617,O
not,2617,O
HER2,2617,B-GENE-Y
.,2617,O
Due,2618,O
to,2618,O
drug,2618,O
accumulation,2618,O
",",2618,O
the,2618,O
t,2618,O
(,2618,O
1/2,2618,O
),2618,O
of,2618,O
lapatinib,2618,B-CHEMICAL
is,2618,O
24,2618,O
hours,2618,O
with,2618,O
continuous,2618,O
dosing,2618,O
.,2618,O
In,2619,O
a,2619,O
Phase,2619,O
III,2619,O
trial,2619,O
comparing,2619,O
lapatinib,2619,B-CHEMICAL
and,2619,O
capecitabine,2619,B-CHEMICAL
with,2619,O
capecitabine,2619,B-CHEMICAL
alone,2619,O
in,2619,O
women,2619,O
with,2619,O
HER2-positive,2619,B-GENE-Y
",",2619,O
locally,2619,O
advanced,2619,O
breast,2619,O
cancer,2619,O
or,2619,O
MBC,2619,O
that,2619,O
had,2619,O
progressed,2619,O
after,2619,O
treatment,2619,O
with,2619,O
an,2619,O
anthracycline,2619,B-CHEMICAL
",",2619,O
a,2619,O
taxane,2619,B-CHEMICAL
",",2619,O
and,2619,O
trastuzumab,2619,O
",",2619,O
the,2619,O
combination,2619,O
of,2619,O
lapatinib,2619,B-CHEMICAL
and,2619,O
capecitabine,2619,B-CHEMICAL
was,2619,O
associated,2619,O
with,2619,O
a,2619,O
numeric,2619,O
improvement,2619,O
in,2619,O
response,2619,O
rate,2619,O
compared,2619,O
with,2619,O
capecitabine,2619,B-CHEMICAL
alone,2619,O
(,2619,O
22,2619,O
%,2619,O
vs,2619,O
14,2619,O
%,2619,O
",",2619,O
respectively,2619,O
;,2619,O
P,2619,O
=,2619,O
NS,2619,O
),2619,O
and,2619,O
a,2619,O
significant,2619,O
increase,2619,O
in,2619,O
time,2619,O
to,2619,O
progression,2619,O
(,2619,O
6.2,2619,O
vs,2619,O
4.3,2619,O
months,2619,O
;,2619,O
hazard,2619,O
ratio,2619,O
=,2619,O
0.57,2619,O
;,2619,O
95,2619,O
%,2619,O
CI,2619,O
",",2619,O
0.43-0.77,2619,O
;,2619,O
P,2619,O
<,2619,O
0.001,2619,O
),2619,O
.,2619,O
Lapatinib,2620,B-CHEMICAL
has,2620,O
been,2620,O
reported,2620,O
to,2620,O
have,2620,O
antitumor,2620,O
activity,2620,O
in,2620,O
Phase,2620,O
II,2620,O
trials,2620,O
when,2620,O
used,2620,O
as,2620,O
first-line,2620,O
therapy,2620,O
for,2620,O
MBC,2620,O
",",2620,O
in,2620,O
patients,2620,O
with,2620,O
inflammatory,2620,O
breast,2620,O
cancer,2620,O
",",2620,O
and,2620,O
in,2620,O
patients,2620,O
with,2620,O
central,2620,O
nervous,2620,O
system,2620,O
metastases,2620,O
.,2620,O
Phase,2621,O
II,2621,O
trials,2621,O
in,2621,O
other,2621,O
solid,2621,O
tumor,2621,O
types,2621,O
found,2621,O
modest,2621,O
activity,2621,O
.,2621,O
The,2622,O
approved,2622,O
dosing,2622,O
of,2622,O
lapatinib,2622,B-CHEMICAL
is,2622,O
"1,250",2622,O
mg,2622,O
PO,2622,O
QD,2622,O
given,2622,O
continuously,2622,O
in,2622,O
combination,2622,O
with,2622,O
capecitabine,2622,B-CHEMICAL
"2,000",2622,O
mg/m,2622,O
(,2622,O
2,2622,O
),2622,O
daily,2622,O
administered,2622,O
in,2622,O
2,2622,O
divided,2622,O
doses,2622,O
on,2622,O
days,2622,O
1,2622,O
to,2622,O
14,2622,O
of,2622,O
a,2622,O
21-day,2622,O
cycle,2622,O
.,2622,O
The,2623,O
most,2623,O
common,2623,O
clinical,2623,O
toxicities,2623,O
of,2623,O
all,2623,O
grades,2623,O
associated,2623,O
with,2623,O
lapatinib,2623,B-CHEMICAL
used,2623,O
in,2623,O
combination,2623,O
with,2623,O
capecitabine,2623,B-CHEMICAL
in,2623,O
the,2623,O
pivotal,2623,O
clinical,2623,O
trial,2623,O
were,2623,O
diarrhea,2623,O
(,2623,O
65,2623,O
%,2623,O
),2623,O
",",2623,O
hand-foot,2623,O
syndrome,2623,O
(,2623,O
53,2623,O
%,2623,O
),2623,O
",",2623,O
nausea,2623,O
(,2623,O
44,2623,O
%,2623,O
),2623,O
",",2623,O
rash,2623,O
(,2623,O
29,2623,O
%,2623,O
),2623,O
",",2623,O
and,2623,O
fatigue,2623,O
(,2623,O
24,2623,O
%,2623,O
),2623,O
.,2623,O
Cardiac,2624,O
toxicity,2624,O
appears,2624,O
to,2624,O
be,2624,O
less,2624,O
frequent,2624,O
with,2624,O
lapatinib,2624,B-CHEMICAL
than,2624,O
with,2624,O
trastuzumab,2624,O
.,2624,O
CONCLUSIONS,2625,O
:,2625,O
Lapatinib,2625,B-CHEMICAL
is,2625,O
a,2625,O
dual,2625,O
inhibitor,2625,O
of,2625,O
the,2625,O
EGFR,2625,B-GENE-Y
and,2625,O
HER2,2625,B-GENE-Y
tyrosine,2625,B-GENE-N
kinases,2625,I-GENE-N
.,2625,O
It,2626,O
is,2626,O
approved,2626,O
by,2626,O
the,2626,O
FDA,2626,O
for,2626,O
use,2626,O
in,2626,O
combination,2626,O
with,2626,O
capecitabine,2626,B-CHEMICAL
for,2626,O
the,2626,O
treatment,2626,O
of,2626,O
HER2-positive,2626,B-GENE-Y
MBC,2626,O
that,2626,O
has,2626,O
progressed,2626,O
with,2626,O
standard,2626,O
treatment,2626,O
.,2626,O
In,2627,O
clinical,2627,O
trials,2627,O
",",2627,O
this,2627,O
combination,2627,O
was,2627,O
associated,2627,O
with,2627,O
a,2627,O
significant,2627,O
improvement,2627,O
in,2627,O
the,2627,O
time,2627,O
to,2627,O
progression,2627,O
in,2627,O
patients,2627,O
with,2627,O
MBC,2627,O
.,2627,O
Lapatinib,2628,O
's,2628,O
efficacy,2628,O
in,2628,O
other,2628,O
malignancies,2628,O
that,2628,O
overexpress,2628,O
EGFR,2628,B-GENE-Y
and/or,2628,O
HER2,2628,B-GENE-Y
is,2628,O
under,2628,O
evaluation,2628,O
.,2628,O
N2-acetylphenelzine,2629,B-CHEMICAL
:,2629,O
effects,2629,O
on,2629,O
rat,2629,O
brain,2629,O
GABA,2629,B-CHEMICAL
",",2629,O
alanine,2629,B-CHEMICAL
and,2629,O
biogenic,2629,O
amines,2629,B-CHEMICAL
.,2629,O
The,2630,O
neurochemical,2630,O
properties,2630,O
of,2630,O
N2-acetylphenelzine,2630,B-CHEMICAL
were,2630,O
compared,2630,O
with,2630,O
those,2630,O
of,2630,O
phenelzine,2630,B-CHEMICAL
in,2630,O
a,2630,O
rat,2630,O
model,2630,O
.,2630,O
N2-Acetylphenelzine,2631,B-CHEMICAL
is,2631,O
a,2631,O
relatively,2631,O
potent,2631,O
inhibitor,2631,O
of,2631,O
monoamine,2631,B-CHEMICAL
oxidase-A,2631,I-GENE-N
and,2631,I-GENE-N
-B,2631,I-GENE-N
and,2631,O
causes,2631,O
increases,2631,O
in,2631,O
whole-brain,2631,O
levels,2631,O
of,2631,O
noradrenaline,2631,B-CHEMICAL
and,2631,O
5-hydroxytryptamine,2631,B-CHEMICAL
",",2631,O
and,2631,O
decreases,2631,O
in,2631,O
homovanillic,2631,B-CHEMICAL
acid,2631,I-CHEMICAL
",",2631,O
5-hydroxyindole-3-acetic,2631,B-CHEMICAL
acid,2631,I-CHEMICAL
",",2631,O
and,2631,O
"3,4-dihydroxyphenylacetic",2631,B-CHEMICAL
acetic,2631,I-CHEMICAL
after,2631,O
acute,2631,O
i.p,2631,O
.,2631,O
administration,2632,O
of,2632,O
the,2632,O
drug,2632,O
.,2632,O
Phenelzine,2633,B-CHEMICAL
is,2633,O
a,2633,O
more,2633,O
potent,2633,O
monoamine,2633,B-GENE-N
oxidase,2633,I-GENE-N
inhibitor,2633,O
than,2633,O
is,2633,O
N2-acetylphenelzine,2633,B-CHEMICAL
.,2633,O
The,2634,O
most,2634,O
marked,2634,O
difference,2634,O
in,2634,O
the,2634,O
profile,2634,O
was,2634,O
that,2634,O
N2-acetylphenelzine,2634,B-CHEMICAL
had,2634,O
no,2634,O
effect,2634,O
on,2634,O
whole,2634,O
brain,2634,O
levels,2634,O
of,2634,O
the,2634,O
amino,2634,B-CHEMICAL
acid,2634,I-CHEMICAL
neurotransmitters,2634,O
alanine,2634,B-CHEMICAL
and,2634,O
gamma-aminobutyric,2634,B-CHEMICAL
acid,2634,I-CHEMICAL
",",2634,O
whereas,2634,O
phenelzine,2634,B-CHEMICAL
caused,2634,O
dramatic,2634,O
increases,2634,O
.,2634,O
Acetylation,2635,O
of,2635,O
phenelzine,2635,B-CHEMICAL
at,2635,O
the,2635,O
N2,2635,B-CHEMICAL
position,2635,O
presumably,2635,O
interferes,2635,O
with,2635,O
the,2635,O
inhibition,2635,O
of,2635,O
the,2635,O
transaminase,2635,B-GENE-N
enzymes,2635,O
for,2635,O
gamma-aminobutyric,2635,B-CHEMICAL
acid,2635,I-CHEMICAL
and,2635,O
alanine,2635,B-CHEMICAL
.,2635,O
Dopamine,2636,B-GENE-Y
D3,2636,I-GENE-Y
receptor-preferring,2636,O
agonists,2636,O
increase,2636,O
dendrite,2636,O
arborization,2636,O
of,2636,O
mesencephalic,2636,O
dopaminergic,2636,O
neurons,2636,O
via,2636,O
extracellular,2636,B-GENE-N
signal-regulated,2636,I-GENE-N
kinase,2636,I-GENE-N
phosphorylation,2636,O
.,2636,O
Clinical,2637,O
improvements,2637,O
in,2637,O
Parkinson,2637,O
's,2637,O
disease,2637,O
produced,2637,O
by,2637,O
dopamine,2637,B-GENE-Y
D3,2637,I-GENE-Y
receptor-preferring,2637,O
agonists,2637,O
have,2637,O
been,2637,O
related,2637,O
to,2637,O
their,2637,O
neuroprotective,2637,O
actions,2637,O
and,2637,O
",",2637,O
more,2637,O
recently,2637,O
",",2637,O
to,2637,O
their,2637,O
neuroregenerative,2637,O
properties,2637,O
.,2637,O
However,2638,O
",",2638,O
it,2638,O
is,2638,O
unclear,2638,O
whether,2638,O
dopamine,2638,B-CHEMICAL
agonists,2638,O
produce,2638,O
their,2638,O
neurotrophic,2638,O
effects,2638,O
by,2638,O
acting,2638,O
directly,2638,O
on,2638,O
receptors,2638,O
expressed,2638,O
by,2638,O
the,2638,O
mesencephalic,2638,O
dopaminergic,2638,O
neurons,2638,O
or,2638,O
indirectly,2638,O
on,2638,O
receptors,2638,O
expressed,2638,O
by,2638,O
astrocytes,2638,O
",",2638,O
via,2638,O
release,2638,O
of,2638,O
neurotrophic,2638,B-GENE-N
factors,2638,I-GENE-N
.,2638,O
In,2639,O
this,2639,O
study,2639,O
",",2639,O
we,2639,O
investigated,2639,O
the,2639,O
effects,2639,O
of,2639,O
the,2639,O
dopamine,2639,B-GENE-Y
D3,2639,I-GENE-Y
receptor-preferring,2639,O
agonists,2639,O
quinpirole,2639,B-CHEMICAL
and,2639,O
7-hydroxy-N,2639,B-CHEMICAL
",",2639,I-CHEMICAL
N-di-propyl-2-aminotetralin,2639,I-CHEMICAL
(,2639,O
7-OH-DPAT,2639,B-CHEMICAL
),2639,O
",",2639,O
as,2639,O
well,2639,O
as,2639,O
of,2639,O
the,2639,O
indirect,2639,O
agonist,2639,O
amphetamine,2639,B-CHEMICAL
",",2639,O
on,2639,O
dopaminergic,2639,O
neurons,2639,O
identified,2639,O
by,2639,O
tyrosine,2639,B-GENE-Y
hydroxylase,2639,I-GENE-Y
immunoreactivity,2639,O
(,2639,O
TH-IR,2639,B-GENE-Y
),2639,O
.,2639,O
Experiments,2640,O
were,2640,O
performed,2640,O
on,2640,O
neuronal-enriched,2640,O
primary,2640,O
cultures,2640,O
containing,2640,O
less,2640,O
than,2640,O
0.5,2640,O
%,2640,O
of,2640,O
astrocytes,2640,O
prepared,2640,O
from,2640,O
the,2640,O
mouse,2640,O
embryo,2640,O
mesencephalon,2640,O
.,2640,O
After,2641,O
3,2641,O
days,2641,O
of,2641,O
incubation,2641,O
",",2641,O
both,2641,O
quinpirole,2641,B-CHEMICAL
(,2641,O
1-10,2641,O
microm,2641,O
),2641,O
and,2641,O
7-OH-DPAT,2641,B-CHEMICAL
(,2641,O
5-500,2641,O
nm,2641,O
),2641,O
dose-dependently,2641,O
increased,2641,O
the,2641,O
maximal,2641,O
dendrite,2641,O
length,2641,O
(,2641,O
P,2641,O
<,2641,O
0.001,2641,O
),2641,O
",",2641,O
number,2641,O
of,2641,O
primary,2641,O
dendrites,2641,O
(,2641,O
P,2641,O
<,2641,O
0.01,2641,O
),2641,O
and,2641,O
[,2641,B-CHEMICAL
3H,2641,I-CHEMICAL
],2641,I-CHEMICAL
dopamine,2641,I-CHEMICAL
uptake,2641,O
(,2641,O
P,2641,O
<,2641,O
0.01,2641,O
),2641,O
of,2641,O
TH-IR-positive,2641,B-GENE-Y
mesencephalic,2641,O
neurons,2641,O
.,2641,O
Similar,2642,O
effects,2642,O
were,2642,O
observed,2642,O
with,2642,O
10,2642,O
microm,2642,O
amphetamine,2642,B-CHEMICAL
.,2642,O
All,2643,O
neurotrophic,2643,O
effects,2643,O
were,2643,O
blocked,2643,O
by,2643,O
the,2643,O
unselective,2643,O
D2/D3,2643,B-GENE-N
receptor,2643,I-GENE-N
antagonist,2643,O
sulpiride,2643,B-CHEMICAL
(,2643,O
5,2643,O
microm,2643,O
),2643,O
and,2643,O
by,2643,O
the,2643,O
selective,2643,O
D3,2643,B-GENE-Y
receptor,2643,I-GENE-Y
antagonist,2643,O
SB-277011-A,2643,B-CHEMICAL
at,2643,O
a,2643,O
low,2643,O
dose,2643,O
(,2643,O
50,2643,O
nm,2643,O
),2643,O
.,2643,O
Quinpirole,2644,B-CHEMICAL
and,2644,O
7-OH-DPAT,2644,B-CHEMICAL
also,2644,O
increased,2644,O
the,2644,O
phosphorylation,2644,O
of,2644,O
extracellular,2644,B-GENE-N
signal-regulated,2644,I-GENE-N
kinase,2644,I-GENE-N
(,2644,O
ERK,2644,B-GENE-N
),2644,O
within,2644,O
minutes,2644,O
",",2644,O
an,2644,O
effect,2644,O
blocked,2644,O
by,2644,O
pretreatment,2644,O
with,2644,O
SB-277011-A,2644,B-CHEMICAL
.,2644,O
Inhibition,2645,O
of,2645,O
the,2645,O
D2/D3,2645,B-GENE-N
receptor,2645,I-GENE-N
signalling,2645,O
pathway,2645,O
to,2645,O
ERK,2645,B-GENE-N
was,2645,O
obtained,2645,O
with,2645,O
PD98059,2645,B-CHEMICAL
",",2645,O
GF109203,2645,B-CHEMICAL
or,2645,O
LY294002,2645,B-CHEMICAL
",",2645,O
resulting,2645,O
in,2645,O
blockade,2645,O
of,2645,O
neurotrophic,2645,O
effects,2645,O
.,2645,O
These,2646,O
data,2646,O
suggest,2646,O
that,2646,O
dopamine,2646,B-CHEMICAL
agonists,2646,O
increase,2646,O
dendritic,2646,O
arborizations,2646,O
of,2646,O
mesencephalic,2646,O
dopaminergic,2646,O
neurons,2646,O
via,2646,O
a,2646,O
direct,2646,O
effect,2646,O
on,2646,O
D2/D3,2646,B-GENE-N
receptors,2646,I-GENE-N
",",2646,O
preferentially,2646,O
involving,2646,O
D3,2646,B-GENE-Y
receptor-dependent,2646,O
neurotransmission,2646,O
.,2646,O
Molecular,2647,O
pharmacology,2647,O
of,2647,O
human,2647,B-GENE-Y
Cav3.2,2647,I-GENE-Y
T-type,2647,B-GENE-N
Ca2+,2647,I-GENE-N
channels,2647,I-GENE-N
:,2647,O
block,2647,O
by,2647,O
antihypertensives,2647,O
",",2647,O
antiarrhythmics,2647,O
",",2647,O
and,2647,O
their,2647,O
analogs,2647,O
.,2647,O
Antihypertensive,2648,O
drugs,2648,O
of,2648,O
the,2648,O
``,2648,O
calcium,2648,B-CHEMICAL
channel,2648,I-GENE-N
blocker,2648,O
'',2648,O
or,2648,O
``,2648,O
calcium,2648,B-CHEMICAL
antagonist,2648,O
'',2648,O
class,2648,O
have,2648,O
been,2648,O
used,2648,O
to,2648,O
establish,2648,O
the,2648,O
physiological,2648,O
role,2648,O
of,2648,O
L-type,2648,B-GENE-N
Ca,2648,B-CHEMICAL
(,2648,I-CHEMICAL
2+,2648,I-CHEMICAL
),2648,I-CHEMICAL
channels,2648,I-GENE-N
in,2648,O
vascular,2648,O
smooth,2648,O
muscle,2648,O
.,2648,O
In,2649,O
contrast,2649,O
",",2649,O
there,2649,O
has,2649,O
been,2649,O
limited,2649,O
progress,2649,O
on,2649,O
the,2649,O
pharmacology,2649,O
T-type,2649,B-GENE-N
Ca,2649,B-CHEMICAL
(,2649,I-CHEMICAL
2+,2649,I-CHEMICAL
),2649,I-CHEMICAL
channels,2649,I-GENE-N
.,2649,O
T-type,2650,B-GENE-N
channels,2650,I-GENE-N
play,2650,O
a,2650,O
role,2650,O
in,2650,O
cardiac,2650,O
pacemaking,2650,O
",",2650,O
aldosterone,2650,B-CHEMICAL
secretion,2650,O
",",2650,O
and,2650,O
renal,2650,O
hemodynamics,2650,O
",",2650,O
leading,2650,O
to,2650,O
the,2650,O
hypothesis,2650,O
that,2650,O
mixed,2650,O
T-,2650,O
and,2650,O
L-type,2650,O
blockers,2650,O
may,2650,O
have,2650,O
therapeutic,2650,O
advantages,2650,O
over,2650,O
selective,2650,O
L-type,2650,O
blockers,2650,O
.,2650,O
The,2651,O
goal,2651,O
of,2651,O
this,2651,O
study,2651,O
was,2651,O
to,2651,O
identify,2651,O
compounds,2651,O
that,2651,O
block,2651,O
the,2651,O
Ca,2651,B-GENE-Y
(,2651,I-GENE-Y
v,2651,I-GENE-Y
),2651,I-GENE-Y
3.2,2651,I-GENE-Y
T-type,2651,B-GENE-N
channel,2651,I-GENE-N
with,2651,O
high,2651,O
affinity,2651,O
",",2651,O
focusing,2651,O
on,2651,O
two,2651,O
classes,2651,O
of,2651,O
compounds,2651,O
:,2651,O
phenylalkylamines,2651,B-CHEMICAL
(,2651,O
e.g.,2651,O
",",2651,O
mibefradil,2651,B-CHEMICAL
),2651,O
and,2651,O
dihydropyridines,2651,B-CHEMICAL
(,2651,O
e.g.,2651,O
",",2651,O
efonidipine,2651,B-CHEMICAL
),2651,O
.,2651,O
Compounds,2652,O
were,2652,O
tested,2652,O
using,2652,O
a,2652,O
validated,2652,O
Ca,2652,B-CHEMICAL
(,2652,I-CHEMICAL
2+,2652,I-CHEMICAL
),2652,I-CHEMICAL
influx,2652,O
assay,2652,O
into,2652,O
a,2652,O
cell,2652,O
line,2652,O
expressing,2652,O
recombinant,2652,O
Ca,2652,B-GENE-Y
(,2652,I-GENE-Y
v,2652,I-GENE-Y
),2652,I-GENE-Y
3.2,2652,I-GENE-Y
channels,2652,O
.,2652,O
This,2653,O
study,2653,O
identified,2653,O
four,2653,O
clinically,2653,O
approved,2653,O
antihypertensive,2653,O
drugs,2653,O
(,2653,O
efonidipine,2653,B-CHEMICAL
",",2653,O
felodipine,2653,B-CHEMICAL
",",2653,O
isradipine,2653,B-CHEMICAL
",",2653,O
and,2653,O
nitrendipine,2653,B-CHEMICAL
),2653,O
as,2653,O
potent,2653,O
T-channel,2653,B-GENE-N
blockers,2653,O
(,2653,O
IC,2653,O
(,2653,O
50,2653,O
),2653,O
<,2653,O
3,2653,O
microM,2653,O
),2653,O
.,2653,O
In,2654,O
contrast,2654,O
",",2654,O
other,2654,O
widely,2654,O
prescribed,2654,O
dihydropyridines,2654,B-CHEMICAL
",",2654,O
such,2654,O
as,2654,O
amlodipine,2654,B-CHEMICAL
and,2654,O
nifedipine,2654,B-CHEMICAL
",",2654,O
were,2654,O
10-fold,2654,O
less,2654,O
potent,2654,O
",",2654,O
making,2654,O
them,2654,O
a,2654,O
more,2654,O
appropriate,2654,O
choice,2654,O
in,2654,O
research,2654,O
studies,2654,O
on,2654,O
the,2654,O
role,2654,O
of,2654,O
L-type,2654,O
currents,2654,O
.,2654,O
In,2655,O
summary,2655,O
",",2655,O
the,2655,O
present,2655,O
results,2655,O
support,2655,O
the,2655,O
notion,2655,O
that,2655,O
many,2655,O
available,2655,O
antihypertensive,2655,O
drugs,2655,O
block,2655,O
a,2655,O
substantial,2655,O
fraction,2655,O
of,2655,O
T-current,2655,O
at,2655,O
therapeutically,2655,O
relevant,2655,O
concentrations,2655,O
",",2655,O
contributing,2655,O
to,2655,O
their,2655,O
mechanism,2655,O
of,2655,O
action,2655,O
.,2655,O
The,2656,O
role,2656,O
of,2656,O
combination,2656,O
medical,2656,O
therapy,2656,O
in,2656,O
benign,2656,O
prostatic,2656,O
hyperplasia,2656,O
.,2656,O
To,2657,O
review,2657,O
key,2657,O
trials,2657,O
of,2657,O
monotherapy,2657,O
and,2657,O
combination,2657,O
therapy,2657,O
of,2657,O
alpha,2657,B-GENE-N
(,2657,I-GENE-N
1,2657,I-GENE-N
),2657,I-GENE-N
-adrenergic,2657,I-GENE-N
receptor,2657,I-GENE-N
antagonists,2657,O
(,2657,O
alpha,2657,O
(,2657,O
1,2657,O
),2657,O
-ARAs,2657,O
),2657,O
",",2657,O
5alpha-reductase,2657,B-GENE-N
inhibitors,2657,O
(,2657,O
5alphaRIs,2657,O
),2657,O
and,2657,O
anti-muscarinic,2657,O
agents,2657,O
in,2657,O
the,2657,O
treatment,2657,O
of,2657,O
lower,2657,O
urinary,2657,O
tract,2657,O
symptoms,2657,O
(,2657,O
LUTS,2657,O
),2657,O
associated,2657,O
with,2657,O
benign,2657,O
prostatic,2657,O
hyperplasia,2657,O
(,2657,O
BPH,2657,O
),2657,O
.,2657,O
To,2658,O
assess,2658,O
the,2658,O
safety,2658,O
and,2658,O
efficacy,2658,O
of,2658,O
combination,2658,O
therapies,2658,O
for,2658,O
LUTS,2658,O
associated,2658,O
with,2658,O
BPH,2658,O
",",2658,O
a,2658,O
search,2658,O
of,2658,O
the,2658,O
MEDLINE,2658,O
and,2658,O
Cochrane,2658,O
databases,2658,O
(,2658,O
1976-2008,2658,O
),2658,O
was,2658,O
conducted,2658,O
for,2658,O
relevant,2658,O
trials,2658,O
and,2658,O
reviews,2658,O
using,2658,O
the,2658,O
terms,2658,O
benign,2658,O
prostatic,2658,O
hyperplasia,2658,O
",",2658,O
lower,2658,O
urinary,2658,O
tract,2658,O
symptoms,2658,O
",",2658,O
alpha,2658,B-GENE-N
(,2658,I-GENE-N
1,2658,I-GENE-N
),2658,I-GENE-N
-adrenergic,2658,I-GENE-N
receptor,2658,I-GENE-N
antagonists,2658,O
",",2658,O
5alpha-reductase,2658,B-GENE-N
inhibitors,2658,O
",",2658,O
anti-muscarinics,2658,O
",",2658,O
anticholinergics,2658,O
",",2658,O
combination,2658,O
therapy,2658,O
",",2658,O
alfuzosin,2658,B-CHEMICAL
",",2658,O
doxazosin,2658,B-CHEMICAL
",",2658,O
tamsulosin,2658,B-CHEMICAL
",",2658,O
terazosin,2658,B-CHEMICAL
",",2658,O
dutasteride,2658,B-CHEMICAL
",",2658,O
finasteride,2658,B-CHEMICAL
",",2658,O
tolterodine,2658,B-CHEMICAL
",",2658,O
flavoxate,2658,B-CHEMICAL
",",2658,O
propiverine,2658,B-CHEMICAL
",",2658,O
oxybutynin,2658,B-CHEMICAL
",",2658,O
erectile,2658,O
dysfunction,2658,O
",",2658,O
sildenafil,2658,B-CHEMICAL
",",2658,O
vardenafil,2658,B-CHEMICAL
and,2658,O
tadalafil,2658,B-CHEMICAL
.,2658,O
Data,2659,O
from,2659,O
the,2659,O
Medical,2659,O
Therapy,2659,O
of,2659,O
Prostatic,2659,O
Symptoms,2659,O
(,2659,O
MTOPS,2659,O
),2659,O
study,2659,O
indicated,2659,O
a,2659,O
role,2659,O
for,2659,O
long-term,2659,O
use,2659,O
of,2659,O
alpha,2659,O
(,2659,O
1,2659,O
),2659,O
-ARAs,2659,O
and,2659,O
5alphaRIs,2659,O
in,2659,O
combination,2659,O
.,2659,O
In,2660,O
the,2660,O
MTOPS,2660,O
study,2660,O
",",2660,O
combination,2660,O
therapy,2660,O
with,2660,O
the,2660,O
alpha,2660,O
(,2660,O
1,2660,O
),2660,O
-ARA,2660,O
doxazosin,2660,B-CHEMICAL
and,2660,O
the,2660,O
5alphaRI,2660,O
finasteride,2660,B-CHEMICAL
was,2660,O
significantly,2660,O
more,2660,O
effective,2660,O
than,2660,O
either,2660,O
component,2660,O
alone,2660,O
in,2660,O
reducing,2660,O
symptoms,2660,O
(,2660,O
P=0.006,2660,O
vs,2660,O
doxazosin,2660,B-CHEMICAL
monotherapy,2660,O
;,2660,O
P,2660,O
<,2660,O
0.001,2660,O
vs,2660,O
finasteride,2660,O
monotherapy,2660,O
),2660,O
and,2660,O
in,2660,O
lowering,2660,O
the,2660,O
rate,2660,O
of,2660,O
clinical,2660,O
progression,2660,O
(,2660,O
P,2660,O
<,2660,O
0.001,2660,O
vs,2660,O
either,2660,O
monotherapy,2660,O
),2660,O
.,2660,O
These,2661,O
findings,2661,O
were,2661,O
confirmed,2661,O
by,2661,O
the,2661,O
2-year,2661,O
preliminary,2661,O
results,2661,O
of,2661,O
the,2661,O
Combination,2661,O
of,2661,O
Avodart,2661,B-CHEMICAL
and,2661,O
Tamsulosin,2661,B-CHEMICAL
study,2661,O
.,2661,O
In,2662,O
this,2662,O
study,2662,O
",",2662,O
combination,2662,O
therapy,2662,O
of,2662,O
the,2662,O
alpha,2662,O
(,2662,O
1,2662,O
),2662,O
-ARA,2662,O
tamsulosin,2662,B-CHEMICAL
and,2662,O
the,2662,O
5alphaRI,2662,O
dutasteride,2662,B-CHEMICAL
resulted,2662,O
in,2662,O
a,2662,O
significantly,2662,O
greater,2662,O
decrease,2662,O
in,2662,O
International,2662,O
Prostate,2662,O
Symptom,2662,O
Score,2662,O
(,2662,O
IPSS,2662,O
),2662,O
when,2662,O
compared,2662,O
with,2662,O
either,2662,O
monotherapy,2662,O
.,2662,O
Several,2663,O
recent,2663,O
trials,2663,O
have,2663,O
studied,2663,O
the,2663,O
efficacy,2663,O
of,2663,O
combining,2663,O
alpha,2663,O
(,2663,O
1,2663,O
),2663,O
-ARAs,2663,O
and,2663,O
anti-muscarinic,2663,O
agents,2663,O
in,2663,O
the,2663,O
treatment,2663,O
of,2663,O
BPH,2663,O
.,2663,O
These,2664,O
studies,2664,O
have,2664,O
found,2664,O
this,2664,O
combination,2664,O
to,2664,O
result,2664,O
in,2664,O
statistically,2664,O
significant,2664,O
benefits,2664,O
in,2664,O
quality,2664,O
of,2664,O
life,2664,O
scores,2664,O
",",2664,O
patient,2664,O
satisfaction,2664,O
",",2664,O
urinary,2664,O
frequency,2664,O
",",2664,O
storage,2664,O
symptoms,2664,O
and,2664,O
IPSS,2664,O
scores,2664,O
.,2664,O
Studies,2665,O
have,2665,O
not,2665,O
shown,2665,O
an,2665,O
increased,2665,O
risk,2665,O
of,2665,O
urinary,2665,O
retention,2665,O
associated,2665,O
with,2665,O
the,2665,O
use,2665,O
of,2665,O
anti-muscarinics,2665,O
in,2665,O
a,2665,O
highly,2665,O
select,2665,O
cohort,2665,O
of,2665,O
men,2665,O
with,2665,O
BPH,2665,O
.,2665,O
The,2666,O
available,2666,O
data,2666,O
suggest,2666,O
that,2666,O
combination,2666,O
therapy,2666,O
can,2666,O
be,2666,O
beneficial,2666,O
in,2666,O
the,2666,O
treatment,2666,O
of,2666,O
BPH,2666,O
and,2666,O
associated,2666,O
LUTS,2666,O
.,2666,O
The,2667,O
greatest,2667,O
efficacy,2667,O
for,2667,O
the,2667,O
alpha,2667,O
(,2667,O
1,2667,O
),2667,O
-ARA,2667,O
and,2667,O
5alphaRI,2667,O
combination,2667,O
was,2667,O
shown,2667,O
in,2667,O
patients,2667,O
with,2667,O
larger,2667,O
prostate,2667,O
size,2667,O
and,2667,O
more,2667,O
severe,2667,O
symptoms,2667,O
.,2667,O
The,2668,O
combination,2668,O
of,2668,O
alpha,2668,O
(,2668,O
1,2668,O
),2668,O
-ARAs,2668,O
and,2668,O
5alphaRIs,2668,O
appears,2668,O
to,2668,O
prevent,2668,O
disease,2668,O
progression,2668,O
in,2668,O
these,2668,O
patients,2668,O
.,2668,O
The,2669,O
combination,2669,O
of,2669,O
alpha,2669,O
(,2669,O
1,2669,O
),2669,O
-ARAs,2669,O
with,2669,O
anti-muscarinic,2669,O
agents,2669,O
is,2669,O
useful,2669,O
for,2669,O
relieving,2669,O
symptoms,2669,O
of,2669,O
bladder,2669,O
outlet,2669,O
obstruction,2669,O
and,2669,O
detrusor,2669,O
overactivity,2669,O
.,2669,O
Theoretic,2670,O
concerns,2670,O
regarding,2670,O
the,2670,O
risk,2670,O
of,2670,O
acute,2670,O
urinary,2670,O
retention,2670,O
have,2670,O
been,2670,O
refuted,2670,O
in,2670,O
several,2670,O
recent,2670,O
clinical,2670,O
trials,2670,O
;,2670,O
however,2670,O
",",2670,O
it,2670,O
must,2670,O
be,2670,O
noted,2670,O
that,2670,O
the,2670,O
patients,2670,O
in,2670,O
these,2670,O
trials,2670,O
were,2670,O
a,2670,O
highly,2670,O
select,2670,O
cohort,2670,O
of,2670,O
men,2670,O
.,2670,O
Men,2671,O
with,2671,O
overactive,2671,O
bladder,2671,O
and,2671,O
BPH,2671,O
who,2671,O
are,2671,O
not,2671,O
receiving,2671,O
adequate,2671,O
alleviation,2671,O
of,2671,O
symptoms,2671,O
from,2671,O
the,2671,O
first-line,2671,O
alpha,2671,O
(,2671,O
1,2671,O
),2671,O
-ARAs,2671,O
may,2671,O
benefit,2671,O
from,2671,O
the,2671,O
addition,2671,O
of,2671,O
an,2671,O
anti-muscarinic,2671,O
agent,2671,O
.,2671,O
Pharmacological,2672,O
characterization,2672,O
of,2672,O
pannexin-1,2672,B-GENE-Y
currents,2672,O
expressed,2672,O
in,2672,O
mammalian,2672,O
cells,2672,O
.,2672,O
Pannexin,2673,B-GENE-Y
(,2673,I-GENE-Y
Panx,2673,I-GENE-Y
),2673,I-GENE-Y
1,2673,I-GENE-Y
is,2673,O
a,2673,O
widely,2673,O
expressed,2673,O
protein,2673,O
that,2673,O
shares,2673,O
structural,2673,O
",",2673,O
but,2673,O
not,2673,O
amino,2673,B-CHEMICAL
acid,2673,I-CHEMICAL
",",2673,O
homology,2673,O
with,2673,O
gap,2673,O
junction,2673,O
proteins,2673,O
",",2673,O
the,2673,O
connexins,2673,B-GENE-N
.,2673,O
Panx1,2674,B-GENE-Y
does,2674,O
not,2674,O
form,2674,O
gap,2674,O
junctions,2674,O
in,2674,O
mammalian,2674,O
cells,2674,O
",",2674,O
but,2674,O
it,2674,O
may,2674,O
function,2674,O
as,2674,O
a,2674,O
plasma,2674,B-GENE-N
membrane,2674,I-GENE-N
hemichannel,2674,I-GENE-N
.,2674,O
Little,2675,O
is,2675,O
known,2675,O
of,2675,O
the,2675,O
pharmacological,2675,O
properties,2675,O
of,2675,O
panx1,2675,B-GENE-Y
expression,2675,O
in,2675,O
mammalian,2675,O
cells,2675,O
.,2675,O
Here,2676,O
",",2676,O
we,2676,O
identify,2676,O
three,2676,O
variants,2676,O
in,2676,O
the,2676,O
human,2676,B-GENE-Y
PANX1,2676,I-GENE-Y
gene,2676,O
.,2676,O
We,2677,O
expressed,2677,O
these,2677,O
variants,2677,O
and,2677,O
mouse,2677,B-GENE-Y
Panx1,2677,I-GENE-Y
in,2677,O
mammalian,2677,O
cells,2677,O
and,2677,O
compared,2677,O
Panx1-induced,2677,B-GENE-Y
currents,2677,O
.,2677,O
All,2678,O
human,2678,B-GENE-Y
Panx1,2678,I-GENE-Y
variants,2678,O
and,2678,O
the,2678,O
mouse,2678,B-GENE-Y
Panx1,2678,I-GENE-Y
showed,2678,O
identical,2678,O
protein,2678,O
expression,2678,O
levels,2678,O
",",2678,O
localization,2678,O
patterns,2678,O
",",2678,O
and,2678,O
functional,2678,O
properties,2678,O
",",2678,O
although,2678,O
the,2678,O
frequency,2678,O
of,2678,O
functional,2678,O
expression,2678,O
was,2678,O
species-dependent,2678,O
.,2678,O
Panx1,2679,B-GENE-Y
currents,2679,O
were,2679,O
independent,2679,O
of,2679,O
changes,2679,O
in,2679,O
extracellular,2679,O
or,2679,O
intracellular,2679,O
calcium,2679,O
or,2679,O
phospholipase,2679,B-GENE-N
C,2679,I-GENE-N
transduction,2679,O
.,2679,O
We,2680,O
found,2680,O
compounds,2680,O
that,2680,O
inhibited,2680,O
Panx1,2680,B-GENE-Y
currents,2680,O
with,2680,O
a,2680,O
rank,2680,O
order,2680,O
of,2680,O
potency,2680,O
:,2680,O
carbenoxolone,2680,B-CHEMICAL
>,2680,O
disodium,2680,B-CHEMICAL
"4,4'-diisothiocyanatostilbene-2,2'-disulfonate",2680,I-CHEMICAL
(,2680,O
DIDS,2680,B-CHEMICAL
),2680,O
approximately,2680,O
disodium,2680,B-CHEMICAL
"4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate",2680,I-CHEMICAL
approximately,2680,O
5-nitro-2-,2680,B-CHEMICAL
(,2680,I-CHEMICAL
3-phenylpropylamino,2680,I-CHEMICAL
),2680,I-CHEMICAL
benzoic,2680,I-CHEMICAL
acid,2680,I-CHEMICAL
>,2680,O
indanyloxyacetic,2680,B-CHEMICAL
acid,2680,I-CHEMICAL
94,2680,I-CHEMICAL
>,2680,O
>,2680,O
probenecid,2680,B-CHEMICAL
>,2680,O
>,2680,O
flufenamic,2680,B-CHEMICAL
acid,2680,I-CHEMICAL
=,2680,O
niflumic,2680,B-CHEMICAL
acid,2680,I-CHEMICAL
.,2680,O
Triphosphate,2681,B-CHEMICAL
nucleotides,2681,I-CHEMICAL
(,2681,O
ATP,2681,B-CHEMICAL
",",2681,O
GTP,2681,B-CHEMICAL
",",2681,O
and,2681,O
UTP,2681,B-CHEMICAL
),2681,O
rapidly,2681,O
and,2681,O
reversibly,2681,O
inhibited,2681,O
Panx1,2681,B-GENE-Y
currents,2681,O
via,2681,O
mechanism,2681,O
(,2681,O
s,2681,O
),2681,O
independent,2681,O
of,2681,O
purine,2681,B-GENE-N
receptors,2681,I-GENE-N
.,2681,O
When,2682,O
Panx1,2682,B-GENE-Y
was,2682,O
coexpressed,2682,O
with,2682,O
purinergic,2682,B-GENE-Y
P2X,2682,I-GENE-Y
(,2682,I-GENE-Y
7,2682,I-GENE-Y
),2682,I-GENE-Y
receptor,2682,I-GENE-Y
(,2682,O
P2X,2682,B-GENE-Y
(,2682,I-GENE-Y
7,2682,I-GENE-Y
),2682,I-GENE-Y
R,2682,I-GENE-Y
),2682,O
",",2682,O
DIDS,2682,B-CHEMICAL
was,2682,O
found,2682,O
to,2682,O
act,2682,O
as,2682,O
a,2682,O
P2X,2682,B-GENE-Y
(,2682,I-GENE-Y
7,2682,I-GENE-Y
),2682,I-GENE-Y
R,2682,I-GENE-Y
antagonist,2682,O
to,2682,O
inhibit,2682,O
ATP-evoked,2682,B-CHEMICAL
currents,2682,O
",",2682,O
but,2682,O
none,2682,O
of,2682,O
the,2682,O
other,2682,O
compounds,2682,O
inhibited,2682,O
P2X,2682,B-GENE-Y
(,2682,I-GENE-Y
7,2682,I-GENE-Y
),2682,I-GENE-Y
R,2682,I-GENE-Y
currents,2682,O
.,2682,O
This,2683,O
is,2683,O
the,2683,O
first,2683,O
detailed,2683,O
pharmacological,2683,O
characterization,2683,O
of,2683,O
Panx1-mediated,2683,B-GENE-Y
currents,2683,O
in,2683,O
mammalian,2683,O
cells,2683,O
and,2683,O
sheds,2683,O
new,2683,O
",",2683,O
although,2683,O
contradictory,2683,O
",",2683,O
light,2683,O
on,2683,O
the,2683,O
hypothesis,2683,O
that,2683,O
Panx1,2683,B-GENE-Y
acts,2683,O
as,2683,O
a,2683,O
hemichannel,2683,O
to,2683,O
allow,2683,O
passage,2683,O
of,2683,O
large,2683,O
molecules,2683,O
in,2683,O
response,2683,O
to,2683,O
P2X,2683,B-GENE-Y
(,2683,I-GENE-Y
7,2683,I-GENE-Y
),2683,I-GENE-Y
R,2683,I-GENE-Y
activation,2683,O
.,2683,O
Captopril,2684,B-CHEMICAL
attenuates,2684,O
matrix,2684,B-GENE-N
metalloproteinase-2,2684,I-GENE-N
and,2684,I-GENE-N
-9,2684,I-GENE-N
in,2684,O
monocrotaline-induced,2684,B-CHEMICAL
right,2684,O
ventricular,2684,O
hypertrophy,2684,O
in,2684,O
rats,2684,O
.,2684,O
Little,2685,O
is,2685,O
known,2685,O
about,2685,O
the,2685,O
influence,2685,O
of,2685,O
angiotensin,2685,B-GENE-Y
converting,2685,I-GENE-Y
enzyme,2685,I-GENE-Y
(,2685,O
ACE,2685,B-GENE-Y
),2685,O
inhibitors,2685,O
on,2685,O
matrix,2685,B-GENE-N
metalloproteinase,2685,I-GENE-N
(,2685,O
MMP,2685,B-GENE-N
),2685,O
in,2685,O
right,2685,O
ventricular,2685,O
remodeling,2685,O
.,2685,O
We,2686,O
investigated,2686,O
the,2686,O
effect,2686,O
of,2686,O
captopril,2686,B-CHEMICAL
",",2686,O
an,2686,O
ACE,2686,B-GENE-Y
inhibitor,2686,O
",",2686,O
on,2686,O
MMP-2,2686,B-GENE-Y
and,2686,O
MMP-9,2686,B-GENE-Y
in,2686,O
monocrotaline-induced,2686,B-CHEMICAL
right,2686,O
ventricular,2686,O
hypertrophy,2686,O
.,2686,O
Six-week-old,2687,O
male,2687,O
Wistar,2687,O
rats,2687,O
were,2687,O
injected,2687,O
intraperitoneally,2687,O
with,2687,O
monocrotaline,2687,B-CHEMICAL
(,2687,O
60,2687,O
mg/kg,2687,O
),2687,O
or,2687,O
saline,2687,O
.,2687,O
The,2688,O
rats,2688,O
were,2688,O
administrated,2688,O
captopril,2688,B-CHEMICAL
(,2688,O
30,2688,O
mg/kg,2688,O
per,2688,O
day,2688,O
),2688,O
or,2688,O
a,2688,O
vehicle,2688,O
orally,2688,O
for,2688,O
24,2688,O
days,2688,O
from,2688,O
the,2688,O
day,2688,O
of,2688,O
monocrotaline,2688,B-CHEMICAL
injection,2688,O
.,2688,O
At,2689,O
day,2689,O
25,2689,O
",",2689,O
echocardiography,2689,O
was,2689,O
performed,2689,O
and,2689,O
hearts,2689,O
were,2689,O
excised,2689,O
.,2689,O
Expressions,2690,O
and,2690,O
activities,2690,O
of,2690,O
MMP-2,2690,B-GENE-Y
and,2690,O
MMP-9,2690,B-GENE-Y
were,2690,O
measured,2690,O
by,2690,O
Western,2690,O
blotting,2690,O
and,2690,O
by,2690,O
gelatin,2690,O
zymography,2690,O
",",2690,O
respectively,2690,O
.,2690,O
In,2691,O
monocrotaline-injected,2691,B-CHEMICAL
rats,2691,O
",",2691,O
right,2691,O
ventricular,2691,O
weight/tail,2691,O
length,2691,O
ratio,2691,O
increased,2691,O
significantly,2691,O
.,2691,O
Histological,2692,O
analysis,2692,O
revealed,2692,O
cardiomyocyte,2692,O
hypertrophy,2692,O
and,2692,O
fibrosis,2692,O
in,2692,O
right,2692,O
ventricular,2692,O
sections,2692,O
.,2692,O
Echocardiography,2693,O
showed,2693,O
right,2693,O
ventricular,2693,O
dysfunction,2693,O
compared,2693,O
with,2693,O
saline-injected,2693,O
rats,2693,O
.,2693,O
The,2694,O
right,2694,O
ventricular,2694,O
hypertrophy,2694,O
",",2694,O
fibrosis,2694,O
",",2694,O
and,2694,O
dysfunction,2694,O
were,2694,O
inhibited,2694,O
by,2694,O
captopril,2694,B-CHEMICAL
.,2694,O
However,2695,O
",",2695,O
captopril,2695,B-CHEMICAL
did,2695,O
not,2695,O
attenuate,2695,O
an,2695,O
increase,2695,O
in,2695,O
pulmonary,2695,O
artery,2695,O
pressure,2695,O
.,2695,O
MMP-2,2696,B-GENE-Y
and,2696,O
MMP-9,2696,B-GENE-Y
expressions,2696,O
and,2696,O
activities,2696,O
in,2696,O
right,2696,O
ventricles,2696,O
increased,2696,O
significantly,2696,O
in,2696,O
monocrotaline-injected,2696,B-CHEMICAL
rats,2696,O
and,2696,O
captopril,2696,B-CHEMICAL
inhibited,2696,O
them,2696,O
.,2696,O
These,2697,O
findings,2697,O
indicate,2697,O
that,2697,O
captopril,2697,B-CHEMICAL
attenuates,2697,O
the,2697,O
development,2697,O
of,2697,O
monocrotaline-induced,2697,B-CHEMICAL
right,2697,O
ventricular,2697,O
hypertrophy,2697,O
in,2697,O
association,2697,O
with,2697,O
inhibition,2697,O
of,2697,O
MMP-2,2697,B-GENE-Y
and,2697,O
MMP-9,2697,B-GENE-Y
in,2697,O
rats,2697,O
.,2697,O
Carbonic,2698,B-GENE-N
anhydrase,2698,I-GENE-N
inhibitors,2698,O
.,2698,O
Comparison,2699,O
of,2699,O
chlorthalidone,2699,B-CHEMICAL
",",2699,O
indapamide,2699,B-CHEMICAL
",",2699,O
trichloromethiazide,2699,B-CHEMICAL
",",2699,O
and,2699,O
furosemide,2699,B-CHEMICAL
X-ray,2699,O
crystal,2699,O
structures,2699,O
in,2699,O
adducts,2699,O
with,2699,O
isozyme,2699,O
II,2699,O
",",2699,O
when,2699,O
several,2699,O
water,2699,O
molecules,2699,O
make,2699,O
the,2699,O
difference,2699,O
.,2699,O
Thiazide,2700,B-CHEMICAL
and,2700,O
high,2700,O
ceiling,2700,O
diuretics,2700,O
were,2700,O
recently,2700,O
shown,2700,O
to,2700,O
inhibit,2700,O
all,2700,O
mammalian,2700,O
isoforms,2700,O
of,2700,O
carbonic,2700,B-GENE-N
anhydrase,2700,I-GENE-N
(,2700,O
CA,2700,B-GENE-N
",",2700,O
EC,2700,B-GENE-Y
4.2.1.1,2700,I-GENE-Y
),2700,O
with,2700,O
a,2700,O
very,2700,O
different,2700,O
profile,2700,O
as,2700,O
compared,2700,O
to,2700,O
classical,2700,O
inhibitors,2700,O
",",2700,O
such,2700,O
as,2700,O
acetazolamide,2700,B-CHEMICAL
",",2700,O
methazolamide,2700,B-CHEMICAL
",",2700,O
and,2700,O
ethoxzolamide,2700,B-CHEMICAL
.,2700,O
Some,2701,O
of,2701,O
these,2701,O
structurally,2701,O
related,2701,O
compounds,2701,O
have,2701,O
a,2701,O
very,2701,O
different,2701,O
behavior,2701,O
against,2701,O
the,2701,O
widespread,2701,O
isozyme,2701,O
CA,2701,B-GENE-Y
II,2701,I-GENE-Y
",",2701,O
with,2701,O
chlorthalidone,2701,B-CHEMICAL
",",2701,O
trichloromethiazide,2701,B-CHEMICAL
",",2701,O
and,2701,O
furosemide,2701,B-CHEMICAL
being,2701,O
efficient,2701,O
inhibitors,2701,O
against,2701,O
CA,2701,B-GENE-Y
II,2701,I-GENE-Y
(,2701,O
K,2701,O
(,2701,O
I,2701,O
),2701,O
s,2701,O
of,2701,O
65-138,2701,O
nM,2701,O
),2701,O
",",2701,O
whereas,2701,O
indapamide,2701,B-CHEMICAL
is,2701,O
a,2701,O
much,2701,O
weaker,2701,O
one,2701,O
(,2701,O
K,2701,O
(,2701,O
I,2701,O
),2701,O
of,2701,O
2520,2701,O
nM,2701,O
),2701,O
.,2701,O
Furthermore,2702,O
",",2702,O
some,2702,O
of,2702,O
these,2702,O
diuretics,2702,O
are,2702,O
quite,2702,O
efficient,2702,O
(,2702,O
low,2702,O
nanomolar,2702,O
),2702,O
inhibitors,2702,O
of,2702,O
other,2702,O
isoforms,2702,O
",",2702,O
for,2702,O
example,2702,O
",",2702,O
chlorthalidone,2702,B-CHEMICAL
against,2702,O
hCA,2702,B-GENE-N
VB,2702,I-GENE-N
",",2702,I-GENE-N
VII,2702,I-GENE-N
",",2702,I-GENE-N
IX,2702,I-GENE-N
",",2702,I-GENE-N
and,2702,I-GENE-N
XIII,2702,I-GENE-N
;,2702,O
indapamide,2702,B-CHEMICAL
against,2702,O
CA,2702,B-GENE-N
VII,2702,I-GENE-N
",",2702,I-GENE-N
IX,2702,I-GENE-N
",",2702,I-GENE-N
XII,2702,I-GENE-N
",",2702,I-GENE-N
and,2702,I-GENE-N
XIII,2702,I-GENE-N
",",2702,O
trichloromethiazide,2702,B-CHEMICAL
against,2702,O
CA,2702,B-GENE-N
VII,2702,I-GENE-N
and,2702,I-GENE-N
IX,2702,I-GENE-N
",",2702,O
and,2702,O
furosemide,2702,B-CHEMICAL
against,2702,O
CA,2702,B-GENE-N
I,2702,I-GENE-N
and,2702,I-GENE-N
XIV,2702,I-GENE-N
.,2702,O
Examining,2703,O
the,2703,O
four,2703,O
X-ray,2703,O
crystal,2703,O
structures,2703,O
of,2703,O
their,2703,O
CA,2703,B-GENE-Y
II,2703,I-GENE-Y
adducts,2703,O
",",2703,O
we,2703,O
observed,2703,O
several,2703,O
(,2703,O
2-3,2703,O
),2703,O
active,2703,O
site,2703,O
water,2703,O
molecules,2703,O
interacting,2703,O
with,2703,O
the,2703,O
chlorthalidone,2703,B-CHEMICAL
",",2703,O
trichloromethiazide,2703,B-CHEMICAL
",",2703,O
and,2703,O
furosemide,2703,B-CHEMICAL
scaffolds,2703,O
which,2703,O
may,2703,O
be,2703,O
responsible,2703,O
for,2703,O
this,2703,O
important,2703,O
difference,2703,O
of,2703,O
activity,2703,O
.,2703,O
Indeed,2704,O
",",2704,O
indapamide,2704,B-CHEMICAL
bound,2704,O
to,2704,O
CA,2704,B-GENE-Y
II,2704,I-GENE-Y
has,2704,O
no,2704,O
interactions,2704,O
with,2704,O
active,2704,O
site,2704,O
water,2704,O
molecules,2704,O
.,2704,O
Chlorthalidone,2705,B-CHEMICAL
bound,2705,O
within,2705,O
the,2705,O
CA,2705,B-GENE-Y
II,2705,I-GENE-Y
active,2705,O
site,2705,O
is,2705,O
in,2705,O
an,2705,O
enolic,2705,O
(,2705,O
lactimic,2705,O
),2705,O
tautomeric,2705,O
form,2705,O
",",2705,O
with,2705,O
the,2705,O
enolic,2705,O
OH,2705,B-CHEMICAL
also,2705,O
participating,2705,O
in,2705,O
two,2705,O
strong,2705,O
hydrogen,2705,B-CHEMICAL
bonds,2705,O
with,2705,O
Asn67,2705,O
and,2705,O
a,2705,O
water,2705,O
molecule,2705,O
.,2705,O
The,2706,O
newly,2706,O
evidenced,2706,O
binding,2706,O
modes,2706,O
of,2706,O
these,2706,O
diuretics,2706,O
may,2706,O
be,2706,O
exploited,2706,O
for,2706,O
designing,2706,O
better,2706,O
CA,2706,B-GENE-Y
II,2706,I-GENE-Y
inhibitors,2706,O
as,2706,O
well,2706,O
as,2706,O
compounds,2706,O
with,2706,O
selectivity/affinity,2706,O
for,2706,O
various,2706,O
isoforms,2706,O
with,2706,O
medicinal,2706,O
chemistry,2706,O
applications,2706,O
.,2706,O
Sergliflozin,2707,B-CHEMICAL
etabonate,2707,I-CHEMICAL
",",2707,O
a,2707,O
selective,2707,O
SGLT2,2707,B-GENE-Y
inhibitor,2707,O
",",2707,O
improves,2707,O
glycemic,2707,O
control,2707,O
in,2707,O
streptozotocin-induced,2707,B-CHEMICAL
diabetic,2707,O
rats,2707,O
and,2707,O
Zucker,2707,O
fatty,2707,O
rats,2707,O
.,2707,O
The,2708,O
low-affinity,2708,O
sodium,2708,B-GENE-N
glucose,2708,I-GENE-N
cotransporter,2708,I-GENE-N
(,2708,O
SGLT2,2708,B-GENE-Y
),2708,O
is,2708,O
responsible,2708,O
for,2708,O
most,2708,O
of,2708,O
the,2708,O
glucose,2708,B-CHEMICAL
reabsorption,2708,O
in,2708,O
the,2708,O
kidney,2708,O
and,2708,O
has,2708,O
been,2708,O
highlighted,2708,O
as,2708,O
a,2708,O
novel,2708,O
therapeutic,2708,O
target,2708,O
for,2708,O
the,2708,O
treatment,2708,O
of,2708,O
diabetes,2708,O
.,2708,O
We,2709,O
discovered,2709,O
sergliflozin,2709,B-CHEMICAL
etabonate,2709,I-CHEMICAL
",",2709,O
a,2709,O
novel,2709,O
selective,2709,O
SGLT2,2709,B-GENE-Y
inhibitor,2709,O
",",2709,O
and,2709,O
found,2709,O
that,2709,O
selective,2709,O
inhibition,2709,O
of,2709,O
SGLT2,2709,B-GENE-Y
increased,2709,O
urinary,2709,O
glucose,2709,B-CHEMICAL
excretion,2709,O
and,2709,O
consequently,2709,O
decreased,2709,O
plasma,2709,O
glucose,2709,B-CHEMICAL
levels,2709,O
.,2709,O
In,2710,O
this,2710,O
report,2710,O
",",2710,O
we,2710,O
examined,2710,O
the,2710,O
antihyperglycemic,2710,O
effects,2710,O
of,2710,O
sergliflozin,2710,B-CHEMICAL
etabonate,2710,I-CHEMICAL
in,2710,O
normal,2710,O
and,2710,O
diabetic,2710,O
rats,2710,O
in,2710,O
comparison,2710,O
with,2710,O
those,2710,O
of,2710,O
a,2710,O
sulfonylurea,2710,B-CHEMICAL
(,2710,O
gliclazide,2710,B-CHEMICAL
),2710,O
and,2710,O
an,2710,O
alpha-glucosidase,2710,B-GENE-Y
inhibitor,2710,O
(,2710,O
voglibose,2710,B-CHEMICAL
),2710,O
.,2710,O
Sergliflozin,2711,B-CHEMICAL
etabonate,2711,I-CHEMICAL
increased,2711,O
urinary,2711,O
glucose,2711,B-CHEMICAL
excretion,2711,O
in,2711,O
a,2711,O
dose-dependent,2711,O
manner,2711,O
",",2711,O
and,2711,O
inhibited,2711,O
the,2711,O
increase,2711,O
in,2711,O
plasma,2711,O
glucose,2711,B-CHEMICAL
after,2711,O
sucrose,2711,B-CHEMICAL
loading,2711,O
independently,2711,O
of,2711,O
insulin,2711,B-GENE-N
secretion,2711,O
in,2711,O
normal,2711,O
rats,2711,O
.,2711,O
Sergliflozin,2712,B-CHEMICAL
etabonate,2712,I-CHEMICAL
also,2712,O
improved,2712,O
postprandial,2712,O
hyperglycemia,2712,O
in,2712,O
neonatal,2712,O
streptozotocin-induced,2712,B-CHEMICAL
diabetic,2712,O
rats,2712,O
;,2712,O
whereas,2712,O
gliclazide,2712,B-CHEMICAL
did,2712,O
not,2712,O
improve,2712,O
it,2712,O
.,2712,O
In,2713,O
rats,2713,O
with,2713,O
mild,2713,O
or,2713,O
moderate,2713,O
streptozotocin-induced,2713,B-CHEMICAL
diabetes,2713,O
",",2713,O
the,2713,O
degree,2713,O
of,2713,O
the,2713,O
antihyperglycemic,2713,O
effects,2713,O
of,2713,O
sergliflozin,2713,B-CHEMICAL
etabonate,2713,I-CHEMICAL
correlated,2713,O
with,2713,O
the,2713,O
severity,2713,O
of,2713,O
the,2713,O
diabetic,2713,O
condition,2713,O
.,2713,O
Sergliflozin,2714,B-CHEMICAL
etabonate,2714,I-CHEMICAL
did,2714,O
not,2714,O
affect,2714,O
the,2714,O
plasma,2714,O
glucose,2714,B-CHEMICAL
level,2714,O
of,2714,O
normal,2714,O
rats,2714,O
as,2714,O
seen,2714,O
with,2714,O
gliclazide,2714,B-CHEMICAL
.,2714,O
Chronic,2715,O
treatment,2715,O
with,2715,O
sergliflozin,2715,B-CHEMICAL
etabonate,2715,I-CHEMICAL
reduced,2715,O
the,2715,O
levels,2715,O
of,2715,O
glycated,2715,B-GENE-N
hemoglobin,2715,I-GENE-N
and,2715,O
fasting,2715,O
plasma,2715,O
glucose,2715,B-CHEMICAL
",",2715,O
and,2715,O
improved,2715,O
the,2715,O
glycemic,2715,O
response,2715,O
after,2715,O
glucose,2715,B-CHEMICAL
loading,2715,O
in,2715,O
Zucker,2715,O
fatty,2715,O
rats,2715,O
.,2715,O
In,2716,O
addition,2716,O
",",2716,O
sergliflozin,2716,B-CHEMICAL
etabonate,2716,I-CHEMICAL
did,2716,O
not,2716,O
affect,2716,O
the,2716,O
body,2716,O
weight,2716,O
or,2716,O
food,2716,O
intake,2716,O
.,2716,O
These,2717,O
data,2717,O
indicate,2717,O
that,2717,O
sergliflozin,2717,B-CHEMICAL
etabonate,2717,I-CHEMICAL
could,2717,O
improve,2717,O
glycemic,2717,O
control,2717,O
without,2717,O
its,2717,O
use,2717,O
resulting,2717,O
in,2717,O
insulin,2717,B-GENE-N
secretion,2717,O
",",2717,O
hypoglycemia,2717,O
",",2717,O
and,2717,O
body,2717,O
weight,2717,O
gain,2717,O
",",2717,O
and,2717,O
may,2717,O
provide,2717,O
a,2717,O
unique,2717,O
approach,2717,O
to,2717,O
the,2717,O
treatment,2717,O
of,2717,O
diabetes,2717,O
.,2717,O
D1-like,2718,B-GENE-N
receptors,2718,I-GENE-N
inhibit,2718,O
insulin-induced,2718,B-GENE-Y
vascular,2718,O
smooth,2718,O
muscle,2718,O
cell,2718,O
proliferation,2718,O
via,2718,O
down-regulation,2718,O
of,2718,O
insulin,2718,B-GENE-Y
receptor,2718,I-GENE-Y
expression,2718,O
.,2718,O
OBJECTIVE,2719,O
:,2719,O
Vascular,2719,O
smooth,2719,O
muscle,2719,O
cell,2719,O
(,2719,O
VSMC,2719,O
),2719,O
proliferation,2719,O
is,2719,O
central,2719,O
to,2719,O
the,2719,O
development,2719,O
of,2719,O
vascular,2719,O
diseases,2719,O
",",2719,O
including,2719,O
hypertension,2719,O
",",2719,O
which,2719,O
is,2719,O
regulated,2719,O
by,2719,O
numerous,2719,O
hormones,2719,O
and,2719,O
humoral,2719,O
factors,2719,O
.,2719,O
Our,2720,O
previous,2720,O
study,2720,O
showed,2720,O
that,2720,O
the,2720,O
stimulatory,2720,O
effect,2720,O
of,2720,O
norepinephrine,2720,B-CHEMICAL
on,2720,O
VSMC,2720,O
proliferation,2720,O
is,2720,O
inhibited,2720,O
by,2720,O
D1-like,2720,B-GENE-N
receptors,2720,I-GENE-N
and,2720,O
the,2720,O
D3,2720,B-GENE-Y
dopamine,2720,B-CHEMICAL
receptor,2720,I-GENE-Y
",",2720,O
a,2720,O
member,2720,O
of,2720,O
the,2720,O
D2-like,2720,B-GENE-N
receptor,2720,I-GENE-N
family,2720,O
.,2720,O
Insulin,2721,B-GENE-Y
is,2721,O
a,2721,O
proliferative,2721,O
hormone,2721,O
but,2721,O
it,2721,O
is,2721,O
not,2721,O
known,2721,O
if,2721,O
there,2721,O
is,2721,O
any,2721,O
interaction,2721,O
between,2721,O
insulin,2721,B-GENE-Y
and,2721,O
D1-like,2721,B-GENE-N
receptors,2721,I-GENE-N
.,2721,O
We,2722,O
hypothesized,2722,O
that,2722,O
Dl-like,2722,B-GENE-N
receptors,2722,I-GENE-N
may,2722,O
have,2722,O
an,2722,O
inhibitory,2722,O
effect,2722,O
on,2722,O
the,2722,O
insulin-induced,2722,B-GENE-Y
VSMC,2722,O
proliferation,2722,O
;,2722,O
aberrant,2722,O
insulin,2722,B-GENE-Y
and,2722,O
Dl-like,2722,B-GENE-N
receptor,2722,I-GENE-N
functions,2722,O
could,2722,O
be,2722,O
involved,2722,O
in,2722,O
the,2722,O
pathogenesis,2722,O
of,2722,O
essential,2722,O
hypertension,2722,O
.,2722,O
METHODS,2723,O
:,2723,O
VSMC,2723,O
proliferation,2723,O
was,2723,O
determined,2723,O
by,2723,O
[,2723,B-CHEMICAL
H,2723,I-CHEMICAL
],2723,I-CHEMICAL
-thymidine,2723,I-CHEMICAL
incorporation,2723,O
;,2723,O
insulin,2723,B-GENE-Y
receptor,2723,I-GENE-Y
mRNA,2723,O
and,2723,O
protein,2723,O
expressions,2723,O
were,2723,O
determined,2723,O
by,2723,O
RT-PCR,2723,O
",",2723,O
immunoblotting,2723,O
",",2723,O
and,2723,O
immunohistochemistry,2723,O
.,2723,O
RESULTS,2724,O
:,2724,O
Insulin,2724,B-GENE-Y
increased,2724,O
VSMC,2724,O
proliferation,2724,O
in,2724,O
immortalized,2724,O
aortic,2724,O
A10,2724,O
cells,2724,O
",",2724,O
determined,2724,O
by,2724,O
[,2724,B-CHEMICAL
H,2724,I-CHEMICAL
],2724,I-CHEMICAL
-thymidine,2724,I-CHEMICAL
incorporation,2724,O
.,2724,O
Although,2725,O
the,2725,O
D1-like,2725,B-GENE-N
receptor,2725,I-GENE-N
",",2725,O
by,2725,O
itself,2725,O
",",2725,O
had,2725,O
no,2725,O
effect,2725,O
on,2725,O
VSMC,2725,O
proliferation,2725,O
",",2725,O
stimulation,2725,O
with,2725,O
fenoldopam,2725,B-CHEMICAL
",",2725,O
a,2725,O
D1-like,2725,B-GENE-N
receptor,2725,I-GENE-N
agonist,2725,O
",",2725,O
inhibited,2725,O
the,2725,O
stimulatory,2725,O
effect,2725,O
of,2725,O
insulin,2725,B-GENE-Y
.,2725,O
The,2726,O
inhibitory,2726,O
effect,2726,O
of,2726,O
fenoldopam,2726,B-CHEMICAL
on,2726,O
insulin-mediated,2726,B-GENE-Y
VSMC,2726,O
proliferation,2726,O
was,2726,O
receptor,2726,O
specific,2726,O
",",2726,O
because,2726,O
its,2726,O
effect,2726,O
could,2726,O
be,2726,O
blocked,2726,O
by,2726,O
SCH23390,2726,B-CHEMICAL
",",2726,O
a,2726,O
D1-like,2726,B-GENE-N
receptor,2726,I-GENE-N
antagonist,2726,O
.,2726,O
Fenoldopam,2727,B-CHEMICAL
also,2727,O
inhibited,2727,O
insulin,2727,B-GENE-Y
receptor,2727,I-GENE-Y
mRNA,2727,O
and,2727,O
protein,2727,O
expression,2727,O
",",2727,O
which,2727,O
was,2727,O
time,2727,O
dependent,2727,O
and,2727,O
concentration,2727,O
dependent,2727,O
.,2727,O
A,2728,O
PKC,2728,B-GENE-N
or,2728,O
MAP,2728,B-GENE-N
kinase,2728,I-GENE-N
inhibitor,2728,O
blocked,2728,O
the,2728,O
inhibitory,2728,O
effect,2728,O
of,2728,O
fenoldopam,2728,B-CHEMICAL
on,2728,O
insulin,2728,B-GENE-Y
receptor,2728,I-GENE-Y
expression,2728,O
",",2728,O
indicating,2728,O
that,2728,O
PKC,2728,B-GENE-N
and,2728,O
MAP,2728,B-GENE-N
kinase,2728,I-GENE-N
were,2728,O
involved,2728,O
in,2728,O
the,2728,O
signaling,2728,O
pathway,2728,O
.,2728,O
CONCLUSION,2729,O
:,2729,O
The,2729,O
inhibitory,2729,O
effect,2729,O
of,2729,O
D1-like,2729,B-GENE-N
receptors,2729,I-GENE-N
on,2729,O
insulin-mediated,2729,B-GENE-Y
VSMC,2729,O
proliferation,2729,O
may,2729,O
play,2729,O
an,2729,O
important,2729,O
role,2729,O
in,2729,O
the,2729,O
regulation,2729,O
of,2729,O
blood,2729,O
pressure,2729,O
.,2729,O
Successful,2730,O
liver,2730,O
transplantation,2730,O
for,2730,O
Budd-Chiari,2730,O
syndrome,2730,O
in,2730,O
a,2730,O
patient,2730,O
with,2730,O
paroxysmal,2730,O
nocturnal,2730,O
hemoglobinuria,2730,O
treated,2730,O
with,2730,O
the,2730,O
anti-complement,2730,O
antibody,2730,O
eculizumab,2730,O
.,2730,O
Paroxysmal,2731,O
nocturnal,2731,O
hemoglobinuria,2731,O
(,2731,O
PNH,2731,O
),2731,O
is,2731,O
a,2731,O
rare,2731,O
",",2731,O
acquired,2731,O
hemolytic,2731,O
anemia,2731,O
caused,2731,O
by,2731,O
somatic,2731,O
mutations,2731,O
in,2731,O
the,2731,O
phosphatidylinositol,2731,B-GENE-Y
glycan-complementation,2731,I-GENE-Y
class,2731,I-GENE-Y
A,2731,I-GENE-Y
gene,2731,O
and,2731,O
the,2731,O
resulting,2731,O
absence,2731,O
of,2731,O
a,2731,O
key,2731,O
complement,2731,O
regulatory,2731,O
protein,2731,O
",",2731,O
CD59,2731,B-GENE-Y
.,2731,O
Affected,2732,O
red,2732,O
blood,2732,O
cells,2732,O
in,2732,O
patients,2732,O
with,2732,O
PNH,2732,O
undergo,2732,O
intravascular,2732,O
complement-mediated,2732,O
lysis,2732,O
with,2732,O
resulting,2732,O
anemia,2732,O
",",2732,O
hemoglobinuria,2732,O
",",2732,O
and,2732,O
venous,2732,O
thromboses,2732,O
.,2732,O
Hepatic,2733,O
venous,2733,O
outflow,2733,O
thrombosis,2733,O
[,2733,O
Budd-Chiari,2733,O
syndrome,2733,O
(,2733,O
BCS,2733,O
),2733,O
],2733,O
is,2733,O
especially,2733,O
common,2733,O
in,2733,O
PNH,2733,O
patients,2733,O
and,2733,O
often,2733,O
fatal,2733,O
.,2733,O
The,2734,O
few,2734,O
case,2734,O
reports,2734,O
of,2734,O
outcomes,2734,O
in,2734,O
patients,2734,O
undergoing,2734,O
liver,2734,O
transplant,2734,O
for,2734,O
BCS,2734,O
secondary,2734,O
to,2734,O
PNH,2734,O
detail,2734,O
instances,2734,O
of,2734,O
recurrent,2734,O
BCS,2734,O
as,2734,O
well,2734,O
as,2734,O
early,2734,O
thrombotic,2734,O
portal,2734,O
vein,2734,O
occlusion,2734,O
and,2734,O
hepatic,2734,O
artery,2734,O
thrombosis,2734,O
requiring,2734,O
retransplantation,2734,O
.,2734,O
PNH,2735,O
is,2735,O
therefore,2735,O
generally,2735,O
considered,2735,O
a,2735,O
contraindication,2735,O
to,2735,O
liver,2735,O
transplantation,2735,O
.,2735,O
Here,2736,O
we,2736,O
present,2736,O
the,2736,O
first,2736,O
report,2736,O
of,2736,O
a,2736,O
patient,2736,O
with,2736,O
PNH,2736,O
and,2736,O
BCS,2736,O
undergoing,2736,O
successful,2736,O
liver,2736,O
transplantation,2736,O
while,2736,O
receiving,2736,O
eculizumab,2736,O
",",2736,O
a,2736,O
humanized,2736,O
monoclonal,2736,O
antibody,2736,O
that,2736,O
blocks,2736,O
the,2736,O
activation,2736,O
of,2736,O
the,2736,O
terminal,2736,O
complement,2736,O
at,2736,O
C5,2736,B-GENE-Y
.,2736,O
Screening,2737,O
of,2737,O
acetylcholinesterase,2737,B-GENE-Y
inhibitors,2737,O
by,2737,O
CE,2737,O
after,2737,O
enzymatic,2737,O
reaction,2737,O
at,2737,O
capillary,2737,O
inlet,2737,O
.,2737,O
In,2738,O
this,2738,O
study,2738,O
the,2738,O
development,2738,O
of,2738,O
a,2738,O
procedure,2738,O
based,2738,O
on,2738,O
capillary,2738,O
electrophoresis,2738,O
after,2738,O
enzymatic,2738,O
reaction,2738,O
at,2738,O
capillary,2738,O
inlet,2738,O
methodology,2738,O
for,2738,O
the,2738,O
screening,2738,O
and,2738,O
in,2738,O
vitro,2738,O
evaluation,2738,O
of,2738,O
the,2738,O
biological,2738,O
activity,2738,O
of,2738,O
acetylcholinesterase,2738,B-GENE-Y
(,2738,O
AChE,2738,B-GENE-Y
),2738,O
inhibitors,2738,O
is,2738,O
presented,2738,O
.,2738,O
The,2739,O
progress,2739,O
of,2739,O
the,2739,O
enzymatic,2739,O
reaction,2739,O
of,2739,O
the,2739,O
hydrolysis,2739,O
of,2739,O
acetylthiocholine,2739,B-CHEMICAL
at,2739,O
pH,2739,O
8,2739,O
in,2739,O
the,2739,O
presence,2739,O
of,2739,O
AChE,2739,B-GENE-Y
and,2739,O
the,2739,O
inhibitor,2739,O
studied,2739,O
is,2739,O
determined,2739,O
by,2739,O
measuring,2739,O
at,2739,O
230,2739,O
nm,2739,O
the,2739,O
peak,2739,O
area,2739,O
of,2739,O
the,2739,O
reaction,2739,O
product,2739,O
thiocholine,2739,B-CHEMICAL
(,2739,O
TCh,2739,O
),2739,O
.,2739,O
In,2740,O
the,2740,O
method,2740,O
employed,2740,O
the,2740,O
capillary,2740,O
was,2740,O
first,2740,O
filled,2740,O
with,2740,O
30,2740,O
mM,2740,O
borate-phosphate,2740,B-CHEMICAL
buffer,2740,O
(,2740,O
pH,2740,O
8.0,2740,O
),2740,O
and,2740,O
subsequently,2740,O
",",2740,O
plugs,2740,O
of,2740,O
:,2740,O
(,2740,O
i,2740,O
),2740,O
water,2740,O
",",2740,O
(,2740,O
ii,2740,O
),2740,O
AChE,2740,B-GENE-Y
solution,2740,O
",",2740,O
(,2740,O
iii,2740,O
),2740,O
substrate,2740,O
solution,2740,O
with,2740,O
or,2740,O
without,2740,O
inhibitor,2740,O
",",2740,O
(,2740,O
iv,2740,O
),2740,O
AChE,2740,B-GENE-Y
solution,2740,O
",",2740,O
and,2740,O
(,2740,O
v,2740,O
),2740,O
water,2740,O
",",2740,O
were,2740,O
hydrodynamically,2740,O
injected,2740,O
into,2740,O
the,2740,O
capillary,2740,O
",",2740,O
and,2740,O
were,2740,O
allowed,2740,O
to,2740,O
stand,2740,O
(,2740,O
and,2740,O
react,2740,O
),2740,O
during,2740,O
a,2740,O
waiting,2740,O
period,2740,O
of,2740,O
2,2740,O
min,2740,O
.,2740,O
The,2741,O
applicability,2741,O
of,2741,O
the,2741,O
proposed,2741,O
methodology,2741,O
to,2741,O
estimate,2741,O
different,2741,O
kinetic,2741,O
parameters,2741,O
of,2741,O
interest,2741,O
such,2741,O
as,2741,O
inhibition,2741,O
constants,2741,O
K,2741,O
(,2741,O
i,2741,O
),2741,O
",",2741,O
identification,2741,O
of,2741,O
inhibitory,2741,O
action,2741,O
mechanism,2741,O
and,2741,O
IC,2741,O
(,2741,O
50,2741,O
),2741,O
",",2741,O
is,2741,O
evaluated,2741,O
using,2741,O
compounds,2741,O
with,2741,O
known,2741,O
activity,2741,O
",",2741,O
tacrine,2741,B-CHEMICAL
edrophonium,2741,B-CHEMICAL
",",2741,O
and,2741,O
neostigmine,2741,B-CHEMICAL
.,2741,O
The,2742,O
results,2742,O
obtained,2742,O
are,2742,O
compared,2742,O
with,2742,O
bibliographic,2742,O
values,2742,O
and,2742,O
confirm,2742,O
the,2742,O
effectiveness,2742,O
of,2742,O
the,2742,O
methodology,2742,O
proposed,2742,O
.,2742,O
Finally,2743,O
a,2743,O
method,2743,O
for,2743,O
AChE,2743,B-GENE-Y
Inhibitor,2743,O
screening,2743,O
is,2743,O
proposed,2743,O
.,2743,O
Dopamine,2744,B-GENE-N
D2/3,2744,I-GENE-N
receptor,2744,I-GENE-N
binding,2744,O
potential,2744,O
and,2744,O
occupancy,2744,O
in,2744,O
midbrain,2744,O
and,2744,O
temporal,2744,O
cortex,2744,O
by,2744,O
haloperidol,2744,B-CHEMICAL
",",2744,O
olanzapine,2744,B-CHEMICAL
and,2744,O
clozapine,2744,B-CHEMICAL
.,2744,O
AIMS,2745,O
:,2745,O
Aberrant,2745,O
dopamine,2745,B-CHEMICAL
transmission,2745,O
in,2745,O
extrastriatal,2745,O
brain,2745,O
regions,2745,O
has,2745,O
been,2745,O
repeatedly,2745,O
illustrated,2745,O
among,2745,O
patients,2745,O
with,2745,O
schizophrenia,2745,O
.,2745,O
Differences,2746,O
between,2746,O
typical,2746,O
and,2746,O
second-generation,2746,O
antipsychotics,2746,O
in,2746,O
dopamine,2746,B-CHEMICAL
D,2746,I-GENE-Y
(,2746,I-GENE-Y
2,2746,I-GENE-Y
),2746,I-GENE-Y
receptor,2746,I-GENE-Y
modulation,2746,O
within,2746,O
various,2746,O
brain,2746,O
areas,2746,O
remain,2746,O
a,2746,O
topic,2746,O
for,2746,O
debate,2746,O
.,2746,O
The,2747,O
aim,2747,O
of,2747,O
the,2747,O
present,2747,O
study,2747,O
was,2747,O
therefore,2747,O
to,2747,O
investigate,2747,O
dopamine,2747,B-GENE-N
D,2747,I-GENE-N
(,2747,I-GENE-N
2/3,2747,I-GENE-N
),2747,I-GENE-N
receptor,2747,I-GENE-N
apparent,2747,O
binding,2747,O
potential,2747,O
(,2747,O
BP,2747,O
(,2747,O
app,2747,O
),2747,O
),2747,O
and,2747,O
occupancy,2747,O
in,2747,O
midbrain,2747,O
and,2747,O
temporal,2747,O
cortex,2747,O
among,2747,O
clozapine-,2747,B-CHEMICAL
",",2747,O
olanzapine-,2747,B-CHEMICAL
and,2747,O
haloperidol-treated,2747,B-CHEMICAL
schizophrenia,2747,O
patients,2747,O
.,2747,O
METHODS,2748,O
:,2748,O
Dopamine,2748,B-GENE-N
D,2748,I-GENE-N
(,2748,I-GENE-N
2/3,2748,I-GENE-N
),2748,I-GENE-N
binding,2748,O
was,2748,O
studied,2748,O
on,2748,O
single-photon,2748,O
emission,2748,O
computed,2748,O
tomography,2748,O
ligand,2748,O
[,2748,B-CHEMICAL
(,2748,I-CHEMICAL
123,2748,I-CHEMICAL
),2748,I-CHEMICAL
I,2748,I-CHEMICAL
],2748,I-CHEMICAL
epidepride,2748,I-CHEMICAL
in,2748,O
13,2748,O
schizophrenia,2748,O
patients,2748,O
treated,2748,O
with,2748,O
medication,2748,O
(,2748,O
two,2748,O
with,2748,O
haloperidol,2748,B-CHEMICAL
",",2748,O
four,2748,O
with,2748,O
olanzapine,2748,B-CHEMICAL
and,2748,O
seven,2748,O
with,2748,O
clozapine,2748,B-CHEMICAL
),2748,O
",",2748,O
six,2748,O
drug-naive,2748,O
patients,2748,O
and,2748,O
seven,2748,O
healthy,2748,O
controls,2748,O
.,2748,O
RESULTS,2749,O
:,2749,O
Statistically,2749,O
significant,2749,O
differences,2749,O
in,2749,O
midbrain,2749,O
dopamine,2749,B-GENE-N
D,2749,I-GENE-N
(,2749,I-GENE-N
2/3,2749,I-GENE-N
),2749,I-GENE-N
receptor,2749,I-GENE-N
BP,2749,O
(,2749,O
app,2749,O
),2749,O
(,2749,O
P,2749,O
=,2749,O
0.015,2749,O
),2749,O
and,2749,O
occupancy,2749,O
(,2749,O
P,2749,O
=,2749,O
0.016,2749,O
),2749,O
were,2749,O
observed,2749,O
between,2749,O
the,2749,O
clozapine,2749,B-CHEMICAL
",",2749,O
olanzapine,2749,B-CHEMICAL
and,2749,O
haloperidol,2749,B-CHEMICAL
groups,2749,O
.,2749,O
The,2750,O
lowest,2750,O
occupancy,2750,O
was,2750,O
found,2750,O
in,2750,O
clozapine-treated,2750,B-CHEMICAL
patients,2750,O
(,2750,O
5,2750,O
%,2750,O
),2750,O
",",2750,O
followed,2750,O
by,2750,O
olanzapine-treated,2750,B-CHEMICAL
patients,2750,O
(,2750,O
28,2750,O
%,2750,O
),2750,O
",",2750,O
compared,2750,O
to,2750,O
haloperidol-treated,2750,B-CHEMICAL
patients,2750,O
(,2750,O
40,2750,O
%,2750,O
),2750,O
.,2750,O
No,2751,O
significant,2751,O
differences,2751,O
were,2751,O
observed,2751,O
in,2751,O
the,2751,O
temporal,2751,O
poles,2751,O
.,2751,O
Occupancy,2752,O
changed,2752,O
substantially,2752,O
depending,2752,O
on,2752,O
the,2752,O
comparison,2752,O
group,2752,O
used,2752,O
(,2752,O
either,2752,O
drug-naive,2752,O
vs,2752,O
healthy,2752,O
controls,2752,O
),2752,O
in,2752,O
the,2752,O
examined,2752,O
brain,2752,O
areas,2752,O
(,2752,O
P,2752,O
=,2752,O
0.001,2752,O
),2752,O
",",2752,O
showing,2752,O
an,2752,O
overestimation,2752,O
with,2752,O
all,2752,O
antipsychotics,2752,O
when,2752,O
the,2752,O
healthy,2752,O
control,2752,O
group,2752,O
was,2752,O
used,2752,O
.,2752,O
CONCLUSION,2753,O
:,2753,O
Both,2753,O
typical,2753,O
and,2753,O
second-generation,2753,O
antipsychotics,2753,O
occupy,2753,O
cortical,2753,O
dopamine,2753,B-CHEMICAL
D,2753,I-GENE-N
(,2753,I-GENE-N
2/3,2753,I-GENE-N
),2753,I-GENE-N
receptors,2753,I-GENE-N
",",2753,O
thus,2753,O
mediating,2753,O
therapeutic,2753,O
efficacy,2753,O
.,2753,O
Observed,2754,O
differences,2754,O
in,2754,O
midbrain,2754,O
dopamine,2754,B-CHEMICAL
D,2754,I-GENE-N
(,2754,I-GENE-N
2/3,2754,I-GENE-N
),2754,I-GENE-N
occupancy,2754,O
between,2754,O
classical,2754,O
antipsychotics,2754,O
and,2754,O
second-generation,2754,O
antipsychotics,2754,O
may,2754,O
have,2754,O
clinical,2754,O
relevance,2754,O
by,2754,O
modulating,2754,O
altered,2754,O
nigrostriatal,2754,O
dopamine,2754,B-CHEMICAL
neurotransmission,2754,O
during,2754,O
the,2754,O
acute,2754,O
phase,2754,O
of,2754,O
schizophrenia,2754,O
.,2754,O
Medical,2755,O
treatment,2755,O
of,2755,O
acute,2755,O
poisoning,2755,O
with,2755,O
organophosphorus,2755,B-CHEMICAL
and,2755,O
carbamate,2755,B-CHEMICAL
pesticides,2755,O
.,2755,O
Organophosphorus,2756,B-CHEMICAL
compounds,2756,O
(,2756,O
OPs,2756,O
),2756,O
are,2756,O
used,2756,O
as,2756,O
pesticides,2756,O
and,2756,O
developed,2756,O
as,2756,O
warfare,2756,O
nerve,2756,O
agents,2756,O
such,2756,O
as,2756,O
tabun,2756,B-CHEMICAL
",",2756,O
soman,2756,B-CHEMICAL
",",2756,O
sarin,2756,B-CHEMICAL
",",2756,O
VX,2756,O
and,2756,O
others,2756,O
.,2756,O
Exposure,2757,O
to,2757,O
even,2757,O
small,2757,O
amounts,2757,O
of,2757,O
an,2757,O
OP,2757,B-CHEMICAL
can,2757,O
be,2757,O
fatal,2757,O
and,2757,O
death,2757,O
is,2757,O
usually,2757,O
caused,2757,O
by,2757,O
respiratory,2757,O
failure,2757,O
.,2757,O
The,2758,O
mechanism,2758,O
of,2758,O
OP,2758,B-CHEMICAL
poisoning,2758,O
involves,2758,O
inhibition,2758,O
of,2758,O
acetylcholinesterase,2758,B-GENE-Y
(,2758,O
AChE,2758,B-GENE-Y
),2758,O
leading,2758,O
to,2758,O
inactivation,2758,O
of,2758,O
the,2758,O
enzyme,2758,O
which,2758,O
has,2758,O
an,2758,O
important,2758,O
role,2758,O
in,2758,O
neurotransmission,2758,O
.,2758,O
AChE,2759,B-GENE-Y
inhibition,2759,O
results,2759,O
in,2759,O
the,2759,O
accumulation,2759,O
of,2759,O
acetylcholine,2759,B-CHEMICAL
at,2759,O
cholinergic,2759,O
receptor,2759,O
sites,2759,O
",",2759,O
producing,2759,O
continuous,2759,O
stimulation,2759,O
of,2759,O
cholinergic,2759,O
fibers,2759,O
throughout,2759,O
the,2759,O
nervous,2759,O
systems,2759,O
.,2759,O
During,2760,O
more,2760,O
than,2760,O
five,2760,O
decades,2760,O
",",2760,O
pyridinium,2760,B-CHEMICAL
oximes,2760,I-CHEMICAL
have,2760,O
been,2760,O
developed,2760,O
as,2760,O
therapeutic,2760,O
agents,2760,O
used,2760,O
in,2760,O
the,2760,O
medical,2760,O
treatment,2760,O
of,2760,O
poisoning,2760,O
with,2760,O
OP,2760,B-CHEMICAL
.,2760,O
They,2761,O
act,2761,O
by,2761,O
reactivation,2761,O
of,2761,O
AChE,2761,B-GENE-Y
inhibited,2761,O
by,2761,O
OP,2761,B-CHEMICAL
.,2761,O
However,2762,O
",",2762,O
they,2762,O
differ,2762,O
in,2762,O
their,2762,O
activity,2762,O
in,2762,O
poisoning,2762,O
with,2762,O
pesticides,2762,O
and,2762,O
warfare,2762,O
nerve,2762,O
agents,2762,O
and,2762,O
there,2762,O
is,2762,O
still,2762,O
no,2762,O
universal,2762,O
broad-spectrum,2762,O
oxime,2762,B-CHEMICAL
capable,2762,O
of,2762,O
protecting,2762,O
against,2762,O
all,2762,O
known,2762,O
OP,2762,B-CHEMICAL
.,2762,O
In,2763,O
spite,2763,O
of,2763,O
enormous,2763,O
efforts,2763,O
devoted,2763,O
to,2763,O
development,2763,O
of,2763,O
new,2763,O
pyridinium,2763,B-CHEMICAL
oximes,2763,I-CHEMICAL
as,2763,O
potential,2763,O
antidotes,2763,O
against,2763,O
poisoning,2763,O
with,2763,O
OP,2763,B-CHEMICAL
only,2763,O
four,2763,O
compounds,2763,O
so,2763,O
far,2763,O
have,2763,O
found,2763,O
its,2763,O
application,2763,O
in,2763,O
human,2763,O
medicine,2763,O
.,2763,O
Presently,2764,O
",",2764,O
a,2764,O
combination,2764,O
of,2764,O
an,2764,O
antimuscarinic,2764,O
agent,2764,O
",",2764,O
e.g,2764,O
.,2764,O
atropine,2765,B-CHEMICAL
",",2765,O
AChE,2765,B-GENE-Y
reactivator,2765,O
such,2765,O
as,2765,O
one,2765,O
of,2765,O
the,2765,O
recommended,2765,O
pyridinium,2765,B-CHEMICAL
oximes,2765,I-CHEMICAL
(,2765,O
pralidoxime,2765,B-CHEMICAL
",",2765,O
trimedoxime,2765,B-CHEMICAL
",",2765,O
obidoxime,2765,B-CHEMICAL
and,2765,O
HI-6,2765,B-CHEMICAL
),2765,O
and,2765,O
diazepam,2765,B-CHEMICAL
are,2765,O
used,2765,O
for,2765,O
the,2765,O
treatment,2765,O
of,2765,O
OP,2765,B-CHEMICAL
poisoning,2765,O
in,2765,O
humans,2765,O
.,2765,O
In,2766,O
this,2766,O
article,2766,O
the,2766,O
available,2766,O
data,2766,O
related,2766,O
to,2766,O
medical,2766,O
treatment,2766,O
of,2766,O
poisoning,2766,O
with,2766,O
OP,2766,B-CHEMICAL
pesticides,2766,O
are,2766,O
reviewed,2766,O
and,2766,O
the,2766,O
current,2766,O
recommendations,2766,O
are,2766,O
presented,2766,O
.,2766,O
Preclinical,2767,O
properties,2767,O
of,2767,O
18F-AV-45,2767,B-CHEMICAL
:,2767,O
a,2767,O
PET,2767,O
agent,2767,O
for,2767,O
Abeta,2767,B-GENE-Y
plaques,2767,O
in,2767,O
the,2767,O
brain,2767,O
.,2767,O
UNLABELLED,2768,O
:,2768,O
beta-amyloid,2768,B-GENE-Y
plaques,2768,O
(,2768,O
Abeta,2768,B-GENE-Y
plaques,2768,O
),2768,O
in,2768,O
the,2768,O
brain,2768,O
",",2768,O
containing,2768,O
predominantly,2768,O
fibrillary,2768,O
Abeta,2768,B-GENE-Y
peptide,2768,O
aggregates,2768,O
",",2768,O
represent,2768,O
a,2768,O
defining,2768,O
pathologic,2768,O
feature,2768,O
of,2768,O
Alzheimer,2768,O
disease,2768,O
(,2768,O
AD,2768,O
),2768,O
.,2768,O
Imaging,2769,O
agents,2769,O
targeting,2769,O
the,2769,O
Abeta,2769,B-GENE-Y
plaques,2769,O
in,2769,O
the,2769,O
living,2769,O
human,2769,O
brain,2769,O
are,2769,O
potentially,2769,O
valuable,2769,O
as,2769,O
biomarkers,2769,O
of,2769,O
pathogenesis,2769,O
processes,2769,O
in,2769,O
AD,2769,O
.,2769,O
(,2770,B-CHEMICAL
E,2770,I-CHEMICAL
),2770,I-CHEMICAL
-4-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
2-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
6-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
2-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
2-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
2-,2770,I-CHEMICAL
(,2770,I-CHEMICAL
18,2770,I-CHEMICAL
),2770,I-CHEMICAL
F-fluoroethoxy,2770,I-CHEMICAL
),2770,I-CHEMICAL
ethoxy,2770,I-CHEMICAL
),2770,I-CHEMICAL
ethoxy,2770,I-CHEMICAL
),2770,I-CHEMICAL
pyridin-3-yl,2770,I-CHEMICAL
),2770,I-CHEMICAL
vinyl,2770,I-CHEMICAL
),2770,I-CHEMICAL
-N-methy,2770,I-CHEMICAL
l,2770,I-CHEMICAL
benzenamine,2770,I-CHEMICAL
(,2770,O
(,2770,B-CHEMICAL
18,2770,I-CHEMICAL
),2770,I-CHEMICAL
F-AV-45,2770,I-CHEMICAL
),2770,O
is,2770,O
such,2770,O
as,2770,O
an,2770,O
agent,2770,O
currently,2770,O
in,2770,O
phase,2770,O
III,2770,O
clinical,2770,O
studies,2770,O
for,2770,O
PET,2770,O
of,2770,O
Abeta,2770,B-GENE-Y
plaques,2770,O
in,2770,O
the,2770,O
brain,2770,O
.,2770,O
METHODS,2771,O
:,2771,O
In,2771,O
vitro,2771,O
binding,2771,O
of,2771,O
(,2771,B-CHEMICAL
18,2771,I-CHEMICAL
),2771,I-CHEMICAL
F-AV-45,2771,I-CHEMICAL
to,2771,O
Abeta,2771,B-GENE-Y
plaques,2771,O
in,2771,O
the,2771,O
postmortem,2771,O
AD,2771,O
brain,2771,O
tissue,2771,O
was,2771,O
evaluated,2771,O
by,2771,O
in,2771,O
vitro,2771,O
binding,2771,O
assay,2771,O
and,2771,O
autoradiography,2771,O
.,2771,O
In,2772,O
vivo,2772,O
biodistribution,2772,O
of,2772,O
(,2772,B-CHEMICAL
18,2772,I-CHEMICAL
),2772,I-CHEMICAL
F-AV-45,2772,I-CHEMICAL
in,2772,O
mice,2772,O
and,2772,O
ex,2772,O
vivo,2772,O
autoradiography,2772,O
of,2772,O
AD,2772,O
transgenic,2772,O
mice,2772,O
(,2772,O
APPswe/PSEN1,2772,B-GENE-Y
),2772,O
with,2772,O
Abeta,2772,B-GENE-Y
aggregates,2772,O
in,2772,O
the,2772,O
brain,2772,O
were,2772,O
performed,2772,O
.,2772,O
Small-animal,2773,O
PET,2773,O
of,2773,O
a,2773,O
monkey,2773,O
brain,2773,O
after,2773,O
an,2773,O
intravenous,2773,O
injection,2773,O
of,2773,O
(,2773,B-CHEMICAL
18,2773,I-CHEMICAL
),2773,I-CHEMICAL
F-AV-45,2773,I-CHEMICAL
was,2773,O
evaluated,2773,O
.,2773,O
RESULTS,2774,O
:,2774,O
(,2774,B-CHEMICAL
18,2774,I-CHEMICAL
),2774,I-CHEMICAL
F-AV-45,2774,I-CHEMICAL
displayed,2774,O
a,2774,O
high,2774,O
binding,2774,O
affinity,2774,O
and,2774,O
specificity,2774,O
to,2774,O
Abeta,2774,B-GENE-Y
plaques,2774,O
(,2774,O
K,2774,O
(,2774,O
d,2774,O
),2774,O
",",2774,O
3.72,2774,O
+/-,2774,O
0.30,2774,O
nM,2774,O
),2774,O
.,2774,O
In,2775,O
vitro,2775,O
autoradiography,2775,O
of,2775,O
postmortem,2775,O
human,2775,O
brain,2775,O
sections,2775,O
showed,2775,O
substantial,2775,O
plaque,2775,O
labeling,2775,O
in,2775,O
AD,2775,O
brains,2775,O
and,2775,O
not,2775,O
in,2775,O
the,2775,O
control,2775,O
brains,2775,O
.,2775,O
Initial,2776,O
high,2776,O
brain,2776,O
uptake,2776,O
and,2776,O
rapid,2776,O
washout,2776,O
from,2776,O
the,2776,O
brain,2776,O
of,2776,O
healthy,2776,O
mice,2776,O
and,2776,O
monkey,2776,O
were,2776,O
observed,2776,O
.,2776,O
Metabolites,2777,O
produced,2777,O
in,2777,O
the,2777,O
blood,2777,O
of,2777,O
healthy,2777,O
mice,2777,O
after,2777,O
an,2777,O
intravenous,2777,O
injection,2777,O
were,2777,O
identified,2777,O
.,2777,O
(,2778,B-CHEMICAL
18,2778,I-CHEMICAL
),2778,I-CHEMICAL
F-AV-45,2778,I-CHEMICAL
displayed,2778,O
excellent,2778,O
binding,2778,O
affinity,2778,O
to,2778,O
Abeta,2778,B-GENE-Y
plaques,2778,O
in,2778,O
the,2778,O
AD,2778,O
brain,2778,O
by,2778,O
ex,2778,O
vivo,2778,O
autoradiography,2778,O
in,2778,O
transgenic,2778,O
AD,2778,O
model,2778,O
mice,2778,O
.,2778,O
The,2779,O
results,2779,O
lend,2779,O
support,2779,O
that,2779,O
(,2779,B-CHEMICAL
18,2779,I-CHEMICAL
),2779,I-CHEMICAL
F-AV-45,2779,I-CHEMICAL
may,2779,O
be,2779,O
a,2779,O
useful,2779,O
PET,2779,O
agent,2779,O
for,2779,O
detecting,2779,O
Abeta,2779,B-GENE-Y
plaques,2779,O
in,2779,O
the,2779,O
living,2779,O
human,2779,O
brain,2779,O
.,2779,O
Palonosetron,2780,B-CHEMICAL
:,2780,O
in,2780,O
the,2780,O
prevention,2780,O
of,2780,O
nausea,2780,O
and,2780,O
vomiting,2780,O
.,2780,O
Palonosetron,2781,B-CHEMICAL
is,2781,O
a,2781,O
second-generation,2781,O
serotonin,2781,B-GENE-N
5-HT3,2781,I-GENE-N
receptor,2781,I-GENE-N
antagonist,2781,O
",",2781,O
with,2781,O
a,2781,O
distinct,2781,O
pharmacological,2781,O
profile,2781,O
that,2781,O
differs,2781,O
from,2781,O
first-generation,2781,O
5-HT3,2781,B-GENE-N
receptor,2781,I-GENE-N
antagonists,2781,O
.,2781,O
Intravenous,2782,O
palonosetron,2782,B-CHEMICAL
is,2782,O
widely,2782,O
indicated,2782,O
for,2782,O
the,2782,O
prevention,2782,O
of,2782,O
chemotherapy-induced,2782,O
nausea,2782,O
and,2782,O
vomiting,2782,O
(,2782,O
CINV,2782,O
),2782,O
in,2782,O
the,2782,O
acute,2782,O
and,2782,O
delayed,2782,O
phases,2782,O
following,2782,O
moderately,2782,O
emetogenic,2782,O
chemotherapy,2782,O
(,2782,O
MEC,2782,O
),2782,O
and,2782,O
the,2782,O
prevention,2782,O
of,2782,O
CINV,2782,O
in,2782,O
the,2782,O
acute,2782,O
phase,2782,O
following,2782,O
highly,2782,O
emetogenic,2782,O
chemotherapy,2782,O
(,2782,O
HEC,2782,O
),2782,O
.,2782,O
In,2783,O
the,2783,O
US,2783,O
",",2783,O
oral,2783,O
palonosetron,2783,B-CHEMICAL
is,2783,O
approved,2783,O
for,2783,O
the,2783,O
prevention,2783,O
of,2783,O
CINV,2783,O
in,2783,O
the,2783,O
acute,2783,O
phase,2783,O
following,2783,O
MEC,2783,O
(,2783,O
although,2783,O
this,2783,O
formulation,2783,O
is,2783,O
not,2783,O
currently,2783,O
available,2783,O
),2783,O
",",2783,O
and,2783,O
intravenous,2783,O
palonosetron,2783,B-CHEMICAL
is,2783,O
indicated,2783,O
for,2783,O
the,2783,O
prevention,2783,O
of,2783,O
postoperative,2783,O
nausea,2783,O
and,2783,O
vomiting,2783,O
(,2783,O
PONV,2783,O
),2783,O
in,2783,O
the,2783,O
first,2783,O
24,2783,O
hours,2783,O
following,2783,O
surgery,2783,O
.,2783,O
All,2784,O
indications,2784,O
are,2784,O
currently,2784,O
limited,2784,O
to,2784,O
adult,2784,O
patients,2784,O
.,2784,O
Intravenous,2785,O
palonosetron,2785,B-CHEMICAL
was,2785,O
noninferior,2785,O
to,2785,O
intravenous,2785,O
ondansetron,2785,B-CHEMICAL
(,2785,O
with,2785,O
statistically,2785,O
greater,2785,O
efficacy,2785,O
than,2785,O
ondansetron,2785,B-CHEMICAL
),2785,O
or,2785,O
dolasetron,2785,B-CHEMICAL
in,2785,O
preventing,2785,O
CINV,2785,O
following,2785,O
MEC,2785,O
",",2785,O
or,2785,O
to,2785,O
intravenous,2785,O
ondansetron,2785,B-CHEMICAL
or,2785,O
granisetron,2785,B-CHEMICAL
in,2785,O
preventing,2785,O
CINV,2785,O
following,2785,O
HEC,2785,O
",",2785,O
in,2785,O
the,2785,O
acute,2785,O
phase,2785,O
.,2785,O
Statistically,2786,O
greater,2786,O
efficacy,2786,O
was,2786,O
seen,2786,O
with,2786,O
intravenous,2786,O
palonosetron,2786,B-CHEMICAL
than,2786,O
ondansetron,2786,B-CHEMICAL
or,2786,O
dolasetron,2786,B-CHEMICAL
in,2786,O
preventing,2786,O
CINV,2786,O
following,2786,O
MEC,2786,O
in,2786,O
the,2786,O
delayed,2786,O
phase,2786,O
.,2786,O
Oral,2787,O
palonosetron,2787,B-CHEMICAL
was,2787,O
noninferior,2787,O
to,2787,O
intravenous,2787,O
palonosetron,2787,B-CHEMICAL
in,2787,O
preventing,2787,O
CINV,2787,O
in,2787,O
the,2787,O
acute,2787,O
phase,2787,O
in,2787,O
patients,2787,O
receiving,2787,O
MEC,2787,O
.,2787,O
Intravenous,2788,O
palonosetron,2788,B-CHEMICAL
was,2788,O
superior,2788,O
to,2788,O
placebo,2788,O
in,2788,O
preventing,2788,O
PONV,2788,O
in,2788,O
the,2788,O
first,2788,O
24,2788,O
hours,2788,O
following,2788,O
surgery,2788,O
.,2788,O
Palonosetron,2789,B-CHEMICAL
was,2789,O
generally,2789,O
well,2789,O
tolerated,2789,O
in,2789,O
clinical,2789,O
trials,2789,O
.,2789,O
Intravenous,2790,O
palonosetron,2790,B-CHEMICAL
is,2790,O
a,2790,O
valuable,2790,O
option,2790,O
in,2790,O
the,2790,O
prevention,2790,O
of,2790,O
acute-,2790,O
and,2790,O
delayed-phase,2790,O
CINV,2790,O
in,2790,O
adult,2790,O
patients,2790,O
receiving,2790,O
MEC,2790,O
",",2790,O
and,2790,O
of,2790,O
acute-phase,2790,O
CINV,2790,O
in,2790,O
patients,2790,O
receiving,2790,O
HEC,2790,O
.,2790,O
Oral,2791,O
palonosetron,2791,B-CHEMICAL
is,2791,O
likely,2791,O
to,2791,O
be,2791,O
a,2791,O
useful,2791,O
addition,2791,O
to,2791,O
oral,2791,O
formulations,2791,O
of,2791,O
other,2791,O
5-HT3,2791,B-GENE-N
receptor,2791,O
antagonists,2791,O
in,2791,O
preventing,2791,O
CINV,2791,O
in,2791,O
patients,2791,O
receiving,2791,O
MEC,2791,O
.,2791,O
Intravenous,2792,O
palonosetron,2792,B-CHEMICAL
is,2792,O
a,2792,O
useful,2792,O
alternative,2792,O
to,2792,O
currently,2792,O
recommended,2792,O
agents,2792,O
in,2792,O
PONV,2792,O
prevention,2792,O
.,2792,O
Structural,2793,O
features,2793,O
of,2793,O
low-molecular-weight,2793,O
heparins,2793,O
affecting,2793,O
their,2793,O
affinity,2793,O
to,2793,O
antithrombin,2793,O
.,2793,O
As,2794,O
part,2794,O
of,2794,O
a,2794,O
more,2794,O
extensive,2794,O
investigation,2794,O
on,2794,O
structural,2794,O
features,2794,O
of,2794,O
different,2794,O
low-molecular-weight,2794,O
heparins,2794,O
(,2794,O
LMWHs,2794,O
),2794,O
that,2794,O
can,2794,O
affect,2794,O
their,2794,O
biological,2794,O
activities,2794,O
",",2794,O
Enoxaparin,2794,O
",",2794,O
Tinzaparin,2794,O
and,2794,O
Dalteparin,2794,O
were,2794,O
characterised,2794,O
with,2794,O
regards,2794,O
to,2794,O
the,2794,O
distribution,2794,O
of,2794,O
different,2794,O
chain,2794,O
length,2794,O
oligosaccharides,2794,O
as,2794,O
determined,2794,O
by,2794,O
size-exclusion,2794,O
(,2794,O
SE,2794,O
),2794,O
chromatography,2794,O
",",2794,O
as,2794,O
well,2794,O
as,2794,O
their,2794,O
structure,2794,O
as,2794,O
defined,2794,O
by,2794,O
2D-NMR,2794,O
spectra,2794,O
(,2794,O
HSQC,2794,O
),2794,O
.,2794,O
The,2795,O
three,2795,O
LMWHs,2795,O
were,2795,O
also,2795,O
fractionated,2795,O
into,2795,O
high,2795,O
affinity,2795,O
(,2795,O
HA,2795,O
),2795,O
and,2795,O
no,2795,O
affinity,2795,O
(,2795,O
NA,2795,O
),2795,O
pools,2795,O
with,2795,O
regards,2795,O
to,2795,O
their,2795,O
ability,2795,O
to,2795,O
bind,2795,O
antithrombin,2795,O
(,2795,O
AT,2795,O
),2795,O
.,2795,O
The,2796,O
HA,2796,O
fractions,2796,O
were,2796,O
further,2796,O
subfractionated,2796,O
and,2796,O
characterised,2796,O
.,2796,O
For,2797,O
the,2797,O
parent,2797,O
LMWHs,2797,O
and,2797,O
selected,2797,O
fractions,2797,O
",",2797,O
molecular,2797,O
weight,2797,O
parameters,2797,O
were,2797,O
measured,2797,O
using,2797,O
a,2797,O
SE,2797,O
chromatographic,2797,O
system,2797,O
with,2797,O
a,2797,O
triple,2797,O
detector,2797,O
(,2797,O
TDA,2797,O
),2797,O
to,2797,O
obtain,2797,O
absolute,2797,O
molecular,2797,O
weights,2797,O
.,2797,O
The,2798,O
SE,2798,O
chromatograms,2798,O
clearly,2798,O
indicate,2798,O
that,2798,O
Enoxaparin,2798,O
is,2798,O
consistently,2798,O
richer,2798,O
in,2798,O
shorter,2798,O
oligosaccharides,2798,O
than,2798,O
Tinzaparin,2798,O
and,2798,O
Dalteparin,2798,O
.,2798,O
Besides,2799,O
providing,2799,O
the,2799,O
content,2799,O
of,2799,O
terminal,2799,O
groups,2799,O
and,2799,O
individual,2799,O
glucosamine,2799,B-CHEMICAL
and,2799,O
uronic,2799,B-CHEMICAL
acid,2799,I-CHEMICAL
residues,2799,O
with,2799,O
different,2799,O
sulfate,2799,B-CHEMICAL
substituents,2799,O
",",2799,O
the,2799,O
HSQC-NMR,2799,O
spectra,2799,O
permitted,2799,O
us,2799,O
to,2799,O
evaluate,2799,O
and,2799,O
correlate,2799,O
the,2799,O
content,2799,O
of,2799,O
the,2799,O
pentasaccharide,2799,B-CHEMICAL
",",2799,O
AT-binding,2799,O
sequence,2799,O
A-G-A,2799,B-GENE-N
*,2799,I-GENE-N
-I-A,2799,I-GENE-N
(,2799,O
AT-bs,2799,O
),2799,O
through,2799,O
quantification,2799,O
of,2799,O
signals,2799,O
of,2799,O
the,2799,O
disaccharide,2799,B-CHEMICAL
sequence,2799,O
G-A,2799,O
*,2799,O
.,2799,O
Whereas,2800,O
the,2800,O
percent,2800,O
content,2800,O
of,2800,O
HA,2800,O
species,2800,O
is,2800,O
approximately,2800,O
the,2800,O
same,2800,O
for,2800,O
the,2800,O
three,2800,O
LMWHs,2800,O
",",2800,O
substantial,2800,O
differences,2800,O
were,2800,O
observed,2800,O
for,2800,O
the,2800,O
chain,2800,O
distribution,2800,O
of,2800,O
AT-bs,2800,O
as,2800,O
a,2800,O
function,2800,O
of,2800,O
length,2800,O
",",2800,O
with,2800,O
the,2800,O
AT-bs,2800,O
being,2800,O
preferentially,2800,O
contained,2800,O
in,2800,O
the,2800,O
longest,2800,O
chains,2800,O
of,2800,O
each,2800,O
LMWH,2800,O
.,2800,O
The,2801,O
above,2801,O
information,2801,O
will,2801,O
be,2801,O
useful,2801,O
in,2801,O
establishing,2801,O
structure-activity,2801,O
relationships,2801,O
currently,2801,O
under,2801,O
way,2801,O
.,2801,O
This,2802,O
study,2802,O
is,2802,O
therefore,2802,O
critical,2802,O
for,2802,O
establishing,2802,O
correlations,2802,O
between,2802,O
structural,2802,O
features,2802,O
of,2802,O
LMWHs,2802,O
and,2802,O
their,2802,O
AT-mediated,2802,O
anticoagulant,2802,O
activity,2802,O
.,2802,O
Abarelix,2803,B-CHEMICAL
and,2803,O
other,2803,O
gonadotrophin-releasing,2803,B-GENE-Y
hormone,2803,I-GENE-Y
antagonists,2803,O
in,2803,O
prostate,2803,O
cancer,2803,O
.,2803,O
Hormonal,2804,O
therapy,2804,O
is,2804,O
the,2804,O
main,2804,O
recommended,2804,O
treatment,2804,O
for,2804,O
locally,2804,O
advanced,2804,O
and,2804,O
metastatic,2804,O
prostate,2804,O
cancer,2804,O
.,2804,O
Luteinizing,2805,B-GENE-Y
hormone-releasing,2805,I-GENE-Y
hormone,2805,I-GENE-Y
(,2805,O
LHRH,2805,B-GENE-Y
),2805,O
agonists,2805,O
",",2805,O
such,2805,O
as,2805,O
buserelin,2805,B-CHEMICAL
",",2805,O
goserelin,2805,B-CHEMICAL
",",2805,O
leuprorelin,2805,B-CHEMICAL
and,2805,O
triptorelin,2805,B-CHEMICAL
",",2805,O
stimulate,2805,O
the,2805,O
pituitary,2805,O
's,2805,O
gonadotrophin-releasing,2805,B-CHEMICAL
hormone,2805,I-CHEMICAL
(,2805,I-GENE-Y
GnRH,2805,I-GENE-Y
),2805,I-GENE-Y
receptor,2805,I-GENE-Y
",",2805,O
ultimately,2805,O
leading,2805,O
to,2805,O
its,2805,O
de-sensitization,2805,O
and,2805,O
subsequent,2805,O
reduction,2805,O
of,2805,O
LH,2805,B-GENE-N
and,2805,O
testosterone,2805,B-CHEMICAL
levels,2805,O
.,2805,O
However,2806,O
",",2806,O
this,2806,O
reduction,2806,O
is,2806,O
accompanied,2806,O
by,2806,O
a,2806,O
well,2806,O
described,2806,O
increase,2806,O
or,2806,O
'surge,2806,O
',2806,O
in,2806,O
LH,2806,B-GENE-N
and,2806,O
testosterone,2806,B-CHEMICAL
levels,2806,O
",",2806,O
necessitating,2806,O
the,2806,O
concomitant,2806,O
administration,2806,O
of,2806,O
an,2806,O
antiandrogen,2806,O
to,2806,O
combat,2806,O
the,2806,O
potential,2806,O
effects,2806,O
of,2806,O
transient,2806,O
acceleration,2806,O
in,2806,O
cancer,2806,O
activity,2806,O
.,2806,O
Two,2807,O
pure,2807,O
GnRH,2807,B-GENE-Y
antagonists,2807,O
have,2807,O
been,2807,O
developed,2807,O
",",2807,O
abarelix,2807,B-CHEMICAL
and,2807,O
degarelix,2807,B-CHEMICAL
",",2807,O
that,2807,O
are,2807,O
devoid,2807,O
of,2807,O
any,2807,O
agonist,2807,O
effect,2807,O
on,2807,O
the,2807,O
GnRH,2807,B-GENE-Y
receptor,2807,I-GENE-Y
and,2807,O
consequently,2807,O
do,2807,O
not,2807,O
result,2807,O
in,2807,O
testosterone,2807,B-CHEMICAL
flare,2807,O
.,2807,O
Abarelix,2808,B-CHEMICAL
was,2808,O
the,2808,O
first,2808,O
GnRH,2808,B-GENE-Y
antagonist,2808,O
to,2808,O
be,2808,O
developed,2808,O
and,2808,O
was,2808,O
approved,2808,O
by,2808,O
the,2808,O
USA,2808,O
Food,2808,O
and,2808,O
Drug,2808,O
Administration,2808,O
in,2808,O
2004,2808,O
for,2808,O
the,2808,O
initiation,2808,O
of,2808,O
hormonal,2808,O
castration,2808,O
in,2808,O
advanced,2808,O
or,2808,O
metastasizing,2808,O
hormone-dependent,2808,O
prostate,2808,O
carcinoma,2808,O
",",2808,O
when,2808,O
rapid,2808,O
androgen,2808,B-CHEMICAL
suppression,2808,O
is,2808,O
necessary,2808,O
.,2808,O
Clinical,2809,O
data,2809,O
on,2809,O
both,2809,O
abarelix,2809,B-CHEMICAL
and,2809,O
degarelix,2809,B-CHEMICAL
show,2809,O
that,2809,O
they,2809,O
can,2809,O
produce,2809,O
rapid,2809,O
and,2809,O
sustained,2809,O
decreases,2809,O
in,2809,O
testosterone,2809,B-CHEMICAL
to,2809,O
castrate,2809,O
levels,2809,O
without,2809,O
the,2809,O
need,2809,O
for,2809,O
co-administration,2809,O
of,2809,O
an,2809,O
antiandrogen,2809,O
",",2809,O
and,2809,O
with,2809,O
a,2809,O
very,2809,O
low,2809,O
complication,2809,O
rate,2809,O
in,2809,O
the,2809,O
short,2809,O
term,2809,O
.,2809,O
Fulvestrant,2810,B-CHEMICAL
:,2810,O
a,2810,O
unique,2810,O
antiendocrine,2810,O
agent,2810,O
for,2810,O
estrogen-sensitive,2810,B-CHEMICAL
breast,2810,O
cancer,2810,O
.,2810,O
IMPORTANCE,2811,O
OF,2811,O
THE,2811,O
FIELD,2811,O
:,2811,O
The,2811,O
role,2811,O
of,2811,O
estrogen,2811,B-CHEMICAL
deprivation,2811,O
for,2811,O
the,2811,O
treatment,2811,O
of,2811,O
breast,2811,O
cancer,2811,O
has,2811,O
been,2811,O
understood,2811,O
since,2811,O
the,2811,O
1800s,2811,O
.,2811,O
Pharmacologic,2812,O
advances,2812,O
in,2812,O
the,2812,O
field,2812,O
in,2812,O
the,2812,O
past,2812,O
decades,2812,O
",",2812,O
including,2812,O
tamoxifen,2812,B-CHEMICAL
and,2812,O
the,2812,O
aromatase,2812,B-GENE-Y
inhibitors,2812,O
",",2812,O
have,2812,O
contributed,2812,O
significantly,2812,O
to,2812,O
the,2812,O
reduced,2812,O
mortality,2812,O
of,2812,O
estrogen-sensitive,2812,B-CHEMICAL
breast,2812,O
cancer,2812,O
.,2812,O
However,2813,O
",",2813,O
this,2813,O
subtype,2813,O
of,2813,O
breast,2813,O
cancer,2813,O
still,2813,O
presents,2813,O
with,2813,O
relapses,2813,O
and,2813,O
",",2813,O
once,2813,O
metastatic,2813,O
",",2813,O
progression,2813,O
to,2813,O
hormone-refractory,2813,O
state,2813,O
and,2813,O
loss,2813,O
of,2813,O
disease,2813,O
control,2813,O
remain,2813,O
an,2813,O
expected,2813,O
disease,2813,O
course,2813,O
.,2813,O
Fulvestrant,2814,B-CHEMICAL
",",2814,O
a,2814,O
pure,2814,O
estrogen,2814,B-CHEMICAL
receptor,2814,I-GENE-Y
downregulator,2814,O
",",2814,O
is,2814,O
a,2814,O
new,2814,O
addition,2814,O
to,2814,O
the,2814,O
antiestrogen,2814,O
therapeutic,2814,O
armamentarium,2814,O
since,2814,O
its,2814,O
FDA,2814,O
approval,2814,O
in,2814,O
2002,2814,O
.,2814,O
Its,2815,O
unique,2815,O
mechanism,2815,O
of,2815,O
action,2815,O
offers,2815,O
potential,2815,O
advantages,2815,O
over,2815,O
other,2815,O
estrogen,2815,B-CHEMICAL
targeted,2815,O
therapies,2815,O
.,2815,O
AREAS,2816,O
COVERED,2816,O
IN,2816,O
THIS,2816,O
REVIEW,2816,O
:,2816,O
Published,2816,O
scientific,2816,O
literature,2816,O
",",2816,O
including,2816,O
presented,2816,O
abstracts,2816,O
",",2816,O
on,2816,O
fulvestrant,2816,B-CHEMICAL
from,2816,O
1985,2816,O
to,2816,O
the,2816,O
present,2816,O
were,2816,O
reviewed,2816,O
with,2816,O
selected,2816,O
publications,2816,O
included,2816,O
.,2816,O
WHAT,2817,O
THE,2817,O
READER,2817,O
WILL,2817,O
GAIN,2817,O
:,2817,O
This,2817,O
review,2817,O
addresses,2817,O
current,2817,O
issues,2817,O
and,2817,O
therapies,2817,O
for,2817,O
estrogen-sensitive,2817,B-CHEMICAL
breast,2817,O
cancer,2817,O
",",2817,O
highlights,2817,O
the,2817,O
role,2817,O
of,2817,O
fulvestrant,2817,B-CHEMICAL
in,2817,O
current,2817,O
treatment,2817,O
guidelines,2817,O
and,2817,O
outlines,2817,O
some,2817,O
of,2817,O
the,2817,O
ongoing,2817,O
investigations,2817,O
of,2817,O
this,2817,O
compound,2817,O
.,2817,O
TAKE,2818,O
HOME,2818,O
MESSAGE,2818,O
:,2818,O
Fulvestrant,2818,B-CHEMICAL
is,2818,O
an,2818,O
effective,2818,O
and,2818,O
well-tolerated,2818,O
drug,2818,O
for,2818,O
treatment,2818,O
of,2818,O
metastatic,2818,O
estrogen-sensitive,2818,B-CHEMICAL
breast,2818,O
cancer,2818,O
.,2818,O
Work,2819,O
is,2819,O
underway,2819,O
to,2819,O
enhance,2819,O
its,2819,O
clinical,2819,O
benefit,2819,O
to,2819,O
patients,2819,O
as,2819,O
a,2819,O
single,2819,O
agent,2819,O
and,2819,O
in,2819,O
combination,2819,O
with,2819,O
other,2819,O
therapies,2819,O
.,2819,O
Alpha-2B,2820,B-GENE-Y
adrenergic,2820,I-GENE-Y
receptor,2820,I-GENE-Y
mediated,2820,O
hemodynamic,2820,O
profile,2820,O
of,2820,O
etomidate,2820,B-CHEMICAL
.,2820,O
Etomidate,2821,B-CHEMICAL
has,2821,O
been,2821,O
used,2821,O
since,2821,O
1972,2821,O
as,2821,O
an,2821,O
inductor,2821,O
and,2821,O
in,2821,O
maintaining,2821,O
anesthesia,2821,O
.,2821,O
There,2822,O
are,2822,O
multiple,2822,O
mechanisms,2822,O
that,2822,O
account,2822,O
for,2822,O
the,2822,O
biologic,2822,O
effects,2822,O
of,2822,O
etomidate,2822,B-CHEMICAL
.,2822,O
One,2823,O
of,2823,O
the,2823,O
most,2823,O
prominent,2823,O
features,2823,O
of,2823,O
this,2823,O
drug,2823,O
is,2823,O
that,2823,O
it,2823,O
provides,2823,O
anesthesia,2823,O
without,2823,O
gross,2823,O
changes,2823,O
in,2823,O
hemodynamic,2823,O
parameters,2823,O
.,2823,O
This,2824,O
feature,2824,O
allows,2824,O
using,2824,O
etomidate,2824,B-CHEMICAL
in,2824,O
patients,2824,O
with,2824,O
considerable,2824,O
cardiopulmonary,2824,O
compromise,2824,O
avoiding,2824,O
the,2824,O
characteristic,2824,O
hypotension,2824,O
produced,2824,O
by,2824,O
other,2824,O
anesthetics,2824,O
.,2824,O
The,2825,O
mechanism,2825,O
that,2825,O
provides,2825,O
the,2825,O
basis,2825,O
for,2825,O
its,2825,O
cardiovascular,2825,O
stability,2825,O
is,2825,O
the,2825,O
capacity,2825,O
to,2825,O
bind,2825,O
and,2825,O
stimulate,2825,O
peripheral,2825,O
alpha-2B,2825,B-GENE-Y
adrenergic,2825,I-GENE-Y
receptors,2825,I-GENE-Y
with,2825,O
a,2825,O
subsequent,2825,O
vasoconstriction,2825,O
.,2825,O
Alterations,2826,O
in,2826,O
the,2826,O
function,2826,O
or,2826,O
number,2826,O
of,2826,O
these,2826,O
receptors,2826,O
may,2826,O
account,2826,O
for,2826,O
abnormal,2826,O
responses,2826,O
during,2826,O
etomidate,2826,B-CHEMICAL
induction,2826,O
.,2826,O
N-carbamylglutamate,2827,B-CHEMICAL
treatment,2827,O
for,2827,O
acute,2827,O
neonatal,2827,O
hyperammonemia,2827,O
in,2827,O
isovaleric,2827,O
acidemia,2827,O
.,2827,O
Hyperammonemia,2828,O
occurs,2828,O
mainly,2828,O
in,2828,O
patients,2828,O
with,2828,O
branched-chain,2828,O
organic,2828,O
acidemias,2828,O
such,2828,O
as,2828,O
propionic,2828,O
",",2828,O
methylmalonic,2828,O
",",2828,O
and,2828,O
isovaleric,2828,O
acidemias,2828,O
.,2828,O
Its,2829,O
pathophysiological,2829,O
process,2829,O
is,2829,O
mainly,2829,O
via,2829,O
the,2829,O
competitive,2829,O
inhibition,2829,O
of,2829,O
N-acetylglutamate,2829,B-CHEMICAL
synthetase,2829,I-GENE-Y
.,2829,O
Oral,2830,O
carglumic,2830,B-CHEMICAL
acid,2830,I-CHEMICAL
(,2830,O
N-carbamylglutamate,2830,B-CHEMICAL
),2830,O
administration,2830,O
can,2830,O
correct,2830,O
hyperammonemia,2830,O
in,2830,O
neonates,2830,O
with,2830,O
propionic,2830,O
and,2830,O
methylmalonic,2830,O
acidemias,2830,O
",",2830,O
thus,2830,O
avoiding,2830,O
dialysis,2830,O
therapy,2830,O
.,2830,O
Isovaleric,2831,O
acidemia,2831,O
is,2831,O
an,2831,O
autosomal,2831,O
recessive,2831,O
disease,2831,O
of,2831,O
leucine,2831,B-CHEMICAL
metabolism,2831,O
due,2831,O
to,2831,O
deficiency,2831,O
of,2831,O
isovaleryl-CoA,2831,B-CHEMICAL
dehydrogenase,2831,I-GENE-Y
.,2831,O
For,2832,O
the,2832,O
first,2832,O
time,2832,O
",",2832,O
we,2832,O
report,2832,O
a,2832,O
neonate,2832,O
with,2832,O
isovaleric,2832,O
acidemia,2832,O
",",2832,O
whose,2832,O
plasma,2832,O
ammonia,2832,B-CHEMICAL
concentration,2832,O
dropped,2832,O
dramatically,2832,O
after,2832,O
one,2832,O
oral,2832,O
load,2832,O
of,2832,O
carglumic,2832,B-CHEMICAL
acid,2832,I-CHEMICAL
.,2832,O
This,2833,O
experience,2833,O
suggests,2833,O
that,2833,O
carglumic,2833,B-CHEMICAL
acid,2833,I-CHEMICAL
could,2833,O
be,2833,O
considered,2833,O
for,2833,O
acute,2833,O
hyperammonemia,2833,O
resulting,2833,O
from,2833,O
isovaleric,2833,O
acidemia,2833,O
.,2833,O
However,2834,O
",",2834,O
trials,2834,O
with,2834,O
more,2834,O
patients,2834,O
are,2834,O
needed,2834,O
.,2834,O
Stoichiometry,2835,O
of,2835,O
estramustine,2835,B-CHEMICAL
phosphate,2835,I-CHEMICAL
binding,2835,O
to,2835,O
MAP2,2835,B-GENE-Y
measured,2835,O
by,2835,O
the,2835,O
disassembly,2835,O
of,2835,O
chick,2835,B-GENE-Y
brain,2835,I-GENE-Y
MAP2,2835,I-GENE-Y
:,2835,O
tubulin,2835,B-GENE-N
microtubules,2835,O
.,2835,O
The,2836,O
concentration,2836,O
of,2836,O
estramustine,2836,B-CHEMICAL
phosphate,2836,I-CHEMICAL
required,2836,O
to,2836,O
inhibit,2836,O
the,2836,O
assembly,2836,O
or,2836,O
to,2836,O
induce,2836,O
the,2836,O
disassembly,2836,O
of,2836,O
chick,2836,B-GENE-Y
brain,2836,I-GENE-Y
MAP2,2836,I-GENE-Y
:,2836,O
tubulin,2836,B-GENE-N
microtubules,2836,O
is,2836,O
markedly,2836,O
dependent,2836,O
upon,2836,O
the,2836,O
microtubule,2836,O
protein,2836,O
concentration,2836,O
.,2836,O
Analysis,2837,O
of,2837,O
this,2837,O
relationship,2837,O
shows,2837,O
that,2837,O
estramustine,2837,B-CHEMICAL
phosphate,2837,I-CHEMICAL
and,2837,O
tubulin,2837,B-GENE-N
compete,2837,O
for,2837,O
common,2837,O
MAP2,2837,B-GENE-Y
sites,2837,O
",",2837,O
that,2837,O
MAP2,2837,B-GENE-Y
can,2837,O
bind,2837,O
5-6,2837,O
moles.mole-1,2837,O
estramustine,2837,B-CHEMICAL
phosphate,2837,I-CHEMICAL
",",2837,O
and,2837,O
that,2837,O
the,2837,O
Kd,2837,O
of,2837,O
these,2837,O
sites,2837,O
is,2837,O
congruent,2837,O
to,2837,O
20,2837,O
microM,2837,O
estramustine,2837,B-CHEMICAL
phosphate,2837,I-CHEMICAL
.,2837,O
It,2838,O
is,2838,O
proposed,2838,O
that,2838,O
two,2838,O
molecules,2838,O
of,2838,O
estramustine,2838,B-CHEMICAL
phosphate,2838,I-CHEMICAL
interact,2838,O
with,2838,O
each,2838,O
of,2838,O
the,2838,O
three,2838,O
tubulin-binding,2838,O
sites,2838,O
of,2838,O
MAP2,2838,B-GENE-Y
and,2838,O
inhibit,2838,O
the,2838,O
MAP2,2838,B-GENE-Y
:,2838,O
tubulin,2838,B-GENE-N
interaction,2838,O
by,2838,O
neutralising,2838,O
two,2838,O
highly,2838,O
conserved,2838,O
basic,2838,O
residues,2838,O
.,2838,O
Activity,2839,O
of,2839,O
XL184,2839,B-CHEMICAL
(,2839,O
Cabozantinib,2839,B-CHEMICAL
),2839,O
",",2839,O
an,2839,O
oral,2839,O
tyrosine,2839,B-CHEMICAL
kinase,2839,I-GENE-N
inhibitor,2839,O
",",2839,O
in,2839,O
patients,2839,O
with,2839,O
medullary,2839,O
thyroid,2839,O
cancer,2839,O
.,2839,O
PURPOSE,2840,O
:,2840,O
XL184,2840,B-CHEMICAL
(,2840,O
cabozantinib,2840,B-CHEMICAL
),2840,O
is,2840,O
a,2840,O
potent,2840,O
inhibitor,2840,O
of,2840,O
MET,2840,B-GENE-Y
",",2840,O
vascular,2840,B-GENE-Y
endothelial,2840,I-GENE-Y
growth,2840,I-GENE-Y
factor,2840,I-GENE-Y
receptor,2840,I-GENE-Y
2,2840,I-GENE-Y
(,2840,O
VEGFR2,2840,B-GENE-Y
),2840,O
",",2840,O
and,2840,O
RET,2840,B-GENE-Y
",",2840,O
with,2840,O
robust,2840,O
antiangiogenic,2840,O
",",2840,O
antitumor,2840,O
",",2840,O
and,2840,O
anti-invasive,2840,O
effects,2840,O
in,2840,O
preclinical,2840,O
models,2840,O
.,2840,O
Early,2841,O
observations,2841,O
of,2841,O
clinical,2841,O
benefit,2841,O
in,2841,O
a,2841,O
phase,2841,O
I,2841,O
study,2841,O
of,2841,O
cabozantinib,2841,B-CHEMICAL
",",2841,O
which,2841,O
included,2841,O
patients,2841,O
with,2841,O
medullary,2841,O
thyroid,2841,O
cancer,2841,O
(,2841,O
MTC,2841,O
),2841,O
",",2841,O
led,2841,O
to,2841,O
expansion,2841,O
of,2841,O
an,2841,O
MTC-enriched,2841,O
cohort,2841,O
",",2841,O
which,2841,O
is,2841,O
the,2841,O
focus,2841,O
of,2841,O
this,2841,O
article,2841,O
.,2841,O
PATIENTS,2842,O
AND,2842,O
METHODS,2842,O
:,2842,O
A,2842,O
phase,2842,O
I,2842,O
dose-escalation,2842,O
study,2842,O
of,2842,O
oral,2842,O
cabozantinib,2842,B-CHEMICAL
was,2842,O
conducted,2842,O
in,2842,O
patients,2842,O
with,2842,O
advanced,2842,O
solid,2842,O
tumors,2842,O
.,2842,O
Primary,2843,O
end,2843,O
points,2843,O
included,2843,O
evaluation,2843,O
of,2843,O
safety,2843,O
",",2843,O
pharmacokinetics,2843,O
",",2843,O
and,2843,O
maximum-tolerated,2843,O
dose,2843,O
(,2843,O
MTD,2843,O
),2843,O
determination,2843,O
.,2843,O
Additional,2844,O
end,2844,O
points,2844,O
included,2844,O
RECIST,2844,O
(,2844,O
Response,2844,O
Evaluation,2844,O
Criteria,2844,O
in,2844,O
Solid,2844,O
Tumors,2844,O
),2844,O
response,2844,O
",",2844,O
pharmacodynamics,2844,O
",",2844,O
RET,2844,B-GENE-Y
mutational,2844,O
status,2844,O
",",2844,O
and,2844,O
biomarker,2844,O
analyses,2844,O
.,2844,O
RESULTS,2845,O
:,2845,O
Eighty-five,2845,O
patients,2845,O
were,2845,O
enrolled,2845,O
",",2845,O
including,2845,O
37,2845,O
with,2845,O
MTC,2845,O
.,2845,O
The,2846,O
MTD,2846,O
was,2846,O
175,2846,O
mg,2846,O
daily,2846,O
.,2846,O
Dose-limiting,2847,O
toxicities,2847,O
were,2847,O
grade,2847,O
3,2847,O
palmar,2847,O
plantar,2847,O
erythrodysesthesia,2847,O
(,2847,O
PPE,2847,O
),2847,O
",",2847,O
mucositis,2847,O
",",2847,O
and,2847,O
AST,2847,B-GENE-N
",",2847,O
ALT,2847,B-GENE-N
",",2847,O
and,2847,O
lipase,2847,B-GENE-N
elevations,2847,O
and,2847,O
grade,2847,O
2,2847,O
mucositis,2847,O
that,2847,O
resulted,2847,O
in,2847,O
dose,2847,O
interruption,2847,O
and,2847,O
reduction,2847,O
.,2847,O
Ten,2848,O
(,2848,O
29,2848,O
%,2848,O
),2848,O
of,2848,O
35,2848,O
patients,2848,O
with,2848,O
MTC,2848,O
with,2848,O
measurable,2848,O
disease,2848,O
had,2848,O
a,2848,O
confirmed,2848,O
partial,2848,O
response,2848,O
.,2848,O
Overall,2849,O
",",2849,O
18,2849,O
patients,2849,O
experienced,2849,O
tumor,2849,O
shrinkage,2849,O
of,2849,O
30,2849,O
%,2849,O
or,2849,O
more,2849,O
",",2849,O
including,2849,O
17,2849,O
(,2849,O
49,2849,O
%,2849,O
),2849,O
of,2849,O
35,2849,O
patients,2849,O
with,2849,O
MTC,2849,O
with,2849,O
measurable,2849,O
disease,2849,O
.,2849,O
Additionally,2850,O
",",2850,O
15,2850,O
(,2850,O
41,2850,O
%,2850,O
),2850,O
of,2850,O
37,2850,O
patients,2850,O
with,2850,O
MTC,2850,O
had,2850,O
stable,2850,O
disease,2850,O
(,2850,O
SD,2850,O
),2850,O
for,2850,O
at,2850,O
least,2850,O
6,2850,O
months,2850,O
",",2850,O
resulting,2850,O
in,2850,O
SD,2850,O
for,2850,O
6,2850,O
months,2850,O
or,2850,O
longer,2850,O
or,2850,O
confirmed,2850,O
partial,2850,O
response,2850,O
in,2850,O
68,2850,O
%,2850,O
of,2850,O
patients,2850,O
with,2850,O
MTC,2850,O
.,2850,O
CONCLUSION,2851,O
:,2851,O
Cabozantinib,2851,B-CHEMICAL
has,2851,O
an,2851,O
acceptable,2851,O
safety,2851,O
profile,2851,O
and,2851,O
is,2851,O
active,2851,O
in,2851,O
MTC,2851,O
.,2851,O
Cabozantinib,2852,B-CHEMICAL
may,2852,O
provide,2852,O
clinical,2852,O
benefit,2852,O
by,2852,O
simultaneously,2852,O
targeting,2852,O
multiple,2852,O
pathways,2852,O
of,2852,O
importance,2852,O
in,2852,O
MTC,2852,O
",",2852,O
including,2852,O
MET,2852,B-GENE-Y
",",2852,O
VEGFR2,2852,B-GENE-Y
",",2852,O
and,2852,O
RET,2852,B-GENE-Y
.,2852,O
A,2853,O
global,2853,O
phase,2853,O
III,2853,O
pivotal,2853,O
study,2853,O
in,2853,O
MTC,2853,O
is,2853,O
ongoing,2853,O
(,2853,O
ClinicalTrials.gov,2853,O
number,2853,O
NCT00215605,2853,O
),2853,O
.,2853,O
Toxic,2854,O
effects,2854,O
of,2854,O
chromium,2854,B-CHEMICAL
on,2854,O
tannery,2854,O
workers,2854,O
at,2854,O
Sialkot,2854,O
(,2854,O
Pakistan,2854,O
),2854,O
.,2854,O
Chromium,2855,B-CHEMICAL
is,2855,O
widely,2855,O
used,2855,O
in,2855,O
the,2855,O
leather,2855,O
industry,2855,O
",",2855,O
and,2855,O
tannery,2855,O
workers,2855,O
are,2855,O
under,2855,O
constant,2855,O
threat,2855,O
of,2855,O
adverse,2855,O
health,2855,O
effects,2855,O
due,2855,O
to,2855,O
its,2855,O
excessive,2855,O
exposure,2855,O
.,2855,O
Our,2856,O
objective,2856,O
was,2856,O
to,2856,O
find,2856,O
out,2856,O
the,2856,O
toxic,2856,O
effects,2856,O
of,2856,O
chromium,2856,B-CHEMICAL
on,2856,O
tannery,2856,O
workers,2856,O
at,2856,O
Sialkot,2856,O
",",2856,O
Pakistan,2856,O
.,2856,O
A,2857,O
total,2857,O
of,2857,O
240,2857,O
males,2857,O
consisting,2857,O
of,2857,O
120,2857,O
workers,2857,O
from,2857,O
tanneries,2857,O
at,2857,O
Sialkot,2857,O
and,2857,O
equal,2857,O
number,2857,O
of,2857,O
controls,2857,O
were,2857,O
included,2857,O
.,2857,O
Blood,2858,O
complete,2858,O
counts,2858,O
",",2858,O
high-sensitive,2858,O
C-reactive,2858,B-GENE-Y
protein,2858,I-GENE-Y
",",2858,O
malondialdehyde,2858,B-CHEMICAL
and,2858,O
routine,2858,O
biochemical,2858,O
tests,2858,O
were,2858,O
carried,2858,O
out,2858,O
by,2858,O
routine,2858,O
procedures,2858,O
.,2858,O
Chromium,2859,B-CHEMICAL
levels,2859,O
in,2859,O
blood,2859,O
(,2859,O
BCr,2859,O
),2859,O
and,2859,O
urine,2859,O
were,2859,O
analyzed,2859,O
using,2859,O
graphite,2859,B-CHEMICAL
furnace,2859,O
atomic,2859,O
absorption,2859,O
spectrophotometer,2859,O
Perkin,2859,O
Elmer,2859,O
analyst-200,2859,O
.,2859,O
Results,2860,O
revealed,2860,O
that,2860,O
all,2860,O
the,2860,O
workers,2860,O
were,2860,O
male,2860,O
with,2860,O
average,2860,O
age,2860,O
of,2860,O
33,2860,O
years,2860,O
and,2860,O
15,2860,O
(,2860,O
13,2860,O
%,2860,O
),2860,O
had,2860,O
skin,2860,O
rashes,2860,O
",",2860,O
14,2860,O
(,2860,O
12,2860,O
%,2860,O
),2860,O
had,2860,O
chronic,2860,O
bronchitis,2860,O
",",2860,O
10,2860,O
(,2860,O
8,2860,O
%,2860,O
),2860,O
had,2860,O
gastritis,2860,O
and,2860,O
4,2860,O
(,2860,O
3,2860,O
%,2860,O
),2860,O
conjunctivitis,2860,O
.,2860,O
The,2861,O
tannery,2861,O
workers,2861,O
had,2861,O
significantly,2861,O
raised,2861,O
median,2861,O
(,2861,O
interquartile,2861,O
range,2861,O
),2861,O
of,2861,O
BCr,2861,O
569,2861,O
(,2861,O
377-726,2861,O
),2861,O
nmol/L,2861,O
as,2861,O
compared,2861,O
to,2861,O
318,2861,O
(,2861,O
245-397,2861,O
),2861,O
nmol/L,2861,O
in,2861,O
the,2861,O
control,2861,O
(,2861,O
p,2861,O
<,2861,O
0.001,2861,O
),2861,O
.,2861,O
Sixty-five,2862,O
(,2862,O
54,2862,O
%,2862,O
),2862,O
workers,2862,O
had,2862,O
BCr,2862,O
levels,2862,O
above,2862,O
the,2862,O
upper,2862,O
limit,2862,O
set,2862,O
by,2862,O
Agency,2862,O
for,2862,O
Toxic,2862,O
Substance,2862,O
and,2862,O
Drug,2862,O
Registry,2862,O
.,2862,O
The,2863,O
urinary,2863,O
chromium,2863,B-CHEMICAL
excretion,2863,O
was,2863,O
significantly,2863,O
high,2863,O
in,2863,O
workers,2863,O
131,2863,O
(,2863,O
46-312,2863,O
),2863,O
nmol/L,2863,O
as,2863,O
compared,2863,O
to,2863,O
13,2863,O
(,2863,O
3-26,2863,O
),2863,O
nmol/L,2863,O
in,2863,O
controls,2863,O
(,2863,O
p,2863,O
<,2863,O
0.01,2863,O
),2863,O
.,2863,O
The,2864,O
workers,2864,O
had,2864,O
hematological,2864,O
",",2864,O
hepatic,2864,O
and,2864,O
renal,2864,O
function,2864,O
impairment,2864,O
because,2864,O
of,2864,O
oxidative,2864,O
stress,2864,O
on,2864,O
body,2864,O
systems,2864,O
.,2864,O
It,2865,O
is,2865,O
concluded,2865,O
that,2865,O
about,2865,O
half,2865,O
of,2865,O
the,2865,O
workers,2865,O
had,2865,O
excessive,2865,O
exposure,2865,O
to,2865,O
chromium,2865,B-CHEMICAL
in,2865,O
the,2865,O
tanneries,2865,O
at,2865,O
Sialkot,2865,O
.,2865,O
They,2866,O
had,2866,O
significantly,2866,O
raised,2866,O
chromium,2866,B-CHEMICAL
levels,2866,O
in,2866,O
their,2866,O
biological,2866,O
fluids,2866,O
and,2866,O
adverse,2866,O
health,2866,O
effects,2866,O
due,2866,O
to,2866,O
enhanced,2866,O
oxidative,2866,O
stress,2866,O
and,2866,O
inflammatory,2866,O
changes,2866,O
.,2866,O
Protective,2867,O
effect,2867,O
of,2867,O
vitamin,2867,B-CHEMICAL
E,2867,I-CHEMICAL
and,2867,O
epicatechin,2867,B-CHEMICAL
against,2867,O
nicotine-induced,2867,B-CHEMICAL
oxidative,2867,O
stress,2867,O
in,2867,O
rats,2867,O
.,2867,O
Nicotine,2868,B-CHEMICAL
is,2868,O
a,2868,O
major,2868,O
pharmacologically,2868,O
active,2868,O
and,2868,O
addictive,2868,O
component,2868,O
of,2868,O
tobacco,2868,O
smoke,2868,O
",",2868,O
which,2868,O
is,2868,O
regarded,2868,O
to,2868,O
be,2868,O
a,2868,O
primary,2868,O
risk,2868,O
factor,2868,O
in,2868,O
the,2868,O
development,2868,O
of,2868,O
cardiovascular,2868,O
and,2868,O
pulmonary,2868,O
diseases,2868,O
.,2868,O
Epicatechin,2869,B-CHEMICAL
is,2869,O
one,2869,O
of,2869,O
the,2869,O
most,2869,O
potent,2869,O
antioxidants,2869,O
present,2869,O
in,2869,O
the,2869,O
human,2869,O
diet,2869,O
.,2869,O
Particularly,2870,O
high,2870,O
levels,2870,O
of,2870,O
this,2870,O
compound,2870,O
are,2870,O
found,2870,O
in,2870,O
tea,2870,O
",",2870,O
apples,2870,O
and,2870,O
chocolate,2870,O
.,2870,O
It,2871,O
has,2871,O
been,2871,O
reported,2871,O
that,2871,O
tea,2871,O
extracts,2871,O
and/or,2871,O
its,2871,O
constituents,2871,O
have,2871,O
antibacterial,2871,O
",",2871,O
antiviral,2871,O
",",2871,O
antioxidative,2871,O
",",2871,O
antitumor,2871,O
and,2871,O
antimutagenic,2871,O
activities,2871,O
.,2871,O
Vitamin,2872,B-CHEMICAL
E,2872,I-CHEMICAL
is,2872,O
a,2872,O
major,2872,O
lipid-soluble,2872,O
antioxidant,2872,O
vitamin,2872,O
and,2872,O
free,2872,O
radical,2872,O
scavenger,2872,O
",",2872,O
presents,2872,O
as,2872,O
an,2872,O
integral,2872,O
component,2872,O
of,2872,O
cellular,2872,O
membranes,2872,O
and,2872,O
has,2872,O
important,2872,O
biological,2872,O
functions,2872,O
.,2872,O
The,2873,O
primary,2873,O
mechanism,2873,O
by,2873,O
which,2873,O
vitamin,2873,B-CHEMICAL
E,2873,I-CHEMICAL
is,2873,O
proposed,2873,O
to,2873,O
prevent,2873,O
cancer,2873,O
is,2873,O
through,2873,O
their,2873,O
antioxidant,2873,O
properties,2873,O
.,2873,O
The,2874,O
goal,2874,O
of,2874,O
this,2874,O
study,2874,O
is,2874,O
to,2874,O
evaluate,2874,O
the,2874,O
effect,2874,O
of,2874,O
epicatechin,2874,B-CHEMICAL
alone,2874,O
or,2874,O
combined,2874,O
with,2874,O
vitamin,2874,B-CHEMICAL
E,2874,I-CHEMICAL
in,2874,O
inhibiting,2874,O
the,2874,O
oxidative,2874,O
stress,2874,O
induced,2874,O
by,2874,O
nicotine,2874,B-CHEMICAL
in,2874,O
rats,2874,O
.,2874,O
Results,2875,O
obtained,2875,O
indicated,2875,O
that,2875,O
there,2875,O
was,2875,O
a,2875,O
significant,2875,O
elevation,2875,O
in,2875,O
the,2875,O
levels,2875,O
of,2875,O
malondialdhyde,2875,B-CHEMICAL
(,2875,O
MDA,2875,B-CHEMICAL
),2875,O
in,2875,O
nicotine,2875,B-CHEMICAL
injected,2875,O
rats,2875,O
.,2875,O
The,2876,O
combined,2876,O
treatment,2876,O
(,2876,O
epicatechin,2876,B-CHEMICAL
+,2876,O
Vit,2876,B-CHEMICAL
E,2876,I-CHEMICAL
),2876,O
group,2876,O
showed,2876,O
a,2876,O
potential,2876,O
reduction,2876,O
of,2876,O
these,2876,O
parameters,2876,O
more,2876,O
than,2876,O
individual,2876,O
treatment,2876,O
.,2876,O
The,2877,O
activities,2877,O
of,2877,O
superoxide,2877,B-CHEMICAL
dismutase,2877,I-GENE-N
",",2877,O
catalase,2877,B-GENE-Y
and,2877,O
glutathione,2877,B-CHEMICAL
peroxidase,2877,I-GENE-N
were,2877,O
found,2877,O
significantly,2877,O
higher,2877,O
in,2877,O
combined,2877,O
treated,2877,O
than,2877,O
untreated,2877,O
rats,2877,O
.,2877,O
In,2878,O
nicotine,2878,B-CHEMICAL
group,2878,O
",",2878,O
a,2878,O
negative,2878,O
significant,2878,O
correlation,2878,O
between,2878,O
reduced,2878,O
glutathione,2878,B-CHEMICAL
and,2878,O
MDA,2878,B-CHEMICAL
(,2878,O
r,2878,O
=,2878,O
-0.92,2878,O
),2878,O
was,2878,O
observed,2878,O
.,2878,O
In,2879,O
conclusion,2879,O
",",2879,O
these,2879,O
results,2879,O
suggested,2879,O
that,2879,O
the,2879,O
supplementation,2879,O
of,2879,O
diet,2879,O
with,2879,O
epicatechin,2879,B-CHEMICAL
and,2879,O
vitamin,2879,B-CHEMICAL
E,2879,I-CHEMICAL
provided,2879,O
antioxidant,2879,O
defense,2879,O
with,2879,O
strong,2879,O
chemopreventive,2879,O
activity,2879,O
against,2879,O
nicotine-induced,2879,B-CHEMICAL
carcinogenesis,2879,O
.,2879,O
Conditional,2880,O
activation,2880,O
of,2880,O
Pik3ca,2880,B-GENE-Y
(,2880,O
H1047R,2880,B-GENE-N
),2880,O
in,2880,O
a,2880,O
knock-in,2880,O
mouse,2880,O
model,2880,O
promotes,2880,O
mammary,2880,O
tumorigenesis,2880,O
and,2880,O
emergence,2880,O
of,2880,O
mutations,2880,O
.,2880,O
Oncogenic,2881,O
mutations,2881,O
in,2881,O
PIK3CA,2881,B-GENE-Y
",",2881,O
which,2881,O
encodes,2881,O
the,2881,O
phosphoinositide-3-kinase,2881,B-CHEMICAL
(,2881,I-GENE-Y
PI3K,2881,I-GENE-Y
),2881,I-GENE-Y
catalytic,2881,I-GENE-Y
subunit,2881,I-GENE-Y
p110,2881,I-GENE-Y
",",2881,O
occur,2881,O
in,2881,O
25,2881,O
%,2881,O
of,2881,O
human,2881,O
breast,2881,O
cancers,2881,O
.,2881,O
In,2882,O
this,2882,O
study,2882,O
",",2882,O
we,2882,O
report,2882,O
the,2882,O
development,2882,O
of,2882,O
a,2882,O
knock-in,2882,O
mouse,2882,O
model,2882,O
for,2882,O
breast,2882,O
cancer,2882,O
where,2882,O
the,2882,O
endogenous,2882,O
Pik3ca,2882,B-GENE-Y
allele,2882,O
was,2882,O
modified,2882,O
to,2882,O
allow,2882,O
tissue-specific,2882,O
conditional,2882,O
expression,2882,O
of,2882,O
a,2882,O
frequently,2882,O
found,2882,O
Pik3ca,2882,B-GENE-Y
(,2882,O
H1047R,2882,B-GENE-N
),2882,O
(,2882,O
Pik3ca,2882,B-GENE-Y
(,2882,O
e20H1047R,2882,B-GENE-N
),2882,O
),2882,O
mutant,2882,O
allele,2882,O
.,2882,O
We,2883,O
found,2883,O
that,2883,O
activation,2883,O
of,2883,O
the,2883,O
latent,2883,O
Pik3ca,2883,B-GENE-Y
(,2883,O
H1047R,2883,B-GENE-N
),2883,O
allele,2883,O
resulted,2883,O
in,2883,O
breast,2883,O
tumors,2883,O
with,2883,O
multiple,2883,O
histological,2883,O
types,2883,O
.,2883,O
Whole-exome,2884,O
analysis,2884,O
of,2884,O
the,2884,O
Pik3ca,2884,B-GENE-Y
(,2884,O
H1047R,2884,B-GENE-N
),2884,O
-driven,2884,O
mammary,2884,O
tumors,2884,O
identified,2884,O
multiple,2884,O
mutations,2884,O
",",2884,O
including,2884,O
Trp53,2884,B-CHEMICAL
mutations,2884,O
that,2884,O
appeared,2884,O
spontaneously,2884,O
during,2884,O
the,2884,O
development,2884,O
of,2884,O
adenocarinoma,2884,O
and,2884,O
spindle,2884,O
cell,2884,O
tumors,2884,O
.,2884,O
Further,2885,O
",",2885,O
we,2885,O
used,2885,O
this,2885,O
model,2885,O
to,2885,O
test,2885,O
the,2885,O
efficacy,2885,O
of,2885,O
GDC-0941,2885,B-CHEMICAL
",",2885,O
a,2885,O
PI3K,2885,B-GENE-N
inhibitor,2885,O
",",2885,O
in,2885,O
clinical,2885,O
development,2885,O
",",2885,O
and,2885,O
showed,2885,O
that,2885,O
the,2885,O
tumors,2885,O
respond,2885,O
to,2885,O
PI3K,2885,B-GENE-N
inhibition,2885,O
.,2885,O
Quercetin,2886,B-CHEMICAL
reduces,2886,O
high-fat,2886,O
diet-induced,2886,O
fat,2886,O
accumulation,2886,O
in,2886,O
the,2886,O
liver,2886,O
by,2886,O
regulating,2886,O
lipid,2886,O
metabolism,2886,O
genes,2886,O
.,2886,O
To,2887,O
understand,2887,O
the,2887,O
molecular,2887,O
mechanisms,2887,O
underlying,2887,O
the,2887,O
influence,2887,O
of,2887,O
quercetin,2887,B-CHEMICAL
on,2887,O
the,2887,O
physiological,2887,O
effects,2887,O
of,2887,O
hyperlipidemia,2887,O
",",2887,O
we,2887,O
investigated,2887,O
its,2887,O
role,2887,O
in,2887,O
the,2887,O
prevention,2887,O
of,2887,O
high-fat,2887,O
diet,2887,O
(,2887,O
HFD,2887,O
),2887,O
-induced,2887,O
obesity,2887,O
and,2887,O
found,2887,O
that,2887,O
it,2887,O
regulated,2887,O
hepatic,2887,O
gene,2887,O
expression,2887,O
related,2887,O
to,2887,O
lipid,2887,O
metabolism,2887,O
.,2887,O
Quercetin,2888,B-CHEMICAL
supplementation,2888,O
in,2888,O
mice,2888,O
significantly,2888,O
reduced,2888,O
the,2888,O
HFD-induced,2888,O
gains,2888,O
in,2888,O
body,2888,O
weight,2888,O
",",2888,O
liver,2888,O
weight,2888,O
",",2888,O
and,2888,O
white,2888,O
adipose,2888,O
tissue,2888,O
weight,2888,O
compared,2888,O
with,2888,O
the,2888,O
mice,2888,O
fed,2888,O
only,2888,O
with,2888,O
HFD,2888,O
.,2888,O
It,2889,O
also,2889,O
significantly,2889,O
reduced,2889,O
HFD-induced,2889,O
increases,2889,O
in,2889,O
serum,2889,O
lipids,2889,O
",",2889,O
including,2889,O
cholesterol,2889,B-CHEMICAL
",",2889,O
triglyceride,2889,B-CHEMICAL
",",2889,O
and,2889,O
thiobarbituric,2889,B-CHEMICAL
acid-reactive,2889,O
substance,2889,O
(,2889,O
TBARS,2889,O
),2889,O
.,2889,O
Consistent,2890,O
with,2890,O
the,2890,O
reduced,2890,O
liver,2890,O
weight,2890,O
and,2890,O
white,2890,O
adipose,2890,O
tissue,2890,O
weight,2890,O
",",2890,O
hepatic,2890,O
lipid,2890,O
accumulation,2890,O
and,2890,O
the,2890,O
size,2890,O
of,2890,O
lipid,2890,O
droplets,2890,O
in,2890,O
the,2890,O
epididymal,2890,O
fat,2890,O
pads,2890,O
were,2890,O
also,2890,O
reduced,2890,O
by,2890,O
quercetin,2890,B-CHEMICAL
supplementation,2890,O
.,2890,O
To,2891,O
further,2891,O
investigate,2891,O
how,2891,O
quercetin,2891,B-CHEMICAL
may,2891,O
reduce,2891,O
obesity,2891,O
",",2891,O
we,2891,O
analyzed,2891,O
lipid,2891,O
metabolism-related,2891,O
genes,2891,O
in,2891,O
the,2891,O
liver,2891,O
.,2891,O
Quercetin,2892,B-CHEMICAL
supplementation,2892,O
altered,2892,O
expression,2892,O
profiles,2892,O
of,2892,O
several,2892,O
lipid,2892,O
metabolism-related,2892,O
genes,2892,O
",",2892,O
including,2892,O
Fnta,2892,B-GENE-Y
",",2892,O
Pon1,2892,B-GENE-Y
",",2892,O
Pparg,2892,B-GENE-Y
",",2892,O
Aldh1b1,2892,B-GENE-Y
",",2892,O
Apoa4,2892,B-GENE-Y
",",2892,O
Abcg5,2892,B-GENE-Y
",",2892,O
Gpam,2892,B-GENE-Y
",",2892,O
Acaca,2892,B-GENE-Y
",",2892,O
Cd36,2892,B-GENE-Y
",",2892,O
Fdft1,2892,B-GENE-Y
",",2892,O
and,2892,O
Fasn,2892,B-GENE-Y
",",2892,O
relative,2892,O
to,2892,O
those,2892,O
in,2892,O
HFD,2892,O
control,2892,O
mice,2892,O
.,2892,O
The,2893,O
expression,2893,O
patterns,2893,O
of,2893,O
these,2893,O
genes,2893,O
observed,2893,O
by,2893,O
quantitative,2893,O
reverse,2893,O
transcriptase-polymerase,2893,O
chain,2893,O
reaction,2893,O
were,2893,O
confirmed,2893,O
by,2893,O
immunoblot,2893,O
assays,2893,O
.,2893,O
Collectively,2894,O
",",2894,O
our,2894,O
results,2894,O
indicate,2894,O
that,2894,O
quercetin,2894,B-CHEMICAL
prevents,2894,O
HFD-induced,2894,O
obesity,2894,O
in,2894,O
C57B1/6,2894,O
mice,2894,O
",",2894,O
and,2894,O
its,2894,O
anti-obesity,2894,O
effects,2894,O
may,2894,O
be,2894,O
related,2894,O
to,2894,O
the,2894,O
regulation,2894,O
of,2894,O
lipogenesis,2894,O
at,2894,O
the,2894,O
level,2894,O
of,2894,O
transcription,2894,O
.,2894,O
In,2895,O
vivo,2895,O
and,2895,O
in,2895,O
vitro,2895,O
models,2895,O
for,2895,O
the,2895,O
therapeutic,2895,O
targeting,2895,O
of,2895,O
Wnt,2895,B-GENE-N
signaling,2895,O
using,2895,O
a,2895,O
Tet-ON89-catenin,2895,O
system,2895,O
.,2895,O
Although,2896,O
significant,2896,O
progress,2896,O
has,2896,O
been,2896,O
made,2896,O
in,2896,O
understanding,2896,O
the,2896,O
importance,2896,O
of,2896,O
Wnt,2896,B-GENE-N
signaling,2896,O
in,2896,O
the,2896,O
initiation,2896,O
of,2896,O
colorectal,2896,O
cancer,2896,O
",",2896,O
less,2896,O
is,2896,O
known,2896,O
about,2896,O
responses,2896,O
that,2896,O
accompany,2896,O
the,2896,O
reversal,2896,O
of,2896,O
oncogenic,2896,O
Wnt,2896,B-GENE-N
signaling,2896,O
.,2896,O
The,2897,O
aim,2897,O
of,2897,O
this,2897,O
study,2897,O
was,2897,O
to,2897,O
analyze,2897,O
in,2897,O
vivo,2897,O
and,2897,O
in,2897,O
vitro,2897,O
responses,2897,O
to,2897,O
an,2897,O
'ideal,2897,O
',2897,O
Wnt,2897,B-GENE-N
pathway,2897,O
inhibitor,2897,O
as,2897,O
a,2897,O
model,2897,O
for,2897,O
the,2897,O
therapeutic,2897,O
targeting,2897,O
of,2897,O
the,2897,O
pathway,2897,O
.,2897,O
A,2898,O
tetracycline-inducible,2898,B-CHEMICAL
transgenic,2898,O
mouse,2898,O
model,2898,O
expressing,2898,O
truncated,2898,O
-catenin,2898,B-GENE-Y
(,2898,O
N89-catenin,2898,O
),2898,O
that,2898,O
exhibited,2898,O
a,2898,O
strong,2898,O
intestinal,2898,O
hyperplasia,2898,O
was,2898,O
analyzed,2898,O
during,2898,O
the,2898,O
removal,2898,O
of,2898,O
oncogenic,2898,O
-catenin,2898,B-GENE-Y
expression,2898,O
both,2898,O
in,2898,O
3D,2898,O
'crypt,2898,O
culture,2898,O
',2898,O
and,2898,O
in,2898,O
vivo,2898,O
.,2898,O
Oncogenic,2899,O
Wnt,2899,B-GENE-N
signaling,2899,O
was,2899,O
rapidly,2899,O
and,2899,O
completely,2899,O
reversed,2899,O
.,2899,O
The,2900,O
strongest,2900,O
inhibition,2900,O
of,2900,O
Wnt,2900,B-GENE-N
target,2900,O
gene,2900,O
expression,2900,O
occurred,2900,O
within,2900,O
24,2900,O
h,2900,O
of,2900,O
doxycycline,2900,O
removal,2900,O
at,2900,O
which,2900,O
time,2900,O
the,2900,O
target,2900,O
genes,2900,O
Ascl2,2900,B-GENE-Y
",",2900,O
Axin2,2900,B-GENE-Y
and,2900,O
C-myc,2900,B-GENE-Y
were,2900,O
downregulated,2900,O
to,2900,O
levels,2900,O
below,2900,O
that,2900,O
in,2900,O
the,2900,O
control,2900,O
intestine,2900,O
.,2900,O
In,2901,O
vitro,2901,O
",",2901,O
the,2901,O
small,2901,O
molecule,2901,O
Wnt,2901,B-GENE-N
inhibitor,2901,O
CCT036477,2901,O
induced,2901,O
a,2901,O
response,2901,O
within,2901,O
4,2901,O
h,2901,O
of,2901,O
treatment,2901,O
.,2901,O
By,2902,O
7,2902,O
days,2902,O
following,2902,O
doxycycline,2902,B-CHEMICAL
withdrawal,2902,O
",",2902,O
gene,2902,O
expression,2902,O
",",2902,O
cell,2902,O
proliferation,2902,O
and,2902,O
tissue,2902,O
morphology,2902,O
were,2902,O
undistinguishable,2902,O
from,2902,O
control,2902,O
animals.In,2902,O
conclusion,2902,O
",",2902,O
these,2902,O
results,2902,O
demonstrate,2902,O
that,2902,O
the,2902,O
reversal,2902,O
of,2902,O
Wnt,2902,B-GENE-N
signaling,2902,O
by,2902,O
inhibitors,2902,O
should,2902,O
ideally,2902,O
be,2902,O
studied,2902,O
within,2902,O
hours,2902,O
of,2902,O
treatment,2902,O
.,2902,O
The,2903,O
reversible,2903,O
system,2903,O
described,2903,O
",",2903,O
involving,2903,O
medium,2903,O
throughput,2903,O
in,2903,O
vitro,2903,O
approaches,2903,O
and,2903,O
rapid,2903,O
in,2903,O
vivo,2903,O
responses,2903,O
",",2903,O
should,2903,O
allow,2903,O
the,2903,O
rapid,2903,O
advance,2903,O
of,2903,O
early,2903,O
stage,2903,O
compounds,2903,O
into,2903,O
efficacy,2903,O
models,2903,O
that,2903,O
are,2903,O
more,2903,O
usually,2903,O
considered,2903,O
later,2903,O
in,2903,O
the,2903,O
drug,2903,O
discovery,2903,O
pipeline,2903,O
.,2903,O
Discovery,2904,O
and,2904,O
structural,2904,O
characterization,2904,O
of,2904,O
a,2904,O
phospholamban-binding,2904,B-GENE-Y
cyclic,2904,O
peptide,2904,O
and,2904,O
design,2904,O
of,2904,O
novel,2904,O
inhibitors,2904,O
of,2904,O
phospholamban,2904,B-GENE-Y
.,2904,O
The,2905,O
interplay,2905,O
between,2905,O
cardiac,2905,O
sarcoplasmic,2905,O
Ca,2905,B-CHEMICAL
(,2905,I-CHEMICAL
2+,2905,I-CHEMICAL
),2905,I-CHEMICAL
ATPase,2905,I-GENE-N
and,2905,O
phospholamban,2905,B-GENE-Y
is,2905,O
a,2905,O
key,2905,O
regulating,2905,O
factor,2905,O
of,2905,O
contraction,2905,O
and,2905,O
relaxation,2905,O
in,2905,O
the,2905,O
cardiac,2905,O
muscle,2905,O
.,2905,O
In,2906,O
heart,2906,O
failure,2906,O
",",2906,O
aberrations,2906,O
in,2906,O
the,2906,O
inhibition,2906,O
of,2906,O
sarcoplasmic,2906,O
Ca,2906,B-CHEMICAL
(,2906,I-CHEMICAL
2+,2906,I-CHEMICAL
),2906,I-CHEMICAL
ATPase,2906,I-GENE-N
by,2906,O
phospholamban,2906,B-GENE-Y
are,2906,O
associated,2906,O
with,2906,O
anomalies,2906,O
in,2906,O
cardiac,2906,O
functions,2906,O
.,2906,O
In,2907,O
experimental,2907,O
heart,2907,O
failure,2907,O
models,2907,O
",",2907,O
modulation,2907,O
of,2907,O
the,2907,O
interaction,2907,O
between,2907,O
these,2907,O
two,2907,O
proteins,2907,O
has,2907,O
been,2907,O
shown,2907,O
to,2907,O
be,2907,O
a,2907,O
potential,2907,O
therapeutic,2907,O
approach,2907,O
.,2907,O
The,2908,O
aim,2908,O
of,2908,O
our,2908,O
research,2908,O
was,2908,O
to,2908,O
find,2908,O
molecules,2908,O
able,2908,O
to,2908,O
interfere,2908,O
with,2908,O
the,2908,O
inhibitory,2908,O
activity,2908,O
of,2908,O
phospholamban,2908,B-GENE-Y
on,2908,O
sarcoplasmic,2908,O
Ca,2908,B-CHEMICAL
(,2908,I-CHEMICAL
2+,2908,I-CHEMICAL
),2908,I-CHEMICAL
ATPase,2908,I-GENE-N
.,2908,O
For,2909,O
this,2909,O
purpose,2909,O
",",2909,O
a,2909,O
portion,2909,O
of,2909,O
phospholamban,2909,B-GENE-Y
was,2909,O
synthesized,2909,O
and,2909,O
used,2909,O
as,2909,O
target,2909,O
for,2909,O
a,2909,O
phage-display,2909,O
peptide,2909,O
library,2909,O
screening,2909,O
.,2909,O
The,2910,O
cyclic,2910,O
peptide,2910,O
C-Y-W-E-L-E-W-L-P-C-A,2910,B-GENE-N
was,2910,O
found,2910,O
to,2910,O
bind,2910,O
to,2910,O
phospholamban,2910,B-GENE-Y
(,2910,I-GENE-Y
1-36,2910,I-GENE-Y
),2910,I-GENE-Y
with,2910,O
high,2910,O
specificity,2910,O
.,2910,O
Its,2911,O
functional,2911,O
activity,2911,O
was,2911,O
tested,2911,O
in,2911,O
Ca,2911,B-CHEMICAL
(,2911,I-CHEMICAL
2+,2911,I-CHEMICAL
),2911,I-CHEMICAL
uptake,2911,O
assays,2911,O
utilizing,2911,O
preparations,2911,O
from,2911,O
cardiac,2911,O
sarcoplasmic,2911,O
reticulum,2911,O
.,2911,O
By,2912,O
synthesizing,2912,O
and,2912,O
testing,2912,O
a,2912,O
series,2912,O
of,2912,O
alanine,2912,B-CHEMICAL
point-mutated,2912,O
cyclic,2912,B-GENE-N
peptides,2912,I-GENE-N
",",2912,O
we,2912,O
identified,2912,O
which,2912,O
amino,2912,B-CHEMICAL
acid,2912,I-CHEMICAL
was,2912,O
important,2912,O
for,2912,O
the,2912,O
inhibition,2912,O
of,2912,O
the,2912,O
phospholamban,2912,B-GENE-Y
function,2912,O
.,2912,O
The,2913,O
structures,2913,O
of,2913,O
active,2913,O
and,2913,O
inactive,2913,O
alanine-mutated,2913,B-CHEMICAL
cyclic,2913,B-GENE-N
peptides,2913,I-GENE-N
",",2913,O
and,2913,O
of,2913,O
phospholamban,2913,B-GENE-Y
(,2913,I-GENE-Y
1-36,2913,I-GENE-Y
),2913,I-GENE-Y
",",2913,O
were,2913,O
determined,2913,O
by,2913,O
NMR,2913,O
.,2913,O
This,2914,O
structure-activity,2914,O
analysis,2914,O
allowed,2914,O
building,2914,O
a,2914,O
model,2914,O
of,2914,O
phospholamban,2914,B-GENE-Y
-cyclic,2914,O
peptide,2914,O
complex,2914,O
.,2914,O
Thereafter,2915,O
",",2915,O
a,2915,O
simple,2915,O
pharmacophore,2915,O
was,2915,O
defined,2915,O
and,2915,O
used,2915,O
for,2915,O
the,2915,O
design,2915,O
of,2915,O
small,2915,O
molecules,2915,O
.,2915,O
Finally,2916,O
",",2916,O
examples,2916,O
of,2916,O
such,2916,O
molecules,2916,O
were,2916,O
synthesized,2916,O
and,2916,O
characterized,2916,O
as,2916,O
phospholamban,2916,B-GENE-Y
inhibitors,2916,O
.,2916,O
Macrophage,2917,O
cathepsin,2917,B-GENE-Y
K,2917,I-GENE-Y
promotes,2917,O
prostate,2917,O
tumor,2917,O
progression,2917,O
in,2917,O
bone,2917,O
.,2917,O
Bone,2918,O
marrow,2918,O
macrophages,2918,O
(,2918,O
BMMs,2918,O
),2918,O
share,2918,O
common,2918,O
progenitors,2918,O
with,2918,O
osteoclasts,2918,O
and,2918,O
are,2918,O
critical,2918,O
components,2918,O
of,2918,O
bone-tumor,2918,O
microenvironment,2918,O
;,2918,O
however,2918,O
",",2918,O
their,2918,O
function,2918,O
in,2918,O
prostate,2918,O
tumor,2918,O
growth,2918,O
in,2918,O
the,2918,O
skeleton,2918,O
has,2918,O
not,2918,O
been,2918,O
explored,2918,O
.,2918,O
BMMs,2919,O
are,2919,O
the,2919,O
major,2919,O
source,2919,O
of,2919,O
inflammatory,2919,O
factors,2919,O
and,2919,O
proteases,2919,B-GENE-N
",",2919,O
including,2919,O
cysteine,2919,B-GENE-N
protease,2919,I-GENE-N
cathepsin,2919,B-GENE-Y
K,2919,I-GENE-Y
(,2919,O
CTSK,2919,B-GENE-Y
),2919,O
.,2919,O
In,2920,O
this,2920,O
study,2920,O
",",2920,O
utilizing,2920,O
mice,2920,O
deficient,2920,O
in,2920,O
CTSK,2920,B-GENE-Y
",",2920,O
we,2920,O
demonstrate,2920,O
the,2920,O
critical,2920,O
involvement,2920,O
of,2920,O
this,2920,O
potent,2920,O
collagenase,2920,B-GENE-N
in,2920,O
tumor,2920,O
progression,2920,O
in,2920,O
bone,2920,O
.,2920,O
We,2921,O
present,2921,O
the,2921,O
evidence,2921,O
that,2921,O
tumor,2921,O
growth,2921,O
and,2921,O
progression,2921,O
in,2921,O
the,2921,O
bone,2921,O
are,2921,O
impaired,2921,O
in,2921,O
the,2921,O
absence,2921,O
of,2921,O
CTSK,2921,B-GENE-Y
.,2921,O
Most,2922,O
importantly,2922,O
",",2922,O
we,2922,O
show,2922,O
for,2922,O
the,2922,O
first,2922,O
time,2922,O
that,2922,O
BMM-supplied,2922,O
CTSK,2922,B-GENE-Y
may,2922,O
be,2922,O
involved,2922,O
in,2922,O
CCL2-,2922,B-GENE-Y
and,2922,O
COX-2-driven,2922,B-GENE-Y
pathways,2922,O
that,2922,O
contribute,2922,O
to,2922,O
tumor,2922,O
progression,2922,O
in,2922,O
bone,2922,O
.,2922,O
Together,2923,O
",",2923,O
our,2923,O
data,2923,O
unravel,2923,O
novel,2923,O
roles,2923,O
for,2923,O
CTSK,2923,B-GENE-Y
in,2923,O
macrophage-regulated,2923,O
processes,2923,O
",",2923,O
and,2923,O
provide,2923,O
evidence,2923,O
for,2923,O
close,2923,O
interplay,2923,O
between,2923,O
inflammatory,2923,O
",",2923,O
osteolytic,2923,O
and,2923,O
tumor,2923,O
cell-driven,2923,O
events,2923,O
in,2923,O
the,2923,O
bone-tumor,2923,O
microenvironment,2923,O
.,2923,O
Effect,2924,O
of,2924,O
tetrabrombisphenol,2924,B-CHEMICAL
A,2924,I-CHEMICAL
on,2924,O
induction,2924,O
of,2924,O
apoptosis,2924,O
in,2924,O
the,2924,O
testes,2924,O
and,2924,O
changes,2924,O
in,2924,O
expression,2924,O
of,2924,O
selected,2924,O
testicular,2924,O
genes,2924,O
in,2924,O
CD1,2924,O
mice,2924,O
.,2924,O
Tetrabromobisphenol,2925,B-CHEMICAL
A,2925,I-CHEMICAL
(,2925,O
TBBPA,2925,B-CHEMICAL
),2925,O
is,2925,O
a,2925,O
substance,2925,O
widely,2925,O
used,2925,O
in,2925,O
industry,2925,O
as,2925,O
a,2925,O
flame,2925,O
retardant,2925,O
.,2925,O
TBBPA,2926,B-CHEMICAL
was,2926,O
found,2926,O
in,2926,O
the,2926,O
environment,2926,O
and,2926,O
was,2926,O
detected,2926,O
even,2926,O
in,2926,O
the,2926,O
human,2926,O
body,2926,O
.,2926,O
The,2927,O
effect,2927,O
of,2927,O
this,2927,O
chemical,2927,O
was,2927,O
observed,2927,O
in,2927,O
different,2927,O
cell,2927,O
lines,2927,O
in,2927,O
vitro,2927,O
and,2927,O
it,2927,O
is,2927,O
supposed,2927,O
that,2927,O
TBBPA,2927,B-CHEMICAL
may,2927,O
affect,2927,O
various,2927,O
hormonal,2927,O
systems,2927,O
in,2927,O
vivo,2927,O
.,2927,O
In,2928,O
this,2928,O
study,2928,O
we,2928,O
examined,2928,O
the,2928,O
effect,2928,O
of,2928,O
TBBPA,2928,B-CHEMICAL
on,2928,O
the,2928,O
reproductive,2928,O
parameters,2928,O
of,2928,O
two,2928,O
generations,2928,O
of,2928,O
outbred,2928,O
mice,2928,O
in,2928,O
vivo,2928,O
.,2928,O
Experimental,2929,O
and,2929,O
control,2929,O
animals,2929,O
of,2929,O
F1,2929,O
generation,2929,O
were,2929,O
bred,2929,O
in,2929,O
various,2929,O
conditions,2929,O
to,2929,O
enable,2929,O
evaluation,2929,O
of,2929,O
the,2929,O
possible,2929,O
trans-generational,2929,O
effect,2929,O
.,2929,O
An,2930,O
increased,2930,O
incidence,2930,O
of,2930,O
apoptosis,2930,O
in,2930,O
the,2930,O
testes,2930,O
and,2930,O
changes,2930,O
in,2930,O
the,2930,O
morphometry,2930,O
of,2930,O
seminiferous,2930,O
tubules,2930,O
was,2930,O
detected,2930,O
in,2930,O
the,2930,O
experimental,2930,O
animals,2930,O
.,2930,O
In,2931,O
addition,2931,O
",",2931,O
changes,2931,O
in,2931,O
the,2931,O
expression,2931,O
pattern,2931,O
of,2931,O
selected,2931,O
genes,2931,O
encoding,2931,O
proteins,2931,O
that,2931,O
play,2931,O
an,2931,O
important,2931,O
role,2931,O
during,2931,O
spermatogenesis,2931,O
were,2931,O
observed,2931,O
.,2931,O
In,2932,O
contrast,2932,O
",",2932,O
sperm,2932,O
quality,2932,O
and,2932,O
reproduction,2932,O
were,2932,O
not,2932,O
affected,2932,O
by,2932,O
TBBPA,2932,B-CHEMICAL
.,2932,O
Inhibitory,2933,O
effect,2933,O
of,2933,O
synthetic,2933,O
progestins,2933,B-CHEMICAL
",",2933,O
4-MA,2933,B-CHEMICAL
and,2933,O
cyanoketone,2933,B-CHEMICAL
on,2933,O
human,2933,B-GENE-N
placental,2933,I-GENE-N
3,2933,I-GENE-N
beta-hydroxysteroid,2933,I-GENE-N
dehydrogenase/5,2933,I-GENE-N
--,2933,I-GENE-N
--,2933,I-GENE-N
4-ene-isomerase,2933,I-GENE-N
activity,2933,O
.,2933,O
Human,2934,B-GENE-N
placental,2934,I-GENE-N
3,2934,B-CHEMICAL
beta-hydroxysteroid,2934,I-CHEMICAL
dehydrogenase/5,2934,I-GENE-N
--,2934,I-GENE-N
--,2934,I-GENE-N
4-ene,2934,I-GENE-N
isomerase,2934,I-GENE-N
(,2934,O
3,2934,B-GENE-N
beta-HSD,2934,I-GENE-N
),2934,O
purified,2934,O
from,2934,O
human,2934,O
placenta,2934,O
transforms,2934,O
C-21,2934,O
(,2934,O
pregnenolone,2934,B-CHEMICAL
and,2934,O
17,2934,B-CHEMICAL
alpha-hydroxy,2934,I-CHEMICAL
pregnenolone,2934,I-CHEMICAL
),2934,O
as,2934,O
well,2934,O
as,2934,O
C-19,2934,O
(,2934,O
dehydroepiandrosterone,2934,B-CHEMICAL
and,2934,O
androst-5-ene-3,2934,B-CHEMICAL
beta,2934,I-CHEMICAL
",",2934,I-CHEMICAL
17,2934,I-CHEMICAL
beta-diol,2934,I-CHEMICAL
),2934,O
steroids,2934,O
into,2934,O
the,2934,O
corresponding,2934,O
3-keto-4-ene-steroids,2934,B-CHEMICAL
and,2934,O
is,2934,O
thus,2934,O
involved,2934,O
in,2934,O
the,2934,O
biosynthesis,2934,O
of,2934,O
all,2934,O
classes,2934,O
of,2934,O
hormonal,2934,O
steroids,2934,O
.,2934,O
Trilostane,2935,B-CHEMICAL
",",2935,O
epostane,2935,B-CHEMICAL
and,2935,O
cyanoketone,2935,B-CHEMICAL
are,2935,O
potent,2935,O
inhibitors,2935,O
of,2935,O
3,2935,B-GENE-N
beta-HSD,2935,I-GENE-N
with,2935,O
Ki,2935,O
values,2935,O
of,2935,O
approximately,2935,O
50,2935,O
nM,2935,O
.,2935,O
4-MA,2936,B-CHEMICAL
",",2936,O
a,2936,O
well,2936,O
known,2936,O
5,2936,B-GENE-N
alpha-reductase,2936,I-GENE-N
inhibitor,2936,O
",",2936,O
is,2936,O
also,2936,O
a,2936,O
potent,2936,O
inhibitor,2936,O
of,2936,O
3,2936,B-GENE-N
beta-HSD,2936,I-GENE-N
with,2936,O
a,2936,O
Ki,2936,O
value,2936,O
of,2936,O
56,2936,O
nM,2936,O
.,2936,O
Synthetic,2937,O
progestin,2937,B-CHEMICAL
compounds,2937,O
such,2937,O
as,2937,O
promegestone,2937,B-CHEMICAL
and,2937,O
RU2323,2937,B-CHEMICAL
show,2937,O
relatively,2937,O
strong,2937,O
inhibitory,2937,O
effects,2937,O
with,2937,O
Ki,2937,O
values,2937,O
of,2937,O
110,2937,O
and,2937,O
190,2937,O
nM,2937,O
",",2937,O
respectively,2937,O
.,2937,O
Cyproterone,2938,B-CHEMICAL
acetate,2938,I-CHEMICAL
",",2938,O
a,2938,O
progestin,2938,B-CHEMICAL
used,2938,O
in,2938,O
the,2938,O
treatment,2938,O
of,2938,O
hirsutism,2938,O
",",2938,O
acne,2938,O
and,2938,O
prostate,2938,O
cancer,2938,O
as,2938,O
well,2938,O
as,2938,O
norgestrel,2938,B-CHEMICAL
and,2938,O
norethindrone,2938,B-CHEMICAL
that,2938,O
are,2938,O
widely,2938,O
used,2938,O
as,2938,O
oral,2938,O
contraceptives,2938,O
also,2938,O
inhibit,2938,O
3,2938,B-GENE-N
beta-HSD,2938,I-GENE-N
activity,2938,O
at,2938,O
Ki,2938,O
values,2938,O
of,2938,O
1.5,2938,O
",",2938,O
1.7,2938,O
and,2938,O
2.5,2938,O
microM,2938,O
",",2938,O
respectively,2938,O
.,2938,O
Enhanced,2939,O
mGlu5-receptor,2939,B-GENE-Y
dependent,2939,O
long-term,2939,O
depression,2939,O
at,2939,O
the,2939,O
Schaffer,2939,O
collateral-CA1,2939,O
synapse,2939,O
of,2939,O
congenitally,2939,O
learned,2939,O
helpless,2939,O
rats,2939,O
.,2939,O
Alterations,2940,O
of,2940,O
the,2940,O
glutamatergic,2940,O
system,2940,O
have,2940,O
been,2940,O
implicated,2940,O
in,2940,O
the,2940,O
pathophysiology,2940,O
and,2940,O
treatment,2940,O
of,2940,O
major,2940,O
depression,2940,O
.,2940,O
In,2941,O
order,2941,O
to,2941,O
investigate,2941,O
the,2941,O
expression,2941,O
and,2941,O
function,2941,O
of,2941,O
mGlu5,2941,B-GENE-Y
receptors,2941,I-GENE-Y
in,2941,O
an,2941,O
animal,2941,O
model,2941,O
for,2941,O
treatment-resistant,2941,O
depression,2941,O
we,2941,O
used,2941,O
rats,2941,O
bred,2941,O
for,2941,O
congenital,2941,O
learned,2941,O
helplessness,2941,O
(,2941,O
cLH,2941,O
),2941,O
and,2941,O
the,2941,O
control,2941,O
strain,2941,O
",",2941,O
bred,2941,O
for,2941,O
resistance,2941,O
against,2941,O
inescapable,2941,O
stress,2941,O
",",2941,O
congenitally,2941,O
.,2941,O
not,2942,O
learned,2942,O
helpless,2942,O
rats,2942,O
(,2942,O
cNLH,2942,O
),2942,O
.,2942,O
Western,2943,O
blot,2943,O
analysis,2943,O
showed,2943,O
an,2943,O
increased,2943,O
expression,2943,O
of,2943,O
mGlu5,2943,B-GENE-Y
(,2943,O
but,2943,O
not,2943,O
mGlu1a,2943,B-GENE-Y
),2943,O
receptors,2943,O
in,2943,O
the,2943,O
hippocampus,2943,O
of,2943,O
cLH,2943,O
rats,2943,O
",",2943,O
as,2943,O
compared,2943,O
with,2943,O
control,2943,O
cNLH,2943,O
rats,2943,O
.,2943,O
We,2944,O
also,2944,O
examined,2944,O
mGlu1/5,2944,B-GENE-N
receptor,2944,O
signaling,2944,O
by,2944,O
in,2944,O
vivo,2944,O
measurement,2944,O
of,2944,O
DHPG-stimulated,2944,B-CHEMICAL
polyphosphoinositides,2944,B-CHEMICAL
hydrolysis,2944,O
.,2944,O
Stimulation,2945,O
of,2945,O
(,2945,B-CHEMICAL
3,2945,I-CHEMICAL
),2945,I-CHEMICAL
H-inositolmonophosphate,2945,I-CHEMICAL
formation,2945,O
induced,2945,O
by,2945,O
i.c.v,2945,O
.,2945,O
injection,2946,O
of,2946,O
DHPG,2946,B-CHEMICAL
was,2946,O
enhanced,2946,O
by,2946,O
about,2946,O
50,2946,O
%,2946,O
in,2946,O
the,2946,O
hippocampus,2946,O
of,2946,O
cLH,2946,O
rats,2946,O
.,2946,O
Correspondingly,2947,O
",",2947,O
DHPG-induced,2947,B-CHEMICAL
long-term,2947,O
depression,2947,O
(,2947,O
LTD,2947,O
),2947,O
at,2947,O
Schaffer,2947,O
collateral/CA1,2947,O
pyramidal,2947,O
cell,2947,O
synapses,2947,O
was,2947,O
amplified,2947,O
in,2947,O
hippocampal,2947,O
slices,2947,O
of,2947,O
cLH,2947,O
rats,2947,O
",",2947,O
whereas,2947,O
LTD,2947,O
induced,2947,O
by,2947,O
low,2947,O
frequency,2947,O
stimulation,2947,O
of,2947,O
the,2947,O
Schaffer,2947,O
collaterals,2947,O
did,2947,O
not,2947,O
change,2947,O
.,2947,O
Moreover,2948,O
",",2948,O
these,2948,O
effects,2948,O
were,2948,O
associated,2948,O
with,2948,O
decreased,2948,O
basal,2948,O
dendritic,2948,O
spine,2948,O
density,2948,O
of,2948,O
CA1,2948,O
pyramidal,2948,O
cell,2948,O
in,2948,O
cLH,2948,O
rats,2948,O
.,2948,O
These,2949,O
data,2949,O
raise,2949,O
the,2949,O
attractive,2949,O
possibility,2949,O
that,2949,O
changes,2949,O
in,2949,O
the,2949,O
expression,2949,O
and,2949,O
function,2949,O
of,2949,O
mGlu5,2949,B-GENE-Y
receptors,2949,I-GENE-Y
in,2949,O
the,2949,O
hippocampus,2949,O
might,2949,O
underlie,2949,O
the,2949,O
changes,2949,O
in,2949,O
synaptic,2949,O
plasticity,2949,O
associated,2949,O
with,2949,O
the,2949,O
depressive-like,2949,O
phenotype,2949,O
of,2949,O
cLH,2949,O
rats,2949,O
.,2949,O
However,2950,O
",",2950,O
chronic,2950,O
treatment,2950,O
of,2950,O
cLH,2950,O
rats,2950,O
with,2950,O
MPEP,2950,B-CHEMICAL
did,2950,O
not,2950,O
reverse,2950,O
learned,2950,O
helplessness,2950,O
",",2950,O
indicating,2950,O
that,2950,O
the,2950,O
enhanced,2950,O
mGlu5,2950,B-GENE-Y
receptor,2950,I-GENE-Y
function,2950,O
is,2950,O
not,2950,O
the,2950,O
only,2950,O
player,2950,O
in,2950,O
the,2950,O
behavioral,2950,O
phenotype,2950,O
of,2950,O
this,2950,O
genetic,2950,O
model,2950,O
of,2950,O
depression,2950,O
.,2950,O
This,2951,O
article,2951,O
is,2951,O
part,2951,O
of,2951,O
a,2951,O
Special,2951,O
Issue,2951,O
entitled,2951,O
'Metabotropic,2951,O
Glutamate,2951,B-CHEMICAL
Receptors,2951,I-GENE-N
',2951,O
.,2951,O
Deep,2952,O
brain,2952,O
stimulation,2952,O
",",2952,O
histone,2952,B-GENE-N
deacetylase,2952,I-GENE-N
inhibitors,2952,O
and,2952,O
glutamatergic,2952,O
drugs,2952,O
rescue,2952,O
resistance,2952,O
to,2952,O
fear,2952,O
extinction,2952,O
in,2952,O
a,2952,O
genetic,2952,O
mouse,2952,O
model,2952,O
.,2952,O
Anxiety,2953,O
disorders,2953,O
are,2953,O
characterized,2953,O
by,2953,O
persistent,2953,O
",",2953,O
excessive,2953,O
fear,2953,O
.,2953,O
Therapeutic,2954,O
interventions,2954,O
that,2954,O
reverse,2954,O
deficits,2954,O
in,2954,O
fear,2954,O
extinction,2954,O
represent,2954,O
a,2954,O
tractable,2954,O
approach,2954,O
to,2954,O
treating,2954,O
these,2954,O
disorders,2954,O
.,2954,O
We,2955,O
previously,2955,O
reported,2955,O
that,2955,O
129S1/SvImJ,2955,O
(,2955,O
S1,2955,O
),2955,O
mice,2955,O
show,2955,O
no,2955,O
extinction,2955,O
learning,2955,O
following,2955,O
normal,2955,O
fear,2955,O
conditioning,2955,O
.,2955,O
We,2956,O
now,2956,O
demonstrate,2956,O
that,2956,O
weak,2956,O
fear,2956,O
conditioning,2956,O
does,2956,O
permit,2956,O
fear,2956,O
reduction,2956,O
during,2956,O
massed,2956,O
extinction,2956,O
training,2956,O
in,2956,O
S1,2956,O
mice,2956,O
",",2956,O
but,2956,O
reveals,2956,O
specific,2956,O
deficiency,2956,O
in,2956,O
extinction,2956,O
memory,2956,O
consolidation/retrieval,2956,O
.,2956,O
Rescue,2957,O
of,2957,O
this,2957,O
impaired,2957,O
extinction,2957,O
consolidation/retrieval,2957,O
was,2957,O
achieved,2957,O
with,2957,O
d-cycloserine,2957,B-CHEMICAL
(,2957,O
N-methly-d-aspartate,2957,B-CHEMICAL
partial,2957,O
agonist,2957,O
),2957,O
or,2957,O
MS-275,2957,B-CHEMICAL
(,2957,O
histone,2957,B-GENE-N
deacetylase,2957,I-GENE-N
(,2957,O
HDAC,2957,B-GENE-N
),2957,O
inhibitor,2957,O
),2957,O
",",2957,O
applied,2957,O
after,2957,O
extinction,2957,O
training,2957,O
.,2957,O
We,2958,O
next,2958,O
examined,2958,O
the,2958,O
ability,2958,O
of,2958,O
different,2958,O
drugs,2958,O
and,2958,O
non-pharmacological,2958,O
manipulations,2958,O
to,2958,O
rescue,2958,O
the,2958,O
extreme,2958,O
fear,2958,O
extinction,2958,O
deficit,2958,O
in,2958,O
S1,2958,O
following,2958,O
normal,2958,O
fear,2958,O
conditioning,2958,O
with,2958,O
the,2958,O
ultimate,2958,O
aim,2958,O
to,2958,O
produce,2958,O
low,2958,O
fear,2958,O
levels,2958,O
in,2958,O
extinction,2958,O
retrieval,2958,O
tests,2958,O
.,2958,O
Results,2959,O
showed,2959,O
that,2959,O
deep,2959,O
brain,2959,O
stimulation,2959,O
(,2959,O
DBS,2959,O
),2959,O
by,2959,O
applying,2959,O
high,2959,O
frequency,2959,O
stimulation,2959,O
to,2959,O
the,2959,O
nucleus,2959,O
accumbens,2959,O
(,2959,O
ventral,2959,O
striatum,2959,O
),2959,O
during,2959,O
extinction,2959,O
training,2959,O
",",2959,O
indeed,2959,O
significantly,2959,O
reduced,2959,O
fear,2959,O
during,2959,O
extinction,2959,O
retrieval,2959,O
compared,2959,O
to,2959,O
sham,2959,O
stimulation,2959,O
controls,2959,O
.,2959,O
Rescue,2960,O
of,2960,O
both,2960,O
impaired,2960,O
extinction,2960,O
acquisition,2960,O
and,2960,O
deficient,2960,O
extinction,2960,O
consolidation/retrieval,2960,O
was,2960,O
achieved,2960,O
with,2960,O
prior,2960,O
extinction,2960,O
training,2960,O
administration,2960,O
of,2960,O
valproic,2960,B-CHEMICAL
acid,2960,I-CHEMICAL
(,2960,O
a,2960,O
GABAergic,2960,O
enhancer,2960,O
and,2960,O
HDAC,2960,B-GENE-N
inhibitor,2960,O
),2960,O
or,2960,O
AMN082,2960,B-CHEMICAL
[,2960,O
metabotropic,2960,B-GENE-Y
glutamate,2960,B-CHEMICAL
receptor,2960,I-GENE-Y
7,2960,I-GENE-Y
(,2960,O
mGlu7,2960,B-GENE-Y
),2960,O
agonist,2960,O
],2960,O
",",2960,O
while,2960,O
MS-275,2960,B-CHEMICAL
or,2960,O
PEPA,2960,B-CHEMICAL
(,2960,O
AMPA,2960,B-CHEMICAL
receptor,2960,I-GENE-N
potentiator,2960,O
),2960,O
failed,2960,O
to,2960,O
affect,2960,O
extinction,2960,O
acquisition,2960,O
in,2960,O
S1,2960,O
mice,2960,O
.,2960,O
Collectively,2961,O
",",2961,O
these,2961,O
data,2961,O
identify,2961,O
potential,2961,O
beneficial,2961,O
effects,2961,O
of,2961,O
DBS,2961,O
and,2961,O
various,2961,O
drug,2961,O
treatments,2961,O
",",2961,O
including,2961,O
those,2961,O
with,2961,O
HDAC,2961,B-GENE-N
inhibiting,2961,O
or,2961,O
mGlu7,2961,B-GENE-Y
agonism,2961,O
properties,2961,O
",",2961,O
as,2961,O
adjuncts,2961,O
to,2961,O
overcome,2961,O
treatment,2961,O
resistance,2961,O
in,2961,O
exposure-based,2961,O
therapies,2961,O
.,2961,O
This,2962,O
article,2962,O
is,2962,O
part,2962,O
of,2962,O
a,2962,O
Special,2962,O
Issue,2962,O
entitled,2962,O
'Cognitive,2962,O
Enhancers,2962,O
',2962,O
.,2962,O
Nicotine,2963,B-CHEMICAL
facilitates,2963,O
memory,2963,O
consolidation,2963,O
in,2963,O
perceptual,2963,O
learning,2963,O
.,2963,O
Perceptual,2964,O
learning,2964,O
is,2964,O
a,2964,O
special,2964,O
type,2964,O
of,2964,O
non-declarative,2964,O
learning,2964,O
that,2964,O
involves,2964,O
experience-dependent,2964,O
plasticity,2964,O
in,2964,O
sensory,2964,O
cortices,2964,O
.,2964,O
The,2965,O
cholinergic,2965,O
system,2965,O
is,2965,O
known,2965,O
to,2965,O
modulate,2965,O
declarative,2965,O
learning,2965,O
.,2965,O
In,2966,O
particular,2966,O
",",2966,O
reduced,2966,O
levels,2966,O
or,2966,O
efficacy,2966,O
of,2966,O
the,2966,O
neurotransmitter,2966,O
acetylcholine,2966,B-CHEMICAL
were,2966,O
found,2966,O
to,2966,O
facilitate,2966,O
declarative,2966,O
memory,2966,O
consolidation,2966,O
.,2966,O
However,2967,O
",",2967,O
little,2967,O
is,2967,O
known,2967,O
about,2967,O
the,2967,O
role,2967,O
of,2967,O
the,2967,O
cholinergic,2967,O
system,2967,O
in,2967,O
memory,2967,O
consolidation,2967,O
of,2967,O
non-declarative,2967,O
learning,2967,O
.,2967,O
Here,2968,O
we,2968,O
compared,2968,O
two,2968,O
groups,2968,O
of,2968,O
non-smoking,2968,O
men,2968,O
who,2968,O
learned,2968,O
a,2968,O
visual,2968,O
texture,2968,O
discrimination,2968,O
task,2968,O
(,2968,O
TDT,2968,O
),2968,O
.,2968,O
One,2969,O
group,2969,O
received,2969,O
chewing,2969,O
tobacco,2969,O
containing,2969,O
nicotine,2969,B-CHEMICAL
for,2969,O
1,2969,O
h,2969,O
directly,2969,O
following,2969,O
the,2969,O
TDT,2969,O
training,2969,O
.,2969,O
The,2970,O
other,2970,O
group,2970,O
received,2970,O
a,2970,O
similar,2970,O
tasting,2970,O
control,2970,O
substance,2970,O
without,2970,O
nicotine,2970,B-CHEMICAL
.,2970,O
Electroencephalographic,2971,O
recordings,2971,O
during,2971,O
substance,2971,O
consumption,2971,O
showed,2971,O
reduced,2971,O
alpha,2971,O
activity,2971,O
and,2971,O
P300,2971,B-GENE-Y
latencies,2971,O
in,2971,O
the,2971,O
nicotine,2971,B-CHEMICAL
group,2971,O
compared,2971,O
to,2971,O
the,2971,O
control,2971,O
group,2971,O
.,2971,O
When,2972,O
re-tested,2972,O
on,2972,O
the,2972,O
TDT,2972,O
the,2972,O
following,2972,O
day,2972,O
",",2972,O
both,2972,O
groups,2972,O
responded,2972,O
more,2972,O
accurately,2972,O
and,2972,O
more,2972,O
rapidly,2972,O
than,2972,O
during,2972,O
training,2972,O
.,2972,O
These,2973,O
improvements,2973,O
were,2973,O
specific,2973,O
to,2973,O
the,2973,O
retinal,2973,O
location,2973,O
and,2973,O
orientation,2973,O
of,2973,O
the,2973,O
texture,2973,O
elements,2973,O
of,2973,O
the,2973,O
TDT,2973,O
suggesting,2973,O
that,2973,O
learning,2973,O
involved,2973,O
early,2973,O
visual,2973,O
cortex,2973,O
.,2973,O
A,2974,O
group,2974,O
comparison,2974,O
showed,2974,O
that,2974,O
learning,2974,O
effects,2974,O
were,2974,O
more,2974,O
pronounced,2974,O
in,2974,O
the,2974,O
nicotine,2974,B-CHEMICAL
group,2974,O
than,2974,O
in,2974,O
the,2974,O
control,2974,O
group,2974,O
.,2974,O
These,2975,O
findings,2975,O
suggest,2975,O
that,2975,O
oral,2975,O
consumption,2975,O
of,2975,O
nicotine,2975,B-CHEMICAL
enhances,2975,O
the,2975,O
efficacy,2975,O
of,2975,O
nicotinic,2975,B-GENE-N
acetylcholine,2975,B-CHEMICAL
receptors,2975,I-GENE-N
.,2975,O
Our,2976,O
findings,2976,O
further,2976,O
suggest,2976,O
that,2976,O
enhanced,2976,O
efficacy,2976,O
of,2976,O
the,2976,O
cholinergic,2976,O
system,2976,O
facilitates,2976,O
memory,2976,O
consolidation,2976,O
in,2976,O
perceptual,2976,O
learning,2976,O
(,2976,O
and,2976,O
possibly,2976,O
other,2976,O
types,2976,O
of,2976,O
non-declarative,2976,O
learning,2976,O
),2976,O
.,2976,O
In,2977,O
that,2977,O
regard,2977,O
acetylcholine,2977,B-CHEMICAL
seems,2977,O
to,2977,O
affect,2977,O
consolidation,2977,O
processes,2977,O
in,2977,O
perceptual,2977,O
learning,2977,O
in,2977,O
a,2977,O
different,2977,O
manner,2977,O
than,2977,O
in,2977,O
declarative,2977,O
learning,2977,O
.,2977,O
Alternatively,2978,O
",",2978,O
our,2978,O
findings,2978,O
might,2978,O
reflect,2978,O
dose-dependent,2978,O
cholinergic,2978,O
modulation,2978,O
of,2978,O
memory,2978,O
consolidation,2978,O
.,2978,O
This,2979,O
article,2979,O
is,2979,O
part,2979,O
of,2979,O
a,2979,O
Special,2979,O
Issue,2979,O
entitled,2979,O
'Cognitive,2979,O
Enhancers,2979,O
',2979,O
.,2979,O
Increased,2980,O
expression,2980,O
of,2980,O
P450scc,2980,B-GENE-Y
and,2980,O
CYP17,2980,B-GENE-Y
in,2980,O
development,2980,O
of,2980,O
endogenous,2980,O
hyperandrogenism,2980,O
in,2980,O
a,2980,O
rat,2980,O
model,2980,O
of,2980,O
PCOS,2980,O
.,2980,O
The,2981,O
objective,2981,O
of,2981,O
the,2981,O
present,2981,O
study,2981,O
was,2981,O
to,2981,O
characterize,2981,O
the,2981,O
effect,2981,O
of,2981,O
insulin,2981,B-GENE-N
plus,2981,O
hCG,2981,B-GENE-N
on,2981,O
the,2981,O
expression,2981,O
of,2981,O
steroidogenic,2981,O
enzymes,2981,O
(,2981,O
P450scc,2981,B-GENE-Y
and,2981,O
CYP17,2981,B-GENE-Y
),2981,O
in,2981,O
polycystic,2981,O
ovaries,2981,O
of,2981,O
rats,2981,O
.,2981,O
Changes,2982,O
in,2982,O
estrous,2982,O
cycle,2982,O
",",2982,O
ovarian,2982,O
morphology,2982,O
",",2982,O
hormonal,2982,O
levels,2982,O
",",2982,O
and,2982,O
protein,2982,O
levels,2982,O
by,2982,O
immunohistochemistry,2982,O
and,2982,O
western-blot,2982,O
were,2982,O
determined,2982,O
.,2982,O
Rats,2983,O
treated,2983,O
with,2983,O
insulin,2983,B-GENE-N
plus,2983,O
hCG,2983,B-GENE-N
displayed,2983,O
abnormal,2983,O
estrous,2983,O
cycles,2983,O
with,2983,O
increasing,2983,O
androgen,2983,B-CHEMICAL
biosynthesis,2983,O
.,2983,O
Meanwhile,2984,O
",",2984,O
insulin,2984,B-GENE-N
plus,2984,O
hCG,2984,B-GENE-N
resulted,2984,O
in,2984,O
multiple,2984,O
large,2984,O
cysts,2984,O
with,2984,O
diminished,2984,O
granulosa,2984,O
layers,2984,O
and,2984,O
increased,2984,O
thecal,2984,O
layers,2984,O
and,2984,O
stromal-interstitial,2984,O
tissue,2984,O
.,2984,O
Moreover,2985,O
",",2985,O
there,2985,O
was,2985,O
an,2985,O
increase,2985,O
in,2985,O
the,2985,O
expression,2985,O
of,2985,O
P450scc,2985,B-GENE-Y
and,2985,O
CYP17,2985,B-GENE-Y
in,2985,O
thecal,2985,O
and,2985,O
stromal,2985,O
cells,2985,O
in,2985,O
our,2985,O
PCOS,2985,O
rat,2985,O
model,2985,O
compared,2985,O
with,2985,O
control,2985,O
rats,2985,O
.,2985,O
These,2986,O
results,2986,O
indicate,2986,O
that,2986,O
administration,2986,O
of,2986,O
insulin,2986,B-GENE-N
with,2986,O
hCG,2986,B-GENE-N
can,2986,O
synergistically,2986,O
result,2986,O
in,2986,O
endogenous,2986,O
hyperandrogenism,2986,O
which,2986,O
may,2986,O
partially,2986,O
upregulate,2986,O
the,2986,O
expression,2986,O
of,2986,O
steroidogenic,2986,O
enzymes,2986,O
in,2986,O
ovarian,2986,O
tissue,2986,O
.,2986,O
Can,2987,O
the,2987,O
chemical,2987,O
reactivity,2987,O
of,2987,O
an,2987,O
ultimate,2987,O
carcinogen,2987,O
be,2987,O
related,2987,O
to,2987,O
its,2987,O
carcinogenicity,2987,O
?,2987,O
An,2988,O
application,2988,O
to,2988,O
propylene,2988,B-CHEMICAL
oxide,2988,I-CHEMICAL
.,2988,O
In,2989,O
this,2989,O
article,2989,O
we,2989,O
report,2989,O
calculations,2989,O
of,2989,O
the,2989,O
activation,2989,O
free,2989,O
energy,2989,O
for,2989,O
a,2989,O
chemical,2989,O
reaction,2989,O
between,2989,O
propylene,2989,B-CHEMICAL
oxide,2989,I-CHEMICAL
and,2989,O
DNA,2989,O
",",2989,O
in,2989,O
particular,2989,O
with,2989,O
the,2989,O
guanine,2989,B-CHEMICAL
at,2989,O
the,2989,O
N7,2989,O
position,2989,O
.,2989,O
Calculations,2990,O
were,2990,O
performed,2990,O
using,2990,O
Hartree-Fock,2990,O
and,2990,O
MP2,2990,O
methods,2990,O
in,2990,O
conjunction,2990,O
with,2990,O
flexible,2990,O
basis,2990,O
sets,2990,O
.,2990,O
The,2991,O
effects,2991,O
of,2991,O
solvation,2991,O
were,2991,O
considered,2991,O
using,2991,O
the,2991,O
Langevin,2991,O
dipoles,2991,O
and,2991,O
solvent,2991,O
reaction,2991,O
field,2991,O
methods,2991,O
.,2991,O
The,2992,O
calculated,2992,O
activation,2992,O
free,2992,O
energies,2992,O
are,2992,O
in,2992,O
good,2992,O
agreement,2992,O
with,2992,O
the,2992,O
experimental,2992,O
value,2992,O
of,2992,O
25.36,2992,O
kcal/mol,2992,O
.,2992,O
Moreover,2993,O
",",2993,O
the,2993,O
reactivities,2993,O
of,2993,O
a,2993,O
series,2993,O
of,2993,O
ultimate,2993,O
carcinogens,2993,O
of,2993,O
the,2993,O
epoxy,2993,B-CHEMICAL
type,2993,O
toward,2993,O
DNA,2993,O
are,2993,O
shown,2993,O
to,2993,O
be,2993,O
related,2993,O
to,2993,O
their,2993,O
carcinogenicities,2993,O
.,2993,O
Higher,2994,O
reactivity,2994,O
is,2994,O
generally,2994,O
associated,2994,O
with,2994,O
higher,2994,O
carcinogenicity,2994,O
",",2994,O
although,2994,O
transport,2994,O
properties,2994,O
",",2994,O
reactions,2994,O
with,2994,O
ultimate,2994,O
carcinogen,2994,O
scavengers,2994,O
",",2994,O
and,2994,O
the,2994,O
DNA,2994,O
correction,2994,O
mechanism,2994,O
are,2994,O
also,2994,O
very,2994,O
important,2994,O
.,2994,O
It,2995,O
is,2995,O
very,2995,O
likely,2995,O
that,2995,O
the,2995,O
window,2995,O
of,2995,O
reactivity,2995,O
rather,2995,O
than,2995,O
a,2995,O
high,2995,O
reactivity,2995,O
value,2995,O
is,2995,O
the,2995,O
relevant,2995,O
measure,2995,O
of,2995,O
carcinogenicity,2995,O
",",2995,O
since,2995,O
highly,2995,O
reactive,2995,O
ultimate,2995,O
carcinogens,2995,O
interact,2995,O
with,2995,O
water,2995,O
and,2995,O
proteins,2995,O
before,2995,O
they,2995,O
reach,2995,O
DNA,2995,O
.,2995,O
A,2996,O
significant,2996,O
dose-dependent,2996,O
relationship,2996,O
between,2996,O
mercury,2996,B-CHEMICAL
exposure,2996,O
from,2996,O
dental,2996,O
amalgams,2996,O
and,2996,O
kidney,2996,O
integrity,2996,O
biomarkers,2996,O
:,2996,O
A,2996,O
further,2996,O
assessment,2996,O
of,2996,O
the,2996,O
Casa,2996,O
Pia,2996,O
children,2996,O
's,2996,O
dental,2996,O
amalgam,2996,O
trial,2996,O
.,2996,O
Dental,2997,O
amalgams,2997,O
are,2997,O
a,2997,O
commonly,2997,O
used,2997,O
dental,2997,O
restorative,2997,O
material,2997,O
.,2997,O
Amalgams,2998,O
are,2998,O
about,2998,O
50,2998,O
%,2998,O
mercury,2998,B-CHEMICAL
(,2998,O
Hg,2998,B-CHEMICAL
),2998,O
",",2998,O
and,2998,O
Hg,2998,B-CHEMICAL
is,2998,O
known,2998,O
to,2998,O
significantly,2998,O
accumulate,2998,O
in,2998,O
the,2998,O
kidney,2998,O
.,2998,O
It,2999,O
was,2999,O
hypothesized,2999,O
that,2999,O
because,2999,O
Hg,2999,B-CHEMICAL
accumulates,2999,O
in,2999,O
the,2999,O
proximal,2999,O
tubules,2999,O
(,2999,O
PTs,2999,O
),2999,O
",",2999,O
glutathione-S-transferases,2999,B-CHEMICAL
(,2999,I-GENE-N
GST,2999,I-GENE-N
),2999,I-GENE-N
-,2999,I-GENE-N
(,2999,O
suggestive,2999,O
of,2999,O
kidney,2999,O
damage,2999,O
at,2999,O
the,2999,O
level,2999,O
of,2999,O
PT,2999,O
),2999,O
would,2999,O
be,2999,O
expected,2999,O
to,2999,O
be,2999,O
more,2999,O
related,2999,O
to,2999,O
Hg,2999,B-CHEMICAL
exposure,2999,O
than,2999,O
GST-,2999,B-GENE-Y
(,2999,O
suggestive,2999,O
of,2999,O
kidney,2999,O
damage,2999,O
at,2999,O
the,2999,O
level,2999,O
of,2999,O
the,2999,O
distal,2999,O
tubules,2999,O
),2999,O
.,2999,O
Urinary,3000,O
biomarkers,3000,O
of,3000,O
kidney,3000,O
integrity,3000,O
were,3000,O
examined,3000,O
in,3000,O
children,3000,O
of,3000,O
8-18,3000,O
years,3000,O
old,3000,O
",",3000,O
with,3000,O
and,3000,O
without,3000,O
dental,3000,O
amalgam,3000,O
fillings,3000,O
",",3000,O
from,3000,O
a,3000,O
completed,3000,O
clinical,3000,O
trial,3000,O
(,3000,O
parent,3000,O
study,3000,O
),3000,O
.,3000,O
Our,3001,O
study,3001,O
determined,3001,O
whether,3001,O
there,3001,O
was,3001,O
a,3001,O
significant,3001,O
dose-dependent,3001,O
correlation,3001,O
between,3001,O
increasing,3001,O
Hg,3001,B-CHEMICAL
exposure,3001,O
from,3001,O
dental,3001,O
amalgams,3001,O
and,3001,O
GST-,3001,B-GENE-N
and,3001,O
GST-,3001,B-GENE-Y
as,3001,O
biomarkers,3001,O
of,3001,O
kidney,3001,O
integrity,3001,O
.,3001,O
Overall,3002,O
",",3002,O
the,3002,O
present,3002,O
study,3002,O
",",3002,O
using,3002,O
a,3002,O
different,3002,O
and,3002,O
more,3002,O
sensitive,3002,O
statistical,3002,O
model,3002,O
than,3002,O
the,3002,O
parent,3002,O
study,3002,O
",",3002,O
revealed,3002,O
a,3002,O
statistically,3002,O
significant,3002,O
dose-dependent,3002,O
correlation,3002,O
between,3002,O
cumulative,3002,O
exposure,3002,O
to,3002,O
Hg,3002,B-CHEMICAL
from,3002,O
dental,3002,O
amalgams,3002,O
and,3002,O
urinary,3002,O
levels,3002,O
of,3002,O
GST-,3002,B-GENE-N
",",3002,O
after,3002,O
covariate,3002,O
adjustment,3002,O
;,3002,O
where,3002,O
as,3002,O
",",3002,O
a,3002,O
nonsignificant,3002,O
relationship,3002,O
was,3002,O
observed,3002,O
with,3002,O
urinary,3002,O
levels,3002,O
of,3002,O
GST-,3002,B-GENE-Y
.,3002,O
Furthermore,3003,O
",",3003,O
it,3003,O
was,3003,O
observed,3003,O
that,3003,O
urinary,3003,O
GST-,3003,B-GENE-N
levels,3003,O
increased,3003,O
by,3003,O
about,3003,O
10,3003,O
%,3003,O
over,3003,O
the,3003,O
8-year,3003,O
course,3003,O
of,3003,O
the,3003,O
study,3003,O
among,3003,O
individuals,3003,O
with,3003,O
an,3003,O
average,3003,O
exposure,3003,O
to,3003,O
amalgams,3003,O
among,3003,O
the,3003,O
study,3003,O
subjects,3003,O
from,3003,O
the,3003,O
amalgam,3003,O
group,3003,O
",",3003,O
in,3003,O
comparison,3003,O
with,3003,O
study,3003,O
subjects,3003,O
with,3003,O
no,3003,O
exposure,3003,O
to,3003,O
dental,3003,O
amalgams,3003,O
.,3003,O
The,3004,O
results,3004,O
of,3004,O
our,3004,O
study,3004,O
suggest,3004,O
that,3004,O
dental,3004,O
amalgams,3004,O
contribute,3004,O
to,3004,O
ongoing,3004,O
kidney,3004,O
damage,3004,O
at,3004,O
the,3004,O
level,3004,O
of,3004,O
the,3004,O
PTs,3004,O
in,3004,O
a,3004,O
dose-dependent,3004,O
fashion,3004,O
.,3004,O
Liver,3005,O
glycogen,3005,O
loading,3005,O
dampens,3005,O
glycogen,3005,O
synthesis,3005,O
seen,3005,O
in,3005,O
response,3005,O
to,3005,O
either,3005,O
hyperinsulinemia,3005,O
or,3005,O
intraportal,3005,O
glucose,3005,B-CHEMICAL
infusion,3005,O
.,3005,O
The,3006,O
purpose,3006,O
of,3006,O
this,3006,O
study,3006,O
was,3006,O
to,3006,O
determine,3006,O
the,3006,O
effect,3006,O
of,3006,O
liver,3006,O
glycogen,3006,O
loading,3006,O
on,3006,O
net,3006,O
hepatic,3006,O
glycogen,3006,O
synthesis,3006,O
during,3006,O
hyperinsulinemia,3006,O
or,3006,O
hepatic,3006,O
portal,3006,O
vein,3006,O
glucose,3006,B-CHEMICAL
infusion,3006,O
in,3006,O
vivo,3006,O
.,3006,O
Liver,3007,O
glycogen,3007,O
levels,3007,O
were,3007,O
supercompensated,3007,O
(,3007,O
SCGly,3007,O
),3007,O
in,3007,O
two,3007,O
groups,3007,O
(,3007,O
using,3007,O
intraportal,3007,O
fructose,3007,B-CHEMICAL
infusion,3007,O
),3007,O
but,3007,O
not,3007,O
in,3007,O
two,3007,O
others,3007,O
(,3007,O
Gly,3007,O
),3007,O
during,3007,O
hyperglycemic-normoinsulinemia,3007,O
.,3007,O
Following,3008,O
a,3008,O
2-h,3008,O
control,3008,O
period,3008,O
during,3008,O
which,3008,O
fructose,3008,B-CHEMICAL
infusion,3008,O
was,3008,O
stopped,3008,O
",",3008,O
there,3008,O
was,3008,O
a,3008,O
2-h,3008,O
experimental,3008,O
period,3008,O
in,3008,O
which,3008,O
the,3008,O
response,3008,O
to,3008,O
hyperglycemia,3008,O
plus,3008,O
either,3008,O
4,3008,O
basal,3008,O
insulin,3008,B-GENE-Y
(,3008,O
INS,3008,B-GENE-Y
),3008,O
or,3008,O
portal,3008,O
vein,3008,O
glucose,3008,B-CHEMICAL
infusion,3008,O
(,3008,O
PoG,3008,O
),3008,O
was,3008,O
measured,3008,O
.,3008,O
Increased,3009,O
hepatic,3009,O
glycogen,3009,O
reduced,3009,O
the,3009,O
percent,3009,O
of,3009,O
glucose,3009,B-CHEMICAL
taken,3009,O
up,3009,O
by,3009,O
the,3009,O
liver,3009,O
that,3009,O
was,3009,O
deposited,3009,O
in,3009,O
glycogen,3009,O
(,3009,O
74,3009,O
,3009,O
3,3009,O
vs.,3009,O
53,3009,O
,3009,O
5,3009,O
%,3009,O
in,3009,O
Gly+INS,3009,O
and,3009,O
SCGly+INS,3009,O
",",3009,O
respectively,3009,O
",",3009,O
and,3009,O
72,3009,O
,3009,O
3,3009,O
vs.,3009,O
50,3009,O
,3009,O
6,3009,O
%,3009,O
in,3009,O
Gly+PoG,3009,O
and,3009,O
SCGly+PoG,3009,O
",",3009,O
respectively,3009,O
),3009,O
.,3009,O
The,3010,O
reduction,3010,O
in,3010,O
liver,3010,O
glycogen,3010,O
synthesis,3010,O
in,3010,O
SCGly+INS,3010,O
was,3010,O
accompanied,3010,O
by,3010,O
a,3010,O
decrease,3010,O
in,3010,O
both,3010,O
insulin,3010,B-GENE-Y
signaling,3010,O
and,3010,O
an,3010,O
increase,3010,O
in,3010,O
AMPK,3010,B-GENE-N
activation,3010,O
",",3010,O
whereas,3010,O
only,3010,O
the,3010,O
latter,3010,O
was,3010,O
observed,3010,O
in,3010,O
SCGly+PoG,3010,O
.,3010,O
These,3011,O
data,3011,O
indicate,3011,O
that,3011,O
liver,3011,O
glycogen,3011,O
loading,3011,O
impairs,3011,O
glycogen,3011,O
synthesis,3011,O
regardless,3011,O
of,3011,O
the,3011,O
signal,3011,O
used,3011,O
to,3011,O
stimulate,3011,O
it,3011,O
.,3011,O
Quantitation,3012,O
of,3012,O
UGT1A1,3012,B-GENE-Y
in,3012,O
human,3012,O
liver,3012,O
microsomes,3012,O
using,3012,O
stable,3012,O
isotope-labelled,3012,O
peptides,3012,O
and,3012,O
mass,3012,O
spectrometry,3012,O
based,3012,O
proteomic,3012,O
approaches,3012,O
.,3012,O
1,3013,O
.,3013,O
UDP-glucuronosyltransferases,3014,B-GENE-N
(,3014,O
UGTs,3014,B-GENE-N
),3014,O
are,3014,O
a,3014,O
group,3014,O
of,3014,O
drug-metabolizing,3014,O
enzymes,3014,O
that,3014,O
catalyse,3014,O
the,3014,O
conjugation,3014,O
of,3014,O
endogeonous,3014,O
compounds,3014,O
and,3014,O
xenobiotics,3014,O
to,3014,O
yield,3014,O
hydrophilic,3014,O
glucuronides,3014,O
which,3014,O
subsequently,3014,O
undergo,3014,O
excretion,3014,O
.,3014,O
This,3015,O
report,3015,O
describes,3015,O
an,3015,O
approach,3015,O
for,3015,O
the,3015,O
identification,3015,O
and,3015,O
accurate,3015,O
quantitation,3015,O
of,3015,O
human,3015,B-GENE-Y
UGT1A1,3015,I-GENE-Y
in,3015,O
complex,3015,O
biological,3015,O
matrices,3015,O
using,3015,O
liquid,3015,O
chromatography/mass,3015,O
spectrometry/mass,3015,O
spectrometry,3015,O
(,3015,O
LC-MS/MS,3015,O
),3015,O
analysis,3015,O
of,3015,O
protein,3015,O
digests,3015,O
.,3015,O
2,3016,O
.,3016,O
A,3017,O
stable,3017,O
isotope-labelled,3017,O
(,3017,O
SIL,3017,O
),3017,O
peptide,3017,O
of,3017,O
a,3017,O
unique,3017,O
peptide,3017,O
spanning,3017,O
residues,3017,O
54-69,3017,O
in,3017,O
exon,3017,O
1,3017,O
of,3017,O
the,3017,O
human,3017,B-GENE-Y
UGT1A1,3017,I-GENE-Y
protein,3017,O
with,3017,O
the,3017,O
sequence,3017,O
RIYLSADPALVVIEHG,3017,B-GENE-N
was,3017,O
synthesized,3017,O
.,3017,O
The,3018,O
peptide,3018,O
sequence,3018,O
synthesized,3018,O
was,3018,O
in,3018,O
the,3018,O
reverse,3018,O
order,3018,O
of,3018,O
the,3018,O
human,3018,O
peptide,3018,O
with,3018,O
the,3018,O
stable,3018,O
isotope-labels,3018,O
in,3018,O
the,3018,O
amino,3018,B-CHEMICAL
acid,3018,I-CHEMICAL
arginine,3018,B-CHEMICAL
(,3018,O
(,3018,B-CHEMICAL
13,3018,I-CHEMICAL
),3018,I-CHEMICAL
C6,3018,I-CHEMICAL
(,3018,I-CHEMICAL
15,3018,I-CHEMICAL
),3018,I-CHEMICAL
N4,3018,I-CHEMICAL
),3018,O
resulting,3018,O
in,3018,O
an,3018,O
increase,3018,O
in,3018,O
the,3018,O
mass,3018,O
of,3018,O
the,3018,O
SIL,3018,O
peptide,3018,O
of,3018,O
10,3018,O
amu,3018,O
",",3018,O
from,3018,O
1753,3018,O
to,3018,O
1763,3018,O
.,3018,O
The,3019,O
SIL,3019,O
peptide,3019,O
was,3019,O
quantitated,3019,O
by,3019,O
injecting,3019,O
increasing,3019,O
concentrations,3019,O
of,3019,O
the,3019,O
peptide,3019,O
into,3019,O
the,3019,O
LC-MS,3019,O
to,3019,O
obtain,3019,O
a,3019,O
standard,3019,O
curve,3019,O
.,3019,O
3,3020,O
.,3020,O
The,3021,O
labelled,3021,O
peptide,3021,O
along,3021,O
with,3021,O
precursor,3021,O
ion,3021,O
monitoring,3021,O
was,3021,O
used,3021,O
to,3021,O
quantify,3021,O
the,3021,O
levels,3021,O
of,3021,O
UGT1A1,3021,B-GENE-Y
in,3021,O
commercial,3021,O
recombinant,3021,O
preparations,3021,O
(,3021,O
supersomes,3021,O
),3021,O
and,3021,O
individual,3021,O
human,3021,O
liver,3021,O
microsomal,3021,O
samples,3021,O
and,3021,O
pooled,3021,O
human,3021,O
liver,3021,O
micrsomes,3021,O
obtained,3021,O
from,3021,O
BD,3021,O
Biosciences,3021,O
.,3021,O
4,3022,O
.,3022,O
Glucuronidation,3023,O
activity,3023,O
studies,3023,O
were,3023,O
performed,3023,O
",",3023,O
which,3023,O
demonstrated,3023,O
a,3023,O
positive,3023,O
correlation,3023,O
between,3023,O
enzyme,3023,O
activity,3023,O
levels,3023,O
and,3023,O
the,3023,O
UGT1A1,3023,B-GENE-Y
content,3023,O
in,3023,O
the,3023,O
liver,3023,O
microsomes,3023,O
obtained,3023,O
from,3023,O
individual,3023,O
human,3023,O
donors,3023,O
.,3023,O
Toxicity,3024,O
profile,3024,O
of,3024,O
small-molecule,3024,O
IAP,3024,B-GENE-N
antagonist,3024,O
GDC-0152,3024,B-CHEMICAL
is,3024,O
linked,3024,O
to,3024,O
TNF-,3024,B-GENE-Y
pharmacology,3024,O
.,3024,O
Inhibitor-of-apoptosis,3025,B-GENE-N
(,3025,O
IAP,3025,B-GENE-N
),3025,O
proteins,3025,O
suppress,3025,O
apoptosis,3025,O
and,3025,O
are,3025,O
overexpressed,3025,O
in,3025,O
a,3025,O
variety,3025,O
of,3025,O
cancers,3025,O
.,3025,O
Small-molecule,3026,O
IAP,3026,B-GENE-N
antagonists,3026,O
are,3026,O
currently,3026,O
being,3026,O
tested,3026,O
in,3026,O
clinical,3026,O
trials,3026,O
as,3026,O
novel,3026,O
cancer,3026,O
therapeutics,3026,O
.,3026,O
GDC-0152,3027,B-CHEMICAL
is,3027,O
a,3027,O
small-molecule,3027,O
drug,3027,O
that,3027,O
triggers,3027,O
tumor,3027,O
cell,3027,O
apoptosis,3027,O
by,3027,O
selectively,3027,O
antagonizing,3027,O
IAPs,3027,B-GENE-N
.,3027,O
GDC-0152,3028,B-CHEMICAL
induces,3028,O
NF-B,3028,B-GENE-N
transcriptional,3028,O
activity,3028,O
leading,3028,O
to,3028,O
expression,3028,O
of,3028,O
several,3028,O
chemokines,3028,B-GENE-N
and,3028,O
cytokines,3028,B-GENE-N
",",3028,O
of,3028,O
which,3028,O
tumor,3028,B-GENE-Y
necrosis,3028,I-GENE-Y
factor,3028,I-GENE-Y
alpha,3028,I-GENE-Y
(,3028,O
TNF-,3028,B-GENE-Y
),3028,O
is,3028,O
the,3028,O
most,3028,O
important,3028,O
for,3028,O
single-agent,3028,O
tumor,3028,O
activity,3028,O
.,3028,O
TNF-,3029,B-GENE-Y
is,3029,O
a,3029,O
pleiotropic,3029,O
cytokine,3029,B-GENE-N
that,3029,O
drives,3029,O
a,3029,O
variety,3029,O
of,3029,O
cellular,3029,O
responses,3029,O
",",3029,O
comprising,3029,O
inflammation,3029,O
",",3029,O
proliferation,3029,O
",",3029,O
and,3029,O
cell,3029,O
survival,3029,O
or,3029,O
death,3029,O
depending,3029,O
on,3029,O
the,3029,O
cellular,3029,O
context,3029,O
.,3029,O
As,3030,O
malignant,3030,O
and,3030,O
normal,3030,O
cells,3030,O
produce,3030,O
TNF-,3030,B-GENE-Y
upon,3030,O
IAP,3030,B-GENE-N
antagonism,3030,O
",",3030,O
increased,3030,O
TNF-,3030,B-GENE-Y
could,3030,O
drive,3030,O
both,3030,O
efficacy,3030,O
and,3030,O
toxicity,3030,O
.,3030,O
The,3031,O
toxicity,3031,O
profile,3031,O
of,3031,O
GDC-0152,3031,B-CHEMICAL
in,3031,O
dogs,3031,O
and,3031,O
rats,3031,O
was,3031,O
characterized,3031,O
after,3031,O
iv,3031,O
dose,3031,O
administration,3031,O
once,3031,O
every,3031,O
2,3031,O
weeks,3031,O
for,3031,O
four,3031,O
doses,3031,O
.,3031,O
Findings,3032,O
in,3032,O
both,3032,O
species,3032,O
consisted,3032,O
of,3032,O
a,3032,O
dose-related,3032,O
",",3032,O
acute,3032,O
",",3032,O
systemic,3032,O
inflammatory,3032,O
response,3032,O
",",3032,O
and,3032,O
hepatic,3032,O
injury,3032,O
.,3032,O
Laboratory,3033,O
findings,3033,O
included,3033,O
elevated,3033,O
plasma,3033,O
cytokines,3033,B-GENE-N
",",3033,O
an,3033,O
inflammatory,3033,O
leukogram,3033,O
",",3033,O
and,3033,O
increased,3033,O
liver,3033,B-GENE-N
transaminases,3033,I-GENE-N
with,3033,O
histopathological,3033,O
findings,3033,O
of,3033,O
inflammatory,3033,O
infiltrates,3033,O
and,3033,O
apoptosis/necrosis,3033,O
in,3033,O
multiple,3033,O
tissues,3033,O
;,3033,O
a,3033,O
toxicology,3033,O
profile,3033,O
consistent,3033,O
with,3033,O
TNF--mediated,3033,B-GENE-Y
toxicity,3033,O
.,3033,O
Dogs,3034,O
exhibited,3034,O
more,3034,O
severe,3034,O
findings,3034,O
than,3034,O
rats,3034,O
",",3034,O
and,3034,O
humans,3034,O
did,3034,O
not,3034,O
exhibit,3034,O
these,3034,O
findings,3034,O
",",3034,O
at,3034,O
comparable,3034,O
exposures,3034,O
across,3034,O
species,3034,O
.,3034,O
Furthermore,3035,O
",",3035,O
elevations,3035,O
in,3035,O
blood,3035,O
neutrophil,3035,O
count,3035,O
",",3035,O
serum,3035,O
monocyte,3035,B-GENE-Y
chemoattractant,3035,I-GENE-Y
protein-1,3035,I-GENE-Y
",",3035,O
and,3035,O
other,3035,O
markers,3035,O
of,3035,O
inflammation,3035,O
corresponded,3035,O
to,3035,O
GDC-0152,3035,B-CHEMICAL
exposure,3035,O
and,3035,O
toxicity,3035,O
and,3035,O
thus,3035,O
may,3035,O
have,3035,O
utility,3035,O
as,3035,O
safety,3035,O
biomarkers,3035,O
.,3035,O
Tub,3036,B-GENE-Y
has,3036,O
a,3036,O
key,3036,O
role,3036,O
in,3036,O
insulin,3036,B-GENE-N
and,3036,O
leptin,3036,B-GENE-Y
signaling,3036,O
and,3036,O
action,3036,O
in,3036,O
vivo,3036,O
in,3036,O
hypothalamic,3036,O
nuclei,3036,O
.,3036,O
Mutation,3037,O
of,3037,O
tub,3037,B-GENE-Y
gene,3037,O
in,3037,O
mice,3037,O
induces,3037,O
obesity,3037,O
",",3037,O
suggesting,3037,O
that,3037,O
tub,3037,B-GENE-Y
could,3037,O
be,3037,O
an,3037,O
important,3037,O
regulator,3037,O
of,3037,O
energy,3037,O
balance,3037,O
.,3037,O
In,3038,O
the,3038,O
current,3038,O
study,3038,O
",",3038,O
we,3038,O
investigated,3038,O
whether,3038,O
insulin,3038,B-GENE-N
",",3038,O
leptin,3038,B-GENE-Y
",",3038,O
and,3038,O
obesity,3038,O
can,3038,O
modulate,3038,O
Tub,3038,B-GENE-Y
in,3038,O
vivo,3038,O
in,3038,O
hypothalamic,3038,O
nuclei,3038,O
",",3038,O
and,3038,O
we,3038,O
investigated,3038,O
possible,3038,O
consequences,3038,O
on,3038,O
energy,3038,O
balance,3038,O
",",3038,O
neuropeptide,3038,O
expression,3038,O
",",3038,O
and,3038,O
hepatic,3038,O
glucose,3038,B-CHEMICAL
metabolism,3038,O
.,3038,O
Food,3039,O
intake,3039,O
",",3039,O
metabolic,3039,O
characteristics,3039,O
",",3039,O
signaling,3039,O
proteins,3039,O
",",3039,O
and,3039,O
neuropeptide,3039,O
expression,3039,O
were,3039,O
measured,3039,O
in,3039,O
response,3039,O
to,3039,O
fasting,3039,O
and,3039,O
refeeding,3039,O
",",3039,O
intracerebroventricular,3039,O
insulin,3039,B-GENE-N
and,3039,O
leptin,3039,B-GENE-Y
",",3039,O
and,3039,O
Tub,3039,B-GENE-Y
antisense,3039,O
oligonucleotide,3039,O
(,3039,O
ASO,3039,O
),3039,O
.,3039,O
Tub,3040,B-GENE-Y
tyrosine,3040,B-CHEMICAL
phosphorylation,3040,O
(,3040,O
Tub-p-tyr,3040,O
),3040,O
is,3040,O
modulated,3040,O
by,3040,O
nutritional,3040,O
status,3040,O
.,3040,O
Tub,3041,B-GENE-Y
is,3041,O
a,3041,O
substrate,3041,O
of,3041,O
insulin,3041,B-GENE-Y
receptor,3041,I-GENE-Y
tyrosine,3041,B-CHEMICAL
kinase,3041,I-GENE-Y
(,3041,O
IRTK,3041,B-GENE-Y
),3041,O
and,3041,O
leptin,3041,B-GENE-Y
receptor,3041,I-GENE-Y
(,3041,O
LEPR,3041,B-GENE-Y
),3041,O
-Janus,3041,O
kinase,3041,I-GENE-Y
2,3041,I-GENE-Y
(,3041,O
JAK2,3041,B-GENE-Y
),3041,O
in,3041,O
hypothalamic,3041,O
nuclei,3041,O
.,3041,O
After,3042,O
leptin,3042,B-GENE-Y
or,3042,O
insulin,3042,B-GENE-N
stimulation,3042,O
",",3042,O
Tub,3042,B-GENE-Y
translocates,3042,O
to,3042,O
the,3042,O
nucleus,3042,O
.,3042,O
Inhibition,3043,O
of,3043,O
Tub,3043,B-GENE-Y
expression,3043,O
in,3043,O
hypothalamus,3043,O
by,3043,O
ASO,3043,O
increased,3043,O
food,3043,O
intake,3043,O
",",3043,O
fasting,3043,O
blood,3043,O
glucose,3043,B-CHEMICAL
",",3043,O
and,3043,O
hepatic,3043,O
glucose,3043,B-CHEMICAL
output,3043,O
",",3043,O
decreased,3043,O
O,3043,B-CHEMICAL
(,3043,I-CHEMICAL
2,3043,I-CHEMICAL
),3043,I-CHEMICAL
consumption,3043,O
",",3043,O
and,3043,O
blunted,3043,O
the,3043,O
effect,3043,O
of,3043,O
insulin,3043,B-GENE-N
or,3043,O
leptin,3043,B-GENE-Y
on,3043,O
proopiomelanocortin,3043,B-GENE-Y
",",3043,O
thyroid-releasing,3043,B-GENE-Y
hormone,3043,I-GENE-Y
",",3043,O
melanin-concentrating,3043,B-GENE-Y
hormone,3043,I-GENE-Y
",",3043,O
and,3043,O
orexin,3043,B-GENE-Y
expression,3043,O
.,3043,O
In,3044,O
hypothalamus,3044,O
of,3044,O
mice,3044,O
administered,3044,O
a,3044,O
high-fat,3044,O
diet,3044,O
",",3044,O
there,3044,O
is,3044,O
a,3044,O
reduction,3044,O
in,3044,O
leptin,3044,B-GENE-Y
and,3044,O
insulin-induced,3044,B-GENE-N
Tub-p-tyr,3044,B-GENE-Y
and,3044,O
nuclear,3044,O
translocation,3044,O
",",3044,O
which,3044,O
is,3044,O
reversed,3044,O
by,3044,O
reducing,3044,O
protein,3044,B-GENE-Y
tyrosine,3044,B-CHEMICAL
phosphatase,3044,I-GENE-Y
1B,3044,I-GENE-Y
expression,3044,O
.,3044,O
These,3045,O
results,3045,O
indicate,3045,O
that,3045,O
Tub,3045,B-GENE-Y
has,3045,O
a,3045,O
key,3045,O
role,3045,O
in,3045,O
the,3045,O
control,3045,O
of,3045,O
insulin,3045,B-GENE-N
and,3045,O
leptin,3045,B-GENE-Y
effects,3045,O
on,3045,O
food,3045,O
intake,3045,O
",",3045,O
and,3045,O
the,3045,O
modulation,3045,O
of,3045,O
Tub,3045,B-GENE-Y
may,3045,O
contribute,3045,O
to,3045,O
insulin,3045,B-GENE-N
and,3045,O
leptin,3045,B-GENE-Y
resistance,3045,O
in,3045,O
DIO,3045,O
mice,3045,O
.,3045,O
The,3046,O
PARP,3046,B-GENE-N
inhibitor,3046,O
PJ34,3046,B-CHEMICAL
modifies,3046,O
proliferation,3046,O
",",3046,O
NIS,3046,B-GENE-Y
expression,3046,O
and,3046,O
epigenetic,3046,O
marks,3046,O
in,3046,O
thyroid,3046,O
cancer,3046,O
cell,3046,O
lines,3046,O
.,3046,O
Since,3047,O
PARP-1,3047,B-GENE-Y
is,3047,O
supposed,3047,O
to,3047,O
be,3047,O
part,3047,O
of,3047,O
a,3047,O
multimeric,3047,O
repressor,3047,O
of,3047,O
sodium,3047,B-CHEMICAL
iodide,3047,I-CHEMICAL
symporter,3047,I-GENE-Y
(,3047,O
NIS,3047,B-GENE-Y
),3047,O
expression,3047,O
",",3047,O
in,3047,O
this,3047,O
study,3047,O
the,3047,O
effect,3047,O
of,3047,O
the,3047,O
PARP,3047,B-GENE-N
inhibitor,3047,O
PJ34,3047,B-CHEMICAL
on,3047,O
several,3047,O
properties,3047,O
of,3047,O
thyroid,3047,O
cancer,3047,O
cell,3047,O
lines,3047,O
was,3047,O
investigated,3047,O
.,3047,O
In,3048,O
TPC1,3048,O
",",3048,O
BCPAP,3048,O
",",3048,O
FRO,3048,O
",",3048,O
WRO,3048,O
cell,3048,O
lines,3048,O
PJ34,3048,B-CHEMICAL
induced,3048,O
a,3048,O
strong,3048,O
increase,3048,O
in,3048,O
NIS,3048,B-GENE-Y
mRNA,3048,O
levels,3048,O
.,3048,O
In,3049,O
BCPAP,3049,O
and,3049,O
TPC1,3049,O
cells,3049,O
also,3049,O
significant,3049,O
increase,3049,O
of,3049,O
radio-iodine,3049,B-CHEMICAL
uptake,3049,O
was,3049,O
induced,3049,O
.,3049,O
Accordingly,3050,O
",",3050,O
in,3050,O
transfection,3050,O
experiments,3050,O
performed,3050,O
in,3050,O
TPC1,3050,O
cells,3050,O
",",3050,O
treatment,3050,O
with,3050,O
PJ34,3050,B-CHEMICAL
increased,3050,O
NIS,3050,B-GENE-N
promoter,3050,I-GENE-N
activity,3050,O
without,3050,O
affecting,3050,O
PARP-1,3050,B-GENE-Y
binding,3050,O
to,3050,O
the,3050,O
promoter,3050,O
sequence,3050,O
.,3050,O
We,3051,O
also,3051,O
investigated,3051,O
the,3051,O
epigenetic,3051,O
status,3051,O
of,3051,O
NIS,3051,B-GENE-N
promoter,3051,I-GENE-N
after,3051,O
PJ34,3051,B-CHEMICAL
treatment,3051,O
in,3051,O
TPC1,3051,O
cell,3051,O
line,3051,O
:,3051,O
in,3051,O
addition,3051,O
to,3051,O
an,3051,O
increase,3051,O
of,3051,O
histone,3051,B-GENE-N
modification,3051,I-GENE-N
activation,3051,I-GENE-N
marks,3051,I-GENE-N
(,3051,O
H3K9K14ac,3051,B-GENE-N
",",3051,O
H3K4me3,3051,B-GENE-N
),3051,O
",",3051,O
surprisingly,3051,O
we,3051,O
observed,3051,O
also,3051,O
an,3051,O
increase,3051,O
of,3051,O
H3K27me3,3051,O
",",3051,O
a,3051,O
classical,3051,O
repressive,3051,O
mark,3051,O
.,3051,O
Our,3052,O
data,3052,O
demonstrate,3052,O
that,3052,O
in,3052,O
various,3052,O
thyroid,3052,O
cancer,3052,O
cell,3052,O
lines,3052,O
PARP,3052,B-GENE-N
inhibition,3052,O
increases,3052,O
NIS,3052,B-GENE-Y
gene,3052,O
expression,3052,O
through,3052,O
a,3052,O
particular,3052,O
modulation,3052,O
of,3052,O
transcriptional,3052,O
regulatory,3052,O
mechanisms,3052,O
.,3052,O
Therefore,3053,O
",",3053,O
we,3053,O
suggest,3053,O
that,3053,O
PARP,3053,B-GENE-N
inhibitors,3053,O
may,3053,O
deserve,3053,O
future,3053,O
investigations,3053,O
as,3053,O
tools,3053,O
for,3053,O
medical,3053,O
treatment,3053,O
of,3053,O
thyroid,3053,O
cancer,3053,O
.,3053,O
Comparative,3054,O
antioxidant,3054,O
effects,3054,O
of,3054,O
lycopene,3054,O
",",3054,O
apo-10'-lycopenoic,3054,B-CHEMICAL
acid,3054,I-CHEMICAL
and,3054,O
apo-14'-lycopenoic,3054,B-CHEMICAL
acid,3054,I-CHEMICAL
in,3054,O
human,3054,O
macrophages,3054,O
exposed,3054,O
to,3054,O
H2O2,3054,B-CHEMICAL
and,3054,O
cigarette,3054,O
smoke,3054,O
extract,3054,O
.,3054,O
Much,3055,O
of,3055,O
the,3055,O
beneficial,3055,O
effects,3055,O
of,3055,O
tomato,3055,O
lycopene,3055,B-CHEMICAL
in,3055,O
the,3055,O
prevention,3055,O
of,3055,O
chronic,3055,O
diseases,3055,O
has,3055,O
been,3055,O
attributed,3055,O
to,3055,O
its,3055,O
antioxidant,3055,O
properties,3055,O
",",3055,O
which,3055,O
could,3055,O
be,3055,O
mediated,3055,O
by,3055,O
its,3055,O
metabolites,3055,O
and/or,3055,O
oxidation,3055,O
products,3055,O
.,3055,O
However,3056,O
",",3056,O
the,3056,O
biological,3056,O
functions,3056,O
of,3056,O
these,3056,O
lycopene,3056,B-CHEMICAL
derivatives,3056,O
remain,3056,O
still,3056,O
unknown,3056,O
.,3056,O
In,3057,O
the,3057,O
present,3057,O
study,3057,O
",",3057,O
we,3057,O
evaluated,3057,O
and,3057,O
compared,3057,O
the,3057,O
antioxidant,3057,O
efficacy,3057,O
of,3057,O
the,3057,O
lycopene,3057,B-CHEMICAL
eccentric,3057,O
cleavage,3057,O
products,3057,O
apo-10'-lycopenoic,3057,B-CHEMICAL
acid,3057,I-CHEMICAL
and,3057,O
apo-14'-lycopenoic,3057,B-CHEMICAL
acid,3057,I-CHEMICAL
in,3057,O
counteracting,3057,O
the,3057,O
oxidative,3057,O
effects,3057,O
of,3057,O
H,3057,B-CHEMICAL
(,3057,I-CHEMICAL
2,3057,I-CHEMICAL
),3057,I-CHEMICAL
O,3057,I-CHEMICAL
(,3057,I-CHEMICAL
2,3057,I-CHEMICAL
),3057,I-CHEMICAL
and,3057,O
cigarette,3057,O
smoke,3057,O
extract,3057,O
(,3057,O
CSE,3057,O
),3057,O
in,3057,O
THP-1,3057,O
macrophages,3057,O
.,3057,O
Both,3058,O
apo-10'-lycopenoic,3058,B-CHEMICAL
acid,3058,I-CHEMICAL
and,3058,O
apo-14'-lycopenoic,3058,B-CHEMICAL
acid,3058,I-CHEMICAL
were,3058,O
able,3058,O
to,3058,O
inhibit,3058,O
spontaneous,3058,O
and,3058,O
H,3058,B-CHEMICAL
(,3058,I-CHEMICAL
2,3058,I-CHEMICAL
),3058,I-CHEMICAL
O,3058,I-CHEMICAL
(,3058,I-CHEMICAL
2,3058,I-CHEMICAL
),3058,I-CHEMICAL
-induced,3058,O
ROS,3058,O
production,3058,O
in,3058,O
a,3058,O
dose-dependent,3058,O
manner,3058,O
.,3058,O
Such,3059,O
an,3059,O
effect,3059,O
was,3059,O
accompanied,3059,O
by,3059,O
an,3059,O
inhibition,3059,O
of,3059,O
MAPK,3059,B-GENE-N
phosphorylation,3059,O
",",3059,O
by,3059,O
NF-B,3059,B-GENE-N
inactivation,3059,O
",",3059,O
and,3059,O
by,3059,O
inhibition,3059,O
of,3059,O
hsp-70,3059,B-GENE-N
and,3059,O
hsp-90,3059,B-GENE-N
expressions,3059,O
.,3059,O
Both,3060,O
apo-lycopenoic,3060,B-CHEMICAL
acids,3060,I-CHEMICAL
also,3060,O
decreased,3060,O
CSE-induced,3060,O
ROS,3060,O
production,3060,O
",",3060,O
8-OHdG,3060,B-CHEMICAL
formation,3060,O
and,3060,O
reduced,3060,O
the,3060,O
increase,3060,O
in,3060,O
NOX-4,3060,B-GENE-Y
and,3060,O
COX-2,3060,B-GENE-Y
expressions,3060,O
caused,3060,O
by,3060,O
CSE,3060,O
.,3060,O
However,3061,O
",",3061,O
in,3061,O
both,3061,O
the,3061,O
models,3061,O
of,3061,O
oxidative,3061,O
stress,3061,O
",",3061,O
apo-14'-lycopenoic,3061,B-CHEMICAL
acid,3061,I-CHEMICAL
was,3061,O
much,3061,O
more,3061,O
potent,3061,O
as,3061,O
an,3061,O
antioxidant,3061,O
than,3061,O
apo-10'-lycopenoic,3061,B-CHEMICAL
acid,3061,I-CHEMICAL
",",3061,O
showing,3061,O
antioxidant,3061,O
properties,3061,O
similar,3061,O
to,3061,O
lycopene,3061,B-CHEMICAL
.,3061,O
These,3062,O
data,3062,O
strongly,3062,O
suggest,3062,O
that,3062,O
apo-lycopenoic,3062,B-CHEMICAL
acids,3062,I-CHEMICAL
",",3062,O
and,3062,O
particularly,3062,O
apo-14'-lycopenoic,3062,B-CHEMICAL
acid,3062,I-CHEMICAL
",",3062,O
may,3062,O
mediate,3062,O
some,3062,O
of,3062,O
the,3062,O
antioxidant,3062,O
functions,3062,O
of,3062,O
lycopene,3062,O
in,3062,O
cells,3062,O
.,3062,O
Plants,3063,O
as,3063,O
a,3063,O
source,3063,O
of,3063,O
butyrylcholinesterase,3063,B-GENE-Y
variants,3063,O
designed,3063,O
for,3063,O
enhanced,3063,O
cocaine,3063,B-CHEMICAL
hydrolase,3063,I-GENE-N
activity,3063,O
.,3063,O
Cocaine,3064,B-CHEMICAL
addiction,3064,O
affects,3064,O
millions,3064,O
of,3064,O
people,3064,O
with,3064,O
disastrous,3064,O
personal,3064,O
and,3064,O
social,3064,O
consequences,3064,O
.,3064,O
Cocaine,3065,B-CHEMICAL
is,3065,O
one,3065,O
of,3065,O
the,3065,O
most,3065,O
reinforcing,3065,O
of,3065,O
all,3065,O
drugs,3065,O
of,3065,O
abuse,3065,O
",",3065,O
and,3065,O
even,3065,O
those,3065,O
who,3065,O
undergo,3065,O
rehabilitation,3065,O
and,3065,O
experience,3065,O
long,3065,O
periods,3065,O
of,3065,O
abstinence,3065,O
have,3065,O
more,3065,O
than,3065,O
80,3065,O
%,3065,O
chance,3065,O
of,3065,O
relapse,3065,O
.,3065,O
Yet,3066,O
there,3066,O
is,3066,O
no,3066,O
FDA-approved,3066,O
treatment,3066,O
to,3066,O
decrease,3066,O
the,3066,O
likelihood,3066,O
of,3066,O
relapse,3066,O
in,3066,O
rehabilitated,3066,O
addicts,3066,O
.,3066,O
Recent,3067,O
studies,3067,O
",",3067,O
however,3067,O
",",3067,O
have,3067,O
demonstrated,3067,O
a,3067,O
promising,3067,O
potential,3067,O
treatment,3067,O
option,3067,O
with,3067,O
the,3067,O
help,3067,O
of,3067,O
the,3067,O
serum,3067,O
enzyme,3067,O
butyrylcholinesterase,3067,B-GENE-Y
(,3067,O
BChE,3067,B-GENE-Y
),3067,O
",",3067,O
which,3067,O
is,3067,O
capable,3067,O
of,3067,O
breaking,3067,O
down,3067,O
naturally,3067,O
occurring,3067,O
(,3067,B-CHEMICAL
-,3067,I-CHEMICAL
),3067,I-CHEMICAL
-cocaine,3067,I-CHEMICAL
before,3067,O
the,3067,O
drug,3067,O
can,3067,O
influence,3067,O
the,3067,O
reward,3067,O
centers,3067,O
of,3067,O
the,3067,O
brain,3067,O
or,3067,O
affect,3067,O
other,3067,O
areas,3067,O
of,3067,O
the,3067,O
body,3067,O
.,3067,O
This,3068,O
activity,3068,O
of,3068,O
wild-type,3068,O
(,3068,O
WT,3068,O
),3068,O
BChE,3068,B-GENE-Y
",",3068,O
however,3068,O
",",3068,O
is,3068,O
relatively,3068,O
low,3068,O
.,3068,O
This,3069,O
prompted,3069,O
the,3069,O
design,3069,O
of,3069,O
variants,3069,O
of,3069,O
BChE,3069,B-GENE-Y
which,3069,O
exhibit,3069,O
significantly,3069,O
improved,3069,O
catalytic,3069,O
activity,3069,O
against,3069,O
(,3069,B-CHEMICAL
-,3069,I-CHEMICAL
),3069,I-CHEMICAL
-cocaine,3069,I-CHEMICAL
.,3069,O
Plants,3070,O
are,3070,O
a,3070,O
promising,3070,O
means,3070,O
to,3070,O
produce,3070,O
large,3070,O
amounts,3070,O
of,3070,O
these,3070,O
cocaine,3070,B-CHEMICAL
hydrolase,3070,I-GENE-N
variants,3070,O
of,3070,O
BChE,3070,B-GENE-N
",",3070,O
cheaply,3070,O
",",3070,O
safely,3070,O
with,3070,O
no,3070,O
concerns,3070,O
regarding,3070,O
human,3070,O
pathogens,3070,O
and,3070,O
functionally,3070,O
equivalent,3070,O
to,3070,O
enzymes,3070,O
derived,3070,O
from,3070,O
other,3070,O
sources,3070,O
.,3070,O
Here,3071,O
",",3071,O
in,3071,O
expressing,3071,O
cocaine-hydrolyzing,3071,B-CHEMICAL
mutants,3071,O
of,3071,O
BChE,3071,B-GENE-N
in,3071,O
Nicotiana,3071,O
benthamiana,3071,O
using,3071,O
the,3071,O
MagnICON,3071,O
virus-assisted,3071,O
transient,3071,O
expression,3071,O
system,3071,O
",",3071,O
and,3071,O
in,3071,O
reporting,3071,O
their,3071,O
initial,3071,O
biochemical,3071,O
analysis,3071,O
",",3071,O
we,3071,O
provide,3071,O
proof-of-principle,3071,O
that,3071,O
plants,3071,O
can,3071,O
express,3071,O
engineered,3071,O
BChE,3071,B-GENE-N
proteins,3071,O
with,3071,O
desired,3071,O
properties,3071,O
.,3071,O
Experimental,3072,O
tooth,3072,O
movement-induced,3072,O
osteoclast,3072,O
activation,3072,O
is,3072,O
regulated,3072,O
by,3072,O
sympathetic,3072,O
signaling,3072,O
.,3072,O
Experimental,3073,O
tooth,3073,O
movement,3073,O
(,3073,O
ETM,3073,O
),3073,O
changes,3073,O
the,3073,O
distribution,3073,O
of,3073,O
sensory,3073,O
nerve,3073,O
fibers,3073,O
in,3073,O
periodontal,3073,O
ligament,3073,O
and,3073,O
the,3073,O
bone,3073,O
architecture,3073,O
through,3073,O
the,3073,O
stimulation,3073,O
of,3073,O
bone,3073,O
remodeling,3073,O
.,3073,O
As,3074,O
the,3074,O
sympathetic,3074,O
nervous,3074,O
system,3074,O
is,3074,O
involved,3074,O
in,3074,O
bone,3074,O
remodeling,3074,O
",",3074,O
we,3074,O
examined,3074,O
whether,3074,O
ETM,3074,O
is,3074,O
controlled,3074,O
by,3074,O
sympathetic,3074,O
signaling,3074,O
or,3074,O
not,3074,O
.,3074,O
In,3075,O
male,3075,O
mice,3075,O
",",3075,O
elastic,3075,O
rubber,3075,O
was,3075,O
inserted,3075,O
between,3075,O
upper,3075,O
left,3075,O
first,3075,O
molar,3075,O
(,3075,O
M1,3075,O
),3075,O
and,3075,O
second,3075,O
molar,3075,O
(,3075,O
M2,3075,O
),3075,O
for,3075,O
3,3075,O
or,3075,O
5,3075,O
days,3075,O
.,3075,O
Nerve,3076,O
fibers,3076,O
immunoreactive,3076,O
for,3076,O
not,3076,O
only,3076,O
sensory,3076,O
neuromarkers,3076,O
",",3076,O
such,3076,O
as,3076,O
calcitonin,3076,B-GENE-N
gene-related,3076,I-GENE-N
peptide,3076,I-GENE-N
(,3076,O
CGRP,3076,B-GENE-N
),3076,O
",",3076,O
but,3076,O
also,3076,O
sympathetic,3076,O
neuromarkers,3076,O
",",3076,O
such,3076,O
as,3076,O
tyrosine,3076,B-CHEMICAL
hydroxylase,3076,I-GENE-Y
(,3076,O
TH,3076,B-GENE-Y
),3076,O
and,3076,O
neuropeptide,3076,B-GENE-Y
Y,3076,I-GENE-Y
(,3076,O
NPY,3076,B-GENE-Y
),3076,O
were,3076,O
increased,3076,O
in,3076,O
the,3076,O
periodontal,3076,O
ligament,3076,O
during,3076,O
ETM,3076,O
.,3076,O
To,3077,O
elucidate,3077,O
the,3077,O
effect,3077,O
of,3077,O
the,3077,O
sympathetic,3077,O
signal,3077,O
mediated,3077,O
by,3077,O
ETM,3077,O
",",3077,O
mice,3077,O
were,3077,O
intraperitoneally,3077,O
injected,3077,O
with,3077,O
a,3077,O
-antagonist,3077,O
",",3077,O
propranolol,3077,B-CHEMICAL
(,3077,O
PRO,3077,B-CHEMICAL
:,3077,O
20,3077,O
g/g/day,3077,O
),3077,O
",",3077,O
or,3077,O
a,3077,O
-agonist,3077,O
",",3077,O
isoproterenol,3077,B-CHEMICAL
(,3077,O
ISO,3077,B-CHEMICAL
:,3077,O
5,3077,O
g/g/day,3077,O
),3077,O
from,3077,O
7,3077,O
days,3077,O
before,3077,O
ETM,3077,O
.,3077,O
PRO,3078,B-CHEMICAL
treatment,3078,O
suppressed,3078,O
the,3078,O
amount,3078,O
of,3078,O
tooth,3078,O
movement,3078,O
by,3078,O
12.9,3078,O
%,3078,O
in,3078,O
3-day,3078,O
ETM,3078,O
and,3078,O
by,3078,O
32.2,3078,O
%,3078,O
in,3078,O
5-day,3078,O
ETM,3078,O
compared,3078,O
with,3078,O
vehicle,3078,O
treatment,3078,O
.,3078,O
On,3079,O
the,3079,O
other,3079,O
hand,3079,O
",",3079,O
ISO,3079,B-CHEMICAL
treatment,3079,O
increased,3079,O
it,3079,O
.,3079,O
Furthermore,3080,O
",",3080,O
ETM,3080,O
remarkably,3080,O
increased,3080,O
the,3080,O
osteoclast,3080,O
number,3080,O
on,3080,O
the,3080,O
bone,3080,O
surface,3080,O
(,3080,O
alveolar,3080,O
socket,3080,O
),3080,O
(,3080,O
Oc.N/BS,3080,O
),3080,O
in,3080,O
all,3080,O
drug,3080,O
treatments,3080,O
.,3080,O
PRO,3081,B-CHEMICAL
treatment,3081,O
suppressed,3081,O
Oc.N/BS,3081,O
by,3081,O
39.4,3081,O
%,3081,O
in,3081,O
3-day,3081,O
ETM,3081,O
",",3081,O
while,3081,O
ISO,3081,B-CHEMICAL
treatment,3081,O
increased,3081,O
it,3081,O
by,3081,O
32.1,3081,O
%,3081,O
in,3081,O
3-day,3081,O
ETM,3081,O
compared,3081,O
with,3081,O
vehicle,3081,O
treatment,3081,O
.,3081,O
Chemical,3082,O
sympathectomy,3082,O
using,3082,O
6-hydroxydopamine,3082,B-CHEMICAL
(,3082,O
6-OHDA,3082,B-CHEMICAL
:,3082,O
250,3082,O
g/g,3082,O
),3082,O
showed,3082,O
results,3082,O
similar,3082,O
to,3082,O
those,3082,O
for,3082,O
PRO,3082,B-CHEMICAL
treatment,3082,O
in,3082,O
terms,3082,O
of,3082,O
both,3082,O
the,3082,O
amount,3082,O
of,3082,O
tooth,3082,O
movement,3082,O
and,3082,O
osteoclast,3082,O
parameters,3082,O
.,3082,O
Our,3083,O
data,3083,O
showed,3083,O
that,3083,O
blockade,3083,O
of,3083,O
sympathetic,3083,O
signaling,3083,O
inhibited,3083,O
the,3083,O
tooth,3083,O
movement,3083,O
and,3083,O
osteoclast,3083,O
increase,3083,O
induced,3083,O
by,3083,O
ETM,3083,O
",",3083,O
and,3083,O
stimulation,3083,O
of,3083,O
sympathetic,3083,O
signaling,3083,O
accelerated,3083,O
these,3083,O
responses,3083,O
.,3083,O
These,3084,O
data,3084,O
suggest,3084,O
that,3084,O
the,3084,O
mechano-adaptive,3084,O
response,3084,O
induced,3084,O
by,3084,O
ETM,3084,O
is,3084,O
controlled,3084,O
by,3084,O
sympathetic,3084,O
signaling,3084,O
through,3084,O
osteoclast,3084,O
activation,3084,O
.,3084,O
Resistin,3085,B-GENE-Y
knockout,3085,O
mice,3085,O
exhibit,3085,O
impaired,3085,O
adipocyte,3085,O
glucose-dependent,3085,B-CHEMICAL
insulinotropic,3085,I-GENE-Y
polypeptide,3085,I-GENE-Y
receptor,3085,I-GENE-Y
(,3085,O
GIPR,3085,B-GENE-Y
),3085,O
expression,3085,O
.,3085,O
Glucose-dependent,3086,B-GENE-Y
insulinotropic,3086,I-GENE-Y
polypeptide,3086,I-GENE-Y
(,3086,O
GIP,3086,B-GENE-Y
),3086,O
is,3086,O
an,3086,O
incretin,3086,B-GENE-N
hormone,3086,I-GENE-N
that,3086,O
also,3086,O
plays,3086,O
a,3086,O
regulatory,3086,O
role,3086,O
in,3086,O
fat,3086,O
metabolism,3086,O
.,3086,O
In,3087,O
3T3-L1,3087,O
cells,3087,O
",",3087,O
resistin,3087,B-GENE-Y
was,3087,O
demonstrated,3087,O
to,3087,O
be,3087,O
a,3087,O
key,3087,O
mediator,3087,O
of,3087,O
GIP,3087,B-GENE-Y
stimulation,3087,O
of,3087,O
lipoprotein,3087,B-GENE-Y
lipase,3087,I-GENE-Y
(,3087,O
LPL,3087,B-GENE-Y
),3087,O
activity,3087,O
",",3087,O
involving,3087,O
activation,3087,O
of,3087,O
protein,3087,B-GENE-Y
kinase,3087,I-GENE-Y
B,3087,I-GENE-Y
(,3087,O
PKB,3087,B-GENE-Y
),3087,O
and,3087,O
reduced,3087,O
phosphorylation,3087,O
of,3087,O
liver,3087,B-GENE-Y
kinase,3087,I-GENE-Y
B1,3087,I-GENE-Y
(,3087,O
LKB1,3087,B-GENE-Y
),3087,O
and,3087,O
AMP-activated,3087,B-CHEMICAL
protein,3087,I-GENE-Y
kinase,3087,I-GENE-Y
(,3087,O
AMPK,3087,B-GENE-Y
),3087,O
.,3087,O
The,3088,O
current,3088,O
study,3088,O
was,3088,O
initiated,3088,O
to,3088,O
determine,3088,O
whether,3088,O
resistin,3088,B-GENE-Y
has,3088,O
additional,3088,O
roles,3088,O
in,3088,O
GIP-regulated,3088,B-GENE-Y
adipocyte,3088,O
functions,3088,O
.,3088,O
Analysis,3089,O
of,3089,O
primary,3089,O
adipocytes,3089,O
isolated,3089,O
from,3089,O
Retn,3089,B-GENE-Y
(,3089,O
-/-,3089,O
),3089,O
",",3089,O
Retn,3089,B-GENE-Y
(,3089,O
+/-,3089,O
),3089,O
",",3089,O
and,3089,O
Retn,3089,B-GENE-Y
(,3089,O
+/+,3089,O
),3089,O
mice,3089,O
found,3089,O
that,3089,O
GIP,3089,B-GENE-Y
stimulated,3089,O
the,3089,O
PKB/LKB1/AMPK/LPL,3089,B-GENE-Y
pathway,3089,O
and,3089,O
fatty,3089,B-CHEMICAL
acid,3089,I-CHEMICAL
uptake,3089,O
only,3089,O
in,3089,O
Retn,3089,B-GENE-Y
(,3089,O
+/+,3089,O
),3089,O
adipocytes,3089,O
",",3089,O
suggesting,3089,O
that,3089,O
GIP,3089,B-GENE-Y
signaling,3089,O
and/or,3089,O
GIP,3089,B-GENE-Y
responsiveness,3089,O
were,3089,O
compromised,3089,O
in,3089,O
Retn,3089,B-GENE-Y
(,3089,O
+/-,3089,O
),3089,O
and,3089,O
Retn,3089,B-GENE-Y
(,3089,O
-/-,3089,O
),3089,O
adipocytes,3089,O
.,3089,O
GIP,3090,B-GENE-Y
receptor,3090,I-GENE-Y
(,3090,O
GIPR,3090,B-GENE-Y
),3090,O
protein,3090,O
and,3090,O
mRNA,3090,O
were,3090,O
decreased,3090,O
in,3090,O
Retn,3090,B-GENE-Y
(,3090,O
+/-,3090,O
),3090,O
and,3090,O
Retn,3090,B-GENE-Y
(,3090,O
-/-,3090,O
),3090,O
adipocytes,3090,O
",",3090,O
but,3090,O
resistin,3090,B-GENE-Y
treatment,3090,O
rescued,3090,O
LPL,3090,O
responsiveness,3090,O
to,3090,O
GIP,3090,B-GENE-Y
.,3090,O
In,3091,O
addition,3091,O
",",3091,O
genes,3091,O
encoding,3091,O
tumor,3091,B-GENE-Y
necrosis,3091,I-GENE-Y
factor,3091,I-GENE-Y
(,3091,O
TNF,3091,B-GENE-Y
),3091,O
",",3091,O
TNF,3091,B-GENE-Y
receptor,3091,I-GENE-Y
2,3091,I-GENE-Y
(,3091,O
TNFR2,3091,B-GENE-Y
),3091,O
",",3091,O
and,3091,O
the,3091,O
signaling,3091,O
proteins,3091,O
stress-activated,3091,B-GENE-N
protein,3091,I-GENE-N
kinase,3091,I-GENE-N
(,3091,O
SAPK,3091,B-GENE-N
),3091,O
/Jun,3091,O
NH,3091,B-CHEMICAL
(,3091,I-CHEMICAL
2,3091,I-CHEMICAL
),3091,I-CHEMICAL
-terminal,3091,I-GENE-N
kinase,3091,I-GENE-N
(,3091,O
JNK,3091,B-GENE-N
),3091,O
",",3091,O
were,3091,O
downregulated,3091,O
",",3091,O
and,3091,O
phosphorylated,3091,O
levels,3091,O
of,3091,O
SAPK/JNK/c-Jun,3091,B-GENE-N
were,3091,O
decreased,3091,O
in,3091,O
Retn,3091,B-GENE-Y
(,3091,O
-/-,3091,O
),3091,O
mice,3091,O
.,3091,O
Chromatin,3092,O
immunoprecipitation,3092,O
assays,3092,O
were,3092,O
used,3092,O
to,3092,O
identify,3092,O
a,3092,O
12-O-tetradecanoylphorbol-13-acetate,3092,B-CHEMICAL
(,3092,I-GENE-N
TPA,3092,B-CHEMICAL
),3092,I-GENE-N
-response,3092,I-GENE-N
element,3092,I-GENE-N
(,3092,O
TRE-III,3092,B-GENE-N
),3092,O
responsible,3092,O
for,3092,O
c-Jun-mediated,3092,B-GENE-Y
transcriptional,3092,O
activation,3092,O
of,3092,O
Gipr,3092,B-GENE-Y
.,3092,O
Blunted,3093,O
GIP,3093,B-GENE-Y
responsiveness,3093,O
in,3093,O
Retn,3093,B-GENE-Y
(,3093,O
+/-,3093,O
),3093,O
and,3093,O
Retn,3093,B-GENE-Y
(,3093,O
-/-,3093,O
),3093,O
adipocytes,3093,O
was,3093,O
therefore,3093,O
largely,3093,O
due,3093,O
to,3093,O
the,3093,O
greatly,3093,O
reduced,3093,O
GIPR,3093,B-GENE-Y
expression,3093,O
associated,3093,O
with,3093,O
decreased,3093,O
c-Jun-mediated,3093,B-GENE-N
transcriptional,3093,O
activation,3093,O
of,3093,O
Gipr,3093,B-GENE-Y
.,3093,O
Cyclooxygenase,3094,B-GENE-Y
(,3094,I-GENE-Y
COX,3094,I-GENE-Y
),3094,I-GENE-Y
-1,3094,I-GENE-Y
and,3094,O
COX-2,3094,B-GENE-Y
both,3094,O
play,3094,O
an,3094,O
important,3094,O
role,3094,O
in,3094,O
the,3094,O
protection,3094,O
of,3094,O
the,3094,O
duodenal,3094,O
mucosa,3094,O
in,3094,O
cats,3094,O
.,3094,O
Although,3095,O
nonsteroidal,3095,O
anti-inflammatory,3095,O
drugs,3095,O
often,3095,O
cause,3095,O
ulcers,3095,O
in,3095,O
the,3095,O
duodenum,3095,O
in,3095,O
humans,3095,O
",",3095,O
the,3095,O
role,3095,O
of,3095,O
cyclooxygenase,3095,B-GENE-N
(,3095,O
COX,3095,B-GENE-N
),3095,O
isoforms,3095,O
in,3095,O
the,3095,O
pathogenesis,3095,O
of,3095,O
duodenal,3095,O
ulcers,3095,O
has,3095,O
not,3095,O
been,3095,O
fully,3095,O
elucidated,3095,O
.,3095,O
We,3096,O
examined,3096,O
in,3096,O
cats,3096,O
the,3096,O
1,3096,O
),3096,O
ulcerogenic,3096,O
effects,3096,O
of,3096,O
selective,3096,O
COX-1,3096,B-GENE-Y
(,3096,O
SC-560,3096,B-CHEMICAL
",",3096,O
ketorolac,3096,B-CHEMICAL
),3096,O
and,3096,O
COX-2,3096,B-GENE-Y
(,3096,O
celecoxib,3096,B-CHEMICAL
",",3096,O
meloxicam,3096,B-CHEMICAL
),3096,O
inhibitors,3096,O
on,3096,O
the,3096,O
gastrointestinal,3096,O
mucosa,3096,O
",",3096,O
2,3096,O
),3096,O
effect,3096,O
of,3096,O
feeding,3096,O
and,3096,O
cimetidine,3096,B-CHEMICAL
on,3096,O
the,3096,O
expression,3096,O
of,3096,O
COX,3096,B-GENE-N
isoforms,3096,O
and,3096,O
prostaglandin,3096,B-CHEMICAL
E,3096,I-CHEMICAL
(,3096,I-CHEMICAL
2,3096,I-CHEMICAL
),3096,I-CHEMICAL
(,3096,O
PGE,3096,B-CHEMICAL
(,3096,I-CHEMICAL
2,3096,I-CHEMICAL
),3096,I-CHEMICAL
),3096,O
level,3096,O
in,3096,O
the,3096,O
duodenum,3096,O
",",3096,O
and,3096,O
3,3096,O
),3096,O
localization,3096,O
of,3096,O
COX,3096,B-GENE-N
isoforms,3096,O
in,3096,O
the,3096,O
duodenum,3096,O
.,3096,O
COX,3097,B-GENE-N
inhibitors,3097,O
were,3097,O
administered,3097,O
after,3097,O
the,3097,O
morning,3097,O
meal,3097,O
in,3097,O
cats,3097,O
once,3097,O
daily,3097,O
for,3097,O
3,3097,O
days,3097,O
.,3097,O
Gastrointestinal,3098,O
lesions,3098,O
were,3098,O
examined,3098,O
on,3098,O
day,3098,O
4,3098,O
.,3098,O
Localization,3099,O
and,3099,O
expression,3099,O
of,3099,O
COX,3099,B-GENE-N
isoforms,3099,O
(,3099,O
by,3099,O
immunohistochemistry,3099,O
",",3099,O
Western,3099,O
blot,3099,O
),3099,O
and,3099,O
PGE,3099,B-CHEMICAL
(,3099,I-CHEMICAL
2,3099,I-CHEMICAL
),3099,I-CHEMICAL
level,3099,O
(,3099,O
by,3099,O
enzyme,3099,O
immunoassay,3099,O
),3099,O
were,3099,O
examined,3099,O
.,3099,O
Results,3100,O
were,3100,O
as,3100,O
follows,3100,O
.,3100,O
First,3101,O
",",3101,O
selective,3101,O
COX-1,3101,B-GENE-Y
or,3101,O
COX-2,3101,B-GENE-Y
inhibitors,3101,O
alone,3101,O
produced,3101,O
marked,3101,O
ulcers,3101,O
in,3101,O
the,3101,O
duodenum,3101,O
but,3101,O
did,3101,O
not,3101,O
cause,3101,O
obvious,3101,O
lesions,3101,O
in,3101,O
the,3101,O
small,3101,O
intestine,3101,O
.,3101,O
Coadministration,3102,O
of,3102,O
SC-560,3102,B-CHEMICAL
and,3102,O
celecoxib,3102,B-CHEMICAL
produced,3102,O
marked,3102,O
lesions,3102,O
in,3102,O
the,3102,O
small,3102,O
intestine,3102,O
.,3102,O
Second,3103,O
",",3103,O
feeding,3103,O
increased,3103,O
both,3103,O
the,3103,O
expression,3103,O
of,3103,O
COX,3103,B-GENE-N
isoforms,3103,O
and,3103,O
PGE,3103,B-CHEMICAL
(,3103,I-CHEMICAL
2,3103,I-CHEMICAL
),3103,I-CHEMICAL
level,3103,O
in,3103,O
the,3103,O
duodenum,3103,O
",",3103,O
and,3103,O
the,3103,O
effects,3103,O
were,3103,O
markedly,3103,O
inhibited,3103,O
by,3103,O
pretreatment,3103,O
with,3103,O
cimetidine,3103,B-CHEMICAL
.,3103,O
Third,3104,O
",",3104,O
COX-1,3104,B-GENE-Y
was,3104,O
localized,3104,O
in,3104,O
goblet,3104,O
and,3104,O
Brunner,3104,O
's,3104,O
gland,3104,O
cells,3104,O
",",3104,O
Meissner,3104,O
's,3104,O
and,3104,O
Auerbach,3104,O
's,3104,O
plexus,3104,O
",",3104,O
smooth,3104,O
muscle,3104,O
cells,3104,O
",",3104,O
and,3104,O
arterioles,3104,O
;,3104,O
and,3104,O
COX-2,3104,B-GENE-Y
was,3104,O
observed,3104,O
in,3104,O
capillaries,3104,O
",",3104,O
venules,3104,O
",",3104,O
and,3104,O
basal,3104,O
granulated,3104,O
cells,3104,O
.,3104,O
The,3105,O
expression,3105,O
of,3105,O
COX,3105,B-GENE-N
isoforms,3105,O
in,3105,O
the,3105,O
duodenum,3105,O
is,3105,O
up-regulated,3105,O
by,3105,O
feeding,3105,O
",",3105,O
and,3105,O
inhibition,3105,O
of,3105,O
either,3105,O
COX-1,3105,B-GENE-Y
or,3105,O
COX-2,3105,B-GENE-Y
causes,3105,O
ulcers,3105,O
in,3105,O
the,3105,O
duodenum,3105,O
",",3105,O
suggesting,3105,O
that,3105,O
both,3105,O
isoforms,3105,O
play,3105,O
an,3105,O
important,3105,O
role,3105,O
in,3105,O
the,3105,O
protection,3105,O
of,3105,O
the,3105,O
duodenal,3105,O
mucosa,3105,O
.,3105,O
Reversal,3106,O
of,3106,O
dopamine,3106,B-GENE-Y
D2,3106,I-GENE-Y
agonist-induced,3106,O
inhibition,3106,O
of,3106,O
ventral,3106,O
tegmental,3106,O
area,3106,O
neurons,3106,O
by,3106,O
Gq-linked,3106,B-GENE-N
neurotransmitters,3106,O
is,3106,O
dependent,3106,O
on,3106,O
protein,3106,B-GENE-N
kinase,3106,I-GENE-N
C,3106,I-GENE-N
",",3106,O
G,3106,B-GENE-N
protein-coupled,3106,I-GENE-N
receptor,3106,I-GENE-N
kinase,3106,I-GENE-N
",",3106,O
and,3106,O
dynamin,3106,B-GENE-N
.,3106,O
Dopaminergic,3107,O
neurons,3107,O
of,3107,O
the,3107,O
ventral,3107,O
tegmental,3107,O
area,3107,O
are,3107,O
important,3107,O
components,3107,O
of,3107,O
brain,3107,O
pathways,3107,O
related,3107,O
to,3107,O
addiction,3107,O
.,3107,O
Prolonged,3108,O
exposure,3108,O
of,3108,O
these,3108,O
neurons,3108,O
to,3108,O
moderate,3108,O
concentrations,3108,O
of,3108,O
dopamine,3108,B-CHEMICAL
(,3108,O
DA,3108,O
),3108,O
decreases,3108,O
their,3108,O
sensitivity,3108,O
to,3108,O
inhibition,3108,O
by,3108,O
DA,3108,O
",",3108,O
a,3108,O
process,3108,O
called,3108,O
DA-inhibition,3108,O
reversal,3108,O
(,3108,O
DIR,3108,O
),3108,O
.,3108,O
DIR,3109,O
is,3109,O
mediated,3109,O
by,3109,O
phospholipase,3109,B-GENE-N
C,3109,I-GENE-N
and,3109,O
conventional,3109,B-GENE-N
subtype,3109,I-GENE-N
of,3109,I-GENE-N
protein,3109,I-GENE-N
kinase,3109,I-GENE-N
C,3109,I-GENE-N
(,3109,O
cPKC,3109,B-GENE-N
),3109,O
through,3109,O
concurrent,3109,O
stimulation,3109,O
of,3109,O
D2,3109,B-GENE-Y
and,3109,O
D1-like,3109,B-GENE-N
DA,3109,I-GENE-N
receptors,3109,I-GENE-N
",",3109,O
or,3109,O
by,3109,O
D2,3109,B-GENE-Y
stimulation,3109,O
concurrent,3109,O
with,3109,O
activation,3109,O
of,3109,O
5-HT,3109,B-CHEMICAL
(,3109,I-GENE-N
2,3109,I-GENE-N
),3109,I-GENE-N
or,3109,O
neurotensin,3109,B-CHEMICAL
receptors,3109,I-GENE-N
.,3109,O
In,3110,O
the,3110,O
present,3110,O
study,3110,O
",",3110,O
we,3110,O
further,3110,O
characterized,3110,O
this,3110,O
phenomenon,3110,O
by,3110,O
use,3110,O
of,3110,O
extracellular,3110,O
recordings,3110,O
in,3110,O
brain,3110,O
slices,3110,O
to,3110,O
examine,3110,O
whether,3110,O
DIR,3110,O
is,3110,O
linked,3110,O
to,3110,O
G,3110,B-GENE-Y
protein-coupled,3110,I-GENE-Y
receptor,3110,I-GENE-Y
kinase-2,3110,I-GENE-Y
(,3110,O
GRK2,3110,B-GENE-Y
),3110,O
or,3110,O
dynamin,3110,B-GENE-N
by,3110,O
assessing,3110,O
DIR,3110,O
in,3110,O
the,3110,O
presence,3110,O
of,3110,O
antagonists,3110,O
of,3110,O
these,3110,O
enzymes,3110,O
.,3110,O
DIR,3111,O
was,3111,O
blocked,3111,O
by,3111,O
-ARK1,3111,O
inhibitor,3111,O
",",3111,O
which,3111,O
inhibits,3111,O
GRK2,3111,B-GENE-Y
",",3111,O
and,3111,O
by,3111,O
dynasore,3111,O
",",3111,O
which,3111,O
blocks,3111,O
dynamin,3111,B-GENE-N
.,3111,O
Reversal,3112,O
of,3112,O
inhibition,3112,O
by,3112,O
D2,3112,B-GENE-Y
agonist,3112,O
quinpirole,3112,B-CHEMICAL
was,3112,O
produced,3112,O
by,3112,O
serotonin,3112,B-CHEMICAL
(,3112,O
50,3112,O
M,3112,O
),3112,O
and,3112,O
by,3112,O
neurotensin,3112,B-GENE-Y
(,3112,O
5-10,3112,O
nM,3112,O
),3112,O
.,3112,O
Serotonin-induced,3113,B-CHEMICAL
or,3113,O
neurotensin-induced,3113,B-CHEMICAL
reversal,3113,O
was,3113,O
blocked,3113,O
by,3113,O
-ARK1,3113,O
inhibitor,3113,O
",",3113,O
dynasore,3113,O
",",3113,O
or,3113,O
cPKC,3113,B-GENE-N
antagonist,3113,O
"5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo",3113,B-CHEMICAL
[,3113,I-CHEMICAL
"2,3-a",3113,I-CHEMICAL
],3113,I-CHEMICAL
pyrrolo,3113,I-CHEMICAL
[,3113,I-CHEMICAL
"3,4c",3113,I-CHEMICAL
],3113,I-CHEMICAL
carbazole-12-propanenitrile,3113,I-CHEMICAL
(,3113,O
G6976,3113,B-CHEMICAL
),3113,O
.,3113,O
This,3114,O
further,3114,O
characterization,3114,O
of,3114,O
DIR,3114,O
indicates,3114,O
that,3114,O
cPKC,3114,B-GENE-N
",",3114,O
GRK2,3114,B-GENE-Y
",",3114,O
and,3114,O
dynamin,3114,B-GENE-N
play,3114,O
important,3114,O
roles,3114,O
in,3114,O
the,3114,O
desensitization,3114,O
of,3114,O
D2,3114,B-GENE-Y
receptors,3114,O
.,3114,O
As,3115,O
drugs,3115,O
of,3115,O
abuse,3115,O
produce,3115,O
persistent,3115,O
increases,3115,O
in,3115,O
DA,3115,O
concentration,3115,O
in,3115,O
the,3115,O
ventral,3115,O
tegmental,3115,O
area,3115,O
",",3115,O
reduction,3115,O
of,3115,O
D2,3115,B-GENE-Y
receptor,3115,I-GENE-Y
sensitivity,3115,O
as,3115,O
a,3115,O
result,3115,O
of,3115,O
drug,3115,O
abuse,3115,O
may,3115,O
be,3115,O
a,3115,O
critical,3115,O
factor,3115,O
in,3115,O
the,3115,O
processes,3115,O
of,3115,O
addiction,3115,O
.,3115,O
Differential,3116,O
cell-protective,3116,O
function,3116,O
of,3116,O
two,3116,O
resveratrol,3116,B-CHEMICAL
(,3116,B-CHEMICAL
"trans-3,5,4'-trihydroxystilbene",3116,I-CHEMICAL
),3116,I-CHEMICAL
glucosides,3116,I-CHEMICAL
against,3116,O
oxidative,3116,O
stress,3116,O
.,3116,O
Resveratrol,3117,B-CHEMICAL
(,3117,O
"trans-3,5,4'-trihydroxystilbene",3117,B-CHEMICAL
;,3117,O
RSV,3117,B-CHEMICAL
),3117,O
",",3117,O
a,3117,O
natural,3117,O
polyphenol,3117,B-CHEMICAL
",",3117,O
exerts,3117,O
a,3117,O
beneficial,3117,O
effect,3117,O
on,3117,O
health,3117,O
and,3117,O
diseases,3117,O
.,3117,O
RSV,3118,B-CHEMICAL
targets,3118,O
and,3118,O
activates,3118,O
the,3118,O
NAD,3118,B-GENE-Y
(,3118,I-GENE-Y
+,3118,I-GENE-Y
),3118,I-GENE-Y
-dependent,3118,I-GENE-Y
protein,3118,I-GENE-Y
deacetylase,3118,I-GENE-Y
SIRT1,3118,I-GENE-Y
;,3118,O
in,3118,O
turn,3118,O
",",3118,O
SIRT1,3118,B-GENE-Y
induces,3118,O
an,3118,O
intracellular,3118,O
antioxidative,3118,O
mechanism,3118,O
by,3118,O
inducing,3118,O
mitochondrial,3118,B-GENE-Y
superoxide,3118,I-GENE-Y
dismutase,3118,I-GENE-Y
(,3118,O
SOD2,3118,B-GENE-Y
),3118,O
.,3118,O
Most,3119,O
RSV,3119,O
found,3119,O
in,3119,O
plants,3119,O
is,3119,O
glycosylated,3119,O
",",3119,O
and,3119,O
the,3119,O
effect,3119,O
of,3119,O
these,3119,O
glycosylated,3119,O
forms,3119,O
on,3119,O
SIRT1,3119,B-GENE-Y
has,3119,O
not,3119,O
been,3119,O
studied,3119,O
.,3119,O
In,3120,O
this,3120,O
study,3120,O
",",3120,O
we,3120,O
compared,3120,O
the,3120,O
effects,3120,O
of,3120,O
RSV,3120,B-CHEMICAL
and,3120,O
two,3120,O
glycosyl,3120,B-CHEMICAL
RSVs,3120,I-CHEMICAL
",",3120,O
resveratrol-3-O--d-glucoside,3120,B-CHEMICAL
(,3120,O
3G-RSV,3120,B-CHEMICAL
;,3120,O
polydatin/piceid,3120,B-CHEMICAL
),3120,O
and,3120,O
resveratrol-4'-O--d-glucoside,3120,B-CHEMICAL
(,3120,O
4,3120,B-CHEMICAL
',3120,I-CHEMICAL
G-RSV,3120,I-CHEMICAL
),3120,O
",",3120,O
at,3120,O
the,3120,O
cellular,3120,O
level,3120,O
.,3120,O
In,3121,O
oxygen,3121,O
radical,3121,O
absorbance,3121,O
capacity,3121,O
and,3121,O
"2,2-diphenyl-1-picrylhydrazyl",3121,B-CHEMICAL
radical,3121,O
scavenging,3121,O
assays,3121,O
",",3121,O
the,3121,O
antioxidant,3121,O
activity,3121,O
of,3121,O
3G-RSV,3121,B-CHEMICAL
was,3121,O
comparable,3121,O
to,3121,O
that,3121,O
of,3121,O
RSV,3121,B-CHEMICAL
",",3121,O
whereas,3121,O
the,3121,O
radical-scavenging,3121,O
efficiency,3121,O
of,3121,O
4,3121,B-CHEMICAL
',3121,I-CHEMICAL
G-RSV,3121,I-CHEMICAL
was,3121,O
less,3121,O
than,3121,O
50,3121,O
%,3121,O
of,3121,O
that,3121,O
of,3121,O
RSV,3121,B-CHEMICAL
.,3121,O
However,3122,O
",",3122,O
4,3122,B-CHEMICAL
',3122,I-CHEMICAL
G-RSV,3122,I-CHEMICAL
",",3122,O
but,3122,O
not,3122,O
3G-RSV,3122,B-CHEMICAL
",",3122,O
induced,3122,O
SIRT1-dependent,3122,B-GENE-Y
histone,3122,B-GENE-N
H3,3122,I-GENE-N
deacetylation,3122,O
and,3122,O
SOD2,3122,B-GENE-Y
expression,3122,O
in,3122,O
mouse,3122,O
C2C12,3122,O
skeletal,3122,O
myoblasts,3122,O
;,3122,O
as,3122,O
with,3122,O
RSV,3122,B-CHEMICAL
",",3122,O
SIRT1,3122,B-GENE-Y
knockdown,3122,O
blunted,3122,O
these,3122,O
effects,3122,O
.,3122,O
RSV,3123,B-CHEMICAL
and,3123,O
4,3123,B-CHEMICAL
',3123,I-CHEMICAL
G-RSV,3123,I-CHEMICAL
",",3123,O
but,3123,O
not,3123,O
3G-RSV,3123,B-CHEMICAL
",",3123,O
mitigated,3123,O
oxidative,3123,O
stress-induced,3123,O
cell,3123,O
death,3123,O
in,3123,O
C2C12,3123,O
cells,3123,O
and,3123,O
primary,3123,O
neonatal,3123,O
rat,3123,O
cardiomyocytes,3123,O
.,3123,O
RSV,3124,B-CHEMICAL
and,3124,O
4,3124,B-CHEMICAL
',3124,I-CHEMICAL
G-RSV,3124,I-CHEMICAL
inhibited,3124,O
C2C12,3124,O
cell,3124,O
proliferation,3124,O
",",3124,O
but,3124,O
3G-RSV,3124,B-CHEMICAL
did,3124,O
not,3124,O
.,3124,O
RSV,3125,B-CHEMICAL
was,3125,O
found,3125,O
in,3125,O
both,3125,O
the,3125,O
intracellular,3125,O
and,3125,O
extracellular,3125,O
fractions,3125,O
of,3125,O
C2C12,3125,O
cells,3125,O
that,3125,O
had,3125,O
been,3125,O
incubated,3125,O
with,3125,O
4,3125,B-CHEMICAL
',3125,I-CHEMICAL
G-RSV,3125,I-CHEMICAL
",",3125,O
indicating,3125,O
that,3125,O
4,3125,B-CHEMICAL
',3125,I-CHEMICAL
G-RSV,3125,I-CHEMICAL
was,3125,O
extracellularly,3125,O
deglycosylated,3125,O
to,3125,O
RSV,3125,B-CHEMICAL
",",3125,O
which,3125,O
was,3125,O
then,3125,O
taken,3125,O
up,3125,O
by,3125,O
the,3125,O
cells,3125,O
.,3125,O
C2C12,3126,O
cells,3126,O
did,3126,O
not,3126,O
deglycosylate,3126,O
3G-RSV,3126,B-CHEMICAL
.,3126,O
Our,3127,O
results,3127,O
point,3127,O
to,3127,O
4,3127,B-CHEMICAL
',3127,I-CHEMICAL
G-RSV,3127,I-CHEMICAL
as,3127,O
a,3127,O
useful,3127,O
RSV,3127,B-CHEMICAL
prodrug,3127,O
with,3127,O
high,3127,O
water,3127,O
solubility,3127,O
.,3127,O
These,3128,O
data,3128,O
also,3128,O
show,3128,O
that,3128,O
the,3128,O
in,3128,O
vitro,3128,O
antioxidative,3128,O
activity,3128,O
of,3128,O
these,3128,O
molecules,3128,O
did,3128,O
not,3128,O
correlate,3128,O
with,3128,O
their,3128,O
ability,3128,O
to,3128,O
protect,3128,O
cells,3128,O
from,3128,O
oxidative,3128,O
stress-induced,3128,O
apoptosis,3128,O
.,3128,O
Hydrophobic,3129,O
amino,3129,B-CHEMICAL
acids,3129,I-CHEMICAL
in,3129,O
the,3129,O
hinge,3129,O
region,3129,O
of,3129,O
the,3129,O
5A,3129,B-GENE-Y
apolipoprotein,3129,I-GENE-Y
mimetic,3129,O
peptide,3129,O
are,3129,O
essential,3129,O
for,3129,O
promoting,3129,O
cholesterol,3129,B-CHEMICAL
efflux,3129,O
by,3129,O
the,3129,O
ABCA1,3129,B-GENE-Y
transporter,3129,O
.,3129,O
The,3130,O
bihelical,3130,O
apolipoprotein,3130,B-GENE-Y
mimetic,3130,I-GENE-Y
peptide,3130,I-GENE-Y
5A,3130,I-GENE-Y
effluxes,3130,O
cholesterol,3130,B-CHEMICAL
from,3130,O
cells,3130,O
and,3130,O
reduces,3130,O
inflammation,3130,O
and,3130,O
atherosclerosis,3130,O
in,3130,O
animal,3130,O
models,3130,O
.,3130,O
We,3131,O
investigated,3131,O
how,3131,O
hydrophobic,3131,O
residues,3131,O
in,3131,O
the,3131,O
hinge,3131,O
region,3131,O
between,3131,O
the,3131,O
two,3131,O
helices,3131,O
are,3131,O
important,3131,O
in,3131,O
the,3131,O
structure,3131,O
and,3131,O
function,3131,O
of,3131,O
this,3131,O
peptide,3131,O
.,3131,O
By,3132,O
simulated,3132,O
annealing,3132,O
analysis,3132,O
and,3132,O
molecular,3132,O
dynamics,3132,O
modeling,3132,O
",",3132,O
two,3132,O
hydrophobic,3132,O
amino,3132,B-CHEMICAL
acids,3132,I-CHEMICAL
",",3132,O
F-18,3132,O
and,3132,O
W-21,3132,O
",",3132,O
in,3132,O
the,3132,O
hinge,3132,O
region,3132,O
were,3132,O
predicted,3132,O
to,3132,O
be,3132,O
relatively,3132,O
surface-exposed,3132,O
and,3132,O
to,3132,O
interact,3132,O
with,3132,O
the,3132,O
aqueous,3132,O
solvent,3132,O
.,3132,O
Using,3133,O
a,3133,O
series,3133,O
of,3133,O
5A,3133,O
peptide,3133,O
analogs,3133,O
in,3133,O
which,3133,O
F-18,3133,O
or,3133,O
W-21,3133,O
was,3133,O
changed,3133,O
to,3133,O
either,3133,O
F,3133,O
",",3133,O
W,3133,O
",",3133,O
A,3133,O
",",3133,O
or,3133,O
E,3133,O
",",3133,O
only,3133,O
peptides,3133,O
with,3133,O
hydrophobic,3133,O
amino,3133,B-CHEMICAL
acids,3133,I-CHEMICAL
in,3133,O
these,3133,O
two,3133,O
positions,3133,O
were,3133,O
able,3133,O
to,3133,O
readily,3133,O
bind,3133,O
and,3133,O
solubilize,3133,O
phospholipid,3133,O
vesicles,3133,O
.,3133,O
Compared,3134,O
with,3134,O
active,3134,O
peptides,3134,O
containing,3134,O
F,3134,O
or,3134,O
W,3134,O
",",3134,O
peptides,3134,O
containing,3134,O
E,3134,O
in,3134,O
either,3134,O
of,3134,O
these,3134,O
two,3134,O
positions,3134,O
were,3134,O
more,3134,O
than,3134,O
10-fold,3134,O
less,3134,O
effective,3134,O
in,3134,O
effluxing,3134,O
cholesterol,3134,B-CHEMICAL
by,3134,O
the,3134,O
ABCA1,3134,B-GENE-Y
transporter,3134,O
.,3134,O
Intravenous,3135,O
injection,3135,O
of,3135,O
5A,3135,O
in,3135,O
C57BL/6,3135,O
mice,3135,O
increased,3135,O
plasma-free,3135,O
cholesterol,3135,B-CHEMICAL
(,3135,O
5A,3135,O
:,3135,O
89.9,3135,O
,3135,O
13.6,3135,O
mg/dl,3135,O
;,3135,O
control,3135,O
:,3135,O
38.7,3135,O
,3135,O
4.3,3135,O
mg/dl,3135,O
(,3135,O
mean,3135,O
,3135,O
S.D,3135,O
.,3135,O
),3136,O
;,3136,O
P,3136,O
<,3136,O
0.05,3136,O
),3136,O
and,3136,O
triglycerides,3136,O
(,3136,O
5A,3136,O
:,3136,O
887.0,3136,O
,3136,O
172.0,3136,O
mg/dl,3136,O
;,3136,O
control,3136,O
:,3136,O
108.9,3136,O
,3136,O
9.9,3136,O
mg/dl,3136,O
;,3136,O
P,3136,O
<,3136,O
0.05,3136,O
),3136,O
",",3136,O
whereas,3136,O
the,3136,O
EE,3136,O
peptide,3136,O
containing,3136,O
E,3136,O
in,3136,O
both,3136,O
positions,3136,O
had,3136,O
no,3136,O
effect,3136,O
.,3136,O
Finally,3137,O
",",3137,O
5A,3137,O
increased,3137,O
cholesterol,3137,O
efflux,3137,O
approximately,3137,O
2.5-fold,3137,O
in,3137,O
vivo,3137,O
from,3137,O
radiolabeled,3137,O
macrophages,3137,O
",",3137,O
whereas,3137,O
the,3137,O
EE,3137,O
peptide,3137,O
was,3137,O
inactive,3137,O
.,3137,O
These,3138,O
results,3138,O
provide,3138,O
a,3138,O
rationale,3138,O
for,3138,O
future,3138,O
design,3138,O
of,3138,O
therapeutic,3138,O
apolipoprotein,3138,O
mimetic,3138,O
peptides,3138,O
and,3138,O
provide,3138,O
new,3138,O
insights,3138,O
into,3138,O
the,3138,O
interaction,3138,O
of,3138,O
hydrophobic,3138,O
residues,3138,O
on,3138,O
apolipoproteins,3138,O
with,3138,O
phospholipids,3138,O
in,3138,O
the,3138,O
lipid,3138,O
microdomain,3138,O
created,3138,O
by,3138,O
the,3138,O
ABCA1,3138,O
transporter,3138,O
during,3138,O
the,3138,O
cholesterol,3138,O
efflux,3138,O
process,3138,O
.,3138,O
Efficacy,3139,O
of,3139,O
the,3139,O
GluK1/AMPA,3139,B-GENE-Y
receptor,3139,I-GENE-N
antagonist,3139,O
LY293558,3139,B-CHEMICAL
against,3139,O
seizures,3139,O
and,3139,O
neuropathology,3139,O
in,3139,O
a,3139,O
soman-exposure,3139,O
model,3139,O
without,3139,O
pretreatment,3139,O
and,3139,O
its,3139,O
pharmacokinetics,3139,O
after,3139,O
intramuscular,3139,O
administration,3139,O
.,3139,O
Control,3140,O
of,3140,O
brain,3140,O
seizures,3140,O
after,3140,O
exposure,3140,O
to,3140,O
nerve,3140,O
agents,3140,O
is,3140,O
imperative,3140,O
for,3140,O
the,3140,O
prevention,3140,O
of,3140,O
brain,3140,O
damage,3140,O
and,3140,O
death,3140,O
.,3140,O
Animal,3141,O
models,3141,O
of,3141,O
nerve,3141,O
agent,3141,O
exposure,3141,O
make,3141,O
use,3141,O
of,3141,O
pretreatments,3141,O
",",3141,O
or,3141,O
medication,3141,O
administered,3141,O
within,3141,O
1,3141,O
minute,3141,O
after,3141,O
exposure,3141,O
",",3141,O
in,3141,O
order,3141,O
to,3141,O
prevent,3141,O
rapid,3141,O
death,3141,O
from,3141,O
peripheral,3141,O
toxic,3141,O
effects,3141,O
and,3141,O
respiratory,3141,O
failure,3141,O
",",3141,O
which,3141,O
then,3141,O
allows,3141,O
the,3141,O
testing,3141,O
of,3141,O
anticonvulsant,3141,O
compounds,3141,O
.,3141,O
However,3142,O
",",3142,O
in,3142,O
a,3142,O
real-case,3142,O
scenario,3142,O
of,3142,O
an,3142,O
unexpected,3142,O
attack,3142,O
with,3142,O
nerve,3142,O
agents,3142,O
",",3142,O
pretreatment,3142,O
would,3142,O
not,3142,O
be,3142,O
possible,3142,O
",",3142,O
and,3142,O
medical,3142,O
assistance,3142,O
may,3142,O
not,3142,O
be,3142,O
available,3142,O
immediately,3142,O
.,3142,O
To,3143,O
determine,3143,O
if,3143,O
control,3143,O
of,3143,O
seizures,3143,O
and,3143,O
survival,3143,O
are,3143,O
still,3143,O
possible,3143,O
without,3143,O
pretreatment,3143,O
or,3143,O
immediate,3143,O
pharmacologic,3143,O
intervention,3143,O
",",3143,O
we,3143,O
studied,3143,O
the,3143,O
anticonvulsant,3143,O
efficacy,3143,O
of,3143,O
the,3143,O
GluK1,3143,B-GENE-Y
(,3143,O
GluR5,3143,B-GENE-Y
),3143,O
/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic,3143,O
acid,3143,I-CHEMICAL
(,3143,I-GENE-N
AMPA,3143,B-CHEMICAL
),3143,I-GENE-N
receptor,3143,I-GENE-N
antagonist,3143,O
(,3143,B-CHEMICAL
"3S,4aR,6R,8aR",3143,I-CHEMICAL
),3143,I-CHEMICAL
-6-,3143,I-CHEMICAL
[,3143,I-CHEMICAL
2-,3143,I-CHEMICAL
(,3143,I-CHEMICAL
1,3143,I-CHEMICAL
(,3143,I-CHEMICAL
2,3143,I-CHEMICAL
),3143,I-CHEMICAL
H-tetrazole-5-yl,3143,I-CHEMICAL
),3143,I-CHEMICAL
ethyl,3143,I-CHEMICAL
],3143,I-CHEMICAL
decahydroisoquinoline-3-carboxylic,3143,I-CHEMICAL
acid,3143,I-CHEMICAL
(,3143,O
LY293558,3143,B-CHEMICAL
),3143,O
in,3143,O
rats,3143,O
that,3143,O
did,3143,O
not,3143,O
receive,3143,O
any,3143,O
treatment,3143,O
until,3143,O
20,3143,O
minutes,3143,O
after,3143,O
exposure,3143,O
to,3143,O
the,3143,O
nerve,3143,O
agent,3143,O
soman,3143,O
.,3143,O
We,3144,O
injected,3144,O
LY293558,3144,B-CHEMICAL
intramuscularly,3144,O
",",3144,O
as,3144,O
this,3144,O
would,3144,O
be,3144,O
the,3144,O
most,3144,O
likely,3144,O
route,3144,O
of,3144,O
administration,3144,O
to,3144,O
humans,3144,O
.,3144,O
LY293558,3145,B-CHEMICAL
(,3145,O
15,3145,O
mg/kg,3145,O
),3145,O
",",3145,O
injected,3145,O
along,3145,O
with,3145,O
atropine,3145,O
and,3145,O
the,3145,O
oxime,3145,B-CHEMICAL
HI-6,3145,B-CHEMICAL
at,3145,O
20,3145,O
minutes,3145,O
after,3145,O
soman,3145,O
exposure,3145,O
",",3145,O
stopped,3145,O
seizures,3145,O
and,3145,O
increased,3145,O
survival,3145,O
rate,3145,O
from,3145,O
64,3145,O
%,3145,O
to,3145,O
100,3145,O
%,3145,O
.,3145,O
LY293558,3146,B-CHEMICAL
also,3146,O
prevented,3146,O
neuronal,3146,O
loss,3146,O
in,3146,O
the,3146,O
amygdala,3146,O
and,3146,O
hippocampus,3146,O
",",3146,O
and,3146,O
reduced,3146,O
neurodegeneration,3146,O
in,3146,O
a,3146,O
number,3146,O
of,3146,O
brain,3146,O
regions,3146,O
studied,3146,O
7,3146,O
days,3146,O
after,3146,O
soman,3146,O
exposure,3146,O
.,3146,O
Analysis,3147,O
of,3147,O
the,3147,O
LY293558,3147,B-CHEMICAL
pharmacokinetics,3147,O
after,3147,O
intramuscular,3147,O
administration,3147,O
showed,3147,O
that,3147,O
this,3147,O
compound,3147,O
readily,3147,O
crosses,3147,O
the,3147,O
blood-brain,3147,O
barrier,3147,O
.,3147,O
There,3148,O
was,3148,O
good,3148,O
correspondence,3148,O
between,3148,O
the,3148,O
time,3148,O
course,3148,O
of,3148,O
seizure,3148,O
suppression,3148,O
by,3148,O
LY293558,3148,B-CHEMICAL
and,3148,O
the,3148,O
brain,3148,O
levels,3148,O
of,3148,O
the,3148,O
compound,3148,O
.,3148,O
Overexpression,3149,O
of,3149,O
H1,3149,B-GENE-Y
calponin,3149,I-GENE-Y
in,3149,O
osteoblast,3149,O
lineage,3149,O
cells,3149,O
leads,3149,O
to,3149,O
a,3149,O
decrease,3149,O
in,3149,O
bone,3149,O
mass,3149,O
by,3149,O
disrupting,3149,O
osteoblast,3149,O
function,3149,O
and,3149,O
promoting,3149,O
osteoclast,3149,O
formation,3149,O
.,3149,O
H1,3150,B-GENE-Y
calponin,3150,I-GENE-Y
(,3150,O
CNN1,3150,B-GENE-Y
),3150,O
is,3150,O
known,3150,O
as,3150,O
a,3150,O
smooth,3150,O
muscle-specific,3150,O
",",3150,O
actin-binding,3150,B-GENE-N
protein,3150,O
which,3150,O
regulates,3150,O
smooth,3150,O
muscle,3150,O
contractive,3150,O
activity,3150,O
.,3150,O
Although,3151,O
previous,3151,O
studies,3151,O
have,3151,O
shown,3151,O
that,3151,O
CNN1,3151,B-GENE-Y
has,3151,O
effect,3151,O
on,3151,O
bone,3151,O
",",3151,O
the,3151,O
mechanism,3151,O
is,3151,O
not,3151,O
well,3151,O
defined,3151,O
.,3151,O
To,3152,O
investigate,3152,O
the,3152,O
role,3152,O
of,3152,O
CNN1,3152,B-GENE-Y
in,3152,O
maintaining,3152,O
bone,3152,O
homeostasis,3152,O
",",3152,O
we,3152,O
generated,3152,O
transgenic,3152,O
mice,3152,O
overexpressing,3152,O
Cnn1,3152,B-GENE-Y
under,3152,O
the,3152,O
control,3152,O
of,3152,O
the,3152,O
osteoblast-specific,3152,O
3.6-kb,3152,O
Col1a1,3152,B-GENE-N
promoter,3152,I-GENE-N
.,3152,O
Col1a1-Cnn1,3153,B-GENE-Y
transgenic,3153,O
mice,3153,O
showed,3153,O
delayed,3153,O
bone,3153,O
formation,3153,O
at,3153,O
embryonic,3153,O
stage,3153,O
and,3153,O
decreased,3153,O
bone,3153,O
mass,3153,O
at,3153,O
adult,3153,O
stage,3153,O
.,3153,O
Morphology,3154,O
analyses,3154,O
showed,3154,O
reduced,3154,O
trabecular,3154,O
number,3154,O
",",3154,O
thickness,3154,O
and,3154,O
defects,3154,O
in,3154,O
bone,3154,O
formation,3154,O
.,3154,O
The,3155,O
proliferation,3155,O
and,3155,O
migration,3155,O
of,3155,O
osteoblasts,3155,O
were,3155,O
decreased,3155,O
in,3155,O
Col1a1-Cnn1,3155,B-GENE-Y
mice,3155,O
due,3155,O
to,3155,O
alterations,3155,O
in,3155,O
cytoskeleton,3155,O
.,3155,O
The,3156,O
early,3156,O
osteoblast,3156,O
differentiation,3156,O
of,3156,O
Col1a1-Cnn1,3156,B-GENE-Y
mice,3156,O
was,3156,O
increased,3156,O
",",3156,O
but,3156,O
the,3156,O
late,3156,O
stage,3156,O
differentiation,3156,O
and,3156,O
mineralization,3156,O
of,3156,O
osteoblasts,3156,O
derived,3156,O
from,3156,O
Col1a1-Cnn1,3156,B-GENE-Y
mice,3156,O
were,3156,O
significantly,3156,O
decreased,3156,O
.,3156,O
In,3157,O
addition,3157,O
to,3157,O
impaired,3157,O
bone,3157,O
formation,3157,O
",",3157,O
the,3157,O
decreased,3157,O
bone,3157,O
mass,3157,O
was,3157,O
also,3157,O
associated,3157,O
with,3157,O
enhanced,3157,O
osteoclastogenesis,3157,O
.,3157,O
Tartrate-resistant,3158,B-GENE-Y
acid,3158,I-GENE-Y
phosphatase,3158,I-GENE-Y
(,3158,O
TRAP,3158,B-GENE-Y
),3158,O
staining,3158,O
revealed,3158,O
increased,3158,O
osteoclast,3158,O
numbers,3158,O
in,3158,O
tibias,3158,O
of,3158,O
2-month-old,3158,O
Col1a1-Cnn1,3158,B-GENE-Y
mice,3158,O
",",3158,O
and,3158,O
increased,3158,O
numbers,3158,O
of,3158,O
osteoclasts,3158,O
co-cultured,3158,O
with,3158,O
Col1a1-Cnn1,3158,B-GENE-Y
osteoblasts,3158,O
.,3158,O
The,3159,O
ratio,3159,O
of,3159,O
RANKL,3159,B-GENE-Y
to,3159,O
OPG,3159,B-GENE-Y
was,3159,O
significantly,3159,O
increased,3159,O
in,3159,O
Col1a1-Cnn1,3159,B-GENE-Y
osteoblasts,3159,O
.,3159,O
These,3160,O
findings,3160,O
reveal,3160,O
a,3160,O
novel,3160,O
function,3160,O
of,3160,O
CNN1,3160,B-GENE-Y
in,3160,O
maintaining,3160,O
bone,3160,O
homeostasis,3160,O
by,3160,O
coupling,3160,O
bone,3160,O
formation,3160,O
to,3160,O
bone,3160,O
resorption,3160,O
.,3160,O
Characterisation,3161,O
of,3161,O
acetylcholinesterase,3161,B-GENE-N
release,3161,O
from,3161,O
neuronal,3161,O
cells,3161,O
.,3161,O
Although,3162,O
acetylcholinesterase,3162,B-GENE-Y
(,3162,O
AChE,3162,B-GENE-Y
),3162,O
is,3162,O
primarily,3162,O
a,3162,O
hydrolytic,3162,O
enzyme,3162,O
",",3162,O
metabolising,3162,O
the,3162,O
neurotransmitter,3162,O
acetylcholine,3162,B-CHEMICAL
in,3162,O
cholinergic,3162,O
synapses,3162,O
",",3162,O
it,3162,O
also,3162,O
has,3162,O
some,3162,O
non-catalytic,3162,O
functions,3162,O
in,3162,O
the,3162,O
brain,3162,O
which,3162,O
are,3162,O
far,3162,O
less,3162,O
well,3162,O
characterised,3162,O
.,3162,O
AChE,3163,B-GENE-Y
was,3163,O
shown,3163,O
to,3163,O
be,3163,O
secreted,3163,O
or,3163,O
shed,3163,O
from,3163,O
the,3163,O
neuronal,3163,O
cell,3163,O
surface,3163,O
like,3163,O
several,3163,O
other,3163,O
membrane,3163,O
proteins,3163,O
",",3163,O
such,3163,O
as,3163,O
the,3163,O
amyloid,3163,B-GENE-Y
precursor,3163,I-GENE-Y
protein,3163,I-GENE-Y
(,3163,O
APP,3163,B-GENE-Y
),3163,O
.,3163,O
Since,3164,O
AChE,3164,B-GENE-Y
does,3164,O
not,3164,O
possess,3164,O
a,3164,O
transmembrane,3164,B-GENE-N
domain,3164,I-GENE-N
",",3164,O
its,3164,O
anchorage,3164,O
in,3164,O
the,3164,O
membrane,3164,O
is,3164,O
established,3164,O
via,3164,O
the,3164,O
Proline,3164,B-GENE-Y
Rich,3164,I-GENE-Y
Membrane,3164,I-GENE-Y
Anchor,3164,I-GENE-Y
(,3164,O
PRiMA,3164,B-GENE-Y
),3164,O
",",3164,O
a,3164,O
transmembrane,3164,O
protein,3164,O
.,3164,O
Both,3165,O
the,3165,O
subunit,3165,O
oligomerisation,3165,O
and,3165,O
membrane,3165,O
anchor,3165,O
of,3165,O
AChE,3165,B-GENE-Y
are,3165,O
shared,3165,O
by,3165,O
a,3165,O
related,3165,O
enzyme,3165,O
",",3165,O
butyrylcholinesterase,3165,B-GENE-Y
(,3165,O
BChE,3165,B-GENE-Y
),3165,O
",",3165,O
the,3165,O
physiological,3165,O
function,3165,O
of,3165,O
which,3165,O
in,3165,O
the,3165,O
brain,3165,O
is,3165,O
unclear,3165,O
.,3165,O
In,3166,O
this,3166,O
work,3166,O
",",3166,O
we,3166,O
have,3166,O
assayed,3166,O
the,3166,O
relative,3166,O
activities,3166,O
of,3166,O
AChE,3166,B-GENE-Y
and,3166,O
BChE,3166,B-GENE-Y
in,3166,O
membrane,3166,O
fractions,3166,O
and,3166,O
culture,3166,O
medium,3166,O
of,3166,O
three,3166,O
different,3166,O
neuronal,3166,O
cell,3166,O
lines,3166,O
",",3166,O
namely,3166,O
the,3166,O
neuroblastoma,3166,O
cell,3166,O
lines,3166,O
SH-SY5Y,3166,O
and,3166,O
NB7,3166,O
and,3166,O
the,3166,O
mouse,3166,O
basal,3166,O
forebrain,3166,O
cell,3166,O
line,3166,O
SN56,3166,O
.,3166,O
In,3167,O
an,3167,O
effort,3167,O
to,3167,O
understand,3167,O
the,3167,O
shedding,3167,O
process,3167,O
of,3167,O
AChE,3167,B-GENE-Y
",",3167,O
we,3167,O
have,3167,O
used,3167,O
several,3167,O
pharmacological,3167,O
treatments,3167,O
",",3167,O
which,3167,O
showed,3167,O
that,3167,O
it,3167,O
is,3167,O
likely,3167,O
to,3167,O
be,3167,O
mediated,3167,O
in,3167,O
part,3167,O
by,3167,O
an,3167,O
EDTA-,3167,B-CHEMICAL
and,3167,O
batimastat-sensitive,3167,B-CHEMICAL
",",3167,O
but,3167,O
GM6001-insensitive,3167,B-CHEMICAL
metalloprotease,3167,B-GENE-N
",",3167,O
with,3167,O
the,3167,O
possible,3167,O
additional,3167,O
involvement,3167,O
of,3167,O
a,3167,O
thiol,3167,B-CHEMICAL
isomerase,3167,I-GENE-N
.,3167,O
Cellular,3168,O
release,3168,O
of,3168,O
AChE,3168,B-GENE-Y
by,3168,O
SH-SY5Y,3168,O
is,3168,O
significantly,3168,O
enhanced,3168,O
by,3168,O
the,3168,O
muscarinic,3168,B-GENE-N
acetylcholine,3168,B-CHEMICAL
receptor,3168,I-GENE-N
(,3168,O
mAChR,3168,B-GENE-N
),3168,O
agonists,3168,O
carbachol,3168,B-CHEMICAL
or,3168,O
muscarine,3168,B-CHEMICAL
",",3168,O
with,3168,O
the,3168,O
effect,3168,O
of,3168,O
carbachol,3168,B-CHEMICAL
blocked,3168,O
by,3168,O
the,3168,O
mAChR,3168,B-GENE-N
antagonist,3168,O
atropine,3168,B-CHEMICAL
.,3168,O
AChE,3169,B-GENE-Y
has,3169,O
been,3169,O
implicated,3169,O
in,3169,O
the,3169,O
pathogenesis,3169,O
of,3169,O
Alzheimer,3169,O
's,3169,O
disease,3169,O
and,3169,O
it,3169,O
has,3169,O
been,3169,O
shown,3169,O
that,3169,O
it,3169,O
accelerates,3169,O
formation,3169,O
and,3169,O
increases,3169,O
toxicity,3169,O
of,3169,O
amyloid,3169,B-GENE-Y
fibrils,3169,I-GENE-Y
",",3169,O
which,3169,O
have,3169,O
been,3169,O
closely,3169,O
linked,3169,O
to,3169,O
the,3169,O
pathology,3169,O
of,3169,O
AD,3169,O
.,3169,O
In,3170,O
light,3170,O
of,3170,O
this,3170,O
",",3170,O
greater,3170,O
understanding,3170,O
of,3170,O
AChE,3170,B-GENE-Y
and,3170,O
BChE,3170,B-GENE-Y
physiology,3170,O
may,3170,O
also,3170,O
benefit,3170,O
AD,3170,O
research,3170,O
.,3170,O
Circulating,3171,O
very-low-density,3171,O
lipoprotein,3171,I-GENE-N
from,3171,O
subjects,3171,O
with,3171,O
impaired,3171,O
glucose,3171,B-CHEMICAL
tolerance,3171,O
accelerates,3171,O
adrenocortical,3171,O
cortisol,3171,B-CHEMICAL
and,3171,O
aldosterone,3171,B-CHEMICAL
synthesis,3171,O
.,3171,O
Apart,3172,O
from,3172,O
their,3172,O
role,3172,O
in,3172,O
cardiovascular,3172,O
homeostasis,3172,O
and,3172,O
immunomodulation,3172,O
",",3172,O
aldosterone,3172,B-CHEMICAL
and,3172,O
cortisol,3172,B-CHEMICAL
are,3172,O
also,3172,O
implicated,3172,O
in,3172,O
the,3172,O
pathogenesis,3172,O
of,3172,O
insulin,3172,B-GENE-Y
resistance,3172,O
and,3172,O
type,3172,O
2,3172,O
diabetes,3172,O
mellitus,3172,O
(,3172,O
T2DM,3172,O
),3172,O
.,3172,O
Furthermore,3173,O
",",3173,O
glycoxidative,3173,O
modifications,3173,O
of,3173,O
lipoproteins,3173,O
are,3173,O
increasingly,3173,O
recognized,3173,O
as,3173,O
an,3173,O
etiological,3173,O
factor,3173,O
for,3173,O
increased,3173,O
cardiovascular,3173,O
morbidity,3173,O
and,3173,O
mortality,3173,O
in,3173,O
prediabetic,3173,O
individuals,3173,O
.,3173,O
The,3174,O
causative,3174,O
relationship,3174,O
between,3174,O
in,3174,O
vivo,3174,O
lipoprotein,3174,O
modifications,3174,O
and,3174,O
steroidogenesis,3174,O
in,3174,O
subjects,3174,O
with,3174,O
impaired,3174,O
glucose,3174,B-CHEMICAL
tolerance,3174,O
(,3174,O
IGT,3174,O
),3174,O
",",3174,O
however,3174,O
",",3174,O
is,3174,O
not,3174,O
well,3174,O
defined,3174,O
.,3174,O
Therefore,3175,O
",",3175,O
we,3175,O
aimed,3175,O
to,3175,O
investigate,3175,O
the,3175,O
impact,3175,O
of,3175,O
in,3175,O
vivo,3175,O
modified,3175,O
lipoproteins,3175,O
on,3175,O
aldosterone,3175,B-CHEMICAL
and,3175,O
cortisol,3175,B-CHEMICAL
release,3175,O
from,3175,O
human,3175,O
adrenocortical,3175,O
H295R,3175,O
cells,3175,O
.,3175,O
Following,3176,O
an,3176,O
oral,3176,O
glucose,3176,B-CHEMICAL
tolerance,3176,O
test,3176,O
",",3176,O
20,3176,O
individuals,3176,O
with,3176,O
normal,3176,O
glucose,3176,B-CHEMICAL
tolerance,3176,O
(,3176,O
NGT,3176,O
),3176,O
and,3176,O
20,3176,O
IGT,3176,O
subjects,3176,O
were,3176,O
randomly,3176,O
selected,3176,O
from,3176,O
the,3176,O
ongoing,3176,O
PRAEDIAS,3176,O
prevention,3176,O
study,3176,O
in,3176,O
our,3176,O
department,3176,O
.,3176,O
Cells,3177,O
were,3177,O
incubated,3177,O
for,3177,O
24,3177,O
h,3177,O
with,3177,O
lipoproteins,3177,O
isolated,3177,O
from,3177,O
NGT,3177,O
and,3177,O
IGT,3177,O
individuals,3177,O
and,3177,O
aldosterone,3177,B-CHEMICAL
and,3177,O
cortisol,3177,B-CHEMICAL
release,3177,O
was,3177,O
measured,3177,O
in,3177,O
the,3177,O
supernatants,3177,O
.,3177,O
VLDL,3178,B-GENE-N
induced,3178,O
a,3178,O
greater,3178,O
stimulating,3178,O
effect,3178,O
on,3178,O
adrenocortical,3178,O
aldosterone,3178,B-CHEMICAL
and,3178,O
cortisol,3178,B-CHEMICAL
release,3178,O
compared,3178,O
to,3178,O
HDL,3178,B-GENE-N
and,3178,O
LDL,3178,B-GENE-N
.,3178,O
Moreover,3179,O
",",3179,O
IGT-VLDL,3179,O
evoked,3179,O
a,3179,O
significantly,3179,O
higher,3179,O
effect,3179,O
(,3179,O
p,3179,O
<,3179,O
0.05,3179,O
),3179,O
on,3179,O
hormone,3179,O
release,3179,O
than,3179,O
NGT-VLDL,3179,O
.,3179,O
Incubation,3180,O
of,3180,O
cells,3180,O
with,3180,O
in,3180,O
vitro,3180,O
modified,3180,O
lipoproteins,3180,O
and,3180,O
specific,3180,O
pharmacological,3180,O
inhibitors,3180,O
suggests,3180,O
that,3180,O
VLDL,3180,B-GENE-N
presumably,3180,O
recruits,3180,O
ERK1/2,3180,B-GENE-N
as,3180,O
one,3180,O
of,3180,O
the,3180,O
downstream,3180,O
effectors,3180,O
of,3180,O
Jak-2,3180,B-GENE-Y
.,3180,O
In,3181,O
summary,3181,O
",",3181,O
in,3181,O
vivo,3181,O
modified,3181,O
VLDL,3181,B-GENE-N
are,3181,O
able,3181,O
to,3181,O
promote,3181,O
prediabetic,3181,O
hormonal,3181,O
dysregulation,3181,O
by,3181,O
modulating,3181,O
adrenocortical,3181,O
steroidogenesis,3181,O
via,3181,O
Jak-2-ERK,3181,B-GENE-Y
dependent,3181,O
pathway,3181,O
.,3181,O
L-BMAA,3182,B-CHEMICAL
induced,3182,O
ER,3182,O
stress,3182,O
and,3182,O
enhanced,3182,O
caspase,3182,B-GENE-Y
12,3182,I-GENE-Y
cleavage,3182,O
in,3182,O
human,3182,O
neuroblastoma,3182,O
SH-SY5Y,3182,O
cells,3182,O
at,3182,O
low,3182,O
nonexcitotoxic,3182,O
concentrations,3182,O
.,3182,O
The,3183,O
cyanobacterial,3183,O
-N-methylamino-L-alanine,3183,B-CHEMICAL
(,3183,O
L-BMAA,3183,B-CHEMICAL
),3183,O
is,3183,O
described,3183,O
as,3183,O
a,3183,O
low-potency,3183,O
excitotoxin,3183,O
",",3183,O
possibly,3183,O
a,3183,O
factor,3183,O
in,3183,O
the,3183,O
increased,3183,O
incidence,3183,O
of,3183,O
amyotrophic,3183,O
lateral,3183,O
sclerosis,3183,O
(,3183,O
ALS,3183,O
),3183,O
and,3183,O
Parkinsonism-dementia,3183,O
complex,3183,O
(,3183,O
PDC,3183,O
),3183,O
in,3183,O
Guam,3183,O
.,3183,O
The,3184,O
latter,3184,O
association,3184,O
is,3184,O
intensively,3184,O
disputed,3184,O
",",3184,O
as,3184,O
L-BMAA,3184,B-CHEMICAL
concentrations,3184,O
required,3184,O
for,3184,O
toxic,3184,O
effects,3184,O
exceed,3184,O
those,3184,O
assumed,3184,O
to,3184,O
occur,3184,O
via,3184,O
food,3184,O
.,3184,O
The,3185,O
question,3185,O
thus,3185,O
was,3185,O
raised,3185,O
whether,3185,O
L-BMAA,3185,B-CHEMICAL
leads,3185,O
to,3185,O
neurodegeneration,3185,O
at,3185,O
nonexcitotoxic,3185,O
conditions,3185,O
.,3185,O
Using,3186,O
human,3186,O
SH-SY5Y,3186,O
neuroblastoma,3186,O
cells,3186,O
",",3186,O
L-BMAA-transport,3186,B-CHEMICAL
",",3186,O
incorporation,3186,O
into,3186,O
proteins,3186,O
",",3186,O
and,3186,O
subsequent,3186,O
impairment,3186,O
of,3186,O
cellular,3186,O
protein,3186,O
homeostasis,3186,O
were,3186,O
investigated,3186,O
.,3186,O
Binding,3187,O
of,3187,O
L-BMAA,3187,B-CHEMICAL
to,3187,O
intracellular,3187,O
proteins,3187,O
",",3187,O
but,3187,O
no,3187,O
clear,3187,O
protein,3187,O
incorporation,3187,O
was,3187,O
detected,3187,O
in,3187,O
response,3187,O
to,3187,O
(,3187,B-CHEMICAL
14,3187,I-CHEMICAL
),3187,I-CHEMICAL
C-L-BMAA,3187,O
exposures,3187,O
.,3187,O
Nevertheless,3188,O
",",3188,O
low,3188,O
L-BMAA,3188,B-CHEMICAL
concentrations,3188,O
(,3188,O
,3188,O
0.1mM,3188,O
",",3188,O
48,3188,O
h,3188,O
),3188,O
increased,3188,O
protein,3188,O
ubiquitination,3188,O
",",3188,O
20S,3188,B-GENE-N
proteasomal,3188,I-GENE-N
and,3188,O
caspase,3188,B-GENE-Y
12,3188,I-GENE-Y
activity,3188,O
",",3188,O
expression,3188,O
of,3188,O
the,3188,O
endoplasmic,3188,O
reticulum,3188,O
(,3188,O
ER,3188,O
),3188,O
stress,3188,O
marker,3188,O
CHOP,3188,B-GENE-Y
",",3188,O
and,3188,O
enhanced,3188,O
phosphorylation,3188,O
of,3188,O
elf2,3188,B-GENE-Y
in,3188,O
SH-SY5Y,3188,O
cells,3188,O
.,3188,O
In,3189,O
contrast,3189,O
",",3189,O
high,3189,O
L-BMAA,3189,B-CHEMICAL
concentrations,3189,O
(,3189,O
,3189,O
1mM,3189,O
",",3189,O
48,3189,O
h,3189,O
),3189,O
increased,3189,O
reactive,3189,O
oxygen,3189,B-CHEMICAL
species,3189,O
and,3189,O
protein,3189,O
oxidization,3189,O
",",3189,O
which,3189,O
were,3189,O
partially,3189,O
ameliorated,3189,O
by,3189,O
coincubation,3189,O
with,3189,O
vitamin,3189,B-CHEMICAL
E.,3189,O
L-BMAA-mediated,3189,B-CHEMICAL
cytotoxicity,3189,O
was,3189,O
observable,3189,O
48,3189,O
h,3189,O
following,3189,O
,3189,O
2mM,3189,O
L-BMAA,3189,B-CHEMICAL
treatment,3189,O
.,3189,O
Consequently,3190,O
",",3190,O
the,3190,O
data,3190,O
presented,3190,O
here,3190,O
suggest,3190,O
that,3190,O
low,3190,O
L-BMAA,3190,B-CHEMICAL
concentrations,3190,O
result,3190,O
in,3190,O
a,3190,O
dysregulation,3190,O
of,3190,O
the,3190,O
cellular,3190,O
protein,3190,O
homeostasis,3190,O
with,3190,O
ensuing,3190,O
ER,3190,O
stress,3190,O
that,3190,O
is,3190,O
independent,3190,O
from,3190,O
high-concentration,3190,O
effects,3190,O
such,3190,O
as,3190,O
excitotoxicity,3190,O
and,3190,O
oxidative,3190,O
stress,3190,O
.,3190,O
Thus,3191,O
",",3191,O
the,3191,O
latter,3191,O
could,3191,O
be,3191,O
a,3191,O
contributing,3191,O
factor,3191,O
in,3191,O
the,3191,O
onset,3191,O
and,3191,O
slow,3191,O
progression,3191,O
of,3191,O
ALS/PDC,3191,O
in,3191,O
Guam,3191,O
.,3191,O
Ribavirin-induced,3192,B-CHEMICAL
intracellular,3192,O
GTP,3192,B-CHEMICAL
depletion,3192,O
activates,3192,O
transcription,3192,O
elongation,3192,O
in,3192,O
coagulation,3192,B-GENE-Y
factor,3192,I-GENE-Y
VII,3192,I-GENE-Y
gene,3192,O
expression,3192,O
.,3192,O
Coagulation,3193,B-GENE-Y
FVII,3193,I-GENE-Y
(,3193,O
Factor,3193,B-GENE-Y
VII,3193,I-GENE-Y
),3193,O
is,3193,O
a,3193,O
vitamin,3193,B-CHEMICAL
K-dependent,3193,O
glycoprotein,3193,O
synthesized,3193,O
in,3193,O
hepatocytes,3193,O
.,3193,O
It,3194,O
was,3194,O
reported,3194,O
previously,3194,O
that,3194,O
FVII,3194,B-GENE-Y
gene,3194,O
(,3194,O
F7,3194,B-GENE-Y
),3194,O
expression,3194,O
was,3194,O
up-regulated,3194,O
by,3194,O
ribavirin,3194,B-CHEMICAL
treatment,3194,O
in,3194,O
hepatitis,3194,O
C,3194,O
virus-infected,3194,O
haemophilia,3194,O
patients,3194,O
;,3194,O
however,3194,O
",",3194,O
its,3194,O
precise,3194,O
mechanism,3194,O
is,3194,O
still,3194,O
unknown,3194,O
.,3194,O
In,3195,O
the,3195,O
present,3195,O
study,3195,O
",",3195,O
we,3195,O
investigated,3195,O
the,3195,O
molecular,3195,O
mechanism,3195,O
of,3195,O
ribavirin-induced,3195,B-CHEMICAL
up-regulation,3195,O
of,3195,O
F7,3195,B-GENE-Y
expression,3195,O
in,3195,O
HepG2,3195,O
(,3195,O
human,3195,O
hepatoma,3195,O
cell,3195,O
line,3195,O
),3195,O
.,3195,O
We,3196,O
found,3196,O
that,3196,O
intracellular,3196,O
GTP,3196,B-CHEMICAL
depletion,3196,O
by,3196,O
ribavirin,3196,B-CHEMICAL
as,3196,O
well,3196,O
as,3196,O
other,3196,O
IMPDH,3196,B-GENE-N
(,3196,O
inosine-5'-monophosphate,3196,B-GENE-N
dehydrogenase,3196,I-GENE-N
),3196,O
inhibitors,3196,O
",",3196,O
such,3196,O
as,3196,O
mycophenolic,3196,B-CHEMICAL
acid,3196,I-CHEMICAL
and,3196,O
6-mercaptopurine,3196,B-CHEMICAL
",",3196,O
up-regulated,3196,O
F7,3196,B-GENE-Y
expression,3196,O
.,3196,O
FVII,3197,B-GENE-Y
mRNA,3197,O
transcription,3197,O
was,3197,O
mainly,3197,O
enhanced,3197,O
by,3197,O
accelerated,3197,O
transcription,3197,O
elongation,3197,O
",",3197,O
which,3197,O
was,3197,O
mediated,3197,O
by,3197,O
the,3197,O
P-TEFb,3197,B-GENE-N
(,3197,O
positive-transcription,3197,B-GENE-N
elongation,3197,I-GENE-N
factor,3197,I-GENE-N
b,3197,I-GENE-N
),3197,O
complex,3197,O
",",3197,O
rather,3197,O
than,3197,O
by,3197,O
promoter,3197,O
activation,3197,O
.,3197,O
Ribavirin,3198,B-CHEMICAL
unregulated,3198,O
ELL,3198,B-GENE-Y
(,3198,O
eleven-nineteen,3198,B-GENE-Y
lysine-rich,3198,I-GENE-Y
leukaemia,3198,I-GENE-Y
),3198,I-GENE-Y
3,3198,I-GENE-Y
mRNA,3198,O
expression,3198,O
before,3198,O
F7,3198,B-GENE-Y
up-regulation,3198,O
.,3198,O
We,3199,O
observed,3199,O
that,3199,O
ribavirin,3199,B-CHEMICAL
enhanced,3199,O
ELL3,3199,B-GENE-Y
recruitment,3199,O
to,3199,O
F7,3199,B-GENE-Y
",",3199,O
whereas,3199,O
knockdown,3199,O
of,3199,O
ELL3,3199,B-GENE-Y
diminished,3199,O
ribavirin-induced,3199,B-CHEMICAL
FVII,3199,B-GENE-Y
mRNA,3199,O
up-regulation,3199,O
.,3199,O
Ribavirin,3200,B-CHEMICAL
also,3200,O
enhanced,3200,O
recruitment,3200,O
of,3200,O
CDK9,3200,B-GENE-Y
(,3200,O
cyclin-dependent,3200,B-GENE-Y
kinase,3200,I-GENE-Y
9,3200,I-GENE-Y
),3200,O
and,3200,O
AFF4,3200,B-GENE-Y
to,3200,O
F7,3200,B-GENE-Y
.,3200,O
These,3201,O
data,3201,O
suggest,3201,O
that,3201,O
ribavirin-induced,3201,B-CHEMICAL
intracellular,3201,O
GTP,3201,B-CHEMICAL
depletion,3201,O
recruits,3201,O
a,3201,O
super,3201,O
elongation,3201,O
complex,3201,O
containing,3201,O
P-TEFb,3201,B-GENE-N
",",3201,O
AFF4,3201,B-GENE-Y
and,3201,O
ELL3,3201,B-GENE-Y
",",3201,O
to,3201,O
F7,3201,B-GENE-Y
",",3201,O
and,3201,O
modulates,3201,O
FVII,3201,B-GENE-Y
mRNA,3201,O
transcription,3201,O
elongation,3201,O
.,3201,O
Collectively,3202,O
",",3202,O
we,3202,O
have,3202,O
elucidated,3202,O
a,3202,O
basal,3202,O
mechanism,3202,O
for,3202,O
ribavirin-induced,3202,B-CHEMICAL
FVII,3202,B-GENE-Y
mRNA,3202,O
up-regulation,3202,O
by,3202,O
acceleration,3202,O
of,3202,O
transcription,3202,O
elongation,3202,O
",",3202,O
which,3202,O
may,3202,O
be,3202,O
crucial,3202,O
in,3202,O
understanding,3202,O
its,3202,O
pleiotropic,3202,O
functions,3202,O
in,3202,O
vivo,3202,O
.,3202,O
Neuropeptide,3203,B-GENE-Y
Y,3203,I-GENE-Y
Y1,3203,I-GENE-Y
receptor,3203,I-GENE-Y
knockdown,3203,O
can,3203,O
modify,3203,O
glutathione,3203,B-GENE-N
peroxidase,3203,I-GENE-N
and,3203,O
c-AMP,3203,B-GENE-N
response,3203,I-GENE-N
element-binding,3203,I-GENE-N
protein,3203,I-GENE-N
in,3203,O
phenylpropanolamine-treated,3203,B-CHEMICAL
rats,3203,O
.,3203,O
It,3204,O
has,3204,O
been,3204,O
reported,3204,O
that,3204,O
antioxidative,3204,O
enzymes,3204,O
",",3204,O
neuropeptide,3204,B-GENE-Y
Y,3204,I-GENE-Y
(,3204,O
NPY,3204,B-GENE-Y
),3204,O
",",3204,O
and,3204,O
c-AMP,3204,B-CHEMICAL
response,3204,I-GENE-N
element-binding,3204,I-GENE-N
protein,3204,I-GENE-N
(,3204,O
CREB,3204,B-GENE-N
),3204,O
are,3204,O
involved,3204,O
in,3204,O
regulating,3204,O
phenylpropanolamine,3204,B-CHEMICAL
(,3204,O
PPA,3204,B-CHEMICAL
),3204,O
-mediated,3204,O
appetite,3204,O
suppression,3204,O
.,3204,O
Here,3205,O
",",3205,O
we,3205,O
investigated,3205,O
whether,3205,O
Y1,3205,B-GENE-Y
receptor,3205,I-GENE-Y
(,3205,O
Y1R,3205,B-GENE-Y
),3205,O
might,3205,O
be,3205,O
involved,3205,O
in,3205,O
this,3205,O
regulation,3205,O
.,3205,O
Rats,3206,O
were,3206,O
daily,3206,O
treated,3206,O
with,3206,O
PPA,3206,B-CHEMICAL
for,3206,O
4,3206,O
days,3206,O
.,3206,O
Changes,3207,O
in,3207,O
the,3207,O
contents,3207,O
of,3207,O
NPY,3207,B-GENE-Y
",",3207,O
Y1R,3207,B-GENE-Y
",",3207,O
glutathione,3207,B-CHEMICAL
peroxidase,3207,I-GENE-N
(,3207,O
GP,3207,B-GENE-N
),3207,O
",",3207,O
and,3207,O
CREB,3207,B-GENE-N
were,3207,O
assessed,3207,O
and,3207,O
compared,3207,O
.,3207,O
Results,3208,O
showed,3208,O
that,3208,O
Y1R,3208,B-GENE-Y
",",3208,O
GP,3208,B-GENE-N
",",3208,O
and,3208,O
CREB,3208,B-GENE-N
increased,3208,O
",",3208,O
with,3208,O
a,3208,O
maximal,3208,O
increase,3208,O
about,3208,O
100,3208,O
",",3208,O
200,3208,O
",",3208,O
and,3208,O
150,3208,O
%,3208,O
",",3208,O
respectively,3208,O
",",3208,O
on,3208,O
Day,3208,O
2,3208,O
.,3208,O
By,3209,O
contrast,3209,O
",",3209,O
NPY,3209,B-GENE-Y
decreased,3209,O
with,3209,O
a,3209,O
biggest,3209,O
reduction,3209,O
about,3209,O
48,3209,O
%,3209,O
on,3209,O
Day,3209,O
2,3209,O
and,3209,O
the,3209,O
pattern,3209,O
of,3209,O
expression,3209,O
during,3209,O
PPA,3209,B-CHEMICAL
treatment,3209,O
was,3209,O
opposite,3209,O
to,3209,O
those,3209,O
of,3209,O
Y1R,3209,B-GENE-Y
",",3209,O
GP,3209,B-GENE-N
",",3209,O
and,3209,O
CREB,3209,B-GENE-N
.,3209,O
Central,3210,O
knockdown,3210,O
(,3210,O
using,3210,O
antisense,3210,O
),3210,O
or,3210,O
inhibition,3210,O
(,3210,O
using,3210,O
antagonist,3210,O
),3210,O
of,3210,O
Y1R,3210,B-GENE-Y
expression,3210,O
modulated,3210,O
the,3210,O
anorectic,3210,O
response,3210,O
of,3210,O
PPA,3210,B-CHEMICAL
and,3210,O
the,3210,O
reciprocal,3210,O
regulation,3210,O
between,3210,O
NPY,3210,B-GENE-Y
and,3210,O
GP,3210,B-GENE-N
(,3210,O
or,3210,O
CREB,3210,B-GENE-N
),3210,O
",",3210,O
revealing,3210,O
an,3210,O
essential,3210,O
role,3210,O
of,3210,O
Y1R,3210,B-GENE-Y
in,3210,O
regulating,3210,O
NPY,3210,B-GENE-Y
",",3210,O
GP,3210,B-GENE-N
",",3210,O
and,3210,O
CREB,3210,B-GENE-N
.,3210,O
These,3211,O
results,3211,O
suggest,3211,O
that,3211,O
Y1R,3211,B-GENE-Y
participates,3211,O
in,3211,O
the,3211,O
reciprocal,3211,O
regulation,3211,O
of,3211,O
NPY,3211,B-GENE-Y
",",3211,O
GP,3211,B-GENE-N
",",3211,O
and,3211,O
CREB,3211,B-GENE-N
in,3211,O
the,3211,O
hypothalamus,3211,O
during,3211,O
PPA,3211,B-CHEMICAL
treatment,3211,O
in,3211,O
conscious,3211,O
rats,3211,O
.,3211,O
The,3212,O
present,3212,O
results,3212,O
may,3212,O
aid,3212,O
the,3212,O
therapeutic,3212,O
research,3212,O
of,3212,O
PPA,3212,B-CHEMICAL
and,3212,O
related,3212,O
antiobesity,3212,O
drugs,3212,O
.,3212,O
Activation,3213,O
of,3213,O
group,3213,B-GENE-N
I,3213,I-GENE-N
metabotropic,3213,I-GENE-N
glutamate,3213,I-GENE-N
receptors,3213,I-GENE-N
potentiates,3213,O
heteromeric,3213,O
kainate,3213,B-GENE-N
receptors,3213,I-GENE-N
.,3213,O
Kainate,3214,B-GENE-N
receptors,3214,I-GENE-N
(,3214,O
KARs,3214,B-GENE-N
),3214,O
",",3214,O
a,3214,O
family,3214,O
of,3214,O
ionotropic,3214,B-GENE-N
glutamate,3214,I-GENE-N
receptors,3214,I-GENE-N
",",3214,O
are,3214,O
widely,3214,O
expressed,3214,O
in,3214,O
the,3214,O
central,3214,O
nervous,3214,O
system,3214,O
and,3214,O
are,3214,O
critically,3214,O
involved,3214,O
in,3214,O
synaptic,3214,O
transmission,3214,O
.,3214,O
KAR,3215,B-GENE-N
activation,3215,O
is,3215,O
influenced,3215,O
by,3215,O
metabotropic,3215,B-GENE-N
glutamate,3215,I-GENE-N
receptor,3215,I-GENE-N
(,3215,O
mGlu,3215,B-GENE-N
),3215,O
signaling,3215,O
",",3215,O
but,3215,O
the,3215,O
underlying,3215,O
mechanisms,3215,O
are,3215,O
not,3215,O
understood,3215,O
.,3215,O
We,3216,O
undertook,3216,O
studies,3216,O
to,3216,O
examine,3216,O
how,3216,O
mGlu,3216,B-GENE-N
modulation,3216,O
affects,3216,O
activation,3216,O
of,3216,O
KARs,3216,B-GENE-N
.,3216,O
Confocal,3217,O
immunohistochemistry,3217,O
of,3217,O
rat,3217,O
hippocampus,3217,O
and,3217,O
cultured,3217,O
rat,3217,O
cortex,3217,O
revealed,3217,O
colocalization,3217,O
of,3217,O
the,3217,O
high-affinity,3217,O
KAR,3217,B-GENE-N
subunits,3217,O
with,3217,O
group,3217,B-GENE-N
I,3217,I-GENE-N
mGlu,3217,I-GENE-N
receptors,3217,I-GENE-N
.,3217,O
In,3218,O
hippocampal,3218,O
and,3218,O
cortical,3218,O
cultures,3218,O
",",3218,O
the,3218,O
calcium,3218,B-CHEMICAL
signal,3218,O
caused,3218,O
by,3218,O
activation,3218,O
of,3218,O
native,3218,O
KARs,3218,B-GENE-N
was,3218,O
potentiated,3218,O
by,3218,O
activation,3218,O
of,3218,O
group,3218,B-GENE-N
I,3218,I-GENE-N
mGlu,3218,I-GENE-N
receptors,3218,I-GENE-N
.,3218,O
In,3219,O
Xenopus,3219,O
laevis,3219,O
oocytes,3219,O
",",3219,O
activation,3219,O
of,3219,O
group,3219,B-GENE-N
I,3219,I-GENE-N
mGlu,3219,I-GENE-N
receptors,3219,I-GENE-N
potentiated,3219,O
heteromeric,3219,O
but,3219,O
not,3219,O
homomeric,3219,O
KAR-mediated,3219,B-GENE-N
currents,3219,O
",",3219,O
with,3219,O
no,3219,O
change,3219,O
in,3219,O
agonist,3219,O
potency,3219,O
.,3219,O
The,3220,O
potentiation,3220,O
of,3220,O
heteromeric,3220,O
KARs,3220,B-GENE-N
by,3220,O
mGlu1,3220,B-GENE-Y
activation,3220,O
was,3220,O
attenuated,3220,O
by,3220,O
GDPS,3220,O
",",3220,O
blocked,3220,O
by,3220,O
an,3220,O
inhibitor,3220,O
of,3220,O
phospholipase,3220,B-GENE-N
C,3220,I-GENE-N
or,3220,O
the,3220,O
calcium,3220,B-CHEMICAL
chelator,3220,O
"1,2-bis",3220,B-CHEMICAL
(,3220,I-CHEMICAL
o-aminophenoxy,3220,I-CHEMICAL
),3220,I-CHEMICAL
ethane-N,3220,I-CHEMICAL
",",3220,I-CHEMICAL
N,3220,I-CHEMICAL
",",3220,I-CHEMICAL
N,3220,I-CHEMICAL
',3220,I-CHEMICAL
",",3220,I-CHEMICAL
N'-tetraacetic,3220,I-CHEMICAL
acid,3220,I-CHEMICAL
(,3220,O
BAPTA,3220,B-CHEMICAL
),3220,O
",",3220,O
prolonged,3220,O
by,3220,O
the,3220,O
phosphatase,3220,B-GENE-N
inhibitor,3220,O
okadaic,3220,B-CHEMICAL
acid,3220,I-CHEMICAL
",",3220,O
but,3220,O
unaffected,3220,O
by,3220,O
the,3220,O
tyrosine,3220,B-CHEMICAL
kinase,3220,I-GENE-N
inhibitor,3220,O
lavendustin,3220,B-CHEMICAL
A,3220,I-CHEMICAL
.,3220,O
Protein,3221,B-GENE-N
kinase,3221,I-GENE-N
C,3221,I-GENE-N
(,3221,O
PKC,3221,B-GENE-N
),3221,O
inhibition,3221,O
reduced,3221,O
the,3221,O
potentiation,3221,O
by,3221,O
mGlu1,3221,B-GENE-Y
of,3221,O
GluK2/GluK5,3221,B-GENE-Y
",",3221,O
and,3221,O
conversely,3221,O
",",3221,O
direct,3221,O
activation,3221,O
of,3221,O
PKC,3221,B-GENE-N
by,3221,O
phorbol,3221,B-CHEMICAL
"12-myristate,13-acetate",3221,I-CHEMICAL
potentiated,3221,O
GluK2/GluK5,3221,B-GENE-Y
.,3221,O
Using,3222,O
site-directed,3222,O
mutagenesis,3222,O
",",3222,O
we,3222,O
identified,3222,O
three,3222,O
serines,3222,B-CHEMICAL
(,3222,O
Ser833,3222,B-CHEMICAL
",",3222,O
Ser836,3222,B-CHEMICAL
",",3222,O
and,3222,O
Ser840,3222,B-CHEMICAL
),3222,O
within,3222,O
the,3222,O
membrane,3222,O
proximal,3222,O
region,3222,O
of,3222,O
the,3222,O
GluK5,3222,B-GENE-Y
C-terminal,3222,B-CHEMICAL
domain,3222,O
that,3222,O
",",3222,O
in,3222,O
combination,3222,O
",",3222,O
are,3222,O
required,3222,O
for,3222,O
mGlu1-mediated,3222,B-GENE-Y
potentiation,3222,O
of,3222,O
KARs,3222,B-GENE-N
.,3222,O
Together,3223,O
",",3223,O
these,3223,O
data,3223,O
suggest,3223,O
that,3223,O
phosphorylation,3223,O
of,3223,O
key,3223,O
residues,3223,O
in,3223,O
the,3223,O
C-terminal,3223,B-CHEMICAL
domain,3223,O
changes,3223,O
the,3223,O
overall,3223,O
charge,3223,O
of,3223,O
this,3223,O
domain,3223,O
",",3223,O
resulting,3223,O
in,3223,O
potentiated,3223,O
agonist,3223,O
responses,3223,O
.,3223,O
Fingolimod,3224,B-CHEMICAL
protects,3224,O
cultured,3224,O
cortical,3224,O
neurons,3224,O
against,3224,O
excitotoxic,3224,O
death,3224,O
.,3224,O
Fingolimod,3225,B-CHEMICAL
(,3225,O
FTY720,3225,B-CHEMICAL
),3225,O
",",3225,O
a,3225,O
novel,3225,O
drug,3225,O
approved,3225,O
for,3225,O
the,3225,O
treatment,3225,O
of,3225,O
relapsing-remitting,3225,O
multiple,3225,O
sclerosis,3225,O
",",3225,O
activates,3225,O
different,3225,O
sphingosine-1-phosphate,3225,B-CHEMICAL
receptor,3225,I-GENE-N
(,3225,O
S1PR,3225,B-GENE-N
),3225,O
subtypes,3225,O
.,3225,O
Its,3226,O
primary,3226,O
mechanism,3226,O
of,3226,O
action,3226,O
is,3226,O
to,3226,O
reduce,3226,O
the,3226,O
egress,3226,O
of,3226,O
T,3226,O
lymphocytes,3226,O
from,3226,O
secondary,3226,O
lymphoid,3226,O
organs,3226,O
",",3226,O
thus,3226,O
restraining,3226,O
neuroinflammation,3226,O
and,3226,O
autoimmunity,3226,O
.,3226,O
However,3227,O
",",3227,O
recent,3227,O
evidence,3227,O
suggests,3227,O
that,3227,O
the,3227,O
action,3227,O
of,3227,O
FTY720,3227,B-CHEMICAL
involves,3227,O
S1PRs,3227,B-GENE-N
expressed,3227,O
by,3227,O
cells,3227,O
resident,3227,O
in,3227,O
the,3227,O
CNS,3227,O
",",3227,O
including,3227,O
neurons,3227,O
.,3227,O
Here,3228,O
",",3228,O
we,3228,O
examined,3228,O
the,3228,O
effect,3228,O
of,3228,O
FTY720,3228,B-CHEMICAL
",",3228,O
its,3228,O
active,3228,O
metabolite,3228,O
",",3228,O
FTY720-P,3228,B-CHEMICAL
",",3228,O
and,3228,O
sphingosine-1-phosphate,3228,B-CHEMICAL
(,3228,O
S1P,3228,B-CHEMICAL
),3228,O
on,3228,O
neuronal,3228,O
viability,3228,O
using,3228,O
a,3228,O
classical,3228,O
in,3228,O
vitro,3228,O
model,3228,O
of,3228,O
excitotoxic,3228,O
neuronal,3228,O
death,3228,O
.,3228,O
Mixed,3229,O
cultures,3229,O
of,3229,O
mouse,3229,O
cortical,3229,O
cells,3229,O
were,3229,O
challenged,3229,O
with,3229,O
toxic,3229,O
concentrations,3229,O
of,3229,O
N-methyl-d-aspartate,3229,B-CHEMICAL
(,3229,O
NMDA,3229,B-CHEMICAL
),3229,O
for,3229,O
10,3229,O
min,3229,O
",",3229,O
and,3229,O
neuronal,3229,O
death,3229,O
was,3229,O
assessed,3229,O
20,3229,O
h,3229,O
later,3229,O
.,3229,O
FTY720,3230,B-CHEMICAL
",",3230,O
FTY720-P,3230,B-CHEMICAL
",",3230,O
and,3230,O
S1P,3230,B-CHEMICAL
were,3230,O
all,3230,O
neuroprotective,3230,O
when,3230,O
applied,3230,O
18-20,3230,O
h,3230,O
prior,3230,O
to,3230,O
the,3230,O
NMDA,3230,B-CHEMICAL
pulse,3230,O
.,3230,O
Neuroprotection,3231,O
was,3231,O
attenuated,3231,O
by,3231,O
pertussis,3231,B-GENE-N
toxin,3231,I-GENE-N
",",3231,O
and,3231,O
inhibited,3231,O
by,3231,O
the,3231,O
selective,3231,O
type-1,3231,B-GENE-Y
S1PR,3231,I-GENE-Y
(,3231,O
S1P1R,3231,B-GENE-Y
),3231,O
antagonist,3231,O
",",3231,O
W146,3231,B-CHEMICAL
",",3231,O
and,3231,O
by,3231,O
inhibitors,3231,O
of,3231,O
the,3231,O
mitogen,3231,B-GENE-N
associated,3231,I-GENE-N
protein,3231,I-GENE-N
kinase,3231,I-GENE-N
(,3231,O
MAPK,3231,B-GENE-N
),3231,O
and,3231,O
the,3231,O
phosphatidylinositol-3-kinase,3231,B-CHEMICAL
(,3231,O
PtdIns-3-K,3231,B-GENE-N
),3231,O
pathways,3231,O
.,3231,O
Both,3232,O
FTY720,3232,B-CHEMICAL
and,3232,O
FTY720-P,3232,B-CHEMICAL
retained,3232,O
their,3232,O
protective,3232,O
activity,3232,O
in,3232,O
pure,3232,O
cultures,3232,O
of,3232,O
mouse,3232,O
or,3232,O
rat,3232,O
cortical,3232,O
neurons,3232,O
.,3232,O
These,3233,O
data,3233,O
offer,3233,O
the,3233,O
first,3233,O
direct,3233,O
demonstration,3233,O
that,3233,O
FTY720,3233,B-CHEMICAL
and,3233,O
its,3233,O
active,3233,O
metabolite,3233,O
protect,3233,O
neurons,3233,O
against,3233,O
excitotoxic,3233,O
death,3233,O
.,3233,O
Pharmacokinetics,3234,O
and,3234,O
metabolism,3234,O
of,3234,O
[,3234,B-CHEMICAL
(,3234,I-CHEMICAL
14,3234,I-CHEMICAL
),3234,I-CHEMICAL
C,3234,I-CHEMICAL
],3234,I-CHEMICAL
anagliptin,3234,I-CHEMICAL
",",3234,O
a,3234,O
novel,3234,O
dipeptidyl,3234,B-GENE-Y
peptidase-4,3234,I-GENE-Y
inhibitor,3234,O
",",3234,O
in,3234,O
humans,3234,O
.,3234,O
1,3235,O
.,3235,O
The,3236,O
disposition,3236,O
of,3236,O
anagliptin,3236,B-CHEMICAL
",",3236,O
an,3236,O
orally,3236,O
active,3236,O
",",3236,O
highly,3236,O
selective,3236,O
dipeptidyl,3236,B-GENE-Y
peptidase-4,3236,I-GENE-Y
inhibitor,3236,O
",",3236,O
was,3236,O
investigated,3236,O
after,3236,O
a,3236,O
single,3236,O
oral,3236,O
dose,3236,O
of,3236,O
100,3236,O
mg/1.92,3236,O
MBq,3236,O
[,3236,B-CHEMICAL
(,3236,I-CHEMICAL
14,3236,I-CHEMICAL
),3236,I-CHEMICAL
C,3236,I-CHEMICAL
],3236,I-CHEMICAL
anagliptin,3236,I-CHEMICAL
to,3236,O
six,3236,O
healthy,3236,O
men,3236,O
.,3236,O
Almost,3237,O
all,3237,O
the,3237,O
dose,3237,O
(,3237,O
98.2,3237,O
%,3237,O
),3237,O
was,3237,O
recovered,3237,O
within,3237,O
168,3237,O
h,3237,O
:,3237,O
73.2,3237,O
%,3237,O
in,3237,O
urine,3237,O
and,3237,O
25.0,3237,O
%,3237,O
in,3237,O
faeces,3237,O
.,3237,O
2,3238,O
.,3238,O
Anagliptin,3239,B-CHEMICAL
was,3239,O
rapidly,3239,O
absorbed,3239,O
",",3239,O
with,3239,O
peak,3239,O
plasma,3239,O
concentrations,3239,O
of,3239,O
unchanged,3239,O
drug,3239,O
attained,3239,O
at,3239,O
a,3239,O
mean,3239,O
time,3239,O
of,3239,O
1.8-h,3239,O
postdose,3239,O
.,3239,O
Mean,3240,O
fraction,3240,O
of,3240,O
the,3240,O
dose,3240,O
absorbed,3240,O
was,3240,O
>,3240,O
73,3240,O
%,3240,O
.,3240,O
Unchanged,3241,O
drug,3241,O
and,3241,O
a,3241,O
carboxylate,3241,B-CHEMICAL
metabolite,3241,O
(,3241,O
M1,3241,O
),3241,O
were,3241,O
the,3241,O
major,3241,O
components,3241,O
in,3241,O
plasma,3241,O
",",3241,O
accounting,3241,O
for,3241,O
66.0,3241,O
and,3241,O
23.4,3241,O
%,3241,O
of,3241,O
total,3241,O
plasma,3241,O
radioactivity,3241,O
area,3241,O
under,3241,O
the,3241,O
curve,3241,O
",",3241,O
respectively,3241,O
.,3241,O
3,3242,O
.,3242,O
Anagliptin,3243,B-CHEMICAL
was,3243,O
incompletely,3243,O
metabolized,3243,O
",",3243,O
with,3243,O
about,3243,O
50,3243,O
%,3243,O
dose,3243,O
eliminated,3243,O
as,3243,O
unchanged,3243,O
drug,3243,O
(,3243,O
46.6,3243,O
%,3243,O
in,3243,O
urine,3243,O
and,3243,O
4.1,3243,O
%,3243,O
in,3243,O
faeces,3243,O
),3243,O
.,3243,O
Metabolism,3244,O
to,3244,O
M1,3244,O
accounted,3244,O
for,3244,O
29.2,3244,O
%,3244,O
of,3244,O
the,3244,O
dose,3244,O
.,3244,O
No,3245,O
other,3245,O
metabolite,3245,O
accounted,3245,O
for,3245,O
>,3245,O
1,3245,O
%,3245,O
dose,3245,O
in,3245,O
excreta,3245,O
or,3245,O
yielded,3245,O
measurable,3245,O
systemic,3245,O
exposure,3245,O
.,3245,O
Terminal,3246,O
half-life,3246,O
of,3246,O
anagliptin,3246,B-CHEMICAL
and,3246,O
M1,3246,O
was,3246,O
4.37,3246,O
and,3246,O
9.88,3246,O
h,3246,O
",",3246,O
respectively,3246,O
.,3246,O
Renal,3247,O
clearance,3247,O
of,3247,O
unbound,3247,O
anagliptin,3247,B-CHEMICAL
and,3247,O
unbound,3247,O
M1,3247,O
far,3247,O
exceeded,3247,O
glomerular,3247,O
filtration,3247,O
rate,3247,O
",",3247,O
indicating,3247,O
active,3247,O
renal,3247,O
elimination,3247,O
:,3247,O
that,3247,O
might,3247,O
reflect,3247,O
the,3247,O
fact,3247,O
that,3247,O
anagliptin,3247,B-CHEMICAL
may,3247,O
be,3247,O
a,3247,O
substrate,3247,O
of,3247,O
OAT1,3247,B-GENE-Y
",",3247,O
OAT3,3247,B-GENE-Y
",",3247,O
MDR1,3247,B-GENE-Y
and,3247,O
MRP2,3247,B-GENE-Y
",",3247,O
and,3247,O
M1,3247,O
a,3247,O
substrate,3247,O
of,3247,O
OAT3,3247,B-GENE-Y
",",3247,O
BCRP,3247,B-GENE-Y
",",3247,O
MRP2,3247,B-GENE-Y
and,3247,O
MRP4,3247,B-GENE-Y
.,3247,O
Chemical,3248,O
cholecystokinin,3248,B-GENE-N
receptor,3248,I-GENE-N
activation,3248,O
protects,3248,O
against,3248,O
obesity-diabetes,3248,O
in,3248,O
high,3248,O
fat,3248,O
fed,3248,O
mice,3248,O
and,3248,O
has,3248,O
sustainable,3248,O
beneficial,3248,O
effects,3248,O
in,3248,O
genetic,3248,O
ob/ob,3248,O
mice,3248,O
.,3248,O
The,3249,O
current,3249,O
study,3249,O
has,3249,O
determined,3249,O
the,3249,O
ability,3249,O
of,3249,O
(,3249,B-GENE-Y
pGlu-Gln,3249,I-GENE-Y
),3249,I-GENE-Y
-CCK-8,3249,I-GENE-Y
to,3249,O
counter,3249,O
the,3249,O
development,3249,O
of,3249,O
diet-induced,3249,O
obesity-diabetes,3249,O
and,3249,O
examined,3249,O
persistence,3249,O
of,3249,O
beneficial,3249,O
metabolic,3249,O
effects,3249,O
in,3249,O
high,3249,O
fat,3249,O
and,3249,O
ob/ob,3249,O
mice,3249,O
",",3249,O
respectively,3249,O
.,3249,O
Twice,3250,O
daily,3250,O
injection,3250,O
of,3250,O
(,3250,B-GENE-Y
pGlu-Gln,3250,I-GENE-Y
),3250,I-GENE-Y
-CCK-8,3250,I-GENE-Y
in,3250,O
normal,3250,O
mice,3250,O
transferred,3250,O
to,3250,O
a,3250,O
high,3250,O
fat,3250,O
diet,3250,O
reduced,3250,O
energy,3250,O
intake,3250,O
(,3250,O
p,3250,O
<,3250,O
0.001,3250,O
),3250,O
",",3250,O
body,3250,O
weight,3250,O
(,3250,O
p,3250,O
<,3250,O
0.01,3250,O
),3250,O
",",3250,O
circulating,3250,O
insulin,3250,B-GENE-N
and,3250,O
LDL-cholesterol,3250,B-GENE-N
(,3250,O
p,3250,O
<,3250,O
0.001,3250,O
),3250,O
and,3250,O
improved,3250,O
insulin,3250,B-GENE-N
sensitivity,3250,O
(,3250,O
p,3250,O
<,3250,O
0.001,3250,O
),3250,O
as,3250,O
well,3250,O
as,3250,O
oral,3250,O
and,3250,O
intraperitoneal,3250,O
(,3250,O
p,3250,O
<,3250,O
0.001,3250,O
),3250,O
glucose,3250,B-CHEMICAL
tolerance,3250,O
.,3250,O
Energy,3251,O
intake,3251,O
",",3251,O
body,3251,O
weight,3251,O
",",3251,O
circulating,3251,O
insulin,3251,B-GENE-N
and,3251,O
glucose,3251,B-CHEMICAL
tolerance,3251,O
of,3251,O
(,3251,B-GENE-Y
pGlu-Gln,3251,I-GENE-Y
),3251,I-GENE-Y
-CCK-8,3251,I-GENE-Y
mice,3251,O
were,3251,O
similar,3251,O
to,3251,O
lean,3251,O
controls,3251,O
.,3251,O
In,3252,O
addition,3252,O
",",3252,O
(,3252,B-GENE-Y
pGlu-Gln,3252,I-GENE-Y
),3252,I-GENE-Y
-CCK-8,3252,I-GENE-Y
prevented,3252,O
the,3252,O
effect,3252,O
of,3252,O
high,3252,O
fat,3252,O
feeding,3252,O
on,3252,O
triacylglycerol,3252,B-CHEMICAL
accumulation,3252,O
in,3252,O
liver,3252,O
and,3252,O
muscle,3252,O
.,3252,O
Interestingly,3253,O
",",3253,O
(,3253,B-GENE-Y
pGlu-Gln,3253,I-GENE-Y
),3253,I-GENE-Y
-CCK-8,3253,I-GENE-Y
significantly,3253,O
(,3253,O
p,3253,O
<,3253,O
0.001,3253,O
),3253,O
elevated,3253,O
pancreatic,3253,O
glucagon,3253,B-GENE-Y
content,3253,O
.,3253,O
Histological,3254,O
examination,3254,O
of,3254,O
the,3254,O
pancreata,3254,O
of,3254,O
(,3254,B-GENE-Y
pGlu-Gln,3254,I-GENE-Y
),3254,I-GENE-Y
-CCK-8,3254,I-GENE-Y
mice,3254,O
revealed,3254,O
no,3254,O
changes,3254,O
in,3254,O
islet,3254,O
number,3254,O
or,3254,O
size,3254,O
",",3254,O
but,3254,O
there,3254,O
was,3254,O
increased,3254,O
turnover,3254,O
of,3254,O
beta-cells,3254,O
with,3254,O
significantly,3254,O
(,3254,O
p,3254,O
<,3254,O
0.001,3254,O
),3254,O
increased,3254,O
numbers,3254,O
of,3254,O
peripherally,3254,O
located,3254,O
alpha-cells,3254,O
",",3254,O
co-expressing,3254,O
both,3254,O
glucagon,3254,B-GENE-Y
and,3254,O
GLP-1,3254,B-GENE-Y
.,3254,O
Beneficial,3255,O
metabolic,3255,O
effects,3255,O
were,3255,O
observed,3255,O
similarly,3255,O
in,3255,O
ob/ob,3255,O
mice,3255,O
treated,3255,O
twice,3255,O
daily,3255,O
with,3255,O
(,3255,B-GENE-Y
pGlu-Gln,3255,I-GENE-Y
),3255,I-GENE-Y
-CCK-8,3255,I-GENE-Y
for,3255,O
18,3255,O
days,3255,O
",",3255,O
including,3255,O
significantly,3255,O
reduced,3255,O
energy,3255,O
intake,3255,O
(,3255,O
p,3255,O
<,3255,O
0.05,3255,O
),3255,O
",",3255,O
body,3255,O
weight,3255,O
(,3255,O
p,3255,O
<,3255,O
0.05,3255,O
to,3255,O
p,3255,O
<,3255,O
0.01,3255,O
),3255,O
",",3255,O
circulating,3255,O
glucose,3255,B-CHEMICAL
(,3255,O
p,3255,O
<,3255,O
0.05,3255,O
to,3255,O
p,3255,O
<,3255,O
0.01,3255,O
),3255,O
and,3255,O
insulin,3255,B-GENE-N
(,3255,O
p,3255,O
<,3255,O
0.05,3255,O
to,3255,O
p,3255,O
<,3255,O
0.001,3255,O
),3255,O
and,3255,O
improved,3255,O
glucose,3255,B-CHEMICAL
tolerance,3255,O
(,3255,O
p,3255,O
<,3255,O
0.05,3255,O
),3255,O
and,3255,O
insulin,3255,B-GENE-N
sensitivity,3255,O
(,3255,O
p,3255,O
<,3255,O
0.001,3255,O
),3255,O
.,3255,O
Notably,3256,O
",",3256,O
these,3256,O
beneficial,3256,O
effects,3256,O
were,3256,O
still,3256,O
evident,3256,O
18,3256,O
days,3256,O
following,3256,O
cessation,3256,O
of,3256,O
treatment,3256,O
.,3256,O
These,3257,O
studies,3257,O
emphasize,3257,O
the,3257,O
potential,3257,O
of,3257,O
(,3257,B-GENE-Y
pGlu-Gln,3257,I-GENE-Y
),3257,I-GENE-Y
-CCK-8,3257,I-GENE-Y
for,3257,O
the,3257,O
treatment,3257,O
of,3257,O
obesity-diabetes,3257,O
.,3257,O
Combination,3258,O
lopinavir,3258,B-CHEMICAL
and,3258,O
ritonavir,3258,B-CHEMICAL
alter,3258,O
exogenous,3258,O
and,3258,O
endogenous,3258,O
bile,3258,B-CHEMICAL
acid,3258,I-CHEMICAL
disposition,3258,O
in,3258,O
sandwich-cultured,3258,O
rat,3258,O
hepatocytes,3258,O
.,3258,O
Inhibition,3259,O
of,3259,O
the,3259,O
bile,3259,B-GENE-Y
salt,3259,I-GENE-Y
export,3259,I-GENE-Y
pump,3259,I-GENE-Y
(,3259,O
BSEP,3259,B-GENE-Y
),3259,O
can,3259,O
cause,3259,O
intracellular,3259,O
accumulation,3259,O
of,3259,O
bile,3259,B-CHEMICAL
acids,3259,I-CHEMICAL
and,3259,O
is,3259,O
a,3259,O
risk,3259,O
factor,3259,O
for,3259,O
drug-induced,3259,O
liver,3259,O
injury,3259,O
in,3259,O
humans,3259,O
.,3259,O
Antiretroviral,3260,O
protease,3260,B-GENE-N
inhibitors,3260,O
lopinavir,3260,B-CHEMICAL
(,3260,O
LPV,3260,B-CHEMICAL
),3260,O
and,3260,O
ritonavir,3260,B-CHEMICAL
(,3260,O
RTV,3260,B-CHEMICAL
),3260,O
are,3260,O
reported,3260,O
BSEP,3260,B-GENE-Y
inhibitors,3260,O
.,3260,O
However,3261,O
",",3261,O
the,3261,O
consequences,3261,O
of,3261,O
LPV,3261,B-CHEMICAL
and,3261,O
RTV,3261,B-CHEMICAL
",",3261,O
alone,3261,O
and,3261,O
combined,3261,O
(,3261,O
LPV/r,3261,B-CHEMICAL
),3261,O
",",3261,O
on,3261,O
hepatocyte,3261,O
viability,3261,O
",",3261,O
bile,3261,B-CHEMICAL
acid,3261,I-CHEMICAL
transport,3261,O
",",3261,O
and,3261,O
endogenous,3261,O
bile,3261,B-CHEMICAL
acid,3261,I-CHEMICAL
disposition,3261,O
in,3261,O
rat,3261,O
hepatocytes,3261,O
have,3261,O
not,3261,O
been,3261,O
examined,3261,O
.,3261,O
The,3262,O
effect,3262,O
of,3262,O
LPV,3262,B-CHEMICAL
",",3262,O
RTV,3262,B-CHEMICAL
",",3262,O
and,3262,O
LPV/r,3262,B-CHEMICAL
on,3262,O
cellular,3262,O
viability,3262,O
and,3262,O
the,3262,O
disposition,3262,O
of,3262,O
[,3262,B-CHEMICAL
(,3262,I-CHEMICAL
3,3262,I-CHEMICAL
),3262,I-CHEMICAL
H,3262,I-CHEMICAL
],3262,I-CHEMICAL
taurocholic,3262,I-CHEMICAL
acid,3262,I-CHEMICAL
(,3262,O
TCA,3262,B-CHEMICAL
),3262,O
and,3262,O
[,3262,B-CHEMICAL
(,3262,I-CHEMICAL
14,3262,I-CHEMICAL
),3262,I-CHEMICAL
C,3262,I-CHEMICAL
],3262,I-CHEMICAL
chenodeoxycholic,3262,I-CHEMICAL
acid,3262,I-CHEMICAL
(,3262,O
CDCA,3262,B-CHEMICAL
),3262,O
was,3262,O
determined,3262,O
in,3262,O
sandwich-cultured,3262,O
rat,3262,O
hepatocytes,3262,O
(,3262,O
SCRH,3262,O
),3262,O
and,3262,O
suspended,3262,O
rat,3262,O
hepatocytes,3262,O
.,3262,O
Lactate,3263,B-CHEMICAL
dehydrogenase,3263,O
and,3263,O
ATP,3263,B-CHEMICAL
assays,3263,O
revealed,3263,O
a,3263,O
concentration-dependent,3263,O
effect,3263,O
of,3263,O
LPV,3263,B-CHEMICAL
and,3263,O
RTV,3263,B-CHEMICAL
on,3263,O
cellular,3263,O
viability,3263,O
.,3263,O
LPV,3264,B-CHEMICAL
(,3264,O
5,3264,O
M,3264,O
),3264,O
",",3264,O
alone,3264,O
and,3264,O
combined,3264,O
with,3264,O
5,3264,O
M,3264,O
RTV,3264,B-CHEMICAL
",",3264,O
significantly,3264,O
decreased,3264,O
[,3264,B-CHEMICAL
(,3264,I-CHEMICAL
3,3264,I-CHEMICAL
),3264,I-CHEMICAL
H,3264,I-CHEMICAL
],3264,I-CHEMICAL
TCA,3264,I-CHEMICAL
accumulation,3264,O
in,3264,O
cells,3264,O
+,3264,O
bile,3264,O
of,3264,O
SCRHs,3264,O
compared,3264,O
with,3264,O
control,3264,O
.,3264,O
LPV/r,3265,B-CHEMICAL
significantly,3265,O
increased,3265,O
[,3265,B-CHEMICAL
(,3265,I-CHEMICAL
3,3265,I-CHEMICAL
),3265,I-CHEMICAL
H,3265,I-CHEMICAL
],3265,I-CHEMICAL
TCA,3265,I-CHEMICAL
cellular,3265,O
accumulation,3265,O
(,3265,O
7.7,3265,O
,3265,O
0.1,3265,O
pmol/mg,3265,O
of,3265,O
protein,3265,O
),3265,O
compared,3265,O
with,3265,O
vehicle,3265,O
and,3265,O
5,3265,O
M,3265,O
LPV,3265,B-CHEMICAL
alone,3265,O
(,3265,O
5.1,3265,O
,3265,O
0.7,3265,O
and,3265,O
5.0,3265,O
,3265,O
0.5,3265,O
pmol/mg,3265,O
of,3265,O
protein,3265,O
),3265,O
.,3265,O
The,3266,O
[,3266,B-CHEMICAL
(,3266,I-CHEMICAL
3,3266,I-CHEMICAL
),3266,I-CHEMICAL
H,3266,I-CHEMICAL
],3266,I-CHEMICAL
TCA,3266,I-CHEMICAL
biliary,3266,O
clearance,3266,O
was,3266,O
reduced,3266,O
significantly,3266,O
by,3266,O
LPV,3266,B-CHEMICAL
and,3266,O
RTV,3266,B-CHEMICAL
and,3266,O
further,3266,O
reduced,3266,O
by,3266,O
LPV/r,3266,B-CHEMICAL
.,3266,O
LPV,3267,B-CHEMICAL
and,3267,O
RTV,3267,B-CHEMICAL
did,3267,O
not,3267,O
affect,3267,O
the,3267,O
initial,3267,O
uptake,3267,O
rates,3267,O
of,3267,O
[,3267,B-CHEMICAL
(,3267,I-CHEMICAL
3,3267,I-CHEMICAL
),3267,I-CHEMICAL
H,3267,I-CHEMICAL
],3267,I-CHEMICAL
TCA,3267,I-CHEMICAL
or,3267,O
[,3267,B-CHEMICAL
(,3267,I-CHEMICAL
14,3267,I-CHEMICAL
),3267,I-CHEMICAL
C,3267,I-CHEMICAL
],3267,I-CHEMICAL
CDCA,3267,I-CHEMICAL
in,3267,O
suspended,3267,O
rat,3267,O
hepatocytes,3267,O
.,3267,O
LPV,3268,B-CHEMICAL
(,3268,O
50,3268,O
M,3268,O
),3268,O
",",3268,O
RTV,3268,B-CHEMICAL
(,3268,O
5,3268,O
M,3268,O
),3268,O
",",3268,O
and,3268,O
LPV/r,3268,B-CHEMICAL
(,3268,O
5,3268,O
and,3268,O
50,3268,O
M/5,3268,O
M,3268,O
),3268,O
significantly,3268,O
decreased,3268,O
the,3268,O
accumulation,3268,O
of,3268,O
total,3268,O
measured,3268,O
endogenous,3268,O
bile,3268,B-CHEMICAL
acids,3268,I-CHEMICAL
(,3268,O
TCA,3268,B-CHEMICAL
",",3268,O
glycocholic,3268,B-CHEMICAL
acid,3268,I-CHEMICAL
",",3268,O
taurochenodeoxycholic,3268,B-CHEMICAL
acid,3268,I-CHEMICAL
",",3268,O
glycochenodeoxycholic,3268,B-CHEMICAL
acid,3268,I-CHEMICAL
",",3268,O
and,3268,O
/-tauromuricholic,3268,B-CHEMICAL
acid,3268,I-CHEMICAL
),3268,O
in,3268,O
SCRH,3268,O
.,3268,O
Quantification,3269,O
of,3269,O
endogenous,3269,O
bile,3269,B-CHEMICAL
acids,3269,I-CHEMICAL
in,3269,O
SCRH,3269,O
may,3269,O
reveal,3269,O
important,3269,O
adaptive,3269,O
responses,3269,O
associated,3269,O
with,3269,O
exposure,3269,O
to,3269,O
known,3269,O
BSEP,3269,B-GENE-Y
inhibitors,3269,O
.,3269,O
Pharmacokinetic,3270,O
study,3270,O
of,3270,O
Growth,3270,B-CHEMICAL
Hormone-Releasing,3270,I-CHEMICAL
Peptide,3270,I-CHEMICAL
6,3270,I-CHEMICAL
(,3270,O
GHRP-6,3270,B-CHEMICAL
),3270,O
in,3270,O
nine,3270,O
male,3270,O
healthy,3270,O
volunteers,3270,O
.,3270,O
GHRP-6,3271,B-CHEMICAL
is,3271,O
a,3271,O
growth,3271,B-GENE-Y
hormone,3271,I-GENE-Y
secretagogue,3271,O
that,3271,O
also,3271,O
enhances,3271,O
tissue,3271,O
viability,3271,O
in,3271,O
different,3271,O
organs,3271,O
.,3271,O
In,3272,O
the,3272,O
present,3272,O
work,3272,O
",",3272,O
we,3272,O
studied,3272,O
the,3272,O
pharmacokinetics,3272,O
of,3272,O
this,3272,O
short,3272,O
therapeutic,3272,O
hexapeptide,3272,O
(,3272,O
His-,3272,B-CHEMICAL
(,3272,I-CHEMICAL
D-Trp,3272,I-CHEMICAL
),3272,I-CHEMICAL
-Ala-Trp-,3272,I-CHEMICAL
(,3272,I-CHEMICAL
D-Phe,3272,I-CHEMICAL
),3272,I-CHEMICAL
-Lys-NH,3272,I-CHEMICAL
(,3272,I-CHEMICAL
2,3272,I-CHEMICAL
",",3272,I-CHEMICAL
),3272,I-CHEMICAL
MW=872.44,3272,O
Da,3272,O
),3272,O
in,3272,O
nine,3272,O
male,3272,O
healthy,3272,O
volunteers,3272,O
after,3272,O
a,3272,O
single,3272,O
intravenous,3272,O
bolus,3272,O
administration,3272,O
of,3272,O
100,3272,O
",",3272,O
200,3272,O
and,3272,O
400,3272,O
g/kg,3272,O
of,3272,O
body,3272,O
weight,3272,O
.,3272,O
GHRP-6,3273,B-CHEMICAL
was,3273,O
quantified,3273,O
in,3273,O
human,3273,O
plasma,3273,O
by,3273,O
a,3273,O
specific,3273,O
LC-MS,3273,O
method,3273,O
",",3273,O
previously,3273,O
developed,3273,O
and,3273,O
validated,3273,O
following,3273,O
FDA,3273,O
guidelines,3273,O
",",3273,O
using,3273,O
(,3273,B-CHEMICAL
13,3273,I-CHEMICAL
),3273,I-CHEMICAL
C,3273,I-CHEMICAL
(,3273,I-CHEMICAL
3,3273,I-CHEMICAL
),3273,I-CHEMICAL
Ala-GHRP-6,3273,I-CHEMICAL
as,3273,O
internal,3273,O
standard,3273,O
(,3273,O
Gil,3273,O
et,3273,O
al.,3273,O
",",3273,O
2012,3273,O
",",3273,O
J.,3273,O
Pharm,3273,O
.,3273,O
Biomed,3274,O
.,3274,O
Anal,3275,O
.,3275,O
60,3276,O
",",3276,O
19-25,3276,O
),3276,O
.,3276,O
The,3277,O
Lower,3277,O
Limit,3277,O
of,3277,O
Quantification,3277,O
(,3277,O
5,3277,O
ng/mL,3277,O
),3277,O
was,3277,O
reached,3277,O
in,3277,O
all,3277,O
subjects,3277,O
at,3277,O
12h,3277,O
post-administration,3277,O
",",3277,O
which,3277,O
was,3277,O
sufficient,3277,O
for,3277,O
modeling,3277,O
a,3277,O
pharmacokinetic,3277,O
profile,3277,O
including,3277,O
over,3277,O
85,3277,O
%,3277,O
of,3277,O
the,3277,O
Area,3277,O
under,3277,O
the,3277,O
Curve,3277,O
(,3277,O
AUC,3277,O
),3277,O
.,3277,O
Disposition,3278,O
of,3278,O
GHRP-6,3278,B-CHEMICAL
best,3278,O
fitted,3278,O
a,3278,O
bi-exponential,3278,O
function,3278,O
with,3278,O
R,3278,O
(,3278,O
2,3278,O
),3278,O
higher,3278,O
than,3278,O
0.99,3278,O
",",3278,O
according,3278,O
to,3278,O
a,3278,O
mathematic,3278,O
modeling,3278,O
and,3278,O
confirmed,3278,O
by,3278,O
an,3278,O
Akaike,3278,O
index,3278,O
(,3278,O
AIC,3278,O
),3278,O
lower,3278,O
than,3278,O
that,3278,O
of,3278,O
the,3278,O
corresponding,3278,O
one-compartment,3278,O
model,3278,O
for,3278,O
all,3278,O
subjects,3278,O
.,3278,O
Averaging,3279,O
all,3279,O
three,3279,O
dose,3279,O
levels,3279,O
",",3279,O
the,3279,O
distribution,3279,O
and,3279,O
elimination,3279,O
half-life,3279,O
of,3279,O
GHRP-6,3279,B-CHEMICAL
were,3279,O
7.6,3279,O
,3279,O
1.9,3279,O
min,3279,O
and,3279,O
2.5,3279,O
,3279,O
1.1h,3279,O
",",3279,O
respectively,3279,O
.,3279,O
These,3280,O
values,3280,O
are,3280,O
coherent,3280,O
with,3280,O
existing,3280,O
data,3280,O
for,3280,O
other,3280,O
drugs,3280,O
whose,3280,O
disposition,3280,O
also,3280,O
fits,3280,O
this,3280,O
model,3280,O
.,3280,O
Dose,3281,O
dependence,3281,O
analysis,3281,O
revealed,3281,O
a,3281,O
noticeable,3281,O
trend,3281,O
for,3281,O
AUC,3281,O
to,3281,O
increase,3281,O
proportionally,3281,O
with,3281,O
administered,3281,O
dose,3281,O
.,3281,O
Atypical,3282,O
GHRP-6,3282,B-CHEMICAL
concentration,3282,O
spikes,3282,O
were,3282,O
observed,3282,O
during,3282,O
the,3282,O
elimination,3282,O
phase,3282,O
in,3282,O
four,3282,O
out,3282,O
of,3282,O
the,3282,O
nine,3282,O
subjects,3282,O
studied,3282,O
.,3282,O
Efficacy,3283,O
of,3283,O
asiatic,3283,B-CHEMICAL
acid,3283,I-CHEMICAL
",",3283,O
a,3283,O
pentacyclic,3283,B-CHEMICAL
triterpene,3283,I-CHEMICAL
on,3283,O
attenuating,3283,O
the,3283,O
key,3283,O
enzymes,3283,O
activities,3283,O
of,3283,O
carbohydrate,3283,B-CHEMICAL
metabolism,3283,O
in,3283,O
streptozotocin-induced,3283,B-CHEMICAL
diabetic,3283,O
rats,3283,O
.,3283,O
Asiatic,3284,B-CHEMICAL
acid,3284,I-CHEMICAL
(,3284,O
AA,3284,O
),3284,O
",",3284,O
a,3284,O
triterpenoid,3284,B-CHEMICAL
derivative,3284,O
of,3284,O
Centella,3284,O
asiatica,3284,O
",",3284,O
has,3284,O
shown,3284,O
significant,3284,O
biological,3284,O
effects,3284,O
of,3284,O
antioxidant,3284,O
and,3284,O
anti-inflammatory,3284,O
activities,3284,O
.,3284,O
Aim,3285,O
of,3285,O
this,3285,O
investigation,3285,O
was,3285,O
to,3285,O
evaluate,3285,O
the,3285,O
antihyperglycemic,3285,O
effect,3285,O
of,3285,O
AA,3285,O
on,3285,O
the,3285,O
activities,3285,O
of,3285,O
hepatic,3285,O
enzymes,3285,O
of,3285,O
carbohydrate,3285,B-CHEMICAL
metabolism,3285,O
in,3285,O
streptozotocin,3285,B-CHEMICAL
(,3285,O
STZ,3285,B-CHEMICAL
),3285,O
-induced,3285,O
diabetic,3285,O
rats,3285,O
.,3285,O
To,3286,O
induce,3286,O
diabetes,3286,O
mellitus,3286,O
",",3286,O
rats,3286,O
were,3286,O
injected,3286,O
with,3286,O
streptozotocin,3286,B-CHEMICAL
intraperitoneally,3286,O
at,3286,O
a,3286,O
single,3286,O
dose,3286,O
of,3286,O
40,3286,O
mg/kg,3286,O
b.w,3286,O
.,3286,O
Diabetic,3287,O
rats,3287,O
showed,3287,O
significant,3287,O
(,3287,O
p,3287,O
<,3287,O
0.05,3287,O
),3287,O
increased,3287,O
in,3287,O
plasma,3287,O
glucose,3287,B-CHEMICAL
",",3287,O
glycosylated,3287,B-GENE-N
hemoglobin,3287,I-GENE-N
and,3287,O
significant,3287,O
(,3287,O
p,3287,O
<,3287,O
0.05,3287,O
),3287,O
decreased,3287,O
in,3287,O
circulating,3287,O
insulin,3287,B-GENE-N
and,3287,O
hemoglobin,3287,B-GENE-N
.,3287,O
The,3288,O
altered,3288,O
activities,3288,O
of,3288,O
key,3288,O
enzymes,3288,O
such,3288,O
as,3288,O
glucose-6-phosphatase,3288,B-GENE-Y
and,3288,O
"fructose-1,6-bisphosphatase",3288,B-GENE-Y
of,3288,O
carbohydrate,3288,B-CHEMICAL
metabolism,3288,O
significantly,3288,O
(,3288,O
p,3288,O
<,3288,O
0.05,3288,O
),3288,O
increased,3288,O
whereas,3288,O
hexokinase,3288,B-GENE-N
",",3288,O
pyruvate,3288,B-GENE-N
kinase,3288,I-GENE-N
",",3288,O
glucose-6-phosphate,3288,B-GENE-Y
dehydrogenase,3288,I-GENE-Y
and,3288,O
glycogen,3288,O
content,3288,O
significantly,3288,O
(,3288,O
p,3288,O
<,3288,O
0.05,3288,O
),3288,O
decreased,3288,O
in,3288,O
the,3288,O
liver,3288,O
of,3288,O
diabetic,3288,O
rats,3288,O
and,3288,O
also,3288,O
increased,3288,O
activities,3288,O
of,3288,O
aspartate,3288,B-GENE-N
transaminase,3288,I-GENE-N
(,3288,O
AST,3288,B-GENE-N
),3288,O
",",3288,O
alanine,3288,B-CHEMICAL
transaminase,3288,I-GENE-N
(,3288,O
ALT,3288,B-GENE-N
),3288,O
and,3288,O
alkaline,3288,B-GENE-N
phosphatase,3288,I-GENE-N
(,3288,O
ALP,3288,B-GENE-N
),3288,O
.,3288,O
Oral,3289,O
administration,3289,O
of,3289,O
AA,3289,O
(,3289,O
5,3289,O
",",3289,O
10,3289,O
and,3289,O
20,3289,O
mg/kg,3289,O
b.w,3289,O
.,3289,O
),3289,O
and,3290,O
glibenclamide,3290,B-CHEMICAL
(,3290,O
600,3290,O
g/kg,3290,O
b.w,3290,O
.,3290,O
),3290,O
to,3291,O
diabetic,3291,O
rats,3291,O
for,3291,O
45,3291,O
days,3291,O
prevented,3291,O
the,3291,O
above,3291,O
alteration,3291,O
and,3291,O
reverted,3291,O
to,3291,O
near,3291,O
normalcy,3291,O
.,3291,O
Protection,3292,O
of,3292,O
body,3292,O
weight,3292,O
loss,3292,O
of,3292,O
diabetic,3292,O
rats,3292,O
by,3292,O
AA,3292,O
was,3292,O
also,3292,O
observed,3292,O
.,3292,O
No,3293,O
significant,3293,O
effect,3293,O
was,3293,O
observed,3293,O
in,3293,O
normal,3293,O
rats,3293,O
treated,3293,O
with,3293,O
AA,3293,O
(,3293,O
20,3293,O
mg/kg,3293,O
b.w,3293,O
.,3293,O
),3293,O
.,3293,O
In,3294,O
this,3294,O
search,3294,O
",",3294,O
AA,3294,O
found,3294,O
to,3294,O
be,3294,O
potential,3294,O
bioactive,3294,O
compound,3294,O
to,3294,O
regulate,3294,O
the,3294,O
carbohydrate,3294,B-CHEMICAL
metabolism,3294,O
by,3294,O
modulating,3294,O
the,3294,O
key,3294,O
regulatory,3294,O
enzymes,3294,O
in,3294,O
diabetic,3294,O
rats,3294,O
.,3294,O
These,3295,O
findings,3295,O
merit,3295,O
further,3295,O
research,3295,O
in,3295,O
this,3295,O
field,3295,O
.,3295,O
Ibandronate,3296,B-CHEMICAL
increases,3296,O
the,3296,O
expression,3296,O
of,3296,O
the,3296,O
pro-apoptotic,3296,O
gene,3296,O
FAS,3296,B-GENE-Y
by,3296,O
epigenetic,3296,O
mechanisms,3296,O
in,3296,O
tumor,3296,O
cells,3296,O
.,3296,O
There,3297,O
is,3297,O
growing,3297,O
evidence,3297,O
that,3297,O
aminobisphosphonates,3297,B-CHEMICAL
like,3297,O
ibandronate,3297,B-CHEMICAL
show,3297,O
anticancer,3297,O
activity,3297,O
by,3297,O
an,3297,O
unknown,3297,O
mechanism,3297,O
.,3297,O
Biochemically,3298,O
",",3298,O
they,3298,O
prevent,3298,O
posttranslational,3298,O
isoprenylation,3298,O
of,3298,O
small,3298,O
GTPases,3298,B-GENE-N
",",3298,O
thus,3298,O
inhibiting,3298,O
their,3298,O
activity,3298,O
.,3298,O
In,3299,O
tumor,3299,O
cells,3299,O
",",3299,O
activated,3299,O
RAS-GTPase,3299,B-GENE-N
",",3299,O
the,3299,O
founding,3299,O
member,3299,O
of,3299,O
the,3299,O
gene,3299,O
family,3299,O
",",3299,O
down-regulates,3299,O
the,3299,O
expression,3299,O
of,3299,O
the,3299,O
pro-apoptotic,3299,O
gene,3299,O
FAS,3299,B-GENE-Y
via,3299,O
epigenetic,3299,O
DNA-methylation,3299,O
by,3299,O
DNMT1,3299,B-GENE-Y
.,3299,O
We,3300,O
compared,3300,O
ibandronate,3300,B-CHEMICAL
treatment,3300,O
in,3300,O
neoplastic,3300,O
human,3300,O
U-2,3300,O
osteosarcoma,3300,O
and,3300,O
in,3300,O
mouse,3300,O
CCL-51,3300,O
breast,3300,O
cancer,3300,O
cells,3300,O
as,3300,O
well,3300,O
as,3300,O
in,3300,O
the,3300,O
immortalized,3300,O
non-neoplastic,3300,O
MC3T3-E1,3300,O
osteoblastic,3300,O
cells,3300,O
.,3300,O
Ibandronate,3301,B-CHEMICAL
attenuated,3301,O
cell,3301,O
proliferation,3301,O
in,3301,O
all,3301,O
cell,3301,O
lines,3301,O
tested,3301,O
.,3301,O
In,3302,O
the,3302,O
neoplastic,3302,O
cells,3302,O
we,3302,O
found,3302,O
up-regulation,3302,O
of,3302,O
caspases,3302,B-GENE-N
suggesting,3302,O
apoptosis,3302,O
.,3302,O
Further,3303,O
we,3303,O
found,3303,O
stimulation,3303,O
of,3303,O
FAS-expression,3303,B-GENE-Y
as,3303,O
a,3303,O
result,3303,O
of,3303,O
epigenetic,3303,O
DNA,3303,O
demethylation,3303,O
that,3303,O
was,3303,O
due,3303,O
to,3303,O
down-regulation,3303,O
of,3303,O
DNMT1,3303,B-GENE-Y
",",3303,O
which,3303,O
was,3303,O
rescued,3303,O
by,3303,O
re-isoprenylation,3303,O
by,3303,O
both,3303,O
geranylgeranyl-pyrophosphate,3303,B-CHEMICAL
and,3303,O
farnesylpyrophosphate,3303,B-CHEMICAL
.,3303,O
In,3304,O
contrast,3304,O
",",3304,O
ibandronate,3304,B-CHEMICAL
did,3304,O
not,3304,O
affect,3304,O
FAS,3304,B-GENE-Y
and,3304,O
DNMT1,3304,B-GENE-Y
expression,3304,O
in,3304,O
MC3T3-E1,3304,O
non-neoplastic,3304,O
cells,3304,O
.,3304,O
Data,3305,O
suggest,3305,O
that,3305,O
bisphosphonates,3305,B-CHEMICAL
via,3305,O
modulation,3305,O
of,3305,O
the,3305,O
activity,3305,O
of,3305,O
small-GTPases,3305,O
induce,3305,O
apoptosis,3305,O
in,3305,O
neoplastic,3305,O
cells,3305,O
by,3305,O
DNA-CpG-demethylation,3305,O
and,3305,O
stimulation,3305,O
of,3305,O
FAS-expression,3305,B-GENE-Y
.,3305,O
In,3306,O
conclusion,3306,O
the,3306,O
shown,3306,O
epigenetic,3306,O
mechanism,3306,O
underlying,3306,O
the,3306,O
anti-neoplastic,3306,O
activity,3306,O
of,3306,O
farnesyl-transferase-inhibition,3306,B-CHEMICAL
",",3306,O
also,3306,O
explains,3306,O
the,3306,O
clinical,3306,O
success,3306,O
of,3306,O
other,3306,O
drugs,3306,O
",",3306,O
which,3306,O
target,3306,O
this,3306,O
pathway,3306,O
.,3306,O
Androgen,3307,B-GENE-Y
receptor,3307,I-GENE-Y
CAG,3307,B-GENE-N
repeat,3307,I-GENE-N
length,3307,O
modifies,3307,O
the,3307,O
effect,3307,O
of,3307,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",3307,B-CHEMICAL
on,3307,O
receptor,3307,O
activity,3307,O
in,3307,O
human,3307,O
prostate,3307,O
cells,3307,O
.,3307,O
Increased,3308,O
incidence,3308,O
of,3308,O
prostate,3308,O
cancer,3308,O
has,3308,O
been,3308,O
reported,3308,O
in,3308,O
men,3308,O
exposed,3308,O
to,3308,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",3308,B-CHEMICAL
(,3308,O
TCDD,3308,B-CHEMICAL
),3308,O
.,3308,O
TCDD,3309,B-CHEMICAL
acts,3309,O
through,3309,O
the,3309,O
aryl,3309,B-CHEMICAL
hydrocarbon,3309,I-CHEMICAL
receptor,3309,I-GENE-Y
(,3309,O
AhR,3309,B-GENE-Y
),3309,O
",",3309,O
which,3309,O
interacts,3309,O
with,3309,O
the,3309,O
androgen,3309,B-CHEMICAL
receptor,3309,I-GENE-Y
(,3309,O
AR,3309,B-GENE-Y
),3309,O
.,3309,O
The,3310,O
AR,3310,B-GENE-Y
gene,3310,O
contains,3310,O
a,3310,O
polymorphic,3310,O
CAG,3310,B-GENE-N
repeat,3310,I-GENE-N
that,3310,O
influences,3310,O
its,3310,O
transcriptional,3310,O
activity,3310,O
.,3310,O
We,3311,O
investigated,3311,O
the,3311,O
influence,3311,O
of,3311,O
TCDD,3311,B-CHEMICAL
on,3311,O
prostate,3311,O
cancer,3311,O
cells,3311,O
(,3311,O
PC-3,3311,O
),3311,O
and,3311,O
non-tumor,3311,O
prostate,3311,O
cells,3311,O
(,3311,O
PNT1A,3311,O
),3311,O
on,3311,O
5-dihydrotestosterone-activated,3311,B-CHEMICAL
ARs,3311,B-GENE-Y
containing,3311,O
CAG,3311,B-GENE-N
repeats,3311,I-GENE-N
within,3311,O
normal,3311,O
length,3311,O
range,3311,O
(,3311,O
16,3311,O
",",3311,O
22,3311,O
",",3311,O
and,3311,O
28,3311,O
),3311,O
.,3311,O
The,3312,O
AhR,3312,B-GENE-Y
target,3312,O
gene,3312,O
CYP1A1,3312,B-GENE-Y
mRNA,3312,O
expression,3312,O
was,3312,O
induced,3312,O
by,3312,O
TCDD,3312,B-CHEMICAL
",",3312,O
but,3312,O
was,3312,O
not,3312,O
affected,3312,O
by,3312,O
the,3312,O
AR,3312,B-GENE-Y
CAG,3312,B-GENE-N
length,3312,O
.,3312,O
TCDD,3313,B-CHEMICAL
had,3313,O
no,3313,O
effect,3313,O
on,3313,O
AR,3313,B-GENE-Y
activity,3313,O
in,3313,O
PC-3,3313,O
cells,3313,O
",",3313,O
whereas,3313,O
the,3313,O
shortest,3313,O
AR,3313,B-GENE-Y
variant,3313,O
was,3313,O
induced,3313,O
by,3313,O
TCDD,3313,B-CHEMICAL
in,3313,O
PNT1A,3313,O
cells,3313,O
.,3313,O
In,3314,O
conclusion,3314,O
",",3314,O
the,3314,O
CAG,3314,B-GENE-N
length,3314,O
dependent,3314,O
effect,3314,O
of,3314,O
TCDD,3314,B-CHEMICAL
on,3314,O
AR,3314,B-GENE-Y
activity,3314,O
in,3314,O
PNT1A,3314,O
",",3314,O
but,3314,O
not,3314,O
in,3314,O
PC-3,3314,O
cells,3314,O
",",3314,O
indicates,3314,O
as,3314,O
a,3314,O
cell-specific,3314,O
effect,3314,O
of,3314,O
TCDD,3314,B-CHEMICAL
on,3314,O
AR,3314,B-GENE-Y
activity,3314,O
.,3314,O
An,3315,O
improved,3315,O
mass,3315,O
spectrometric,3315,O
method,3315,O
for,3315,O
identification,3315,O
and,3315,O
quantification,3315,O
of,3315,O
phenolic,3315,B-CHEMICAL
compounds,3315,O
in,3315,O
apple,3315,O
fruits,3315,O
.,3315,O
Thirty-nine,3316,O
phenolic,3316,B-CHEMICAL
compounds,3316,O
were,3316,O
analysed,3316,O
using,3316,O
ultra,3316,O
high,3316,O
performance,3316,O
liquid,3316,O
chromatography,3316,O
(,3316,O
UHPLC,3316,O
),3316,O
coupled,3316,O
with,3316,O
diode,3316,O
array,3316,O
and,3316,O
accurate,3316,O
mass,3316,O
spectrometry,3316,O
detection,3316,O
using,3316,O
electrospray,3316,O
ionisation,3316,O
(,3316,O
DAD/ESI-am-MS,3316,O
),3316,O
.,3316,O
Instrumental,3317,O
parameters,3317,O
such,3317,O
as,3317,O
scan,3317,O
speed,3317,O
",",3317,O
resolution,3317,O
",",3317,O
and,3317,O
mass,3317,O
accuracy,3317,O
were,3317,O
optimised,3317,O
to,3317,O
establish,3317,O
accurate,3317,O
mass,3317,O
measurements,3317,O
.,3317,O
The,3318,O
method,3318,O
was,3318,O
fully,3318,O
validated,3318,O
in,3318,O
terms,3318,O
of,3318,O
model,3318,O
deviation,3318,O
(,3318,O
r,3318,O
(,3318,O
2,3318,O
),3318,O
>,3318,O
0.9990,3318,O
),3318,O
",",3318,O
range,3318,O
(,3318,O
typically,3318,O
10-3500,3318,O
ngg,3318,O
(,3318,O
-1,3318,O
),3318,O
),3318,O
",",3318,O
intra/inter-day,3318,O
precision,3318,O
(,3318,O
<,3318,O
6,3318,O
%,3318,O
and,3318,O
<,3318,O
8,3318,O
%,3318,O
",",3318,O
respectively,3318,O
),3318,O
and,3318,O
accuracy,3318,O
(,3318,O
typically,3318,O
100,3318,O
,3318,O
10,3318,O
%,3318,O
),3318,O
.,3318,O
The,3319,O
mass,3319,O
accuracy,3319,O
of,3319,O
each,3319,O
selected,3319,O
phenolic,3319,B-CHEMICAL
compound,3319,O
was,3319,O
below,3319,O
1.5,3319,O
ppm,3319,O
.,3319,O
The,3320,O
results,3320,O
confirmed,3320,O
that,3320,O
the,3320,O
UHPLC-DAD/ESI-am-MS,3320,O
method,3320,O
developed,3320,O
here,3320,O
was,3320,O
convenient,3320,O
and,3320,O
reliable,3320,O
for,3320,O
the,3320,O
determination,3320,O
of,3320,O
phenolic,3320,B-CHEMICAL
compounds,3320,O
in,3320,O
apple,3320,O
extracts,3320,O
.,3320,O
Reduced,3321,O
in,3321,O
vitro,3321,O
and,3321,O
in,3321,O
vivo,3321,O
toxicity,3321,O
of,3321,O
siRNA-lipoplexes,3321,O
with,3321,O
addition,3321,O
of,3321,O
polyglutamate,3321,B-CHEMICAL
.,3321,O
We,3322,O
previously,3322,O
designed,3322,O
a,3322,O
new,3322,O
siRNA,3322,O
vector,3322,O
that,3322,O
efficiently,3322,O
silences,3322,O
genes,3322,O
in,3322,O
vitro,3322,O
and,3322,O
in,3322,O
vivo,3322,O
.,3322,O
The,3323,O
vector,3323,O
originality,3323,O
is,3323,O
based,3323,O
on,3323,O
the,3323,O
fact,3323,O
that,3323,O
",",3323,O
in,3323,O
addition,3323,O
to,3323,O
the,3323,O
siRNA,3323,O
molecule,3323,O
",",3323,O
it,3323,O
contains,3323,O
two,3323,O
components,3323,O
:,3323,O
1,3323,O
),3323,O
a,3323,O
cationic,3323,O
liposome,3323,O
that,3323,O
auto-associates,3323,O
with,3323,O
the,3323,O
siRNA,3323,O
to,3323,O
form,3323,O
particles,3323,O
called,3323,O
``,3323,O
lipoplexes,3323,O
'',3323,O
and,3323,O
",",3323,O
2,3323,O
),3323,O
an,3323,O
anionic,3323,O
polymer,3323,O
which,3323,O
enhances,3323,O
the,3323,O
lipoplex,3323,O
's,3323,O
efficiency,3323,O
.,3323,O
This,3324,O
anionic,3324,O
polymer,3324,O
can,3324,O
be,3324,O
a,3324,O
nucleic,3324,O
acid,3324,O
",",3324,O
a,3324,O
polypeptide,3324,O
or,3324,O
a,3324,O
polysaccharide,3324,O
.,3324,O
We,3325,O
show,3325,O
here,3325,O
how,3325,O
the,3325,O
nature,3325,O
of,3325,O
the,3325,O
added,3325,O
anionic,3325,O
polymer,3325,O
into,3325,O
our,3325,O
siRNA,3325,O
delivery,3325,O
system,3325,O
impacts,3325,O
the,3325,O
toxic,3325,O
effects,3325,O
induced,3325,O
by,3325,O
siRNA,3325,O
lipoplexes,3325,O
.,3325,O
We,3326,O
first,3326,O
observed,3326,O
that,3326,O
:,3326,O
(,3326,O
i,3326,O
),3326,O
siRNA,3326,O
lipoplexes-induced,3326,O
toxicity,3326,O
was,3326,O
cell,3326,O
line,3326,O
dependent,3326,O
",",3326,O
tumoral,3326,O
cell,3326,O
lines,3326,O
being,3326,O
the,3326,O
more,3326,O
sensitive,3326,O
;,3326,O
and,3326,O
(,3326,O
ii,3326,O
),3326,O
plasmid,3326,O
DNA-containing,3326,O
siRNA,3326,O
lipoplexes,3326,O
were,3326,O
more,3326,O
toxic,3326,O
than,3326,O
polyglutamate-containing,3326,B-CHEMICAL
ones,3326,O
or,3326,O
cationic,3326,O
liposomes,3326,O
.,3326,O
We,3327,O
next,3327,O
determined,3327,O
that,3327,O
the,3327,O
toxicity,3327,O
induced,3327,O
by,3327,O
plasmid-containing,3327,O
lipoplexes,3327,O
is,3327,O
a,3327,O
long-lasting,3327,O
effect,3327,O
that,3327,O
decreased,3327,O
cell,3327,O
survival,3327,O
capacity,3327,O
for,3327,O
several,3327,O
generations,3327,O
.,3327,O
We,3328,O
also,3328,O
found,3328,O
that,3328,O
treated,3328,O
cells,3328,O
underwent,3328,O
death,3328,O
following,3328,O
apoptosis,3328,O
pathway,3328,O
.,3328,O
Systemic,3329,O
injection,3329,O
to,3329,O
mice,3329,O
of,3329,O
siRNA,3329,O
lipoplexes,3329,O
",",3329,O
rather,3329,O
than,3329,O
of,3329,O
cationic,3329,O
liposome,3329,O
",",3329,O
triggered,3329,O
a,3329,O
production,3329,O
of,3329,O
several,3329,O
cytokines,3329,B-GENE-N
in,3329,O
mice,3329,O
and,3329,O
replacement,3329,O
of,3329,O
plasmid,3329,O
by,3329,O
polyglutamate,3329,B-CHEMICAL
reduced,3329,O
the,3329,O
elevation,3329,O
of,3329,O
all,3329,O
assayed,3329,O
cytokines,3329,B-GENE-N
.,3329,O
In,3330,O
order,3330,O
to,3330,O
enhance,3330,O
siRNA,3330,O
lipoplexes,3330,O
efficiency,3330,O
",",3330,O
the,3330,O
addition,3330,O
of,3330,O
polyglutamate,3330,B-CHEMICAL
as,3330,O
anionic,3330,O
polymer,3330,O
should,3330,O
be,3330,O
preferred,3330,O
to,3330,O
plasmid,3330,O
DNA,3330,O
as,3330,O
far,3330,O
as,3330,O
in,3330,O
vitro,3330,O
as,3330,O
well,3330,O
as,3330,O
in,3330,O
vivo,3330,O
toxicity,3330,O
is,3330,O
concerned,3330,O
.,3330,O
Helenalin-induced,3331,B-CHEMICAL
apoptosis,3331,O
is,3331,O
dependent,3331,O
on,3331,O
production,3331,O
of,3331,O
reactive,3331,O
oxygen,3331,B-CHEMICAL
species,3331,O
and,3331,O
independent,3331,O
of,3331,O
induction,3331,O
of,3331,O
endoplasmic,3331,O
reticulum,3331,O
stress,3331,O
in,3331,O
renal,3331,O
cell,3331,O
carcinoma,3331,O
.,3331,O
Helenalin,3332,B-CHEMICAL
",",3332,O
a,3332,O
sesquiterpene,3332,B-CHEMICAL
lactone,3332,I-CHEMICAL
",",3332,O
exhibits,3332,O
anti-inflammatory,3332,O
and,3332,O
anti-tumor,3332,O
activities,3332,O
.,3332,O
Here,3333,O
",",3333,O
we,3333,O
investigated,3333,O
whether,3333,O
helenalin,3333,B-CHEMICAL
could,3333,O
induce,3333,O
apoptosis,3333,O
in,3333,O
human,3333,O
renal,3333,O
carcinoma,3333,O
Caki,3333,O
cells,3333,O
.,3333,O
Helenalin,3334,B-CHEMICAL
increased,3334,O
apoptosis,3334,O
in,3334,O
dose,3334,O
dependent,3334,O
manner,3334,O
in,3334,O
Caki,3334,O
cells,3334,O
",",3334,O
and,3334,O
also,3334,O
induced,3334,O
apoptosis,3334,O
in,3334,O
other,3334,O
carcinoma,3334,O
cells,3334,O
",",3334,O
such,3334,O
as,3334,O
human,3334,O
renal,3334,O
carcinoma,3334,O
ACHN,3334,O
cells,3334,O
",",3334,O
human,3334,O
colon,3334,O
carcinoma,3334,O
HT29,3334,O
and,3334,O
HCT116,3334,O
cells,3334,O
.,3334,O
We,3335,O
found,3335,O
that,3335,O
helenalin,3335,B-CHEMICAL
markedly,3335,O
induced,3335,O
endoplasmic,3335,O
reticulum,3335,O
(,3335,O
ER,3335,O
),3335,O
stress-related,3335,O
genes,3335,O
",",3335,O
such,3335,O
as,3335,O
regulated,3335,B-GENE-Y
in,3335,I-GENE-Y
development,3335,I-GENE-Y
and,3335,I-GENE-Y
DNA,3335,I-GENE-Y
damage,3335,I-GENE-Y
responses,3335,I-GENE-Y
(,3335,I-GENE-Y
REDD,3335,I-GENE-Y
),3335,I-GENE-Y
1,3335,I-GENE-Y
",",3335,O
activating,3335,B-GENE-Y
transcription,3335,I-GENE-Y
factor-4,3335,I-GENE-Y
(,3335,O
ATF4,3335,B-GENE-Y
),3335,O
and/or,3335,O
the,3335,O
CCAAT,3335,B-GENE-Y
enhancer-binding,3335,I-GENE-Y
protein-homologous,3335,I-GENE-Y
protein,3335,I-GENE-Y
(,3335,O
CHOP,3335,B-GENE-Y
),3335,O
.,3335,O
However,3336,O
",",3336,O
down-regulation,3336,O
of,3336,O
ATF4,3336,B-GENE-Y
and/or,3336,O
CHOP,3336,B-GENE-Y
expression,3336,O
by,3336,O
siRNA,3336,O
had,3336,O
no,3336,O
effect,3336,O
on,3336,O
helenalin-induced,3336,B-CHEMICAL
apoptosis,3336,O
in,3336,O
Caki,3336,O
and,3336,O
HCT116,3336,O
cells,3336,O
.,3336,O
Helenalin,3337,B-CHEMICAL
increased,3337,O
production,3337,O
of,3337,O
intracellular,3337,O
reactive,3337,O
oxygen,3337,B-CHEMICAL
species,3337,O
(,3337,O
ROS,3337,O
),3337,O
.,3337,O
Furthermore,3338,O
",",3338,O
ROS,3338,O
scavengers,3338,O
",",3338,O
N-acetylcystine,3338,B-CHEMICAL
(,3338,O
NAC,3338,B-CHEMICAL
),3338,O
",",3338,O
and,3338,O
glutathione,3338,B-CHEMICAL
ethyl,3338,I-CHEMICAL
ester,3338,I-CHEMICAL
(,3338,O
GEE,3338,B-CHEMICAL
),3338,O
",",3338,O
reduced,3338,O
helenalin-induced,3338,B-CHEMICAL
apoptosis,3338,O
.,3338,O
Taken,3339,O
together,3339,O
",",3339,O
helenalin,3339,B-CHEMICAL
induced,3339,O
apoptosis,3339,O
via,3339,O
ROS,3339,O
generation,3339,O
in,3339,O
human,3339,O
renal,3339,O
carcinoma,3339,O
Caki,3339,O
cells,3339,O
.,3339,O
Contributions,3340,O
of,3340,O
rat,3340,B-GENE-Y
Ctr1,3340,I-GENE-Y
to,3340,O
the,3340,O
uptake,3340,O
and,3340,O
toxicity,3340,O
of,3340,O
copper,3340,B-CHEMICAL
and,3340,O
platinum,3340,B-CHEMICAL
anticancer,3340,O
drugs,3340,O
in,3340,O
dorsal,3340,O
root,3340,O
ganglion,3340,O
neurons,3340,O
.,3340,O
Dorsal,3341,O
root,3341,O
ganglion,3341,O
(,3341,O
DRG,3341,O
),3341,O
neurons,3341,O
are,3341,O
affected,3341,O
by,3341,O
platinum-induced,3341,B-CHEMICAL
neurotoxicity,3341,O
and,3341,O
neurodegenerative,3341,O
processes,3341,O
associated,3341,O
with,3341,O
disturbed,3341,O
copper,3341,B-CHEMICAL
homeostasis,3341,O
and,3341,O
transport,3341,O
.,3341,O
This,3342,O
study,3342,O
aimed,3342,O
to,3342,O
understand,3342,O
the,3342,O
role,3342,O
of,3342,O
copper,3342,B-GENE-Y
transporter,3342,I-GENE-Y
1,3342,I-GENE-Y
(,3342,O
Ctr1,3342,B-GENE-Y
),3342,O
in,3342,O
the,3342,O
uptake,3342,O
and,3342,O
toxicity,3342,O
of,3342,O
copper,3342,B-CHEMICAL
and,3342,O
platinum,3342,B-CHEMICAL
drugs,3342,O
in,3342,O
cultured,3342,O
rat,3342,O
DRG,3342,O
neurons,3342,O
",",3342,O
and,3342,O
the,3342,O
functional,3342,O
activities,3342,O
of,3342,O
rat,3342,B-GENE-Y
Ctr1,3342,I-GENE-Y
(,3342,O
rCtr1,3342,B-GENE-Y
),3342,O
as,3342,O
a,3342,O
membrane,3342,O
transporter,3342,O
of,3342,O
copper,3342,B-CHEMICAL
and,3342,O
platinum,3342,B-CHEMICAL
drugs,3342,O
.,3342,O
Heterologous,3343,O
expression,3343,O
of,3343,O
rCtr1,3343,B-GENE-Y
in,3343,O
HEK293,3343,O
cells,3343,O
(,3343,O
HEK/rCtr1,3343,O
cells,3343,O
),3343,O
increased,3343,O
the,3343,O
uptake,3343,O
and,3343,O
cytotoxicity,3343,O
of,3343,O
copper,3343,B-CHEMICAL
",",3343,O
oxaliplatin,3343,B-CHEMICAL
",",3343,O
cisplatin,3343,B-CHEMICAL
and,3343,O
carboplatin,3343,B-CHEMICAL
",",3343,O
in,3343,O
comparison,3343,O
to,3343,O
isogenic,3343,O
vector-transfected,3343,O
control,3343,O
cells,3343,O
.,3343,O
Cultured,3344,O
rat,3344,O
DRG,3344,O
neurons,3344,O
endogenously,3344,O
expressed,3344,O
rCtr1,3344,B-GENE-Y
protein,3344,O
on,3344,O
their,3344,O
neuronal,3344,O
cell,3344,O
body,3344,O
plasma,3344,O
membranes,3344,O
and,3344,O
cytoplasm,3344,O
",",3344,O
and,3344,O
displayed,3344,O
substantial,3344,O
capacity,3344,O
for,3344,O
taking,3344,O
up,3344,O
copper,3344,B-CHEMICAL
",",3344,O
but,3344,O
were,3344,O
resistant,3344,O
to,3344,O
copper,3344,B-CHEMICAL
toxicity,3344,O
.,3344,O
The,3345,O
uptake,3345,O
of,3345,O
copper,3345,B-CHEMICAL
by,3345,O
both,3345,O
cultured,3345,O
rat,3345,O
DRG,3345,O
neurons,3345,O
and,3345,O
HEK/rCtr1,3345,O
cells,3345,O
was,3345,O
saturable,3345,O
and,3345,O
inhibited,3345,O
by,3345,O
cold,3345,O
temperature,3345,O
",",3345,O
silver,3345,B-CHEMICAL
and,3345,O
zinc,3345,B-CHEMICAL
",",3345,O
consistent,3345,O
with,3345,O
it,3345,O
being,3345,O
mediated,3345,O
by,3345,O
rCtr1,3345,B-GENE-Y
.,3345,O
Cultured,3346,O
rat,3346,O
DRG,3346,O
neurons,3346,O
accumulated,3346,O
platinum,3346,B-CHEMICAL
during,3346,O
their,3346,O
exposure,3346,O
to,3346,O
oxaliplatin,3346,B-CHEMICAL
and,3346,O
were,3346,O
sensitive,3346,O
to,3346,O
oxaliplatin,3346,B-CHEMICAL
cytotoxicity,3346,O
.,3346,O
The,3347,O
accumulation,3347,O
of,3347,O
platinum,3347,B-CHEMICAL
by,3347,O
both,3347,O
cultured,3347,O
rat,3347,O
DRG,3347,O
neurons,3347,O
and,3347,O
HEK/rCtr1,3347,O
cells,3347,O
",",3347,O
during,3347,O
oxaliplatin,3347,B-CHEMICAL
exposure,3347,O
",",3347,O
was,3347,O
saturable,3347,O
and,3347,O
temperature,3347,O
dependent,3347,O
",",3347,O
but,3347,O
was,3347,O
inhibited,3347,O
by,3347,O
copper,3347,B-CHEMICAL
only,3347,O
in,3347,O
HEK/rCtr1,3347,O
cells,3347,O
.,3347,O
In,3348,O
conclusion,3348,O
",",3348,O
rCtr1,3348,B-GENE-Y
can,3348,O
transport,3348,O
copper,3348,B-CHEMICAL
and,3348,O
platinum,3348,B-CHEMICAL
drugs,3348,O
",",3348,O
and,3348,O
sensitizes,3348,O
cells,3348,O
to,3348,O
their,3348,O
cytotoxicities,3348,O
.,3348,O
DRG,3349,O
neurons,3349,O
display,3349,O
substantial,3349,O
capacity,3349,O
for,3349,O
accumulating,3349,O
copper,3349,B-CHEMICAL
via,3349,O
a,3349,O
transport,3349,O
process,3349,O
mediated,3349,O
by,3349,O
rCtr1,3349,B-GENE-Y
",",3349,O
but,3349,O
appear,3349,O
able,3349,O
to,3349,O
resist,3349,O
copper,3349,B-CHEMICAL
toxicity,3349,O
and,3349,O
use,3349,O
alternative,3349,O
mechanisms,3349,O
to,3349,O
take,3349,O
up,3349,O
oxaliplatin,3349,B-CHEMICAL
.,3349,O
Cell,3350,O
cycle,3350,O
regulation,3350,O
by,3350,O
glucosamine,3350,B-CHEMICAL
in,3350,O
human,3350,O
pulmonary,3350,O
epithelial,3350,O
cells,3350,O
.,3350,O
Airway,3351,O
epithelial,3351,O
cells,3351,O
play,3351,O
an,3351,O
important,3351,O
role,3351,O
against,3351,O
intruding,3351,O
pathogens,3351,O
.,3351,O
Glucosamine,3352,B-CHEMICAL
",",3352,O
a,3352,O
commonly,3352,O
used,3352,O
supplemental,3352,O
compound,3352,O
",",3352,O
has,3352,O
recently,3352,O
begun,3352,O
to,3352,O
be,3352,O
regarded,3352,O
as,3352,O
a,3352,O
potential,3352,O
anti-inflammatory,3352,O
molecule,3352,O
.,3352,O
This,3353,O
study,3353,O
aimed,3353,O
to,3353,O
uncover,3353,O
how,3353,O
glucosamine,3353,B-CHEMICAL
impacts,3353,O
on,3353,O
cellular,3353,O
proliferation,3353,O
in,3353,O
human,3353,O
alveolar,3353,O
epithelial,3353,O
cells,3353,O
(,3353,O
A549,3353,O
),3353,O
and,3353,O
bronchial,3353,O
epithelial,3353,O
cells,3353,O
(,3353,O
HBECs,3353,O
),3353,O
.,3353,O
With,3354,O
trypan,3354,B-CHEMICAL
blue-exclusion,3354,O
assay,3354,O
",",3354,O
we,3354,O
observed,3354,O
that,3354,O
glucosamine,3354,B-CHEMICAL
(,3354,O
10,3354,O
",",3354,O
20,3354,O
",",3354,O
50,3354,O
mM,3354,O
),3354,O
caused,3354,O
a,3354,O
decrease,3354,O
in,3354,O
cell,3354,O
number,3354,O
at,3354,O
24,3354,O
and,3354,O
48,3354,O
h,3354,O
;,3354,O
with,3354,O
a,3354,O
flow,3354,O
cytometric,3354,O
analysis,3354,O
",",3354,O
we,3354,O
also,3354,O
noted,3354,O
an,3354,O
enhanced,3354,O
cell,3354,O
accumulation,3354,O
within,3354,O
the,3354,O
G,3354,O
(,3354,O
0,3354,O
),3354,O
/G,3354,O
(,3354,O
1,3354,O
),3354,O
phase,3354,O
at,3354,O
24,3354,O
h,3354,O
and,3354,O
induction,3354,O
of,3354,O
late,3354,O
apoptosis,3354,O
at,3354,O
24,3354,O
and,3354,O
48,3354,O
h,3354,O
by,3354,O
glucosamine,3354,B-CHEMICAL
(,3354,O
10,3354,O
",",3354,O
20,3354,O
",",3354,O
50,3354,O
mM,3354,O
),3354,O
in,3354,O
A549,3354,O
cells,3354,O
and,3354,O
HBECs,3354,O
.,3354,O
Examination,3355,O
of,3355,O
phosphorylation,3355,O
in,3355,O
retinoblastoma,3355,B-GENE-Y
(,3355,I-GENE-Y
Rb,3355,I-GENE-Y
),3355,I-GENE-Y
protein,3355,I-GENE-Y
",",3355,O
we,3355,O
found,3355,O
an,3355,O
inhibitory,3355,O
effect,3355,O
by,3355,O
glucosamine,3355,B-CHEMICAL
at,3355,O
20,3355,O
and,3355,O
50,3355,O
mM,3355,O
.,3355,O
Glucosamine,3356,B-CHEMICAL
at,3356,O
50,3356,O
mM,3356,O
was,3356,O
demonstrated,3356,O
to,3356,O
elevate,3356,O
both,3356,O
the,3356,O
mRNA,3356,O
and,3356,O
protein,3356,O
expression,3356,O
of,3356,O
p53,3356,B-GENE-N
and,3356,O
heme,3356,B-GENE-Y
oxygenase-1,3356,I-GENE-Y
(,3356,O
HO-1,3356,B-GENE-Y
),3356,O
",",3356,O
but,3356,O
also,3356,O
caused,3356,O
a,3356,O
reduction,3356,O
in,3356,O
p21,3356,B-GENE-Y
protein,3356,O
expression,3356,O
.,3356,O
In,3357,O
addition,3357,O
",",3357,O
glucosamine,3357,B-CHEMICAL
attenuated,3357,O
p21,3357,B-GENE-Y
protein,3357,O
stability,3357,O
via,3357,O
the,3357,O
proteasomal,3357,O
proteolytic,3357,O
pathway,3357,O
",",3357,O
as,3357,O
well,3357,O
as,3357,O
inducing,3357,O
p21,3357,B-GENE-Y
nuclear,3357,O
accumulation,3357,O
.,3357,O
Altogether,3358,O
",",3358,O
our,3358,O
results,3358,O
suggest,3358,O
that,3358,O
a,3358,O
high,3358,O
dose,3358,O
of,3358,O
glucosamine,3358,B-CHEMICAL
may,3358,O
inhibit,3358,O
cell,3358,O
proliferation,3358,O
through,3358,O
apoptosis,3358,O
and,3358,O
disturb,3358,O
cell,3358,O
cycle,3358,O
progression,3358,O
with,3358,O
a,3358,O
halt,3358,O
at,3358,O
G,3358,O
(,3358,O
0,3358,O
),3358,O
/G,3358,O
(,3358,O
1,3358,O
),3358,O
phase,3358,O
",",3358,O
and,3358,O
that,3358,O
this,3358,O
occurs,3358,O
",",3358,O
at,3358,O
least,3358,O
in,3358,O
part,3358,O
",",3358,O
by,3358,O
a,3358,O
reduction,3358,O
in,3358,O
Rb,3358,B-GENE-Y
phosphorylation,3358,O
together,3358,O
with,3358,O
modulation,3358,O
of,3358,O
p21,3358,B-GENE-Y
",",3358,O
p53,3358,B-GENE-N
and,3358,O
HO-1,3358,B-GENE-Y
expression,3358,O
",",3358,O
and,3358,O
nuclear,3358,O
p21,3358,B-GENE-Y
accumulation,3358,O
.,3358,O
Characterization,3359,O
of,3359,O
substituted,3359,O
phenylpropylamides,3359,B-CHEMICAL
as,3359,O
highly,3359,O
selective,3359,O
agonists,3359,O
at,3359,O
the,3359,O
melatonin,3359,B-GENE-Y
MT2,3359,I-GENE-Y
receptor,3359,I-GENE-Y
.,3359,O
Melatonin,3360,B-CHEMICAL
is,3360,O
a,3360,O
widely,3360,O
distributed,3360,O
hormone,3360,O
that,3360,O
regulates,3360,O
several,3360,O
major,3360,O
physiological,3360,O
processes,3360,O
",",3360,O
including,3360,O
the,3360,O
circadian,3360,O
rhythm,3360,O
and,3360,O
seasonal,3360,O
adaptation,3360,O
.,3360,O
The,3361,O
two,3361,O
subtypes,3361,O
of,3361,O
mammalian,3361,B-GENE-N
G,3361,I-GENE-N
protein-coupled,3361,I-GENE-N
melatonin,3361,I-GENE-N
receptors,3361,I-GENE-N
are,3361,O
primarily,3361,O
responsible,3361,O
for,3361,O
mediating,3361,O
the,3361,O
actions,3361,O
of,3361,O
melatonin,3361,B-CHEMICAL
.,3361,O
Because,3362,O
synthetic,3362,O
melatonin,3362,B-CHEMICAL
agonists,3362,O
have,3362,O
considerable,3362,O
therapeutic,3362,O
potentials,3362,O
in,3362,O
modulating,3362,O
insomnia,3362,O
and,3362,O
circadian-,3362,O
related,3362,O
sleep,3362,O
disorders,3362,O
",",3362,O
it,3362,O
is,3362,O
highly,3362,O
desirable,3362,O
to,3362,O
develop,3362,O
subtype-selective,3362,O
melatoninergic,3362,O
compounds,3362,O
.,3362,O
The,3363,O
pharmacological,3363,O
potencies,3363,O
of,3363,O
a,3363,O
series,3363,O
of,3363,O
substituted,3363,O
N-,3363,B-CHEMICAL
[,3363,I-CHEMICAL
3-,3363,I-CHEMICAL
(,3363,I-CHEMICAL
3-methoxyphenyl,3363,I-CHEMICAL
),3363,I-CHEMICAL
propyl,3363,I-CHEMICAL
],3363,I-CHEMICAL
amides,3363,I-CHEMICAL
towards,3363,O
human,3363,B-GENE-Y
melatonin,3363,B-CHEMICAL
MT,3363,I-GENE-Y
(,3363,I-GENE-Y
1,3363,I-GENE-Y
),3363,I-GENE-Y
and,3363,O
MT,3363,B-GENE-Y
(,3363,I-GENE-Y
2,3363,I-GENE-Y
),3363,I-GENE-Y
receptors,3363,I-GENE-Y
were,3363,O
evaluated,3363,O
by,3363,O
the,3363,O
FLIPR,3363,O
high-throughput,3363,O
screening,3363,O
assay,3363,O
",",3363,O
whilst,3363,O
their,3363,O
subtype-selectivity,3363,O
was,3363,O
subsequently,3363,O
verified,3363,O
with,3363,O
ERK,3363,B-GENE-N
phosphorylation,3363,O
and,3363,O
cAMP,3363,B-CHEMICAL
assays,3363,O
.,3363,O
Structure-activity,3364,O
relationship,3364,O
analysis,3364,O
of,3364,O
highly,3364,O
potent,3364,O
subtype-selective,3364,O
ligands,3364,O
(,3364,O
MT,3364,B-GENE-Y
(,3364,I-GENE-Y
2,3364,I-GENE-Y
),3364,I-GENE-Y
EC,3364,O
(,3364,O
50,3364,O
),3364,O
10-90,3364,O
pM,3364,O
),3364,O
revealed,3364,O
that,3364,O
a,3364,O
benzyloxyl,3364,B-CHEMICAL
substituent,3364,O
incorporated,3364,O
at,3364,O
C6,3364,O
position,3364,O
of,3364,O
the,3364,O
3-methoxyphenyl,3364,B-CHEMICAL
ring,3364,O
dramatically,3364,O
enhanced,3364,O
the,3364,O
MT,3364,B-GENE-Y
(,3364,I-GENE-Y
2,3364,I-GENE-Y
),3364,I-GENE-Y
potency,3364,O
and,3364,O
at,3364,O
the,3364,O
same,3364,O
time,3364,O
decreased,3364,O
MT,3364,B-GENE-Y
(,3364,I-GENE-Y
1,3364,I-GENE-Y
),3364,I-GENE-Y
potency,3364,O
.,3364,O
Incorporation,3365,O
of,3365,O
structural,3365,O
moieties,3365,O
conferring,3365,O
the,3365,O
subtype,3365,O
selectivity,3365,O
produced,3365,O
several,3365,O
extremely,3365,O
potent,3365,O
MT,3365,B-GENE-Y
(,3365,I-GENE-Y
2,3365,I-GENE-Y
),3365,I-GENE-Y
-selective,3365,O
ligands,3365,O
.,3365,O
The,3366,O
most,3366,O
potent,3366,O
subtype-selective,3366,O
ligand,3366,O
",",3366,O
2q,3366,O
had,3366,O
a,3366,O
substantially,3366,O
higher,3366,O
potency,3366,O
for,3366,O
MT,3366,B-GENE-Y
(,3366,I-GENE-Y
2,3366,I-GENE-Y
),3366,I-GENE-Y
receptor,3366,I-GENE-Y
than,3366,O
melatonin,3366,B-CHEMICAL
for,3366,O
elevation,3366,O
of,3366,O
[,3366,O
Ca,3366,B-CHEMICAL
(,3366,I-CHEMICAL
2+,3366,I-CHEMICAL
),3366,I-CHEMICAL
],3366,O
i,3366,O
and,3366,O
inhibition,3366,O
of,3366,O
forskolin-elevated,3366,O
cAMP,3366,O
.,3366,O
Representative,3367,O
MT,3367,B-GENE-Y
(,3367,I-GENE-Y
2,3367,I-GENE-Y
),3367,I-GENE-Y
-selective,3367,O
ligands,3367,O
also,3367,O
induced,3367,O
ERK,3367,B-GENE-N
phosphorylation,3367,O
in,3367,O
both,3367,O
recombinant,3367,O
and,3367,O
native,3367,O
cell,3367,O
lines,3367,O
",",3367,O
and,3367,O
no,3367,O
cross-reactivity,3367,O
to,3367,O
17,3367,O
other,3367,O
GPCRs,3367,B-GENE-N
could,3367,O
be,3367,O
detected,3367,O
.,3367,O
These,3368,O
ligands,3368,O
represent,3368,O
invaluable,3368,O
tools,3368,O
for,3368,O
delineating,3368,O
the,3368,O
functional,3368,O
roles,3368,O
of,3368,O
distinct,3368,O
melatonin,3368,B-CHEMICAL
receptor,3368,I-GENE-N
subtypes,3368,O
and,3368,O
are,3368,O
viable,3368,O
candidates,3368,O
for,3368,O
drug,3368,O
development,3368,O
.,3368,O
Proto-oncogene,3369,B-GENE-N
PIM-1,3369,B-GENE-Y
is,3369,O
a,3369,O
novel,3369,O
estrogen,3369,B-CHEMICAL
receptor,3369,I-GENE-Y
target,3369,O
associating,3369,O
with,3369,O
high,3369,O
grade,3369,O
breast,3369,O
tumors,3369,O
.,3369,O
We,3370,O
searched,3370,O
ER,3370,B-GENE-Y
cistromes,3370,O
of,3370,O
MCF-7,3370,O
breast,3370,O
cancer,3370,O
cells,3370,O
for,3370,O
previously,3370,O
unrecognized,3370,O
ER,3370,B-GENE-Y
targets,3370,O
and,3370,O
identified,3370,O
proto-oncogene,3370,B-GENE-N
PIM-1,3370,B-GENE-Y
as,3370,O
a,3370,O
novel,3370,O
potential,3370,O
target,3370,O
gene,3370,O
.,3370,O
We,3371,O
show,3371,O
that,3371,O
the,3371,O
expression,3371,O
of,3371,O
PIM-1,3371,B-GENE-Y
is,3371,O
induced,3371,O
in,3371,O
response,3371,O
to,3371,O
estradiol,3371,B-CHEMICAL
in,3371,O
MCF-7,3371,O
cells,3371,O
and,3371,O
that,3371,O
the,3371,O
induction,3371,O
is,3371,O
mediated,3371,O
by,3371,O
ER-regulated,3371,B-GENE-Y
enhancers,3371,O
located,3371,O
distally,3371,O
upstream,3371,O
from,3371,O
the,3371,O
gene,3371,O
.,3371,O
In,3372,O
keeping,3372,O
with,3372,O
the,3372,O
growth-promoting,3372,O
role,3372,O
of,3372,O
the,3372,O
PIM-1,3372,B-GENE-Y
",",3372,O
depletion,3372,O
of,3372,O
the,3372,O
PIM-1,3372,B-GENE-Y
attenuated,3372,O
the,3372,O
proliferation,3372,O
of,3372,O
the,3372,O
MCF-7,3372,O
cells,3372,O
",",3372,O
which,3372,O
was,3372,O
paralleled,3372,O
with,3372,O
up-regulation,3372,O
of,3372,O
cyclin-dependent,3372,B-GENE-N
protein,3372,I-GENE-N
kinase,3372,I-GENE-N
inhibitor,3372,I-GENE-N
CDKN1A,3372,B-GENE-Y
and,3372,O
CDKN2B,3372,B-GENE-Y
expression,3372,O
.,3372,O
Analysis,3373,O
of,3373,O
PIM-1,3373,B-GENE-Y
expression,3373,O
between,3373,O
invasive,3373,O
breast,3373,O
tumors,3373,O
and,3373,O
benign,3373,O
breast,3373,O
tissue,3373,O
samples,3373,O
showed,3373,O
that,3373,O
elevated,3373,O
PIM-1,3373,B-GENE-Y
expression,3373,O
is,3373,O
associated,3373,O
with,3373,O
malignancy,3373,O
and,3373,O
a,3373,O
higher,3373,O
tumor,3373,O
grade,3373,O
.,3373,O
In,3374,O
sum,3374,O
",",3374,O
identification,3374,O
of,3374,O
PIM-1,3374,B-GENE-Y
as,3374,O
an,3374,O
ER,3374,B-GENE-Y
target,3374,O
gene,3374,O
adds,3374,O
a,3374,O
novel,3374,O
potential,3374,O
mechanism,3374,O
by,3374,O
which,3374,O
estrogens,3374,B-CHEMICAL
can,3374,O
contribute,3374,O
to,3374,O
breast,3374,O
cancer,3374,O
cell,3374,O
proliferation,3374,O
and,3374,O
carcinogenesis,3374,O
.,3374,O
Metabolic,3375,O
pathways,3375,O
of,3375,O
inhaled,3375,O
glucocorticoids,3375,O
by,3375,O
the,3375,O
CYP3A,3375,B-GENE-N
enzymes,3375,O
.,3375,O
Asthma,3376,O
is,3376,O
one,3376,O
of,3376,O
the,3376,O
most,3376,O
prevalent,3376,O
diseases,3376,O
in,3376,O
the,3376,O
world,3376,O
",",3376,O
for,3376,O
which,3376,O
the,3376,O
mainstay,3376,O
treatment,3376,O
has,3376,O
been,3376,O
inhaled,3376,O
glucocorticoids,3376,O
(,3376,O
GCs,3376,O
),3376,O
.,3376,O
Despite,3377,O
the,3377,O
widespread,3377,O
use,3377,O
of,3377,O
these,3377,O
drugs,3377,O
",",3377,O
approximately,3377,O
30,3377,O
%,3377,O
of,3377,O
asthma,3377,O
sufferers,3377,O
exhibit,3377,O
some,3377,O
degree,3377,O
of,3377,O
steroid,3377,B-CHEMICAL
insensitivity,3377,O
or,3377,O
are,3377,O
refractory,3377,O
to,3377,O
inhaled,3377,O
GCs,3377,O
.,3377,O
One,3378,O
hypothesis,3378,O
to,3378,O
explain,3378,O
this,3378,O
phenomenon,3378,O
is,3378,O
interpatient,3378,O
variability,3378,O
in,3378,O
the,3378,O
clearance,3378,O
of,3378,O
these,3378,O
compounds,3378,O
.,3378,O
The,3379,O
objective,3379,O
of,3379,O
this,3379,O
research,3379,O
is,3379,O
to,3379,O
determine,3379,O
how,3379,O
metabolism,3379,O
of,3379,O
GCs,3379,O
by,3379,O
the,3379,O
CYP3A,3379,B-GENE-N
family,3379,O
of,3379,O
enzymes,3379,O
could,3379,O
affect,3379,O
their,3379,O
effectiveness,3379,O
in,3379,O
asthmatic,3379,O
patients,3379,O
.,3379,O
In,3380,O
this,3380,O
work,3380,O
",",3380,O
the,3380,O
metabolism,3380,O
of,3380,O
four,3380,O
frequently,3380,O
prescribed,3380,O
inhaled,3380,O
GCs,3380,O
",",3380,O
triamcinolone,3380,B-CHEMICAL
acetonide,3380,I-CHEMICAL
",",3380,O
flunisolide,3380,B-CHEMICAL
",",3380,O
budesonide,3380,B-CHEMICAL
",",3380,O
and,3380,O
fluticasone,3380,B-CHEMICAL
propionate,3380,I-CHEMICAL
",",3380,O
by,3380,O
the,3380,O
CYP3A,3380,B-GENE-N
family,3380,O
of,3380,O
enzymes,3380,O
was,3380,O
studied,3380,O
to,3380,O
identify,3380,O
differences,3380,O
in,3380,O
their,3380,O
rates,3380,O
of,3380,O
clearance,3380,O
and,3380,O
to,3380,O
identify,3380,O
their,3380,O
metabolites,3380,O
.,3380,O
Both,3381,O
interenzyme,3381,O
and,3381,O
interdrug,3381,O
variability,3381,O
in,3381,O
rates,3381,O
of,3381,O
metabolism,3381,O
and,3381,O
metabolic,3381,O
fate,3381,O
were,3381,O
observed,3381,O
.,3381,O
CYP3A4,3382,B-GENE-Y
was,3382,O
the,3382,O
most,3382,O
efficient,3382,O
metabolic,3382,O
catalyst,3382,O
for,3382,O
all,3382,O
the,3382,O
compounds,3382,O
",",3382,O
and,3382,O
CYP3A7,3382,B-GENE-Y
had,3382,O
the,3382,O
slowest,3382,O
rates,3382,O
.,3382,O
CYP3A5,3383,B-GENE-Y
",",3383,O
which,3383,O
is,3383,O
particularly,3383,O
relevant,3383,O
to,3383,O
GC,3383,O
metabolism,3383,O
in,3383,O
the,3383,O
lungs,3383,O
",",3383,O
was,3383,O
also,3383,O
shown,3383,O
to,3383,O
efficiently,3383,O
metabolize,3383,O
triamcinolone,3383,B-CHEMICAL
acetonide,3383,I-CHEMICAL
",",3383,O
budesonide,3383,B-CHEMICAL
",",3383,O
and,3383,O
fluticasone,3383,B-CHEMICAL
propionate,3383,I-CHEMICAL
.,3383,O
In,3384,O
contrast,3384,O
",",3384,O
flunisolide,3384,B-CHEMICAL
was,3384,O
only,3384,O
metabolized,3384,O
via,3384,O
CYP3A4,3384,B-GENE-Y
",",3384,O
with,3384,O
no,3384,O
significant,3384,O
turnover,3384,O
by,3384,O
CYP3A5,3384,B-GENE-Y
or,3384,O
CYP3A7,3384,B-GENE-Y
.,3384,O
Common,3385,O
metabolites,3385,O
included,3385,O
6-hydroxylation,3385,O
and,3385,O
,3385,O
(,3385,O
6,3385,O
),3385,O
-dehydrogenation,3385,O
for,3385,O
triamcinolone,3385,B-CHEMICAL
acetonide,3385,I-CHEMICAL
",",3385,O
budesonide,3385,B-CHEMICAL
",",3385,O
and,3385,O
flunisolide,3385,B-CHEMICAL
.,3385,O
The,3386,O
structure,3386,O
of,3386,O
,3386,B-CHEMICAL
(,3386,I-CHEMICAL
6,3386,I-CHEMICAL
),3386,I-CHEMICAL
-flunisolide,3386,I-CHEMICAL
was,3386,O
unambiguously,3386,O
established,3386,O
by,3386,O
NMR,3386,O
analysis,3386,O
.,3386,O
Metabolism,3387,O
also,3387,O
occurred,3387,O
on,3387,O
the,3387,O
D-ring,3387,O
substituents,3387,O
",",3387,O
including,3387,O
the,3387,O
21-carboxy,3387,B-CHEMICAL
metabolites,3387,O
for,3387,O
triamcinolone,3387,B-CHEMICAL
acetonide,3387,I-CHEMICAL
and,3387,O
flunisolide,3387,B-CHEMICAL
.,3387,O
The,3388,O
novel,3388,O
metabolite,3388,O
21-nortriamcinolone,3388,B-CHEMICAL
acetonide,3388,I-CHEMICAL
was,3388,O
also,3388,O
identified,3388,O
by,3388,O
liquid,3388,O
chromatography-mass,3388,O
spectrometry,3388,O
and,3388,O
NMR,3388,O
analysis,3388,O
.,3388,O
Distinct,3389,O
roles,3389,O
of,3389,O
methamphetamine,3389,B-CHEMICAL
in,3389,O
modulating,3389,O
spatial,3389,O
memory,3389,O
consolidation,3389,O
",",3389,O
retrieval,3389,O
",",3389,O
reconsolidation,3389,O
and,3389,O
the,3389,O
accompanying,3389,O
changes,3389,O
of,3389,O
ERK,3389,B-GENE-N
and,3389,O
CREB,3389,B-GENE-N
activation,3389,O
in,3389,O
hippocampus,3389,O
and,3389,O
prefrontal,3389,O
cortex,3389,O
.,3389,O
Drugs,3390,O
of,3390,O
abuse,3390,O
modulated,3390,O
learning,3390,O
and,3390,O
memory,3390,O
in,3390,O
humans,3390,O
yet,3390,O
the,3390,O
underlying,3390,O
mechanism,3390,O
remained,3390,O
unclear,3390,O
.,3390,O
The,3391,O
extracellular,3391,B-GENE-N
signal-regulated,3391,I-GENE-N
kinase,3391,I-GENE-N
(,3391,O
ERK,3391,B-GENE-N
),3391,O
and,3391,O
the,3391,O
transcription,3391,O
factor,3391,O
cAMP,3391,B-CHEMICAL
response,3391,I-GENE-N
element-binding,3391,I-GENE-N
protein,3391,I-GENE-N
(,3391,O
CREB,3391,B-GENE-N
),3391,O
were,3391,O
involved,3391,O
in,3391,O
neuroplastic,3391,O
changes,3391,O
associated,3391,O
with,3391,O
learning,3391,O
and,3391,O
memory,3391,O
.,3391,O
In,3392,O
the,3392,O
current,3392,O
study,3392,O
",",3392,O
we,3392,O
used,3392,O
a,3392,O
Morris,3392,O
water,3392,O
maze,3392,O
to,3392,O
examine,3392,O
the,3392,O
effect,3392,O
of,3392,O
methamphetamine,3392,B-CHEMICAL
(,3392,O
METH,3392,B-CHEMICAL
),3392,O
on,3392,O
different,3392,O
processes,3392,O
of,3392,O
spatial,3392,O
memory,3392,O
in,3392,O
mice,3392,O
.,3392,O
We,3393,O
then,3393,O
investigated,3393,O
the,3393,O
status,3393,O
of,3393,O
ERK,3393,B-GENE-N
and,3393,O
CREB,3393,B-GENE-N
in,3393,O
the,3393,O
hippocampus,3393,O
and,3393,O
prefrontal,3393,O
cortex,3393,O
(,3393,O
PFC,3393,O
),3393,O
.,3393,O
We,3394,O
found,3394,O
that,3394,O
1.0,3394,O
mg/kg,3394,O
dose,3394,O
of,3394,O
METH,3394,B-CHEMICAL
facilitated,3394,O
spatial,3394,O
memory,3394,O
consolidation,3394,O
when,3394,O
it,3394,O
was,3394,O
injected,3394,O
immediately,3394,O
after,3394,O
the,3394,O
last,3394,O
learning,3394,O
trial,3394,O
.,3394,O
In,3395,O
contrast,3395,O
",",3395,O
the,3395,O
same,3395,O
dose,3395,O
of,3395,O
METH,3395,B-CHEMICAL
had,3395,O
no,3395,O
effect,3395,O
on,3395,O
spatial,3395,O
memory,3395,O
retrieval,3395,O
when,3395,O
it,3395,O
was,3395,O
injected,3395,O
30,3395,O
min,3395,O
before,3395,O
the,3395,O
test,3395,O
.,3395,O
Furthermore,3396,O
",",3396,O
1.0,3396,O
mg/kg,3396,O
dose,3396,O
of,3396,O
METH,3396,B-CHEMICAL
injected,3396,O
immediately,3396,O
after,3396,O
retrieval,3396,O
had,3396,O
no,3396,O
effect,3396,O
on,3396,O
spatial,3396,O
memory,3396,O
reconsolidation,3396,O
.,3396,O
Activation,3397,O
of,3397,O
both,3397,O
ERK,3397,B-GENE-N
and,3397,O
CREB,3397,B-GENE-N
in,3397,O
the,3397,O
hippocampus,3397,O
was,3397,O
found,3397,O
following,3397,O
memory,3397,O
consolidation,3397,O
but,3397,O
not,3397,O
after,3397,O
retrieval,3397,O
or,3397,O
reconsolidation,3397,O
in,3397,O
METH-treated,3397,B-CHEMICAL
mouse,3397,O
groups,3397,O
.,3397,O
In,3398,O
contrast,3398,O
",",3398,O
activation,3398,O
of,3398,O
both,3398,O
ERK,3398,B-GENE-N
and,3398,O
CREB,3398,B-GENE-N
in,3398,O
the,3398,O
PFC,3398,O
was,3398,O
found,3398,O
following,3398,O
memory,3398,O
retrieval,3398,O
but,3398,O
not,3398,O
other,3398,O
processes,3398,O
in,3398,O
METH-treated,3398,B-CHEMICAL
mouse,3398,O
groups,3398,O
.,3398,O
These,3399,O
results,3399,O
suggested,3399,O
that,3399,O
METH,3399,B-CHEMICAL
facilitated,3399,O
spatial,3399,O
memory,3399,O
consolidation,3399,O
but,3399,O
not,3399,O
retrieval,3399,O
or,3399,O
reconsolidation,3399,O
.,3399,O
Moreover,3400,O
",",3400,O
activation,3400,O
of,3400,O
the,3400,O
ERK,3400,B-GENE-N
and,3400,O
CREB,3400,B-GENE-N
signaling,3400,O
pathway,3400,O
in,3400,O
the,3400,O
hippocampus,3400,O
might,3400,O
be,3400,O
involved,3400,O
in,3400,O
METH-induced,3400,B-CHEMICAL
spatial,3400,O
memory,3400,O
changes,3400,O
.,3400,O
The,3401,O
impact,3401,O
of,3401,O
oxytocin,3401,B-CHEMICAL
administration,3401,O
and,3401,O
maternal,3401,O
love,3401,O
withdrawal,3401,O
on,3401,O
event-related,3401,O
potential,3401,O
(,3401,O
ERP,3401,O
),3401,O
responses,3401,O
to,3401,O
emotional,3401,O
faces,3401,O
with,3401,O
performance,3401,O
feedback,3401,O
.,3401,O
This,3402,O
is,3402,O
the,3402,O
first,3402,O
experimental,3402,O
study,3402,O
on,3402,O
the,3402,O
effect,3402,O
of,3402,O
oxytocin,3402,B-GENE-Y
administration,3402,O
on,3402,O
the,3402,O
neural,3402,O
processing,3402,O
of,3402,O
facial,3402,O
stimuli,3402,O
conducted,3402,O
with,3402,O
female,3402,O
participants,3402,O
that,3402,O
uses,3402,O
event-related,3402,O
potentials,3402,O
(,3402,O
ERPs,3402,O
),3402,O
.,3402,O
Using,3403,O
a,3403,O
double-blind,3403,O
",",3403,O
placebo-controlled,3403,O
within-subjects,3403,O
design,3403,O
",",3403,O
we,3403,O
studied,3403,O
the,3403,O
effects,3403,O
of,3403,O
16,3403,O
IU,3403,O
of,3403,O
intranasal,3403,O
oxytocin,3403,B-GENE-Y
on,3403,O
ERPs,3403,O
to,3403,O
pictures,3403,O
combining,3403,O
performance,3403,O
feedback,3403,O
with,3403,O
emotional,3403,O
facial,3403,O
expressions,3403,O
in,3403,O
48,3403,O
female,3403,O
undergraduate,3403,O
students,3403,O
.,3403,O
Participants,3404,O
also,3404,O
reported,3404,O
on,3404,O
the,3404,O
amount,3404,O
of,3404,O
love,3404,O
withdrawal,3404,O
they,3404,O
experienced,3404,O
from,3404,O
their,3404,O
mothers,3404,O
.,3404,O
Vertex,3405,O
positive,3405,O
potential,3405,O
(,3405,O
VPP,3405,O
),3405,O
and,3405,O
late,3405,O
positive,3405,O
potential,3405,O
(,3405,O
LPP,3405,O
),3405,O
amplitudes,3405,O
were,3405,O
more,3405,O
positive,3405,O
after,3405,O
oxytocin,3405,B-GENE-Y
compared,3405,O
to,3405,O
placebo,3405,O
administration,3405,O
.,3405,O
This,3406,O
suggests,3406,O
that,3406,O
oxytocin,3406,B-CHEMICAL
increased,3406,O
attention,3406,O
to,3406,O
the,3406,O
feedback,3406,O
stimuli,3406,O
(,3406,O
LPP,3406,O
),3406,O
and,3406,O
enhanced,3406,O
the,3406,O
processing,3406,O
of,3406,O
emotional,3406,O
faces,3406,O
(,3406,O
VPP,3406,O
),3406,O
.,3406,O
Oxytocin,3407,B-CHEMICAL
heightened,3407,O
processing,3407,O
of,3407,O
the,3407,O
happy,3407,O
and,3407,O
disgusted,3407,O
faces,3407,O
primarily,3407,O
for,3407,O
those,3407,O
reporting,3407,O
less,3407,O
love,3407,O
withdrawal,3407,O
.,3407,O
Significant,3408,O
associations,3408,O
with,3408,O
LPP,3408,O
amplitude,3408,O
suggest,3408,O
that,3408,O
more,3408,O
maternal,3408,O
love,3408,O
withdrawal,3408,O
relates,3408,O
to,3408,O
the,3408,O
allocation,3408,O
of,3408,O
attention,3408,O
toward,3408,O
the,3408,O
motivationally,3408,O
relevant,3408,O
combination,3408,O
of,3408,O
negative,3408,O
feedback,3408,O
with,3408,O
a,3408,O
disgusted,3408,O
face,3408,O
.,3408,O
Ras-dva,3409,B-GENE-Y
is,3409,O
a,3409,O
novel,3409,O
Pit-1-,3409,B-GENE-Y
and,3409,O
glucocorticoid-regulated,3409,O
gene,3409,O
in,3409,O
the,3409,O
embryonic,3409,O
anterior,3409,O
pituitary,3409,O
gland,3409,O
.,3409,O
Glucocorticoids,3410,O
play,3410,O
a,3410,O
role,3410,O
in,3410,O
functional,3410,O
differentiation,3410,O
of,3410,O
pituitary,3410,O
somatotrophs,3410,O
and,3410,O
lactotrophs,3410,O
during,3410,O
embryogenesis,3410,O
.,3410,O
Ras-dva,3411,B-GENE-Y
was,3411,O
identified,3411,O
as,3411,O
a,3411,O
gene,3411,O
regulated,3411,O
by,3411,O
anterior,3411,B-GENE-Y
neural,3411,I-GENE-Y
fold,3411,I-GENE-Y
protein-1/homeobox,3411,I-GENE-Y
expressed,3411,O
in,3411,O
embryonic,3411,O
stem,3411,O
cells-1,3411,O
",",3411,O
a,3411,O
transcription,3411,O
factor,3411,O
known,3411,O
to,3411,O
be,3411,O
critical,3411,O
in,3411,O
pituitary,3411,O
development,3411,O
",",3411,O
and,3411,O
has,3411,O
an,3411,O
expression,3411,O
profile,3411,O
in,3411,O
the,3411,O
chicken,3411,O
embryonic,3411,O
pituitary,3411,O
gland,3411,O
that,3411,O
is,3411,O
consistent,3411,O
with,3411,O
in,3411,O
vivo,3411,O
regulation,3411,O
by,3411,O
glucocorticoids,3411,O
.,3411,O
The,3412,O
objective,3412,O
of,3412,O
this,3412,O
study,3412,O
was,3412,O
to,3412,O
characterize,3412,O
expression,3412,O
and,3412,O
regulation,3412,O
of,3412,O
ras-dva,3412,B-GENE-Y
mRNA,3412,O
in,3412,O
the,3412,O
developing,3412,O
chicken,3412,O
anterior,3412,O
pituitary,3412,O
.,3412,O
Pituitary,3413,O
ras-dva,3413,B-GENE-Y
mRNA,3413,O
levels,3413,O
increased,3413,O
during,3413,O
embryogenesis,3413,O
to,3413,O
a,3413,O
maximum,3413,O
on,3413,O
embryonic,3413,O
day,3413,O
(,3413,O
e,3413,O
),3413,O
18,3413,O
and,3413,O
then,3413,O
decreased,3413,O
and,3413,O
remained,3413,O
low,3413,O
or,3413,O
undetectable,3413,O
after,3413,O
hatch,3413,O
.,3413,O
Ras-dva,3414,B-GENE-Y
expression,3414,O
was,3414,O
highly,3414,O
enriched,3414,O
in,3414,O
the,3414,O
pituitary,3414,O
gland,3414,O
on,3414,O
e18,3414,O
relative,3414,O
to,3414,O
other,3414,O
tissues,3414,O
examined,3414,O
.,3414,O
Glucocorticoid,3415,O
treatment,3415,O
of,3415,O
pituitary,3415,O
cells,3415,O
from,3415,O
mid-,3415,O
and,3415,O
late-stage,3415,O
embryos,3415,O
rapidly,3415,O
increased,3415,O
ras-dva,3415,B-GENE-Y
mRNA,3415,O
",",3415,O
suggesting,3415,O
it,3415,O
may,3415,O
be,3415,O
a,3415,O
direct,3415,O
transcriptional,3415,O
target,3415,O
of,3415,O
glucocorticoids,3415,O
.,3415,O
A,3416,O
reporter,3416,O
construct,3416,O
driven,3416,O
by,3416,O
4,3416,O
kb,3416,O
of,3416,O
the,3416,O
chicken,3416,B-GENE-Y
ras-dva,3416,I-GENE-Y
5'-flanking,3416,O
region,3416,O
",",3416,O
containing,3416,O
six,3416,O
putative,3416,O
pituitary-specific,3416,B-GENE-N
transcription,3416,I-GENE-N
factor-1,3416,I-GENE-N
(,3416,I-GENE-N
Pit-1,3416,I-GENE-N
),3416,I-GENE-N
binding,3416,I-GENE-N
sites,3416,I-GENE-N
and,3416,O
two,3416,O
potential,3416,O
glucocorticoid,3416,B-GENE-N
receptor,3416,I-GENE-N
(,3416,I-GENE-N
GR,3416,I-GENE-N
),3416,I-GENE-N
binding,3416,I-GENE-N
sites,3416,I-GENE-N
",",3416,O
was,3416,O
highly,3416,O
activated,3416,O
in,3416,O
embryonic,3416,O
pituitary,3416,O
cells,3416,O
and,3416,O
up-regulated,3416,O
by,3416,O
corticosterone,3416,B-CHEMICAL
.,3416,O
Mutagenesis,3417,O
of,3417,O
the,3417,O
most,3417,O
proximal,3417,O
Pit-1,3417,B-GENE-N
site,3417,I-GENE-N
decreased,3417,O
promoter,3417,O
activity,3417,O
in,3417,O
chicken,3417,O
e11,3417,O
pituitary,3417,O
cells,3417,O
",",3417,O
indicating,3417,O
regulation,3417,O
of,3417,O
ras-dva,3417,B-GENE-Y
by,3417,O
Pit-1,3417,B-GENE-Y
.,3417,O
However,3418,O
",",3418,O
mutating,3418,O
putative,3418,O
GR,3418,B-GENE-N
binding,3418,I-GENE-N
sites,3418,I-GENE-N
did,3418,O
not,3418,O
substantially,3418,O
reduce,3418,O
induction,3418,O
of,3418,O
ras-dva,3418,B-GENE-N
promoter,3418,I-GENE-N
activity,3418,O
by,3418,O
corticosterone,3418,B-CHEMICAL
",",3418,O
suggesting,3418,O
additional,3418,O
DNA,3418,B-GENE-N
elements,3418,I-GENE-N
within,3418,O
the,3418,O
5'-flanking,3418,O
region,3418,O
are,3418,O
responsible,3418,O
for,3418,O
glucocorticoid,3418,O
regulation,3418,O
.,3418,O
We,3419,O
have,3419,O
identified,3419,O
ras-dva,3419,B-GENE-Y
as,3419,O
a,3419,O
glucocorticoid-regulated,3419,O
gene,3419,O
that,3419,O
is,3419,O
likely,3419,O
expressed,3419,O
in,3419,O
cells,3419,O
of,3419,O
the,3419,O
Pit-1,3419,B-GENE-Y
lineage,3419,O
within,3419,O
the,3419,O
developing,3419,O
anterior,3419,O
pituitary,3419,O
gland,3419,O
.,3419,O
Differential,3420,O
modulation,3420,O
of,3420,O
retinal,3420,O
ganglion,3420,O
cell,3420,O
light,3420,O
responses,3420,O
by,3420,O
orthosteric,3420,O
and,3420,O
allosteric,3420,O
metabotropic,3420,B-GENE-Y
glutamate,3420,B-CHEMICAL
receptor,3420,I-GENE-Y
8,3420,I-GENE-Y
compounds,3420,O
.,3420,O
To,3421,O
investigate,3421,O
the,3421,O
role,3421,O
of,3421,O
mGluR8,3421,B-GENE-Y
in,3421,O
modulating,3421,O
the,3421,O
synaptic,3421,O
responses,3421,O
of,3421,O
retinal,3421,O
ganglion,3421,O
cells,3421,O
",",3421,O
we,3421,O
used,3421,O
a,3421,O
recently,3421,O
identified,3421,O
positive,3421,O
allosteric,3421,O
modulator,3421,O
of,3421,O
mGluR8,3421,B-GENE-Y
",",3421,O
AZ12216052,3421,B-CHEMICAL
(,3421,O
AZ,3421,O
),3421,O
and,3421,O
the,3421,O
mGluR8-specific,3421,B-GENE-Y
orthosteric,3421,O
agonist,3421,O
(,3421,B-CHEMICAL
S,3421,I-CHEMICAL
),3421,I-CHEMICAL
"-3,4-dicarboxyphenylglycine",3421,I-CHEMICAL
(,3421,O
DCPG,3421,B-CHEMICAL
),3421,O
.,3421,O
These,3422,O
agents,3422,O
were,3422,O
applied,3422,O
to,3422,O
whole-cell,3422,O
voltage-clamped,3422,O
ganglion,3422,O
cells,3422,O
from,3422,O
an,3422,O
isolated,3422,O
",",3422,O
superfused,3422,O
mouse,3422,O
retina,3422,O
preparation,3422,O
.,3422,O
DCPG,3423,B-CHEMICAL
reduced,3423,O
OFF-ganglion,3423,O
cell,3423,O
excitatory,3423,O
currents,3423,O
",",3423,O
whereas,3423,O
AZ,3423,O
enhanced,3423,O
the,3423,O
peak,3423,O
excitatory,3423,O
currents,3423,O
in,3423,O
ON-,3423,O
",",3423,O
OFF-,3423,O
",",3423,O
and,3423,O
ON-OFF-ganglion,3423,O
cells,3423,O
.,3423,O
The,3424,O
effects,3424,O
on,3424,O
ganglion,3424,O
cell,3424,O
inhibitory,3424,O
currents,3424,O
were,3424,O
more,3424,O
varied,3424,O
.,3424,O
The,3425,O
effects,3425,O
of,3425,O
the,3425,O
allosteric,3425,O
modulator,3425,O
were,3425,O
stronger,3425,O
for,3425,O
bright,3425,O
stimuli,3425,O
than,3425,O
for,3425,O
dim,3425,O
stimuli,3425,O
",",3425,O
consistent,3425,O
with,3425,O
receptor,3425,O
stimulation,3425,O
by,3425,O
endogenous,3425,O
glutamate,3425,B-CHEMICAL
being,3425,O
stronger,3425,O
during,3425,O
bright,3425,O
light,3425,O
stimulation,3425,O
and,3425,O
with,3425,O
mGluR8,3425,B-GENE-Y
receptors,3425,O
mainly,3425,O
being,3425,O
localized,3425,O
away,3425,O
from,3425,O
glutamate,3425,B-CHEMICAL
release,3425,O
sites,3425,O
",",3425,O
immuno-labeled,3425,O
with,3425,O
VGLUT1,3425,B-GENE-Y
.,3425,O
The,3426,O
differential,3426,O
sensitivity,3426,O
of,3426,O
ganglion,3426,O
cell,3426,O
light,3426,O
responses,3426,O
to,3426,O
DCPG,3426,B-CHEMICAL
and,3426,O
AZ,3426,O
supports,3426,O
multiple,3426,O
sites,3426,O
where,3426,O
mGluR8,3426,B-GENE-Y
modulates,3426,O
the,3426,O
light,3426,O
responses,3426,O
of,3426,O
ganglion,3426,O
cells,3426,O
.,3426,O
UCCB01-125,3427,B-CHEMICAL
",",3427,O
a,3427,O
dimeric,3427,O
inhibitor,3427,O
of,3427,O
PSD-95,3427,O
",",3427,O
reduces,3427,O
inflammatory,3427,O
pain,3427,O
without,3427,O
disrupting,3427,O
cognitive,3427,O
or,3427,O
motor,3427,O
performance,3427,O
:,3427,O
comparison,3427,O
with,3427,O
the,3427,O
NMDA,3427,B-GENE-N
receptor,3427,I-GENE-N
antagonist,3427,O
MK-801,3427,B-CHEMICAL
.,3427,O
Excessive,3428,O
N-Methyl-d-aspartate,3428,B-CHEMICAL
receptor,3428,I-GENE-N
(,3428,O
NMDAR,3428,B-GENE-N
),3428,O
-dependent,3428,O
production,3428,O
of,3428,O
nitric,3428,B-CHEMICAL
oxide,3428,I-CHEMICAL
(,3428,O
NO,3428,B-CHEMICAL
),3428,O
is,3428,O
involved,3428,O
in,3428,O
the,3428,O
development,3428,O
and,3428,O
maintenance,3428,O
of,3428,O
chronic,3428,O
pain,3428,O
states,3428,O
",",3428,O
and,3428,O
is,3428,O
mediated,3428,O
by,3428,O
postsynaptic,3428,B-GENE-Y
density,3428,I-GENE-Y
protein-95,3428,I-GENE-Y
(,3428,O
PSD-95,3428,B-GENE-Y
),3428,O
.,3428,O
By,3429,O
binding,3429,O
to,3429,O
both,3429,O
the,3429,O
NMDAR,3429,B-GENE-N
and,3429,O
neuronal,3429,B-GENE-Y
NO,3429,B-CHEMICAL
synthase,3429,I-GENE-Y
(,3429,O
nNOS,3429,B-GENE-Y
),3429,O
",",3429,O
PSD-95,3429,B-GENE-Y
mediates,3429,O
a,3429,O
specific,3429,O
coupling,3429,O
between,3429,O
NMDAR,3429,B-GENE-N
activation,3429,O
and,3429,O
NO,3429,B-CHEMICAL
production,3429,O
.,3429,O
NMDAR,3430,B-GENE-N
antagonism,3430,O
shows,3430,O
anti-nociceptive,3430,O
action,3430,O
in,3430,O
humans,3430,O
and,3430,O
animal,3430,O
models,3430,O
of,3430,O
chronic,3430,O
pain,3430,O
but,3430,O
is,3430,O
associated,3430,O
with,3430,O
severe,3430,O
disturbances,3430,O
of,3430,O
cognitive,3430,O
and,3430,O
motor,3430,O
functions,3430,O
.,3430,O
An,3431,O
alternative,3431,O
approach,3431,O
to,3431,O
modulate,3431,O
the,3431,O
NMDAR-related,3431,B-GENE-N
activity,3431,O
is,3431,O
to,3431,O
perturb,3431,O
the,3431,O
NMDAR/PSD-95/nNOS,3431,B-GENE-N
complex,3431,O
by,3431,O
targeting,3431,O
PSD-95,3431,B-GENE-N
",",3431,O
thereby,3431,O
decreasing,3431,O
NO,3431,B-CHEMICAL
production,3431,O
without,3431,O
interfering,3431,O
with,3431,O
the,3431,O
NMDAR,3431,B-GENE-N
ion,3431,B-GENE-N
channel,3431,I-GENE-N
function,3431,O
.,3431,O
Here,3432,O
",",3432,O
we,3432,O
compared,3432,O
the,3432,O
effects,3432,O
of,3432,O
a,3432,O
dimeric,3432,O
PSD-95,3432,B-GENE-Y
inhibitor,3432,O
",",3432,O
UCCB01-125,3432,B-CHEMICAL
",",3432,O
and,3432,O
the,3432,O
NMDAR,3432,B-GENE-N
antagonist,3432,O
",",3432,O
MK-801,3432,B-CHEMICAL
",",3432,O
on,3432,O
mechanical,3432,O
hypersensitivity,3432,O
in,3432,O
the,3432,O
complete,3432,O
Freund,3432,O
's,3432,O
adjuvant,3432,O
(,3432,O
CFA,3432,O
),3432,O
model,3432,O
of,3432,O
inflammatory,3432,O
pain,3432,O
.,3432,O
To,3433,O
examine,3433,O
side-effect,3433,O
profiles,3433,O
we,3433,O
also,3433,O
compared,3433,O
the,3433,O
effects,3433,O
of,3433,O
UCCB01-125,3433,B-CHEMICAL
and,3433,O
MK-801,3433,B-CHEMICAL
in,3433,O
tests,3433,O
of,3433,O
attention,3433,O
",",3433,O
long-term,3433,O
memory,3433,O
",",3433,O
and,3433,O
motor,3433,O
performance,3433,O
.,3433,O
When,3434,O
administered,3434,O
concurrently,3434,O
with,3434,O
CFA,3434,O
",",3434,O
both,3434,O
MK-801,3434,B-CHEMICAL
and,3434,O
UCCB01-125,3434,B-CHEMICAL
prevented,3434,O
the,3434,O
development,3434,O
of,3434,O
CFA-induced,3434,O
mechanical,3434,O
hypersensitivity,3434,O
1,3434,O
and,3434,O
24,3434,O
h,3434,O
after,3434,O
treatment,3434,O
.,3434,O
Moreover,3435,O
",",3435,O
UCCB01-125,3435,B-CHEMICAL
was,3435,O
found,3435,O
to,3435,O
reverse,3435,O
CFA-induced,3435,O
hypersensitivity,3435,O
when,3435,O
administered,3435,O
24,3435,O
h,3435,O
after,3435,O
CFA,3435,O
treatment,3435,O
",",3435,O
an,3435,O
effect,3435,O
lasting,3435,O
for,3435,O
at,3435,O
least,3435,O
3,3435,O
days,3435,O
.,3435,O
At,3436,O
the,3436,O
dose,3436,O
reducing,3436,O
hypersensitivity,3436,O
",",3436,O
MK-801,3436,B-CHEMICAL
disrupted,3436,O
attention,3436,O
",",3436,O
long-term,3436,O
memory,3436,O
",",3436,O
and,3436,O
motor,3436,O
performance,3436,O
.,3436,O
By,3437,O
contrast,3437,O
",",3437,O
even,3437,O
high,3437,O
doses,3437,O
of,3437,O
UCCB01-125,3437,B-CHEMICAL
were,3437,O
devoid,3437,O
of,3437,O
side-effects,3437,O
in,3437,O
these,3437,O
tests,3437,O
.,3437,O
The,3438,O
data,3438,O
suggest,3438,O
that,3438,O
PSD-95,3438,B-GENE-Y
inhibition,3438,O
is,3438,O
a,3438,O
feasible,3438,O
strategy,3438,O
to,3438,O
prevent,3438,O
both,3438,O
development,3438,O
and,3438,O
maintenance,3438,O
of,3438,O
chronic,3438,O
inflammatory,3438,O
pain,3438,O
",",3438,O
while,3438,O
avoiding,3438,O
NMDAR,3438,B-GENE-N
antagonism-related,3438,O
side-effects,3438,O
.,3438,O
Conformational,3439,O
landscape,3439,O
of,3439,O
diisopropyl,3439,B-CHEMICAL
ketone,3439,I-CHEMICAL
:,3439,O
quantum,3439,O
chemical,3439,O
calculations,3439,O
validated,3439,O
by,3439,O
microwave,3439,O
spectroscopy,3439,O
.,3439,O
We,3440,O
report,3440,O
on,3440,O
the,3440,O
gas-phase,3440,O
structure,3440,O
of,3440,O
the,3440,O
most,3440,O
abundant,3440,O
conformer,3440,O
of,3440,O
diisopropyl,3440,B-CHEMICAL
ketone,3440,I-CHEMICAL
",",3440,O
(,3440,B-CHEMICAL
CH,3440,I-CHEMICAL
(,3440,I-CHEMICAL
3,3440,I-CHEMICAL
),3440,I-CHEMICAL
),3440,I-CHEMICAL
(,3440,I-CHEMICAL
2,3440,I-CHEMICAL
),3440,I-CHEMICAL
HC-CO-CH,3440,I-CHEMICAL
(,3440,I-CHEMICAL
CH,3440,I-CHEMICAL
(,3440,I-CHEMICAL
3,3440,I-CHEMICAL
),3440,I-CHEMICAL
),3440,I-CHEMICAL
(,3440,I-CHEMICAL
2,3440,I-CHEMICAL
),3440,I-CHEMICAL
",",3440,O
as,3440,O
observed,3440,O
by,3440,O
molecular,3440,O
beam,3440,O
Fourier,3440,O
transform,3440,O
microwave,3440,O
spectroscopy,3440,O
.,3440,O
The,3441,O
gas-phase,3441,O
structures,3441,O
of,3441,O
five,3441,O
conformers,3441,O
of,3441,O
diisopropyl,3441,B-CHEMICAL
ketone,3441,I-CHEMICAL
were,3441,O
optimized,3441,O
using,3441,O
ab,3441,O
initio,3441,O
calculations,3441,O
at,3441,O
the,3441,O
MP2/6-311++G,3441,O
(,3441,O
d,3441,O
",",3441,O
p,3441,O
),3441,O
level,3441,O
of,3441,O
theory,3441,O
.,3441,O
The,3442,O
natures,3442,O
of,3442,O
the,3442,O
stationary,3442,O
points,3442,O
were,3442,O
verified,3442,O
using,3442,O
harmonic,3442,O
frequency,3442,O
calculations,3442,O
.,3442,O
The,3443,O
only,3443,O
conformer,3443,O
observed,3443,O
in,3443,O
the,3443,O
supersonic,3443,O
jet,3443,O
possesses,3443,O
C,3443,O
(,3443,O
2,3443,O
),3443,O
symmetry,3443,O
and,3443,O
appears,3443,O
as,3443,O
an,3443,O
enantiomeric,3443,O
pair,3443,O
.,3443,O
From,3444,O
the,3444,O
microwave,3444,O
spectrum,3444,O
",",3444,O
a,3444,O
set,3444,O
of,3444,O
three,3444,O
highly,3444,O
accurate,3444,O
rotational,3444,O
constants,3444,O
",",3444,O
five,3444,O
centrifugal,3444,O
distortion,3444,O
constants,3444,O
",",3444,O
and,3444,O
three,3444,O
sextic,3444,O
centrifugal,3444,O
distortion,3444,O
constants,3444,O
were,3444,O
determined,3444,O
.,3444,O
The,3445,O
structure,3445,O
of,3445,O
the,3445,O
observed,3445,O
conformer,3445,O
was,3445,O
optimized,3445,O
again,3445,O
at,3445,O
different,3445,O
levels,3445,O
of,3445,O
theory,3445,O
using,3445,O
the,3445,O
HF,3445,O
",",3445,O
MP2,3445,O
",",3445,O
and,3445,O
B3LYP,3445,O
methods,3445,O
.,3445,O
The,3446,O
theoretical,3446,O
constants,3446,O
of,3446,O
the,3446,O
C,3446,O
(,3446,O
2,3446,O
),3446,O
conformer,3446,O
were,3446,O
subsequently,3446,O
validated,3446,O
using,3446,O
the,3446,O
experimental,3446,O
constants,3446,O
.,3446,O
To,3447,O
understand,3447,O
the,3447,O
transitions,3447,O
of,3447,O
one,3447,O
conformer,3447,O
to,3447,O
the,3447,O
others,3447,O
",",3447,O
the,3447,O
isopropyl,3447,B-CHEMICAL
groups,3447,O
were,3447,O
rotated,3447,O
against,3447,O
each,3447,O
other,3447,O
.,3447,O
The,3448,O
resulting,3448,O
two-dimensional,3448,O
potential,3448,O
energy,3448,O
surface,3448,O
shows,3448,O
nicely,3448,O
the,3448,O
symmetry,3448,O
of,3448,O
the,3448,O
conformational,3448,O
landscape,3448,O
and,3448,O
also,3448,O
indicates,3448,O
the,3448,O
enantiomeric,3448,O
pairs,3448,O
of,3448,O
the,3448,O
conformers,3448,O
.,3448,O
The,3449,O
barriers,3449,O
to,3449,O
internal,3449,O
rotation,3449,O
of,3449,O
the,3449,O
methyl,3449,B-CHEMICAL
groups,3449,O
were,3449,O
determined,3449,O
to,3449,O
be,3449,O
1052,3449,O
and,3449,O
905,3449,O
cm,3449,O
(,3449,O
-1,3449,O
),3449,O
at,3449,O
the,3449,O
MP2/6-311++G,3449,O
(,3449,O
d,3449,O
",",3449,O
p,3449,O
),3449,O
and,3449,O
the,3449,O
B3LYP/6-311++G,3449,O
(,3449,O
d,3449,O
",",3449,O
p,3449,O
),3449,O
levels,3449,O
",",3449,O
respectively,3449,O
.,3449,O
In,3450,O
agreement,3450,O
with,3450,O
the,3450,O
theoretical,3450,O
predictions,3450,O
",",3450,O
no,3450,O
internal,3450,O
rotation,3450,O
patterns,3450,O
could,3450,O
be,3450,O
observed,3450,O
in,3450,O
the,3450,O
microwave,3450,O
spectrum,3450,O
.,3450,O
Control,3451,O
of,3451,O
hypercholesterolemia,3451,O
and,3451,O
atherosclerosis,3451,O
using,3451,O
the,3451,O
cholesterol,3451,B-CHEMICAL
recognition/interaction,3451,O
amino,3451,B-CHEMICAL
acid,3451,I-CHEMICAL
sequence,3451,O
of,3451,O
the,3451,O
translocator,3451,B-GENE-Y
protein,3451,I-GENE-Y
TSPO,3451,I-GENE-Y
.,3451,O
The,3452,O
translocator,3452,B-GENE-Y
protein,3452,I-GENE-Y
(,3452,I-GENE-Y
18-kDa,3452,I-GENE-Y
),3452,I-GENE-Y
TSPO,3452,I-GENE-Y
is,3452,O
an,3452,O
ubiquitous,3452,O
high,3452,O
affinity,3452,O
cholesterol-binding,3452,B-CHEMICAL
protein,3452,O
reported,3452,O
to,3452,O
be,3452,O
present,3452,O
in,3452,O
the,3452,O
endothelial,3452,O
and,3452,O
smooth,3452,O
muscle,3452,O
cells,3452,O
of,3452,O
the,3452,O
blood,3452,O
vessels,3452,O
;,3452,O
its,3452,O
expression,3452,O
dramatically,3452,O
increased,3452,O
in,3452,O
macrophages,3452,O
found,3452,O
in,3452,O
atherosclerotic,3452,O
plaques,3452,O
.,3452,O
A,3453,O
domain,3453,O
in,3453,O
the,3453,O
carboxy-terminus,3453,B-CHEMICAL
of,3453,O
TSPO,3453,B-GENE-Y
was,3453,O
identified,3453,O
and,3453,O
characterized,3453,O
as,3453,O
the,3453,O
cholesterol,3453,B-CHEMICAL
recognition/interaction,3453,O
amino,3453,B-CHEMICAL
acid,3453,I-CHEMICAL
consensus,3453,O
(,3453,O
CRAC,3453,O
),3453,O
.,3453,O
The,3454,O
ability,3454,O
of,3454,O
the,3454,O
CRAC,3454,O
domain,3454,O
to,3454,O
bind,3454,O
to,3454,O
cholesterol,3454,B-CHEMICAL
led,3454,O
us,3454,O
to,3454,O
hypothesize,3454,O
that,3454,O
this,3454,O
peptide,3454,O
could,3454,O
be,3454,O
used,3454,O
as,3454,O
an,3454,O
hypocholesterolemic,3454,O
",",3454,O
with,3454,O
potential,3454,O
anti-atherogenic,3454,O
properties,3454,O
",",3454,O
agent,3454,O
.,3454,O
We,3455,O
report,3455,O
herein,3455,O
the,3455,O
therapeutic,3455,O
benefit,3455,O
that,3455,O
resulted,3455,O
for,3455,O
the,3455,O
administration,3455,O
of,3455,O
the,3455,O
VLNYYVWR,3455,O
human,3455,O
CRAC,3455,O
sequence,3455,O
to,3455,O
guinea,3455,O
pigs,3455,O
fed,3455,O
with,3455,O
a,3455,O
high,3455,O
cholesterol,3455,B-CHEMICAL
diet,3455,O
and,3455,O
ApoE,3455,B-GENE-Y
knock-out,3455,O
B6.129P2-Apoetm1Unc/J,3455,O
mice,3455,O
.,3455,O
CRAC,3456,O
treatment,3456,O
(,3456,O
3,3456,O
and,3456,O
30mg/kg,3456,O
once,3456,O
daily,3456,O
for,3456,O
6,3456,O
weeks,3456,O
),3456,O
resulted,3456,O
in,3456,O
reduced,3456,O
circulating,3456,O
cholesterol,3456,B-CHEMICAL
levels,3456,O
in,3456,O
guinea,3456,O
pigs,3456,O
fed,3456,O
with,3456,O
2,3456,O
%,3456,O
high,3456,O
cholesterol,3456,B-CHEMICAL
diet,3456,O
and,3456,O
ApoE,3456,B-GENE-Y
knock-out,3456,O
B6.129P2-Apoetm1Unc/J,3456,O
mice,3456,O
.,3456,O
In,3457,O
high,3457,O
cholesterol,3457,B-CHEMICAL
fed,3457,O
guinea,3457,O
pigs,3457,O
",",3457,O
CRAC,3457,O
treatment,3457,O
administered,3457,O
once,3457,O
daily,3457,O
induced,3457,O
an,3457,O
increase,3457,O
in,3457,O
circulating,3457,O
HDL,3457,O
",",3457,O
decreased,3457,O
total,3457,O
",",3457,O
free,3457,O
and,3457,O
LDL,3457,O
cholesterol,3457,B-CHEMICAL
",",3457,O
and,3457,O
removed,3457,O
atheroma,3457,O
deposits,3457,O
in,3457,O
the,3457,O
aorta,3457,O
in,3457,O
a,3457,O
dose-dependent,3457,O
manner,3457,O
.,3457,O
The,3458,O
treatment,3458,O
also,3458,O
prevented,3458,O
the,3458,O
high,3458,O
cholesterol,3458,B-CHEMICAL
diet-induced,3458,O
increase,3458,O
in,3458,O
serum,3458,O
creatine,3458,B-CHEMICAL
kinase,3458,I-GENE-N
",",3458,O
total,3458,O
and,3458,O
isoforms,3458,O
",",3458,O
markers,3458,O
of,3458,O
neurological,3458,O
",",3458,O
cardiac,3458,O
and,3458,O
muscular,3458,O
damage,3458,O
.,3458,O
No,3459,O
toxicity,3459,O
was,3459,O
observed,3459,O
.,3459,O
Taken,3460,O
together,3460,O
these,3460,O
results,3460,O
support,3460,O
a,3460,O
role,3460,O
of,3460,O
TSPO,3460,B-GENE-Y
in,3460,O
lipid,3460,O
homeostasis,3460,O
and,3460,O
atherosclerosis,3460,O
and,3460,O
indicate,3460,O
that,3460,O
CRAC,3460,O
may,3460,O
constitute,3460,O
a,3460,O
novel,3460,O
and,3460,O
safe,3460,O
treatment,3460,O
of,3460,O
hypercholesterolemia,3460,O
and,3460,O
atherosclerosis,3460,O
.,3460,O
Effects,3461,O
of,3461,O
bidentate,3461,O
coordination,3461,O
on,3461,O
the,3461,O
molecular,3461,O
properties,3461,O
rapta-C,3461,B-CHEMICAL
based,3461,O
complex,3461,O
using,3461,O
theoretical,3461,O
approach,3461,O
.,3461,O
In,3462,O
this,3462,O
work,3462,O
several,3462,O
quantum,3462,O
properties,3462,O
including,3462,O
the,3462,O
NEDA,3462,O
and,3462,O
QTAIM,3462,O
are,3462,O
computed,3462,O
on,3462,O
three,3462,O
models,3462,O
of,3462,O
rapta-C,3462,B-CHEMICAL
complexes,3462,O
using,3462,O
DFT,3462,O
with,3462,O
hybrid,3462,O
functional,3462,O
and,3462,O
basis,3462,O
set,3462,O
with,3462,O
ECP,3462,O
and,3462,O
without,3462,O
ECP,3462,O
.,3462,O
Several,3463,O
interesting,3463,O
correlations,3463,O
within,3463,O
the,3463,O
observed,3463,O
properties,3463,O
and,3463,O
also,3463,O
with,3463,O
the,3463,O
reported,3463,O
experimental,3463,O
behaviors,3463,O
of,3463,O
these,3463,O
complexes,3463,O
including,3463,O
their,3463,O
biological,3463,O
activities,3463,O
are,3463,O
presented,3463,O
.,3463,O
The,3464,O
study,3464,O
shows,3464,O
that,3464,O
the,3464,O
stability,3464,O
of,3464,O
the,3464,O
two,3464,O
complexes,3464,O
with,3464,O
bidentate,3464,O
ligands,3464,O
is,3464,O
associated,3464,O
with,3464,O
their,3464,O
high,3464,O
hydrogen,3464,B-CHEMICAL
bonding,3464,O
stability,3464,O
and,3464,O
existence,3464,O
of,3464,O
stronger,3464,O
non-covalent,3464,O
metal-ligand,3464,O
bonds,3464,O
.,3464,O
The,3465,O
energy,3465,O
decomposition,3465,O
analysis,3465,O
indicated,3465,O
that,3465,O
inter-atomic,3465,O
interactions,3465,O
in,3465,O
the,3465,O
three,3465,O
forms,3465,O
of,3465,O
rapta-C,3465,B-CHEMICAL
complexes,3465,O
and,3465,O
their,3465,O
stability,3465,O
are,3465,O
governed,3465,O
by,3465,O
the,3465,O
charge,3465,O
transfer,3465,O
term,3465,O
with,3465,O
significant,3465,O
contributions,3465,O
from,3465,O
polarization,3465,O
and,3465,O
electrostatic,3465,O
terms,3465,O
.,3465,O
The,3466,O
higher,3466,O
stability,3466,O
of,3466,O
complex,3466,O
1,3466,O
and,3466,O
2,3466,O
over,3466,O
3,3466,O
comes,3466,O
from,3466,O
the,3466,O
lower,3466,O
exchange,3466,O
repulsion,3466,O
and,3466,O
higher,3466,O
polarization,3466,O
contributions,3466,O
to,3466,O
their,3466,O
stability,3466,O
which,3466,O
agrees,3466,O
perfectly,3466,O
with,3466,O
the,3466,O
experimental,3466,O
observation,3466,O
.,3466,O
Our,3467,O
results,3467,O
provide,3467,O
insight,3467,O
into,3467,O
the,3467,O
nature,3467,O
of,3467,O
intramolecular,3467,O
forces,3467,O
that,3467,O
influence,3467,O
the,3467,O
structural,3467,O
stability,3467,O
of,3467,O
the,3467,O
three,3467,O
complexes,3467,O
.,3467,O
Transcriptional,3468,B-GENE-Y
regulatory,3468,I-GENE-Y
factor,3468,I-GENE-Y
X6,3468,I-GENE-Y
(,3468,O
Rfx6,3468,B-GENE-Y
),3468,O
increases,3468,O
gastric,3468,B-GENE-Y
inhibitory,3468,I-GENE-Y
polypeptide,3468,I-GENE-Y
(,3468,O
GIP,3468,B-GENE-Y
),3468,O
expression,3468,O
in,3468,O
enteroendocrine,3468,O
K-cells,3468,O
and,3468,O
is,3468,O
involved,3468,O
in,3468,O
GIP,3468,B-GENE-Y
hypersecretion,3468,O
in,3468,O
high,3468,O
fat,3468,O
diet-induced,3468,O
obesity,3468,O
.,3468,O
Gastric,3469,B-GENE-Y
inhibitory,3469,I-GENE-Y
polypeptide,3469,I-GENE-Y
(,3469,O
GIP,3469,B-GENE-Y
),3469,O
is,3469,O
an,3469,O
incretin,3469,B-GENE-Y
released,3469,O
from,3469,O
enteroendocrine,3469,O
K-cells,3469,O
in,3469,O
response,3469,O
to,3469,O
nutrient,3469,O
ingestion,3469,O
.,3469,O
GIP,3470,B-GENE-Y
potentiates,3470,O
glucose-stimulated,3470,B-CHEMICAL
insulin,3470,B-GENE-Y
secretion,3470,O
and,3470,O
induces,3470,O
energy,3470,O
accumulation,3470,O
into,3470,O
adipose,3470,O
tissue,3470,O
",",3470,O
resulting,3470,O
in,3470,O
obesity,3470,O
.,3470,O
Plasma,3471,O
GIP,3471,B-GENE-Y
levels,3471,O
are,3471,O
reported,3471,O
to,3471,O
be,3471,O
increased,3471,O
in,3471,O
the,3471,O
obese,3471,O
state,3471,O
.,3471,O
However,3472,O
",",3472,O
the,3472,O
molecular,3472,O
mechanisms,3472,O
of,3472,O
GIP,3472,B-GENE-Y
secretion,3472,O
and,3472,O
high,3472,O
fat,3472,O
diet,3472,O
(,3472,O
HFD,3472,O
),3472,O
-induced,3472,O
GIP,3472,B-GENE-Y
hypersecretion,3472,O
remain,3472,O
unclear,3472,O
",",3472,O
primarily,3472,O
due,3472,O
to,3472,O
difficulties,3472,O
in,3472,O
separating,3472,O
K-cells,3472,O
from,3472,O
other,3472,O
intestinal,3472,O
epithelial,3472,O
cells,3472,O
in,3472,O
vivo,3472,O
.,3472,O
In,3473,O
this,3473,O
study,3473,O
",",3473,O
GIP-GFP,3473,B-GENE-Y
knock-in,3473,O
mice,3473,O
that,3473,O
enable,3473,O
us,3473,O
to,3473,O
visualize,3473,O
K-cells,3473,O
by,3473,O
enhanced,3473,O
GFP,3473,B-GENE-Y
were,3473,O
established,3473,O
.,3473,O
Microarray,3474,O
analysis,3474,O
of,3474,O
isolated,3474,O
K-cells,3474,O
from,3474,O
these,3474,O
mice,3474,O
revealed,3474,O
that,3474,O
transcriptional,3474,B-GENE-Y
regulatory,3474,I-GENE-Y
factor,3474,I-GENE-Y
X6,3474,I-GENE-Y
(,3474,O
Rfx6,3474,B-GENE-Y
),3474,O
is,3474,O
expressed,3474,O
exclusively,3474,O
in,3474,O
K-cells,3474,O
.,3474,O
In,3475,O
vitro,3475,O
experiments,3475,O
using,3475,O
the,3475,O
mouse,3475,O
intestinal,3475,O
cell,3475,O
line,3475,O
STC-1,3475,O
showed,3475,O
that,3475,O
knockdown,3475,O
of,3475,O
Rfx6,3475,B-GENE-Y
decreased,3475,O
mRNA,3475,O
expression,3475,O
",",3475,O
cellular,3475,O
content,3475,O
",",3475,O
and,3475,O
secretion,3475,O
of,3475,O
GIP,3475,B-GENE-Y
.,3475,O
Rfx6,3476,B-GENE-Y
bound,3476,O
to,3476,O
the,3476,O
region,3476,O
in,3476,O
the,3476,O
gip,3476,B-GENE-N
promoter,3476,I-GENE-N
that,3476,O
regulates,3476,O
gip,3476,B-GENE-N
promoter,3476,I-GENE-N
activity,3476,O
",",3476,O
and,3476,O
overexpression,3476,O
of,3476,O
Rfx6,3476,B-GENE-Y
increased,3476,O
GIP,3476,B-GENE-Y
mRNA,3476,O
expression,3476,O
.,3476,O
HFD,3477,O
induced,3477,O
obesity,3477,O
and,3477,O
GIP,3477,B-GENE-Y
hypersecretion,3477,O
in,3477,O
GIP-GFP,3477,B-GENE-Y
heterozygous,3477,O
mice,3477,O
in,3477,O
vivo,3477,O
.,3477,O
Immunohistochemical,3478,O
and,3478,O
flow,3478,O
cytometry,3478,O
analysis,3478,O
showed,3478,O
no,3478,O
significant,3478,O
difference,3478,O
in,3478,O
K-cell,3478,O
number,3478,O
between,3478,O
control,3478,O
fat,3478,O
diet-fed,3478,O
(,3478,O
CFD,3478,O
),3478,O
and,3478,O
HFD-fed,3478,O
mice,3478,O
.,3478,O
However,3479,O
",",3479,O
GIP,3479,B-GENE-Y
content,3479,O
in,3479,O
the,3479,O
upper,3479,O
small,3479,O
intestine,3479,O
and,3479,O
GIP,3479,B-GENE-Y
mRNA,3479,O
expression,3479,O
in,3479,O
K-cells,3479,O
were,3479,O
significantly,3479,O
increased,3479,O
in,3479,O
HFD-fed,3479,O
mice,3479,O
compared,3479,O
with,3479,O
those,3479,O
in,3479,O
CFD-fed,3479,O
mice,3479,O
.,3479,O
Furthermore,3480,O
",",3480,O
expression,3480,O
levels,3480,O
of,3480,O
Rfx6,3480,B-GENE-Y
mRNA,3480,O
were,3480,O
increased,3480,O
in,3480,O
K-cells,3480,O
of,3480,O
HFD-fed,3480,O
mice,3480,O
.,3480,O
These,3481,O
results,3481,O
suggest,3481,O
that,3481,O
Rfx6,3481,B-GENE-Y
increases,3481,O
GIP,3481,B-GENE-Y
expression,3481,O
and,3481,O
content,3481,O
in,3481,O
K-cells,3481,O
and,3481,O
is,3481,O
involved,3481,O
in,3481,O
GIP,3481,B-GENE-Y
hypersecretion,3481,O
in,3481,O
HFD-induced,3481,O
obesity,3481,O
.,3481,O
Diet,3482,O
",",3482,O
physical,3482,O
exercise,3482,O
and,3482,O
Orlistat,3482,B-CHEMICAL
administration,3482,O
increase,3482,O
serum,3482,O
Anti-Mllerian,3482,B-GENE-Y
Hormone,3482,I-GENE-Y
(,3482,O
AMH,3482,B-GENE-Y
),3482,O
levels,3482,O
in,3482,O
women,3482,O
with,3482,O
polycystic,3482,O
ovary,3482,O
syndrome,3482,O
(,3482,O
PCOS,3482,O
),3482,O
.,3482,O
The,3483,O
present,3483,O
study,3483,O
investigates,3483,O
the,3483,O
combined,3483,O
effect,3483,O
of,3483,O
diet,3483,O
",",3483,O
physical,3483,O
exercise,3483,O
and,3483,O
Orlistat,3483,B-CHEMICAL
for,3483,O
24,3483,O
weeks,3483,O
",",3483,O
on,3483,O
serum,3483,O
Anti-Mllerian,3483,B-GENE-Y
Hormone,3483,O
(,3483,O
AMH,3483,B-GENE-Y
),3483,O
levels,3483,O
in,3483,O
overweight,3483,O
and,3483,O
obese,3483,O
women,3483,O
with,3483,O
polycystic,3483,O
ovary,3483,O
syndrome,3483,O
(,3483,O
PCOS,3483,O
),3483,O
and,3483,O
in,3483,O
overweight,3483,O
and,3483,O
obese,3483,O
controls,3483,O
.,3483,O
Sixty-one,3484,O
(,3484,O
61,3484,O
),3484,O
selected,3484,O
women,3484,O
with,3484,O
PCOS,3484,O
and,3484,O
20,3484,O
overweight,3484,O
and,3484,O
obese,3484,O
controls,3484,O
followed,3484,O
an,3484,O
energy-restricted,3484,O
diet,3484,O
",",3484,O
physical,3484,O
exercise,3484,O
plus,3484,O
Orlistat,3484,B-CHEMICAL
administration,3484,O
(,3484,O
120,3484,O
mg,3484,O
",",3484,O
3,3484,O
times,3484,O
per,3484,O
day,3484,O
),3484,O
for,3484,O
24,3484,O
weeks,3484,O
.,3484,O
At,3485,O
baseline,3485,O
",",3485,O
week,3485,O
12,3485,O
and,3485,O
week,3485,O
24,3485,O
",",3485,O
serum,3485,O
levels,3485,O
of,3485,O
AMH,3485,B-GENE-Y
",",3485,O
FSH,3485,B-GENE-N
",",3485,O
LH,3485,B-GENE-N
",",3485,O
PRL,3485,B-GENE-Y
",",3485,O
androgens,3485,B-CHEMICAL
",",3485,O
sex,3485,B-GENE-Y
hormone-binding,3485,I-GENE-Y
globulin,3485,I-GENE-Y
(,3485,O
SHBG,3485,B-GENE-Y
),3485,O
",",3485,O
glucose,3485,B-CHEMICAL
",",3485,O
and,3485,O
insulin,3485,B-GENE-Y
were,3485,O
measured,3485,O
and,3485,O
Free,3485,O
Androgen,3485,B-CHEMICAL
Index,3485,O
(,3485,O
FAI,3485,O
),3485,O
and,3485,O
Insulin,3485,B-GENE-Y
Resistance,3485,O
(,3485,O
IR,3485,O
),3485,O
indices,3485,O
were,3485,O
calculated,3485,O
.,3485,O
In,3486,O
PCOS,3486,O
women,3486,O
",",3486,O
serum,3486,O
AMH,3486,B-GENE-Y
levels,3486,O
increased,3486,O
after,3486,O
12,3486,O
and,3486,O
24,3486,O
weeks,3486,O
of,3486,O
treatment,3486,O
.,3486,O
After,3487,O
12,3487,O
weeks,3487,O
LH,3487,B-GENE-N
and,3487,O
SHBG,3487,B-GENE-Y
were,3487,O
increased,3487,O
",",3487,O
while,3487,O
Testosterone,3487,B-CHEMICAL
decreased,3487,O
.,3487,O
After,3488,O
12,3488,O
and,3488,O
24,3488,O
weeks,3488,O
",",3488,O
FAI,3488,O
was,3488,O
decreased,3488,O
and,3488,O
all,3488,O
indices,3488,O
of,3488,O
IR,3488,O
were,3488,O
significantly,3488,O
improved,3488,O
.,3488,O
We,3489,O
concluded,3489,O
that,3489,O
in,3489,O
overweight,3489,O
and,3489,O
obese,3489,O
women,3489,O
with,3489,O
PCOS,3489,O
Orlistat,3489,B-CHEMICAL
administration,3489,O
",",3489,O
combined,3489,O
with,3489,O
diet,3489,O
and,3489,O
physical,3489,O
exercise,3489,O
",",3489,O
for,3489,O
24,3489,O
weeks,3489,O
",",3489,O
resulted,3489,O
in,3489,O
significant,3489,O
weight,3489,O
loss,3489,O
",",3489,O
improvement,3489,O
of,3489,O
hyperandrogenism,3489,O
and,3489,O
insulin,3489,B-GENE-Y
sensitivity,3489,O
",",3489,O
and,3489,O
increased,3489,O
serum,3489,O
AMH,3489,B-GENE-Y
levels,3489,O
.,3489,O
Phenolic,3490,O
profiles,3490,O
and,3490,O
antioxidant,3490,O
activity,3490,O
of,3490,O
litchi,3490,O
pulp,3490,O
of,3490,O
different,3490,O
cultivars,3490,O
cultivated,3490,O
in,3490,O
Southern,3490,O
China,3490,O
.,3490,O
The,3491,O
phenolic,3491,O
profiles,3491,O
and,3491,O
antioxidant,3491,O
activity,3491,O
of,3491,O
litchi,3491,O
pulp,3491,O
of,3491,O
13,3491,O
varieties,3491,O
were,3491,O
investigated,3491,O
.,3491,O
The,3492,O
free,3492,O
",",3492,O
bound,3492,O
and,3492,O
total,3492,O
phenolic,3492,O
contents,3492,O
were,3492,O
66.17-226.03,3492,O
",",3492,O
11.18-40.54,3492,O
",",3492,O
and,3492,O
101.51-259.18,3492,O
mg,3492,O
of,3492,O
gallic,3492,B-CHEMICAL
acid,3492,I-CHEMICAL
equivalents/100,3492,O
g,3492,O
",",3492,O
respectively,3492,O
.,3492,O
The,3493,O
free,3493,O
",",3493,O
bound,3493,O
and,3493,O
total,3493,O
flavonoid,3493,B-CHEMICAL
contents,3493,O
were,3493,O
16.68-110.33,3493,O
",",3493,O
10.48-22.75,3493,O
",",3493,O
and,3493,O
39.43-129.86,3493,O
mg,3493,O
of,3493,O
catechin,3493,B-CHEMICAL
equivalents/100,3493,O
g,3493,O
",",3493,O
respectively,3493,O
.,3493,O
Free,3494,O
phenolics,3494,B-CHEMICAL
and,3494,O
flavonoids,3494,B-CHEMICAL
contributed,3494,O
averagely,3494,O
80.1,3494,O
%,3494,O
and,3494,O
75,3494,O
%,3494,O
to,3494,O
their,3494,O
total,3494,O
contents,3494,O
",",3494,O
respectively,3494,O
.,3494,O
Six,3495,O
individual,3495,O
phenolics,3495,B-CHEMICAL
(,3495,O
gallic,3495,B-CHEMICAL
acid,3495,I-CHEMICAL
",",3495,O
chlorogenic,3495,B-CHEMICAL
acid,3495,I-CHEMICAL
",",3495,O
(,3495,B-CHEMICAL
+,3495,I-CHEMICAL
),3495,I-CHEMICAL
-catechin,3495,I-CHEMICAL
",",3495,O
caffeic,3495,B-CHEMICAL
acid,3495,I-CHEMICAL
",",3495,O
(,3495,B-CHEMICAL
-,3495,I-CHEMICAL
),3495,I-CHEMICAL
-epicatechin,3495,I-CHEMICAL
",",3495,O
and,3495,O
rutin,3495,B-CHEMICAL
),3495,O
were,3495,O
detected,3495,O
in,3495,O
litchi,3495,O
pulp,3495,O
by,3495,O
HPLC,3495,O
.,3495,O
The,3496,O
contents,3496,O
of,3496,O
each,3496,O
compound,3496,O
in,3496,O
free,3496,O
and,3496,O
bound,3496,O
fractions,3496,O
were,3496,O
determined,3496,O
.,3496,O
Significant,3497,O
varietal,3497,O
discrepancy,3497,O
in,3497,O
antioxidant,3497,O
activity,3497,O
was,3497,O
also,3497,O
found,3497,O
by,3497,O
FRAP,3497,O
and,3497,O
DPPH,3497,B-CHEMICAL
scavenging,3497,O
capacity,3497,O
methods,3497,O
.,3497,O
Antioxidant,3498,O
activity,3498,O
was,3498,O
significantly,3498,O
correlated,3498,O
with,3498,O
phenolic,3498,O
and,3498,O
flavonoid,3498,B-CHEMICAL
contents,3498,O
.,3498,O
Thus,3499,O
",",3499,O
phenolics,3499,B-CHEMICAL
and,3499,O
flavonoids,3499,B-CHEMICAL
exist,3499,O
mainly,3499,O
in,3499,O
the,3499,O
free,3499,O
form,3499,O
in,3499,O
litchi,3499,O
pulp,3499,O
.,3499,O
There,3500,O
were,3500,O
significant,3500,O
varietal,3500,O
differences,3500,O
in,3500,O
phytochemical,3500,O
contents,3500,O
and,3500,O
antioxidant,3500,O
activity,3500,O
of,3500,O
litchi,3500,O
pulp,3500,O
.,3500,O
Purification,3501,O
",",3501,O
physicochemical,3501,O
characterisation,3501,O
and,3501,O
anticancer,3501,O
activity,3501,O
of,3501,O
a,3501,O
polysaccharide,3501,O
from,3501,O
Cyclocarya,3501,O
paliurus,3501,O
leaves,3501,O
.,3501,O
A,3502,O
Cyclocarya,3502,O
paliurus,3502,O
(,3502,O
Batal,3502,O
.,3502,O
),3502,O
Iljinskaja,3503,O
polysaccharide,3503,O
(,3503,O
CPP,3503,O
),3503,O
was,3503,O
isolated,3503,O
and,3503,O
purified,3503,O
by,3503,O
hot,3503,O
water,3503,O
extraction,3503,O
",",3503,O
ethanol,3503,B-CHEMICAL
precipitation,3503,O
",",3503,O
deproteinisation,3503,O
and,3503,O
anion-exchange,3503,O
chromatography,3503,O
.,3503,O
Its,3504,O
physicochemical,3504,O
properties,3504,O
were,3504,O
characterised,3504,O
by,3504,O
gel,3504,O
permeation,3504,O
chromatography,3504,O
(,3504,O
GPC,3504,O
),3504,O
",",3504,O
gas,3504,O
chromatography-mass,3504,O
spectrometry,3504,O
(,3504,O
GC-MS,3504,O
),3504,O
",",3504,O
thermal,3504,O
gravimetric,3504,O
analysis,3504,O
(,3504,O
TGA,3504,O
),3504,O
",",3504,O
Fourier,3504,O
transform,3504,O
infrared,3504,O
spectrometry,3504,O
(,3504,O
FTIR,3504,O
),3504,O
",",3504,O
UV-visible,3504,O
spectrophotometry,3504,O
",",3504,O
dynamic,3504,O
light,3504,O
scattering,3504,O
(,3504,O
DLS,3504,O
),3504,O
and,3504,O
viscometry,3504,O
analysis,3504,O
.,3504,O
The,3505,O
anticancer,3505,O
effect,3505,O
of,3505,O
CPP,3505,O
in,3505,O
human,3505,O
gastric,3505,O
cancer,3505,O
HeLa,3505,O
cells,3505,O
was,3505,O
also,3505,O
evaluated,3505,O
by,3505,O
3-,3505,B-CHEMICAL
(,3505,I-CHEMICAL
"4,5-dimethylthiazol-2-yl",3505,I-CHEMICAL
),3505,I-CHEMICAL
"-2,5-diphenyltetrazolium",3505,I-CHEMICAL
bromide,3505,I-CHEMICAL
(,3505,O
MTT,3505,B-CHEMICAL
),3505,O
assay,3505,O
.,3505,O
The,3506,O
results,3506,O
showed,3506,O
that,3506,O
the,3506,O
molecular,3506,O
weight,3506,O
of,3506,O
CPP,3506,O
was,3506,O
900,3506,O
kDa,3506,O
",",3506,O
and,3506,O
it,3506,O
contained,3506,O
64.8,3506,O
%,3506,O
total,3506,O
sugar,3506,O
",",3506,O
23.5,3506,O
%,3506,O
uronic,3506,B-CHEMICAL
acid,3506,I-CHEMICAL
",",3506,O
9.26,3506,O
%,3506,O
protein,3506,O
",",3506,O
and,3506,O
six,3506,O
kinds,3506,O
of,3506,O
monosaccharides,3506,B-CHEMICAL
",",3506,O
including,3506,O
glucose,3506,B-CHEMICAL
",",3506,O
rhamnose,3506,B-CHEMICAL
",",3506,O
arabinose,3506,B-CHEMICAL
",",3506,O
xylose,3506,B-CHEMICAL
",",3506,O
mannose,3506,B-CHEMICAL
and,3506,O
galactose,3506,B-CHEMICAL
",",3506,O
with,3506,O
molar,3506,O
percentages,3506,O
of,3506,O
32.7,3506,O
%,3506,O
",",3506,O
9.33,3506,O
%,3506,O
",",3506,O
30.6,3506,O
%,3506,O
",",3506,O
3.48,3506,O
%,3506,O
",",3506,O
10.4,3506,O
%,3506,O
",",3506,O
and,3506,O
13.5,3506,O
%,3506,O
",",3506,O
respectively,3506,O
.,3506,O
Furthermore,3507,O
",",3507,O
the,3507,O
results,3507,O
showed,3507,O
that,3507,O
CPP,3507,O
exhibited,3507,O
a,3507,O
strong,3507,O
inhibition,3507,O
effect,3507,O
on,3507,O
the,3507,O
growth,3507,O
of,3507,O
human,3507,O
gastric,3507,O
cancer,3507,O
HeLa,3507,O
cells,3507,O
.,3507,O
Bioinspired,3508,O
and,3508,O
highly,3508,O
oriented,3508,O
clay,3508,O
nanocomposites,3508,O
with,3508,O
a,3508,O
xyloglucan,3508,O
biopolymer,3508,O
matrix,3508,O
:,3508,O
extending,3508,O
the,3508,O
range,3508,O
of,3508,O
mechanical,3508,O
and,3508,O
barrier,3508,O
properties,3508,O
.,3508,O
The,3509,O
development,3509,O
of,3509,O
clay,3509,O
bionanocomposites,3509,O
requires,3509,O
processing,3509,O
routes,3509,O
with,3509,O
nanostructural,3509,O
control,3509,O
.,3509,O
Moreover,3510,O
",",3510,O
moisture,3510,O
durability,3510,O
is,3510,O
a,3510,O
concern,3510,O
with,3510,O
water-soluble,3510,O
biopolymers,3510,O
.,3510,O
Here,3511,O
",",3511,O
oriented,3511,O
bionanocomposite,3511,O
coatings,3511,O
with,3511,O
strong,3511,O
in-plane,3511,O
orientation,3511,O
of,3511,O
clay,3511,O
platelets,3511,O
are,3511,O
for,3511,O
the,3511,O
first,3511,O
time,3511,O
prepared,3511,O
by,3511,O
continuous,3511,O
water-based,3511,O
processing,3511,O
.,3511,O
Montmorillonite,3512,B-CHEMICAL
(,3512,O
MTM,3512,B-CHEMICAL
),3512,O
and,3512,O
a,3512,O
``,3512,O
new,3512,O
'',3512,O
unmodified,3512,O
biological,3512,O
polymer,3512,O
(,3512,O
xyloglucan,3512,O
(,3512,O
XG,3512,O
),3512,O
),3512,O
are,3512,O
combined,3512,O
.,3512,O
The,3513,O
resulting,3513,O
nanocomposites,3513,O
are,3513,O
characterized,3513,O
by,3513,O
FE-SEM,3513,O
",",3513,O
TEM,3513,O
",",3513,O
and,3513,O
XRD,3513,O
.,3513,O
XG,3514,O
adsorption,3514,O
on,3514,O
MTM,3514,B-CHEMICAL
is,3514,O
measured,3514,O
by,3514,O
quartz,3514,B-CHEMICAL
crystal,3514,O
microbalance,3514,O
analysis,3514,O
.,3514,O
Mechanical,3515,O
and,3515,O
gas,3515,O
barrier,3515,O
properties,3515,O
are,3515,O
measured,3515,O
",",3515,O
also,3515,O
at,3515,O
high,3515,O
relative,3515,O
humidity,3515,O
.,3515,O
The,3516,O
reinforcement,3516,O
effects,3516,O
are,3516,O
modeled,3516,O
.,3516,O
XG,3517,O
dimensions,3517,O
in,3517,O
composites,3517,O
are,3517,O
estimated,3517,O
using,3517,O
atomistic,3517,O
simulations,3517,O
.,3517,O
The,3518,O
nanostructure,3518,O
shows,3518,O
highly,3518,O
oriented,3518,O
and,3518,O
intercalated,3518,O
clay,3518,O
platelets,3518,O
.,3518,O
The,3519,O
reinforcement,3519,O
efficiency,3519,O
and,3519,O
effects,3519,O
on,3519,O
barrier,3519,O
properties,3519,O
are,3519,O
remarkable,3519,O
and,3519,O
are,3519,O
likely,3519,O
to,3519,O
be,3519,O
due,3519,O
to,3519,O
highly,3519,O
oriented,3519,O
and,3519,O
well-dispersed,3519,O
MTM,3519,B-CHEMICAL
and,3519,O
strong,3519,O
XG-MTM,3519,O
interactions,3519,O
.,3519,O
Properties,3520,O
are,3520,O
well,3520,O
preserved,3520,O
in,3520,O
humid,3520,O
conditions,3520,O
and,3520,O
the,3520,O
reasons,3520,O
for,3520,O
this,3520,O
are,3520,O
discussed,3520,O
.,3520,O
Lessons,3521,O
from,3521,O
the,3521,O
dissection,3521,O
of,3521,O
the,3521,O
activation,3521,B-GENE-N
functions,3521,I-GENE-N
(,3521,O
AF-1,3521,B-GENE-N
and,3521,O
AF-2,3521,B-GENE-N
),3521,O
of,3521,O
the,3521,O
estrogen,3521,B-CHEMICAL
receptor,3521,I-GENE-Y
alpha,3521,I-GENE-Y
in,3521,O
vivo,3521,O
.,3521,O
Estrogens,3522,B-CHEMICAL
influence,3522,O
most,3522,O
of,3522,O
the,3522,O
physiological,3522,O
processes,3522,O
in,3522,O
mammals,3522,O
",",3522,O
including,3522,O
but,3522,O
not,3522,O
limited,3522,O
to,3522,O
reproduction,3522,O
",",3522,O
cognition,3522,O
",",3522,O
behavior,3522,O
",",3522,O
vascular,3522,O
system,3522,O
",",3522,O
metabolism,3522,O
and,3522,O
bone,3522,O
integrity,3522,O
.,3522,O
Given,3523,O
this,3523,O
widespread,3523,O
role,3523,O
for,3523,O
estrogen,3523,B-CHEMICAL
in,3523,O
human,3523,O
physiology,3523,O
",",3523,O
it,3523,O
is,3523,O
not,3523,O
surprising,3523,O
that,3523,O
estrogen,3523,B-CHEMICAL
influence,3523,O
the,3523,O
pathophysiology,3523,O
of,3523,O
numerous,3523,O
diseases,3523,O
",",3523,O
including,3523,O
cancer,3523,O
(,3523,O
of,3523,O
the,3523,O
reproductive,3523,O
tract,3523,O
as,3523,O
breast,3523,O
",",3523,O
endometrial,3523,O
but,3523,O
also,3523,O
colorectal,3523,O
",",3523,O
prostate,3523,O
",",3523,O
,3523,O
),3523,O
",",3523,O
as,3523,O
well,3523,O
as,3523,O
neurodegenerative,3523,O
",",3523,O
inflammatory-immune,3523,O
",",3523,O
cardiovascular,3523,O
and,3523,O
metabolic,3523,O
diseases,3523,O
",",3523,O
and,3523,O
osteoporosis,3523,O
.,3523,O
These,3524,O
actions,3524,O
are,3524,O
mediated,3524,O
by,3524,O
the,3524,O
activation,3524,O
of,3524,O
estrogen,3524,B-CHEMICAL
receptors,3524,I-GENE-N
(,3524,I-GENE-N
ER,3524,I-GENE-N
),3524,I-GENE-N
alpha,3524,I-GENE-N
(,3524,I-GENE-N
ER,3524,I-GENE-N
),3524,I-GENE-N
and,3524,I-GENE-N
beta,3524,I-GENE-N
(,3524,O
ER,3524,B-GENE-Y
),3524,O
",",3524,O
which,3524,O
regulate,3524,O
target,3524,O
gene,3524,O
transcription,3524,O
(,3524,O
genomic,3524,O
action,3524,O
),3524,O
through,3524,O
two,3524,O
independent,3524,O
activation,3524,B-GENE-N
functions,3524,I-GENE-N
(,3524,B-GENE-N
AF,3524,I-GENE-N
),3524,I-GENE-N
-1,3524,I-GENE-N
and,3524,O
AF-2,3524,B-GENE-N
",",3524,O
but,3524,O
can,3524,O
also,3524,O
elicit,3524,O
rapid,3524,O
membrane,3524,O
initiated,3524,O
steroid,3524,B-CHEMICAL
signals,3524,O
(,3524,O
MISS,3524,O
),3524,O
.,3524,O
Targeted,3525,O
ER,3525,B-GENE-Y
gene,3525,O
inactivation,3525,O
has,3525,O
shown,3525,O
that,3525,O
although,3525,O
ER,3525,B-GENE-Y
plays,3525,O
an,3525,O
important,3525,O
role,3525,O
in,3525,O
the,3525,O
central,3525,O
nervous,3525,O
system,3525,O
and,3525,O
in,3525,O
the,3525,O
heart,3525,O
",",3525,O
ER,3525,B-GENE-Y
appears,3525,O
to,3525,O
play,3525,O
a,3525,O
prominent,3525,O
role,3525,O
in,3525,O
most,3525,O
of,3525,O
the,3525,O
other,3525,O
tissues,3525,O
.,3525,O
Pharmacological,3526,O
activation,3526,O
or,3526,O
inhibition,3526,O
of,3526,O
ER,3526,B-GENE-Y
and/or,3526,O
ER,3526,B-GENE-Y
provides,3526,O
already,3526,O
the,3526,O
basis,3526,O
for,3526,O
many,3526,O
therapeutic,3526,O
interventions,3526,O
",",3526,O
from,3526,O
hormone,3526,O
replacement,3526,O
at,3526,O
menopause,3526,O
to,3526,O
prevention,3526,O
of,3526,O
the,3526,O
recurrence,3526,O
of,3526,O
breast,3526,O
cancer,3526,O
.,3526,O
However,3527,O
",",3527,O
the,3527,O
use,3527,O
of,3527,O
these,3527,O
estrogens,3527,B-CHEMICAL
or,3527,O
selective,3527,O
estrogen,3527,B-CHEMICAL
receptors,3527,I-GENE-Y
modulators,3527,O
(,3527,O
SERMs,3527,O
),3527,O
have,3527,O
also,3527,O
induced,3527,O
undesired,3527,O
effects,3527,O
.,3527,O
Thus,3528,O
",",3528,O
an,3528,O
important,3528,O
challenge,3528,O
consists,3528,O
now,3528,O
to,3528,O
uncouple,3528,O
the,3528,O
beneficial,3528,O
actions,3528,O
from,3528,O
other,3528,O
deleterious,3528,O
ones,3528,O
.,3528,O
The,3529,O
in,3529,O
vivo,3529,O
molecular,3529,O
``,3529,O
dissection,3529,O
'',3529,O
of,3529,O
ER,3529,B-GENE-Y
represents,3529,O
both,3529,O
a,3529,O
molecular,3529,O
and,3529,O
integrated,3529,O
approach,3529,O
that,3529,O
already,3529,O
allowed,3529,O
to,3529,O
delineate,3529,O
in,3529,O
mouse,3529,O
the,3529,O
role,3529,O
of,3529,O
the,3529,O
main,3529,O
``,3529,O
subfunctions,3529,O
'',3529,O
of,3529,O
the,3529,O
receptor,3529,O
and,3529,O
that,3529,O
could,3529,O
pave,3529,O
the,3529,O
way,3529,O
to,3529,O
an,3529,O
optimization,3529,O
of,3529,O
the,3529,O
ER,3529,B-GENE-Y
modulation,3529,O
.,3529,O
Inhibitory,3530,O
effect,3530,O
of,3530,O
"1,25-dihydroxyvitamin",3530,B-CHEMICAL
D,3530,I-CHEMICAL
on,3530,O
excretion,3530,O
of,3530,O
JBP485,3530,B-CHEMICAL
via,3530,O
organic,3530,B-GENE-N
anion,3530,I-GENE-N
transporters,3530,I-GENE-N
in,3530,O
rats,3530,O
.,3530,O
The,3531,O
aim,3531,O
of,3531,O
this,3531,O
study,3531,O
was,3531,O
to,3531,O
investigate,3531,O
the,3531,O
pharmacokinetic,3531,O
mechanism,3531,O
of,3531,O
interaction,3531,O
between,3531,O
JBP485,3531,B-CHEMICAL
and,3531,O
"1,25-dihydroxyvitamin",3531,B-CHEMICAL
D,3531,I-CHEMICAL
(,3531,I-CHEMICAL
3,3531,I-CHEMICAL
),3531,I-CHEMICAL
[,3531,O
"1,25",3531,B-CHEMICAL
(,3531,I-CHEMICAL
OH,3531,I-CHEMICAL
),3531,I-CHEMICAL
(,3531,I-CHEMICAL
2,3531,I-CHEMICAL
),3531,I-CHEMICAL
D,3531,I-CHEMICAL
(,3531,I-CHEMICAL
3,3531,I-CHEMICAL
),3531,I-CHEMICAL
],3531,O
.,3531,O
Rats,3532,O
were,3532,O
injected,3532,O
intraperitoneally,3532,O
with,3532,O
0.64,3532,O
nmol/kg/day,3532,O
"1,25",3532,B-CHEMICAL
(,3532,I-CHEMICAL
OH,3532,I-CHEMICAL
),3532,I-CHEMICAL
(,3532,I-CHEMICAL
2,3532,I-CHEMICAL
),3532,I-CHEMICAL
D,3532,I-CHEMICAL
(,3532,I-CHEMICAL
3,3532,I-CHEMICAL
),3532,I-CHEMICAL
in,3532,O
1,3532,O
ml/kg,3532,O
corn,3532,O
oil,3532,O
for,3532,O
5,3532,O
days,3532,O
.,3532,O
The,3533,O
plasma,3533,O
and,3533,O
urine,3533,O
concentrations,3533,O
of,3533,O
JBP485,3533,B-CHEMICAL
after,3533,O
intravenous,3533,O
administration,3533,O
and,3533,O
the,3533,O
uptake,3533,O
of,3533,O
JBP485,3533,B-CHEMICAL
in,3533,O
kidney,3533,O
slices,3533,O
in,3533,O
vitro,3533,O
were,3533,O
determined,3533,O
by,3533,O
liquid,3533,O
chromatography/tandem,3533,O
mass,3533,O
spectrometry,3533,O
.,3533,O
Quantitative,3534,O
polymerase,3534,O
chain,3534,O
reaction,3534,O
",",3534,O
western,3534,O
blotting,3534,O
",",3534,O
immunohistochemical,3534,O
analysis,3534,O
and,3534,O
immunofluorescence,3534,O
were,3534,O
used,3534,O
to,3534,O
determine,3534,O
the,3534,O
changes,3534,O
in,3534,O
the,3534,O
expression,3534,O
of,3534,O
organic,3534,B-GENE-N
anion,3534,I-GENE-N
transporter,3534,I-GENE-N
(,3534,B-GENE-Y
Oat,3534,I-GENE-Y
),3534,I-GENE-Y
1,3534,I-GENE-Y
and,3534,O
Oat3,3534,B-GENE-Y
in,3534,O
rat,3534,O
kidney,3534,O
in,3534,O
response,3534,O
to,3534,O
"1,25",3534,B-CHEMICAL
(,3534,I-CHEMICAL
OH,3534,I-CHEMICAL
),3534,I-CHEMICAL
(,3534,I-CHEMICAL
2,3534,I-CHEMICAL
),3534,I-CHEMICAL
D,3534,I-CHEMICAL
(,3534,I-CHEMICAL
3,3534,I-CHEMICAL
),3534,I-CHEMICAL
treatment,3534,O
.,3534,O
The,3535,O
plasma,3535,O
concentrations,3535,O
and,3535,O
AUCs,3535,O
of,3535,O
JBP485,3535,B-CHEMICAL
were,3535,O
significantly,3535,O
increased,3535,O
",",3535,O
while,3535,O
the,3535,O
renal,3535,O
clearance,3535,O
of,3535,O
JBP485,3535,B-CHEMICAL
and,3535,O
uptake,3535,O
of,3535,O
JBP485,3535,B-CHEMICAL
in,3535,O
kidney,3535,O
slices,3535,O
were,3535,O
significantly,3535,O
decreased,3535,O
after,3535,O
"1,25",3535,B-CHEMICAL
(,3535,I-CHEMICAL
OH,3535,I-CHEMICAL
),3535,I-CHEMICAL
(,3535,I-CHEMICAL
2,3535,I-CHEMICAL
),3535,I-CHEMICAL
D,3535,I-CHEMICAL
(,3535,I-CHEMICAL
3,3535,I-CHEMICAL
),3535,I-CHEMICAL
treatment,3535,O
.,3535,O
These,3536,O
results,3536,O
confirmed,3536,O
that,3536,O
"1,25",3536,B-CHEMICAL
(,3536,I-CHEMICAL
OH,3536,I-CHEMICAL
),3536,I-CHEMICAL
(,3536,I-CHEMICAL
2,3536,I-CHEMICAL
),3536,I-CHEMICAL
D,3536,I-CHEMICAL
(,3536,I-CHEMICAL
3,3536,I-CHEMICAL
),3536,I-CHEMICAL
inhibited,3536,O
renal,3536,O
excretion,3536,O
of,3536,O
JBP485,3536,B-CHEMICAL
.,3536,O
Moreover,3537,O
",",3537,O
"1,25",3537,B-CHEMICAL
(,3537,I-CHEMICAL
OH,3537,I-CHEMICAL
),3537,I-CHEMICAL
(,3537,I-CHEMICAL
2,3537,I-CHEMICAL
),3537,I-CHEMICAL
D,3537,I-CHEMICAL
(,3537,I-CHEMICAL
3,3537,I-CHEMICAL
),3537,I-CHEMICAL
decreased,3537,O
expression,3537,O
of,3537,O
Oat1,3537,B-GENE-Y
and,3537,O
Oat3,3537,B-GENE-Y
in,3537,O
rat,3537,O
kidney,3537,O
.,3537,O
Our,3538,O
results,3538,O
are,3538,O
novel,3538,O
in,3538,O
demonstrating,3538,O
an,3538,O
interaction,3538,O
between,3538,O
JBP485,3538,B-CHEMICAL
and,3538,O
"1,25",3538,B-CHEMICAL
(,3538,I-CHEMICAL
OH,3538,I-CHEMICAL
),3538,I-CHEMICAL
(,3538,I-CHEMICAL
2,3538,I-CHEMICAL
),3538,I-CHEMICAL
D,3538,I-CHEMICAL
(,3538,I-CHEMICAL
3,3538,I-CHEMICAL
),3538,I-CHEMICAL
when,3538,O
they,3538,O
are,3538,O
co-administered,3538,O
.,3538,O
The,3539,O
mechanism,3539,O
of,3539,O
interaction,3539,O
between,3539,O
JBP485,3539,B-CHEMICAL
and,3539,O
"1,25",3539,B-CHEMICAL
(,3539,I-CHEMICAL
OH,3539,I-CHEMICAL
),3539,I-CHEMICAL
(,3539,I-CHEMICAL
2,3539,I-CHEMICAL
),3539,I-CHEMICAL
D,3539,I-CHEMICAL
(,3539,I-CHEMICAL
3,3539,I-CHEMICAL
),3539,I-CHEMICAL
could,3539,O
be,3539,O
explained,3539,O
at,3539,O
least,3539,O
in,3539,O
part,3539,O
by,3539,O
inhibitory,3539,O
effect,3539,O
of,3539,O
"1,25",3539,B-CHEMICAL
(,3539,I-CHEMICAL
OH,3539,I-CHEMICAL
),3539,I-CHEMICAL
(,3539,I-CHEMICAL
2,3539,I-CHEMICAL
),3539,I-CHEMICAL
D,3539,I-CHEMICAL
(,3539,I-CHEMICAL
3,3539,I-CHEMICAL
),3539,I-CHEMICAL
on,3539,O
expression,3539,O
of,3539,O
Oats,3539,B-GENE-N
in,3539,O
rat,3539,O
kidney,3539,O
.,3539,O
Nanoparticle,3540,O
toxicity,3540,O
in,3540,O
Daphnia,3540,O
magna,3540,O
reproduction,3540,O
studies,3540,O
:,3540,O
the,3540,O
importance,3540,O
of,3540,O
test,3540,O
design,3540,O
.,3540,O
The,3541,O
increasing,3541,O
use,3541,O
of,3541,O
titanium,3541,B-CHEMICAL
dioxide,3541,I-CHEMICAL
nanoparticles,3541,O
(,3541,O
nTiO,3541,O
(,3541,I-CHEMICAL
2,3541,I-CHEMICAL
),3541,I-CHEMICAL
),3541,O
inevitably,3541,O
results,3541,O
in,3541,O
their,3541,O
release,3541,O
into,3541,O
the,3541,O
environment,3541,O
",",3541,O
raising,3541,O
concerns,3541,O
about,3541,O
potential,3541,O
adverse,3541,O
effects,3541,O
in,3541,O
wildlife,3541,O
.,3541,O
By,3542,O
following,3542,O
standard,3542,O
test,3542,O
protocols,3542,O
",",3542,O
several,3542,O
studies,3542,O
investigated,3542,O
the,3542,O
ecotoxicity,3542,O
of,3542,O
nTiO,3542,O
(,3542,I-CHEMICAL
2,3542,I-CHEMICAL
),3542,I-CHEMICAL
among,3542,O
others,3542,O
to,3542,O
Daphnia,3542,O
magna,3542,O
.,3542,O
These,3543,O
studies,3543,O
indicated,3543,O
a,3543,O
large,3543,O
variability,3543,O
-,3543,O
several,3543,O
orders,3543,O
of,3543,O
magnitude,3543,O
-,3543,O
in,3543,O
the,3543,O
response,3543,O
variables,3543,O
.,3543,O
However,3544,O
",",3544,O
other,3544,O
factors,3544,O
",",3544,O
like,3544,O
nanoparticle,3544,O
characteristics,3544,O
and,3544,O
test,3544,O
design,3544,O
",",3544,O
potentially,3544,O
triggering,3544,O
these,3544,O
differences,3544,O
",",3544,O
were,3544,O
largely,3544,O
ignored,3544,O
.,3544,O
Therefore,3545,O
",",3545,O
the,3545,O
present,3545,O
study,3545,O
assessed,3545,O
the,3545,O
chronic,3545,O
ecotoxicity,3545,O
of,3545,O
two,3545,O
nTiO,3545,O
(,3545,I-CHEMICAL
2,3545,I-CHEMICAL
),3545,I-CHEMICAL
products,3545,O
with,3545,O
varying,3545,O
crystalline,3545,O
structure,3545,O
(,3545,O
A-100,3545,O
;,3545,O
P25,3545,O
),3545,O
to,3545,O
D.,3545,O
magna,3545,O
.,3545,O
A,3546,O
semi-static,3546,O
and,3546,O
a,3546,O
flow-through,3546,O
exposure,3546,O
scenario,3546,O
were,3546,O
compared,3546,O
",",3546,O
ensuring,3546,O
that,3546,O
both,3546,O
contained,3546,O
environmentally,3546,O
relevant,3546,O
concentrations,3546,O
of,3546,O
dissolved,3546,O
organic,3546,O
carbon,3546,B-CHEMICAL
.,3546,O
Utilizing,3547,O
the,3547,O
semi-static,3547,O
test,3547,O
design,3547,O
",",3547,O
a,3547,O
concentration,3547,O
as,3547,O
low,3547,O
as,3547,O
0.06,3547,O
mg/L,3547,O
A-100,3547,O
(,3547,O
330,3547,O
nm,3547,O
),3547,O
significantly,3547,O
reduced,3547,O
the,3547,O
reproduction,3547,O
of,3547,O
daphnia,3547,O
indicating,3547,O
environmental,3547,O
risk,3547,O
.,3547,O
In,3548,O
contrast,3548,O
",",3548,O
no,3548,O
implication,3548,O
in,3548,O
the,3548,O
number,3548,O
of,3548,O
released,3548,O
offspring,3548,O
was,3548,O
observed,3548,O
during,3548,O
the,3548,O
flow-through,3548,O
experiment,3548,O
with,3548,O
A-100,3548,O
(,3548,O
140,3548,O
nm,3548,O
),3548,O
.,3548,O
Likewise,3549,O
",",3549,O
P25,3549,O
(,3549,O
130,3549,O
nm,3549,O
),3549,O
did,3549,O
not,3549,O
adversely,3549,O
affect,3549,O
reproduction,3549,O
irrespective,3549,O
of,3549,O
the,3549,O
test,3549,O
design,3549,O
utilized,3549,O
.,3549,O
Given,3550,O
the,3550,O
present,3550,O
study,3550,O
's,3550,O
results,3550,O
",",3550,O
the,3550,O
particle,3550,O
size,3550,O
",",3550,O
the,3550,O
product,3550,O
composition,3550,O
",",3550,O
i.e,3550,O
.,3550,O
the,3551,O
crystalline,3551,O
structure,3551,O
",",3551,O
and,3551,O
the,3551,O
accumulation,3551,O
of,3551,O
nTiO,3551,O
(,3551,I-CHEMICAL
2,3551,I-CHEMICAL
),3551,I-CHEMICAL
at,3551,O
the,3551,O
bottom,3551,O
of,3551,O
the,3551,O
test,3551,O
vessel,3551,O
-,3551,O
the,3551,O
latter,3551,O
is,3551,O
relevant,3551,O
for,3551,O
a,3551,O
semi-static,3551,O
test,3551,O
design,3551,O
-,3551,O
may,3551,O
be,3551,O
suggested,3551,O
as,3551,O
factors,3551,O
potentially,3551,O
triggering,3551,O
differences,3551,O
in,3551,O
nTiO,3551,O
(,3551,I-CHEMICAL
2,3551,I-CHEMICAL
),3551,I-CHEMICAL
toxicity,3551,O
to,3551,O
D.,3551,O
magna,3551,O
.,3551,O
Hence,3552,O
",",3552,O
these,3552,O
factors,3552,O
should,3552,O
be,3552,O
considered,3552,O
to,3552,O
improve,3552,O
environmental,3552,O
risk,3552,O
assessment,3552,O
of,3552,O
nanoparticles,3552,O
.,3552,O
Magnetic,3553,O
nanoclusters,3553,O
exhibiting,3553,O
protein-activated,3553,O
near-infrared,3553,O
fluorescence,3553,O
.,3553,O
Composite,3554,O
nanoclusters,3554,O
with,3554,O
chemical,3554,O
",",3554,O
magnetic,3554,O
",",3554,O
and,3554,O
biofunctionality,3554,O
offer,3554,O
broad,3554,O
opportunities,3554,O
for,3554,O
targeted,3554,O
cellular,3554,O
imaging,3554,O
.,3554,O
A,3555,O
key,3555,O
challenge,3555,O
is,3555,O
to,3555,O
load,3555,O
a,3555,O
high,3555,O
degree,3555,O
of,3555,O
targeting,3555,O
",",3555,O
imaging,3555,O
",",3555,O
and,3555,O
therapeutic,3555,O
functionality,3555,O
onto,3555,O
stable,3555,O
metal-oxide,3555,B-CHEMICAL
nanoparticles,3555,O
.,3555,O
Here,3556,O
we,3556,O
report,3556,O
a,3556,O
route,3556,O
for,3556,O
producing,3556,O
magnetic,3556,O
nanoclusters,3556,O
(,3556,O
MNCs,3556,O
),3556,O
with,3556,O
alkyne,3556,B-CHEMICAL
surface,3556,O
functionality,3556,O
that,3556,O
can,3556,O
be,3556,O
utilized,3556,O
as,3556,O
multimodal,3556,O
imaging,3556,O
probes,3556,O
.,3556,O
We,3557,O
form,3557,O
MNCs,3557,O
composed,3557,O
of,3557,O
magnetic,3557,O
Fe,3557,O
(,3557,O
3,3557,O
),3557,O
O,3557,O
(,3557,O
4,3557,O
),3557,O
nanoparticles,3557,O
and,3557,O
poly,3557,O
(,3557,O
acrylic,3557,O
acid-co-propargyl,3557,O
acrylate,3557,O
),3557,O
by,3557,O
the,3557,O
co-precipitation,3557,O
of,3557,O
iron,3557,O
salts,3557,O
in,3557,O
the,3557,O
presence,3557,O
of,3557,O
copolymer,3557,O
stabilizers,3557,O
.,3557,O
The,3558,O
MNCs,3558,O
were,3558,O
surface-modified,3558,O
with,3558,O
near-infrared,3558,O
(,3558,O
NIR,3558,O
),3558,O
emitting,3558,O
fluorophore,3558,O
used,3558,O
in,3558,O
photodynamic,3558,O
therapy,3558,O
",",3558,O
an,3558,O
azide-modified,3558,B-CHEMICAL
indocyanine,3558,B-CHEMICAL
green,3558,I-CHEMICAL
.,3558,O
The,3559,O
fluorophores,3559,O
engaged,3559,O
and,3559,O
complexed,3559,O
with,3559,O
bovine,3559,B-GENE-Y
serum,3559,I-GENE-Y
albumin,3559,I-GENE-Y
",",3559,O
forming,3559,O
an,3559,O
extended,3559,O
coverage,3559,O
of,3559,O
serum,3559,O
proteins,3559,O
on,3559,O
the,3559,O
MNCs,3559,O
.,3559,O
These,3560,O
proteins,3560,O
isolated,3560,O
indocyanine,3560,B-CHEMICAL
green,3560,I-CHEMICAL
fluorophores,3560,O
from,3560,O
the,3560,O
aqueous,3560,O
environment,3560,O
and,3560,O
induced,3560,O
an,3560,O
effective,3560,O
``,3560,O
turn-on,3560,O
'',3560,O
of,3560,O
NIR,3560,O
emission,3560,O
.,3560,O
From,3561,O
in,3561,O
situ,3561,O
to,3561,O
in,3561,O
vivo,3561,O
:,3561,O
an,3561,O
in,3561,O
situ,3561,O
click-chemistry-derived,3561,O
carbonic,3561,O
anhydrase,3561,O
II,3561,O
imaging,3561,O
agent,3561,O
for,3561,O
positron,3561,O
emission,3561,O
tomography,3561,O
.,3561,O
CA,3562,O
II,3562,O
makes,3562,O
a,3562,O
good,3562,O
PET,3562,O
:,3562,O
Discovering,3562,O
positron,3562,O
emission,3562,O
tomography,3562,O
(,3562,O
PET,3562,O
),3562,O
probes,3562,O
with,3562,O
high,3562,O
target,3562,O
affinities,3562,O
is,3562,O
challenging,3562,O
.,3562,O
PET,3563,O
probe,3563,O
discovery,3563,O
using,3563,O
in,3563,O
situ,3563,O
click,3563,O
chemistry,3563,O
uses,3563,O
(,3563,B-CHEMICAL
19,3563,I-CHEMICAL
),3563,I-CHEMICAL
F-bearing,3563,O
fragments,3563,O
as,3563,O
(,3563,B-CHEMICAL
18,3563,I-CHEMICAL
),3563,I-CHEMICAL
F,3563,I-CHEMICAL
surrogates,3563,O
.,3563,O
This,3564,O
ensures,3564,O
that,3564,O
the,3564,O
lead,3564,O
hits,3564,O
and,3564,O
PET,3564,O
probes,3564,O
have,3564,O
equivalent,3564,O
chemical,3564,O
or,3564,O
biological,3564,O
characteristics,3564,O
",",3564,O
making,3564,O
PET,3564,O
probe,3564,O
discovery,3564,O
predictable,3564,O
and,3564,O
reliable,3564,O
.,3564,O
Dendronized,3565,B-GENE-N
albumin,3565,I-GENE-N
core-shell,3565,I-GENE-N
transporters,3565,I-GENE-N
with,3565,O
high,3565,O
drug,3565,O
loading,3565,O
capacity,3565,O
.,3565,O
We,3566,O
describe,3566,O
the,3566,O
synthesis,3566,O
of,3566,O
a,3566,O
core-shell,3566,O
biohybrid,3566,O
consisting,3566,O
of,3566,O
a,3566,O
human,3566,B-GENE-Y
serum,3566,I-GENE-Y
albumin,3566,I-GENE-Y
(,3566,O
HSA,3566,B-GENE-Y
),3566,O
core,3566,O
that,3566,O
serves,3566,O
as,3566,O
a,3566,O
reservoir,3566,O
for,3566,O
lipophilic,3566,O
molecules,3566,O
and,3566,O
a,3566,O
cationized,3566,O
shell,3566,O
region,3566,O
consisting,3566,O
of,3566,O
ethynyl-G2.0-PAMAM,3566,B-CHEMICAL
or,3566,O
ethynyl-G3.0-PAMAM,3566,B-CHEMICAL
dendrons,3566,O
.,3566,O
The,3567,O
binding,3567,O
capacity,3567,O
of,3567,O
lipophilic,3567,O
guests,3567,O
was,3567,O
quantified,3567,O
applying,3567,O
electron,3567,O
paramagnetic,3567,O
resonance,3567,O
(,3567,O
EPR,3567,O
),3567,O
spectroscopy,3567,O
",",3567,O
and,3567,O
five,3567,O
to,3567,O
six,3567,O
out,3567,O
of,3567,O
seven,3567,O
pockets,3567,O
were,3567,O
still,3567,O
available,3567,O
compared,3567,O
with,3567,O
HSA,3567,B-GENE-Y
.,3567,O
The,3568,O
attachment,3568,O
of,3568,O
ethynyl-G2.0-PAMAM,3568,B-CHEMICAL
dendrons,3568,O
to,3568,O
HSA,3568,B-GENE-Y
yielded,3568,O
a,3568,O
nontoxic,3568,O
core-shell,3568,O
macromolecule,3568,O
that,3568,O
was,3568,O
clearly,3568,O
uptaken,3568,O
by,3568,O
A549,3568,O
human,3568,O
epithelial,3568,O
cells,3568,O
due,3568,O
to,3568,O
the,3568,O
presence,3568,O
of,3568,O
the,3568,O
dendritic,3568,O
PAMAM,3568,B-CHEMICAL
shell,3568,O
.,3568,O
Significantly,3569,O
higher,3569,O
loading,3569,O
of,3569,O
doxorubicin,3569,B-CHEMICAL
was,3569,O
observed,3569,O
for,3569,O
dendronized,3569,O
G2-DHSA,3569,O
compared,3569,O
with,3569,O
the,3569,O
native,3569,O
protein,3569,O
due,3569,O
to,3569,O
the,3569,O
availability,3569,O
of,3569,O
binding,3569,O
pockets,3569,O
of,3569,O
the,3569,O
HSA,3569,B-GENE-Y
core,3569,O
",",3569,O
and,3569,O
interaction,3569,O
with,3569,O
the,3569,O
dendritic,3569,O
shell,3569,O
.,3569,O
Dendronized,3570,O
G2-DHSA-doxorubicin,3570,O
displayed,3570,O
significant,3570,O
cytotoxicity,3570,O
resulting,3570,O
from,3570,O
high,3570,O
drug,3570,O
loading,3570,O
and,3570,O
high,3570,O
stability,3570,O
under,3570,O
different,3570,O
conditions,3570,O
",",3570,O
thus,3570,O
demonstrating,3570,O
its,3570,O
great,3570,O
potential,3570,O
as,3570,O
a,3570,O
transporter,3570,O
for,3570,O
drug,3570,O
molecules,3570,O
.,3570,O
Impairment,3571,O
of,3571,O
novel,3571,O
object,3571,O
recognition,3571,O
in,3571,O
adulthood,3571,O
after,3571,O
neonatal,3571,O
exposure,3571,O
to,3571,O
diazinon,3571,B-CHEMICAL
.,3571,O
Diazinon,3572,B-CHEMICAL
is,3572,O
an,3572,O
organophosphate,3572,B-CHEMICAL
pesticide,3572,O
that,3572,O
is,3572,O
still,3572,O
heavily,3572,O
used,3572,O
in,3572,O
agriculture,3572,O
",",3572,O
home,3572,O
gardening,3572,O
",",3572,O
and,3572,O
indoor,3572,O
pest,3572,O
control,3572,O
in,3572,O
Japan,3572,O
.,3572,O
The,3573,O
present,3573,O
study,3573,O
investigated,3573,O
the,3573,O
effect,3573,O
of,3573,O
neonatal,3573,O
exposure,3573,O
to,3573,O
diazinon,3573,B-CHEMICAL
on,3573,O
hippocampus-dependent,3573,O
novel,3573,O
object,3573,O
recognition,3573,O
test,3573,O
performance,3573,O
and,3573,O
the,3573,O
expression,3573,O
of,3573,O
the,3573,O
N-methyl-D-aspartate,3573,B-GENE-N
(,3573,I-GENE-N
NMDA,3573,I-GENE-N
),3573,I-GENE-N
receptor,3573,I-GENE-N
and,3573,O
its,3573,O
signal,3573,O
transduction,3573,O
pathway-related,3573,O
genes,3573,O
in,3573,O
the,3573,O
hippocampi,3573,O
of,3573,O
young,3573,O
adult,3573,O
and,3573,O
adult,3573,O
mice,3573,O
.,3573,O
Male,3574,O
offspring,3574,O
of,3574,O
C3H/HeN,3574,O
mice,3574,O
were,3574,O
subcutaneously,3574,O
treated,3574,O
with,3574,O
0,3574,O
",",3574,O
0.5,3574,O
",",3574,O
or,3574,O
5,3574,O
mg/kg,3574,O
of,3574,O
diazinon,3574,B-CHEMICAL
for,3574,O
4,3574,O
consecutive,3574,O
days,3574,O
beginning,3574,O
on,3574,O
postnatal,3574,O
day,3574,O
(,3574,O
PND,3574,O
),3574,O
8,3574,O
.,3574,O
Beginning,3575,O
on,3575,O
PND,3575,O
46,3575,O
or,3575,O
PND,3575,O
81,3575,O
",",3575,O
a,3575,O
novel,3575,O
object,3575,O
recognition,3575,O
test,3575,O
was,3575,O
performed,3575,O
on,3575,O
4,3575,O
consecutive,3575,O
days,3575,O
.,3575,O
The,3576,O
hippocampi,3576,O
were,3576,O
collected,3576,O
on,3576,O
PND,3576,O
50,3576,O
or,3576,O
PND,3576,O
85,3576,O
after,3576,O
the,3576,O
completion,3576,O
of,3576,O
the,3576,O
novel,3576,O
object,3576,O
recognition,3576,O
test,3576,O
",",3576,O
and,3576,O
the,3576,O
expression,3576,O
levels,3576,O
of,3576,O
neurotrophins,3576,B-GENE-N
and,3576,O
the,3576,O
NMDA,3576,B-GENE-N
receptor,3576,I-GENE-N
and,3576,O
its,3576,O
signal,3576,O
transduction,3576,O
pathway-related,3576,O
genes,3576,O
were,3576,O
examined,3576,O
using,3576,O
real-time,3576,O
RT-PCR,3576,O
.,3576,O
Diazinon-injected,3577,B-CHEMICAL
mice,3577,O
exhibited,3577,O
a,3577,O
poor,3577,O
ability,3577,O
to,3577,O
discriminate,3577,O
between,3577,O
novel,3577,O
and,3577,O
familiar,3577,O
objects,3577,O
during,3577,O
both,3577,O
the,3577,O
PND,3577,O
49,3577,O
and,3577,O
the,3577,O
PND,3577,O
84,3577,O
tests,3577,O
.,3577,O
The,3578,O
NMDA,3578,B-CHEMICAL
receptor,3578,I-GENE-N
subunits,3578,I-GENE-N
NR1,3578,I-GENE-N
and,3578,I-GENE-N
NR2B,3578,I-GENE-N
and,3578,O
the,3578,O
related,3578,O
protein,3578,O
kinase,3578,B-GENE-N
calcium/calmodulin-dependent,3578,B-CHEMICAL
protein,3578,I-GENE-Y
kinase,3578,I-GENE-Y
(,3578,I-GENE-Y
CaMK,3578,I-GENE-Y
),3578,I-GENE-Y
-IV,3578,I-GENE-Y
and,3578,O
the,3578,O
transcription,3578,O
factor,3578,O
cyclic,3578,B-CHEMICAL
AMP,3578,I-CHEMICAL
responsive,3578,I-GENE-Y
element,3578,I-GENE-Y
binding,3578,I-GENE-Y
protein,3578,I-GENE-Y
(,3578,I-GENE-Y
CREB,3578,I-GENE-Y
),3578,I-GENE-Y
-1,3578,I-GENE-Y
mRNA,3578,O
levels,3578,O
were,3578,O
reduced,3578,O
in,3578,O
the,3578,O
PND,3578,O
50,3578,O
mice,3578,O
.,3578,O
However,3579,O
",",3579,O
no,3579,O
significant,3579,O
changes,3579,O
in,3579,O
the,3579,O
expressions,3579,O
of,3579,O
the,3579,O
NMDA,3579,B-CHEMICAL
subunits,3579,O
and,3579,O
their,3579,O
signal,3579,O
transduction,3579,O
molecules,3579,O
were,3579,O
observed,3579,O
in,3579,O
the,3579,O
hippocampi,3579,O
of,3579,O
the,3579,O
PND,3579,O
85,3579,O
mice,3579,O
.,3579,O
The,3580,O
expression,3580,O
level,3580,O
of,3580,O
nerve,3580,B-GENE-Y
growth,3580,I-GENE-Y
factor,3580,I-GENE-Y
mRNA,3580,O
was,3580,O
significantly,3580,O
reduced,3580,O
in,3580,O
the,3580,O
PND,3580,O
50,3580,O
or,3580,O
85,3580,O
mice,3580,O
.,3580,O
These,3581,O
results,3581,O
indicate,3581,O
that,3581,O
neonatal,3581,O
diazinon,3581,B-CHEMICAL
exposure,3581,O
impaired,3581,O
the,3581,O
hippocampus-dependent,3581,O
novel,3581,O
object,3581,O
recognition,3581,O
ability,3581,O
",",3581,O
accompanied,3581,O
by,3581,O
a,3581,O
modulation,3581,O
in,3581,O
the,3581,O
expressions,3581,O
of,3581,O
the,3581,O
NMDA,3581,B-CHEMICAL
receptor,3581,I-GENE-N
and,3581,O
neurotrophin,3581,O
in,3581,O
young,3581,O
adult,3581,O
and,3581,O
adult,3581,O
mice,3581,O
.,3581,O
Functional,3582,O
imaging,3582,O
of,3582,O
legumain,3582,B-GENE-Y
in,3582,O
cancer,3582,O
using,3582,O
a,3582,O
new,3582,O
quenched,3582,O
activity-based,3582,O
probe,3582,O
.,3582,O
Legumain,3583,B-GENE-Y
is,3583,O
a,3583,O
lysosomal,3583,O
cysteine,3583,B-GENE-N
protease,3583,I-GENE-N
whose,3583,O
biological,3583,O
function,3583,O
remains,3583,O
poorly,3583,O
defined,3583,O
.,3583,O
Legumain,3584,B-GENE-Y
activity,3584,O
is,3584,O
up-regulated,3584,O
in,3584,O
most,3584,O
human,3584,O
cancers,3584,O
and,3584,O
inflammatory,3584,O
diseases,3584,O
most,3584,O
likely,3584,O
as,3584,O
the,3584,O
result,3584,O
of,3584,O
high,3584,O
expression,3584,O
in,3584,O
populations,3584,O
of,3584,O
activated,3584,O
macrophages,3584,O
.,3584,O
Within,3585,O
the,3585,O
tumor,3585,O
microenvironment,3585,O
",",3585,O
legumain,3585,B-GENE-Y
activity,3585,O
is,3585,O
thought,3585,O
to,3585,O
promote,3585,O
tumorigenesis,3585,O
.,3585,O
To,3586,O
obtain,3586,O
a,3586,O
greater,3586,O
understanding,3586,O
of,3586,O
the,3586,O
role,3586,O
of,3586,O
legumain,3586,B-GENE-Y
activity,3586,O
during,3586,O
cancer,3586,O
progression,3586,O
and,3586,O
inflammation,3586,O
",",3586,O
we,3586,O
developed,3586,O
an,3586,O
activity-based,3586,O
probe,3586,O
that,3586,O
becomes,3586,O
fluorescent,3586,O
only,3586,O
upon,3586,O
binding,3586,O
active,3586,O
legumain,3586,B-GENE-Y
.,3586,O
This,3587,O
probe,3587,O
is,3587,O
highly,3587,O
selective,3587,O
for,3587,O
legumain,3587,B-GENE-Y
",",3587,O
even,3587,O
in,3587,O
the,3587,O
context,3587,O
of,3587,O
whole,3587,O
cells,3587,O
and,3587,O
tissues,3587,O
",",3587,O
and,3587,O
is,3587,O
also,3587,O
a,3587,O
more,3587,O
effective,3587,O
label,3587,O
of,3587,O
legumain,3587,O
than,3587,O
previously,3587,O
reported,3587,O
probes,3587,O
.,3587,O
Here,3588,O
we,3588,O
present,3588,O
the,3588,O
synthesis,3588,O
and,3588,O
application,3588,O
of,3588,O
our,3588,O
probe,3588,O
to,3588,O
the,3588,O
analysis,3588,O
of,3588,O
legumain,3588,B-GENE-Y
activity,3588,O
in,3588,O
primary,3588,O
macrophages,3588,O
and,3588,O
in,3588,O
two,3588,O
mouse,3588,O
models,3588,O
of,3588,O
cancer,3588,O
.,3588,O
We,3589,O
find,3589,O
that,3589,O
legumain,3589,B-GENE-Y
activity,3589,O
is,3589,O
highly,3589,O
correlated,3589,O
with,3589,O
macrophage,3589,O
activation,3589,O
and,3589,O
furthermore,3589,O
that,3589,O
it,3589,O
is,3589,O
an,3589,O
ideal,3589,O
marker,3589,O
for,3589,O
primary,3589,O
tumor,3589,O
inflammation,3589,O
and,3589,O
early,3589,O
stage,3589,O
metastatic,3589,O
lesions,3589,O
.,3589,O
Mutational,3590,O
consequences,3590,O
of,3590,O
dNTP,3590,O
pool,3590,O
imbalances,3590,O
in,3590,O
E.,3590,O
coli,3590,O
.,3590,O
The,3591,O
accuracy,3591,O
of,3591,O
DNA,3591,O
synthesis,3591,O
depends,3591,O
on,3591,O
the,3591,O
accuracy,3591,O
of,3591,O
the,3591,O
polymerase,3591,B-GENE-N
as,3591,O
well,3591,O
as,3591,O
the,3591,O
quality,3591,O
and,3591,O
concentration,3591,O
(,3591,O
s,3591,O
),3591,O
of,3591,O
the,3591,O
available,3591,O
5'-deoxynucleoside-triphosphate,3591,B-CHEMICAL
DNA,3591,O
precursors,3591,O
(,3591,O
dNTPs,3591,B-CHEMICAL
),3591,O
.,3591,O
The,3592,O
relationships,3592,O
between,3592,O
dNTPs,3592,B-CHEMICAL
and,3592,O
error,3592,O
rates,3592,O
have,3592,O
been,3592,O
studied,3592,O
in,3592,O
vitro,3592,O
",",3592,O
but,3592,O
only,3592,O
limited,3592,O
insights,3592,O
exist,3592,O
into,3592,O
these,3592,O
correlations,3592,O
during,3592,O
in,3592,O
vivo,3592,O
replication,3592,O
.,3592,O
We,3593,O
have,3593,O
investigated,3593,O
this,3593,O
issue,3593,O
in,3593,O
the,3593,O
bacterium,3593,O
Escherichia,3593,O
coli,3593,O
by,3593,O
analyzing,3593,O
the,3593,O
mutational,3593,O
properties,3593,O
of,3593,O
dcd,3593,B-GENE-Y
and,3593,O
ndk,3593,B-GENE-Y
strains,3593,O
.,3593,O
These,3594,O
strains,3594,O
",",3594,O
defective,3594,O
in,3594,O
dCTP,3594,B-CHEMICAL
deaminase,3594,I-GENE-Y
and,3594,O
nucleoside,3594,B-GENE-Y
diphosphate,3594,I-GENE-Y
kinase,3594,I-GENE-Y
",",3594,O
respectively,3594,O
",",3594,O
are,3594,O
characterized,3594,O
by,3594,O
both,3594,O
disturbances,3594,O
of,3594,O
dNTP,3594,B-CHEMICAL
pools,3594,O
and,3594,O
a,3594,O
mutator,3594,O
phenotype,3594,O
.,3594,O
ndk,3595,B-GENE-Y
strains,3595,O
have,3595,O
been,3595,O
studied,3595,O
before,3595,O
",",3595,O
but,3595,O
were,3595,O
included,3595,O
in,3595,O
this,3595,O
study,3595,O
",",3595,O
as,3595,O
controversies,3595,O
exist,3595,O
regarding,3595,O
the,3595,O
source,3595,O
of,3595,O
its,3595,O
mutator,3595,O
phenotype,3595,O
.,3595,O
We,3596,O
show,3596,O
that,3596,O
dcd,3596,B-GENE-Y
strains,3596,O
suffer,3596,O
from,3596,O
increased,3596,O
intracellular,3596,O
levels,3596,O
of,3596,O
dCTP,3596,B-CHEMICAL
(,3596,O
4-fold,3596,O
),3596,O
and,3596,O
reduced,3596,O
levels,3596,O
of,3596,O
dGTP,3596,B-CHEMICAL
(,3596,O
2-fold,3596,O
),3596,O
",",3596,O
while,3596,O
displaying,3596,O
",",3596,O
as,3596,O
measured,3596,O
using,3596,O
a,3596,O
set,3596,O
of,3596,O
lacZ,3596,O
reversion,3596,O
markers,3596,O
in,3596,O
a,3596,O
mismatch-repair,3596,O
defective,3596,O
(,3596,O
mutL,3596,O
),3596,O
background,3596,O
",",3596,O
a,3596,O
strong,3596,O
mutator,3596,O
effect,3596,O
for,3596,O
GCTA,3596,B-GENE-N
and,3596,O
ATTA,3596,B-GENE-N
transversions,3596,O
(,3596,O
27-,3596,O
and,3596,O
42-fold,3596,O
enhancement,3596,O
",",3596,O
respectively,3596,O
),3596,O
.,3596,O
In,3597,O
contrast,3597,O
",",3597,O
ndk,3597,B-GENE-Y
strains,3597,O
possess,3597,O
a,3597,O
lowered,3597,O
dATP,3597,B-CHEMICAL
level,3597,O
(,3597,O
4-fold,3597,O
),3597,O
and,3597,O
modestly,3597,O
enhanced,3597,O
dCTP,3597,B-CHEMICAL
level,3597,O
(,3597,O
2-fold,3597,O
),3597,O
",",3597,O
while,3597,O
its,3597,O
mutator,3597,O
effect,3597,O
is,3597,O
specific,3597,O
for,3597,O
just,3597,O
the,3597,O
ATTA,3597,B-GENE-N
transversions,3597,O
.,3597,O
The,3598,O
two,3598,O
strains,3598,O
also,3598,O
display,3598,O
differential,3598,O
mutability,3598,O
for,3598,O
rifampicin-resistant,3598,B-CHEMICAL
mutants,3598,O
.,3598,O
Overall,3599,O
",",3599,O
our,3599,O
analysis,3599,O
reveals,3599,O
for,3599,O
both,3599,O
strains,3599,O
a,3599,O
satisfactory,3599,O
correlation,3599,O
between,3599,O
dNTP,3599,B-CHEMICAL
pool,3599,O
alterations,3599,O
and,3599,O
the,3599,O
replication,3599,O
error,3599,O
rates,3599,O
",",3599,O
and,3599,O
also,3599,O
suggests,3599,O
that,3599,O
a,3599,O
minimal,3599,O
explanation,3599,O
for,3599,O
the,3599,O
ndk,3599,B-GENE-Y
mutator,3599,O
does,3599,O
not,3599,O
require,3599,O
assumptions,3599,O
beyond,3599,O
the,3599,O
predicted,3599,O
effect,3599,O
of,3599,O
the,3599,O
dNTP,3599,B-CHEMICAL
pools,3599,O
.,3599,O
MAPK,3600,B-GENE-N
signaling,3600,O
pathways,3600,O
regulate,3600,O
mitochondrial-mediated,3600,O
apoptosis,3600,O
induced,3600,O
by,3600,O
isoorientin,3600,B-CHEMICAL
in,3600,O
human,3600,O
hepatoblastoma,3600,O
cancer,3600,O
cells,3600,O
.,3600,O
Isoorientin,3601,B-CHEMICAL
(,3601,O
ISO,3601,B-CHEMICAL
),3601,O
(,3601,O
CAS,3601,O
RN,3601,O
:,3601,O
4261-42-1,3601,B-CHEMICAL
),3601,O
is,3601,O
a,3601,O
flavonoid,3601,B-CHEMICAL
compound,3601,O
that,3601,O
can,3601,O
be,3601,O
extracted,3601,O
from,3601,O
several,3601,O
plant,3601,O
species,3601,O
",",3601,O
such,3601,O
as,3601,O
Phyllostachys,3601,O
pubescens,3601,O
",",3601,O
Patrinia,3601,O
",",3601,O
and,3601,O
Drosophyllum,3601,O
lusitanicum,3601,O
.,3601,O
ISO,3602,B-CHEMICAL
is,3602,O
able,3602,O
to,3602,O
induce,3602,O
apoptosis,3602,O
through,3602,O
mitochondrial,3602,O
dysfunction,3602,O
and,3602,O
inhibition,3602,O
of,3602,O
PI3K/Akt,3602,B-GENE-N
signaling,3602,O
pathway,3602,O
in,3602,O
HepG2,3602,O
cells,3602,O
",",3602,O
however,3602,O
",",3602,O
the,3602,O
effects,3602,O
of,3602,O
ISO,3602,B-CHEMICAL
on,3602,O
MAPK,3602,B-GENE-N
signaling,3602,O
pathways,3602,O
remain,3602,O
unknown,3602,O
.,3602,O
The,3603,O
present,3603,O
study,3603,O
investigated,3603,O
the,3603,O
effects,3603,O
of,3603,O
ISO,3603,B-CHEMICAL
on,3603,O
this,3603,O
pathway,3603,O
",",3603,O
and,3603,O
the,3603,O
roles,3603,O
of,3603,O
MAPK,3603,B-GENE-N
kinases,3603,B-GENE-N
on,3603,O
mitochondrial-mediated,3603,O
apoptosis,3603,O
in,3603,O
HepG2,3603,O
cells,3603,O
.,3603,O
The,3604,O
results,3604,O
showed,3604,O
that,3604,O
ISO,3604,B-CHEMICAL
induced,3604,O
cell,3604,O
death,3604,O
in,3604,O
a,3604,O
dose-,3604,O
and,3604,O
time-dependent,3604,O
manner,3604,O
",",3604,O
and,3604,O
induction,3604,O
apoptosis,3604,O
is,3604,O
main,3604,O
cause,3604,O
for,3604,O
ISO-induced,3604,B-CHEMICAL
cytotoxicity,3604,O
in,3604,O
HepG2,3604,O
cells,3604,O
.,3604,O
ISO,3605,B-CHEMICAL
significantly,3605,O
inhibited,3605,O
the,3605,O
levels,3605,O
of,3605,O
ERK1/2,3605,B-GENE-N
kinase,3605,O
and,3605,O
increased,3605,O
the,3605,O
expression,3605,O
of,3605,O
JNK,3605,B-GENE-N
and,3605,O
p38,3605,B-GENE-N
kinases,3605,B-GENE-N
.,3605,O
Furthermore,3606,O
",",3606,O
U0126,3606,B-CHEMICAL
(,3606,O
an,3606,O
ERK1/2,3606,B-GENE-N
inhibitor,3606,O
),3606,O
significantly,3606,O
enhanced,3606,O
the,3606,O
ISO-induced,3606,B-CHEMICAL
the,3606,O
Bax/Bcl-2,3606,B-GENE-Y
ratio,3606,O
",",3606,O
the,3606,O
release,3606,O
of,3606,O
cytochrome,3606,B-GENE-Y
c,3606,I-GENE-Y
to,3606,O
the,3606,O
cytosol,3606,O
fraction,3606,O
",",3606,O
and,3606,O
the,3606,O
levels,3606,O
of,3606,O
cleaved,3606,O
caspase-3,3606,B-GENE-Y
.,3606,O
While,3607,O
SP600125,3607,B-CHEMICAL
(,3607,O
a,3607,O
JNK,3607,B-GENE-N
inhibitor,3607,O
),3607,O
and,3607,O
SB203580,3607,B-CHEMICAL
(,3607,O
a,3607,O
p38,3607,B-GENE-N
inhibitor,3607,O
),3607,O
markedly,3607,O
prevented,3607,O
the,3607,O
expression,3607,O
of,3607,O
these,3607,O
proteins,3607,O
induced,3607,O
by,3607,O
ISO,3607,B-CHEMICAL
.,3607,O
Furthermore,3608,O
",",3608,O
the,3608,O
ROS,3608,O
inhibitor,3608,O
(,3608,O
NAC,3608,B-CHEMICAL
),3608,O
notably,3608,O
promoted,3608,O
the,3608,O
inhibited,3608,O
effect,3608,O
of,3608,O
ISO,3608,B-CHEMICAL
on,3608,O
the,3608,O
ERK1/2,3608,B-GENE-N
kinase,3608,O
.,3608,O
NAC,3609,B-CHEMICAL
also,3609,O
suppressed,3609,O
the,3609,O
p-JNK,3609,O
and,3609,O
p-p38,3609,B-GENE-N
",",3609,O
but,3609,O
failed,3609,O
to,3609,O
reverse,3609,O
the,3609,O
effects,3609,O
of,3609,O
ISO,3609,B-CHEMICAL
.,3609,O
These,3610,O
results,3610,O
demonstrated,3610,O
for,3610,O
the,3610,O
first,3610,O
time,3610,O
that,3610,O
ISO,3610,B-CHEMICAL
induces,3610,O
apoptosis,3610,O
in,3610,O
HepG2,3610,O
cells,3610,O
through,3610,O
inactivating,3610,O
ERK1/2,3610,B-GENE-N
kinase,3610,O
and,3610,O
activating,3610,O
JNK,3610,B-GENE-N
and,3610,O
p38,3610,B-GENE-N
kinases,3610,B-GENE-N
",",3610,O
and,3610,O
ROS,3610,O
stimulated,3610,O
by,3610,O
ISO,3610,B-CHEMICAL
is,3610,O
able,3610,O
to,3610,O
activate,3610,O
the,3610,O
MAPK,3610,B-GENE-N
singaling,3610,O
pathway,3610,O
as,3610,O
the,3610,O
upstream,3610,O
signaling,3610,O
molecules,3610,O
.,3610,O
Initiating,3611,O
event,3611,O
of,3611,O
the,3611,O
mitochondrial-mediated,3611,O
apoptosis,3611,O
induced,3611,O
by,3611,O
ISO,3611,B-CHEMICAL
is,3611,O
MAPK,3611,B-GENE-N
signals,3611,O
.,3611,O
Antithrombotic,3612,O
and,3612,O
profibrinolytic,3612,O
activities,3612,O
of,3612,O
isorhamnetin-3-O-galactoside,3612,B-CHEMICAL
and,3612,O
hyperoside,3612,B-CHEMICAL
.,3612,O
The,3613,O
potential,3613,O
anticoagulant,3613,O
activities,3613,O
of,3613,O
two,3613,O
single,3613,O
compounds,3613,O
",",3613,O
isorhamnetin-3-O-galactoside,3613,B-CHEMICAL
(,3613,O
IMG,3613,B-CHEMICAL
),3613,O
and,3613,O
hyperoside,3613,B-CHEMICAL
",",3613,O
from,3613,O
Oenanthe,3613,O
javanica,3613,O
",",3613,O
were,3613,O
tested,3613,O
.,3613,O
The,3614,O
anticoagulant,3614,O
activities,3614,O
were,3614,O
investigated,3614,O
by,3614,O
measuring,3614,O
activated,3614,O
partial,3614,O
thromboplastin,3614,B-GENE-Y
time,3614,O
(,3614,O
aPTT,3614,O
),3614,O
and,3614,O
prothrombin,3614,B-GENE-Y
time,3614,O
(,3614,O
PT,3614,O
),3614,O
",",3614,O
and,3614,O
the,3614,O
ability,3614,O
to,3614,O
inhibit,3614,O
production,3614,O
of,3614,O
thrombin,3614,B-GENE-Y
and,3614,O
activated,3614,B-GENE-Y
factor,3614,I-GENE-Y
X,3614,I-GENE-Y
(,3614,O
FXa,3614,B-GENE-Y
),3614,O
was,3614,O
investigated,3614,O
in,3614,O
human,3614,O
umbilical,3614,O
vein,3614,O
endothelial,3614,O
cells,3614,O
(,3614,O
HUVECs,3614,O
),3614,O
.,3614,O
And,3615,O
",",3615,O
the,3615,O
effects,3615,O
of,3615,O
the,3615,O
compounds,3615,O
on,3615,O
expression,3615,O
of,3615,O
plasminogen,3615,B-GENE-Y
activator,3615,I-GENE-Y
inhibitor,3615,I-GENE-Y
type,3615,I-GENE-Y
1,3615,I-GENE-Y
(,3615,O
PAI-1,3615,B-GENE-Y
),3615,O
and,3615,O
tissue-type,3615,B-GENE-Y
plasminogen,3615,I-GENE-Y
activator,3615,I-GENE-Y
(,3615,B-GENE-Y
t-PA,3615,I-GENE-Y
),3615,O
were,3615,O
tested,3615,O
in,3615,O
tumor,3615,B-GENE-Y
necrosis,3615,I-GENE-Y
factor-,3615,I-GENE-Y
(,3615,I-GENE-Y
TNF,3615,I-GENE-Y
),3615,I-GENE-Y
-,3615,I-GENE-Y
activated,3615,O
HUVECs,3615,O
.,3615,O
Treatment,3616,O
with,3616,O
IMG,3616,B-CHEMICAL
and,3616,O
hyperoside,3616,B-CHEMICAL
resulted,3616,O
in,3616,O
significantly,3616,O
prolonged,3616,O
aPTT,3616,O
and,3616,O
PT,3616,O
and,3616,O
inhibition,3616,O
of,3616,O
the,3616,O
activities,3616,O
of,3616,O
thrombin,3616,B-GENE-Y
and,3616,O
FXa,3616,B-GENE-Y
",",3616,O
and,3616,O
IMG,3616,B-CHEMICAL
or,3616,O
hyperoside,3616,B-CHEMICAL
inhibited,3616,O
production,3616,O
of,3616,O
thrombin,3616,B-GENE-Y
and,3616,O
FXa,3616,B-GENE-Y
in,3616,O
HUVECs,3616,O
.,3616,O
In,3617,O
accordance,3617,O
with,3617,O
these,3617,O
anticoagulant,3617,O
activities,3617,O
",",3617,O
both,3617,O
agents,3617,O
elicited,3617,O
anticoagulant,3617,O
effects,3617,O
in,3617,O
mouse,3617,O
.,3617,O
In,3618,O
addition,3618,O
",",3618,O
treatment,3618,O
with,3618,O
IMG,3618,B-CHEMICAL
and,3618,O
hyperoside,3618,B-CHEMICAL
resulted,3618,O
in,3618,O
inhibition,3618,O
of,3618,O
TNF--induced,3618,B-GENE-Y
production,3618,O
of,3618,O
PAI-1,3618,B-GENE-Y
",",3618,O
and,3618,O
treatment,3618,O
with,3618,O
IMG,3618,B-CHEMICAL
resulted,3618,O
in,3618,O
significant,3618,O
reduction,3618,O
of,3618,O
the,3618,O
PAI-1,3618,B-GENE-Y
to,3618,O
t-PA,3618,B-GENE-Y
ratio,3618,O
.,3618,O
The,3619,O
anticoagulant,3619,O
and,3619,O
profibrinolytic,3619,O
effects,3619,O
of,3619,O
IMG,3619,B-CHEMICAL
were,3619,O
greater,3619,O
than,3619,O
those,3619,O
of,3619,O
hyperoside,3619,B-CHEMICAL
",",3619,O
indicating,3619,O
positive,3619,O
regulation,3619,O
of,3619,O
its,3619,O
anticoagulant,3619,O
function,3619,O
by,3619,O
the,3619,O
methoxy,3619,B-CHEMICAL
group,3619,O
of,3619,O
IMG,3619,B-CHEMICAL
.,3619,O
IMG,3620,B-CHEMICAL
and,3620,O
hyperoside,3620,B-CHEMICAL
possess,3620,O
antithrombotic,3620,O
activities,3620,O
and,3620,O
offer,3620,O
bases,3620,O
for,3620,O
development,3620,O
of,3620,O
a,3620,O
novel,3620,O
anticoagulant,3620,O
.,3620,O
Optimization,3621,O
of,3621,O
5-hydroxytryptamines,3621,B-CHEMICAL
as,3621,O
dual,3621,O
function,3621,O
inhibitors,3621,O
targeting,3621,O
phospholipase,3621,B-GENE-N
A2,3621,I-GENE-N
and,3621,O
leukotriene,3621,B-GENE-Y
A4,3621,I-GENE-Y
hydrolase,3621,I-GENE-Y
.,3621,O
Dual,3622,O
function,3622,O
inhibitors,3622,O
targeting,3622,O
phospholipase,3622,B-GENE-N
A,3622,I-GENE-N
(,3622,I-GENE-N
2,3622,I-GENE-N
),3622,I-GENE-N
(,3622,O
PLA,3622,B-GENE-N
(,3622,I-GENE-N
2,3622,I-GENE-N
),3622,I-GENE-N
),3622,O
and,3622,O
leukotriene,3622,B-GENE-Y
A,3622,I-GENE-Y
(,3622,I-GENE-Y
4,3622,I-GENE-Y
),3622,I-GENE-Y
hydrolase,3622,I-GENE-Y
(,3622,O
LTA,3622,B-GENE-Y
(,3622,I-GENE-Y
4,3622,I-GENE-Y
),3622,I-GENE-Y
H,3622,I-GENE-Y
),3622,O
may,3622,O
balance,3622,O
the,3622,O
arachidonic,3622,B-CHEMICAL
acid,3622,I-CHEMICAL
(,3622,O
AA,3622,O
),3622,O
metabolic,3622,O
network,3622,O
and,3622,O
be,3622,O
used,3622,O
as,3622,O
new,3622,O
anti-inflammatory,3622,O
drugs,3622,O
.,3622,O
In,3623,O
previous,3623,O
study,3623,O
",",3623,O
we,3623,O
discovered,3623,O
multi-target,3623,O
drugs,3623,O
towards,3623,O
the,3623,O
AA,3623,O
metabolic,3623,O
network,3623,O
",",3623,O
among,3623,O
which,3623,O
a,3623,O
dual-target,3623,O
inhibitor,3623,O
(,3623,O
JMC08-4,3623,B-CHEMICAL
),3623,O
for,3623,O
human,3623,B-GENE-Y
nonpancreatic,3623,I-GENE-Y
secretory,3623,I-GENE-Y
phospholipase,3623,I-GENE-Y
A,3623,I-GENE-Y
(,3623,I-GENE-Y
2,3623,I-GENE-Y
),3623,I-GENE-Y
(,3623,O
hnps-PLA,3623,B-GENE-Y
(,3623,I-GENE-Y
2,3623,I-GENE-Y
),3623,I-GENE-Y
),3623,O
and,3623,O
human,3623,B-GENE-Y
leukotriene,3623,I-GENE-Y
A,3623,I-GENE-Y
(,3623,I-GENE-Y
4,3623,I-GENE-Y
),3623,I-GENE-Y
hydrolase,3623,I-GENE-Y
(,3623,O
LTA,3623,B-GENE-Y
(,3623,I-GENE-Y
4,3623,I-GENE-Y
),3623,I-GENE-Y
H-h,3623,I-GENE-Y
),3623,O
was,3623,O
found,3623,O
.,3623,O
Based,3624,O
on,3624,O
the,3624,O
structure,3624,O
of,3624,O
compound,3624,O
JMC08-4,3624,B-CHEMICAL
",",3624,O
new,3624,O
dual-target,3624,O
inhibitors,3624,O
were,3624,O
designed,3624,O
assisted,3624,O
by,3624,O
molecular,3624,O
docking,3624,O
.,3624,O
In,3625,O
this,3625,O
report,3625,O
",",3625,O
a,3625,O
series,3625,O
of,3625,O
5-hydroxytryptamine,3625,B-CHEMICAL
compounds,3625,O
were,3625,O
synthesized,3625,O
;,3625,O
and,3625,O
most,3625,O
of,3625,O
these,3625,O
title,3625,O
compounds,3625,O
showed,3625,O
more,3625,O
potent,3625,O
inhibitory,3625,O
activity,3625,O
than,3625,O
compound,3625,O
JMC08-4,3625,B-CHEMICAL
in,3625,O
the,3625,O
in,3625,O
vitro,3625,O
bioassay,3625,O
against,3625,O
these,3625,O
two,3625,O
enzymes,3625,O
.,3625,O
The,3626,O
best,3626,O
one,3626,O
inhibited,3626,O
hnps-PLA,3626,B-GENE-Y
(,3626,I-GENE-Y
2,3626,I-GENE-Y
),3626,I-GENE-Y
and,3626,O
LTA,3626,B-GENE-Y
(,3626,I-GENE-Y
4,3626,I-GENE-Y
),3626,I-GENE-Y
H-h,3626,I-GENE-Y
with,3626,O
IC,3626,O
(,3626,O
50,3626,O
),3626,O
values,3626,O
of,3626,O
9.2,3626,O
,3626,O
0.5,3626,O
M,3626,O
and,3626,O
2.4,3626,O
,3626,O
1.4,3626,O
M,3626,O
",",3626,O
respectively,3626,O
.,3626,O
Apomorphine,3627,B-CHEMICAL
is,3627,O
a,3627,O
bimodal,3627,O
modulator,3627,O
of,3627,O
TRPA1,3627,B-GENE-Y
channels,3627,O
.,3627,O
Apomorphine,3628,B-CHEMICAL
is,3628,O
a,3628,O
non-narcotic,3628,O
derivative,3628,O
of,3628,O
morphine,3628,B-CHEMICAL
",",3628,O
which,3628,O
acts,3628,O
as,3628,O
a,3628,O
dopamine,3628,B-CHEMICAL
agonist,3628,O
and,3628,O
is,3628,O
clinically,3628,O
used,3628,O
to,3628,O
treat,3628,O
``,3628,O
off-states,3628,O
'',3628,O
in,3628,I-CHEMICAL
patients,3628,O
suffering,3628,O
from,3628,O
Parkinson,3628,O
's,3628,O
disease,3628,O
.,3628,O
Adverse,3629,O
effects,3629,O
of,3629,O
apomorphine,3629,B-CHEMICAL
treatment,3629,O
include,3629,O
severe,3629,O
emesis,3629,O
and,3629,O
nausea,3629,O
",",3629,O
and,3629,O
ulceration,3629,O
and,3629,O
pain,3629,O
at,3629,O
the,3629,O
injection,3629,O
site,3629,O
.,3629,O
We,3630,O
wanted,3630,O
to,3630,O
test,3630,O
whether,3630,O
sensory,3630,O
transient,3630,B-GENE-N
receptor,3630,I-GENE-N
potential,3630,I-GENE-N
(,3630,I-GENE-N
TRP,3630,I-GENE-N
),3630,I-GENE-N
channels,3630,I-GENE-N
are,3630,O
a,3630,O
molecular,3630,O
target,3630,O
for,3630,O
apomorphine,3630,B-CHEMICAL
.,3630,O
Here,3631,O
",",3631,O
we,3631,O
show,3631,O
that,3631,O
rTRPV1,3631,B-GENE-Y
",",3631,O
rTRPV2,3631,B-GENE-Y
",",3631,O
rTRPV3,3631,B-GENE-Y
",",3631,O
and,3631,O
mTRPV4,3631,B-GENE-Y
",",3631,O
as,3631,O
well,3631,O
as,3631,O
hTRPM8,3631,B-GENE-Y
",",3631,O
and,3631,O
rTRPM3,3631,B-GENE-Y
",",3631,O
which,3631,O
are,3631,O
expressed,3631,O
in,3631,O
dorsal,3631,O
root,3631,O
ganglion,3631,O
neurons,3631,O
",",3631,O
are,3631,O
insensitive,3631,O
toward,3631,O
apomorphine,3631,B-CHEMICAL
treatment,3631,O
.,3631,O
This,3632,O
also,3632,O
applied,3632,O
to,3632,O
the,3632,O
cellular,3632,O
redox,3632,O
sensor,3632,O
hTRPM2,3632,B-GENE-Y
.,3632,O
On,3633,O
the,3633,O
contrary,3633,O
",",3633,O
human,3633,B-GENE-Y
TRPA1,3633,I-GENE-Y
could,3633,O
be,3633,O
concentration-dependently,3633,O
modulated,3633,O
by,3633,O
apomorphine,3633,B-CHEMICAL
.,3633,O
Whereas,3634,O
the,3634,O
addition,3634,O
of,3634,O
apomorphine,3634,B-CHEMICAL
in,3634,O
the,3634,O
low,3634,O
micromolar,3634,O
range,3634,O
produced,3634,O
an,3634,O
irreversible,3634,O
activation,3634,O
of,3634,O
the,3634,O
channel,3634,O
",",3634,O
application,3634,O
of,3634,O
higher,3634,O
concentrations,3634,O
caused,3634,O
a,3634,O
reversible,3634,O
voltage-dependent,3634,O
inhibition,3634,O
of,3634,O
heterologously,3634,O
expressed,3634,O
TRPA1,3634,B-GENE-Y
channels,3634,O
",",3634,O
resulting,3634,O
from,3634,O
a,3634,O
reduction,3634,O
of,3634,O
single-channel,3634,O
open,3634,O
times,3634,O
.,3634,O
In,3635,O
addition,3635,O
",",3635,O
we,3635,O
provide,3635,O
evidence,3635,O
that,3635,O
apomorphine,3635,B-CHEMICAL
also,3635,O
acts,3635,O
on,3635,O
endogenous,3635,O
TRPA1,3635,B-GENE-N
in,3635,O
cultured,3635,O
dorsal,3635,O
root,3635,O
ganglion,3635,O
neurons,3635,O
from,3635,O
rats,3635,O
and,3635,O
in,3635,O
the,3635,O
enterochromaffin,3635,O
model,3635,O
cell,3635,O
line,3635,O
QGP-1,3635,O
",",3635,O
from,3635,O
which,3635,O
serotonin,3635,B-CHEMICAL
is,3635,O
released,3635,O
upon,3635,O
activation,3635,O
of,3635,O
TRPA1,3635,B-GENE-Y
.,3635,O
Our,3636,O
study,3636,O
shows,3636,O
that,3636,O
human,3636,B-GENE-Y
TRPA1,3636,I-GENE-Y
is,3636,O
a,3636,O
target,3636,O
for,3636,O
apomorphine,3636,B-CHEMICAL
",",3636,O
suggesting,3636,O
that,3636,O
an,3636,O
activation,3636,O
of,3636,O
TRPA1,3636,B-GENE-Y
might,3636,O
contribute,3636,O
to,3636,O
adverse,3636,O
side,3636,O
effects,3636,O
such,3636,O
as,3636,O
nausea,3636,O
and,3636,O
painful,3636,O
injections,3636,O
",",3636,O
which,3636,O
can,3636,O
occur,3636,O
during,3636,O
treatment,3636,O
with,3636,O
apomorphine,3636,B-CHEMICAL
.,3636,O
Human,3637,B-GENE-Y
stearoyl-CoA,3637,B-CHEMICAL
desaturase,3637,I-GENE-Y
1,3637,I-GENE-Y
(,3637,O
SCD-1,3637,B-GENE-Y
),3637,O
gene,3637,O
expression,3637,O
is,3637,O
negatively,3637,O
regulated,3637,O
by,3637,O
thyroid,3637,B-CHEMICAL
hormone,3637,I-CHEMICAL
without,3637,O
direct,3637,O
binding,3637,O
of,3637,O
thyroid,3637,B-CHEMICAL
hormone,3637,I-CHEMICAL
receptor,3637,I-GENE-N
to,3637,O
the,3637,O
gene,3637,O
promoter,3637,O
.,3637,O
Stearoyl-CoA,3638,B-CHEMICAL
desaturase-1,3638,I-GENE-Y
(,3638,O
SCD-1,3638,B-GENE-Y
),3638,O
plays,3638,O
a,3638,O
pivotal,3638,O
role,3638,O
in,3638,O
an,3638,O
increase,3638,O
of,3638,O
triglyceride,3638,B-CHEMICAL
by,3638,O
an,3638,O
excess,3638,O
of,3638,O
dietary,3638,O
carbohydrate,3638,B-CHEMICAL
intake,3638,O
.,3638,O
Dietary,3639,O
carbohydrates,3639,B-CHEMICAL
increase,3639,O
SCD-1,3639,B-GENE-Y
gene,3639,O
expression,3639,O
in,3639,O
liver,3639,O
by,3639,O
sterol,3639,B-CHEMICAL
response,3639,I-GENE-Y
element,3639,I-GENE-Y
binding,3639,I-GENE-Y
protein,3639,I-GENE-Y
(,3639,I-GENE-Y
SREBP,3639,I-GENE-Y
),3639,I-GENE-Y
-1c-dependent,3639,O
and,3639,O
SREBP-1c,3639,B-GENE-Y
-independent,3639,O
pathways,3639,O
.,3639,O
Previous,3640,O
report,3640,O
demonstrated,3640,O
that,3640,O
thyroid,3640,B-CHEMICAL
hormone,3640,I-CHEMICAL
(,3640,O
TH,3640,O
),3640,O
negatively,3640,O
regulates,3640,O
mouse,3640,B-GENE-N
SCD-1,3640,I-GENE-N
gene,3640,I-GENE-N
promoter,3640,I-GENE-N
before,3640,O
SREBP-1c,3640,B-GENE-Y
was,3640,O
revealed,3640,O
.,3640,O
We,3641,O
reported,3641,O
that,3641,O
TH,3641,O
negatively,3641,O
regulates,3641,O
SREBP-1c,3641,B-GENE-Y
recently,3641,O
.,3641,O
Therefore,3642,O
",",3642,O
in,3642,O
the,3642,O
current,3642,O
study,3642,O
",",3642,O
we,3642,O
examined,3642,O
whether,3642,O
and,3642,O
how,3642,O
TH,3642,O
regulates,3642,O
human,3642,B-GENE-Y
SCD-1,3642,I-GENE-Y
gene,3642,O
expression,3642,O
and,3642,O
evaluated,3642,O
SREBP-1c,3642,B-GENE-Y
effect,3642,O
on,3642,O
the,3642,O
negative,3642,O
regulation,3642,O
.,3642,O
Luciferase,3643,O
assays,3643,O
revealed,3643,O
that,3643,O
TH,3643,O
suppresses,3643,O
both,3643,O
mouse,3643,B-GENE-N
and,3643,I-GENE-N
human,3643,I-GENE-N
SCD-1,3643,I-GENE-N
gene,3643,I-GENE-N
promoter,3643,I-GENE-N
activity,3643,O
.,3643,O
In,3644,O
SREBP-1,3644,B-GENE-Y
knockdown,3644,O
HepG2,3644,O
cells,3644,O
",",3644,O
TH,3644,O
still,3644,O
suppresses,3644,O
SCD-1,3644,B-GENE-N
gene,3644,I-GENE-N
promoter,3644,I-GENE-N
activity,3644,O
",",3644,O
and,3644,O
it,3644,O
also,3644,O
exerted,3644,O
the,3644,O
negative,3644,O
regulation,3644,O
under,3644,O
cotransfection,3644,O
of,3644,O
a,3644,O
small,3644,O
amount,3644,O
of,3644,O
SREBP-1c,3644,B-GENE-Y
.,3644,O
These,3645,O
data,3645,O
indicated,3645,O
that,3645,O
SREBP-1c,3645,B-GENE-Y
does,3645,O
not,3645,O
play,3645,O
the,3645,O
decisive,3645,O
role,3645,O
for,3645,O
the,3645,O
negative,3645,O
regulation,3645,O
by,3645,O
TH,3645,O
.,3645,O
The,3646,O
responsible,3646,O
region,3646,O
for,3646,O
the,3646,O
negative,3646,O
regulation,3646,O
in,3646,O
human,3646,B-GENE-N
SCD-1,3646,I-GENE-N
gene,3646,I-GENE-N
promoter,3646,I-GENE-N
turned,3646,O
out,3646,O
to,3646,O
be,3646,O
between,3646,O
-124,3646,O
and,3646,O
-92,3646,O
bp,3646,O
",",3646,O
referred,3646,O
to,3646,O
as,3646,O
site,3646,B-GENE-N
A.,3646,O
Chromatin,3646,O
immunoprecipitation,3646,O
assays,3646,O
demonstrated,3646,O
that,3646,O
TH,3646,B-GENE-Y
receptor-,3646,I-GENE-Y
is,3646,O
recruited,3646,O
to,3646,O
the,3646,O
region,3646,O
upon,3646,O
T,3646,O
(,3646,O
3,3646,O
),3646,O
administration,3646,O
",",3646,O
although,3646,O
TR-,3646,B-GENE-Y
does,3646,O
not,3646,O
bind,3646,O
directly,3646,O
to,3646,O
site,3646,B-GENE-N
A,3646,I-GENE-N
.,3646,O
In,3647,O
conclusion,3647,O
",",3647,O
TH,3647,O
negatively,3647,O
regulates,3647,O
human,3647,B-GENE-Y
SCD-1,3647,I-GENE-Y
gene,3647,O
expression,3647,O
in,3647,O
without,3647,O
direct,3647,O
binding,3647,O
of,3647,O
the,3647,O
TH,3647,B-GENE-N
receptor,3647,I-GENE-N
to,3647,O
the,3647,O
SCD-1,3647,B-GENE-N
gene,3647,I-GENE-N
promoter,3647,I-GENE-N
.,3647,O
Dissociation,3648,O
of,3648,O
Bcl-2-Beclin1,3648,B-GENE-Y
complex,3648,O
by,3648,O
activated,3648,O
AMPK,3648,B-GENE-Y
enhances,3648,O
cardiac,3648,O
autophagy,3648,O
and,3648,O
protects,3648,O
against,3648,O
cardiomyocyte,3648,O
apoptosis,3648,O
in,3648,O
diabetes,3648,O
.,3648,O
Diabetic,3649,O
cardiomyopathy,3649,O
is,3649,O
associated,3649,O
with,3649,O
suppression,3649,O
of,3649,O
cardiac,3649,O
autophagy,3649,O
",",3649,O
and,3649,O
activation,3649,O
of,3649,O
AMP-activated,3649,B-CHEMICAL
protein,3649,I-GENE-Y
kinase,3649,I-GENE-Y
(,3649,O
AMPK,3649,B-GENE-Y
),3649,O
restores,3649,O
cardiac,3649,O
autophagy,3649,O
and,3649,O
prevents,3649,O
cardiomyopathy,3649,O
in,3649,O
diabetic,3649,O
mice,3649,O
",",3649,O
albeit,3649,O
by,3649,O
an,3649,O
unknown,3649,O
mechanism,3649,O
.,3649,O
We,3650,O
hypothesized,3650,O
that,3650,O
AMPK-induced,3650,B-GENE-N
autophagy,3650,O
ameliorates,3650,O
diabetic,3650,O
cardiomyopathy,3650,O
by,3650,O
inhibiting,3650,O
cardiomyocyte,3650,O
apoptosis,3650,O
and,3650,O
examined,3650,O
the,3650,O
effects,3650,O
of,3650,O
AMPK,3650,B-GENE-N
on,3650,O
the,3650,O
interaction,3650,O
between,3650,O
Beclin1,3650,B-GENE-N
and,3650,O
Bcl-2,3650,B-GENE-N
",",3650,O
a,3650,O
switch,3650,O
between,3650,O
autophagy,3650,O
and,3650,O
apoptosis,3650,O
",",3650,O
in,3650,O
diabetic,3650,O
mice,3650,O
and,3650,O
high,3650,O
glucose-treated,3650,B-CHEMICAL
H9c2,3650,O
cardiac,3650,O
myoblast,3650,O
cells,3650,O
.,3650,O
Exposure,3651,O
of,3651,O
H9c2,3651,O
cells,3651,O
to,3651,O
high,3651,O
glucose,3651,B-CHEMICAL
reduced,3651,O
AMPK,3651,B-GENE-Y
activity,3651,O
",",3651,O
inhibited,3651,O
Jun,3651,B-GENE-Y
NH2-terminal,3651,B-CHEMICAL
kinase,3651,I-GENE-Y
1,3651,I-GENE-Y
(,3651,O
JNK1,3651,B-GENE-Y
),3651,O
-B-cell,3651,O
lymphoma,3651,I-GENE-Y
2,3651,I-GENE-Y
(,3651,O
Bcl-2,3651,B-GENE-Y
),3651,O
signaling,3651,O
",",3651,O
and,3651,O
promoted,3651,O
Beclin1,3651,B-GENE-Y
binding,3651,O
to,3651,O
Bcl-2,3651,B-GENE-Y
.,3651,O
Conversely,3652,O
",",3652,O
activation,3652,O
of,3652,O
AMPK,3652,B-GENE-Y
by,3652,O
metformin,3652,O
stimulated,3652,O
JNK1-Bcl-2,3652,B-GENE-Y
signaling,3652,O
and,3652,O
disrupted,3652,O
the,3652,O
Beclin1-Bcl-2,3652,B-GENE-Y
complex,3652,O
.,3652,O
Activation,3653,O
of,3653,O
AMPK,3653,B-GENE-Y
",",3653,O
which,3653,O
normalized,3653,O
cardiac,3653,O
autophagy,3653,O
",",3653,O
attenuated,3653,O
high,3653,O
glucose-induced,3653,B-CHEMICAL
apoptosis,3653,O
in,3653,O
cultured,3653,O
H9c2,3653,O
cells,3653,O
.,3653,O
This,3654,O
effect,3654,O
was,3654,O
attenuated,3654,O
by,3654,O
inhibition,3654,O
of,3654,O
autophagy,3654,O
.,3654,O
Finally,3655,O
",",3655,O
chronic,3655,O
administration,3655,O
of,3655,O
metformin,3655,B-CHEMICAL
in,3655,O
diabetic,3655,O
mice,3655,O
restored,3655,O
cardiac,3655,O
autophagy,3655,O
by,3655,O
activating,3655,O
JNK1-Bcl-2,3655,B-GENE-Y
pathways,3655,O
and,3655,O
dissociating,3655,O
Beclin1,3655,B-GENE-Y
and,3655,O
Bcl-2,3655,B-GENE-Y
.,3655,O
The,3656,O
induction,3656,O
of,3656,O
autophagy,3656,O
protected,3656,O
against,3656,O
cardiac,3656,O
apoptosis,3656,O
and,3656,O
improved,3656,O
cardiac,3656,O
structure,3656,O
and,3656,O
function,3656,O
in,3656,O
diabetic,3656,O
mice,3656,O
.,3656,O
We,3657,O
concluded,3657,O
that,3657,O
dissociation,3657,O
of,3657,O
Bcl-2,3657,B-GENE-Y
from,3657,O
Beclin1,3657,B-GENE-Y
may,3657,O
be,3657,O
an,3657,O
important,3657,O
mechanism,3657,O
for,3657,O
preventing,3657,O
diabetic,3657,O
cardiomyopathy,3657,O
via,3657,O
AMPK,3657,B-GENE-N
activation,3657,O
that,3657,O
restores,3657,O
autophagy,3657,O
and,3657,O
protects,3657,O
against,3657,O
cardiac,3657,O
apoptosis,3657,O
.,3657,O
Metformin-mediated,3658,B-CHEMICAL
downregulation,3658,O
of,3658,O
p38,3658,B-GENE-N
mitogen-activated,3658,B-GENE-N
protein,3658,I-GENE-N
kinase-dependent,3658,O
excision,3658,O
repair,3658,O
cross-complementing,3658,O
1,3658,O
decreases,3658,O
DNA,3658,O
repair,3658,O
capacity,3658,O
and,3658,O
sensitizes,3658,O
human,3658,O
lung,3658,O
cancer,3658,O
cells,3658,O
to,3658,O
paclitaxel,3658,B-CHEMICAL
.,3658,O
Metformin,3659,B-CHEMICAL
",",3659,O
an,3659,O
extensively,3659,O
used,3659,O
and,3659,O
well-tolerated,3659,O
drug,3659,O
for,3659,O
treating,3659,O
individuals,3659,O
with,3659,O
type,3659,O
2,3659,O
diabetes,3659,O
",",3659,O
has,3659,O
recently,3659,O
gained,3659,O
significant,3659,O
attention,3659,O
as,3659,O
an,3659,O
anticancer,3659,O
drug,3659,O
.,3659,O
On,3660,O
the,3660,O
other,3660,O
hand,3660,O
",",3660,O
paclitaxel,3660,B-CHEMICAL
(,3660,O
Taxol,3660,B-CHEMICAL
),3660,O
is,3660,O
a,3660,O
new,3660,O
antineoplastic,3660,O
drug,3660,O
that,3660,O
has,3660,O
shown,3660,O
promise,3660,O
in,3660,O
the,3660,O
treatment,3660,O
of,3660,O
non-small,3660,O
cell,3660,O
lung,3660,O
cancer,3660,O
(,3660,O
NSCLC,3660,O
),3660,O
.,3660,O
High,3661,O
expression,3661,O
levels,3661,O
of,3661,O
excision,3661,B-GENE-Y
repair,3661,I-GENE-Y
cross-complementary,3661,I-GENE-Y
1,3661,I-GENE-Y
(,3661,O
ERCC1,3661,B-GENE-Y
),3661,O
in,3661,O
cancers,3661,O
have,3661,O
been,3661,O
positively,3661,O
associated,3661,O
with,3661,O
the,3661,O
DNA,3661,O
repair,3661,O
capacity,3661,O
and,3661,O
a,3661,O
poor,3661,O
prognosis,3661,O
in,3661,O
NSCLC,3661,O
patients,3661,O
treated,3661,O
with,3661,O
platinum-containing,3661,B-CHEMICAL
chemotherapy,3661,O
.,3661,O
In,3662,O
this,3662,O
current,3662,O
study,3662,O
",",3662,O
paclitaxel,3662,B-CHEMICAL
was,3662,O
found,3662,O
to,3662,O
increase,3662,O
phosphorylation,3662,O
of,3662,O
mitogen-activated,3662,B-GENE-N
protein,3662,I-GENE-N
kinase,3662,I-GENE-N
(,3662,O
MAPK,3662,O
),3662,O
kinase,3662,O
3/6,3662,O
(,3662,O
MKK3/6,3662,B-GENE-N
),3662,O
-p38,3662,O
MAPK,3662,B-GENE-N
as,3662,O
well,3662,O
as,3662,O
protein,3662,O
and,3662,O
mRNA,3662,O
levels,3662,O
of,3662,O
ERCC1,3662,B-GENE-Y
in,3662,O
H1650,3662,O
and,3662,O
H1703,3662,O
cells,3662,O
.,3662,O
Moreover,3663,O
",",3663,O
paclitaxel-induced,3663,B-CHEMICAL
ERCC1,3663,B-GENE-Y
protein,3663,O
and,3663,O
mRNA,3663,O
levels,3663,O
significantly,3663,O
decreased,3663,O
via,3663,O
the,3663,O
downregulation,3663,O
of,3663,O
p38,3663,B-GENE-N
activity,3663,O
by,3663,O
either,3663,O
a,3663,O
p38,3663,B-GENE-N
MAPK,3663,B-GENE-N
inhibitor,3663,O
SB202190,3663,B-CHEMICAL
or,3663,O
p38,3663,B-GENE-N
knockdown,3663,O
with,3663,O
specific,3663,O
small,3663,O
interfering,3663,O
RNA,3663,O
(,3663,O
siRNA,3663,O
),3663,O
.,3663,O
Specific,3664,O
inhibition,3664,O
of,3664,O
ERCC1,3664,B-GENE-Y
with,3664,O
siRNA,3664,O
was,3664,O
found,3664,O
to,3664,O
enhance,3664,O
the,3664,O
paclitaxel-induced,3664,B-CHEMICAL
cytotoxic,3664,O
effect,3664,O
and,3664,O
growth,3664,O
inhibition,3664,O
.,3664,O
Furthermore,3665,O
",",3665,O
metformin,3665,B-CHEMICAL
was,3665,O
able,3665,O
to,3665,O
not,3665,O
only,3665,O
decrease,3665,O
the,3665,O
paclitaxel-induced,3665,B-CHEMICAL
p38,3665,B-GENE-N
MAPK-mediated,3665,B-GENE-N
ERCC1,3665,B-GENE-Y
expression,3665,O
",",3665,O
but,3665,O
also,3665,O
augment,3665,O
the,3665,O
cytotoxic,3665,O
effect,3665,O
induced,3665,O
by,3665,O
paclitaxel,3665,B-CHEMICAL
.,3665,O
Finally,3666,O
",",3666,O
expression,3666,O
of,3666,O
constitutive,3666,O
activate,3666,O
MKK6,3666,B-GENE-Y
or,3666,O
HA-p38,3666,O
MAPK,3666,B-GENE-N
vectors,3666,O
in,3666,O
lung,3666,O
cancer,3666,O
cells,3666,O
was,3666,O
able,3666,O
to,3666,O
abrogate,3666,O
ERCC1,3666,B-GENE-Y
downregulation,3666,O
by,3666,O
metformin,3666,B-CHEMICAL
and,3666,O
paclitaxel,3666,B-CHEMICAL
as,3666,O
well,3666,O
as,3666,O
cell,3666,O
viability,3666,O
and,3666,O
DNA,3666,O
repair,3666,O
capacity,3666,O
.,3666,O
Overall,3667,O
",",3667,O
our,3667,O
results,3667,O
suggest,3667,O
that,3667,O
inhibition,3667,O
of,3667,O
the,3667,O
p38,3667,B-GENE-N
MAPK,3667,B-GENE-N
signaling,3667,O
by,3667,O
metformin,3667,B-CHEMICAL
coupled,3667,O
with,3667,O
paclitaxel,3667,B-CHEMICAL
therapy,3667,O
in,3667,O
human,3667,O
NSCLC,3667,O
cells,3667,O
may,3667,O
be,3667,O
a,3667,O
clinically,3667,O
useful,3667,O
combination,3667,O
",",3667,O
which,3667,O
however,3667,O
will,3667,O
require,3667,O
further,3667,O
validation,3667,O
.,3667,O
Carboxylesterase-2,3668,B-GENE-Y
is,3668,O
a,3668,O
highly,3668,O
sensitive,3668,O
target,3668,O
of,3668,O
the,3668,O
antiobesity,3668,O
agent,3668,O
orlistat,3668,B-CHEMICAL
with,3668,O
profound,3668,O
implications,3668,O
in,3668,O
the,3668,O
activation,3668,O
of,3668,O
anticancer,3668,O
prodrugs,3668,O
.,3668,O
Orlistat,3669,B-CHEMICAL
has,3669,O
been,3669,O
the,3669,O
most,3669,O
used,3669,O
anti-obesity,3669,O
drug,3669,O
and,3669,O
the,3669,O
mechanism,3669,O
of,3669,O
its,3669,O
action,3669,O
is,3669,O
to,3669,O
reduce,3669,O
lipid,3669,O
absorption,3669,O
by,3669,O
inhibiting,3669,O
gastrointestinal,3669,O
lipases,3669,B-GENE-N
.,3669,O
These,3670,O
enzymes,3670,O
",",3670,O
like,3670,O
carboxylesterases,3670,B-GENE-N
(,3670,O
CESs,3670,B-GENE-N
),3670,O
",",3670,O
structurally,3670,O
belong,3670,O
to,3670,O
the,3670,O
/,3670,B-GENE-N
hydrolase,3670,I-GENE-N
fold,3670,O
superfamily,3670,O
.,3670,O
Lipases,3671,B-GENE-N
and,3671,O
CESs,3671,B-GENE-N
are,3671,O
functionally,3671,O
related,3671,O
as,3671,O
well,3671,O
.,3671,O
Some,3672,O
CESs,3672,B-GENE-N
(,3672,O
e.g.,3672,O
",",3672,O
human,3672,B-GENE-Y
CES1,3672,I-GENE-Y
),3672,O
have,3672,O
been,3672,O
shown,3672,O
to,3672,O
hydrolyze,3672,O
lipids,3672,O
.,3672,O
This,3673,O
study,3673,O
was,3673,O
designed,3673,O
to,3673,O
test,3673,O
the,3673,O
hypothesis,3673,O
that,3673,O
orlistat,3673,B-CHEMICAL
inhibits,3673,O
CESs,3673,B-GENE-N
with,3673,O
higher,3673,O
potency,3673,O
toward,3673,O
CES1,3673,B-GENE-Y
than,3673,O
CES2,3673,B-GENE-Y
",",3673,O
a,3673,O
carboxylesterase,3673,B-GENE-N
with,3673,O
little,3673,O
lipase,3673,B-GENE-N
activity,3673,O
.,3673,O
Liver,3674,O
microsomes,3674,O
and,3674,O
recombinant,3674,O
CESs,3674,B-GENE-N
were,3674,O
tested,3674,O
for,3674,O
the,3674,O
inhibition,3674,O
of,3674,O
the,3674,O
hydrolysis,3674,O
of,3674,O
standard,3674,O
substrates,3674,O
and,3674,O
the,3674,O
anticancer,3674,O
prodrugs,3674,O
pentyl,3674,B-CHEMICAL
carbamate,3674,I-CHEMICAL
of,3674,O
p-aminobenzyl,3674,B-CHEMICAL
carbamate,3674,I-CHEMICAL
of,3674,O
doxazolidine,3674,B-CHEMICAL
(,3674,O
PPD,3674,B-CHEMICAL
),3674,O
and,3674,O
irinotecan,3674,B-CHEMICAL
.,3674,O
Contrary,3675,O
to,3675,O
the,3675,O
hypothesis,3675,O
",",3675,O
orlistat,3675,O
at,3675,O
1,3675,O
nM,3675,O
inhibited,3675,O
CES2,3675,B-GENE-Y
activity,3675,O
by,3675,O
75,3675,O
%,3675,O
but,3675,O
no,3675,O
inhibition,3675,O
on,3675,O
CES1,3675,B-GENE-Y
",",3675,O
placing,3675,O
CES2,3675,B-GENE-Y
one,3675,O
of,3675,O
the,3675,O
most,3675,O
sensitive,3675,O
targets,3675,O
of,3675,O
orlistat,3675,B-CHEMICAL
.,3675,O
The,3676,O
inhibition,3676,O
varied,3676,O
among,3676,O
some,3676,O
CES2,3676,B-GENE-Y
polymorphic,3676,O
variants,3676,O
.,3676,O
Pretreatment,3677,O
with,3677,O
orlistat,3677,B-CHEMICAL
reduced,3677,O
the,3677,O
cell,3677,O
killing,3677,O
activity,3677,O
of,3677,O
PPD,3677,B-CHEMICAL
.,3677,O
Certain,3678,O
mouse,3678,O
but,3678,O
not,3678,O
rat,3678,B-GENE-N
CESs,3678,I-GENE-N
were,3678,O
also,3678,O
highly,3678,O
sensitive,3678,O
.,3678,O
CES2,3679,B-GENE-Y
is,3679,O
responsible,3679,O
for,3679,O
the,3679,O
hydrolysis,3679,O
of,3679,O
many,3679,O
common,3679,O
drugs,3679,O
and,3679,O
abundantly,3679,O
expressed,3679,O
in,3679,O
the,3679,O
gastrointestinal,3679,O
track,3679,O
and,3679,O
liver,3679,O
.,3679,O
Inhibition,3680,O
of,3680,O
this,3680,O
carboxylesterase,3680,B-GENE-N
probably,3680,O
presents,3680,O
a,3680,O
major,3680,O
source,3680,O
for,3680,O
altered,3680,O
therapeutic,3680,O
activity,3680,O
of,3680,O
these,3680,O
medicines,3680,O
if,3680,O
co-administered,3680,O
with,3680,O
orlistat,3680,B-CHEMICAL
.,3680,O
In,3681,O
addition,3681,O
",",3681,O
orlistat,3681,B-CHEMICAL
has,3681,O
been,3681,O
linked,3681,O
to,3681,O
various,3681,O
types,3681,O
of,3681,O
organ,3681,O
toxicities,3681,O
",",3681,O
and,3681,O
this,3681,O
study,3681,O
provides,3681,O
an,3681,O
alternative,3681,O
target,3681,O
potentially,3681,O
involved,3681,O
in,3681,O
these,3681,O
toxicological,3681,O
responses,3681,O
.,3681,O
Regions,3682,O
on,3682,O
adenylyl,3682,B-CHEMICAL
cyclase,3682,I-GENE-Y
VII,3682,I-GENE-Y
required,3682,O
for,3682,O
selective,3682,O
regulation,3682,O
by,3682,O
the,3682,O
G13,3682,B-GENE-Y
pathway,3682,O
.,3682,O
Regulation,3683,O
of,3683,O
multiple,3683,O
adenylyl,3683,B-CHEMICAL
cyclases,3683,I-GENE-N
(,3683,O
AC,3683,B-GENE-N
),3683,O
provides,3683,O
unique,3683,O
inputs,3683,O
to,3683,O
mediate,3683,O
the,3683,O
synthesis,3683,O
of,3683,O
cAMP,3683,B-CHEMICAL
",",3683,O
a,3683,O
ubiquitous,3683,O
second,3683,O
messenger,3683,O
that,3683,O
controls,3683,O
many,3683,O
aspects,3683,O
of,3683,O
cellular,3683,O
function,3683,O
.,3683,O
On,3684,O
stimulation,3684,O
by,3684,O
G,3684,B-GENE-N
(,3684,I-GENE-N
s,3684,I-GENE-N
),3684,I-GENE-N
",",3684,O
the,3684,O
activities,3684,O
of,3684,O
ACs,3684,B-GENE-N
can,3684,O
be,3684,O
further,3684,O
selectively,3684,O
modulated,3684,O
by,3684,O
other,3684,O
pathways,3684,O
to,3684,O
ensure,3684,O
precise,3684,O
control,3684,O
of,3684,O
intracellular,3684,O
cAMP,3684,B-CHEMICAL
responses,3684,O
to,3684,O
specific,3684,O
stimuli,3684,O
.,3684,O
Recently,3685,O
",",3685,O
we,3685,O
reported,3685,O
that,3685,O
one,3685,O
of,3685,O
the,3685,O
AC,3685,B-GENE-N
isoforms,3685,O
",",3685,O
AC7,3685,B-GENE-Y
",",3685,O
is,3685,O
uniquely,3685,O
regulated,3685,O
by,3685,O
the,3685,O
G,3685,B-GENE-Y
(,3685,I-GENE-Y
13,3685,I-GENE-Y
),3685,I-GENE-Y
pathway,3685,O
.,3685,O
To,3686,O
understand,3686,O
more,3686,O
fully,3686,O
the,3686,O
molecular,3686,O
mechanism,3686,O
of,3686,O
this,3686,O
regulation,3686,O
",",3686,O
we,3686,O
compared,3686,O
the,3686,O
regulation,3686,O
of,3686,O
AC7,3686,B-GENE-Y
with,3686,O
that,3686,O
of,3686,O
AC2,3686,B-GENE-Y
in,3686,O
bone,3686,O
marrow-derived,3686,O
macrophages,3686,O
devoid,3686,O
of,3686,O
AC7,3686,B-GENE-Y
.,3686,O
Although,3687,O
both,3687,O
enzymes,3687,O
could,3687,O
fully,3687,O
restore,3687,O
regulation,3687,O
of,3687,O
cAMP,3687,B-CHEMICAL
by,3687,O
G,3687,B-GENE-N
",",3687,O
activation,3687,O
of,3687,O
the,3687,O
G,3687,B-GENE-Y
(,3687,I-GENE-Y
13,3687,I-GENE-Y
),3687,I-GENE-Y
pathway,3687,O
preferentially,3687,O
synergized,3687,O
with,3687,O
AC7,3687,B-GENE-Y
.,3687,O
Exchange,3688,O
of,3688,O
domains,3688,O
between,3688,O
the,3688,O
two,3688,O
isoforms,3688,O
indicates,3688,O
that,3688,O
the,3688,O
C1b,3688,B-GENE-N
domain,3688,I-GENE-N
and,3688,O
the,3688,O
N-terminus,3688,B-CHEMICAL
of,3688,O
the,3688,O
C1a,3688,B-GENE-N
domain,3688,I-GENE-N
are,3688,O
important,3688,O
for,3688,O
directing,3688,O
selective,3688,O
regulation,3688,O
of,3688,O
AC7,3688,B-GENE-Y
by,3688,O
the,3688,O
G,3688,B-GENE-Y
(,3688,I-GENE-Y
13,3688,I-GENE-Y
),3688,I-GENE-Y
pathway,3688,O
.,3688,O
A,3689,O
mutagenesis,3689,O
screen,3689,O
identified,3689,O
more,3689,O
specific,3689,O
regions,3689,O
of,3689,O
AC7,3689,B-GENE-Y
that,3689,O
differentially,3689,O
mediate,3689,O
its,3689,O
regulation,3689,O
by,3689,O
distinct,3689,O
pathways,3689,O
.,3689,O
Identification,3690,O
and,3690,O
characterization,3690,O
of,3690,O
a,3690,O
potent,3690,O
activator,3690,O
of,3690,O
p53-independent,3690,B-GENE-Y
cellular,3690,O
senescence,3690,O
via,3690,O
a,3690,O
small-molecule,3690,O
screen,3690,O
for,3690,O
modifiers,3690,O
of,3690,O
the,3690,O
integrated,3690,O
stress,3690,O
response,3690,O
.,3690,O
The,3691,O
Integrated,3691,O
Stress,3691,O
Response,3691,O
(,3691,O
ISR,3691,O
),3691,O
is,3691,O
a,3691,O
signaling,3691,O
program,3691,O
that,3691,O
enables,3691,O
cellular,3691,O
adaptation,3691,O
to,3691,O
stressful,3691,O
conditions,3691,O
like,3691,O
hypoxia,3691,O
and,3691,O
nutrient,3691,O
deprivation,3691,O
in,3691,O
the,3691,O
tumor,3691,O
microenvironment,3691,O
.,3691,O
An,3692,O
important,3692,O
effector,3692,O
of,3692,O
the,3692,O
ISR,3692,O
is,3692,O
activating,3692,B-GENE-Y
transcription,3692,I-GENE-Y
factor,3692,I-GENE-Y
4,3692,I-GENE-Y
(,3692,O
ATF4,3692,B-GENE-Y
),3692,O
",",3692,O
a,3692,O
transcription,3692,O
factor,3692,O
that,3692,O
regulates,3692,O
genes,3692,O
involved,3692,O
in,3692,O
redox,3692,O
homeostasis,3692,O
and,3692,O
amino,3692,B-CHEMICAL
acid,3692,I-CHEMICAL
metabolism,3692,O
and,3692,O
transport,3692,O
.,3692,O
Because,3693,O
both,3693,O
inhibition,3693,O
and,3693,O
overactivation,3693,O
of,3693,O
the,3693,O
ISR,3693,O
can,3693,O
induce,3693,O
tumor,3693,O
cell,3693,O
death,3693,O
",",3693,O
modulators,3693,O
of,3693,O
ATF4,3693,B-GENE-Y
expression,3693,O
could,3693,O
prove,3693,O
to,3693,O
be,3693,O
clinically,3693,O
useful,3693,O
.,3693,O
In,3694,O
this,3694,O
study,3694,O
",",3694,O
chemical,3694,O
libraries,3694,O
were,3694,O
screened,3694,O
for,3694,O
modulators,3694,O
of,3694,O
ATF4,3694,B-GENE-Y
expression,3694,O
.,3694,O
We,3695,O
identified,3695,O
one,3695,O
compound,3695,O
",",3695,O
E235,3695,B-CHEMICAL
(,3695,B-CHEMICAL
N-,3695,I-CHEMICAL
(,3695,I-CHEMICAL
1-benzyl-piperidin-4-yl,3695,I-CHEMICAL
),3695,I-CHEMICAL
-2-,3695,I-CHEMICAL
(,3695,I-CHEMICAL
4-fluoro-phenyl,3695,I-CHEMICAL
),3695,I-CHEMICAL
-benzo,3695,I-CHEMICAL
[,3695,I-CHEMICAL
d,3695,I-CHEMICAL
],3695,I-CHEMICAL
imidazo,3695,I-CHEMICAL
[,3695,I-CHEMICAL
"2,1-b",3695,I-CHEMICAL
],3695,I-CHEMICAL
thiazole-7-carboxamide,3695,I-CHEMICAL
),3695,I-CHEMICAL
",",3695,O
that,3695,O
activated,3695,O
the,3695,O
ISR,3695,O
and,3695,O
dose-dependently,3695,O
increased,3695,O
levels,3695,O
of,3695,O
ATF4,3695,B-GENE-Y
in,3695,O
transformed,3695,O
cells,3695,O
.,3695,O
A,3696,O
dose-dependent,3696,O
decrease,3696,O
in,3696,O
viability,3696,O
was,3696,O
observed,3696,O
in,3696,O
several,3696,O
mouse,3696,O
and,3696,O
human,3696,O
tumor,3696,O
cell,3696,O
lines,3696,O
",",3696,O
and,3696,O
knockdown,3696,O
of,3696,O
ATF4,3696,B-GENE-Y
significantly,3696,O
increased,3696,O
the,3696,O
antiproliferative,3696,O
effects,3696,O
of,3696,O
E235,3696,B-CHEMICAL
.,3696,O
Interestingly,3697,O
",",3697,O
low,3697,O
M,3697,O
doses,3697,O
of,3697,O
E235,3697,B-CHEMICAL
induced,3697,O
senescence,3697,O
in,3697,O
many,3697,O
cell,3697,O
types,3697,O
",",3697,O
including,3697,O
HT1080,3697,O
human,3697,O
fibrosarcoma,3697,O
and,3697,O
B16F10,3697,O
mouse,3697,O
melanoma,3697,O
cells,3697,O
.,3697,O
E235-mediated,3698,B-CHEMICAL
induction,3698,O
of,3698,O
senescence,3698,O
was,3698,O
not,3698,O
dependent,3698,O
on,3698,O
p21,3698,B-GENE-Y
or,3698,O
p53,3698,B-GENE-Y
;,3698,O
however,3698,O
",",3698,O
p21,3698,B-GENE-Y
conferred,3698,O
protection,3698,O
against,3698,O
the,3698,O
growth,3698,O
inhibitory,3698,O
effects,3698,O
of,3698,O
E235,3698,B-CHEMICAL
.,3698,O
Treatment,3699,O
with,3699,O
E235,3699,B-CHEMICAL
resulted,3699,O
in,3699,O
an,3699,O
increase,3699,O
in,3699,O
cells,3699,O
arrested,3699,O
at,3699,O
the,3699,O
G2/M,3699,O
phase,3699,O
with,3699,O
a,3699,O
concurrent,3699,O
decrease,3699,O
in,3699,O
S-phase,3699,O
cells,3699,O
.,3699,O
E235,3700,B-CHEMICAL
also,3700,O
activated,3700,O
DNA,3700,O
damage,3700,O
response,3700,O
signaling,3700,O
",",3700,O
resulting,3700,O
in,3700,O
increased,3700,O
levels,3700,O
of,3700,O
Ser15-phosphorylated,3700,B-CHEMICAL
p53,3700,I-GENE-Y
",",3700,O
-H2AX,3700,B-GENE-Y
",",3700,O
and,3700,O
phosphorylated,3700,B-GENE-Y
checkpoint,3700,I-GENE-Y
kinase,3700,I-GENE-Y
2,3700,I-GENE-Y
(,3700,O
Chk2,3700,B-GENE-Y
),3700,O
",",3700,O
although,3700,O
E235,3700,B-CHEMICAL
does,3700,O
not,3700,O
appear,3700,O
to,3700,O
cause,3700,O
physical,3700,O
DNA,3700,O
damage,3700,O
.,3700,O
Induction,3701,O
of,3701,O
-H2AX,3701,B-GENE-Y
was,3701,O
abrogated,3701,O
in,3701,O
ATF4,3701,B-GENE-Y
knockdown,3701,O
cells,3701,O
.,3701,O
Together,3702,O
",",3702,O
these,3702,O
results,3702,O
suggest,3702,O
that,3702,O
modulation,3702,O
of,3702,O
the,3702,O
ISR,3702,O
pathway,3702,O
with,3702,O
the,3702,O
small,3702,O
molecule,3702,O
E235,3702,B-CHEMICAL
could,3702,O
be,3702,O
a,3702,O
promising,3702,O
antitumor,3702,O
strategy,3702,O
.,3702,O
Tilting,3703,O
the,3703,O
balance,3703,O
between,3703,O
canonical,3703,O
and,3703,O
noncanonical,3703,O
conformations,3703,O
for,3703,O
the,3703,O
H1,3703,B-GENE-N
hypervariable,3703,I-GENE-N
loop,3703,I-GENE-N
of,3703,O
a,3703,O
llama,3703,O
VHH,3703,B-GENE-N
through,3703,O
point,3703,O
mutations,3703,O
.,3703,O
Nanobodies,3704,O
are,3704,O
single-domain,3704,O
antibodies,3704,O
found,3704,O
in,3704,O
camelids,3704,O
.,3704,O
These,3705,O
are,3705,O
the,3705,O
smallest,3705,O
naturally,3705,O
occurring,3705,O
binding,3705,O
domains,3705,O
and,3705,O
derive,3705,O
functionality,3705,O
via,3705,O
three,3705,O
hypervariable,3705,B-GENE-N
loops,3705,I-GENE-N
(,3705,O
H1-H3,3705,B-GENE-N
),3705,O
that,3705,O
form,3705,O
the,3705,O
binding,3705,O
surface,3705,O
.,3705,O
They,3706,O
are,3706,O
excellent,3706,O
candidates,3706,O
for,3706,O
antibody,3706,O
engineering,3706,O
because,3706,O
of,3706,O
their,3706,O
favorable,3706,O
characteristics,3706,O
like,3706,O
small,3706,O
size,3706,O
",",3706,O
high,3706,O
solubility,3706,O
",",3706,O
and,3706,O
stability,3706,O
.,3706,O
To,3707,O
rationally,3707,O
engineer,3707,O
antibodies,3707,O
with,3707,O
affinity,3707,O
for,3707,O
a,3707,O
specific,3707,O
target,3707,O
",",3707,O
the,3707,O
hypervariable,3707,B-GENE-N
loops,3707,I-GENE-N
can,3707,O
be,3707,O
tailored,3707,O
to,3707,O
obtain,3707,O
the,3707,O
desired,3707,O
binding,3707,O
surface,3707,O
.,3707,O
As,3708,O
a,3708,O
first,3708,O
step,3708,O
toward,3708,O
such,3708,O
a,3708,O
goal,3708,O
",",3708,O
we,3708,O
consider,3708,O
the,3708,O
design,3708,O
of,3708,O
loops,3708,O
with,3708,O
a,3708,O
desired,3708,O
conformation,3708,O
.,3708,O
In,3709,O
this,3709,O
study,3709,O
",",3709,O
we,3709,O
focus,3709,O
on,3709,O
the,3709,O
H1,3709,B-GENE-N
loop,3709,I-GENE-N
of,3709,O
the,3709,O
anti-hCG,3709,O
llama,3709,O
nanobody,3709,O
that,3709,O
exhibits,3709,O
a,3709,O
noncanonical,3709,O
conformation,3709,O
.,3709,O
We,3710,O
aim,3710,O
to,3710,O
``,3710,O
tilt,3710,O
'',3710,O
the,3710,O
stability,3710,O
of,3710,O
the,3710,O
H1,3710,B-GENE-N
loop,3710,I-GENE-N
structure,3710,O
from,3710,O
a,3710,O
noncanonical,3710,O
conformation,3710,O
to,3710,O
a,3710,O
(,3710,O
humanized,3710,O
),3710,O
type,3710,O
1,3710,O
canonical,3710,O
conformation,3710,O
by,3710,O
studying,3710,O
the,3710,O
effect,3710,O
of,3710,O
selected,3710,O
mutations,3710,O
to,3710,O
the,3710,O
amino,3710,B-CHEMICAL
acid,3710,I-CHEMICAL
sequence,3710,O
of,3710,O
the,3710,O
H1,3710,B-GENE-N
",",3710,O
H2,3710,B-GENE-N
",",3710,O
and,3710,O
proximal,3710,O
residues,3710,O
.,3710,O
We,3711,O
use,3711,O
all-atomistic,3711,O
",",3711,O
explicit-solvent,3711,O
",",3711,O
biased,3711,O
molecular,3711,O
dynamic,3711,O
simulations,3711,O
to,3711,O
simulate,3711,O
the,3711,O
wild-type,3711,O
and,3711,O
mutant,3711,O
loops,3711,O
in,3711,O
a,3711,O
prefolded,3711,O
framework,3711,O
.,3711,O
We,3712,O
thus,3712,O
find,3712,O
mutants,3712,O
with,3712,O
increasing,3712,O
propensity,3712,O
to,3712,O
form,3712,O
a,3712,O
stable,3712,O
type,3712,O
1,3712,O
canonical,3712,O
conformation,3712,O
of,3712,O
the,3712,O
H1,3712,B-GENE-N
loop,3712,I-GENE-N
.,3712,O
Free,3713,O
energy,3713,O
landscapes,3713,O
reveal,3713,O
the,3713,O
existence,3713,O
of,3713,O
conformational,3713,O
isomers,3713,O
of,3713,O
the,3713,O
canonical,3713,O
conformation,3713,O
that,3713,O
may,3713,O
play,3713,O
a,3713,O
role,3713,O
in,3713,O
binding,3713,O
different,3713,O
antigenic,3713,O
surfaces,3713,O
.,3713,O
We,3714,O
also,3714,O
elucidate,3714,O
the,3714,O
approximate,3714,O
mechanism,3714,O
and,3714,O
kinetics,3714,O
of,3714,O
transitions,3714,O
between,3714,O
such,3714,O
conformational,3714,O
isomers,3714,O
by,3714,O
using,3714,O
a,3714,O
Markovian,3714,O
model,3714,O
.,3714,O
We,3715,O
find,3715,O
that,3715,O
a,3715,O
particular,3715,O
three-point,3715,O
mutant,3715,O
has,3715,O
the,3715,O
strongest,3715,O
thermodynamic,3715,O
propensity,3715,O
to,3715,O
form,3715,O
the,3715,O
H1,3715,B-GENE-N
type,3715,O
1,3715,O
canonical,3715,O
structure,3715,O
but,3715,O
also,3715,O
to,3715,O
exhibit,3715,O
transitions,3715,O
between,3715,O
conformational,3715,O
isomers,3715,O
",",3715,O
while,3715,O
a,3715,O
different,3715,O
",",3715,O
more,3715,O
rigid,3715,O
three-point,3715,O
mutant,3715,O
has,3715,O
the,3715,O
strongest,3715,O
propensity,3715,O
to,3715,O
be,3715,O
kinetically,3715,O
trapped,3715,O
in,3715,O
such,3715,O
a,3715,O
canonical,3715,O
structure,3715,O
.,3715,O
Synthesis,3716,O
and,3716,O
NIR,3716,O
optical,3716,O
properties,3716,O
of,3716,O
hollow,3716,O
gold,3716,O
nanospheres,3716,O
with,3716,O
LSPR,3716,O
greater,3716,O
than,3716,O
one,3716,O
micrometer,3716,O
.,3716,O
Optical,3717,O
analysis,3717,O
in,3717,O
the,3717,O
near,3717,O
infrared,3717,O
region,3717,O
is,3717,O
of,3717,O
significant,3717,O
biological,3717,O
importance,3717,O
due,3717,O
to,3717,O
better,3717,O
tissue,3717,O
penetration,3717,O
and,3717,O
reduced,3717,O
autofluorescence,3717,O
.,3717,O
In,3718,O
this,3718,O
work,3718,O
",",3718,O
an,3718,O
improved,3718,O
synthesis,3718,O
of,3718,O
hollow,3718,O
gold,3718,O
nanospheres,3718,O
(,3718,O
HGNs,3718,O
),3718,O
",",3718,O
which,3718,O
provides,3718,O
a,3718,O
tunable,3718,O
localized,3718,O
surface,3718,O
plasmon,3718,O
resonance,3718,O
(,3718,O
LSPR,3718,O
),3718,O
from,3718,O
610,3718,O
nm,3718,O
up,3718,O
to,3718,O
1320,3718,O
nm,3718,O
",",3718,O
is,3718,O
demonstrated,3718,O
.,3718,O
The,3719,O
scattering,3719,O
properties,3719,O
of,3719,O
these,3719,O
nanoparticles,3719,O
are,3719,O
shown,3719,O
using,3719,O
surface,3719,O
enhanced,3719,O
Raman,3719,O
scattering,3719,O
(,3719,O
SERS,3719,O
),3719,O
at,3719,O
1064,3719,O
nm,3719,O
excitation,3719,O
wavelength,3719,O
and,3719,O
are,3719,O
compared,3719,O
to,3719,O
citrate,3719,B-CHEMICAL
reduced,3719,O
gold,3719,O
and,3719,O
silver,3719,B-CHEMICAL
nanoparticles,3719,O
of,3719,O
similar,3719,O
physical,3719,O
sizes,3719,O
and,3719,O
surface,3719,O
properties,3719,O
.,3719,O
After,3720,O
the,3720,O
addition,3720,O
of,3720,O
salts,3720,O
",",3720,O
a,3720,O
strong,3720,O
signal,3720,O
was,3720,O
observed,3720,O
from,3720,O
hollow,3720,O
gold,3720,O
with,3720,O
a,3720,O
LSPR,3720,O
of,3720,O
650,3720,O
nm,3720,O
and,3720,O
a,3720,O
weaker,3720,O
",",3720,O
yet,3720,O
observable,3720,O
",",3720,O
signal,3720,O
from,3720,O
HGNs,3720,O
with,3720,O
a,3720,O
LSPR,3720,O
of,3720,O
775,3720,O
nm,3720,O
.,3720,O
However,3721,O
",",3721,O
no,3721,O
obvious,3721,O
signals,3721,O
were,3721,O
observed,3721,O
in,3721,O
the,3721,O
case,3721,O
of,3721,O
standard,3721,O
citrate,3721,B-CHEMICAL
reduced,3721,O
gold,3721,O
",",3721,O
silver,3721,B-CHEMICAL
or,3721,O
HGNs,3721,O
with,3721,O
a,3721,O
LSPR,3721,O
of,3721,O
1080,3721,O
nm,3721,O
.,3721,O
The,3722,O
absorption,3722,O
properties,3722,O
of,3722,O
HGNs,3722,O
were,3722,O
investigated,3722,O
by,3722,O
monitoring,3722,O
their,3722,O
photothermal,3722,O
activity,3722,O
.,3722,O
In,3723,O
this,3723,O
case,3723,O
",",3723,O
different,3723,O
nanoparticle,3723,O
suspensions,3723,O
including,3723,O
citrate,3723,B-CHEMICAL
reduced,3723,O
gold,3723,O
",",3723,O
silver,3723,B-CHEMICAL
",",3723,O
and,3723,O
HGNs,3723,O
were,3723,O
illuminated,3723,O
by,3723,O
a,3723,O
continuous,3723,O
laser,3723,O
at,3723,O
785,3723,O
nm,3723,O
excitation,3723,O
wavelength,3723,O
and,3723,O
the,3723,O
absorption,3723,O
efficiency,3723,O
of,3723,O
HGNs,3723,O
with,3723,O
a,3723,O
LSPR,3723,O
of,3723,O
775,3723,O
nm,3723,O
was,3723,O
calculated,3723,O
to,3723,O
be,3723,O
0.81,3723,O
%,3723,O
which,3723,O
is,3723,O
more,3723,O
than,3723,O
5,3723,O
times,3723,O
higher,3723,O
than,3723,O
the,3723,O
absorption,3723,O
efficiency,3723,O
of,3723,O
citrate,3723,B-CHEMICAL
reduced,3723,O
gold,3723,O
nanoparticles,3723,O
under,3723,O
similar,3723,O
conditions,3723,O
.,3723,O
Influence,3724,O
of,3724,O
surface,3724,O
groups,3724,O
on,3724,O
poly,3724,B-CHEMICAL
(,3724,I-CHEMICAL
propylene,3724,I-CHEMICAL
imine,3724,I-CHEMICAL
),3724,I-CHEMICAL
dendrimers,3724,O
antiprion,3724,O
activity,3724,O
.,3724,O
Prion,3725,B-GENE-N
diseases,3725,O
are,3725,O
characterized,3725,O
by,3725,O
the,3725,O
accumulation,3725,O
of,3725,O
PrP,3725,B-GENE-Y
(,3725,I-GENE-Y
Sc,3725,I-GENE-Y
),3725,I-GENE-Y
",",3725,O
an,3725,O
aberrantly,3725,O
folded,3725,O
isoform,3725,O
of,3725,O
the,3725,O
host,3725,O
protein,3725,O
PrP,3725,B-GENE-Y
(,3725,I-GENE-Y
C,3725,I-GENE-Y
),3725,I-GENE-Y
.,3725,O
Specific,3726,O
forms,3726,O
of,3726,O
synthetic,3726,O
molecules,3726,O
known,3726,O
as,3726,O
dendrimers,3726,O
are,3726,O
able,3726,O
to,3726,O
eliminate,3726,O
protease-resistant,3726,O
PrP,3726,B-GENE-Y
(,3726,I-GENE-Y
Sc,3726,I-GENE-Y
),3726,I-GENE-Y
in,3726,O
both,3726,O
an,3726,O
intracellular,3726,O
and,3726,O
in,3726,O
vitro,3726,O
setting,3726,O
.,3726,O
The,3727,O
properties,3727,O
of,3727,O
a,3727,O
dendrimer,3727,O
which,3727,O
govern,3727,O
this,3727,O
ability,3727,O
are,3727,O
unknown,3727,O
.,3727,O
We,3728,O
addressed,3728,O
the,3728,O
issue,3728,O
by,3728,O
comparing,3728,O
the,3728,O
in,3728,O
vitro,3728,O
antiprion,3728,O
ability,3728,O
of,3728,O
numerous,3728,O
modified,3728,O
poly,3728,B-CHEMICAL
(,3728,I-CHEMICAL
propylene-imine,3728,I-CHEMICAL
),3728,I-CHEMICAL
dendrimers,3728,O
",",3728,O
which,3728,O
varied,3728,O
in,3728,O
size,3728,O
",",3728,O
structure,3728,O
",",3728,O
charge,3728,O
",",3728,O
and,3728,O
surface,3728,O
group,3728,O
composition,3728,O
.,3728,O
Several,3729,O
of,3729,O
the,3729,O
modified,3729,O
dendrimers,3729,O
",",3729,O
including,3729,O
an,3729,O
anionic,3729,O
glycodendrimer,3729,O
",",3729,O
reduced,3729,O
the,3729,O
level,3729,O
of,3729,O
protease,3729,B-GENE-N
resistant,3729,O
PrP,3729,B-GENE-Y
(,3729,I-GENE-Y
Sc,3729,I-GENE-Y
),3729,I-GENE-Y
in,3729,O
a,3729,O
prion,3729,O
strain-dependent,3729,O
manner,3729,O
.,3729,O
This,3730,O
led,3730,O
to,3730,O
the,3730,O
formulation,3730,O
of,3730,O
a,3730,O
new,3730,O
working,3730,O
model,3730,O
for,3730,O
dendrimer/prion,3730,O
interactions,3730,O
which,3730,O
proposes,3730,O
dendrimers,3730,O
eliminate,3730,O
PrP,3730,B-GENE-Y
(,3730,I-GENE-Y
Sc,3730,I-GENE-Y
),3730,I-GENE-Y
by,3730,O
destabilizing,3730,O
the,3730,O
protein,3730,O
and,3730,O
rendering,3730,O
it,3730,O
susceptible,3730,O
to,3730,O
proteolysis,3730,O
.,3730,O
This,3731,O
ability,3731,O
is,3731,O
not,3731,O
dependent,3731,O
on,3731,O
any,3731,O
particular,3731,O
charge,3731,O
of,3731,O
dendrimer,3731,O
",",3731,O
but,3731,O
does,3731,O
require,3731,O
a,3731,O
high,3731,O
density,3731,O
of,3731,O
reactive,3731,O
surface,3731,O
groups,3731,O
.,3731,O
Acid-degradable,3732,O
cationic,3732,O
poly,3732,B-CHEMICAL
(,3732,I-CHEMICAL
ketal,3732,I-CHEMICAL
amidoamine,3732,I-CHEMICAL
),3732,I-CHEMICAL
for,3732,O
enhanced,3732,O
RNA,3732,O
interference,3732,O
in,3732,O
vitro,3732,O
and,3732,O
in,3732,O
vivo,3732,O
.,3732,O
Efficient,3733,O
delivery,3733,O
of,3733,O
small,3733,O
interfering,3733,O
RNA,3733,O
(,3733,O
siRNA,3733,O
),3733,O
is,3733,O
one,3733,O
of,3733,O
major,3733,O
challenges,3733,O
in,3733,O
the,3733,O
successful,3733,O
applications,3733,O
of,3733,O
siRNA,3733,O
in,3733,O
clinic,3733,O
.,3733,O
In,3734,O
the,3734,O
present,3734,O
study,3734,O
",",3734,O
we,3734,O
report,3734,O
a,3734,O
new,3734,O
acid-degradable,3734,O
poly,3734,B-CHEMICAL
(,3734,I-CHEMICAL
ketal,3734,I-CHEMICAL
amidoamine,3734,I-CHEMICAL
),3734,I-CHEMICAL
(,3734,O
PKAA,3734,B-CHEMICAL
),3734,O
as,3734,O
a,3734,O
siRNA,3734,O
carrier,3734,O
",",3734,O
which,3734,O
has,3734,O
high,3734,O
delivery,3734,O
efficiency,3734,O
and,3734,O
low,3734,O
cytotoxicity,3734,O
.,3734,O
PKAA,3735,B-CHEMICAL
was,3735,O
designed,3735,O
to,3735,O
have,3735,O
acid-cleavable,3735,O
ketal,3735,O
linkages,3735,O
in,3735,O
the,3735,O
backbone,3735,O
of,3735,O
cationic,3735,O
biodegradable,3735,O
poly,3735,B-CHEMICAL
(,3735,I-CHEMICAL
amidoamine,3735,I-CHEMICAL
),3735,I-CHEMICAL
.,3735,O
PKAA,3736,B-CHEMICAL
efficiently,3736,O
self-assembled,3736,O
with,3736,O
siRNA,3736,O
to,3736,O
form,3736,O
nanocomplexes,3736,O
with,3736,O
a,3736,O
diameter,3736,O
of,3736,O
~200,3736,O
nm,3736,O
and,3736,O
slightly,3736,O
positive,3736,O
charges,3736,O
",",3736,O
which,3736,O
are,3736,O
stable,3736,O
under,3736,O
physiological,3736,O
conditions,3736,O
",",3736,O
but,3736,O
rapidly,3736,O
release,3736,O
siRNA,3736,O
at,3736,O
acidic,3736,O
pH,3736,O
.,3736,O
PKAA,3737,B-CHEMICAL
exhibited,3737,O
sufficient,3737,O
buffering,3737,O
capability,3737,O
and,3737,O
endosomolytic,3737,O
activity,3737,O
due,3737,O
mainly,3737,O
to,3737,O
the,3737,O
presence,3737,O
of,3737,O
secondary,3737,B-CHEMICAL
amine,3737,I-CHEMICAL
groups,3737,O
in,3737,O
its,3737,O
backbone,3737,O
and,3737,O
rapid,3737,O
degradation,3737,O
in,3737,O
acidic,3737,O
endosomes,3737,O
",",3737,O
leading,3737,O
to,3737,O
the,3737,O
enhanced,3737,O
release,3737,O
of,3737,O
siRNA,3737,O
to,3737,O
cytoplasm,3737,O
.,3737,O
Cell,3738,O
culture,3738,O
studies,3738,O
demonstrated,3738,O
that,3738,O
PKAA,3738,B-CHEMICAL
is,3738,O
capable,3738,O
of,3738,O
delivering,3738,O
anti-TNF,3738,O
(,3738,B-GENE-Y
tumor,3738,I-GENE-Y
necrosis,3738,I-GENE-Y
factor,3738,I-GENE-Y
),3738,I-GENE-Y
-,3738,I-GENE-Y
siRNA,3738,O
to,3738,O
lipopolysaccharide,3738,O
(,3738,O
LPS,3738,O
),3738,O
-stimulated,3738,O
macrophages,3738,O
and,3738,O
significantly,3738,O
inhibits,3738,O
the,3738,O
expression,3738,O
of,3738,O
TNF-,3738,B-GENE-Y
.,3738,O
A,3739,O
mouse,3739,O
model,3739,O
of,3739,O
acetaminophen,3739,B-CHEMICAL
(,3739,O
APAP,3739,B-CHEMICAL
),3739,O
-induced,3739,O
acute,3739,O
liver,3739,O
failure,3739,O
was,3739,O
used,3739,O
to,3739,O
evaluate,3739,O
in,3739,O
vivo,3739,O
siRNA,3739,O
delivery,3739,O
efficacy,3739,O
of,3739,O
PKAA,3739,B-CHEMICAL
.,3739,O
PKAA/anti-TNF-,3740,B-CHEMICAL
siRNA,3740,O
nanocomplexes,3740,O
significantly,3740,O
reduced,3740,O
the,3740,O
ALT,3740,B-GENE-N
(,3740,O
alanine,3740,B-CHEMICAL
transaminase,3740,I-GENE-N
),3740,O
and,3740,O
the,3740,O
hepatic,3740,O
cellular,3740,O
damages,3740,O
in,3740,O
APAP-intoxicated,3740,B-CHEMICAL
mice,3740,O
.,3740,O
We,3741,O
anticipate,3741,O
that,3741,O
acid-degradable,3741,O
PKAA,3741,B-CHEMICAL
has,3741,O
great,3741,O
potential,3741,O
as,3741,O
siRNA,3741,O
carriers,3741,O
based,3741,O
on,3741,O
its,3741,O
excellent,3741,O
biocompatibility,3741,O
",",3741,O
pH,3741,O
sensitivity,3741,O
",",3741,O
potential,3741,O
endosomolytic,3741,O
activity,3741,O
",",3741,O
and,3741,O
high,3741,O
delivery,3741,O
efficiency,3741,O
.,3741,O
Wogonin,3742,B-CHEMICAL
inhibits,3742,O
H2O2-induced,3742,B-CHEMICAL
vascular,3742,O
permeability,3742,O
through,3742,O
suppressing,3742,O
the,3742,O
phosphorylation,3742,O
of,3742,O
caveolin-1,3742,B-GENE-Y
.,3742,O
Wogonin,3743,B-CHEMICAL
",",3743,O
a,3743,O
naturally,3743,O
occurring,3743,O
monoflavonoid,3743,B-CHEMICAL
extracted,3743,O
from,3743,O
the,3743,O
root,3743,O
of,3743,O
Scutellaria,3743,O
baicalensis,3743,O
Georgi,3743,O
",",3743,O
has,3743,O
been,3743,O
reported,3743,O
for,3743,O
its,3743,O
anti-oxidant,3743,O
activity,3743,O
.,3743,O
However,3744,O
",",3744,O
it,3744,O
is,3744,O
still,3744,O
unclear,3744,O
whether,3744,O
wogonin,3744,B-CHEMICAL
can,3744,O
inhibit,3744,O
oxidant-induced,3744,O
vascular,3744,O
permeability,3744,O
.,3744,O
In,3745,O
this,3745,O
study,3745,O
",",3745,O
we,3745,O
evaluated,3745,O
the,3745,O
effects,3745,O
of,3745,O
wogonin,3745,B-CHEMICAL
on,3745,O
H2O2-induced,3745,B-CHEMICAL
vascular,3745,O
permeability,3745,O
in,3745,O
human,3745,O
umbilical,3745,O
vein,3745,O
endothelial,3745,O
cells,3745,O
(,3745,O
HUVECs,3745,O
),3745,O
.,3745,O
We,3746,O
found,3746,O
that,3746,O
wogonin,3746,B-CHEMICAL
can,3746,O
suppress,3746,O
the,3746,O
H2O2-stimulated,3746,B-CHEMICAL
actin,3746,B-GENE-N
remodeling,3746,O
and,3746,O
albumin,3746,B-GENE-Y
uptake,3746,O
of,3746,O
HUVECs,3746,O
",",3746,O
as,3746,O
well,3746,O
as,3746,O
transendothelial,3746,O
cell,3746,O
migration,3746,O
of,3746,O
the,3746,O
human,3746,O
breast,3746,O
carcinoma,3746,O
cell,3746,O
MDA-MB-231,3746,O
.,3746,O
The,3747,O
mechanism,3747,O
revealed,3747,O
that,3747,O
wogonin,3747,B-CHEMICAL
inhibited,3747,O
H2O2-induced,3747,B-CHEMICAL
phosphorylation,3747,O
of,3747,O
caveolin-1,3747,B-GENE-Y
(,3747,O
cav-1,3747,B-GENE-Y
),3747,O
associating,3747,O
with,3747,O
the,3747,O
suppression,3747,O
of,3747,O
stabilization,3747,O
of,3747,O
VE-cadherin,3747,B-GENE-Y
and,3747,O
-catenin,3747,B-GENE-Y
.,3747,O
Moreover,3748,O
",",3748,O
wogonin,3748,B-CHEMICAL
repressed,3748,O
anisomycin-induced,3748,B-CHEMICAL
phosphorylation,3748,O
of,3748,O
p38,3748,B-GENE-N
",",3748,O
cav-1,3748,B-GENE-Y
and,3748,O
vascular,3748,O
permeability,3748,O
.,3748,O
These,3749,O
results,3749,O
suggested,3749,O
that,3749,O
wogonin,3749,B-CHEMICAL
could,3749,O
inhibit,3749,O
H2O2-induced,3749,B-CHEMICAL
vascular,3749,O
permeability,3749,O
by,3749,O
downregulating,3749,O
the,3749,O
phosphorylation,3749,O
of,3749,O
cav-1,3749,B-GENE-Y
",",3749,O
and,3749,O
that,3749,O
it,3749,O
might,3749,O
have,3749,O
a,3749,O
therapeutic,3749,O
potential,3749,O
for,3749,O
the,3749,O
diseases,3749,O
associated,3749,O
with,3749,O
the,3749,O
development,3749,O
of,3749,O
both,3749,O
oxidant,3749,O
and,3749,O
vascular,3749,O
permeability,3749,O
.,3749,O
The,3750,O
discovery,3750,O
of,3750,O
fused,3750,O
oxadiazepines,3750,B-CHEMICAL
as,3750,O
gamma,3750,B-GENE-N
secretase,3750,I-GENE-N
modulators,3750,O
for,3750,O
treatment,3750,O
of,3750,O
Alzheimer,3750,O
's,3750,O
disease,3750,O
.,3750,O
In,3751,O
an,3751,O
attempt,3751,O
to,3751,O
further,3751,O
improve,3751,O
overall,3751,O
profiles,3751,O
of,3751,O
the,3751,O
oxadiazine,3751,B-CHEMICAL
series,3751,O
of,3751,O
GSMs,3751,O
",",3751,O
in,3751,O
particular,3751,O
the,3751,O
hERG,3751,B-GENE-Y
activity,3751,O
",",3751,O
conformational,3751,O
modifications,3751,O
of,3751,O
the,3751,O
core,3751,O
structure,3751,O
resulted,3751,O
in,3751,O
the,3751,O
identification,3751,O
of,3751,O
fused,3751,O
oxadiazepines,3751,B-CHEMICAL
such,3751,O
as,3751,O
7i,3751,O
which,3751,O
had,3751,O
an,3751,O
improved,3751,O
hERG,3751,B-GENE-Y
inhibition,3751,O
profile,3751,O
and,3751,O
was,3751,O
a,3751,O
highly,3751,O
efficacious,3751,O
GSM,3751,O
in,3751,O
vitro,3751,O
and,3751,O
in,3751,O
vivo,3751,O
in,3751,O
rats,3751,O
.,3751,O
These,3752,O
SAR,3752,O
explorations,3752,O
offer,3752,O
opportunities,3752,O
to,3752,O
identify,3752,O
potential,3752,O
drugs,3752,O
to,3752,O
treat,3752,O
Alzheimer,3752,O
's,3752,O
disease,3752,O
.,3752,O
Inhibitory,3753,O
effects,3753,O
of,3753,O
a,3753,O
bazedoxifene/conjugated,3753,B-CHEMICAL
equine,3753,O
estrogen,3753,B-CHEMICAL
combination,3753,O
on,3753,O
human,3753,O
breast,3753,O
cancer,3753,O
cells,3753,O
in,3753,O
vitro,3753,O
.,3753,O
Breast,3754,O
cancer,3754,O
incidence,3754,O
is,3754,O
increased,3754,O
in,3754,O
women,3754,O
receiving,3754,O
menopausal,3754,O
hormone,3754,O
therapy,3754,O
with,3754,O
estrogen,3754,B-CHEMICAL
plus,3754,O
progestin,3754,O
but,3754,O
not,3754,O
with,3754,O
estrogen,3754,B-CHEMICAL
alone,3754,O
.,3754,O
The,3755,O
use,3755,O
of,3755,O
a,3755,O
tissue-selective,3755,O
estrogen,3755,B-CHEMICAL
complex,3755,O
(,3755,O
TSEC,3755,O
),3755,O
has,3755,O
been,3755,O
proposed,3755,O
as,3755,O
a,3755,O
novel,3755,O
menopausal,3755,O
hormone,3755,O
therapy,3755,O
strategy,3755,O
to,3755,O
eliminate,3755,O
the,3755,O
requirement,3755,O
for,3755,O
a,3755,O
progestogen,3755,B-CHEMICAL
.,3755,O
Combination,3756,O
of,3756,O
bazedoxifene,3756,B-CHEMICAL
(,3756,O
BZA,3756,B-CHEMICAL
),3756,O
with,3756,O
conjugated,3756,O
estrogens,3756,B-CHEMICAL
(,3756,O
CEs,3756,O
),3756,O
",",3756,O
the,3756,O
first,3756,O
TSEC,3756,O
",",3756,O
has,3756,O
shown,3756,O
beneficial,3756,O
effects,3756,O
.,3756,O
Whether,3757,O
it,3757,O
would,3757,O
exert,3757,O
antiestrogenic,3757,O
effects,3757,O
on,3757,O
breast,3757,O
cancer,3757,O
is,3757,O
not,3757,O
clear,3757,O
.,3757,O
To,3758,O
address,3758,O
this,3758,O
issue,3758,O
",",3758,O
we,3758,O
compared,3758,O
estradiol,3758,B-CHEMICAL
(,3758,O
E,3758,O
(,3758,O
2,3758,O
),3758,O
),3758,O
and,3758,O
CE,3758,O
alone,3758,O
on,3758,O
proliferation,3758,O
and,3758,O
apoptosis,3758,O
in,3758,O
MCF-7,3758,O
breast,3758,O
cancer,3758,O
cells,3758,O
.,3758,O
CE,3759,O
stimulated,3759,O
growth,3759,O
of,3759,O
MCF-7,3759,O
cells,3759,O
at,3759,O
a,3759,O
peak,3759,O
concentration,3759,O
10-fold,3759,O
higher,3759,O
than,3759,O
required,3759,O
for,3759,O
E,3759,O
(,3759,O
2,3759,O
),3759,O
.,3759,O
Both,3760,O
CE,3760,O
and,3760,O
E,3760,O
(,3760,O
2,3760,O
),3760,O
alone,3760,O
increased,3760,O
DNA,3760,O
synthesis,3760,O
and,3760,O
reduced,3760,O
apoptosis,3760,O
with,3760,O
activation,3760,O
of,3760,O
MAPK,3760,B-GENE-N
",",3760,O
Akt,3760,B-GENE-N
",",3760,O
and,3760,O
p70S6K,3760,B-GENE-N
and,3760,O
up-regulation,3760,O
of,3760,O
antiapoptotic,3760,O
factors,3760,O
survivin,3760,B-GENE-Y
",",3760,O
Bcl-2,3760,B-GENE-Y
",",3760,O
and,3760,O
X-linked,3760,B-GENE-Y
inhibitor,3760,I-GENE-Y
of,3760,I-GENE-Y
apoptosis,3760,I-GENE-Y
protein,3760,I-GENE-Y
",",3760,O
These,3760,O
effects,3760,O
could,3760,O
be,3760,O
completely,3760,O
blocked,3760,O
by,3760,O
BZA,3760,B-CHEMICAL
.,3760,O
Gene,3761,O
expression,3761,O
studies,3761,O
demonstrated,3761,O
that,3761,O
CE,3761,O
and,3761,O
E,3761,O
(,3761,O
2,3761,O
),3761,O
were,3761,O
equally,3761,O
potent,3761,O
on,3761,O
expression,3761,O
of,3761,O
cMyc,3761,B-GENE-Y
",",3761,O
pS2,3761,B-GENE-Y
",",3761,O
and,3761,O
WNT1,3761,B-GENE-Y
inducible,3761,I-GENE-Y
signaling,3761,I-GENE-Y
pathway,3761,I-GENE-Y
protein,3761,I-GENE-Y
2,3761,I-GENE-Y
",",3761,O
whereas,3761,O
the,3761,O
stimulatory,3761,O
effects,3761,O
of,3761,O
CE,3761,O
on,3761,O
progesterone,3761,B-GENE-Y
receptor,3761,I-GENE-Y
and,3761,O
amphiregulin,3761,B-GENE-Y
expression,3761,O
were,3761,O
weaker,3761,O
than,3761,O
E,3761,O
(,3761,O
2,3761,O
),3761,O
.,3761,O
BZA,3762,B-CHEMICAL
effectively,3762,O
blocked,3762,O
each,3762,O
of,3762,O
these,3762,O
effects,3762,O
and,3762,O
showed,3762,O
no,3762,O
estrogen,3762,B-CHEMICAL
agonistic,3762,O
effects,3762,O
when,3762,O
used,3762,O
alone,3762,O
.,3762,O
Our,3763,O
results,3763,O
indicate,3763,O
that,3763,O
the,3763,O
stimulatory,3763,O
effects,3763,O
of,3763,O
E,3763,O
(,3763,O
2,3763,O
),3763,O
or,3763,O
CE,3763,O
on,3763,O
breast,3763,O
cancer,3763,O
cells,3763,O
could,3763,O
be,3763,O
completely,3763,O
abrogated,3763,O
by,3763,O
BZA,3763,B-CHEMICAL
.,3763,O
These,3764,O
studies,3764,O
imply,3764,O
that,3764,O
the,3764,O
CE/BZA,3764,O
",",3764,O
TSEC,3764,O
",",3764,O
exerts,3764,O
antiestrogenic,3764,O
effects,3764,O
on,3764,O
breast,3764,O
cancer,3764,O
cells,3764,O
and,3764,O
might,3764,O
block,3764,O
the,3764,O
growth,3764,O
of,3764,O
occult,3764,O
breast,3764,O
neoplasms,3764,O
in,3764,O
postmenopausal,3764,O
women,3764,O
",",3764,O
resulting,3764,O
in,3764,O
an,3764,O
overall,3764,O
reduction,3764,O
in,3764,O
tumor,3764,O
incidence,3764,O
.,3764,O
Characterization,3765,O
of,3765,O
steroidogenic,3765,O
enzyme,3765,O
expression,3765,O
in,3765,O
aldosterone-producing,3765,B-CHEMICAL
adenoma,3765,O
:,3765,O
a,3765,O
comparison,3765,O
with,3765,O
various,3765,O
human,3765,O
adrenal,3765,O
tumors,3765,O
.,3765,O
We,3766,O
analyzed,3766,O
the,3766,O
expression,3766,O
profiles,3766,O
of,3766,O
several,3766,O
steroidogenic,3766,O
enzymes,3766,O
in,3766,O
normal,3766,O
adrenals,3766,O
",",3766,O
aldosterone-producing,3766,B-CHEMICAL
adenomas,3766,O
(,3766,O
APA,3766,O
),3766,O
",",3766,O
cortisol-producing,3766,B-CHEMICAL
adenomas,3766,O
combined,3766,O
with,3766,O
Cushing,3766,O
's,3766,O
syndrome,3766,O
(,3766,O
CPA,3766,O
),3766,O
or,3766,O
with,3766,O
subclinical,3766,O
Cushing,3766,O
's,3766,O
syndrome,3766,O
(,3766,O
SCPA,3766,O
),3766,O
",",3766,O
and,3766,O
nonfunctioning,3766,O
adrenal,3766,O
adenomas,3766,O
(,3766,O
NFA,3766,O
),3766,O
to,3766,O
clarify,3766,O
the,3766,O
nature,3766,O
and,3766,O
characteristics,3766,O
of,3766,O
steroidogenesis,3766,O
in,3766,O
APA,3766,O
.,3766,O
Clinical,3767,O
data,3767,O
were,3767,O
collected,3767,O
for,3767,O
all,3767,O
subjects,3767,O
.,3767,O
In,3768,O
resected,3768,O
adrenal,3768,O
glands,3768,O
(,3768,O
normal,3768,O
adrenals,3768,O
",",3768,O
APA,3768,O
",",3768,O
CPA,3768,O
",",3768,O
SCPA,3768,O
",",3768,O
and,3768,O
NFA,3768,O
),3768,O
",",3768,O
the,3768,O
mRNA,3768,O
expression,3768,O
levels,3768,O
of,3768,O
the,3768,O
CYP17,3768,B-GENE-Y
",",3768,O
HSD3B2,3768,B-GENE-Y
",",3768,O
CYP11B1,3768,B-GENE-Y
",",3768,O
and,3768,O
CYP11B2,3768,B-GENE-Y
genes,3768,O
were,3768,O
studied,3768,O
using,3768,O
real-time,3768,O
quantitative,3768,O
PCR,3768,O
and,3768,O
immunohistochemistry,3768,O
.,3768,O
The,3769,O
CYP11B2,3769,B-GENE-Y
mRNA,3769,O
level,3769,O
in,3769,O
APA,3769,O
was,3769,O
significantly,3769,O
higher,3769,O
than,3769,O
that,3769,O
in,3769,O
other,3769,O
groups,3769,O
.,3769,O
The,3770,O
CYP17/HSD3B2,3770,B-GENE-Y
ratio,3770,O
for,3770,O
mRNA,3770,O
in,3770,O
APA,3770,O
was,3770,O
significantly,3770,O
lower,3770,O
than,3770,O
those,3770,O
in,3770,O
the,3770,O
other,3770,O
groups,3770,O
.,3770,O
Low,3771,O
ratio,3771,O
of,3771,O
CYP17/HSD3B2,3771,B-GENE-Y
with,3771,O
high,3771,O
expression,3771,O
of,3771,O
CYP11B2,3771,B-GENE-Y
seems,3771,O
to,3771,O
explain,3771,O
steroidogenic,3771,O
characteristics,3771,O
of,3771,O
APA,3771,O
.,3771,O
Live-cell,3772,O
imaging,3772,O
of,3772,O
p53,3772,B-GENE-Y
interactions,3772,O
using,3772,O
a,3772,O
novel,3772,O
Venus-based,3772,O
bimolecular,3772,O
fluorescence,3772,O
complementation,3772,O
system,3772,O
.,3772,O
p53,3773,B-GENE-Y
plays,3773,O
an,3773,O
important,3773,O
role,3773,O
in,3773,O
regulating,3773,O
a,3773,O
wide,3773,O
variety,3773,O
of,3773,O
cellular,3773,O
processes,3773,O
",",3773,O
such,3773,O
as,3773,O
cell,3773,O
cycle,3773,O
arrest,3773,O
and/or,3773,O
apoptosis,3773,O
.,3773,O
Dysfunction,3774,O
of,3774,O
p53,3774,B-GENE-Y
is,3774,O
frequently,3774,O
associated,3774,O
with,3774,O
several,3774,O
pathologies,3774,O
",",3774,O
such,3774,O
as,3774,O
cancer,3774,O
and,3774,O
neurodegenerative,3774,O
diseases,3774,O
.,3774,O
In,3775,O
recent,3775,O
years,3775,O
substantial,3775,O
progress,3775,O
has,3775,O
been,3775,O
made,3775,O
in,3775,O
developing,3775,O
novel,3775,O
p53-activating,3775,B-GENE-Y
molecules,3775,O
.,3775,O
Importantly,3776,O
",",3776,O
modulation,3776,O
of,3776,O
p53,3776,B-GENE-Y
interaction,3776,O
with,3776,O
its,3776,O
main,3776,O
inhibitor,3776,O
",",3776,O
Mdm2,3776,B-GENE-Y
",",3776,O
has,3776,O
been,3776,O
highlighted,3776,O
as,3776,O
a,3776,O
promising,3776,O
therapeutic,3776,O
target,3776,O
.,3776,O
In,3777,O
this,3777,O
regard,3777,O
",",3777,O
bimolecular,3777,O
fluorescence,3777,O
complementation,3777,O
(,3777,O
BiFC,3777,O
),3777,O
analysis,3777,O
",",3777,O
by,3777,O
providing,3777,O
direct,3777,O
visualization,3777,O
of,3777,O
protein,3777,O
interactions,3777,O
in,3777,O
living,3777,O
cells,3777,O
",",3777,O
offers,3777,O
a,3777,O
straightforward,3777,O
method,3777,O
to,3777,O
identify,3777,O
potential,3777,O
modulators,3777,O
of,3777,O
protein,3777,O
interactions,3777,O
.,3777,O
In,3778,O
this,3778,O
study,3778,O
",",3778,O
we,3778,O
developed,3778,O
a,3778,O
simple,3778,O
and,3778,O
robust,3778,O
Venus-based,3778,O
BiFC,3778,O
system,3778,O
to,3778,O
screen,3778,O
for,3778,O
modulators,3778,O
of,3778,O
p53-p53,3778,B-GENE-N
and,3778,O
p53-Mdm2,3778,B-GENE-N
interactions,3778,O
in,3778,O
live,3778,O
mammalian,3778,O
cells,3778,O
.,3778,O
We,3779,O
used,3779,O
nutlin-3,3779,B-CHEMICAL
",",3779,O
a,3779,O
well-known,3779,O
disruptor,3779,O
of,3779,O
p53-Mdm2,3779,B-GENE-Y
interaction,3779,O
",",3779,O
to,3779,O
validate,3779,O
the,3779,O
specificity,3779,O
of,3779,O
the,3779,O
assay,3779,O
.,3779,O
The,3780,O
reduction,3780,O
of,3780,O
BiFC,3780,O
signal,3780,O
mediated,3780,O
by,3780,O
nutlin-3,3780,B-CHEMICAL
was,3780,O
correlated,3780,O
with,3780,O
an,3780,O
increase,3780,O
in,3780,O
Puma,3780,B-GENE-Y
transactivation,3780,O
",",3780,O
PARP,3780,B-GENE-N
cleavage,3780,O
",",3780,O
and,3780,O
cell,3780,O
death,3780,O
.,3780,O
Finally,3781,O
",",3781,O
this,3781,O
novel,3781,O
BiFC,3781,O
approach,3781,O
was,3781,O
exploited,3781,O
to,3781,O
identify,3781,O
potential,3781,O
modulators,3781,O
of,3781,O
p53-Mdm2,3781,B-GENE-Y
complex,3781,O
formation,3781,O
among,3781,O
a,3781,O
commercially,3781,O
available,3781,O
chemical,3781,O
library,3781,O
of,3781,O
33,3781,O
protein,3781,B-GENE-N
phosphatase,3781,I-GENE-N
inhibitors,3781,O
.,3781,O
Our,3782,O
results,3782,O
constitute,3782,O
``,3782,O
proof-of-concept,3782,O
'',3782,O
that,3782,O
this,3782,O
model,3782,O
has,3782,O
strong,3782,O
potential,3782,O
as,3782,O
an,3782,O
alternative,3782,O
to,3782,O
traditional,3782,O
target-based,3782,O
drug,3782,O
discovery,3782,O
strategies,3782,O
.,3782,O
Identification,3783,O
of,3783,O
new,3783,O
modulators,3783,O
of,3783,O
p53-p53,3783,B-GENE-Y
and,3783,O
p53-Mdm2,3783,B-GENE-Y
interactions,3783,O
will,3783,O
be,3783,O
useful,3783,O
to,3783,O
achieve,3783,O
synergistic,3783,O
drug,3783,O
efficacy,3783,O
with,3783,O
currently,3783,O
used,3783,O
anti-tumor,3783,O
therapies,3783,O
.,3783,O
Salsolinol,3784,B-CHEMICAL
induced,3784,O
apoptotic,3784,O
changes,3784,O
in,3784,O
neural,3784,O
stem,3784,O
cells,3784,O
:,3784,O
amelioration,3784,O
by,3784,O
neurotrophin,3784,B-GENE-N
support,3784,O
.,3784,O
Salsolinol,3785,B-CHEMICAL
(,3785,O
SAL,3785,B-CHEMICAL
),3785,O
",",3785,O
a,3785,O
catechol,3785,B-CHEMICAL
isoquinoline,3785,I-CHEMICAL
has,3785,O
invited,3785,O
considerable,3785,O
attention,3785,O
due,3785,O
to,3785,O
its,3785,O
structural,3785,O
similarity,3785,O
with,3785,O
dopaminergic,3785,O
neurotoxin,3785,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",3785,B-CHEMICAL
(,3785,O
MPTP,3785,B-CHEMICAL
),3785,O
.,3785,O
Its,3786,O
high,3786,O
endogenous,3786,O
presence,3786,O
in,3786,O
Parkinsonian,3786,O
brain,3786,O
implicated,3786,O
its,3786,O
possible,3786,O
association,3786,O
with,3786,O
the,3786,O
disease,3786,O
process,3786,O
.,3786,O
SAL,3787,B-CHEMICAL
is,3787,O
also,3787,O
present,3787,O
in,3787,O
alcohol,3787,O
beverages,3787,O
and,3787,O
certain,3787,O
food,3787,O
materials,3787,O
and,3787,O
can,3787,O
get,3787,O
access,3787,O
to,3787,O
brain,3787,O
especially,3787,O
in,3787,O
conditions,3787,O
of,3787,O
immature,3787,O
or,3787,O
impaired,3787,O
BBB,3787,O
.,3787,O
Besides,3788,O
this,3788,O
",",3788,O
the,3788,O
effect,3788,O
of,3788,O
SAL,3788,B-CHEMICAL
on,3788,O
neural,3788,O
stem,3788,O
cells,3788,O
(,3788,O
NSCs,3788,O
),3788,O
which,3788,O
are,3788,O
potential,3788,O
candidates,3788,O
for,3788,O
adult,3788,O
neurogenesis,3788,O
and,3788,O
transplantation,3788,O
mediated,3788,O
rejuvenating,3788,O
attempts,3788,O
for,3788,O
Parkinson,3788,O
's,3788,O
disease,3788,O
(,3788,O
PD,3788,O
),3788,O
brain,3788,O
has,3788,O
not,3788,O
been,3788,O
known,3788,O
so,3788,O
far,3788,O
.,3788,O
NSCs,3789,O
in,3789,O
both,3789,O
the,3789,O
cases,3789,O
have,3789,O
to,3789,O
overcome,3789,O
suppressive,3789,O
cues,3789,O
of,3789,O
diseased,3789,O
brain,3789,O
for,3789,O
their,3789,O
survival,3789,O
and,3789,O
function,3789,O
.,3789,O
In,3790,O
this,3790,O
study,3790,O
we,3790,O
explored,3790,O
the,3790,O
toxicity,3790,O
of,3790,O
SAL,3790,B-CHEMICAL
toward,3790,O
NSCs,3790,O
focusing,3790,O
on,3790,O
apoptosis,3790,O
and,3790,O
status,3790,O
of,3790,O
PI3K,3790,B-GENE-N
survival,3790,O
signaling,3790,O
.,3790,O
NSCs,3791,O
cultured,3791,O
from,3791,O
embryonic,3791,O
day,3791,O
11,3791,O
rat,3791,O
fetal,3791,O
brain,3791,O
including,3791,O
those,3791,O
differentiated,3791,O
to,3791,O
TH,3791,O
(,3791,O
+ve,3791,O
),3791,O
colonies,3791,O
",",3791,O
when,3791,O
challenged,3791,O
with,3791,O
SAL,3791,B-CHEMICAL
(,3791,O
1-100M,3791,O
),3791,O
",",3791,O
elicited,3791,O
a,3791,O
concentration,3791,O
and,3791,O
time,3791,O
dependent,3791,O
cell,3791,O
death/loss,3791,O
of,3791,O
mitochondrial,3791,O
viability,3791,O
.,3791,O
10M,3792,O
SAL,3792,B-CHEMICAL
on,3792,O
which,3792,O
significant,3792,O
mitochondrial,3792,O
impairment,3792,O
initiated,3792,O
was,3792,O
further,3792,O
used,3792,O
to,3792,O
study,3792,O
mechanism,3792,O
of,3792,O
toxicity,3792,O
.,3792,O
Morphological,3793,O
impairment,3793,O
",",3793,O
enhanced,3793,O
TUNEL,3793,O
positivity,3793,O
",",3793,O
cleaved,3793,O
caspase-3,3793,B-GENE-Y
and,3793,O
decreased,3793,O
Bcl-2,3793,B-GENE-Y
:,3793,O
Bax,3793,B-GENE-Y
suggested,3793,O
apoptosis,3793,O
.,3793,O
Sal,3794,B-CHEMICAL
toxicity,3794,O
coincided,3794,O
with,3794,O
reduced,3794,O
pAkt,3794,B-GENE-N
level,3794,O
and,3794,O
its,3794,O
downstream,3794,O
effectors,3794,O
:,3794,O
pCREB,3794,B-GENE-N
",",3794,O
pGSK-3,3794,B-GENE-Y
",",3794,O
Bcl-2,3794,B-GENE-Y
and,3794,O
neurotrophins,3794,B-GENE-N
GDNF,3794,B-GENE-Y
",",3794,O
BDNF,3794,B-GENE-Y
suggesting,3794,O
repressed,3794,O
PI3K/Akt,3794,B-GENE-N
signaling,3794,O
.,3794,O
Multiple,3795,O
neurotrophic,3795,O
factor,3795,O
support,3795,O
in,3795,O
the,3795,O
form,3795,O
of,3795,O
Olfactory,3795,O
Ensheathing,3795,O
Cell,3795,O
's,3795,O
Conditioned,3795,O
Media,3795,O
(,3795,O
OEC,3795,O
CM,3795,O
),3795,O
potentially,3795,O
protected,3795,O
NSCs,3795,O
against,3795,O
SAL,3795,B-CHEMICAL
through,3795,O
activating,3795,O
PI3K/Akt,3795,B-GENE-N
pathway,3795,O
.,3795,O
This,3796,O
was,3796,O
confirmed,3796,O
on,3796,O
adding,3796,O
LY294002,3796,B-CHEMICAL
the,3796,O
PI3K,3796,B-GENE-N
inhibitor,3796,O
which,3796,O
abolished,3796,O
the,3796,O
protection,3796,O
.,3796,O
We,3797,O
inferred,3797,O
that,3797,O
SAL,3797,B-CHEMICAL
exerts,3797,O
substantial,3797,O
toxicity,3797,O
toward,3797,O
NSCs,3797,O
.,3797,O
These,3798,O
findings,3798,O
will,3798,O
lead,3798,O
to,3798,O
better,3798,O
understanding,3798,O
of,3798,O
endogenous,3798,O
threats,3798,O
that,3798,O
might,3798,O
affect,3798,O
the,3798,O
fate,3798,O
of,3798,O
transplanted,3798,O
NSCs,3798,O
and,3798,O
their,3798,O
probable,3798,O
antidotes,3798,O
.,3798,O
Central,3799,O
nervous,3799,O
system,3799,O
damage,3799,O
due,3799,O
to,3799,O
acute,3799,O
paraquat,3799,B-CHEMICAL
poisoning,3799,O
:,3799,O
an,3799,O
experimental,3799,O
study,3799,O
with,3799,O
rat,3799,O
model,3799,O
.,3799,O
Paraquat,3800,B-CHEMICAL
(,3800,O
PQ,3800,O
),3800,O
is,3800,O
a,3800,O
common,3800,O
herbicide,3800,O
and,3800,O
PQ,3800,O
poisoning,3800,O
is,3800,O
a,3800,O
major,3800,O
medical,3800,O
problem,3800,O
in,3800,O
Asia,3800,O
.,3800,O
However,3801,O
",",3801,O
few,3801,O
studies,3801,O
have,3801,O
focused,3801,O
on,3801,O
the,3801,O
acute,3801,O
neurotoxic,3801,O
changes,3801,O
caused,3801,O
by,3801,O
PQ,3801,O
.,3801,O
Here,3802,O
we,3802,O
report,3802,O
the,3802,O
acute,3802,O
neurotoxicological,3802,O
findings,3802,O
of,3802,O
rats,3802,O
treated,3802,O
with,3802,O
lethal,3802,O
dose,3802,O
of,3802,O
PQ,3802,O
.,3802,O
In,3803,O
substantia,3803,O
nigra,3803,O
(,3803,O
SN,3803,O
),3803,O
and,3803,O
striatum,3803,O
we,3803,O
found,3803,O
obvious,3803,O
microglia,3803,O
(,3803,O
labeled,3803,O
by,3803,O
Iba-1,3803,B-GENE-Y
),3803,O
activation,3803,O
within,3803,O
one,3803,O
week,3803,O
.,3803,O
In,3804,O
SN,3804,O
and,3804,O
hippocampus,3804,O
",",3804,O
we,3804,O
detected,3804,O
increased,3804,O
oxidative,3804,O
stress,3804,O
in,3804,O
the,3804,O
neurons,3804,O
based,3804,O
on,3804,O
NeuN/8-OHdG,3804,O
immunofluorescence,3804,O
double,3804,O
labeling,3804,O
and,3804,O
laser,3804,O
cofocal,3804,O
microscopy,3804,O
.,3804,O
Moreover,3805,O
",",3805,O
we,3805,O
provided,3805,O
ultrastructural,3805,O
evidences,3805,O
of,3805,O
astrocyte,3805,O
edema,3805,O
and,3805,O
neurons,3805,O
apoptosis,3805,O
in,3805,O
rat,3805,O
brain,3805,O
by,3805,O
electron,3805,O
microscopy,3805,O
.,3805,O
Further,3806,O
studies,3806,O
will,3806,O
be,3806,O
needed,3806,O
with,3806,O
non-lethal,3806,O
dose,3806,O
of,3806,O
PQ,3806,O
to,3806,O
confirm,3806,O
these,3806,O
results,3806,O
and,3806,O
demonstrate,3806,O
the,3806,O
direct,3806,O
CNS,3806,O
toxicity,3806,O
of,3806,O
PQ,3806,O
.,3806,O
(,3807,B-CHEMICAL
-,3807,I-CHEMICAL
),3807,I-CHEMICAL
Epicatechin,3807,I-CHEMICAL
attenuates,3807,O
mitochondrial,3807,O
damage,3807,O
by,3807,O
enhancing,3807,O
mitochondrial,3807,O
multi-marker,3807,O
enzymes,3807,O
",",3807,O
adenosine,3807,B-CHEMICAL
triphosphate,3807,I-CHEMICAL
and,3807,O
lowering,3807,O
calcium,3807,B-CHEMICAL
in,3807,O
isoproterenol,3807,B-CHEMICAL
induced,3807,O
myocardial,3807,O
infarcted,3807,O
rats,3807,O
.,3807,O
Cardiac,3808,O
mitochondrial,3808,O
damage,3808,O
plays,3808,O
an,3808,O
important,3808,O
role,3808,O
in,3808,O
the,3808,O
pathology,3808,O
of,3808,O
myocardial,3808,O
infarction,3808,O
.,3808,O
The,3809,O
protective,3809,O
effects,3809,O
of,3809,O
(,3809,B-CHEMICAL
-,3809,I-CHEMICAL
),3809,I-CHEMICAL
epicatechin,3809,I-CHEMICAL
on,3809,O
cardiac,3809,O
mitochondrial,3809,O
damage,3809,O
in,3809,O
isoproterenol,3809,B-CHEMICAL
induced,3809,O
myocardial,3809,O
infarction,3809,O
were,3809,O
evaluated,3809,O
in,3809,O
rats,3809,O
.,3809,O
Rats,3810,O
were,3810,O
pretreated,3810,O
with,3810,O
(,3810,B-CHEMICAL
-,3810,I-CHEMICAL
),3810,I-CHEMICAL
epicatechin,3810,I-CHEMICAL
(,3810,O
20,3810,O
mg/kg,3810,O
body,3810,O
weight,3810,O
),3810,O
daily,3810,O
for,3810,O
a,3810,O
period,3810,O
of,3810,O
21,3810,O
days,3810,O
.,3810,O
After,3811,O
the,3811,O
pretreatment,3811,O
period,3811,O
",",3811,O
isoproterenol,3811,B-CHEMICAL
(,3811,O
100,3811,O
mg/kg,3811,O
body,3811,O
weight,3811,O
),3811,O
was,3811,O
injected,3811,O
subcutaneously,3811,O
into,3811,O
rats,3811,O
twice,3811,O
at,3811,O
an,3811,O
interval,3811,O
of,3811,O
24,3811,O
h,3811,O
to,3811,O
induce,3811,O
myocardial,3811,O
infarction,3811,O
.,3811,O
Isoproterenol,3812,B-CHEMICAL
induced,3812,O
myocardial,3812,O
infarcted,3812,O
rats,3812,O
showed,3812,O
a,3812,O
significant,3812,O
increase,3812,O
in,3812,O
the,3812,O
levels,3812,O
of,3812,O
cardiac,3812,O
diagnostic,3812,O
markers,3812,O
",",3812,O
heart,3812,O
mitochondrial,3812,O
lipid,3812,O
peroxidation,3812,O
",",3812,O
calcium,3812,B-CHEMICAL
",",3812,O
and,3812,O
a,3812,O
significant,3812,O
decrease,3812,O
in,3812,O
the,3812,O
activities/levels,3812,O
of,3812,O
heart,3812,O
mitochondrial,3812,O
glutathione,3812,B-GENE-N
peroxidase,3812,I-GENE-N
",",3812,O
glutathione,3812,B-GENE-Y
reductase,3812,I-GENE-Y
",",3812,O
reduced,3812,B-CHEMICAL
glutathione,3812,I-CHEMICAL
",",3812,O
isocitrate,3812,B-CHEMICAL
",",3812,O
succinate,3812,B-CHEMICAL
",",3812,O
malate,3812,B-CHEMICAL
",",3812,O
-ketoglutarate,3812,B-CHEMICAL
and,3812,O
NADH-dehydrogenases,3812,B-GENE-N
",",3812,O
cytochrome-C-oxidase,3812,B-GENE-N
and,3812,O
adenosine,3812,B-CHEMICAL
triphosphate,3812,I-CHEMICAL
.,3812,O
(,3813,B-CHEMICAL
-,3813,I-CHEMICAL
),3813,I-CHEMICAL
Epicatechin,3813,I-CHEMICAL
pretreatment,3813,O
showed,3813,O
significant,3813,O
protective,3813,O
effects,3813,O
on,3813,O
all,3813,O
the,3813,O
biochemical,3813,O
parameters,3813,O
evaluated,3813,O
.,3813,O
The,3814,O
in,3814,O
vitro,3814,O
study,3814,O
revealed,3814,O
the,3814,O
superoxide,3814,B-CHEMICAL
and,3814,O
hydroxyl,3814,B-CHEMICAL
radical,3814,O
scavenging,3814,O
activity,3814,O
of,3814,O
(,3814,B-CHEMICAL
-,3814,I-CHEMICAL
),3814,I-CHEMICAL
epicatechin,3814,I-CHEMICAL
.,3814,O
The,3815,O
possible,3815,O
mechanisms,3815,O
for,3815,O
the,3815,O
beneficial,3815,O
effects,3815,O
of,3815,O
(,3815,B-CHEMICAL
-,3815,I-CHEMICAL
),3815,I-CHEMICAL
epicatechin,3815,I-CHEMICAL
on,3815,O
cardiac,3815,O
mitochondria,3815,O
could,3815,O
be,3815,O
attributed,3815,O
to,3815,O
scavenging,3815,O
of,3815,O
free,3815,O
radicals,3815,O
",",3815,O
decreasing,3815,O
calcium,3815,B-CHEMICAL
",",3815,O
increasing,3815,O
multi-enzymes,3815,O
(,3815,O
antioxidant,3815,O
",",3815,O
tricarboxylic,3815,B-CHEMICAL
acid,3815,I-CHEMICAL
cycle,3815,O
and,3815,O
respiratory,3815,O
chain,3815,O
enzymes,3815,O
),3815,O
",",3815,O
reduced,3815,O
glutathione,3815,B-CHEMICAL
and,3815,O
adenosine,3815,B-CHEMICAL
triphosphate,3815,I-CHEMICAL
.,3815,O
Thus,3816,O
",",3816,O
(,3816,B-CHEMICAL
-,3816,I-CHEMICAL
),3816,I-CHEMICAL
epicatechin,3816,I-CHEMICAL
attenuated,3816,O
mitochondrial,3816,O
damage,3816,O
in,3816,O
isoproterenol,3816,B-CHEMICAL
induced,3816,O
myocardial,3816,O
infarcted,3816,O
rats,3816,O
.,3816,O
Increased,3817,O
urinary,3817,O
excretion,3817,O
of,3817,O
albumin,3817,B-GENE-N
",",3817,O
hemopexin,3817,B-GENE-Y
",",3817,O
transferrin,3817,B-GENE-Y
and,3817,O
VDBP,3817,B-GENE-Y
correlates,3817,O
with,3817,O
chronic,3817,O
sensitization,3817,O
to,3817,O
gentamicin,3817,B-CHEMICAL
nephrotoxicity,3817,O
in,3817,O
rats,3817,O
.,3817,O
Drug,3818,O
nephrotoxicity,3818,O
is,3818,O
a,3818,O
serious,3818,O
health,3818,O
and,3818,O
economic,3818,O
problem,3818,O
worldwide,3818,O
.,3818,O
Rats,3819,O
can,3819,O
be,3819,O
acutely,3819,O
sensitized,3819,O
to,3819,O
acute,3819,O
kidney,3819,O
injury,3819,O
(,3819,O
AKI,3819,O
),3819,O
by,3819,O
subnephrotoxic,3819,O
treatments,3819,O
with,3819,O
potentially,3819,O
nephrotoxic,3819,O
drugs,3819,O
.,3819,O
Acquired,3820,O
sensitization,3820,O
to,3820,O
AKI,3820,O
poses,3820,O
a,3820,O
silent,3820,O
risk,3820,O
impossible,3820,O
to,3820,O
diagnose,3820,O
pre-emptively,3820,O
with,3820,O
the,3820,O
technology,3820,O
available,3820,O
at,3820,O
the,3820,O
clinical,3820,O
level,3820,O
.,3820,O
Herein,3821,O
",",3821,O
we,3821,O
hypothesized,3821,O
whether,3821,O
a,3821,O
chronic,3821,O
",",3821,O
subnephrotoxic,3821,O
insult,3821,O
to,3821,O
the,3821,O
kidneys,3821,O
might,3821,O
result,3821,O
in,3821,O
chronically,3821,O
acquired,3821,O
sensitization,3821,O
to,3821,O
AKI,3821,O
",",3821,O
and,3821,O
whether,3821,O
chronic,3821,O
sensitization,3821,O
might,3821,O
be,3821,O
detected,3821,O
through,3821,O
specific,3821,O
urinary,3821,O
markers,3821,O
.,3821,O
To,3822,O
this,3822,O
end,3822,O
",",3822,O
rats,3822,O
were,3822,O
treated,3822,O
with,3822,O
a,3822,O
subtoxic,3822,O
dosage,3822,O
of,3822,O
the,3822,O
experimental,3822,O
nephrotoxin,3822,O
uranyl,3822,O
nitrate,3822,B-CHEMICAL
(,3822,O
UN,3822,O
),3822,O
in,3822,O
the,3822,O
drinking,3822,O
water,3822,O
for,3822,O
21,3822,O
weeks,3822,O
",",3822,O
or,3822,O
plain,3822,O
water,3822,O
(,3822,O
as,3822,O
control,3822,O
),3822,O
",",3822,O
and,3822,O
then,3822,O
with,3822,O
low-dose,3822,O
gentamicin,3822,B-CHEMICAL
for,3822,O
7,3822,O
days,3822,O
.,3822,O
Renal,3823,O
function,3823,O
and,3823,O
renal,3823,O
tissue,3823,O
damage,3823,O
were,3823,O
evaluated,3823,O
through,3823,O
the,3823,O
experiment,3823,O
.,3823,O
The,3824,O
mild,3824,O
renal,3824,O
damage,3824,O
caused,3824,O
by,3824,O
gentamicin,3824,B-CHEMICAL
was,3824,O
markedly,3824,O
magnified,3824,O
in,3824,O
rats,3824,O
having,3824,O
received,3824,O
UN,3824,O
chronically,3824,O
",",3824,O
which,3824,O
was,3824,O
evident,3824,O
both,3824,O
at,3824,O
the,3824,O
functional,3824,O
and,3824,O
histological,3824,O
level,3824,O
.,3824,O
Four,3825,O
proteins,3825,O
",",3825,O
namely,3825,O
albumin,3825,B-GENE-N
",",3825,O
hemopexin,3825,B-GENE-Y
",",3825,O
transferrin,3825,B-GENE-Y
and,3825,O
vitamin,3825,B-CHEMICAL
D,3825,I-CHEMICAL
binding,3825,I-GENE-Y
protein,3825,I-GENE-Y
were,3825,O
increased,3825,O
in,3825,O
the,3825,O
urine,3825,O
in,3825,O
temporal,3825,O
association,3825,O
with,3825,O
the,3825,O
appearance,3825,O
of,3825,O
chronic,3825,O
predisposition,3825,O
.,3825,O
Although,3826,O
further,3826,O
studies,3826,O
are,3826,O
necessary,3826,O
",",3826,O
our,3826,O
results,3826,O
suggest,3826,O
that,3826,O
these,3826,O
proteins,3826,O
might,3826,O
be,3826,O
potentially,3826,O
used,3826,O
as,3826,O
markers,3826,O
of,3826,O
hidden,3826,O
",",3826,O
chronic,3826,O
predisposition,3826,O
to,3826,O
gentamicin,3826,B-CHEMICAL
nephrotoxicity,3826,O
",",3826,O
in,3826,O
order,3826,O
to,3826,O
appropriately,3826,O
and,3826,O
pre-emptively,3826,O
stratify,3826,O
and,3826,O
handle,3826,O
individuals,3826,O
according,3826,O
to,3826,O
their,3826,O
specific,3826,O
risk,3826,O
in,3826,O
the,3826,O
long,3826,O
term,3826,O
",",3826,O
and,3826,O
to,3826,O
conveniently,3826,O
optimize,3826,O
their,3826,O
life,3826,O
conditions,3826,O
or,3826,O
additional,3826,O
clinical,3826,O
procedures,3826,O
or,3826,O
treatments,3826,O
that,3826,O
might,3826,O
trigger,3826,O
the,3826,O
disease,3826,O
.,3826,O
This,3827,O
might,3827,O
reduce,3827,O
AKI,3827,O
incidence,3827,O
and,3827,O
severity,3827,O
and,3827,O
the,3827,O
associated,3827,O
costs,3827,O
.,3827,O
Antioxidant,3828,O
and,3828,O
immunomodulatory,3828,O
activity,3828,O
of,3828,O
selenium,3828,B-CHEMICAL
exopolysaccharide,3828,O
produced,3828,O
by,3828,O
Lactococcus,3828,O
lactis,3828,O
subsp,3828,O
.,3828,O
lactis,3829,O
.,3829,O
Exopolysaccharide,3830,O
(,3830,O
EPS,3830,O
),3830,O
was,3830,O
isolated,3830,O
and,3830,O
purified,3830,O
from,3830,O
Lactococcus,3830,O
lactis,3830,O
subsp,3830,O
.,3830,O
Lactis,3831,O
culture,3831,O
broth,3831,O
.,3831,O
Selenium,3832,B-CHEMICAL
chloride,3832,I-CHEMICAL
oxide,3832,I-CHEMICAL
(,3832,O
SeCl,3832,B-CHEMICAL
(,3832,I-CHEMICAL
2,3832,I-CHEMICAL
),3832,I-CHEMICAL
O,3832,I-CHEMICAL
),3832,O
was,3832,O
added,3832,O
to,3832,O
the,3832,O
EPS,3832,O
to,3832,O
synthesize,3832,O
selenium-exopolysaccharide,3832,B-CHEMICAL
(,3832,O
Se-EPS,3832,B-CHEMICAL
),3832,O
.,3832,O
The,3833,O
in,3833,O
vitro,3833,O
and,3833,O
in,3833,O
vivo,3833,O
antioxidant,3833,O
and,3833,O
in,3833,O
vivo,3833,O
immunomodulatory,3833,O
activity,3833,O
of,3833,O
EPS,3833,O
and,3833,O
Se-EPS,3833,B-CHEMICAL
were,3833,O
compared,3833,O
.,3833,O
EPS,3834,O
and,3834,O
Se-EPS,3834,B-CHEMICAL
scavenged,3834,O
superoxide,3834,B-CHEMICAL
anions,3834,O
and,3834,O
hydroxyl,3834,B-CHEMICAL
radicals,3834,O
.,3834,O
They,3835,O
also,3835,O
increased,3835,O
catalase,3835,B-GENE-Y
(,3835,O
CAT,3835,B-GENE-Y
),3835,O
",",3835,O
superoxide,3835,B-CHEMICAL
dismutase,3835,I-GENE-N
(,3835,O
SOD,3835,B-GENE-N
),3835,O
and,3835,O
glutathione,3835,B-GENE-N
peroxidase,3835,I-GENE-N
(,3835,O
GSH-Px,3835,B-GENE-N
),3835,O
activity,3835,O
",",3835,O
while,3835,O
decreasing,3835,O
malondialdehyde,3835,B-CHEMICAL
(,3835,O
MDA,3835,B-CHEMICAL
),3835,O
levels,3835,O
in,3835,O
serum,3835,O
and,3835,O
in,3835,O
the,3835,O
livers,3835,O
of,3835,O
mice,3835,O
.,3835,O
Se-EPS,3836,B-CHEMICAL
showed,3836,O
stronger,3836,O
in,3836,O
vitro,3836,O
and,3836,O
in,3836,O
vivo,3836,O
antioxidant,3836,O
activity,3836,O
than,3836,O
were,3836,O
shown,3836,O
by,3836,O
EPS,3836,O
.,3836,O
The,3837,O
in,3837,O
vivo,3837,O
immunoenhancement,3837,O
activity,3837,O
of,3837,O
EPS,3837,O
and,3837,O
Se-EPS,3837,B-CHEMICAL
induced,3837,O
by,3837,O
cyclophosphamide,3837,B-CHEMICAL
(,3837,O
CY,3837,O
),3837,O
treatment,3837,O
in,3837,O
immunosuppressed,3837,O
mice,3837,O
was,3837,O
researched,3837,O
.,3837,O
EPS,3838,O
and,3838,O
Se-EPS,3838,B-CHEMICAL
treatments,3838,O
increased,3838,O
macrophage,3838,O
phagocytosis,3838,O
",",3838,O
spleen,3838,O
and,3838,O
thymus,3838,O
indices,3838,O
and,3838,O
haemolytic,3838,O
complement,3838,O
activity,3838,O
(,3838,O
HC,3838,O
(,3838,O
50,3838,O
),3838,O
),3838,O
.,3838,O
Se-EPS,3839,B-CHEMICAL
showed,3839,O
stronger,3839,O
immunomodulatory,3839,O
activity,3839,O
than,3839,O
did,3839,O
EPS,3839,O
.,3839,O
Influence,3840,O
of,3840,O
extraction,3840,O
procedures,3840,O
on,3840,O
phenolic,3840,O
content,3840,O
and,3840,O
antioxidant,3840,O
activity,3840,O
of,3840,O
Cretan,3840,O
barberry,3840,O
herb,3840,O
.,3840,O
The,3841,O
main,3841,O
goal,3841,O
of,3841,O
present,3841,O
study,3841,O
was,3841,O
the,3841,O
development,3841,O
",",3841,O
optimization,3841,O
and,3841,O
application,3841,O
of,3841,O
different,3841,O
extraction,3841,O
protocols,3841,O
",",3841,O
especially,3841,O
those,3841,O
employing,3841,O
green,3841,O
technologies,3841,O
",",3841,O
in,3841,O
order,3841,O
to,3841,O
obtain,3841,O
from,3841,O
Berberis,3841,O
cretica,3841,O
extracts,3841,O
with,3841,O
high,3841,O
antioxidant,3841,O
capacity,3841,O
.,3841,O
For,3842,O
this,3842,O
purpose,3842,O
",",3842,O
the,3842,O
applied,3842,O
methods,3842,O
:,3842,O
maceration,3842,O
",",3842,O
ASE,3842,O
and,3842,O
SFE,3842,O
coupled,3842,O
with,3842,O
ASE,3842,O
were,3842,O
incorporated,3842,O
.,3842,O
The,3843,O
antioxidant,3843,O
assessment,3843,O
was,3843,O
carried,3843,O
out,3843,O
using,3843,O
DPPH,3843,B-CHEMICAL
and,3843,O
total,3843,O
phenolic,3843,O
content,3843,O
(,3843,O
Folin-Ciocalteu,3843,O
),3843,O
assays,3843,O
.,3843,O
Major,3844,O
constituents,3844,O
were,3844,O
elucidated,3844,O
using,3844,O
HPLC-DAD,3844,O
and,3844,O
UHPLC-HRMS/MS,3844,O
(,3844,O
hybrid,3844,O
IT-Orbital,3844,O
trap,3844,O
spectrometer,3844,O
),3844,O
equipped,3844,O
with,3844,O
an,3844,O
ESI,3844,O
probe,3844,O
.,3844,O
The,3845,O
chromatographic,3845,O
and,3845,O
spectral,3845,O
data,3845,O
revealed,3845,O
the,3845,O
presence,3845,O
of,3845,O
several,3845,O
simple,3845,O
phenolic,3845,B-CHEMICAL
acids,3845,I-CHEMICAL
",",3845,O
derivatives,3845,O
of,3845,O
both,3845,O
caffeic,3845,B-CHEMICAL
and,3845,I-CHEMICAL
benzoic,3845,I-CHEMICAL
acids,3845,I-CHEMICAL
",",3845,O
and,3845,O
flavonoids,3845,B-CHEMICAL
in,3845,O
the,3845,O
produced,3845,O
extracts,3845,O
.,3845,O
It,3846,O
was,3846,O
clearly,3846,O
evidenced,3846,O
that,3846,O
the,3846,O
extraction,3846,O
method,3846,O
and,3846,O
solvents,3846,O
used,3846,O
affected,3846,O
both,3846,O
the,3846,O
activity,3846,O
and,3846,O
the,3846,O
chemical,3846,O
content,3846,O
of,3846,O
the,3846,O
results,3846,O
",",3846,O
significantly,3846,O
.,3846,O
The,3847,O
most,3847,O
beneficial,3847,O
conditions,3847,O
were,3847,O
calculated,3847,O
for,3847,O
methanol,3847,B-CHEMICAL
and,3847,O
water,3847,O
:,3847,O
ethanol,3847,B-CHEMICAL
(,3847,O
50:50,3847,O
),3847,O
extracts,3847,O
derived,3847,O
from,3847,O
the,3847,O
combination,3847,O
of,3847,O
SFE,3847,O
and,3847,O
ASE,3847,O
methodologies,3847,O
.,3847,O
Obtained,3848,O
results,3848,O
classify,3848,O
Cretan,3848,O
barberry,3848,O
as,3848,O
a,3848,O
strong,3848,O
antioxidant,3848,O
agent,3848,O
.,3848,O
Shelf-life,3849,O
of,3849,O
infrared,3849,O
dry-roasted,3849,O
almonds,3849,O
.,3849,O
Infrared,3850,O
heating,3850,O
was,3850,O
recently,3850,O
used,3850,O
to,3850,O
develop,3850,O
a,3850,O
more,3850,O
efficient,3850,O
roasting,3850,O
technology,3850,O
than,3850,O
traditional,3850,O
hot,3850,O
air,3850,O
roasting,3850,O
.,3850,O
Therefore,3851,O
",",3851,O
in,3851,O
this,3851,O
study,3851,O
",",3851,O
we,3851,O
evaluated,3851,O
the,3851,O
shelf-life,3851,O
of,3851,O
almonds,3851,O
roasted,3851,O
with,3851,O
three,3851,O
different,3851,O
approaches,3851,O
",",3851,O
namely,3851,O
infrared,3851,O
(,3851,O
IR,3851,O
),3851,O
",",3851,O
sequential,3851,O
infrared,3851,O
and,3851,O
hot,3851,O
air,3851,O
(,3851,O
SIRHA,3851,O
),3851,O
and,3851,O
regular,3851,O
hot,3851,O
air,3851,O
(,3851,O
HA,3851,O
),3851,O
.,3851,O
Nine,3852,O
medium,3852,O
roasted,3852,O
almond,3852,O
samples,3852,O
produced,3852,O
by,3852,O
the,3852,O
aforementioned,3852,O
heating,3852,O
methods,3852,O
were,3852,O
processed,3852,O
at,3852,O
three,3852,O
different,3852,O
temperatures,3852,O
(,3852,O
130,3852,O
",",3852,O
140,3852,O
and,3852,O
150,3852,O
C,3852,O
),3852,O
",",3852,O
packed,3852,O
in,3852,O
paper,3852,O
bags,3852,O
and,3852,O
then,3852,O
stored,3852,O
at,3852,O
37,3852,O
C,3852,O
for,3852,O
three,3852,O
",",3852,O
six,3852,O
or,3852,O
eight,3852,O
months,3852,O
.,3852,O
Shelf-life,3853,O
of,3853,O
the,3853,O
roasted,3853,O
almonds,3853,O
was,3853,O
determined,3853,O
by,3853,O
measuring,3853,O
the,3853,O
changes,3853,O
in,3853,O
colour,3853,O
",",3853,O
peroxide,3853,B-CHEMICAL
value,3853,O
",",3853,O
moisture,3853,O
content,3853,O
",",3853,O
water,3853,O
activity,3853,O
",",3853,O
volatile,3853,O
components,3853,O
and,3853,O
sensory,3853,O
quality,3853,O
.,3853,O
No,3854,O
significant,3854,O
difference,3854,O
was,3854,O
observed,3854,O
in,3854,O
moisture,3854,O
content,3854,O
and,3854,O
water,3854,O
activity,3854,O
among,3854,O
the,3854,O
almond,3854,O
samples,3854,O
processed,3854,O
with,3854,O
different,3854,O
roasting,3854,O
methods,3854,O
and,3854,O
stored,3854,O
under,3854,O
the,3854,O
same,3854,O
conditions,3854,O
.,3854,O
GC/MS,3855,O
analysis,3855,O
showed,3855,O
that,3855,O
aldehydes,3855,B-CHEMICAL
",",3855,O
alcohols,3855,B-CHEMICAL
",",3855,O
and,3855,O
pyrazines,3855,B-CHEMICAL
were,3855,O
the,3855,O
main,3855,O
volatile,3855,O
components,3855,O
of,3855,O
almonds,3855,O
.,3855,O
Aliphatic,3856,B-CHEMICAL
aldehydes,3856,I-CHEMICAL
such,3856,O
as,3856,O
hexanal,3856,B-CHEMICAL
",",3856,O
(,3856,B-CHEMICAL
E,3856,I-CHEMICAL
),3856,I-CHEMICAL
-2-octenal,3856,I-CHEMICAL
",",3856,O
and,3856,O
nonanal,3856,B-CHEMICAL
were,3856,O
produced,3856,O
as,3856,O
off-odours,3856,O
during,3856,O
storage,3856,O
.,3856,O
Although,3857,O
the,3857,O
overall,3857,O
quality,3857,O
of,3857,O
roasted,3857,O
almonds,3857,O
produced,3857,O
with,3857,O
SIRHA,3857,O
and,3857,O
HA,3857,O
heating,3857,O
was,3857,O
similar,3857,O
during,3857,O
the,3857,O
first,3857,O
three,3857,O
months,3857,O
of,3857,O
storage,3857,O
",",3857,O
their,3857,O
peroxide,3857,B-CHEMICAL
value,3857,O
and,3857,O
concentration,3857,O
of,3857,O
aliphatic,3857,B-CHEMICAL
aldehydes,3857,I-CHEMICAL
differed,3857,O
significantly,3857,O
for,3857,O
different,3857,O
roasting,3857,O
methods,3857,O
and,3857,O
increased,3857,O
significantly,3857,O
in,3857,O
all,3857,O
roasted,3857,O
samples,3857,O
during,3857,O
storage,3857,O
.,3857,O
We,3858,O
postulate,3858,O
that,3858,O
hexanal,3858,B-CHEMICAL
and,3858,O
nonanal,3858,B-CHEMICAL
might,3858,O
be,3858,O
better,3858,O
indicators,3858,O
of,3858,O
the,3858,O
shelf,3858,O
life,3858,O
of,3858,O
roasted,3858,O
almonds,3858,O
than,3858,O
the,3858,O
current,3858,O
standard,3858,O
",",3858,O
peroxide,3858,B-CHEMICAL
value,3858,O
.,3858,O
Design,3859,O
and,3859,O
synthesis,3859,O
of,3859,O
novel,3859,O
"2-methyl-4,5-substitutedbenzo",3859,B-CHEMICAL
[,3859,I-CHEMICAL
f,3859,I-CHEMICAL
],3859,I-CHEMICAL
"-3,3a,4,5-tetrahydro-pyrazolo",3859,I-CHEMICAL
[,3859,I-CHEMICAL
"1,5-d",3859,I-CHEMICAL
],3859,I-CHEMICAL
[,3859,I-CHEMICAL
"1,4",3859,I-CHEMICAL
],3859,I-CHEMICAL
oxazepin-8,3859,I-CHEMICAL
(,3859,I-CHEMICAL
7H,3859,I-CHEMICAL
),3859,I-CHEMICAL
-one,3859,I-CHEMICAL
derivatives,3859,O
as,3859,O
telomerase,3859,B-GENE-N
inhibitors,3859,O
.,3859,O
Eight,3860,O
novel,3860,O
"4,5-tetrahydropyrazolo",3860,B-CHEMICAL
[,3860,I-CHEMICAL
"1,5-d",3860,I-CHEMICAL
],3860,I-CHEMICAL
[,3860,I-CHEMICAL
"1,4",3860,I-CHEMICAL
],3860,I-CHEMICAL
oxazepine,3860,I-CHEMICAL
derivatives,3860,O
have,3860,O
been,3860,O
synthesized,3860,O
and,3860,O
purified,3860,O
to,3860,O
be,3860,O
screened,3860,O
for,3860,O
anticancer,3860,O
activity,3860,O
.,3860,O
By,3861,O
a,3861,O
modified,3861,O
TRAP,3861,O
assay,3861,O
",",3861,O
some,3861,O
titled,3861,O
compounds,3861,O
were,3861,O
tested,3861,O
against,3861,O
telomerase,3861,B-GENE-N
",",3861,O
and,3861,O
compound,3861,O
4a,3861,O
showed,3861,O
the,3861,O
most,3861,O
potent,3861,O
inhibitory,3861,O
activity,3861,O
with,3861,O
IC,3861,O
(,3861,O
50,3861,O
),3861,O
value,3861,O
at,3861,O
0.78,3861,O
,3861,O
0.22,3861,O
M,3861,O
.,3861,O
Western,3862,O
blot,3862,O
assays,3862,O
showed,3862,O
that,3862,O
compounds,3862,O
4a,3862,O
and,3862,O
4b,3862,O
could,3862,O
inhibit,3862,O
expression,3862,O
of,3862,O
Cyclin,3862,B-GENE-Y
D1,3862,I-GENE-Y
",",3862,O
TERT,3862,B-GENE-Y
",",3862,O
phospho-AKT,3862,B-GENE-N
and,3862,O
PI3K/AKT,3862,B-GENE-N
pathway,3862,O
.,3862,O
Anti-inflammatory,3863,O
effects,3863,O
of,3863,O
"trans-1,3-diphenyl-2,3-epoxypropane-1-one",3863,B-CHEMICAL
mediated,3863,O
by,3863,O
suppression,3863,O
of,3863,O
inflammatory,3863,O
mediators,3863,O
in,3863,O
LPS-stimulated,3863,O
RAW,3863,O
264.7,3863,O
macrophages,3863,O
.,3863,O
To,3864,O
assess,3864,O
the,3864,O
potential,3864,O
therapeutic,3864,O
properties,3864,O
of,3864,O
"trans-1,3-diphenyl-2,3-epoxypropane-1-one",3864,B-CHEMICAL
(,3864,O
DPEP,3864,B-CHEMICAL
),3864,O
",",3864,O
its,3864,O
anti-inflammatory,3864,O
effects,3864,O
were,3864,O
investigated,3864,O
in,3864,O
lipopolysaccharide,3864,O
(,3864,O
LPS,3864,O
),3864,O
-stimulated,3864,O
mouse,3864,O
macrophage,3864,O
(,3864,O
RAW,3864,O
264.7,3864,O
),3864,O
cells,3864,O
.,3864,O
DPEP,3865,B-CHEMICAL
induced,3865,O
dose-dependent,3865,O
reduction,3865,O
of,3865,O
the,3865,O
protein,3865,O
levels,3865,O
of,3865,O
inducible,3865,B-GENE-Y
nitric,3865,B-CHEMICAL
oxide,3865,I-CHEMICAL
synthase,3865,I-GENE-Y
(,3865,O
iNOS,3865,B-GENE-Y
),3865,O
and,3865,O
cyclooxygenase-2,3865,B-GENE-Y
(,3865,O
COX-2,3865,B-GENE-Y
),3865,O
and,3865,O
concomitant,3865,O
reduction,3865,O
in,3865,O
the,3865,O
production,3865,O
of,3865,O
NO,3865,B-CHEMICAL
and,3865,O
prostaglandin,3865,B-CHEMICAL
E,3865,I-CHEMICAL
(,3865,I-CHEMICAL
2,3865,I-CHEMICAL
),3865,I-CHEMICAL
(,3865,O
PGE,3865,B-CHEMICAL
(,3865,I-CHEMICAL
2,3865,I-CHEMICAL
),3865,I-CHEMICAL
),3865,O
.,3865,O
Additionally,3866,O
",",3866,O
DPEP,3866,B-CHEMICAL
suppressed,3866,O
the,3866,O
production,3866,O
of,3866,O
inflammatory,3866,O
cytokines,3866,B-GENE-N
",",3866,O
including,3866,O
tumor,3866,B-GENE-Y
necrosis,3866,I-GENE-Y
factor-,3866,I-GENE-Y
(,3866,O
TNF-,3866,B-GENE-Y
),3866,O
",",3866,O
interleukin,3866,B-GENE-Y
(,3866,I-GENE-Y
IL,3866,I-GENE-Y
),3866,I-GENE-Y
-1,3866,I-GENE-Y
",",3866,O
and,3866,O
IL-6,3866,B-GENE-Y
.,3866,O
We,3867,O
investigated,3867,O
the,3867,O
mechanism,3867,O
by,3867,O
which,3867,O
DPEP,3867,B-CHEMICAL
inhibits,3867,O
NO,3867,B-CHEMICAL
and,3867,O
PGE,3867,B-CHEMICAL
(,3867,I-CHEMICAL
2,3867,I-CHEMICAL
),3867,I-CHEMICAL
by,3867,O
examining,3867,O
the,3867,O
level,3867,O
of,3867,O
nuclear,3867,B-GENE-N
factor-B,3867,I-GENE-N
(,3867,O
NF-B,3867,B-GENE-N
),3867,O
activation,3867,O
within,3867,O
the,3867,O
mitogen-activated,3867,B-GENE-N
protein,3867,I-GENE-N
kinase,3867,I-GENE-N
(,3867,O
MAPK,3867,B-GENE-N
),3867,O
pathway,3867,O
",",3867,O
which,3867,O
is,3867,O
an,3867,O
inflammation-induced,3867,O
signaling,3867,O
pathway,3867,O
in,3867,O
RAW,3867,O
264.7,3867,O
cells,3867,O
.,3867,O
DPEP,3868,B-CHEMICAL
inhibited,3868,O
LPS-induced,3868,O
phosphorylation,3868,O
of,3868,O
ERK,3868,B-GENE-N
",",3868,O
JNK,3868,B-GENE-N
",",3868,O
and,3868,O
p38,3868,B-GENE-N
.,3868,O
Furthermore,3869,O
",",3869,O
DPEP,3869,B-CHEMICAL
inhibited,3869,O
the,3869,O
LPS-induced,3869,O
phosphorylation,3869,O
of,3869,O
inhibitor,3869,B-GENE-Y
B,3869,I-GENE-Y
(,3869,I-GENE-Y
IB,3869,I-GENE-Y
),3869,I-GENE-Y
-,3869,I-GENE-Y
and,3869,O
NF-B,3869,B-GENE-N
p50,3869,B-GENE-Y
.,3869,O
Taken,3870,O
together,3870,O
",",3870,O
the,3870,O
results,3870,O
of,3870,O
this,3870,O
study,3870,O
demonstrate,3870,O
that,3870,O
DPEP,3870,B-CHEMICAL
inhibits,3870,O
LPS-stimulated,3870,O
inflammation,3870,O
by,3870,O
blocking,3870,O
the,3870,O
NF-B,3870,B-GENE-N
and,3870,O
MAPK,3870,B-GENE-N
pathways,3870,O
in,3870,O
macrophages,3870,O
.,3870,O
Radioprotection,3871,O
by,3871,O
two,3871,O
phenolic,3871,B-CHEMICAL
compounds,3871,O
:,3871,O
chlorogenic,3871,B-CHEMICAL
and,3871,I-CHEMICAL
quinic,3871,I-CHEMICAL
acid,3871,I-CHEMICAL
",",3871,O
on,3871,O
X-ray,3871,O
induced,3871,O
DNA,3871,O
damage,3871,O
in,3871,O
human,3871,O
blood,3871,O
lymphocytes,3871,O
in,3871,O
vitro,3871,O
.,3871,O
The,3872,O
present,3872,O
study,3872,O
was,3872,O
designed,3872,O
to,3872,O
determine,3872,O
the,3872,O
radioprotective,3872,O
effect,3872,O
of,3872,O
two,3872,O
phytochemicals,3872,O
",",3872,O
namely,3872,O
",",3872,O
quinic,3872,B-CHEMICAL
acid,3872,I-CHEMICAL
and,3872,O
chlorogenic,3872,B-CHEMICAL
acid,3872,I-CHEMICAL
",",3872,O
against,3872,O
X-ray,3872,O
irradiation-induced,3872,O
genomic,3872,O
instability,3872,O
in,3872,O
non-tumorigenic,3872,O
human,3872,O
blood,3872,O
lymphocytes,3872,O
.,3872,O
The,3873,O
protective,3873,O
ability,3873,O
of,3873,O
two,3873,O
phenolic,3873,B-CHEMICAL
acids,3873,I-CHEMICAL
against,3873,O
radiation-induced,3873,O
DNA,3873,O
damage,3873,O
was,3873,O
assessed,3873,O
using,3873,O
the,3873,O
alkaline,3873,O
comet,3873,O
assay,3873,O
in,3873,O
human,3873,O
blood,3873,O
lymphocytes,3873,O
isolated,3873,O
from,3873,O
two,3873,O
healthy,3873,O
human,3873,O
donors,3873,O
.,3873,O
A,3874,O
Siemens,3874,O
Mevatron,3874,O
MD2,3874,O
(,3874,O
Siemens,3874,O
AG,3874,O
",",3874,O
USA,3874,O
",",3874,O
1994,3874,O
),3874,O
linear,3874,O
accelerator,3874,O
was,3874,O
used,3874,O
for,3874,O
irradiation,3874,O
.,3874,O
The,3875,O
results,3875,O
of,3875,O
the,3875,O
alkaline,3875,O
comet,3875,O
assay,3875,O
revealed,3875,O
that,3875,O
quinic,3875,B-CHEMICAL
acid,3875,I-CHEMICAL
and,3875,O
chlorogenic,3875,B-CHEMICAL
acid,3875,I-CHEMICAL
decreased,3875,O
the,3875,O
DNA,3875,O
damage,3875,O
induced,3875,O
by,3875,O
X-ray,3875,O
irradiation,3875,O
and,3875,O
provided,3875,O
a,3875,O
significant,3875,O
radioprotective,3875,O
effect,3875,O
.,3875,O
Quinic,3876,B-CHEMICAL
acid,3876,I-CHEMICAL
decreased,3876,O
the,3876,O
presence,3876,O
of,3876,O
irradiation-induced,3876,O
DNA,3876,O
damage,3876,O
by,3876,O
5.99-53.57,3876,O
%,3876,O
and,3876,O
chlorogenic,3876,B-CHEMICAL
acid,3876,I-CHEMICAL
by,3876,O
4.49-48.15,3876,O
%,3876,O
",",3876,O
as,3876,O
determined,3876,O
by,3876,O
the,3876,O
alkaline,3876,O
comet,3876,O
assay,3876,O
.,3876,O
The,3877,O
results,3877,O
show,3877,O
that,3877,O
quinic,3877,B-CHEMICAL
acid,3877,I-CHEMICAL
and,3877,O
chlorogenic,3877,B-CHEMICAL
acid,3877,I-CHEMICAL
may,3877,O
act,3877,O
as,3877,O
radioprotective,3877,O
compounds,3877,O
.,3877,O
Future,3878,O
studies,3878,O
should,3878,O
focus,3878,O
on,3878,O
determining,3878,O
the,3878,O
mechanism,3878,O
by,3878,O
which,3878,O
these,3878,O
phenolic,3878,B-CHEMICAL
acids,3878,I-CHEMICAL
provide,3878,O
radioprotection,3878,O
.,3878,O
DNA,3879,B-GENE-N
polymerase,3879,I-GENE-N
minor,3879,I-GENE-N
groove,3879,I-GENE-N
interactions,3879,O
modulate,3879,O
mutagenic,3879,O
bypass,3879,O
of,3879,O
a,3879,O
templating,3879,O
8-oxoguanine,3879,B-CHEMICAL
lesion,3879,O
.,3879,O
A,3880,O
major,3880,O
base,3880,O
lesion,3880,O
resulting,3880,O
from,3880,O
oxidative,3880,O
stress,3880,O
is,3880,O
"8-oxo-7,8-dihydro-2'-deoxyguanosine",3880,B-CHEMICAL
(,3880,O
8-oxoG,3880,B-CHEMICAL
),3880,O
that,3880,O
has,3880,O
ambiguous,3880,O
coding,3880,O
potential,3880,O
.,3880,O
Error-free,3881,O
DNA,3881,O
synthesis,3881,O
involves,3881,O
8-oxoG,3881,B-CHEMICAL
adopting,3881,O
an,3881,O
anti-conformation,3881,O
to,3881,O
base,3881,O
pair,3881,O
with,3881,O
cytosine,3881,B-CHEMICAL
whereas,3881,O
mutagenic,3881,O
bypass,3881,O
involves,3881,O
8-oxoG,3881,B-CHEMICAL
adopting,3881,O
a,3881,O
syn-conformation,3881,O
to,3881,O
base,3881,O
pair,3881,O
with,3881,O
adenine,3881,B-CHEMICAL
.,3881,O
Left,3882,O
unrepaired,3882,O
the,3882,O
syn-8-oxoG/dAMP,3882,B-CHEMICAL
base,3882,O
pair,3882,O
results,3882,O
in,3882,O
a,3882,O
G-C,3882,O
to,3882,O
T-A,3882,O
transversion,3882,O
.,3882,O
During,3883,O
base,3883,O
excision,3883,O
repair,3883,O
of,3883,O
this,3883,O
mispair,3883,O
",",3883,O
DNA,3883,B-GENE-Y
polymerase,3883,I-GENE-Y
(,3883,I-GENE-Y
pol,3883,I-GENE-Y
),3883,I-GENE-Y
,3883,I-GENE-Y
is,3883,O
confronted,3883,O
with,3883,O
gap,3883,O
filling,3883,O
opposite,3883,O
8-oxoG,3883,B-CHEMICAL
.,3883,O
To,3884,O
determine,3884,O
how,3884,O
pol,3884,B-GENE-Y
,3884,I-GENE-Y
discriminates,3884,O
between,3884,O
anti-,3884,B-CHEMICAL
and,3884,I-CHEMICAL
syn-8-oxoG,3884,I-CHEMICAL
",",3884,O
we,3884,O
introduced,3884,O
a,3884,O
point,3884,O
mutation,3884,O
(,3884,O
R283K,3884,B-GENE-N
),3884,O
to,3884,O
alter,3884,O
insertion,3884,O
specificity,3884,O
.,3884,O
Kinetic,3885,O
studies,3885,O
demonstrate,3885,O
that,3885,O
this,3885,O
substitution,3885,O
results,3885,O
in,3885,O
an,3885,O
increased,3885,O
fidelity,3885,O
opposite,3885,O
8-oxoG,3885,B-CHEMICAL
.,3885,O
Structural,3886,O
studies,3886,O
with,3886,O
R283K,3886,B-GENE-N
pol,3886,B-GENE-Y
,3886,I-GENE-Y
show,3886,O
that,3886,O
the,3886,O
binary,3886,O
DNA,3886,O
complex,3886,O
has,3886,O
8-oxoG,3886,B-CHEMICAL
in,3886,O
equilibrium,3886,O
between,3886,O
anti-,3886,O
and,3886,O
syn-forms,3886,O
.,3886,O
Ternary,3887,O
complexes,3887,O
with,3887,O
incoming,3887,O
dCTP,3887,B-CHEMICAL
resemble,3887,O
the,3887,O
wild-type,3887,O
enzyme,3887,O
",",3887,O
with,3887,O
templating,3887,O
anti-8-oxoG,3887,B-CHEMICAL
base,3887,O
pairing,3887,O
with,3887,O
incoming,3887,O
cytosine,3887,B-CHEMICAL
.,3887,O
In,3888,O
contrast,3888,O
to,3888,O
wild-type,3888,O
pol,3888,B-GENE-Y
,3888,I-GENE-Y
",",3888,O
the,3888,O
ternary,3888,O
complex,3888,O
of,3888,O
the,3888,O
R283K,3888,B-GENE-N
mutant,3888,O
with,3888,O
an,3888,O
incoming,3888,O
dATP-analogue,3888,B-CHEMICAL
and,3888,O
templating,3888,O
8-oxoG,3888,B-CHEMICAL
resembles,3888,O
a,3888,O
G-A,3888,O
mismatched,3888,O
structure,3888,O
with,3888,O
8-oxoG,3888,B-CHEMICAL
adopting,3888,O
an,3888,O
anti-conformation,3888,O
.,3888,O
These,3889,O
results,3889,O
demonstrate,3889,O
that,3889,O
the,3889,O
incoming,3889,O
nucleotide,3889,B-CHEMICAL
is,3889,O
unable,3889,O
to,3889,O
induce,3889,O
a,3889,O
syn-8-oxoG,3889,B-CHEMICAL
conformation,3889,O
without,3889,O
minor,3889,B-GENE-N
groove,3889,I-GENE-N
DNA,3889,B-GENE-N
polymerase,3889,I-GENE-N
interactions,3889,O
that,3889,O
influence,3889,O
templating,3889,O
(,3889,O
anti-/syn-equilibrium,3889,O
),3889,O
of,3889,O
8-oxoG,3889,B-CHEMICAL
while,3889,O
modulating,3889,O
fidelity,3889,O
.,3889,O
NMDA,3890,B-GENE-N
and,3890,I-GENE-N
AMPA,3890,I-GENE-N
receptor,3890,I-GENE-N
mediated,3890,O
excitotoxicity,3890,O
in,3890,O
cerebral,3890,O
cortex,3890,O
of,3890,O
streptozotocin,3890,B-CHEMICAL
induced,3890,O
diabetic,3890,O
rat,3890,O
:,3890,O
ameliorating,3890,O
effects,3890,O
of,3890,O
curcumin,3890,B-CHEMICAL
.,3890,O
Functional,3891,O
activity,3891,O
of,3891,O
neurotransmitter,3891,B-GENE-N
receptor,3891,I-GENE-N
and,3891,O
their,3891,O
sensitivity,3891,O
to,3891,O
regulation,3891,O
are,3891,O
altered,3891,O
in,3891,O
DM,3891,O
.,3891,O
We,3892,O
evaluated,3892,O
the,3892,O
neuroprotective,3892,O
effect,3892,O
of,3892,O
curcumin,3892,B-CHEMICAL
in,3892,O
glutamate,3892,B-CHEMICAL
mediated,3892,O
excitotoxicity,3892,O
in,3892,O
cerebral,3892,O
cortex,3892,O
of,3892,O
streptozotocin,3892,B-CHEMICAL
induced,3892,O
diabetic,3892,O
rats,3892,O
.,3892,O
Gene,3893,O
expression,3893,O
studies,3893,O
in,3893,O
diabetic,3893,O
rats,3893,O
showed,3893,O
a,3893,O
down,3893,O
regulation,3893,O
of,3893,O
glutamate,3893,B-CHEMICAL
decarboxylase,3893,I-GENE-Y
mRNA,3893,O
leading,3893,O
to,3893,O
accumulation,3893,O
of,3893,O
glutamate,3893,B-CHEMICAL
.,3893,O
Radioreceptor,3894,O
binding,3894,O
assays,3894,O
showed,3894,O
a,3894,O
significant,3894,O
increase,3894,O
in,3894,O
-amino-3-hydroxy-5-methyl-4-isoxazole,3894,B-CHEMICAL
propionate,3894,I-CHEMICAL
and,3894,I-GENE-N
N-methyl-D-aspartate,3894,B-CHEMICAL
receptors,3894,I-GENE-N
density,3894,O
which,3894,O
was,3894,O
confirmed,3894,O
by,3894,O
immunohistochemical,3894,O
studies,3894,O
.,3894,O
Decreased,3895,O
glutathione,3895,B-GENE-N
peroxidases,3895,I-GENE-N
gene,3895,O
expression,3895,O
indicates,3895,O
enhanced,3895,O
oxidative,3895,O
stress,3895,O
in,3895,O
diabetic,3895,O
rats,3895,O
.,3895,O
This,3896,O
leads,3896,O
to,3896,O
decreased,3896,O
expression,3896,O
of,3896,O
glutamate,3896,B-GENE-Y
aspartate,3896,I-GENE-Y
transporter,3896,I-GENE-Y
",",3896,O
which,3896,O
in,3896,O
turn,3896,O
reduces,3896,O
glutamate,3896,B-CHEMICAL
transport,3896,O
.,3896,O
All,3897,O
these,3897,O
events,3897,O
lead,3897,O
to,3897,O
excitotoxic,3897,O
neuronal,3897,O
death,3897,O
in,3897,O
the,3897,O
cerebral,3897,O
cortex,3897,O
",",3897,O
which,3897,O
was,3897,O
confirmed,3897,O
by,3897,O
the,3897,O
increased,3897,O
expression,3897,O
of,3897,O
caspase,3897,B-GENE-Y
3,3897,I-GENE-Y
",",3897,O
caspase,3897,B-GENE-Y
8,3897,I-GENE-Y
and,3897,O
BCL2-associated,3897,B-GENE-Y
X,3897,I-GENE-Y
protein,3897,I-GENE-Y
.,3897,O
Curcumin,3898,B-CHEMICAL
and,3898,O
insulin,3898,B-GENE-Y
treatment,3898,O
reversed,3898,O
these,3898,O
altered,3898,O
parameters,3898,O
to,3898,O
near,3898,O
control,3898,O
.,3898,O
We,3899,O
establish,3899,O
",",3899,O
a,3899,O
novel,3899,O
therapeutic,3899,O
role,3899,O
of,3899,O
curcumin,3899,B-CHEMICAL
by,3899,O
reducing,3899,O
the,3899,O
glutamate,3899,B-CHEMICAL
mediated,3899,O
excitotoxicity,3899,O
in,3899,O
cerebral,3899,O
cortex,3899,O
of,3899,O
diabetes,3899,O
through,3899,O
modulating,3899,O
the,3899,O
altered,3899,O
neurochemical,3899,O
parameters,3899,O
.,3899,O
AMPK,3900,B-GENE-N
is,3900,O
a,3900,O
negative,3900,O
regulator,3900,O
of,3900,O
the,3900,O
Warburg,3900,O
effect,3900,O
and,3900,O
suppresses,3900,O
tumor,3900,O
growth,3900,O
in,3900,O
vivo,3900,O
.,3900,O
AMPK,3901,B-GENE-N
is,3901,O
a,3901,O
metabolic,3901,O
sensor,3901,O
that,3901,O
helps,3901,O
maintain,3901,O
cellular,3901,O
energy,3901,O
homeostasis,3901,O
.,3901,O
Despite,3902,O
evidence,3902,O
linking,3902,O
AMPK,3902,B-GENE-N
with,3902,O
tumor,3902,O
suppressor,3902,O
functions,3902,O
",",3902,O
the,3902,O
role,3902,O
of,3902,O
AMPK,3902,B-GENE-N
in,3902,O
tumorigenesis,3902,O
and,3902,O
tumor,3902,O
metabolism,3902,O
is,3902,O
unknown,3902,O
.,3902,O
Here,3903,O
we,3903,O
show,3903,O
that,3903,O
AMPK,3903,B-GENE-N
negatively,3903,O
regulates,3903,O
aerobic,3903,O
glycolysis,3903,O
(,3903,O
the,3903,O
Warburg,3903,O
effect,3903,O
),3903,O
in,3903,O
cancer,3903,O
cells,3903,O
and,3903,O
suppresses,3903,O
tumor,3903,O
growth,3903,O
in,3903,O
vivo,3903,O
.,3903,O
Genetic,3904,O
ablation,3904,O
of,3904,O
the,3904,O
1,3904,B-GENE-Y
catalytic,3904,I-GENE-Y
subunit,3904,I-GENE-Y
of,3904,I-GENE-Y
AMPK,3904,I-GENE-Y
accelerates,3904,O
Myc-induced,3904,B-GENE-Y
lymphomagenesis,3904,O
.,3904,O
Inactivation,3905,O
of,3905,O
AMPK,3905,B-GENE-N
in,3905,O
both,3905,O
transformed,3905,O
and,3905,O
nontransformed,3905,O
cells,3905,O
promotes,3905,O
a,3905,O
metabolic,3905,O
shift,3905,O
to,3905,O
aerobic,3905,O
glycolysis,3905,O
",",3905,O
increased,3905,O
allocation,3905,O
of,3905,O
glucose,3905,B-CHEMICAL
carbon,3905,B-CHEMICAL
into,3905,O
lipids,3905,O
",",3905,O
and,3905,O
biomass,3905,O
accumulation,3905,O
.,3905,O
These,3906,O
metabolic,3906,O
effects,3906,O
require,3906,O
normoxic,3906,O
stabilization,3906,O
of,3906,O
the,3906,O
hypoxia-inducible,3906,B-GENE-Y
factor-1,3906,I-GENE-Y
(,3906,O
HIF-1,3906,B-GENE-Y
),3906,O
",",3906,O
as,3906,O
silencing,3906,O
HIF-1,3906,B-GENE-Y
reverses,3906,O
the,3906,O
shift,3906,O
to,3906,O
aerobic,3906,O
glycolysis,3906,O
and,3906,O
the,3906,O
biosynthetic,3906,O
and,3906,O
proliferative,3906,O
advantages,3906,O
conferred,3906,O
by,3906,O
reduced,3906,O
AMPK,3906,B-GENE-N
signaling,3906,O
.,3906,O
Together,3907,O
our,3907,O
findings,3907,O
suggest,3907,O
that,3907,O
AMPK,3907,B-GENE-N
activity,3907,O
opposes,3907,O
tumor,3907,O
development,3907,O
and,3907,O
that,3907,O
its,3907,O
loss,3907,O
fosters,3907,O
tumor,3907,O
progression,3907,O
in,3907,O
part,3907,O
by,3907,O
regulating,3907,O
cellular,3907,O
metabolic,3907,O
pathways,3907,O
that,3907,O
support,3907,O
cell,3907,O
growth,3907,O
and,3907,O
proliferation,3907,O
.,3907,O
Tetrahydropyrroloquinolinone,3908,B-CHEMICAL
type,3908,O
dual,3908,O
inhibitors,3908,O
of,3908,O
aromatase/aldosterone,3908,B-GENE-Y
synthase,3908,I-GENE-Y
as,3908,O
a,3908,O
novel,3908,O
strategy,3908,O
for,3908,O
breast,3908,O
cancer,3908,O
patients,3908,O
with,3908,O
elevated,3908,O
cardiovascular,3908,O
risks,3908,O
.,3908,O
The,3909,O
application,3909,O
of,3909,O
aromatase,3909,O
inhibitors,3909,O
to,3909,O
postmenopausal,3909,O
breast,3909,O
cancer,3909,O
patients,3909,O
increases,3909,O
the,3909,O
risk,3909,O
of,3909,O
cardiovascular,3909,O
diseases,3909,O
(,3909,O
CVD,3909,O
),3909,O
",",3909,O
which,3909,O
is,3909,O
believed,3909,O
to,3909,O
be,3909,O
caused,3909,O
by,3909,O
the,3909,O
abnormally,3909,O
high,3909,O
concentrations,3909,O
of,3909,O
aldosterone,3909,B-CHEMICAL
as,3909,O
a,3909,O
consequence,3909,O
of,3909,O
the,3909,O
estrogen,3909,B-CHEMICAL
deficiency,3909,O
.,3909,O
Dual,3910,O
inhibitors,3910,O
of,3910,O
aromatase,3910,B-GENE-Y
(,3910,O
CYP19,3910,B-GENE-Y
),3910,O
and,3910,O
aldosterone,3910,B-CHEMICAL
synthase,3910,I-GENE-Y
(,3910,O
CYP11B2,3910,B-GENE-Y
),3910,O
are,3910,O
therefore,3910,O
proposed,3910,O
as,3910,O
a,3910,O
novel,3910,O
strategy,3910,O
for,3910,O
the,3910,O
adjuvant,3910,O
therapy,3910,O
to,3910,O
reduce,3910,O
the,3910,O
CVD,3910,O
risk,3910,O
for,3910,O
these,3910,O
patients,3910,O
.,3910,O
By,3911,O
combining,3911,O
decisive,3911,O
structural,3911,O
features,3911,O
of,3911,O
CYP11B2,3911,B-GENE-Y
and,3911,O
CYP19,3911,B-GENE-Y
inhibitors,3911,O
into,3911,O
a,3911,O
common,3911,O
template,3911,O
",",3911,O
a,3911,O
series,3911,O
of,3911,O
pyridinylmethyl,3911,B-CHEMICAL
substituted,3911,I-CHEMICAL
"1,2,5,6-tetrahydro-pyrrolo",3911,I-CHEMICAL
[,3911,I-CHEMICAL
"3,2,1-ij",3911,I-CHEMICAL
],3911,I-CHEMICAL
quinolin-4-ones,3911,I-CHEMICAL
were,3911,O
designed,3911,O
and,3911,O
synthesized,3911,O
.,3911,O
Interestingly,3912,O
",",3912,O
the,3912,O
substituents,3912,O
on,3912,O
the,3912,O
methylene,3912,B-CHEMICAL
bridge,3912,O
showed,3912,O
strong,3912,O
influences,3912,O
on,3912,O
the,3912,O
inhibitory,3912,O
activities,3912,O
leading,3912,O
to,3912,O
opposite,3912,O
effects,3912,O
",",3912,O
that,3912,O
is,3912,O
",",3912,O
a,3912,O
given,3912,O
substituent,3912,O
showed,3912,O
an,3912,O
increase,3912,O
in,3912,O
inhibition,3912,O
of,3912,O
one,3912,O
enzyme,3912,O
",",3912,O
while,3912,O
it,3912,O
led,3912,O
to,3912,O
a,3912,O
decrease,3912,O
for,3912,O
the,3912,O
other,3912,O
enzyme,3912,O
.,3912,O
The,3913,O
compromise,3913,O
of,3913,O
this,3913,O
conflict,3913,O
led,3913,O
to,3913,O
compounds,3913,O
3j,3913,O
",",3913,O
3k,3913,O
",",3913,O
3n,3913,O
",",3913,O
and,3913,O
3p,3913,O
as,3913,O
potent,3913,O
and,3913,O
selective,3913,O
dual,3913,O
inhibitors,3913,O
of,3913,O
CYP19,3913,B-GENE-Y
and,3913,O
CYP11B2,3913,B-GENE-Y
",",3913,O
especially,3913,O
compound,3913,O
3p,3913,O
",",3913,O
which,3913,O
exhibited,3913,O
IC,3913,O
(,3913,O
50,3913,O
),3913,O
values,3913,O
of,3913,O
32,3913,O
and,3913,O
41,3913,O
nM,3913,O
for,3913,O
CYP19,3913,B-GENE-Y
and,3913,O
CYP11B2,3913,B-GENE-Y
",",3913,O
respectively,3913,O
",",3913,O
and,3913,O
a,3913,O
high,3913,O
selectivity,3913,O
toward,3913,O
CYP17,3913,B-GENE-Y
and,3913,O
CYP11B1,3913,B-GENE-Y
.,3913,O
This,3914,O
compound,3914,O
is,3914,O
considered,3914,O
as,3914,O
a,3914,O
candidate,3914,O
for,3914,O
further,3914,O
evaluation,3914,O
in,3914,O
vivo,3914,O
.,3914,O
Evaluation,3915,O
of,3915,O
animal,3915,O
models,3915,O
for,3915,O
intestinal,3915,O
first-pass,3915,O
metabolism,3915,O
of,3915,O
drug,3915,O
candidates,3915,O
to,3915,O
be,3915,O
metabolized,3915,O
by,3915,O
CYP3A,3915,B-GENE-Y
enzymes,3915,O
via,3915,O
in,3915,O
vivo,3915,O
and,3915,O
in,3915,O
vitro,3915,O
oxidation,3915,O
of,3915,O
midazolam,3915,B-CHEMICAL
and,3915,O
triazolam,3915,B-CHEMICAL
.,3915,O
Abstract,3916,O
1,3916,O
.,3916,O
To,3917,O
search,3917,O
an,3917,O
appropriate,3917,O
evaluation,3917,O
methodology,3917,O
for,3917,O
the,3917,O
intestinal,3917,O
first-pass,3917,O
metabolism,3917,O
of,3917,O
new,3917,O
drug,3917,O
candidates,3917,O
",",3917,O
grapefruit,3917,O
juice,3917,O
(,3917,O
GFJ,3917,O
),3917,O
-,3917,O
and,3917,O
vehicle,3917,O
(,3917,O
tap,3917,O
water,3917,O
),3917,O
-pretreated,3917,O
mice,3917,O
or,3917,O
rats,3917,O
were,3917,O
orally,3917,O
administered,3917,O
midazolam,3917,B-CHEMICAL
(,3917,O
MDZ,3917,B-CHEMICAL
),3917,O
or,3917,O
triazolam,3917,B-CHEMICAL
(,3917,O
TRZ,3917,B-CHEMICAL
),3917,O
",",3917,O
and,3917,O
blood,3917,O
levels,3917,O
of,3917,O
the,3917,O
parent,3917,O
compounds,3917,O
and,3917,O
their,3917,O
metabolites,3917,O
were,3917,O
measured,3917,O
by,3917,O
liquid,3917,O
chromatography/MS/MS,3917,O
.,3917,O
A,3918,O
significant,3918,O
effect,3918,O
of,3918,O
GFJ,3918,O
to,3918,O
elevate,3918,O
the,3918,O
blood,3918,O
levels,3918,O
was,3918,O
observed,3918,O
only,3918,O
for,3918,O
TRZ,3918,B-CHEMICAL
in,3918,O
mice,3918,O
.,3918,O
2,3919,O
.,3919,O
In,3920,O
vitro,3920,O
experiments,3920,O
using,3920,O
mouse,3920,O
",",3920,O
rat,3920,O
and,3920,O
human,3920,O
intestinal,3920,O
and,3920,O
hepatic,3920,O
microsomal,3920,O
fractions,3920,O
demonstrated,3920,O
that,3920,O
GFJ,3920,O
suppressed,3920,O
the,3920,O
intestinal,3920,O
microsomal,3920,O
oxidation,3920,O
of,3920,O
MDZ,3920,B-CHEMICAL
and,3920,O
especially,3920,O
TRZ,3920,B-CHEMICAL
.,3920,O
Substrate,3921,O
inhibition,3921,O
by,3921,O
MDZ,3921,B-CHEMICAL
caused,3921,O
reduction,3921,O
in,3921,O
1'-hydroxylation,3921,O
but,3921,O
not,3921,O
4-hydroxylation,3921,O
in,3921,O
both,3921,O
intestinal,3921,O
and,3921,O
hepatic,3921,O
microsomal,3921,O
fractions,3921,O
.,3921,O
The,3922,O
kinetic,3922,O
profiles,3922,O
of,3922,O
MDZ,3922,B-CHEMICAL
oxidation,3922,O
and,3922,O
the,3922,O
substrate,3922,O
inhibition,3922,O
in,3922,O
mouse,3922,O
intestinal,3922,O
and,3922,O
hepatic,3922,O
microsomal,3922,O
fractions,3922,O
were,3922,O
very,3922,O
similar,3922,O
to,3922,O
those,3922,O
in,3922,O
human,3922,O
microsomes,3922,O
but,3922,O
were,3922,O
different,3922,O
from,3922,O
those,3922,O
in,3922,O
rat,3922,O
microsomes,3922,O
.,3922,O
Furthermore,3923,O
",",3923,O
MDZ,3923,B-CHEMICAL
caused,3923,O
mechanism-based,3923,O
inactivation,3923,O
of,3923,O
cytochrome,3923,B-GENE-N
P450,3923,I-GENE-N
3A-dependent,3923,O
TRZ,3923,B-CHEMICAL
1'-hydroxylation,3923,O
in,3923,O
mouse,3923,O
",",3923,O
rat,3923,O
and,3923,O
human,3923,O
intestinal,3923,O
microsomes,3923,O
with,3923,O
similar,3923,O
potencies,3923,O
.,3923,O
3,3924,O
.,3924,O
These,3925,O
results,3925,O
are,3925,O
useful,3925,O
information,3925,O
in,3925,O
the,3925,O
analysis,3925,O
of,3925,O
data,3925,O
obtained,3925,O
in,3925,O
mouse,3925,O
and,3925,O
rat,3925,O
for,3925,O
the,3925,O
evaluation,3925,O
of,3925,O
first-pass,3925,O
effects,3925,O
of,3925,O
drug,3925,O
candidates,3925,O
to,3925,O
be,3925,O
metabolized,3925,O
by,3925,O
CYP3A,3925,B-GENE-N
enzymes,3925,O
.,3925,O
The,3926,O
physico-chemical,3926,O
``,3926,O
anatomy,3926,O
'',3926,O
of,3926,O
the,3926,O
tautomerization,3926,O
through,3926,O
the,3926,O
DPT,3926,O
of,3926,O
the,3926,O
biologically,3926,O
important,3926,O
pairs,3926,O
of,3926,O
hypoxanthine,3926,B-CHEMICAL
with,3926,O
DNA,3926,O
bases,3926,O
:,3926,O
QM,3926,O
and,3926,O
QTAIM,3926,O
perspectives,3926,O
.,3926,O
The,3927,O
biologically,3927,O
important,3927,O
tautomerization,3927,O
of,3927,O
the,3927,O
HypCyt,3927,B-CHEMICAL
",",3927,O
Hyp,3927,B-CHEMICAL
*,3927,O
Thy,3927,O
and,3927,O
HypHyp,3927,B-CHEMICAL
base,3927,O
pairs,3927,O
to,3927,O
the,3927,O
Hyp,3927,B-CHEMICAL
*,3927,O
Cyt,3927,O
*,3927,O
",",3927,O
HypThy,3927,B-CHEMICAL
*,3927,O
and,3927,O
Hyp,3927,B-CHEMICAL
*,3927,O
Hyp,3927,O
*,3927,O
base,3927,O
pairs,3927,O
",",3927,O
respectively,3927,O
",",3927,O
by,3927,O
the,3927,O
double,3927,O
proton,3927,O
transfer,3927,O
(,3927,O
DPT,3927,O
),3927,O
was,3927,O
comprehensively,3927,O
studied,3927,O
in,3927,O
vacuo,3927,O
and,3927,O
in,3927,O
the,3927,O
continuum,3927,O
with,3927,O
a,3927,O
low,3927,O
dielectric,3927,O
constant,3927,O
(,3927,O
,3927,O
=,3927,O
4,3927,O
),3927,O
corresponding,3927,O
to,3927,O
hydrophobic,3927,O
interfaces,3927,O
of,3927,O
protein-nucleic,3927,O
acid,3927,O
interactions,3927,O
by,3927,O
combining,3927,O
theoretical,3927,O
investigations,3927,O
at,3927,O
the,3927,O
B3LYP/6-311++G,3927,O
(,3927,O
d,3927,O
",",3927,O
p,3927,O
),3927,O
level,3927,O
of,3927,O
QM,3927,O
theory,3927,O
with,3927,O
QTAIM,3927,O
topological,3927,O
analysis,3927,O
.,3927,O
Based,3928,O
on,3928,O
the,3928,O
sweeps,3928,O
of,3928,O
the,3928,O
energetic,3928,O
",",3928,O
electron-topological,3928,O
",",3928,O
geometric,3928,O
and,3928,O
polar,3928,O
parameters,3928,O
",",3928,O
which,3928,O
describe,3928,O
the,3928,O
course,3928,O
of,3928,O
the,3928,O
tautomerization,3928,O
along,3928,O
the,3928,O
intrinsic,3928,O
reaction,3928,O
coordinate,3928,O
(,3928,O
IRC,3928,O
),3928,O
",",3928,O
it,3928,O
was,3928,O
proved,3928,O
that,3928,O
the,3928,O
tautomerization,3928,O
through,3928,O
the,3928,O
DPT,3928,O
is,3928,O
concerted,3928,O
and,3928,O
asynchronous,3928,O
process,3928,O
for,3928,O
the,3928,O
HypCyt,3928,B-CHEMICAL
and,3928,O
Hyp,3928,B-CHEMICAL
*,3928,O
Thy,3928,O
base,3928,O
pairs,3928,O
",",3928,O
while,3928,O
concerted,3928,O
and,3928,O
synchronous,3928,O
for,3928,O
the,3928,O
HypHyp,3928,B-CHEMICAL
homodimer,3928,O
.,3928,O
The,3929,O
continuum,3929,O
with,3929,O
,3929,O
=,3929,O
4,3929,O
does,3929,O
not,3929,O
affect,3929,O
qualitatively,3929,O
the,3929,O
course,3929,O
of,3929,O
the,3929,O
tautomerization,3929,O
reaction,3929,O
for,3929,O
all,3929,O
studied,3929,O
complexes,3929,O
.,3929,O
The,3930,O
nine,3930,O
key,3930,O
points,3930,O
along,3930,O
the,3930,O
IRC,3930,O
of,3930,O
the,3930,O
HypCytHyp,3930,B-CHEMICAL
*,3930,O
Cyt,3930,O
*,3930,O
and,3930,O
Hyp,3930,B-CHEMICAL
*,3930,O
ThyHypThy,3930,O
*,3930,O
tautomerizations,3930,O
and,3930,O
the,3930,O
six,3930,O
key,3930,O
points,3930,O
of,3930,O
the,3930,O
HypHypHyp,3930,B-CHEMICAL
*,3930,O
Hyp,3930,O
*,3930,O
tautomerization,3930,O
have,3930,O
been,3930,O
identified,3930,O
and,3930,O
fully,3930,O
characterized,3930,O
.,3930,O
These,3931,O
key,3931,O
points,3931,O
could,3931,O
be,3931,O
considered,3931,O
as,3931,O
electron-topological,3931,O
``,3931,O
fingerprints,3931,O
'',3931,O
of,3931,O
concerted,3931,O
asynchronous,3931,O
(,3931,O
for,3931,O
HypCyt,3931,B-CHEMICAL
and,3931,O
Hyp,3931,B-CHEMICAL
*,3931,O
Thy,3931,O
),3931,O
or,3931,O
synchronous,3931,O
(,3931,O
for,3931,O
HypHyp,3931,B-CHEMICAL
),3931,O
tautomerization,3931,O
process,3931,O
via,3931,O
the,3931,O
DPT,3931,O
.,3931,O
It,3932,O
was,3932,O
found,3932,O
",",3932,O
that,3932,O
in,3932,O
the,3932,O
Hyp,3932,B-CHEMICAL
*,3932,O
Cyt,3932,O
*,3932,O
",",3932,O
HypThy,3932,B-CHEMICAL
*,3932,O
",",3932,O
HypHyp,3932,B-CHEMICAL
and,3932,O
Hyp,3932,B-CHEMICAL
*,3932,O
Hyp,3932,O
*,3932,O
base,3932,O
pairs,3932,O
all,3932,O
H-bonds,3932,B-CHEMICAL
are,3932,O
significantly,3932,O
cooperative,3932,O
and,3932,O
mutually,3932,O
reinforce,3932,O
each,3932,O
other,3932,O
",",3932,O
while,3932,O
the,3932,O
C2HO2,3932,B-CHEMICAL
H-bond,3932,O
in,3932,O
the,3932,O
HypCyt,3932,B-CHEMICAL
base,3932,O
pair,3932,O
and,3932,O
the,3932,O
O6HO4,3932,B-CHEMICAL
H-bond,3932,B-CHEMICAL
in,3932,O
the,3932,O
Hyp,3932,B-CHEMICAL
*,3932,O
Thy,3932,O
base,3932,O
pair,3932,O
behave,3932,O
anti-cooperatively,3932,O
",",3932,O
i.e.,3932,O
",",3932,O
they,3932,O
become,3932,O
weakened,3932,O
",",3932,O
while,3932,O
two,3932,O
others,3932,O
become,3932,O
strengthened,3932,O
.,3932,O
Density,3933,O
of,3933,O
GM1,3933,O
in,3933,O
nanoclusters,3933,O
is,3933,O
a,3933,O
critical,3933,O
factor,3933,O
in,3933,O
the,3933,O
formation,3933,O
of,3933,O
a,3933,O
spherical,3933,O
assembly,3933,O
of,3933,O
amyloid,3933,B-GENE-Y
-protein,3933,I-GENE-Y
on,3933,O
synaptic,3933,O
plasma,3933,O
membranes,3933,O
.,3933,O
The,3934,O
deposition,3934,O
of,3934,O
amyloid,3934,B-GENE-Y
-protein,3934,I-GENE-Y
(,3934,O
A,3934,B-GENE-Y
),3934,O
is,3934,O
a,3934,O
pathological,3934,O
hallmark,3934,O
of,3934,O
Alzheimer,3934,O
's,3934,O
disease,3934,O
(,3934,O
AD,3934,O
),3934,O
.,3934,O
We,3935,O
previously,3935,O
found,3935,O
that,3935,O
the,3935,O
ganglioside-enriched,3935,B-CHEMICAL
microdomains,3935,O
(,3935,O
ganglioside,3935,B-CHEMICAL
clusters,3935,O
),3935,O
in,3935,O
presynaptic,3935,O
neuronal,3935,O
membranes,3935,O
play,3935,O
a,3935,O
key,3935,O
role,3935,O
in,3935,O
the,3935,O
initiation,3935,O
of,3935,O
the,3935,O
A,3935,B-GENE-Y
assembly,3935,O
process,3935,O
.,3935,O
However,3936,O
",",3936,O
not,3936,O
all,3936,O
ganglioside,3936,B-CHEMICAL
clusters,3936,O
accelerate,3936,O
A,3936,B-GENE-Y
assembly,3936,O
.,3936,O
In,3937,O
the,3937,O
present,3937,O
study,3937,O
",",3937,O
we,3937,O
directly,3937,O
observed,3937,O
a,3937,O
spherical,3937,O
A,3937,B-GENE-Y
in,3937,O
an,3937,O
atomic,3937,O
force,3937,O
microscopic,3937,O
study,3937,O
on,3937,O
the,3937,O
morphology,3937,O
of,3937,O
a,3937,O
reconstituted,3937,O
lipid,3937,O
bilayer,3937,O
composed,3937,O
of,3937,O
lipids,3937,O
that,3937,O
were,3937,O
extracted,3937,O
from,3937,O
a,3937,O
detergent-resistant,3937,O
membrane,3937,O
microdomain,3937,O
(,3937,O
DRM,3937,O
),3937,O
fraction,3937,O
of,3937,O
synaptosomes,3937,O
prepared,3937,O
from,3937,O
aged,3937,O
mouse,3937,O
brain,3937,O
.,3937,O
The,3938,O
A,3938,B-GENE-Y
assembly,3938,O
was,3938,O
generated,3938,O
on,3938,O
a,3938,O
distinctive,3938,O
GM1,3938,B-GENE-N
domain,3938,I-GENE-N
",",3938,O
which,3938,O
was,3938,O
characterized,3938,O
as,3938,O
the,3938,O
A-sensitive,3938,B-GENE-Y
ganglioside,3938,B-CHEMICAL
nanocluster,3938,O
(,3938,O
ASIGN,3938,O
),3938,O
.,3938,O
By,3939,O
using,3939,O
an,3939,O
artificial,3939,O
GM1,3939,O
cluster-binding,3939,O
peptide,3939,O
",",3939,O
ASIGN,3939,O
was,3939,O
found,3939,O
to,3939,O
have,3939,O
a,3939,O
high,3939,O
density,3939,O
of,3939,O
GM1,3939,O
;,3939,O
therefore,3939,O
",",3939,O
there,3939,O
would,3939,O
be,3939,O
a,3939,O
critical,3939,O
density,3939,O
of,3939,O
GM1,3939,O
in,3939,O
nanoclusters,3939,O
to,3939,O
induce,3939,O
A,3939,B-GENE-Y
binding,3939,O
and,3939,O
assembly,3939,O
.,3939,O
These,3940,O
results,3940,O
suggest,3940,O
that,3940,O
ganglioside-bound,3940,B-CHEMICAL
A,3940,B-GENE-Y
(,3940,O
GA,3940,O
),3940,O
",",3940,O
which,3940,O
acts,3940,O
as,3940,O
an,3940,O
endogenous,3940,O
seed,3940,O
for,3940,O
A,3940,B-GENE-Y
fibril,3940,O
formation,3940,O
in,3940,O
AD,3940,O
brains,3940,O
",",3940,O
is,3940,O
generated,3940,O
on,3940,O
ASIGN,3940,O
on,3940,O
synaptosomal,3940,O
membranes,3940,O
.,3940,O
Tamoxifen,3941,B-CHEMICAL
represses,3941,O
miR-200,3941,B-GENE-N
microRNAs,3941,O
and,3941,O
promotes,3941,O
epithelial-to-mesenchymal,3941,O
transition,3941,O
by,3941,O
up-regulating,3941,O
c-Myc,3941,B-GENE-Y
in,3941,O
endometrial,3941,O
carcinoma,3941,O
cell,3941,O
lines,3941,O
.,3941,O
Although,3942,O
tamoxifen,3942,B-CHEMICAL
(,3942,O
TAM,3942,B-CHEMICAL
),3942,O
",",3942,O
a,3942,O
selective,3942,O
estrogen,3942,B-GENE-Y
receptor,3942,I-GENE-Y
modulator,3942,O
",",3942,O
has,3942,O
been,3942,O
widely,3942,O
used,3942,O
in,3942,O
the,3942,O
treatment,3942,O
of,3942,O
hormone-responsive,3942,O
breast,3942,O
cancer,3942,O
",",3942,O
its,3942,O
estrogen-like,3942,B-CHEMICAL
effect,3942,O
increases,3942,O
the,3942,O
risk,3942,O
of,3942,O
endometrial,3942,O
cancer,3942,O
.,3942,O
However,3943,O
",",3943,O
the,3943,O
molecular,3943,O
mechanisms,3943,O
of,3943,O
TAM-induced,3943,B-CHEMICAL
endometrial,3943,O
carcinoma,3943,O
still,3943,O
remain,3943,O
unclear,3943,O
.,3943,O
In,3944,O
this,3944,O
report,3944,O
",",3944,O
we,3944,O
explored,3944,O
the,3944,O
role,3944,O
of,3944,O
microRNAs,3944,O
(,3944,O
miRNAs,3944,O
),3944,O
in,3944,O
TAM-induced,3944,B-CHEMICAL
epithelial-mesenchymal,3944,O
transition,3944,O
(,3944,O
EMT,3944,O
),3944,O
in,3944,O
ECC-1,3944,O
and,3944,O
Ishikawa,3944,O
endometrial,3944,O
cancer,3944,O
cell,3944,O
lines,3944,O
and,3944,O
found,3944,O
miR-200,3944,B-GENE-N
is,3944,O
involved,3944,O
in,3944,O
this,3944,O
process,3944,O
via,3944,O
the,3944,O
regulation,3944,O
of,3944,O
c-Myc,3944,B-GENE-Y
.,3944,O
When,3945,O
treated,3945,O
with,3945,O
TAM,3945,B-CHEMICAL
",",3945,O
ECC-1,3945,O
and,3945,O
Ishikawa,3945,O
cells,3945,O
were,3945,O
characterized,3945,O
by,3945,O
higher,3945,O
invasiveness,3945,O
and,3945,O
motility,3945,O
and,3945,O
underwent,3945,O
EMT,3945,O
.,3945,O
miR-200,3946,B-GENE-N
",",3946,O
a,3946,O
miRNA,3946,O
family,3946,O
with,3946,O
tumor,3946,O
suppressive,3946,O
functions,3946,O
in,3946,O
a,3946,O
wide,3946,O
range,3946,O
of,3946,O
cancers,3946,O
",",3946,O
was,3946,O
found,3946,O
reduced,3946,O
in,3946,O
response,3946,O
to,3946,O
TAM,3946,B-CHEMICAL
treatment,3946,O
.,3946,O
Consistent,3947,O
with,3947,O
zinc,3947,B-GENE-Y
finger,3947,I-GENE-Y
E-box,3947,I-GENE-Y
binding,3947,I-GENE-Y
homeobox,3947,I-GENE-Y
2,3947,I-GENE-Y
",",3947,O
which,3947,O
was,3947,O
confirmed,3947,O
as,3947,O
a,3947,O
direct,3947,O
target,3947,O
of,3947,O
miR-200b,3947,B-GENE-Y
in,3947,O
endometrial,3947,O
cancer,3947,O
cell,3947,O
lines,3947,O
",",3947,O
some,3947,O
other,3947,O
key,3947,O
factors,3947,O
of,3947,O
EMT,3947,O
such,3947,O
as,3947,O
Snail,3947,B-GENE-Y
and,3947,O
N-cadherin,3947,B-GENE-Y
increased,3947,O
",",3947,O
whereas,3947,O
E-cadherin,3947,B-GENE-Y
decreased,3947,O
in,3947,O
the,3947,O
TAM-treated,3947,B-CHEMICAL
cells,3947,O
",",3947,O
contributing,3947,O
to,3947,O
TAM-induced,3947,B-CHEMICAL
EMT,3947,O
in,3947,O
these,3947,O
endometrial,3947,O
cancer,3947,O
cells,3947,O
.,3947,O
In,3948,O
addition,3948,O
",",3948,O
we,3948,O
showed,3948,O
that,3948,O
c-Myc,3948,B-GENE-Y
directly,3948,O
binds,3948,O
to,3948,O
and,3948,O
represses,3948,O
the,3948,O
promoter,3948,O
of,3948,O
miR-200,3948,B-GENE-N
miRNAs,3948,O
",",3948,O
and,3948,O
its,3948,O
up-regulation,3948,O
in,3948,O
TAM-treated,3948,B-CHEMICAL
endometrial,3948,O
cancer,3948,O
cells,3948,O
leads,3948,O
to,3948,O
the,3948,O
down-regulation,3948,O
of,3948,O
miR-200,3948,B-GENE-N
and,3948,O
eventually,3948,O
to,3948,O
EMT,3948,O
.,3948,O
Collectively,3949,O
",",3949,O
our,3949,O
data,3949,O
suggest,3949,O
that,3949,O
TAM,3949,B-CHEMICAL
can,3949,O
repress,3949,O
the,3949,O
miR-200,3949,B-GENE-N
family,3949,O
and,3949,O
induce,3949,O
EMT,3949,O
via,3949,O
the,3949,O
up-regulation,3949,O
of,3949,O
c-Myc,3949,B-GENE-Y
in,3949,O
endometrial,3949,O
cancer,3949,O
cells,3949,O
.,3949,O
These,3950,O
findings,3950,O
describe,3950,O
a,3950,O
possible,3950,O
mechanism,3950,O
of,3950,O
TAM-induced,3950,B-CHEMICAL
EMT,3950,O
in,3950,O
endometrial,3950,O
cancer,3950,O
and,3950,O
provide,3950,O
a,3950,O
potential,3950,O
new,3950,O
therapeutic,3950,O
strategy,3950,O
for,3950,O
it,3950,O
.,3950,O
Manganese-induced,3951,B-CHEMICAL
oxidative,3951,O
DNA,3951,O
damage,3951,O
in,3951,O
neuronal,3951,O
SH-SY5Y,3951,O
cells,3951,O
:,3951,O
attenuation,3951,O
of,3951,O
thymine,3951,B-CHEMICAL
base,3951,O
lesions,3951,O
by,3951,O
glutathione,3951,B-CHEMICAL
and,3951,O
N-acetylcysteine,3951,B-CHEMICAL
.,3951,O
Manganese,3952,B-CHEMICAL
(,3952,O
Mn,3952,B-CHEMICAL
),3952,O
is,3952,O
an,3952,O
essential,3952,O
trace,3952,O
element,3952,O
required,3952,O
for,3952,O
normal,3952,O
function,3952,O
and,3952,O
development,3952,O
.,3952,O
However,3953,O
",",3953,O
exposure,3953,O
to,3953,O
this,3953,O
metal,3953,O
at,3953,O
elevated,3953,O
levels,3953,O
may,3953,O
cause,3953,O
manganism,3953,O
",",3953,O
a,3953,O
progressive,3953,O
neurodegenerative,3953,O
disorder,3953,O
with,3953,O
neurological,3953,O
symptoms,3953,O
similar,3953,O
to,3953,O
idiopathic,3953,O
Parkinson,3953,O
's,3953,O
disease,3953,O
(,3953,O
IPD,3953,O
),3953,O
.,3953,O
Elevated,3954,O
body,3954,O
burdens,3954,O
of,3954,O
Mn,3954,B-CHEMICAL
from,3954,O
exposure,3954,O
to,3954,O
parental,3954,O
nutrition,3954,O
",",3954,O
vapors,3954,O
in,3954,O
mines,3954,O
and,3954,O
smelters,3954,O
and,3954,O
welding,3954,O
fumes,3954,O
have,3954,O
been,3954,O
associated,3954,O
with,3954,O
neurological,3954,O
health,3954,O
concerns,3954,O
.,3954,O
The,3955,O
underlying,3955,O
mechanism,3955,O
of,3955,O
Mn,3955,B-CHEMICAL
neurotoxicity,3955,O
remains,3955,O
unclear,3955,O
.,3955,O
Accordingly,3956,O
",",3956,O
the,3956,O
present,3956,O
study,3956,O
was,3956,O
designed,3956,O
to,3956,O
investigate,3956,O
the,3956,O
toxic,3956,O
effects,3956,O
of,3956,O
Mn,3956,B-CHEMICAL
(,3956,I-CHEMICAL
2+,3956,I-CHEMICAL
),3956,I-CHEMICAL
in,3956,O
human,3956,O
neuroblastoma,3956,O
SH-SY5Y,3956,O
cells,3956,O
.,3956,O
Mn,3957,B-CHEMICAL
(,3957,I-CHEMICAL
2+,3957,I-CHEMICAL
),3957,I-CHEMICAL
caused,3957,O
a,3957,O
concentration,3957,O
dependent,3957,O
decrease,3957,O
in,3957,O
SH-SY5Y,3957,O
cellular,3957,O
viability,3957,O
compared,3957,O
to,3957,O
controls,3957,O
.,3957,O
The,3958,O
LD50,3958,O
value,3958,O
was,3958,O
12.98,3958,O
M,3958,O
Mn,3958,B-CHEMICAL
(,3958,I-CHEMICAL
2+,3958,I-CHEMICAL
),3958,I-CHEMICAL
(,3958,O
p,3958,O
<,3958,O
0.001,3958,O
for,3958,O
control,3958,O
vs.,3958,O
24h,3958,O
Mn,3958,B-CHEMICAL
treatment,3958,O
),3958,O
.,3958,O
Both,3959,O
TUNEL,3959,O
and,3959,O
annexin,3959,O
V/propidium,3959,O
iodide,3959,I-CHEMICAL
(,3959,O
PI,3959,O
),3959,O
apoptosis,3959,O
assays,3959,O
confirmed,3959,O
the,3959,O
induction,3959,O
of,3959,O
apoptosis,3959,O
in,3959,O
the,3959,O
cells,3959,O
following,3959,O
exposure,3959,O
to,3959,O
Mn,3959,B-CHEMICAL
(,3959,I-CHEMICAL
2+,3959,I-CHEMICAL
),3959,I-CHEMICAL
(,3959,O
2,3959,O
M,3959,O
",",3959,O
62,3959,O
M,3959,O
or,3959,O
125,3959,O
M,3959,O
),3959,O
.,3959,O
In,3960,O
addition,3960,O
",",3960,O
Mn,3960,B-CHEMICAL
(,3960,I-CHEMICAL
2+,3960,I-CHEMICAL
),3960,I-CHEMICAL
induced,3960,O
both,3960,O
the,3960,O
formation,3960,O
and,3960,O
accumulation,3960,O
of,3960,O
DNA,3960,O
single,3960,O
strand,3960,O
breaks,3960,O
(,3960,O
via,3960,O
alkaline,3960,O
comet,3960,O
assay,3960,O
analysis,3960,O
),3960,O
and,3960,O
oxidatively,3960,O
modified,3960,O
thymine,3960,B-CHEMICAL
bases,3960,O
(,3960,O
via,3960,O
gas,3960,O
chromatography/mass,3960,O
spectrometry,3960,O
analysis,3960,O
),3960,O
.,3960,O
Pre-incubation,3961,O
of,3961,O
the,3961,O
cells,3961,O
with,3961,O
characteristic,3961,O
antioxidants,3961,O
",",3961,O
either,3961,O
1mM,3961,O
N-acetylcysteine,3961,B-CHEMICAL
(,3961,O
NAC,3961,B-CHEMICAL
),3961,O
or,3961,O
1mM,3961,O
glutathione,3961,B-CHEMICAL
(,3961,O
GSH,3961,B-CHEMICAL
),3961,O
reduced,3961,O
the,3961,O
level,3961,O
of,3961,O
DNA,3961,O
strand,3961,O
breaks,3961,O
and,3961,O
the,3961,O
formation,3961,O
of,3961,O
thymine,3961,B-CHEMICAL
base,3961,O
lesions,3961,O
",",3961,O
suggesting,3961,O
protection,3961,O
against,3961,O
oxidative,3961,O
cellular,3961,O
damage,3961,O
.,3961,O
Our,3962,O
findings,3962,O
indicate,3962,O
that,3962,O
(,3962,O
1,3962,O
),3962,O
exposure,3962,O
of,3962,O
SH-SY5Y,3962,O
cells,3962,O
to,3962,O
Mn,3962,B-CHEMICAL
promotes,3962,O
both,3962,O
the,3962,O
formation,3962,O
and,3962,O
accumulation,3962,O
of,3962,O
oxidative,3962,O
DNA,3962,O
damage,3962,O
",",3962,O
(,3962,O
2,3962,O
),3962,O
SH-SY5Y,3962,O
cells,3962,O
with,3962,O
accumulated,3962,O
DNA,3962,O
damage,3962,O
are,3962,O
more,3962,O
likely,3962,O
to,3962,O
die,3962,O
via,3962,O
an,3962,O
apoptotic,3962,O
pathway,3962,O
and,3962,O
(,3962,O
3,3962,O
),3962,O
the,3962,O
accumulated,3962,O
levels,3962,O
of,3962,O
DNA,3962,O
damage,3962,O
can,3962,O
be,3962,O
abrogated,3962,O
by,3962,O
the,3962,O
addition,3962,O
of,3962,O
exogenous,3962,O
chemical,3962,O
antioxidants,3962,O
.,3962,O
This,3963,O
is,3963,O
the,3963,O
first,3963,O
known,3963,O
report,3963,O
of,3963,O
Mn,3963,B-CHEMICAL
(,3963,I-CHEMICAL
2+,3963,I-CHEMICAL
),3963,I-CHEMICAL
-induction,3963,O
and,3963,O
antioxidant,3963,O
protection,3963,O
of,3963,O
thymine,3963,B-CHEMICAL
lesions,3963,O
in,3963,O
this,3963,O
SH-SY5Y,3963,O
cell,3963,O
line,3963,O
and,3963,O
contributes,3963,O
new,3963,O
information,3963,O
to,3963,O
the,3963,O
potential,3963,O
use,3963,O
of,3963,O
antioxidants,3963,O
as,3963,O
a,3963,O
therapeutic,3963,O
strategy,3963,O
for,3963,O
protection,3963,O
against,3963,O
Mn,3963,B-CHEMICAL
(,3963,I-CHEMICAL
2+,3963,I-CHEMICAL
),3963,I-CHEMICAL
-induced,3963,O
oxidative,3963,O
DNA,3963,O
damage,3963,O
.,3963,O
Resveratrol,3964,B-CHEMICAL
improves,3964,O
cardiomyopathy,3964,O
in,3964,O
dystrophin-deficient,3964,B-GENE-Y
mice,3964,O
through,3964,O
SIRT1,3964,B-GENE-Y
protein-mediated,3964,O
modulation,3964,O
of,3964,O
p300,3964,B-GENE-Y
protein,3964,O
.,3964,O
Cardiomyopathy,3965,O
is,3965,O
the,3965,O
main,3965,O
cause,3965,O
of,3965,O
death,3965,O
in,3965,O
Duchenne,3965,O
muscular,3965,O
dystrophy,3965,O
.,3965,O
Here,3966,O
",",3966,O
we,3966,O
show,3966,O
that,3966,O
oral,3966,O
administration,3966,O
of,3966,O
resveratrol,3966,B-CHEMICAL
",",3966,O
which,3966,O
leads,3966,O
to,3966,O
activation,3966,O
of,3966,O
an,3966,O
NAD,3966,B-CHEMICAL
(,3966,I-CHEMICAL
+,3966,I-CHEMICAL
),3966,I-CHEMICAL
-dependent,3966,I-GENE-Y
protein,3966,I-GENE-Y
deacetylase,3966,I-GENE-Y
SIRT1,3966,I-GENE-Y
",",3966,O
suppresses,3966,O
cardiac,3966,O
hypertrophy,3966,O
and,3966,O
fibrosis,3966,O
and,3966,O
restores,3966,O
cardiac,3966,O
diastolic,3966,O
function,3966,O
in,3966,O
dystrophin-deficient,3966,B-GENE-Y
mdx,3966,O
mice,3966,O
.,3966,O
The,3967,O
pro-hypertrophic,3967,O
co-activator,3967,O
p300,3967,B-GENE-Y
protein,3967,O
but,3967,O
not,3967,O
p300,3967,B-GENE-Y
mRNA,3967,O
was,3967,O
up-regulated,3967,O
in,3967,O
the,3967,O
mdx,3967,O
heart,3967,O
",",3967,O
and,3967,O
resveratrol,3967,B-CHEMICAL
administration,3967,O
down-regulated,3967,O
the,3967,O
p300,3967,B-GENE-Y
protein,3967,O
level,3967,O
.,3967,O
In,3968,O
cultured,3968,O
cardiomyocytes,3968,O
",",3968,O
cardiomyocyte,3968,O
hypertrophy,3968,O
induced,3968,O
by,3968,O
the,3968,O
,3968,O
(,3968,O
1,3968,O
),3968,O
-agonist,3968,O
phenylephrine,3968,B-CHEMICAL
was,3968,O
inhibited,3968,O
by,3968,O
the,3968,O
overexpression,3968,O
of,3968,O
SIRT1,3968,B-GENE-Y
as,3968,O
well,3968,O
as,3968,O
resveratrol,3968,B-CHEMICAL
",",3968,O
both,3968,O
of,3968,O
which,3968,O
down-regulated,3968,O
p300,3968,B-GENE-Y
protein,3968,O
levels,3968,O
but,3968,O
not,3968,O
p300,3968,B-GENE-Y
mRNA,3968,O
levels,3968,O
.,3968,O
In,3969,O
addition,3969,O
",",3969,O
activation,3969,O
of,3969,O
atrial,3969,B-GENE-N
natriuretic,3969,I-GENE-N
peptide,3969,I-GENE-N
promoter,3969,I-GENE-N
by,3969,O
p300,3969,B-GENE-Y
was,3969,O
inhibited,3969,O
by,3969,O
SIRT1,3969,B-GENE-Y
.,3969,O
We,3970,O
found,3970,O
that,3970,O
SIRT1,3970,B-GENE-Y
induced,3970,O
p300,3970,B-GENE-Y
down-regulation,3970,O
via,3970,O
the,3970,O
ubiquitin-proteasome,3970,B-GENE-N
pathway,3970,O
by,3970,O
deacetylation,3970,O
of,3970,O
lysine,3970,B-CHEMICAL
residues,3970,O
for,3970,O
ubiquitination,3970,O
.,3970,O
These,3971,O
findings,3971,O
indicate,3971,O
the,3971,O
pathological,3971,O
significance,3971,O
of,3971,O
p300,3971,B-GENE-Y
up-regulation,3971,O
in,3971,O
the,3971,O
dystrophic,3971,O
heart,3971,O
and,3971,O
indicate,3971,O
that,3971,O
SIRT1,3971,B-GENE-Y
activation,3971,O
has,3971,O
therapeutic,3971,O
potential,3971,O
for,3971,O
dystrophic,3971,O
cardiomyopathy,3971,O
.,3971,O
Synthesis,3972,O
",",3972,O
characterization,3972,O
and,3972,O
targeting,3972,O
potential,3972,O
of,3972,O
zidovudine,3972,B-CHEMICAL
loaded,3972,O
sialic,3972,B-CHEMICAL
acid,3972,I-CHEMICAL
conjugated-mannosylated,3972,O
poly,3972,I-CHEMICAL
(,3972,I-CHEMICAL
propyleneimine,3972,I-CHEMICAL
),3972,I-CHEMICAL
dendrimers,3972,O
.,3972,O
The,3973,O
present,3973,O
investigation,3973,O
was,3973,O
aimed,3973,O
at,3973,O
exploring,3973,O
dual,3973,O
targeting,3973,O
of,3973,O
anti-HIV,3973,O
drug,3973,O
",",3973,O
zidovudine,3973,B-CHEMICAL
(,3973,O
ZDV,3973,B-CHEMICAL
),3973,O
via,3973,O
sialic,3973,B-CHEMICAL
acid,3973,I-CHEMICAL
conjugated-mannosylated,3973,O
poly,3973,I-CHEMICAL
(,3973,I-CHEMICAL
propyleneimine,3973,I-CHEMICAL
),3973,I-CHEMICAL
(,3973,O
PPI,3973,B-CHEMICAL
),3973,O
dendritic,3973,O
nano-constructs,3973,O
.,3973,O
Fourth,3974,O
generation,3974,O
PPI,3974,B-CHEMICAL
dendrimers,3974,O
",",3974,O
sialic,3974,B-CHEMICAL
acid,3974,I-CHEMICAL
conjugated,3974,O
PPI,3974,B-CHEMICAL
dendrimers,3974,O
(,3974,O
SPPI,3974,O
),3974,O
",",3974,O
mannose,3974,B-CHEMICAL
conjugated,3974,O
PPI,3974,B-CHEMICAL
dendrimers,3974,O
(,3974,O
MPPI,3974,O
),3974,O
and,3974,O
dual,3974,O
ligand,3974,O
system,3974,O
i.e,3974,O
.,3974,O
sialic,3975,B-CHEMICAL
acid,3975,I-CHEMICAL
conjugated-mannosylated,3975,O
PPI,3975,I-CHEMICAL
dendrimers,3975,O
(,3975,O
SMPPI,3975,O
),3975,O
were,3975,O
synthesized,3975,O
and,3975,O
characterized,3975,O
by,3975,O
FT-IR,3975,O
and,3975,O
(,3975,B-CHEMICAL
1,3975,I-CHEMICAL
),3975,I-CHEMICAL
H,3975,I-CHEMICAL
NMR,3975,O
spectroscopies,3975,O
and,3975,O
were,3975,O
further,3975,O
confirmed,3975,O
by,3975,O
size,3975,O
exclusion,3975,O
chromatography,3975,O
and,3975,O
differential,3975,O
scanning,3975,O
calorimetry,3975,O
.,3975,O
Various,3976,O
parameters,3976,O
like,3976,O
drug,3976,O
loading,3976,O
",",3976,O
pH,3976,O
dependent,3976,O
in,3976,O
vitro,3976,O
release,3976,O
",",3976,O
hemolytic,3976,O
toxicity,3976,O
",",3976,O
macrophage,3976,O
uptake,3976,O
and,3976,O
cytotoxicity,3976,O
concerning,3976,O
PPI,3976,B-CHEMICAL
",",3976,O
SPPI,3976,O
",",3976,O
MPPI,3976,O
and,3976,O
SMPPI,3976,O
dendrimers,3976,O
were,3976,O
evaluated,3976,O
.,3976,O
ZDV,3977,B-CHEMICAL
loaded,3977,O
SMPPI,3977,O
",",3977,O
SPPI,3977,O
and,3977,O
MPPI,3977,O
have,3977,O
shown,3977,O
reduced,3977,O
hemolytic,3977,O
toxicity,3977,O
",",3977,O
cytotoxicity,3977,O
and,3977,O
in,3977,O
vitro,3977,O
drug,3977,O
release,3977,O
at,3977,O
pH,3977,O
7.4,3977,O
.,3977,O
Extremely,3978,O
significant,3978,O
(,3978,O
P,3978,O
<,3978,O
0.001,3978,O
),3978,O
increase,3978,O
in,3978,O
cellular,3978,O
uptake,3978,O
of,3978,O
ZDV,3978,B-CHEMICAL
by,3978,O
macrophage,3978,O
cells,3978,O
was,3978,O
observed,3978,O
in,3978,O
case,3978,O
of,3978,O
SMPPI,3978,O
as,3978,O
compared,3978,O
to,3978,O
PPI,3978,B-CHEMICAL
and,3978,O
free,3978,O
drug,3978,O
.,3978,O
The,3979,O
in,3979,O
vivo,3979,O
blood,3979,O
level,3979,O
and,3979,O
tissue,3979,O
distribution,3979,O
studies,3979,O
in,3979,O
albino,3979,O
rats,3979,O
also,3979,O
demonstrated,3979,O
potential,3979,O
of,3979,O
dual,3979,O
targeted,3979,O
system,3979,O
towards,3979,O
sialoadhesin,3979,B-GENE-Y
and,3979,O
carbohydrate,3979,B-CHEMICAL
receptors,3979,I-GENE-N
.,3979,O
The,3980,O
drug,3980,O
concentration,3980,O
in,3980,O
lymph,3980,O
nodes,3980,O
was,3980,O
increased,3980,O
to,3980,O
about,3980,O
28,3980,O
times,3980,O
in,3980,O
case,3980,O
of,3980,O
SMPPI,3980,O
(,3980,O
1335,3980,O
,3980,O
17.6,3980,O
ng/g,3980,O
),3980,O
as,3980,O
compared,3980,O
to,3980,O
free,3980,O
drug,3980,O
(,3980,O
48,3980,O
,3980,O
5.8,3980,O
ng/g,3980,O
),3980,O
at,3980,O
6th,3980,O
hr,3980,O
.,3980,O
The,3981,O
results,3981,O
suggested,3981,O
that,3981,O
such,3981,O
dual,3981,O
ligand,3981,O
dendritic,3981,O
system,3981,O
(,3981,O
SMPPI,3981,O
),3981,O
hold,3981,O
potential,3981,O
to,3981,O
enhance,3981,O
biocompatibility,3981,O
and,3981,O
site,3981,O
specific,3981,O
delivery,3981,O
of,3981,O
antiretroviral,3981,O
drug,3981,O
",",3981,O
ZDV,3981,B-CHEMICAL
.,3981,O
3D,3982,O
structures,3982,O
and,3982,O
ligand,3982,O
specificities,3982,O
of,3982,O
nuclear,3982,O
xenobiotic,3982,O
receptors,3982,O
CAR,3982,B-GENE-Y
",",3982,O
PXR,3982,B-GENE-Y
and,3982,O
VDR,3982,B-GENE-Y
.,3982,O
The,3983,O
nuclear,3983,B-GENE-N
receptors,3983,I-GENE-N
constitutive,3983,B-GENE-Y
androstane,3983,I-GENE-Y
receptor,3983,I-GENE-Y
(,3983,O
CAR,3983,B-GENE-Y
),3983,O
",",3983,O
pregnane,3983,B-CHEMICAL
X,3983,I-GENE-Y
receptor,3983,I-GENE-Y
(,3983,O
PXR,3983,B-GENE-Y
),3983,O
and,3983,O
vitamin,3983,B-CHEMICAL
D,3983,I-CHEMICAL
receptor,3983,I-GENE-Y
(,3983,O
VDR,3983,B-GENE-Y
),3983,O
control,3983,O
a,3983,O
large,3983,O
array,3983,O
of,3983,O
genes,3983,O
that,3983,O
code,3983,O
for,3983,O
important,3983,O
proteins,3983,O
in,3983,O
humans,3983,O
including,3983,O
metabolic,3983,O
enzymes,3983,O
and,3983,O
transporters,3983,O
.,3983,O
3D,3984,O
structures,3984,O
for,3984,O
the,3984,O
ligand-binding,3984,B-GENE-N
domain,3984,I-GENE-N
(,3984,O
LBD,3984,B-GENE-N
),3984,O
of,3984,O
these,3984,O
receptors,3984,O
are,3984,O
abundantly,3984,O
available,3984,O
",",3984,O
providing,3984,O
valuable,3984,O
insights,3984,O
into,3984,O
the,3984,O
ligand-binding,3984,O
specificity,3984,O
as,3984,O
well,3984,O
as,3984,O
the,3984,O
activation,3984,O
mechanisms,3984,O
.,3984,O
The,3985,O
ligand-binding,3985,O
site,3985,O
of,3985,O
PXR,3985,B-GENE-Y
is,3985,O
large,3985,O
and,3985,O
flexible,3985,O
",",3985,O
whereas,3985,O
those,3985,O
of,3985,O
CAR,3985,B-GENE-Y
and,3985,O
VDR,3985,B-GENE-Y
are,3985,O
compact,3985,O
and,3985,O
rigid,3985,O
",",3985,O
respectively,3985,O
.,3985,O
In,3986,O
general,3986,O
",",3986,O
the,3986,O
ligand,3986,O
profiles,3986,O
of,3986,O
the,3986,O
receptors,3986,O
are,3986,O
in,3986,O
agreement,3986,O
with,3986,O
the,3986,O
LBD,3986,B-GENE-N
structures,3986,O
.,3986,O
The,3987,O
crystal,3987,O
structures,3987,O
have,3987,O
greatly,3987,O
helped,3987,O
us,3987,O
to,3987,O
understand,3987,O
the,3987,O
promiscuity,3987,O
and/or,3987,O
specificity,3987,O
of,3987,O
CAR,3987,B-GENE-Y
",",3987,O
PXR,3987,B-GENE-Y
and,3987,O
VDR,3987,B-GENE-Y
.,3987,O
Synthesis,3988,O
and,3988,O
dual,3988,O
biological,3988,O
effects,3988,O
of,3988,O
hydroxycinnamoyl,3988,B-CHEMICAL
phenylalanyl/prolyl,3988,O
hydroxamic,3988,I-CHEMICAL
acid,3988,I-CHEMICAL
derivatives,3988,O
as,3988,O
tyrosinase,3988,B-GENE-Y
inhibitor,3988,O
and,3988,O
antioxidant,3988,O
.,3988,O
We,3989,O
previously,3989,O
reported,3989,O
that,3989,O
caffeoyl-amino,3989,B-CHEMICAL
acidyl-hydroxamic,3989,I-CHEMICAL
acid,3989,I-CHEMICAL
(,3989,O
CA-Xaa-NHOH,3989,B-CHEMICAL
),3989,O
acted,3989,O
as,3989,O
both,3989,O
a,3989,O
good,3989,O
antioxidant,3989,O
and,3989,O
tyrosinase,3989,B-GENE-Y
inhibitor,3989,O
",",3989,O
in,3989,O
particular,3989,O
when,3989,O
caffeic,3989,B-CHEMICAL
acid,3989,I-CHEMICAL
was,3989,O
conjugated,3989,O
with,3989,O
proline,3989,B-CHEMICAL
or,3989,O
amino,3989,B-CHEMICAL
acids,3989,I-CHEMICAL
having,3989,O
aromatic,3989,O
ring,3989,O
like,3989,O
phenylalanine,3989,B-CHEMICAL
.,3989,O
Here,3990,O
",",3990,O
various,3990,O
hydroxycinnamic,3990,B-CHEMICAL
acid,3990,I-CHEMICAL
(,3990,O
HCA,3990,B-CHEMICAL
),3990,O
derivatives,3990,O
were,3990,O
further,3990,O
conjugated,3990,O
with,3990,O
phenylalanyl,3990,B-CHEMICAL
hydroxamic,3990,I-CHEMICAL
acid,3990,I-CHEMICAL
and,3990,O
prolyl,3990,B-CHEMICAL
hydroxamic,3990,I-CHEMICAL
acid,3990,I-CHEMICAL
(,3990,O
HCA-Phe-NHOH,3990,B-CHEMICAL
and,3990,O
HCA-Pro-NHOH,3990,B-CHEMICAL
),3990,O
to,3990,O
study,3990,O
the,3990,O
structure,3990,O
and,3990,O
activity,3990,O
relationship,3990,O
as,3990,O
both,3990,O
antioxidants,3990,O
and,3990,O
tyrosinase,3990,B-GENE-Y
inhibitors,3990,O
.,3990,O
When,3991,O
their,3991,O
biological,3991,O
activities,3991,O
were,3991,O
evaluated,3991,O
",",3991,O
all,3991,O
HCA-Phe-NHOH,3991,B-CHEMICAL
and,3991,O
HCA-Pro-NHOH,3991,B-CHEMICAL
exhibited,3991,O
enhanced,3991,O
antioxidant,3991,O
activity,3991,O
compared,3991,O
to,3991,O
HCA,3991,B-CHEMICAL
alone,3991,O
.,3991,O
Moreover,3992,O
",",3992,O
derivatives,3992,O
of,3992,O
caffeic,3992,B-CHEMICAL
acid,3992,I-CHEMICAL
",",3992,O
ferulic,3992,B-CHEMICAL
acid,3992,I-CHEMICAL
",",3992,O
and,3992,O
sinapic,3992,B-CHEMICAL
acid,3992,I-CHEMICAL
inhibited,3992,O
lipid,3992,O
peroxidation,3992,O
more,3992,O
efficiently,3992,O
than,3992,O
vitamin,3992,B-CHEMICAL
E,3992,I-CHEMICAL
analogue,3992,O
(,3992,O
Trolox,3992,B-CHEMICAL
),3992,O
.,3992,O
In,3993,O
addition,3993,O
",",3993,O
derivatives,3993,O
of,3993,O
caffeic,3993,B-CHEMICAL
acid,3993,I-CHEMICAL
and,3993,O
sinapic,3993,B-CHEMICAL
acid,3993,I-CHEMICAL
efficiently,3993,O
inhibited,3993,O
tyrosinase,3993,B-GENE-Y
activity,3993,O
and,3993,O
reduced,3993,O
melanin,3993,O
content,3993,O
in,3993,O
melanocytes,3993,O
Mel-Ab,3993,O
cell,3993,O
.,3993,O
Ruxolitinib,3994,B-CHEMICAL
:,3994,O
a,3994,O
new,3994,O
treatment,3994,O
option,3994,O
for,3994,O
myelofibrosis,3994,O
.,3994,O
Myelofibrosis,3995,O
is,3995,O
a,3995,O
myeloproliferative,3995,O
neoplasm,3995,O
characterized,3995,O
by,3995,O
bone,3995,O
marrow,3995,O
fibrosis,3995,O
and,3995,O
extramedullary,3995,O
hematopoiesis,3995,O
.,3995,O
Evolution,3996,O
of,3996,O
myelofibrosis,3996,O
can,3996,O
lead,3996,O
to,3996,O
life-threatening,3996,O
complications,3996,O
",",3996,O
including,3996,O
transformation,3996,O
to,3996,O
leukemia,3996,O
",",3996,O
thrombotic,3996,O
events,3996,O
",",3996,O
and,3996,O
hemorrhagic,3996,O
episodes,3996,O
.,3996,O
The,3997,O
only,3997,O
curative,3997,O
therapy,3997,O
for,3997,O
myelofibrosis,3997,O
is,3997,O
allogeneic,3997,O
hematopoietic,3997,O
stem,3997,O
cell,3997,O
transplantation,3997,O
.,3997,O
Because,3998,O
this,3998,O
disease,3998,O
manifests,3998,O
primarily,3998,O
in,3998,O
the,3998,O
older,3998,O
population,3998,O
",",3998,O
many,3998,O
patients,3998,O
diagnosed,3998,O
with,3998,O
myelofibrosis,3998,O
are,3998,O
not,3998,O
considered,3998,O
medically,3998,O
fit,3998,O
for,3998,O
such,3998,O
aggressive,3998,O
therapy,3998,O
.,3998,O
Other,3999,O
available,3999,O
medical,3999,O
therapies,3999,O
do,3999,O
not,3999,O
halt,3999,O
disease,3999,O
progression,3999,O
;,3999,O
instead,3999,O
",",3999,O
current,3999,O
treatment,3999,O
strategies,3999,O
have,3999,O
focused,3999,O
on,3999,O
targeting,3999,O
specific,3999,O
symptomology,3999,O
",",3999,O
although,3999,O
with,3999,O
limited,3999,O
efficacy,3999,O
.,3999,O
The,4000,O
lack,4000,O
of,4000,O
effective,4000,O
treatment,4000,O
options,4000,O
for,4000,O
patients,4000,O
with,4000,O
myelofibrosis,4000,O
has,4000,O
rendered,4000,O
this,4000,O
orphan,4000,O
disease,4000,O
state,4000,O
an,4000,O
unmet,4000,O
medical,4000,O
need,4000,O
",",4000,O
and,4000,O
novel,4000,O
approaches,4000,O
to,4000,O
improve,4000,O
outcomes,4000,O
are,4000,O
necessary,4000,O
.,4000,O
Emerging,4001,O
research,4001,O
has,4001,O
identified,4001,O
numerous,4001,O
molecular,4001,O
mutations,4001,O
in,4001,O
patients,4001,O
with,4001,O
myelofibrosis,4001,O
",",4001,O
making,4001,O
this,4001,O
disease,4001,O
a,4001,O
potential,4001,O
candidate,4001,O
for,4001,O
molecularly,4001,O
targeted,4001,O
therapy,4001,O
.,4001,O
The,4002,O
most,4002,O
prevalent,4002,O
mutation,4002,O
identified,4002,O
is,4002,O
a,4002,O
gain-of-function,4002,O
mutation,4002,O
in,4002,O
the,4002,O
Janus,4002,B-GENE-N
kinase,4002,I-GENE-N
(,4002,O
JAK,4002,B-GENE-N
),4002,O
family,4002,O
",",4002,O
JAK2,4002,B-GENE-Y
V617F,4002,B-GENE-N
",",4002,O
which,4002,O
has,4002,O
been,4002,O
identified,4002,O
in,4002,O
more,4002,O
than,4002,O
half,4002,O
of,4002,O
patients,4002,O
with,4002,O
myelofibrosis,4002,O
.,4002,O
This,4003,O
mutation,4003,O
results,4003,O
in,4003,O
a,4003,O
constitutively,4003,O
active,4003,O
JAK-signal,4003,B-GENE-N
transducer,4003,I-GENE-N
and,4003,I-GENE-N
activator,4003,I-GENE-N
of,4003,I-GENE-N
transcription,4003,I-GENE-N
pathway,4003,O
resulting,4003,O
in,4003,O
dysregulated,4003,O
cellular,4003,O
proliferation,4003,O
and,4003,O
hematopoiesis,4003,O
.,4003,O
Ruxolitinib,4004,B-CHEMICAL
is,4004,O
a,4004,O
small-molecule,4004,O
inhibitor,4004,O
of,4004,O
JAK1,4004,B-GENE-Y
and,4004,O
JAK2,4004,B-GENE-Y
and,4004,O
recently,4004,O
became,4004,O
the,4004,O
first,4004,O
drug,4004,O
approved,4004,O
by,4004,O
the,4004,O
United,4004,O
States,4004,O
Food,4004,O
and,4004,O
Drug,4004,O
Administration,4004,O
for,4004,O
the,4004,O
treatment,4004,O
of,4004,O
symptomatic,4004,O
intermediate-,4004,O
or,4004,O
high-risk,4004,O
myelofibrosis,4004,O
.,4004,O
In,4005,O
clinical,4005,O
trials,4005,O
",",4005,O
ruxolitinib,4005,B-CHEMICAL
demonstrated,4005,O
promising,4005,O
efficacy,4005,O
in,4005,O
reducing,4005,O
splenomegaly,4005,O
and,4005,O
myelofibrosis-related,4005,O
symptoms,4005,O
.,4005,O
However,4006,O
",",4006,O
ruxolitinib,4006,B-CHEMICAL
did,4006,O
not,4006,O
demonstrate,4006,O
disease-modifying,4006,O
potential,4006,O
and,4006,O
is,4006,O
not,4006,O
considered,4006,O
a,4006,O
curative,4006,O
therapeutic,4006,O
option,4006,O
.,4006,O
Adverse,4007,O
events,4007,O
associated,4007,O
with,4007,O
ruxolitinib,4007,B-CHEMICAL
are,4007,O
primarily,4007,O
hematologic,4007,O
",",4007,O
with,4007,O
thrombocytopenia,4007,O
and,4007,O
anemia,4007,O
being,4007,O
the,4007,O
most,4007,O
common,4007,O
toxicologic,4007,O
events,4007,O
identified,4007,O
.,4007,O
Future,4008,O
research,4008,O
will,4008,O
shed,4008,O
light,4008,O
on,4008,O
whether,4008,O
ruxolitinib,4008,B-CHEMICAL
in,4008,O
combination,4008,O
with,4008,O
other,4008,O
treatments,4008,O
will,4008,O
further,4008,O
enhance,4008,O
outcomes,4008,O
in,4008,O
myelofibrosis,4008,O
.,4008,O
Tipping,4009,O
the,4009,O
energy,4009,O
balance,4009,O
toward,4009,O
longevity,4009,O
.,4009,O
AMPK,4010,B-GENE-Y
is,4010,O
a,4010,O
cellular,4010,O
energy,4010,O
sensor,4010,O
conserved,4010,O
across,4010,O
eukaryotes,4010,O
that,4010,O
in,4010,O
C.,4010,O
elegans,4010,O
prolongs,4010,O
life,4010,O
span,4010,O
and,4010,O
mimics,4010,O
dietary,4010,O
restriction,4010,O
.,4010,O
Stenesen,4011,O
and,4011,O
colleagues,4011,O
(,4011,O
2012,4011,O
),4011,O
activate,4011,O
AMPK,4011,B-GENE-N
both,4011,O
directly,4011,O
and,4011,O
indirectly,4011,O
by,4011,O
altering,4011,O
AMP,4011,B-CHEMICAL
biosynthesis,4011,O
to,4011,O
slow,4011,O
aging,4011,O
in,4011,O
Drosophila,4011,O
",",4011,O
highlighting,4011,O
AMPK,4011,B-GENE-N
as,4011,O
a,4011,O
conserved,4011,O
life,4011,O
span,4011,O
modulator,4011,O
that,4011,O
links,4011,O
energy,4011,O
sensing,4011,O
to,4011,O
longevity,4011,O
.,4011,O
Oxidative,4012,O
and,4012,O
nitrosative,4012,O
stress,4012,O
and,4012,O
apoptosis,4012,O
in,4012,O
oral,4012,O
mucosa,4012,O
cells,4012,O
after,4012,O
ex,4012,O
vivo,4012,O
exposure,4012,O
to,4012,O
lead,4012,O
and,4012,O
benzo,4012,B-CHEMICAL
[,4012,I-CHEMICAL
a,4012,I-CHEMICAL
],4012,I-CHEMICAL
pyrene,4012,I-CHEMICAL
.,4012,O
Exposure,4013,O
of,4013,O
human,4013,O
oral,4013,O
mucosa,4013,O
to,4013,O
lead,4013,O
(,4013,O
Pb,4013,B-CHEMICAL
),4013,O
and,4013,O
benzo,4013,B-CHEMICAL
[,4013,I-CHEMICAL
a,4013,I-CHEMICAL
],4013,I-CHEMICAL
pyrene,4013,I-CHEMICAL
(,4013,O
BaP,4013,B-CHEMICAL
),4013,O
by,4013,O
inhalation,4013,O
and,4013,O
ingestion,4013,O
can,4013,O
lead,4013,O
to,4013,O
pathological,4013,O
conditions,4013,O
via,4013,O
apoptosis,4013,O
and,4013,O
oxidative,4013,O
and,4013,O
nitrosative,4013,O
stress,4013,O
.,4013,O
However,4014,O
",",4014,O
few,4014,O
studies,4014,O
have,4014,O
investigated,4014,O
the,4014,O
effects,4014,O
of,4014,O
Pb,4014,B-CHEMICAL
and,4014,O
BaP,4014,B-CHEMICAL
on,4014,O
oral,4014,O
mucosa,4014,O
cells,4014,O
.,4014,O
Furthermore,4015,O
",",4015,O
previous,4015,O
studies,4015,O
focused,4015,O
on,4015,O
chronic,4015,O
Pb,4015,B-CHEMICAL
and,4015,O
BaP,4015,B-CHEMICAL
exposure,4015,O
.,4015,O
Therefore,4016,O
",",4016,O
we,4016,O
evaluated,4016,O
important,4016,O
markers,4016,O
of,4016,O
apoptosis,4016,O
and,4016,O
oxidative,4016,O
and,4016,O
nitrosative,4016,O
stress,4016,O
in,4016,O
oral,4016,O
mucosa,4016,O
cells,4016,O
by,4016,O
incubating,4016,O
the,4016,O
cells,4016,O
with,4016,O
Pb,4016,B-CHEMICAL
and,4016,O
BaP,4016,B-CHEMICAL
for,4016,O
5-360,4016,O
min,4016,O
.,4016,O
Ex,4017,O
vivo,4017,O
samples,4017,O
of,4017,O
human,4017,O
oral,4017,O
mucosa,4017,O
were,4017,O
exposed,4017,O
to,4017,O
Pb,4017,B-CHEMICAL
or,4017,O
BaP,4017,B-CHEMICAL
",",4017,O
and,4017,O
immunohistochemical,4017,O
staining,4017,O
was,4017,O
performed,4017,O
to,4017,O
evaluate,4017,O
active,4017,O
caspase-3,4017,B-GENE-Y
",",4017,O
8-epi-prostaglandin,4017,B-CHEMICAL
F2,4017,I-CHEMICAL
alpha,4017,I-CHEMICAL
(,4017,O
8-epi-PGF2a,4017,B-CHEMICAL
),4017,O
",",4017,O
and,4017,O
3-nitrotyrosine,4017,B-CHEMICAL
(,4017,O
3-NT,4017,B-CHEMICAL
),4017,O
.,4017,O
Pb,4018,B-CHEMICAL
and,4018,O
BaP,4018,B-CHEMICAL
treatments,4018,O
significantly,4018,O
increased,4018,O
active,4018,O
caspase-3,4018,B-GENE-Y
levels,4018,O
in,4018,O
a,4018,O
time-dependent,4018,O
manner,4018,O
.,4018,O
Furthermore,4019,O
",",4019,O
the,4019,O
treatments,4019,O
induced,4019,O
an,4019,O
early,4019,O
increase,4019,O
in,4019,O
3-NT,4019,B-CHEMICAL
level,4019,O
",",4019,O
which,4019,O
ceased,4019,O
with,4019,O
longer,4019,O
incubation,4019,O
times,4019,O
.,4019,O
8-Epi-PGF2a,4020,B-CHEMICAL
level,4020,O
increased,4020,O
only,4020,O
after,4020,O
prolonged,4020,O
incubation,4020,O
with,4020,O
Pb,4020,B-CHEMICAL
",",4020,O
and,4020,O
this,4020,O
elevation,4020,O
was,4020,O
irrespective,4020,O
of,4020,O
BaP,4020,B-CHEMICAL
incubation,4020,O
duration,4020,O
.,4020,O
Smokers,4021,O
',4021,O
samples,4021,O
had,4021,O
significantly,4021,O
lower,4021,O
levels,4021,O
of,4021,O
markers,4021,O
of,4021,O
oxidative,4021,O
and,4021,O
nitrosative,4021,O
stress,4021,O
than,4021,O
did,4021,O
nonsmokers,4021,O
',4021,O
samples,4021,O
.,4021,O
Thus,4022,O
",",4022,O
single,4022,O
",",4022,O
short-term,4022,O
exposure,4022,O
to,4022,O
Pb,4022,B-CHEMICAL
or,4022,O
BaP,4022,B-CHEMICAL
increases,4022,O
the,4022,O
levels,4022,O
of,4022,O
apoptosis,4022,O
markers,4022,O
and,4022,O
markers,4022,O
of,4022,O
oxidative,4022,O
and,4022,O
nitrosative,4022,O
stress,4022,O
.,4022,O
Effect,4023,O
of,4023,O
enzymatically,4023,O
modified,4023,O
isoquercitrin,4023,B-CHEMICAL
on,4023,O
preneoplastic,4023,O
liver,4023,O
cell,4023,O
lesions,4023,O
induced,4023,O
by,4023,O
thioacetamide,4023,B-CHEMICAL
promotion,4023,O
in,4023,O
a,4023,O
two-stage,4023,O
hepatocarcinogenesis,4023,O
model,4023,O
using,4023,O
rats,4023,O
.,4023,O
To,4024,O
investigate,4024,O
the,4024,O
protective,4024,O
effect,4024,O
of,4024,O
enzymatically,4024,O
modified,4024,O
isoquercitrin,4024,B-CHEMICAL
(,4024,O
EMIQ,4024,O
),4024,O
on,4024,O
the,4024,O
hepatocarcinogenic,4024,O
process,4024,O
",",4024,O
we,4024,O
used,4024,O
a,4024,O
two-stage,4024,O
hepatocarcinogenesis,4024,O
model,4024,O
in,4024,O
N-diethylnitrosamine-initiated,4024,B-CHEMICAL
and,4024,O
thioacetamide,4024,B-CHEMICAL
(,4024,O
TAA,4024,B-CHEMICAL
),4024,O
-promoted,4024,O
rats,4024,O
.,4024,O
We,4025,O
examined,4025,O
the,4025,O
modifying,4025,O
effect,4025,O
of,4025,O
co-administration,4025,O
with,4025,O
EMIQ,4025,O
on,4025,O
the,4025,O
liver,4025,O
tissue,4025,O
environment,4025,O
including,4025,O
hepatic,4025,O
macrophages,4025,O
and,4025,O
lymphocytes,4025,O
and,4025,O
on,4025,O
the,4025,O
induction,4025,O
mechanism,4025,O
of,4025,O
preneoplastic,4025,O
cell,4025,O
apoptosis,4025,O
during,4025,O
early,4025,O
stages,4025,O
of,4025,O
hepatocellular,4025,O
tumor,4025,O
promotion,4025,O
.,4025,O
TAA,4026,B-CHEMICAL
increased,4026,O
the,4026,O
number,4026,O
and,4026,O
area,4026,O
of,4026,O
glutathione,4026,B-CHEMICAL
S-transferase,4026,I-GENE-N
placental,4026,I-GENE-N
form,4026,I-GENE-N
(,4026,O
GST-P,4026,B-GENE-N
),4026,O
(,4026,O
+,4026,O
),4026,O
liver,4026,O
cell,4026,O
foci,4026,O
and,4026,O
the,4026,O
numbers,4026,O
of,4026,O
proliferating,4026,O
and,4026,O
apoptotic,4026,O
cells,4026,O
in,4026,O
randomly,4026,O
selected,4026,O
areas,4026,O
in,4026,O
liver,4026,O
sections,4026,O
.,4026,O
Co-administration,4027,O
with,4027,O
EMIQ,4027,O
suppressed,4027,O
these,4027,O
effects,4027,O
.,4027,O
TAA,4028,B-CHEMICAL
also,4028,O
increased,4028,O
the,4028,O
numbers,4028,O
of,4028,O
ED2,4028,O
(,4028,O
+,4028,O
),4028,O
",",4028,O
cyclooxygenase-2,4028,B-GENE-Y
(,4028,O
+,4028,O
),4028,O
",",4028,O
and,4028,O
heme,4028,B-GENE-Y
oxygenase-1,4028,I-GENE-Y
(,4028,O
+,4028,O
),4028,O
liver,4028,O
cells,4028,O
",",4028,O
as,4028,O
well,4028,O
as,4028,O
the,4028,O
number,4028,O
of,4028,O
CD3,4028,B-GENE-N
(,4028,O
+,4028,O
),4028,O
lymphocytes,4028,O
.,4028,O
These,4029,O
effects,4029,O
were,4029,O
also,4029,O
suppressed,4029,O
by,4029,O
EMIQ,4029,O
.,4029,O
EMIQ,4030,O
increased,4030,O
liver,4030,O
levels,4030,O
of,4030,O
thiobarbituric,4030,B-CHEMICAL
acid-reactive,4030,O
substance,4030,O
and,4030,O
8-hydroxydeoxyguanosine,4030,B-CHEMICAL
",",4030,O
and,4030,O
TUNEL,4030,O
(,4030,O
+,4030,O
),4030,O
apoptotic,4030,O
cells,4030,O
",",4030,O
death,4030,B-GENE-Y
receptor,4030,I-GENE-Y
5,4030,I-GENE-Y
(,4030,O
DR5,4030,B-GENE-Y
),4030,O
(,4030,O
+,4030,O
),4030,O
cells,4030,O
and,4030,O
4-hydroxy-2-nonenal,4030,B-CHEMICAL
(,4030,O
+,4030,O
),4030,O
cells,4030,O
within,4030,O
GST-P,4030,B-GENE-N
(,4030,O
+,4030,O
),4030,O
foci,4030,O
.,4030,O
Outside,4031,O
the,4031,O
GST-P,4031,B-GENE-N
(,4031,O
+,4031,O
),4031,O
foci,4031,O
",",4031,O
EMIQ,4031,O
decreased,4031,O
the,4031,O
numbers,4031,O
of,4031,O
apoptotic,4031,O
cells,4031,O
and,4031,O
DR5,4031,B-GENE-Y
(,4031,O
+,4031,O
),4031,O
cells,4031,O
.,4031,O
These,4032,O
results,4032,O
suggest,4032,O
that,4032,O
TAA-induced,4032,B-CHEMICAL
tumor,4032,O
promotion,4032,O
involves,4032,O
activation,4032,O
of,4032,O
hepatic,4032,O
macrophages,4032,O
producing,4032,O
proinflammatory,4032,O
factors,4032,O
.,4032,O
EMIQ,4033,O
may,4033,O
suppress,4033,O
the,4033,O
TAA-induced,4033,B-CHEMICAL
tumor-promoting,4033,O
activity,4033,O
by,4033,O
an,4033,O
anti-inflammatory,4033,O
mechanism,4033,O
mediated,4033,O
by,4033,O
suppressing,4033,O
the,4033,O
activation,4033,O
of,4033,O
these,4033,O
macrophages,4033,O
.,4033,O
Furthermore,4034,O
",",4034,O
EMIQ,4034,O
may,4034,O
suppress,4034,O
tumor-promoting,4034,O
activity,4034,O
differentially,4034,O
between,4034,O
the,4034,O
inside,4034,O
and,4034,O
outside,4034,O
of,4034,O
GST-P,4034,B-GENE-N
(,4034,O
+,4034,O
),4034,O
foci,4034,O
.,4034,O
Within,4035,O
GST-P,4035,B-GENE-N
(,4035,O
+,4035,O
),4035,O
foci,4035,O
",",4035,O
EMIQ,4035,O
facilitates,4035,O
the,4035,O
apoptosis,4035,O
of,4035,O
preneoplastic,4035,O
cells,4035,O
through,4035,O
the,4035,O
upregulation,4035,O
of,4035,O
DR5,4035,B-GENE-Y
.,4035,O
Outside,4036,O
the,4036,O
GST-P,4036,B-GENE-N
(,4036,O
+,4036,O
),4036,O
foci,4036,O
",",4036,O
EMIQ,4036,O
suppresses,4036,O
apoptosis,4036,O
and,4036,O
the,4036,O
subsequent,4036,O
regeneration,4036,O
of,4036,O
non-transformed,4036,O
liver,4036,O
cells,4036,O
.,4036,O
ICA-105574,4037,B-CHEMICAL
interacts,4037,O
with,4037,O
a,4037,O
common,4037,O
binding,4037,O
site,4037,O
to,4037,O
elicit,4037,O
opposite,4037,O
effects,4037,O
on,4037,O
inactivation,4037,O
gating,4037,O
of,4037,O
EAG,4037,B-GENE-Y
and,4037,O
ERG,4037,B-GENE-Y
potassium,4037,B-GENE-N
channels,4037,I-GENE-N
.,4037,O
Rapid,4038,O
and,4038,O
voltage-dependent,4038,O
inactivation,4038,O
greatly,4038,O
attenuates,4038,O
outward,4038,O
currents,4038,O
in,4038,O
ether-a-go-go-related,4038,B-GENE-Y
gene,4038,I-GENE-Y
(,4038,O
ERG,4038,B-GENE-Y
),4038,O
K,4038,B-GENE-N
(,4038,I-GENE-N
+,4038,I-GENE-N
),4038,I-GENE-N
channels,4038,I-GENE-N
.,4038,O
In,4039,O
contrast,4039,O
",",4039,O
inactivation,4039,O
of,4039,O
related,4039,O
ether-a-go-go,4039,B-CHEMICAL
(,4039,O
EAG,4039,B-GENE-Y
),4039,O
K,4039,B-CHEMICAL
(,4039,I-CHEMICAL
+,4039,I-CHEMICAL
),4039,I-CHEMICAL
channels,4039,I-GENE-N
is,4039,O
very,4039,O
slow,4039,O
and,4039,O
minimally,4039,O
reduces,4039,O
outward,4039,O
currents,4039,O
.,4039,O
ICA-105574,4040,B-CHEMICAL
(,4040,O
ICA,4040,B-CHEMICAL
",",4040,O
or,4040,O
3-nitro-N-,4040,B-CHEMICAL
[,4040,I-CHEMICAL
4-phenoxyphenyl,4040,I-CHEMICAL
],4040,I-CHEMICAL
-benzamide,4040,I-CHEMICAL
),4040,O
has,4040,O
opposite,4040,O
effects,4040,O
on,4040,O
inactivation,4040,O
of,4040,O
these,4040,O
two,4040,O
channel,4040,O
types,4040,O
.,4040,O
Although,4041,O
ICA,4041,B-CHEMICAL
greatly,4041,O
attenuates,4041,O
ERG,4041,B-GENE-Y
inactivation,4041,O
by,4041,O
shifting,4041,O
its,4041,O
voltage,4041,O
dependence,4041,O
to,4041,O
more,4041,O
positive,4041,O
potentials,4041,O
",",4041,O
it,4041,O
enhances,4041,O
the,4041,O
rate,4041,O
and,4041,O
extent,4041,O
of,4041,O
EAG,4041,B-GENE-Y
inactivation,4041,O
without,4041,O
altering,4041,O
its,4041,O
voltage,4041,O
dependence,4041,O
.,4041,O
Here,4042,O
",",4042,O
we,4042,O
investigate,4042,O
whether,4042,O
the,4042,O
inverse,4042,O
functional,4042,O
response,4042,O
to,4042,O
ICA,4042,B-CHEMICAL
in,4042,O
EAG,4042,B-GENE-Y
and,4042,O
ERG,4042,B-GENE-Y
channels,4042,O
is,4042,O
related,4042,O
to,4042,O
differences,4042,O
in,4042,O
ICA,4042,B-CHEMICAL
binding,4042,O
site,4042,O
or,4042,O
to,4042,O
intrinsic,4042,O
mechanisms,4042,O
of,4042,O
inactivation,4042,O
.,4042,O
Molecular,4043,O
modeling,4043,O
coupled,4043,O
with,4043,O
site-directed,4043,O
mutagenesis,4043,O
suggests,4043,O
that,4043,O
ICA,4043,B-CHEMICAL
binds,4043,O
in,4043,O
a,4043,O
channel-specific,4043,O
orientation,4043,O
to,4043,O
a,4043,O
hydrophobic,4043,O
pocket,4043,O
bounded,4043,O
by,4043,O
the,4043,O
S5/pore,4043,O
helix/S6,4043,O
of,4043,O
one,4043,O
subunit,4043,O
and,4043,O
S6,4043,O
of,4043,O
an,4043,O
adjacent,4043,O
subunit,4043,O
.,4043,O
ICA,4044,B-CHEMICAL
is,4044,O
a,4044,O
mixed,4044,O
agonist,4044,O
of,4044,O
mutant,4044,O
EAG,4044,B-GENE-Y
and,4044,O
EAG/ERG,4044,B-GENE-Y
chimera,4044,O
channels,4044,O
that,4044,O
inactivate,4044,O
by,4044,O
a,4044,O
combination,4044,O
of,4044,O
slow,4044,O
and,4044,O
fast,4044,O
mechanisms,4044,O
.,4044,O
With,4045,O
the,4045,O
exception,4045,O
of,4045,O
three,4045,O
residues,4045,O
",",4045,O
the,4045,O
specific,4045,O
amino,4045,B-CHEMICAL
acids,4045,I-CHEMICAL
that,4045,O
form,4045,O
the,4045,O
putative,4045,O
binding,4045,O
pocket,4045,O
for,4045,O
ICA,4045,B-CHEMICAL
in,4045,O
ERG,4045,B-GENE-Y
are,4045,O
conserved,4045,O
in,4045,O
EAG,4045,B-GENE-Y
.,4045,O
Mutations,4046,O
introduced,4046,O
into,4046,O
EAG,4046,B-GENE-Y
to,4046,O
replicate,4046,O
the,4046,O
ICA,4046,B-CHEMICAL
binding,4046,O
site,4046,O
in,4046,O
ERG,4046,B-GENE-Y
did,4046,O
not,4046,O
alter,4046,O
the,4046,O
functional,4046,O
response,4046,O
to,4046,O
ICA,4046,B-CHEMICAL
.,4046,O
Together,4047,O
these,4047,O
findings,4047,O
suggest,4047,O
that,4047,O
ICA,4047,B-CHEMICAL
binds,4047,O
to,4047,O
the,4047,O
same,4047,O
site,4047,O
in,4047,O
EAG,4047,B-GENE-Y
and,4047,O
ERG,4047,B-GENE-Y
channels,4047,O
to,4047,O
elicit,4047,O
opposite,4047,O
functional,4047,O
effects,4047,O
.,4047,O
The,4048,O
resultant,4048,O
agonist,4048,O
or,4048,O
antagonist,4048,O
activity,4048,O
is,4048,O
determined,4048,O
solely,4048,O
by,4048,O
channel-specific,4048,O
differences,4048,O
in,4048,O
the,4048,O
mechanisms,4048,O
of,4048,O
inactivation,4048,O
gating,4048,O
.,4048,O
Methylation,4049,O
of,4049,O
histone,4049,B-GENE-N
H3,4049,I-GENE-N
on,4049,O
lysine,4049,B-CHEMICAL
4,4049,O
by,4049,O
the,4049,O
lysine,4049,B-CHEMICAL
methyltransferase,4049,I-GENE-N
SET1,4049,B-GENE-Y
protein,4049,O
is,4049,O
needed,4049,O
for,4049,O
normal,4049,O
clock,4049,O
gene,4049,O
expression,4049,O
.,4049,O
The,4050,O
circadian,4050,O
oscillator,4050,O
controls,4050,O
time-of-day,4050,O
gene,4050,O
expression,4050,O
by,4050,O
a,4050,O
network,4050,O
of,4050,O
interconnected,4050,O
feedback,4050,O
loops,4050,O
and,4050,O
is,4050,O
reset,4050,O
by,4050,O
light,4050,O
.,4050,O
The,4051,O
requisite,4051,O
for,4051,O
chromatin,4051,O
regulation,4051,O
in,4051,O
eukaryotic,4051,O
transcription,4051,O
necessitates,4051,O
temporal,4051,O
regulation,4051,O
of,4051,O
histone-modifying,4051,O
and,4051,O
chromatin-remodeling,4051,O
enzymes,4051,O
for,4051,O
proper,4051,O
clock,4051,O
function,4051,O
.,4051,O
CHD1,4052,B-GENE-N
is,4052,O
known,4052,O
to,4052,O
bind,4052,O
H3K4me3,4052,O
in,4052,O
mammalian,4052,O
cells,4052,O
",",4052,O
and,4052,O
Neurospora,4052,B-GENE-N
CHD1,4052,I-GENE-N
is,4052,O
required,4052,O
for,4052,O
proper,4052,O
regulation,4052,O
of,4052,O
the,4052,O
frequency,4052,B-GENE-Y
(,4052,O
frq,4052,B-GENE-Y
),4052,O
gene,4052,O
.,4052,O
Based,4053,O
on,4053,O
this,4053,O
",",4053,O
we,4053,O
examined,4053,O
a,4053,O
strain,4053,O
lacking,4053,O
SET1,4053,B-GENE-Y
to,4053,O
determine,4053,O
the,4053,O
role,4053,O
of,4053,O
H3K4,4053,O
methylation,4053,O
in,4053,O
clock-,4053,O
and,4053,O
light-mediated,4053,O
frq,4053,B-GENE-Y
regulation,4053,O
.,4053,O
Expression,4054,O
of,4054,O
frq,4054,B-GENE-Y
was,4054,O
altered,4054,O
in,4054,O
strains,4054,O
lacking,4054,O
set1,4054,O
under,4054,O
both,4054,O
circadian-,4054,O
and,4054,O
light-regulated,4054,O
gene,4054,O
expression,4054,O
.,4054,O
There,4055,O
is,4055,O
a,4055,O
delay,4055,O
in,4055,O
the,4055,O
phasing,4055,O
of,4055,O
H3K4me3,4055,O
relative,4055,O
to,4055,O
the,4055,O
peak,4055,O
in,4055,O
frq,4055,B-GENE-Y
expression,4055,O
.,4055,O
White,4056,O
Collar,4056,O
2,4056,O
(,4056,O
WC-2,4056,O
),4056,O
association,4056,O
with,4056,O
the,4056,O
frq,4056,B-GENE-N
promoter,4056,I-GENE-N
persists,4056,O
longer,4056,O
in,4056,O
set1,4056,B-GENE-Y
",",4056,O
suggesting,4056,O
a,4056,O
more,4056,O
permissible,4056,O
chromatin,4056,O
state,4056,O
.,4056,O
Surprisingly,4057,O
",",4057,O
SET1,4057,B-GENE-Y
is,4057,O
required,4057,O
for,4057,O
DNA,4057,O
methylation,4057,O
in,4057,O
the,4057,O
frq,4057,B-GENE-N
promoter,4057,I-GENE-N
",",4057,O
indicating,4057,O
a,4057,O
dependence,4057,O
on,4057,O
H3K4me,4057,O
for,4057,O
DNA,4057,O
methylation,4057,O
.,4057,O
The,4058,O
data,4058,O
support,4058,O
a,4058,O
model,4058,O
where,4058,O
SET1,4058,B-GENE-Y
is,4058,O
needed,4058,O
for,4058,O
proper,4058,O
regulation,4058,O
by,4058,O
modulating,4058,O
chromatin,4058,O
at,4058,O
frq,4058,B-GENE-Y
.,4058,O
Activation,4059,O
of,4059,O
the,4059,O
7,4059,B-GENE-Y
nicotinic,4059,I-GENE-Y
ACh,4059,I-GENE-Y
receptor,4059,I-GENE-Y
induces,4059,O
anxiogenic,4059,O
effects,4059,O
in,4059,O
rats,4059,O
which,4059,O
is,4059,O
blocked,4059,O
by,4059,O
a,4059,O
5-HT1a,4059,B-GENE-Y
receptor,4059,O
antagonist,4059,O
.,4059,O
The,4060,O
7,4060,B-GENE-Y
nicotinic,4060,I-GENE-Y
acetylcholine,4060,B-CHEMICAL
receptor,4060,I-GENE-Y
(,4060,O
nAChR,4060,B-GENE-N
),4060,O
is,4060,O
highly,4060,O
expressed,4060,O
in,4060,O
different,4060,O
regions,4060,O
of,4060,O
the,4060,O
brain,4060,O
and,4060,O
is,4060,O
associated,4060,O
with,4060,O
cognitive,4060,O
function,4060,O
as,4060,O
well,4060,O
as,4060,O
anxiety,4060,O
.,4060,O
Agonists,4061,O
and,4061,O
positive,4061,O
allosteric,4061,O
modulators,4061,O
(,4061,O
PAMs,4061,O
),4061,O
of,4061,O
the,4061,O
7,4061,B-GENE-Y
subtype,4061,I-GENE-Y
of,4061,I-GENE-Y
nAChRs,4061,I-GENE-Y
have,4061,O
been,4061,O
shown,4061,O
to,4061,O
improve,4061,O
cognition,4061,O
.,4061,O
Previously,4062,O
nicotine,4062,B-CHEMICAL
",",4062,O
which,4062,O
activates,4062,O
both,4062,O
7,4062,B-GENE-N
and,4062,I-GENE-N
non-7,4062,I-GENE-N
subtypes,4062,I-GENE-N
of,4062,I-GENE-N
nAChRs,4062,I-GENE-N
",",4062,O
has,4062,O
been,4062,O
shown,4062,O
to,4062,O
have,4062,O
an,4062,O
anxiogenic,4062,O
effect,4062,O
in,4062,O
behavioral,4062,O
tests,4062,O
.,4062,O
In,4063,O
this,4063,O
study,4063,O
",",4063,O
we,4063,O
compared,4063,O
the,4063,O
effects,4063,O
of,4063,O
the,4063,O
7-selective,4063,O
agonist,4063,O
(,4063,O
PNU-282987,4063,B-CHEMICAL
),4063,O
and,4063,O
PAM,4063,O
(,4063,O
PNU-120596,4063,B-CHEMICAL
),4063,O
in,4063,O
a,4063,O
variety,4063,O
of,4063,O
behavioral,4063,O
tests,4063,O
in,4063,O
Sprague,4063,O
Dawley,4063,O
rats,4063,O
to,4063,O
look,4063,O
at,4063,O
their,4063,O
effects,4063,O
on,4063,O
learning,4063,O
and,4063,O
memory,4063,O
as,4063,O
well,4063,O
as,4063,O
anxiety,4063,O
.,4063,O
We,4064,O
found,4064,O
that,4064,O
neither,4064,O
PNU-282987,4064,B-CHEMICAL
nor,4064,O
PNU-120596,4064,B-CHEMICAL
improved,4064,O
spatial-learning,4064,O
or,4064,O
episodic,4064,O
memory,4064,O
by,4064,O
themselves,4064,O
.,4064,O
However,4065,O
when,4065,O
cognitive,4065,O
impairment,4065,O
was,4065,O
induced,4065,O
in,4065,O
the,4065,O
rats,4065,O
with,4065,O
scopolamine,4065,B-CHEMICAL
(,4065,O
1,4065,O
mg/kg,4065,O
),4065,O
",",4065,O
both,4065,O
PNU-120596,4065,B-CHEMICAL
and,4065,O
PNU-282987,4065,B-CHEMICAL
were,4065,O
able,4065,O
to,4065,O
reverse,4065,O
this,4065,O
memory,4065,O
impairment,4065,O
and,4065,O
restore,4065,O
it,4065,O
back,4065,O
to,4065,O
normal,4065,O
levels,4065,O
.,4065,O
While,4066,O
PNU-120596,4066,B-CHEMICAL
reversed,4066,O
the,4066,O
scopolamine-induced,4066,O
cognitive,4066,O
impairment,4066,O
",",4066,O
it,4066,O
did,4066,O
not,4066,O
have,4066,O
any,4066,O
adverse,4066,O
effect,4066,O
on,4066,O
anxiety,4066,O
.,4066,O
PNU-282987,4067,B-CHEMICAL
on,4067,O
the,4067,O
other,4067,O
hand,4067,O
displayed,4067,O
an,4067,O
increase,4067,O
in,4067,O
anxiety-like,4067,O
behavior,4067,O
at,4067,O
a,4067,O
higher,4067,O
dose,4067,O
(,4067,O
10,4067,O
mg/kg,4067,O
),4067,O
that,4067,O
was,4067,O
significantly,4067,O
reduced,4067,O
by,4067,O
the,4067,O
serotonin,4067,B-GENE-Y
5-HT1a,4067,I-GENE-Y
receptor,4067,I-GENE-Y
antagonist,4067,O
WAY-100135,4067,B-CHEMICAL
.,4067,O
However,4068,O
the,4068,O
7,4068,B-GENE-Y
receptor,4068,I-GENE-Y
antagonist,4068,O
methyllycaconitine,4068,B-CHEMICAL
was,4068,O
unable,4068,O
to,4068,O
reverse,4068,O
these,4068,O
anxiety-like,4068,O
effects,4068,O
seen,4068,O
with,4068,O
PNU-282987,4068,B-CHEMICAL
.,4068,O
These,4069,O
results,4069,O
suggest,4069,O
that,4069,O
7,4069,B-GENE-Y
nAChR,4069,I-GENE-Y
PAMs,4069,O
are,4069,O
pharmacologically,4069,O
advantageous,4069,O
over,4069,O
agonists,4069,O
",",4069,O
and,4069,O
should,4069,O
be,4069,O
considered,4069,O
for,4069,O
further,4069,O
development,4069,O
as,4069,O
therapeutic,4069,O
drugs,4069,O
targeting,4069,O
the,4069,O
7,4069,B-GENE-Y
receptors,4069,I-GENE-Y
.,4069,O
Carnitine,4070,B-GENE-Y
palmitoyltransferase,4070,I-GENE-Y
2,4070,I-GENE-Y
and,4070,O
carnitine/acylcarnitine,4070,B-GENE-Y
translocase,4070,I-GENE-Y
are,4070,O
involved,4070,O
in,4070,O
the,4070,O
mitochondrial,4070,O
synthesis,4070,O
and,4070,O
export,4070,O
of,4070,O
acylcarnitines,4070,B-CHEMICAL
.,4070,O
Acylcarnitines,4071,B-CHEMICAL
are,4071,O
commonly,4071,O
used,4071,O
in,4071,O
the,4071,O
diagnosis,4071,O
of,4071,O
mitochondrial,4071,O
fatty,4071,B-CHEMICAL
acid,4071,I-CHEMICAL
-oxidation,4071,O
disorders,4071,O
(,4071,O
mFAODs,4071,O
),4071,O
.,4071,O
It,4072,O
is,4072,O
generally,4072,O
assumed,4072,O
that,4072,O
this,4072,O
plasma,4072,O
acylcarnitine,4072,B-CHEMICAL
profile,4072,O
reflects,4072,O
the,4072,O
mitochondrial,4072,O
accumulation,4072,O
of,4072,O
acyl-CoAs,4072,B-CHEMICAL
.,4072,O
The,4073,O
identity,4073,O
of,4073,O
the,4073,O
enzymes,4073,O
and,4073,O
the,4073,O
mitochondrial,4073,O
and,4073,O
plasmalemmal,4073,O
transporters,4073,O
involved,4073,O
in,4073,O
the,4073,O
synthesis,4073,O
and,4073,O
export,4073,O
of,4073,O
these,4073,O
metabolites,4073,O
have,4073,O
remained,4073,O
undefined,4073,O
.,4073,O
We,4074,O
used,4074,O
lentiviral,4074,O
shRNA,4074,O
to,4074,O
knock,4074,O
down,4074,O
the,4074,O
expression,4074,O
of,4074,O
medium-chain,4074,B-GENE-Y
acyl-CoA,4074,I-GENE-Y
dehydrogenase,4074,I-GENE-Y
(,4074,O
MCAD,4074,B-GENE-Y
),4074,O
in,4074,O
control,4074,O
and,4074,O
carnitine,4074,B-GENE-Y
palmitoyltransferase,4074,I-GENE-Y
2,4074,I-GENE-Y
(,4074,O
CPT2,4074,B-GENE-Y
),4074,O
-,4074,O
",",4074,O
carnitine/acylcarnitine,4074,B-GENE-Y
translocase,4074,I-GENE-Y
(,4074,O
CACT,4074,B-GENE-Y
),4074,O
-,4074,O
",",4074,O
and,4074,O
plasmalemmal,4074,O
carnitine,4074,B-GENE-N
transporter,4074,I-GENE-N
(,4074,O
OCTN2,4074,B-GENE-Y
),4074,O
-deficient,4074,O
human,4074,O
fibroblasts,4074,O
.,4074,O
These,4075,O
cell,4075,O
lines,4075,O
",",4075,O
including,4075,O
mock-transduced,4075,O
controls,4075,O
",",4075,O
were,4075,O
loaded,4075,O
with,4075,O
decanoic,4075,B-CHEMICAL
acid,4075,I-CHEMICAL
and,4075,O
carnitine,4075,B-CHEMICAL
",",4075,O
followed,4075,O
by,4075,O
the,4075,O
measurement,4075,O
of,4075,O
the,4075,O
acylcarnitine,4075,B-CHEMICAL
profile,4075,O
in,4075,O
the,4075,O
extracellular,4075,O
medium,4075,O
.,4075,O
In,4076,O
control,4076,O
fibroblasts,4076,O
",",4076,O
MCAD,4076,B-GENE-Y
knockdown,4076,O
markedly,4076,O
increased,4076,O
the,4076,O
production,4076,O
of,4076,O
octanoylcarnitine,4076,B-CHEMICAL
(,4076,O
3-fold,4076,O
",",4076,O
P,4076,O
<,4076,O
0.01,4076,O
),4076,O
.,4076,O
OCTN2-deficient,4077,B-GENE-Y
cell,4077,O
lines,4077,O
also,4077,O
showed,4077,O
extracellular,4077,O
accumulation,4077,O
of,4077,O
octanoylcarnitine,4077,B-CHEMICAL
(,4077,O
2.8-fold,4077,O
",",4077,O
P,4077,O
<,4077,O
0.01,4077,O
),4077,O
",",4077,O
suggesting,4077,O
that,4077,O
the,4077,O
cellular,4077,O
export,4077,O
of,4077,O
acylcarnitines,4077,B-CHEMICAL
does,4077,O
not,4077,O
depend,4077,O
on,4077,O
OCTN2,4077,B-GENE-Y
.,4077,O
In,4078,O
contrast,4078,O
",",4078,O
in,4078,O
CPT2-,4078,B-GENE-Y
and,4078,O
CACT-deficient,4078,B-GENE-Y
cells,4078,O
",",4078,O
the,4078,O
accumulation,4078,O
of,4078,O
octanoylcarnitine,4078,B-CHEMICAL
in,4078,O
the,4078,O
medium,4078,O
did,4078,O
not,4078,O
significantly,4078,O
increase,4078,O
in,4078,O
the,4078,O
MCAD,4078,B-GENE-Y
knockdown,4078,O
.,4078,O
Similar,4079,O
results,4079,O
were,4079,O
obtained,4079,O
using,4079,O
pharmacological,4079,O
inhibition,4079,O
of,4079,O
CPT2,4079,B-GENE-Y
in,4079,O
fibroblasts,4079,O
from,4079,O
MCAD-deficient,4079,B-GENE-Y
individuals,4079,O
.,4079,O
This,4080,O
shows,4080,O
that,4080,O
CPT2,4080,B-GENE-Y
and,4080,O
CACT,4080,B-GENE-Y
are,4080,O
crucial,4080,O
for,4080,O
mitochondrial,4080,O
acylcarnitine,4080,B-CHEMICAL
formation,4080,O
and,4080,O
export,4080,O
to,4080,O
the,4080,O
extracellular,4080,O
fluids,4080,O
in,4080,O
mFAOD.-Violante,4080,O
",",4080,O
S.,4080,O
",",4080,O
IJlst,4080,O
",",4080,O
L.,4080,O
",",4080,O
te,4080,O
Brinke,4080,O
",",4080,O
H.,4080,O
",",4080,O
Tavares,4080,O
de,4080,O
Almeida,4080,O
",",4080,O
I.,4080,O
",",4080,O
Wanders,4080,O
",",4080,O
R.,4080,O
J,4080,O
.,4080,O
A.,4081,O
",",4081,O
Ventura,4081,O
",",4081,O
F.,4081,O
V.,4081,O
",",4081,O
Houten,4081,O
",",4081,O
S.,4081,O
M.,4081,O
Carnitine,4081,B-CHEMICAL
palmitoyltransferase,4081,I-GENE-Y
2,4081,I-GENE-Y
and,4081,O
carnitine/acylcarnitine,4081,B-CHEMICAL
translocase,4081,I-GENE-Y
are,4081,O
involved,4081,O
in,4081,O
the,4081,O
mitochondrial,4081,O
synthesis,4081,O
and,4081,O
export,4081,O
of,4081,O
acylcarnitines,4081,B-CHEMICAL
.,4081,O
HOW,4082,O
GOOD,4082,O
IS,4082,O
THE,4082,O
LEVOTHYROXINE,4082,B-CHEMICAL
REPLACEMENT,4082,O
IN,4082,O
PRIMARY,4082,O
HYPOTHYROIDISM,4082,O
PATIENTS,4082,O
IN,4082,O
BRAZIL,4082,O
?,4082,O
-,4082,O
DATA,4082,O
OF,4082,O
A,4082,O
MULTICENTRE,4082,O
STUDY,4082,O
.,4082,O
Background,4083,O
:,4083,O
Studies,4083,O
done,4083,O
in,4083,O
every,4083,O
continent,4083,O
has,4083,O
shown,4083,O
that,4083,O
only,4083,O
around,4083,O
50,4083,O
%,4083,O
of,4083,O
the,4083,O
patients,4083,O
subjected,4083,O
to,4083,O
thyroid,4083,O
hormone,4083,O
replacement,4083,O
have,4083,O
TSH,4083,B-GENE-N
in,4083,O
the,4083,O
normal,4083,O
range,4083,O
.,4083,O
However,4084,O
",",4084,O
until,4084,O
to,4084,O
date,4084,O
",",4084,O
there,4084,O
are,4084,O
no,4084,O
consistent,4084,O
data,4084,O
about,4084,O
Brazil,4084,O
.,4084,O
Objectives,4085,O
:,4085,O
To,4085,O
evaluate,4085,O
levothyroxine,4085,B-CHEMICAL
(,4085,O
LT4,4085,B-CHEMICAL
),4085,O
replacement,4085,O
treatment,4085,O
in,4085,O
patients,4085,O
with,4085,O
primary,4085,O
hypothyroidism,4085,O
followed,4085,O
in,4085,O
referral,4085,O
centers,4085,O
in,4085,O
Brazil,4085,O
.,4085,O
Methods,4086,O
:,4086,O
Patients,4086,O
with,4086,O
primary,4086,O
hypothyroidism,4086,O
followed,4086,O
in,4086,O
referral,4086,O
centers,4086,O
(,4086,O
University,4086,O
Hospitals,4086,O
from,4086,O
Universidade,4086,O
Federal,4086,O
do,4086,O
Rio,4086,O
de,4086,O
Janeiro,4086,O
-UFRJ,4086,O
",",4086,O
Unicamp,4086,O
",",4086,O
Universidade,4086,O
Federal,4086,O
do,4086,O
Paran,4086,O
-,4086,O
UFPR,4086,O
and,4086,O
Universidade,4086,O
Federal,4086,O
do,4086,O
Cear-UFC,4086,O
),4086,O
answered,4086,O
a,4086,O
questionnairethat,4086,O
inquired,4086,O
about,4086,O
clinical,4086,O
and,4086,O
biochemical,4086,O
conditions,4086,O
",",4086,O
social-economic,4086,O
status,4086,O
",",4086,O
life,4086,O
quality,4086,O
and,4086,O
clinicians,4086,O
',4086,O
orientations,4086,O
as,4086,O
well,4086,O
as,4086,O
their,4086,O
understanding,4086,O
about,4086,O
the,4086,O
information,4086,O
given,4086,O
.,4086,O
Serum,4087,O
TSH,4087,B-GENE-N
was,4087,O
checked,4087,O
close,4087,O
to,4087,O
the,4087,O
interview,4087,O
.,4087,O
Results,4088,O
:,4088,O
2292,4088,O
consecutive,4088,O
patients,4088,O
met,4088,O
the,4088,O
inclusion,4088,O
criteria,4088,O
.,4088,O
Mean,4089,O
age,4089,O
51.2,4089,O
years,4089,O
and,4089,O
TSH,4089,B-GENE-N
values,4089,O
between,4089,O
0.4,4089,O
and,4089,O
4.0,4089,O
mUI/l,4089,O
were,4089,O
considered,4089,O
to,4089,O
be,4089,O
within,4089,O
the,4089,O
reference,4089,O
range,4089,O
.,4089,O
Among,4090,O
all,4090,O
patients,4090,O
taking,4090,O
thyroid,4090,O
medication,4090,O
",",4090,O
42.7,4090,O
%,4090,O
%,4090,O
had,4090,O
an,4090,O
abnormal,4090,O
serum,4090,O
TSH,4090,B-GENE-N
(,4090,O
28.3,4090,O
%,4090,O
were,4090,O
undertreated,4090,O
and,4090,O
14.4,4090,O
%,4090,O
were,4090,O
over,4090,O
treated,4090,O
),4090,O
.,4090,O
Approximately,4091,O
all,4091,O
patients,4091,O
(,4091,O
99,4091,O
%,4091,O
),4091,O
took,4091,O
LT4,4091,B-CHEMICAL
in,4091,O
the,4091,O
morning,4091,O
but,4091,O
less,4091,O
than,4091,O
30,4091,O
minutes,4091,O
before,4091,O
breakfast,4091,O
(,4091,O
85.4,4091,O
%,4091,O
),4091,O
.,4091,O
Regarding,4092,O
the,4092,O
clinicians,4092,O
orientations,4092,O
:,4092,O
97.5,4092,O
%,4092,O
of,4092,O
the,4092,O
patients,4092,O
were,4092,O
instructed,4092,O
to,4092,O
take,4092,O
the,4092,O
medication,4092,O
daily,4092,O
",",4092,O
and,4092,O
92.6,4092,O
%,4092,O
to,4092,O
take,4092,O
30,4092,O
minutes,4092,O
before,4092,O
breakfast,4092,O
(,4092,O
92.6,4092,O
%,4092,O
),4092,O
.,4092,O
However,4093,O
",",4093,O
only,4093,O
52.1,4093,O
%,4093,O
were,4093,O
told,4093,O
that,4093,O
not,4093,O
to,4093,O
take,4093,O
LT4,4093,B-CHEMICAL
along,4093,O
with,4093,O
other,4093,O
medication,4093,O
.,4093,O
Conclusions,4094,O
:,4094,O
Our,4094,O
study,4094,O
found,4094,O
that,4094,O
there,4094,O
was,4094,O
a,4094,O
significant,4094,O
number,4094,O
of,4094,O
patients,4094,O
taking,4094,O
thyroid,4094,O
hormones,4094,O
were,4094,O
not,4094,O
in,4094,O
the,4094,O
therapeutic,4094,O
range,4094,O
.,4094,O
Clinicians,4095,O
should,4095,O
",",4095,O
therefore,4095,O
",",4095,O
consider,4095,O
monitoring,4095,O
patients,4095,O
on,4095,O
thyroid,4095,O
replacement,4095,O
more,4095,O
frequently,4095,O
and,4095,O
being,4095,O
more,4095,O
precise,4095,O
on,4095,O
giving,4095,O
recommendations,4095,O
about,4095,O
the,4095,O
correct,4095,O
use,4095,O
of,4095,O
LT4,4095,B-CHEMICAL
.,4095,O
Bioactive,4096,O
abietane,4096,B-CHEMICAL
and,4096,O
ent-kaurane,4096,B-CHEMICAL
diterpenoids,4096,B-CHEMICAL
from,4096,O
Isodon,4096,O
tenuifolius,4096,O
.,4096,O
Three,4097,O
new,4097,O
abietane,4097,B-CHEMICAL
diterpenoids,4097,B-CHEMICAL
",",4097,O
isoabietenins,4097,B-CHEMICAL
A-C,4097,I-CHEMICAL
(,4097,O
1-3,4097,O
),4097,O
",",4097,O
and,4097,O
13,4097,O
new,4097,O
ent-kauranoids,4097,B-CHEMICAL
",",4097,O
tenuifolins,4097,B-CHEMICAL
A-M,4097,I-CHEMICAL
(,4097,O
4-16,4097,O
),4097,O
",",4097,O
along,4097,O
with,4097,O
four,4097,O
known,4097,O
compounds,4097,O
(,4097,O
17-20,4097,O
),4097,O
",",4097,O
were,4097,O
isolated,4097,O
from,4097,O
the,4097,O
aerial,4097,O
parts,4097,O
of,4097,O
Isodon,4097,O
tenuifolius,4097,O
.,4097,O
The,4098,O
structures,4098,O
of,4098,O
the,4098,O
new,4098,O
metabolites,4098,O
were,4098,O
established,4098,O
on,4098,O
the,4098,O
basis,4098,O
of,4098,O
detailed,4098,O
spectroscopic,4098,O
analysis,4098,O
.,4098,O
The,4099,O
absolute,4099,O
configurations,4099,O
of,4099,O
1,4099,O
",",4099,O
15,4099,O
",",4099,O
and,4099,O
16,4099,O
were,4099,O
confirmed,4099,O
by,4099,O
single-crystal,4099,O
X-ray,4099,O
diffraction,4099,O
.,4099,O
Selected,4100,O
compounds,4100,O
were,4100,O
evaluated,4100,O
for,4100,O
their,4100,O
cytotoxicity,4100,O
against,4100,O
a,4100,O
small,4100,O
panel,4100,O
of,4100,O
human,4100,O
tumor,4100,O
cell,4100,O
lines,4100,O
",",4100,O
and,4100,O
some,4100,O
compounds,4100,O
showed,4100,O
inhibitory,4100,O
effects,4100,O
.,4100,O
Furthermore,4101,O
",",4101,O
several,4101,O
isolates,4101,O
exhibited,4101,O
inhibitory,4101,O
activity,4101,O
against,4101,O
nitric,4101,B-CHEMICAL
oxide,4101,I-CHEMICAL
production,4101,O
in,4101,O
LPS-activated,4101,O
RAW264.7,4101,O
macrophages,4101,O
.,4101,O
Alkaloids,4102,O
from,4102,O
Microcos,4102,O
paniculata,4102,O
with,4102,O
cytotoxic,4102,O
and,4102,O
nicotinic,4102,B-GENE-N
receptor,4102,I-GENE-N
antagonistic,4102,O
activities,4102,O
.,4102,O
Microcos,4103,O
paniculata,4103,O
is,4103,O
a,4103,O
large,4103,O
shrub,4103,O
or,4103,O
small,4103,O
tree,4103,O
that,4103,O
grows,4103,O
in,4103,O
several,4103,O
countries,4103,O
in,4103,O
South,4103,O
and,4103,O
Southeast,4103,O
Asia,4103,O
.,4103,O
In,4104,O
the,4104,O
present,4104,O
study,4104,O
",",4104,O
three,4104,O
new,4104,O
piperidine,4104,B-CHEMICAL
alkaloids,4104,I-CHEMICAL
",",4104,O
microgrewiapines,4104,B-CHEMICAL
A-C,4104,I-CHEMICAL
(,4104,O
1-3,4104,O
),4104,O
",",4104,O
as,4104,O
well,4104,O
as,4104,O
three,4104,O
known,4104,O
compounds,4104,O
",",4104,O
inclusive,4104,O
of,4104,O
microcosamine,4104,B-CHEMICAL
A,4104,I-CHEMICAL
(,4104,O
4,4104,O
),4104,O
",",4104,O
7'-,4104,B-CHEMICAL
(,4104,I-CHEMICAL
"3',4'-dihydroxyphenyl",4104,I-CHEMICAL
),4104,I-CHEMICAL
-N-,4104,I-CHEMICAL
[,4104,I-CHEMICAL
4-methoxyphenyl,4104,I-CHEMICAL
),4104,I-CHEMICAL
ethyl,4104,I-CHEMICAL
],4104,I-CHEMICAL
propenamide,4104,I-CHEMICAL
(,4104,O
5,4104,O
),4104,O
",",4104,O
and,4104,O
liriodenine,4104,B-CHEMICAL
(,4104,O
6,4104,O
),4104,O
",",4104,O
were,4104,O
isolated,4104,O
from,4104,O
cytotoxic,4104,O
fractions,4104,O
of,4104,O
the,4104,O
separate,4104,O
chloroform-soluble,4104,B-CHEMICAL
extracts,4104,O
of,4104,O
the,4104,O
stem,4104,O
bark,4104,O
",",4104,O
branches,4104,O
",",4104,O
and,4104,O
leaves,4104,O
of,4104,O
M.,4104,O
paniculata,4104,O
.,4104,O
Compounds,4105,O
1-6,4105,O
and,4105,O
1a,4105,O
(,4105,O
microgrewiapine,4105,B-CHEMICAL
A,4105,I-CHEMICAL
3-acetate,4105,I-CHEMICAL
),4105,O
showed,4105,O
a,4105,O
range,4105,O
of,4105,O
cytotoxicity,4105,O
values,4105,O
against,4105,O
the,4105,O
HT-29,4105,O
human,4105,O
colon,4105,O
cancer,4105,O
cell,4105,O
line,4105,O
.,4105,O
When,4106,O
evaluated,4106,O
for,4106,O
their,4106,O
effects,4106,O
on,4106,O
human,4106,B-GENE-N
34,4106,I-GENE-N
or,4106,I-GENE-N
42,4106,I-GENE-N
nicotinic,4106,I-GENE-N
acetylcholine,4106,B-CHEMICAL
receptors,4106,I-GENE-N
(,4106,O
nAChRs,4106,B-GENE-N
),4106,O
",",4106,O
several,4106,O
of,4106,O
these,4106,O
compounds,4106,O
were,4106,O
shown,4106,O
to,4106,O
be,4106,O
active,4106,O
as,4106,O
nAChR,4106,B-GENE-N
antagonists,4106,O
.,4106,O
As,4107,O
a,4107,O
result,4107,O
of,4107,O
this,4107,O
study,4107,O
",",4107,O
microgrewiapine,4107,B-CHEMICAL
A,4107,I-CHEMICAL
(,4107,O
1,4107,O
),4107,O
was,4107,O
found,4107,O
to,4107,O
be,4107,O
a,4107,O
selective,4107,O
cytotoxic,4107,O
agent,4107,O
for,4107,O
colon,4107,O
cancer,4107,O
cells,4107,O
over,4107,O
normal,4107,O
colon,4107,O
cells,4107,O
and,4107,O
to,4107,O
exhibit,4107,O
nicotinic,4107,B-GENE-N
receptor,4107,I-GENE-N
antagonistic,4107,O
activity,4107,O
for,4107,O
both,4107,O
the,4107,O
h34,4107,B-GENE-N
and,4107,I-GENE-N
h42,4107,I-GENE-N
receptor,4107,I-GENE-N
subtypes,4107,O
.,4107,O
The,4108,O
transcription,4108,B-GENE-Y
factor,4108,I-GENE-Y
Pitx3,4108,I-GENE-Y
is,4108,O
expressed,4108,O
selectively,4108,O
in,4108,O
midbrain,4108,O
dopaminergic,4108,O
neurons,4108,O
susceptible,4108,O
to,4108,O
neurodegenerative,4108,O
stress,4108,O
.,4108,O
The,4109,O
homeodomain,4109,B-GENE-Y
transcription,4109,I-GENE-Y
factor,4109,I-GENE-Y
Pitx3,4109,I-GENE-Y
is,4109,O
critical,4109,O
for,4109,O
the,4109,O
survival,4109,O
of,4109,O
midbrain,4109,O
dopaminergic,4109,O
(,4109,O
mDA,4109,O
),4109,O
neurons,4109,O
.,4109,O
Pitx3-deficient,4110,B-GENE-Y
mice,4110,O
exhibit,4110,O
severe,4110,O
but,4110,O
selective,4110,O
developmental,4110,O
loss,4110,O
of,4110,O
mDA,4110,O
neurons,4110,O
",",4110,O
with,4110,O
accompanying,4110,O
locomotor,4110,O
deficits,4110,O
resembling,4110,O
those,4110,O
seen,4110,O
in,4110,O
Parkinson,4110,O
's,4110,O
disease,4110,O
(,4110,O
PD,4110,O
),4110,O
models,4110,O
.,4110,O
Here,4111,O
",",4111,O
we,4111,O
identify,4111,O
specific,4111,O
mDA,4111,O
cell,4111,O
subpopulations,4111,O
that,4111,O
are,4111,O
consistently,4111,O
spared,4111,O
in,4111,O
adult,4111,O
Pitx3-hypomorphic,4111,B-GENE-Y
(,4111,O
aphakia,4111,O
),4111,O
mice,4111,O
",",4111,O
demonstrating,4111,O
that,4111,O
Pitx3,4111,B-GENE-Y
is,4111,O
not,4111,O
indiscriminately,4111,O
required,4111,O
by,4111,O
all,4111,O
mDA,4111,O
neurons,4111,O
for,4111,O
their,4111,O
survival,4111,O
.,4111,O
In,4112,O
aphakia,4112,O
mice,4112,O
",",4112,O
virtually,4112,O
all,4112,O
surviving,4112,O
mDA,4112,O
neurons,4112,O
in,4112,O
the,4112,O
substantia,4112,O
nigra,4112,O
(,4112,O
SN,4112,O
),4112,O
and,4112,O
the,4112,O
majority,4112,O
of,4112,O
neurons,4112,O
in,4112,O
the,4112,O
adjacent,4112,O
ventral,4112,O
tegmental,4112,O
area,4112,O
(,4112,O
VTA,4112,O
),4112,O
also,4112,O
express,4112,O
calbindin-D28k,4112,B-GENE-Y
",",4112,O
a,4112,O
calcium-binding,4112,B-CHEMICAL
protein,4112,I-GENE-N
previously,4112,O
associated,4112,O
with,4112,O
resistance,4112,O
to,4112,O
injury,4112,O
in,4112,O
PD,4112,O
and,4112,O
in,4112,O
animal,4112,O
models,4112,O
.,4112,O
Cell-mapping,4113,O
studies,4113,O
in,4113,O
wild-type,4113,O
mice,4113,O
revealed,4113,O
that,4113,O
Pitx3,4113,B-GENE-Y
is,4113,O
primarily,4113,O
expressed,4113,O
in,4113,O
the,4113,O
ventral,4113,O
SN,4113,O
",",4113,O
a,4113,O
region,4113,O
particularly,4113,O
susceptible,4113,O
to,4113,O
MPTP,4113,B-CHEMICAL
and,4113,O
other,4113,O
dopaminergic,4113,O
neurotoxins,4113,O
.,4113,O
Furthermore,4114,O
",",4114,O
Pitx3-expressing,4114,B-GENE-Y
SN,4114,O
cells,4114,O
are,4114,O
preferentially,4114,O
lost,4114,O
following,4114,O
MPTP,4114,B-CHEMICAL
treatment,4114,O
.,4114,O
Finally,4115,O
",",4115,O
SN,4115,O
mDA,4115,O
neurons,4115,O
in,4115,O
Pitx3,4115,B-GENE-Y
hemizygous,4115,O
mice,4115,O
show,4115,O
increased,4115,O
sensitivity,4115,O
when,4115,O
exposed,4115,O
to,4115,O
MPTP,4115,B-CHEMICAL
.,4115,O
Thus,4116,O
",",4116,O
SN,4116,O
mDA,4116,O
neurons,4116,O
are,4116,O
represented,4116,O
by,4116,O
at,4116,O
least,4116,O
two,4116,O
distinct,4116,O
subpopulations,4116,O
including,4116,O
MPTP-resistant,4116,B-CHEMICAL
Pitx3-autonomous,4116,B-GENE-Y
",",4116,O
calbindin-positive,4116,B-GENE-Y
neurons,4116,O
",",4116,O
and,4116,O
calbindin-negative,4116,B-GENE-Y
Pitx-3-dependent,4116,B-GENE-Y
cells,4116,O
that,4116,O
display,4116,O
elevated,4116,O
vulnerability,4116,O
to,4116,O
toxic,4116,O
injury,4116,O
",",4116,O
and,4116,O
probably,4116,O
correspond,4116,O
to,4116,O
the,4116,O
subpopulation,4116,O
that,4116,O
degenerates,4116,O
in,4116,O
PD,4116,O
.,4116,O
Impairment,4117,O
of,4117,O
Pitx3-dependent,4117,B-GENE-Y
pathways,4117,O
therefore,4117,O
increases,4117,O
vulnerability,4117,O
of,4117,O
mDA,4117,O
neurons,4117,O
to,4117,O
toxic,4117,O
injury,4117,O
.,4117,O
Together,4118,O
",",4118,O
these,4118,O
data,4118,O
suggest,4118,O
a,4118,O
novel,4118,O
link,4118,O
between,4118,O
Pitx3,4118,B-GENE-Y
function,4118,O
and,4118,O
the,4118,O
selective,4118,O
pattern,4118,O
of,4118,O
mDA,4118,O
cell,4118,O
loss,4118,O
observed,4118,O
in,4118,O
PD,4118,O
.,4118,O
Inactivation,4119,O
of,4119,O
BAD,4119,B-GENE-Y
by,4119,O
IKK,4119,B-GENE-N
inhibits,4119,O
TNF-induced,4119,B-GENE-Y
apoptosis,4119,O
independently,4119,O
of,4119,O
NF-B,4119,B-GENE-N
activation,4119,O
.,4119,O
The,4120,O
IB,4120,B-GENE-N
kinase,4120,I-GENE-N
complex,4120,O
(,4120,O
IKK,4120,B-GENE-N
),4120,O
is,4120,O
a,4120,O
key,4120,O
regulator,4120,O
of,4120,O
immune,4120,O
responses,4120,O
",",4120,O
inflammation,4120,O
",",4120,O
cell,4120,O
survival,4120,O
",",4120,O
and,4120,O
tumorigenesis,4120,O
.,4120,O
The,4121,O
prosurvival,4121,O
function,4121,O
of,4121,O
IKK,4121,B-GENE-N
centers,4121,O
on,4121,O
activation,4121,O
of,4121,O
the,4121,O
transcription,4121,O
factor,4121,O
NF-B,4121,B-GENE-N
",",4121,O
whose,4121,O
target,4121,O
gene,4121,O
products,4121,O
inhibit,4121,O
caspases,4121,B-GENE-N
and,4121,O
prevent,4121,O
prolonged,4121,O
JNK,4121,B-GENE-N
activation,4121,O
.,4121,O
Here,4122,O
",",4122,O
we,4122,O
report,4122,O
that,4122,O
inactivation,4122,O
of,4122,O
the,4122,O
BH3-only,4122,B-GENE-N
protein,4122,O
BAD,4122,B-GENE-Y
by,4122,O
IKK,4122,B-GENE-N
independently,4122,O
of,4122,O
NF-B,4122,B-GENE-N
activation,4122,O
suppresses,4122,O
TNF-induced,4122,B-GENE-Y
apoptosis,4122,O
.,4122,O
TNF-treated,4123,B-GENE-Y
Ikk,4123,B-GENE-Y
(,4123,O
-/-,4123,O
),4123,O
mouse,4123,O
embryonic,4123,O
fibroblasts,4123,O
(,4123,O
MEFs,4123,O
),4123,O
undergo,4123,O
apoptosis,4123,O
significantly,4123,O
faster,4123,O
than,4123,O
MEFs,4123,O
deficient,4123,O
in,4123,O
both,4123,O
RelA,4123,B-GENE-Y
and,4123,O
cRel,4123,B-GENE-Y
due,4123,O
to,4123,O
lack,4123,O
of,4123,O
inhibition,4123,O
of,4123,O
BAD,4123,B-GENE-Y
by,4123,O
IKK,4123,B-GENE-N
.,4123,O
IKK,4124,B-GENE-N
phosphorylates,4124,O
BAD,4124,B-GENE-Y
at,4124,O
serine-26,4124,B-CHEMICAL
(,4124,O
Ser26,4124,B-CHEMICAL
),4124,O
and,4124,O
primes,4124,O
it,4124,O
for,4124,O
inactivation,4124,O
.,4124,O
Elimination,4125,O
of,4125,O
Ser26,4125,B-CHEMICAL
phosphorylation,4125,O
promotes,4125,O
BAD,4125,B-GENE-Y
proapoptotic,4125,O
activity,4125,O
",",4125,O
thereby,4125,O
accelerating,4125,O
TNF-induced,4125,B-GENE-Y
apoptosis,4125,O
in,4125,O
cultured,4125,O
cells,4125,O
and,4125,O
increasing,4125,O
mortality,4125,O
in,4125,O
animals,4125,O
.,4125,O
Our,4126,O
results,4126,O
reveal,4126,O
that,4126,O
IKK,4126,B-GENE-N
inhibits,4126,O
TNF-induced,4126,B-GENE-Y
apoptosis,4126,O
through,4126,O
two,4126,O
distinct,4126,O
but,4126,O
cooperative,4126,O
mechanisms,4126,O
:,4126,O
activation,4126,O
of,4126,O
the,4126,O
survival,4126,O
factor,4126,O
NF-B,4126,B-GENE-N
and,4126,O
inactivation,4126,O
of,4126,O
the,4126,O
proapoptotic,4126,O
BH3-only,4126,B-GENE-N
BAD,4126,B-GENE-Y
protein,4126,O
.,4126,O
Almorexant,4127,B-CHEMICAL
effects,4127,O
on,4127,O
CYP3A4,4127,B-GENE-Y
activity,4127,O
studied,4127,O
by,4127,O
its,4127,O
simultaneous,4127,O
and,4127,O
time-separated,4127,O
administration,4127,O
with,4127,O
simvastatin,4127,B-CHEMICAL
and,4127,O
atorvastatin,4127,B-CHEMICAL
.,4127,O
PURPOSE,4128,O
:,4128,O
To,4128,O
characterise,4128,O
further,4128,O
the,4128,O
previously,4128,O
observed,4128,O
cytochrome,4128,B-GENE-Y
P450,4128,I-GENE-Y
3A4,4128,I-GENE-Y
(,4128,O
CYP3A4,4128,B-GENE-Y
),4128,O
interaction,4128,O
of,4128,O
the,4128,O
dual,4128,O
orexin,4128,B-GENE-N
receptor,4128,I-GENE-N
antagonist,4128,O
almorexant,4128,B-CHEMICAL
.,4128,O
METHODS,4129,O
:,4129,O
Pharmacokinetic,4129,O
interactions,4129,O
were,4129,O
investigated,4129,O
(,4129,O
n,4129,O
=,4129,O
14,4129,O
healthy,4129,O
male,4129,O
subjects,4129,O
in,4129,O
two,4129,O
treatment,4129,O
groups,4129,O
),4129,O
between,4129,O
almorexant,4129,B-CHEMICAL
at,4129,O
steady-state,4129,O
when,4129,O
administered,4129,O
either,4129,O
concomitantly,4129,O
or,4129,O
2,4129,O
h,4129,O
after,4129,O
administration,4129,O
of,4129,O
single,4129,O
doses,4129,O
of,4129,O
simvastatin,4129,B-CHEMICAL
(,4129,O
40,4129,O
mg,4129,O
),4129,O
or,4129,O
atorvastatin,4129,B-CHEMICAL
(,4129,O
40,4129,O
mg,4129,O
),4129,O
.,4129,O
RESULTS,4130,O
:,4130,O
Almorexant,4130,B-CHEMICAL
dose-dependently,4130,O
increased,4130,O
simvastatin,4130,B-CHEMICAL
exposure,4130,O
(,4130,O
AUC,4130,O
(,4130,O
0-,4130,O
),4130,O
),4130,O
when,4130,O
administered,4130,O
concomitantly,4130,O
[,4130,O
geometric,4130,O
mean,4130,O
ratios,4130,O
(,4130,O
90,4130,O
%,4130,O
CI,4130,O
),4130,O
:,4130,O
2.5,4130,O
(,4130,O
2.1,4130,O
",",4130,O
2.9,4130,O
),4130,O
(,4130,O
100,4130,O
mg,4130,O
),4130,O
",",4130,O
3.9,4130,O
(,4130,O
3.3,4130,O
",",4130,O
4.6,4130,O
),4130,O
(,4130,O
200,4130,O
mg,4130,O
),4130,O
],4130,O
",",4130,O
but,4130,O
not,4130,O
C,4130,O
(,4130,O
max,4130,O
),4130,O
[,4130,O
3.7,4130,O
(,4130,O
3.0,4130,O
",",4130,O
4.5,4130,O
),4130,O
for,4130,O
both,4130,O
doses,4130,O
],4130,O
.,4130,O
Time-separated,4131,O
administration,4131,O
resulted,4131,O
in,4131,O
relevant,4131,O
reductions,4131,O
of,4131,O
the,4131,O
interaction,4131,O
[,4131,O
AUC,4131,O
(,4131,O
0-,4131,O
),4131,O
:,4131,O
1.4,4131,O
(,4131,O
1.2,4131,O
",",4131,O
1.7,4131,O
),4131,O
(,4131,O
100,4131,O
mg,4131,O
),4131,O
",",4131,O
1.7,4131,O
(,4131,O
1.5,4131,O
",",4131,O
2.0,4131,O
),4131,O
(,4131,O
200,4131,O
mg,4131,O
),4131,O
;,4131,O
C,4131,O
(,4131,O
max,4131,O
),4131,O
:,4131,O
1.5,4131,O
(,4131,O
1.3,4131,O
",",4131,O
1.9,4131,O
),4131,O
(,4131,O
100,4131,O
mg,4131,O
),4131,O
",",4131,O
1.9,4131,O
(,4131,O
1.6,4131,O
",",4131,O
2.4,4131,O
),4131,O
(,4131,O
200,4131,O
mg,4131,O
),4131,O
],4131,O
.,4131,O
Similar,4132,O
results,4132,O
were,4132,O
obtained,4132,O
for,4132,O
hydroxyacid,4132,B-CHEMICAL
simvastatin,4132,I-CHEMICAL
.,4132,O
Independent,4133,O
of,4133,O
almorexant,4133,B-CHEMICAL
dose,4133,O
and,4133,O
relative,4133,O
time,4133,O
of,4133,O
administration,4133,O
",",4133,O
AUC,4133,O
(,4133,O
0-,4133,O
),4133,O
and,4133,O
C,4133,O
(,4133,O
max,4133,O
),4133,O
of,4133,O
atorvastatin,4133,B-CHEMICAL
increased,4133,O
(,4133,O
ratios,4133,O
ranged,4133,O
from,4133,O
1.1,4133,O
to,4133,O
1.5,4133,O
),4133,O
.,4133,O
AUC,4134,O
(,4134,O
0-,4134,O
),4134,O
and,4134,O
C,4134,O
(,4134,O
max,4134,O
),4134,O
of,4134,O
o-hydroxy,4134,B-CHEMICAL
atorvastatin,4134,I-CHEMICAL
decreased,4134,O
dose-independently,4134,O
[,4134,O
AUC,4134,O
(,4134,O
0-,4134,O
),4134,O
:,4134,O
0.8,4134,O
(,4134,O
0.8,4134,O
",",4134,O
0.9,4134,O
),4134,O
(,4134,O
100,4134,O
mg,4134,O
),4134,O
",",4134,O
0.6,4134,O
(,4134,O
0.5,4134,O
",",4134,O
0.6,4134,O
),4134,O
(,4134,O
200,4134,O
mg,4134,O
),4134,O
;,4134,O
C,4134,O
(,4134,O
max,4134,O
),4134,O
:,4134,O
0.3,4134,O
(,4134,O
0.3,4134,O
",",4134,O
0.4,4134,O
),4134,O
(,4134,O
100,4134,O
mg,4134,O
),4134,O
",",4134,O
0.2,4134,O
(,4134,O
0.2,4134,O
",",4134,O
0.3,4134,O
),4134,O
(,4134,O
200,4134,O
mg,4134,O
),4134,O
],4134,O
when,4134,O
atorvastatin,4134,B-CHEMICAL
was,4134,O
concomitantly,4134,O
administered,4134,O
.,4134,O
C,4135,O
(,4135,O
max,4135,O
),4135,O
of,4135,O
o-hydroxy,4135,B-CHEMICAL
atorvastatin,4135,I-CHEMICAL
slightly,4135,O
decreased,4135,O
(,4135,O
0.8,4135,O
for,4135,O
both,4135,O
doses,4135,O
),4135,O
following,4135,O
time-separated,4135,O
administration,4135,O
;,4135,O
AUC,4135,O
(,4135,O
0-,4135,O
),4135,O
was,4135,O
unchanged,4135,O
.,4135,O
CONCLUSIONS,4136,O
:,4136,O
Whereas,4136,O
almorexant,4136,B-CHEMICAL
increased,4136,O
simvastatin,4136,B-CHEMICAL
exposure,4136,O
dose-,4136,O
and,4136,O
relative,4136,O
time,4136,O
of,4136,O
administration-dependently,4136,O
",",4136,O
atorvastatin,4136,B-CHEMICAL
exposure,4136,O
increased,4136,O
to,4136,O
a,4136,O
smaller,4136,O
extent,4136,O
and,4136,O
irrespective,4136,O
of,4136,O
dose,4136,O
and,4136,O
time,4136,O
.,4136,O
This,4137,O
suggests,4137,O
that,4137,O
the,4137,O
observed,4137,O
interaction,4137,O
of,4137,O
almorexant,4137,B-CHEMICAL
with,4137,O
simvastatin,4137,B-CHEMICAL
is,4137,O
mainly,4137,O
caused,4137,O
by,4137,O
intestinal,4137,O
CYP3A4,4137,B-GENE-Y
inhibition,4137,O
",",4137,O
whereas,4137,O
the,4137,O
interaction,4137,O
with,4137,O
atorvastatin,4137,B-CHEMICAL
is,4137,O
more,4137,O
due,4137,O
to,4137,O
hepatic,4137,O
CYP3A4,4137,B-GENE-Y
inhibition,4137,O
.,4137,O
Assessment,4138,O
of,4138,O
effects,4138,O
of,4138,O
IR,4138,O
and,4138,O
IPC,4138,O
on,4138,O
activities,4138,O
of,4138,O
cytochrome,4138,B-GENE-N
P450,4138,I-GENE-N
isozymes,4138,O
in,4138,O
rats,4138,O
by,4138,O
a,4138,O
five-drug,4138,O
cocktail,4138,O
approach,4138,O
.,4138,O
Abstract,4139,O
Background,4139,O
and,4139,O
objective,4139,O
:,4139,O
To,4139,O
evaluate,4139,O
the,4139,O
effects,4139,O
of,4139,O
ischemia,4139,O
and,4139,O
reperfusion,4139,O
(,4139,O
IR,4139,O
),4139,O
and,4139,O
ischemic,4139,O
preconditioning,4139,O
(,4139,O
IPC,4139,O
),4139,O
on,4139,O
the,4139,O
metabolic,4139,O
activities,4139,O
of,4139,O
cytochrome,4139,B-GENE-N
P450,4139,I-GENE-N
(,4139,O
CYP,4139,B-GENE-N
),4139,O
isozymes,4139,O
in,4139,O
rats,4139,O
by,4139,O
a,4139,O
five-drug,4139,O
cocktail,4139,O
approach,4139,O
.,4139,O
Methods,4140,O
:,4140,O
Cocktail,4140,O
approach,4140,O
was,4140,O
used,4140,O
to,4140,O
evaluate,4140,O
the,4140,O
influence,4140,O
of,4140,O
IR,4140,O
and,4140,O
IPC,4140,O
on,4140,O
the,4140,O
activities,4140,O
of,4140,O
CYP1A2,4140,B-GENE-Y
",",4140,O
CYP2C9,4140,B-GENE-Y
",",4140,O
CYP2E1,4140,B-GENE-Y
",",4140,O
CYP2D6,4140,B-GENE-Y
and,4140,O
CYP3A4,4140,B-GENE-Y
",",4140,O
which,4140,O
were,4140,O
reflected,4140,O
by,4140,O
the,4140,O
changes,4140,O
of,4140,O
pharmacokinetic,4140,O
parameters,4140,O
of,4140,O
five,4140,O
specific,4140,O
probe,4140,O
drugs,4140,O
:,4140,O
caffeine,4140,B-CHEMICAL
",",4140,O
chlorzoxazone,4140,B-CHEMICAL
",",4140,O
tolbutamide,4140,B-CHEMICAL
",",4140,O
metoprolol,4140,B-CHEMICAL
and,4140,O
midazolam,4140,B-CHEMICAL
",",4140,O
respectively,4140,O
.,4140,O
Rats,4141,O
were,4141,O
randomly,4141,O
divided,4141,O
into,4141,O
IR,4141,O
",",4141,O
IPC,4141,O
and,4141,O
sham,4141,O
groups,4141,O
",",4141,O
and,4141,O
then,4141,O
injected,4141,O
the,4141,O
mixture,4141,O
of,4141,O
five,4141,O
probe,4141,O
drugs,4141,O
.,4141,O
Blood,4142,O
samples,4142,O
were,4142,O
collected,4142,O
at,4142,O
a,4142,O
series,4142,O
of,4142,O
time-points,4142,O
and,4142,O
the,4142,O
concentrations,4142,O
of,4142,O
probe,4142,O
drugs,4142,O
in,4142,O
plasma,4142,O
were,4142,O
determined,4142,O
by,4142,O
a,4142,O
HPLC,4142,O
method,4142,O
with,4142,O
UV,4142,O
detection,4142,O
.,4142,O
The,4143,O
pharmacokinetic,4143,O
parameters,4143,O
were,4143,O
calculated,4143,O
by,4143,O
the,4143,O
software,4143,O
of,4143,O
DAS,4143,O
2.0,4143,O
.,4143,O
Results,4144,O
:,4144,O
The,4144,O
parameters,4144,O
including,4144,O
t,4144,O
(,4144,O
1/2,4144,O
),4144,O
",",4144,O
CLs,4144,O
",",4144,O
AUC,4144,O
",",4144,O
MRT,4144,O
and,4144,O
K,4144,O
(,4144,O
10,4144,O
),4144,O
exhibited,4144,O
a,4144,O
similar,4144,O
tendency,4144,O
for,4144,O
both,4144,O
IR,4144,O
and,4144,O
IPC,4144,O
groups,4144,O
.,4144,O
Compared,4145,O
with,4145,O
sham,4145,O
group,4145,O
",",4145,O
CLs,4145,O
and,4145,O
K,4145,O
(,4145,O
10,4145,O
),4145,O
of,4145,O
five,4145,O
probe,4145,O
drugs,4145,O
were,4145,O
significantly,4145,O
lower,4145,O
(,4145,O
p,4145,O
<,4145,O
0.05,4145,O
),4145,O
",",4145,O
AUC,4145,O
and,4145,O
t,4145,O
(,4145,O
1/2,4145,O
),4145,O
of,4145,O
five,4145,O
or,4145,O
some,4145,O
probe,4145,O
drugs,4145,O
were,4145,O
significantly,4145,O
increased,4145,O
in,4145,O
IR,4145,O
and,4145,O
IPC,4145,O
groups,4145,O
(,4145,O
p,4145,O
<,4145,O
0.05,4145,O
),4145,O
.,4145,O
Compared,4146,O
with,4146,O
IPC,4146,O
group,4146,O
",",4146,O
CLs,4146,O
of,4146,O
five,4146,O
probe,4146,O
drugs,4146,O
were,4146,O
decreased,4146,O
and,4146,O
AUC,4146,O
were,4146,O
significantly,4146,O
increased,4146,O
in,4146,O
the,4146,O
IR,4146,O
group,4146,O
(,4146,O
p,4146,O
<,4146,O
0.05,4146,O
),4146,O
.,4146,O
Conclusion,4147,O
:,4147,O
IR,4147,O
can,4147,O
variably,4147,O
decrease,4147,O
the,4147,O
activities,4147,O
of,4147,O
CYP,4147,B-GENE-N
isozymes,4147,I-GENE-N
in,4147,O
rats,4147,O
and,4147,O
this,4147,O
decrease,4147,O
can,4147,O
be,4147,O
attenuated,4147,O
by,4147,O
IPC,4147,O
.,4147,O
The,4148,O
factor,4148,B-GENE-Y
VII-activating,4148,I-GENE-Y
protease,4148,I-GENE-Y
(,4148,O
FSAP,4148,B-GENE-Y
),4148,O
enhances,4148,O
the,4148,O
activity,4148,O
of,4148,O
bone,4148,B-GENE-Y
morphogenetic,4148,I-GENE-Y
protein-2,4148,I-GENE-Y
(,4148,O
BMP-2,4148,B-GENE-Y
),4148,O
.,4148,O
Factor,4149,B-GENE-Y
VII-activating,4149,I-GENE-Y
protease,4149,I-GENE-Y
(,4149,O
FSAP,4149,B-GENE-Y
),4149,O
is,4149,O
a,4149,O
circulating,4149,O
protease,4149,B-GENE-N
involved,4149,O
in,4149,O
the,4149,O
pathogenesis,4149,O
of,4149,O
atherosclerosis,4149,O
",",4149,O
calcification,4149,O
",",4149,O
and,4149,O
fibrotic,4149,O
processes,4149,O
.,4149,O
To,4150,O
understand,4150,O
how,4150,O
FSAP,4150,B-GENE-Y
controls,4150,O
the,4150,O
balance,4150,O
of,4150,O
local,4150,O
growth,4150,O
factors,4150,O
",",4150,O
we,4150,O
have,4150,O
investigated,4150,O
its,4150,O
effect,4150,O
on,4150,O
the,4150,O
regulation,4150,O
of,4150,O
bone,4150,B-GENE-N
morphogenetic,4150,I-GENE-N
proteins,4150,I-GENE-N
(,4150,O
BMPs,4150,B-GENE-N
),4150,O
.,4150,O
BMP-2,4151,B-GENE-Y
is,4151,O
produced,4151,O
as,4151,O
a,4151,O
large,4151,O
pro-form,4151,O
and,4151,O
secreted,4151,O
as,4151,O
a,4151,O
mature,4151,O
heparin-binding,4151,B-GENE-Y
growth,4151,I-GENE-Y
factor,4151,I-GENE-Y
after,4151,O
intracellular,4151,O
processing,4151,O
by,4151,O
pro-protein,4151,B-GENE-N
convertases,4151,I-GENE-N
(,4151,O
PCs,4151,B-GENE-N
),4151,O
.,4151,O
In,4152,O
this,4152,O
study,4152,O
",",4152,O
we,4152,O
discovered,4152,O
that,4152,O
FSAP,4152,B-GENE-Y
enhances,4152,O
the,4152,O
biological,4152,O
activity,4152,O
of,4152,O
mature,4152,O
BMP-2,4152,B-GENE-Y
as,4152,O
well,4152,O
as,4152,O
its,4152,O
pro-form,4152,O
",",4152,O
as,4152,O
shown,4152,O
by,4152,O
osteogenic,4152,O
differentiation,4152,O
of,4152,O
C2C12,4152,O
myoblasts,4152,O
.,4152,O
These,4153,O
findings,4153,O
were,4153,O
complemented,4153,O
by,4153,O
knockdown,4153,O
of,4153,O
FSAP,4153,B-GENE-Y
in,4153,O
hepatocytes,4153,O
",",4153,O
which,4153,O
revealed,4153,O
BMP-2,4153,B-GENE-Y
processing,4153,O
by,4153,O
endogenous,4153,O
FSAP,4153,B-GENE-Y
.,4153,O
N-terminal,4154,B-CHEMICAL
sequencing,4154,O
indicated,4154,O
that,4154,O
pro-BMP-2,4154,B-GENE-Y
was,4154,O
cleaved,4154,O
by,4154,O
FSAP,4154,B-GENE-Y
at,4154,O
the,4154,O
canonical,4154,O
PC,4154,B-GENE-N
cleavage,4154,I-GENE-N
site,4154,I-GENE-N
",",4154,O
giving,4154,O
rise,4154,O
to,4154,O
mature,4154,O
BMP-2,4154,B-GENE-Y
(,4154,O
Arg,4154,B-CHEMICAL
(,4154,O
282,4154,O
),4154,O
Gln,4154,O
(,4154,O
283,4154,O
),4154,O
),4154,O
",",4154,O
as,4154,O
well,4154,O
as,4154,O
in,4154,O
the,4154,O
N-terminal,4154,B-CHEMICAL
heparin,4154,I-GENE-N
binding,4154,I-GENE-N
region,4154,I-GENE-N
of,4154,O
mature,4154,O
BMP-2,4154,B-GENE-Y
",",4154,O
generating,4154,O
a,4154,O
truncated,4154,O
mature,4154,O
BMP-2,4154,B-GENE-Y
peptide,4154,O
(,4154,O
Arg,4154,B-CHEMICAL
(,4154,O
289,4154,O
),4154,O
Lys,4154,O
(,4154,O
290,4154,O
),4154,O
),4154,O
.,4154,O
Similarly,4155,O
",",4155,O
mature,4155,O
BMP-2,4155,B-GENE-Y
was,4155,O
also,4155,O
cleaved,4155,O
to,4155,O
a,4155,O
truncated,4155,O
peptide,4155,O
within,4155,O
its,4155,O
N-terminal,4155,B-CHEMICAL
region,4155,O
(,4155,O
Arg,4155,B-CHEMICAL
(,4155,O
289,4155,O
),4155,O
Lys,4155,O
(,4155,O
290,4155,O
),4155,O
),4155,O
.,4155,O
Plasmin,4156,B-GENE-Y
exhibited,4156,O
a,4156,O
similar,4156,O
activity,4156,O
",",4156,O
but,4156,O
it,4156,O
was,4156,O
weaker,4156,O
compared,4156,O
with,4156,O
FSAP,4156,B-GENE-Y
.,4156,O
Thrombin,4157,B-GENE-Y
",",4157,O
Factor,4157,B-GENE-Y
VIIa,4157,I-GENE-Y
",",4157,O
Factor,4157,B-GENE-Y
Xa,4157,I-GENE-Y
",",4157,O
and,4157,O
activated,4157,B-GENE-Y
protein,4157,I-GENE-Y
C,4157,I-GENE-Y
were,4157,O
not,4157,O
effective,4157,O
.,4157,O
These,4158,O
results,4158,O
were,4158,O
further,4158,O
supported,4158,O
by,4158,O
the,4158,O
observation,4158,O
that,4158,O
the,4158,O
mutation,4158,O
of,4158,O
the,4158,O
heparin,4158,B-GENE-N
binding,4158,I-GENE-N
region,4158,I-GENE-N
of,4158,O
BMP-2,4158,B-GENE-Y
inhibited,4158,O
the,4158,O
processing,4158,O
by,4158,O
FSAP,4158,B-GENE-Y
but,4158,O
not,4158,O
by,4158,O
PC,4158,B-GENE-N
.,4158,O
Thus,4159,O
",",4159,O
the,4159,O
proteolysis,4159,O
and,4159,O
activation,4159,O
of,4159,O
pro-BMP-2,4159,B-GENE-Y
and,4159,O
mature,4159,O
BMP-2,4159,B-GENE-Y
by,4159,O
FSAP,4159,B-GENE-Y
can,4159,O
regulate,4159,O
cell,4159,O
differentiation,4159,O
and,4159,O
calcification,4159,O
in,4159,O
vasculature,4159,O
and,4159,O
may,4159,O
explain,4159,O
why,4159,O
polymorphisms,4159,O
in,4159,O
the,4159,O
gene,4159,O
encoding,4159,O
for,4159,O
FSAP,4159,B-GENE-Y
are,4159,O
related,4159,O
to,4159,O
vascular,4159,O
diseases,4159,O
.,4159,O
A,4160,O
brief,4160,O
history,4160,O
of,4160,O
oxytocin,4160,B-GENE-Y
and,4160,O
its,4160,O
role,4160,O
in,4160,O
modulating,4160,O
psychostimulant,4160,O
effects,4160,O
.,4160,O
Over,4161,O
the,4161,O
past,4161,O
century,4161,O
",",4161,O
the,4161,O
polypeptide,4161,O
oxytocin,4161,B-CHEMICAL
has,4161,O
played,4161,O
an,4161,O
important,4161,O
role,4161,O
in,4161,O
medicine,4161,O
with,4161,O
major,4161,O
highlights,4161,O
including,4161,O
the,4161,O
identification,4161,O
of,4161,O
its,4161,O
involvement,4161,O
in,4161,O
parturition,4161,O
and,4161,O
the,4161,O
milk,4161,O
let-down,4161,O
reflex,4161,O
.,4161,O
Oxytocin,4162,B-CHEMICAL
is,4162,O
now,4162,O
implicated,4162,O
in,4162,O
an,4162,O
extensive,4162,O
range,4162,O
of,4162,O
psychological,4162,O
phenomena,4162,O
including,4162,O
reward,4162,O
and,4162,O
memory,4162,O
processes,4162,O
and,4162,O
has,4162,O
been,4162,O
investigated,4162,O
as,4162,O
a,4162,O
treatment,4162,O
for,4162,O
several,4162,O
psychiatric,4162,O
disorders,4162,O
including,4162,O
addiction,4162,O
",",4162,O
anxiety,4162,O
",",4162,O
autism,4162,O
",",4162,O
and,4162,O
schizophrenia,4162,O
.,4162,O
In,4163,O
this,4163,O
review,4163,O
",",4163,O
we,4163,O
first,4163,O
provide,4163,O
an,4163,O
historical,4163,O
overview,4163,O
of,4163,O
oxytocin,4163,B-CHEMICAL
and,4163,O
describe,4163,O
key,4163,O
aspects,4163,O
of,4163,O
its,4163,O
physiological,4163,O
activity,4163,O
.,4163,O
We,4164,O
then,4164,O
outline,4164,O
some,4164,O
pharmacological,4164,O
limitations,4164,O
in,4164,O
this,4164,O
field,4164,O
of,4164,O
research,4164,O
before,4164,O
highlighting,4164,O
the,4164,O
role,4164,O
of,4164,O
oxytocin,4164,B-GENE-Y
in,4164,O
a,4164,O
wide,4164,O
range,4164,O
of,4164,O
behavioral,4164,O
and,4164,O
neuronal,4164,O
processes,4164,O
.,4164,O
Finally,4165,O
",",4165,O
we,4165,O
review,4165,O
evidence,4165,O
for,4165,O
a,4165,O
modulatory,4165,O
role,4165,O
of,4165,O
oxytocin,4165,B-GENE-Y
with,4165,O
regard,4165,O
to,4165,O
psychostimulant,4165,O
effects,4165,O
.,4165,O
Key,4166,O
findings,4166,O
suggest,4166,O
that,4166,O
oxytocin,4166,B-GENE-Y
attenuates,4166,O
a,4166,O
broad,4166,O
number,4166,O
of,4166,O
cocaine,4166,B-CHEMICAL
and,4166,O
methamphetamine,4166,B-CHEMICAL
induced,4166,O
behaviors,4166,O
and,4166,O
associated,4166,O
neuronal,4166,O
activity,4166,O
in,4166,O
rodents,4166,O
.,4166,O
Evidence,4167,O
also,4167,O
outlines,4167,O
a,4167,O
role,4167,O
for,4167,O
oxytocin,4167,B-CHEMICAL
in,4167,O
the,4167,O
prosocial,4167,O
effects,4167,O
of,4167,O
"3,4-methylenedioxymethamphetamine",4167,B-CHEMICAL
(,4167,O
MDMA,4167,B-CHEMICAL
",",4167,O
Ecstasy,4167,B-CHEMICAL
),4167,O
in,4167,O
both,4167,O
rodents,4167,O
and,4167,O
humans,4167,O
.,4167,O
Clinical,4168,O
trials,4168,O
should,4168,O
now,4168,O
investigate,4168,O
the,4168,O
effectiveness,4168,O
of,4168,O
oxytocin,4168,B-CHEMICAL
as,4168,O
a,4168,O
novel,4168,O
intervention,4168,O
for,4168,O
psychostimulant,4168,O
addiction,4168,O
and,4168,O
should,4168,O
aim,4168,O
to,4168,O
determine,4168,O
its,4168,O
specific,4168,O
role,4168,O
in,4168,O
the,4168,O
therapeutic,4168,O
properties,4168,O
of,4168,O
MDMA,4168,B-CHEMICAL
that,4168,O
are,4168,O
currently,4168,O
being,4168,O
investigated,4168,O
.,4168,O
The,4169,O
type,4169,O
2,4169,O
diabetes,4169,O
associated,4169,O
gene,4169,O
Ide,4169,B-GENE-Y
is,4169,O
required,4169,O
for,4169,O
insulin,4169,B-GENE-N
secretion,4169,O
and,4169,O
suppression,4169,O
of,4169,O
-synuclein,4169,B-GENE-Y
levels,4169,O
in,4169,O
-cells,4169,O
.,4169,O
Genome,4170,O
wide,4170,O
association,4170,O
studies,4170,O
have,4170,O
identified,4170,O
several,4170,O
type,4170,O
2,4170,O
diabetes,4170,O
(,4170,O
T2D,4170,O
),4170,O
risk,4170,O
loci,4170,O
linked,4170,O
to,4170,O
impaired,4170,O
-cell,4170,O
function,4170,O
.,4170,O
The,4171,O
identity,4171,O
and,4171,O
function,4171,O
of,4171,O
the,4171,O
causal,4171,O
genes,4171,O
in,4171,O
these,4171,O
susceptibility,4171,O
loci,4171,O
remain,4171,O
",",4171,O
however,4171,O
",",4171,O
elusive,4171,O
.,4171,O
The,4172,O
HHEX/IDE,4172,B-GENE-Y
T2D,4172,O
locus,4172,O
is,4172,O
associated,4172,O
with,4172,O
decreased,4172,O
insulin,4172,B-GENE-Y
secretion,4172,O
in,4172,O
response,4172,O
to,4172,O
oral,4172,O
glucose,4172,B-CHEMICAL
stimulation,4172,O
in,4172,O
humans,4172,O
.,4172,O
Here,4173,O
we,4173,O
have,4173,O
assessed,4173,O
-cell,4173,O
function,4173,O
in,4173,O
Ide,4173,B-GENE-Y
knock-out,4173,O
(,4173,O
KO,4173,O
),4173,O
mice,4173,O
.,4173,O
We,4174,O
find,4174,O
that,4174,O
glucose,4174,B-CHEMICAL
stimulated,4174,O
insulin,4174,B-GENE-N
secretion,4174,O
(,4174,O
GSIS,4174,O
),4174,O
is,4174,O
decreased,4174,O
in,4174,O
Ide,4174,B-GENE-Y
KO,4174,O
mice,4174,O
due,4174,O
to,4174,O
impaired,4174,O
replenishment,4174,O
of,4174,O
the,4174,O
releasable,4174,O
pool,4174,O
of,4174,O
granules,4174,O
and,4174,O
that,4174,O
the,4174,O
Ide,4174,B-GENE-Y
gene,4174,O
is,4174,O
haploinsufficient,4174,O
.,4174,O
We,4175,O
also,4175,O
show,4175,O
that,4175,O
autophagic,4175,O
flux,4175,O
and,4175,O
microtubule,4175,B-GENE-N
content,4175,O
is,4175,O
reduced,4175,O
in,4175,O
-cells,4175,O
of,4175,O
Ide,4175,B-GENE-Y
KO,4175,O
mice,4175,O
.,4175,O
One,4176,O
important,4176,O
cellular,4176,O
role,4176,O
for,4176,O
IDE,4176,B-GENE-Y
involves,4176,O
the,4176,O
neutralization,4176,O
of,4176,O
amyloidogenic,4176,O
proteins,4176,O
and,4176,O
we,4176,O
find,4176,O
that,4176,O
-synuclein,4176,B-GENE-Y
and,4176,O
IDE,4176,B-GENE-Y
levels,4176,O
are,4176,O
inversely,4176,O
correlated,4176,O
in,4176,O
-cells,4176,O
of,4176,O
Ide,4176,B-GENE-Y
KO,4176,O
mice,4176,O
and,4176,O
T2D,4176,O
patients,4176,O
.,4176,O
Moreover,4177,O
",",4177,O
we,4177,O
provide,4177,O
evidence,4177,O
that,4177,O
both,4177,O
gain-,4177,O
and,4177,O
loss-of-function,4177,O
of,4177,O
-synuclein,4177,B-GENE-Y
in,4177,O
-cells,4177,O
in,4177,O
vivo,4177,O
not,4177,O
only,4177,O
impair,4177,O
GSIS,4177,O
but,4177,O
also,4177,O
autophagy,4177,O
.,4177,O
Together,4178,O
",",4178,O
these,4178,O
data,4178,O
identify,4178,O
the,4178,O
Ide,4178,B-GENE-Y
gene,4178,O
as,4178,O
a,4178,O
regulator,4178,O
of,4178,O
GSIS,4178,O
",",4178,O
suggest,4178,O
a,4178,O
molecular,4178,O
mechanism,4178,O
for,4178,O
-cell,4178,O
degeneration,4178,O
as,4178,O
a,4178,O
consequence,4178,O
of,4178,O
Ide,4178,B-GENE-Y
deficiency,4178,O
",",4178,O
and,4178,O
additionally,4178,O
corroborates,4178,O
and,4178,O
extends,4178,O
a,4178,O
previously,4178,O
established,4178,O
important,4178,O
role,4178,O
for,4178,O
-synuclein,4178,B-GENE-Y
in,4178,O
-cell,4178,O
function,4178,O
.,4178,O
-Cells,4179,O
Are,4179,O
Not,4179,O
Generated,4179,O
in,4179,O
Pancreatic,4179,O
Duct,4179,O
Ligation-Induced,4179,O
Injury,4179,O
in,4179,O
Adult,4179,O
Mice,4179,O
.,4179,O
The,4180,O
existence,4180,O
of,4180,O
adult,4180,O
-cell,4180,O
progenitors,4180,O
remains,4180,O
the,4180,O
most,4180,O
controversial,4180,O
developmental,4180,O
biology,4180,O
topic,4180,O
in,4180,O
diabetes,4180,O
research,4180,O
.,4180,O
It,4181,O
has,4181,O
been,4181,O
reported,4181,O
that,4181,O
-cell,4181,O
progenitors,4181,O
can,4181,O
be,4181,O
activated,4181,O
by,4181,O
ductal,4181,O
ligation-induced,4181,O
injury,4181,O
of,4181,O
adult,4181,O
mouse,4181,O
pancreas,4181,O
and,4181,O
apparently,4181,O
act,4181,O
in,4181,O
a,4181,O
cell-autonomous,4181,O
manner,4181,O
to,4181,O
double,4181,O
the,4181,O
functional,4181,O
-cell,4181,O
mass,4181,O
within,4181,O
a,4181,O
week,4181,O
by,4181,O
differentiation,4181,O
and,4181,O
proliferation,4181,O
.,4181,O
Here,4182,O
",",4182,O
we,4182,O
demonstrate,4182,O
that,4182,O
pancreatic,4182,O
duct,4182,O
ligation,4182,O
(,4182,O
PDL,4182,O
),4182,O
does,4182,O
not,4182,O
activate,4182,O
progenitors,4182,O
to,4182,O
contribute,4182,O
to,4182,O
-cell,4182,O
mass,4182,O
expansion,4182,O
.,4182,O
Rather,4183,O
",",4183,O
PDL,4183,O
stimulates,4183,O
massive,4183,O
pancreatic,4183,O
injury,4183,O
",",4183,O
which,4183,O
alters,4183,O
pancreatic,4183,O
composition,4183,O
and,4183,O
thus,4183,O
complicates,4183,O
accurate,4183,O
measurement,4183,O
of,4183,O
-cell,4183,O
content,4183,O
via,4183,O
traditional,4183,O
morphometry,4183,O
methodologies,4183,O
that,4183,O
superficially,4183,O
sample,4183,O
the,4183,O
pancreas,4183,O
.,4183,O
To,4184,O
overcome,4184,O
this,4184,O
potential,4184,O
bias,4184,O
",",4184,O
we,4184,O
quantified,4184,O
-cells,4184,O
from,4184,O
the,4184,O
entire,4184,O
pancreas,4184,O
and,4184,O
observed,4184,O
that,4184,O
-cell,4184,O
mass,4184,O
and,4184,O
insulin,4184,B-GENE-N
content,4184,O
are,4184,O
totally,4184,O
unchanged,4184,O
by,4184,O
PDL-induced,4184,O
injury,4184,O
.,4184,O
Lineage-tracing,4185,O
studies,4185,O
using,4185,O
sequential,4185,O
administration,4185,O
of,4185,O
thymidine,4185,B-CHEMICAL
analogs,4185,O
",",4185,O
rat,4185,B-GENE-N
insulin,4185,I-GENE-N
2,4185,I-GENE-N
promoter-driven,4185,O
cre-lox,4185,B-GENE-N
",",4185,O
and,4185,O
low-frequency,4185,O
ubiquitous,4185,O
cre-lox,4185,B-GENE-N
reveal,4185,O
that,4185,O
PDL,4185,O
does,4185,O
not,4185,O
convert,4185,O
progenitors,4185,O
to,4185,O
the,4185,O
-cell,4185,O
lineage,4185,O
.,4185,O
Thus,4186,O
",",4186,O
we,4186,O
conclude,4186,O
that,4186,O
-cells,4186,O
are,4186,O
not,4186,O
generated,4186,O
in,4186,O
injured,4186,O
adult,4186,O
mouse,4186,O
pancreas,4186,O
.,4186,O
Support,4187,O
for,4187,O
5-HT2C,4187,B-GENE-Y
receptor,4187,O
functional,4187,O
selectivity,4187,O
in,4187,O
vivo,4187,O
utilizing,4187,O
structurally,4187,O
diverse,4187,O
",",4187,O
selective,4187,O
5-HT2C,4187,B-GENE-Y
receptor,4187,O
ligands,4187,O
and,4187,O
the,4187,O
"2,5-dimethoxy-4-iodoamphetamine",4187,B-CHEMICAL
elicited,4187,O
head-twitch,4187,O
response,4187,O
model,4187,O
.,4187,O
There,4188,O
are,4188,O
seemingly,4188,O
conflicting,4188,O
data,4188,O
in,4188,O
the,4188,O
literature,4188,O
regarding,4188,O
the,4188,O
role,4188,O
of,4188,O
serotonin,4188,B-CHEMICAL
(,4188,O
5-HT,4188,B-CHEMICAL
),4188,O
5-HT2C,4188,B-GENE-Y
receptors,4188,O
in,4188,O
the,4188,O
mouse,4188,O
head-twitch,4188,O
response,4188,O
(,4188,O
HTR,4188,O
),4188,O
elicited,4188,O
by,4188,O
the,4188,O
hallucinogenic,4188,O
5-HT2A/2B/2C,4188,B-GENE-N
receptor,4188,I-GENE-N
agonist,4188,O
"2,5-dimethoxy-4-iodoamphetamine",4188,B-CHEMICAL
(,4188,O
DOI,4188,B-CHEMICAL
),4188,O
.,4188,O
Namely,4189,O
",",4189,O
both,4189,O
5-HT2C,4189,B-GENE-Y
receptor,4189,O
agonists,4189,O
and,4189,O
antagonists,4189,O
",",4189,O
regarding,4189,O
5-HT2C,4189,B-GENE-Y
receptor-mediated,4189,O
Gq-phospholipase,4189,B-GENE-N
C,4189,I-GENE-N
(,4189,O
PLC,4189,B-GENE-N
),4189,O
signaling,4189,O
",",4189,O
reportedly,4189,O
attenuate,4189,O
the,4189,O
HTR,4189,O
response,4189,O
.,4189,O
The,4190,O
present,4190,O
experiments,4190,O
tested,4190,O
the,4190,O
hypothesis,4190,O
that,4190,O
both,4190,O
classes,4190,O
of,4190,O
5-HT2C,4190,B-GENE-Y
receptor,4190,O
compounds,4190,O
could,4190,O
attenuate,4190,O
the,4190,O
DOI-elicited-HTR,4190,B-CHEMICAL
in,4190,O
a,4190,O
single,4190,O
strain,4190,O
of,4190,O
mice,4190,O
",",4190,O
C57Bl/6J,4190,O
.,4190,O
The,4191,O
expected,4191,O
results,4191,O
were,4191,O
considered,4191,O
in,4191,O
accordance,4191,O
with,4191,O
ligand,4191,O
functional,4191,O
selectivity,4191,O
.,4191,O
Commercially-available,4192,O
5-HT2C,4192,B-GENE-Y
agonists,4192,O
(,4192,O
CP,4192,B-CHEMICAL
809101,4192,I-CHEMICAL
",",4192,O
Ro,4192,B-CHEMICAL
60-0175,4192,I-CHEMICAL
",",4192,O
WAY,4192,B-CHEMICAL
161503,4192,I-CHEMICAL
",",4192,O
mCPP,4192,B-CHEMICAL
",",4192,O
and,4192,O
1-methylpsilocin,4192,B-CHEMICAL
),4192,O
",",4192,O
novel,4192,O
4-phenyl-2-N,4192,B-CHEMICAL
",",4192,I-CHEMICAL
N-dimethyl-aminotetralin,4192,I-CHEMICAL
(,4192,O
PAT,4192,B-CHEMICAL
),4192,O
-type,4192,O
5-HT2C,4192,B-GENE-Y
agonists,4192,O
(,4192,O
with,4192,O
5-HT2A/2B,4192,B-GENE-N
antagonist,4192,O
activity,4192,O
),4192,O
",",4192,O
and,4192,O
antagonists,4192,O
selective,4192,O
for,4192,O
5-HT2A,4192,B-GENE-Y
(,4192,O
M100907,4192,B-CHEMICAL
),4192,O
",",4192,O
5-HT2C,4192,B-GENE-Y
(,4192,O
SB-242084,4192,B-CHEMICAL
),4192,O
",",4192,O
and,4192,O
5-HT2B/2C,4192,B-GENE-N
(,4192,O
SB-206553,4192,B-CHEMICAL
),4192,O
receptors,4192,O
attenuated,4192,O
the,4192,O
DOI-elicited-HTR,4192,B-CHEMICAL
.,4192,O
In,4193,O
contrast,4193,O
",",4193,O
there,4193,O
were,4193,O
differential,4193,O
effects,4193,O
on,4193,O
locomotion,4193,O
across,4193,O
classes,4193,O
of,4193,O
compounds,4193,O
.,4193,O
The,4194,O
5-HT2C,4194,B-GENE-Y
agonists,4194,O
and,4194,O
M100907,4194,B-CHEMICAL
decreased,4194,O
locomotion,4194,O
",",4194,O
SB-242084,4194,B-CHEMICAL
increased,4194,O
locomotion,4194,O
",",4194,O
SB-206553,4194,B-CHEMICAL
resulted,4194,O
in,4194,O
dose-dependent,4194,O
biphasic,4194,O
effects,4194,O
on,4194,O
locomotion,4194,O
",",4194,O
and,4194,O
the,4194,O
PATs,4194,O
did,4194,O
not,4194,O
alter,4194,O
locomotion,4194,O
.,4194,O
In,4195,O
vitro,4195,O
molecular,4195,O
pharmacology,4195,O
studies,4195,O
showed,4195,O
that,4195,O
5-HT2C,4195,B-GENE-Y
agonists,4195,O
potent,4195,O
for,4195,O
attenuating,4195,O
the,4195,O
DOI-elicited-HTR,4195,B-CHEMICAL
also,4195,O
reduced,4195,O
the,4195,O
efficacy,4195,O
of,4195,O
DOI,4195,B-CHEMICAL
to,4195,O
activate,4195,O
mouse,4195,B-GENE-Y
5-HT2C,4195,I-GENE-Y
receptor-mediated,4195,O
PLC,4195,B-GENE-N
signaling,4195,O
in,4195,O
HEK,4195,O
cells,4195,O
.,4195,O
Although,4196,O
there,4196,O
were,4196,O
differences,4196,O
in,4196,O
affinities,4196,O
of,4196,O
a,4196,O
few,4196,O
compounds,4196,O
at,4196,O
mouse,4196,O
compared,4196,O
to,4196,O
human,4196,B-GENE-Y
5-HT2A,4196,I-GENE-Y
or,4196,O
5-HT2C,4196,B-GENE-Y
receptors,4196,O
",",4196,O
all,4196,O
compounds,4196,O
tested,4196,O
retained,4196,O
their,4196,O
selectivity,4196,O
for,4196,O
either,4196,O
receptor,4196,O
",",4196,O
regardless,4196,O
of,4196,O
receptor,4196,O
species,4196,O
.,4196,O
Results,4197,O
indicate,4197,O
that,4197,O
5-HT2C,4197,B-GENE-N
receptor,4197,O
agonists,4197,O
and,4197,O
antagonists,4197,O
attenuate,4197,O
the,4197,O
DOI-elicited-HTR,4197,B-CHEMICAL
in,4197,O
C57Bl/6J,4197,O
mice,4197,O
",",4197,O
and,4197,O
suggest,4197,O
that,4197,O
structurally,4197,O
diverse,4197,O
5-HT2C,4197,B-GENE-Y
ligands,4197,O
result,4197,O
in,4197,O
different,4197,O
5-HT2C,4197,B-GENE-Y
receptor,4197,O
signaling,4197,O
outcomes,4197,O
compared,4197,O
to,4197,O
DOI,4197,B-CHEMICAL
.,4197,O
Role,4198,O
of,4198,O
cytochrome,4198,B-GENE-Y
P4502B6,4198,I-GENE-Y
in,4198,O
methadone,4198,B-CHEMICAL
metabolism,4198,O
and,4198,O
clearance,4198,O
.,4198,O
Methadone,4199,B-CHEMICAL
N-demethylation,4199,B-CHEMICAL
in,4199,O
vitro,4199,O
is,4199,O
catalyzed,4199,O
by,4199,O
hepatic,4199,O
cytochrome,4199,B-GENE-Y
P4502B6,4199,I-GENE-Y
(,4199,O
CYP2B6,4199,B-GENE-Y
),4199,O
and,4199,O
CYP3A4,4199,B-GENE-Y
",",4199,O
but,4199,O
clinical,4199,O
disposition,4199,O
is,4199,O
often,4199,O
attributed,4199,O
to,4199,O
CYP3A4,4199,B-GENE-Y
.,4199,O
This,4200,O
investigation,4200,O
tested,4200,O
the,4200,O
hypothesis,4200,O
that,4200,O
CYP2B6,4200,B-GENE-Y
is,4200,O
a,4200,O
prominent,4200,O
CYP,4200,B-GENE-N
isoform,4200,O
responsible,4200,O
for,4200,O
clinical,4200,O
methadone,4200,B-CHEMICAL
N-demethylation,4200,B-CHEMICAL
and,4200,O
clearance,4200,O
",",4200,O
using,4200,O
the,4200,O
in,4200,O
vivo,4200,O
mechanism-based,4200,O
CYP2B6,4200,B-GENE-Y
inhibitor,4200,O
ticlopidine,4200,B-CHEMICAL
",",4200,O
given,4200,O
orally,4200,O
for,4200,O
4,4200,O
days,4200,O
.,4200,O
A,4201,O
preliminary,4201,O
clinical,4201,O
investigation,4201,O
with,4201,O
the,4201,O
CYP3A4/5,4201,B-GENE-N
substrate,4201,O
probe,4201,O
alfentanil,4201,B-CHEMICAL
established,4201,O
that,4201,O
ticlopidine,4201,B-CHEMICAL
did,4201,O
not,4201,O
inhibit,4201,O
intestinal,4201,O
or,4201,O
hepatic,4201,O
CYP3A4/5,4201,B-GENE-N
.,4201,O
Subjects,4202,O
received,4202,O
intravenous,4202,O
plus,4202,O
oral,4202,O
(,4202,O
deuterium-labeled,4202,B-CHEMICAL
),4202,O
racemic,4202,B-CHEMICAL
methadone,4202,I-CHEMICAL
before,4202,O
and,4202,O
after,4202,O
ticlopidine,4202,B-CHEMICAL
.,4202,O
Ticlopidine,4203,B-CHEMICAL
significantly,4203,O
and,4203,O
stereoselectively,4203,O
(,4203,O
S,4203,O
>,4203,O
R,4203,O
),4203,O
inhibited,4203,O
methadone,4203,B-CHEMICAL
N-demethylation,4203,B-CHEMICAL
",",4203,O
decreasing,4203,O
plasma,4203,O
metabolite/methadone,4203,O
area,4203,O
under,4203,O
the,4203,O
curve,4203,O
ratios,4203,O
and,4203,O
metabolite,4203,O
formation,4203,O
clearances,4203,O
.,4203,O
Ticlopidine,4204,B-CHEMICAL
also,4204,O
significantly,4204,O
increased,4204,O
the,4204,O
dose-adjusted,4204,O
plasma,4204,O
area,4204,O
under,4204,O
the,4204,O
curve,4204,O
for,4204,O
R-,4204,B-CHEMICAL
and,4204,I-CHEMICAL
S-methadone,4204,I-CHEMICAL
by,4204,O
20,4204,O
%,4204,O
and,4204,O
60,4204,O
%,4204,O
",",4204,O
respectively,4204,O
",",4204,O
after,4204,O
both,4204,O
intravenous,4204,O
and,4204,O
oral,4204,O
dosing,4204,O
.,4204,O
CYP2B6,4205,B-GENE-Y
inhibition,4205,O
reduces,4205,O
methadone,4205,B-CHEMICAL
N-demethylation,4205,B-CHEMICAL
and,4205,O
clearance,4205,O
",",4205,O
and,4205,O
alters,4205,O
methadone,4205,B-CHEMICAL
concentrations,4205,O
",",4205,O
demonstrating,4205,O
an,4205,O
important,4205,O
role,4205,O
for,4205,O
CYP2B6,4205,B-GENE-Y
in,4205,O
clinical,4205,O
methadone,4205,B-CHEMICAL
disposition,4205,O
.,4205,O
Computationally,4206,O
assisted,4206,O
assignment,4206,O
of,4206,O
kahalalide,4206,B-CHEMICAL
Y,4206,I-CHEMICAL
configuration,4206,O
using,4206,O
an,4206,O
NMR-constrained,4206,O
conformational,4206,O
search,4206,O
.,4206,O
Assignment,4207,O
of,4207,O
the,4207,O
absolute,4207,O
configuration,4207,O
of,4207,O
cyclic,4207,O
peptides,4207,O
frequently,4207,O
yields,4207,O
challenges,4207,O
",",4207,O
leaving,4207,O
one,4207,O
or,4207,O
more,4207,O
stereogenic,4207,O
centers,4207,O
unassigned,4207,O
due,4207,O
to,4207,O
small,4207,O
quantities,4207,O
of,4207,O
sample,4207,O
and,4207,O
the,4207,O
limited,4207,O
utility,4207,O
of,4207,O
Marfey,4207,O
's,4207,O
or,4207,O
other,4207,O
methods,4207,O
for,4207,O
assigning,4207,O
amino,4207,B-CHEMICAL
or,4207,I-CHEMICAL
hydroxy,4207,I-CHEMICAL
acids,4207,I-CHEMICAL
.,4207,O
Here,4208,O
",",4208,O
we,4208,O
report,4208,O
isolation,4208,O
of,4208,O
kahalalide,4208,B-CHEMICAL
Y,4208,I-CHEMICAL
(,4208,O
1,4208,O
),4208,O
from,4208,O
Bryopsis,4208,O
pennata,4208,O
for,4208,O
the,4208,O
first,4208,O
time,4208,O
;,4208,O
in,4208,O
addition,4208,O
",",4208,O
the,4208,O
application,4208,O
of,4208,O
a,4208,O
combination,4208,O
of,4208,O
molecular,4208,O
modeling,4208,O
and,4208,O
NOE,4208,O
distance,4208,O
constraint,4208,O
calculations,4208,O
was,4208,O
utilized,4208,O
to,4208,O
determine,4208,O
the,4208,O
conformation,4208,O
of,4208,O
1,4208,O
and,4208,O
the,4208,O
absolute,4208,O
configuration,4208,O
of,4208,O
the,4208,O
final,4208,O
stereogenic,4208,O
center,4208,O
of,4208,O
1,4208,O
.,4208,O
Using,4209,O
the,4209,O
Schrdinger,4209,O
suite,4209,O
",",4209,O
the,4209,O
structure,4209,O
of,4209,O
1,4209,O
was,4209,O
sketched,4209,O
in,4209,O
Maestro,4209,O
and,4209,O
minimized,4209,O
using,4209,O
the,4209,O
OPLS2005,4209,O
force,4209,O
field,4209,O
in,4209,O
Macromodel,4209,O
.,4209,O
A,4210,O
conformational,4210,O
search,4210,O
was,4210,O
performed,4210,O
separately,4210,O
for,4210,O
structures,4210,O
having,4210,O
an,4210,O
R,4210,O
or,4210,O
S,4210,O
configuration,4210,O
at,4210,O
C-3,4210,O
of,4210,O
the,4210,O
beta-hydroxy,4210,B-CHEMICAL
fatty,4210,I-CHEMICAL
acid,4210,I-CHEMICAL
subunit,4210,O
that,4210,O
completes,4210,O
the,4210,O
cyclic,4210,O
scaffold,4210,O
of,4210,O
1,4210,O
",",4210,O
after,4210,O
which,4210,O
multiple,4210,O
minimizations,4210,O
for,4210,O
all,4210,O
generated,4210,O
conformers,4210,O
were,4210,O
carried,4210,O
out,4210,O
.,4210,O
The,4211,O
lowest,4211,O
energy,4211,O
conformers,4211,O
of,4211,O
R,4211,O
and,4211,O
S,4211,O
stereoisomers,4211,O
were,4211,O
then,4211,O
subjected,4211,O
to,4211,O
B3LYP,4211,O
geometry,4211,O
optimizations,4211,O
including,4211,O
solvent,4211,O
effects,4211,O
.,4211,O
The,4212,O
S,4212,O
stereoisomer,4212,O
was,4212,O
shown,4212,O
to,4212,O
be,4212,O
in,4212,O
excellent,4212,O
agreement,4212,O
with,4212,O
the,4212,O
NOE-derived,4212,O
distance,4212,O
constraints,4212,O
and,4212,O
hydrogen-bonding,4212,B-CHEMICAL
stability,4212,O
studies,4212,O
.,4212,O
Green,4213,O
approach,4213,O
&,4213,O
#,4213,O
8212,4213,O
;,4213,O
multicomponent,4213,O
production,4213,O
of,4213,O
boron,4213,B-CHEMICAL
&,4213,O
#,4213,O
8212,4213,O
;,4213,O
containing,4213,O
hantzsch,4213,O
and,4213,O
biginelli,4213,O
esters,4213,O
.,4213,O
Multicomponent,4214,O
reactions,4214,O
are,4214,O
excellent,4214,O
methods,4214,O
that,4214,O
meet,4214,O
the,4214,O
requirements,4214,O
of,4214,O
green,4214,O
chemistry,4214,O
",",4214,O
by,4214,O
reducing,4214,O
the,4214,O
number,4214,O
of,4214,O
steps,4214,O
",",4214,O
and,4214,O
consequently,4214,O
reducing,4214,O
purification,4214,O
requirements,4214,O
.,4214,O
Accordingly,4215,O
",",4215,O
in,4215,O
this,4215,O
work,4215,O
",",4215,O
11,4215,O
novel,4215,O
hybrid-boron-containing,4215,O
molecules,4215,O
",",4215,O
namely,4215,O
eight,4215,O
"1,4-dihydropyridines",4215,B-CHEMICAL
and,4215,O
three,4215,O
"3,4-dihydropyrimidinones",4215,B-CHEMICAL
",",4215,O
derived,4215,O
from,4215,O
formylphenylboronic,4215,B-CHEMICAL
acids,4215,I-CHEMICAL
(,4215,O
ortho,4215,O
",",4215,O
meta,4215,O
and,4215,O
para,4215,O
),4215,O
",",4215,O
were,4215,O
obtained,4215,O
using,4215,O
a,4215,O
green,4215,O
approach,4215,O
",",4215,O
involving,4215,O
H-4CR,4215,O
and,4215,O
B-3CR,4215,O
practices,4215,O
",",4215,O
in,4215,O
the,4215,O
presence,4215,O
of,4215,O
ethanol,4215,B-CHEMICAL
",",4215,O
which,4215,O
is,4215,O
a,4215,O
green,4215,O
solvent,4215,O
",",4215,O
and,4215,O
using,4215,O
three,4215,O
comparatively,4215,O
different,4215,O
modes,4215,O
of,4215,O
activation,4215,O
(,4215,O
mantle,4215,O
heating,4215,O
",",4215,O
yield,4215,O
3,4215,O
%,4215,O
-7,4215,O
%,4215,O
in,4215,O
24,4215,O
h,4215,O
",",4215,O
Infrared,4215,O
Radiation,4215,O
(,4215,O
IR,4215,O
),4215,O
irradiation,4215,O
",",4215,O
yield,4215,O
12,4215,O
%,4215,O
-17,4215,O
%,4215,O
in,4215,O
12,4215,O
h,4215,O
",",4215,O
and,4215,O
microwave,4215,O
irradiation,4215,O
",",4215,O
yield,4215,O
18,4215,O
%,4215,O
-80,4215,O
%,4215,O
",",4215,O
requiring,4215,O
very,4215,O
low,4215,O
reaction,4215,O
times,4215,O
of,4215,O
0.25-0.33,4215,O
h,4215,O
),4215,O
.,4215,O
In,4216,O
addition,4216,O
",",4216,O
as,4216,O
a,4216,O
green-approach,4216,O
is,4216,O
offered,4216,O
",",4216,O
a,4216,O
convenient,4216,O
analysis,4216,O
",",4216,O
of,4216,O
the,4216,O
12,4216,O
green,4216,O
chemistry,4216,O
principles,4216,O
for,4216,O
the,4216,O
overall,4216,O
procedure,4216,O
was,4216,O
performed,4216,O
.,4216,O
Finally,4217,O
",",4217,O
since,4217,O
all,4217,O
the,4217,O
products,4217,O
are,4217,O
new,4217,O
",",4217,O
characterizations,4217,O
were,4217,O
carried,4217,O
out,4217,O
using,4217,O
common,4217,O
analytic,4217,O
procedures,4217,O
(,4217,O
1H,4217,B-CHEMICAL
",",4217,O
11B,4217,B-CHEMICAL
",",4217,O
and,4217,O
13C,4217,B-CHEMICAL
NMR,4217,O
",",4217,O
FAB+MS,4217,O
",",4217,O
HRMS,4217,O
",",4217,O
and,4217,O
IR,4217,O
),4217,O
.,4217,O
The,4218,O
accurate,4218,O
mass,4218,O
data,4218,O
of,4218,O
unexpected,4218,O
ions,4218,O
related,4218,O
to,4218,O
interactions,4218,O
between,4218,O
thioglycerol,4218,B-CHEMICAL
and,4218,O
the,4218,O
expected,4218,O
products,4218,O
",",4218,O
in,4218,O
the,4218,O
FAB+-mode,4218,O
",",4218,O
enabled,4218,O
unequivocal,4218,O
characterization,4218,O
of,4218,O
the,4218,O
target,4218,O
molecules,4218,O
.,4218,O
Structures,4219,O
and,4219,O
cytotoxic,4219,O
evaluation,4219,O
of,4219,O
new,4219,O
and,4219,O
known,4219,O
acyclic,4219,O
Ene-Ynes,4219,O
from,4219,O
an,4219,O
American,4219,O
Samoa,4219,O
Petrosia,4219,O
sp,4219,O
.,4219,O
Sponge,4220,O
.,4220,O
Four,4221,O
new,4221,O
compounds,4221,O
",",4221,O
(,4221,B-CHEMICAL
-,4221,I-CHEMICAL
),4221,I-CHEMICAL
-petrosynoic,4221,I-CHEMICAL
acids,4221,I-CHEMICAL
A-D,4221,I-CHEMICAL
(,4221,O
1-4,4221,O
),4221,O
",",4221,O
and,4221,O
five,4221,O
known,4221,O
congeners,4221,O
",",4221,O
pellynols,4221,B-CHEMICAL
A,4221,I-CHEMICAL
(,4221,I-CHEMICAL
5,4221,I-CHEMICAL
),4221,I-CHEMICAL
",",4221,I-CHEMICAL
C,4221,I-CHEMICAL
(,4221,I-CHEMICAL
6,4221,I-CHEMICAL
),4221,I-CHEMICAL
",",4221,I-CHEMICAL
D,4221,I-CHEMICAL
(,4221,I-CHEMICAL
7,4221,I-CHEMICAL
),4221,I-CHEMICAL
",",4221,I-CHEMICAL
F,4221,I-CHEMICAL
(,4221,I-CHEMICAL
8,4221,I-CHEMICAL
),4221,I-CHEMICAL
",",4221,I-CHEMICAL
and,4221,I-CHEMICAL
I,4221,I-CHEMICAL
(,4221,O
9,4221,O
),4221,O
",",4221,O
were,4221,O
isolated,4221,O
from,4221,O
a,4221,O
Petrosia,4221,O
sp,4221,O
.,4221,O
marine,4222,O
sponge,4222,O
collected,4222,O
in,4222,O
American,4222,O
Samoa,4222,O
.,4222,O
Isolation,4223,O
work,4223,O
was,4223,O
guided,4223,O
by,4223,O
cytotoxicity,4223,O
against,4223,O
human,4223,O
lung,4223,O
cancer,4223,O
cells,4223,O
(,4223,O
H460,4223,O
),4223,O
.,4223,O
The,4224,O
structures,4224,O
of,4224,O
the,4224,O
C31-C33,4224,B-CHEMICAL
polyacetylenes,4224,I-CHEMICAL
(,4224,O
1-9,4224,O
),4224,O
were,4224,O
determined,4224,O
on,4224,O
the,4224,O
basis,4224,O
of,4224,O
1D-,4224,O
and,4224,O
2D-NMR,4224,O
analysis,4224,O
",",4224,O
mass,4224,O
spectrometry,4224,O
",",4224,O
and,4224,O
comparison,4224,O
of,4224,O
specific,4224,O
rotation,4224,O
values,4224,O
.,4224,O
Compounds,4225,O
1-9,4225,O
were,4225,O
found,4225,O
to,4225,O
be,4225,O
broadly,4225,O
cytotoxic,4225,O
with,4225,O
limited,4225,O
selectivity,4225,O
for,4225,O
cancer,4225,O
cells,4225,O
",",4225,O
as,4225,O
they,4225,O
were,4225,O
all,4225,O
moderately,4225,O
active,4225,O
against,4225,O
the,4225,O
A2058,4225,O
(,4225,O
melanoma,4225,O
),4225,O
",",4225,O
H522-T1,4225,O
(,4225,O
lung,4225,O
),4225,O
",",4225,O
and,4225,O
H460,4225,O
(,4225,O
lung,4225,O
),4225,O
human,4225,O
cancer,4225,O
cell,4225,O
lines,4225,O
as,4225,O
well,4225,O
as,4225,O
IMR-90,4225,O
quiescent,4225,O
human,4225,O
fibroblast,4225,O
cells,4225,O
.,4225,O
Dopamine,4226,B-CHEMICAL
D2,4226,I-GENE-Y
receptor,4226,I-GENE-Y
activation,4226,O
leads,4226,O
to,4226,O
an,4226,O
up-regulation,4226,O
of,4226,O
glial,4226,B-GENE-Y
cell,4226,I-GENE-Y
line-derived,4226,I-GENE-Y
neurotrophic,4226,I-GENE-Y
factor,4226,I-GENE-Y
via,4226,O
G-Erk1/2-dependent,4226,O
induction,4226,O
of,4226,O
Zif268,4226,B-GENE-Y
.,4226,O
Glial,4227,B-GENE-Y
cell,4227,I-GENE-Y
line-derived,4227,I-GENE-Y
neurotrophic,4227,I-GENE-Y
factor,4227,I-GENE-Y
(,4227,O
GDNF,4227,B-GENE-Y
),4227,O
is,4227,O
a,4227,O
potent,4227,O
growth,4227,O
factor,4227,O
essential,4227,O
to,4227,O
the,4227,O
development,4227,O
",",4227,O
survival,4227,O
",",4227,O
and,4227,O
function,4227,O
of,4227,O
dopaminergic,4227,O
neurons,4227,O
(,4227,O
Airaksinen,4227,O
and,4227,O
Saarma,4227,O
2002,4227,O
),4227,O
.,4227,O
The,4228,O
molecular,4228,O
mechanisms,4228,O
underlying,4228,O
GDNF,4228,B-GENE-Y
expression,4228,O
remain,4228,O
elusive,4228,O
;,4228,O
thus,4228,O
",",4228,O
we,4228,O
set,4228,O
out,4228,O
to,4228,O
identify,4228,O
a,4228,O
signaling,4228,O
pathway,4228,O
that,4228,O
governs,4228,O
GDNF,4228,B-GENE-Y
levels,4228,O
.,4228,O
We,4229,O
found,4229,O
that,4229,O
treatment,4229,O
of,4229,O
both,4229,O
differentiated,4229,O
dopaminergic-like,4229,O
SH-SY5Y,4229,O
cells,4229,O
and,4229,O
rat,4229,O
midbrain,4229,O
slices,4229,O
with,4229,O
the,4229,O
dopamine,4229,B-GENE-N
D2,4229,I-GENE-N
receptor,4229,I-GENE-N
(,4229,O
D2R,4229,B-GENE-N
),4229,O
agonist,4229,O
",",4229,O
quinpirole,4229,B-CHEMICAL
",",4229,O
triggered,4229,O
an,4229,O
increase,4229,O
in,4229,O
the,4229,O
expression,4229,O
of,4229,O
GDNF,4229,B-GENE-N
that,4229,O
was,4229,O
temporally,4229,O
preceded,4229,O
by,4229,O
an,4229,O
increase,4229,O
in,4229,O
the,4229,O
levels,4229,O
of,4229,O
zinc-finger,4229,B-CHEMICAL
protein,4229,I-GENE-N
268,4229,I-GENE-N
(,4229,O
Zif268,4229,B-GENE-N
),4229,O
",",4229,O
a,4229,O
DNA-binding,4229,O
transcription,4229,O
factor,4229,O
encoded,4229,O
by,4229,O
an,4229,O
immediate-early,4229,O
gene,4229,O
.,4229,O
Moreover,4230,O
",",4230,O
the,4230,O
D2R,4230,B-GENE-Y
inhibitor,4230,O
raclopride,4230,B-CHEMICAL
blocked,4230,O
the,4230,O
increase,4230,O
of,4230,O
both,4230,O
GDNF,4230,B-GENE-Y
and,4230,O
Zif268,4230,B-GENE-Y
expression,4230,O
following,4230,O
potassium-evoked,4230,B-CHEMICAL
dopamine,4230,B-CHEMICAL
release,4230,O
in,4230,O
SH-SY5Y,4230,O
cells,4230,O
.,4230,O
We,4231,O
used,4231,O
adenoviral,4231,O
delivery,4231,O
of,4231,O
small,4231,O
hairpin,4231,O
RNA,4231,O
(,4231,O
shRNA,4231,O
),4231,O
targeting,4231,O
Zif268,4231,B-GENE-Y
to,4231,O
down-regulate,4231,O
its,4231,O
expression,4231,O
and,4231,O
found,4231,O
that,4231,O
Zif268,4231,B-GENE-Y
is,4231,O
specifically,4231,O
required,4231,O
for,4231,O
the,4231,O
D2R-mediated,4231,B-GENE-Y
up-regulation,4231,O
of,4231,O
GDNF,4231,B-GENE-Y
.,4231,O
Furthermore,4232,O
",",4232,O
the,4232,O
D2R-mediated,4232,B-GENE-Y
induction,4232,O
of,4232,O
GDNF,4232,B-GENE-Y
and,4232,O
Zif268,4232,B-GENE-N
expression,4232,O
was,4232,O
dependent,4232,O
on,4232,O
G-mediated,4232,O
signaling,4232,O
and,4232,O
activation,4232,O
of,4232,O
extracellular,4232,B-GENE-N
signal-regulated,4232,I-GENE-N
kinase,4232,I-GENE-N
1/2,4232,I-GENE-N
.,4232,O
Importantly,4233,O
",",4233,O
using,4233,O
chromatin,4233,O
immunoprecipitation,4233,O
assay,4233,O
",",4233,O
we,4233,O
identified,4233,O
a,4233,O
direct,4233,O
association,4233,O
of,4233,O
Zif268,4233,B-GENE-Y
with,4233,O
the,4233,O
GDNF,4233,B-GENE-N
promoter,4233,I-GENE-N
.,4233,O
These,4234,O
results,4234,O
suggest,4234,O
that,4234,O
D2R,4234,B-GENE-Y
activation,4234,O
induces,4234,O
a,4234,O
G-,4234,O
and,4234,O
extracellular,4234,B-GENE-N
signal-regulated,4234,I-GENE-N
kinase,4234,I-GENE-N
1/2-dependent,4234,O
increase,4234,O
in,4234,O
the,4234,O
level,4234,O
of,4234,O
Zif268,4234,B-GENE-Y
",",4234,O
which,4234,O
functions,4234,O
to,4234,O
directly,4234,O
up-regulate,4234,O
the,4234,O
expression,4234,O
of,4234,O
GDNF,4234,B-GENE-Y
.,4234,O
Fast,4235,O
protein,4235,O
motions,4235,O
are,4235,O
coupled,4235,O
to,4235,O
enzyme,4235,O
H-transfer,4235,B-CHEMICAL
reactions,4235,O
.,4235,O
Coupling,4236,O
of,4236,O
fast,4236,O
protein,4236,O
dynamics,4236,O
to,4236,O
enzyme,4236,O
chemistry,4236,O
is,4236,O
controversial,4236,O
and,4236,O
has,4236,O
ignited,4236,O
considerable,4236,O
debate,4236,O
",",4236,O
especially,4236,O
over,4236,O
the,4236,O
past,4236,O
15,4236,O
years,4236,O
in,4236,O
relation,4236,O
to,4236,O
enzyme-catalyzed,4236,O
H-transfer,4236,B-CHEMICAL
.,4236,O
H-transfer,4237,B-CHEMICAL
can,4237,O
occur,4237,O
by,4237,O
quantum,4237,O
tunneling,4237,O
",",4237,O
and,4237,O
the,4237,O
temperature,4237,O
dependence,4237,O
of,4237,O
kinetic,4237,O
isotope,4237,O
effects,4237,O
(,4237,O
KIEs,4237,O
),4237,O
has,4237,O
emerged,4237,O
as,4237,O
the,4237,O
``,4237,O
gold,4237,O
standard,4237,O
'',4237,O
descriptor,4237,O
of,4237,O
these,4237,O
reactions,4237,O
.,4237,O
The,4238,O
anomalous,4238,O
temperature,4238,O
dependence,4238,O
of,4238,O
KIEs,4238,O
is,4238,O
often,4238,O
rationalized,4238,O
by,4238,O
invoking,4238,O
fast,4238,O
motions,4238,O
to,4238,O
facilitate,4238,O
H-transfer,4238,B-CHEMICAL
",",4238,O
yet,4238,O
crucially,4238,O
",",4238,O
direct,4238,O
evidence,4238,O
for,4238,O
coupled,4238,O
motions,4238,O
is,4238,O
lacking,4238,O
.,4238,O
The,4239,O
fast,4239,O
motions,4239,O
hypothesis,4239,O
underpinning,4239,O
the,4239,O
temperature,4239,O
dependence,4239,O
of,4239,O
KIEs,4239,O
is,4239,O
based,4239,O
on,4239,O
inference,4239,O
.,4239,O
Here,4240,O
",",4240,O
we,4240,O
have,4240,O
perturbed,4240,O
vibrational,4240,O
motions,4240,O
in,4240,O
pentaerythritol,4240,B-GENE-N
tetranitrate,4240,I-GENE-N
reductase,4240,I-GENE-N
(,4240,O
PETNR,4240,B-GENE-N
),4240,O
by,4240,O
isotopic,4240,O
substitution,4240,O
where,4240,O
all,4240,O
non-exchangeable,4240,O
atoms,4240,O
were,4240,O
replaced,4240,O
with,4240,O
the,4240,O
corresponding,4240,O
heavy,4240,O
isotope,4240,O
(,4240,O
(,4240,B-CHEMICAL
13,4240,I-CHEMICAL
),4240,I-CHEMICAL
C,4240,I-CHEMICAL
",",4240,O
(,4240,B-CHEMICAL
15,4240,I-CHEMICAL
),4240,I-CHEMICAL
N,4240,I-CHEMICAL
",",4240,O
and,4240,O
(,4240,B-CHEMICAL
2,4240,I-CHEMICAL
),4240,I-CHEMICAL
H,4240,I-CHEMICAL
),4240,O
.,4240,O
The,4241,O
KIE,4241,O
temperature,4241,O
dependence,4241,O
is,4241,O
perturbed,4241,O
by,4241,O
heavy,4241,O
isotope,4241,O
labeling,4241,O
",",4241,O
demonstrating,4241,O
a,4241,O
direct,4241,O
link,4241,O
between,4241,O
(,4241,O
promoting,4241,O
),4241,O
vibrations,4241,O
in,4241,O
the,4241,O
protein,4241,O
and,4241,O
the,4241,O
observed,4241,O
KIE,4241,O
.,4241,O
Further,4242,O
we,4242,O
show,4242,O
that,4242,O
temperature-independent,4242,O
KIEs,4242,O
do,4242,O
not,4242,O
necessarily,4242,O
rule,4242,O
out,4242,O
a,4242,O
role,4242,O
for,4242,O
fast,4242,O
dynamics,4242,O
coupled,4242,O
to,4242,O
reaction,4242,O
chemistry,4242,O
.,4242,O
We,4243,O
show,4243,O
causality,4243,O
between,4243,O
fast,4243,O
motions,4243,O
and,4243,O
enzyme,4243,O
chemistry,4243,O
and,4243,O
demonstrate,4243,O
how,4243,O
this,4243,O
impacts,4243,O
on,4243,O
experimental,4243,O
KIEs,4243,O
for,4243,O
enzyme,4243,O
reactions,4243,O
.,4243,O
Characterization,4244,O
of,4244,O
the,4244,O
mouse,4244,O
promoter,4244,O
region,4244,O
of,4244,O
the,4244,O
acyl-CoA,4244,B-CHEMICAL
synthetase,4244,I-GENE-Y
4,4244,I-GENE-Y
gene,4244,O
:,4244,O
role,4244,O
of,4244,O
Sp1,4244,B-GENE-Y
and,4244,O
CREB,4244,B-GENE-N
.,4244,O
Acyl-CoA,4245,B-GENE-Y
synthetase,4245,I-GENE-Y
4,4245,I-GENE-Y
(,4245,O
Acsl4,4245,B-GENE-Y
),4245,O
is,4245,O
involved,4245,O
in,4245,O
several,4245,O
cellular,4245,O
functions,4245,O
including,4245,O
steroidogenesis,4245,O
",",4245,O
synaptic,4245,O
development,4245,O
and,4245,O
cancer,4245,O
metastasis,4245,O
.,4245,O
Although,4246,O
the,4246,O
expression,4246,O
of,4246,O
Acsl4,4246,B-GENE-Y
seems,4246,O
to,4246,O
be,4246,O
regulated,4246,O
by,4246,O
tissue-,4246,O
and,4246,O
cell-specific,4246,O
factors,4246,O
as,4246,O
well,4246,O
as,4246,O
pituitary,4246,O
hormones,4246,O
and,4246,O
growth,4246,O
factors,4246,O
",",4246,O
the,4246,O
transcriptional,4246,O
mechanisms,4246,O
involved,4246,O
remain,4246,O
unknown,4246,O
.,4246,O
We,4247,O
demonstrated,4247,O
hCG,4247,B-GENE-N
and,4247,O
cAMP,4247,B-CHEMICAL
regulation,4247,O
of,4247,O
Acsl4,4247,B-GENE-Y
mRNA,4247,O
in,4247,O
mouse,4247,O
steroidogenic,4247,O
MA-10,4247,O
Leydig,4247,O
cells,4247,O
.,4247,O
We,4248,O
characterized,4248,O
the,4248,O
transcription,4248,B-GENE-N
initiation,4248,I-GENE-N
site,4248,I-GENE-N
and,4248,O
promoter,4248,O
of,4248,O
the,4248,O
Acsl4,4248,B-GENE-Y
mouse,4248,O
gene,4248,O
and,4248,O
identified,4248,O
three,4248,O
alternative,4248,O
splice,4248,O
variants,4248,O
present,4248,O
in,4248,O
MA-10,4248,O
cells,4248,O
.,4248,O
Sequence,4249,O
analysis,4249,O
of,4249,O
a,4249,O
1.5-kb,4249,O
fragment,4249,O
of,4249,O
the,4249,O
Acsl4,4249,B-GENE-N
promoter,4249,I-GENE-N
revealed,4249,O
the,4249,O
absence,4249,O
of,4249,O
a,4249,O
TATA,4249,B-GENE-N
box,4249,I-GENE-N
and,4249,O
the,4249,O
presence,4249,O
of,4249,O
many,4249,O
putative,4249,O
binding,4249,O
sites,4249,O
for,4249,O
transcription,4249,O
factors,4249,O
including,4249,O
Sp1,4249,B-GENE-Y
and,4249,O
CREB,4249,B-GENE-N
.,4249,O
Functional,4250,O
characterization,4250,O
revealed,4250,O
that,4250,O
the,4250,O
specificity,4250,B-GENE-N
protein/Krppel-like,4250,O
factor,4250,I-GENE-N
Sp1,4250,B-GENE-Y
binding,4250,O
site,4250,O
in,4250,O
the,4250,O
proximal,4250,O
promoter,4250,O
is,4250,O
involved,4250,O
in,4250,O
basal,4250,O
activity,4250,O
and,4250,O
that,4250,O
the,4250,O
cAMP,4250,B-CHEMICAL
response,4250,I-GENE-N
element-binding,4250,O
site,4250,O
is,4250,O
involved,4250,O
in,4250,O
cAMP,4250,B-CHEMICAL
stimulation,4250,O
of,4250,O
Acsl4,4250,B-GENE-Y
transcription,4250,O
.,4250,O
Synthesis,4251,O
and,4251,O
biological,4251,O
evaluation,4251,O
of,4251,O
"1,3,4-thiadiazole",4251,B-CHEMICAL
analogues,4251,O
as,4251,O
novel,4251,O
AChE,4251,B-GENE-Y
and,4251,O
BuChE,4251,B-GENE-Y
inhibitors,4251,O
.,4251,O
In,4252,O
this,4252,O
paper,4252,O
a,4252,O
series,4252,O
of,4252,O
new,4252,O
"1,3,4-thiadiazole",4252,B-CHEMICAL
derivatives,4252,O
has,4252,O
been,4252,O
designed,4252,O
",",4252,O
synthesized,4252,O
and,4252,O
evaluated,4252,O
as,4252,O
the,4252,O
acetyl-,4252,B-GENE-N
and,4252,I-GENE-N
butyrylcholinesterase,4252,I-GENE-N
inhibitors,4252,O
.,4252,O
Some,4253,O
analogues,4253,O
showed,4253,O
promising,4253,O
inhibition,4253,O
of,4253,O
both,4253,O
enzymes,4253,O
in,4253,O
vitro,4253,O
in,4253,O
the,4253,O
nM,4253,O
range,4253,O
.,4253,O
Generally,4254,O
",",4254,O
inhibitory,4254,O
potency,4254,O
of,4254,O
compounds,4254,O
was,4254,O
stronger,4254,O
against,4254,O
AChE,4254,B-GENE-Y
than,4254,O
BuChE,4254,B-GENE-Y
",",4254,O
and,4254,O
one,4254,O
of,4254,O
them,4254,O
was,4254,O
1154-fold,4254,O
more,4254,O
active,4254,O
inhibiting,4254,O
AChE,4254,B-GENE-Y
(,4254,O
IC50,4254,O
=,4254,O
0.17,4254,O
M,4254,O
),4254,O
than,4254,O
BuChE,4254,B-GENE-Y
.,4254,O
The,4255,O
kinetic,4255,O
studies,4255,O
showed,4255,O
that,4255,O
one,4255,O
of,4255,O
the,4255,O
most,4255,O
active,4255,O
analogues,4255,O
8,4255,O
(,4255,O
IC50,4255,O
=,4255,O
0.09,4255,O
M,4255,O
",",4255,O
AChE,4255,B-GENE-Y
),4255,O
acted,4255,O
as,4255,O
a,4255,O
non-competitive,4255,O
AChE,4255,B-GENE-Y
inhibitor,4255,O
and,4255,O
was,4255,O
characterized,4255,O
by,4255,O
the,4255,O
high,4255,O
selectivity,4255,O
index,4255,O
(,4255,O
300,4255,O
),4255,O
.,4255,O
The,4256,O
other,4256,O
derivative,4256,O
(,4256,O
1,4256,O
),4256,O
exhibited,4256,O
a,4256,O
mixed-type,4256,O
of,4256,O
AChE,4256,B-GENE-Y
inhibition,4256,O
.,4256,O
Docking,4257,O
simulations,4257,O
enabled,4257,O
the,4257,O
detection,4257,O
of,4257,O
key,4257,O
binding,4257,O
interactions,4257,O
of,4257,O
the,4257,O
compounds,4257,O
with,4257,O
AChE,4257,B-GENE-Y
and,4257,O
revealed,4257,O
that,4257,O
they,4257,O
occupied,4257,O
mainly,4257,O
the,4257,O
catalytic,4257,O
active,4257,O
site,4257,O
.,4257,O
The,4258,O
scoring,4258,O
function,4258,O
for,4258,O
the,4258,O
novel,4258,O
compounds,4258,O
was,4258,O
similar,4258,O
or,4258,O
higher,4258,O
than,4258,O
for,4258,O
the,4258,O
reference,4258,O
inhibitor,4258,O
.,4258,O
Additionally,4259,O
",",4259,O
based,4259,O
on,4259,O
Lipinski,4259,O
and,4259,O
other,4259,O
filters,4259,O
",",4259,O
the,4259,O
drug-likeness,4259,O
of,4259,O
compounds,4259,O
was,4259,O
assessed,4259,O
.,4259,O
They,4260,O
revealed,4260,O
that,4260,O
the,4260,O
compounds,4260,O
possess,4260,O
properties,4260,O
which,4260,O
can,4260,O
suggest,4260,O
the,4260,O
favourable,4260,O
pharmacokinetics,4260,O
in,4260,O
the,4260,O
human,4260,O
body,4260,O
after,4260,O
oral,4260,O
admission,4260,O
.,4260,O
PI3,4261,B-GENE-N
k/akt,4261,O
inhibition,4261,O
induces,4261,O
apoptosis,4261,O
through,4261,O
p38,4261,B-GENE-N
activation,4261,O
in,4261,O
neurons,4261,O
.,4261,O
Accumulating,4262,O
evidence,4262,O
suggests,4262,O
that,4262,O
the,4262,O
PI3K/AKT,4262,B-GENE-N
pathway,4262,O
is,4262,O
a,4262,O
pro-survival,4262,O
signalling,4262,O
system,4262,O
in,4262,O
neurons,4262,O
.,4262,O
Therefore,4263,O
",",4263,O
the,4263,O
inhibition,4263,O
of,4263,O
this,4263,O
pathway,4263,O
may,4263,O
be,4263,O
implicated,4263,O
in,4263,O
the,4263,O
degeneration,4263,O
of,4263,O
neurons,4263,O
in,4263,O
Parkinson,4263,O
's,4263,O
disease,4263,O
(,4263,O
PD,4263,O
),4263,O
",",4263,O
Alzheimer,4263,O
's,4263,O
disease,4263,O
(,4263,O
AD,4263,O
),4263,O
",",4263,O
and,4263,O
other,4263,O
neurological,4263,O
disorders,4263,O
.,4263,O
Here,4264,O
we,4264,O
study,4264,O
the,4264,O
participation,4264,O
of,4264,O
the,4264,O
mitogen-activated,4264,B-GENE-N
protein,4264,I-GENE-N
kinase,4264,I-GENE-N
(,4264,O
MAPK,4264,B-GENE-N
),4264,O
pathway,4264,O
on,4264,O
apoptosis,4264,O
induced,4264,O
by,4264,O
PI3K/AKT,4264,B-GENE-N
inhibition,4264,O
in,4264,O
cultured,4264,O
cerebellar,4264,O
granule,4264,O
cells,4264,O
(,4264,O
CGCs,4264,O
),4264,O
.,4264,O
LY294002,4265,B-CHEMICAL
",",4265,O
a,4265,O
specific,4265,O
PI3K/AKT,4265,B-GENE-N
inhibitor,4265,O
",",4265,O
selectively,4265,O
activated,4265,O
the,4265,O
p38,4265,B-GENE-N
MAPK,4265,B-GENE-N
kinase,4265,B-GENE-N
pathway,4265,O
and,4265,O
enhanced,4265,O
c-Jun,4265,B-GENE-Y
phosphorylation,4265,O
",",4265,O
but,4265,O
did,4265,O
not,4265,O
activate,4265,O
JNK,4265,B-GENE-N
.,4265,O
The,4266,O
pharmacological,4266,O
inhibitors,4266,O
SB203580,4266,B-CHEMICAL
(,4266,O
p38,4266,B-GENE-N
inhibitor,4266,O
),4266,O
and,4266,O
SP600125,4266,B-CHEMICAL
(,4266,O
a,4266,O
JNK,4266,B-GENE-N
inhibitor,4266,O
),4266,O
protected,4266,O
primary,4266,O
cultures,4266,O
of,4266,O
rat,4266,O
CGCs,4266,O
from,4266,O
LY294002-induced,4266,B-CHEMICAL
apoptosis,4266,O
.,4266,O
Furthermore,4267,O
",",4267,O
both,4267,O
compounds,4267,O
decreased,4267,O
the,4267,O
phosphorylation,4267,O
of,4267,O
c-Jun,4267,B-GENE-Y
and,4267,O
lowered,4267,O
mRNA,4267,O
levels,4267,O
of,4267,O
the,4267,O
pro-apoptotic,4267,O
gene,4267,O
dp5,4267,B-GENE-Y
",",4267,O
a,4267,O
direct,4267,O
target,4267,O
of,4267,O
c-Jun,4267,B-GENE-Y
.,4267,O
Taken,4268,O
together,4268,O
",",4268,O
our,4268,O
data,4268,O
demonstrate,4268,O
that,4268,O
PI3K/AKT,4268,B-GENE-N
inhibition,4268,O
induces,4268,O
neuronal,4268,O
apoptosis,4268,O
",",4268,O
a,4268,O
process,4268,O
that,4268,O
is,4268,O
mediated,4268,O
by,4268,O
the,4268,O
activation,4268,O
of,4268,O
p38,4268,B-GENE-N
MAPK/c-Jun/dp5,4268,B-GENE-N
.,4268,O
Gender,4269,O
and,4269,O
strain,4269,O
contributions,4269,O
to,4269,O
the,4269,O
variability,4269,O
of,4269,O
buprenorphine-related,4269,B-CHEMICAL
respiratory,4269,O
toxicity,4269,O
in,4269,O
mice,4269,O
.,4269,O
While,4270,O
most,4270,O
deaths,4270,O
from,4270,O
asphyxia,4270,O
related,4270,O
to,4270,O
buprenorphine,4270,B-CHEMICAL
(,4270,O
BUP,4270,B-CHEMICAL
),4270,O
overdose,4270,O
have,4270,O
been,4270,O
reported,4270,O
in,4270,O
males,4270,O
",",4270,O
higher,4270,O
plasma,4270,O
concentrations,4270,O
of,4270,O
BUP,4270,B-CHEMICAL
and,4270,O
its,4270,O
toxic,4270,O
metabolite,4270,O
norbuprenorphine,4270,B-CHEMICAL
(,4270,O
NBUP,4270,B-CHEMICAL
),4270,O
have,4270,O
been,4270,O
observed,4270,O
in,4270,O
females,4270,O
.,4270,O
We,4271,O
previously,4271,O
demonstrated,4271,O
that,4271,O
P-glycoprotein,4271,B-GENE-N
(,4271,O
P-gp,4271,B-GENE-N
),4271,O
modulation,4271,O
at,4271,O
the,4271,O
blood-brain,4271,O
barrier,4271,O
(,4271,O
BBB,4271,O
),4271,O
contributes,4271,O
highly,4271,O
to,4271,O
BUP-related,4271,B-CHEMICAL
respiratory,4271,O
toxicity,4271,O
",",4271,O
by,4271,O
limiting,4271,O
NBUP,4271,B-CHEMICAL
entrance,4271,O
into,4271,O
the,4271,O
brain,4271,O
.,4271,O
In,4272,O
this,4272,O
work,4272,O
",",4272,O
we,4272,O
sought,4272,O
to,4272,O
investigate,4272,O
the,4272,O
role,4272,O
of,4272,O
P-gp-mediated,4272,B-GENE-N
transport,4272,O
at,4272,O
the,4272,O
BBB,4272,O
in,4272,O
gender,4272,O
and,4272,O
strain-related,4272,O
variability,4272,O
of,4272,O
BUP,4272,B-CHEMICAL
and,4272,O
NBUP-induced,4272,B-CHEMICAL
respiratory,4272,O
effects,4272,O
in,4272,O
mice,4272,O
.,4272,O
Ventilation,4273,O
was,4273,O
studied,4273,O
using,4273,O
plethysmography,4273,O
",",4273,O
P-gp,4273,B-GENE-N
expression,4273,O
using,4273,O
western,4273,O
blot,4273,O
",",4273,O
and,4273,O
transport,4273,O
at,4273,O
the,4273,O
BBB,4273,O
using,4273,O
in,4273,O
situ,4273,O
cerebral,4273,O
perfusion,4273,O
.,4273,O
In,4274,O
male,4274,O
Fvb,4274,O
and,4274,O
Swiss,4274,O
mice,4274,O
",",4274,O
BUP,4274,B-CHEMICAL
was,4274,O
responsible,4274,O
for,4274,O
ceiling,4274,O
respiratory,4274,O
effects,4274,O
.,4274,O
NBUP-related,4275,B-CHEMICAL
reduction,4275,O
in,4275,O
minute,4275,O
volume,4275,O
was,4275,O
dose-dependent,4275,O
but,4275,O
more,4275,O
marked,4275,O
in,4275,O
Fvb,4275,O
(,4275,O
p,4275,O
<,4275,O
0.01,4275,O
at,4275,O
1mg/kg,4275,O
NBUP,4275,B-CHEMICAL
and,4275,O
p,4275,O
<,4275,O
0.001,4275,O
at,4275,O
3,4275,O
and,4275,O
9mg/kg,4275,O
NBUP,4275,B-CHEMICAL
),4275,O
than,4275,O
in,4275,O
Swiss,4275,O
mice,4275,O
(,4275,O
p,4275,O
<,4275,O
0.001,4275,O
at,4275,O
9mg/kg,4275,O
NBUP,4275,B-CHEMICAL
),4275,O
.,4275,O
Female,4276,O
Fvb,4276,O
mice,4276,O
were,4276,O
more,4276,O
susceptible,4276,O
to,4276,O
BUP,4276,B-CHEMICAL
than,4276,O
males,4276,O
with,4276,O
significantly,4276,O
increased,4276,O
inspiratory,4276,O
time,4276,O
(,4276,O
p,4276,O
<,4276,O
0.05,4276,O
),4276,O
and,4276,O
to,4276,O
NBUP,4276,B-CHEMICAL
with,4276,O
significantly,4276,O
increased,4276,O
expiratory,4276,O
time,4276,O
(,4276,O
p,4276,O
<,4276,O
0.01,4276,O
),4276,O
.,4276,O
Following,4277,O
BUP,4277,B-CHEMICAL
administration,4277,O
",",4277,O
plasma,4277,O
BUP,4277,B-CHEMICAL
concentrations,4277,O
were,4277,O
significantly,4277,O
higher,4277,O
(,4277,O
p,4277,O
<,4277,O
0.01,4277,O
),4277,O
and,4277,O
plasma,4277,O
NBUP,4277,B-CHEMICAL
concentrations,4277,O
significantly,4277,O
lower,4277,O
(,4277,O
p,4277,O
<,4277,O
0.001,4277,O
),4277,O
in,4277,O
Fvb,4277,O
mice,4277,O
compared,4277,O
to,4277,O
Swiss,4277,O
mice,4277,O
.,4277,O
Plasma,4278,O
BUP,4278,B-CHEMICAL
concentrations,4278,O
were,4278,O
significantly,4278,O
higher,4278,O
(,4278,O
p,4278,O
<,4278,O
0.05,4278,O
),4278,O
and,4278,O
plasma,4278,O
NBUP,4278,B-CHEMICAL
concentrations,4278,O
significantly,4278,O
lower,4278,O
(,4278,O
p,4278,O
<,4278,O
0.01,4278,O
),4278,O
in,4278,O
male,4278,O
compared,4278,O
to,4278,O
female,4278,O
Fvb,4278,O
mice,4278,O
.,4278,O
In,4279,O
contrast,4279,O
",",4279,O
following,4279,O
NBUP,4279,B-CHEMICAL
administration,4279,O
",",4279,O
comparable,4279,O
plasma,4279,O
NBUP,4279,B-CHEMICAL
concentrations,4279,O
were,4279,O
observed,4279,O
in,4279,O
both,4279,O
genders,4279,O
and,4279,O
strains,4279,O
.,4279,O
No,4280,O
differences,4280,O
in,4280,O
P-gp,4280,B-GENE-N
expression,4280,O
or,4280,O
BUP,4280,B-CHEMICAL
and,4280,O
NBUP,4280,B-CHEMICAL
transport,4280,O
across,4280,O
the,4280,O
BBB,4280,O
were,4280,O
observed,4280,O
between,4280,O
male,4280,O
and,4280,O
female,4280,O
Fvb,4280,O
mice,4280,O
as,4280,O
well,4280,O
as,4280,O
between,4280,O
Swiss,4280,O
and,4280,O
Fvb,4280,O
mice,4280,O
.,4280,O
Our,4281,O
results,4281,O
suggest,4281,O
that,4281,O
P-gp-mediated,4281,B-GENE-N
transport,4281,O
across,4281,O
the,4281,O
BBB,4281,O
does,4281,O
not,4281,O
play,4281,O
a,4281,O
key-role,4281,O
in,4281,O
gender,4281,O
and,4281,O
strain-related,4281,O
variability,4281,O
in,4281,O
BUP,4281,B-CHEMICAL
and,4281,O
NBUP-induced,4281,B-CHEMICAL
respiratory,4281,O
toxicity,4281,O
in,4281,O
mice,4281,O
.,4281,O
Both,4282,O
gender-,4282,O
and,4282,O
strain-related,4282,O
differences,4282,O
in,4282,O
respiratory,4282,O
effects,4282,O
of,4282,O
BUP,4282,B-CHEMICAL
could,4282,O
be,4282,O
attributed,4282,O
to,4282,O
BUP,4282,B-CHEMICAL
itself,4282,O
rather,4282,O
than,4282,O
to,4282,O
its,4282,O
metabolite,4282,O
",",4282,O
NBUP,4282,B-CHEMICAL
.,4282,O
Autophagy,4283,O
takes,4283,O
place,4283,O
in,4283,O
mutated,4283,O
p53,4283,B-GENE-Y
neuroblastoma,4283,O
cells,4283,O
in,4283,O
response,4283,O
to,4283,O
hypoxia,4283,O
mimetic,4283,O
CoCl,4283,B-CHEMICAL
(,4283,I-CHEMICAL
2,4283,I-CHEMICAL
),4283,I-CHEMICAL
.,4283,O
Solid,4284,O
tumors,4284,O
like,4284,O
neuroblastoma,4284,O
exhibit,4284,O
hypoxic,4284,O
areas,4284,O
",",4284,O
which,4284,O
can,4284,O
lead,4284,O
both,4284,O
to,4284,O
cell,4284,O
death,4284,O
or,4284,O
aggressiveness,4284,O
increase,4284,O
.,4284,O
Hypoxia,4285,O
is,4285,O
a,4285,O
known,4285,O
stress,4285,O
able,4285,O
to,4285,O
induce,4285,O
stabilization,4285,O
of,4285,O
p53,4285,B-GENE-Y
",",4285,O
implicated,4285,O
in,4285,O
cell,4285,O
fate,4285,O
regulation,4285,O
.,4285,O
Recently,4286,O
",",4286,O
p53,4286,B-GENE-Y
appeared,4286,O
to,4286,O
be,4286,O
involved,4286,O
in,4286,O
autophagy,4286,O
in,4286,O
an,4286,O
opposite,4286,O
manner,4286,O
",",4286,O
depending,4286,O
on,4286,O
its,4286,O
location,4286,O
:,4286,O
when,4286,O
nuclear,4286,O
",",4286,O
it,4286,O
enhanced,4286,O
transcription,4286,O
of,4286,O
pro-autophagic,4286,O
genes,4286,O
whereas,4286,O
when,4286,O
cytoplasmic,4286,O
",",4286,O
it,4286,O
inhibited,4286,O
the,4286,O
autophagic,4286,O
process,4286,O
.,4286,O
Today,4287,O
",",4287,O
we,4287,O
used,4287,O
cobalt,4287,B-CHEMICAL
chloride,4287,I-CHEMICAL
",",4287,O
a,4287,O
hypoxia,4287,O
mimetic,4287,O
that,4287,O
inhibits,4287,O
proteasomal,4287,O
HIF-1,4287,B-GENE-Y
degradation,4287,O
and,4287,O
generates,4287,O
reactive,4287,O
oxygen,4287,B-CHEMICAL
species,4287,O
(,4287,O
ROS,4287,O
),4287,O
.,4287,O
We,4288,O
focused,4288,O
on,4288,O
CoCl2-induced,4288,B-CHEMICAL
cell,4288,O
death,4288,O
in,4288,O
a,4288,O
DNA-binding,4288,O
mutated,4288,O
p53,4288,B-GENE-Y
neuroblastoma,4288,O
cell,4288,O
line,4288,O
(,4288,O
SKNBE,4288,O
(,4288,O
2c,4288,O
),4288,O
),4288,O
.,4288,O
An,4289,O
autophagic,4289,O
signaling,4289,O
was,4289,O
evidenced,4289,O
by,4289,O
an,4289,O
increase,4289,O
of,4289,O
Beclin-1,4289,B-GENE-Y
",",4289,O
ATG,4289,B-GENE-N
5-12,4289,I-GENE-N
",",4289,O
and,4289,O
LC3-II,4289,B-GENE-Y
expression,4289,O
whereas,4289,O
the,4289,O
p53,4289,B-GENE-Y
(,4289,O
mut,4289,O
),4289,O
presence,4289,O
decreased,4289,O
with,4289,O
CoCl2,4289,B-CHEMICAL
time,4289,O
exposure,4289,O
.,4289,O
Activation,4290,O
of,4290,O
the,4290,O
pathway,4290,O
seemed,4290,O
to,4290,O
protect,4290,O
cells,4290,O
from,4290,O
ROS,4290,O
production,4290,O
and,4290,O
",",4290,O
at,4290,O
least,4290,O
in,4290,O
part,4290,O
",",4290,O
from,4290,O
death,4290,O
.,4290,O
The,4291,O
autophagic,4291,O
inhibitors,4291,O
activated,4291,O
the,4291,O
apoptotic,4291,O
signaling,4291,O
and,4291,O
the,4291,O
death,4291,O
was,4291,O
enhanced,4291,O
.,4291,O
To,4292,O
delineate,4292,O
the,4292,O
eventual,4292,O
implication,4292,O
of,4292,O
the,4292,O
p53,4292,B-GENE-Y
(,4292,O
mut,4292,O
),4292,O
in,4292,O
the,4292,O
autophagic,4292,O
process,4292,O
in,4292,O
response,4292,O
to,4292,O
hypoxia,4292,O
",",4292,O
we,4292,O
monitored,4292,O
signaling,4292,O
in,4292,O
p53,4292,B-GENE-Y
(,4292,O
WT,4292,O
),4292,O
SHSY5Y,4292,O
cells,4292,O
",",4292,O
after,4292,O
either,4292,O
shRNA-p53,4292,O
down-regulation,4292,O
or,4292,O
transcriptional,4292,O
activity,4292,O
inhibition,4292,O
by,4292,O
pifithrin,4292,O
alpha,4292,O
.,4292,O
We,4293,O
did,4293,O
not,4293,O
detect,4293,O
autophagy,4293,O
neither,4293,O
with,4293,O
p53,4293,B-GENE-Y
(,4293,O
wt,4293,O
),4293,O
nor,4293,O
when,4293,O
p53,4293,B-GENE-Y
was,4293,O
lacking,4293,O
whereas,4293,O
such,4293,O
a,4293,O
response,4293,O
was,4293,O
effective,4293,O
with,4293,O
a,4293,O
mutated,4293,O
or,4293,O
inactivated,4293,O
p53,4293,B-GENE-Y
.,4293,O
To,4294,O
conclude,4294,O
",",4294,O
mutated,4294,O
p53,4294,B-GENE-Y
in,4294,O
neuroblastoma,4294,O
cells,4294,O
could,4294,O
be,4294,O
linked,4294,O
with,4294,O
the,4294,O
switch,4294,O
between,4294,O
apoptotic,4294,O
response,4294,O
and,4294,O
cell,4294,O
death,4294,O
by,4294,O
autophagy,4294,O
in,4294,O
response,4294,O
to,4294,O
hypoxic,4294,O
mimetic,4294,O
stress,4294,O
.,4294,O
Mammalian,4295,O
myosin-18A,4295,B-GENE-Y
",",4295,O
a,4295,O
highly,4295,O
divergent,4295,O
myosin,4295,B-GENE-N
.,4295,O
The,4296,O
Mus,4296,B-GENE-Y
musculus,4296,I-GENE-Y
myosin-18A,4296,I-GENE-Y
gene,4296,O
is,4296,O
expressed,4296,O
as,4296,O
two,4296,O
alternatively,4296,O
spliced,4296,O
isoforms,4296,O
",",4296,O
,4296,O
and,4296,O
,4296,O
",",4296,O
with,4296,O
reported,4296,O
roles,4296,O
in,4296,O
Golgi,4296,O
localization,4296,O
",",4296,O
in,4296,O
maintenance,4296,O
of,4296,O
cytoskeleton,4296,O
",",4296,O
and,4296,O
as,4296,O
receptors,4296,O
for,4296,O
immunological,4296,O
surfactant,4296,O
proteins,4296,O
.,4296,O
Both,4297,O
myosin-18A,4297,B-GENE-Y
isoforms,4297,O
feature,4297,O
a,4297,O
myosin,4297,B-GENE-N
motor,4297,I-GENE-N
domain,4297,I-GENE-N
",",4297,O
a,4297,O
single,4297,O
predicted,4297,O
IQ,4297,B-GENE-N
motif,4297,I-GENE-N
",",4297,O
and,4297,O
a,4297,O
long,4297,O
coiled-coil,4297,O
reminiscent,4297,O
of,4297,O
myosin-2,4297,B-GENE-Y
.,4297,O
The,4298,O
myosin-18A,4298,B-GENE-Y
isoform,4298,O
",",4298,O
additionally,4298,O
",",4298,O
has,4298,O
an,4298,O
N-terminal,4298,B-CHEMICAL
PDZ,4298,B-GENE-N
domain,4298,I-GENE-N
.,4298,O
Recombinant,4299,O
heavy,4299,O
meromyosin-,4299,O
and,4299,O
subfragment-1,4299,O
(,4299,O
S1,4299,O
),4299,O
-like,4299,O
constructs,4299,O
for,4299,O
both,4299,O
myosin-18A,4299,B-GENE-N
and,4299,I-GENE-N
-18,4299,I-GENE-N
species,4299,O
were,4299,O
purified,4299,O
from,4299,O
the,4299,O
baculovirus/Sf9,4299,O
cell,4299,O
expression,4299,O
system,4299,O
.,4299,O
These,4300,O
constructs,4300,O
bound,4300,O
both,4300,O
essential,4300,O
and,4300,O
regulatory,4300,O
light,4300,O
chains,4300,O
",",4300,O
indicating,4300,O
an,4300,O
additional,4300,O
noncanonical,4300,O
light,4300,O
chain,4300,O
binding,4300,O
site,4300,O
in,4300,O
the,4300,O
neck,4300,O
.,4300,O
Myosin-18A-S1,4301,B-GENE-N
and,4301,I-GENE-N
-18A-S1,4301,I-GENE-N
molecules,4301,O
bound,4301,O
actin,4301,O
weakly,4301,O
with,4301,O
Kd,4301,O
values,4301,O
of,4301,O
4.9,4301,O
and,4301,O
54,4301,O
m,4301,O
",",4301,O
respectively,4301,O
.,4301,O
The,4302,O
actin,4302,O
binding,4302,O
data,4302,O
could,4302,O
be,4302,O
modeled,4302,O
by,4302,O
assuming,4302,O
an,4302,O
equilibrium,4302,O
between,4302,O
two,4302,O
myosin,4302,O
conformations,4302,O
",",4302,O
a,4302,O
competent,4302,O
and,4302,O
an,4302,O
incompetent,4302,O
form,4302,O
to,4302,O
bind,4302,O
actin,4302,O
.,4302,O
Actin,4303,B-GENE-N
binding,4303,O
was,4303,O
unchanged,4303,O
by,4303,O
presence,4303,O
of,4303,O
nucleotide,4303,B-CHEMICAL
.,4303,O
Both,4304,O
myosin-18A,4304,B-GENE-Y
isoforms,4304,O
bound,4304,O
N-methylanthraniloyl-nucleotides,4304,B-CHEMICAL
",",4304,O
but,4304,O
the,4304,O
rate,4304,O
of,4304,O
ATP,4304,B-CHEMICAL
hydrolysis,4304,O
was,4304,O
very,4304,O
slow,4304,O
(,4304,O
<,4304,O
0.002,4304,O
s,4304,O
(,4304,O
-1,4304,O
),4304,O
),4304,O
and,4304,O
not,4304,O
significantly,4304,O
enhanced,4304,O
by,4304,O
actin,4304,B-GENE-N
.,4304,O
Phosphorylation,4305,O
of,4305,O
the,4305,O
regulatory,4305,O
light,4305,O
chain,4305,O
had,4305,O
no,4305,O
effect,4305,O
on,4305,O
ATP,4305,B-CHEMICAL
hydrolysis,4305,O
",",4305,O
and,4305,O
neither,4305,O
did,4305,O
the,4305,O
addition,4305,O
of,4305,O
tropomyosin,4305,O
or,4305,O
of,4305,O
GOLPH3,4305,O
",",4305,O
a,4305,O
myosin-18A,4305,B-GENE-Y
binding,4305,O
partner,4305,O
.,4305,O
Electron,4306,O
microscopy,4306,O
of,4306,O
myosin-18A-S1,4306,B-GENE-Y
showed,4306,O
that,4306,O
the,4306,O
lever,4306,O
is,4306,O
strongly,4306,O
angled,4306,O
with,4306,O
respect,4306,O
to,4306,O
the,4306,O
long,4306,O
axis,4306,O
of,4306,O
the,4306,O
motor,4306,O
domain,4306,O
",",4306,O
suggesting,4306,O
a,4306,O
pre-power,4306,O
stroke,4306,O
conformation,4306,O
regardless,4306,O
of,4306,O
the,4306,O
presence,4306,O
of,4306,O
ATP,4306,B-CHEMICAL
.,4306,O
These,4307,O
data,4307,O
lead,4307,O
us,4307,O
to,4307,O
conclude,4307,O
that,4307,O
myosin-18A,4307,B-GENE-Y
does,4307,O
not,4307,O
operate,4307,O
as,4307,O
a,4307,O
traditional,4307,O
molecular,4307,O
motor,4307,O
in,4307,O
cells,4307,O
.,4307,O
Supervillin-mediated,4308,B-GENE-Y
suppression,4308,O
of,4308,O
p53,4308,B-GENE-Y
protein,4308,O
enhances,4308,O
cell,4308,O
survival,4308,O
.,4308,O
Integrin-based,4309,B-GENE-N
adhesions,4309,O
promote,4309,O
cell,4309,O
survival,4309,O
as,4309,O
well,4309,O
as,4309,O
cell,4309,O
motility,4309,O
and,4309,O
invasion,4309,O
.,4309,O
We,4310,O
show,4310,O
here,4310,O
that,4310,O
the,4310,O
adhesion,4310,B-GENE-N
regulatory,4310,I-GENE-N
protein,4310,I-GENE-N
supervillin,4310,B-GENE-Y
increases,4310,O
cell,4310,O
survival,4310,O
by,4310,O
decreasing,4310,O
levels,4310,O
of,4310,O
the,4310,O
tumor,4310,B-GENE-N
suppressor,4310,I-GENE-N
protein,4310,I-GENE-N
p53,4310,B-GENE-Y
and,4310,O
downstream,4310,O
target,4310,O
genes,4310,O
.,4310,O
RNAi-mediated,4311,O
knockdown,4311,O
of,4311,O
a,4311,O
new,4311,O
splice,4311,O
form,4311,O
of,4311,O
supervillin,4311,B-GENE-N
(,4311,I-GENE-N
isoform,4311,I-GENE-N
4,4311,I-GENE-N
),4311,I-GENE-N
or,4311,I-GENE-N
both,4311,I-GENE-N
isoforms,4311,I-GENE-N
1,4311,I-GENE-N
and,4311,I-GENE-N
4,4311,I-GENE-N
increases,4311,O
the,4311,O
amount,4311,O
of,4311,O
p53,4311,B-GENE-Y
and,4311,O
cell,4311,O
death,4311,O
",",4311,O
whereas,4311,O
p53,4311,B-GENE-Y
levels,4311,O
decrease,4311,O
after,4311,O
overexpression,4311,O
of,4311,O
either,4311,O
supervillin,4311,B-GENE-Y
isoform,4311,O
.,4311,O
Cellular,4312,O
responses,4312,O
to,4312,O
DNA,4312,O
damage,4312,O
induced,4312,O
by,4312,O
etoposide,4312,B-CHEMICAL
or,4312,O
doxorubicin,4312,B-CHEMICAL
include,4312,O
down-regulation,4312,O
of,4312,O
endogenous,4312,O
supervillin,4312,B-GENE-Y
coincident,4312,O
with,4312,O
increases,4312,O
in,4312,O
p53,4312,B-GENE-Y
.,4312,O
In,4313,O
DNA-damaged,4313,O
supervillin,4313,B-GENE-Y
knockdown,4313,O
cells,4313,O
",",4313,O
p53,4313,B-GENE-Y
knockdown,4313,O
or,4313,O
inhibition,4313,O
partially,4313,O
rescues,4313,O
the,4313,O
loss,4313,O
of,4313,O
cell,4313,O
metabolic,4313,O
activity,4313,O
",",4313,O
a,4313,O
measure,4313,O
of,4313,O
cell,4313,O
proliferation,4313,O
.,4313,O
Knockdown,4314,O
of,4314,O
the,4314,O
p53,4314,B-GENE-Y
deubiquitinating,4314,O
enzyme,4314,O
USP7/HAUSP,4314,B-GENE-Y
also,4314,O
reverses,4314,O
the,4314,O
supervillin,4314,B-GENE-Y
phenotype,4314,O
",",4314,O
blocking,4314,O
the,4314,O
increase,4314,O
in,4314,O
p53,4314,B-GENE-Y
levels,4314,O
seen,4314,O
after,4314,O
supervillin,4314,B-GENE-Y
knockdown,4314,O
and,4314,O
accentuating,4314,O
the,4314,O
decrease,4314,O
in,4314,O
p53,4314,B-GENE-Y
levels,4314,O
triggered,4314,O
by,4314,O
supervillin,4314,B-GENE-Y
overexpression,4314,O
.,4314,O
Conversely,4315,O
",",4315,O
supervillin,4315,B-GENE-Y
overexpression,4315,O
decreases,4315,O
the,4315,O
association,4315,O
of,4315,O
USP7,4315,B-GENE-Y
and,4315,O
p53,4315,B-GENE-Y
and,4315,O
attenuates,4315,O
USP7-mediated,4315,B-GENE-N
p53,4315,B-GENE-Y
deubiquitination,4315,O
.,4315,O
USP7,4316,B-GENE-N
binds,4316,O
directly,4316,O
to,4316,O
the,4316,O
supervillin,4316,B-GENE-Y
N,4316,B-CHEMICAL
terminus,4316,O
and,4316,O
can,4316,O
deubiquitinate,4316,O
and,4316,O
stabilize,4316,O
supervillin,4316,B-GENE-Y
.,4316,O
Supervillin,4317,B-GENE-N
also,4317,O
is,4317,O
stabilized,4317,O
by,4317,O
derivatization,4317,O
with,4317,O
the,4317,O
ubiquitin-like,4317,B-GENE-N
protein,4317,O
SUMO1,4317,B-GENE-Y
.,4317,O
These,4318,O
results,4318,O
show,4318,O
that,4318,O
supervillin,4318,B-GENE-Y
regulates,4318,O
cell,4318,O
survival,4318,O
through,4318,O
control,4318,O
of,4318,O
p53,4318,B-GENE-Y
levels,4318,O
and,4318,O
suggest,4318,O
that,4318,O
supervillin,4318,B-GENE-Y
and,4318,O
its,4318,O
interaction,4318,O
partners,4318,O
at,4318,O
sites,4318,O
of,4318,O
cell-substrate,4318,O
adhesion,4318,O
constitute,4318,O
a,4318,O
locus,4318,O
for,4318,O
cross-talk,4318,O
between,4318,O
survival,4318,O
signaling,4318,O
and,4318,O
cell,4318,O
motility,4318,O
pathways,4318,O
.,4318,O
Novel,4319,O
acylethanolamide,4319,B-CHEMICAL
derivatives,4319,O
that,4319,O
modulate,4319,O
body,4319,O
weight,4319,O
through,4319,O
enhancement,4319,O
of,4319,O
hypothalamic,4319,O
pro-opiomelanocortin,4319,B-GENE-Y
(,4319,O
POMC,4319,B-GENE-Y
),4319,O
and/or,4319,O
decreased,4319,O
neuropeptide,4319,B-GENE-Y
Y,4319,I-GENE-Y
(,4319,O
NPY,4319,B-GENE-Y
),4319,O
.,4319,O
Newly,4320,O
synthesized,4320,O
acylethanolamide,4320,B-CHEMICAL
derivatives,4320,O
oleoyl-L-valinolamide,4320,B-CHEMICAL
(,4320,O
1,4320,O
),4320,O
",",4320,O
oleoyl-D-valinolamide,4320,B-CHEMICAL
(,4320,O
2,4320,O
),4320,O
",",4320,O
elaidoyl-L-valinolamide,4320,B-CHEMICAL
(,4320,O
3,4320,O
),4320,O
",",4320,O
elaidoyl-D-valinolamide,4320,B-CHEMICAL
(,4320,O
4,4320,O
),4320,O
stearoyl-L-valinolamide,4320,B-CHEMICAL
(,4320,O
5,4320,O
),4320,O
",",4320,O
and,4320,O
palmitoyl-L-valinolamide,4320,B-CHEMICAL
(,4320,O
6,4320,O
),4320,O
were,4320,O
investigated,4320,O
in,4320,O
mice,4320,O
as,4320,O
antiobesity,4320,O
compounds,4320,O
.,4320,O
Compounds,4321,O
1,4321,O
",",4321,O
2,4321,O
",",4321,O
5,4321,O
",",4321,O
6,4321,O
significantly,4321,O
decreased,4321,O
body,4321,O
weight,4321,O
by,4321,O
6.57,4321,O
%,4321,O
following,4321,O
eight,4321,O
injections,4321,O
of,4321,O
1,4321,O
mg/kg,4321,O
i.p,4321,O
.,4321,O
during,4322,O
39,4322,O
days,4322,O
",",4322,O
while,4322,O
3,4322,O
and,4322,O
4,4322,O
showed,4322,O
no,4322,O
such,4322,O
activity,4322,O
.,4322,O
Receptor,4323,O
binding,4323,O
indicated,4323,O
that,4323,O
no,4323,O
compound,4323,O
activated,4323,O
CB1,4323,B-GENE-Y
",",4323,O
CB2,4323,B-GENE-Y
",",4323,O
PPAR,4323,B-GENE-Y
",",4323,O
or,4323,O
TRPV1,4323,B-GENE-Y
receptors,4323,O
.,4323,O
Hypothalamic,4324,O
RT-PCR,4324,O
showed,4324,O
that,4324,O
mRNA,4324,O
expression,4324,O
of,4324,O
the,4324,O
anorexigenic,4324,O
genes,4324,O
POMC,4324,B-GENE-Y
and,4324,O
CART,4324,B-GENE-Y
was,4324,O
up-regulated,4324,O
by,4324,O
1,4324,O
",",4324,O
2,4324,O
",",4324,O
5,4324,O
and,4324,O
1,4324,O
",",4324,O
2,4324,O
",",4324,O
respectively,4324,O
",",4324,O
while,4324,O
that,4324,O
of,4324,O
the,4324,O
orexigenic,4324,O
genes,4324,O
NPY,4324,B-GENE-Y
and,4324,O
CaMKK2,4324,B-GENE-Y
was,4324,O
down-regulated,4324,O
by,4324,O
the,4324,O
respective,4324,O
compounds,4324,O
1,4324,O
",",4324,O
5,4324,O
",",4324,O
6,4324,O
and,4324,O
1,4324,O
",",4324,O
2,4324,O
",",4324,O
5,4324,O
.,4324,O
Oleoyl-L-valinolamide,4325,B-CHEMICAL
enhances,4325,O
anorectic,4325,O
pathways,4325,O
and,4325,O
lead,4325,O
to,4325,O
decreased,4325,O
glucose,4325,B-CHEMICAL
levels,4325,O
",",4325,O
enhanced,4325,O
locomotor,4325,O
activity,4325,O
",",4325,O
and,4325,O
improved,4325,O
cognition,4325,O
.,4325,O
Effects,4326,O
of,4326,O
oleoyl-L-valinolamide,4326,B-CHEMICAL
on,4326,O
weight,4326,O
were,4326,O
dose-dependent,4326,O
",",4326,O
and,4326,O
it,4326,O
could,4326,O
be,4326,O
given,4326,O
orally,4326,O
.,4326,O
1,4327,O
",",4327,O
2,4327,O
",",4327,O
4,4327,O
",",4327,O
5,4327,O
down-regulated,4327,O
FAAH,4327,B-GENE-Y
mRNA,4327,O
expression,4327,O
.,4327,O
Northern,4328,O
contaminant,4328,O
mixtures,4328,O
induced,4328,O
morphological,4328,O
and,4328,O
functional,4328,O
changes,4328,O
in,4328,O
human,4328,O
coronary,4328,O
artery,4328,O
endothelial,4328,O
cells,4328,O
under,4328,O
culture,4328,O
conditions,4328,O
typifying,4328,O
high,4328,O
fat/sugar,4328,O
diet,4328,O
and,4328,O
ethanol,4328,B-CHEMICAL
exposure,4328,O
.,4328,O
It,4329,O
has,4329,O
been,4329,O
reported,4329,O
that,4329,O
Northern,4329,O
populations,4329,O
are,4329,O
exposed,4329,O
to,4329,O
mixtures,4329,O
of,4329,O
various,4329,O
environmental,4329,O
contaminants,4329,O
unique,4329,O
to,4329,O
the,4329,O
Arctic,4329,O
(,4329,O
Northern,4329,O
contaminant,4329,O
mixtures,4329,O
-,4329,O
NCM,4329,O
),4329,O
at,4329,O
a,4329,O
large,4329,O
range,4329,O
of,4329,O
concentrations,4329,O
",",4329,O
depending,4329,O
on,4329,O
their,4329,O
geological,4329,O
location,4329,O
",",4329,O
age,4329,O
",",4329,O
lifestyle,4329,O
and,4329,O
dietary,4329,O
habits,4329,O
.,4329,O
To,4330,O
determine,4330,O
if,4330,O
these,4330,O
contaminants,4330,O
may,4330,O
contribute,4330,O
to,4330,O
a,4330,O
cardiovascular,4330,O
health,4330,O
risk,4330,O
",",4330,O
especially,4330,O
when,4330,O
combined,4330,O
with,4330,O
a,4330,O
high,4330,O
fat,4330,O
and,4330,O
sugar,4330,B-CHEMICAL
diet,4330,O
and,4330,O
ethanol,4330,B-CHEMICAL
exposure,4330,O
",",4330,O
we,4330,O
treated,4330,O
human,4330,O
coronary,4330,O
artery,4330,O
endothelial,4330,O
cells,4330,O
(,4330,O
HCAEC,4330,O
),4330,O
with,4330,O
two,4330,O
mixtures,4330,O
of,4330,O
4,4330,O
organic,4330,O
(,4330,O
NCM1,4330,O
),4330,O
or,4330,O
22,4330,O
organic,4330,O
and,4330,O
inorganic,4330,O
(,4330,O
NCM2,4330,O
),4330,O
chemicals,4330,O
detected,4330,O
in,4330,O
Northerners,4330,O
',4330,O
blood,4330,O
during,4330,O
2004-2005,4330,O
in,4330,O
the,4330,O
presence,4330,O
or,4330,O
absence,4330,O
of,4330,O
low-density,4330,B-GENE-N
lipoprotein,4330,I-GENE-N
(,4330,O
1.5mg/ml,4330,O
),4330,O
",",4330,O
very-low-density,4330,B-GENE-N
lipoprotein,4330,I-GENE-N
(,4330,O
1.0mg/ml,4330,O
),4330,O
and,4330,O
glucose,4330,B-CHEMICAL
(,4330,O
10mmol/L,4330,O
),4330,O
(,4330,O
LVG,4330,O
),4330,O
",",4330,O
and,4330,O
in,4330,O
the,4330,O
absence,4330,O
or,4330,O
presence,4330,O
of,4330,O
0.1,4330,O
%,4330,O
ethanol,4330,B-CHEMICAL
.,4330,O
After,4331,O
24h,4331,O
of,4331,O
exposure,4331,O
",",4331,O
cell,4331,O
morphology,4331,O
and,4331,O
markers,4331,O
of,4331,O
cytotoxicity,4331,O
and,4331,O
endothelial,4331,O
function,4331,O
were,4331,O
examined,4331,O
.,4331,O
NCM1,4332,O
treatment,4332,O
did,4332,O
not,4332,O
affect,4332,O
cell,4332,O
viability,4332,O
",",4332,O
but,4332,O
increased,4332,O
cell,4332,O
size,4332,O
",",4332,O
disrupted,4332,O
cell,4332,O
membrane,4332,O
integrity,4332,O
",",4332,O
and,4332,O
decreased,4332,O
cell,4332,O
density,4332,O
",",4332,O
uptake,4332,O
of,4332,O
small,4332,O
peptides,4332,O
",",4332,O
release,4332,O
of,4332,O
endothelin-1,4332,B-GENE-Y
(,4332,O
ET-1,4332,B-GENE-Y
),4332,O
and,4332,O
plasminogen,4332,B-GENE-N
activator,4332,I-GENE-N
inhibitor,4332,I-GENE-N
(,4332,O
PAI,4332,B-GENE-N
),4332,O
",",4332,O
while,4332,O
causing,4332,O
no,4332,O
changes,4332,O
in,4332,O
endothelial,4332,B-GENE-Y
nitric,4332,B-CHEMICAL
oxide,4332,I-CHEMICAL
synthase,4332,I-GENE-Y
(,4332,O
eNOS,4332,B-GENE-Y
),4332,O
protein,4332,O
expression,4332,O
and,4332,O
nitric,4332,B-CHEMICAL
oxide,4332,I-CHEMICAL
(,4332,O
NO,4332,B-CHEMICAL
),4332,O
release,4332,O
.,4332,O
In,4333,O
contrast,4333,O
",",4333,O
NCM2,4333,O
decreased,4333,O
cell,4333,O
viability,4333,O
",",4333,O
total,4333,O
protein,4333,O
yield,4333,O
",",4333,O
uptake,4333,O
of,4333,O
small,4333,O
peptides,4333,O
",",4333,O
eNOS,4333,B-GENE-Y
protein,4333,O
expression,4333,O
",",4333,O
and,4333,O
NO,4333,B-CHEMICAL
release,4333,O
and,4333,O
caused,4333,O
membrane,4333,O
damage,4333,O
",",4333,O
but,4333,O
caused,4333,O
no,4333,O
changes,4333,O
in,4333,O
the,4333,O
secretion,4333,O
of,4333,O
ET-1,4333,B-GENE-Y
",",4333,O
prostacyclin,4333,B-CHEMICAL
and,4333,O
PAI,4333,B-GENE-N
.,4333,O
The,4334,O
presence,4334,O
of,4334,O
LVG,4334,O
and/or,4334,O
alcohol,4334,B-CHEMICAL
did,4334,O
or,4334,O
did,4334,O
not,4334,O
influence,4334,O
the,4334,O
effects,4334,O
of,4334,O
NCM1,4334,O
or,4334,O
NCM2,4334,O
depending,4334,O
on,4334,O
the,4334,O
endpoint,4334,O
and,4334,O
the,4334,O
mixture,4334,O
examined,4334,O
.,4334,O
These,4335,O
results,4335,O
suggested,4335,O
that,4335,O
the,4335,O
effects,4335,O
of,4335,O
one,4335,O
or,4335,O
one,4335,O
group,4335,O
of,4335,O
contaminants,4335,O
may,4335,O
be,4335,O
altered,4335,O
by,4335,O
the,4335,O
presence,4335,O
of,4335,O
other,4335,O
contaminants,4335,O
",",4335,O
and,4335,O
that,4335,O
with,4335,O
or,4335,O
without,4335,O
the,4335,O
interaction,4335,O
of,4335,O
high,4335,O
fat,4335,O
and,4335,O
sugar,4335,B-CHEMICAL
diet,4335,O
and/or,4335,O
ethanol,4335,B-CHEMICAL
exposure,4335,O
",",4335,O
NCMs,4335,O
at,4335,O
the,4335,O
concentrations,4335,O
used,4335,O
caused,4335,O
endothelial,4335,O
dysfunction,4335,O
in,4335,O
vitro,4335,O
.,4335,O
It,4336,O
remains,4336,O
to,4336,O
be,4336,O
investigated,4336,O
if,4336,O
these,4336,O
effects,4336,O
of,4336,O
NCMs,4336,O
also,4336,O
occur,4336,O
in,4336,O
vivo,4336,O
.,4336,O
QM/MM,4337,O
simulations,4337,O
of,4337,O
vibrational,4337,O
spectra,4337,O
of,4337,O
bacteriorhodopsin,4337,B-GENE-N
and,4337,O
channelrhodopsin-2,4337,B-GENE-N
.,4337,O
Channelrhodopsin-2,4338,B-GENE-N
is,4338,O
a,4338,O
light-gated,4338,B-GENE-N
ion,4338,I-GENE-N
channel,4338,I-GENE-N
",",4338,O
which,4338,O
has,4338,O
been,4338,O
studied,4338,O
intensively,4338,O
over,4338,O
the,4338,O
last,4338,O
decade,4338,O
.,4338,O
Vibrational,4339,O
spectroscopic,4339,O
experiments,4339,O
started,4339,O
to,4339,O
shed,4339,O
light,4339,O
on,4339,O
the,4339,O
structural,4339,O
changes,4339,O
",",4339,O
that,4339,O
occur,4339,O
during,4339,O
the,4339,O
photocycle,4339,O
",",4339,O
especially,4339,O
in,4339,O
the,4339,O
hydrogen-bonded,4339,B-CHEMICAL
network,4339,O
surrounding,4339,O
the,4339,O
protonated,4339,O
D156,4339,O
and,4339,O
C128,4339,O
-,4339,O
the,4339,O
DC,4339,O
gate,4339,O
.,4339,O
However,4340,O
",",4340,O
the,4340,O
interpretation,4340,O
of,4340,O
these,4340,O
experiments,4340,O
was,4340,O
only,4340,O
based,4340,O
on,4340,O
homology,4340,O
models,4340,O
.,4340,O
Since,4341,O
then,4341,O
",",4341,O
an,4341,O
X-ray,4341,O
structure,4341,O
and,4341,O
better,4341,O
computational,4341,O
models,4341,O
became,4341,O
available,4341,O
.,4341,O
In,4342,O
this,4342,O
article,4342,O
",",4342,O
we,4342,O
show,4342,O
that,4342,O
in,4342,O
combination,4342,O
with,4342,O
a,4342,O
recent,4342,O
reparametrization,4342,O
",",4342,O
the,4342,O
approximate,4342,O
DFT,4342,O
method,4342,O
",",4342,O
DFTB,4342,O
",",4342,O
is,4342,O
able,4342,O
to,4342,O
describe,4342,O
the,4342,O
effects,4342,O
of,4342,O
hydrogen,4342,B-CHEMICAL
bonding,4342,O
on,4342,O
the,4342,O
C,4342,B-CHEMICAL
[,4342,O
double,4342,O
bond,4342,O
",",4342,O
length,4342,O
as,4342,O
m-dash,4342,O
],4342,O
O,4342,B-CHEMICAL
stretch,4342,O
vibration,4342,O
in,4342,O
carboxylic,4342,B-CHEMICAL
acids,4342,I-CHEMICAL
reliably,4342,O
and,4342,O
agrees,4342,O
well,4342,O
with,4342,O
full,4342,O
DFT,4342,O
results,4342,O
.,4342,O
We,4343,O
apply,4343,O
DFTB,4343,O
in,4343,O
a,4343,O
QM/MM,4343,O
framework,4343,O
to,4343,O
perform,4343,O
vibrational,4343,O
analysis,4343,O
of,4343,O
buried,4343,O
aspartic,4343,B-CHEMICAL
acids,4343,I-CHEMICAL
in,4343,O
bacteriorhodopsin,4343,B-GENE-N
and,4343,O
channelrhodopsin-2,4343,B-GENE-N
.,4343,O
Using,4344,O
this,4344,O
approach,4344,O
",",4344,O
we,4344,O
can,4344,O
simulate,4344,O
the,4344,O
FTIR,4344,O
spectral,4344,O
difference,4344,O
between,4344,O
D115,4344,O
in,4344,O
the,4344,O
dark-adapted,4344,O
and,4344,O
K,4344,O
states,4344,O
of,4344,O
bacteriorhodopsin,4344,B-GENE-N
.,4344,O
The,4345,O
FTIR,4345,O
experiments,4345,O
on,4345,O
the,4345,O
DC,4345,O
gate,4345,O
in,4345,O
channelrhodopsin-2,4345,B-GENE-N
are,4345,O
well,4345,O
described,4345,O
using,4345,O
an,4345,O
indirect,4345,O
model,4345,O
",",4345,O
where,4345,O
D156,4345,O
and,4345,O
C128,4345,O
are,4345,O
bridged,4345,O
via,4345,O
a,4345,O
water,4345,O
molecule,4345,O
.,4345,O
Refining,4346,O
the,4346,O
UGT1A,4346,B-GENE-N
haplotype,4346,O
associated,4346,O
with,4346,O
irinotecan-induced,4346,B-CHEMICAL
hematological,4346,O
toxicity,4346,O
in,4346,O
metastatic,4346,O
colorectal,4346,O
cancer,4346,O
patients,4346,O
treated,4346,O
with,4346,O
5-fluorouracil/irinotecan-based,4346,B-CHEMICAL
regimens,4346,O
.,4346,O
Despite,4347,O
the,4347,O
importance,4347,O
of,4347,O
UDP-glucuronosyltransferase,4347,B-CHEMICAL
(,4347,I-GENE-Y
UGT,4347,I-GENE-Y
),4347,I-GENE-Y
1A1,4347,I-GENE-Y
*,4347,O
28,4347,O
in,4347,O
irinotecan,4347,B-CHEMICAL
pharmacogenetics,4347,O
",",4347,O
our,4347,O
capability,4347,O
to,4347,O
predict,4347,O
drug-induced,4347,O
severe,4347,O
toxicity,4347,O
remains,4347,O
limited,4347,O
.,4347,O
We,4348,O
aimed,4348,O
at,4348,O
identifying,4348,O
novel,4348,O
genetic,4348,O
markers,4348,O
that,4348,O
would,4348,O
improve,4348,O
prediction,4348,O
of,4348,O
irinotecan,4348,B-CHEMICAL
toxicity,4348,O
and,4348,O
response,4348,O
in,4348,O
advanced,4348,O
colorectal,4348,O
cancer,4348,O
patients,4348,O
treated,4348,O
with,4348,O
folic,4348,B-CHEMICAL
acid,4348,I-CHEMICAL
(,4348,O
leucovorin,4348,B-CHEMICAL
),4348,O
",",4348,O
fluorouracil,4348,B-CHEMICAL
(,4348,O
5-FU,4348,B-CHEMICAL
),4348,O
",",4348,O
and,4348,O
irinotecan,4348,B-CHEMICAL
(,4348,O
camptosar,4348,B-CHEMICAL
),4348,O
-based,4348,O
regimens,4348,O
.,4348,O
The,4349,O
relationships,4349,O
between,4349,O
UGT1A,4349,B-GENE-N
candidate,4349,O
markers,4349,O
across,4349,O
the,4349,O
gene,4349,O
(,4349,O
n,4349,O
=,4349,O
21,4349,O
),4349,O
and,4349,O
toxicity,4349,O
were,4349,O
prospectively,4349,O
evaluated,4349,O
in,4349,O
167,4349,O
patients,4349,O
.,4349,O
We,4350,O
included,4350,O
variants,4350,O
in,4350,O
the,4350,O
3'untranscribed,4350,O
region,4350,O
(,4350,O
3'UTR,4350,O
),4350,O
of,4350,O
the,4350,O
UGT1A,4350,B-GENE-N
locus,4350,O
",",4350,O
not,4350,O
studied,4350,O
in,4350,O
this,4350,O
context,4350,O
yet,4350,O
.,4350,O
These,4351,O
genetic,4351,O
markers,4351,O
were,4351,O
further,4351,O
investigated,4351,O
in,4351,O
250,4351,O
Italian,4351,O
FOLFIRI-treated,4351,B-CHEMICAL
patients,4351,O
.,4351,O
Several,4352,O
functional,4352,O
UGT1A,4352,B-GENE-N
variants,4352,O
",",4352,O
including,4352,O
UGT1A1,4352,B-GENE-Y
*,4352,O
28,4352,O
",",4352,O
significantly,4352,O
influenced,4352,O
risk,4352,O
of,4352,O
severe,4352,O
hematologic,4352,O
toxicity,4352,O
.,4352,O
As,4353,O
previously,4353,O
reported,4353,O
in,4353,O
the,4353,O
Italian,4353,O
cohort,4353,O
",",4353,O
a,4353,O
5-marker,4353,O
risk,4353,O
haplotype,4353,O
[,4353,O
haplotype,4353,O
II,4353,O
(,4353,O
HII,4353,O
),4353,O
;,4353,O
UGTs,4353,B-GENE-N
1A9/1A7/1A1,4353,O
],4353,O
was,4353,O
associated,4353,O
with,4353,O
severe,4353,O
neutropenia,4353,O
in,4353,O
our,4353,O
cohort,4353,O
[,4353,O
odds,4353,O
ratio,4353,O
(,4353,O
OR,4353,O
),4353,O
=,4353,O
2.43,4353,O
;,4353,O
P,4353,O
=,4353,O
0.004,4353,O
],4353,O
.,4353,O
The,4354,O
inclusion,4354,O
of,4354,O
a,4354,O
3'UTR,4354,O
single-nucleotide,4354,O
polymorphism,4354,O
(,4354,O
SNP,4354,O
),4354,O
permitted,4354,O
refinement,4354,O
of,4354,O
the,4354,O
previously,4354,O
defined,4354,O
HI,4354,O
",",4354,O
in,4354,O
which,4354,O
HIa,4354,O
was,4354,O
associated,4354,O
with,4354,O
the,4354,O
absence,4354,O
of,4354,O
severe,4354,O
neutropenia,4354,O
in,4354,O
combined,4354,O
cohorts,4354,O
(,4354,O
OR,4354,O
=,4354,O
0.55,4354,O
;,4354,O
P,4354,O
=,4354,O
0.038,4354,O
),4354,O
.,4354,O
Among,4355,O
all,4355,O
tested,4355,O
UGT1A,4355,B-GENE-N
variations,4355,O
and,4355,O
upon,4355,O
multivariate,4355,O
analyses,4355,O
",",4355,O
no,4355,O
UGT1A1,4355,B-GENE-Y
SNPs,4355,O
remained,4355,O
significant,4355,O
",",4355,O
whereas,4355,O
three,4355,O
SNPs,4355,O
located,4355,O
in,4355,O
the,4355,O
central,4355,O
region,4355,O
of,4355,O
UGT1A,4355,B-GENE-N
were,4355,O
linked,4355,O
to,4355,O
neutropenia,4355,O
grade,4355,O
3-4,4355,O
.,4355,O
Haplotype,4356,O
analyses,4356,O
of,4356,O
these,4356,O
markers,4356,O
with,4356,O
the,4356,O
3'UTR,4356,O
SNP,4356,O
allowed,4356,O
the,4356,O
identification,4356,O
of,4356,O
a,4356,O
protective,4356,O
HI,4356,O
(,4356,O
OR,4356,O
=,4356,O
0.50,4356,O
;,4356,O
P,4356,O
=,4356,O
0.048,4356,O
),4356,O
and,4356,O
two,4356,O
risk,4356,O
haplotypes,4356,O
",",4356,O
HII,4356,O
and,4356,O
HIII,4356,O
",",4356,O
characterized,4356,O
by,4356,O
2,4356,O
and,4356,O
3,4356,O
unfavorable,4356,O
alleles,4356,O
",",4356,O
respectively,4356,O
",",4356,O
revealing,4356,O
a,4356,O
dosage,4356,O
effect,4356,O
(,4356,O
ORs,4356,O
of,4356,O
2.15,4356,O
and,4356,O
5.28,4356,O
;,4356,O
P,4356,O
,4356,O
0.030,4356,O
),4356,O
.,4356,O
Our,4357,O
results,4357,O
suggest,4357,O
that,4357,O
specific,4357,O
SNPs,4357,O
in,4357,O
UGT1A,4357,B-GENE-N
",",4357,O
other,4357,O
than,4357,O
UGT1A1,4357,B-GENE-Y
*,4357,O
28,4357,O
",",4357,O
may,4357,O
influence,4357,O
irinotecan,4357,B-CHEMICAL
toxicity,4357,O
and,4357,O
should,4357,O
be,4357,O
considered,4357,O
to,4357,O
refine,4357,O
pharmacogenetic,4357,O
testing,4357,O
.,4357,O
Androgen,4358,B-GENE-Y
Receptor,4358,I-GENE-Y
mRNA,4358,O
Measured,4358,O
by,4358,O
Quantitative,4358,O
Real,4358,O
Time,4358,O
PCR,4358,O
is,4358,O
Decreased,4358,O
in,4358,O
the,4358,O
Urethral,4358,O
Mucosa,4358,O
of,4358,O
Patients,4358,O
with,4358,O
Middle,4358,O
Idiopathic,4358,O
Hypospadias,4358,O
.,4358,O
Androgen,4359,B-CHEMICAL
action,4359,O
is,4359,O
exerted,4359,O
through,4359,O
the,4359,O
androgen,4359,B-CHEMICAL
receptor,4359,I-GENE-Y
.,4359,O
The,4360,O
normal,4360,O
46,4360,O
",",4360,O
XY,4360,O
genital,4360,O
virilization,4360,O
depends,4360,O
on,4360,O
androgen,4360,B-CHEMICAL
receptor,4360,I-GENE-Y
gene,4360,O
expression,4360,O
",",4360,O
which,4360,O
is,4360,O
tissue,4360,O
specific,4360,O
",",4360,O
and,4360,O
requires,4360,O
normal,4360,O
androgen,4360,B-CHEMICAL
receptor,4360,I-GENE-Y
mRNA,4360,O
levels,4360,O
in,4360,O
androgen,4360,B-CHEMICAL
sensitive,4360,O
tissues,4360,O
.,4360,O
Hypospadias,4361,O
is,4361,O
a,4361,O
frequent,4361,O
male,4361,O
genital,4361,O
abnormality,4361,O
",",4361,O
potentially,4361,O
related,4361,O
to,4361,O
reduced,4361,O
androgen,4361,B-CHEMICAL
sensitivity,4361,O
in,4361,O
genital,4361,O
tissues,4361,O
.,4361,O
The,4362,O
aim,4362,O
of,4362,O
this,4362,O
study,4362,O
was,4362,O
to,4362,O
compare,4362,O
",",4362,O
by,4362,O
quantitative,4362,O
real,4362,O
time,4362,O
PCR,4362,O
",",4362,O
the,4362,O
amount,4362,O
of,4362,O
androgen,4362,B-GENE-Y
receptor,4362,I-GENE-Y
mRNA,4362,O
in,4362,O
cells,4362,O
obtained,4362,O
from,4362,O
the,4362,O
urethral,4362,O
mucosa,4362,O
of,4362,O
patients,4362,O
with,4362,O
middle,4362,O
idiopathic,4362,O
hypospadias,4362,O
with,4362,O
the,4362,O
androgen,4362,B-GENE-Y
receptor,4362,I-GENE-Y
mRNA,4362,O
levels,4362,O
observed,4362,O
in,4362,O
control,4362,O
phimosis,4362,O
subjects,4362,O
with,4362,O
eutopic,4362,O
urethral,4362,O
opening,4362,O
.,4362,O
Prepubertal,4363,O
individuals,4363,O
were,4363,O
studied,4363,O
",",4363,O
including,4363,O
41,4363,O
controls,4363,O
and,4363,O
17,4363,O
hypospadias,4363,O
patients,4363,O
with,4363,O
mean,4363,O
(,4363,O
SD,4363,O
),4363,O
ages,4363,O
of,4363,O
4.7,4363,O
(,4363,O
2.1,4363,O
),4363,O
years,4363,O
and,4363,O
4.0,4363,O
(,4363,O
3.0,4363,O
),4363,O
years,4363,O
",",4363,O
respectively,4363,O
.,4363,O
We,4364,O
observed,4364,O
significantly,4364,O
less,4364,O
androgen,4364,B-GENE-Y
receptor,4364,I-GENE-Y
mRNA,4364,O
in,4364,O
the,4364,O
urethral,4364,O
mucosa,4364,O
of,4364,O
patients,4364,O
with,4364,O
hypospadias,4364,O
than,4364,O
in,4364,O
the,4364,O
controls,4364,O
(,4364,O
p=0.002,4364,O
),4364,O
.,4364,O
The,4365,O
correlation,4365,O
between,4365,O
the,4365,O
level,4365,O
of,4365,O
androgen,4365,B-CHEMICAL
receptor,4365,I-GENE-Y
mRNA,4365,O
expression,4365,O
and,4365,O
the,4365,O
penile,4365,O
size,4365,O
was,4365,O
almost,4365,O
statistically,4365,O
significant,4365,O
only,4365,O
in,4365,O
hypospadias,4365,O
patients,4365,O
(,4365,O
r=0.47,4365,O
;,4365,O
p=0.053,4365,O
),4365,O
.,4365,O
We,4366,O
also,4366,O
established,4366,O
the,4366,O
number,4366,O
of,4366,O
CAG,4366,B-GENE-N
repeats,4366,I-GENE-N
in,4366,O
exon,4366,O
1,4366,O
of,4366,O
the,4366,O
androgen,4366,B-CHEMICAL
receptor,4366,I-GENE-Y
gene,4366,O
by,4366,O
GeneScan,4366,O
analysis,4366,O
.,4366,O
No,4367,O
significant,4367,O
difference,4367,O
was,4367,O
observed,4367,O
in,4367,O
the,4367,O
number,4367,O
of,4367,O
CAG,4367,B-GENE-N
repeats,4367,I-GENE-N
when,4367,O
patients,4367,O
and,4367,O
controls,4367,O
were,4367,O
compared,4367,O
.,4367,O
A,4368,O
negative,4368,O
correlation,4368,O
between,4368,O
the,4368,O
CAG,4368,B-GENE-N
repeats,4368,I-GENE-N
and,4368,O
penile,4368,O
size,4368,O
was,4368,O
detected,4368,O
in,4368,O
patients,4368,O
with,4368,O
hypospadias,4368,O
",",4368,O
but,4368,O
not,4368,O
in,4368,O
controls,4368,O
.,4368,O
Our,4369,O
data,4369,O
suggest,4369,O
that,4369,O
a,4369,O
critical,4369,O
lower,4369,O
level,4369,O
of,4369,O
androgen,4369,B-CHEMICAL
receptor,4369,I-GENE-Y
mRNA,4369,O
expression,4369,O
could,4369,O
be,4369,O
a,4369,O
determining,4369,O
factor,4369,O
in,4369,O
the,4369,O
development,4369,O
of,4369,O
middle,4369,O
hypospadias,4369,O
.,4369,O
Oxidative,4370,O
Stress,4370,O
and,4370,O
DNA,4370,O
Damage,4370,O
in,4370,O
Human,4370,O
Gastric,4370,O
Carcinoma,4370,O
:,4370,O
8-Oxo-7,4370,B-CHEMICAL
',4370,I-CHEMICAL
8-dihydro-2'-deoxyguanosine,4370,I-CHEMICAL
(,4370,O
8-oxo-dG,4370,B-CHEMICAL
),4370,O
as,4370,O
a,4370,O
Possible,4370,O
Tumor,4370,O
Marker,4370,O
.,4370,O
We,4371,O
characterized,4371,O
the,4371,O
oxidative,4371,O
stress,4371,O
(,4371,O
OS,4371,O
),4371,O
status,4371,O
by,4371,O
the,4371,O
levels,4371,O
of,4371,O
reduced/oxidized,4371,B-CHEMICAL
glutathione,4371,I-CHEMICAL
(,4371,O
GSH/GSSG,4371,B-CHEMICAL
),4371,O
",",4371,O
malondialdehyde,4371,B-CHEMICAL
(,4371,O
MDA,4371,B-CHEMICAL
),4371,O
and,4371,O
the,4371,O
mutagenic,4371,O
base,4371,O
8-oxo-7,4371,B-CHEMICAL
',4371,I-CHEMICAL
8-dihydro-2'-deoxyguanosine,4371,I-CHEMICAL
(,4371,O
8-oxo-dG,4371,B-CHEMICAL
),4371,O
in,4371,O
human,4371,O
gastric,4371,O
carcinoma,4371,O
(,4371,O
HGC,4371,O
),4371,O
samples,4371,O
and,4371,O
compared,4371,O
the,4371,O
results,4371,O
with,4371,O
normal,4371,O
tissue,4371,O
from,4371,O
the,4371,O
same,4371,O
patients,4371,O
.,4371,O
We,4372,O
also,4372,O
analyzed,4372,O
8-oxo-dG,4372,B-CHEMICAL
in,4372,O
peripheral,4372,O
mononuclear,4372,O
cells,4372,O
(,4372,O
PMNC,4372,O
),4372,O
and,4372,O
urine,4372,O
from,4372,O
healthy,4372,O
control,4372,O
subjects,4372,O
and,4372,O
in,4372,O
affected,4372,O
patients,4372,O
in,4372,O
the,4372,O
basal,4372,O
state,4372,O
and,4372,O
one,4372,O
",",4372,O
three,4372,O
",",4372,O
six,4372,O
",",4372,O
nine,4372,O
and,4372,O
twelve,4372,O
months,4372,O
after,4372,O
tumor,4372,O
resection,4372,O
.,4372,O
The,4373,O
levels,4373,O
of,4373,O
DNA,4373,O
repair,4373,O
enzyme,4373,O
mRNA,4373,O
expression,4373,O
(,4373,O
hOGG1,4373,B-GENE-Y
",",4373,O
RAD51,4373,B-GENE-Y
",",4373,O
MUYTH,4373,B-GENE-Y
and,4373,O
MTH1,4373,B-GENE-Y
),4373,O
were,4373,O
determined,4373,O
in,4373,O
tumor,4373,O
specimens,4373,O
and,4373,O
compared,4373,O
with,4373,O
normal,4373,O
mucosa,4373,O
.,4373,O
Tumor,4374,O
specimens,4374,O
exhibited,4374,O
increased,4374,O
levels,4374,O
of,4374,O
MDA,4374,B-CHEMICAL
and,4374,O
8-oxo-dG,4374,B-CHEMICAL
compared,4374,O
with,4374,O
normal,4374,O
gastric,4374,O
tissue,4374,O
.,4374,O
GSH,4375,B-CHEMICAL
levels,4375,O
were,4375,O
also,4375,O
increased,4375,O
",",4375,O
while,4375,O
GSSG,4375,B-CHEMICAL
levels,4375,O
remained,4375,O
stable,4375,O
.,4375,O
DNA,4376,O
repair,4376,O
enzyme,4376,O
mRNA,4376,O
expression,4376,O
was,4376,O
induced,4376,O
in,4376,O
the,4376,O
tumor,4376,O
tissues,4376,O
.,4376,O
Levels,4377,O
of,4377,O
8-oxo-dG,4377,B-CHEMICAL
were,4377,O
significantly,4377,O
elevated,4377,O
in,4377,O
both,4377,O
urine,4377,O
and,4377,O
PMNC,4377,O
of,4377,O
gastric,4377,O
cancer,4377,O
patients,4377,O
compared,4377,O
with,4377,O
healthy,4377,O
controls,4377,O
.,4377,O
After,4378,O
gastrectomy,4378,O
",",4378,O
the,4378,O
levels,4378,O
of,4378,O
the,4378,O
damaged,4378,O
base,4378,O
in,4378,O
urine,4378,O
and,4378,O
PMNC,4378,O
decreased,4378,O
progressively,4378,O
to,4378,O
values,4378,O
close,4378,O
to,4378,O
those,4378,O
found,4378,O
in,4378,O
the,4378,O
healthy,4378,O
population,4378,O
.,4378,O
The,4379,O
high,4379,O
levels,4379,O
of,4379,O
8-oxo-dG,4379,B-CHEMICAL
in,4379,O
urine,4379,O
may,4379,O
be,4379,O
related,4379,O
to,4379,O
the,4379,O
increased,4379,O
induction,4379,O
of,4379,O
DNA,4379,O
repair,4379,O
activity,4379,O
in,4379,O
tumor,4379,O
tissue,4379,O
",",4379,O
and,4379,O
the,4379,O
changes,4379,O
observed,4379,O
after,4379,O
tumor,4379,O
resection,4379,O
support,4379,O
its,4379,O
potential,4379,O
use,4379,O
as,4379,O
a,4379,O
tumor,4379,O
marker,4379,O
.,4379,O
An,4380,O
intra-articular,4380,O
salmon,4380,O
calcitonin-based,4380,O
nanocomplex,4380,O
reduces,4380,O
experimental,4380,O
inflammatory,4380,O
arthritis,4380,O
.,4380,O
Prolonged,4381,O
inappropriate,4381,O
inflammatory,4381,O
responses,4381,O
contribute,4381,O
to,4381,O
the,4381,O
pathogenesis,4381,O
of,4381,O
rheumatoid,4381,O
arthritis,4381,O
(,4381,O
RA,4381,O
),4381,O
and,4381,O
to,4381,O
aspects,4381,O
of,4381,O
osteoarthritis,4381,O
(,4381,O
OA,4381,O
),4381,O
.,4381,O
The,4382,O
orphan,4382,B-GENE-Y
nuclear,4382,I-GENE-Y
receptor,4382,I-GENE-Y
",",4382,I-GENE-Y
NR4A2,4382,I-GENE-Y
",",4382,O
is,4382,O
a,4382,O
key,4382,O
regulator,4382,O
and,4382,O
potential,4382,O
biomarker,4382,O
for,4382,O
inflammation,4382,O
and,4382,O
represents,4382,O
a,4382,O
potentially,4382,O
valuable,4382,O
therapeutic,4382,O
target,4382,O
.,4382,O
Both,4383,O
salmon,4383,O
calcitonin,4383,O
(,4383,O
sCT,4383,O
),4383,O
and,4383,O
hyaluronic,4383,O
acid,4383,O
(,4383,O
HA,4383,O
),4383,O
attenuated,4383,O
activated,4383,O
mRNA,4383,O
expression,4383,O
of,4383,O
NR4A1,4383,B-GENE-Y
",",4383,O
NR4A2,4383,B-GENE-Y
",",4383,O
NR4A3,4383,B-GENE-Y
",",4383,O
and,4383,O
matrix,4383,B-GENE-N
metalloproteinases,4383,I-GENE-N
(,4383,I-GENE-N
MMPs,4383,I-GENE-N
),4383,I-GENE-N
1,4383,I-GENE-N
",",4383,I-GENE-N
3,4383,I-GENE-N
and,4383,I-GENE-N
13,4383,I-GENE-N
in,4383,O
three,4383,O
human,4383,O
cell,4383,O
lines,4383,O
:,4383,O
SW1353,4383,O
chondrocytes,4383,O
",",4383,O
U937,4383,O
and,4383,O
THP-1,4383,O
monocytes,4383,O
.,4383,O
Ad-mixtures,4384,O
of,4384,O
sCT,4384,O
and,4384,O
HA,4384,O
further,4384,O
down-regulated,4384,O
expression,4384,O
of,4384,O
NR4A2,4384,B-GENE-Y
compared,4384,O
to,4384,O
either,4384,O
agent,4384,O
alone,4384,O
at,4384,O
specific,4384,O
concentrations,4384,O
",",4384,O
hence,4384,O
the,4384,O
rationale,4384,O
for,4384,O
their,4384,O
formulation,4384,O
in,4384,O
nanocomplexes,4384,O
(,4384,O
NPs,4384,O
),4384,O
using,4384,O
chitosan,4384,O
.,4384,O
The,4385,O
sCT,4385,O
released,4385,O
from,4385,O
NP,4385,O
stimulated,4385,O
cAMP,4385,B-CHEMICAL
production,4385,O
in,4385,O
human,4385,O
T47D,4385,O
breast,4385,O
cancer,4385,O
cells,4385,O
expressing,4385,O
sCT,4385,B-GENE-Y
receptors,4385,I-GENE-Y
.,4385,O
When,4386,O
NP,4386,O
were,4386,O
injected,4386,O
by,4386,O
the,4386,O
intra-articular,4386,O
(,4386,O
I.A,4386,O
.,4386,O
),4386,O
route,4387,O
to,4387,O
the,4387,O
mouse,4387,O
knee,4387,O
during,4387,O
on-going,4387,O
inflammatory,4387,O
arthritis,4387,O
of,4387,O
the,4387,O
K/BxN,4387,O
serum,4387,O
transfer,4387,O
model,4387,O
",",4387,O
joint,4387,O
inflammation,4387,O
was,4387,O
reduced,4387,O
together,4387,O
with,4387,O
NR4A2,4387,B-GENE-Y
expression,4387,O
",",4387,O
and,4387,O
local,4387,O
bone,4387,O
architecture,4387,O
was,4387,O
preserved,4387,O
.,4387,O
These,4388,O
data,4388,O
highlight,4388,O
remarkable,4388,O
anti-inflammatory,4388,O
effects,4388,O
of,4388,O
sCT,4388,O
and,4388,O
HA,4388,O
at,4388,O
the,4388,O
level,4388,O
of,4388,O
reducing,4388,O
NR4A2,4388,B-GENE-Y
mRNA,4388,O
expression,4388,O
in,4388,O
vitro,4388,O
.,4388,O
Combining,4389,O
them,4389,O
in,4389,O
NP,4389,O
elicits,4389,O
anti-arthritic,4389,O
effects,4389,O
in,4389,O
vivo,4389,O
following,4389,O
I.A,4389,O
.,4389,O
delivery,4390,O
.,4390,O
Prolactin,4391,B-GENE-Y
regulates,4391,O
transcription,4391,O
of,4391,O
the,4391,O
ion,4391,O
uptake,4391,O
Na+/Cl-,4391,B-CHEMICAL
cotransporter,4391,I-GENE-Y
(,4391,O
ncc,4391,B-GENE-Y
),4391,O
gene,4391,O
in,4391,O
zebrafish,4391,O
gill,4391,O
.,4391,O
Prolactin,4392,B-GENE-Y
(,4392,O
PRL,4392,B-GENE-Y
),4392,O
is,4392,O
a,4392,O
well-known,4392,O
regulator,4392,O
of,4392,O
ion,4392,O
and,4392,O
water,4392,O
transport,4392,O
within,4392,O
osmoregulatory,4392,O
tissues,4392,O
across,4392,O
vertebrate,4392,O
species,4392,O
",",4392,O
yet,4392,O
how,4392,O
PRL,4392,B-GENE-Y
acts,4392,O
on,4392,O
some,4392,O
of,4392,O
its,4392,O
target,4392,O
tissues,4392,O
remains,4392,O
poorly,4392,O
understood,4392,O
.,4392,O
Using,4393,O
zebrafish,4393,O
as,4393,O
a,4393,O
model,4393,O
",",4393,O
we,4393,O
show,4393,O
that,4393,O
ionocytes,4393,O
in,4393,O
the,4393,O
gill,4393,O
directly,4393,O
respond,4393,O
to,4393,O
systemic,4393,O
PRL,4393,B-GENE-Y
to,4393,O
regulate,4393,O
mechanisms,4393,O
of,4393,O
ion,4393,O
uptake,4393,O
.,4393,O
Ion-poor,4394,O
conditions,4394,O
led,4394,O
to,4394,O
increases,4394,O
in,4394,O
the,4394,O
expression,4394,O
of,4394,O
PRL,4394,B-GENE-N
receptor,4394,I-GENE-N
(,4394,O
prlra,4394,B-GENE-Y
),4394,O
",",4394,O
Na,4394,B-CHEMICAL
(,4394,I-CHEMICAL
+,4394,I-CHEMICAL
),4394,I-CHEMICAL
/Cl,4394,I-GENE-Y
(,4394,I-CHEMICAL
-,4394,I-CHEMICAL
),4394,I-CHEMICAL
cotransporter,4394,I-GENE-Y
(,4394,O
ncc,4394,B-GENE-Y
;,4394,O
slc12a10.2,4394,B-GENE-Y
),4394,O
",",4394,O
Na,4394,B-CHEMICAL
(,4394,I-CHEMICAL
+,4394,I-CHEMICAL
),4394,I-CHEMICAL
/H,4394,I-GENE-Y
(,4394,I-CHEMICAL
+,4394,I-CHEMICAL
),4394,I-CHEMICAL
exchanger,4394,I-GENE-Y
(,4394,O
nhe3b,4394,B-GENE-Y
;,4394,O
slc9a3.2,4394,B-GENE-Y
),4394,O
",",4394,O
and,4394,O
epithelial,4394,B-GENE-Y
Ca,4394,B-CHEMICAL
(,4394,I-CHEMICAL
2+,4394,I-CHEMICAL
),4394,I-CHEMICAL
channel,4394,I-GENE-Y
(,4394,O
ecac,4394,B-GENE-Y
;,4394,O
trpv6,4394,B-GENE-Y
),4394,O
transcripts,4394,O
within,4394,O
the,4394,O
gill,4394,O
.,4394,O
Intraperitoneal,4395,O
injection,4395,O
of,4395,O
ovine,4395,B-GENE-Y
PRL,4395,I-GENE-Y
(,4395,O
oPRL,4395,B-GENE-Y
),4395,O
increased,4395,O
ncc,4395,B-GENE-Y
and,4395,O
prlra,4395,B-GENE-Y
transcripts,4395,O
",",4395,O
but,4395,O
did,4395,O
not,4395,O
affect,4395,O
nhe3b,4395,B-GENE-Y
or,4395,O
ecac,4395,B-GENE-Y
.,4395,O
Consistent,4396,O
with,4396,O
direct,4396,O
PRL,4396,B-GENE-Y
action,4396,O
in,4396,O
the,4396,O
gill,4396,O
",",4396,O
addition,4396,O
of,4396,O
oPRL,4396,B-GENE-Y
to,4396,O
cultured,4396,O
gill,4396,O
filaments,4396,O
stimulated,4396,O
ncc,4396,B-GENE-Y
in,4396,O
a,4396,O
concentration-dependent,4396,O
manner,4396,O
",",4396,O
an,4396,O
effect,4396,O
blocked,4396,O
by,4396,O
a,4396,O
pure,4396,O
human,4396,B-GENE-Y
PRL,4396,I-GENE-Y
receptor,4396,I-GENE-Y
antagonist,4396,O
(,4396,O
1-9-G129R-hPRL,4396,O
),4396,O
.,4396,O
These,4397,O
results,4397,O
suggest,4397,O
that,4397,O
PRL,4397,B-GENE-Y
signaling,4397,O
through,4397,O
PRL,4397,B-GENE-N
receptors,4397,I-GENE-N
in,4397,O
the,4397,O
gill,4397,O
regulates,4397,O
the,4397,O
expression,4397,O
of,4397,O
ncc,4397,B-GENE-Y
",",4397,O
thereby,4397,O
linking,4397,O
this,4397,O
pituitary,4397,B-GENE-N
hormone,4397,I-GENE-N
with,4397,O
an,4397,O
effector,4397,O
of,4397,O
Cl,4397,B-CHEMICAL
(,4397,I-CHEMICAL
-,4397,I-CHEMICAL
),4397,I-CHEMICAL
uptake,4397,O
in,4397,O
zebrafish,4397,O
for,4397,O
the,4397,O
first,4397,O
time,4397,O
.,4397,O
Parathyroid,4398,B-GENE-Y
hormone,4398,I-GENE-Y
(,4398,I-GENE-Y
1-34,4398,I-GENE-Y
),4398,I-GENE-Y
counteracts,4398,O
the,4398,O
suppression,4398,O
of,4398,O
interleukin-11,4398,B-GENE-Y
expression,4398,O
by,4398,O
glucocorticoid,4398,O
in,4398,O
murine,4398,O
osteoblasts,4398,O
:,4398,O
a,4398,O
possible,4398,O
mechanism,4398,O
for,4398,O
stimulating,4398,O
osteoblast,4398,O
differentiation,4398,O
against,4398,O
glucocorticoid,4398,O
excess,4398,O
.,4398,O
Glucocorticoid,4399,O
(,4399,O
GC,4399,O
),4399,O
excess,4399,O
causes,4399,O
a,4399,O
rapid,4399,O
loss,4399,O
of,4399,O
bone,4399,O
with,4399,O
a,4399,O
reduction,4399,O
in,4399,O
bone,4399,O
formation,4399,O
.,4399,O
Intermittent,4400,O
PTH,4400,B-GENE-Y
(,4400,I-GENE-Y
1-34,4400,I-GENE-Y
),4400,I-GENE-Y
administration,4400,O
stimulates,4400,O
bone,4400,O
formation,4400,O
and,4400,O
counteracts,4400,O
the,4400,O
inhibition,4400,O
of,4400,O
bone,4400,O
formation,4400,O
by,4400,O
GC,4400,O
excess,4400,O
.,4400,O
We,4401,O
have,4401,O
previously,4401,O
demonstrated,4401,O
that,4401,O
mechanical,4401,O
strain,4401,O
enhances,4401,O
interleukin,4401,B-GENE-Y
(,4401,I-GENE-Y
IL,4401,I-GENE-Y
),4401,I-GENE-Y
-11,4401,I-GENE-Y
gene,4401,O
transcription,4401,O
by,4401,O
a,4401,O
rapid,4401,O
induction,4401,O
of,4401,O
FosB,4401,B-GENE-Y
expression,4401,O
and,4401,O
protein,4401,B-GENE-Y
kinase,4401,I-GENE-Y
C,4401,I-GENE-Y
(,4401,I-GENE-Y
PKC,4401,I-GENE-Y
),4401,I-GENE-Y
--mediated,4401,O
phosphorylation,4401,O
of,4401,O
phosphorylated,4401,O
mothers,4401,O
against,4401,O
decapentaplegic,4401,O
(,4401,O
Smad,4401,O
),4401,O
-1,4401,O
.,4401,O
Because,4402,O
IL-11,4402,B-GENE-Y
suppresses,4402,O
the,4402,O
expression,4402,O
of,4402,O
dickkopf-1,4402,B-GENE-N
and,4402,I-GENE-N
-2,4402,I-GENE-N
and,4402,O
stimulates,4402,O
Wnt,4402,B-GENE-N
signaling,4402,O
",",4402,O
IL-11,4402,B-GENE-Y
appears,4402,O
to,4402,O
mediate,4402,O
at,4402,O
least,4402,O
a,4402,O
part,4402,O
of,4402,O
the,4402,O
effect,4402,O
of,4402,O
mechanical,4402,O
strain,4402,O
on,4402,O
osteoblast,4402,O
differentiation,4402,O
and,4402,O
bone,4402,O
formation,4402,O
.,4402,O
The,4403,O
present,4403,O
study,4403,O
was,4403,O
undertaken,4403,O
to,4403,O
examine,4403,O
the,4403,O
effect,4403,O
of,4403,O
PTH,4403,B-GENE-Y
(,4403,I-GENE-Y
1-34,4403,I-GENE-Y
),4403,I-GENE-Y
and,4403,O
GCs,4403,O
on,4403,O
IL-11,4403,B-GENE-Y
expression,4403,O
in,4403,O
murine,4403,O
primary,4403,O
osteoblasts,4403,O
(,4403,O
mPOBs,4403,O
),4403,O
.,4403,O
PTH,4404,B-GENE-Y
(,4404,I-GENE-Y
1-34,4404,I-GENE-Y
),4404,I-GENE-Y
treatment,4404,O
of,4404,O
mPOBs,4404,O
enhanced,4404,O
IL-11,4404,B-GENE-Y
expression,4404,O
in,4404,O
a,4404,O
time-,4404,O
and,4404,O
dose-dependent,4404,O
manner,4404,O
.,4404,O
PTH,4405,B-GENE-Y
(,4405,I-GENE-Y
1-34,4405,I-GENE-Y
),4405,I-GENE-Y
also,4405,O
stimulated,4405,O
FosB,4405,B-GENE-Y
expression,4405,O
and,4405,O
Smad1,4405,B-GENE-Y
phosphorylation,4405,O
",",4405,O
which,4405,O
cooperatively,4405,O
stimulated,4405,O
IL-11,4405,B-GENE-Y
gene,4405,O
transcription,4405,O
.,4405,O
PTH,4406,B-GENE-Y
(,4406,I-GENE-Y
1-34,4406,I-GENE-Y
),4406,I-GENE-Y
-induced,4406,O
Smad1,4406,B-GENE-Y
phosphorylation,4406,O
was,4406,O
mediated,4406,O
via,4406,O
PKC,4406,B-GENE-Y
and,4406,O
was,4406,O
abrogated,4406,O
in,4406,O
mPOBs,4406,O
from,4406,O
PKC,4406,B-GENE-Y
knockout,4406,O
mice,4406,O
.,4406,O
Dexamethasone,4407,B-CHEMICAL
suppressed,4407,O
IL-11,4407,B-GENE-Y
gene,4407,O
transcription,4407,O
enhanced,4407,O
by,4407,O
PTH,4407,B-GENE-Y
(,4407,I-GENE-Y
1-34,4407,I-GENE-Y
),4407,I-GENE-Y
without,4407,O
affecting,4407,O
FosB,4407,B-GENE-Y
expression,4407,O
or,4407,O
Smad1,4407,O
phosphorylation,4407,O
",",4407,O
and,4407,O
dexamethasone-GC,4407,B-CHEMICAL
receptor,4407,I-GENE-Y
complex,4407,O
was,4407,O
bound,4407,O
to,4407,O
JunD,4407,B-GENE-Y
",",4407,O
which,4407,O
forms,4407,O
heterodimers,4407,O
with,4407,O
FosB,4407,B-GENE-Y
.,4407,O
High,4408,O
doses,4408,O
of,4408,O
PTH,4408,B-GENE-Y
(,4408,I-GENE-Y
1-34,4408,I-GENE-Y
),4408,I-GENE-Y
counteracted,4408,O
the,4408,O
effect,4408,O
of,4408,O
dexamethasone,4408,B-CHEMICAL
on,4408,O
apoptosis,4408,O
of,4408,O
mPOBs,4408,O
",",4408,O
which,4408,O
was,4408,O
blunted,4408,O
by,4408,O
neutralizing,4408,O
anti-IL-11,4408,O
antibody,4408,O
or,4408,O
IL-11,4408,B-GENE-Y
small,4408,O
interfering,4408,O
RNA,4408,O
.,4408,O
These,4409,O
results,4409,O
demonstrate,4409,O
that,4409,O
PTH,4409,B-GENE-Y
(,4409,I-GENE-Y
1-34,4409,I-GENE-Y
),4409,I-GENE-Y
and,4409,O
GCs,4409,O
interact,4409,O
to,4409,O
regulate,4409,O
IL-11,4409,B-GENE-Y
expression,4409,O
in,4409,O
parallel,4409,O
with,4409,O
osteoblast,4409,O
differentiation,4409,O
and,4409,O
apoptosis,4409,O
and,4409,O
suggest,4409,O
that,4409,O
PTH,4409,B-GENE-Y
(,4409,I-GENE-Y
1-34,4409,I-GENE-Y
),4409,I-GENE-Y
and,4409,O
dexamethasone,4409,B-CHEMICAL
may,4409,O
regulate,4409,O
osteoblast,4409,O
differentiation,4409,O
and,4409,O
apoptosis,4409,O
via,4409,O
their,4409,O
effect,4409,O
on,4409,O
IL-11,4409,B-GENE-Y
expression,4409,O
.,4409,O
Effects,4410,O
of,4410,O
amlodipine,4410,B-CHEMICAL
on,4410,O
the,4410,O
oral,4410,O
bioavailability,4410,O
of,4410,O
cephalexin,4410,B-CHEMICAL
and,4410,O
cefuroxime,4410,B-CHEMICAL
axetil,4410,I-CHEMICAL
in,4410,O
healthy,4410,O
volunteers,4410,O
.,4410,O
In,4411,O
this,4411,O
study,4411,O
",",4411,O
the,4411,O
authors,4411,O
compared,4411,O
the,4411,O
effects,4411,O
of,4411,O
amlodipine,4411,B-CHEMICAL
(,4411,O
AML,4411,B-CHEMICAL
),4411,O
on,4411,O
the,4411,O
bioavailability,4411,O
of,4411,O
cephalexin,4411,B-CHEMICAL
(,4411,O
LEX,4411,B-CHEMICAL
),4411,O
and,4411,O
cefuroxime,4411,B-CHEMICAL
axetil,4411,I-CHEMICAL
(,4411,O
CXM,4411,B-CHEMICAL
),4411,O
.,4411,O
Twenty-four,4412,O
healthy,4412,O
men,4412,O
were,4412,O
randomized,4412,O
to,4412,O
4,4412,O
treatments,4412,O
according,4412,O
to,4412,O
a,4412,O
crossover,4412,O
design,4412,O
with,4412,O
a,4412,O
14-day,4412,O
washout,4412,O
.,4412,O
After,4413,O
an,4413,O
overnight,4413,O
fast,4413,O
",",4413,O
they,4413,O
were,4413,O
administered,4413,O
orally,4413,O
LEX,4413,B-CHEMICAL
500,4413,O
mg,4413,O
alone,4413,O
",",4413,O
LEX,4413,B-CHEMICAL
500,4413,O
mg,4413,O
2,4413,O
hours,4413,O
after,4413,O
oral,4413,O
administration,4413,O
of,4413,O
AML,4413,B-CHEMICAL
5,4413,O
mg,4413,O
",",4413,O
CXM,4413,B-CHEMICAL
500,4413,O
mg,4413,O
alone,4413,O
",",4413,O
and,4413,O
CXM,4413,B-CHEMICAL
500,4413,O
mg,4413,O
2,4413,O
hours,4413,O
after,4413,O
oral,4413,O
administration,4413,O
of,4413,O
AML,4413,B-CHEMICAL
5,4413,O
mg.,4413,O
All,4413,O
participants,4413,O
completed,4413,O
the,4413,O
whole,4413,O
study,4413,O
without,4413,O
side,4413,O
effects,4413,O
being,4413,O
observed,4413,O
.,4413,O
Pharmacokinetic,4414,O
data,4414,O
were,4414,O
analyzed,4414,O
by,4414,O
noncompartmental,4414,O
modeling,4414,O
with,4414,O
WinNonlin,4414,O
software,4414,O
.,4414,O
The,4415,O
geometric,4415,O
mean,4415,O
(,4415,O
GM,4415,O
),4415,O
ratios,4415,O
were,4415,O
1.38,4415,O
(,4415,O
90,4415,O
%,4415,O
confidence,4415,O
interval,4415,O
[,4415,O
CI,4415,O
],4415,O
",",4415,O
1.32-1.45,4415,O
),4415,O
for,4415,O
the,4415,O
area,4415,O
under,4415,O
the,4415,O
concentration-time,4415,O
curve,4415,O
(,4415,O
AUC,4415,O
),4415,O
for,4415,O
LEX,4415,B-CHEMICAL
and,4415,O
1.27,4415,O
(,4415,O
1.18-1.36,4415,O
),4415,O
for,4415,O
the,4415,O
maximum,4415,O
concentration,4415,O
of,4415,O
drug,4415,O
in,4415,O
serum,4415,O
(,4415,O
C,4415,O
(,4415,O
max,4415,O
),4415,O
),4415,O
for,4415,O
LEX,4415,B-CHEMICAL
followed,4415,O
by,4415,O
AML,4415,B-CHEMICAL
versus,4415,O
alone,4415,O
.,4415,O
In,4416,O
contrast,4416,O
",",4416,O
no,4416,O
significant,4416,O
differences,4416,O
were,4416,O
found,4416,O
in,4416,O
the,4416,O
pharmacokinetic,4416,O
parameters,4416,O
of,4416,O
CXM,4416,B-CHEMICAL
between,4416,O
treatments,4416,O
(,4416,O
P,4416,O
<,4416,O
.05,4416,O
),4416,O
.,4416,O
They,4417,O
authors,4417,O
conclude,4417,O
that,4417,O
AML,4417,B-CHEMICAL
possesses,4417,O
an,4417,O
enhancement,4417,O
effect,4417,O
in,4417,O
-lactam,4417,B-CHEMICAL
antibiotic,4417,O
bioavailability,4417,O
(,4417,O
in,4417,O
this,4417,O
case,4417,O
",",4417,O
LEX,4417,B-CHEMICAL
),4417,O
",",4417,O
and,4417,O
this,4417,O
interaction,4417,O
may,4417,O
be,4417,O
specific,4417,O
to,4417,O
the,4417,O
peptidomimetic,4417,O
-lactam,4417,B-CHEMICAL
antibiotics,4417,O
.,4417,O
Binding,4418,O
between,4418,O
proteins,4418,O
and,4418,O
cationic,4418,O
spherical,4418,O
polyelectrolyte,4418,O
brushes,4418,O
:,4418,O
effect,4418,O
of,4418,O
pH,4418,O
",",4418,O
ionic,4418,O
strength,4418,O
",",4418,O
and,4418,O
stoichiometry,4418,O
.,4418,O
Cationic,4419,O
spherical,4419,O
polyelectrolyte,4419,O
brushes,4419,O
(,4419,O
SPBs,4419,O
),4419,O
were,4419,O
synthesized,4419,O
by,4419,O
photoemulsion,4419,O
polymerization,4419,O
",",4419,O
consisting,4419,O
of,4419,O
a,4419,O
polystyrene,4419,B-CHEMICAL
core,4419,O
with,4419,O
a,4419,O
diameter,4419,O
around,4419,O
80,4419,O
nm,4419,O
and,4419,O
a,4419,O
poly,4419,B-CHEMICAL
(,4419,I-CHEMICAL
2-aminoethylmethacrylate,4419,I-CHEMICAL
hydrochloride,4419,I-CHEMICAL
),4419,I-CHEMICAL
(,4419,O
PAEMH,4419,B-CHEMICAL
),4419,O
shell,4419,O
with,4419,O
a,4419,O
thickness,4419,O
from,4419,O
10,4419,O
to,4419,O
50,4419,O
nm,4419,O
densely,4419,O
grafted,4419,O
on,4419,O
the,4419,O
core,4419,O
surface,4419,O
.,4419,O
The,4420,O
binding,4420,O
of,4420,O
various,4420,O
proteins,4420,O
onto,4420,O
SPBs,4420,O
was,4420,O
observed,4420,O
by,4420,O
turbidimetric,4420,O
titration,4420,O
",",4420,O
dynamic,4420,O
light,4420,O
scattering,4420,O
(,4420,O
DLS,4420,O
),4420,O
",",4420,O
zeta,4420,O
potential,4420,O
",",4420,O
and,4420,O
isothermal,4420,O
titration,4420,O
calorimetry,4420,O
(,4420,O
ITC,4420,O
),4420,O
.,4420,O
The,4421,O
binding,4421,O
",",4421,O
aggregation,4421,O
",",4421,O
and,4421,O
releasing,4421,O
of,4421,O
proteins,4421,O
by,4421,O
SPB,4421,O
can,4421,O
be,4421,O
tuned,4421,O
by,4421,O
modulating,4421,O
pH,4421,O
.,4421,O
The,4422,O
pH,4422,O
regions,4422,O
of,4422,O
binding,4422,O
for,4422,O
bovine,4422,B-GENE-Y
serum,4422,I-GENE-Y
albumin,4422,I-GENE-Y
(,4422,O
BSA,4422,B-GENE-Y
),4422,O
",",4422,O
-lactoglobulin,4422,B-GENE-Y
(,4422,O
BLG,4422,B-GENE-Y
),4422,O
",",4422,O
and,4422,O
papain,4422,B-GENE-Y
onto,4422,O
SPBs,4422,O
are,4422,O
markedly,4422,O
different,4422,O
and,4422,O
tunable,4422,O
by,4422,O
ionic,4422,O
strength,4422,O
and,4422,O
stoichiometry,4422,O
between,4422,O
protein,4422,O
and,4422,O
SPB,4422,O
.,4422,O
Binding,4423,O
energetics,4423,O
",",4423,O
affinity,4423,O
",",4423,O
and,4423,O
amount,4423,O
of,4423,O
various,4423,O
proteins,4423,O
onto,4423,O
cationic,4423,O
SPBs,4423,O
were,4423,O
determined,4423,O
by,4423,O
ITC,4423,O
.,4423,O
These,4424,O
findings,4424,O
lay,4424,O
the,4424,O
foundation,4424,O
for,4424,O
SPB,4424,O
applications,4424,O
in,4424,O
the,4424,O
protein,4424,O
purification,4424,O
and,4424,O
selective,4424,O
immobilization,4424,O
of,4424,O
different,4424,O
proteins,4424,O
",",4424,O
enzymes,4424,O
",",4424,O
and,4424,O
antibodies,4424,O
.,4424,O
Combined,4425,O
effects,4425,O
of,4425,O
organochlorine,4425,B-CHEMICAL
pesticides,4425,O
heptachlor,4425,B-CHEMICAL
and,4425,O
hexachlorobenzene,4425,B-CHEMICAL
on,4425,O
the,4425,O
promotion,4425,O
stage,4425,O
of,4425,O
hepatocarcinogenesis,4425,O
in,4425,O
rats,4425,O
.,4425,O
We,4426,O
aimed,4426,O
to,4426,O
investigate,4426,O
the,4426,O
combined,4426,O
effect,4426,O
of,4426,O
organochlorine,4426,B-CHEMICAL
pesticides,4426,O
heptachlor,4426,B-CHEMICAL
(,4426,O
HEP,4426,B-CHEMICAL
),4426,O
and,4426,O
hexachlorobenzene,4426,B-CHEMICAL
(,4426,O
HCB,4426,B-CHEMICAL
),4426,O
by,4426,O
using,4426,O
a,4426,O
medium-term,4426,O
rat,4426,O
liver,4426,O
bioassay,4426,O
.,4426,O
Male,4427,O
F344,4427,O
rats,4427,O
were,4427,O
initially,4427,O
administered,4427,O
diethylnitrosamine,4427,B-CHEMICAL
(,4427,O
DEN,4427,B-CHEMICAL
",",4427,O
200mg/kgi.p,4427,O
.,4427,O
),4428,O
;,4428,O
after,4428,O
a,4428,O
2-week,4428,O
non-dosing,4428,O
period,4428,O
",",4428,O
they,4428,O
were,4428,O
given,4428,O
diets,4428,O
containing,4428,O
HEP,4428,O
(,4428,O
5,4428,O
or,4428,O
25ppm,4428,O
),4428,O
",",4428,O
HCB,4428,O
(,4428,O
70,4428,O
or,4428,O
350ppm,4428,O
),4428,O
",",4428,O
or,4428,O
their,4428,O
mixtures,4428,O
(,4428,O
5,4428,O
and,4428,O
70ppm,4428,O
or,4428,O
25,4428,O
and,4428,O
350ppm,4428,O
),4428,O
for,4428,O
6weeks,4428,O
.,4428,O
All,4429,O
rats,4429,O
were,4429,O
subjected,4429,O
to,4429,O
partial,4429,O
hepatectomy,4429,O
at,4429,O
week,4429,O
3,4429,O
and,4429,O
killed,4429,O
at,4429,O
week,4429,O
8,4429,O
.,4429,O
We,4430,O
observed,4430,O
additive,4430,O
or,4430,O
synergistic,4430,O
effects,4430,O
of,4430,O
HEP,4430,O
and,4430,O
HCB,4430,O
in,4430,O
groups,4430,O
treated,4430,O
with,4430,O
mixtures,4430,O
of,4430,O
these,4430,O
pesticides,4430,O
.,4430,O
Number,4431,O
and,4431,O
area,4431,O
of,4431,O
preneoplastic,4431,O
foci,4431,O
positive,4431,O
for,4431,O
glutathione,4431,I-GENE-N
S-transferase,4431,I-GENE-N
placental,4431,I-GENE-N
form,4431,O
(,4431,B-GENE-N
GST-P,4431,O
),4431,O
were,4431,O
consistently,4431,O
higher,4431,O
in,4431,O
these,4431,O
groups,4431,O
than,4431,O
the,4431,O
sum,4431,O
of,4431,O
individual,4431,O
values,4431,O
in,4431,O
the,4431,O
groups,4431,O
treated,4431,O
with,4431,O
HEP,4431,O
or,4431,O
HCB,4431,O
alone,4431,O
.,4431,O
Consistent,4432,O
with,4432,O
these,4432,O
findings,4432,O
",",4432,O
HEP,4432,O
and,4432,O
HCB,4432,O
had,4432,O
additive,4432,O
or,4432,O
synergistic,4432,O
effects,4432,O
on,4432,O
cell,4432,O
proliferation,4432,O
induction,4432,O
within,4432,O
the,4432,O
preneoplastic,4432,O
foci,4432,O
and,4432,O
cytochrome,4432,I-GENE-N
P450,4432,I-GENE-N
(,4432,I-GENE-N
CYP,4432,I-GENE-N
),4432,I-GENE-N
2B1,4432,I-GENE-N
and,4432,I-GENE-N
3A1,4432,O
induction,4432,O
",",4432,O
which,4432,O
may,4432,O
lead,4432,O
to,4432,O
more,4432,O
efficient,4432,O
metabolic,4432,O
activation,4432,O
of,4432,O
HEP,4432,O
and,4432,O
HCB,4432,O
.,4432,O
On,4433,O
the,4433,O
basis,4433,O
of,4433,O
these,4433,O
findings,4433,O
",",4433,O
we,4433,O
conclude,4433,O
that,4433,O
HEP,4433,O
and,4433,O
HCB,4433,O
have,4433,O
additive,4433,O
and,4433,O
synergistic,4433,O
effects,4433,O
on,4433,O
the,4433,O
development,4433,O
of,4433,O
GST-P-positive,4433,O
foci,4433,O
and,4433,O
that,4433,O
higher,4433,O
risks,4433,O
are,4433,O
associated,4433,O
with,4433,O
a,4433,O
combination,4433,O
of,4433,O
residual,4433,O
organochlorine,4433,O
pesticides,4433,O
in,4433,O
foods,4433,O
than,4433,O
with,4433,O
individual,4433,O
residual,4433,O
organochlorine,4433,O
pesticides,4433,O
.,4433,O
The,4434,O
food,4434,O
contaminant,4434,O
deoxynivalenol,4434,B-CHEMICAL
activates,4434,O
the,4434,O
mitogen,4434,B-GENE-N
activated,4434,I-GENE-N
protein,4434,I-GENE-N
kinases,4434,I-GENE-N
in,4434,O
the,4434,O
intestine,4434,O
:,4434,O
interest,4434,O
of,4434,O
ex,4434,O
vivo,4434,O
models,4434,O
as,4434,O
an,4434,O
alternative,4434,O
to,4434,O
in,4434,O
vivo,4434,O
experiments,4434,O
.,4434,O
Trichothecenes,4435,B-CHEMICAL
induce,4435,O
changes,4435,O
in,4435,O
the,4435,O
intestinal,4435,O
barrier,4435,O
function,4435,O
through,4435,O
decreased,4435,O
expression,4435,O
of,4435,O
cell,4435,O
junction,4435,O
proteins,4435,O
and,4435,O
apoptosis,4435,O
of,4435,O
enterocytes,4435,O
.,4435,O
The,4436,O
mitogen,4436,B-GENE-N
activated,4436,I-GENE-N
protein,4436,I-GENE-N
kinases,4436,I-GENE-N
(,4436,O
MAPK,4436,B-GENE-N
),4436,O
play,4436,O
an,4436,O
important,4436,O
role,4436,O
in,4436,O
the,4436,O
signaling,4436,O
pathways,4436,O
of,4436,O
cell,4436,O
turnover,4436,O
and,4436,O
differentiation,4436,O
.,4436,O
Using,4437,O
ex,4437,O
vivo,4437,O
and,4437,O
in,4437,O
vivo,4437,O
approaches,4437,O
",",4437,O
the,4437,O
purpose,4437,O
of,4437,O
this,4437,O
study,4437,O
was,4437,O
to,4437,O
investigate,4437,O
the,4437,O
ability,4437,O
of,4437,O
low,4437,O
doses,4437,O
of,4437,O
DON,4437,B-CHEMICAL
to,4437,O
induce,4437,O
histological,4437,O
changes,4437,O
in,4437,O
the,4437,O
intestine,4437,O
and,4437,O
to,4437,O
activate,4437,O
the,4437,O
MAPK,4437,B-GENE-N
ERK,4437,B-GENE-N
1/2,4437,I-GENE-N
",",4437,O
p38,4437,B-GENE-N
and,4437,O
JNK,4437,B-GENE-N
.,4437,O
Twelve,4438,O
weaning,4438,O
piglets,4438,O
received,4438,O
during,4438,O
four,4438,O
weeks,4438,O
a,4438,O
control,4438,O
diet,4438,O
or,4438,O
a,4438,O
DON-contaminated,4438,B-CHEMICAL
diet,4438,O
(,4438,O
2.3,4438,O
mg,4438,O
DON/kg,4438,B-CHEMICAL
feed,4438,O
),4438,O
.,4438,O
Six,4439,O
weaning,4439,O
piglets,4439,O
were,4439,O
used,4439,O
to,4439,O
prepare,4439,O
jejunal,4439,O
explants,4439,O
(,4439,O
ex,4439,O
vivo,4439,O
model,4439,O
),4439,O
.,4439,O
Explants,4440,O
were,4440,O
exposed,4440,O
during,4440,O
4,4440,O
h,4440,O
to,4440,O
vehicle,4440,O
",",4440,O
5,4440,O
or,4440,O
10,4440,O
M,4440,O
DON,4440,B-CHEMICAL
.,4440,O
Intestinal,4441,O
changes,4441,O
were,4441,O
graded,4441,O
using,4441,O
a,4441,O
histological,4441,O
score,4441,O
.,4441,O
Pigs,4442,O
fed,4442,O
a,4442,O
DON-diet,4442,B-CHEMICAL
and,4442,O
explants,4442,O
exposed,4442,O
to,4442,O
DON,4442,B-CHEMICAL
showed,4442,O
a,4442,O
significant,4442,O
decrease,4442,O
in,4442,O
the,4442,O
jejunal,4442,O
score,4442,O
.,4442,O
In,4443,O
both,4443,O
models,4443,O
",",4443,O
the,4443,O
toxin,4443,O
significantly,4443,O
enhanced,4443,O
phosphorylation,4443,O
of,4443,O
ERK,4443,B-GENE-N
1/2,4443,I-GENE-N
and,4443,O
p38,4443,B-GENE-N
",",4443,O
whereas,4443,O
the,4443,O
increased,4443,O
phosphorylation,4443,O
of,4443,O
JNK,4443,B-GENE-N
was,4443,O
non,4443,O
significant,4443,O
.,4443,O
Taken,4444,O
together,4444,O
these,4444,O
results,4444,O
indicate,4444,O
that,4444,O
in,4444,O
vivo,4444,O
or,4444,O
ex,4444,O
vivo,4444,O
exposure,4444,O
of,4444,O
intestinal,4444,O
tissue,4444,O
to,4444,O
DON,4444,B-CHEMICAL
lead,4444,O
to,4444,O
similar,4444,O
intestinal,4444,O
lesions,4444,O
and,4444,O
activation,4444,O
of,4444,O
MAPK,4444,B-GENE-N
.,4444,O
These,4445,O
effects,4445,O
could,4445,O
impair,4445,O
the,4445,O
homeostasis,4445,O
of,4445,O
intestinal,4445,O
tissue,4445,O
in,4445,O
the,4445,O
aspects,4445,O
of,4445,O
barrier,4445,O
function,4445,O
and,4445,O
immune,4445,O
protection,4445,O
.,4445,O
The,4446,O
similarity,4446,O
of,4446,O
the,4446,O
in,4446,O
vivo,4446,O
and,4446,O
ex,4446,O
vivo,4446,O
results,4446,O
provides,4446,O
also,4446,O
strong,4446,O
evidence,4446,O
that,4446,O
the,4446,O
jejunal,4446,O
explant,4446,O
model,4446,O
is,4446,O
a,4446,O
good,4446,O
alternative,4446,O
for,4446,O
toxicological,4446,O
studies,4446,O
in,4446,O
intestinal,4446,O
tissue,4446,O
.,4446,O
Paeoniflorin,4447,B-CHEMICAL
protects,4447,O
human,4447,O
EA.hy926,4447,O
endothelial,4447,O
cells,4447,O
against,4447,O
gamma-radiation,4447,O
induced,4447,O
oxidative,4447,O
injury,4447,O
by,4447,O
activating,4447,O
the,4447,O
NF-E2-related,4447,B-GENE-Y
factor,4447,I-GENE-Y
2/heme,4447,O
oxygenase-1,4447,I-GENE-Y
pathway,4447,O
.,4447,O
Pulmonary,4448,O
endothelial,4448,O
cells,4448,O
have,4448,O
been,4448,O
demonstrated,4448,O
to,4448,O
have,4448,O
a,4448,O
critical,4448,O
role,4448,O
in,4448,O
the,4448,O
pathogenesis,4448,O
of,4448,O
radiation-induced,4448,O
lung,4448,O
injury,4448,O
.,4448,O
Our,4449,O
preliminary,4449,O
experiments,4449,O
indicated,4449,O
that,4449,O
Paeoniflorin,4449,B-CHEMICAL
protected,4449,O
human,4449,O
EA.hy926,4449,O
endothelial,4449,O
cells,4449,O
from,4449,O
radiation-induced,4449,O
oxidative,4449,O
injury,4449,O
.,4449,O
This,4450,O
study,4450,O
was,4450,O
designed,4450,O
to,4450,O
confirm,4450,O
the,4450,O
protective,4450,O
effect,4450,O
of,4450,O
Paeoniflorin,4450,B-CHEMICAL
against,4450,O
radiation-induced,4450,O
endothelial,4450,O
cellular,4450,O
damage,4450,O
and,4450,O
to,4450,O
elucidate,4450,O
the,4450,O
underlying,4450,O
mechanisms,4450,O
.,4450,O
Preincubation,4451,O
of,4451,O
EA.hy926,4451,O
cells,4451,O
with,4451,O
Paeoniflorin,4451,B-CHEMICAL
before,4451,O
-radiation,4451,O
resulted,4451,O
in,4451,O
significant,4451,O
inhibition,4451,O
of,4451,O
apoptosis,4451,O
",",4451,O
a,4451,O
decrease,4451,O
in,4451,O
mitochondrial,4451,O
membrane,4451,O
potential,4451,O
and,4451,O
enhanced,4451,O
cell,4451,O
viability,4451,O
.,4451,O
In,4452,O
particular,4452,O
",",4452,O
we,4452,O
showed,4452,O
that,4452,O
Paeoniflorin,4452,B-CHEMICAL
significantly,4452,O
reduced,4452,O
the,4452,O
formation,4452,O
of,4452,O
intracellular,4452,O
reactive,4452,O
oxygen,4452,B-CHEMICAL
species,4452,O
(,4452,O
ROS,4452,O
),4452,O
",",4452,O
the,4452,O
level,4452,O
of,4452,O
malondialdehyde,4452,B-CHEMICAL
(,4452,O
MDA,4452,B-CHEMICAL
),4452,O
and,4452,O
lactate,4452,B-GENE-N
dehydrogenase,4452,I-GENE-N
(,4452,O
LDH,4452,B-GENE-N
),4452,O
leakage,4452,O
",",4452,O
and,4452,O
enhanced,4452,O
production,4452,O
of,4452,O
the,4452,O
endogenous,4452,O
antioxidants,4452,O
",",4452,O
glutathione,4452,B-CHEMICAL
(,4452,O
GSH,4452,B-CHEMICAL
),4452,O
and,4452,O
superoxide,4452,B-GENE-N
dismutase,4452,I-GENE-N
(,4452,O
SOD,4452,B-GENE-N
),4452,O
in,4452,O
EA.hy926,4452,O
cells,4452,O
.,4452,O
Treatment,4453,O
of,4453,O
these,4453,O
cells,4453,O
with,4453,O
Paeoniflorin,4453,B-CHEMICAL
significantly,4453,O
induced,4453,O
HO-1,4453,B-GENE-Y
expression,4453,O
.,4453,O
Moreover,4454,O
",",4454,O
Paeoniflorin,4454,B-CHEMICAL
promoted,4454,O
the,4454,O
nuclear,4454,O
translocation,4454,O
of,4454,O
nuclear,4454,B-GENE-Y
factor,4454,I-GENE-Y
erythroid,4454,I-GENE-Y
2,4454,I-GENE-Y
related,4454,I-GENE-Y
factor-2,4454,I-GENE-Y
(,4454,O
Nrf-2,4454,B-GENE-Y
),4454,O
.,4454,O
The,4455,O
Paeoniflorin-induced,4455,B-CHEMICAL
HO-1,4455,B-GENE-Y
expression,4455,O
was,4455,O
abrogated,4455,O
by,4455,O
Nrf2,4455,B-GENE-Y
siRNA,4455,O
.,4455,O
Furthermore,4456,O
",",4456,O
inhibition,4456,O
of,4456,O
HO-1,4456,B-GENE-Y
with,4456,O
zinc,4456,B-CHEMICAL
protoporphyrin,4456,I-CHEMICAL
IX,4456,I-CHEMICAL
(,4456,O
ZNPP,4456,B-CHEMICAL
),4456,O
significantly,4456,O
reversed,4456,O
the,4456,O
protective,4456,O
effect,4456,O
of,4456,O
Paeoniflorin,4456,B-CHEMICAL
against,4456,O
radiation-induced,4456,O
damage,4456,O
in,4456,O
EA.hy926,4456,O
cells,4456,O
.,4456,O
Our,4457,O
findings,4457,O
confirmed,4457,O
that,4457,O
Paeoniflorin,4457,B-CHEMICAL
protected,4457,O
EA.hy926,4457,O
cells,4457,O
against,4457,O
radiation-induced,4457,O
injury,4457,O
through,4457,O
the,4457,O
Nrf2/HO-1,4457,B-GENE-Y
pathway,4457,O
.,4457,O
Accurate,4458,O
quantum,4458,O
chemical,4458,O
energies,4458,O
for,4458,O
tetrapeptide,4458,B-CHEMICAL
conformations,4458,O
:,4458,O
why,4458,O
MP2,4458,O
data,4458,O
with,4458,O
an,4458,O
insufficient,4458,O
basis,4458,O
set,4458,O
should,4458,O
be,4458,O
handled,4458,O
with,4458,O
caution,4458,O
.,4458,O
High-level,4459,O
quantum,4459,O
chemical,4459,O
calculations,4459,O
have,4459,O
been,4459,O
carried,4459,O
out,4459,O
for,4459,O
biologically-relevant,4459,O
conformers,4459,O
of,4459,O
tetrapeptides,4459,B-CHEMICAL
.,4459,O
Our,4460,O
results,4460,O
indicate,4460,O
potential,4460,O
problems,4460,O
if,4460,O
the,4460,O
widely-applied,4460,O
MP2,4460,O
approach,4460,O
is,4460,O
used,4460,O
in,4460,O
such,4460,O
situations,4460,O
with,4460,O
basis,4460,O
sets,4460,O
of,4460,O
insufficient,4460,O
size,4460,O
.,4460,O
Efficient,4461,O
alternatives,4461,O
are,4461,O
discussed,4461,O
.,4461,O
Management,4462,O
of,4462,O
chemotherapy-induced,4462,O
nausea,4462,O
and,4462,O
vomiting,4462,O
:,4462,O
focus,4462,O
on,4462,O
newer,4462,O
agents,4462,O
and,4462,O
new,4462,O
uses,4462,O
for,4462,O
older,4462,O
agents,4462,O
.,4462,O
Chemotherapy-induced,4463,O
nausea,4463,O
and,4463,O
vomiting,4463,O
(,4463,O
CINV,4463,O
),4463,O
is,4463,O
associated,4463,O
with,4463,O
a,4463,O
significant,4463,O
deterioration,4463,O
in,4463,O
quality,4463,O
of,4463,O
life,4463,O
.,4463,O
The,4464,O
emetogenicity,4464,O
of,4464,O
the,4464,O
chemotherapeutic,4464,O
agents,4464,O
",",4464,O
repeated,4464,O
chemotherapy,4464,O
cycles,4464,O
",",4464,O
and,4464,O
patient,4464,O
risk,4464,O
factors,4464,O
significantly,4464,O
influence,4464,O
CINV,4464,O
.,4464,O
The,4465,O
use,4465,O
of,4465,O
a,4465,O
combination,4465,O
of,4465,O
a,4465,O
serotonin,4465,B-CHEMICAL
5-HT3,4465,B-GENE-Y
receptor,4465,O
antagonist,4465,O
",",4465,O
dexamethasone,4465,B-CHEMICAL
and,4465,O
a,4465,O
neurokinin,4465,B-GENE-Y
1,4465,I-GENE-Y
(,4465,I-GENE-Y
NK1,4465,I-GENE-Y
),4465,I-GENE-Y
receptor,4465,I-GENE-Y
antagonist,4465,O
has,4465,O
significantly,4465,O
improved,4465,O
the,4465,O
control,4465,O
of,4465,O
acute,4465,O
and,4465,O
delayed,4465,O
emesis,4465,O
in,4465,O
single-day,4465,O
chemotherapy,4465,O
.,4465,O
Palonosetron,4466,B-CHEMICAL
",",4466,O
a,4466,O
second-generation,4466,O
5-HT3,4466,B-GENE-Y
receptor,4466,O
antagonist,4466,O
with,4466,O
a,4466,O
different,4466,O
half-life,4466,O
",",4466,O
a,4466,O
different,4466,O
binding,4466,O
capacity,4466,O
and,4466,O
a,4466,O
different,4466,O
mechanism,4466,O
of,4466,O
action,4466,O
than,4466,O
the,4466,O
first-generation,4466,O
5-HT3,4466,B-GENE-Y
receptor,4466,O
antagonists,4466,O
appears,4466,O
to,4466,O
be,4466,O
the,4466,O
most,4466,O
effective,4466,O
agent,4466,O
in,4466,O
its,4466,O
class,4466,O
.,4466,O
Aprepitant,4467,B-CHEMICAL
",",4467,O
the,4467,O
first,4467,O
and,4467,O
only,4467,O
agent,4467,O
clinically,4467,O
available,4467,O
in,4467,O
the,4467,O
NK1,4467,B-GENE-Y
receptor,4467,I-GENE-Y
antagonist,4467,O
drug,4467,O
class,4467,O
has,4467,O
been,4467,O
used,4467,O
effectively,4467,O
as,4467,O
an,4467,O
additive,4467,O
agent,4467,O
to,4467,O
the,4467,O
5-HT3,4467,B-GENE-Y
receptor,4467,O
antagonists,4467,O
and,4467,O
dexamethasone,4467,B-CHEMICAL
to,4467,O
control,4467,O
CINV,4467,O
.,4467,O
Rolapitant,4468,B-CHEMICAL
and,4468,O
netupitant,4468,B-CHEMICAL
are,4468,O
other,4468,O
NK1,4468,B-GENE-Y
receptor,4468,I-GENE-Y
antagonists,4468,O
that,4468,O
are,4468,O
currently,4468,O
in,4468,O
phase,4468,O
III,4468,O
clinical,4468,O
trials,4468,O
.,4468,O
Despite,4469,O
the,4469,O
control,4469,O
of,4469,O
emesis,4469,O
",",4469,O
nausea,4469,O
has,4469,O
not,4469,O
been,4469,O
well,4469,O
controlled,4469,O
by,4469,O
current,4469,O
agents,4469,O
.,4469,O
Olanzapine,4470,B-CHEMICAL
",",4470,O
a,4470,O
US-FDA,4470,O
approved,4470,O
antipsychotic,4470,O
",",4470,O
has,4470,O
emerged,4470,O
in,4470,O
recent,4470,O
trials,4470,O
as,4470,O
an,4470,O
effective,4470,O
preventative,4470,O
agent,4470,O
for,4470,O
CINV,4470,O
",",4470,O
as,4470,O
well,4470,O
as,4470,O
a,4470,O
very,4470,O
effective,4470,O
agent,4470,O
for,4470,O
the,4470,O
treatment,4470,O
of,4470,O
breakthrough,4470,O
emesis,4470,O
and,4470,O
nausea,4470,O
.,4470,O
Clinical,4471,O
trials,4471,O
using,4471,O
gabapentin,4471,B-CHEMICAL
",",4471,O
cannabinoids,4471,O
and,4471,O
ginger,4471,O
have,4471,O
not,4471,O
been,4471,O
definitive,4471,O
regarding,4471,O
their,4471,O
efficacy,4471,O
in,4471,O
the,4471,O
prevention,4471,O
of,4471,O
CINV,4471,O
.,4471,O
Additional,4472,O
studies,4472,O
are,4472,O
necessary,4472,O
for,4472,O
the,4472,O
control,4472,O
of,4472,O
nausea,4472,O
and,4472,O
for,4472,O
the,4472,O
control,4472,O
of,4472,O
CINV,4472,O
in,4472,O
the,4472,O
clinical,4472,O
settings,4472,O
of,4472,O
multiple-day,4472,O
chemotherapy,4472,O
and,4472,O
bone,4472,O
marrow,4472,O
transplantation,4472,O
.,4472,O
In,4473,O
vitro,4473,O
polyphenolics,4473,B-CHEMICAL
erythrocyte,4473,O
model,4473,O
and,4473,O
in,4473,O
vivo,4473,O
chicken,4473,O
embryo,4473,O
model,4473,O
revealed,4473,O
gallic,4473,B-CHEMICAL
acid,4473,I-CHEMICAL
to,4473,O
be,4473,O
a,4473,O
potential,4473,O
hemorrhage,4473,O
inducer,4473,O
:,4473,O
physicochemical,4473,O
action,4473,O
mechanisms,4473,O
.,4473,O
The,4474,O
in,4474,O
vivo,4474,O
chicken,4474,O
embryo,4474,O
model,4474,O
(,4474,O
CEM,4474,O
),4474,O
demonstrated,4474,O
that,4474,O
gallic,4474,B-CHEMICAL
acid,4474,I-CHEMICAL
(,4474,O
GA,4474,O
),4474,O
induced,4474,O
dysvascularization,4474,O
and,4474,O
hypoxia,4474,O
.,4474,O
Inflammatory,4475,O
edema,4475,O
",",4475,O
Zenker,4475,O
's,4475,O
necrosis,4475,O
",",4475,O
hemolysis,4475,O
",",4475,O
and,4475,O
liposis,4475,O
of,4475,O
cervical,4475,O
muscles,4475,O
were,4475,O
the,4475,O
common,4475,O
symptoms,4475,O
.,4475,O
Levels,4476,O
of,4476,O
the,4476,O
gene,4476,O
hif-1,4476,B-GENE-Y
",",4476,O
HIF-1,4476,B-GENE-Y
",",4476,O
TNF-,4476,B-GENE-Y
",",4476,O
IL-6,4476,B-GENE-Y
",",4476,O
and,4476,O
NFB,4476,B-GENE-N
in,4476,O
cervical,4476,O
muscles,4476,O
were,4476,O
all,4476,O
significantly,4476,O
upregulated,4476,O
",",4476,O
while,4476,O
the,4476,O
vascular,4476,B-GENE-Y
endothelial,4476,I-GENE-Y
growth,4476,I-GENE-Y
factor,4476,I-GENE-Y
(,4476,O
VEGF,4476,B-GENE-Y
),4476,O
was,4476,O
downregulated,4476,O
in,4476,O
a,4476,O
dose-responsive,4476,O
manner,4476,O
.,4476,O
Consequently,4477,O
",",4477,O
the,4477,O
cervical,4477,O
muscle,4477,O
inflammation,4477,O
and,4477,O
hemolysis,4477,O
could,4477,O
have,4477,O
been,4477,O
stimulated,4477,O
en,4477,O
route,4477,O
to,4477,O
the,4477,O
tissue,4477,O
TNF--canonical,4477,B-GENE-Y
and,4477,O
the,4477,O
atypical,4477,O
pathways,4477,O
.,4477,O
We,4478,O
hypothesized,4478,O
that,4478,O
GA,4478,O
could,4478,O
deplete,4478,O
the,4478,O
dissolved,4478,O
oxygen,4478,B-CHEMICAL
(,4478,O
DO,4478,O
),4478,O
at,4478,O
the,4478,O
expense,4478,O
of,4478,O
semiquinone,4478,B-CHEMICAL
and,4478,O
quinone,4478,B-CHEMICAL
formation,4478,O
",",4478,O
favoring,4478,O
the,4478,O
reactive,4478,O
oxygen,4478,B-CHEMICAL
species,4478,O
(,4478,O
ROS,4478,O
),4478,O
production,4478,O
to,4478,O
induce,4478,O
RBC,4478,O
disruption,4478,O
and,4478,O
Fe,4478,B-CHEMICAL
(,4478,I-CHEMICAL
2+,4478,I-CHEMICAL
),4478,I-CHEMICAL
ion,4478,O
release,4478,O
.,4478,O
To,4479,O
explore,4479,O
this,4479,O
",",4479,O
the,4479,O
in,4479,O
vitro,4479,O
polyphenolics-erythrocyte,4479,B-CHEMICAL
model,4479,O
(,4479,O
PEM,4479,O
),4479,O
was,4479,O
established,4479,O
.,4479,O
PEM,4480,O
revealed,4480,O
that,4480,O
the,4480,O
DO,4480,O
was,4480,O
rapidly,4480,O
depleted,4480,O
",",4480,O
leading,4480,O
to,4480,O
the,4480,O
release,4480,O
of,4480,O
a,4480,O
huge,4480,O
amount,4480,O
of,4480,O
Fe,4480,B-CHEMICAL
(,4480,I-CHEMICAL
II,4480,I-CHEMICAL
),4480,I-CHEMICAL
ions,4480,O
and,4480,O
hydrogen,4480,B-CHEMICAL
peroxide,4480,I-CHEMICAL
(,4480,O
HPO,4480,B-CHEMICAL
),4480,O
in,4480,O
a,4480,O
two-phase,4480,O
kinetic,4480,O
pattern,4480,O
.,4480,O
The,4481,O
kinetic,4481,O
coefficients,4481,O
for,4481,O
Fe,4481,B-CHEMICAL
(,4481,I-CHEMICAL
II,4481,I-CHEMICAL
),4481,I-CHEMICAL
ion,4481,O
release,4481,O
ranged,4481,O
from,4481,O
0.347,4481,O
h,4481,O
(,4481,O
-1,4481,O
),4481,O
to,4481,O
0.774,4481,O
h,4481,O
(,4481,O
-1,4481,O
),4481,O
;,4481,O
and,4481,O
those,4481,O
for,4481,O
Fe,4481,B-CHEMICAL
(,4481,I-CHEMICAL
III,4481,I-CHEMICAL
),4481,I-CHEMICAL
ion,4481,O
production,4481,O
were,4481,O
from,4481,O
6.66,4481,O
,4481,O
10,4481,O
(,4481,O
-3,4481,O
),4481,O
h,4481,O
(,4481,O
-1,4481,O
),4481,O
to,4481,O
8.93,4481,O
,4481,O
10,4481,O
(,4481,O
-3,4481,O
),4481,O
h,4481,O
(,4481,O
-1,4481,O
),4481,O
.,4481,O
For,4482,O
phase,4482,O
I,4482,O
HPO,4482,B-CHEMICAL
production,4482,O
",",4482,O
they,4482,O
ranged,4482,O
from,4482,O
0.236,4482,O
h,4482,O
(,4482,O
-1,4482,O
),4482,O
to,4482,O
0.774,4482,O
h,4482,O
(,4482,O
-1,4482,O
),4482,O
and,4482,O
for,4482,O
phase,4482,O
II,4482,O
HPO,4482,B-CHEMICAL
production,4482,O
from,4482,O
0.764,4482,O
h,4482,O
(,4482,O
-1,4482,O
),4482,O
to,4482,O
2.560,4482,O
h,4482,O
(,4482,O
-1,4482,O
),4482,O
at,4482,O
GA,4482,O
within,4482,O
6,4482,O
M,4482,O
to,4482,O
14,4482,O
M,4482,O
.,4482,O
Thus,4483,O
",",4483,O
evidence,4483,O
obtained,4483,O
from,4483,O
PEM,4483,O
could,4483,O
strongly,4483,O
support,4483,O
the,4483,O
phenomena,4483,O
of,4483,O
CEM,4483,O
.,4483,O
To,4484,O
conclude,4484,O
",",4484,O
GA,4484,O
tends,4484,O
to,4484,O
elicit,4484,O
hypoxia-related,4484,O
inflammation,4484,O
and,4484,O
hemolysis,4484,O
in,4484,O
chicken,4484,O
cervical,4484,O
muscles,4484,O
through,4484,O
its,4484,O
extremely,4484,O
high,4484,O
prooxidant,4484,O
activity,4484,O
.,4484,O
Impact,4485,O
of,4485,O
quaternary,4485,O
structure,4485,O
dynamics,4485,O
on,4485,O
allosteric,4485,O
drug,4485,O
discovery,4485,O
.,4485,O
The,4486,O
morpheein,4486,O
model,4486,O
of,4486,O
allosteric,4486,O
regulation,4486,O
draws,4486,O
attention,4486,O
to,4486,O
proteins,4486,O
that,4486,O
can,4486,O
exist,4486,O
as,4486,O
an,4486,O
equilibrium,4486,O
of,4486,O
functionally,4486,O
distinct,4486,O
assemblies,4486,O
where,4486,O
:,4486,O
one,4486,O
subunit,4486,O
conformation,4486,O
assembles,4486,O
into,4486,O
one,4486,O
multimer,4486,O
;,4486,O
a,4486,O
different,4486,O
subunit,4486,O
conformation,4486,O
assembles,4486,O
into,4486,O
a,4486,O
different,4486,O
multimer,4486,O
;,4486,O
and,4486,O
the,4486,O
various,4486,O
multimers,4486,O
are,4486,O
in,4486,O
a,4486,O
dynamic,4486,O
equilibrium,4486,O
whose,4486,O
position,4486,O
can,4486,O
be,4486,O
modulated,4486,O
by,4486,O
ligands,4486,O
that,4486,O
bind,4486,O
to,4486,O
a,4486,O
multimer-specific,4486,O
ligand,4486,O
binding,4486,O
site,4486,O
.,4486,O
The,4487,O
case,4487,O
study,4487,O
of,4487,O
porphobilinogen,4487,B-GENE-Y
synthase,4487,I-GENE-Y
(,4487,O
PBGS,4487,B-GENE-Y
),4487,O
illustrates,4487,O
how,4487,O
such,4487,O
an,4487,O
equilibrium,4487,O
holds,4487,O
lessons,4487,O
for,4487,O
disease,4487,O
mechanisms,4487,O
",",4487,O
drug,4487,O
discovery,4487,O
",",4487,O
understanding,4487,O
drug,4487,O
side,4487,O
effects,4487,O
",",4487,O
and,4487,O
identifying,4487,O
proteins,4487,O
wherein,4487,O
drug,4487,O
discovery,4487,O
efforts,4487,O
might,4487,O
focus,4487,O
on,4487,O
quaternary,4487,O
structure,4487,O
dynamics,4487,O
.,4487,O
The,4488,O
morpheein,4488,O
model,4488,O
of,4488,O
allostery,4488,O
has,4488,O
been,4488,O
proposed,4488,O
as,4488,O
applicable,4488,O
for,4488,O
a,4488,O
wide,4488,O
assortment,4488,O
of,4488,O
disease-associated,4488,O
proteins,4488,O
(,4488,O
Selwood,4488,O
",",4488,O
T.,4488,O
",",4488,O
Jaffe,4488,O
",",4488,O
E.,4488,O
",",4488,O
(,4488,O
2012,4488,O
),4488,O
Arch,4488,O
.,4488,O
Bioch,4489,O
.,4489,O
Biophys,4490,O
",",4490,O
519:131-143,4490,O
),4490,O
.,4490,O
Herein,4491,O
we,4491,O
discuss,4491,O
quaternary,4491,O
structure,4491,O
dynamics,4491,O
aspects,4491,O
to,4491,O
drug,4491,O
discovery,4491,O
for,4491,O
the,4491,O
disease-associated,4491,O
putative,4491,O
morpheeins,4491,O
phenylalanine,4491,B-GENE-Y
hydroxylase,4491,I-GENE-Y
",",4491,O
HIV,4491,B-GENE-Y
integrase,4491,I-GENE-Y
",",4491,O
pyruvate,4491,B-GENE-N
kinase,4491,I-GENE-N
",",4491,O
and,4491,O
tumor,4491,B-GENE-Y
necrosis,4491,I-GENE-Y
factor,4491,I-GENE-Y
,4491,I-GENE-Y
.,4491,O
Also,4492,O
highlighted,4492,O
is,4492,O
the,4492,O
quaternary,4492,O
structure,4492,O
equilibrium,4492,O
of,4492,O
transthyretin,4492,B-GENE-Y
and,4492,O
successful,4492,O
drug,4492,O
discovery,4492,O
efforts,4492,O
focused,4492,O
on,4492,O
controlling,4492,O
its,4492,O
quaternary,4492,O
structure,4492,O
dynamics,4492,O
.,4492,O
Antioxidant,4493,O
activity,4493,O
of,4493,O
phytosteryl,4493,B-CHEMICAL
phenolates,4493,I-CHEMICAL
in,4493,O
different,4493,O
model,4493,O
systems,4493,O
.,4493,O
As,4494,O
part,4494,O
of,4494,O
a,4494,O
comprehensive,4494,O
study,4494,O
of,4494,O
the,4494,O
physiochemical,4494,O
and,4494,O
biological,4494,O
properties,4494,O
of,4494,O
phytosteryl,4494,B-CHEMICAL
phenolates,4494,I-CHEMICAL
",",4494,O
successfully,4494,O
synthesized,4494,O
chemoenzymatically,4494,O
in,4494,O
our,4494,O
lab,4494,O
",",4494,O
their,4494,O
antioxidant,4494,O
activity,4494,O
was,4494,O
evaluated,4494,O
using,4494,O
three,4494,O
different,4494,O
in,4494,O
vitro,4494,O
model,4494,O
systems,4494,O
",",4494,O
namely,4494,O
bulk,4494,O
oil,4494,O
model,4494,O
system,4494,O
",",4494,O
-carotene-linoleate,4494,B-CHEMICAL
model,4494,O
system,4494,O
and,4494,O
low-density,4494,B-GENE-N
lipoprotein,4494,I-GENE-N
cholesterol,4494,B-CHEMICAL
(,4494,O
LDL-C,4494,B-GENE-N
),4494,O
oxidation,4494,O
assay,4494,O
.,4494,O
In,4495,O
the,4495,O
bulk,4495,O
oil,4495,O
system,4495,O
",",4495,O
phytosteryl,4495,B-CHEMICAL
phenolates,4495,I-CHEMICAL
showed,4495,O
similar,4495,O
or,4495,O
lower,4495,O
antioxidant,4495,O
activity,4495,O
compared,4495,O
with,4495,O
those,4495,O
of,4495,O
phenolic,4495,B-CHEMICAL
acids,4495,I-CHEMICAL
.,4495,O
However,4496,O
",",4496,O
in,4496,O
-carotene-linoleate,4496,B-CHEMICAL
assay,4496,O
",",4496,O
an,4496,O
emulsion,4496,O
model,4496,O
system,4496,O
",",4496,O
phytosteryl,4496,B-CHEMICAL
phenolates,4496,I-CHEMICAL
showed,4496,O
enhanced,4496,O
antioxidant,4496,O
activity,4496,O
except,4496,O
phytosteryl,4496,B-CHEMICAL
ferulates,4496,I-CHEMICAL
.,4496,O
Moderate,4497,O
inhibitory,4497,O
effect,4497,O
of,4497,O
LDL-C,4497,B-GENE-N
oxidation,4497,O
by,4497,O
phytosteryl,4497,B-CHEMICAL
phenolates,4497,I-CHEMICAL
was,4497,O
observed,4497,O
.,4497,O
These,4498,O
findings,4498,O
demonstrate,4498,O
that,4498,O
use,4498,O
of,4498,O
multidimensional,4498,O
antioxidant,4498,O
activity,4498,O
determinations,4498,O
with,4498,O
differing,4498,O
reaction,4498,O
mechanisms,4498,O
is,4498,O
necessary,4498,O
to,4498,O
provide,4498,O
an,4498,O
overall,4498,O
understanding,4498,O
of,4498,O
the,4498,O
mechanisms,4498,O
of,4498,O
antioxidant,4498,O
action,4498,O
of,4498,O
phytosteryl,4498,B-CHEMICAL
phenolates,4498,I-CHEMICAL
.,4498,O
Evaluation,4499,O
of,4499,O
antioxidant,4499,O
activities,4499,O
and,4499,O
chemical,4499,O
characterisation,4499,O
of,4499,O
staghorn,4499,O
sumac,4499,O
fruit,4499,O
(,4499,O
Rhus,4499,O
hirta,4499,O
L.,4499,O
),4499,O
.,4499,O
Staghorn,4500,O
sumac,4500,O
(,4500,O
Rhus,4500,O
hirta,4500,O
L.,4500,O
),4500,O
is,4500,O
a,4500,O
native,4500,O
tree,4500,O
in,4500,O
Eastern,4500,O
Canada,4500,O
whose,4500,O
fruit,4500,O
has,4500,O
been,4500,O
used,4500,O
by,4500,O
aboriginal,4500,O
peoples,4500,O
to,4500,O
treat,4500,O
various,4500,O
illnesses,4500,O
",",4500,O
and,4500,O
has,4500,O
recently,4500,O
been,4500,O
found,4500,O
to,4500,O
be,4500,O
a,4500,O
good,4500,O
source,4500,O
of,4500,O
antioxidants,4500,O
.,4500,O
However,4501,O
",",4501,O
the,4501,O
phytochemical,4501,O
composition,4501,O
of,4501,O
R.,4501,O
hirta,4501,O
is,4501,O
not,4501,O
known,4501,O
.,4501,O
In,4502,O
this,4502,O
study,4502,O
",",4502,O
we,4502,O
used,4502,O
Four,4502,O
highly,4502,O
accepted,4502,O
assays,4502,O
and,4502,O
confirmed,4502,O
its,4502,O
FRAP,4502,O
",",4502,O
ORAC,4502,O
",",4502,O
-CLAMS,4502,O
and,4502,O
PCL,4502,O
values,4502,O
to,4502,O
be,4502,O
79.95,4502,O
mol,4502,O
AAE/g,4502,O
DW,4502,O
",",4502,O
1544,4502,O
mol,4502,O
TE/g,4502,O
DW,4502,O
",",4502,O
RAA,4502,O
129,4502,O
%,4502,O
and,4502,O
4513,4502,O
mol,4502,O
TE/g,4502,O
DW,4502,O
",",4502,O
respectively,4502,O
.,4502,O
The,4503,O
antioxidant,4503,O
activities,4503,O
correlated,4503,O
positively,4503,O
to,4503,O
the,4503,O
total,4503,O
polyphenols,4503,B-CHEMICAL
content,4503,O
",",4503,O
which,4503,O
was,4503,O
higher,4503,O
in,4503,O
the,4503,O
ethanolic,4503,O
extract,4503,O
(,4503,O
81.6,4503,O
mg,4503,O
GAE/,4503,O
g,4503,O
DW,4503,O
),4503,O
compared,4503,O
to,4503,O
the,4503,O
water,4503,O
extract,4503,O
(,4503,O
46.3mg,4503,O
GAE/g,4503,O
DW,4503,O
),4503,O
",",4503,O
suggesting,4503,O
polyphenols,4503,B-CHEMICAL
play,4503,O
an,4503,O
important,4503,O
role,4503,O
.,4503,O
Quantitative,4504,O
data,4504,O
from,4504,O
UHPLC,4504,O
and,4504,O
qualitative,4504,O
studies,4504,O
using,4504,O
HPLC-DAD-MS,4504,O
showed,4504,O
that,4504,O
in,4504,O
addition,4504,O
to,4504,O
commonly,4504,O
found,4504,O
phenolic,4504,B-CHEMICAL
acids,4504,I-CHEMICAL
",",4504,O
flavonoids,4504,B-CHEMICAL
and,4504,O
anthocyanins,4504,B-CHEMICAL
",",4504,O
R.,4504,O
hirta,4504,O
fruit,4504,O
contained,4504,O
a,4504,O
novel,4504,O
group,4504,O
of,4504,O
unique,4504,O
anthocyanins,4504,B-CHEMICAL
with,4504,O
aglycones,4504,O
(,4504,O
anthocyanidins,4504,B-CHEMICAL
),4504,O
at,4504,O
449,4504,O
",",4504,O
419,4504,O
and,4504,O
433,4504,O
Da,4504,O
.,4504,O
Further,4505,O
studies,4505,O
on,4505,O
the,4505,O
identification,4505,O
and,4505,O
their,4505,O
health,4505,O
beneficial,4505,O
effects,4505,O
are,4505,O
being,4505,O
conducted,4505,O
.,4505,O
Phenolics,4506,B-CHEMICAL
content,4506,O
and,4506,O
antioxidant,4506,O
and,4506,O
anti-inflammatory,4506,O
activities,4506,O
of,4506,O
legume,4506,O
fractions,4506,O
.,4506,O
Two,4507,O
faba,4507,O
bean,4507,O
(,4507,O
Vicia,4507,O
faba,4507,O
L.,4507,O
),4507,O
subspecies,4507,O
major,4507,O
and,4507,O
minor,4507,O
and,4507,O
lentil,4507,O
seeds,4507,O
grown,4507,O
in,4507,O
Algeria,4507,O
were,4507,O
separated,4507,O
into,4507,O
cotyledons,4507,O
and,4507,O
hulls,4507,O
.,4507,O
These,4508,O
fractions,4508,O
",",4508,O
together,4508,O
with,4508,O
their,4508,O
corresponding,4508,O
whole,4508,O
seeds,4508,O
",",4508,O
were,4508,O
extracted,4508,O
with,4508,O
two,4508,O
solvents,4508,O
",",4508,O
aqueous,4508,O
(,4508,O
70,4508,O
%,4508,O
),4508,O
acetone,4508,B-CHEMICAL
and,4508,O
(,4508,O
80,4508,O
%,4508,O
),4508,O
ethanol,4508,B-CHEMICAL
",",4508,O
and,4508,O
evaluated,4508,O
for,4508,O
antioxidant,4508,O
activity,4508,O
in,4508,O
relation,4508,O
to,4508,O
their,4508,O
phenolic,4508,B-CHEMICAL
contents,4508,O
.,4508,O
Acetone,4509,B-CHEMICAL
selectively,4509,O
extracted,4509,O
tannins,4509,B-CHEMICAL
from,4509,O
faba,4509,O
beans,4509,O
.,4509,O
The,4510,O
hulls,4510,O
always,4510,O
exhibited,4510,O
high,4510,O
antioxidant,4510,O
activity,4510,O
",",4510,O
measured,4510,O
using,4510,O
the,4510,O
reducing,4510,O
power,4510,O
(,4510,O
RP,4510,O
),4510,O
",",4510,O
antiradical,4510,O
activity,4510,O
(,4510,O
DPPH,4510,B-CHEMICAL
),4510,O
or,4510,O
oxygen,4510,B-CHEMICAL
radical,4510,O
absorbance,4510,O
capacity,4510,O
(,4510,O
ORAC,4510,O
),4510,O
assays,4510,O
.,4510,O
Aqueous,4511,O
ethanol,4511,B-CHEMICAL
(,4511,O
80,4511,O
%,4511,O
),4511,O
extract,4511,O
of,4511,O
lentil,4511,O
hulls,4511,O
exhibited,4511,O
high,4511,O
antioxidant,4511,O
and,4511,O
anti-inflammatory,4511,O
activities,4511,O
preferentially,4511,O
inhibiting,4511,O
15-LOX,4511,B-GENE-Y
(,4511,O
IC,4511,O
(,4511,O
50,4511,O
),4511,O
",",4511,O
55,4511,O
g/ml,4511,O
),4511,O
",",4511,O
with,4511,O
moderate,4511,O
COX-1,4511,B-GENE-Y
(,4511,O
IC,4511,O
(,4511,O
50,4511,O
),4511,O
",",4511,O
66,4511,O
g/ml,4511,O
),4511,O
and,4511,O
COX-2,4511,B-GENE-Y
(,4511,O
IC,4511,O
(,4511,O
50,4511,O
),4511,O
",",4511,O
119,4511,O
g/ml,4511,O
),4511,O
inhibitory,4511,O
effects,4511,O
on,4511,O
the,4511,O
COX,4511,B-GENE-N
pathway,4511,O
",",4511,O
whereas,4511,O
faba,4511,O
bean,4511,O
hull,4511,O
extracts,4511,O
exerted,4511,O
relatively,4511,O
mild,4511,O
LOX,4511,B-GENE-N
inhibitory,4511,O
activity,4511,O
.,4511,O
Inhibitory,4512,O
activity,4512,O
of,4512,O
Filipendula,4512,O
ulmaria,4512,O
constituents,4512,O
on,4512,O
recombinant,4512,O
human,4512,B-GENE-N
histidine,4512,I-GENE-N
decarboxylase,4512,I-GENE-N
.,4512,O
Histidine,4513,B-CHEMICAL
decarboxylase,4513,I-GENE-Y
(,4513,O
HDC,4513,B-GENE-Y
),4513,O
catalyses,4513,O
the,4513,O
formation,4513,O
of,4513,O
histamine,4513,B-CHEMICAL
",",4513,O
a,4513,O
bioactive,4513,O
amine,4513,B-CHEMICAL
.,4513,O
Agents,4514,O
that,4514,O
control,4514,O
HDC,4514,B-GENE-Y
activity,4514,O
are,4514,O
beneficial,4514,O
for,4514,O
treating,4514,O
histamine-mediated,4514,B-CHEMICAL
symptoms,4514,O
",",4514,O
such,4514,O
as,4514,O
allergies,4514,O
and,4514,O
stomach,4514,O
ulceration,4514,O
.,4514,O
We,4515,O
searched,4515,O
for,4515,O
inhibitors,4515,O
of,4515,O
HDC,4515,B-GENE-Y
from,4515,O
the,4515,O
ethyl,4515,B-CHEMICAL
acetate,4515,I-CHEMICAL
extract,4515,O
of,4515,O
the,4515,O
petal,4515,O
of,4515,O
Filipendula,4515,O
ulmaria,4515,O
",",4515,O
also,4515,O
called,4515,O
meadowsweet,4515,O
.,4515,O
Rugosin,4516,B-CHEMICAL
D,4516,I-CHEMICAL
",",4516,O
rugosin,4516,B-CHEMICAL
A,4516,I-CHEMICAL
",",4516,O
rugosin,4516,B-CHEMICAL
A,4516,I-CHEMICAL
methyl,4516,I-CHEMICAL
ester,4516,I-CHEMICAL
(,4516,O
a,4516,O
novel,4516,O
compound,4516,O
),4516,O
",",4516,O
and,4516,O
tellimagrandin,4516,B-CHEMICAL
II,4516,I-CHEMICAL
were,4516,O
the,4516,O
main,4516,O
components,4516,O
;,4516,O
these,4516,O
4,4516,O
ellagitannins,4516,O
exhibited,4516,O
a,4516,O
non-competitive,4516,O
type,4516,O
of,4516,O
inhibition,4516,O
",",4516,O
with,4516,O
K,4516,O
(,4516,O
i,4516,O
),4516,O
values,4516,O
of,4516,O
approximately,4516,O
0.35-1,4516,O
M,4516,O
.,4516,O
These,4517,O
K,4517,O
(,4517,O
i,4517,O
),4517,O
values,4517,O
are,4517,O
nearly,4517,O
equal,4517,O
to,4517,O
that,4517,O
of,4517,O
histidine,4517,B-CHEMICAL
methyl,4517,I-CHEMICAL
ester,4517,I-CHEMICAL
(,4517,O
K,4517,O
(,4517,O
i,4517,O
),4517,O
=0.46,4517,O
M,4517,O
),4517,O
",",4517,O
an,4517,O
existing,4517,O
substrate,4517,O
analogue,4517,O
inhibitor,4517,O
.,4517,O
Our,4518,O
results,4518,O
show,4518,O
that,4518,O
food,4518,O
products,4518,O
contain,4518,O
potent,4518,O
HDC,4518,B-GENE-Y
inhibitors,4518,O
and,4518,O
that,4518,O
these,4518,O
active,4518,O
food,4518,O
constituents,4518,O
might,4518,O
be,4518,O
useful,4518,O
for,4518,O
designing,4518,O
clinically,4518,O
available,4518,O
HDC,4518,B-GENE-Y
inhibitors,4518,O
.,4518,O
Discovery,4519,O
of,4519,O
a,4519,O
novel,4519,O
series,4519,O
of,4519,O
quinolone,4519,B-CHEMICAL
7,4519,B-GENE-Y
nicotinic,4519,I-GENE-Y
acetylcholine,4519,B-CHEMICAL
receptor,4519,I-GENE-Y
agonists,4519,O
.,4519,O
High,4520,O
throughput,4520,O
screening,4520,O
led,4520,O
to,4520,O
the,4520,O
identification,4520,O
of,4520,O
a,4520,O
novel,4520,O
series,4520,O
of,4520,O
quinolone,4520,B-CHEMICAL
7,4520,B-GENE-Y
nicotinic,4520,I-GENE-Y
acetylcholine,4520,I-GENE-Y
receptor,4520,I-GENE-Y
(,4520,O
nAChR,4520,B-GENE-N
),4520,O
agonists,4520,O
.,4520,O
Optimization,4521,O
of,4521,O
an,4521,O
HTS,4521,O
hit,4521,O
(,4521,O
1,4521,O
),4521,O
led,4521,O
to,4521,O
4-phenyl-1-,4521,B-CHEMICAL
(,4521,I-CHEMICAL
quinuclidin-3-ylmethyl,4521,I-CHEMICAL
),4521,I-CHEMICAL
quinolin-2,4521,I-CHEMICAL
(,4521,I-CHEMICAL
1H,4521,I-CHEMICAL
),4521,I-CHEMICAL
-one,4521,I-CHEMICAL
",",4521,O
which,4521,O
was,4521,O
found,4521,O
to,4521,O
be,4521,O
potent,4521,O
and,4521,O
selective,4521,O
.,4521,O
Poor,4522,O
brain,4522,O
penetrance,4522,O
in,4522,O
this,4522,O
series,4522,O
was,4522,O
attributed,4522,O
to,4522,O
transporter-mediated,4522,O
efflux,4522,O
",",4522,O
which,4522,O
was,4522,O
in,4522,O
turn,4522,O
due,4522,O
to,4522,O
high,4522,O
pKa,4522,O
.,4522,O
A,4523,O
novel,4523,O
4-fluoroquinuclidine,4523,B-CHEMICAL
significantly,4523,O
lowered,4523,O
the,4523,O
pKa,4523,O
of,4523,O
the,4523,O
quinuclidine,4523,B-CHEMICAL
moiety,4523,O
",",4523,O
reducing,4523,O
efflux,4523,O
as,4523,O
measured,4523,O
by,4523,O
a,4523,O
Caco-2,4523,O
assay,4523,O
.,4523,O
Amino,4524,B-CHEMICAL
acid,4524,I-CHEMICAL
derived,4524,O
quinazolines,4524,B-CHEMICAL
as,4524,O
Rock/PKA,4524,B-GENE-N
inhibitors,4524,O
.,4524,O
SAR,4525,O
and,4525,O
lead,4525,O
optimization,4525,O
studies,4525,O
for,4525,O
Rock,4525,B-GENE-N
inhibitors,4525,O
based,4525,O
on,4525,O
amino,4525,B-CHEMICAL
acid-derived,4525,O
quinazolines,4525,B-CHEMICAL
are,4525,O
described,4525,O
.,4525,O
Studies,4526,O
demonstrated,4526,O
that,4526,O
these,4526,O
amino,4526,B-CHEMICAL
acid,4526,I-CHEMICAL
derived,4526,O
quinazolinones,4526,B-CHEMICAL
were,4526,O
mainly,4526,O
pan-Rock,4526,O
(,4526,I-GENE-N
I,4526,I-GENE-N
&,4526,I-GENE-N
II,4526,I-GENE-N
),4526,I-GENE-N
inhibitors,4526,O
.,4526,O
While,4527,O
selectivity,4527,O
against,4527,O
other,4527,O
kinases,4527,B-GENE-N
could,4527,O
be,4527,O
achieved,4527,O
",",4527,O
selectivity,4527,O
for,4527,O
most,4527,O
of,4527,O
these,4527,O
compounds,4527,O
against,4527,O
PKA,4527,B-GENE-N
was,4527,O
not,4527,O
achieved,4527,O
.,4527,O
This,4528,O
is,4528,O
distinct,4528,O
from,4528,O
Rock,4528,B-GENE-N
inhibitors,4528,O
based,4528,O
on,4528,O
non-amino,4528,O
acid,4528,I-CHEMICAL
derived,4528,O
quinazolinones,4528,B-CHEMICAL
",",4528,O
where,4528,O
high,4528,O
selectivity,4528,O
against,4528,O
PKA,4528,B-GENE-N
could,4528,O
be,4528,O
obtained,4528,O
.,4528,O
(,4529,O
22,4529,O
),4529,O
The,4529,O
inhibitors,4529,O
presented,4529,O
here,4529,O
in,4529,O
some,4529,O
cases,4529,O
possessed,4529,O
sub-nanomolar,4529,O
inhibition,4529,O
of,4529,O
Rock,4529,O
",",4529,O
nanomolar,4529,O
potency,4529,O
in,4529,O
ppMLC,4529,O
cell,4529,O
based,4529,O
assays,4529,O
",",4529,O
low,4529,O
to,4529,O
fair,4529,O
cytochrome,4529,I-GENE-N
P-450,4529,O
inhibition,4529,O
",",4529,O
and,4529,O
good,4529,O
human,4529,O
microsomal,4529,O
stability,4529,O
.,4529,O
Human,4530,B-GENE-Y
serum,4530,I-GENE-Y
albumin-based,4530,O
design,4530,O
of,4530,O
a,4530,O
diflunisal,4530,B-CHEMICAL
prodrug,4530,O
.,4530,O
The,4531,O
cyclooxygenase-2,4531,B-GENE-Y
inhibitor,4531,O
",",4531,O
diflunisal,4531,B-CHEMICAL
",",4531,O
is,4531,O
used,4531,O
in,4531,O
the,4531,O
clinic,4531,O
for,4531,O
its,4531,O
anti-inflammatory,4531,O
activity,4531,O
.,4531,O
About,4532,O
99,4532,O
%,4532,O
of,4532,O
a,4532,O
dose,4532,O
of,4532,O
diflunisal,4532,B-CHEMICAL
is,4532,O
unavailable,4532,O
for,4532,O
reaction,4532,O
with,4532,O
the,4532,O
target,4532,O
enzyme,4532,O
",",4532,O
because,4532,O
diflunisal,4532,B-CHEMICAL
strongly,4532,O
binds,4532,O
to,4532,O
human,4532,B-GENE-Y
serum,4532,I-GENE-Y
albumin,4532,I-GENE-Y
(,4532,O
HSA,4532,B-GENE-Y
),4532,O
.,4532,O
To,4533,O
reduce,4533,O
the,4533,O
binding,4533,O
affinity,4533,O
of,4533,O
diflunisal,4533,B-CHEMICAL
to,4533,O
albumin,4533,B-GENE-Y
",",4533,O
we,4533,O
designed,4533,O
and,4533,O
synthesized,4533,O
the,4533,O
prodrug,4533,O
acetyldiflunisal,4533,B-CHEMICAL
.,4533,O
The,4534,O
crystal,4534,O
structure,4534,O
of,4534,O
HSA,4534,B-GENE-Y
complexed,4534,O
with,4534,O
fatty,4534,B-CHEMICAL
acid,4534,I-CHEMICAL
and,4534,O
acetyldiflunisal,4534,B-CHEMICAL
revealed,4534,O
that,4534,O
acetyldiflunisal,4534,B-CHEMICAL
binds,4534,O
to,4534,O
the,4534,O
IIA,4534,B-GENE-N
subdomain,4534,I-GENE-N
and,4534,O
that,4534,O
upon,4534,O
binding,4534,O
",",4534,O
it,4534,O
acetylates,4534,O
lysine,4534,B-CHEMICAL
199,4534,O
.,4534,O
Mass,4535,O
spectrometry,4535,O
confirmed,4535,O
that,4535,O
acetyldiflunisal,4535,B-CHEMICAL
acetylates,4535,O
Lys199,4535,B-CHEMICAL
.,4535,O
The,4536,O
acetylated,4536,B-GENE-Y
albumin,4536,I-GENE-Y
had,4536,O
twofold,4536,O
weaker,4536,O
binding,4536,O
affinity,4536,O
for,4536,O
diflunisal,4536,B-CHEMICAL
as,4536,O
demonstrated,4536,O
by,4536,O
fluorescence,4536,O
quenching,4536,O
.,4536,O
Reduced,4537,O
binding,4537,O
affinity,4537,O
means,4537,O
that,4537,O
diflunisal,4537,B-CHEMICAL
is,4537,O
more,4537,O
easily,4537,O
released,4537,O
from,4537,O
acetylated,4537,B-GENE-Y
albumin,4537,I-GENE-Y
into,4537,O
the,4537,O
circulation,4537,O
.,4537,O
Therefore,4538,O
",",4538,O
lower,4538,O
doses,4538,O
of,4538,O
acetyldiflunisal,4538,B-CHEMICAL
compared,4538,O
to,4538,O
diflunisal,4538,B-CHEMICAL
will,4538,O
be,4538,O
required,4538,O
.,4538,O
Taken,4539,O
together,4539,O
",",4539,O
our,4539,O
results,4539,O
not,4539,O
only,4539,O
provide,4539,O
a,4539,O
template,4539,O
for,4539,O
design,4539,O
of,4539,O
HSA-based,4539,B-GENE-Y
prodrugs,4539,O
",",4539,O
but,4539,O
also,4539,O
pave,4539,O
the,4539,O
way,4539,O
toward,4539,O
more,4539,O
effective,4539,O
use,4539,O
of,4539,O
diflunisal,4539,B-CHEMICAL
in,4539,O
the,4539,O
clinic,4539,O
.,4539,O
Use,4540,O
of,4540,O
gene,4540,O
expression,4540,O
data,4540,O
to,4540,O
determine,4540,O
effects,4540,O
on,4540,O
gonad,4540,O
phenotype,4540,O
in,4540,O
japanese,4540,O
medaka,4540,O
after,4540,O
exposure,4540,O
to,4540,O
trenbolone,4540,B-CHEMICAL
or,4540,O
estradiol,4540,B-CHEMICAL
.,4540,O
Various,4541,O
aquatic,4541,O
bioassays,4541,O
using,4541,O
one,4541,O
of,4541,O
several,4541,O
fish,4541,O
species,4541,O
have,4541,O
been,4541,O
developed,4541,O
or,4541,O
are,4541,O
in,4541,O
the,4541,O
process,4541,O
of,4541,O
being,4541,O
developed,4541,O
by,4541,O
organizations,4541,O
like,4541,O
the,4541,O
US,4541,O
Environmental,4541,O
Protection,4541,O
Agency,4541,O
and,4541,O
the,4541,O
Office,4541,O
of,4541,O
Economic,4541,O
Cooperation,4541,O
and,4541,O
Development,4541,O
for,4541,O
testing,4541,O
potential,4541,O
endocrine-disrupting,4541,O
chemicals,4541,O
(,4541,O
EDCs,4541,O
),4541,O
.,4541,O
Often,4542,O
",",4542,O
these,4542,O
involve,4542,O
assessment,4542,O
of,4542,O
the,4542,O
gonad,4542,O
phenotype,4542,O
of,4542,O
individuals,4542,O
as,4542,O
a,4542,O
key,4542,O
endpoint,4542,O
that,4542,O
is,4542,O
inputted,4542,O
into,4542,O
a,4542,O
risk,4542,O
or,4542,O
hazard,4542,O
assessment,4542,O
.,4542,O
Typically,4543,O
",",4543,O
gonad,4543,O
phenotype,4543,O
is,4543,O
determined,4543,O
histologically,4543,O
",",4543,O
which,4543,O
involves,4543,O
specialized,4543,O
and,4543,O
time-consuming,4543,O
techniques,4543,O
.,4543,O
The,4544,O
methods,4544,O
detailed,4544,O
here,4544,O
utilize,4544,O
an,4544,O
entirely,4544,O
different,4544,O
methodology,4544,O
",",4544,O
reverse-transcription,4544,O
quantitative,4544,O
polymerase,4544,O
chain,4544,O
reaction,4544,O
",",4544,O
to,4544,O
determine,4544,O
the,4544,O
relative,4544,O
expression,4544,O
levels,4544,O
of,4544,O
4,4544,O
genes,4544,O
after,4544,O
exposure,4544,O
to,4544,O
either,4544,O
17-estradiol,4544,B-CHEMICAL
or,4544,O
17-trenbolone,4544,B-CHEMICAL
and,4544,O
",",4544,O
by,4544,O
extension,4544,O
",",4544,O
the,4544,O
effects,4544,O
of,4544,O
EDCs,4544,O
on,4544,O
the,4544,O
phenotypic,4544,O
status,4544,O
of,4544,O
the,4544,O
gonad,4544,O
.,4544,O
The,4545,O
4,4545,O
genes,4545,O
quantified,4545,O
",",4545,O
Sox9b,4545,B-GENE-Y
",",4545,O
protamine,4545,B-GENE-Y
",",4545,O
Fig1,4545,B-GENE-N
",",4545,O
and,4545,O
ZPC1,4545,B-GENE-N
",",4545,O
are,4545,O
all,4545,O
involved,4545,O
in,4545,O
gonad,4545,O
development,4545,O
and,4545,O
maintenance,4545,O
in,4545,O
Japanese,4545,O
medaka,4545,O
(,4545,O
Oryzias,4545,O
latipes,4545,O
),4545,O
;,4545,O
these,4545,O
data,4545,O
were,4545,O
then,4545,O
inputted,4545,O
into,4545,O
a,4545,O
permutational,4545,O
multivariate,4545,O
analysis,4545,O
of,4545,O
variance,4545,O
to,4545,O
determine,4545,O
whether,4545,O
significant,4545,O
differences,4545,O
exist,4545,O
between,4545,O
treatment,4545,O
groups,4545,O
.,4545,O
This,4546,O
information,4546,O
in,4546,O
conjunction,4546,O
with,4546,O
the,4546,O
sexual,4546,O
genotype,4546,O
",",4546,O
which,4546,O
can,4546,O
be,4546,O
determined,4546,O
in,4546,O
medaka,4546,O
",",4546,O
can,4546,O
be,4546,O
used,4546,O
to,4546,O
determine,4546,O
adverse,4546,O
effects,4546,O
of,4546,O
exposure,4546,O
to,4546,O
EDCs,4546,O
in,4546,O
a,4546,O
similar,4546,O
fashion,4546,O
to,4546,O
the,4546,O
histologically,4546,O
determined,4546,O
gonad,4546,O
phenotype,4546,O
.,4546,O
Environ,4547,O
Toxicol,4547,O
Chem,4547,O
2013,4547,O
;,4547,O
32:1344-1353,4547,O
.,4547,O
,4548,O
2013,4548,O
SETAC,4548,O
.,4548,O
Absorption,4549,O
",",4549,O
distribution,4549,O
",",4549,O
and,4549,O
biotransformation,4549,O
of,4549,O
"hexahydro-1,3,5-trinitro-1,3,5-triazine",4549,B-CHEMICAL
in,4549,O
B6C3F1,4549,O
mice,4549,O
(,4549,O
Mus,4549,O
musculus,4549,O
),4549,O
.,4549,O
Absorption,4550,O
",",4550,O
distribution,4550,O
",",4550,O
and,4550,O
biotransformation,4550,O
are,4550,O
3,4550,O
critical,4550,O
aspects,4550,O
affecting,4550,O
toxicant,4550,O
action,4550,O
in,4550,O
animals,4550,O
.,4550,O
In,4551,O
the,4551,O
present,4551,O
study,4551,O
",",4551,O
B6C3F1,4551,O
mice,4551,O
(,4551,O
Mus,4551,O
musculus,4551,O
),4551,O
were,4551,O
exposed,4551,O
for,4551,O
28,4551,O
d,4551,O
to,4551,O
contaminated,4551,O
feed,4551,O
that,4551,O
contained,4551,O
1,4551,O
of,4551,O
5,4551,O
different,4551,O
"hexahydro-1,3,5-trinitro-1,3,5-triazine",4551,B-CHEMICAL
(,4551,O
RDX,4551,O
),4551,O
concentrations,4551,O
:,4551,O
0,4551,O
mg/kg,4551,O
",",4551,O
0.5,4551,O
mg/kg,4551,O
",",4551,O
5,4551,O
mg/kg,4551,O
",",4551,O
50,4551,O
mg/kg,4551,O
",",4551,O
and,4551,O
500,4551,O
mg/kg,4551,O
.,4551,O
The,4552,O
authors,4552,O
quantified,4552,O
RDX,4552,O
and,4552,O
its,4552,O
reductive,4552,O
transformation,4552,O
products,4552,O
"hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine",4552,B-CHEMICAL
(,4552,O
MNX,4552,O
),4552,O
",",4552,O
"hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine",4552,B-CHEMICAL
(,4552,O
DNX,4552,O
),4552,O
",",4552,O
and,4552,O
"hexahydro-1,3,5-trinitroso-1,3,5-triazine",4552,B-CHEMICAL
(,4552,O
TNX,4552,O
),4552,O
in,4552,O
the,4552,O
stomach,4552,O
",",4552,O
intestine,4552,O
",",4552,O
plasma,4552,O
",",4552,O
liver,4552,O
",",4552,O
and,4552,O
brain,4552,O
of,4552,O
these,4552,O
mice,4552,O
.,4552,O
Average,4553,O
RDX,4553,O
concentrations,4553,O
followed,4553,O
a,4553,O
dose-dependent,4553,O
pattern,4553,O
for,4553,O
all,4553,O
matrices,4553,O
tested,4553,O
.,4553,O
No,4554,O
controls,4554,O
had,4554,O
concentrations,4554,O
above,4554,O
limits,4554,O
of,4554,O
detection,4554,O
.,4554,O
Average,4555,O
RDX,4555,O
concentrations,4555,O
in,4555,O
tissues,4555,O
of,4555,O
exposed,4555,O
mice,4555,O
ranged,4555,O
from,4555,O
11.1,4555,O
ng/mL,4555,O
to,4555,O
182,4555,O
ng/mL,4555,O
",",4555,O
25.6,4555,O
ng/g,4555,O
to,4555,O
3319,4555,O
ng/g,4555,O
",",4555,O
123,4555,O
ng/g,4555,O
to,4555,O
233,4555,O
ng/g,4555,O
",",4555,O
144,4555,O
ng/g,4555,O
to,4555,O
35,4555,O
900,4555,O
ng/g,4555,O
",",4555,O
and,4555,O
51.1,4555,O
ng/g,4555,O
to,4555,O
2697,4555,O
ng/g,4555,O
in,4555,O
the,4555,O
plasma,4555,O
",",4555,O
brain,4555,O
",",4555,O
liver,4555,O
",",4555,O
stomach,4555,O
",",4555,O
and,4555,O
intestine,4555,O
",",4555,O
respectively,4555,O
.,4555,O
A,4556,O
considerable,4556,O
amount,4556,O
of,4556,O
RDX,4556,O
was,4556,O
present,4556,O
in,4556,O
the,4556,O
brain,4556,O
",",4556,O
especially,4556,O
in,4556,O
the,4556,O
highest-exposure,4556,O
group,4556,O
.,4556,O
This,4557,O
is,4557,O
consistent,4557,O
with,4557,O
the,4557,O
widely,4557,O
observed,4557,O
central,4557,O
nervous,4557,O
system,4557,O
effects,4557,O
caused,4557,O
by,4557,O
-aminobutyric,4557,B-CHEMICAL
acid,4557,I-CHEMICAL
inhibition,4557,O
associated,4557,O
with,4557,O
RDX,4557,O
exposure,4557,O
.,4557,O
N-nitroso,4558,B-CHEMICAL
metabolites,4558,O
of,4558,O
RDX,4558,O
were,4558,O
also,4558,O
present,4558,O
in,4558,O
tested,4558,O
tissues,4558,O
in,4558,O
a,4558,O
dose-dependent,4558,O
pattern,4558,O
.,4558,O
Average,4559,O
MNX,4559,O
concentrations,4559,O
in,4559,O
the,4559,O
stomachs,4559,O
of,4559,O
mice,4559,O
exposed,4559,O
to,4559,O
RDX,4559,O
ranged,4559,O
from,4559,O
nondetectable,4559,O
in,4559,O
control,4559,O
exposures,4559,O
to,4559,O
490,4559,O
ng/g,4559,O
in,4559,O
the,4559,O
highest-exposure,4559,O
groups,4559,O
.,4559,O
In,4560,O
the,4560,O
brain,4560,O
",",4560,O
MNX,4560,O
accumulated,4560,O
at,4560,O
a,4560,O
maximum,4560,O
average,4560,O
concentration,4560,O
of,4560,O
165.1,4560,O
ng/g,4560,O
",",4560,O
suggesting,4560,O
the,4560,O
potential,4560,O
formation,4560,O
of,4560,O
MNX,4560,O
from,4560,O
RDX,4560,O
within,4560,O
the,4560,O
brain,4560,O
.,4560,O
At,4561,O
higher,4561,O
exposures,4561,O
",",4561,O
DNX,4561,O
and,4561,O
TNX,4561,O
were,4561,O
present,4561,O
in,4561,O
the,4561,O
stomach,4561,O
",",4561,O
plasma,4561,O
",",4561,O
and,4561,O
brain,4561,O
of,4561,O
mice,4561,O
.,4561,O
The,4562,O
presence,4562,O
of,4562,O
RDX,4562,O
metabolites,4562,O
at,4562,O
notable,4562,O
amounts,4562,O
in,4562,O
different,4562,O
tissues,4562,O
suggests,4562,O
that,4562,O
RDX,4562,O
can,4562,O
transform,4562,O
into,4562,O
its,4562,O
N-nitroso,4562,B-CHEMICAL
metabolites,4562,O
in,4562,O
vivo,4562,O
by,4562,O
an,4562,O
undefined,4562,O
mechanism,4562,O
.,4562,O
Environ,4563,O
Toxicol,4563,O
Chem,4563,O
2013,4563,O
;,4563,O
32:1295-1303,4563,O
.,4563,O
,4564,O
2013,4564,O
SETAC,4564,O
.,4564,O
Effect,4565,O
of,4565,O
bisphenol-A,4565,B-CHEMICAL
on,4565,O
insulin,4565,B-GENE-N
signal,4565,O
transduction,4565,O
and,4565,O
glucose,4565,B-CHEMICAL
oxidation,4565,O
in,4565,O
skeletal,4565,O
muscle,4565,O
of,4565,O
adult,4565,O
male,4565,O
albino,4565,O
rat,4565,O
.,4565,O
The,4566,O
estrogenic,4566,O
monomer,4566,O
bisphenol-A,4566,B-CHEMICAL
(,4566,O
BPA,4566,B-CHEMICAL
),4566,O
is,4566,O
an,4566,O
endocrine-disrupting,4566,O
chemical,4566,O
used,4566,O
in,4566,O
the,4566,O
production,4566,O
of,4566,O
epoxy,4566,B-CHEMICAL
resins,4566,O
",",4566,O
plastic,4566,O
food,4566,O
and,4566,O
beverage,4566,O
containers,4566,O
",",4566,O
leading,4566,O
to,4566,O
ubiquitous,4566,O
human,4566,O
exposure,4566,O
.,4566,O
Environmentally,4567,O
relevant,4567,O
doses,4567,O
of,4567,O
BPA,4567,B-CHEMICAL
have,4567,O
profound,4567,O
effects,4567,O
on,4567,O
mice,4567,O
endocrine,4567,O
pancreas,4567,O
.,4567,O
It,4568,O
increases,4568,O
pancreatic,4568,O
insulin,4568,B-GENE-N
content,4568,O
and,4568,O
favors,4568,O
postprandial,4568,O
hyperinsulinemia,4568,O
and,4568,O
insulin,4568,B-GENE-N
resistance,4568,O
in,4568,O
male,4568,O
mice,4568,O
.,4568,O
Skeletal,4569,O
muscle,4569,O
plays,4569,O
a,4569,O
crucial,4569,O
role,4569,O
in,4569,O
maintaining,4569,O
systemic,4569,O
glucose,4569,B-CHEMICAL
metabolism,4569,O
.,4569,O
In,4570,O
the,4570,O
present,4570,O
study,4570,O
",",4570,O
we,4570,O
investigated,4570,O
the,4570,O
possible,4570,O
effects,4570,O
of,4570,O
BPA,4570,B-CHEMICAL
on,4570,O
insulin-signaling,4570,B-GENE-N
molecules,4570,O
and,4570,O
glucose,4570,B-CHEMICAL
oxidation,4570,O
in,4570,O
skeletal,4570,O
muscle,4570,O
of,4570,O
male,4570,O
rat,4570,O
.,4570,O
Adult,4571,O
male,4571,O
Wistar,4571,O
albino,4571,O
rats,4571,O
were,4571,O
divided,4571,O
into,4571,O
three,4571,O
groups,4571,O
.,4571,O
Group,4572,O
I,4572,O
:,4572,O
control,4572,O
(,4572,O
vehicle,4572,O
treated,4572,O
),4572,O
and,4572,O
groups,4572,O
II,4572,O
and,4572,O
III,4572,O
were,4572,O
administered,4572,O
with,4572,O
BPA,4572,B-CHEMICAL
orally,4572,O
(,4572,O
20,4572,O
and,4572,O
200,4572,O
mg/kg,4572,O
bw/day,4572,O
",",4572,O
respectively,4572,O
),4572,O
.,4572,O
Although,4573,O
there,4573,O
was,4573,O
no,4573,O
change,4573,O
in,4573,O
the,4573,O
levels,4573,O
of,4573,O
insulin,4573,B-GENE-Y
receptor,4573,I-GENE-Y
(,4573,O
IR,4573,B-GENE-Y
),4573,O
",",4573,O
Akt,4573,B-GENE-N
(,4573,O
protein,4573,B-GENE-N
kinase,4573,I-GENE-N
B,4573,I-GENE-N
),4573,O
and,4573,O
glucose,4573,B-GENE-Y
transporter-4,4573,I-GENE-Y
(,4573,O
GLUT4,4573,B-GENE-Y
),4573,O
messenger,4573,O
RNA,4573,O
",",4573,O
BPA,4573,B-CHEMICAL
significantly,4573,O
decreased,4573,O
the,4573,O
IR,4573,B-GENE-Y
",",4573,O
Akt,4573,B-GENE-N
and,4573,O
GLUT4,4573,B-GENE-Y
protein,4573,O
levels,4573,O
(,4573,O
both,4573,O
plasma,4573,O
membrane,4573,O
and,4573,O
cytosolic,4573,O
fraction,4573,O
),4573,O
of,4573,O
the,4573,O
gastrocnemius,4573,O
muscle,4573,O
.,4573,O
There,4574,O
was,4574,O
an,4574,O
increase,4574,O
in,4574,O
serum,4574,O
insulin,4574,B-GENE-N
and,4574,O
decrease,4574,O
in,4574,O
serum,4574,O
testosterone,4574,B-CHEMICAL
levels,4574,O
but,4574,O
fasting,4574,O
blood,4574,O
glucose,4574,B-CHEMICAL
level,4574,O
remained,4574,O
unaltered,4574,O
.,4574,O
In,4575,O
conclusion,4575,O
",",4575,O
BPA,4575,B-CHEMICAL
has,4575,O
adverse,4575,O
effects,4575,O
on,4575,O
phosphorylation,4575,O
of,4575,O
Akt,4575,B-GENE-N
",",4575,O
GLUT4,4575,B-GENE-Y
translocation,4575,O
and,4575,O
(,4575,B-CHEMICAL
14,4575,I-CHEMICAL
),4575,I-CHEMICAL
C-glucose,4575,I-CHEMICAL
oxidation,4575,O
.,4575,O
Rutin-,4576,B-CHEMICAL
and,4576,O
Selenium-attenuated,4576,B-CHEMICAL
cadmium-induced,4576,B-CHEMICAL
testicular,4576,O
pathophysiology,4576,O
in,4576,O
rats,4576,O
.,4576,O
Cadmium,4577,B-CHEMICAL
(,4577,O
Cd,4577,B-CHEMICAL
),4577,O
is,4577,O
known,4577,O
to,4577,O
cause,4577,O
oxidative,4577,O
damage,4577,O
in,4577,O
the,4577,O
testes,4577,O
of,4577,O
rats,4577,O
.,4577,O
The,4578,O
aim,4578,O
of,4578,O
this,4578,O
study,4578,O
was,4578,O
to,4578,O
investigate,4578,O
the,4578,O
protective,4578,O
role,4578,O
of,4578,O
rutin,4578,B-CHEMICAL
(,4578,O
RUT,4578,B-CHEMICAL
",",4578,O
30,4578,O
mg/kg,4578,O
),4578,O
and,4578,O
selenium,4578,B-CHEMICAL
(,4578,O
Se,4578,B-CHEMICAL
",",4578,O
0.15,4578,O
ppm,4578,O
),4578,O
alone,4578,O
or,4578,O
in,4578,O
combination,4578,O
against,4578,O
Cd,4578,B-CHEMICAL
(,4578,O
200,4578,O
ppm,4578,O
),4578,O
-induced,4578,O
lipid,4578,O
peroxidation,4578,O
",",4578,O
steroidogenesis,4578,O
and,4578,O
changes,4578,O
in,4578,O
antioxidant,4578,O
defence,4578,O
system,4578,O
in,4578,O
the,4578,O
rat,4578,O
testes,4578,O
.,4578,O
The,4579,O
obtained,4579,O
results,4579,O
showed,4579,O
that,4579,O
Cd,4579,B-CHEMICAL
increased,4579,O
lipid,4579,O
peroxidation,4579,O
and,4579,O
abnormal,4579,O
sperm,4579,O
count,4579,O
and,4579,O
decreased,4579,O
plasma,4579,O
testosterone,4579,B-CHEMICAL
",",4579,O
lactate,4579,B-GENE-N
dehydrogenase,4579,I-GENE-N
",",4579,O
acid,4579,B-GENE-N
phosphatase,4579,I-GENE-N
",",4579,O
alkaline,4579,B-GENE-N
phosphatase,4579,I-GENE-N
and,4579,O
testicular,4579,B-GENE-N
steroidogenic,4579,I-GENE-N
enzymes,4579,I-GENE-N
:,4579,O
3-hydroxysteroid,4579,B-GENE-N
dehydrogenase,4579,I-GENE-N
(,4579,O
HSD,4579,B-GENE-N
),4579,O
",",4579,O
17-HSD,4579,B-GENE-N
activities,4579,O
as,4579,O
well,4579,O
as,4579,O
epididymal,4579,O
sperm,4579,O
counts,4579,O
and,4579,O
motility,4579,O
",",4579,O
while,4579,O
RUT,4579,B-CHEMICAL
and,4579,O
Se,4579,B-CHEMICAL
treatment,4579,O
reversed,4579,O
this,4579,O
change,4579,O
to,4579,O
control,4579,O
values,4579,O
.,4579,O
Acute,4580,O
intoxication,4580,O
with,4580,O
Cd,4580,B-CHEMICAL
was,4580,O
also,4580,O
followed,4580,O
by,4580,O
significantly,4580,O
decreased,4580,O
activity,4580,O
of,4580,O
the,4580,O
antioxidant,4580,O
defence,4580,O
system,4580,O
(,4580,O
superoxide,4580,B-GENE-N
dismutase,4580,I-GENE-N
(,4580,O
SOD,4580,B-GENE-N
),4580,O
",",4580,O
catalase,4580,B-GENE-Y
(,4580,O
CAT,4580,B-GENE-Y
),4580,O
",",4580,O
glutathione,4580,B-GENE-N
peroxidase,4580,I-GENE-N
(,4580,O
GSH-Px,4580,B-GENE-N
),4580,O
",",4580,O
glutathione,4580,B-GENE-Y
reductase,4580,I-GENE-Y
(,4580,O
GR,4580,B-GENE-Y
),4580,O
",",4580,O
glutathione,4580,B-CHEMICAL
(,4580,O
GSH,4580,B-CHEMICAL
),4580,O
",",4580,O
and,4580,O
glutathione-S-transferase,4580,B-GENE-N
(,4580,O
GST,4580,B-GENE-N
),4580,O
),4580,O
.,4580,O
Treatment,4581,O
with,4581,O
RUT,4581,B-CHEMICAL
and,4581,O
Se,4581,B-CHEMICAL
reversed,4581,O
Cd-induced,4581,B-CHEMICAL
alterations,4581,O
of,4581,O
antioxidant,4581,O
defence,4581,O
system,4581,O
and,4581,O
significantly,4581,O
prevented,4581,O
Cd-induced,4581,B-CHEMICAL
testes,4581,O
damage,4581,O
and,4581,O
depletion,4581,O
of,4581,O
plasma,4581,O
and,4581,O
testicular,4581,O
Se,4581,B-CHEMICAL
levels,4581,O
.,4581,O
RUT,4582,B-CHEMICAL
and,4582,O
Se,4582,B-CHEMICAL
appear,4582,O
not,4582,O
to,4582,O
have,4582,O
more,4582,O
profound,4582,O
effects,4582,O
than,4582,O
their,4582,O
separate,4582,O
effects,4582,O
against,4582,O
Cd-induced,4582,B-CHEMICAL
testicular,4582,O
toxicity,4582,O
",",4582,O
although,4582,O
Se,4582,B-CHEMICAL
was,4582,O
more,4582,O
potent,4582,O
than,4582,O
RUT,4582,B-CHEMICAL
in,4582,O
the,4582,O
recovery,4582,O
of,4582,O
testosterone,4582,B-CHEMICAL
levels,4582,O
.,4582,O
These,4583,O
results,4583,O
suggest,4583,O
that,4583,O
both,4583,O
RUT,4583,B-CHEMICAL
and,4583,O
Se,4583,B-CHEMICAL
do,4583,O
not,4583,O
have,4583,O
synergistic,4583,O
role,4583,O
against,4583,O
Cd-induced,4583,B-CHEMICAL
testicular,4583,O
injury,4583,O
.,4583,O
The,4584,O
role,4584,O
of,4584,O
de,4584,O
novo,4584,O
catecholamine,4584,B-CHEMICAL
synthesis,4584,O
in,4584,O
mediating,4584,O
methylmercury-induced,4584,B-CHEMICAL
vesicular,4584,O
dopamine,4584,B-CHEMICAL
release,4584,O
from,4584,O
rat,4584,O
pheochromocytoma,4584,O
(,4584,O
PC12,4584,O
),4584,O
cells,4584,O
.,4584,O
The,4585,O
purpose,4585,O
of,4585,O
this,4585,O
study,4585,O
was,4585,O
to,4585,O
characterize,4585,O
methylmercury,4585,B-CHEMICAL
(,4585,O
MeHg,4585,B-CHEMICAL
),4585,O
-induced,4585,O
dopamine,4585,B-CHEMICAL
(,4585,O
DA,4585,O
),4585,O
release,4585,O
from,4585,O
undifferentiated,4585,O
pheochromocytoma,4585,O
(,4585,O
PC12,4585,O
),4585,O
cells,4585,O
and,4585,O
to,4585,O
examine,4585,O
the,4585,O
potential,4585,O
role,4585,O
for,4585,O
DA,4585,O
synthesis,4585,O
in,4585,O
this,4585,O
process,4585,O
.,4585,O
MeHg,4586,B-CHEMICAL
caused,4586,O
a,4586,O
significant,4586,O
increase,4586,O
in,4586,O
DA,4586,O
release,4586,O
that,4586,O
was,4586,O
both,4586,O
concentration-,4586,O
and,4586,O
time-dependent,4586,O
.,4586,O
DA,4587,O
release,4587,O
was,4587,O
significantly,4587,O
increased,4587,O
by,4587,O
2M,4587,O
MeHg,4587,B-CHEMICAL
at,4587,O
60min,4587,O
and,4587,O
by,4587,O
5M,4587,O
MeHg,4587,B-CHEMICAL
at,4587,O
30min,4587,O
;,4587,O
1M,4587,O
MeHg,4587,B-CHEMICAL
was,4587,O
without,4587,O
effect,4587,O
.,4587,O
Because,4588,O
DA,4588,O
release,4588,O
induced,4588,O
by,4588,O
5M,4588,O
MeHg,4588,B-CHEMICAL
was,4588,O
associated,4588,O
with,4588,O
a,4588,O
significant,4588,O
percentage,4588,O
of,4588,O
cell,4588,O
death,4588,O
at,4588,O
60,4588,O
and,4588,O
120min,4588,O
",",4588,O
2M,4588,O
MeHg,4588,B-CHEMICAL
was,4588,O
chosen,4588,O
for,4588,O
further,4588,O
characterization,4588,O
of,4588,O
release,4588,O
mechanisms,4588,O
.,4588,O
MeHg-induced,4589,B-CHEMICAL
DA,4589,O
release,4589,O
was,4589,O
attenuated,4589,O
but,4589,O
not,4589,O
abolished,4589,O
in,4589,O
the,4589,O
absence,4589,O
of,4589,O
extracellular,4589,O
calcium,4589,B-CHEMICAL
",",4589,O
whereas,4589,O
the,4589,O
vesicular,4589,O
content,4589,O
depleting,4589,O
drug,4589,O
reserpine,4589,O
(,4589,O
50nM,4589,O
),4589,O
abolished,4589,O
release,4589,O
.,4589,O
Thus,4590,O
",",4590,O
MeHg-induced,4590,B-CHEMICAL
DA,4590,O
release,4590,O
requires,4590,O
vesicular,4590,O
exocytosis,4590,O
but,4590,O
not,4590,O
extracellular,4590,O
calcium,4590,B-CHEMICAL
.,4590,O
MeHg,4591,B-CHEMICAL
also,4591,O
increased,4591,O
intracellular,4591,O
DA,4591,O
and,4591,O
the,4591,O
rate,4591,O
of,4591,O
DA,4591,O
storage,4591,O
utilization,4591,O
",",4591,O
suggesting,4591,O
a,4591,O
role,4591,O
for,4591,O
DA,4591,O
synthesis,4591,O
in,4591,O
MeHg-induced,4591,B-CHEMICAL
DA,4591,O
release,4591,O
.,4591,O
The,4592,O
tyrosine,4592,B-CHEMICAL
hydroxylase,4592,I-GENE-Y
inhibitor,4592,O
-methyltyrosine,4592,B-CHEMICAL
(,4592,O
300M,4592,O
",",4592,O
24h,4592,O
),4592,O
completely,4592,O
abolished,4592,O
MeHg-induced,4592,B-CHEMICAL
DA,4592,O
release,4592,O
.,4592,O
MeHg,4593,B-CHEMICAL
significantly,4593,O
increased,4593,O
DA,4593,O
precursor,4593,O
accumulation,4593,O
in,4593,O
cells,4593,O
treated,4593,O
with,4593,O
3-hydroxybenzylhydrazine,4593,B-CHEMICAL
(,4593,O
10M,4593,O
),4593,O
",",4593,O
revealing,4593,O
that,4593,O
MeHg,4593,B-CHEMICAL
increases,4593,O
tyrosine,4593,B-CHEMICAL
hydroxylase,4593,I-GENE-Y
activity,4593,O
.,4593,O
Overall,4594,O
",",4594,O
these,4594,O
data,4594,O
demonstrate,4594,O
that,4594,O
MeHg,4594,B-CHEMICAL
facilitates,4594,O
DA,4594,O
synthesis,4594,O
",",4594,O
increases,4594,O
intracellular,4594,O
DA,4594,O
",",4594,O
and,4594,O
augments,4594,O
vesicular,4594,O
exocytosis,4594,O
.,4594,O
Solubility-driven,4595,O
optimization,4595,O
of,4595,O
(,4595,B-CHEMICAL
pyridin-3-yl,4595,I-CHEMICAL
),4595,I-CHEMICAL
benzoxazinyl-oxazolidinones,4595,I-CHEMICAL
leading,4595,O
to,4595,O
a,4595,O
promising,4595,O
antibacterial,4595,O
agent,4595,O
.,4595,O
The,4596,O
solubility-driven,4596,O
structural,4596,O
modification,4596,O
of,4596,O
(,4596,B-CHEMICAL
pyridin-3-yl,4596,I-CHEMICAL
),4596,I-CHEMICAL
benzoxazinyl-oxazolidinones,4596,I-CHEMICAL
is,4596,O
described,4596,O
",",4596,O
which,4596,O
resulted,4596,O
in,4596,O
the,4596,O
development,4596,O
of,4596,O
a,4596,O
new,4596,O
series,4596,O
of,4596,O
benzoxazinyl-oxazolidinone,4596,B-CHEMICAL
analogues,4596,O
with,4596,O
high,4596,O
antibacterial,4596,O
activity,4596,O
against,4596,O
Gram-positive,4596,O
pathogens,4596,O
",",4596,O
including,4596,O
that,4596,O
against,4596,O
linezolid-resistant,4596,B-CHEMICAL
strains,4596,O
and,4596,O
low,4596,O
hERG,4596,B-GENE-Y
inhibition,4596,O
.,4596,O
With,4597,O
regard,4597,O
to,4597,O
structure-activity,4597,O
relationship,4597,O
(,4597,O
SAR,4597,O
),4597,O
trends,4597,O
among,4597,O
the,4597,O
various,4597,O
substituents,4597,O
on,4597,O
the,4597,O
pyridyl,4597,B-CHEMICAL
ring,4597,O
",",4597,O
relatively,4597,O
small,4597,O
and,4597,O
nonbasic,4597,O
substituents,4597,O
were,4597,O
preferable,4597,O
to,4597,O
sterically,4597,O
demanding,4597,O
or,4597,O
basic,4597,O
substituents,4597,O
.,4597,O
Oxazolidinone,4598,B-CHEMICAL
ring,4598,O
substitution,4598,O
on,4598,O
the,4598,O
pyridyl,4598,B-CHEMICAL
ring,4598,O
generated,4598,O
analogues,4598,O
with,4598,O
antibacterial,4598,O
activity,4598,O
superior,4598,O
to,4598,O
imidazolidinone,4598,B-CHEMICAL
ring,4598,O
.,4598,O
Solubility,4599,O
was,4599,O
enhanced,4599,O
by,4599,O
the,4599,O
incorporation,4599,O
of,4599,O
polar,4599,O
groups,4599,O
",",4599,O
especially,4599,O
when,4599,O
compounds,4599,O
were,4599,O
converted,4599,O
to,4599,O
their,4599,O
prodrugs,4599,O
.,4599,O
Among,4600,O
the,4600,O
prodrugs,4600,O
",",4600,O
compound,4600,O
85,4600,O
exhibited,4600,O
excellent,4600,O
solubility,4600,O
and,4600,O
a,4600,O
good,4600,O
pharmacokinetic,4600,O
profile,4600,O
.,4600,O
In,4601,O
a,4601,O
MRSA,4601,O
systemic,4601,O
infection,4601,O
model,4601,O
",",4601,O
compound,4601,O
85,4601,O
displayed,4601,O
an,4601,O
ED50,4601,O
=,4601,O
5.00,4601,O
mg/kg,4601,O
",",4601,O
a,4601,O
potency,4601,O
that,4601,O
is,4601,O
2-fold,4601,O
better,4601,O
than,4601,O
that,4601,O
of,4601,O
linezolid,4601,B-CHEMICAL
.,4601,O
Activity,4602,O
of,4602,O
ponatinib,4602,B-CHEMICAL
against,4602,O
clinically-relevant,4602,O
AC220-resistant,4602,B-CHEMICAL
kinase,4602,B-GENE-N
domain,4602,I-GENE-N
mutants,4602,O
of,4602,O
FLT3-ITD,4602,B-GENE-Y
.,4602,O
Secondary,4603,O
point,4603,O
mutations,4603,O
in,4603,O
the,4603,O
Fms-like,4603,B-GENE-N
tyrosine,4603,I-GENE-N
kinase,4603,I-GENE-N
3,4603,I-GENE-N
(,4603,I-GENE-N
FLT3,4603,I-GENE-N
),4603,I-GENE-N
tyrosine,4603,I-GENE-N
kinase,4603,I-GENE-N
domain,4603,I-GENE-N
(,4603,O
KD,4603,B-GENE-N
),4603,O
are,4603,O
common,4603,O
causes,4603,O
of,4603,O
acquired,4603,O
clinical,4603,O
resistance,4603,O
to,4603,O
the,4603,O
FLT3,4603,B-GENE-Y
inhibitors,4603,O
AC220,4603,B-CHEMICAL
(,4603,O
quizartinib,4603,B-CHEMICAL
),4603,O
and,4603,O
sorafenib,4603,B-CHEMICAL
.,4603,O
Ponatinib,4604,B-CHEMICAL
(,4604,O
AP24534,4604,B-CHEMICAL
),4604,O
is,4604,O
a,4604,O
multikinase,4604,B-GENE-N
inhibitor,4604,O
with,4604,O
in,4604,O
vitro,4604,O
and,4604,O
clinical,4604,O
activity,4604,O
in,4604,O
tyrosine,4604,B-CHEMICAL
kinase,4604,I-GENE-N
inhibitor,4604,O
(,4604,O
TKI,4604,O
),4604,O
-resistant,4604,O
chronic,4604,O
myeloid,4604,O
leukemia,4604,O
",",4604,O
irrespective,4604,O
of,4604,O
BCR-ABL,4604,B-GENE-N
KD,4604,I-GENE-N
mutation,4604,O
.,4604,O
Ponatinib,4605,B-CHEMICAL
has,4605,O
demonstrated,4605,O
early,4605,O
clinical,4605,O
efficacy,4605,O
in,4605,O
chemotherapy-resistant,4605,O
acute,4605,O
myeloid,4605,O
leukemia,4605,O
(,4605,O
AML,4605,O
),4605,O
patients,4605,O
with,4605,O
internal,4605,O
tandem,4605,O
duplication,4605,O
(,4605,O
ITD,4605,O
),4605,O
mutations,4605,O
in,4605,O
FLT3,4605,B-GENE-Y
.,4605,O
We,4606,O
assessed,4606,O
the,4606,O
in,4606,O
vitro,4606,O
activity,4606,O
of,4606,O
ponatinib,4606,B-CHEMICAL
against,4606,O
clinically,4606,O
relevant,4606,O
FLT3-ITD,4606,B-GENE-Y
mutant,4606,O
isoforms,4606,O
that,4606,O
confer,4606,O
resistance,4606,O
to,4606,O
AC220,4606,B-CHEMICAL
or,4606,O
sorafenib,4606,B-CHEMICAL
.,4606,O
Substitution,4607,O
of,4607,O
the,4607,O
FLT3,4607,B-GENE-Y
``,4607,O
gatekeeper,4607,O
'',4607,O
phenylalanine,4607,B-CHEMICAL
with,4607,O
leucine,4607,B-CHEMICAL
(,4607,O
F691L,4607,B-GENE-N
),4607,O
conferred,4607,O
mild,4607,O
resistance,4607,O
to,4607,O
ponatinib,4607,B-CHEMICAL
",",4607,O
but,4607,O
substitutions,4607,O
at,4607,O
the,4607,O
FLT3,4607,B-GENE-N
activation,4607,I-GENE-N
loop,4607,I-GENE-N
(,4607,O
AL,4607,B-GENE-N
),4607,O
residue,4607,O
D835,4607,O
conferred,4607,O
a,4607,O
high,4607,O
degree,4607,O
of,4607,O
resistance,4607,O
.,4607,O
Saturation,4608,O
mutagenesis,4608,O
of,4608,O
FLT3-ITD,4608,B-GENE-Y
exclusively,4608,O
identified,4608,O
FLT3,4608,B-GENE-Y
AL,4608,O
mutations,4608,O
at,4608,O
positions,4608,O
D835,4608,O
",",4608,O
D839,4608,O
",",4608,O
and,4608,O
Y842,4608,O
.,4608,O
The,4609,O
switch,4609,O
control,4609,O
inhibitor,4609,O
DCC-2036,4609,B-CHEMICAL
was,4609,O
similarly,4609,O
inactive,4609,O
against,4609,O
FLT3,4609,B-GENE-Y
AL,4609,O
mutations,4609,O
.,4609,O
On,4610,O
the,4610,O
basis,4610,O
of,4610,O
its,4610,O
in,4610,O
vitro,4610,O
activity,4610,O
against,4610,O
FLT3,4610,B-GENE-Y
TKI-resistant,4610,O
F691,4610,O
substitutions,4610,O
",",4610,O
further,4610,O
clinical,4610,O
evaluation,4610,O
of,4610,O
ponatinib,4610,B-CHEMICAL
in,4610,O
TKI-naive,4610,O
and,4610,O
select,4610,O
TKI-resistant,4610,O
FLT3-ITD+,4610,B-GENE-Y
AML,4610,O
patients,4610,O
is,4610,O
warranted,4610,O
.,4610,O
Alternative,4611,O
strategies,4611,O
will,4611,O
be,4611,O
required,4611,O
for,4611,O
patients,4611,O
with,4611,O
TKI-resistant,4611,O
FLT3-ITD,4611,B-GENE-Y
D835,4611,O
mutations,4611,O
.,4611,O
Bisacylimidoselenocarbamates,4612,B-CHEMICAL
Cause,4612,O
G2/M,4612,O
Arrest,4612,O
Associated,4612,O
with,4612,O
the,4612,O
Modulation,4612,O
of,4612,O
CDK1,4612,B-GENE-Y
and,4612,O
Chk2,4612,B-GENE-Y
in,4612,O
Human,4612,O
Breast,4612,O
Cancer,4612,O
MCF-7,4612,O
Cells,4612,O
.,4612,O
Bisacylimidoselenocarbamate,4613,B-CHEMICAL
derivatives,4613,O
(,4613,O
BSC,4613,B-CHEMICAL
),4613,O
are,4613,O
potent,4613,O
anticancer,4613,O
agents,4613,O
with,4613,O
a,4613,O
strong,4613,O
cytotoxic,4613,O
activity,4613,O
against,4613,O
different,4613,O
types,4613,O
of,4613,O
tumour,4613,O
cells,4613,O
.,4613,O
Based,4614,O
in,4614,O
phosphatidylserine,4614,B-CHEMICAL
exposure,4614,O
on,4614,O
the,4614,O
cell,4614,O
membranes,4614,O
we,4614,O
show,4614,O
that,4614,O
BSC,4614,B-CHEMICAL
treatment,4614,O
resulted,4614,O
in,4614,O
enhanced,4614,O
cell,4614,O
death,4614,O
in,4614,O
leukaemia,4614,O
CCRF-CEM,4614,O
cells,4614,O
.,4614,O
DNA,4615,O
fragmentation,4615,O
detection,4615,O
in,4615,O
breast,4615,O
adenocarcinoma,4615,O
MCF-7,4615,O
cells,4615,O
showed,4615,O
that,4615,O
BSC,4615,B-CHEMICAL
triggered,4615,O
cell,4615,O
death,4615,O
is,4615,O
concentration,4615,O
and,4615,O
time,4615,O
dependent,4615,O
.,4615,O
We,4616,O
also,4616,O
show,4616,O
that,4616,O
two,4616,O
of,4616,O
these,4616,O
compounds,4616,O
",",4616,O
BSC,4616,B-CHEMICAL
3g,4616,O
and,4616,O
3n,4616,O
",",4616,O
cause,4616,O
cell-cycle,4616,O
arrest,4616,O
in,4616,O
the,4616,O
late,4616,O
G2/M,4616,O
in,4616,O
MCF-7,4616,O
cells,4616,O
.,4616,O
Consistent,4617,O
with,4617,O
this,4617,O
",",4617,O
a,4617,O
reduction,4617,O
in,4617,O
CDK1,4617,B-GENE-Y
and,4617,O
CDK2,4617,B-GENE-Y
expression,4617,O
with,4617,O
no,4617,O
change,4617,O
in,4617,O
cyclin,4617,B-GENE-N
A,4617,I-GENE-N
an,4617,I-GENE-N
B1,4617,I-GENE-N
was,4617,O
observed,4617,O
in,4617,O
this,4617,O
cell,4617,O
line,4617,O
.,4617,O
Activation,4618,O
of,4618,O
caspase-2,4618,B-GENE-Y
was,4618,O
also,4618,O
detected,4618,O
.,4618,O
However,4619,O
",",4619,O
the,4619,O
involvement,4619,O
of,4619,O
the,4619,O
caspase-dependent,4619,B-GENE-N
pathway,4619,O
in,4619,O
the,4619,O
process,4619,O
of,4619,O
cell,4619,O
death,4619,O
induced,4619,O
by,4619,O
either,4619,O
BSC,4619,B-CHEMICAL
3g,4619,O
or,4619,O
3n,4619,O
is,4619,O
discarded,4619,O
since,4619,O
cell,4619,O
death,4619,O
could,4619,O
not,4619,O
be,4619,O
prevented,4619,O
by,4619,O
pretreatment,4619,O
with,4619,O
the,4619,O
pancaspase,4619,O
inhibitor,4619,O
z-VAD-fmk,4619,B-CHEMICAL
.,4619,O
Moreover,4620,O
",",4620,O
since,4620,O
reduced,4620,O
levels,4620,O
of,4620,O
p21CIP1,4620,B-GENE-Y
and,4620,O
Chk2,4620,B-GENE-Y
proteins,4620,O
but,4620,O
no,4620,O
change,4620,O
in,4620,O
p53,4620,B-GENE-Y
levels,4620,O
could,4620,O
be,4620,O
detected,4620,O
in,4620,O
MCF-7,4620,O
cells,4620,O
after,4620,O
BSC,4620,B-CHEMICAL
3g,4620,O
or,4620,O
3n,4620,O
treatment,4620,O
our,4620,O
results,4620,O
suggest,4620,O
that,4620,O
BSC,4620,B-CHEMICAL
treated,4620,O
cells,4620,O
die,4620,O
from,4620,O
lethal,4620,O
mitosis,4620,O
.,4620,O
A,4621,O
one-pot,4621,O
domino,4621,O
synthesis,4621,O
and,4621,O
discovery,4621,O
of,4621,O
highly,4621,O
functionalized,4621,O
dihydrobenzo,4621,B-CHEMICAL
[,4621,I-CHEMICAL
b,4621,I-CHEMICAL
],4621,I-CHEMICAL
thiophenes,4621,I-CHEMICAL
as,4621,O
AChE,4621,B-GENE-Y
inhibitors,4621,O
.,4621,O
A,4622,O
library,4622,O
of,4622,O
novel,4622,O
"5-amino-2,7-diaryl-2,3-dihydrobenzo",4622,B-CHEMICAL
[,4622,I-CHEMICAL
b,4622,I-CHEMICAL
],4622,I-CHEMICAL
"thiophene-4,6-dicarbonitriles",4622,I-CHEMICAL
have,4622,O
been,4622,O
synthesized,4622,O
regioselectively,4622,O
in,4622,O
good,4622,O
yields,4622,O
through,4622,O
the,4622,O
one-pot,4622,O
domino,4622,O
reactions,4622,O
of,4622,O
5-aryldihydro-3,4622,B-CHEMICAL
(,4622,I-CHEMICAL
2H,4622,I-CHEMICAL
),4622,I-CHEMICAL
-thiophenones,4622,I-CHEMICAL
",",4622,O
malononitrile,4622,B-CHEMICAL
and,4622,O
aromatic,4622,B-CHEMICAL
aldehydes,4622,I-CHEMICAL
in,4622,O
the,4622,O
presence,4622,O
of,4622,O
morpholine,4622,B-CHEMICAL
.,4622,O
This,4623,O
transformation,4623,O
presumably,4623,O
involves,4623,O
Knoevenagel,4623,O
condensation-Michael,4623,O
addition-intramolecular,4623,O
Thorpe-Ziegler,4623,O
cyclization-Tautomerization-Elimination,4623,O
sequence,4623,O
of,4623,O
reactions,4623,O
.,4623,O
These,4624,O
compounds,4624,O
were,4624,O
evaluated,4624,O
for,4624,O
their,4624,O
acetylcholinesterase,4624,B-GENE-Y
(,4624,O
AChE,4624,B-GENE-Y
),4624,O
inhibitory,4624,O
activity,4624,O
and,4624,O
"5-amino-2,7-bis",4624,B-CHEMICAL
(,4624,I-CHEMICAL
4-methoxyphenyl,4624,I-CHEMICAL
),4624,I-CHEMICAL
"-2,3-dihydrobenzo",4624,I-CHEMICAL
[,4624,I-CHEMICAL
b,4624,I-CHEMICAL
],4624,I-CHEMICAL
"thiophene-4,6-dicarbonitrile",4624,I-CHEMICAL
was,4624,O
found,4624,O
to,4624,O
be,4624,O
the,4624,O
most,4624,O
potent,4624,O
against,4624,O
AChE,4624,B-GENE-Y
with,4624,O
IC50,4624,O
4.16,4624,O
mol/L,4624,O
.,4624,O
Synthesis,4625,O
and,4625,O
cytotoxicity,4625,O
of,4625,O
3-aryl,4625,B-CHEMICAL
acrylic,4625,I-CHEMICAL
amide,4625,I-CHEMICAL
derivatives,4625,O
of,4625,O
the,4625,O
simplified,4625,O
saframycin-ecteinascidin,4625,B-CHEMICAL
skeleton,4625,O
prepared,4625,O
from,4625,O
l-dopa,4625,B-CHEMICAL
.,4625,O
Twenty,4626,O
four,4626,O
compounds,4626,O
with,4626,O
diversified,4626,O
3-aryl,4626,B-CHEMICAL
acrylic,4626,I-CHEMICAL
amide,4626,I-CHEMICAL
side,4626,O
chains,4626,O
of,4626,O
the,4626,O
simplified,4626,O
saframycin-ecteinascidin,4626,B-CHEMICAL
pentacyclic,4626,O
skeleton,4626,O
were,4626,O
synthesized,4626,O
via,4626,O
a,4626,O
14-step,4626,O
stereospecific,4626,O
route,4626,O
starting,4626,O
from,4626,O
l-dopa,4626,B-CHEMICAL
.,4626,O
The,4627,O
cytotoxicities,4627,O
of,4627,O
these,4627,O
compounds,4627,O
were,4627,O
tested,4627,O
against,4627,O
eight,4627,O
human,4627,O
tumor,4627,O
cell,4627,O
lines,4627,O
including,4627,O
HCT-8,4627,O
",",4627,O
BEL-7402,4627,O
",",4627,O
BGC-803,4627,O
",",4627,O
A549,4627,O
",",4627,O
A2780,4627,O
",",4627,O
MCF-7,4627,O
",",4627,O
MX-1,4627,O
",",4627,O
and,4627,O
MDA-MB-231,4627,O
.,4627,O
Most,4628,O
of,4628,O
these,4628,O
compounds,4628,O
exhibited,4628,O
potent,4628,O
antitumor,4628,O
activity,4628,O
",",4628,O
and,4628,O
a,4628,O
preliminary,4628,O
structure-activity,4628,O
relationship,4628,O
(,4628,O
SAR,4628,O
),4628,O
was,4628,O
discussed,4628,O
.,4628,O
Compound,4629,O
28,4629,O
with,4629,O
3-thiophenyl,4629,B-CHEMICAL
acrylic,4629,I-CHEMICAL
amide,4629,I-CHEMICAL
side,4629,O
chain,4629,O
exhibited,4629,O
selective,4629,O
cytotoxicity,4629,O
against,4629,O
MDA-MB-231,4629,O
cell,4629,O
line,4629,O
with,4629,O
the,4629,O
IC50,4629,O
value,4629,O
of,4629,O
50,4629,O
nM,4629,O
.,4629,O
Upregulation,4630,O
of,4630,O
drug,4630,O
transporter,4630,O
expression,4630,O
by,4630,O
osteopontin,4630,B-GENE-Y
in,4630,O
prostate,4630,O
cancer,4630,O
cells,4630,O
.,4630,O
Multidrug,4631,O
resistance,4631,O
is,4631,O
a,4631,O
major,4631,O
cause,4631,O
of,4631,O
chemotherapy,4631,O
failure,4631,O
.,4631,O
Recent,4632,O
studies,4632,O
indicate,4632,O
that,4632,O
drug,4632,O
resistance,4632,O
can,4632,O
be,4632,O
rapidly,4632,O
induced,4632,O
by,4632,O
some,4632,O
soluble,4632,O
factors,4632,O
",",4632,O
such,4632,O
as,4632,O
cytokines,4632,B-GENE-N
",",4632,O
chemokines,4632,B-GENE-N
",",4632,O
growth,4632,O
factors,4632,O
",",4632,O
and,4632,O
cell,4632,B-GENE-N
adhesion,4632,I-GENE-N
factors,4632,I-GENE-N
in,4632,O
the,4632,O
tumor,4632,O
microenvironment,4632,O
.,4632,O
Osteopontin,4633,B-GENE-Y
(,4633,O
OPN,4633,B-GENE-Y
),4633,O
",",4633,O
an,4633,O
extracellular,4633,O
matrix,4633,O
protein,4633,O
",",4633,O
has,4633,O
a,4633,O
functional,4633,O
arginine-glycine-aspartic,4633,B-CHEMICAL
acid,4633,I-GENE-N
(,4633,I-GENE-N
RGD,4633,I-GENE-N
),4633,I-GENE-N
domain,4633,I-GENE-N
for,4633,O
binding,4633,O
to,4633,O
integrin,4633,B-GENE-N
.,4633,O
Here,4634,O
we,4634,O
found,4634,O
OPN,4634,B-GENE-Y
expression,4634,O
to,4634,O
be,4634,O
upregulated,4634,O
by,4634,O
hypoxic,4634,O
condition,4634,O
in,4634,O
PC-3,4634,O
prostate,4634,O
tumor,4634,O
cells,4634,O
.,4634,O
OPN,4635,B-GENE-Y
increased,4635,O
the,4635,O
mRNA,4635,O
and,4635,O
protein,4635,O
expression,4635,O
of,4635,O
p-glycoprotein,4635,B-GENE-N
(,4635,O
P-gp,4635,B-GENE-N
),4635,O
",",4635,O
a,4635,O
subfamily,4635,O
of,4635,O
ATP-binding,4635,B-GENE-N
cassette,4635,I-GENE-N
transporter,4635,I-GENE-N
in,4635,O
a,4635,O
concentration-,4635,O
and,4635,O
time-dependent,4635,O
manner,4635,O
.,4635,O
The,4636,O
increase,4636,O
in,4636,O
P-gp,4636,B-GENE-N
transporter,4636,O
by,4636,O
OPN,4636,B-GENE-Y
was,4636,O
mediated,4636,O
by,4636,O
binding,4636,O
to,4636,O
v3,4636,B-GENE-N
integrin,4636,I-GENE-N
.,4636,O
Daunomycin,4637,B-CHEMICAL
(,4637,O
DUN,4637,B-CHEMICAL
),4637,O
",",4637,O
a,4637,O
chemotherapeutic,4637,O
agent,4637,O
with,4637,O
autofluorescence,4637,O
",",4637,O
was,4637,O
used,4637,O
to,4637,O
evaluate,4637,O
the,4637,O
pump,4637,O
activity,4637,O
",",4637,O
and,4637,O
OPN,4637,B-GENE-Y
increased,4637,O
the,4637,O
drug,4637,O
pumping-out,4637,O
activity,4637,O
.,4637,O
OPN,4638,B-GENE-Y
inhibited,4638,O
DUN-induced,4638,B-CHEMICAL
cell,4638,O
death,4638,O
",",4638,O
which,4638,O
was,4638,O
antagonized,4638,O
by,4638,O
v3,4638,B-GENE-N
monoclonal,4638,O
antibody,4638,O
.,4638,O
Long-term,4639,O
treatment,4639,O
with,4639,O
DUN,4639,B-CHEMICAL
further,4639,O
enhanced,4639,O
the,4639,O
expression,4639,O
of,4639,O
OPN,4639,B-GENE-Y
.,4639,O
Knockdown,4640,O
of,4640,O
endogenous,4640,O
OPN,4640,B-GENE-Y
potentiated,4640,O
the,4640,O
DUN-induced,4640,B-CHEMICAL
apoptosis,4640,O
of,4640,O
PC-3,4640,O
cells,4640,O
.,4640,O
Furthermore,4641,O
",",4641,O
knockdown,4641,O
of,4641,O
OPN,4641,B-GENE-Y
enhanced,4641,O
cell,4641,O
death,4641,O
caused,4641,O
by,4641,O
other,4641,O
drugs,4641,O
",",4641,O
including,4641,O
paclitaxel,4641,B-CHEMICAL
",",4641,O
doxorubicin,4641,B-CHEMICAL
",",4641,O
actinomycin-D,4641,B-CHEMICAL
",",4641,O
and,4641,O
rapamycin,4641,B-CHEMICAL
",",4641,O
which,4641,O
are,4641,O
also,4641,O
P-gp,4641,B-GENE-N
substrates,4641,O
.,4641,O
The,4642,O
animal,4642,O
studies,4642,O
also,4642,O
showed,4642,O
that,4642,O
OPN,4642,B-GENE-Y
knockdown,4642,O
enhanced,4642,O
the,4642,O
cytotoxic,4642,O
action,4642,O
of,4642,O
DUN,4642,B-CHEMICAL
.,4642,O
These,4643,O
results,4643,O
indicate,4643,O
that,4643,O
OPN,4643,B-GENE-Y
is,4643,O
a,4643,O
potential,4643,O
therapeutic,4643,O
target,4643,O
for,4643,O
cancer,4643,O
therapy,4643,O
to,4643,O
reduce,4643,O
drug,4643,O
resistance,4643,O
in,4643,O
sensitive,4643,O
tumors,4643,O
.,4643,O
A,4644,O
combination,4644,O
strategy,4644,O
to,4644,O
inhibit,4644,O
Pim-1,4644,B-GENE-Y
:,4644,O
synergism,4644,O
between,4644,O
noncompetitive,4644,O
and,4644,O
ATP-competitive,4644,B-CHEMICAL
inhibitors,4644,O
.,4644,O
Pim-1,4645,B-GENE-Y
is,4645,O
a,4645,O
serine/threonine,4645,B-CHEMICAL
kinase,4645,I-GENE-N
critically,4645,O
involved,4645,O
in,4645,O
the,4645,O
initiation,4645,O
and,4645,O
progression,4645,O
of,4645,O
various,4645,O
types,4645,O
of,4645,O
cancer,4645,O
",",4645,O
especially,4645,O
leukemia,4645,O
",",4645,O
lymphomas,4645,O
and,4645,O
solid,4645,O
tumors,4645,O
such,4645,O
as,4645,O
prostate,4645,O
",",4645,O
pancreas,4645,O
and,4645,O
colon,4645,O
",",4645,O
and,4645,O
is,4645,O
considered,4645,O
a,4645,O
potential,4645,O
drug,4645,O
target,4645,O
against,4645,O
these,4645,O
malignancies,4645,O
.,4645,O
In,4646,O
an,4646,O
effort,4646,O
to,4646,O
discover,4646,O
new,4646,O
potent,4646,O
Pim-1,4646,B-GENE-Y
inhibitors,4646,O
",",4646,O
a,4646,O
previously,4646,O
identified,4646,O
ATP-competitive,4646,B-CHEMICAL
indolyl-pyrrolone,4646,B-CHEMICAL
scaffold,4646,O
was,4646,O
expanded,4646,O
to,4646,O
derive,4646,O
structure-activity,4646,O
relationship,4646,O
data,4646,O
.,4646,O
A,4647,O
virtual,4647,O
screening,4647,O
campaign,4647,O
was,4647,O
also,4647,O
performed,4647,O
",",4647,O
which,4647,O
led,4647,O
to,4647,O
the,4647,O
discovery,4647,O
of,4647,O
additional,4647,O
ATP-competitive,4647,B-CHEMICAL
inhibitors,4647,O
as,4647,O
well,4647,O
as,4647,O
a,4647,O
series,4647,O
of,4647,O
2-aminothiazole,4647,B-CHEMICAL
derivatives,4647,O
",",4647,O
which,4647,O
are,4647,O
noncompetitive,4647,O
with,4647,O
respect,4647,O
to,4647,O
both,4647,O
ATP,4647,B-CHEMICAL
and,4647,O
peptide,4647,O
substrate,4647,O
.,4647,O
This,4648,O
mechanism,4648,O
of,4648,O
action,4648,O
",",4648,O
which,4648,O
resembles,4648,O
allosteric,4648,O
inhibition,4648,O
",",4648,O
has,4648,O
not,4648,O
previously,4648,O
been,4648,O
characterized,4648,O
for,4648,O
Pim-1,4648,B-GENE-Y
.,4648,O
Notably,4649,O
",",4649,O
further,4649,O
evaluation,4649,O
of,4649,O
the,4649,O
2-aminothiazoles,4649,B-CHEMICAL
indicated,4649,O
a,4649,O
synergistic,4649,O
inhibitory,4649,O
effect,4649,O
in,4649,O
enzymatic,4649,O
assays,4649,O
when,4649,O
tested,4649,O
in,4649,O
combination,4649,O
with,4649,O
ATP-competitive,4649,B-CHEMICAL
inhibitors,4649,O
.,4649,O
A,4650,O
synergistic,4650,O
effect,4650,O
in,4650,O
the,4650,O
inhibition,4650,O
of,4650,O
cell,4650,O
proliferation,4650,O
by,4650,O
ATP-competitive,4650,B-CHEMICAL
and,4650,O
ATP-noncompetitive,4650,B-CHEMICAL
compounds,4650,O
was,4650,O
also,4650,O
observed,4650,O
in,4650,O
prostate,4650,O
cancer,4650,O
cell,4650,O
lines,4650,O
(,4650,O
PC3,4650,O
),4650,O
",",4650,O
where,4650,O
all,4650,O
Pim-1,4650,B-GENE-Y
inhibitors,4650,O
tested,4650,O
in,4650,O
showed,4650,O
synergism,4650,O
with,4650,O
the,4650,O
known,4650,O
anticancer,4650,O
agent,4650,O
",",4650,O
paclitaxel,4650,B-CHEMICAL
.,4650,O
These,4651,O
results,4651,O
further,4651,O
establish,4651,O
Pim-1,4651,B-GENE-Y
as,4651,O
a,4651,O
target,4651,O
in,4651,O
cancer,4651,O
therapy,4651,O
",",4651,O
and,4651,O
highlight,4651,O
the,4651,O
potential,4651,O
of,4651,O
these,4651,O
agents,4651,O
for,4651,O
use,4651,O
as,4651,O
adjuvant,4651,O
agents,4651,O
in,4651,O
the,4651,O
treatment,4651,O
of,4651,O
cancer,4651,O
diseases,4651,O
in,4651,O
which,4651,O
Pim-1,4651,B-GENE-Y
is,4651,O
associated,4651,O
with,4651,O
chemotherapeutic,4651,O
resistance,4651,O
.,4651,O
A,4652,O
population-based,4652,O
study,4652,O
of,4652,O
dosing,4652,O
and,4652,O
persistence,4652,O
with,4652,O
anti-dementia,4652,O
medications,4652,O
.,4652,O
PURPOSE,4653,O
:,4653,O
Cholinesterase,4653,B-GENE-Y
inhibitors,4653,O
and,4653,O
memantine,4653,B-CHEMICAL
are,4653,O
the,4653,O
mainstay,4653,O
of,4653,O
pharmacological,4653,O
intervention,4653,O
for,4653,O
the,4653,O
cognitive,4653,O
symptoms,4653,O
of,4653,O
Alzheimer,4653,O
's,4653,O
disease,4653,O
(,4653,O
AD,4653,O
),4653,O
.,4653,O
This,4654,O
study,4654,O
assessed,4654,O
the,4654,O
adequacy,4654,O
of,4654,O
dosing,4654,O
and,4654,O
persistence,4654,O
with,4654,O
AD,4654,O
medications,4654,O
and,4654,O
the,4654,O
predictors,4654,O
of,4654,O
these,4654,O
variables,4654,O
in,4654,O
the,4654,O
'real,4654,O
world,4654,O
',4654,O
(,4654,O
outside,4654,O
the,4654,O
clinical,4654,O
trial,4654,O
setting,4654,O
),4654,O
.,4654,O
METHODS,4655,O
:,4655,O
The,4655,O
Health,4655,O
Service,4655,O
Executive-Primary,4655,O
Care,4655,O
Reimbursement,4655,O
Services,4655,O
prescription,4655,O
claims,4655,O
database,4655,O
in,4655,O
the,4655,O
Republic,4655,O
of,4655,O
Ireland,4655,O
contains,4655,O
prescription,4655,O
information,4655,O
for,4655,O
1.6,4655,O
million,4655,O
people,4655,O
.,4655,O
Patients,4656,O
aged,4656,O
>,4656,O
70,4656,O
years,4656,O
who,4656,O
received,4656,O
at,4656,O
least,4656,O
two,4656,O
prescriptions,4656,O
for,4656,O
donepezil,4656,B-CHEMICAL
",",4656,O
rivastigmine,4656,B-CHEMICAL
",",4656,O
galantamine,4656,B-CHEMICAL
and,4656,O
memantine,4656,B-CHEMICAL
between,4656,O
January,4656,O
2006,4656,O
and,4656,O
December,4656,O
2010,4656,O
were,4656,O
included,4656,O
in,4656,O
the,4656,O
study,4656,O
.,4656,O
Rates,4657,O
of,4657,O
dose-maximisation,4657,O
were,4657,O
recorded,4657,O
by,4657,O
examining,4657,O
the,4657,O
initiation,4657,O
dose,4657,O
of,4657,O
each,4657,O
AD,4657,O
drug,4657,O
commenced,4657,O
during,4657,O
the,4657,O
study,4657,O
period,4657,O
and,4657,O
any,4657,O
subsequent,4657,O
dose,4657,O
titrations,4657,O
.,4657,O
Non-persistence,4658,O
was,4658,O
defined,4658,O
by,4658,O
a,4658,O
gap,4658,O
in,4658,O
prescribing,4658,O
of,4658,O
more,4658,O
than,4658,O
63,4658,O
consecutive,4658,O
days,4658,O
.,4658,O
Predictors,4659,O
of,4659,O
dose-maximisation,4659,O
and,4659,O
non-persistence,4659,O
were,4659,O
also,4659,O
analysed,4659,O
.,4659,O
RESULTS,4660,O
:,4660,O
Between,4660,O
January,4660,O
2006,4660,O
and,4660,O
December,4660,O
2010,4660,O
",",4660,O
"20,729",4660,O
patients,4660,O
aged,4660,O
>,4660,O
70,4660,O
years,4660,O
received,4660,O
a,4660,O
prescription,4660,O
for,4660,O
an,4660,O
AD,4660,O
medication,4660,O
.,4660,O
Despite,4661,O
most,4661,O
patients,4661,O
on,4661,O
donepezil,4661,B-CHEMICAL
and,4661,O
memantine,4661,B-CHEMICAL
receiving,4661,O
a,4661,O
prescription,4661,O
for,4661,O
the,4661,O
maximum,4661,O
drug,4661,O
dose,4661,O
",",4661,O
this,4661,O
dose,4661,O
was,4661,O
maintained,4661,O
for,4661,O
2,4661,O
consecutive,4661,O
months,4661,O
in,4661,O
only,4661,O
two-thirds,4661,O
of,4661,O
patients,4661,O
.,4661,O
Patients,4662,O
were,4662,O
significantly,4662,O
more,4662,O
likely,4662,O
to,4662,O
have,4662,O
their,4662,O
doses,4662,O
of,4662,O
donepezil,4662,B-CHEMICAL
and,4662,O
memantine,4662,B-CHEMICAL
maximised,4662,O
if,4662,O
prescribed,4662,O
in,4662,O
more,4662,O
recent,4662,O
years,4662,O
(,4662,O
2010,4662,O
vs.,4662,O
2007,4662,O
),4662,O
.,4662,O
Rates,4663,O
of,4663,O
non-persistence,4663,O
were,4663,O
30.1,4663,O
%,4663,O
at,4663,O
6,4663,O
months,4663,O
and,4663,O
43.8,4663,O
%,4663,O
at,4663,O
12,4663,O
months,4663,O
.,4663,O
Older,4664,O
age,4664,O
[,4664,O
75+,4664,O
vs.,4664,O
<,4664,O
75,4664,O
years,4664,O
;,4664,O
hazards,4664,O
ratio,4664,O
(,4664,O
HR,4664,O
),4664,O
1.16,4664,O
",",4664,O
95,4664,O
%,4664,O
confidence,4664,O
interval,4664,O
(,4664,O
CI,4664,O
),4664,O
1.06-1.27,4664,O
],4664,O
and,4664,O
drug,4664,O
type,4664,O
(,4664,O
rivastigmine,4664,B-CHEMICAL
vs.,4664,O
donepezil,4664,B-CHEMICAL
;,4664,O
HR,4664,O
1.15,4664,O
",",4664,O
95,4664,O
%,4664,O
CI,4664,O
1.03-1.27,4664,O
),4664,O
increased,4664,O
the,4664,O
risk,4664,O
of,4664,O
non-persistence,4664,O
.,4664,O
Non-persistence,4665,O
was,4665,O
lower,4665,O
for,4665,O
those,4665,O
commencing,4665,O
therapy,4665,O
in,4665,O
more,4665,O
recent,4665,O
years,4665,O
(,4665,O
2010,4665,O
vs.,4665,O
2007,4665,O
;,4665,O
HR,4665,O
0.81,4665,O
",",4665,O
95,4665,O
%,4665,O
CI,4665,O
0.73-0.89,4665,O
",",4665,O
p,4665,O
<,4665,O
0.001,4665,O
),4665,O
and,4665,O
for,4665,O
those,4665,O
on,4665,O
multiple,4665,O
anti-dementia,4665,O
medications,4665,O
(,4665,O
HR,4665,O
0.59,4665,O
",",4665,O
95,4665,O
%,4665,O
CI,4665,O
0.54-0.65,4665,O
",",4665,O
p,4665,O
<,4665,O
0.001,4665,O
),4665,O
.,4665,O
Persistence,4666,O
was,4666,O
significantly,4666,O
higher,4666,O
when,4666,O
memantine,4666,B-CHEMICAL
was,4666,O
co-prescribed,4666,O
with,4666,O
donepezil,4666,B-CHEMICAL
(,4666,O
p,4666,O
<,4666,O
0.0001,4666,O
),4666,O
.,4666,O
CONCLUSION,4667,O
:,4667,O
Future,4667,O
studies,4667,O
should,4667,O
explore,4667,O
the,4667,O
reasons,4667,O
underlying,4667,O
non-persistence,4667,O
and,4667,O
failure,4667,O
to,4667,O
maintain,4667,O
dose-maximisation,4667,O
in,4667,O
patients,4667,O
on,4667,O
AD,4667,O
medications,4667,O
.,4667,O
There,4668,O
may,4668,O
be,4668,O
scope,4668,O
to,4668,O
improve,4668,O
the,4668,O
dosing,4668,O
and,4668,O
persistence,4668,O
with,4668,O
these,4668,O
medications,4668,O
in,4668,O
the,4668,O
community,4668,O
.,4668,O
mGluR2,4669,B-GENE-Y
positive,4669,O
allosteric,4669,O
modulators,4669,O
:,4669,O
a,4669,O
patent,4669,O
review,4669,O
(,4669,O
2009,4669,O
-,4669,O
present,4669,O
),4669,O
.,4669,O
Introduction,4670,O
:,4670,O
The,4670,O
mGlu2,4670,B-GENE-Y
receptor,4670,I-GENE-Y
",",4670,O
which,4670,O
belongs,4670,O
to,4670,O
the,4670,O
group,4670,B-GENE-Y
II,4670,I-GENE-Y
subfamily,4670,I-GENE-Y
of,4670,I-GENE-Y
metabotropic,4670,I-GENE-Y
glutamate,4670,B-CHEMICAL
receptors,4670,I-GENE-Y
(,4670,O
mGlu,4670,O
),4670,O
along,4670,O
with,4670,O
the,4670,O
mGlu3,4670,B-GENE-Y
receptor,4670,I-GENE-Y
",",4670,O
has,4670,O
proven,4670,O
to,4670,O
be,4670,O
of,4670,O
particular,4670,O
importance,4670,O
in,4670,O
neuropharmacology,4670,O
.,4670,O
Preferentially,4671,O
expressed,4671,O
on,4671,O
presynaptic,4671,O
nerve,4671,O
terminals,4671,O
",",4671,O
the,4671,O
mGlu2,4671,B-GENE-Y
receptor,4671,I-GENE-Y
negatively,4671,O
modulates,4671,O
glutamate,4671,B-CHEMICAL
and,4671,O
GABA,4671,B-CHEMICAL
release,4671,O
and,4671,O
is,4671,O
widely,4671,O
distributed,4671,O
in,4671,O
the,4671,O
brain,4671,O
.,4671,O
High,4672,O
levels,4672,O
of,4672,O
mGlu2,4672,B-GENE-Y
receptors,4672,I-GENE-Y
are,4672,O
seen,4672,O
in,4672,O
brain,4672,O
areas,4672,O
such,4672,O
as,4672,O
prefrontal,4672,O
cortex,4672,O
",",4672,O
hippocampus,4672,O
and,4672,O
amygdala,4672,O
where,4672,O
glutamate,4672,B-CHEMICAL
hyperfunction,4672,O
may,4672,O
be,4672,O
implicated,4672,O
in,4672,O
disorders,4672,O
and,4672,O
diseases,4672,O
such,4672,O
as,4672,O
anxiety,4672,O
and,4672,O
schizophrenia,4672,O
.,4672,O
Given,4673,O
the,4673,O
promise,4673,O
offered,4673,O
by,4673,O
mGlu2/3,4673,B-GENE-N
receptor,4673,I-GENE-N
activation,4673,O
",",4673,O
there,4673,O
is,4673,O
increased,4673,O
interest,4673,O
in,4673,O
identifying,4673,O
small,4673,O
molecules,4673,O
which,4673,O
activate,4673,O
the,4673,O
receptor,4673,O
.,4673,O
A,4674,O
preferred,4674,O
approach,4674,O
is,4674,O
via,4674,O
positive,4674,O
allosteric,4674,O
modulators,4674,O
(,4674,O
PAMs,4674,O
),4674,O
which,4674,O
bind,4674,O
at,4674,O
an,4674,O
alternative,4674,O
site,4674,O
to,4674,O
agonists,4674,O
.,4674,O
Areas,4675,O
covered,4675,O
:,4675,O
This,4675,O
review,4675,O
covers,4675,O
the,4675,O
patent,4675,O
applications,4675,O
which,4675,O
were,4675,O
published,4675,O
between,4675,O
April,4675,O
2009,4675,O
and,4675,O
December,4675,O
2012,4675,O
on,4675,O
PAMs,4675,O
of,4675,O
the,4675,O
mGlu2,4675,B-GENE-Y
",",4675,O
and,4675,O
it,4675,O
is,4675,O
a,4675,O
continuation,4675,O
of,4675,O
an,4675,O
earlier,4675,O
review,4675,O
published,4675,O
in,4675,O
this,4675,O
journal,4675,O
.,4675,O
Expert,4676,O
opinion,4676,O
:,4676,O
Advances,4676,O
in,4676,O
medicinal,4676,O
chemistry,4676,O
and,4676,O
pharmacology,4676,O
have,4676,O
set,4676,O
the,4676,O
stage,4676,O
in,4676,O
the,4676,O
field,4676,O
of,4676,O
mGlu2,4676,B-GENE-Y
receptor,4676,I-GENE-Y
PAMs,4676,O
.,4676,O
Compounds,4677,O
currently,4677,O
advancing,4677,O
in,4677,O
clinical,4677,O
trials,4677,O
will,4677,O
soon,4677,O
establish,4677,O
the,4677,O
therapeutic,4677,O
potential,4677,O
of,4677,O
this,4677,O
allosteric,4677,O
approach,4677,O
.,4677,O
Effect,4678,O
of,4678,O
protein,4678,O
malnutrition,4678,O
on,4678,O
the,4678,O
metabolism,4678,O
and,4678,O
toxicity,4678,O
of,4678,O
cisplatin,4678,B-CHEMICAL
",",4678,O
5-fluorouracil,4678,B-CHEMICAL
and,4678,O
mitomycin,4678,B-CHEMICAL
C,4678,I-CHEMICAL
in,4678,O
rat,4678,O
stomach,4678,O
.,4678,O
This,4679,O
study,4679,O
investigated,4679,O
the,4679,O
effect,4679,O
of,4679,O
protein,4679,O
malnutrition,4679,O
on,4679,O
metabolism,4679,O
and,4679,O
toxicity,4679,O
of,4679,O
cisplatin,4679,B-CHEMICAL
(,4679,O
CP,4679,O
),4679,O
",",4679,O
5-fluorouracil,4679,B-CHEMICAL
(,4679,O
FU,4679,O
),4679,O
and,4679,O
mitomycin,4679,B-CHEMICAL
C,4679,I-CHEMICAL
(,4679,O
MMC,4679,B-CHEMICAL
),4679,O
in,4679,O
rat,4679,O
stomach,4679,O
.,4679,O
Weanling,4680,O
male,4680,O
Wistar,4680,O
rats,4680,O
received,4680,O
a,4680,O
normal,4680,O
(,4680,O
24,4680,O
%,4680,O
),4680,O
or,4680,O
low,4680,O
(,4680,O
2.5,4680,O
%,4680,O
),4680,O
protein,4680,O
diet,4680,O
for,4680,O
28days,4680,O
and,4680,O
were,4680,O
allocated,4680,O
into,4680,O
:,4680,O
normally-fed,4680,O
control,4680,O
",",4680,O
protein-malnourished,4680,O
control,4680,O
(,4680,O
PM,4680,O
),4680,O
",",4680,O
3,4680,O
normally-fed,4680,O
drug-treated,4680,O
groups,4680,O
and,4680,O
3,4680,O
protein-malnourished,4680,O
drug-treated,4680,O
groups,4680,O
(,4680,O
PM-CP,4680,O
",",4680,O
PM-FU,4680,O
and,4680,O
PM-MMC,4680,O
),4680,O
.,4680,O
Cisplatin,4681,B-CHEMICAL
and,4681,O
MMC,4681,B-CHEMICAL
were,4681,O
injected,4681,O
intraperitoneally,4681,O
(,4681,O
8mg/kg,4681,O
on,4681,O
day,4681,O
26,4681,O
and,4681,O
1mg/kg/day,4681,O
for,4681,O
7days,4681,O
",",4681,O
respectively,4681,O
),4681,O
.,4681,O
5-Fluorouracil,4682,B-CHEMICAL
was,4682,O
given,4682,O
orally,4682,O
(,4682,O
50mg/kg/day,4682,O
for,4682,O
5days,4682,O
),4682,O
.,4682,O
Compared,4683,O
with,4683,O
normally-fed,4683,O
counterparts,4683,O
",",4683,O
PM-CP,4683,O
rats,4683,O
exhibited,4683,O
higher,4683,O
glutathione,4683,B-GENE-N
S-transferase,4683,I-GENE-N
",",4683,O
aminopeptidase,4683,B-GENE-Y
N,4683,I-GENE-Y
and,4683,O
cysteine,4683,B-GENE-Y
S-conjugate,4683,I-GENE-Y
beta-lyase,4683,I-GENE-Y
(,4683,O
CCBL,4683,B-GENE-Y
),4683,O
and,4683,O
lower,4683,O
gamma-glutamyltransferase,4683,B-GENE-Y
activities,4683,O
",",4683,O
PM-FU,4683,O
rats,4683,O
exhibited,4683,O
decreased,4683,O
dihydropyrimidine,4683,B-GENE-Y
dehydrogenase,4683,I-GENE-Y
and,4683,O
cytochrome,4683,B-GENE-N
P450,4683,I-GENE-N
1A1/2,4683,I-GENE-N
activities,4683,O
and,4683,O
PM-MMC,4683,O
rats,4683,O
showed,4683,O
higher,4683,O
quinone,4683,B-GENE-N
reductase,4683,I-GENE-N
and,4683,O
depleted,4683,O
xanthine,4683,B-GENE-Y
oxidase,4683,I-GENE-Y
activities,4683,O
.,4683,O
Protein-malnourished,4684,O
drug-treated,4684,O
groups,4684,O
exhibited,4684,O
exacerbated,4684,O
gastrotoxicity,4684,O
",",4684,O
relative,4684,O
to,4684,O
normally-fed,4684,O
counterparts,4684,O
",",4684,O
manifested,4684,O
by,4684,O
lower,4684,O
mucus,4684,O
levels,4684,O
",",4684,O
higher,4684,O
permeability,4684,O
and,4684,O
histopathological,4684,O
deterioration,4684,O
",",4684,O
along,4684,O
with,4684,O
increased,4684,O
oxidative,4684,O
stress,4684,O
in,4684,O
PM-CP,4684,O
rats,4684,O
and,4684,O
exaggerated,4684,O
prostaglandin,4684,B-CHEMICAL
E2,4684,I-CHEMICAL
production,4684,O
in,4684,O
PM-MMC,4684,O
rats,4684,O
.,4684,O
Conclusively,4685,O
",",4685,O
protein,4685,O
malnutrition,4685,O
alters,4685,O
CP,4685,O
",",4685,O
FU,4685,O
and,4685,O
MMC,4685,B-CHEMICAL
metabolism,4685,O
in,4685,O
rat,4685,O
stomach,4685,O
by,4685,O
enhancing,4685,O
CCBL,4685,B-GENE-Y
pathway,4685,O
for,4685,O
CP,4685,O
activation,4685,O
",",4685,O
delaying,4685,O
FU,4685,O
elimination,4685,O
and,4685,O
activating,4685,O
two-electron,4685,O
reduction,4685,O
of,4685,O
MMC,4685,B-CHEMICAL
",",4685,O
potentiating,4685,O
their,4685,O
gastrotoxicity,4685,O
.,4685,O
Effect,4686,O
of,4686,O
serum,4686,O
on,4686,O
diesel,4686,O
exhaust,4686,O
particles,4686,O
(,4686,O
DEP,4686,O
),4686,O
-induced,4686,O
apoptosis,4686,O
of,4686,O
airway,4686,O
epithelial,4686,O
cells,4686,O
in,4686,O
vitro,4686,O
.,4686,O
Patients,4687,O
with,4687,O
chronic,4687,O
airway,4687,O
diseases,4687,O
may,4687,O
be,4687,O
more,4687,O
susceptible,4687,O
to,4687,O
adverse,4687,O
effects,4687,O
of,4687,O
air,4687,O
pollutants,4687,O
including,4687,O
diesel,4687,O
exhaust,4687,O
particles,4687,O
(,4687,O
DEP,4687,O
),4687,O
.,4687,O
We,4688,O
investigated,4688,O
effects,4688,O
of,4688,O
foetal,4688,O
calf,4688,O
serum,4688,O
(,4688,O
FCS,4688,O
),4688,O
on,4688,O
DEP-induced,4688,O
changes,4688,O
in,4688,O
airway,4688,O
epithelial,4688,O
cell,4688,O
apoptosis,4688,O
and,4688,O
inflammation,4688,O
.,4688,O
DEP,4689,O
(,4689,O
50-200,4689,O
g/ml,4689,O
),4689,O
increased,4689,O
A549,4689,O
cell,4689,O
viability,4689,O
in,4689,O
the,4689,O
absence,4689,O
of,4689,O
FCS,4689,O
.,4689,O
In,4690,O
the,4690,O
presence,4690,O
of,4690,O
3.3,4690,O
%,4690,O
FCS,4690,O
",",4690,O
DEP,4690,O
(,4690,O
50-400,4690,O
g/ml,4690,O
),4690,O
decreased,4690,O
A549,4690,O
cell,4690,O
viability,4690,O
.,4690,O
N-acetylcysteine,4691,B-CHEMICAL
(,4691,O
NAC,4691,B-CHEMICAL
",",4691,O
33,4691,O
mM,4691,O
),4691,O
and,4691,O
the,4691,O
c-jun,4691,B-GENE-N
N-terminal,4691,I-GENE-N
kinase,4691,I-GENE-N
(,4691,O
JNK,4691,B-GENE-N
),4691,O
inhibitor,4691,O
(,4691,O
SP600125,4691,B-CHEMICAL
",",4691,O
33,4691,O
M,4691,O
),4691,O
further,4691,O
decreased,4691,O
the,4691,O
viability,4691,O
in,4691,O
the,4691,O
presence,4691,O
of,4691,O
DEP,4691,O
(,4691,O
200,4691,O
g/ml,4691,O
),4691,O
and,4691,O
3.3,4691,O
%,4691,O
FCS,4691,O
.,4691,O
Under,4692,O
serum-free,4692,O
(,4692,O
SF,4692,O
),4692,O
condition,4692,O
",",4692,O
DEP,4692,O
(,4692,O
50,4692,O
g/ml,4692,O
),4692,O
reduced,4692,O
apoptotic,4692,O
cells,4692,O
;,4692,O
however,4692,O
",",4692,O
when,4692,O
3.3,4692,O
%,4692,O
FCS,4692,O
added,4692,O
to,4692,O
the,4692,O
culture,4692,O
medium,4692,O
",",4692,O
this,4692,O
effect,4692,O
was,4692,O
abolished,4692,O
.,4692,O
DEP,4693,O
(,4693,O
200,4693,O
g/ml,4693,O
),4693,O
induced,4693,O
mRNA,4693,O
expression,4693,O
of,4693,O
p21,4693,B-GENE-Y
(,4693,O
CIP1/WAF1,4693,B-GENE-Y
),4693,O
both,4693,O
in,4693,O
absence,4693,O
or,4693,O
presence,4693,O
of,4693,O
3.3,4693,O
%,4693,O
FCS,4693,O
and,4693,O
enhanced,4693,O
JNK2,4693,B-GENE-Y
mRNA,4693,O
expression,4693,O
only,4693,O
in,4693,O
the,4693,O
presence,4693,O
of,4693,O
3.3,4693,O
%,4693,O
FCS,4693,O
.,4693,O
Under,4694,O
SF,4694,O
condition,4694,O
",",4694,O
DEP,4694,O
(,4694,O
50,4694,O
g/ml,4694,O
),4694,O
induced,4694,O
mRNA,4694,O
expression,4694,O
for,4694,O
p27,4694,B-GENE-Y
and,4694,O
p53,4694,B-GENE-Y
",",4694,O
whereas,4694,O
cyclin,4694,B-GENE-Y
E,4694,I-GENE-Y
mRNA,4694,O
expression,4694,O
was,4694,O
inhibited,4694,O
by,4694,O
DEP,4694,O
(,4694,O
50,4694,O
and,4694,O
200,4694,O
g/ml,4694,O
),4694,O
.,4694,O
Furthermore,4695,O
",",4695,O
DEP,4695,O
(,4695,O
200,4695,O
g/ml,4695,O
),4695,O
decreased,4695,O
the,4695,O
release,4695,O
of,4695,O
interleukin,4695,B-GENE-Y
(,4695,I-GENE-Y
IL,4695,I-GENE-Y
),4695,I-GENE-Y
-8,4695,I-GENE-Y
in,4695,O
the,4695,O
absence,4695,O
of,4695,O
FCS,4695,O
.,4695,O
In,4696,O
conclusion,4696,O
",",4696,O
FCS,4696,O
modulates,4696,O
effects,4696,O
of,4696,O
DEP,4696,O
on,4696,O
cell,4696,O
death,4696,O
",",4696,O
cell,4696,O
cycle,4696,O
and,4696,O
apoptosis,4696,O
regulating,4696,O
proteins,4696,O
",",4696,O
and,4696,O
IL-8,4696,B-GENE-Y
release,4696,O
by,4696,O
activating,4696,O
oxidant,4696,O
stress,4696,O
pathways,4696,O
",",4696,O
JNK,4696,B-GENE-N
and,4696,O
NF-B,4696,B-GENE-N
.,4696,O
Extravasation,4697,O
of,4697,O
serum,4697,O
",",4697,O
as,4697,O
occurs,4697,O
in,4697,O
the,4697,O
inflamed,4697,O
airways,4697,O
of,4697,O
patients,4697,O
with,4697,O
chronic,4697,O
airway,4697,O
diseases,4697,O
such,4697,O
as,4697,O
asthma,4697,O
and,4697,O
COPD,4697,O
",",4697,O
may,4697,O
render,4697,O
airway,4697,O
epithelial,4697,O
cells,4697,O
more,4697,O
susceptible,4697,O
to,4697,O
the,4697,O
deleterious,4697,O
effects,4697,O
of,4697,O
DEP,4697,O
.,4697,O
Cerebrovascular,4698,O
Dilation,4698,O
via,4698,O
Selective,4698,O
Targeting,4698,O
of,4698,O
the,4698,O
Cholane,4698,B-CHEMICAL
Steroid-Recognition,4698,B-CHEMICAL
Site,4698,O
in,4698,O
the,4698,O
BK,4698,B-GENE-Y
Channel,4698,I-GENE-Y
1-Subunit,4698,I-GENE-Y
by,4698,O
a,4698,O
Novel,4698,O
Nonsteroidal,4698,O
Agent,4698,O
.,4698,O
The,4699,O
Ca,4699,B-GENE-Y
(,4699,I-GENE-Y
2+,4699,I-GENE-Y
),4699,I-GENE-Y
/voltage-gated,4699,I-GENE-Y
K,4699,I-GENE-Y
(,4699,I-GENE-Y
+,4699,I-GENE-Y
),4699,I-GENE-Y
large,4699,I-GENE-Y
conductance,4699,I-GENE-Y
(,4699,I-GENE-Y
BK,4699,I-GENE-Y
),4699,I-GENE-Y
channel,4699,I-GENE-Y
1,4699,I-GENE-Y
subunit,4699,O
is,4699,O
particularly,4699,O
abundant,4699,O
in,4699,O
vascular,4699,O
smooth,4699,O
muscle,4699,O
.,4699,O
By,4700,O
determining,4700,O
their,4700,O
phenotype,4700,O
",",4700,O
BK,4700,B-GENE-Y
1,4700,I-GENE-Y
allows,4700,O
the,4700,O
BK,4700,B-GENE-N
channels,4700,I-GENE-N
to,4700,O
reduce,4700,O
myogenic,4700,O
tone,4700,O
",",4700,O
facilitating,4700,O
vasodilation,4700,O
.,4700,O
The,4701,O
endogenous,4701,O
steroid,4701,B-CHEMICAL
lithocholic,4701,B-CHEMICAL
acid,4701,I-CHEMICAL
(,4701,O
LCA,4701,B-CHEMICAL
),4701,O
dilates,4701,O
cerebral,4701,O
arteries,4701,O
via,4701,O
BK,4701,B-GENE-N
channel,4701,I-GENE-N
activation,4701,O
",",4701,O
which,4701,O
requires,4701,O
recognition,4701,O
by,4701,O
a,4701,O
BK,4701,B-GENE-Y
1,4701,I-GENE-Y
site,4701,O
that,4701,O
includes,4701,O
Thr169,4701,B-CHEMICAL
.,4701,O
Whether,4702,O
exogenous,4702,O
nonsteroidal,4702,O
agents,4702,O
can,4702,O
access,4702,O
this,4702,O
site,4702,O
to,4702,O
selectively,4702,O
activate,4702,O
1-containing,4702,B-GENE-Y
BK,4702,I-GENE-Y
channels,4702,I-GENE-Y
and,4702,O
evoke,4702,O
vasodilation,4702,O
remain,4702,O
unknown,4702,O
.,4702,O
We,4703,O
performed,4703,O
a,4703,O
chemical,4703,O
structure,4703,O
database,4703,O
similarity,4703,O
search,4703,O
using,4703,O
LCA,4703,B-CHEMICAL
as,4703,O
a,4703,O
template,4703,O
",",4703,O
along,4703,O
with,4703,O
a,4703,O
two-step,4703,O
reaction,4703,O
to,4703,O
generate,4703,O
sodium,4703,B-CHEMICAL
3-hydroxyolean-12-en-30-oate,4703,I-CHEMICAL
(,4703,O
HENA,4703,B-CHEMICAL
),4703,O
.,4703,O
HENA,4704,B-CHEMICAL
activated,4704,O
the,4704,O
BK,4704,B-GENE-Y
(,4704,I-GENE-Y
cbv1,4704,I-GENE-Y
+,4704,I-GENE-Y
1,4704,I-GENE-Y
),4704,I-GENE-Y
channels,4704,I-GENE-Y
cloned,4704,O
from,4704,O
rat,4704,O
cerebral,4704,O
artery,4704,O
myocytes,4704,O
with,4704,O
a,4704,O
potency,4704,O
(,4704,O
EC50,4704,O
=,4704,O
53,4704,O
M,4704,O
),4704,O
similar,4704,O
to,4704,O
and,4704,O
an,4704,O
efficacy,4704,O
(,4704,O
2.5,4704,O
potentiation,4704,O
),4704,O
significantly,4704,O
greater,4704,O
than,4704,O
that,4704,O
of,4704,O
LCA,4704,B-CHEMICAL
.,4704,O
This,4705,O
HENA,4705,B-CHEMICAL
action,4705,O
was,4705,O
replicated,4705,O
on,4705,O
native,4705,O
channels,4705,O
in,4705,O
rat,4705,O
cerebral,4705,O
artery,4705,O
myocytes,4705,O
.,4705,O
HENA,4706,B-CHEMICAL
failed,4706,O
to,4706,O
activate,4706,O
the,4706,O
channels,4706,O
made,4706,O
of,4706,O
cbv1,4706,O
+,4706,O
2,4706,O
",",4706,O
3,4706,O
",",4706,O
4,4706,O
",",4706,O
or,4706,O
1T169A,4706,O
",",4706,O
indicating,4706,O
that,4706,O
this,4706,O
drug,4706,O
selectively,4706,O
targets,4706,O
1-containing,4706,B-GENE-N
BK,4706,I-GENE-N
channels,4706,I-GENE-N
via,4706,O
the,4706,O
BK,4706,B-GENE-Y
1,4706,I-GENE-Y
steroid-sensing,4706,B-CHEMICAL
site,4706,O
.,4706,O
HENA,4707,B-CHEMICAL
(,4707,O
3-45,4707,O
M,4707,O
),4707,O
dilated,4707,O
the,4707,O
rat,4707,O
and,4707,O
C57BL/6,4707,O
mouse,4707,O
pressurized,4707,O
cerebral,4707,O
arteries,4707,O
.,4707,O
Consistent,4708,O
with,4708,O
the,4708,O
electrophysiologic,4708,O
results,4708,O
",",4708,O
this,4708,O
effect,4708,O
was,4708,O
larger,4708,O
than,4708,O
that,4708,O
of,4708,O
LCA,4708,B-CHEMICAL
.,4708,O
HENA,4709,B-CHEMICAL
failed,4709,O
to,4709,O
dilate,4709,O
the,4709,O
arteries,4709,O
from,4709,O
the,4709,O
KCNMB1,4709,B-GENE-Y
knockout,4709,O
mouse,4709,O
",",4709,O
underscoring,4709,O
BK,4709,B-GENE-Y
1,4709,I-GENE-Y
's,4709,O
role,4709,O
in,4709,O
HENA,4709,B-CHEMICAL
action,4709,O
.,4709,O
Finally,4710,O
",",4710,O
carotid,4710,O
artery-infusion,4710,O
of,4710,O
HENA,4710,B-CHEMICAL
(,4710,O
45,4710,O
M,4710,O
),4710,O
dilated,4710,O
the,4710,O
pial,4710,O
cerebral,4710,O
arterioles,4710,O
via,4710,O
selective,4710,O
BK-channel,4710,B-GENE-N
targeting,4710,O
.,4710,O
In,4711,O
conclusion,4711,O
",",4711,O
we,4711,O
have,4711,O
identified,4711,O
for,4711,O
the,4711,O
first,4711,O
time,4711,O
a,4711,O
nonsteroidal,4711,O
agent,4711,O
that,4711,O
selectively,4711,O
activates,4711,O
1-containing,4711,B-GENE-N
BK,4711,I-GENE-N
channels,4711,I-GENE-N
by,4711,O
targeting,4711,O
the,4711,O
steroid-sensing,4711,B-CHEMICAL
site,4711,O
in,4711,O
BK,4711,B-GENE-Y
1,4711,I-GENE-Y
",",4711,O
rendering,4711,O
vasodilation,4711,O
.,4711,O
Assessment,4712,O
of,4712,O
the,4712,O
abuse,4712,O
liability,4712,O
of,4712,O
ABT-288,4712,B-CHEMICAL
",",4712,O
a,4712,O
novel,4712,O
histamine,4712,B-GENE-Y
H3,4712,I-GENE-Y
receptor,4712,I-GENE-Y
antagonist,4712,O
.,4712,O
RATIONALE,4713,O
:,4713,O
Histamine,4713,B-CHEMICAL
H3,4713,I-GENE-Y
receptor,4713,I-GENE-Y
antagonists,4713,O
",",4713,O
such,4713,O
as,4713,O
ABT-288,4713,B-CHEMICAL
",",4713,O
have,4713,O
been,4713,O
shown,4713,O
to,4713,O
possess,4713,O
cognitive-enhancing,4713,O
and,4713,O
wakefulness-promoting,4713,O
effects,4713,O
.,4713,O
On,4714,O
the,4714,O
surface,4714,O
",",4714,O
this,4714,O
might,4714,O
suggest,4714,O
that,4714,O
H3,4714,B-GENE-Y
antagonists,4714,O
possess,4714,O
psychomotor,4714,O
stimulant-like,4714,O
effects,4714,O
and,4714,O
",",4714,O
as,4714,O
such,4714,O
",",4714,O
may,4714,O
have,4714,O
the,4714,O
potential,4714,O
for,4714,O
abuse,4714,O
.,4714,O
OBJECTIVES,4715,O
:,4715,O
The,4715,O
aim,4715,O
of,4715,O
the,4715,O
present,4715,O
study,4715,O
was,4715,O
to,4715,O
further,4715,O
characterize,4715,O
whether,4715,O
ABT-288,4715,B-CHEMICAL
possesses,4715,O
stimulant-like,4715,O
properties,4715,O
and,4715,O
whether,4715,O
its,4715,O
pharmacology,4715,O
gives,4715,O
rise,4715,O
to,4715,O
abuse,4715,O
liability,4715,O
.,4715,O
METHODS,4716,O
:,4716,O
The,4716,O
locomotor-stimulant,4716,O
effects,4716,O
of,4716,O
ABT-288,4716,B-CHEMICAL
were,4716,O
measured,4716,O
in,4716,O
mice,4716,O
and,4716,O
rats,4716,O
",",4716,O
and,4716,O
potential,4716,O
development,4716,O
of,4716,O
sensitization,4716,O
was,4716,O
addressed,4716,O
.,4716,O
Drug,4717,O
discrimination,4717,O
was,4717,O
used,4717,O
to,4717,O
assess,4717,O
amphetamine-like,4717,B-CHEMICAL
stimulus,4717,O
properties,4717,O
",",4717,O
and,4717,O
drug,4717,O
self-administration,4717,O
was,4717,O
used,4717,O
to,4717,O
evaluate,4717,O
reinforcing,4717,O
effects,4717,O
of,4717,O
ABT-288,4717,B-CHEMICAL
.,4717,O
The,4718,O
potential,4718,O
development,4718,O
of,4718,O
physical,4718,O
dependence,4718,O
was,4718,O
also,4718,O
studied,4718,O
.,4718,O
RESULTS,4719,O
:,4719,O
ABT-288,4719,B-CHEMICAL
lacked,4719,O
locomotor-stimulant,4719,O
effects,4719,O
in,4719,O
both,4719,O
rats,4719,O
and,4719,O
mice,4719,O
.,4719,O
Repeated,4720,O
administration,4720,O
of,4720,O
ABT-288,4720,B-CHEMICAL
did,4720,O
not,4720,O
result,4720,O
in,4720,O
cross-sensitization,4720,O
to,4720,O
the,4720,O
stimulant,4720,O
effects,4720,O
of,4720,O
d-amphetamine,4720,B-CHEMICAL
in,4720,O
mice,4720,O
",",4720,O
suggesting,4720,O
that,4720,O
there,4720,O
is,4720,O
little,4720,O
overlap,4720,O
in,4720,O
circuitries,4720,O
upon,4720,O
which,4720,O
the,4720,O
two,4720,O
drugs,4720,O
interact,4720,O
for,4720,O
motor,4720,O
activity,4720,O
.,4720,O
ABT-288,4721,B-CHEMICAL
did,4721,O
not,4721,O
produce,4721,O
amphetamine-like,4721,B-CHEMICAL
discriminative,4721,O
stimulus,4721,O
effects,4721,O
in,4721,O
drug,4721,O
discrimination,4721,O
studies,4721,O
nor,4721,O
was,4721,O
it,4721,O
self-administered,4721,O
by,4721,O
rats,4721,O
trained,4721,O
to,4721,O
self-administer,4721,O
cocaine,4721,B-CHEMICAL
.,4721,O
There,4722,O
were,4722,O
no,4722,O
signs,4722,O
of,4722,O
physical,4722,O
dependence,4722,O
upon,4722,O
termination,4722,O
of,4722,O
repeated,4722,O
administration,4722,O
of,4722,O
ABT-288,4722,B-CHEMICAL
for,4722,O
30,4722,O
days,4722,O
.,4722,O
CONCLUSIONS,4723,O
:,4723,O
The,4723,O
sum,4723,O
of,4723,O
these,4723,O
preclinical,4723,O
data,4723,O
",",4723,O
the,4723,O
first,4723,O
of,4723,O
their,4723,O
kind,4723,O
applied,4723,O
to,4723,O
H3,4723,B-GENE-Y
antagonists,4723,O
",",4723,O
indicates,4723,O
that,4723,O
ABT-288,4723,B-CHEMICAL
is,4723,O
unlikely,4723,O
to,4723,O
possess,4723,O
a,4723,O
high,4723,O
potential,4723,O
for,4723,O
abuse,4723,O
in,4723,O
the,4723,O
human,4723,O
population,4723,O
and,4723,O
suggests,4723,O
that,4723,O
H3,4723,B-GENE-Y
antagonists,4723,O
",",4723,O
as,4723,O
a,4723,O
class,4723,O
",",4723,O
are,4723,O
similar,4723,O
in,4723,O
this,4723,O
regard,4723,O
.,4723,O
Unraveling,4724,O
a,4724,O
phosphorylation,4724,O
event,4724,O
in,4724,O
a,4724,O
folded,4724,O
protein,4724,O
by,4724,O
NMR,4724,O
spectroscopy,4724,O
:,4724,O
phosphorylation,4724,O
of,4724,O
the,4724,O
Pin1,4724,B-GENE-N
WW,4724,I-GENE-N
domain,4724,I-GENE-N
by,4724,O
PKA,4724,B-GENE-N
.,4724,O
The,4725,O
Pin1,4725,B-GENE-Y
protein,4725,O
plays,4725,O
a,4725,O
critical,4725,O
role,4725,O
in,4725,O
the,4725,O
functional,4725,O
regulation,4725,O
of,4725,O
the,4725,O
hyperphosphorylated,4725,O
neuronal,4725,O
Tau,4725,B-GENE-Y
protein,4725,I-GENE-Y
in,4725,O
Alzheimer,4725,O
's,4725,O
disease,4725,O
and,4725,O
is,4725,O
by,4725,O
itself,4725,O
regulated,4725,O
by,4725,O
phosphorylation,4725,O
.,4725,O
We,4726,O
have,4726,O
used,4726,O
Nuclear,4726,O
Magnetic,4726,O
Resonance,4726,O
(,4726,O
NMR,4726,O
),4726,O
spectroscopy,4726,O
to,4726,O
both,4726,O
identify,4726,O
the,4726,O
PKA,4726,B-GENE-N
phosphorylation,4726,O
site,4726,O
in,4726,O
the,4726,O
Pin1,4726,B-GENE-N
WW,4726,I-GENE-N
domain,4726,I-GENE-N
and,4726,O
investigate,4726,O
the,4726,O
functional,4726,O
consequences,4726,O
of,4726,O
this,4726,O
phosphorylation,4726,O
.,4726,O
Detection,4727,O
and,4727,O
identification,4727,O
of,4727,O
phosphorylation,4727,O
on,4727,O
serine/threonine,4727,B-CHEMICAL
residues,4727,O
in,4727,O
a,4727,O
globular,4727,O
protein,4727,O
",",4727,O
while,4727,O
mostly,4727,O
occurring,4727,O
in,4727,O
solvent-exposed,4727,O
flexible,4727,O
loops,4727,O
",",4727,O
does,4727,O
not,4727,O
lead,4727,O
to,4727,O
chemical,4727,O
shift,4727,O
changes,4727,O
as,4727,O
obvious,4727,O
as,4727,O
in,4727,O
disordered,4727,O
proteins,4727,O
and,4727,O
hence,4727,O
does,4727,O
not,4727,O
necessarily,4727,O
shift,4727,O
the,4727,O
resonances,4727,O
outside,4727,O
the,4727,O
spectrum,4727,O
of,4727,O
the,4727,O
folded,4727,O
protein,4727,O
.,4727,O
Other,4728,O
complications,4728,O
were,4728,O
encountered,4728,O
to,4728,O
characterize,4728,O
the,4728,O
extent,4728,O
of,4728,O
the,4728,O
phosphorylation,4728,O
",",4728,O
as,4728,O
part,4728,O
of,4728,O
the,4728,O
(,4728,B-CHEMICAL
1,4728,I-CHEMICAL
),4728,I-CHEMICAL
H,4728,I-CHEMICAL
",",4728,O
(,4728,B-CHEMICAL
15,4728,I-CHEMICAL
),4728,I-CHEMICAL
N,4728,I-CHEMICAL
amide,4728,B-CHEMICAL
resonances,4728,O
around,4728,O
the,4728,O
phosphorylation,4728,O
site,4728,O
are,4728,O
specifically,4728,O
broadened,4728,O
in,4728,O
the,4728,O
unphosphorylated,4728,O
state,4728,O
.,4728,O
Despite,4729,O
these,4729,O
obstacles,4729,O
",",4729,O
NMR,4729,O
spectroscopy,4729,O
was,4729,O
an,4729,O
efficient,4729,O
tool,4729,O
to,4729,O
confirm,4729,O
phosphorylation,4729,O
on,4729,O
S16,4729,O
of,4729,O
the,4729,O
WW,4729,B-GENE-N
domain,4729,I-GENE-N
and,4729,O
to,4729,O
quantify,4729,O
the,4729,O
level,4729,O
of,4729,O
phosphorylation,4729,O
.,4729,O
Based,4730,O
on,4730,O
this,4730,O
analytical,4730,O
characterization,4730,O
",",4730,O
we,4730,O
show,4730,O
that,4730,O
WW,4730,B-GENE-N
phosphorylation,4730,O
on,4730,O
S16,4730,O
abolishes,4730,O
its,4730,O
binding,4730,O
capacity,4730,O
to,4730,O
a,4730,O
phosphorylated,4730,B-GENE-Y
Tau,4730,I-GENE-Y
peptide,4730,I-GENE-Y
.,4730,O
A,4731,O
reduced,4731,O
conformational,4731,O
heterogeneity,4731,O
and,4731,O
flexibility,4731,O
of,4731,O
the,4731,O
phospho-binding,4731,B-CHEMICAL
loop,4731,O
upon,4731,O
S16,4731,O
phosphorylation,4731,O
could,4731,O
account,4731,O
for,4731,O
part,4731,O
of,4731,O
the,4731,O
decreased,4731,O
affinity,4731,O
for,4731,O
its,4731,O
phosphorylated,4731,O
partner,4731,O
.,4731,O
Additionally,4732,O
",",4732,O
a,4732,O
structural,4732,O
model,4732,O
of,4732,O
the,4732,O
phospho-WW,4732,B-CHEMICAL
obtained,4732,O
by,4732,O
molecular,4732,O
dynamics,4732,O
simulation,4732,O
and,4732,O
energy,4732,O
minimization,4732,O
suggests,4732,O
that,4732,O
the,4732,O
phosphate,4732,B-CHEMICAL
moiety,4732,O
of,4732,O
phospho-S16,4732,B-CHEMICAL
could,4732,O
compete,4732,O
with,4732,O
the,4732,O
phospho-substrate,4732,B-CHEMICAL
.,4732,O
Dissecting,4733,O
the,4733,O
relative,4733,O
contribution,4733,O
of,4733,O
OATP1B1-mediated,4733,B-GENE-Y
uptake,4733,O
of,4733,O
xenobiotics,4733,O
into,4733,O
human,4733,O
hepatocytes,4733,O
using,4733,O
siRNA,4733,O
.,4733,O
Abstract,4734,O
1,4734,O
.,4734,O
Organic,4735,B-GENE-Y
anion,4735,I-GENE-Y
transporting,4735,I-GENE-Y
polypeptide,4735,I-GENE-Y
1B1,4735,I-GENE-Y
plays,4735,O
a,4735,O
pivotal,4735,O
role,4735,O
in,4735,O
the,4735,O
disposition,4735,O
of,4735,O
many,4735,O
anionic,4735,O
drugs,4735,O
.,4735,O
Significant,4736,O
overlap,4736,O
in,4736,O
substrate,4736,O
specificity,4736,O
between,4736,O
individual,4736,O
OATP,4736,B-GENE-N
isoforms,4736,O
has,4736,O
hampered,4736,O
the,4736,O
identification,4736,O
of,4736,O
the,4736,O
relative,4736,O
importance,4736,O
of,4736,O
individual,4736,O
isoforms,4736,O
for,4736,O
hepatic,4736,O
uptake,4736,O
of,4736,O
xenobiotics,4736,O
.,4736,O
2,4737,O
.,4737,O
The,4738,O
present,4738,O
study,4738,O
focused,4738,O
on,4738,O
the,4738,O
use,4738,O
of,4738,O
siRNA,4738,O
technology,4738,O
to,4738,O
decrease,4738,O
OATP1B1,4738,B-GENE-Y
selectively,4738,O
in,4738,O
human,4738,O
hepatocytes,4738,O
.,4738,O
Following,4739,O
delivery,4739,O
of,4739,O
siRNA,4739,O
by,4739,O
the,4739,O
novel,4739,O
lipid,4739,O
",",4739,O
AtuFECT01,4739,O
",",4739,O
mRNA,4739,O
expression,4739,O
of,4739,O
OATP1B1,4739,B-GENE-Y
was,4739,O
reduced,4739,O
by,4739,O
94,4739,O
%,4739,O
-98,4739,O
%,4739,O
with,4739,O
no,4739,O
significant,4739,O
toxicity,4739,O
.,4739,O
Off-target,4740,O
effects,4740,O
were,4740,O
also,4740,O
shown,4740,O
to,4740,O
be,4740,O
minimal,4740,O
as,4740,O
evidenced,4740,O
by,4740,O
the,4740,O
expression,4740,O
of,4740,O
common,4740,O
drug,4740,O
metabolizing,4740,O
enzymes,4740,O
",",4740,O
transporters,4740,O
",",4740,O
nuclear,4740,O
receptors,4740,O
and,4740,O
associated,4740,O
co-regulators,4740,O
.,4740,O
Uptake,4741,O
of,4741,O
estrone-3-sulfate,4741,B-CHEMICAL
(,4741,O
5,4741,O
nM,4741,O
),4741,O
by,4741,O
OATP1B1,4741,B-GENE-Y
was,4741,O
reduced,4741,O
by,4741,O
82,4741,O
%,4741,O
-95,4741,O
%,4741,O
.,4741,O
This,4742,O
methodology,4742,O
was,4742,O
subsequently,4742,O
used,4742,O
to,4742,O
assess,4742,O
the,4742,O
relative,4742,O
contribution,4742,O
of,4742,O
OATP1B1,4742,B-GENE-Y
uptake,4742,O
in,4742,O
human,4742,O
hepatocytes,4742,O
for,4742,O
olmesartan,4742,B-CHEMICAL
(,4742,O
42,4742,O
%,4742,O
-62,4742,O
%,4742,O
),4742,O
",",4742,O
valsartan,4742,B-CHEMICAL
(,4742,O
28,4742,O
%,4742,O
-81,4742,O
%,4742,O
),4742,O
",",4742,O
rosuvastatin,4742,B-CHEMICAL
(,4742,O
64,4742,O
%,4742,O
-72,4742,O
%,4742,O
),4742,O
",",4742,O
pitavastatin,4742,B-CHEMICAL
(,4742,O
84,4742,O
%,4742,O
-98,4742,O
%,4742,O
),4742,O
and,4742,O
lopinavir,4742,B-CHEMICAL
(,4742,O
64,4742,O
%,4742,O
-89,4742,O
%,4742,O
),4742,O
.,4742,O
These,4743,O
data,4743,O
are,4743,O
consistent,4743,O
with,4743,O
previous,4743,O
values,4743,O
obtained,4743,O
using,4743,O
a,4743,O
relative,4743,O
activity,4743,O
factor,4743,O
approach,4743,O
.,4743,O
3,4744,O
.,4744,O
The,4745,O
siRNA,4745,O
approach,4745,O
provides,4745,O
a,4745,O
robust,4745,O
and,4745,O
reproducible,4745,O
method,4745,O
for,4745,O
assessing,4745,O
the,4745,O
relative,4745,O
contribution,4745,O
of,4745,O
OATP1B1,4745,B-GENE-Y
to,4745,O
hepatic,4745,O
uptake,4745,O
of,4745,O
new,4745,O
chemical,4745,O
entities,4745,O
.,4745,O
The,4746,O
technique,4746,O
also,4746,O
has,4746,O
potential,4746,O
utility,4746,O
in,4746,O
facilitating,4746,O
detailed,4746,O
characterization,4746,O
of,4746,O
drug-drug,4746,O
interactions,4746,O
involving,4746,O
hepatic,4746,O
drug,4746,O
transporters,4746,O
.,4746,O
Serum,4747,O
free,4747,O
fatty,4747,B-CHEMICAL
acid,4747,I-CHEMICAL
levels,4747,O
in,4747,O
PCOS,4747,O
patients,4747,O
treated,4747,O
with,4747,O
glucophage,4747,O
",",4747,O
magnesium,4747,B-CHEMICAL
oxide,4747,I-CHEMICAL
and,4747,O
spironolactone,4747,B-CHEMICAL
.,4747,O
Abstract,4748,O
To,4748,O
assess,4748,O
the,4748,O
effect,4748,O
of,4748,O
glucophage,4748,O
",",4748,O
magnesium,4748,B-CHEMICAL
oxide,4748,I-CHEMICAL
and,4748,O
spironolactone,4748,B-CHEMICAL
in,4748,O
altering,4748,O
free,4748,O
fatty,4748,B-CHEMICAL
acids,4748,I-CHEMICAL
(,4748,O
FFAs,4748,O
),4748,O
",",4748,O
36,4748,O
PCOS,4748,O
women,4748,O
were,4748,O
randomly,4748,O
divided,4748,O
into,4748,O
three,4748,O
groups,4748,O
.,4748,O
Group,4749,O
1,4749,O
(,4749,O
n,4749,O
=,4749,O
14,4749,O
),4749,O
was,4749,O
treated,4749,O
with,4749,O
500,4749,O
mg,4749,O
glucophage,4749,O
po,4749,O
bid,4749,O
",",4749,O
group,4749,O
2,4749,O
(,4749,O
n,4749,O
=,4749,O
10,4749,O
),4749,O
was,4749,O
treated,4749,O
with,4749,O
400,4749,O
mg,4749,O
magnesium,4749,B-CHEMICAL
oxide,4749,I-CHEMICAL
po,4749,O
bid,4749,O
and,4749,O
group,4749,O
3,4749,O
(,4749,O
n,4749,O
=,4749,O
12,4749,O
),4749,O
was,4749,O
treated,4749,O
with,4749,O
50,4749,O
mg,4749,O
spironolactone,4749,B-CHEMICAL
po,4749,O
bid,4749,O
for,4749,O
12,4749,O
weeks,4749,O
.,4749,O
A,4750,O
glucose,4750,B-CHEMICAL
tolerance,4750,O
test,4750,O
with,4750,O
75,4750,O
g,4750,O
glucose,4750,B-CHEMICAL
load,4750,O
was,4750,O
performed,4750,O
before,4750,O
and,4750,O
after,4750,O
treatment,4750,O
",",4750,O
collecting,4750,O
blood,4750,O
at,4750,O
0,4750,O
",",4750,O
1,4750,O
and,4750,O
2,4750,O
h,4750,O
for,4750,O
insulin,4750,B-GENE-Y
",",4750,O
glucose,4750,B-CHEMICAL
",",4750,O
FFA,4750,O
and,4750,O
aldosterone,4750,B-CHEMICAL
.,4750,O
Amount,4751,O
of,4751,O
FFA,4751,O
before,4751,O
and,4751,O
after,4751,O
treatment,4751,O
were,4751,O
compared,4751,O
by,4751,O
repeated,4751,O
measure,4751,O
ANOVA,4751,O
and,4751,O
represented,4751,O
as,4751,O
area,4751,O
under,4751,O
the,4751,O
curve,4751,O
.,4751,O
FFA,4752,O
levels,4752,O
before,4752,O
treatment,4752,O
were,4752,O
0.83,4752,O
,4752,O
0.23,4752,O
",",4752,O
0.77,4752,O
,4752,O
0.15,4752,O
and,4752,O
0.85,4752,O
,4752,O
0.28,4752,O
and,4752,O
after,4752,O
treatment,4752,O
were,4752,O
0.77,4752,O
,4752,O
0.48,4752,O
",",4752,O
0.71,4752,O
,4752,O
0.18,4752,O
and,4752,O
0.66,4752,O
,4752,O
0.25,4752,O
for,4752,O
glucophage,4752,O
",",4752,O
magnesium,4752,B-CHEMICAL
oxide,4752,I-CHEMICAL
and,4752,O
spironolactone-treated,4752,B-CHEMICAL
patients,4752,O
",",4752,O
respectively,4752,O
.,4752,O
The,4753,O
FFA,4753,O
levels,4753,O
were,4753,O
unchanged,4753,O
in,4753,O
the,4753,O
groups,4753,O
treated,4753,O
with,4753,O
glucophage,4753,O
and,4753,O
magnesium,4753,B-CHEMICAL
oxide,4753,I-CHEMICAL
but,4753,O
were,4753,O
significantly,4753,O
(,4753,O
p,4753,O
<,4753,O
0.03,4753,O
),4753,O
decreased,4753,O
in,4753,O
the,4753,O
group,4753,O
treated,4753,O
with,4753,O
spironolactone,4753,B-CHEMICAL
.,4753,O
Since,4754,O
FFAs,4754,O
are,4754,O
known,4754,O
to,4754,O
be,4754,O
involved,4754,O
in,4754,O
the,4754,O
development,4754,O
of,4754,O
insulin,4754,B-GENE-Y
resistance,4754,O
",",4754,O
these,4754,O
results,4754,O
suggest,4754,O
that,4754,O
spironolactone,4754,B-CHEMICAL
may,4754,O
be,4754,O
useful,4754,O
for,4754,O
lowering,4754,O
insulin,4754,B-GENE-Y
resistance,4754,O
in,4754,O
PCOS,4754,O
patients,4754,O
.,4754,O
Membranar,4755,O
effects,4755,O
exerted,4755,O
in,4755,O
vitro,4755,O
by,4755,O
polyphenols,4755,B-CHEMICAL
-,4755,O
quercetin,4755,B-CHEMICAL
",",4755,O
epigallocatechin,4755,B-CHEMICAL
gallate,4755,I-CHEMICAL
and,4755,O
curcumin,4755,B-CHEMICAL
-,4755,O
on,4755,O
HUVEC,4755,O
and,4755,O
Jurkat,4755,O
cells,4755,O
",",4755,O
relevant,4755,O
for,4755,O
diabetes,4755,O
mellitus,4755,O
.,4755,O
Polyphenols,4756,B-CHEMICAL
are,4756,O
largely,4756,O
studied,4756,O
for,4756,O
their,4756,O
beneficial,4756,O
action,4756,O
in,4756,O
various,4756,O
pathologies,4756,O
",",4756,O
but,4756,O
the,4756,O
correlation,4756,O
with,4756,O
their,4756,O
effects,4756,O
on,4756,O
cell,4756,O
membranes,4756,O
is,4756,O
still,4756,O
elusive,4756,O
.,4756,O
In,4757,O
the,4757,O
present,4757,O
study,4757,O
we,4757,O
assessed,4757,O
the,4757,O
effects,4757,O
exerted,4757,O
in,4757,O
vitro,4757,O
by,4757,O
quercetin,4757,B-CHEMICAL
",",4757,O
epigallocatechin,4757,B-CHEMICAL
gallate,4757,I-CHEMICAL
and,4757,O
curcumin,4757,B-CHEMICAL
on,4757,O
membrane,4757,O
fluidity,4757,O
and,4757,O
transmembrane,4757,O
potential,4757,O
of,4757,O
human,4757,O
umbilical,4757,O
vein,4757,O
endothelial,4757,O
cells,4757,O
and,4757,O
Jurkat,4757,O
T,4757,O
lymphoblasts,4757,O
",",4757,O
in,4757,O
experimental,4757,O
conditions,4757,O
mimicking,4757,O
diabetes,4757,O
mellitus,4757,O
",",4757,O
i.e,4757,O
.,4757,O
high,4758,O
glucose,4758,B-CHEMICAL
conditions,4758,O
or,4758,O
increased,4758,O
concentration,4758,O
of,4758,O
advanced,4758,O
glycation,4758,O
end,4758,O
products,4758,O
.,4758,O
Results,4759,O
showed,4759,O
that,4759,O
the,4759,O
investigated,4759,O
polyphenols,4759,B-CHEMICAL
had,4759,O
beneficial,4759,O
effects,4759,O
on,4759,O
cell,4759,O
membranes,4759,O
altered,4759,O
in,4759,O
diabetic,4759,O
conditions,4759,O
",",4759,O
by,4759,O
restoring,4759,O
transmembrane,4759,O
potential,4759,O
and,4759,O
by,4759,O
membrane,4759,O
``,4759,O
stiffening,4759,O
'',4759,O
.,4759,O
Moreover,4760,O
",",4760,O
they,4760,O
limited,4760,O
the,4760,O
release,4760,O
of,4760,O
pro-inflammatory,4760,O
factors,4760,O
",",4760,O
like,4760,O
monocyte,4760,B-GENE-Y
chemotactic,4760,I-GENE-Y
protein-1,4760,I-GENE-Y
.,4760,O
These,4761,O
effects,4761,O
were,4761,O
more,4761,O
obvious,4761,O
for,4761,O
cells,4761,O
exposed,4761,O
to,4761,O
advanced,4761,O
glycation,4761,O
end,4761,O
products,4761,O
specific,4761,O
for,4761,O
the,4761,O
late,4761,O
stages,4761,O
of,4761,O
diabetes,4761,O
.,4761,O
Apparently,4762,O
",",4762,O
the,4762,O
inhibitory,4762,O
action,4762,O
of,4762,O
polyphenols,4762,B-CHEMICAL
on,4762,O
lipid,4762,O
peroxidation,4762,O
was,4762,O
associated,4762,O
with,4762,O
a,4762,O
decrease,4762,O
of,4762,O
membrane,4762,O
fluidity,4762,O
.,4762,O
Concluding,4763,O
",",4763,O
our,4763,O
in,4763,O
vitro,4763,O
study,4763,O
highlighted,4763,O
the,4763,O
potential,4763,O
beneficial,4763,O
action,4763,O
of,4763,O
polyphenols,4763,B-CHEMICAL
mainly,4763,O
in,4763,O
the,4763,O
late,4763,O
stages,4763,O
of,4763,O
diabetes,4763,O
",",4763,O
exerted,4763,O
at,4763,O
the,4763,O
level,4763,O
of,4763,O
membrane,4763,O
fluidity,4763,O
and,4763,O
transmembrane,4763,O
potential,4763,O
",",4763,O
accompanied,4763,O
by,4763,O
an,4763,O
anti-inflammatory,4763,O
effect,4763,O
on,4763,O
endothelial,4763,O
and,4763,O
immune,4763,O
cells,4763,O
.,4763,O
Oral,4764,O
l-glutamine,4764,B-CHEMICAL
increases,4764,O
active,4764,O
GLP-1,4764,B-GENE-Y
(,4764,O
7-36,4764,O
),4764,O
amide,4764,B-CHEMICAL
secretion,4764,O
and,4764,O
improves,4764,O
glycemic,4764,O
control,4764,O
in,4764,O
stretpozotocin-nicotinamide,4764,B-CHEMICAL
induced,4764,O
diabetic,4764,O
rats,4764,O
.,4764,O
l-glutamine,4765,B-CHEMICAL
is,4765,O
a,4765,O
non-essential,4765,O
amino,4765,B-CHEMICAL
acid,4765,I-CHEMICAL
.,4765,O
It,4766,O
decreased,4766,O
blood,4766,O
sugar,4766,B-CHEMICAL
",",4766,O
stimulated,4766,O
insulin,4766,B-GENE-N
secretion,4766,O
in,4766,O
type,4766,O
2,4766,O
diabetic,4766,O
patients,4766,O
.,4766,O
The,4767,O
objective,4767,O
of,4767,O
the,4767,O
present,4767,O
investigation,4767,O
was,4767,O
to,4767,O
evaluate,4767,O
l-glutamine,4767,B-CHEMICAL
increases,4767,O
glucagon,4767,B-GENE-Y
like,4767,I-GENE-Y
peptide-1,4767,I-GENE-Y
(,4767,O
GLP-1,4767,B-GENE-Y
),4767,O
(,4767,O
7-36,4767,O
),4767,O
amide,4767,B-CHEMICAL
secretion,4767,O
in,4767,O
streptozotocin-nicotinamide,4767,B-CHEMICAL
(,4767,O
STZ-NTM,4767,B-CHEMICAL
),4767,O
induced,4767,O
diabetic,4767,O
Sprague,4767,O
Dawley,4767,O
rats,4767,O
.,4767,O
Molecular,4768,O
docking,4768,O
study,4768,O
was,4768,O
performed,4768,O
to,4768,O
elucidate,4768,O
the,4768,O
molecular,4768,O
basis,4768,O
for,4768,O
GLP-1,4768,B-GENE-Y
receptor,4768,I-GENE-Y
agonistic,4768,O
activity,4768,O
.,4768,O
Type,4769,O
2,4769,O
diabetes,4769,O
was,4769,O
induced,4769,O
in,4769,O
overnight,4769,O
fasted,4769,O
Sprague,4769,O
Dawley,4769,O
rats,4769,O
pre-treated,4769,O
with,4769,O
nicotinamide,4769,B-CHEMICAL
(,4769,O
100mg/kg,4769,O
",",4769,O
i.p,4769,O
.,4769,O
),4769,O
followed,4770,O
by,4770,O
20min,4770,O
after,4770,O
administration,4770,O
of,4770,O
streptozotocin,4770,B-CHEMICAL
(,4770,O
55mg/kg,4770,O
",",4770,O
i.p,4770,O
.,4770,O
),4770,O
.,4770,O
The,4771,O
rats,4771,O
were,4771,O
divided,4771,O
into,4771,O
;,4771,O
I,4771,O
-,4771,O
nondiabetic,4771,O
",",4771,O
II,4771,O
-,4771,O
diabetic,4771,O
control,4771,O
",",4771,O
III,4771,O
-,4771,O
sitagliptin,4771,B-CHEMICAL
(,4771,O
5mg/kg,4771,O
",",4771,O
p.o,4771,O
.,4771,O
),4772,O
",",4772,O
IV,4772,O
-l-glutamine,4772,B-CHEMICAL
(,4772,O
250mg/kg,4772,O
",",4772,O
p.o,4772,O
.,4772,O
),4773,O
",",4773,O
V,4773,O
-l-glutamine,4773,O
(,4773,O
500mg/kg,4773,O
",",4773,O
p.o,4773,O
.,4773,O
),4773,O
and,4774,O
VI,4774,O
-l-glutamine,4774,O
(,4774,O
1000mg/kg,4774,O
",",4774,O
p.o,4774,O
.,4774,O
),4774,O
.,4774,O
The,4775,O
l-glutamine,4775,O
and,4775,O
sitagliptin,4775,O
treatment,4775,O
was,4775,O
8week,4775,O
.,4775,O
Plasma,4776,O
glucose,4776,O
was,4776,O
estimated,4776,O
every,4776,O
week,4776,O
.,4776,O
Body,4777,O
weight,4777,O
",",4777,O
food,4777,O
and,4777,O
water,4777,O
intake,4777,O
were,4777,O
recorded,4777,O
daily,4777,O
.,4777,O
Glycosylated,4778,O
haemoglobin,4778,O
",",4778,O
lipid,4778,O
profile,4778,O
",",4778,O
plasma,4778,O
and,4778,O
colonic,4778,O
active,4778,O
(,4778,I-GENE-Y
GLP-1,4778,O
),4778,O
(,4778,O
7-36,4778,O
),4778,B-CHEMICAL
amide,4778,O
",",4778,O
mRNA,4778,O
expression,4778,O
of,4778,O
proglucagon,4778,O
GLP-1,4778,O
",",4778,O
plasma,4778,O
and,4778,O
pancreatic,4778,O
insulin,4778,O
",",4778,O
histology,4778,O
of,4778,O
pancreata,4778,O
and,4778,O
biomarkers,4778,O
of,4778,O
oxidative,4778,O
stress,4778,O
(,4778,I-GENE-N
superoxidase,4778,I-GENE-N
dismutase,4778,O
",",4778,O
reduced,4778,O
glutathione,4778,O
",",4778,B-CHEMICAL
malondialdehyde,4778,O
",",4778,B-CHEMICAL
glutathione,4778,I-GENE-N
peroxidase,4778,O
",",4778,B-CHEMICAL
glutathione,4778,I-GENE-N
S,4778,I-GENE-N
transferase,4778,O
),4778,O
were,4778,O
measured,4778,O
after,4778,O
8week,4778,O
.,4778,O
In,4779,O
acute,4779,O
study,4779,O
",",4779,O
the,4779,O
rats,4779,O
were,4779,O
divided,4779,O
into,4779,O
I,4779,O
-,4779,B-CHEMICAL
glucose,4779,O
(,4779,O
2.5g/kg,4779,O
",",4779,O
p.o,4779,O
.,4779,O
),4780,O
",",4780,O
II,4780,O
-,4780,I-CHEMICAL
sitagliptin,4780,O
(,4780,O
5mg/kg,4780,O
",",4780,O
p.o,4780,O
.,4780,O
),4781,O
",",4781,O
III,4781,O
-l-glutamine,4781,O
(,4781,O
250mg/kg,4781,O
",",4781,O
p.o,4781,O
.,4781,O
),4782,O
",",4782,O
IV,4782,I-CHEMICAL
-l-glutamine,4782,O
(,4782,O
500mg/kg,4782,O
",",4782,O
p.o,4782,O
.,4782,O
),4782,O
and,4783,O
V,4783,I-CHEMICAL
-l-glutamine,4783,O
(,4783,O
1000mg/kg,4783,O
",",4783,O
p.o,4783,O
.,4783,O
),4783,O
.,4783,O
Plasma,4784,O
glucose,4784,O
",",4784,O
active,4784,O
GLP-1,4784,O
(,4784,O
7-36,4784,O
),4784,I-CHEMICAL
amide,4784,O
concentration,4784,O
and,4784,I-GENE-N
insulin,4784,O
levels,4784,O
were,4784,O
measured,4784,O
after,4784,O
glucose,4784,O
loading,4784,O
.,4784,O
The,4785,O
docking,4785,O
data,4785,O
indicated,4785,O
that,4785,B-CHEMICAL
l-glutamine,4785,O
bind,4785,O
to,4785,O
the,4785,I-GENE-Y
GLP-1,4785,I-GENE-Y
receptor,4785,O
.,4785,O
l-glutamine,4786,O
decreased,4786,O
plasma,4786,O
glucose,4786,O
",",4786,O
increased,4786,O
plasma,4786,O
and,4786,O
pancreatic,4786,O
insulin,4786,O
",",4786,O
increased,4786,O
plasma,4786,O
and,4786,O
colonic,4786,O
active,4786,O
GLP-1,4786,O
(,4786,O
7-36,4786,O
),4786,I-CHEMICAL
amide,4786,O
secretion,4786,O
as,4786,O
well,4786,O
as,4786,O
decreased,4786,O
oxidative,4786,O
stress,4786,O
in,4786,I-CHEMICAL
streptozotocin-nicotinamide,4786,O
induced,4786,O
diabetic,4786,O
rats,4786,O
.,4786,O
ZEB2,4787,B-GENE-Y
zinc-finger,4787,B-CHEMICAL
missense,4787,O
mutations,4787,O
lead,4787,O
to,4787,O
hypomorphic,4787,O
alleles,4787,O
and,4787,O
a,4787,O
mild,4787,O
Mowat-Wilson,4787,O
syndrome,4787,O
.,4787,O
Mowat-Wilson,4788,O
syndrome,4788,O
(,4788,O
MWS,4788,O
),4788,O
is,4788,O
a,4788,O
severe,4788,O
intellectual,4788,O
disability,4788,O
(,4788,O
ID,4788,O
),4788,O
-distinctive,4788,O
facial,4788,O
gestalt-multiple,4788,O
congenital,4788,O
anomaly,4788,O
syndrome,4788,O
",",4788,O
commonly,4788,O
associating,4788,O
microcephaly,4788,O
",",4788,O
epilepsy,4788,O
",",4788,O
corpus,4788,O
callosum,4788,O
agenesis,4788,O
",",4788,O
conotruncal,4788,O
heart,4788,O
defects,4788,O
",",4788,O
urogenital,4788,O
malformations,4788,O
and,4788,O
Hirschsprung,4788,O
disease,4788,O
(,4788,O
HSCR,4788,O
),4788,O
.,4788,O
MWS,4789,O
is,4789,O
caused,4789,O
by,4789,O
de,4789,O
novo,4789,O
heterozygous,4789,O
mutations,4789,O
in,4789,O
the,4789,O
ZEB2,4789,B-GENE-Y
gene,4789,O
.,4789,O
The,4790,O
majority,4790,O
of,4790,O
mutations,4790,O
lead,4790,O
to,4790,O
haplo-insufficiency,4790,O
through,4790,O
premature,4790,O
stop,4790,O
codons,4790,O
or,4790,O
large,4790,O
gene,4790,O
deletions,4790,O
.,4790,O
Only,4791,O
three,4791,O
missense,4791,O
mutations,4791,O
have,4791,O
been,4791,O
reported,4791,O
so,4791,O
far,4791,O
;,4791,O
none,4791,O
of,4791,O
which,4791,O
resides,4791,O
in,4791,O
a,4791,O
known,4791,O
functional,4791,O
domain,4791,O
of,4791,O
ZEB2,4791,B-GENE-Y
.,4791,O
In,4792,O
this,4792,O
study,4792,O
",",4792,O
we,4792,O
report,4792,O
and,4792,O
analyze,4792,O
the,4792,O
functional,4792,O
consequences,4792,O
of,4792,O
three,4792,O
novel,4792,O
missense,4792,O
mutations,4792,O
",",4792,O
p.Tyr1055Cys,4792,B-GENE-N
",",4792,O
p.Ser1071Pro,4792,B-GENE-N
and,4792,O
p.His1045Arg,4792,B-GENE-N
",",4792,O
identified,4792,O
in,4792,O
the,4792,O
highly,4792,O
conserved,4792,O
C-zinc-finger,4792,B-GENE-N
(,4792,I-GENE-N
C-ZF,4792,I-GENE-N
),4792,I-GENE-N
domain,4792,I-GENE-N
of,4792,O
ZEB2,4792,B-GENE-Y
.,4792,O
Patients,4793,O
',4793,O
phenotype,4793,O
included,4793,O
the,4793,O
facial,4793,O
gestalt,4793,O
of,4793,O
MWS,4793,O
and,4793,O
moderate,4793,O
ID,4793,O
",",4793,O
but,4793,O
no,4793,O
microcephaly,4793,O
",",4793,O
heart,4793,O
defects,4793,O
or,4793,O
HSCR,4793,O
.,4793,O
In,4794,O
vitro,4794,O
studies,4794,O
showed,4794,O
that,4794,O
all,4794,O
the,4794,O
three,4794,O
mutations,4794,O
prevented,4794,O
binding,4794,O
and,4794,O
repression,4794,O
of,4794,O
the,4794,O
E-cadherin,4794,B-GENE-N
promoter,4794,I-GENE-N
",",4794,O
a,4794,O
characterized,4794,O
ZEB2,4794,B-GENE-Y
target,4794,O
gene,4794,O
.,4794,O
Taking,4795,O
advantage,4795,O
of,4795,O
the,4795,O
zebrafish,4795,O
morphant,4795,O
technology,4795,O
",",4795,O
we,4795,O
performed,4795,O
rescue,4795,O
experiments,4795,O
using,4795,O
wild-type,4795,O
(,4795,O
WT,4795,O
),4795,O
and,4795,O
mutant,4795,O
human,4795,B-GENE-Y
ZEB2,4795,I-GENE-Y
mRNAs,4795,O
.,4795,O
Variable,4796,O
",",4796,O
mutation-dependent,4796,O
",",4796,O
embryo,4796,O
rescue,4796,O
",",4796,O
correlating,4796,O
with,4796,O
the,4796,O
severity,4796,O
of,4796,O
patients,4796,O
',4796,O
phenotype,4796,O
",",4796,O
was,4796,O
observed,4796,O
.,4796,O
Our,4797,O
data,4797,O
provide,4797,O
evidence,4797,O
that,4797,O
these,4797,O
missense,4797,O
mutations,4797,O
cause,4797,O
a,4797,O
partial,4797,O
loss,4797,O
of,4797,O
function,4797,O
of,4797,O
ZEB2,4797,B-GENE-Y
",",4797,O
suggesting,4797,O
that,4797,O
its,4797,O
role,4797,O
is,4797,O
not,4797,O
restricted,4797,O
to,4797,O
repression,4797,O
of,4797,O
E-cadherin,4797,B-GENE-Y
.,4797,O
Functional,4798,O
domains,4798,O
other,4798,O
than,4798,O
C-ZF,4798,B-GENE-N
may,4798,O
play,4798,O
a,4798,O
role,4798,O
in,4798,O
early,4798,O
embryonic,4798,O
development,4798,O
.,4798,O
Finally,4799,O
",",4799,O
these,4799,O
findings,4799,O
broaden,4799,O
the,4799,O
clinical,4799,O
spectrum,4799,O
of,4799,O
ZEB2,4799,B-GENE-Y
mutations,4799,O
",",4799,O
indicating,4799,O
that,4799,O
MWS,4799,O
ought,4799,O
to,4799,O
be,4799,O
considered,4799,O
in,4799,O
patients,4799,O
with,4799,O
lesser,4799,O
degrees,4799,O
of,4799,O
ID,4799,O
and,4799,O
a,4799,O
suggestive,4799,O
facial,4799,O
gestalt,4799,O
",",4799,O
even,4799,O
in,4799,O
the,4799,O
absence,4799,O
of,4799,O
congenital,4799,O
malformation,4799,O
.,4799,O
Corticotropin,4800,B-GENE-Y
releasing,4800,I-GENE-Y
factor,4800,I-GENE-Y
and,4800,O
catecholamines,4800,B-CHEMICAL
enhance,4800,O
glutamatergic,4800,O
neurotransmission,4800,O
in,4800,O
the,4800,O
lateral,4800,O
subdivision,4800,O
of,4800,O
the,4800,O
central,4800,O
amygdala,4800,O
.,4800,O
Glutamatergic,4801,O
neurotransmission,4801,O
in,4801,O
the,4801,O
central,4801,O
nucleus,4801,O
of,4801,O
the,4801,O
amygdala,4801,O
(,4801,O
CeA,4801,O
),4801,O
plays,4801,O
an,4801,O
important,4801,O
role,4801,O
in,4801,O
many,4801,O
behaviors,4801,O
including,4801,O
anxiety,4801,O
",",4801,O
memory,4801,O
consolidation,4801,O
and,4801,O
cardiovascular,4801,O
responses,4801,O
.,4801,O
While,4802,O
these,4802,O
behaviors,4802,O
can,4802,O
be,4802,O
modulated,4802,O
by,4802,O
corticotropin,4802,B-GENE-Y
releasing,4802,I-GENE-Y
factor,4802,I-GENE-Y
(,4802,O
CRF,4802,B-GENE-Y
),4802,O
and,4802,O
catecholamine,4802,B-CHEMICAL
signaling,4802,O
",",4802,O
the,4802,O
mechanism,4802,O
(,4802,O
s,4802,O
),4802,O
by,4802,O
which,4802,O
these,4802,O
signals,4802,O
modify,4802,O
CeA,4802,O
glutamatergic,4802,O
neurotransmission,4802,O
remains,4802,O
unclear,4802,O
.,4802,O
Utilizing,4803,O
whole-cell,4803,O
patch-clamp,4803,O
electrophysiology,4803,O
recordings,4803,O
from,4803,O
neurons,4803,O
in,4803,O
the,4803,O
lateral,4803,O
subdivision,4803,O
of,4803,O
the,4803,O
CeA,4803,O
(,4803,O
CeAL,4803,O
),4803,O
",",4803,O
we,4803,O
show,4803,O
that,4803,O
CRF,4803,B-GENE-Y
",",4803,O
dopamine,4803,B-CHEMICAL
(,4803,I-GENE-N
DA,4803,I-GENE-N
),4803,I-GENE-N
and,4803,I-GENE-N
the,4803,I-GENE-N
-adrenergic,4803,I-GENE-N
receptor,4803,I-GENE-N
agonist,4803,O
isoproterenol,4803,B-CHEMICAL
(,4803,O
ISO,4803,B-CHEMICAL
),4803,O
all,4803,O
enhance,4803,O
the,4803,O
frequency,4803,O
of,4803,O
spontaneous,4803,O
excitatory,4803,O
postsynaptic,4803,O
currents,4803,O
(,4803,O
sEPSC,4803,O
),4803,O
without,4803,O
altering,4803,O
sEPSC,4803,O
kinetics,4803,O
",",4803,O
suggesting,4803,O
they,4803,O
increase,4803,O
presynaptic,4803,O
glutamate,4803,B-CHEMICAL
release,4803,O
.,4803,O
The,4804,O
effect,4804,O
of,4804,O
CRF,4804,B-GENE-Y
on,4804,O
sEPSCs,4804,O
was,4804,O
mediated,4804,O
by,4804,O
a,4804,O
combination,4804,O
of,4804,O
CRFR1,4804,B-GENE-Y
and,4804,O
CRFR2,4804,B-GENE-Y
receptors,4804,O
.,4804,O
While,4805,O
previous,4805,O
work,4805,O
from,4805,O
our,4805,O
lab,4805,O
suggests,4805,O
that,4805,O
CRFRs,4805,B-GENE-N
mediate,4805,O
the,4805,O
effect,4805,O
of,4805,O
catecholamines,4805,B-CHEMICAL
on,4805,O
excitatory,4805,O
transmission,4805,O
in,4805,O
other,4805,O
subregions,4805,O
of,4805,O
the,4805,O
extended,4805,O
amygdala,4805,O
",",4805,O
blockade,4805,O
of,4805,O
CRFRs,4805,B-GENE-N
in,4805,O
the,4805,O
CeAL,4805,O
failed,4805,O
to,4805,O
significantly,4805,O
alter,4805,O
effects,4805,O
of,4805,O
DA,4805,O
and,4805,O
ISO,4805,B-CHEMICAL
on,4805,O
glutamatergic,4805,O
transmission,4805,O
.,4805,O
These,4806,O
findings,4806,O
suggest,4806,O
that,4806,O
catecholamine,4806,B-CHEMICAL
and,4806,O
CRF,4806,B-GENE-Y
enhancement,4806,O
of,4806,O
glutamatergic,4806,O
transmission,4806,O
onto,4806,O
CeAL,4806,O
neurons,4806,O
occurs,4806,O
via,4806,O
distinct,4806,O
mechanisms,4806,O
.,4806,O
While,4807,O
CRF,4807,B-GENE-Y
increased,4807,O
spontaneous,4807,O
glutamate,4807,B-CHEMICAL
release,4807,O
in,4807,O
the,4807,O
CeAL,4807,O
",",4807,O
CRF,4807,B-GENE-Y
caused,4807,O
no,4807,O
significant,4807,O
changes,4807,O
to,4807,O
optogenetically,4807,O
evoked,4807,O
glutamate,4807,B-CHEMICAL
release,4807,O
in,4807,O
this,4807,O
region,4807,O
.,4807,O
The,4808,O
dissociable,4808,O
effects,4808,O
of,4808,O
CRF,4808,B-GENE-Y
on,4808,O
different,4808,O
types,4808,O
of,4808,O
glutamatergic,4808,O
neurotransmission,4808,O
suggest,4808,O
that,4808,O
CRF,4808,B-GENE-Y
may,4808,O
specifically,4808,O
regulate,4808,O
spontaneous,4808,O
excitatory,4808,O
transmission,4808,O
.,4808,O
Environmental,4809,O
stress,4809,O
",",4809,O
oxytocin,4809,B-GENE-Y
receptor,4809,I-GENE-Y
gene,4809,O
(,4809,O
OXTR,4809,B-GENE-Y
),4809,O
polymorphism,4809,O
",",4809,O
and,4809,O
mental,4809,O
health,4809,O
following,4809,O
collective,4809,O
stress,4809,O
.,4809,O
We,4810,O
examined,4810,O
whether,4810,O
the,4810,O
oxytocin,4810,B-GENE-Y
receptor,4810,I-GENE-Y
gene,4810,O
(,4810,O
OXTR,4810,B-GENE-Y
),4810,O
single,4810,O
nucleotide,4810,B-CHEMICAL
polymorphism,4810,O
(,4810,O
SNP,4810,O
),4810,O
rs53576,4810,O
genotype,4810,O
buffers,4810,O
the,4810,O
combined,4810,O
impact,4810,O
of,4810,O
negative,4810,O
social,4810,O
environments,4810,O
(,4810,O
e.g.,4810,O
",",4810,O
interpersonal,4810,O
conflict/constraint,4810,O
),4810,O
and,4810,O
economic,4810,O
stress,4810,O
on,4810,O
post-traumatic,4810,O
stress,4810,O
(,4810,O
PTS,4810,O
),4810,O
symptoms,4810,O
and,4810,O
impaired,4810,O
daily,4810,O
functioning,4810,O
following,4810,O
collective,4810,O
stress,4810,O
(,4810,O
September,4810,O
11th,4810,O
terrorist,4810,O
attacks,4810,O
),4810,O
.,4810,O
Saliva,4811,O
was,4811,O
collected,4811,O
by,4811,O
mail,4811,O
and,4811,O
used,4811,O
to,4811,O
genotype,4811,O
704,4811,O
respondents,4811,O
.,4811,O
Participants,4812,O
completed,4812,O
Web-based,4812,O
assessments,4812,O
of,4812,O
pre-9/11,4812,O
mental,4812,O
health,4812,O
",",4812,O
acute,4812,O
stress,4812,O
9-23days,4812,O
after,4812,O
9/11,4812,O
",",4812,O
the,4812,O
quality,4812,O
of,4812,O
social,4812,O
environments,4812,O
1year,4812,O
post-9/11,4812,O
",",4812,O
economic,4812,O
stress,4812,O
18months,4812,O
post-9/11,4812,O
",",4812,O
and,4812,O
PTS,4812,O
symptoms,4812,O
and,4812,O
impaired,4812,O
functioning,4812,O
2,4812,O
and,4812,O
3years,4812,O
post-9/11,4812,O
.,4812,O
Interactions,4813,O
between,4813,O
negative,4813,O
social,4813,O
environments,4813,O
and,4813,O
economic,4813,O
stress,4813,O
were,4813,O
examined,4813,O
separately,4813,O
based,4813,O
on,4813,O
OXTR,4813,B-GENE-Y
rs53576,4813,O
genotype,4813,O
(,4813,O
GG,4813,O
vs.,4813,O
any,4813,O
A,4813,O
allele,4813,O
),4813,O
.,4813,O
For,4814,O
individuals,4814,O
with,4814,O
an,4814,O
A,4814,O
allele,4814,O
",",4814,O
a,4814,O
negative,4814,O
social,4814,O
environment,4814,O
significantly,4814,O
increased,4814,O
PTS,4814,O
symptoms,4814,O
without,4814,O
regard,4814,O
to,4814,O
the,4814,O
level,4814,O
of,4814,O
economic,4814,O
stress,4814,O
experienced,4814,O
.,4814,O
However,4815,O
",",4815,O
for,4815,O
respondents,4815,O
with,4815,O
a,4815,O
GG,4815,O
genotype,4815,O
",",4815,O
negative,4815,O
social,4815,O
environments,4815,O
predicted,4815,O
elevated,4815,O
PTS,4815,O
symptoms,4815,O
only,4815,O
for,4815,O
those,4815,O
also,4815,O
experiencing,4815,O
high,4815,O
economic,4815,O
stress,4815,O
.,4815,O
Gender,4816,O
moderated,4816,O
associations,4816,O
between,4816,O
negative,4816,O
social,4816,O
environments,4816,O
",",4816,O
economic,4816,O
stress,4816,O
",",4816,O
and,4816,O
impaired,4816,O
functioning,4816,O
.,4816,O
The,4817,O
functioning,4817,O
of,4817,O
females,4817,O
was,4817,O
most,4817,O
affected,4817,O
by,4817,O
negative,4817,O
social,4817,O
environments,4817,O
regardless,4817,O
of,4817,O
genotype,4817,O
and,4817,O
economic,4817,O
stress,4817,O
",",4817,O
whereas,4817,O
the,4817,O
functioning,4817,O
of,4817,O
males,4817,O
was,4817,O
differentially,4817,O
susceptible,4817,O
to,4817,O
economic,4817,O
stress,4817,O
depending,4817,O
on,4817,O
OXTR,4817,B-GENE-Y
genotype,4817,O
and,4817,O
negative,4817,O
social,4817,O
environments,4817,O
.,4817,O
These,4818,O
findings,4818,O
suggest,4818,O
that,4818,O
it,4818,O
is,4818,O
important,4818,O
to,4818,O
consider,4818,O
the,4818,O
combined,4818,O
impact,4818,O
of,4818,O
gender,4818,O
and,4818,O
ongoing,4818,O
stress,4818,O
in,4818,O
different,4818,O
domains,4818,O
as,4818,O
moderators,4818,O
of,4818,O
genetic,4818,O
vulnerability,4818,O
following,4818,O
collective,4818,O
stress,4818,O
.,4818,O
Identification,4819,O
of,4819,O
a,4819,O
SIRT1,4819,B-GENE-Y
mutation,4819,O
in,4819,O
a,4819,O
family,4819,O
with,4819,O
type,4819,O
1,4819,O
diabetes,4819,O
.,4819,O
Type,4820,O
1,4820,O
diabetes,4820,O
is,4820,O
caused,4820,O
by,4820,O
autoimmune-mediated,4820,O
,4820,O
cell,4820,O
destruction,4820,O
leading,4820,O
to,4820,O
insulin,4820,B-GENE-Y
deficiency,4820,O
.,4820,O
The,4821,O
histone,4821,B-GENE-N
deacetylase,4821,I-GENE-N
SIRT1,4821,B-GENE-Y
plays,4821,O
an,4821,O
essential,4821,O
role,4821,O
in,4821,O
modulating,4821,O
several,4821,O
age-related,4821,O
diseases,4821,O
.,4821,O
Here,4822,O
we,4822,O
describe,4822,O
a,4822,O
family,4822,O
carrying,4822,O
a,4822,O
mutation,4822,O
in,4822,O
the,4822,O
SIRT1,4822,B-GENE-Y
gene,4822,O
",",4822,O
in,4822,O
which,4822,O
all,4822,O
five,4822,O
affected,4822,O
members,4822,O
developed,4822,O
an,4822,O
autoimmune,4822,O
disorder,4822,O
:,4822,O
four,4822,O
developed,4822,O
type,4822,O
1,4822,O
diabetes,4822,O
",",4822,O
and,4822,O
one,4822,O
developed,4822,O
ulcerative,4822,O
colitis,4822,O
.,4822,O
Initially,4823,O
",",4823,O
a,4823,O
26-year-old,4823,O
man,4823,O
was,4823,O
diagnosed,4823,O
with,4823,O
the,4823,O
typical,4823,O
features,4823,O
of,4823,O
type,4823,O
1,4823,O
diabetes,4823,O
",",4823,O
including,4823,O
lean,4823,O
body,4823,O
mass,4823,O
",",4823,O
autoantibodies,4823,O
",",4823,O
T,4823,O
cell,4823,O
reactivity,4823,O
to,4823,O
,4823,O
cell,4823,O
antigens,4823,O
",",4823,O
and,4823,O
a,4823,O
rapid,4823,O
dependence,4823,O
on,4823,O
insulin,4823,B-GENE-Y
.,4823,O
Direct,4824,O
and,4824,O
exome,4824,O
sequencing,4824,O
identified,4824,O
the,4824,O
presence,4824,O
of,4824,O
a,4824,O
T-to-C,4824,O
exchange,4824,O
in,4824,O
exon,4824,O
1,4824,O
of,4824,O
SIRT1,4824,B-GENE-Y
",",4824,O
corresponding,4824,O
to,4824,O
a,4824,O
leucine-to-proline,4824,B-GENE-N
mutation,4824,I-GENE-N
at,4824,I-GENE-N
residue,4824,I-GENE-N
107,4824,I-GENE-N
.,4824,O
Expression,4825,O
of,4825,O
SIRT1-L107P,4825,B-GENE-Y
in,4825,O
insulin-producing,4825,B-GENE-Y
cells,4825,O
resulted,4825,O
in,4825,O
overproduction,4825,O
of,4825,O
nitric,4825,B-CHEMICAL
oxide,4825,I-CHEMICAL
",",4825,O
cytokines,4825,B-GENE-N
",",4825,O
and,4825,O
chemokines,4825,B-GENE-N
.,4825,O
These,4826,O
observations,4826,O
identify,4826,O
a,4826,O
role,4826,O
for,4826,O
SIRT1,4826,B-GENE-Y
in,4826,O
human,4826,O
autoimmunity,4826,O
and,4826,O
unveil,4826,O
a,4826,O
monogenic,4826,O
form,4826,O
of,4826,O
type,4826,O
1,4826,O
diabetes,4826,O
.,4826,O
Melanoma,4827,O
targeting,4827,O
property,4827,O
of,4827,O
a,4827,O
Lu-177-labeled,4827,B-CHEMICAL
lactam,4827,B-CHEMICAL
bridge-cyclized,4827,O
alpha-MSH,4827,B-GENE-Y
peptide,4827,O
.,4827,O
The,4828,O
purpose,4828,O
of,4828,O
this,4828,O
study,4828,O
was,4828,O
to,4828,O
determine,4828,O
the,4828,O
melanoma,4828,O
targeting,4828,O
property,4828,O
of,4828,O
(,4828,B-CHEMICAL
177,4828,I-CHEMICAL
),4828,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4828,I-CHEMICAL
in,4828,O
B16/F1,4828,O
melanoma-bearing,4828,O
C57,4828,O
mice,4828,O
.,4828,O
(,4829,B-CHEMICAL
177,4829,I-CHEMICAL
),4829,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4829,I-CHEMICAL
exhibited,4829,O
high,4829,O
receptor-mediated,4829,O
melanoma,4829,O
uptake,4829,O
and,4829,O
fast,4829,O
urinary,4829,O
clearance,4829,O
.,4829,O
The,4830,O
tumor,4830,O
uptake,4830,O
of,4830,O
(,4830,B-CHEMICAL
177,4830,I-CHEMICAL
),4830,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4830,I-CHEMICAL
was,4830,O
20.25,4830,O
,4830,O
4.59,4830,O
and,4830,O
21.63,4830,O
,4830,O
6.27,4830,O
%,4830,O
ID/g,4830,O
at,4830,O
0.5,4830,O
and,4830,O
2h,4830,O
post-injection,4830,O
",",4830,O
respectively,4830,O
.,4830,O
Approximately,4831,O
83,4831,O
%,4831,O
of,4831,O
injected,4831,O
dose,4831,O
cleared,4831,O
out,4831,O
the,4831,O
body,4831,O
via,4831,O
urinary,4831,O
system,4831,O
at,4831,O
2h,4831,O
post-injection,4831,O
.,4831,O
(,4832,B-CHEMICAL
177,4832,I-CHEMICAL
),4832,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4832,I-CHEMICAL
showed,4832,O
high,4832,O
tumor,4832,O
to,4832,O
normal,4832,O
organ,4832,O
uptake,4832,O
ratios,4832,O
except,4832,O
for,4832,O
the,4832,O
kidneys,4832,O
.,4832,O
The,4833,O
tumor/kidney,4833,O
uptake,4833,O
ratios,4833,O
of,4833,O
(,4833,B-CHEMICAL
177,4833,I-CHEMICAL
),4833,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4833,I-CHEMICAL
were,4833,O
2.76,4833,O
and,4833,O
1.74,4833,O
at,4833,O
2,4833,O
and,4833,O
24h,4833,O
post-injection,4833,O
.,4833,O
The,4834,O
melanoma,4834,O
lesions,4834,O
were,4834,O
clearly,4834,O
visualized,4834,O
by,4834,O
SPECT/CT,4834,O
using,4834,O
(,4834,B-CHEMICAL
177,4834,I-CHEMICAL
),4834,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4834,I-CHEMICAL
as,4834,O
an,4834,O
imaging,4834,O
probe,4834,O
at,4834,O
2h,4834,O
post-injection,4834,O
.,4834,O
Overall,4835,O
",",4835,O
high,4835,O
melanoma,4835,O
uptake,4835,O
coupled,4835,O
with,4835,O
fast,4835,O
urinary,4835,O
clearance,4835,O
of,4835,O
(,4835,B-CHEMICAL
177,4835,I-CHEMICAL
),4835,I-CHEMICAL
Lu-DOTA-GGNle-CycMSHhex,4835,I-CHEMICAL
underscored,4835,O
its,4835,O
potential,4835,O
for,4835,O
melanoma,4835,O
treatment,4835,O
in,4835,O
the,4835,O
future,4835,O
.,4835,O
Hinokitiol,4836,B-CHEMICAL
inhibits,4836,O
platelet,4836,O
activation,4836,O
ex,4836,O
vivo,4836,O
and,4836,O
thrombus,4836,O
formation,4836,O
in,4836,O
vivo,4836,O
.,4836,O
Hinokitiol,4837,B-CHEMICAL
is,4837,O
a,4837,O
tropolone-related,4837,O
bioactive,4837,O
compound,4837,O
that,4837,O
has,4837,O
been,4837,O
used,4837,O
in,4837,O
hair,4837,O
tonics,4837,O
",",4837,O
cosmetics,4837,O
",",4837,O
and,4837,O
food,4837,O
as,4837,O
an,4837,O
antimicrobial,4837,O
agent,4837,O
.,4837,O
Recently,4838,O
",",4838,O
hinokitiol,4838,B-CHEMICAL
has,4838,O
attracted,4838,O
considerable,4838,O
interest,4838,O
because,4838,O
of,4838,O
its,4838,O
anticancer,4838,O
activities,4838,O
.,4838,O
Platelet,4839,O
activation,4839,O
plays,4839,O
a,4839,O
crucial,4839,O
role,4839,O
in,4839,O
atherothrombotic,4839,O
processes,4839,O
.,4839,O
We,4840,O
examined,4840,O
the,4840,O
effects,4840,O
of,4840,O
hinokitiol,4840,B-CHEMICAL
treatment,4840,O
on,4840,O
platelet,4840,O
activation,4840,O
using,4840,O
human,4840,O
platelets,4840,O
.,4840,O
In,4841,O
the,4841,O
present,4841,O
study,4841,O
",",4841,O
hinokitiol,4841,B-CHEMICAL
(,4841,O
1,4841,O
and,4841,O
2M,4841,O
),4841,O
inhibited,4841,O
the,4841,O
collagen-induced,4841,B-GENE-N
aggregation,4841,O
of,4841,O
human,4841,O
platelets,4841,O
",",4841,O
but,4841,O
did,4841,O
not,4841,O
inhibit,4841,O
the,4841,O
activation,4841,O
of,4841,O
platelets,4841,O
by,4841,O
other,4841,O
agonists,4841,O
",",4841,O
including,4841,O
thrombin,4841,B-GENE-Y
",",4841,O
arachidonic,4841,B-CHEMICAL
acid,4841,I-CHEMICAL
",",4841,O
and,4841,O
ADP,4841,B-CHEMICAL
.,4841,O
Hinokitiol,4842,B-CHEMICAL
inhibited,4842,O
the,4842,O
phosphorylation,4842,O
of,4842,O
phospholipase,4842,B-GENE-Y
C,4842,I-GENE-Y
(,4842,I-GENE-Y
PLC,4842,I-GENE-Y
),4842,I-GENE-Y
2,4842,I-GENE-Y
",",4842,O
protein,4842,B-GENE-N
kinase,4842,I-GENE-N
C,4842,I-GENE-N
(,4842,O
PKC,4842,B-GENE-N
),4842,O
",",4842,O
mitogen-activated,4842,B-GENE-N
protein,4842,I-GENE-N
kinases,4842,I-GENE-N
(,4842,O
MAPKs,4842,B-GENE-N
),4842,O
",",4842,O
and,4842,O
Akt,4842,B-GENE-N
in,4842,O
collagen-activated,4842,B-GENE-N
human,4842,O
platelets,4842,O
",",4842,O
and,4842,O
significantly,4842,O
reduced,4842,O
intracellular,4842,O
calcium,4842,B-CHEMICAL
mobilization,4842,O
and,4842,O
hydroxyl,4842,B-CHEMICAL
radical,4842,O
(,4842,O
OH,4842,B-CHEMICAL
),4842,O
formation,4842,O
.,4842,O
Hinokitiol,4843,B-CHEMICAL
also,4843,O
reduced,4843,O
the,4843,O
PKC,4843,B-GENE-N
activation,4843,O
and,4843,O
platelet,4843,O
aggregation,4843,O
stimulated,4843,O
by,4843,O
PDBu,4843,O
.,4843,O
In,4844,O
addition,4844,O
",",4844,O
hinokitiol,4844,B-CHEMICAL
significantly,4844,O
prolonged,4844,O
thrombogenesis,4844,O
in,4844,O
mice,4844,O
.,4844,O
Hinokitiol,4845,B-CHEMICAL
did,4845,O
not,4845,O
influence,4845,O
the,4845,O
binding,4845,O
of,4845,O
a,4845,O
fluorescent,4845,O
triflavin,4845,O
probe,4845,O
to,4845,O
the,4845,O
IIb3,4845,B-GENE-Y
integrin,4845,I-GENE-Y
on,4845,O
platelet,4845,O
membrane,4845,O
",",4845,O
and,4845,O
neither,4845,O
ODQ,4845,B-CHEMICAL
nor,4845,O
SQ22536,4845,B-CHEMICAL
significantly,4845,O
reversed,4845,O
the,4845,O
hinokitiol-mediated,4845,B-CHEMICAL
inhibition,4845,O
of,4845,O
platelet,4845,O
aggregation,4845,O
.,4845,O
In,4846,O
conclusion,4846,O
",",4846,O
hinokitiol,4846,B-CHEMICAL
may,4846,O
inhibit,4846,O
platelet,4846,O
activation,4846,O
by,4846,O
inhibiting,4846,O
the,4846,O
PLC2-PKC,4846,B-GENE-Y
cascade,4846,O
and,4846,O
hydroxyl,4846,B-CHEMICAL
radical,4846,O
formation,4846,O
",",4846,O
followed,4846,O
by,4846,O
suppressing,4846,O
the,4846,O
activation,4846,O
of,4846,O
MAPKs,4846,B-GENE-N
and,4846,O
Akt,4846,B-GENE-N
.,4846,O
Our,4847,O
study,4847,O
suggests,4847,O
that,4847,O
hinokitiol,4847,B-CHEMICAL
may,4847,O
represent,4847,O
a,4847,O
potential,4847,O
therapeutic,4847,O
agent,4847,O
for,4847,O
the,4847,O
prevention,4847,O
or,4847,O
treatment,4847,O
of,4847,O
thromboembolic,4847,O
disorders,4847,O
.,4847,O
Time-dependent,4848,O
effects,4848,O
of,4848,O
corticosterone,4848,B-CHEMICAL
on,4848,O
reward-based,4848,O
decision-making,4848,O
in,4848,O
a,4848,O
rodent,4848,O
model,4848,O
of,4848,O
the,4848,O
Iowa,4848,O
Gambling,4848,O
Task,4848,O
.,4848,O
Corticosteroid,4849,O
hormones,4849,O
",",4849,O
released,4849,O
after,4849,O
stress,4849,O
",",4849,O
are,4849,O
known,4849,O
to,4849,O
change,4849,O
neuronal,4849,O
activity,4849,O
in,4849,O
two,4849,O
time-domains,4849,O
:,4849,O
within,4849,O
minutes,4849,O
via,4849,O
non-genomic,4849,O
pathways,4849,O
and,4849,O
with,4849,O
a,4849,O
delay,4849,O
of,4849,O
>,4849,O
1,4849,O
h,4849,O
through,4849,O
pathways,4849,O
involving,4849,O
transcriptional,4849,O
regulation,4849,O
.,4849,O
Recent,4850,O
evidence,4850,O
in,4850,O
rodents,4850,O
and,4850,O
humans,4850,O
indicates,4850,O
that,4850,O
these,4850,O
two,4850,O
modes,4850,O
of,4850,O
corticosteroid,4850,O
action,4850,O
differently,4850,O
affect,4850,O
cognitive,4850,O
tasks,4850,O
.,4850,O
Here,4851,O
",",4851,O
we,4851,O
investigated,4851,O
whether,4851,O
reward-based,4851,O
decision-making,4851,O
",",4851,O
in,4851,O
a,4851,O
rat,4851,O
model,4851,O
of,4851,O
the,4851,O
Iowa,4851,O
Gambling,4851,O
Task,4851,O
(,4851,O
rIGT,4851,O
),4851,O
",",4851,O
is,4851,O
also,4851,O
differently,4851,O
altered,4851,O
by,4851,O
rapid,4851,O
versus,4851,O
delayed,4851,O
actions,4851,O
of,4851,O
corticosterone,4851,B-CHEMICAL
.,4851,O
We,4852,O
targeted,4852,O
the,4852,O
rapid,4852,O
and,4852,O
delayed,4852,O
time,4852,O
domain,4852,O
by,4852,O
injecting,4852,O
corticosterone,4852,B-CHEMICAL
(,4852,O
CORT,4852,B-CHEMICAL
",",4852,O
1,4852,O
mg/kg,4852,O
",",4852,O
s.c.,4852,O
),4852,O
at,4852,O
30,4852,O
min,4852,O
(,4852,O
rapid,4852,O
),4852,O
or,4852,O
180,4852,O
min,4852,O
(,4852,O
delayed,4852,O
),4852,O
respectively,4852,O
prior,4852,O
to,4852,O
behavioural,4852,O
testing,4852,O
",",4852,O
during,4852,O
the,4852,O
final,4852,O
3,4852,O
days,4852,O
of,4852,O
the,4852,O
behavioural,4852,O
paradigm,4852,O
.,4852,O
In,4853,O
saline,4853,O
treated,4853,O
rats,4853,O
",",4853,O
the,4853,O
number,4853,O
of,4853,O
visits,4853,O
to,4853,O
the,4853,O
disadvantageous,4853,O
arm,4853,O
decreased,4853,O
over,4853,O
trial,4853,O
blocks,4853,O
",",4853,O
whilst,4853,O
this,4853,O
was,4853,O
attenuated,4853,O
when,4853,O
CORT,4853,B-CHEMICAL
was,4853,O
administered,4853,O
30,4853,O
min,4853,O
before,4853,O
testing,4853,O
.,4853,O
This,4854,O
attenuation,4854,O
was,4854,O
associated,4854,O
with,4854,O
a,4854,O
significantly,4854,O
increased,4854,O
c-Fos,4854,B-GENE-Y
expression,4854,O
in,4854,O
the,4854,O
lateral,4854,O
orbitofrontal,4854,O
cortex,4854,O
and,4854,O
insular,4854,O
cortex,4854,O
",",4854,O
and,4854,O
a,4854,O
trend,4854,O
for,4854,O
an,4854,O
increase,4854,O
in,4854,O
the,4854,O
infralimbic,4854,O
cortex,4854,O
.,4854,O
The,4855,O
rapid,4855,O
corticosteroid,4855,O
effect,4855,O
contrasted,4855,O
with,4855,O
treatment,4855,O
180,4855,O
min,4855,O
before,4855,O
testing,4855,O
",",4855,O
where,4855,O
the,4855,O
number,4855,O
of,4855,O
visits,4855,O
to,4855,O
the,4855,O
disadvantageous,4855,O
arm,4855,O
as,4855,O
well,4855,O
as,4855,O
c-Fos,4855,B-GENE-Y
labelling,4855,O
was,4855,O
not,4855,O
affected,4855,O
.,4855,O
These,4856,O
findings,4856,O
indicate,4856,O
that,4856,O
rapid,4856,O
corticosteroid,4856,O
actions,4856,O
impair,4856,O
reward-based,4856,O
decision-making,4856,O
.,4856,O
Novel,4857,O
5-,4857,B-CHEMICAL
(,4857,I-CHEMICAL
benzyloxy,4857,I-CHEMICAL
),4857,I-CHEMICAL
pyridin-2,4857,I-CHEMICAL
(,4857,I-CHEMICAL
1H,4857,I-CHEMICAL
),4857,I-CHEMICAL
-one,4857,I-CHEMICAL
derivatives,4857,O
as,4857,O
potent,4857,O
c-Met,4857,B-GENE-Y
inhibitors,4857,O
.,4857,O
A,4858,O
series,4858,O
of,4858,O
novel,4858,O
5-,4858,B-CHEMICAL
(,4858,I-CHEMICAL
benzyloxy,4858,I-CHEMICAL
),4858,I-CHEMICAL
pyridin-2,4858,I-CHEMICAL
(,4858,I-CHEMICAL
1H,4858,I-CHEMICAL
),4858,I-CHEMICAL
-ones,4858,I-CHEMICAL
were,4858,O
designed,4858,O
",",4858,O
synthesized,4858,O
and,4858,O
biologically,4858,O
evaluated,4858,O
for,4858,O
c-Met,4858,B-GENE-Y
inhibition,4858,O
.,4858,O
Various,4859,O
amides,4859,B-CHEMICAL
and,4859,O
benzoimidazoles,4859,B-CHEMICAL
at,4859,O
C-3,4859,O
position,4859,O
were,4859,O
investigated,4859,O
.,4859,O
A,4860,O
potent,4860,O
compound,4860,O
12b,4860,O
with,4860,O
a,4860,O
c-Met,4860,B-GENE-Y
IC50,4860,O
of,4860,O
12nM,4860,O
was,4860,O
identified,4860,O
.,4860,O
This,4861,O
compound,4861,O
exhibited,4861,O
potent,4861,O
inhibition,4861,O
of,4861,O
EBC-1,4861,O
cell,4861,O
associated,4861,O
with,4861,O
c-Met,4861,B-GENE-Y
constitutive,4861,O
activation,4861,O
and,4861,O
showed,4861,O
high,4861,O
selectivity,4861,O
for,4861,O
c-Met,4861,B-GENE-Y
than,4861,O
other,4861,O
tested,4861,O
11,4861,O
kinases,4861,B-GENE-N
.,4861,O
The,4862,O
binding,4862,O
model,4862,O
12b,4862,O
with,4862,O
c-Met,4862,B-GENE-Y
was,4862,O
disclosed,4862,O
by,4862,O
docking,4862,O
analysis,4862,O
.,4862,O
Design,4863,O
",",4863,O
Synthesis,4863,O
",",4863,O
and,4863,O
Pharmacological,4863,O
Characterization,4863,O
of,4863,O
Novel,4863,O
Endomorphin-1,4863,B-CHEMICAL
Analogues,4863,O
as,4863,O
Extremely,4863,O
Potent,4863,O
-Opioid,4863,B-GENE-Y
Agonists,4863,O
.,4863,O
Recently,4864,O
we,4864,O
reported,4864,O
the,4864,O
synthesis,4864,O
and,4864,O
structure-activity,4864,O
study,4864,O
of,4864,O
endomorphin-1,4864,B-CHEMICAL
(,4864,O
EM-1,4864,B-CHEMICAL
),4864,O
analogues,4864,O
containing,4864,O
novel,4864,O
",",4864,O
unnatural,4864,O
-methylene--aminopropanoic,4864,B-CHEMICAL
acids,4864,I-CHEMICAL
(,4864,O
Map,4864,B-CHEMICAL
),4864,O
.,4864,O
In,4865,O
the,4865,O
present,4865,O
study,4865,O
",",4865,O
we,4865,O
describe,4865,O
new,4865,O
EM-1,4865,B-CHEMICAL
analogues,4865,O
containing,4865,O
Dmt,4865,B-CHEMICAL
(,4865,O
1,4865,O
),4865,O
",",4865,O
(,4865,B-CHEMICAL
R/S,4865,I-CHEMICAL
),4865,I-CHEMICAL
-Pro,4865,I-CHEMICAL
(,4865,O
2,4865,O
),4865,O
",",4865,O
and,4865,O
(,4865,B-CHEMICAL
ph,4865,I-CHEMICAL
),4865,I-CHEMICAL
Map,4865,I-CHEMICAL
(,4865,O
4,4865,O
),4865,O
/,4865,O
(,4865,B-CHEMICAL
2-furyl,4865,I-CHEMICAL
),4865,I-CHEMICAL
Map,4865,I-CHEMICAL
(,4865,O
4,4865,O
),4865,O
.,4865,O
All,4866,O
of,4866,O
the,4866,O
analogues,4866,O
showed,4866,O
a,4866,O
high,4866,O
affinity,4866,O
for,4866,O
the,4866,O
-opioid,4866,B-GENE-Y
receptor,4866,I-GENE-Y
(,4866,O
MOR,4866,B-GENE-Y
),4866,O
and,4866,O
increased,4866,O
stability,4866,O
in,4866,O
mouse,4866,O
brain,4866,O
homogenates,4866,O
.,4866,O
Of,4867,O
the,4867,O
new,4867,O
compounds,4867,O
",",4867,O
Dmt,4867,B-CHEMICAL
(,4867,O
1,4867,O
),4867,O
-,4867,O
(,4867,B-CHEMICAL
R,4867,I-CHEMICAL
),4867,I-CHEMICAL
-Pro,4867,I-CHEMICAL
(,4867,O
2,4867,O
),4867,O
-Trp,4867,O
(,4867,O
3,4867,O
),4867,O
-,4867,O
(,4867,B-CHEMICAL
2-furyl,4867,I-CHEMICAL
),4867,I-CHEMICAL
Map,4867,I-CHEMICAL
(,4867,O
4,4867,O
),4867,O
(,4867,O
analogue,4867,O
12,4867,O
),4867,O
displayed,4867,O
the,4867,O
highest,4867,O
affinity,4867,O
toward,4867,O
MOR,4867,B-GENE-Y
",",4867,O
in,4867,O
the,4867,O
picomolar,4867,O
range,4867,O
(,4867,O
Ki,4867,O
(,4867,O
,4867,O
),4867,O
=,4867,O
3.72,4867,O
pM,4867,O
),4867,O
.,4867,O
Forskolin-induced,4868,B-CHEMICAL
cAMP,4868,B-CHEMICAL
accumulation,4868,O
assays,4868,O
indicated,4868,O
that,4868,O
this,4868,O
analogue,4868,O
displayed,4868,O
an,4868,O
extremely,4868,O
high,4868,O
agonistic,4868,O
potency,4868,O
",",4868,O
in,4868,O
the,4868,O
subpicomolar,4868,O
range,4868,O
(,4868,O
EC50,4868,O
=,4868,O
0.0421,4868,O
pM,4868,O
",",4868,O
Emax,4868,O
=,4868,O
99.5,4868,O
%,4868,O
),4868,O
.,4868,O
This,4869,O
compound,4869,O
also,4869,O
displayed,4869,O
stronger,4869,O
in,4869,O
vivo,4869,O
antinociceptive,4869,O
activity,4869,O
after,4869,O
iv,4869,O
administration,4869,O
when,4869,O
compared,4869,O
to,4869,O
morphine,4869,B-CHEMICAL
in,4869,O
the,4869,O
tail-flick,4869,O
test,4869,O
",",4869,O
which,4869,O
indicates,4869,O
that,4869,O
this,4869,O
analogue,4869,O
was,4869,O
able,4869,O
to,4869,O
cross,4869,O
the,4869,O
blood-brain,4869,O
barrier,4869,O
.,4869,O
Age-Related,4870,O
Macular,4870,O
Degeneration-Associated,4870,O
Silent,4870,O
Polymorphisms,4870,O
in,4870,O
HtrA1,4870,B-GENE-Y
Impair,4870,O
Its,4870,O
Ability,4870,O
To,4870,O
Antagonize,4870,O
Insulin-Like,4870,B-GENE-Y
Growth,4870,I-GENE-Y
Factor,4870,I-GENE-Y
1,4870,I-GENE-Y
.,4870,O
Synonymous,4871,O
single,4871,O
nucleotide,4871,O
polymorphisms,4871,O
(,4871,O
SNPs,4871,O
),4871,O
within,4871,O
a,4871,O
transcript,4871,O
's,4871,O
coding,4871,O
region,4871,O
produce,4871,O
no,4871,O
change,4871,O
in,4871,O
the,4871,O
amino,4871,B-CHEMICAL
acid,4871,I-CHEMICAL
sequence,4871,O
of,4871,O
the,4871,O
protein,4871,O
product,4871,O
and,4871,O
are,4871,O
therefore,4871,O
intuitively,4871,O
assumed,4871,O
to,4871,O
have,4871,O
a,4871,O
neutral,4871,O
effect,4871,O
on,4871,O
protein,4871,O
function,4871,O
.,4871,O
We,4872,O
report,4872,O
that,4872,O
two,4872,O
common,4872,O
variants,4872,O
of,4872,O
high-temperature,4872,B-GENE-Y
requirement,4872,I-GENE-Y
A1,4872,I-GENE-Y
(,4872,O
HTRA1,4872,B-GENE-Y
),4872,O
that,4872,O
increase,4872,O
the,4872,O
inherited,4872,O
risk,4872,O
of,4872,O
neovascular,4872,O
age-related,4872,O
macular,4872,O
degeneration,4872,O
(,4872,O
NvAMD,4872,O
),4872,O
harbor,4872,O
synonymous,4872,O
SNPs,4872,O
within,4872,O
exon,4872,O
1,4872,O
of,4872,O
HTRA1,4872,B-GENE-Y
that,4872,O
convert,4872,O
common,4872,O
codons,4872,O
for,4872,O
Ala34,4872,B-CHEMICAL
and,4872,O
Gly36,4872,B-CHEMICAL
to,4872,O
less,4872,O
frequently,4872,O
used,4872,O
codons,4872,O
.,4872,O
The,4873,O
frequent-to-rare,4873,O
codon,4873,O
conversion,4873,O
reduced,4873,O
the,4873,O
mRNA,4873,O
translation,4873,O
rate,4873,O
and,4873,O
appeared,4873,O
to,4873,O
compromise,4873,O
HtrA1,4873,B-GENE-Y
's,4873,I-GENE-Y
conformation,4873,O
and,4873,O
function,4873,O
.,4873,O
The,4874,O
protein,4874,O
product,4874,O
generated,4874,O
from,4874,O
the,4874,O
SNP-containing,4874,O
cDNA,4874,O
displayed,4874,O
enhanced,4874,O
susceptibility,4874,O
to,4874,O
proteolysis,4874,O
and,4874,O
a,4874,O
reduced,4874,O
affinity,4874,O
for,4874,O
an,4874,O
anti-HtrA1,4874,O
antibody,4874,O
.,4874,O
The,4875,O
NvAMD-associated,4875,O
synonymous,4875,O
polymorphisms,4875,O
lie,4875,O
within,4875,O
HtrA1,4875,B-GENE-N
's,4875,I-GENE-N
putative,4875,I-GENE-N
insulin-like,4875,I-GENE-N
growth,4875,I-GENE-N
factor,4875,I-GENE-N
1,4875,I-GENE-N
(,4875,I-GENE-N
IGF-1,4875,I-GENE-N
),4875,I-GENE-N
binding,4875,I-GENE-N
domain,4875,I-GENE-N
.,4875,O
They,4876,O
reduced,4876,O
HtrA1,4876,B-GENE-Y
's,4876,I-GENE-Y
abilities,4876,O
to,4876,O
associate,4876,O
with,4876,O
IGF-1,4876,B-GENE-Y
and,4876,O
to,4876,O
ameliorate,4876,O
IGF-1-stimulated,4876,B-GENE-Y
signaling,4876,O
events,4876,O
and,4876,O
cellular,4876,O
responses,4876,O
.,4876,O
These,4877,O
observations,4877,O
highlight,4877,O
the,4877,O
relevance,4877,O
of,4877,O
synonymous,4877,O
codon,4877,O
usage,4877,O
to,4877,O
protein,4877,O
function,4877,O
and,4877,O
implicate,4877,O
homeostatic,4877,O
protein,4877,O
quality,4877,O
control,4877,O
mechanisms,4877,O
that,4877,O
may,4877,O
go,4877,O
awry,4877,O
in,4877,O
NvAMD,4877,O
.,4877,O
Therapeutic,4878,O
effectiveness,4878,O
of,4878,O
botulinum,4878,B-GENE-Y
neurotoxin,4878,I-GENE-Y
A,4878,I-GENE-Y
:,4878,O
Potent,4878,O
blockade,4878,O
of,4878,O
autonomic,4878,O
transmission,4878,O
by,4878,O
targeted,4878,O
cleavage,4878,O
of,4878,O
only,4878,O
the,4878,O
pertinent,4878,O
SNAP-25,4878,B-GENE-Y
.,4878,O
In,4879,O
search,4879,O
of,4879,O
a,4879,O
basis,4879,O
for,4879,O
the,4879,O
impressive,4879,O
potency,4879,O
of,4879,O
an,4879,O
endoprotease,4879,B-GENE-N
that,4879,O
cleaves,4879,O
SNAP-25,4879,B-GENE-Y
",",4879,O
botulinum,4879,B-GENE-Y
neurotoxin,4879,I-GENE-Y
type,4879,I-GENE-Y
A,4879,I-GENE-Y
(,4879,O
BoNT/A,4879,B-GENE-Y
),4879,O
",",4879,O
in,4879,O
treating,4879,O
numerous,4879,O
diseases,4879,O
due,4879,O
to,4879,O
hyper-active,4879,O
autonomic,4879,O
nerves,4879,O
",",4879,O
truncation,4879,O
of,4879,O
its,4879,O
target,4879,O
and,4879,O
inhibition,4879,O
of,4879,O
neurotransmission,4879,O
were,4879,O
studied,4879,O
in,4879,O
rat,4879,O
sympathetic,4879,O
neurons,4879,O
.,4879,O
Tetrodotoxin-sensitive,4880,B-CHEMICAL
spontaneous,4880,O
cholinergic,4880,O
neurotransmission,4880,O
was,4880,O
blocked,4880,O
>,4880,O
80,4880,O
%,4880,O
by,4880,O
1,4880,O
pM,4880,O
BoNT/A,4880,B-GENE-Y
despite,4880,O
cleaving,4880,O
<,4880,O
20,4880,O
%,4880,O
of,4880,O
the,4880,O
SNAP-25,4880,B-GENE-Y
.,4880,O
A,4881,O
maximum,4881,O
cleavage,4881,O
of,4881,O
60,4881,O
%,4881,O
SNAP-25,4881,B-GENE-Y
could,4881,O
be,4881,O
achieved,4881,O
with,4881,O
>,4881,O
1,4881,O
nM,4881,O
BoNT/A,4881,B-GENE-Y
",",4881,O
despite,4881,O
an,4881,O
absence,4881,O
of,4881,O
non-cleavable,4881,O
SNAP-25,4881,B-GENE-Y
in,4881,O
the,4881,O
detergent-solubilised,4881,O
neurons,4881,O
.,4881,O
In,4882,O
contrast,4882,O
",",4882,O
BoNT/E,4882,B-GENE-Y
(,4882,O
100,4882,O
nM,4882,O
),4882,O
truncated,4882,O
nearly,4882,O
all,4882,O
the,4882,O
SNAP-25,4882,B-GENE-Y
in,4882,O
the,4882,O
intact,4882,O
cells,4882,O
",",4882,O
but,4882,O
was,4882,O
unable,4882,O
to,4882,O
block,4882,O
neurotransmission,4882,O
at,4882,O
low,4882,O
concentrations,4882,O
like,4882,O
BoNT/A,4882,B-GENE-Y
.,4882,O
Chimeras,4883,O
created,4883,O
by,4883,O
inserting,4883,O
the,4883,O
acceptor-binding,4883,O
HC,4883,B-GENE-N
domain,4883,I-GENE-N
of,4883,O
BoNT/A,4883,B-GENE-Y
into,4883,O
BoNT/E,4883,B-GENE-Y
still,4883,O
cleaved,4883,O
all,4883,O
the,4883,O
SNAP-25,4883,B-GENE-Y
",",4883,O
indicating,4883,O
ubiquitous,4883,O
expression,4883,O
of,4883,O
BoNT/A,4883,B-GENE-Y
acceptors,4883,O
.,4883,O
Accordingly,4884,O
",",4884,O
SV2,4884,B-GENE-N
and,4884,O
SNAP-25,4884,B-GENE-Y
were,4884,O
found,4884,O
to,4884,O
be,4884,O
co-expressed,4884,O
and,4884,O
broadly,4884,O
co-localised,4884,O
in,4884,O
neurons,4884,O
",",4884,O
but,4884,O
absent,4884,O
from,4884,O
non-neuronal,4884,O
cells,4884,O
.,4884,O
On,4885,O
the,4885,O
other,4885,O
hand,4885,O
",",4885,O
partial,4885,O
cleavage,4885,O
by,4885,O
the,4885,O
BoNT/A,4885,B-GENE-Y
protease,4885,O
persisted,4885,O
upon,4885,O
replacing,4885,O
its,4885,O
HC,4885,O
with,4885,O
counterparts,4885,O
from,4885,O
BoNT/E,4885,B-GENE-Y
or,4885,O
BoNT/B,4885,B-GENE-Y
.,4885,O
Moreover,4886,O
",",4886,O
limited,4886,O
cleavage,4886,O
of,4886,O
SNAP-25,4886,B-GENE-Y
was,4886,O
conferred,4886,O
onto,4886,O
the,4886,O
protease,4886,B-GENE-N
from,4886,O
BoNT/E,4886,B-GENE-Y
when,4886,O
fused,4886,O
to,4886,O
the,4886,O
N-terminus,4886,B-CHEMICAL
of,4886,O
BoNT/A,4886,B-GENE-Y
.,4886,O
Thus,4887,O
",",4887,O
the,4887,O
BoNT/A,4887,B-GENE-Y
protease,4887,B-GENE-N
is,4887,O
uniquely,4887,O
well-adapted,4887,O
for,4887,O
selectively,4887,O
inactivating,4887,O
the,4887,O
SNAP-25,4887,B-GENE-Y
directly,4887,O
involved,4887,O
in,4887,O
neurotransmission,4887,O
;,4887,O
this,4887,O
together,4887,O
with,4887,O
the,4887,O
toxin,4887,O
's,4887,O
acceptor,4887,O
and,4887,O
its,4887,O
target,4887,O
being,4887,O
localised,4887,O
on,4887,O
the,4887,O
peri-somatic,4887,O
boutons,4887,O
likely,4887,O
contribute,4887,O
to,4887,O
its,4887,O
exceptional,4887,O
therapeutic,4887,O
utility,4887,O
in,4887,O
the,4887,O
clinic,4887,O
.,4887,O
Dexamethasone-mediated,4888,B-CHEMICAL
changes,4888,O
in,4888,O
adipose,4888,O
triacylglycerol,4888,B-CHEMICAL
metabolism,4888,O
are,4888,O
exaggerated,4888,O
",",4888,O
not,4888,O
diminished,4888,O
",",4888,O
in,4888,O
the,4888,O
absence,4888,O
of,4888,O
a,4888,O
functional,4888,O
GR,4888,B-GENE-N
dimerization,4888,I-GENE-N
domain,4888,I-GENE-N
.,4888,O
The,4889,O
glucocorticoid,4889,B-GENE-Y
(,4889,I-GENE-Y
GC,4889,I-GENE-Y
),4889,I-GENE-Y
receptor,4889,I-GENE-Y
(,4889,O
GR,4889,B-GENE-Y
),4889,O
has,4889,O
multiple,4889,O
effector,4889,O
mechanisms,4889,O
",",4889,O
including,4889,O
dimerization-mediated,4889,O
transactivation,4889,O
of,4889,O
target,4889,O
genes,4889,O
via,4889,O
DNA,4889,O
binding,4889,O
and,4889,O
transcriptional,4889,O
repression,4889,O
mediated,4889,O
by,4889,O
protein-protein,4889,O
interactions,4889,O
.,4889,O
Much,4890,O
attention,4890,O
has,4890,O
been,4890,O
focused,4890,O
on,4890,O
developing,4890,O
selective,4890,O
GR,4890,B-GENE-Y
modulators,4890,O
that,4890,O
would,4890,O
dissociate,4890,O
adverse,4890,O
effects,4890,O
from,4890,O
therapeutic,4890,O
anti-inflammatory,4890,O
effects,4890,O
.,4890,O
The,4891,O
GR,4891,B-GENE-Y
(,4891,O
dim/dim,4891,O
),4891,O
mouse,4891,O
has,4891,O
a,4891,O
mutation,4891,O
in,4891,O
the,4891,O
dimerization,4891,O
domain,4891,O
of,4891,O
GR,4891,B-GENE-Y
and,4891,O
has,4891,O
been,4891,O
shown,4891,O
to,4891,O
have,4891,O
attenuated,4891,O
transactivation,4891,O
with,4891,O
intact,4891,O
repression,4891,O
.,4891,O
To,4892,O
understand,4892,O
the,4892,O
role,4892,O
of,4892,O
GR,4892,B-GENE-Y
dimerization-dependent,4892,O
targets,4892,O
in,4892,O
multiple,4892,O
tissues,4892,O
",",4892,O
we,4892,O
measured,4892,O
metabolic,4892,O
fluxes,4892,O
through,4892,O
several,4892,O
disease-relevant,4892,O
GC,4892,O
target,4892,O
pathways,4892,O
using,4892,O
heavy,4892,O
water,4892,O
labeling,4892,O
and,4892,O
mass,4892,O
spectrometry,4892,O
in,4892,O
wild-type,4892,O
and,4892,O
GR,4892,B-GENE-Y
(,4892,O
dim/dim,4892,O
),4892,O
mice,4892,O
administered,4892,O
the,4892,O
potent,4892,O
GC,4892,O
dexamethasone,4892,B-CHEMICAL
(,4892,O
DEX,4892,B-CHEMICAL
),4892,O
.,4892,O
Absolute,4893,O
triglyceride,4893,B-CHEMICAL
synthesis,4893,O
was,4893,O
increased,4893,O
in,4893,O
both,4893,O
wild-type,4893,O
and,4893,O
GR,4893,B-GENE-Y
(,4893,O
dim/dim,4893,O
),4893,O
mice,4893,O
by,4893,O
DEX,4893,B-CHEMICAL
in,4893,O
the,4893,O
inguinal,4893,O
and,4893,O
epididymal,4893,O
fat,4893,O
depots,4893,O
.,4893,O
GR,4894,B-GENE-Y
(,4894,O
dim/dim,4894,O
),4894,O
mice,4894,O
showed,4894,O
an,4894,O
exaggerated,4894,O
response,4894,O
to,4894,O
DEX,4894,B-CHEMICAL
in,4894,O
both,4894,O
depots,4894,O
.,4894,O
De,4895,O
novo,4895,O
lipogenesis,4895,O
was,4895,O
also,4895,O
greatly,4895,O
increased,4895,O
in,4895,O
both,4895,O
depots,4895,O
in,4895,O
response,4895,O
to,4895,O
DEX,4895,B-CHEMICAL
in,4895,O
GR,4895,B-GENE-Y
(,4895,O
dim/dim,4895,O
),4895,O
",",4895,O
but,4895,O
not,4895,O
wild-type,4895,O
mice,4895,O
.,4895,O
In,4896,O
contrast,4896,O
",",4896,O
the,4896,O
inhibitory,4896,O
effect,4896,O
of,4896,O
DEX,4896,B-CHEMICAL
on,4896,O
bone,4896,O
and,4896,O
skin,4896,O
collagen,4896,O
synthesis,4896,O
rates,4896,O
was,4896,O
greater,4896,O
in,4896,O
wild-type,4896,O
compared,4896,O
with,4896,O
GR,4896,B-GENE-Y
(,4896,O
dim/dim,4896,O
),4896,O
mice,4896,O
.,4896,O
Wild-type,4897,O
mice,4897,O
were,4897,O
more,4897,O
sensitive,4897,O
to,4897,O
DEX-dependent,4897,B-CHEMICAL
decreases,4897,O
in,4897,O
insulin,4897,B-GENE-N
sensitivity,4897,O
than,4897,O
GR,4897,B-GENE-Y
(,4897,O
dim/dim,4897,O
),4897,O
mice,4897,O
.,4897,O
Wild-type,4898,O
and,4898,O
GR,4898,B-GENE-Y
(,4898,O
dim/dim,4898,O
),4898,O
mice,4898,O
were,4898,O
equally,4898,O
sensitive,4898,O
to,4898,O
DEX-dependent,4898,B-CHEMICAL
decreases,4898,O
in,4898,O
muscle,4898,O
protein,4898,O
synthesis,4898,O
.,4898,O
Chronic,4899,O
elevation,4899,O
of,4899,O
GCs,4899,O
in,4899,O
GR,4899,B-GENE-Y
(,4899,O
dim/dim,4899,O
),4899,O
mice,4899,O
results,4899,O
in,4899,O
severe,4899,O
runting,4899,O
and,4899,O
lethality,4899,O
.,4899,O
In,4900,O
conclusion,4900,O
",",4900,O
some,4900,O
metabolic,4900,O
effects,4900,O
of,4900,O
GC,4900,O
treatment,4900,O
are,4900,O
exaggerated,4900,O
in,4900,O
adipose,4900,O
tissue,4900,O
of,4900,O
GR,4900,B-GENE-Y
(,4900,O
dim/dim,4900,O
),4900,O
mice,4900,O
",",4900,O
suggesting,4900,O
that,4900,O
selective,4900,O
GR,4900,B-GENE-Y
modulators,4900,O
based,4900,O
on,4900,O
dissociating,4900,O
GR,4900,B-GENE-Y
transactivation,4900,O
from,4900,O
repression,4900,O
should,4900,O
be,4900,O
evaluated,4900,O
carefully,4900,O
.,4900,O
X-box,4901,B-GENE-Y
binding,4901,I-GENE-Y
protein,4901,I-GENE-Y
1,4901,I-GENE-Y
is,4901,O
essential,4901,O
for,4901,O
insulin,4901,B-GENE-Y
regulation,4901,O
of,4901,O
pancreatic,4901,O
alpha,4901,O
cell,4901,O
function,4901,O
.,4901,O
Type,4902,O
2,4902,O
diabetes,4902,O
mellitus,4902,O
(,4902,O
T2D,4902,O
),4902,O
patients,4902,O
often,4902,O
exhibit,4902,O
hyperglucagonemia,4902,O
despite,4902,O
hyperglycemia,4902,O
suggesting,4902,O
defective,4902,O
-cell,4902,O
function,4902,O
.,4902,O
While,4903,O
endoplasmic,4903,O
reticulum,4903,O
(,4903,O
ER,4903,O
),4903,O
stress,4903,O
has,4903,O
been,4903,O
suggested,4903,O
to,4903,O
underlie,4903,O
-cell,4903,O
dysfunction,4903,O
in,4903,O
T2D,4903,O
",",4903,O
its,4903,O
role,4903,O
in,4903,O
-cell,4903,O
biology,4903,O
remains,4903,O
unclear,4903,O
.,4903,O
X-box,4904,B-GENE-Y
binding,4904,I-GENE-Y
protein,4904,I-GENE-Y
1,4904,I-GENE-Y
(,4904,O
XBP1,4904,B-GENE-Y
),4904,O
is,4904,O
a,4904,O
transcription,4904,O
factor,4904,O
that,4904,O
plays,4904,O
a,4904,O
crucial,4904,O
role,4904,O
in,4904,O
the,4904,O
unfolded,4904,O
protein,4904,O
response,4904,O
(,4904,O
UPR,4904,O
),4904,O
and,4904,O
its,4904,O
deficiency,4904,O
in,4904,O
-cells,4904,O
has,4904,O
been,4904,O
reported,4904,O
to,4904,O
impair,4904,O
insulin,4904,B-GENE-N
secretion,4904,O
leading,4904,O
to,4904,O
glucose,4904,B-CHEMICAL
intolerance,4904,O
.,4904,O
To,4905,O
evaluate,4905,O
the,4905,O
role,4905,O
of,4905,O
XBP1,4905,B-GENE-Y
in,4905,O
-cells,4905,O
",",4905,O
we,4905,O
created,4905,O
complementary,4905,O
in,4905,O
vivo,4905,O
(,4905,O
-cell,4905,O
specific,4905,O
XBP1,4905,B-GENE-Y
knockout,4905,O
(,4905,O
XBPKO,4905,O
),4905,O
mice,4905,O
),4905,O
and,4905,O
in,4905,O
vitro,4905,O
(,4905,O
stable,4905,O
XBP1,4905,B-GENE-Y
knock,4905,O
down,4905,O
-cell,4905,O
line,4905,O
",",4905,O
XBPKD,4905,O
),4905,O
models,4905,O
.,4905,O
XBPKO,4906,O
mice,4906,O
exhibited,4906,O
glucose,4906,B-CHEMICAL
intolerance,4906,O
",",4906,O
mild,4906,O
insulin,4906,B-GENE-N
resistance,4906,O
and,4906,O
an,4906,O
inability,4906,O
to,4906,O
suppress,4906,O
glucagon,4906,B-GENE-Y
secretion,4906,O
following,4906,O
glucose,4906,B-CHEMICAL
stimulation,4906,O
.,4906,O
XBPKD,4907,O
cells,4907,O
exhibited,4907,O
activation,4907,O
of,4907,O
IRE1,4907,B-GENE-Y
",",4907,O
an,4907,O
upstream,4907,O
activator,4907,O
of,4907,O
XBP1,4907,B-GENE-Y
",",4907,O
leading,4907,O
to,4907,O
phosphorylation,4907,O
of,4907,O
JNK,4907,B-GENE-N
.,4907,O
Interestingly,4908,O
",",4908,O
insulin,4908,B-GENE-Y
treatment,4908,O
of,4908,O
XBPKD,4908,O
cells,4908,O
reduced,4908,O
tyrosine,4908,B-CHEMICAL
phosphorylation,4908,O
of,4908,O
IRS-1,4908,B-GENE-Y
(,4908,O
pY,4908,O
(,4908,O
896,4908,O
),4908,O
),4908,O
",",4908,O
and,4908,O
phosphorylation,4908,O
of,4908,O
Akt,4908,B-GENE-N
",",4908,O
while,4908,O
enhancing,4908,O
serine,4908,B-CHEMICAL
phosphorylation,4908,O
(,4908,O
pS,4908,O
(,4908,O
307,4908,O
),4908,O
),4908,O
of,4908,O
IRS-1,4908,B-GENE-Y
.,4908,O
Consequently,4909,O
the,4909,O
XBPKD,4909,O
cells,4909,O
exhibited,4909,O
blunted,4909,O
suppression,4909,O
of,4909,O
glucagon,4909,B-GENE-Y
secretion,4909,O
following,4909,O
insulin,4909,B-GENE-Y
treatment,4909,O
in,4909,O
the,4909,O
presence,4909,O
of,4909,O
high,4909,O
glucose,4909,B-CHEMICAL
.,4909,O
Together,4910,O
",",4910,O
these,4910,O
data,4910,O
indicate,4910,O
that,4910,O
XBP1,4910,B-GENE-Y
deficiency,4910,O
in,4910,O
pancreatic,4910,O
-cells,4910,O
induces,4910,O
altered,4910,O
insulin,4910,B-GENE-Y
signaling,4910,O
and,4910,O
dysfunctional,4910,O
glucagon,4910,B-GENE-Y
secretion,4910,O
.,4910,O
Toxicological,4911,O
profiles,4911,O
of,4911,O
selected,4911,O
synthetic,4911,O
cannabinoids,4911,B-CHEMICAL
showing,4911,O
high,4911,O
binding,4911,O
affinities,4911,O
to,4911,O
the,4911,O
cannabinoid,4911,B-GENE-Y
receptor,4911,I-GENE-Y
subtype,4911,I-GENE-Y
CB1,4911,I-GENE-Y
.,4911,O
Products,4912,O
containing,4912,O
synthetic,4912,O
cannabinoids,4912,B-CHEMICAL
are,4912,O
consumed,4912,O
as,4912,O
a,4912,O
surrogate,4912,O
for,4912,O
marihuana,4912,O
due,4912,O
to,4912,O
their,4912,O
non-detectability,4912,O
with,4912,O
commonly,4912,O
used,4912,O
drug,4912,O
tests,4912,O
and,4912,O
their,4912,O
strong,4912,O
cannabimimetic,4912,O
effects,4912,O
.,4912,O
Because,4913,O
data,4913,O
concerning,4913,O
their,4913,O
toxicological,4913,O
properties,4913,O
are,4913,O
scarce,4913,O
",",4913,O
the,4913,O
cytotoxic,4913,O
",",4913,O
genotoxic,4913,O
",",4913,O
immunomodulatory,4913,O
",",4913,O
and,4913,O
hormonal,4913,O
activities,4913,O
of,4913,O
four,4913,O
naphthoylindole,4913,B-CHEMICAL
compounds,4913,O
(,4913,O
JWH-018,4913,B-CHEMICAL
",",4913,O
JWH-073,4913,B-CHEMICAL
",",4913,O
JWH-122,4913,B-CHEMICAL
and,4913,O
JWH-210,4913,B-CHEMICAL
),4913,O
and,4913,O
of,4913,O
one,4913,O
benzoylindole,4913,B-CHEMICAL
(,4913,O
AM-694,4913,B-CHEMICAL
),4913,O
were,4913,O
studied,4913,O
in,4913,O
human,4913,O
cell,4913,O
lines,4913,O
and,4913,O
primary,4913,O
cells,4913,O
;,4913,O
tetrahydrocannabinol,4913,B-CHEMICAL
was,4913,O
included,4913,O
as,4913,O
the,4913,O
classical,4913,O
non-endogenous,4913,O
cannabinoid,4913,B-GENE-N
receptor,4913,I-GENE-N
ligand,4913,O
.,4913,O
All,4914,O
compounds,4914,O
induced,4914,O
damage,4914,O
to,4914,O
the,4914,O
cell,4914,O
membranes,4914,O
of,4914,O
buccal,4914,O
(,4914,O
TR146,4914,O
),4914,O
and,4914,O
breast,4914,O
(,4914,O
MCF-7,4914,O
),4914,O
derived,4914,O
cells,4914,O
at,4914,O
concentrations,4914,O
of,4914,O
75-100,4914,O
M,4914,O
.,4914,O
No,4915,O
cytotoxic,4915,O
responses,4915,O
were,4915,O
seen,4915,O
in,4915,O
other,4915,O
assays,4915,O
which,4915,O
reflect,4915,O
mitochondrial,4915,O
damage,4915,O
",",4915,O
protein,4915,O
synthesis,4915,O
",",4915,O
and,4915,O
lysosomal,4915,O
activities,4915,O
.,4915,O
JWH-073,4916,B-CHEMICAL
and,4916,O
JWH-122,4916,B-CHEMICAL
induced,4916,O
DNA,4916,O
migration,4916,O
in,4916,O
buccal,4916,O
and,4916,O
liver,4916,O
cells,4916,O
(,4916,O
HepG2,4916,O
),4916,O
in,4916,O
single,4916,O
cell,4916,O
gel,4916,O
electrophoresis,4916,O
assays,4916,O
",",4916,O
while,4916,O
JWH-210,4916,B-CHEMICAL
was,4916,O
only,4916,O
in,4916,O
the,4916,O
latter,4916,O
cell,4916,O
line,4916,O
active,4916,O
.,4916,O
No,4917,O
estrogenic,4917,O
activities,4917,O
were,4917,O
detected,4917,O
in,4917,O
bone,4917,O
marrow,4917,O
cells,4917,O
(,4917,O
U2-OS,4917,O
),4917,O
",",4917,O
but,4917,O
all,4917,O
compounds,4917,O
caused,4917,O
anti-estrogenic,4917,O
effects,4917,O
at,4917,O
levels,4917,O
between,4917,O
2.1,4917,O
and,4917,O
23.0,4917,O
M,4917,O
.,4917,O
Furthermore,4918,O
",",4918,O
no,4918,O
impact,4918,O
on,4918,O
cytokine,4918,B-GENE-N
release,4918,O
(,4918,O
i.e.,4918,O
",",4918,O
on,4918,O
IL-10,4918,B-GENE-Y
",",4918,O
IL-6,4918,B-GENE-Y
",",4918,O
IL-12/23p40,4918,B-GENE-N
and,4918,O
TNF,4918,B-GENE-Y
levels,4918,O
),4918,O
was,4918,O
seen,4918,O
in,4918,O
LPS-stimulated,4918,O
human,4918,O
PBMCs,4918,O
",",4918,O
except,4918,O
with,4918,O
JWH-210,4918,B-CHEMICAL
and,4918,O
JWH-122,4918,B-CHEMICAL
which,4918,O
caused,4918,O
a,4918,O
decrease,4918,O
of,4918,O
TNF,4918,B-GENE-Y
and,4918,O
IL-12/23p40,4918,B-GENE-N
.,4918,O
All,4919,O
toxic,4919,O
effects,4919,O
were,4919,O
observed,4919,O
with,4919,O
concentrations,4919,O
higher,4919,O
than,4919,O
those,4919,O
expected,4919,O
in,4919,O
body,4919,O
fluids,4919,O
of,4919,O
users,4919,O
.,4919,O
Since,4920,O
genotoxic,4920,O
effects,4920,O
are,4920,O
in,4920,O
general,4920,O
linear,4920,O
over,4920,O
a,4920,O
wide,4920,O
concentration,4920,O
range,4920,O
and,4920,O
the,4920,O
exposure,4920,O
levels,4920,O
may,4920,O
be,4920,O
higher,4920,O
in,4920,O
epithelial,4920,O
cells,4920,O
or,4920,O
in,4920,O
serum,4920,O
",",4920,O
further,4920,O
experimental,4920,O
work,4920,O
is,4920,O
required,4920,O
to,4920,O
find,4920,O
out,4920,O
if,4920,O
DNA,4920,O
damage,4920,O
takes,4920,O
place,4920,O
in,4920,O
drug,4920,O
users,4920,O
.,4920,O
Curcuminoids,4921,B-CHEMICAL
Modulate,4921,O
Pro-Oxidant-Antioxidant,4921,O
Balance,4921,O
but,4921,O
not,4921,O
the,4921,O
Immune,4921,O
Response,4921,O
to,4921,O
Heat,4921,B-GENE-Y
Shock,4921,I-GENE-Y
Protein,4921,I-GENE-Y
27,4921,I-GENE-Y
and,4921,O
Oxidized,4921,B-GENE-N
LDL,4921,I-GENE-N
in,4921,O
Obese,4921,O
Individuals,4921,O
.,4921,O
Curcuminoids,4922,B-CHEMICAL
have,4922,O
potentially,4922,O
important,4922,O
functional,4922,O
qualities,4922,O
including,4922,O
anti-inflammatory,4922,O
and,4922,O
antioxidant,4922,O
properties,4922,O
.,4922,O
In,4923,O
this,4923,O
randomized,4923,O
double-blind,4923,O
placebo-controlled,4923,O
cross-over,4923,O
trial,4923,O
",",4923,O
the,4923,O
effects,4923,O
of,4923,O
a,4923,O
curcuminoid,4923,B-CHEMICAL
supplement,4923,O
on,4923,O
serum,4923,O
pro-oxidant-antioxidant,4923,O
balance,4923,O
(,4923,O
PAB,4923,O
),4923,O
and,4923,O
antibody,4923,O
titres,4923,O
to,4923,O
Hsp27,4923,B-GENE-Y
(,4923,O
anti-Hsp27,4923,O
),4923,O
and,4923,O
oxLDL,4923,B-GENE-N
(,4923,O
anti-oxLDL,4923,O
),4923,O
were,4923,O
investigated,4923,O
.,4923,O
Thirty,4924,O
obese,4924,O
individuals,4924,O
were,4924,O
randomized,4924,O
to,4924,O
receive,4924,O
either,4924,O
curcuminoids,4924,B-CHEMICAL
(,4924,O
1,4924,O
g/day,4924,O
),4924,O
or,4924,O
placebo,4924,O
for,4924,O
a,4924,O
period,4924,O
of,4924,O
30,4924,O
days,4924,O
.,4924,O
After,4925,O
a,4925,O
wash-out,4925,O
period,4925,O
of,4925,O
2,4925,O
weeks,4925,O
",",4925,O
subjects,4925,O
were,4925,O
crossed,4925,O
over,4925,O
to,4925,O
the,4925,O
alternate,4925,O
regimen,4925,O
for,4925,O
another,4925,O
30,4925,O
days,4925,O
.,4925,O
Serum,4926,O
PAB,4926,O
along,4926,O
with,4926,O
anti-Hsp27,4926,O
and,4926,O
anti-oxLDL,4926,O
titres,4926,O
was,4926,O
measured,4926,O
at,4926,O
the,4926,O
beginning,4926,O
and,4926,O
at,4926,O
the,4926,O
end,4926,O
of,4926,O
each,4926,O
study,4926,O
period,4926,O
.,4926,O
There,4927,O
was,4927,O
no,4927,O
significant,4927,O
carry-over,4927,O
effect,4927,O
for,4927,O
any,4927,O
of,4927,O
the,4927,O
assessed,4927,O
parameters,4927,O
.,4927,O
Curcuminoid,4928,B-CHEMICAL
supplementation,4928,O
was,4928,O
associated,4928,O
with,4928,O
a,4928,O
significant,4928,O
decrease,4928,O
in,4928,O
PAB,4928,O
(,4928,O
p,4928,O
=,4928,O
0.044,4928,O
),4928,O
.,4928,O
However,4929,O
",",4929,O
no,4929,O
significant,4929,O
change,4929,O
was,4929,O
observed,4929,O
in,4929,O
serum,4929,O
concentrations,4929,O
of,4929,O
anti-Hsp27,4929,O
or,4929,O
anti-oxLDL,4929,O
(,4929,O
p,4929,O
>,4929,O
0.05,4929,O
),4929,O
.,4929,O
These,4930,O
findings,4930,O
suggest,4930,O
that,4930,O
oral,4930,O
curcuminoids,4930,B-CHEMICAL
supplementation,4930,O
(,4930,O
1g/day,4930,O
),4930,O
is,4930,O
effective,4930,O
in,4930,O
reducing,4930,O
oxidative,4930,O
stress,4930,O
burden,4930,O
",",4930,O
though,4930,O
this,4930,O
needs,4930,O
to,4930,O
be,4930,O
validated,4930,O
in,4930,O
larger,4930,O
study,4930,O
populations,4930,O
.,4930,O
Copyright,4931,O
,4931,O
2013,4931,O
John,4931,O
Wiley,4931,O
&,4931,O
Sons,4931,O
",",4931,O
Ltd,4931,O
.,4931,O
Influence,4932,O
of,4932,O
the,4932,O
Green,4932,O
Tea,4932,O
Leaf,4932,O
Extract,4932,O
on,4932,O
Neurotoxicity,4932,O
of,4932,O
Aluminium,4932,B-CHEMICAL
Chloride,4932,I-CHEMICAL
in,4932,O
Rats,4932,O
.,4932,O
Aluminium,4933,B-CHEMICAL
may,4933,O
have,4933,O
an,4933,O
important,4933,O
role,4933,O
in,4933,O
the,4933,O
aetiology/pathogenesis/precipitation,4933,O
of,4933,O
Alzheimer,4933,O
's,4933,O
disease,4933,O
.,4933,O
Because,4934,O
green,4934,O
tea,4934,O
(,4934,O
Camellia,4934,O
sinensis,4934,O
L.,4934,O
),4934,O
reportedly,4934,O
has,4934,O
health-promoting,4934,O
effects,4934,O
in,4934,O
the,4934,O
central,4934,O
nervous,4934,O
system,4934,O
",",4934,O
we,4934,O
evaluated,4934,O
the,4934,O
effects,4934,O
of,4934,O
green,4934,O
tea,4934,O
leaf,4934,O
extract,4934,O
(,4934,O
GTLE,4934,O
),4934,O
on,4934,O
aluminium,4934,B-CHEMICAL
chloride,4934,I-CHEMICAL
(,4934,O
AlCl3,4934,B-CHEMICAL
),4934,O
neurotoxicity,4934,O
in,4934,O
rats,4934,O
.,4934,O
All,4935,O
solutions,4935,O
were,4935,O
injected,4935,O
into,4935,O
the,4935,O
cornu,4935,O
ammonis,4935,O
region,4935,O
1,4935,O
hippocampal,4935,O
region,4935,O
.,4935,O
We,4936,O
measured,4936,O
the,4936,O
performance,4936,O
of,4936,O
active,4936,O
avoidance,4936,O
(,4936,O
AA,4936,O
),4936,O
tasks,4936,O
",",4936,O
various,4936,O
enzyme,4936,O
activities,4936,O
and,4936,O
total,4936,O
glutathione,4936,B-CHEMICAL
content,4936,O
(,4936,O
TGC,4936,O
),4936,O
in,4936,O
the,4936,O
forebrain,4936,O
cortex,4936,O
(,4936,O
FbC,4936,O
),4936,O
",",4936,O
striatum,4936,O
",",4936,O
basal,4936,O
forebrain,4936,O
(,4936,O
BFb,4936,O
),4936,O
",",4936,O
hippocampus,4936,O
",",4936,O
brain,4936,O
stem,4936,O
and,4936,O
cerebellum,4936,O
.,4936,O
AlCl3,4937,B-CHEMICAL
markedly,4937,O
reduced,4937,O
AA,4937,O
performance,4937,O
and,4937,O
activities,4937,O
of,4937,O
cytochrome,4937,B-GENE-N
c,4937,I-GENE-N
oxidase,4937,I-GENE-N
(,4937,O
COX,4937,B-GENE-N
),4937,O
and,4937,O
acetylcholinesterase,4937,B-GENE-Y
(,4937,O
AChE,4937,B-GENE-Y
),4937,O
in,4937,O
all,4937,O
regions,4937,O
.,4937,O
It,4938,O
decreased,4938,O
TGC,4938,O
in,4938,O
the,4938,O
FbC,4938,O
",",4938,O
striatum,4938,O
",",4938,O
BFb,4938,O
",",4938,O
hippocampus,4938,O
",",4938,O
brain,4938,O
stem,4938,O
and,4938,O
cerebellum,4938,O
",",4938,O
and,4938,O
increased,4938,O
superoxide,4938,B-CHEMICAL
dismutase,4938,O
activity,4938,O
in,4938,O
the,4938,O
FbC,4938,O
",",4938,O
cerebellum,4938,O
and,4938,O
BFb,4938,O
.,4938,O
GTLE,4939,O
pretreatment,4939,O
completely,4939,O
reversed,4939,O
the,4939,O
damaging,4939,O
effects,4939,O
of,4939,O
AlCl3,4939,B-CHEMICAL
on,4939,O
AA,4939,O
and,4939,O
superoxide,4939,B-CHEMICAL
dismutase,4939,I-GENE-N
activity,4939,O
",",4939,O
markedly,4939,O
corrected,4939,O
COX,4939,B-GENE-N
and,4939,O
AChE,4939,B-GENE-Y
activities,4939,O
",",4939,O
and,4939,O
moderately,4939,O
improved,4939,O
TGC,4939,O
.,4939,O
GTLE,4940,O
alone,4940,O
increased,4940,O
COX,4940,B-GENE-N
and,4940,O
AChE,4940,B-GENE-Y
activities,4940,O
in,4940,O
almost,4940,O
all,4940,O
regions,4940,O
.,4940,O
GTLE,4941,O
reduces,4941,O
AlCl3,4941,B-CHEMICAL
neurotoxicity,4941,O
probably,4941,O
via,4941,O
antioxidative,4941,O
effects,4941,O
and,4941,O
improves,4941,O
mitochondrial,4941,O
and,4941,O
cholinergic,4941,O
synaptic,4941,O
functions,4941,O
through,4941,O
the,4941,O
actions,4941,O
of,4941,O
(,4941,B-CHEMICAL
-,4941,I-CHEMICAL
),4941,I-CHEMICAL
-epigallocatechin,4941,I-CHEMICAL
gallate,4941,I-CHEMICAL
and,4941,O
(,4941,B-CHEMICAL
-,4941,I-CHEMICAL
),4941,I-CHEMICAL
-epicatechin,4941,I-CHEMICAL
",",4941,O
compounds,4941,O
most,4941,O
abundantly,4941,O
found,4941,O
in,4941,O
GTLE,4941,O
.,4941,O
Our,4942,O
results,4942,O
suggest,4942,O
that,4942,O
green,4942,O
tea,4942,O
might,4942,O
be,4942,O
beneficial,4942,O
in,4942,O
Alzheimer,4942,O
's,4942,O
disease,4942,O
.,4942,O
Copyright,4943,O
,4943,O
2013,4943,O
John,4943,O
Wiley,4943,O
&,4943,O
Sons,4943,O
",",4943,O
Ltd,4943,O
.,4943,O
From,4944,O
synaptic,4944,O
spines,4944,O
to,4944,O
nuclear,4944,O
signaling,4944,O
:,4944,O
nuclear,4944,O
and,4944,O
synaptic,4944,O
actions,4944,O
of,4944,O
the,4944,O
amyloid,4944,B-GENE-Y
precursor,4944,I-GENE-Y
protein,4944,I-GENE-Y
.,4944,O
Despite,4945,O
intensive,4945,O
studies,4945,O
of,4945,O
the,4945,O
secretase-mediated,4945,B-GENE-N
processing,4945,O
of,4945,O
the,4945,O
amyloid,4945,B-GENE-Y
precursor,4945,I-GENE-Y
protein,4945,I-GENE-Y
(,4945,O
APP,4945,B-GENE-Y
),4945,O
to,4945,O
form,4945,O
the,4945,O
amyloid,4945,B-GENE-Y
-peptide,4945,I-GENE-Y
(,4945,O
A,4945,B-GENE-Y
),4945,O
",",4945,O
in,4945,O
relation,4945,O
to,4945,O
Alzheimer,4945,O
's,4945,O
disease,4945,O
(,4945,O
AD,4945,O
),4945,O
",",4945,O
no,4945,O
new,4945,O
therapeutic,4945,O
agents,4945,O
have,4945,O
reached,4945,O
the,4945,O
clinics,4945,O
based,4945,O
on,4945,O
reducing,4945,O
A,4945,B-GENE-Y
levels,4945,O
through,4945,O
the,4945,O
use,4945,O
of,4945,O
secretase,4945,B-GENE-N
inhibitors,4945,O
or,4945,O
immunotherapy,4945,O
.,4945,O
Furthermore,4946,O
",",4946,O
the,4946,O
normal,4946,O
neuronal,4946,O
functions,4946,O
of,4946,O
APP,4946,B-GENE-Y
and,4946,O
its,4946,O
various,4946,O
metabolites,4946,O
still,4946,O
remain,4946,O
under-investigated,4946,O
and,4946,O
unclear,4946,O
.,4946,O
Here,4947,O
",",4947,O
we,4947,O
highlight,4947,O
emerging,4947,O
areas,4947,O
of,4947,O
APP,4947,B-GENE-Y
function,4947,O
that,4947,O
may,4947,O
provide,4947,O
new,4947,O
insights,4947,O
into,4947,O
synaptic,4947,O
development,4947,O
",",4947,O
cognition,4947,O
",",4947,O
and,4947,O
gene,4947,O
regulation,4947,O
.,4947,O
By,4948,O
modulating,4948,O
expression,4948,O
levels,4948,O
of,4948,O
endogenous,4948,O
APP,4948,B-GENE-Y
in,4948,O
primary,4948,O
cortical,4948,O
neurons,4948,O
",",4948,O
the,4948,O
frequency,4948,O
and,4948,O
amplitude,4948,O
of,4948,O
calcium,4948,B-CHEMICAL
oscillations,4948,O
is,4948,O
modified,4948,O
",",4948,O
implying,4948,O
a,4948,O
key,4948,O
role,4948,O
for,4948,O
APP,4948,B-GENE-Y
in,4948,O
maintaining,4948,O
neuronal,4948,O
calcium,4948,B-CHEMICAL
homeostasis,4948,O
essential,4948,O
for,4948,O
synaptic,4948,O
transmission,4948,O
.,4948,O
Disruption,4949,O
of,4949,O
this,4949,O
homeostatic,4949,O
mechanism,4949,O
predisposes,4949,O
to,4949,O
aging,4949,O
and,4949,O
AD,4949,O
.,4949,O
Synaptic,4950,O
spine,4950,O
loss,4950,O
is,4950,O
a,4950,O
feature,4950,O
of,4950,O
neurogeneration,4950,O
resulting,4950,O
in,4950,O
learning,4950,O
and,4950,O
memory,4950,O
deficits,4950,O
",",4950,O
and,4950,O
emerging,4950,O
evidence,4950,O
indicates,4950,O
a,4950,O
role,4950,O
for,4950,O
APP,4950,B-GENE-Y
",",4950,O
probably,4950,O
mediated,4950,O
via,4950,O
one,4950,O
or,4950,O
more,4950,O
of,4950,O
its,4950,O
metabolites,4950,O
",",4950,O
in,4950,O
spine,4950,O
structure,4950,O
and,4950,O
functions,4950,O
.,4950,O
The,4951,O
intracellular,4951,B-GENE-N
domain,4951,I-GENE-N
of,4951,I-GENE-N
APP,4951,I-GENE-N
(,4951,O
AICD,4951,B-GENE-N
),4951,O
has,4951,O
also,4951,O
emerged,4951,O
as,4951,O
a,4951,O
key,4951,O
epigenetic,4951,O
regulator,4951,O
of,4951,O
gene,4951,O
expression,4951,O
controlling,4951,O
a,4951,O
diverse,4951,O
range,4951,O
of,4951,O
genes,4951,O
",",4951,O
including,4951,O
APP,4951,B-GENE-Y
itself,4951,O
",",4951,O
the,4951,O
amyloid-degrading,4951,B-GENE-Y
enzyme,4951,O
neprilysin,4951,B-GENE-Y
",",4951,O
and,4951,O
aquaporin-1,4951,B-GENE-Y
.,4951,O
A,4952,O
fuller,4952,O
understanding,4952,O
of,4952,O
the,4952,O
physiological,4952,O
and,4952,O
pathological,4952,O
actions,4952,O
of,4952,O
APP,4952,B-GENE-Y
and,4952,O
its,4952,O
metabolic,4952,O
network,4952,O
could,4952,O
provide,4952,O
new,4952,O
opportunities,4952,O
for,4952,O
therapeutic,4952,O
intervention,4952,O
in,4952,O
AD,4952,O
.,4952,O
The,4953,O
influence,4953,O
of,4953,O
Goishi,4953,O
tea,4953,O
on,4953,O
adipocytokines,4953,B-GENE-N
in,4953,O
obese,4953,O
mice,4953,O
.,4953,O
This,4954,O
study,4954,O
investigated,4954,O
the,4954,O
influence,4954,O
of,4954,O
Goishi-tea,4954,O
on,4954,O
visceral,4954,O
fat,4954,O
weight,4954,O
in,4954,O
induced,4954,O
obese,4954,O
mice,4954,O
.,4954,O
Mice,4955,O
were,4955,O
divided,4955,O
into,4955,O
two,4955,O
main,4955,O
groups,4955,O
",",4955,O
normal,4955,O
and,4955,O
obesity,4955,O
.,4955,O
In,4956,O
obesity,4956,O
group,4956,O
",",4956,O
mice,4956,O
were,4956,O
fed,4956,O
with,4956,O
high-fat,4956,O
diet,4956,O
.,4956,O
Goishi-tea,4957,O
including,4957,O
its,4957,O
fractions,4957,O
(,4957,O
ethyl-acetate,4957,B-CHEMICAL
layer,4957,O
and,4957,O
water,4957,O
layer,4957,O
),4957,O
was,4957,O
administrated,4957,O
in,4957,O
normal,4957,O
and,4957,O
obesity,4957,O
three,4957,O
sub-groups,4957,O
.,4957,O
Results,4958,O
showed,4958,O
no,4958,O
influence,4958,O
of,4958,O
Goishi-tea,4958,O
in,4958,O
normal,4958,O
group,4958,O
.,4958,O
However,4959,O
",",4959,O
visceral,4959,O
fat,4959,O
weight,4959,O
",",4959,O
size,4959,O
of,4959,O
adipose,4959,O
cell,4959,O
and,4959,O
cholesterol,4959,B-CHEMICAL
level,4959,O
were,4959,O
significantly,4959,O
decreased,4959,O
in,4959,O
obesity,4959,O
group,4959,O
fed,4959,O
Goishi-tea,4959,O
compared,4959,O
to,4959,O
control,4959,O
group,4959,O
.,4959,O
Moreover,4960,O
",",4960,O
adiponectin,4960,B-GENE-Y
levels,4960,O
tended,4960,O
to,4960,O
increase,4960,O
and,4960,O
adipocytokines,4960,B-GENE-N
has,4960,O
significant,4960,O
values,4960,O
lower,4960,O
in,4960,O
obesity,4960,O
group,4960,O
fed,4960,O
Goishi-tea,4960,O
compared,4960,O
to,4960,O
control,4960,O
group,4960,O
.,4960,O
Interestingly,4961,O
",",4961,O
Goishi,4961,O
tea,4961,O
involved,4961,O
in,4961,O
the,4961,O
high-fat,4961,O
diet,4961,O
induced-obese,4961,O
mice,4961,O
can,4961,O
inhibit,4961,O
fat,4961,O
accumulation,4961,O
and,4961,O
maintain,4961,O
adiponectins,4961,B-GENE-Y
without,4961,O
increasing,4961,O
tumor,4961,B-GENE-Y
necrosis,4961,I-GENE-Y
factor-alpha,4961,I-GENE-Y
and,4961,O
interleukin-6,4961,B-GENE-Y
.,4961,O
It,4962,O
would,4962,O
be,4962,O
beneficial,4962,O
for,4962,O
the,4962,O
prevention,4962,O
of,4962,O
metabolic,4962,O
syndrome,4962,O
and,4962,O
obesity-related,4962,O
disorder,4962,O
.,4962,O
Steroidal,4963,B-CHEMICAL
glycosides,4963,I-CHEMICAL
from,4963,O
the,4963,O
bulbs,4963,O
of,4963,O
Fritillaria,4963,O
meleagris,4963,O
and,4963,O
their,4963,O
cytotoxic,4963,O
activities,4963,O
.,4963,O
Steroidal,4964,B-CHEMICAL
glycosides,4964,I-CHEMICAL
(,4964,O
1-18,4964,O
),4964,O
",",4964,O
including,4964,O
10,4964,O
new,4964,O
compounds,4964,O
(,4964,O
1-10,4964,O
),4964,O
",",4964,O
were,4964,O
isolated,4964,O
from,4964,O
the,4964,O
bulbs,4964,O
of,4964,O
Fritillaria,4964,O
meleagris,4964,O
(,4964,O
Liliaceae,4964,O
),4964,O
.,4964,O
The,4965,O
structures,4965,O
of,4965,O
the,4965,O
new,4965,O
compounds,4965,O
were,4965,O
determined,4965,O
by,4965,O
two-dimensional,4965,O
(,4965,O
2D,4965,O
),4965,O
NMR,4965,O
analysis,4965,O
",",4965,O
and,4965,O
by,4965,O
hydrolytic,4965,O
cleavage,4965,O
followed,4965,O
by,4965,O
spectroscopic,4965,O
and,4965,O
chromatographic,4965,O
analysis,4965,O
.,4965,O
The,4966,O
isolated,4966,O
compounds,4966,O
and,4966,O
their,4966,O
aglycones,4966,O
were,4966,O
evaluated,4966,O
for,4966,O
cytotoxic,4966,O
activity,4966,O
against,4966,O
HL-60,4966,O
human,4966,O
promyelocytic,4966,O
leukemia,4966,O
cells,4966,O
and,4966,O
A549,4966,O
human,4966,O
lung,4966,O
adenocarcinoma,4966,O
cells,4966,O
.,4966,O
Morphological,4967,O
observation,4967,O
and,4967,O
flow,4967,O
cytometry,4967,O
analysis,4967,O
showed,4967,O
that,4967,O
5-spirostanol,4967,B-CHEMICAL
glycoside,4967,I-CHEMICAL
(,4967,O
2,4967,O
),4967,O
and,4967,O
a,4967,O
cholestane,4967,B-CHEMICAL
derivative,4967,O
(,4967,O
17a,4967,O
),4967,O
induced,4967,O
apoptotic,4967,O
cell,4967,O
death,4967,O
in,4967,O
HL-60,4967,O
cells,4967,O
through,4967,O
different,4967,O
mechanisms,4967,O
of,4967,O
action,4967,O
.,4967,O
Furthermore,4968,O
",",4968,O
the,4968,O
(,4968,B-CHEMICAL
22R,4968,I-CHEMICAL
),4968,I-CHEMICAL
-spirosolanol,4968,I-CHEMICAL
glycoside,4968,I-CHEMICAL
(,4968,O
11,4968,O
),4968,O
selectively,4968,O
induced,4968,O
apoptosis,4968,O
in,4968,O
A549,4968,O
cells,4968,O
without,4968,O
affecting,4968,O
the,4968,O
caspase-3,4968,B-GENE-Y
activity,4968,O
level,4968,O
.,4968,O
Gene,4969,O
silencing,4969,O
of,4969,O
TNF-alpha,4969,B-GENE-Y
in,4969,O
a,4969,O
murine,4969,O
model,4969,O
of,4969,O
acute,4969,O
colitis,4969,O
using,4969,O
a,4969,O
modified,4969,O
cyclodextrin,4969,O
delivery,4969,O
system,4969,O
.,4969,O
Inflammatory,4970,O
bowel,4970,O
disease,4970,O
(,4970,O
IBD,4970,O
),4970,O
is,4970,O
a,4970,O
chronic,4970,O
relapsing,4970,O
inflammation,4970,O
of,4970,O
the,4970,O
gastrointestinal,4970,O
tract,4970,O
.,4970,O
The,4971,O
cytokine,4971,B-GENE-N
TNF-alpha,4971,B-GENE-Y
(,4971,O
TNF-,4971,B-GENE-Y
),4971,O
plays,4971,O
a,4971,O
pivotal,4971,O
role,4971,O
in,4971,O
mediating,4971,O
this,4971,O
inflammatory,4971,O
response,4971,O
.,4971,O
RNA,4972,O
interference,4972,O
(,4972,O
RNAi,4972,O
),4972,O
holds,4972,O
great,4972,O
promise,4972,O
for,4972,O
the,4972,O
specific,4972,O
and,4972,O
selective,4972,O
silencing,4972,O
of,4972,O
aberrantly,4972,O
expressed,4972,O
genes,4972,O
",",4972,O
such,4972,O
as,4972,O
TNF-,4972,B-GENE-Y
in,4972,O
IBD,4972,O
.,4972,O
The,4973,O
aim,4973,O
of,4973,O
this,4973,O
study,4973,O
was,4973,O
to,4973,O
investigate,4973,O
the,4973,O
efficacy,4973,O
of,4973,O
an,4973,O
amphiphilic,4973,O
cationic,4973,O
cyclodextrin,4973,O
(,4973,O
CD,4973,O
),4973,O
vector,4973,O
for,4973,O
effective,4973,O
TNF-,4973,B-GENE-Y
siRNA,4973,O
delivery,4973,O
to,4973,O
macrophage,4973,O
cells,4973,O
and,4973,O
to,4973,O
mice,4973,O
with,4973,O
induced,4973,O
acute-colitis,4973,O
.,4973,O
The,4974,O
stability,4974,O
of,4974,O
CD.siRNA,4974,O
was,4974,O
examined,4974,O
by,4974,O
gel,4974,O
electrophoresis,4974,O
in,4974,O
biorelevant,4974,O
media,4974,O
reflecting,4974,O
colonic,4974,O
fluids,4974,O
.,4974,O
RAW264.7,4975,O
cells,4975,O
were,4975,O
transfected,4975,O
with,4975,O
CD.TNF-,4975,O
siRNA,4975,O
",",4975,O
stimulated,4975,O
with,4975,O
lipopolysaccharide,4975,O
(,4975,O
LPS,4975,O
),4975,O
and,4975,O
TNF-,4975,B-GENE-Y
and,4975,O
IL-6,4975,B-GENE-Y
responses,4975,O
were,4975,O
measured,4975,O
by,4975,O
PCR,4975,O
and,4975,O
ELISA,4975,O
.,4975,O
Female,4976,O
C57BL/6,4976,O
mice,4976,O
were,4976,O
exposed,4976,O
to,4976,O
dextran,4976,O
sodium,4976,B-CHEMICAL
sulphate,4976,I-CHEMICAL
(,4976,O
DSS,4976,O
),4976,O
and,4976,O
treated,4976,O
by,4976,O
intrarectal,4976,O
administration,4976,O
with,4976,O
either,4976,O
CD.siRNA,4976,O
TNF-,4976,B-GENE-Y
or,4976,O
a,4976,O
control,4976,O
solution,4976,O
.,4976,O
In,4977,O
vitro,4977,O
",",4977,O
siRNA,4977,O
in,4977,O
CD,4977,O
nanocomplexes,4977,O
remained,4977,O
intact,4977,O
and,4977,O
stable,4977,O
in,4977,O
both,4977,O
fed,4977,O
and,4977,O
fasted,4977,O
simulated,4977,O
colonic,4977,O
fluids,4977,O
.,4977,O
RAW264.7,4978,O
cells,4978,O
transfected,4978,O
with,4978,O
CD.TNF-,4978,O
siRNA,4978,O
and,4978,O
stimulated,4978,O
with,4978,O
LPS,4978,O
displayed,4978,O
a,4978,O
significant,4978,O
reduction,4978,O
in,4978,O
both,4978,O
gene,4978,O
and,4978,O
protein,4978,O
levels,4978,O
of,4978,O
TNF-,4978,B-GENE-Y
and,4978,O
IL-6,4978,B-GENE-Y
.,4978,O
CD.TNF-,4979,O
siRNA-treated,4979,O
mice,4979,O
revealed,4979,O
a,4979,O
mild,4979,O
amelioration,4979,O
in,4979,O
clinical,4979,O
signs,4979,O
of,4979,O
colitis,4979,O
",",4979,O
but,4979,O
significant,4979,O
reductions,4979,O
in,4979,O
total,4979,O
colon,4979,O
weight,4979,O
and,4979,O
colonic,4979,O
mRNA,4979,O
expression,4979,O
of,4979,O
TNF-,4979,B-GENE-Y
and,4979,O
IL-6,4979,B-GENE-Y
compared,4979,O
to,4979,O
DSS-control,4979,O
mice,4979,O
were,4979,O
detected,4979,O
.,4979,O
This,4980,O
data,4980,O
indicates,4980,O
the,4980,O
clinical,4980,O
potential,4980,O
of,4980,O
a,4980,O
local,4980,O
CD-based,4980,O
TNF-,4980,B-GENE-Y
siRNA,4980,O
delivery,4980,O
system,4980,O
for,4980,O
the,4980,O
treatment,4980,O
of,4980,O
IBD,4980,O
.,4980,O
Curcumin,4981,B-CHEMICAL
attenuates,4981,O
allergic,4981,O
airway,4981,O
inflammation,4981,O
by,4981,O
regulation,4981,O
of,4981,O
CD4,4981,O
(,4981,O
+,4981,O
),4981,O
CD25,4981,O
(,4981,O
+,4981,O
),4981,O
regulatory,4981,O
T,4981,O
cells,4981,O
(,4981,O
Tregs,4981,O
),4981,O
/Th17,4981,O
balance,4981,O
in,4981,O
ovalbumin-sensitized,4981,B-GENE-Y
mice,4981,O
.,4981,O
The,4982,O
present,4982,O
study,4982,O
aimed,4982,O
to,4982,O
determine,4982,O
the,4982,O
protective,4982,O
effects,4982,O
and,4982,O
the,4982,O
underlying,4982,O
mechanisms,4982,O
of,4982,O
curcumin,4982,B-CHEMICAL
on,4982,O
ovalbumin,4982,B-GENE-Y
(,4982,O
OVA,4982,B-GENE-Y
),4982,O
-induced,4982,O
allergic,4982,O
inflammation,4982,O
in,4982,O
a,4982,O
mouse,4982,O
model,4982,O
of,4982,O
allergic,4982,O
asthma,4982,O
.,4982,O
Asthma,4983,O
mice,4983,O
model,4983,O
was,4983,O
established,4983,O
by,4983,O
ovalbumin,4983,B-GENE-Y
.,4983,O
A,4984,O
total,4984,O
of,4984,O
60,4984,O
mice,4984,O
were,4984,O
randomly,4984,O
assigned,4984,O
to,4984,O
six,4984,O
experimental,4984,O
groups,4984,O
:,4984,O
control,4984,O
",",4984,O
model,4984,O
",",4984,O
dexamethasone,4984,B-CHEMICAL
(,4984,O
2mg/kg,4984,O
),4984,O
",",4984,O
and,4984,O
curcumin,4984,B-CHEMICAL
(,4984,O
50mg/kg,4984,O
",",4984,O
100mg/kg,4984,O
",",4984,O
200mg/kg,4984,O
),4984,O
.,4984,O
Airway,4985,O
resistance,4985,O
(,4985,O
Raw,4985,O
),4985,O
was,4985,O
measured,4985,O
by,4985,O
the,4985,O
forced,4985,O
oscillation,4985,O
technique,4985,O
",",4985,O
differential,4985,O
cell,4985,O
count,4985,O
in,4985,O
BAL,4985,O
fluid,4985,O
(,4985,O
BALF,4985,O
),4985,O
was,4985,O
measured,4985,O
by,4985,O
Wright-Giemsa,4985,O
staining,4985,O
",",4985,O
histological,4985,O
assessment,4985,O
was,4985,O
measured,4985,O
by,4985,O
hematoxylin,4985,B-CHEMICAL
and,4985,O
eosin,4985,B-CHEMICAL
(,4985,O
HE,4985,O
),4985,O
staining,4985,O
",",4985,O
BALF,4985,O
levels,4985,O
of,4985,O
Treg/Th17,4985,O
cytokines,4985,B-GENE-N
were,4985,O
measured,4985,O
by,4985,O
enzyme-linked,4985,O
immunosorbent,4985,O
assay,4985,O
",",4985,O
Treg,4985,O
cells,4985,O
and,4985,O
Th17,4985,O
cells,4985,O
were,4985,O
evaluated,4985,O
by,4985,O
flow,4985,O
cytometry,4985,O
(,4985,O
FCM,4985,O
),4985,O
.,4985,O
Our,4986,O
study,4986,O
demonstrated,4986,O
that,4986,O
curcumin,4986,B-CHEMICAL
inhibited,4986,O
OVA-induced,4986,B-GENE-Y
increases,4986,O
in,4986,O
eosinophil,4986,O
count,4986,O
;,4986,O
interleukin,4986,B-GENE-Y
(,4986,I-GENE-Y
IL,4986,I-GENE-Y
),4986,I-GENE-Y
-17A,4986,I-GENE-Y
level,4986,O
were,4986,O
recovered,4986,O
in,4986,O
bronchoalveolar,4986,O
lavage,4986,O
fluid,4986,O
increased,4986,O
IL-10,4986,B-GENE-Y
level,4986,O
in,4986,O
bronchoalveolar,4986,O
lavage,4986,O
fluid,4986,O
.,4986,O
Histological,4987,O
studies,4987,O
demonstrated,4987,O
that,4987,O
curcumin,4987,B-CHEMICAL
substantially,4987,O
inhibited,4987,O
OVA-induced,4987,B-GENE-Y
eosinophilia,4987,O
in,4987,O
lung,4987,O
tissue,4987,O
.,4987,O
Flow,4988,O
cytometry,4988,O
(,4988,O
FCM,4988,O
),4988,O
studies,4988,O
demonstrated,4988,O
that,4988,O
curcumin,4988,B-CHEMICAL
remarkably,4988,O
inhibited,4988,O
Th17,4988,O
cells,4988,O
and,4988,O
significantly,4988,O
increased,4988,O
Treg,4988,O
cells,4988,O
.,4988,O
The,4989,O
results,4989,O
in,4989,O
vivo,4989,O
show,4989,O
ovalbumin-induced,4989,B-GENE-Y
significantly,4989,O
broke,4989,O
Treg/Th17,4989,O
balance,4989,O
;,4989,O
curcumin,4989,B-CHEMICAL
treatments,4989,O
markedly,4989,O
attenuated,4989,O
the,4989,O
inflammatory,4989,O
in,4989,O
asthma,4989,O
model,4989,O
by,4989,O
regulating,4989,O
Treg/Th17,4989,O
balance,4989,O
.,4989,O
Our,4990,O
findings,4990,O
support,4990,O
the,4990,O
possible,4990,O
use,4990,O
of,4990,O
curcumin,4990,B-CHEMICAL
as,4990,O
a,4990,O
therapeutic,4990,O
drug,4990,O
for,4990,O
patients,4990,O
with,4990,O
allergic,4990,O
asthma,4990,O
.,4990,O
Structural,4991,O
Basis,4991,O
for,4991,O
the,4991,O
ATP-Induced,4991,B-CHEMICAL
Isomerization,4991,O
of,4991,O
Kinesin,4991,B-GENE-N
.,4991,O
Kinesin,4992,B-GENE-N
superfamily,4992,I-GENE-N
proteins,4992,I-GENE-N
(,4992,O
KIFs,4992,B-GENE-N
),4992,O
are,4992,O
microtubule-based,4992,B-GENE-N
molecular,4992,I-GENE-N
motors,4992,I-GENE-N
driven,4992,O
by,4992,O
the,4992,O
energy,4992,O
derived,4992,O
from,4992,O
the,4992,O
hydrolysis,4992,O
of,4992,O
ATP,4992,B-CHEMICAL
.,4992,O
Previous,4993,O
studies,4993,O
have,4993,O
revealed,4993,O
that,4993,O
the,4993,O
ATP,4993,B-CHEMICAL
binding,4993,O
step,4993,O
is,4993,O
crucial,4993,O
both,4993,O
for,4993,O
the,4993,O
power,4993,O
stroke,4993,O
to,4993,O
produce,4993,O
motility,4993,O
and,4993,O
for,4993,O
the,4993,O
inter-domain,4993,O
regulation,4993,O
of,4993,O
ATPase,4993,B-GENE-N
activity,4993,O
to,4993,O
guarantee,4993,O
the,4993,O
processive,4993,O
movement,4993,O
of,4993,O
dimeric,4993,O
KIFs,4993,B-GENE-N
.,4993,O
Here,4994,O
",",4994,O
we,4994,O
report,4994,O
the,4994,O
first,4994,O
crystal,4994,O
structure,4994,O
of,4994,O
KIF4,4994,B-GENE-Y
complexed,4994,O
with,4994,O
the,4994,O
non-hydrolyzable,4994,O
ATP,4994,B-CHEMICAL
analog,4994,O
",",4994,O
AMPPNP,4994,B-CHEMICAL
(,4994,O
adenylyl,4994,B-CHEMICAL
imidodiphosphate,4994,I-CHEMICAL
),4994,O
",",4994,O
at,4994,O
1.7,4994,O
resolution,4994,O
.,4994,O
By,4995,O
combining,4995,O
our,4995,O
structure,4995,O
with,4995,O
previously,4995,O
solved,4995,O
KIF1A,4995,B-GENE-Y
structures,4995,O
complexed,4995,O
with,4995,O
two,4995,O
ATP,4995,B-CHEMICAL
analogs,4995,O
",",4995,O
molecular,4995,O
snapshots,4995,O
during,4995,O
ATP,4995,B-CHEMICAL
binding,4995,O
reveal,4995,O
that,4995,O
the,4995,O
closure,4995,O
of,4995,O
the,4995,O
nucleotide-binding,4995,B-CHEMICAL
pocket,4995,O
during,4995,O
ATP,4995,B-CHEMICAL
binding,4995,O
is,4995,O
achieved,4995,O
by,4995,O
closure,4995,O
of,4995,O
the,4995,O
backdoor,4995,O
.,4995,O
Closure,4996,O
of,4996,O
the,4996,O
backdoor,4996,O
stabilizes,4996,O
two,4996,O
mobile,4996,O
regions,4996,O
",",4996,O
switch,4996,O
I,4996,O
and,4996,O
switch,4996,O
II,4996,O
",",4996,O
to,4996,O
generate,4996,O
the,4996,O
phosphate,4996,B-CHEMICAL
tube,4996,O
from,4996,O
which,4996,O
hydrolyzed,4996,O
phosphate,4996,B-CHEMICAL
is,4996,O
released,4996,O
.,4996,O
Through,4997,O
the,4997,O
stabilization,4997,O
of,4997,O
switch,4997,O
II,4997,O
",",4997,O
the,4997,O
local,4997,O
conformational,4997,O
change,4997,O
at,4997,O
the,4997,O
catalytic,4997,O
center,4997,O
is,4997,O
further,4997,O
relayed,4997,O
to,4997,O
the,4997,O
neck-linker,4997,O
element,4997,O
that,4997,O
fully,4997,O
docks,4997,O
to,4997,O
the,4997,O
catalytic,4997,O
core,4997,O
to,4997,O
produce,4997,O
the,4997,O
power,4997,O
stroke,4997,O
.,4997,O
Because,4998,O
the,4998,O
neck,4998,O
linker,4998,O
is,4998,O
a,4998,O
sole,4998,O
element,4998,O
that,4998,O
connects,4998,O
the,4998,O
partner,4998,O
heads,4998,O
in,4998,O
dimeric,4998,O
KIFs,4998,B-GENE-N
",",4998,O
this,4998,O
tight,4998,O
structural,4998,O
coordination,4998,O
between,4998,O
the,4998,O
catalytic,4998,O
center,4998,O
and,4998,O
neck,4998,O
linker,4998,O
enables,4998,O
inter-domain,4998,O
communication,4998,O
between,4998,O
the,4998,O
partner,4998,O
heads,4998,O
.,4998,O
This,4999,O
study,4999,O
also,4999,O
revealed,4999,O
the,4999,O
putative,4999,O
microtubule-binding,4999,B-GENE-N
site,4999,I-GENE-N
of,4999,O
KIF4,4999,B-GENE-Y
",",4999,O
thus,4999,O
providing,4999,O
structural,4999,O
insights,4999,O
that,4999,O
describe,4999,O
the,4999,O
specific,4999,O
binding,4999,O
of,4999,O
KIF4,4999,B-GENE-Y
to,4999,O
the,4999,O
microtubule,4999,O
.,4999,O
Current,5000,O
perspectives,5000,O
on,5000,O
parathyroid,5000,B-GENE-Y
hormone,5000,I-GENE-Y
(,5000,O
PTH,5000,B-GENE-Y
),5000,O
and,5000,O
PTH-related,5000,B-GENE-Y
protein,5000,I-GENE-Y
(,5000,O
PTHrP,5000,B-GENE-Y
),5000,O
as,5000,O
bone,5000,O
anabolic,5000,O
therapies,5000,O
.,5000,O
Osteoporosis,5001,O
is,5001,O
characterized,5001,O
by,5001,O
low,5001,O
bone,5001,O
mineral,5001,O
density,5001,O
and/or,5001,O
poor,5001,O
bone,5001,O
microarchitecture,5001,O
leading,5001,O
to,5001,O
an,5001,O
increased,5001,O
risk,5001,O
of,5001,O
fractures,5001,O
.,5001,O
The,5002,O
skeletal,5002,O
alterations,5002,O
in,5002,O
osteoporosis,5002,O
are,5002,O
a,5002,O
consequence,5002,O
of,5002,O
a,5002,O
relative,5002,O
deficit,5002,O
of,5002,O
bone,5002,O
formation,5002,O
compared,5002,O
to,5002,O
bone,5002,O
resorption,5002,O
.,5002,O
Osteoporosis,5003,O
therapies,5003,O
have,5003,O
mostly,5003,O
relied,5003,O
on,5003,O
antiresorptive,5003,O
drugs,5003,O
.,5003,O
An,5004,O
alternative,5004,O
therapeutic,5004,O
approach,5004,O
for,5004,O
osteoporosis,5004,O
is,5004,O
currently,5004,O
available,5004,O
",",5004,O
based,5004,O
on,5004,O
the,5004,O
intermittent,5004,O
administration,5004,O
of,5004,O
parathyroid,5004,B-GENE-Y
hormone,5004,I-GENE-Y
(,5004,O
PTH,5004,B-GENE-Y
),5004,O
.,5004,O
Bone,5005,O
anabolism,5005,O
caused,5005,O
by,5005,O
PTH,5005,B-GENE-Y
therapy,5005,O
is,5005,O
mainly,5005,O
accounted,5005,O
for,5005,O
by,5005,O
the,5005,O
ability,5005,O
of,5005,O
PTH,5005,B-GENE-Y
to,5005,O
increase,5005,O
osteoblastogenesis,5005,O
and,5005,O
osteoblast,5005,O
survival,5005,O
.,5005,O
PTH,5006,B-GENE-Y
and,5006,O
PTH-related,5006,B-GENE-Y
protein,5006,I-GENE-Y
(,5006,O
PTHrP,5006,B-GENE-Y
),5006,O
-an,5006,O
abundant,5006,O
local,5006,O
factor,5006,O
in,5006,O
bone-,5006,O
interact,5006,O
with,5006,O
the,5006,O
common,5006,O
PTH,5006,B-GENE-Y
type,5006,I-GENE-Y
1,5006,I-GENE-Y
receptor,5006,I-GENE-Y
with,5006,O
similar,5006,O
affinities,5006,O
in,5006,O
osteoblasts,5006,O
.,5006,O
Studies,5007,O
mainly,5007,O
in,5007,O
osteoporosis,5007,O
rodent,5007,O
models,5007,O
and,5007,O
limited,5007,O
data,5007,O
in,5007,O
postmenopausal,5007,O
women,5007,O
suggest,5007,O
that,5007,O
N-terminal,5007,B-CHEMICAL
PTHrP,5007,B-GENE-Y
peptides,5007,O
might,5007,O
be,5007,O
considered,5007,O
a,5007,O
promising,5007,O
bone,5007,O
anabolic,5007,O
therapy,5007,O
.,5007,O
In,5008,O
addition,5008,O
",",5008,O
putative,5008,O
osteogenic,5008,O
actions,5008,O
of,5008,O
PTHrP,5008,B-GENE-Y
might,5008,O
be,5008,O
ascribed,5008,O
not,5008,O
only,5008,O
to,5008,O
its,5008,O
N-terminal,5008,B-CHEMICAL
domain,5008,O
but,5008,O
also,5008,O
to,5008,O
its,5008,O
PTH-unrelated,5008,B-GENE-Y
C-terminal,5008,B-CHEMICAL
region,5008,O
.,5008,O
In,5009,O
this,5009,O
review,5009,O
",",5009,O
we,5009,O
discuss,5009,O
the,5009,O
underlying,5009,O
cellular,5009,O
and,5009,O
molecular,5009,O
mechanisms,5009,O
of,5009,O
the,5009,O
anabolic,5009,O
actions,5009,O
of,5009,O
PTH,5009,B-GENE-Y
and,5009,O
the,5009,O
similar,5009,O
potential,5009,O
of,5009,O
PTH-related,5009,B-GENE-Y
protein,5009,I-GENE-Y
(,5009,O
PTHrP,5009,B-GENE-Y
),5009,O
to,5009,O
increase,5009,O
bone,5009,O
mass,5009,O
and,5009,O
improve,5009,O
bone,5009,O
regeneration,5009,O
.,5009,O
Pharmacotherapy,5010,O
for,5010,O
the,5010,O
core,5010,O
symptoms,5010,O
in,5010,O
autistic,5010,O
disorder,5010,O
:,5010,O
current,5010,O
status,5010,O
of,5010,O
the,5010,O
research,5010,O
.,5010,O
The,5011,O
current,5011,O
review,5011,O
covers,5011,O
extant,5011,O
literature,5011,O
on,5011,O
pharmacotherapy,5011,O
for,5011,O
core,5011,O
symptoms,5011,O
of,5011,O
autism,5011,O
.,5011,O
The,5012,O
core,5012,O
symptoms,5012,O
of,5012,O
autism,5012,O
include,5012,O
impairments,5012,O
in,5012,O
social,5012,O
interaction,5012,O
and,5012,O
communication,5012,O
",",5012,O
as,5012,O
well,5012,O
as,5012,O
the,5012,O
presence,5012,O
of,5012,O
restricted,5012,O
and,5012,O
repetitive,5012,O
behaviors,5012,O
.,5012,O
There,5013,O
are,5013,O
no,5013,O
known,5013,O
efficacious,5013,O
treatments,5013,O
for,5013,O
the,5013,O
core,5013,O
social,5013,O
symptoms,5013,O
",",5013,O
although,5013,O
effects,5013,O
on,5013,O
repetitive,5013,O
behaviors,5013,O
are,5013,O
indicated,5013,O
with,5013,O
some,5013,O
data,5013,O
.,5013,O
While,5014,O
studies,5014,O
of,5014,O
fenfluramine,5014,B-CHEMICAL
",",5014,O
secretin,5014,B-GENE-Y
",",5014,O
opiates,5014,O
",",5014,O
and,5014,O
mood,5014,O
stabilizers,5014,O
generally,5014,O
find,5014,O
no,5014,O
effect,5014,O
",",5014,O
mixed,5014,O
results,5014,O
suggest,5014,O
more,5014,O
research,5014,O
is,5014,O
needed,5014,O
on,5014,O
antidepressants,5014,O
and,5014,O
atypical,5014,O
antipsychotics,5014,O
.,5014,O
Newer,5015,O
lines,5015,O
of,5015,O
research,5015,O
",",5015,O
including,5015,O
cholinergic,5015,O
and,5015,O
glutamatergic,5015,O
agents,5015,O
and,5015,O
oxytocin,5015,B-GENE-Y
",",5015,O
will,5015,O
be,5015,O
of,5015,O
considerable,5015,O
interest,5015,O
in,5015,O
the,5015,O
future,5015,O
.,5015,O
However,5016,O
",",5016,O
research,5016,O
on,5016,O
the,5016,O
treatment,5016,O
of,5016,O
core,5016,O
symptoms,5016,O
is,5016,O
plagued,5016,O
by,5016,O
limitations,5016,O
in,5016,O
study,5016,O
design,5016,O
",",5016,O
statistical,5016,O
power,5016,O
",",5016,O
and,5016,O
other,5016,O
issues,5016,O
inherent,5016,O
to,5016,O
the,5016,O
study,5016,O
of,5016,O
treatments,5016,O
for,5016,O
autism,5016,O
(,5016,O
e.g.,5016,O
",",5016,O
heterogeneity,5016,O
of,5016,O
the,5016,O
disorder,5016,O
),5016,O
that,5016,O
continue,5016,O
to,5016,O
prevent,5016,O
the,5016,O
elucidation,5016,O
of,5016,O
efficacious,5016,O
treatments,5016,O
.,5016,O
Ectopic,5017,O
Thyroid,5017,O
Tissue,5017,O
in,5017,O
the,5017,O
Adrenal,5017,O
Gland,5017,O
:,5017,O
Report,5017,O
of,5017,O
2,5017,O
Cases,5017,O
with,5017,O
Pathogenetic,5017,O
Implications,5017,O
.,5017,O
Background,5018,O
:,5018,O
Ectopic,5018,O
thyroid,5018,O
tissue,5018,O
is,5018,O
usually,5018,O
found,5018,O
anywhere,5018,O
along,5018,O
the,5018,O
embryonic,5018,O
descent,5018,O
pathway,5018,O
of,5018,O
the,5018,O
medial,5018,O
thyroid,5018,O
anlage,5018,O
from,5018,O
the,5018,O
tongue,5018,O
to,5018,O
the,5018,O
trachea,5018,O
(,5018,O
Wlfler,5018,O
area,5018,O
),5018,O
.,5018,O
However,5019,O
",",5019,O
ectopic,5019,O
thyroid,5019,O
tissue,5019,O
in,5019,O
the,5019,O
adrenal,5019,O
gland,5019,O
(,5019,O
ETTAG,5019,O
),5019,O
is,5019,O
not,5019,O
easy,5019,O
to,5019,O
understand,5019,O
on,5019,O
the,5019,O
basis,5019,O
of,5019,O
thyroid,5019,O
embryology,5019,O
;,5019,O
because,5019,O
it,5019,O
is,5019,O
so,5019,O
rare,5019,O
",",5019,O
the,5019,O
possibility,5019,O
of,5019,O
metastasis,5019,O
should,5019,O
first,5019,O
be,5019,O
considered,5019,O
.,5019,O
Here,5020,O
",",5020,O
we,5020,O
describe,5020,O
2,5020,O
cases,5020,O
of,5020,O
ETTAG,5020,O
with,5020,O
pathogenetic,5020,O
implications,5020,O
and,5020,O
review,5020,O
the,5020,O
literature,5020,O
.,5020,O
Patient,5021,O
findings,5021,O
:,5021,O
Two,5021,O
cases,5021,O
of,5021,O
ETTAG,5021,O
presented,5021,O
as,5021,O
incidental,5021,O
cystic,5021,O
adrenal,5021,O
masses,5021,O
in,5021,O
adult,5021,O
females,5021,O
",",5021,O
one,5021,O
having,5021,O
a,5021,O
congenital,5021,O
hernia,5021,O
of,5021,O
Morgagni,5021,O
.,5021,O
The,5022,O
ETTAG,5022,O
was,5022,O
histologically,5022,O
indistinguishable,5022,O
from,5022,O
normal,5022,O
orthotopic,5022,O
thyroid,5022,O
tissue,5022,O
",",5022,O
and,5022,O
its,5022,O
follicular,5022,O
nature,5022,O
was,5022,O
confirmed,5022,O
by,5022,O
immunohistochemical,5022,O
positivity,5022,O
for,5022,O
thyroglobulin,5022,B-GENE-Y
",",5022,O
thyroperoxidase,5022,B-GENE-Y
",",5022,O
thyroid,5022,B-GENE-Y
transcription,5022,I-GENE-Y
factor-1,5022,I-GENE-Y
(,5022,O
TTF-1/Titf-1/Nkx2.1,5022,B-GENE-Y
),5022,O
",",5022,O
cytokeratin,5022,B-GENE-N
(,5022,O
CK,5022,B-GENE-N
),5022,O
AE1/AE3,5022,O
",",5022,O
CK,5022,B-GENE-Y
7,5022,I-GENE-Y
",",5022,O
pendrin,5022,B-GENE-Y
",",5022,O
human,5022,B-GENE-Y
sodium,5022,I-GENE-Y
iodide,5022,I-GENE-Y
symporter,5022,I-GENE-Y
(,5022,O
hNIS,5022,B-GENE-Y
),5022,O
",",5022,O
paired,5022,B-GENE-Y
box,5022,I-GENE-Y
gene,5022,I-GENE-Y
8,5022,I-GENE-Y
(,5022,O
PAX8,5022,B-GENE-Y
),5022,O
and,5022,O
FOXE1,5022,B-GENE-Y
(,5022,O
TTF-2,5022,B-GENE-Y
),5022,O
",",5022,O
as,5022,O
well,5022,O
as,5022,O
positivity,5022,O
for,5022,O
the,5022,O
messenger,5022,O
RNA,5022,O
of,5022,O
the,5022,O
thyroglobulin,5022,B-GENE-Y
gene,5022,O
by,5022,O
in,5022,O
situ,5022,O
hybridization,5022,O
analysis,5022,O
.,5022,O
No,5023,O
C,5023,O
cells,5023,O
(,5023,O
negativity,5023,O
for,5023,O
calcitonin,5023,B-GENE-Y
",",5023,O
cromogranin,5023,B-GENE-N
and,5023,O
synaptophysin,5023,B-GENE-Y
),5023,O
were,5023,O
present,5023,O
.,5023,O
Neither,5024,O
BRAF,5024,B-GENE-Y
nor,5024,O
KRAS,5024,B-GENE-Y
mutations,5024,O
were,5024,O
detected,5024,O
with,5024,O
real-time,5024,O
polymerase,5024,O
chain,5024,O
reaction,5024,O
analysis,5024,O
.,5024,O
Further,5025,O
work-up,5025,O
did,5025,O
not,5025,O
show,5025,O
evidence,5025,O
of,5025,O
thyroid,5025,O
malignancy,5025,O
.,5025,O
Summary,5026,O
:,5026,O
ETTAG,5026,O
is,5026,O
a,5026,O
rare,5026,O
finding,5026,O
",",5026,O
with,5026,O
only,5026,O
7,5026,O
cases,5026,O
reported,5026,O
;,5026,O
women,5026,O
are,5026,O
much,5026,O
more,5026,O
frequently,5026,O
affected,5026,O
than,5026,O
men,5026,O
(,5026,O
8:1,5026,O
),5026,O
and,5026,O
it,5026,O
usually,5026,O
clinically,5026,O
presents,5026,O
in,5026,O
the,5026,O
fifth,5026,O
decade,5026,O
(,5026,O
mean,5026,O
age,5026,O
:,5026,O
54,5026,O
",",5026,O
range,5026,O
:,5026,O
38-67,5026,O
),5026,O
as,5026,O
a,5026,O
cystic,5026,O
adrenal,5026,O
mass,5026,O
incidentally,5026,O
discovered,5026,O
on,5026,O
abdominal,5026,O
ultrasonography,5026,O
and/or,5026,O
in,5026,O
computed,5026,O
tomography,5026,O
images,5026,O
.,5026,O
ETTAG,5027,O
is,5027,O
composed,5027,O
of,5027,O
normal,5027,O
follicular,5027,O
cells,5027,O
without,5027,O
C,5027,O
cells,5027,O
.,5027,O
The,5028,O
expression,5028,O
of,5028,O
some,5028,O
transcription,5028,O
factors,5028,O
(,5028,O
TTF-1,5028,B-GENE-Y
",",5028,O
PAX8,5028,B-GENE-Y
and,5028,O
FOXE1,5028,B-GENE-Y
),5028,O
involved,5028,O
in,5028,O
development,5028,O
and/or,5028,O
migration,5028,O
of,5028,O
the,5028,O
medial,5028,O
thyroid,5028,O
anlage,5028,O
is,5028,O
preserved,5028,O
.,5028,O
Coexistence,5029,O
of,5029,O
a,5029,O
congenital,5029,O
hernia,5029,O
of,5029,O
Morgagni,5029,O
in,5029,O
one,5029,O
patient,5029,O
suggests,5029,O
an,5029,O
over-descent,5029,O
of,5029,O
medial,5029,O
thyroid,5029,O
anlage,5029,O
derived,5029,O
cells,5029,O
in,5029,O
its,5029,O
pathogenesis,5029,O
.,5029,O
Conclusion,5030,O
:,5030,O
Although,5030,O
ETTAG,5030,O
pathogenesis,5030,O
remains,5030,O
unknown,5030,O
",",5030,O
the,5030,O
lack,5030,O
of,5030,O
C,5030,O
cells,5030,O
together,5030,O
with,5030,O
the,5030,O
coexistence,5030,O
of,5030,O
a,5030,O
congenital,5030,O
defect,5030,O
of,5030,O
the,5030,O
anterior,5030,O
diaphragm,5030,O
(,5030,O
hernia,5030,O
of,5030,O
Morgagni,5030,O
),5030,O
in,5030,O
one,5030,O
of,5030,O
our,5030,O
patients,5030,O
could,5030,O
suggest,5030,O
an,5030,O
over-descent,5030,O
of,5030,O
medial,5030,O
thyroid,5030,O
anlagen,5030,O
derived,5030,O
cells,5030,O
in,5030,O
the,5030,O
origin,5030,O
of,5030,O
this,5030,O
heterotopia,5030,O
.,5030,O
Synthesis,5031,O
of,5031,O
a,5031,O
DOTA,5031,B-CHEMICAL
(,5031,O
Gd,5031,B-CHEMICAL
(,5031,I-CHEMICAL
3+,5031,I-CHEMICAL
),5031,I-CHEMICAL
),5031,O
-conjugate,5031,O
of,5031,O
proton-pump,5031,B-GENE-N
inhibitor,5031,O
pantoprazole,5031,B-CHEMICAL
for,5031,O
gastric,5031,O
wall,5031,O
imaging,5031,O
studies,5031,O
.,5031,O
Magnetic,5032,O
resonance,5032,O
imaging,5032,O
(,5032,O
MRI,5032,O
),5032,O
is,5032,O
used,5032,O
to,5032,O
evaluate,5032,O
gastrointestinal,5032,O
(,5032,O
GI,5032,O
),5032,O
structure,5032,O
and,5032,O
functions,5032,O
in,5032,O
humans,5032,O
.,5032,O
Despite,5033,O
filling,5033,O
the,5033,O
viscus,5033,O
lumen,5033,O
with,5033,O
a,5033,O
contrast,5033,O
agent,5033,O
",",5033,O
visualization,5033,O
of,5033,O
the,5033,O
viscus,5033,O
wall,5033,O
is,5033,O
limited,5033,O
.,5033,O
To,5034,O
overcome,5034,O
this,5034,O
limitation,5034,O
",",5034,O
we,5034,O
de,5034,O
novo,5034,O
synthesized,5034,O
a,5034,O
conjugate,5034,O
that,5034,O
covalently,5034,O
combines,5034,O
a,5034,O
Gd-based,5034,B-CHEMICAL
MRI,5034,O
contrast,5034,O
agent,5034,O
",",5034,O
encaged,5034,O
with,5034,O
a,5034,O
chelating,5034,O
agent,5034,O
(,5034,O
DOTA,5034,B-CHEMICAL
),5034,O
",",5034,O
with,5034,O
pantoprazole,5034,B-CHEMICAL
",",5034,O
which,5034,O
is,5034,O
a,5034,O
widely,5034,O
used,5034,O
proton,5034,B-GENE-N
pump,5034,I-GENE-N
inhibitor,5034,O
that,5034,O
binds,5034,O
to,5034,O
proton,5034,B-GENE-N
pumps,5034,I-GENE-N
in,5034,O
the,5034,O
stomach,5034,O
and,5034,O
colon,5034,O
.,5034,O
The,5035,O
DOTA,5035,B-CHEMICAL
linkage,5035,O
was,5035,O
installed,5035,O
at,5035,O
a,5035,O
mechanism-based,5035,O
strategic,5035,O
location,5035,O
in,5035,O
the,5035,O
pantoprazole,5035,B-CHEMICAL
molecule,5035,O
to,5035,O
minimize,5035,O
a,5035,O
possible,5035,O
negative,5035,O
effect,5035,O
of,5035,O
the,5035,O
structural,5035,O
modification,5035,O
on,5035,O
the,5035,O
drug,5035,O
.,5035,O
It,5036,O
is,5036,O
anticipated,5036,O
that,5036,O
by,5036,O
defining,5036,O
the,5036,O
wall,5036,O
of,5036,O
the,5036,O
stomach,5036,O
and,5036,O
colon,5036,O
",",5036,O
this,5036,O
compound,5036,O
will,5036,O
facilitate,5036,O
functional,5036,O
MRI,5036,O
of,5036,O
the,5036,O
GI,5036,O
tract,5036,O
in,5036,O
humans,5036,O
.,5036,O
Acetylcholinesterase,5037,B-GENE-Y
inhibition,5037,O
reveals,5037,O
endogenous,5037,O
nicotinic,5037,O
modulation,5037,O
of,5037,O
glutamate,5037,B-CHEMICAL
inputs,5037,O
to,5037,O
CA1,5037,O
stratum,5037,O
radiatum,5037,O
interneurons,5037,O
in,5037,O
hippocampal,5037,O
slices,5037,O
.,5037,O
The,5038,O
involvement,5038,O
of,5038,O
brain,5038,O
nicotinic,5038,B-GENE-N
acetylcholine,5038,B-CHEMICAL
receptors,5038,I-GENE-N
(,5038,O
nAChRs,5038,B-GENE-N
),5038,O
in,5038,O
the,5038,O
neurotoxicological,5038,O
effects,5038,O
of,5038,O
soman,5038,O
",",5038,O
a,5038,O
potent,5038,O
acetylcholinesterase,5038,B-GENE-Y
(,5038,O
AChE,5038,B-GENE-Y
),5038,O
inhibitor,5038,O
and,5038,O
a,5038,O
chemical,5038,O
warfare,5038,O
agent,5038,O
",",5038,O
is,5038,O
not,5038,O
clear,5038,O
.,5038,O
This,5039,O
is,5039,O
partly,5039,O
due,5039,O
to,5039,O
a,5039,O
poor,5039,O
understanding,5039,O
of,5039,O
the,5039,O
role,5039,O
of,5039,O
AChE,5039,B-GENE-Y
in,5039,O
brain,5039,O
nAChR-mediated,5039,B-GENE-N
functions,5039,O
.,5039,O
To,5040,O
test,5040,O
the,5040,O
hypothesis,5040,O
that,5040,O
AChE,5040,B-GENE-Y
inhibition,5040,O
builds,5040,O
sufficient,5040,O
acetylcholine,5040,B-CHEMICAL
(,5040,O
ACh,5040,O
),5040,O
in,5040,O
the,5040,O
brain,5040,O
and,5040,O
facilitates,5040,O
nAChR-dependent,5040,B-GENE-N
glutamate,5040,B-CHEMICAL
transmission,5040,O
",",5040,O
we,5040,O
used,5040,O
whole-cell,5040,O
patch-clamp,5040,O
technique,5040,O
to,5040,O
record,5040,O
spontaneous,5040,O
glutamate,5040,B-CHEMICAL
excitatory,5040,O
postsynaptic,5040,O
currents,5040,O
(,5040,O
EPSCs,5040,O
),5040,O
from,5040,O
CA1,5040,O
stratum,5040,O
radiatum,5040,O
interneurons,5040,O
(,5040,O
SRI,5040,O
),5040,O
in,5040,O
hippocampal,5040,O
slices,5040,O
.,5040,O
First,5041,O
",",5041,O
the,5041,O
frequency,5041,O
",",5041,O
amplitude,5041,O
and,5041,O
kinetics,5041,O
of,5041,O
EPSCs,5041,O
recorded,5041,O
from,5041,O
slices,5041,O
of,5041,O
control,5041,O
guinea,5041,O
pigs,5041,O
were,5041,O
compared,5041,O
to,5041,O
those,5041,O
recorded,5041,O
from,5041,O
slices,5041,O
of,5041,O
guinea,5041,O
pigs,5041,O
after,5041,O
a,5041,O
single,5041,O
injection,5041,O
of,5041,O
the,5041,O
irreversible,5041,O
AChE,5041,B-GENE-Y
inhibitor,5041,O
soman,5041,O
(,5041,O
25.2g/kg,5041,O
",",5041,O
s.c.,5041,O
),5041,O
.,5041,O
Second,5042,O
",",5042,O
EPSCs,5042,O
were,5042,O
recorded,5042,O
from,5042,O
rat,5042,O
hippocampal,5042,O
slices,5042,O
before,5042,O
and,5042,O
after,5042,O
their,5042,O
superfusion,5042,O
with,5042,O
the,5042,O
reversible,5042,O
AChE,5042,B-GENE-Y
inhibitor,5042,O
donepezil,5042,B-CHEMICAL
(,5042,O
100nM,5042,O
),5042,O
.,5042,O
The,5043,O
frequency,5043,O
of,5043,O
EPSCs,5043,O
was,5043,O
significantly,5043,O
higher,5043,O
in,5043,O
slices,5043,O
taken,5043,O
from,5043,O
guinea,5043,O
pigs,5043,O
24h,5043,O
but,5043,O
not,5043,O
7,5043,O
days,5043,O
after,5043,O
the,5043,O
soman,5043,O
injection,5043,O
than,5043,O
in,5043,O
slices,5043,O
from,5043,O
control,5043,O
animals,5043,O
.,5043,O
In,5044,O
52,5044,O
%,5044,O
of,5044,O
the,5044,O
rat,5044,O
hippocampal,5044,O
slices,5044,O
tested,5044,O
",",5044,O
bath,5044,O
application,5044,O
of,5044,O
donepezil,5044,B-CHEMICAL
increased,5044,O
the,5044,O
frequency,5044,O
of,5044,O
EPSCs,5044,O
.,5044,O
Further,5045,O
",",5045,O
exposure,5045,O
to,5045,O
donepezil,5045,B-CHEMICAL
increased,5045,O
both,5045,O
burst-like,5045,O
and,5045,O
large-amplitude,5045,O
EPSCs,5045,O
",",5045,O
and,5045,O
increased,5045,O
the,5045,O
proportion,5045,O
of,5045,O
short,5045,O
(,5045,O
20-100ms,5045,O
),5045,O
inter-event,5045,O
intervals,5045,O
.,5045,O
Donepezil,5046,B-CHEMICAL
's,5046,O
effects,5046,O
were,5046,O
suppressed,5046,O
significantly,5046,O
in,5046,O
presence,5046,O
of,5046,O
10M,5046,O
mecamylamine,5046,B-CHEMICAL
or,5046,O
10nM,5046,O
methyllycaconitine,5046,B-CHEMICAL
.,5046,O
These,5047,O
results,5047,O
support,5047,O
the,5047,O
concept,5047,O
that,5047,O
AChE,5047,B-GENE-Y
inhibition,5047,O
is,5047,O
able,5047,O
to,5047,O
recruit,5047,O
nAChR-dependent,5047,B-GENE-N
glutamate,5047,B-CHEMICAL
transmission,5047,O
in,5047,O
the,5047,O
hippocampus,5047,O
and,5047,O
such,5047,O
a,5047,O
mechanism,5047,O
can,5047,O
contribute,5047,O
to,5047,O
the,5047,O
acute,5047,O
neurotoxicological,5047,O
actions,5047,O
of,5047,O
soman,5047,O
.,5047,O
A,5048,O
Nanogram,5048,O
Dose,5048,O
of,5048,O
the,5048,O
CYP3A,5048,B-GENE-N
Probe,5048,O
Substrate,5048,O
Midazolam,5048,B-CHEMICAL
to,5048,O
Evaluate,5048,O
Drug,5048,O
Interactions,5048,O
.,5048,O
The,5049,O
objective,5049,O
of,5049,O
the,5049,O
study,5049,O
was,5049,O
to,5049,O
establish,5049,O
an,5049,O
in,5049,O
vivo,5049,O
method,5049,O
for,5049,O
assessing,5049,O
cytochrome,5049,B-GENE-N
P450,5049,I-GENE-N
3A,5049,I-GENE-N
(,5049,O
CYP3A,5049,B-GENE-N
),5049,O
activity,5049,O
using,5049,O
therapeutically,5049,O
inert,5049,O
nanogram,5049,O
doses,5049,O
of,5049,O
midazolam,5049,B-CHEMICAL
.,5049,O
We,5050,O
administered,5050,O
four,5050,O
escalating,5050,O
single,5050,O
doses,5050,O
of,5050,O
oral,5050,O
midazolam,5050,B-CHEMICAL
(,5050,O
0.0001-3,5050,O
mg,5050,O
),5050,O
to,5050,O
12,5050,O
healthy,5050,O
participants,5050,O
",",5050,O
stratified,5050,O
according,5050,O
to,5050,O
CYP3A5,5050,B-GENE-Y
carrier,5050,O
status,5050,O
",",5050,O
to,5050,O
assess,5050,O
pharmacokinetics,5050,O
linearity,5050,O
.,5050,O
We,5051,O
then,5051,O
evaluated,5051,O
the,5051,O
interactions,5051,O
with,5051,O
the,5051,O
CYP3A,5051,B-GENE-N
inhibitor,5051,O
ketoconazole,5051,B-CHEMICAL
(,5051,O
400,5051,O
mg,5051,O
q.d,5051,O
.,5051,O
),5051,O
after,5052,O
nanogram,5052,O
and,5052,O
regular,5052,O
doses,5052,O
of,5052,O
midazolam,5052,B-CHEMICAL
.,5052,O
Area,5053,O
under,5053,O
the,5053,O
plasma,5053,O
concentration-time,5053,O
curve,5053,O
(,5053,O
AUC,5053,O
),5053,O
and,5053,O
peak,5053,O
plasma,5053,O
concentration,5053,O
(,5053,O
Cmax,5053,O
),5053,O
were,5053,O
linear,5053,O
over,5053,O
the,5053,O
entire,5053,O
range,5053,O
of,5053,O
doses,5053,O
.,5053,O
Ketoconazole,5054,B-CHEMICAL
reduced,5054,O
midazolam,5054,B-CHEMICAL
oral,5054,O
clearance,5054,O
by,5054,O
92.8,5054,O
%,5054,O
.,5054,O
AUC,5055,O
and,5055,O
Cmax,5055,O
increased,5055,O
by,5055,O
"1,540",5055,O
and,5055,O
363,5055,O
%,5055,O
",",5055,O
respectively,5055,O
.,5055,O
CYP3A5,5056,B-GENE-Y
carrier,5056,O
status,5056,O
had,5056,O
no,5056,O
influence,5056,O
on,5056,O
midazolam,5056,B-CHEMICAL
oral,5056,O
clearance,5056,O
or,5056,O
its,5056,O
inhibition,5056,O
by,5056,O
ketoconazole,5056,B-CHEMICAL
.,5056,O
This,5057,O
is,5057,O
the,5057,O
first,5057,O
study,5057,O
showing,5057,O
that,5057,O
midazolam,5057,B-CHEMICAL
pharmacokinetics,5057,O
is,5057,O
linear,5057,O
in,5057,O
a,5057,O
"30,000-fold",5057,O
concentration,5057,O
range,5057,O
",",5057,O
and,5057,O
therefore,5057,O
that,5057,O
nano-,5057,O
and,5057,O
microgram,5057,O
doses,5057,O
of,5057,O
midazolam,5057,B-CHEMICAL
can,5057,O
reliably,5057,O
predict,5057,O
the,5057,O
pharmacokinetics,5057,O
of,5057,O
midazolam,5057,B-CHEMICAL
in,5057,O
therapeutic,5057,O
doses,5057,O
and,5057,O
can,5057,O
be,5057,O
used,5057,O
to,5057,O
assess,5057,O
CYP3A,5057,B-GENE-Y
activity,5057,O
even,5057,O
in,5057,O
the,5057,O
presence,5057,O
of,5057,O
strong,5057,O
CYP3A,5057,B-GENE-Y
inhibitors.Clinical,5057,O
Pharmacology,5057,O
&,5057,O
Therapeutics,5057,O
(,5057,O
2013,5057,O
),5057,O
;,5057,O
advance,5057,O
online,5057,O
publication,5057,O
20,5057,O
March,5057,O
2013.,5057,O
doi:10.1038/clpt.2013.27,5057,O
.,5057,O
NAD,5058,B-GENE-Y
(,5058,I-GENE-Y
P,5058,I-GENE-Y
),5058,I-GENE-Y
H,5058,I-GENE-Y
:,5058,I-GENE-Y
Quinone,5058,I-GENE-Y
Oxidoreductase,5058,I-GENE-Y
1,5058,I-GENE-Y
Inducer,5058,O
Activity,5058,O
of,5058,O
Some,5058,O
Saudi,5058,O
Arabian,5058,O
Medicinal,5058,O
Plants,5058,O
.,5058,O
Medicinal,5059,O
plants,5059,O
are,5059,O
a,5059,O
rich,5059,O
source,5059,O
of,5059,O
biologically-active,5059,O
phytochemicals,5059,O
and,5059,O
have,5059,O
been,5059,O
used,5059,O
in,5059,O
traditional,5059,O
medicine,5059,O
for,5059,O
centuries,5059,O
.,5059,O
Specific,5060,O
phytochemicals,5060,O
and,5060,O
extracts,5060,O
of,5060,O
their,5060,O
plant,5060,O
sources,5060,O
have,5060,O
the,5060,O
ability,5060,O
to,5060,O
reduce,5060,O
the,5060,O
risk,5060,O
for,5060,O
chronic,5060,O
degenerative,5060,O
diseases,5060,O
by,5060,O
induction,5060,O
of,5060,O
enzymes,5060,O
involved,5060,O
in,5060,O
xenobiotic,5060,O
metabolism,5060,O
",",5060,O
many,5060,O
of,5060,O
which,5060,O
also,5060,O
have,5060,O
antioxidant,5060,O
and,5060,O
anti-inflammatory,5060,O
functions,5060,O
.,5060,O
One,5061,O
such,5061,O
multifunctional,5061,O
cytoprotective,5061,O
enzyme,5061,O
is,5061,O
NAD,5061,B-CHEMICAL
(,5061,I-CHEMICAL
P,5061,I-CHEMICAL
),5061,I-CHEMICAL
H,5061,I-CHEMICAL
:,5061,I-GENE-N
quinone,5061,B-CHEMICAL
oxidoreductase,5061,I-GENE-N
.,5061,O
In,5062,O
this,5062,O
study,5062,O
",",5062,O
we,5062,O
prepared,5062,O
extracts,5062,O
of,5062,O
27,5062,O
Saudi,5062,O
Arabian,5062,O
medicinal,5062,O
plants,5062,O
which,5062,O
belong,5062,O
to,5062,O
18,5062,O
different,5062,O
plant,5062,O
families,5062,O
and,5062,O
tested,5062,O
their,5062,O
ability,5062,O
to,5062,O
induce,5062,O
NAD,5062,B-CHEMICAL
(,5062,I-CHEMICAL
P,5062,I-CHEMICAL
),5062,I-CHEMICAL
H,5062,I-CHEMICAL
:,5062,I-GENE-N
quinone,5062,I-GENE-N
oxidoreductase,5062,I-GENE-N
in,5062,O
murine,5062,O
hepatoma,5062,O
cells,5062,O
grown,5062,O
in,5062,O
microtiter,5062,O
plate,5062,O
wells,5062,O
.,5062,O
In,5063,O
addition,5063,O
to,5063,O
the,5063,O
Brassicaceae,5063,O
",",5063,O
a,5063,O
known,5063,O
source,5063,O
of,5063,O
NAD,5063,B-GENE-N
(,5063,I-GENE-N
P,5063,I-GENE-N
),5063,I-GENE-N
H,5063,I-GENE-N
:,5063,I-GENE-N
quinone,5063,I-GENE-N
oxidoreductase,5063,I-GENE-N
inducer,5063,I-GENE-N
activity,5063,I-GENE-N
",",5063,O
we,5063,O
found,5063,O
substantial,5063,O
inducer,5063,O
activity,5063,O
in,5063,O
extracts,5063,O
from,5063,O
the,5063,O
Apiaceae,5063,O
",",5063,O
Apocynaceae,5063,O
",",5063,O
and,5063,O
the,5063,O
Asteraceae,5063,O
families,5063,O
.,5063,O
Five,5064,O
out,5064,O
of,5064,O
a,5064,O
total,5064,O
of,5064,O
eight,5064,O
active,5064,O
extracts,5064,O
are,5064,O
from,5064,O
plants,5064,O
which,5064,O
belong,5064,O
to,5064,O
the,5064,O
Asteraceae,5064,O
family,5064,O
.,5064,O
We,5065,O
further,5065,O
show,5065,O
that,5065,O
artemisinin,5065,B-CHEMICAL
",",5065,O
an,5065,O
agent,5065,O
which,5065,O
is,5065,O
used,5065,O
clinically,5065,O
for,5065,O
the,5065,O
treatment,5065,O
of,5065,O
malaria,5065,O
",",5065,O
contributes,5065,O
but,5065,O
does,5065,O
not,5065,O
fully,5065,O
account,5065,O
for,5065,O
the,5065,O
inducer,5065,O
activity,5065,O
of,5065,O
the,5065,O
extract,5065,O
of,5065,O
Artemisia,5065,O
monosperma,5065,O
.,5065,O
In,5066,O
contrast,5066,O
to,5066,O
artemisinin,5066,B-CHEMICAL
",",5066,O
deoxyartemisinin,5066,B-CHEMICAL
is,5066,O
inactive,5066,O
in,5066,O
this,5066,O
assay,5066,O
",",5066,O
demonstrating,5066,O
the,5066,O
critical,5066,O
role,5066,O
of,5066,O
the,5066,O
endoperoxide,5066,O
moiety,5066,O
of,5066,O
artemisinin,5066,B-CHEMICAL
for,5066,O
inducer,5066,O
activity,5066,O
.,5066,O
Thus,5067,O
",",5067,O
the,5067,O
NAD,5067,B-CHEMICAL
(,5067,I-CHEMICAL
P,5067,I-CHEMICAL
),5067,I-CHEMICAL
H,5067,I-CHEMICAL
:,5067,I-GENE-N
quinone,5067,B-CHEMICAL
oxidoreductase,5067,I-GENE-N
inducer,5067,O
activity,5067,O
of,5067,O
extracts,5067,O
of,5067,O
some,5067,O
Saudi,5067,O
Arabian,5067,O
medicinal,5067,O
plants,5067,O
indicates,5067,O
the,5067,O
presence,5067,O
of,5067,O
specific,5067,O
phytochemicals,5067,O
which,5067,O
have,5067,O
the,5067,O
potential,5067,O
to,5067,O
protect,5067,O
against,5067,O
chronic,5067,O
degenerative,5067,O
diseases,5067,O
.,5067,O
Metabolism,5068,O
of,5068,O
Beclomethasone,5068,B-CHEMICAL
Dipropionate,5068,I-CHEMICAL
by,5068,O
Cytochrome,5068,B-GENE-N
P450,5068,I-GENE-N
3A,5068,I-GENE-N
Enzymes,5068,O
.,5068,O
Inhaled,5069,O
glucocorticoids,5069,O
",",5069,O
such,5069,O
as,5069,O
beclomethasone,5069,B-CHEMICAL
dipropionate,5069,I-CHEMICAL
(,5069,O
BDP,5069,B-CHEMICAL
),5069,O
",",5069,O
are,5069,O
the,5069,O
mainstay,5069,O
treatment,5069,O
of,5069,O
asthma,5069,O
.,5069,O
However,5070,O
",",5070,O
30,5070,O
%,5070,O
of,5070,O
patients,5070,O
exhibit,5070,O
little,5070,O
to,5070,O
no,5070,O
benefit,5070,O
from,5070,O
treatment,5070,O
.,5070,O
It,5071,O
has,5071,O
been,5071,O
postulated,5071,O
that,5071,O
glucocorticoid,5071,O
resistance,5071,O
",",5071,O
or,5071,O
insensitivity,5071,O
",",5071,O
is,5071,O
attributable,5071,O
to,5071,O
individual,5071,O
differences,5071,O
in,5071,O
glucocorticoid,5071,B-GENE-Y
receptor-mediated,5071,O
processes,5071,O
.,5071,O
It,5072,O
is,5072,O
possible,5072,O
that,5072,O
variations,5072,O
in,5072,O
cytochrome,5072,B-GENE-N
P450,5072,I-GENE-N
3A,5072,I-GENE-N
enzyme-mediated,5072,O
metabolism,5072,O
of,5072,O
BDP,5072,B-CHEMICAL
may,5072,O
contribute,5072,O
to,5072,O
this,5072,O
phenomenon,5072,O
.,5072,O
This,5073,O
hypothesis,5073,O
was,5073,O
explored,5073,O
by,5073,O
evaluating,5073,O
the,5073,O
contributions,5073,O
of,5073,O
CYP3A4,5073,B-GENE-N
",",5073,I-GENE-N
3A5,5073,I-GENE-N
",",5073,I-GENE-N
3A7,5073,I-GENE-N
",",5073,O
and,5073,O
esterase,5073,B-GENE-N
enzymes,5073,O
in,5073,O
the,5073,O
metabolism,5073,O
of,5073,O
BDP,5073,B-CHEMICAL
in,5073,O
vitro,5073,O
and,5073,O
relating,5073,O
metabolism,5073,O
to,5073,O
changes,5073,O
in,5073,O
CYP3A,5073,B-GENE-N
enzyme,5073,O
mRNA,5073,O
expression,5073,O
via,5073,O
the,5073,O
glucocorticoid,5073,B-GENE-Y
receptor,5073,I-GENE-Y
in,5073,O
lung,5073,O
and,5073,O
liver,5073,O
cells,5073,O
.,5073,O
CYP3A4,5074,B-GENE-Y
and,5074,O
CYP3A5,5074,B-GENE-Y
metabolized,5074,O
BDP,5074,B-CHEMICAL
via,5074,O
hydroxylation,5074,O
(,5074,O
[,5074,O
M4,5074,O
],5074,O
and,5074,O
[,5074,O
M6,5074,O
],5074,O
),5074,O
and,5074,O
dehydrogenation,5074,O
(,5074,O
[,5074,O
M5,5074,O
],5074,O
),5074,O
at,5074,O
similar,5074,O
rates,5074,O
;,5074,O
CYP3A7,5074,B-GENE-Y
did,5074,O
not,5074,O
metabolize,5074,O
BDP,5074,B-CHEMICAL
.,5074,O
A,5075,O
new,5075,O
metabolite,5075,O
[,5075,O
M6,5075,O
],5075,O
",",5075,O
formed,5075,O
by,5075,O
the,5075,O
combined,5075,O
action,5075,O
of,5075,O
esterases,5075,O
and,5075,O
CYP3A4,5075,B-GENE-Y
hydroxylation,5075,O
",",5075,O
was,5075,O
also,5075,O
characterized,5075,O
.,5075,O
To,5076,O
validate,5076,O
the,5076,O
results,5076,O
observed,5076,O
using,5076,O
microsomes,5076,O
and,5076,O
recombinant,5076,O
enzymes,5076,O
",",5076,O
studies,5076,O
were,5076,O
also,5076,O
conducted,5076,O
using,5076,O
A549,5076,O
lung,5076,O
and,5076,O
DPX2,5076,O
liver,5076,O
cells,5076,O
.,5076,O
Both,5077,O
liver,5077,O
and,5077,O
lung,5077,O
cells,5077,O
produced,5077,O
esterase-dependent,5077,O
metabolites,5077,O
[,5077,O
M1-M3,5077,O
],5077,O
",",5077,O
with,5077,O
[,5077,O
M1,5077,O
],5077,O
correlating,5077,O
with,5077,O
CYP3A5,5077,B-GENE-Y
mRNA,5077,O
induction,5077,O
in,5077,O
A549,5077,O
cells,5077,O
.,5077,O
Liver,5078,O
cells,5078,O
produced,5078,O
both,5078,O
hydroxylated,5078,O
and,5078,O
dehydrogenated,5078,O
metabolites,5078,O
[,5078,O
M4,5078,O
",",5078,O
M5,5078,O
",",5078,O
and,5078,O
M6,5078,O
],5078,O
",",5078,O
but,5078,O
lung,5078,O
cells,5078,O
produced,5078,O
only,5078,O
the,5078,O
dehydrogenated,5078,O
metabolite,5078,O
[,5078,O
M5,5078,O
],5078,O
.,5078,O
These,5079,O
studies,5079,O
show,5079,O
that,5079,O
CYP3A4,5079,B-GENE-Y
and,5079,O
CYP3A5,5079,B-GENE-Y
metabolize,5079,O
BDP,5079,B-CHEMICAL
to,5079,O
inactive,5079,O
metabolites,5079,O
and,5079,O
suggest,5079,O
that,5079,O
differences,5079,O
in,5079,O
the,5079,O
expression,5079,O
or,5079,O
function,5079,O
of,5079,O
these,5079,O
enzymes,5079,O
in,5079,O
the,5079,O
lung,5079,O
and/or,5079,O
liver,5079,O
could,5079,O
influence,5079,O
BDP,5079,B-CHEMICAL
disposition,5079,O
in,5079,O
humans,5079,O
.,5079,O
Effect,5080,O
of,5080,O
the,5080,O
Potent,5080,O
Antiviral,5080,O
"1-Cinnamoyl-3,11-Dihydroxymeliacarpin",5080,B-CHEMICAL
on,5080,O
Cytokine,5080,B-GENE-N
Production,5080,O
by,5080,O
Murine,5080,O
Macrophages,5080,O
Stimulated,5080,O
with,5080,O
HSV-2,5080,O
.,5080,O
The,5081,O
limonoid,5081,O
"1-cinnamoyl-3,11-dihydroxymeliacarpin",5081,B-CHEMICAL
(,5081,O
CDM,5081,B-CHEMICAL
),5081,O
isolated,5081,O
from,5081,O
leaf,5081,O
extracts,5081,O
of,5081,O
Melia,5081,O
azedarach,5081,O
L,5081,O
",",5081,O
has,5081,O
potent,5081,O
antiherpetic,5081,O
effect,5081,O
in,5081,O
epithelial,5081,O
cells,5081,O
.,5081,O
Since,5082,O
Meliacine,5082,O
",",5082,O
the,5082,O
partially,5082,O
purified,5082,O
extract,5082,O
source,5082,O
of,5082,O
CDM,5082,B-CHEMICAL
",",5082,O
has,5082,O
therapeutic,5082,O
effect,5082,O
on,5082,O
murine,5082,O
genital,5082,O
herpes,5082,O
",",5082,O
the,5082,O
potential,5082,O
use,5082,O
of,5082,O
CDM,5082,B-CHEMICAL
as,5082,O
microbicide,5082,O
against,5082,O
herpetic,5082,O
infections,5082,O
was,5082,O
studied,5082,O
here,5082,O
.,5082,O
To,5083,O
determine,5083,O
the,5083,O
cytotoxic,5083,O
effect,5083,O
of,5083,O
CDM,5083,B-CHEMICAL
",",5083,O
the,5083,O
MTT,5083,B-CHEMICAL
assay,5083,O
and,5083,O
acridine,5083,O
orange,5083,O
staining,5083,O
of,5083,O
living,5083,O
cells,5083,O
were,5083,O
performed,5083,O
.,5083,O
The,5084,O
antiherpetic,5084,O
action,5084,O
of,5084,O
CDM,5084,B-CHEMICAL
was,5084,O
measured,5084,O
by,5084,O
plaque,5084,O
reduction,5084,O
assay,5084,O
",",5084,O
and,5084,O
the,5084,O
immunomodulatory,5084,O
effect,5084,O
was,5084,O
determined,5084,O
by,5084,O
measuring,5084,O
the,5084,O
cytokine,5084,B-GENE-N
production,5084,O
using,5084,O
a,5084,O
bioassay,5084,O
and,5084,O
ELISA,5084,O
method,5084,O
.,5084,O
The,5085,O
results,5085,O
presented,5085,O
here,5085,O
showed,5085,O
that,5085,O
CDM,5085,B-CHEMICAL
inhibited,5085,O
Herpes,5085,O
Simplex,5085,O
Virus,5085,O
type,5085,O
2,5085,O
(,5085,O
HSV-2,5085,O
),5085,O
multiplication,5085,O
in,5085,O
Vero,5085,O
cells,5085,O
but,5085,O
did,5085,O
not,5085,O
affect,5085,O
its,5085,O
replication,5085,O
in,5085,O
macrophages,5085,O
which,5085,O
were,5085,O
not,5085,O
permissive,5085,O
to,5085,O
HSV,5085,O
infection,5085,O
.,5085,O
In,5086,O
macrophages,5086,O
",",5086,O
levels,5086,O
of,5086,O
TNF-,5086,B-GENE-Y
",",5086,O
IFN-,5086,B-GENE-Y
",",5086,O
NO,5086,O
",",5086,O
IL-6,5086,B-GENE-Y
and,5086,O
IL-10,5086,B-GENE-Y
were,5086,O
increased,5086,O
by,5086,O
CDM,5086,B-CHEMICAL
used,5086,O
alone,5086,O
or,5086,O
in,5086,O
combination,5086,O
with,5086,O
HSV-2,5086,O
.,5086,O
Besides,5087,O
",",5087,O
CDM,5087,B-CHEMICAL
not,5087,O
only,5087,O
synergized,5087,O
TNF-,5087,B-GENE-Y
production,5087,O
combined,5087,O
with,5087,O
IFN-,5087,B-GENE-Y
",",5087,O
but,5087,O
also,5087,O
prolonged,5087,O
its,5087,O
expression,5087,O
in,5087,O
time,5087,O
.,5087,O
Results,5088,O
indicate,5088,O
that,5088,O
CDM,5088,B-CHEMICAL
inhibits,5088,O
HSV-2,5088,O
multiplication,5088,O
in,5088,O
epithelial,5088,O
cells,5088,O
and,5088,O
also,5088,O
increases,5088,O
cytokine,5088,B-GENE-N
production,5088,O
in,5088,O
macrophages,5088,O
",",5088,O
both,5088,O
important,5088,O
actions,5088,O
to,5088,O
the,5088,O
clearance,5088,O
of,5088,O
infecting,5088,O
virus,5088,O
in,5088,O
the,5088,O
mouse,5088,O
vagina,5088,O
.,5088,O
Copyright,5089,O
,5089,O
2013,5089,O
John,5089,O
Wiley,5089,O
&,5089,O
Sons,5089,O
",",5089,O
Ltd,5089,O
.,5089,O
Intestinal,5090,O
and,5090,O
hepatic,5090,O
first-pass,5090,O
extraction,5090,O
of,5090,O
the,5090,O
11-HSD1,5090,B-GENE-Y
inhibitor,5090,O
AMG,5090,B-CHEMICAL
221,5090,I-CHEMICAL
in,5090,O
rats,5090,O
with,5090,O
chronic,5090,O
vascular,5090,O
catheters,5090,O
.,5090,O
Abstract,5091,O
1,5091,O
.,5091,O
A,5092,O
catheterized,5092,O
rat,5092,O
model,5092,O
was,5092,O
used,5092,O
to,5092,O
define,5092,O
the,5092,O
intestinal,5092,O
and,5092,O
hepatic,5092,O
components,5092,O
of,5092,O
oral,5092,O
bioavailability,5092,O
for,5092,O
an,5092,O
11-HSD1,5092,B-GENE-Y
inhibitor,5092,O
",",5092,O
AMG,5092,B-CHEMICAL
221,5092,I-CHEMICAL
.,5092,O
These,5093,O
data,5093,O
were,5093,O
integrated,5093,O
with,5093,O
standard,5093,O
in,5093,O
vivo,5093,O
metabolism,5093,O
studies,5093,O
to,5093,O
elucidate,5093,O
the,5093,O
components,5093,O
contributing,5093,O
to,5093,O
the,5093,O
oral,5093,O
disposition,5093,O
of,5093,O
a,5093,O
novel,5093,O
drug,5093,O
candidate,5093,O
.,5093,O
2,5094,O
.,5094,O
Intestinal,5095,O
and,5095,O
hepatic,5095,O
extraction,5095,O
ratios,5095,O
of,5095,O
AMG,5095,B-CHEMICAL
221,5095,I-CHEMICAL
obtained,5095,O
using,5095,O
a,5095,O
five-catheter,5095,O
rat,5095,O
model,5095,O
were,5095,O
0.56,5095,O
and,5095,O
0.32,5095,O
",",5095,O
respectively,5095,O
.,5095,O
Therefore,5096,O
",",5096,O
both,5096,O
intestinal,5096,O
and,5096,O
hepatic,5096,O
extraction,5096,O
contributed,5096,O
to,5096,O
the,5096,O
first-pass,5096,O
component,5096,O
of,5096,O
oral,5096,O
bioavailability,5096,O
.,5096,O
There,5097,O
was,5097,O
no,5097,O
evidence,5097,O
for,5097,O
significant,5097,O
gut,5097,O
extraction,5097,O
of,5097,O
systemically,5097,O
administered,5097,O
drug,5097,O
.,5097,O
3,5098,O
.,5098,O
Mass,5099,O
balance,5099,O
data,5099,O
and,5099,O
in,5099,O
vivo,5099,O
metabolite,5099,O
characterization,5099,O
obtained,5099,O
after,5099,O
administration,5099,O
of,5099,O
[,5099,B-CHEMICAL
(,5099,I-CHEMICAL
14,5099,I-CHEMICAL
),5099,I-CHEMICAL
C,5099,I-CHEMICAL
],5099,I-CHEMICAL
AMG,5099,I-CHEMICAL
221,5099,I-CHEMICAL
to,5099,O
rat,5099,O
showed,5099,O
that,5099,O
AMG,5099,B-CHEMICAL
221,5099,I-CHEMICAL
was,5099,O
completely,5099,O
absorbed,5099,O
from,5099,O
the,5099,O
gut,5099,O
lumen,5099,O
following,5099,O
an,5099,O
oral,5099,O
dose,5099,O
",",5099,O
primarily,5099,O
excreted,5099,O
in,5099,O
urine,5099,O
and,5099,O
was,5099,O
almost,5099,O
completely,5099,O
metabolized,5099,O
prior,5099,O
to,5099,O
excretion,5099,O
.,5099,O
4,5100,O
.,5100,O
Hepatic,5101,O
bioavailability,5101,O
(,5101,O
FH,5101,O
),5101,O
",",5101,O
measured,5101,O
in,5101,O
two,5101,O
animals,5101,O
at,5101,O
various,5101,O
time,5101,O
points,5101,O
after,5101,O
oral,5101,O
dose,5101,O
administration,5101,O
was,5101,O
somewhat,5101,O
variable,5101,O
but,5101,O
generally,5101,O
characterized,5101,O
by,5101,O
an,5101,O
initial,5101,O
reduction,5101,O
during,5101,O
the,5101,O
absorption,5101,O
phase,5101,O
followed,5101,O
by,5101,O
an,5101,O
increase,5101,O
during,5101,O
the,5101,O
elimination,5101,O
phase,5101,O
",",5101,O
consistent,5101,O
with,5101,O
hepatic,5101,O
distribution,5101,O
of,5101,O
AMG,5101,B-CHEMICAL
221,5101,I-CHEMICAL
.,5101,O
5,5102,O
.,5102,O
The,5103,O
five-catheter,5103,O
rat,5103,O
model,5103,O
afforded,5103,O
estimates,5103,O
of,5103,O
hepatic,5103,O
and,5103,O
intestinal,5103,O
contribution,5103,O
to,5103,O
oral,5103,O
bioavailability,5103,O
that,5103,O
were,5103,O
used,5103,O
with,5103,O
other,5103,O
data,5103,O
to,5103,O
define,5103,O
the,5103,O
preclinical,5103,O
ADME,5103,O
characteristics,5103,O
of,5103,O
a,5103,O
drug,5103,O
candidate,5103,O
.,5103,O
Synthesis,5104,O
and,5104,O
selected,5104,O
immunological,5104,O
properties,5104,O
of,5104,O
substituted,5104,O
quino,5104,B-CHEMICAL
[,5104,I-CHEMICAL
"3,2-b",5104,I-CHEMICAL
],5104,I-CHEMICAL
benzo,5104,I-CHEMICAL
[,5104,I-CHEMICAL
"1,4",5104,I-CHEMICAL
],5104,I-CHEMICAL
thiazines,5104,I-CHEMICAL
.,5104,O
A,5105,O
new,5105,O
type,5105,O
of,5105,O
azaphenothiazines,5105,B-CHEMICAL
-,5105,O
tetracyclic,5105,B-CHEMICAL
quino,5105,I-CHEMICAL
[,5105,I-CHEMICAL
"3,2-b",5105,I-CHEMICAL
],5105,I-CHEMICAL
benzo,5105,I-CHEMICAL
[,5105,I-CHEMICAL
"1,4",5105,I-CHEMICAL
],5105,I-CHEMICAL
thiazines,5105,I-CHEMICAL
",",5105,O
possessing,5105,O
common,5105,O
substituents,5105,O
(,5105,O
H,5105,B-CHEMICAL
",",5105,O
CH3,5105,B-CHEMICAL
",",5105,O
Cl,5105,B-CHEMICAL
",",5105,O
Br,5105,B-CHEMICAL
",",5105,O
F,5105,B-CHEMICAL
",",5105,O
CF3,5105,B-CHEMICAL
",",5105,O
SCH3,5105,B-CHEMICAL
),5105,O
in,5105,O
positions,5105,O
8-10,5105,O
and,5105,O
pharmacophoric,5105,O
aminoalkyl,5105,B-CHEMICAL
substituents,5105,O
in,5105,O
position,5105,O
6,5105,O
",",5105,O
were,5105,O
obtained,5105,O
from,5105,O
diquinodithiin,5105,B-CHEMICAL
and,5105,O
"2,2'-dichloro-3,3'-diquinolinyl",5105,B-CHEMICAL
disulfide,5105,I-CHEMICAL
in,5105,O
several-step,5105,O
syntheses,5105,O
.,5105,O
Sixty,5106,O
one,5106,O
compounds,5106,O
",",5106,O
grouped,5106,O
as,5106,O
the,5106,O
6H,5106,O
",",5106,O
6-dialkylaminoalkyl,5106,B-CHEMICAL
",",5106,O
6-acylaminoalkyl,5106,B-CHEMICAL
and,5106,O
sulfonylaminoalkyl,5106,B-CHEMICAL
derivatives,5106,O
",",5106,O
were,5106,O
tested,5106,O
for,5106,O
cytotoxicity,5106,O
",",5106,O
their,5106,O
effects,5106,O
on,5106,O
phytohemagglutin,5106,B-GENE-N
A,5106,I-GENE-N
(,5106,O
PHA,5106,B-GENE-N
),5106,O
-induced,5106,O
proliferative,5106,O
response,5106,O
of,5106,O
human,5106,O
peripheral,5106,O
blood,5106,O
mononuclear,5106,O
cells,5106,O
(,5106,O
PBMC,5106,O
),5106,O
and,5106,O
lipopolysaccharide,5106,O
(,5106,O
LPS,5106,O
),5106,O
-induced,5106,O
tumor,5106,B-GENE-Y
necrosis,5106,I-GENE-Y
factor,5106,I-GENE-Y
alpha,5106,I-GENE-Y
(,5106,O
TNF-,5106,B-GENE-Y
),5106,O
production,5106,O
by,5106,O
these,5106,O
cells,5106,O
.,5106,O
The,5107,O
compounds,5107,O
exhibited,5107,O
differential,5107,O
inhibitory,5107,O
activities,5107,O
in,5107,O
these,5107,O
tests,5107,O
and,5107,O
significantly,5107,O
varied,5107,O
in,5107,O
terms,5107,O
of,5107,O
cytotoxicity,5107,O
.,5107,O
The,5108,O
most,5108,O
promising,5108,O
compounds,5108,O
were,5108,O
tested,5108,O
for,5108,O
growth,5108,O
inhibition,5108,O
of,5108,O
leukemia,5108,O
L-1210,5108,O
cells,5108,O
",",5108,O
colon,5108,O
cancer,5108,O
SV-948,5108,O
cells,5108,O
and,5108,O
epidermal,5108,O
carcinoma,5108,O
A-341,5108,O
cells,5108,O
.,5108,O
The,5109,O
most,5109,O
active,5109,O
compounds,5109,O
exhibited,5109,O
anticancer,5109,O
activity,5109,O
against,5109,O
these,5109,O
cell,5109,O
lines,5109,O
comparable,5109,O
to,5109,O
that,5109,O
of,5109,O
cisplatin,5109,B-CHEMICAL
.,5109,O
The,5110,O
structure-activity,5110,O
relationship,5110,O
of,5110,O
the,5110,O
compounds,5110,O
were,5110,O
discussed,5110,O
.,5110,O
Predictive,5111,O
factors,5111,O
of,5111,O
sensitivity,5111,O
to,5111,O
elisidepsin,5111,B-CHEMICAL
",",5111,O
a,5111,O
novel,5111,O
kahalalide,5111,B-CHEMICAL
f-derived,5111,O
marine,5111,O
compound,5111,O
.,5111,O
Elisidepsin,5112,B-CHEMICAL
(,5112,O
PM02734,5112,B-CHEMICAL
",",5112,O
Irvalec,5112,B-CHEMICAL
),5112,O
is,5112,O
a,5112,O
synthetic,5112,O
marine-derived,5112,O
cyclic,5112,O
peptide,5112,O
of,5112,O
the,5112,O
Kahalalide,5112,B-CHEMICAL
F,5112,I-CHEMICAL
family,5112,O
currently,5112,O
in,5112,O
phase,5112,O
II,5112,O
clinical,5112,O
development,5112,O
.,5112,O
Elisidepsin,5113,B-CHEMICAL
was,5113,O
shown,5113,O
to,5113,O
induce,5113,O
rapid,5113,O
oncosis,5113,O
in,5113,O
ErbB3-expressing,5113,B-GENE-Y
cells,5113,O
.,5113,O
Other,5114,O
predictive,5114,O
factors,5114,O
of,5114,O
elisidepsin,5114,B-CHEMICAL
sensitivity,5114,O
remained,5114,O
unknown,5114,O
.,5114,O
A,5115,O
panel,5115,O
of,5115,O
23,5115,O
cancer,5115,O
cell,5115,O
lines,5115,O
of,5115,O
different,5115,O
origin,5115,O
was,5115,O
assessed,5115,O
for,5115,O
elisidepsin,5115,B-CHEMICAL
cytotoxicity,5115,O
and,5115,O
correlated,5115,O
with,5115,O
mutational,5115,O
state,5115,O
",",5115,O
mRNA,5115,O
and,5115,O
protein,5115,O
expression,5115,O
of,5115,O
selected,5115,O
genes,5115,O
.,5115,O
Elisidepsin,5116,B-CHEMICAL
showed,5116,O
potent,5116,O
and,5116,O
broad,5116,O
cytotoxic,5116,O
effects,5116,O
in,5116,O
our,5116,O
cancer,5116,O
cell,5116,O
line,5116,O
panel,5116,O
",",5116,O
being,5116,O
active,5116,O
at,5116,O
concentrations,5116,O
ranging,5116,O
from,5116,O
0.4,5116,O
to,5116,O
2,5116,O
M,5116,O
that,5116,O
may,5116,O
be,5116,O
relevant,5116,O
for,5116,O
clinical,5116,O
settings,5116,O
.,5116,O
We,5117,O
have,5117,O
shown,5117,O
that,5117,O
elisidepsin,5117,B-CHEMICAL
is,5117,O
more,5117,O
active,5117,O
in,5117,O
cells,5117,O
harboring,5117,O
epithelial,5117,O
phenotype,5117,O
with,5117,O
high,5117,O
E-cadherin,5117,B-GENE-Y
and,5117,O
low,5117,O
vimentin,5117,B-GENE-Y
expression,5117,O
.,5117,O
In,5118,O
addition,5118,O
",",5118,O
high,5118,O
ErbB3,5118,B-GENE-Y
and,5118,O
Muc1,5118,B-GENE-Y
expression,5118,O
was,5118,O
correlated,5118,O
with,5118,O
sensitivity,5118,O
to,5118,O
elisidepsin,5118,B-CHEMICAL
",",5118,O
whereas,5118,O
the,5118,O
presence,5118,O
of,5118,O
KRAS,5118,B-GENE-Y
activating,5118,O
mutations,5118,O
was,5118,O
associated,5118,O
with,5118,O
resistance,5118,O
.,5118,O
In,5119,O
DU-PM,5119,O
cells,5119,O
with,5119,O
acquired,5119,O
resistance,5119,O
to,5119,O
elisidepsin,5119,B-CHEMICAL
",",5119,O
ErbB3,5119,B-GENE-Y
expression,5119,O
was,5119,O
decreased,5119,O
",",5119,O
while,5119,O
Bcl2,5119,B-GENE-Y
was,5119,O
increased,5119,O
.,5119,O
DU-PM,5120,O
cells,5120,O
displayed,5120,O
higher,5120,O
sensitivity,5120,O
to,5120,O
ErbB1-inhibitors,5120,B-GENE-Y
suggesting,5120,O
possible,5120,O
cross-talk,5120,O
of,5120,O
ErbB1,5120,B-GENE-Y
and,5120,O
ErbB3,5120,B-GENE-Y
signaling,5120,O
pathways,5120,O
.,5120,O
Combinations,5121,O
of,5121,O
elisidepsin,5121,B-CHEMICAL
with,5121,O
lapatinib,5121,B-CHEMICAL
and,5121,O
several,5121,O
chemotherapies,5121,O
including,5121,O
5-FU,5121,B-CHEMICAL
and,5121,O
oxaliplatin,5121,B-CHEMICAL
resulted,5121,O
in,5121,O
synergistic,5121,O
effects,5121,O
that,5121,O
offer,5121,O
the,5121,O
potential,5121,O
of,5121,O
clinical,5121,O
use,5121,O
of,5121,O
elisidepsin,5121,B-CHEMICAL
in,5121,O
combination,5121,O
settings,5121,O
.,5121,O
Controlled,5122,O
Assembly,5122,O
of,5122,O
Gold,5122,O
Nanoparticles,5122,O
through,5122,O
Antibody,5122,O
Recognition,5122,O
:,5122,O
Study,5122,O
and,5122,O
Utilizing,5122,O
the,5122,O
Effect,5122,O
of,5122,O
Particle,5122,O
Size,5122,O
on,5122,O
Interparticle,5122,O
Distance,5122,O
.,5122,O
An,5123,O
assembly,5123,O
of,5123,O
gold,5123,O
nanoparticle,5123,O
through,5123,O
the,5123,O
recognition,5123,O
of,5123,O
unmodified,5123,O
antibody,5123,O
was,5123,O
developed,5123,O
.,5123,O
The,5124,O
use,5124,O
of,5124,O
peptide,5124,O
(,5124,O
Cys-Ala-Leu-Asn-Asn,5124,B-GENE-N
),5124,O
as,5124,O
ligands,5124,O
to,5124,O
stabilize,5124,O
and,5124,O
functionalize,5124,O
gold,5124,O
nanoparticles,5124,O
provides,5124,O
technical,5124,O
and,5124,O
operational,5124,O
convenience,5124,O
.,5124,O
These,5125,O
peptide-capped,5125,O
particles,5125,O
in,5125,O
different,5125,O
sizes,5125,O
are,5125,O
recognized,5125,O
by,5125,O
antibody,5125,O
and,5125,O
assembly,5125,O
to,5125,O
form,5125,O
dimers,5125,O
and,5125,O
expanded,5125,O
hybrid,5125,O
material,5125,O
by,5125,O
controlling,5125,O
the,5125,O
conditions,5125,O
.,5125,O
The,5126,O
interparticle,5126,O
spacing,5126,O
of,5126,O
these,5126,O
assemblies,5126,O
was,5126,O
well,5126,O
studied,5126,O
with,5126,O
small-angle,5126,O
X-ray,5126,O
scattering,5126,O
measurements,5126,O
",",5126,O
and,5126,O
it,5126,O
was,5126,O
found,5126,O
that,5126,O
the,5126,O
interparticle,5126,O
spacing,5126,O
is,5126,O
inversely,5126,O
dependent,5126,O
on,5126,O
the,5126,O
particle,5126,O
size,5126,O
.,5126,O
This,5127,O
relationship,5127,O
of,5127,O
interparticle,5127,O
spacing,5127,O
and,5127,O
particle,5127,O
size,5127,O
is,5127,O
closely,5127,O
related,5127,O
to,5127,O
the,5127,O
structure,5127,O
of,5127,O
antibody,5127,O
linker,5127,O
.,5127,O
Therefore,5128,O
",",5128,O
analyzing,5128,O
the,5128,O
interparticle,5128,O
spacing,5128,O
of,5128,O
assemblies,5128,O
can,5128,O
reveal,5128,O
the,5128,O
equilibrium,5128,O
configuration,5128,O
of,5128,O
IgG,5128,B-GENE-N
.,5128,O
Based,5129,O
on,5129,O
the,5129,O
investigation,5129,O
",",5129,O
the,5129,O
Fab-Fab,5129,O
angle,5129,O
of,5129,O
IgG,5129,B-GENE-N
is,5129,O
obtained,5129,O
to,5129,O
be,5129,O
102,5129,O
and,5129,O
the,5129,O
Fab,5129,O
arms,5129,O
are,5129,O
7.8,5129,O
nm,5129,O
.,5129,O
These,5130,O
results,5130,O
provide,5130,O
new,5130,O
experimental,5130,O
data,5130,O
on,5130,O
the,5130,O
structure,5130,O
of,5130,O
flexible,5130,O
IgG,5130,B-GENE-N
.,5130,O
Differential,5131,O
responses,5131,O
to,5131,O
-agatoxin,5131,B-GENE-Y
IVA,5131,I-GENE-Y
in,5131,O
murine,5131,O
frontal,5131,O
cortex,5131,O
and,5131,O
spinal,5131,O
cord,5131,O
derived,5131,O
neuronal,5131,O
networks,5131,O
.,5131,O
-Agatoxin-IVA,5132,B-GENE-Y
is,5132,O
a,5132,O
well,5132,O
known,5132,O
P/Q-type,5132,B-GENE-N
Ca,5132,B-CHEMICAL
(,5132,I-CHEMICAL
2+,5132,I-CHEMICAL
),5132,I-CHEMICAL
channel,5132,I-GENE-N
blocker,5132,O
and,5132,O
has,5132,O
been,5132,O
shown,5132,O
to,5132,O
affect,5132,O
presynaptic,5132,O
Ca,5132,B-CHEMICAL
(,5132,I-CHEMICAL
2+,5132,I-CHEMICAL
),5132,I-CHEMICAL
currents,5132,O
as,5132,O
well,5132,O
postsynaptic,5132,O
potentials,5132,O
.,5132,O
P/Q-type,5133,B-GENE-N
voltage,5133,I-GENE-N
gated,5133,I-GENE-N
Ca,5133,I-GENE-N
(,5133,I-GENE-N
2+,5133,I-GENE-N
),5133,I-GENE-N
channels,5133,I-GENE-N
play,5133,O
a,5133,O
vital,5133,O
role,5133,O
in,5133,O
presynaptic,5133,O
neurotransmitter,5133,O
release,5133,O
and,5133,O
thus,5133,O
play,5133,O
a,5133,O
role,5133,O
in,5133,O
action,5133,O
potential,5133,O
generation,5133,O
.,5133,O
Monitoring,5134,O
spontaneous,5134,O
activity,5134,O
of,5134,O
neuronal,5134,O
networks,5134,O
on,5134,O
microelectrode,5134,O
arrays,5134,O
(,5134,O
MEAs,5134,O
),5134,O
provides,5134,O
an,5134,O
important,5134,O
tool,5134,O
for,5134,O
examining,5134,O
this,5134,O
neurotoxin,5134,O
.,5134,O
Changes,5135,O
in,5135,O
extracellular,5135,O
action,5135,O
potentials,5135,O
are,5135,O
readily,5135,O
observed,5135,O
and,5135,O
are,5135,O
dependent,5135,O
on,5135,O
synaptic,5135,O
function,5135,O
.,5135,O
Given,5136,O
the,5136,O
efficacy,5136,O
of,5136,O
murine,5136,O
frontal,5136,O
cortex,5136,O
and,5136,O
spinal,5136,O
cord,5136,O
networks,5136,O
to,5136,O
detect,5136,O
neuroactive,5136,O
substances,5136,O
",",5136,O
we,5136,O
investigated,5136,O
the,5136,O
effects,5136,O
of,5136,O
-agatoxin,5136,B-GENE-N
on,5136,O
spontaneous,5136,O
action,5136,O
potential,5136,O
firing,5136,O
within,5136,O
these,5136,O
networks,5136,O
.,5136,O
We,5137,O
found,5137,O
that,5137,O
networks,5137,O
derived,5137,O
from,5137,O
spinal,5137,O
cord,5137,O
are,5137,O
more,5137,O
sensitive,5137,O
to,5137,O
the,5137,O
toxin,5137,O
than,5137,O
those,5137,O
from,5137,O
frontal,5137,O
cortex,5137,O
;,5137,O
a,5137,O
concentration,5137,O
of,5137,O
only,5137,O
10nM,5137,O
produced,5137,O
statistically,5137,O
significant,5137,O
effects,5137,O
on,5137,O
activity,5137,O
from,5137,O
spinal,5137,O
cord,5137,O
networks,5137,O
whereas,5137,O
50nM,5137,O
was,5137,O
required,5137,O
to,5137,O
alter,5137,O
activity,5137,O
in,5137,O
frontal,5137,O
cortex,5137,O
networks,5137,O
.,5137,O
Furthermore,5138,O
",",5138,O
the,5138,O
effects,5138,O
of,5138,O
the,5138,O
toxin,5138,O
on,5138,O
frontal,5138,O
cortex,5138,O
are,5138,O
more,5138,O
complex,5138,O
as,5138,O
unit,5138,O
specific,5138,O
responses,5138,O
were,5138,O
observed,5138,O
.,5138,O
These,5139,O
manifested,5139,O
as,5139,O
either,5139,O
a,5139,O
decrease,5139,O
or,5139,O
increase,5139,O
in,5139,O
action,5139,O
potential,5139,O
firing,5139,O
rate,5139,O
which,5139,O
could,5139,O
be,5139,O
statistically,5139,O
separated,5139,O
as,5139,O
unique,5139,O
clusters,5139,O
.,5139,O
Administration,5140,O
of,5140,O
bicuculline,5140,B-CHEMICAL
",",5140,O
a,5140,O
GABAA,5140,B-GENE-N
inhibitor,5140,O
",",5140,O
isolated,5140,O
a,5140,O
single,5140,O
response,5140,O
to,5140,O
-agatoxin,5140,B-GENE-N
",",5140,O
which,5140,O
was,5140,O
characterized,5140,O
by,5140,O
a,5140,O
reduction,5140,O
in,5140,O
network,5140,O
activity,5140,O
.,5140,O
These,5141,O
data,5141,O
support,5141,O
the,5141,O
notion,5141,O
that,5141,O
the,5141,O
two,5141,O
clusters,5141,O
detected,5141,O
with,5141,O
-agatoxin,5141,B-GENE-N
exposure,5141,O
represent,5141,O
differential,5141,O
responses,5141,O
from,5141,O
excitatory,5141,O
and,5141,O
inhibitory,5141,O
neuronal,5141,O
populations,5141,O
.,5141,O
Pharmacokinetic,5142,O
",",5142,O
neurochemical,5142,O
",",5142,O
stereological,5142,O
and,5142,O
neuropathological,5142,O
studies,5142,O
on,5142,O
the,5142,O
potential,5142,O
effects,5142,O
of,5142,O
paraquat,5142,B-CHEMICAL
in,5142,O
the,5142,O
substantia,5142,O
nigra,5142,O
pars,5142,O
compacta,5142,O
and,5142,O
striatum,5142,O
of,5142,O
male,5142,O
C57BL/6J,5142,O
mice,5142,O
.,5142,O
The,5143,O
pharmacokinetics,5143,O
and,5143,O
neurotoxicity,5143,O
of,5143,O
paraquat,5143,B-CHEMICAL
dichloride,5143,I-CHEMICAL
(,5143,O
PQ,5143,O
),5143,O
were,5143,O
assessed,5143,O
following,5143,O
once,5143,O
weekly,5143,O
administration,5143,O
to,5143,O
C57BL/6J,5143,O
male,5143,O
mice,5143,O
by,5143,O
intraperitoneal,5143,O
injection,5143,O
for,5143,O
1,5143,O
",",5143,O
2,5143,O
or,5143,O
3,5143,O
weeks,5143,O
at,5143,O
doses,5143,O
of,5143,O
10,5143,O
",",5143,O
15,5143,O
or,5143,O
25mg/kg/week,5143,O
.,5143,O
Approximately,5144,O
0.3,5144,O
%,5144,O
of,5144,O
the,5144,O
administered,5144,O
dose,5144,O
was,5144,O
taken,5144,O
up,5144,O
by,5144,O
the,5144,O
brain,5144,O
and,5144,O
was,5144,O
slowly,5144,O
eliminated,5144,O
",",5144,O
with,5144,O
a,5144,O
half-life,5144,O
of,5144,O
approximately,5144,O
3,5144,O
weeks,5144,O
.,5144,O
PQ,5145,O
did,5145,O
not,5145,O
alter,5145,O
the,5145,O
concentration,5145,O
of,5145,O
dopamine,5145,B-CHEMICAL
(,5145,O
DA,5145,O
),5145,O
",",5145,O
homovanillic,5145,B-CHEMICAL
acid,5145,I-CHEMICAL
(,5145,O
HVA,5145,B-CHEMICAL
),5145,O
or,5145,O
"3,4-dihydroxyphenylacetic",5145,B-CHEMICAL
acid,5145,I-CHEMICAL
(,5145,O
DOPAC,5145,B-CHEMICAL
),5145,O
",",5145,O
or,5145,O
increase,5145,O
dopamine,5145,B-CHEMICAL
turnover,5145,O
in,5145,O
the,5145,O
striatum,5145,O
.,5145,O
There,5146,O
was,5146,O
inconsistent,5146,O
stereological,5146,O
evidence,5146,O
of,5146,O
a,5146,O
loss,5146,O
of,5146,O
DA,5146,O
neurons,5146,O
",",5146,O
as,5146,O
identified,5146,O
by,5146,O
chromogenic,5146,O
or,5146,O
fluorescent-tagged,5146,O
antibodies,5146,O
to,5146,O
tyrosine,5146,B-GENE-Y
hydroxylase,5146,I-GENE-Y
in,5146,O
the,5146,O
substantia,5146,O
nigra,5146,O
pars,5146,O
compacta,5146,O
(,5146,O
SNpc,5146,O
),5146,O
.,5146,O
There,5147,O
was,5147,O
no,5147,O
evidence,5147,O
that,5147,O
PQ,5147,O
induced,5147,O
neuronal,5147,O
degeneration,5147,O
in,5147,O
the,5147,O
SNpc,5147,O
or,5147,O
degenerating,5147,O
neuronal,5147,O
processes,5147,O
in,5147,O
the,5147,O
striatum,5147,O
",",5147,O
as,5147,O
indicated,5147,O
by,5147,O
the,5147,O
absence,5147,O
of,5147,O
uptake,5147,O
of,5147,O
silver,5147,B-CHEMICAL
stain,5147,O
or,5147,O
reduced,5147,O
immunolabeling,5147,O
of,5147,O
tyrosine-hydroxylase-positive,5147,B-GENE-Y
(,5147,O
TH,5147,B-GENE-Y
(,5147,O
+,5147,O
),5147,O
),5147,O
neurons,5147,O
.,5147,O
There,5148,O
was,5148,O
no,5148,O
evidence,5148,O
of,5148,O
apoptotic,5148,O
cell,5148,O
death,5148,O
",",5148,O
which,5148,O
was,5148,O
evaluated,5148,O
using,5148,O
TUNEL,5148,O
or,5148,O
caspase,5148,B-GENE-Y
3,5148,I-GENE-Y
assays,5148,O
.,5148,O
Microglia,5149,O
(,5149,O
IBA-1,5149,O
immunoreactivity,5149,O
),5149,O
and,5149,O
astrocytes,5149,O
(,5149,O
GFAP,5149,O
immunoreactivity,5149,O
),5149,O
were,5149,O
not,5149,O
activated,5149,O
in,5149,O
PQ-treated,5149,O
mice,5149,O
4,5149,O
",",5149,O
8,5149,O
",",5149,O
16,5149,O
",",5149,O
24,5149,O
",",5149,O
48,5149,O
",",5149,O
96,5149,O
or,5149,O
168h,5149,O
after,5149,O
1,5149,O
",",5149,O
2,5149,O
or,5149,O
3,5149,O
doses,5149,O
of,5149,O
PQ,5149,O
.,5149,O
In,5150,O
contrast,5150,O
",",5150,O
mice,5150,O
dosed,5150,O
with,5150,O
the,5150,O
positive,5150,O
control,5150,O
substance,5150,O
",",5150,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",5150,B-CHEMICAL
(,5150,O
MPTP,5150,B-CHEMICAL
;,5150,O
10mg/kg/dose4,5150,O
doses,5150,O
",",5150,O
2h,5150,O
apart,5150,O
),5150,O
",",5150,O
displayed,5150,O
significantly,5150,O
reduced,5150,O
DA,5150,O
and,5150,O
DOPAC,5150,B-CHEMICAL
concentrations,5150,O
and,5150,O
increased,5150,O
DA,5150,O
turnover,5150,O
in,5150,O
the,5150,O
striatum,5150,O
7,5150,O
days,5150,O
after,5150,O
dosing,5150,O
.,5150,O
The,5151,O
number,5151,O
of,5151,O
TH,5151,B-GENE-Y
(,5151,O
+,5151,O
),5151,O
neurons,5151,O
in,5151,O
the,5151,O
SNpc,5151,O
was,5151,O
reduced,5151,O
",",5151,O
and,5151,O
there,5151,O
were,5151,O
increased,5151,O
numbers,5151,O
of,5151,O
degenerating,5151,O
neurons,5151,O
and,5151,O
neuronal,5151,O
processes,5151,O
in,5151,O
the,5151,O
SNpc,5151,O
and,5151,O
striatum,5151,O
.,5151,O
MPTP-mediated,5152,B-CHEMICAL
cell,5152,O
death,5152,O
was,5152,O
not,5152,O
attributed,5152,O
to,5152,O
apoptosis,5152,O
.,5152,O
MPTP,5153,B-CHEMICAL
activated,5153,O
microglia,5153,O
and,5153,O
astrocytes,5153,O
within,5153,O
4h,5153,O
of,5153,O
the,5153,O
last,5153,O
dose,5153,O
",",5153,O
reaching,5153,O
a,5153,O
peak,5153,O
within,5153,O
48h,5153,O
.,5153,O
The,5154,O
microglial,5154,O
response,5154,O
ended,5154,O
by,5154,O
96h,5154,O
in,5154,O
the,5154,O
SNpc,5154,O
",",5154,O
but,5154,O
the,5154,O
astrocytic,5154,O
response,5154,O
continued,5154,O
through,5154,O
168h,5154,O
in,5154,O
the,5154,O
striatum,5154,O
.,5154,O
These,5155,O
results,5155,O
bring,5155,O
into,5155,O
question,5155,O
previous,5155,O
published,5155,O
stereological,5155,O
studies,5155,O
that,5155,O
report,5155,O
loss,5155,O
of,5155,O
TH,5155,B-GENE-Y
(,5155,O
+,5155,O
),5155,O
neurons,5155,O
in,5155,O
the,5155,O
SNpc,5155,O
of,5155,O
PQ-treated,5155,O
mice,5155,O
.,5155,O
This,5156,O
study,5156,O
also,5156,O
suggests,5156,O
that,5156,O
even,5156,O
if,5156,O
the,5156,O
reduction,5156,O
in,5156,O
TH,5156,B-GENE-Y
(,5156,O
+,5156,O
),5156,O
neurons,5156,O
reported,5156,O
by,5156,O
others,5156,O
occurs,5156,O
in,5156,O
PQ-treated,5156,O
mice,5156,O
",",5156,O
this,5156,O
apparent,5156,O
phenotypic,5156,O
change,5156,O
is,5156,O
unaccompanied,5156,O
by,5156,O
neuronal,5156,O
cell,5156,O
death,5156,O
or,5156,O
by,5156,O
modification,5156,O
of,5156,O
dopamine,5156,B-CHEMICAL
levels,5156,O
in,5156,O
the,5156,O
striatum,5156,O
.,5156,O
FGFR4,5157,B-GENE-Y
genetic,5157,O
polymorphisms,5157,O
determine,5157,O
the,5157,O
chemotherapy,5157,O
response,5157,O
of,5157,O
Chinese,5157,O
patients,5157,O
with,5157,O
non-small,5157,O
cell,5157,O
lung,5157,O
cancer,5157,O
.,5157,O
Aim,5158,O
:,5158,O
To,5158,O
investigate,5158,O
the,5158,O
relationship,5158,O
of,5158,O
fibroblast,5158,B-GENE-Y
growth,5158,I-GENE-Y
factor,5158,I-GENE-Y
receptor,5158,I-GENE-Y
4,5158,I-GENE-Y
(,5158,O
FGFR4,5158,B-GENE-Y
),5158,O
gene,5158,O
polymorphisms,5158,O
with,5158,O
the,5158,O
response,5158,O
of,5158,O
Chinese,5158,O
patients,5158,O
with,5158,O
non-small,5158,O
cell,5158,O
lung,5158,O
cancer,5158,O
(,5158,O
NSCLC,5158,O
),5158,O
to,5158,O
chemotherapy.Methods,5158,O
:,5158,O
A,5158,O
total,5158,O
of,5158,O
629,5158,O
patients,5158,O
with,5158,O
Stage,5158,O
III,5158,O
(,5158,O
A+B,5158,O
),5158,O
or,5158,O
IV,5158,O
NSCLC,5158,O
",",5158,O
as,5158,O
well,5158,O
as,5158,O
729,5158,O
age-,5158,O
and,5158,O
gender-matched,5158,O
healthy,5158,O
controls,5158,O
were,5158,O
recruited,5158,O
.,5158,O
All,5159,O
the,5159,O
patients,5159,O
received,5159,O
platinum-based,5159,B-CHEMICAL
chemotherapy,5159,O
",",5159,O
and,5159,O
the,5159,O
therapeutic,5159,O
effects,5159,O
were,5159,O
evaluated,5159,O
.,5159,O
Three,5160,O
polymorphisms,5160,O
in,5160,O
the,5160,O
FGFR4,5160,B-GENE-Y
gene,5160,O
(,5160,O
rs351855G/A,5160,O
",",5160,O
rs145302848C/G,5160,O
",",5160,O
and,5160,O
rs147603016G/A,5160,O
),5160,O
were,5160,O
genotyped,5160,O
",",5160,O
and,5160,O
the,5160,O
association,5160,O
between,5160,O
the,5160,O
3,5160,O
polymorphisms,5160,O
and,5160,O
the,5160,O
chemotherapy,5160,O
effect,5160,O
was,5160,O
analyzed,5160,O
using,5160,O
SPSS,5160,O
software,5160,O
",",5160,O
version,5160,O
16.0.Results,5160,O
:,5160,O
The,5160,O
genotype,5160,O
frequencies,5160,O
of,5160,O
rs145302848C/G,5160,O
and,5160,O
rs147603016G/A,5160,O
were,5160,O
not,5160,O
significantly,5160,O
different,5160,O
between,5160,O
NSCLC,5160,O
patients,5160,O
and,5160,O
healthy,5160,O
controls,5160,O
on,5160,O
one,5160,O
hand,5160,O
",",5160,O
and,5160,O
between,5160,O
the,5160,O
responders,5160,O
and,5160,O
non-responders,5160,O
to,5160,O
the,5160,O
chemotherapy,5160,O
on,5160,O
the,5160,O
other,5160,O
hand,5160,O
.,5160,O
The,5161,O
distribution,5161,O
of,5161,O
AA,5161,O
genotype,5161,O
and,5161,O
A-allele,5161,O
of,5161,O
rs351855G/A,5161,O
was,5161,O
significantly,5161,O
lower,5161,O
in,5161,O
NSCLC,5161,O
patients,5161,O
than,5161,O
in,5161,O
healthy,5161,O
controls,5161,O
.,5161,O
Using,5162,O
patients,5162,O
with,5162,O
the,5162,O
GG,5162,O
genotype,5162,O
as,5162,O
a,5162,O
reference,5162,O
",",5162,O
the,5162,O
AA,5162,O
carrier,5162,O
had,5162,O
a,5162,O
significantly,5162,O
reduced,5162,O
risk,5162,O
for,5162,O
the,5162,O
development,5162,O
of,5162,O
NSCLC,5162,O
after,5162,O
normalizing,5162,O
to,5162,O
age,5162,O
",",5162,O
sex,5162,O
and,5162,O
smoking,5162,O
habits,5162,O
.,5162,O
In,5163,O
NSCLC,5163,O
patients,5163,O
",",5163,O
this,5163,O
genotype,5163,O
occurred,5163,O
more,5163,O
frequently,5163,O
in,5163,O
the,5163,O
responders,5163,O
to,5163,O
the,5163,O
chemotherapy,5163,O
than,5163,O
in,5163,O
non-responders,5163,O
.,5163,O
The,5164,O
chance,5164,O
of,5164,O
being,5164,O
a,5164,O
responder,5164,O
was,5164,O
significantly,5164,O
increased,5164,O
with,5164,O
the,5164,O
AA,5164,O
genotype,5164,O
as,5164,O
compared,5164,O
to,5164,O
G,5164,O
genotype,5164,O
.,5164,O
The,5165,O
AA,5165,O
genotype,5165,O
of,5165,O
rs351855G/A,5165,O
had,5165,O
a,5165,O
better,5165,O
prognosis,5165,O
compared,5165,O
with,5165,O
GA,5165,O
and,5165,O
GG,5165,O
genotype,5165,O
carriers,5165,O
:,5165,O
the,5165,O
overall,5165,O
survival,5165,O
of,5165,O
patients,5165,O
with,5165,O
the,5165,O
AA,5165,O
genotype,5165,O
of,5165,O
rs351855G/A,5165,O
was,5165,O
significantly,5165,O
longer,5165,O
than,5165,O
those,5165,O
with,5165,O
the,5165,O
GG+GA,5165,O
genotype,5165,O
(,5165,O
21.1,5165,O
vs,5165,O
16.5,5165,O
months,5165,O
),5165,O
.Conclusion,5165,O
:,5165,O
The,5165,O
rs351855G/A,5165,O
polymorphisms,5165,O
of,5165,O
FGFR4,5165,B-GENE-Y
gene,5165,O
can,5165,O
be,5165,O
used,5165,O
to,5165,O
predict,5165,O
the,5165,O
occurrence,5165,O
",",5165,O
chemotherapy,5165,O
response,5165,O
and,5165,O
prognosis,5165,O
of,5165,O
NSCLC,5165,O
.,5165,O
NMR,5166,O
characterisation,5166,O
of,5166,O
dynamics,5166,O
in,5166,O
solvates,5166,O
and,5166,O
desolvates,5166,O
of,5166,O
formoterol,5166,B-CHEMICAL
fumarate,5166,I-CHEMICAL
.,5166,O
Solid-state,5167,O
NMR,5167,O
is,5167,O
used,5167,O
to,5167,O
characterise,5167,O
dynamics,5167,O
in,5167,O
the,5167,O
ethanol,5167,B-CHEMICAL
solvate,5167,O
of,5167,O
the,5167,O
pharmaceutical,5167,O
material,5167,O
formoterol,5167,B-CHEMICAL
fumarate,5167,I-CHEMICAL
and,5167,O
its,5167,O
associated,5167,O
desolvate,5167,O
.,5167,O
Jump,5168,O
rates,5168,O
and,5168,O
activation,5168,O
barriers,5168,O
for,5168,O
dynamic,5168,O
processes,5168,O
such,5168,O
as,5168,O
phenyl,5168,B-CHEMICAL
ring,5168,O
rotation,5168,O
and,5168,O
methyl,5168,B-CHEMICAL
group,5168,O
rotational,5168,O
diffusion,5168,O
are,5168,O
derived,5168,O
from,5168,O
1D-EXSY,5168,O
and,5168,O
(,5168,B-CHEMICAL
13,5168,I-CHEMICAL
),5168,I-CHEMICAL
C,5168,I-CHEMICAL
spin-lattice,5168,O
relaxation,5168,O
times,5168,O
respectively,5168,O
.,5168,O
(,5169,B-CHEMICAL
2,5169,I-CHEMICAL
),5169,I-CHEMICAL
H,5169,I-CHEMICAL
and,5169,O
(,5169,B-CHEMICAL
13,5169,I-CHEMICAL
),5169,I-CHEMICAL
C,5169,I-CHEMICAL
spin-lattice,5169,O
relaxation,5169,O
times,5169,O
measured,5169,O
under,5169,O
magic-angle,5169,O
spinning,5169,O
conditions,5169,O
are,5169,O
used,5169,O
to,5169,O
show,5169,O
that,5169,O
the,5169,O
fumarate,5169,B-CHEMICAL
ion,5169,O
in,5169,O
the,5169,O
desolvate,5169,O
is,5169,O
undergoing,5169,O
small-amplitude,5169,O
motion,5169,O
on,5169,O
a,5169,O
frequency,5169,O
scale,5169,O
of,5169,O
100s,5169,O
of,5169,O
MHz,5169,O
at,5169,O
ambient,5169,O
temperature,5169,O
with,5169,O
an,5169,O
activation,5169,O
parameter,5169,O
of,5169,O
about,5169,O
32,5169,O
kJ,5169,O
mol,5169,O
(,5169,O
-1,5169,O
),5169,O
.,5169,O
Exact,5170,O
calculations,5170,O
of,5170,O
relaxation,5170,O
times,5170,O
under,5170,O
MAS,5170,O
provide,5170,O
a,5170,O
simple,5170,O
and,5170,O
robust,5170,O
means,5170,O
to,5170,O
test,5170,O
motional,5170,O
models,5170,O
in,5170,O
cases,5170,O
where,5170,O
relaxation,5170,O
rate,5170,O
maxima,5170,O
are,5170,O
observed,5170,O
",",5170,O
including,5170,O
for,5170,O
systems,5170,O
where,5170,O
the,5170,O
crystal,5170,O
structure,5170,O
of,5170,O
the,5170,O
material,5170,O
is,5170,O
unknown,5170,O
.,5170,O
tert-Butylcarbamate-Containing,5171,B-CHEMICAL
Histone,5171,B-GENE-N
Deacetylase,5171,I-GENE-N
Inhibitors,5171,O
:,5171,O
Apoptosis,5171,O
Induction,5171,O
",",5171,O
Cytodifferentiation,5171,O
",",5171,O
and,5171,O
Antiproliferative,5171,O
Activities,5171,O
in,5171,O
Cancer,5171,O
Cells,5171,O
.,5171,O
Herein,5172,O
we,5172,O
report,5172,O
novel,5172,O
pyrrole-,5172,B-CHEMICAL
and,5172,O
benzene-based,5172,B-CHEMICAL
hydroxamates,5172,B-CHEMICAL
(,5172,O
8,5172,O
",",5172,O
10,5172,O
),5172,O
and,5172,O
2'-aminoanilides,5172,B-CHEMICAL
(,5172,O
9,5172,O
",",5172,O
11,5172,O
),5172,O
bearing,5172,O
the,5172,O
tert-butylcarbamate,5172,B-CHEMICAL
group,5172,O
at,5172,O
the,5172,O
CAP,5172,O
moiety,5172,O
as,5172,O
histone,5172,B-GENE-N
deacetylase,5172,I-GENE-N
(,5172,O
HDAC,5172,B-GENE-N
),5172,O
inhibitors,5172,O
.,5172,O
Compounds,5173,O
8,5173,O
b,5173,O
and,5173,O
10,5173,O
c,5173,O
selectively,5173,O
inhibited,5173,O
HDAC6,5173,B-GENE-Y
at,5173,O
the,5173,O
nanomolar,5173,O
level,5173,O
",",5173,O
whereas,5173,O
the,5173,O
other,5173,O
hydroxamates,5173,B-CHEMICAL
effected,5173,O
an,5173,O
increase,5173,O
in,5173,O
acetyl--tubulin,5173,B-GENE-N
levels,5173,O
in,5173,O
human,5173,O
acute,5173,O
myeloid,5173,O
leukemia,5173,O
U937,5173,O
cells,5173,O
.,5173,O
In,5174,O
the,5174,O
same,5174,O
cell,5174,O
line,5174,O
",",5174,O
compounds,5174,O
8,5174,O
b,5174,O
and,5174,O
10,5174,O
c,5174,O
elicited,5174,O
18.4,5174,O
and,5174,O
21.4,5174,O
%,5174,O
apoptosis,5174,O
",",5174,O
respectively,5174,O
(,5174,O
SAHA,5174,B-CHEMICAL
:,5174,O
16.9,5174,O
%,5174,O
),5174,O
",",5174,O
and,5174,O
the,5174,O
pyrrole,5174,B-CHEMICAL
anilide,5174,I-CHEMICAL
9,5174,O
c,5174,O
displayed,5174,O
the,5174,O
highest,5174,O
cytodifferentiating,5174,O
effect,5174,O
(,5174,O
90.9,5174,O
%,5174,O
),5174,O
.,5174,O
In,5175,O
tests,5175,O
against,5175,O
a,5175,O
wide,5175,O
range,5175,O
of,5175,O
various,5175,O
cancer,5175,O
cell,5175,O
lines,5175,O
to,5175,O
determine,5175,O
its,5175,O
antiproliferative,5175,O
effects,5175,O
",",5175,O
compound,5175,O
10,5175,O
c,5175,O
exhibited,5175,O
growth,5175,O
inhibition,5175,O
from,5175,O
sub-micromolar,5175,O
(,5175,O
neuroblastoma,5175,O
LAN-5,5175,O
and,5175,O
SH-SY5Y,5175,O
cells,5175,O
",",5175,O
chronic,5175,O
myeloid,5175,O
leukemia,5175,O
K562,5175,O
cells,5175,O
),5175,O
to,5175,O
low-micromolar,5175,O
(,5175,O
lung,5175,O
H1299,5175,O
and,5175,O
A549,5175,O
",",5175,O
colon,5175,O
HCT116,5175,O
and,5175,O
HT29,5175,O
cancer,5175,O
cells,5175,O
),5175,O
concentrations,5175,O
.,5175,O
In,5176,O
HT29,5176,O
cells,5176,O
",",5176,O
10,5176,O
c,5176,O
increased,5176,O
histone,5176,B-GENE-N
H3,5176,I-GENE-N
acetylation,5176,O
",",5176,O
and,5176,O
decreased,5176,O
the,5176,O
colony-forming,5176,O
potential,5176,O
of,5176,O
the,5176,O
cancer,5176,O
cells,5176,O
by,5176,O
up,5176,O
to,5176,O
60,5176,O
%,5176,O
.,5176,O
Discovery,5177,O
of,5177,O
a,5177,O
synthetic,5177,O
Aminopeptidase,5177,B-GENE-Y
N,5177,I-GENE-Y
inhibitor,5177,O
LB-4b,5177,B-CHEMICAL
as,5177,O
a,5177,O
potential,5177,O
anticancer,5177,O
agent,5177,O
.,5177,O
APN,5178,B-GENE-Y
inhibitors,5178,O
have,5178,O
been,5178,O
considered,5178,O
as,5178,O
potential,5178,O
anticancer,5178,O
agents,5178,O
for,5178,O
years,5178,O
.,5178,O
LB-4b,5179,B-CHEMICAL
is,5179,O
the,5179,O
first,5179,O
synthetic,5179,O
APN,5179,B-GENE-Y
inhibitor,5179,O
to,5179,O
be,5179,O
evaluated,5179,O
for,5179,O
both,5179,O
of,5179,O
its,5179,O
anti-invasion,5179,O
and,5179,O
anti-angiogenesis,5179,O
effects,5179,O
.,5179,O
As,5180,O
a,5180,O
potent,5180,O
synthetic,5180,O
APN,5180,B-GENE-Y
inhibitor,5180,O
(,5180,O
IC50=850nM,5180,O
",",5180,O
versus,5180,O
bestatin,5180,B-CHEMICAL
of,5180,O
8.1M,5180,O
),5180,O
",",5180,O
LB-4b,5180,B-CHEMICAL
was,5180,O
determined,5180,O
to,5180,O
have,5180,O
more,5180,O
significant,5180,O
block,5180,O
effects,5180,O
to,5180,O
cancer,5180,O
cell,5180,O
invasion,5180,O
and,5180,O
angiogenesis,5180,O
than,5180,O
bestatin,5180,B-CHEMICAL
.,5180,O
Besides,5181,O
",",5181,O
it,5181,O
is,5181,O
able,5181,O
to,5181,O
be,5181,O
easily,5181,O
synthesized,5181,O
with,5181,O
a,5181,O
high,5181,O
total,5181,O
yield,5181,O
",",5181,O
while,5181,O
the,5181,O
reported,5181,O
synthetic,5181,O
methods,5181,O
of,5181,O
bestatin,5181,B-CHEMICAL
are,5181,O
much,5181,O
more,5181,O
complex,5181,O
.,5181,O
Multipart,5182,O
Copolyelectrolyte,5182,O
Adhesive,5182,O
of,5182,O
the,5182,O
Sandcastle,5182,O
Worm,5182,O
",",5182,O
Phragmatopoma,5182,O
californica,5182,O
(,5182,O
Fewkes,5182,O
),5182,O
:,5182,O
Catechol,5182,B-CHEMICAL
Oxidase,5182,I-GENE-N
Catalyzed,5182,O
Curing,5182,O
through,5182,O
Peptidyl-DOPA,5182,O
.,5182,O
Tube-building,5183,O
sabellariid,5183,O
polychaetes,5183,O
have,5183,O
major,5183,O
impacts,5183,O
on,5183,O
the,5183,O
geology,5183,O
and,5183,O
ecology,5183,O
of,5183,O
shorelines,5183,O
worldwide,5183,O
.,5183,O
Sandcastle,5184,O
worms,5184,O
",",5184,O
Phragmatopoma,5184,O
californica,5184,O
(,5184,O
Fewkes,5184,O
),5184,O
",",5184,O
live,5184,O
along,5184,O
the,5184,O
western,5184,O
coast,5184,O
of,5184,O
North,5184,O
America,5184,O
.,5184,O
Individual,5185,O
sabellariid,5185,O
worms,5185,O
build,5185,O
tubular,5185,O
shells,5185,O
by,5185,O
gluing,5185,O
together,5185,O
mineral,5185,O
particles,5185,O
with,5185,O
a,5185,O
multipart,5185,O
polyelectrolytic,5185,O
adhesive,5185,O
.,5185,O
Distinct,5186,O
sets,5186,O
of,5186,O
oppositely,5186,O
charged,5186,O
components,5186,O
are,5186,O
packaged,5186,O
and,5186,O
stored,5186,O
in,5186,O
concentrated,5186,O
granules,5186,O
in,5186,O
separate,5186,O
cell,5186,O
types,5186,O
.,5186,O
Homogeneous,5187,O
granules,5187,O
contain,5187,O
sulfated,5187,O
macromolecules,5187,O
as,5187,O
counter-polyanion,5187,O
to,5187,O
polycationic,5187,O
Pc2,5187,B-GENE-Y
and,5187,O
Pc5,5187,B-GENE-N
proteins,5187,O
",",5187,O
which,5187,O
become,5187,O
major,5187,O
components,5187,O
of,5187,O
the,5187,O
fully,5187,O
cured,5187,O
glue,5187,O
.,5187,O
Heterogeneous,5188,O
granules,5188,O
contain,5188,O
polyphosphoproteins,5188,O
",",5188,O
Pc3A/B,5188,B-GENE-N
",",5188,O
paired,5188,O
with,5188,O
divalent,5188,O
cations,5188,O
and,5188,O
polycationic,5188,O
Pc1,5188,B-GENE-Y
and,5188,O
Pc4,5188,B-GENE-N
proteins,5188,O
.,5188,O
Both,5189,O
types,5189,O
of,5189,O
granules,5189,O
contain,5189,O
catechol,5189,B-CHEMICAL
oxidase,5189,I-GENE-N
that,5189,O
catalyzes,5189,O
oxidative,5189,O
cross-linking,5189,O
of,5189,O
L-DOPA,5189,B-CHEMICAL
.,5189,O
Co-secretion,5190,O
of,5190,O
catechol,5190,B-CHEMICAL
oxidase,5190,I-GENE-N
guarantees,5190,O
rapid,5190,O
and,5190,O
spatially,5190,O
homogeneous,5190,O
curing,5190,O
with,5190,O
limited,5190,O
mixing,5190,O
of,5190,O
the,5190,O
preassembled,5190,O
adhesive,5190,O
packets,5190,O
.,5190,O
Catechol,5191,B-CHEMICAL
oxidase,5191,I-GENE-N
remains,5191,O
active,5191,O
long,5191,O
after,5191,O
the,5191,O
glue,5191,O
is,5191,O
fully,5191,O
cured,5191,O
",",5191,O
perhaps,5191,O
providing,5191,O
an,5191,O
active,5191,O
cue,5191,O
for,5191,O
conspecific,5191,O
larval,5191,O
settlement,5191,O
.,5191,O
Disruption,5192,O
of,5192,O
AtWNK8,5192,B-GENE-Y
Enhances,5192,O
Tolerance,5192,O
of,5192,O
Arabidopsis,5192,O
to,5192,O
Salt,5192,O
and,5192,O
Osmotic,5192,O
Stresses,5192,O
via,5192,O
Modulating,5192,O
Proline,5192,B-CHEMICAL
Content,5192,O
and,5192,O
Activities,5192,O
of,5192,O
Catalase,5192,B-GENE-N
and,5192,O
Peroxidase,5192,B-GENE-N
.,5192,O
With,5193,B-GENE-N
no,5193,I-GENE-N
lysine,5193,I-GENE-N
kinases,5193,I-GENE-N
(,5193,O
WNKs,5193,B-GENE-N
),5193,O
play,5193,O
important,5193,O
roles,5193,O
in,5193,O
plant,5193,O
growth,5193,O
and,5193,O
development,5193,O
.,5193,O
However,5194,O
",",5194,O
its,5194,O
role,5194,O
in,5194,O
salt,5194,O
and,5194,O
osmotic,5194,O
stress,5194,O
tolerance,5194,O
is,5194,O
unclear,5194,O
.,5194,O
Here,5195,O
",",5195,O
we,5195,O
report,5195,O
that,5195,O
AtWNK8,5195,B-GENE-Y
is,5195,O
mainly,5195,O
expressed,5195,O
in,5195,O
primary,5195,O
root,5195,O
",",5195,O
hypocotyl,5195,O
",",5195,O
stamen,5195,O
and,5195,O
pistil,5195,O
and,5195,O
is,5195,O
induced,5195,O
by,5195,O
NaCl,5195,B-CHEMICAL
and,5195,O
sorbitol,5195,B-CHEMICAL
treatment,5195,O
.,5195,O
Compared,5196,O
to,5196,O
the,5196,O
wild-type,5196,O
",",5196,O
the,5196,O
T-DNA,5196,O
knock-out,5196,O
wnk8,5196,B-GENE-Y
mutant,5196,O
was,5196,O
more,5196,O
tolerant,5196,O
to,5196,O
severe,5196,O
salinity,5196,O
and,5196,O
osmotic,5196,O
stresses,5196,O
",",5196,O
as,5196,O
indicated,5196,O
by,5196,O
27,5196,O
%,5196,O
and,5196,O
198,5196,O
%,5196,O
more,5196,O
fresh,5196,O
weight,5196,O
in,5196,O
the,5196,O
NaCl,5196,B-CHEMICAL
and,5196,O
sorbitol,5196,B-CHEMICAL
treatment,5196,O
",",5196,O
respectively,5196,O
.,5196,O
The,5197,O
wnk8,5197,B-GENE-Y
mutant,5197,O
also,5197,O
accumulated,5197,O
1.43-fold,5197,O
more,5197,O
proline,5197,B-CHEMICAL
than,5197,O
the,5197,O
wild-type,5197,O
in,5197,O
the,5197,O
sorbitol,5197,B-CHEMICAL
treatment,5197,O
.,5197,O
Under,5198,O
NaCl,5198,B-CHEMICAL
and,5198,O
sorbitol,5198,B-CHEMICAL
stresses,5198,O
",",5198,O
catalase,5198,B-GENE-N
(,5198,O
CAT,5198,B-GENE-N
),5198,O
activity,5198,O
in,5198,O
wnk8,5198,B-GENE-Y
mutant,5198,O
was,5198,O
1.92-,5198,O
and,5198,O
3.7-times,5198,O
of,5198,O
that,5198,O
in,5198,O
Col-0,5198,O
",",5198,O
respectively,5198,O
.,5198,O
Similarly,5199,O
",",5199,O
under,5199,O
salt,5199,O
and,5199,O
osmotic,5199,O
stress,5199,O
conditions,5199,O
",",5199,O
peroxidase,5199,B-GENE-N
(,5199,O
POD,5199,B-GENE-N
),5199,O
activities,5199,O
in,5199,O
wnk8,5199,B-GENE-Y
mutant,5199,O
were,5199,O
1.81-,5199,O
and,5199,O
1.58-times,5199,O
of,5199,O
that,5199,O
in,5199,O
Col-0,5199,O
",",5199,O
respectively,5199,O
.,5199,O
Taken,5200,O
together,5200,O
",",5200,O
we,5200,O
revealed,5200,O
that,5200,O
maintaining,5200,O
higher,5200,O
CAT,5200,B-GENE-N
and,5200,O
POD,5200,B-GENE-N
activities,5200,O
might,5200,O
be,5200,O
one,5200,O
of,5200,O
the,5200,O
reasons,5200,O
that,5200,O
the,5200,O
disruption,5200,O
of,5200,O
AtWNK8,5200,B-GENE-Y
enhances,5200,O
the,5200,O
tolerance,5200,O
to,5200,O
salt,5200,O
stress,5200,O
",",5200,O
and,5200,O
accumulating,5200,O
more,5200,O
proline,5200,B-CHEMICAL
and,5200,O
higher,5200,O
activities,5200,O
of,5200,O
CAT,5200,B-GENE-N
and,5200,O
POD,5200,B-GENE-N
might,5200,O
result,5200,O
in,5200,O
the,5200,O
higher,5200,O
tolerance,5200,O
of,5200,O
WNK8,5200,B-GENE-Y
to,5200,O
osmotic,5200,O
stress,5200,O
.,5200,O
Neuroprotective,5201,O
Effects,5201,O
of,5201,O
Cilostazol,5201,B-CHEMICAL
on,5201,O
Retinal,5201,O
Ganglion,5201,O
Cell,5201,O
damage,5201,O
in,5201,O
Diabetic,5201,O
Rats,5201,O
.,5201,O
Neurodegeneration,5202,O
is,5202,O
an,5202,O
important,5202,O
component,5202,O
of,5202,O
diabetic,5202,O
retinopathy,5202,O
with,5202,O
increasing,5202,O
evidence,5202,O
that,5202,O
retinal,5202,O
ganglion,5202,O
cell,5202,O
(,5202,O
RGC,5202,O
),5202,O
death,5202,O
occurs,5202,O
early,5202,O
in,5202,O
diabetes,5202,O
.,5202,O
We,5203,O
investigated,5203,O
the,5203,O
effects,5203,O
of,5203,O
cilostazol,5203,B-CHEMICAL
",",5203,O
which,5203,O
has,5203,O
been,5203,O
widely,5203,O
used,5203,O
to,5203,O
manage,5203,O
diabetic,5203,O
complications,5203,O
",",5203,O
on,5203,O
retinal,5203,O
ganglion,5203,O
cell,5203,O
death,5203,O
in,5203,O
diabetic,5203,O
retina,5203,O
.,5203,O
Four-week-old,5204,O
Otsuka,5204,O
Long-Evans,5204,O
Tokushima,5204,O
Fatty,5204,O
(,5204,O
OLETF,5204,O
),5204,O
rats,5204,O
and,5204,O
Long-Evans,5204,O
Tokushima,5204,O
Otsuka,5204,O
(,5204,O
LETO,5204,O
),5204,O
rats,5204,O
as,5204,O
matched,5204,O
nondiabetic,5204,O
controls,5204,O
were,5204,O
treated,5204,O
with,5204,O
daily,5204,O
oral,5204,O
cilostazol,5204,B-CHEMICAL
at,5204,O
30mg/kg,5204,O
or,5204,O
0.9,5204,O
%,5204,O
saline,5204,O
solution,5204,O
.,5204,O
In,5205,O
OLETF,5205,O
rats,5205,O
at,5205,O
the,5205,O
age,5205,O
of,5205,O
40,5205,O
weeks,5205,O
",",5205,O
glial,5205,B-GENE-Y
fibrillary,5205,I-GENE-Y
acidic,5205,I-GENE-Y
protein,5205,I-GENE-Y
(,5205,O
GFAP,5205,B-GENE-Y
),5205,O
immunofluorescence,5205,O
staining,5205,O
was,5205,O
upregulated,5205,O
in,5205,O
vertical,5205,O
sections,5205,O
and,5205,O
showed,5205,O
a,5205,O
more,5205,O
ramified,5205,O
pattern,5205,O
in,5205,O
whole-mount,5205,O
retinas,5205,O
compared,5205,O
with,5205,O
that,5205,O
in,5205,O
LETO,5205,O
rats,5205,O
.,5205,O
Vascular,5206,B-GENE-Y
endothelial,5206,I-GENE-Y
growth,5206,I-GENE-Y
factor,5206,I-GENE-Y
(,5206,O
VEGF,5206,B-GENE-Y
),5206,O
expression,5206,O
was,5206,O
limited,5206,O
to,5206,O
the,5206,O
ganglion,5206,O
cell,5206,O
layer,5206,O
in,5206,O
LETO,5206,O
rats,5206,O
",",5206,O
but,5206,O
extended,5206,O
into,5206,O
the,5206,O
outer,5206,O
plexiform,5206,O
layer,5206,O
in,5206,O
OLETF,5206,O
rats,5206,O
.,5206,O
Immunofluorescence,5207,O
staining,5207,O
and,5207,O
western,5207,O
blotting,5207,O
demonstrated,5207,O
that,5207,O
cilostazol,5207,B-CHEMICAL
treatment,5207,O
reduced,5207,O
GFAP,5207,B-GENE-Y
and,5207,O
VEGF,5207,B-GENE-Y
expression,5207,O
in,5207,O
the,5207,O
retinas,5207,O
of,5207,O
OLETF,5207,O
rats,5207,O
.,5207,O
Terminal,5208,O
deoxynucleotidyl,5208,O
transferase-mediated,5208,O
dUTP,5208,B-CHEMICAL
nick-end,5208,O
labeling,5208,O
(,5208,O
TUNLEL,5208,O
),5208,O
staining,5208,O
revealed,5208,O
an,5208,O
increase,5208,O
in,5208,O
the,5208,O
RGC,5208,O
layer,5208,O
in,5208,O
OLETF,5208,O
compared,5208,O
with,5208,O
LETO,5208,O
rats,5208,O
(,5208,O
P,5208,O
<,5208,O
0.05,5208,O
),5208,O
",",5208,O
and,5208,O
cilostazol,5208,B-CHEMICAL
treatment,5208,O
reduced,5208,O
the,5208,O
number,5208,O
of,5208,O
TUNEL-positive,5208,O
cells,5208,O
in,5208,O
OLETF,5208,O
rats,5208,O
(,5208,O
P,5208,O
<,5208,O
0.05,5208,O
),5208,O
.,5208,O
Relieving,5209,O
retinal,5209,O
ischemia,5209,O
by,5209,O
systemic,5209,O
cilostazol,5209,B-CHEMICAL
treatment,5209,O
had,5209,O
a,5209,O
noticeable,5209,O
protective,5209,O
effect,5209,O
on,5209,O
RGCs,5209,O
in,5209,O
diabetic,5209,O
rats,5209,O
.,5209,O
Cilostazol,5210,B-CHEMICAL
treatment,5210,O
may,5210,O
be,5210,O
useful,5210,O
for,5210,O
the,5210,O
management,5210,O
of,5210,O
diabetic,5210,O
retinal,5210,O
vascular,5210,O
dysfunction,5210,O
and,5210,O
neuronal,5210,O
degeneration,5210,O
.,5210,O
Effects,5211,O
of,5211,O
lactational,5211,O
and/or,5211,O
in,5211,O
utero,5211,O
exposure,5211,O
to,5211,O
environmental,5211,O
contaminants,5211,O
on,5211,O
the,5211,O
glucocorticoid,5211,O
stress-response,5211,O
and,5211,O
DNA,5211,O
methylation,5211,O
of,5211,O
the,5211,O
glucocorticoid,5211,B-GENE-N
receptor,5211,I-GENE-N
promoter,5211,I-GENE-N
in,5211,O
male,5211,O
rats,5211,O
.,5211,O
Perinatal,5212,O
events,5212,O
can,5212,O
reprogram,5212,O
the,5212,O
hypothalamo-pituitary-adrenal,5212,O
axis,5212,O
for,5212,O
the,5212,O
entire,5212,O
lifespan,5212,O
leading,5212,O
to,5212,O
abnormal,5212,O
glucocorticoid,5212,O
stress-response,5212,O
(,5212,O
GSR,5212,O
),5212,O
in,5212,O
adulthood,5212,O
:,5212,O
a,5212,O
phenomenon,5212,O
reported,5212,O
to,5212,O
be,5212,O
mediated,5212,O
by,5212,O
changes,5212,O
in,5212,O
DNA,5212,O
methylation,5212,O
of,5212,O
the,5212,O
glucocorticoid,5212,B-GENE-N
receptor,5212,I-GENE-N
(,5212,I-GENE-N
GR,5212,I-GENE-N
),5212,I-GENE-N
gene,5212,I-GENE-N
promoter,5212,I-GENE-N
.,5212,O
We,5213,O
examined,5213,O
whether,5213,O
in,5213,O
utero,5213,O
and/or,5213,O
lactational,5213,O
exposure,5213,O
to,5213,O
mixtures,5213,O
of,5213,O
environmental,5213,O
contaminants,5213,O
can,5213,O
also,5213,O
induce,5213,O
abnormal,5213,O
GSR,5213,O
during,5213,O
adulthood,5213,O
.,5213,O
The,5214,O
experiment,5214,O
included,5214,O
nine,5214,O
treatment,5214,O
groups,5214,O
.,5214,O
From,5215,O
gestation,5215,O
day,5215,O
(,5215,O
GD,5215,O
),5215,O
0,5215,O
until,5215,O
postnatal,5215,O
day,5215,O
(,5215,O
PND,5215,O
),5215,O
20,5215,O
",",5215,O
dams,5215,O
were,5215,O
fed,5215,O
daily,5215,O
with,5215,O
a,5215,O
cookie,5215,O
laced,5215,O
with,5215,O
corn,5215,O
oil,5215,O
(,5215,O
control,5215,O
),5215,O
or,5215,O
a,5215,O
chemical,5215,O
mixture,5215,O
(,5215,O
M,5215,O
),5215,O
[,5215,O
polychlorinated,5215,B-CHEMICAL
biphenyls,5215,I-CHEMICAL
(,5215,O
PCBs,5215,B-CHEMICAL
),5215,O
",",5215,O
organochlorine,5215,B-CHEMICAL
pesticides,5215,O
",",5215,O
and,5215,O
methylmercury,5215,B-CHEMICAL
],5215,O
at,5215,O
0.5,5215,O
or,5215,O
1.0mg/kg/day,5215,O
(,5215,O
0.5M,5215,O
",",5215,O
and,5215,O
M,5215,O
),5215,O
.,5215,O
At,5216,O
birth,5216,O
",",5216,O
some,5216,O
control,5216,O
(,5216,O
C,5216,O
),5216,O
and,5216,O
M,5216,O
litters,5216,O
were,5216,O
cross-fostered,5216,O
to,5216,O
create,5216,O
four,5216,O
groups,5216,O
with,5216,O
the,5216,O
following,5216,O
in,5216,O
utero/postnatal,5216,O
exposure,5216,O
:,5216,O
C/C,5216,O
",",5216,O
M/C,5216,O
",",5216,O
C/M,5216,O
",",5216,O
M/M,5216,O
.,5216,O
Other,5217,O
dams,5217,O
received,5217,O
1.8ng/kg/day,5217,O
of,5217,O
a,5217,O
mixture,5217,O
of,5217,O
aryl,5217,B-GENE-Y
hydrocarbon,5217,B-CHEMICAL
receptor,5217,I-GENE-Y
(,5217,O
AhR,5217,B-GENE-Y
),5217,O
agonists,5217,O
(,5217,O
non-ortho,5217,B-CHEMICAL
PCBs,5217,O
",",5217,O
PC-dibenzodioxins,5217,B-CHEMICAL
and,5217,O
PC-dibenzofurans,5217,B-CHEMICAL
),5217,O
without,5217,O
or,5217,O
with,5217,O
0.5M,5217,O
(,5217,O
0.5MAhR,5217,O
),5217,O
.,5217,O
In,5218,O
adult,5218,O
male,5218,O
offspring,5218,O
the,5218,O
abundance,5218,O
of,5218,O
GR,5218,B-GENE-Y
in,5218,O
treated,5218,O
groups,5218,O
was,5218,O
not,5218,O
different,5218,O
from,5218,O
the,5218,O
control,5218,O
",",5218,O
but,5218,O
the,5218,O
AhR,5218,B-GENE-Y
and,5218,O
M,5218,O
groups,5218,O
were,5218,O
significantly,5218,O
different,5218,O
from,5218,O
each,5218,O
other,5218,O
with,5218,O
opposite,5218,O
effects,5218,O
in,5218,O
the,5218,O
hippocampus,5218,O
and,5218,O
liver,5218,O
.,5218,O
There,5219,O
was,5219,O
no,5219,O
change,5219,O
in,5219,O
DNA,5219,O
methylation,5219,O
of,5219,O
the,5219,O
GR,5219,B-GENE-N
promoter,5219,I-GENE-N
(,5219,O
exon-17,5219,O
and,5219,O
-110,5219,O
),5219,O
.,5219,O
Abnormal,5220,O
GSRs,5220,O
were,5220,O
detected,5220,O
in,5220,O
the,5220,O
AhR,5220,B-GENE-Y
",",5220,O
0.5MAhR,5220,O
",",5220,O
CM,5220,O
",",5220,O
and,5220,O
MM,5220,O
groups,5220,O
.,5220,O
The,5221,O
literature,5221,O
associates,5221,O
abnormal,5221,O
GSR,5221,O
with,5221,O
metabolic,5221,O
and,5221,O
mental,5221,O
health,5221,O
impairments,5221,O
",",5221,O
thus,5221,O
these,5221,O
results,5221,O
support,5221,O
further,5221,O
investigation,5221,O
of,5221,O
the,5221,O
influence,5221,O
of,5221,O
developmental,5221,O
exposure,5221,O
to,5221,O
environmental,5221,O
contaminants,5221,O
and,5221,O
predisposition,5221,O
to,5221,O
stress-induced,5221,O
diseases,5221,O
.,5221,O
Systematic,5222,O
evaluation,5222,O
of,5222,O
640,5222,O
FDA,5222,O
drugs,5222,O
for,5222,O
their,5222,O
effect,5222,O
on,5222,O
CD4,5222,O
(,5222,O
+,5222,O
),5222,O
Foxp3,5222,B-GENE-Y
(,5222,O
+,5222,O
),5222,O
regulatory,5222,O
T,5222,O
cells,5222,O
using,5222,O
a,5222,O
novel,5222,O
cell-based,5222,O
high,5222,O
throughput,5222,O
screening,5222,O
assay,5222,O
.,5222,O
Regulatory,5223,O
T,5223,O
cells,5223,O
(,5223,O
Treg,5223,O
),5223,O
",",5223,O
which,5223,O
play,5223,O
a,5223,O
pivotal,5223,O
role,5223,O
in,5223,O
maintaining,5223,O
immune,5223,O
homeostasis,5223,O
by,5223,O
suppressing,5223,O
the,5223,O
proliferation,5223,O
of,5223,O
effector,5223,O
T,5223,O
cells,5223,O
",",5223,O
have,5223,O
great,5223,O
therapeutic,5223,O
potential,5223,O
for,5223,O
autoimmune,5223,O
diseases,5223,O
and,5223,O
transplantation,5223,O
.,5223,O
However,5224,O
",",5224,O
progress,5224,O
on,5224,O
their,5224,O
clinical,5224,O
application,5224,O
has,5224,O
been,5224,O
hampered,5224,O
by,5224,O
the,5224,O
lack,5224,O
of,5224,O
high,5224,O
throughput,5224,O
screening,5224,O
(,5224,O
HTS,5224,O
),5224,O
strategies,5224,O
for,5224,O
the,5224,O
systematic,5224,O
and,5224,O
rapid,5224,O
evaluation,5224,O
of,5224,O
existing,5224,O
drugs,5224,O
and,5224,O
the,5224,O
identification,5224,O
of,5224,O
novel,5224,O
drug,5224,O
candidates,5224,O
.,5224,O
In,5225,O
this,5225,O
report,5225,O
",",5225,O
we,5225,O
present,5225,O
an,5225,O
innovative,5225,O
in,5225,O
vitro,5225,O
HTS,5225,O
assay,5225,O
using,5225,O
CD4,5225,O
(,5225,O
+,5225,O
),5225,O
T,5225,O
cells,5225,O
from,5225,O
Foxp3-GFP,5225,B-GENE-Y
transgenic,5225,O
mice,5225,O
that,5225,O
specifically,5225,O
express,5225,O
the,5225,O
GFP,5225,O
signal,5225,O
in,5225,O
Foxp3,5225,B-GENE-Y
(,5225,O
+,5225,O
),5225,O
Treg,5225,O
cells,5225,O
detectable,5225,O
by,5225,O
FACS,5225,O
analysis,5225,O
in,5225,O
a,5225,O
high,5225,O
throughput,5225,O
manner,5225,O
.,5225,O
Systematic,5226,O
evaluation,5226,O
of,5226,O
640,5226,O
FDA-approved,5226,O
drugs,5226,O
revealed,5226,O
that,5226,O
70,5226,O
drugs,5226,O
increased,5226,O
the,5226,O
number,5226,O
of,5226,O
Treg,5226,O
cells,5226,O
with,5226,O
suppression,5226,O
function,5226,O
only,5226,O
in,5226,O
the,5226,O
presence,5226,O
of,5226,O
TGF,5226,B-GENE-Y
",",5226,O
75,5226,O
drugs,5226,O
increased,5226,O
Treg,5226,O
numbers,5226,O
even,5226,O
in,5226,O
the,5226,O
absence,5226,O
of,5226,O
TGF,5226,B-GENE-Y
",",5226,O
and,5226,O
32,5226,O
drugs,5226,O
increased,5226,O
Treg,5226,O
numbers,5226,O
synergistically,5226,O
with,5226,O
TGF,5226,B-GENE-Y
.,5226,O
The,5227,O
identified,5227,O
Treg-promoting,5227,O
drugs,5227,O
include,5227,O
those,5227,O
previously,5227,O
known,5227,O
to,5227,O
induce,5227,O
Treg,5227,O
(,5227,O
rapamycin,5227,B-CHEMICAL
and,5227,O
retinoic,5227,B-CHEMICAL
acid,5227,I-CHEMICAL
),5227,I-CHEMICAL
",",5227,O
statins,5227,O
",",5227,O
glucocorticoids,5227,O
and,5227,O
drugs,5227,O
in,5227,O
many,5227,O
other,5227,O
categories,5227,O
.,5227,O
Furthermore,5228,O
",",5228,O
Treg,5228,O
cells,5228,O
cultured,5228,O
with,5228,O
the,5228,O
identified,5228,O
drugs,5228,O
possess,5228,O
surface,5228,O
and,5228,O
intracellular,5228,O
markers,5228,O
characteristic,5228,O
of,5228,O
natural,5228,O
Treg,5228,O
cells,5228,O
and,5228,O
possess,5228,O
suppressive,5228,O
function,5228,O
.,5228,O
These,5229,O
results,5229,O
suggest,5229,O
that,5229,O
this,5229,O
Treg,5229,O
HTS,5229,O
assay,5229,O
can,5229,O
be,5229,O
used,5229,O
to,5229,O
screen,5229,O
compound,5229,O
libraries,5229,O
to,5229,O
identify,5229,O
novel,5229,O
chemical,5229,O
entities,5229,O
for,5229,O
Treg-based,5229,O
immune,5229,O
therapies,5229,O
.,5229,O
EZETIMIBE,5230,B-CHEMICAL
INCREASES,5230,O
HEPATIC,5230,O
IRON,5230,B-CHEMICAL
LEVELS,5230,O
IN,5230,O
MICE,5230,O
FED,5230,O
A,5230,O
HIGH-FAT,5230,O
DIET,5230,O
.,5230,O
Accumulating,5231,O
evidence,5231,O
suggests,5231,O
that,5231,O
ezetimibe,5231,B-CHEMICAL
may,5231,O
be,5231,O
a,5231,O
promising,5231,O
agent,5231,O
for,5231,O
treatment,5231,O
of,5231,O
non-alcoholic,5231,O
fatty,5231,O
liver,5231,O
disease,5231,O
and,5231,O
steatohepatitis,5231,O
(,5231,O
NAFLD/NASH,5231,O
),5231,O
.,5231,O
Phlebotomy,5232,O
and,5232,O
dietary,5232,O
iron,5232,B-CHEMICAL
restriction,5232,O
reduces,5232,O
serum,5232,B-GENE-N
transaminase,5232,I-GENE-N
in,5232,O
NAFLD/NASH,5232,O
patients,5232,O
.,5232,O
Recent,5233,O
studies,5233,O
showed,5233,O
that,5233,O
mutual,5233,O
effects,5233,O
exist,5233,O
between,5233,O
lipid,5233,O
metabolism,5233,O
and,5233,O
iron,5233,B-CHEMICAL
metabolism,5233,O
.,5233,O
Accordingly,5234,O
",",5234,O
the,5234,O
effects,5234,O
of,5234,O
ezetimibe,5234,B-CHEMICAL
on,5234,O
iron,5234,B-CHEMICAL
metabolism,5234,O
were,5234,O
examined,5234,O
in,5234,O
mice,5234,O
fed,5234,O
a,5234,O
high-fat,5234,O
diet,5234,O
with,5234,O
or,5234,O
without,5234,O
iron,5234,B-CHEMICAL
.,5234,O
C57BL/6,5235,O
mice,5235,O
were,5235,O
fed,5235,O
the,5235,O
following,5235,O
diets,5235,O
for,5235,O
12,5235,O
weeks,5235,O
.,5235,O
Experiment,5236,O
1:1,5236,O
),5236,O
a,5236,O
control,5236,O
diet,5236,O
;,5236,O
C,5236,O
2,5236,O
),5236,O
C,5236,O
plus,5236,O
ezetimibe,5236,B-CHEMICAL
(,5236,O
0.3mg/day,5236,O
;,5236,O
4,5236,O
weeks,5236,O
),5236,O
;,5236,O
CE,5236,O
3,5236,O
),5236,O
a,5236,O
high-fat,5236,O
diet,5236,O
;,5236,O
H,5236,O
4,5236,O
),5236,O
H,5236,O
plus,5236,O
ezetimibe,5236,B-CHEMICAL
;,5236,O
HE,5236,O
.,5236,O
Experiment,5237,O
2,5237,O
:,5237,O
1,5237,O
),5237,O
C,5237,O
containing,5237,O
carbonyl,5237,B-CHEMICAL
iron,5237,I-CHEMICAL
(,5237,O
average,5237,O
;,5237,O
22.4mg/day,5237,O
;,5237,O
6,5237,O
weeks,5237,O
),5237,O
;,5237,O
CI,5237,O
2,5237,O
),5237,O
CI,5237,O
plus,5237,O
ezetimibe,5237,B-CHEMICAL
;,5237,O
CIE,5237,O
3,5237,O
),5237,O
H,5237,O
containing,5237,O
carbonyl,5237,B-CHEMICAL
iron,5237,I-CHEMICAL
;,5237,O
HI,5237,O
4,5237,O
),5237,O
HI,5237,O
plus,5237,O
ezetimibe,5237,B-CHEMICAL
;,5237,O
HIE,5237,O
.,5237,O
Blood,5238,O
",",5238,O
livers,5238,O
",",5238,O
and,5238,O
duodenum,5238,O
were,5238,O
removed,5238,O
after,5238,O
12,5238,O
weeks,5238,O
.,5238,O
In,5239,O
Experiment,5239,O
1,5239,O
",",5239,O
hepatic,5239,O
iron,5239,B-CHEMICAL
levels,5239,O
were,5239,O
higher,5239,O
in,5239,O
HE,5239,O
than,5239,O
H,5239,O
",",5239,O
whereas,5239,O
there,5239,O
was,5239,O
no,5239,O
difference,5239,O
between,5239,O
C,5239,O
and,5239,O
CE,5239,O
.,5239,O
Hepatic,5240,O
mRNA,5240,O
expression,5240,O
of,5240,O
transferrin,5240,B-GENE-N
receptor,5240,I-GENE-N
1,5240,I-GENE-N
and,5240,I-GENE-N
2,5240,I-GENE-N
",",5240,O
ferritins,5240,B-GENE-N
",",5240,O
and,5240,O
hepcidin,5240,B-GENE-Y
were,5240,O
increased,5240,O
more,5240,O
in,5240,O
CE,5240,O
than,5240,O
C,5240,O
",",5240,O
and,5240,O
in,5240,O
HE,5240,O
than,5240,O
H.,5240,O
In,5240,O
duodenum,5240,O
",",5240,O
DMT1,5240,B-GENE-Y
",",5240,O
ferritinH,5240,B-GENE-Y
",",5240,O
and,5240,O
hephaestin,5240,B-GENE-Y
mRNA,5240,O
levels,5240,O
were,5240,O
increased,5240,O
in,5240,O
CE,5240,O
compared,5240,O
to,5240,O
C.,5240,O
In,5240,O
Experiment,5240,O
2,5240,O
",",5240,O
hepatic,5240,O
iron,5240,B-CHEMICAL
concentrations,5240,O
were,5240,O
higher,5240,O
in,5240,O
HIE,5240,O
than,5240,O
HI,5240,O
.,5240,O
Hepatic,5241,O
mRNA,5241,O
expression,5241,O
of,5241,O
ferritinL,5241,B-GENE-Y
and,5241,O
hepcidin,5241,B-GENE-Y
were,5241,O
increased,5241,O
in,5241,O
HIE,5241,O
compared,5241,O
to,5241,O
HI,5241,O
.,5241,O
In,5242,O
duodenum,5242,O
",",5242,O
ferritinL,5242,B-GENE-Y
mRNA,5242,O
was,5242,O
increased,5242,O
in,5242,O
HIE,5242,O
compared,5242,O
to,5242,O
CIE.,5242,O
Ezetimibe,5242,B-CHEMICAL
induced,5242,O
hepatic,5242,O
iron,5242,B-CHEMICAL
uptake,5242,O
transporter,5242,O
expression,5242,O
in,5242,O
mice,5242,O
fed,5242,O
a,5242,O
high-fat,5242,O
diet,5242,O
",",5242,O
causing,5242,O
increased,5242,O
hepatic,5242,O
iron,5242,B-CHEMICAL
concentrations,5242,O
.,5242,O
Androgen,5243,B-CHEMICAL
deprivation,5243,O
from,5243,O
pre-puberty,5243,O
to,5243,O
peripuberty,5243,O
interferes,5243,O
in,5243,O
proteins,5243,O
expression,5243,O
in,5243,O
pubertal,5243,O
and,5243,O
adult,5243,O
rat,5243,O
epididymis,5243,O
.,5243,O
Few,5244,O
studies,5244,O
have,5244,O
focused,5244,O
on,5244,O
experimental,5244,O
testosterone,5244,B-CHEMICAL
deprivation,5244,O
in,5244,O
immature,5244,O
animals,5244,O
.,5244,O
Therefore,5245,O
",",5245,O
this,5245,O
study,5245,O
used,5245,O
sexually,5245,O
immature,5245,O
rats,5245,O
aiming,5245,O
to,5245,O
evaluate,5245,O
the,5245,O
testes,5245,O
and,5245,O
epididymis,5245,O
histology,5245,O
and,5245,O
proteins,5245,O
expression,5245,O
in,5245,O
these,5245,O
organs,5245,O
on,5245,O
PND50,5245,O
and,5245,O
75,5245,O
",",5245,O
after,5245,O
premature,5245,O
antiandrogen,5245,O
exposure,5245,O
",",5245,O
from,5245,O
PND21,5245,O
to,5245,O
44,5245,O
.,5245,O
Although,5246,O
the,5246,O
androgen,5246,B-CHEMICAL
deprivation,5246,O
from,5246,O
pre-puberty,5246,O
up,5246,O
to,5246,O
peripuberty,5246,O
did,5246,O
not,5246,O
alter,5246,O
the,5246,O
histological,5246,O
organization,5246,O
of,5246,O
the,5246,O
testes,5246,O
and,5246,O
epididymis,5246,O
either,5246,O
at,5246,O
puberty,5246,O
or,5246,O
at,5246,O
adulthood,5246,O
",",5246,O
the,5246,O
treatment,5246,O
impaired,5246,O
the,5246,O
expression,5246,O
of,5246,O
specific,5246,O
proteins,5246,O
in,5246,O
epididymal,5246,O
tissue,5246,O
at,5246,O
puberty,5246,O
and,5246,O
adulthood,5246,O
(,5246,O
androgen,5246,B-GENE-Y
receptor,5246,I-GENE-Y
",",5246,O
calmodulin,5246,B-GENE-N
",",5246,O
Rab11A,5246,B-GENE-Y
),5246,O
.,5246,O
These,5247,O
changes,5247,O
may,5247,O
be,5247,O
related,5247,O
to,5247,O
impaired,5247,O
epididymal,5247,O
function,5247,O
",",5247,O
sperm,5247,O
quality,5247,O
and,5247,O
fertility,5247,O
capacity,5247,O
as,5247,O
observed,5247,O
in,5247,O
a,5247,O
previous,5247,O
study,5247,O
.,5247,O
Further,5248,O
studies,5248,O
are,5248,O
necessary,5248,O
to,5248,O
better,5248,O
investigate,5248,O
the,5248,O
molecular,5248,O
mechanisms,5248,O
involved,5248,O
in,5248,O
the,5248,O
impairment,5248,O
on,5248,O
reproductive,5248,O
competence,5248,O
of,5248,O
male,5248,O
rats,5248,O
after,5248,O
precocious,5248,O
hormonal,5248,O
injury,5248,O
.,5248,O
Discovery,5249,O
of,5249,O
a,5249,O
series,5249,O
of,5249,O
novel,5249,O
5H-pyrrolo,5249,B-CHEMICAL
[,5249,I-CHEMICAL
"2,3-b",5249,I-CHEMICAL
],5249,I-CHEMICAL
pyrazine-2-phenyl,5249,I-CHEMICAL
ethers,5249,I-CHEMICAL
",",5249,O
as,5249,O
potent,5249,O
JAK3,5249,B-GENE-Y
kinase,5249,B-GENE-N
inhibitors,5249,O
.,5249,O
We,5250,O
report,5250,O
the,5250,O
discovery,5250,O
of,5250,O
a,5250,O
novel,5250,O
series,5250,O
of,5250,O
ATP-competitive,5250,B-CHEMICAL
Janus,5250,B-GENE-Y
kinase,5250,I-GENE-Y
3,5250,I-GENE-Y
(,5250,O
JAK3,5250,B-GENE-Y
),5250,O
inhibitors,5250,O
based,5250,O
on,5250,O
the,5250,O
5H-pyrrolo,5250,B-CHEMICAL
[,5250,I-CHEMICAL
"2,3-b",5250,I-CHEMICAL
],5250,I-CHEMICAL
pyrazine,5250,I-CHEMICAL
scaffold,5250,O
.,5250,O
The,5251,O
initial,5251,O
leads,5251,O
in,5251,O
this,5251,O
series,5251,O
",",5251,O
compounds,5251,O
1a,5251,O
and,5251,O
1h,5251,O
",",5251,O
showed,5251,O
promising,5251,O
potencies,5251,O
",",5251,O
but,5251,O
a,5251,O
lack,5251,O
of,5251,O
selectivity,5251,O
against,5251,O
other,5251,O
isoforms,5251,O
in,5251,O
the,5251,O
JAK,5251,B-GENE-N
family,5251,O
.,5251,O
Computational,5252,O
and,5252,O
crystallographic,5252,O
analysis,5252,O
suggested,5252,O
that,5252,O
the,5252,O
phenyl,5252,O
ether,5252,O
moiety,5252,O
possessed,5252,O
a,5252,O
favorable,5252,O
vector,5252,O
to,5252,O
achieve,5252,O
selectivity,5252,O
.,5252,O
Exploration,5253,O
of,5253,O
this,5253,O
vector,5253,O
resulted,5253,O
in,5253,O
the,5253,O
identification,5253,O
of,5253,O
12b,5253,O
and,5253,O
12d,5253,O
",",5253,O
as,5253,O
potent,5253,O
JAK3,5253,B-GENE-Y
inhibitors,5253,O
",",5253,O
demonstrating,5253,O
improved,5253,O
JAK,5253,B-GENE-N
family,5253,O
and,5253,O
kinase,5253,B-GENE-N
selectivity,5253,O
.,5253,O
Arsenic,5254,B-CHEMICAL
trioxide,5254,I-CHEMICAL
depletes,5254,O
cancer,5254,O
stem-like,5254,O
cells,5254,O
and,5254,O
inhibits,5254,O
repopulation,5254,O
of,5254,O
neurosphere,5254,O
derived,5254,O
from,5254,O
glioblastoma,5254,O
by,5254,O
downregulation,5254,O
of,5254,O
Notch,5254,B-GENE-N
pathway,5254,O
.,5254,O
Notch,5255,B-GENE-N
signaling,5255,O
has,5255,O
been,5255,O
demonstrated,5255,O
to,5255,O
have,5255,O
a,5255,O
central,5255,O
role,5255,O
in,5255,O
cancer,5255,O
stem-like,5255,O
cells,5255,O
(,5255,O
CSLCs,5255,O
),5255,O
in,5255,O
glioblastoma,5255,O
multiforme,5255,O
(,5255,O
GBM,5255,O
),5255,O
.,5255,O
We,5256,O
have,5256,O
recently,5256,O
demonstrated,5256,O
the,5256,O
inhibitory,5256,O
effect,5256,O
of,5256,O
arsenic,5256,B-CHEMICAL
trioxide,5256,I-CHEMICAL
(,5256,O
ATO,5256,B-CHEMICAL
),5256,O
on,5256,O
CSLCs,5256,O
in,5256,O
glioblastoma,5256,O
cell,5256,O
lines,5256,O
.,5256,O
In,5257,O
this,5257,O
study,5257,O
we,5257,O
used,5257,O
neurosphere,5257,O
recovery,5257,O
assay,5257,O
that,5257,O
measured,5257,O
neurosphere,5257,O
formation,5257,O
at,5257,O
three,5257,O
time,5257,O
points,5257,O
to,5257,O
assess,5257,O
the,5257,O
capacity,5257,O
of,5257,O
the,5257,O
culture,5257,O
to,5257,O
repopulate,5257,O
after,5257,O
ATO,5257,B-CHEMICAL
treatment,5257,O
.,5257,O
Our,5258,O
results,5258,O
provided,5258,O
strong,5258,O
evidence,5258,O
that,5258,O
ATO,5258,B-CHEMICAL
depleted,5258,O
CSLCs,5258,O
in,5258,O
GBM,5258,O
",",5258,O
and,5258,O
inhibited,5258,O
neurosphere,5258,O
recovery,5258,O
and,5258,O
secondary,5258,O
neurosphere,5258,O
formation,5258,O
.,5258,O
ATO,5259,B-CHEMICAL
inhibited,5259,O
the,5259,O
phosphorylation,5259,O
and,5259,O
activation,5259,O
of,5259,O
AKT,5259,B-GENE-N
and,5259,O
STAT3,5259,B-GENE-Y
through,5259,O
Notch,5259,B-GENE-N
signaling,5259,O
blockade,5259,O
.,5259,O
These,5260,O
data,5260,O
show,5260,O
that,5260,O
the,5260,O
ATO,5260,B-CHEMICAL
is,5260,O
a,5260,O
promising,5260,O
new,5260,O
approach,5260,O
to,5260,O
decrease,5260,O
glioblastoma,5260,O
proliferation,5260,O
and,5260,O
recurrence,5260,O
by,5260,O
downregulation,5260,O
of,5260,O
Notch,5260,B-GENE-N
pathway,5260,O
.,5260,O
Total,5261,O
saponins,5261,B-CHEMICAL
of,5261,O
Panax,5261,O
notoginseng,5261,O
enhance,5261,O
VEGF,5261,O
and,5261,O
relative,5261,O
receptors,5261,O
signals,5261,O
and,5261,O
promote,5261,O
angiogenesis,5261,O
derived,5261,O
from,5261,O
rat,5261,O
bone,5261,O
marrow,5261,O
mesenchymal,5261,O
stem,5261,O
cells,5261,O
.,5261,O
ETHNOPHARMACOLOGICAL,5262,O
RELEVANCE,5262,O
:,5262,O
Total,5262,O
saponins,5262,O
of,5262,O
Panax,5262,O
notoginseng,5262,O
(,5262,O
tPNS,5262,O
),5262,O
",",5262,O
main,5262,O
constituents,5262,O
extracted,5262,O
from,5262,O
Panax,5262,O
Notoginseng,5262,O
",",5262,O
a,5262,O
highly,5262,O
valued,5262,O
traditional,5262,O
Chinese,5262,O
medicine,5262,O
",",5262,O
has,5262,O
been,5262,O
shown,5262,O
to,5262,O
increase,5262,O
protein,5262,O
expression,5262,O
and,5262,O
the,5262,O
secretion,5262,O
of,5262,O
vascular,5262,B-GENE-Y
endothelial,5262,I-GENE-Y
growth,5262,I-GENE-Y
factor,5262,I-GENE-Y
(,5262,O
VEGF,5262,B-GENE-Y
),5262,O
in,5262,O
human,5262,O
umbilical,5262,O
vein,5262,O
endothelial,5262,O
cells,5262,O
.,5262,O
AIMS,5263,O
OF,5263,O
THE,5263,O
STUDY,5263,O
:,5263,O
The,5263,O
effects,5263,O
of,5263,O
tPNS,5263,O
on,5263,O
angiogenesis,5263,O
were,5263,O
studied,5263,O
in,5263,O
rat,5263,O
bone,5263,O
marrow,5263,O
mesenchymal,5263,O
stem,5263,O
cells,5263,O
(,5263,O
rBMSCs,5263,O
),5263,O
.,5263,O
MATERIALS,5264,O
AND,5264,O
METHODS,5264,O
:,5264,O
rBMSCs,5264,O
were,5264,O
stimulated,5264,O
by,5264,O
tPNS,5264,O
of,5264,O
48h,5264,O
.,5264,O
The,5265,O
mRNA,5265,O
expression,5265,O
levels,5265,O
of,5265,O
VEGF-A,5265,B-GENE-Y
",",5265,O
Flt-1,5265,B-GENE-Y
and,5265,O
Kdr,5265,B-GENE-Y
in,5265,O
rBMSCs,5265,O
were,5265,O
determined,5265,O
by,5265,O
quantitative,5265,O
real,5265,O
time,5265,O
PCR,5265,O
(,5265,O
qRT-PCR,5265,O
),5265,O
.,5265,O
rBMSCs,5266,O
were,5266,O
induced,5266,O
to,5266,O
differentiate,5266,O
into,5266,O
endothelial-like,5266,O
cells,5266,O
and,5266,O
the,5266,O
effects,5266,O
of,5266,O
tPNS,5266,O
on,5266,O
the,5266,O
angiogenesis,5266,O
ability,5266,O
of,5266,O
rBMSCs,5266,O
and,5266,O
rBMSCs,5266,O
after,5266,O
endothelial,5266,O
differentiation,5266,O
were,5266,O
assayed,5266,O
by,5266,O
a,5266,O
Matrigel,5266,O
model,5266,O
in,5266,O
vivo,5266,O
and,5266,O
in,5266,O
vitro,5266,O
.,5266,O
RESULTS,5267,O
:,5267,O
tPNS,5267,O
(,5267,O
100g/ml,5267,O
),5267,O
significantly,5267,O
enhanced,5267,O
the,5267,O
mRNA,5267,O
expression,5267,O
level,5267,O
of,5267,O
VEGF-A,5267,B-GENE-Y
and,5267,O
Kdr,5267,B-GENE-Y
compared,5267,O
to,5267,O
the,5267,O
control,5267,O
group,5267,O
",",5267,O
while,5267,O
they,5267,O
had,5267,O
no,5267,O
obvious,5267,O
effect,5267,O
on,5267,O
the,5267,O
expression,5267,O
of,5267,O
Flt-1,5267,B-GENE-Y
.,5267,O
tPNS,5268,O
(,5268,O
1g/ml,5268,O
and,5268,O
100g/ml,5268,O
),5268,O
significantly,5268,O
increased,5268,O
capillary,5268,O
network,5268,O
forming,5268,O
of,5268,O
rBMSCs,5268,O
after,5268,O
endothelial,5268,O
differentiation,5268,O
in,5268,O
Matrigel,5268,O
in,5268,O
vitro,5268,O
.,5268,O
tPNS,5269,O
(,5269,O
50g/kg,5269,O
",",5269,O
100g/kg,5269,O
and,5269,O
150g/kg,5269,O
),5269,O
also,5269,O
significantly,5269,O
increased,5269,O
angiogenesis,5269,O
induced,5269,O
by,5269,O
the,5269,O
combination,5269,O
with,5269,O
implantation,5269,O
of,5269,O
rBMSCs,5269,O
and,5269,O
Matrigel,5269,O
in,5269,O
vivo,5269,O
.,5269,O
CONCLUSION,5270,O
:,5270,O
tPNS,5270,O
up-regulate,5270,O
VEGF-A,5270,B-GENE-Y
and,5270,O
Kdr,5270,B-GENE-Y
expression,5270,O
",",5270,O
and,5270,O
promote,5270,O
angiogenesis,5270,O
in,5270,O
rat,5270,O
bone,5270,O
marrow,5270,O
mesenchymal,5270,O
stem,5270,O
cells,5270,O
.,5270,O
Ovarian,5271,O
Expression,5271,O
of,5271,O
Insulin-Like,5271,B-GENE-Y
Peptide,5271,I-GENE-Y
3,5271,I-GENE-Y
(,5271,O
INSL3,5271,B-GENE-Y
),5271,O
and,5271,O
Its,5271,O
Receptor,5271,O
(,5271,O
RXFP2,5271,B-GENE-Y
),5271,O
During,5271,O
Development,5271,O
of,5271,O
Bovine,5271,O
Antral,5271,O
Follicles,5271,O
and,5271,O
Corpora,5271,O
Lutea,5271,O
and,5271,O
Measurement,5271,O
of,5271,O
Circulating,5271,O
INSL3,5271,B-GENE-Y
Levels,5271,O
During,5271,O
Synchronized,5271,O
Estrous,5271,O
Cycles,5271,O
.,5271,O
Insulin-like,5272,B-GENE-Y
peptide,5272,I-GENE-Y
3,5272,I-GENE-Y
(,5272,O
INSL3,5272,B-GENE-Y
),5272,O
",",5272,O
a,5272,O
major,5272,O
product,5272,O
of,5272,O
testicular,5272,O
Leydig,5272,O
cells,5272,O
",",5272,O
is,5272,O
also,5272,O
expressed,5272,O
by,5272,O
the,5272,O
ovary,5272,O
",",5272,O
but,5272,O
its,5272,O
functional,5272,O
role,5272,O
remains,5272,O
poorly,5272,O
understood,5272,O
.,5272,O
Here,5273,O
",",5273,O
we,5273,O
quantified,5273,O
expression,5273,O
of,5273,O
INSL3,5273,B-GENE-Y
and,5273,O
its,5273,O
receptor,5273,O
RXFP2,5273,B-GENE-Y
in,5273,O
theca,5273,O
interna,5273,O
cell,5273,O
(,5273,O
TIC,5273,O
),5273,O
and,5273,O
granulosa,5273,O
cell,5273,O
compartments,5273,O
of,5273,O
developing,5273,O
bovine,5273,O
antral,5273,O
follicles,5273,O
and,5273,O
in,5273,O
corpora,5273,O
lutea,5273,O
(,5273,O
CL,5273,O
),5273,O
.,5273,O
INSL3,5274,B-GENE-Y
and,5274,O
RXFP2,5274,B-GENE-Y
mRNA,5274,O
levels,5274,O
were,5274,O
much,5274,O
higher,5274,O
in,5274,O
TIC,5274,O
than,5274,O
granulosa,5274,O
cell,5274,O
and,5274,O
increased,5274,O
progressively,5274,O
during,5274,O
follicle,5274,O
maturation,5274,O
with,5274,O
INSL3,5274,B-GENE-Y
peaking,5274,O
in,5274,O
large,5274,O
(,5274,O
11-18,5274,O
mm,5274,O
),5274,O
estrogen-active,5274,B-CHEMICAL
follicles,5274,O
and,5274,O
RXFP2,5274,B-GENE-Y
peaking,5274,O
in,5274,O
9-,5274,O
to,5274,O
10-mm,5274,O
follicles,5274,O
before,5274,O
declining,5274,O
in,5274,O
larger,5274,O
(,5274,O
11-18,5274,O
mm,5274,O
),5274,O
follicles,5274,O
.,5274,O
Expression,5275,O
of,5275,O
both,5275,O
INSL3,5275,B-GENE-Y
and,5275,O
RXFP2,5275,B-GENE-Y
in,5275,O
CL,5275,O
was,5275,O
much,5275,O
lower,5275,O
than,5275,O
in,5275,O
TIC,5275,O
.,5275,O
In,5276,O
situ,5276,O
hybridization,5276,O
and,5276,O
immunohistochemistry,5276,O
confirmed,5276,O
abundant,5276,O
expression,5276,O
of,5276,O
INSL3,5276,B-GENE-Y
mRNA,5276,O
and,5276,O
protein,5276,O
in,5276,O
TIC,5276,O
.,5276,O
These,5277,O
observations,5277,O
indicate,5277,O
follicular,5277,O
TIC,5277,O
rather,5277,O
than,5277,O
CL,5277,O
as,5277,O
the,5277,O
primary,5277,O
site,5277,O
of,5277,O
both,5277,O
INSL3,5277,B-GENE-Y
production,5277,O
and,5277,O
action,5277,O
",",5277,O
implying,5277,O
a,5277,O
predominantly,5277,O
autocrine/paracrine,5277,O
role,5277,O
in,5277,O
TIC,5277,O
.,5277,O
To,5278,O
corroborate,5278,O
the,5278,O
above,5278,O
findings,5278,O
",",5278,O
we,5278,O
showed,5278,O
that,5278,O
in,5278,O
vitro,5278,O
exposure,5278,O
of,5278,O
TIC,5278,O
to,5278,O
a,5278,O
luteinizing,5278,O
concentration,5278,O
of,5278,O
LH,5278,B-GENE-N
greatly,5278,O
attenuated,5278,O
expression,5278,O
of,5278,O
both,5278,O
INSL3,5278,B-GENE-Y
and,5278,O
its,5278,O
receptor,5278,O
while,5278,O
increasing,5278,O
progesterone,5278,B-CHEMICAL
secretion,5278,O
and,5278,O
expression,5278,O
of,5278,O
STAR,5278,B-GENE-Y
and,5278,O
CYP11A1,5278,B-GENE-Y
.,5278,O
Moreover,5279,O
",",5279,O
in,5279,O
vivo,5279,O
",",5279,O
a,5279,O
significant,5279,O
cyclic,5279,O
variation,5279,O
in,5279,O
plasma,5279,O
INSL3,5279,B-GENE-Y
was,5279,O
observed,5279,O
during,5279,O
synchronized,5279,O
estrous,5279,O
cycles,5279,O
.,5279,O
INSL3,5280,B-GENE-Y
and,5280,O
estradiol-17,5280,B-CHEMICAL
followed,5280,O
a,5280,O
similar,5280,O
pattern,5280,O
",",5280,O
both,5280,O
increasing,5280,O
after,5280,O
luteolysis,5280,O
",",5280,O
before,5280,O
falling,5280,O
sharply,5280,O
after,5280,O
the,5280,O
LH,5280,B-GENE-N
surge,5280,O
.,5280,O
Thus,5281,O
",",5281,O
theca-derived,5281,O
INSL3,5281,B-GENE-Y
",",5281,O
likely,5281,O
from,5281,O
the,5281,O
dominant,5281,O
preovulatory,5281,O
follicle,5281,O
",",5281,O
is,5281,O
detectable,5281,O
in,5281,O
peripheral,5281,O
blood,5281,O
of,5281,O
cattle,5281,O
",",5281,O
and,5281,O
expression,5281,O
is,5281,O
down-regulated,5281,O
during,5281,O
luteinization,5281,O
induced,5281,O
by,5281,O
the,5281,O
preovulatory,5281,O
LH,5281,B-GENE-N
surge,5281,O
.,5281,O
Collectively,5282,O
",",5282,O
these,5282,O
findings,5282,O
underscore,5282,O
the,5282,O
likely,5282,O
role,5282,O
of,5282,O
INSL3,5282,B-GENE-Y
as,5282,O
an,5282,O
important,5282,O
intrafollicular,5282,O
modulator,5282,O
of,5282,O
TIC,5282,O
function/steroidogenesis,5282,O
",",5282,O
while,5282,O
raising,5282,O
doubts,5282,O
about,5282,O
its,5282,O
potential,5282,O
contribution,5282,O
to,5282,O
CL,5282,O
function,5282,O
.,5282,O
Cytotoxicity,5283,O
and,5283,O
Modulation,5283,O
of,5283,O
Cancer-Related,5283,O
Signaling,5283,O
by,5283,O
(,5283,B-CHEMICAL
Z,5283,I-CHEMICAL
),5283,I-CHEMICAL
-,5283,I-CHEMICAL
and,5283,I-CHEMICAL
(,5283,I-CHEMICAL
E,5283,I-CHEMICAL
),5283,I-CHEMICAL
"-3,4,3',5'-Tetramethoxystilbene",5283,I-CHEMICAL
Isolated,5283,O
from,5283,O
Eugenia,5283,O
rigida,5283,O
.,5283,O
Bioassay-guided,5284,O
fractionation,5284,O
of,5284,O
the,5284,O
leaves,5284,O
of,5284,O
Eugenia,5284,O
rigida,5284,O
yielded,5284,O
three,5284,O
stilbenes,5284,B-CHEMICAL
",",5284,O
(,5284,B-CHEMICAL
Z,5284,I-CHEMICAL
),5284,I-CHEMICAL
"-3,4,3',5'-tetramethoxystilbene",5284,I-CHEMICAL
(,5284,O
1,5284,O
),5284,O
",",5284,O
(,5284,B-CHEMICAL
E,5284,I-CHEMICAL
),5284,I-CHEMICAL
"-3,4,3',5'-tetramethoxystilbene",5284,I-CHEMICAL
(,5284,O
2,5284,O
),5284,O
",",5284,O
and,5284,O
(,5284,B-CHEMICAL
E,5284,I-CHEMICAL
),5284,I-CHEMICAL
"-3,5,4'-trimethoxystilbene",5284,I-CHEMICAL
(,5284,O
3,5284,O
),5284,O
.,5284,O
Their,5285,O
structures,5285,O
were,5285,O
determined,5285,O
using,5285,O
1D-,5285,O
and,5285,O
2D-NMR,5285,O
spectroscopy,5285,O
and,5285,O
HRESIMS,5285,O
.,5285,O
The,5286,O
sterically,5286,O
hindered,5286,O
Z-stereoisomer,5286,O
1,5286,O
",",5286,O
a,5286,O
new,5286,O
natural,5286,O
product,5286,O
",",5286,O
was,5286,O
prepared,5286,O
by,5286,O
time-dependent,5286,O
photoisomerization,5286,O
of,5286,O
the,5286,O
E-isomer,5286,O
(,5286,O
2,5286,O
),5286,O
under,5286,O
UV,5286,O
irradiation,5286,O
at,5286,O
254,5286,O
nm,5286,O
",",5286,O
while,5286,O
"2,3,5,7-tetramethoxyphenanthrene",5286,B-CHEMICAL
(,5286,O
5,5286,O
),5286,O
was,5286,O
identified,5286,O
at,5286,O
365,5286,O
nm,5286,O
by,5286,O
UHPLC/APCI-MS,5286,O
and,5286,O
NMR,5286,O
spectroscopy,5286,O
.,5286,O
Compounds,5287,O
1-3,5287,O
were,5287,O
tested,5287,O
against,5287,O
a,5287,O
panel,5287,O
of,5287,O
luciferase,5287,O
reporter,5287,O
gene,5287,O
assays,5287,O
that,5287,O
assess,5287,O
the,5287,O
activity,5287,O
of,5287,O
many,5287,O
cancer-related,5287,O
signaling,5287,O
pathways,5287,O
",",5287,O
and,5287,O
the,5287,O
Z-isomer,5287,O
(,5287,O
1,5287,O
),5287,O
was,5287,O
found,5287,O
to,5287,O
be,5287,O
more,5287,O
potent,5287,O
than,5287,O
the,5287,O
E-isomer,5287,O
(,5287,O
2,5287,O
),5287,O
in,5287,O
inhibiting,5287,O
the,5287,O
activation,5287,O
of,5287,O
Stat3,5287,B-GENE-Y
",",5287,O
Smad3/4,5287,B-GENE-N
",",5287,O
myc,5287,B-GENE-Y
",",5287,O
Ets,5287,B-GENE-N
",",5287,O
Notch,5287,B-GENE-N
",",5287,O
and,5287,O
Wnt,5287,B-GENE-N
signaling,5287,O
",",5287,O
with,5287,O
IC50,5287,O
values,5287,O
between,5287,O
40,5287,O
and,5287,O
80,5287,O
M,5287,O
.,5287,O
However,5288,O
",",5288,O
both,5288,O
compounds,5288,O
showed,5288,O
similar,5288,O
inhibition,5288,O
against,5288,O
Ap-1,5288,B-GENE-Y
and,5288,O
NF-B,5288,B-GENE-N
signaling,5288,O
.,5288,O
In,5289,O
addition,5289,O
",",5289,O
1,5289,O
demonstrated,5289,O
cytotoxic,5289,O
activity,5289,O
toward,5289,O
human,5289,O
leukemia,5289,O
cells,5289,O
",",5289,O
solid,5289,O
tumor,5289,O
cells,5289,O
of,5289,O
epidermal,5289,O
",",5289,O
breast,5289,O
",",5289,O
and,5289,O
cervical,5289,O
carcinomas,5289,O
",",5289,O
and,5289,O
skin,5289,O
melanoma,5289,O
",",5289,O
with,5289,O
IC50,5289,O
values,5289,O
between,5289,O
3.6,5289,O
and,5289,O
4.3,5289,O
M,5289,O
",",5289,O
while,5289,O
2,5289,O
was,5289,O
weakly,5289,O
active,5289,O
against,5289,O
leukemia,5289,O
",",5289,O
cervical,5289,O
carcinoma,5289,O
",",5289,O
and,5289,O
skin,5289,O
melanoma,5289,O
cells,5289,O
.,5289,O
Interestingly,5290,O
",",5290,O
2,5290,O
showed,5290,O
antioxidant,5290,O
activity,5290,O
by,5290,O
inhibition,5290,O
of,5290,O
ROS,5290,O
generation,5290,O
to,5290,O
50,5290,O
%,5290,O
at,5290,O
33.3,5290,O
M,5290,O
in,5290,O
PMA-induced,5290,B-CHEMICAL
HL-60,5290,O
cells,5290,O
",",5290,O
while,5290,O
1,5290,O
was,5290,O
inactive,5290,O
at,5290,O
100,5290,O
M,5290,O
(,5290,O
vs,5290,O
Trolox,5290,B-CHEMICAL
1.4,5290,O
M,5290,O
),5290,O
.,5290,O
Genomic,5291,O
variation,5291,O
in,5291,O
the,5291,O
MAP3K5,5291,B-GENE-Y
gene,5291,O
is,5291,O
associated,5291,O
with,5291,O
-thalassemia,5291,O
disease,5291,O
severity,5291,O
and,5291,O
hydroxyurea,5291,B-CHEMICAL
treatment,5291,O
efficacy,5291,O
.,5291,O
Aim,5292,O
:,5292,O
In,5292,O
this,5292,O
study,5292,O
we,5292,O
explored,5292,O
the,5292,O
association,5292,O
between,5292,O
genetic,5292,O
variations,5292,O
in,5292,O
MAP3K5,5292,B-GENE-Y
and,5292,O
PDE7B,5292,B-GENE-Y
genes,5292,O
",",5292,O
residing,5292,O
on,5292,O
chromosome,5292,O
6q23,5292,O
",",5292,O
and,5292,O
disease,5292,O
severity,5292,O
in,5292,O
-hemoglobinopathy,5292,O
patients,5292,O
",",5292,O
as,5292,O
well,5292,O
as,5292,O
the,5292,O
association,5292,O
between,5292,O
these,5292,O
variants,5292,O
with,5292,O
response,5292,O
to,5292,O
hydroxyurea,5292,B-CHEMICAL
(,5292,O
HU,5292,O
),5292,O
treatment,5292,O
.,5292,O
Furthermore,5293,O
",",5293,O
we,5293,O
examined,5293,O
MAP3K5,5293,B-GENE-Y
expression,5293,O
in,5293,O
the,5293,O
context,5293,O
of,5293,O
high,5293,O
fetal,5293,O
hemoglobin,5293,O
(,5293,O
HbF,5293,O
),5293,O
and,5293,O
upon,5293,O
HU,5293,O
treatment,5293,O
in,5293,O
erythroid,5293,O
progenitor,5293,O
cells,5293,O
from,5293,O
healthy,5293,O
and,5293,O
KLF1,5293,O
haploinsufficient,5293,O
individuals,5293,O
.,5293,O
Materials,5294,O
&,5294,O
methods,5294,O
:,5294,O
For,5294,O
this,5294,O
purpose,5294,O
",",5294,O
we,5294,O
genotyped,5294,O
-thalassemia,5294,O
intermedia,5294,O
and,5294,O
major,5294,O
patients,5294,O
and,5294,O
healthy,5294,O
controls,5294,O
",",5294,O
as,5294,O
well,5294,O
as,5294,O
a,5294,O
cohort,5294,O
of,5294,O
compound,5294,O
heterozygous,5294,O
sickle,5294,O
cell,5294,O
disease/-thalassemia,5294,O
patients,5294,O
receiving,5294,O
HU,5294,O
as,5294,O
HbF,5294,O
augmentation,5294,O
treatment,5294,O
.,5294,O
Furthermore,5295,O
",",5295,O
we,5295,O
examined,5295,O
MAP3K5,5295,B-GENE-Y
expression,5295,O
in,5295,O
the,5295,O
context,5295,O
of,5295,O
high,5295,O
HbF,5295,O
and,5295,O
upon,5295,O
HU,5295,O
treatment,5295,O
in,5295,O
erythroid,5295,O
progenitor,5295,O
cells,5295,O
from,5295,O
healthy,5295,O
and,5295,O
KLF1,5295,O
haploinsufficient,5295,O
individuals,5295,O
.,5295,O
Results,5296,O
:,5296,O
A,5296,O
short,5296,O
tandem,5296,O
repeat,5296,O
in,5296,O
the,5296,O
MAP3K5,5296,B-GENE-N
promoter,5296,I-GENE-N
and,5296,O
two,5296,O
intronic,5296,O
MAP3K5,5296,B-GENE-Y
gene,5296,O
variants,5296,O
",",5296,O
as,5296,O
well,5296,O
as,5296,O
a,5296,O
PDE7B,5296,B-GENE-Y
variant,5296,O
",",5296,O
are,5296,O
associated,5296,O
with,5296,O
low,5296,O
HbF,5296,O
levels,5296,O
and,5296,O
a,5296,O
severe,5296,O
disease,5296,O
phenotype,5296,O
.,5296,O
Moreover,5297,O
",",5297,O
MAP3K5,5297,B-GENE-Y
mRNA,5297,O
expression,5297,O
levels,5297,O
are,5297,O
altered,5297,O
in,5297,O
the,5297,O
context,5297,O
of,5297,O
high,5297,O
HbF,5297,O
and,5297,O
are,5297,O
affected,5297,O
by,5297,O
the,5297,O
presence,5297,O
of,5297,O
HU,5297,O
.,5297,O
Lastly,5298,O
",",5298,O
the,5298,O
abovementioned,5298,O
MAP3K5,5298,B-GENE-Y
variants,5298,O
are,5298,O
associated,5298,O
with,5298,O
HU,5298,O
treatment,5298,O
efficacy,5298,O
.,5298,O
Conclusion,5299,O
:,5299,O
Our,5299,O
data,5299,O
suggest,5299,O
that,5299,O
these,5299,O
MAP3K5,5299,B-GENE-Y
variants,5299,O
are,5299,O
indicative,5299,O
of,5299,O
-thalassemia,5299,O
disease,5299,O
severity,5299,O
and,5299,O
response,5299,O
to,5299,O
HU,5299,O
treatment,5299,O
.,5299,O
Original,5300,O
submitted,5300,O
24,5300,O
September,5300,O
2012,5300,O
;,5300,O
Revision,5300,O
submitted,5300,O
4,5300,O
February,5300,O
2013,5300,O
.,5300,O
Annexin,5301,B-GENE-Y
A2,5301,I-GENE-Y
regulates,5301,O
1,5301,B-GENE-Y
integrin,5301,I-GENE-Y
internalization,5301,O
and,5301,O
intestinal,5301,O
epithelial,5301,O
cell,5301,O
migration,5301,O
.,5301,O
The,5302,O
gastrointestinal,5302,O
epithelium,5302,O
functions,5302,O
as,5302,O
an,5302,O
important,5302,O
barrier,5302,O
that,5302,O
separates,5302,O
luminal,5302,B-CHEMICAL
contents,5302,O
from,5302,O
the,5302,O
underlying,5302,O
tissue,5302,O
compartment,5302,O
and,5302,O
is,5302,O
vital,5302,O
in,5302,O
maintaining,5302,O
mucosal,5302,O
homeostasis,5302,O
.,5302,O
Mucosal,5303,O
wounds,5303,O
in,5303,O
inflammatory,5303,O
disorders,5303,O
compromise,5303,O
the,5303,O
critical,5303,O
epithelial,5303,O
barrier,5303,O
.,5303,O
In,5304,O
response,5304,O
to,5304,O
injury,5304,O
",",5304,O
intestinal,5304,O
epithelial,5304,O
cells,5304,O
(,5304,O
IECs,5304,O
),5304,O
rapidly,5304,O
migrate,5304,O
to,5304,O
reseal,5304,O
wounds,5304,O
.,5304,O
We,5305,O
have,5305,O
previously,5305,O
observed,5305,O
that,5305,O
a,5305,O
membrane,5305,O
associated,5305,O
",",5305,O
Actin,5305,B-GENE-N
binding,5305,I-GENE-N
protein,5305,I-GENE-N
",",5305,O
Annexin,5305,B-GENE-N
A2,5305,I-GENE-N
(,5305,O
AnxA2,5305,B-GENE-N
),5305,O
",",5305,O
is,5305,O
up-regulated,5305,O
in,5305,O
migrating,5305,O
IECs,5305,O
and,5305,O
plays,5305,O
an,5305,O
important,5305,O
role,5305,O
in,5305,O
promoting,5305,O
wound,5305,O
closure,5305,O
.,5305,O
To,5306,O
identify,5306,O
the,5306,O
mechanisms,5306,O
by,5306,O
which,5306,O
AnxA2,5306,B-GENE-Y
promotes,5306,O
IEC,5306,O
movement,5306,O
and,5306,O
wound,5306,O
closure,5306,O
we,5306,O
used,5306,O
a,5306,O
loss,5306,O
of,5306,O
function,5306,O
approach,5306,O
.,5306,O
AnxA2,5307,B-GENE-Y
specific,5307,O
shRNA,5307,O
was,5307,O
utilized,5307,O
to,5307,O
generate,5307,O
IECs,5307,O
with,5307,O
stable,5307,O
down-regulation,5307,O
of,5307,O
AnxA2,5307,B-GENE-Y
.,5307,O
Loss,5308,O
of,5308,O
AnxA2,5308,B-GENE-Y
inhibited,5308,O
IEC,5308,O
migration,5308,O
while,5308,O
promoting,5308,O
enhanced,5308,O
cell-matrix,5308,O
adhesion,5308,O
.,5308,O
These,5309,O
functional,5309,O
effects,5309,O
were,5309,O
associated,5309,O
with,5309,O
increased,5309,O
levels,5309,O
of,5309,O
1,5309,B-GENE-Y
integrin,5309,I-GENE-Y
protein,5309,O
",",5309,O
which,5309,O
is,5309,O
reported,5309,O
to,5309,O
play,5309,O
an,5309,O
important,5309,O
role,5309,O
in,5309,O
mediating,5309,O
the,5309,O
cell-matrix,5309,O
adhesive,5309,O
properties,5309,O
of,5309,O
epithelial,5309,O
cells,5309,O
.,5309,O
Since,5310,O
cell,5310,O
migration,5310,O
requires,5310,O
dynamic,5310,O
turnover,5310,O
of,5310,O
integrin,5310,O
based,5310,O
adhesions,5310,O
",",5310,O
we,5310,O
tested,5310,O
if,5310,O
AnxA2,5310,B-GENE-Y
modulates,5310,O
internalization,5310,O
of,5310,O
cell,5310,O
surface,5310,O
1,5310,B-GENE-Y
integrin,5310,I-GENE-Y
required,5310,O
for,5310,O
forward,5310,O
cell,5310,O
movement,5310,O
.,5310,O
Indeed,5311,O
",",5311,O
pulse-chase,5311,O
biotinylation,5311,O
experiments,5311,O
in,5311,O
IECs,5311,O
lacking,5311,O
AnxA2,5311,B-GENE-Y
demonstrated,5311,O
a,5311,O
significant,5311,O
increase,5311,O
in,5311,O
cell,5311,O
surface,5311,O
1,5311,B-GENE-Y
integrin,5311,I-GENE-Y
that,5311,O
was,5311,O
accompanied,5311,O
by,5311,O
decreased,5311,O
1,5311,B-GENE-Y
integrin,5311,I-GENE-Y
internalization,5311,O
and,5311,O
degradation,5311,O
.,5311,O
These,5312,O
findings,5312,O
support,5312,O
an,5312,O
important,5312,O
role,5312,O
of,5312,O
AnxA2,5312,B-GENE-Y
in,5312,O
controlling,5312,O
dynamics,5312,O
of,5312,O
1,5312,B-GENE-Y
integrin,5312,I-GENE-Y
at,5312,O
the,5312,O
cell,5312,O
surface,5312,O
that,5312,O
in,5312,O
turn,5312,O
is,5312,O
required,5312,O
for,5312,O
the,5312,O
active,5312,O
turnover,5312,O
of,5312,O
cell-matrix,5312,O
associations,5312,O
",",5312,O
cell,5312,O
migration,5312,O
and,5312,O
wound,5312,O
closure,5312,O
.,5312,O
Effects,5313,O
of,5313,O
fisetin,5313,B-CHEMICAL
supplementation,5313,O
on,5313,O
hepatic,5313,O
lipogenesis,5313,O
and,5313,O
glucose,5313,B-CHEMICAL
metabolism,5313,O
in,5313,O
Sprague-Dawley,5313,O
rats,5313,O
fed,5313,O
on,5313,O
a,5313,O
high,5313,O
fat,5313,O
diet,5313,O
.,5313,O
The,5314,O
modulatory,5314,O
effects,5314,O
of,5314,O
daily,5314,O
fisetin,5314,B-CHEMICAL
supplementation,5314,O
for,5314,O
8weeks,5314,O
on,5314,O
genes,5314,O
involved,5314,O
in,5314,O
hepatic,5314,O
lipogenesis,5314,O
and,5314,O
gluconeogenesis,5314,O
and,5314,O
hyperglycemia,5314,O
in,5314,O
rats,5314,O
fed,5314,O
a,5314,O
high,5314,O
fat,5314,O
(,5314,O
HF,5314,O
),5314,O
diet,5314,O
were,5314,O
evaluated,5314,O
.,5314,O
Elevated,5315,O
levels,5315,O
of,5315,O
triglyceride,5315,B-CHEMICAL
(,5315,O
TG,5315,O
),5315,O
",",5315,O
along,5315,O
with,5315,O
hepatic,5315,O
TG,5315,O
content,5315,O
and,5315,O
glucose,5315,B-CHEMICAL
concentrations,5315,O
in,5315,O
a,5315,O
high,5315,O
fat,5315,O
diet,5315,O
group,5315,O
were,5315,O
found,5315,O
to,5315,O
be,5315,O
reduced,5315,O
by,5315,O
fisetin,5315,B-CHEMICAL
supplementation,5315,O
.,5315,O
The,5316,O
high,5316,O
fat,5316,O
diet,5316,O
significantly,5316,O
increased,5316,O
hepatic,5316,O
mRNA,5316,O
expressions,5316,O
of,5316,O
PPAR,5316,B-GENE-Y
",",5316,O
SREBP1C,5316,B-GENE-Y
and,5316,O
SCD-1,5316,B-GENE-Y
genes,5316,O
in,5316,O
comparison,5316,O
to,5316,O
the,5316,O
control,5316,O
diet,5316,O
",",5316,O
which,5316,O
was,5316,O
subsequently,5316,O
reversed,5316,O
by,5316,O
supplementation,5316,O
with,5316,O
fisetin,5316,B-CHEMICAL
.,5316,O
In,5317,O
addition,5317,O
",",5317,O
fisetin,5317,B-CHEMICAL
supplementation,5317,O
significantly,5317,O
reduced,5317,O
hepatic,5317,O
mRNA,5317,O
abundance,5317,O
of,5317,O
FAS,5317,B-GENE-Y
",",5317,O
ATPCL,5317,B-GENE-Y
and,5317,O
G6Pase,5317,B-GENE-Y
compared,5317,O
to,5317,O
the,5317,O
control,5317,O
group,5317,O
.,5317,O
Finally,5318,O
",",5318,O
epididymal,5318,O
mRNA,5318,O
abundance,5318,O
of,5318,O
GLUT4,5318,B-GENE-Y
was,5318,O
significantly,5318,O
increased,5318,O
by,5318,O
fisetin,5318,B-CHEMICAL
supplementation,5318,O
",",5318,O
compared,5318,O
to,5318,O
levels,5318,O
in,5318,O
the,5318,O
control,5318,O
and,5318,O
HF,5318,O
groups,5318,O
.,5318,O
Enhancement,5319,O
of,5319,O
GLUT4,5319,B-GENE-Y
expression,5319,O
by,5319,O
fisetin,5319,B-CHEMICAL
was,5319,O
further,5319,O
confirmed,5319,O
in,5319,O
differentiated,5319,O
3T3-L1,5319,O
adipocytes,5319,O
.,5319,O
Fisetin,5320,B-CHEMICAL
supplementation,5320,O
decreases,5320,O
cardiovascular,5320,O
risks,5320,O
by,5320,O
ameliorating,5320,O
hepatic,5320,O
steatosis,5320,O
and,5320,O
lowering,5320,O
circulating,5320,O
glucose,5320,B-CHEMICAL
concentrations,5320,O
.,5320,O
Discovery,5321,O
of,5321,O
ML326,5321,B-CHEMICAL
:,5321,O
The,5321,O
first,5321,O
sub-micromolar,5321,O
",",5321,O
selective,5321,O
M5,5321,B-GENE-Y
PAM,5321,O
.,5321,O
This,5322,O
Letter,5322,O
describes,5322,O
the,5322,O
further,5322,O
chemical,5322,O
optimization,5322,O
of,5322,O
the,5322,O
M5,5322,B-GENE-Y
PAM,5322,O
MLPCN,5322,O
probes,5322,O
ML129,5322,B-CHEMICAL
and,5322,O
ML172,5322,B-CHEMICAL
.,5322,O
A,5323,O
multi-dimensional,5323,O
iterative,5323,O
parallel,5323,O
synthesis,5323,O
effort,5323,O
quickly,5323,O
explored,5323,O
isatin,5323,B-CHEMICAL
replacements,5323,O
and,5323,O
a,5323,O
number,5323,O
of,5323,O
southern,5323,O
heterobiaryl,5323,O
variations,5323,O
with,5323,O
no,5323,O
improvement,5323,O
over,5323,O
ML129,5323,B-CHEMICAL
and,5323,O
ML172,5323,B-CHEMICAL
.,5323,O
An,5324,O
HTS,5324,O
campaign,5324,O
identified,5324,O
several,5324,O
weak,5324,O
M5,5324,B-GENE-Y
PAMs,5324,O
(,5324,O
M5,5324,B-GENE-Y
EC50,5324,O
>,5324,O
10M,5324,O
),5324,O
with,5324,O
a,5324,O
structurally,5324,O
related,5324,O
isatin,5324,B-CHEMICAL
core,5324,O
that,5324,O
possessed,5324,O
a,5324,O
southern,5324,O
phenethyl,5324,B-CHEMICAL
ether,5324,I-CHEMICAL
linkage,5324,O
.,5324,O
While,5325,O
SAR,5325,O
within,5325,O
the,5325,O
HTS,5325,O
series,5325,O
was,5325,O
very,5325,O
shallow,5325,O
and,5325,O
unable,5325,O
to,5325,O
be,5325,O
optimized,5325,O
",",5325,O
grafting,5325,O
the,5325,O
phenethyl,5325,B-CHEMICAL
ether,5325,I-CHEMICAL
linkage,5325,O
onto,5325,O
the,5325,O
ML129/ML172,5325,B-CHEMICAL
cores,5325,O
led,5325,O
to,5325,O
the,5325,O
first,5325,O
sub-micromolar,5325,O
M5,5325,B-GENE-Y
PAM,5325,O
",",5325,O
ML326,5325,B-CHEMICAL
(,5325,O
VU0467903,5325,B-CHEMICAL
),5325,O
",",5325,O
(,5325,O
human,5325,O
and,5325,O
rat,5325,O
M5,5325,B-GENE-N
EC50s,5325,O
of,5325,O
409nM,5325,O
and,5325,O
500nM,5325,O
",",5325,O
respectively,5325,O
),5325,O
with,5325,O
excellent,5325,O
mAChR,5325,B-GENE-N
selectivity,5325,O
(,5325,O
M1-M4,5325,O
EC50s,5325,O
>,5325,O
30M,5325,O
),5325,O
and,5325,O
a,5325,O
robust,5325,O
20-fold,5325,O
leftward,5325,O
shift,5325,O
of,5325,O
the,5325,O
ACh,5325,B-CHEMICAL
CRC,5325,O
.,5325,O
Improved,5326,O
Insulin,5326,B-GENE-N
Sensitivity,5326,O
despite,5326,O
Increased,5326,O
Visceral,5326,O
Adiposity,5326,O
in,5326,O
Mice,5326,O
Deficient,5326,O
for,5326,O
the,5326,O
Immune,5326,B-GENE-N
Cell,5326,I-GENE-N
Transcription,5326,I-GENE-N
Factor,5326,I-GENE-N
T-bet,5326,B-GENE-Y
.,5326,O
Low-grade,5327,O
inflammation,5327,O
in,5327,O
fat,5327,O
is,5327,O
associated,5327,O
with,5327,O
insulin,5327,B-GENE-N
resistance,5327,O
",",5327,O
although,5327,O
the,5327,O
mechanisms,5327,O
are,5327,O
unclear,5327,O
.,5327,O
We,5328,O
report,5328,O
that,5328,O
mice,5328,O
deficient,5328,O
in,5328,O
the,5328,O
immune,5328,B-GENE-N
cell,5328,I-GENE-N
transcription,5328,I-GENE-N
factor,5328,I-GENE-N
T-bet,5328,B-GENE-Y
have,5328,O
lower,5328,O
energy,5328,O
expenditure,5328,O
and,5328,O
increased,5328,O
visceral,5328,O
fat,5328,O
compared,5328,O
with,5328,O
wild-type,5328,O
mice,5328,O
",",5328,O
yet,5328,O
paradoxically,5328,O
are,5328,O
more,5328,O
insulin,5328,B-GENE-N
sensitive,5328,O
.,5328,O
This,5329,O
striking,5329,O
phenotype,5329,O
",",5329,O
present,5329,O
in,5329,O
young,5329,O
T-bet,5329,B-GENE-Y
(,5329,O
-/-,5329,O
),5329,O
mice,5329,O
",",5329,O
persisted,5329,O
with,5329,O
high-fat,5329,O
diet,5329,O
and,5329,O
increasing,5329,O
host,5329,O
age,5329,O
and,5329,O
was,5329,O
associated,5329,O
with,5329,O
altered,5329,O
immune,5329,O
cell,5329,O
numbers,5329,O
and,5329,O
cytokine,5329,B-GENE-N
secretion,5329,O
specifically,5329,O
in,5329,O
visceral,5329,O
adipose,5329,O
tissue,5329,O
.,5329,O
However,5330,O
",",5330,O
the,5330,O
favorable,5330,O
metabolic,5330,O
phenotype,5330,O
observed,5330,O
in,5330,O
T-bet-deficient,5330,B-GENE-Y
hosts,5330,O
was,5330,O
lost,5330,O
in,5330,O
T-bet,5330,B-GENE-Y
(,5330,O
-/-,5330,O
),5330,O
mice,5330,O
also,5330,O
lacking,5330,O
adaptive,5330,O
immunity,5330,O
(,5330,O
T-bet,5330,B-GENE-Y
(,5330,O
-/-,5330,O
),5330,O
xRag2,5330,O
(,5330,O
-/-,5330,O
),5330,O
),5330,O
",",5330,O
demonstrating,5330,O
that,5330,O
T-bet,5330,B-GENE-Y
expression,5330,O
in,5330,O
the,5330,O
adaptive,5330,O
rather,5330,O
than,5330,O
the,5330,O
innate,5330,O
immune,5330,O
system,5330,O
impacts,5330,O
host,5330,O
glucose,5330,B-CHEMICAL
homeostasis,5330,O
.,5330,O
Indeed,5331,O
",",5331,O
adoptive,5331,O
transfer,5331,O
of,5331,O
T-bet-deficient,5331,B-GENE-Y
",",5331,O
but,5331,O
not,5331,O
wild-type,5331,O
",",5331,O
CD4,5331,O
(,5331,O
+,5331,O
),5331,O
T,5331,O
cells,5331,O
to,5331,O
Rag2,5331,B-GENE-Y
(,5331,O
-/-,5331,O
),5331,O
mice,5331,O
improved,5331,O
insulin,5331,B-GENE-N
sensitivity,5331,O
.,5331,O
Our,5332,O
results,5332,O
reveal,5332,O
a,5332,O
role,5332,O
for,5332,O
T-bet,5332,B-GENE-Y
in,5332,O
metabolic,5332,O
physiology,5332,O
and,5332,O
obesity-associated,5332,O
insulin,5332,B-GENE-N
resistance,5332,O
.,5332,O
Evidence,5333,O
for,5333,O
a,5333,O
new,5333,O
mechanism,5333,O
behind,5333,O
HIFU-triggered,5333,O
release,5333,O
from,5333,O
liposomes,5333,O
.,5333,O
A,5334,O
promising,5334,O
approach,5334,O
for,5334,O
local,5334,O
drug,5334,O
delivery,5334,O
is,5334,O
high-intensity,5334,O
focused,5334,O
ultrasound,5334,O
(,5334,O
HIFU,5334,O
),5334,O
-triggered,5334,O
release,5334,O
of,5334,O
drugs,5334,O
from,5334,O
stimuli-responsive,5334,O
nanoparticles,5334,O
such,5334,O
as,5334,O
liposomes,5334,O
.,5334,O
The,5335,O
aim,5335,O
of,5335,O
this,5335,O
study,5335,O
was,5335,O
to,5335,O
investigate,5335,O
whether,5335,O
another,5335,O
release,5335,O
mechanism,5335,O
is,5335,O
involved,5335,O
with,5335,O
HIFU-triggered,5335,O
release,5335,O
from,5335,O
liposomes,5335,O
beside,5335,O
cavitation,5335,O
and,5335,O
temperature,5335,O
.,5335,O
Furthermore,5336,O
",",5336,O
it,5336,O
was,5336,O
studied,5336,O
whether,5336,O
this,5336,O
new,5336,O
release,5336,O
mechanism,5336,O
allows,5336,O
the,5336,O
release,5336,O
of,5336,O
lipophilic,5336,O
compounds,5336,O
.,5336,O
Therefore,5337,O
",",5337,O
both,5337,O
a,5337,O
lipophilic,5337,O
(,5337,O
Nile,5337,B-CHEMICAL
red,5337,I-CHEMICAL
),5337,O
and,5337,O
a,5337,O
hydrophilic,5337,O
(,5337,O
fluorescein,5337,B-CHEMICAL
),5337,O
compound,5337,O
were,5337,O
loaded,5337,O
into,5337,O
thermosensitive,5337,O
(,5337,O
TSL,5337,O
),5337,O
or,5337,O
non-thermosensitive,5337,O
liposomes,5337,O
(,5337,O
NTSL,5337,O
),5337,O
and,5337,O
the,5337,O
liposomes,5337,O
were,5337,O
subjected,5337,O
both,5337,O
to,5337,O
continuous,5337,O
wave-,5337,O
(,5337,O
CW,5337,O
),5337,O
and,5337,O
pulsed,5337,O
wave,5337,O
(,5337,O
PW,5337,O
),5337,O
-HIFU,5337,O
.,5337,O
The,5338,O
mean,5338,O
liposome,5338,O
size,5338,O
varied,5338,O
from,5338,O
97,5338,O
to,5338,O
139nm,5338,O
with,5338,O
a,5338,O
polydispersity,5338,O
index,5338,O
(,5338,O
PDI,5338,O
),5338,O
0.06,5338,O
for,5338,O
the,5338,O
different,5338,O
formulations,5338,O
.,5338,O
The,5339,O
Tm,5339,O
of,5339,O
the,5339,O
phospholipid,5339,O
bilayer,5339,O
of,5339,O
the,5339,O
TSL,5339,O
was,5339,O
around,5339,O
42C,5339,O
.,5339,O
Approximately,5340,O
80,5340,O
%,5340,O
of,5340,O
fluorescein,5340,B-CHEMICAL
was,5340,O
released,5340,O
within,5340,O
15min,5340,O
from,5340,O
TSL,5340,O
at,5340,O
temperatures42C,5340,O
.,5340,O
In,5341,O
contrast,5341,O
",",5341,O
no,5341,O
fluorescein,5341,B-CHEMICAL
release,5341,O
from,5341,O
NTSL,5341,O
and,5341,O
NR,5341,O
release,5341,O
from,5341,O
both,5341,O
TSL,5341,O
and,5341,O
NTSL,5341,O
was,5341,O
observed,5341,O
at,5341,O
temperatures,5341,O
up,5341,O
to,5341,O
60C,5341,O
.,5341,O
CW-HIFU,5342,O
exposure,5342,O
of,5342,O
TSL,5342,O
resulted,5342,O
in,5342,O
rapid,5342,O
temperature,5342,O
elevation,5342,O
up,5342,O
to,5342,O
52C,5342,O
and,5342,O
subsequently,5342,O
almost,5342,O
quantitative,5342,O
fluorescein,5342,B-CHEMICAL
release,5342,O
.,5342,O
Fluorescein,5343,B-CHEMICAL
release,5343,O
from,5343,O
NTSL,5343,O
was,5343,O
also,5343,O
substantial,5343,O
(,5343,O
~64,5343,O
%,5343,O
after,5343,O
16min,5343,O
at,5343,O
20W,5343,O
),5343,O
.,5343,O
Surprisingly,5344,O
",",5344,O
CW-HIFU,5344,O
exposure,5344,O
(,5344,O
20W,5344,O
for,5344,O
16min,5344,O
),5344,O
resulted,5344,O
in,5344,O
the,5344,O
release,5344,O
of,5344,O
NR,5344,O
from,5344,O
TSL,5344,O
(,5344,O
~66,5344,O
%,5344,O
of,5344,O
the,5344,O
loaded,5344,O
amount,5344,O
),5344,O
",",5344,O
and,5344,O
this,5344,O
was,5344,O
even,5344,O
higher,5344,O
from,5344,O
NTSL,5344,O
(,5344,O
~78,5344,O
%,5344,O
),5344,O
.,5344,O
PW-HIFU,5345,O
exposure,5345,O
did,5345,O
not,5345,O
result,5345,O
in,5345,O
temperatures,5345,O
above,5345,O
the,5345,O
Tm,5345,O
of,5345,O
TSL,5345,O
.,5345,O
However,5346,O
",",5346,O
nearly,5346,O
85,5346,O
%,5346,O
of,5346,O
fluorescein,5346,B-CHEMICAL
was,5346,O
released,5346,O
from,5346,O
TSL,5346,O
after,5346,O
32min,5346,O
at,5346,O
20W,5346,O
of,5346,O
PW-HIFU,5346,O
exposure,5346,O
",",5346,O
whereas,5346,O
the,5346,O
release,5346,O
from,5346,O
NTSL,5346,O
was,5346,O
around,5346,O
27,5346,O
%,5346,O
.,5346,O
Interestingly,5347,O
",",5347,O
NR,5347,O
release,5347,O
from,5347,O
NTSL,5347,O
was~30,5347,O
%,5347,O
after,5347,O
2min,5347,O
PW-HIFU,5347,O
exposure,5347,O
and,5347,O
increased,5347,O
to~70,5347,O
%,5347,O
after,5347,O
32min,5347,O
.,5347,O
Furthermore,5348,O
",",5348,O
addition,5348,O
of,5348,O
microbubbles,5348,O
to,5348,O
the,5348,O
liposomes,5348,O
prior,5348,O
to,5348,O
PW-HIFU,5348,O
exposure,5348,O
did,5348,O
not,5348,O
result,5348,O
in,5348,O
more,5348,O
release,5348,O
",",5348,O
which,5348,O
suggests,5348,O
that,5348,O
cavitation,5348,O
can,5348,O
be,5348,O
excluded,5348,O
as,5348,O
the,5348,O
main,5348,O
mechanism,5348,O
responsible,5348,O
for,5348,O
the,5348,O
triggered,5348,O
release,5348,O
of,5348,O
both,5348,O
a,5348,O
hydrophilic,5348,O
and,5348,O
a,5348,O
lipophilic,5348,O
model,5348,O
compound,5348,O
from,5348,O
liposomes,5348,O
.,5348,O
Dynamic,5349,O
light,5349,O
scattering,5349,O
analysis,5349,O
showed,5349,O
that,5349,O
the,5349,O
mean,5349,O
size,5349,O
and,5349,O
PDI,5349,O
of,5349,O
the,5349,O
liposomes,5349,O
did,5349,O
not,5349,O
significantly,5349,O
change,5349,O
after,5349,O
CW-,5349,O
and,5349,O
PW-HIFU,5349,O
exposure,5349,O
.,5349,O
Taken,5350,O
together,5350,O
",",5350,O
it,5350,O
is,5350,O
therefore,5350,O
concluded,5350,O
that,5350,O
neither,5350,O
temperature,5350,O
elevation,5350,O
nor,5350,O
inertial,5350,O
cavitation,5350,O
is,5350,O
essential,5350,O
for,5350,O
the,5350,O
release,5350,O
of,5350,O
both,5350,O
hydrophilic,5350,O
and,5350,O
lipophilic,5350,O
compounds,5350,O
from,5350,O
liposomes,5350,O
.,5350,O
It,5351,O
is,5351,O
assumed,5351,O
that,5351,O
the,5351,O
release,5351,O
originates,5351,O
from,5351,O
radiation,5351,O
force-induced,5351,O
acoustic,5351,O
streaming,5351,O
",",5351,O
causing,5351,O
the,5351,O
liposomes,5351,O
to,5351,O
collide,5351,O
at,5351,O
the,5351,O
walls,5351,O
of,5351,O
the,5351,O
exposure,5351,O
chamber,5351,O
leading,5351,O
to,5351,O
shear,5351,O
forces,5351,O
which,5351,O
in,5351,O
turn,5351,O
results,5351,O
in,5351,O
reversible,5351,O
liposome,5351,O
destabilization,5351,O
and,5351,O
release,5351,O
of,5351,O
both,5351,O
hydrophilic,5351,O
and,5351,O
lipophilic,5351,O
compounds,5351,O
.,5351,O
DICO,5352,B-CHEMICAL
",",5352,O
a,5352,O
novel,5352,O
nonaromatic,5352,O
B-ring,5352,O
flavonoid,5352,B-CHEMICAL
",",5352,O
induces,5352,O
G2/M,5352,O
cell,5352,O
cycle,5352,O
arrest,5352,O
and,5352,O
apoptosis,5352,O
in,5352,O
human,5352,O
hepatoma,5352,O
cells,5352,O
.,5352,O
DICO,5353,B-CHEMICAL
was,5353,O
a,5353,O
novel,5353,O
nonaromatic,5353,O
B-ring,5353,O
flavonoid,5353,B-CHEMICAL
obtained,5353,O
from,5353,O
Macrothelypteris,5353,O
torresiana,5353,O
.,5353,O
In,5354,O
the,5354,O
present,5354,O
work,5354,O
",",5354,O
we,5354,O
investigated,5354,O
the,5354,O
antitumor,5354,O
activity,5354,O
and,5354,O
the,5354,O
antineoplastic,5354,O
mechanism,5354,O
of,5354,O
DICO,5354,B-CHEMICAL
.,5354,O
Our,5355,O
study,5355,O
showed,5355,O
that,5355,O
DICO,5355,B-CHEMICAL
inhibited,5355,O
the,5355,O
growth,5355,O
of,5355,O
HepG2,5355,O
cells,5355,O
in,5355,O
dose,5355,O
and,5355,O
time-dependent,5355,O
manners,5355,O
.,5355,O
As,5356,O
well,5356,O
as,5356,O
DICO,5356,B-CHEMICAL
induced,5356,O
G2/M,5356,O
cell,5356,O
cycle,5356,O
arrest,5356,O
and,5356,O
apoptosis,5356,O
via,5356,O
a,5356,O
ROS-mediated,5356,O
mitochondrial,5356,O
pathway,5356,O
.,5356,O
Western,5357,O
blot,5357,O
assay,5357,O
demonstrated,5357,O
that,5357,O
DICO,5357,B-CHEMICAL
decreased,5357,O
Bcl-2,5357,B-GENE-Y
level,5357,O
and,5357,O
induced,5357,O
Bax,5357,B-GENE-Y
translocation,5357,O
to,5357,O
cause,5357,O
cytochrome,5357,B-GENE-Y
c,5357,I-GENE-Y
release,5357,O
.,5357,O
Subsequently,5358,O
",",5358,O
caspase-9,5358,B-GENE-Y
and,5358,O
caspase-3,5358,B-GENE-Y
were,5358,O
activated,5358,O
.,5358,O
Meanwhile,5359,O
",",5359,O
the,5359,O
alterations,5359,O
of,5359,O
cyclin,5359,B-GENE-N
A,5359,I-GENE-N
and,5359,I-GENE-N
B1,5359,I-GENE-N
",",5359,O
p-CDK1,5359,B-GENE-Y
and,5359,O
p-cdc25c,5359,B-GENE-Y
levels,5359,O
were,5359,O
also,5359,O
observed,5359,O
in,5359,O
response,5359,O
to,5359,O
DICO,5359,B-CHEMICAL
treatment,5359,O
.,5359,O
Taken,5360,O
together,5360,O
",",5360,O
DICO,5360,B-CHEMICAL
displayed,5360,O
a,5360,O
significant,5360,O
antitumor,5360,O
effect,5360,O
through,5360,O
G2/M,5360,O
cell,5360,O
cycle,5360,O
arrest,5360,O
and,5360,O
apoptosis,5360,O
induction,5360,O
",",5360,O
which,5360,O
suggested,5360,O
DICO,5360,B-CHEMICAL
might,5360,O
have,5360,O
therapeutic,5360,O
potential,5360,O
against,5360,O
tumors,5360,O
.,5360,O
Assessment,5361,O
of,5361,O
the,5361,O
role,5361,O
of,5361,O
flavonoids,5361,B-CHEMICAL
for,5361,O
inducing,5361,O
osteoblast,5361,O
differentiation,5361,O
in,5361,O
isolated,5361,O
mouse,5361,O
bone,5361,O
marrow,5361,O
derived,5361,O
mesenchymal,5361,O
stem,5361,O
cells,5361,O
.,5361,O
Quercetin,5362,B-CHEMICAL
and,5362,O
rutin,5362,B-CHEMICAL
are,5362,O
common,5362,O
flavonoids,5362,B-CHEMICAL
in,5362,O
fruit,5362,O
and,5362,O
vegetables,5362,O
",",5362,O
and,5362,O
have,5362,O
been,5362,O
reported,5362,O
to,5362,O
affect,5362,O
bone,5362,O
development,5362,O
.,5362,O
However,5363,O
",",5363,O
the,5363,O
effect,5363,O
of,5363,O
flavonoids,5363,B-CHEMICAL
on,5363,O
osteoblast,5363,O
differentiation,5363,O
remains,5363,O
a,5363,O
matter,5363,O
of,5363,O
controversy,5363,O
.,5363,O
In,5364,O
the,5364,O
present,5364,O
study,5364,O
",",5364,O
mouse,5364,O
bone,5364,O
marrow,5364,O
mesenchymal,5364,O
stem,5364,O
cells,5364,O
(,5364,O
BMMSCs,5364,O
),5364,O
were,5364,O
isolated,5364,O
and,5364,O
characterized,5364,O
for,5364,O
their,5364,O
use,5364,O
in,5364,O
osteoblast,5364,O
differentiation,5364,O
using,5364,O
two,5364,O
flavonoids,5364,B-CHEMICAL
",",5364,O
quercetin,5364,B-CHEMICAL
and,5364,O
rutin,5364,B-CHEMICAL
.,5364,O
BMMSCs,5365,O
were,5365,O
cultured,5365,O
in,5365,O
various,5365,O
concentrations,5365,O
of,5365,O
quercetin,5365,B-CHEMICAL
and,5365,O
rutin,5365,B-CHEMICAL
during,5365,O
the,5365,O
osteoblast,5365,O
differentiation,5365,O
period,5365,O
of,5365,O
10,5365,O
days,5365,O
.,5365,O
Both,5366,O
quercetin,5366,B-CHEMICAL
and,5366,O
rutin,5366,B-CHEMICAL
were,5366,O
found,5366,O
to,5366,O
up,5366,O
regulate,5366,O
the,5366,O
osteoblast,5366,O
differentiation,5366,O
in,5366,O
dose,5366,O
dependent,5366,O
manner,5366,O
",",5366,O
albeit,5366,O
to,5366,O
lesser,5366,O
extent,5366,O
in,5366,O
case,5366,O
of,5366,O
former,5366,O
than,5366,O
that,5366,O
of,5366,O
latter,5366,O
.,5366,O
Quercetin,5367,B-CHEMICAL
and,5367,O
rutin,5367,B-CHEMICAL
also,5367,O
increased,5367,O
alkaline,5367,B-GENE-N
phosphatase,5367,I-GENE-N
activity,5367,O
by,5367,O
about,5367,O
150,5367,O
and,5367,O
240,5367,O
%,5367,O
and,5367,O
demonstrated,5367,O
mineralization,5367,O
up,5367,O
to,5367,O
110,5367,O
and,5367,O
200,5367,O
%,5367,O
respectively,5367,O
as,5367,O
compared,5367,O
to,5367,O
control,5367,O
(,5367,O
which,5367,O
was,5367,O
considered,5367,O
as,5367,O
100,5367,O
%,5367,O
),5367,O
.,5367,O
Further,5368,O
",",5368,O
both,5368,O
the,5368,O
flavonoids,5368,B-CHEMICAL
were,5368,O
also,5368,O
found,5368,O
to,5368,O
increase,5368,O
the,5368,O
expression,5368,O
of,5368,O
some,5368,O
of,5368,O
the,5368,O
prominent,5368,O
markers,5368,O
for,5368,O
differentiation,5368,O
of,5368,O
osteoblast,5368,O
like,5368,O
osteopontin,5368,B-GENE-Y
",",5368,O
osterix,5368,B-GENE-Y
",",5368,O
RunX2,5368,B-GENE-Y
",",5368,O
osteoprotegerin,5368,B-GENE-Y
and,5368,O
osteocalcin,5368,B-GENE-Y
.,5368,O
The,5369,O
current,5369,O
data,5369,O
suggests,5369,O
that,5369,O
certain,5369,O
classes,5369,O
of,5369,O
flavonoids,5369,B-CHEMICAL
like,5369,O
rutin,5369,B-CHEMICAL
and,5369,O
quercetin,5369,B-CHEMICAL
can,5369,O
be,5369,O
used,5369,O
in,5369,O
the,5369,O
cure,5369,O
and,5369,O
management,5369,O
of,5369,O
osteodegenerative,5369,O
disorders,5369,O
due,5369,O
to,5369,O
their,5369,O
osteoblast,5369,O
specific,5369,O
differentiation,5369,O
activities,5369,O
.,5369,O
S-nitrosation,5370,B-CHEMICAL
of,5370,O
glutathione,5370,B-GENE-Y
transferase,5370,I-GENE-Y
P1-1,5370,I-GENE-Y
is,5370,O
controlled,5370,O
by,5370,O
the,5370,O
conformation,5370,O
of,5370,O
a,5370,O
dynamic,5370,O
active-site,5370,O
helix,5370,O
.,5370,O
S-nitrosation,5371,B-CHEMICAL
is,5371,O
a,5371,O
post-translational,5371,O
modification,5371,O
of,5371,O
protein,5371,O
cysteine,5371,B-CHEMICAL
residues,5371,O
which,5371,O
occurs,5371,O
in,5371,O
response,5371,O
to,5371,O
cellular,5371,O
oxidative,5371,O
stress,5371,O
.,5371,O
Although,5372,O
it,5372,O
is,5372,O
increasingly,5372,O
being,5372,O
linked,5372,O
to,5372,O
physiologically,5372,O
important,5372,O
processes,5372,O
",",5372,O
the,5372,O
molecular,5372,O
basis,5372,O
for,5372,O
protein,5372,O
regulation,5372,O
by,5372,O
this,5372,O
modification,5372,O
remains,5372,O
poorly,5372,O
understood,5372,O
.,5372,O
We,5373,O
used,5373,O
transient,5373,O
kinetic,5373,O
methods,5373,O
to,5373,O
determine,5373,O
a,5373,O
minimal,5373,O
mechanism,5373,O
for,5373,O
spontaneous,5373,O
GSNO-mediated,5373,O
transnitrosation,5373,O
of,5373,O
human,5373,B-GENE-Y
glutathione,5373,B-CHEMICAL
transferase,5373,I-GENE-Y
(,5373,I-GENE-Y
GST,5373,I-GENE-Y
),5373,I-GENE-Y
P1-1,5373,I-GENE-Y
",",5373,O
a,5373,O
major,5373,O
detoxification,5373,O
enzyme,5373,O
and,5373,O
key,5373,O
regulator,5373,O
of,5373,O
cell,5373,O
proliferation,5373,O
.,5373,O
C47,5374,O
of,5374,O
GSTP1-1,5374,B-GENE-Y
is,5374,O
S-nitrosated,5374,B-CHEMICAL
in,5374,O
two,5374,O
steps,5374,O
",",5374,O
with,5374,O
the,5374,O
chemical,5374,O
step,5374,O
limited,5374,O
by,5374,O
a,5374,O
pre-equilibrium,5374,O
between,5374,O
the,5374,O
open,5374,O
and,5374,O
closed,5374,O
conformations,5374,O
of,5374,O
helix,5374,O
2,5374,O
at,5374,O
the,5374,O
active,5374,O
site,5374,O
.,5374,O
C101,5375,O
",",5375,O
in,5375,O
contrast,5375,O
",",5375,O
is,5375,O
S-nitrosated,5375,B-CHEMICAL
in,5375,O
a,5375,O
single,5375,O
step,5375,O
but,5375,O
is,5375,O
subject,5375,O
to,5375,O
negative,5375,O
cooperativity,5375,O
due,5375,O
to,5375,O
steric,5375,O
hindrance,5375,O
at,5375,O
the,5375,O
dimer,5375,O
interface,5375,O
.,5375,O
Despite,5376,O
the,5376,O
presence,5376,O
of,5376,O
a,5376,O
GSNO,5376,B-GENE-N
binding,5376,I-GENE-N
site,5376,I-GENE-N
at,5376,O
the,5376,O
active,5376,O
site,5376,O
of,5376,O
GSTP1-1,5376,B-GENE-Y
",",5376,O
isothermal,5376,O
titration,5376,O
calorimetry,5376,O
as,5376,O
well,5376,O
as,5376,O
nitrosation,5376,O
experiments,5376,O
using,5376,O
CysNO,5376,B-CHEMICAL
demonstrate,5376,O
that,5376,O
GSNO,5376,O
binding,5376,O
does,5376,O
not,5376,O
precede,5376,O
S-nitrosation,5376,B-CHEMICAL
of,5376,O
GSTP1-1,5376,B-GENE-Y
.,5376,O
Kinetics,5377,O
experiments,5377,O
using,5377,O
the,5377,O
cellular,5377,O
reductant,5377,O
GSH,5377,B-CHEMICAL
show,5377,O
that,5377,O
C101-NO,5377,O
is,5377,O
substantially,5377,O
more,5377,O
resistant,5377,O
to,5377,O
denitrosation,5377,O
than,5377,O
C47-NO,5377,O
",",5377,O
suggesting,5377,O
a,5377,O
potential,5377,O
role,5377,O
for,5377,O
C101-NO,5377,O
in,5377,O
long,5377,O
term,5377,O
nitric,5377,B-CHEMICAL
oxide,5377,I-CHEMICAL
storage,5377,O
or,5377,O
transfer,5377,O
.,5377,O
These,5378,O
results,5378,O
constitute,5378,O
the,5378,O
first,5378,O
report,5378,O
of,5378,O
the,5378,O
molecular,5378,O
mechanism,5378,O
of,5378,O
spontaneous,5378,O
protein,5378,O
transnitrosation,5378,O
",",5378,O
providing,5378,O
insight,5378,O
into,5378,O
the,5378,O
post-translational,5378,O
control,5378,O
of,5378,O
GSTP1-1,5378,B-GENE-Y
as,5378,O
well,5378,O
as,5378,O
the,5378,O
process,5378,O
of,5378,O
protein,5378,O
transnitrosation,5378,O
in,5378,O
general,5378,O
.,5378,O
Effect,5379,O
of,5379,O
N-acetyl,5379,B-CHEMICAL
cysteine,5379,I-CHEMICAL
(,5379,O
NAC,5379,B-CHEMICAL
),5379,O
",",5379,O
an,5379,O
organosulfur,5379,B-CHEMICAL
compound,5379,O
from,5379,O
Allium,5379,O
plants,5379,O
",",5379,O
on,5379,O
experimentally,5379,O
induced,5379,O
hepatic,5379,O
prefibrogenic,5379,O
events,5379,O
in,5379,O
wistar,5379,O
rat,5379,O
.,5379,O
Aim,5380,O
of,5380,O
present,5380,O
study,5380,O
was,5380,O
to,5380,O
investigate,5380,O
the,5380,O
effect,5380,O
of,5380,O
NAC,5380,B-CHEMICAL
on,5380,O
experimental,5380,O
chronic,5380,O
hepatotoxicity,5380,O
models,5380,O
induced,5380,O
by,5380,O
carbon,5380,B-CHEMICAL
tetrachloride,5380,I-CHEMICAL
(,5380,O
CCl4,5380,B-CHEMICAL
),5380,O
and,5380,O
thioacetamide,5380,B-CHEMICAL
(,5380,O
TAA,5380,B-CHEMICAL
),5380,O
.,5380,O
CCl4,5381,O
toxicity,5381,O
was,5381,O
induced,5381,O
by,5381,O
administering,5381,O
200l,5381,O
CCl4,5381,B-CHEMICAL
(,5381,O
diluted,5381,O
2:3,5381,O
in,5381,O
coconut,5381,O
oil,5381,O
),5381,O
/100g,5381,O
body,5381,O
weight,5381,O
",",5381,O
p.o.,5381,O
",",5381,O
twice,5381,O
weekly,5381,O
for,5381,O
8,5381,O
weeks,5381,O
.,5381,O
TAA,5382,B-CHEMICAL
toxicity,5382,O
was,5382,O
induced,5382,O
by,5382,O
administering,5382,O
150mg/kg,5382,O
b.,5382,O
wt,5382,O
.,5382,O
of,5383,O
TAA,5383,B-CHEMICAL
i.p.,5383,O
",",5383,O
twice,5383,O
weekly,5383,O
for,5383,O
8,5383,O
weeks,5383,O
.,5383,O
NAC,5384,B-CHEMICAL
treatment,5384,O
was,5384,O
started,5384,O
along,5384,O
with,5384,O
toxicants,5384,O
(,5384,O
CCl4,5384,B-CHEMICAL
and,5384,O
TAA,5384,B-CHEMICAL
),5384,O
for,5384,O
8,5384,O
weeks,5384,O
and,5384,O
continued,5384,O
for,5384,O
further,5384,O
4,5384,O
weeks,5384,O
.,5384,O
Self,5385,O
reversal,5385,O
group,5385,O
was,5385,O
kept,5385,O
without,5385,O
any,5385,O
treatment,5385,O
for,5385,O
4,5385,O
weeks,5385,O
after,5385,O
completion,5385,O
of,5385,O
toxicant,5385,O
treatments,5385,O
.,5385,O
Alanine,5386,B-GENE-N
aminotransferase,5386,I-GENE-N
(,5386,O
ALT,5386,B-GENE-N
),5386,O
",",5386,O
Aspartate,5386,B-GENE-N
aminotransferase,5386,I-GENE-N
(,5386,O
AST,5386,B-GENE-N
),5386,O
",",5386,O
Alkaline,5386,B-GENE-N
phosphatase,5386,I-GENE-N
(,5386,O
ALP,5386,B-GENE-N
),5386,O
",",5386,O
Bilirubin,5386,B-CHEMICAL
were,5386,O
measured,5386,O
in,5386,O
serum,5386,O
.,5386,O
Hydroxyproline,5387,B-CHEMICAL
(,5387,O
HP,5387,O
),5387,O
",",5387,O
lipid,5387,O
peroxidation,5387,O
(,5387,O
LPO,5387,O
),5387,O
",",5387,O
catalase,5387,B-GENE-Y
(,5387,O
CAT,5387,B-GENE-Y
),5387,O
",",5387,O
Glutathione,5387,B-GENE-N
peroxidase,5387,I-GENE-N
(,5387,O
GPx,5387,B-GENE-N
),5387,O
and,5387,O
Glutathione,5387,B-CHEMICAL
(,5387,O
GSH,5387,B-CHEMICAL
),5387,O
were,5387,O
determined,5387,O
in,5387,O
liver,5387,O
samples,5387,O
by,5387,O
colorimetric,5387,O
methods,5387,O
.,5387,O
Cytochrome,5388,B-GENE-Y
P450,5388,I-GENE-Y
2E1,5388,I-GENE-Y
(,5388,O
CYP,5388,B-GENE-Y
450,5388,I-GENE-Y
2E1,5388,I-GENE-Y
),5388,O
",",5388,O
activity,5388,O
was,5388,O
determined,5388,O
as,5388,O
hydroxylation,5388,O
of,5388,O
aniline,5388,B-CHEMICAL
in,5388,O
liver,5388,O
microsomes,5388,O
.,5388,O
General,5389,O
examination,5389,O
and,5389,O
histological,5389,O
analysis,5389,O
were,5389,O
also,5389,O
performed,5389,O
.,5389,O
Serum,5390,O
markers,5390,O
of,5390,O
liver,5390,O
damage,5390,O
(,5390,O
AST,5390,B-GENE-N
",",5390,O
ALT,5390,B-GENE-N
",",5390,O
ALP,5390,B-GENE-N
and,5390,O
Bilirubin,5390,B-CHEMICAL
),5390,O
were,5390,O
increased,5390,O
by,5390,O
CCl4,5390,B-CHEMICAL
and,5390,O
TAA,5390,B-CHEMICAL
intoxication,5390,O
(,5390,O
p,5390,O
<,5390,O
0.001,5390,O
),5390,O
",",5390,O
whereas,5390,O
co-treatment,5390,O
with,5390,O
NAC,5390,B-CHEMICAL
reversed,5390,O
such,5390,O
changes,5390,O
(,5390,O
p,5390,O
<,5390,O
0.001,5390,O
),5390,O
.,5390,O
HP,5391,O
was,5391,O
enhanced,5391,O
in,5391,O
toxicant,5391,O
groups,5391,O
(,5391,O
p,5391,O
<,5391,O
0.001,5391,O
in,5391,O
CCl4,5391,B-CHEMICAL
and,5391,O
TAA,5391,B-CHEMICAL
),5391,O
",",5391,O
but,5391,O
inhibited,5391,O
by,5391,O
NAC,5391,B-CHEMICAL
(,5391,O
p,5391,O
<,5391,O
0.001,5391,O
),5391,O
.,5391,O
LPO,5392,O
was,5392,O
increased,5392,O
while,5392,O
as,5392,O
GSH,5392,B-CHEMICAL
",",5392,O
CAT,5392,B-GENE-Y
and,5392,O
GPx,5392,B-GENE-N
decreased,5392,O
by,5392,O
the,5392,O
administration,5392,O
of,5392,O
CCl4,5392,O
and,5392,O
TAA,5392,O
(,5392,O
p,5392,O
<,5392,O
0.001,5392,O
),5392,O
;,5392,O
co-administration,5392,O
of,5392,O
NAC,5392,B-CHEMICAL
restored,5392,O
these,5392,O
liver,5392,O
markers,5392,O
to,5392,O
normal,5392,O
levels,5392,O
(,5392,O
p,5392,O
<,5392,O
0.001,5392,O
),5392,O
.,5392,O
Biochemical,5393,O
determinations,5393,O
were,5393,O
corroborated,5393,O
by,5393,O
general,5393,O
and,5393,O
histological,5393,O
findings,5393,O
.,5393,O
Keeping,5394,O
in,5394,O
view,5394,O
the,5394,O
biochemical,5394,O
and,5394,O
histopathological,5394,O
studies,5394,O
",",5394,O
it,5394,O
was,5394,O
concluded,5394,O
that,5394,O
CCl4,5394,B-CHEMICAL
and,5394,O
TAA,5394,B-CHEMICAL
are,5394,O
strong,5394,O
hepatotoxic,5394,O
agents,5394,O
that,5394,O
produce,5394,O
liver,5394,O
fibrosis,5394,O
with,5394,O
close,5394,O
proximity,5394,O
to,5394,O
human,5394,O
etiology,5394,O
(,5394,O
micronodular,5394,O
cirrhosis,5394,O
),5394,O
and,5394,O
NAC,5394,B-CHEMICAL
has,5394,O
a,5394,O
significant,5394,O
protective,5394,O
activity,5394,O
against,5394,O
CCl4,5394,B-CHEMICAL
and,5394,O
TAA,5394,B-CHEMICAL
.,5394,O
NAC,5395,B-CHEMICAL
has,5395,O
also,5395,O
been,5395,O
validated,5395,O
as,5395,O
a,5395,O
model,5395,O
against,5395,O
oxidative,5395,O
burden,5395,O
in,5395,O
chronic,5395,O
liver,5395,O
pathology,5395,O
.,5395,O
Phenolic,5396,B-CHEMICAL
compounds,5396,O
present,5396,O
in,5396,O
Sardinian,5396,O
wine,5396,O
extracts,5396,O
protect,5396,O
against,5396,O
the,5396,O
production,5396,O
of,5396,O
inflammatory,5396,O
cytokines,5396,O
induced,5396,O
by,5396,O
oxysterols,5396,B-CHEMICAL
in,5396,O
CaCo-2,5396,O
human,5396,O
enterocyte-like,5396,O
cells,5396,O
.,5396,O
Cholesterol,5397,B-CHEMICAL
auto-oxidation,5397,O
products,5397,O
",",5397,O
namely,5397,O
oxysterols,5397,B-CHEMICAL
",",5397,O
are,5397,O
widely,5397,O
present,5397,O
in,5397,O
cholesterol-rich,5397,B-CHEMICAL
foods,5397,O
.,5397,O
They,5398,O
are,5398,O
thought,5398,O
to,5398,O
potentially,5398,O
interfere,5398,O
with,5398,O
homeostasis,5398,O
of,5398,O
the,5398,O
human,5398,O
digestive,5398,O
tract,5398,O
",",5398,O
playing,5398,O
a,5398,O
role,5398,O
in,5398,O
intestinal,5398,O
mucosal,5398,O
damage,5398,O
.,5398,O
This,5399,O
report,5399,O
concerns,5399,O
the,5399,O
marked,5399,O
up-regulation,5399,O
in,5399,O
differentiated,5399,O
CaCo-2,5399,O
colonic,5399,O
epithelial,5399,O
cells,5399,O
of,5399,O
two,5399,O
key,5399,O
inflammatory,5399,O
interleukins,5399,B-GENE-N
",",5399,O
IL-6,5399,B-GENE-Y
and,5399,O
IL-8,5399,B-GENE-Y
",",5399,O
caused,5399,O
by,5399,O
a,5399,O
mixture,5399,O
of,5399,O
oxysterols,5399,B-CHEMICAL
representative,5399,O
of,5399,O
a,5399,O
high,5399,O
cholesterol,5399,B-CHEMICAL
diet,5399,O
.,5399,O
This,5400,O
strong,5400,O
pro-inflammatory,5400,O
effect,5400,O
appeared,5400,O
to,5400,O
be,5400,O
dependent,5400,O
on,5400,O
the,5400,O
net,5400,O
imbalance,5400,O
of,5400,O
red-ox,5400,O
equilibrium,5400,O
with,5400,O
the,5400,O
production,5400,O
of,5400,O
excessive,5400,O
levels,5400,O
of,5400,O
reactive,5400,O
oxygen,5400,B-CHEMICAL
species,5400,O
through,5400,O
the,5400,O
colonic,5400,O
NADPH-oxidase,5400,B-GENE-N
NOX1,5400,B-GENE-Y
activation,5400,O
.,5400,O
Induction,5401,O
of,5401,O
NOX1,5401,B-GENE-Y
was,5401,O
markedly,5401,O
while,5401,O
not,5401,O
fully,5401,O
inhibited,5401,O
by,5401,O
CaCo-2,5401,O
cell,5401,O
pre-incubation,5401,O
with,5401,O
phenolic,5401,O
extracts,5401,O
obtained,5401,O
from,5401,O
well-selected,5401,O
wines,5401,O
from,5401,O
typical,5401,O
grape,5401,O
varieties,5401,O
grown,5401,O
in,5401,O
Sardinia,5401,O
.,5401,O
Oxysterol-dependent,5402,B-CHEMICAL
NOX1,5402,B-GENE-Y
activation,5402,O
",",5402,O
as,5402,O
well,5402,O
as,5402,O
interleukin,5402,B-GENE-N
synthesis,5402,O
",",5402,O
were,5402,O
completely,5402,O
prevented,5402,O
by,5402,O
Cannonau,5402,O
red,5402,O
wine,5402,O
extract,5402,O
that,5402,O
contains,5402,O
an,5402,O
abundant,5402,O
phenolic,5402,O
fraction,5402,O
",",5402,O
in,5402,O
particular,5402,O
phenolic,5402,B-CHEMICAL
acids,5402,I-CHEMICAL
and,5402,O
flavonoids,5402,B-CHEMICAL
.,5402,O
Conversely,5403,O
",",5403,O
cell,5403,O
pre-treatment,5403,O
with,5403,O
Vermentino,5403,O
white,5403,O
wine,5403,O
extract,5403,O
with,5403,O
smaller,5403,O
phenolic,5403,O
fraction,5403,O
showed,5403,O
only,5403,O
a,5403,O
partial,5403,O
NOX1,5403,B-GENE-Y
down-regulation,5403,O
and,5403,O
was,5403,O
ineffective,5403,O
in,5403,O
interleukin,5403,B-GENE-N
synthesis,5403,O
induced,5403,O
by,5403,O
dietary,5403,O
oxysterols,5403,B-CHEMICAL
.,5403,O
It,5404,O
is,5404,O
thus,5404,O
likely,5404,O
that,5404,O
the,5404,O
effects,5404,O
of,5404,O
Sardinian,5404,O
wine,5404,O
extracts,5404,O
against,5404,O
intestinal,5404,O
inflammation,5404,O
induced,5404,O
by,5404,O
dietary,5404,O
oxysterols,5404,B-CHEMICAL
are,5404,O
mainly,5404,O
due,5404,O
to,5404,O
their,5404,O
high,5404,O
phenolic,5404,O
content,5404,O
:,5404,O
low,5404,O
doses,5404,O
of,5404,O
phenolics,5404,B-CHEMICAL
would,5404,O
be,5404,O
responsible,5404,O
only,5404,O
for,5404,O
direct,5404,O
scavenging,5404,O
oxysterol-dependent,5404,B-CHEMICAL
ROS,5404,O
production,5404,O
.,5404,O
Besides,5405,O
this,5405,O
direct,5405,O
activity,5405,O
",",5405,O
an,5405,O
excess,5405,O
of,5405,O
phenolic,5405,B-CHEMICAL
compounds,5405,O
detectable,5405,O
in,5405,O
red,5405,O
wine,5405,O
",",5405,O
may,5405,O
exert,5405,O
an,5405,O
additional,5405,O
indirect,5405,O
action,5405,O
by,5405,O
blocking,5405,O
oxysterol-related,5405,B-CHEMICAL
NOX1,5405,B-GENE-Y
induction,5405,O
",",5405,O
thus,5405,O
totally,5405,O
preventing,5405,O
the,5405,O
pro-oxidant,5405,O
and,5405,O
pro-inflammatory,5405,O
events,5405,O
triggered,5405,O
by,5405,O
dietary,5405,O
oxysterols,5405,B-CHEMICAL
.,5405,O
Tandem,5406,O
Assays,5406,O
of,5406,O
Protein,5406,O
and,5406,O
Glucose,5406,B-CHEMICAL
with,5406,O
Functionalized,5406,O
Core/Shell,5406,O
Particles,5406,O
Based,5406,O
on,5406,O
Magnetic,5406,O
Separation,5406,O
and,5406,O
Surface-Enhanced,5406,O
Raman,5406,O
Scattering,5406,O
.,5406,O
Tandem,5407,O
assays,5407,O
of,5407,O
protein,5407,O
and,5407,O
glucose,5407,B-CHEMICAL
in,5407,O
combination,5407,O
with,5407,O
mannose-functionalized,5407,B-CHEMICAL
Fe3,5407,B-CHEMICAL
O4,5407,I-CHEMICAL
@,5407,O
SiO2,5407,B-CHEMICAL
and,5407,O
Ag,5407,B-CHEMICAL
@,5407,O
SiO2,5407,B-CHEMICAL
tag,5407,O
particles,5407,O
have,5407,O
promising,5407,O
potential,5407,O
in,5407,O
effective,5407,O
magnetic,5407,O
separation,5407,O
and,5407,O
highly,5407,O
sensitive,5407,O
and,5407,O
selective,5407,O
SERS,5407,O
assays,5407,O
of,5407,O
biomaterials,5407,O
.,5407,O
It,5408,O
is,5408,O
for,5408,O
the,5408,O
first,5408,O
time,5408,O
that,5408,O
tandem,5408,O
assay,5408,O
of,5408,O
glucose,5408,B-CHEMICAL
is,5408,O
developed,5408,O
using,5408,O
SERS,5408,O
based,5408,O
on,5408,O
the,5408,O
Con,5408,O
A-sandwiched,5408,O
microstructures,5408,O
between,5408,O
the,5408,O
functionalized,5408,O
magnetic,5408,O
and,5408,O
tag,5408,O
particles,5408,O
.,5408,O
Relationship,5409,O
between,5409,O
serum,5409,B-GENE-N
thyrotropin,5409,I-GENE-N
levels,5409,O
and,5409,O
intrarenal,5409,O
hemodynamic,5409,O
parameters,5409,O
in,5409,O
euthyroid,5409,O
subjects,5409,O
.,5409,O
OBJECTIVE,5410,O
:,5410,O
Low,5410,O
thyroid,5410,O
function,5410,O
may,5410,O
be,5410,O
associated,5410,O
with,5410,O
a,5410,O
reduced,5410,O
glomerular,5410,O
filtration,5410,O
rate,5410,O
(,5410,O
GFR,5410,O
),5410,O
calculated,5410,O
on,5410,O
the,5410,O
basis,5410,O
of,5410,O
creatinine,5410,B-CHEMICAL
metabolism,5410,O
.,5410,O
Thyroid,5411,B-CHEMICAL
hormone,5411,I-CHEMICAL
directly,5411,O
affects,5411,O
serum,5411,O
creatinine,5411,B-CHEMICAL
in,5411,O
muscle,5411,O
and,5411,O
low,5411,O
thyroid,5411,O
function,5411,O
might,5411,O
exert,5411,O
a,5411,O
similar,5411,O
direct,5411,O
effect,5411,O
in,5411,O
the,5411,O
kidney,5411,O
.,5411,O
The,5412,O
goal,5412,O
of,5412,O
the,5412,O
study,5412,O
was,5412,O
to,5412,O
evaluate,5412,O
this,5412,O
possibility,5412,O
by,5412,O
assessment,5412,O
of,5412,O
the,5412,O
inulin-based,5412,O
GFR,5412,O
and,5412,O
to,5412,O
examine,5412,O
the,5412,O
mechanism,5412,O
underlying,5412,O
the,5412,O
reduction,5412,O
of,5412,O
GFR,5412,O
.,5412,O
PATIENTS,5413,O
AND,5413,O
METHODS,5413,O
:,5413,O
Renal,5413,O
and,5413,O
glomerular,5413,O
hemodynamics,5413,O
were,5413,O
assessed,5413,O
by,5413,O
simultaneous,5413,O
measurements,5413,O
of,5413,O
plasma,5413,O
clearance,5413,O
of,5413,O
para-aminohippurate,5413,B-CHEMICAL
(,5413,O
CPAH,5413,O
),5413,O
and,5413,O
inulin,5413,O
(,5413,O
Cin,5413,O
),5413,O
in,5413,O
26,5413,O
patients,5413,O
with,5413,O
serum,5413,O
creatinine,5413,B-CHEMICAL
<,5413,O
1.00,5413,O
mg/dl,5413,O
and,5413,O
without,5413,O
thyroid,5413,O
disease,5413,O
.,5413,O
All,5414,O
subjects,5414,O
were,5414,O
normotensive,5414,O
with,5414,O
or,5414,O
without,5414,O
antihypertensive,5414,O
treatment,5414,O
and,5414,O
were,5414,O
kept,5414,O
in,5414,O
a,5414,O
sodium-replete,5414,B-CHEMICAL
state,5414,O
.,5414,O
Renal,5415,O
and,5415,O
glomerular,5415,O
hemodynamics,5415,O
were,5415,O
calculated,5415,O
using,5415,O
Gomez,5415,O
`,5415,O
s,5415,O
formulae,5415,O
.,5415,O
RESULTS,5416,O
:,5416,O
Serum,5416,B-GENE-N
thyroid,5416,I-GENE-N
stimulating,5416,I-GENE-N
hormone,5416,I-GENE-N
(,5416,O
TSH,5416,B-GENE-N
),5416,O
",",5416,O
including,5416,O
within,5416,O
the,5416,O
normal,5416,O
range,5416,O
(,5416,O
0.69-4.30,5416,O
IU/ml,5416,O
),5416,O
",",5416,O
was,5416,O
positively,5416,O
correlated,5416,O
with,5416,O
vascular,5416,O
resistance,5416,O
at,5416,O
the,5416,O
afferent,5416,O
arteriole,5416,O
(,5416,O
Ra,5416,O
),5416,O
(,5416,O
r,5416,O
=,5416,O
0.609,5416,O
",",5416,O
p,5416,O
=,5416,O
0.0010,5416,O
),5416,O
",",5416,O
but,5416,O
not,5416,O
at,5416,O
the,5416,O
efferent,5416,O
arteriole,5416,O
(,5416,O
Re,5416,O
),5416,O
.,5416,O
Serum,5417,B-GENE-N
TSH,5417,I-GENE-N
was,5417,O
significantly,5417,O
and,5417,O
negatively,5417,O
correlated,5417,O
with,5417,O
renal,5417,O
plasma,5417,O
flow,5417,O
(,5417,O
RPF,5417,O
),5417,O
",",5417,O
renal,5417,O
blood,5417,O
flow,5417,O
(,5417,O
RBF,5417,O
),5417,O
",",5417,O
and,5417,O
glomerular,5417,O
filtration,5417,O
rate,5417,O
(,5417,O
GFR,5417,O
),5417,O
(,5417,O
r,5417,O
=,5417,O
-0.456,5417,O
",",5417,O
p,5417,O
=,5417,O
0.0192,5417,O
;,5417,O
r,5417,O
=,5417,O
-0.438,5417,O
",",5417,O
p,5417,O
=,5417,O
0.0252,5417,O
;,5417,O
r,5417,O
=,5417,O
-0.505,5417,O
",",5417,O
p,5417,O
=,5417,O
0.0086,5417,O
",",5417,O
respectively,5417,O
),5417,O
.,5417,O
In,5418,O
multiple,5418,O
regression,5418,O
analysis,5418,O
",",5418,O
serum,5418,B-GENE-N
TSH,5418,I-GENE-N
was,5418,O
significantly,5418,O
positively,5418,O
associated,5418,O
with,5418,O
Ra,5418,O
after,5418,O
adjustment,5418,O
for,5418,O
age,5418,O
and,5418,O
mean,5418,O
blood,5418,O
pressure,5418,O
.,5418,O
CONCLUSIONS,5419,O
:,5419,O
These,5419,O
findings,5419,O
suggest,5419,O
that,5419,O
low,5419,O
thyroid,5419,O
function,5419,O
",",5419,O
even,5419,O
within,5419,O
the,5419,O
normal,5419,O
range,5419,O
",",5419,O
is,5419,O
associated,5419,O
with,5419,O
reduced,5419,O
RPF,5419,O
",",5419,O
RBF,5419,O
and,5419,O
GFR,5419,O
",",5419,O
which,5419,O
might,5419,O
be,5419,O
caused,5419,O
by,5419,O
a,5419,O
preferential,5419,O
increase,5419,O
of,5419,O
Ra,5419,O
.,5419,O
A,5420,O
Physiologically-Based,5420,O
Pharmacokinetic,5420,O
Modelling,5420,O
Approach,5420,O
to,5420,O
Predict,5420,O
Disease-Drug,5420,O
Interactions,5420,O
:,5420,O
Suppression,5420,O
of,5420,O
CYP3A,5420,B-GENE-N
by,5420,O
IL-6,5420,B-GENE-Y
.,5420,O
Elevated,5421,O
cytokine,5421,B-GENE-N
levels,5421,O
can,5421,O
down-regulate,5421,O
expression,5421,O
of,5421,O
cytochrome,5421,B-GENE-N
P450,5421,I-GENE-N
enzymes,5421,O
(,5421,O
CYPs,5421,B-GENE-N
),5421,O
and,5421,O
suppress,5421,O
their,5421,O
activity,5421,O
.,5421,O
Treatment,5422,O
of,5422,O
inflammation,5422,O
or,5422,O
infection,5422,O
with,5422,O
cytokine-modulating,5422,B-GENE-N
therapeutic,5422,O
proteins,5422,O
(,5422,O
TP,5422,O
),5422,O
could,5422,O
reverse,5422,O
suppression,5422,O
manifesting,5422,O
as,5422,O
therapeutic,5422,O
protein-drug,5422,O
drug,5422,O
interactions,5422,O
(,5422,O
TP-DDI,5422,O
),5422,O
.,5422,O
A,5423,O
physiologically-based,5423,O
pharmacokinetic,5423,O
model,5423,O
was,5423,O
used,5423,O
to,5423,O
quantitatively,5423,O
predict,5423,O
the,5423,O
impact,5423,O
of,5423,O
IL-6,5423,B-GENE-Y
on,5423,O
sensitive,5423,O
CYP3A4,5423,B-GENE-Y
substrates,5423,O
.,5423,O
Elevated,5424,O
simvastatin,5424,B-CHEMICAL
AUC,5424,O
in,5424,O
virtual,5424,O
rheumatoid,5424,O
arthritis,5424,O
patients,5424,O
",",5424,O
following,5424,O
100,5424,O
pg/mL,5424,O
of,5424,O
IL-6,5424,B-GENE-Y
was,5424,O
comparable,5424,O
to,5424,O
observed,5424,O
clinical,5424,O
data,5424,O
(,5424,O
59,5424,O
%,5424,O
versus,5424,O
58,5424,O
%,5424,O
),5424,O
.,5424,O
In,5425,O
virtual,5425,O
bone,5425,O
marrow,5425,O
transplant,5425,O
(,5425,O
BMT,5425,O
),5425,O
patients,5425,O
",",5425,O
500,5425,O
pg/ml,5425,O
of,5425,O
IL-6,5425,B-GENE-Y
resulted,5425,O
in,5425,O
increase,5425,O
in,5425,O
cyclosporine,5425,B-CHEMICAL
AUC,5425,O
that,5425,O
was,5425,O
in,5425,O
good,5425,O
agreement,5425,O
with,5425,O
the,5425,O
observed,5425,O
data,5425,O
(,5425,O
45,5425,O
%,5425,O
versus,5425,O
39,5425,O
%,5425,O
),5425,O
.,5425,O
In,5426,O
a,5426,O
different,5426,O
group,5426,O
of,5426,O
BMT,5426,O
patients,5426,O
treated,5426,O
with,5426,O
cyclosporine,5426,B-CHEMICAL
",",5426,O
the,5426,O
magnitude,5426,O
of,5426,O
interaction,5426,O
with,5426,O
IL-6,5426,B-GENE-Y
was,5426,O
under,5426,O
predicted,5426,O
~3-fold,5426,O
.,5426,O
The,5427,O
complexity,5427,O
of,5427,O
TP-DDI,5427,O
highlights,5427,O
underlying,5427,O
pathophysiological,5427,O
factors,5427,O
to,5427,O
be,5427,O
considered,5427,O
but,5427,O
these,5427,O
simulations,5427,O
provide,5427,O
valuable,5427,O
first,5427,O
steps,5427,O
towards,5427,O
predictions,5427,O
of,5427,O
TP-DDI,5427,O
risk.Clinical,5427,O
Pharmacology,5427,O
&,5427,O
Therapeutics,5427,O
(,5427,O
2013,5427,O
),5427,O
;,5427,O
accepted,5427,O
article,5427,O
preview,5427,O
online,5427,O
10,5427,O
April,5427,O
2013,5427,O
doi:10.1038/clpt.2013.79,5427,O
.,5427,O
A,5428,O
DPYD,5428,B-GENE-Y
Variant,5428,O
(,5428,O
Y186C,5428,B-GENE-N
),5428,O
in,5428,O
Individuals,5428,O
of,5428,O
African,5428,O
Ancestry,5428,O
Is,5428,O
Associated,5428,O
With,5428,O
Reduced,5428,O
DPD,5428,B-GENE-Y
Enzyme,5428,O
Activity,5428,O
.,5428,O
5-Fluorouracil,5429,B-CHEMICAL
(,5429,O
5-FU,5429,B-CHEMICAL
),5429,O
is,5429,O
used,5429,O
to,5429,O
treat,5429,O
many,5429,O
aggressive,5429,O
cancers,5429,O
",",5429,O
such,5429,O
as,5429,O
those,5429,O
of,5429,O
the,5429,O
colon,5429,O
",",5429,O
breast,5429,O
",",5429,O
and,5429,O
head,5429,O
and,5429,O
neck,5429,O
.,5429,O
The,5430,O
responses,5430,O
to,5430,O
5-FU,5430,B-CHEMICAL
",",5430,O
with,5430,O
respect,5430,O
to,5430,O
both,5430,O
toxicity,5430,O
and,5430,O
efficacy,5430,O
",",5430,O
vary,5430,O
among,5430,O
racial,5430,O
groups,5430,O
",",5430,O
potentially,5430,O
because,5430,O
of,5430,O
variability,5430,O
in,5430,O
the,5430,O
activity,5430,O
levels,5430,O
of,5430,O
the,5430,O
enzyme,5430,O
dihydropyrimidine,5430,B-GENE-Y
dehydrogenase,5430,I-GENE-Y
(,5430,O
DPD,5430,B-GENE-Y
",",5430,O
encoded,5430,O
by,5430,O
the,5430,O
DPYD,5430,B-GENE-Y
gene,5430,O
),5430,O
.,5430,O
In,5431,O
this,5431,O
study,5431,O
",",5431,O
the,5431,O
genetic,5431,O
associations,5431,O
between,5431,O
DPYD,5431,B-GENE-Y
variations,5431,O
and,5431,O
circulating,5431,O
mononuclear-cell,5431,O
DPD,5431,B-GENE-Y
enzyme,5431,O
activity,5431,O
were,5431,O
evaluated,5431,O
in,5431,O
94,5431,O
African-American,5431,O
and,5431,O
81,5431,O
European-American,5431,O
volunteers,5431,O
.,5431,O
The,5432,O
DPYD-Y186C,5432,B-GENE-Y
variant,5432,O
was,5432,O
unique,5432,O
to,5432,O
individuals,5432,O
of,5432,O
African,5432,O
ancestry,5432,O
",",5432,O
and,5432,O
DPD,5432,B-GENE-Y
activity,5432,O
was,5432,O
46,5432,O
%,5432,O
lower,5432,O
in,5432,O
carriers,5432,O
as,5432,O
compared,5432,O
with,5432,O
noncarriers,5432,O
(,5432,O
279,5432,O
,5432,O
35,5432,O
vs.,5432,O
514,5432,O
,5432,O
168,5432,O
pmol,5432,O
5-FU,5432,B-CHEMICAL
min,5432,O
(,5432,O
-1,5432,O
),5432,O
mg,5432,O
(,5432,O
-1,5432,O
),5432,O
;,5432,O
P,5432,O
=,5432,O
0.00029,5432,O
),5432,O
.,5432,O
In,5433,O
this,5433,O
study,5433,O
",",5433,O
26,5433,O
%,5433,O
of,5433,O
the,5433,O
African,5433,O
Americans,5433,O
with,5433,O
reduced,5433,O
DPD,5433,B-GENE-Y
activity,5433,O
were,5433,O
carriers,5433,O
of,5433,O
Y186C,5433,B-GENE-N
.,5433,O
In,5434,O
the,5434,O
African-American,5434,O
cohort,5434,O
",",5434,O
after,5434,O
excluding,5434,O
Y186C,5434,B-GENE-N
carriers,5434,O
",",5434,O
homozygous,5434,O
carriers,5434,O
of,5434,O
C29R,5434,B-GENE-N
showed,5434,O
27,5434,O
%,5434,O
higher,5434,O
DPD,5434,B-GENE-Y
activity,5434,O
as,5434,O
compared,5434,O
with,5434,O
noncarriers,5434,O
(,5434,O
609,5434,O
,5434,O
152,5434,O
and,5434,O
480,5434,O
,5434,O
152,5434,O
pmol,5434,O
5-FU,5434,B-CHEMICAL
min,5434,O
(,5434,O
-1,5434,O
),5434,O
mg,5434,O
(,5434,O
-1,5434,O
),5434,O
",",5434,O
respectively,5434,O
;,5434,O
P,5434,O
=,5434,O
0.013,5434,O
),5434,O
.Clinical,5434,O
Pharmacology,5434,O
&,5434,O
Therapeutics,5434,O
(,5434,O
2013,5434,O
),5434,O
;,5434,O
advance,5434,O
online,5434,O
publication,5434,O
1,5434,O
May,5434,O
2013.,5434,O
doi:10.1038/clpt.2013.69,5434,O
.,5434,O
Arsenic,5435,B-CHEMICAL
inhibits,5435,O
autophagic,5435,O
flux,5435,O
activating,5435,O
the,5435,O
Nrf2-Keap1,5435,B-GENE-Y
pathway,5435,O
in,5435,O
a,5435,O
p62-dependent,5435,B-GENE-Y
manner,5435,O
.,5435,O
The,5436,O
Nrf2-Keap1,5436,B-GENE-Y
signaling,5436,O
pathway,5436,O
is,5436,O
a,5436,O
protective,5436,O
mechanism,5436,O
promoting,5436,O
cell,5436,O
survival,5436,O
.,5436,O
Activation,5437,O
of,5437,O
the,5437,O
Nrf2,5437,B-GENE-Y
pathway,5437,O
by,5437,O
natural,5437,O
compounds,5437,O
has,5437,O
been,5437,O
proven,5437,O
to,5437,O
be,5437,O
an,5437,O
effective,5437,O
strategy,5437,O
for,5437,O
chemoprevention,5437,O
.,5437,O
Interestingly,5438,O
",",5438,O
a,5438,O
cancer-promoting,5438,O
function,5438,O
of,5438,O
Nrf2,5438,B-GENE-Y
has,5438,O
been,5438,O
recently,5438,O
observed,5438,O
in,5438,O
many,5438,O
types,5438,O
of,5438,O
tumors,5438,O
due,5438,O
to,5438,O
deregulation,5438,O
of,5438,O
the,5438,O
Nrf2-Keap1,5438,B-GENE-Y
axis,5438,O
",",5438,O
which,5438,O
leads,5438,O
to,5438,O
constitutive,5438,O
activation,5438,O
of,5438,O
Nrf2,5438,B-GENE-Y
.,5438,O
Here,5439,O
",",5439,O
we,5439,O
report,5439,O
a,5439,O
novel,5439,O
mechanism,5439,O
of,5439,O
Nrf2,5439,B-GENE-Y
activation,5439,O
by,5439,O
arsenic,5439,O
that,5439,O
is,5439,O
distinct,5439,O
from,5439,O
that,5439,O
of,5439,O
chemopreventive,5439,O
compounds,5439,O
.,5439,O
Arsenic,5440,B-CHEMICAL
deregulates,5440,O
the,5440,O
autophagic,5440,O
pathway,5440,O
through,5440,O
blockage,5440,O
of,5440,O
autophagic,5440,O
flux,5440,O
",",5440,O
resulting,5440,O
in,5440,O
accumulation,5440,O
of,5440,O
autophagosomes,5440,O
and,5440,O
sequestration,5440,O
of,5440,O
p62,5440,B-GENE-Y
",",5440,O
Keap1,5440,B-GENE-Y
",",5440,O
and,5440,O
LC3,5440,B-GENE-N
.,5440,O
Thus,5441,O
",",5441,O
arsenic,5441,B-CHEMICAL
activates,5441,O
Nrf2,5441,B-GENE-Y
through,5441,O
a,5441,O
non-canonical,5441,O
mechanism,5441,O
(,5441,O
p62-dependent,5441,B-GENE-Y
),5441,O
",",5441,O
leading,5441,O
to,5441,O
a,5441,O
chronic,5441,O
",",5441,O
sustained,5441,O
activation,5441,O
of,5441,O
Nrf2,5441,B-GENE-Y
.,5441,O
In,5442,O
contrast,5442,O
",",5442,O
activation,5442,O
of,5442,O
Nrf2,5442,B-GENE-Y
by,5442,O
sulforaphane,5442,B-CHEMICAL
and,5442,O
tert-butylhydroquinone,5442,B-CHEMICAL
depend,5442,O
upon,5442,O
Keap1-C151,5442,B-GENE-Y
and,5442,O
not,5442,O
p62,5442,B-GENE-Y
(,5442,O
the,5442,O
canonical,5442,O
mechanism,5442,O
),5442,O
.,5442,O
More,5443,O
importantly,5443,O
",",5443,O
SF,5443,O
and,5443,O
tBHQ,5443,B-CHEMICAL
do,5443,O
not,5443,O
have,5443,O
any,5443,O
effect,5443,O
on,5443,O
autophagy,5443,O
.,5443,O
In,5444,O
fact,5444,O
",",5444,O
SF,5444,O
and,5444,O
tBHQ,5444,B-CHEMICAL
alleviate,5444,O
arsenic-mediated,5444,B-CHEMICAL
deregulation,5444,O
of,5444,O
autophagy,5444,O
.,5444,O
Collectively,5445,O
",",5445,O
these,5445,O
findings,5445,O
provide,5445,O
evidence,5445,O
that,5445,O
arsenic,5445,B-CHEMICAL
causes,5445,O
prolonged,5445,O
activation,5445,O
of,5445,O
Nrf2,5445,B-GENE-Y
through,5445,O
autophagy,5445,O
dysfunction,5445,O
",",5445,O
possibly,5445,O
providing,5445,O
a,5445,O
similar,5445,O
scenario,5445,O
to,5445,O
constitutive,5445,O
activation,5445,O
of,5445,O
Nrf2,5445,B-GENE-Y
found,5445,O
in,5445,O
certain,5445,O
human,5445,O
cancers,5445,O
.,5445,O
This,5446,O
may,5446,O
represent,5446,O
a,5446,O
previously,5446,O
unrecognized,5446,O
mechanism,5446,O
underlying,5446,O
arsenic,5446,B-CHEMICAL
toxicity,5446,O
and,5446,O
carcinogenicity,5446,O
in,5446,O
humans,5446,O
.,5446,O
Melatonin,5447,B-CHEMICAL
and,5447,O
ethanol,5447,B-CHEMICAL
intake,5447,O
exert,5447,O
opposite,5447,O
effects,5447,O
on,5447,O
circulating,5447,O
estradiol,5447,B-CHEMICAL
and,5447,O
progesterone,5447,B-CHEMICAL
and,5447,O
differentially,5447,O
regulate,5447,O
sex,5447,B-GENE-N
steroid,5447,I-GENE-N
receptors,5447,I-GENE-N
in,5447,O
the,5447,O
ovaries,5447,O
",",5447,O
oviducts,5447,O
",",5447,O
and,5447,O
uteri,5447,O
of,5447,O
adult,5447,O
rats,5447,O
.,5447,O
Chronic,5448,O
ethanol,5448,B-CHEMICAL
intake,5448,O
is,5448,O
associated,5448,O
with,5448,O
sex,5448,O
hormone,5448,O
disturbances,5448,O
",",5448,O
and,5448,O
it,5448,O
is,5448,O
well,5448,O
known,5448,O
that,5448,O
melatonin,5448,B-CHEMICAL
plays,5448,O
a,5448,O
key,5448,O
role,5448,O
in,5448,O
regulating,5448,O
several,5448,O
reproductive,5448,O
processes,5448,O
.,5448,O
We,5449,O
report,5449,O
the,5449,O
effects,5449,O
of,5449,O
ethanol,5449,B-CHEMICAL
intake,5449,O
and,5449,O
melatonin,5449,B-CHEMICAL
treatment,5449,O
(,5449,O
at,5449,O
doses,5449,O
of,5449,O
100g/100gBW/day,5449,O
),5449,O
on,5449,O
sex,5449,O
hormones,5449,O
and,5449,O
steroid,5449,B-GENE-N
receptors,5449,I-GENE-N
in,5449,O
the,5449,O
ovaries,5449,O
",",5449,O
oviducts,5449,O
and,5449,O
uteri,5449,O
of,5449,O
ethanol-preferring,5449,B-CHEMICAL
rats,5449,O
.,5449,O
After,5450,O
150,5450,O
days,5450,O
of,5450,O
treatment,5450,O
",",5450,O
animals,5450,O
were,5450,O
euthanized,5450,O
",",5450,O
and,5450,O
tissue,5450,O
samples,5450,O
were,5450,O
harvested,5450,O
to,5450,O
evaluate,5450,O
androgen,5450,B-GENE-N
",",5450,I-GENE-N
estrogen,5450,I-GENE-N
",",5450,I-GENE-N
progesterone,5450,I-GENE-N
and,5450,I-GENE-N
melatonin,5450,I-GENE-N
receptor,5450,I-GENE-N
subunits,5450,O
(,5450,O
AR,5450,B-GENE-Y
",",5450,O
ER-,5450,B-GENE-Y
and,5450,O
ER-,5450,B-GENE-Y
",",5450,O
PRA,5450,B-GENE-Y
",",5450,O
PRB,5450,B-GENE-Y
and,5450,O
MT1R,5450,B-GENE-Y
",",5450,O
respectively,5450,O
),5450,O
.,5450,O
Melatonin,5451,B-CHEMICAL
decreased,5451,O
estradiol,5451,B-CHEMICAL
(,5451,O
E2,5451,O
),5451,O
and,5451,O
increased,5451,O
progesterone,5451,B-CHEMICAL
(,5451,O
P4,5451,O
),5451,O
and,5451,O
6-sulfatoxymelatonin,5451,B-CHEMICAL
(,5451,O
6-STM,5451,B-CHEMICAL
),5451,O
",",5451,O
while,5451,O
an,5451,O
ethanol-melatonin,5451,B-CHEMICAL
combination,5451,O
reduced,5451,O
both,5451,O
P4,5451,O
and,5451,O
E2,5451,O
.,5451,O
Ovarian,5452,O
AR,5452,B-GENE-Y
was,5452,O
not,5452,O
influenced,5452,O
by,5452,O
either,5452,O
treatment,5452,O
",",5452,O
and,5452,O
oviduct,5452,O
AR,5452,B-GENE-Y
was,5452,O
reduced,5452,O
after,5452,O
ethanol-melatonin,5452,B-CHEMICAL
combination,5452,O
.,5452,O
Oviduct,5453,O
ER-,5453,B-GENE-Y
",",5453,O
ER-,5453,B-GENE-Y
and,5453,O
uterine,5453,O
ER-,5453,B-GENE-Y
were,5453,O
down-regulated,5453,O
by,5453,O
either,5453,O
ethanol,5453,B-CHEMICAL
or,5453,O
melatonin,5453,B-CHEMICAL
.,5453,O
Conversely,5454,O
",",5454,O
ovarian,5454,O
PRA,5454,B-GENE-Y
and,5454,O
PRB,5454,B-GENE-Y
were,5454,O
positively,5454,O
regulated,5454,O
by,5454,O
ethanol,5454,B-CHEMICAL
and,5454,O
ethanol-melatonin,5454,B-CHEMICAL
combination,5454,O
",",5454,O
whereas,5454,O
PRA,5454,B-GENE-Y
was,5454,O
down-regulated,5454,O
in,5454,O
the,5454,O
uterus,5454,O
and,5454,O
oviduct,5454,O
after,5454,O
ethanol,5454,B-CHEMICAL
consumption,5454,O
.,5454,O
MT1R,5455,B-GENE-Y
was,5455,O
increased,5455,O
in,5455,O
ovaries,5455,O
and,5455,O
uteri,5455,O
of,5455,O
melatonin-treated,5455,B-CHEMICAL
rats,5455,O
.,5455,O
Ethanol,5456,B-CHEMICAL
and,5456,O
melatonin,5456,B-CHEMICAL
exert,5456,O
opposite,5456,O
effects,5456,O
on,5456,O
E2,5456,O
and,5456,O
P4,5456,O
",",5456,O
and,5456,O
they,5456,O
differentially,5456,O
regulate,5456,O
the,5456,O
expression,5456,O
of,5456,O
sex,5456,B-GENE-N
steroid,5456,B-CHEMICAL
receptors,5456,I-GENE-N
in,5456,O
female,5456,O
reproductive,5456,O
tissues,5456,O
.,5456,O
Ph1,5457,O
toxin,5457,O
prevents,5457,O
capsaicin-induced,5457,B-CHEMICAL
nociceptive,5457,O
behavior,5457,O
and,5457,O
mechanical,5457,O
hypersensitivity,5457,O
without,5457,O
acting,5457,O
on,5457,O
TRPV1,5457,B-GENE-Y
channels,5457,O
.,5457,O
Ph1,5458,O
toxin,5458,O
is,5458,O
a,5458,O
peptide,5458,O
purified,5458,O
from,5458,O
the,5458,O
venom,5458,O
of,5458,O
the,5458,O
armed,5458,O
spider,5458,O
Phoneutria,5458,O
nigriventer,5458,O
",",5458,O
with,5458,O
markedly,5458,O
antinociceptive,5458,O
action,5458,O
in,5458,O
models,5458,O
of,5458,O
acute,5458,O
and,5458,O
persistent,5458,O
pain,5458,O
in,5458,O
rats,5458,O
.,5458,O
Similarly,5459,O
to,5459,O
ziconotide,5459,O
",",5459,O
its,5459,O
analgesic,5459,O
action,5459,O
is,5459,O
related,5459,O
to,5459,O
inhibition,5459,O
of,5459,O
high,5459,O
voltage,5459,O
activated,5459,O
calcium,5459,B-CHEMICAL
channels,5459,O
with,5459,O
more,5459,O
selectivity,5459,O
for,5459,O
N-type,5459,O
.,5459,O
In,5460,O
this,5460,O
study,5460,O
we,5460,O
evaluated,5460,O
the,5460,O
effect,5460,O
of,5460,O
Ph1,5460,O
when,5460,O
injected,5460,O
peripherally,5460,O
or,5460,O
intrathecally,5460,O
in,5460,O
a,5460,O
rat,5460,O
model,5460,O
of,5460,O
spontaneous,5460,O
pain,5460,O
induced,5460,O
by,5460,O
capsaicin,5460,B-CHEMICAL
.,5460,O
We,5461,O
also,5461,O
investigated,5461,O
the,5461,O
effect,5461,O
of,5461,O
Ph1,5461,O
on,5461,O
Ca,5461,B-CHEMICAL
(,5461,I-CHEMICAL
2+,5461,I-CHEMICAL
),5461,I-CHEMICAL
transients,5461,O
in,5461,O
cultured,5461,O
dorsal,5461,O
root,5461,O
ganglia,5461,O
(,5461,O
DRG,5461,O
),5461,O
neurons,5461,O
and,5461,O
HEK293,5461,O
cells,5461,O
expressing,5461,O
the,5461,O
TRPV1,5461,B-GENE-Y
receptor,5461,O
.,5461,O
Intraplantar,5462,O
or,5462,O
intrathecal,5462,O
administered,5462,O
Ph1,5462,O
reduced,5462,O
both,5462,O
nocifensive,5462,O
behavior,5462,O
and,5462,O
mechanical,5462,O
hypersensitivity,5462,O
induced,5462,O
by,5462,O
capsaicin,5462,B-CHEMICAL
similarly,5462,O
to,5462,O
that,5462,O
observed,5462,O
with,5462,O
SB366791,5462,B-CHEMICAL
",",5462,O
a,5462,O
specific,5462,O
TRPV1,5462,B-GENE-Y
antagonist,5462,O
.,5462,O
Peripheral,5463,O
nifedipine,5463,B-CHEMICAL
and,5463,O
mibefradil,5463,B-CHEMICAL
did,5463,O
also,5463,O
decrease,5463,O
nociceptive,5463,O
behavior,5463,O
induced,5463,O
by,5463,O
intraplantar,5463,O
capsaicin,5463,B-CHEMICAL
.,5463,O
In,5464,O
contrast,5464,O
",",5464,O
-conotoxin,5464,O
MVIIA,5464,O
(,5464,O
a,5464,O
selective,5464,O
N-type,5464,B-GENE-N
Ca,5464,I-GENE-N
(,5464,I-GENE-N
2+,5464,I-GENE-N
),5464,I-GENE-N
channel,5464,I-GENE-N
blocker,5464,O
),5464,O
was,5464,O
effective,5464,O
only,5464,O
when,5464,O
administered,5464,O
intrathecally,5464,O
.,5464,O
Ph1,5465,O
",",5465,O
MVIIA,5465,O
and,5465,O
SB366791,5465,B-CHEMICAL
inhibited,5465,O
",",5465,O
with,5465,O
similar,5465,O
potency,5465,O
",",5465,O
the,5465,O
capsaicin-induced,5465,B-CHEMICAL
Ca,5465,B-CHEMICAL
(,5465,I-CHEMICAL
2+,5465,I-CHEMICAL
),5465,I-CHEMICAL
transients,5465,O
in,5465,O
DRG,5465,O
neurons,5465,O
.,5465,O
The,5466,O
simultaneous,5466,O
administration,5466,O
of,5466,O
Ph1,5466,O
and,5466,O
SB366791,5466,B-CHEMICAL
inhibited,5466,O
the,5466,O
capsaicin-induced,5466,B-CHEMICAL
Ca,5466,B-CHEMICAL
(,5466,I-CHEMICAL
2+,5466,I-CHEMICAL
),5466,I-CHEMICAL
transients,5466,O
that,5466,O
were,5466,O
additive,5466,O
suggesting,5466,O
that,5466,O
they,5466,O
act,5466,O
through,5466,O
different,5466,O
targets,5466,O
.,5466,O
Moreover,5467,O
",",5467,O
Ph1,5467,O
did,5467,O
not,5467,O
inhibit,5467,O
capsaicin-activated,5467,B-CHEMICAL
currents,5467,O
in,5467,O
patch-clamp,5467,O
recordings,5467,O
of,5467,O
HEK293,5467,O
cells,5467,O
that,5467,O
expressed,5467,O
TRPV1,5467,B-GENE-Y
receptors,5467,O
.,5467,O
Our,5468,O
results,5468,O
show,5468,O
that,5468,O
Ph1,5468,O
may,5468,O
be,5468,O
effective,5468,O
as,5468,O
a,5468,O
therapeutic,5468,O
strategy,5468,O
for,5468,O
pain,5468,O
and,5468,O
this,5468,O
effect,5468,O
is,5468,O
not,5468,O
related,5468,O
to,5468,O
the,5468,O
inhibition,5468,O
of,5468,O
TRPV1,5468,B-GENE-Y
receptors,5468,O
.,5468,O
Rescue,5469,O
of,5469,O
platinum-damaged,5469,B-CHEMICAL
oocytes,5469,O
from,5469,O
programmed,5469,O
cell,5469,O
death,5469,O
through,5469,O
inactivation,5469,O
of,5469,O
the,5469,O
p53,5469,B-GENE-Y
family,5469,O
signaling,5469,O
network,5469,O
.,5469,O
Non-proliferating,5470,O
oocytes,5470,O
within,5470,O
avascular,5470,O
regions,5470,O
of,5470,O
the,5470,O
ovary,5470,O
are,5470,O
exquisitely,5470,O
susceptible,5470,O
to,5470,O
chemotherapy,5470,O
.,5470,O
Early,5471,O
menopause,5471,O
and,5471,O
sterility,5471,O
are,5471,O
unintended,5471,O
consequences,5471,O
of,5471,O
chemotherapy,5471,O
",",5471,O
and,5471,O
efforts,5471,O
to,5471,O
understand,5471,O
the,5471,O
oocyte,5471,O
apoptotic,5471,O
pathway,5471,O
may,5471,O
provide,5471,O
new,5471,O
targets,5471,O
for,5471,O
mitigating,5471,O
this,5471,O
outcome,5471,O
.,5471,O
Recently,5472,O
",",5472,O
the,5472,O
c-Abl,5472,B-GENE-Y
kinase,5472,B-GENE-N
inhibitor,5472,O
imatinib,5472,B-CHEMICAL
mesylate,5472,I-CHEMICAL
(,5472,O
imatinib,5472,B-CHEMICAL
),5472,O
has,5472,O
become,5472,O
the,5472,O
focus,5472,O
of,5472,O
research,5472,O
as,5472,O
a,5472,O
fertoprotective,5472,O
drug,5472,O
against,5472,O
cisplatin,5472,B-CHEMICAL
.,5472,O
However,5473,O
",",5473,O
the,5473,O
mechanism,5473,O
by,5473,O
which,5473,O
imatinib,5473,B-CHEMICAL
protects,5473,O
oocytes,5473,O
is,5473,O
not,5473,O
fully,5473,O
understood,5473,O
",",5473,O
and,5473,O
reports,5473,O
of,5473,O
the,5473,O
drug,5473,O
's,5473,O
efficacy,5473,O
have,5473,O
been,5473,O
contradictory,5473,O
.,5473,O
Using,5474,O
in,5474,O
vitro,5474,O
culture,5474,O
and,5474,O
subrenal,5474,O
grafting,5474,O
of,5474,O
mouse,5474,O
ovaries,5474,O
",",5474,O
we,5474,O
demonstrated,5474,O
that,5474,O
imatinib,5474,B-CHEMICAL
inhibits,5474,O
the,5474,O
cisplatin-induced,5474,B-CHEMICAL
apoptosis,5474,O
of,5474,O
oocytes,5474,O
within,5474,O
primordial,5474,O
follicles,5474,O
.,5474,O
We,5475,O
found,5475,O
that,5475,O
",",5475,O
before,5475,O
apoptosis,5475,O
",",5475,O
cisplatin,5475,B-CHEMICAL
induces,5475,O
c-Abl,5475,B-GENE-Y
and,5475,O
TAp73,5475,B-GENE-Y
expression,5475,O
in,5475,O
the,5475,O
oocyte,5475,O
.,5475,O
Oocytes,5476,O
undergoing,5476,O
apoptosis,5476,O
showed,5476,O
downregulation,5476,O
of,5476,O
TAp63,5476,B-GENE-Y
and,5476,O
upregulation,5476,O
of,5476,O
Bax,5476,B-GENE-Y
.,5476,O
While,5477,O
imatinib,5477,B-CHEMICAL
was,5477,O
unable,5477,O
to,5477,O
block,5477,O
cisplatin-induced,5477,B-CHEMICAL
DNA,5477,O
damage,5477,O
and,5477,O
damage,5477,O
response,5477,O
",",5477,O
such,5477,O
as,5477,O
the,5477,O
upregulation,5477,O
of,5477,O
p53,5477,B-GENE-Y
",",5477,O
imatinib,5477,B-CHEMICAL
inhibited,5477,O
the,5477,O
cisplatin-induced,5477,B-CHEMICAL
nuclear,5477,O
accumulation,5477,O
of,5477,O
c-Abl/TAp73,5477,B-GENE-Y
and,5477,O
the,5477,O
subsequent,5477,O
downregulation,5477,O
of,5477,O
TAp63,5477,B-GENE-Y
and,5477,O
upregulation,5477,O
of,5477,O
Bax,5477,B-GENE-Y
",",5477,O
thereby,5477,O
abrogating,5477,O
oocyte,5477,O
cell,5477,O
death,5477,O
.,5477,O
Surprisingly,5478,O
",",5478,O
the,5478,O
conditional,5478,O
deletion,5478,O
of,5478,O
Trp63,5478,B-CHEMICAL
",",5478,O
but,5478,O
not,5478,O
Np63,5478,B-GENE-Y
",",5478,O
in,5478,O
oocytes,5478,O
inhibited,5478,O
apoptosis,5478,O
",",5478,O
as,5478,O
well,5478,O
as,5478,O
the,5478,O
accumulation,5478,O
of,5478,O
c-Abl,5478,B-GENE-Y
and,5478,O
TAp73,5478,B-GENE-Y
caused,5478,O
by,5478,O
cisplatin,5478,B-CHEMICAL
.,5478,O
These,5479,O
data,5479,O
suggest,5479,O
that,5479,O
TAp63,5479,B-GENE-Y
is,5479,O
the,5479,O
master,5479,O
regulator,5479,O
of,5479,O
cisplatin-induced,5479,B-CHEMICAL
oocyte,5479,O
death,5479,O
.,5479,O
The,5480,O
expression,5480,O
kinetics,5480,O
of,5480,O
TAp63,5480,B-GENE-Y
",",5480,O
c-Abl,5480,B-GENE-Y
and,5480,O
TAp73,5480,B-GENE-Y
suggest,5480,O
that,5480,O
cisplatin,5480,B-CHEMICAL
activates,5480,O
TAp63-dependent,5480,B-GENE-Y
expression,5480,O
of,5480,O
c-Abl,5480,B-GENE-Y
and,5480,O
TAp73,5480,B-GENE-Y
and,5480,O
",",5480,O
in,5480,O
turn,5480,O
",",5480,O
the,5480,O
activation,5480,O
of,5480,O
TAp73,5480,B-GENE-Y
by,5480,O
c-Abl-induced,5480,B-GENE-Y
BAX,5480,B-GENE-Y
expression,5480,O
.,5480,O
Our,5481,O
findings,5481,O
indicate,5481,O
that,5481,O
imatinib,5481,B-CHEMICAL
protects,5481,O
oocytes,5481,O
from,5481,O
cisplatin-induced,5481,B-CHEMICAL
cell,5481,O
death,5481,O
by,5481,O
inhibiting,5481,O
c-Abl,5481,B-GENE-Y
kinase,5481,B-GENE-N
",",5481,O
which,5481,O
would,5481,O
otherwise,5481,O
activate,5481,O
TAp73-BAX-mediated,5481,B-GENE-Y
apoptosis,5481,O
.,5481,O
Thus,5482,O
",",5482,O
imatinib,5482,B-CHEMICAL
and,5482,O
other,5482,O
c-Abl,5482,B-GENE-Y
kinase,5482,B-GENE-N
inhibitors,5482,O
provide,5482,O
an,5482,O
intriguing,5482,O
new,5482,O
way,5482,O
to,5482,O
halt,5482,O
cisplatin-induced,5482,B-CHEMICAL
oocyte,5482,O
death,5482,O
in,5482,O
early,5482,O
follicles,5482,O
and,5482,O
perhaps,5482,O
conserve,5482,O
the,5482,O
endocrine,5482,O
function,5482,O
of,5482,O
the,5482,O
ovary,5482,O
against,5482,O
chemotherapy.Cell,5482,O
Death,5482,O
and,5482,O
Differentiation,5482,O
advance,5482,O
online,5482,O
publication,5482,O
",",5482,O
19,5482,O
April,5482,O
2013,5482,O
;,5482,O
doi:10.1038/cdd.2013.31,5482,O
.,5482,O
Suppression,5483,O
of,5483,O
ZIP8,5483,B-GENE-Y
expression,5483,O
is,5483,O
a,5483,O
common,5483,O
feature,5483,O
of,5483,O
cadmium-resistant,5483,B-CHEMICAL
and,5483,O
manganese-resistant,5483,B-CHEMICAL
RBL-2H3,5483,O
cells,5483,O
.,5483,O
Rat,5484,O
basophilic,5484,O
leukemia,5484,O
RBL-2H3,5484,O
cells,5484,O
show,5484,O
markedly,5484,O
high,5484,O
sensitivity,5484,O
to,5484,O
both,5484,O
CdCl2,5484,B-CHEMICAL
and,5484,O
MnCl2,5484,B-CHEMICAL
compared,5484,O
with,5484,O
other,5484,O
rat,5484,O
cell,5484,O
lines,5484,O
",",5484,O
due,5484,O
to,5484,O
efficient,5484,O
accumulation,5484,O
of,5484,O
cadmium,5484,B-CHEMICAL
and,5484,O
manganese,5484,B-CHEMICAL
.,5484,O
To,5485,O
clarify,5485,O
the,5485,O
roles,5485,O
of,5485,O
metal,5485,B-GENE-N
transporters,5485,I-GENE-N
in,5485,O
hyperaccumulation,5485,O
of,5485,O
cadmium,5485,B-CHEMICAL
and,5485,O
manganese,5485,B-CHEMICAL
in,5485,O
RBL-2H3,5485,O
cells,5485,O
",",5485,O
Cd-resistant,5485,B-CHEMICAL
and,5485,O
Mn-resistant,5485,B-CHEMICAL
cells,5485,O
were,5485,O
developed,5485,O
from,5485,O
RBL-2H3,5485,O
cells,5485,O
by,5485,O
continuous,5485,O
exposure,5485,O
to,5485,O
CdCl2,5485,B-CHEMICAL
and,5485,O
MnCl2,5485,B-CHEMICAL
",",5485,O
respectively,5485,O
.,5485,O
The,5486,O
established,5486,O
Cd-resistant,5486,B-CHEMICAL
(,5486,O
RBL-Cdr,5486,O
),5486,O
and,5486,O
Mn-resistant,5486,B-CHEMICAL
(,5486,O
RBL-Mnr,5486,O
),5486,O
cells,5486,O
exhibited,5486,O
about,5486,O
20,5486,O
times,5486,O
higher,5486,O
LC50,5486,O
values,5486,O
of,5486,O
CdCl2,5486,B-CHEMICAL
and,5486,O
MnCl2,5486,B-CHEMICAL
",",5486,O
respectively,5486,O
",",5486,O
than,5486,O
parental,5486,O
RBL-2H3,5486,O
cells,5486,O
",",5486,O
and,5486,O
showed,5486,O
cross-resistance,5486,O
to,5486,O
each,5486,O
metal,5486,O
.,5486,O
The,5487,O
resistance,5487,O
to,5487,O
cadmium,5487,B-CHEMICAL
and,5487,O
manganese,5487,B-CHEMICAL
was,5487,O
primarily,5487,O
conferred,5487,O
by,5487,O
a,5487,O
marked,5487,O
decrease,5487,O
in,5487,O
the,5487,O
uptake,5487,O
of,5487,O
both,5487,O
metals,5487,O
.,5487,O
RBL-Cdr,5488,O
cells,5488,O
also,5488,O
showed,5488,O
cross-resistance,5488,O
to,5488,O
HgCl2,5488,B-CHEMICAL
and,5488,O
AgNO3,5488,B-CHEMICAL
probably,5488,O
due,5488,O
to,5488,O
enhanced,5488,O
expression,5488,O
of,5488,O
metallothionein,5488,B-GENE-N
.,5488,O
Among,5489,O
the,5489,O
possible,5489,O
transporters,5489,O
involved,5489,O
in,5489,O
the,5489,O
uptake,5489,O
of,5489,O
Cd,5489,B-CHEMICAL
(,5489,I-CHEMICAL
2+,5489,I-CHEMICAL
),5489,I-CHEMICAL
and,5489,O
Mn,5489,B-CHEMICAL
(,5489,I-CHEMICAL
2+,5489,I-CHEMICAL
),5489,I-CHEMICAL
",",5489,O
the,5489,O
expression,5489,O
of,5489,O
ZIP8,5489,B-GENE-Y
(,5489,O
Zrt-,5489,B-GENE-Y
",",5489,I-GENE-Y
Irt-related,5489,I-GENE-Y
protein,5489,I-GENE-Y
8,5489,I-GENE-Y
),5489,O
",",5489,O
encoded,5489,O
by,5489,O
Slc39a8,5489,B-GENE-Y
",",5489,O
showed,5489,O
a,5489,O
marked,5489,O
suppression,5489,O
in,5489,O
both,5489,O
RBL-Cdr,5489,O
and,5489,O
RBL-Mnr,5489,O
cells,5489,O
.,5489,O
These,5490,O
results,5490,O
suggest,5490,O
that,5490,O
ZIP8,5490,B-GENE-Y
plays,5490,O
a,5490,O
pivotal,5490,O
role,5490,O
in,5490,O
the,5490,O
transport,5490,O
and,5490,O
toxicity,5490,O
of,5490,O
Cd,5490,B-CHEMICAL
(,5490,I-CHEMICAL
2+,5490,I-CHEMICAL
),5490,I-CHEMICAL
and,5490,O
Mn,5490,B-CHEMICAL
(,5490,I-CHEMICAL
2+,5490,I-CHEMICAL
),5490,I-CHEMICAL
in,5490,O
RBL-2H3,5490,O
cells,5490,O
.,5490,O
In,5491,O
Vitro,5491,O
Reconstitution,5491,O
of,5491,O
Complexes,5491,O
between,5491,O
proMatrix,5491,B-GENE-Y
Metalloproteinase-9,5491,I-GENE-Y
and,5491,O
the,5491,O
Proteoglycans,5491,O
Serglycin,5491,O
and,5491,O
Versican,5491,O
.,5491,O
Previously,5492,O
we,5492,O
have,5492,O
shown,5492,O
that,5492,O
a,5492,O
fraction,5492,O
of,5492,O
the,5492,O
matrix,5492,B-GENE-Y
metalloproteinase-9,5492,I-GENE-Y
(,5492,O
MMP-9,5492,B-GENE-Y
),5492,O
synthesized,5492,O
by,5492,O
the,5492,O
macrophage,5492,O
cell,5492,O
line,5492,O
THP-1,5492,O
was,5492,O
bound,5492,O
to,5492,O
a,5492,O
chondroitin,5492,B-GENE-N
sulphate,5492,I-GENE-N
proteoglycan,5492,I-GENE-N
(,5492,I-GENE-N
CSPG,5492,I-GENE-N
),5492,I-GENE-N
core,5492,I-GENE-N
protein,5492,I-GENE-N
as,5492,O
a,5492,O
reduction,5492,O
sensitive,5492,O
heteromer,5492,O
.,5492,O
It,5493,O
was,5493,O
also,5493,O
shown,5493,O
that,5493,O
the,5493,O
hemopexin-like,5493,B-GENE-N
(,5493,I-GENE-N
PEX,5493,I-GENE-N
),5493,I-GENE-N
domain,5493,I-GENE-N
and,5493,O
the,5493,O
fibronectin-like,5493,B-GENE-N
(,5493,I-GENE-N
FnII,5493,I-GENE-N
),5493,I-GENE-N
module,5493,I-GENE-N
in,5493,O
the,5493,O
enzyme,5493,O
are,5493,O
involved,5493,O
in,5493,O
the,5493,O
heteromer,5493,O
formation,5493,O
.,5493,O
In,5494,O
the,5494,O
present,5494,O
work,5494,O
we,5494,O
show,5494,O
that,5494,O
reduction,5494,O
sensitive,5494,O
and,5494,O
SDS-stable,5494,B-CHEMICAL
heteromers,5494,O
can,5494,O
be,5494,O
reconstituted,5494,O
in,5494,O
vitro,5494,O
by,5494,O
mixing,5494,O
proMMP-9,5494,B-GENE-Y
with,5494,O
either,5494,O
serglycin,5494,O
",",5494,O
versican,5494,O
or,5494,O
CSPGs,5494,B-GENE-N
isolated,5494,O
from,5494,O
various,5494,O
monocytic,5494,O
cell,5494,O
lines,5494,O
.,5494,O
In,5495,O
addition,5495,O
",",5495,O
a,5495,O
strong,5495,O
but,5495,O
SDS-soluble,5495,B-CHEMICAL
proMMP-9CSPG,5495,B-GENE-Y
heteromer,5495,O
was,5495,O
formed,5495,O
.,5495,O
The,5496,O
two,5496,O
macromolecules,5496,O
in,5496,O
the,5496,O
SDS-stable,5496,B-CHEMICAL
reduction,5496,O
sensitive,5496,O
heteromers,5496,O
were,5496,O
not,5496,O
linked,5496,O
together,5496,O
by,5496,O
disulphide,5496,B-CHEMICAL
bonds,5496,O
.,5496,O
As,5497,O
for,5497,O
the,5497,O
heteromer,5497,O
isolated,5497,O
from,5497,O
THP-1,5497,O
cells,5497,O
",",5497,O
the,5497,O
in,5497,O
vitro,5497,O
reconstituted,5497,O
SDS-stable,5497,B-CHEMICAL
and,5497,O
SDS-soluble,5497,B-CHEMICAL
heteromers,5497,O
had,5497,O
a,5497,O
weaker,5497,O
binding,5497,O
to,5497,O
gelatin,5497,O
than,5497,O
the,5497,O
proMMP-9,5497,B-GENE-Y
monomer,5497,O
.,5497,O
Furthermore,5498,O
",",5498,O
gelatin,5498,O
inhibited,5498,O
the,5498,O
in,5498,O
vitro,5498,O
reconstitution,5498,O
of,5498,O
the,5498,O
heteromers,5498,O
",",5498,O
showing,5498,O
that,5498,O
the,5498,O
FnII,5498,B-GENE-N
module,5498,I-GENE-N
is,5498,O
involved,5498,O
in,5498,O
the,5498,O
complex,5498,O
formation,5498,O
.,5498,O
TIMP-1,5499,B-GENE-Y
could,5499,O
not,5499,O
be,5499,O
detected,5499,O
in,5499,O
the,5499,O
formed,5499,O
proMMP-9CSPG,5499,B-GENE-Y
complexes,5499,O
.,5499,O
However,5500,O
",",5500,O
the,5500,O
presence,5500,O
of,5500,O
TIMP-1,5500,B-GENE-Y
inhibited,5500,O
the,5500,O
formation,5500,O
of,5500,O
the,5500,O
SDS-soluble,5500,B-CHEMICAL
heteromer,5500,O
",",5500,O
but,5500,O
not,5500,O
the,5500,O
SDS-stable,5500,B-CHEMICAL
reduction,5500,O
sensitive,5500,O
heteromer,5500,O
.,5500,O
This,5501,O
indicates,5501,O
that,5501,O
different,5501,O
regions,5501,O
in,5501,O
the,5501,O
PEX,5501,B-GENE-N
domain,5501,I-GENE-N
are,5501,O
involved,5501,O
the,5501,O
formation,5501,O
of,5501,O
these,5501,O
heteromers,5501,O
.,5501,O
This,5502,O
article,5502,O
is,5502,O
protected,5502,O
by,5502,O
copyright,5502,O
.,5502,O
All,5503,O
rights,5503,O
reserved,5503,O
.,5503,O
Optimization,5504,O
of,5504,O
a,5504,O
"1,5-dihydrobenzo",5504,B-CHEMICAL
[,5504,I-CHEMICAL
b,5504,I-CHEMICAL
],5504,I-CHEMICAL
[,5504,I-CHEMICAL
"1,4",5504,I-CHEMICAL
],5504,I-CHEMICAL
"diazepine-2,4-dione",5504,I-CHEMICAL
series,5504,O
of,5504,O
HIV,5504,B-GENE-N
capsid,5504,I-GENE-N
assembly,5504,O
inhibitors,5504,O
2,5504,O
:,5504,O
Structure-activity,5504,O
relationships,5504,O
(,5504,O
SAR,5504,O
),5504,O
of,5504,O
the,5504,O
C3-phenyl,5504,O
moiety,5504,O
.,5504,O
Detailed,5505,O
structure-activity,5505,O
relationships,5505,O
of,5505,O
the,5505,O
C3-phenyl,5505,O
moiety,5505,O
that,5505,O
allow,5505,O
for,5505,O
the,5505,O
optimization,5505,O
of,5505,O
antiviral,5505,O
potency,5505,O
of,5505,O
a,5505,O
series,5505,O
of,5505,O
"1,5-dihydrobenzo",5505,B-CHEMICAL
[,5505,I-CHEMICAL
b,5505,I-CHEMICAL
],5505,I-CHEMICAL
[,5505,I-CHEMICAL
"1,4",5505,I-CHEMICAL
],5505,I-CHEMICAL
"diazepine-2,4-dione",5505,I-CHEMICAL
inhibitors,5505,O
of,5505,O
HIV,5505,B-GENE-N
capsid,5505,I-GENE-N
(,5505,O
CA,5505,B-GENE-N
),5505,O
assembly,5505,O
are,5505,O
described,5505,O
.,5505,O
Combination,5506,O
of,5506,O
favorable,5506,O
substitutions,5506,O
gave,5506,O
additive,5506,O
SAR,5506,O
and,5506,O
allowed,5506,O
for,5506,O
the,5506,O
identification,5506,O
of,5506,O
the,5506,O
most,5506,O
potent,5506,O
compound,5506,O
in,5506,O
the,5506,O
series,5506,O
",",5506,O
analog,5506,O
27,5506,O
.,5506,O
Productive,5507,O
SAR,5507,O
also,5507,O
transferred,5507,O
to,5507,O
the,5507,O
benzotriazepine,5507,B-CHEMICAL
and,5507,O
spirobenzodiazepine,5507,B-CHEMICAL
scaffolds,5507,O
",",5507,O
providing,5507,O
a,5507,O
solution,5507,O
to,5507,O
the,5507,O
labile,5507,O
stereocenter,5507,O
at,5507,O
the,5507,O
C3,5507,O
position,5507,O
.,5507,O
The,5508,O
molecular,5508,O
basis,5508,O
of,5508,O
how,5508,O
compound,5508,O
27,5508,O
inhibits,5508,O
mature,5508,O
CA,5508,B-GENE-N
assembly,5508,O
is,5508,O
rationalized,5508,O
using,5508,O
high-resolution,5508,O
structural,5508,O
information,5508,O
.,5508,O
Our,5509,O
understanding,5509,O
of,5509,O
how,5509,O
compound,5509,O
27,5509,O
may,5509,O
inhibit,5509,O
immature,5509,O
Gag,5509,B-GENE-N
assembly,5509,O
is,5509,O
also,5509,O
discussed,5509,O
.,5509,O
Neuroactive,5510,O
effects,5510,O
of,5510,O
cotinine,5510,B-CHEMICAL
on,5510,O
the,5510,O
hippocampus,5510,O
:,5510,O
Behavioral,5510,O
and,5510,O
biochemical,5510,O
parameters,5510,O
.,5510,O
The,5511,O
present,5511,O
work,5511,O
evaluated,5511,O
the,5511,O
effects,5511,O
of,5511,O
nicotine,5511,B-CHEMICAL
(,5511,O
NIC,5511,B-CHEMICAL
),5511,O
",",5511,O
cotinine,5511,B-CHEMICAL
(,5511,O
COT,5511,B-CHEMICAL
),5511,O
",",5511,O
mecamylamine,5511,B-CHEMICAL
(,5511,O
MEC,5511,B-CHEMICAL
),5511,O
",",5511,O
methyllycaconitine,5511,B-CHEMICAL
(,5511,O
MLA,5511,B-CHEMICAL
),5511,O
and,5511,O
dihydro-beta-eritroidine,5511,B-CHEMICAL
(,5511,O
DHE,5511,B-CHEMICAL
),5511,O
on,5511,O
memory,5511,O
extinction,5511,O
and,5511,O
the,5511,O
following,5511,O
biochemical,5511,O
parameters,5511,O
of,5511,O
the,5511,O
hippocampus,5511,O
:,5511,O
lipid,5511,O
peroxidation,5511,O
(,5511,O
LPO,5511,O
),5511,O
",",5511,O
antioxidant,5511,O
capacity,5511,O
(,5511,O
AC,5511,O
),5511,O
and,5511,O
the,5511,O
phosphorylation,5511,O
of,5511,O
Extracellular-Signal-Regulated,5511,B-GENE-N
Kinase,5511,I-GENE-N
(,5511,O
ERK,5511,B-GENE-N
1/2,5511,I-GENE-N
),5511,O
.,5511,O
Young,5512,O
male,5512,O
rats,5512,O
that,5512,O
were,5512,O
implanted,5512,O
bilaterally,5512,O
with,5512,O
cannulae,5512,O
were,5512,O
submitted,5512,O
to,5512,O
memory,5512,O
extinction,5512,O
tests,5512,O
sessions,5512,O
",",5512,O
and,5512,O
their,5512,O
hippocampi,5512,O
were,5512,O
dissected,5512,O
for,5512,O
biochemical,5512,O
assays,5512,O
.,5512,O
The,5513,O
extinction,5513,O
of,5513,O
fear,5513,O
memory,5513,O
was,5513,O
significantly,5513,O
improved,5513,O
by,5513,O
both,5513,O
nicotine,5513,B-CHEMICAL
and,5513,O
its,5513,O
metabolite,5513,O
.,5513,O
Cotinine,5514,B-CHEMICAL
significantly,5514,O
increased,5514,O
LPO,5514,O
",",5514,O
while,5514,O
nicotine,5514,B-CHEMICAL
significantly,5514,O
decreased,5514,O
it,5514,O
.,5514,O
Antioxidant,5515,O
capacity,5515,O
was,5515,O
increased,5515,O
by,5515,O
all,5515,O
treatments,5515,O
.,5515,O
Our,5516,O
results,5516,O
showed,5516,O
that,5516,O
cotinine,5516,B-CHEMICAL
",",5516,O
unlike,5516,O
nicotine,5516,B-CHEMICAL
",",5516,O
may,5516,O
increase,5516,O
oxidative,5516,O
stress,5516,O
in,5516,O
the,5516,O
hippocampus,5516,O
",",5516,O
but,5516,O
this,5516,O
increase,5516,O
depends,5516,O
upon,5516,O
the,5516,O
dose,5516,O
used,5516,O
and,5516,O
happens,5516,O
without,5516,O
causing,5516,O
corresponding,5516,O
impairments,5516,O
in,5516,O
cognitive,5516,O
function,5516,O
.,5516,O
Cotinine,5517,B-CHEMICAL
also,5517,O
increased,5517,O
the,5517,O
phosphorylation,5517,O
of,5517,O
ERK,5517,B-GENE-N
1/2,5517,I-GENE-N
in,5517,O
a,5517,O
similar,5517,O
fashion,5517,O
as,5517,O
nicotine,5517,B-CHEMICAL
.,5517,O
Considering,5518,O
these,5518,O
results,5518,O
",",5518,O
it,5518,O
is,5518,O
plausible,5518,O
to,5518,O
wonder,5518,O
to,5518,O
what,5518,O
extent,5518,O
nicotine-attributed,5518,B-CHEMICAL
effects,5518,O
are,5518,O
really,5518,O
due,5518,O
to,5518,O
the,5518,O
actions,5518,O
of,5518,O
this,5518,O
alkaloid,5518,O
and,5518,O
whether,5518,O
they,5518,O
could,5518,O
be,5518,O
due,5518,O
instead,5518,O
to,5518,O
cotinine,5518,B-CHEMICAL
or,5518,O
to,5518,O
cotinine-nicotine,5518,B-CHEMICAL
interactions,5518,O
within,5518,O
the,5518,O
brain,5518,O
.,5518,O
Arsenic,5519,B-CHEMICAL
upregulates,5519,O
the,5519,O
expression,5519,O
of,5519,O
angiotensin,5519,B-GENE-N
II,5519,I-GENE-N
Type,5519,I-GENE-N
I,5519,I-GENE-N
receptor,5519,I-GENE-N
in,5519,O
mouse,5519,O
aortic,5519,O
endothelial,5519,O
cells,5519,O
.,5519,O
Although,5520,O
chronic,5520,O
arsenic,5520,B-CHEMICAL
exposure,5520,O
is,5520,O
a,5520,O
well-known,5520,O
risk,5520,O
for,5520,O
cardiovascular,5520,O
disease,5520,O
and,5520,O
has,5520,O
a,5520,O
strong,5520,O
correlation,5520,O
with,5520,O
hypertension,5520,O
",",5520,O
the,5520,O
molecular,5520,O
pathogenesis,5520,O
underlying,5520,O
arsenic,5520,B-CHEMICAL
exposure-induced,5520,O
hypertension,5520,O
remains,5520,O
poorly,5520,O
understood,5520,O
.,5520,O
To,5521,O
delineate,5521,O
the,5521,O
pathogenesis,5521,O
",",5521,O
we,5521,O
examined,5521,O
changes,5521,O
in,5521,O
the,5521,O
mRNA,5521,O
levels,5521,O
of,5521,O
2,5521,O
angiotensin,5521,B-GENE-N
II,5521,I-GENE-N
Type,5521,I-GENE-N
I,5521,I-GENE-N
receptor,5521,I-GENE-N
(,5521,O
AT1R,5521,B-GENE-N
),5521,O
subtypes,5521,O
",",5521,O
AT1AR,5521,B-GENE-Y
and,5521,O
AT1BR,5521,B-GENE-Y
",",5521,O
in,5521,O
a,5521,O
mouse,5521,O
aortic,5521,O
endothelial,5521,O
cell,5521,O
line,5521,O
",",5521,O
END-D.,5521,O
Quantitative,5521,O
real-time,5521,O
PCR,5521,O
analysis,5521,O
revealed,5521,O
significant,5521,O
increases,5521,O
in,5521,O
the,5521,O
mRNA,5521,O
levels,5521,O
of,5521,O
2,5521,O
AT1R,5521,B-GENE-N
subtypes,5521,O
",",5521,O
AT1AR,5521,B-GENE-Y
and,5521,O
AT1BR,5521,B-GENE-Y
following,5521,O
sodium,5521,B-CHEMICAL
arsenite,5521,I-CHEMICAL
(,5521,O
SA,5521,O
),5521,O
treatment,5521,O
.,5521,O
Flow,5522,O
cytometry,5522,O
analysis,5522,O
revealed,5522,O
that,5522,O
SA,5522,O
increases,5522,O
the,5522,O
generation,5522,O
of,5522,O
reactive,5522,O
oxygen,5522,B-CHEMICAL
species,5522,O
(,5522,O
ROS,5522,O
),5522,O
in,5522,O
a,5522,O
dose-dependent,5522,O
manner,5522,O
.,5522,O
In,5523,O
addition,5523,O
",",5523,O
western,5523,O
blot,5523,O
analysis,5523,O
revealed,5523,O
that,5523,O
SA,5523,O
enhances,5523,O
the,5523,O
phosphorylations,5523,O
of,5523,O
c-Jun,5523,B-GENE-N
N-terminal,5523,B-CHEMICAL
kinases,5523,I-GENE-N
(,5523,O
JNK,5523,B-GENE-N
),5523,O
and,5523,O
activated,5523,B-GENE-Y
protein,5523,I-GENE-Y
1,5523,I-GENE-Y
(,5523,O
AP-1,5523,B-GENE-Y
),5523,O
.,5523,O
These,5524,O
phosphorylations,5524,O
were,5524,O
inhibited,5524,O
by,5524,O
N-acetylcysteine,5524,B-CHEMICAL
(,5524,O
NAC,5524,B-CHEMICAL
),5524,O
",",5524,O
an,5524,O
anti-oxidant,5524,O
.,5524,O
Finally,5525,O
",",5525,O
SA-induced,5525,O
AT1R,5525,B-GENE-N
expression,5525,O
was,5525,O
found,5525,O
to,5525,O
be,5525,O
prevented,5525,O
both,5525,O
by,5525,O
NAC,5525,O
and,5525,O
specific,5525,O
JNK,5525,B-GENE-N
inhibitor,5525,O
",",5525,O
SP6001325,5525,B-CHEMICAL
",",5525,O
strongly,5525,O
indicating,5525,O
that,5525,O
AT1R,5525,B-GENE-N
upregulation,5525,O
is,5525,O
a,5525,O
result,5525,O
of,5525,O
the,5525,O
ROS-mediated,5525,O
activation,5525,O
of,5525,O
the,5525,O
JNK,5525,B-GENE-N
signaling,5525,O
pathway,5525,O
.,5525,O
Taken,5526,O
together,5526,O
",",5526,O
our,5526,O
results,5526,O
indicate,5526,O
that,5526,O
arsenic,5526,B-CHEMICAL
indeed,5526,O
upregulates,5526,O
the,5526,O
AT1R,5526,B-GENE-N
expression,5526,O
",",5526,O
thus,5526,O
highlighting,5526,O
a,5526,O
role,5526,O
of,5526,O
arsenic-induced,5526,B-CHEMICAL
aberrant,5526,O
AT1R,5526,B-GENE-N
signaling,5526,O
in,5526,O
the,5526,O
pathogenesis,5526,O
of,5526,O
hypertension,5526,O
.,5526,O
Protective,5527,O
effects,5527,O
of,5527,O
selenium,5527,B-CHEMICAL
on,5527,O
oxidative,5527,O
damage,5527,O
and,5527,O
oxidative,5527,O
stress,5527,O
related,5527,O
gene,5527,O
expression,5527,O
in,5527,O
rat,5527,O
liver,5527,O
under,5527,O
chronic,5527,O
poisoning,5527,O
of,5527,O
arsenic,5527,B-CHEMICAL
.,5527,O
Arsenic,5528,B-CHEMICAL
(,5528,O
As,5528,B-CHEMICAL
),5528,O
is,5528,O
a,5528,O
toxic,5528,O
metalloid,5528,O
existing,5528,O
widely,5528,O
in,5528,O
the,5528,O
environment,5528,O
",",5528,O
and,5528,O
chronic,5528,O
exposure,5528,O
to,5528,O
it,5528,O
through,5528,O
contaminated,5528,O
drinking,5528,O
water,5528,O
has,5528,O
become,5528,O
a,5528,O
global,5528,O
problem,5528,O
of,5528,O
public,5528,O
health,5528,O
.,5528,O
The,5529,O
present,5529,O
study,5529,O
focused,5529,O
on,5529,O
the,5529,O
protective,5529,O
effects,5529,O
of,5529,O
selenium,5529,B-CHEMICAL
on,5529,O
oxidative,5529,O
damage,5529,O
of,5529,O
chronic,5529,O
arsenic,5529,B-CHEMICAL
poisoning,5529,O
in,5529,O
rat,5529,O
liver,5529,O
.,5529,O
Rats,5530,O
were,5530,O
divided,5530,O
into,5530,O
four,5530,O
groups,5530,O
at,5530,O
random,5530,O
and,5530,O
given,5530,O
designed,5530,O
treatments,5530,O
for,5530,O
20weeks,5530,O
.,5530,O
The,5531,O
oxidative,5531,O
damage,5531,O
of,5531,O
liver,5531,O
tissue,5531,O
was,5531,O
evaluated,5531,O
by,5531,O
lipid,5531,O
peroxidation,5531,O
and,5531,O
antioxidant,5531,O
enzymes,5531,O
.,5531,O
Oxidative,5532,O
stress,5532,O
related,5532,O
genes,5532,O
were,5532,O
detected,5532,O
to,5532,O
reflect,5532,O
the,5532,O
liver,5532,O
stress,5532,O
state,5532,O
at,5532,O
the,5532,O
molecular,5532,O
level,5532,O
.,5532,O
Compared,5533,O
to,5533,O
the,5533,O
control,5533,O
and,5533,O
Na2SeO3,5533,B-CHEMICAL
groups,5533,O
",",5533,O
the,5533,O
MDA,5533,B-CHEMICAL
content,5533,O
in,5533,O
liver,5533,O
tissue,5533,O
was,5533,O
decreased,5533,O
and,5533,O
the,5533,O
activities,5533,O
of,5533,O
antioxidant,5533,O
enzymes,5533,O
were,5533,O
increased,5533,O
in,5533,O
the,5533,O
Na2SeO3,5533,B-CHEMICAL
intervention,5533,O
group,5533,O
.,5533,O
The,5534,O
mRNA,5534,O
levels,5534,O
of,5534,O
SOD1,5534,B-GENE-Y
",",5534,O
CAT,5534,B-GENE-Y
",",5534,O
GPx,5534,B-GENE-N
and,5534,O
Txnrd1,5534,B-GENE-Y
were,5534,O
increased,5534,O
significantly,5534,O
(,5534,O
P,5534,O
<,5534,O
0.05,5534,O
),5534,O
in,5534,O
the,5534,O
combined,5534,O
Na2SeO3+NaAsO2,5534,B-CHEMICAL
treatment,5534,O
group,5534,O
.,5534,O
The,5535,O
expressions,5535,O
of,5535,O
HSP70,5535,B-GENE-N
and,5535,O
HO-1,5535,B-GENE-Y
were,5535,O
significantly,5535,O
(,5535,O
P,5535,O
<,5535,O
0.05,5535,O
),5535,O
increased,5535,O
in,5535,O
the,5535,O
NaAsO2,5535,B-CHEMICAL
group,5535,O
and,5535,O
reduced,5535,O
in,5535,O
the,5535,O
combined,5535,O
treatment,5535,O
group,5535,O
.,5535,O
The,5536,O
results,5536,O
indicate,5536,O
that,5536,O
long-term,5536,O
intake,5536,O
of,5536,O
NaAsO2,5536,B-CHEMICAL
causes,5536,O
oxidative,5536,O
damage,5536,O
in,5536,O
the,5536,O
rat,5536,O
liver,5536,O
",",5536,O
and,5536,O
Na2SeO3,5536,B-CHEMICAL
protects,5536,O
liver,5536,O
cells,5536,O
by,5536,O
adjusting,5536,O
the,5536,O
expression,5536,O
of,5536,O
oxidative,5536,O
stress,5536,O
related,5536,O
genes,5536,O
to,5536,O
improve,5536,O
the,5536,O
activities,5536,O
of,5536,O
antioxidant,5536,O
enzymes,5536,O
.,5536,O
Aldose,5537,B-GENE-Y
Reductase,5537,I-GENE-Y
Inhibitory,5537,O
Compounds,5537,O
from,5537,O
Xanthium,5537,O
strumarium,5537,O
.,5537,O
As,5538,O
part,5538,O
of,5538,O
our,5538,O
ongoing,5538,O
search,5538,O
for,5538,O
natural,5538,O
sources,5538,O
of,5538,O
therapeutic,5538,O
and,5538,O
preventive,5538,O
agents,5538,O
for,5538,O
diabetic,5538,O
complications,5538,O
",",5538,O
we,5538,O
evaluated,5538,O
the,5538,O
inhibitory,5538,O
effects,5538,O
of,5538,O
components,5538,O
of,5538,O
the,5538,O
fruit,5538,O
of,5538,O
Xanthium,5538,O
strumarium,5538,O
(,5538,O
X.,5538,O
strumarium,5538,O
),5538,O
on,5538,O
aldose,5538,B-CHEMICAL
reductase,5538,I-GENE-Y
(,5538,O
AR,5538,B-GENE-Y
),5538,O
and,5538,O
galactitol,5538,B-CHEMICAL
formation,5538,O
in,5538,O
rat,5538,O
lenses,5538,O
with,5538,O
high,5538,O
levels,5538,O
of,5538,O
glucose,5538,B-CHEMICAL
.,5538,O
To,5539,O
identify,5539,O
the,5539,O
bioactive,5539,O
components,5539,O
of,5539,O
X.,5539,O
strumarium,5539,O
",",5539,O
7,5539,O
caffeoylquinic,5539,B-CHEMICAL
acids,5539,I-CHEMICAL
and,5539,O
3,5539,O
phenolic,5539,B-CHEMICAL
compounds,5539,O
were,5539,O
isolated,5539,O
and,5539,O
their,5539,O
chemical,5539,O
structures,5539,O
were,5539,O
elucidated,5539,O
on,5539,O
the,5539,O
basis,5539,O
of,5539,O
spectroscopic,5539,O
evidence,5539,O
and,5539,O
comparison,5539,O
with,5539,O
published,5539,O
data,5539,O
.,5539,O
The,5540,O
abilities,5540,O
of,5540,O
10,5540,O
X.,5540,O
strumarium-derived,5540,O
components,5540,O
to,5540,O
counteract,5540,O
diabetic,5540,O
complications,5540,O
were,5540,O
investigated,5540,O
by,5540,O
means,5540,O
of,5540,O
inhibitory,5540,O
assays,5540,O
with,5540,O
rat,5540,B-GENE-Y
lens,5540,I-GENE-Y
AR,5540,I-GENE-Y
(,5540,O
rAR,5540,B-GENE-Y
),5540,O
and,5540,O
recombinant,5540,O
human,5540,B-GENE-Y
AR,5540,I-GENE-Y
(,5540,O
rhAR,5540,B-GENE-Y
),5540,O
.,5540,O
From,5541,O
the,5541,O
10,5541,O
isolated,5541,O
compounds,5541,O
",",5541,O
"methyl-3,5-di-O-caffeoylquinate",5541,B-CHEMICAL
showed,5541,O
the,5541,O
most,5541,O
potent,5541,O
inhibition,5541,O
",",5541,O
with,5541,O
IC50,5541,O
values,5541,O
of,5541,O
0.30,5541,O
and,5541,O
0.67,5541,O
M,5541,O
for,5541,O
rAR,5541,B-GENE-Y
and,5541,O
rhAR,5541,B-GENE-Y
",",5541,O
respectively,5541,O
.,5541,O
In,5542,O
the,5542,O
kinetic,5542,O
analyses,5542,O
using,5542,O
Lineweaver-Burk,5542,O
plots,5542,O
of,5542,O
1/velocity,5542,O
and,5542,O
1/substrate,5542,O
",",5542,O
"methyl-3,5-di-O-caffeoylquinate",5542,B-CHEMICAL
showed,5542,O
competitive,5542,O
inhibition,5542,O
of,5542,O
rhAR,5542,B-GENE-Y
.,5542,O
Furthermore,5543,O
",",5543,O
"methyl-3,5-di-O-caffeoylquinate",5543,B-CHEMICAL
inhibited,5543,O
galactitol,5543,B-CHEMICAL
formation,5543,O
in,5543,O
the,5543,O
rat,5543,O
lens,5543,O
and,5543,O
in,5543,O
erythrocytes,5543,O
incubated,5543,O
with,5543,O
a,5543,O
high,5543,O
concentration,5543,O
of,5543,O
glucose,5543,B-CHEMICAL
",",5543,O
indicating,5543,O
that,5543,O
this,5543,O
compound,5543,O
may,5543,O
be,5543,O
effective,5543,O
in,5543,O
preventing,5543,O
diabetic,5543,O
complications,5543,O
.,5543,O
Synthesis,5544,O
",",5544,O
cytotoxicity,5544,O
and,5544,O
QSAR,5544,O
study,5544,O
of,5544,O
"N-tosyl-1,2,3,4-tetrahydroisoquinoline",5544,B-CHEMICAL
derivatives,5544,O
.,5544,O
"1-Substituted-N-tosyl-1,2,3,4-tetrahydroisoquinoline",5545,B-CHEMICAL
analogs,5545,O
(,5545,O
4a-4l,5545,O
),5545,O
were,5545,O
synthesized,5545,O
using,5545,O
the,5545,O
modified,5545,O
Pictet-Spengler,5545,O
reaction,5545,O
and,5545,O
evaluated,5545,O
for,5545,O
cytotoxicity,5545,O
.,5545,O
All,5546,O
tetrahydroisoquinolines,5546,B-CHEMICAL
displayed,5546,O
cytotoxicity,5546,O
against,5546,O
MOLT-3,5546,O
cell,5546,O
lines,5546,O
",",5546,O
except,5546,O
for,5546,O
p-methoxy,5546,B-CHEMICAL
analog,5546,O
4d,5546,O
.,5546,O
Interestingly,5547,O
",",5547,O
the,5547,O
o-hydroxy,5547,B-CHEMICAL
derivative,5547,O
4k,5547,O
was,5547,O
shown,5547,O
to,5547,O
be,5547,O
the,5547,O
most,5547,O
potent,5547,O
cytotoxic,5547,O
against,5547,O
HuCCA-1,5547,O
",",5547,O
A-549,5547,O
and,5547,O
MOLT-3,5547,O
cell,5547,O
lines,5547,O
.,5547,O
The,5548,O
lowest,5548,O
IC50,5548,O
value,5548,O
of,5548,O
1.23,5548,O
M,5548,O
was,5548,O
observed,5548,O
for,5548,O
MOLT-3,5548,O
cells,5548,O
.,5548,O
Trimethoxy,5549,B-CHEMICAL
analog,5549,O
4f,5549,O
exerted,5549,O
the,5549,O
most,5549,O
potent,5549,O
activity,5549,O
against,5549,O
HepG2,5549,O
with,5549,O
an,5549,O
IC50,5549,O
of,5549,O
22.70,5549,O
M,5549,O
",",5549,O
which,5549,O
is,5549,O
lower,5549,O
than,5549,O
the,5549,O
reference,5549,O
drug,5549,O
",",5549,O
etoposide,5549,O
.,5549,O
QSAR,5550,O
studies,5550,O
showed,5550,O
that,5550,O
total,5550,O
symmetry,5550,O
index,5550,O
(,5550,O
Gu,5550,O
),5550,O
",",5550,O
3D-MoRSE,5550,O
(,5550,O
Mor31v,5550,O
and,5550,O
Mor32u,5550,O
),5550,O
and,5550,O
3D,5550,O
Petitjean,5550,O
index,5550,O
(,5550,O
PJI3,5550,O
),5550,O
were,5550,O
the,5550,O
most,5550,O
important,5550,O
descriptors,5550,O
accounting,5550,O
for,5550,O
the,5550,O
observed,5550,O
cytotoxicities,5550,O
.,5550,O
The,5551,O
most,5551,O
potent,5551,O
cytotoxic,5551,O
compound,5551,O
(,5551,O
4k,5551,O
),5551,O
against,5551,O
MOLT-3,5551,O
had,5551,O
the,5551,O
highest,5551,O
Gu,5551,O
value,5551,O
",",5551,O
correspondingly,5551,O
the,5551,O
inactive,5551,O
p-methoxy,5551,B-CHEMICAL
analog,5551,O
(,5551,O
4d,5551,O
),5551,O
had,5551,O
the,5551,O
lowest,5551,O
Gu,5551,O
value,5551,O
.,5551,O
On,5552,O
the,5552,O
other,5552,O
hand,5552,O
",",5552,O
the,5552,O
highest,5552,O
molecular,5552,O
mass,5552,O
compound,5552,O
(,5552,O
4f,5552,O
),5552,O
was,5552,O
shown,5552,O
to,5552,O
be,5552,O
the,5552,O
most,5552,O
potent,5552,O
cytotoxic,5552,O
against,5552,O
HepG2,5552,O
cells,5552,O
.,5552,O
The,5553,O
studies,5553,O
disclose,5553,O
that,5553,O
tetrahydroisoquinolines,5553,B-CHEMICAL
4f,5553,O
and,5553,O
4k,5553,O
are,5553,O
potentially,5553,O
interesting,5553,O
lead,5553,O
pharmacophores,5553,O
that,5553,O
should,5553,O
be,5553,O
further,5553,O
explored,5553,O
.,5553,O
The,5554,O
QSAR,5554,O
models,5554,O
provided,5554,O
insights,5554,O
into,5554,O
the,5554,O
physicochemical,5554,O
properties,5554,O
of,5554,O
the,5554,O
investigated,5554,O
compounds,5554,O
.,5554,O
Hydrothermal,5555,O
Growth,5555,O
of,5555,O
TiO2,5555,B-CHEMICAL
Nanorod,5555,O
Arrays,5555,O
and,5555,O
In,5555,O
Situ,5555,O
Conversion,5555,O
to,5555,O
Nanotube,5555,O
Arrays,5555,O
for,5555,O
Highly,5555,O
Efficient,5555,O
Quantum,5555,O
Dot-Sensitized,5555,O
Solar,5555,O
Cells,5555,O
.,5555,O
TiO2,5556,B-CHEMICAL
nanorod,5556,O
(,5556,O
NR,5556,O
),5556,O
and,5556,O
nanotube,5556,O
(,5556,O
NT,5556,O
),5556,O
arrays,5556,O
grown,5556,O
on,5556,O
transparent,5556,O
conductive,5556,O
substrates,5556,O
are,5556,O
attractive,5556,O
electrode,5556,O
for,5556,O
solar,5556,O
cells,5556,O
.,5556,O
In,5557,O
this,5557,O
paper,5557,O
",",5557,O
TiO2,5557,B-CHEMICAL
NR,5557,O
arrays,5557,O
are,5557,O
hydrothermally,5557,O
grown,5557,O
on,5557,O
FTO,5557,B-CHEMICAL
substrate,5557,O
",",5557,O
and,5557,O
are,5557,O
in,5557,O
situ,5557,O
converted,5557,O
into,5557,O
NT,5557,O
arrays,5557,O
by,5557,O
hydrothermally,5557,O
etching,5557,O
.,5557,O
The,5558,O
TiO2,5558,B-CHEMICAL
NR,5558,O
arrays,5558,O
are,5558,O
reported,5558,O
as,5558,O
single,5558,O
crystalline,5558,O
",",5558,O
but,5558,O
the,5558,O
TiO2,5558,B-CHEMICAL
NR,5558,O
arrays,5558,O
are,5558,O
demonstrated,5558,O
to,5558,O
be,5558,O
polycrystalline,5558,O
with,5558,O
a,5558,O
bundle,5558,O
of,5558,O
2-5,5558,O
nm,5558,O
single,5558,O
crystalline,5558,O
nanocolumns,5558,O
grown,5558,O
along,5558,O
[,5558,O
001,5558,O
],5558,O
throughout,5558,O
the,5558,O
whole,5558,O
NR,5558,O
from,5558,O
bottom,5558,O
to,5558,O
top,5558,O
.,5558,O
TiO2,5559,B-CHEMICAL
NRs,5559,O
can,5559,O
be,5559,O
converted,5559,O
to,5559,O
NTs,5559,O
by,5559,O
hydrothermal,5559,O
selective,5559,O
etching,5559,O
of,5559,O
the,5559,O
(,5559,O
001,5559,O
),5559,O
core,5559,O
and,5559,O
remaining,5559,O
the,5559,O
inert,5559,O
sidewall,5559,O
of,5559,O
(,5559,O
110,5559,O
),5559,O
face,5559,O
.,5559,O
A,5560,O
growth,5560,O
mechanism,5560,O
of,5560,O
the,5560,O
NR,5560,O
and,5560,O
NT,5560,O
arrays,5560,O
is,5560,O
proposed,5560,O
.,5560,O
Quantum,5561,O
dot-sensitized,5561,O
solar,5561,O
cells,5561,O
(,5561,O
QDSCs,5561,O
),5561,O
are,5561,O
fabricated,5561,O
by,5561,O
coating,5561,O
CdSe,5561,B-CHEMICAL
QDs,5561,O
on,5561,O
to,5561,O
the,5561,O
TiO2,5561,B-CHEMICAL
arrays,5561,O
.,5561,O
After,5562,O
conversion,5562,O
from,5562,O
NRs,5562,O
to,5562,O
NTs,5562,O
",",5562,O
more,5562,O
QDs,5562,O
can,5562,O
be,5562,O
filled,5562,O
in,5562,O
the,5562,O
NTs,5562,O
and,5562,O
the,5562,O
energy,5562,O
conversion,5562,O
efficiency,5562,O
of,5562,O
the,5562,O
QDSCs,5562,O
almost,5562,O
double,5562,O
.,5562,O
Protective,5563,O
effect,5563,O
of,5563,O
ethyl,5563,B-CHEMICAL
acetate,5563,I-CHEMICAL
fraction,5563,O
of,5563,O
Acacia,5563,O
ferruginea,5563,O
DC,5563,O
.,5563,O
against,5564,O
ethanol-induced,5564,B-CHEMICAL
gastric,5564,O
ulcer,5564,O
in,5564,O
rats,5564,O
.,5564,O
ETHNOPHARMACOLOGICAL,5565,O
RELEVANCE,5565,O
:,5565,O
In,5565,O
traditional,5565,O
systems,5565,O
of,5565,O
medicine,5565,O
",",5565,O
stem,5565,O
bark,5565,O
of,5565,O
Acacia,5565,O
ferruginea,5565,O
DC,5565,O
.,5565,O
is,5566,O
used,5566,O
for,5566,O
the,5566,O
treatment,5566,O
of,5566,O
itching,5566,O
",",5566,O
leucoderma,5566,O
",",5566,O
ulcers,5566,O
",",5566,O
stomatitis,5566,O
and,5566,O
diseases,5566,O
of,5566,O
the,5566,O
blood,5566,O
.,5566,O
In,5567,O
the,5567,O
present,5567,O
study,5567,O
",",5567,O
we,5567,O
determined,5567,O
antioxidant,5567,O
and,5567,O
anti-ulcerogenic,5567,O
activities,5567,O
of,5567,O
Acacia,5567,O
ferruginea,5567,O
stem,5567,O
bark,5567,O
.,5567,O
MATERIALS,5568,O
AND,5568,O
METHODS,5568,O
:,5568,O
Acetone,5568,B-CHEMICAL
extract,5568,O
and,5568,O
its,5568,O
sub-fractions,5568,O
of,5568,O
Acacia,5568,O
ferruginea,5568,O
stem,5568,O
bark,5568,O
were,5568,O
subjected,5568,O
to,5568,O
assess,5568,O
their,5568,O
antioxidant,5568,O
potential,5568,O
using,5568,O
various,5568,O
in,5568,O
vitro,5568,O
systems,5568,O
such,5568,O
as,5568,O
DPPH,5568,B-CHEMICAL
(,5568,I-CHEMICAL
,5568,I-CHEMICAL
),5568,I-CHEMICAL
",",5568,O
ABTS,5568,B-CHEMICAL
(,5568,I-CHEMICAL
+,5568,I-CHEMICAL
),5568,I-CHEMICAL
scavenging,5568,O
",",5568,O
FRAP,5568,O
and,5568,O
phosphomolybdenum,5568,B-CHEMICAL
reduction,5568,O
activities,5568,O
.,5568,O
Based,5569,O
on,5569,O
the,5569,O
antioxidant,5569,O
potential,5569,O
",",5569,O
the,5569,O
ethyl,5569,O
acetate,5569,O
fraction,5569,O
was,5569,O
used,5569,O
to,5569,O
evaluate,5569,O
the,5569,O
protective,5569,O
effect,5569,O
of,5569,O
ethanol-induced,5569,B-CHEMICAL
gastric,5569,O
damage,5569,O
in,5569,O
rat,5569,O
model,5569,O
.,5569,O
Enzyme,5570,O
activities,5570,O
such,5570,O
as,5570,O
superoxide,5570,B-GENE-N
dismutase,5570,I-GENE-N
",",5570,O
glutathione,5570,B-CHEMICAL
",",5570,O
catalase,5570,B-GENE-Y
and,5570,O
lipid,5570,O
peroxidation,5570,O
were,5570,O
also,5570,O
determined,5570,O
in,5570,O
the,5570,O
stomach,5570,O
tissues,5570,O
.,5570,O
RESULTS,5571,O
:,5571,O
Ethyl,5571,B-CHEMICAL
acetate,5571,I-CHEMICAL
fraction,5571,O
(,5571,O
AFE,5571,O
),5571,O
of,5571,O
Acacia,5571,O
ferruginea,5571,O
stem,5571,O
bark,5571,O
registered,5571,O
higher,5571,O
antioxidant,5571,O
and,5571,O
free,5571,O
radical,5571,O
scavenging,5571,O
activities,5571,O
than,5571,O
the,5571,O
crude,5571,O
acetone,5571,B-CHEMICAL
extract,5571,O
and,5571,O
other,5571,O
fractions,5571,O
.,5571,O
In,5572,O
addition,5572,O
",",5572,O
AFE,5572,O
exhibited,5572,O
that,5572,O
the,5572,O
IC50,5572,O
values,5572,O
of,5572,O
DPPH,5572,B-CHEMICAL
(,5572,O
2.5g/ml,5572,O
),5572,O
and,5572,O
ABTS,5572,B-CHEMICAL
(,5572,O
1.8g/ml,5572,O
),5572,O
were,5572,O
lower,5572,O
when,5572,O
compared,5572,O
to,5572,O
the,5572,O
standard,5572,O
quercetin,5572,B-CHEMICAL
(,5572,O
12.4g/ml,5572,O
and,5572,O
4.7g/ml,5572,O
",",5572,O
respectively,5572,O
),5572,O
.,5572,O
In,5573,O
ethanol,5573,B-CHEMICAL
induced,5573,O
gastric,5573,O
ulcer,5573,O
",",5573,O
administration,5573,O
of,5573,O
AFE,5573,O
at,5573,O
doses,5573,O
of,5573,O
10mg/kg,5573,O
",",5573,O
50mg/kg,5573,O
and,5573,O
100mg/kg,5573,O
body,5573,O
weight,5573,O
prior,5573,O
to,5573,O
ethanol,5573,B-CHEMICAL
ingestion,5573,O
significantly,5573,O
protected,5573,O
the,5573,O
stomach,5573,O
ulceration,5573,O
.,5573,O
Consequently,5574,O
significant,5574,O
changes,5574,O
were,5574,O
observed,5574,O
in,5574,O
enzyme,5574,O
activities,5574,O
such,5574,O
as,5574,O
SOD,5574,B-GENE-N
",",5574,O
CAT,5574,B-GENE-Y
",",5574,O
GSH,5574,B-CHEMICAL
and,5574,O
LPO,5574,O
in,5574,O
the,5574,O
stomach,5574,O
tissues,5574,O
when,5574,O
compared,5574,O
with,5574,O
ethanol,5574,B-CHEMICAL
control,5574,O
group,5574,O
.,5574,O
CONCLUSION,5575,O
:,5575,O
It,5575,O
is,5575,O
concluded,5575,O
that,5575,O
the,5575,O
ethyl,5575,B-CHEMICAL
acetate,5575,I-CHEMICAL
fraction,5575,O
of,5575,O
Acacia,5575,O
ferruginea,5575,O
stem,5575,O
bark,5575,O
possessed,5575,O
higher,5575,O
antioxidant,5575,O
and,5575,O
anti-ulcerogenic,5575,O
activities,5575,O
.,5575,O
Based,5576,O
on,5576,O
the,5576,O
results,5576,O
we,5576,O
suggest,5576,O
that,5576,O
Acacia,5576,O
ferruginea,5576,O
stem,5576,O
bark,5576,O
has,5576,O
potential,5576,O
to,5576,O
provide,5576,O
a,5576,O
therapeutic,5576,O
approach,5576,O
to,5576,O
ethanol,5576,B-CHEMICAL
mediated,5576,O
ulcer,5576,O
as,5576,O
an,5576,O
effective,5576,O
anti-ulcer,5576,O
agent,5576,O
.,5576,O
MAPKAPK2/3,5577,B-GENE-N
Regulate,5577,O
SERCA2a,5577,B-GENE-Y
Expression,5577,O
and,5577,O
Fiber,5577,O
Type,5577,O
Composition,5577,O
to,5577,O
Modulate,5577,O
Skeletal,5577,O
Muscle,5577,O
and,5577,O
Cardiomyocyte,5577,O
Function,5577,O
.,5577,O
The,5578,O
MAPK-activated,5578,B-GENE-N
protein,5578,I-GENE-N
kinases,5578,I-GENE-N
2,5578,I-GENE-N
and,5578,I-GENE-N
3,5578,I-GENE-N
(,5578,O
MAPKAPK2/3,5578,B-GENE-N
",",5578,O
MK2/3,5578,B-GENE-N
),5578,O
represent,5578,O
protein,5578,B-GENE-N
kinases,5578,I-GENE-N
downstream,5578,O
of,5578,O
the,5578,O
p38,5578,B-GENE-N
mitogen-activated,5578,B-GENE-N
protein,5578,I-GENE-N
kinase,5578,I-GENE-N
(,5578,O
MAPK,5578,B-GENE-N
),5578,O
.,5578,O
Using,5579,O
MK2/3,5579,B-GENE-N
double,5579,O
knockout,5579,O
mice,5579,O
(,5579,O
MK2/3,5579,B-GENE-N
(,5579,O
-/-,5579,O
),5579,O
),5579,O
",",5579,O
we,5579,O
analyzed,5579,O
the,5579,O
role,5579,O
of,5579,O
MK2/3,5579,B-GENE-N
in,5579,O
cross-striated,5579,O
muscle,5579,O
by,5579,O
transcriptome,5579,O
and,5579,O
proteome,5579,O
analyses,5579,O
",",5579,O
and,5579,O
by,5579,O
histology,5579,O
.,5579,O
We,5580,O
demonstrated,5580,O
enhanced,5580,O
expression,5580,O
of,5580,O
the,5580,O
slow,5580,O
oxidative,5580,O
skeletal,5580,O
muscle,5580,O
myofiber,5580,O
gene,5580,O
program,5580,O
",",5580,O
including,5580,O
the,5580,O
PPAR,5580,B-GENE-Y
coactivator,5580,I-GENE-Y
1,5580,I-GENE-Y
(,5580,O
PGC-1,5580,B-GENE-Y
),5580,O
.,5580,O
Using,5581,O
reporter,5581,O
gene,5581,O
and,5581,O
electrophoretic,5581,O
gel,5581,O
mobility,5581,O
shift,5581,O
assays,5581,O
we,5581,O
demonstrated,5581,O
that,5581,O
MK2,5581,B-GENE-Y
catalytic,5581,O
activity,5581,O
directly,5581,O
regulated,5581,O
the,5581,O
promoters,5581,O
of,5581,O
the,5581,O
fast,5581,O
fiber-specific,5581,O
myosin,5581,B-GENE-N
heavy,5581,I-GENE-N
chain,5581,I-GENE-N
IId/x,5581,I-GENE-N
and,5581,O
the,5581,O
slow,5581,O
fiber-specific,5581,O
sarco/endoplasmic,5581,B-GENE-Y
reticulum,5581,I-GENE-Y
Ca,5581,B-CHEMICAL
(,5581,I-CHEMICAL
2+,5581,I-CHEMICAL
),5581,I-CHEMICAL
-ATPase,5581,I-GENE-Y
(,5581,I-GENE-Y
SERCA,5581,I-GENE-Y
),5581,I-GENE-Y
2,5581,I-GENE-Y
gene,5581,O
.,5581,O
Elevated,5582,O
SERCA2a,5582,B-GENE-Y
gene,5582,O
expression,5582,O
caused,5582,O
by,5582,O
a,5582,O
decreased,5582,O
transcription,5582,O
factor,5582,O
Egr-1,5582,B-GENE-Y
to,5582,O
Sp1,5582,B-GENE-Y
ratio,5582,O
was,5582,O
associated,5582,O
with,5582,O
accelerated,5582,O
relaxation,5582,O
and,5582,O
enhanced,5582,O
contractility,5582,O
in,5582,O
MK2/3,5582,B-GENE-N
(,5582,O
-/-,5582,O
),5582,O
cardiomyocytes,5582,O
",",5582,O
concomitant,5582,O
with,5582,O
improved,5582,O
force,5582,O
parameters,5582,O
in,5582,O
MK2/3,5582,B-GENE-N
(,5582,O
-/-,5582,O
),5582,O
soleus,5582,O
muscle,5582,O
.,5582,O
These,5583,O
results,5583,O
link,5583,O
MK2/3,5583,B-GENE-N
to,5583,O
the,5583,O
regulation,5583,O
of,5583,O
calcium,5583,B-CHEMICAL
dynamics,5583,O
and,5583,O
identify,5583,O
enzymatic,5583,O
activity,5583,O
of,5583,O
MK2/3,5583,B-GENE-N
as,5583,O
a,5583,O
critical,5583,O
factor,5583,O
for,5583,O
modulating,5583,O
cross-striated,5583,O
muscle,5583,O
function,5583,O
by,5583,O
generating,5583,O
a,5583,O
unique,5583,O
muscle,5583,O
phenotype,5583,O
exhibiting,5583,O
both,5583,O
",",5583,O
reduced,5583,O
fatigability,5583,O
and,5583,O
enhanced,5583,O
force,5583,O
in,5583,O
MK2/3,5583,B-GENE-N
(,5583,O
-/-,5583,O
),5583,O
mice,5583,O
.,5583,O
Hence,5584,O
",",5584,O
the,5584,O
p38-MK2/3,5584,B-GENE-N
axis,5584,O
may,5584,O
represent,5584,O
a,5584,O
novel,5584,O
target,5584,O
for,5584,O
the,5584,O
design,5584,O
of,5584,O
therapeutic,5584,O
strategies,5584,O
for,5584,O
diseases,5584,O
related,5584,O
to,5584,O
fiber,5584,O
type,5584,O
changes,5584,O
or,5584,O
impaired,5584,O
SERCA2,5584,B-GENE-Y
function,5584,O
.,5584,O
Human,5585,B-GENE-Y
UGT2B10,5585,I-GENE-Y
in,5585,O
Drug,5585,O
N-glucuronidations,5585,O
:,5585,O
Substrate,5585,O
Screening,5585,O
and,5585,O
Comparison,5585,O
with,5585,O
UGT1A3,5585,B-GENE-Y
and,5585,O
UGT1A4,5585,B-GENE-Y
.,5585,O
Recent,5586,O
observations,5586,O
revealed,5586,O
that,5586,O
human,5586,B-GENE-Y
UDP-glucuronosyltransferase,5586,I-GENE-Y
(,5586,I-GENE-Y
UGT,5586,I-GENE-Y
),5586,I-GENE-Y
2B10,5586,I-GENE-Y
catalyzes,5586,O
N-glucuronidation,5586,O
of,5586,O
amine-containing,5586,B-CHEMICAL
compounds,5586,O
.,5586,O
Knowledge,5587,O
of,5587,O
the,5587,O
substrate,5587,O
specificity,5587,O
and,5587,O
clinical,5587,O
significance,5587,O
of,5587,O
UGT2B10,5587,B-GENE-Y
is,5587,O
still,5587,O
limited,5587,O
.,5587,O
The,5588,O
purpose,5588,O
of,5588,O
this,5588,O
study,5588,O
was,5588,O
to,5588,O
expand,5588,O
the,5588,O
knowledge,5588,O
of,5588,O
UGT2B10,5588,B-GENE-Y
substrates,5588,O
and,5588,O
to,5588,O
evaluate,5588,O
its,5588,O
significance,5588,O
in,5588,O
drug,5588,O
clearance,5588,O
.,5588,O
Using,5589,O
recombinant,5589,O
UGT2B10,5589,B-GENE-Y
",",5589,O
we,5589,O
found,5589,O
that,5589,O
it,5589,O
catalyzes,5589,O
the,5589,O
N-glucuronidation,5589,O
of,5589,O
amitriptyline,5589,B-CHEMICAL
",",5589,O
imipramine,5589,B-CHEMICAL
",",5589,O
ketotifen,5589,B-CHEMICAL
",",5589,O
pizotifen,5589,B-CHEMICAL
",",5589,O
olanzapine,5589,B-CHEMICAL
",",5589,O
diphenhydramine,5589,B-CHEMICAL
",",5589,O
tamoxifen,5589,B-CHEMICAL
",",5589,O
ketoconazole,5589,B-CHEMICAL
and,5589,O
midazolam,5589,B-CHEMICAL
.,5589,O
These,5590,O
are,5590,O
drugs,5590,O
that,5590,O
were,5590,O
previously,5590,O
reported,5590,O
to,5590,O
be,5590,O
substrates,5590,O
for,5590,O
UGT1A4,5590,B-GENE-Y
or,5590,O
UGT1A3,5590,B-GENE-Y
and,5590,O
that,5590,O
contain,5590,O
in,5590,O
their,5590,O
structure,5590,O
either,5590,O
tertiary,5590,B-CHEMICAL
aliphatic,5590,I-CHEMICAL
amines,5590,I-CHEMICAL
",",5590,O
cyclic,5590,B-CHEMICAL
amines,5590,I-CHEMICAL
",",5590,O
or,5590,O
an,5590,O
imidazole,5590,B-CHEMICAL
group,5590,O
.,5590,O
UGT2B10,5591,B-GENE-Y
was,5591,O
inactive,5591,O
in,5591,O
the,5591,O
glucuronidation,5591,O
of,5591,O
desipramine,5591,B-CHEMICAL
",",5591,O
nortriptyline,5591,B-CHEMICAL
",",5591,O
carbamazepine,5591,B-CHEMICAL
and,5591,O
afloqualone,5591,B-CHEMICAL
.,5591,O
This,5592,O
group,5592,O
of,5592,O
drugs,5592,O
contains,5592,O
secondary,5592,B-CHEMICAL
or,5592,I-CHEMICAL
primary,5592,I-CHEMICAL
amines,5592,I-CHEMICAL
",",5592,O
and,5592,O
these,5592,O
results,5592,O
suggest,5592,O
that,5592,O
UGT2B10,5592,B-GENE-Y
preferably,5592,O
conjugates,5592,O
tertiary,5592,B-CHEMICAL
amines,5592,I-CHEMICAL
.,5592,O
This,5593,O
preference,5593,O
is,5593,O
partial,5593,O
because,5593,O
UGT2B10,5593,B-GENE-Y
did,5593,O
not,5593,O
conjugate,5593,O
the,5593,O
tertiary,5593,B-CHEMICAL
cyclic,5593,I-CHEMICAL
amine,5593,I-CHEMICAL
in,5593,O
trifluoperazine,5593,B-CHEMICAL
.,5593,O
Kinetic,5594,O
analyses,5594,O
revealed,5594,O
that,5594,O
the,5594,O
affinity,5594,O
and,5594,O
clearance,5594,O
of,5594,O
UGT2B10,5594,B-GENE-Y
for,5594,O
amitriptyline,5594,B-CHEMICAL
",",5594,O
imipramine,5594,B-CHEMICAL
",",5594,O
and,5594,O
diphenhydramine,5594,B-CHEMICAL
are,5594,O
significantly,5594,O
higher,5594,O
than,5594,O
the,5594,O
corresponding,5594,O
values,5594,O
of,5594,O
UGT1A4,5594,B-GENE-Y
and,5594,O
UGT1A3,5594,B-GENE-Y
",",5594,O
although,5594,O
the,5594,O
Vmax,5594,O
values,5594,O
of,5594,O
UGT1A4,5594,B-GENE-Y
toward,5594,O
these,5594,O
drugs,5594,O
are,5594,O
considerably,5594,O
higher,5594,O
.,5594,O
These,5595,O
findings,5595,O
suggest,5595,O
that,5595,O
UGT2B10,5595,B-GENE-Y
plays,5595,O
a,5595,O
major,5595,O
role,5595,O
in,5595,O
the,5595,O
N-glucuronidation,5595,O
of,5595,O
these,5595,O
drugs,5595,O
at,5595,O
therapeutic,5595,O
concentrations,5595,O
.,5595,O
These,5596,O
results,5596,O
are,5596,O
also,5596,O
supported,5596,O
by,5596,O
inhibition,5596,O
studies,5596,O
with,5596,O
nicotine,5596,B-CHEMICAL
and,5596,O
hecogenin,5596,B-CHEMICAL
.,5596,O
In,5597,O
conclusion,5597,O
",",5597,O
this,5597,O
study,5597,O
expands,5597,O
the,5597,O
understanding,5597,O
of,5597,O
the,5597,O
substrate,5597,O
specificity,5597,O
of,5597,O
UGT2B10,5597,B-GENE-Y
",",5597,O
highlighting,5597,O
its,5597,O
preference,5597,O
for,5597,O
tertiary,5597,B-CHEMICAL
amines,5597,I-CHEMICAL
with,5597,O
higher,5597,O
affinities,5597,O
and,5597,O
clearance,5597,O
values,5597,O
than,5597,O
those,5597,O
of,5597,O
UGT1A4,5597,B-GENE-Y
and,5597,O
UGT1A3,5597,B-GENE-Y
.,5597,O
Molecular,5598,O
Mechanisms,5598,O
of,5598,O
the,5598,O
antitumor,5598,O
activity,5598,O
of,5598,O
SB225002,5598,B-CHEMICAL
:,5598,O
A,5598,O
novel,5598,O
microtubule,5598,O
inhibitor,5598,O
.,5598,O
SB225002,5599,B-CHEMICAL
(,5599,O
SB,5599,O
),5599,O
is,5599,O
an,5599,O
IL-8,5599,B-GENE-Y
receptor,5599,I-GENE-Y
B,5599,I-GENE-Y
(,5599,O
IL-8RB,5599,B-GENE-Y
),5599,O
antagonist,5599,O
that,5599,O
has,5599,O
previously,5599,O
been,5599,O
shown,5599,O
to,5599,O
inhibit,5599,O
IL-8-based,5599,B-GENE-Y
cancer,5599,O
cell,5599,O
invasion,5599,O
",",5599,O
and,5599,O
to,5599,O
possess,5599,O
in,5599,O
vivo,5599,O
anti-inflammatory,5599,O
and,5599,O
anti-nociceptive,5599,O
effects,5599,O
.,5599,O
The,5600,O
present,5600,O
study,5600,O
presented,5600,O
an,5600,O
evidence,5600,O
for,5600,O
the,5600,O
cell,5600,O
cycle-targeting,5600,O
activity,5600,O
of,5600,O
SB,5600,O
in,5600,O
a,5600,O
panel,5600,O
of,5600,O
p53-mutant,5600,B-GENE-Y
human,5600,O
cancer,5600,O
cell,5600,O
lines,5600,O
of,5600,O
different,5600,O
origin,5600,O
",",5600,O
and,5600,O
investigated,5600,O
the,5600,O
underlying,5600,O
molecular,5600,O
mechanisms,5600,O
.,5600,O
A,5601,O
combination,5601,O
of,5601,O
cell,5601,O
cycle,5601,O
analysis,5601,O
",",5601,O
immunocytometry,5601,O
",",5601,O
immunoblotting,5601,O
",",5601,O
and,5601,O
RNA,5601,O
interference,5601,O
revealed,5601,O
that,5601,O
SB,5601,O
induced,5601,O
a,5601,O
BubR1-dependent,5601,B-GENE-Y
mitotic,5601,O
arrest,5601,O
.,5601,O
Mechanistically,5602,O
",",5602,O
SB,5602,O
was,5602,O
shown,5602,O
to,5602,O
possess,5602,O
a,5602,O
microtubule,5602,O
destabilizing,5602,O
activity,5602,O
evidenced,5602,O
by,5602,O
hyperphosphorylation,5602,O
of,5602,O
Bcl2,5602,B-GENE-Y
and,5602,O
BclxL,5602,B-GENE-Y
",",5602,O
suppression,5602,O
of,5602,O
microtubule,5602,O
polymerization,5602,O
and,5602,O
induction,5602,O
of,5602,O
a,5602,O
prometaphase,5602,O
arrest,5602,O
.,5602,O
Molecular,5603,O
docking,5603,O
studies,5603,O
suggested,5603,O
that,5603,O
SB,5603,O
has,5603,O
a,5603,O
good,5603,O
affinity,5603,O
towards,5603,O
vinblastine-binding,5603,B-CHEMICAL
site,5603,O
on,5603,O
-tubulin,5603,B-GENE-Y
subunit,5603,O
.,5603,O
Of,5604,O
note,5604,O
",",5604,O
SB265610,5604,B-CHEMICAL
which,5604,O
is,5604,O
a,5604,O
close,5604,O
structural,5604,O
analogue,5604,O
of,5604,O
SB225002,5604,B-CHEMICAL
with,5604,O
a,5604,O
potent,5604,O
IL-8RB,5604,B-GENE-Y
antagonistic,5604,O
activity,5604,O
did,5604,O
not,5604,O
exhibit,5604,O
a,5604,O
similar,5604,O
antimitotic,5604,O
activity,5604,O
.,5604,O
Importantly,5605,O
",",5605,O
in,5605,O
P-glycoprotein,5605,B-GENE-Y
overexpressing,5605,O
NCI/Adr-Res,5605,O
cells,5605,O
the,5605,O
antitumor,5605,O
activity,5605,O
of,5605,O
SB,5605,O
was,5605,O
unaffected,5605,O
by,5605,O
multidrug,5605,O
resistance,5605,O
.,5605,O
Interestingly,5606,O
",",5606,O
the,5606,O
mechanisms,5606,O
of,5606,O
SB-induced,5606,O
cell,5606,O
death,5606,O
were,5606,O
cell-line,5606,O
dependent,5606,O
",",5606,O
where,5606,O
in,5606,O
invasive,5606,O
hepatocellular,5606,O
carcinoma,5606,O
HLE,5606,O
cells,5606,O
the,5606,O
significant,5606,O
contribution,5606,O
of,5606,O
BAK-dependent,5606,B-GENE-Y
mitochondrial,5606,O
apoptosis,5606,O
was,5606,O
demonstrated,5606,O
.,5606,O
Conversely,5607,O
",",5607,O
SB,5607,O
activated,5607,O
p38,5607,B-GENE-N
MAPK,5607,B-GENE-N
signaling,5607,O
in,5607,O
colorectal,5607,O
adenocarcinoma,5607,O
cells,5607,O
SW480,5607,O
",",5607,O
and,5607,O
pharmacologic,5607,O
inhibition,5607,O
of,5607,O
p38,5607,B-GENE-N
MAPK,5607,B-GENE-N
activity,5607,O
revealed,5607,O
its,5607,O
key,5607,O
role,5607,O
in,5607,O
mediating,5607,O
SB-induced,5607,O
caspase-independent,5607,B-GENE-N
cell,5607,O
death,5607,O
.,5607,O
In,5608,O
summary,5608,O
",",5608,O
the,5608,O
present,5608,O
study,5608,O
introduced,5608,O
SB,5608,O
as,5608,O
a,5608,O
promising,5608,O
antitumor,5608,O
agent,5608,O
which,5608,O
has,5608,O
the,5608,O
potential,5608,O
to,5608,O
exert,5608,O
its,5608,O
activity,5608,O
through,5608,O
dual,5608,O
mechanisms,5608,O
involving,5608,O
microtubules,5608,O
targeting,5608,O
and,5608,O
interference,5608,O
with,5608,O
IL-8-drivin,5608,B-GENE-Y
cancer,5608,O
progression,5608,O
.,5608,O
Dimerized,5609,O
Glycosaminoglycan,5609,O
Chains,5609,O
Increase,5609,O
FGF,5609,B-GENE-N
Signaling,5609,O
during,5609,O
Zebrafish,5609,O
Development,5609,O
.,5609,O
Proteoglycans,5610,O
(,5610,O
PGs,5610,O
),5610,O
modulate,5610,O
numerous,5610,O
signaling,5610,O
pathways,5610,O
during,5610,O
development,5610,O
through,5610,O
binding,5610,O
of,5610,O
their,5610,O
glycosaminoglycan,5610,O
(,5610,O
GAG,5610,O
),5610,O
side,5610,O
chains,5610,O
to,5610,O
various,5610,O
signaling,5610,O
molecules,5610,O
",",5610,O
including,5610,O
fibroblast,5610,B-GENE-N
growth,5610,I-GENE-N
factors,5610,I-GENE-N
(,5610,O
FGFs,5610,B-GENE-N
),5610,O
.,5610,O
A,5611,O
majority,5611,O
of,5611,O
PGs,5611,O
possess,5611,O
two,5611,O
or,5611,O
more,5611,O
GAG,5611,O
side,5611,O
chains,5611,O
",",5611,O
suggesting,5611,O
that,5611,O
GAG,5611,O
multivalency,5611,O
is,5611,O
imperative,5611,O
for,5611,O
biological,5611,O
functions,5611,O
in,5611,O
vivo,5611,O
.,5611,O
However,5612,O
",",5612,O
only,5612,O
a,5612,O
few,5612,O
studies,5612,O
have,5612,O
examined,5612,O
the,5612,O
biological,5612,O
significance,5612,O
of,5612,O
GAG,5612,O
multivalency,5612,O
.,5612,O
In,5613,O
this,5613,O
report,5613,O
",",5613,O
we,5613,O
utilized,5613,O
a,5613,O
library,5613,O
of,5613,O
bis-,5613,B-CHEMICAL
and,5613,I-CHEMICAL
tris-xylosides,5613,I-CHEMICAL
that,5613,O
produce,5613,O
two,5613,O
and,5613,O
three,5613,O
GAG,5613,O
chains,5613,O
on,5613,O
the,5613,O
same,5613,O
scaffold,5613,O
",",5613,O
respectively,5613,O
",",5613,O
thus,5613,O
mimicking,5613,O
PGs,5613,O
",",5613,O
to,5613,O
examine,5613,O
the,5613,O
importance,5613,O
of,5613,O
GAG,5613,O
valency,5613,O
and,5613,O
chain,5613,O
type,5613,O
in,5613,O
regulating,5613,O
FGF/FGFR,5613,B-GENE-N
interactions,5613,O
in,5613,O
vivo,5613,O
in,5613,O
zebrafish,5613,O
.,5613,O
A,5614,O
number,5614,O
of,5614,O
bis-,5614,B-CHEMICAL
and,5614,I-CHEMICAL
tris-xylosides,5614,I-CHEMICAL
",",5614,O
but,5614,O
not,5614,O
mono-xylosides,5614,B-CHEMICAL
",",5614,O
caused,5614,O
an,5614,O
elongation,5614,O
phenotype,5614,O
upon,5614,O
their,5614,O
injection,5614,O
into,5614,O
embryos,5614,O
.,5614,O
In,5615,O
situ,5615,O
hybridization,5615,O
showed,5615,O
that,5615,O
elongated,5615,O
embryos,5615,O
have,5615,O
elevated,5615,O
expression,5615,O
of,5615,O
the,5615,O
FGF,5615,B-GENE-N
target,5615,O
gene,5615,O
mkp3,5615,B-GENE-Y
but,5615,O
unchanged,5615,O
expression,5615,O
of,5615,O
reporters,5615,O
for,5615,O
other,5615,O
pathways,5615,O
",",5615,O
indicating,5615,O
that,5615,O
FGF/FGFR,5615,B-GENE-N
signaling,5615,O
was,5615,O
specifically,5615,O
hyperactivated,5615,O
.,5615,O
In,5616,O
support,5616,O
of,5616,O
this,5616,O
observation,5616,O
",",5616,O
elongation,5616,O
can,5616,O
be,5616,O
reversed,5616,O
by,5616,O
the,5616,O
tyrosine,5616,B-GENE-N
kinase,5616,I-GENE-N
inhibitor,5616,O
SU5402,5616,B-CHEMICAL
",",5616,O
mRNA,5616,O
for,5616,O
the,5616,O
FGFR,5616,B-GENE-N
antagonist,5616,O
sprouty4,5616,B-GENE-Y
",",5616,O
or,5616,O
FGF8,5616,B-GENE-Y
morpholino,5616,O
.,5616,O
Endogenous,5617,O
GAGs,5617,O
seem,5617,O
to,5617,O
be,5617,O
unaffected,5617,O
after,5617,O
xyloside,5617,B-CHEMICAL
treatment,5617,O
",",5617,O
suggesting,5617,O
that,5617,O
this,5617,O
is,5617,O
a,5617,O
gain-of-function,5617,O
phenotype,5617,O
.,5617,O
Furthermore,5618,O
",",5618,O
expression,5618,O
of,5618,O
a,5618,O
multivalent,5618,O
but,5618,O
not,5618,O
a,5618,O
monovalent,5618,O
GAG,5618,O
containing,5618,O
syndecan-1,5618,B-GENE-N
proteoglycan,5618,O
recapitulates,5618,O
the,5618,O
elongation,5618,O
phenotype,5618,O
observed,5618,O
with,5618,O
the,5618,O
bivalent,5618,O
xylosides,5618,B-CHEMICAL
.,5618,O
On,5619,O
the,5619,O
basis,5619,O
of,5619,O
these,5619,O
in,5619,O
vivo,5619,O
findings,5619,O
",",5619,O
we,5619,O
propose,5619,O
a,5619,O
new,5619,O
model,5619,O
for,5619,O
GAG/FGF/FGFR,5619,O
interactions,5619,O
in,5619,O
which,5619,O
dimerized,5619,O
GAG,5619,O
chains,5619,O
can,5619,O
activate,5619,O
FGF-mediated,5619,B-GENE-N
signal,5619,O
transduction,5619,O
pathways,5619,O
.,5619,O
Caffeic,5620,B-CHEMICAL
Acid,5620,I-CHEMICAL
Phenethyl,5620,I-CHEMICAL
Ester,5620,I-CHEMICAL
Suppresses,5620,O
Proliferation,5620,O
and,5620,O
Survival,5620,O
of,5620,O
TW2.6,5620,O
Human,5620,O
Oral,5620,O
Cancer,5620,O
Cells,5620,O
via,5620,O
Inhibition,5620,O
of,5620,O
Akt,5620,B-GENE-N
Signaling,5620,O
.,5620,O
Caffeic,5621,B-CHEMICAL
acid,5621,I-CHEMICAL
phenethyl,5621,I-CHEMICAL
ester,5621,I-CHEMICAL
(,5621,O
CAPE,5621,B-CHEMICAL
),5621,O
is,5621,O
a,5621,O
bioactive,5621,O
component,5621,O
extracted,5621,O
from,5621,O
honeybee,5621,O
hive,5621,O
propolis,5621,O
.,5621,O
Our,5622,O
observations,5622,O
indicated,5622,O
that,5622,O
CAPE,5622,B-CHEMICAL
treatment,5622,O
suppressed,5622,O
cell,5622,O
proliferation,5622,O
and,5622,O
colony,5622,O
formation,5622,O
of,5622,O
TW2.6,5622,O
human,5622,O
oral,5622,O
squamous,5622,O
cell,5622,O
carcinoma,5622,O
(,5622,O
OSCC,5622,O
),5622,O
cells,5622,O
dose-dependently,5622,O
.,5622,O
CAPE,5623,B-CHEMICAL
treatment,5623,O
decreased,5623,O
G1,5623,O
phase,5623,O
cell,5623,O
population,5623,O
",",5623,O
increased,5623,O
G2/M,5623,O
phase,5623,O
cell,5623,O
population,5623,O
",",5623,O
and,5623,O
induced,5623,O
apoptosis,5623,O
in,5623,O
TW2.6,5623,O
cells,5623,O
.,5623,O
Treatment,5624,O
with,5624,O
CAPE,5624,B-CHEMICAL
decreased,5624,O
protein,5624,O
abundance,5624,O
of,5624,O
Akt,5624,B-GENE-N
",",5624,O
Akt1,5624,B-GENE-Y
",",5624,O
Akt2,5624,B-GENE-Y
",",5624,O
Akt3,5624,B-GENE-Y
",",5624,O
phospho-Akt,5624,B-CHEMICAL
Ser473,5624,B-CHEMICAL
",",5624,O
phospho-Akt,5624,B-CHEMICAL
Thr,5624,O
308,5624,O
",",5624,O
GSK3,5624,B-GENE-Y
",",5624,O
FOXO1,5624,B-GENE-Y
",",5624,O
FOXO3a,5624,B-GENE-Y
",",5624,O
phospho-FOXO1,5624,B-GENE-Y
Thr24,5624,O
",",5624,O
phospho-FoxO3a,5624,B-GENE-Y
Thr32,5624,O
",",5624,O
NF-B,5624,B-GENE-N
",",5624,O
phospho-NF-B,5624,B-GENE-N
Ser536,5624,O
",",5624,O
Rb,5624,B-GENE-Y
",",5624,O
phospho-Rb,5624,B-GENE-Y
Ser807/811,5624,B-CHEMICAL
",",5624,O
Skp2,5624,B-GENE-Y
",",5624,O
and,5624,O
cyclin,5624,B-GENE-Y
D1,5624,I-GENE-Y
",",5624,O
but,5624,O
increased,5624,O
cell,5624,O
cycle,5624,O
inhibitor,5624,O
p27Kip,5624,B-GENE-Y
.,5624,O
Overexpression,5625,O
of,5625,O
Akt1,5625,B-GENE-Y
or,5625,O
Akt2,5625,B-GENE-Y
in,5625,O
TW2.6,5625,O
cells,5625,O
rescued,5625,O
growth,5625,O
inhibition,5625,O
caused,5625,O
by,5625,O
CAPE,5625,B-CHEMICAL
treatment,5625,O
.,5625,O
Co-treating,5626,O
TW2.6,5626,O
cells,5626,O
with,5626,O
CAPE,5626,B-CHEMICAL
and,5626,O
5-fluorouracil,5626,B-CHEMICAL
",",5626,O
a,5626,O
commonly,5626,O
used,5626,O
chemotherapeutic,5626,O
drug,5626,O
for,5626,O
oral,5626,O
cancers,5626,O
",",5626,O
exhibited,5626,O
additive,5626,O
cell,5626,O
proliferation,5626,O
inhibition,5626,O
.,5626,O
Our,5627,O
study,5627,O
suggested,5627,O
that,5627,O
administration,5627,O
of,5627,O
CAPE,5627,B-CHEMICAL
is,5627,O
a,5627,O
potential,5627,O
adjuvant,5627,O
therapy,5627,O
for,5627,O
patients,5627,O
with,5627,O
OSCC,5627,O
oral,5627,O
cancer,5627,O
.,5627,O
Concurrent,5628,O
Regulation,5628,O
of,5628,O
the,5628,O
Transcription,5628,O
Factors,5628,O
Nrf2,5628,B-GENE-Y
and,5628,O
ATF4,5628,B-GENE-Y
Mediates,5628,O
the,5628,O
Enhancement,5628,O
of,5628,O
Glutathione,5628,B-CHEMICAL
Levels,5628,O
by,5628,O
the,5628,O
Flavonoid,5628,B-CHEMICAL
Fisetin,5628,B-CHEMICAL
.,5628,O
Glutathione,5629,B-CHEMICAL
(,5629,O
GSH,5629,B-CHEMICAL
),5629,O
and,5629,O
GSH-associated,5629,B-CHEMICAL
metabolism,5629,O
provide,5629,O
the,5629,O
major,5629,O
line,5629,O
of,5629,O
defense,5629,O
for,5629,O
the,5629,O
protection,5629,O
of,5629,O
cells,5629,O
from,5629,O
various,5629,O
forms,5629,O
of,5629,O
toxic,5629,O
stress,5629,O
.,5629,O
GSH,5630,B-CHEMICAL
also,5630,O
plays,5630,O
a,5630,O
key,5630,O
role,5630,O
in,5630,O
regulating,5630,O
the,5630,O
intracellular,5630,O
redox,5630,O
environment,5630,O
.,5630,O
Thus,5631,O
",",5631,O
maintenance,5631,O
of,5631,O
GSH,5631,B-CHEMICAL
levels,5631,O
is,5631,O
developing,5631,O
into,5631,O
an,5631,O
important,5631,O
therapeutic,5631,O
objective,5631,O
for,5631,O
the,5631,O
treatment,5631,O
of,5631,O
a,5631,O
variety,5631,O
of,5631,O
diseases,5631,O
.,5631,O
Among,5632,O
the,5632,O
transcription,5632,O
factors,5632,O
that,5632,O
play,5632,O
critical,5632,O
roles,5632,O
in,5632,O
GSH,5632,B-CHEMICAL
metabolism,5632,O
are,5632,O
NF-E2-related,5632,B-GENE-Y
factor,5632,I-GENE-Y
2,5632,I-GENE-Y
(,5632,O
Nrf2,5632,B-GENE-Y
),5632,O
and,5632,O
activating,5632,B-GENE-Y
transcription,5632,I-GENE-Y
factor,5632,I-GENE-Y
4,5632,I-GENE-Y
(,5632,O
ATF4,5632,B-GENE-Y
),5632,O
.,5632,O
Thus,5633,O
",",5633,O
compounds,5633,O
that,5633,O
can,5633,O
upregulate,5633,O
these,5633,O
transcription,5633,O
factors,5633,O
may,5633,O
be,5633,O
particularly,5633,O
useful,5633,O
as,5633,O
treatment,5633,O
options,5633,O
through,5633,O
their,5633,O
effects,5633,O
on,5633,O
GSH,5633,B-CHEMICAL
metabolism,5633,O
.,5633,O
We,5634,O
previously,5634,O
showed,5634,O
that,5634,O
the,5634,O
flavonoid,5634,B-CHEMICAL
fisetin,5634,B-CHEMICAL
not,5634,O
only,5634,O
increases,5634,O
basal,5634,O
levels,5634,O
of,5634,O
GSH,5634,B-CHEMICAL
but,5634,O
also,5634,O
maintains,5634,O
GSH,5634,B-CHEMICAL
levels,5634,O
under,5634,O
oxidative,5634,O
stress,5634,O
conditions,5634,O
.,5634,O
However,5635,O
",",5635,O
the,5635,O
mechanisms,5635,O
underlying,5635,O
these,5635,O
effects,5635,O
have,5635,O
remained,5635,O
unknown,5635,O
until,5635,O
now,5635,O
.,5635,O
Here,5636,O
we,5636,O
show,5636,O
that,5636,O
fisetin,5636,B-CHEMICAL
rapidly,5636,O
increases,5636,O
the,5636,O
levels,5636,O
of,5636,O
both,5636,O
Nrf2,5636,B-GENE-Y
and,5636,O
ATF4,5636,B-GENE-Y
as,5636,O
well,5636,O
as,5636,O
Nrf2-,5636,B-GENE-Y
and,5636,O
ATF4-dependent,5636,B-GENE-Y
gene,5636,O
transcription,5636,O
via,5636,O
distinct,5636,O
mechanisms,5636,O
.,5636,O
Although,5637,O
fisetin,5637,B-CHEMICAL
greatly,5637,O
increases,5637,O
the,5637,O
stability,5637,O
of,5637,O
both,5637,O
Nrf2,5637,B-GENE-Y
and,5637,O
ATF4,5637,B-GENE-Y
",",5637,O
only,5637,O
the,5637,O
effect,5637,O
on,5637,O
ATF4,5637,B-GENE-Y
is,5637,O
dependent,5637,O
on,5637,O
protein,5637,B-GENE-N
kinase,5637,I-GENE-N
activity,5637,O
.,5637,O
Using,5638,O
siRNA,5638,O
we,5638,O
found,5638,O
that,5638,O
ATF4,5638,B-GENE-Y
",",5638,O
but,5638,O
not,5638,O
Nrf2,5638,B-GENE-Y
",",5638,O
is,5638,O
important,5638,O
for,5638,O
fisetin,5638,B-CHEMICAL
's,5638,O
ability,5638,O
to,5638,O
increase,5638,O
GSH,5638,B-CHEMICAL
levels,5638,O
under,5638,O
basal,5638,O
conditions,5638,O
whereas,5638,O
both,5638,O
ATF4,5638,B-GENE-Y
and,5638,O
Nrf2,5638,B-GENE-Y
appear,5638,O
to,5638,O
cooperate,5638,O
to,5638,O
increase,5638,O
GSH,5638,B-CHEMICAL
levels,5638,O
under,5638,O
oxidative,5638,O
stress,5638,O
conditions,5638,O
.,5638,O
Based,5639,O
upon,5639,O
these,5639,O
results,5639,O
",",5639,O
we,5639,O
hypothesize,5639,O
that,5639,O
compounds,5639,O
able,5639,O
to,5639,O
increase,5639,O
GSH,5639,B-CHEMICAL
levels,5639,O
via,5639,O
multiple,5639,O
mechanisms,5639,O
",",5639,O
such,5639,O
as,5639,O
fisetin,5639,B-CHEMICAL
",",5639,O
will,5639,O
be,5639,O
particularly,5639,O
effective,5639,O
for,5639,O
maintaining,5639,O
GSH,5639,B-CHEMICAL
levels,5639,O
under,5639,O
a,5639,O
variety,5639,O
of,5639,O
different,5639,O
stresses,5639,O
.,5639,O
GALACTOSYLATED,5640,O
MICELLES,5640,O
FOR,5640,O
A,5640,O
RIBAVIRIN,5640,B-CHEMICAL
PRODRUG,5640,O
TARGETING,5640,O
TO,5640,O
HEPATOCYTES,5640,O
.,5640,O
Polymeric,5641,O
micelles,5641,O
potentially,5641,O
able,5641,O
to,5641,O
carry,5641,O
to,5641,O
hepatocytes,5641,O
a,5641,O
ribavirin,5641,B-CHEMICAL
(,5641,O
RBV,5641,B-CHEMICAL
),5641,O
prodrug,5641,O
",",5641,O
exploiting,5641,O
the,5641,O
presence,5641,O
of,5641,O
carbohydrate,5641,B-CHEMICAL
receptors,5641,I-GENE-N
",",5641,O
i.e.,5641,O
",",5641,O
ASGPR,5641,B-GENE-N
",",5641,O
were,5641,O
prepared,5641,O
starting,5641,O
from,5641,O
a,5641,O
galactosylated,5641,B-CHEMICAL
polylactide-polyaminoacid,5641,I-CHEMICAL
conjugate,5641,O
.,5641,O
This,5642,O
latter,5642,O
was,5642,O
obtained,5642,O
by,5642,O
chemical,5642,O
reaction,5642,O
of,5642,O
alpha,5642,B-CHEMICAL
",",5642,I-CHEMICAL
beta-poly,5642,I-CHEMICAL
(,5642,I-CHEMICAL
N-2-hydroxyethyl,5642,I-CHEMICAL
),5642,I-CHEMICAL
(,5642,I-CHEMICAL
2-aminoethylcarbamate,5642,I-CHEMICAL
),5642,I-CHEMICAL
-DL-aspartamide,5642,I-CHEMICAL
(,5642,O
PHEA-EDA,5642,B-CHEMICAL
),5642,O
with,5642,O
polylactic,5642,B-CHEMICAL
acid,5642,I-CHEMICAL
(,5642,O
PLA,5642,B-CHEMICAL
),5642,O
",",5642,O
and,5642,O
subsequent,5642,O
reaction,5642,O
with,5642,O
lactose,5642,B-CHEMICAL
",",5642,O
obtaining,5642,O
PHEA-EDA-PLA-GAL,5642,B-CHEMICAL
copolymer,5642,O
.,5642,O
To,5643,O
enhance,5643,O
the,5643,O
entrapment,5643,O
into,5643,O
obtained,5643,O
nanostructures,5643,O
",",5643,O
a,5643,O
hydrophobic,5643,O
RBV,5643,B-CHEMICAL
prodrug,5643,O
",",5643,O
i.e,5643,O
.,5643,O
RBV,5644,B-CHEMICAL
tripalmitate,5644,I-CHEMICAL
",",5644,O
was,5644,O
synthesized,5644,O
and,5644,O
its,5644,O
capability,5644,O
to,5644,O
release,5644,O
RBV,5644,B-CHEMICAL
in,5644,O
the,5644,O
presence,5644,O
of,5644,O
an,5644,O
adequate,5644,O
enzymatic,5644,O
activity,5644,O
was,5644,O
demonstrated,5644,O
.,5644,O
Liver-targeted,5645,O
RBV,5645,B-CHEMICAL
tripalmitate-loaded,5645,O
micelles,5645,O
were,5645,O
obtained,5645,O
in,5645,O
aqueous,5645,O
media,5645,O
at,5645,O
low,5645,O
PHEA-EDA-PLA-GAL,5645,B-CHEMICAL
copolymer,5645,O
concentration,5645,O
value,5645,O
with,5645,O
nanometric,5645,O
size,5645,O
.,5645,O
By,5646,O
in,5646,O
vitro,5646,O
experiments,5646,O
",",5646,O
the,5646,O
specificity,5646,O
of,5646,O
RBV,5646,B-CHEMICAL
tripalmitate-loaded,5646,O
PHEA-EDA-PLA-GAL,5646,B-CHEMICAL
micelles,5646,O
toward,5646,O
HepG2,5646,O
was,5646,O
demonstrated,5646,O
by,5646,O
using,5646,O
a,5646,O
competitive,5646,O
inhibition,5646,O
assay,5646,O
in,5646,O
the,5646,O
presence,5646,O
of,5646,O
free,5646,O
GAL,5646,B-CHEMICAL
.,5646,O
This,5647,O
finding,5647,O
raises,5647,O
hope,5647,O
in,5647,O
terms,5647,O
of,5647,O
future,5647,O
micelles-based,5647,O
liver-targeted,5647,O
drug,5647,O
delivery,5647,O
strategy,5647,O
for,5647,O
the,5647,O
hepatitis,5647,O
C,5647,O
treatment,5647,O
.,5647,O
Molecular,5648,O
and,5648,O
functional,5648,O
characterization,5648,O
of,5648,O
flavin-containing,5648,B-GENE-N
monooxygenases,5648,I-GENE-N
in,5648,O
cynomolgus,5648,O
macaque,5648,O
.,5648,O
Flavin-containing,5649,B-CHEMICAL
monooxygenases,5649,I-GENE-N
(,5649,O
FMOs,5649,B-GENE-N
),5649,O
",",5649,O
drug-metabolizing,5649,O
enzymes,5649,O
essential,5649,O
for,5649,O
the,5649,O
metabolism,5649,O
of,5649,O
endogenous,5649,O
biochemicals,5649,O
and,5649,O
foreign,5649,O
compounds,5649,O
",",5649,O
have,5649,O
been,5649,O
characterized,5649,O
in,5649,O
human,5649,O
(,5649,O
including,5649,O
FMO1-5,5649,B-GENE-N
and,5649,O
FMO6P,5649,B-GENE-Y
),5649,O
",",5649,O
but,5649,O
remain,5649,O
to,5649,O
be,5649,O
investigated,5649,O
in,5649,O
cynomolgus,5649,O
macaque,5649,O
.,5649,O
In,5650,O
this,5650,O
study,5650,O
",",5650,O
cDNAs,5650,O
of,5650,O
cynomolgus,5650,O
FMO1-5,5650,B-GENE-N
and,5650,O
FMO6,5650,B-GENE-Y
were,5650,O
isolated,5650,O
and,5650,O
characterized,5650,O
.,5650,O
Amino,5651,B-CHEMICAL
acid,5651,I-CHEMICAL
sequences,5651,O
of,5651,O
cynomolgus,5651,O
FMO1-5,5651,B-GENE-N
",",5651,O
respectively,5651,O
",",5651,O
shared,5651,O
high,5651,O
sequence,5651,O
identities,5651,O
(,5651,O
94-98,5651,O
%,5651,O
),5651,O
and,5651,O
were,5651,O
closely,5651,O
clustered,5651,O
in,5651,O
a,5651,O
phylogenetic,5651,O
tree,5651,O
",",5651,O
with,5651,O
human,5651,B-GENE-N
FMO1-5,5651,I-GENE-N
.,5651,O
Eight,5652,O
different,5652,O
transcripts,5652,O
",",5652,O
due,5652,O
to,5652,O
alternative,5652,O
splicing,5652,O
",",5652,O
were,5652,O
isolated,5652,O
for,5652,O
cynomolgus,5652,B-GENE-Y
FMO6,5652,I-GENE-Y
",",5652,O
which,5652,O
is,5652,O
highly,5652,O
identical,5652,O
(,5652,O
96,5652,O
%,5652,O
),5652,O
to,5652,O
human,5652,B-GENE-Y
FMO6P,5652,I-GENE-Y
.,5652,O
Among,5653,O
the,5653,O
10,5653,O
tissue,5653,O
types,5653,O
analyzed,5653,O
",",5653,O
cynomolgus,5653,O
FMO1,5653,B-GENE-Y
",",5653,O
FMO2,5653,B-GENE-Y
",",5653,O
FMO4,5653,B-GENE-Y
",",5653,O
and,5653,O
FMO6,5653,B-GENE-Y
were,5653,O
most,5653,O
abundantly,5653,O
expressed,5653,O
in,5653,O
kidney,5653,O
",",5653,O
while,5653,O
cynomolgus,5653,B-GENE-Y
FMO3,5653,I-GENE-Y
and,5653,O
FMO5,5653,B-GENE-Y
were,5653,O
most,5653,O
abundantly,5653,O
expressed,5653,O
in,5653,O
liver,5653,O
.,5653,O
In,5654,O
kidney,5654,O
and,5654,O
liver,5654,O
",",5654,O
the,5654,O
most,5654,O
abundantly,5654,O
expressed,5654,O
cynomolgus,5654,B-GENE-N
FMO,5654,I-GENE-N
genes,5654,O
were,5654,O
FMO1,5654,B-GENE-Y
and,5654,O
FMO3,5654,B-GENE-Y
respectively,5654,O
.,5654,O
Cynomolgus,5655,B-GENE-Y
FMO1,5655,I-GENE-Y
",",5655,O
FMO2,5655,B-GENE-Y
",",5655,O
FMO3,5655,B-GENE-Y
",",5655,O
and,5655,O
FMO5,5655,B-GENE-Y
metabolized,5655,O
benzydamine,5655,B-CHEMICAL
",",5655,O
and,5655,O
FMO1/FMO3,5655,B-GENE-Y
and,5655,O
FMO3,5655,B-GENE-Y
also,5655,O
metabolized,5655,O
methimazole,5655,B-CHEMICAL
and,5655,O
trimethylamine,5655,B-CHEMICAL
",",5655,O
respectively,5655,O
.,5655,O
Rates,5656,O
of,5656,O
benzydamine,5656,B-CHEMICAL
N-oxygenation,5656,B-CHEMICAL
(,5656,O
catalyzed,5656,O
by,5656,O
FMO3,5656,B-GENE-Y
),5656,O
varied,5656,O
(,5656,O
approximately,5656,O
20-fold,5656,O
),5656,O
among,5656,O
the,5656,O
28,5656,O
cynomolgus,5656,O
livers,5656,O
and,5656,O
were,5656,O
significantly,5656,O
correlated,5656,O
with,5656,O
FMO3,5656,B-GENE-Y
protein,5656,O
expression,5656,O
",",5656,O
indicating,5656,O
that,5656,O
the,5656,O
inter-animal,5656,O
variations,5656,O
in,5656,O
benzydamine,5656,B-CHEMICAL
N-oxygenation,5656,B-CHEMICAL
might,5656,O
be,5656,O
partly,5656,O
accounted,5656,O
for,5656,O
by,5656,O
the,5656,O
variable,5656,O
FMO3,5656,B-GENE-Y
expression,5656,O
.,5656,O
Cynomolgus,5657,B-GENE-Y
FMO6,5657,I-GENE-Y
metabolized,5657,O
benzydamine,5657,B-CHEMICAL
only,5657,O
slightly,5657,O
",",5657,O
but,5657,O
minimal,5657,O
expression,5657,O
of,5657,O
FMO6,5657,B-GENE-Y
in,5657,O
all,5657,O
tissue,5657,O
precludes,5657,O
the,5657,O
importance,5657,O
of,5657,O
FMO6,5657,B-GENE-Y
in,5657,O
drug,5657,O
metabolism,5657,O
",",5657,O
unlike,5657,O
cynomolgus,5657,O
FMO1,5657,B-GENE-Y
",",5657,O
FMO2,5657,B-GENE-Y
",",5657,O
FMO3,5657,B-GENE-Y
",",5657,O
and,5657,O
FMO5,5657,B-GENE-Y
which,5657,O
were,5657,O
all,5657,O
functional,5657,O
.,5657,O
Abundant,5658,O
expression,5658,O
of,5658,O
FMO1,5658,B-GENE-Y
and,5658,O
FMO3,5658,B-GENE-Y
in,5658,O
kidney,5658,O
and,5658,O
liver,5658,O
",",5658,O
respectively,5658,O
",",5658,O
suggest,5658,O
their,5658,O
importance,5658,O
in,5658,O
drug,5658,O
metabolism,5658,O
in,5658,O
cynomolgus,5658,O
macaque,5658,O
",",5658,O
similar,5658,O
to,5658,O
human,5658,O
.,5658,O
Glomerular,5659,O
Filtration,5659,O
Rate,5659,O
Equations,5659,O
Overestimate,5659,O
Creatinine,5659,B-CHEMICAL
Clearance,5659,O
in,5659,O
Older,5659,O
Individuals,5659,O
Enrolled,5659,O
in,5659,O
the,5659,O
Baltimore,5659,O
Longitudinal,5659,O
Study,5659,O
on,5659,O
Aging,5659,O
:,5659,O
Impact,5659,O
on,5659,O
Renal,5659,O
Drug,5659,O
Dosing,5659,O
.,5659,O
OBJECTIVES,5660,O
:,5660,O
To,5660,O
evaluate,5660,O
the,5660,O
performance,5660,O
of,5660,O
kidney,5660,O
function,5660,O
estimation,5660,O
equations,5660,O
and,5660,O
to,5660,O
determine,5660,O
the,5660,O
frequency,5660,O
of,5660,O
drug,5660,O
dose,5660,O
discordance,5660,O
in,5660,O
an,5660,O
older,5660,O
population,5660,O
.,5660,O
DESIGN,5661,O
:,5661,O
Cross-sectional,5661,O
analysis,5661,O
of,5661,O
data,5661,O
from,5661,O
community-dwelling,5661,O
volunteers,5661,O
randomly,5661,O
selected,5661,O
from,5661,O
the,5661,O
Baltimore,5661,O
Longitudinal,5661,O
Study,5661,O
of,5661,O
Aging,5661,O
from,5661,O
January,5661,O
1,5661,O
",",5661,O
2005,5661,O
",",5661,O
to,5661,O
December,5661,O
31,5661,O
",",5661,O
2010,5661,O
.,5661,O
SUBJECTS,5662,O
:,5662,O
A,5662,O
total,5662,O
of,5662,O
269,5662,O
men,5662,O
and,5662,O
women,5662,O
with,5662,O
a,5662,O
mean,5662,O
,5662,O
SD,5662,O
age,5662,O
of,5662,O
81,5662,O
,5662,O
6,5662,O
years,5662,O
",",5662,O
mean,5662,O
serum,5662,O
creatinine,5662,B-CHEMICAL
concentration,5662,O
(,5662,O
Scr,5662,O
),5662,O
of,5662,O
1.1,5662,O
,5662,O
0.4,5662,O
mg/dl,5662,O
",",5662,O
and,5662,O
mean,5662,O
24-hour,5662,O
measured,5662,O
creatinine,5662,B-CHEMICAL
clearance,5662,O
(,5662,O
mClcr,5662,O
),5662,O
of,5662,O
53,5662,O
,5662,O
13,5662,O
ml/minute,5662,O
.,5662,O
MEASUREMENTS,5663,O
AND,5663,O
MAIN,5663,O
RESULTS,5663,O
:,5663,O
Kidney,5663,O
function,5663,O
was,5663,O
estimated,5663,O
by,5663,O
using,5663,O
the,5663,O
following,5663,O
equations,5663,O
:,5663,O
Cockcroft-Gault,5663,O
(,5663,O
CG,5663,O
),5663,O
",",5663,O
Modification,5663,O
of,5663,O
Diet,5663,O
in,5663,O
Renal,5663,O
Disease,5663,O
(,5663,O
MDRD,5663,O
),5663,O
",",5663,O
and,5663,O
Chronic,5663,O
Kidney,5663,O
Disease,5663,O
Epidemiology,5663,O
Collaboration,5663,O
(,5663,O
CKD-EPI,5663,O
),5663,O
.,5663,O
The,5664,O
performance,5664,O
of,5664,O
each,5664,O
equation,5664,O
was,5664,O
assessed,5664,O
by,5664,O
measuring,5664,O
bias,5664,O
and,5664,O
precision,5664,O
relative,5664,O
to,5664,O
mClcr,5664,O
.,5664,O
Dose,5665,O
calculation,5665,O
errors,5665,O
(,5665,O
discordance,5665,O
),5665,O
were,5665,O
determined,5665,O
for,5665,O
10,5665,O
drugs,5665,O
requiring,5665,O
renal,5665,O
dosage,5665,O
adjustments,5665,O
to,5665,O
avoid,5665,O
toxicity,5665,O
when,5665,O
compared,5665,O
with,5665,O
the,5665,O
dosages,5665,O
approved,5665,O
by,5665,O
the,5665,O
Food,5665,O
and,5665,O
Drug,5665,O
Administration,5665,O
.,5665,O
The,5666,O
CG,5666,O
equation,5666,O
was,5666,O
the,5666,O
least,5666,O
biased,5666,O
estimate,5666,O
of,5666,O
mClcr,5666,O
.,5666,O
The,5667,O
MDRD,5667,O
and,5667,O
CKD-EPI,5667,O
equations,5667,O
were,5667,O
significantly,5667,O
positively,5667,O
biased,5667,O
compared,5667,O
with,5667,O
CG,5667,O
(,5667,O
mean,5667,O
,5667,O
SD,5667,O
34,5667,O
,5667,O
20,5667,O
%,5667,O
and,5667,O
22,5667,O
,5667,O
15,5667,O
%,5667,O
",",5667,O
respectively,5667,O
",",5667,O
p,5667,O
<,5667,O
0.001,5667,O
),5667,O
and,5667,O
mClcr,5667,O
(,5667,O
29,5667,O
,5667,O
47,5667,O
%,5667,O
and,5667,O
18,5667,O
,5667,O
40,5667,O
%,5667,O
",",5667,O
respectively,5667,O
",",5667,O
p,5667,O
<,5667,O
0.001,5667,O
),5667,O
.,5667,O
Rounding,5668,O
low,5668,O
Scr,5668,O
values,5668,O
(,5668,O
less,5668,O
than,5668,O
1.0,5668,O
mg/dl,5668,O
),5668,O
up,5668,O
to,5668,O
an,5668,O
arbitrary,5668,O
value,5668,O
of,5668,O
1.0,5668,O
mg/dl,5668,O
resulted,5668,O
in,5668,O
CG,5668,O
values,5668,O
(,5668,O
44,5668,O
,5668,O
10,5668,O
ml/minute,5668,O
),5668,O
that,5668,O
were,5668,O
significantly,5668,O
lower,5668,O
than,5668,O
mClcr,5668,O
(,5668,O
56,5668,O
,5668,O
12,5668,O
ml/minute,5668,O
",",5668,O
p,5668,O
<,5668,O
0.001,5668,O
),5668,O
and,5668,O
CG,5668,O
(,5668,O
56,5668,O
,5668,O
15,5668,O
ml/minute,5668,O
",",5668,O
p,5668,O
<,5668,O
0.001,5668,O
),5668,O
.,5668,O
The,5669,O
MDRD,5669,O
and,5669,O
CKD-EPI,5669,O
equations,5669,O
had,5669,O
median,5669,O
dose,5669,O
discordance,5669,O
rates,5669,O
of,5669,O
28.6,5669,O
%,5669,O
and,5669,O
22.9,5669,O
%,5669,O
",",5669,O
respectively,5669,O
.,5669,O
CONCLUSION,5670,O
:,5670,O
The,5670,O
MDRD,5670,O
and,5670,O
CKD-EPI,5670,O
equations,5670,O
significantly,5670,O
overestimated,5670,O
creatinine,5670,B-CHEMICAL
clearance,5670,O
(,5670,O
mClcr,5670,O
and,5670,O
CG,5670,O
),5670,O
in,5670,O
elderly,5670,O
individuals,5670,O
.,5670,O
This,5671,O
leads,5671,O
to,5671,O
dose,5671,O
calculation,5671,O
errors,5671,O
for,5671,O
many,5671,O
drugs,5671,O
",",5671,O
particularly,5671,O
in,5671,O
individuals,5671,O
with,5671,O
severe,5671,O
renal,5671,O
impairment,5671,O
.,5671,O
Thus,5672,O
equations,5672,O
estimating,5672,O
glomerular,5672,O
filtration,5672,O
rate,5672,O
should,5672,O
not,5672,O
be,5672,O
substituted,5672,O
in,5672,O
place,5672,O
of,5672,O
the,5672,O
CG,5672,O
equation,5672,O
in,5672,O
older,5672,O
adults,5672,O
for,5672,O
the,5672,O
purpose,5672,O
of,5672,O
renal,5672,O
dosage,5672,O
adjustments,5672,O
.,5672,O
In,5673,O
addition,5673,O
",",5673,O
the,5673,O
common,5673,O
practice,5673,O
of,5673,O
rounding,5673,O
or,5673,O
replacing,5673,O
low,5673,O
Scr,5673,O
values,5673,O
with,5673,O
an,5673,O
arbitrary,5673,O
value,5673,O
of,5673,O
1.0,5673,O
mg/dl,5673,O
for,5673,O
use,5673,O
in,5673,O
the,5673,O
CG,5673,O
equation,5673,O
should,5673,O
be,5673,O
avoided,5673,O
.,5673,O
Additional,5674,O
studies,5674,O
that,5674,O
evaluate,5674,O
alternative,5674,O
eGFR,5674,O
equations,5674,O
in,5674,O
the,5674,O
older,5674,O
populations,5674,O
that,5674,O
incorporate,5674,O
pharmacokinetic,5674,O
and,5674,O
pharmacodynamic,5674,O
outcomes,5674,O
measures,5674,O
are,5674,O
needed,5674,O
.,5674,O
Effect,5675,O
of,5675,O
paraoxonase,5675,B-GENE-Y
1,5675,I-GENE-Y
192,5675,B-GENE-N
Q/R,5675,I-GENE-N
polymorphism,5675,O
on,5675,O
paraoxonase,5675,B-GENE-Y
and,5675,O
acetylcholinesterase,5675,B-GENE-Y
enzyme,5675,O
activities,5675,O
in,5675,O
Turkish,5675,O
population,5675,O
exposed,5675,O
to,5675,O
organophosphate,5675,B-CHEMICAL
.,5675,O
Organophosphate,5676,B-CHEMICAL
(,5676,O
OP,5676,O
),5676,O
compounds,5676,O
are,5676,O
the,5676,O
most,5676,O
commonly,5676,O
used,5676,O
pesticide,5676,O
groups,5676,O
and,5676,O
they,5676,O
are,5676,O
commercially,5676,O
used,5676,O
in,5676,O
the,5676,O
market,5676,O
for,5676,O
local,5676,O
and,5676,O
industrial,5676,O
purposes,5676,O
.,5676,O
Paraoxonase,5677,B-GENE-Y
1,5677,I-GENE-Y
(,5677,O
PON1,5677,B-GENE-Y
),5677,O
enzyme,5677,O
plays,5677,O
an,5677,O
important,5677,O
role,5677,O
in,5677,O
biotransformation,5677,O
of,5677,O
OP,5677,O
compounds,5677,O
",",5677,O
which,5677,O
shows,5677,O
toxic,5677,O
effects,5677,O
via,5677,O
inhibiting,5677,O
the,5677,O
acetylcholinesterase,5677,B-GENE-Y
(,5677,O
AChE,5677,B-GENE-Y
),5677,O
.,5677,O
The,5678,O
aim,5678,O
of,5678,O
this,5678,O
study,5678,O
was,5678,O
to,5678,O
determine,5678,O
the,5678,O
effects,5678,O
of,5678,O
PON1,5678,B-GENE-Y
gene,5678,O
polymorphism,5678,O
and,5678,O
its,5678,O
effects,5678,O
on,5678,O
PON,5678,B-GENE-Y
and,5678,O
AChE,5678,B-GENE-Y
enzyme,5678,O
activities,5678,O
in,5678,O
individuals,5678,O
who,5678,O
were,5678,O
exposed,5678,O
to,5678,O
organophosphorus,5678,B-CHEMICAL
insecticides,5678,O
due,5678,O
to,5678,O
occupational,5678,O
reasons,5678,O
",",5678,O
and,5678,O
to,5678,O
profile,5678,O
the,5678,O
probability,5678,O
of,5678,O
susceptibility,5678,O
to,5678,O
organophosphorus,5678,B-CHEMICAL
compounds,5678,O
.,5678,O
For,5679,O
this,5679,O
purpose,5679,O
",",5679,O
54,5679,O
individuals,5679,O
who,5679,O
were,5679,O
exposed,5679,O
to,5679,O
OPs,5679,O
and,5679,O
54,5679,O
healthy,5679,O
unrelated,5679,O
controls,5679,O
were,5679,O
studied,5679,O
.,5679,O
First,5680,O
",",5680,O
PON1,5680,B-GENE-Y
and,5680,O
AChE,5680,B-GENE-Y
enzyme,5680,O
activities,5680,O
were,5680,O
measured,5680,O
.,5680,O
Second,5681,O
",",5681,O
PON1,5681,B-GENE-Y
192,5681,B-GENE-N
Q/R,5681,I-GENE-N
polymorphism,5681,O
was,5681,O
determined,5681,O
by,5681,O
standard,5681,O
polymerase,5681,O
chain,5681,O
reaction-restriction,5681,O
fragment,5681,O
length,5681,O
polymorphism,5681,O
technique,5681,O
.,5681,O
When,5682,O
the,5682,O
PON1,5682,B-GENE-Y
192,5682,B-GENE-N
Q/R,5682,I-GENE-N
polymorphism,5682,O
was,5682,O
compared,5682,O
with,5682,O
PON1,5682,B-GENE-Y
enzyme,5682,O
activities,5682,O
",",5682,O
statistically,5682,O
significant,5682,O
association,5682,O
was,5682,O
found,5682,O
in,5682,O
both,5682,O
OP-exposed,5682,O
and,5682,O
control,5682,O
groups,5682,O
(,5682,O
p,5682,O
<,5682,O
0.05,5682,O
),5682,O
.,5682,O
PON1,5683,B-GENE-Y
192,5683,O
R,5683,O
(,5683,O
+,5683,O
),5683,O
(,5683,O
QR,5683,O
+,5683,O
RR,5683,O
genotypes,5683,O
),5683,O
genotype,5683,O
carriers,5683,O
had,5683,O
higher,5683,O
PON1,5683,B-GENE-Y
activities,5683,O
than,5683,O
192,5683,O
R,5683,O
(,5683,O
-,5683,O
),5683,O
(,5683,O
QQ,5683,O
),5683,O
genotype,5683,O
carriers,5683,O
.,5683,O
On,5684,O
the,5684,O
other,5684,O
hand,5684,O
",",5684,O
results,5684,O
were,5684,O
statistically,5684,O
analyzed,5684,O
in,5684,O
terms,5684,O
of,5684,O
AChE,5684,B-GENE-Y
enzyme,5684,O
activities,5684,O
and,5684,O
there,5684,O
were,5684,O
statistically,5684,O
significant,5684,O
differences,5684,O
only,5684,O
in,5684,O
the,5684,O
OP-exposed,5684,O
group,5684,O
(,5684,O
p,5684,O
<,5684,O
0.05,5684,O
),5684,O
.,5684,O
The,5685,O
mean,5685,O
AChE,5685,B-GENE-Y
concentration,5685,O
in,5685,O
the,5685,O
OP-exposed,5685,O
group,5685,O
was,5685,O
determined,5685,O
as,5685,O
33.79,5685,O
,5685,O
6.84,5685,O
U/g,5685,O
haemoglobin,5685,B-GENE-N
(,5685,O
Hb,5685,B-GENE-N
),5685,O
for,5685,O
PON1,5685,B-GENE-Y
192,5685,O
R,5685,O
(,5685,O
+,5685,O
),5685,O
carriers,5685,O
and,5685,O
30.37,5685,O
,5685,O
7.62,5685,O
U/g,5685,O
Hb,5685,B-GENE-N
for,5685,O
PON1,5685,B-GENE-Y
192,5685,O
R,5685,O
(,5685,O
+,5685,O
),5685,O
carriers,5685,O
.,5685,O
As,5686,O
a,5686,O
conclusion,5686,O
",",5686,O
PON1,5686,B-GENE-Y
and,5686,O
AChE,5686,B-GENE-Y
activities,5686,O
were,5686,O
increasing,5686,O
according,5686,O
to,5686,O
the,5686,O
genotypes,5686,O
found,5686,O
in,5686,O
individuals,5686,O
having,5686,O
been,5686,O
exposed,5686,O
to,5686,O
OPs,5686,O
at,5686,O
a,5686,O
chronic,5686,O
level,5686,O
;,5686,O
192,5686,O
R,5686,O
(,5686,O
+,5686,O
),5686,O
>,5686,O
192,5686,O
R,5686,O
(,5686,O
-,5686,O
),5686,O
",",5686,O
respectively,5686,O
.,5686,O
Store-operated,5687,O
Ca2+,5687,B-CHEMICAL
Entry,5687,O
(,5687,O
SOCE,5687,O
),5687,O
Induced,5687,O
by,5687,O
Protease-activated,5687,B-GENE-Y
Receptor-1,5687,I-GENE-Y
mediates,5687,O
STIM1,5687,B-GENE-Y
Phosphorylation,5687,O
to,5687,O
inhibit,5687,O
SOCE,5687,O
in,5687,O
Endothelial,5687,O
Cells,5687,O
through,5687,O
AMP-activated,5687,B-GENE-Y
Protein,5687,I-GENE-Y
Kinase,5687,I-GENE-Y
and,5687,O
p38beta,5687,B-GENE-Y
Mitogen-activated,5687,B-GENE-N
Protein,5687,I-GENE-N
Kinase,5687,I-GENE-N
.,5687,O
The,5688,O
Ca2+,5688,B-CHEMICAL
sensor,5688,O
STIM1,5688,B-GENE-Y
is,5688,O
crucial,5688,O
for,5688,O
activation,5688,O
of,5688,O
store-operated,5688,O
Ca2+,5688,B-CHEMICAL
entry,5688,O
(,5688,O
SOCE,5688,O
),5688,O
through,5688,O
TRPC,5688,B-GENE-N
and,5688,O
Orai,5688,B-GENE-N
channels,5688,I-GENE-N
.,5688,O
STIM1,5689,B-GENE-Y
phosphorylation,5689,O
serves,5689,O
as,5689,O
an,5689,O
off-switch,5689,O
for,5689,O
SOCE,5689,O
.,5689,O
However,5690,O
",",5690,O
the,5690,O
signaling,5690,O
pathway,5690,O
for,5690,O
STIM1,5690,B-GENE-Y
phosphorylation,5690,O
is,5690,O
unknown,5690,O
.,5690,O
Here,5691,O
we,5691,O
show,5691,O
that,5691,O
SOCE,5691,O
activates,5691,O
AMP-activated,5691,B-GENE-Y
protein,5691,I-GENE-Y
kinase,5691,I-GENE-Y
(,5691,O
AMPK,5691,B-GENE-Y
),5691,O
;,5691,O
its,5691,O
effector,5691,O
p38,5691,B-GENE-Y
mitogen-activated,5691,B-GENE-N
protein,5691,I-GENE-N
kinase,5691,I-GENE-N
(,5691,O
p38,5691,B-GENE-Y
MAPK,5691,B-GENE-N
),5691,O
phosphorylates,5691,O
STIM1,5691,B-GENE-Y
",",5691,O
thus,5691,O
inhibiting,5691,O
SOCE,5691,O
in,5691,O
human,5691,O
lung,5691,O
microvascular,5691,O
endothelial,5691,O
cells,5691,O
(,5691,O
ECs,5691,O
),5691,O
.,5691,O
Activation,5692,O
of,5692,O
AMPK,5692,B-GENE-Y
using,5692,O
AICAR,5692,B-CHEMICAL
resulted,5692,O
in,5692,O
STIM1,5692,B-GENE-Y
phosphorylation,5692,O
on,5692,O
serine,5692,B-CHEMICAL
residues,5692,O
and,5692,O
prevented,5692,O
PAR-1-induced,5692,B-GENE-Y
Ca2+,5692,B-CHEMICAL
entry,5692,O
.,5692,O
Further,5693,O
",",5693,O
AICAR,5693,B-CHEMICAL
pretreatment,5693,O
blocked,5693,O
PAR-1-induced,5693,B-GENE-Y
increase,5693,O
in,5693,O
permeability,5693,O
of,5693,O
mouse-lung,5693,O
microvessels,5693,O
.,5693,O
Activation,5694,O
of,5694,O
SOCE,5694,O
with,5694,O
thrombin,5694,B-GENE-Y
caused,5694,O
phosphorylation,5694,O
of,5694,O
isoform,5694,O
1,5694,O
",",5694,O
but,5694,O
not,5694,O
2,5694,O
of,5694,O
the,5694,O
AMPK,5694,B-GENE-Y
catalytic,5694,O
subunit,5694,O
.,5694,O
Moreover,5695,O
",",5695,O
knockdown,5695,O
of,5695,O
AMPK1,5695,B-GENE-Y
augmented,5695,O
SOCE,5695,O
induced,5695,O
by,5695,O
thrombin,5695,B-GENE-Y
.,5695,O
Interestingly,5696,O
",",5696,O
SB203580,5696,B-CHEMICAL
",",5696,O
a,5696,O
selective,5696,O
inhibitor,5696,O
of,5696,O
p38,5696,B-GENE-N
MAPK,5696,B-GENE-N
",",5696,O
blocked,5696,O
STIM1,5696,B-GENE-Y
phosphorylation,5696,O
and,5696,O
led,5696,O
to,5696,O
sustained,5696,O
STIM1-puncta,5696,B-GENE-Y
formation,5696,O
and,5696,O
Ca2+,5696,B-CHEMICAL
entry,5696,O
.,5696,O
Of,5697,O
the,5697,O
three,5697,O
p38,5697,B-GENE-N
MAPK,5697,B-GENE-N
isoforms,5697,O
expressed,5697,O
in,5697,O
ECs,5697,O
",",5697,O
p38,5697,B-GENE-Y
knockdown,5697,O
prevented,5697,O
PAR-1-mediated,5697,B-GENE-Y
STIM1,5697,B-GENE-Y
phosphorylation,5697,O
and,5697,O
potentiated,5697,O
SOCE,5697,O
.,5697,O
In,5698,O
addition,5698,O
",",5698,O
inhibition,5698,O
of,5698,O
the,5698,O
SOCE,5698,O
downstream,5698,O
target,5698,O
CaMKK,5698,B-GENE-Y
or,5698,O
knockdown,5698,O
of,5698,O
AMPK1,5698,B-GENE-Y
suppressed,5698,O
PAR-1-mediated,5698,B-GENE-Y
phosphorylation,5698,O
of,5698,O
p38,5698,B-GENE-Y
and,5698,O
hence,5698,O
STIM1,5698,B-GENE-Y
.,5698,O
Thus,5699,O
",",5699,O
our,5699,O
findings,5699,O
demonstrate,5699,O
that,5699,O
SOCE,5699,O
activates,5699,O
CaMKK-AMPK1-p38,5699,B-GENE-Y
MAPK,5699,B-GENE-N
signaling,5699,O
to,5699,O
phosphorylate,5699,O
STIM1,5699,B-GENE-Y
",",5699,O
thereby,5699,O
suppressing,5699,O
endothelial,5699,O
SOCE,5699,O
and,5699,O
permeability,5699,O
responses,5699,O
.,5699,O
Scientific,5700,O
evidence,5700,O
for,5700,O
traditional,5700,O
claim,5700,O
of,5700,O
antiobesity,5700,O
activity,5700,O
of,5700,O
Tecomella,5700,O
undulata,5700,O
bark,5700,O
.,5700,O
ETHNOPHARMACOLOGICAL,5701,O
RELEVANCE,5701,O
:,5701,O
The,5701,O
bark,5701,O
of,5701,O
Tecomella,5701,O
undulata,5701,O
is,5701,O
traditionally,5701,O
claimed,5701,O
in,5701,O
the,5701,O
treatment,5701,O
of,5701,O
various,5701,O
disease,5701,O
ailments,5701,O
including,5701,O
obesity,5701,O
and,5701,O
cancer,5701,O
.,5701,O
Till,5702,O
now,5702,O
there,5702,O
are,5702,O
no,5702,O
studies,5702,O
about,5702,O
anti,5702,O
obesity,5702,O
activity,5702,O
of,5702,O
Tecomella,5702,O
undulata,5702,O
bark,5702,O
.,5702,O
AIM,5703,O
OF,5703,O
THE,5703,O
STUDY,5703,O
:,5703,O
The,5703,O
present,5703,O
study,5703,O
was,5703,O
aimed,5703,O
to,5703,O
establish,5703,O
a,5703,O
scientific,5703,O
evidence,5703,O
for,5703,O
anti,5703,O
obesity,5703,O
efficiency,5703,O
of,5703,O
ethyl,5703,B-CHEMICAL
acetate,5703,I-CHEMICAL
extract,5703,O
of,5703,O
Tecomella,5703,O
undulata,5703,O
bark,5703,O
(,5703,O
EATUB,5703,O
),5703,O
.,5703,O
Further,5704,O
to,5704,O
standardize,5704,O
the,5704,O
active,5704,O
fractions,5704,O
of,5704,O
EATUB,5704,O
using,5704,O
different,5704,O
biomarkers,5704,O
.,5704,O
MATERIALS,5705,O
AND,5705,O
METHODS,5705,O
:,5705,O
We,5705,O
investigated,5705,O
activity,5705,O
of,5705,O
EATUB,5705,O
fractions,5705,O
(,5705,O
F1-F7,5705,O
),5705,O
using,5705,O
3T3-L1,5705,O
fibroblasts,5705,O
.,5705,O
Further,5706,O
",",5706,O
F1-mediated,5706,O
effects,5706,O
were,5706,O
characterized,5706,O
by,5706,O
determining,5706,O
mRNA,5706,O
and,5706,O
protein,5706,O
levels,5706,O
of,5706,O
SIRT1,5706,B-GENE-Y
",",5706,O
one,5706,O
of,5706,O
the,5706,O
key,5706,O
targets,5706,O
for,5706,O
the,5706,O
treatment,5706,O
of,5706,O
obesity,5706,O
",",5706,O
using,5706,O
semi,5706,O
quantitative,5706,O
RT-PCR,5706,O
(,5706,O
sqRT-PCR,5706,O
),5706,O
and,5706,O
western,5706,O
blot,5706,O
analysis,5706,O
.,5706,O
The,5707,O
consequences,5707,O
of,5707,O
modulation,5707,O
of,5707,O
SIRT1,5707,B-GENE-Y
on,5707,O
mRNA,5707,O
and,5707,O
protein,5707,O
levels,5707,O
of,5707,O
various,5707,O
adipogenesis,5707,O
mediators,5707,O
like,5707,O
PPAR,5707,B-GENE-Y
",",5707,O
C/EBP,5707,B-GENE-Y
",",5707,O
E2F1,5707,B-GENE-Y
",",5707,O
leptin,5707,B-GENE-Y
",",5707,O
adiponectin,5707,B-GENE-Y
and,5707,O
LPL,5707,B-GENE-Y
were,5707,O
also,5707,O
studied,5707,O
.,5707,O
In-vivo,5708,O
studies,5708,O
were,5708,O
performed,5708,O
using,5708,O
High,5708,O
Fat,5708,O
Diet,5708,O
(,5708,O
HFD,5708,O
),5708,O
obese,5708,O
mice,5708,O
.,5708,O
RESULTS,5709,O
:,5709,O
Our,5709,O
data,5709,O
showed,5709,O
that,5709,O
compared,5709,O
to,5709,O
controls,5709,O
",",5709,O
preadipocytes,5709,O
and,5709,O
adipocytes,5709,O
incubated,5709,O
with,5709,O
F1,5709,O
exhibited,5709,O
a,5709,O
significant,5709,O
decrease,5709,O
in,5709,O
adipogenesis,5709,O
and,5709,O
lipogenesis,5709,O
.,5709,O
In,5710,O
addition,5710,O
",",5710,O
sqRT-PCR,5710,O
and,5710,O
western,5710,O
blot,5710,O
analysis,5710,O
showed,5710,O
significant,5710,O
increase,5710,O
in,5710,O
SIRT1,5710,B-GENE-Y
and,5710,O
adiponectin,5710,B-GENE-Y
levels,5710,O
and,5710,O
decrease,5710,O
in,5710,O
PPAR,5710,B-GENE-Y
",",5710,O
C/EBP,5710,B-GENE-Y
",",5710,O
E2F1,5710,B-GENE-Y
",",5710,O
leptin,5710,B-GENE-Y
and,5710,O
LPL,5710,B-GENE-Y
levels,5710,O
in,5710,O
preadipocytes,5710,O
and,5710,O
adipocytes,5710,O
.,5710,O
In-vivo,5711,O
studies,5711,O
of,5711,O
F1,5711,O
in,5711,O
HFD,5711,O
induced,5711,O
obese,5711,O
mice,5711,O
showed,5711,O
significant,5711,O
improvement,5711,O
in,5711,O
lipid,5711,O
profile,5711,O
and,5711,O
glucose,5711,B-CHEMICAL
levels,5711,O
.,5711,O
The,5712,O
bioactive,5712,O
fraction,5712,O
(,5712,O
F1,5712,O
),5712,O
was,5712,O
determined,5712,O
to,5712,O
possess,5712,O
4.95,5712,O
%,5712,O
of,5712,O
ferulic,5712,B-CHEMICAL
acid,5712,I-CHEMICAL
.,5712,O
CONCLUSION,5713,O
:,5713,O
Thus,5713,O
",",5713,O
our,5713,O
findings,5713,O
signified,5713,O
the,5713,O
beneficial,5713,O
effects,5713,O
of,5713,O
Tecomella,5713,O
undulata,5713,O
bark,5713,O
in,5713,O
pharmacologic,5713,O
interventions,5713,O
related,5713,O
to,5713,O
obesity,5713,O
and,5713,O
metabolic,5713,O
disorders,5713,O
.,5713,O
Ferulic,5714,B-CHEMICAL
acid,5714,I-CHEMICAL
and,5714,O
rutin,5714,B-CHEMICAL
are,5714,O
being,5714,O
reported,5714,O
and,5714,O
quantified,5714,O
for,5714,O
the,5714,O
first,5714,O
time,5714,O
from,5714,O
the,5714,O
bark,5714,O
of,5714,O
Tecomella,5714,O
undulata,5714,O
.,5714,O
Steroid,5715,B-CHEMICAL
hormone,5715,O
synthesis,5715,O
in,5715,O
mitochondria,5715,O
.,5715,O
Mitochondria,5716,O
are,5716,O
essential,5716,O
sites,5716,O
for,5716,O
steroid,5716,B-CHEMICAL
hormone,5716,O
biosynthesis,5716,O
.,5716,O
Mitochondria,5717,O
in,5717,O
the,5717,O
steroidogenic,5717,O
cells,5717,O
of,5717,O
the,5717,O
adrenal,5717,O
",",5717,O
gonad,5717,O
",",5717,O
placenta,5717,O
and,5717,O
brain,5717,O
contain,5717,O
the,5717,O
cholesterol,5717,B-CHEMICAL
side-chain,5717,O
cleavage,5717,O
enzyme,5717,O
",",5717,O
P450scc,5717,B-GENE-Y
",",5717,O
and,5717,O
its,5717,O
two,5717,O
electron-transfer,5717,O
partners,5717,O
",",5717,O
ferredoxin,5717,B-GENE-N
reductase,5717,I-GENE-N
and,5717,O
ferredoxin,5717,B-GENE-N
.,5717,O
This,5718,O
enzyme,5718,O
system,5718,O
converts,5718,O
cholesterol,5718,B-CHEMICAL
to,5718,O
pregnenolone,5718,B-CHEMICAL
and,5718,O
determines,5718,O
net,5718,O
steroidogenic,5718,O
capacity,5718,O
",",5718,O
so,5718,O
that,5718,O
it,5718,O
serves,5718,O
as,5718,O
the,5718,O
chronic,5718,O
regulator,5718,O
of,5718,O
steroidogenesis,5718,O
.,5718,O
Several,5719,O
other,5719,O
steroidogenic,5719,O
enzymes,5719,O
",",5719,O
including,5719,O
3-hydroxysteroid,5719,B-CHEMICAL
dehydrogenase,5719,I-GENE-Y
",",5719,O
11-hydroxylase,5719,B-GENE-Y
and,5719,O
aldosterone,5719,B-CHEMICAL
synthase,5719,I-GENE-Y
also,5719,O
reside,5719,O
in,5719,O
mitochondria,5719,O
.,5719,O
Similarly,5720,O
",",5720,O
the,5720,O
mitochondria,5720,O
of,5720,O
renal,5720,O
tubular,5720,O
cells,5720,O
contain,5720,O
two,5720,O
key,5720,O
enzymes,5720,O
participating,5720,O
in,5720,O
the,5720,O
activation,5720,O
and,5720,O
degradation,5720,O
of,5720,O
vitamin,5720,B-CHEMICAL
D.,5720,O
The,5720,O
access,5720,O
of,5720,O
cholesterol,5720,B-CHEMICAL
to,5720,O
the,5720,O
mitochondria,5720,O
is,5720,O
regulated,5720,O
by,5720,O
the,5720,O
steroidogenic,5720,B-GENE-Y
acute,5720,I-GENE-Y
regulatory,5720,I-GENE-Y
protein,5720,I-GENE-Y
",",5720,O
StAR,5720,B-GENE-Y
",",5720,O
serving,5720,O
as,5720,O
the,5720,O
acute,5720,O
regulator,5720,O
of,5720,O
steroidogenesis,5720,O
.,5720,O
StAR,5721,B-GENE-Y
action,5721,O
requires,5721,O
a,5721,O
complex,5721,O
multi-component,5721,O
molecular,5721,O
machine,5721,O
on,5721,O
the,5721,O
outer,5721,O
mitochondrial,5721,O
membrane,5721,O
(,5721,O
OMM,5721,O
),5721,O
.,5721,O
Components,5722,O
of,5722,O
this,5722,O
machine,5722,O
include,5722,O
the,5722,O
18kDa,5722,O
translocator,5722,B-GENE-Y
protein,5722,I-GENE-Y
(,5722,O
TSPO,5722,B-GENE-Y
),5722,O
",",5722,O
the,5722,O
voltage-dependent,5722,B-GENE-N
anion,5722,I-GENE-N
chanel,5722,I-GENE-N
(,5722,O
VDAC-1,5722,B-GENE-Y
),5722,O
",",5722,O
TSPO-associated,5722,B-GENE-Y
protein,5722,I-GENE-Y
7,5722,I-GENE-Y
(,5722,O
PAP7,5722,B-GENE-Y
",",5722,O
ACBD3,5722,B-GENE-Y
),5722,O
",",5722,O
and,5722,O
protein,5722,B-GENE-Y
kinase,5722,I-GENE-Y
A,5722,I-GENE-Y
regulatory,5722,I-GENE-Y
subunit,5722,I-GENE-Y
1,5722,I-GENE-Y
(,5722,O
PKAR1A,5722,B-GENE-Y
),5722,O
.,5722,O
The,5723,O
precise,5723,O
fashion,5723,O
in,5723,O
which,5723,O
these,5723,O
proteins,5723,O
interact,5723,O
and,5723,O
move,5723,O
cholesterol,5723,B-CHEMICAL
from,5723,O
the,5723,O
OMM,5723,O
to,5723,O
P450scc,5723,B-GENE-Y
",",5723,O
and,5723,O
the,5723,O
means,5723,O
by,5723,O
which,5723,O
cholesterol,5723,B-CHEMICAL
is,5723,O
loaded,5723,O
into,5723,O
the,5723,O
OMM,5723,O
",",5723,O
remain,5723,O
unclear,5723,O
.,5723,O
Human,5724,O
deficiency,5724,O
diseases,5724,O
have,5724,O
been,5724,O
described,5724,O
for,5724,O
StAR,5724,B-GENE-Y
and,5724,O
for,5724,O
all,5724,O
the,5724,O
mitochondrial,5724,O
steroidogenic,5724,O
enzymes,5724,O
",",5724,O
but,5724,O
not,5724,O
for,5724,O
the,5724,O
electron,5724,O
transfer,5724,O
proteins,5724,O
or,5724,O
for,5724,O
the,5724,O
components,5724,O
of,5724,O
the,5724,O
cholesterol,5724,B-CHEMICAL
import,5724,O
machine,5724,O
.,5724,O
Matrix,5725,B-GENE-N
Metalloproteinase,5725,I-GENE-N
Inhibitors,5725,O
Based,5725,O
on,5725,O
the,5725,O
3-Mercaptopyrrolidine,5725,B-CHEMICAL
Core,5725,O
.,5725,O
New,5726,O
series,5726,O
of,5726,O
pyrrolidine,5726,B-CHEMICAL
mercaptosulfide,5726,I-CHEMICAL
",",5726,O
2-mercaptocyclopentane,5726,B-CHEMICAL
arylsulfonamide,5726,I-CHEMICAL
",",5726,O
and,5726,O
3-mercapto-4-arylsulfonamido,5726,B-CHEMICAL
pyrrolidine,5726,I-CHEMICAL
matrix,5726,B-GENE-N
metalloproteinase,5726,I-GENE-N
inhibitors,5726,O
(,5726,O
MMPIs,5726,O
),5726,O
were,5726,O
designed,5726,O
",",5726,O
synthesized,5726,O
",",5726,O
and,5726,O
evaluated,5726,O
.,5726,O
Exhibiting,5727,O
unique,5727,O
properties,5727,O
over,5727,O
other,5727,O
MMPIs,5727,O
(,5727,O
e.g.,5727,O
",",5727,O
hydroxamates,5727,B-CHEMICAL
),5727,O
",",5727,O
these,5727,O
newly,5727,O
reported,5727,O
compounds,5727,O
are,5727,O
capable,5727,O
of,5727,O
modulating,5727,O
activities,5727,O
of,5727,O
several,5727,O
MMPs,5727,B-GENE-N
in,5727,O
the,5727,O
low,5727,O
nanomolar,5727,O
range,5727,O
",",5727,O
including,5727,O
MMP-2,5727,B-GENE-Y
(,5727,O
~2,5727,O
to,5727,O
50,5727,O
nM,5727,O
),5727,O
",",5727,O
MMP-13,5727,B-GENE-Y
(,5727,O
~2,5727,O
to,5727,O
50,5727,O
nM,5727,O
),5727,O
",",5727,O
and,5727,O
MMP-14,5727,B-GENE-Y
(,5727,O
~4,5727,O
to,5727,O
60,5727,O
nM,5727,O
),5727,O
.,5727,O
Additionally,5728,O
these,5728,O
compounds,5728,O
are,5728,O
selective,5728,O
to,5728,O
intermediate-,5728,O
and,5728,O
deep-pocket,5728,O
MMPs,5728,B-GENE-N
but,5728,O
not,5728,O
shallow-pocketed,5728,O
MMPs,5728,B-GENE-N
(,5728,O
e.g.,5728,O
",",5728,O
MMP-1,5728,B-GENE-Y
",",5728,O
~850,5728,O
to,5728,O
>,5728,O
"50,000",5728,O
nM,5728,O
;,5728,O
MMP-7,5728,B-GENE-Y
",",5728,O
"~4,000",5728,O
to,5728,O
>,5728,O
"25,000",5728,O
nM,5728,O
),5728,O
.,5728,O
Our,5729,O
previous,5729,O
work,5729,O
with,5729,O
the,5729,O
mercaptosulfide,5729,B-CHEMICAL
functionality,5729,O
attached,5729,O
to,5729,O
both,5729,O
cyclopentane,5729,B-CHEMICAL
and,5729,O
pyrrolidine,5729,B-CHEMICAL
frameworks,5729,O
demonstrated,5729,O
that,5729,O
the,5729,O
cis-,5729,O
(,5729,O
"3S,4R",5729,O
),5729,O
-,5729,O
stereochemistry,5729,O
was,5729,O
optimal,5729,O
for,5729,O
all,5729,O
of,5729,O
the,5729,O
MMPs,5729,B-GENE-N
tested,5729,O
.,5729,O
However,5730,O
",",5730,O
in,5730,O
our,5730,O
newest,5730,O
compounds,5730,O
an,5730,O
interesting,5730,O
shift,5730,O
of,5730,O
preference,5730,O
to,5730,O
the,5730,O
trans-,5730,O
form,5730,O
of,5730,O
the,5730,O
mercaptosulfonamides,5730,B-CHEMICAL
was,5730,O
observed,5730,O
with,5730,O
increased,5730,O
oxidative,5730,O
stability,5730,O
and,5730,O
biological,5730,O
compatibility,5730,O
.,5730,O
We,5731,O
also,5731,O
report,5731,O
several,5731,O
kinetic,5731,O
and,5731,O
biological,5731,O
characteristics,5731,O
showing,5731,O
that,5731,O
these,5731,O
compounds,5731,O
may,5731,O
be,5731,O
used,5731,O
to,5731,O
probe,5731,O
the,5731,O
mechanistic,5731,O
activities,5731,O
of,5731,O
MMPs,5731,B-GENE-N
in,5731,O
disease,5731,O
.,5731,O
A,5732,O
Structural,5732,O
Snapshot,5732,O
of,5732,O
Cytochrome,5732,B-GENE-Y
P450,5732,I-GENE-Y
2B4,5732,I-GENE-Y
in,5732,O
Complex,5732,O
with,5732,O
Paroxetine,5732,B-CHEMICAL
Provides,5732,O
Insights,5732,O
into,5732,O
Ligand,5732,O
Binding,5732,O
and,5732,O
Clusters,5732,O
of,5732,O
Conformational,5732,O
States,5732,O
.,5732,O
An,5733,O
X-ray,5733,O
crystal,5733,O
structure,5733,O
of,5733,O
cytochrome,5733,B-GENE-Y
P450,5733,I-GENE-Y
2B4,5733,I-GENE-Y
in,5733,O
complex,5733,O
with,5733,O
the,5733,O
drug,5733,O
paroxetine,5733,B-CHEMICAL
was,5733,O
solved,5733,O
at,5733,O
2.14,5733,O
,5733,O
resolution,5733,O
.,5733,O
The,5734,O
structure,5734,O
revealed,5734,O
a,5734,O
conformation,5734,O
intermediate,5734,O
to,5734,O
that,5734,O
of,5734,O
the,5734,O
recently,5734,O
solved,5734,O
complex,5734,O
with,5734,O
amlodipine,5734,B-CHEMICAL
and,5734,O
of,5734,O
the,5734,O
more,5734,O
compact,5734,O
complex,5734,O
with,5734,O
4-,5734,B-CHEMICAL
(,5734,I-CHEMICAL
4-chlorophenyl,5734,I-CHEMICAL
),5734,I-CHEMICAL
imidazole,5734,I-CHEMICAL
in,5734,O
terms,5734,O
of,5734,O
the,5734,O
placement,5734,O
of,5734,O
the,5734,O
F-G,5734,O
cassette,5734,O
.,5734,O
Moreover,5735,O
",",5735,O
the,5735,O
comparison,5735,O
of,5735,O
the,5735,O
new,5735,O
structure,5735,O
with,5735,O
15,5735,O
previously,5735,O
solved,5735,O
structures,5735,O
of,5735,O
P450,5735,B-GENE-Y
2B4,5735,I-GENE-Y
revealed,5735,O
some,5735,O
new,5735,O
insights,5735,O
into,5735,O
determinants,5735,O
of,5735,O
active,5735,O
site,5735,O
size,5735,O
and,5735,O
shape,5735,O
.,5735,O
The,5736,O
2B4-paroxetine,5736,B-GENE-Y
structure,5736,O
is,5736,O
nearly,5736,O
superimposable,5736,O
on,5736,O
a,5736,O
previously,5736,O
solved,5736,O
closed,5736,O
structure,5736,O
in,5736,O
a,5736,O
ligand,5736,O
free,5736,O
state,5736,O
.,5736,O
Despite,5737,O
the,5737,O
overall,5737,O
conformational,5737,O
similarity,5737,O
among,5737,O
multiple,5737,O
closed,5737,O
structures,5737,O
",",5737,O
the,5737,O
active,5737,O
site,5737,O
cavity,5737,O
volume,5737,O
of,5737,O
the,5737,O
paroxetine,5737,B-CHEMICAL
complex,5737,O
is,5737,O
enlarged,5737,O
.,5737,O
Further,5738,O
analysis,5738,O
of,5738,O
the,5738,O
accessible,5738,O
space,5738,O
and,5738,O
binding,5738,O
pocket,5738,O
near,5738,O
the,5738,O
heme,5738,O
reveals,5738,O
a,5738,O
new,5738,O
sub-chamber,5738,O
that,5738,O
resulted,5738,O
from,5738,O
the,5738,O
movement,5738,O
of,5738,O
secondary,5738,O
structural,5738,O
elements,5738,O
and,5738,O
rearrangements,5738,O
of,5738,O
active,5738,O
site,5738,O
side,5738,O
chains,5738,O
.,5738,O
Overall,5739,O
",",5739,O
the,5739,O
results,5739,O
from,5739,O
the,5739,O
comparison,5739,O
of,5739,O
all,5739,O
the,5739,O
16,5739,O
structures,5739,O
of,5739,O
P450,5739,B-GENE-Y
2B4,5739,I-GENE-Y
demonstrate,5739,O
a,5739,O
cluster,5739,O
of,5739,O
protein,5739,O
conformations,5739,O
that,5739,O
were,5739,O
observed,5739,O
in,5739,O
the,5739,O
presence,5739,O
or,5739,O
absence,5739,O
of,5739,O
various,5739,O
ligands,5739,O
.,5739,O
Protective,5740,O
Role,5740,O
of,5740,O
(,5740,B-CHEMICAL
RS,5740,I-CHEMICAL
),5740,I-CHEMICAL
-glucoraphanin,5740,I-CHEMICAL
Bioactivated,5740,O
with,5740,O
Myrosinase,5740,B-GENE-N
in,5740,O
an,5740,O
Experimental,5740,O
Model,5740,O
of,5740,O
Multiple,5740,O
Sclerosis,5740,O
.,5740,O
AIM,5741,O
:,5741,O
The,5741,O
discovery,5741,O
of,5741,O
new,5741,O
natural,5741,O
compounds,5741,O
with,5741,O
pharmacological,5741,O
properties,5741,O
is,5741,O
a,5741,O
field,5741,O
of,5741,O
interest,5741,O
widely,5741,O
growing,5741,O
.,5741,O
Recent,5742,O
literature,5742,O
shows,5742,O
that,5742,O
Brassica,5742,O
vegetables,5742,O
(,5742,O
Cruciferae,5742,O
),5742,O
possess,5742,O
therapeutic,5742,O
effects,5742,O
particularly,5742,O
ascribed,5742,O
due,5742,O
to,5742,O
their,5742,O
content,5742,O
in,5742,O
glucosinolates,5742,B-CHEMICAL
",",5742,O
which,5742,O
upon,5742,O
myrosinase,5742,B-GENE-N
hydrolysis,5742,O
release,5742,O
the,5742,O
corresponding,5742,O
isothiocyanates,5742,B-CHEMICAL
.,5742,O
This,5743,O
study,5743,O
examines,5743,O
the,5743,O
potential,5743,O
neuroprotective,5743,O
and,5743,O
immunomodulatory,5743,O
effects,5743,O
of,5743,O
(,5743,B-CHEMICAL
RS,5743,I-CHEMICAL
),5743,I-CHEMICAL
-glucoraphanin,5743,I-CHEMICAL
from,5743,O
Tuscan,5743,O
black,5743,O
kale,5743,O
(,5743,O
Brassica,5743,O
oleracea,5743,O
L.,5743,O
var,5743,O
.,5743,O
acephala,5744,O
sabellica,5744,O
),5744,O
bioactivated,5744,O
with,5744,O
myrosinase,5744,B-GENE-N
(,5744,O
bioactive,5744,O
RS,5744,B-CHEMICAL
-GRA,5744,I-CHEMICAL
),5744,O
(,5744,O
10,5744,O
mg/kg/day,5744,O
intraperitoneally,5744,O
),5744,O
",",5744,O
in,5744,O
an,5744,O
experimental,5744,O
autoimmune,5744,O
encephalomyelitis,5744,O
(,5744,O
EAE,5744,O
),5744,O
",",5744,O
a,5744,O
model,5744,O
of,5744,O
multiple,5744,O
sclerosis,5744,O
.,5744,O
METHODS,5745,O
:,5745,O
EAE,5745,O
was,5745,O
induced,5745,O
by,5745,O
immunization,5745,O
with,5745,O
myelin,5745,B-GENE-Y
oligodendroglial,5745,I-GENE-Y
glycoprotein,5745,I-GENE-Y
peptide,5745,I-GENE-Y
(,5745,O
MOG35-55,5745,B-GENE-Y
),5745,O
in,5745,O
mice,5745,O
.,5745,O
After,5746,O
immunization,5746,O
",",5746,O
mice,5746,O
were,5746,O
observed,5746,O
daily,5746,O
for,5746,O
signs,5746,O
of,5746,O
EAE,5746,O
and,5746,O
weight,5746,O
loss,5746,O
.,5746,O
Clinical,5747,O
score,5747,O
was,5747,O
evaluated,5747,O
using,5747,O
a,5747,O
standardized,5747,O
scoring,5747,O
system,5747,O
.,5747,O
RESULTS,5748,O
:,5748,O
By,5748,O
Western,5748,O
blot,5748,O
analysis,5748,O
of,5748,O
spinal,5748,O
cord,5748,O
tissues,5748,O
",",5748,O
we,5748,O
have,5748,O
demonstrated,5748,O
that,5748,O
treatment,5748,O
with,5748,O
bioactive,5748,O
RS,5748,B-CHEMICAL
-GRA,5748,I-CHEMICAL
significantly,5748,O
decreased,5748,O
nuclear,5748,B-GENE-N
factor,5748,I-GENE-N
(,5748,I-GENE-N
NF,5748,I-GENE-N
),5748,I-GENE-N
-kB,5748,I-GENE-N
translocation,5748,O
",",5748,O
pro-inflammatory,5748,O
cytokine,5748,B-GENE-N
production,5748,O
such,5748,O
as,5748,O
interleukin-1,5748,B-GENE-Y
(,5748,O
IL-1,5748,B-GENE-Y
),5748,O
",",5748,O
and,5748,O
apoptosis,5748,O
(,5748,O
Bax,5748,B-GENE-Y
and,5748,O
caspase,5748,B-GENE-Y
3,5748,I-GENE-Y
expression,5748,O
),5748,O
.,5748,O
CONCLUSION,5749,O
:,5749,O
Our,5749,O
results,5749,O
clearly,5749,O
demonstrate,5749,O
that,5749,O
bioactive,5749,O
RS,5749,B-CHEMICAL
-GRA,5749,I-CHEMICAL
treatment,5749,O
may,5749,O
represent,5749,O
a,5749,O
useful,5749,O
therapeutic,5749,O
perspective,5749,O
in,5749,O
the,5749,O
treatment,5749,O
of,5749,O
this,5749,O
disease,5749,O
.,5749,O
Involvement,5750,O
of,5750,O
p-CREB,5750,B-GENE-N
and,5750,O
phase,5750,B-GENE-N
II,5750,I-GENE-N
detoxifying,5750,I-GENE-N
enzyme,5750,I-GENE-N
system,5750,O
in,5750,O
neuroprotection,5750,O
mediated,5750,O
by,5750,O
the,5750,O
flavonoid,5750,O
calycopterin,5750,B-CHEMICAL
isolated,5750,O
from,5750,O
Dracocephalum,5750,O
kotschyi,5750,O
.,5750,O
PURPOSE,5751,O
:,5751,O
There,5751,O
is,5751,O
an,5751,O
increasing,5751,O
amount,5751,O
of,5751,O
experimental,5751,O
evidence,5751,O
that,5751,O
oxidative,5751,O
stress,5751,O
has,5751,O
a,5751,O
central,5751,O
role,5751,O
in,5751,O
the,5751,O
neuropathology,5751,O
of,5751,O
neurodegenerative,5751,O
diseases,5751,O
.,5751,O
It,5752,O
has,5752,O
been,5752,O
suggested,5752,O
that,5752,O
the,5752,O
loss,5752,O
of,5752,O
cell,5752,O
function,5752,O
results,5752,O
from,5752,O
the,5752,O
increased,5752,O
oxidative,5752,O
damage,5752,O
to,5752,O
proteins,5752,O
and,5752,O
DNA,5752,O
.,5752,O
Herein,5753,O
",",5753,O
we,5753,O
investigated,5753,O
the,5753,O
effect,5753,O
of,5753,O
a,5753,O
natural,5753,O
neuroprotective,5753,O
flavonoid,5753,O
",",5753,O
calycopterin,5753,B-CHEMICAL
",",5753,O
on,5753,O
H2O2-induced,5753,B-CHEMICAL
disruption,5753,O
of,5753,O
phase,5753,B-GENE-N
II,5753,I-GENE-N
detoxifying,5753,I-GENE-N
enzyme,5753,I-GENE-N
system,5753,O
and,5753,O
cAMP,5753,B-GENE-N
response,5753,I-GENE-N
element,5753,I-GENE-N
binding,5753,I-GENE-N
protein,5753,I-GENE-N
(,5753,O
CREB,5753,B-GENE-N
),5753,O
phosphorylation,5753,O
.,5753,O
METHODS,5754,O
:,5754,O
PC12,5754,O
cells,5754,O
were,5754,O
treated,5754,O
with,5754,O
25,5754,O
",",5754,O
50,5754,O
and,5754,O
100M,5754,O
of,5754,O
calycopterin,5754,B-CHEMICAL
for,5754,O
3h,5754,O
",",5754,O
followed,5754,O
by,5754,O
adding,5754,O
H2O2,5754,B-CHEMICAL
(,5754,O
150M,5754,O
),5754,O
for,5754,O
24h,5754,O
.,5754,O
The,5755,O
extent,5755,O
of,5755,O
apoptosis,5755,O
was,5755,O
assessed,5755,O
by,5755,O
comet,5755,O
assay,5755,O
.,5755,O
The,5756,O
level,5756,O
of,5756,O
phosphorylated,5756,B-GENE-N
CREB,5756,I-GENE-N
",",5756,O
nuclear,5756,B-GENE-Y
factor,5756,I-GENE-Y
erythroid,5756,I-GENE-Y
2-related,5756,I-GENE-Y
factor,5756,I-GENE-Y
2,5756,I-GENE-Y
(,5756,O
Nrf2,5756,B-GENE-Y
),5756,O
",",5756,O
glutamylcysteine,5756,B-GENE-Y
synthetase,5756,I-GENE-Y
(,5756,O
-GCS,5756,B-GENE-Y
),5756,O
and,5756,O
heme,5756,B-GENE-Y
oxygenase,5756,I-GENE-Y
1,5756,I-GENE-Y
(,5756,O
HO-1,5756,B-GENE-Y
),5756,O
were,5756,O
measured,5756,O
by,5756,O
western,5756,O
blot,5756,O
method,5756,O
.,5756,O
The,5757,O
concentration,5757,O
of,5757,O
glutathione,5757,B-CHEMICAL
(,5757,O
GSH,5757,B-CHEMICAL
),5757,O
was,5757,O
determined,5757,O
in,5757,O
whole,5757,O
cell,5757,O
lysate,5757,O
using,5757,O
dithionitrobenzoic,5757,O
acid,5757,O
method,5757,O
.,5757,O
Superoxide,5758,B-GENE-N
dismutase,5758,I-GENE-N
(,5758,O
SOD,5758,B-GENE-N
),5758,O
activity,5758,O
was,5758,O
measured,5758,O
by,5758,O
colorimetric,5758,O
assay,5758,O
.,5758,O
RESULT,5759,O
:,5759,O
Morphological,5759,O
analysis,5759,O
of,5759,O
protection,5759,O
induced,5759,O
by,5759,O
calycopterin,5759,B-CHEMICAL
",",5759,O
determined,5759,O
by,5759,O
comet,5759,O
assay,5759,O
",",5759,O
showed,5759,O
that,5759,O
calycopterin,5759,B-CHEMICAL
reduced,5759,O
DNA,5759,O
in,5759,O
tail,5759,O
.,5759,O
We,5760,O
found,5760,O
that,5760,O
H2O2,5760,B-CHEMICAL
decreased,5760,O
mitochondrial,5760,O
membrane,5760,O
potential,5760,O
(,5760,O
MMP,5760,O
),5760,O
",",5760,O
while,5760,O
",",5760,O
calycopterin,5760,B-CHEMICAL
prevented,5760,O
this,5760,O
decrease,5760,O
in,5760,O
MMP,5760,O
in,5760,O
presence,5760,O
of,5760,O
H2O2,5760,B-CHEMICAL
.,5760,O
In,5761,O
H2O2-treated,5761,B-CHEMICAL
cells,5761,O
",",5761,O
calycopterin,5761,B-CHEMICAL
also,5761,O
suppressed,5761,O
cytochrome,5761,B-GENE-Y
C,5761,I-GENE-Y
release,5761,O
to,5761,O
cytosol,5761,O
that,5761,O
is,5761,O
necessary,5761,O
for,5761,O
maintaining,5761,O
mitochondrial,5761,O
homeostasis,5761,O
in,5761,O
survived,5761,O
cells,5761,O
.,5761,O
Moreover,5762,O
",",5762,O
calycopterin,5762,B-CHEMICAL
",",5762,O
in,5762,O
presence,5762,O
of,5762,O
H2O2,5762,B-CHEMICAL
inhibited,5762,O
the,5762,O
decrease,5762,O
caused,5762,O
by,5762,O
oxidative,5762,O
stress,5762,O
in,5762,O
stress-sensing,5762,O
transcription,5762,O
factors,5762,O
",",5762,O
CREB,5762,B-GENE-N
and,5762,O
Nrf2,5762,B-GENE-Y
",",5762,O
which,5762,O
play,5762,O
an,5762,O
important,5762,O
role,5762,O
in,5762,O
antioxidant,5762,O
capacity,5762,O
of,5762,O
the,5762,O
cell,5762,O
.,5762,O
There,5763,O
was,5763,O
also,5763,O
an,5763,O
increase,5763,O
in,5763,O
-GCS,5763,B-GENE-Y
and,5763,O
HO-1,5763,B-GENE-Y
levels,5763,O
in,5763,O
calycopterin,5763,B-CHEMICAL
pretreated,5763,O
cells,5763,O
.,5763,O
In,5764,O
the,5764,O
presence,5764,O
of,5764,O
H2O2,5764,B-CHEMICAL
",",5764,O
calycopterin,5764,B-CHEMICAL
inhibited,5764,O
decrease,5764,O
in,5764,O
GSH,5764,B-CHEMICAL
level,5764,O
and,5764,O
SOD,5764,B-GENE-N
activity,5764,O
.,5764,O
CONCLUSION,5765,O
:,5765,O
We,5765,O
provided,5765,O
documentation,5765,O
of,5765,O
neuroprotective,5765,O
effect,5765,O
of,5765,O
a,5765,O
natural,5765,O
flavone,5765,O
",",5765,O
calycopterin,5765,B-CHEMICAL
",",5765,O
against,5765,O
H2O2-induced,5765,B-CHEMICAL
oxidative,5765,O
stress,5765,O
in,5765,O
differentiated,5765,O
PC12,5765,O
cells,5765,O
by,5765,O
modulating,5765,O
the,5765,O
level,5765,O
of,5765,O
CREB,5765,B-GENE-N
phosphorylation,5765,O
and,5765,O
Nrf2,5765,B-GENE-Y
pathway,5765,O
.,5765,O
Indoxyl,5766,B-CHEMICAL
3-sulfate,5766,I-CHEMICAL
stimulates,5766,O
Th17,5766,O
differentiation,5766,O
enhancing,5766,O
phosphorylation,5766,O
of,5766,O
c-Src,5766,B-GENE-Y
and,5766,O
STAT3,5766,B-GENE-Y
to,5766,O
worsen,5766,O
experimental,5766,O
autoimmune,5766,O
encephalomyelitis,5766,O
.,5766,O
Although,5767,O
AhR,5767,B-GENE-Y
activation,5767,O
regulates,5767,O
CD4T,5767,O
cell,5767,O
differentiation,5767,O
",",5767,O
how,5767,O
it,5767,O
works,5767,O
has,5767,O
yet,5767,O
to,5767,O
be,5767,O
elucidated,5767,O
.,5767,O
In,5768,O
the,5768,O
present,5768,O
study,5768,O
",",5768,O
using,5768,O
in,5768,O
vitro,5768,O
Th17,5768,O
differentiation,5768,O
model,5768,O
",",5768,O
we,5768,O
examined,5768,O
effects,5768,O
of,5768,O
AhR,5768,B-GENE-Y
activation,5768,O
by,5768,O
indoxyl,5768,B-CHEMICAL
3-sulfate,5768,I-CHEMICAL
(,5768,O
I3S,5768,B-CHEMICAL
),5768,O
",",5768,O
a,5768,O
uremic,5768,O
toxin,5768,O
",",5768,O
on,5768,O
Th17,5768,O
differentiation,5768,O
and,5768,O
investigated,5768,O
underlying,5768,O
mechanisms,5768,O
.,5768,O
I3S,5769,B-CHEMICAL
increased,5769,O
expression,5769,O
of,5769,O
RORt,5769,B-GENE-Y
",",5769,O
the,5769,O
master,5769,O
transcription,5769,O
factor,5769,O
for,5769,O
Th17,5769,O
differentiation,5769,O
",",5769,O
and,5769,O
stimulated,5769,O
Th17,5769,O
differentiation,5769,O
",",5769,O
in,5769,O
a,5769,O
comparative,5769,O
manner,5769,O
as,5769,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",5769,B-CHEMICAL
(,5769,O
TCDD,5769,B-CHEMICAL
),5769,O
",",5769,O
a,5769,O
prototypical,5769,O
AhR,5769,B-GENE-Y
ligand,5769,O
.,5769,O
Activation,5770,O
of,5770,O
STAT3,5770,B-GENE-Y
",",5770,O
which,5770,O
is,5770,O
phosphorylated,5770,O
by,5770,O
the,5770,O
IL-6,5770,B-GENE-Y
signaling,5770,O
pathways,5770,O
and,5770,O
thus,5770,O
is,5770,O
necessary,5770,O
for,5770,O
Th17,5770,O
differentiation,5770,O
",",5770,O
was,5770,O
strongly,5770,O
stimulated,5770,O
by,5770,O
I3S,5770,B-CHEMICAL
and,5770,O
TCDD,5770,B-CHEMICAL
.,5770,O
Phosphorylation,5771,O
of,5771,O
c-Src,5771,B-GENE-Y
",",5771,O
which,5771,O
was,5771,O
shown,5771,O
to,5771,O
be,5771,O
activated,5771,O
by,5771,O
AhR,5771,B-GENE-Y
ligands,5771,O
",",5771,O
was,5771,O
also,5771,O
increased,5771,O
by,5771,O
I3S,5771,B-CHEMICAL
and,5771,O
TCDD,5771,B-CHEMICAL
",",5771,O
and,5771,O
blocking,5771,O
of,5771,O
c-Src,5771,B-GENE-Y
activity,5771,O
by,5771,O
4-amino-5-,5771,B-CHEMICAL
(,5771,I-CHEMICAL
4-chlorophenyl,5771,I-CHEMICAL
),5771,I-CHEMICAL
-7-,5771,I-CHEMICAL
(,5771,I-CHEMICAL
t-butyl,5771,I-CHEMICAL
),5771,I-CHEMICAL
pyrazolo,5771,I-CHEMICAL
[,5771,I-CHEMICAL
"3,4-d",5771,I-CHEMICAL
],5771,I-CHEMICAL
pyrimidine,5771,I-CHEMICAL
(,5771,O
PP2,5771,O
),5771,O
inhibited,5771,O
phosphorylation,5771,O
of,5771,O
both,5771,O
c-Src,5771,B-GENE-Y
and,5771,O
STAT3,5771,B-GENE-Y
",",5771,O
raising,5771,O
a,5771,O
possibility,5771,O
that,5771,O
stimulatory,5771,O
activities,5771,O
of,5771,O
I3S,5771,B-CHEMICAL
and,5771,O
TCDD,5771,B-CHEMICAL
on,5771,O
Th17,5771,O
differentiation,5771,O
could,5771,O
be,5771,O
exerted,5771,O
via,5771,O
increased,5771,O
phosphorylation,5771,O
of,5771,O
c-Src,5771,B-GENE-Y
",",5771,O
which,5771,O
in,5771,O
turn,5771,O
stimulates,5771,O
STAT3,5771,B-GENE-Y
activation,5771,O
.,5771,O
Finally,5772,O
",",5772,O
we,5772,O
found,5772,O
that,5772,O
I3S,5772,B-CHEMICAL
worsened,5772,O
experimental,5772,O
autoimmune,5772,O
encephalomyelitis,5772,O
(,5772,O
EAE,5772,O
),5772,O
",",5772,O
which,5772,O
is,5772,O
primarily,5772,O
mediated,5772,O
by,5772,O
Th17,5772,O
cells,5772,O
",",5772,O
enhancing,5772,O
the,5772,O
frequency,5772,O
of,5772,O
IL-17-producing,5772,B-GENE-Y
cells,5772,O
in,5772,O
draining,5772,O
lymph,5772,O
nodes,5772,O
.,5772,O
Gene,5773,O
expression,5773,O
profiling,5773,O
and,5773,O
pathway,5773,O
analysis,5773,O
of,5773,O
hepatotoxicity,5773,O
induced,5773,O
by,5773,O
triptolide,5773,B-CHEMICAL
in,5773,O
Wistar,5773,O
rats,5773,O
.,5773,O
Triptolide,5774,B-CHEMICAL
(,5774,O
TP,5774,O
),5774,O
",",5774,O
a,5774,O
major,5774,O
component,5774,O
of,5774,O
TWHF,5774,O
",",5774,O
is,5774,O
widely,5774,O
used,5774,O
to,5774,O
treat,5774,O
rheumatoid,5774,O
arthritis,5774,O
",",5774,O
systemic,5774,O
lupus,5774,O
erythematosus,5774,O
",",5774,O
nephritis,5774,O
and,5774,O
leprosy,5774,O
.,5774,O
However,5775,O
",",5775,O
its,5775,O
clinical,5775,O
use,5775,O
is,5775,O
limited,5775,O
by,5775,O
hepatotoxicity,5775,O
.,5775,O
To,5776,O
further,5776,O
elucidate,5776,O
the,5776,O
underlying,5776,O
mechanism,5776,O
of,5776,O
its,5776,O
hepatotoxic,5776,O
effects,5776,O
",",5776,O
hepatic,5776,O
gene,5776,O
expression,5776,O
profiles,5776,O
were,5776,O
analyzed,5776,O
.,5776,O
TP,5777,O
(,5777,O
1000,5777,O
and,5777,O
300g/kg,5777,O
),5777,O
was,5777,O
orally,5777,O
administered,5777,O
to,5777,O
Wistar,5777,O
rats,5777,O
for,5777,O
14days,5777,O
.,5777,O
Current,5778,O
study,5778,O
indicated,5778,O
that,5778,O
female,5778,O
rats,5778,O
were,5778,O
more,5778,O
sensitive,5778,O
to,5778,O
TP-induced,5778,O
hepatotoxicity,5778,O
than,5778,O
males,5778,O
.,5778,O
Genome-wide,5779,O
microarray,5779,O
analyses,5779,O
identified,5779,O
3329,5779,O
differentially,5779,O
expressed,5779,O
genes,5779,O
in,5779,O
liver,5779,O
of,5779,O
female,5779,O
rats,5779,O
.,5779,O
Analyses,5780,O
of,5780,O
these,5780,O
genes,5780,O
identified,5780,O
over-represented,5780,O
functions,5780,O
associated,5780,O
with,5780,O
insulin,5780,B-GENE-N
signaling,5780,O
pathway,5780,O
",",5780,O
glucose,5780,B-CHEMICAL
metabolism,5780,O
",",5780,O
cell,5780,O
cycle,5780,O
",",5780,O
oxidative,5780,O
stress,5780,O
and,5780,O
apoptosis,5780,O
",",5780,O
which,5780,O
were,5780,O
consistent,5780,O
with,5780,O
the,5780,O
results,5780,O
of,5780,O
significant,5780,O
increase,5780,O
of,5780,O
Caspase-3,5780,B-GENE-Y
activity,5780,O
and,5780,O
reduction,5780,O
of,5780,O
serum,5780,O
glucose,5780,B-CHEMICAL
",",5780,O
GSH/GSSG,5780,B-CHEMICAL
ratio,5780,O
",",5780,O
glucose-6-phosphatase,5780,B-CHEMICAL
and,5780,O
phosphoenolpyruvate,5780,B-CHEMICAL
carboxykinase,5780,I-GENE-Y
activities,5780,O
",",5780,O
liver,5780,O
glycogen,5780,O
.,5780,O
In,5781,O
addition,5781,O
",",5781,O
it,5781,O
was,5781,O
observed,5781,O
for,5781,O
the,5781,O
first,5781,O
time,5781,O
that,5781,O
glucocorticoids,5781,O
and,5781,O
IGF1,5781,B-GENE-Y
might,5781,O
get,5781,O
involved,5781,O
in,5781,O
TP-induced,5781,O
hepatotoxicity,5781,O
.,5781,O
These,5782,O
data,5782,O
suggest,5782,O
that,5782,O
TP,5782,O
treatment,5782,O
could,5782,O
alter,5782,O
the,5782,O
hepatic,5782,O
redox,5782,O
status,5782,O
",",5782,O
reduce,5782,O
serum,5782,O
glucose,5782,B-CHEMICAL
and,5782,O
induce,5782,O
hepatocyte,5782,O
apoptosis,5782,O
",",5782,O
consistent,5782,O
with,5782,O
the,5782,O
differential,5782,O
expression,5782,O
of,5782,O
genes,5782,O
involved,5782,O
in,5782,O
insulin,5782,B-GENE-N
signaling,5782,O
pathway,5782,O
",",5782,O
glucose,5782,B-CHEMICAL
metabolism,5782,O
pathway,5782,O
and,5782,O
cell,5782,O
stress,5782,O
pathway,5782,O
",",5782,O
all,5782,O
of,5782,O
which,5782,O
might,5782,O
contribute,5782,O
to,5782,O
the,5782,O
overall,5782,O
TP-induced,5782,O
hepatotoxicity,5782,O
.,5782,O
TCDD,5783,B-CHEMICAL
induces,5783,O
the,5783,O
expression,5783,O
of,5783,O
insulin-like,5783,B-GENE-Y
growth,5783,I-GENE-Y
factor,5783,I-GENE-Y
binding,5783,I-GENE-Y
protein,5783,I-GENE-Y
4,5783,I-GENE-Y
in,5783,O
5L,5783,O
rat,5783,O
hepatoma,5783,O
cells,5783,O
:,5783,O
a,5783,O
cautionary,5783,O
tale,5783,O
of,5783,O
the,5783,O
use,5783,O
of,5783,O
this,5783,O
cell,5783,O
line,5783,O
in,5783,O
studies,5783,O
on,5783,O
dioxin,5783,B-CHEMICAL
toxicity,5783,O
.,5783,O
Previous,5784,O
quantitative,5784,O
proteomic,5784,O
studies,5784,O
on,5784,O
the,5784,O
actions,5784,O
of,5784,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",5784,B-CHEMICAL
(,5784,O
TCDD,5784,B-CHEMICAL
),5784,O
in,5784,O
5L,5784,O
rat,5784,O
hepatoma,5784,O
cells,5784,O
",",5784,O
a,5784,O
cell,5784,O
model,5784,O
frequently,5784,O
used,5784,O
for,5784,O
investigating,5784,O
the,5784,O
mechanisms,5784,O
of,5784,O
TCDD,5784,B-CHEMICAL
toxicity,5784,O
",",5784,O
had,5784,O
indicated,5784,O
that,5784,O
dioxin,5784,B-CHEMICAL
exposure,5784,O
reduced,5784,O
the,5784,O
abundance,5784,O
of,5784,O
numerous,5784,O
proteins,5784,O
which,5784,O
are,5784,O
regulated,5784,O
at,5784,O
the,5784,O
level,5784,O
of,5784,O
protein,5784,O
synthesis,5784,O
initiation,5784,O
.,5784,O
In,5785,O
the,5785,O
present,5785,O
study,5785,O
",",5785,O
we,5785,O
have,5785,O
analysed,5785,O
the,5785,O
mechanism,5785,O
mediating,5785,O
this,5785,O
inhibition,5785,O
.,5785,O
TCDD,5786,B-CHEMICAL
treatment,5786,O
of,5786,O
the,5786,O
cells,5786,O
largely,5786,O
prevented,5786,O
the,5786,O
activation,5786,O
of,5786,O
eukaryotic,5786,B-GENE-Y
translation,5786,I-GENE-Y
initiation,5786,I-GENE-Y
factor,5786,I-GENE-Y
4E-binding,5786,I-GENE-Y
protein,5786,I-GENE-Y
1,5786,I-GENE-Y
",",5786,O
a,5786,O
regulator,5786,O
of,5786,O
translation,5786,O
initiation,5786,O
and,5786,O
substrate,5786,O
of,5786,O
the,5786,O
mammalian,5786,B-GENE-Y
target,5786,I-GENE-Y
of,5786,I-GENE-Y
rapamycin,5786,I-GENE-Y
(,5786,O
mTOR,5786,B-GENE-Y
),5786,O
.,5786,O
By,5787,O
``,5787,O
working,5787,O
upwards,5787,O
'',5787,O
from,5787,O
mTOR,5787,B-GENE-Y
",",5787,O
we,5787,O
observed,5787,O
that,5787,O
TCDD,5787,B-CHEMICAL
inhibited,5787,O
endogenous,5787,O
and,5787,O
IGF-I-induced,5787,B-GENE-Y
AKT,5787,B-GENE-N
and,5787,O
ERK,5787,B-GENE-N
activation,5787,O
by,5787,O
interfering,5787,O
with,5787,O
tyrosine,5787,B-CHEMICAL
phosphorylation,5787,O
of,5787,O
insulin,5787,B-GENE-Y
receptor,5787,I-GENE-Y
substrate,5787,I-GENE-Y
1,5787,I-GENE-Y
.,5787,O
This,5788,O
inhibition,5788,O
was,5788,O
mediated,5788,O
by,5788,O
a,5788,O
TCDD-induced,5788,B-CHEMICAL
secreted,5788,O
factor,5788,O
which,5788,O
was,5788,O
identified,5788,O
as,5788,O
insulin-like,5788,B-GENE-Y
growth,5788,I-GENE-Y
factor,5788,I-GENE-Y
binding,5788,I-GENE-Y
protein,5788,I-GENE-Y
4,5788,I-GENE-Y
(,5788,O
IGFBP-4,5788,B-GENE-Y
),5788,O
.,5788,O
The,5789,O
induction,5789,O
of,5789,O
IGFBP-4,5789,B-GENE-Y
protein,5789,O
was,5789,O
dependent,5789,O
on,5789,O
a,5789,O
functional,5789,O
aryl,5789,B-CHEMICAL
hydrocarbon,5789,I-CHEMICAL
receptor,5789,I-GENE-Y
and,5789,O
was,5789,O
preceded,5789,O
by,5789,O
a,5789,O
rapid,5789,O
increase,5789,O
in,5789,O
the,5789,O
level,5789,O
of,5789,O
IGFBP-4,5789,B-GENE-Y
mRNA,5789,O
indicating,5789,O
that,5789,O
IGFBP-4,5789,B-GENE-Y
is,5789,O
a,5789,O
previously,5789,O
unknown,5789,O
transcriptional,5789,O
target,5789,O
of,5789,O
TCDD,5789,B-CHEMICAL
in,5789,O
5L,5789,O
cells,5789,O
.,5789,O
IGFBP-4,5790,B-GENE-Y
was,5790,O
not,5790,O
induced,5790,O
by,5790,O
TCDD,5790,B-CHEMICAL
in,5790,O
the,5790,O
parental,5790,O
cell,5790,O
line,5790,O
of,5790,O
5L,5790,O
cells,5790,O
",",5790,O
Fao,5790,O
",",5790,O
and,5790,O
in,5790,O
various,5790,O
closely,5790,O
related,5790,O
rat,5790,O
hepatoma,5790,O
cell,5790,O
lines,5790,O
as,5790,O
well,5790,O
as,5790,O
in,5790,O
other,5790,O
unrelated,5790,O
cell,5790,O
types,5790,O
.,5790,O
Analysis,5791,O
of,5791,O
5L,5791,O
cell,5791,O
chromosomes,5791,O
by,5791,O
multicolour,5791,O
spectral,5791,O
karyotyping,5791,O
(,5791,O
SKY,5791,O
),5791,O
revealed,5791,O
that,5791,O
the,5791,O
cells,5791,O
carry,5791,O
several,5791,O
hitherto,5791,O
uncharacterised,5791,O
chromosomal,5791,O
translocations,5791,O
.,5791,O
The,5792,O
observations,5792,O
suggest,5792,O
that,5792,O
in,5792,O
5L,5792,O
cells,5792,O
the,5792,O
Igfbp-4,5792,B-GENE-Y
gene,5792,O
may,5792,O
have,5792,O
got,5792,O
under,5792,O
the,5792,O
control,5792,O
of,5792,O
a,5792,O
promoter,5792,O
containing,5792,O
dioxin,5792,B-CHEMICAL
responsive,5792,I-GENE-N
element,5792,I-GENE-N
(,5792,I-GENE-N
s,5792,I-GENE-N
),5792,I-GENE-N
leading,5792,O
to,5792,O
the,5792,O
induction,5792,O
of,5792,O
IGFBP-4,5792,B-GENE-Y
by,5792,O
TCDD,5792,B-CHEMICAL
.,5792,O
These,5793,O
findings,5793,O
emphasise,5793,O
a,5793,O
particular,5793,O
caution,5793,O
when,5793,O
interpreting,5793,O
and,5793,O
extrapolating,5793,O
results,5793,O
on,5793,O
the,5793,O
action,5793,O
mechanisms,5793,O
of,5793,O
TCDD,5793,B-CHEMICAL
obtained,5793,O
in,5793,O
studies,5793,O
using,5793,O
5L,5793,O
cells,5793,O
as,5793,O
a,5793,O
model,5793,O
system,5793,O
.,5793,O
Glycosylation,5794,O
enhances,5794,O
the,5794,O
anti-migratory,5794,O
activities,5794,O
of,5794,O
isomalyngamide,5794,B-CHEMICAL
A,5794,I-CHEMICAL
analogs,5794,O
.,5794,O
Three,5795,O
",",5795,O
new,5795,O
",",5795,O
fully,5795,O
synthetic,5795,O
glycosylated,5795,B-CHEMICAL
isomalyngamide,5795,I-CHEMICAL
A,5795,I-CHEMICAL
analogs,5795,O
4-6,5795,O
were,5795,O
prepared,5795,O
and,5795,O
evaluated,5795,O
for,5795,O
their,5795,O
anti-migratory,5795,O
activities,5795,O
in,5795,O
human,5795,O
breast,5795,O
cancer,5795,O
cells,5795,O
.,5795,O
The,5796,O
results,5796,O
of,5796,O
the,5796,O
study,5796,O
show,5796,O
that,5796,O
two,5796,O
glycosylated,5796,O
derivatives,5796,O
4,5796,O
and,5796,O
5,5796,O
",",5796,O
containing,5796,O
mannose,5796,B-CHEMICAL
and,5796,O
galactose,5796,B-CHEMICAL
appendages,5796,O
",",5796,O
suppress,5796,O
metastatic,5796,O
events,5796,O
(,5796,O
e.g.,5796,O
",",5796,O
migration,5796,O
",",5796,O
invasion,5796,O
and,5796,O
adhesion,5796,O
),5796,O
in,5796,O
human,5796,O
breast,5796,O
adenocarcinoma,5796,O
MDA-MB-231,5796,O
cells,5796,O
at,5796,O
``,5796,O
nontoxic,5796,O
'',5796,O
concentration,5796,O
levels,5796,O
.,5796,O
In,5797,O
contrast,5797,O
",",5797,O
derivative,5797,O
6,5797,O
that,5797,O
contains,5797,O
a,5797,O
lactose,5797,B-CHEMICAL
moiety,5797,O
",",5797,O
displays,5797,O
a,5797,O
less,5797,O
potent,5797,O
activity,5797,O
.,5797,O
The,5798,O
findings,5798,O
show,5798,O
that,5798,O
monosaccharide,5798,B-CHEMICAL
rather,5798,O
than,5798,O
disaccharide,5798,B-CHEMICAL
appendages,5798,O
to,5798,O
the,5798,O
isomalyngamide,5798,B-CHEMICAL
A,5798,I-CHEMICAL
backbone,5798,O
more,5798,O
greatly,5798,O
influence,5798,O
cell,5798,O
migration,5798,O
and,5798,O
invasive,5798,O
ability,5798,O
.,5798,O
Evidence,5799,O
has,5799,O
been,5799,O
gained,5799,O
for,5799,O
a,5799,O
mechanism,5799,O
for,5799,O
inhibition,5799,O
of,5799,O
metastatic,5799,O
activities,5799,O
in,5799,O
MDA-MB-231,5799,O
cells,5799,O
by,5799,O
4,5799,O
and,5799,O
5,5799,O
",",5799,O
involving,5799,O
inactivation,5799,O
of,5799,O
the,5799,O
expression,5799,O
of,5799,O
p-FAK,5799,B-GENE-Y
and,5799,O
paxillin,5799,B-GENE-Y
through,5799,O
the,5799,O
integrin-mediated,5799,O
antimetastatic,5799,O
pathway,5799,O
.,5799,O
Inhibition,5800,O
of,5800,O
human,5800,O
breast,5800,O
cancer,5800,O
cell,5800,O
proliferation,5800,O
in,5800,O
tissue,5800,O
culture,5800,O
by,5800,O
the,5800,O
neuroleptic,5800,O
agents,5800,O
pimozide,5800,B-CHEMICAL
and,5800,O
thioridazine,5800,B-CHEMICAL
.,5800,O
Permanent,5801,O
cell,5801,O
culture,5801,O
lines,5801,O
derived,5801,O
from,5801,O
human,5801,O
breast,5801,O
cancer,5801,O
tissue,5801,O
are,5801,O
important,5801,O
experimental,5801,O
models,5801,O
in,5801,O
the,5801,O
study,5801,O
of,5801,O
human,5801,O
breast,5801,O
cancer,5801,O
cell,5801,O
proliferation,5801,O
.,5801,O
In,5802,O
the,5802,O
present,5802,O
work,5802,O
",",5802,O
pimozide,5802,B-CHEMICAL
",",5802,O
thioridazine,5802,B-CHEMICAL
",",5802,O
W-13,5802,B-CHEMICAL
",",5802,O
and,5802,O
W-12,5802,B-CHEMICAL
were,5802,O
shown,5802,O
to,5802,O
inhibit,5802,O
MCF-7,5802,O
human,5802,O
breast,5802,O
cancer,5802,O
cell,5802,O
growth,5802,O
.,5802,O
The,5803,O
50,5803,O
%,5803,O
inhibition,5803,O
concentration,5803,O
values,5803,O
determined,5803,O
in,5803,O
two,5803,O
proliferation,5803,O
assays,5803,O
",",5803,O
[,5803,B-CHEMICAL
3H,5803,I-CHEMICAL
],5803,I-CHEMICAL
thymidine,5803,I-CHEMICAL
incorporation,5803,O
and,5803,O
cell,5803,O
number,5803,O
",",5803,O
were,5803,O
in,5803,O
close,5803,O
agreement,5803,O
for,5803,O
each,5803,O
compound,5803,O
tested,5803,O
.,5803,O
The,5804,O
order,5804,O
of,5804,O
potency,5804,O
for,5804,O
growth,5804,O
inhibition,5804,O
in,5804,O
the,5804,O
presence,5804,O
of,5804,O
2,5804,O
%,5804,O
stripped,5804,O
calf,5804,O
serum,5804,O
was,5804,O
pimozide,5804,B-CHEMICAL
(,5804,O
Ki,5804,O
2,5804,O
microM,5804,O
),5804,O
greater,5804,O
than,5804,O
thioridazine,5804,B-CHEMICAL
(,5804,O
Ki,5804,O
5,5804,O
microM,5804,O
),5804,O
greater,5804,O
than,5804,O
W-13,5804,B-CHEMICAL
(,5804,O
Ki,5804,O
15,5804,O
microM,5804,O
),5804,O
greater,5804,O
than,5804,O
W-12,5804,B-CHEMICAL
(,5804,O
Ki,5804,O
39,5804,O
microM,5804,O
),5804,O
.,5804,O
Similar,5805,O
concentrations,5805,O
of,5805,O
these,5805,O
compounds,5805,O
blocked,5805,O
estradiol-induced,5805,B-CHEMICAL
growth,5805,O
of,5805,O
MCF-7,5805,O
cells,5805,O
",",5805,O
but,5805,O
estrogen,5805,B-GENE-Y
receptor,5805,I-GENE-Y
(,5805,O
ER,5805,B-GENE-Y
),5805,O
interactions,5805,O
do,5805,O
not,5805,O
seem,5805,O
to,5805,O
be,5805,O
involved,5805,O
.,5805,O
Pimozide,5806,B-CHEMICAL
and,5806,O
thioridazine,5806,B-CHEMICAL
had,5806,O
no,5806,O
effect,5806,O
on,5806,O
the,5806,O
estradiol,5806,B-CHEMICAL
binding,5806,O
properties,5806,O
of,5806,O
the,5806,O
MCF-7,5806,O
ER,5806,B-GENE-Y
",",5806,O
nor,5806,O
did,5806,O
pimozide,5806,B-CHEMICAL
interfere,5806,O
with,5806,O
the,5806,O
induction,5806,O
of,5806,O
progesterone,5806,B-GENE-Y
receptors,5806,I-GENE-Y
by,5806,O
estradiol,5806,B-CHEMICAL
.,5806,O
Furthermore,5807,O
",",5807,O
pimozide,5807,B-CHEMICAL
also,5807,O
inhibited,5807,O
incorporation,5807,O
of,5807,O
[,5807,B-CHEMICAL
3H,5807,I-CHEMICAL
],5807,I-CHEMICAL
thymidine,5807,I-CHEMICAL
into,5807,O
MCF-7,5807,O
cells,5807,O
stimulated,5807,O
by,5807,O
polypeptide,5807,B-GENE-N
hormones,5807,I-GENE-N
in,5807,O
serum-free,5807,O
medium,5807,O
.,5807,O
The,5808,O
Ki,5808,O
for,5808,O
pimozide,5808,B-CHEMICAL
in,5808,O
serum-free,5808,O
medium,5808,O
alone,5808,O
",",5808,O
0.46,5808,O
microM,5808,O
",",5808,O
was,5808,O
similar,5808,O
to,5808,O
that,5808,O
determined,5808,O
in,5808,O
the,5808,O
presence,5808,O
of,5808,O
insulin,5808,B-GENE-Y
(,5808,O
0.42,5808,O
microM,5808,O
),5808,O
",",5808,O
insulin-like,5808,B-GENE-Y
growth,5808,I-GENE-Y
factor,5808,I-GENE-Y
I,5808,I-GENE-Y
(,5808,O
0.54,5808,O
microM,5808,O
),5808,O
",",5808,O
and,5808,O
epidermal,5808,B-GENE-Y
growth,5808,I-GENE-Y
factor,5808,I-GENE-Y
(,5808,O
0.43,5808,O
microM,5808,O
),5808,O
.,5808,O
The,5809,O
effects,5809,O
of,5809,O
pimozide,5809,B-CHEMICAL
on,5809,O
breast,5809,O
cancer,5809,O
cell,5809,O
growth,5809,O
were,5809,O
not,5809,O
limited,5809,O
to,5809,O
the,5809,O
MCF-7,5809,O
cell,5809,O
line,5809,O
.,5809,O
Pimozide,5810,B-CHEMICAL
also,5810,O
blocked,5810,O
cell,5810,O
growth,5810,O
and,5810,O
[,5810,B-CHEMICAL
3H,5810,I-CHEMICAL
],5810,I-CHEMICAL
thymidine,5810,I-CHEMICAL
incorporation,5810,O
into,5810,O
the,5810,O
ER-positive,5810,B-GENE-Y
T47D,5810,O
and,5810,O
ZR75-1B,5810,O
human,5810,O
breast,5810,O
cancer,5810,O
cell,5810,O
lines,5810,O
and,5810,O
the,5810,O
ER-negative,5810,B-GENE-Y
human,5810,O
breast,5810,O
cancer,5810,O
cell,5810,O
line,5810,O
",",5810,O
MDA-MB-231,5810,O
.,5810,O
Although,5811,O
numerous,5811,O
mechanisms,5811,O
of,5811,O
action,5811,O
of,5811,O
pimozide,5811,B-CHEMICAL
and,5811,O
thioridazine,5811,B-CHEMICAL
have,5811,O
been,5811,O
identified,5811,O
",",5811,O
both,5811,O
drugs,5811,O
are,5811,O
calmodulin,5811,B-GENE-Y
antagonists,5811,O
at,5811,O
drug,5811,O
concentrations,5811,O
that,5811,O
inhibit,5811,O
breast,5811,O
cancer,5811,O
cell,5811,O
growth,5811,O
in,5811,O
vitro,5811,O
.,5811,O
Inhibition,5812,O
of,5812,O
MCF-7,5812,O
cell,5812,O
growth,5812,O
by,5812,O
the,5812,O
selective,5812,O
calmodulin,5812,B-GENE-Y
antagonists,5812,O
W-13,5812,B-CHEMICAL
and,5812,O
W-12,5812,B-CHEMICAL
is,5812,O
consistent,5812,O
with,5812,O
a,5812,O
role,5812,O
for,5812,O
calmodulin,5812,B-GENE-Y
antagonism,5812,O
in,5812,O
the,5812,O
broad,5812,O
growth-inhibitory,5812,O
properties,5812,O
of,5812,O
pimozide,5812,B-CHEMICAL
.,5812,O
We,5813,O
conclude,5813,O
that,5813,O
pimozide,5813,B-CHEMICAL
and,5813,O
thioridazine,5813,B-CHEMICAL
may,5813,O
be,5813,O
useful,5813,O
in,5813,O
the,5813,O
control,5813,O
of,5813,O
estradiol-,5813,B-CHEMICAL
and,5813,O
polypeptide,5813,B-GENE-N
hormone-induced,5813,O
growth,5813,O
of,5813,O
ER-positive,5813,B-GENE-Y
and,5813,O
ER-negative,5813,B-GENE-Y
human,5813,O
breast,5813,O
tumors,5813,O
.,5813,O
Effects,5814,O
of,5814,O
monoamine,5814,B-GENE-N
oxidase,5814,I-GENE-N
inhibitors,5814,O
on,5814,O
levels,5814,O
of,5814,O
catechols,5814,B-CHEMICAL
and,5814,O
homovanillic,5814,B-CHEMICAL
acid,5814,I-CHEMICAL
in,5814,O
striatum,5814,O
and,5814,O
plasma,5814,O
.,5814,O
Levels,5815,O
of,5815,O
homovanillic,5815,B-CHEMICAL
acid,5815,I-CHEMICAL
(,5815,O
HVA,5815,B-CHEMICAL
),5815,O
",",5815,O
dihydroxyphenylacetic,5815,B-CHEMICAL
acid,5815,I-CHEMICAL
(,5815,O
DOPAC,5815,B-CHEMICAL
),5815,O
and,5815,O
dihydroxyphenylglycol,5815,B-CHEMICAL
(,5815,O
DHPG,5815,B-CHEMICAL
),5815,O
in,5815,O
plasma,5815,O
and,5815,O
the,5815,O
striatium,5815,O
were,5815,O
measured,5815,O
after,5815,O
inhibition,5815,O
of,5815,O
monoamine,5815,B-CHEMICAL
oxidase,5815,I-GENE-Y
type,5815,I-GENE-Y
A,5815,I-GENE-Y
(,5815,O
MAO-A,5815,B-GENE-Y
),5815,O
by,5815,O
clorgyline,5815,B-CHEMICAL
(,5815,O
4,5815,O
mg/kg,5815,O
i.p,5815,O
.,5815,O
),5816,O
",",5816,O
MAO-B,5816,O
by,5816,O
(,5816,I-CHEMICAL
-,5816,I-CHEMICAL
),5816,I-CHEMICAL
deprenyl,5816,O
(,5816,O
1,5816,O
mg/kg,5816,O
i.p,5816,O
.,5816,O
),5817,O
",",5817,O
both,5817,O
MAO-A,5817,O
and,5817,O
MAO-B,5817,O
by,5817,O
nialamide,5817,O
(,5817,O
75,5817,O
mg/kg,5817,O
i.p,5817,O
.,5817,O
),5817,O
or,5818,O
peripheral,5818,O
neuronal,5818,O
MAO,5818,O
by,5818,O
debrisoquin,5818,O
(,5818,O
40,5818,O
mg/kg,5818,O
i.p,5818,O
.,5818,O
),5818,O
.,5818,O
Levels,5819,O
of,5819,O
HVA,5819,O
in,5819,O
plasma,5819,O
decreased,5819,O
by,5819,O
about,5819,O
60,5819,O
%,5819,O
after,5819,O
single,5819,O
doses,5819,O
of,5819,O
nialamide,5819,O
or,5819,O
clorgyline,5819,O
",",5819,O
by,5819,O
about,5819,O
80,5819,O
%,5819,O
after,5819,O
repeated,5819,O
doses,5819,O
of,5819,O
nialamide,5819,O
",",5819,O
by,5819,O
about,5819,O
40,5819,O
%,5819,O
after,5819,O
a,5819,O
single,5819,O
dose,5819,O
of,5819,O
debrisoquin,5819,O
and,5819,O
by,5819,O
about,5819,O
50,5819,O
%,5819,O
after,5819,O
repeated,5819,O
doses,5819,O
of,5819,O
debrisoquin,5819,O
.,5819,O
The,5820,O
administration,5820,O
of,5820,O
clorgyline,5820,O
",",5820,B-CHEMICAL
nialamide,5820,O
or,5820,O
debrisoquin,5820,O
significantly,5820,O
decreased,5820,O
concentrations,5820,O
of,5820,O
DOPAC,5820,O
and,5820,O
DHPG,5820,O
in,5820,O
plasma,5820,O
",",5820,O
whereas,5820,O
(,5820,I-CHEMICAL
-,5820,I-CHEMICAL
),5820,I-CHEMICAL
deprenyl,5820,O
did,5820,O
not,5820,O
affect,5820,O
levels,5820,O
of,5820,O
DHPG,5820,O
or,5820,O
HVA,5820,O
.,5820,O
None,5821,O
of,5821,O
the,5821,O
MAO,5821,O
inhibitors,5821,O
produced,5821,O
more,5821,O
than,5821,O
about,5821,O
80,5821,O
%,5821,O
depression,5821,O
of,5821,O
levels,5821,O
of,5821,O
any,5821,O
of,5821,O
the,5821,O
deaminated,5821,O
metabolites,5821,O
.,5821,O
The,5822,O
results,5822,O
suggest,5822,O
that,5822,O
most,5822,O
of,5822,O
the,5822,O
HVA,5822,O
in,5822,O
plasma,5822,O
is,5822,O
derived,5822,O
from,5822,O
deamination,5822,O
of,5822,O
DA,5822,O
by,5822,O
MAO-A,5822,O
in,5822,O
peripheral,5822,O
neurons,5822,O
;,5822,O
that,5822,O
DOPAC,5822,O
in,5822,O
plasma,5822,O
is,5822,O
derived,5822,O
from,5822,O
cells,5822,O
outside,5822,O
the,5822,O
central,5822,O
nervous,5822,O
system,5822,O
;,5822,O
that,5822,O
DHPG,5822,O
in,5822,O
plasma,5822,O
is,5822,O
derived,5822,O
virtually,5822,O
exclusively,5822,O
from,5822,O
the,5822,O
metabolism,5822,O
of,5822,O
norepinephrine,5822,O
in,5822,O
sympathetic,5822,O
nerve,5822,O
endings,5822,O
and,5822,O
that,5822,O
residual,5822,O
levels,5822,O
of,5822,O
HVA,5822,O
after,5822,O
treatment,5822,O
with,5822,O
debrisoquin,5822,O
provide,5822,O
an,5822,O
improved,5822,O
but,5822,O
limited,5822,O
indication,5822,O
of,5822,O
central,5822,O
dopaminergic,5822,O
activity,5822,O
.,5822,O
The,5823,O
decrease,5823,O
of,5823,O
catalase,5823,B-GENE-Y
or,5823,O
esterase,5823,B-GENE-Y
D,5823,I-GENE-Y
activity,5823,O
in,5823,O
patients,5823,O
with,5823,O
microdeletions,5823,O
of,5823,O
11p,5823,O
or,5823,O
13q,5823,O
does,5823,O
not,5823,O
increase,5823,O
their,5823,O
radiosensitivity,5823,O
.,5823,O
Lymphocyte,5824,O
cultures,5824,O
from,5824,O
patients,5824,O
affected,5824,O
by,5824,O
retinoblastoma,5824,O
(,5824,O
Rb,5824,O
),5824,O
",",5824,O
with,5824,O
or,5824,O
without,5824,O
a,5824,O
microdeletion,5824,O
of,5824,O
chromosome,5824,O
13,5824,O
",",5824,O
and,5824,O
Wilms,5824,O
tumor,5824,O
(,5824,O
WT,5824,O
),5824,O
",",5824,O
with,5824,O
a,5824,O
microdeletion,5824,O
of,5824,O
chromosome,5824,O
11p,5824,O
where,5824,O
exposed,5824,O
to,5824,O
gamma-ray,5824,O
radiation,5824,O
during,5824,O
S,5824,O
and,5824,O
G2,5824,O
phases,5824,O
.,5824,O
Chromatid,5825,O
and,5825,O
chromosome,5825,O
lesions,5825,O
were,5825,O
scored,5825,O
and,5825,O
compared,5825,O
to,5825,O
those,5825,O
observed,5825,O
in,5825,O
controls,5825,O
.,5825,O
No,5826,O
significant,5826,O
differences,5826,O
were,5826,O
detected,5826,O
",",5826,O
neither,5826,O
between,5826,O
patients,5826,O
and,5826,O
controls,5826,O
",",5826,O
nor,5826,O
between,5826,O
patients,5826,O
carrying,5826,O
or,5826,O
not,5826,O
a,5826,O
microdeletion,5826,O
.,5826,O
This,5827,O
lack,5827,O
of,5827,O
difference,5827,O
was,5827,O
unexpected,5827,O
since,5827,O
the,5827,O
genes,5827,O
for,5827,O
catalase,5827,B-GENE-Y
and,5827,O
esterase,5827,B-GENE-Y
D,5827,I-GENE-Y
",",5827,O
also,5827,O
called,5827,O
S-formyl,5827,B-GENE-Y
glutathione,5827,I-GENE-Y
hydrolase,5827,I-GENE-Y
",",5827,O
which,5827,O
are,5827,O
two,5827,O
detoxication,5827,O
enzymes,5827,O
",",5827,O
are,5827,O
deleted,5827,O
in,5827,O
case,5827,O
of,5827,O
microdeletion,5827,O
of,5827,O
11p,5827,O
and,5827,O
13q,5827,O
",",5827,O
respectively,5827,O
.,5827,O
Developmental,5828,O
changes,5828,O
in,5828,O
lactate,5828,B-CHEMICAL
dehydrogenase-X,5828,I-GENE-Y
activity,5828,O
in,5828,O
young,5828,O
jaundiced,5828,O
male,5828,O
rats,5828,O
.,5828,O
This,5829,O
study,5829,O
was,5829,O
designed,5829,O
to,5829,O
examine,5829,O
the,5829,O
testicular,5829,O
maturation,5829,O
in,5829,O
both,5829,O
jaundiced,5829,O
(,5829,O
jj,5829,O
),5829,O
and,5829,O
nonjaundiced,5829,O
(,5829,O
Jj,5829,O
),5829,O
male,5829,O
Gunn,5829,O
rats,5829,O
as,5829,O
indicated,5829,O
by,5829,O
the,5829,O
activity,5829,O
of,5829,O
a,5829,O
testis,5829,O
and,5829,O
sperm-specific,5829,O
enzyme,5829,O
",",5829,O
lactate,5829,B-CHEMICAL
dehydrogenase-X,5829,I-GENE-Y
(,5829,O
LDH-X,5829,B-GENE-Y
),5829,O
",",5829,O
and,5829,O
serum,5829,O
testosterone,5829,B-CHEMICAL
levels,5829,O
.,5829,O
Testicular,5830,O
cytosolic,5830,O
LDH-X,5830,B-GENE-Y
activity,5830,O
was,5830,O
determined,5830,O
by,5830,O
oxidation,5830,O
of,5830,O
reduced,5830,O
nicotinamide,5830,B-CHEMICAL
adenine,5830,I-CHEMICAL
dinucleotide,5830,I-CHEMICAL
(,5830,O
NADH,5830,B-CHEMICAL
),5830,O
.,5830,O
Serum,5831,O
testosterone,5831,B-CHEMICAL
levels,5831,O
were,5831,O
measured,5831,O
by,5831,O
radioimmunoassay,5831,O
(,5831,O
RIA,5831,O
),5831,O
.,5831,O
Testicular,5832,O
LDH-X,5832,B-GENE-Y
activity,5832,O
increased,5832,O
rapidly,5832,O
between,5832,O
30,5832,O
and,5832,O
50,5832,O
days,5832,O
of,5832,O
age,5832,O
in,5832,O
both,5832,O
Jj,5832,O
and,5832,O
jj,5832,O
Gunn,5832,O
rats,5832,O
.,5832,O
LDH-X,5833,B-GENE-Y
activity,5833,O
was,5833,O
significantly,5833,O
lower,5833,O
in,5833,O
the,5833,O
jj,5833,O
Gunn,5833,O
rats,5833,O
at,5833,O
50,5833,O
and,5833,O
60,5833,O
days,5833,O
of,5833,O
age,5833,O
.,5833,O
Testosterone,5834,B-CHEMICAL
level,5834,O
was,5834,O
significantly,5834,O
lower,5834,O
in,5834,O
the,5834,O
jj,5834,O
Gunn,5834,O
rats,5834,O
at,5834,O
50,5834,O
days,5834,O
of,5834,O
age,5834,O
.,5834,O
LDH-X,5835,B-GENE-Y
activity,5835,O
and,5835,O
serum,5835,O
testosterone,5835,B-CHEMICAL
levels,5835,O
were,5835,O
similar,5835,O
for,5835,O
both,5835,O
genotypes,5835,O
at,5835,O
180,5835,O
days,5835,O
of,5835,O
age,5835,O
.,5835,O
The,5836,O
delay,5836,O
of,5836,O
testicular,5836,O
maturation,5836,O
in,5836,O
the,5836,O
jaundiced,5836,O
males,5836,O
seems,5836,O
to,5836,O
be,5836,O
due,5836,O
to,5836,O
lower,5836,O
LDH-X,5836,B-GENE-Y
activity,5836,O
and,5836,O
serum,5836,O
testosterone,5836,B-CHEMICAL
levels,5836,O
.,5836,O
Loperamide,5837,B-CHEMICAL
modifies,5837,O
but,5837,O
does,5837,O
not,5837,O
block,5837,O
the,5837,O
corticotropin-releasing,5837,B-GENE-Y
hormone-induced,5837,O
ACTH,5837,B-GENE-Y
response,5837,O
in,5837,O
patients,5837,O
with,5837,O
Addison,5837,O
's,5837,O
disease,5837,O
.,5837,O
The,5838,O
effect,5838,O
of,5838,O
loperamide,5838,B-CHEMICAL
-,5838,O
a,5838,O
peripheral,5838,O
opiate,5838,O
agonist,5838,O
-,5838,O
on,5838,O
plasma,5838,O
ACTH,5838,B-GENE-Y
response,5838,O
to,5838,O
Corticotropin-releasing,5838,B-GENE-Y
Hormone,5838,I-GENE-Y
(,5838,O
CRH,5838,B-GENE-Y
),5838,O
has,5838,O
been,5838,O
investigated,5838,O
in,5838,O
6,5838,O
patients,5838,O
with,5838,O
Addison,5838,O
's,5838,O
disease,5838,O
.,5838,O
After,5839,O
placebo,5839,O
administration,5839,O
CRH,5839,B-GENE-Y
induced,5839,O
a,5839,O
marked,5839,O
ACTH,5839,B-GENE-Y
increase,5839,O
.,5839,O
After,5840,O
loperamide,5840,B-CHEMICAL
administration,5840,O
ACTH,5840,B-GENE-Y
levels,5840,O
fell,5840,O
to,5840,O
a,5840,O
nadir,5840,O
of,5840,O
135,5840,O
+/-,5840,O
76,5840,O
pg/ml,5840,O
",",5840,O
and,5840,O
then,5840,O
CRH,5840,B-GENE-Y
was,5840,O
still,5840,O
able,5840,O
to,5840,O
induce,5840,O
an,5840,O
ACTH,5840,B-GENE-Y
increase,5840,O
;,5840,O
the,5840,O
pattern,5840,O
of,5840,O
ACTH,5840,B-GENE-Y
response,5840,O
to,5840,O
CRH,5840,B-GENE-Y
was,5840,O
slightly,5840,O
delayed,5840,O
.,5840,O
There,5841,O
was,5841,O
a,5841,O
significant,5841,O
difference,5841,O
between,5841,O
the,5841,O
two,5841,O
ACTH,5841,B-GENE-Y
curves,5841,O
after,5841,O
CRH,5841,B-GENE-Y
only,5841,O
in,5841,O
the,5841,O
early,5841,O
phase,5841,O
of,5841,O
the,5841,O
response,5841,O
.,5841,O
These,5842,O
data,5842,O
suggest,5842,O
that,5842,O
the,5842,O
inhibitory,5842,O
role,5842,O
of,5842,O
loperamide,5842,O
on,5842,O
ACTH,5842,B-GENE-Y
secretion,5842,O
is,5842,O
exerted,5842,O
at,5842,O
supra-pituitary,5842,O
level,5842,O
",",5842,O
although,5842,O
a,5842,O
pituitary,5842,O
site,5842,O
of,5842,O
action,5842,O
can,5842,O
not,5842,O
be,5842,O
excluded,5842,O
.,5842,O
Self-cancellation,5843,O
of,5843,O
drug,5843,O
properties,5843,O
as,5843,O
a,5843,O
mode,5843,O
of,5843,O
organ,5843,O
selectivity,5843,O
:,5843,O
the,5843,O
antimuscarinic,5843,O
effects,5843,O
of,5843,O
ambenonium,5843,B-CHEMICAL
.,5843,O
Ambenonium,5844,B-CHEMICAL
is,5844,O
known,5844,O
to,5844,O
be,5844,O
an,5844,O
inhibitor,5844,O
of,5844,O
acetylcholinesterase,5844,B-GENE-Y
",",5844,O
and,5844,O
recent,5844,O
data,5844,O
have,5844,O
shown,5844,O
this,5844,O
drug,5844,O
to,5844,O
antagonize,5844,O
muscarinic,5844,B-GENE-N
receptors,5844,I-GENE-N
as,5844,O
well,5844,O
.,5844,O
This,5845,O
latter,5845,O
property,5845,O
was,5845,O
confirmed,5845,O
by,5845,O
Schild,5845,O
analyses,5845,O
of,5845,O
ambenonium-induced,5845,B-CHEMICAL
blockade,5845,O
of,5845,O
responses,5845,O
to,5845,O
bethanechol,5845,B-CHEMICAL
in,5845,O
guinea-pig,5845,O
ileal,5845,O
longitudinal,5845,O
smooth,5845,O
muscle,5845,O
",",5845,O
taenia,5845,O
caeci,5845,O
",",5845,O
trachea,5845,O
and,5845,O
rat,5845,O
anococcygeus,5845,O
muscle,5845,O
.,5845,O
Statistical,5846,O
analysis,5846,O
showed,5846,O
ambenonium,5846,B-CHEMICAL
to,5846,O
be,5846,O
a,5846,O
simple,5846,O
competitive,5846,O
antagonist,5846,O
of,5846,O
responses,5846,O
to,5846,O
bethanechol,5846,B-CHEMICAL
in,5846,O
these,5846,O
tissues,5846,O
with,5846,O
pKB,5846,O
values,5846,O
in,5846,O
each,5846,O
tissue,5846,O
not,5846,O
significantly,5846,O
different,5846,O
from,5846,O
each,5846,O
other,5846,O
(,5846,O
mean,5846,O
pKB,5846,O
=,5846,O
6.0,5846,O
),5846,O
.,5846,O
However,5847,O
",",5847,O
considerable,5847,O
variability,5847,O
in,5847,O
pKB,5847,O
estimates,5847,O
was,5847,O
encountered,5847,O
when,5847,O
ambenonium,5847,B-CHEMICAL
was,5847,O
utilized,5847,O
to,5847,O
block,5847,O
responses,5847,O
to,5847,O
acetylcholine,5847,B-CHEMICAL
.,5847,O
Ambenonium,5848,B-CHEMICAL
was,5848,O
a,5848,O
less,5848,O
potent,5848,O
antagonist,5848,O
of,5848,O
tissue,5848,O
responses,5848,O
to,5848,O
acetylcholine,5848,B-CHEMICAL
",",5848,O
and,5848,O
the,5848,O
underestimation,5848,O
in,5848,O
the,5848,O
pKB,5848,O
(,5848,O
as,5848,O
compared,5848,O
to,5848,O
that,5848,O
obtained,5848,O
with,5848,O
bethanechol,5848,B-CHEMICAL
),5848,O
could,5848,O
be,5848,O
eliminated,5848,O
by,5848,O
prior,5848,O
treatment,5848,O
of,5848,O
tissues,5848,O
with,5848,O
the,5848,O
acetylcholinesterase,5848,B-GENE-Y
inhibitor,5848,O
neostigmine,5848,B-CHEMICAL
.,5848,O
These,5849,O
data,5849,O
suggested,5849,O
that,5849,O
ambenonium,5849,B-CHEMICAL
had,5849,O
a,5849,O
dual,5849,O
effect,5849,O
on,5849,O
tissue,5849,O
responses,5849,O
to,5849,O
acetylcholine-producing,5849,B-CHEMICAL
potentiation,5849,O
by,5849,O
blockade,5849,O
of,5849,O
acetylcholinesterase,5849,B-GENE-Y
and,5849,O
concomitant,5849,O
antagonism,5849,O
by,5849,O
blockade,5849,O
of,5849,O
muscarinic,5849,B-GENE-N
receptors,5849,I-GENE-N
.,5849,O
The,5850,O
Schild,5850,O
regressions,5850,O
obtained,5850,O
for,5850,O
ambenonium,5850,B-CHEMICAL
antagonism,5850,O
of,5850,O
acetylcholine,5850,B-CHEMICAL
responses,5850,O
formally,5850,O
satisfied,5850,O
criteria,5850,O
for,5850,O
simple,5850,O
competitive,5850,O
antagonism,5850,O
of,5850,O
a,5850,O
homogenous,5850,O
population,5850,O
of,5850,O
receptors,5850,O
(,5850,O
linear,5850,O
regression,5850,O
",",5850,O
slope,5850,O
equal,5850,O
to,5850,O
unity,5850,O
),5850,O
.,5850,O
The,5851,O
fact,5851,O
that,5851,O
these,5851,O
regressions,5851,O
yielded,5851,O
erroneous,5851,O
apparent,5851,O
pKB,5851,O
values,5851,O
suggests,5851,O
how,5851,O
two,5851,O
properties,5851,O
of,5851,O
a,5851,O
drug,5851,O
in,5851,O
one,5851,O
molecule,5851,O
could,5851,O
provide,5851,O
misleading,5851,O
information,5851,O
about,5851,O
drug,5851,O
receptors,5851,O
.,5851,O
(,5852,O
ABSTRACT,5852,O
TRUNCATED,5852,O
AT,5852,O
250,5852,O
WORDS,5852,O
),5852,O
Comparison,5853,O
of,5853,O
ophthalmic,5853,O
beta-blocking,5853,O
agents,5853,O
.,5853,O
Glaucoma,5854,O
is,5854,O
described,5854,O
",",5854,O
and,5854,O
the,5854,O
chemistry,5854,O
",",5854,O
pharmacology,5854,O
",",5854,O
pharmacokinetics,5854,O
",",5854,O
clinical,5854,O
efficacy,5854,O
",",5854,O
adverse,5854,O
effects,5854,O
",",5854,O
and,5854,O
dosage,5854,O
and,5854,O
administration,5854,O
of,5854,O
betaxolol,5854,B-CHEMICAL
and,5854,O
levobunolol,5854,B-CHEMICAL
in,5854,O
comparison,5854,O
with,5854,O
timolol,5854,B-CHEMICAL
are,5854,O
reviewed,5854,O
.,5854,O
Betaxolol,5855,B-CHEMICAL
and,5855,O
levobunolol,5855,B-CHEMICAL
are,5855,O
two,5855,O
beta-adrenergic,5855,O
blocking,5855,O
agents,5855,O
being,5855,O
marketed,5855,O
as,5855,O
ophthalmic,5855,O
solutions,5855,O
for,5855,O
treatment,5855,O
of,5855,O
primary,5855,O
open-angle,5855,O
glaucoma,5855,O
(,5855,O
POAG,5855,O
),5855,O
and,5855,O
ocular,5855,O
hypertension,5855,O
(,5855,O
OHT,5855,O
),5855,O
.,5855,O
Betaxolol,5856,B-CHEMICAL
is,5856,O
a,5856,O
relatively,5856,O
cardioselective,5856,O
beta-adrenergic,5856,O
blocker,5856,O
",",5856,O
while,5856,O
levobunolol,5856,B-CHEMICAL
is,5856,O
a,5856,O
nonselective,5856,O
beta-adrenergic,5856,O
blocking,5856,O
agent,5856,O
.,5856,O
Double-blind,5857,O
comparative,5857,O
trials,5857,O
have,5857,O
suggested,5857,O
that,5857,O
betaxolol,5857,B-CHEMICAL
has,5857,O
an,5857,O
equal,5857,O
to,5857,O
slightly,5857,O
lower,5857,O
efficacy,5857,O
and,5857,O
levobunolol,5857,B-CHEMICAL
has,5857,O
equal,5857,O
efficacy,5857,O
in,5857,O
reducing,5857,O
intraocular,5857,O
pressure,5857,O
(,5857,O
IOP,5857,O
),5857,O
compared,5857,O
with,5857,O
timolol,5857,B-CHEMICAL
",",5857,O
the,5857,O
first,5857,O
ophthalmic,5857,O
beta,5857,O
blocker,5857,O
.,5857,O
A,5858,O
mean,5858,O
reduction,5858,O
in,5858,O
intraocular,5858,O
pressure,5858,O
of,5858,O
15-35,5858,O
%,5858,O
occurs,5858,O
with,5858,O
both,5858,O
betaxolol,5858,B-CHEMICAL
and,5858,O
levobunolol,5858,B-CHEMICAL
and,5858,O
is,5858,O
reported,5858,O
to,5858,O
be,5858,O
maintained,5858,O
with,5858,O
prolonged,5858,O
use,5858,O
.,5858,O
Betaxolol,5859,B-CHEMICAL
is,5859,O
associated,5859,O
with,5859,O
a,5859,O
higher,5859,O
(,5859,O
25,5859,O
%,5859,O
),5859,O
incidence,5859,O
of,5859,O
local,5859,O
ocular,5859,O
adverse,5859,O
reactions,5859,O
than,5859,O
timolol,5859,B-CHEMICAL
.,5859,O
However,5860,O
",",5860,O
betaxolol,5860,B-CHEMICAL
produces,5860,O
less,5860,O
systemic,5860,O
beta,5860,O
2-,5860,O
and,5860,O
possibly,5860,O
beta,5860,B-GENE-Y
1-adrenergic,5860,I-GENE-Y
receptor,5860,I-GENE-Y
blockade,5860,O
than,5860,O
either,5860,O
timolol,5860,B-CHEMICAL
or,5860,O
levobunolol,5860,B-CHEMICAL
.,5860,O
Betaxolol,5861,B-CHEMICAL
may,5861,O
be,5861,O
relatively,5861,O
safer,5861,O
to,5861,O
use,5861,O
in,5861,O
patients,5861,O
with,5861,O
reactive,5861,O
airway,5861,O
disease,5861,O
than,5861,O
either,5861,O
timolol,5861,B-CHEMICAL
or,5861,O
levobunolol,5861,B-CHEMICAL
.,5861,O
Levobunolol,5862,B-CHEMICAL
causes,5862,O
a,5862,O
similar,5862,O
to,5862,O
greater,5862,O
incidence,5862,O
of,5862,O
local,5862,O
ocular,5862,O
adverse,5862,O
reactions,5862,O
and,5862,O
similar,5862,O
systemic,5862,O
beta,5862,O
blockade,5862,O
compared,5862,O
with,5862,O
timolol,5862,B-CHEMICAL
.,5862,O
Levobunolol,5863,B-CHEMICAL
may,5863,O
possibly,5863,O
be,5863,O
longer,5863,O
acting,5863,O
than,5863,O
timolol,5863,B-CHEMICAL
",",5863,O
allowing,5863,O
more,5863,O
patients,5863,O
to,5863,O
be,5863,O
controlled,5863,O
by,5863,O
once-daily,5863,O
dosing,5863,O
.,5863,O
Betaxolol,5864,B-CHEMICAL
and,5864,O
levobunolol,5864,B-CHEMICAL
appear,5864,O
to,5864,O
be,5864,O
similar,5864,O
to,5864,O
timolol,5864,B-CHEMICAL
in,5864,O
controlling,5864,O
IOP,5864,O
in,5864,O
patients,5864,O
with,5864,O
POAG,5864,O
and,5864,O
OHT,5864,O
;,5864,O
additional,5864,O
experience,5864,O
with,5864,O
these,5864,O
agents,5864,O
is,5864,O
needed,5864,O
to,5864,O
assess,5864,O
the,5864,O
advantages,5864,O
and,5864,O
disadvantages,5864,O
of,5864,O
each,5864,O
agent,5864,O
.,5864,O
Nucleotide,5865,B-CHEMICAL
sequence,5865,O
of,5865,O
the,5865,O
gene,5865,O
for,5865,O
human,5865,B-GENE-Y
factor,5865,I-GENE-Y
IX,5865,I-GENE-Y
(,5865,O
antihemophilic,5865,B-GENE-Y
factor,5865,I-GENE-Y
B,5865,I-GENE-Y
),5865,O
.,5865,O
Two,5866,O
different,5866,O
human,5866,O
genomic,5866,O
DNA,5866,O
libraries,5866,O
were,5866,O
screened,5866,O
for,5866,O
the,5866,O
gene,5866,O
for,5866,O
blood,5866,O
coagulation,5866,B-GENE-Y
factor,5866,I-GENE-Y
IX,5866,I-GENE-Y
by,5866,O
employing,5866,O
a,5866,O
cDNA,5866,O
for,5866,O
the,5866,O
human,5866,O
protein,5866,O
as,5866,O
a,5866,O
hybridization,5866,O
probe,5866,O
.,5866,O
Five,5867,O
overlapping,5867,O
lambda,5867,O
phages,5867,O
were,5867,O
identified,5867,O
that,5867,O
contained,5867,O
the,5867,O
gene,5867,O
for,5867,O
factor,5867,B-GENE-Y
IX,5867,I-GENE-Y
.,5867,O
The,5868,O
complete,5868,O
DNA,5868,O
sequence,5868,O
of,5868,O
about,5868,O
38,5868,O
kilobases,5868,O
for,5868,O
the,5868,O
gene,5868,O
and,5868,O
the,5868,O
adjacent,5868,O
5,5868,O
',5868,O
and,5868,O
3,5868,O
',5868,O
flanking,5868,O
regions,5868,O
was,5868,O
established,5868,O
by,5868,O
the,5868,O
dideoxy,5868,O
chain,5868,O
termination,5868,O
and,5868,O
chemical,5868,O
degradation,5868,O
methods,5868,O
.,5868,O
The,5869,O
gene,5869,O
contained,5869,O
about,5869,O
33.5,5869,O
kilobases,5869,O
of,5869,O
DNA,5869,O
",",5869,O
including,5869,O
seven,5869,O
introns,5869,O
and,5869,O
eight,5869,O
exons,5869,O
within,5869,O
the,5869,O
coding,5869,O
and,5869,O
3,5869,O
',5869,O
noncoding,5869,O
regions,5869,O
of,5869,O
the,5869,O
gene,5869,O
.,5869,O
The,5870,O
eight,5870,O
exons,5870,O
code,5870,O
for,5870,O
a,5870,O
prepro,5870,O
leader,5870,O
sequence,5870,O
and,5870,O
415,5870,O
amino,5870,B-CHEMICAL
acids,5870,I-CHEMICAL
that,5870,O
make,5870,O
up,5870,O
the,5870,O
mature,5870,O
protein,5870,O
circulating,5870,O
in,5870,O
plasma,5870,O
.,5870,O
The,5871,O
intervening,5871,O
sequences,5871,O
range,5871,O
in,5871,O
size,5871,O
from,5871,O
188,5871,O
to,5871,O
9473,5871,O
nucleotides,5871,B-CHEMICAL
and,5871,O
contain,5871,O
four,5871,O
Alu,5871,O
repetitive,5871,O
sequences,5871,O
",",5871,O
including,5871,O
one,5871,O
in,5871,O
intron,5871,O
A,5871,O
and,5871,O
three,5871,O
in,5871,O
intron,5871,O
F.,5871,O
A,5871,O
fifth,5871,O
Alu,5871,O
repetitive,5871,O
sequence,5871,O
was,5871,O
found,5871,O
immediately,5871,O
flanking,5871,O
the,5871,O
3,5871,O
',5871,O
end,5871,O
of,5871,O
the,5871,O
gene,5871,O
.,5871,O
A,5872,O
50,5872,O
base,5872,O
pair,5872,O
insert,5872,O
in,5872,O
intron,5872,O
A,5872,O
was,5872,O
found,5872,O
in,5872,O
a,5872,O
clone,5872,O
from,5872,O
one,5872,O
of,5872,O
the,5872,O
genomic,5872,O
libraries,5872,O
but,5872,O
was,5872,O
absent,5872,O
in,5872,O
clones,5872,O
from,5872,O
the,5872,O
other,5872,O
library,5872,O
.,5872,O
Intron,5873,O
A,5873,O
as,5873,O
well,5873,O
as,5873,O
the,5873,O
3,5873,O
',5873,O
noncoding,5873,O
region,5873,O
of,5873,O
the,5873,O
gene,5873,O
also,5873,O
contained,5873,O
alternating,5873,O
purine-pyrimidine,5873,B-CHEMICAL
sequences,5873,O
that,5873,O
provide,5873,O
potential,5873,O
left-handed,5873,O
helical,5873,O
DNA,5873,O
or,5873,O
Z-DNA,5873,O
structures,5873,O
for,5873,O
the,5873,O
gene,5873,O
.,5873,O
KpnI,5874,B-GENE-N
repetitive,5874,I-GENE-N
sequences,5874,I-GENE-N
were,5874,O
identified,5874,O
in,5874,O
intron,5874,O
D,5874,O
and,5874,O
the,5874,O
region,5874,O
flanking,5874,O
the,5874,O
5,5874,O
',5874,O
end,5874,O
of,5874,O
the,5874,O
gene,5874,O
.,5874,O
The,5875,O
5,5875,O
',5875,O
flanking,5875,O
region,5875,O
also,5875,O
contained,5875,O
a,5875,O
1.9-kb,5875,O
HindIII,5875,O
subfamily,5875,O
repeat,5875,O
.,5875,O
The,5876,O
seven,5876,O
introns,5876,O
in,5876,O
the,5876,O
gene,5876,O
for,5876,O
factor,5876,B-GENE-Y
IX,5876,I-GENE-Y
were,5876,O
located,5876,O
in,5876,O
essentially,5876,O
the,5876,O
same,5876,O
position,5876,O
as,5876,O
the,5876,O
seven,5876,O
introns,5876,O
in,5876,O
the,5876,O
gene,5876,O
for,5876,O
human,5876,O
protein,5876,O
C,5876,O
",",5876,O
while,5876,O
the,5876,O
first,5876,O
three,5876,O
were,5876,O
found,5876,O
in,5876,O
positions,5876,O
identical,5876,O
with,5876,O
those,5876,O
in,5876,O
the,5876,O
gene,5876,O
for,5876,O
human,5876,O
prothrombin,5876,O
.,5876,O
Purification,5877,O
and,5877,O
characterization,5877,O
of,5877,O
calcitonin,5877,B-GENE-N
receptors,5877,I-GENE-N
in,5877,O
rat,5877,O
kidney,5877,O
membranes,5877,O
by,5877,O
covalent,5877,O
cross-linking,5877,O
techniques,5877,O
.,5877,O
We,5878,O
have,5878,O
characterized,5878,O
the,5878,O
binding,5878,O
parameters,5878,O
of,5878,O
renal,5878,B-GENE-N
receptors,5878,I-GENE-N
(,5878,O
Scatchard,5878,O
analysis,5878,O
revealed,5878,O
the,5878,O
presence,5878,O
of,5878,O
two,5878,O
binding,5878,O
sites,5878,O
:,5878,O
site,5878,O
I,5878,O
",",5878,O
Ka1,5878,O
=,5878,O
1.29,5878,O
X,5878,O
10,5878,O
(,5878,O
9,5878,O
),5878,O
M-1,5878,O
",",5878,O
number,5878,O
of,5878,O
binding,5878,O
sites,5878,O
=,5878,O
9.9,5878,O
X,5878,O
10,5878,O
(,5878,O
6,5878,O
),5878,O
/micrograms,5878,O
protein,5878,O
;,5878,O
site,5878,O
II,5878,O
",",5878,O
Ka2,5878,O
=,5878,O
0.93,5878,O
X,5878,O
10,5878,O
(,5878,O
8,5878,O
),5878,O
M-1,5878,O
",",5878,O
number,5878,O
of,5878,O
binding,5878,O
sites,5878,O
=,5878,O
4.27,5878,O
X,5878,O
10,5878,O
(,5878,O
8,5878,O
),5878,O
/micrograms,5878,O
protein,5878,O
),5878,O
and,5878,O
studied,5878,O
the,5878,O
effect,5878,O
of,5878,O
solubilization,5878,O
.,5878,O
The,5879,O
high-affinity,5879,O
sites,5879,O
are,5879,O
preserved,5879,O
during,5879,O
affinity,5879,O
chromatography,5879,O
and,5879,O
the,5879,O
process,5879,O
results,5879,O
in,5879,O
a,5879,O
6080-fold,5879,O
purification,5879,O
of,5879,O
those,5879,O
sites,5879,O
.,5879,O
The,5880,O
lower-affinity,5880,O
sites,5880,O
are,5880,O
also,5880,O
preserved,5880,O
but,5880,O
the,5880,O
overall,5880,O
purification,5880,O
factor,5880,O
is,5880,O
about,5880,O
40,5880,O
%,5880,O
lower,5880,O
than,5880,O
that,5880,O
obtained,5880,O
using,5880,O
molecular,5880,O
sieving,5880,O
.,5880,O
The,5881,O
purification,5881,O
of,5881,O
the,5881,O
renal,5881,O
calcitonin,5881,B-GENE-N
receptor,5881,I-GENE-N
by,5881,O
molecular,5881,O
sieving,5881,O
(,5881,O
Sephacryl,5881,O
S-200,5881,O
),5881,O
is,5881,O
accompanied,5881,O
by,5881,O
total,5881,O
loss,5881,O
of,5881,O
the,5881,O
high-affinity,5881,O
site,5881,O
;,5881,O
however,5881,O
",",5881,O
the,5881,O
low-affinity,5881,O
site,5881,O
is,5881,O
enriched,5881,O
over,5881,O
1642-fold,5881,O
.,5881,O
Binding,5882,O
parameters,5882,O
were,5882,O
obtained,5882,O
for,5882,O
the,5882,O
purified,5882,O
fractions,5882,O
.,5882,O
Synthetic,5883,O
salmon,5883,O
calcitonin,5883,O
was,5883,O
also,5883,O
bound,5883,O
to,5883,O
renal,5883,O
membranes,5883,O
using,5883,O
the,5883,O
bifunctional,5883,O
reagent,5883,O
disuccinimidyl,5883,B-CHEMICAL
suberate,5883,I-CHEMICAL
and,5883,O
photo-affinity,5883,O
cross-linking,5883,O
using,5883,O
hydroxysuccinimidyl,5883,B-CHEMICAL
azidobenzonate,5883,I-CHEMICAL
reagent,5883,O
.,5883,O
Cross-linked,5884,O
receptor,5884,O
eluted,5884,O
in,5884,O
the,5884,O
same,5884,O
volume,5884,O
as,5884,O
solubilized,5884,O
membranes,5884,O
specifically,5884,O
binding,5884,O
salmon,5884,O
calcitonin,5884,O
(,5884,O
S-200,5884,O
chromatography,5884,O
),5884,O
.,5884,O
Sodium,5885,B-CHEMICAL
dodecyl,5885,I-CHEMICAL
sulfate,5885,I-CHEMICAL
polyacrylamide,5885,B-CHEMICAL
gel,5885,O
electrophoresis,5885,O
analysis,5885,O
of,5885,O
purified,5885,O
fractions,5885,O
showed,5885,O
several,5885,O
protein,5885,O
bands,5885,O
with,5885,O
apparent,5885,O
molecular,5885,O
masses,5885,O
ranging,5885,O
from,5885,O
18,5885,O
000,5885,O
Da,5885,O
to,5885,O
100,5885,O
000,5885,O
Da,5885,O
in,5885,O
the,5885,O
presence,5885,O
or,5885,O
absence,5885,O
of,5885,O
a,5885,O
reducing,5885,O
agent,5885,O
(,5885,O
2-mercaptoethanol,5885,B-CHEMICAL
),5885,O
.,5885,O
Autoradiography,5886,O
of,5886,O
polyacrylamide,5886,B-CHEMICAL
gels,5886,O
of,5886,O
cross-linked,5886,O
calcitonin,5886,B-GENE-N
receptor,5886,I-GENE-N
showed,5886,O
only,5886,O
three,5886,O
protein,5886,O
bands,5886,O
specifically,5886,O
binding,5886,O
salmon,5886,O
calcitonin,5886,O
.,5886,O
Their,5887,O
molecular,5887,O
masses,5887,O
were,5887,O
70,5887,O
000,5887,O
Da,5887,O
",",5887,O
40,5887,O
000,5887,O
Da,5887,O
and,5887,O
33,5887,O
000,5887,O
Da,5887,O
respectively,5887,O
.,5887,O
The,5888,O
40,5888,O
000-Da,5888,O
molecule,5888,O
represents,5888,O
a,5888,O
major,5888,O
band,5888,O
(,5888,O
47,5888,O
%,5888,O
total,5888,O
binding,5888,O
species,5888,O
),5888,O
.,5888,O
This,5889,O
suggests,5889,O
that,5889,O
these,5889,O
three,5889,O
proteins,5889,O
are,5889,O
the,5889,O
principal,5889,O
components,5889,O
of,5889,O
the,5889,O
calcitonin,5889,O
receptor,5889,O
and,5889,O
that,5889,O
S-S,5889,B-CHEMICAL
bonds,5889,O
are,5889,O
not,5889,O
involved,5889,O
in,5889,O
the,5889,O
assembly,5889,O
of,5889,O
the,5889,O
receptor,5889,O
subunits,5889,O
.,5889,O
Tyrosinase,5890,B-GENE-Y
catalyzes,5890,O
an,5890,O
unusual,5890,O
oxidative,5890,O
decarboxylation,5890,O
of,5890,O
"3,4-dihydroxymandelate",5890,B-CHEMICAL
.,5890,O
Tyrosinase,5891,B-GENE-Y
usually,5891,O
catalyzes,5891,O
the,5891,O
conversion,5891,O
of,5891,O
monophenols,5891,B-CHEMICAL
to,5891,O
o-diphenols,5891,O
and,5891,O
oxidation,5891,O
of,5891,O
diphenols,5891,B-CHEMICAL
to,5891,O
the,5891,O
corresponding,5891,O
quinones,5891,O
.,5891,O
However,5892,O
",",5892,O
when,5892,O
"3,4-dihydroxymandelic",5892,B-CHEMICAL
acid,5892,I-CHEMICAL
was,5892,O
provided,5892,O
as,5892,O
the,5892,O
substrate,5892,O
",",5892,O
it,5892,O
catalyzed,5892,O
an,5892,O
unusual,5892,O
oxidative,5892,O
decarboxylation,5892,O
reaction,5892,O
generating,5892,O
"3,4-dihydroxybenzaldehyde",5892,B-CHEMICAL
as,5892,O
the,5892,O
sole,5892,O
product,5892,O
.,5892,O
The,5893,O
identity,5893,O
of,5893,O
the,5893,O
product,5893,O
was,5893,O
confirmed,5893,O
by,5893,O
high-performance,5893,O
liquid,5893,O
chromatography,5893,O
(,5893,O
HPLC,5893,O
),5893,O
as,5893,O
well,5893,O
as,5893,O
ultraviolet,5893,O
and,5893,O
infrared,5893,O
spectral,5893,O
studies,5893,O
.,5893,O
None,5894,O
of,5894,O
the,5894,O
following,5894,O
enzymes,5894,O
tested,5894,O
catalyzed,5894,O
the,5894,O
new,5894,O
reaction,5894,O
:,5894,O
galactose,5894,B-GENE-N
oxidase,5894,I-GENE-N
",",5894,O
ceruloplasmin,5894,B-GENE-Y
",",5894,O
superoxide,5894,B-GENE-N
dismutase,5894,I-GENE-N
",",5894,O
ascorbate,5894,B-GENE-N
oxidase,5894,I-GENE-N
",",5894,O
dopamine,5894,B-GENE-Y
beta-hydroxylase,5894,I-GENE-Y
",",5894,O
and,5894,O
peroxidase,5894,B-GENE-N
.,5894,O
Phenol,5895,B-GENE-N
oxidase,5895,I-GENE-N
inhibitors,5895,O
such,5895,O
as,5895,O
phenylthiourea,5895,B-CHEMICAL
",",5895,O
potassium,5895,B-CHEMICAL
cyanide,5895,I-CHEMICAL
",",5895,O
and,5895,O
sodium,5895,B-CHEMICAL
azide,5895,I-CHEMICAL
inhibited,5895,O
the,5895,O
reaction,5895,O
drastically,5895,O
",",5895,O
suggesting,5895,O
the,5895,O
participation,5895,O
of,5895,O
the,5895,O
active,5895,O
site,5895,O
copper,5895,B-CHEMICAL
of,5895,O
the,5895,O
enzyme,5895,O
in,5895,O
the,5895,O
catalysis,5895,O
.,5895,O
Mimosine,5896,B-CHEMICAL
",",5896,O
a,5896,O
well-known,5896,O
competitive,5896,O
inhibitor,5896,O
of,5896,O
tyrosinase,5896,B-GENE-Y
",",5896,O
competitively,5896,O
inhibited,5896,O
the,5896,O
new,5896,O
reaction,5896,O
also,5896,O
.,5896,O
4-Hydroxymandelic,5897,B-CHEMICAL
acid,5897,I-CHEMICAL
and,5897,O
3-methoxy-4-hydroxymandelic,5897,B-CHEMICAL
acid,5897,I-CHEMICAL
neither,5897,O
served,5897,O
as,5897,O
substrates,5897,O
nor,5897,O
inhibited,5897,O
the,5897,O
reaction,5897,O
.,5897,O
Putative,5898,O
intermediates,5898,O
such,5898,O
as,5898,O
"3,4-dihydroxybenzyl",5898,B-CHEMICAL
alcohol,5898,I-CHEMICAL
and,5898,O
(,5898,B-CHEMICAL
"3,4-dihydroxybenzoyl",5898,I-CHEMICAL
),5898,I-CHEMICAL
formic,5898,I-CHEMICAL
acid,5898,I-CHEMICAL
did,5898,O
not,5898,O
accumulate,5898,O
during,5898,O
the,5898,O
reaction,5898,O
.,5898,O
Oxidation,5899,O
to,5899,O
a,5899,O
quinone,5899,B-CHEMICAL
methide,5899,I-CHEMICAL
derivative,5899,O
rather,5899,O
than,5899,O
conventional,5899,O
quinone,5899,B-CHEMICAL
accounts,5899,O
for,5899,O
this,5899,O
unusual,5899,O
oxidative,5899,O
decarboxylation,5899,O
reaction,5899,O
.,5899,O
Earlier,5900,O
from,5900,O
this,5900,O
laboratory,5900,O
",",5900,O
we,5900,O
reported,5900,O
the,5900,O
conversion,5900,O
of,5900,O
4-alkylcatechols,5900,B-CHEMICAL
to,5900,O
quinone,5900,B-CHEMICAL
methides,5900,I-CHEMICAL
catalyzed,5900,O
by,5900,O
a,5900,O
cuticular,5900,O
phenol,5900,B-CHEMICAL
oxidase,5900,O
[,5900,O
Sugumaran,5900,O
",",5900,O
M.,5900,O
",",5900,O
&,5900,O
Lipke,5900,O
",",5900,O
H.,5900,O
(,5900,O
1983,5900,O
),5900,O
FEBS,5900,O
Lett,5900,O
.,5900,O
155,5901,O
",",5901,O
65-68,5901,O
],5901,O
.,5901,O
Present,5902,O
studies,5902,O
demonstrate,5902,O
that,5902,O
mushroom,5902,B-GENE-N
tyrosinase,5902,I-GENE-N
will,5902,O
also,5902,O
catalyze,5902,O
quinone,5902,B-CHEMICAL
methide,5902,I-CHEMICAL
production,5902,O
with,5902,O
the,5902,O
same,5902,O
active,5902,O
site,5902,O
copper,5902,O
if,5902,O
a,5902,O
suitable,5902,O
substrate,5902,O
such,5902,O
as,5902,O
"3,4-dihydroxymandelic",5902,B-CHEMICAL
acid,5902,I-CHEMICAL
is,5902,O
provided,5902,O
.,5902,O
Effectors,5903,O
of,5903,O
the,5903,O
activation,5903,O
of,5903,O
human,5903,B-GENE-Y
[,5903,I-GENE-Y
Glu1,5903,I-GENE-Y
],5903,I-GENE-Y
plasminogen,5903,I-GENE-Y
by,5903,O
human,5903,B-GENE-Y
tissue,5903,I-GENE-Y
plasminogen,5903,I-GENE-Y
activator,5903,I-GENE-Y
.,5903,O
The,5904,O
activation,5904,O
of,5904,O
human,5904,B-GENE-Y
[,5904,I-GENE-Y
Glu1,5904,I-GENE-Y
],5904,I-GENE-Y
plasminogen,5904,I-GENE-Y
[,5904,O
(,5904,B-GENE-Y
Glu1,5904,I-GENE-Y
],5904,I-GENE-Y
Pg,5904,I-GENE-Y
),5904,O
by,5904,O
human,5904,O
recombinant,5904,O
(,5904,O
rec,5904,O
),5904,O
two-chain,5904,O
tissue,5904,B-GENE-Y
plasminogen,5904,I-GENE-Y
activator,5904,I-GENE-Y
(,5904,O
t-PA,5904,B-GENE-Y
),5904,O
is,5904,O
inhibited,5904,O
by,5904,O
Cl-,5904,B-CHEMICAL
",",5904,O
at,5904,O
physiological,5904,O
concentrations,5904,O
",",5904,O
and,5904,O
stimulated,5904,O
by,5904,O
epsilon-aminocaproic,5904,B-CHEMICAL
acid,5904,I-CHEMICAL
(,5904,O
EACA,5904,B-CHEMICAL
),5904,O
",",5904,O
as,5904,O
well,5904,O
as,5904,O
fibrin,5904,O
(,5904,O
ogen,5904,O
),5904,O
.,5904,O
Chloride,5905,B-CHEMICAL
functions,5905,O
as,5905,O
a,5905,O
result,5905,O
of,5905,O
its,5905,O
binding,5905,O
to,5905,O
[,5905,B-GENE-Y
Glu1,5905,I-GENE-Y
],5905,I-GENE-Y
Pg,5905,I-GENE-Y
",",5905,O
with,5905,O
a,5905,O
Ki,5905,O
of,5905,O
approximately,5905,O
9.0,5905,O
mM,5905,O
",",5905,O
thereby,5905,O
rendering,5905,O
[,5905,B-GENE-Y
Glu1,5905,I-GENE-Y
],5905,I-GENE-Y
Pg,5905,I-GENE-Y
a,5905,O
less,5905,O
effective,5905,O
substrate,5905,O
for,5905,O
two-chain,5905,O
rec-t-PA.,5905,O
EACA,5905,B-CHEMICAL
stimulates,5905,O
the,5905,O
activation,5905,O
in,5905,O
Cl-,5905,B-CHEMICAL
(,5905,I-CHEMICAL
-,5905,I-CHEMICAL
),5905,I-CHEMICAL
containing,5905,O
solutions,5905,O
",",5905,O
with,5905,O
a,5905,O
Ka,5905,O
of,5905,O
approximately,5905,O
4.0,5905,O
mM,5905,O
",",5905,O
primarily,5905,O
by,5905,O
reversal,5905,O
of,5905,O
the,5905,O
Cl-,5905,B-CHEMICAL
(,5905,I-CHEMICAL
-,5905,I-CHEMICAL
),5905,I-CHEMICAL
inhibitory,5905,O
effect,5905,O
.,5905,O
Fibrinogen,5906,B-GENE-N
appears,5906,O
to,5906,O
exert,5906,O
its,5906,O
stimulatory,5906,O
properties,5906,O
mainly,5906,O
through,5906,O
effects,5906,O
on,5906,O
the,5906,O
enzyme,5906,O
",",5906,O
two-chain,5906,O
rec-t-PA,5906,O
",",5906,O
with,5906,O
a,5906,O
Ka,5906,O
of,5906,O
approximately,5906,O
3.7,5906,O
microM,5906,O
in,5906,O
activation,5906,O
systems,5906,O
containing,5906,O
physiological,5906,O
levels,5906,O
of,5906,O
Cl-,5906,B-CHEMICAL
.,5906,O
Analysis,5907,O
of,5907,O
the,5907,O
results,5907,O
of,5907,O
this,5907,O
paper,5907,O
reveals,5907,O
that,5907,O
normal,5907,O
plasma,5907,O
components,5907,O
",",5907,O
Cl-,5907,B-CHEMICAL
and,5907,O
fibrinogen,5907,B-GENE-N
",",5907,O
exert,5907,O
major,5907,O
regulatory,5907,O
roles,5907,O
on,5907,O
the,5907,O
ability,5907,O
of,5907,O
[,5907,B-GENE-Y
Glu1,5907,I-GENE-Y
],5907,I-GENE-Y
Pg,5907,I-GENE-Y
to,5907,O
be,5907,O
activated,5907,O
by,5907,O
two-chain,5907,O
rec-t-PA,5907,O
",",5907,O
in,5907,O
in,5907,O
vitro,5907,O
systems,5907,O
.,5907,O
The,5908,O
presence,5908,O
of,5908,O
Cl-,5908,B-CHEMICAL
inhibits,5908,O
the,5908,O
stimulation,5908,O
of,5908,O
[,5908,B-GENE-Y
Glu1,5908,I-GENE-Y
],5908,I-GENE-Y
Pg,5908,I-GENE-Y
activation,5908,O
that,5908,O
would,5908,O
normally,5908,O
occur,5908,O
in,5908,O
the,5908,O
presence,5908,O
of,5908,O
fibrinogen,5908,B-GENE-N
",",5908,O
a,5908,O
result,5908,O
of,5908,O
possible,5908,O
importance,5908,O
to,5908,O
the,5908,O
observation,5908,O
that,5908,O
some,5908,O
degree,5908,O
of,5908,O
systemic,5908,O
fibrinogenolysis,5908,O
accompanies,5908,O
therapeutic,5908,O
use,5908,O
of,5908,O
tissue,5908,B-GENE-Y
plasminogen,5908,I-GENE-Y
activator,5908,I-GENE-Y
.,5908,O
Vitamin,5909,B-CHEMICAL
B12,5909,I-CHEMICAL
responsive,5909,O
homocystinuria,5909,O
and,5909,O
megaloblastic,5909,O
anemia,5909,O
:,5909,O
heterogeneity,5909,O
in,5909,O
methylcobalamin,5909,B-CHEMICAL
deficiency,5909,O
.,5909,O
A,5910,O
male,5910,O
infant,5910,O
with,5910,O
methyl-B12,5910,B-CHEMICAL
deficiency,5910,O
(,5910,O
cblE,5910,O
),5910,O
presented,5910,O
at,5910,O
age,5910,O
6,5910,O
weeks,5910,O
with,5910,O
lethargy,5910,O
",",5910,O
staring,5910,O
spells,5910,O
",",5910,O
and,5910,O
vomiting,5910,O
.,5910,O
He,5911,O
later,5911,O
became,5911,O
hypotonic,5911,O
and,5911,O
unresponsive,5911,O
to,5911,O
stimuli,5911,O
and,5911,O
required,5911,O
intubation,5911,O
and,5911,O
ventilation,5911,O
.,5911,O
He,5912,O
had,5912,O
homocystinuria,5912,O
and,5912,O
hypomethioninemia,5912,O
with,5912,O
megaloblastic,5912,O
anemia,5912,O
but,5912,O
normal,5912,O
serum,5912,O
folate,5912,B-CHEMICAL
and,5912,O
vitamin,5912,B-CHEMICAL
B12,5912,I-CHEMICAL
concentrations,5912,O
.,5912,O
No,5913,O
methylmalonic,5913,B-CHEMICAL
aciduria,5913,I-CHEMICAL
was,5913,O
detected,5913,O
.,5913,O
Fibroblasts,5914,O
",",5914,O
cultured,5914,O
from,5914,O
the,5914,O
patient,5914,O
",",5914,O
were,5914,O
unable,5914,O
to,5914,O
grow,5914,O
in,5914,O
medium,5914,O
in,5914,O
which,5914,O
homocysteine,5914,B-CHEMICAL
replaced,5914,O
methionine,5914,B-CHEMICAL
and,5914,O
incorporated,5914,O
abnormally,5914,O
small,5914,O
amounts,5914,O
of,5914,O
[,5914,B-CHEMICAL
14C,5914,I-CHEMICAL
],5914,I-CHEMICAL
-methyl-tetrahydrofolate,5914,I-CHEMICAL
but,5914,O
normal,5914,O
amounts,5914,O
of,5914,O
[,5914,B-CHEMICAL
14C,5914,I-CHEMICAL
],5914,I-CHEMICAL
-propionate,5914,I-CHEMICAL
into,5914,O
protein,5914,O
.,5914,O
Methyl-B12,5915,B-CHEMICAL
content,5915,O
of,5915,O
fibroblasts,5915,O
was,5915,O
low,5915,O
",",5915,O
while,5915,O
the,5915,O
adenosyl-B12,5915,B-CHEMICAL
content,5915,O
was,5915,O
normal,5915,O
.,5915,O
Methionine,5916,B-GENE-Y
synthase,5916,I-GENE-Y
activity,5916,O
was,5916,O
decreased,5916,O
when,5916,O
the,5916,O
assay,5916,O
was,5916,O
performed,5916,O
under,5916,O
both,5916,O
optimal,5916,O
and,5916,O
suboptimal,5916,O
reducing,5916,O
conditions,5916,O
",",5916,O
suggesting,5916,O
heterogeneity,5916,O
in,5916,O
the,5916,O
cblE,5916,O
disease,5916,O
.,5916,O
The,5917,O
patient,5917,O
responded,5917,O
dramatically,5917,O
to,5917,O
hydroxocobalamin,5917,B-CHEMICAL
treatment,5917,O
.,5917,O
Homocystinuria,5918,O
disappeared,5918,O
after,5918,O
10,5918,O
days,5918,O
of,5918,O
therapy,5918,O
",",5918,O
and,5918,O
methionine,5918,B-CHEMICAL
was,5918,O
normalized,5918,O
after,5918,O
3,5918,O
weeks,5918,O
.,5918,O
Psychometric,5919,O
testing,5919,O
at,5919,O
age,5919,O
15,5919,O
months,5919,O
showed,5919,O
a,5919,O
developmental,5919,O
age,5919,O
of,5919,O
9,5919,O
months,5919,O
.,5919,O
Inactivation,5920,O
of,5920,O
factor,5920,B-GENE-Y
XII,5920,I-GENE-Y
active,5920,O
fragment,5920,O
in,5920,O
normal,5920,O
plasma,5920,O
.,5920,O
Predominant,5921,O
role,5921,O
of,5921,O
C-1-inhibitor,5921,B-GENE-Y
.,5921,O
To,5922,O
define,5922,O
the,5922,O
factors,5922,O
responsible,5922,O
for,5922,O
the,5922,O
inactivation,5922,O
of,5922,O
the,5922,O
active,5922,O
fragment,5922,O
derived,5922,O
from,5922,O
Factor,5922,B-GENE-Y
XII,5922,I-GENE-Y
(,5922,O
Factor,5922,B-GENE-Y
XIIf,5922,I-GENE-Y
),5922,O
in,5922,O
plasma,5922,O
",",5922,O
we,5922,O
studied,5922,O
the,5922,O
inactivation,5922,O
kinetics,5922,O
of,5922,O
Factor,5922,B-GENE-Y
XIIf,5922,I-GENE-Y
in,5922,O
various,5922,O
purified,5922,O
and,5922,O
plasma,5922,O
mixtures,5922,O
.,5922,O
We,5923,O
also,5923,O
analyzed,5923,O
the,5923,O
formation,5923,O
of,5923,O
125I-Factor,5923,B-CHEMICAL
XIIf,5923,I-GENE-Y
-inhibitor,5923,O
complexes,5923,O
by,5923,O
sodium,5923,B-CHEMICAL
dodecyl,5923,I-CHEMICAL
sulfate,5923,I-CHEMICAL
polyacrylamide,5923,B-CHEMICAL
gel,5923,O
electrophoresis,5923,O
(,5923,O
SDS-PAGE,5923,O
),5923,O
.,5923,O
In,5924,O
purified,5924,O
systems,5924,O
",",5924,O
the,5924,O
bimolecular,5924,O
rate,5924,O
constants,5924,O
for,5924,O
the,5924,O
reactions,5924,O
of,5924,O
Factor,5924,B-GENE-Y
XIIf,5924,I-GENE-Y
with,5924,O
C-1-inhibitor,5924,B-GENE-Y
",",5924,O
alpha,5924,B-GENE-Y
2-antiplasmin,5924,I-GENE-Y
",",5924,O
and,5924,O
antithrombin,5924,B-GENE-Y
III,5924,I-GENE-Y
were,5924,O
18.5,5924,O
",",5924,O
0.91,5924,O
",",5924,O
and,5924,O
0.32,5924,O
X,5924,O
10,5924,O
(,5924,O
4,5924,O
),5924,O
M-1,5924,O
min-1,5924,O
",",5924,O
respectively,5924,O
.,5924,O
Furthermore,5925,O
",",5925,O
SDS-PAGE,5925,O
analysis,5925,O
revealed,5925,O
that,5925,O
1:1,5925,O
stoichiometric,5925,O
complexes,5925,O
were,5925,O
formed,5925,O
between,5925,O
125I-Factor,5925,B-CHEMICAL
XIIf,5925,I-GENE-Y
and,5925,O
each,5925,O
of,5925,O
these,5925,O
three,5925,O
inhibitors,5925,O
.,5925,O
In,5926,O
contrast,5926,O
",",5926,O
kinetic,5926,O
and,5926,O
SDS-PAGE,5926,O
studies,5926,O
indicated,5926,O
that,5926,O
Factor,5926,B-GENE-Y
XIIf,5926,I-GENE-Y
did,5926,O
not,5926,O
react,5926,O
with,5926,O
alpha,5926,B-GENE-Y
1-antitrypsin,5926,I-GENE-Y
or,5926,O
alpha,5926,B-GENE-Y
2-macroglobulin,5926,I-GENE-Y
.,5926,O
The,5927,O
inactivation,5927,O
rate,5927,O
constant,5927,O
of,5927,O
Factor,5927,B-GENE-Y
XIIf,5927,I-GENE-Y
by,5927,O
prekallikrein-deficient,5927,B-GENE-Y
plasma,5927,O
was,5927,O
14.4,5927,O
X,5927,O
10,5927,O
(,5927,O
-2,5927,O
),5927,O
min-1,5927,O
",",5927,O
a,5927,O
value,5927,O
that,5927,O
was,5927,O
essentially,5927,O
identical,5927,O
to,5927,O
the,5927,O
value,5927,O
predicted,5927,O
from,5927,O
the,5927,O
studies,5927,O
in,5927,O
purified,5927,O
systems,5927,O
(,5927,O
15.5,5927,O
X,5927,O
10,5927,O
(,5927,O
-2,5927,O
),5927,O
min-1,5927,O
),5927,O
.,5927,O
This,5928,O
constant,5928,O
was,5928,O
reduced,5928,O
to,5928,O
1.8,5928,O
X,5928,O
10,5928,O
(,5928,O
-2,5928,O
),5928,O
min-1,5928,O
when,5928,O
Factor,5928,B-GENE-Y
XIIf,5928,I-GENE-Y
was,5928,O
inactivated,5928,O
by,5928,O
prekallikrein-deficient,5928,B-GENE-Y
plasma,5928,O
that,5928,O
had,5928,O
been,5928,O
immunodepleted,5928,O
(,5928,O
less,5928,O
than,5928,O
5,5928,O
%,5928,O
),5928,O
of,5928,O
C-1-inhibitor,5928,B-CHEMICAL
.,5928,O
In,5929,O
addition,5929,O
",",5929,O
after,5929,O
inactivation,5929,O
in,5929,O
normal,5929,O
plasma,5929,O
",",5929,O
74,5929,O
%,5929,O
of,5929,O
the,5929,O
active,5929,O
125I-Factor,5929,B-CHEMICAL
XIIf,5929,I-GENE-Y
was,5929,O
found,5929,O
to,5929,O
form,5929,O
a,5929,O
complex,5929,O
with,5929,O
C-1-inhibitor,5929,B-CHEMICAL
",",5929,O
whereas,5929,O
26,5929,O
%,5929,O
of,5929,O
the,5929,O
enzyme,5929,O
formed,5929,O
complexes,5929,O
with,5929,O
alpha,5929,B-GENE-Y
2-antiplasmin,5929,I-GENE-Y
and,5929,O
antithrombin,5929,B-GENE-Y
III,5929,I-GENE-Y
.,5929,O
Furthermore,5930,O
",",5930,O
42,5930,O
%,5930,O
of,5930,O
the,5930,O
labeled,5930,O
enzyme,5930,O
was,5930,O
still,5930,O
complexed,5930,O
with,5930,O
C-1-inhibitor,5930,B-CHEMICAL
when,5930,O
125I-Factor,5930,B-CHEMICAL
XII,5930,I-GENE-Y
was,5930,O
inactivated,5930,O
in,5930,O
hereditary,5930,O
angioedema,5930,O
plasma,5930,O
that,5930,O
contained,5930,O
32,5930,O
%,5930,O
of,5930,O
functional,5930,O
C-1-inhibitor,5930,B-CHEMICAL
.,5930,O
This,5931,O
study,5931,O
quantitatively,5931,O
demonstrates,5931,O
the,5931,O
dominant,5931,O
role,5931,O
of,5931,O
C-1-inhibitor,5931,B-CHEMICAL
in,5931,O
the,5931,O
inactivation,5931,O
of,5931,O
Factor,5931,B-GENE-Y
XIIf,5931,I-GENE-Y
in,5931,O
the,5931,O
plasma,5931,O
milieu,5931,O
.,5931,O
Sodium-dependent,5932,B-CHEMICAL
norepinephrine-induced,5932,B-CHEMICAL
currents,5932,O
in,5932,O
norepinephrine-transporter-transfected,5932,B-GENE-Y
HEK-293,5932,O
cells,5932,O
blocked,5932,O
by,5932,O
cocaine,5932,B-CHEMICAL
and,5932,O
antidepressants,5932,O
.,5932,O
Transport,5933,O
of,5933,O
norepinephrine,5933,B-CHEMICAL
(,5933,O
NE+,5933,B-CHEMICAL
),5933,O
by,5933,O
cocaine-,5933,B-CHEMICAL
and,5933,O
antidepressant-sensitive,5933,O
transporters,5933,O
in,5933,O
presynaptic,5933,O
terminals,5933,O
is,5933,O
predicted,5933,O
to,5933,O
involve,5933,O
the,5933,O
cotransport,5933,O
of,5933,O
Na+,5933,B-CHEMICAL
and,5933,O
Cl-,5933,B-CHEMICAL
",",5933,O
resulting,5933,O
in,5933,O
a,5933,O
net,5933,O
movement,5933,O
of,5933,O
charge,5933,O
per,5933,O
transport,5933,O
cycle,5933,O
.,5933,O
To,5934,O
explore,5934,O
the,5934,O
relationship,5934,O
between,5934,O
catecholamine,5934,B-CHEMICAL
transport,5934,O
and,5934,O
ion,5934,O
permeation,5934,O
through,5934,O
the,5934,O
NE,5934,B-GENE-Y
transporter,5934,I-GENE-Y
",",5934,O
we,5934,O
established,5934,O
a,5934,O
human,5934,B-GENE-Y
norepinephrine,5934,I-GENE-Y
transporter,5934,I-GENE-Y
(,5934,O
hNET,5934,B-GENE-Y
),5934,O
cell,5934,O
line,5934,O
suitable,5934,O
for,5934,O
biochemical,5934,O
analysis,5934,O
and,5934,O
patch-clamp,5934,O
recording,5934,O
.,5934,O
Stable,5935,O
transfection,5935,O
of,5935,O
hNET,5935,B-GENE-Y
cDNA,5935,O
into,5935,O
HEK-293,5935,O
(,5935,O
human,5935,O
embryonic,5935,O
kidney,5935,O
),5935,O
cells,5935,O
results,5935,O
in,5935,O
lines,5935,O
exhibiting,5935,O
(,5935,O
1,5935,O
),5935,O
a,5935,O
high,5935,O
number,5935,O
of,5935,O
transporter,5935,O
copies,5935,O
per,5935,O
cell,5935,O
(,5935,O
10,5935,O
(,5935,O
6,5935,O
),5935,O
),5935,O
",",5935,O
as,5935,O
detected,5935,O
by,5935,O
radioligand,5935,O
binding,5935,O
and,5935,O
hNET-specific,5935,B-GENE-Y
antibodies,5935,O
",",5935,O
(,5935,O
2,5935,O
),5935,O
high-affinity,5935,O
",",5935,O
Na,5935,B-CHEMICAL
(,5935,I-CHEMICAL
+,5935,I-CHEMICAL
),5935,I-CHEMICAL
-dependent,5935,O
transport,5935,O
of,5935,O
NE,5935,B-CHEMICAL
",",5935,O
and,5935,O
(,5935,O
3,5935,O
),5935,O
inhibitor,5935,O
sensitivities,5935,O
similar,5935,O
to,5935,O
those,5935,O
of,5935,O
native,5935,O
membranes,5935,O
.,5935,O
Whole-cell,5936,O
voltage-clamp,5936,O
of,5936,O
hNET-293,5936,B-GENE-Y
cells,5936,O
reveals,5936,O
NE-induced,5936,B-CHEMICAL
",",5936,O
Na,5936,B-CHEMICAL
(,5936,I-CHEMICAL
+,5936,I-CHEMICAL
),5936,I-CHEMICAL
-dependent,5936,O
currents,5936,O
blocked,5936,O
by,5936,O
antidepressants,5936,O
and,5936,O
cocaine,5936,B-CHEMICAL
that,5936,O
are,5936,O
absent,5936,O
in,5936,O
parental,5936,O
cells,5936,O
.,5936,O
In,5937,O
addition,5937,O
to,5937,O
NE-dependent,5937,B-CHEMICAL
currents,5937,O
",",5937,O
transfected,5937,O
cells,5937,O
posses,5937,O
an,5937,O
NE-independent,5937,B-CHEMICAL
mode,5937,O
of,5937,O
charge,5937,O
movement,5937,O
mediated,5937,O
by,5937,O
hNET,5937,B-GENE-Y
.,5937,O
hNET,5938,B-GENE-Y
antagonists,5938,O
without,5938,O
effect,5938,O
in,5938,O
non-transfected,5938,O
cells,5938,O
abolish,5938,O
both,5938,O
NE-dependent,5938,B-CHEMICAL
and,5938,O
NE-independent,5938,B-CHEMICAL
modes,5938,O
of,5938,O
charge,5938,O
movement,5938,O
in,5938,O
transfected,5938,O
cells,5938,O
.,5938,O
The,5939,O
magnitude,5939,O
of,5939,O
NE-dependent,5939,B-CHEMICAL
currents,5939,O
in,5939,O
these,5939,O
cells,5939,O
exceeds,5939,O
the,5939,O
expectations,5939,O
of,5939,O
simple,5939,O
carrier,5939,O
models,5939,O
using,5939,O
previous,5939,O
estimates,5939,O
of,5939,O
transport,5939,O
rates,5939,O
.,5939,O
To,5940,O
explain,5940,O
our,5940,O
observations,5940,O
",",5940,O
we,5940,O
propose,5940,O
that,5940,O
hNETs,5940,B-GENE-Y
function,5940,O
as,5940,O
ion-gated,5940,B-GENE-N
ligand,5940,I-GENE-N
channels,5940,I-GENE-N
with,5940,O
an,5940,O
indefinite,5940,O
stoichiometry,5940,O
relating,5940,O
ion,5940,O
flux,5940,O
to,5940,O
NE,5940,B-CHEMICAL
transport,5940,O
.,5940,O
In,5941,O
this,5941,O
view,5941,O
",",5941,O
external,5941,O
Na+,5941,B-CHEMICAL
and,5941,O
NE,5941,B-CHEMICAL
bind,5941,O
to,5941,O
the,5941,O
transporter,5941,O
with,5941,O
finite,5941,O
affinities,5941,O
in,5941,O
a,5941,O
cooperative,5941,O
fashion,5941,O
.,5941,O
However,5942,O
",",5942,O
coupled,5942,O
transport,5942,O
may,5942,O
not,5942,O
predict,5942,O
the,5942,O
magnitude,5942,O
or,5942,O
the,5942,O
kinetics,5942,O
of,5942,O
the,5942,O
total,5942,O
current,5942,O
through,5942,O
the,5942,O
transporter,5942,O
.,5942,O
We,5943,O
propose,5943,O
instead,5943,O
that,5943,O
Na+,5943,B-CHEMICAL
gates,5943,O
NE,5943,B-CHEMICAL
transport,5943,O
and,5943,O
also,5943,O
the,5943,O
parallel,5943,O
inward,5943,O
flux,5943,O
of,5943,O
an,5943,O
indeterminate,5943,O
number,5943,O
of,5943,O
ions,5943,O
through,5943,O
a,5943,O
channel-like,5943,O
pore,5943,O
.,5943,O
TSG-6,5944,B-GENE-Y
",",5944,O
an,5944,O
arthritis-associated,5944,O
hyaluronan,5944,B-GENE-N
binding,5944,I-GENE-N
protein,5944,I-GENE-N
",",5944,O
forms,5944,O
a,5944,O
stable,5944,O
complex,5944,O
with,5944,O
the,5944,O
serum,5944,B-GENE-N
protein,5944,I-GENE-N
inter-alpha-inhibitor,5944,I-GENE-N
.,5944,O
TSG-6,5945,B-GENE-Y
is,5945,O
a,5945,O
secreted,5945,O
35-kDa,5945,B-GENE-N
glycoprotein,5945,I-GENE-N
",",5945,O
inducible,5945,O
by,5945,O
TNF,5945,B-GENE-Y
and,5945,O
IL-1,5945,B-GENE-N
.,5945,O
The,5946,O
N-terminal,5946,B-CHEMICAL
portion,5946,O
of,5946,O
TSG-6,5946,B-GENE-Y
shows,5946,O
sequence,5946,O
homology,5946,O
to,5946,O
members,5946,O
of,5946,O
the,5946,O
cartilage,5946,O
link,5946,O
protein,5946,O
family,5946,O
of,5946,O
hyaluronan,5946,B-GENE-N
binding,5946,I-GENE-N
proteins,5946,I-GENE-N
.,5946,O
The,5947,O
C-terminal,5947,B-CHEMICAL
half,5947,O
of,5947,O
TSG-6,5947,B-GENE-Y
contains,5947,O
a,5947,O
so-called,5947,O
CUB,5947,B-GENE-N
domain,5947,I-GENE-N
",",5947,O
characteristic,5947,O
for,5947,O
developmentally,5947,O
regulated,5947,O
proteins,5947,O
.,5947,O
High,5948,O
levels,5948,O
of,5948,O
TSG-6,5948,B-GENE-Y
protein,5948,O
are,5948,O
found,5948,O
in,5948,O
the,5948,O
synovial,5948,O
fluid,5948,O
of,5948,O
patients,5948,O
with,5948,O
rheumatoid,5948,O
arthritis,5948,O
and,5948,O
some,5948,O
other,5948,O
arthritic,5948,O
diseases,5948,O
.,5948,O
Here,5949,O
we,5949,O
show,5949,O
that,5949,O
TSG-6,5949,B-GENE-N
readily,5949,O
formed,5949,O
a,5949,O
complex,5949,O
with,5949,O
a,5949,O
protein,5949,O
present,5949,O
in,5949,O
human,5949,O
",",5949,O
bovine,5949,O
",",5949,O
rabbit,5949,O
",",5949,O
and,5949,O
mouse,5949,O
serum,5949,O
.,5949,O
This,5950,O
complex,5950,O
was,5950,O
stable,5950,O
during,5950,O
SDS-PAGE,5950,O
under,5950,O
reducing,5950,O
conditions,5950,O
",",5950,O
and,5950,O
in,5950,O
the,5950,O
presence,5950,O
of,5950,O
8,5950,O
M,5950,O
urea,5950,B-CHEMICAL
.,5950,O
The,5951,O
protein,5951,O
that,5951,O
binds,5951,O
TSG-6,5951,B-GENE-Y
was,5951,O
purified,5951,O
from,5951,O
human,5951,O
serum,5951,O
and,5951,O
identified,5951,O
as,5951,O
inter-alpha-inhibitor,5951,B-GENE-N
(,5951,O
I,5951,B-GENE-N
alpha,5951,I-GENE-N
I,5951,I-GENE-N
),5951,O
by,5951,O
N-terminal,5951,B-CHEMICAL
microsequencing,5951,O
.,5951,O
Microsequencing,5952,O
of,5952,O
the,5952,O
complex,5952,O
itself,5952,O
revealed,5952,O
the,5952,O
presence,5952,O
of,5952,O
TSG-6,5952,B-GENE-Y
and,5952,O
two,5952,O
of,5952,O
the,5952,O
three,5952,O
polypeptide,5952,O
chains,5952,O
of,5952,O
I,5952,B-GENE-N
alpha,5952,I-GENE-N
I,5952,I-GENE-N
(,5952,O
bikunin,5952,B-GENE-Y
and,5952,O
HC2,5952,B-GENE-Y
),5952,O
.,5952,O
Experiments,5953,O
with,5953,O
recombinant,5953,O
TSG-6,5953,B-GENE-Y
and,5953,O
I,5953,B-GENE-N
alpha,5953,I-GENE-N
I,5953,I-GENE-N
purified,5953,O
from,5953,O
human,5953,O
serum,5953,O
showed,5953,O
that,5953,O
the,5953,O
TSG-6/I,5953,B-GENE-Y
alpha,5953,I-GENE-N
I,5953,I-GENE-N
complex,5953,O
is,5953,O
rapidly,5953,O
formed,5953,O
even,5953,O
in,5953,O
the,5953,O
apparent,5953,O
absence,5953,O
of,5953,O
other,5953,O
proteins,5953,O
at,5953,O
37,5953,O
degrees,5953,O
C,5953,O
",",5953,O
but,5953,O
not,5953,O
at,5953,O
4,5953,O
degrees,5953,O
C.,5953,O
The,5953,O
TSG-6/I,5953,B-GENE-Y
alpha,5953,I-GENE-N
I,5953,I-GENE-N
complex,5953,O
was,5953,O
cleaved,5953,O
by,5953,O
chondroitin,5953,B-GENE-N
sulfate,5953,B-CHEMICAL
ABC,5953,I-GENE-N
lyase,5953,I-GENE-N
",",5953,O
suggesting,5953,O
that,5953,O
cross-linking,5953,O
by,5953,O
chondroitin,5953,O
sulfate,5953,B-CHEMICAL
is,5953,O
required,5953,O
for,5953,O
the,5953,O
stability,5953,O
of,5953,O
the,5953,O
complex,5953,O
.,5953,O
(,5954,O
ABSTRACT,5954,O
TRUNCATED,5954,O
AT,5954,O
250,5954,O
WORDS,5954,O
),5954,O
Effects,5955,O
of,5955,O
nabumetone,5955,B-CHEMICAL
on,5955,O
prostanoid,5955,B-CHEMICAL
biosynthesis,5955,O
in,5955,O
humans,5955,O
.,5955,O
BACKGROUND,5956,O
:,5956,O
The,5956,O
active,5956,O
metabolite,5956,O
of,5956,O
the,5956,O
anti-inflammatory,5956,O
drug,5956,O
nabumetone,5956,B-CHEMICAL
has,5956,O
been,5956,O
characterized,5956,O
as,5956,O
a,5956,O
selective,5956,O
inhibitor,5956,O
of,5956,O
the,5956,O
inducible,5956,O
prostaglandin,5956,B-CHEMICAL
H,5956,I-GENE-N
synthase,5956,I-GENE-N
(,5956,O
PGHS,5956,B-GENE-N
),5956,O
.,5956,O
The,5957,O
aim,5957,O
of,5957,O
this,5957,O
study,5957,O
was,5957,O
to,5957,O
investigate,5957,O
the,5957,O
rate,5957,O
of,5957,O
eicosanoid,5957,B-CHEMICAL
biosynthesis,5957,O
after,5957,O
oral,5957,O
dosing,5957,O
with,5957,O
nabumetone,5957,B-CHEMICAL
in,5957,O
nine,5957,O
healthy,5957,O
subjects,5957,O
.,5957,O
METHODS,5958,O
:,5958,O
We,5958,O
measured,5958,O
the,5958,O
urinary,5958,O
excretion,5958,O
of,5958,O
products,5958,O
of,5958,O
platelet,5958,O
(,5958,O
11-dehydro-thromboxane,5958,B-CHEMICAL
B2,5958,I-CHEMICAL
[,5958,O
TXB2,5958,B-CHEMICAL
],5958,O
),5958,O
and,5958,O
renal,5958,O
(,5958,O
prostaglandin,5958,B-CHEMICAL
IF2,5958,I-CHEMICAL
alpha,5958,I-CHEMICAL
[,5958,O
PGF2,5958,B-CHEMICAL
alpha,5958,I-CHEMICAL
],5958,O
),5958,O
arachidonate,5958,B-CHEMICAL
metabolism,5958,O
as,5958,O
in,5958,O
vivo,5958,O
indexes,5958,O
of,5958,O
the,5958,O
constitutive,5958,O
PGHS-1,5958,B-GENE-Y
pathway,5958,O
.,5958,O
Moreover,5959,O
",",5959,O
the,5959,O
production,5959,O
of,5959,O
TXB2,5959,B-CHEMICAL
during,5959,O
whole,5959,O
blood,5959,O
clotting,5959,O
was,5959,O
assessed,5959,O
as,5959,O
an,5959,O
index,5959,O
of,5959,O
the,5959,O
cyclooxygenase,5959,B-GENE-N
activity,5959,O
of,5959,O
platelet,5959,O
PGHS-1,5959,B-GENE-Y
ex,5959,O
vivo,5959,O
.,5959,O
RESULTS,5960,O
:,5960,O
At,5960,O
steady,5960,O
state,5960,O
",",5960,O
nabumetone,5960,B-CHEMICAL
(,5960,O
500,5960,O
and,5960,O
1000,5960,O
mg,5960,O
daily,5960,O
for,5960,O
7,5960,O
days,5960,O
),5960,O
was,5960,O
associated,5960,O
with,5960,O
statistically,5960,O
significant,5960,O
dose-dependent,5960,O
reduction,5960,O
in,5960,O
the,5960,O
urinary,5960,O
excretion,5960,O
of,5960,O
11-dehydro-TXB2,5960,B-CHEMICAL
and,5960,O
serum,5960,O
TXB2,5960,B-CHEMICAL
levels,5960,O
by,5960,O
approximately,5960,O
50,5960,O
%,5960,O
to,5960,O
70,5960,O
%,5960,O
.,5960,O
However,5961,O
",",5961,O
the,5961,O
drug,5961,O
did,5961,O
not,5961,O
significantly,5961,O
affect,5961,O
the,5961,O
urinary,5961,O
excretion,5961,O
of,5961,O
PGF2,5961,B-CHEMICAL
alpha,5961,I-CHEMICAL
.,5961,O
After,5962,O
discontinuation,5962,O
of,5962,O
nabumetone,5962,B-CHEMICAL
",",5962,O
urinary,5962,O
11-dehydro-TXB2,5962,B-CHEMICAL
excretion,5962,O
and,5962,O
whole,5962,O
blood,5962,O
TXB2,5962,B-CHEMICAL
production,5962,O
returned,5962,O
to,5962,O
predrug,5962,O
levels,5962,O
with,5962,O
a,5962,O
similar,5962,O
timecourse,5962,O
that,5962,O
was,5962,O
consistent,5962,O
with,5962,O
the,5962,O
elimination,5962,O
half-life,5962,O
of,5962,O
its,5962,O
active,5962,O
metabolite,5962,O
.,5962,O
The,5963,O
daily,5963,O
administration,5963,O
of,5963,O
low-dose,5963,O
aspirin,5963,B-CHEMICAL
(,5963,O
40,5963,O
mg,5963,O
),5963,O
",",5963,O
a,5963,O
selective,5963,O
inhibitor,5963,O
of,5963,O
platelet,5963,O
PGHS-1,5963,B-GENE-Y
",",5963,O
caused,5963,O
a,5963,O
cumulative,5963,O
inhibition,5963,O
of,5963,O
urinary,5963,O
11-dehydro-TXB2,5963,B-CHEMICAL
and,5963,O
whole,5963,O
blood,5963,O
TXB2,5963,B-CHEMICAL
production,5963,O
that,5963,O
recovered,5963,O
with,5963,O
a,5963,O
timecourse,5963,O
consistent,5963,O
with,5963,O
platelet,5963,O
turnover,5963,O
.,5963,O
CONCLUSIONS,5964,O
:,5964,O
Nabumetone,5964,B-CHEMICAL
does,5964,O
dose-dependently,5964,O
inhibit,5964,O
the,5964,O
cyclooxygenase,5964,B-GENE-N
activity,5964,O
of,5964,O
platelet,5964,O
PGHS-1,5964,B-GENE-Y
of,5964,O
healthy,5964,O
subjects,5964,O
both,5964,O
in,5964,O
vivo,5964,O
and,5964,O
ex,5964,O
vivo,5964,O
.,5964,O
Thus,5965,O
it,5965,O
is,5965,O
unlikely,5965,O
that,5965,O
its,5965,O
safety,5965,O
profile,5965,O
in,5965,O
patients,5965,O
may,5965,O
be,5965,O
related,5965,O
to,5965,O
selective,5965,O
inhibition,5965,O
of,5965,O
the,5965,O
inducible,5965,O
PGHS-2,5965,B-GENE-Y
.,5965,O
Altered,5966,O
gene,5966,O
expression,5966,O
in,5966,O
murine,5966,O
branchial,5966,O
arches,5966,O
following,5966,O
in,5966,O
utero,5966,O
exposure,5966,O
to,5966,O
retinoic,5966,B-CHEMICAL
acid,5966,I-CHEMICAL
.,5966,O
Retinoic,5967,B-CHEMICAL
acid,5967,I-CHEMICAL
(,5967,O
RA,5967,B-CHEMICAL
),5967,O
in,5967,O
the,5967,O
form,5967,O
of,5967,O
isotretinoin,5967,B-CHEMICAL
(,5967,O
Accutane,5967,B-CHEMICAL
),5967,O
and,5967,O
tretinoin,5967,B-CHEMICAL
(,5967,O
Retin-A,5967,B-CHEMICAL
),5967,O
is,5967,O
a,5967,O
clinically,5967,O
important,5967,O
compound,5967,O
in,5967,O
the,5967,O
treatment,5967,O
of,5967,O
dermatologic,5967,O
disorders,5967,O
.,5967,O
However,5968,O
",",5968,O
it,5968,O
is,5968,O
also,5968,O
a,5968,O
potent,5968,O
teratogen,5968,O
associated,5968,O
with,5968,O
a,5968,O
number,5968,O
of,5968,O
serious,5968,O
congenital,5968,O
malformations,5968,O
.,5968,O
Generally,5969,O
",",5969,O
these,5969,O
malformations,5969,O
involve,5969,O
the,5969,O
craniofacial,5969,O
structures,5969,O
derived,5969,O
from,5969,O
the,5969,O
first,5969,O
and,5969,O
second,5969,O
branchial,5969,O
arches,5969,O
.,5969,O
To,5970,O
determine,5970,O
how,5970,O
altered,5970,O
gene,5970,O
expression,5970,O
may,5970,O
contribute,5970,O
to,5970,O
the,5970,O
observed,5970,O
RA-induced,5970,B-CHEMICAL
defects,5970,O
",",5970,O
pregnant,5970,O
LM/Bc,5970,O
mice,5970,O
were,5970,O
administered,5970,O
(,5970,O
5,5970,O
mg/kg,5970,O
),5970,O
all-trans,5970,B-CHEMICAL
RA,5970,I-CHEMICAL
on,5970,O
gestational,5970,O
day,5970,O
(,5970,O
GD,5970,O
),5970,O
8:12,5970,O
.,5970,O
First,5971,O
and,5971,O
second,5971,O
branchial,5971,O
arches,5971,O
were,5971,O
removed,5971,O
from,5971,O
control,5971,O
and,5971,O
teratogen-treated,5971,O
embryos,5971,O
on,5971,O
GD,5971,O
10:00,5971,O
10:12,5971,O
",",5971,O
or,5971,O
12:00,5971,O
",",5971,O
processed,5971,O
by,5971,O
in,5971,O
situ,5971,O
transcription/aRNA,5971,O
techniques,5971,O
",",5971,O
and,5971,O
analyzed,5971,O
for,5971,O
alterations,5971,O
in,5971,O
gene,5971,O
expression,5971,O
.,5971,O
In,5972,O
these,5972,O
studies,5972,O
",",5972,O
a,5972,O
panel,5972,O
of,5972,O
40,5972,O
candidate,5972,O
genes,5972,O
that,5972,O
are,5972,O
known,5972,O
to,5972,O
be,5972,O
important,5972,O
in,5972,O
mammalian,5972,O
craniofacial,5972,O
development,5972,O
were,5972,O
examined,5972,O
.,5972,O
This,5973,O
analysis,5973,O
revealed,5973,O
significant,5973,O
differences,5973,O
in,5973,O
the,5973,O
expression,5973,O
level,5973,O
of,5973,O
the,5973,O
nicotinic,5973,B-GENE-Y
acetylcholine,5973,B-CHEMICAL
receptor,5973,I-GENE-Y
subunit,5973,I-GENE-Y
alpha,5973,I-GENE-Y
(,5973,O
NAChR,5973,B-GENE-Y
),5973,O
",",5973,O
transforming,5973,B-GENE-Y
growth,5973,I-GENE-Y
factor,5973,I-GENE-Y
beta,5973,I-GENE-Y
2,5973,I-GENE-Y
(,5973,O
TGF,5973,B-GENE-Y
beta,5973,I-GENE-Y
2,5973,I-GENE-Y
),5973,O
",",5973,O
type,5973,B-GENE-Y
1,5973,I-GENE-Y
cellular,5973,I-GENE-Y
retinoid,5973,B-CHEMICAL
binding,5973,I-GENE-Y
protein,5973,I-GENE-Y
(,5973,O
CRBP-1,5973,B-GENE-Y
),5973,O
",",5973,O
retinoic,5973,B-CHEMICAL
acid,5973,I-CHEMICAL
receptor,5973,I-GENE-Y
gamma,5973,I-GENE-Y
(,5973,O
RAR,5973,B-GENE-Y
gamma,5973,I-GENE-Y
),5973,O
",",5973,O
and,5973,O
cAMP,5973,B-CHEMICAL
response,5973,I-GENE-N
element,5973,I-GENE-N
binding,5973,I-GENE-N
protein,5973,I-GENE-N
(,5973,O
CREB,5973,B-GENE-N
),5973,O
.,5973,O
The,5974,O
alterations,5974,O
observed,5974,O
in,5974,O
the,5974,O
expression,5974,O
of,5974,O
these,5974,O
genes,5974,O
following,5974,O
RA,5974,B-CHEMICAL
exposure,5974,O
may,5974,O
prohibit,5974,O
normal,5974,O
morphogenetic,5974,O
processes,5974,O
within,5974,O
the,5974,O
second,5974,O
branchial,5974,O
arch,5974,O
and,5974,O
lead,5974,O
to,5974,O
the,5974,O
observed,5974,O
malformations,5974,O
.,5974,O
Estramustine,5975,B-CHEMICAL
binding,5975,I-GENE-N
protein,5975,I-GENE-N
in,5975,O
primary,5975,O
tumours,5975,O
and,5975,O
metastases,5975,O
of,5975,O
malignant,5975,O
melanoma,5975,O
.,5975,O
The,5976,O
presence,5976,O
of,5976,O
estramustine,5976,B-GENE-N
binding,5976,I-GENE-N
protein,5976,I-GENE-N
(,5976,O
EMBP,5976,B-GENE-N
),5976,O
",",5976,O
a,5976,O
54,5976,O
kD,5976,O
cytosolic,5976,O
glycoprotein,5976,O
",",5976,O
which,5976,O
is,5976,O
distinct,5976,O
from,5976,O
the,5976,O
estrogen,5976,B-GENE-Y
receptor,5976,I-GENE-Y
",",5976,O
was,5976,O
investigated,5976,O
in,5976,O
a,5976,O
pilot,5976,O
study,5976,O
of,5976,O
primary,5976,O
malignant,5976,O
melanomas,5976,O
and,5976,O
their,5976,O
metastases,5976,O
.,5976,O
In,5977,O
11,5977,O
primary,5977,O
melanomas,5977,O
EMBP,5977,B-GENE-N
was,5977,O
demonstrated,5977,O
by,5977,O
immunohistochemistry,5977,O
.,5977,O
The,5978,O
percentage,5978,O
of,5978,O
positive,5978,O
melanoma,5978,O
cells,5978,O
ranged,5978,O
between,5978,O
11-91,5978,O
%,5978,O
with,5978,O
a,5978,O
mean,5978,O
of,5978,O
57,5978,O
%,5978,O
.,5978,O
Radioimmunoassay,5979,O
on,5979,O
metastatic,5979,O
tissue,5979,O
revealed,5979,O
significant,5979,O
amounts,5979,O
of,5979,O
EMBP,5979,B-GENE-N
",",5979,O
with,5979,O
values,5979,O
ranging,5979,O
between,5979,O
0.6-4.2,5979,O
with,5979,O
a,5979,O
mean,5979,O
of,5979,O
1.6,5979,O
ng/mg,5979,O
protein,5979,O
.,5979,O
A,5980,O
high,5980,O
number,5980,O
of,5980,O
cells,5980,O
with,5980,O
a,5980,O
positive,5980,O
stain,5980,O
for,5980,O
EMBP,5980,B-GENE-N
in,5980,O
the,5980,O
primary,5980,O
tumours,5980,O
was,5980,O
significantly,5980,O
correlated,5980,O
to,5980,O
a,5980,O
short,5980,O
interval,5980,O
between,5980,O
diagnosis,5980,O
and,5980,O
the,5980,O
occurrence,5980,O
of,5980,O
metastases,5980,O
.,5980,O
Presence,5981,O
of,5981,O
EMBP,5981,B-GENE-N
in,5981,O
malignant,5981,O
melanoma,5981,O
may,5981,O
have,5981,O
prognostic,5981,O
significance,5981,O
and,5981,O
the,5981,O
role,5981,O
of,5981,O
hormone-linked,5981,O
cytostatic,5981,O
drugs,5981,O
in,5981,O
the,5981,O
treatment,5981,O
of,5981,O
this,5981,O
disease,5981,O
needs,5981,O
further,5981,O
investigation,5981,O
.,5981,O
Preclinical,5982,O
efficacy,5982,O
of,5982,O
emedastine,5982,B-CHEMICAL
",",5982,O
a,5982,O
potent,5982,O
",",5982,O
selective,5982,O
histamine,5982,B-GENE-Y
H1,5982,I-GENE-Y
antagonist,5982,O
for,5982,O
topical,5982,O
ocular,5982,O
use,5982,O
.,5982,O
Emedastine,5983,B-CHEMICAL
[,5983,O
1-,5983,B-CHEMICAL
(,5983,I-CHEMICAL
2-ethoxyethyl,5983,I-CHEMICAL
),5983,I-CHEMICAL
-2-,5983,I-CHEMICAL
(,5983,I-CHEMICAL
4-methyl-1-homopiperazinyl,5983,I-CHEMICAL
),5983,I-CHEMICAL
-,5983,I-CHEMICAL
benzimidazole,5983,I-CHEMICAL
difumarate,5983,I-CHEMICAL
],5983,O
was,5983,O
evaluated,5983,O
for,5983,O
topical,5983,O
ocular,5983,O
anti-histaminic,5983,O
activity,5983,O
in,5983,O
histamine,5983,B-CHEMICAL
and,5983,O
antigen,5983,O
stimulated,5983,O
conjunctivitis,5983,O
models,5983,O
.,5983,O
Concentration-dependent,5984,O
inhibition,5984,O
of,5984,O
histamine,5984,B-CHEMICAL
induced,5984,O
vascular,5984,O
permeability,5984,O
changes,5984,O
occurring,5984,O
in,5984,O
the,5984,O
conjunctiva,5984,O
was,5984,O
observed,5984,O
when,5984,O
the,5984,O
time,5984,O
interval,5984,O
between,5984,O
topical,5984,O
ocular,5984,O
administration,5984,O
and,5984,O
histamine,5984,B-CHEMICAL
challenge,5984,O
ranged,5984,O
from,5984,O
1,5984,O
min,5984,O
to,5984,O
8,5984,O
hr,5984,O
.,5984,O
The,5985,O
calculated,5985,O
ED50,5985,O
values,5985,O
obtained,5985,O
using,5985,O
intervals,5985,O
of,5985,O
1,5985,O
min,5985,O
",",5985,O
30,5985,O
min,5985,O
",",5985,O
2,5985,O
",",5985,O
4,5985,O
and,5985,O
8,5985,O
hr,5985,O
were,5985,O
0.0002,5985,O
%,5985,O
",",5985,O
0.000035,5985,O
%,5985,O
",",5985,O
0.0029,5985,O
%,5985,O
",",5985,O
0.019,5985,O
%,5985,O
and,5985,O
0.19,5985,O
%,5985,O
",",5985,O
w/v,5985,O
",",5985,O
respectively,5985,O
.,5985,O
Comparisons,5986,O
of,5986,O
relative,5986,O
potency,5986,O
30,5986,O
min,5986,O
post,5986,O
dosing,5986,O
between,5986,O
emedastine,5986,O
and,5986,O
other,5986,O
anti-histamines,5986,O
demonstrated,5986,O
that,5986,O
emedastine,5986,B-CHEMICAL
is,5986,O
equipotent,5986,O
to,5986,O
ketotifen,5986,B-CHEMICAL
",",5986,O
and,5986,O
7,5986,O
",",5986,O
7,5986,O
",",5986,O
10,5986,O
",",5986,O
10,5986,O
",",5986,O
100,5986,O
",",5986,O
357,5986,O
",",5986,O
3333,5986,O
",",5986,O
and,5986,O
5813,5986,O
times,5986,O
more,5986,O
potent,5986,O
than,5986,O
brompheniramine,5986,B-CHEMICAL
",",5986,O
chlorpheniramine,5986,B-CHEMICAL
",",5986,O
clemastine,5986,B-CHEMICAL
",",5986,O
pyrilamine,5986,B-CHEMICAL
",",5986,O
levocabastine,5986,B-CHEMICAL
",",5986,O
pheniramine,5986,B-CHEMICAL
",",5986,O
diphenhydramine,5986,B-CHEMICAL
",",5986,O
and,5986,O
antazoline,5986,B-CHEMICAL
",",5986,O
respectively,5986,O
.,5986,O
Emedastine,5987,B-CHEMICAL
(,5987,O
0.1,5987,O
%,5987,O
),5987,O
failed,5987,O
to,5987,O
significantly,5987,O
attenuate,5987,O
either,5987,O
serotonin,5987,O
or,5987,O
platelet-activating-factor,5987,O
induced,5987,O
vascular,5987,O
permeability,5987,O
changes,5987,O
indicating,5987,O
high,5987,O
selectivity,5987,O
for,5987,O
the,5987,O
histamine,5987,B-CHEMICAL
H1,5987,I-GENE-Y
receptor,5987,I-GENE-Y
.,5987,O
In,5988,O
a,5988,O
passive,5988,O
conjunctival,5988,O
anaphylaxis,5988,O
model,5988,O
in,5988,O
guinea,5988,O
pigs,5988,O
",",5988,O
significant,5988,O
inhibition,5988,O
of,5988,O
the,5988,O
allergic,5988,O
response,5988,O
was,5988,O
observed,5988,O
following,5988,O
topical,5988,O
ocular,5988,O
administration,5988,O
of,5988,O
emedastine,5988,B-CHEMICAL
5,5988,O
min,5988,O
or,5988,O
30,5988,O
min,5988,O
prior,5988,O
to,5988,O
antigen,5988,O
challenge,5988,O
(,5988,O
ED50s,5988,O
0.0046,5988,O
%,5988,O
and,5988,O
0.00022,5988,O
%,5988,O
",",5988,O
respectively,5988,O
),5988,O
.,5988,O
These,5989,O
data,5989,O
clearly,5989,O
indicate,5989,O
that,5989,O
emedastine,5989,B-CHEMICAL
has,5989,O
potential,5989,O
as,5989,O
a,5989,O
topical,5989,O
ocular,5989,O
anti-histamine,5989,O
for,5989,O
treating,5989,O
allergic,5989,O
conjunctivitis,5989,O
.,5989,O
ALL-1,5990,B-GENE-Y
gene,5990,O
rearrangements,5990,O
in,5990,O
DNA,5990,B-GENE-Y
topoisomerase,5990,I-GENE-Y
II,5990,I-GENE-Y
inhibitor-related,5990,O
leukemia,5990,O
in,5990,O
children,5990,O
.,5990,O
We,5991,O
examined,5991,O
clinical,5991,O
",",5991,O
morphologic,5991,O
",",5991,O
and,5991,O
cytogenetic,5991,O
features,5991,O
and,5991,O
ALL-1,5991,B-GENE-Y
(,5991,O
MLL,5991,B-GENE-Y
",",5991,O
Htrxl,5991,B-GENE-Y
",",5991,O
HRX,5991,B-GENE-Y
),5991,O
gene,5991,O
rearrangements,5991,O
in,5991,O
17,5991,O
cases,5991,O
of,5991,O
secondary,5991,O
leukemia,5991,O
that,5991,O
occurred,5991,O
11,5991,O
months,5991,O
to,5991,O
9,5991,O
years,5991,O
from,5991,O
diagnoses,5991,O
of,5991,O
primary,5991,O
cancers,5991,O
in,5991,O
children,5991,O
who,5991,O
received,5991,O
topoisomerase,5991,B-GENE-Y
II,5991,I-GENE-Y
inhibitors,5991,O
or,5991,O
developed,5991,O
secondary,5991,O
leukemias,5991,O
typical,5991,O
of,5991,O
those,5991,O
associated,5991,O
with,5991,O
this,5991,O
therapy,5991,O
.,5991,O
Primary,5992,O
diagnoses,5992,O
included,5992,O
nine,5992,O
solid,5992,O
tumors,5992,O
and,5992,O
eight,5992,O
leukemias,5992,O
.,5992,O
Ten,5993,O
secondary,5993,O
leukemias,5993,O
were,5993,O
acute,5993,O
myeloid,5993,O
leukemia,5993,O
(,5993,O
AML,5993,O
),5993,O
",",5993,O
one,5993,O
was,5993,O
of,5993,O
mixed,5993,O
lineage,5993,O
",",5993,O
two,5993,O
were,5993,O
acute,5993,O
lymphoblastic,5993,O
leukemia,5993,O
(,5993,O
ALL,5993,O
),5993,O
",",5993,O
and,5993,O
four,5993,O
presented,5993,O
as,5993,O
myelodysplasia,5993,O
.,5993,O
Of,5994,O
15,5994,O
cases,5994,O
with,5994,O
11q23,5994,O
involvement,5994,O
",",5994,O
11,5994,O
(,5994,O
73,5994,O
%,5994,O
),5994,O
were,5994,O
cytogenetically,5994,O
identifiable,5994,O
;,5994,O
four,5994,O
cases,5994,O
had,5994,O
molecular,5994,O
rearrangement,5994,O
only,5994,O
.,5994,O
By,5995,O
Southern,5995,O
blot,5995,O
",",5995,O
rearrangements,5995,O
within,5995,O
the,5995,O
ALL-1,5995,B-GENE-Y
gene,5995,O
were,5995,O
similar,5995,O
to,5995,O
sporadic,5995,O
cases,5995,O
.,5995,O
The,5996,O
results,5996,O
of,5996,O
this,5996,O
analysis,5996,O
suggest,5996,O
the,5996,O
following,5996,O
:,5996,O
(,5996,O
1,5996,O
),5996,O
In,5996,O
most,5996,O
pediatric,5996,O
cases,5996,O
of,5996,O
topoisomerase,5996,B-GENE-Y
II,5996,I-GENE-Y
inhibitor-associated,5996,O
leukemia,5996,O
",",5996,O
there,5996,O
is,5996,O
disruption,5996,O
of,5996,O
the,5996,O
breakpoint,5996,O
cluster,5996,O
region,5996,O
of,5996,O
the,5996,O
ALL-1,5996,B-GENE-Y
gene,5996,O
at,5996,O
chromosomal,5996,O
band,5996,O
11q23,5996,O
.,5996,O
(,5997,O
2,5997,O
),5997,O
Exposure,5997,O
histories,5997,O
vary,5997,O
in,5997,O
secondary,5997,O
11q23,5997,O
leukemia,5997,O
",",5997,O
as,5997,O
the,5997,O
only,5997,O
topoisomerase,5997,B-GENE-Y
II,5997,I-GENE-Y
inhibitor,5997,O
was,5997,O
dactinomycin,5997,B-CHEMICAL
in,5997,O
one,5997,O
case,5997,O
",",5997,O
and,5997,O
",",5997,O
in,5997,O
another,5997,O
case,5997,O
",",5997,O
no,5997,O
topoisomerase,5997,B-GENE-Y
II,5997,I-GENE-Y
inhibitor,5997,O
was,5997,O
administered,5997,O
.,5997,O
(,5998,O
3,5998,O
),5998,O
There,5998,O
is,5998,O
clinical,5998,O
",",5998,O
morphologic,5998,O
",",5998,O
cytogenetic,5998,O
",",5998,O
and,5998,O
molecular,5998,O
heterogeneity,5998,O
in,5998,O
pediatric,5998,O
secondary,5998,O
11q23,5998,O
leukemia,5998,O
.,5998,O
(,5999,O
4,5999,O
),5999,O
There,5999,O
are,5999,O
some,5999,O
survivors,5999,O
of,5999,O
pediatric,5999,O
secondary,5999,O
11q23,5999,O
leukemia,5999,O
",",5999,O
but,5999,O
the,5999,O
outcome,5999,O
is,5999,O
most,5999,O
often,5999,O
fatal,5999,O
.,5999,O
Interactions,6000,O
of,6000,O
PGH,6000,B-GENE-N
synthase,6000,I-GENE-N
isozymes-1,6000,I-GENE-N
and,6000,I-GENE-N
-2,6000,I-GENE-N
with,6000,O
NSAIDs,6000,O
.,6000,O
There,6001,O
are,6001,O
two,6001,O
isozymes,6001,O
of,6001,O
prostaglandin,6001,B-GENE-N
endoperoxide,6001,I-GENE-N
(,6001,I-GENE-N
PGH,6001,I-GENE-N
),6001,I-GENE-N
synthase,6001,I-GENE-N
(,6001,O
cyclooxygenase,6001,B-GENE-N
),6001,O
called,6001,O
PGH,6001,B-GENE-N
synthase-1,6001,I-GENE-N
and,6001,I-GENE-N
-2,6001,I-GENE-N
or,6001,O
COX,6001,B-GENE-N
I,6001,I-GENE-N
and,6001,I-GENE-N
II,6001,I-GENE-N
.,6001,O
Both,6002,O
isozymes,6002,O
catalyze,6002,O
the,6002,O
same,6002,O
two,6002,O
reactions,6002,O
:,6002,O
oxygenation,6002,O
of,6002,O
arachidonate,6002,B-CHEMICAL
to,6002,O
yield,6002,O
PGG2,6002,O
and,6002,O
reduction,6002,O
of,6002,O
PGG2,6002,O
to,6002,O
PGH2,6002,O
.,6002,O
PGH,6003,B-GENE-Y
synthase-1,6003,I-GENE-Y
is,6003,O
expressed,6003,O
constitutively,6003,O
and,6003,O
is,6003,O
found,6003,O
in,6003,O
most,6003,O
tissues,6003,O
.,6003,O
PGH,6004,B-GENE-Y
synthase-2,6004,I-GENE-Y
is,6004,O
undetectable,6004,O
in,6004,O
most,6004,O
cells,6004,O
but,6004,O
can,6004,O
be,6004,O
induced,6004,O
in,6004,O
fibroblasts,6004,O
",",6004,O
endothelial,6004,O
cells,6004,O
",",6004,O
ovarian,6004,O
follicles,6004,O
",",6004,O
and,6004,O
macrophages,6004,O
by,6004,O
various,6004,O
mitogens,6004,O
",",6004,O
cytokines,6004,B-GENE-N
",",6004,O
and,6004,O
tumor,6004,O
promoters,6004,O
.,6004,O
PGH,6005,B-GENE-Y
synthase-1,6005,I-GENE-Y
(,6005,O
PGHS-1,6005,B-GENE-Y
),6005,O
has,6005,O
been,6005,O
presumed,6005,O
to,6005,O
be,6005,O
the,6005,O
site,6005,O
of,6005,O
action,6005,O
of,6005,O
nonsteroidal,6005,O
antiinflammatory,6005,O
drugs,6005,O
(,6005,O
NSAIDs,6005,O
),6005,O
.,6005,O
However,6006,O
",",6006,O
the,6006,O
discovery,6006,O
of,6006,O
the,6006,O
second,6006,O
isozyme,6006,O
",",6006,O
PGH,6006,B-GENE-Y
synthase-2,6006,I-GENE-Y
(,6006,O
PGHS-2,6006,B-GENE-Y
),6006,O
",",6006,O
and,6006,O
its,6006,O
association,6006,O
with,6006,O
inflammation,6006,O
has,6006,O
suggested,6006,O
that,6006,O
this,6006,O
latter,6006,O
enzyme,6006,O
may,6006,O
be,6006,O
the,6006,O
therapeutic,6006,O
target,6006,O
of,6006,O
NSAIDs,6006,O
functioning,6006,O
in,6006,O
their,6006,O
antiinflammatory,6006,O
capacities,6006,O
.,6006,O
We,6007,O
have,6007,O
cloned,6007,O
cDNAs,6007,O
for,6007,O
murine,6007,O
PGHS-1,6007,B-GENE-Y
and,6007,O
PGHS-2,6007,B-GENE-Y
",",6007,O
expressed,6007,O
these,6007,O
enzymes,6007,O
in,6007,O
cos-1,6007,O
cells,6007,O
",",6007,O
and,6007,O
compared,6007,O
the,6007,O
relative,6007,O
sensitivities,6007,O
of,6007,O
the,6007,O
two,6007,O
isozymes,6007,O
to,6007,O
some,6007,O
common,6007,O
NSAIDs,6007,O
.,6007,O
Indomethacin,6008,B-CHEMICAL
",",6008,O
piroxicam,6008,B-CHEMICAL
",",6008,O
and,6008,O
sulindac,6008,B-CHEMICAL
sulfide,6008,I-CHEMICAL
were,6008,O
found,6008,O
to,6008,O
preferentially,6008,O
inhibit,6008,O
PGHS-1,6008,B-GENE-Y
.,6008,O
Ibuprofen,6009,B-CHEMICAL
and,6009,O
meclofenamate,6009,O
inhibit,6009,O
both,6009,O
enzymes,6009,O
with,6009,O
comparable,6009,O
potencies,6009,O
.,6009,O
6-Methoxy-2-naphthylacetic,6010,B-CHEMICAL
acid,6010,I-CHEMICAL
",",6010,O
the,6010,O
active,6010,O
metabolite,6010,O
of,6010,O
Relafen,6010,B-CHEMICAL
",",6010,O
inhibits,6010,O
murine,6010,O
PGHS-2,6010,B-GENE-Y
preferentially,6010,O
.,6010,O
Aspirin,6011,B-CHEMICAL
irreversibly,6011,O
inhibits,6011,O
PGHS-1,6011,B-GENE-Y
",",6011,O
preventing,6011,O
this,6011,O
isozyme,6011,O
from,6011,O
forming,6011,O
PGH2,6011,O
or,6011,O
any,6011,O
other,6011,O
oxygenated,6011,O
product,6011,O
;,6011,O
in,6011,O
contrast,6011,O
",",6011,O
aspirin,6011,B-CHEMICAL
treatment,6011,O
of,6011,O
PGHS-2,6011,B-GENE-Y
causes,6011,O
this,6011,O
enzyme,6011,O
to,6011,O
form,6011,O
"15-hydroxy-5c,8c,11c,13t-eicosatetraenoic",6011,B-CHEMICAL
acid,6011,I-CHEMICAL
(,6011,O
15-HETE,6011,B-CHEMICAL
),6011,O
instead,6011,O
of,6011,O
PGH2,6011,O
.,6011,O
Our,6012,O
results,6012,O
indicate,6012,O
mouse,6012,O
PGHS-1,6012,B-GENE-Y
and,6012,O
PGHS-2,6012,B-GENE-Y
are,6012,O
pharmacologically,6012,O
distinct,6012,O
.,6012,O
Thus,6013,O
",",6013,O
it,6013,O
should,6013,O
be,6013,O
possible,6013,O
to,6013,O
develop,6013,O
agents,6013,O
highly,6013,O
selective,6013,O
for,6013,O
each,6013,O
PGHS,6013,B-GENE-N
isozyme,6013,O
.,6013,O
PGHS-2,6014,B-GENE-Y
is,6014,O
not,6014,O
expressed,6014,O
in,6014,O
stomach,6014,O
but,6014,O
is,6014,O
increased,6014,O
by,6014,O
inflammatory,6014,O
cytokines,6014,B-GENE-N
in,6014,O
cells,6014,O
such,6014,O
as,6014,O
macrophages,6014,O
.,6014,O
Thus,6015,O
",",6015,O
a,6015,O
selective,6015,O
inhibitor,6015,O
of,6015,O
PGHS-2,6015,B-GENE-Y
could,6015,O
be,6015,O
an,6015,O
antiinflammatory,6015,O
agent,6015,O
but,6015,O
without,6015,O
being,6015,O
ulcerogenic,6015,O
.,6015,O
Neurochemical,6016,O
mechanism,6016,O
of,6016,O
action,6016,O
of,6016,O
anorectic,6016,O
drugs,6016,O
.,6016,O
Studies,6017,O
with,6017,O
dexfenfluramine,6017,B-CHEMICAL
",",6017,O
an,6017,O
anorectic,6017,O
agent,6017,O
which,6017,O
releases,6017,O
5-hydroxytryptamine,6017,B-CHEMICAL
(,6017,O
5-HT,6017,B-CHEMICAL
),6017,O
from,6017,O
nerve,6017,O
terminals,6017,O
and,6017,O
inhibits,6017,O
its,6017,O
reuptake,6017,O
",",6017,O
have,6017,O
considerably,6017,O
increased,6017,O
our,6017,O
knowledge,6017,O
of,6017,O
the,6017,O
role,6017,O
of,6017,O
5-HT,6017,B-CHEMICAL
in,6017,O
feeding,6017,O
control,6017,O
.,6017,O
5-HT1B,6018,B-GENE-Y
receptors,6018,O
mediate,6018,O
the,6018,O
satiating,6018,O
effect,6018,O
of,6018,O
dexfenfluramine,6018,B-CHEMICAL
",",6018,O
whereas,6018,O
the,6018,O
mechanism,6018,O
by,6018,O
which,6018,O
5-HT,6018,B-CHEMICAL
uptake,6018,O
inhibitors,6018,O
such,6018,O
as,6018,O
fluoxetine,6018,B-CHEMICAL
and,6018,O
sertraline,6018,B-CHEMICAL
cause,6018,O
anorexia,6018,O
is,6018,O
not,6018,O
clear,6018,O
.,6018,O
Anorexia,6019,O
induced,6019,O
by,6019,O
(,6019,B-CHEMICAL
+,6019,I-CHEMICAL
),6019,I-CHEMICAL
-amphetamine,6019,I-CHEMICAL
",",6019,O
phentermine,6019,B-CHEMICAL
",",6019,O
diethylpropion,6019,B-CHEMICAL
and,6019,O
phenylpropanolamine,6019,B-CHEMICAL
seems,6019,O
to,6019,O
be,6019,O
the,6019,O
result,6019,O
of,6019,O
their,6019,O
ability,6019,O
to,6019,O
increase,6019,O
the,6019,O
release,6019,O
of,6019,O
noradrenaline,6019,B-CHEMICAL
and/or,6019,O
dopamine,6019,B-CHEMICAL
from,6019,O
nerve,6019,O
terminals,6019,O
and,6019,O
inhibit,6019,O
their,6019,O
reuptake,6019,O
or,6019,O
",",6019,O
in,6019,O
the,6019,O
case,6019,O
of,6019,O
phenylpropanolamine,6019,B-CHEMICAL
",",6019,O
to,6019,O
stimulate,6019,O
directly,6019,O
alpha,6019,B-GENE-N
1-adrenoceptors,6019,I-GENE-N
.,6019,O
It,6020,O
has,6020,O
been,6020,O
suggested,6020,O
that,6020,O
beta-,6020,B-GENE-N
and,6020,I-GENE-N
alpha,6020,I-GENE-N
1-adrenoceptors,6020,I-GENE-N
and,6020,O
D1,6020,B-GENE-Y
dopamine,6020,I-GENE-Y
receptors,6020,I-GENE-Y
are,6020,O
involved,6020,O
in,6020,O
their,6020,O
effect,6020,O
on,6020,O
food,6020,O
intake,6020,O
.,6020,O
The,6021,O
difficulties,6021,O
of,6021,O
extrapolation,6021,O
across,6021,O
species,6021,O
limit,6021,O
our,6021,O
knowledge,6021,O
of,6021,O
the,6021,O
mechanism,6021,O
of,6021,O
the,6021,O
anorectic,6021,O
action,6021,O
in,6021,O
humans,6021,O
.,6021,O
Significant,6022,O
advances,6022,O
in,6022,O
the,6022,O
treatment,6022,O
of,6022,O
feeding,6022,O
pathology,6022,O
will,6022,O
be,6022,O
linked,6022,O
to,6022,O
identifying,6022,O
new,6022,O
receptor,6022,O
types,6022,O
and,6022,O
subtypes,6022,O
for,6022,O
neurotransmitters,6022,O
and,6022,O
quantifying,6022,O
and,6022,O
modelling,6022,O
eating,6022,O
disorders,6022,O
such,6022,O
as,6022,O
binge-eating,6022,O
and,6022,O
food,6022,O
craving,6022,O
.,6022,O
Further,6023,O
characterization,6023,O
of,6023,O
5-hydroxytryptamine,6023,B-GENE-N
receptors,6023,I-GENE-N
(,6023,O
putative,6023,O
5-HT2B,6023,B-GENE-Y
),6023,O
in,6023,O
rat,6023,O
stomach,6023,O
fundus,6023,O
longitudinal,6023,O
muscle,6023,O
.,6023,O
1,6024,O
.,6024,O
The,6025,O
present,6025,O
study,6025,O
was,6025,O
undertaken,6025,O
to,6025,O
isolate,6025,O
and,6025,O
characterize,6025,O
pharmacologically,6025,O
homogeneous,6025,O
populations,6025,O
of,6025,O
5-hydroxytryptamine,6025,B-CHEMICAL
(,6025,I-GENE-N
5-HT,6025,I-GENE-N
),6025,I-GENE-N
receptors,6025,I-GENE-N
from,6025,O
a,6025,O
possible,6025,O
mixed,6025,O
receptor,6025,O
population,6025,O
mediating,6025,O
concentration,6025,O
of,6025,O
the,6025,O
longitudinal,6025,O
muscle,6025,O
of,6025,O
rat,6025,O
stomach,6025,O
fundus,6025,O
.,6025,O
Our,6026,O
aim,6026,O
was,6026,O
to,6026,O
extend,6026,O
the,6026,O
pharmacological,6026,O
characterization,6026,O
of,6026,O
the,6026,O
5-HT2B,6026,B-GENE-Y
receptor,6026,O
which,6026,O
is,6026,O
reported,6026,O
to,6026,O
be,6026,O
expressed,6026,O
in,6026,O
this,6026,O
preparation,6026,O
.,6026,O
2,6027,O
.,6027,O
To,6028,O
minimize,6028,O
spontaneous,6028,O
activity,6028,O
and,6028,O
any,6028,O
influence,6028,O
of,6028,O
circular,6028,O
muscle,6028,O
on,6028,O
the,6028,O
contractile,6028,O
response,6028,O
",",6028,O
narrow,6028,O
(,6028,O
1-1.5,6028,O
x,6028,O
20,6028,O
mm,6028,O
),6028,O
segments,6028,O
of,6028,O
mucosa-denuded,6028,O
longitudinal,6028,O
muscle,6028,O
were,6028,O
used,6028,O
.,6028,O
Under,6029,O
these,6029,O
conditions,6029,O
",",6029,O
blockade,6029,O
of,6029,O
monoamine,6029,B-GENE-N
oxidase,6029,I-GENE-N
with,6029,O
pargyline,6029,B-CHEMICAL
(,6029,O
100,6029,O
microM,6029,O
for,6029,O
15,6029,O
min,6029,O
),6029,O
caused,6029,O
a,6029,O
leftward,6029,O
displacement,6029,O
of,6029,O
concentration-effect,6029,O
curves,6029,O
for,6029,O
both,6029,O
5-methoxytryptamine,6029,B-CHEMICAL
(,6029,O
5-MeO-T,6029,B-CHEMICAL
),6029,O
and,6029,O
tryptamine,6029,B-CHEMICAL
.,6029,O
Neither,6030,O
pargyline,6030,B-CHEMICAL
nor,6030,O
a,6030,O
number,6030,O
of,6030,O
uptake,6030,O
inhibitors,6030,O
affected,6030,O
responses,6030,O
to,6030,O
5-HT,6030,B-CHEMICAL
.,6030,O
3,6031,O
.,6031,O
In,6032,O
pargyline,6032,B-CHEMICAL
pretreated,6032,O
preparations,6032,O
",",6032,O
the,6032,O
order,6032,O
of,6032,O
potency,6032,O
of,6032,O
a,6032,O
number,6032,O
of,6032,O
tryptamine,6032,B-CHEMICAL
analogues,6032,O
was,6032,O
as,6032,O
follows,6032,O
:,6032,O
5-MeO-T,6032,B-CHEMICAL
>,6032,O
or,6032,O
=,6032,O
alpha-Me-5-HT,6032,B-CHEMICAL
>,6032,O
or,6032,O
=,6032,O
5-HT,6032,B-CHEMICAL
>,6032,O
5-carboxamidotryptamine,6032,B-CHEMICAL
(,6032,O
5-CT,6032,B-CHEMICAL
),6032,O
>,6032,O
tryptamine,6032,B-CHEMICAL
>,6032,O
2-Me-5-HT,6032,B-CHEMICAL
.,6032,O
In,6033,O
addition,6033,O
several,6033,O
ligands,6033,O
known,6033,O
to,6033,O
act,6033,O
as,6033,O
agonists,6033,O
at,6033,O
either,6033,O
5-HT2A,6033,B-GENE-Y
or,6033,O
5-HT2C,6033,B-GENE-Y
receptors,6033,O
including,6033,O
1-m-chlorophenylpiperazine,6033,B-CHEMICAL
(,6033,O
m-CPP,6033,B-CHEMICAL
),6033,O
",",6033,O
Ru,6033,B-CHEMICAL
24969,6033,I-CHEMICAL
",",6033,O
MK,6033,B-CHEMICAL
212,6033,I-CHEMICAL
and,6033,O
SCH,6033,B-CHEMICAL
23390,6033,I-CHEMICAL
were,6033,O
also,6033,O
agonists,6033,O
in,6033,O
rat,6033,O
fundus,6033,O
whilst,6033,O
sumatriptan,6033,B-CHEMICAL
",",6033,O
renzapride,6033,B-CHEMICAL
and,6033,O
8-hydroxy-2-,6033,B-CHEMICAL
(,6033,I-CHEMICAL
di-n-propylamino,6033,I-CHEMICAL
),6033,I-CHEMICAL
tetralin,6033,I-CHEMICAL
(,6033,O
8-OH-DPAT,6033,B-CHEMICAL
),6033,O
were,6033,O
very,6033,O
weak,6033,O
or,6033,O
inactive,6033,O
.,6033,O
With,6034,O
the,6034,O
exception,6034,O
of,6034,O
2-Me-5-HT,6034,B-CHEMICAL
and,6034,O
m-CPP,6034,B-CHEMICAL
",",6034,O
most,6034,O
agonists,6034,O
produced,6034,O
monophasic,6034,O
concentration-effect,6034,O
curves,6034,O
consistent,6034,O
with,6034,O
an,6034,O
interaction,6034,O
at,6034,O
a,6034,O
single,6034,O
site,6034,O
.,6034,O
High,6035,O
concentrations,6035,O
of,6035,O
2-Me-5-HT,6035,O
evoked,6035,O
relaxations,6035,O
which,6035,O
were,6035,O
blocked,6035,O
by,6035,O
phentolamine,6035,O
(,6035,O
1,6035,O
MicroM,6035,O
),6035,O
suggesting,6035,O
an,6035,O
interaction,6035,O
with,6035,O
alpha-adrenoceptors,6035,B-GENE-N
.,6035,O
m-CPP,6036,O
often,6036,O
evoked,6036,O
biphasic,6036,O
concentration-effect,6036,O
curves,6036,O
with,6036,O
a,6036,O
second,6036,O
contractile,6036,O
phase,6036,O
which,6036,O
was,6036,O
insensitive,6036,O
to,6036,O
yohimbine,6036,B-CHEMICAL
at,6036,O
concentrations,6036,O
higher,6036,O
than,6036,O
required,6036,O
for,6036,O
antagonism,6036,O
of,6036,O
responses,6036,O
to,6036,O
5-HT.4,6036,B-CHEMICAL
.,6036,O
LY,6037,B-CHEMICAL
53857,6037,I-CHEMICAL
",",6037,O
methiothepin,6037,B-CHEMICAL
",",6037,O
methysergide,6037,B-CHEMICAL
",",6037,O
ritanserin,6037,B-CHEMICAL
and,6037,O
ICI,6037,B-CHEMICAL
170809,6037,I-CHEMICAL
were,6037,O
potent,6037,O
but,6037,O
non-surmountable,6037,O
antagonists,6037,O
of,6037,O
5-HT,6037,B-CHEMICAL
in,6037,O
rat,6037,O
fundus,6037,O
.,6037,O
In,6038,O
contrast,6038,O
",",6038,O
several,6038,O
ligands,6038,O
behaved,6038,O
as,6038,O
surmountable,6038,O
antagonists,6038,O
with,6038,O
the,6038,O
following,6038,O
order,6038,O
of,6038,O
potency,6038,O
:,6038,O
rauwolscine,6038,B-CHEMICAL
>,6038,O
yohimbine,6038,B-CHEMICAL
=,6038,O
mesulergine,6038,B-CHEMICAL
>,6038,O
mianserin,6038,B-CHEMICAL
=,6038,O
SB,6038,B-CHEMICAL
204070,6038,I-CHEMICAL
>,6038,O
WY,6038,B-CHEMICAL
26703,6038,I-CHEMICAL
>,6038,O
SB,6038,B-CHEMICAL
200646,6038,I-CHEMICAL
>,6038,O
pirenpirone,6038,B-CHEMICAL
>,6038,O
renzapride,6038,B-CHEMICAL
.,6038,O
DAU,6039,B-CHEMICAL
6285,6039,I-CHEMICAL
",",6039,O
granisetron,6039,B-CHEMICAL
",",6039,O
spiperone,6039,B-CHEMICAL
",",6039,O
ketanserin,6039,B-CHEMICAL
",",6039,O
phentolamine,6039,B-CHEMICAL
and,6039,O
GR,6039,B-CHEMICAL
127935,6039,I-CHEMICAL
did,6039,O
not,6039,O
affect,6039,O
responses,6039,O
to,6039,O
5-HT,6039,B-CHEMICAL
at,6039,O
concentrations,6039,O
up,6039,O
to,6039,O
1,6039,O
pM,6039,O
.,6039,O
The,6040,O
agonist,6040,O
and,6040,O
concentration,6040,O
independent,6040,O
profile,6040,O
of,6040,O
antagonism,6040,O
supported,6040,O
a,6040,O
single,6040,O
site,6040,O
interaction,6040,O
for,6040,O
both,6040,O
agonists,6040,O
and,6040,O
antagonists.5,6040,O
.,6040,O
We,6041,O
conclude,6041,O
that,6041,O
despite,6041,O
small,6041,O
differences,6041,O
concerning,6041,O
the,6041,O
enantiomeric,6041,O
selectivity,6041,O
and,6041,O
affinity,6041,O
of,6041,O
rauwolscine,6041,B-CHEMICAL
and,6041,O
yohimbine,6041,B-CHEMICAL
",",6041,O
the,6041,O
close,6041,O
pharmacological,6041,O
identity,6041,O
of,6041,O
5-HT,6041,B-GENE-N
receptors,6041,I-GENE-N
in,6041,O
rat,6041,O
stomach,6041,O
fundus,6041,O
and,6041,O
the,6041,O
recently,6041,O
cloned,6041,O
5-HT2B,6041,B-GENE-Y
receptor,6041,O
is,6041,O
maintained,6041,O
.,6041,O
SB,6042,B-CHEMICAL
200646,6042,I-CHEMICAL
",",6042,O
which,6042,O
demonstrates,6042,O
some,6042,O
selectivity,6042,O
for,6042,O
5-HT,6042,B-GENE-N
receptors,6042,I-GENE-N
in,6042,O
rat,6042,O
stomach,6042,O
fundus,6042,O
",",6042,O
should,6042,O
provide,6042,O
a,6042,O
useful,6042,O
ligand,6042,O
for,6042,O
confirmation,6042,O
of,6042,O
this,6042,O
view,6042,O
and,6042,O
allow,6042,O
discrimination,6042,O
of,6042,O
5-HT2B,6042,B-GENE-Y
function,6042,O
both,6042,O
in,6042,O
vitro,6042,O
and,6042,O
in,6042,O
vivo,6042,O
.,6042,O
Cefepime,6043,B-CHEMICAL
:,6043,O
overview,6043,O
of,6043,O
activity,6043,O
in,6043,O
vitro,6043,O
and,6043,O
in,6043,O
vivo,6043,O
.,6043,O
Cefepime,6044,B-CHEMICAL
is,6044,O
a,6044,O
novel,6044,O
methoxyimino-aminothiazolyl,6044,B-CHEMICAL
cephalosporin,6044,I-CHEMICAL
with,6044,O
a,6044,O
quaternized,6044,O
N-methyl-pyrrolidine,6044,B-CHEMICAL
moiety,6044,O
at,6044,O
the,6044,O
3,6044,O
',6044,O
position,6044,O
conferring,6044,O
zwitterionic,6044,O
properties,6044,O
.,6044,O
Because,6045,O
of,6045,O
this,6045,O
the,6045,O
molecule,6045,O
penetrates,6045,O
the,6045,O
outer,6045,O
cell,6045,O
membrane,6045,O
of,6045,O
Gram-negative,6045,O
bacteria,6045,O
rapidly,6045,O
.,6045,O
In,6046,O
addition,6046,O
it,6046,O
is,6046,O
resistant,6046,O
to,6046,O
degradation,6046,O
by,6046,O
several,6046,O
plasmid,6046,O
and,6046,O
chromosomally-mediated,6046,O
beta-lactamases,6046,B-GENE-N
",",6046,O
for,6046,O
which,6046,O
it,6046,O
also,6046,O
shows,6046,O
very,6046,O
low,6046,O
affinity,6046,O
and,6046,O
no,6046,O
inducing,6046,O
capacity,6046,O
.,6046,O
It,6047,O
has,6047,O
good,6047,O
affinity,6047,O
for,6047,O
PBPs,6047,B-GENE-N
2,6047,I-GENE-N
and,6047,I-GENE-N
3,6047,I-GENE-N
of,6047,O
Escherichia,6047,O
coli,6047,O
and,6047,O
for,6047,O
PBP,6047,B-GENE-Y
3,6047,I-GENE-Y
of,6047,O
Pseudomonas,6047,O
aeruginosa,6047,O
.,6047,O
Its,6048,O
broad-spectrum,6048,O
of,6048,O
activity,6048,O
includes,6048,O
Gram-positive,6048,O
and,6048,O
Gram-negative,6048,O
pathogens,6048,O
.,6048,O
It,6049,O
is,6049,O
more,6049,O
active,6049,O
than,6049,O
cefotaxime,6049,B-CHEMICAL
or,6049,O
ceftazidime,6049,B-CHEMICAL
",",6049,O
against,6049,O
Enterobacteriaceae,6049,O
.,6049,O
The,6050,O
MIC90,6050,O
for,6050,O
P.,6050,O
aeruginosa,6050,O
is,6050,O
higher,6050,O
than,6050,O
that,6050,O
of,6050,O
ceftazidime,6050,B-CHEMICAL
",",6050,O
but,6050,O
lower,6050,O
than,6050,O
those,6050,O
of,6050,O
cefpirome,6050,B-CHEMICAL
",",6050,O
cefoperazone,6050,B-CHEMICAL
and,6050,O
latamoxef,6050,B-CHEMICAL
.,6050,O
Other,6051,O
Gram-negative,6051,O
organisms,6051,O
",",6051,O
Haemophilus,6051,O
influenzae,6051,O
",",6051,O
Neiserria,6051,O
meningitidis,6051,O
",",6051,O
Neiserria,6051,O
gonorrhoeae,6051,O
",",6051,O
Moraxella,6051,O
catarrhalis,6051,O
are,6051,O
highly,6051,O
susceptible,6051,O
to,6051,O
cefepime,6051,B-CHEMICAL
.,6051,O
Among,6052,O
Gram-positive,6052,O
species,6052,O
methicillin-susceptible,6052,O
Staphylococcus,6052,O
aureus,6052,O
and,6052,O
coagulase-negative,6052,B-GENE-N
staphylococci,6052,O
",",6052,O
whether,6052,O
beta-lactamase,6052,B-GENE-N
producers,6052,O
or,6052,O
not,6052,O
",",6052,O
Streptococcus,6052,O
pneumoniae,6052,O
and,6052,O
Streptococcus,6052,O
pyogenes,6052,O
are,6052,O
susceptible,6052,O
.,6052,O
Cefepime,6053,B-CHEMICAL
is,6053,O
active,6053,O
against,6053,O
cefotaxime-,6053,B-CHEMICAL
and/or,6053,O
ceftazidime-resistant,6053,B-CHEMICAL
Enterobacteriaceae,6053,O
.,6053,O
Only,6054,O
strains,6054,O
of,6054,O
P.,6054,O
aeruginosa,6054,O
producing,6054,O
large,6054,O
amounts,6054,O
of,6054,O
beta-lactamase,6054,B-GENE-N
may,6054,O
be,6054,O
resistant,6054,O
to,6054,O
both,6054,O
ceftazidime,6054,B-CHEMICAL
and,6054,O
cefepime,6054,B-CHEMICAL
.,6054,O
In,6055,O
experimental,6055,O
infections,6055,O
such,6055,O
as,6055,O
meningitis,6055,O
",",6055,O
induced,6055,O
with,6055,O
various,6055,O
bacterial,6055,O
species,6055,O
in,6055,O
neonatal,6055,O
rats,6055,O
and,6055,O
chronic,6055,O
staphylococcal,6055,O
osteomyelitis,6055,O
in,6055,O
rabbits,6055,O
",",6055,O
cefepime,6055,B-CHEMICAL
has,6055,O
shown,6055,O
good,6055,O
efficacy,6055,O
.,6055,O
Phorbol,6056,O
esters,6056,O
and,6056,O
norepinephrine,6056,B-CHEMICAL
destabilize,6056,O
alpha,6056,B-GENE-Y
1B-adrenergic,6056,I-GENE-Y
receptor,6056,I-GENE-Y
mRNA,6056,O
in,6056,O
vascular,6056,O
smooth,6056,O
muscle,6056,O
cells,6056,O
.,6056,O
The,6057,O
mechanism,6057,O
by,6057,O
which,6057,O
norepinephrine,6057,B-CHEMICAL
(,6057,O
NE,6057,B-CHEMICAL
),6057,O
down-regulates,6057,O
alpha,6057,B-GENE-Y
1B-adrenergic,6057,I-GENE-Y
receptor,6057,I-GENE-Y
(,6057,O
alpha-AR,6057,B-GENE-N
),6057,O
mRNA,6057,O
was,6057,O
studied,6057,O
in,6057,O
rabbit,6057,O
aortic,6057,O
smooth,6057,O
muscle,6057,O
cells,6057,O
.,6057,O
NE,6058,B-CHEMICAL
",",6058,O
phorbol,6058,B-CHEMICAL
esters,6058,I-CHEMICAL
",",6058,O
and,6058,O
bradykinin,6058,B-GENE-Y
each,6058,O
decreased,6058,O
alpha-AR,6058,B-GENE-N
mRNA,6058,O
levels,6058,O
by,6058,O
70-80,6058,O
%,6058,O
.,6058,O
The,6059,O
protein,6059,B-GENE-N
kinase,6059,I-GENE-N
C,6059,I-GENE-N
inhibitor,6059,O
(,6059,B-CHEMICAL
+,6059,I-CHEMICAL
),6059,I-CHEMICAL
-1-,6059,I-CHEMICAL
(,6059,I-CHEMICAL
5-isoquinolinesulfonyl,6059,I-CHEMICAL
),6059,I-CHEMICAL
-2-methylpiperazine,6059,I-CHEMICAL
dihydrochloride,6059,I-CHEMICAL
(,6059,O
H-7,6059,B-CHEMICAL
),6059,O
abolished,6059,O
the,6059,O
effects,6059,O
of,6059,O
phorbol,6059,B-CHEMICAL
esters,6059,I-CHEMICAL
and,6059,O
NE,6059,B-CHEMICAL
and,6059,O
decreased,6059,O
basal,6059,O
mRNA,6059,O
levels,6059,O
by,6059,O
52,6059,O
+/-,6059,O
3,6059,O
%,6059,O
.,6059,O
Neither,6060,O
ryanodine,6060,B-CHEMICAL
nor,6060,O
EGTA,6060,B-CHEMICAL
inhibited,6060,O
down-regulation,6060,O
of,6060,O
alpha-AR,6060,B-GENE-N
mRNA,6060,O
by,6060,O
NE,6060,B-CHEMICAL
.,6060,O
Actinomycin,6061,B-CHEMICAL
D,6061,I-CHEMICAL
caused,6061,O
alpha-AR,6061,B-GENE-N
mRNA,6061,O
level,6061,O
to,6061,O
decrease,6061,O
with,6061,O
a,6061,O
half-life,6061,O
of,6061,O
3.2,6061,O
+/-,6061,O
0.4,6061,O
h,6061,O
and,6061,O
blocked,6061,O
the,6061,O
effect,6061,O
of,6061,O
H-7,6061,B-CHEMICAL
to,6061,O
decrease,6061,O
basal,6061,O
alpha-AR,6061,B-GENE-N
mRNA,6061,O
level,6061,O
.,6061,O
Both,6062,O
NE,6062,B-CHEMICAL
and,6062,O
phorbol,6062,B-CHEMICAL
esters,6062,I-CHEMICAL
increased,6062,O
the,6062,O
rate,6062,O
of,6062,O
alpha-AR,6062,B-GENE-N
mRNA,6062,O
degradation,6062,O
.,6062,O
In,6063,O
NE-desensitized,6063,B-CHEMICAL
cells,6063,O
",",6063,O
phorbol,6063,B-CHEMICAL
esters,6063,I-CHEMICAL
and,6063,O
bradykinin,6063,B-GENE-Y
each,6063,O
caused,6063,O
the,6063,O
expected,6063,O
down-regulation,6063,O
of,6063,O
alpha-AR,6063,B-GENE-N
mRNA,6063,O
.,6063,O
The,6064,O
protein,6064,B-GENE-N
phosphatase,6064,I-GENE-N
inhibitor,6064,O
okadaic,6064,B-CHEMICAL
acid,6064,I-CHEMICAL
prolonged,6064,O
the,6064,O
normally,6064,O
transient,6064,O
effect,6064,O
of,6064,O
NE,6064,B-CHEMICAL
for,6064,O
at,6064,O
least,6064,O
24,6064,O
h.,6064,O
We,6064,O
conclude,6064,O
that,6064,O
protein,6064,B-GENE-N
kinase,6064,I-GENE-N
C,6064,I-GENE-N
exerts,6064,O
two,6064,O
opposing,6064,O
effects,6064,O
on,6064,O
alpha-AR,6064,B-GENE-N
mRNA,6064,O
levels,6064,O
",",6064,O
1,6064,O
),6064,O
a,6064,O
decrease,6064,O
in,6064,O
the,6064,O
stability,6064,O
of,6064,O
the,6064,O
mRNA,6064,O
that,6064,O
requires,6064,O
the,6064,O
sustained,6064,O
phosphorylation,6064,O
of,6064,O
a,6064,O
protein,6064,B-GENE-N
kinase,6064,I-GENE-N
C,6064,I-GENE-N
substrate,6064,O
and,6064,O
2,6064,O
),6064,O
a,6064,O
permissive,6064,O
effect,6064,O
on,6064,O
alpha-AR,6064,B-GENE-N
gene,6064,O
transcription,6064,O
.,6064,O
Molecular,6065,O
cloning,6065,O
and,6065,O
functional,6065,O
expression,6065,O
of,6065,O
5-HT1E-like,6065,B-GENE-N
rat,6065,B-GENE-N
and,6065,I-GENE-N
human,6065,I-GENE-N
5-hydroxytryptamine,6065,I-GENE-N
receptor,6065,I-GENE-N
genes,6065,O
.,6065,O
Sequential,6066,O
polymerase,6066,O
chain,6066,O
reaction,6066,O
experiments,6066,O
were,6066,O
performed,6066,O
to,6066,O
amplify,6066,O
a,6066,O
unique,6066,O
sequence,6066,O
representing,6066,O
a,6066,O
guanine,6066,B-GENE-N
nucleotide-binding,6066,I-GENE-N
protein,6066,I-GENE-N
(,6066,I-GENE-N
G-protein,6066,I-GENE-N
),6066,I-GENE-N
-coupled,6066,I-GENE-N
receptor,6066,I-GENE-N
from,6066,O
rat,6066,O
hypothalamic,6066,O
cDNA,6066,O
.,6066,O
Degenerate,6067,O
oligonucleotides,6067,B-CHEMICAL
corresponding,6067,O
to,6067,O
conserved,6067,O
amino,6067,B-CHEMICAL
acids,6067,I-CHEMICAL
from,6067,O
transmembrane,6067,O
domains,6067,O
III,6067,O
",",6067,O
V,6067,O
",",6067,O
and,6067,O
VI,6067,O
of,6067,O
known,6067,O
receptors,6067,O
[,6067,O
5-HT1A,6067,B-GENE-Y
",",6067,O
5-HT1C,6067,B-GENE-Y
",",6067,O
and,6067,O
5-HT2,6067,B-GENE-Y
;,6067,O
5-HT,6067,B-CHEMICAL
is,6067,O
serotonin,6067,B-CHEMICAL
(,6067,O
5-hydroxytryptamine,6067,B-CHEMICAL
),6067,O
],6067,O
were,6067,O
used,6067,O
as,6067,O
primers,6067,O
for,6067,O
the,6067,O
sequential,6067,O
reactions,6067,O
.,6067,O
The,6068,O
resulting,6068,O
product,6068,O
was,6068,O
subcloned,6068,O
and,6068,O
used,6068,O
to,6068,O
screen,6068,O
a,6068,O
rat,6068,O
genomic,6068,O
library,6068,O
to,6068,O
identify,6068,O
a,6068,O
full-length,6068,O
clone,6068,O
(,6068,O
MR77,6068,B-GENE-Y
),6068,O
containing,6068,O
an,6068,O
intronless,6068,B-GENE-N
open,6068,I-GENE-N
reading,6068,I-GENE-N
frame,6068,I-GENE-N
encoding,6068,O
a,6068,O
366-amino,6068,B-GENE-N
acid,6068,I-GENE-N
seven-transmembrane,6068,I-GENE-N
domain,6068,I-GENE-N
protein,6068,I-GENE-N
.,6068,O
The,6069,O
human,6069,O
homolog,6069,O
was,6069,O
isolated,6069,O
",",6069,O
and,6069,O
its,6069,O
encoded,6069,O
protein,6069,O
had,6069,O
93,6069,O
%,6069,O
overall,6069,O
amino,6069,B-CHEMICAL
acid,6069,I-CHEMICAL
identity,6069,O
with,6069,O
the,6069,O
rat,6069,O
sequence,6069,O
.,6069,O
Within,6070,O
the,6070,O
conserved,6070,O
transmembrane,6070,O
domains,6070,O
",",6070,O
the,6070,O
sequences,6070,O
exhibit,6070,O
approximately,6070,O
52,6070,O
%,6070,O
",",6070,O
59,6070,O
%,6070,O
",",6070,O
65,6070,O
%,6070,O
",",6070,O
and,6070,O
68,6070,O
%,6070,O
amino,6070,B-CHEMICAL
acid,6070,I-CHEMICAL
identity,6070,O
with,6070,O
the,6070,O
known,6070,O
rat,6070,B-GENE-Y
5-HT1A,6070,I-GENE-Y
",",6070,O
rat,6070,B-GENE-Y
5-HT1B,6070,I-GENE-Y
",",6070,O
rat,6070,B-GENE-Y
5-HT1D,6070,I-GENE-Y
",",6070,O
and,6070,O
human,6070,B-GENE-Y
5-HT1E,6070,I-GENE-Y
receptors,6070,O
",",6070,O
respectively,6070,O
.,6070,O
MR77,6071,B-GENE-Y
was,6071,O
subcloned,6071,O
into,6071,O
a,6071,O
eukaryotic,6071,O
expression,6071,O
vector,6071,O
system,6071,O
and,6071,O
expressed,6071,O
in,6071,O
CosM6,6071,O
cells,6071,O
.,6071,O
Studies,6072,O
on,6072,O
broken,6072,O
cell,6072,O
preparations,6072,O
indicate,6072,O
that,6072,O
the,6072,O
expressed,6072,O
receptor,6072,O
exhibits,6072,O
125I-labeled,6072,B-CHEMICAL
d-lysergic,6072,I-CHEMICAL
acid,6072,I-CHEMICAL
diethylamide,6072,I-CHEMICAL
(,6072,O
LSD,6072,B-CHEMICAL
),6072,O
binding,6072,O
that,6072,O
can,6072,O
be,6072,O
displaced,6072,O
by,6072,O
serotonin,6072,B-CHEMICAL
but,6072,O
not,6072,O
by,6072,O
other,6072,O
biogenic,6072,O
amines,6072,B-CHEMICAL
.,6072,O
The,6073,O
specific,6073,O
binding,6073,O
is,6073,O
displaced,6073,O
by,6073,O
the,6073,O
selective,6073,O
5-HT1D,6073,B-GENE-Y
agonist,6073,O
sumatriptan,6073,B-CHEMICAL
but,6073,O
not,6073,O
by,6073,O
the,6073,O
mixed,6073,O
5-HT1A/1D,6073,B-GENE-N
agonist,6073,O
5-carboxyamidotryptamine,6073,B-CHEMICAL
.,6073,O
125I-labeled,6074,B-CHEMICAL
LSD,6074,I-CHEMICAL
binding,6074,O
was,6074,O
competitively,6074,O
antagonized,6074,O
by,6074,O
the,6074,O
ergot,6074,O
alkaloids,6074,O
methysergide,6074,B-CHEMICAL
and,6074,O
ergotamine,6074,B-CHEMICAL
.,6074,O
HeLa,6075,O
cells,6075,O
transfected,6075,O
with,6075,O
the,6075,O
MR77,6075,B-GENE-Y
gene,6075,O
exhibited,6075,O
inhibition,6075,O
of,6075,O
adenylate,6075,B-GENE-N
cyclase,6075,I-GENE-N
in,6075,O
response,6075,O
to,6075,O
serotonin,6075,B-CHEMICAL
.,6075,O
MR77,6076,B-GENE-Y
is,6076,O
expressed,6076,O
at,6076,O
low,6076,O
levels,6076,O
throughout,6076,O
the,6076,O
brain,6076,O
",",6076,O
with,6076,O
the,6076,O
greatest,6076,O
expression,6076,O
in,6076,O
the,6076,O
cortex,6076,O
",",6076,O
hippocampus,6076,O
",",6076,O
and,6076,O
striatum,6076,O
.,6076,O
MR77,6077,B-GENE-Y
thus,6077,O
represents,6077,O
a,6077,O
5-HT,6077,B-GENE-N
receptor,6077,I-GENE-N
of,6077,O
the,6077,O
5-HT1,6077,B-GENE-N
class,6077,O
",",6077,O
and,6077,O
we,6077,O
propose,6077,O
that,6077,O
",",6077,O
based,6077,O
on,6077,O
the,6077,O
pharmacological,6077,O
characterization,6077,O
",",6077,O
MR77,6077,B-GENE-Y
represents,6077,O
an,6077,O
additional,6077,O
5-HT1E-like,6077,B-GENE-Y
receptor,6077,O
.,6077,O
Response,6078,O
of,6078,O
nonreentrant,6078,O
catecholamine-mediated,6078,B-CHEMICAL
ventricular,6078,O
tachycardia,6078,O
to,6078,O
endogenous,6078,O
adenosine,6078,B-CHEMICAL
and,6078,O
acetylcholine,6078,B-CHEMICAL
.,6078,O
Evidence,6079,O
for,6079,O
myocardial,6079,O
receptor-mediated,6079,O
effects,6079,O
.,6079,O
BACKGROUND,6080,O
:,6080,O
Reentrant,6080,O
ventricular,6080,O
tachycardia,6080,O
(,6080,O
VT,6080,O
),6080,O
is,6080,O
known,6080,O
to,6080,O
be,6080,O
insensitive,6080,O
to,6080,O
the,6080,O
nucleoside,6080,B-CHEMICAL
adenosine,6080,B-CHEMICAL
.,6080,O
However,6081,O
",",6081,O
we,6081,O
have,6081,O
previously,6081,O
identified,6081,O
a,6081,O
form,6081,O
of,6081,O
nonreentrant,6081,O
",",6081,O
catecholamine-mediated,6081,B-CHEMICAL
VT,6081,O
that,6081,O
can,6081,O
be,6081,O
initiated,6081,O
with,6081,O
rapid,6081,O
pacing,6081,O
",",6081,O
demonstrates,6081,O
cycle,6081,O
length,6081,O
dependence,6081,O
",",6081,O
and,6081,O
is,6081,O
sensitive,6081,O
to,6081,O
exogenous,6081,O
adenosine,6081,B-CHEMICAL
as,6081,O
well,6081,O
as,6081,O
to,6081,O
the,6081,O
Valsalva,6081,O
maneuver,6081,O
.,6081,O
The,6082,O
mechanism,6082,O
of,6082,O
this,6082,O
tachycardia,6082,O
is,6082,O
thought,6082,O
to,6082,O
be,6082,O
due,6082,O
to,6082,O
a,6082,O
catecholamine-induced,6082,B-CHEMICAL
",",6082,O
cAMP-mediated,6082,B-CHEMICAL
increase,6082,O
in,6082,O
intracellular,6082,O
calcium,6082,B-CHEMICAL
",",6082,O
resulting,6082,O
in,6082,O
delayed,6082,O
afterdepolarizations,6082,O
and,6082,O
triggered,6082,O
activity,6082,O
.,6082,O
The,6083,O
antiarrhythmic,6083,O
effects,6083,O
of,6083,O
exogenous,6083,O
adenosine,6083,B-CHEMICAL
and,6083,O
Valsalva,6083,O
on,6083,O
this,6083,O
form,6083,O
of,6083,O
VT,6083,O
may,6083,O
be,6083,O
due,6083,O
to,6083,O
receptor-mediated,6083,O
inhibition,6083,O
of,6083,O
adenylate,6083,B-GENE-N
cyclase,6083,I-GENE-N
or,6083,O
to,6083,O
noncardiac,6083,O
receptor-mediated,6083,O
effects,6083,O
",",6083,O
i.e.,6083,O
",",6083,O
exogenous,6083,O
adenosine,6083,B-CHEMICAL
may,6083,O
modulate,6083,O
VT,6083,O
through,6083,O
alterations,6083,O
in,6083,O
autonomic,6083,O
tone,6083,O
by,6083,O
activation,6083,O
of,6083,O
arterial,6083,O
chemoreceptors,6083,B-GENE-N
",",6083,O
and,6083,O
Valsalva,6083,O
has,6083,O
been,6083,O
shown,6083,O
to,6083,O
decrease,6083,O
venous,6083,O
return,6083,O
",",6083,O
resulting,6083,O
in,6083,O
a,6083,O
reduction,6083,O
in,6083,O
cardiac,6083,O
dimensions,6083,O
and,6083,O
myocardial,6083,O
stretch,6083,O
.,6083,O
To,6084,O
clarify,6084,O
this,6084,O
issue,6084,O
and,6084,O
circumvent,6084,O
both,6084,O
autonomic,6084,O
and,6084,O
noncardiac,6084,O
receptor,6084,O
effects,6084,O
",",6084,O
the,6084,O
response,6084,O
of,6084,O
nonreentrant,6084,O
catecholamine-mediated,6084,B-CHEMICAL
VT,6084,O
to,6084,O
endogenous,6084,O
adenosine,6084,B-CHEMICAL
and,6084,O
acetylcholine,6084,B-CHEMICAL
was,6084,O
evaluated,6084,O
.,6084,O
METHODS,6085,O
AND,6085,O
RESULTS,6085,O
:,6085,O
Group,6085,O
1,6085,O
(,6085,O
n,6085,O
=,6085,O
8,6085,O
),6085,O
:,6085,O
Dipyridamole,6085,B-CHEMICAL
(,6085,O
0.56,6085,O
mg/kg,6085,O
i.v,6085,O
.,6085,O
),6086,O
",",6086,O
a,6086,O
nucleoside,6086,O
transport,6086,O
blocker,6086,O
that,6086,O
potentiates,6086,O
the,6086,O
effects,6086,O
of,6086,O
endogenous,6086,O
adenosine,6086,O
",",6086,O
reproducibly,6086,O
abolished,6086,O
sustained,6086,O
nonreentrant,6086,O
",",6086,O
nonautomatic,6086,O
",",6086,O
catecholamine-mediated,6086,O
VT,6086,O
in,6086,O
the,6086,O
five,6086,O
patients,6086,O
in,6086,O
whom,6086,O
it,6086,O
was,6086,O
evaluated,6086,O
.,6086,O
VT,6087,O
recurred,6087,O
with,6087,O
the,6087,O
addition,6087,O
of,6087,O
aminophylline,6087,O
",",6087,O
a,6087,O
competitive,6087,O
adenosine,6087,I-GENE-Y
A1-receptor,6087,O
antagonist,6087,O
.,6087,O
Edrophonium,6088,O
(,6088,O
10,6088,O
mg,6088,O
i.v,6088,O
.,6088,O
),6089,O
",",6089,O
a,6089,B-GENE-Y
cholinesterase,6089,O
inhibitor,6089,O
that,6089,O
potentiates,6089,O
the,6089,O
effects,6089,O
of,6089,O
acetylcholine,6089,O
at,6089,O
the,6089,O
muscarinic,6089,I-GENE-N
cholinergic,6089,I-GENE-N
receptor,6089,O
",",6089,O
terminated,6089,O
VT,6089,O
in,6089,O
four,6089,O
of,6089,O
four,6089,O
patients,6089,O
",",6089,O
an,6089,O
effect,6089,O
that,6089,O
was,6089,O
reversed,6089,O
by,6089,O
atropine,6089,O
.,6089,O
Group,6090,O
2,6090,O
(,6090,O
n,6090,O
=,6090,O
6,6090,O
),6090,O
:,6090,O
In,6090,O
patients,6090,O
with,6090,O
reentrant,6090,O
VT,6090,O
",",6090,B-CHEMICAL
dipyridamole,6090,O
and,6090,O
edrophonium,6090,O
had,6090,O
no,6090,O
effect,6090,O
on,6090,O
VT,6090,O
cycle,6090,O
length,6090,O
or,6090,O
duration,6090,O
.,6090,O
Group,6091,O
3,6091,O
(,6091,O
n,6091,O
=,6091,O
4,6091,O
),6091,O
:,6091,B-CHEMICAL
Adenosine,6091,O
and,6091,O
vagal,6091,O
maneuvers,6091,O
had,6091,O
no,6091,O
effect,6091,O
on,6091,O
catecholamine-mediated,6091,O
VT,6091,O
caused,6091,O
by,6091,O
automaticity,6091,O
in,6091,O
three,6091,O
of,6091,O
four,6091,O
patients,6091,O
tested,6091,O
.,6091,O
In,6092,O
one,6092,O
patient,6092,O
",",6092,B-CHEMICAL
adenosine,6092,O
transiently,6092,O
suppressed,6092,O
VT,6092,O
(,6092,O
<,6092,O
5,6092,O
seconds,6092,O
),6092,O
",",6092,O
after,6092,O
which,6092,O
it,6092,O
spontaneously,6092,O
resumed,6092,O
.,6092,O
CONCLUSIONS,6093,O
:,6093,O
The,6093,O
results,6093,O
of,6093,O
this,6093,O
study,6093,O
further,6093,O
delineate,6093,O
the,6093,O
mechanism,6093,O
of,6093,O
a,6093,O
newly,6093,O
recognized,6093,O
form,6093,O
of,6093,O
clinical,6093,O
VT,6093,O
.,6093,O
It,6094,O
can,6094,O
be,6094,O
identified,6094,O
by,6094,O
termination,6094,O
of,6094,O
the,6094,O
tachycardia,6094,O
in,6094,O
response,6094,O
to,6094,O
activation,6094,O
of,6094,O
the,6094,O
adenosine,6094,I-GENE-Y
A1,6094,O
or,6094,O
muscarinic,6094,I-GENE-N
cholinergic,6094,I-GENE-N
receptor,6094,O
",",6094,O
which,6094,O
results,6094,O
in,6094,O
inhibition,6094,O
of,6094,O
adenylate,6094,I-GENE-N
cyclase,6094,O
.,6094,O
These,6095,O
receptor-mediated,6095,O
effects,6095,O
appear,6095,O
to,6095,O
be,6095,O
specific,6095,O
for,6095,O
identifying,6095,O
nonreentrant,6095,O
",",6095,O
nonautomatic,6095,O
",",6095,B-CHEMICAL
catecholamine-mediated,6095,O
VT,6095,O
.,6095,O
Amantadine,6096,B-CHEMICAL
induces,6096,O
c-fos,6096,B-GENE-Y
in,6096,O
rat,6096,O
striatum,6096,O
:,6096,O
reversal,6096,O
with,6096,O
dopamine,6096,B-GENE-Y
D1,6096,I-GENE-Y
and,6096,O
NMDA,6096,B-GENE-N
receptor,6096,I-GENE-N
antagonists,6096,O
.,6096,O
Amantadine,6097,B-CHEMICAL
(,6097,O
1-aminoadamantane,6097,B-CHEMICAL
),6097,O
induced,6097,O
Fos,6097,B-GENE-Y
expression,6097,O
in,6097,O
the,6097,O
central,6097,O
",",6097,O
dorsal-medial,6097,O
and,6097,O
ventral-medial,6097,O
part,6097,O
of,6097,O
the,6097,O
striatum,6097,O
.,6097,O
The,6098,O
distribution,6098,O
pattern,6098,O
of,6098,O
Fos,6098,B-GENE-Y
induced,6098,O
by,6098,O
amantadine,6098,B-CHEMICAL
was,6098,O
more,6098,O
similar,6098,O
to,6098,O
those,6098,O
seen,6098,O
with,6098,O
dopaminomimetics,6098,O
than,6098,O
with,6098,O
N-methyl-D-aspartate,6098,B-CHEMICAL
(,6098,I-GENE-N
NMDA,6098,B-CHEMICAL
),6098,I-GENE-N
receptor,6098,I-GENE-N
antagonists,6098,O
.,6098,O
Pretreatment,6099,O
with,6099,O
the,6099,O
dopamine,6099,B-CHEMICAL
D1,6099,I-GENE-Y
receptor,6099,I-GENE-Y
antagonist,6099,O
",",6099,O
SCH23390,6099,B-CHEMICAL
",",6099,O
and,6099,O
the,6099,O
NMDA,6099,B-CHEMICAL
receptor,6099,I-GENE-N
antagonist,6099,O
",",6099,O
MK-801,6099,B-CHEMICAL
",",6099,O
blocked,6099,O
amantadine,6099,B-CHEMICAL
induction,6099,O
of,6099,O
Fos,6099,B-GENE-Y
in,6099,O
the,6099,O
striatum,6099,O
.,6099,O
However,6100,O
",",6100,O
amantadine,6100,B-CHEMICAL
induction,6100,O
of,6100,O
Fos,6100,B-GENE-Y
in,6100,O
the,6100,O
striatum,6100,O
was,6100,O
unaffected,6100,O
by,6100,O
the,6100,O
dopamine,6100,B-GENE-Y
D2,6100,I-GENE-Y
receptor,6100,I-GENE-Y
antagonist,6100,O
",",6100,O
sulpiride,6100,B-CHEMICAL
.,6100,O
These,6101,O
results,6101,O
suggest,6101,O
that,6101,O
amantadine,6101,B-CHEMICAL
induction,6101,O
of,6101,O
Fos,6101,B-GENE-Y
in,6101,O
the,6101,O
rat,6101,O
striatum,6101,O
is,6101,O
related,6101,O
to,6101,O
dopamine,6101,B-GENE-Y
D1,6101,I-GENE-Y
and,6101,O
NMDA,6101,B-GENE-N
receptors,6101,I-GENE-N
.,6101,O
[,6102,O
Inactivated,6102,B-GENE-Y
factor,6102,I-GENE-Y
VII,6102,I-GENE-Y
exercises,6102,O
a,6102,O
powerful,6102,O
antithrombotic,6102,O
activity,6102,O
in,6102,O
an,6102,O
experimental,6102,O
model,6102,O
of,6102,O
recurrent,6102,O
arterial,6102,O
thrombosis,6102,O
],6102,O
.,6102,O
The,6103,O
extrinsic,6103,O
coagulation,6103,O
pathway,6103,O
is,6103,O
activated,6103,O
when,6103,O
tissue,6103,B-GENE-Y
factor,6103,I-GENE-Y
(,6103,O
TF,6103,B-GENE-Y
),6103,O
is,6103,O
exposed,6103,O
as,6103,O
a,6103,O
consequence,6103,O
of,6103,O
arterial,6103,O
damage,6103,O
.,6103,O
TF,6104,B-GENE-Y
binds,6104,O
to,6104,O
factor,6104,B-GENE-Y
VII,6104,I-GENE-Y
(,6104,O
FVII,6104,B-GENE-Y
),6104,O
or,6104,O
activated,6104,B-GENE-Y
FVII,6104,I-GENE-Y
(,6104,O
FVIIa,6104,B-GENE-Y
),6104,O
",",6104,O
generating,6104,O
a,6104,O
complex,6104,O
that,6104,O
activates,6104,O
both,6104,O
FX,6104,B-GENE-Y
and,6104,O
FIX,6104,B-GENE-Y
",",6104,O
ultimately,6104,O
leading,6104,O
to,6104,O
thrombin,6104,B-GENE-Y
formation,6104,O
.,6104,O
To,6105,O
determine,6105,O
whether,6105,O
inhibition,6105,O
of,6105,O
FVII,6105,B-GENE-Y
binding,6105,O
to,6105,O
TF,6105,B-GENE-Y
would,6105,O
result,6105,O
in,6105,O
antithrombotic,6105,O
effects,6105,O
",",6105,O
active,6105,B-GENE-Y
site-blocked,6105,I-GENE-Y
FVIIa,6105,I-GENE-Y
(,6105,O
FVIIai,6105,B-GENE-Y
),6105,O
was,6105,O
used,6105,O
in,6105,O
a,6105,O
rabbit,6105,O
model,6105,O
of,6105,O
intravascular,6105,O
thrombus,6105,O
formation,6105,O
.,6105,O
In,6106,O
addition,6106,O
",",6106,O
to,6106,O
study,6106,O
the,6106,O
interaction,6106,O
between,6106,O
extrinsic,6106,O
coagulation,6106,O
pathway,6106,O
activation,6106,O
and,6106,O
platelet,6106,O
aggregation,6106,O
",",6106,O
in,6106,O
the,6106,O
same,6106,O
model,6106,O
of,6106,O
intravascular,6106,O
thrombus,6106,O
formation,6106,O
",",6106,O
recombinant,6106,O
human,6106,B-GENE-Y
FVIIa,6106,I-GENE-Y
was,6106,O
administered,6106,O
in,6106,O
antiplatelet-treated,6106,O
rabbits,6106,O
.,6106,O
Cyclic,6107,O
flow,6107,O
variations,6107,O
(,6107,O
CFVs,6107,O
),6107,O
",",6107,O
due,6107,O
to,6107,O
recurrent,6107,O
thrombus,6107,O
formation,6107,O
",",6107,O
were,6107,O
initiated,6107,O
by,6107,O
placing,6107,O
an,6107,O
external,6107,O
constrictor,6107,O
around,6107,O
the,6107,O
endothelially-injured,6107,O
rabbit,6107,O
carotid,6107,O
arteries,6107,O
(,6107,O
Folt,6107,O
's,6107,O
model,6107,O
),6107,O
.,6107,O
Carotid,6108,O
blood,6108,O
flow,6108,O
was,6108,O
measured,6108,O
continuously,6108,O
by,6108,O
a,6108,O
Doppler,6108,O
flow,6108,O
probe,6108,O
placed,6108,O
proximally,6108,O
to,6108,O
the,6108,O
constrictor,6108,O
.,6108,O
CFVs,6109,O
were,6109,O
induced,6109,O
in,6109,O
29,6109,O
New,6109,O
Zealand,6109,O
White,6109,O
rabbits,6109,O
.,6109,O
After,6110,O
CFVs,6110,O
were,6110,O
observed,6110,O
for,6110,O
30,6110,O
min,6110,O
",",6110,O
the,6110,O
animals,6110,O
were,6110,O
randomly,6110,O
divided,6110,O
in,6110,O
four,6110,O
groups,6110,O
:,6110,O
5,6110,O
animals,6110,O
received,6110,O
via,6110,O
a,6110,O
small,6110,O
catheter,6110,O
(,6110,O
26G,6110,O
),6110,O
placed,6110,O
proximally,6110,O
to,6110,O
the,6110,O
stenosis,6110,O
",",6110,O
an,6110,O
intra-arterial,6110,O
infusion,6110,O
of,6110,O
human,6110,B-GENE-Y
recombinant,6110,I-GENE-Y
FVIIai,6110,I-GENE-Y
(,6110,O
0.1,6110,O
mg/kg/min,6110,O
for,6110,O
10,6110,O
min,6110,O
),6110,O
;,6110,O
9,6110,O
animals,6110,O
received,6110,O
AP-1,6110,O
",",6110,O
a,6110,O
monoclonal,6110,O
antibody,6110,O
against,6110,O
rabbit,6110,B-GENE-Y
TF,6110,I-GENE-Y
(,6110,O
0.1,6110,O
mg/kg,6110,O
i.v,6110,O
.,6110,O
bolus,6111,O
),6111,O
;,6111,O
7,6111,O
animals,6111,O
received,6111,O
ridogrel,6111,O
",",6111,O
a,6111,O
dual,6111,O
thromboxane,6111,B-GENE-Y
A2,6111,I-GENE-Y
synthetase,6111,I-GENE-Y
inhibitor,6111,O
and,6111,O
thromboxane,6111,B-GENE-Y
A2,6111,I-GENE-Y
receptor,6111,I-GENE-Y
antagonist,6111,O
(,6111,O
10,6111,O
mg/kg,6111,O
i.v,6111,O
.,6111,O
bolus,6112,O
),6112,O
;,6112,O
finally,6112,O
",",6112,O
8,6112,O
rabbits,6112,O
received,6112,O
aurintrycarboxilic,6112,B-CHEMICAL
acid,6112,I-CHEMICAL
(,6112,O
ATA,6112,B-CHEMICAL
),6112,O
",",6112,O
an,6112,O
inhibitor,6112,O
of,6112,O
platelet,6112,O
glycoprotein,6112,B-GENE-N
Ib/von,6112,O
Willebrand,6112,I-GENE-Y
factor,6112,I-GENE-Y
interaction,6112,O
(,6112,O
10,6112,O
mg/kg,6112,O
i.v,6112,O
.,6112,O
bolus,6113,O
),6113,O
.,6113,O
FVIIai,6114,B-GENE-Y
abolished,6114,O
CFVs,6114,O
in,6114,O
5,6114,O
of,6114,O
5,6114,O
animals,6114,O
(,6114,O
CFV,6114,O
frequency,6114,O
minutes,6114,O
0,6114,O
cycles/hour,6114,O
;,6114,O
p,6114,O
<,6114,O
0.05,6114,O
;,6114,O
carotid,6114,O
blood,6114,O
flow,6114,O
velocity,6114,O
minutes,6114,O
106,6114,O
+/-,6114,O
9,6114,O
%,6114,O
of,6114,O
the,6114,O
baseline,6114,O
values,6114,O
;,6114,O
NS,6114,O
vs,6114,O
baseline,6114,O
),6114,O
.,6114,O
AP-1,6115,O
abolished,6115,O
CFVs,6115,O
in,6115,O
7,6115,O
of,6115,O
9,6115,O
animals,6115,O
(,6115,O
CFV,6115,O
frequency,6115,O
minutes,6115,O
0,6115,O
cycles/hour,6115,O
;,6115,O
p,6115,O
<,6115,O
0.05,6115,O
;,6115,O
carotid,6115,O
blood,6115,O
flow,6115,O
velocity,6115,O
minutes,6115,O
58,6115,O
+/-,6115,O
35,6115,O
%,6115,O
of,6115,O
the,6115,O
baseline,6115,O
values,6115,O
;,6115,O
NS,6115,O
vs,6115,O
baseline,6115,O
),6115,O
.,6115,O
Finally,6116,O
",",6116,O
in,6116,O
all,6116,O
the,6116,O
animals,6116,O
receiving,6116,O
ridogrel,6116,O
or,6116,O
ATA,6116,B-CHEMICAL
CFVs,6116,O
were,6116,O
abolished,6116,O
(,6116,O
CFV,6116,O
frequency,6116,O
0,6116,O
cycles/hour,6116,O
;,6116,O
p,6116,O
<,6116,O
0.05,6116,O
in,6116,O
both,6116,O
groups,6116,O
;,6116,O
carotid,6116,O
blood,6116,O
flow,6116,O
velocity,6116,O
",",6116,O
respectively,6116,O
62,6116,O
+/-,6116,O
32,6116,O
and,6116,O
66,6116,O
+/-,6116,O
40,6116,O
%,6116,O
of,6116,O
the,6116,O
baseline,6116,O
values,6116,O
;,6116,O
NS,6116,O
vs,6116,O
baseline,6116,O
in,6116,O
both,6116,O
groups,6116,O
),6116,O
.,6116,O
Thirty,6117,O
minutes,6117,O
following,6117,O
inhibition,6117,O
of,6117,O
CFVs,6117,O
",",6117,O
in,6117,O
the,6117,O
FVIIai,6117,B-GENE-Y
treated,6117,O
rabbits,6117,O
",",6117,O
human,6117,B-GENE-Y
recombinant,6117,I-GENE-Y
FVIIa,6117,I-GENE-Y
was,6117,O
infused,6117,O
",",6117,O
via,6117,O
the,6117,O
small,6117,O
catheter,6117,O
placed,6117,O
proximally,6117,O
to,6117,O
the,6117,O
stenosis,6117,O
",",6117,O
at,6117,O
the,6117,O
dose,6117,O
of,6117,O
0.1,6117,O
mg/kg/min,6117,O
for,6117,O
10,6117,O
min,6117,O
.,6117,O
In,6118,O
the,6118,O
other,6118,O
three,6118,O
groups,6118,O
",",6118,O
FVIIa,6118,B-GENE-Y
",",6118,O
at,6118,O
the,6118,O
same,6118,O
dose,6118,O
",",6118,O
was,6118,O
infused,6118,O
i.v,6118,O
.,6118,O
Infusion,6119,O
of,6119,O
FVIIa,6119,B-GENE-Y
restored,6119,O
CFVs,6119,O
in,6119,O
all,6119,O
FVIIai,6119,B-GENE-Y
treated,6119,O
animals,6119,O
and,6119,O
in,6119,O
6,6119,O
of,6119,O
7,6119,O
AP-1,6119,O
treated,6119,O
animals,6119,O
",",6119,O
thus,6119,O
indicating,6119,O
that,6119,O
AP-1,6119,O
and,6119,O
FVIIai,6119,B-GENE-Y
bindings,6119,O
to,6119,O
TF,6119,B-GENE-Y
was,6119,O
competitive,6119,O
and,6119,O
was,6119,O
replaced,6119,O
by,6119,O
FVIIa,6119,B-GENE-Y
.,6119,O
Infusion,6120,O
of,6120,O
FVIIa,6120,B-GENE-Y
failed,6120,O
to,6120,O
restore,6120,O
CFVs,6120,O
in,6120,O
ridogrel,6120,O
e,6120,O
ATA,6120,B-CHEMICAL
treated,6120,O
rabbits,6120,O
(,6120,O
1,6120,O
of,6120,O
7,6120,O
and,6120,O
0,6120,O
of,6120,O
8,6120,O
rabbits,6120,O
",",6120,O
respectively,6120,O
),6120,O
",",6120,O
showing,6120,O
that,6120,O
activation,6120,O
of,6120,O
extrinsic,6120,O
coagulation,6120,O
by,6120,O
FVIIa,6120,B-GENE-Y
was,6120,O
overcome,6120,O
by,6120,O
inhibition,6120,O
of,6120,O
platelet,6120,O
function,6120,O
.,6120,O
Activated,6121,O
partial,6121,O
thromboplastin,6121,O
time,6121,O
",",6121,O
and,6121,O
ex,6121,O
vivo,6121,O
platelet,6121,O
aggregation,6121,O
in,6121,O
response,6121,O
to,6121,O
ADP,6121,B-CHEMICAL
and,6121,O
thrombin,6121,B-GENE-Y
",",6121,O
were,6121,O
not,6121,O
different,6121,O
after,6121,O
FVIIai,6121,B-GENE-Y
infusion,6121,O
",",6121,O
while,6121,O
prothrombin,6121,O
time,6121,O
was,6121,O
slightly,6121,O
but,6121,O
significantly,6121,O
prolonged,6121,O
as,6121,O
compared,6121,O
to,6121,O
baseline,6121,O
values,6121,O
.,6121,O
Thus,6122,O
",",6122,O
FVII-VIIa,6122,B-GENE-N
plays,6122,O
an,6122,O
important,6122,O
role,6122,O
in,6122,O
initiating,6122,O
thrombus,6122,O
formation,6122,O
in,6122,O
vivo,6122,O
.,6122,O
Administration,6123,O
of,6123,O
FVIIai,6123,B-GENE-Y
exerts,6123,O
a,6123,O
potent,6123,O
antithrombotic,6123,O
effects,6123,O
in,6123,O
this,6123,O
model,6123,O
without,6123,O
affecting,6123,O
systemic,6123,O
coagulation,6123,O
.,6123,O
In,6124,O
addition,6124,O
",",6124,O
in,6124,O
this,6124,O
model,6124,O
platelets,6124,O
exert,6124,O
an,6124,O
important,6124,O
role,6124,O
in,6124,O
arterial,6124,O
thrombosis,6124,O
",",6124,O
since,6124,O
in,6124,O
the,6124,O
presence,6124,O
of,6124,O
inhibition,6124,O
of,6124,O
platelet,6124,O
function,6124,O
",",6124,O
activation,6124,O
of,6124,O
the,6124,O
extrinsic,6124,O
coagulation,6124,O
pathway,6124,O
failed,6124,O
to,6124,O
restore,6124,O
thrombus,6124,O
formation,6124,O
.,6124,O
Norepinephrine,6125,B-GENE-Y
transporters,6125,I-GENE-Y
have,6125,O
channel,6125,O
modes,6125,O
of,6125,O
conduction,6125,O
.,6125,O
Neurotransmitter,6126,B-GENE-N
transporters,6126,I-GENE-N
couple,6126,O
to,6126,O
existing,6126,O
ion,6126,O
gradients,6126,O
to,6126,O
achieve,6126,O
reuptake,6126,O
of,6126,O
transmitter,6126,O
into,6126,O
presynaptic,6126,O
terminals,6126,O
.,6126,O
For,6127,O
coupled,6127,O
cotransport,6127,O
",",6127,O
substrates,6127,O
and,6127,O
ions,6127,O
cross,6127,O
the,6127,O
membrane,6127,O
in,6127,O
fixed,6127,O
stoichiometry,6127,O
.,6127,O
This,6128,O
is,6128,O
in,6128,O
contrast,6128,O
to,6128,O
ion,6128,B-GENE-N
channels,6128,I-GENE-N
",",6128,O
which,6128,O
carry,6128,O
an,6128,O
arbitrary,6128,O
number,6128,O
of,6128,O
ions,6128,O
depending,6128,O
on,6128,O
the,6128,O
channel,6128,O
open,6128,O
time,6128,O
.,6128,O
Members,6129,O
of,6129,O
the,6129,O
gamma-aminobutyric,6129,B-CHEMICAL
acid,6129,I-CHEMICAL
transporter,6129,I-GENE-N
gene,6129,O
family,6129,O
presumably,6129,O
function,6129,O
with,6129,O
fixed,6129,O
stoichiometry,6129,O
in,6129,O
which,6129,O
a,6129,O
set,6129,O
number,6129,O
of,6129,O
ions,6129,O
cotransport,6129,O
with,6129,O
one,6129,O
transmitter,6129,O
molecule,6129,O
.,6129,O
Here,6130,O
we,6130,O
report,6130,O
channel-like,6130,O
events,6130,O
from,6130,O
a,6130,O
presumably,6130,O
fixed,6130,O
stoichiometry,6130,O
[,6130,O
norepinephrine,6130,B-CHEMICAL
(,6130,O
NE,6130,B-CHEMICAL
),6130,O
+,6130,O
",",6130,O
Na+,6130,B-CHEMICAL
",",6130,O
and,6130,O
Cl-,6130,B-CHEMICAL
],6130,O
",",6130,O
human,6130,O
NE,6130,B-CHEMICAL
(,6130,O
hNET,6130,B-GENE-Y
),6130,O
in,6130,O
the,6130,O
gamma-aminobutyric,6130,B-CHEMICAL
acid,6130,I-CHEMICAL
transporter,6130,I-GENE-N
gene,6130,O
family,6130,O
.,6130,O
These,6131,O
events,6131,O
are,6131,O
stimulated,6131,O
by,6131,O
NE,6131,B-CHEMICAL
and,6131,O
by,6131,O
guanethidine,6131,B-CHEMICAL
",",6131,O
an,6131,O
hNET,6131,B-GENE-Y
substrate,6131,O
",",6131,O
and,6131,O
they,6131,O
are,6131,O
blocked,6131,O
by,6131,O
cocaine,6131,B-CHEMICAL
and,6131,O
the,6131,O
antidepressant,6131,O
desipramine,6131,B-CHEMICAL
.,6131,O
Voltage-clamp,6132,O
data,6132,O
combined,6132,O
with,6132,O
NE,6132,B-CHEMICAL
uptake,6132,O
data,6132,O
from,6132,O
these,6132,O
same,6132,O
cells,6132,O
indicate,6132,O
that,6132,O
hNETs,6132,B-GENE-Y
have,6132,O
two,6132,O
functional,6132,O
modes,6132,O
of,6132,O
conduction,6132,O
:,6132,O
a,6132,O
classical,6132,O
transporter,6132,O
mode,6132,O
(,6132,O
T-mode,6132,O
),6132,O
and,6132,O
a,6132,O
novel,6132,O
channel,6132,O
mode,6132,O
(,6132,O
C-mode,6132,O
),6132,O
.,6132,O
Both,6133,O
T-mode,6133,O
and,6133,O
C-mode,6133,O
are,6133,O
gated,6133,O
by,6133,O
the,6133,O
same,6133,O
substrates,6133,O
and,6133,O
antagonized,6133,O
by,6133,O
the,6133,O
same,6133,O
blockers,6133,O
.,6133,O
T-mode,6134,O
is,6134,O
putatively,6134,O
electrogenic,6134,O
because,6134,O
the,6134,O
transmitter,6134,O
and,6134,O
cotransported,6134,O
ions,6134,O
sum,6134,O
to,6134,O
one,6134,O
net,6134,O
charge,6134,O
.,6134,O
However,6135,O
",",6135,O
C-mode,6135,O
carries,6135,O
virtually,6135,O
all,6135,O
of,6135,O
the,6135,O
transmitter-induced,6135,O
current,6135,O
",",6135,O
even,6135,O
though,6135,O
it,6135,O
occurs,6135,O
with,6135,O
low,6135,O
probability,6135,O
.,6135,O
This,6136,O
is,6136,O
because,6136,O
each,6136,O
C-mode,6136,O
opening,6136,O
transports,6136,O
hundreds,6136,O
of,6136,O
charges,6136,O
per,6136,O
event,6136,O
.,6136,O
The,6137,O
existence,6137,O
of,6137,O
a,6137,O
channel,6137,O
mode,6137,O
of,6137,O
conduction,6137,O
in,6137,O
a,6137,O
previously,6137,O
established,6137,O
fixed-stoichiometry,6137,O
transporter,6137,O
suggests,6137,O
the,6137,O
appearance,6137,O
of,6137,O
an,6137,O
aqueous,6137,O
pore,6137,O
through,6137,O
the,6137,O
transporter,6137,O
protein,6137,O
during,6137,O
the,6137,O
transport,6137,O
cycle,6137,O
and,6137,O
may,6137,O
have,6137,O
significance,6137,O
for,6137,O
transporter,6137,O
regulation,6137,O
.,6137,O
Mineralocorticoids,6138,O
",",6138,O
salt,6138,O
",",6138,O
hypertension,6138,O
:,6138,O
effects,6138,O
on,6138,O
the,6138,O
heart,6138,O
.,6138,O
In,6139,O
uninephrectomized,6139,O
rats,6139,O
on,6139,O
1,6139,O
%,6139,O
NaCl,6139,B-CHEMICAL
solution,6139,O
to,6139,O
drink,6139,O
",",6139,O
aldosterone,6139,B-CHEMICAL
(,6139,O
0.75,6139,O
micrograms/h,6139,O
subcutaneously,6139,O
for,6139,O
8,6139,O
weeks,6139,O
),6139,O
raises,6139,O
blood,6139,O
pressure,6139,O
and,6139,O
causes,6139,O
marked,6139,O
interstitial,6139,O
and,6139,O
perivascular,6139,O
cardiac,6139,O
fibrosis,6139,O
",",6139,O
effects,6139,O
not,6139,O
seen,6139,O
in,6139,O
animals,6139,O
on,6139,O
a,6139,O
low,6139,O
salt,6139,O
intake,6139,O
.,6139,O
In,6140,O
extending,6140,O
these,6140,O
initial,6140,O
findings,6140,O
",",6140,O
we,6140,O
have,6140,O
shown,6140,O
that,6140,O
cardiac,6140,O
fibrosis,6140,O
(,6140,O
i,6140,O
),6140,O
is,6140,O
not,6140,O
reversed,6140,O
by,6140,O
correction,6140,O
of,6140,O
mineralocorticoid-induced,6140,O
hypokalemia,6140,O
;,6140,O
(,6140,O
ii,6140,O
),6140,O
appears,6140,O
not,6140,O
to,6140,O
involve,6140,O
the,6140,O
plasma,6140,O
or,6140,O
tissue,6140,O
renin-angiotensin,6140,B-GENE-Y
systems,6140,O
",",6140,O
as,6140,O
fibrosis,6140,O
is,6140,O
largely,6140,O
unaffected,6140,O
by,6140,O
concurrent,6140,O
administration,6140,O
of,6140,O
Losartan,6140,B-CHEMICAL
or,6140,O
Perindopril,6140,B-CHEMICAL
;,6140,O
(,6140,O
iii,6140,O
),6140,O
is,6140,O
independent,6140,O
of,6140,O
cardiac,6140,O
hypertrophy,6140,O
",",6140,O
in,6140,O
that,6140,O
it,6140,O
is,6140,O
equally,6140,O
seen,6140,O
in,6140,O
right,6140,O
and,6140,O
left,6140,O
ventricles,6140,O
",",6140,O
and,6140,O
in,6140,O
rats,6140,O
rendered,6140,O
hypertensive,6140,O
without,6140,O
cardiac,6140,O
hypertrophy,6140,O
by,6140,O
the,6140,O
administration,6140,O
of,6140,O
9,6140,B-CHEMICAL
alpha-fluorocortisol,6140,I-CHEMICAL
;,6140,O
(,6140,O
iv,6140,O
),6140,O
is,6140,O
independent,6140,O
of,6140,O
elevated,6140,O
blood,6140,O
pressure,6140,O
",",6140,O
in,6140,O
that,6140,O
it,6140,O
is,6140,O
found,6140,O
in,6140,O
normotensive,6140,O
animals,6140,O
infused,6140,O
peripherally,6140,O
with,6140,O
aldosterone,6140,B-CHEMICAL
and,6140,O
intracerebroventricularly,6140,O
with,6140,O
the,6140,O
mineralocorticoid,6140,B-GENE-Y
receptor,6140,I-GENE-Y
(,6140,O
MR,6140,B-GENE-Y
),6140,O
antagonist,6140,O
RU28318,6140,B-CHEMICAL
;,6140,O
(,6140,O
v,6140,O
),6140,O
is,6140,O
via,6140,O
classical,6140,O
MR,6140,B-GENE-Y
",",6140,O
in,6140,O
that,6140,O
it,6140,O
is,6140,O
blocked,6140,O
by,6140,O
concurrent,6140,O
administration,6140,O
of,6140,O
the,6140,O
MR,6140,B-GENE-Y
antagonist,6140,O
potassium,6140,B-CHEMICAL
canrenoate,6140,I-CHEMICAL
;,6140,O
and,6140,O
(,6140,O
vi,6140,O
),6140,O
may,6140,O
or,6140,O
may,6140,O
not,6140,O
be,6140,O
a,6140,O
direct,6140,O
cardiac,6140,O
effect,6140,O
",",6140,O
inasmuch,6140,O
as,6140,O
data,6140,O
for,6140,O
in,6140,O
vivo,6140,O
effects,6140,O
on,6140,O
collagen,6140,B-GENE-N
formation,6140,O
by,6140,O
cardiac,6140,O
fibroblasts,6140,O
are,6140,O
conflicting,6140,O
.,6140,O
Although,6141,O
there,6141,O
is,6141,O
a,6141,O
high,6141,O
probability,6141,O
that,6141,O
the,6141,O
action,6141,O
of,6141,O
aldosterone,6141,B-CHEMICAL
to,6141,O
cause,6141,O
cardiac,6141,O
fibrosis,6141,O
in,6141,O
this,6141,O
experimental,6141,O
model,6141,O
is,6141,O
an,6141,O
effect,6141,O
via,6141,O
non-epithelial,6141,O
MR,6141,B-GENE-Y
",",6141,O
the,6141,O
locus,6141,O
of,6141,O
aldosterone,6141,B-CHEMICAL
action,6141,O
remains,6141,O
to,6141,O
be,6141,O
established,6141,O
",",6141,O
as,6141,O
do,6141,O
the,6141,O
molecular,6141,O
mechanisms,6141,O
linking,6141,O
MR,6141,B-GENE-Y
occupancy,6141,O
by,6141,O
aldosterone,6141,B-CHEMICAL
and,6141,O
collagen,6141,O
deposition,6141,O
.,6141,O
In,6142,O
addition,6142,O
",",6142,O
and,6142,O
in,6142,O
particular,6142,O
",",6142,O
the,6142,O
mechanisms,6142,O
underlying,6142,O
the,6142,O
crucial,6142,O
contribution,6142,O
of,6142,O
high,6142,O
salt,6142,O
intake,6142,O
in,6142,O
this,6142,O
model,6142,O
of,6142,O
mineralocorticoid,6142,O
excess,6142,O
await,6142,O
exploration,6142,O
.,6142,O
Amezinium,6143,B-CHEMICAL
and,6143,O
debrisoquine,6143,B-CHEMICAL
are,6143,O
substrates,6143,O
of,6143,O
uptake1,6143,B-GENE-N
and,6143,O
potent,6143,O
inhibitors,6143,O
of,6143,O
monoamine,6143,B-GENE-N
oxidase,6143,I-GENE-N
in,6143,O
perfused,6143,O
lungs,6143,O
of,6143,O
rats,6143,O
.,6143,O
Previous,6144,O
studies,6144,O
have,6144,O
resulted,6144,O
in,6144,O
the,6144,O
classification,6144,O
of,6144,O
amezinium,6144,B-CHEMICAL
as,6144,O
a,6144,O
selective,6144,O
inhibitor,6144,O
of,6144,O
neuronal,6144,O
monoamine,6144,B-GENE-N
oxidase,6144,I-GENE-N
(,6144,O
MAO,6144,B-GENE-N
),6144,O
",",6144,O
because,6144,O
it,6144,O
is,6144,O
a,6144,O
much,6144,O
more,6144,O
potent,6144,O
MAO,6144,B-GENE-N
inhibitor,6144,O
in,6144,O
intact,6144,O
tissues,6144,O
",",6144,O
in,6144,O
which,6144,O
it,6144,O
is,6144,O
accumulated,6144,O
in,6144,O
noradrenergic,6144,O
neurones,6144,O
by,6144,O
uptake1,6144,O
",",6144,O
than,6144,O
in,6144,O
tissue,6144,O
homogenates,6144,O
.,6144,O
In,6145,O
the,6145,O
present,6145,O
study,6145,O
",",6145,O
the,6145,O
effects,6145,O
of,6145,O
amezinium,6145,B-CHEMICAL
on,6145,O
the,6145,O
deamination,6145,O
of,6145,O
noradrenaline,6145,B-CHEMICAL
were,6145,O
investigated,6145,O
in,6145,O
intact,6145,O
lungs,6145,O
of,6145,O
rats,6145,O
",",6145,O
since,6145,O
the,6145,O
pulmonary,6145,O
endothelial,6145,O
cells,6145,O
are,6145,O
a,6145,O
site,6145,O
where,6145,O
the,6145,O
catecholamine,6145,B-CHEMICAL
transporter,6145,O
is,6145,O
non-neuronal,6145,O
uptake1,6145,B-GENE-N
.,6145,O
In,6146,O
addition,6146,O
",",6146,O
another,6146,O
drug,6146,O
that,6146,O
is,6146,O
both,6146,O
a,6146,O
substrate,6146,O
of,6146,O
uptake1,6146,B-GENE-N
and,6146,O
a,6146,O
MAO,6146,B-GENE-N
inhibitor,6146,O
",",6146,O
debrisoquine,6146,B-CHEMICAL
",",6146,O
was,6146,O
investigated,6146,O
in,6146,O
the,6146,O
study,6146,O
.,6146,O
The,6147,O
first,6147,O
aim,6147,O
of,6147,O
the,6147,O
study,6147,O
was,6147,O
to,6147,O
show,6147,O
whether,6147,O
amezinium,6147,B-CHEMICAL
and,6147,O
debrisoquine,6147,B-CHEMICAL
are,6147,O
substrates,6147,O
of,6147,O
uptake1,6147,B-GENE-N
in,6147,O
rat,6147,O
lungs,6147,O
.,6147,O
After,6148,O
loading,6148,O
of,6148,O
isolated,6148,O
perfused,6148,O
lungs,6148,O
with,6148,O
3H-noradrenaline,6148,B-CHEMICAL
(,6148,O
MAO,6148,B-GENE-N
and,6148,O
catechol-O-methyltransferase,6148,B-GENE-Y
(,6148,O
COMT,6148,B-GENE-Y
),6148,O
inhibited,6148,O
),6148,O
",",6148,O
the,6148,O
efflux,6148,O
of,6148,O
3H-noradrenaline,6148,B-CHEMICAL
was,6148,O
measured,6148,O
for,6148,O
30,6148,O
min,6148,O
.,6148,O
When,6149,O
1,6149,O
mumol/l,6149,O
amezinium,6149,B-CHEMICAL
or,6149,O
15,6149,O
mumol/l,6149,O
debrisoquine,6149,B-CHEMICAL
was,6149,O
added,6149,O
for,6149,O
the,6149,O
last,6149,O
15,6149,O
min,6149,O
of,6149,O
efflux,6149,O
",",6149,O
there,6149,O
was,6149,O
a,6149,O
rapid,6149,O
and,6149,O
marked,6149,O
increase,6149,O
in,6149,O
the,6149,O
fractional,6149,O
rate,6149,O
of,6149,O
loss,6149,O
of,6149,O
3H-noradrenaline,6149,B-CHEMICAL
",",6149,O
which,6149,O
was,6149,O
reduced,6149,O
by,6149,O
about,6149,O
70,6149,O
%,6149,O
when,6149,O
1,6149,O
mumol/l,6149,O
desipramine,6149,B-CHEMICAL
was,6149,O
present,6149,O
throughout,6149,O
the,6149,O
efflux,6149,O
period,6149,O
.,6149,O
These,6150,O
results,6150,O
showed,6150,O
that,6150,O
both,6150,O
drugs,6150,O
were,6150,O
substrates,6150,O
for,6150,O
uptake1,6150,B-GENE-N
in,6150,O
rat,6150,O
lungs,6150,O
.,6150,O
In,6151,O
lungs,6151,O
perfused,6151,O
with,6151,O
1,6151,O
nmol/l,6151,O
3H-noradrenaline,6151,B-CHEMICAL
(,6151,O
COMT,6151,B-GENE-Y
inhibited,6151,O
),6151,O
",",6151,O
10,6151,O
",",6151,O
30,6151,O
and,6151,O
300,6151,O
nmol/l,6151,O
amezinium,6151,B-CHEMICAL
caused,6151,O
58,6151,O
%,6151,O
",",6151,O
76,6151,O
%,6151,O
and,6151,O
74,6151,O
%,6151,O
inhibition,6151,O
of,6151,O
noradrenaline,6151,B-CHEMICAL
deamination,6151,O
",",6151,O
respectively,6151,O
",",6151,O
and,6151,O
30,6151,O
",",6151,O
300,6151,O
and,6151,O
3000,6151,O
nmol/l,6151,O
debrisoquine,6151,B-CHEMICAL
caused,6151,O
56,6151,O
%,6151,O
",",6151,O
89,6151,O
%,6151,O
and,6151,O
96,6151,O
%,6151,O
inhibition,6151,O
of,6151,O
noradrenaline,6151,B-CHEMICAL
deamination,6151,O
",",6151,O
respectively,6151,O
.,6151,O
When,6152,O
MAO-B,6152,B-GENE-Y
was,6152,O
also,6152,O
inhibited,6152,O
",",6152,O
10,6152,O
nmol/l,6152,O
amezinium,6152,B-CHEMICAL
caused,6152,O
84,6152,O
%,6152,O
inhibition,6152,O
of,6152,O
the,6152,O
deamination,6152,O
of,6152,O
noradrenaline,6152,B-CHEMICAL
by,6152,O
MAO-A,6152,B-GENE-Y
in,6152,O
the,6152,O
lungs,6152,O
.,6152,O
In,6153,O
contrast,6153,O
",",6153,O
in,6153,O
hearts,6153,O
perfused,6153,O
with,6153,O
10,6153,O
nmol/l,6153,O
3H-noradrenaline,6153,B-CHEMICAL
under,6153,O
conditions,6153,O
where,6153,O
the,6153,O
amine,6153,O
was,6153,O
accumulated,6153,O
by,6153,O
uptake2,6153,B-GENE-N
(,6153,O
COMT,6153,B-GENE-Y
",",6153,O
uptake1,6153,B-GENE-N
and,6153,O
vesicular,6153,O
transport,6153,O
inhibited,6153,O
),6153,O
",",6153,O
10,6153,O
nmol/l,6153,O
amezinium,6153,B-CHEMICAL
had,6153,O
no,6153,O
effect,6153,O
and,6153,O
300,6153,O
nmol/l,6153,O
amezinium,6153,B-CHEMICAL
caused,6153,O
only,6153,O
36,6153,O
%,6153,O
inhibition,6153,O
of,6153,O
deamination,6153,O
of,6153,O
noradrenaline,6153,B-CHEMICAL
.,6153,O
The,6154,O
results,6154,O
when,6154,O
considered,6154,O
with,6154,O
previous,6154,O
reports,6154,O
in,6154,O
the,6154,O
literature,6154,O
show,6154,O
that,6154,O
amezinium,6154,B-CHEMICAL
is,6154,O
about,6154,O
1000,6154,O
times,6154,O
more,6154,O
potent,6154,O
and,6154,O
debrisoquine,6154,B-CHEMICAL
is,6154,O
about,6154,O
20,6154,O
times,6154,O
more,6154,O
potent,6154,O
for,6154,O
MAO,6154,B-GENE-N
inhibition,6154,O
in,6154,O
rat,6154,O
lungs,6154,O
than,6154,O
in,6154,O
tissue,6154,O
homogenates,6154,O
",",6154,O
and,6154,O
the,6154,O
reason,6154,O
for,6154,O
their,6154,O
high,6154,O
potencies,6154,O
in,6154,O
the,6154,O
intact,6154,O
lungs,6154,O
is,6154,O
transport,6154,O
and,6154,O
accumulation,6154,O
of,6154,O
the,6154,O
drugs,6154,O
in,6154,O
the,6154,O
pulmonary,6154,O
endothelial,6154,O
cells,6154,O
by,6154,O
uptake1,6154,B-GENE-N
.,6154,O
Amezinium,6155,B-CHEMICAL
is,6155,O
much,6155,O
less,6155,O
potent,6155,O
as,6155,O
a,6155,O
MAO,6155,B-GENE-N
inhibitor,6155,O
in,6155,O
cells,6155,O
with,6155,O
the,6155,O
uptake2,6155,B-GENE-N
transporter,6155,I-GENE-N
",",6155,O
such,6155,O
as,6155,O
the,6155,O
myocardial,6155,O
cells,6155,O
of,6155,O
the,6155,O
heart,6155,O
.,6155,O
The,6156,O
results,6156,O
also,6156,O
confirmed,6156,O
previous,6156,O
reports,6156,O
that,6156,O
amezinium,6156,B-CHEMICAL
is,6156,O
highly,6156,O
selective,6156,O
for,6156,O
MAO-A,6156,B-GENE-Y
.,6156,O
Role,6157,O
of,6157,O
tachykinin,6157,B-GENE-N
and,6157,I-GENE-N
bradykinin,6157,I-GENE-N
receptors,6157,I-GENE-N
and,6157,O
mast,6157,O
cells,6157,O
in,6157,O
gaseous,6157,O
formaldehyde-induced,6157,B-CHEMICAL
airway,6157,O
microvascular,6157,O
leakage,6157,O
in,6157,O
rats,6157,O
.,6157,O
We,6158,O
have,6158,O
investigated,6158,O
the,6158,O
effects,6158,O
of,6158,O
"CP-99,994",6158,B-CHEMICAL
[,6158,B-CHEMICAL
(,6158,I-CHEMICAL
+,6158,I-CHEMICAL
),6158,I-CHEMICAL
-,6158,I-CHEMICAL
(,6158,I-CHEMICAL
"2s,3s",6158,I-CHEMICAL
),6158,I-CHEMICAL
-3-,6158,I-CHEMICAL
(,6158,I-CHEMICAL
2-methoxybenzylamino,6158,I-CHEMICAL
),6158,I-CHEMICAL
-2-phenylpiperidine,6158,I-CHEMICAL
],6158,I-CHEMICAL
",",6158,O
a,6158,O
tachykinin,6158,B-GENE-Y
NK1,6158,I-GENE-Y
receptor,6158,I-GENE-Y
antagonist,6158,O
",",6158,O
HOE,6158,B-CHEMICAL
140,6158,I-CHEMICAL
(,6158,B-CHEMICAL
D-Arg,6158,I-CHEMICAL
[,6158,I-CHEMICAL
Hyp3,6158,I-CHEMICAL
",",6158,I-CHEMICAL
Thi5,6158,I-CHEMICAL
",",6158,I-CHEMICAL
D-Tic7,6158,I-CHEMICAL
",",6158,I-CHEMICAL
Oic8,6158,I-CHEMICAL
],6158,I-CHEMICAL
bradykinin,6158,I-CHEMICAL
),6158,I-CHEMICAL
",",6158,O
a,6158,O
bradykinin,6158,B-CHEMICAL
B2,6158,I-GENE-Y
receptor,6158,I-GENE-Y
antagonist,6158,O
",",6158,O
and,6158,O
ketotifen,6158,B-CHEMICAL
(,6158,B-CHEMICAL
4-,6158,I-CHEMICAL
(,6158,I-CHEMICAL
1-methyl-4-piperidylidene,6158,I-CHEMICAL
),6158,I-CHEMICAL
4,6158,I-CHEMICAL
H-benzo,6158,I-CHEMICAL
[,6158,I-CHEMICAL
"4,5",6158,I-CHEMICAL
],6158,I-CHEMICAL
cycloheptal,6158,I-CHEMICAL
[,6158,I-CHEMICAL
"1,2-b",6158,I-CHEMICAL
],6158,I-CHEMICAL
thiophen-10,6158,I-CHEMICAL
(,6158,I-CHEMICAL
9H,6158,I-CHEMICAL
),6158,I-CHEMICAL
-one,6158,I-CHEMICAL
hydrogen,6158,I-CHEMICAL
fumarate,6158,I-CHEMICAL
),6158,I-CHEMICAL
",",6158,O
a,6158,O
histamine,6158,B-GENE-Y
H1,6158,I-GENE-Y
receptor,6158,I-GENE-Y
antagonist,6158,O
with,6158,O
mast,6158,O
cell-stabilizing,6158,O
properties,6158,O
",",6158,O
on,6158,O
microvascular,6158,O
leakage,6158,O
induced,6158,O
by,6158,O
gaseous,6158,O
formaldehyde,6158,B-CHEMICAL
.,6158,O
Extravasation,6159,O
of,6159,O
Evans,6159,B-CHEMICAL
blue,6159,I-CHEMICAL
dye,6159,I-CHEMICAL
into,6159,O
airway,6159,O
tissues,6159,O
was,6159,O
used,6159,O
as,6159,O
an,6159,O
index,6159,O
of,6159,O
airway,6159,O
microvascular,6159,O
leakage,6159,O
.,6159,O
Leakage,6160,O
of,6160,O
dye,6160,O
in,6160,O
the,6160,O
trachea,6160,O
and,6160,O
main,6160,O
bronchi,6160,O
increased,6160,O
significantly,6160,O
in,6160,O
a,6160,O
concentration-dependent,6160,O
fashion,6160,O
after,6160,O
10,6160,O
min,6160,O
inhalation,6160,O
of,6160,O
formaldehyde,6160,B-CHEMICAL
(,6160,O
5-45,6160,O
parts,6160,O
per,6160,O
million,6160,O
(,6160,O
ppm,6160,O
),6160,O
),6160,O
.,6160,O
The,6161,O
airway,6161,O
response,6161,O
induced,6161,O
by,6161,O
10,6161,O
min,6161,O
inhalation,6161,O
of,6161,O
15,6161,O
ppm,6161,O
formaldehyde,6161,B-CHEMICAL
(,6161,O
trachea,6161,O
:,6161,O
119.5,6161,O
+/-,6161,O
13.9,6161,O
ng/mg,6161,O
",",6161,O
n,6161,O
=,6161,O
7,6161,O
;,6161,O
main,6161,O
bronchi,6161,O
:,6161,O
139.6,6161,O
+/-,6161,O
7.9,6161,O
ng/mg,6161,O
",",6161,O
n,6161,O
=,6161,O
7,6161,O
),6161,O
was,6161,O
abolished,6161,O
by,6161,O
the,6161,O
administration,6161,O
of,6161,O
"CP-99,994",6161,B-CHEMICAL
(,6161,O
3,6161,O
and,6161,O
6,6161,O
mg/kg,6161,O
i.v,6161,O
.,6161,O
),6162,O
",",6162,O
but,6162,O
not,6162,O
by,6162,O
the,6162,O
administration,6162,O
of,6162,O
HOE,6162,I-CHEMICAL
140,6162,O
(,6162,O
0.65,6162,O
mg/kg,6162,O
i.v,6162,O
.,6162,O
),6162,O
nor,6163,O
ketotifen,6163,O
(,6163,O
1,6163,O
mg/kg,6163,O
i.v,6163,O
.,6163,O
),6163,O
.,6163,O
The,6164,O
increase,6164,O
in,6164,O
vascular,6164,O
permeability,6164,O
induced,6164,O
by,6164,O
formaldehyde,6164,O
in,6164,O
the,6164,O
rat,6164,O
airway,6164,O
was,6164,O
mediated,6164,O
predominantly,6164,O
by,6164,O
NK1,6164,I-GENE-Y
receptor,6164,O
stimulation,6164,O
.,6164,O
Activation,6165,O
of,6165,O
bradykinin,6165,I-GENE-N
receptors,6165,O
and,6165,O
mast,6165,O
cells,6165,O
did,6165,O
not,6165,O
appear,6165,O
to,6165,O
play,6165,O
an,6165,O
important,6165,O
role,6165,O
in,6165,O
this,6165,O
airway,6165,O
response,6165,O
.,6165,O
Molecular,6166,O
determinants,6166,O
of,6166,O
dofetilide,6166,B-CHEMICAL
block,6166,O
of,6166,O
HERG,6166,B-GENE-Y
K+,6166,B-GENE-N
channels,6166,I-GENE-N
.,6166,O
The,6167,O
human,6167,B-GENE-Y
ether-a-go-go-related,6167,I-GENE-Y
gene,6167,I-GENE-Y
(,6167,O
HERG,6167,B-GENE-Y
),6167,O
encodes,6167,O
a,6167,O
K+,6167,B-GENE-N
channel,6167,I-GENE-N
with,6167,O
biophysical,6167,O
properties,6167,O
nearly,6167,O
identical,6167,O
to,6167,O
the,6167,O
rapid,6167,B-GENE-N
component,6167,I-GENE-N
of,6167,I-GENE-N
the,6167,I-GENE-N
cardiac,6167,I-GENE-N
delayed,6167,I-GENE-N
rectifier,6167,I-GENE-N
K+,6167,B-CHEMICAL
current,6167,I-GENE-N
(,6167,O
IKr,6167,B-GENE-N
),6167,O
.,6167,O
HERG/IKr,6168,B-GENE-Y
channels,6168,O
are,6168,O
a,6168,O
prime,6168,O
target,6168,O
for,6168,O
the,6168,O
pharmacological,6168,O
management,6168,O
of,6168,O
arrhythmias,6168,O
and,6168,O
are,6168,O
selectively,6168,O
blocked,6168,O
by,6168,O
class,6168,O
III,6168,O
antiarrhythmic,6168,O
methanesulfonanilide,6168,B-CHEMICAL
drugs,6168,O
",",6168,O
such,6168,O
as,6168,O
dofetilide,6168,B-CHEMICAL
",",6168,O
E4031,6168,B-CHEMICAL
",",6168,O
and,6168,O
MK-499,6168,B-CHEMICAL
",",6168,O
at,6168,O
submicromolar,6168,O
concentrations,6168,O
.,6168,O
By,6169,O
contrast,6169,O
",",6169,O
the,6169,O
closely,6169,O
related,6169,O
bovine,6169,B-GENE-Y
ether-a-go-go,6169,I-GENE-Y
channel,6169,I-GENE-Y
(,6169,O
BEAG,6169,B-GENE-Y
),6169,O
is,6169,O
100-fold,6169,O
less,6169,O
sensitive,6169,O
to,6169,O
dofetilide,6169,B-CHEMICAL
.,6169,O
To,6170,O
identify,6170,O
the,6170,O
molecular,6170,O
determinants,6170,O
for,6170,O
dofetilide,6170,B-CHEMICAL
block,6170,O
",",6170,O
we,6170,O
first,6170,O
engineered,6170,O
chimeras,6170,O
between,6170,O
HERG,6170,B-GENE-Y
and,6170,O
BEAG,6170,B-GENE-Y
and,6170,O
then,6170,O
used,6170,O
site-directed,6170,O
mutagenesis,6170,O
to,6170,O
localize,6170,O
single,6170,O
amino,6170,B-CHEMICAL
acid,6170,I-CHEMICAL
residues,6170,O
responsible,6170,O
for,6170,O
block,6170,O
.,6170,O
Using,6171,O
constructs,6171,O
heterologously,6171,O
expressed,6171,O
in,6171,O
Xenopus,6171,O
oocytes,6171,O
",",6171,O
we,6171,O
found,6171,O
that,6171,O
transplantation,6171,O
of,6171,O
the,6171,O
S5-S6,6171,O
linker,6171,O
from,6171,O
BEAG,6171,B-GENE-Y
into,6171,O
HERG,6171,B-GENE-Y
removed,6171,O
high-affinity,6171,O
block,6171,O
by,6171,O
dofetilide,6171,O
.,6171,O
A,6172,O
point,6172,O
mutation,6172,O
in,6172,O
the,6172,O
S5-S6,6172,O
linker,6172,O
region,6172,O
",",6172,O
HERG,6172,B-GENE-Y
S620T,6172,B-GENE-N
",",6172,O
abolished,6172,O
high-affinity,6172,O
block,6172,O
and,6172,O
interfered,6172,O
with,6172,O
C-type,6172,O
inactivation,6172,O
.,6172,O
Thus,6173,O
",",6173,O
our,6173,O
results,6173,O
indicate,6173,O
that,6173,O
important,6173,O
determinants,6173,O
of,6173,O
dofetilide,6173,B-CHEMICAL
binding,6173,O
are,6173,O
localized,6173,O
to,6173,O
the,6173,O
pore,6173,O
region,6173,O
of,6173,O
HERG,6173,B-GENE-Y
.,6173,O
Since,6174,O
the,6174,O
loss,6174,O
of,6174,O
high-affinity,6174,O
drug,6174,O
binding,6174,O
was,6174,O
always,6174,O
correlated,6174,O
with,6174,O
a,6174,O
loss,6174,O
of,6174,O
C-type,6174,O
inactivation,6174,O
",",6174,O
it,6174,O
is,6174,O
possible,6174,O
that,6174,O
the,6174,O
changes,6174,O
observed,6174,O
in,6174,O
drug,6174,O
binding,6174,O
are,6174,O
due,6174,O
to,6174,O
indirect,6174,O
allosteric,6174,O
modifications,6174,O
in,6174,O
the,6174,O
structure,6174,O
of,6174,O
the,6174,O
channel,6174,O
protein,6174,O
and,6174,O
not,6174,O
to,6174,O
the,6174,O
direct,6174,O
interaction,6174,O
of,6174,O
dofetilide,6174,B-CHEMICAL
with,6174,O
the,6174,O
respective,6174,O
mutated,6174,O
site,6174,O
chains,6174,O
.,6174,O
However,6175,O
",",6175,O
the,6175,O
chimeric,6175,O
approach,6175,O
was,6175,O
not,6175,O
able,6175,O
to,6175,O
identify,6175,O
domains,6175,O
outside,6175,O
the,6175,O
S5-S6,6175,O
linker,6175,O
region,6175,O
of,6175,O
the,6175,O
HERG,6175,B-GENE-Y
channel,6175,O
as,6175,O
putative,6175,O
candidates,6175,O
involved,6175,O
in,6175,O
drug,6175,O
binding,6175,O
.,6175,O
Moreover,6176,O
",",6176,O
the,6176,O
reverse,6176,O
mutation,6176,O
BEAG,6176,B-GENE-Y
T432S,6176,B-GENE-N
increased,6176,O
the,6176,O
affinity,6176,O
of,6176,O
BEAG,6176,B-GENE-Y
K+,6176,B-CHEMICAL
channels,6176,I-GENE-N
for,6176,O
dofetilide,6176,B-CHEMICAL
",",6176,O
whereas,6176,O
C-type,6176,O
inactivation,6176,O
could,6176,O
not,6176,O
be,6176,O
recovered,6176,O
.,6176,O
Thus,6177,O
",",6177,O
the,6177,O
serine,6177,B-CHEMICAL
in,6177,O
position,6177,O
HERG,6177,B-GENE-Y
620,6177,O
may,6177,O
participate,6177,O
directly,6177,O
in,6177,O
dofetilide,6177,B-CHEMICAL
binding,6177,O
;,6177,O
however,6177,O
",",6177,O
an,6177,O
intact,6177,O
C-type,6177,O
inactivation,6177,O
process,6177,O
seems,6177,O
to,6177,O
be,6177,O
crucial,6177,O
for,6177,O
high-affinity,6177,O
drug,6177,O
binding,6177,O
.,6177,O
Testosterone,6178,B-CHEMICAL
versus,6178,O
testosterone,6178,B-CHEMICAL
and,6178,O
testolactone,6178,B-CHEMICAL
in,6178,O
treating,6178,O
reproductive,6178,O
and,6178,O
sexual,6178,O
dysfunction,6178,O
in,6178,O
men,6178,O
with,6178,O
epilepsy,6178,O
and,6178,O
hypogonadism,6178,O
.,6178,O
Antiepileptic,6179,O
drug-induced,6179,O
reductions,6179,O
in,6179,O
serum,6179,O
levels,6179,O
of,6179,O
biologically,6179,O
active,6179,O
testosterone,6179,B-CHEMICAL
and,6179,O
elevations,6179,O
in,6179,O
serum,6179,O
estradiol,6179,B-CHEMICAL
(,6179,O
E2,6179,B-CHEMICAL
),6179,O
may,6179,O
contribute,6179,O
to,6179,O
sexual,6179,O
dysfunction,6179,O
among,6179,O
men,6179,O
with,6179,O
epilepsy,6179,O
.,6179,O
Treatment,6180,O
using,6180,O
a,6180,O
combination,6180,O
of,6180,O
testosterone,6180,B-CHEMICAL
and,6180,O
the,6180,O
aromatase,6180,B-GENE-Y
inhibitor,6180,O
testolactone,6180,B-CHEMICAL
may,6180,O
have,6180,O
significantly,6180,O
better,6180,O
effects,6180,O
on,6180,O
sexual,6180,O
function,6180,O
and,6180,O
also,6180,O
seizure,6180,O
frequency,6180,O
than,6180,O
testosterone,6180,B-CHEMICAL
alone,6180,O
.,6180,O
Identification,6181,O
of,6181,O
binding,6181,O
sites,6181,O
for,6181,O
bepridil,6181,B-CHEMICAL
and,6181,O
trifluoperazine,6181,B-CHEMICAL
on,6181,O
cardiac,6181,B-GENE-Y
troponin,6181,I-GENE-Y
C.,6181,O
The,6181,O
solution,6181,O
structure,6181,O
of,6181,O
cardiac,6181,B-GENE-Y
troponin,6181,I-GENE-Y
C,6181,I-GENE-Y
(,6181,O
cTnC,6181,B-GENE-Y
),6181,O
(,6181,O
Sia,6181,O
",",6181,O
S.,6181,O
",",6181,O
Li,6181,O
",",6181,O
M.,6181,O
X.,6181,O
",",6181,O
Spyracopoulos,6181,O
",",6181,O
L.,6181,O
",",6181,O
Gagne,6181,O
",",6181,O
S.,6181,O
M.,6181,O
",",6181,O
Liu,6181,O
",",6181,O
W.,6181,O
",",6181,O
Putkey,6181,O
",",6181,O
J,6181,O
.,6181,O
A,6182,O
.,6182,O
&,6183,O
Sykes,6183,O
",",6183,O
B.,6183,O
D.,6183,O
(,6183,O
1997,6183,O
),6183,O
J.,6183,O
Biol,6183,O
.,6183,O
Chem,6184,O
.,6184,O
272,6185,O
",",6185,O
18216-18221,6185,O
),6185,O
challenges,6185,O
existing,6185,O
structure/function,6185,O
models,6185,O
for,6185,O
this,6185,O
critical,6185,O
regulatory,6185,O
protein,6185,O
.,6185,O
For,6186,O
example,6186,O
",",6186,O
it,6186,O
is,6186,O
clear,6186,O
that,6186,O
the,6186,O
closed,6186,O
conformation,6186,O
of,6186,O
the,6186,O
regulatory,6186,O
N-terminal,6186,B-CHEMICAL
domain,6186,O
in,6186,O
Ca2+-bound,6186,B-CHEMICAL
cardiac,6186,B-GENE-Y
troponin,6186,I-GENE-Y
C,6186,I-GENE-Y
(,6186,O
cTnC,6186,B-GENE-Y
),6186,O
presents,6186,O
a,6186,O
much,6186,O
different,6186,O
binding,6186,O
surface,6186,O
for,6186,O
Ca2+-sensitizing,6186,B-CHEMICAL
compounds,6186,O
than,6186,O
previously,6186,O
thought,6186,O
.,6186,O
We,6187,O
report,6187,O
here,6187,O
the,6187,O
use,6187,O
of,6187,O
Met,6187,O
methyl,6187,O
groups,6187,O
as,6187,O
site-specific,6187,O
structural,6187,O
markers,6187,O
to,6187,O
identify,6187,O
drug,6187,O
binding,6187,O
sites,6187,O
for,6187,O
trifluoperazine,6187,B-CHEMICAL
and,6187,O
bepridil,6187,B-CHEMICAL
on,6187,O
cTnC,6187,B-GENE-Y
.,6187,O
Drug,6188,O
dependent,6188,O
changes,6188,O
in,6188,O
the,6188,O
NMR,6188,O
heteronuclear,6188,O
single-quantum,6188,O
coherence,6188,O
spectra,6188,O
of,6188,O
[,6188,O
methyl-13C,6188,B-CHEMICAL
],6188,O
Met-labeled,6188,O
cTnC,6188,B-GENE-Y
indicate,6188,O
that,6188,O
bepridil,6188,B-CHEMICAL
and,6188,O
trifluoperazine,6188,B-CHEMICAL
bind,6188,O
to,6188,O
similar,6188,O
sites,6188,O
but,6188,O
only,6188,O
in,6188,O
the,6188,O
presence,6188,O
of,6188,O
Ca2+,6188,B-CHEMICAL
.,6188,O
There,6189,O
are,6189,O
3-4,6189,O
drug,6189,O
binding,6189,O
sites,6189,O
in,6189,O
the,6189,O
N-,6189,B-CHEMICAL
and,6189,O
C-terminal,6189,B-CHEMICAL
domains,6189,O
of,6189,O
intact,6189,O
cTnC,6189,B-GENE-Y
that,6189,O
exhibit,6189,O
fast,6189,O
exchange,6189,O
on,6189,O
the,6189,O
NMR,6189,O
time,6189,O
scale,6189,O
.,6189,O
Use,6190,O
of,6190,O
a,6190,O
novel,6190,O
spin-labeled,6190,O
phenothiazine,6190,B-CHEMICAL
and,6190,O
detection,6190,O
of,6190,O
isotope-filtered,6190,O
nuclear,6190,O
Overhauser,6190,O
effects,6190,O
allowed,6190,O
identification,6190,O
of,6190,O
drug,6190,O
binding,6190,O
sites,6190,O
in,6190,O
the,6190,O
shallow,6190,O
hydrophobic,6190,O
cup,6190,O
in,6190,O
the,6190,O
C-terminal,6190,O
domain,6190,O
and,6190,O
on,6190,O
two,6190,O
hydrophobic,6190,O
surfaces,6190,O
on,6190,O
the,6190,O
N-terminal,6190,B-CHEMICAL
regulatory,6190,O
domain,6190,O
.,6190,O
The,6191,O
data,6191,O
presented,6191,O
here,6191,O
",",6191,O
coupled,6191,O
with,6191,O
our,6191,O
previous,6191,O
study,6191,O
using,6191,O
covalent,6191,O
blocking,6191,O
groups,6191,O
",",6191,O
support,6191,O
a,6191,O
model,6191,O
in,6191,O
which,6191,O
the,6191,O
Ca2+-sensitizing,6191,B-CHEMICAL
binding,6191,O
site,6191,O
includes,6191,O
Met-45,6191,O
in,6191,O
helix,6191,O
B,6191,O
of,6191,O
site,6191,O
I,6191,O
",",6191,O
and,6191,O
Met-60,6191,O
and,6191,O
-80,6191,O
in,6191,O
helices,6191,O
B,6191,O
and,6191,O
C,6191,O
of,6191,O
the,6191,O
regulatory,6191,O
site,6191,O
II,6191,O
.,6191,O
This,6192,O
subregion,6192,O
in,6192,O
cTnC,6192,B-GENE-Y
makes,6192,O
a,6192,O
likely,6192,O
target,6192,O
against,6192,O
which,6192,O
to,6192,O
design,6192,O
new,6192,O
and,6192,O
selective,6192,O
Ca2+-sensitizing,6192,B-CHEMICAL
compounds,6192,O
.,6192,O
Peripheral,6193,O
blood,6193,O
mononuclear,6193,O
cells,6193,O
express,6193,O
mutated,6193,O
NCCT,6193,B-GENE-Y
mRNA,6193,O
in,6193,O
Gitelman,6193,O
's,6193,O
syndrome,6193,O
:,6193,O
evidence,6193,O
for,6193,O
abnormal,6193,O
thiazide-sensitive,6193,B-CHEMICAL
NaCl,6193,B-CHEMICAL
cotransport,6193,O
.,6193,O
Genetic,6194,O
analysis,6194,O
has,6194,O
demonstrated,6194,O
complete,6194,O
linkage,6194,O
between,6194,O
the,6194,O
human,6194,B-GENE-Y
thiazide-sensitive,6194,I-GENE-Y
sodium,6194,I-GENE-Y
chloride,6194,I-GENE-Y
cotransporter,6194,I-GENE-Y
gene,6194,O
(,6194,O
NCCT,6194,B-GENE-Y
or,6194,O
TSC,6194,B-GENE-Y
),6194,O
and,6194,O
Gitelman,6194,O
's,6194,O
syndrome,6194,O
(,6194,O
GS,6194,O
),6194,O
.,6194,O
Several,6195,O
genomic,6195,O
NCCT,6195,B-GENE-Y
mutations,6195,O
have,6195,O
been,6195,O
reported,6195,O
.,6195,O
This,6196,O
study,6196,O
was,6196,O
performed,6196,O
to,6196,O
determine,6196,O
whether,6196,O
peripheral,6196,O
blood,6196,O
mononuclear,6196,O
cells,6196,O
(,6196,O
PBMC,6196,O
),6196,O
express,6196,O
NCCT,6196,B-GENE-Y
mRNA,6196,O
and,6196,O
whether,6196,O
defective,6196,O
PBMC,6196,O
NaCl,6196,B-CHEMICAL
cotransport,6196,O
could,6196,O
be,6196,O
demonstrated,6196,O
in,6196,O
GS,6196,O
.,6196,O
PBMC,6197,O
were,6197,O
isolated,6197,O
from,6197,O
two,6197,O
brothers,6197,O
with,6197,O
GS,6197,O
",",6197,O
their,6197,O
parents,6197,O
",",6197,O
and,6197,O
healthy,6197,O
control,6197,O
subjects,6197,O
.,6197,O
Northern,6198,O
analysis,6198,O
revealed,6198,O
that,6198,O
NCCT,6198,B-GENE-Y
mRNA,6198,O
is,6198,O
expressed,6198,O
in,6198,O
PBMC,6198,O
.,6198,O
The,6199,O
sequence,6199,O
of,6199,O
full-length,6199,O
NCCT,6199,B-GENE-Y
cDNA,6199,O
amplified,6199,O
from,6199,O
normal,6199,O
PBMC,6199,O
was,6199,O
identical,6199,O
to,6199,O
human,6199,B-GENE-Y
renal,6199,I-GENE-Y
NCCT,6199,I-GENE-Y
cDNA,6199,O
.,6199,O
Two,6200,O
different,6200,O
mutations,6200,O
were,6200,O
detected,6200,O
in,6200,O
the,6200,O
patients,6200,O
',6200,O
NCCT,6200,B-GENE-Y
cDNA,6200,O
(,6200,O
compound,6200,O
heterozygote,6200,O
),6200,O
.,6200,O
In,6201,O
cDNA,6201,O
derived,6201,O
from,6201,O
the,6201,O
patient,6201,O
's,6201,O
maternal,6201,O
allele,6201,O
",",6201,O
exon,6201,O
24,6201,O
was,6201,O
deleted,6201,O
",",6201,O
resulting,6201,O
in,6201,O
a,6201,O
premature,6201,O
stop,6201,O
codon,6201,O
(,6201,O
after,6201,O
amino,6201,B-CHEMICAL
acid,6201,I-CHEMICAL
920,6201,O
),6201,O
.,6201,O
cDNA,6202,O
derived,6202,O
from,6202,O
the,6202,O
patient,6202,O
's,6202,O
paternal,6202,O
allele,6202,O
had,6202,O
an,6202,O
additional,6202,O
119-bp,6202,O
insertion,6202,O
between,6202,O
exons,6202,O
3,6202,O
and,6202,O
4,6202,O
",",6202,O
generating,6202,O
a,6202,O
premature,6202,O
stop,6202,O
codon,6202,O
(,6202,O
after,6202,O
amino,6202,B-CHEMICAL
acid,6202,I-CHEMICAL
187,6202,O
),6202,O
.,6202,O
The,6203,O
patient,6203,O
's,6203,O
genomic,6203,O
DNA,6203,O
had,6203,O
a,6203,O
previously,6203,O
described,6203,O
5,6203,O
',6203,O
splice,6203,O
site,6203,O
mutation,6203,O
in,6203,O
intron,6203,O
24,6203,O
",",6203,O
GGT,6203,B-GENE-N
--,6203,I-GENE-N
>,6203,I-GENE-N
GTT,6203,I-GENE-N
(,6203,O
maternal,6203,O
allele,6203,O
),6203,O
",",6203,O
and,6203,O
a,6203,O
new,6203,O
3,6203,O
',6203,O
splice,6203,O
site,6203,O
mutation,6203,O
in,6203,O
intron,6203,O
3,6203,O
",",6203,O
CAG,6203,B-GENE-N
--,6203,I-GENE-N
>,6203,I-GENE-N
CAA,6203,I-GENE-N
(,6203,O
paternal,6203,O
allele,6203,O
),6203,O
",",6203,O
which,6203,O
resulted,6203,O
in,6203,O
the,6203,O
activation,6203,O
of,6203,O
a,6203,O
nearby,6203,O
cryptic,6203,O
splice,6203,O
site,6203,O
in,6203,O
intron,6203,O
3,6203,O
.,6203,O
The,6204,O
latter,6204,O
mutation,6204,O
was,6204,O
not,6204,O
present,6204,O
in,6204,O
300,6204,O
normal,6204,O
chromosomes,6204,O
.,6204,O
To,6205,O
determine,6205,O
the,6205,O
functional,6205,O
significance,6205,O
of,6205,O
these,6205,O
findings,6205,O
",",6205,O
chlorothiazide-inhibitable,6205,B-CHEMICAL
22Na,6205,B-CHEMICAL
uptake,6205,O
was,6205,O
measured,6205,O
in,6205,O
PBMC,6205,O
from,6205,O
control,6205,O
subjects,6205,O
",",6205,O
the,6205,O
parents,6205,O
",",6205,O
and,6205,O
the,6205,O
patients,6205,O
with,6205,O
GS,6205,O
in,6205,O
the,6205,O
presence,6205,O
of,6205,O
bumetanide,6205,B-CHEMICAL
.,6205,O
In,6206,O
control,6206,O
PBMC,6206,O
",",6206,O
chlorothiazide,6206,B-CHEMICAL
inhibited,6206,O
22Na,6206,B-CHEMICAL
uptake,6206,O
by,6206,O
approximately,6206,O
9,6206,O
%,6206,O
.,6206,O
PBMC,6207,O
from,6207,O
the,6207,O
two,6207,O
patients,6207,O
with,6207,O
GS,6207,O
failed,6207,O
to,6207,O
respond,6207,O
to,6207,O
chlorothiazide,6207,B-CHEMICAL
.,6207,O
These,6208,O
results,6208,O
demonstrate,6208,O
that,6208,O
PBMC,6208,O
can,6208,O
be,6208,O
used,6208,O
for,6208,O
mutational,6208,O
analysis,6208,O
of,6208,O
NCCT,6208,B-GENE-Y
mRNA,6208,O
in,6208,O
patients,6208,O
with,6208,O
GS,6208,O
.,6208,O
Furthermore,6209,O
",",6209,O
functional,6209,O
evidence,6209,O
is,6209,O
provided,6209,O
that,6209,O
the,6209,O
underlying,6209,O
cause,6209,O
of,6209,O
GS,6209,O
is,6209,O
defective,6209,O
NCCT,6209,B-GENE-Y
NaCl,6209,B-CHEMICAL
cotransport,6209,O
.,6209,O
A,6210,O
case,6210,O
of,6210,O
therapy-related,6210,O
acute,6210,O
myeloblastic,6210,O
leukemia,6210,O
with,6210,O
t,6210,O
(,6210,O
16,6210,O
;,6210,O
21,6210,O
),6210,O
(,6210,O
q24,6210,O
;,6210,O
q22,6210,O
),6210,O
after,6210,O
chemotherapy,6210,O
with,6210,O
DNA-topoisomerase,6210,B-GENE-Y
II,6210,I-GENE-Y
inhibitors,6210,O
",",6210,O
etoposide,6210,B-CHEMICAL
and,6210,O
mitoxantrone,6210,B-CHEMICAL
",",6210,O
and,6210,O
the,6210,O
alkylating,6210,O
agent,6210,O
",",6210,O
cyclophosphamide,6210,B-CHEMICAL
.,6210,O
A,6211,O
59-year-old,6211,O
female,6211,O
suffering,6211,O
from,6211,O
malignant,6211,O
lymphoma,6211,O
developed,6211,O
therapy-related,6211,O
acute,6211,O
myeloblastic,6211,O
leukemia,6211,O
(,6211,O
t-AML,6211,O
),6211,O
after,6211,O
chemotherapy,6211,O
consisting,6211,O
of,6211,O
treatment,6211,O
with,6211,O
DNA-topoisomerase,6211,B-GENE-Y
II,6211,I-GENE-Y
inhibitors,6211,O
",",6211,O
etoposide,6211,B-CHEMICAL
and,6211,O
mitoxantrone,6211,B-CHEMICAL
",",6211,O
and,6211,O
an,6211,O
alkylating,6211,O
agent,6211,O
",",6211,O
cyclophosphamide,6211,B-CHEMICAL
.,6211,O
The,6212,O
cumulative,6212,O
dose,6212,O
of,6212,O
etoposide,6212,B-CHEMICAL
administration,6212,O
was,6212,O
5500,6212,O
mg,6212,O
;,6212,O
1500,6212,O
mg,6212,O
given,6212,O
intravenously,6212,O
and,6212,O
4000,6212,O
mg,6212,O
orally,6212,O
.,6212,O
One,6213,O
year,6213,O
later,6213,O
",",6213,O
she,6213,O
suddenly,6213,O
developed,6213,O
AML,6213,O
of,6213,O
FAB,6213,O
M2,6213,O
.,6213,O
Cytogenetic,6214,O
analysis,6214,O
of,6214,O
bone,6214,O
marrow,6214,O
cells,6214,O
revealed,6214,O
deletion,6214,O
of,6214,O
7q,6214,O
and,6214,O
a,6214,O
rare,6214,O
translocation,6214,O
",",6214,O
t,6214,O
(,6214,O
16,6214,O
;,6214,O
21,6214,O
),6214,O
(,6214,O
q24,6214,O
;,6214,O
q22,6214,O
),6214,O
.,6214,O
Southern,6215,O
blot,6215,O
analysis,6215,O
of,6215,O
bone,6215,O
marrow,6215,O
cells,6215,O
did,6215,O
not,6215,O
detect,6215,O
rearrangement,6215,O
of,6215,O
the,6215,O
AML1,6215,B-GENE-Y
gene,6215,O
",",6215,O
however,6215,O
",",6215,O
fluorescence,6215,O
in,6215,O
situ,6215,O
hybridization,6215,O
(,6215,O
FISH,6215,O
),6215,O
analysis,6215,O
of,6215,O
bone,6215,O
marrow,6215,O
cells,6215,O
at,6215,O
interphase,6215,O
and,6215,O
metaphase,6215,O
revealed,6215,O
a,6215,O
translocational,6215,O
splitting,6215,O
between,6215,O
chromosome,6215,O
21,6215,O
involving,6215,O
AML1,6215,B-GENE-Y
gene,6215,O
and,6215,O
chromosome,6215,O
16,6215,O
.,6215,O
These,6216,O
results,6216,O
suggest,6216,O
that,6216,O
the,6216,O
breakpoint,6216,O
is,6216,O
not,6216,O
located,6216,O
in,6216,O
the,6216,O
breakpoint,6216,B-GENE-N
cluster,6216,I-GENE-N
region,6216,I-GENE-N
for,6216,O
t,6216,O
(,6216,O
8,6216,O
;,6216,O
21,6216,O
),6216,O
.,6216,O
The,6217,O
patient,6217,O
was,6217,O
treated,6217,O
with,6217,O
chemotherapy,6217,O
and,6217,O
entered,6217,O
complete,6217,O
remission,6217,O
.,6217,O
Safety,6218,O
of,6218,O
selegiline,6218,B-CHEMICAL
(,6218,O
deprenyl,6218,B-CHEMICAL
),6218,O
in,6218,O
the,6218,O
treatment,6218,O
of,6218,O
Parkinson,6218,O
's,6218,O
disease,6218,O
.,6218,O
Selegiline,6219,B-CHEMICAL
(,6219,O
deprenyl,6219,B-CHEMICAL
),6219,O
",",6219,O
a,6219,O
selective,6219,O
",",6219,O
irreversible,6219,O
inhibitor,6219,O
of,6219,O
monoamine,6219,B-GENE-Y
oxidase,6219,I-GENE-Y
type,6219,I-GENE-Y
B,6219,I-GENE-Y
(,6219,O
MAO-B,6219,B-GENE-Y
),6219,O
is,6219,O
widely,6219,O
used,6219,O
in,6219,O
the,6219,O
treatment,6219,O
of,6219,O
Parkinson,6219,O
's,6219,O
disease,6219,O
.,6219,O
As,6220,O
the,6220,O
first,6220,O
MAO-B,6220,B-GENE-Y
inhibitor,6220,O
approved,6220,O
for,6220,O
the,6220,O
treatment,6220,O
of,6220,O
Parkinson,6220,O
's,6220,O
disease,6220,O
",",6220,O
concerns,6220,O
were,6220,O
raised,6220,O
about,6220,O
the,6220,O
safety,6220,O
of,6220,O
the,6220,O
drug,6220,O
based,6220,O
on,6220,O
the,6220,O
adverse,6220,O
effect,6220,O
profiles,6220,O
of,6220,O
older,6220,O
",",6220,O
nonselective,6220,O
MAO,6220,B-GENE-N
inhibitors,6220,O
.,6220,O
Unlike,6221,O
the,6221,O
nonselective,6221,O
MAO,6221,B-GENE-N
inhibitors,6221,O
",",6221,O
selegiline,6221,B-CHEMICAL
does,6221,O
not,6221,O
significantly,6221,O
potentiate,6221,O
tyramine-induced,6221,B-CHEMICAL
hypertension,6221,O
(,6221,O
the,6221,O
'cheese,6221,O
effect,6221,O
',6221,O
),6221,O
at,6221,O
the,6221,O
dosages,6221,O
(,6221,O
5,6221,O
to,6221,O
10,6221,O
mg,6221,O
daily,6221,O
),6221,O
used,6221,O
for,6221,O
the,6221,O
treatment,6221,O
of,6221,O
Parkinson,6221,O
's,6221,O
disease,6221,O
.,6221,O
Selegiline,6222,B-CHEMICAL
has,6222,O
been,6222,O
well,6222,O
tolerated,6222,O
when,6222,O
given,6222,O
alone,6222,O
.,6222,O
The,6223,O
most,6223,O
frequent,6223,O
adverse,6223,O
events,6223,O
seen,6223,O
during,6223,O
monotherapy,6223,O
have,6223,O
been,6223,O
insomnia,6223,O
",",6223,O
nausea,6223,O
",",6223,O
benign,6223,O
cardiac,6223,O
arrhythmias,6223,O
",",6223,O
dizziness,6223,O
and,6223,O
headache,6223,O
.,6223,O
When,6224,O
combined,6224,O
with,6224,O
levodopa,6224,B-CHEMICAL
",",6224,O
selegiline,6224,B-CHEMICAL
can,6224,O
potentiate,6224,O
the,6224,O
typical,6224,O
adverse,6224,O
effects,6224,O
of,6224,O
levodopa,6224,B-CHEMICAL
",",6224,O
if,6224,O
the,6224,O
dose,6224,O
of,6224,O
levodopa,6224,B-CHEMICAL
is,6224,O
not,6224,O
reduced,6224,O
sufficiently,6224,O
.,6224,O
Thus,6225,O
",",6225,O
the,6225,O
most,6225,O
common,6225,O
adverse,6225,O
effects,6225,O
associated,6225,O
with,6225,O
this,6225,O
combination,6225,O
are,6225,O
nausea,6225,O
",",6225,O
dizziness,6225,O
",",6225,O
fatigue,6225,O
",",6225,O
constipation,6225,O
and,6225,O
insomnia,6225,O
.,6225,O
At,6226,O
the,6226,O
later,6226,O
stages,6226,O
of,6226,O
Parkinson,6226,O
's,6226,O
disease,6226,O
when,6226,O
fluctuations,6226,O
in,6226,O
disability,6226,O
occur,6226,O
",",6226,O
peak,6226,O
dose,6226,O
dyskinesias,6226,O
",",6226,O
psychiatric,6226,O
complications,6226,O
like,6226,O
hallucinations,6226,O
and,6226,O
insomnia,6226,O
",",6226,O
and,6226,O
orthostatic,6226,O
hypotension,6226,O
are,6226,O
further,6226,O
potentiated,6226,O
by,6226,O
selegiline,6226,B-CHEMICAL
.,6226,O
Mortality,6227,O
was,6227,O
recently,6227,O
reported,6227,O
to,6227,O
be,6227,O
increased,6227,O
when,6227,O
selegiline,6227,B-CHEMICAL
and,6227,O
levodopa,6227,B-CHEMICAL
were,6227,O
given,6227,O
together,6227,O
in,6227,O
comparison,6227,O
with,6227,O
treatment,6227,O
with,6227,O
levodopa,6227,B-CHEMICAL
alone,6227,O
",",6227,O
but,6227,O
a,6227,O
large,6227,O
meta-analysis,6227,O
of,6227,O
5,6227,O
long,6227,O
term,6227,O
studies,6227,O
and,6227,O
4,6227,O
separate,6227,O
studies,6227,O
did,6227,O
not,6227,O
support,6227,O
this,6227,O
conclusion,6227,O
.,6227,O
Selegiline,6228,B-CHEMICAL
seems,6228,O
to,6228,O
be,6228,O
generally,6228,O
well,6228,O
tolerated,6228,O
in,6228,O
combination,6228,O
with,6228,O
other,6228,O
drugs,6228,O
.,6228,O
However,6229,O
",",6229,O
when,6229,O
pethidine,6229,B-CHEMICAL
(,6229,O
meperidine,6229,B-CHEMICAL
),6229,O
has,6229,O
been,6229,O
given,6229,O
to,6229,O
patients,6229,O
who,6229,O
are,6229,O
receiving,6229,O
selegiline,6229,B-CHEMICAL
therapy,6229,O
",",6229,O
severe,6229,O
adverse,6229,O
effects,6229,O
have,6229,O
been,6229,O
reported,6229,O
.,6229,O
Thus,6230,O
",",6230,O
the,6230,O
concomitant,6230,O
use,6230,O
of,6230,O
these,6230,O
drugs,6230,O
is,6230,O
not,6230,O
recommended,6230,O
.,6230,O
A,6231,O
low,6231,O
tyramine,6231,B-CHEMICAL
diet,6231,O
is,6231,O
recommended,6231,O
if,6231,O
selegiline,6231,B-CHEMICAL
is,6231,O
used,6231,O
together,6231,O
with,6231,O
nonselective,6231,O
MAO,6231,B-GENE-N
inhibitors,6231,O
or,6231,O
the,6231,O
selective,6231,O
",",6231,O
reversible,6231,O
MAO-A,6231,B-GENE-Y
inhibitor,6231,O
",",6231,O
moclobemide,6231,B-CHEMICAL
.,6231,O
Several,6232,O
adverse,6232,O
effects,6232,O
have,6232,O
been,6232,O
reported,6232,O
when,6232,O
fluoxetine,6232,B-CHEMICAL
and,6232,O
selegiline,6232,B-CHEMICAL
have,6232,O
been,6232,O
used,6232,O
together,6232,O
.,6232,O
A,6233,O
recent,6233,O
survey,6233,O
revealed,6233,O
that,6233,O
the,6233,O
incidence,6233,O
of,6233,O
a,6233,O
true,6233,O
serotonin,6233,B-CHEMICAL
syndrome,6233,O
is,6233,O
",",6233,O
however,6233,O
",",6233,O
very,6233,O
low,6233,O
with,6233,O
this,6233,O
combination,6233,O
.,6233,O
Concomitant,6234,O
use,6234,O
of,6234,O
selegiline,6234,B-CHEMICAL
and,6234,O
other,6234,O
selective,6234,O
serotonin,6234,B-CHEMICAL
(,6234,O
5-hydroxytryptamine,6234,B-CHEMICAL
;,6234,O
5-HT,6234,B-CHEMICAL
),6234,O
reuptake,6234,O
inhibitors,6234,O
(,6234,O
SSRIs,6234,O
),6234,O
like,6234,O
citalopram,6234,B-CHEMICAL
",",6234,O
which,6234,O
have,6234,O
generally,6234,O
less,6234,O
interactions,6234,O
than,6234,O
fluoxetine,6234,B-CHEMICAL
",",6234,O
seems,6234,O
to,6234,O
be,6234,O
well,6234,O
tolerated,6234,O
.,6234,O
Nevertheless,6235,O
",",6235,O
caution,6235,O
is,6235,O
advised,6235,O
when,6235,O
combining,6235,O
a,6235,O
SSRI,6235,O
or,6235,O
a,6235,O
tricyclic,6235,B-CHEMICAL
antidepressant,6235,O
and,6235,O
selegiline,6235,B-CHEMICAL
.,6235,O
Ibuprofen,6236,B-CHEMICAL
inhibits,6236,O
cystic,6236,B-GENE-Y
fibrosis,6236,I-GENE-Y
transmembrane,6236,I-GENE-Y
conductance,6236,I-GENE-Y
regulator-mediated,6236,O
Cl-,6236,O
secretion,6236,O
.,6236,O
We,6237,O
evaluated,6237,O
the,6237,O
acute,6237,O
effects,6237,O
of,6237,O
ibuprofen,6237,B-CHEMICAL
and,6237,O
salicylic,6237,B-CHEMICAL
acid,6237,I-CHEMICAL
on,6237,O
cAMP-mediated,6237,B-CHEMICAL
Cl-,6237,O
secretion,6237,O
(,6237,O
Isc,6237,O
),6237,O
in,6237,O
both,6237,O
colonic,6237,O
and,6237,O
airway,6237,O
epithelia,6237,O
.,6237,O
In,6238,O
T84,6238,O
cells,6238,O
",",6238,O
ibuprofen,6238,B-CHEMICAL
inhibited,6238,O
the,6238,O
forskolin-dependent,6238,B-CHEMICAL
Isc,6238,O
in,6238,O
a,6238,O
concentration-dependent,6238,O
manner,6238,O
",",6238,O
having,6238,O
an,6238,O
apparent,6238,O
Ki,6238,O
of,6238,O
142,6238,O
microM,6238,O
.,6238,O
Salicylic,6239,B-CHEMICAL
acid,6239,I-CHEMICAL
inhibited,6239,O
Isc,6239,O
with,6239,O
an,6239,O
apparent,6239,O
Ki,6239,O
of,6239,O
646,6239,O
microM,6239,O
.,6239,O
We,6240,O
determined,6240,O
whether,6240,O
ibuprofen,6240,B-CHEMICAL
would,6240,O
also,6240,O
inhibit,6240,O
the,6240,O
forskolin-stimulated,6240,B-CHEMICAL
Isc,6240,O
in,6240,O
primary,6240,O
cultures,6240,O
of,6240,O
mouse,6240,O
trachea,6240,O
epithelia,6240,O
(,6240,O
MTE,6240,O
),6240,O
and,6240,O
human,6240,O
bronchial,6240,O
epithelia,6240,O
(,6240,O
HBE,6240,O
),6240,O
.,6240,O
Similar,6241,O
to,6241,O
our,6241,O
results,6241,O
in,6241,O
T84,6241,O
cells,6241,O
",",6241,O
ibuprofen,6241,B-CHEMICAL
(,6241,O
500,6241,O
microM,6241,O
),6241,O
inhibited,6241,O
the,6241,O
forskolin-induced,6241,B-CHEMICAL
Isc,6241,O
in,6241,O
MTEs,6241,O
and,6241,O
HBEs,6241,O
by,6241,O
59+/-4,6241,O
%,6241,O
(,6241,O
n,6241,O
=,6241,O
11,6241,O
),6241,O
and,6241,O
39+/-6,6241,O
%,6241,O
(,6241,O
n,6241,O
=,6241,O
8,6241,O
),6241,O
",",6241,O
respectively,6241,O
.,6241,O
Nystatin,6242,B-CHEMICAL
was,6242,O
employed,6242,O
to,6242,O
selectively,6242,O
permeabilize,6242,O
the,6242,O
basolateral,6242,O
or,6242,O
apical,6242,O
membrane,6242,O
to,6242,O
determine,6242,O
the,6242,O
effect,6242,O
of,6242,O
ibuprofen,6242,B-CHEMICAL
on,6242,O
apical,6242,O
Cl-,6242,O
(,6242,O
ICl,6242,O
),6242,O
and,6242,O
basolateral,6242,O
K+,6242,B-CHEMICAL
(,6242,O
IK,6242,O
),6242,O
currents,6242,O
after,6242,O
stimulation,6242,O
by,6242,O
forskolin,6242,B-CHEMICAL
.,6242,O
After,6243,O
forskolin,6243,B-CHEMICAL
stimulation,6243,O
",",6243,O
ibuprofen,6243,B-CHEMICAL
(,6243,O
500,6243,O
microM,6243,O
),6243,O
reduced,6243,O
both,6243,O
the,6243,O
ICl,6243,O
and,6243,O
IK,6243,O
;,6243,O
reducing,6243,O
ICl,6243,O
and,6243,O
IK,6243,O
by,6243,O
60,6243,O
and,6243,O
15,6243,O
%,6243,O
",",6243,O
respectively,6243,O
.,6243,O
To,6244,O
determine,6244,O
whether,6244,O
this,6244,O
inhibition,6244,O
of,6244,O
ICl,6244,O
was,6244,O
due,6244,O
to,6244,O
the,6244,O
inhibition,6244,O
of,6244,O
CFTR,6244,B-GENE-Y
",",6244,O
the,6244,O
effects,6244,O
of,6244,O
ibuprofen,6244,B-CHEMICAL
and,6244,O
salicylic,6244,B-CHEMICAL
acid,6244,I-CHEMICAL
on,6244,O
CFTR,6244,B-GENE-Y
Cl-,6244,B-GENE-N
channels,6244,I-GENE-N
in,6244,O
excised,6244,O
",",6244,O
inside-out,6244,O
patches,6244,O
from,6244,O
L-cells,6244,O
were,6244,O
evaluated,6244,O
.,6244,O
Ibuprofen,6245,B-CHEMICAL
(,6245,O
300,6245,O
microM,6245,O
),6245,O
reduced,6245,O
CFTR,6245,B-GENE-Y
Cl-,6245,O
current,6245,O
by,6245,O
60+/-16,6245,O
%,6245,O
and,6245,O
this,6245,O
was,6245,O
explained,6245,O
by,6245,O
a,6245,O
short-lived,6245,O
block,6245,O
(,6245,O
approximately,6245,O
1.2,6245,O
ms,6245,O
),6245,O
which,6245,O
causes,6245,O
an,6245,O
apparent,6245,O
reduction,6245,O
in,6245,O
single,6245,O
channel,6245,O
amplitude,6245,O
from,6245,O
1.07+/-0.04,6245,O
pA,6245,O
to,6245,O
0.59+/-0.04,6245,O
pA,6245,O
(,6245,O
n,6245,O
=,6245,O
3,6245,O
),6245,O
.,6245,O
Similarly,6246,O
",",6246,O
salicylic,6246,B-CHEMICAL
acid,6246,I-CHEMICAL
(,6246,O
3,6246,O
mM,6246,O
),6246,O
reduced,6246,O
CFTR,6246,B-GENE-Y
Cl-,6246,O
current,6246,O
by,6246,O
50+/-8,6246,O
%,6246,O
with,6246,O
an,6246,O
apparent,6246,O
reduction,6246,O
in,6246,O
single,6246,O
channel,6246,O
amplitude,6246,O
from,6246,O
1.08+/-0.03,6246,O
pA,6246,O
to,6246,O
0.48+/-0.06,6246,O
pA,6246,O
(,6246,O
n,6246,O
=,6246,O
4,6246,O
),6246,O
.,6246,O
Based,6247,O
on,6247,O
these,6247,O
results,6247,O
",",6247,O
we,6247,O
conclude,6247,O
that,6247,O
the,6247,O
NSAIDs,6247,O
ibuprofen,6247,B-CHEMICAL
and,6247,O
salicylic,6247,B-CHEMICAL
acid,6247,I-CHEMICAL
inhibit,6247,O
cAMP-mediated,6247,B-CHEMICAL
Cl-,6247,O
secretion,6247,O
in,6247,O
human,6247,O
colonic,6247,O
and,6247,O
airway,6247,O
epithelia,6247,O
via,6247,O
a,6247,O
direct,6247,O
inhibition,6247,O
of,6247,O
CFTR,6247,B-GENE-Y
Cl-,6247,B-GENE-N
channels,6247,I-GENE-N
as,6247,O
well,6247,O
as,6247,O
basolateral,6247,O
membrane,6247,O
K+,6247,B-GENE-N
channels,6247,I-GENE-N
.,6247,O
This,6248,O
may,6248,O
reduce,6248,O
their,6248,O
efficacy,6248,O
in,6248,O
conjunction,6248,O
with,6248,O
other,6248,O
therapeutic,6248,O
strategies,6248,O
designed,6248,O
to,6248,O
increase,6248,O
CFTR,6248,B-GENE-Y
expression,6248,O
and/or,6248,O
function,6248,O
in,6248,O
secretory,6248,O
epithelia,6248,O
.,6248,O
Antagonism,6249,O
of,6249,O
meta-chlorophenylpiperazine-induced,6249,B-CHEMICAL
inhibition,6249,O
of,6249,O
exploratory,6249,O
activity,6249,O
in,6249,O
an,6249,O
emergence,6249,O
procedure,6249,O
",",6249,O
the,6249,O
open,6249,O
field,6249,O
test,6249,O
",",6249,O
in,6249,O
rats,6249,O
.,6249,O
The,6250,O
effects,6250,O
of,6250,O
meta-chlorophenylpiperazine,6250,B-CHEMICAL
(,6250,O
mCPP,6250,B-CHEMICAL
),6250,O
were,6250,O
studied,6250,O
on,6250,O
exploratory,6250,O
behaviour,6250,O
in,6250,O
the,6250,O
open,6250,O
field,6250,O
test,6250,O
",",6250,O
using,6250,O
a,6250,O
procedure,6250,O
designed,6250,O
to,6250,O
evaluate,6250,O
the,6250,O
emergence,6250,O
of,6250,O
rats,6250,O
into,6250,O
a,6250,O
novel,6250,O
environment,6250,O
.,6250,O
mCPP,6251,B-CHEMICAL
reduced,6251,O
the,6251,O
exploratory,6251,O
activity,6251,O
in,6251,O
a,6251,O
dose-related,6251,O
manner,6251,O
after,6251,O
subcutaneous,6251,O
(,6251,O
s.c.,6251,O
),6251,O
",",6251,O
intraperitoneal,6251,O
(,6251,O
i.p,6251,O
.,6251,O
),6251,O
and,6252,O
intravenous,6252,O
(,6252,O
i.v,6252,O
.,6252,O
),6252,O
administration,6253,O
.,6253,O
The,6254,O
inhibition,6254,O
was,6254,O
manifest,6254,O
in,6254,O
all,6254,O
the,6254,O
parameters,6254,O
used,6254,O
to,6254,O
quantify,6254,O
the,6254,O
exploration,6254,O
of,6254,O
the,6254,O
open,6254,O
field,6254,O
area,6254,O
.,6254,O
Additional,6255,O
neuroendocrine,6255,O
experiments,6255,O
in,6255,O
a,6255,O
parallel,6255,O
group,6255,O
of,6255,O
rats,6255,O
revealed,6255,O
a,6255,O
dose-related,6255,O
increase,6255,O
in,6255,O
plasma,6255,B-GENE-Y
prolactin,6255,I-GENE-Y
and,6255,O
ACTH,6255,B-GENE-Y
levels,6255,O
after,6255,O
i.v,6255,O
.,6255,O
mCPP,6256,B-CHEMICAL
",",6256,O
pointing,6256,O
to,6256,O
a,6256,O
general,6256,O
state,6256,O
of,6256,O
arousal,6256,O
in,6256,O
these,6256,O
mCPP-treated,6256,B-CHEMICAL
animals,6256,O
.,6256,O
A,6257,O
number,6257,O
of,6257,O
5-HT,6257,B-CHEMICAL
antagonists,6257,O
were,6257,O
tested,6257,O
for,6257,O
their,6257,O
ability,6257,O
to,6257,O
prevent,6257,O
or,6257,O
reverse,6257,O
the,6257,O
behavioural,6257,O
inhibition,6257,O
induced,6257,O
by,6257,O
an,6257,O
i.v,6257,O
.,6257,O
injection,6258,O
of,6258,O
1.0,6258,O
g/kg,6258,O
mCPP,6258,B-CHEMICAL
given,6258,O
15,6258,O
min,6258,O
before,6258,O
testing,6258,O
in,6258,O
the,6258,O
open,6258,O
field,6258,O
.,6258,O
The,6259,O
antagonists,6259,O
were,6259,O
injected,6259,O
s.c.,6259,O
or,6259,O
given,6259,O
orally,6259,O
at,6259,O
various,6259,O
time,6259,O
intervals,6259,O
before,6259,O
mCPP,6259,B-CHEMICAL
",",6259,O
or,6259,O
they,6259,O
were,6259,O
injected,6259,O
i.v,6259,O
.,6259,O
10,6260,O
min,6260,O
after,6260,O
mCPP,6260,B-CHEMICAL
.,6260,O
The,6261,O
lowest,6261,O
active,6261,O
doses,6261,O
for,6261,O
the,6261,O
attentuation,6261,O
of,6261,O
the,6261,O
mCPP-induced,6261,B-CHEMICAL
behavioural,6261,O
inhibition,6261,O
after,6261,O
s.c.,6261,O
",",6261,O
oral,6261,O
and,6261,O
i.v,6261,O
.,6261,O
administration,6262,O
",",6262,O
respectively,6262,O
",",6262,O
were,6262,O
0.04,6262,O
",",6262,O
40,6262,O
and,6262,O
10,6262,O
mg/kg,6262,O
for,6262,O
pizotifen,6262,O
;,6262,O
0.16,6262,O
",",6262,O
0.16,6262,O
and,6262,O
0.16,6262,O
mg/kg,6262,O
for,6262,O
mianserin,6262,O
;,6262,O
0.63,6262,O
",",6262,O
0.16,6262,O
and,6262,O
0.16,6262,O
mg/kg,6262,O
for,6262,O
methysergide,6262,B-CHEMICAL
",",6262,O
and,6262,O
0.16,6262,O
",",6262,O
2.5,6262,O
and,6262,O
2.5,6262,O
mg/kg,6262,O
for,6262,O
ritanserin,6262,B-CHEMICAL
.,6262,O
The,6263,O
lowest,6263,O
active,6263,O
doses,6263,O
of,6263,O
mirtazapine,6263,B-CHEMICAL
after,6263,O
s.c.,6263,O
and,6263,O
i.v,6263,O
.,6263,O
treatment,6264,O
were,6264,O
0.01,6264,O
and,6264,O
0.16,6264,O
mg/kg,6264,O
.,6264,O
These,6265,O
data,6265,O
indicate,6265,O
that,6265,O
mixed,6265,O
5-HT1/5-HT2,6265,B-GENE-N
receptor,6265,O
antagonists,6265,O
such,6265,O
as,6265,O
pizotifen,6265,B-CHEMICAL
and,6265,O
methysergide,6265,B-CHEMICAL
",",6265,O
and,6265,O
mixed,6265,O
5-HT,6265,B-CHEMICAL
and,6265,O
catecholamine,6265,B-CHEMICAL
antagonists,6265,O
such,6265,O
as,6265,O
mianserin,6265,B-CHEMICAL
and,6265,O
mirtazapine,6265,B-CHEMICAL
are,6265,O
more,6265,O
potent,6265,O
antagonists,6265,O
of,6265,O
mCPP-induced,6265,B-CHEMICAL
behavioural,6265,O
inhibition,6265,O
in,6265,O
rats,6265,O
than,6265,O
the,6265,O
more,6265,O
selective,6265,O
5-HT2A/5-HT2C,6265,B-GENE-Y
antagonist,6265,O
ritanserin,6265,B-CHEMICAL
.,6265,O
Pressor,6266,O
and,6266,O
bradycardic,6266,O
effects,6266,O
of,6266,O
tacrine,6266,B-CHEMICAL
and,6266,O
other,6266,O
acetylcholinesterase,6266,B-GENE-Y
inhibitors,6266,O
in,6266,O
the,6266,O
rat,6266,O
.,6266,O
The,6267,O
cardiovascular,6267,O
effects,6267,O
of,6267,O
three,6267,O
different,6267,O
acetylcholinesterase,6267,B-GENE-Y
inhibitors,6267,O
:,6267,O
physostigmine,6267,B-CHEMICAL
",",6267,O
tacrine,6267,B-CHEMICAL
and,6267,O
rivastigmine,6267,B-CHEMICAL
injected,6267,O
by,6267,O
intravenous,6267,O
(,6267,O
i.v,6267,O
.,6267,O
),6267,O
route,6268,O
were,6268,O
compared,6268,O
in,6268,O
freely,6268,O
moving,6268,O
Wistar,6268,O
rats,6268,O
.,6268,O
The,6269,O
three,6269,O
drugs,6269,O
significantly,6269,O
increased,6269,O
both,6269,O
systolic,6269,O
and,6269,O
diastolic,6269,O
blood,6269,O
pressure,6269,O
and,6269,O
decreased,6269,O
heart,6269,O
rate,6269,O
.,6269,O
Compared,6270,O
to,6270,O
physostigmine,6270,B-CHEMICAL
",",6270,O
a,6270,O
20-fold,6270,O
higher,6270,O
dose,6270,O
of,6270,O
tacrine,6270,B-CHEMICAL
and,6270,O
a,6270,O
40-fold,6270,O
higher,6270,O
dose,6270,O
of,6270,O
rivastigmine,6270,B-CHEMICAL
was,6270,O
necessary,6270,O
to,6270,O
induce,6270,O
a,6270,O
comparable,6270,O
pressor,6270,O
effect,6270,O
.,6270,O
Tacrine,6271,B-CHEMICAL
was,6271,O
chosen,6271,O
as,6271,O
a,6271,O
model,6271,O
to,6271,O
study,6271,O
the,6271,O
mechanisms,6271,O
underlying,6271,O
the,6271,O
cardiovascular,6271,O
effects,6271,O
of,6271,O
i.v,6271,O
.,6271,O
cholinesterase,6272,B-GENE-Y
inhibitors,6272,O
.,6272,O
Atropine,6273,B-CHEMICAL
totally,6273,O
abolished,6273,O
while,6273,O
methylatropine,6273,B-CHEMICAL
did,6273,O
not,6273,O
affect,6273,O
tacrine,6273,B-CHEMICAL
pressor,6273,O
effects,6273,O
.,6273,O
Conversely,6274,O
",",6274,O
both,6274,O
drugs,6274,O
abolished,6274,O
tacrine-induced,6274,B-CHEMICAL
bradycardia,6274,O
.,6274,O
The,6275,O
alpha1-adrenoceptor,6275,B-GENE-N
antagonist,6275,O
prazosin,6275,B-CHEMICAL
or,6275,O
the,6275,O
vasopressin,6275,B-GENE-N
V1,6275,I-GENE-N
receptor,6275,I-GENE-N
antagonist,6275,O
",",6275,O
[,6275,B-CHEMICAL
beta-mercapto-beta,6275,I-CHEMICAL
",",6275,I-CHEMICAL
beta-cyclopenta-methylenepropionyl1,6275,I-CHEMICAL
",",6275,I-CHEMICAL
O-Me-Tyr2,6275,I-CHEMICAL
",",6275,I-CHEMICAL
Arg8,6275,I-CHEMICAL
],6275,I-CHEMICAL
vasopressin,6275,B-GENE-Y
partially,6275,O
but,6275,O
significantly,6275,O
reduced,6275,O
tacrine,6275,B-CHEMICAL
pressor,6275,O
effect,6275,O
and,6275,O
mostly,6275,O
abolished,6275,O
it,6275,O
when,6275,O
administered,6275,O
concomitantly,6275,O
.,6275,O
The,6276,O
tacrine,6276,B-CHEMICAL
pressor,6276,O
response,6276,O
was,6276,O
inhibited,6276,O
in,6276,O
a,6276,O
dose-dependent,6276,O
manner,6276,O
by,6276,O
the,6276,O
i.c.v,6276,O
.,6276,O
administration,6277,O
of,6277,O
the,6277,O
non-selective,6277,O
muscarinic,6277,B-GENE-N
receptor,6277,I-GENE-N
antagonist,6277,O
atropine,6277,B-CHEMICAL
(,6277,O
ID50,6277,O
=,6277,O
1.45,6277,O
microg,6277,O
),6277,O
",",6277,O
the,6277,O
muscarinic,6277,B-GENE-Y
M1,6277,I-GENE-Y
receptor,6277,I-GENE-Y
antagonist,6277,O
pirenzepine,6277,B-CHEMICAL
(,6277,O
ID50,6277,O
=,6277,O
4.33,6277,O
microg,6277,O
),6277,O
",",6277,O
the,6277,O
muscarinic,6277,B-GENE-Y
M2,6277,I-GENE-Y
receptor,6277,I-GENE-Y
antagonist,6277,O
methoctramine,6277,B-CHEMICAL
(,6277,O
ID50,6277,O
=,6277,O
1.39,6277,O
microg,6277,O
),6277,O
and,6277,O
the,6277,O
muscarinic,6277,B-GENE-Y
M3,6277,I-GENE-Y
receptor,6277,I-GENE-Y
antagonist,6277,O
para-fluoro-hexahydro-sila-difenidol,6277,B-CHEMICAL
(,6277,O
ID50,6277,O
=,6277,O
31.19,6277,O
microg,6277,O
),6277,O
.,6277,O
Central,6278,O
injection,6278,O
of,6278,O
such,6278,O
muscarinic,6278,B-GENE-N
receptor,6278,I-GENE-N
antagonists,6278,O
did,6278,O
not,6278,O
affect,6278,O
tacrine-induced,6278,B-CHEMICAL
bradycardia,6278,O
.,6278,O
Our,6279,O
results,6279,O
show,6279,O
that,6279,O
acetylcholinesterase,6279,B-GENE-Y
inhibitors,6279,O
induce,6279,O
significant,6279,O
cardiovascular,6279,O
effects,6279,O
with,6279,O
a,6279,O
pressor,6279,O
response,6279,O
mediated,6279,O
mainly,6279,O
by,6279,O
the,6279,O
stimulation,6279,O
of,6279,O
central,6279,O
muscarinic,6279,B-GENE-Y
M2,6279,I-GENE-Y
receptors,6279,I-GENE-Y
inducing,6279,O
a,6279,O
secondary,6279,O
increase,6279,O
in,6279,O
sympathetic,6279,O
outflow,6279,O
and,6279,O
vasopressin,6279,B-CHEMICAL
release,6279,O
.,6279,O
Conversely,6280,O
",",6280,O
acetylcholinesterase,6280,B-GENE-Y
inhibitor-induced,6280,O
bradycardia,6280,O
appears,6280,O
to,6280,O
be,6280,O
mediated,6280,O
by,6280,O
peripheral,6280,O
muscarinic,6280,O
mechanisms,6280,O
.,6280,O
State-dependent,6281,O
cocaine,6281,B-CHEMICAL
block,6281,O
of,6281,O
sodium,6281,B-CHEMICAL
channel,6281,I-GENE-N
isoforms,6281,O
",",6281,O
chimeras,6281,O
",",6281,O
and,6281,O
channels,6281,O
coexpressed,6281,O
with,6281,O
the,6281,O
beta1,6281,O
subunit,6281,O
.,6281,O
Cocaine,6282,B-CHEMICAL
block,6282,O
of,6282,O
human,6282,B-GENE-Y
cardiac,6282,I-GENE-Y
(,6282,I-GENE-Y
hH1,6282,I-GENE-Y
),6282,I-GENE-Y
and,6282,O
rat,6282,B-GENE-Y
skeletal,6282,I-GENE-Y
(,6282,I-GENE-Y
mu1,6282,I-GENE-Y
),6282,I-GENE-Y
muscle,6282,I-GENE-Y
sodium,6282,B-CHEMICAL
channels,6282,I-GENE-Y
was,6282,O
examined,6282,O
under,6282,O
whole-cell,6282,O
voltage,6282,O
clamp,6282,O
in,6282,O
transiently,6282,O
transfected,6282,O
HEK293t,6282,O
cells,6282,O
.,6282,O
Low,6283,O
affinity,6283,O
block,6283,O
of,6283,O
resting,6283,O
mu1,6283,B-GENE-Y
and,6283,O
hH1,6283,B-GENE-Y
channels,6283,I-GENE-Y
at,6283,O
-180,6283,O
mV,6283,O
was,6283,O
the,6283,O
same,6283,O
",",6283,O
and,6283,O
high,6283,O
affinity,6283,O
block,6283,O
of,6283,O
inactivated,6283,O
channels,6283,O
at,6283,O
-70,6283,O
mV,6283,O
was,6283,O
the,6283,O
same,6283,O
.,6283,O
Cocaine,6284,B-CHEMICAL
block,6284,O
of,6284,O
hH1,6284,B-GENE-Y
channels,6284,I-GENE-Y
was,6284,O
greater,6284,O
than,6284,O
block,6284,O
of,6284,O
mu1,6284,B-GENE-Y
channels,6284,I-GENE-Y
at,6284,O
voltages,6284,O
between,6284,O
-120,6284,O
mV,6284,O
and,6284,O
-90,6284,O
mV,6284,O
",",6284,O
suggesting,6284,O
that,6284,O
greater,6284,O
steady-state,6284,O
inactivation,6284,O
of,6284,O
hH1,6284,B-GENE-Y
channels,6284,I-GENE-Y
in,6284,O
this,6284,O
voltage,6284,O
range,6284,O
makes,6284,O
them,6284,O
more,6284,O
susceptible,6284,O
to,6284,O
cocaine,6284,B-CHEMICAL
block,6284,O
.,6284,O
We,6285,O
induced,6285,O
shifts,6285,O
in,6285,O
the,6285,O
voltage,6285,O
dependence,6285,O
of,6285,O
steady-state,6285,O
inactivation,6285,O
at,6285,O
mu1,6285,B-GENE-Y
and,6285,O
hH1,6285,B-GENE-Y
channels,6285,I-GENE-Y
by,6285,O
constructing,6285,O
mu1/hH1,6285,B-GENE-Y
channel,6285,I-GENE-Y
chimeras,6285,O
or,6285,O
by,6285,O
coexpressing,6285,O
the,6285,O
wild-type,6285,O
channels,6285,O
with,6285,O
the,6285,O
rat,6285,O
brain,6285,O
beta1,6285,O
subunit,6285,O
.,6285,O
In,6286,O
contrast,6286,O
to,6286,O
several,6286,O
previous,6286,O
reports,6286,O
",",6286,O
coexpression,6286,O
of,6286,O
the,6286,O
rat,6286,O
brain,6286,O
beta1,6286,O
subunit,6286,O
with,6286,O
mu1,6286,B-GENE-Y
or,6286,O
hH1,6286,B-GENE-Y
produced,6286,O
large,6286,O
positive,6286,O
shifts,6286,O
in,6286,O
steady-state,6286,O
inactivation,6286,O
.,6286,O
Shifts,6287,O
in,6287,O
the,6287,O
voltage,6287,O
dependence,6287,O
of,6287,O
steady-state,6287,O
inactivation,6287,O
elicited,6287,O
linear,6287,O
shifts,6287,O
in,6287,O
steady-state,6287,O
cocaine,6287,B-CHEMICAL
block,6287,O
",",6287,O
yet,6287,O
these,6287,O
manipulations,6287,O
did,6287,O
not,6287,O
affect,6287,O
the,6287,O
cocaine,6287,B-CHEMICAL
affinity,6287,O
of,6287,O
resting,6287,O
or,6287,O
inactivated,6287,O
channels,6287,O
.,6287,O
These,6288,O
data,6288,O
",",6288,O
as,6288,O
well,6288,O
as,6288,O
simulations,6288,O
used,6288,O
to,6288,O
predict,6288,O
block,6288,O
",",6288,O
indicate,6288,O
that,6288,O
state-dependent,6288,O
cocaine,6288,B-CHEMICAL
block,6288,O
depends,6288,O
on,6288,O
both,6288,O
steady-state,6288,O
inactivation,6288,O
and,6288,O
channel,6288,O
activation,6288,O
",",6288,O
although,6288,O
inactivation,6288,O
appears,6288,O
to,6288,O
have,6288,O
the,6288,O
predominant,6288,O
role,6288,O
.,6288,O
